#Release Date: 2020-2-12
id	pmid	geneids	genes	sentence	type	solid
1	10021299	7157;1026	p53;WAF1	The functional ***link*** between ***p53*** and ***WAF1*** suggests the possibility that alteration in WAF1 function constitutes an alternative mechanism to p53 inactivation .	parallel	0
2	10021336	1908;284217	endothelin-3;laminin alpha1	In contrast , transcription of ***laminin alpha1*** , a smooth muscle-derived promoter of neuronal development , was ***inhibited*** by ***endothelin-3*** , but promoted by BQ 788 .	negative	1
3	10021362	5727;6608	Ptc;Smo	The ***inhibition*** of ***Smo*** by ***Ptc*** can be relieved by the addition of Shh .	negative	1
4	10021362	6608;5727	Smo;Ptc	Mapping of the Smo domains required for binding to Ptc and for signaling revealed that the ******Smo-Ptc****** ***interaction*** involves mainly the amino terminus of Smo , and that the third intracellular loop and the seventh transmembrane domain are required for signaling .	parallel	1
5	10021362	5727;6608	Ptc;Smo	CONCLUSIONS : These data demonstrate that Smo is the signaling component of a multicomponent Hh receptor complex and that ***Ptc*** is a ligand-regulated ***inhibitor*** of ***Smo*** .	negative	1
6	10021367	10097;10096	Arp2;Arp3	To date , several actin-cytoskeleton-associated proteins have been implicated in the motility of Listeria or Shigella : vasodilator-stimulated phosphoprotein ( VASP ) , vinculin and the actin-related protein ***complex*** of ***Arp2*** and ***Arp3*** [ 4 ] [ 5 ] [ 6 ] [ 7 ] .	parallel	1
7	10021463	596;4790	Bcl-2;NF-kappaB	In addition , ***Bcl-2*** or Bcl-XL ***inhibits*** activation of ***NF-kappaB*** and thus upregulation of proinflammatory genes .	negative	1
8	10021463	598;4790	Bcl-XL;NF-kappaB	In addition , Bcl-2 or ***Bcl-XL*** ***inhibits*** activation of ***NF-kappaB*** and thus upregulation of proinflammatory genes .	negative	1
9	10021463	596;4790	Bcl-2;NF-kappaB	***Bcl-2-mediated*** ***inhibition*** of ***NF-kappaB*** in EC occurs upstream of IkappaBalpha degradation without affecting p65-mediated transactivation .	negative	1
10	10021466	3329;4790	HSP 60;NF-kappaB	In ECs , either ***HSP 60*** ***triggered*** activation of ***NF-kappaB*** complexes containing p65 and p50 Rel proteins .	positive	0
11	10022118	836;1026	caspase-3;p21	We report herein that ***p21*** was ***cleaved*** by ***caspase-3/CPP32*** at the site of DHVD112L during the DNA damage-induced apoptosis of cancer cells .	target	1
12	10022118	836;1026	caspase-3;p21	Thus , ***caspase-3-mediated*** ***cleavage*** and inactivation of ***p21*** protein may convert cancer cells from growth arrest to undergoing apoptosis , leading to the acceleration of chemotherapy-induced apoptotic process in cancer cells .	target	1
13	10022120	7535;868	Zap-70;Cbl-b	In heterogeneous COS-1 cells , ***Cbl-b*** was ***phosphorylated*** on tyrosine residues by both Syk - ( ***Syk/Zap-70*** ) and Src - ( Fyn/Lck ) family kinases , with Syk kinase inducing the most prominent effect .	target	1
14	10022120	868;2885	Cbl-b;Grb2	***Cbl-b*** constitutively ***binds*** ***Grb2*** and becomes associated with Crk-L upon TCR stimulation .	parallel	1
15	10022123	7157;4609	p53;C-myc	***C-myc*** overexpression and ***p53*** loss ***cooperate*** to promote genomic instability .	parallel	0
16	10022234	3458;3717	IFNgamma;Jak2	LPS caused intranuclear translocation of NF-kappaB , and ***IFNgamma*** ***induced*** phosphorylation of ***Jak2*** and Stat1 , followed by the translocation of Stat1 into the nucleus .	target	1
17	10022234	3458;6772	IFNgamma;Stat1	LPS caused intranuclear translocation of NF-kappaB , and ***IFNgamma*** ***induced*** phosphorylation of Jak2 and ***Stat1*** , followed by the translocation of Stat1 into the nucleus .	target	1
18	10022303	356;355	FasL;Fas	Both ***Fas*** ***ligand*** ( ***FasL*** ) and Fas receptor ( Fas ) were expressed postnatally in rat testis with peak expression associated with the high levels of germ cell apoptosis found during the first wave of spermatogenesis .	parallel	1
19	10022379	5328;5329	uPA;uPAR	The latter antibody was capable of binding the preformed complex , forming a transient trimolecular assembly , and promoting the dissociation of the ******uPA/uPAR****** ***complex*** .	parallel	1
20	10022386	7409;5599	Vav;JNK	Expression of GFP ***tagged-Vav*** , an ***activator*** of stress-activated protein kinase ( ***SAPK/JNK*** ) , resulted in the expected induction of JNK activity and in the normal redistribution of Vav in response to engagement of the high affinity receptor for IgE ( FcepsilonRI ) .	positive	1
21	10022386	7409;5601	Vav;SAPK	Expression of GFP ***tagged-Vav*** , an ***activator*** of stress-activated protein kinase ( ***SAPK/JNK*** ) , resulted in the expected induction of JNK activity and in the normal redistribution of Vav in response to engagement of the high affinity receptor for IgE ( FcepsilonRI ) .	positive	1
22	10022436	3952;3630	Leptin;Proinsulin	***Proinsulin*** messenger ribonucleic acid expression in islets was ***inhibited*** by ***Leptin*** at 11.1 mM , but not at 5.6 mM glucose .	negative	1
23	10022436	3952;3630	Leptin;Proinsulin	***Leptin*** also ***reduced*** ***Proinsulin*** messenger ribonucleic acid levels that were increased in islets by treatment with 10 nM glucagon-like peptide-1 in the presence of either 5.6 or 11.1 mM glucose .	negative	1
24	10022437	3558;5617	Interleukin-2;prolactin	***Interleukin-2*** ***inhibits*** the synthesis and release of ***prolactin*** from human decidual cells .	negative	1
25	10022437	3558;5617	Interleukin-2;PRL	As ***Interleukin-2*** ( IL-2 ) ***stimulates*** the synthesis and release of pituitary ***PRL*** , and decidual stromal cells have receptors for IL-2 , we examined whether IL-2 also regulates the release of decidual PRL .	positive	0
26	10022437	3558;5617	IL-2;PRL	These findings strongly suggest that ***IL-2*** ***inhibits*** the synthesis and release of decidual ***PRL*** and provide further support for a critical role of cytokines in the regulation of decidual PRL gene expression .	negative	1
27	10022504	6750;3558	Somatostatin;interleukin-2	Neuropeptide ***Somatostatin*** ( SRIF ) has been shown to ***modulate*** ***interleukin-2*** ( IL-2 ) secretion by mitogen-activated T cells .	target	0
28	10022505	3458;4609	IFNgamma;c-Myc	We found that whereas ***IFNgamma*** ***inhibits*** CSF-1-stimulated ***c-Myc*** gene expression , it induces Mad1 expression .	negative	1
29	10022505	4609;4149	Myc;Max	These results suggest that IFNgamma treatment could shift the ******Myc-Max****** ***complex*** to the Mad1-Max complex in cells .	parallel	1
30	10022505	4084;4149	Mad1;Max	These results suggest that IFNgamma treatment could shift the Myc-Max complex to the ******Mad1-Max****** ***complex*** in cells .	parallel	1
31	10022507	8600;4982	OPGL;Osteoprotegerin	***Osteoprotegerin*** ( OPG ) and its ***ligand*** ( ***OPGL*** ) negatively and positively regulate osteoclastogenesis in the mouse .	parallel	1
32	10022507	4982;8600	OPG;OPGL	***OPG*** ( 5-250 ng/ml ) ***antagonizes*** the effects of ***OPGL*** on the morphology of the osteoclast-like cells that form , as well as bone erosion .	negative	1
33	10022541	2641;3099	glucagon;HK II	Moreover , treatment of the transfectants with glucagon did not inhibit promoter activation in the transformed H661 cells , while endogenous ***HK II*** in NHBECs is ***suppressed*** by ***glucagon*** .	negative	1
34	10022686	7157;1026	p53;CIP1	CONCLUSIONS : Our results indicate that ***p21WAF-1-CIP1*** seems to be ***regulated*** by ***p53*** independent pathways in superficial bladder cancer .	target	1
35	10022686	7157;1026	p53;p21	Among p21 positive tumors 15 ( 65.2 % ) were p53 and p21 positive , suggesting that ***p21*** may also be ***regulated*** by ***p53*** independent pathways .	target	1
36	10022737	3440;1437	interferon alpha-2B;GM-CSF	RESULTS : BCG and/or ***interferon alpha-2B*** differentially ***increased*** IL-1beta , IL-6 , IL-8 , ***GM-CSF*** and TNF-alpha production in the bladder cancer cells .	positive	0
37	10022737	3440;3553	interferon alpha-2B;IL-1beta	RESULTS : BCG and/or ***interferon alpha-2B*** differentially ***increased*** ***IL-1beta*** , IL-6 , IL-8 , GM-CSF and TNF-alpha production in the bladder cancer cells .	positive	0
38	10022737	3440;3569	interferon alpha-2B;IL-6	RESULTS : BCG and/or ***interferon alpha-2B*** differentially ***increased*** IL-1beta , ***IL-6*** , IL-8 , GM-CSF and TNF-alpha production in the bladder cancer cells .	positive	0
39	10022737	3440;3576	interferon alpha-2B;IL-8	RESULTS : BCG and/or ***interferon alpha-2B*** differentially ***increased*** IL-1beta , IL-6 , ***IL-8*** , GM-CSF and TNF-alpha production in the bladder cancer cells .	positive	0
40	10022737	3440;7124	interferon alpha-2B;TNF-alpha	RESULTS : BCG and/or ***interferon alpha-2B*** differentially ***increased*** IL-1beta , IL-6 , IL-8 , GM-CSF and ***TNF-alpha*** production in the bladder cancer cells .	positive	0
41	10022737	3440;7040	interferon alpha-2B;TGF-beta1	The combination of BCG and ***interferon alpha-2B*** also completely ***suppressed*** ***TGF-beta1*** production in the MGH and RT112 cell lines .	negative	1
42	10022739	4233;3082	MET;HGF	PURPOSE : Several lines of evidence show that hepatocyte growth factor ( ***HGF*** ) and its ***receptor*** ***MET*** play a significant role in the progression of various cancers including renal cell carcinoma ( RCC ) .	parallel	1
43	10022764	8204;5465	RIP140;PPARalpha	However , protein binding studies carried out in vitro showed that full-length ***RIP140*** ***bound*** efficiently to ***PPARalpha*** in the absence of exogenously added ligand .	parallel	1
44	10022764	8204;6256	RIP140;retinoid-X-receptor alpha	In contrast , a strong ***interaction*** of ***RIP140*** with the PPARalpha and LXRalpha heterodimerization partner ***retinoid-X-receptor alpha*** ( RXRalpha ) required the presence of its cognate ligand , 9-cis retinoic acid .	parallel	1
45	10022777	5578;2690	protein kinase C alpha;growth hormone-binding protein	Activation of ***protein kinase C alpha*** ***enhances*** human ***growth hormone-binding protein*** release .	positive	0
46	10022812	6237;5898	Rap1/Ras;Ral	In COS cells , Ral GDP dissociation stimulator ( RalGDS ) - induced ***Ral*** activation was ***stimulated*** by RasG12V or a ***Rap1/Ras*** chimera in which the N-terminal region of Rap1 was ligated to the C-terminal region of Ras but not by Rap1G12V or a Ras/Rap1 chimera in which the N-terminal region of Ras was ligated to the C-terminal region of Rap1 , although RalGDS interacted with these small GTP-binding proteins .	positive	0
47	10022814	2885;5609	Grb2;MEK	Upon activation , RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 ( ***Grb2*** ) , which in turn binds to SOS and ***activates*** the ***Ras/Raf/MEK*** / mitogen-activated protein ( MAP ) kinase pathway .	positive	1
48	10022815	6667;4605	SP1;B-MYB	The B-MYB-responsive element does not contain myb-binding sites and gel-shift analysis shows that ***SP1*** , but not B-MYB , protein contained in SAOS2 cell extracts ***binds*** to the 120 bp ***B-MYB*** promoter fragment .	parallel	1
49	10022815	4605;6667	B-MYB;SP1	These observations suggest that ***B-MYB*** functions as a ***coactivator*** of ***SP1*** , and that diverse combinations of myb and SP1 sites may dictate the responsiveness of myb-target genes to the various members of the myb family .	positive	1
50	10022833	8651;3815	Socs1;Kit	We show that the expression of Socs1 mRNA is rapidly increased in primary bone marrow-derived mast cells following exposure to steel factor , and ***Socs1*** inducibly ***binds*** to the ***Kit*** receptor tyrosine kinase via its Src homology 2 ( SH2 ) domain .	parallel	1
51	10022833	8651;3815	Socs1;Kit	In contrast , constitutive expression of ***Socs1*** ***suppresses*** the mitogenic potential of ***Kit*** while maintaining steel factor-dependent cell survival signals .	negative	1
52	10022833	8651;7409	Socs1;Vav	We show that Grb2 binds Socs1 via its SH3 domains to putative diproline determinants located in the N-terminus of Socs1 , and ***Socs1*** ***binds*** to the N-terminal regulatory region of ***Vav*** .	parallel	1
53	10022833	2885;8651	Grb2;Socs1	We show that ***Grb2*** ***binds*** ***Socs1*** via its SH3 domains to putative diproline determinants located in the N-terminus of Socs1 , and Socs1 binds to the N-terminal regulatory region of Vav .	parallel	1
54	10022835	4654;1019	MyoD;cdk4	Coupling of the cell cycle and myogenesis through the cyclin D1-dependent ***interaction*** of ***MyoD*** with ***cdk4*** .	parallel	1
55	10022835	1019;4654	cdk4;MyoD	Here we show that a mitogen-sensitive mechanism , involving the direct ***interaction*** between ***MyoD*** and ***cdk4*** , restricts myoblast differentiation to cells that have entered into the G0 phase of the cell cycle under mitogen withdrawal .	parallel	1
56	10022835	4654;1019	MyoD;cdk4	***Interaction*** between ***MyoD*** and ***cdk4*** disrupts MyoD DNA-binding , muscle-specific gene activation and myogenic conversion of 10T1/2 cells independently of cyclin D1 and the CAK activation of cdk4 .	parallel	1
57	10022835	1022;1019	CAK;cdk4	Interaction between MyoD and cdk4 disrupts MyoD DNA-binding , muscle-specific gene activation and myogenic conversion of 10T1/2 cells independently of cyclin D1 and the ***CAK*** ***activation*** of ***cdk4*** .	positive	1
58	10022835	4654;1019	MyoD;cdk4	The specific ******MyoD-cdk4****** ***interaction*** in dividing myoblasts , coupled with the cyclin D1-dependent nuclear targeting of cdk4 , suggests a mitogen-sensitive mechanism whereby cyclin D1 can regulate MyoD function and the onset of myogenesis by controlling the cellular location of cdk4 rather than the phosphorylation status of MyoD .	parallel	1
59	10022835	595;4654	cyclin D1;MyoD	The specific MyoD-cdk4 interaction in dividing myoblasts , coupled with the cyclin D1-dependent nuclear targeting of cdk4 , suggests a mitogen-sensitive mechanism whereby ***cyclin D1*** can ***regulate*** ***MyoD*** function and the onset of myogenesis by controlling the cellular location of cdk4 rather than the phosphorylation status of MyoD .	target	1
60	10022843	6426;6426	SF2;ASF	The splicing factor-associated protein , p32 , regulates RNA splicing by inhibiting ******ASF/SF2****** RNA ***binding*** and phosphorylation .	parallel	1
61	10022843	708;6426	p32;ASF	Here we present evidence that ***p32*** ***interacts*** with ***ASF/SF2*** and SRp30c , another member of the SR protein family .	parallel	1
62	10022843	708;8683	p32;SRp30c	Here we present evidence that ***p32*** ***interacts*** with ASF/SF2 and ***SRp30c*** , another member of the SR protein family .	parallel	1
63	10022843	6426;6426	ASF;SF2	We further show that p32 inhibits ASF/SF2 function as both a splicing enhancer and splicing repressor protein by preventing stable ******ASF/SF2****** ***interaction*** with RNA , but p32 does not block SRp30c function .	parallel	1
64	10022843	708;6426	p32;SF2	We further show that ***p32*** ***inhibits*** ***ASF/SF2*** function as both a splicing enhancer and splicing repressor protein by preventing stable ASF/SF2 interaction with RNA , but p32 does not block SRp30c function .	negative	1
65	10022843	6426;6426	SF2;ASF	Our results suggest that p32 functions as an ASF/SF2 inhibitory factor , regulating ******ASF/SF2****** RNA ***binding*** and phosphorylation .	parallel	1
66	10022848	54536;5870	Sec15p;rab GTPase	***Sec15p*** , an exocyst component , can associate with secretory vesicles and ***interact*** specifically with the ***rab GTPase*** , Sec4p , in its GTP-bound form .	parallel	1
67	10022862	7157;4193	p53;Mdm2	Mutation of the phosphorylation sites to alanine did not affect the sensitivity of p53 to binding to or degradation by Mdm2 , although alteration of residues 15 and 37 to aspartic acid , which could mimic phosphorylation , resulted in a slight resistance to Mdm2-mediated degradation , consistent with recent reports that phosphorylation at these sites inhibits the ******p53-Mdm2****** ***interaction*** .	parallel	1
68	10022865	1029;1019	INK4;CDK4	Here we show that although all four ***INK4*** proteins ***associate*** with ***CDK4*** and CDK6 in vitro , only p16 ( INK4a ) can form stable , binary complexes with both CDK4 and CDK6 in proliferating cells .	parallel	0
69	10022865	1029;1021	INK4;CDK6	Here we show that although all four ***INK4*** proteins ***associate*** with CDK4 and ***CDK6*** in vitro , only p16 ( INK4a ) can form stable , binary complexes with both CDK4 and CDK6 in proliferating cells .	parallel	0
70	10022865	1029;1019	p16;CDK4	Here we show that although all four INK4 proteins associate with CDK4 and CDK6 in vitro , only ***p16*** ( INK4a ) can form stable , binary ***complexes*** with both ***CDK4*** and CDK6 in proliferating cells .	parallel	1
71	10022865	1029;1021	p16;CDK6	Here we show that although all four INK4 proteins associate with CDK4 and CDK6 in vitro , only ***p16*** ( INK4a ) can form stable , binary ***complexes*** with both CDK4 and ***CDK6*** in proliferating cells .	parallel	1
72	10022865	1029;1019	INK4;CDK4	The other ***INK4*** family members form stable complexes with CDK6 but ***associate*** only transiently with ***CDK4*** .	parallel	0
73	10022865	1029;1021	INK4;CDK6	The other ***INK4*** family members form stable ***complexes*** with ***CDK6*** but associate only transiently with CDK4 .	parallel	1
74	10022865	1019;1026	CDK4;p21	Conversely , ***CDK4*** stably ***associates*** with both ***p21*** ( CIP1 ) and p27 ( KIP1 ) in cyclin-containing complexes , suggesting that CDK4 is in equilibrium between INK4 and p21 ( CIP1 ) - or p27 ( KIP1 ) - bound states .	parallel	0
75	10022865	1019;5715	CDK4;p27	Conversely , ***CDK4*** stably ***associates*** with both p21 ( CIP1 ) and ***p27*** ( KIP1 ) in cyclin-containing complexes , suggesting that CDK4 is in equilibrium between INK4 and p21 ( CIP1 ) - or p27 ( KIP1 ) - bound states .	parallel	0
76	10022865	1026;1019	p21;CDK4	In agreement with this hypothesis , overexpression of ***p21*** ( CIP1 ) in 293 cells , where CDK4 is bound to p16 ( INK4a ) , ***stimulates*** the formation of ternary cyclin ***D-CDK4-p21*** ( CIP1 ) complexes .	positive	0
77	10022866	2549;5781	Gab1;SHP2	Following stimulation of epithelial cells with HGF , ***Gab1*** ***associates*** with phosphatidylinositol 3-kinase and the tyrosine phosphatase ***SHP2*** .	parallel	0
78	10022869	4088;4089	Smad3;Smad4	******Smad3-Smad4****** and AP-1 ***complexes*** synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta .	parallel	1
79	10022869	4088;4089	Smad3;Smad4	Here , we describe a concurrent requirement for two discrete responsive elements in the regulation of the c-Jun promoter , one a binding site for a ******Smad3-Smad4****** ***complex*** and the other an AP-1 binding site .	parallel	1
80	10022869	7040;3725	TGF-beta;c-Jun	This simultaneous requirement for two distinct and independent DNA binding elements suggests that Smad and AP-1 complexes function synergistically to mediate ***TGF-beta-induced*** transcriptional ***activation*** of the ***c-Jun*** promoter .	positive	1
81	10022874	8569;1977	Mnk1;eIF4E	Expression of dominant-negative ***Mnk1*** ***reduces*** mitogen-induced ***eIF4E*** phosphorylation , while expression of activated Mnk1 increases basal eIF4E phosphorylation .	negative	1
82	10022874	8569;1977	Mnk1;eIF4E	Activated mutant ***Mnk1*** also ***induces*** extensive phosphorylation of ***eIF4E*** in cells overexpressing 4EBP1 .	target	1
83	10022874	8569;1977	Mnk1;eIF4E	This suggests that phosphorylation of ***eIF4E*** is ***catalyzed*** by ***Mnk1*** or a very similar kinase in cells and is independent of other mitogenic signals that release eIF4E from 4EBP1 .	positive	1
84	10022874	8569;1977	Mnk1;eukaryotic translation initiation factor 4E	***Phosphorylation*** of the cap-binding protein ***eukaryotic translation initiation factor 4E*** by protein kinase ***Mnk1*** in vivo .	target	1
85	10022874	8569;1977	Mnk1;eIF4E	We previously showed that a mitogen - and stress-activated kinase , ***Mnk1*** , ***phosphorylates*** ***eIF4E*** in vitro at the physiological site .	target	1
86	10022874	8569;1977	Mnk1;eIF4E	Here we show that ***Mnk1*** ***regulates*** ***eIF4E*** phosphorylation in vivo .	target	1
87	10022874	8569;1981	Mnk1;eIF4G	***Mnk1*** ***binds*** directly to ***eIF4G*** and copurifies with eIF4G and eIF4E .	parallel	1
88	10022875	207;5594	Rac;ERK	All combinations of ***Rac/Raf*** and Ras/Raf and Rho/Raf effector mutants that transform cells cooperatively ***stimulated*** ***ERK*** .	positive	0
89	10022879	2099;2100	ERalpha;ERbeta	Using ER subunits with modified DNA recognition specificity , we were able to measure the transcriptional properties of ******ERalpha-ERbeta****** ***heterodimers*** in transfected cells without interference from the two ER homodimer complexes .	parallel	1
90	10022879	2100;2099	ERbeta;ERalpha	Using ligand-binding and AF-2-defective mutants , we further demonstrated that while the ******ERalpha-ERbeta****** ***heterodimer*** can be activated when only one E2-binding competent partner is present per dimer , two functional AF-2 domains are required for transcriptional activity .	parallel	1
91	10022879	2100;2099	ERbeta;ERalpha	Taken together , the results of this study of a retinoid X receptor-independent heterodimer complex , the first such study , provide evidence of different stoichiometric requirements for AF-1 and -2 activity and demonstrate that AF-1 receptor-specific properties are maintained within the ******ERalpha-ERbeta****** ***heterodimer*** .	parallel	1
92	10022882	3553;4790	IL-1beta;NF-kappaB	This pathway involves the Rac1 and Cdc42 GTPases , two enzymes which are not required for ***NF-kappaB*** ***activation*** by ***IL-1beta*** in epithelial cells .	positive	1
93	10022882	3553;4790	IL-1beta;NF-kappaB	In conclusion , three different cell-specific pathways lead to ***NF-kappaB*** ***activation*** by ***IL-1beta*** : a pathway dependent on ROI production by 5-LOX in lymphoid cells , an ROI - and 5-LOX-independent pathway in epithelial cells , and a pathway requiring ROI production by NADPH oxidase in monocytic cells .	positive	1
94	10022883	3084;6667	Neu differentiation factor;Sp1 transcription factor	***Neu differentiation factor*** ***stimulates*** phosphorylation and activation of the ***Sp1 transcription factor*** .	positive	0
95	10022897	356;355	CD95L;Fas	Fas ( CD95 ) and ***Fas*** ***ligand*** ( ***CD95L*** ) are an interacting receptor-ligand pair required for immune homeostasis .	parallel	1
96	10022897	4790;5970	p50;p65	Electrophoretic mobility shift assay ( EMSA ) and supershift analyses of this region documented constitutive binding of Sp1 in unactivated nuclear extracts and inducible binding of ******p50-p65****** NF-kappaB ***heterodimers*** after P/I activation .	parallel	1
97	10022897	4790;4790	p50;NF-kappaB	Electrophoretic mobility shift assay ( EMSA ) and supershift analyses of this region documented constitutive binding of Sp1 in unactivated nuclear extracts and inducible ***binding*** of ***p50-p65*** ***NF-kappaB*** heterodimers after P/I activation .	parallel	1
98	10022897	4790;5970	p50;p65	Electrophoretic mobility shift assay ( EMSA ) and supershift analyses of this region documented constitutive binding of Sp1 in unactivated nuclear extracts and inducible ***binding*** of ******p50-p65****** NF-kappaB heterodimers after P/I activation .	parallel	1
99	10022897	5970;4790	p65;NF-kappaB	Electrophoretic mobility shift assay ( EMSA ) and supershift analyses of this region documented constitutive binding of Sp1 in unactivated nuclear extracts and inducible ***binding*** of ***p50-p65*** ***NF-kappaB*** heterodimers after P/I activation .	parallel	1
100	10022898	1026;1017	p21;Cdk2	We show that the Cdk inhibitor ***p21*** ( Sdi1 , Cip1 , Waf1 ) , which accumulates progressively in aging cells , ***binds*** to and inactivates all cyclin ***E-Cdk2*** complexes in senescent cells , whereas in young cells only p21-free Cdk2 complexes are active .	parallel	1
101	10022898	1019;595	Cdk4;cyclin D1	Instead , the ******cyclin D1-Cdk4****** and cyclin D1-Cdk6 ***complexes*** in these cells are associated with an increased amount of p21 , suggesting that p21 may be responsible for inactivation of both cyclin E - and cyclin D1-associated kinase activity at the early stage of senescence .	parallel	1
102	10022898	1021;595	Cdk6;cyclin D1	Instead , the cyclin D1-Cdk4 and ******cyclin D1-Cdk6****** ***complexes*** in these cells are associated with an increased amount of p21 , suggesting that p21 may be responsible for inactivation of both cyclin E - and cyclin D1-associated kinase activity at the early stage of senescence .	parallel	1
103	10022898	1019;1026	Cdk4;p21	Instead , the ***cyclin D1-Cdk4*** and cyclin D1-Cdk6 complexes in these cells are ***associated*** with an increased amount of ***p21*** , suggesting that p21 may be responsible for inactivation of both cyclin E - and cyclin D1-associated kinase activity at the early stage of senescence .	parallel	0
104	10022898	1021;1026	Cdk6;p21	Instead , the cyclin D1-Cdk4 and ***cyclin D1-Cdk6*** complexes in these cells are ***associated*** with an increased amount of ***p21*** , suggesting that p21 may be responsible for inactivation of both cyclin E - and cyclin D1-associated kinase activity at the early stage of senescence .	parallel	0
105	10022898	595;1026	cyclin D1;p21	Instead , the cyclin D1-Cdk4 and ***cyclin D1-Cdk6*** complexes in these cells are ***associated*** with an increased amount of ***p21*** , suggesting that p21 may be responsible for inactivation of both cyclin E - and cyclin D1-associated kinase activity at the early stage of senescence .	parallel	0
106	10022904	7124;3551	TNF-alpha;IKKbeta	In contrast , the inhibition of alphaPKC does not affect the ***activation*** of ***IKKbeta*** by ***TNF-alpha*** .	positive	1
107	10022911	3925;8201	Op18;MTs	It was originally proposed that ***Op18*** specifically ***regulates*** dynamic properties of ***MTs*** by associating with tubulin , but it has subsequently been proposed that Op18 acts simply by sequestering of tubulin heterodimers .	target	1
108	10022914	26155;2185	Nir;PYK2	The three ***Nir*** proteins ( Nir1 , Nir2 , and Nir3 ) ***bind*** to the amino-terminal domain of ***PYK2*** via a conserved sequence motif located in the carboxy terminus .	parallel	1
109	10022914	26155;2185	Nir;PYK2	In addition , ******PYK2-Nir****** ***complexes*** are detected in lysates prepared from cultured cells or from brain tissues .	parallel	1
110	10022917	6227;3921	RpS21;P40	***RpS21*** can ***interact*** strongly with ***P40*** , a ribosomal peripheral protein encoded by the stubarista ( sta ) gene .	parallel	1
111	10022923	7157;1026	p53;p21	However , the p53-dependent G1 checkpoint was intact as assessed by functional activation of p53 protein in response to ionizing radiation and subsequent ***p53-mediated*** ***induction*** of ***p21*** ( Waf1/Cip1/Sdi1 ) .	target	1
112	10022926	8900;1869	cyclin A1;E2F-1	The in vitro ***interaction*** of ***cyclin A1*** with ***E2F-1*** was greatly enhanced when cyclin A1 was complexed with CDK2 .	parallel	1
113	10022926	8900;1017	cyclin A1;CDK2	The in vitro interaction of cyclin A1 with E2F-1 was greatly enhanced when ***cyclin A1*** was ***complexed*** with ***CDK2*** .	parallel	1
114	10022926	8900;1869	cyclin A1;E2F-1	***Associations*** of ***cyclin A1*** with Rb and ***E2F-1*** were observed in vivo in several cell lines .	parallel	0
115	10022926	8900;1017	cyclin A1;CDK2	When cyclin A1 was coexpressed with CDK2 in sf9 insect cells , the ******CDK2-cyclin A1****** ***complex*** had kinase activities for histone H1 , E2F-1 , and the Rb family of proteins .	parallel	1
116	10022928	3458;834	IFN-gamma;caspase 1	Furthermore , ***IFN-gamma*** ***induced*** a higher level of ***caspase 1*** expression in Shp-2 ( - / - ) cells than in wild-type cells .	target	1
117	10022929	3987;3611	PINCH;integrin-linked kinase	The LIM-only protein ***PINCH*** directly ***interacts*** with ***integrin-linked kinase*** and is recruited to integrin-rich sites in spreading cells .	parallel	1
118	10022929	3611;3987	ILK;PINCH	The ***interaction*** between ***ILK*** and ***PINCH*** has been consistently observed under a variety of experimental conditions .	parallel	1
119	10022929	3611;3987	ILK;PINCH	The ******PINCH-ILK****** ***interaction*** is mediated by the N-terminal-most LIM domain ( LIM1 , residues 1 to 70 ) of PINCH and multiple ankyrin ( ANK ) repeats located within the N-terminal domain ( residues 1 to 163 ) of ILK .	parallel	1
120	10022950	652;2247	BMP-4;bFGF	BMP-2 plus bFGF also induced numerous leukocytes and fewer erythrocytes , but ***BMP-4*** ***antagonized*** the leukopoietic effect of ***bFGF*** .	negative	1
121	10023011	596;947	Bcl-2;CD34	***Bcl-2*** over-expression is ***associated*** with ***CD34*** positivity , poor response to chemotherapy and reduced overall survival in AML patients .	parallel	0
122	10023660	8945;8454	beta-Trcp;Cul1	The human F box protein ***beta-Trcp*** ***associates*** with the ***Cul1/Skp1*** complex and regulates the stability of beta-catenin .	parallel	0
123	10023660	8945;6500	beta-Trcp;Skp1	The human F box protein ***beta-Trcp*** ***associates*** with the ***Cul1/Skp1*** complex and regulates the stability of beta-catenin .	parallel	0
124	10023660	6500;8454	Skp1;Cul1	The human F box protein beta-Trcp associates with the ******Cul1/Skp1****** ***complex*** and regulates the stability of beta-catenin .	parallel	1
125	10023660	8945;1499	beta-Trcp;beta-catenin	The human F box protein ***beta-Trcp*** associates with the Cul1/Skp1 complex and ***regulates*** the stability of ***beta-catenin*** .	target	1
126	10023660	8945;1499	beta-Trcp;beta-catenin	Consistent with recent reports indicating that Xenopus and Drosophila beta-Trcp homologs act as negative regulators of the Wnt/beta-catenin signaling pathway , we report here that human ***beta-Trcp*** ***interacts*** with ***beta-catenin*** in vivo .	parallel	1
127	10023660	8945;1499	beta-Trcp;beta-catenin	Furthermore , ***beta-catenin*** is specifically ***stabilized*** in vivo by the expression of a dominant negative ***beta-Trcp*** .	positive	0
128	10023668	7704;890	PLZF;cyclin A2	***PLZF*** can ***bind*** and repress the ***cyclin A2*** promoter while expression of cyclin A2 reverts the growth suppressed phenotype of myeloid cells expressing PLZF .	parallel	1
129	10023669	5371;7341	PML;SUMO-1	***PML*** and Sp100 proteins are covalently ***linked*** to ***SUMO-1*** , and ubiquitin-like peptide .	parallel	0
130	10023669	6672;7341	Sp100;SUMO-1	PML and ***Sp100*** proteins are covalently ***linked*** to ***SUMO-1*** , and ubiquitin-like peptide .	parallel	0
131	10023673	8312;1499	Axin;beta-catenin	***Axin*** ***prevents*** Wnt-3a-induced accumulation of ***beta-catenin*** .	negative	0
132	10023673	6934;1499	Tcf-4;beta-catenin	Axin also suppressed Wnt-3a-dependent activation of ***Tcf-4*** which ***binds*** to ***beta-catenin*** and acts as a transcription factor .	parallel	1
133	10023673	8312;6934	Axin;Tcf-4	***Axin*** also ***suppressed*** Wnt-3a-dependent activation of ***Tcf-4*** which binds to beta-catenin and acts as a transcription factor .	negative	1
134	10023675	4066;4790	LYL1;p105	Physical ***interaction*** of the bHLH ***LYL1*** protein and NF-kappaB1 ***p105*** .	parallel	1
135	10023675	4066;4790	LYL1;p105	The ***association*** between ***LYL1*** and ***p105*** was confirmed both in vitro and in vivo in mammalian cells .	parallel	0
136	10023677	861;3562	AML1;IL-3	Our results demonstrate that ***TEL-AML1*** ***represses*** basal ***IL-3*** promoter activity in lymphoid cells , and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression ; the HLH ( pointed ) motif contained in the TEL portion of TEL-AML1 , and both the runt homology domain ( Rhd ) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein .	negative	1
137	10023677	2120;3562	TEL;IL-3	Our results demonstrate that ***TEL-AML1*** ***represses*** basal ***IL-3*** promoter activity in lymphoid cells , and deletion mutant analysis identified three distinct domains of TEL-AML1 that are required for repression ; the HLH ( pointed ) motif contained in the TEL portion of TEL-AML1 , and both the runt homology domain ( Rhd ) and the 74 amino acids downstream of the Rhd that are present in the AML1 portion of the fusion protein .	negative	1
138	10023679	1457;328	CKII;REF-1	***Phosphorylation*** of the DNA repair protein ***APE/REF-1*** by ***CKII*** affects redox regulation of AP-1 .	target	1
139	10023679	1457;328	CKII;REF-1	Here we demonstrate that ***APE/REF-1*** is ***phosphorylated*** by casein kinase II ( ***CKII*** ) .	target	1
140	10023679	1457;328	CKII;REF-1	***CKII*** ***mediated*** phosphorylation of ***APE/REF-1*** and concomitant increase in AP-1 binding activity appears to be a novel mechanism of cellular stress response , forcing transcription of AP-1 target gene ( s ) the product ( s ) of which may exert protective function .	target	0
141	10023684	7040;1490	TGFbeta;CTGF	***TGFbeta*** ***increased*** ***CTGF*** transcript levels in 2/7 pancreatic cancer cell lines after 4 h of treatment and this elevation was sustained after 24 h.	positive	0
142	10023772	3821;3824	NKG2;CD94	The formation of this dimer reveals a putative ligand-binding region for HLA-E and suggests how ***NKG2*** ***interacts*** with ***CD94*** .	parallel	1
143	10023776	29760;6850	BLNK;Syk	***BLNK*** ( B cell LiNKer protein ) , a ***substrate*** for ***Syk*** , is now shown to be essential in activating phospholipase C (PLC)gamma 2 and JNK .	parallel	1
144	10023776	29760;5599	BLNK;JNK	As JNK activation requires both Rac1 and PLC gamma 2 , our results suggest that ***BLNK*** ***regulates*** the ***Rac1-JNK*** pathway , in addition to modulating PLC gamma 2 localization .	target	1
145	10023776	29760;5879	BLNK;Rac1	As JNK activation requires both Rac1 and PLC gamma 2 , our results suggest that ***BLNK*** ***regulates*** the ***Rac1-JNK*** pathway , in addition to modulating PLC gamma 2 localization .	target	1
146	10023776	5599;5336	JNK;PLC gamma 2	As ***JNK*** activation ***requires*** both Rac1 and ***PLC gamma 2*** , our results suggest that BLNK regulates the Rac1-JNK pathway , in addition to modulating PLC gamma 2 localization .	target	0
147	10023776	5599;5879	JNK;Rac1	As ***JNK*** activation ***requires*** both ***Rac1*** and PLC gamma 2 , our results suggest that BLNK regulates the Rac1-JNK pathway , in addition to modulating PLC gamma 2 localization .	target	0
148	10023777	3606;3576	IL-18;IL-8	IL-18BP abolished ***IL-18*** ***induction*** of interferon-gamma ( IFNgamma ) , ***IL-8*** , and activation of NF-kappaB in vitro .	target	1
149	10023777	3606;3458	IL-18;interferon-gamma	IL-18BP abolished ***IL-18*** ***induction*** of ***interferon-gamma*** ( IFNgamma ) , IL-8 , and activation of NF-kappaB in vitro .	target	1
150	10023777	3606;4790	IL-18;NF-kappaB	IL-18BP abolished ***IL-18*** ***induction*** of interferon-gamma ( IFNgamma ) , IL-8 , and activation of ***NF-kappaB*** in vitro .	target	1
151	10023777	10068;3606	IL-18BP;IL-18	***IL-18BP*** ***abolished*** ***IL-18*** induction of interferon-gamma ( IFNgamma ) , IL-8 , and activation of NF-kappaB in vitro .	negative	0
152	10023777	10068;3458	IL-18BP;IFNgamma	Administration of ***IL-18BP*** to mice ***abrogated*** circulating ***IFNgamma*** following LPS .	negative	0
153	10023777	10068;51497	IL-18BP;Th1	Thus , ***IL-18BP*** functions as an ***inhibitor*** of the early ***Th1*** cytokine response .	negative	1
154	10023862	3458;941	IFN-gamma;CD80	We concluded that CD80 and CD86 were differentially expressed and modulated on monocytes and the defective ***IFN-gamma-induced*** ***up-regulation*** of ***CD80*** and CD86 expression on SLE monocytes might be a factor in the pathogenesis of SLE .	positive	1
155	10023862	3458;942	IFN-gamma;CD86	We concluded that CD80 and CD86 were differentially expressed and modulated on monocytes and the defective ***IFN-gamma-induced*** ***up-regulation*** of CD80 and ***CD86*** expression on SLE monocytes might be a factor in the pathogenesis of SLE .	positive	1
156	10023862	3586;942	IL-10;CD86	***IL-10*** ***down-regulated*** the expression of ***CD86*** while it slightly enhanced that of CD80 .	negative	1
157	10023862	3458;941	Interferon-gamma;CD80	***Interferon-gamma*** ( IFN-gamma ) ***increased*** both ***CD80*** and CD86 expression on monocytes from both SLE patients and normal groups , albeit less significantly in the former than in the latter , i.e.	positive	0
158	10023862	3458;942	Interferon-gamma;CD86	***Interferon-gamma*** ( IFN-gamma ) ***increased*** both CD80 and ***CD86*** expression on monocytes from both SLE patients and normal groups , albeit less significantly in the former than in the latter , i.e.	positive	0
159	10024310	183;9312	Angiotensin II;kv2.2	***Angiotensin II*** type 1 receptor-mediated ***inhibition*** of K + channel subunit ***kv2.2*** in brain stem and hypothalamic neurons .	negative	1
160	10024503	3949;4018	LDLR;lipoprotein	In the absence of at least the ***low-density-lipoprotein*** ***receptor*** ( ***LDLR*** ) , it was shown that APOC1 overexpression in transgenic mice inhibited the hepatic uptake of VLDL via the LDLR-related protein .	parallel	1
161	10024512	2321;7422	FLT-1;vascular endothelial growth factor	We identified ***vascular endothelial growth factor*** ( VEGF ) and its ***receptor*** fms-like tyrosine kinase ( ***FLT-1*** ) to be under the regulatory control of exogenously applied NO in these cells .	parallel	1
162	10024512	2321;7422	FLT-1;VEGF	Obviously , there is a differential regulation of ***VEGF*** and its ***receptor*** ***FLT-1*** by NO , cytokines and growth factors in rat mesangial cells .	parallel	1
163	10024514	207;5599	Rac;JNK	N17 ***Rac*** non-selectively ***reduced*** ***JNK*** activity by 30 % in resting or stimulated cells ( IL-1 alone , or with PDGF ) .	negative	1
164	10024514	207;5599	Rac;JNK	V12 ***Rac*** weakly ***activated*** ***JNK*** and synergized with IL-1 , but not with PDGF .	positive	1
165	10024514	998;5599	Cdc42;JNK	V12 ***Cdc42*** weakly ***activated*** ***JNK*** , but synergized with PDGF and not IL-1 .	positive	1
166	10024519	6774;2353	STAT3;c-Fos	We have examined the effects of l-thyroxine ( T4 ) on the activation of signal transducer and activator of transcription 3 ( STAT3 ) and on the ***STAT3-dependent*** ***induction*** of ***c-Fos*** expression by epidermal growth factor ( EGF ) .	target	1
167	10024877	2073;4913	XPG;hNth1	***XPG*** protein ***promotes*** binding of ***hNth1*** to damaged DNA .	positive	0
168	10025511	1050;1647	C/EBP alpha;gadd45	Reciprocal ***regulation*** of ***gadd45*** by ***C/EBP alpha*** and c-Myc .	target	1
169	10025511	4609;1647	c-Myc;gadd45	Reciprocal ***regulation*** of ***gadd45*** by C/EBP alpha and ***c-Myc*** .	target	1
170	10025511	1050;1647	C/EBP alpha;gadd45	We report here that ***C/EBP alpha*** directly ***regulates*** ***gadd45*** through a C/EBP-binding site in the proximal promoter .	target	1
171	10025511	1050;1647	C/EBP alpha;gadd45	We also found that c-Myc antagonized ***C/EBP alpha-mediated*** ***transactivation*** of ***gadd45*** .	positive	1
172	10025511	4609;1647	c-Myc;gadd45	We also found that ***c-Myc*** ***antagonized*** C/EBP alpha-mediated transactivation of ***gadd45*** .	negative	1
173	10025673	2885;867	Grb2;Cbl	In the membrane fraction of cells stimulated at 4 degrees C , the ***association*** of p58Shc and ***Grb2*** with ***Cbl*** is stable , whereas its association with Sos and p85 is transient and their dissociation occurs at the time CSF-1 R and Cbl multiubiquitination commence .	parallel	0
174	10025891	596;1029	bcl-2;p16ink4a	Among the cell cycle-related proteins we analyzed , only p21waf1 ***bcl-2*** and CDK4 were significantly and positively ***correlated*** to ***p16ink4a*** .	parallel	0
175	10025891	1019;1029	CDK4;p16ink4a	Among the cell cycle-related proteins we analyzed , only p21waf1 bcl-2 and ***CDK4*** were significantly and positively ***correlated*** to ***p16ink4a*** .	parallel	0
176	10025918	3553;7040	IL-1beta;TGFbeta	RESULTS : ***IL-1beta*** ***increased*** active ***TGFbeta*** in chondrocyte CM by 12 hours ; by 24 hours , significant increases in both active and latent TGFbeta were detectable .	positive	0
177	10026128	3479;4191	IGF-I;MDH	***IGF-I*** ***induced*** PK and ***MDH*** activities in class 1 follicles but negatively influenced PFK activity for class 1 follicles .	target	1
178	10026131	10457;2064	transmembrane glycoprotein;ErbB2	ASGP2 , a ***transmembrane glycoprotein*** found on the surface of the highly metastatic ascites 13762 rat mammary adenocarcinoma cell line , is constitutively ***associated*** with ***ErbB2*** in these cells and in mammary tissue from pregnant rats .	parallel	0
179	10026131	2064;3084	ErbB2;neuregulin-1	Ectopic expression of ASGP2 in human melanoma tumor cells potentiates the ***response*** of endogenous ***ErbB2*** to the ***neuregulin-1*** growth factor .	parallel	0
180	10026136	3483;3486	ALS;IGFBP-3	Ionic interactions are known to be involved in the ***association*** between ***ALS*** and ***IGFBP-3*** .	parallel	0
181	10026138	9474;836	Asp;caspase-3	The pretreatment with ***acetyl-Tyr-Val-Ala-Asp-aldehyde*** , a relatively selective ***inhibitor*** of ***caspase-3*** , or benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone ( z-VAD .	negative	1
182	10026139	3217;4792	HOXB7;IkappaB-alpha	In this report , we demonstrated that the ***HOXB7*** homeodomain-containing protein , which plays a key role in development and differentiation , physically ***interacted*** in vitro with ***IkappaB-alpha*** , an inhibitor of NF-kappaB activity .	parallel	1
183	10026139	4792;4790	IkappaB-alpha;NF-kappaB	In this report , we demonstrated that the HOXB7 homeodomain-containing protein , which plays a key role in development and differentiation , physically interacted in vitro with ***IkappaB-alpha*** , an ***inhibitor*** of ***NF-kappaB*** activity .	negative	1
184	10026141	3717;23368	Jak2;p85	These results suggest that stimulation of the activity of PI3-kinase induced by GM-CSF is mediated by Jak2 and that the ***association*** between ***Jak2*** and ***p85*** depends on an adaptor protein yet to be identified .	parallel	0
185	10026156	6624;1499	actin-bundling protein;beta-catenin	We have discovered that , as part of this process , the synthetic glucocorticoid dexamethasone strongly and reversibly down-regulated the expression of fascin , an ***actin-bundling protein*** that also ***interacts*** with the adherens junction component ***beta-catenin*** .	parallel	1
186	10026169	8440;25	Grb4;v-Abl	Although neither protein was transforming on its own , both Nck and ***Grb4*** ***cooperated*** with ***v-Abl*** to transform NIH 3T3 cells and influenced the morphology and anchorage-dependent growth of wild type Ras-transformed cells .	parallel	0
187	10026169	4690;25	Nck;v-Abl	Although neither protein was transforming on its own , both ***Nck*** and Grb4 ***cooperated*** with ***v-Abl*** to transform NIH 3T3 cells and influenced the morphology and anchorage-dependent growth of wild type Ras-transformed cells .	parallel	0
188	10026178	3791;7422	VEGFR;Vascular endothelial growth factor	The potential binding site of VEGF with its receptor was identified using cellulose-bound overlapping peptides of the extracytosolic part of the human ***Vascular endothelial growth factor*** ***receptor*** II ( ***VEGFR*** II ) .	parallel	1
189	10026179	4036;5741	Megalin;PTH	Here , we demonstrate that ***Megalin*** , a multifunctional endocytic receptor in the proximal tubular epithelium , ***mediates*** the uptake and degradation of ***PTH*** .	target	0
190	10026179	4036;5741	Megalin;PTH	These data provide evidence that ***Megalin*** is involved in the renal catabolism of PTH and potentially ***antagonizes*** ***PTH/PTHrP*** receptor activity in the proximal tubular epithelium .	negative	1
191	10026184	580;672	BARD1;BRCA1	To characterize functional aspects of the ******BRCA1/BARD1****** ***interaction*** , we have defined the structural domains required for the interaction , as well as their oligomerization state , relative stability , and possible nucleic acid binding activity .	parallel	1
192	10026196	3589;3572	IL-11;gp130	In this study , we have identified residues crucial for the ***binding*** of murine ***IL-11*** ( mIL-11 ) to both the IL-11R and ***gp130*** by examining the activities of mIL-11 mutants in receptor binding and cell proliferation assays .	parallel	1
193	10026205	7040;1490	TGF-beta1;CTGF	High glucose stimulated expression of transforming growth factor beta1 ( TGF-beta1 ) , and addition of ***TGF-beta1*** to mesangial cells ***triggered*** ***CTGF*** expression .	positive	0
194	10026206	959;958	CD154;CD40	Ligation of CD40 on monocytes through its interaction with ***CD40*** ***ligand*** ( ***CD154*** ) present on activated T helper cells , results in activation of monocyte inflammatory cytokine synthesis and rescue of monocytes from apoptosis induced through serum deprivation .	parallel	1
195	10026206	958;3553	CD40;IL-1beta	Together , the data demonstrate that ***CD40-mediated*** ***induction*** of ***IL-1beta*** and tumor necrosis factor-alpha synthesis is dependent on a MEK/ERK pathway which is obstructed by signals generated through the action of IL-4 and il-10 .	target	1
196	10026206	958;7124	CD40;tumor necrosis factor-alpha	Together , the data demonstrate that ***CD40-mediated*** ***induction*** of IL-1beta and ***tumor necrosis factor-alpha*** synthesis is dependent on a MEK/ERK pathway which is obstructed by signals generated through the action of IL-4 and il-10 .	target	1
197	10026208	4773;3170	NFATp;HNF-3beta	A mutational analysis of G2 function and nuclear protein binding as well as the effect of FK506 indicate that calcium responsiveness is conferred to the G2 element by ***NFATp*** functionally ***interacting*** with ***HNF-3beta*** binding to a closely associated site .	parallel	1
198	10026215	190;2516	DAX-1;SF-1	In contrast , overexpression of ***DAX-1*** markedly ***diminished*** the ***SF-1*** mRNA expression , and concomitantly abolished T3-mediated responses .	negative	0
199	10026222	3937;2207	SLP-76;FcR gamma	Immunoprecipitation studies demonstrate ***association*** of ***SLP-76*** with SLAP-130 , Vav , Fyn , Lyn , and the ***FcR gamma-chain*** in CRP-stimulated platelets .	parallel	0
200	10026222	3937;2534	SLP-76;Fyn	Immunoprecipitation studies demonstrate ***association*** of ***SLP-76*** with SLAP-130 , Vav , ***Fyn*** , Lyn , and the FcR gamma-chain in CRP-stimulated platelets .	parallel	0
201	10026222	3937;4067	SLP-76;Lyn	Immunoprecipitation studies demonstrate ***association*** of ***SLP-76*** with SLAP-130 , Vav , Fyn , ***Lyn*** , and the FcR gamma-chain in CRP-stimulated platelets .	parallel	0
202	10026222	3937;2533	SLP-76;SLAP-130	Immunoprecipitation studies demonstrate ***association*** of ***SLP-76*** with ***SLAP-130*** , Vav , Fyn , Lyn , and the FcR gamma-chain in CRP-stimulated platelets .	parallel	0
203	10026223	5590;5594	PKC zeta;ERK	The data are explained by a model in which ***ERK*** activity is ***modulated*** by differential effects of ***PKC zeta*** and PKA on Raf isoforms .	target	0
204	10026224	100506658;7082	occludin;ZO-1	Consistently , ***occludin*** as well as alpha catenin directly ***bound*** to N-ZO-2 as well as the NH2-terminal dlg-like portion of ***ZO-1*** ( N-ZO-1 ) in vitro .	parallel	1
205	10026224	100506658;9414	occludin;ZO-2	Consistently , ***occludin*** as well as alpha catenin directly ***bound*** to ***N-ZO-2*** as well as the NH2-terminal dlg-like portion of ZO-1 ( N-ZO-1 ) in vitro .	parallel	1
206	10026224	9414;100506658	ZO-2;occludin	These findings indicated that ***ZO-2*** forms a ***complex*** with ***ZO-1/occludin*** or ZO-1/alpha catenin to establish TJ or AJ domains , respectively .	parallel	1
207	10026224	9414;7082	ZO-2;ZO-1	These findings indicated that ***ZO-2*** forms a ***complex*** with ***ZO-1/occludin*** or ZO-1/alpha catenin to establish TJ or AJ domains , respectively .	parallel	1
208	10026226	6261;3708	RYR1;IP3 receptor	These results indicate that RYR1 functions as a Ca2 + release channel during BCR-stimulated Ca2 + signaling and suggest that complex Ca2 + signals that control the cellular activities of B cells may be generated by ***cooperation*** of the ***IP3 receptor*** and ***RYR1*** .	parallel	0
209	10026253	998;396	Cdc42;RhoGDI	We propose that this slow step in the observed kinetics reflects the time-course of translocation of the geranyl-geranyl lipid tail of Cdc42 from the outer leaflet of the membrane to the isoprenyl binding site observed in the previously reported NMR structure of the ******Cdc42-RhoGDI****** ***complex*** [ Gosser et al. ( 1997 ) Nature 387 , 814 ] .	parallel	1
210	10026253	396;998	RhoGDI;Cdc42	In this report , we have set out to address this issue by using fluorescence resonance energy transfer approaches to examine the functional ***interactions*** of the ***RhoGDI*** with membrane-associated ***Cdc42*** .	parallel	1
211	10026253	396;998	RhoGDI;Cdc42	This assay allowed us to directly monitor the ***binding*** of ***RhoGDI*** to membrane-associated ***Cdc42*** .	parallel	1
212	10026253	998;396	Cdc42;RhoGDI	Specifically , we propose that the GDI first binds rapidly to membrane-associated Cdc42 and then a slower isomerization occurs which represents the rate-limiting step for the dissociation of the ******Cdc42-RhoGDI****** ***complex*** from membranes .	parallel	1
213	10026256	960;2252	Heparan sulfate proteoglycan;keratinocyte growth factor	***Heparan sulfate proteoglycan*** ***modulates*** ***keratinocyte growth factor*** signaling through interaction with both ligand and receptor .	target	0
214	10026256	2252;2263	KGF;KGFR	In contrast to events on the cell surface , added heparin was not required for high-affinity soluble ******KGF-KGFR****** ***interaction*** .	parallel	1
215	10026303	5970;2353	p65;c-Fos	Moreover , incubating MCF-7 nuclear extracts with antibodies specific for NF-kappa B/p65 or c-Fos in EMSAs almost completely inhibited formation of the complex , supporting the ***association*** of NF-kappa ***B/p65*** and ***c-Fos*** .	parallel	0
216	10026303	5970;2353	p65;c-Fos	Therefore , this study provides evidence that molecular ***interplay*** between the NF-kappa ***B/p65*** and ***c-Fos*** transcription factors exhibits a negative regulatory function on MDR1 promoter by interacting with the CAAT region in MCF-7 .	parallel	1
217	10026833	551;359	AVP;AQP2	Thus , non-osmotic release of ***AVP*** in CHF ***upregulates*** ***AQP2*** water channels , enhances water reabsorption and causes hyponatremia .	positive	1
218	10027007	5979;2668	Ret;glial cell line-derived neurotrophic factor	***Ret*** is the ***receptor*** for ***glial cell line-derived neurotrophic factor*** ( GDNF ) and neurturin ( NTN ) .	parallel	1
219	10027007	5979;4902	Ret;neurturin	***Ret*** is the ***receptor*** for glial cell line-derived neurotrophic factor ( GDNF ) and ***neurturin*** ( NTN ) .	parallel	1
220	10027289	4915;627	TrkB;BDNF	We show here that brain-derived neurotrophic factor ( BDNF ) is present in the HVC of adult males but is not detectable in that of females , though the HVC of both sexes has ***BDNF*** ***receptors*** ( ***TrkB*** ) .	parallel	1
221	10027393	7422;7057	VEGF;thrombospondin-1	In bovine retinal microcapillary endothelial cells , VEGF induced a biphasic response of thrombospondin-1 expression ; ***VEGF*** ***decreased*** ***thrombospondin-1*** mRNA 0.41-fold after 4 hours , whereas it increased , with a threefold peak response , after 24 hours .	negative	0
222	10027393	7422;7057	VEGF;thrombospondin-1	The present findings suggest that , in the ischemic retina , retinal neovascular cells increase thrombospondin-1 expression , and ***VEGF*** may ***stimulate*** endogenous ***thrombospondin-1*** induction , which inhibits endothelial cell growth .	positive	0
223	10027409	84260;1499	tumor suppressor protein;beta-catenin	This suggests a link with disruption of Apc ***tumor suppressor protein-mediated*** ***regulation*** of ***beta-catenin/Tcf-4*** signaling , which is crucial in initiating tumorigenesis .	target	1
224	10027409	84260;6934	tumor suppressor protein;Tcf-4	This suggests a link with disruption of Apc ***tumor suppressor protein-mediated*** ***regulation*** of ***beta-catenin/Tcf-4*** signaling , which is crucial in initiating tumorigenesis .	target	1
225	10027409	1499;6934	beta-catenin;Tcf-4	This suggests a link with disruption of Apc tumor suppressor protein-mediated regulation of ******beta-catenin/Tcf-4****** ***signaling*** , which is crucial in initiating tumorigenesis .	parallel	0
226	10027414	3479;7157	Insulin-like growth factor-1;p53	***Insulin-like growth factor-1*** induces Mdm2 and ***down-regulates*** ***p53*** , attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis .	negative	1
227	10027414	3479;4193	Insulin-like growth factor-1;Mdm2	***Insulin-like growth factor-1*** ***induces*** ***Mdm2*** and down-regulates p53 , attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis .	target	1
228	10027414	7157;183	p53;angiotensinogen	Additionally , ***p53*** DNA ***binding*** to ***angiotensinogen*** ( Aogen ) , AT1 receptor , and Bax was markedly down-regulated by IGF-1 via the induction of Mdm2 and the formation of Mdm2-p53 complexes .	parallel	1
229	10027414	7157;581	p53;Bax	Additionally , ***p53*** DNA ***binding*** to angiotensinogen ( Aogen ) , AT1 receptor , and ***Bax*** was markedly down-regulated by IGF-1 via the induction of Mdm2 and the formation of Mdm2-p53 complexes .	parallel	1
230	10027414	7157;4193	p53;Mdm2	Additionally , p53 DNA binding to angiotensinogen ( Aogen ) , AT1 receptor , and Bax was markedly down-regulated by IGF-1 via the induction of Mdm2 and the formation of ******Mdm2-p53****** ***complexes*** .	parallel	1
231	10027414	3479;7157	IGF-1;p53	Additionally , ***p53*** DNA binding to angiotensinogen ( Aogen ) , AT1 receptor , and Bax was markedly ***down-regulated*** by ***IGF-1*** via the induction of Mdm2 and the formation of Mdm2-p53 complexes .	negative	1
232	10027414	4193;7157	Mdm2;p53	The effects of IGF-1 on cell death , Ang II synthesis , and Bax protein were the consequence of ***Mdm2-induced*** ***down-regulation*** of ***p53*** function .	negative	1
233	10027616	5020;5021	oxytocin;oxytocin receptor	In the present study , we investigated the possible mechanisms by which ***oxytocin*** might ***regulate*** ***oxytocin receptor*** ( OTR ) density .	target	1
234	10027649	3458;10379	IFN-gamma;p48	To understand how ***IFN-gamma*** ***regulates*** the expression of the ***p48*** gene , we have previously isolated and characterized the promoter of murine p48 gene and identified a novel gamma-IFN activated transcriptional element ( GATE ) .	target	1
235	10027715	3700;2353	gp120;c-fos	HIV-1 ***gp120*** ***induces*** the activation of both ***c-fos*** and c-jun immediate-early genes in HEL megakaryocytic cells .	target	1
236	10027715	3700;3725	gp120;c-jun	HIV-1 ***gp120*** ***induces*** the activation of both c-fos and ***c-jun*** immediate-early genes in HEL megakaryocytic cells .	target	1
237	10027778	3586;3558	IL-10;IL-2	Exogenous recombinant ***IL-10*** ***inhibited*** proliferation and ***IL-2*** induction in response to peptide 358-375 .	negative	1
238	10027780	3566;3565	CD124;IL-4	There was no increase in the ***IL-4*** ***receptor*** ( ***CD124*** ) .	parallel	1
239	10027830	7124;1571	TNF-alpha;CYP2E1	CYP2D9 and CYP2E1 activities show differential responses to LPS between wild-type and TNF p55/p75 receptor knockout mice , indicating the down-regulation of CYP2D9 and ***CYP2E1*** is differentially ***modulated*** by ***TNF-alpha*** expression .	target	0
240	10027830	7124;1571	TNF-alpha;CYP2E1	Furthermore , ***TNF-alpha*** appears to ***affect*** the constitutive expression of CYP2D9 and ***CYP2E1*** .	target	0
241	10027904	860;3381	Osf2;BSP	***Osf2*** , a member of the Cbf/runt family of transcription factors , is required for the development of osteoblasts in vivo and has been reported to ***stimulate*** the transcription of ***BSP*** when overexpressed in mesenchymal cell lines .	positive	0
242	10027904	860;3381	Osf2;BSP	These results suggest that ***Osf2*** ***binding*** to the ***BSP*** promoter is not essential for its osteoblast-selective expression .	parallel	1
243	10027928	1356;4353	ceruloplasmin;myeloperoxidase	The ***inhibition*** of ***myeloperoxidase*** by ***ceruloplasmin*** can be reversed by anti-myeloperoxidase antibodies .	negative	1
244	10027928	1356;4353	ceruloplasmin;myeloperoxidase	BACKGROUND : The purpose of this study was to characterize the recently reported ***inhibition*** of ***myeloperoxidase*** ( MPO ) by ***ceruloplasmin*** and to determine whether this may be disturbed in the presence of anti-MPO antibodies .	negative	1
245	10028017	958;959	CD40;CD40L	The ***interaction*** of ***CD40*** on antigen presenting cells ( APC ) with ***CD40L*** on mouse thyroglobulin ( MTg ) - specific T cells may deliver an essential signal for the development of CD4 ( + ) experimental autoimmune thyroiditis ( EAT ) effector cells and anti-MTg producing B cells .	parallel	1
246	10028017	958;959	CD40;CD40L	To determine the requirement for ******CD40-CD40L****** ***interactions*** in G-EAT , donor mice were injected with an anti-CD40L monoclonal antibody ( mAb ) on days -1 , 0 , and +1 relative to immunization with MTg and adjuvant .	parallel	1
247	10028017	958;959	CD40;CD40L	Addition of anti-CD40L during in vitro activation of MTg-primed spleen cells or treatment of recipients with anti-CD40L had no effect on EAT severity , indicating that ******CD40-CD40L****** ***interactions*** are not required after EAT effector cells are primed to MTg .	parallel	1
248	10029063	5727;8643	PTCH1;PTCH2	In situ hybridization revealed high expression of PTCH2 transcripts in both familial and sporadic basal cell carcinomas in similarity to what has been observed for PTCH1 , suggesting a negative ***regulation*** of ***PTCH2*** by ***PTCH1*** .	negative	1
249	10029089	1009;1499	Cadherin-11;beta-catenin	***Cadherin-11*** is localized to a detergent-soluble pool and is ***associated*** with both alpha - and ***beta-catenin*** .	parallel	0
250	10029091	2925;2922	GRP-R;Bombesin	The pathophysiological relevance of the ***Bombesin/GRP*** ***receptor*** ( ***GRP-R*** ) , which is expressed in 30 % of human colon tumor cell lines and in 24-40 % of native tumors , has not been clearly assessed at this time .	parallel	1
251	10029157	3458;1033	Interferon-gamma;cyclin-dependent kinase inhibitor	***Interferon-gamma*** ***impairs*** physiologic downregulation of ***cyclin-dependent kinase inhibitor*** , p27Kip1 , during G1 phase progression in macrophages .	negative	0
252	10029157	1027;1017	p27Kip1;CDK2	The steady , relatively high-level ***attachment*** of ***p27Kip1*** to ***CDK2*** contributed to the insufficient formation of active cyclin/CDK2 , possibly deferring cells from entering S phase .	parallel	0
253	10029158	3553;1440	IL-1beta;granulocyte colony-stimulating factor	***IL-1beta*** ***mediates*** diethyldithiocarbamate-induced ***granulocyte colony-stimulating factor*** production and hematopoiesis .	target	0
254	10029158	3553;1440	IL-1beta;G-CSF	Administration of IL-1 receptor antagonist ( IL-1ra ) to DDTC-treated hLTBMCs obviated the G-CSF induction profile and blocked the resultant colony proliferation , indicating that ***IL-1beta*** ***mediates*** DDTC-induced ***G-CSF*** release and hematopoiesis .	target	0
255	10029247	920;3700	CD4;gp120	CD4-specific monoclonal antibodies ( CG1 , CG7 , and CG8 ) , which bind with a 5 - to 10-fold higher avidity to preformed ******CD4-gp120****** ***complexes*** than to CD4 , were previously shown to recognize newly identified conformational epitopes in the D1-CDR3 region of CD4 .	parallel	1
256	10029247	920;3700	CD4;gp120	In these assays , the CD4-specific MAbs CG1 , -7 , and -8 stabilized the ***association*** of coreceptor , ***gp120*** , and ***CD4*** in trimolecular complexes .	parallel	0
257	10029249	942;941	CD86;CD80	Using this approach , we found an ***association*** between productive infection and increased expression of ***CD80*** and ***CD86*** .	parallel	0
258	10029294	4312;7076	MMP-1;tissue inhibitor of metalloproteinases (TIMP)-1	Our objectives in the present study were to observe the change in the serum MMP-1 protein concentration using recently developed specific enzyme immunoassays for ***MMP-1*** and MMP-1 ***complexed*** with ***tissue inhibitor of metalloproteinases (TIMP)-1*** and to elucidate the clinical usefulness of the serum MMP-1 test in chronic viral hepatitis .	parallel	1
259	10029294	4312;7076	MMP-1;TIMP-1	We measured the serum concentrations of MMP-1 and ******MMP-1/TIMP-1****** ***complex*** using these immunoassays in 64 patients with histologically characterized chronic viral hepatitis .	parallel	1
260	10029294	4312;7076	MMP-1;TIMP-1	The serum concentration of ******MMP-1/TIMP-1****** ***complex*** was also related to the histological severity of chronic hepatitis ( P < 0.0001 ) .	parallel	1
261	10029406	7157;1026	p53;p21	Differential ***regulation*** of ***p21*** by ***p53*** and Rb in cellular response to oxidative stress .	target	1
262	10029409	1019;595	cdk4;cyclin D1	Indeed , G1 cell-cycle arrest was accompanied by reduced induction and nuclear accumulation of the ******cyclin D1-cdk4****** ***complex*** and inhibited nuclear translocation of cdk2 .	parallel	1
263	10029448	1634;7040	decorin;TGF-beta1	TGF-beta1 stimulates the synthesis of decorin , and ***decorin*** is considered to ***bind*** ***TGF-beta1*** .	parallel	1
264	10029448	7040;1634	TGF-beta1;decorin	***TGF-beta1*** ***stimulates*** the synthesis of ***decorin*** , and decorin is considered to bind TGF-beta1 .	positive	0
265	10029448	1634;7040	decorin;TGF-beta1	The activity of decorin in neutralizing TGF-beta1 activity suggests that ***decorin*** serves as a negative-feedback ***regulator*** of ***TGF-beta1*** activity .	target	1
266	10029454	7072;4582	TIA-1;EMA	***TIA-1*** staining strongly ***correlated*** with young patient age ( < or = 32 years , P < .05 ) and ***EMA*** expression ( P < .05 ) .	parallel	0
267	10029562	183;1906	Angiotensin II;endothelin-1	***Angiotensin II*** ***increases*** the release of ***endothelin-1*** from human cultured endothelial cells but does not regulate its circulating levels .	positive	0
268	10029562	183;1906	Angiotensin II;endothelin-1	In contrast , ***Angiotensin II*** ( 10 ( -9 ) , 10 ( -8 ) , 10 ( -7 ) mol/l ) ***stimulated*** ***endothelin-1*** secretion from cultured human vascular endothelial cells derived from umbilical cord veins in a time - and dose-dependent manner .	positive	0
269	10029562	183;1906	Angiotensin II;endothelin-1	Our findings indicate that ***Angiotensin II*** ***regulates*** ***endothelin-1*** release by cultured endothelial cells through an AT1 receptor-dependent pathway , but does not influence circulating endothelin-1 levels in vivo .	target	1
270	10029570	7040;3458	TGF-beta;interferon-gamma	Our data indicate that ***TGF-beta*** ***induced*** an inhibition of ***interferon-gamma*** ( IFN-gamma ) production without affecting the IL-12Rbeta1 and IL-12Rbeta2 subunits mRNA expression by activated T cells .	target	1
271	10029585	2057;2056	EPOR;Erythropoietin	***Erythropoietin*** ( EPO ) and its cell surface ***receptor*** ( ***EPOR*** ) play a central role in proliferation , differentiation , and survival of erythroid progenitors .	parallel	1
272	10029626	3458;355	interferon gamma;CD95	In this study , ***modulation*** of the hepatic ***CD95*** receptor/ligand system by ***interferon gamma*** and cyclosporin A was investigated .	target	0
273	10029626	3458;355	interferon gamma;CD95	In liver parenchymal cells , ***interferon gamma*** ***increased*** messenger RNA levels of the transmembrane ***CD95*** isoform and sensitivity of these cells toward CD95-mediated apoptosis .	positive	0
274	10030281	925;7040	CD8;TGF-beta1	***CD8*** cross-linking on BMC ***induced*** secretion of active transforming growth factor-beta1 ( ***TGF-beta1*** ) , suggesting a regulatory mechanism ( s ) operating via a CD8-mediated signaling pathway .	target	1
275	10030292	356;355	FasL;Fas	Finally , recombinant human FasL induced apoptosis in Fas expressing porcine EC cells , demonstrating that human ***FasL*** ***interacted*** with and activated ***Fas*** on porcine EC cells .	parallel	1
276	10030296	7035;2152	hTFPI;tissue factor	They are based on two naturally occurring soluble anticoagulant proteins , human ***tissue factor*** pathway ***inhibitor*** ( ***hTFPI*** ) and the leech protein hirudin , which act early and late in the clotting cascade , respectively .	negative	1
277	10030420	51497;3558	TH1;IL-2	RESULTS : The cellular immune response to recombinant adenovirus is ( 1 ) averted by T lymphocyte depletion , ( 2 ) marked by a ***TH1*** ***response*** with increased ***IL-2*** production , ( 3 ) directed against both the transgene product and viral proteins , and ( 4 ) associated with increased hepatocyte MHC Class I expression .	parallel	0
278	10030670	1869;1026	E2F1;p21	We have found that ***E2F1*** and E2F3 , transcription factors that activate genes required for cell cycle progression , are strong ***activators*** of the ***p21*** promoter .	positive	1
279	10030670	1871;1026	E2F3;p21	We have found that E2F1 and ***E2F3*** , transcription factors that activate genes required for cell cycle progression , are strong ***activators*** of the ***p21*** promoter .	positive	1
280	10030670	26959;1026	HBP1;p21	In contrast , ***HBP1*** ( HMG-box protein-1 ) , a novel retinoblastoma protein-binding protein , can ***repress*** the ***p21*** promoter and inhibit induction of p21 expression by E2F .	negative	1
281	10030670	26959;1026	HBP1;p21	Both E2Fs and ***HBP1*** ***regulate*** ***p21*** transcription through cis-acting elements located between nucleotides -119 to +16 of the p21 promoter and the DNA binding domains of each of these proteins are required for activity .	target	1
282	10030673	5594;3725	Erk2;AP-1	Expression of dominant negative ***Erk2*** ***inhibits*** ***AP-1*** transactivation and neoplastic transformation .	negative	1
283	10030838	3458;6348	IFN-gamma;MIP-1alpha	***IFN-gamma*** ***potentiates*** the release of TNF-alpha and ***MIP-1alpha*** by alveolar macrophages during allergic reactions .	positive	0
284	10030838	3458;7124	IFN-gamma;TNF-alpha	***IFN-gamma*** ***potentiates*** the release of ***TNF-alpha*** and MIP-1alpha by alveolar macrophages during allergic reactions .	positive	0
285	10030838	3497;6348	IgE;MIP-1alpha	Interestingly , IgE/anti-GeneGene 3 treatment did not stimulate the release of MIP-1alpha ( 15 + / - 5 pg/10 ( 6 ) cells ) , but IFN-gamma treatment alone and with IgE / ***anti-IgE*** significantly ***increased*** and potentiated ***MIP-1alpha*** release ( 98 + / - 40 pg/10 ( 6 ) cells ) by alveolar macrophages , respectively .	positive	0
286	10030839	7124;4586	Tumor necrosis factor-alpha;mucin	***Tumor necrosis factor-alpha*** ***stimulates*** ***mucin*** secretion and cyclic GMP production by guinea pig tracheal epithelial cells in vitro .	positive	0
287	10030839	7124;4586	TNF-alpha;mucin	Collectively , the results suggest that ***TNF-alpha*** ***stimulates*** secretion of ***mucin*** by GPTE cells via a mechanism ( s ) dependent on PC-PLC and PKC , and involving activation of NOS , generation of NO , production of cGMP , and activation of PKG .	positive	0
288	10030841	3553;5156	IL-1beta;PDGF-Ralpha	Because ***IL-1beta*** ***upregulates*** both PGE2 production and ***PDGF-Ralpha*** expression , these data suggest that PGE2 functions in a negative feedback loop to limit expression of PDGF-Ralpha and suppress PDGF-stimulated myofibroblast proliferation .	positive	1
289	10030846	3596;7124	IL-13;TNF-alpha	Because activation of eosinophils has been regarded as a crucial event in the pathogenesis of asthmatic inflammation , we tested the hypothesis that IL-4 and ***IL-13*** could ***enhance*** the effects of ***TNF-alpha*** on eosinophil activation .	positive	0
290	10030846	3565;7124	IL-4;TNF-alpha	Because activation of eosinophils has been regarded as a crucial event in the pathogenesis of asthmatic inflammation , we tested the hypothesis that ***IL-4*** and IL-13 could ***enhance*** the effects of ***TNF-alpha*** on eosinophil activation .	positive	0
291	10036234	8676;8773	Syntaxin 11;SNAP-23	***Syntaxin 11*** is ***associated*** with ***SNAP-23*** on late endosomes and the trans-Golgi network .	parallel	0
292	10036235	382;5879	ARF6;Rac1	These observations suggest that ***ARF6*** , a non-Rho family GTPase , can , by itself , alter cortical actin and can ***influence*** the ability of ***Rac1*** to form lamellipodia , in part , by regulating its trafficking to the plasma membrane .	target	0
293	10036238	7432;1080	VIP;CFTR	***CFTR*** channel insertion to the apical surface in rat duodenal villus epithelial cells is ***upregulated*** by ***VIP*** in vivo .	positive	1
294	10036239	4771;7430	merlin;ezrin	Homotypic and heterotypic ***interaction*** of the neurofibromatosis 2 tumor suppressor protein ***merlin*** and the ERM protein ***ezrin*** .	parallel	1
295	10036239	7430;4771	ezrin;merlin	***ezrin*** was ***coimmunoprecipitated*** with ***merlin*** from lysates of human U251 glioma cells and from COS-1 cells transfected with cDNA encoding for merlin isoform I.	parallel	1
296	10036239	7430;4771	ezrin;merlin	The heterotypic ***binding*** of ***merlin*** and ***ezrin*** and the homotypic association of merlin involves interaction between the amino - and carboxy-termini .	parallel	1
297	10036244	8506;1500	p190;p120	We found that activation of v-Src induced ***association*** of tyrosine phosphorylated ***p190*** with ***p120*** ( RasGAP ) and stimulation of p120 ( RasGAP ) - associated RhoGAP activity , although p120 ( RasGAP ) itself was not a target for phosphorylation by v-Src in chicken embryo cells .	parallel	0
298	10036244	8506;1500	p190;p120	Furthermore , these effects were rapidly reversible since switching off v-Src led to dissociation of the ******p190/p120****** ( RasGAP ) ***complex*** , inactivation of p120 ( RasGAP ) - associated RhoGAP activity and re-induction of actin stress fibres .	parallel	1
299	10036280	4803;6336	nerve growth factor;SNS	TTX-R sodium currents and ***SNS*** mRNA expression have been shown to be ***modulated*** by ***nerve growth factor*** ( NGF ) in vitro and in vivo .	target	0
300	10036617	2;5327	alpha 2-macroglobulin;tPA	The present data also demonstrates that the ***activation*** of ***tPA*** by the ***alpha 2-macroglobulin*** fraction is due to the action of a bound proteinase distinct from hPK , indicating the presence of an additional tPA activator .	positive	1
301	10037006	3553;3569	IL-1beta;IL-6	Cytokines , of which TNF-alpha and ***IL-1beta*** produced by MM or accessory cells , were also able to ***stimulate*** ***IL-6*** production by fibroblasts and show additive effects .	positive	0
302	10037006	7124;3569	TNF-alpha;IL-6	Cytokines , of which ***TNF-alpha*** and IL-1beta produced by MM or accessory cells , were also able to ***stimulate*** ***IL-6*** production by fibroblasts and show additive effects .	positive	0
303	10037022	4233;3082	c-Met;hepatocyte growth factor	The role of ***hepatocyte growth factor*** and its ***receptor*** ***c-Met*** in multiple myeloma and other blood malignancies .	parallel	1
304	10037022	4233;3082	c-Met;hepatocyte growth factor	The cytokine ***hepatocyte growth factor*** ( HGF ) and its ***receptor*** ***c-Met*** are a ligand-receptor pair with important functions in a communicative interplay between HGF-producing , mesenchymal cells and c-Met-expressing target cells .	parallel	1
305	10037043	1437;6402	GM-CSF;CD62L	In vivo administration of G-CSF reduced the adherence capacity of CD34 + cells to normal BM stroma ; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34 + cells , while ***GM-CSF*** ***reduced*** the expression of ***CD62L*** .	negative	1
306	10037138	10664;4609	CTCF;c-myc	Differential expression and phosphorylation of ***CTCF*** , a ***c-myc*** transcriptional ***regulator*** , during differentiation of human myeloid cells .	target	1
307	10037138	10664;4609	CTCF;c-myc	***CTCF*** is a transcriptional ***repressor*** of the ***c-myc*** gene .	negative	1
308	10037141	796;43	Calcitonin;acetylcholinesterase	***Calcitonin*** gene-related peptide ***decreases*** expression of ***acetylcholinesterase*** in mammalian myotubes .	negative	0
309	10037150	5894;5604	Raf-1;MEK1	In vitro , however , SB203580-stimulated ***Raf-1*** ***activates*** ***MEK1*** in a coupled assay .	positive	1
310	10037150	5594;5609	ERK;MEK	We conclude that activation of Raf-1 by SB203580 is not mediated by an inhibition of p38 MAPK , is Ras-independent , and is uncoupled from ******MEK/ERK****** ***signaling*** .	parallel	0
311	10037193	355;356	Fas;FasL	USA , 94 : 8144-8149 , 1997 ) that thymineless death in thymidylate synthase-deficient ( TS - ) colon carcinoma cells is mediated via ******Fas/FasL****** ***interactions*** after deoxythymidine ( dThd ) deprivation , and that Fas-dependent sensitivity of human colon carcinoma cell lines may be dependent upon the level of Fas expressed .	parallel	1
312	10037193	355;356	Fas;FasL	The cytotoxic activity of FUra/LV was inhibited by dThd in HT29 cells and also , in part , by NOK-1 + NOK-2 MoAbs that prevent ******Fas/FasL****** ***interactions*** .	parallel	1
313	10037278	7157;596	p53;bcl-2	Since ***bcl-2*** is negatively ***regulated*** by ***p53*** , it could be presumed that the p53 detected in the tumour cells may be non-functional or inactive possibly because of interaction with proteins such as E6 or mdm-2 .	negative	1
314	10037443	2100;2099	ER-beta;ER-alpha	***Binding*** of ***ER-alpha*** and ***ER-beta*** occurred at similar DNA concentrations for some EREs , but different DNA concentrations were required to form complexes of the two receptors with other elements .	parallel	1
315	10037444	2159;5502	factor Xa;inhibitor-1	When added to confluent HUVEC , ***factor Xa*** ***induced*** the expression of tissue factor and the release of tissue-type plasminogen activator and plasminogen activator ***inhibitor-1*** without affecting urokinase expression .	target	1
316	10037444	2159;2152	factor Xa;tissue factor	When added to confluent HUVEC , ***factor Xa*** ***induced*** the expression of ***tissue factor*** and the release of tissue-type plasminogen activator and plasminogen activator inhibitor-1 without affecting urokinase expression .	target	1
317	10037468	2956;4436	MSH6;MSH2	The MutS homologues ***MSH2*** and ***MSH6*** form a heterodimeric protein ***complex*** that is involved in the recognition of base/base mismatches and insertion/deletion loops , as well as some other types of DNA damage .	parallel	1
318	10037506	2743;10243	glycine receptor beta-subunit;gephyrin	Hydrophobic interactions mediate ***binding*** of the ***glycine receptor beta-subunit*** to ***gephyrin*** .	parallel	1
319	10037681	5578;5337	PKC-alpha;PLD1	Successful ***interaction*** of ARF and ***PKC-alpha*** with ***PLD1*** was not achieved , but a C-terminal fragment of human PLD1 ( denoted " D4 " ) interacted with the active mutant of RhoA , RhoAVal-14 .	parallel	1
320	10037682	4001;836	lamin B1;caspase-3	Lithium pretreatment blocks glutamate-induced cytochrome c release and cleavage of ***lamin B1*** , a nuclear ***substrate*** for ***caspase-3*** .	parallel	1
321	10037686	8784;7185	AITR;TNF receptor-associated factor 1	***AITR*** ***associates*** with TRAF1 ( ***TNF receptor-associated factor 1*** ) , TRAF2 , and TRAF3 , and induces nuclear factor ( NF ) - kappaB activation via TRAF2 .	parallel	0
322	10037686	8784;7186	AITR;TRAF2	***AITR*** ***associates*** with TRAF1 ( TNF receptor-associated factor 1 ) , ***TRAF2*** , and TRAF3 , and induces nuclear factor ( NF ) - kappaB activation via TRAF2 .	parallel	0
323	10037686	8784;7187	AITR;TRAF3	***AITR*** ***associates*** with TRAF1 ( TNF receptor-associated factor 1 ) , TRAF2 , and ***TRAF3*** , and induces nuclear factor ( NF ) - kappaB activation via TRAF2 .	parallel	0
324	10037694	3667;3643	IRS-1;insulin receptor	Phosphotyrosine binding ( PTB ) domains of the adaptor protein Shc and ***insulin receptor*** ***substrate*** ( ***IRS-1*** ) interact with a distinct set of activated and tyrosine-phosphorylated cytokine and growth factor receptors and play important roles in mediating mitogenic signal transduction .	parallel	1
325	10037706	5034;811	PDI;calreticulin	Using this technique we demonstrate that ***PDI*** ***interacts*** with ***calreticulin*** at low Ca2 + concentration ( below 100 microM ) , whereas the protein complex dissociates at > 400 microM Ca2 + .	parallel	1
326	10037706	2923;811	ERp57;calreticulin	***ERp57*** also ***interacts*** with ***calreticulin*** through the N-domain of the protein .	parallel	1
327	10037723	4292;5395	hMLH1;hPMS2	These data confirm that functional deficiencies in the ***interaction*** of ***hMLH1*** with ***hPMS2*** are associated with HNPCC as well as suggest that other unknown functional alteration of the human MutL homologues may lead to tumorigenesis in HNPCC kindreds .	parallel	1
328	10037736	9603;7975	Nrf3;MafK	In vitro and in vivo analyses showed that ***Nrf3*** can ***heterodimerize*** with ***MafK*** and that this complex binds to the MARE in the chicken beta-globin enhancer and can activate transcription .	parallel	1
329	10037739	596;7157	Bcl-2;p53	***Inhibition*** of ***p53*** transcriptional activity by ***Bcl-2*** requires its membrane-anchoring domain .	negative	1
330	10037743	960;3082	CD44;hepatocyte growth factor	In the present study , we have explored the possibility of a physical and functional ***interaction*** between ***CD44*** and ***hepatocyte growth factor/scatter factor*** ( HGF/SF ) , the ligand of the receptor tyrosine kinase c-Met .	parallel	1
331	10037743	3082;960	scatter factor;CD44	In the present study , we have explored the possibility of a physical and functional ***interaction*** between ***CD44*** and ***hepatocyte growth factor/scatter factor*** ( HGF/SF ) , the ligand of the receptor tyrosine kinase c-Met .	parallel	1
332	10037743	3082;3082	scatter factor;hepatocyte growth factor	In the present study , we have explored the possibility of a physical and functional ***interaction*** between CD44 and ******hepatocyte growth factor/scatter factor****** ( HGF/SF ) , the ligand of the receptor tyrosine kinase c-Met .	parallel	1
333	10037743	3082;4233	HGF;c-Met	We show that , as compared with CD44s , CD44v3 promotes : ( i ) ***HGF/SF-induced*** ***phosphorylation*** of ***c-Met*** , ( ii ) phosphorylation of several downstream proteins , and ( iii ) activation of the MAP kinases ERK1 and -2 .	target	1
334	10037745	6493;405	Sim;Arnt	HIF-1alpha ( hypoxia-inducible factor 1alpha ) is a basic-helix-loop-helix PAS ( ***Per/Arnt/Sim*** ) transcription factor that , under hypoxic conditions , ***dimerizes*** with a partner factor , the basic-helix-loop-helix / PAS protein ***Arnt*** , to recognize hypoxia-responsive elements of target genes .	parallel	1
335	10037749	4609;5604	c-Myc;mitogen-activated protein kinase kinase-1	Expression of ***c-Myc*** in response to colony-stimulating factor-1 ***requires*** ***mitogen-activated protein kinase kinase-1*** .	target	0
336	10037749	1436;4609	CSF-1R;c-Myc	Therefore , MEK1 participates in an obligate signaling pathway ***linking*** ***CSF-1R*** to ***c-Myc*** expression , but other signals from CSF-1R must cooperate with the MEK/ERK pathway to induce c-Myc expression and S phase entry in response to CSF-1 stimulation .	parallel	0
337	10037764	10499;5469	TIF 2;TRAP220	In light of the functional differences identified between p160 and TRAP coactivator complexes in NR activation , we have attempted to compare ***interaction*** and functional characteristics of ***TIF 2*** and ***TRAP220*** .	parallel	1
338	10037767	6775;3659	signal transducer and activator of transcription-4;IRF-1	We demonstrate that IL-12-induced up-regulation of ***IRF-1*** is ***mediated*** by ***signal transducer and activator of transcription-4*** , which binds to the interferon ( IFN ) - gamma-activated sequence present in the promoter of the IRF-1 gene .	target	0
339	10037770	5467;1387	PPARdelta;CREB-binding protein	Both PPARgamma and ***PPARdelta*** directly ***interacted*** with a nuclear receptor co-activator ( ***CREB-binding protein*** ) in an agonist-dependent manner .	parallel	1
340	10037770	5468;1387	PPARgamma;CREB-binding protein	Both ***PPARgamma*** and PPARdelta directly ***interacted*** with a nuclear receptor co-activator ( ***CREB-binding protein*** ) in an agonist-dependent manner .	parallel	1
341	10037772	940;2185	CD28;Pyk2	***CD28*** ligation ***induces*** tyrosine phosphorylation of ***Pyk2*** but not Fak in Jurkat T cells .	target	1
342	10037772	5829;5747	Paxillin;Fak	***Paxillin*** , a ***substrate*** for Pyk2 and ***Fak*** , was not tyrosine-phosphorylated after CD28 ligation .	parallel	1
343	10037772	5829;2185	Paxillin;Pyk2	***Paxillin*** , a ***substrate*** for ***Pyk2*** and Fak , was not tyrosine-phosphorylated after CD28 ligation .	parallel	1
344	10037772	940;2185	CD28;Pyk2	***CD28-induced*** tyrosine ***phosphorylation*** of ***Pyk2*** was markedly reduced in the absence of external Ca2 + .	target	1
345	10037774	5008;3949	oncostatin M;LDLR	***Induction*** of low density lipoprotein receptor ( ***LDLR*** ) transcription by ***oncostatin M*** is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter .	target	1
346	10037774	5008;3949	oncostatin M;LDLR	***oncostatin M*** ( OM ) ***activates*** the transcription of the human low density lipoprotein receptor ( ***LDLR*** ) in HepG2 cells through a sterol-independent mechanism .	positive	1
347	10037782	4792;4790	IkappaBalpha;NF-kappaB	Here , we report that IkappaBalpha , when not bound to NF-kappaB , is constitutively transported to the nucleus , and we confirm that the ***interaction*** of ***IkappaBalpha*** with ***NF-kappaB*** retains IkappaBalpha in the cytoplasm .	parallel	1
348	10037790	999;1499	E-cadherin;beta-catenin	Coupling assembly of the ******E-cadherin/beta-catenin****** ***complex*** to efficient endoplasmic reticulum exit and basal-lateral membrane targeting of E-cadherin in polarized MDCK cells .	parallel	1
349	10037790	1499;999	beta-catenin;E-cadherin	Thus , ***beta-catenin*** binding to the whole cytoplasmic domain of E-cadherin ***correlates*** with efficient and targeted delivery of ***E-cadherin*** to the lateral plasma membrane .	parallel	0
350	10037790	1499;999	beta-catenin;E-cadherin	In this capacity , we suggest that ***beta-catenin*** acts as a chauffeur , to ***facilitate*** transport of ***E-cadherin*** out of the ER and the plasma membrane .	positive	0
351	10037796	6352;1234	RANTES;CCR5	Using CCR5-transfected HEK-293 cells , we show that both the ***CCR5*** ***ligand*** , ***RANTES*** , as well as its derivative , aminooxypentane ( AOP ) - RANTES , trigger immediate responses such as Ca2 + influx , receptor dimerization , tyrosine phosphorylation , and Galphai as well as JAK/STAT association to the receptor .	parallel	1
352	10037796	5747;7852	FAK;chemokine receptor	In contrast to RANTES , ( AOP ) - RANTES is unable to trigger late responses , as measured by the ***association*** of focal adhesion kinase ( ***FAK*** ) to the ***chemokine receptor*** complex , impaired cell polarization required for migration , or chemotaxis .	parallel	0
353	10037797	961;3685	CD47;vitronectin receptor	***CD47*** , a member of the multispan transmembrane receptor family , physically and functionally ***associates*** with ***vitronectin receptor*** ( VnR ) .	parallel	0
354	10047452	5329;5328	UPAR;UPA	Finally , the expression of both urokinase plasminogen activator ( ***UPA*** ) and its ***receptor*** ( ***UPAR*** ) were induced after TPA treatment by 8 - and 7-fold , respectively .	parallel	1
355	10047779	7518;3981	XRCC4;DNA ligase IV	Recent studies have shown that ***XRCC4*** ***interacts*** with and enhances the activity of ***DNA ligase IV*** in vitro .	parallel	1
356	10047779	7518;3981	XRCC4;DNA ligase IV	These data strongly suggest that an important function of ***XRCC4*** is to ***stabilize*** the ***DNA ligase IV*** protein .	positive	0
357	10048020	100;2648	ADA;GCN5	We found that gan1 is identical to ADA1 , which encodes a component of the ******ADA/GCN5****** co-activator ***complex*** .	parallel	1
358	10048132	1392;5443	CRH;ACTH	Support for the TCDD-AhR-mediated increases in ACTH concentrations is provided by the following observations : ( 1 ) ANF inhibited both the 1.3 - to 2-fold TCDD-induced increase in basal medium and intracellular ACTH concentrations and the 30 % TCDD-induced decrease in medium ACTH levels and the 1.2-fold increase in intracellular ACTH levels in corticotropin-releasing hormone ( CRH ) - stimulated cells , ( 2 ) BNF increased basal medium ( 1.7-fold ) and intracellular ( 1.3-fold ) ACTH concentrations , ( 3 ) BNF + TCDD demonstrated additivity by increasing basal medium ( 2.4-fold ) and intracellular ( 1.7-fold ) ACTH concentrations , ( 4 ) PCB increased basal medium ( 1.8 - to 2.1-fold ) and intracellular ( 1.3 - to 1.8-fold ) ACTH concentrations and inhibited medium ACTH secretion in CRH stimulated cells by 24-43 % , and ( 5 ) HCB did not effect basal or ***CRH*** ***stimulated*** medium and intracellular ***ACTH*** concentrations .	positive	0
359	10048154	196;405	AhR;ARNT	In human palates , ***AhR*** expression ***correlated*** with ***ARNT*** and CYP1A1 mRNA expression .	parallel	0
360	10048154	196;1543	AhR;CYP1A1	In human palates , ***AhR*** expression ***correlated*** with ARNT and ***CYP1A1*** mRNA expression .	parallel	0
361	10048431	3815;4254	c-kit;SCF	The receptor for FL belongs to the class III family of receptor tyrosine kinases which also includes ***c-kit*** , the ***receptor*** for stem cell factor ( ***SCF*** ) .	parallel	1
362	10048449	5604;23552	MKK1;p42	In contrast , constitutive active ***MKK1*** , the classical ***p42/44*** MAPK ***activator*** , increased cyclin D1 promoter activity and level of protein .	positive	1
363	10048449	5604;595	MKK1;cyclin D1	In contrast , constitutive active ***MKK1*** , the classical p42/44 MAPK activator , ***increased*** ***cyclin D1*** promoter activity and level of protein .	positive	0
364	10048580	5747;1445	pp125FAK;CSK	De novo expression of ***pp125FAK*** in human macrophages ***regulates*** ***CSK*** distribution and MAP kinase activation but does not affect focal contact structure .	target	1
365	10048580	5747;1445	FAK;CSK	***FAK*** ***associates*** with ***CSK*** 48 h after infection and recruits it to focal contacts .	parallel	0
366	10048979	7040;4091	TGF-beta1;Smad6	***TGF-beta1*** ***induced*** endogenous PAI-1 protein synthesis , Smad binding element / ( CAGA ) 12-luciferase-reporter activity , as well as mRNA expression of ***Smad6*** and Smad7 in all gliomas .	target	1
367	10048979	7040;4092	TGF-beta1;Smad7	***TGF-beta1*** ***induced*** endogenous PAI-1 protein synthesis , Smad binding element / ( CAGA ) 12-luciferase-reporter activity , as well as mRNA expression of Smad6 and ***Smad7*** in all gliomas .	target	1
368	10048979	7040;5054	TGF-beta1;PAI-1	***TGF-beta1*** ***induced*** endogenous ***PAI-1*** protein synthesis , Smad binding element / ( CAGA ) 12-luciferase-reporter activity , as well as mRNA expression of Smad6 and Smad7 in all gliomas .	target	1
369	10048979	7040;7046	TGF-beta1;TbetaR-I	Interestingly , ***TGF-beta1*** differentially ***stimulated*** or inhibited the expression of ***TbetaR-I*** and TbetaR-II mRNA in the gliomas .	positive	0
370	10048979	7040;7048	TGF-beta1;TbetaR-II	Interestingly , ***TGF-beta1*** differentially ***stimulated*** or inhibited the expression of TbetaR-I and ***TbetaR-II*** mRNA in the gliomas .	positive	0
371	10048979	7040;4087	TGF-beta1;Smad2	In all gliomas , ***TGF-beta1*** ***induced*** phosphorylation of ***Smad2*** .	target	1
372	10049059	356;2187	Fas ligand;FAB	***Fas ligand*** expression in the bone marrow in myelodysplastic syndromes ***correlates*** with ***FAB*** subtype and anemia , and predicts survival .	parallel	0
373	10049060	3562;1440	IL-3;G-CSF	We report that ***IL-3*** ***inhibited*** the ability of ***G-CSF*** to induce Stat3 DNA binding .	negative	1
374	10049060	1440;6774	G-CSF;Stat3	Moreover , we find that ***G-CSF*** ***activation*** of ***Stat3*** binding to DNA is biphasic , peaking at 15-30 min and again at 6-8 h ; both peaks are inhibited by IL-3 .	positive	1
375	10049302	9622;83716	kallikrein;trypsin inhibitor	In the second group , represented by the ***complex*** of ***kallikrein*** and pancreatic ***trypsin inhibitor*** , the overall stability results from the rather nonspecific electrostatic attraction , whereas the affinity toward the binding region is determined by desolvation interactions .	parallel	1
376	10049357	9612;9611	SMRT;N-CoR	The ******N-CoR/SMRT****** ***complex*** containing mSin3 and histone deacetylase ( HDAC ) mediates transcriptional repression by nuclear hormone receptors and Mad .	parallel	1
377	10049387	55651;54433	NolA2;NolA1	The expression of both ***NolA2*** and NolA3 ***requires*** the presence of ***NolA1*** .	target	0
378	10049387	55505;54433	NolA3;NolA1	The expression of both NolA2 and ***NolA3*** ***requires*** the presence of ***NolA1*** .	target	0
379	10049518	3569;973	IL-6;IgA	More importantly , culture supernatants from LPS stimulated IEC-6 cells contained enhanced levels of ***IL-6*** which ***enhanced*** both IgG and ***IgA*** production and partially overcame the suppressive effect of TGF-beta on IgM secretion .	positive	0
380	10049521	3552;3569	IL-1alpha;IL-6	***IL-1alpha*** ***upregulates*** ***IL-6*** production ; therefore , the correlation between IL-1alpha and IL-6 immunoreactivity and OR-positivity in paraffin-embedded human breast tumours was further investigated.The results indicate IL-6 immunoreactivity in 40 of 66 paraffin embedded breast tumour specimens , a finding which did not correlate with the clinical evaluation of oestrogen receptor positivity ( P = 0.32 by Fisher 's exact test ) .	positive	1
381	10049569	8851;1020	p35;cdk5	Thus , ******cdk5/p35****** ***complexes*** function in aspects of neural differentiation and patterning in the early embryo and particularly in formation of the eye .	parallel	1
382	10049647	3458;6590	Interferon-gamma;SLPI	***Interferon-gamma*** ( IFN-gamma ) , which corrects the defective LPS response in Lps ( d ) macrophages , ***suppressed*** the LPS-induced expression of ***SLPI*** and restored LPS response to SLPI-overexpressing macrophages .	negative	1
383	10049647	3603;6590	interleukin-10 and -6;SLPI	The expression of ***SLPI*** was strongly ***enhanced*** by ***interleukin-10 and -6*** .	positive	0
384	10049690	283120;3481	H19;IGF2	The ***H19*** gene is closely ***linked*** to the human IGF-II gene ( ***IGF2*** ) on chromosome 11p15 .5 and these genes are reciprocally imprinted in most fetal tissues .	parallel	0
385	10049699	3586;6348	interleukin-10;macrophage inflammatory protein-1 alpha	***Regulation*** of ***macrophage inflammatory protein-1 alpha*** expression and function by endogenous ***interleukin-10*** in a model of acute inflammation .	target	1
386	10049709	598;581	Bcl-XL;Bax	Furthermore , several binding assays demonstrated that ***Bcl-XL*** , an anti-apoptotic member of the Bcl-2 family , can ***bind*** to the oligomeric form of ***Bax*** without requiring Bax to dissociate to monomers .	parallel	1
387	10049710	8773;6616	SNAP-23;SNAP	We have reexamined the intracellular localization of the ubiquitously expressed target membrane ***SNAP*** ***receptor*** ( t-SNARE ) , ***SNAP-23*** .	parallel	1
388	10049733	3458;6357	IFN-gamma;MCP-4	Like MCP-3 , ***MCP-4*** mRNA expression in dermal fibroblasts is ***upregulated*** by TNF-alpha , IL-1alpha , ***IFN-gamma*** or IL-4 and differs from RANTES and eotaxin mRNA expression in its response to IFN-gamma and/or IL-4 .	positive	1
389	10049733	3552;6357	IL-1alpha;MCP-4	Like MCP-3 , ***MCP-4*** mRNA expression in dermal fibroblasts is ***upregulated*** by TNF-alpha , ***IL-1alpha*** , IFN-gamma or IL-4 and differs from RANTES and eotaxin mRNA expression in its response to IFN-gamma and/or IL-4 .	positive	1
390	10049733	3565;6357	IL-4;MCP-4	Like MCP-3 , ***MCP-4*** mRNA expression in dermal fibroblasts is ***upregulated*** by TNF-alpha , IL-1alpha , IFN-gamma or ***IL-4*** and differs from RANTES and eotaxin mRNA expression in its response to IFN-gamma and/or IL-4 .	positive	1
391	10049733	7124;6357	TNF-alpha;MCP-4	Like MCP-3 , ***MCP-4*** mRNA expression in dermal fibroblasts is ***upregulated*** by ***TNF-alpha*** , IL-1alpha , IFN-gamma or IL-4 and differs from RANTES and eotaxin mRNA expression in its response to IFN-gamma and/or IL-4 .	positive	1
392	10049734	836;142	CPP32;PARP	Since ***PARP*** is ***cleaved*** by ***CPP32*** ( caspase-3 ) , we next determined if H2O2 was capable of effecting changes in CPP32 activity .	target	1
393	10049757	6732;3930	SRPK1;LBR	Using synthetic peptides representing different regions of LBR and recombinant proteins produced in bacteria we now demonstrate that ***SRPK1*** ***modifies*** ***LBR*** with similar kinetics and on the same sites as the LBR kinase , that are also phosphorylated in vivo .	target	0
394	10049759	3479;3667	IGF-I;IRS-1	***IGF-I*** ***regulates*** ***IRS-1*** expression in 3T3-L1 adipocytes .	target	1
395	10049759	3479;3667	IGF-I;IRS-1	Actinomycin D and cycloheximide blocked the IGF-I effect , but not the insulin effect , suggesting that ***IGF-I*** ***stimulated*** the synthesis of ***IRS-1*** .	positive	0
396	10049762	1020;4137	Cdk5;tau	Active ***Cdk5*** is thought to be involved in the in vivo ***phosphorylation*** of the neurofilament proteins and ***tau*** which are hyperphosphorylated in neurodegenerative diseases .	target	1
397	10049762	6164;1019	L34;Cdk4	***L34*** also ***interacts*** with ***Cdk4*** and , in parallel , inhibits the Cdk4/cyclin D1 activity .	parallel	1
398	10049767	9546;351	X11L2;beta-amyloid precursor protein	***X11L2*** , a new member of the X11 protein family , ***interacts*** with Alzheimer 's ***beta-amyloid precursor protein*** .	parallel	1
399	10049778	581;834	Bax;Caspase-1	***Caspase-1*** was ***activated*** only by ***Bax*** significantly when coexpressed with mutated p53 but not with wt p53 .	positive	1
400	10049787	5741;4254	PTH;SCF	The major osteoblastic ***SCF*** mRNA , approximately 5 kB , was ***augmented*** by ***PTH*** .	positive	0
401	10049825	100188830;2033	Ad12;p300	We analyzed the ***interaction*** of the ***Ad12*** E1A 235R protein with ***p300*** and CBP .	parallel	1
402	10049915	11200;10926	RAD53;DBF4	***RAD53*** ***regulates*** ***DBF4*** independently of checkpoint function in Saccharomyces cerevisiae .	target	1
403	10049915	11200;10926	RAD53;DBF4	Furthermore , the steady-state level of DBF4 message and Dbf4p protein is reduced in several RAD53 mutant strains , indicating that ***RAD53*** positively ***regulates*** ***DBF4*** .	positive	1
404	10049941	356;5551	FasL;perforin	The contribution of specific cytotoxic T lymphocytes ( CTLs ) to the CHS reaction was examined both in vivo and in vitro , using mice deficient in ***perforin*** and/or Fas/Fas ***ligand*** ( ***FasL*** ) pathways involved in cytotoxicity .	parallel	1
405	10049948	959;958	CD40 ligand;CD40	Expression of stromelysin-3 in atherosclerotic lesions : regulation via ******CD40-CD40 ligand****** ***signaling*** in vitro and in vivo .	parallel	0
406	10049948	959;958	CD40L;CD40	These observations establish the expression of the unusual matrix metalloproteinase stromelysin-3 in human atherosclerotic lesions and implicate ******CD40-CD40L****** ***signaling*** in its regulation , thus providing a possible new pathway that triggers complications within atherosclerotic lesions .	parallel	0
407	10050087	3487;3479	IGFBP-1 and 4;IGF-1	Initial glomerular hypertrophy of diabetic nephropathy is a related ***IGF-1*** action , which may be ***modulated*** by ***IGFBP-1 and 4*** .	target	0
408	10050668	3383;3689	ICAM-1;Mac-1	Taken together , our results suggest that eotaxin-induced eosinophil transendothelial migration in vivo and in vitro relies on ******Mac-1/ICAM-1****** and VLA-4NCAM-1 ***interactions*** , the latter ones becoming more relevant at later time points of the eotaxin-induced recruitment process .	parallel	1
409	10050675	958;959	CD40;CD154	******CD154-CD40****** ***interactions*** are of central importance for the induction of antibody responses to T-dependent antigens .	parallel	1
410	10050701	7852;6387	CXCR4;SDF-1	***CXCR4*** is also a natural ***receptor*** for the chemokine ***SDF-1*** .	parallel	1
411	10050758	1173;10618	mu2;TGN38	Phosphorylation of mu2 was shown to have no significant effect on the in vitro ***interaction*** of ***mu2*** with the cytosolic domain of ***TGN38*** , indicating that reversible phosphorylation of mu2 does not play a role in regulating its direct interaction with tyrosine based internalisation motifs .	parallel	1
412	10050772	6750;2641	Somatostatin;glucagon	***Somatostatin*** ***inhibits*** ***glucagon-secretion*** from pancreatic alpha cells but its underlying mechanism is unknown .	negative	1
413	10050876	1326;5604	Cot;MEK-1	Expression of oncogenic Cot in 293 , NIH3T3 and PC12 cells leads to in vivo phosphorylation of endogenous c-Jun and Erk-1/2 suggesting that the serine/threonine kinase ***Cot*** functions beside c-Raf-1 and Mos as a direct ***activator*** of ***MEK-1*** .	positive	1
414	10050884	4613;581	MycN;Bax	***MycN*** overexpression and cytotoxic drugs also synergized to ***induce*** p53 and ***Bax*** protein expression , while Bcl-2 and Bcl-X ( L ) protein levels remained unchanged .	target	1
415	10050884	4613;7157	MycN;p53	***MycN*** overexpression and cytotoxic drugs also synergized to ***induce*** ***p53*** and Bax protein expression , while Bcl-2 and Bcl-X ( L ) protein levels remained unchanged .	target	1
416	10050886	1387;6688	CBP;PU.1	Physical and functional ***interactions*** between the transcription factor ***PU.1*** and the coactivator ***CBP*** .	parallel	1
417	10050886	1387;6688	CBP;PU.1	CBP potentiated PU.1-mediated transcription of the reporter gene driven by the multimerized PU.1-binding sites , suggesting that ***CBP*** functions as a ***coactivator*** for ***PU.1*** .	positive	1
418	10051099	983;891	Cdc2;cyclin B1	HSP70-2 is required for ***Cdc2*** to form a ***heterodimer*** with ***cyclin B1*** , suggesting that it is a chaperone necessary for the progression of meiosis in the germ cells of male mice .	parallel	1
419	10051290	4018;4318	lipoprotein;matrix metalloproteinase-9	Oxidized low-density ***lipoprotein*** ***regulates*** ***matrix metalloproteinase-9*** and its tissue inhibitor in human monocyte-derived macrophages .	target	1
420	10051406	3667;3643	IRS-1;insulin receptor	The GRB2/Sos complex can connect with ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) , which is one of the primary targets of the insulin and insulin-like growth factor receptors .	parallel	1
421	10051439	6416;5599	MKK4;JNK	In addition , HA-tagged forms of the dual-specificity mitogen-activated protein kinase kinases ( MKKs ) , ***MKK4*** and MKK7 , which are specific ***activators*** of the ***JNK*** enzymes , were similarly expressed .	positive	1
422	10051439	5609;5599	MKK7;JNK	In addition , HA-tagged forms of the dual-specificity mitogen-activated protein kinase kinases ( MKKs ) , MKK4 and ***MKK7*** , which are specific ***activators*** of the ***JNK*** enzymes , were similarly expressed .	positive	1
423	10051443	8773;6810	SNAP-23;syntaxin 4	Co-immunoprecipitation of syntaxin 4 and SNAP-23 shows association of these two proteins in rat adipose cell plasma membranes , and insulin stimulation does not alter the ******SNAP-23/syntaxin 4****** ***complex*** .	parallel	1
424	10051443	8773;6810	SNAP-23;syntaxin 4	These data demonstrate that rat ***SNAP-23*** ***associates*** with ***syntaxin 4*** before insulin stimulation and is present in the SNARE complexes known to mediate the translocation of GLUT4 from intracellular vesicles to the plasma membrane of rat adipose cells .	parallel	0
425	10051448	4586;4843	mucin;NOS2	Taken together , these observations indicate ( 1 ) that ITF-binding molecules that are up-regulated by mucin exist on the intestinal epithelial surface , and ( 2 ) that ITF modulates epithelial NO production via the ***NOS2*** pathway , which is ***enhanced*** by ***mucin*** .	positive	0
426	10051455	7020;3481	AP-2;IGF-II	From these results we conclude that ***AP-2*** is an important ***regulator*** in vivo and in vitro of ***IGF-II*** P3 activity .	target	1
427	10051478	3383;3558	ICAM-1;interleukin-2	***Anti-ICAM-1*** treatment also ***decreased*** both the percentage of T cells and the production of ***interleukin-2*** ( IL-2 ) and IL-12 in the liver ( P < .01 ) , but had no effect on IL-4 , IL-10 , and interferon gamma .	negative	0
428	10051489	2908;3725	Glucocorticoid receptor;c-Jun	***Glucocorticoid receptor*** ***down-regulates*** ***c-Jun*** amino terminal kinases induced by tumor necrosis factor alpha in fetal rat hepatocyte primary cultures .	negative	1
429	10051543	7124;4790	tumor necrosis factor (TNF)-alpha;NF-kappaB	We tested the hypothesis that activation of protein kinase C ( PKC ) and generation of oxidants are critical sequential signals mediating ***tumor necrosis factor (TNF)-alpha-induced*** ***activation*** of nuclear factor-kappaB ( ***NF-kappaB*** ) and transcription of the intercellular adhesion molecule ( ICAM ) -1 gene .	positive	1
430	10051543	7124;4790	TNF-alpha;NF-kappaB	However , both PKC activation and oxidant generation were necessary for ICAM-1 mRNA expression because the pretreatment of HPAE cells with either calphostin C or N-acetylcysteine inhibited the ***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** and prevented the activation of ICAM-1 promoter .	positive	1
431	10051583	6256;5914	retinoid X receptor alpha;retinoic acid receptor alpha	Ligand-dependent activation of transcription in vitro by ******retinoic acid receptor alpha/retinoid X receptor alpha****** ***heterodimers*** that mimics transactivation by retinoids in vivo .	parallel	1
432	10051602	2288;5264	FKBP52;PAHX	Whereas the binding of calcineurin to FKBP12 is potentiated by FK506 , the specific ***association*** of ***PAHX*** and ***FKBP52*** is maintained in the presence of FK506 .	parallel	0
433	10051628	834;3458	caspase 1;IFN-gamma	In PBMCs , mature but not precursor IL-18 induces IFN-gamma ; in whole human blood stimulated with endotoxin , inhibition of ***caspase 1*** ***reduces*** ***IFN-gamma*** production by an IL-1beta-independent mechanism .	positive	1
434	10051665	627;2534	BDNF;Fyn	In vitro kinase assay revealed that ***BDNF*** can indeed ***activate*** the ***Fyn*** kinase : It enhanced tyrosine phosphorylation of Fyn as well as that of enolase supplemented exogenously .	positive	1
435	10051672	6000;10681	RGS7;Gbeta5	The specific ******Gbeta5-RGS7****** ***interaction*** is determined by a distinct domain in RGS that has a striking homology to Ggamma subunits .	parallel	1
436	10051672	10681;6000	Gbeta5;RGS7	Deletion of this domain prevents the ******RGS7-Gbeta5****** ***binding*** , although the interaction with Galpha is retained .	parallel	1
437	10051672	6000;8802	RGS7;Galpha	The interaction of Gbeta5 with RGS7 blocked the ***binding*** of ***RGS7*** to the ***Galpha*** subunit Galphao , indicating that Gbeta5 is a specific RGS inhibitor .	parallel	1
438	10051672	10681;6000	Gbeta5;RGS7	The ***interaction*** of ***Gbeta5*** with ***RGS7*** blocked the binding of RGS7 to the Galpha subunit Galphao , indicating that Gbeta5 is a specific RGS inhibitor .	parallel	1
439	10051672	10681;6000	Gbeta5;RGS7	The interaction of ***Gbeta5*** with RGS7 ***blocked*** the binding of ***RGS7*** to the Galpha subunit Galphao , indicating that Gbeta5 is a specific RGS inhibitor .	negative	0
440	10051679	1081;5047	hCG;glycodelin	Synthesis of the glandular secretory protein ***glycodelin*** , as assessed by Western blot analysis , was markedly ***up-regulated*** by ***hCG*** , and this increase was confirmed by immunocytochemistry , Northern blot analysis , and reverse transcriptase-PCR .	positive	1
441	10052459	5111;10036	PCNA;p150	***PCNA*** ***binds*** directly to ***p150*** , the largest subunit of CAF-1 , and the two proteins colocalize at sites of DNA replication in cells .	parallel	1
442	10052460	5087;3211	Pbx1;HoxB1	Structure of a ******HoxB1-Pbx1****** ***heterodimer*** bound to DNA : role of the hexapeptide and a fourth homeodomain helix in complex formation .	parallel	1
443	10052460	5087;3211	Pbx1;HoxB1	We report here the 2.35 A structure of a ternary complex containing a human ******HoxB1-Pbx1****** ***heterodimer*** bound to DNA .	parallel	1
444	10052685	2572;1493	GAD65;CTLA-4	In 84 patients , we also investigated ***associations*** between this ***CTLA-4*** gene polymorphism and ***GAD65*** antibody positivity .	parallel	0
445	10052934	7276;5950	TTR;RBP	We report here the crystallographic structure at 3.2 A of the protein-protein ***complex*** of human ***RBP*** and ***TTR*** .	parallel	1
446	100578	7200;5443	thyrotropin releasing hormone;alpha-melanocyte stimulating hormone	Demonstration of a temperature-dependent ***association*** of ***thyrotropin releasing hormone*** , ***alpha-melanocyte stimulating hormone*** , and luteinizing hormone releasing hormone with subneuronal particles in hypothalamic synaptosomes .	parallel	0
447	10063314	1029;1019	p16;cdk4	RESULTS : The newly-expressed ***p16*** formed a ***complex*** with ***cdk4*** , and phosphorylated pRB was decreased , although cyclin D1 and pRB : cyclin D1 complex were unchanged .	parallel	1
448	10063359	4233;3082	c-Met;hepatocyte growth factor	The clinical importance of the expression of ***c-Met*** protein , the ***receptor*** of ***hepatocyte growth factor/scatter factor*** , was evaluated in neuroepithelial tissue tumors .	parallel	1
449	10063405	3383;3684	ICAM-1;CD11b	Soluble ***ICAM-1*** ***decreased*** ***CD11b*** expression and adhesion in neutrophils exposed to reperfusion plasma only ( CD11b expression fell from 15.9 to 3.4 mcf , p < 0.01 Mann-Whitney U-test and adhesion fell to 11.6 % cells adhered , p < 0.01 ) .	negative	0
450	10063910	7124;4790	TNF-alpha;NF-kappaB	***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** activity was suppressed by NAC , and H2O2 caused significant activation of NF-kappaB .	positive	1
451	10064053	356;355	FasL;Fas	We show that an influenza hemagglutinin-specific CD4 + murine T cell hybridoma ( IP-12-7 ) enters the apoptotic suicide program via the ***Fas*** ***ligand*** ( ***FasL*** ) / Fas-mediated pathway upon T cell receptor ( TCR ) stimulation .	parallel	1
452	10064061	355;356	Fas;Fas ligand	Apoptosis of pancreatic beta-cells detected in accelerated diabetes of NOD mice : no role of ******Fas-Fas ligand****** ***interaction*** in autoimmune diabetes .	parallel	1
453	10064070	3606;3458	IL-18;IFN-gamma	However , IL-12 and ***IL-18*** together fully ***induce*** ***IFN-gamma*** transcription independently of TCR-activated signals , by a mechanism that does not simply involve Stat4 and NF-kappaB activation , but requires additional protein synthesis .	target	1
454	10064078	959;958	CD40L;CD40	These results show that the ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) interaction in vivo is essential for anergy induction and the subsequent development of immunodeficiency and pathologic expansion of lymphocytes .	parallel	1
455	10064078	958;959	CD40;CD40L	Our data demonstrate that antibody class switch to IgE and IgG1 can be induced by a retroviral infection in vivo even in the absence of ******CD40-CD40L****** ***interaction*** and an apparent switch to a Th2 cytokine production .	parallel	1
456	10064085	3458;6354	interferon-gamma;monocyte chemotactic protein-3	Differential ***induction*** of ***monocyte chemotactic protein-3*** in mononuclear leukocytes and fibroblasts by interferon-alpha/beta and ***interferon-gamma*** reveals MCP-3 heterogeneity .	target	1
457	10064088	3579;2919	CXCR2;GRO-alpha	Consequently , inhibition experiments with blocking peptide analogues and monoclonal antibodies revealed that ***GRO-alpha*** and its ***receptor*** ***CXCR2*** but not MCP-1 and its receptors substantially contributed to conversion of rolling into firm , shear-resistant arrest of monocytes to TNF-alpha-stimulated endothelium in physiological flow .	parallel	1
458	10064103	4790;7056	NF-kappaB;thrombomodulin	***NF-kappaB*** binding activity ***correlated*** with the degree of albuminuria ( r = 0.316 ) and with ***thrombomodulin*** plasma concentrations ( r = 0.33 ) , indicative for albuminuria associated endothelial dysfunction .	parallel	0
459	10064583	1999;2060	Ese1;Eps15	***Ese1*** is constitutively ***associated*** with ***Eps15*** proteins to form a complex with at least 14 protein-protein interaction surfaces .	parallel	0
460	10064589	1026;4217	p21;ASK1	Biochemical analysis showed that cytoplasmic ***p21*** ( Cip1/WAF1 ) forms a ***complex*** with the apoptosis signal-regulating kinase 1 ( ***ASK1*** ) and inhibits stress-activated MAP kinase cascade .	parallel	1
461	10064598	2950;5599	GSTp;JNK	***Regulation*** of ***JNK*** signaling by ***GSTp*** .	target	1
462	10064598	5599;2950	JNK;GSTp	UV irradiation or H2O2 treatment caused GSTp oligomerization and dissociation of the ******GSTp-JNK****** ***complex*** , indicating that it is the monomeric form of GSTp that elicits JNK inhibition .	parallel	1
463	10064598	5599;3725	JNK;Jun	Addition of purified GSTp to the ******Jun-JNK****** ***complex*** caused a dose-dependent inhibition of JNK activity .	parallel	1
464	10064598	2950;5599	GSTp;JNK	Conversely , immunodepleting ***GSTp*** from protein extracts ***attenuated*** ***JNK*** inhibition .	negative	0
465	10064598	2950;5599	GSTp;JNK	Forced expression of ***GSTp*** ***decreased*** MKK4 and ***JNK*** phosphorylation which coincided with decreased JNK activity , increased c-Jun ubiquitination and decreased c-Jun-mediated transcription .	negative	0
466	10064598	2950;6416	GSTp;MKK4	Forced expression of ***GSTp*** ***decreased*** ***MKK4*** and JNK phosphorylation which coincided with decreased JNK activity , increased c-Jun ubiquitination and decreased c-Jun-mediated transcription .	negative	0
467	10064598	2950;3725	GSTp;c-Jun	Forced expression of ***GSTp*** decreased MKK4 and JNK phosphorylation which coincided with decreased JNK activity , ***increased*** ***c-Jun*** ubiquitination and decreased c-Jun-mediated transcription .	positive	0
468	10064598	2950;5599	GSTp;JNK	Co-transfection of MEKK1 and GSTp restored MKK4 phosphorylation but did not affect ***GSTp*** ***inhibition*** of ***JNK*** activity , suggesting that the effect of GSTp on JNK is independent of the MEKK1-MKK4 module .	negative	1
469	10064599	79800;1387	calcium-responsive transcription factor;CREB-binding protein	***Recruitment*** of the coactivator ***CREB-binding protein*** , CBP , by the prototypical ***calcium-responsive transcription factor*** , CREB and stimulation of CBP activity by nuclear calcium signals is one mechanism through which calcium influx into excitable cells activates gene expression .	target	0
470	10064599	1385;1387	CREB;CREB-binding protein	***Recruitment*** of the coactivator ***CREB-binding protein*** , CBP , by the prototypical calcium-responsive transcription factor , ***CREB*** and stimulation of CBP activity by nuclear calcium signals is one mechanism through which calcium influx into excitable cells activates gene expression .	target	0
471	10064600	3725;1386	Jun;ATF-2	The human fibronectin promoter contains three CRE elements , one of which has been shown to bind a ******c-Jun-ATF-2****** ***heterodimer*** .	parallel	1
472	10064600	5599;1386	JNK;ATF-2	These results demonstrate that TGF-beta-mediated fibronectin induction requires activation of ***JNK*** which in turn ***modulates*** the activity of c-Jun and ***ATF-2*** in a Smad4independent manner .	target	0
473	10064600	5599;3725	JNK;Jun	These results demonstrate that TGF-beta-mediated fibronectin induction requires activation of ***JNK*** which in turn ***modulates*** the activity of ***c-Jun*** and ATF-2 in a Smad4independent manner .	target	0
474	10064601	2068;780	XPD;CAK	Western blot analysis and enzymatic assays indicate that XPD mutations affect the stoichiometric composition of TFIIH due to a weakness in the interaction between ******XPD-CAK****** ***complex*** and the core TFIIH , resulting in a partial reduction of transcription activity .	parallel	1
475	10064601	780;2068	CAK;TFIIH	Western blot analysis and enzymatic assays indicate that XPD mutations affect the stoichiometric composition of TFIIH due to a weakness in the ***interaction*** between ***XPD-CAK*** complex and the core ***TFIIH*** , resulting in a partial reduction of transcription activity .	parallel	1
476	10064601	2068;780	XPD;CAK	Western blot analysis and enzymatic assays indicate that XPD mutations affect the stoichiometric composition of TFIIH due to a weakness in the ***interaction*** between ******XPD-CAK****** complex and the core TFIIH , resulting in a partial reduction of transcription activity .	parallel	1
477	10064601	2068;2068	XPD;TFIIH	Western blot analysis and enzymatic assays indicate that XPD mutations affect the stoichiometric composition of TFIIH due to a weakness in the ***interaction*** between ***XPD-CAK*** complex and the core ***TFIIH*** , resulting in a partial reduction of transcription activity .	parallel	1
478	10064602	6777;595	STAT5;cyclin D1	Thus ***STAT5*** , in addition to ras signaling , appears to ***mediate*** transcriptional regulation of ***cyclin D1*** , thereby contributing to cytokine-dependent growth of hematopoietic cells .	target	0
479	10064602	6777;595	STAT5;cyclin D1	Transcriptional ***regulation*** of the ***cyclin D1*** promoter by ***STAT5*** : its involvement in cytokine-dependent growth of hematopoietic cells .	target	1
480	10064602	6776;595	STAT5A;cyclin D1	In NIH 3T3 cells , 1 * ***6-STAT5A*** and H-rasG12V individually and cooperatively ***transactivated*** the ***cyclin D1*** promoter in luciferase assays .	positive	1
481	10064602	6777;595	STAT5;cyclin D1	Both ***dn-STAT5*** and dn-ras ***suppressed*** IL-3-induced ***cyclin D1*** promoter activities in F-36P-mpl cells .	negative	1
482	10064602	6776;595	STAT5A;cyclin D1	Using a series of mutant cyclin D1 promoters , 1 * ***6-STAT5A*** was found to ***transactivate*** the ***cyclin D1*** promoter through the potential STAT-binding sequence at -481 bp .	positive	1
483	10064605	5591;6117	DNA-PKcs;RPA1	***DNA-PKcs*** ***interacted*** directly with ***RPA1*** in vitro .	parallel	1
484	10064617	3700;6348	gp120;MIP-1alpha	When preincubated with the CD4 + ve MM6 macrophage cell line , which expresses mRNA for the CCR3 and CCR5 chemokine receptors , both 3.7 and ***gp120*** ***inhibit*** binding of the chemokine ***MIP-1alpha*** .	negative	1
485	10064741	335;4018	Apolipoprotein A-I;lipoprotein	While low ***Apolipoprotein A-I*** ( apoA-I ) levels are primarily ***associated*** with increased high density ***lipoprotein*** ( HDL ) fractional catabolic rate ( FCR ) , the factors that regulate the clearance of HDL from the plasma are unclear .	parallel	0
486	10064788	4803;4790	NGF;NF-kappaB	***NF-kappaB*** was ***activated*** by ***NGF*** withdrawal in reversibly differentiated PC12 cells during dedifferentiation and reentry into the cell cycle , whereas in NGF/cAMP-differentiated cells , it was activated , at a late stage of the apoptotic process , concomitantly with cell death .	positive	1
487	10064822	5327;3082	tPA;HGF	These results are consistent with the hypothesis that HGF/SF plays a role in the development and maintenance of both the cerebral cortex and hippocampus , and that ***tPA*** may act as a ***regulator*** of ***HGF/SF*** activity in these structures .	target	1
488	10064822	4233;3082	c-met;hepatocyte growth factor	The expression of mRNAs for ***hepatocyte growth factor/scatter factor*** , its ***receptor*** ***c-met*** , and one of its activators tissue-type plasminogen activator show a systematic relationship in the developing and adult cerebral cortex and hippocampus .	parallel	1
489	10064822	4233;3082	c-met;hepatocyte growth factor	The temporal and spatial expression in brain of the mRNAs for the pleiotropic cytokine ***hepatocyte growth factor/scatter factor*** ( HGF/SF ) and its ***receptor*** ***c-met*** were compared to those of a known HGF/SF activator , tissue-type plasminogen activator ( tPA ) .	parallel	1
490	10065155	7157;4193	p53;MDM2	******MDM2-p53****** ***complexes*** in the nucleus are transported to the cytoplasm via signals present in the MDM2 protein , where p53 is degraded in the proteasome .	parallel	1
491	10065155	4193;7157	MDM2;p53	The transcription of the MDM2 oncogene is induced by the p53 protein after DNA damage , and the ***MDM2*** protein then ***binds*** to ***p53*** and blocks its activities as a tumour suppressor and promotes its degradation .	parallel	1
492	10065155	7157;4193	p53;MDM2	These two proteins thus form an autoregulatory feedback loop in which ***p53*** positively ***regulates*** MDM2 levels and ***MDM2*** negatively regulates p53 levels and activity .	positive	1
493	10065737	596;25	bcl2;v-abl	***bcl2*** and ***v-abl*** oncogenes ***cooperate*** to immortalize murine B cells that secrete antigen specific antibodies .	parallel	0
494	10065743	940;942	CD28;CD86	The expression of ***CD28*** was decreased on T cells of HIV-infected individuals and was negatively ***correlated*** to the expression of HLA-DR and ***CD86*** ( mean CD28 within CD3 + T cells : HIV + 29.5 % , HIV - 67.6 % ; correlation coefficient , - 0.75 and - 0.71 , respectively ) .	negative	0
495	10065863	7039;3973	TGFalpha;LHR	EGF and ***TGFalpha*** ***suppress*** oestradiol synthesis at a step beyond the production of cAMP and also ***LHR*** binding with more effect in granulosa cells from polycystic ovaries .	negative	1
496	10065895	7035;2152	tissue factor pathway inhibitor;tissue factor	Plasma ***tissue factor pathway inhibitor*** levels ***correlated*** positively with plasma ***tissue factor*** and prothrombin fragment 1 +2 levels .	positive	0
497	10065947	3553;7124	IL-1beta;TNFalpha	In this study , the ***effects*** and interactions between ***IL-1beta*** and ***TNFalpha*** on prostaglandin production and its regulation were investigated .	parallel	0
498	10065947	3553;5743	IL-1beta;cyclooxygenase-2	Furthermore , ***IL-1beta*** and , to a lesser extent , TNFalpha ***induced*** the expression of ***cyclooxygenase-2*** ( COX-2 ) mRNA .	target	1
499	10065947	7124;5743	TNFalpha;cyclooxygenase-2	Furthermore , IL-1beta and , to a lesser extent , ***TNFalpha*** ***induced*** the expression of ***cyclooxygenase-2*** ( COX-2 ) mRNA .	target	1
500	10065947	3553;5743	IL-1beta;COX-2	Simultaneous addition of ***IL-1beta*** and TNFalpha synergistically ***enhanced*** ***COX-2*** mRNA levels , accompanied by a corresponding stimulation of PGE2 synthesis .	positive	0
501	10065947	7124;5743	TNFalpha;COX-2	Simultaneous addition of IL-1beta and ***TNFalpha*** synergistically ***enhanced*** ***COX-2*** mRNA levels , accompanied by a corresponding stimulation of PGE2 synthesis .	positive	0
502	10065947	3553;5742	IL-1beta;COX-1	Neither ***IL-1beta*** , TNFalpha , nor the combination of these two cytokines ***affected*** ***COX-1*** mRNA levels .	target	0
503	10065947	7124;5742	TNFalpha;COX-1	Neither IL-1beta , ***TNFalpha*** , nor the combination of these two cytokines ***affected*** ***COX-1*** mRNA levels .	target	0
504	10066081	3482;3481	M6P/IGF2R;IGF2	Evidence for this statement includes : a ) breast cancers are infiltrated with IGF2 expressing stromal cells ; b ) mannose ***6-phosphate/IGF2*** ***receptor*** ( ***M6P/IGF2R*** ) is mutated in breast cancer , leading to loss of IGF2 degradation ; c ) IGF1R is overexpressed by malignant breast epithelial cells , and in some cases IGF1R is amplified ; and d ) complex changes in IGF binding protein expression occur during breast cancer progression which most likely also affect IGF1 and 2 signaling .	parallel	1
505	10066262	2047;1948	EphB1;ephrin-B2	In addition , we show that ephrin-B2 expression is upregulated by cocaine and amphetamine in adult mice , suggesting that ******ephrin-B2/EphB1****** ***interaction*** may play a role in drug-induced plasticity in adults as well .	parallel	1
506	10066375	7040;1191	Transforming growth factor beta-1;clusterin	***Transforming growth factor beta-1*** ***up-regulates*** ***clusterin*** synthesis in thyroid epithelial cells .	positive	1
507	10066377	5601;5599	SAPK;JNK	VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and ******SAPK/JNK****** ***signaling*** .	parallel	0
508	10066377	7422;5594	VEGF;ERK2	***VEGF*** ***activated*** the phosphorylation of extracellular signal regulated kinase (ERK)1 ( p44 mitogen-activated protein kinase ; MAPK ) and ***ERK2*** ( p42 MAPK ) in a time - and concentration-dependent manner .	positive	1
509	10066377	7422;5595	VEGF;extracellular signal regulated kinase (ERK)1	***VEGF*** ***activated*** the phosphorylation of ***extracellular signal regulated kinase (ERK)1*** ( p44 mitogen-activated protein kinase ; MAPK ) and ERK2 ( p42 MAPK ) in a time - and concentration-dependent manner .	positive	1
510	10066377	7422;5599	VEGF;JNK	Activation of the MAPK pathway together with ***inhibition*** of ***SAPK/JNK*** activity by ***VEGF*** appears to be a key event in determining whether an endothelial cell survives or undergoes programmed cell death .	negative	1
511	10066377	7422;5601	VEGF;SAPK	Activation of the MAPK pathway together with ***inhibition*** of ***SAPK/JNK*** activity by ***VEGF*** appears to be a key event in determining whether an endothelial cell survives or undergoes programmed cell death .	negative	1
512	10066378	841;836	caspase-8;caspase-3	These results do not support an alternative pathway in which ***caspase-8*** directly ***activates*** ***caspase-3*** .	positive	1
513	10066421	5801;5594	PTPBR7;ERK	When overexpressed in mammalian cells , wild-type ***PTPBR7*** ***suppressed*** the phosphorylation and activation of ***ERK*** by epidermal growth factor ( EGF ) , nerve growth factor ( NGF ) , and constitutively active MEK1 , a mutant MAPK kinase .	negative	1
514	10066434	4790;4792	NF-kappaB;IkappaBalpha	Moreover , the putative IkappaBalpha-Ub ligase ( IkappaBalpha-E3 ) present in HeLa cell cytosol associated in vitro with an IKK-phosphorylated recombinant IkappaBalpha , a process independent of ***NF-kappaB*** ***binding*** to ***IkappaBalpha*** or TNFalpha stimulation .	parallel	1
515	10066434	4790;7124	NF-kappaB;TNFalpha	Moreover , the putative IkappaBalpha-Ub ligase ( IkappaBalpha-E3 ) present in HeLa cell cytosol associated in vitro with an IKK-phosphorylated recombinant IkappaBalpha , a process independent of ***NF-kappaB*** ***binding*** to IkappaBalpha or ***TNFalpha*** stimulation .	parallel	1
516	10066445	7422;857	VEGF;caveolin-1	***VEGF*** ***induces*** nuclear translocation of Flk-1 / KDR , endothelial nitric oxide synthase , and ***caveolin-1*** in vascular endothelial cells .	target	1
517	10066664	5265;1991	alpha-1-protease inhibitor;neutrophil elastase	Interleukin-8 ( IL-8 ) , tumor necrosis factor alpha ( TNF-alpha ) , ******neutrophil elastase-alpha-1-protease inhibitor****** ***complex*** ( NE complex ) , protein , and alpha-1-protease inhibitor ( alpha-1-PI ) were measured in serum and sputum collected from CF patients during respiratory exacerbations and periods of well-being .	parallel	1
518	10066673	4790;3383	NF-kappaB;ICAM-1	Decoy ***NF-kappaB*** but not control oligonucleotides ***blocked*** ***ICAM-1*** upregulation and inhibited the subacute increase in PMN adhesion .	negative	0
519	10066681	387;5594	RhoA;ERK2	Overexpression of the Rho GDP dissociation inhibitor ( Rho-GDI ) , dominant-negative mutants of ***RhoA*** ( DNRhoA ) , or DNRac1 significantly ***inhibited*** stretch-induced activation of transfected ***ERK2*** .	positive	1
520	10066731	387;1609	RhoA;DGKtheta	Through accumulation of newly produced diacylglycerol , ***RhoA-mediated*** ***inhibition*** of ***DGKtheta*** may lead to enhanced PKC activity in response to external stimuli .	negative	1
521	10066731	387;1609	RhoA;Diacylglycerol kinase theta	***Diacylglycerol kinase theta*** binds to and is negatively ***regulated*** by active ***RhoA*** .	negative	1
522	10066731	1609;387	DGKtheta;RhoA	We now report that ***DGKtheta*** ***binds*** specifically to activated ***RhoA*** in transfected COS cells as well as in nontransfected neuronal N1E-115 cells .	parallel	1
523	10066731	387;1609	RhoA;DGKtheta	Strikingly , the ***binding*** of activated ***RhoA*** to ***DGKtheta*** completely inhibits DGK catalytic activity .	parallel	1
524	10066731	387;1716	RhoA;DGK	Strikingly , the binding of activated ***RhoA*** to DGKtheta completely ***inhibits*** ***DGK*** catalytic activity .	negative	1
525	10066740	1191;213	Clusterin;albumin	Enzyme-linked immunosorbent assay data showed that ***Clusterin*** ***bound*** preferentially to heat-stressed glutathione S-transferase and to dithiothreitol-treated bovine serum ***albumin*** and alpha-lactalbumin .	parallel	1
526	10066754	369;5609	A-Raf;MEK	However , dominant negative ***A-Raf*** effectively ***blocked*** ***MEK*** activation , suggesting that activation of the MEK-ERK signaling cascade is mediated through A-Raf .	negative	0
527	10066760	26279;22925	sPLA2s;M-type receptor	Both mouse group IB and group IIA ***sPLA2s*** are high affinity ***ligands*** ( in the 1-10 nM range ) for the mouse ***M-type receptor*** .	parallel	1
528	10066760	26279;22925	sPLA2s;M-type receptor	These two sPLA2s are expressed in the mouse tissues where the M-type receptor is also expressed , making it likely that both types of ***sPLA2s*** are physiological ***ligands*** of the mouse ***M-type receptor*** .	parallel	1
529	10066769	7040;1634	TGF-beta1;decorin	***decorin*** synthesis was ***reduced*** by either ***TGF-beta1*** or serum .	negative	1
530	10066772	3848;3827	cytokeratin 1;high molecular weight kininogen	Human ***cytokeratin 1*** ( CK1 ) in human umbilical vein endothelial cells ( HUVEC ) is expressed on their membranes and is able to ***bind*** ***high molecular weight kininogen*** ( HK ) ( Hasan , A.	parallel	1
531	10066780	1387;1045	CREB-binding [corrected] protein;Cdx2	***CREB-binding [corrected] protein*** ***interacts*** with the homeodomain protein ***Cdx2*** and enhances transcriptional activity .	parallel	1
532	10066798	5594;5601	p38;Jun kinase	pp60 ( v-src ) induction of cyclin D1 requires collaborative ***interactions*** between the extracellular signal-regulated kinase , ***p38*** , and ***Jun kinase*** pathways .	parallel	1
533	10066820	3553;4790	IL-1beta;NF-kappaB	Moreover , wortmannin had no effect on LPS - or ***IL-1beta-mediated*** ***activation*** of MAP kinase and ***NF-kappaB*** , suggesting that wortmannin induced the expression of iNOS in LPS - or IL-1beta-stimulated C6 glial cells without modulating the activation of MAP kinase and NF-kappaB .	positive	1
534	10066823	3059;2268	HS1;c-Fgr	We also show that a stable ***association*** of ***phospho-HS1*** with ***c-Fgr*** through its SH2 domain requires previous autophosphorylation of the kinase and is prevented by subsequent phosphorylation of Tyr-222 .	parallel	0
535	10066849	7056;5624	thrombomodulin;protein C	BACKGROUND AND PURPOSE : ***Activation*** of plasma ***protein C*** ( PC ) zymogen by ***thrombin-thrombomodulin*** at the endothelial surface is an important endogenous antithrombotic mechanism .	positive	1
536	10066882	5741;113091	PTH;PTH2	In an analogous manner , the presence of two receptors , PTH/PTHrP ( PTH1 ) and PTH2 , which differ in their ligand selectivity ( ***PTH2*** is ***activated*** by ***PTH*** , not PTHrP ) has provided a unique vehicle for probing the structural motifs of the receptor required for ligand recognition and binding .	positive	1
537	10067818	2950;2947	GSTP1;GSTM3	The ***associations*** between larynx cancer risk and ***GSTM3*** and ***GSTP1*** gene polymorphisms , either separately or in combination with GSTM1 and GSTT1 gene polymorphisms , were evaluated using peripheral blood DNA from 129 cancer patients and 172 controls , all regular smokers .	parallel	0
538	10067826	796;799	Calcitonin;calcitonin receptor	***Calcitonin-dependent*** ***down-regulation*** of the mouse C1a ***calcitonin receptor*** in cells of the osteoclast lineage involves a transcriptional mechanism .	negative	1
539	10067826	799;796	CTR;Calcitonin	Although expression of the ***Calcitonin*** ( CT ) ***receptor*** ( ***CTR*** ) decreases after CT binding , there has been no evidence that it occurs at the transcriptional level .	parallel	1
540	10067827	2247;3082	Fibroblast growth factor-2;scatter factor	***Fibroblast growth factor-2*** ***induces*** ***hepatocyte growth factor/scatter factor*** expression in osteoblasts .	target	1
541	10067828	5741;5950	PTH;RBP	Further , both ***PTH*** and ( Bu ) 2cAMP markedly ***induced*** the expression of ***RBP*** mRNA by about 10-fold at 3 h and by about 40-fold at 24 h , indicating a pretranslational regulation .	target	1
542	10067851	5741;2353	PTH;c-fos	***PTH*** ***induces*** ***c-fos*** expression rapidly and transiently in osteoblastic cells and requires the activity of the cAMP response element-binding protein ( CREB ) .	target	1
543	10067851	5741;1385	PTH;CREB	***PTH*** ***increases*** the level of phosphorylation of ***CREB*** at S133 in a time - and dose-dependent manner , correlating with the time and level of activation of PKA in response to PTH .	positive	0
544	10067855	116;820	PACAP;cAMP	Both ***PACAP*** and VIP ***stimulated*** ***cAMP*** accumulation through the cloned receptor with an EC50 of about 30 nM .	positive	0
545	10067856	5741;5744	PTH;PTHrP	A point mutation in the third cytoplasmic loop ( K382A ) that severely impairs ******PTH/PTHrP****** receptor ***signaling*** significantly reduced internalization , whereas two mutant receptors that displayed only partial defects in signaling were internalized normally .	parallel	0
546	10067858	2798;5594	GnRH receptor;p38	Separation of phosphorylated proteins by ion exchange chromatography suggested that ***GnRH receptor*** stimulation can ***activate*** the ***p38*** MAPK pathway .	positive	1
547	10067858	2796;5594	GnRH;p38	Immunoblot analysis of whole cell lysates using a phospho-specific antibody directed against dual phosphorylated p38 kinase revealed that ***GnRH-induced*** ***phosphorylation*** of ***p38*** kinase was dose and time dependent and was correlated with increased p38 kinase activity in vitro .	target	1
548	10067876	2626;3623	GATA-4;inhibin alpha	Cotransfection studies using a GATA-4 expression plasmid and an inhibin alpha promoter/reporter gene construct in Leydig and granulosa tumor cell lines revealed that the ***inhibin alpha*** promoter harboring essential GATA-binding sites can be ***trans-activated*** by ***GATA-4*** .	positive	1
549	10067896	3716;6772	Jak1;Stat1	TGF-beta signals through a receptor serine kinase that phosphorylates and activates the transcription factors Smads 2 and 3 , whereas the IFN-gamma receptor and its associated protein tyrosine kinase ***Jak1*** ***mediate*** phosphorylation and activation of the transcription factor ***Stat1*** .	target	0
550	10067896	7040;4088	TGF beta;Smad3	IFN-gamma inhibits the ***TGF beta-induced*** ***phosphorylation*** of ***Smad3*** and its attendant events , namely , the association of Smad3 with Smad4 , the accumulation of Smad3 in the nucleus , and the activation of TGFbeta-responsive genes .	target	1
551	10067896	3458;4088	IFN-gamma;Smad3	***IFN-gamma*** ***inhibits*** the TGF beta-induced phosphorylation of ***Smad3*** and its attendant events , namely , the association of Smad3 with Smad4 , the accumulation of Smad3 in the nucleus , and the activation of TGFbeta-responsive genes .	negative	1
552	10067896	4088;4089	Smad3;Smad4	IFN-gamma inhibits the TGF beta-induced phosphorylation of Smad3 and its attendant events , namely , the ***association*** of ***Smad3*** with ***Smad4*** , the accumulation of Smad3 in the nucleus , and the activation of TGFbeta-responsive genes .	parallel	0
553	10067896	3458;4092	IFN-gamma;Smad7	Acting through Jak1 and Stat1 , ***IFN-gamma*** ***induces*** the expression of ***Smad7*** , an antagonistic SMAD , which prevents the interaction of Smad3 with the TGF-beta receptor .	target	1
554	10067896	4092;4088	Smad7;Smad3	Acting through Jak1 and Stat1 , IFN-gamma induces the expression of ***Smad7*** , an antagonistic SMAD , which ***prevents*** the interaction of ***Smad3*** with the TGF-beta receptor .	negative	0
555	10067969	824;4284	m-calpain;MIP	***MIP*** ***cleavage*** by ***m-calpain*** was carried out by incubation with purified enzyme , and peptides released from the membrane were analyzed by Edman sequencing .	target	1
556	10068058	3561;3718	Gammac;JAK3	***Gammac*** is physically and functionally ***associated*** with the ***JAK3*** tyrosine kinase .	parallel	0
557	10068058	3600;6774	IL-15;STAT3	IL-2 , IL-7 , IL-9 and ***IL-15*** ***activate*** ***STAT3*** and STAT5 , in contrast to IL-4 , which activates STAT6 .	positive	1
558	10068058	3558;6774	IL-2;STAT3	***IL-2*** , IL-7 , IL-9 and IL-15 ***activate*** ***STAT3*** and STAT5 , in contrast to IL-4 , which activates STAT6 .	positive	1
559	10068058	3574;6774	IL-7;STAT3	IL-2 , ***IL-7*** , IL-9 and IL-15 ***activate*** ***STAT3*** and STAT5 , in contrast to IL-4 , which activates STAT6 .	positive	1
560	10068058	3578;6774	IL-9;STAT3	IL-2 , IL-7 , ***IL-9*** and IL-15 ***activate*** ***STAT3*** and STAT5 , in contrast to IL-4 , which activates STAT6 .	positive	1
561	10068058	3565;6778	IL-4;STAT6	IL-2 , IL-7 , IL-9 and IL-15 activate STAT3 and STAT5 , in contrast to ***IL-4*** , which ***activates*** ***STAT6*** .	positive	1
562	10068107	4233;3082	MET;hepatocyte growth factor	Western blot analyses and co-immunoprecipitations were used to investigate the association of proteins involved in epidermal growth factor and hepatocyte growth factor activation and signaling : epidermal growth factor receptor , ***hepatocyte growth factor*** ***receptor*** ( ***MET*** ) , urokinase-type plasminogen activator and its receptor , and a member of the signal transducer and activator of transcription family , STAT-3 .	parallel	1
563	10068204	5594;3791	ERK;VEGFR-2	In the first trimester trophoblast cells , PIGF-1 increased the association of phosphorylated extracellular signal-related kinase ( ERK ) with VEGFR-1 immunoprecipitates while both PIGF-1 and PIGF-2 also potentiated endogenous VEGF mediated ***association*** of phosphorylated extracellular related kinase ( ***ERK*** ) with ***VEGFR-2*** ( KDR ) .	parallel	0
564	10068344	3572;3569	gp130;IL-6	Sequential immunoprecipitation and immunoblotting were performed to assay for expression of the signal-transducing component of the ***IL-6*** ***receptor*** , ***gp130*** .	parallel	1
565	10068443	3308;7421	Hsp 70;VDR	These results suggest that ***DnaK/Hsp 70*** may ***interact*** with ***VDR*** prior to the activation of the latter by 1,25 ( OH ) 2D3-binding .	parallel	1
566	10068454	1674;419	desmin;mono-ADP-ribosyltransferase	Previous studies have shown that ***desmin*** , the muscle-specific intermediate filament protein , is a ***substrate*** for the endogenous muscle arginine-specific ***mono-ADP-ribosyltransferase*** and that ADP-ribosylation inhibits assembly of desmin into intermediate filaments ( Huang et al. , Exp .	parallel	1
567	10068462	5933;1871	p107;E2F3	While ***p107*** is upregulated and ***interacts*** with the putative Rb target ***E2F3*** in neural precursor cells , our results indicate that it clearly can not restore normal E2F regulation .	parallel	1
568	10068472	8900;983	cyclin A1;Cdk1	In the testis , ***cyclin A1*** has been shown to ***bind*** both ***Cdk1*** and Cdk2 but we show here that cyclin A2 binds only Cdk2 .	parallel	1
569	10068472	8900;1017	cyclin A1;Cdk2	In the testis , ***cyclin A1*** has been shown to ***bind*** both Cdk1 and ***Cdk2*** but we show here that cyclin A2 binds only Cdk2 .	parallel	1
570	10068472	890;1017	cyclin A2;Cdk2	In the testis , cyclin A1 has been shown to bind both Cdk1 and Cdk2 but we show here that ***cyclin A2*** ***binds*** only ***Cdk2*** .	parallel	1
571	10068474	1111;995	Chk1;Cdc25C	***Chk1*** kinase , a DNA damage/replication G2 checkpoint kinase , has recently been shown to ***phosphorylate*** and inhibit ***Cdc25C*** , a Cdc2 Tyr-15 phosphatase , thereby directly linking the G2 checkpoint to negative regulation of Cdc2 .	target	1
572	10068590	5594;4843	ERK;iNOS	Thus , both the p38 and ***ERK*** pathways are involved in the ***up-regulation*** of ***iNOS*** and TNF production by murine macrophages , and specific inhibitors of these pathways block macrophage iNOS production even when added 1 h after activation of these cells .	positive	1
573	10068651	2549;5266	Gab1;PI-3	We previously found that the adapter protein ***Gab1*** ( 110 kD ) is tyrosine-phosphorylated and forms a ***complex*** with SHP-2 and ***PI-3*** kinase upon stimulation through either the interleukin-3 receptor ( IL-3R ) or gp130 , the common receptor subunit of IL-6-family cytokines .	parallel	1
574	10068651	2549;5781	Gab1;SHP-2	We previously found that the adapter protein ***Gab1*** ( 110 kD ) is tyrosine-phosphorylated and forms a ***complex*** with ***SHP-2*** and PI-3 kinase upon stimulation through either the interleukin-3 receptor ( IL-3R ) or gp130 , the common receptor subunit of IL-6-family cytokines .	parallel	1
575	10068651	2549;5781	Gab1;SHP-2	***Gab1*** and Gab2 were shown to be ***substrates*** for ***SHP-2*** in vitro .	parallel	1
576	10068651	9846;5781	Gab2;SHP-2	Gab1 and ***Gab2*** were shown to be ***substrates*** for ***SHP-2*** in vitro .	parallel	1
577	10068651	9846;5594	Gab2;ERK2	Overexpression of ***Gab2*** ***enhanced*** the gp130 or Src-related kinases-mediated ***ERK2*** activation as that of Gab1 did .	positive	0
578	10068651	9846;3572	Gab2;gp130	Overexpression of ***Gab2*** ***enhanced*** the ***gp130*** or Src-related kinases-mediated ERK2 activation as that of Gab1 did .	positive	0
579	10068653	7448;5502	Vitronectin;inhibitor-1	***Vitronectin*** ( VN ) ***binds*** to plasminogen activator ***inhibitor-1*** ( PAI-1 ) and integrins and may play an important role in the vascular response to injury by regulating fibrinolysis and cell migration .	parallel	1
580	10068666	3977;3976	LIFR;LIF	leukemia inhibitory factor ( LIF ) induces growth arrest and macrophage differentiation of mouse myeloid leukemic cells through the functional ***LIF*** ***receptor*** ( ***LIFR*** ) , which comprises a heterodimeric complex of the LIFR subunit and gp130 .	parallel	1
581	10068666	3572;3977	gp130;LIFR	leukemia inhibitory factor ( LIF ) induces growth arrest and macrophage differentiation of mouse myeloid leukemic cells through the functional LIF receptor ( LIFR ) , which comprises a heterodimeric ***complex*** of the ***LIFR*** subunit and ***gp130*** .	parallel	1
582	10068670	7422;7075	VEGF;tie-1	This study demonstrated that the release of soluble ***tie-1*** from endothelial cells is ***stimulated*** by inflammatory cytokines and ***VEGF*** through the activation of an endothelial membrane-associated metalloprotease .	positive	0
583	10068671	3439;6772	IFN-alpha;STAT1	***IFN-alpha*** ***enhanced*** tyrosine phosphorylation of ***STAT1*** , STAT3 , STAT4 , STAT5a , and STAT5b .	positive	0
584	10068671	3439;6774	IFN-alpha;STAT3	***IFN-alpha*** ***enhanced*** tyrosine phosphorylation of STAT1 , ***STAT3*** , STAT4 , STAT5a , and STAT5b .	positive	0
585	10068671	3439;6775	IFN-alpha;STAT4	***IFN-alpha*** ***enhanced*** tyrosine phosphorylation of STAT1 , STAT3 , ***STAT4*** , STAT5a , and STAT5b .	positive	0
586	10068671	3439;6776	IFN-alpha;STAT5a	***IFN-alpha*** ***enhanced*** tyrosine phosphorylation of STAT1 , STAT3 , STAT4 , ***STAT5a*** , and STAT5b .	positive	0
587	10068671	3439;6777	IFN-alpha;STAT5b	***IFN-alpha*** ***enhanced*** tyrosine phosphorylation of STAT1 , STAT3 , STAT4 , STAT5a , and ***STAT5b*** .	positive	0
588	10068671	3600;6777	IL-15;STAT5	IL-12 induced STAT4 and IL-2 and ***IL-15*** ***induced*** ***STAT5*** binding to the GAS elements .	target	1
589	10068671	6774;6772	STAT3;STAT1	When we analyzed the nature of STAT proteins capable of binding to IL-2Ralpha , pim-1 , and IRF-1 GAS elements after cytokine stimulation , we observed IFN-alpha-induced ***binding*** of ***STAT1*** , ***STAT3*** , and STAT4 , but not STAT5 to all of these elements .	parallel	1
590	10068671	6774;6775	STAT3;STAT4	When we analyzed the nature of STAT proteins capable of binding to IL-2Ralpha , pim-1 , and IRF-1 GAS elements after cytokine stimulation , we observed IFN-alpha-induced ***binding*** of STAT1 , ***STAT3*** , and ***STAT4*** , but not STAT5 to all of these elements .	parallel	1
591	10068671	6775;6772	STAT4;STAT1	When we analyzed the nature of STAT proteins capable of binding to IL-2Ralpha , pim-1 , and IRF-1 GAS elements after cytokine stimulation , we observed IFN-alpha-induced ***binding*** of ***STAT1*** , STAT3 , and ***STAT4*** , but not STAT5 to all of these elements .	parallel	1
592	10068671	3439;6777	IFN-alpha;STAT5	Yet , ***IFN-alpha*** was able to ***activate*** binding of ***STAT5*** to the high-affinity IFP53 GAS site .	positive	1
593	10068671	6777;7453	STAT5;IFP53	Yet , IFN-alpha was able to activate ***binding*** of ***STAT5*** to the high-affinity ***IFP53*** GAS site .	parallel	1
594	10068674	26191;867	Lyp1;proto-oncogene c-Cbl	***Lyp1*** was found to be constitutively ***associated*** with the ***proto-oncogene c-Cbl*** in thymocytes and T cells .	parallel	0
595	10068674	26191;867	Lyp1;Cbl	Overexpression of ***Lyp1*** ***reduces*** ***Cbl*** tyrosine phosphorylation , suggesting that it may be a substrate of the phosphatase .	negative	1
596	10068683	5269;1511	PI-6;cathepsin G	Native ***cathepsin G*** and recombinant ***PI-6*** formed an SDS-stable ***complex*** in vitro similar in size to that observed in the extracts .	parallel	1
597	10068683	5269;1511	PI-6;cathepsin G	Further kinetic analysis demonstrated that ***cathepsin G*** and ***PI-6*** rapidly form a tight 1:1 ***complex*** ( ka = 6.8 + / - 0.2 x 10 ( 6 ) mol/L -1 s-1 at 17 degrees C ; Ki = 9.2 + / - 0.04 x 10 ( -10 ) mol/L ) .	parallel	1
598	10068868	4880;133	CNP;ADM	These data indicate that circulating ***CNP*** is not involved in the ***regulation*** of ***ADM*** release , renal haemodynamics and sodium excretion in man .	target	1
599	10069452	7040;5743	TGF-beta1;COX-2	***TGF-beta1*** ***induced*** the expression of ***COX-2*** mRNA and protein in intestinal epithelial cells ( IEC-6 ) .	target	1
600	10069452	7040;5743	TGF-beta1;COX-2	***TGF-beta1*** may ***regulate*** ***COX-2*** expression during the colonic adenoma to carcinoma sequence .	target	1
601	10069525	6343;885	secretin;CCK	***secretin*** significantly ( P < 0.005-P < 0.05 ) ***increased*** volume and bicarbonate output and ***CCK*** significantly ( P < 0.01 ) increased the output of bilirubin , pancreatic enzymes , bicarbonate and volume , both during normoglycemia and hyperglycemia .	positive	0
602	10069661	3479;2690	IGF-I;GHBP	The insulin and free fatty acid ( FFA ) areas under curves ( AUC ) during the OGTT , and the ***IGF-I*** level , were also positively ***correlated*** with ***GHBP*** levels ( r = 0.474 , P < 0.005 ; r = 0.572 , P < 0.005 ; r = 0.453 .	positive	0
603	10069682	185;183	AT1R;angiotensin II	It is presently unknown if newer specific ***angiotensin II*** subtype 1 ***receptor*** ( ***AT1R*** ) antagonists are as effective or more effective in treating these conditions compared with ACE inhibitors .	parallel	1
604	10069879	3439;3596	IFN-alpha;IL-13	CONCLUSION : ***IFN-alpha*** differentially ***regulates*** antigen-stimulated IL-4 and ***IL-13*** generation .	target	1
605	10069879	3439;3565	IFN-alpha;IL-4	CONCLUSION : ***IFN-alpha*** differentially ***regulates*** antigen-stimulated ***IL-4*** and IL-13 generation .	target	1
606	10069879	3439;3596	IFN-alpha;IL-13	Differential ***regulation*** of antigen-induced IL-4 and ***IL-13*** generation from T lymphocytes by ***IFN-alpha*** .	target	1
607	10069879	3439;3565	IFN-alpha;IL-4	Differential ***regulation*** of antigen-induced ***IL-4*** and IL-13 generation from T lymphocytes by ***IFN-alpha*** .	target	1
608	10069890	6367;729230	MDC;CCR2	***MDC*** ***binds*** to CC chemokine receptor 4 ( CCR4 ) but not to CCR1 , ***CCR2*** , CCR3 , CCR5 , CCR6 , or CCR7 .	parallel	1
609	10069890	6367;1232	MDC;CCR3	***MDC*** ***binds*** to CC chemokine receptor 4 ( CCR4 ) but not to CCR1 , CCR2 , ***CCR3*** , CCR5 , CCR6 , or CCR7 .	parallel	1
610	10069890	6367;1234	MDC;CCR5	***MDC*** ***binds*** to CC chemokine receptor 4 ( CCR4 ) but not to CCR1 , CCR2 , CCR3 , ***CCR5*** , CCR6 , or CCR7 .	parallel	1
611	10069890	6367;1235	MDC;CCR6	***MDC*** ***binds*** to CC chemokine receptor 4 ( CCR4 ) but not to CCR1 , CCR2 , CCR3 , CCR5 , ***CCR6*** , or CCR7 .	parallel	1
612	10069890	6367;1236	MDC;CCR7	***MDC*** ***binds*** to CC chemokine receptor 4 ( CCR4 ) but not to CCR1 , CCR2 , CCR3 , CCR5 , CCR6 , or ***CCR7*** .	parallel	1
613	10069890	6367;7852	MDC;chemokine receptor 4	***MDC*** ***binds*** to CC ***chemokine receptor 4*** ( CCR4 ) but not to CCR1 , CCR2 , CCR3 , CCR5 , CCR6 , or CCR7 .	parallel	1
614	10069998	7124;6352	TNF-alpha;RANTES	Correction of the CF transmembrane conductance regulator ( CFTR ) defect in CF airway epithelial cells restored the ***induction*** of ***RANTES*** protein and mRNA by ***TNF-alpha*** in combination with IFN-gamma ( P < / = 0.05 ) but had little effect on IL-8 or MCP-1 production compared with mock controls .	target	1
615	10070011	3976;4322	Leukemia inhibitory factor;collagenase-3	***Leukemia inhibitory factor*** and oncostatin M ***stimulate*** ***collagenase-3*** expression in osteoblasts .	positive	0
616	10070011	5008;4322	oncostatin M;collagenase-3	Leukemia inhibitory factor and ***oncostatin M*** ***stimulate*** ***collagenase-3*** expression in osteoblasts .	positive	0
617	10070011	3976;4322	LIF;collagenase-3	***LIF*** and OSM ***increased*** ***collagenase-3*** ( MMP-13 ) mRNA and immunoreactive protein levels in a time - and dose-dependent manner .	positive	0
618	10070011	5008;4322	OSM;collagenase-3	LIF and ***OSM*** ***increased*** ***collagenase-3*** ( MMP-13 ) mRNA and immunoreactive protein levels in a time - and dose-dependent manner .	positive	0
619	10070011	3976;4322	LIF;collagenase-3	In conclusion , ***LIF*** and OSM ***stimulate*** ***collagenase-3*** and TIMP-1 expression in osteoblasts , and these effects may be involved in mediating the bone remodeling actions of these cytokines .	positive	0
620	10070011	5008;4322	OSM;collagenase-3	In conclusion , LIF and ***OSM*** ***stimulate*** ***collagenase-3*** and TIMP-1 expression in osteoblasts , and these effects may be involved in mediating the bone remodeling actions of these cytokines .	positive	0
621	10070021	3486;3481	IGFBP-3;IGF-II	These observations suggest the possibility of an autocrine ***IGF-II*** loop that is ***regulated*** by the relative expression of IGF-II , ***IGFBP-3*** , and IGFBP-6 , and IGFBP proteases in these keratinocytes , although demonstration of this loop requires further study .	target	1
622	10070021	3489;3481	IGFBP-6;IGF-II	These observations suggest the possibility of an autocrine ***IGF-II*** loop that is ***regulated*** by the relative expression of IGF-II , IGFBP-3 , and ***IGFBP-6*** , and IGFBP proteases in these keratinocytes , although demonstration of this loop requires further study .	target	1
623	10070035	355;356	Fas;Fas ligand	******Fas-Fas ligand****** ***interactions*** in the intestinal mucosa may lead to complex signal transduction cascades and gene regulation that culminate in apoptosis , cytokine secretion , or other novel functions .	parallel	1
624	10070035	355;5599	Fas;JNK	***Fas*** ***activates*** the ***JNK*** pathway in human colonic epithelial cells : lack of a direct role in apoptosis .	positive	1
625	10070035	3458;355	IFN-gamma;Fas	***IFN-gamma*** ***increases*** expression of ***Fas*** on HT-29 cells .	positive	0
626	10070049	3484;3479	IGFBP-1;IGF-I	Because ***IGFBP-1*** ***inhibits*** many anabolic actions of ***IGF-I*** , increases in IGFBP-1 may be partly responsible for the decrease in lean body mass observed in catabolic/inflammatory conditions .	negative	1
627	10070167	551;3553	AVP;IL-1beta	***AVP*** ***inhibited*** lipopolysaccharide ( LPS ) - and interleukin-1beta ( ***IL-1beta*** ) - induced nitrite production in a dose - and time-dependent manner , with concomitant changes in cGMP content , iNOS mRNA , and iNOS protein .	negative	1
628	10070274	5970;4790	p65;p50	The complexes consisted of p50/p50 homodimers and ******p50/p65****** ***heterodimers*** .	parallel	1
629	10070307	1500;999	p120;E-cadherin	Our data indicate that the ******E-cadherin-p120****** ***complex*** may be a useful prognostic marker in bladder cancer .	parallel	1
630	10070366	7040;1009	transforming growth factor beta 1;cadherin-11	***transforming growth factor beta 1*** was shown to ***increase*** ***cadherin-11*** mRNA and protein expression in these cultured extravillous cytotrophoblasts in a dose-dependent manner .	positive	0
631	10070954	317;836	Apaf-1;caspase-9 and -3	It can also block ***activation*** of ***caspase-9 and -3*** by ***Apaf-1*** in an in vitro cytochrome c-dependent caspase activation assay .	positive	1
632	10070954	317;842	Apaf-1;caspase-9	These results suggest that caspase-9b functions as an endogenous apoptosis inhibitory molecule by interfering with the formation of a functional ******Apaf-1-caspase-9****** ***complex*** .	parallel	1
633	10070972	5979;1445	Ret;c-Src kinase	These experiments demonstrate that activated ***Ret*** is able to ***bind*** and stimulate ***c-Src kinase*** and that Src activation is essential for the mitogenic activity of Ret .	parallel	1
634	10071234	960;1509	CD44;cathepsin D	***CD44*** expression in carcinomas was positively ***correlated*** with tumour size ( P = 0.018 ) , tumour cells cathepsin D ( P = 0.022 ) , stromal cell ***cathepsin D*** ( P = 0.003 ) and Rb protein ( P = 0.021 ) .	positive	0
635	10071250	891;983	cyclin B1;cdc2	***cyclin B1*** ***activates*** ***cdc2*** , which regulates cell progression through the G2 and M phases .	positive	1
636	10071756	6752;6750	SSTR2;somatostatin	A microplate binding assay for the ***somatostatin*** type-2 ***receptor*** ( ***SSTR2*** ) .	parallel	1
637	10071756	6752;6750	SSTR2;somatostatin	The clinical importance of ***somatostatin*** type-2 ***receptors*** ( ***SSTR2*** ) and the study of novel analogues of somatostatin such as OctreoScan or [ Tyr3 ] - octreotide containing DOTA ( 1,4,7,10-tetraazacyclododecane-1 ,4,7,10 - tetraacetic acid ) as metal chelator led us to develop a methodology to monitor the expression of SSTR2 on tumours of pancreatic origin ( e.g. rat AR4-2J cancer cells ) .	parallel	1
638	10071757	3565;3596	IL-4;IL-13	After occupation of the shared high affinity receptors by the non-signaling , double mutant IL-4 ( 121 ) R -- > D , 124Y -- > D ( ***RY-IL-4*** ) the high affinity ***binding*** of ***IL-13*** could be abolished .	parallel	1
639	10071932	2597;3329	GAPDH;GroEL	The ***binding*** of denatured B. stearothermophilus D-glyceraldehyde-3-phosphate dehydrogenase ( ***GAPDH*** ) to the E. coli chaperonin ***GroEL*** was investigated in two systems : ( 1 ) GroEL immobilized on Sepharose via a single subunit was titrated with urea-denatured soluble GAPDH and ( 2 ) a Sepharose-bound denatured GAPDH monomer was titrated with soluble GroEL .	parallel	1
640	10072067	1385;4261	CREB;CIITA	Transient transactivation experiments showed that ***CREB*** can ***cooperate*** with ***CIITA*** to enhance activation of transcription from MHC class II promoters in a dose-dependent manner .	parallel	0
641	10072067	1385;4261	CREB;CIITA	These results demonstrate that ***CREB*** binds to the X2 box in vivo and ***cooperates*** with ***CIITA*** to direct MHC class II expression .	parallel	0
642	10072076	974;973	Ig-beta;Ig-alpha	BCR destabilization occurs at the cell surface and " dissociated " ******Ig-alpha/Ig-beta****** ***complexes*** remain responsive to anti-Ig-beta stimulation , suggesting that mIg-transducer uncoupling may mediate receptor desensitization .	parallel	1
643	10072079	1326;9020	Cot;NIK	Consistent with such a sequential function of these two kinases , ***Cot*** physically assembles with and ***phosphorylates*** ***NIK*** in vivo .	target	1
644	10072173	4838;4288	Nodal;MIB1	***Nodal*** involvement and vascular invasion were significantly ***associated*** with ***MIB1*** .	parallel	0
645	10072196	5443;4953	beta-endorphin;ODC	These results suggest that CNS ***beta-endorphin*** ***suppresses*** tissue ***ODC*** responsiveness to trophic hormones by downregulating the expression of c-myc and max mRNAs , the encoded proteins of which are known to act physiologically as transcriptional activators of the ODC gene .	negative	1
646	10072219	7040;7422	TGF-beta1;VEGF	These findings suggest that the production of ***VEGF*** is increased and may be ***upregulated*** by ***TGF-beta1*** in acute KD .	positive	1
647	10072388	3725;7157	c-Jun;p53	Rather , ***c-Jun*** ***regulates*** transcription of ***p53*** negatively by direct binding to a variant AP-1 site in the p53 promoter .	negative	1
648	10072389	4342;7465	Mos;Wee1	***Mos*** positively ***regulates*** ***Xe-Wee1*** to lengthen the first mitotic cell cycle of Xenopus .	positive	1
649	10072389	4342;7465	Mos;Wee1	These findings indicate that ***Mos*** positively ***regulates*** ***Xe-Wee1*** to generate the G2 phase in the first cell cycle and establish a direct link between the MAPK signal transduction pathway and Wee1 in vertebrates .	positive	1
650	10072445	4193;7157	MDM2;p53 tumor suppressor	BACKGROUND : The ***MDM2*** oncogene functions as a negative feedback ***regulator*** of the ***p53 tumor suppressor*** .	negative	1
651	10072486	3596;6356	IL-13;eotaxin	Effects of Th2 cytokines on chemokine expression in the lung : ***IL-13*** potently ***induces*** ***eotaxin*** expression by airway epithelial cells .	target	1
652	10072486	3565;6347	IL-4;monocyte-chemotactic protein-1	We tested the major cytokines individually and found that IL-4 and IL-5 induced higher levels of macrophage-inflammatory protein-1alpha and KC ; ***IL-4*** also ***increased*** the production of ***monocyte-chemotactic protein-1*** ; IL-13 and IL-4 induced eotaxin .	positive	0
653	10072486	3596;6356	IL-13;eotaxin	We tested the major cytokines individually and found that IL-4 and IL-5 induced higher levels of macrophage-inflammatory protein-1alpha and KC ; IL-4 also increased the production of monocyte-chemotactic protein-1 ; ***IL-13*** and IL-4 ***induced*** ***eotaxin*** .	target	1
654	10072486	3565;6356	IL-4;eotaxin	We tested the major cytokines individually and found that IL-4 and IL-5 induced higher levels of macrophage-inflammatory protein-1alpha and KC ; IL-4 also increased the production of monocyte-chemotactic protein-1 ; IL-13 and ***IL-4*** ***induced*** ***eotaxin*** .	target	1
655	10072486	3596;6356	IL-13;eotaxin	While TNF-alpha did not stimulate eotaxin production by itself , it markedly augmented ***eotaxin*** ***induction*** by ***IL-13*** .	target	1
656	10072486	3596;6356	IL-13;eotaxin	***IL-13*** was able to ***induce*** ***eotaxin*** in the lung of JAK3-deficient mice , suggesting that JAK3 is not required for IL-13 signaling in airway epithelial cells ; however , eosinophilia was not induced in this situation , suggesting that JAK3 transduces other IL-13-mediated mechanisms critical for eosinophil recruitment .	target	1
657	10072505	3700;920	gp120;CD4	As a follow up to our previous findings that gp17 binds to CD4 with high affinity and interferes with both HIV-1 ***gp120*** ***binding*** to ***CD4*** and syncytium formation , we investigated whether gp17 could affect the T lymphocyte apoptosis induced by a separate ligation of CD4 and TCR .	parallel	1
658	10072514	3565;6778	IL-4;STAT6	***IL-4*** preferentially ***activates*** a novel ***STAT6*** isoform in mast cells .	positive	1
659	10072520	3902;7124	Lymphocyte activation gene-3;TNF-alpha	***Lymphocyte activation gene-3*** , a MHC class II ligand expressed on activated T cells , ***stimulates*** ***TNF-alpha*** and IL-12 production by monocytes and dendritic cells .	positive	0
660	10072521	3600;799	IL-15;calcitonin receptor	Moreover , low ***IL-15*** concentration ( 0.1 ng/ml ) strongly ***increased*** the level of ***calcitonin receptor*** mRNA of mononuclear preosteoclast-like cells .	positive	0
661	10072521	3600;7124	IL-15;TNF-alpha	Although ***IL-15*** is known as a potent ***stimulator*** of ***TNF-alpha*** , its activity was not abolished by addition of anti-TNF-alpha Ab .	positive	0
662	10072547	3383;2017	ICAM-1;cortactin	***ICAM-1-stimulated*** tyrosine ***phosphorylation*** of the actin-associated molecule ***cortactin*** and ICAM-1-mediated , Ag/IL-2-stimulated T lymphocyte migration through EC monolayers were inhibited following pretreatment of EC with cytochalasin D.	target	1
663	10072548	7040;3458	TGF-beta;IFN-gamma	***TGF-beta*** has been reported to ***inhibit*** IL-12 - and IL-2-induced cell proliferation and ***IFN-gamma*** production by T cells and NK cells ; however , the mechanisms of inhibition have not been clearly defined .	negative	1
664	10072548	7040;3558	TGF-beta;IL-2	***TGF-beta*** has been reported to ***inhibit*** IL-12 - and ***IL-2-induced*** cell proliferation and IFN-gamma production by T cells and NK cells ; however , the mechanisms of inhibition have not been clearly defined .	negative	1
665	10072548	3558;3718	IL-2;JAK3	Similarly , but in contrast to previous reports , we found that TGF-beta1 did not inhibit ***IL-2-induced*** ***phosphorylation*** of JAK1 , ***JAK3*** , and STAT5A .	target	1
666	10072548	3558;6776	IL-2;STAT5A	Similarly , but in contrast to previous reports , we found that TGF-beta1 did not inhibit ***IL-2-induced*** ***phosphorylation*** of JAK1 , JAK3 , and ***STAT5A*** .	target	1
667	10072766	7538;7124	TTP;tumor necrosis factor alpha	Recent evidence suggests that a physiological function of ***TTP*** is to ***inhibit*** ***tumor necrosis factor alpha*** secretion from macrophages by binding to and destabilizing its mRNA ( Carballo , E. , Lai , W.S. , Blackshear , P.J. , 1998 .	negative	1
668	10072879	3569;7039	IL-6;TGF alpha	CONCLUSION : TGF alpha , TGF beta 1 , bFGF , ***IL-6*** , IL-8 and ANG may be involved in the autocrine ***regulation*** of the growth and proliferation of pulmonary giant cell carcinoma , ***TGF alpha*** and IL-6 may play an important role in the metastasis of the tumor cells .	target	1
669	10072879	3576;3569	IL-8;IL-6	CONCLUSION : TGF alpha , TGF beta 1 , bFGF , IL-6 , ***IL-8*** and ANG may be involved in the autocrine ***regulation*** of the growth and proliferation of pulmonary giant cell carcinoma , TGF alpha and ***IL-6*** may play an important role in the metastasis of the tumor cells .	target	1
670	10072879	3576;7039	IL-8;TGF alpha	CONCLUSION : TGF alpha , TGF beta 1 , bFGF , IL-6 , ***IL-8*** and ANG may be involved in the autocrine ***regulation*** of the growth and proliferation of pulmonary giant cell carcinoma , ***TGF alpha*** and IL-6 may play an important role in the metastasis of the tumor cells .	target	1
671	10072879	7039;3569	TGF alpha;IL-6	CONCLUSION : ***TGF alpha*** , TGF beta 1 , bFGF , IL-6 , IL-8 and ANG may be involved in the autocrine ***regulation*** of the growth and proliferation of pulmonary giant cell carcinoma , TGF alpha and ***IL-6*** may play an important role in the metastasis of the tumor cells .	target	1
672	10072879	7040;3569	TGF beta 1;IL-6	CONCLUSION : TGF alpha , ***TGF beta 1*** , bFGF , IL-6 , IL-8 and ANG may be involved in the autocrine ***regulation*** of the growth and proliferation of pulmonary giant cell carcinoma , TGF alpha and ***IL-6*** may play an important role in the metastasis of the tumor cells .	target	1
673	10072879	7040;7039	TGF beta 1;TGF alpha	CONCLUSION : TGF alpha , ***TGF beta 1*** , bFGF , IL-6 , IL-8 and ANG may be involved in the autocrine ***regulation*** of the growth and proliferation of pulmonary giant cell carcinoma , ***TGF alpha*** and IL-6 may play an important role in the metastasis of the tumor cells .	target	1
674	10072926	80312;2353	Tet 1;c-fos	***Tet 1*** , 2 , and 4 mg.kg-1 given by i.g. 30 min prior to lindane ***reduced*** ***c-fos*** gene expression in a concentration-dependent manner .	negative	1
675	10073575	3169;7031	HNF-3 alpha;pS2	In gel retardation assays , ***HNF-3 alpha*** and beta ***bound*** predominantly to the site in TFF1 ( formerly ***pS2*** ) and , to a lesser extent , to the sites in TFF2 or TFF3 .	parallel	1
676	10073576	3131;1628	HLF;DBP	Enhanced binding of ******HLF/DBP****** ***heterodimers*** represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes .	parallel	1
677	10073576	3131;1628	HLF;DBP	Enhanced ***binding*** of ******HLF/DBP****** heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes .	parallel	1
678	10073576	1628;3131	DBP;HLF	At least some of the synergistic activation of the Factor VIII promoter seen with HLF and DBP cotransfection can be attributed to increased binding of ******HLF-DBP****** ***heterodimers*** to two Factor VIII promoter sites .	parallel	1
679	10073576	3131;1628	HLF;DBP	These observations indicate that the PAR family of transcription factors plays an important and complex role in regulating expression of the Factor VIII and factor IX genes , involving the binding of both homodimeric and heterodimeric ***complexes*** of ***HLF*** and ***DBP*** to several sites in the promoters .	parallel	1
680	10073576	1628;3131	DBP;HLF	Finally , these studies reaffirm the potential role of dimeric transcription factor complexes in mediating interactions with specific promoter elements , which , in the case of the Factor VIII promoter , results in dramatically enhanced binding of ******HLF-DBP****** ***heterodimers*** to two cis-acting sequences .	parallel	1
681	10073597	4880;4882	CNP;NPR-B	In addition to NPR-A , which is bound by atrial natriuretic peptide ( ANP ) , brain natriuretic peptide ( BNP ) , and urodilatin ( URO ) , a novel form of ***NPR-B*** that might be ***bound*** by C-type natriuretic peptide ( ***CNP*** ) was identified using PCR .	parallel	1
682	10073683	3569;973	IL-6;IgA	Recently , we determined that IEC-derived ***IL-6*** and TGF-beta could ***enhance*** ***IgA*** secretion and suppress IgM secretion by isolated mucosal B cells .	positive	0
683	10073683	7040;973	TGF-beta;IgA	Recently , we determined that IEC-derived IL-6 and ***TGF-beta*** could ***enhance*** ***IgA*** secretion and suppress IgM secretion by isolated mucosal B cells .	positive	0
684	10073698	1026;5111	p21;proliferating cell nuclear antigen	The cdk-inhibitor ***p21*** ( CIP1/WAF1 ) ***inhibits*** the activities of cyclin-dependent kinases and ***proliferating cell nuclear antigen*** , thereby repressing cell-cycle progression and DNA replication .	negative	1
685	10073767	3479;3383	Insulin like growth factor-1;intercellular adhesion molecule-1	***Insulin like growth factor-1*** activates nuclear factor-kappaB and ***increases*** transcription of the ***intercellular adhesion molecule-1*** gene in endothelial cells .	positive	0
686	10073939	3226;9496	HoxC10;Tbx4	Misexpression of Pitx1 in the chick wing bud ***induced*** distal expression of ***Tbx4*** , as well as ***HoxC10*** and HoxC11 , which are normally restricted to hindlimb expression domains .	target	1
687	10073939	5307;3226	Pitx1;HoxC10	Misexpression of ***Pitx1*** in the chick wing bud ***induced*** distal expression of Tbx4 , as well as ***HoxC10*** and HoxC11 , which are normally restricted to hindlimb expression domains .	target	1
688	10073939	5307;9496	Pitx1;Tbx4	Misexpression of ***Pitx1*** in the chick wing bud ***induced*** distal expression of ***Tbx4*** , as well as HoxC10 and HoxC11 , which are normally restricted to hindlimb expression domains .	target	1
689	10073954	7124;7422	TNF-alpha;VEGF	***Cooperation*** between ***VEGF*** and ***TNF-alpha*** is necessary for exposure of active tissue factor on the surface of human endothelial cells .	parallel	0
690	10074122	6387;7852	SDF-1;CXCR4	The ***interaction*** of the chemokine stromal cell-derived factor 1 ( ***SDF-1*** ) with its receptor ***CXCR4*** is vital for cell trafficking during development , is capable of inhibiting human immunodeficiency virus type 1 ( HIV-1 ) utilization of CXCR4 as a coreceptor , and has been implicated in delaying disease progression to AIDS in vivo .	parallel	1
691	10074122	6387;7852	SDF-1;CXCR4	Using CXCR4 chimeras and mutants , we determined that ***SDF-1*** ***requires*** the ***CXCR4*** amino terminus for binding and activates downstream signaling pathways by interacting with the second extracellular loop of CXCR4 .	target	0
692	10074122	6387;7852	SDF-1;CXCR4	***SDF-1-mediated*** ***activation*** of ***CXCR4*** required the Asp-Arg-Tyr motif in the second intracellular loop of CXCR4 , was pertussis toxin sensitive , and did not require the distal C-terminal tail of CXCR4 .	positive	1
693	10074208	3553;3383	IL-1beta;ICAM-1	***Induction*** of interleukin-6 ( IL-6 ) and ***ICAM-1*** by ***IL-1beta*** was not suppressed by infection with EZ , suggesting that the inhibition of IFN signaling is specific .	target	1
694	10074208	3553;3569	IL-1beta;interleukin-6	***Induction*** of ***interleukin-6*** ( IL-6 ) and ICAM-1 by ***IL-1beta*** was not suppressed by infection with EZ , suggesting that the inhibition of IFN signaling is specific .	target	1
695	10074208	3553;4790	IL-1beta;NF-kappaB	In contrast , infection with EZ did not block ***activation*** of the transcription factor ***NF-kappaB*** by ***IL-1beta*** .	positive	1
696	10074428	8995;8784	hGITRL;GITR	We have identified a new TNF-related ligand , designated human ***GITR*** ***ligand*** ( ***hGITRL*** ) , and its human receptor ( hGITR ) , an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [ 4 ] .	parallel	1
697	10074428	8995;4790	hGITRL;NF-kappaB	Cotransfection of ***hGITRL*** and hGITR in embryonic kidney 293 cells ***activated*** the anti-apoptotic transcription factor ***NF-kappaB*** , via a pathway that appeared to involve TNFR-associated factor 2 ( TRAF2 ) [ 7 ] and NF-kappaB-inducing kinase ( NIK ) [ 8 ] .	positive	1
698	10074428	8784;4790	hGITR;NF-kappaB	Cotransfection of hGITRL and ***hGITR*** in embryonic kidney 293 cells ***activated*** the anti-apoptotic transcription factor ***NF-kappaB*** , via a pathway that appeared to involve TNFR-associated factor 2 ( TRAF2 ) [ 7 ] and NF-kappaB-inducing kinase ( NIK ) [ 8 ] .	positive	1
699	10074429	29765;10121	actin-capping protein;Arp1	In dynactin , the ***Arp1*** filament is ***bounded*** by ***actin-capping protein*** at one end and a heterotetrameric protein complex containing the p62 subunit ( D.M.	parallel	1
700	10074432	868;7535	Cbl-b;zap-70	A direct ***interaction*** between the adaptor protein ***Cbl-b*** and the kinase ***zap-70*** induces a positive signal in T cells .	parallel	1
701	10074432	868;7535	Cbl-b;zap-70	A loss-of-function mutation in Cbl-b disrupted the ***interaction*** between ***Cbl-b*** and ***zap-70*** and nearly completely abrogated the Cbl-b-mediated activation of NFAT .	parallel	1
702	10074433	8945;1499	beta-TrCP;beta-catenin	The F-box protein ***beta-TrCP*** ***associates*** with phosphorylated ***beta-catenin*** and regulates its activity in the cell .	parallel	0
703	10074433	8945;1499	beta-TrCP;beta-catenin	We found that the ***binding*** of ***beta-TrCP*** to ***beta-catenin*** was direct and dependent upon the WD40 repeat sequences in beta-TrCP and on phosphorylation of the GSK3beta sites in beta-catenin .	parallel	1
704	10074433	8945;1499	beta-TrCP;beta-catenin	Overexpression of wild-type ***beta-TrCP*** in mammalian cells ***promoted*** the downregulation of ***beta-catenin*** , whereas overexpression of a dominant-negative deletion mutant upregulated beta-catenin protein levels and activated signaling dependent on the transcription factor Tcf .	positive	0
705	10074455	2072;2067	XPF;ERCC1	Immunoblotting revealed that the testis tumour cells had normal amounts of most NER proteins , but low levels of the xeroderma pigmentosum group A protein ( XPA ) and the ******ERCC1-XPF****** endonuclease ***complex*** .	parallel	1
706	10074902	4193;84260	Mdm2;tumor suppressor protein	Degradation of the p53 ***tumor suppressor protein*** has been shown to be ***regulated*** by ***Mdm2*** .	target	1
707	10074903	7158;9338	p202;p21	Transient transfection of a p202-encoding plasmid in Saos-2 cells , which do not harbor a wild-type p53 protein , resulted in an increase in p21 protein , which indicated that ***p202*** could ***regulate*** expression of ***p21*** protein independent of p53 protein .	target	1
708	10074904	1026;1017	p21cip1;cyclin-dependent kinase 2	We propose that an appropriately timed induction of cyclin E/cyclin-dependent kinase 2 by HPV E7 in postmitotic cells enables S-phase reentry and HPV DNA amplification , whereas prematurely induced cyclin E stabilizes ***p21cip1*** protein , which then ***inhibits*** cyclin ***E/cyclin-dependent kinase 2*** .	negative	1
709	10074923	5443;2821	alpha-MSH;AMF	***alpha-MSH*** significantly ***blocked*** the autocrine motility factor ( ***AMF*** ) - enhanced cell motility .	negative	0
710	10074923	267;2821	gp78;AMF	However , alpha-MSH did neither prevent the secretion of AMF from B16-BL6 cells nor alter the expression level of ***AMF*** ***receptor*** ( ***gp78*** ) .	parallel	1
711	10074923	5443;2821	alpha-MSH;AMF	However , ***alpha-MSH*** did neither ***prevent*** the secretion of ***AMF*** from B16-BL6 cells nor alter the expression level of AMF receptor ( gp78 ) .	negative	0
712	10075017	7040;3558	TGF-beta1;IL-2	***TGF-beta1*** was able to ***inhibit*** ***IL-2*** synthesis by the activation of PKA and MAPK .	negative	1
713	10075021	3565;3660	IL-4;IRF-2	Furthermore , ***IL-4*** substantially ***augmented*** the IFN-gamma-induced expression of ***IRF-2*** , which is known to compete with IRF-1 for the DNA recognition site , ISRE ( interferon-stimulated response element ) .	positive	0
714	10075021	3660;3659	IRF-2;IRF-1	Our findings could indicate that IL-4 suppresses IFN-gamma-stimulated iNOS transcription by elevating the level of ***IRF-2*** which , through competition , ***prevents*** ***IRF-1*** from binding to ISRE in the iNOS promoter .	negative	0
715	10075021	3565;4843	IL-4;iNOS	Our findings could indicate that ***IL-4*** ***suppresses*** IFN-gamma-stimulated ***iNOS*** transcription by elevating the level of IRF-2 which , through competition , prevents IRF-1 from binding to ISRE in the iNOS promoter .	negative	1
716	10075082	4790;5970	p50;p65	Direct treatment of the ******p50-p65****** ***heterodimer*** of NF-kappaB with beta-lapachone had no effect on its ability to bind to the DNA .	parallel	1
717	10075644	9568;2550	gb2;gb1	Characterization of the tissue distribution of each of the receptors by in situ hybridization histochemistry in rat brain revealed co-localization of gb1 and gb2 transcripts in many brain regions , suggesting the hypothesis that ***gb1*** and ***gb2*** may ***interact*** in vivo .	parallel	1
718	10075656	1387;5468	CBP;PPARgamma	We show here that the ***interaction*** between ***p300/CBP*** and ***PPARgamma*** is complex and involves multiple domains in each protein .	parallel	1
719	10075656	2033;1387	p300;CBP	We show here that the ***interaction*** between ******p300/CBP****** and PPARgamma is complex and involves multiple domains in each protein .	parallel	1
720	10075656	2033;5468	p300;PPARgamma	We show here that the ***interaction*** between ***p300/CBP*** and ***PPARgamma*** is complex and involves multiple domains in each protein .	parallel	1
721	10075666	6667;356	Sp1;Fas ligand	Constitutive ***Fas ligand*** gene transcription in Sertoli cells is ***regulated*** by ***Sp1*** .	target	1
722	10075666	6667;356	Sp1;FasL	The data presented demonstrates that constitutive ***FasL*** gene transcription in Sertoli cells is ***regulated*** by ***Sp1*** .	target	1
723	10075666	6667;356	Sp1;FasL	In addition , it is shown that basal ***FasL*** expression in Jurkat T cells is also ***controlled*** by ***Sp1*** and this is in contrast to induced FasL expression , which is NFAT-dependent .	target	0
724	10075671	3572;3553	gp130;IL-1	However , in the absence of Box3 , ***gp130*** still stimulates the expression of alpha2-macroglobulin and ***synergizes*** with ***IL-1*** to up-regulate alpha1-acid glycoprotein .	parallel	0
725	10075690	8945;4792	betaTrCP;IkappaBalpha	Expression of a F-box-deleted ***betaTrCP*** ***inhibits*** ***IkappaBalpha*** degradation , promotes accumulation of phosphorylated Ser32-Ser36 IkappaBalpha , and prevents NF-kappaB-dependent transcription .	negative	1
726	10075690	8945;4792	betaTrCP;IkappaBalpha	Expression of a F-box-deleted ***betaTrCP*** inhibits IkappaBalpha degradation , ***promotes*** accumulation of phosphorylated Ser32-Ser36 ***IkappaBalpha*** , and prevents NF-kappaB-dependent transcription .	positive	0
727	10075695	8739;598	DP5;Bcl-xl	Moreover , ***DP5*** specifically ***interacts*** with ***Bcl-xl*** during neuronal apoptosis following exposure to A beta , and its binding could impair the survival-promoting activities of Bcl-xl .	parallel	1
728	10075695	8739;598	DP5;Bcl-xl	Thus , the induction of DP5 mRNA and the ***interaction*** of ***DP5*** and ***Bcl-xl*** could play significant roles in neuronal degeneration following exposure to A beta .	parallel	1
729	10075695	8739;598	DP5;Bcl-xl	The 30-kDa Bcl-xl was co-immunoprecipitated with Myc-tagged DP5 , suggesting that ***DP5*** physically ***interacts*** with ***Bcl-xl*** in mammalian cells .	parallel	1
730	10075695	598;8739	Bcl-xl;DP5	The 30-kDa ***Bcl-xl*** was ***co-immunoprecipitated*** with Myc-tagged ***DP5*** , suggesting that DP5 physically interacts with Bcl-xl in mammalian cells .	parallel	1
731	10075695	8739;598	DP5;Bcl-xl	Here , we analyzed DP5 gene expression and the specific ***interaction*** of ***DP5*** with ***Bcl-xl*** during neuronal death induced by amyloid-beta protein ( A beta ) .	parallel	1
732	10075696	8844;7453	KSR-1;gamma2	***KSR-1*** also ***interacted*** with ***gamma2*** and gamma3 in a two-hybrid assay .	parallel	1
733	10075698	7124;231	tumor necrosis factor-alpha;aldose reductase	Osmotic response element is required for the ***induction*** of ***aldose reductase*** by ***tumor necrosis factor-alpha*** .	target	1
734	10075705	8775;6804	alpha-SNAP;syntaxin 1A	We conclude that 1 ) alpha-SNAP plays a crucial role in insulin exocytosis via large dense core vesicles , but not GABA released via synaptic-like microvesicles , in pancreatic beta cells ; and 2 ) the ***interaction*** of ***alpha-SNAP*** and ***syntaxin 1A*** may play an important role in the insulin exocytotic process .	parallel	1
735	10075705	8775;6804	alpha-SNAP;syntaxin 1A	An in vitro binding study showed that both wild-type alpha-SNAP and C-terminal-deleted ***alpha-SNAP*** mutant ( 1-285 ) can ***bind*** to ***syntaxin 1A*** .	parallel	1
736	10075710	5464;2017	PP1;cortactin	***cortactin*** phosphorylation was triggered by shrinkage and not by changes in osmolarity or pHi and was ***abrogated*** by ***PP1*** .	negative	0
737	10075717	6469;2735	Sonic Hedgehog;Gli1	***Sonic Hedgehog-induced*** ***activation*** of the ***Gli1*** promoter is mediated by GLI3 .	positive	1
738	10075717	6469;2737	Shh;GLI3	The trans-activating capacity of ***GLI3*** is positively and negatively ***regulated*** by ***Shh*** and cAMP-dependent protein kinase , respectively , through a specific region of GLI3 , which contains the CBP-binding domain and the phosphorylation sites of cAMP-dependent protein kinase .	target	1
739	10075717	2737;2735	GLI3;Gli1	***GLI3*** directly ***binds*** to the ***Gli1*** promoter and induces Gli1 transcription in response to Shh .	parallel	1
740	10075717	2737;2735	GLI3;Gli1	***GLI3*** directly binds to the Gli1 promoter and ***induces*** ***Gli1*** transcription in response to Shh .	target	1
741	10075735	990;4998	CDC6;Orc1	To further investigate the molecular mechanism of nucleotide-binding function , we have demonstrated that the ***CDC6*** protein ***associates*** with ***Orc1*** in vitro and in vivo .	parallel	0
742	10075735	990;4998	CDC6;Orc1	Intriguingly , the ***interaction*** between ***Orc1*** and ***CDC6*** is disrupted when the CDC6 ( K114E ) protein is used .	parallel	1
743	10075735	990;4998	CDC6;Orc1	Our results suggest that a proper molecular ***interaction*** between ***Orc1*** and ***CDC6*** depends on the functional ATP-binding of CDC6 , which may be a prerequisite step to assemble the operational replicative complex at the G1/S transition .	parallel	1
744	10075736	4194;4193	MDMX;MDM2	The ***MDMX*** gene product is ***related*** to the ***MDM2*** oncoprotein , both of which interact with the p53 tumor suppressor .	parallel	0
745	10075736	4194;7157	MDMX;p53	This truncated ***MDMX*** protein is termed MDMX-S ( " short form " ) , represents only the p53-binding domain , and appears to ***bind*** ***p53*** better than full-length MDMX .	parallel	1
746	10075738	7041;367	ARA55;androgen receptor	Cloning and characterization of ***androgen receptor*** ***coactivator*** , ***ARA55*** , in human prostate .	positive	1
747	10075741	6714;1956	c-Src;epidermal growth factor receptor	***c-Src-mediated*** ***phosphorylation*** of the ***epidermal growth factor receptor*** on Tyr845 and Tyr1101 is associated with modulation of receptor function .	target	1
748	10075741	1956;6714	EGFR;c-Src	Accumulating evidence indicates that ***interactions*** between the epidermal growth factor receptor ( ***EGFR*** ) and the nonreceptor tyrosine kinase ***c-Src*** may contribute to an aggressive phenotype in multiple human tumors .	parallel	1
749	10075741	1956;6714	EGFR;c-Src	Here we provide evidence that ***association*** between ***c-Src*** and ***EGFR*** can occur directly , as shown by receptor overlay experiments , and that it results in the appearance of two novel tyrosine phosphorylations on the receptor that are seen both in vitro and in vivo following EGF stimulation .	parallel	0
750	10075741	6714;1956	c-Src;EGFR	Phosphorylation of Tyr416 and homologous residues in other tyrosine kinase receptors has been shown to be required for or to increase catalytic activity , suggesting that ***c-Src*** can ***influence*** ***EGFR*** activity by mediating phosphorylation of Tyr845 .	target	0
751	10075822	7187;5604	cRaf-1;MEK1	When the purified components are incubated together , ***cRaf-1*** phosphorylates and ***activates*** ***MEK1*** , MEK1 phosphorylates and activates ERK2 , and ERK2 phosphorylates the peptide , biotin-AAATGPLSPGPFA .	positive	1
752	10075822	5604;5594	MEK1;ERK2	When the purified components are incubated together , cRaf-1 phosphorylates and activates MEK1 , ***MEK1*** ***phosphorylates*** and activates ***ERK2*** , and ERK2 phosphorylates the peptide , biotin-AAATGPLSPGPFA .	target	1
753	10075854	10468;10220	follistatin;BMP-11	Interestingly , the activin antagonist , ***follistatin*** , but not noggin , an antagonist of BMPs 2 and 4 , ***inhibited*** ***BMP-11*** activity on animal caps .	negative	1
754	10075858	5599;3725	JNK;AP-1	We demonstrate that transcriptional activation of the human RANTES promoter by LPS is dependent on specific ***AP-1*** and NF-kappaB response elements , which are ***regulated*** by c-Jun N-terminal kinase ( ***JNK*** ) and NF-kappaB kinase cascades , respectively .	target	1
755	10075858	5599;4790	JNK;NF-kappaB	We demonstrate that transcriptional activation of the human RANTES promoter by LPS is dependent on specific AP-1 and ***NF-kappaB*** response elements , which are ***regulated*** by c-Jun N-terminal kinase ( ***JNK*** ) and NF-kappaB kinase cascades , respectively .	target	1
756	10075858	4790;3725	NF-kappaB;AP-1	We demonstrate that transcriptional activation of the human RANTES promoter by LPS is dependent on specific ***AP-1*** and NF-kappaB response elements , which are ***regulated*** by c-Jun N-terminal kinase ( JNK ) and ***NF-kappaB*** kinase cascades , respectively .	target	1
757	10075862	958;959	CD40;CD40L	We found that the inhibition of the ******CD40L-CD40****** ***interaction*** in GvH animals by the administration of an anti-CD40L antibody ( MR-1 ) completely prevents the development of crypt hyperplasia and villous atrophy in GvH animals .	parallel	1
758	10075862	958;959	CD40;CD40L	In conclusion , the ******CD40L-CD40****** ***interaction*** is crucial in the pathogenesis of T-cell-mediated mucosal atrophy .	parallel	1
759	10075921	1080;3301	CFTR;Hdj-2	Interestingly , complex ***formation*** between ***Hdj-2*** and nascent ***CFTR*** was greatly reduced after expression of the R-domain .	parallel	0
760	10075926	3716;3561	Jak1;gammac	For example , ***Jak1*** and Jak3 ***bind*** specifically to the IL-2 receptor beta ( IL-2Rbeta ) and common gamma ( ***gammac*** ) chains , respectively , and initiate biochemical signals critical in controlling immune responses .	parallel	1
761	10075926	3718;3561	Jak3;gammac	For example , Jak1 and ***Jak3*** ***bind*** specifically to the IL-2 receptor beta ( IL-2Rbeta ) and common gamma ( ***gammac*** ) chains , respectively , and initiate biochemical signals critical in controlling immune responses .	parallel	1
762	10075926	3716;3561	Jak1;gammac	Furthermore , a ***Jak3-Jak1*** chimera containing only the JH6 and JH7 domains of Jak3 ***interacts*** with ***gammac*** and can reconstitute IL-2-dependent responses , including receptor phosphorylation and activation of signal transducer and activator of transcription (STAT) 5b .	parallel	1
763	10075926	3718;3561	Jak3;gammac	Furthermore , a ***Jak3-Jak1*** chimera containing only the JH6 and JH7 domains of Jak3 ***interacts*** with ***gammac*** and can reconstitute IL-2-dependent responses , including receptor phosphorylation and activation of signal transducer and activator of transcription (STAT) 5b .	parallel	1
764	10075927	5599;1869	JNK1;E2F1	Here we report that two kinases involved in signal transduction have opposite effects on E2F function : the stress-induced kinase ***JNK1*** ***inhibits*** ***E2F1*** activity whereas the related p38 kinase reverses Rb-mediated repression of E2F1 .	negative	1
765	10075927	5599;1869	JNK1;E2F1	***JNK1*** ***phosphorylates*** ***E2F1*** in vitro , and co-transfection of JNK1 reduces the DNA binding activity of E2F1 ; treatment of cells with TNFalpha had a similar effect .	target	1
766	10075927	355;1432	Fas;p38	***Fas*** stimulation of Jurkat cells is known to ***induce*** ***p38*** kinase and we find a pronounced increase in Rb phosphorylation within 30 min of Fas stimulation .	target	1
767	10075936	4193;7157	MDM2;p53	Although the p53-binding protein ***MDM2*** has an NES and has been proposed to ***mediate*** ***p53*** export , we show that the intrinsic p53 NES is both necessary and sufficient for export .	target	0
768	10075937	8894;1983	eIF2;eIF5	We also find that three lysine-rich boxes in the N-terminal segment of eIF2beta mediate the ***binding*** of ***eIF2*** to both ***eIF5*** and eIF2B .	parallel	1
769	10075994	5989;5994	RFX;RFXAP	Our results suggest possible stoichiometry of the RFX subunits and potential ***interaction*** between ***RFX-B/Ank*** and ***RFXAP*** with one of the subunits of X2BP .	parallel	1
770	10075997	2547;7520	Ku70;Ku80	Electrophoretic mobility shift assays demonstrated that the ubiquitous factor that binds the -75 GATA sequence was the ******Ku70-Ku80****** ( Ku ) ***heterodimer*** .	parallel	1
771	10076053	3565;3976	Interleukin-4;leukemia inhibitory factor	***Interleukin-4*** ( IL-4 ) , but not IL-10 , ***regulates*** the synthesis of IL-6 , IL-8 and ***leukemia inhibitory factor*** by human bone marrow stromal cells .	target	1
772	10076189	4914;4803	Trk-A;NGF	Moreover , ***Trk-A*** , the nerve growth factor ( ***NGF*** ) high-affinity ***receptor*** , is expressed in vivo in mature rat islets and early during development in the pancreatic ductal network that represents the source of putative stem cells .	parallel	1
773	10076194	3569;7422	IL-6;VEGF	The endocrine and auto - / paracrine ***control*** of ***VEGF*** production in pituitary FS cells by PACAP , ***IL-6*** and glucocorticoids may play an important role both in angiogenesis and vascular permeability regulation within the pituitary under physiological and pathophysiological conditions .	target	0
774	10076194	116;7422	PACAP;VEGF	The endocrine and auto - / paracrine ***control*** of ***VEGF*** production in pituitary FS cells by ***PACAP*** , IL-6 and glucocorticoids may play an important role both in angiogenesis and vascular permeability regulation within the pituitary under physiological and pathophysiological conditions .	target	0
775	10076194	3569;7422	interleukin-6;vascular endothelial growth factor	Pituitary adenylate cyclase-activating polypeptide , ***interleukin-6*** and glucocorticoids ***regulate*** the release of ***vascular endothelial growth factor*** in pituitary folliculostellate cells .	target	1
776	10076194	116;7422	Pituitary adenylate cyclase-activating polypeptide;vascular endothelial growth factor	***Pituitary adenylate cyclase-activating polypeptide*** , interleukin-6 and glucocorticoids ***regulate*** the release of ***vascular endothelial growth factor*** in pituitary folliculostellate cells .	target	1
777	10076194	116;7422	Pituitary adenylate cyclase-activating polypeptide;VEGF	Interestingly , the ***VEGF*** secretion was ***stimulated*** by both forms of ***Pituitary adenylate cyclase-activating polypeptide*** ( PACAP-38 and PACAP-27 ) , indicating that this hypothalamic peptide regulates endothelial cell function and growth within the pituitary .	positive	0
778	10076194	3569;7422	interleukin-6;VEGF	***VEGF*** secretion was also ***stimulated*** by ***interleukin-6*** ( IL-6 ) whereas basal , IL-6 - and PACAP-stimulated secretion was inhibited by the synthetic glucocorticoid dexamethasone .	positive	0
779	10076538	3553;6647	IL-1 beta;Cu/Zn-superoxide dismutase	***IL-1 beta*** also ***increased*** cytosolic ***Cu/Zn-superoxide dismutase*** ( SOD ) and mitochondrial Mn-SOD in RINm5F cells .	positive	0
780	10076538	3553;6648	IL-1 beta;Mn-SOD	***IL-1 beta*** also ***increased*** cytosolic Cu/Zn-superoxide dismutase ( SOD ) and mitochondrial ***Mn-SOD*** in RINm5F cells .	positive	0
781	10076566	862;3320	MTG8;HSP90	***Association*** of ***MTG8*** ( ETO/CDR ) , a leukemia-related protein , with serine/threonine protein kinases and heat shock protein ***HSP90*** in human hematopoietic cell lines .	parallel	0
782	10076566	3320;862	HSP90;MTG8	In addition , we demonstrated that heat shock protein 90 ( ***HSP90*** ) specifically ***binds*** to the amino-terminal domain of ***MTG8*** in vitro and in vivo .	parallel	1
783	10076567	7157;1026	p53;WAF1	The ***p53-dependent*** ***induction*** of ***p21/WAF1*** and the following dephosphorylation of the retinoblastoma protein by CAV could account for the observed CAV-mediated G1 phase arrest .	target	1
784	10077002	7421;5741	vitamin D receptor;parathyroid hormone	Turning a negative into a positive : ***vitamin D receptor*** ***interactions*** with the avian ***parathyroid hormone*** response element .	positive	1
785	10077003	2247;885	bFGF;CCK	We conclude that ***bFGF*** and forskolin ***stimulate*** the ***CCK*** gene promoter via the CRE/TRE ( -80 ) in the proximal promoter region .	positive	0
786	10077051	5320;4843	PLA2;inducible NO synthase	***PLA2*** ( 50 ng/ml ) ***induced*** significant amounts of NO production , ***inducible NO synthase*** mRNA expression , and cytotoxicity toward the human umbilical vein endothelial cells in normal rat AMs , and these activities were significantly inhibited by quinacrine .	target	1
787	10077163	3458;6890	IFN-gamma;TAP1	***IFN-gamma*** ***up-regulates*** the expression of MHC-class-I antigens and ***TAP1*** both in control and in TAP1-transfected RCC cells to a similar level .	positive	1
788	10077343	3569;5741	IL-6;PTH	***IL-6*** levels ***correlated*** with ***PTH*** ( r = 0.22 , p = 0.04 ) and with ICTP ( r = 0.31 , p = 0.004 ) .	parallel	0
789	10077431	183;5154	angiotensin II;PDGF-A chain	***angiotensin II*** ***induced*** ***PDGF-A chain*** messenger RNA expression , and genistein inhibited angiotensin-induced PDGF gene expression .	target	1
790	10077561	1385;5371	CREB;PML	Here , we demonstrate that the cAMP enhancer binding protein ( ***CREB*** ) - binding protein ( CBP ) ***associates*** with ***PML*** in vitro and is recruited to the PODs in vivo .	parallel	0
791	10077576	10657;6714	Sam68;Src	***Sam68*** , the 68-kDa ***Src*** ***substrate*** associated during mitosis , is an RNA-binding protein with signaling properties that contains a GSG ( GRP33 , Sam68 , GLD-1 ) domain .	parallel	1
792	10077579	904;1025	cyclin T1;Cdk9	We found that P-TEFb complexes containing human ***cyclin T1*** ***complexed*** with either human or rodent ***Cdk9*** supported Tat transactivation and interacted with the Tat activation domain and the HIV-1 TAR RNA element to form TAR loop-dependent ribonucleoprotein complexes .	parallel	1
793	10077598	54521;8766	rab11BP;rab11	We have identified and cloned the cDNA for a 912-aa protein , ***rab11BP*** , that ***interacts*** with the GTP-containing active form of ***rab11*** , a GTP-binding protein that plays a critical role in receptor recycling .	parallel	1
794	10077598	8766;54521	rab11;rab11BP	In vitro ***binding*** of ***rab11*** to native ***rab11BP*** requires partial denaturation of the latter to expose an internal binding site located between residues 334 and 504 that is apparently masked by the C-terminal portion of the protein , which includes six repeats known as WD40 domains .	parallel	1
795	10077605	2737;5727	GLI3;PTCH1	Here we show that full-length ***GLI3*** localizes to the cytoplasm and ***activates*** ***PTCH1*** expression , which is similar to full-length Ci155 .	positive	1
796	10077605	2737;5727	GLI3;PTCH1	PHS mutant protein ( ***GLI3-PHS*** ) localizes to the nucleus and ***represses*** GLI3-activated ***PTCH1*** expression , which is similar to Ci75 .	negative	1
797	10077605	2737;5727	GLI3;PTCH1	The PAP-A mutant protein ( ***GLI3-PAP-A*** ) showed less specific subcellular localization but still ***inhibited*** GLI3-activated ***PTCH1*** transcription , suggesting it may be a weaker allele than the GLI3-PHS mutation .	negative	1
798	10077630	3383;3565	Intercellular adhesion molecule-1;interleukin 4	***Intercellular adhesion molecule-1*** ***inhibits*** ***interleukin 4*** production by naive T cells .	negative	1
799	10077630	3383;3565	ICAM-1;IL-4	However , coexpression of ***ICAM-1*** and B7 on Drosophila APC ***induced*** little ***IL-4*** , suggesting an inhibitory role for Intercellular adhesion molecule-1 ( ICAM-1 ) .	target	1
800	10077638	7422;8829	Vascular endothelial growth factor;neuropilin-1	***Vascular endothelial growth factor*** ( VEGF ) - like protein from orf virus NZ2 ***binds*** to VEGFR2 and ***neuropilin-1*** .	parallel	1
801	10077638	7422;3791	Vascular endothelial growth factor;VEGFR2	***Vascular endothelial growth factor*** ( VEGF ) - like protein from orf virus NZ2 ***binds*** to ***VEGFR2*** and neuropilin-1 .	parallel	1
802	10077639	4193;7157	Hdm2;p53	Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for ***Hdm2-mediated*** ***degradation*** of ***p53*** .	negative	1
803	10077639	4193;7157	Hdm2;p53	The ***Hdm2*** oncoprotein ***inhibits*** ***p53*** functions by two means : ( i ) it blocks p53 's transactivation activity and ( ii ) it targets p53 for degradation in a proteasome-dependent manner .	negative	1
804	10077639	4193;7157	Hdm2;p53	Recent data indicate that Hdm2 shuttles between the nucleus and the cytoplasm and that the ***regulation*** of ***p53*** levels by ***Hdm2*** requires its nuclear export activity .	target	1
805	10077639	4193;7157	Hdm2;p53	In the first , ***Hdm2*** ***binds*** to ***p53*** in the nucleus and shuttles p53 from the nucleus to the cytoplasm , and then it targets p53 to the cytoplasmic proteasome .	parallel	1
806	10077639	4193;7157	Hdm2;p53	Alternatively , Hdm2 and p53 could be exported separately from the nucleus and then associate in the cytoplasm , where ***Hdm2*** ***promotes*** the degradation of ***p53*** .	positive	0
807	10077639	4193;7157	Hdm2;p53	Hdm2NLS , Hdm2NES , or the combination of both mutants were unable to promote p53 degradation in the cotransfected 2KO cells ( which were null for both the p53 and mdm2 genes ) , although wild-type ***Hdm2*** efficiently ***reduced*** ***p53*** levels under the same conditions .	negative	1
808	10077642	1634;1956	decorin;epidermal growth factor receptor	This process is caused by a ***decorin-mediated*** ***activation*** of the ***epidermal growth factor receptor*** , which leads to a sustained induction of endogenous p21 ( WAF1/CIP1 ) ( the cyclin-dependent kinase inhibitor p21 ) and growth arrest .	positive	1
809	10077651	7037;7018	TfR;transferrin	We recently reported that HFE , the protein defective in HH , was physically associated with the ***transferrin*** ***receptor*** ( ***TfR*** ) in duodenal crypt cells and proposed that mutations in HFE attenuate the uptake of transferrin-bound iron from plasma by duodenal crypt cells , leading to up-regulation of transporters for dietary iron .	parallel	1
810	10077651	3077;7037	HFE;TfR	We recently reported that ***HFE*** , the protein defective in HH , was physically ***associated*** with the transferrin receptor ( ***TfR*** ) in duodenal crypt cells and proposed that mutations in HFE attenuate the uptake of transferrin-bound iron from plasma by duodenal crypt cells , leading to up-regulation of transporters for dietary iron .	parallel	0
811	10077665	375790;7402	agrin;utrophin	The ***modulation*** of ***utrophin*** gene expression in muscle by the nerve-derived factor ***agrin*** plausibly involves the trophic factor ARIA/heregulin .	target	0
812	10077697	4916;4908	TrkC;NT-3	In situ hybridization revealed that mRNA for the full-length ( catalytic ) ***NT-3*** ***receptor*** , ***TrkC*** , was present in , and limited to , the neural plate ( including the neural folds ) coincident with its formation .	parallel	1
813	10077990	5335;3558	PLC gamma 1;IL-2	Consequently , Ras/MAP kinase and ***PLC gamma 1*** pathways are activated to ***induce*** ***IL-2*** gene transcription through AP-1 and NF-AT generation .	target	1
814	10078198	5468;1050	PPAR gamma;C/EBP alpha	C/EBP alpha-deficient adipocytes accumulates less lipid , and they do not induce endogenous PPAR gamma , indicating that ***cross-regulation*** between ***C/EBP alpha*** and ***PPAR gamma*** is important in maintaining the differentiated state .	parallel	0
815	10078198	5468;1050	PPAR gamma;C/EBP alpha	These results define multiple roles for C/EBP alpha in adipogenesis and show that ***cross-regulation*** between ***PPAR gamma*** and ***C/EBP alpha*** is a key component of the transcriptional control of this cell lineage .	parallel	0
816	10078201	4193;7157	MDM2;p53	The binding of RB to MDM2 is shown to be essential for RB to overcome both the antiapoptotic function of MDM2 and the ***MDM2-dependent*** ***degradation*** of ***p53*** .	negative	1
817	10078201	4193;7157	MDM2;p53	The RB-MDM2 interaction does not prevent MDM2 from inhibiting p53-dependent transcription , but the ***RB-MDM2*** complex still ***binds*** to ***p53*** .	parallel	1
818	10078201	7157;4193	p53;MDM2	However , an ******RB-MDM2-p53****** trimeric ***complex*** is active in p53-mediated transrepression .	parallel	1
819	10078204	161882;2623	FOG;GATA-1	***FOG*** , a zinc finger protein , interacts with the amino ( N ) finger of GATA-1 and ***cooperates*** with ***GATA-1*** to promote differentiation .	parallel	0
820	10078204	161882;2623	FOG;GATA-1	Thus , ***interaction*** of ***FOG*** with ***GATA-1*** is essential for the function of GATA-1 in erythroid differentiation .	parallel	1
821	10078242	5340;5345	plasmin;alpha 2 plasmin inhibitor	The fibrinolytic system also became activated during LVAD treatment as was indicated by a marked increase in FDP-D-dimer and ******alpha 2 plasmin inhibitor-plasmin****** ***complex*** ( PIC ) .	parallel	1
822	10078535	867;7535	Cbl;ZAP-70	In T cells , ***Cbl-N*** ***binds*** to the tyrosine-phosphorylated inhibitory site of the protein tyrosine kinase ***ZAP-70*** .	parallel	1
823	10078551	2646;2645	glucokinase regulatory protein;glucokinase	This hitherto unknown new protein factor may have the function of a ***glucokinase regulatory protein*** in the pancreatic beta-cell , which may ***regulate*** ***glucokinase*** enzyme activity in a glucose-dependent manner .	target	1
824	100786	6750;7200	Somatostatin;thyrotropin releasing factor	***Somatostatin*** ***inhibits*** release of ***thyrotropin releasing factor*** from organ cultures of rat hypothalamus .	negative	1
825	100786	6750;7200	Somatostatin;thyrotropin releasing factor	***Somatostatin*** in concentrations of 10 ( -6 ) to 10 ( -8 ) M ***inhibited*** basal release of ***thyrotropin releasing factor*** in organ culture of rat hypothalamus .	negative	1
826	10079103	1436;1440	CSFR;G-CSF	Because ***G-CSF*** ***receptor*** ( ***G-CSFR*** ) - deficient mice do not have the expected neutrophilia after administration of human interleukin-8 ( IL-8 ) , we examined the effect of the loss of G-CSFR on IL-8-stimulated PMN function .	parallel	1
827	10079106	5606;5594	MKK3;p38	Although ***MKK3*** , MKK4 , and MKK6 all activated p38 MAPk in experimental models , only MKK3 was found to ***activate*** recombinant ***p38*** MAPk in LPS-treated neutrophils .	positive	1
828	10079106	6416;5594	MKK4;p38	Although MKK3 , ***MKK4*** , and MKK6 all activated p38 MAPk in experimental models , only MKK3 was found to ***activate*** recombinant ***p38*** MAPk in LPS-treated neutrophils .	positive	1
829	10079106	5608;5594	MKK6;p38	Although MKK3 , MKK4 , and ***MKK6*** all activated p38 MAPk in experimental models , only MKK3 was found to ***activate*** recombinant ***p38*** MAPk in LPS-treated neutrophils .	positive	1
830	10079106	5606;1432	MKK3;p38alpha	These findings support a pathway by which LPS stimulation of neutrophils results in activation of ***MKK3*** , which in turn ***activates*** ***p38alpha*** MAPk , ultimately regulating adhesion , NF-kappaB activation , enhanced gene expression of TNF-alpha , and regulation of TNF-alpha synthesis .	positive	1
831	10079115	335;351	apo;Abeta	These findings suggest that human ***apo*** E isoforms ***decrease*** Abeta aggregation or increase ***Abeta*** clearance relative to an environment in which mouse apo E or no apo E is present .	negative	0
832	10079137	5080;3859	PAX-6;K12	The paired box homeotic gene 6 ( ***PAX-6*** ) , which is involved in controlling eye development , ***stimulated*** the activity of keratin ***K12*** promoter .	positive	0
833	10079141	7124;6347	TNFalpha;MCP-1	Levels of aqueous IL-8 and ***MCP-1*** at 12 hr are ***regulated*** by ***TNFalpha*** , while levels at 24 hr are regulated by TNFalpha and IL-1 .	target	1
834	10079194	3921;6227	LBP/p40;S21	Ribosome-associated protein ***LBP/p40*** ***binds*** to ***S21*** protein of 40S ribosome : analysis using a yeast two-hybrid system .	parallel	1
835	10079200	7040;2662	TGF-beta1;BMP-3b	In contrast , ***TGF-beta1*** treatment , which suppresses ALPase activity , rapidly and completely ***inhibited*** gene expression of ***BMP-3b*** .	negative	1
836	10079231	4654;3516	MyoD;CBF1	Moreover , Notch-induced antagonism of ***MyoD*** ***requires*** ***CBF1*** suggesting that the CBF1-dependent pathway mediates a cell-type-specific block in the myogenic program .	target	0
837	10079269	1026;1017	p21;cdk2	These results suggest that : ( i ) within an emerging extension made up of peripherally located tumor cells , their high proliferative potential gradually wanes as their relative topographical position becomes more central in the expanding tumor ; ( ii ) peripherally located tumor cells maintain their proliferative potential by higher cyclin A-cdk2 complex activity ; and ( iii ) intermediate expression of ***p21/p27*** in the peripherally located cells ***promotes*** higher cyclin ***A-cdk2*** kinase activity , whereas high p21/p27 expression in nonneoplastic cells inhibits kinase activity .	positive	0
838	10080242	885;3359	CCK;5-HT3	In the IMB model , specificity of 5-HT3-DA2 interactions , and of ******5-HT3-CCK****** ( A ) ***interactions*** from previous studies , prompted investigation of CCK ( A ) - DA2 interactions ; there appeared to be none .	parallel	1
839	1008045	885;796	CCK;calcitonin	It is postulated that these pancreatic secretion changes are the result of the ***interplay*** of released ***CCK*** and ***calcitonin*** .	parallel	1
840	10080532	3596;6778	IL-13;STAT6	We propose a model in which stimulation of monocytes by IFN activates de novo synthesis of an inhibitory factor , possibly one or more members of the SOCS / SSI/CIS gene family , capable of suppressing ***activation*** of ***STAT6*** by IL-4 and ***IL-13*** .	positive	1
841	10080532	3565;6778	IL-4;STAT6	We propose a model in which stimulation of monocytes by IFN activates de novo synthesis of an inhibitory factor , possibly one or more members of the SOCS / SSI/CIS gene family , capable of suppressing ***activation*** of ***STAT6*** by ***IL-4*** and IL-13 .	positive	1
842	10080538	4486;4485	RON;MSP	AKT kinase is a component of a separate branch of the ***RON/PI3-K*** pathway that ***mediates*** the ***MSP*** anti-apoptotic effect on epithelial cells .	target	0
843	10080538	4485;4486	MSP;RON	Kinases involved in ******MSP/RON****** ***signaling*** .	parallel	0
844	10080538	4485;207	MSP;AKT	In addition to previously identified involvement of phosphatidylinositol 3-kinase ( PI3-K ) , JNK , and MAPK , we found that FAK , c-Src , and ***AKT*** are rapidly and transiently ***activated*** by ***MSP*** .	positive	1
845	10080538	4485;6714	MSP;c-Src	In addition to previously identified involvement of phosphatidylinositol 3-kinase ( PI3-K ) , JNK , and MAPK , we found that FAK , ***c-Src*** , and AKT are rapidly and transiently ***activated*** by ***MSP*** .	positive	1
846	10080538	4485;5747	MSP;FAK	In addition to previously identified involvement of phosphatidylinositol 3-kinase ( PI3-K ) , JNK , and MAPK , we found that ***FAK*** , c-Src , and AKT are rapidly and transiently ***activated*** by ***MSP*** .	positive	1
847	10080539	7124;8174	TNF-alpha;MAdCAM-1	***MAdCAM-1*** expression in these tissues was significantly ***enhanced*** , in a time-dependent manner , by systemic administration of ***TNF-alpha*** .	positive	0
848	10080539	7124;8174	TNF-alpha;MAdCAM-1	Taken together , these data demonstrate that ***TNF-alpha*** ***enhances*** surface expression of ***MAdCAM-1*** in intestinal and colonic tissues to the same extent in both wild-type and IL-10 k/o mice with no colonic inflammation , whereas IL-10 k/o mice with active colitis exhibited a profound up-regulation of MAdCAM-1 in the colon .	positive	0
849	10080542	2322;2885	Flt3;Grb2	Like the chimeric murine Flt3 , human ***Flt3*** undergoes autophosphorylation , ***associates*** with ***Grb2*** , and leads to tyrosine phosphorylation of Shc on ligand binding .	parallel	0
850	10080542	5781;2885	SHP-2;Grb2	***SHP-2*** does not associate with Flt3 , but ***binds*** directly to ***Grb2*** .	parallel	1
851	10080875	4790;5970	p50;p65	Involvement of NF-kappaB ******p50/p65****** ***heterodimer*** in activation of the human pro-interleukin-1beta gene at two subregions of the upstream enhancer element .	parallel	1
852	10080878	7124;4803	TNF-alpha;NGF	These observations indicate that the basal level of brain ***NGF*** can be ***influenced*** negatively or positively by local expression of ***TNF-alpha*** and that this cytokine , through dose-dependent regulation of NGF synthesis and release , may be involved in neurodegenerative events associated with aging .	negative	0
853	10080908	861;1050	AML1;C/EBPalpha	Thus , ***AML1/ETO*** can ***bind*** to the transcription factor ***C/EBPalpha*** , inhibit C/EBPalpha-dependent transcription , and block granulocytic differentiation .	parallel	1
854	10080908	862;1050	ETO;C/EBPalpha	Thus , ***AML1/ETO*** can ***bind*** to the transcription factor ***C/EBPalpha*** , inhibit C/EBPalpha-dependent transcription , and block granulocytic differentiation .	parallel	1
855	10080908	862;861	ETO;AML1	However , ***AML1/ETO*** can also ***synergize*** with the transcription factor ***AML1*** to enhance the activity of the M-CSF receptor promoter .	parallel	0
856	10080918	8600;4982	OPGL;osteoprotegerin	Osteoblasts/stromal cells express a new member of the TNF-ligand family " osteoclast differentiation factor ( ODF ) / ***osteoprotegerin*** ***ligand*** ( ***OPGL*** ) / TNF-related activation-induced cytokine ( TRANCE ) / receptor activator of NF-kB ligand ( RANKL ) " as a membrane associated factor .	parallel	1
857	10080918	4982;8600	osteoprotegerin;ODF	***osteoprotegerin*** ( OPG ) / osteoclastogenesis inhibitory factor ( OCIF ) / TNF receptor-like molecule 1 ( TR1 ) is a soluble decoy ***receptor*** for ***ODF/OPGL/TRANCE*** / RANKL .	parallel	1
858	10080923	3953;6774	leptin receptor;STAT3	Tyrosine ***phosphorylation*** of ***STAT3*** by leptin through ***leptin receptor*** in mouse metaphase 2 stage oocyte .	target	1
859	10080923	3952;6774	leptin;STAT3	Tyrosine ***phosphorylation*** of ***STAT3*** by ***leptin*** through leptin receptor in mouse metaphase 2 stage oocyte .	target	1
860	10080930	943;944	CD30;CD153	These results indicated a differential regulation of CD30 and CD153 expression in T cells , which may be relevant to immuno-regulatory role of the ******CD30-CD153****** ***interaction*** .	parallel	1
861	10080941	1499;999	beta-catenin;E-cadherin	We found that the ***binding*** of ***beta-catenin*** to Tcf4 , APC , or ***E-cadherin*** was mutually exclusive .	parallel	1
862	10080943	355;7157	Fas;p53	Here , we report that although ***Fas*** induction is closely ***linked*** to the expression of wild type ***p53*** , it is not correlated with JNK activation induced by apoptotic stimuli .	parallel	0
863	10080948	8027;958	signal transducing adaptor molecule;CD40	TRAF2 is a ***signal transducing adaptor molecule*** which ***binds*** to the ***CD40*** cytoplasmic domain .	parallel	1
864	10080949	3569;6774	IL-6;Stat3	Interestingly , a short pretreatment of cells with alpha-thrombin significantly inhibited ***IL-6-induced*** tyrosine ***phosphorylation*** of ***Stat3*** .	target	1
865	10080955	4286;7306	MITF;TRP-1	Microphthalmia transcription factor ***MITF*** , a melanocyte-specific basic helix-loop-helix protein , has been shown to ***transactivate*** Tyrosinase and ***TRP-1*** genes in vitro by binding to a shared regulatory sequence known as M box .	positive	1
866	10080955	4286;7299	MITF;Tyrosinase	Microphthalmia transcription factor ***MITF*** , a melanocyte-specific basic helix-loop-helix protein , has been shown to ***transactivate*** ***Tyrosinase*** and TRP-1 genes in vitro by binding to a shared regulatory sequence known as M box .	positive	1
867	10080957	4145;5829	Chk;paxillin	Using Far Western analysis , we revealed that the ***Chk*** SH2 domain directly ***associates*** with tyrosine phosphorylated ***paxillin*** .	parallel	0
868	10080957	2288;5829	p52;paxillin	Finally , ***p52*** ( Chk ) expression in Csk-deficient mouse embryo fibroblasts ***decreased*** total phosphotyrosine levels of ***paxillin*** , implying a physiological role for Chk .	negative	0
869	10080957	4145;5829	Csk homologous kinase;paxillin	The ***Csk homologous kinase*** , Chk , ***binds*** tyrosine phosphorylated ***paxillin*** in human blastic T cells .	parallel	1
870	10080957	4145;5829	Chk;paxillin	Interestingly , ***Chk*** specifically ***bound*** tyrosine phosphorylated ***paxillin*** .	parallel	1
871	10080957	4145;5829	Chk;paxillin	Using GST fusion proteins , we determined that the ***Chk*** SH2 domain , not the SH3 domain , ***bound*** tyrosine phosphorylated ***paxillin*** .	parallel	1
872	10081488	4363;4613	MRP;N-myc	We found a close ***association*** between ***MRP*** and ***N-myc*** expression in each neuroblastoma sample but no significant relationship between MRP expression and the patients ' outcome .	parallel	0
873	10081488	4613;4363	N-myc;MRP	The forced expression of ***N-myc*** failed to ***enhance*** the expression of ***MRP*** in N-myc transfected neuroblastoma cell lines .	positive	0
874	10081495	7039;1890	TGF-alpha;thymidine phosphorylase	EGF and ***TGF-alpha*** ***up-regulated*** ***thymidine phosphorylase*** ( dThdPase ) expression of tumor cells and consequently enhanced the antiproliferative action of 5 ' - dFUrd , which is converted to 5-fluorouracil by dThdPase .	positive	1
875	10081611	3572;3976	gp130;Leukemia inhibitory factor	Leukemia inhibitory factor action is mediated by a heterodimeric receptor consisting of two subunits , ***gp130*** and the low-affinity ***Leukemia inhibitory factor*** ***receptor*** ( LIFR ) .	parallel	1
876	10081611	3977;3976	LIFR;Leukemia inhibitory factor	Leukemia inhibitory factor action is mediated by a heterodimeric receptor consisting of two subunits , gp130 and the low-affinity ***Leukemia inhibitory factor*** ***receptor*** ( ***LIFR*** ) .	parallel	1
877	10081660	3486;3479	IGFBP-3;IGF-I	In a third series of experiments , ***IGFBP-3*** ***inhibited*** ***125I-IGF-I*** binding to granulosa cells .	negative	1
878	10082132	7039;1956	TGFalpha;EGFR	We recently reported that ***TGFalpha*** ***induces*** less efficient ***EGFR*** heterodimerization and downregulation than does EGF ( Gulliford et al. , 1997 , Oncogene , 15:2219 -2223 ) .	target	1
879	10082132	7039;1956	TGFalpha;EGFR	This suggests that BFA blocks EGFR recycling and thus shortens EGF-dependent receptor signalling , whereas ***TGFalpha*** shortens receptor signalling and thus ***blocks*** ***EGFR*** downregulation .	negative	0
880	10082137	3458;1277	IFN-gamma;COL1A1	The results indicate that ***IFN-gamma*** ***inhibits*** ***COL1A1*** expression in fibroblasts principally at the level of gene transcription .	negative	1
881	10082137	3458;1277	IFN-gamma;alpha1(I) procollagen	In this study , we examined the ***modulation*** of ***alpha1(I) procollagen*** gene ( COL1A1 ) expression by recombinant ***IFN-gamma*** .	target	0
882	10082137	3439;3458	IFN-alpha;IFN-gamma	IFN-alpha and IFN-beta by themselves had little effect on promoter activity , but ***IFN-alpha*** ***augmented*** the inhibitory effect of ***IFN-gamma*** .	positive	0
883	10082424	7124;4790	Tumor necrosis factor-alpha;NF-kappaB	***Tumor necrosis factor-alpha*** ( TNF ) induces apoptosis in confluent LLC-PK1 epithelial cells , but also ***activates*** ***NF-kappaB*** , a negative regulator of apoptosis .	positive	1
884	10082520	3303;5599	HSP72;JNK	Elevation of cellular levels of the major heat shock protein HSP72 inhibited a repression of JNK dephosphorylation by these stressful treatments , which explains recent reports of the ***suppression*** of ***JNK*** activation by ***HSP72*** .	negative	1
885	10082522	2796;1958	GnRH;Egr-1	We now show that ***GnRH*** is a potent ***stimulator*** of ***Egr-1*** , but not Ptx1 or SF-1 , expression .	positive	0
886	10082522	1958;2516	Egr-1;SF-1	***Egr-1*** ***interacts*** directly with Ptx1 and with ***SF-1*** , leading to an enhancement of Ptx1 - and SF-1-induced LHbeta transcription .	parallel	1
887	10082523	4654;4656	MyoD;myogenin	In vitro and in vivo assays revealed a direct ***association*** of Sp1 and ******myogenin-MyoD****** mediated by the DNA-binding domain of Sp1 and the HLH motif of myogenin .	parallel	0
888	10082523	4654;6667	MyoD;Sp1	In vitro and in vivo assays revealed a direct ***association*** of ***Sp1*** and ***myogenin-MyoD*** mediated by the DNA-binding domain of Sp1 and the HLH motif of myogenin .	parallel	0
889	10082523	6667;4656	Sp1;myogenin	In vitro and in vivo assays revealed a direct ***association*** of ***Sp1*** and ***myogenin-MyoD*** mediated by the DNA-binding domain of Sp1 and the HLH motif of myogenin .	parallel	0
890	10082528	2114;598	Ets2;bcl-x	The bcl-x promoter contains potential Ets binding sites , and we show that the transcription factor , ***Ets2*** , first identified by its sequence identity to v-ets of the E26 retrovirus , can ***transactivate*** the ***bcl-x*** promoter .	positive	1
891	10082535	4790;595	NF-kappaB;cyclin D1	***NF-kappaB*** was found to ***stimulate*** transcription of ***cyclin D1*** , a key regulator of G1 checkpoint control .	positive	0
892	10082537	4904;5813	YB-1;Puralpha	Reciprocal ***interaction*** between two cellular proteins , ***Puralpha*** and ***YB-1*** , modulates transcriptional activity of JCVCY in glial cells .	parallel	1
893	10082537	4904;5813	YB-1;Puralpha	Here we have examined the structural and functional ***interaction*** between two cellular regulatory proteins , ***YB-1*** and ***Puralpha*** , on the 23-bp sequence element derived from the enhancer-promoter of the human polyomavirus JCV .	parallel	1
894	10082537	4904;5813	YB-1;Puralpha	Affinity chromatography and coimmunoprecipitation provide evidence for a direct ***interaction*** between ***Puralpha*** and ***YB-1*** in the absence of the DNA sequence .	parallel	1
895	10082537	4904;5813	YB-1;Puralpha	The results of this study suggest that the cooperative ***interaction*** between ***YB-1*** and ***Puralpha*** mediates the synergistic activation of the human polyomavirus JCV genome by these cellular proteins .	parallel	1
896	10082538	6597;2353	BRG1;c-fos	Human SWI-SNF component ***BRG1*** ***represses*** transcription of the ***c-fos*** gene .	negative	1
897	10082538	6597;2353	BRG1;c-fos	***BRG1*** also specifically repressed transcription from a transfected c-fos promoter and correspondingly ***blocked*** transcriptional activation of the endogenous ***c-fos*** gene .	negative	0
898	10082545	9013;7343	SL1;UBF	A kinase activity associated with simian virus 40 large T antigen phosphorylates upstream binding factor ( UBF ) and promotes ***formation*** of a stable initiation complex between ***UBF*** and ***SL1*** .	parallel	0
899	10082545	7343;9013	UBF;SL1	Moreover , we showed that large T antigen-induced ***UBF*** phosphorylation ***promotes*** the formation of a stable ***UBF-SL1*** complex .	positive	0
900	10082545	9013;7343	SL1;UBF	Moreover , we showed that large T antigen-induced UBF phosphorylation promotes the formation of a stable ******UBF-SL1****** ***complex*** .	parallel	1
901	10082552	1022;2968	CAK;TFIIH	Recent reports have shown that Tat can also interact with the multisubunit transcription factor TFIIH complex and increase the phosphorylation of CTD by the Cdk-activating kinase ( ***CAK*** ) complex ***associated*** with the core ***TFIIH*** .	parallel	0
902	10082552	1022;2968	CAK;TFIIH	Therefore , unlike the P-TEFb kinase activity that is essential for Tat activation of HIV-1 transcriptional elongation , the ***CAK*** kinase ***associated*** with ***TFIIH*** appears to be dispensable for Tat function .	parallel	0
903	10082553	9013;7343	SL1;UBF	Alkaline phosphatase treatment of UBF completely abolished the ability of UBF to interact with SL1 ; moreover , incubation of the dephosphorylated UBF with nuclear extracts from exponentially growing cells was able to restore the ******UBF-SL1****** ***interaction*** .	parallel	1
904	10082553	7343;9013	UBF;SL1	Recruitment of TATA-binding protein-TAFI complex ***SL1*** to the human ribosomal DNA promoter is mediated by the carboxy-terminal activation domain of upstream binding factor ( UBF ) and is ***regulated*** by ***UBF*** phosphorylation .	target	1
905	10082554	10260;4609	c-myc promoter binding protein;c-myc	We initially identified ***c-myc promoter binding protein*** 1 ( MBP-1 ) , which negatively ***regulates*** ***c-myc*** promoter activity , from a human cervical carcinoma cell expression library .	negative	1
906	10082561	1050;5933	C/EBPalpha;p107	Coimmunoprecipitation analyses revealed an ***interaction*** of ***C/EBPalpha*** with ***p107*** but none with cdk2 , E2F1 , or cyclin A.	parallel	1
907	10082561	1050;5933	C/EBPalpha;p107	***C/EBPalpha*** ***regulates*** formation of S-phase-specific ***E2F-p107*** complexes in livers of newborn mice .	target	1
908	10082562	7030;2113	TFE3;Ets-1	Both ***TFE3*** and USF ***enhanced*** ***Ets-1*** DNA binding in vitro by relieving the influence of an autoinhibitory domain in Ets-1 by direct protein-protein associations .	positive	0
909	10082566	836;5888	caspase 3;Rad51	In vitro studies show that ***Rad51*** is ***cleaved*** by ***caspase 3*** at a DVLD/N site .	target	1
910	10082572	4211;3205	MEIS1;HOXA9	***MEIS1*** ***enhances*** in vitro ***HOXA9-PBX*** protein complex formation in the absence of DNA and forms a trimeric electrophoretic mobility shift assay ( EMSA ) complex with these proteins on an oligonucleotide containing a PBX-HOXA9 site .	positive	0
911	10082572	4211;3205	MEIS1;HOXA9	Taken together , these data suggest that in myeloid leukemia cells ***MEIS1*** forms trimeric ***complexes*** with PBX and ***HOXA9*** , which in turn can bind to consensus PBX-HOXA9 DNA targets .	parallel	1
912	10082579	3667;5747	insulin receptor substrate 1;FAK	On the other hand , IGF-I promotes the ***association*** of ***insulin receptor substrate 1*** with the focal adhesion kinase ( ***FAK*** ) , paxillin , and the tyrosine phosphatase SHP-2 , resulting in FAK and paxillin dephosphorylation .	parallel	0
913	10082579	3667;5829	insulin receptor substrate 1;paxillin	On the other hand , IGF-I promotes the ***association*** of ***insulin receptor substrate 1*** with the focal adhesion kinase ( FAK ) , ***paxillin*** , and the tyrosine phosphatase SHP-2 , resulting in FAK and paxillin dephosphorylation .	parallel	0
914	10082579	3667;5781	insulin receptor substrate 1;SHP-2	On the other hand , IGF-I promotes the ***association*** of ***insulin receptor substrate 1*** with the focal adhesion kinase ( FAK ) , paxillin , and the tyrosine phosphatase ***SHP-2*** , resulting in FAK and paxillin dephosphorylation .	parallel	0
915	10082579	3479;3667	IGF-I;insulin receptor substrate 1	On the other hand , ***IGF-I*** ***promotes*** the association of ***insulin receptor substrate 1*** with the focal adhesion kinase ( FAK ) , paxillin , and the tyrosine phosphatase SHP-2 , resulting in FAK and paxillin dephosphorylation .	positive	0
916	10082583	983;4654	cdk1;MyoD	***MyoD*** can be efficiently ***phosphorylated*** in vitro by either purified cdk1-cyclin B or ***cdk1*** and cdk2 immunoprecipitated from proliferative myoblasts .	target	1
917	10082583	1017;4654	cdk2;MyoD	***MyoD*** can be efficiently ***phosphorylated*** in vitro by either purified cdk1-cyclin B or cdk1 and ***cdk2*** immunoprecipitated from proliferative myoblasts .	target	1
918	10082583	983;4654	cdk1;MyoD	Comparative two-dimensional tryptic phosphopeptide mapping combined with site-directed mutagenesis revealed that ***cdk1*** and cdk2 ***phosphorylate*** ***MyoD*** on serine 200 in proliferative myoblasts .	target	1
919	10082583	1017;4654	cdk2;MyoD	Comparative two-dimensional tryptic phosphopeptide mapping combined with site-directed mutagenesis revealed that cdk1 and ***cdk2*** ***phosphorylate*** ***MyoD*** on serine 200 in proliferative myoblasts .	target	1
920	10082587	5781;140885	SHP-2;SHPS-1	Previous studies revealed that a fraction of SHP-2 moves to focal contacts upon integrin engagement and that ***SHP-2*** ***binds*** to SHP substrate 1 ( ***SHPS-1*** ) / SIRP-1alpha , a transmembrane glycoprotein with adhesion molecule characteristics ( Y.	parallel	1
921	10082587	6714;140885	Src;SHPS-1	Both in vitro and in vivo studies indicate that ***SHPS-1*** tyrosyl phosphorylation is ***catalyzed*** by ***Src*** family protein tyrosine kinases ( PTKs ) .	positive	1
922	10082648	3329;25824	groEL;thioredoxin reductase	Fluorescence spectroscopy has been used to investigate the ***interaction*** of ***groEL*** and protein disulfide isomerase with denatured ***thioredoxin reductase*** tagged with a fluorescent probe .	parallel	1
923	10082656	7124;3383	TNF-alpha;ICAM-1	***TNF-alpha*** ***induced*** a transient ***ICAM-1*** increase in NHK , which reached peak-levels 2-4 days post cytokine stimulus .	target	1
924	10082658	6606;213	SMA;albumin	A comb-shaped polymeric modifier , ***SMA*** [ poly ( styrene comaleic anhydride ) ] , which ***binds*** to plasma ***albumin*** in blood was used to modify the synthetic cell-adhesive laminin peptide YIGSR , and its inhibitory effect on experimental lung metastasis of B16-BL6 melanoma cells was examined .	parallel	1
925	10082670	3553;1244	IL-1;MRP2	These results suggest that LPS activates Kupffer cells to secrete ***IL-1*** and TNFalpha , which in turn activate MAP kinases and ***decrease*** ***CMOAT/MRP2*** expression .	negative	0
926	10082809	1270;3977	CNTF;LIFR	***CNTF*** ***induced*** the tyrosine phosphorylation of ***LIFR*** and gp130 , as well as of proteins with the molecular weights of 88/91 and 42 kDa .	target	1
927	10082812	3479;2691	IGF-1;GHRH	The simultaneous inhibition of the somatotropic axis and sleep raises the possibility that the sleep alterations also result from an ***IGF-1-induced*** ***suppression*** of ***GHRH*** .	negative	1
928	10082837	9607;2353	CART;c-Fos	Recombinant ***CART*** peptide ***induces*** ***c-Fos*** expression in central areas involved in control of feeding behaviour .	target	1
929	10082837	9607;2353	CART;c-Fos	Compared to vehicle , ***CART*** ***induced*** ***c-Fos*** expression in several hypothalamic and brainstem structures implicated in the central control of food intake .	target	1
930	10082852	627;4852	BDNF;neuropeptide Y	Moreover , the specific ***BDNF*** increase was significantly ***correlated*** with contents of ***neuropeptide Y*** .	parallel	0
931	10082946	2006;1991	elastin;leukocyte elastase	***Interaction*** between ***leukocyte elastase*** and ***elastin*** : quantitative and catalytic analyses .	parallel	1
932	10082946	1991;2006	HLE;elastin	We now report quantitative measurements of the ***binding*** and catalytic interaction between ***HLE*** and ***elastin*** permitted by analogy to receptor-ligand systems .	parallel	1
933	10082946	1991;2006	HLE;elastin	Analysis of the ***binding*** of ***HLE*** to ***elastin*** at 0 degrees C , in the absence of significant catalytic activity , demonstrated two classes of binding sites ( Kd = 9.3 x10 ( -9 ) M and 2.5 x10 ( -7 ) M ) .	parallel	1
934	10082946	1991;2006	HLE;elastin	Our studies suggest that ***interaction*** of ***HLE*** with ***elastin*** in vivo may be very persistent and permit progressive solubilization of this structurally important extracellular matrix component .	parallel	1
935	10082949	7134;7138	TnC;TnT	Ca2 + regulation of vertebrate striated muscle contraction is initiated by conformational changes in the N-terminal , regulatory domain of the Ca2 + - binding protein troponin C ( TnC ) , altering the ***interaction*** of ***TnC*** with the other subunits of troponin complex , TnI and ***TnT*** .	parallel	1
936	10083623	3553;1906	Interleukin-1 beta;endothelin-1	***Interleukin-1 beta*** ***induces*** ***endothelin-1*** gene by multiple mechanisms .	target	1
937	10083766	2247;7422	bFGF;VEGF	By means of an enzyme-linked immunosorbent assay of CH-157MN meningioma cell supernatants , we demonstrated that EGF and ***bFGF*** similarly ***induce*** ***VEGF*** secretion by CH-157MN meningioma cells .	target	1
938	10084597	3952;3479	Leptin;IGF-I	These data demonstrate that ***Leptin*** can directly ***inhibit*** ***IGF-I*** action in ovarian theca and GC at concentrations commonly present in obese women .	negative	1
939	10084688	4684;1385	NCAM;CREB	***NCAM*** ***stimulates*** the Ras-MAPK pathway and ***CREB*** phosphorylation in neuronal cells .	positive	0
940	10084754	959;958	CD154;CD40	Central role for ***CD40/CD40*** ***ligand*** ( ***CD154*** ) interactions in transplant rejection .	parallel	1
941	10084754	959;958	CD154;CD40	Major advances have been made in understanding the expression and function of ***CD40*** and its ***ligand*** ***CD154*** .	parallel	1
942	10084754	958;959	CD40;CD154	It is now clear that ******CD40/CD154****** ***interactions*** are critical in many aspects of the immune response , including T cell activation , T cell-dependent macrophage activation , T cell-B cell interactions and endothelial activation .	parallel	1
943	10084754	958;959	CD40;CD154	Moreover , increasing evidence supports a central role for ******CD40/CD154****** ***interactions*** in the immune processes of allograft rejection .	parallel	1
944	10084951	356;355	FasL;Fas	The Fas ( APO-1 / CD95 ) receptor , a transmembrane protein that induces apoptosis in the cell when bound to ***Fas*** ***ligand*** ( ***FasL*** ) , may be involved .	parallel	1
945	10084962	5228;5601	PlGF;SAPK	Exogenous ***PlGF*** ***induced*** specific activation of the stress-activated protein kinase ( ***SAPK*** ) pathways , c-Jun-N terminal kinase ( JNK ) and p38 kinase , in primary term trophoblast with little to no induction of the extracellular signal regulated kinase ( ERK-1 and -2 ) pathways .	target	1
946	10084962	5228;5599	PlGF;JNK	Exogenous ***PlGF*** ***induced*** specific activation of the stress-activated protein kinase ( SAPK ) pathways , c-Jun-N terminal kinase ( ***JNK*** ) and p38 kinase , in primary term trophoblast with little to no induction of the extracellular signal regulated kinase ( ERK-1 and -2 ) pathways .	target	1
947	10084962	5228;1432	PlGF;p38	Exogenous ***PlGF*** ***induced*** specific activation of the stress-activated protein kinase ( SAPK ) pathways , c-Jun-N terminal kinase ( JNK ) and ***p38*** kinase , in primary term trophoblast with little to no induction of the extracellular signal regulated kinase ( ERK-1 and -2 ) pathways .	target	1
948	10084962	5228;5594	PlGF;ERK-1 and -2	In contrast , ***PlGF*** ***induced*** significant ***ERK-1 and -2*** activity in human umbilical vein endothelial cells but did not induce JNK or p38 activity .	target	1
949	10084962	5228;5601	PlGF;SAPK	***PlGF-induced*** ***activation*** of the ***SAPK*** signaling pathways protected trophoblast from growth factor withdrawal-induced apoptosis , but it did not protect trophoblast from apoptosis induced by the pro-inflammatory cytokines , interferon gamma and tumor necrosis factor alpha .	positive	1
950	10084970	2908;5743	Glucocorticoid receptor;prostaglandin endoperoxide synthase-2	***Glucocorticoid receptor-mediated*** post-ceramide ***inhibition*** of the interleukin-1beta-dependent induction of ovarian ***prostaglandin endoperoxide synthase-2*** in rats .	negative	1
951	10084996	3569;7422	interleukin-6;VEGF	Prevotella intermedia LPS , phorbol 12-myristate 13-acetate , and ***interleukin-6*** also ***induced*** ***VEGF*** mRNA expression in HPC .	target	1
952	10085038	959;958	CD40L;CD40	Because of the critical role of the ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) pathway in the induction and effector phases of immune responses , we investigated the effects of CD40 ligation on the control of Trypanosoma cruzi infection .	parallel	1
953	10085062	10746;1147	MEKK2;IKK-alpha	We now show that ***MEKK2*** and MEKK3 can in vivo ***activate*** ***IKK-alpha*** and IKK-beta , induce site-specific IkappaBalpha phosphorylation , and , relatively modestly , activate an NF-kappaB reporter gene .	positive	1
954	10085062	10746;3551	MEKK2;IKK-beta	We now show that ***MEKK2*** and MEKK3 can in vivo ***activate*** IKK-alpha and ***IKK-beta*** , induce site-specific IkappaBalpha phosphorylation , and , relatively modestly , activate an NF-kappaB reporter gene .	positive	1
955	10085062	4215;1147	MEKK3;IKK-alpha	We now show that MEKK2 and ***MEKK3*** can in vivo ***activate*** ***IKK-alpha*** and IKK-beta , induce site-specific IkappaBalpha phosphorylation , and , relatively modestly , activate an NF-kappaB reporter gene .	positive	1
956	10085062	4215;3551	MEKK3;IKK-beta	We now show that MEKK2 and ***MEKK3*** can in vivo ***activate*** IKK-alpha and ***IKK-beta*** , induce site-specific IkappaBalpha phosphorylation , and , relatively modestly , activate an NF-kappaB reporter gene .	positive	1
957	10085062	10746;4790	MEKK2;NF-kappaB	We now show that ***MEKK2*** and MEKK3 can in vivo activate IKK-alpha and IKK-beta , induce site-specific IkappaBalpha phosphorylation , and , relatively modestly , ***activate*** an ***NF-kappaB*** reporter gene .	positive	1
958	10085062	10746;4792	MEKK2;IkappaBalpha	We now show that ***MEKK2*** and MEKK3 can in vivo activate IKK-alpha and IKK-beta , ***induce*** site-specific ***IkappaBalpha*** phosphorylation , and , relatively modestly , activate an NF-kappaB reporter gene .	target	1
959	10085065	718;727	C3a;C5a	The mutants were transiently expressed in HEK-293 cells ( with or without Galpha-16 ) and analyzed for cell surface expression , ***binding*** of ***C3a*** and ***C5a*** , and functional responsiveness ( calcium mobilization ) toward C3a , C5a , and a C3a as well as a C5a analogue peptide .	parallel	1
960	10085066	4193;7157	Mdm2;p53	In addition , ***Mdm2*** ***promotes*** ***p53*** degradation , thereby terminating its growth inhibitory signal .	positive	0
961	10085066	25;7157	c-Abl;p53	Recent studies have shown that the ***c-Abl*** protein-tyrosine kinase ***binds*** ***p53*** and enhances its transcriptional activity .	parallel	1
962	10085066	25;7157	c-Abl;p53	We demonstrate that ***c-Abl*** ***increases*** the expression level of the ***p53*** protein .	positive	0
963	10085066	4193;7157	Mdm2;p53	The enhanced expression is achieved by inhibiting ***Mdm2-mediated*** ***degradation*** of ***p53*** .	negative	1
964	10085083	387;6722	RhoA;serum response factor	***Activation*** of ***serum response factor*** by ***RhoA*** is mediated by the nuclear factor-kappaB and C/EBP transcription factors .	positive	1
965	10085083	387;4790	RhoA;NF-kappaB	Here , we demonstrate that ***activation*** of ***NF-kappaB*** by ***RhoA*** does not exclusively promote its nuclear translocation and binding to the specific kappaB sequences .	positive	1
966	10085083	4790;6722	NF-kappaB;serum response factor	***NF-kappaB*** is also involved in the ***regulation*** of the transcriptional activity of the c-fos ***serum response factor*** ( SRF ) , since the activation of a SRE-dependent promoter by RhoA can be efficiently interfered by the double mutant IkappaBalphaS32A/S36A , an inhibitor of the NF-kappaB activity .	target	1
967	10085083	4790;1051	p50;C/EBPbeta	We also present evidence that RelA and ***p50*** NF-kappaB subunits ***cooperate*** with the transcription factor ***C/EBPbeta*** in the transactivation of the 4 x SRE-CAT reporter .	parallel	0
968	10085083	5970;1051	RelA;C/EBPbeta	We also present evidence that ***RelA*** and p50 NF-kappaB subunits ***cooperate*** with the transcription factor ***C/EBPbeta*** in the transactivation of the 4 x SRE-CAT reporter .	parallel	0
969	10085083	387;1051	RhoA;C/EBPbeta	Furthermore , ***RhoA*** ***increases*** the levels of ***C/EBPbeta*** protein , facilitating the functional cooperation between NF-kappaB , C/EBPbeta , and SRF proteins .	positive	0
970	10085083	4790;1051	NF-kappaB;C/EBPbeta	Furthermore , RhoA increases the levels of C/EBPbeta protein , facilitating the functional ***cooperation*** between ***NF-kappaB*** , ***C/EBPbeta*** , and SRF proteins .	parallel	0
971	10085083	4790;6722	NF-kappaB;SRF	Furthermore , RhoA increases the levels of C/EBPbeta protein , facilitating the functional ***cooperation*** between ***NF-kappaB*** , C/EBPbeta , and ***SRF*** proteins .	parallel	0
972	10085083	6722;1051	SRF;C/EBPbeta	Furthermore , RhoA increases the levels of C/EBPbeta protein , facilitating the functional ***cooperation*** between NF-kappaB , ***C/EBPbeta*** , and ***SRF*** proteins .	parallel	0
973	10085086	4790;596	NFkappaB;Bcl-2	Expression of the mutant ***NFkappaB*** completely inhibited NFkappaB DNA binding activity and ***inhibited*** both TNF-induced up-regulation of ***Bcl-2*** and Bcl-x expression and neuroprotective effect .	negative	1
974	10085086	4790;598	NFkappaB;Bcl-x	Expression of the mutant ***NFkappaB*** completely inhibited NFkappaB DNA binding activity and ***inhibited*** both TNF-induced up-regulation of Bcl-2 and ***Bcl-x*** expression and neuroprotective effect .	negative	1
975	10085086	4790;596	NFkappaB;Bcl-2	These findings indicate that ***induction*** of ***Bcl-2*** and Bcl-x expression through ***NFkappaB*** activation is involved in the neuroprotective action of TNF against hypoxia - or nitric oxide-induced injury .	target	1
976	10085086	4790;598	NFkappaB;Bcl-x	These findings indicate that ***induction*** of Bcl-2 and ***Bcl-x*** expression through ***NFkappaB*** activation is involved in the neuroprotective action of TNF against hypoxia - or nitric oxide-induced injury .	target	1
977	10085098	2185;5599	RAFTK;JNK	These findings indicate that ***RAFTK-dependent*** ***induction*** of ***JNK*** in response to MMS is sensitive to Bcl-xL , but not to CrmA and p35 , by a mechanism that inhibits tyrosine phosphorylation and thereby activation of RAFTK .	target	1
978	10085098	598;2185	Bcl-xL;related adhesion focal tyrosine kinase	***Bcl-xL*** ***blocks*** activation of ***related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2*** and stress-activated protein kinase/c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate .	negative	0
979	10085102	6892;6890	tapasin;TAP1	Like human tapasin , mouse ***tapasin*** ***binds*** both to ***TAP1/2*** and MHC class I.	parallel	1
980	10085102	6892;6890	tapasin;TAP1	In TAP2-mutated RMA-S cells , both TAP1 and MHC class I were coprecipitated by anti-tapasin antiserum indicative of ***association*** of ***tapasin*** with ***TAP1*** but not TAP2 .	parallel	0
981	10085109	6667;5409	Sp1;PNMT	Furthermore , ***activation*** of the ***PNMT*** promoter by ***Sp1*** depends on both its binding affinity for its cognate target sequences and its intracellular concentrations .	positive	1
982	10085109	6667;5409	Sp1;PNMT	Finally , another transcription factor expressed in the Neuro2A cells competes with Sp1 by interacting with DNA sequences 3 ' to the -48 base pair Sp1 site to prevent ***Sp1*** ***binding*** and induction of the ***PNMT*** promoter .	parallel	1
983	10085114	5911;5900	Rap2;RalGEF	When co-transfected in HeLa cells , an activated Rap2 mutant ( Rap2Val-12 ) but not an inactive protein ( Rap2Ala-35 ) co-immunoprecipitates with RalGDS and Rlf ; moreover , ******Rap2-RalGEF****** ***complexes*** can be isolated from the particulate fraction of transfected cells and were localized by confocal microscopy to the resident compartment of Rap2 , i.e. the endoplasmic reticulum .	parallel	1
984	10085115	1022;1017	CAK1;CDK2	***Phosphorylation*** of monomeric human ***CDK2*** by ***CAK1*** is more efficient than phosphorylation of the binary CDK2-cyclin A complex .	target	1
985	10085121	4214;4087	MEKK-1;Smad2	***Activation*** of ***Smad2*** by active ***MEKK-1*** results in enhanced Smad2-Smad4 interactions , nuclear localization of Smad2 and Smad4 , and the stimulation of Smad protein-transcriptional coactivator interactions in endothelial cells .	positive	1
986	10085121	4087;4089	Smad2;Smad4	Activation of Smad2 by active MEKK-1 results in enhanced ******Smad2-Smad4****** ***interactions*** , nuclear localization of Smad2 and Smad4 , and the stimulation of Smad protein-transcriptional coactivator interactions in endothelial cells .	parallel	1
987	10085121	4214;4087	MEKK-1;Smad2	Overexpression of Smad7 can inhibit the ***MEKK-1-mediated*** ***stimulation*** of ***Smad2*** transcriptional activity .	positive	0
988	10085125	4023;4043	lipoprotein lipase;RAP	We have investigated if ***lipoprotein lipase*** ***interacts*** with the ***RAP*** binding but structurally distinct receptor sortilin/neurotensin receptor-3 .	parallel	1
989	10085129	156;857	GRK2;caveolin-1	Based on the identification of a consensus caveolin binding motif within the pleckstrin homology domain of GRK2 , we tested the direct ***binding*** of purified full-length ***GRK2*** to various glutathione ***S-transferase-caveolin-1*** fusion proteins , and we discovered a specific interaction of GRK2 with the caveolin scaffolding domain .	parallel	1
990	10085131	6352;1234	RANTES;CCR5	***Aminooxypentane-RANTES*** profoundly ***induced*** ***CCR5*** phosphorylation , but had no effect on CCR1 .	target	1
991	10085134	2064;2885	ErbB2;GRB2	In contrast , EGFR truncation did not impair EGF mitogenic signaling , and in c ' 1000 cells EGF was able to stimulate the ***association*** of ***ErbB2*** with ***GRB2*** and SHC .	parallel	0
992	10085134	2064;6464	ErbB2;SHC	In contrast , EGFR truncation did not impair EGF mitogenic signaling , and in c ' 1000 cells EGF was able to stimulate the ***association*** of ***ErbB2*** with GRB2 and ***SHC*** .	parallel	0
993	10085136	5747;2185	FAK;CADTK	In contrast , ***FAK*** carboxyl terminus overexpression ***inhibited*** both FAK and ***CADTK*** autophosphorylation , suggesting that a FAK-dependent cytoskeletal function may be necessary for CADTK activation .	negative	1
994	10085136	2185;5747	CADTK;FAK	Biochemical experiments confirmed direct ***CADTK*** ***phosphorylation*** of ***FAK*** .	target	1
995	10085140	4088;1386	Smad3;ATF-2	The ***binding*** between ***ATF-2*** and ***Smad3/4*** is mediated via the MH1 region of the Smad proteins and the basic leucine zipper region of ATF-2 .	parallel	1
996	10085140	7040;1386	TGF-beta;ATF-2	***TGF-beta*** signaling also ***induces*** the phosphorylation of ***ATF-2*** via TAK1 and p38 .	target	1
997	10085143	5054;5270	PAI-1;PN-1	We have analyzed the ***binding*** of RAP , ***uPA.PAI-1*** , and ***uPA.PN-1*** to two naturally occurring VLDLR variants , VLDLR-I , containing all eight complement-type repeats , and VLDLR-III , lacking the third complement-type repeat , encoded by exon 4 .	parallel	1
998	10085143	5054;4043	PAI-1;RAP	We have analyzed the ***binding*** of ***RAP*** , ***uPA.PAI-1*** , and uPA.PN-1 to two naturally occurring VLDLR variants , VLDLR-I , containing all eight complement-type repeats , and VLDLR-III , lacking the third complement-type repeat , encoded by exon 4 .	parallel	1
999	10085143	4043;5270	RAP;PN-1	We have analyzed the ***binding*** of ***RAP*** , uPA.PAI-1 , and ***uPA.PN-1*** to two naturally occurring VLDLR variants , VLDLR-I , containing all eight complement-type repeats , and VLDLR-III , lacking the third complement-type repeat , encoded by exon 4 .	parallel	1
1000	10085143	5270;4043	PN-1;RAP	Surprisingly , ***uPA.PN-1*** , but not uPA.PAI-1 , ***competed*** ***RAP*** binding to both VLDLR variants .	negative	0
1001	10085149	1387;3172	CBP;HNF-4	These findings demonstrate that ***CBP*** acts as a transcriptional ***coactivator*** for ***HNF-4*** and provide new insights into the regulatory function of HNF-4 .	positive	1
1002	10085149	3172;1387	HNF-4;CBP	***HNF-4*** ***interacts*** with the N-terminal region of ***CBP*** ( amino acids 1-771 ) and the C-terminal region of CBP ( amino acids 1812-2441 ) .	parallel	1
1003	10085149	1387;3172	CBP;HNF-4	In addition , we show that in contrast to the other nuclear hormone receptors the ***interaction*** between ***HNF-4*** and ***CBP*** is ligand-independent .	parallel	1
1004	10085149	3172;1387	HNF-4;CBP	***Recruitment*** of ***CBP*** by ***HNF-4*** results in an enhancement of the transcriptional activity of the latter .	target	0
1005	10085149	3172;1387	HNF-4;CBP	CBP does not activate gene expression in the absence of HNF-4 , and dominant negative forms of HNF-4 prevent transcriptional activation by CBP , suggesting that the mere ***recruitment*** of ***CBP*** by ***HNF-4*** is not sufficient for enhancement of gene expression .	target	0
1006	10085150	3077;7037	HFE;TfR	At the cell surface , ***HFE*** ***complexes*** with transferrin receptor ( ***TfR*** ) , increasing the dissociation constant of transferrin ( Tf ) for its receptor 10-fold ( Gross , C.	parallel	1
1007	10085150	7037;7018	TfR;transferrin	At the cell surface , HFE complexes with ***transferrin*** ***receptor*** ( ***TfR*** ) , increasing the dissociation constant of transferrin ( Tf ) for its receptor 10-fold ( Gross , C.	parallel	1
1008	10085237	468;1649	ATF4;Gadd153	We further demonstrated that ***ATF4*** ***activates*** , while ATF3 represses , ***Gadd153*** promoter activity through the C/EBP-ATF site .	positive	1
1009	10085237	468;1649	ATF4;Gadd153	ATF3 also repressed ***ATF4-mediated*** ***transactivation*** and arsenite-induced activation of the ***Gadd153*** promoter .	positive	1
1010	10085252	7040;387	transforming growth factor beta-1;RhoA	Furthermore , ***transforming growth factor beta-1*** ***upregulates*** considerably the levels of the RhoB small GTPase and less the ***RhoA*** levels .	positive	1
1011	10085252	7040;388	transforming growth factor beta-1;RhoB	Furthermore , ***transforming growth factor beta-1*** ***upregulates*** considerably the levels of the ***RhoB*** small GTPase and less the RhoA levels .	positive	1
1012	10085258	999;1499	E-cadherin;beta-catenin	***E-cadherin*** binding ***prevents*** beta-catenin nuclear localization and ***beta-catenin/LEF*** -1 - mediated transactivation .	negative	0
1013	10085258	999;1499	E-cadherin;beta-catenin	Using recombinant proteins , we found that E-cadherin and lymphocyte-enhancer factor-1 ( LEF-1 ) form mutually exclusive complexes with beta-catenin ; the association of ***beta-catenin*** with LEF-1 was ***competed*** out by the ***E-cadherin*** cytoplasmic domain .	negative	0
1014	10085289	637;581	Bid;Bax	Using isolated mitochondria and various BH3 mutants of Bid , we demonstrate that direct ***binding*** of ***Bid*** to ***Bax*** is a prerequisite for Bax structural change and cytochrome c release .	parallel	1
1015	10085289	598;637	Bcl-xL;Bid	***Bcl-xL*** can ***inhibit*** the effect of ***Bid*** by interacting directly with Bax .	negative	1
1016	10085289	637;581	Bid;Bax	Taken together , our results suggest that , during certain types of apoptosis , ***Bid*** translocates to mitochondria and ***binds*** to ***Bax*** , leading to a change in conformation of Bax and to cytochrome c release from mitochondria .	parallel	1
1017	10085291	596;836	Bcl-2;procaspase-3	Activation of membrane-associated ***procaspase-3*** is ***regulated*** by ***Bcl-2*** .	target	1
1018	10085297	4301;10580	l-afadin;Ponsin	The third proline-rich region of ***l-afadin*** ***bound*** to the region of ***Ponsin*** containing the second and third SH3 domains .	parallel	1
1019	10085298	5829;5782	paxillin;PTP-PEST	This phenomenon appears to be due in part to a constitutive increase in tyrosine phosphorylation of p130 ( CAS ) , a known PTP-PEST substrate , ***paxillin*** , which ***associates*** with ***PTP-PEST*** in vitro , and focal adhesion kinase ( FAK ) .	parallel	0
1020	10085298	5829;5782	paxillin;PTP-PEST	This phenomenon appears to be due in part to a constitutive increase in tyrosine phosphorylation of p130 ( CAS ) , a known ***PTP-PEST*** ***substrate*** , ***paxillin*** , which associates with PTP-PEST in vitro , and focal adhesion kinase ( FAK ) .	parallel	1
1021	10085405	958;959	CD40;CD154	******CD40-CD154****** ***interaction*** in experimental and human disease ( review ) .	parallel	1
1022	10085405	959;958	CD154;CD40	It has clearly emerged that among these signals few cell surface receptor-ligand pairs , such as ***CD40*** and its ***ligand*** , ***CD154*** , are mandatory for the induction of lymphocyte activation .	parallel	1
1023	10085405	958;959	CD40;CD154	Indeed , various approaches aimed to disrupt natural ******CD40-CD154****** ***interaction*** were highly effective in the prevention and treatment of several experimental models of autoimmune disease and transplant rejection .	parallel	1
1024	10085415	5970;4790	p65;p50	Supershift assays for the NF-kappaB region showed that there are ******p50-p65****** ***heterodimers*** and p50 homodimers in the nuclear extracts of the two types of B cells , while those from tumor bearers lack the c-Rel component that is present in normal B cells .	parallel	1
1025	10085445	3565;3586	Interleukin-4;interleukin-10	***Interleukin-4*** ***cooperates*** with ***interleukin-10*** to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome .	parallel	0
1026	10085445	3565;7422	Interleukin-4;vascular permeability factor	***Interleukin-4*** cooperates with interleukin-10 to ***inhibit*** ***vascular permeability factor*** release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome .	negative	1
1027	10085445	3565;7422	IL-4;VPF	These data demonstrate that ***IL-4*** acts in concert with IL-10 to ***inhibit*** ***VPF*** release and suggest that they are effective biologic regulators of the VPF responses in vitro .	negative	1
1028	10085539	1756;1605	dystrophin;beta-dystroglycan	It has been biochemically shown that ***dystrophin*** and alpha - and ***beta-dystroglycan*** form an oligomeric ***complex*** which links laminin , a component of the basement membrane , to components of the subsarcolemmal cytoskeleton in skeletal muscle fibers .	parallel	1
1029	10086274	4914;4803	TrkA;nerve growth factor	The recent advances in neuroblastoma research have revealed that the neurotrophin signals , especially those through ***nerve growth factor*** and its ***receptor*** , ***TrkA*** , play an important role in regulating the regression of neuroblastoma .	parallel	1
1030	10086320	3312;10049	Hsc70;DnaJ	Because Hsc70s represent a diverse group of cellular effectors and because ***Hsc70*** function frequently ***requires*** a ***DnaJ*** molecular chaperone , the specificity of DSG for different Hsc70s and the ability of DSG to block the productive interaction between an Hsc70 and its DnaJ partner were examined .	target	0
1031	10086322	213;3700	albumin;gp120	In the present study , we described the ***interaction*** of succinylated human serum ***albumin*** ( Suc-HSA ) , a negatively charged anti-HIV-1 active protein , with HIV-1 ***gp120*** and in detail with the third variable domain of gp120 ( V3 loop ) .	parallel	1
1032	10086332	596;835	Bcl-2;caspase-2	***Bcl-2*** ***regulates*** a ***caspase-3/caspase-2*** apoptotic cascade in cytosolic extracts .	target	1
1033	10086332	596;836	Bcl-2;caspase-3	***Bcl-2*** ***regulates*** a ***caspase-3/caspase-2*** apoptotic cascade in cytosolic extracts .	target	1
1034	10086338	7040;1294	TGF-beta;COL7A1	We have previously demonstrated that transforming growth factor-beta ( ***TGF-beta*** ) and pro-inflammatory cytokines , such as tumor necrosis factor-alpha ( TNF-alpha ) or interleukin-1beta , synergistically ***enhance*** the expression of type VII collagen gene ( ***COL7A1*** ) in human dermal fibroblasts in culture ( Mauviel et al. , 1994 ) .	positive	0
1035	10086338	4790;7124	NF-kappaB;TNF-alpha	In particular , we demonstrate that the ***TNF-alpha*** effect is ***mediated*** by NF-kappaB1 / RelA ( p50/p65 ) and RelA/RelA ( p65/p65 ) ***NF-kappaB*** complexes binding the TNF-alpha response element ( TaRE ) located in the region [ -252 / -230 ] , with RelA acting as the transcriptional activator .	target	0
1036	10086338	5970;7124	p65;TNF-alpha	In particular , we demonstrate that the ***TNF-alpha*** effect is ***mediated*** by NF-kappaB1 / RelA ( p50/p65 ) and RelA/RelA ( ***p65/p65*** ) NF-kappaB complexes binding the TNF-alpha response element ( TaRE ) located in the region [ -252 / -230 ] , with RelA acting as the transcriptional activator .	target	0
1037	10086339	9133;983	cyclin B2;p34cdc2	***cyclin B2*** is a ***regulator*** of ***p34cdc2*** kinase , involved in G2/M progression of the cell cycle , whose gene is strictly regulated at the transcriptional level in cycling cells .	target	1
1038	10086340	868;1956	cbl-b;epidermal growth factor receptor	***cbl-b*** ***inhibits*** ***epidermal growth factor receptor*** signaling .	negative	1
1039	10086382	2064;367	HER-2/neu;androgen receptor	A mechanism for hormone-independent prostate cancer through ***modulation*** of ***androgen receptor*** signaling by the ***HER-2/neu*** tyrosine kinase .	target	0
1040	10086382	2064;367	HER-2/neu;androgen receptor	***HER-2/neu*** ***activated*** the ***androgen receptor*** pathway in the absence of ligand and synergized with low levels of androgen to ' superactivate ' the pathway .	positive	1
1041	10086384	356;355	CD95 ligand;Fas	***Fas*** ***ligand*** ( ***CD95 ligand*** ) controls angiogenesis beneath the retina .	parallel	1
1042	10086384	355;356	Fas;FasL	We found that cultured choroidal endothelial cells were induced to undergo apoptosis by retinal pigment epithelial cells through a ******Fas-FasL****** ***interaction*** .	parallel	1
1043	10086725	861;7040	AML1;TGF-beta1	Furthermore , we show that whereas the expression of the fusion protein ***AML1/MDS1/EVI1*** completely ***abrogates*** the growth-inhibitory effect of ***TGF-beta1*** and allows 32Dcl3 cells to proliferate , expression of the normal protein MDS1/EVI1 has the opposite effect , and it strengthens the response of cells to the growth-inhibitory effect of TGF-beta1 .	negative	0
1044	10086725	861;4088	EVI1;SMAD3	By using the yeast two-hybrid system , we also show that ***EVI1*** ( contained in its entirety in MDS1/EVI1 and AML1/MDS1/EVI1 ) physically ***interacts*** with ***SMAD3*** , which is an intracellular mediator of TGF-beta1 signaling .	parallel	1
1045	10086725	861;7040	EVI1;TGF-beta1	***MDS1/EVI1*** ***enhances*** ***TGF-beta1*** signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1 , product of the t ( 3 ; 21 ) , abrogates growth-inhibition in response to TGF-beta1 .	positive	0
1046	10086739	3569;598	IL-6;Bcl-X	We also found that ***IL-6*** but not IFN-alpha ***up-regulates*** ***Bcl-X*** ( L ) expression .	positive	1
1047	10086856	3458;3600	IFN-gamma;IL-15	***IFN-gamma*** ( 200 and 400 U/ml ) slightly ***increased*** the ***IL-15*** message level in a squamous cell carcinoma cell line , HSC-5 , in a dose-dependent fashion , whereas no significant change was observed in cultured normal human keratinocytes .	positive	0
1048	10086975	7133;7124	TNF-R1/R2;TNF-alpha	To determine this , we studied the expression and protein localization of ***TNF-alpha*** and its 2 main ***receptors*** ( ***TNF-R1/R2*** ) in a rat model of large infarction .	parallel	1
1049	10086980	3949;348	LDL receptor;apolipoprotein E	We demonstrated earlier that small ***apolipoprotein E*** ( apoE ) - exposing liposomes were specifically ***recognized*** by the ***LDL receptor*** .	target	1
1050	10087073	6469;3670	Shh;Islet-1	Moreover , ***Shh*** did ***induce*** ***Islet-1*** expression in neural tube explants , suggesting that it acts in combination with neural tube factors to induce motoneurons .	target	1
1051	10087073	6469;3670	Shh;Islet-1	However , the combination of N-terminal ***Shh*** and NT3 ***induced*** ***Islet-1*** expression in the majority of neurons in low-density cultures of caudal intermediate neural plate .	target	1
1052	10087091	3553;2353	IL-1beta;c-fos	Intraperitoneal ***IL-1beta*** also ***induces*** expression of the activation marker ***c-fos*** in vagal primary afferent neurons , suggesting that IL-1beta is a key component of vagally mediated immune-to-brain communication .	target	1
1053	10087180	3384;3683	CD102;CD11a	To account for the different effects of CD11a and CD54 blockade in vivo , an additional ***CD11a/CD18*** ***ligand*** , ***CD102*** ( ICAM-2 ) , was demonstrated on tumor-associated macrophages but not on tumor cells .	parallel	1
1054	10087182	3458;3717	IFN-gamma;Jak2	Immunoprecipitation and Western blot analyses indicated that ***IFN-gamma-induced*** ***phosphorylation*** of Stat1 and ***Jak2*** was blocked by dextran sulfate .	target	1
1055	10087182	3458;6772	IFN-gamma;Stat1	Immunoprecipitation and Western blot analyses indicated that ***IFN-gamma-induced*** ***phosphorylation*** of ***Stat1*** and Jak2 was blocked by dextran sulfate .	target	1
1056	10087267	55740;51466	Ena;Evl	Hence VASP / ******Ena/Evl****** ***link*** the bacterium to the actin tail , which is required for movement .	parallel	0
1057	10087335	2057;2056	EpoR;Erythropoietin	Recent investigations have shown that the glycoprotein ***Erythropoietin*** ( Epo ) and its specific ***receptor*** ( ***EpoR*** ) are present in the mammalian brain including human , monkey and mouse .	parallel	1
1058	10087446	3952;5367	leptin;MCH	It may also indicate that MCH mediates the metabolic actions of leptin indirectly or else that ***leptin*** ***influences*** actions of ***MCH*** other than those related to the regulation of energy balance .	target	0
1059	10087446	5367;3952	MCH;leptin	It may also indicate that ***MCH*** ***mediates*** the metabolic actions of ***leptin*** indirectly or else that leptin influences actions of MCH other than those related to the regulation of energy balance .	target	0
1060	10087612	7456;8976	WIP;NWASP	In this review , the authors discuss the possible role of WASP/NWASP and of the newly described protein ***WIP*** , which ***interacts*** with WASP and ***NWASP*** , in coupling signals from the T-cell receptor to the actin-based cytoskeleton .	parallel	1
1061	10087612	7456;7454	WIP;WASP	In this review , the authors discuss the possible role of WASP/NWASP and of the newly described protein ***WIP*** , which ***interacts*** with ***WASP*** and NWASP , in coupling signals from the T-cell receptor to the actin-based cytoskeleton .	parallel	1
1062	10087648	3439;4760	IFN-alpha;beta 2	Whereas IL-4 appears to repress functional IL-12 signaling through inhibition of IL-12R beta 2 expression , IFN-gamma in the mouse , and ***IFN-alpha*** in the human appear to ***induce*** IL-12R ***beta 2*** expression and promote IL-12 responsiveness .	target	1
1063	10087648	3458;4760	IFN-gamma;beta 2	Whereas IL-4 appears to repress functional IL-12 signaling through inhibition of IL-12R beta 2 expression , ***IFN-gamma*** in the mouse , and IFN-alpha in the human appear to ***induce*** IL-12R ***beta 2*** expression and promote IL-12 responsiveness .	target	1
1064	10087648	3439;6775	IFN-alpha;Stat4	In the human , this may also occur via ***IFN-alpha*** , which is able to ***activate*** ***Stat4*** .	positive	1
1065	10087648	6775;51497	Stat4;Th1	It is perhaps possible that all of Stat4 actions on Th1 development may be exert directly by Stat4 at the IFN-gamma gene , however we suggest that , more likely , ***Stat4*** may act to ***induce*** ***Th1*** development through the induction of other non-cytokine genes , whose stable expression maintains the transcriptional state of a Th1 cell .	target	1
1066	10087872	3567;3082	IL-5;HGF	It was also shown that ***IL-5*** ***induced*** the production of ***HGF*** by peripheral eosinophiles in vitro .	target	1
1067	10088202	5972;183	renin;angiotensin II	Furthermore , ***angiotensin II*** formation was believed to be ***regulated*** by ***renin*** secreted from the kidneys .	target	1
1068	10088603	1437;6892	Granulocyte-macrophage colony-stimulating factor;tapasin	***Granulocyte-macrophage colony-stimulating factor*** ***modulates*** ***tapasin*** expression in human neutrophils .	target	0
1069	10088610	729230;6347	CCR2;MCP-1	The CC-chemokine monocyte chemoattractant protein-1 ( ***MCP-1*** ) and its specific ***receptor*** ***CCR2*** are essential in monocytic infiltration and have been associated with several inflammatory diseases .	parallel	1
1070	10088650	3484;3479	IGF binding protein-1;IGF-I	In transgenic ( Tg ) mice , IGF-I overexpression stimulates postnatal brain growth , whereas decreased IGF-I availability caused by ectopic brain expression of ***IGF binding protein-1*** [ ( IGFBP-1 ) , an ***inhibitor*** of ***IGF-I*** action ] retards postnatal brain growth .	negative	1
1071	10088664	185;183	AT1R;angiotensin II	The type 1 ***angiotensin II*** ***receptor*** ( ***AT1R*** ) predominates in adult vascular smooth muscle ( VSM ) and mediates vasoconstriction .	parallel	1
1072	10088720	960;6696	CD44;osteopontin	These studies suggest that ******CD44-osteopontin****** ***interactions*** may not be common in vivo and may be limited to a specific CD44 isoform ( s ) , and/or a particular modified form of osteopontin .	parallel	1
1073	10088730	7040;860	TGF-beta1;CBFA1	***TGF-beta1*** treatment effectively suppressed myogenesis and ***induced*** ***CBFA1*** expression but was insufficient to support osteoblast differentiation reflected by the absence of ALP , OPN , and OCN .	target	1
1074	10088775	142;836	PARP;caspase 3	In addition , FAS ligation to TNFalpha-treated cultured OA synoviocytes induced activation of caspase 8 and caspase 3 , with subsequent cleavage of poly ( ADP-ribose ) polymerase ( ***PARP*** ) , a ***substrate*** of activated ***caspase 3*** .	parallel	1
1075	10088775	355;836	FAS;caspase 3	In addition , ***FAS*** ligation to TNFalpha-treated cultured OA synoviocytes ***induced*** activation of caspase 8 and ***caspase 3*** , with subsequent cleavage of poly ( ADP-ribose ) polymerase ( PARP ) , a substrate of activated caspase 3 .	target	1
1076	10088775	355;841	FAS;caspase 8	In addition , ***FAS*** ligation to TNFalpha-treated cultured OA synoviocytes ***induced*** activation of ***caspase 8*** and caspase 3 , with subsequent cleavage of poly ( ADP-ribose ) polymerase ( PARP ) , a substrate of activated caspase 3 .	target	1
1077	10089132	3553;4790	IL-1beta;NF-kappaB	PD 098059 , a selective inhibitor of the ERK activating kinase MEK1 , had no effect on IL-1beta-induced MCP-1 mRNA or protein levels , or on ***IL-1beta*** ***activation*** of ***NF-kappaB*** .	positive	1
1078	10089132	3553;6347	IL-1beta;MCP-1	These data indicate that p38 kinase is necessary for the ***induction*** of ***MCP-1*** expression by ***IL-1beta*** , but is not involved at the level of cytoplasmic activation of NF-kappaB .	target	1
1079	10089132	3553;4790	IL-1beta;NF-kappaB	Because NF-kappaB is necessary for MCP-1 gene expression , the effect of p38 kinase inhibition on ***IL-1beta*** ***induction*** of ***NF-kappaB*** was measured .	target	1
1080	10089132	3553;5594	IL-1beta;ERK2	Our previous work showed that ***IL-1beta*** also ***activates*** the MAP kinase ***ERK2*** in human mesangial cells .	positive	1
1081	10089138	3553;1906	IL-1beta;endothelin 1	***Upregulation*** of ***endothelin 1*** and its precursor by ***IL-1beta*** , TNF-alpha , and TGF-beta in the PC3 human prostate cancer cell line .	positive	1
1082	10089138	7040;1906	TGF-beta;endothelin 1	***Upregulation*** of ***endothelin 1*** and its precursor by IL-1beta , TNF-alpha , and ***TGF-beta*** in the PC3 human prostate cancer cell line .	positive	1
1083	10089138	7124;1906	TNF-alpha;endothelin 1	***Upregulation*** of ***endothelin 1*** and its precursor by IL-1beta , ***TNF-alpha*** , and TGF-beta in the PC3 human prostate cancer cell line .	positive	1
1084	10089877	578;598	BAK;BCL-XL	Furthermore , we modeled a complex of BCL-XL and BID by aligning the BID and BAK BH3 motifs in the known ******BCL-XL-BAK****** BH3 ***complex*** .	parallel	1
1085	10089877	637;598	BID;BCL-XL	Furthermore , we modeled a ***complex*** of ***BCL-XL*** and ***BID*** by aligning the BID and BAK BH3 motifs in the known BCL-XL-BAK BH3 complex .	parallel	1
1086	10089882	920;3700	CD4;gp120	Sulfated tyrosines contribute to the binding of CCR5 to MIP-1 alpha , MIP-1 beta , and HIV-1 ******gp120/CD4****** ***complexes*** and to the ability of HIV-1 to enter cells expressing CCR5 and CD4 .	parallel	1
1087	10089902	3586;1437	IL-10;CSF	It was shown earlier than ***IL-10*** ***regulates*** ***CSF*** secretion by monocytes in an autocrine manner .	target	1
1088	10089905	3458;355	interferon-gamma;CD95	Fas antigen ( ***CD95*** ) in pure erythroid cell line AS-E2 is ***induced*** by ***interferon-gamma*** and tumor necrosis factor-alpha and potentiates apoptotic death .	target	1
1089	10089905	7124;355	tumor necrosis factor-alpha;CD95	Fas antigen ( ***CD95*** ) in pure erythroid cell line AS-E2 is ***induced*** by interferon-gamma and ***tumor necrosis factor-alpha*** and potentiates apoptotic death .	target	1
1090	10090153	4091;4087	Smad6;Smad2	Finally , the Smadl-specific antagonist ***Smad6*** can ***inhibit*** a ***Smad2*** molecule harboring Smadl C1 and C2 sequences .	negative	1
1091	10090156	1906;3383	endothelin-1;intercellular adhesion molecule-1	***Downregulation*** of ***intercellular adhesion molecule-1*** expression on human synovial fibroblasts by ***endothelin-1*** .	negative	1
1092	10090156	7124;3383	TNF-alpha;ICAM-1	RESULTS : Tumor necrosis factor-alpha ( ***TNF-alpha*** ) ***increased*** the expression of ***ICAM-1*** by RA and OA fibroblasts .	positive	0
1093	10090177	3553;7132	IL-1beta;TNF-R55	CONCLUSION : The expression of ***TNF-R55*** and TNF-R75 on human articular chondrocytes is ***modulated*** independently by ***IL-1beta*** , TNF-alpha , and bFGF , suggesting a role of these regulatory mechanisms in the degradation processes of human articular cartilage in inflammatory joint diseases .	target	0
1094	10090177	3553;7133	IL-1beta;TNF-R75	CONCLUSION : The expression of TNF-R55 and ***TNF-R75*** on human articular chondrocytes is ***modulated*** independently by ***IL-1beta*** , TNF-alpha , and bFGF , suggesting a role of these regulatory mechanisms in the degradation processes of human articular cartilage in inflammatory joint diseases .	target	0
1095	10090177	7124;7132	TNF-alpha;TNF-R55	CONCLUSION : The expression of ***TNF-R55*** and TNF-R75 on human articular chondrocytes is ***modulated*** independently by IL-1beta , ***TNF-alpha*** , and bFGF , suggesting a role of these regulatory mechanisms in the degradation processes of human articular cartilage in inflammatory joint diseases .	target	0
1096	10090177	7124;7133	TNF-alpha;TNF-R75	CONCLUSION : The expression of TNF-R55 and ***TNF-R75*** on human articular chondrocytes is ***modulated*** independently by IL-1beta , ***TNF-alpha*** , and bFGF , suggesting a role of these regulatory mechanisms in the degradation processes of human articular cartilage in inflammatory joint diseases .	target	0
1097	10090417	183;7432	angiotensin II;vasoactive intestinal peptide	***angiotensin II*** did not stimulate cyclic AMP or ***suppress*** ***vasoactive intestinal peptide*** stimulated cyclic AMP production over the concentration range that caused Ca2 + signaling .	negative	1
1098	10090720	5649;1600	Reln;Dab1	In primary neuronal cultures , ***Dab1*** tyrosine phosphorylation is ***stimulated*** by exogenous ***Reln*** .	positive	0
1099	10090723	7029;1874	DP2;E2F4	The crystal structure of an ******E2F4-DP2-DNA****** ***complex*** shows that the DNA-binding domains of the E2F and DP proteins both have a fold related to the winged-helix DNA-binding motif .	parallel	1
1100	10090724	1111;995	Chk1;Cdc25C	An additional role for 14-3-3 proteins in the DNA-damage checkpoint has been suggested based on the observation that human ***Chk1*** can ***phosphorylate*** ***Cdc25C*** in vitro creating a 14-3-3 binding site .	target	1
1101	10090765	5337;857	PLD1;caveolin-1	Purified ***PLD1*** directly ***bound*** to a glutathione ***S-transferase-caveolin-1*** fusion protein in in vitro binding assays .	parallel	1
1102	10090765	857;5337	caveolin-1;PLD1	The association of PLD1 with caveolin-1 could be completely eliminated by preincubation of PLD1 with an oligopeptide corresponding to the scaffolding domain ( amino acids 82-101 ) of caveolin-1 , indicating that ***caveolin-1*** ***interacts*** with ***PLD1*** through the scaffolding domain .	parallel	1
1103	10090765	5337;857	PLD1;caveolin-1	The ***association*** of ***PLD1*** with ***caveolin-1*** could be completely eliminated by preincubation of PLD1 with an oligopeptide corresponding to the scaffolding domain ( amino acids 82-101 ) of caveolin-1 , indicating that caveolin-1 interacts with PLD1 through the scaffolding domain .	parallel	0
1104	10090765	857;5337	caveolin-1;PLD1	***caveolin-1*** also ***coimmunoprecipitated*** with ***PLD1*** in the absence of PMA , and the amounts of coimmunoprecipitated caveolin-1 decreased in response to treatment with PMA .	parallel	1
1105	10090765	5337;857	PLD1;caveolin-1	Taken together , our results suggest a new mechanism for the regulation of the PKCalpha-dependent PLD activity through the molecular ***interaction*** between ***PLD1*** , PKCalpha , and ***caveolin-1*** in caveolae .	parallel	1
1106	10090848	7057;5340	thrombospondin 1;plasmin	We previously showed that ***thrombospondin 1*** ( TSP-1 ) ***upregulates*** the ***plasminogen/plasmin*** system and promotes breast tumor cell invasion .	positive	1
1107	10090924	7124;7852	tumor necrosis factor-alpha;chemokine receptor	Metalloproteinases are involved in lipopolysaccharide - and ***tumor necrosis factor-alpha-mediated*** ***regulation*** of CXCR1 and CXCR2 ***chemokine receptor*** expression .	target	1
1108	10090924	7124;3577	tumor necrosis factor-alpha;CXCR1	Metalloproteinases are involved in lipopolysaccharide - and ***tumor necrosis factor-alpha-mediated*** ***regulation*** of ***CXCR1*** and CXCR2 chemokine receptor expression .	target	1
1109	10090924	7124;3579	tumor necrosis factor-alpha;CXCR2	Metalloproteinases are involved in lipopolysaccharide - and ***tumor necrosis factor-alpha-mediated*** ***regulation*** of CXCR1 and ***CXCR2*** chemokine receptor expression .	target	1
1110	10090941	3558;596	IL-2;Bcl-2	In contrast , ***IL-2-dependent*** ***induction*** of ***Bcl-2*** was unaffected .	target	1
1111	10090941	3561;3718	gammac;JAK3	In naive T cells , but not primed T cells , PGE2 and other cAMP elevating agents also caused a modest reduction in surface expression of the common gamma chain ( ***gammac*** ) that ***associates*** with ***JAK3*** .	parallel	0
1112	10090945	355;356	CD95;CD95L	We have previously shown that nitric oxide ( NO ) stimulates apoptosis in different human neoplastic lymphoid cell lines through activation of caspases not only via ******CD95/CD95L****** ***interaction*** , but also independently of such death receptors .	parallel	1
1113	10090947	5970;4790	p65;p50	Whereas the NF-kappaB binding activity in Tax-expressing T-cell lines consisted mostly of p50/c-Rel , fresh ATL samples contained p50/p50 and ******p50/p65****** ***heterodimers*** .	parallel	1
1114	10090948	25;3717	BCR/ABL;JAK2	The constitutive activation of ***JAK2/STAT5*** in Dami/HEL cells is ***triggered*** by a mechanism other than autocrine cytokines or the ***BCR/ABL*** oncoprotein .	positive	0
1115	10090948	25;6776	BCR/ABL;STAT5	The constitutive activation of ***JAK2/STAT5*** in Dami/HEL cells is ***triggered*** by a mechanism other than autocrine cytokines or the ***BCR/ABL*** oncoprotein .	positive	0
1116	1009100	847;392636	catalase;alkylglycerol monooxygenase	***Stimulation*** of the microsomal ***alkylglycerol monooxygenase*** by ***catalase*** .	positive	0
1117	10091598	3929;929	LBP;CD14	An ***LPS/LBP*** complex was an effective ***stimulator*** for LBP and ***CD14*** production in HepG2 cells , but stimulation of the cells with either LPS or LBP alone did not significantly accelerate the production of these proteins .	positive	0
1118	10091607	3596;5743	IL-13;COX-2	***IL-13*** ***inhibited*** IL-1 beta/TNF-alpha-elicited PGE2 production , as well as ***COX-2*** protein and mRNA expression in a concentration-dependent fashion .	negative	1
1119	10092062	958;959	CD40;CD40 ligand	We determined the role of ***interactions*** between ***CD40*** and ***CD40 ligand*** ( CD40L ) in these infiltrating lymphocytes on B-cell differentiation and expression of Bcl-2 family proteins .	parallel	1
1120	10092076	4790;356	NF-kappaB;Fas ligand	Apoptosis-resistant T cells have a deficiency in ***NF-kappaB-mediated*** ***induction*** of ***Fas ligand*** transcription .	target	1
1121	10092077	3821;3824	NKG2;CD94	They include killer inhibitory receptors and ******CD94/NKG2****** ***heterodimers*** in humans and the Ly49 family in mice .	parallel	1
1122	10092081	940;896	CD28;cyclin D3	***CD28*** costimulation ***enhanced*** expression of ***cyclin D3*** and induced down-regulation of p27kip1 expression .	positive	0
1123	10092084	4179;718	CD46;C3b	These data indicate that ***CD46*** ***prevents*** the ***C3b*** deposition amplification loop mediated by the alternative C3 convertase and , consequently , inhibits the formation of the alternative C5 convertase .	negative	0
1124	10092084	4179;718	CD46;C3b	***Control*** of ***C3b*** and C5b deposition by ***CD46*** ( membrane cofactor protein ) after alternative but not classical complement activation .	target	0
1125	10092084	4179;727	CD46;C5b	***Control*** of C3b and ***C5b*** deposition by ***CD46*** ( membrane cofactor protein ) after alternative but not classical complement activation .	target	0
1126	10092086	1493;3725	CTLA4;AP-1	***CTLA4*** ligation ***attenuates*** ***AP-1*** , NFAT and NF-kappaB activity in activated T cells .	negative	0
1127	10092086	1493;4790	CTLA4;NF-kappaB	***CTLA4*** ligation ***attenuates*** AP-1 , NFAT and ***NF-kappaB*** activity in activated T cells .	negative	0
1128	10092086	1493;3725	CTLA4;AP-1	We found that cross-linking ***CTLA4*** on activated T cells completely ***blocks*** ***AP-1*** and NFAT transcription factor activity before any effects on T cell proliferation can be observed , with NF-kappaB activity affected to a lesser degree .	negative	0
1129	10092086	3725;1493	AP-1;CTLA4	The suppression of ***AP-1*** and NFAT transcriptional activity ***correlates*** with reduced levels of AP-1 and NFAT DNA binding as early as 10 h after T cell activation , prior to detectable up-regulation of ***CTLA4*** on the T cell surface .	parallel	0
1130	10092088	1493;4792	CTLA-4;IkappaBalpha	Cytotoxic T lymphocyte antigen 4 ( ***CTLA-4*** ) ***inhibits*** CD28-induced ***IkappaBalpha*** degradation and RelA activation .	negative	1
1131	10092088	1493;5970	CTLA-4;RelA	Cytotoxic T lymphocyte antigen 4 ( ***CTLA-4*** ) ***inhibits*** CD28-induced IkappaBalpha degradation and ***RelA*** activation .	negative	1
1132	10092088	1493;3558	CTLA-4;IL-2	The results show that ***CTLA-4*** stimulation ***inhibits*** ***IL-2*** production induced by CD3-CD28 co-stimulation .	negative	1
1133	10092091	4790;355	NF-kappaB;Fas	***NF-kappaB*** ***regulates*** ***Fas/APO-1/CD95*** - and TCR - mediated apoptosis of T lymphocytes .	target	1
1134	10092212	1191;4609	clusterin;c-myc	We examined the ***response*** of the rat ***clusterin*** gene to two oncogenes , Ha-ras and ***c-myc*** , in transfected Rat1 fibroblasts .	parallel	0
1135	10092305	7039;8513	transforming growth factor alpha;gastric lipase	Epidermal growth factor and ***transforming growth factor alpha*** ***down-regulate*** human ***gastric lipase*** gene expression .	negative	1
1136	10092305	7039;8513	TGF-alpha;HGL	EGF and/or ***TGF-alpha*** ***down-regulated*** ***HGL*** mRNA levels and decreased enzymic activity .	negative	1
1137	10092317	885;5867	CCK;Rab4	CONCLUSIONS : ***Rab4*** negatively modulates regulated exocytosis of pancreatic acini and is ***controlled*** by ***CCK*** through a protein kinase C pathway .	target	0
1138	10092317	885;5867	cholecystokinin;Rab4	The ***regulation*** of ***Rab4*** by ***cholecystokinin*** ( CCK ) and 12-O-tetradecanoyl-phorbol 13-acetate ( TPA ) was investigated by examining their effects on [ 32P ] GTP binding rate into the Rab4 immunoprecipitates .	target	1
1139	10092317	885;5867	CCK;Rab4	The participation of protein kinase C in the ***Rab4*** ***regulation*** by ***CCK*** was confirmed by calphostin C pretreatment of acini .	target	1
1140	10092515	1950;5335	EGF;PLC-gamma1	In cultured hepatocytes from control rats , ***EGF*** rapidly ***induced*** tyrosine phosphorylation of both the EGFR and of ***PLC-gamma1*** .	target	1
1141	10092515	1950;5335	EGF;PLC-gamma1	***EGF*** also ***stimulated*** ***PLC-gamma1*** translocation from cytosol to a cytoskeletal compartment where PLC-gamma1 interacted with EGFR .	positive	0
1142	10092517	4738;8453	NEDD8;cullin-2	Here , we show that human ***cullin-2*** is also ***conjugated*** by a single molecule of the ***NEDD8*** .	parallel	1
1143	10092522	1500;3055	p120;Hck	The proto-oncogene ***p120*** ( Cbl ) is a downstream ***substrate*** of the ***Hck*** protein-tyrosine kinase .	parallel	1
1144	10092522	867;3055	Cbl;Hck	Hck phosphorylates Cbl in vitro and the ***interaction*** between ***Cbl*** and ***Hck*** is direct , requiring Hck 's unique , SH3 and SH2 domains for optimal binding .	parallel	1
1145	10092522	3055;867	Hck;Cbl	***Hck*** ***phosphorylates*** ***Cbl*** in vitro and the interaction between Cbl and Hck is direct , requiring Hck 's unique , SH3 and SH2 domains for optimal binding .	target	1
1146	10092522	867;3055	Cbl;Hck	Using a novel estrogen-regulated chimera of Hck we have shown a hormone-dependent ***association*** between ***Hck*** and ***Cbl*** in murine fibroblasts .	parallel	0
1147	10092539	183;5747	angiotensin II;FAK	In adherent cells , both ***FAK*** and paxillin were tyrosine ***phosphorylated*** by ***angiotensin II*** , while the cell detachment completely inhibited the tyrosine phosphorylation of paxillin .	target	1
1148	10092539	183;5829	angiotensin II;paxillin	In adherent cells , both FAK and ***paxillin*** were tyrosine ***phosphorylated*** by ***angiotensin II*** , while the cell detachment completely inhibited the tyrosine phosphorylation of paxillin .	target	1
1149	10092539	8506;5829	p190;paxillin	Moreover , ***p190*** , a member of Rho GTPase activating protein ( GAP ) , and RasGAP were coprecipitated with paxillin in adherent cells and angiotensin II stimulation ***reduced*** the formation of paxillin-p190 and ***paxillin-RasGAP*** complexes .	negative	1
1150	10092539	8506;5921	p190;RasGAP	Moreover , ***p190*** , a member of Rho GTPase activating protein ( GAP ) , and RasGAP were coprecipitated with paxillin in adherent cells and angiotensin II stimulation ***reduced*** the formation of paxillin-p190 and ***paxillin-RasGAP*** complexes .	negative	1
1151	10092539	5829;8506	paxillin;p190	Moreover , p190 , a member of Rho GTPase activating protein ( GAP ) , and RasGAP were coprecipitated with paxillin in adherent cells and angiotensin II stimulation reduced the formation of ******paxillin-p190****** and paxillin-RasGAP ***complexes*** .	parallel	1
1152	10092539	5829;5921	paxillin;RasGAP	Moreover , p190 , a member of Rho GTPase activating protein ( GAP ) , and RasGAP were coprecipitated with paxillin in adherent cells and angiotensin II stimulation reduced the formation of paxillin-p190 and ******paxillin-RasGAP****** ***complexes*** .	parallel	1
1153	10092546	10859;3107	LIR-1;HLA-C	We show that ***HLA-C*** recognition by decidual NK cells can be ***mediated*** by p58 , ***LIR-1*** and ( indirectly ) by CD94/NKG2A receptors .	target	0
1154	10092546	3804;3107	p58;HLA-C	We show that ***HLA-C*** recognition by decidual NK cells can be ***mediated*** by ***p58*** , LIR-1 and ( indirectly ) by CD94/NKG2A receptors .	target	0
1155	10092546	3824;3135	CD94;HLA-G	On the other hand , ***HLA-G*** recognition is not only ***mediated*** by LIR-1 and ( indirectly ) by ***CD94/NKG2A*** but also by a newly identified receptor termed p49 .	target	0
1156	10092546	10859;3135	LIR-1;HLA-G	On the other hand , ***HLA-G*** recognition is not only ***mediated*** by ***LIR-1*** and ( indirectly ) by CD94/NKG2A but also by a newly identified receptor termed p49 .	target	0
1157	10092546	3821;3135	NKG2A;HLA-G	On the other hand , ***HLA-G*** recognition is not only ***mediated*** by LIR-1 and ( indirectly ) by ***CD94/NKG2A*** but also by a newly identified receptor termed p49 .	target	0
1158	10092547	3824;3133	CD94;HLA-E	By contrast , our data support that NK recognition of cells expressing HLA-G1 involves at least two non-overlapping receptor-ligand systems : ( 1 ) the direct engagement of the ILT2 ( LIR1 ) receptor by HLA-G1 ; and ( 2 ) the ***interaction*** of CD94/NKG2A and ***CD94/NKG2C*** receptors with the non-classical class I molecule ***HLA-E*** , co-expressed on the surface upon binding to a nonamer ( VMAPRTLFL ) from the HLA-G leader sequence .	parallel	1
1159	10092547	3821;3133	NKG2A;HLA-E	By contrast , our data support that NK recognition of cells expressing HLA-G1 involves at least two non-overlapping receptor-ligand systems : ( 1 ) the direct engagement of the ILT2 ( LIR1 ) receptor by HLA-G1 ; and ( 2 ) the ***interaction*** of ***CD94/NKG2A*** and CD94/NKG2C receptors with the non-classical class I molecule ***HLA-E*** , co-expressed on the surface upon binding to a nonamer ( VMAPRTLFL ) from the HLA-G leader sequence .	parallel	1
1160	10092585	5663;8502	presenilin 1;p0071	Direct ***interaction*** of Alzheimer 's disease-related ***presenilin 1*** with armadillo protein ***p0071*** .	parallel	1
1161	10092585	1499;5663	armadillo;presenilin 1	We utilized the yeast two-hybrid system to identify an interacting ***armadillo*** protein , termed p0071 , that ***binds*** specifically to the hydrophilic loop of ***presenilin 1*** .	parallel	1
1162	10092585	5663;8502	presenilin 1;p0071	Here , we show that the C-terminal fragment of ***presenilin 1*** directly ***binds*** to ***p0071*** .	parallel	1
1163	10092586	715;716	C1r;C1s	Ca2 + - dependent ***interaction*** of intact ***C1r*** with ***C1s*** was studied using surface plasmon resonance spectroscopy , yielding KD values of 10.9-29 .7 nM .	parallel	1
1164	10092624	7040;5054	TGFbeta;PAI-1	Transforming growth factor beta ( ***TGFbeta*** ) ***activates*** transcription of the plasminogen activator inhibitor type-1 ( ***PAI-1*** ) gene through a major TGFbeta-responsive region ( -740 and -647 ) in the PAI-1 promoter .	positive	1
1165	10092624	4089;5054	Smad4;PAI-1	Both elements were required for TGFbeta-induced , Smad3 - and ***Smad4-dependent*** ***activation*** of ***PAI-1*** transcription .	positive	1
1166	10092648	1234;3700	CCR5;gp120	By contrast , N-terminal mAbs blocked ******gp120-CCR5****** ***binding*** more effectively than ECL2 mAbs .	parallel	1
1167	10092656	3458;3394	interferon gamma;ICSBP	Furthermore , transcriptional ***activation*** of ***ICSBP*** gene by ***interferon gamma*** is accompanied by selective nuclear localization of ICSBP in proliferating epithelial cells but not in the nuclei of nondividing cells in the lens fiber compartment .	positive	1
1168	10092660	719;718	C3aR;C3a	The ***C3a*** anaphylatoxin ***receptor*** ( ***C3aR*** ) is a G protein-coupled receptor with an unusually large second extracellular loop ( e2 loop , approximately 172 amino acids ) .	parallel	1
1169	10092660	728;727	C5aR;C5a	Whereas replacement of the C3aR N-terminal segment with that from the human C5a receptor had minimal effect on C3a binding , substitution of the e2 loop with a smaller e2 loop from the ***C5a*** ***receptor*** ( ***C5aR*** ) abolished binding of 125I-C3a and C3a-stimulated calcium mobilization .	parallel	1
1170	10092676	7041;5782	Hic-5;PTP-PEST	***Hic-5*** , a paxillin homologue , ***binds*** to the protein-tyrosine phosphatase PEST ( ***PTP-PEST*** ) through its LIM 3 domain .	parallel	1
1171	10092678	6464;10818	Shc;FRS-2	Importantly , we demonstrate that the phosphotyrosine binding domain of FRS-2 directly binds the Trk receptors at the same phosphotyrosine residue that binds the signaling adapter Shc , suggesting a model in which competitive ***binding*** between ***FRS-2*** and ***Shc*** regulates differentiation versus proliferation .	parallel	1
1172	10092678	10818;1398	FRS-2;Crk	Consistent with this model , ***FRS-2*** ***binds*** Grb-2 , ***Crk*** , the SH2 domain containing tyrosine phosphatase SH-PTP-2 , the cyclin-dependent kinase substrate p13 ( suc1 ) , and the Src homology 3 ( SH3 ) domain of Src , providing a functional link between TrkA , cell cycle , and multiple NGF signaling effectors .	parallel	1
1173	10092678	10818;2885	FRS-2;Grb-2	Consistent with this model , ***FRS-2*** ***binds*** ***Grb-2*** , Crk , the SH2 domain containing tyrosine phosphatase SH-PTP-2 , the cyclin-dependent kinase substrate p13 ( suc1 ) , and the Src homology 3 ( SH3 ) domain of Src , providing a functional link between TrkA , cell cycle , and multiple NGF signaling effectors .	parallel	1
1174	10092696	941;920	CD80;CD4	Expression of ***CD80*** in macrophages ***correlated*** with the BAL ***CD4/CD8*** ratio .	parallel	0
1175	10092696	941;925	CD80;CD8	Expression of ***CD80*** in macrophages ***correlated*** with the BAL ***CD4/CD8*** ratio .	parallel	0
1176	10092768	5599;3725	JNK;AP-1	In contrast , the dominant-active ***JNK*** kinase kinase , MEKK1 , ***induced*** ***CD28RE/AP-1*** luciferase activity , in parallel with induction of c-Jun and c-Rel binding to this combined promoter site .	target	1
1177	10092768	4214;3725	MEKK1;AP-1	In contrast , the dominant-active JNK kinase kinase , ***MEKK1*** , ***induced*** ***CD28RE/AP-1*** luciferase activity , in parallel with induction of c-Jun and c-Rel binding to this combined promoter site .	target	1
1178	10092768	4214;3551	MEKK1;IKK beta	Dominant-active ***MEKK1*** also ***induced*** transfected ***IKK beta*** , but not IKK alpha , activity .	target	1
1179	10092779	356;355	FasL;Fas	Contrary to the prevailing view that tumor cells cause the death of anti-tumor T cells by expressing ***Fas*** ***ligand*** ( ***FasL*** ) , our data suggested that FasL was instead expressed by T lymphocytes upon activation .	parallel	1
1180	10092813	3553;3458	IL-1 beta;IFN-gamma	We found that IFN-gamma , but not TNF-alpha or IL-1 beta , strongly induced IP-10 , Mig , and I-TAC mRNA accumulation mainly in NHBEC and that TNF-alpha and ***IL-1 beta*** ***synergized*** with ***IFN-gamma*** induction in all three cell types .	parallel	0
1181	10092813	7124;3458	TNF-alpha;IFN-gamma	We found that IFN-gamma , but not TNF-alpha or IL-1 beta , strongly induced IP-10 , Mig , and I-TAC mRNA accumulation mainly in NHBEC and that ***TNF-alpha*** and IL-1 beta ***synergized*** with ***IFN-gamma*** induction in all three cell types .	parallel	0
1182	10092813	3458;3627	IFN-gamma;IP-10	We found that ***IFN-gamma*** , but not TNF-alpha or IL-1 beta , strongly ***induced*** ***IP-10*** , Mig , and I-TAC mRNA accumulation mainly in NHBEC and that TNF-alpha and IL-1 beta synergized with IFN-gamma induction in all three cell types .	target	1
1183	10092813	3458;6373	IFN-gamma;I-TAC	We found that ***IFN-gamma*** , but not TNF-alpha or IL-1 beta , strongly ***induced*** IP-10 , Mig , and ***I-TAC*** mRNA accumulation mainly in NHBEC and that TNF-alpha and IL-1 beta synergized with IFN-gamma induction in all three cell types .	target	1
1184	10092818	3586;5724	IL-10;platelet-activating factor receptor	Hence , we observed that ***IL-10*** ***augmented*** two-to threefold ***platelet-activating factor receptor*** ( PAF-R ) expression , whereas it had no significant effect on the fifth component of complement ( C5a ) receptor ( C5a-R ) expression .	positive	0
1185	10092882	3339;2199	perlecan;fibulin-2	Recombinant domain IV of ***perlecan*** ***binds*** to nidogens , laminin-nidogen complex , fibronectin , ***fibulin-2*** and heparin .	parallel	1
1186	10092883	1509;1514	cathepsin D;cathepsin L	Aspartic protease ***cathepsin D*** was shown to ***cleave*** denatured , but not active ***cathepsin L*** , suggesting a potential mechanism for in-vivo regulation and turnover of cathepsin L inside lysosomes .	target	1
1187	10092989	3458;3383	Interferon-gamma;ICAM-1	***Interferon-gamma*** ***up-regulated*** HLA-DR and ***ICAM-1*** expression on both cells , whereas lipopolysaccharide increased ICAM-1 expression only on SW 1116 .	positive	1
1188	10093540	3929;929	lipopolysaccharide-binding protein;CD14 molecule	The activation of monocytes and macrophages induced by lipopolysaccharide has been shown to contribute to the ***binding*** of lipopolysaccharide and ***lipopolysaccharide-binding protein*** complex to the cell surface ***CD14 molecule*** .	parallel	1
1189	10093970	2185;6714	PYK2;Src	Suppression of protein kinase C is associated with inhibition of PYK2 tyrosine phosphorylation and enhancement of ***PYK2*** ***interaction*** with ***Src*** in thrombin-activated platelets .	parallel	1
1190	10093970	2185;6714	PYK2;Src	While PYK2 tyrosine phosphorylation induced by thrombin was inhibited by preincubation of platelets with PKC inhibitors , staurosporine and Ro31-8220 , ***PYK2*** ***association*** with ***Src*** was markedly enhanced under the same conditions .	parallel	0
1191	10093970	2185;6714	PYK2;Src	These results suggest that PKC activation ( but not Ca2 + mobilization ) is involved in PYK2 tyrosine phosphorylation and that ***PYK2*** ***associates*** with ***Src*** without PYK2 tyrosine phosphorylation or p130Cas involvement in platelets .	parallel	0
1192	10094049	6885;7189	TAK1;TRAF6	Here we show that the MAPKK kinase TAK1 acts upstream of NIK in the IL-1-activated signalling pathway and that ***TAK1*** ***associates*** with ***TRAF6*** during IL-1 signalling .	parallel	0
1193	10094049	6885;4790	TAK1;NF-kappaB	Stimulation of TAK1 causes activation of NF-kappaB , which is blocked by dominant-negative mutants of NIK , and an inactive ***TAK1*** mutant ***prevents*** activation of ***NF-kappaB*** that is mediated by IL-1 but not by NIK .	positive	0
1194	10094049	9020;4790	NIK;NF-kappaB	Stimulation of TAK1 causes activation of ***NF-kappaB*** , which is ***blocked*** by dominant-negative mutants of ***NIK*** , and an inactive TAK1 mutant prevents activation of NF-kappaB that is mediated by IL-1 but not by NIK .	positive	0
1195	10094049	6885;9020	TAK1;NIK	Activated ***TAK1*** ***phosphorylates*** ***NIK*** , which stimulates IKK-alpha activity .	target	1
1196	10094049	9020;1147	NIK;IKK-alpha	Activated TAK1 phosphorylates ***NIK*** , which ***stimulates*** ***IKK-alpha*** activity .	positive	0
1197	10094132	7124;1232	TNF-alpha;CCR3	Interestingly , ***TNF-alpha*** was able to ***induce*** CCR1 , ***CCR3*** as well as CXCR1 , CXCR2 , CXCR4 receptors and Burkitt 's lymphoma receptor BLR2 .	target	1
1198	10094132	7124;3577	TNF-alpha;CXCR1	Interestingly , ***TNF-alpha*** was able to ***induce*** CCR1 , CCR3 as well as ***CXCR1*** , CXCR2 , CXCR4 receptors and Burkitt 's lymphoma receptor BLR2 .	target	1
1199	10094144	351;57419	amyloid precursor protein;sodium/calcium exchanger	C-terminal fragment of Alzheimer 's ***amyloid precursor protein*** ***inhibits*** ***sodium/calcium exchanger*** activity in SK-N-SH cell .	negative	1
1200	10094147	351;43	Abeta;acetylcholinesterase	In particular , ***Abeta*** has been shown to ***induce*** the expression of ***acetylcholinesterase*** in the brains of CT-100-expressing transgenic mice and in cell culture experiments .	target	1
1201	10094400	689;1457	BTF3a;protein kinase CK2	We report here on the ***interaction*** between the other isoform , ***BTF3a*** , and ***protein kinase CK2*** .	parallel	1
1202	10094400	1457;689	protein kinase CK2;BTF3a	The data show a weak , nevertheless specific ***interaction*** of ***protein kinase CK2*** via subunit beta with the putative transcription factor ***BTF3a*** in vitro and in vivo , and a role of BTF3a as a potential new substrate for CK2 .	parallel	1
1203	10094408	1457;7157	Protein kinase CK2;p53	***Protein kinase CK2-dependent*** ***regulation*** of ***p53*** function : evidence that the phosphorylation status of the serine 386 ( CK2 ) site of p53 is constitutive and stable .	target	1
1204	10094466	2520;5747	Gastrin;p125FAK	***Gastrin*** ***stimulates*** the formation of a ***p60Src/p125FAK*** complex upstream of the phosphatidylinositol 3-kinase signaling pathway .	positive	0
1205	10094469	7157;6273	p53;S100A2	Transcriptional ***activation*** of the human ***S100A2*** promoter by wild-type ***p53*** .	positive	1
1206	10094469	6273;7157	S100A2;p53	A potential p53 binding site was identified in the promoter of the ***S100A2*** gene , which ***binds*** to purified p53 as well as ***p53*** in nuclear extract activated by etoposide .	parallel	1
1207	10094469	7157;6273	p53;S100A2	Transactivation assays using the promoter driven luciferase reporters revealed that the ***S100A2*** promoter was transcriptionally ***activated*** by wild-type ***p53*** , but not by p53 mutants , in a dose-dependent as well as a p53 binding site-dependent manner .	positive	1
1208	10094469	7157;6273	p53;S100A2	The ***p53-induced*** ***transactivation*** of the ***S100A2*** promoter was enhanced by etoposide and blocked by a dominant negative p53 mutant .	positive	1
1209	10094469	7157;6273	p53;S100A2	Thus , ***p53*** appears to positively ***regulate*** ***S100A2*** expression .	positive	1
1210	10094478	5080;1045	Pax6;Cdx2/3	***Pax6*** and ***Cdx2/3*** form a functional ***complex*** on the rat glucagon gene promoter G1-element .	parallel	1
1211	10094478	5080;1045	Pax6;Cdx2/3	Two distinct mutations in the G1-element , that both reduce promoter activity by 85-90 % , is shown to eliminate ***binding*** of either ***Pax6*** or ***Cdx2/3*** .	parallel	1
1212	10094478	5080;1045	Pax6;Cdx2/3	Additionally , ***Pax6*** ***enhanced*** ***Cdx2/3*** mediated activation of a glucagon reporter in heterologous cells .	positive	0
1213	10094480	5080;3651	Pax6;Pdx1	***Pax6*** and ***Pdx1*** form a functional ***complex*** on the rat somatostatin gene upstream enhancer .	parallel	1
1214	10094480	3651;5080	Pdx1;Pax6	In heterologous cells , ***Pdx1*** ***potentiated*** ***Pax6*** mediated activation of a somatostatin reporter .	positive	0
1215	10094483	4803;1958	NGF;NGFI-A	Thus , activation of Ras alone is sufficient for the ***induction*** of ***NGFI-A*** by ***NGF*** , whereas an additional pathway ( s ) , besides Ras , is required for the stimulation of NGFI-B and c-fos gene expression .	target	1
1216	10094578	4018;3952	lipoprotein;leptin	***lipoprotein*** ***binding*** of endogenous and exogenously radiolabelled ***leptin*** was studied by preparative ultracentrifugation .	parallel	1
1217	10094816	902;1017	p34;Cdk2	Olomoucine , a potent ***p34*** ( cdc2 ) and ***Cdk2*** ***inhibitor*** , effectively blocked RA-mediated p34 ( cdc2 ) kinase activation and prevented RA-induced apoptosis .	negative	1
1218	10094942	5320;4586	sPLA2;mucin	The increased ***sPLA2*** levels were ***associated*** with a concomitant increase in lysophosphatidylcholine , prostaglandin E2 ( PGE2 ) , and total ***mucin*** concentrations .	parallel	0
1219	10094943	3569;5706	interleukin-6;p44	Lipopolysaccharide induces cholangiocyte proliferation via an ***interleukin-6-mediated*** ***activation*** of ***p44/p42*** mitogen-activated protein kinase .	positive	1
1220	10095033	5594;3308	p38;HSP70	These results suggest that ***p38*** MAPK positively ***regulates*** hypoxia-induced ***HSP70*** expression in astrocytes .	positive	1
1221	10095040	966;4129	min-1;MAOB	Subgroups of animals of each genotype received a continuous intravenous infusion over 30 min of phenylethylamine ( PEA ) , an endogenous ***substrate*** of ***MAOB*** , ( 8 nmol g-1 ***min-1*** in normal saline at a volume rate of 0.11 microl g-1 min-1 ) or saline at the same volume rate .	parallel	1
1222	10095078	627;6616	BDNF;SNAP25	***BDNF*** , but not GDNF , significantly ***enhanced*** the expression of the calcium binding protein calbindin and synaptic protein ***SNAP25*** .	positive	0
1223	10095085	6416;5599	MKK4;JNK	It is well established that ***SAPK/JNK*** activation is ***controlled*** by ***SEK1/MKK4*** , an up-stream MAP kinase kinase .	target	0
1224	10095085	6416;5601	MKK4;SAPK	It is well established that ***SAPK/JNK*** activation is ***controlled*** by ***SEK1/MKK4*** , an up-stream MAP kinase kinase .	target	0
1225	10095448	4193;7157	MDM2;p53	Functional ***inactivation*** of ***p53*** wildtype protein by ***MDM2-expression*** seems to be the major cause of p53-accumulation in chondromatous neoplasms and emphasizes the role of these parameters as additional hint for malignancy .	negative	1
1226	10095788	3952;2194	leptin;fatty acid synthase	Transcriptional ***regulation*** of ***fatty acid synthase*** gene by insulin/glucose , polyunsaturated fatty acid and ***leptin*** in hepatocytes and adipocytes in normal and genetically obese rats .	target	1
1227	10095788	3952;2194	leptin;fatty acid synthase	Transcriptional ***regulation*** of the ***fatty acid synthase*** ( FAS ) gene by insulin/glucose , polyunsaturated fatty acids and ***leptin*** was investigated in hepatocytes and adipocytes of Wistar fatty rats and their lean littermates .	target	1
1228	10096248	2022;7040	CD105;TGF-beta1	***CD105*** , the specific type III vascular ***receptor*** for ***TGF-beta1*** and - beta3 , modulates cell proliferation and ECM production in response to TGF-beta in vitro .	parallel	1
1229	10096248	2022;7040	CD105;TGF-beta1	In this study , we have quantified the levels of TGF-beta1 and soluble ******CD105-TGF-beta1****** ***complex*** in 91 pre-radiotherapy plasma samples from early-stage ( T1 or T2 ) breast cancer patients utilising an enhanced chemiluminescence ELISA system .	parallel	1
1230	10096254	7157;596	p53;Bcl-2	Because ***Bcl-2*** has been reported to be transcriptionally ***repressed*** by ***p53*** , using immuno-histochemistry and mRNA analyses , we have examined Bcl-2 expression in a panel of 10 classical and 3 anaplastic nephroblastomas in which the p53 status had been previously analyzed .	negative	1
1231	10096254	581;596	Bax;Bcl-2	Therefore , we examined the expression of the Bcl-X and ***Bax*** genes , which are known to ***synergize*** and antagonize ***Bcl-2*** , respectively .	parallel	0
1232	10096254	598;596	Bcl-X;Bcl-2	Therefore , we examined the expression of the ***Bcl-X*** and Bax genes , which are known to ***synergize*** and antagonize ***Bcl-2*** , respectively .	parallel	0
1233	10096294	7018;6036	transferrin;EDN	To elicit cellular targeting as well as to block RI binding , ***transferrin*** was ***conjugated*** to a mutant human RNase , rhRNase ( Gly89 ) -- > Cys ) and a mutant ***EDN*** ( Thr87 -- > Cys ) .	parallel	1
1234	10096546	5599;5601	JNK;SAPK	Taken together , our results suggest that Rb is a target protein of SAPK/JNK and that the ***association*** of ******SAPK/JNK****** and Rb mediates IR-induced apoptosis in MM cells .	parallel	0
1235	10096561	958;1437	CD40;granulocyte macrophage colony-stimulating factor	***CD40*** ligation on MM by CD40L-transfected murine L-cells or by a soluble CD40L fusion protein ***up-regulated*** their expression of intercellular adhesion molecule-1 and MHC class I and class II molecules and their secretion of IL-6 , IL-8 , tumor necrosis factor-a , and ***granulocyte macrophage colony-stimulating factor*** and also induced a rapid activation of the transcription factor nuclear factor kappaB .	positive	1
1236	10096561	958;3569	CD40;IL-6	***CD40*** ligation on MM by CD40L-transfected murine L-cells or by a soluble CD40L fusion protein ***up-regulated*** their expression of intercellular adhesion molecule-1 and MHC class I and class II molecules and their secretion of ***IL-6*** , IL-8 , tumor necrosis factor-a , and granulocyte macrophage colony-stimulating factor and also induced a rapid activation of the transcription factor nuclear factor kappaB .	positive	1
1237	10096561	958;3576	CD40;IL-8	***CD40*** ligation on MM by CD40L-transfected murine L-cells or by a soluble CD40L fusion protein ***up-regulated*** their expression of intercellular adhesion molecule-1 and MHC class I and class II molecules and their secretion of IL-6 , ***IL-8*** , tumor necrosis factor-a , and granulocyte macrophage colony-stimulating factor and also induced a rapid activation of the transcription factor nuclear factor kappaB .	positive	1
1238	10096561	958;3383	CD40;intercellular adhesion molecule-1	***CD40*** ligation on MM by CD40L-transfected murine L-cells or by a soluble CD40L fusion protein ***up-regulated*** their expression of ***intercellular adhesion molecule-1*** and MHC class I and class II molecules and their secretion of IL-6 , IL-8 , tumor necrosis factor-a , and granulocyte macrophage colony-stimulating factor and also induced a rapid activation of the transcription factor nuclear factor kappaB .	positive	1
1239	10096561	958;959	CD40;CD40L	These results indicate that ******CD40-CD40L****** ***interactions*** may play an important role in augmenting antitumor immunity and inducing apoptosis in some CD40-positive immunogenic human MMs .	parallel	1
1240	10096602	5727;6469	Ptc;sonic hedgehog	Lingual expression of the signaling molecule ***sonic hedgehog*** ( Shh ) , its ***receptor*** Patched ( ***Ptc*** ) , and the Shh-activated transcription factor Gli1 were assayed by using in situ hybridization .	parallel	1
1241	10096784	1113;3643	pancreastatin;insulin receptor	***Modulation*** of ***insulin receptor*** signalling by ***pancreastatin*** in HTC hepatoma cells .	target	0
1242	10097072	8600;8792	OPGL;RANK	Recombinant ***OPGL*** ***binds*** specifically to ***RANK*** expressed by transfected cell lines and purified osteoclast progenitors .	parallel	1
1243	10097072	8792;8600	RANK;OPGL	Furthermore , polyclonal Ab against the RANK extracellular domain promotes osteoclastogenesis in bone marrow cultures suggesting that ***RANK*** activation ***mediates*** the effects of ***OPGL*** on the osteoclast pathway .	target	0
1244	10097092	1385;1387	CREB;CBP	Here we report that the adenovirus E1A protein inhibits the acetyltransferase activity of CBP on binding to the C/H3 domain , whereas binding of CREB , or a ***CREB/E1A*** fusion protein to the KIX domain , fails to ***inhibit*** ***CBP*** acetyltransferase activity .	negative	1
1245	10097092	8202;1387	p/CIP;CBP	Surprisingly , ***p/CIP*** can either ***inhibit*** or stimulate ***CBP*** acetyltransferase activity depending on the specific substrate evaluated and the functional domains present in the p/CIP protein .	negative	1
1246	10097113	5599;596	JNK;Bcl-2	***JNK*** , but not ERK or p38 MAPK , appear to be involved in the ***phosphorylation*** of ***Bcl-2*** induced by paclitaxel .	target	1
1247	10097128	8945;4792	FWD1;IkappaBalpha	Ubiquitin-dependent degradation of ***IkappaBalpha*** is ***mediated*** by a ubiquitin ligase Skp1/Cul 1/F-box protein ***FWD1*** .	target	0
1248	10097128	8945;4792	FWD1;IkappaBalpha	Here , we show that ***FWD1*** ( a mouse homologue of Slimb/betaTrCP ) , a member of the F-box/WD40-repeat proteins , is ***associated*** specifically with ***IkappaBalpha*** only when IkappaBalpha is phosphorylated .	parallel	0
1249	10097128	8945;4792	FWD1;IkappaBalpha	The introduction of ***FWD1*** into cells significantly ***promotes*** ubiquitination and degradation of ***IkappaBalpha*** in concert with IkappaB kinases , resulting in nuclear translocation of NF-kappaB .	positive	0
1250	10097128	8945;4792	FWD1;IkappaBalpha	In addition , ***FWD1*** strikingly ***evoked*** the ubiquitination of ***IkappaBalpha*** in the in vitro system .	positive	0
1251	10097128	8945;4792	FWD1;IkappaBalpha	These results suggest that the substrate-specific degradation of IkappaBalpha is mediated by a Skp1/Cull 1/F-box protein ( SCF ) FWD1 ubiquitin-ligase complex and that ***FWD1*** serves as an intracellular ***receptor*** for phosphorylated ***IkappaBalpha*** .	parallel	1
1252	10097128	6500;4792	Skp1;IkappaBalpha	These results suggest that the substrate-specific degradation of ***IkappaBalpha*** is ***mediated*** by a ***Skp1/Cull*** 1/F-box protein ( SCF ) FWD1 ubiquitin-ligase complex and that FWD1 serves as an intracellular receptor for phosphorylated IkappaBalpha .	target	0
1253	10097133	2119;3458	ERM;IFN-gamma	Retroviral expression of ***ERM*** did not restore IFN-gamma production in Stat4-deficient T cells , but ***augmented*** ***IFN-gamma*** expression in Stat4-heterozygous T cells .	positive	0
1254	10097147	8930;4292	MED1;MLH1	***MED1*** , a novel human methyl-CpG-binding endonuclease , ***interacts*** with DNA mismatch repair protein ***MLH1*** .	parallel	1
1255	10097147	8930;4292	MED1;MLH1	The ***MED1*** protein forms a ***complex*** with ***MLH1*** , binds to methyl-CpG-containing DNA , has homology to bacterial DNA repair glycosylases/lyases , and displays endonuclease activity .	parallel	1
1256	10097151	9988;1029	DMP1;ARF	***Induction*** of ***ARF*** tumor suppressor gene expression and cell cycle arrest by transcription factor ***DMP1*** .	target	1
1257	10097151	1869;1029	E2F-1;ARF	Unlike genes such as Myc , adenovirus E1A , and ***E2F-1*** , which , when overexpressed , ***activate*** the ***ARF-p53*** pathway and trigger apoptosis , DMP1 , like ARF itself , does not induce programmed cell death .	positive	1
1258	10097151	1869;9988	E2F-1;DMP1	Unlike genes such as Myc , adenovirus E1A , and ***E2F-1*** , which , when overexpressed , ***activate*** the ARF-p53 pathway and trigger apoptosis , ***DMP1*** , like ARF itself , does not induce programmed cell death .	positive	1
1259	10097151	4609;1029	Myc;ARF	Unlike genes such as ***Myc*** , adenovirus E1A , and E2F-1 , which , when overexpressed , ***activate*** the ***ARF-p53*** pathway and trigger apoptosis , DMP1 , like ARF itself , does not induce programmed cell death .	positive	1
1260	10097151	4609;9988	Myc;DMP1	Unlike genes such as ***Myc*** , adenovirus E1A , and E2F-1 , which , when overexpressed , ***activate*** the ARF-p53 pathway and trigger apoptosis , ***DMP1*** , like ARF itself , does not induce programmed cell death .	positive	1
1261	10098488	3589;9021	IL-11;SOCS-3	***IL-11*** ***induction*** of ***SOCS-3*** indicates an intracellular negative feedback control of cytokine-induced POMC expression and ACTH secretion .	target	1
1262	10098488	3589;5443	Interleukin-11;adrenocorticotropin	***Interleukin-11*** ***stimulates*** proopiomelanocortin gene expression and ***adrenocorticotropin*** secretion in corticotroph cells : evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis .	positive	0
1263	10098488	3589;5443	IL-11;POMC	***POMC*** mRNA expression was ***induced*** by ***IL-11*** ( 0.5 x 10 ( -9 ) M ) and LIF ( 0.5 x 10 ( -9 ) M ) 1.5 + / - 0.18-fold ( P < 0.05 ) and 1.7 + / - 0.13-fold ( P < 0.01 ) , respectively .	target	1
1264	10098488	3589;5443	IL-11;POMC	***POMC*** promoter activity , assayed by a -706 / +64 rat POMC promoter-luciferase construct , was ***stimulated*** by 0.5 x 10 ( -9 ) M ***IL-11*** ( 1.9 + / - 0.06-fold ; P < 0.001 ) and 5 mM Bu2cAMP ( 7.1 + / - 0.52-fold , P < 0.001 ) , and combined treatment of IL-11 plus Bu2cAMP caused a synergistic 11.7 + / -0.71 - fold increase ofluciferase activity ( P < 0.001 vs.	positive	0
1265	10098490	7040;1490	TGFbeta;CTGF	We conclude that in large vessel endothelial cells , cAMP increased intact CTGF protein by inhibiting degradation of CTGF , whereas TGFbeta stimulated neither CTGF mRNA nor protein ; in microvessel cells , ***TGFbeta*** ***increased*** ***CTGF*** mRNA , while both TGFbeta and cAMP stimulated CTGF degradation .	positive	0
1266	10098490	7040;1490	TGFbeta;CTGF	We conclude that in large vessel endothelial cells , cAMP increased intact CTGF protein by inhibiting degradation of CTGF , whereas TGFbeta stimulated neither CTGF mRNA nor protein ; in microvessel cells , TGFbeta increased CTGF mRNA , while both ***TGFbeta*** and cAMP ***stimulated*** ***CTGF*** degradation .	positive	0
1267	10098491	3952;2796	leptin;GnRH	In particular , it has been shown that ***leptin*** may indirectly ***stimulate*** ***GnRH*** release from hypothalamic fragments by acting on interneurons impinging on GnRH-secreting neurons .	positive	0
1268	10098492	7026;5468	ARP-1;PPARgamma	The COUP-TFII ( ***ARP-1*** ) protein specifically bound the LPL PPAR recognition element inelectromobility shift assays and ***interacted*** directly with the ligand-binding domain of ***PPARgamma*** in pull-down experiments .	parallel	1
1269	10098497	3952;1675	Leptin;adipsin	***Leptin*** increased mRNA levels of lipoprotein lipase at 3 days , but ***decreased*** mRNA levels of ***adipsin*** and Leptin at 9 days and decreased lipid droplet formation by 50 % .	negative	0
1270	10098497	3952;4023	Leptin;lipoprotein lipase	***Leptin*** ***increased*** mRNA levels of ***lipoprotein lipase*** at 3 days , but decreased mRNA levels of adipsin and Leptin at 9 days and decreased lipid droplet formation by 50 % .	positive	0
1271	10098502	5443;1545	ACTH;CYP1B1	Twice daily injections of ***ACTH*** to rat pups ( pd3-10 ) failed to significantly ***increase*** the expression of ***CYP1B1*** in pd 10 adrenals , although the injections weakly stimulated steroidogenesis .	positive	0
1272	10098510	3952;3725	Leptin;c-Jun	We find that ***Leptin*** ***induces*** ***c-Jun*** expression and attenuates the transcriptional activity of the glucocorticoid receptor ( GR ) in granulosa cells .	target	1
1273	10098521	5744;5741	PTHrP;PTH	As a model for studying the actions of locally produced PTHrP in vascular smooth muscle in vivo , we developed transgenic mice that overexpress the ***PTH/PTHrP*** ***receptor*** ( ***PTHrP-R*** ) in smooth muscle .	parallel	1
1274	10098589	3976;5443	leukemia inhibitory factor;ACTH	We recently reported ***leukemia inhibitory factor*** ( LIF ) ***increased*** ***ACTH*** secretion and pro-opiomelanocortin mRNA level in the murine corticotroph tumor cell line ( AtT-20 ) .	positive	0
1275	10098589	1392;5443	CRH;ACTH	***CRH*** ( 10 nM ) also ***induced*** ***ACTH*** secretion 2.5-fold ( P < 0.01 ) , and co-treatment of LIF and CRH exhibited 2.8-fold increase of ACTH secretion but no statistical difference from CRH treated group .	target	1
1276	10098731	5443;3576	alpha-melanocyte-stimulating hormone;interleukin 8	Tumour necrosis factor alpha , ( TNF-alpha ) , not , however , IL-2 , interferon-gamma ( IFN-gamma ) , or ( ***alpha-melanocyte-stimulating hormone*** ( alpha-MSH ) was able to ***up-regulate*** RANTES and ***interleukin 8*** secretion .	positive	1
1277	10098731	5443;6352	alpha-melanocyte-stimulating hormone;RANTES	Tumour necrosis factor alpha , ( TNF-alpha ) , not , however , IL-2 , interferon-gamma ( IFN-gamma ) , or ( ***alpha-melanocyte-stimulating hormone*** ( alpha-MSH ) was able to ***up-regulate*** ***RANTES*** and interleukin 8 secretion .	positive	1
1278	10098731	3458;3576	interferon-gamma;interleukin 8	Tumour necrosis factor alpha , ( TNF-alpha ) , not , however , IL-2 , ***interferon-gamma*** ( IFN-gamma ) , or ( alpha-melanocyte-stimulating hormone ( alpha-MSH ) was able to ***up-regulate*** RANTES and ***interleukin 8*** secretion .	positive	1
1279	10098731	3458;6352	interferon-gamma;RANTES	Tumour necrosis factor alpha , ( TNF-alpha ) , not , however , IL-2 , ***interferon-gamma*** ( IFN-gamma ) , or ( alpha-melanocyte-stimulating hormone ( alpha-MSH ) was able to ***up-regulate*** ***RANTES*** and interleukin 8 secretion .	positive	1
1280	10098769	356;355	FasL;Fas	Colorectal carcinoma cells have recently been shown to express ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
1281	10098850	3586;3553	IL-10;IL-1beta	***IL-10*** ***inhibited*** lipopolysaccharide-induced ***IL-1beta*** and tumor necrosis factor-alpha production , lysosomal enzyme activity , and superoxide anion production in a dose-dependent manner , but did not affect granulocyte/ macrophage colony-stimulating factor-dependent proliferation of microglia .	negative	1
1282	10098850	3586;7124	IL-10;tumor necrosis factor-alpha	***IL-10*** ***inhibited*** lipopolysaccharide-induced IL-1beta and ***tumor necrosis factor-alpha*** production , lysosomal enzyme activity , and superoxide anion production in a dose-dependent manner , but did not affect granulocyte/ macrophage colony-stimulating factor-dependent proliferation of microglia .	negative	1
1283	10098850	3586;3558	IL-10;IL-2	***IL-10*** also ***decreased*** mRNA expression of ***IL-2*** and IL-6 cytokine receptors .	negative	0
1284	10098850	3586;3569	IL-10;IL-6	***IL-10*** also ***decreased*** mRNA expression of IL-2 and ***IL-6*** cytokine receptors .	negative	0
1285	10098873	2885;1605	Grb2;beta-dystroglycan	***Grb2*** , an adaptor protein involved in signal transduction and cytoskeleton organization , has been shown to ***bind*** ***beta-dystroglycan*** .	parallel	1
1286	10098873	5747;1605	FAK;beta-dystroglycan	At the synapses , the adaptor protein Grb2 may mediate ******FAK-beta-dystroglycan****** ***interaction*** , and it may play a role in transferring information between the dystroglycan complex and other signaling pathways .	parallel	1
1287	10098873	2885;1605	Grb2;beta-dystroglycan	At the synapses , the adaptor protein ***Grb2*** may ***mediate*** ***FAK-beta-dystroglycan*** interaction , and it may play a role in transferring information between the dystroglycan complex and other signaling pathways .	target	0
1288	10098873	2885;5747	Grb2;FAK	At the synapses , the adaptor protein ***Grb2*** may ***mediate*** ***FAK-beta-dystroglycan*** interaction , and it may play a role in transferring information between the dystroglycan complex and other signaling pathways .	target	0
1289	10098943	4804;627	p75;neurotrophin	In addition , we used double-label immunohistochemistry to examine colocalization of ER-alpha with the low - and high-affinity ***neurotrophin*** ***receptors*** , ***p75*** and trkA , and with the cholinergic marker choline acetyltransferase .	parallel	1
1290	10098943	4914;627	trkA;neurotrophin	In addition , we used double-label immunohistochemistry to examine colocalization of ER-alpha with the low - and high-affinity ***neurotrophin*** ***receptors*** , p75 and ***trkA*** , and with the cholinergic marker choline acetyltransferase .	parallel	1
1291	10099114	3700;1234	gp120;CCR5	Surface ***CCR5*** could be ***up-regulated*** on the monocytes but not the intestinal macrophages by HIV-1 and ***gp120*** .	positive	1
1292	10099693	133;183	PAMP;angiotensin II	In the adrenal gland both AM and ***PAMP*** ***inhibit*** potassium and ***angiotensin II-stimulated*** aldosterone secretion .	negative	1
1293	10099828	4193;1869	MDM2;E2F1	Because ***MDM2*** also ***binds*** and activates the S phase-specific transcription factor ***E2F1*** , we hypothesized that increased E2F1 activity causes the development of the BLGmdm2 phenotype .	parallel	1
1294	10100098	185;183	AT1;angiotensin II	Activities of the circulating Renin-angiotensin system were measured by radioimmunoassay and the gene expression of tissue angiotensinogen , the ***angiotensin II*** type 1 ***receptor*** ( ***AT1*** ) and fibronectin were analyzed by Northern blot analysis .	parallel	1
1295	10100611	6804;6844	syntaxin 1a;synaptobrevin 2	A stable ***interaction*** between ***syntaxin 1a*** and ***synaptobrevin 2*** mediated by their transmembrane domains .	parallel	1
1296	10100614	1977;1978	eIF-4E;4E-BP1	Incubation of hepatocytes under hypoxia increases ***binding*** of translation initiation factor ***eIF-4E*** to its inhibitory regulator ***4E-BP1*** , and this correlates with dephosphorylation of 4E-BP1 .	parallel	1
1297	10100614	1978;1977	4E-BP1;eIF-4E	This enhanced ***association*** of ***4E-BP1*** with ***eIF-4E*** might be mediated by mTOR .	parallel	0
1298	10100614	2475;1978	mTOR;4E-BP1	This enhanced association of ***4E-BP1*** with eIF-4E might be ***mediated*** by ***mTOR*** .	target	0
1299	10100620	861;2353	acute myeloid leukemia 1;c-fos	***Regulation*** of ***c-fos*** gene transcription and myeloid cell differentiation by ***acute myeloid leukemia 1*** and acute myeloid leukemia-MTG8 , a chimeric leukemogenic derivative of acute myeloid leukemia 1 .	target	1
1300	10100620	862;2353	MTG8;c-fos	***Regulation*** of ***c-fos*** gene transcription and myeloid cell differentiation by acute myeloid leukemia 1 and acute myeloid ***leukemia-MTG8*** , a chimeric leukemogenic derivative of acute myeloid leukemia 1 .	target	1
1301	10100620	861;2353	acute myeloid leukemia 1;c-fos	In 32Dcl3 myeloid cells , stable overexpression of ***acute myeloid leukemia 1-MTG8*** ***blocked*** the ***c-fos*** gene transcription and cell differentiation , but that of acute myeloid leukemia did not .	negative	0
1302	10100620	862;2353	MTG8;c-fos	In 32Dcl3 myeloid cells , stable overexpression of ***acute myeloid leukemia 1-MTG8*** ***blocked*** the ***c-fos*** gene transcription and cell differentiation , but that of acute myeloid leukemia did not .	negative	0
1303	10100634	3565;7124	interleukin-4;TNF-alpha	Moreover , this study showed that in vitro treatment of neuroblastoma cells with ***interleukin-4*** ( IL-4 ) , which ***inhibits*** ***TNF-alpha*** production , reduced the expression of the neuronal ELAV-like proteins .	negative	1
1304	10100920	116;7432	pituitary adenylate cyclase-activating polypeptide;VIP	***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) ***interacts*** with three types of ***PACAP/VIP-receptors*** .	parallel	1
1305	10100924	6750;7124	Somatostatin;TNF-alpha	These findings demonstrate that ***Somatostatin*** and octreotide ***modulate*** the release of nitric oxide , ***TNF-alpha*** and H2O2 by Kupffer cells in cirrhotic livers depending on the concentrations of hormones used .	target	0
1306	10100926	796;2520	calcitonin;gastrin	The aims of the present study were to examine ( 1 ) if ***calcitonin*** ( CT ) , parathyroid hormone ( PTH ) and vitamin D ***affect*** the ***gastrin-ECL-cell*** axis ( by measuring the activity of the histamine-forming enzyme , histidine decarboxylase ( HDC ) , and the expression of HDC mRNA and CGA mRNA in the ECL cells ) , and ( 2 ) if activation of the gastrin-ECL-cell axis affects the parathyroid glands ( by measuring plasma PTH and mRNA expression ) .	target	0
1307	10100926	5741;2520	parathyroid hormone;gastrin	The aims of the present study were to examine ( 1 ) if calcitonin ( CT ) , ***parathyroid hormone*** ( PTH ) and vitamin D ***affect*** the ***gastrin-ECL-cell*** axis ( by measuring the activity of the histamine-forming enzyme , histidine decarboxylase ( HDC ) , and the expression of HDC mRNA and CGA mRNA in the ECL cells ) , and ( 2 ) if activation of the gastrin-ECL-cell axis affects the parathyroid glands ( by measuring plasma PTH and mRNA expression ) .	target	0
1308	10101004	3567;596	IL-5;Bcl-2	This investigation indicates a specific profile of apoptotic molecules in eosinophils distinct from that of neutrophils , and indicates that survival-enhancing ***IL-5*** ***modulates*** the expression of ***Bcl-2*** in vitro .	target	0
1309	10101011	3565;7124	IL-4;TNF-alpha	Interestingly , ***IL-4*** ***synergized*** with ***TNF-alpha*** to increase greatly the production of three biochemically distinct eotaxin forms .	parallel	0
1310	10101011	3565;6356	IL-4;eotaxin	Interestingly , ***IL-4*** synergized with TNF-alpha to ***increase*** greatly the production of three biochemically distinct ***eotaxin*** forms .	positive	0
1311	10101011	3458;7124	IFN-gamma;TNF-alpha	In contrast , ***IFN-gamma*** ***synergized*** with ***TNF-alpha*** to increase RANTES production .	parallel	0
1312	10101017	3977;3976	LIFR;Leukemia inhibitory factor	The distribution and regulation of ***Leukemia inhibitory factor*** ( LIF ) and its ***receptor*** ( ***LIFR*** ) in human lung tissue is unknown .	parallel	1
1313	10101030	196;405	AhR;Arnt	In contrast , ***AhR*** in TCDD-treated cells was primarily immunoprecipitated from nuclear extracts and was ***associated*** with ***Arnt*** but not 90 kDa heat shock protein .	parallel	0
1314	10101031	136;3576	adenosine A2B receptor;IL-8	These results indicate that extracellular adenosine can regulate ERK , c-Jun N-terminal kinase , and p38 MAPK signaling cascades and that activation of ERK and p38 MAPK pathways are essential steps in ***adenosine A2B receptor-dependent*** ***stimulation*** of ***IL-8*** production in HMC-1 .	positive	0
1315	10101129	4617;4654	Myf-5;MyoD	These data support the hypothesis that LS-14 and LS-15 define the core enhancer targets for ***Myf-5-dependent*** ***activation*** of ***MyoD*** in myotomal muscles .	positive	1
1316	10101198	4541;4540	ND6;ND5	The cDNA for the sea urchin mitochondrial D-loop-binding protein ( mtDBP ) , a 40 kDa protein which binds two homologous regions of mitochondrial DNA ( the D-loop region and the ***boundary*** between the oppositely transcribed ***ND5*** and ***ND6*** genes ) , has been cloned .	parallel	0
1317	10101232	4760;203	NeuroD;AK1	The CAT reporter assay of the 5 ' - flanking region of the AK1 gene suggests that ***NeuroD*** ***activates*** the ***AK1*** expression through E-boxes in the promoter region .	positive	1
1318	10101252	5663;1508	PS1;APPs	These results indicate that PKC deficits are unlikely to contribute to increased Abeta seen with APP and PS1 mutations , and also that ***PS1*** mutations ***decrease*** alpha-secretase derived ***APPs*** production independently of altered PKC activity .	positive	0
1319	10101680	940;941	CD28;CD80	***Interaction*** of ***CD28*** with ***CD80*** or CD86 molecules on APC initiates a costimulatory or second signal within the T cell which augments and sustains T cell activation initiated through the TCR .	parallel	1
1320	10101680	940;942	CD28;CD86	***Interaction*** of ***CD28*** with CD80 or ***CD86*** molecules on APC initiates a costimulatory or second signal within the T cell which augments and sustains T cell activation initiated through the TCR .	parallel	1
1321	10102250	3952;6462	leptin;sex hormone-binding globulin	***leptin*** was significantly ***associated*** with fasting insulin in both sexes independent of age , sex hormones , ***sex hormone-binding globulin*** , VAT and SAT .	parallel	0
1322	10102271	146059;8506	DLT;Neurexin IV	At subsequent stages of development , ***DLT*** ***interacts*** with the apical determinant Crumbs ( CRB ) and the laterally localized protein ***Neurexin IV*** ( NRX IV ) .	parallel	1
1323	10102273	207;2309	Akt;FKHRL1	In this study , we demonstrate that ***Akt*** also ***regulates*** the activity of ***FKHRL1*** , a member of the Forkhead family of transcription factors .	target	1
1324	10102273	207;2309	Akt;FKHRL1	In the presence of survival factors , ***Akt*** ***phosphorylates*** ***FKHRL1*** , leading to FKHRL1 's association with 14-3-3 proteins and FKHRL1 's retention in the cytoplasm .	target	1
1325	10102358	983;3320	Cdc2;Hsp90	Genetic interactions were not observed in combination with point mutations in other cdc genes , suggesting that ***Cdc2*** specifically ***interacts*** with ***Hsp90*** .	parallel	1
1326	10102472	3553;5502	IL-1beta;inhibitor-1	The ***activation*** of plasminogen activator ***inhibitor-1*** expression by ***IL-1beta*** is attenuated by estrogen in hepatoblastoma HepG2 cells expressing estrogen receptor alpha .	positive	1
1327	10102566	3952;7351	leptin;UCP2	There was no indication that the expression of ***UCP2*** was markedly ***affected*** by the addition of ***leptin*** , dexamethasone or isoprenaline .	target	0
1328	10102579	5451;4790	Oct-1;NF-kappaB	These data suggest that , besides the NF-kappaB site , the octamer motif is essential for the maximal expression of the iNOS gene in murine macrophages , and the direct ***interaction*** of ***Oct-1*** and ***NF-kappaB*** is important for the regulation of this gene .	parallel	1
1329	10102625	7124;7299	TNFalpha;tyrosinase	First , we show that ***TNFalpha*** ***inhibits*** the activity and protein expression of ***tyrosinase*** which is the key enzyme of melanogenesis .	negative	1
1330	10102627	8061;3725	Fra-1;AP-1	Previously , we have shown that nuclear extracts from cultured mouse keratinocytes induced to differentiate by increasing the levels of extra-cellular calcium contain ***Fra-1*** , Fra-2 , Jun B , Jun D and c-Jun proteins that ***bind*** to the ***AP-1*** DNA binding sequence .	parallel	1
1331	10102627	2355;3725	Fra-2;AP-1	Previously , we have shown that nuclear extracts from cultured mouse keratinocytes induced to differentiate by increasing the levels of extra-cellular calcium contain Fra-1 , ***Fra-2*** , Jun B , Jun D and c-Jun proteins that ***bind*** to the ***AP-1*** DNA binding sequence .	parallel	1
1332	10102627	3725;466	AP-1;ATF-1	***AP-1*** and CRE DNA binding activity ***correlated*** with the induction of CREB , CREMalpha and ***ATF-1*** and CREB phosphorylation at ser133 ( ser133 phospho-CREB ) in the transition from basal to differentiating keratinocytes , but the activity of a CRE reporter remained unchanged .	parallel	0
1333	10102627	3725;1385	AP-1;CREB	***AP-1*** and CRE DNA binding activity ***correlated*** with the induction of ***CREB*** , CREMalpha and ATF-1 and CREB phosphorylation at ser133 ( ser133 phospho-CREB ) in the transition from basal to differentiating keratinocytes , but the activity of a CRE reporter remained unchanged .	parallel	0
1334	10102627	1385;3725	CREB;AP-1	In experiments where the A-CREB mutant was co-transfected with an AP-1 reporter construct , transcriptional activity was also increased indicating that a ***CREB*** family member ***binds*** ***AP-1*** sites and represses AP-1 transcriptional activity as well .	parallel	1
1335	10102627	1385;3725	CREB;AP-1	In experiments where the A-CREB mutant was co-transfected with an AP-1 reporter construct , transcriptional activity was also increased indicating that a ***CREB*** family member binds AP-1 sites and ***represses*** ***AP-1*** transcriptional activity as well .	negative	1
1336	10102631	4301;1499	l-afadin;beta-catenin	Neither ***l-afadin*** nor neurabin-II significantly ***interacted*** with alpha - , ***beta-catenin*** , E-cadherin , ZO-1 or occludin .	parallel	1
1337	10102631	4301;999	l-afadin;E-cadherin	Neither ***l-afadin*** nor neurabin-II significantly ***interacted*** with alpha - , beta-catenin , ***E-cadherin*** , ZO-1 or occludin .	parallel	1
1338	10102631	4301;100506658	l-afadin;occludin	Neither ***l-afadin*** nor neurabin-II significantly ***interacted*** with alpha - , beta-catenin , E-cadherin , ZO-1 or ***occludin*** .	parallel	1
1339	10102631	4301;7082	l-afadin;ZO-1	Neither ***l-afadin*** nor neurabin-II significantly ***interacted*** with alpha - , beta-catenin , E-cadherin , ***ZO-1*** or occludin .	parallel	1
1340	10102631	84687;1499	neurabin-II;beta-catenin	Neither l-afadin nor ***neurabin-II*** significantly ***interacted*** with alpha - , ***beta-catenin*** , E-cadherin , ZO-1 or occludin .	parallel	1
1341	10102631	84687;999	neurabin-II;E-cadherin	Neither l-afadin nor ***neurabin-II*** significantly ***interacted*** with alpha - , beta-catenin , ***E-cadherin*** , ZO-1 or occludin .	parallel	1
1342	10102631	84687;100506658	neurabin-II;occludin	Neither l-afadin nor ***neurabin-II*** significantly ***interacted*** with alpha - , beta-catenin , E-cadherin , ZO-1 or ***occludin*** .	parallel	1
1343	10102631	84687;7082	neurabin-II;ZO-1	Neither l-afadin nor ***neurabin-II*** significantly ***interacted*** with alpha - , beta-catenin , E-cadherin , ***ZO-1*** or occludin .	parallel	1
1344	10102632	7422;3791	VEGF;KDR	***VEGF*** ***binding*** to KDR ( Y951F ) and ***KDR*** ( Y996F ) expressing cells resulted in phosphorylation of all cellular substrates tested , although the level of PLCgamma phosphorylation was decreased for KDR ( Y996F ) .	parallel	1
1345	10102636	7040;4087	TGFbeta;Smad2	***TGFbeta*** binding to heteromeric complexes of transmembrane Ser/Thr kinases ***induces*** ***Smad2*** and Smad3 phosphorylation on their C terminus residues .	target	1
1346	10102636	7040;4088	TGFbeta;Smad3	***TGFbeta*** binding to heteromeric complexes of transmembrane Ser/Thr kinases ***induces*** Smad2 and ***Smad3*** phosphorylation on their C terminus residues .	target	1
1347	10102692	1803;2695	DPP IV;GIP	The formation of ***GIP*** ( 3-42 ) was almost completely ***abolished*** by inhibition of plasma ***DPP IV*** with diprotin A.	positive	0
1348	10102704	7124;7412	TNF-alpha;vascular cell adhesion molecule-1	The augmented TNF-alpha-induced NF-kappaB activation in HG was associated with increased ***TNF-alpha-mediated*** transcriptional ***activation*** of the ***vascular cell adhesion molecule-1*** promoter .	positive	1
1349	10102943	1113;2520	CgA;gastrin	RESULTS : Fasting serum ***CgA*** levels positively ***correlated*** with serum ***gastrin*** in the entire study population ( r = 0 .	positive	0
1350	10102967	2520;6750	gastrin;somatostatin	CONCLUSIONS : Conventional mice with gastric ulcers can be successfully infected by both toxigenic and nontoxigenic H. pylori strains , and this infection causes an immediate suppression of gastric secretion and markedly delays the healing of ulcers due to the fall in mucosal microcirculation in the ulcer region , cytokine release and an impairment in the ******gastrin-somatostatin****** ***link*** that appears to be independent of gastritis and more pronounced with infection of toxigenic than nontoxigenic strains .	parallel	0
1351	10102987	8851;3005	p25;histone H1	Crp is highly related to the mammalian Cdk5 , and ***p25*** ( a truncated form of p35 , the activating subunit of Cdk5 from mammalian brain ) ***stimulates*** the ***histone H1*** kinase activity of GST-Crp by several fold .	positive	0
1352	10103006	2230;1583	adrenodoxin;P450SCC	Because no similar effects were observed in Tween 20 micelles , these results suggest that the phospholipid membrane may play an important role in the ***interaction*** of human ***adrenodoxin*** with human ***P450SCC*** .	parallel	1
1353	10103073	4760;27429	beta2;htra2	***htra2-beta2*** is not translated into protein , and probably helps to ***regulate*** the relative amounts of ***htra2-beta1*** to beta3 .	target	1
1354	1012339	2922;5972	bombesin;renin	***bombesin*** , a tetradecapeptide isolated from the skin of some European discoglossid frogs , has been reported previously to reduce renal blood flow and glomerular filtration rate and to ***increase*** plasma ***renin*** activity in anaesthetized dogs .	positive	0
1355	10168548	4018;338	apo;apoB-100	It consists of one molecule of low density Lipoprotein and an additional molecule of ***apo*** ( a ) ***linked*** to ***apoB-100*** by a disulfide bridge .	parallel	0
1356	10187764	3458;4842	IFNgamma;NOS	Furthermore , LPS plus ***IFNgamma*** ***increased*** the tyrosine phosphorylation of ***NOS-I*** , with a concomitant inhibition of its enzyme activity .	positive	0
1357	10187765	3827;4790	bradykinin;NF-kappaB	Requirement of phosphatidylinositol 3-kinase activity for ***bradykinin*** ***stimulation*** of ***NF-kappaB*** activation in cultured human epithelial cells .	positive	0
1358	10187765	4790;387	NF-kappaB;RhoA	We previously demonstrated that BK-stimulated ***NF-kappaB*** activation ***requires*** the small GTPase ***RhoA*** .	target	0
1359	10187771	8837;841	c-FLIP;caspase-8	We have previously reported on the death effector domain containing E8 gene product from equine herpesvirus-2 , designated FLICE inhibitory protein ( v-FLIP ) , and on its cellular homologue , ***c-FLIP*** , which ***inhibit*** the activation of ***caspase-8*** by death receptors .	negative	1
1360	10187774	7040;94	TGF-beta1;ALK-1	We show that ***TGF-beta1*** and TGF-beta3 , as well as a third unknown ligand present in serum , can ***activate*** chimeric ***ALK-1*** .	positive	1
1361	10187774	7043;94	TGF-beta3;ALK-1	We show that TGF-beta1 and ***TGF-beta3*** , as well as a third unknown ligand present in serum , can ***activate*** chimeric ***ALK-1*** .	positive	1
1362	10187783	10045;5599	NSP1;JNK1	Increased expression of ***NSP1*** in 293 cells ***induces*** activation of ***JNK1*** , but not of ERK2 .	target	1
1363	10187789	10645;8536	CaMKK;CaMKI	Several recent studies have shown that Ca2 + / calmodulin-dependent protein kinase I ( ***CaMKI*** ) is ***phosphorylated*** and activated by a protein kinase ( ***CaMKK*** ) that is itself subject to regulation by Ca2 + / calmodulin .	target	1
1364	10187789	8536;10645	CaMKI;CaMKK	In vitro , ***CaMKK*** is also ***phosphorylated*** by ***CaMKI*** at the same sites as PKA , suggesting that this regulatory phosphorylation might play a role as a negative-feedback mechanism .	target	1
1365	10187797	5606;5594	MKK3;ERK	***MKK3*** and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and MEK1 are upstream ***activators*** of SAPK/JNK and ***ERK*** pathways , respectively .	positive	1
1366	10187797	5606;5599	MKK3;JNK	***MKK3*** and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and MEK1 are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1367	10187797	5606;5601	MKK3;SAPK	***MKK3*** and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and MEK1 are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1368	10187797	5608;5594	MKK6;ERK	MKK3 and ***MKK6*** are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and MEK1 are upstream ***activators*** of SAPK/JNK and ***ERK*** pathways , respectively .	positive	1
1369	10187797	5608;5599	MKK6;JNK	MKK3 and ***MKK6*** are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and MEK1 are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1370	10187797	5608;5601	MKK6;SAPK	MKK3 and ***MKK6*** are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and MEK1 are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1371	10187797	5604;5594	MEK1;ERK	MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and ***MEK1*** are upstream ***activators*** of SAPK/JNK and ***ERK*** pathways , respectively .	positive	1
1372	10187797	5604;5599	MEK1;JNK	MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and ***MEK1*** are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1373	10187797	5604;5601	MEK1;SAPK	MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas SEK1 and ***MEK1*** are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1374	10187797	6416;5594	SEK1;ERK	MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas ***SEK1*** and MEK1 are upstream ***activators*** of SAPK/JNK and ***ERK*** pathways , respectively .	positive	1
1375	10187797	6416;5599	SEK1;JNK	MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas ***SEK1*** and MEK1 are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1376	10187797	6416;5601	SEK1;SAPK	MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway , whereas ***SEK1*** and MEK1 are upstream ***activators*** of ***SAPK/JNK*** and ERK pathways , respectively .	positive	1
1377	10187797	5604;5594	MEK1;p38	We observe that the dominant-negative mutant of MKK3 but not of MKK6 , SEK1 , or ***MEK1*** ***inhibits*** RAFTK-induced ***p38*** MAPK activity .	positive	1
1378	10187797	5606;5594	MKK3;p38	We observe that the dominant-negative mutant of ***MKK3*** but not of MKK6 , SEK1 , or MEK1 ***inhibits*** RAFTK-induced ***p38*** MAPK activity .	positive	1
1379	10187797	6416;5594	SEK1;p38	We observe that the dominant-negative mutant of MKK3 but not of MKK6 , ***SEK1*** , or MEK1 ***inhibits*** RAFTK-induced ***p38*** MAPK activity .	positive	1
1380	10187798	7341;7132	DAP-1;p60	The ubiquitin-homology protein , ***DAP-1*** , ***associates*** with tumor necrosis factor receptor ( ***p60*** ) death domain and induces apoptosis .	parallel	0
1381	10187798	7341;7132	DAP-1;TNF-R1	The in vivo ***interaction*** between ***DAP-1*** and ***TNF-R1*** was further confirmed in mammalian cells .	parallel	1
1382	10187798	7341;4790	DAP-1;NF-kappaB	In transient transfection assays , overexpression of ***DAP-1*** ***suppresses*** ***NF-kappaB/Rel*** activity in 293T cells , a human kidney embryonic carcinoma cell line .	negative	1
1383	10187804	7786;5609	DLK;MKK7	In confirmatory experiments performed in vivo , ***DLK*** both ***associated*** with and activated ***MKK7*** .	parallel	0
1384	10187821	1906;1910	Endothelin-1;ETB	***Endothelin-1*** ***binding*** to the endothelin B receptor ( ***ETB*** ) , a member of the superfamily of G-protein-coupled receptors , was associated with catalytic activation of the extracellular-regulated kinase 2 ( ERK2 ) and stimulation of AP-1 transcriptional reporter activity .	parallel	1
1385	10187833	4803;2353	nerve growth factor;c-fos	In these studies we confirmed that H7 , but not HA1004 , potently blocks the ***induction*** of zif268 and ***c-fos*** mRNA by ***nerve growth factor*** , carbachol , phorbol ester , Ca2 + ionophore , or forskolin .	target	1
1386	10187847	6285;7157	S100B;p53	Calcium-dependent ***interaction*** of ***S100B*** with the C-terminal domain of the tumor suppressor ***p53*** .	parallel	1
1387	10187847	6285;7157	S100B;p53	In vitro , the ***S100B*** protein ***interacts*** with baculovirus recombinant ***p53*** protein and protects p53 from thermal denaturation .	parallel	1
1388	10187852	6464;2885	Shc;Grb2	PKC was required for maximal activation of mitogen-activated kinase kinase 1 , Raf-1 , and Ras , tyrosine phosphorylation of Shc , and ***Shc*** ***association*** with ***Grb2*** .	parallel	0
1389	10187854	4803;4914	NGF;TrkA	***NGF*** ***binds*** to ***TrkA*** , activates the intrinsic kinase activity of TrkA , and promotes the differentiation of pheochromocytoma ( PC12 ) cells into sympathetic-like neurons .	parallel	1
1390	10187854	4803;4914	NGF;TrkA	***NGF*** binds to TrkA , ***activates*** the intrinsic kinase activity of ***TrkA*** , and promotes the differentiation of pheochromocytoma ( PC12 ) cells into sympathetic-like neurons .	positive	1
1391	10187854	4914;6294	TrkA;glutathione S-transferase fusion protein	In contrast , NGF was unable to stimulate the ***association*** of ***TrkA*** with a ***glutathione S-transferase fusion protein*** containing a mutant SH2-Bbeta ( R555E ) with a defective SH2 domain .	parallel	0
1392	10187857	1052;3479	C/EBPdelta;IGF-I	Taken together , our results provide evidence that ***C/EBPdelta*** is a critical ***activator*** of ***IGF-I*** gene transcription in osteoblasts and potentially in other cell types and species .	positive	1
1393	10187857	1052;3479	CCAAT/enhancer-binding protein delta;IGF-I	We previously determined that ***CCAAT/enhancer-binding protein delta*** ( C/EBPdelta ) is the key cAMP-stimulated ***regulator*** of ***IGF-I*** transcription in these cells and showed that it transactivates the rat IGF-I promoter through the HS3D site .	target	1
1394	10187858	10054;7341	SAE2;SUMO-1	In vitro , recombinant SAE1/SAE2 ( SUMO-1-activating enzyme ) was capable of catalyzing the ATP-dependent formation of a thioester ***linkage*** between ***SUMO-1*** and ***SAE2*** .	parallel	0
1395	10187858	7341;4792	SUMO-1;IkappaBalpha	In the presence of SAE1/SAE2 , Ubch9 , and ATP , ***SUMO-1*** was efficiently ***conjugated*** to the protein substrate ***IkappaBalpha*** .	parallel	1
1396	10187861	6885;1147	TAK1;IKKalpha	***TAK1*** ***activated*** ***IKKalpha*** and IKKbeta in the presence of TAB1 .	positive	1
1397	10187861	6885;3551	TAK1;IKKbeta	***TAK1*** ***activated*** IKKalpha and ***IKKbeta*** in the presence of TAB1 .	positive	1
1398	10187861	1147;6885	IKKalpha;TAK1	***IKKalpha*** and IKKbeta were ***coimmunoprecipitated*** with ***TAK1*** in the absence of TAB1 .	parallel	1
1399	10187861	3551;6885	IKKbeta;TAK1	IKKalpha and ***IKKbeta*** were ***coimmunoprecipitated*** with ***TAK1*** in the absence of TAB1 .	parallel	1
1400	10187861	7124;6885	tumor necrosis factor-alpha;TAK1	Furthermore , ***tumor necrosis factor-alpha*** ***activated*** endogenous ***TAK1*** , and the kinase-negative TAK1 acted as a dominant negative inhibitor against tumor necrosis factor-alpha-induced NF-kappaB activation .	positive	1
1401	10187863	836;6610	caspase-3;N-SMase	Moreover , recombinant purified ***caspase-3*** ***increased*** magnesium-dependent ***N-SMase*** in a cell-free system .	positive	0
1402	10188588	3725;2353	Jun;Fos	***Jun*** and ***Fos*** , b-ZIP transcription factors , form a ***heterodimer*** and bind to DNA enhancer elements , thereby regulating the expression of target genes .	parallel	1
1403	10188588	3725;2353	Jun;Fos	The present study was undertaken to investigate the molecular mechanism underlying nuclear translocation of the ******Jun/Fos****** ***complex*** .	parallel	1
1404	10188588	3725;2353	Jun;Fos	The nuclear accumulation of ***Fos*** was markedly ***enhanced*** by the presence of wildtype ***Jun*** , but not by Jun mutants lacking nuclear targeting or zipper dimerization functions , implying that Jun and Fos mutually interact via their leucine zippers and translocate from the cytoplasm to the nucleus using the markedly stronger nuclear localization signal of Jun .	positive	0
1405	10188714	7433;7432	VIPR1;VIP	Each of the 10 cell lines and 86.2 % of cPNET expressed mRNA for ***VIP*** ***receptor*** 1 ( ***VIPR1*** ) compared to 52.9 % of ESFT .	parallel	1
1406	10188725	7124;3569	TNF-alpha;IL-6	***IL-6-promoter*** activity was ***enhanced*** by ***TNF-alpha*** irrespective of the presence of an AP-1 binding site , while the degree of activation differed in the various clones , being most pronounced in the m-175 and m-248 clones .	positive	0
1407	10188961	5368;4987	orphanin FQ;ORL1	For the further elucidation of the central functions of ***nociceptin/orphanin FQ*** ( noc/OFQ ) , the endogenous ***ligand*** of the G protein-coupled opioid receptor-like receptor ***ORL1*** , centrally acting specific antagonists will be most helpful .	parallel	1
1408	10188995	3576;3579	IL-8;CXCR2	IL-8 displaced [ 125I ] - ***IL-8*** ***binding*** to CXCR1 and ***CXCR2*** with pKi values of 8.89 + / -0.05 and 9.27 + / -0.03 , respectively .	parallel	1
1409	10188995	2919;3579	GROalpha;CXCR2	***GROalpha*** , a selective ***CXCR2*** ***ligand*** , had a pKi value of 9.66 + / -0.39 at CXCR2 but a pKi > 8 at CXCR1 .	parallel	1
1410	10189354	4790;330	NF-kappaB;IAP-1	Transfer of IkappaBalpha reduced human IAP-1 mRNA levels , which suggested that ***IAP-1*** is transcriptionally ***regulated*** by ***NF-kappaB*** .	target	1
1411	10189357	183;3569	Angiotensin II;interleukin-6	***Angiotensin II*** ***induces*** ***interleukin-6*** transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors .	target	1
1412	10189392	10544;5624	EPCR;APC	Current studies seek to identify the substrate for the ******APC-EPCR****** ***complex*** as the next step in elucidating the mechanisms by which the protein C pathway modulates the response to injury and inflammation .	parallel	1
1413	10189392	10544;5624	EPCR;protein C	This approach led to the identification of an endothelial cell ***protein C*** ***receptor*** ( ***EPCR*** ) .	parallel	1
1414	10189687	3558;920	IL-2;CD4	Combinations of ***IL-2*** with antiretroviral drug combinations can ***induce*** a significant increase of ***CD4-counts*** .	target	1
1415	10189888	836;835	CPP32;ICH-1	The CPP32-preferential tetrapeptide inhibitor Ac-DEVD-CHO blocked the cleavage of ICH-1 and PARP precursors , suggesting that ***CPP32*** or some other DEVD-sensitive caspase ( s ) is the upstream ***activator*** of ***ICH-1*** .	positive	1
1416	10189892	4193;7157	MDM2;p53	These interactions are not consistent with the well-known role of ***MDM2*** , which acts as a negative ***regulator*** for ***p53*** by inhibiting its function and promoting its rapid degradation .	negative	1
1417	10189892	4193;7157	MDM2;p53	These results suggest that ***MDM2*** may ***regulate*** the expression of ***p53*** in the steady state and in response to E2 in breast cancer cells , and imply a novel and important role of MDM2 during breast carcinogenesis .	target	1
1418	10189892	4193;7157	MDM2;p53	Overexpression of ***MDM2*** in MCF-7 ***promotes*** both growth advantage and ***p53*** accumulation in response to estradiol .	positive	0
1419	10189892	4193;7157	MDM2;p53	Moreover , ***MDM2*** antisense oligonucleotides ***prevented*** E2-induced accumulation of ***p53*** .	negative	0
1420	10189965	7124;356	TNF alpha;Fas ligand	The inflammatory cytokine ***TNF alpha*** ***downregulates*** ***Fas ligand*** expression with an accompanying decrease in EC cytotoxicity toward Fas-bearing cells in co-culture .	negative	1
1421	10189965	7124;356	TNF alpha;Fas ligand	Endothelial ***Fas ligand*** expression in arteries is also ***downregulated*** by the local administration of ***TNF alpha*** , and this correlates with robust mononuclear cell infiltration of the subendothelial space .	negative	1
1422	10190278	4323;4322	MT-MMP;collagenase 3	Gelatinase A , ***collagenase 3*** and gelatinase B may be ***activated*** by ***MT-MMP*** based mechanisms , as evidenced by both biochemical and cell based studies .	positive	1
1423	10190549	2956;4436	hMSH6;hMSH2	Mismatch recognition in human cells is mediated primarily by a ***heterodimer*** of ***hMSH2*** and ***hMSH6*** .	parallel	1
1424	10190694	3458;3627	IFN-gamma;IP-10	***IFN-gamma*** ***induced*** the expression of ***IP-10*** , but not of IL-8 , MCP-1 or RANTES .	target	1
1425	10190694	3458;6347	IFN-gamma;MCP-1	***IFN-gamma*** ***induced*** the expression of IP-10 , but not of IL-8 , ***MCP-1*** or RANTES .	target	1
1426	10190694	3458;6352	IFN-gamma;RANTES	***IFN-gamma*** ***induced*** the expression of IP-10 , but not of IL-8 , MCP-1 or ***RANTES*** .	target	1
1427	10190694	7040;7124	TGF-beta;TNF-alpha	TGF-beta alone had little or no effect on RANTES , MCP-1 and IL-8 expression ; however , ***TGF-beta*** ***synergized*** with ***TNF-alpha*** to enhance MCP-1 expression in both astroglioma cells and primary astrocytes .	parallel	0
1428	10190694	7040;6347	TGF-beta;MCP-1	TGF-beta alone had little or no effect on RANTES , MCP-1 and IL-8 expression ; however , ***TGF-beta*** synergized with TNF-alpha to ***enhance*** ***MCP-1*** expression in both astroglioma cells and primary astrocytes .	positive	0
1429	10190694	7040;3576	TGF-beta;IL-8	An inhibitory effect of ***TGF-beta*** on TNF-alpha and IL-1beta ***induced*** RANTES and ***IL-8*** expression was observed in human astroglioma cells .	target	1
1430	10190694	7040;6352	TGF-beta;RANTES	An inhibitory effect of ***TGF-beta*** on TNF-alpha and IL-1beta ***induced*** ***RANTES*** and IL-8 expression was observed in human astroglioma cells .	target	1
1431	10190694	7040;3553	TGF-beta;IL-1beta	In contrast , ***TGF-beta*** ***enhanced*** TNF-alpha and ***IL-1beta*** induction ofIL-8 production by human astrocytes .	positive	0
1432	10190694	7040;7124	TGF-beta;TNF-alpha	In contrast , ***TGF-beta*** ***enhanced*** ***TNF-alpha*** and IL-1beta induction ofIL-8 production by human astrocytes .	positive	0
1433	10190738	887;2520	CCK-BR;gastrin	The aim of this study was to identify the expression of ***CCK-B/gastrin*** ***receptor*** ( ***CCK-BR*** ) , proG , G-gly and G-NH2 in normal liver and liver tumours .	parallel	1
1434	10190903	958;959	CD40;CD40 ligand	Production of IFN-gamma by NKT cells in response to alpha-GalCer required IL-12 produced by dendritic cells ( DCs ) and direct contact between NKT cells and DCs through ******CD40/CD40 ligand****** ***interactions*** .	parallel	1
1435	10191197	5610;355	PKR;fas	Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase ***PKR*** ***induces*** apoptosis and ***fas*** receptor expression .	target	1
1436	10191262	5170;2185	PDK1;protein kinase B	The PtdIns ( 3,4,5 ) P3-dependent ***activation*** of ***protein kinase B*** ( PKB ) by 3-phosphoinositide-dependent protein kinases-1 and -2 ( ***PDK1*** and PDK2 respectively ) is a key event in mediating the effects of signals that activate PtdIns 3-kinase .	positive	1
1437	10191275	2171;6278	E-FABP;S100A7	These data indicate that formation of the ******E-FABP-S100A7****** ***complex*** and its FA-binding function might be regulated at least by bivalent cations .	parallel	1
1438	10191277	5347;5300	Plk;Pin1	Recent reports have demonstrated that in mammalian cells ***Plk*** is ***associated*** with components of the anaphase-promoting complex and a peptidyl-prolyl isomerase , ***Pin1*** .	parallel	0
1439	10191281	3816;5267	hK1;kallistatin	We have explored in detail the determinants of specificity for the hydrolysis by human tissue kallikrein ( hK1 ) of substrates containing the Phe-Phe amino acid pair , after which ***hK1*** ***cleaves*** ***kallistatin*** ( human kallikrein-binding protein ) , a specific serpin for this protease , as well as somatostatin 1-14 .	target	1
1440	10191281	3816;6750	hK1;somatostatin	We have explored in detail the determinants of specificity for the hydrolysis by human tissue kallikrein ( hK1 ) of substrates containing the Phe-Phe amino acid pair , after which ***hK1*** ***cleaves*** kallistatin ( human kallikrein-binding protein ) , a specific serpin for this protease , as well as ***somatostatin*** 1-14 .	target	1
1441	10191282	335;338	apo;apoB-100	In conclusion , the extensive modification of Lp [ a ] caused by PLA2 digestion had no significant influence on the reactivity of LBS II , which is the domain involved in the ***binding*** of ***apo*** [ a ] to fibrinogen and ***apoB-100*** .	parallel	1
1442	10191293	4353;338	myeloperoxidase;apoB-100	Selective ***modification*** of ***apoB-100*** in the oxidation of low density lipoproteins by ***myeloperoxidase*** in vitro .	target	0
1443	10191393	3569;213	Interleukin-6;albumin	***Interleukin-6*** increased fibrinogen and ***decreased*** ***albumin*** production .	negative	0
1444	1019160	5972;551	renin;ADH	It was shown that intraventricular ***renin*** ***increased*** water intake , blood pressure and ***ADH*** secretion and that these effects were blocked by saralasin .	positive	0
1445	1019160	5972;183	renin;angiotensinogen	These findings indicated an ***interaction*** between injected ***renin*** , brain ***angiotensinogen*** and converting enzyme , resulting in the formation of angiotensin II in physiologically active concentrations .	parallel	1
1446	10192426	94;238	ALK1;ALK	Both large and small cells were reactive with antibody ***ALK1*** , which ***recognizes*** the chimaeric ***NPM-ALK*** protein associated with the t ( 2 ; 5 ) ( p23 ; q35 ) .	target	1
1447	10192426	94;4869	ALK1;NPM	Both large and small cells were reactive with antibody ***ALK1*** , which ***recognizes*** the chimaeric ***NPM-ALK*** protein associated with the t ( 2 ; 5 ) ( p23 ; q35 ) .	target	1
1448	10192442	356;355	FasL;Fas	Three patients with different clinical symptoms of graft-versus-host disease ( GVHD ) who had received donor lymphocyte transfusion ( DLT ) for the treatment of relapsed leukaemia after an allogeneic bone marrow transplantation ( BMT ) from HLA-matched sibling donors were analysed for the presence of soluble FasL ( sFasL ) in the sera and for the expression of the ***Fas*** ***ligand*** ( ***FasL*** ) gene in the peripheral blood mononuclear cells ( PBMNC ) .	parallel	1
1449	10192446	7076;4602	Epo;c-myb	GATA-2 and ***c-myb*** were ***down-regulated*** by ***Epo*** , and GATA-2 was further down-modulated by the inducers .	negative	1
1450	10192446	7076;2624	Epo;GATA-2	***GATA-2*** and c-myb were ***down-regulated*** by ***Epo*** , and GATA-2 was further down-modulated by the inducers .	negative	1
1451	10192446	7076;6886	Epo;SCL	Conversely , ***SCL*** expression was ***up-regulated*** by ***Epo*** and further increased by haemin and delta-ALA .	positive	1
1452	10192457	5054;7448	PAI-1;vitronectin	Furthermore , megakaryocyte maturation may depend on the intact ***vitronectin-integrin*** adhesion system that is ***influenced*** by ***PAI-1*** , thereby proposing a regulatory role for the inhibitor in cellular differentiation .	target	0
1453	10192566	3558;3569	IL-2;IL-6	The cytokines IL-1beta and IL-1 receptor antagonist , ***IL-2*** and IL-2 soluble receptor-alpha , IL-6 and ***IL-6*** soluble ***receptor*** , TNF-alpha and TNF soluble receptor I , and IL10 in drained and systemic blood after major orthopaedic surgery .	parallel	1
1454	10192566	7124;3569	TNF-alpha;IL-6	The cytokines IL-1beta and IL-1 receptor antagonist , IL-2 and IL-2 soluble receptor-alpha , IL-6 and ***IL-6*** soluble ***receptor*** , ***TNF-alpha*** and TNF soluble receptor I , and IL10 in drained and systemic blood after major orthopaedic surgery .	parallel	1
1455	10192749	1071;335	CETP;apo	***CETP*** gene expression is enhanced in hypercholesterolaemia and ***correlates*** with plasma ***apo*** E concentration .	parallel	0
1456	10192772	8829;10371	Neuropilin-1;sema III	***Neuropilin-1*** , a ***sema III*** ***receptor*** , was expressed in injured neurons with projections to the lesion site , in a subpopulation of scar-associated cells and in blood vessels around the scar .	parallel	1
1457	10192772	8829;10371	Neuropilin-1;sema III	The concomitant expression of ***sema III*** and its ***receptor*** ***Neuropilin-1*** in the scar suggests that sema III/Neuropilin-1-mediated mechanisms are involved in CNS scar formation .	parallel	1
1458	10193420	3586;3824	IL-10;CD94	We also show that , in vitro , ***IL-10*** ***up-regulates*** ***CD94*** expression on CD8 + and CD56 + cells obtained from normal individuals , suggesting that the augmented expression observed in HIV-infected individuals could be related to the high levels of IL-10 previously described in HIV-1-infected individuals .	positive	1
1459	10193578	4353;1738	myeloperoxidase;dihydrolipoamide dehydrogenase	***Inactivation*** of myocardial ***dihydrolipoamide dehydrogenase*** by ***myeloperoxidase*** systems : effect of halides , nitrite and thiol compounds .	negative	1
1460	10193678	3082;3082	scatter factor;Hepatocyte growth factor	******Hepatocyte growth factor/scatter factor-GeneGene****** 3 ***signaling*** in neural crest-derived melanocyte development .	parallel	0
1461	10193678	3082;3082	scatter factor;Hepatocyte growth factor	******Hepatocyte growth factor/scatter factor****** ( HGF/SF ) ***signaling*** through the tyrosine-kinase receptor , MET , is capable of promoting the proliferation , increasing the motility , and maintaining high tyrosinase activity and melanin synthesis of melanocytes in vitro .	parallel	0
1462	10193827	3952;7124	leptin;TNF-alpha	In multiple regression analysis , serum ***leptin*** also ***correlated*** to serum ***TNF-alpha*** .	parallel	0
1463	10193871	2688;2691	somatotropin;GHRH	Compounds thought to inhibit hypothalamic somatostatin ( SRIH ) release ( pyridostigmine , arginine , galanin , atenolol ) consistently improve , though do not normalize , the ***somatotropin*** ***response*** to ***GHRH*** in obesity .	parallel	0
1464	10194136	7157;900	p53;cyclin G1	These two new pathways , p53-EF-1 alpha-microtubule-severing ( - distortion of cytoskeleton ) and ******p53-cyclin G1-COXII****** ( - CytC , ATP-caspase-3 activation ) , may ***cooperate*** to induce apoptosis in this cell line .	parallel	0
1465	10194233	3479;3486	IGF-I;IGFBP-3	The findings show that changes in free IGF-I levels are not accounted for by alterations in the total ******IGF-I/IGFBP-3****** ***complex*** or in IGFBP-3 levels and indicate that there are other important determinants of free IGF-I .	parallel	1
1466	10194379	5327;5340	t-PA;Plasmin	Here , we explore a desensitization mechanism of the PAR1 thrombin receptor by anticoagulant proteases and provide an explanation to the enigma of why ***Plasmin/tissue*** plasminogen ***activator*** ( ***t-PA*** ) can both activate and deactivate platelets prior to thrombin treatment .	positive	1
1467	10194407	7040;7076	TGF-beta1;TIMP	We have examined the ***regulation*** of the ***gelatinase/TIMP*** balance by transforming growth factor-beta1 ( ***TGF-beta1*** ) and phorbol myristate acetate ( PMA ) in bovine endothelial cells .	target	1
1468	10194419	7040;7057	TGF-beta1;thrombospondin-1	***TGF-beta1*** strongly ***activated*** the production of ***thrombospondin-1*** and ( alpha ) vbeta3 integrin in a concentration-dependent manner whereas the expression of thyroglobulin was unaffected .	positive	1
1469	10194422	3700;7852	gp120;CXCR4	A CD4-independent ***interaction*** of human immunodeficiency virus-1 ***gp120*** with ***CXCR4*** induces their cointernalization , cell signaling , and T-cell chemotaxis .	parallel	1
1470	10194422	30816;7852	envelope glycoprotein;chemokine receptor	The gp120 ***envelope glycoprotein*** of human immunodeficiency virus-1 ( HIV-1 ) ***interacts*** with the CXCR4 ***chemokine receptor*** , but it is not known whether gp120 activates CXCR4-mediated signaling cascades in the same manner as its natural ligand , SDF1alpha .	parallel	1
1471	10194422	3700;7852	gp120;CXCR4	Under both experimental conditions , the ***interaction*** of ***CXCR4*** and ***gp120*** resulted in their CD4-independent cointernalization .	parallel	1
1472	10194422	3700;7852	gp120;CXCR4	***Binding*** of ***gp120*** to ***CXCR4*** resulted in a CD4-independent phosphorylation of Pyk2 and an induction of chemotactic activity , demonstrating that this interaction has functional consequences .	parallel	1
1473	10194431	3569;3570	IL-6;interleukin-6 receptor	We have recently shown that stimulation of glycoprotein ( gp ) 130 , the membrane-anchored signal transducing receptor component of IL-6 , by a ***complex*** of human soluble ***interleukin-6 receptor*** ( sIL-6R ) and ***IL-6*** ( sIL-6R / IL-6 ) , potently stimulates the ex vivo expansion as well as erythropoiesis of human stem/progenitor cells in the presence of stem cell factor ( SCF ) .	parallel	1
1474	10194437	2056;2549	Epo;GAB1	***Epo-induced*** tyrosine ***phosphorylation*** of ***GAB1*** was also observed in normal human erythroid progenitors isolated from cord blood .	target	1
1475	10194437	1437;2549	Granulocyte-macrophage colony-stimulating factor;GAB1	***Granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) and thrombopoietin ( TPO ) also ***induced*** the tyrosine phosphorylation of ***GAB1*** in UT-7 cells , indicating that this molecule participates in the signal transduction of several cytokine receptors .	target	1
1476	10194437	7066;2549	thrombopoietin;GAB1	Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) and ***thrombopoietin*** ( TPO ) also ***induced*** the tyrosine phosphorylation of ***GAB1*** in UT-7 cells , indicating that this molecule participates in the signal transduction of several cytokine receptors .	target	1
1477	10194437	2056;2549	Erythropoietin;GAB1	***Erythropoietin*** ***induces*** the tyrosine phosphorylation of ***GAB1*** and its association with SHC , SHP2 , SHIP , and phosphatidylinositol 3-kinase .	target	1
1478	10194437	2056;2549	Epo;GAB1	Indeed , ***Epo*** ***induced*** the transient tyrosine phosphorylation of ***GAB1*** in UT-7 cells .	target	1
1479	10194437	2549;2885	GAB1;GRB2	***GAB1*** was also ***associated*** with the molecular adapter ***GRB2*** in unstimulated cells , and this association dramatically increased after Epo stimulation .	parallel	0
1480	10194441	6814;6810	PSP;syntaxin 4	This platelet Sec1 protein ( ***PSP*** ) ***bound*** to ***syntaxin 4*** and thereby excluded the binding of SNAP-25 with syntaxin 4 , an interaction critical to vesicle docking .	parallel	1
1481	10194442	2056;3717	Epo;Janus Kinase-2	Also , recombinant human ***Epo*** ( rHuEpo ) ***stimulates*** ***Janus Kinase-2*** ( JAK-2 ) phosphorylation , cell proliferation , and matrix metalloproteinase-2 ( MMP-2 ) production in EA.hy926 cells and significantly enhances their differentiation into vascular structures when seeded on Matrigel .	positive	0
1482	10194442	2056;4313	Epo;matrix metalloproteinase-2	Also , recombinant human ***Epo*** ( rHuEpo ) ***stimulates*** Janus Kinase-2 ( JAK-2 ) phosphorylation , cell proliferation , and ***matrix metalloproteinase-2*** ( MMP-2 ) production in EA.hy926 cells and significantly enhances their differentiation into vascular structures when seeded on Matrigel .	positive	0
1483	10194443	2313;2815	Fli-1;glycoprotein IX	***Regulation*** of the megakaryocytic ***glycoprotein IX*** promoter by the oncogenic Ets transcription factor ***Fli-1*** .	target	1
1484	10194443	2313;2815	Fli-1;GPIX	In this study , transient cotransfection of several GPIX promoter/reporter constructs into 293T kidney fibroblasts with a Fli-1 expression vector shows that the oncogenic protein ***Fli-1*** can ***transactivate*** the ***GPIX*** promoter when an intact GPIX Ets site is present .	positive	1
1485	10194443	2313;2815	Fli-1;GPIX	In addition , ***Fli-1*** ***binding*** of the ***GPIX*** Ets site was identified in antibody supershift experiments in nuclear extracts derived from hematopoietic human erythroleukemia cells .	parallel	1
1486	10194443	2313;2811	Fli-1;GPIbalpha	Comparative studies showed that ***Fli-1*** was also able to ***transactivate*** the ***GPIbalpha*** and , to a lesser extent , the GPIIb promoter .	positive	1
1487	10194454	356;355	FasL;Fas	In the present study , we examined the contribution of cytotoxic effector mechanisms , which are mediated by tumor necrosis factor-alpha ( TNF-alpha ) , ***Fas*** ***ligand*** ( ***FasL*** ) , or perforin , to GVHD and GVL effect in a murine BMT model .	parallel	1
1488	10194467	183;5743	Angiotensin II;cyclooxygenase-2	***Angiotensin II*** ***attenuates*** renal cortical ***cyclooxygenase-2*** expression .	negative	0
1489	10194517	3484;5747	IGFBP-1;FAK	We conclude from these data that ***IGFBP-1*** can interact with integrin receptors to ***induce*** ***FAK*** dephosphorylation and subsequently influence attachment and cell death .	target	1
1490	10194520	3952;6774	Leptin;signal transducer and activator of transcription (STAT)3	In the present study , we show that ***Leptin*** ***activates*** a ***signal transducer and activator of transcription (STAT)3*** signalling mechanism in pancreatic islets and in a rat model of the pancreatic beta-cell , RINm5F .	positive	1
1491	10194522	7124;3383	TNF-alpha;ICAM-1	However , ***TNF-alpha*** ( 50 ng/ml ) ***induced*** ***ICAM-1*** mRNA within two hours , peak expression being reached between four and eight hours after initiation of treatment .	target	1
1492	10194549	983;891	CDC2;cyclin B1	Reductions of active ***complex*** and kinase activity of ******CDC2/cyclin B1****** were also observed in the presence of the three drugs .	parallel	1
1493	10194763	2796;2798	GnRH;GnRHR	We suggest that ***GnRH*** ***regulation*** of the ***GnRHR*** gene is partially mediated by an ERK-dependent activation of a canonical AP-1 site located in the proximal promoter of the GnRHR gene .	target	1
1494	10194763	2798;2796	GnRHR;GnRH	Homologous regulation of ***GnRH*** ***receptor*** ( ***GnRHR*** ) gene expression is an established mechanism for controlling the sensitivity of gonadotropes to GnRH .	parallel	1
1495	10194763	2796;2798	GnRH;GnRHR	The present studies were designed to further delineate the molecular mechanisms underlying ***GnRH*** ***regulation*** of ***GnRHR*** gene expression .	target	1
1496	10194764	185;183	AT1;angiotensin II	Determination of peptide contact points in the human ***angiotensin II*** type I ***receptor*** ( ***AT1*** ) with photosensitive analogs of angiotensin II .	parallel	1
1497	10195194	23557;6616	Snapin;SNAP-25	***Binding*** of recombinant ***Snapin-CT*** to ***SNAP-25*** blocked the association of the SNARE complex with synaptotagmin .	parallel	1
1498	10195234	3439;7852	IFN-alpha;CXCR4	***IFN-alpha*** and IFN-gamma also ***inhibited*** ***CXCR4*** gene expression in the promyelocytic cell line U937 , and this inhibition led to a decrease in cell-cell fusion between U937 cells and HeLa-MAGI cells .	negative	1
1499	10195234	3458;7852	IFN-gamma;CXCR4	IFN-alpha and ***IFN-gamma*** also ***inhibited*** ***CXCR4*** gene expression in the promyelocytic cell line U937 , and this inhibition led to a decrease in cell-cell fusion between U937 cells and HeLa-MAGI cells .	negative	1
1500	10195234	7124;7852	TNF-alpha;CXCR4	In U937 cells , ***TNF-alpha*** and phorbol myristate acetate ( PMA ) ***stimulated*** ***CXCR4*** gene transcription ; this effect was reversed with prior treatment of cells with IFN-gamma .	positive	0
1501	10195235	7124;6352	TNF-alpha;RANTES	***TNF-alpha*** levels negatively ***correlated*** with HIV-1 antigen-stimulated ***RANTES*** production ( r = -0.71 ; P = 0.0002 ) and lymphocyte proliferation ( r = -0.37 ; P = 0.09 ) .	negative	0
1502	10195426	3815;2057	c-Kit;erythropoietin receptor	A novel way to induce erythroid progenitor self renewal : ***cooperation*** of ***c-Kit*** with the ***erythropoietin receptor*** .	parallel	0
1503	10195437	728;727	C5aR;C5a	A panel of YSFKPMPLaR analogs with systematic substitutions for Lys68 was evaluated for ***C5a*** ***receptor*** ( ***C5aR*** ) binding affinity and activation in two well-characterized assay systems : human polymorphonuclear leukocytes ( PMNs ) and human fetal artery .	parallel	1
1504	10195568	4254;4233	SCF;c-met	Our present study suggests that stimulation of the HGF/c-met signal is concomitant with ***induction*** of ***c-met*** protein by ***SCF*** .	target	1
1505	10195687	1081;5617	hCG;PRL	The ***hCG*** treatment also ***increased*** the steady state ***PRL*** mRNA levels .	positive	0
1506	10195693	8022;5449	Lhx3;Pit-1	Porcine ***Lhx3*** protein ***interacted*** with ***Pit-1*** protein in solution and also with the LIM domain-binding protein NLI/Lbd1/CLIM .	parallel	1
1507	10195697	6908;8648	TBP;F-SRC-1	In vitro binding assay showed that ***TBP*** and TFIIB ***bound*** to C-terminal half of ***F-SRC-1*** .	parallel	1
1508	10195697	2959;8648	TFIIB;F-SRC-1	In vitro binding assay showed that TBP and ***TFIIB*** ***bound*** to C-terminal half of ***F-SRC-1*** .	parallel	1
1509	10195697	6908;8648	TBP;F-SRC-1	These results suggest that F-SRC-1 can function via both CBP-dependent and independent manners using various sets of activation domains and that direct ***interactions*** between ***F-SRC-1*** and ***TBP*** or TFIIB may not be important for CBP-independent transcription .	parallel	1
1510	10195697	2959;8648	TFIIB;F-SRC-1	These results suggest that F-SRC-1 can function via both CBP-dependent and independent manners using various sets of activation domains and that direct ***interactions*** between ***F-SRC-1*** and TBP or ***TFIIB*** may not be important for CBP-independent transcription .	parallel	1
1511	10195697	2959;6908	TFIIB;TBP	These results suggest that F-SRC-1 can function via both CBP-dependent and independent manners using various sets of activation domains and that direct ***interactions*** between F-SRC-1 and ***TBP*** or ***TFIIB*** may not be important for CBP-independent transcription .	parallel	1
1512	10195897	1147;8517	IKK1;IKKAP1	***IKK1*** ***associated*** with NF-kappaB essential modulator ( ***IKKgamma/IKKAP1*** ) , another component of the IKK complex .	parallel	0
1513	10195897	8517;4790	IKKAP1;NF-kappaB	IKK1 associated with ***NF-kappaB*** essential ***modulator*** ( ***IKKgamma/IKKAP1*** ) , another component of the IKK complex .	target	0
1514	10195925	3569;1401	interleukin-6;C-reactive protein	In this study we have sought ***associations*** of levels of ***C-reactive protein*** and ***interleukin-6*** with measures of obesity and of chronic infection as their putative determinants .	parallel	0
1515	10196135	4905;6295	NSF;arrestin1	We demonstrate that purified recombinant ***beta-arrestin1*** and ***NSF*** ***interact*** in vitro and that these proteins can be coimmunoprecipitated from cells .	parallel	1
1516	10196136	2932;1499	GSK-3beta;beta-catenin	Axin forms a complex with glycogen synthase kinase-3beta ( GSK-3beta ) and beta-catenin and promotes ***GSK-3beta-dependent*** ***phosphorylation*** of ***beta-catenin*** , thereby stimulating the degradation of beta-catenin .	target	1
1517	10196148	5320;6343	PLA2;secretin	Purified porcine pancreatic ***PLA2*** also ***stimulated*** ***secretin*** release concentration-dependently from both STC-1 cells and a mucosal cell preparation enriched in secretin-containing endocrine cells isolated from rat duodenum .	positive	0
1518	10196149	836;4214	caspase-3;MEKK-1	Thus , the ***degradation*** of delta protein kinase C ( PKC ) and ***MEKK-1*** by ***caspase-3*** generates activated fragments corresponding to their catalytic domains , consistent with the observations that both enzymes are important for apoptosis .	negative	1
1519	10196153	3329;3336	GroEL;GroES	The 1:1 ***complex*** of ******GroEL.GroES****** binds with one lysozyme or one dimeric GAPDH folding intermediate to form a stable ternary complex .	parallel	1
1520	10196153	3329;3336	GroEL;GroES	Both complexes of ***GroEL.lysozyme1*** and GroEL.GAPDH2 ***bind*** with one ***GroES*** molecule only at the other end of the GroEL molecule forming a trans ternary complex .	parallel	1
1521	10196159	2978;3000	GCAP-1;RetGC	***GCAP-1*** ***activates*** ***RetGC*** in low Ca2 + and inhibits it in high Ca2 + .	positive	1
1522	10196167	650;2353	Bone morphogenetic protein 2;c-fos	***Bone morphogenetic protein 2*** ***inhibits*** platelet-derived growth factor-induced ***c-fos*** gene transcription and DNA synthesis in mesangial cells .	negative	1
1523	10196167	650;2353	BMP2;c-fos	Furthermore , we demonstrate that ***BMP2*** ***inhibits*** PDGF-induced transcription of ***c-fos*** gene , a natural target of Elk-1 that normally forms a ternary complex that activates the serum response element of the c-fos gene .	negative	1
1524	10196169	7157;5743	p53;Cox-2	The results of this study suggest that ***interactions*** between ***p53*** and ***Cox-2*** could be important for understanding why levels of Cox-2 are undetectable in normal cells and increased in many tumors .	parallel	1
1525	10196169	7157;5743	p53;cyclooxygenase-2	***Inhibition*** of ***cyclooxygenase-2*** gene expression by ***p53*** .	negative	1
1526	10196170	596;4214	Bcl2;MEKK1	Overexpression of anti-apoptotic ***Bcl2*** ***blocked*** ***MEKK1*** and taxol-induced apoptosis but did not block the caspase-dependent cleavage of MEKK1 in response to etoposide .	negative	0
1527	10196178	5879;8685	Rac1;MARCO	Similarly , a dominant-negative mutant of the Rho family GTPase ***Rac1*** partially ***inhibited*** the morphogenic effects of ***MARCO*** in Chinese hamster ovary cells , whereas a dominant-negative form of a related protein , Cdc42 , did not .	positive	1
1528	10196181	185;183	AT1AR;angiotensin II	In this study , we visualize the intracellular trafficking of beta-arrestin2 in response to activation of several distinct GPCRs including the beta2-adrenergic receptor ( beta2AR ) , ***angiotensin II*** type 1A ***receptor*** ( ***AT1AR*** ) , dopamine D1A receptor ( D1AR ) , endothelin type A receptor ( ETAR ) , and neurotensin receptor ( NTR ) .	parallel	1
1529	10196191	5906;2889	Rap1;C3G	H. , Horn , G. , and Wittinghofer , A. ( 1997 ) Oncogene 15 , 845-850 ) prompted us to study possible fundamental differences in the way ***Rap1*** ***interacts*** with ***C3G*** compared with the interaction of Ras with the catalytic domain of the mouse Ras guanine nucleotide exchange factor Cdc25 ( Mm ) .	parallel	1
1530	10196191	5906;2889	Rap1;C3G	These results are discussed in the light of the structure of the Ras-Sos complex and suggest that some important differences in the ***interaction*** of ***Rap1*** with ***C3G*** and Ras with Cdc25 ( Mm ) indeed exist and that marker residues have been identified for the different structural requirements .	parallel	1
1531	10196191	5906;5923	Rap1;Cdc25	These results are discussed in the light of the structure of the Ras-Sos complex and suggest that some important differences in the ***interaction*** of ***Rap1*** with C3G and Ras with ***Cdc25*** ( Mm ) indeed exist and that marker residues have been identified for the different structural requirements .	parallel	1
1532	10196197	6732;373156	SRPK1;GST	Recombinant ***SRPK1*** and SRPK2 ***bound*** to and phosphorylated ***GST-SF2*** / ASF in vitro .	parallel	1
1533	10196197	6732;6426	SRPK1;SF2	Recombinant ***SRPK1*** and SRPK2 ***bound*** to and phosphorylated ***GST-SF2*** / ASF in vitro .	parallel	1
1534	10196197	6733;373156	SRPK2;GST	Recombinant SRPK1 and ***SRPK2*** ***bound*** to and phosphorylated ***GST-SF2*** / ASF in vitro .	parallel	1
1535	10196197	6733;6426	SRPK2;SF2	Recombinant SRPK1 and ***SRPK2*** ***bound*** to and phosphorylated ***GST-SF2*** / ASF in vitro .	parallel	1
1536	10196210	3047;3043	A gamma-globin;beta-globin	***A gamma-globin*** gene with a -161 promoter can competitively ***inhibit*** ***beta-globin*** gene expression .	negative	1
1537	10196218	5741;6550	parathyroid hormone;NHE-3	Dual mechanisms of ***regulation*** of Na/H exchanger ***NHE-3*** by ***parathyroid hormone*** in rat kidney .	target	1
1538	10196222	627;10818	Brain-derived neurotrophic factor;fibroblast growth factor receptor substrate 2	***Brain-derived neurotrophic factor*** ***induces*** phosphorylation of ***fibroblast growth factor receptor substrate 2*** .	target	1
1539	10196222	6464;4915	Shc;TrkB	Expression of mutant TrkB in fibroblasts , where tyrosine 484 was changed to phenylalanine , abrogated ***Shc*** ***association*** with ***TrkB*** , but only attenuated and did not block BDNF-induced phosphorylation of mitogen-activated protein kinase ( MAPK ) .	parallel	0
1540	10196222	4915;6464	TrkB;Shc	Expression of mutant ***TrkB*** in fibroblasts , where tyrosine 484 was changed to phenylalanine , ***abrogated*** ***Shc*** association with TrkB , but only attenuated and did not block BDNF-induced phosphorylation of mitogen-activated protein kinase ( MAPK ) .	negative	0
1541	10196222	627;10818	BDNF;fibroblast growth factor receptor substrate 2	***BDNF*** ***induces*** phosphorylation of ***fibroblast growth factor receptor substrate 2*** ( FRS2 ) in both fibroblasts engineered to express TrkB and human neuroblastoma ( NB ) cells that naturally express TrkB .	target	1
1542	10196222	627;10818	BDNF;FRS2	Additionally , ***BDNF*** ***induces*** phosphorylation of ***FRS2*** in primary cultures of cortical neurons , thus showing that FRS2 is a physiologically relevant substrate of TrkB .	target	1
1543	10196222	10818;4915	FRS2;TrkB	Additionally , BDNF induces phosphorylation of FRS2 in primary cultures of cortical neurons , thus showing that ***FRS2*** is a physiologically relevant ***substrate*** of ***TrkB*** .	parallel	1
1544	10196222	10818;9402	FRS2;growth factor receptor-binding protein	Data are presented demonstrating that BDNF induces ***association*** of ***FRS2*** with ***growth factor receptor-binding protein*** 2 ( GRB2 ) in cortical neurons , fibroblasts , and NB cells , which in turn could activate the RAS/MAPK pathway .	parallel	0
1545	10196222	627;10818	BDNF;FRS2	Data are presented demonstrating that ***BDNF*** ***induces*** association of ***FRS2*** with growth factor receptor-binding protein 2 ( GRB2 ) in cortical neurons , fibroblasts , and NB cells , which in turn could activate the RAS/MAPK pathway .	target	1
1546	10196222	6464;10818	Shc;FRS2	This is not dependent on Shc , since BDNF does not induce ***association*** of ***Shc*** and ***FRS2*** .	parallel	0
1547	10196224	672;5932	BRCA1;CtIP	The ***association*** of ***BRCA1*** with ***CtIP*** was also abrogated in cells treated with DNA-damaging agents including UV , gamma-irradiation , and adriamycin , a response correlated with BRCA1 phosphorylation .	parallel	0
1548	10196224	672;1026	BRCA1;p21	The ***transactivation*** of the ***p21*** promoter by ***BRCA1*** was diminished by expression of exogenous CtIP and CtBP .	positive	1
1549	10196225	8881;3897	Cdc16;Spg1	***Spg1*** is negatively ***regulated*** by Byr4 and ***Cdc16*** , which together form a two-component GTPase-activating protein for the Spg1 GTPase .	negative	1
1550	10196235	4146;3672	CMP;integrin alpha1	The antibody to integrin alpha1 , but not to other subunits , coprecipitated 125I-CMP that was added to MRC5 cell lysates , indicating the ***association*** of ***CMP*** with the ***integrin alpha1*** subunit .	parallel	0
1551	10196238	974;973	Igbeta;Igalpha	Trafficking of the ******Igalpha/Igbeta****** ***heterodimer*** with membrane Ig and bound antigen to the major histocompatibility complex class II peptide-loading compartment .	parallel	1
1552	10196238	973;974	Igalpha;Igbeta	The BCR consists of membrane Ig ( mIg ) and ***Igalpha/Igbeta*** ***heterodimer*** ( ***Igalpha/Igbeta*** ) .	parallel	1
1553	10196238	974;973	Igbeta;Igalpha	The BCR consists of membrane Ig ( mIg ) and ***Igalpha/Igbeta*** ***heterodimer*** ( ***Igalpha/Igbeta*** ) .	parallel	1
1554	10196238	974;973	Igbeta;Igalpha	This suggests that the ******Igalpha/Igbeta****** ***heterodimer*** is involved in BCR-mediated antigen transport through the entire antigen transport pathway .	parallel	1
1555	10196247	1977;2033	CBP;p300	Competition for ******CBP/p300****** ***binding*** by various cellular transcription factors has been suggested as a means of integrating different signalling pathways and may also represent a potential mechanism by which E1A manipulates cell fate .	parallel	1
1556	10196247	7157;4193	p53;MDM2	The CBP TRAM binds p53 sequences targeted by the cellular regulator MDM2 , and we demonstrate that an ******MDM2-p53****** ***interaction*** can be disrupted by the CBP TRAM , leading to stabilization of cellular p53 levels and the activation of p53-dependent transcription .	parallel	1
1557	10196249	10657;5921	Sam68;RasGAP	Here , we report that the RNA-binding and protein-binding protein ***Sam68*** ***associates*** with the p21 ( ras ) GTPase-activating protein ***RasGAP*** .	parallel	0
1558	10196251	3383;3683	CD54;CD11a	Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through ******CD54-CD11a****** ***interaction*** .	parallel	1
1559	10196252	6387;7852	SDF-1;CXCR4	The alpha-chemokine ***SDF-1*** ***binds*** ***CXCR4*** , a coreceptor for human immunodeficiency virus type 1 ( HIV-1 ) , and inhibits viral entry mediated by this receptor .	parallel	1
1560	10196254	355;356	Fas;Fas ligand	Three CD4 ( + ) CTL clones were demonstrated to lyse cognate , antigen-presenting target cells by a mechanism that primarily involves perforin , while bystander lysis occurred through ******Fas/Fas ligand****** ***interactions*** .	parallel	1
1561	10196311	3700;1234	gp120;CCR5	This structural information was correlated with the MAbs ' abilities to inhibit ( i ) HIV-1 entry , ( ii ) HIV-1 envelope glycoprotein-mediated membrane fusion , ( iii ) ***gp120*** ***binding*** to ***CCR5*** , and ( iv ) CC-chemokine activity .	parallel	1
1562	10196311	920;1234	CD4;CCR5	Surprisingly , there was no correlation between the ability of a MAb to inhibit HIV-1 fusion-entry and its ability to inhibit either the ***binding*** of a gp120-soluble ***CD4*** complex to ***CCR5*** or CC-chemokine activity .	parallel	1
1563	10196356	4792;4790	IkappaBalpha;NF-kappaB	Incomplete ***regulation*** of ***NF-kappaB*** by ***IkappaBalpha*** during respiratory syncytial virus infection in A549 cells .	target	1
1564	10196372	10724;3073	beta-hexosaminidase;hexosaminidase A	The severe neurodegenerative disorder , Tays-Sachs disease , is caused by a ***beta-hexosaminidase*** alpha-subunit deficiency which ***prevents*** the formation of lysosomal heterodimeric alpha-beta enzyme , ***hexosaminidase A*** ( HexA ) .	positive	0
1565	10196481	8600;4982	osteoclast differentiation factor;osteoclastogenesis inhibitory factor	***osteoclast differentiation factor*** ( ODF ) , a ***ligand*** for ***osteoclastogenesis inhibitory factor*** ( OCIF ) / osteoprotegerin ( OPG ) , is a member of the membrane-associated tumor necrosis factor ( TNF ) family and induces osteoclast-like cell formation in vitro .	parallel	1
1566	10196543	3778;57582	Slo;Slack	Formation of intermediate-conductance calcium-activated potassium channels by ***interaction*** of ***Slack*** and ***Slo*** subunits .	parallel	1
1567	10196543	3778;57582	Slo;Slack	Our findings indicate that some intermediate-conductance channels in the nervous system may result from an ***interaction*** between ***Slack*** and ***Slo*** channel subunits .	parallel	1
1568	10196546	7869;10371	SemA;SemD	***SemA*** and SemE ***block*** ***SemD*** binding to NP-1 and abolish SemD repulsion in axons expressing NP-1 .	negative	0
1569	10196546	10512;10371	SemE;SemD	SemA and ***SemE*** ***block*** ***SemD*** binding to NP-1 and abolish SemD repulsion in axons expressing NP-1 .	negative	0
1570	10196712	6445;1756	gamma-SG;dystrophin	Based on the pattern of distribution of the SG proteins in patients with LGMD2C and 2D , and on the observed decreased abundance of dystrophin through WB in some sarcoglycans ( SG ) patients , we have recently suggested that alpha , beta and delta subunits of sarcoglycan complex might be more closely associated and that ***gamma-SG*** might ***interact*** more directly with ***dystrophin*** .	parallel	1
1571	10196712	6445;1756	gamma-SG;dystrophin	These two patients represent further evidence of a closer relation of alpha , beta and delta-SG than of gamma-SG and of the possible ***association*** of ***gamma-SG*** with ***dystrophin*** .	parallel	0
1572	10197222	3827;6863	bradykinin;neurokinin A	Angiotensin-converting enzyme ( ACE ) ***inactivates*** ***bradykinin*** , substance P and ***neurokinin A*** , which are believed to play important roles in the pathogenesis of asthma , especially in neurogenic inflammation .	negative	1
1573	10197222	6863;3827	neurokinin A;bradykinin	Angiotensin-converting enzyme ( ACE ) ***inactivates*** ***bradykinin*** , substance P and ***neurokinin A*** , which are believed to play important roles in the pathogenesis of asthma , especially in neurogenic inflammation .	negative	1
1574	10197222	1636;3827	ACE;bradykinin	Angiotensin-converting enzyme ( ***ACE*** ) ***inactivates*** ***bradykinin*** , substance P and neurokinin A , which are believed to play important roles in the pathogenesis of asthma , especially in neurogenic inflammation .	negative	1
1575	10197222	1636;6863	ACE;neurokinin A	Angiotensin-converting enzyme ( ***ACE*** ) ***inactivates*** bradykinin , substance P and ***neurokinin A*** , which are believed to play important roles in the pathogenesis of asthma , especially in neurogenic inflammation .	negative	1
1576	10197373	3558;1234	IL-2;CCR-5	***IL-2*** treatment also ***increased*** the function of ***CCR-5*** in TH cells .	positive	0
1577	10197585	2308;5077	FKHR;PAX3	In addition to functional alterations , our studies demonstrated ***PAX3-FKHR*** and PAX7-FKHR overexpression resulting from two distinct mechanisms , ***increased*** transcription of ***PAX3-FKHR*** by a copy number-independent mechanism , and gene amplification of PAX7-FKHR .	positive	0
1578	10197585	5077;2308	PAX3;FKHR	In addition to functional alterations , our studies demonstrated ***PAX3-FKHR*** and PAX7-FKHR overexpression resulting from two distinct mechanisms , ***increased*** transcription of ***PAX3-FKHR*** by a copy number-independent mechanism , and gene amplification of PAX7-FKHR .	positive	0
1579	10197585	5081;2308	PAX7;FKHR	In addition to functional alterations , our studies demonstrated PAX3-FKHR and ***PAX7-FKHR*** overexpression resulting from two distinct mechanisms , ***increased*** transcription of ***PAX3-FKHR*** by a copy number-independent mechanism , and gene amplification of PAX7-FKHR .	positive	0
1580	10197585	5081;5077	PAX7;PAX3	In addition to functional alterations , our studies demonstrated PAX3-FKHR and ***PAX7-FKHR*** overexpression resulting from two distinct mechanisms , ***increased*** transcription of ***PAX3-FKHR*** by a copy number-independent mechanism , and gene amplification of PAX7-FKHR .	positive	0
1581	10197592	675;672	BRCA2;BRCA1	The ******BRCA1/BRCA2****** ***complex*** may function in postreplicational repair processes activated during the DNA synthesis stage of the cell cycle .	parallel	1
1582	10197631	7471;1499	Wnt-1;beta-catenin	***Wnt-1*** expression in the mouse mammary epithelial cell lines RAC311 and C57MG ***induces*** stabilization of cytosolic ***beta-catenin*** and morphological transformation .	target	1
1583	10197640	7077;4313	tissue inhibitor of metalloproteinase-2;MMP-2	Divalent ligation of beta1 integrins with soluble P4C10 antibodies stimulated expression of ***pro-MMP-2*** and its ***inhibitor*** , ***tissue inhibitor of metalloproteinase-2*** , whereas soluble 21C8 antibodies had no effect .	negative	1
1584	10197640	4323;4313	MT1-MMP;MMP-2	Aggregation of beta1 integrins with immobilized 21C8 or P4C10 antibodies stimulated MMP-dependent pro-MMP-2 activation and accumulation of a M ( r ) 43,000 form of membrane type 1 MMP ( ***MT1-MMP*** ) , a cell surface ***activator*** of ***pro-MMP-2*** , in cell extracts .	positive	1
1585	10197763	1113;4803	chromogranin a;Nerve growth factor	By contrast , the ***response*** of ***chromogranin a*** to ***Nerve growth factor*** was not impaired after blockade of phospholipase C-gamma or phosphoinositide-3 kinase .	parallel	0
1586	10197763	4803;1113	Nerve growth factor;chromogranin a	Chemical blockade of TrkA , Ras , MEK or mitogen-activated protein kinase similarly inhibited ***Nerve growth factor*** ***activation*** of ***chromogranin a*** .	positive	1
1587	10197763	4803;1113	Nerve growth factor;chromogranin a	***Nerve growth factor*** ***activated*** ***chromogranin a*** gene expression 7.6-fold in PC12 pheochromocytoma cells , and similarly activated PC12-transfected mouse , rat or human chromogranin a promoter/reporter constructs .	positive	1
1588	10197820	348;351	ApoE;Abeta	We hypothesize that ***Abeta*** accumulation is ***triggered*** by ***ApoE*** , which may bind and immobilize soluble Abeta produced in SMCs .	positive	0
1589	10197981	7040;4087	TGFbeta;Smad2	Our results suggest a mechanism for the counterbalanced ***regulation*** of ***Smad2/Smad3*** by ***TGFbeta*** and Ras signals in normal cells , and for the silencing of antimitogenic TGFbeta functions by hyperactive Ras in cancer cells .	target	1
1590	10197981	7040;4088	TGFbeta;Smad3	Our results suggest a mechanism for the counterbalanced ***regulation*** of ***Smad2/Smad3*** by ***TGFbeta*** and Ras signals in normal cells , and for the silencing of antimitogenic TGFbeta functions by hyperactive Ras in cancer cells .	target	1
1591	10197985	26823;26824	U12;U11	These results argue that intron recognition in the U12-dependent splicing pathway is carried out by a single ******U11/U12****** di-snRNP ***complex*** , suggesting greater rigidity in the intron recognition process than in the major spliceosome .	parallel	1
1592	10198041	11200;7465	Cds1;Wee1	***Cds1*** is proposed to ***regulate*** ***Wee1*** and Mik1 , two tyrosine kinases that inhibit the mitotic kinase Cdc2 .	target	1
1593	10198041	11200;995	Cds1;Cdc25	Here , we present evidence from in vivo and in vitro studies , which indicates that ***Cds1*** also ***inhibits*** ***Cdc25*** , the phosphatase that activates Cdc2 .	negative	1
1594	10198041	995;983	Cdc25;Cdc2	Cds1 also inhibited ***Cdc25-dependent*** ***activation*** of ***Cdc2*** in vitro .	positive	1
1595	10198041	11200;983	Cds1;Cdc2	***Cds1*** also ***inhibited*** Cdc25-dependent activation of ***Cdc2*** in vitro .	negative	1
1596	10198041	1111;995	Chk1;Cdc25	***Chk1*** , a protein kinase that is required for the G2-M damage checkpoint that prevents mitosis while DNA is being repaired , also ***inhibited*** ***Cdc25*** in the in vitro assay .	negative	1
1597	10198043	6347;3689	monocyte chemotactic protein-1;LFA-1	In contrast , staining for an activation epitope revealed a rapid and transient ***up-regulation*** of ***LFA-1*** activity by ***monocyte chemotactic protein-1*** ( MCP-1 ) in monocytes and Jurkat CCR2 chemokine receptor transfectants or by stromal-derived factor-1alpha in Jurkat cells .	positive	1
1598	10198169	9572;5914	NR1D1;RARA	Since previous results indicate that the ***THRA/NR1D1*** locus is also ***linked*** to the ***RARA*** gene , these results suggest that the two receptor gene clusters were generated by a single large-scale duplication .	parallel	0
1599	10198169	7067;5914	THRA;RARA	Since previous results indicate that the ***THRA/NR1D1*** locus is also ***linked*** to the ***RARA*** gene , these results suggest that the two receptor gene clusters were generated by a single large-scale duplication .	parallel	0
1600	10198187	3315;5594	hsp27;p38	Small heat shock proteins ( hsp ) have been implicated in mediation of classic preconditioning in the rabbit , ***hsp27*** is a terminal ***substrate*** of the ***p38*** MAPK cascade .	parallel	1
1601	10198191	3553;3791	IL-1 beta;KDR	These findings indicate that cardiac ***VEGF-KDR*** / flk-1 system is ***upregulated*** by ***IL-1 beta*** via activation of tyrosine kinases , suggesting that the IL-1 beta-modulated autocrine and/or paracrine system of VEGF has an important role in the process of angiogenesis in ischemic hearts .	positive	1
1602	10198191	3553;7422	IL-1 beta;VEGF	These findings indicate that cardiac ***VEGF-KDR*** / flk-1 system is ***upregulated*** by ***IL-1 beta*** via activation of tyrosine kinases , suggesting that the IL-1 beta-modulated autocrine and/or paracrine system of VEGF has an important role in the process of angiogenesis in ischemic hearts .	positive	1
1603	10198191	3791;7422	flk-1;vascular endothelial growth factor	Interleukin-1 beta upregulates cardiac expression of ***vascular endothelial growth factor*** and its ***receptor*** ***KDR/flk-1*** via activation of protein tyrosine kinases .	parallel	1
1604	10198191	3553;3791	Interleukin-1 beta;flk-1	***Interleukin-1 beta*** ***upregulates*** cardiac expression of vascular endothelial growth factor and its receptor ***KDR/flk-1*** via activation of protein tyrosine kinases .	positive	1
1605	10198191	3553;7422	Interleukin-1 beta;vascular endothelial growth factor	***Interleukin-1 beta*** ***upregulates*** cardiac expression of ***vascular endothelial growth factor*** and its receptor KDR/flk-1 via activation of protein tyrosine kinases .	positive	1
1606	10198191	3553;7422	IL-1 beta;VEGF	To explore the possible ***regulation*** of the ***VEGF*** system by ***IL-1 beta*** in the heart , we examined the regulation of expression of VEGF and KDR/flk-1 ( one of the VEGF receptors ) by IL-1 beta using cardiac myocytes and cardiac microvascular endothelial cells ( CMEC ) .	target	1
1607	10198191	3553;7422	IL-1 beta;VEGF	Both cardiac myocytes and CMEC substantially expressed ***VEGF*** mRNA and its expression was ***increased*** 3.6 - and 2.4-fold by ***IL-1 beta*** , respectively .	positive	0
1608	10198191	3553;7422	IL-1 beta;VEGF	IL-1 beta-induced accumulations of VEGF mRNA in cardiac myocytes were abolished by the tyrosine kinase inhibitor genistein , whereas inhibition of protein kinase C ( PKC ) by staurosporin , calphostin C and phorbol ester-induced PKC depletion , and intracellular Ca2 + chelators did not affect the ***induction*** of ***VEGF*** mRNA by ***IL-1 beta*** .	target	1
1609	10198220	1906;3565	endothelin-1;interleukin-4	We investigated the effect of chronic alcohol ingestion on buccal mucosal ulcer healing by analyzing the ***interplay*** between mucosal expression of tumor necrosis factor-alpha ( TNF-alpha ) , ***endothelin-1*** ( ET-1 ) , and ***interleukin-4*** ( IL-4 ) .	parallel	1
1610	10198224	4790;3383	NF-kappaB;ICAM-1	These findings indicate that NO up-regulates ICAM-1 expression on cancer cells by a regulatory mechanism involving PKC and suggest that ***NF-kappaB*** , but not AP-1 , might be involved in ***induction*** of ***ICAM-1*** by NO in cancer cells .	target	1
1611	10198225	3717;3595	Jak2;interleukin-12 receptor beta 2	Physical interaction between interleukin-12 receptor beta 2 subunit and Jak2 tyrosine kinase : ***Jak2*** ***associates*** with cytoplasmic membrane-proximal region of ***interleukin-12 receptor beta 2*** via amino-terminus .	parallel	0
1612	10198225	3717;3595	Jak2;interleukin-12 receptor beta 2	Physical ***interaction*** between ***interleukin-12 receptor beta 2*** subunit and ***Jak2*** tyrosine kinase : Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor beta 2 via amino-terminus .	parallel	1
1613	10198245	3553;5743	IL-1beta;COX-2	The cytokine ***IL-1beta*** and to a lesser extent EGF , ***enhanced*** ***COX-2*** mRNA levels in gingival fibroblasts .	positive	0
1614	10198245	3553;5742	IL-1beta;COX-1	Neither IL-1beta EGF nor the combination of ***IL-1beta*** and EGF ***enhanced*** ***COX-1*** mRNA levels in gingival fibroblasts .	positive	0
1615	10198256	699;8379	BUB1;MAD1	***Phosphorylation*** of human ***MAD1*** by the ***BUB1*** kinase in vitro .	target	1
1616	10198256	9184;699	BUB3;BUB1	In vitro , ***BUB1*** and ***BUB3*** proteins form a ***complex*** of monomers of each protein .	parallel	1
1617	10198263	3458;3683	Interferon-gamma;CD11a	***Interferon-gamma*** , bacterial lipopolysaccharide , and tumor necrosis factor-alpha ***induce*** ***CD11a*** mRNA and protein via Na + / H + exchange and protein kinase C-dependent mechanisms in tissue macrophages .	target	1
1618	10198263	7124;3683	tumor necrosis factor-alpha;CD11a	Interferon-gamma , bacterial lipopolysaccharide , and ***tumor necrosis factor-alpha*** ***induce*** ***CD11a*** mRNA and protein via Na + / H + exchange and protein kinase C-dependent mechanisms in tissue macrophages .	target	1
1619	10198263	3458;3683	Interferon-gamma;CD11a	Previously ***CD11a*** or leukocyte function-associated antigen alpha-1 was found to be ***induced*** at the surface protein level in thioglycolate-elicited peritoneal macrophages by bacterial lipopolysaccharide and ***Interferon-gamma*** .	target	1
1620	10198263	3458;3683	Interferon-gamma;CD11a	***CD11a*** ***induction*** by ***Interferon-gamma*** conversely is sensitive to inhibition of Na + / H + exchange and insensitive to inhibition of protein kinase C.	target	1
1621	10198298	3458;4843	IFN-gamma;iNOS	However , when used in combination , TNF-alpha , ***IFN-gamma*** , and LPS markedly and synergistically ***increased*** ***iNOS*** activity in these cells .	positive	0
1622	10198298	7124;4843	TNF-alpha;iNOS	However , when used in combination , ***TNF-alpha*** , IFN-gamma , and LPS markedly and synergistically ***increased*** ***iNOS*** activity in these cells .	positive	0
1623	10198344	5578;2822	PKC-alpha;PLD	Taken together , these observations indicate that ***PKC-alpha*** is intimately involved in the ***stimulation*** of ***PLD*** in Caco-2 cells by 1,25 ( OH ) 2D3 or TPA .	positive	0
1624	10198346	1392;3383	CRF;ICAM-1	Intracisternal injection of ***CRF*** ***abrogated*** both the increased expression of ***ICAM-1*** and leukocyte recruitment .	negative	0
1625	10198357	3596;3553	IL-13;IL-1beta	Interleukin ( IL ) -4 and ***IL-13*** dramatically ***enhanced*** the expression of 15-LO , whereas tumor necrosis factor-alpha , ***IL-1beta*** , and interferon ( IFN ) - gamma had no effect .	positive	0
1626	10198357	3596;7124	IL-13;tumor necrosis factor-alpha	Interleukin ( IL ) -4 and ***IL-13*** dramatically ***enhanced*** the expression of 15-LO , whereas ***tumor necrosis factor-alpha*** , IL-1beta , and interferon ( IFN ) - gamma had no effect .	positive	0
1627	10198359	6667;1181	Sp1;ClC-2	This work suggests that ***Sp1*** and Sp3 ***activate*** ***ClC-2*** gene transcription and that reduction in Sp1 and Sp3 at birth explains perinatal downregulation of ClC-2 in the lung .	positive	1
1628	10198359	6670;1181	Sp3;ClC-2	This work suggests that Sp1 and ***Sp3*** ***activate*** ***ClC-2*** gene transcription and that reduction in Sp1 and Sp3 at birth explains perinatal downregulation of ClC-2 in the lung .	positive	1
1629	10198420	1051;4843	C/EBPbeta;NOS2	In trans-activation assays , overexpression of ***C/EBPbeta*** ***stimulated*** basal ***NOS2*** promoter activity .	positive	0
1630	10198433	836;142	caspase-3;PARP	We have demonstrated that particular nucleases of this type are inhibited by poly ( ADP-ribosyl ) ation and suggested that subsequent ***cleavage*** of ***PARP*** by ***caspase-3*** might release these nucleases from poly ( ADP-ribosyl ) ation-induced inhibition .	target	1
1631	10198732	7422;5241	VEGF;progesterone receptor	***VEGF*** was positively associated with age and was inversely ***associated*** with estrogen receptor and ***progesterone receptor*** , whereas TP was not associated with any other variable .	negative	0
1632	10198817	4803;3725	NGF;c-Jun	In this report , we will focus on an ***interaction*** of nerve growth factor ( ***NGF*** ) with the transcription factor ***c-Jun*** in intact and axotomized septohippocampal projection neurons .	parallel	1
1633	1019918	5741;2520	parathyroid hormone;gastrin	***Stimulation*** of ***gastrin*** secretion by ***parathyroid hormone*** .	positive	0
1634	10199400	4089;4087	Smad4;Smad2	Thus , upon entering the nucleus , a ******Smad2-Smad4****** ***complex*** may interact with coactivators , forming a transcriptional activation complex , or with TGIF and HDACs , forming a transcriptional repressor complex .	parallel	1
1635	10199562	3552;5743	Interleukin-1 alpha;cyclooxygenase-2	***Interleukin-1 alpha*** ***induced*** ***cyclooxygenase-2*** expression in bone-derived endothelial cells .	target	1
1636	10199562	3552;5743	IL-1alpha;COX-2	A transcriptional activation assay revealed that the treatment with IL-1alpha increased COX-2 promoter activity in a dose-dependent manner , and ***IL-1alpha*** ***promoted*** ***COX-2*** protein expression in BDECs .	positive	0
1637	10199789	7349;5443	Urocortin;ACTH	A dose-related increase of trophoblast ***ACTH*** or PGE2 was ***induced*** by ***Urocortin*** , whereas astressin inhibited Urocortin-stimulated ACTH or PGE2 release .	target	1
1638	10199789	7349;5443	Urocortin;ACTH	The present study showed that human ***Urocortin*** ***stimulates*** placental secretion of ***ACTH*** and PGE2 , and modulates myometrial contractility , suggesting a role for this peptide in placental and intrauterine CRF pathways .	positive	0
1639	10199789	7349;5443	Urocortin;adrenocorticotropin	***Urocortin*** ***stimulates*** placental ***adrenocorticotropin*** and prostaglandin release and myometrial contractility in vitro .	positive	0
1640	10199811	2321;7422	Flt-1;VEGF	Treatment with either hypoxia or VEGF under normoxic conditions induced a twofold increase in VEGF binding sites and ***VEGF*** ***receptor*** 1 ( ***Flt-1*** ) mRNA expression in BMEC .	parallel	1
1641	10199915	5970;4790	p65;p50	The predominant form of NF-kappaB is a ******p50/p65****** ***heterodimer*** which can be released from IkappaB-alpha and migrate to the nucleus .	parallel	1
1642	10199918	6768;2313	Prss14;Fli1	This gene , ***Prss14*** ( protease , serine , 14 ) , was mapped to mouse chromosome 9 and is closely ***linked*** to the ***Fli1*** ( Friend leukemia integration 1 ) gene .	parallel	0
1643	10199952	1105;6749	CHD1;SSRP1	***CHD1*** ***interacts*** with ***SSRP1*** and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin .	parallel	1
1644	10199952	1105;6749	CHD1;SSRP1	We also present evidence for an in vivo ***interaction*** between ***CHD1*** and a novel HMG box-containing protein , ***SSRP1*** , which involves an amino-terminal segment of CHD1 that does not include the chromodomain .	parallel	1
1645	10199962	3238;6469	Hoxd-12;Sonic hedgehog	This approach has recently revealed that ***Hoxd-12*** can ***induce*** ***Sonic hedgehog*** and suggests a new role for certain 5 ' Hoxd genes in the initiation of Sonic hedgehog expression and its maintenance through feedback regulation .	target	1
1646	10200255	965;914	CD58;CD2	The ***binding*** of the cell surface molecule ***CD58*** ( formerly lymphocyte function-associated antigen 3 ) to its ligand , ***CD2*** , significantly increases the sensitivity of antigen recognition by T cells .	parallel	1
1647	10200259	10537;4085	FAT10;MAD2	A MHC-encoded ubiquitin-like protein ( ***FAT10*** ) ***binds*** noncovalently to the spindle assembly checkpoint protein ***MAD2*** .	parallel	1
1648	10200259	10537;4085	FAT10;MAD2	Yeast two-hybrid screening of a human lymphocyte library and immunoprecipitation studies revealed that ***FAT10*** noncovalently ***associated*** with ***MAD2*** , a protein implicated in a cell-cycle checkpoint for spindle assembly during anaphase .	parallel	0
1649	10200280	2475;5524	FRAP;PP2A	***FRAP*** also is shown to ***phosphorylate*** ***PP2A*** in vitro , consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70 ( s6k ) , whereas amino acid deprivation or rapamycin treatment inhibits FRAP 's ability to restrain the phosphatase .	target	1
1650	10200280	2475;5524	FRAP;PP2A	FRAP also is shown to phosphorylate PP2A in vitro , consistent with a model in which ***phosphorylation*** of ***PP2A*** by ***FRAP*** prevents the dephosphorylation of 4E-BP1 and p70 ( s6k ) , whereas amino acid deprivation or rapamycin treatment inhibits FRAP 's ability to restrain the phosphatase .	target	1
1651	10200280	5524;1978	PP2A;4E-BP1	FRAP also is shown to phosphorylate PP2A in vitro , consistent with a model in which phosphorylation of ***PP2A*** by FRAP ***prevents*** the dephosphorylation of ***4E-BP1*** and p70 ( s6k ) , whereas amino acid deprivation or rapamycin treatment inhibits FRAP 's ability to restrain the phosphatase .	negative	0
1652	10200298	4915;7422	trkB;vascular endothelial growth factor	In a cell culture model of MTC , exogenous ***trkB*** expression resulted in severely impaired tumorigenicity and was ***associated*** with 11-fold lower levels of the angiogenesis factor ***vascular endothelial growth factor*** .	parallel	0
1653	10200336	1026;1017	p21;Cdk2	The increased levels of ***p21*** were ***associated*** with increased binding of p21 and ***Cdk2*** concomitant with marked decrease in Cdk2 and cyclin E-dependent kinase activities with no changes in Cdk2 and cyclin E expression .	parallel	0
1654	10200342	7852;6387	CXCR4;hIRH	In HCV liver biopsies , the expression of ***hIRH*** and its ***receptor*** ***CXCR4*** mRNA , corrected for G3PDH , was not significantly different from that of control non-HCV ( steatosis ) biopsies .	parallel	1
1655	10200473	8772;841	FADD;caspase-8	Usurpin heterodimerized with pro-caspase-8 in vitro and precluded ***pro-caspase-8*** ***recruitment*** by the ***FADD/MORT1*** adapter protein .	target	0
1656	10200483	4804;627	p75NTR;neurotrophin	The p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) and trkA , trkB and trkC mediate the physiological effects of the neurotrophins .	parallel	1
1657	10200513	7157;355	p53;APO-1	It has been reported that ***p53*** ***upregulates*** ***Fas/APO-1*** and Bax expression .	positive	1
1658	10200513	7157;581	p53;Bax	It has been reported that ***p53*** ***upregulates*** Fas/APO-1 and ***Bax*** expression .	positive	1
1659	10200513	7157;355	p53;APO-1	However , elevated ***p53*** protein is not sufficient to ***activate*** ***Fas/APO-1*** gene expression in ara-C-treated cells .	positive	1
1660	10200535	993;1017	cdc25A;cdk2	***cdc25A*** tyrosine phosphatase is an ***activator*** of the ***cdk2-cyclin*** E complex which allows for cell cycle progression .	positive	1
1661	10200551	3558;596	IL-2;Bcl-2	Moreover , the addition of exogenous ***IL-2*** , in the presence of Dex , fails to ***up-regulate*** ***Bcl-2*** expression and to revert Dex-mediated apoptotic phenomena .	positive	1
1662	10200558	10015;85365	Alix;ALG-2	******ALG-2/Alix****** ***interaction*** was also validated by co-immunoprecipitation , but in this case , the binding was found to be strictly calcium dependent .	parallel	1
1663	10200559	8743;5599	TRAIL;JNK	We report here that ***JNK/SAPKs*** are ***activated*** by ***TRAIL*** in parallel to induction of apoptosis in human T and B cell lines .	positive	1
1664	10200559	8743;5599	TRAIL;JNK	Death signaling as well as ***JNK/SAPK*** ***activation*** by ***TRAIL*** in these cells is FADD - and caspase-dependent since dominant-negative FADD or the caspase inhibitor zVAD prevented both , apoptosis and JNK/SAPK activity .	positive	1
1665	10200559	8743;5601	TRAIL;SAPK	Death signaling as well as ***JNK/SAPK*** ***activation*** by ***TRAIL*** in these cells is FADD - and caspase-dependent since dominant-negative FADD or the caspase inhibitor zVAD prevented both , apoptosis and JNK/SAPK activity .	positive	1
1666	10200559	8772;5599	FADD;JNK	***JNK/SAPK*** activity in response to triggering of CD95 by an agonistic antibody ( alphaAPO-1 ) was also ***diminished*** by dominant-negative ***FADD*** or zVAD .	negative	0
1667	10200559	8772;5601	FADD;SAPK	***JNK/SAPK*** activity in response to triggering of CD95 by an agonistic antibody ( alphaAPO-1 ) was also ***diminished*** by dominant-negative ***FADD*** or zVAD .	negative	0
1668	10200559	8743;5599	TRAIL;JNK	Therefore , ***activation*** of ***JNK/SAPKs*** by ***TRAIL*** or alphaAPO-1 occurs downstream of FADD and caspases and contributes to apoptosis in human lymphoid cell lines .	positive	1
1669	10200578	7157;355	p53;CD95	***p53-mediated*** ***up-regulation*** of ***CD95*** is not involved in genotoxic drug-induced apoptosis of human breast tumor cells .	positive	1
1670	10201021	958;959	CD40;CD154	BACKGROUND : ******CD40-CD154****** ( CD40L ) costimulatory ***signaling*** plays a pivotal role in the effector mechanisms of transplant graft rejection .	parallel	0
1671	10201021	958;959	CD40;CD154	Given the critical importance of ******CD40-CD154****** ***interactions*** in the development of chronic transplant allograft rejection , the relevance of in situ CD40 and CD154 expression was assessed in human chronic renal allograft rejection .	parallel	1
1672	10201024	7035;2152	TFPI;tissue factor	RESULTS : Prior to hemofiltration , most patients had increased levels of plasma tissue factor , thrombin-antithrombin ( TAT ) complexes , and ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) ; during hemofiltration , further generation of TAT complexes occurred .	negative	1
1673	10201372	1499;595	Beta-catenin;cyclin D1	***Beta-catenin*** ***regulates*** expression of ***cyclin D1*** in colon carcinoma cells .	target	1
1674	10201372	3265;595	p21ras;cyclin D1	The oncoprotein ***p21ras*** further ***activates*** transcription of the ***cyclin D1*** gene , through sites within the promoter that bind the transcriptional regulators Ets or CREB .	positive	1
1675	10201887	7099;4790	TLR4;NF-kappaB	Overexpression of wild-type ***TLR4*** but not the mutant TLR4 from C3H/HeJ mice ***activated*** ***NF-kappaB*** .	positive	1
1676	10201892	8651;3565	SOCS-1;IL-4	Cutting edge : ***SOCS-1*** is a potent ***inhibitor*** of ***IL-4*** signal transduction .	negative	1
1677	10201892	8651;6778	SOCS-1;Stat6	We have examined the ability of SOCS family members to suppress IL-4 signaling , and we have found that ***SOCS-1*** potently ***inhibits*** the activation of JAK1 kinase and ***Stat6*** in response to IL-4 .	negative	1
1678	10201892	3565;2208	IL-4;CD23	Furthermore , SOCS-1 can inhibit the ***induction*** of ***CD23*** expression by ***IL-4*** .	target	1
1679	10201892	9021;3565	SOCS-3;IL-4	SOCS-2 does not inhibit induction of signaling by IL-4 , while ***inhibition*** of ***IL-4*** signaling by ***SOCS-3*** can be detected in transient transfection systems , but not in stable cell lines .	negative	1
1680	10201899	940;1432	CD28;p38	However , ***p38*** MAPK is ***activated*** strongly and synergistically by either ***CD3/CD28*** coligation or PMA/Ca2 + ionophore stimulation , which mimics TCR-CD3 / CD28-mediated signaling .	positive	1
1681	10201899	5594;3725	MAPK 1;c-Jun	Our findings demonstrate that p38 ***MAPK 1*** ) plays an important role in signal integration during costimulation of primary mouse T cells , 2 ) may be involved in the ***induction*** of ***c-Jun*** activation and augmentation of AP-1 transcriptional activity , and 3 ) regulates whether T cells enter a state of functional unresponsiveness .	target	1
1682	10201904	7124;5594	TNF-alpha;ERK2	***TNF-alpha*** ***induced*** tyrosine phosphorylation and enzymatic activation of ***ERK2*** , SAPK/JNK , and p38mapk , whereas IL-10 did not induce these events .	target	1
1683	10201904	7124;5599	TNF-alpha;JNK	***TNF-alpha*** ***induced*** tyrosine phosphorylation and enzymatic activation of ERK2 , ***SAPK/JNK*** , and p38mapk , whereas IL-10 did not induce these events .	target	1
1684	10201904	7124;5601	TNF-alpha;SAPK	***TNF-alpha*** ***induced*** tyrosine phosphorylation and enzymatic activation of ERK2 , ***SAPK/JNK*** , and p38mapk , whereas IL-10 did not induce these events .	target	1
1685	10201923	728;727	C5aR;C5a	In this study , we present the first evidence that human T cells express the ***C5a*** ***receptor*** ( ***C5aR*** ) and are chemotactic to C5a .	parallel	1
1686	10201924	7124;4792	TNF-alpha;I kappa B alpha	In contrast , ***TNF-alpha*** ***induced*** degradation of ***I kappa B alpha*** in the neuronal cells , suggesting that failure to induce I kappa B alpha degradation is likely due to a defect in virus-mediated signaling rather than to a defect involving neuronal I kappa B alpha .	target	1
1687	10201928	3458;6772	IFN-gamma;Stat1	***Stat1*** , which is ***activated*** by ***IFN-gamma*** , can not recognize the Stat6-specific IL-4 response element in the epsilon promoter .	positive	1
1688	10201929	3725;2353	Jun;Fos	In addition , DNA-binding activities of ******Jun-Fos****** ***heterodimers*** were observed by electrophoretic mobility shift assays during the course of natural cytotoxicity .	parallel	1
1689	10201938	1493;940	CTLA-4;CD28	T cells require ******CD28/CTLA-4****** costimulatory molecule ***interactions*** in addition to Ag-specific signals through the TCR for in vivo effector Th cell function .	parallel	1
1690	10201939	958;959	CD40;CD40 ligand	******CD40 ligand-CD40****** ***interaction*** induces chemokines in cervical carcinoma cells in synergism with IFN-gamma .	parallel	1
1691	10201939	959;958	CD40L;CD40	In this study , we show high CD40 expression on cervical carcinoma cells and CD40 ligand ( CD40L ) staining on attracted T cells in tumor tissue , suggesting a paracrine stimulation mechanism via ******CD40L-CD40****** ***interactions*** .	parallel	1
1692	10201939	959;6347	CD40L;MCP-1	***CD40L*** was able to ***induce*** ***MCP-1*** production ; however , despite much higher CD40 expression in malignant cells , MCP-1 induction was significantly lower compared with nontumorigenic cells .	target	1
1693	10201951	7124;4790	TNF-alpha;NF-kappa B	These data suggest that in fibroblasts ***TNF-alpha*** ***activates*** and initiates the nuclear translocation of ***NF-kappa B*** that binds a divergent NF-kappa B element and plays a critical role in the observed inhibition of alpha 2(I) collagen gene transcription .	positive	1
1694	10201953	566;7124	HBP;TNF-alpha	In the current study , we hypothesize that HBP is internalized in monocytes via endocytosis , and this internalization is an important mechanism by which ***HBP*** ***enhances*** LPS-induced ***TNF-alpha*** release .	positive	0
1695	10201954	3553;1432	IL-1beta;p38alpha	***IL-1beta*** ***activated*** ***p38alpha*** and p38beta in endothelial cells .	positive	1
1696	10201954	3553;5600	IL-1beta;p38beta	***IL-1beta*** ***activated*** p38alpha and ***p38beta*** in endothelial cells .	positive	1
1697	10201956	3553;3569	IL-1;IL-6	We have recently reported that LPS augments IL-1RI mRNA expression in the hepatocytes of mice in vivo , and the augmentation is mediated by the ***interaction*** of ***IL-1*** , ***IL-6*** , and glucocorticoid ( GC ) .	parallel	1
1698	10201958	4803;27306	NGF;PGD2	More recently , ***NGF*** has been demonstrated to ***induce*** ***PGD2*** production by mast cells through the induction of mast cell cyclooxygenase expression .	target	1
1699	10201958	4803;7124	NGF;TNF-alpha	We have observed that ***NGF*** at doses as low as 10 ng/ml will induce IL-6 production and ***inhibit*** ***TNF-alpha*** release from rat peritoneal mast cells in the presence of lysophosphatidylserine as a cofactor .	negative	1
1700	10201960	3558;1232	IL-2;CCR3	We have observed a novel phenomenon that ***IL-2*** and IL-4 ***induce*** the expression of ***CCR3*** on T lymphocytes .	target	1
1701	10201960	3565;1232	IL-4;CCR3	We have observed a novel phenomenon that IL-2 and ***IL-4*** ***induce*** the expression of ***CCR3*** on T lymphocytes .	target	1
1702	10201961	3603;920	IL-16;CD4 molecule	In the synovial tissue , CD8 + T cells were the major source of ***IL-16*** , a natural ***ligand*** of the ***CD4 molecule*** that can anergize CD4-expressing cells .	parallel	1
1703	10201972	3458;6772	IFN-gamma;STAT1	Here , we observed that class II MHC trans-activator and ***STAT1*** alpha mRNA , mediators of the signaling cascade from the IFN-gamma receptor to the DR alpha induction , were markedly ***increased*** by ***IFN-gamma*** stimulation in phorbol ester-activated THP-1 cells ; however , both mRNAs were not increased by phorbol ester treatment alone .	positive	0
1704	10201980	6714;695	Src;Btk	Although ***Btk*** activity can be ***regulated*** by ***Src-family*** and Syk tyrosine kinases , and perhaps by phosphatidylinositol 3,4,5-trisphosphate , BCR-coupled signaling pathways leading to Btk activation are poorly understood .	target	1
1705	10201980	930;695	CD19;Btk	Taken together , the data presented indicate that BCR aggregation-driven ***CD19*** phosphorylation functions to ***promote*** ***Btk*** activation via recruitment and activation of PI3-K .	positive	0
1706	10201981	7124;3576	TNF-alpha;IL-8	***Induction*** of ***IL-8*** gene expression by ***TNF-alpha*** was partially inhibited in Ad5dnTRAF-2-transfected HT-29 , but not in control Ad5LacZ-infected , cells .	target	1
1707	10201989	3600;3458	IL-15;IFN-gamma	***IL-15*** and IL-12 ***induced*** less ***IFN-gamma*** protein ( 24 + / - 10 ng/ml ; p < 0.007 ) and only a 45 + / - 19-fold increase in IFN-gamma gene expression over those in resting NK cells .	target	1
1708	10201989	3600;1437	IL-15;CSF	Granulocyte-macrophage ***CSF*** was optimally ***induced*** by ***IL-15*** and IL-18 .	target	1
1709	10201989	3606;1437	IL-18;CSF	Granulocyte-macrophage ***CSF*** was optimally ***induced*** by IL-15 and ***IL-18*** .	target	1
1710	10201993	3479;596	IGF-I;Bcl-2	We next established that IL-3 , IL-4 , and ***IGF-I*** ***increase*** expression of ***Bcl-2*** by > 3-fold .	positive	0
1711	10201993	3562;596	IL-3;Bcl-2	We next established that ***IL-3*** , IL-4 , and IGF-I ***increase*** expression of ***Bcl-2*** by > 3-fold .	positive	0
1712	10201993	3565;596	IL-4;Bcl-2	We next established that IL-3 , ***IL-4*** , and IGF-I ***increase*** expression of ***Bcl-2*** by > 3-fold .	positive	0
1713	10201998	3458;5743	IFN-gamma;COX-2	***IFN-gamma*** ***up-regulated*** expression and activity of ***COX-2*** in medullary cells , in which COX-2 was expressed constitutively .	positive	1
1714	10202009	7433;7432	VPAC1;VIP	***VPAC1*** , the type 1 VIP receptor , which is constitutively expressed in macrophages , and to a lesser degree VPAC2 , the type 2 ***VIP*** ***receptor*** , which is induced upon macrophage activation , mediate the effect of VIP/PACAP .	parallel	1
1715	10202009	7433;116	VPAC1;PACAP	***VPAC1*** , the type 1 VIP receptor , which is constitutively expressed in macrophages , and to a lesser degree VPAC2 , the type 2 VIP receptor , which is induced upon macrophage activation , ***mediate*** the effect of ***VIP/PACAP*** .	target	0
1716	10202009	7433;7432	VPAC1;VIP	***VPAC1*** , the type 1 VIP receptor , which is constitutively expressed in macrophages , and to a lesser degree VPAC2 , the type 2 VIP receptor , which is induced upon macrophage activation , ***mediate*** the effect of ***VIP/PACAP*** .	target	0
1717	10202009	7434;116	VPAC2;PACAP	VPAC1 , the type 1 VIP receptor , which is constitutively expressed in macrophages , and to a lesser degree ***VPAC2*** , the type 2 VIP receptor , which is induced upon macrophage activation , ***mediate*** the effect of ***VIP/PACAP*** .	target	0
1718	10202009	7434;7432	VPAC2;VIP	VPAC1 , the type 1 VIP receptor , which is constitutively expressed in macrophages , and to a lesser degree ***VPAC2*** , the type 2 VIP receptor , which is induced upon macrophage activation , ***mediate*** the effect of ***VIP/PACAP*** .	target	0
1719	10202009	116;4843	PACAP;iNOS	***VIP/PACAP*** ***inhibit*** ***iNOS*** expression and activity both in vivo and in vitro .	negative	1
1720	10202009	7432;4843	VIP;iNOS	***VIP/PACAP*** ***inhibit*** ***iNOS*** expression and activity both in vivo and in vitro .	negative	1
1721	10202009	4790;4843	NF-kappa B;iNOS	Two transduction pathways appear to be involved , a cAMP-dependent pathway that preferentially inhibits IFN regulatory factor-1 transactivation and a cAMP-independent pathway that blocks ***NF-kappa B*** ***binding*** to the ***iNOS*** promoter .	parallel	1
1722	10202014	3458;4261	IFN-gamma;CIITA	Functionally , the proximal IRF element is essential for ***IFN-gamma*** ***induction*** of type IV ***CIITA*** promoter activity , while the proximal GAS and E box elements contribute to the IFN-gamma inducibility of this promoter .	target	1
1723	10202014	3458;4261	IFN-gamma;CIITA	Our results demonstrate that TNF-alpha does not enhance ***IFN-gamma-induced*** transcriptional ***activation*** of the type IV ***CIITA*** promoter , indicating that the enhancing effect of TNF-alpha is mediated downstream of CIITA transcription .	positive	1
1724	10202026	6346;6348	TCA3;MIP-1alpha	Of the two lymphocyte-attracting chemokines assessed , monocyte-chemotactic protein-1 and macrophage-inflammatory protein-1alpha ( MIP-1alpha ) , only MIP-1alpha was reduced when TCA3 was neutralized , indicating that ***TCA3*** ***affects*** the levels of ***MIP-1alpha*** , which attracts lymphocytes into the sponges .	target	0
1725	10202031	3562;5141	IL-3;PDE4	***IL-3*** and IL-4 ***activate*** cyclic nucleotide phosphodiesterases 3 ( PDE3 ) and 4 ( ***PDE4*** ) by different mechanisms in FDCP2 myeloid cells .	positive	1
1726	10202031	3565;5141	IL-4;PDE4	IL-3 and ***IL-4*** ***activate*** cyclic nucleotide phosphodiesterases 3 ( PDE3 ) and 4 ( ***PDE4*** ) by different mechanisms in FDCP2 myeloid cells .	positive	1
1727	10202031	1437;5141	CSF;PDE4	In FDCP2 myeloid cells , IL-4 activated cyclic nucleotide phosphodiesterases PDE3 and PDE4 , whereas IL-3 , granulocyte-macrophage ***CSF*** ( GM-CSF ) , and phorbol ester ( PMA ) selectively ***activated*** ***PDE4*** .	positive	1
1728	10202031	3562;5141	IL-3;PDE4	In FDCP2 myeloid cells , IL-4 activated cyclic nucleotide phosphodiesterases PDE3 and PDE4 , whereas ***IL-3*** , granulocyte-macrophage CSF ( GM-CSF ) , and phorbol ester ( PMA ) selectively ***activated*** ***PDE4*** .	positive	1
1729	10202031	3565;5141	IL-4;PDE4	In FDCP2 myeloid cells , ***IL-4*** ***activated*** cyclic nucleotide phosphodiesterases PDE3 and ***PDE4*** , whereas IL-3 , granulocyte-macrophage CSF ( GM-CSF ) , and phorbol ester ( PMA ) selectively activated PDE4 .	positive	1
1730	10202031	3565;8660	IL-4;insulin-receptor substrate-2	***IL-4*** ( not IL-3 or GM-CSF ) ***induced*** tyrosine phosphorylation of ***insulin-receptor substrate-2*** ( IRS-2 ) and its association with phosphatidylinositol 3-kinase ( PI3-K ) .	target	1
1731	10202031	7124;5141	TNF-alpha;PDE4	***TNF-alpha*** , AG-490 ( Janus kinase inhibitor ) , and wortmannin ( PI3-K inhibitor ) ***inhibited*** activation of PDE3 and ***PDE4*** by IL-4 .	negative	1
1732	10202031	3565;5141	IL-4;PDE4	TNF-alpha , AG-490 ( Janus kinase inhibitor ) , and wortmannin ( PI3-K inhibitor ) inhibited ***activation*** of PDE3 and ***PDE4*** by ***IL-4*** .	positive	1
1733	10202031	3565;8660	IL-4;IRS-2	TNF-alpha also blocked ***IL-4-induced*** tyrosine ***phosphorylation*** of ***IRS-2*** , but not of STAT6 .	target	1
1734	10202031	7124;8660	TNF-alpha;IRS-2	***TNF-alpha*** also ***blocked*** IL-4-induced tyrosine phosphorylation of ***IRS-2*** , but not of STAT6 .	negative	0
1735	10202031	3562;5141	IL-3;PDE4	AG-490 and wortmannin , not TNF-alpha , inhibited ***activation*** of ***PDE4*** by ***IL-3*** .	positive	1
1736	10202031	3565;5141	IL-4;PDE4	These results suggested that ***IL-4-induced*** ***activation*** of PDE3 and ***PDE4*** was downstream of IRS-2/PI3-K , not STAT6 , and that inhibition of tyrosine phosphorylation of IRS molecules might be one mechnism whereby TNF-alpha could selectively regulate activities of cytokines that utilized IRS proteins as signal transducers .	positive	1
1737	10202034	5594;4790	ERK1/2;NF-kappa B	We conclude that okadaic acid-induced IL-6 gene expression is at least partly mediated through the ***ERK1/2*** and JNK pathway-dependent ***activation*** of ***NF-kappa B*** transcriptional capacity .	positive	1
1738	10202034	5599;4790	JNK;NF-kappa B	We conclude that okadaic acid-induced IL-6 gene expression is at least partly mediated through the ERK1/2 and ***JNK*** pathway-dependent ***activation*** of ***NF-kappa B*** transcriptional capacity .	positive	1
1739	10202035	1803;6356	CD26;eotaxin	***CD26/dipeptidyl-peptidase IV*** ***down-regulates*** the eosinophil chemotactic potency , but not the anti-HIV activity of human ***eotaxin*** by affecting its interaction with CC chemokine receptor 3 .	negative	1
1740	10202035	1803;6356	CD26;eotaxin	In this study we demonstrate that ***eotaxin*** is efficiently ***cleaved*** by ***CD26/DPP IV*** and that the NH2-terminal truncation affects its biological activity .	target	1
1741	10202038	3552;1958	IL-1alpha;Egr-1	***IL-1alpha*** also ***induced*** ***Egr-1*** expression in these cells .	target	1
1742	10202038	3552;960	IL-1alpha;CD44	These studies therefore identify Egr-1 as a critical transcription factor involved in ***CD44*** ***induction*** by ***IL-1alpha*** .	target	1
1743	10202039	3565;3627	IL-4;IP-10	Furthermore , IL-10 and ***IL-4*** significantly ***suppressed*** the expression of MIG , ***IP-10*** , and I-TAC mRNA and the extracellular production of MIG and IP-10 in neutrophils stimulated with IFN-gamma plus either LPS or TNF-alpha .	negative	1
1744	10202039	3565;6373	IL-4;I-TAC	Furthermore , IL-10 and ***IL-4*** significantly ***suppressed*** the expression of MIG , IP-10 , and ***I-TAC*** mRNA and the extracellular production of MIG and IP-10 in neutrophils stimulated with IFN-gamma plus either LPS or TNF-alpha .	negative	1
1745	10202049	8744;941	4-1BBL;B7-1	***4-1BBL*** ***cooperates*** with ***B7-1*** and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine .	parallel	0
1746	10202049	8744;942	4-1BBL;B7-2	***4-1BBL*** ***cooperates*** with B7-1 and ***B7-2*** in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine .	parallel	0
1747	10202109	4267;3559	CD99;CD25	***CD99*** coligation also ***enhanced*** ***CD25*** expression and early markers of T cell activation , CD69 and CD40L .	positive	0
1748	10202109	4267;959	CD99;CD40L	***CD99*** coligation also ***enhanced*** CD25 expression and early markers of T cell activation , CD69 and ***CD40L*** .	positive	0
1749	10202109	4267;969	CD99;CD69	***CD99*** coligation also ***enhanced*** CD25 expression and early markers of T cell activation , ***CD69*** and CD40L .	positive	0
1750	10202109	914;959	CD2;CD40L	Simultaneous costimulation with anti-CD99 and anti-CD28 Abs appeared to have additive effects on CD40L expression while CD99 ligation had no effect on ***CD2-mediated*** T cell ***induction*** of ***CD40L*** expression .	target	1
1751	10202144	7157;4193	p53;Mdm2	This is consistent with the conclusion that phosphorylation of Ser20 in vivo attenuates the ***binding*** of wild-type ***p53*** to ***Mdm2*** .	parallel	1
1752	10202144	4193;7157	Mdm2;p53	This implies a critical role for Ser20 in modulating the negative ***regulation*** of ***p53*** by ***Mdm2*** , probably through phosphorylation-dependent inhibition of p53-Mdm2 interaction .	negative	1
1753	10202144	7157;4193	p53;Mdm2	This implies a critical role for Ser20 in modulating the negative regulation of p53 by Mdm2 , probably through phosphorylation-dependent inhibition of ******p53-Mdm2****** ***interaction*** .	parallel	1
1754	10202144	4193;7157	Mdm2;p53	Critical role for Ser20 of human p53 in the negative ***regulation*** of ***p53*** by ***Mdm2*** .	negative	1
1755	10202144	7157;4193	p53;Mdm2	While the in vitro ***binding*** of ***p53*** to ***Mdm2*** is not increased by the Ala20 mutation , the same mutation results in a markedly enhanced binding in vivo .	parallel	1
1756	10202150	245711;1017	Spy1;cdk2	In addition , we have shown that ***Spy1*** physically ***interacts*** with ***cdk2*** , and prematurely activates cdk2 kinase activity .	parallel	1
1757	10202150	245711;1017	Spy1;cdk2	In addition , we have shown that ***Spy1*** physically interacts with cdk2 , and prematurely ***activates*** ***cdk2*** kinase activity .	positive	1
1758	10202156	6839;10951	SUV39H1;M31	In addition , ***SUV39H1/SUV39H1*** proteins ***associate*** with ***M31*** , currently the only other characterized mammalian SU ( VAR ) homologue .	parallel	0
1759	10202161	9972;7214	nucleoporin Nup153;TRN1	We employed a phage display system to search for proteins that interact with transportin 1 ( TRN1 ) , the import receptor for shuttling hnRNP proteins with an M9 nuclear localization sequence ( NLS ) , and identified a short region within the N-terminus of the ***nucleoporin Nup153*** which ***binds*** ***TRN1*** .	parallel	1
1760	10202163	7518;3981	Xrcc4;DNA ligase IV	***Xrcc4*** also ***binds*** to ***DNA ligase IV*** and enhances its joining activity .	parallel	1
1761	10202187	4233;3082	c-Met;hepatocyte growth factor	Expression of ***hepatocyte growth factor/scatter factor*** and its ***receptor*** ***c-Met*** in brain tumors : evidence for a role in progression of astrocytic tumors ( Review ) .	parallel	1
1762	10202558	940;1493	CD28;CTLA-4	Manipulation of ******CD28/CTLA-4****** ***interactions*** with their natural ligands has provided exciting results in transplantation and tumor therapy settings and also has potential in the treatment of several diseases such as arthritis and multiple sclerosis , asthma and protection against HIV infection .	parallel	1
1763	10203183	7018;3569	transferrin;IL-6	However , the experiments show that despite the absence of a macroscopic effect , Sertoli cells respond to ionizing radiation by increasing transferrin secretion , ***transferrin*** ***response*** to ( Bu ) 2cAMP stimulation and ***IL-6*** activity .	parallel	0
1764	10203248	3458;3162	interferon-gamma;heme oxygenase-1	In rat glial cells , lipopolysaccharide and ***interferon-gamma*** ( LPS/IFN-gamma ) ***induced*** expression of both inducible nitric oxide synthase ( iNOS ) and ***heme oxygenase-1*** ( HO-1 ) .	target	1
1765	10203248	5468;3162	PPARgamma;HO-1	These results suggest that activation of ***PPARgamma*** negatively regulate iNOS expression and positively ***regulates*** ***HO-1*** expression in glial cells .	positive	1
1766	10203281	3486;3481	IGFBP-3;IGF-II	RESULTS : ***IGFBP-3*** levels ***correlated*** with IGF-I levels ( r = .64 ) and with ***IGF-II*** levels ( r = .90 ) .	parallel	0
1767	10203355	5970;4790	p65;p50	PDTC and Dex completely inhibited the ******p65/p50****** ***heterodimer*** , but HerA and AG490 had little effect on p65/p50 .	parallel	1
1768	10203355	3717;4843	JAK2;iNOS	AG490 and ***JAK2*** antisense oligonucleotides ***suppressed*** ***iNOS*** promoter activity .	negative	1
1769	10203356	7040;7422	TGF-beta1;vascular endothelial growth factor	***vascular endothelial growth factor*** ( VEGF ) , a potent promoter of vascular permeability , is ***induced*** in mesangial cells by both mechanical stretch and ***TGF-beta1*** .	target	1
1770	10203363	7040;4313	TGF-beta;MMP-2	***TGF-beta*** completely blocked the conversion of plasminogen to plasmin and markedly ***reduced*** the conversion of latent ***MMP-2*** to active MMP-2 .	negative	1
1771	10203364	5744;3569	PTHrP;IL-6	These results indicate that C-terminal ***PTHrP*** , like its N-terminal domain , ***induces*** ***IL-6*** production by human osteoblastic cells .	target	1
1772	10203364	5741;3569	PTH;interleukin-6	***PTH*** ( 1-34 ) and PTHrP ( 1-34 ) rapidly ***induce*** ***interleukin-6*** ( IL-6 ) expression by osteoblasts .	target	1
1773	10203364	5744;3569	PTHrP;interleukin-6	PTH ( 1-34 ) and ***PTHrP*** ( 1-34 ) rapidly ***induce*** ***interleukin-6*** ( IL-6 ) expression by osteoblasts .	target	1
1774	10203579	596;836	Bcl-2;caspase 3	Retrovirally introduced ***Bcl-2*** ***prevented*** beta-Lap-mediated ***caspase 3*** activation and PARP cleavage and increased the viability of Bcl-2-expressing HL-60 cells compared to cells with vector alone .	negative	0
1775	10203579	596;142	Bcl-2;PARP	Retrovirally introduced ***Bcl-2*** ***prevented*** beta-Lap-mediated caspase 3 activation and ***PARP*** cleavage and increased the viability of Bcl-2-expressing HL-60 cells compared to cells with vector alone .	negative	0
1776	10203687	356;355	CD95-L;CD95	Upon treatment ***CD95*** ***ligand*** ( ***CD95-L*** ) was induced that stimulated the CD95 pathway by crosslinking CD95 via an autocrine/paracrine loop .	parallel	1
1777	10203695	596;836	bcl-2;caspase 8 and 3	Here , we report that ***caspase 8 and 3*** activation , poly ( ADP-ribose ) polymerase cleavage and apoptosis are ***inhibited*** by the lipoxygenase inhibitor , nordihydroguaretic acid ( NDGA ) , or ectopic expression of crm-A or ***bcl-2*** .	negative	1
1778	10203808	4609;7015	MYC;TERT	Recent evidence has shown that ***MYC*** ***upregulates*** the catalytic subunit of telomerase , ***TERT*** , and that TERT cooperates with HPV E7 in cell immortalization .	positive	1
1779	10204571	3458;3455	IFN-gamma;interferon receptor	Interferon gamma ( ***IFN-gamma*** ) ***stimulates*** the ( pro-inflammatory ) type II ***interferon receptor*** and is known to exacerbate multiple sclerosis ( MS ) .	positive	0
1780	10204571	3439;3455	IFN-alpha;interferon receptor	In contrast , ***IFN-alpha*** and IFN-beta are ***ligands*** for the ( anti-inflammatory ) type I ***interferon receptor*** and are beneficial in some ( but not all ) patients with MS.	parallel	1
1781	10204571	3456;3455	IFN-beta;interferon receptor	In contrast , IFN-alpha and ***IFN-beta*** are ***ligands*** for the ( anti-inflammatory ) type I ***interferon receptor*** and are beneficial in some ( but not all ) patients with MS.	parallel	1
1782	10204582	6464;2885	Shc;Grb2	***Shc*** was also inducibly tyrosine phosphorylated and ***bound*** to ***Grb2*** after Fc gammaRI stimulation of the macrophages .	parallel	1
1783	10204582	5464;867	PP1;Cbl	***PP1*** , a specific inhibitor of Src kinases , ***inhibited*** the Fc gammaRI-induced respiratory burst , as well as the tyrosine phosphorylation of ***Cbl*** and its inducible association with CrkL .	negative	1
1784	10204582	867;1399	Cbl;CrkL	These results suggest a fundamental role for the tyrosine phosphorylation of Cbl , CrkL , SLP-76 , and Shc and the ***association*** of ***Cbl*** with ***CrkL*** , SLP-76 , and Nck in Fc gammaRI signaling in human macrophages .	parallel	0
1785	10204582	867;4690	Cbl;Nck	These results suggest a fundamental role for the tyrosine phosphorylation of Cbl , CrkL , SLP-76 , and Shc and the ***association*** of ***Cbl*** with CrkL , SLP-76 , and ***Nck*** in Fc gammaRI signaling in human macrophages .	parallel	0
1786	10204582	867;3937	Cbl;SLP-76	These results suggest a fundamental role for the tyrosine phosphorylation of Cbl , CrkL , SLP-76 , and Shc and the ***association*** of ***Cbl*** with CrkL , ***SLP-76*** , and Nck in Fc gammaRI signaling in human macrophages .	parallel	0
1787	10204582	867;1399	Cbl;CrkL	Experiments performed with PP1 , the specific Src kinase inhibitor , demonstrate the first evidence that Cbl and the ******Cbl-CrkL****** ***interaction*** are downstream targets for myeloid Src kinases required for the activation of myeloid NADPH oxidase activity .	parallel	1
1788	10204582	1399;867	CrkL;Cbl	***CrkL*** ***associated*** with tyrosine-phosphorylated ***Cbl*** and itself became tyrosine phosphorylated after Fc gammaRI cross-linking .	parallel	0
1789	10204582	3937;867	SLP-76;Cbl	***SLP-76*** , a recently cloned Grb2-associated protein , was strongly tyrosine phosphorylated after Fc gammaRI stimulation and was ***associated*** with both ***Cbl*** and Grb2 .	parallel	0
1790	10204582	3937;2885	SLP-76;Grb2	***SLP-76*** , a recently cloned Grb2-associated protein , was strongly tyrosine phosphorylated after Fc gammaRI stimulation and was ***associated*** with both Cbl and ***Grb2*** .	parallel	0
1791	10204802	5743;4316	Cox-2;matrilysin	To determine if there is a direct ***link*** between ***matrilysin*** and ***Cox-2*** , their expression was characterized in two mouse models of intestinal carcinogenesis and in human colorectal tumor samples .	parallel	0
1792	10204996	7201;7200	TRH-R;TRH	C335Stop is a constitutively active mutant of the ***TRH*** ***receptor*** ( ***TRH-R*** ) .	parallel	1
1793	10205054	4086;6774	Smad1;STAT3	Synergistic signaling in fetal brain by ******STAT3-Smad1****** ***complex*** bridged by p300 .	parallel	1
1794	10205054	2033;6774	p300;STAT3	The transcriptional coactivator ***p300*** ***interacts*** physically with ***STAT3*** at its amino terminus in a cytokine stimulation-independent manner , and with Smad1 at its carboxyl terminus in a cytokine stimulation-dependent manner .	parallel	1
1795	10205054	4086;6774	Smad1;STAT3	The ***formation*** of a complex between ***STAT3*** and ***Smad1*** , bridged by p300 , is involved in the cooperative signaling of LIF and BMP2 and the subsequent induction of astrocytes from neural progenitors .	parallel	0
1796	10205060	3308;3184	hsp70;AUF1	Induction of hsp70 by heat shock , down-regulation of the ubiquitin-proteasome network , or inactivation of ubiquitinating enzyme E1 all result in ***hsp70*** ***sequestration*** of ***AUF1*** in the perinucleus-nucleus , and all three processes block decay of AU-rich mRNAs and AUF1 protein .	negative	0
1797	10205143	3479;5972	insulin-like growth factor-1;renin	Overexpression of ***insulin-like growth factor-1*** ***attenuates*** the myocyte ***renin-angiotensin*** system in transgenic mice .	negative	0
1798	10205143	7157;5972	p53;renin	Moreover , activation of ***p53*** ***upregulates*** the cellular ***renin-angiotensin*** system ( RAS ) .	positive	1
1799	10205143	7157;4193	p53;Mdm2	The presence of ******Mdm2-p53****** ***complexes*** was also established .	parallel	1
1800	10205143	4193;7157	Mdm2;p53	Upregulation of IGF-1 in myocytes was associated with a protein-to-protein ***interaction*** between ***Mdm2*** and ***p53*** , which attenuated p53 transcriptional activity for bax , Aogen , and AT1 receptor .	parallel	1
1801	10205150	993;4609	cdc25A;c-myc	We conclude that ***cdc25A*** expression ***modulates*** the ability of ***c-myc*** to induce apoptosis in G1 .	target	0
1802	10205150	4609;993	c-myc;cdc25A	Therefore , the recent identification that ***cdc25A*** , a cell-cycle phosphatase involved in G1 progression , is transcriptionally ***activated*** by ***c-myc*** and regulates c-myc-induced apoptosis has suggested that cdc25A may be the principal mediator of c-myc in VSMCs .	positive	1
1803	10205150	4609;993	c-myc;cdc25A	Ectopic ***c-myc*** ***increased*** ***cdc25A*** expression , but cdc25A was still responsive to serum components , which indicated that c-myc alone is not the main determinant of cdc25A expression .	positive	0
1804	10205150	993;4609	cdc25A;c-myc	Ectopic ***cdc25A*** ***augmented*** the proproliferative and proapoptotic action of ***c-myc*** but did not increase cell proliferation or apoptosis in the absence of ectopic c-myc .	positive	0
1805	10205158	3336;3329	Hsp10;Hsp60	Presence of a pre-apoptotic ***complex*** of pro-caspase-3 , ***Hsp60*** and ***Hsp10*** in the mitochondrial fraction of jurkat cells .	parallel	1
1806	10205159	839;836	caspase-6;caspase-3	We demonstrate that the activation of ***caspase-3*** , in Jurkat cells stimulated to undergo apoptosis by a Fas-independent pathway , is ***catalyzed*** by ***caspase-6*** .	positive	1
1807	10205159	3329;836	Hsp60;caspase-3	Furthermore , an ***interaction*** between ***Hsp60*** and ***caspase-3*** could be demonstrated by co-immunoprecipitation experiments using HeLa as well as Jurkat cell extracts .	parallel	1
1808	10205165	1021;1029	cdk6;p16	The ***cdk6*** protein is found to ***suppress*** ***p16*** ( INK4a ) - mediated inhibition of spreading and is also shown to localize to the ruffling edge of spreading cells , indicating a function for cdk6 in controlling matrix-dependent cell spreading .	negative	1
1809	10205199	7032;7033	hTFF2;TFF3	In addition , endogenous concentrations of rat TFF2 and ***TFF3*** ( intestinal trefoil factor ) were increased in the active phase of colitis and were ***reduced*** to basal levels by ***hTFF2*** treatment .	negative	1
1810	10205202	3458;4843	IFN-gamma;iNOS	AIMS : To examine ***iNOS*** ***induction*** by ***IFN-gamma*** in vitro as a function of enterocyte differentiation .	target	1
1811	10205202	3458;4843	IFN-gamma;iNOS	RESULTS : ***iNOS*** mRNA ***induction*** by ***IFN-gamma*** occurred at two hours and was not blocked by cycloheximide , indicating that it is an immediate early response .	target	1
1812	10205242	56681;183	Sar1;angiotensin II	Specific [ 125I ] ******Sar1-angiotensin II****** ***binding*** was detected by receptor autoradiography .	parallel	1
1813	10205242	56681;183	Sar1;angiotensin II	The ***binding*** of [ 125I ] ******Sar1-angiotensin II****** was completely displaced by the AT1 antagonist losartan but not by the AT2 receptor ligand PD 123319 , confirming the expression of angiotensin II AT1 receptors in NCI-H295 cells .	parallel	1
1814	10205255	4683;4361	nbs1;Mre11	The mammalian ******Mre11-Rad50-nbs1****** protein ***complex*** : integration of functions in the cellular DNA-damage response .	parallel	1
1815	10205255	10111;4361	Rad50;Mre11	The mammalian ******Mre11-Rad50-nbs1****** protein ***complex*** : integration of functions in the cellular DNA-damage response .	parallel	1
1816	10205255	10111;4683	Rad50;nbs1	The mammalian ******Mre11-Rad50-nbs1****** protein ***complex*** : integration of functions in the cellular DNA-damage response .	parallel	1
1817	10205288	183;2353	angiotensin II;c-Fos	The data demonstrate that lovastatin can suppress PDGF - and ***angiotensin II-mediated*** ***induction*** of c-Jun and ***c-Fos*** protein in human SMC .	target	1
1818	10205288	183;3725	angiotensin II;c-Jun	The data demonstrate that lovastatin can suppress PDGF - and ***angiotensin II-mediated*** ***induction*** of ***c-Jun*** and c-Fos protein in human SMC .	target	1
1819	10205665	5925;1029	pRb;p16	INK4a , CDKN2 , or MTS1 , plays an important role in the control of the cell cycle progression , and retinoblastoma protein ( ***pRb*** ) is suggested to be involved in the transcriptional ***regulation*** of ***p16*** .	target	1
1820	10205665	5925;1029	pRb;p16	However , it is not fully understood how ***pRb*** ***regulates*** transcription of the ***p16*** gene .	target	1
1821	10205679	2230;2232	adrenodoxin;adrenodoxin reductase	The ***formation*** of individual complexes between the components of cholesterol side chain cleavage system-cytochrome P450scc , ***adrenodoxin*** ( Ad ) and ***adrenodoxin reductase*** ( AdR ) was kinetically characterized and their association and dissociation rate constants were measured by optical biosensor .	parallel	0
1822	10205679	2230;1583	adrenodoxin;P450scc	The ***formation*** of individual complexes between the components of cholesterol side chain cleavage system-cytochrome ***P450scc*** , ***adrenodoxin*** ( Ad ) and adrenodoxin reductase ( AdR ) was kinetically characterized and their association and dissociation rate constants were measured by optical biosensor .	parallel	0
1823	10205679	1583;2232	P450scc;adrenodoxin reductase	The ***formation*** of individual complexes between the components of cholesterol side chain cleavage system-cytochrome ***P450scc*** , adrenodoxin ( Ad ) and ***adrenodoxin reductase*** ( AdR ) was kinetically characterized and their association and dissociation rate constants were measured by optical biosensor .	parallel	0
1824	10206145	3553;3620	IL-1;IDO	This ***IL-1-mediated*** ***inhibition*** of IFN-gamma-induced ***IDO*** activity and toxoplasmostasis could be blocked by monomethyl L-arginine , an inhibitor of NO production .	negative	1
1825	10206147	3565;3458	IL-4;IFN-gamma	In addition , ***IL-4*** ***antagonized*** in part the bactericidal effect of TNF-alpha and ***IFN-gamma*** .	negative	1
1826	10206147	3565;7124	IL-4;TNF-alpha	In addition , ***IL-4*** ***antagonized*** in part the bactericidal effect of ***TNF-alpha*** and IFN-gamma .	negative	1
1827	10206151	983;9133	cdc2;cyclin B2	The Xenopus prophase-blocked oocyte contains a stockpile of ******cyclin B2-cdc2****** ***complexes*** that are maintained inactive by a double inhibitory phosphorylation on Thr-14 and Tyr-15 of cdc2 .	parallel	1
1828	10206185	1906;7412	Endothelin-1;vascular cell adhesion molecule-1	***Endothelin-1*** ***enhances*** ***vascular cell adhesion molecule-1*** expression in tumor necrosis factor alpha-stimulated vascular endothelial cells .	positive	0
1829	10206185	1906;7412	Endothelin-1;VCAM-1	***Endothelin-1*** ***enhanced*** the surface expression and mRNA accumulation of ***VCAM-1*** in cells treated with tumor necrosis factor alpha ( TNF-alpha ) .	positive	0
1830	10206233	7436;348	VLDL-R;apoE	The 5-repeat allele of a CGG repeat polymorphism in the 5 ' untranslated region of the very low-density lipoprotein receptor ( ***VLDL-R*** ) gene , a ***receptor*** for ***apoE*** , has been found to be associated with increased risk of AD in a Japanese population .	parallel	1
1831	10206287	5054;5328	PAI-1;uPA	Prognostic significance of urokinase ( ***uPA*** ) and its ***inhibitor*** ***PAI-1*** for survival in advanced ovarian carcinoma stage FIGO IIIc .	negative	1
1832	10206287	5054;5328	PAI-1;uPA	We evaluated the prognostic impact of the protease urokinase plasminogen activator ( ***uPA*** ) and its ***inhibitor*** ***PAI-1*** on overall survival in patients with advanced ovarian cancer stage FIGO IIIc in order to select patients at risk .	negative	1
1833	10206332	4233;3082	c-Met;HGF	Generally , mesenchymal cells such as fibroblasts produce HGF/SF but do not express ***c-Met*** , a ***receptor*** for ***HGF/SF*** , yet fibroblasts in dental papilla and cultured fibroblasts prepared from dental papilla did express c-Met , as determined by immunohistochemistry , in situ hybridization and reverse transcription-polymerase chain reaction .	parallel	1
1834	10206347	7040;2353	TGF-beta1;c-fos	In addition , by transient transfection analysis , ***TGF-beta1*** was shown to ***stimulate*** ***c-fos*** serum response element ( SRE ) - driven reporter gene activity in a dose - and time-dependent manner , suggesting that SRE is one of the nuclear targets of TGF-beta1 .	positive	0
1835	10206577	3565;3815	interleukin 4;c-kit	***interleukin 4*** up-regulates mast cell ICAM-1 and cell-bound IgE , but ***down-regulates*** ***c-kit*** .	negative	1
1836	10206577	3565;3383	interleukin 4;ICAM-1	***interleukin 4*** ***up-regulates*** mast cell ***ICAM-1*** and cell-bound IgE , but down-regulates c-kit .	positive	1
1837	10206955	945;5777	CD33;SHP-1	The myeloid-specific sialic acid-binding receptor , ***CD33*** , ***associates*** with the protein-tyrosine phosphatases , ***SHP-1*** and SHP-2 .	parallel	0
1838	10206955	945;5781	CD33;SHP-2	The myeloid-specific sialic acid-binding receptor , ***CD33*** , ***associates*** with the protein-tyrosine phosphatases , SHP-1 and ***SHP-2*** .	parallel	0
1839	10206955	945;5777	CD33;SHP-1	Phosphorylated ***CD33*** ***recruited*** both the protein-tyrosine phosphatases , ***SHP-1*** and SHP-2 .	target	0
1840	10206955	945;5781	CD33;SHP-2	Phosphorylated ***CD33*** ***recruited*** both the protein-tyrosine phosphatases , SHP-1 and ***SHP-2*** .	target	0
1841	10206959	7157;4312	p53;matrix metalloproteinase-1	***p53*** ***down-regulates*** human ***matrix metalloproteinase-1*** ( Collagenase-1 ) gene expression .	negative	1
1842	10206963	336;4018	apoA-II;lipoprotein	In conclusion , overexpression of human ***apoA-II*** in transgenic mice ***induced*** the proatherogenic ***lipoprotein*** profile of low plasma HDL and postprandial hypertriglyceridemia because of decreased VLDL catabolism by LPL .	target	1
1843	10206970	4018;4790	lipoprotein;NF-kappaB	Extensively oxidized low density ***lipoprotein*** ( ox-LDL ) , a modulator of atherogenesis , ***down-regulates*** the lipopolysaccharide ( LPS ) - induced activation of transcription factor ***NF-kappaB*** .	negative	1
1844	10206976	1978;1977	4E-BP1;eIF4E	In the present study , leucine stimulated phosphorylation of the eIF4E-binding protein , 4E-BP1 , in L6 myoblasts , resulting in dissociation of eIF4E from the inactive ******eIF4E.4E-BP1****** ***complex*** .	parallel	1
1845	10206993	3576;3577	IL-8;CXCR1	This study demonstrates that ***IL-8*** ***recognizes*** and activates ***CXCR1*** , CXCR2 , and the Duffy antigen by distinct mechanisms .	target	1
1846	10206993	3576;3579	IL-8;CXCR2	This study demonstrates that ***IL-8*** ***recognizes*** and activates CXCR1 , ***CXCR2*** , and the Duffy antigen by distinct mechanisms .	target	1
1847	10206997	5141;6714	pde46;SRC	It is suggested that ***pde46*** may be ***associated*** with ***SRC*** family tyrosyl kinases in intact cells and that the ensuing SH3 domain interaction with the LR2 region of pde46 alters the conformation of the PDE catalytic unit , as detected by altered rolipram inhibition .	parallel	0
1848	10206997	6714;5141	SRC;pde46	***Interaction*** between ***pde46*** and ***SRC*** family tyrosyl kinases highlights a potentially novel regulatory system and point of signaling system cross-talk .	parallel	1
1849	10206998	1080;360	cystic fibrosis transmembrane conductance regulator;aquaporin 3	The ***cystic fibrosis transmembrane conductance regulator*** ***activates*** ***aquaporin 3*** in airway epithelial cells .	positive	1
1850	10206998	1080;360	CFTR;aquaporin 3	Glycerol uptake and antisense studies suggest ***CFTR-dependent*** ***regulation*** of ***aquaporin 3*** ( AQP3 ) water channels in airway epithelial cells .	target	1
1851	10206998	1080;360	CFTR;AQP3	These findings indicate that ***CFTR*** is a ***regulator*** of ***AQP3*** in airway epithelial cells .	target	1
1852	10207005	3977;3572	LIFR;gp130	IL-6 ) , whereas CNTF and leukemia inhibitory factor ( LIF ) signal via a ***heterodimer*** of ***gp130*** and LIF receptor ( ***LIFR*** ) .	parallel	1
1853	10207005	3977;3572	LIFR;gp130	The resulting IL-6/CNTF chimera lost the capacity to signal via gp130 on cells without LIFR , but acquired the ability to signal via the ******gp130/LIFR****** ***heterodimer*** and STAT3 on responsive cells .	parallel	1
1854	10207023	7027;1874	DP1;E2F4	Consistent with previous data from human and mouse fibroblasts and T-lymphocytes , ***E2F4*** and ***DP1*** form the predominant E2F ***heterodimers*** both in G0 and G1 phases of the human B-lymphocyte cell cycle , whereas E2F1 and -3 are first detected in late G1 , and their expression levels increase towards S phase .	parallel	1
1855	10207024	155;5594	beta3AR;ERK1/2	***ERK1/2*** ***activation*** by the ***beta3AR*** was insensitive to the cAMP-dependent protein kinase inhibitor H-89 but was abolished by genistein and AG1478 .	positive	1
1856	10207032	3667;3643	IRS-1;insulin receptor	CSF-1-treated adipocytes expressing the CSF1R/IRA960 were impaired in their ability to phosphorylate ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) but not in their ability to phosphorylate IRS-2 .	parallel	1
1857	10207032	3643;8660	insulin receptor;IRS-2	These observations suggest that Tyr960 is important for ***interaction*** of the ***insulin receptor*** cytoplasmic domain with ***IRS-2*** , but it is not essential to the ability of the insulin receptor tyrosine kinase to use IRS-2 as a substrate .	parallel	1
1858	10207032	3643;8660	insulin receptor;IRS-2	These observations also suggest that in 3T3-L1 adipocytes , tyrosine ***phosphorylation*** of ***IRS-2*** by the ***insulin receptor*** tyrosine kinase is not sufficient for maximal stimulation of receptor-regulated glucose transport or glycogen synthesis .	target	1
1859	10207038	3091;405	HIF1alpha;ARNT	The ******HIF1alpha.ARNT****** ***complex*** binds to " hypoxia responsive enhancers " and activates the transcription of genes that regulate adaptation to low oxygen , e.g. erythropoietin ( Epo ) .	parallel	1
1860	10207047	6464;2885	Shc;Grb2	The interactions between Shc , Grb2 , and SHIP are therefore analogous to the ***interactions*** between ***Shc*** , ***Grb2*** , and SOS .	parallel	1
1861	10207051	4193;7161	MDM2;p73	***MDM2*** ***suppresses*** ***p73*** function without promoting p73 degradation .	negative	1
1862	10207051	4193;7161	MDM2;p73	***MDM2*** did not promote the degradation of p73 but instead ***disrupted*** the interaction of ***p73*** , but not of p53 , with p300/CBP by competing with p73 for binding to the p300/CBP N terminus .	negative	0
1863	10207051	7161;4193	p73;MDM2	Hence , ***MDM2*** is transcriptionally ***activated*** by ***p73*** and , in turn , negatively regulates the function of this activator through a mechanism distinct from that used for p53 inactivation .	positive	1
1864	10207052	2547;7520	Ku70;Ku80	The mutational change nonetheless abrogates the ******Ku70-Ku80****** ***interaction*** and DNA end-binding activity .	parallel	1
1865	10207054	3725;1386	c-Jun;ATF2	Similarly , overexpression of ***c-Jun*** in 293T human embryo kidney cells ***increased*** ***ATF2*** ubiquitination in vivo and reduced its half-life in a dose-dependent manner .	positive	0
1866	10207070	8850;3151	PCAF;HMG-17	Specific ***acetylation*** of chromosomal protein ***HMG-17*** by ***PCAF*** alters its interaction with nucleosomes .	target	1
1867	10207070	8850;3151	PCAF;HMG-17	Here we report that ***PCAF*** , a transcription coactivator with intrinsic histone acetyltransferase activity , specifically ***acetylates*** ***HMG-17*** but not HMG-14 .	target	1
1868	10207070	3150;8850	HMG-14;PCAF	Thus , the presence of ***HMG-14*** and HMG-17 ***affects*** the ability of ***PCAF*** to acetylate chromatin , while the acetylation of HMG-17 reduces its binding affinity to chromatin .	target	0
1869	10207070	3151;8850	HMG-17;PCAF	Thus , the presence of HMG-14 and ***HMG-17*** ***affects*** the ability of ***PCAF*** to acetylate chromatin , while the acetylation of HMG-17 reduces its binding affinity to chromatin .	target	0
1870	10207071	2033;1103	p300;ChAT	Overexpression of ***p300*** , a coactivator protein endowed with histone acetyltransferase activity , ***stimulated*** the ***ChAT*** promoter and had a synergistic effect on butyrate treatment .	positive	0
1871	10207072	4790;7157	NF-kappaB;p53	Moreover , endogenous , tumor necrosis factor alpha-activated ***NF-kappaB*** will ***inhibit*** endogenous wild-type ***p53*** transactivation .	negative	1
1872	10207072	2033;1387	p300;CBP	Both p53 and RelA ( p65 ) interact with the transcriptional coactivator proteins p300 and CREB-binding protein ( CBP ) , and we demonstrate that these results are consistent with competition for a limiting pool of ******p300/CBP****** ***complexes*** in vivo .	parallel	1
1873	10207073	1387;2623	CREB-Binding protein;GATA-1	We have previously shown that the transcriptional cofactor ***CREB-Binding protein*** ( CBP ) binds to the zinc finger domain of GATA-1 , markedly ***stimulates*** the transcriptional activity of ***GATA-1*** , and is required for erythroid differentiation .	positive	0
1874	10207073	1387;2623	CBP;GATA-1	Here we report that ***CBP*** , but not p/CAF , ***acetylates*** ***GATA-1*** at two highly conserved lysine-rich motifs present at the C-terminal tails of both zinc fingers .	target	1
1875	10207073	1387;2623	CBP;GATA-1	In addition , we show that ***CBP*** ***stimulates*** ***GATA-1*** acetylation in vivo in an E1A-sensitive manner , thus establishing a correlation between acetylation and transcriptional activity of GATA-1 .	positive	0
1876	10207076	4609;4149	c-Myc;Max protein	We show here that constructs containing the Tmp regulatory region fused to a reporter gene are activated by c-Myc through this CACGTG element and that the ******c-Myc-Max protein****** ***complex*** can bind to this element .	parallel	1
1877	10207078	5594;7153	ERK2;topoisomerase IIalpha	In this study , we demonstrated ***interactions*** between ***ERK2*** and ***topoisomerase IIalpha*** proteins by coimmunoprecipitation from mixtures of purified enzymes and from nuclear extracts .	parallel	1
1878	10207078	5594;7153	ERK;topoisomerase IIalpha	Our findings indicate that ***ERK*** ***regulates*** ***topoisomerase IIalpha*** in vitro and in vivo , suggesting a potential target for the MKK/ERK pathway in the modulation of chromatin reorganization events during mitosis and in other phases of the cell cycle .	target	1
1879	10207085	604;7704	BCL-6;PLZF	In addition , Kaiso homodimerized via its POZ domain but it did not heterodimerize with ***BCL-6*** , which ***heterodimerizes*** with ***PLZF*** .	parallel	1
1880	10207085	1500;10009	p120;Kaiso	The catenin ***p120*** ( ctn ) ***interacts*** with ***Kaiso*** , a novel BTB/POZ domain zinc finger transcription factor .	parallel	1
1881	10207085	1500;10009	p120;Kaiso	Monoclonal antibodies to Kaiso were generated and used to immunolocalize the protein and confirm the specificity of the ******p120-Kaiso****** ***interaction*** in mammalian cells .	parallel	1
1882	10207087	861;2113	AML1;ETS protein	Functional and physical ***interactions*** between ***AML1*** proteins and an ***ETS protein*** , MEF : implications for the pathogenesis of t ( 8 ; 21 ) - positive leukemias .	parallel	1
1883	10207087	865;861	CBFbeta;AML1	The AML1 and ETS families of transcription factors play critical roles in hematopoiesis ; ***AML1*** , and its non-DNA-binding ***heterodimer*** partner ***CBFbeta*** , are essential for the development of definitive hematopoiesis in mice , whereas the absence of certain ETS proteins creates specific defects in lymphopoiesis or myelopoiesis .	parallel	1
1884	10207087	2000;861	MEF;AML1	In this study , we demonstrate direct ***interactions*** between ***MEF*** and ***AML1*** proteins , including the AML1/ETO fusion protein , in t ( 8 ; 21 ) - positive acute myeloid leukemia ( AML ) cells .	parallel	1
1885	10207087	2000;3562	MEF;interleukin 3	***MEF*** and AML1B synergistically ***transactivated*** an ***interleukin 3*** promoter reporter gene construct , yet the activating activity of MEF was abolished when MEF was coexpressed with AML1/ETO .	positive	1
1886	10207089	7040;1021	TGF-beta;Cdk6	While ***TGF-beta*** treatment ***decreased*** the expression of ***Cdk6*** , this effect was counteracted by HGF , followed by partial restoration of cyclin D2-associated kinase activity .	negative	0
1887	10207089	3082;7040	HGF;TGF-beta	Notably , ***HGF*** failed to ***prevent*** ***TGF-beta*** induction of p15 and its association with Cdk6 .	negative	0
1888	10207089	7040;1030	TGF-beta;p15	Notably , HGF failed to prevent ***TGF-beta*** ***induction*** of ***p15*** and its association with Cdk6 .	target	1
1889	10207089	3082;7040	HGF;TGF-beta	However , HGF reversed the TGF-beta-mediated decrease in Cdk6-associated p27 and cyclin D2-associated Cdk6 , suggesting that ***HGF*** ***modifies*** the ***TGF-beta*** response at the level of G1 cyclin complex formation .	target	0
1890	10207094	1869;7157	E2F-1;p53	Upregulation of ***E2F-1*** in response to DNA damage seems to ***require*** the presence of wild-type ***p53*** , since we did not observe an increase in the level of E2F-1 protein in several cell lines which possess mutated p53 .	target	0
1891	10207094	4193;7157	Mdm2;p53	Previous experiments showed that p53 is upregulated after microinjection of an antibody which binds to a domain of Mdm2 that is required for the ***interaction*** of ***Mdm2*** with ***p53*** .	parallel	1
1892	10207094	1869;4193	E2F-1;Mdm2	Recently it has been shown that ***E2F-1*** ***binds*** and coprecipitates with the mouse double-minute chromosome 2 protein ( ***Mdm2*** ) .	parallel	1
1893	10207094	4193;7157	Mdm2;p53	It is known that interaction of Mdm2 with p53 through this domain is required for ***Mdm2-dependent*** ***degradation*** of ***p53*** .	negative	1
1894	10207094	4193;7157	Mdm2;p53	It is known that ***interaction*** of ***Mdm2*** with ***p53*** through this domain is required for Mdm2-dependent degradation of p53 .	parallel	1
1895	10207096	5159;6772	PDGFR;Stat1	Using purified recombinant STAT proteins produced in Escherichia coli , we found that ***Stat1*** could be ***activated*** by immunopurified ***PDGFR*** and showed no additional requirement for membrane - or cytosol-derived proteins .	positive	1
1896	10207096	5159;6772	PDGFR;Stat1	We conclude that the mechanisms of ***activation*** of ***Stat1*** and Stat3 by ***PDGFR*** are distinct .	positive	1
1897	10207096	5159;6774	PDGFR;Stat3	We conclude that the mechanisms of ***activation*** of Stat1 and ***Stat3*** by ***PDGFR*** are distinct .	positive	1
1898	10207097	3097;6925	MIBP1;SEF-2	***MIBP1*** ***interacts*** specifically with both the TC box in the SSTR-2 promoter and with the ***SEF-2*** initiator-binding protein to enhance transcription from the basal SSTR-2 promoter .	parallel	1
1899	10207102	5897;5896	RAG2;RAG1	These results suggest how the heptamer element , the recognition surface essential for DNA cleavage , is recognized by the RAG proteins and have implications for the stoichiometry and active site organization of the ******RAG1-RAG2-RSS****** ***complex*** .	parallel	1
1900	10207103	7409;6478	Vav;hSiah2	We report here the ***interaction*** between ***Vav*** and ***hSiah2*** , a mammalian homolog of Drosophila Seven in absentia ( Sina ) that has been implicated in R7 photoreceptor cell formation during Drosophila eye development via the proteasome degradation pathway .	parallel	1
1901	10207103	7409;6478	Vav;hSiah2	***Vav*** and ***hSiah2*** ***interact*** in vitro and in vivo and colocalize in the cytoplasm of hematopoietic cells .	parallel	1
1902	10207103	6478;5599	hSiah2;JNK	Overexpression of ***hSiah2*** also ***inhibits*** the onco-Vav-induced ***JNK*** activation .	negative	1
1903	10207105	3479;4609	IGF-I;c-myc	Both IL-4 and ***IGF-I*** were able to ***induce*** ***c-myc*** early response gene expression , and this expression was maximal in the presence of both factors .	target	1
1904	10207105	3565;4609	IL-4;c-myc	Both ***IL-4*** and IGF-I were able to ***induce*** ***c-myc*** early response gene expression , and this expression was maximal in the presence of both factors .	target	1
1905	10207105	3565;3479	IL-4;IGF-I	Together , our results suggest that ***IL-4*** ***synergizes*** with ***IGF-I*** for hematopoietic cell proliferation , likely through cross talk between SHC/Grb2/MAPK and STAT6 pathways and through c-myc gene up-regulation .	parallel	0
1906	10207105	2885;6464	Grb2;SHC	***Grb2*** ***association*** with ***SHC*** and mitogen-activated protein kinase ( MAPK ) activity was also enhanced in response to IGF-I stimulation .	parallel	0
1907	10207109	4215;595	MEKK3;cyclin D1	***MEKK3*** critically ***blocks*** mitogen-driven expression of ***cyclin D1*** , a cyclin which is essential for progression of fibroblasts through G1 .	negative	0
1908	10207115	1029;1026	p16;p21	In the parental cells , ***p16*** expression also ***augmented*** total cellular and Cdk2-bound ***p21*** .	positive	0
1909	10207115	1026;1017	p21;Cdk2	These findings indicate that ***p21-mediated*** ***inhibition*** of ***Cdk2*** contributes to the cell cycle arrest imposed by p16 and is a potential point of cooperation between the p16/pRB and p14 ( ARF ) / p53 tumor suppressor pathways .	negative	1
1910	10207115	1029;1029	p16;p14	These findings indicate that p21-mediated inhibition of Cdk2 contributes to the cell cycle arrest imposed by p16 and is a potential point of ***cooperation*** between the ***p16/pRB*** and ***p14*** ( ARF ) / p53 tumor suppressor pathways .	parallel	0
1911	10207115	1029;5925	p16;pRB	These findings indicate that p21-mediated inhibition of Cdk2 contributes to the cell cycle arrest imposed by p16 and is a potential point of ***cooperation*** between the ******p16/pRB****** and p14 ( ARF ) / p53 tumor suppressor pathways .	parallel	0
1912	10207115	5925;1029	pRB;p14	These findings indicate that p21-mediated inhibition of Cdk2 contributes to the cell cycle arrest imposed by p16 and is a potential point of ***cooperation*** between the ***p16/pRB*** and ***p14*** ( ARF ) / p53 tumor suppressor pathways .	parallel	0
1913	10207115	1029;1019	p16;cdk4	In these clones , ***binding*** of ***p16*** to ***cdk4*** and cdk6 abrogated binding of cyclin D1 , p27 ( KIP1 ) , and p21 ( WAF1/CIP1 ) .	parallel	1
1914	10207115	1029;1021	p16;cdk6	In these clones , ***binding*** of ***p16*** to cdk4 and ***cdk6*** abrogated binding of cyclin D1 , p27 ( KIP1 ) , and p21 ( WAF1/CIP1 ) .	parallel	1
1915	10207115	1026;595	p21;cyclin D1	In these clones , binding of p16 to cdk4 and cdk6 abrogated ***binding*** of ***cyclin D1*** , p27 ( KIP1 ) , and ***p21*** ( WAF1/CIP1 ) .	parallel	1
1916	10207115	1026;5715	p21;p27	In these clones , binding of p16 to cdk4 and cdk6 abrogated ***binding*** of cyclin D1 , ***p27*** ( KIP1 ) , and ***p21*** ( WAF1/CIP1 ) .	parallel	1
1917	10207115	5715;595	p27;cyclin D1	In these clones , binding of p16 to cdk4 and cdk6 abrogated ***binding*** of ***cyclin D1*** , ***p27*** ( KIP1 ) , and p21 ( WAF1/CIP1 ) .	parallel	1
1918	10207115	1029;595	p16;cyclin D1	In these clones , binding of ***p16*** to cdk4 and cdk6 ***abrogated*** binding of ***cyclin D1*** , p27 ( KIP1 ) , and p21 ( WAF1/CIP1 ) .	negative	0
1919	10207115	1029;1026	p16;p21	In these clones , binding of ***p16*** to cdk4 and cdk6 ***abrogated*** binding of cyclin D1 , p27 ( KIP1 ) , and ***p21*** ( WAF1/CIP1 ) .	negative	0
1920	10207115	1029;5715	p16;p27	In these clones , binding of ***p16*** to cdk4 and cdk6 ***abrogated*** binding of cyclin D1 , ***p27*** ( KIP1 ) , and p21 ( WAF1/CIP1 ) .	negative	0
1921	10207115	1017;1026	Cdk2;p21	Most cyclin ***E-Cdk2*** complexes ***associated*** with ***p21*** and became inactive , expression of cyclin A was curtailed , and DNA synthesis was strongly inhibited .	parallel	0
1922	10207144	4908;4914	NT-3;TrkA	Expression of Trk receptors in the developing mouse trigeminal ganglion : in vivo evidence for ***NT-3*** ***activation*** of ***TrkA*** and TrkB in addition to TrkC .	positive	1
1923	10207144	4908;4915	NT-3;TrkB	Expression of Trk receptors in the developing mouse trigeminal ganglion : in vivo evidence for ***NT-3*** ***activation*** of TrkA and ***TrkB*** in addition to TrkC .	positive	1
1924	10207166	998;3725	Cdc42;AP-1	Although both Cdc42 and Rho were involved in the shear stress-induced transcription factor AP-1 acting on the 12-O-tetradecanoyl-13-phorbol-acetate-responsive element ( TRE ) , only ***Cdc42*** was sufficient to ***activate*** ***AP-1/TRE*** .	positive	1
1925	10207167	941;942	CD80;CD86	Finally , we demonstrate that the defects in antigen priming are likely due to the lack of CD154 expression and insufficient costimulation of T cells by ******CD80/CD86****** ***interactions*** .	parallel	1
1926	10207506	2690;3952	Growth hormone binding protein;leptin	***Growth hormone binding protein*** ***correlates*** strongly with ***leptin*** and percentage body fat in GH-deficient adults , is increased by GH replacement but does not predict IGF-I response .	parallel	0
1927	10207507	5443;3479	adrenocorticotropin;IGF-I	Long-term administration of ***adrenocorticotropin*** ***modulates*** the expression of ***IGF-I*** and TGF-beta 1 mRNAs in the rat adrenal cortex .	target	0
1928	10207507	5443;7040	adrenocorticotropin;TGF-beta 1	Long-term administration of ***adrenocorticotropin*** ***modulates*** the expression of IGF-I and ***TGF-beta 1*** mRNAs in the rat adrenal cortex .	target	0
1929	10207507	5443;7040	ACTH;TGF-beta 1	***ACTH*** also significantly increased proliferating cell nuclear antigen mRNA level ( P < 0.01 ) , at 4 weeks of treatment , which correlated with IGF-I level ( P < 0.01 ) , but ***correlated*** negatively with ACTH-stimulated ***TGF-beta 1*** level ( P < 0.05 ) .	negative	0
1930	10207507	5443;5111	ACTH;proliferating cell nuclear antigen	***ACTH*** also significantly ***increased*** ***proliferating cell nuclear antigen*** mRNA level ( P < 0.01 ) , at 4 weeks of treatment , which correlated with IGF-I level ( P < 0.01 ) , but correlated negatively with ACTH-stimulated TGF-beta 1 level ( P < 0.05 ) .	positive	0
1931	10207622	5600;7422	SAPK2;vascular endothelial growth factor	In vascular endothelial cells , where the basal level of expression of Hsp27 is high , ***SAPK2*** ***mediates*** oxidative stress - and ***vascular endothelial growth factor*** ( VEGF ) - induced actin reorganization and VEGF-induced cell migration , suggesting a key role for this MAP kinase pathway in inflammation and angiogenic processes .	target	0
1932	10207720	3953;3952	LEPR;leptin	Genes that have been shown to have a regulatory function in the control of body fat utilization , eating behavior , and/or metabolic rate in rodent models of obesity include leptin ( LEP ) , ***leptin*** ***receptor*** ( ***LEPR*** ) , neuropeptide Y ( NPY ) , NPY Y1 receptor ( NPYY1 ) , glucagon-like peptide-1 ( GLP-1 ) , GLP-1 receptor ( GLP1R ) , and uncoupling protein 1 ( UCP1 ) .	parallel	1
1933	10207720	2740;2641	GLP1R;GLP-1	Genes that have been shown to have a regulatory function in the control of body fat utilization , eating behavior , and/or metabolic rate in rodent models of obesity include leptin ( LEP ) , leptin receptor ( LEPR ) , neuropeptide Y ( NPY ) , NPY Y1 receptor ( NPYY1 ) , glucagon-like peptide-1 ( GLP-1 ) , ***GLP-1*** ***receptor*** ( ***GLP1R*** ) , and uncoupling protein 1 ( UCP1 ) .	parallel	1
1934	10207913	2752;113451	glutamate decarboxylase;arginine decarboxylase	In contrast to S. typhimurium , E. coli and Shigella have acid resistance systems induced in complex media that include a glucose-repressed system protective at pH 2.5 without amino acid supplementation , a ***glutamate decarboxylase*** system that ***requires*** glutamate and an ***arginine decarboxylase*** system unique to E. coli .	target	0
1935	10207939	7040;3458	TGF beta;IFN gamma	***TGF beta*** , a known ***inhibitor*** of IL12 and ***IFN gamma*** production , is produced at higher levels by lung cells from those patients who undergo remission of their disease , suggesting that TGF gamma is important in downregulating granulomatous inflammation in sarcoidosis .	negative	1
1936	10208413	5781;6714	Shp-2;Src	The ***Shp-2*** tyrosine phosphatase ***activates*** the ***Src*** tyrosine kinase by a non-enzymatic mechanism .	positive	1
1937	10208413	6714;5781	Src;Shp-2	Previously , we demonstrated that the ***Src*** tyrosine kinase ***interacts*** with the ***Shp-2*** tyrosine phosphatase .	parallel	1
1938	10208413	5781;6714	Shp-2;Src	Our findings reveal that the ***Shp-2*** tyrosine phosphatase can ***regulate*** the ***Src*** tyrosine kinase by a non-enzymatic mechanism .	target	1
1939	10208414	4193;7157	MDM2;p53	p53 mediated death of cells overexpressing MDM2 by an inhibitor of ***MDM2*** ***interaction*** with ***p53*** .	parallel	1
1940	10208414	4193;7027	MDM2;DP1	There is also a decrease in E2F activity , that might have been due to the known physical and functional ***interactions*** of ***MDM2*** with ***E2F1/DP1*** .	parallel	1
1941	10208414	4193;1869	MDM2;E2F1	There is also a decrease in E2F activity , that might have been due to the known physical and functional ***interactions*** of ***MDM2*** with ***E2F1/DP1*** .	parallel	1
1942	10208414	7157;4193	p53;MDM2	These results show that a peptide homologue of p53 is sufficient to induce p53 dependent cell death in cells overexpressing MDM2 , and support the notion that disruption of the ******p53-MDM2****** ***complex*** is a target for the development of therapeutic agents .	parallel	1
1943	10208418	5900;5898	RalGDS;Ral	The small GTP-binding protein ***Ral*** is ***activated*** by ***RalGDS*** , one of the effector molecules for Ras .	positive	1
1944	10208419	9564;1398	p130Cas;Crk	Of these , paxillin and ***p130Cas*** ***interacted*** with ***Crk*** proteins in GDNF-treated neuroblastoma cells .	parallel	1
1945	10208419	5829;1398	paxillin;Crk	Of these , ***paxillin*** and p130Cas ***interacted*** with ***Crk*** proteins in GDNF-treated neuroblastoma cells .	parallel	1
1946	10208422	1874;1869	E2F-4;E2F-1	Our findings indicate that ***E2F-4*** is a critical ***regulator*** of ***E2F-1*** , which offer an excellent paradigm for understanding functional diversity within the E2F family .	target	1
1947	10208422	5934;1874	p130;E2F-4	Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and ******E2F-4/p130****** ***complexes*** .	parallel	1
1948	10208422	5925;1874	pRB;E2F-4	Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of ******E2F-4/pRB****** and E2F-4/p130 ***complexes*** .	parallel	1
1949	10208422	3439;1869	IFN-alpha;E2F-1	In this study , we investigated the mechanisms whereby ***IFN-alpha*** ***suppresses*** transcription of the ***E2F-1*** gene .	negative	1
1950	10208422	3439;1869	IFN-alpha;E2F-1	***IFN-alpha*** markedly ***reduced*** ***E2F-1*** promoter activity , but introduction of non-binding mutation at the E2F sites completely abrogated the inhibition .	negative	1
1951	10208422	1874;5934	E2F-4;p130	IFN-alpha induced upregulation of E2F-4 along with dephosphorylation of pRB and p130 , which resulted in the formation of E2F-4/pRB and ******E2F-4/p130****** ***complexes*** on the E2F-1 promoter .	parallel	1
1952	10208422	1874;5925	E2F-4;pRB	IFN-alpha induced upregulation of E2F-4 along with dephosphorylation of pRB and p130 , which resulted in the formation of ******E2F-4/pRB****** and E2F-4/p130 ***complexes*** on the E2F-1 promoter .	parallel	1
1953	10208422	3439;1874	IFN-alpha;E2F-4	***IFN-alpha*** ***induced*** upregulation of ***E2F-4*** along with dephosphorylation of pRB and p130 , which resulted in the formation of E2F-4/pRB and E2F-4/p130 complexes on the E2F-1 promoter .	target	1
1954	10208424	3976;983	CDF;cdc2	In the present study , we have analysed the effect of the SV40 large T oncoprotein ( SV-LT ) on the function of a different cell cycle-regulated transcriptional repressor , ***CDF*** , which is the principal ***regulator*** of the cdc25C , cyclin A and ***cdc2*** genes .	target	1
1955	10208424	3976;995	CDF;cdc25C	In the present study , we have analysed the effect of the SV40 large T oncoprotein ( SV-LT ) on the function of a different cell cycle-regulated transcriptional repressor , ***CDF*** , which is the principal ***regulator*** of the ***cdc25C*** , cyclin A and cdc2 genes .	target	1
1956	10208426	7040;1026	TGFbeta;p21	Our previous data demonstrated that Ras activation was necessary and sufficient for transforming growth factor-beta ( TGFbeta ) - mediated Erk1 activation , and was required for ***TGFbeta*** ***up-regulation*** of the Cdk inhibitors ( CKI 's ) p27 ( Kip1 ) and ***p21*** ( Cip1 ) ( KM Mulder and SL Morris , J.	positive	1
1957	10208426	7040;4086	TGFbeta;Smad1	We demonstrate that both ***TGFbeta*** and bone morphogenetic protein ( BMP ) can ***induce*** endogenous ***Smad1*** phosphorylation in intestinal epithelial cells ( IECs ) .	target	1
1958	10208427	2885;6654	Grb2;Sos1	However , no significant differences were detected in vivo between Isf I - and Isf II-transfected clones regarding the amount , stability and subcellular localization of ******Sos1-Grb2****** ***complex*** , or the level of hSos1 phosphorylation upon cellular stimulation .	parallel	1
1959	10208430	5884;7157	hRAD17;p53	***hRAD17*** , a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene , ***stimulates*** ***p53*** accumulation .	positive	0
1960	10208431	862;861	ETO;AML1	The ***AMLI/ETO*** fusion protein has been shown to function mainly as a transcriptional repressor of AML1 target genes and to ***block*** ***AML1*** function in vitro and in vivo .	negative	0
1961	10208431	862;861	ETO;AML1	The ***AMLI/ETO*** fusion protein has been shown to function mainly as a transcriptional ***repressor*** of ***AML1*** target genes and to block AML1 function in vitro and in vivo .	negative	1
1962	10208431	861;596	AML1;BCL-2	However , ***AML1/ETO*** can also ***activate*** the ***BCL-2*** promoter and cause enhanced hematopoietic progenitor self-renewal in vitro , suggesting gain-of-functions unique to the fusion protein .	positive	1
1963	10208431	862;596	ETO;BCL-2	However , ***AML1/ETO*** can also ***activate*** the ***BCL-2*** promoter and cause enhanced hematopoietic progenitor self-renewal in vitro , suggesting gain-of-functions unique to the fusion protein .	positive	1
1964	10208431	861;3725	AML1;c-Jun	Expression of ***AML1/ETO*** ***increased*** the level of ***c-Jun-P*** ( ser63 ) , and activated AP-1 dependent transcription , which was inhibited by expression of a dominant-negative c-Jun protein .	positive	0
1965	10208431	862;3725	ETO;c-Jun	Expression of ***AML1/ETO*** ***increased*** the level of ***c-Jun-P*** ( ser63 ) , and activated AP-1 dependent transcription , which was inhibited by expression of a dominant-negative c-Jun protein .	positive	0
1966	10208433	4193;7157	Mdm2;p53	However , the level of active Mdm2 must be controlled carefully : overexpression of ***Mdm2*** ***inhibits*** UV induced ***p53*** stabilization .	negative	1
1967	10208434	8061;2353	Fra-1;c-fos	***Fra-1*** containing AP-1 complexes ***repress*** the ***c-fos*** and possibly other immediate early genes thereby preventing the induction of certain delayed early genes such as the T1 gene in response to mitogenic stimulation .	negative	1
1968	10208434	3727;8061	JunD;Fra1	We show that AP-1 , which is abundant in these cells throughout the whole cell cycle , consists predominantly of Fra-1/c-Jun and ******Fra1/JunD****** ***heterodimers*** .	parallel	1
1969	10208434	8061;3725	Fra1;c-Jun	We provide evidence that ******Fra1/c-Jun****** ***heterodimers*** are responsible for the repression of c-fos gene induction following serum stimulation .	parallel	1
1970	10208467	4323;4313	membrane type 1 matrix metalloproteinase;matrix metalloproteinase-2	***membrane type 1 matrix metalloproteinase*** ***activates*** the latent form of ***matrix metalloproteinase-2*** .	positive	1
1971	10208489	3949;4018	LDLR;lipoprotein	FH is caused by mutations in the low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) gene and is characterized by raised plasma LDL-cholesterol , tendon xanthomas , and premature coronary heart disease .	parallel	1
1972	10208489	3949;4018	LDLR;lipoprotein	The fine mapping of LDLR gene close to several highly informative microsatellite markers provide fine mapping details of the LDLR region and additional tools for studies of ***association*** between plasma ***lipoprotein*** levels and ***LDLR*** gene .	parallel	0
1973	10208590	1499;5663	armadillo;PS1	We also found another ***armadillo-protein*** , p0071 , ***interacted*** with ***PS1*** .	parallel	1
1974	10208747	4660;207	myosin phosphatase regulatory subunit;Rac	The Caenorhabditis elegans mel-11 ***myosin phosphatase regulatory subunit*** affects tissue contraction in the somatic gonad and the embryonic epidermis and genetically ***interacts*** with the ***Rac*** signaling pathway .	parallel	1
1975	10208842	3659;3458	IRF-1;IFN-gamma	Taken together , ***IRF-1*** ***mediates*** ***IFN-gamma*** signaling into primary hepatocytes for cell cycle arrest via p53 expression and for apoptosis .	target	0
1976	10208859	1457;373156	CKII;GST	The ***GST-NS5A*** was also ***phosphorylated*** in vitro by the purified casein kinase II ( ***CKII*** ) , a member of the CMCG kinase family .	target	1
1977	10208865	3549;8600	Ihh;OPGL	Our data support the hypothesis that ***Ihh*** stimulated the late-phase chondrogenic differentiation in differentiated ATDC5 cells and ***upregulated*** the gene expression of ***OPGL*** in these cells .	positive	1
1978	10208873	2321;7422	FLT-1;VEGF	We also investigated the expression of vascular endothelial growth factor ( ***VEGF*** ) , placenta growth factor ( PlGF ) and their ***receptor*** ***FLT-1*** .	parallel	1
1979	10208874	3952;5617	leptin;prolactin	The melanocortin 4 receptor mediates ***leptin*** ***stimulation*** of luteinizing hormone and ***prolactin*** surges in steroid-primed ovariectomized rats .	positive	0
1980	10208874	3952;5617	leptin;PRL	These results suggest that the MC4 receptor may be the pivotal subtype of MC receptors mediating the ***leptin*** ***stimulation*** of LH and ***PRL*** surges .	positive	0
1981	10208934	6285;920	Nef;CD4	Human immunodeficiency virus type 1 ( HIV-1 ) ***Nef*** ***down-regulates*** ***CD4*** by triggering rapid endocytosis of cell surface CD4 .	negative	1
1982	10208934	6285;920	Nef;CD4	To better understand how ***Nef*** ***induces*** ***CD4*** down-regulation , we generated a series of Nef mutants with small in-frame deletions in the coding region .	target	1
1983	10208970	183;1906	Angiotensin II;endothelin-1	***Angiotensin II*** ***interacts*** with prostaglandin F2alpha and ***endothelin-1*** as a local luteolytic factor in the bovine corpus luteum in vitro .	parallel	1
1984	10209021	8480;4928	RAE1;NUP98	Both effects are abrogated either by the introduction of point mutations in the GLEBS-like motif or by overexpression of RAE1 , indicating a direct role for RAE1 and the ******NUP98-RAE1****** ***interaction*** in mRNA export .	parallel	1
1985	10209022	7514;10073	CRM1;snurportin 1	However , the ***interaction*** of ***CRM1*** with ***snurportin 1*** differs from that with previously characterized NESs .	parallel	1
1986	10209022	7514;10073	CRM1;snurportin 1	First , ***CRM1*** ***binds*** ***snurportin 1*** 50-fold stronger than the Rev protein and 5,000-fold stronger than the minimum Rev activation domain .	parallel	1
1987	10209033	6347;6348	MCP-1;MIP-1alpha	***Binding*** of labeled ***MCP-1*** and ***MIP-1alpha*** could be inhibited by unlabeled homologous but not heterologous chemokine , and was independent of the presence of heparan sulfate , laminin , or collagen in the subendothelial matrix .	parallel	1
1988	10209040	25;6777	BCR/ABL;STAT5	We show here that ***BCR/ABL*** ***induces*** phosphorylation and activation of ***STAT5*** by a mechanism that requires the BCR/ABL Src homology ( SH ) 2 domain and the proline-rich binding site of the SH3 domain .	target	1
1989	10209040	25;6777	BCR/ABL;STAT5	However , STAT5B-DAM did not rescue the growth factor-independent colony formation of kinase-deficient K1172R ***BCR/ABL*** or the triple mutant Y177F + R522L + Y793F BCR/ABL , both of which also fail to ***activate*** ***STAT5*** .	positive	1
1990	10209040	25;6777	BCR/ABL;STAT5	Together , these data demonstrate that ***STAT5*** ***activation*** by ***BCR/ABL*** is dependent on signaling from more than one domain and document the important role of STAT5-regulated pathways in BCR/ABL leukemogenesis .	positive	1
1991	10209041	10750;3937	Grb2-related adaptor protein;SLP-76	GrpL , a ***Grb2-related adaptor protein*** , ***interacts*** with ***SLP-76*** to regulate nuclear factor of activated T cell activation .	parallel	1
1992	10209041	3937;7409	SLP-76;Vav	SH2 domain-containing protein 76 ( ***SLP-76*** ) ***interacts*** with the guanine nucleotide exchange factor ***Vav*** to activate the nuclear factor of activated cells ( NF-AT ) , and its expression is required for normal T cell development .	parallel	1
1993	10209041	2885;6654	Grb2;Sos1	In contrast , ***Grb2*** can be ***coimmunoprecipitated*** with ***Sos1*** and Sos2 but not with SLP-76 .	parallel	1
1994	10209072	1392;3552	CRF;IL-1alpha	The different ***regulation*** of ***IL-1alpha*** and IL-1beta pro-inflammatory activities by ***CRF*** may attribute special precision and specificity to the neuroendocrine-immune control of inflammatory processes .	target	1
1995	10209072	1392;3553	CRF;IL-1beta	The different ***regulation*** of IL-1alpha and ***IL-1beta*** pro-inflammatory activities by ***CRF*** may attribute special precision and specificity to the neuroendocrine-immune control of inflammatory processes .	target	1
1996	10209101	11215;5501	AKAP220;PP1c	Here , we demonstrate that the PKA-anchoring protein , ***AKAP220*** , ***binds*** ***PP1c*** with a dissociation constant ( KD ) of 12.1 + / - 4 nM in vitro .	parallel	1
1997	10209103	546;5888	Rad54;Rad51	Mouse ***Rad54*** ***affects*** DNA conformation and DNA-damage-induced ***Rad51*** foci formation .	target	0
1998	10209117	998;57126	Cdc42;cell-surface receptor	Inducible ***recruitment*** of ***Cdc42*** or WASP to a ***cell-surface receptor*** triggers actin polymerization and filopodium formation .	target	0
1999	10209123	8615;2804	p115;giantin	In this process , ***p115*** , another coiled-coil protein , is though to ***bind*** to ***giantin*** on vesicles and to GM130 on cisternae , thus acting as a tether holding the two together [ 12 ] [ 13 ] .	parallel	1
2000	10209123	8615;2801	p115;GM130	In this process , ***p115*** , another coiled-coil protein , is though to ***bind*** to giantin on vesicles and to ***GM130*** on cisternae , thus acting as a tether holding the two together [ 12 ] [ 13 ] .	parallel	1
2001	10209263	10413;2222	yAP-1;ERG9	Additionally , the heme activator protein transcription factors HAP1 and HAP2/3/4 , the yeast activator protein transcription factor ***yAP-1*** , and the phospholipid transcription factor complex INO2/4 ***regulate*** ***ERG9*** expression .	target	1
2002	10209275	5502;5327	inhibitor-1;tPA	Plasminogen activator ***inhibitor-1*** ( PAI-1 ) rapidly ***inactivates*** tissue plasminogen activator ( ***tPA*** ) .	negative	1
2003	10209275	5327;5054	tPA;PAI-1	We propose that the antibodies which convert PAI-1 into a substrate for tPA do this by means of preventing the conversion of the initial ******PAI-1/tPA****** ***complex*** into the final complex by sterical intervention .	parallel	1
2004	10209275	5327;5054	tPA;PAI-1	Moreover , the localisation of the binding epitopes on free PAI-1 , as well as on the ******PAI-1/tPA****** ***complex*** , suggests that tPA in the final complex can not be located near helices E and F , as has previously been proposed .	parallel	1
2005	10209302	7124;3667	TNF-alpha;IRS-1	These results suggest that ***TNF-alpha*** ***inhibits*** insulin-stimulated activation of both the tyrosine ***kinase-IRS-1-PI3K-PKCzeta*** pathway and DG-PKC pathway .	negative	1
2006	10209302	7124;5294	TNF-alpha;PI3K	These results suggest that ***TNF-alpha*** ***inhibits*** insulin-stimulated activation of both the tyrosine ***kinase-IRS-1-PI3K-PKCzeta*** pathway and DG-PKC pathway .	negative	1
2007	10209302	7124;5590	TNF-alpha;PKCzeta	These results suggest that ***TNF-alpha*** ***inhibits*** insulin-stimulated activation of both the tyrosine ***kinase-IRS-1-PI3K-PKCzeta*** pathway and DG-PKC pathway .	negative	1
2008	10209447	596;4609	Bcl-2;c-myc	There was no evidence to suggest that ***c-myc*** was ***modulated*** by upregulation of ***Bcl-2*** or p53 inactivation/mutation .	target	0
2009	10209503	7124;7132	TNF-alpha;TNF-RI	***Binding*** of tumour necrosis factor-alpha ( ***TNF-alpha*** ) to ***TNF-RI*** induces caspase ( s ) - dependent apoptosis in human cholangiocarcinoma cell lines .	parallel	1
2010	10209503	7132;7124	TNF-RI;TNF-alpha	These results indicate that the ***interaction*** between ***TNF-alpha*** and ***TNF-RI*** alone generated a sufficient signal to activate a caspase II subfamily-dependent apoptosis in human cholangiocarcinoma cell lines .	parallel	1
2011	10209506	3458;4261	interferon-gamma;CIITA	Here we report that both HLA-DMB mRNA and the protein are expressed in thyrocytes and that ***CIITA*** expression is ***enhanced*** by ***interferon-gamma*** ( IFN-gamma ) treatment and occurs before DMB , Ii and DRA up-regulation , suggesting CIITA expression is a requirement for antigen processing in thyrocytes .	positive	0
2012	10209943	1543;1571	CYP1A1;CYP2E1	Several studies have indicated an ***association*** between variant alleles of the human ***CYP1A1*** , ***CYP2E1*** and GSTM1 genes and lung cancer .	parallel	0
2013	10209959	3817;5502	hK2;inhibitor-1	We show here that ***hK2*** rapidly forms a ***complex*** with plasminogen activator ***inhibitor-1*** ( PAI-1 ) , the primary inhibitor of uPA in tissues .	parallel	1
2014	10209959	3817;5054	hK2;PAI-1	In addition , hK2 inactivated 6 to 7 mol of PAI-1 by cleavage at Arg346-Met347 for every mole of ******hK2-PAI-1****** ***complex*** formed .	parallel	1
2015	10209959	5054;3817	PAI-1;hK2	***PAI-1*** ***inhibited*** ***hK2*** comparably with protein C inhibitor ( PCI ) and at least 20 times more rapidly than alpha1-anti-chymotrypsin ( ACT ) .	negative	1
2016	10209959	3817;5054	hK2;PAI-1	During complex formation , ***hK2*** ***inactivated*** ***PAI-1*** but did not inactivate ACT or PCI .	negative	1
2017	10210201	6714;2934	c-Src;gelsolin	It interacts with phospholipids and we previously showed that phosphatidylinositol 4,5-bisphosphate promotes ***phosphorylation*** of ***gelsolin*** by the tyrosine kinase ***c-Src*** .	target	1
2018	10210201	6714;2934	c-Src;gelsolin	***gelsolin*** ***phosphorylation*** by ***c-Src*** in the presence of lysophosphatidic acid also revealed Tyr438 as the most prominent site .	target	1
2019	10210266	7124;4790	TNF-alpha;NF-kappaB	In the present study , ***NF-kappaB*** was ***activated*** by ***TNF-alpha*** in rat aortic smooth muscle cells as demonstrated by electrophoretic mobility shift assay .	positive	1
2020	10210266	831;4790	calpain inhibitor;NF-kappaB	The activity of NF-kappaB induced by TNF-alpha was blocked by ***calpain inhibitor*** I , a potent ***NF-kappaB*** ***inhibitor*** .	negative	1
2021	10210266	831;4790	calpain inhibitor;NF-kappaB	The activity of ***NF-kappaB*** induced by TNF-alpha was ***blocked*** by ***calpain inhibitor*** I , a potent NF-kappaB inhibitor .	negative	0
2022	10210266	831;4790	calpain inhibitor;NF-kappaB	However , the activation of NF-kappaB was not related to the expression of COX-2 induced by TNF-alpha since ***calpain inhibitor*** I ***blocked*** the activation of ***NF-kappaB*** but not the expression of COX-2 mRNA or protein .	negative	0
2023	10210318	7040;5925	TGF-beta1;pRb	Using anti-retinoblastoma protein ( pRb ) and anti-specific phosphorylated-pRb antibodies , we demonstrated that ***TGF-beta1*** greatly ***inhibited*** ***pRb*** phosphorylation at serine 795 in MV4-11 and Mo7e cells .	negative	1
2024	10210323	3565;3815	IL-4;c-kit	***IL-4*** dose-dependently ***enhanced*** the expression of ***c-kit*** and high-affinity receptor for IgE ( Fc ( epsilon ) RI ) on the cell surface of SCF-cultured BM cells .	positive	0
2025	10210635	7965;7124	p38;TNF-alpha	***p38*** MAPK inhibition ***decreases*** ***TNF-alpha*** production and enhances postischemic human myocardial function .	positive	0
2026	10210635	7965;7124	p38;TNF-alpha	RESULTS : I/R increased human myocardial TNF-alpha levels from 26.9 + / - 9.3 to 83.9 + / - 19.2 pg/g wet tissue ( P < 0.05 perfusion vs I/R ; ANOVA Bonferroni/Dunn ) , while ***p38*** MAPK inhibition ***decreased*** post-I/R myocardial ***TNF-alpha*** levels to 32.3 + / - 8.0 pg/g wet tissue ( P > 0.05 p38 MAPK inhibition vs I/R ) .	positive	0
2027	10210635	7965;7124	p38;TNF-alpha	CONCLUSIONS : ( 1 ) The human heart produces TNF-alpha after I/R , ( 2 ) ***p38*** MAPK ***mediates*** myocardial I/R-induced ***TNF-alpha*** production , ( 3 ) p38 MAPK inhibition limits functional impairment after I/R , and ( 4 ) inhibition of ischemia-induced TNF-alpha production may represent a potent therapeutic strategy for improving myocardial function after angioplasty , coronary bypass , or heart transplantation .	target	0
2028	10210639	3667;3643	IRS-1;insulin receptor	Insulin regulates hepatocellular metabolism and growth following insulin receptor ( IR ) autophosphorylation and activation of the intracellular adapter protein , ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) .	parallel	1
2029	10210643	7124;4792	TNF-alpha;IkappaB-alpha	RESULTS : ***TNF-alpha*** ***induced*** ***IkappaB-alpha*** phosphorylation and degradation , which was inhibited by NaSal in both cell lines .	target	1
2030	10210772	3572;3569	gp130;IL-6	Soluble ***gp130*** had already been shown to ***inhibit*** ***IL-6*** signaling by inactivating the IL-6/IL -6 R complex .	negative	1
2031	10210774	3557;3553	IL-1Ra;IL-1beta	Intra-hypothalamic infusion of IL-1-receptor antagonist ***IL-1Ra*** ( 2 mug/rat ) ***prevented*** this effect of ***IL-1beta*** , but not that of IL-6 , suggesting an IL-1beta-independent mechanism for hypothalamic 5-HT release by this latter cytokine .	negative	0
2032	10210778	3574;3106	IL-7;MHC class I molecule	In AML and ALL , ***IL-7*** ***increased*** ***MHC class I molecule*** expression , while class II molecules were weakly modified .	positive	0
2033	10211111	356;355	FasL;Fas	***Fas*** ***ligand*** ( ***FasL*** ) kills sensitive Fas receptor ( FasR ) - bearing cells by inducing apoptosis .	parallel	1
2034	10211118	8731;3082	Met;HGF	***Met*** protein encoded by Met oncogene is the high affinity ***receptor*** for hepatocyte growth factor ( ***HGF*** ) / scatter factor ( SF ) .	parallel	1
2035	10211120	6382;2247	Syndecan-1;bFGF	***Syndecan-1*** ***binds*** basic fibroblast growth factor ( ***bFGF*** ) , modulates neovascularization , plays a role in epithelial differentiation and is up-regulated by WT1 .	parallel	1
2036	10211121	2321;7422	Flt-1;vascular endothelial growth factor	The immunolocalization and gene expression of ***vascular endothelial growth factor*** ( VEGF ) and its cognate tyrosine kinase ***receptors*** , ***Flt-1*** and KDR , has been studied in ocular melanomas and retinoblastomas using in situ hybridization and immunohistochemistry .	parallel	1
2037	10211121	3791;7422	KDR;vascular endothelial growth factor	The immunolocalization and gene expression of ***vascular endothelial growth factor*** ( VEGF ) and its cognate tyrosine kinase ***receptors*** , Flt-1 and ***KDR*** , has been studied in ocular melanomas and retinoblastomas using in situ hybridization and immunohistochemistry .	parallel	1
2038	10211790	3565;3558	IL-4;IL-2	By contrast , ***IL-4*** ***reduced*** the ***IL-2*** , IL-12 , and IFN-alpha-induced ADCC .	negative	1
2039	10211878	1604;976	CD55;CD97	Expression of the activation antigen ***CD97*** and its ***ligand*** ***CD55*** in rheumatoid synovial tissue .	parallel	1
2040	10211878	1604;976	CD55;CD97	Recently , it was found that ***CD55*** is a specific cellular ***ligand*** for the 7-span transmembrane receptor ***CD97*** .	parallel	1
2041	10211885	3586;5321	IL-10;cPLA2	IL-4 , IL-10 , and IL-13 reduced the TNFalpha-induced COX-2 level , and IL-4 and ***IL-10*** ***reduced*** the ***cPLA2*** level .	negative	1
2042	10211885	3565;5321	IL-4;cPLA2	IL-4 , IL-10 , and IL-13 reduced the TNFalpha-induced COX-2 level , and ***IL-4*** and IL-10 ***reduced*** the ***cPLA2*** level .	negative	1
2043	10211885	3586;5743	IL-10;COX-2	IL-4 , ***IL-10*** , and IL-13 ***reduced*** the TNFalpha-induced ***COX-2*** level , and IL-4 and IL-10 reduced the cPLA2 level .	negative	1
2044	10211885	3596;5743	IL-13;COX-2	IL-4 , IL-10 , and ***IL-13*** ***reduced*** the TNFalpha-induced ***COX-2*** level , and IL-4 and IL-10 reduced the cPLA2 level .	negative	1
2045	10211885	3565;5743	IL-4;COX-2	***IL-4*** , IL-10 , and IL-13 ***reduced*** the TNFalpha-induced ***COX-2*** level , and IL-4 and IL-10 reduced the cPLA2 level .	negative	1
2046	10211885	7124;4790	TNFalpha;NF-kappaB	IL-4 had no effect on ***TNFalpha*** ***up-regulation*** of ***NF-kappaB*** , and a slight decrease was noted with IL-10 and IL-13 at the highest concentration used ( 5 ng/ml ) .	positive	1
2047	10211966	4214;3725	MEKK1;AP-1	IE1-driven activation of ***AP-1*** was ***increased*** dramatically by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 ( ***MEKK1*** ) .	positive	0
2048	10211994	3791;7422	KDR;Vascular endothelial growth factor	***Vascular endothelial growth factor*** and its ***receptor*** , ***KDR*** , in human brain tissue after ischemic stroke .	parallel	1
2049	10211995	3082;3791	HGF;flk-1	This effect would be enhanced by an increased responsiveness of endothelial cells toward VEGF , resulting from the ***HGF/SF-induced*** ***up-regulation*** of ***flk-1*** on these cells .	positive	1
2050	10211995	3082;5502	Hepatocyte growth factor;inhibitor-1	***Hepatocyte growth factor*** ***increases*** expression of vascular endothelial growth factor and plasminogen activator ***inhibitor-1*** in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells .	positive	0
2051	10211995	3082;7422	Hepatocyte growth factor;vascular endothelial growth factor	***Hepatocyte growth factor*** ***increases*** expression of ***vascular endothelial growth factor*** and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells .	positive	0
2052	10211995	3082;3791	Hepatocyte growth factor;flk-1	***Hepatocyte growth factor*** ***increases*** expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor ***flk-1*** in human endothelial cells .	positive	0
2053	10211995	3082;3791	HGF;flk-1	Furthermore , we demonstrate that ***HGF/SF*** ***increases*** the expression of the VEGF receptor ***flk-1*** in human endothelial cells and that , in an angiogenesis co-culture assay of endothelial cells and keratinocytes , HGF/SF increases endothelial cell tube formation significantly .	positive	0
2054	10212141	6294;3178	HAP;hnRNP A1	In in vitro pull-down assays , ***HAP*** ***interacts*** with ***hnRNP A1*** , through its S/K-R/E-rich region , and with several other hnRNPs .	parallel	1
2055	10212189	5594;7157	p38;p53	***p38*** kinase ***mediates*** UV-induced phosphorylation of ***p53*** protein at serine 389 .	target	0
2056	10212189	5594;7157	p38;p53	Here , we report that the UV-induced phosphorylation of ***p53*** at serine 389 is ***mediated*** by ***p38*** kinase .	target	0
2057	10212189	5594;7157	p38;p53	Most importantly , ***p38*** kinase could be ***co-immunoprecipitated*** with ***p53*** by using antibodies against p53 .	parallel	1
2058	10212194	5321;5320	cPLA2;sPLA2	Collectively , the results suggest a model whereby ***cPLA2*** activation ***regulates*** Group V ***sPLA2*** expression , which in turn is responsible for delayed PGE2 production via COX-2 .	target	1
2059	10212207	6714;5747	Src;FAK	Together , these results strongly suggest that PI3K binding is required for FAK to promote cell migration and that the ***binding*** of ***Src*** and p130 ( Cas ) to ***FAK*** may not be sufficient for this event .	parallel	1
2060	10212213	2534;5781	Fyn;SHP-2	Therefore , we have demonstrated for the first time that the activation of SHP-2 by these Gi protein-coupled receptors requires Fyn kinase and that there is a specific physical ***interaction*** of ***Fyn*** kinase with ***SHP-2*** in MDCK cells .	parallel	1
2061	10212213	5781;2534	SHP-2;Fyn	Therefore , we have demonstrated for the first time that the activation of ***SHP-2*** by these Gi protein-coupled receptors ***requires*** ***Fyn*** kinase and that there is a specific physical interaction of Fyn kinase with SHP-2 in MDCK cells .	target	0
2062	10212213	2534;5781	Fyn;SHP-2	***Fyn*** kinase-directed ***activation*** of SH2 domain-containing protein-tyrosine phosphatase ***SHP-2*** by Gi protein-coupled receptors in Madin-Darby canine kidney cells .	positive	1
2063	10212213	2885;5781	Grb2;SHP-2	The agonist-induced direct ***interaction*** of ***Grb2*** with ***SHP-2*** is mediated by the SH2 domain of Grb2 and the tyrosine phosphorylation of SHP-2 .	parallel	1
2064	10212213	5781;2885	SHP-2;Grb2	Pertussis toxin , PP1 ( a selective Src family kinase inhibitor ) , or overexpression of a catalytically inactive mutant of Fyn blocked the UK14304 - or LPA-stimulated activity of SHP-2 , SHP-2 tyrosine phosphorylation , and ***SHP-2*** ***association*** with ***Grb2*** .	parallel	0
2065	10212223	5803;4192	PTPzeta;midkine	A receptor-like protein-tyrosine phosphatase ***PTPzeta/RPTPbeta*** ***binds*** a heparin-binding growth factor ***midkine*** .	parallel	1
2066	10212223	4192;5803	midkine;PTPzeta	In this study , we examined the ***binding*** of ***midkine*** to ***PTPzeta*** by solid-phase binding assay .	parallel	1
2067	10212223	5764;4192	pleiotrophin;midkine	***midkine*** and pleiotrophin binding to PTPzeta were equally ***inhibited*** by soluble ***pleiotrophin*** and also by some specific glycosaminoglycans .	negative	1
2068	10212223	5803;4192	PTPzeta;midkine	These results suggested that ***PTPzeta*** is a common ***receptor*** for ***midkine*** and pleiotrophin .	parallel	1
2069	10212223	5803;5764	PTPzeta;pleiotrophin	These results suggested that ***PTPzeta*** is a common ***receptor*** for midkine and ***pleiotrophin*** .	parallel	1
2070	10212230	3458;4843	IFN-gamma;iNOS	Poly IC + ***IFN-gamma*** ***stimulates*** ***iNOS*** expression and inhibits insulin secretion by primary beta-cells purified by fluorescence-activated cell sorting .	positive	0
2071	10212239	4214;3725	MEK kinase 1;c-Jun	***MEK kinase 1*** ( MEKK1 ) ***transduces*** ***c-Jun*** NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton .	positive	1
2072	10212258	5888;472	Rad51;ATM	Radiation-induced assembly of ***Rad51*** and Rad52 recombination complex ***requires*** ***ATM*** and c-Abl .	target	0
2073	10212258	5888;25	Rad51;c-Abl	Radiation-induced assembly of ***Rad51*** and Rad52 recombination complex ***requires*** ATM and ***c-Abl*** .	target	0
2074	10212258	25;5888	c-Abl;Rad51	Consistent with the physical interaction , ***c-Abl*** ***phosphorylates*** ***Rad51*** in vitro and in vivo .	target	1
2075	10212258	25;5888	c-Abl;Rad51	In assays using purified components , ***phosphorylation*** of ***Rad51*** by ***c-Abl*** enhances complex formation between Rad51 and Rad52 , which cooperates with Rad51 in recombination and repair .	target	1
2076	10212258	5893;5888	Rad52;Rad51	In assays using purified components , phosphorylation of Rad51 by c-Abl enhances complex ***formation*** between ***Rad51*** and ***Rad52*** , which cooperates with Rad51 in recombination and repair .	parallel	0
2077	10212258	5893;5888	Rad52;Rad51	After I-R , an increase in ***association*** between ***Rad51*** and ***Rad52*** occurs in wild-type cells but not in cells with mutations that compromise ATM or c-Abl .	parallel	0
2078	10212267	3976;140628	leukemia inhibitory factor;GATA-5	Last , ***leukemia inhibitory factor*** stimulation markedly ***increased*** transcripts of cardiac ***GATA-5*** , the expression of which is normally restricted to the early embryo .	positive	0
2079	10212268	6722;2626	serum response factor;GATA-4	Gel mobility shift assay supershift analysis demonstrated that the ***serum response factor*** ***binds*** to the CArG element and ***GATA-4*** binds to the GATA element .	parallel	1
2080	10212269	2252;2255	FGF-7;FGF-10	Although ***FGF-10*** and ***FGF-7*** ***bind*** and activate the same resident epithelial cell receptor ( FGFR2IIIb ) , differences in cell type of origin , compartmentation by alternate translation , the affinity for FGFR1IIIb , and access to FGFR by differential interaction with pericellular matrix heparan sulfate suggest they may play both independent and compensatory roles in prostate homeostasis .	parallel	1
2081	10212279	4036;7038	Megalin;thyroglobulin	We recently reported that ***Megalin*** ( gp330 ) , an endocytic receptor found on the apical surface of thyroid cells , ***binds*** ***thyroglobulin*** ( Tg ) with high affinity in solid phase assays .	parallel	1
2082	10212281	6900;3567	Tax1;IL-5	The synergism of GATA3 with either Ets1 or Ets2 may play an important role in calcium - or ***Tax1-dependent*** ***regulation*** of ***IL-5*** expression in Th2 cells or in HTLV-I transformed adult T-cell leukemia cells , respectively .	target	1
2083	10212281	2113;3567	Ets1;IL-5	Studying the regulation of IL-5 gene expression by Ets transcription factors , we found that ***Ets1*** and Ets2 , but not Elf-1 , were able to ***activate*** the human ***IL-5*** promoter in Jurkat T-cells .	positive	1
2084	10212281	2114;3567	Ets2;IL-5	Studying the regulation of IL-5 gene expression by Ets transcription factors , we found that Ets1 and ***Ets2*** , but not Elf-1 , were able to ***activate*** the human ***IL-5*** promoter in Jurkat T-cells .	positive	1
2085	10212281	2113;3567	Ets1;IL-5	In myeloid Kasumi cells , ***Ets1*** and Ets2 failed to ***stimulate*** ***IL-5*** promoter activity , unless the T-cell specific transcription factor GATA3 was added .	positive	0
2086	10212281	2114;3567	Ets2;IL-5	In myeloid Kasumi cells , Ets1 and ***Ets2*** failed to ***stimulate*** ***IL-5*** promoter activity , unless the T-cell specific transcription factor GATA3 was added .	positive	0
2087	10212281	6900;2625	Tax1;GATA3	Both ionomycin and ***Tax1*** ***increased*** the combined effect of ***GATA3*** with Ets1 and Ets2 in the presence of PMA .	positive	0
2088	10212304	2208;7124	CD23;tumor necrosis factor-alpha	***FcepsilonRII/CD23*** is expressed in Parkinson 's disease and ***induces*** , in vitro , production of nitric oxide and ***tumor necrosis factor-alpha*** in glial cells .	target	1
2089	10212304	3458;2208	interferon-gamma;CD23	We show that , in vitro , ***interferon-gamma*** ( IFN-gamma ) together with interleukin-1beta ( Il-1beta ) and tumor necrosis factor-alpha ( TNF-alpha ) can ***induce*** the expression of ***CD23*** in glial cells .	target	1
2090	10212315	3976;627	Leukemia inhibitory factor;neurotrophin	***Leukemia inhibitory factor*** ***augments*** ***neurotrophin*** expression and corticospinal axon growth after adult CNS injury .	positive	0
2091	10212382	83716;5340	trypsin inhibitor;plasmin	Catalytic activity of human ***plasmin*** is ***inhibited*** by bovine basic pancreatic ***trypsin inhibitor*** ( BPTI , also known as aprotinin ) .	negative	1
2092	10212448	7039;1956	transforming growth factor alpha;epidermal growth factor receptor	We conclude by discussing applications of the result to the particular case of the ***transforming growth factor alpha*** ***binding*** to ***epidermal growth factor receptor*** in epidermal wound healing .	parallel	1
2093	10213083	7040;1000	TGF-beta1;N-cadherin	Expression of ***N-cadherin*** , N-CAM , fibronectin and tenascin is ***stimulated*** by ***TGF-beta1*** , beta2 , beta3 and beta5 during the formation of precartilage condensations .	positive	0
2094	10213083	7040;1000	TGF-beta1;N-cadherin	Results showed that ***TGF-beta1*** , TGF-beta2 , TGF-beta3 , and TGF-beta5 differentially ***enhanced*** the expression of ***N-cadherin*** , N-CAM , fibronectin and tenascin in precartilage condensations , suggesting that TGF-beta isoforms play an important role in the establishment of cell-cell and cell-extracellular matrix interactions during precartilage condensations .	positive	0
2095	10213083	7042;1000	TGF-beta2;N-cadherin	Results showed that TGF-beta1 , ***TGF-beta2*** , TGF-beta3 , and TGF-beta5 differentially ***enhanced*** the expression of ***N-cadherin*** , N-CAM , fibronectin and tenascin in precartilage condensations , suggesting that TGF-beta isoforms play an important role in the establishment of cell-cell and cell-extracellular matrix interactions during precartilage condensations .	positive	0
2096	10213083	7043;1000	TGF-beta3;N-cadherin	Results showed that TGF-beta1 , TGF-beta2 , ***TGF-beta3*** , and TGF-beta5 differentially ***enhanced*** the expression of ***N-cadherin*** , N-CAM , fibronectin and tenascin in precartilage condensations , suggesting that TGF-beta isoforms play an important role in the establishment of cell-cell and cell-extracellular matrix interactions during precartilage condensations .	positive	0
2097	10213189	4804;627	p75NTR;neurotrophin	To localize neurotrophin binding sites within the rat dentate gyrus , the distribution of low-affinity p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) immunoreactivity ( IR ) was examined by using antiserum raised against the cytoplasmic domain of the receptor .	parallel	1
2098	10213232	7157;4292	p53;hMLH1	***Cooperation*** between ***p53*** and ***hMLH1*** in a human colocarcinoma cell line in response to DNA damage .	parallel	0
2099	10213385	4487;652	Msx-1;Bmp-4	In the maxillary primordia , mesenchymal expression of Barx-1 is complementary to that of ***Msx-1*** , which ***correlate*** with overlying epithelial expression of FGF-8 and ***Bmp-4*** , respectively .	parallel	0
2100	10213385	4487;2253	Msx-1;FGF-8	In the maxillary primordia , mesenchymal expression of Barx-1 is complementary to that of ***Msx-1*** , which ***correlate*** with overlying epithelial expression of ***FGF-8*** and Bmp-4 , respectively .	parallel	0
2101	10213385	2253;56033	FGF-8;Barx-1	This suggests that in vivo , ***FGF-8/BMP*** signaling may ***regulate*** ***Barx-1*** gene expression .	target	1
2102	10213514	7157;672	p53;BRCA1	Our data indicate that a ***BRCA1*** breast cancer phenotype may be ***recognized*** by an exceptionally high proliferation rate and early and frequent ***p53*** overexpression but infrequent selection for overexpression of several other prognostic factor proteins known to be involved in breast oncogenesis .	target	1
2103	10213614	5900;5898	RalGDS;Ral	***RalGDS*** is a guanine nucleotide dissociation ***stimulator*** for ***Ral*** , and one of its homologues is RGL ( RalGDS-like ) .	positive	0
2104	10213692	9978;997	Rbx1;Cdc34	***Rbx1*** ***promotes*** association of ***Cdc34*** with Cdc53 and stimulates Cdc34 auto-ubiquitination in the context of Cdc53 or SCF complexes .	positive	0
2105	10213914	3558;1392	IL-2;CRH	***IL-2*** ( 10 ( -13 ) M ) ***stimulation*** of ***CRH*** release was unaffected by the lower concentration of ACH ( 10 ( -9 ) M ) , but surprisingly was inhibited by a 100-fold higher concentration .	positive	0
2106	10213916	7349;1392	Urocortin;CRH	***Urocortin*** , a newly isolated 40-amino-acid mammalian peptide homologous to corticotropin-releasing hormone ( CRH ) , ***activates*** both ***CRH*** type 1 and 2 receptors , but may be an endogenous ligand for CRH receptor type 2 .	positive	1
2107	10214348	1869;1029	E2F-1;p19	At other sites where ***E2F-1*** levels ***induce*** ***p19*** , which stabilizes p53 leading to apoptosis , E2F-1 overexpression may lead to tissue atrophy and loss of expression may lead to hyperplasia or tumors .	target	1
2108	10214348	1029;7157	p19;p53	At other sites where E2F-1 levels induce ***p19*** , which ***stabilizes*** ***p53*** leading to apoptosis , E2F-1 overexpression may lead to tissue atrophy and loss of expression may lead to hyperplasia or tumors .	positive	0
2109	10214865	5594;5595	ERK2;ERK1	***ERK2*** phosphorylation was tightly ***correlated*** with ***ERK1*** phosphorylation and MAP kinase activity detected by in vitro kinase assay .	parallel	0
2110	10214867	5524;3684	PP2A;CD11b	Activities of PP1 and ***PP2A*** of AML blasts ***correlated*** positively with the expression of ***CD11b*** , whereas activities of PP1 and PP2B correlated negatively with the expression of CD7 .	positive	0
2111	10214908	7508;5887	XPC;hHR23B	For the bulk of mammalian DNA , the core protein factors needed for damage recognition and incision during nucleotide excision repair ( NER ) are the XPA protein , the heterotrimeric RPA protein , the 6 to 9-subunit TFIIH , the ******XPC-hHR23B****** ***complex*** , the XPG nuclease , and the ERCC1-XPF nuclease .	parallel	1
2112	10214914	7157;5888	p53;Rad51	Complex regulation of HRR by cell cycle checkpoint and surveillance functions is suggested not only by direct ***interactions*** between human ***Rad51*** and ***p53*** , c-Abl , and BRCA2 , but also by very high recombination rates in p53-deficient cells .	parallel	1
2113	10214915	10111;4361	hRad50;hMre11	Two ( sub - ) pathways can be distinguished , the first mediated by DNA-PK-dependent protein kinase ( DNA-PK ) , and the second directed by the ******hMre11/hRad50****** ***complex*** .	parallel	1
2114	10214941	10972;10959	p23;p24	***p24*** and ***p23*** , the major transmembrane proteins of COPI-coated transport vesicles , form hetero-oligomeric ***complexes*** and cycle between the organelles of the early secretory pathway .	parallel	1
2115	10214941	10959;10972	p24;p23	Taken together ***p24*** ***interacts*** with ***p23*** and constitutively cycles between the organelles of the early secretory pathway .	parallel	1
2116	10215323	183;7422	Angiotensin II;vascular endothelial growth factor	***Angiotensin II*** ***stimulates*** the synthesis and secretion of ***vascular permeability factor/vascular endothelial growth factor*** in human mesangial cells .	positive	0
2117	10215594	2641;5105	glucagon;PCK1	These experiments suggested that the CRE1 but not the putative CRE2 was an essential site necessary for the cAMP-mediated ***PCK1*** gene ***activation*** by ***glucagon*** and that the putative CRE2 site was involved in the oxygen-dependent modulation of PCK1 gene activation .	positive	1
2118	10215617	4803;1191	Nerve growth factor;clusterin	***Nerve growth factor*** and epidermal growth factor ***stimulate*** ***clusterin*** gene expression in PC12 cells .	positive	0
2119	10215617	4803;1191	NGF;clusterin	***NGF*** ***induced*** ***clusterin*** mRNA , which preceded neurite outgrowth typical of neuronal differentiation .	target	1
2120	10215635	3558;4051	Interleukin-2;cytochrome P-450	***Interleukin-2*** overexpresses c-myc and ***down-regulates*** ***cytochrome P-450*** in rat hepatocytes .	negative	1
2121	10215635	3558;4051	Interleukin-2;cytochrome P-450	The interaction of ***Interleukin-2*** ( IL-2 ) with its receptor ( IL-2R ) ***decreases*** ***cytochrome P-450*** ( CYP ) expression in rat hepatocytes .	negative	0
2122	10215635	3558;4609	IL-2;c-myc	Because IL-2 increases c-myc in lymphocytes and because c-myc overexpression represses several genes , we postulated that the ***IL-2/IL*** -2 R interaction may ***increase*** ***c-myc*** and thereby down-regulate CYP in hepatocytes .	positive	0
2123	10215635	3558;4609	IL-2;c-myc	Because ***IL-2*** ***increases*** ***c-myc*** in lymphocytes and because c-myc overexpression represses several genes , we postulated that the IL-2/IL -2 R interaction may increase c-myc and thereby down-regulate CYP in hepatocytes .	positive	0
2124	10215635	3558;1576	IL-2;CYP3A	***IL-2*** increased c-myc mRNA and protein but ***decreased*** total CYP and the mRNAs and proteins of CYP2C11 and ***CYP3A*** .	negative	0
2125	10215635	3558;4609	IL-2;c-myc	***IL-2*** ***increased*** ***c-myc*** mRNA and protein but decreased total CYP and the mRNAs and proteins of CYP2C11 and CYP3A .	positive	0
2126	10215647	5742;5743	Cox-1;Cox-2	Healthy older adults ( n = 36 ) were admitted to a clinical research unit , placed on a fixed sodium intake , and randomized under double-blind conditions to receive the specific ***Cox-2*** ***inhibitor*** , MK-966 ( 50 mg every day ) , a nonspecific ***Cox-1*** / Cox-2 inhibitor , indomethacin ( 50 mg t.i.d. ) , or placebo for 2 weeks .	negative	1
2127	10215868	4792;4790	IkappaBalpha;NFkappaB	IRF-1 by itself initiates NFkappaB activation by inducing a reduction in cellular ***MAD3/IkappaBalpha*** , an ***inhibitor*** of ***NFkappaB*** .	negative	1
2128	10215868	4790;3659	NFkappaB;IRF-1	After nuclear translocation , ***NFkappaB*** ***synergizes*** with ***IRF-1*** on the cis-elements positive regulatory domain ( PRD ) II and PRDI/III to induce transcription of the IFN-beta gene .	parallel	0
2129	10215868	4790;3456	NFkappaB;IFN-beta	After nuclear translocation , ***NFkappaB*** synergizes with IRF-1 on the cis-elements positive regulatory domain ( PRD ) II and PRDI/III to ***induce*** transcription of the ***IFN-beta*** gene .	target	1
2130	10215868	1386;3725	ATF-2;c-Jun	In contrast with IFN-beta transcription induced by dsRNA or virus , ******c-Jun/ATF-2****** ***binding*** to PRDIV is not involved .	parallel	1
2131	10215868	5610;4792	PKR;IkappaBalpha	IRF-1-dependent MAD3/IkappaBalpha degradation is not detectable in cells expressing a dominant negative mutant of the protein kinase PKR , suggesting that ***PKR*** ***mediates*** ***MAD3/IkappaBalpha*** degradation .	target	0
2132	10215876	10944;7374	small acidic protein;uracil DNA glycosylase	The equilibrium unfolding of ***uracil DNA glycosylase*** ***inhibitor*** ( Ugi ) , a ***small acidic protein*** of molecular mass 9474 Da , has been studied by a combination of thermal-induced and guanidine hydrochloride ( GdnCl ) - induced denaturation .	negative	1
2133	10215909	627;4842	BDNF;Neuronal NOS	Addition of ***BDNF*** ***upregulated*** the ***Neuronal NOS*** expression as well as NO production in neocortical culture .	positive	1
2134	10215917	627;5327	BDNF;tPA	Here , we report that ***BDNF*** ***stimulates*** the expression of tissue-type plasminogen activator ( ***tPA*** ) in primary cultures of cortical neurons in a time - and concentration-dependent manner .	positive	0
2135	10215917	4909;5327	neurotrophin-4;tPA	Among the other members of the neurotrophin family , ***neurotrophin-4*** ( NT-4 ) and to a lesser extent neurotrophin-3 ( NT-3 ) also ***increased*** ***tPA*** mRNA expression , while nerve growth factor ( NGF ) was devoid of any effect .	positive	0
2136	10215917	627;5327	BDNF;tPA	***Induction*** of ***tPA*** expression by ***BDNF*** is accompanied by an increase in the proteolytic activity of tPA associated with cortical neurons and a release of tPA into the extracellular space .	target	1
2137	10215917	5055;5327	PAI-2;tPA	Up-regulation of tPA expression by BDNF is followed by the induction of plasminogen activator inhibitor 2 ( ***PAI-2*** ) , an ***inhibitor*** of ***tPA*** .	negative	1
2138	10215917	627;5327	BDNF;tPA	***Up-regulation*** of ***tPA*** expression by ***BDNF*** is followed by the induction of plasminogen activator inhibitor 2 ( PAI-2 ) , an inhibitor of tPA .	positive	1
2139	10215917	627;5327	BDNF;tPA	Together these results suggest that ***activation*** of ***tPA*** by ***BDNF*** may contribute to structural changes associated with neuronal development or synaptic plasticity .	positive	1
2140	10215918	4908;4852	neurotrophin-3;NPY	Application of exogenous ***neurotrophin-3*** ( NT-3 ) ***increased*** ***NPY*** and somatostatin protein levels in long-term but not short-term cultures , while nerve growth factor ( NGF ) had no effect .	positive	0
2141	10215918	4908;6750	neurotrophin-3;somatostatin	Application of exogenous ***neurotrophin-3*** ( NT-3 ) ***increased*** NPY and ***somatostatin*** protein levels in long-term but not short-term cultures , while nerve growth factor ( NGF ) had no effect .	positive	0
2142	10215920	4804;627	p75NTR;neurotrophin	Neurotrophins exert their biological functions on neuronal cells through two types of receptors , the trk tyrosine kinases and the low-affinity ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) , which can bind all neurotrophins with similar affinity .	parallel	1
2143	10215920	4803;627	NGF;brain-derived neurotrophic factor	***NGF*** ***antagonizes*** ***brain-derived neurotrophic factor*** ( BDNF ) - and neurotrophin-3 ( NT-3 ) - mediated survival in control but not p75NTR-deficient motoneurons .	negative	1
2144	10215920	4803;4908	NGF;neurotrophin-3	***NGF*** ***antagonizes*** brain-derived neurotrophic factor ( BDNF ) - and ***neurotrophin-3*** ( NT-3 ) - mediated survival in control but not p75NTR-deficient motoneurons .	negative	1
2145	10216092	2812;2815	GPIbbeta;GPIX	Thus , a deletion of one copy of GPIbbeta and a single nucleotide deletion in the codon for Ala 80 within the remaining GPIbbeta allele causes the Bernard-Soulier phenotype through an ***interaction*** of ***GPIbbeta*** with ***GPIX*** resulting in the absence of GPIbalpha on the plasma membrane .	parallel	1
2146	10216092	2812;2815	GPIbbeta;GPIX	The ***interaction*** of ***GPIbbeta*** with ***GPIX*** is essential for the functional expression of GPIbalpha .	parallel	1
2147	10216102	355;356	CD95;CD95 ligand	Because apoptosis induced by anticancer drugs has been proposed to involve ******CD95/CD95 ligand****** ***interaction*** , we investigated the mechanism of caspase activation by daunorubicin , doxorubicin , etoposide , and mitomycin C.	parallel	1
2148	10216102	8772;355	FADD;CD95	The broad caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone prevented apoptosis and caspase-8 activation in response to CD95 and drug treatment , whereas a neutralizing CD95 decoy as well as a dominant-negative ***FADD*** construct selectively ***abrogated*** ***CD95*** , but not drug-induced effects .	negative	0
2149	10216102	9474;841	Asp;caspase-8	The broad caspase inhibitor ***benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone*** ***prevented*** apoptosis and ***caspase-8*** activation in response to CD95 and drug treatment , whereas a neutralizing CD95 decoy as well as a dominant-negative FADD construct selectively abrogated CD95 , but not drug-induced effects .	negative	0
2150	10216108	836;598	caspase-3;Bcl-Xl	This shift of balance of anti- and pro-apoptotic proteins was found to control ***caspase-3*** activity which , in turn , ***downregulated*** ***Bcl-Xl*** expression in PMN undergoing apoptosis .	negative	1
2151	10216139	7035;2152	TFPI;tissue factor	In contrast , mRNA expressions of ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) as well as thrombomodulin were almost undetectable in normal and partially resected livers .	negative	1
2152	10216198	2885;6464	GRB2;SHC	Insulin induces tyrosine phosphorylation of the insulin receptor and SHC , and ******SHC/GRB2****** ***association*** in cerebellum but not in forebrain cortex of rats .	parallel	0
2153	10216227	5015;4684	OTX2;NCAM	The mouse homeodomain protein ***OTX2*** ***regulates*** ***NCAM*** promoter activity .	target	1
2154	10216227	5015;4684	OTX2;NCAM	Taken together , our results argue for a ***regulation*** of ***NCAM*** expression by ***OTX2*** .	target	1
2155	10216229	5970;4790	RelA;p50	In electrophoretic mobility shift assays of kappaB-binding activity , we have found that the predominant activity in rat brain tissue , in primary neurons , and in neuronal cell lines has a mobility inconsistent with that of bona fide NF-kappaB ( ******RelA-p50****** ***heterodimer*** ) .	parallel	1
2156	10216283	335;57126	apo;cell surface receptor	Thus , cAMP-stimulated FC efflux involves probucol-sensitive processes distinct from ***apo*** A-I ***binding*** to its putative ***cell surface receptor*** .	parallel	1
2157	10216428	3553;3827	IL-1 beta;bradykinin	Taken together , our results suggest that ***IL-1 beta*** is able to ***potentiate*** the effect of ***bradykinin*** or tachykinin receptor agonists on the human isolated bronchus .	positive	0
2158	10216919	3240;335	Haptoglobin;apolipoprotein A-1	***Complexes*** of ***Haptoglobin*** with ***apolipoprotein A-1*** were isolated from follicular fluids by affinity chromatography with haemoglobin .	parallel	1
2159	10216942	1977;1981	eIF4E;eIF4G	Growth-regulated mRNAs are preferentially translated under conditions of accentuated ******eIF4E-eIF4G****** ***interaction*** .	parallel	1
2160	10217147	2185;4303	protein kinase B;AFX	Direct ***control*** of the Forkhead transcription factor ***AFX*** by ***protein kinase B*** .	target	0
2161	10217147	2185;4303	protein kinase B;AFX	Here we show that ***protein kinase B*** ***phosphorylates*** ***AFX*** , a human orthologue of daf-16 , both in vitro and in vivo .	target	1
2162	10217147	2185;4303	protein kinase B;AFX	Inhibition of endogenous PI ( 3 ) K and protein kinase B activity prevents ***protein kinase B-dependent*** ***phosphorylation*** of ***AFX*** and reveals residual protein kinase B-independent phosphorylation that requires Ras signalling towards the Ral GTPase .	target	1
2163	10217147	2185;4303	protein kinase B;AFX	In addition , ***phosphorylation*** of ***AFX*** by ***protein kinase B*** inhibits its transcriptional activity .	target	1
2164	10217220	3569;1051	IL-6;NF-IL6	Although ***IL-6*** mRNA levels ***correlated*** with NFkappaB and ***NF-IL6*** activation , tumor necrosis factor-alpha mRNA levels did not , in that they preceded transcription factor activation .	parallel	0
2165	10217220	3569;4790	IL-6;NFkappaB	Although ***IL-6*** mRNA levels ***correlated*** with ***NFkappaB*** and NF-IL6 activation , tumor necrosis factor-alpha mRNA levels did not , in that they preceded transcription factor activation .	parallel	0
2166	10217263	5594;3976	ERK;LIF	These results indicate that ***LIF*** mRNA levels can be ***regulated*** by ***ERK*** activation via stimulation of PKC in Schwann cells .	target	1
2167	10217264	1270;5368	CNTF;N/OFQ	***Regulation*** of ***N/OFQ*** expression by ***CNTF*** might point to a possible function of N/OFQ during development and after neural injury .	target	1
2168	10217264	1270;5368	CNTF;N/OFQ	***CNTF*** ***regulation*** of ***N/OFQ*** expression was sensitive to the kinase inhibitors H-7 and genistein but not to inhibition of protein synthesis .	target	1
2169	10217270	4908;627	neurotrophin-3;Brain-derived neurotrophic factor	Neither antibody crossreacts with neurotrophin homodimers other than Brain-derived neurotrophic factor , although reactivity was detected with ******Brain-derived neurotrophic factor/neurotrophin-3****** ***heterodimers*** .	parallel	1
2170	10217279	23523;84152	calcineurin inhibitor;DARPP-32	Cyclosporin A ( 5 microM ) , a ***calcineurin inhibitor*** , maximally ***increased*** the level of phosphorylated ***DARPP-32*** by 17 + / -2 - fold .	positive	0
2171	10217400	4609;3725	c-Myc;c-Jun	Moreover , ***c-Jun/c-Fos*** stimulation was ***inhibited*** by co-expression of ***c-Myc*** and Max .	negative	1
2172	10217400	4149;3725	Max;c-Jun	Moreover , ***c-Jun/c-Fos*** stimulation was ***inhibited*** by co-expression of c-Myc and ***Max*** .	negative	1
2173	10217420	10266;10203	RAMP2;CRLR	The ******RAMP2/CRLR****** ***complex*** is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells .	parallel	1
2174	10217420	10203;10266	calcitonin receptor-like receptor;receptor activity-modifying protein 2	Thus , the ******receptor activity-modifying protein 2/calcitonin receptor-like receptor****** ***complex*** apparently serves as a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells .	parallel	1
2175	10217702	3569;1401	interleukin-6;C-reactive protein	Evidence for a ***link*** between adipose tissue ***interleukin-6*** content and serum ***C-reactive protein*** concentrations in obese subjects .	parallel	0
2176	10217828	920;3700	CD4;gp120	HIV-1 attachment to host cells is generally considered to take place via high-affinity ***binding*** between ***CD4*** and ***gp120*** .	parallel	1
2177	10217828	3700;920	gp120;CD4	However , the ***binding*** of virion-associated ***gp120*** to cellular ***CD4*** is often weak , and most cell types that are permissive for HIV-1 infection express little CD4 .	parallel	1
2178	10218092	3456;3458	IFN-beta;IFN-gamma	However , ***IFN-beta*** ***inhibits*** ***IFN-gamma*** secretion of T cells , when they are stimulated by antigen presenting cells ( APC ) .	negative	1
2179	10218570	4193;4194	MDM2;MDMX	***MDM2*** ***interacts*** with ***MDMX*** through their RING finger domains .	parallel	1
2180	10218570	4194;7157	MDMX;p53	***MDMX*** is structurally related to MDM2 and also ***binds*** to ***p53*** .	parallel	1
2181	10218570	4194;4193	MDMX;MDM2	***Interaction*** of ***MDMX*** with ***MDM2*** through the C-terminal RING finger domains resulted in inhibiting degradation of MDM2 .	parallel	1
2182	10218570	4194;4193	MDMX;MDM2	These data indicate that ***MDMX*** functions as a ***regulator*** of ***MDM2*** .	target	1
2183	10218586	64375;10320	Eos;Ikaros	***Eos*** protein could ***interact*** with itself and ***Ikaros*** protein through its C-terminal portion in the yeast two hybrid assay .	parallel	1
2184	10218877	5443;1392	ACTH;corticotropin-releasing hormone	A direct ***ACTH*** ***modulation*** of brain electrophysiology or common factors ( e.g. the ***corticotropin-releasing hormone*** ) pacing both ACTH and EEG are suggested and may account for individual EEG differences .	target	0
2185	10218944	3717;3667	JAK2;IRS-1	Tyrosine-phosphorylated JAK2 resulting from GH stimulation was included in the amino-terminal IRS-1 fusion precipitates ; however , neither tyrosine phosphorylation of JAK2 nor treatment of cells with GH before extraction was necessary for the specific ******JAK2-IRS-1****** ***interaction*** to be detected .	parallel	1
2186	10218947	3490;3479	IGFBP-RP-1;IGF-I	IGFBP-related protein-1 ( ***IGFBP-RP-1*** ) , the product of the mac25 gene , ***binds*** ***IGF-I*** , IGF-II , and insulin .	parallel	1
2187	10218947	5741;3490	PTH;IGFBP-RP-1	In conclusion , ***PTH*** ***stimulates*** ***mac25/IGFBP-RP-1*** transcription in osteoblasts , an effect that could be relevant to the actions of PTH in bone .	positive	0
2188	10218952	1270;9021	CNTF;SOCS-3	***CNTF*** ***induced*** SOCS-3 mRNA and ***SOCS-3*** protein levels in an astrocyte cell line .	target	1
2189	10218952	1270;9021	CNTF;SOCS-3	In conclusion , ***SOCS-3*** mRNA is specifically ***induced*** by ***CNTF*** in regions of the hypothalamus that are both overlapping and distinct from that induced by leptin .	target	1
2190	10218952	9021;1270	SOCS-3;CNTF	***SOCS-3*** is a negative ***regulator*** of ***CNTF*** signal transduction , and inhibitors of SOCS-3 function may enhance endogenous CNTF signaling after neuronal injury or enhance the body weight-reducing effect of CNTF after peripheral administration .	negative	1
2191	10218952	1270;9021	CNTF;SOCS-3	Peripheral ***CNTF*** administration to ob/ob mice rapidly ***induced*** ***SOCS-3*** messenger RNA ( mRNA ) in hypothalamus , as determined by Northern blotting and quantitative RT-PCR , but had no effect on cytokine-inducible sequence ( CIS ) , SOCS-1 , or SOCS-2 mRNA .	target	1
2192	10218952	1270;9021	CNTF;SOCS-3	In situ hybridization histochemistry of hypothalamus from ob/ob mice and normal rats demonstrated that ***CNTF*** ***induced*** ***SOCS-3*** mRNA in the arcuate nucleus ( Arc ) .	target	1
2193	10218952	1270;8651	CNTF;SOCS-1	***CNTF*** also ***induced*** expression of CIS , ***SOCS-1*** , SOCS-2 , and SOCS-3 mRNA in the liver , and SOCS-2 and SOCS-3 mRNA in the kidney .	target	1
2194	10218952	1270;8835	CNTF;SOCS-2	***CNTF*** also ***induced*** expression of CIS , SOCS-1 , ***SOCS-2*** , and SOCS-3 mRNA in the liver , and SOCS-2 and SOCS-3 mRNA in the kidney .	target	1
2195	10218952	1270;9021	CNTF;SOCS-3	***CNTF*** also ***induced*** expression of CIS , SOCS-1 , SOCS-2 , and ***SOCS-3*** mRNA in the liver , and SOCS-2 and SOCS-3 mRNA in the kidney .	target	1
2196	10218968	5443;4159	alpha-MSH;MC3	***Desacetyl-alpha-MSH*** ***activated*** mouse MC1 , ***MC3*** , MC4 and MC5 receptors with EC50s = 0.13 , 0.96 , 0.53 , and 0.84 nM , and alpha-MSH activated these receptors with EC50s = 0.17 , 0.88 , 1.05 , and 1.34 nM , respectively .	positive	1
2197	10218974	3084;6462	heregulin-alpha;androgen-binding protein	Here we demonstrate that recombinant human ***heregulin-alpha*** ( Her-alpha ) and Her-beta ***stimulate*** transferrin and ***androgen-binding protein*** production by cultured rat Sertoli cells up to 2.5-fold .	positive	0
2198	10218974	3084;7018	heregulin-alpha;transferrin	Here we demonstrate that recombinant human ***heregulin-alpha*** ( Her-alpha ) and Her-beta ***stimulate*** ***transferrin*** and androgen-binding protein production by cultured rat Sertoli cells up to 2.5-fold .	positive	0
2199	10218975	796;1594	calcitonin;25-hydroxyvitamin D3 1alpha-hydroxylase	Positive and negative ***regulations*** of the renal ***25-hydroxyvitamin D3 1alpha-hydroxylase*** gene by parathyroid hormone , ***calcitonin*** , and 1alpha ,25 ( OH ) 2D3 in intact animals .	negative	1
2200	10218975	5741;1594	parathyroid hormone;25-hydroxyvitamin D3 1alpha-hydroxylase	Positive and negative ***regulations*** of the renal ***25-hydroxyvitamin D3 1alpha-hydroxylase*** gene by ***parathyroid hormone*** , calcitonin , and 1alpha ,25 ( OH ) 2D3 in intact animals .	negative	1
2201	10218975	796;1594	calcitonin;25-hydroxyvitamin D3 1alpha-hydroxylase	Reflecting the prime role of 1alpha ,25 ( OH ) 2D3 in calcium homeostasis , the activity of ***25-hydroxyvitamin D3 1alpha-hydroxylase*** , a key enzyme for 1alpha ,25 ( OH ) 2D3 biosynthesis , is tightly ***regulated*** by 1alpha ,25 ( OH ) 2D3 , PTH and ***calcitonin*** .	target	1
2202	10218975	5741;1594	PTH;25-hydroxyvitamin D3 1alpha-hydroxylase	Reflecting the prime role of 1alpha ,25 ( OH ) 2D3 in calcium homeostasis , the activity of ***25-hydroxyvitamin D3 1alpha-hydroxylase*** , a key enzyme for 1alpha ,25 ( OH ) 2D3 biosynthesis , is tightly ***regulated*** by 1alpha ,25 ( OH ) 2D3 , ***PTH*** and calcitonin .	target	1
2203	10218976	3484;3481	IGFBP-1;IGF-II	***IGF-II*** action is negatively ***regulated*** by ***IGFBP-1*** whose synthesis increases in the presence of glucocorticoids .	negative	1
2204	10218991	367;3488	Androgen receptor;insulin-like growth factor binding protein-5	***Androgen receptor*** ***up-regulates*** ***insulin-like growth factor binding protein-5*** ( IGFBP-5 ) expression in a human prostate cancer xenograft .	positive	1
2205	10218991	3488;3479	IGFBP-5;IGF-I	***IGFBP-5*** protein in tumor extracts ***bound*** 125I-labeled ***IGF-I*** in ligand blot assays and the amounts of IGFBP-5 measured by immunoblotting paralleled the levels of IGFBP-5 mRNA .	parallel	1
2206	10218993	3952;181	leptin;Agrp	These results suggest that in the fed state , ***Agrp*** is normally ***suppressed*** by ***leptin*** , and that release of this suppression during fasting leads to increased ingestive behavior .	negative	1
2207	10218994	2981;2984	uroguanylin;guanylyl cyclase-C	***uroguanylin*** is an endogenous peptide ***ligand*** for ***guanylyl cyclase-C*** , an apical membrane receptor predominantly located in the gastrointestinal epithelium .	parallel	1
2208	10219001	3574;5896	interleukin-7;recombination activating gene 1	***Activation*** of the ***recombination activating gene 1*** ( RAG-1 ) transcript in bone marrow of senescent C57BL/6 mice by recombinant ***interleukin-7*** .	positive	1
2209	10219001	3574;5896	interleukin-7;RAG-1	Recominbant ***interleukin-7*** ( rIL-7 ) is a potent proliferative stimulus for B cell progenitors and ***upregulates*** ***RAG-1*** expression in lymphocyte precursors .	positive	1
2210	10219078	10111;4361	Rad50;Mre11	Formation of the yeast ******Mre11-Rad50-Xrs2****** ***complex*** is correlated with DNA repair and telomere maintenance .	parallel	1
2211	10219078	4361;10111	Mre11;Rad50	Interestingly , deletion of these same 134 amino acids enhanced the ***interaction*** of ***Mre11*** with ***Rad50*** and Xrs2 , which is consistent with the notion that this region is specific for meiotic functions .	parallel	1
2212	10219080	4803;596	nerve growth factor;Bcl-2	***Activation*** of the ***Bcl-2*** promoter by ***nerve growth factor*** is mediated by the p42/p44 MAPK cascade .	positive	1
2213	10219080	4803;596	nerve growth factor;Bcl-2	We show for the first time that the ***Bcl-2*** promoter is ***activated*** by the neuronal survival factor ***nerve growth factor*** ( NGF ) and that this effect is dependent on a region of the promoter from -1472 to -1414 .	positive	1
2214	10219085	7702;5538	SBF;CLN1	Expression of G1cyclins ***CLN1*** and CLN2 is ***regulated*** by the transcription factor ***SBF*** ( composed of Swi4p and Swi6p ) and depends on the cyclin-dependent Cdc28 protein kinase and cyclin Cln3p .	target	1
2215	10219085	7702;1200	SBF;CLN2	Expression of G1cyclins CLN1 and ***CLN2*** is ***regulated*** by the transcription factor ***SBF*** ( composed of Swi4p and Swi6p ) and depends on the cyclin-dependent Cdc28 protein kinase and cyclin Cln3p .	target	1
2216	10219089	1191;2547	apoJ;Ku70	***Interactions*** of ***apoJ/XIP8*** or KUB3 with ***Ku70*** were confirmed by co-immunoprecipitation analyses in MCF-7 : WS8 breast cancer or IMR-90 normal lung fibroblast cells , respectively .	parallel	1
2217	10219089	91419;2547	KUB3;Ku70	***Interactions*** of apoJ/XIP8 or ***KUB3*** with ***Ku70*** were confirmed by co-immunoprecipitation analyses in MCF-7 : WS8 breast cancer or IMR-90 normal lung fibroblast cells , respectively .	parallel	1
2218	10219089	1191;2547	apoJ;Ku70	The ***interaction*** of ***apoJ/XIP8*** with ***Ku70*** was confirmed by far-western analyses .	parallel	1
2219	10219249	3586;3569	IL-10;IL-6	Exogenous ***IL-10*** and IL-4 ***down-regulate*** ***IL-6*** production by SLE-derived PBMC .	negative	1
2220	10219249	3565;3569	IL-4;IL-6	Exogenous IL-10 and ***IL-4*** ***down-regulate*** ***IL-6*** production by SLE-derived PBMC .	negative	1
2221	10219249	3586;3569	IL-10;IL-6	***IL-6*** production by normal monocytes can be ***inhibited*** by ***IL-10*** , and it has been suggested that SLE monocytes are refractory to this negative signal .	negative	1
2222	10219249	3565;3569	IL-4;IL-6	We found that ( 1 ) exogenous rIL-10 and rIL-4 mediated reduction of constitutive and lectin-induced IL-6 in monocytes of SLE patients as effectively as that of controls ; ( 2 ) IL-6 mRNA decay was significantly delayed in SLE with active disease ( P < 0.001 ) ; ( 3 ) adding rIL-10 or neutralizing endogenous IL-1 beta and TNF-alpha down-regulated IL-6 mainly by destabilizing IL-6 transcripts , whereas exogenous ***IL-4*** and TGF beta 1 ***down-regulated*** ***IL-6*** transcriptionally ; ( 4 ) time kinetics and levels of IL-10 were lower than those of IL-6 and IL-1 beta .	negative	1
2223	10219249	7040;3569	TGF beta 1;IL-6	We found that ( 1 ) exogenous rIL-10 and rIL-4 mediated reduction of constitutive and lectin-induced IL-6 in monocytes of SLE patients as effectively as that of controls ; ( 2 ) IL-6 mRNA decay was significantly delayed in SLE with active disease ( P < 0.001 ) ; ( 3 ) adding rIL-10 or neutralizing endogenous IL-1 beta and TNF-alpha down-regulated IL-6 mainly by destabilizing IL-6 transcripts , whereas exogenous IL-4 and ***TGF beta 1*** ***down-regulated*** ***IL-6*** transcriptionally ; ( 4 ) time kinetics and levels of IL-10 were lower than those of IL-6 and IL-1 beta .	negative	1
2224	10219631	7430;1739	ezrin;SAP 97	Immunoprecipitation confirms a direct ***binding*** of ***SAP 97*** and ***ezrin*** .	parallel	1
2225	10219659	1991;2006	HNE;elastin	METHODS : ***elastin*** ***degradation*** by ***HNE*** was monitored spectrophotometrically with elastin-congo red .	negative	1
2226	10219759	958;959	CD40;CD40L	The ***interaction*** between ***CD40*** and ***CD40L*** plays important roles in immune responses .	parallel	1
2227	10219841	3458;3383	IFN-gamma;ICAM-1	These results indicate that ***IFN-gamma*** and TNF-alpha ***induce*** the expression of ***ICAM-1*** on parenchymal hepatocytes and that the LFA-1-ICAM-1 pathway plays an important role in the interaction between hepatocytes and neutrophils or lymphocytes .	target	1
2228	10219841	7124;3383	TNF-alpha;ICAM-1	These results indicate that IFN-gamma and ***TNF-alpha*** ***induce*** the expression of ***ICAM-1*** on parenchymal hepatocytes and that the LFA-1-ICAM-1 pathway plays an important role in the interaction between hepatocytes and neutrophils or lymphocytes .	target	1
2229	10219967	2908;1576	glucocorticoid receptor;CYP3A4	These results highlight differences in the molecular mechanisms of induction of CYP3A4 by the xenobiotics studied and indicate that the ***glucocorticoid receptor*** is involved in the ***induction*** of the ***CYP3A4*** gene by some , but not all , CYP3A4 inducers .	target	1
2230	10220325	7134;7138	TnC;TnT	TnC ( E53A/E54A ) and ***TnC*** ( E85A/D86A ) ***interacted*** weakly with ***TnT*** , as judged by native gel electrophoresis .	parallel	1
2231	10220325	7134;7138	TnC;TnT	***TnC*** ( E60A/E61A ) ***interacted*** normally with ***TnT*** .	parallel	1
2232	10220372	9519;2959	TRF2;TFIIB	Like TRF1 and TBP , ***TRF2*** ***binds*** transcription factor IIA ( TFIIA ) and ***TFIIB*** and appears to be part of a larger protein complex .	parallel	1
2233	10220378	5923;5599	Ras-GRF1;JNK1	Activation of the Rac pathway in the cell was further evidenced by synergistic ***activation*** of the stress kinase ***JNK1*** by ***Ras-GRF1*** and Gbeta gamma , which is sensitive to inhibitory action of dominant-negative Rac1 ( 17N ) .	positive	1
2234	10220378	5923;5879	Ras-GRF1;Rac1	In addition , ***association*** of ***Ras-GRF1*** with ***Rac1*** ( 17N ) was demonstrated by coimmunoprecipitation .	parallel	0
2235	10220378	8801;9181	Gbeta;GEF	Evidence for the involvement of tyrosine kinase ( s ) in ***Gbeta*** gamma-mediated ***induction*** of Rac1-specific ***GEF*** activity was provided by the use of specific inhibitors .	target	1
2236	10220381	4088;3725	Smad3;AP-1	Here , we report that ***Smad3*** and Smad4 can physically ***interact*** with ***AP-1*** family members .	parallel	1
2237	10220381	4089;3725	Smad4;AP-1	Here , we report that Smad3 and ***Smad4*** can physically ***interact*** with ***AP-1*** family members .	parallel	1
2238	10220381	4088;3725	Smad3;Jun	In vitro binding studies demonstrate that both ***Smad3*** and Smad4 ***bind*** all three ***Jun*** family members : JunB , cJun , and JunD .	parallel	1
2239	10220381	4089;3725	Smad4;Jun	In vitro binding studies demonstrate that both Smad3 and ***Smad4*** ***bind*** all three ***Jun*** family members : JunB , cJun , and JunD .	parallel	1
2240	10220405	672;5931	BRCA1;RbAp46	Here we report that ***BRCA1*** ***interacts*** in vivo and in vitro with the Rb-binding proteins , ***RbAp46*** and RbAp48 , as well as with Rb .	parallel	1
2241	10220405	672;5928	BRCA1;RbAp48	Here we report that ***BRCA1*** ***interacts*** in vivo and in vitro with the Rb-binding proteins , RbAp46 and ***RbAp48*** , as well as with Rb .	parallel	1
2242	10220796	947;7157	CD34;p53	***CD34*** expression also ***correlated*** well with ***p53*** accumulation ( r = 0.859 , p = 0.000002 ) .	parallel	0
2243	10221260	1026;596	cip1;bcl-2	RESULTS : The expression of p21 ( ***waf1/cip1*** ) protein was significantly ***associated*** with high Gleason score ( P = 0.001 ) , DNA aneuploidy ( P = 0.013 ) , high S-phase fraction ( P = 0.019 ) , and expression of Ki-67 ( P = 0.021 ) and ***bcl-2*** ( P = 0.001 ) as well as cyclin A ( P = 0.035 ) and D proteins ( P < 0.001 ) .	parallel	0
2244	10221543	1906;3569	endothelin-1;interleukin-6	We previously reported that ***endothelin-1*** ***induces*** synthesis of ***interleukin-6*** ( IL-6 ) via activation of protein kinase C in osteoblast-like MC3T3-E1 cells .	target	1
2245	10221543	1906;5706	endothelin-1;p44	***endothelin-1*** ***stimulated*** ***p42/p44*** MAP kinase activation in a dose-dependent manner in the range between 0.1 nmol/L and 0.1 micromol/L .	positive	0
2246	10221592	133;5443	PAMP;ACTH	Here we report that basal , but not stimulated , ***ACTH*** secretion from cultured rat pituitary cells is also ***inhibited*** by ***PAMP*** .	negative	1
2247	10221598	5618;7409	PRLR;Vav	These observations suggest that PRL signaling reflects the transient formation of a ******PRLR-ZAP-70-Vav****** ***complex*** and its immunomodulatory actions involve diverse interactions that affect TCR expression and signaling mechanisms .	parallel	1
2248	10221598	5618;7535	PRLR;ZAP-70	These observations suggest that PRL signaling reflects the transient formation of a ******PRLR-ZAP-70-Vav****** ***complex*** and its immunomodulatory actions involve diverse interactions that affect TCR expression and signaling mechanisms .	parallel	1
2249	10221598	7409;7535	Vav;ZAP-70	These observations suggest that PRL signaling reflects the transient formation of a ******PRLR-ZAP-70-Vav****** ***complex*** and its immunomodulatory actions involve diverse interactions that affect TCR expression and signaling mechanisms .	parallel	1
2250	10221646	3586;942	IL-10;CD86	In BALB.B macrophages , T. gondii-induced ***IL-10*** ***down-regulates*** surface expression of ***CD86*** , thus indicating an interference of parasite-dependent cytokine release and modulation of CD86 .	negative	1
2251	10221670	4803;4099	Nerve growth factor;myelin-associated glycoprotein	***Nerve growth factor*** ***modulates*** ***myelin-associated glycoprotein*** binding to sensory neurons .	target	0
2252	10221670	4803;4099	Nerve growth factor;MAG	***Nerve growth factor*** ( NGF ) ***upregulated*** expression of the ***MAG*** binding molecule in a dose dependent manner .	positive	1
2253	10221670	4803;4099	NGF;MAG	Schwann cells co-cultured with sensory neurons in serum-free medium stimulated maximal expression of the ***MAG*** binding molecule , which was ***decreased*** by addition of ***anti-NGF*** to the co-cultures .	negative	0
2254	10221778	3553;10468	IL-1beta;follistatin	Production of ***follistatin*** by HepG2 cells was stimulated by activin A , but was ***inhibited*** by both ***IL-1beta*** and IL-6 , indicating a complex regulatory loop is operable to modulate the effects of activin A during inflammation .	negative	1
2255	10221780	5617;3717	Prolactin;Jak2	***Jak2*** and Stat1 phosphorylation were ***induced*** by ***Prolactin*** within 10 min and Stat5 within 30 min .	target	1
2256	10221780	5617;6772	Prolactin;Stat1	Jak2 and ***Stat1*** phosphorylation were ***induced*** by ***Prolactin*** within 10 min and Stat5 within 30 min .	target	1
2257	10221781	7124;7018	tumor necrosis factor alpha;transferrin	In vitro ***regulation*** of rat Sertoli cell ***transferrin*** expression by ***tumor necrosis factor alpha*** and retinoic acid .	target	1
2258	10221781	7124;7018	tumor necrosis factor alpha;transferrin	In the present study , we examined the in vitro ***regulation*** of 20-day-old rat Sertoli cell ***transferrin*** expression by ***tumor necrosis factor alpha*** ( TNFalpha ) , a paracrine factor produced by germ cells .	target	1
2259	10222053	5777;933	SHP-1;CD22	In B lymphocytes , the down-regulatory phosphatase ***SHP-1*** ***associates*** with ***CD22*** and CD32b ( also known as FcgammaRIIB ) and acts as a critical negative regulator of B-cell receptor signaling .	parallel	0
2260	10222053	5777;2213	SHP-1;CD32b	In B lymphocytes , the down-regulatory phosphatase ***SHP-1*** ***associates*** with CD22 and ***CD32b*** ( also known as FcgammaRIIB ) and acts as a critical negative regulator of B-cell receptor signaling .	parallel	0
2261	10222064	3565;960	IL-4;CD44	***IL-4*** ***decreased*** ***CD44-HA*** binding on monocytes initially treated with TNFalpha .	negative	0
2262	10222064	3565;960	IL-4;CD44	In contrast , ***IL-4*** treatment of monocytes ***inhibited*** ***CD44-HA*** binding and reversed the 5 - to 10-kDa decrease in monocyte CD44 Mr.	negative	1
2263	10222136	998;6383	cdc42Hs;Syndecan-2	These results provide a ***link*** between ***Syndecan-2*** , actin cytoskeleton , and ***cdc42Hs*** .	parallel	0
2264	10222137	4193;7157	MDM2;p53	Using a model cell line conditionally expressing MDM2 , the murine analogue of HDM2 , we present evidence indicating that leptomycin B abrogates MDM2 's role in p53 degradation and that the accumulation of ***p53*** in distinct nuclear bodies is ***mediated*** by ***MDM2*** .	target	0
2265	10222149	4485;5747	MSP;FAK	***MSP*** also ***affected*** focal adhesion kinase ( ***FAK*** ) which is important for some types of cell adhesion and motility .	target	0
2266	10222227	1906;3565	endothelin-1;interleukin-4	In this study , we investigated gastric mucosal inflammatory responses during Helicobacter pylori lipopolysaccharide-induced gastritis by analyzing the ***interplay*** between mucosal expression of ***endothelin-1*** ( ET-1 ) , ***interleukin-4*** ( IL-4 ) and tumor necrosis factor-alpha ( TNF-alpha ) .	parallel	1
2267	10222245	3952;3060	leptin;orexin	***orexin*** A concentration in the lateral hypothalamus was significantly ***decreased*** by the ***leptin*** treatment ( -68 % ; p < 0.01 ) .	negative	0
2268	10222798	6387;7852	SDF-1;CXCR4	SDF-1 , a cytokine belonging to the chemokine family has an inhibitory activity against the HIV-1 infection , because ***SDF-1*** Is the physiological ***ligand*** for ***CXCR4*** , the entry coreceptor for T tropic HIV-1 virus .	parallel	1
2269	10223183	3827;2822	bradykinin;PLD	***bradykinin*** ***activated*** ***PLD*** acutely but transiently .	positive	1
2270	10223185	3082;4233	HGF;c-met	These results suggest the possibility of ***cross-talk*** between ******HGF/c-met****** and EGF/EGFR signaling pathways , and the involvement of JNK1 induction in HGF-mediated apoptotic cell death .	parallel	0
2271	10223185	3082;900	HGF;cyclin G1	***HGF*** treatment ***increased*** cyclin A , ***cyclin G1*** and nuclear transcriptional factor ( NFkappaB ) protein expression .	positive	0
2272	10223185	3082;4790	HGF;NFkappaB	***HGF*** treatment ***increased*** cyclin A , cyclin G1 and nuclear transcriptional factor ( ***NFkappaB*** ) protein expression .	positive	0
2273	10223208	51176;1499	LEF-1;beta-catenin	Differential expression of prostaglandin endoperoxide H synthase-2 and formation of activated ******beta-catenin-LEF-1****** transcription ***complex*** in mouse colonic epithelial cells contrasting in Apc .	parallel	1
2274	10223208	324;5743	Apc;PGHS-2	It has been suggested that ***Apc*** mutations are ***linked*** mechanistically to increased ***PGHS-2*** expression by elevated nuclear accumulation of beta-catenin-Tcf-LEF transcription complex .	parallel	0
2275	10223208	51176;1499	LEF-1;beta-catenin	Our data indicate that the differential induction of ******beta-catenin-LEF-1****** ***complex*** correlates closely with differential expression of PGHS-2 .	parallel	1
2276	10223294	7056;5624	thrombomodulin;protein C	Probing the ***activation*** of ***protein C*** by the ***thrombin-thrombomodulin*** complex using structural analysis , site-directed mutagenesis , and computer modeling .	positive	1
2277	10223354	7124;3384	Tumor necrosis factor (TNF)-alpha;intercellular adhesion molecule (ICAM)-2	***Tumor necrosis factor (TNF)-alpha*** and interleukin ( IL ) -1 beta ***down-regulate*** ***intercellular adhesion molecule (ICAM)-2*** expression on the endothelium .	negative	1
2278	10223354	3384;3689	ICAM-2;Mac-1	***ICAM-2*** , a constitutively expressed endothelial ***ligand*** for beta2 integrins LFA-1 and ***Mac-1*** , is involved in leukocyte adhesion to resting endothelium and in transmigration in vitro , however its role in inflammation is unclear .	parallel	1
2279	10223618	958;355	CD40;Fas	***CD40*** stimulation ***enhanced*** ***Fas*** expression on HTC/C3 cells .	positive	0
2280	10223618	958;596	CD40;Bcl-2	***CD40*** stimulation ***enhanced*** ***Bcl-2*** expression , and antisense oligonucleotide against Bcl-2 canceled the inhibition of HTC/C3 cell growth caused by CD40 stimulation .	positive	0
2281	10223633	4133;4137	MAP2b;Tau	Collectively , these results indicate that ***MAP2b*** could ***impair*** the ability of MAP2c and ***Tau*** to redistribute F-actin in Sf9 cells , thereby decreasing their capacity to induce process formation .	negative	0
2282	10223633	4133;4137	MAP2b;Tau	***MAP2b*** ***impairs*** ***Tau*** ability to induce process outgrowth .	negative	0
2283	10223633	4137;4133	Tau;MAP2c	***Tau*** ***affects*** ***MAP2c*** capacity to induce the formation of multiple processes .	target	0
2284	10223719	9241;2353	Noggin;Fos	***Noggin*** ***upregulates*** ***Fos*** expression by a calcium-mediated pathway in amphibian embryos .	positive	1
2285	10224040	317;4790	CED-4;NF-kappaB	Human CARD4 protein is a novel ***CED-4/Apaf*** -1 cell death family member that ***activates*** ***NF-kappaB*** .	positive	1
2286	10224040	10392;8767	CARD4;RICK	***CARD4*** ***interacted*** with the serine-threonine kinase ***RICK*** and potently induced NF-kappaB activity through TRAF-6 and NIK signaling molecules .	parallel	1
2287	10224040	10392;4790	CARD4;NF-kappaB	***CARD4*** interacted with the serine-threonine kinase RICK and potently ***induced*** ***NF-kappaB*** activity through TRAF-6 and NIK signaling molecules .	target	1
2288	10224043	3298;5524	HSF2;PP2A	In addition , overexpression of ***HSF2*** ***stimulates*** ***PP2A*** activity in cells , indicating the relevance of HSF2 as a regulator of PP2A in vivo .	positive	0
2289	10224044	4088;7421	Smad3;vitamin D receptor	Recently , we found that ***Smad3*** , a downstream component of the TGF-beta signaling pathway , ***potentiates*** ligand-induced transactivation of ***vitamin D receptor*** ( VDR ) as a coactivator of VDR ( Yanagisawa , J. , Yanagi , Y. , Masuhiro , Y. , Suzawa , M. , Watanabe , M. , Kashiwagi , K. , Toriyabe , T. , Kawabata , M. , Miyazono , K. , and Kato , S. ( 1999 ) Science 283 , 1317-1321 ) .	positive	0
2290	10224044	4091;7040	Smad6;TGF-beta	Here , we investigated the roles of inhibitory Smads , ***Smad6*** and Smad7 , which are negative ***regulators*** of the ***TGF-beta/bone*** morphogenetic protein signaling pathway , on the Smad3-mediated potentiation of VDR function .	negative	1
2291	10224044	4092;7040	Smad7;TGF-beta	Here , we investigated the roles of inhibitory Smads , Smad6 and ***Smad7*** , which are negative ***regulators*** of the ***TGF-beta/bone*** morphogenetic protein signaling pathway , on the Smad3-mediated potentiation of VDR function .	negative	1
2292	10224044	4092;4088	Smad7;Smad3	Interaction studies in vivo and in vitro showed that ***Smad7*** ***inhibited*** the formation of the ***VDR-Smad3*** complex , whereas Smad6 had no effect .	negative	1
2293	10224044	4092;7421	Smad7;VDR	Interaction studies in vivo and in vitro showed that ***Smad7*** ***inhibited*** the formation of the ***VDR-Smad3*** complex , whereas Smad6 had no effect .	negative	1
2294	10224044	7421;4088	VDR;Smad3	Interaction studies in vivo and in vitro showed that Smad7 inhibited the formation of the ******VDR-Smad3****** ***complex*** , whereas Smad6 had no effect .	parallel	1
2295	10224053	7528;3949	YY1;LDL receptor	The inhibition is independent of ***YY1*** ***binding*** directly to the ***LDL receptor*** promoter , and we show that the same region of YY1 that interacts in solution with Sp1 also interacts with SREBP .	parallel	1
2296	10224058	5340;4318	plasmin;matrix metalloproteinase-9	***Activation*** of ***matrix metalloproteinase-9*** ( MMP-9 ) via a converging ***plasmin/stromelysin*** -1 cascade enhances tumor cell invasion .	positive	1
2297	10224067	7040;5599	TGF-beta;JNK1	Although SEK and MKK7 acted downstream of TAK1 , only a kinase-defective SEK mutant blocked ***TGF-beta-induced*** ***activation*** of ***JNK1*** , indicating that the TGF-beta signal is relayed solely through SEK , but not MKK7 , in vivo .	positive	1
2298	10224067	7040;5599	TGF-beta;JNK1	The ***activation*** of ***JNK1*** by ***TGF-beta*** was abrogated by a kinase-defective HPK1 mutant but not by a kinase-defective mutant of kinase homologous to Ste20/Sps1 .	positive	1
2299	10224067	11184;5599	HPK1;JNK1	The activation of ***JNK1*** by TGF-beta was ***abrogated*** by a kinase-defective ***HPK1*** mutant but not by a kinase-defective mutant of kinase homologous to Ste20/Sps1 .	positive	0
2300	10224067	7040;5599	TGF-beta;JNK1	This result indicates that HPK1 is specifically required for ***TGF-beta-induced*** ***activation*** of ***JNK1*** .	positive	1
2301	10224067	6885;5599	TGF-beta-activated kinase 1;JNK1	We also found that TGF-beta-induced ***JNK1*** activation was ***blocked*** by a kinase-defective mutant of ***TGF-beta-activated kinase 1*** ( TAK1 ) .	positive	0
2302	10224067	6885;11184	TAK1;HPK1	In addition , ***interaction*** between ***HPK1*** and ***TAK1*** was observed in transient transfection assays , and this interaction was enhanced by TGF-beta treatment .	parallel	1
2303	10224067	5609;5599	MKK7;JNK1	Both stress-activated protein kinase/extracellular signal-regulated kinase kinase ( SEK ) and mitogen-activated protein kinase kinase 7 ( ***MKK7*** ) are immediate upstream ***activators*** of ***JNK1*** .	positive	1
2304	10224076	6294;998	glutathione S-transferase fusion protein;cdc42	A p21-binding domain ***glutathione S-transferase fusion protein*** specifically ***binds*** Rac and ***cdc42*** in their GTP-bound forms both in vitro and in cell samples .	parallel	1
2305	10224081	8106;10196	Poly(A)-binding protein II;PRMT3	***Poly(A)-binding protein II*** and deletion mutants expressed in Escherichia coli were in vitro ***substrates*** for two mammalian protein arginine methyltransferases , PRMT1 and ***PRMT3*** , with S-adenosyl-L-methionine as the methyl group donor .	parallel	1
2306	10224090	578;598	Bak;Bcl-xL	***Bak*** BH3 peptides ***antagonize*** ***Bcl-xL*** function and induce apoptosis through cytochrome c-independent activation of caspases .	negative	1
2307	10224093	10391;7414	ClipinC;vinculin	Furthermore , ***ClipinC*** was ***associated*** with ***vinculin*** , which is a major component of focal contacts .	parallel	0
2308	10224094	836;5747	caspase-3;FAK	DCVC treatment activated ***caspase-3*** which was ***associated*** with cleavage of ***FAK*** .	parallel	0
2309	10224109	4790;3576	NF-kappaB;IL-8	In 16HBE human bronchial epithelial cells , ***IL-8*** expression is ***regulated*** predominantly by ***NF-kappaB*** , and PG490 but not cyclosporin A can completely inhibit expression of IL-8 .	target	1
2310	10224110	7124;4790	TNF-alpha;NF-kappaB	PG490 potently inhibited ***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** .	positive	1
2311	10224110	7124;329	TNF-alpha;c-IAP1	PG490 also blocked ***TNF-alpha-mediated*** ***induction*** of c-IAP2 ( hiap-1 ) and ***c-IAP1*** ( hiap-2 ) , members of the inhibitor of apoptosis ( IAP ) family .	target	1
2312	10224110	7124;330	TNF-alpha;c-IAP2	PG490 also blocked ***TNF-alpha-mediated*** ***induction*** of ***c-IAP2*** ( hiap-1 ) and c-IAP1 ( hiap-2 ) , members of the inhibitor of apoptosis ( IAP ) family .	target	1
2313	10224110	7124;4790	TNF-alpha;NF-kappaB	Our identification of a compound that blocks ***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** may enhance the cytotoxicity of TNF-alpha on tumors in vivo and limit its proinflammatory effects .	positive	1
2314	10224114	7066;3717	Thrombopoietin;JAK2	***Thrombopoietin*** signal transduction ***requires*** functional ***JAK2*** , not TYK2 .	target	0
2315	10224114	4352;3717	proto-oncogene c-mpl;JAK2	Upon binding to its receptor , the product of the ***proto-oncogene c-mpl*** , Thrombopoietin ( TPO ) ***activates*** both ***JAK2*** and TYK2 in multiple cell lines as well as megakaryocytes and platelets .	positive	1
2316	10224120	10728;3320	p23;hsp90	Ligand dependence was reconstituted in the presence of molybdate , a transition metal ion known to stabilize the ***interaction*** between the molecular chaperone ***hsp90*** and ***p23*** .	parallel	1
2317	10224122	6385;2247	syndecan-4;bFGF	Further , heparan sulfate proteoglycans and , specifically , ***syndecan-4*** were implicated as the ***modulator*** of ***bFGF*** binding and activity .	target	0
2318	10224125	4301;5906	AF6;Rap1A	Notably , among the Ras-related proteins ***AF6*** ***binds*** most tightly to ***Rap1A*** which could imply a role of Rap1A in AF6 regulation .	parallel	1
2319	10224129	7057;7040	thrombospondin-1;TGF-beta	The mechanism of ***TGF-beta*** ***activation*** by ***thrombospondin-1*** appears to be conserved among TGF-beta isoforms as latent TGF-beta2 can also be activated by thrombospondin-1 or KRFK peptides in a manner that is sensitive to inhibition by LSKL peptides .	positive	1
2320	10224129	7040;7057	latency-associated peptide;thrombospondin-1	We now report that the ***latency-associated peptide*** ( LAP ) of the latent TGF-beta complex also ***interacts*** with ***thrombospondin-1*** as part of a biologically active complex .	parallel	1
2321	10224129	7040;7057	LAP;thrombospondin-1	The ***interactions*** of ***LAP*** with ***thrombospondin-1*** through the LSKL and KRFK sequences are important for thrombospondin-mediated activation of latent TGF-beta since LSKL peptides can competitively inhibit latent TGF-beta activation by thrombospondin or KRFK-containing peptides .	parallel	1
2322	10224129	7040;7040	TGF-beta;LAP	In addition , the association of LAP with thrombospondin-1 may function to prevent the re-formation of an inactive ******LAP.TGF-beta****** ***complex*** since thrombospondin-bound LAP no longer confers latency on active TGF-beta .	parallel	1
2323	10224129	7040;7057	LAP;thrombospondin-1	In addition , the ***association*** of ***LAP*** with ***thrombospondin-1*** may function to prevent the re-formation of an inactive LAP.TGF-beta complex since thrombospondin-bound LAP no longer confers latency on active TGF-beta .	parallel	0
2324	10224131	5106;5468	PCK2;PPARgamma	The human and rat ***PCK2*** elements ***bound*** ***PPARgamma/RXR*** with the same affinities .	parallel	1
2325	10224135	4091;4086	Smad6;Smad1	Moreover , we confirmed that the ectopic expressions of ***Smad6*** and Smad7 ***inhibited*** the hBMP-2-induced ***Smad1/Smad5*** phosphorylation .	negative	1
2326	10224135	4091;4090	Smad6;Smad5	Moreover , we confirmed that the ectopic expressions of ***Smad6*** and Smad7 ***inhibited*** the hBMP-2-induced ***Smad1/Smad5*** phosphorylation .	negative	1
2327	10224135	4092;4086	Smad7;Smad1	Moreover , we confirmed that the ectopic expressions of Smad6 and ***Smad7*** ***inhibited*** the hBMP-2-induced ***Smad1/Smad5*** phosphorylation .	negative	1
2328	10224135	4092;4090	Smad7;Smad5	Moreover , we confirmed that the ectopic expressions of Smad6 and ***Smad7*** ***inhibited*** the hBMP-2-induced ***Smad1/Smad5*** phosphorylation .	negative	1
2329	10224135	4092;4087	Smad7;Smad2	Moreover , we found that the ectopic expression of ***Smad7*** , but not Smad6 , ***inhibited*** the activin A-induced ***Smad2*** phosphorylation in HS-72 cells .	negative	1
2330	10224145	4086;3224	Smad1;Hoxc-8	Our findings suggest that ***Smad1*** ***interaction*** with ***Hoxc-8*** dislodges Hoxc-8 from its DNA binding element , resulting in the induction of gene expression .	parallel	1
2331	10224145	4086;4089	Smad1;Smad4	Upon phosphorylation by the BMP receptors , ***Smad1*** ***interacts*** with ***Smad4*** and translocates into the nucleus where the complex recruits DNA-binding protein ( s ) to activate specific gene transcription .	parallel	1
2332	10224145	4086;3224	Smad1;Hoxc-8	Using a yeast two-hybrid approach , we found that ***Smad1*** ***interacts*** with ***Hoxc-8*** , a homeodomain transcription factor .	parallel	1
2333	10224145	4086;3224	Smad1;Hoxc-8	The ***interaction*** between ***Smad1*** and ***Hoxc-8*** was confirmed by a " pull-down " assay and a co-immunoprecipitation experiment in COS-1 cells .	parallel	1
2334	10224145	3224;6696	Hoxc-8;osteopontin	Interestingly , purified Smad1 inhibited ***Hoxc-8*** ***binding*** to the ***osteopontin*** Hoxc-8 site in a concentration-dependent manner .	parallel	1
2335	10224145	4086;3224	Smad1;Hoxc-8	Interestingly , purified ***Smad1*** ***inhibited*** ***Hoxc-8*** binding to the osteopontin Hoxc-8 site in a concentration-dependent manner .	negative	1
2336	10224160	4043;5054	RAP;PAI-1	Addition of ***RAP*** completely ***blocked*** the VLDL-activated ***PAI-1*** transcription .	negative	0
2337	10224227	355;3297	Fas;HSF1	Activation of ***Fas*** ***inhibits*** heat-induced activation of ***HSF1*** and up-regulation of hsp70 .	negative	1
2338	10224227	355;3308	Fas;hsp70	Activation of ***Fas*** ***inhibits*** heat-induced activation of HSF1 and up-regulation of ***hsp70*** .	negative	1
2339	10224244	80149;6908	Reg1;TBP	***Suppression*** of the ***TBP*** mutant by our ***Reg1*** and SNF4 mutations appears unrelated to glucose repression , since these mutations do not alleviate repression of SUC2 , and glucose levels have little effect on INO1 transcription .	negative	1
2340	10224276	3458;3620	IFN-gamma;IDO	***IDO*** was ***induced*** in macrophages by a synergistic combination of the T cell-derived signals ***IFN-gamma*** and CD40-ligand .	target	1
2341	10224278	9402;27040	Grf40;linker for activation of T cells	Incidentally , ***Grf40*** ***binds*** to ***linker for activation of T cells*** ( LAT ) possibly via its SH2 domain .	parallel	1
2342	10224288	998;207	Cdc42;Rac	However , expression of an effector loop mutant of Cdc42Hs ( Cdc42HsC40 ) unable to bind PAK and other CRIB ( for ******Cdc42/Rac****** interacting ***binding*** ) - containing target proteins resulted in abrogation of both S. typhimurium-induced nuclear and cytoskeletal responses .	parallel	1
2343	10224350	1232;6356	CCR3;eotaxin	METHODS : We have examined phenotypic changes as CD34 + cells develop to the eosinophil lineage in vitro , and have evaluated BM eosinophils from asthmatic and control subjects for expression of the ***eotaxin*** ***receptor*** , ***CCR3*** .	parallel	1
2344	10224454	7040;3596	TGF-beta;IL-13	The production of IL-4 and ***IL-13*** by naive T cells is differentially ***regulated*** by ***TGF-beta*** and IL-12 .	target	1
2345	10224454	7040;3565	TGF-beta;IL-4	The production of ***IL-4*** and IL-13 by naive T cells is differentially ***regulated*** by ***TGF-beta*** and IL-12 .	target	1
2346	10224454	7293;3596	OX40;IL-13	Engagement of ***OX40*** on activated naive T cells ***increases*** their expression of IL-4 and ***IL-13*** , suppresses that of IFN-gamma and promotes their development into Th2-like effectors .	positive	0
2347	10224454	7293;3565	OX40;IL-4	Engagement of ***OX40*** on activated naive T cells ***increases*** their expression of ***IL-4*** and IL-13 , suppresses that of IFN-gamma and promotes their development into Th2-like effectors .	positive	0
2348	10224467	3565;3558	IL-4;IL-2	***IL-4*** ***inhibits*** human CD8 T cell expression of the common ***IL-2*** receptor gamma chain .	negative	1
2349	10224501	7040;5328	TGF-beta;uPA	***TGF-beta*** appeared to ***induce*** also membrane-bound ***uPA*** activity and the release of active plasminogen activator inhibitor-1 , indicating that TGF-beta has the potential to regulate plasminogen activation at the RPE cell surface .	target	1
2350	10224501	7040;5502	TGF-beta;inhibitor-1	***TGF-beta*** appeared to ***induce*** also membrane-bound uPA activity and the release of active plasminogen activator ***inhibitor-1*** , indicating that TGF-beta has the potential to regulate plasminogen activation at the RPE cell surface .	target	1
2351	10224665	3984;1072	LIMK1;cofilin	***LIMK1*** ***phosphorylates*** ***cofilin*** , an actin depolymerisation factor , which is then unable to bind and depolymerise F-actin .	target	1
2352	10225366	3952;1392	Leptin;CRH	Using primary cultures of neonatal ( 5 - to 6-day-old ) rat hypothalamic cells , we confirmed that ***Leptin*** ( 0.1-10 nM ) ***stimulates*** ***CRH*** secretion .	positive	0
2353	10225429	1268;6548	CB1;NHE-1	Cannabinoid receptor ***CB1*** ***activates*** the Na + / H + exchanger ***NHE-1*** isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways .	positive	1
2354	10225429	1268;5706	CB1;p44	These results suggest that ***CB1*** ***stimulates*** NHE-1 by G ( i/o ) - mediated activation of ***p42/p44*** MAP kinase and highlight a cellular physiological process targeted by CB1 .	positive	0
2355	10225429	1268;6548	CB1;NHE-1	These results suggest that ***CB1*** ***stimulates*** ***NHE-1*** by G ( i/o ) - mediated activation of p42/p44 MAP kinase and highlight a cellular physiological process targeted by CB1 .	positive	0
2356	10225447	356;355	FasL;Fas	Fas and ***Fas*** ***ligand*** ( ***FasL*** ) have been found both in lymphoid and in non-lymphoid malignancies , and are thought to play a role in the interplay between tumors and the immune system .	parallel	1
2357	10225458	1235;6364	CCR6;Mip-3alpha	***Mip-3alpha*** and its ***receptor*** ***CCR6*** were expressed in all 4 tested pancreatic cancer cell lines .	parallel	1
2358	10225462	5054;5327	PAI-1;t-PA	Forearm blood flow was assessed by venous plethysmography ; ***t-PA*** and plasminogen activator ***inhibitor*** 1 ( ***PAI-1*** ) antigen values were expressed as flow-dependent ( net release , the product of venoarterial concentration gradient and forearm blood flow ) or independent ( absolute and fractional concentration gradients ) indices .	negative	1
2359	10225948	920;3932	CD4;Lck	Studying the route via which Lck travels from its site of synthesis to the plasma membrane , we found that : ***CD4*** ***associates*** with ***Lck*** within 10 min of synthesis , long before CD4 has reached the plasma membrane ; Lck associates with intracellular CD4 early after synthesis and with cell surface CD4 at later times ; and transport of CD4-bound Lck to the plasma membrane is inhibited by Brefeldin A.	parallel	0
2360	10225948	3932;920	Lck;CD4	Studying the route via which Lck travels from its site of synthesis to the plasma membrane , we found that : CD4 associates with Lck within 10 min of synthesis , long before CD4 has reached the plasma membrane ; ***Lck*** ***associates*** with intracellular ***CD4*** early after synthesis and with cell surface CD4 at later times ; and transport of CD4-bound Lck to the plasma membrane is inhibited by Brefeldin A.	parallel	0
2361	10225948	3932;920	Lck;CD4	These data indicate that the initial ***association*** of newly synthesized ***Lck*** with ***CD4*** , and therefore with membranes , occurs on intracellular membranes of the exocytic pathway .	parallel	0
2362	10225968	3552;3569	IL-1alpha;IL-6	Endogenous ***IL-1alpha*** from systemic sclerosis fibroblasts ***induces*** ***IL-6*** and PDGF-A .	target	1
2363	10225968	3552;5154	IL-1alpha;PDGF-A	Endogenous ***IL-1alpha*** from systemic sclerosis fibroblasts ***induces*** IL-6 and ***PDGF-A*** .	target	1
2364	10225968	3552;3569	IL-1alpha;IL-6	***IL-1alpha*** ***induced*** ***IL-6*** and PDGF-A , which are potent stimulators of collagen production and proliferation in normal fibroblasts .	target	1
2365	10225968	3552;5154	IL-1alpha;PDGF-A	***IL-1alpha*** ***induced*** IL-6 and ***PDGF-A*** , which are potent stimulators of collagen production and proliferation in normal fibroblasts .	target	1
2366	10225971	4485;4486	hepatocyte growth factor-like;Ron	The ***Ron/STK*** receptor tyrosine kinase is a member of the c-Met family of receptors and is ***activated*** by ***hepatocyte growth factor-like*** protein ( HGFL ) .	positive	1
2367	10225978	3605;8600	IL-17;ODF	In addition , ***IL-17*** dose-dependently ***induced*** expression of osteoclast differentiation factor ( ***ODF*** ) mRNA in osteoblasts .	target	1
2368	10225978	4982;8600	OCIF;ODF	Osteoclastogenesis inhibitory factor ( ***OCIF*** ) , a decoy ***receptor*** of ***ODF*** , completely inhibited IL-17-induced osteoclast differentiation in the cocultures .	parallel	1
2369	10226025	5586;5170	PRK2;PDK1	***PRK2*** is a probable ***substrate*** for ***PDK1*** .	parallel	1
2370	10226032	1022;983	CAK;Cdc2	***Cdc2-cyclin*** complexes isolated from the arrested cells could be ***activated*** in vitro by recombinant ***CAK*** , whereas complexes from wild-type cells or either of the single mutants were refractory to activation .	positive	1
2371	10226073	2246;7076	FGF-1;TIMP-1	Neither FGF-1 nor ***FGF-1*** plus heparin ***affected*** the expression of ***TIMP-1*** , TIMP-2 , and gelatinase A.	target	0
2372	10226073	2246;7077	FGF-1;TIMP-2	Neither FGF-1 nor ***FGF-1*** plus heparin ***affected*** the expression of TIMP-1 , ***TIMP-2*** , and gelatinase A.	target	0
2373	10226079	3553;3576	IL-1beta;IL-8	***IL-1beta*** ***induction*** and intracellular accumulation of ***IL-8*** appeared to be unaffected by CF genotype .	target	1
2374	10226093	1051;4790	NF-IL6;NF-kappaB	CCB of all subclasses increased DNA ***binding*** of ***NF-IL6*** and ***NF-kappaB*** as early as 30 minutes after stimulation with the drugs .	parallel	1
2375	10226096	7124;5156	tumor necrosis factor-alpha;PDGF-Ralpha	Concomitantly , in quantitative reverse transcriptase-polymerase chain reaction , interleukin-1beta or ***tumor necrosis factor-alpha*** stimulation specifically ***upregulated*** the expression of ***PDGF-Ralpha*** mRNA but not of other ligand or receptor genes in cultured smooth muscle cells .	positive	1
2376	10226333	4843;4846	iNOS;eNOS	These findings suggest that the decrease in GFR after LPS is caused by local ***inhibition*** of ***eNOS*** by ***iNOS*** possibly via NO autoinhibition .	negative	1
2377	10226586	3084;2064	heregulin alpha;erbB-2	These data suggest that constitutive activation of ***erbB-2*** , erbB-3 and erbB-4 receptors could be ***induced*** by ***heregulin alpha*** via an autocrine loop mechanism , and that the active forms of erbB-4 may cooperate with the other members of the EGF-receptor family in human lung carcinogenesis .	target	1
2378	10226586	3084;2065	heregulin alpha;erbB-3	These data suggest that constitutive activation of erbB-2 , ***erbB-3*** and erbB-4 receptors could be ***induced*** by ***heregulin alpha*** via an autocrine loop mechanism , and that the active forms of erbB-4 may cooperate with the other members of the EGF-receptor family in human lung carcinogenesis .	target	1
2379	10226590	3082;1499	HGF;beta-catenin	Immunoprecipitation studies revealed that ***HGF/SF*** ***elevated*** the level of tyrosine-phosphorylated ***beta-catenin*** within these cells together with reducing the amount of E-cadherin that was observed to co-precipitate with the beta-catenin .	positive	0
2380	10226590	3082;1499	HGF;beta-catenin	We conclude that ***phosphorylation*** of ***beta-catenin*** by ***HGF/SF*** affects its association with E-cadherin at the cell surface and thus regulates E-cadherin function resulting in colony scattering phenomena .	target	1
2381	10226590	1499;999	beta-catenin;E-cadherin	We conclude that phosphorylation of ***beta-catenin*** by HGF/SF affects its association with E-cadherin at the cell surface and thus ***regulates*** ***E-cadherin*** function resulting in colony scattering phenomena .	target	1
2382	10226596	3082;1499	HGF;beta-catenin	Using immunoprecipitation , ***HGF/SF*** ***induced*** tyrosine phosphorylation of ***beta-catenin*** but not desmoplakin .	target	1
2383	10226803	5443;3484	ACTH;IGFBP-1	***ACTH*** treatment predominantly ***increased*** the abundance of ***IGFBP-1*** and to a lesser extent IGFBP-3 in a time and dose-dependent fashion .	positive	0
2384	10226804	3552;3484	Interleukin-1 alpha;insulin-like growth factor binding protein-1	***Interleukin-1 alpha*** ( IL-1 alpha ) and tumor necrosis factor alpha ( TNF alpha ) ***regulate*** ***insulin-like growth factor binding protein-1*** ( IGFBP-1 ) levels and mRNA abundance in vivo and in vitro .	target	1
2385	10226804	7124;3484	tumor necrosis factor alpha;insulin-like growth factor binding protein-1	Interleukin-1 alpha ( IL-1 alpha ) and ***tumor necrosis factor alpha*** ( TNF alpha ) ***regulate*** ***insulin-like growth factor binding protein-1*** ( IGFBP-1 ) levels and mRNA abundance in vivo and in vitro .	target	1
2386	10226804	3552;3484	IL-1 alpha;IGFBP-1	We conclude that ***IL-1 alpha*** and TNF alpha ***increase*** circulating levels of ***IGFBP-1*** , reflecting direct effects on hepatic IGFBP-1 mRNA abundance .	positive	0
2387	10226804	7124;3484	TNF alpha;IGFBP-1	We conclude that IL-1 alpha and ***TNF alpha*** ***increase*** circulating levels of ***IGFBP-1*** , reflecting direct effects on hepatic IGFBP-1 mRNA abundance .	positive	0
2388	10226805	3486;3479	IGFBP-3;IGF-I	To determine if any human proteases act this way , we first studied plasma prekallikrein since it can copurify with IGFBP-3 , and found : 1 ) [ 125 ] IGFBP-3 binds to prekallikrein immobilized either on nitrocellulose or on immunocapture plates ; 2 ) the IGFBP-3 heparin binding domain participates in forming the IGFBP-3/prekallikrein complex ; 3 ) the binary ***IGFBP-3/prekallikrein*** complex can ***bind*** ***IGF-I*** to form a ternary complex ; and 4 ) activation of prekallikrein to alpha-kallikrein by Factor XIIa resulted in proteolysis of bound IGFBP-3 .	parallel	1
2389	10226806	3489;3481	IGFBP-6;IGF-II	***IGFBP-6*** is a relatively specific ***inhibitor*** of ***IGF-II*** actions ; it has not been shown to potentiate IGF actions .	negative	1
2390	10227387	5966;4792	Rel;IkappaB alpha	Numerous studies have shown that stimulus-dependent ***Rel*** activation ***requires*** degradation of ***IkappaB alpha*** , p105 or other member of the IkappaB family , and that this process is precluded by agents that inhibit proteasome activity .	target	0
2391	10227387	5966;4790	Rel;p105	Numerous studies have shown that stimulus-dependent ***Rel*** activation ***requires*** degradation of IkappaB alpha , ***p105*** or other member of the IkappaB family , and that this process is precluded by agents that inhibit proteasome activity .	target	0
2392	10227387	6714;5971	Src;RelB	We show that treatment of SR1 cells with proteasome inhibitors abolishes RelB activity and thus suggest that RelB in these cells is associated with IkappaB and that ***v-Src*** transformation ***activates*** ***RelB*** by accelerating IkappaB proteolysis .	positive	1
2393	10227388	871;928	Hsp47;CD9	Cell surface ***colligin/Hsp47*** ***associates*** with tetraspanin protein ***CD9*** in epidermoid carcinoma cell lines .	parallel	0
2394	10227390	3953;3952	OB-R;leptin	Evidence for ligand-independent homo-oligomerization of ***leptin*** ***receptor*** ( ***OB-R*** ) isoforms : a proposed mechanism permitting productive long-form signaling in the presence of excess short-form expression .	parallel	1
2395	10227390	3953;3952	OB-R;leptin	The adipocyte secreted hormone ***leptin*** ( OB ) and its ***receptor*** ( ***OB-R*** ) are key regulators of mammalian body weight homeostasis .	parallel	1
2396	10227428	3456;355	IFN-beta;CD95	Additional in vitro studies showed that ***IFN-beta*** indeed rapidly ( within 24 h ) ***upregulates*** ***CD95*** expression on both primed and unprimed T cells and augments the release of sCD95 in culture supernatants .	positive	1
2397	10227429	3574;3458	IL-7;IFN-gamma	***IL-7*** was found to ***enhance*** proliferation responses and ***IFN-gamma*** secretion of myelin or recall Ag-specific Th1 cells through the selective up-regulation of the IL-2Ralpha and gamma but not beta chains in both an Ag-dependent and Ag-independent manner , but did not affect monocytes , B cells , or NK cells .	positive	0
2398	10227719	356;355	FasL;Fas	Two cytotoxic mechanisms of CTL have been demonstrated : one perforin/granzyme-based and the other Fas ( CD95 ) / ***Fas*** ***ligand*** ( ***FasL*** ) - based .	parallel	1
2399	10227805	2625;3458	GATA-3;IFN-gamma	***GATA-3*** significantly ***downregulates*** ***IFN-gamma*** production from developing Th1 cells in addition to inducing IL-4 and IL-5 levels .	negative	1
2400	10227805	2625;3458	GATA-3;IFN-gamma	We now show that ectopic expression of ***GATA-3*** in developing Th1 cells significantly ***inhibits*** ***IFN-gamma*** , as well as enhancing IL-4 and IL-5 production .	negative	1
2401	10227805	2625;3458	GATA-3;IFN-gamma	Furthermore , ***GATA-3*** ***inhibits*** production of ***IFN-gamma*** by developing Th1 cells in the complete absence of IL-4 .	negative	1
2402	10227816	959;958	CD40L;CD40	Whereas normals utilized ******CD40/CD40L****** ***interactions*** and IL-12 production for optimal interferon-gamma costimulation in PHA-stimulated cocultures , familial patient interferon-gamma production was low and unaffected by their blockade .	parallel	1
2403	10227816	959;958	CD40L;CD40	Thus , we demonstrate that the familial defect also involves interferon-gamma costimulation pathways requiring both ******CD40/CD40L****** ***interaction*** and IL-12 production , while residual pathways remain that allow low-level interferon-gamma production .	parallel	1
2404	10227974	3606;3458	IL-18;IFN-gamma	As a part of our ongoing studies on the molecular mechanisms of IL-18-induced IFN-gamma production , we have examined the transcriptional ***regulation*** of the ***IFN-gamma*** gene by ***IL-18*** in a human myelomonocytic cell line , KG-1 .	target	1
2405	10227974	3606;3458	IL-18;IFN-gamma	Transient transfection of promoter-reporter gene constructs revealed that the KBBsite is required for full ***IL-18-induced*** ***activation*** of the ***IFN-gamma*** gene transcription induced by IL-18 .	positive	1
2406	10227974	3606;3458	IL-18;IFN-gamma	These results are the first to show the actual significance of the NF-kappa B pathway in the ***regulation*** of ***IFN-gamma*** gene expression by ***IL-18*** .	target	1
2407	10227975	3606;3596	IL-18;IL-13	In this study , we found strong ***induction*** of ***IL-13*** mRNA and protein by IL-2 + ***IL-18*** in NK and T cells .	target	1
2408	10227975	3458;3596	IFN-gamma;IL-13	These results suggest ***IL-13*** expression induced by IL-2 + IL-18 may be ***regulated*** by ***IFN-gamma*** in vivo , while IL-10 expression may be IFN-gamma-independent .	target	1
2409	10227981	3458;5284	IFN-gamma;pIgR	Using an RNase protection assay , we found that IL-4 and ***IFN-gamma*** ***increase*** steady state levels of ***pIgR*** mRNA in both human intestinal ( HT29 ) and airway ( Calu-3 ) epithelial cells .	positive	0
2410	10227981	3565;5284	IL-4;pIgR	Using an RNase protection assay , we found that ***IL-4*** and IFN-gamma ***increase*** steady state levels of ***pIgR*** mRNA in both human intestinal ( HT29 ) and airway ( Calu-3 ) epithelial cells .	positive	0
2411	10227981	3458;3659	IFN-gamma;IRF-1	Both ***IFN-gamma*** and IL-4 ***increased*** expression of the inducible transcription factor IFN regulatory factor-1 ( ***IRF-1*** ) , but levels of IRF-1 only weakly correlated with levels of pIgR mRNA , suggesting that additional transcription factors are required .	positive	0
2412	10227981	3565;3659	IL-4;IRF-1	Both IFN-gamma and ***IL-4*** ***increased*** expression of the inducible transcription factor IFN regulatory factor-1 ( ***IRF-1*** ) , but levels of IRF-1 only weakly correlated with levels of pIgR mRNA , suggesting that additional transcription factors are required .	positive	0
2413	10227991	3683;3383	LFA-1;ICAM-1	***LFA-1*** ***binding*** to ***ICAM-1*** can enhance TCR-dependent proliferation of T cells , but it has been difficult to distinguish contributions from increased adhesion , and thus TCR occupancy , versus costimulatory signaling .	parallel	1
2414	10227994	355;356	Fas;Fas ligand	Activation-induced cell death of peripheral T cells results from the ***interaction*** between ***Fas*** and ***Fas ligand*** .	parallel	1
2415	10227994	8837;355	FLIP;Fas	TCR activation decreases the steady state protein levels of ***FLIP*** ( FLICE-like inhibitory protein ) , an ***inhibitor*** of the ***Fas*** signaling pathway .	negative	1
2416	10227996	3565;7124	IL-4;TNF-alpha	***IL-4*** ***inhibits*** the production of ***TNF-alpha*** and IL-12 by STAT6-dependent and - independent mechanisms .	negative	1
2417	10227996	3565;7124	IL-4;TNF-alpha	***IL-4*** failed to ***inhibit*** the release of ***TNF-alpha*** or IL-12 from STAT6 null macrophages stimulated with LPS alone .	negative	1
2418	10227996	3565;7124	IL-4;TNF-alpha	These data show that STAT6 is required for the ***IL-4-mediated*** ***inhibition*** of the production of ***TNF-alpha*** and IL-12 stimulated by LPS alone , but that IL-4 also activates distinct , STAT6 independent mechanism ( s ) that inhibit the IFN-gamma-mediated enhancement of IL-12 and TNF-alpha production .	negative	1
2419	10228003	5788;933	CD45;CD22	***CD45*** ***regulates*** tyrosine phosphorylation of ***CD22*** and its association with the protein tyrosine phosphatase SHP-1 .	target	1
2420	10228003	5777;933	SHP-1;CD22	Catalytically inactive ***SHP-1*** expressed in CD45-deficient cells ***interacted*** with ***CD22*** and decreased phosphatase activity in CD22 immunoprecipitates to levels that were comparable to those in CD45-positive cells .	parallel	1
2421	10228003	5788;933	CD45;CD22	These results indicate that ***CD45*** ***regulates*** tyrosine phosphorylation of ***CD22*** and binding of SHP-1 .	target	1
2422	10228003	5788;5777	CD45;SHP-1	These results indicate that ***CD45*** ***regulates*** tyrosine phosphorylation of CD22 and binding of ***SHP-1*** .	target	1
2423	10228004	356;355	Fas ligand;CD95	RT-PCR and FACS analyses revealed the expression of CD95 ( Fas ) by XS52 DC and of ***CD95*** ***ligand*** ( CD95L ) ( ***Fas ligand*** ) by activated HDK-1 T cells , suggesting a functional role for these molecules .	parallel	1
2424	10228008	959;5966	CD40L;c-Rel	Electrophoretic mobility shift assays showed that ***p50/p65/c-Rel*** and STAT-6 are effectively ***induced*** by ***CD40L*** and IL-4 , respectively , and bind to specific DNA motifs within the ECS .	target	1
2425	10228008	959;4790	CD40L;p50	Electrophoretic mobility shift assays showed that ***p50/p65/c-Rel*** and STAT-6 are effectively ***induced*** by ***CD40L*** and IL-4 , respectively , and bind to specific DNA motifs within the ECS .	target	1
2426	10228008	959;5970	CD40L;p65	Electrophoretic mobility shift assays showed that ***p50/p65/c-Rel*** and STAT-6 are effectively ***induced*** by ***CD40L*** and IL-4 , respectively , and bind to specific DNA motifs within the ECS .	target	1
2427	10228008	959;6778	CD40L;STAT-6	Electrophoretic mobility shift assays showed that p50/p65/c-Rel and ***STAT-6*** are effectively ***induced*** by ***CD40L*** and IL-4 , respectively , and bind to specific DNA motifs within the ECS .	target	1
2428	10228008	3565;5966	IL-4;c-Rel	Electrophoretic mobility shift assays showed that ***p50/p65/c-Rel*** and STAT-6 are effectively ***induced*** by CD40L and ***IL-4*** , respectively , and bind to specific DNA motifs within the ECS .	target	1
2429	10228008	3565;4790	IL-4;p50	Electrophoretic mobility shift assays showed that ***p50/p65/c-Rel*** and STAT-6 are effectively ***induced*** by CD40L and ***IL-4*** , respectively , and bind to specific DNA motifs within the ECS .	target	1
2430	10228008	3565;5970	IL-4;p65	Electrophoretic mobility shift assays showed that ***p50/p65/c-Rel*** and STAT-6 are effectively ***induced*** by CD40L and ***IL-4*** , respectively , and bind to specific DNA motifs within the ECS .	target	1
2431	10228008	3565;6778	IL-4;STAT-6	Electrophoretic mobility shift assays showed that p50/p65/c-Rel and ***STAT-6*** are effectively ***induced*** by CD40L and ***IL-4*** , respectively , and bind to specific DNA motifs within the ECS .	target	1
2432	10228009	5970;4790	p65;p50	IL-17 induced NF-kappa B protein-DNA complexes consisting of ******p65/p50****** ***heterodimers*** in the rat intestinal epithelial cell line IEC-6 .	parallel	1
2433	10228009	3605;4790	IL-17;NF-kappa B	***IL-17*** ***induced*** ***NF-kappa B*** protein-DNA complexes consisting of p65/p50 heterodimers in the rat intestinal epithelial cell line IEC-6 .	target	1
2434	10228009	3605;4790	IL-17;NF-kappa B	***IL-17*** acted in a synergistic fashion with IL-1 beta to ***induce*** the ***NF-kappa B*** site-dependent CINC promoter .	target	1
2435	10228009	1147;3605	I kappa B kinase-alpha;IL-17	Furthermore , ***IL-17*** induction of the CINC promoter could be ***inhibited*** by kinase-negative mutants of NF-kappa B-inducing kinase and ***I kappa B kinase-alpha*** .	positive	1
2436	10228009	3605;5594	IL-17;p38	In addition to activation of the NF-kappa B , ***IL-17*** ***regulated*** the activities of extracellular regulated kinase , c-Jun N-terminal kinase , and ***p38*** mitogen-activated protein kinases in IEC-6 cells .	target	1
2437	10228010	3002;5552	granzyme B;serglycin	To learn how the ***interaction*** of ***granzyme B*** ( GrB ) with ***serglycin*** might influence the apoptotic potential of this proteases , we have evaluated a model system where desalted CS is combined with isolated human granzyme .	parallel	1
2438	10228026	6647;4790	homodimer;NF-kappa B	Thrombin-induced p65 ***homodimer*** ***binding*** to downstream ***NF-kappa B*** site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion .	parallel	1
2439	10228026	5970;4790	p65;NF-kappa B	Thrombin-induced ***p65*** homodimer ***binding*** to downstream ***NF-kappa B*** site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion .	parallel	1
2440	10228026	6647;3383	homodimer;ICAM-1	Thrombin-induced p65 ***homodimer*** binding to downstream NF-kappa B site of the promoter ***mediates*** endothelial ***ICAM-1*** expression and neutrophil adhesion .	target	0
2441	10228026	5970;3383	p65;ICAM-1	Thrombin-induced ***p65*** homodimer binding to downstream NF-kappa B site of the promoter ***mediates*** endothelial ***ICAM-1*** expression and neutrophil adhesion .	target	0
2442	10228043	958;959	CD40;CD40 ligand	The data demonstrate that functional ******CD40-CD40 ligand****** ***interactions*** are essential for the selection of natural self-reactive B cell repertoires .	parallel	1
2443	10228066	1440;3687	G-CSF;CD11b/c	***G-CSF*** pretreatment ***up-regulated*** ***CD11b/c*** expression on circulating polymorphonuclear leukocytes , augmented the recruitment of neutrophils into the lung , and enhanced the phagocytic activity of circulating and recruited neutrophils in both the absence and presence of acute ethanol intoxication .	positive	1
2444	10228066	1440;2920	G-CSF;MIP-2	***G-CSF*** ***inhibited*** ***MIP-2*** but not TNF-alpha production in the lung .	negative	1
2445	10228073	3586;3458	IL-10;IFN-gamma	***Anti-IL-10*** also ***up-regulated*** SEA-specific ***IFN-gamma*** protein and mRNA responses in most splenocyte cultures from hepatosplenic schistosomiasis patients but had no effect on antigen-specific IL-4 or IL-5 production .	positive	1
2446	10228140	3458;6347	IFN-gamma;MCP-1	***IFN-gamma*** ***enhanced*** the BCG-mediated MIP-1alpha and ***MCP-1*** expression in a concentration-dependent manner .	positive	0
2447	10228140	3458;6348	IFN-gamma;MIP-1alpha	***IFN-gamma*** ***enhanced*** the BCG-mediated ***MIP-1alpha*** and MCP-1 expression in a concentration-dependent manner .	positive	0
2448	10228140	3565;6347	IL-4;MCP-1	***IL-4*** ***inhibited*** the BCG-mediated MIP-1alpha and ***MCP-1*** expression in a concentration-dependent manner .	negative	1
2449	10228140	3565;6348	IL-4;MIP-1alpha	***IL-4*** ***inhibited*** the BCG-mediated ***MIP-1alpha*** and MCP-1 expression in a concentration-dependent manner .	negative	1
2450	10228155	8945;1499	FWD1;beta-catenin	An F-box protein , ***FWD1*** , ***mediates*** ubiquitin-dependent proteolysis of ***beta-catenin*** .	target	0
2451	10228155	8945;8312	FWD1;Axin	Here we show that ***FWD1*** ( the mouse homologue of Slimb/betaTrCP ) , an F-box/WD40-repeat protein , specifically formed a multi-molecular ***complex*** with beta-catenin , ***Axin*** , GSK-3beta and APC .	parallel	1
2452	10228155	8945;1499	FWD1;beta-catenin	Here we show that ***FWD1*** ( the mouse homologue of Slimb/betaTrCP ) , an F-box/WD40-repeat protein , specifically formed a multi-molecular ***complex*** with ***beta-catenin*** , Axin , GSK-3beta and APC .	parallel	1
2453	10228155	8945;2932	FWD1;GSK-3beta	Here we show that ***FWD1*** ( the mouse homologue of Slimb/betaTrCP ) , an F-box/WD40-repeat protein , specifically formed a multi-molecular ***complex*** with beta-catenin , Axin , ***GSK-3beta*** and APC .	parallel	1
2454	10228155	8945;1499	FWD1;beta-catenin	***FWD1*** facilitated ubiquitination and ***promoted*** degradation of ***beta-catenin*** , resulting in reduced cytoplasmic beta-catenin levels .	positive	0
2455	10228155	8945;1499	FWD1;beta-catenin	In contrast , a dominant-negative mutant form of ***FWD1*** inhibited the ubiquitination process and ***stabilized*** ***beta-catenin*** .	positive	0
2456	10228155	8945;1499	FWD1;beta-catenin	These results suggest that the Skp1/Cullin/F-box protein FWD1 ( SCFFWD1 ) - ubiquitin ligase complex is involved in beta-catenin ubiquitination and that ***FWD1*** serves as an intracellular ***receptor*** for phosphorylated ***beta-catenin*** .	parallel	1
2457	10228156	10527;3005	importin 7;histone H1	The importin ***beta/importin 7*** heterodimer is a functional nuclear import ***receptor*** for ***histone H1*** .	parallel	1
2458	10228162	2185;6772	Pyk2;Stat1	Protein tyrosine kinase ***Pyk2*** ***mediates*** the Jak-dependent activation of MAPK and ***Stat1*** in IFN-gamma , but not IFN-alpha , signaling .	target	0
2459	10228162	2185;3717	Pyk2;Jak2	***Pyk2*** is selectively ***associated*** with ***Jak2*** and activated by IFN-gamma .	parallel	0
2460	10228162	3458;5594	IFN-gamma;Erk2	Overexpression of PKM , a dominant interfering form of Pyk2 , in NIH 3T3 cells results in a strong inhibition of the ***IFN-gamma-induced*** ***activation*** of ***Erk2*** , serine phosphorylation of Stat1 and Stat1-dependent gene transcription .	positive	1
2461	10228165	7132;7186	TNFR1;TRAF2	Although both LMP1 and ***TNFR1*** ***interact*** with TRADD and ***TRAF2*** , the different topologies of the signaling complexes correlate with substantial differences between LMP1 and TNFR1 signal transduction to JNK1 .	parallel	1
2462	10228165	7132;5599	TNFR1;JNK1	Further downstream , ***JNK1*** ***activation*** by ***TNFR1*** involves Cdc42 , whereas LMP1 signaling to JNK1 is independent of p21 Rho-like GTPases .	positive	1
2463	10228168	10413;632	YAP;osteocalcin	The ***osteocalcin*** promoter was ***stimulated*** by exogenous PEBP2alphaA and a dominant negative form of ***YAP*** strongly inhibited this activity , suggesting YAP involvement in this promoter activity in vivo .	positive	0
2464	10228171	29107;10482	p15;TAP	Both the FG-repeat domain of nucleoporin CAN/Nup214 and a novel human 15 kDa protein ( ***p15*** ) with homology to NTF2 ( a nuclear transport factor which associates with RanGDP ) , directly ***bind*** to ***TAP*** .	parallel	1
2465	10228171	10482;29107	TAP;p15	Thus , the human ******TAP-p15****** ***complex*** can functionally replace the Mex67p-Mtr2p complex in yeast and thus performs a conserved role in nuclear mRNA export .	parallel	1
2466	10228590	7066;4352	TPO;Mpl	In this paper , the relation between HEL cell metabolism and the ***activation*** of receptor ***Mpl*** by its ligand ***TPO*** was also studied .	positive	1
2467	10228949	7124;5270	tumor necrosis factor-alpha;Protease nexin I	***Protease nexin I*** secretion is ***stimulated*** by ***tumor necrosis factor-alpha*** , transforming growth factor-beta and interleukin-1 .	positive	0
2468	10229072	4690;3937	Nck;SLP-76	***Association*** of ***Nck*** with tyrosine-phosphorylated ***SLP-76*** in activated T lymphocytes .	parallel	0
2469	10229072	4690;3937	Nck;SLP-76	In vitro experiments show that the ***interaction*** between ***Nck*** and ***SLP-76*** is mediated via the Nck SH2 domain .	parallel	1
2470	10229095	3458;4261	IFN-gamma;CIITA	In this study , we investigated the effects of various immunomodulatory cytokines on ***IFN-gamma*** ***induction*** of class II MHC and ***CIITA*** gene expression in microglia , both primary microglia and a murine microglial cell line , EOC 20 .	target	1
2471	10229095	3586;4261	IL-10;CIITA	TGF-beta1 , IL-4 , and ***IL-10*** ***inhibition*** of IFN-gamma-induced ***CIITA*** mRNA accumulation was not due to destabilization of CIITA mRNA , suggesting an effect at the level of transcription .	negative	1
2472	10229095	3586;4261	IL-10;CIITA	In primary murine microglia , ***IL-10*** and TGF-beta1 ***inhibited*** IFN-gamma-induced ***CIITA*** and class II MHC expression .	negative	1
2473	10229095	7040;4261	TGF-beta1;CIITA	In primary murine microglia , IL-10 and ***TGF-beta1*** ***inhibited*** IFN-gamma-induced ***CIITA*** and class II MHC expression .	negative	1
2474	10229103	959;958	CD154;CD40	While the ***binding*** of ***CD154*** to ***CD40*** induces the assembly of a CD40-TRAF receptor complex , IKK is not recruited to this complex .	parallel	1
2475	10229111	3586;942	IL-10;B7-2	By contrast , interferon-gamma raises only B7-2 and CD40 mRNA , and the ***B7-2*** increase is ***inhibited*** by ***IL-10*** .	negative	1
2476	10229111	3458;942	interferon-gamma;B7-2	By contrast , ***interferon-gamma*** ***raises*** only ***B7-2*** and CD40 mRNA , and the B7-2 increase is inhibited by IL-10 .	positive	0
2477	10229111	3458;958	interferon-gamma;CD40	By contrast , ***interferon-gamma*** ***raises*** only B7-2 and ***CD40*** mRNA , and the B7-2 increase is inhibited by IL-10 .	positive	0
2478	10229111	4803;942	NGF;B7-2	IL-4 , transforming growth factor-beta1 , and nerve growth factor ( ***NGF*** ) ***repress*** GM-CSF-induced ***B7-2*** and CD40 , but not B7-1 .	negative	1
2479	10229111	4803;958	NGF;CD40	IL-4 , transforming growth factor-beta1 , and nerve growth factor ( ***NGF*** ) ***repress*** GM-CSF-induced B7-2 and ***CD40*** , but not B7-1 .	negative	1
2480	10229111	3589;942	IL-11;B7-2	***IL-11*** , unrecognized for its effect on antigen presentation , ***represses*** GM-CSF-induced ***B7-2*** .	negative	1
2481	10229115	958;5970	p50;p65	In addition , we performed electrophoretic mobility shift analysis and determined that in microglia , the ******p50/p65****** ***heterodimer*** of NF-kappaB is activated by LPS stimulation , and is inhibited by MG132 .	parallel	1
2482	10229119	3553;3383	IL-1beta;intercellular adhesion molecule-1	TNF alpha and ***IL-1beta*** ***mediate*** ***intercellular adhesion molecule-1*** induction via microglia-astrocyte interaction in CNS radiation injury .	target	0
2483	10229119	7124;3383	TNF alpha;intercellular adhesion molecule-1	***TNF alpha*** and IL-1beta ***mediate*** ***intercellular adhesion molecule-1*** induction via microglia-astrocyte interaction in CNS radiation injury .	target	0
2484	10229163	1401;3569	CRP;IL-6	Peak ***CRP*** levels ***correlated*** well with peak ***IL-6*** levels ( r = 0.49 , p < 0.001 ) .	parallel	0
2485	10229195	1027;1017	p27Kip1;CDK2	This observation , extended to two other IL-2-dependent as well as to three IL-2-independent HTLV-I-infected T-cell lines , suggests that the lack of cyclin E-CDK2 kinase downregulation found in the late phase of HTLV-I transformation may correlate with insufficient amounts of ***p27Kip1*** ***associated*** with the cyclin ***E-CDK2*** complex .	parallel	0
2486	10229198	3481;3643	IGF-II;Insulin receptor	***Insulin receptor*** ***activation*** by ***IGF-II*** in breast cancers : evidence for a new autocrine/paracrine mechanism .	positive	1
2487	10229231	22984;356	apoptosis-linked gene 4;Fas ligand	***Regulation*** of ***Fas ligand*** expression and cell death by ***apoptosis-linked gene 4*** .	target	1
2488	10229231	22984;356	ALG-4;FasL	Overexpression of full-length ***ALG-4*** ***induced*** transcription of ***FasL*** and , consequently , apoptosis .	target	1
2489	10229231	355;356	Fas;FasL	******Fas/FasL****** ***interaction*** initiates cell death in many other systems , and its dysregulation is a mechanism by which several pathologic conditions arise .	parallel	1
2490	10229675	2247;3569	fibroblast growth factor-2;IL-6	We have previously described that the nuclear 24 kDa isoform of ***fibroblast growth factor-2*** ( FGF-2 ) is able to ***increase*** ***IL-6*** gene expression in NIH-3T3 cells .	positive	0
2491	10229683	1984;1725	eIF5A;deoxyhypusine synthase	The ***complex*** of ***deoxyhypusine synthase*** and ***ec-eIF5A*** was separated from the free enzyme and protein substrate by electrophoresis under non-denaturing conditions .	parallel	1
2492	10229797	10803;6370	CCR9;chemokine TECK	Cutting edge : identification of the orphan chemokine receptor GPR-9-6 as ***CCR9*** , the ***receptor*** for the ***chemokine TECK*** .	parallel	1
2493	10229797	10803;6370	GPR-9-6;TECK	These results confirm that ***GPR-9-6*** is a specific ***receptor*** for ***TECK*** .	parallel	1
2494	10229804	4068;6504	SAP;CDw150	Patients with X-linked lymphoproliferative disease have mutations in a gene encoding a protein , ***DSHP/SAP*** , which ***interacts*** with ***CDw150*** and is expressed in B cells .	parallel	1
2495	10229815	1493;3558	CTLA-4;IL-2	***CTLA-4*** engagement by mAbs ***inhibits*** , while CD28 enhances , ***IL-2*** production and proliferation upon T cell activation .	negative	1
2496	10229815	1493;3558	CTLA-4;IL-2	***CTLA-4*** ligation ***inhibited*** CD3/CD28-induced ***IL-2*** mRNA accumulation by inhibiting IL-2 transcription , which appears to be mediated in part through decreasing NF-AT accumulation in the nuclei .	negative	1
2497	10229820	2246;4790	Fibroblast growth factor-1;NF-kappaB	***Fibroblast growth factor-1*** ( FGF-1 ) ***enhances*** IL-2 production and nuclear translocation of ***NF-kappaB*** in FGF receptor-bearing Jurkat T cells .	positive	0
2498	10229820	2246;3558	Fibroblast growth factor-1;IL-2	***Fibroblast growth factor-1*** ( FGF-1 ) ***enhances*** ***IL-2*** production and nuclear translocation of NF-kappaB in FGF receptor-bearing Jurkat T cells .	positive	0
2499	10229821	3565;598	IL-4;Bcl-xL	We report that 1 ) the mature DN T cells are highly resistant to TCR cross-linking-induced apoptosis in the presence of exogenous IL-4 ; 2 ) Fas/Fas-ligand and TNF-alpha/TNFR pathways do not play an apparent role in regulating apoptosis in DN T cells ; 3 ) the DN T cells constitutively express a high level of Bcl-xL , but not Bcl-2 ; 4 ) both Bcl-xL and Bcl-2 are up-regulated following TCR-cross-linking ; and 5 ) ***IL-4*** stimulation significantly ***up-regulates*** ***Bcl-xL*** and c-Jun expression and leads to mitogen-activated protein kinase phosphorylation in DN T cells , which may contribute to the resistance to apoptosis in these T cells .	positive	1
2500	10229821	3565;3725	IL-4;c-Jun	We report that 1 ) the mature DN T cells are highly resistant to TCR cross-linking-induced apoptosis in the presence of exogenous IL-4 ; 2 ) Fas/Fas-ligand and TNF-alpha/TNFR pathways do not play an apparent role in regulating apoptosis in DN T cells ; 3 ) the DN T cells constitutively express a high level of Bcl-xL , but not Bcl-2 ; 4 ) both Bcl-xL and Bcl-2 are up-regulated following TCR-cross-linking ; and 5 ) ***IL-4*** stimulation significantly ***up-regulates*** Bcl-xL and ***c-Jun*** expression and leads to mitogen-activated protein kinase phosphorylation in DN T cells , which may contribute to the resistance to apoptosis in these T cells .	positive	1
2501	10229825	940;3458	CD28;IFN-gamma	These findings illustrate costimulatory pathways that result in potent IFN-gamma responses by NK cells and show that although IL-18 and ***anti-CD28*** can ***enhance*** the synthesis of IL-12-driven ***IFN-gamma*** , they employ molecular mechanisms that are distinct from one another .	positive	0
2502	10229825	3606;3458	IL-18;IFN-gamma	These findings illustrate costimulatory pathways that result in potent IFN-gamma responses by NK cells and show that although ***IL-18*** and anti-CD28 can ***enhance*** the synthesis of IL-12-driven ***IFN-gamma*** , they employ molecular mechanisms that are distinct from one another .	positive	0
2503	10229836	7852;6387	CXCR4;stromal cell-derived factor-1	Genes encoding ***stromal cell-derived factor-1*** and its ***receptor*** ***CXCR4*** were detected in the cortex by in situ hybridization .	parallel	1
2504	10229837	4609;7852	c-Myc;CXCR4	***USF/c-Myc*** ***enhances*** , while Yin-Yang 1 suppresses , the promoter activity of ***CXCR4*** , a coreceptor for HIV-1 entry .	positive	0
2505	10229837	7528;7852	YY1;CXCR4	In this study , we show that USF/c-Myc up-regulates , while ***YY1*** ***down-regulates*** the promoter activity of ***CXCR4*** , a coreceptor for T cell-tropic HIV-1 entry .	negative	1
2506	10229837	4609;7852	c-Myc;CXCR4	Mutation of the E box abolished ***USF/c-Myc-mediated*** ***up-regulation*** of ***CXCR4*** promoter activity , and mutation of the YY1 binding site was associated with unresponsiveness to YY1-mediated inhibition .	positive	1
2507	10229845	5284;973	pIgR;IgA	The human polymeric Ig receptor ( ***pIgR*** ) , also called transmembrane secretory component , is expressed basolaterally on exocrine epithelia , and ***mediates*** specific external transport of dimeric ***IgA*** and pentameric IgM .	target	0
2508	10229845	5284;959	pIgR;IgM	The human polymeric Ig receptor ( ***pIgR*** ) , also called transmembrane secretory component , is expressed basolaterally on exocrine epithelia , and ***mediates*** specific external transport of dimeric IgA and pentameric ***IgM*** .	target	0
2509	10229845	5284;973	pIgR;IgA	While the human ***pIgR*** ***binds*** both dimeric ***IgA*** and pentameric IgM with high affinity , the rabbit counterpart has virtually no binding capacity for pentameric IgM .	parallel	1
2510	10229845	5284;959	pIgR;IgM	While the human ***pIgR*** ***binds*** both dimeric IgA and pentameric ***IgM*** with high affinity , the rabbit counterpart has virtually no binding capacity for pentameric IgM .	parallel	1
2511	10229854	3606;3458	IL-18;IFN-gamma	***IL-18*** ***enhanced*** M. leprae-induced ***IFN-gamma*** production rapidly ( 24 h ) by NK cells and in a more sustained manner ( 5 days ) by T cells .	positive	0
2512	10229854	3606;3458	IL-18;IFN-gamma	Finally , ***IL-18*** directly ***induced*** ***IFN-gamma*** production from mycobacteria-reactive T cell clones .	target	1
2513	10229855	3586;834	IL-10;caspase 1	In contrast , ***anti-IL-10*** ***increased*** ***caspase 1*** activation , p53 expression , and apoptosis , although there was no increment in NO - production .	positive	0
2514	10229869	3565;4586	IL-4;mucin	***IL-4*** ***induces*** ***mucin*** gene expression and goblet cell metaplasia in vitro and in vivo .	target	1
2515	10229869	3565;4586	IL-4;mucin	In this study we hypothesized that ***IL-4*** ***induces*** airway epithelial cell ***mucin*** gene expression and mucous glycoconjugate production by direct action on these cells .	target	1
2516	10229869	3565;4583	IL-4;MUC2	In vitro , cultured airway epithelial cells ( NCI-H292 ) expressed IL-4R constitutively , and ***IL-4*** ( 10 ng/ml ) ***induced*** ***MUC2*** gene expression and mucous glycoconjugate production .	target	1
2517	10229869	3565;4586	IL-4;MUC5	In vivo , mouse airway epithelial cells expressed IL-4R constitutively , and ***IL-4*** ( 250 ng ) ***increased*** ***MUC5*** gene expression and Alcian blue/periodic acid-Schiff-positive staining at 24 h ; IL-4 did not increase inflammatory cell numbers in airway tissue or in bronchoalveolar lavage .	positive	0
2518	10229870	952;54776	CD38;p85	***CD38*** stimulation ***induced*** tyrosine phosphorylation of the ***p85*** regulatory subunit of PI3-K and its association with other tyrosine-phosphorylated proteins .	target	1
2519	10230404	2100;8648	ER beta;SRC-1	We demonstrate here that phosphorylation of AF-1 by MAP kinase ( MAPK ) leads to the ***recruitment*** of steroid receptor coactivator-1 ( ***SRC-1*** ) by ***ER beta*** in vitro .	target	0
2520	10230406	4792;4790	I kappa B alpha;NF-kappa B	Activation of the transcription factor NF-kappa B in response to proinflammatory stimuli requires the phosphorylation-triggered and ubiquitin-dependent degradation of the ***NF-kappa B*** ***inhibitor*** , ***I kappa B alpha*** .	negative	1
2521	10230406	8454;9978	cullin 1;ROC1	***ROC1*** , a novel SCF-associated protein , is ***recruited*** by ***cullin 1*** to form a quatemary SCFHOS-ROC1 holenzyme ( with Skp1 and the beta-TRCP homolog HOS ) .	target	0
2522	10230406	9978;4792	ROC1;I kappa B alpha	***SCFHOS-ROC1*** ***binds*** IKK beta-phosphorylated ***I kappa B alpha*** and catalyzes its ubiquitination in the presence of ubiquitin , E1 , and Cdc34 .	parallel	1
2523	10230407	51529;29882	APC11;APC2	ROC1 and ROC2 commonly interact with all cullins while ***APC11*** specifically ***interacts*** with ***APC2*** , a cullin-related APC subunit .	parallel	1
2524	10230647	821;3643	calnexin;insulin receptor	The monomeric form of P193L insulin proreceptor is retained in the endoplasmic reticulum by a ***calnexin*** and GRP78 mediated mechanism that ***reduces*** mature ***insulin receptor*** expression on the cell surface .	negative	1
2525	10230647	3309;3643	GRP78;insulin receptor	The monomeric form of P193L insulin proreceptor is retained in the endoplasmic reticulum by a calnexin and ***GRP78*** mediated mechanism that ***reduces*** mature ***insulin receptor*** expression on the cell surface .	negative	1
2526	10230699	356;355	FasL;Fas	Sixteen seminomas with surrounding tissue containing normal and precancerous ( cis ) seminiferous tubules were examined for the expression of Fas ( CD95 , APO-1 ) and ***Fas*** ***ligand*** ( ***FasL*** ) ( CD95L ) .	parallel	1
2527	10230790	650;1621	BMP2;DBH	Phox2 proteins are , moreover , necessary for the ***induction*** of both TH and ***DBH*** by bone morphogenetic protein 2 ( ***BMP2*** ) ( which induces Phox2a/b ) and forskolin .	target	1
2528	10230790	650;8929	BMP2;Phox2a/b	Phox2 proteins are , moreover , necessary for the induction of both TH and DBH by bone morphogenetic protein 2 ( ***BMP2*** ) ( which ***induces*** ***Phox2a/b*** ) and forskolin .	target	1
2529	10231012	3336;3329	Hsp10;Hsp60	A prime candidate , however , is the chlamydial GroES homolog ***Hsp10*** , which is genetically and physiologically ***linked*** to ***Hsp60*** .	parallel	0
2530	10231020	998;396	G25K;rhoGDI	In the absence of Mg2 + , the methylation was stimulated by guanine nucleotides ( GTP , GDP and GTPgammaS ) , but in the presence of Mg2 + , only GTPgammaS stimulated the methylation which was similar to the effect on the ******G25K/rhoGDI****** ***complex*** .	parallel	1
2531	10231374	3586;3587	hIL-10;IL-10R1	Both ***hIL-10*** and vIL-10 ***bind*** to the soluble extracellular fragment of the cytokine receptor ***IL-10R1*** ( shIL-10R1 ) .	parallel	1
2532	10231435	4843;3162	iNOS;HO-1	CONCLUSIONS : Our studies demonstrate that both exogenously or ***iNOS-derived*** NO ***enhance*** ***HO-1*** expression in mesangial cells and point to regulatory interactions between the iNOS and HO pathways .	positive	0
2533	10231640	5743;4318	cox2;MMP-9	CONCLUSION : Indomethacin attenuates aneurysm growth , and its effects are mediated via inhibition of the ***cox2*** isoform of cyclooxygenase , which ***decreases*** PGE2 and ***MMP-9*** synthesis .	negative	0
2534	10232395	7040;3458	TGF-beta1;IFN-gamma	The ***suppression*** of the ***IFN-gamma*** production by ***TGF-beta1*** is shown to be an important mechanism by which TGF-beta enhances proliferation of Th2 lymphocytes .	negative	1
2535	10232396	719;718	C3aR;C3a	To elucidate the interaction of the ***C3a*** ***receptor*** ( ***C3aR*** ) with its ligand ( s ) we studied the binding of human recombinant C3a ( rC3a ) and rC3a ( desArg ) to RBL-2H3 transfectants which express the C3aR .	parallel	1
2536	10232396	718;719	C3a;C3aR	Recombinant ***C3a*** ***bound*** to the ***C3aR*** with a half maximal concentration of about 3 nM whereas no evidence for a binding of rC3a ( desArg ) could be obtained .	parallel	1
2537	10232581	581;596	Bax;Bcl-2	Mutation of threonine 169 did not affect the ***binding*** of ***Bax*** to Bax , ***Bcl-2*** , or Bcl-X ( L ) .	parallel	1
2538	10232581	581;598	Bax;Bcl-X	Mutation of threonine 169 did not affect the ***binding*** of ***Bax*** to Bax , Bcl-2 , or ***Bcl-X*** ( L ) .	parallel	1
2539	10232588	4193;7157	MDM2;p53 tumor suppressor	The ***MDM2*** protein ***regulates*** the functional activity of the ***p53 tumor suppressor*** through direct physical association .	target	1
2540	10232607	836;142	caspase-3;PARP	Subsequent degradation of poly ( ADP-ribose ) ( PAR ) , attached to p53 presumably by PAR glycohydrolase , the only reported enzyme to degrade PAR , was apparent concomitant with the onset of proteolytic processing and activation of caspase-3 , ***caspase-3-mediated*** ***cleavage*** of poly ( ADP-ribose ) polymerase ( ***PARP*** ) , and internucleosomal DNA fragmentation during the later stages of cell death .	target	1
2541	10232608	4296;5599	MLK3;JNK	Our combined data show that although ***MLK3*** is primarily an ***activator*** of the ***JNK/SAPK*** pathway , overexpression of the wild type protein leads to a transformed phenotype in NIH 3T3 cells that can be partially reversed by a synthetic MEK inhibitor .	positive	1
2542	10232608	4296;5601	MLK3;SAPK	Our combined data show that although ***MLK3*** is primarily an ***activator*** of the ***JNK/SAPK*** pathway , overexpression of the wild type protein leads to a transformed phenotype in NIH 3T3 cells that can be partially reversed by a synthetic MEK inhibitor .	positive	1
2543	10232608	4296;3725	MLK3;c-Jun	In the same cell system , ***MLK3*** preferentially ***activates*** the ***c-Jun*** NH2-terminal kinase/stress-activated protein kinase ( JNK/SAPK ) mitogen-activated protein kinase cascade and to a lesser degree the extracellular signal-regulated kinase ( ERK ) pathway .	positive	1
2544	10232610	7428;7040	VHL;TGF-beta1	We have demonstrated that the ***VHL*** tumor suppressor gene product ***represses*** ***TGF-beta1*** mRNA and protein levels ( approximately 3-4-fold ) in 786-O RCC cells by decreasing the TGF-beta1 mRNA half-life .	negative	1
2545	10232611	1029;7157	p19ARF;p53	The ***p19ARF*** product of the INK4a/ARF locus is induced in response to potentially oncogenic hyperproliferative signals and ***activates*** ***p53*** by interfering with its negative regulator , Mdm2 .	positive	1
2546	10232657	3827;9622	high-molecular weight kininogen;kallikrein	***high-molecular weight kininogen*** is the ***substrate*** for plasma ***kallikrein*** ( PKa potent kinin-generating enzyme circulating in blood , not of the same gene family ) and for hK1 .	parallel	1
2547	10232657	3817;3827	hK2;HMWK	Our results show that ***hK2*** ***cleaves*** ***HMWK*** to produce bradykinin , not Lys-bradykinin ( like hK1 ) , and the resultant heavy ( 56-kDa ) and light ( 42-kDa ) chains of HMWK show similar electrophoretic mobility to those cleaved by PK .	target	1
2548	10232679	3553;5743	IL-1beta;COX-2	Oligonucleotide decoy experiments confirmed the importance of nuclear factor kappaB ( NF-kappaB ) activation for ***COX-2*** ***induction*** by ***IL-1beta/TNF-alpha*** .	target	1
2549	10232679	7124;5743	TNF-alpha;COX-2	Oligonucleotide decoy experiments confirmed the importance of nuclear factor kappaB ( NF-kappaB ) activation for ***COX-2*** ***induction*** by ***IL-1beta/TNF-alpha*** .	target	1
2550	10232679	3553;4790	IL-1beta;NF-kappaB	Treatment with N ( G ) - nitro-L-arginine methyl ester ( L-NAME ) did not affect initial ***activation*** of ***NF-kappaB*** by ***IL-1beta/TNF-alpha*** , but unveiled an inhibitory effect of NO generation on NF-kappaB activity after 4 h.	positive	1
2551	10232679	7124;4790	TNF-alpha;NF-kappaB	Treatment with N ( G ) - nitro-L-arginine methyl ester ( L-NAME ) did not affect initial ***activation*** of ***NF-kappaB*** by ***IL-1beta/TNF-alpha*** , but unveiled an inhibitory effect of NO generation on NF-kappaB activity after 4 h.	positive	1
2552	10232833	4018;5444	lipoprotein;PON 1	Human serum paraoxonase ( ***PON 1*** ) is ***inactivated*** by oxidized low density ***lipoprotein*** and preserved by antioxidants .	negative	1
2553	10232871	7200;6750	thyrotropin-releasing hormone;somatostatin	Intraluminal ***thyrotropin-releasing hormone*** ***affects*** gastric ***somatostatin*** and acid secretion through its specific receptor in rats .	target	0
2554	10232871	7200;6750	TRH;somatostatin	CONCLUSIONS : These findings suggest that intraluminal ***TRH*** ***affects*** ***somatostatin*** and acid secretion in a paracrine manner via its specific receptor in the rat stomach .	target	0
2555	10233036	3952;5443	leptin;proopiomelanocortin	Relative to controls , ***leptin*** ***increased*** hypothalamic mRNA for corticotropin-releasing hormone ( CRH ; 61 % ) and for ***proopiomelanocortin*** ( POMC ; 31 % ) but did not reduce mRNA for neuropeptide Y .	positive	0
2556	10233167	2064;1956	ErbB2;epidermal growth factor (EGF) receptor	Endocytosis deficiency of ******epidermal growth factor (EGF) receptor-ErbB2****** ***heterodimers*** in response to EGF stimulation .	parallel	1
2557	10233170	5879;2247	rac1;bFGF	Activated alleles of ***rac1*** and rhoA ***blocked*** and reversed ***bFGF*** effects when introduced into astrocytes in dissociated culture and in brain slices using recombinant adenoviruses .	negative	0
2558	10233170	387;2247	rhoA;bFGF	Activated alleles of rac1 and ***rhoA*** ***blocked*** and reversed ***bFGF*** effects when introduced into astrocytes in dissociated culture and in brain slices using recombinant adenoviruses .	negative	0
2559	10233170	2247;5879	bFGF;rac1	Our results show that ***bFGF*** acting through c-Ha-Ras ***inhibits*** endogenous ***rac1*** and rhoA GTPases thereby triggering astrocyte process growth , and they provide evidence for the regulation of this cascade in vivo by a yet undetermined neuron-derived factor .	negative	1
2560	10233170	2247;387	bFGF;rhoA	Our results show that ***bFGF*** acting through c-Ha-Ras ***inhibits*** endogenous rac1 and ***rhoA*** GTPases thereby triggering astrocyte process growth , and they provide evidence for the regulation of this cascade in vivo by a yet undetermined neuron-derived factor .	negative	1
2561	10233377	1437;2056	granulocyte-macrophage colony-stimulating factor;erythropoietin	In vitro studies have indicated that ***granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) ***synergizes*** with ***erythropoietin*** ( EPO ) for the production of erythroid precursors in patients with myelodysplastic syndrome ( MDS ) .	parallel	0
2562	10233392	7066;4352	thrombopoietin;c-mpl	***thrombopoietin*** ( TPO ) is a ***ligand*** for ***c-mpl*** , which regulates the differentiation and maturation of megakaryocytes .	parallel	1
2563	10233418	5175;952	CD31;CD38	These data indicated that PC malignancies co-expressed high levels of both ***CD38*** and its ***ligand*** ***CD31*** , with the exception of plasmablastic MM and PCL .	parallel	1
2564	10233422	7066;4352	TPO;c-Mpl	This implied that binding of EPO and EPO-R was essential for erythropoiesis and the resultant signal transduction may be augmented by the signals emanating from ******TPO-c-Mpl****** ***interaction*** .	parallel	1
2565	10233423	7040;3562	TGF-beta1;interleukin-3	To investigate a possible link between the action of TGF-beta1 and cell death regulators such as bcl-2 , we utilized Ba/F3 cells , the ***interleukin-3*** ( IL-3 ) - dependent growth of which could be ***modulated*** by ***TGF-beta1*** , as well as haemopoietic progenitor cells .	target	0
2566	10233435	2150;2152	protease-activated receptor-2;tissue factor	Endothelial ***protease-activated receptor-2*** ***induces*** ***tissue factor*** expression and von Willebrand factor release .	target	1
2567	10233435	23430;2150	mast cell tryptase;PAR-2	A second protease-activated receptor ( ***PAR-2*** ) that could be ***activated*** by trypsin or more physiologically by ***mast cell tryptase*** has been recently cloned .	positive	1
2568	10233676	940;941	CD28;CD80	U937 cells provide a co-stimulatory signal for CD3-mediated T-cell activation which is independent of the ******CD28/CD80/CD86****** ***interaction*** .	parallel	1
2569	10233676	940;942	CD28;CD86	U937 cells provide a co-stimulatory signal for CD3-mediated T-cell activation which is independent of the ******CD28/CD80/CD86****** ***interaction*** .	parallel	1
2570	10233676	942;941	CD86;CD80	U937 cells provide a co-stimulatory signal for CD3-mediated T-cell activation which is independent of the ******CD28/CD80/CD86****** ***interaction*** .	parallel	1
2571	10233694	3689;682	LFA-1;CD147	The ***CD147*** mAb-induced cell aggregation was ***inhibited*** by leucocyte function-antigen-1 ( ***LFA-1*** ) and intercellular adhesion molecule-1 ( ICAM-1 ) mAbs .	negative	1
2572	10233696	4254;3574	SCF;IL-7	The convergence of the signal transduction pathways of the two cytokines is not known , thus cell line PER-487 provides a unique model for studying the synergistic ***interaction*** of ***IL-7*** and ***SCF*** .	parallel	1
2573	10233697	3600;3458	Interleukin-15;interferon-gamma	***Interleukin-15*** differentially ***enhances*** the expression of ***interferon-gamma*** and interleukin-4 in activated human ( CD4 + ) T lymphocytes .	positive	0
2574	10233697	3600;3565	Interleukin-15;interleukin-4	***Interleukin-15*** differentially ***enhances*** the expression of interferon-gamma and ***interleukin-4*** in activated human ( CD4 + ) T lymphocytes .	positive	0
2575	10233697	3600;3458	IL-15;IFN-gamma	***IFN-gamma*** and IL-4 mRNAs were ***upregulated*** by ***IL-15*** in concanavalin A - ( twofold ) and anti-CD3 plus anti-CD28 - ( fivefold ) stimulated T lymphocytes .	positive	1
2576	10233697	3600;3565	IL-15;IL-4	IFN-gamma and ***IL-4*** mRNAs were ***upregulated*** by ***IL-15*** in concanavalin A - ( twofold ) and anti-CD3 plus anti-CD28 - ( fivefold ) stimulated T lymphocytes .	positive	1
2577	10233697	3600;3458	IL-15;IFN-gamma	***IFN-gamma*** mRNA accumulation , but not IL-4 mRNA , was additively ***upregulated*** by ***IL-15*** plus IL-7 ( ninefold ) in anti-CD3 stimulated T lymphocytes , and bypassed the requirement of CD28 signalling .	positive	1
2578	10233697	3574;3458	IL-7;IFN-gamma	***IFN-gamma*** mRNA accumulation , but not IL-4 mRNA , was additively ***upregulated*** by IL-15 plus ***IL-7*** ( ninefold ) in anti-CD3 stimulated T lymphocytes , and bypassed the requirement of CD28 signalling .	positive	1
2579	10233697	3600;3458	IL-15;IFN-gamma	Fluorescence-activated cell sorting ( FACS ) experiments demonstrated that ***IFN-gamma*** mRNA was ***upregulated*** by ***IL-15*** in both CD4 + and CD8 + T lymphocytes , whereas IL-4 mRNA accumulation predominantly occurred in CD4 + cells .	positive	1
2580	10233733	942;940	CD86;CD28	Effective blockade of ******CD86/CD28****** ***interaction*** was demonstrated by elimination of interleukin ( IL ) -4 and up-regulation of interferon ( IFN ) - gamma responses by P. chabaudi-specific T cells and by reduction of P. chabaudi-specific immunoglobulin G1 ( IgG1 ) .	parallel	1
2581	10233733	941;3458	CD80;IFN-gamma	Moreover , combined ***CD80/CD86*** blockade by using anti-CD80 and anti-CD86 monoclonal antibodies ***raised*** ***IFN-gamma*** production over that seen with CD86 blockade alone , with augmentation of this Th1-associated cytokine reducing levels of peak primary parasitaemia .	negative	0
2582	10233733	942;3458	CD86;IFN-gamma	Moreover , combined ***CD80/CD86*** blockade by using anti-CD80 and anti-CD86 monoclonal antibodies ***raised*** ***IFN-gamma*** production over that seen with CD86 blockade alone , with augmentation of this Th1-associated cytokine reducing levels of peak primary parasitaemia .	negative	0
2583	10233733	940;942	CD28;CD86	These results demonstrate that IL-4 production by T cells in P. chabaudi-infected NIH mice is dependent upon ******CD86/CD28****** ***interaction*** and that IL-4 and IFN-gamma contribute significantly , at different times of infection , to host resistance to blood stage malaria .	parallel	1
2584	10233738	3565;3586	Interleukin-4;interleukin-10	***Interleukin-4*** ***regulation*** of human monocyte and macrophage ***interleukin-10*** and interleukin-12 production .	target	1
2585	10233739	3458;5284	IFN-gamma;pIgR	With this model we show here that IL-4 and ***IFN-gamma*** dose-dependently ***increased*** ***pIgR*** mRNA and protein expression , and sIgA release .	positive	0
2586	10233739	3565;5284	IL-4;pIgR	With this model we show here that ***IL-4*** and IFN-gamma dose-dependently ***increased*** ***pIgR*** mRNA and protein expression , and sIgA release .	positive	0
2587	10233739	3458;5284	IFN-gamma;pIgR	***IFN-gamma*** and IL-4 ***induced*** similar maximal expression of ***pIgR*** , but IFN-gamma enhanced sIgA release more than IL-4 .	target	1
2588	10233739	3565;5284	IL-4;pIgR	IFN-gamma and ***IL-4*** ***induced*** similar maximal expression of ***pIgR*** , but IFN-gamma enhanced sIgA release more than IL-4 .	target	1
2589	10233739	3458;5284	IFN-gamma;pIgR	When added together , IL-4 and ***IFN-gamma*** synergistically ***increased*** ***pIgR*** mRNA and protein expression , but sIgA release was stimulated in an additive manner .	positive	0
2590	10233739	3565;5284	IL-4;pIgR	When added together , ***IL-4*** and IFN-gamma synergistically ***increased*** ***pIgR*** mRNA and protein expression , but sIgA release was stimulated in an additive manner .	positive	0
2591	10233747	959;958	CD40L;CD40	Here , we have investigated whether protection of NOD mice from IDDM was associated with changes on costimulatory pathways of T and B cells , namely CD28/CTLA -4 - B7 and ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) and we also further characterized protective T helper ( Th ) cells with regards to the expression of the differentiation markers CD45RB and CD38 .	parallel	1
2592	10233760	3565;1805	interleukin-4;Dermatopontin	***Dermatopontin*** expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is ***regulated*** by transforming growth factor-beta1 , ***interleukin-4*** , and matrix collagen .	target	1
2593	10233760	3565;1805	interleukin-4;Dermatopontin	Transforming growth factor-beta1 increased Dermatopontin mRNA and protein levels , while ***interleukin-4*** ***reduced*** ***Dermatopontin*** expression .	negative	1
2594	10233762	2833;3627	CXCR3;IP-10	Human IP-9 : A keratinocyte-derived high affinity CXC-chemokine ligand for the ***IP-10/Mig*** ***receptor*** ( ***CXCR3*** ) .	parallel	1
2595	10233762	2833;4283	CXCR3;Mig	Human IP-9 : A keratinocyte-derived high affinity CXC-chemokine ligand for the ***IP-10/Mig*** ***receptor*** ( ***CXCR3*** ) .	parallel	1
2596	10233770	9474;836	Asp;caspase-3	Pretreatments of the cells with a p38 mitogen-activated protein kinase inhibitor , SB203580 , and a ***caspase-3*** ***inhibitor*** , ***Ac-Asp-Met-Gln-Asp-1-aldehyde*** , suppressed the ultraviolet B irradiation-induced apoptosis by approximately 60 % as estimated by nuclear staining and DNA laddering .	negative	1
2597	10233770	9474;834	Asp;caspase-1	Pretreatment with ***caspase-1*** ***inhibitor*** , ***Ac-Tyr-Val-Lys-Asp-aldehyde*** was without effect .	negative	1
2598	10233774	4254;3815	stem cell factor;c-KIT	Previous findings indicate that the protein ***c-KIT*** and its ***ligand*** , ***stem cell factor*** ( SCF ) play a crucial role in the development of melanocytes from their precursors in the embryonic neural crest cells .	parallel	1
2599	10233774	4254;3815	SCF;c-KIT	It was therefore demonstrated that apoptosis was induced in the SCF-dependent c-KIT-positive melanocytes in vitro when the ******SCF/c-KIT****** ***interaction*** was obstructed .	parallel	1
2600	10233774	4254;3815	SCF;c-KIT	These findings elucidate the mechanism of the regulation of melanocyte development , and the survival and proliferation of these precursor cells , by ******SCF/c-KIT****** ***interaction*** .	parallel	1
2601	10233855	2621;558	Gas6;Axl	Expression of receptor tyrosine kinase ***Axl*** and its ***ligand*** ***Gas6*** in rheumatoid arthritis : evidence for a novel endothelial cell survival pathway .	parallel	1
2602	10233855	2621;558	Gas6;Axl	***Gas6*** ( for growth arrest-specific gene 6 ) , which is a ***ligand*** for ***Axl*** and is related to the coagulation factor protein S , was found in synovial fluid and tissue from patients with RA and osteoarthritis .	parallel	1
2603	10233872	4297;7157	MLL;p53	Transcriptional ***inhibition*** of ***p53*** by the ***MLL/MEN*** chimeric protein found in myeloid leukemia .	negative	1
2604	10233872	7157;4297	p53;MLL	Moreover , ***p53*** ***coimmunoprecipitated*** with ***MLL/MEN*** as well as MEN , suggesting that the fusion protein binds to p53 through the MEN region .	parallel	1
2605	10233883	3458;355	IFNgamma;Fas	These results indicate that ***IFNgamma*** acts on ECFC not only to ***upregulate*** ***Fas*** , but also to selectively upregulate caspases-1 , -3 , and -8 , which are activated and produce apoptosis , whereas the concentrations of FasL and FADD are not demonstrably changed .	positive	1
2606	10233883	3458;355	IFNgamma;Fas	Fas ( APO-1 ; CD95 ) and Fas ligand ( FasL ) mediate apoptosis induced by IFNgamma , because ***Fas*** is significantly ***upregulated*** by ***IFNgamma*** , whereas Fas ligand is constitutively present in the ECFC and neutralization of FasL greatly reduces the apoptosis .	positive	1
2607	10233883	3458;834	IFNgamma;caspase-1	RNase protection assays showed that the ***caspase-1*** , -2 , -6 , -8 , and -9 mRNAs were ***upregulated*** by ***IFNgamma*** , whereas the caspase-5 and -7 mRNAs were not increased .	positive	1
2608	10233885	4602;100073347	c-myb;mim-1	Cotransfection of ***c-myb*** with either the p32 or p30 isoform of C/EBPepsilon in CV-1 cells cooperatively ***transactivated*** the ***mim-1*** promoter by 20 - and 16-fold , respectively , and the neutrophil elastase promoter by 10-and 7-fold , respectively .	positive	1
2609	10233885	925;100073347	p32;mim-1	Consistent with this prediction , transfections into the hematopoietic cell line Jurkat showed a 9.0 - and 2.5-fold ***activation*** of the ***mim-1*** promoter by the ***p32*** and p30 isoforms , respectively .	positive	1
2610	10233887	2056;11184	Epo;HPK1	We therefore conclude that ***Epo*** ***induces*** activation of both ***HPK1*** and HS1 , whereas cellular stresses activate only HS1 , and that the HPK1-JNK / SAPK pathway is involved in Epo-induced growth and differentiation signals .	target	1
2611	10233887	2056;3059	Epo;HS1	We therefore conclude that ***Epo*** ***induces*** activation of both HPK1 and ***HS1*** , whereas cellular stresses activate only HS1 , and that the HPK1-JNK / SAPK pathway is involved in Epo-induced growth and differentiation signals .	target	1
2612	10233887	2056;11184	erythropoietin;hematopoietic progenitor kinase-1	***Activation*** of ***hematopoietic progenitor kinase-1*** by ***erythropoietin*** .	positive	1
2613	10233887	2056;11184	Epo;HPK1	We found that ***Epo*** , but not environmental stresses , ***induced*** rapid and transient activation of ***HPK1*** , whereas both induced activation of JNK/SAPK .	target	1
2614	10233887	11184;3059	HPK1;HS1	We found ***HPK1*** constitutively ***associated*** with ***HS1*** and that HS1 was tyrosine-phosphorylated in response to cellular stresses as well as Epo stimulation .	parallel	0
2615	10233889	7076;1649	Epo;CHOP	We now report that ***Epo*** markedly ***upregulates*** ***CHOP*** ( GADD153 ) expression and that this transcription factor plays a role in erythropoiesis .	positive	1
2616	10233900	7040;1215	TGF-beta1;chymase	In conclusion , the expression and extracellular release of the IMMC-specific ***chymase*** , mMCP-1 , is strictly ***regulated*** by ***TGF-beta1*** .	target	1
2617	10233905	4688;653361	p67phox;p47phox	These data support a model in which flavocytochrome b is required for stable membrane ***binding*** of ***p47phox*** and ***p67phox*** , but not their association with the cytoskeleton or transport to the cell periphery .	parallel	1
2618	10233927	9260;4790	LMP-1;NF-kappaB	A20 can be regulated by the ***NF-kappaB*** transcription factor , which is known to be ***activated*** by the EBV ***LMP-1*** protein .	positive	1
2619	10233977	7341;5371	SUMO-1;PML	Here we show that the HSV ICP0 and CMV IE1 proteins specifically abrogate the ***SUMO-1*** ***modification*** of ***PML*** and Sp100 , whereas the adenovirus E4 ORF3 protein does not affect this process .	target	0
2620	10233977	7341;6672	SUMO-1;Sp100	Here we show that the HSV ICP0 and CMV IE1 proteins specifically abrogate the ***SUMO-1*** ***modification*** of PML and ***Sp100*** , whereas the adenovirus E4 ORF3 protein does not affect this process .	target	0
2621	10234545	7124;7412	TNF-alpha;VCAM-1	Percutaneous injection of ***TNF-alpha*** ***induced*** up-regulation of ***VCAM-1*** .	target	1
2622	10234567	5744;654	PTHrP;BMP-6	These latter findings suggest that while ***PTHrP*** directly ***inhibits*** ***BMP-6*** , it indirectly regulates Ihh expression through BMP-6 .	negative	1
2623	10234571	6647;6696	homodimer;osteopontin	Several analogs were examined for their effects on DNA ***binding*** of the vitamin D receptor ( VDR ) ***homodimer*** complex with the murine ***osteopontin*** vitamin D response element .	parallel	1
2624	10234571	7421;6696	vitamin D receptor;osteopontin	Several analogs were examined for their effects on DNA ***binding*** of the ***vitamin D receptor*** ( VDR ) homodimer complex with the murine ***osteopontin*** vitamin D response element .	parallel	1
2625	10234573	1017;5925	Cdk2;pRb	This was consistent with an observed IGF-1-stimulated hyperphosphorylation of retinoblastoma protein ( pRb ) with the possibility that the activated ***Cdk2*** kinase is involved in ***phosphorylation*** of ***pRb*** in IGF-1-induced cell proliferation .	target	1
2626	10235259	355;841	Fas;caspase-8	The CED-4-homologous protein FLASH is involved in ***Fas-mediated*** ***activation*** of ***caspase-8*** during apoptosis .	positive	1
2627	10235265	8556;2313	Cdc14;Sic1	The highly conserved protein phosphatase ***Cdc14*** ***promotes*** both Clb degradation and ***Sic1*** accumulation .	positive	0
2628	10235265	8556;2313	Cdc14;Sic1	***Cdc14*** ***promotes*** ***Sic1*** transcription and the stabilization of Sic1 protein by dephosphorylating Sicl and its transcription factor Swi5 .	positive	0
2629	10235368	1019;1029	CDK4;p16	***CDK4*** , encoded by CDK4 gene , is the ***substrate*** of ***p16*** .	parallel	1
2630	10235446	3383;7448	ICAM-1;vitronectin	Furthermore , monocyte adhesion to vitronectin and fibrinogen was significantly enhanced by the lipoproteins [ respectively 2-fold and 1.7-fold increase with 200 microg/ml of ox-Lp ( a ) ] , due to the increase of micro-PAR and ***ICAM-1*** , which are ***receptors*** for ***vitronectin*** and fibrinogen .	parallel	1
2631	10235530	3479;3486	insulin-like growth factor-1;IGFBP-3	OBJECTIVE : To determine the effects of recombinant human ***insulin-like growth factor-1*** ( IGF-1 ) ***complexed*** with its principal binding protein , ***IGFBP-3*** , on skeletal muscle metabolism in severely burned children .	parallel	1
2632	10235530	3486;3479	IGFBP-3;IGF-1	The infusion of 1.0 mg/kg/day ***IGF-1/IGFBP-3*** ***increased*** serum ***IGF-1*** , which did not further increase with 2.0 and 4.0 mg/kg/day .	positive	0
2633	10235629	887;2520	CCK2 receptor;gastrin	While ***CCK2 receptor*** blockade ***prevents*** ***gastrin*** from evoking acid secretion , it is without effect on basal and vagally stimulated acid secretion .	positive	0
2634	10318759	5829;7145	paxillin;tensin	Studying the quantitative relationships between the various components of the submembrane plaque indicated that the levels of vinculin , ***paxillin*** and phosphotyrosine in adhesion sites are positively correlated with each other and negatively ***correlated*** with the levels of ***tensin*** .	negative	0
2635	10318759	7414;7145	vinculin;tensin	Studying the quantitative relationships between the various components of the submembrane plaque indicated that the levels of ***vinculin*** , paxillin and phosphotyrosine in adhesion sites are positively correlated with each other and negatively ***correlated*** with the levels of ***tensin*** .	negative	0
2636	10318769	581;599	Bax;Bcl-w	In extracts of mammary tissue in vivo , Bak heterodimerized with Bcl-x whereas ***Bax*** ***associated*** with ***Bcl-w*** , but Bak/Bcl-w heterodimers were not detected .	parallel	0
2637	10318769	578;599	Bak;Bcl-w	In extracts of mammary tissue in vivo , Bak heterodimerized with Bcl-x whereas Bax associated with Bcl-w , but ******Bak/Bcl-w****** ***heterodimers*** were not detected .	parallel	1
2638	10318779	7157;1387	p53;CBP	Because ***p53*** ***interacts*** with both MDM2 and ***CBP/p300*** through its trans-activation domain , we examined the role of MDM2 in p53-coactivator interactions .	parallel	1
2639	10318779	7157;2033	p53;p300	Because ***p53*** ***interacts*** with both MDM2 and ***CBP/p300*** through its trans-activation domain , we examined the role of MDM2 in p53-coactivator interactions .	parallel	1
2640	10318779	7157;1387	p53;CBP	MDM2 blocked CBP/p300 recruitment in vitro and inhibited the ***interaction*** of the transactivating region of ***p53*** with both the N - or C-terminal regions of ***CBP/p300*** in a mammalian two-hybrid assay .	parallel	1
2641	10318779	7157;2033	p53;p300	MDM2 blocked CBP/p300 recruitment in vitro and inhibited the ***interaction*** of the transactivating region of ***p53*** with both the N - or C-terminal regions of ***CBP/p300*** in a mammalian two-hybrid assay .	parallel	1
2642	10318789	836;1676	caspase-3;DFF45	Previous studies have shown that upon ***cleavage*** of ***DFF45*** by ***caspase-3*** , the nuclease activity of DFF40 is relieved of inhibition .	target	1
2643	10318789	840;1676	caspase-7;DFF45	We demonstrate that ***DFF45*** can also be ***cleaved*** and inactivated by ***caspase-7*** but not by caspase-6 and caspase-8 .	target	1
2644	10318789	3005;1677	histone H1;DFF40	***histone H1*** directly interacts with DFF , confers DNA binding ability to DFF , and ***stimulates*** the nuclease activity of ***DFF40*** by increasing its Kcat and decreasing its Km .	positive	0
2645	10318795	190;2516	nuclear receptor DAX-1;SF-1	We also found that the ***nuclear receptor DAX-1*** , a ***repressor*** of ***SF-1*** activity , reduced Egr-1-SF-1 synergy and diminished GnRH stimulation of the LHbeta promoter .	negative	1
2646	10318795	190;1958	nuclear receptor DAX-1;Egr-1	We also found that the ***nuclear receptor DAX-1*** , a repressor of SF-1 activity , ***reduced*** ***Egr-1-SF-1*** synergy and diminished GnRH stimulation of the LHbeta promoter .	negative	1
2647	10318795	190;2516	nuclear receptor DAX-1;SF-1	We also found that the ***nuclear receptor DAX-1*** , a repressor of SF-1 activity , ***reduced*** ***Egr-1-SF-1*** synergy and diminished GnRH stimulation of the LHbeta promoter .	negative	1
2648	10318796	7124;6197	Tumor necrosis factor-alpha;HU-3	***Tumor necrosis factor-alpha*** ( TNF-alpha ) ***stimulates*** proliferation of Mo7e , CMK , ***HU-3*** , and M-MOK human leukemic cell lines .	positive	0
2649	10318796	5970;958	p65;p50	The activated NF-kappaB consisted of ***heterodimers*** of ***p65*** and ***p50*** subunits .	parallel	1
2650	10318799	5335;79026	PLC-gamma1;AHNAK	The role of arachidonic acid was to promote a physical ***interaction*** between ***AHNAK*** and ***PLC-gamma1*** , and the activation by AHNAK and arachidonic acid was mainly attributable to reduction in the enzyme 's apparent Km toward the substrate phosphatidylinositol 4,5-bisphosphate .	parallel	1
2651	10318804	7263;3329	rhodanese;GroEL	Under native conditions , truncated ***rhodanese*** ***bound*** to ***GroEL*** and was released and reactivated by adding ATP and GroES , suggesting equilibrium between native and non-native conformers .	parallel	1
2652	10318807	896;1019	cyclin D3;Cdk4	Here we report that in UV-irradiated HeLa and A2058 cells , p16 bound Cdk4 and Cdk6 complexes with increased avidity and inhibited a ******cyclin D3-Cdk4****** ***complex*** normally activated in late S/early G2 phase .	parallel	1
2653	10318807	1029;1019	p16;Cdk4	Here we report that in UV-irradiated HeLa and A2058 cells , ***p16*** ***bound*** ***Cdk4*** and Cdk6 complexes with increased avidity and inhibited a cyclin D3-Cdk4 complex normally activated in late S/early G2 phase .	parallel	1
2654	10318807	1029;1021	p16;Cdk6	Here we report that in UV-irradiated HeLa and A2058 cells , ***p16*** ***bound*** Cdk4 and ***Cdk6*** complexes with increased avidity and inhibited a cyclin D3-Cdk4 complex normally activated in late S/early G2 phase .	parallel	1
2655	10318807	1029;1019	p16;Cdk4	Here we report that in UV-irradiated HeLa and A2058 cells , ***p16*** bound Cdk4 and Cdk6 complexes with increased avidity and ***inhibited*** a ***cyclin D3-Cdk4*** complex normally activated in late S/early G2 phase .	negative	1
2656	10318807	1029;896	p16;cyclin D3	Here we report that in UV-irradiated HeLa and A2058 cells , ***p16*** bound Cdk4 and Cdk6 complexes with increased avidity and ***inhibited*** a ***cyclin D3-Cdk4*** complex normally activated in late S/early G2 phase .	negative	1
2657	10318831	10755;10509	GIPC;SemC	While SEMCAP-1 ( ***GIPC*** ) also ***interacts*** with ***SemC*** , it does not interact with other proteins containing a class I PDZ binding motif , nor does M-SemF interact with other class I PDZ proteins .	parallel	1
2658	10318842	1051;6722	CCAAT/enhancer-binding protein beta;serum response factor	Ras regulates the ***association*** of ***serum response factor*** and ***CCAAT/enhancer-binding protein beta*** .	parallel	0
2659	10318842	1051;2220	C/EBPbeta;p35	Strikingly , in both the mammalian two-hybrid assay and in vivo coimmunoprecipitations , the ***association*** of SRF and ******p35-C/EBPbeta****** but not p20-C/EBPbeta is dramatically stimulated by activated Ras .	parallel	0
2660	10318842	1051;6722	C/EBPbeta;SRF	Strikingly , in both the mammalian two-hybrid assay and in vivo coimmunoprecipitations , the ***association*** of ***SRF*** and ***p35-C/EBPbeta*** but not p20-C/EBPbeta is dramatically stimulated by activated Ras .	parallel	0
2661	10318842	2220;6722	p35;SRF	Strikingly , in both the mammalian two-hybrid assay and in vivo coimmunoprecipitations , the ***association*** of ***SRF*** and ***p35-C/EBPbeta*** but not p20-C/EBPbeta is dramatically stimulated by activated Ras .	parallel	0
2662	10318842	1051;2220	C/EBPbeta;p35	These results suggest a new mechanism by which mitogenic signals may influence transcription activity of the SRE by selectively promoting protein-protein ***interactions*** between SRF and the transactivator ******p35-C/EBPbeta****** .	parallel	1
2663	10318842	1051;6722	C/EBPbeta;SRF	These results suggest a new mechanism by which mitogenic signals may influence transcription activity of the SRE by selectively promoting protein-protein ***interactions*** between ***SRF*** and the transactivator ***p35-C/EBPbeta*** .	parallel	1
2664	10318842	2220;6722	p35;SRF	These results suggest a new mechanism by which mitogenic signals may influence transcription activity of the SRE by selectively promoting protein-protein ***interactions*** between ***SRF*** and the transactivator ***p35-C/EBPbeta*** .	parallel	1
2665	10318843	3932;7535	Lck;ZAP-70	One essential function of ***Lck*** in this process is to ***phosphorylate*** ***ZAP-70*** and up-regulate its catalytic activity .	target	1
2666	10318843	3932;7535	Lck;ZAP-70	We have previously shown that after T-cell antigen receptor stimulation , ***Lck*** ***binds*** to ***ZAP-70*** via its Src homology 2 ( SH2 ) domain ( LckSH2 ) and , more recently , that Tyr319 of ZAP-70 is phosphorylated in vivo and plays a positive regulatory role .	parallel	1
2667	10318843	7535;3932	ZAP-70;Lck	Here , we investigated the possibility that Tyr319 mediates the SH2-dependent ***interaction*** between ***Lck*** and ***ZAP-70*** .	parallel	1
2668	10318844	5813;5814	Puralpha;Purbeta	***Interactions*** between ***Puralpha*** , ***Purbeta*** , and MSY1 do not require the participation of DNA .	parallel	1
2669	10318852	9733;3667	p110;IRS-1	Moreover , ***p110*** ( CAAX ) stimulated IRS-1 Ser/Thr phosphorylation , and ***inhibited*** ***IRS-1*** associated PI 3-kinase activity , without affecting insulin receptor tyrosine phosphorylation , suggesting that it may play an important role as a negative regulator for insulin signaling .	negative	1
2670	10318852	9733;3667	p110;IRS-1	Moreover , ***p110*** ( CAAX ) ***stimulated*** ***IRS-1*** Ser/Thr phosphorylation , and inhibited IRS-1 associated PI 3-kinase activity , without affecting insulin receptor tyrosine phosphorylation , suggesting that it may play an important role as a negative regulator for insulin signaling .	positive	0
2671	10318855	2063;7026	ear2;ARP1	Here we demonstrate that ***ARP1*** and ***ear2*** form ***heterodimers*** in solution and on directly repeated response elements with high efficiency and a specificity differing from that of homodimeric complexes composed of either receptor .	parallel	1
2672	10318855	2063;7026	ear2;ARP1	Heterodimeric ***interactions*** between ***ARP1*** and ***ear2*** may define a distinct pathway of orphan receptor signaling .	parallel	1
2673	10318860	54776;4067	p85;LYN	The results demonstrate that the NO donor S-nitrosoglutathione ( S-NO-glutathione ) inhibits the stimulation of PI3-kinase associated with tyrosine-phosphorylated proteins and of ***p85/PI3-kinase*** ***associated*** with the SRC family kinase member ***LYN*** following the exposure of platelets to thrombin receptor-activating peptide .	parallel	0
2674	10318861	1398;2889	Crk;C3G	Deletion of the amino terminus of C3G to amino acid 61 did not remarkably affect either tyrosine phosphorylation or ***Crk-dependent*** ***activation*** of ***C3G*** .	positive	1
2675	10318861	1398;2889	Crk;C3G	Deletion of the amino terminus of C3G to amino acid 579 significantly reduced the ***Crk-dependent*** tyrosine ***phosphorylation*** of ***C3G*** and increased GTP-bound Rap1 irrespective of the presence of CrkI .	target	1
2676	10318863	5790;3932	CD45-AP;Lck	Moreover , they raise the possibility that one of the functions of ***CD45-AP*** is to ***recognize*** activated ***Lck*** molecules and bring them into the vicinity of CD45 .	target	1
2677	10318863	5790;920	CD45-AP;CD4	The ***association*** of ***CD45-AP*** with TCR , ***CD4*** , and CD8 seemed to occur via the shared ability of these molecules to bind CD45 .	parallel	0
2678	10318863	5790;925	CD45-AP;CD8	The ***association*** of ***CD45-AP*** with TCR , CD4 , and ***CD8*** seemed to occur via the shared ability of these molecules to bind CD45 .	parallel	0
2679	10318863	5790;3932	CD45-AP;Lck	However , ***binding*** of ***CD45-AP*** to p56 ( ***Lck*** ) could take place in the absence of other lymphoid-specific components , suggesting that it can be direct .	parallel	1
2680	10318864	1493;3725	CTLA-4;AP-1	***CTLA-4*** ligation ***suppresses*** CD28-induced NF-kappaB and ***AP-1*** activity in mouse T cell blasts .	negative	1
2681	10318864	1493;4790	CTLA-4;NF-kappaB	***CTLA-4*** ligation ***suppresses*** CD28-induced ***NF-kappaB*** and AP-1 activity in mouse T cell blasts .	negative	1
2682	10318869	9261;6722	MAPKAP kinase 2;serum response factor	***MAPKAP kinase 2*** ***phosphorylates*** ***serum response factor*** in vitro and in vivo .	target	1
2683	10318869	9261;6722	MK2;SRF	***MK2*** ***phosphorylates*** ***SRF*** in vitro at Ser-103 with similar efficiency as the small heat shock protein Hsp25 and significantly better than CREB .	target	1
2684	10318892	8850;595	P/CAF;cyclin D1	***P/CAF*** ***associates*** with ***cyclin D1*** and potentiates its activation of the estrogen receptor .	parallel	0
2685	10318901	3077;7037	HFE;Transferrin receptor	***Transferrin receptor*** is negatively ***modulated*** by the hemochromatosis protein ***HFE*** : implications for cellular iron homeostasis .	negative	0
2686	10318901	3077;7037	HFE;Transferrin receptor	Recent demonstration of an ***association*** between ***Transferrin receptor*** ( TfR ) and ***HFE*** , a major histocompatibility complex class I-like molecule that has been implicated to play a role in hereditary hemochromatosis , further strengthens the notion that HFE is involved in iron metabolism .	parallel	0
2687	10318901	7037;3077	TfR;HFE	Because surface-expressed HFE and TfR remain firmly associated physically , only the fraction of ***TfR*** that is ***associated*** with ***HFE*** during biosynthesis is affected functionally .	parallel	0
2688	10318901	3077;7037	HFE;TfR	Moreover , we show that ***HFE*** binding reduces the number of functional Transferrin binding sites and ***impairs*** ***TfR*** internalization , thus reducing the uptake of Transferrin-bound iron .	negative	0
2689	10318901	3077;7037	HFE;TfR	Thus , iron homeostasis is indirectly regulated by ***HFE*** , a negative ***modulator*** of ***TfR*** .	negative	0
2690	10318904	10049;3308	DnaJ;hsp70	***DnaJ*** ***stimulates*** ***hsp70*** to hydrolyze ATP , a key step that closes its substrate-binding cavity and thus allows stable binding of substrate .	positive	0
2691	10318914	4738;8453	ubiquitin-like protein NEDD8;cullin-2	***Conjugation*** of the ***ubiquitin-like protein NEDD8*** to ***cullin-2*** is linked to von Hippel-Lindau tumor suppressor function .	parallel	1
2692	10318914	4738;7428	ubiquitin-like protein NEDD8;von Hippel-Lindau tumor suppressor	Conjugation of the ***ubiquitin-like protein NEDD8*** to cullin-2 is ***linked*** to ***von Hippel-Lindau tumor suppressor*** function .	parallel	0
2693	10318914	7428;8453	pVHL;cullin-2	The von Hippel-Lindau tumor suppressor protein ***pVHL*** ***assembles*** with ***cullin-2*** ( hCUL-2 ) and elongin B/C forming a protein complex , CBCVHL , that resembles SKP1-CDC53-F-box protein ubiquitin ligases .	parallel	1
2694	10318914	7428;6921	pVHL;elongin B/C	The von Hippel-Lindau tumor suppressor protein ***pVHL*** ***assembles*** with cullin-2 ( hCUL-2 ) and ***elongin B/C*** forming a protein complex , CBCVHL , that resembles SKP1-CDC53-F-box protein ubiquitin ligases .	parallel	1
2695	10318914	4738;8453	ubiquitin-like protein NEDD8;hCUL-2	Here , we show that ***hCUL-2*** is ***modified*** by the conserved ***ubiquitin-like protein NEDD8*** and that NEDD8-hCUL-2 conjugates are part of CBCVHL complexes in vivo .	target	0
2696	10318914	4738;8453	NEDD8;hCUL-2	Thus , ***ligation*** of ***NEDD8*** to ***hCUL-2*** is linked to pVHL activity and may be important for pVHL tumor suppressor function .	parallel	1
2697	10318914	4738;7428	NEDD8;pVHL	Thus , ligation of ***NEDD8*** to hCUL-2 is ***linked*** to ***pVHL*** activity and may be important for pVHL tumor suppressor function .	parallel	0
2698	10318916	1499;595	beta-catenin;cyclin D1	***cyclin D1*** protein levels were ***induced*** by ***beta-catenin*** overexpression and reduced in cells overexpressing the cadherin cytoplasmic domain .	target	1
2699	10318917	3991;2167	HSL;adipocyte lipid-binding protein	By using the yeast two-hybrid system to examine the potential interaction of HSL with other cellular proteins , evidence is provided to demonstrate a direct ***interaction*** of ***HSL*** with ***adipocyte lipid-binding protein*** ( ALBP ) , a member of the family of intracellular lipid-binding proteins that binds fatty acids , retinoids , and other hydrophobic ligands .	parallel	1
2700	10318917	2167;3991	ALBP;HSL	The interaction was demonstrated in vitro by the ***binding*** of ***ALBP*** to ***HSL*** translated in vitro , to HSL in extracts of HSL overexpressing Chinese hamster ovary ( CHO ) cells , and to HSL in extracts of rat adipose tissue .	parallel	1
2701	10318917	2167;3991	ALBP;HSL	The ******HSL-ALBP****** ***interaction*** was mapped to an N-terminal 300-aa region of HSL that is distinct from the C-terminal catalytic domain .	parallel	1
2702	10319191	1557;1559	CYP2C19;CYP2C9	Numerous ***substrates*** and inhibitors of CYP2D6 , ***CYP2C19*** , and ***CYP2C9*** are identified .	parallel	1
2703	10319191	1557;1565	CYP2C19;CYP2D6	Numerous ***substrates*** and inhibitors of ***CYP2D6*** , ***CYP2C19*** , and CYP2C9 are identified .	parallel	1
2704	10319191	1559;1557	CYP2C9;CYP2C19	Numerous ***substrates*** and inhibitors of CYP2D6 , ***CYP2C19*** , and ***CYP2C9*** are identified .	parallel	1
2705	10319191	1559;1565	CYP2C9;CYP2D6	Numerous ***substrates*** and inhibitors of ***CYP2D6*** , CYP2C19 , and ***CYP2C9*** are identified .	parallel	1
2706	10319191	1565;1557	CYP2D6;CYP2C19	Numerous ***substrates*** and inhibitors of ***CYP2D6*** , ***CYP2C19*** , and CYP2C9 are identified .	parallel	1
2707	10319191	1565;1559	CYP2D6;CYP2C9	Numerous ***substrates*** and inhibitors of ***CYP2D6*** , CYP2C19 , and ***CYP2C9*** are identified .	parallel	1
2708	10319265	3135;3133	HLA-G;HLA-E	In addition to the classical MHC class I roles ( antigen presentation and ligation to NK receptors inducing inhibitory and/or activatory signals ) , HLA-G is likely to exert other , novel functions : first , ***HLA-G*** was shown to be involved in the ***control*** of ***HLA-E*** expression by furnishing the appropriate class I leader sequence nonamer peptide ; second , we hypothesize that HLA-G could be a regulator of placental angiogenesis ; third , soluble HLA-G isoforms may act as specific immunosuppressors during pregnancy .	target	0
2709	10319275	3308;5610	HSP70;PKR	This variation in the ***induction*** of 2-5A and ***PKR*** by ***anti-HSP70*** or IFN-beta indicates involvement of IFN-beta in viral induction 2-5A and PKR , and HSP involvement in chemical induction of these enzymes .	target	1
2710	10319275	3456;5610	IFN-beta;PKR	This variation in the ***induction*** of 2-5A and ***PKR*** by anti-HSP70 or ***IFN-beta*** indicates involvement of IFN-beta in viral induction 2-5A and PKR , and HSP involvement in chemical induction of these enzymes .	target	1
2711	10319320	7422;3791	VEGF;Flk-1	The ***VEGF-induced*** tyrosine ***phosphorylation*** of the VEGF receptor , ***Flk-1*** , and its association with the Shc/Grb2/Ras-GAP ( guanosine triphosphatase-activating protein ) complex were unaffected by 16K hPRL treatment .	target	1
2712	10319320	3791;7422	Flk-1;VEGF	The VEGF-induced tyrosine phosphorylation of the ***VEGF*** ***receptor*** , ***Flk-1*** , and its association with the Shc/Grb2/Ras-GAP ( guanosine triphosphatase-activating protein ) complex were unaffected by 16K hPRL treatment .	parallel	1
2713	10319323	2516;1051	SF-1;C/EBP beta	***SF-1*** ( steroidogenic factor-1 ) and ***C/EBP beta*** ( CCAAT/enhancer binding protein-beta ) ***cooperate*** to regulate the murine StAR ( steroidogenic acute regulatory ) promoter .	parallel	0
2714	10319324	5449;2353	GHF-1;c-fos	The tissue-specific transcription factor ***Pit-1/GHF-1*** ***binds*** to the ***c-fos*** serum response element and activates c-fos transcription .	parallel	1
2715	10319324	5449;2353	GHF-1;c-fos	The tissue-specific transcription factor ***Pit-1/GHF-1*** binds to the c-fos serum response element and ***activates*** ***c-fos*** transcription .	positive	1
2716	10319324	5449;2353	Pit-1;c-fos	We show that ***Pit-1*** overexpression in PC12 cells , which do not express Pit-1 , ***increases*** ***c-fos*** expression .	positive	0
2717	10319325	2796;1958	GnRH;Egr1	Thus , ***GnRH*** ***induces*** expression of ***Egr1*** , which subsequently activates the eLH beta promoter .	target	1
2718	10319326	2101;2516	ERR alpha;SF-1	We show that ***ERR alpha*** ***binds*** as a homodimer on a specific target sequence , the SFRE ( ***SF-1*** response element ) , already known to respond to the orphan nuclear receptor SF-1 .	parallel	1
2719	10319327	6722;2353	SRF;c-fos	The ***SRF*** and bHLH proteins appear to bind to the SRE and ***activate*** the ***c-fos*** promoter in Sertoli cells .	positive	1
2720	10319586	10401;6774	PIAS3;STAT3	Mouse ***PIAS3*** ( protein inhibitor of activated STAT3 ) is a specific ***inhibitor*** of ***STAT3*** that downregulates its signaling pathway .	negative	1
2721	10319863	8915;4790	BCL10;NF-kappaB	Wild-type ***BCL10*** ***activated*** ***NF-kappaB*** but induced apoptosis of MCF7 and 293 cells .	positive	1
2722	10319864	7039;1956	transforming growth factor-alpha;Epidermal growth factor receptor	Cleft lip and palate syndromes in humans are associated with polymorphisms in the gene ( TGFA ) encoding ***transforming growth factor-alpha*** ( TGF-alpha ) , an ***Epidermal growth factor receptor*** ( Egfr ) ***ligand*** made by most epithelia .	parallel	1
2723	10319872	4609;6598	c-MYC;INI1	***c-MYC*** ***interacts*** with ***INI1/hSNF5*** and requires the SWI/SNF complex for transactivation function .	parallel	1
2724	10319872	4609;6594	c-MYC;SWI	***c-MYC*** interacts with INI1/hSNF5 and ***requires*** the ***SWI/SNF*** complex for transactivation function .	target	0
2725	10319872	4609;6598	c-MYC;INI1	The ******c-MYC-INI1****** ***interaction*** was observed both in vitro and in vivo .	parallel	1
2726	10319872	4609;6598	c-MYC;INI1	Our results suggest that the SWI/SNF complex is necessary for c-MYC-mediated transactivation and that the ******c-MYC-INI1****** ***interaction*** helps recruit the complex .	parallel	1
2727	10319992	4609;1026	c-Myc;p21	We show here that exogenous ***c-Myc*** ***inhibits*** ***p21*** expression in SkBr3 and LNCaP cells induced to enter into S-phase .	negative	1
2728	10319992	4609;1026	c-Myc;p21	Overexpression of c-Myc reduced the levels of endogenous p21 mRNA , and transfection of ***c-Myc*** ***repressed*** ***p21-promoter*** luciferase-reporter gene expression .	negative	1
2729	10320001	351;3329	beta-amyloid peptide;hsp60	In contrast , treatment with the Alzheimer 's toxin , the ***beta-amyloid peptide*** , ***reduced*** the amount of intracellular ***hsp60*** .	negative	1
2730	10320009	5020;5443	Oxytocin;ACTH	The aim of this study was to investigate how ***Oxytocin*** ( OXT ) ***influences*** plasma levels of ***ACTH*** and corticosterone in rats .	target	0
2731	10320030	2185;627	protein kinase B;brain-derived neurotrophic factor	Sustained phosphorylation and activation of ***protein kinase B*** ***correlates*** with ***brain-derived neurotrophic factor*** and insulin stimulated survival of cerebellar granule cells .	parallel	0
2732	10320322	998;207	Cdc42;Rac	Most of the putative effectors for the Rho-family small GTPases Cdc42 and Rac share a common sequence motif referred to as the ******Cdc42/Rac****** interactive ***binding*** ( CRIB ) motif .	parallel	1
2733	10320322	5062;998	PAK2;Cdc42	***Interaction*** of the 22-residue peptide ***PAK2*** ( 71-92 ) with GTP-gammaS-loaded ***Cdc42*** causes resonance perturbations in the 1H-15N HSQC spectrum of Cdc42 that are similar to those observed for a longer ( 46-amino acid ) CRIB-containing protein fragment [ Guo , W. , et al. ( 1998 ) Biochemistry 37 , 14030-14037 ] .	parallel	1
2734	10320352	4792;3551	IkappaBalpha;IKK2	We have studied the direct ***interaction*** of recombinant ***IkappaBalpha*** , IkappaBbeta1 , IkappaBbeta2 , and IkappaBepsilon with the recombinant homodimeric ***IKK2*** .	parallel	1
2735	10320352	4794;3551	IkappaBepsilon;IKK2	We have studied the direct ***interaction*** of recombinant IkappaBalpha , IkappaBbeta1 , IkappaBbeta2 , and ***IkappaBepsilon*** with the recombinant homodimeric ***IKK2*** .	parallel	1
2736	10320373	3439;7297	IFN-alpha;Tyk2	***Activation*** of ***Tyk2*** in NK cells by ***IFN-alpha/beta*** also required NOS2 .	positive	1
2737	10320482	650;3549	BMP-2;Ihh	We also showed that retrovirally induced ***BMP-2*** ***induces*** the expression of both ***Ihh*** and noggin ( encoding the BMP-inactivating protein ) , and we further present evidence that a negative-feedback loop involving noggin might account for the precise localization of BMP signalling for Ihh induction .	target	1
2738	10320482	650;9241	BMP-2;noggin	We also showed that retrovirally induced ***BMP-2*** ***induces*** the expression of both Ihh and ***noggin*** ( encoding the BMP-inactivating protein ) , and we further present evidence that a negative-feedback loop involving noggin might account for the precise localization of BMP signalling for Ihh induction .	target	1
2739	10320483	9564;5792	p130Cas;LAR	CONCLUSIONS : ***p130Cas*** is an in vivo ***substrate*** of ***LAR*** .	parallel	1
2740	10320483	5792;9564	LAR;p130Cas	***LAR*** specifically ***dephosphorylates*** and destabilizes ***p130Cas*** and may play a role in regulating cell adhesion-mediated cell survival .	target	1
2741	10320526	5741;2247	PTH;FGF-2	We conclude that ***PTH*** and cAMP ***stimulate*** ***FGF-2*** mRNA abundance in part through a transcriptional mechanism .	positive	0
2742	10320526	2247;5741	FGF-2;PTH	We hypothesize that some effects of ***PTH*** on bone remodeling may be ***mediated*** by regulation of ***FGF-2*** and FGFR expression in osteoblastic cells .	target	0
2743	10320526	5741;2247	Parathyroid hormone;fibroblast growth factor-2	***Parathyroid hormone*** ***regulates*** the expression of ***fibroblast growth factor-2*** mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells .	target	1
2744	10320526	5741;2263	PTH;FGFR-2	***PTH*** also increased FGFR-1 mRNA at 2 h and transiently ***increased*** ***FGFR-2*** mRNA at 1 h.	positive	0
2745	10320526	5741;2247	PTH;FGF-2	Immunohistochemistry showed that ***PTH*** and FSK ***increased*** ***FGF-2*** protein labeling in the nuclei of MC3T3-E1 cells .	positive	0
2746	10320526	5741;2247	PTH;FGF-2	***PTH*** also ***increased*** ***FGF-2*** mRNA , and FGFR-1 and FGFR-2 mRNA levels within 30 minutes in neonatal mouse calvarial organ cultures .	positive	0
2747	10320562	7040;5617	TGF-beta1;prolactin	However , in the short term ( up to 12 h ) ***TGF-beta1*** ***inhibition*** of ***prolactin*** secretion was associated with an increase in intracellular prolactin content , dissecting a dual mechanism of action of TGF-beta1 .	negative	1
2748	10320562	7040;5617	TGF-beta1;prolactin	However , pertussis toxin was able to recover a large percentage of ***TGF-beta1-induced*** ***inhibition*** of ***prolactin*** secretion .	negative	1
2749	10320562	7040;5617	TGF-beta1;prolactin	This study characterized the ***regulation*** of in-vitro ***prolactin*** synthesis and secretion by ***TGF-beta1*** using rat anterior pituitary cells in monolayer culture .	target	1
2750	10320562	7040;5617	TGF-beta1;prolactin	***TGF-beta1*** ***inhibited*** ***prolactin*** secretion in a time - and concentration-dependent manner , with half-maximal inhibition occurring at the range of 15-30 pM .	negative	1
2751	10320562	7040;5617	TGF-beta1;prolactin	The effect observed after long-term treatment ( 24 h to 4 days ) is essentially caused by a decrease in prolactin synthesis , since ***TGF-beta1*** ***inhibited*** ***prolactin*** mRNA levels and de novo prolactin protein synthesis .	negative	1
2752	10320618	3586;3458	IL-10;IFNgamma	We studied the role of the Th2 cytokine IL-10 during leishmania infection : removal of endogenous ***IL-10*** by anti-IL-10 treatment did not alter the Th2 cytokine pattern in non-healer mice nor did it modulate DTH reactivity , IgE production or fatal disease progression , but partially ***blocked*** the ***IFNgamma*** inhibiting effect of rIL-4 in healer mice .	positive	0
2753	10320637	3821;3824	NKG2A;CD94	We show that soluble ***NKG2A*** , - B and - C lectin domains ***interact*** with ***CD94*** lectin domains to form complexes , whereas NKG2D and human NKR-P1 lectin domains do not .	parallel	1
2754	10320638	811;6737	calreticulin;SS-A	***calreticulin*** also ***binds*** to the ***Ro/SS-A*** antigen complex , which is composed of at least three immunologically distinct proteins bound to a group of small cytoplasmic RNAs that together form a common target for autoimmune responses .	parallel	1
2755	10320641	3458;3075	interferon-gamma;complement factor H	***Regulation*** of ***complement factor H*** in a human liver cell line by ***interferon-gamma*** .	target	1
2756	10320641	3458;3075	IFN-gamma;factor H	Thus ***induction*** of ***factor H*** by ***IFN-gamma*** apparently involves two factors .	target	1
2757	10320721	2922;5443	gastrin-releasing peptide;adrenocorticotropin	Hypothalamus , anterior pituitary and adrenal gland involvement in the ***activation*** of ***adrenocorticotropin*** and corticosterone secretion by ***gastrin-releasing peptide*** .	positive	1
2758	10320721	2922;5443	GRP;ACTH	In addition , in dispersed anterior pituitary cells which medium contained Ca2 + ( 1.5 mM ) , ***GRP*** ***stimulated*** the secretion of ***ACTH*** , but was without effect when the concentration of Ca2 + in the medium was lower ( 200 nM ) .	positive	0
2759	10320721	2922;5443	GRP;ACTH	These results suggest that : ( 1 ) the hypothalamus , anterior pituitary and adrenal gland seem to contribute to the elevation of ACTH and corticosterone secretion induced by GRP by a mechanism mediated through GRP receptors and ( 2 ) the ***stimulation*** of ***ACTH*** by ***GRP*** in the anterior pituitary appears to be dependent upon the presence of physiological concentrations of extracellular Ca2 + .	positive	0
2760	10320778	627;4915	BDNF;trkB	Previous work had shown that during early ( prenatal ) development , ***trkB*** and its two ***ligands*** , ***BDNF*** and NT-4/5 , were most important for survival of almost all neurons .	parallel	1
2761	10320778	4909;4915	NT-4/5;trkB	Previous work had shown that during early ( prenatal ) development , ***trkB*** and its two ***ligands*** , BDNF and ***NT-4/5*** , were most important for survival of almost all neurons .	parallel	1
2762	10320804	5320;22925	sPLA2;PLA2R	Group IB ***sPLA2*** ( PLA2-IB ) ***binds*** to the PLA2 receptor ( ***PLA2R*** ) , and PLA2R-deficient mice exhibit resistance to endotoxin-induced lethality with reduced plasma levels of proinflammatory cytokines , such as TNF-alpha .	parallel	1
2763	10320804	22925;5319	PLA2R;PLA2	Group IB sPLA2 ( PLA2-IB ) binds to the ***PLA2*** ***receptor*** ( ***PLA2R*** ) , and PLA2R-deficient mice exhibit resistance to endotoxin-induced lethality with reduced plasma levels of proinflammatory cytokines , such as TNF-alpha .	parallel	1
2764	10320804	5319;22925	PLA2;PLA2R	Indoxam was found to block the ***PLA2-IB*** ***binding*** to murine ***PLA2R*** with a high potency ( Ki = 30 nM ) .	parallel	1
2765	10321529	7048;7040	TbetaR-II;TGF-beta	The type II receptors examined were ***TGF-beta*** type II ***receptor*** ( ***TbetaR-II*** ) , activin type II receptor ( ActR-II ) , and BMP type II receptor ( BMPR-II ) .	parallel	1
2766	10321688	4084;7157	Mad;p53	***Mad-overexpression*** down ***regulates*** the malignant growth and ***p53*** mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells .	target	1
2767	10321724	5020;359	oxytocin;aquaporin-2	Administration of ***oxytocin*** ***affects*** vasopressin V2 receptor and ***aquaporin-2*** gene expression in the rat .	target	0
2768	10321724	5020;554	oxytocin;V2R	***oxytocin*** ( OT ) ***binds*** to the vasopressin V2 receptor ( ***V2R*** ) because of its structural similarity to arginine vasopressin ( AVP ) .	parallel	1
2769	10321728	5071;1499	E3 ubiquitin ligase;beta-catenin	These results demonstrate that SCF ( HOS ) ***E3 ubiquitin ligase*** ***regulate*** both NF-kappaB and ***beta-catenin*** signaling pathways .	target	1
2770	10321728	5071;4790	E3 ubiquitin ligase;NF-kappaB	These results demonstrate that SCF ( HOS ) ***E3 ubiquitin ligase*** ***regulate*** both ***NF-kappaB*** and beta-catenin signaling pathways .	target	1
2771	10321733	5926;5934	RBP1;p130	We show here that ***RBP1*** , a known pRB pocket-binding protein , possesses transcriptional repression activity and ***associates*** with ***p130-E2F*** and pRB-E2F complexes specifically during growth arrest .	parallel	0
2772	10321733	5926;5925	RBP1;pRB	We show here that ***RBP1*** , a known pRB pocket-binding protein , possesses transcriptional repression activity and ***associates*** with p130-E2F and ***pRB-E2F*** complexes specifically during growth arrest .	parallel	0
2773	10321734	4193;7161	mdm2;p73	***Inactivation*** of the p53-homologue ***p73*** by the ***mdm2-oncoprotein*** .	negative	1
2774	10321734	4193;7157	mdm2;p53	Complex ***formation*** between ***p53*** and ***mdm2*** results in p53 's transcriptional inactivation and destabilization .	parallel	0
2775	10321735	22800;5599	TC21;JNK	Thus , like Ras , ***TC21*** may ***activate*** a ***Rac/JNK*** pathway .	positive	1
2776	10321735	22800;5599	TC21;JNK	Second , we found that ***TC21*** is an ***activator*** of the ***JNK*** and p38 , but not ERK , mitogen-activated protein kinase cascades and that TC21 transforming activity was dependent on Rac function .	positive	1
2777	10321735	22800;5594	TC21;p38	Second , we found that ***TC21*** is an ***activator*** of the JNK and ***p38*** , but not ERK , mitogen-activated protein kinase cascades and that TC21 transforming activity was dependent on Rac function .	positive	1
2778	10321737	3659;1026	IRF-1;p21	***Activation*** and repression of the 2-5A synthetase and ***p21*** gene promoters by ***IRF-1*** and IRF-2 .	positive	1
2779	10321737	3660;1026	IRF-2;p21	***Activation*** and repression of the 2-5A synthetase and ***p21*** gene promoters by IRF-1 and ***IRF-2*** .	positive	1
2780	10321737	3659;1026	IRF-1;p21	Following ectopic expression , ***IRF-1*** ***transactivated*** 2-5A synthetase and ***p21*** genes , an effect that was counterbalanced by concomitant ectopic expression of IRF-2 .	positive	1
2781	10321737	3659;3660	IRF-1;IRF-2	***IRF-1*** also ***induced*** expression of its homologous repressor ***IRF-2*** as indicated by EMSA analysis using an IRF-E probe from the IRF-2 promoter ; and by cotransfection of IRF-1 together with an IRF-2 promoter CAT construct .	target	1
2782	10321759	3557;7124	interleukin-1 receptor antagonist;TNF alpha	AIMS : To determine potential ***associations*** of ***interleukin-1 receptor antagonist*** ( IL-1ra ) , tumour necrosis factor alpha ( ***TNF alpha*** ) , and tumour necrosis factor beta ( TNF beta ) gene polymorphisms with ulcerative colitis or subsets of ulcerative colitis in a Spanish population .	parallel	0
2783	10322110	4654;4205	MyoD;MEF2	Without pRb , ***MyoD*** ***induces*** the accumulation of nuclear-localized ***MEF2*** that is competent to bind DNA yet transcriptionally inert .	target	1
2784	10322110	4654;4208	MyoD;MEF2C	When pRb is present , ***MyoD*** ***stimulates*** the function of the ***MEF2C*** transcriptional activation domain and the activity of endogenous MEF2-type factors .	positive	0
2785	10322114	2130;2185	EWS;Pyk2	Here , we show that ***EWS*** ***interacts*** with ***Pyk2*** , a protein tyrosine kinase implicated in a variety of signal transduction processes .	parallel	1
2786	10322114	2185;2130	Pyk2;EWS	G-protein-coupled receptor signaling and other stimuli of Pyk2 kinase activity significantly block the ***interaction*** between ***EWS*** and ***Pyk2*** .	parallel	1
2787	10322116	351;4137	beta-amyloid peptide;Tau	Although several groups have reported physical interaction between APP and Tau , and ***induction*** of ***Tau*** phosphorylation by APP and ***beta-amyloid peptide*** , the functional connection between APP and Tau is unclear .	target	1
2788	10322116	351;4137	APP;Tau	Although several groups have reported physical ***interaction*** between ***APP*** and ***Tau*** , and induction of Tau phosphorylation by APP and beta-amyloid peptide , the functional connection between APP and Tau is unclear .	parallel	1
2789	10322638	5310;1499	polycystin-1;beta-catenin	***polycystin-1*** is highly expressed in the ureteric bud and other branching epithelia during development and ***interacts*** with ***beta-catenin*** , a molecule known to play a role in branching morphogenesis .	parallel	1
2790	10322639	554;551	V2R;arginine vasopressin	Concentration of urine requires : 1 ) medullary collecting ducts ( CD ) located within a hypertonic interstitium , 2 ) CD cell expression of functional ***arginine vasopressin*** V2 ***receptors*** ( ***AVP-V2R*** ) , and 3 ) the presence of appropriate CD water channels ( aquaporins , AQP 2 and 3 ) .	parallel	1
2791	10322639	551;359	AVP;AQP2	***AVP*** ***upregulates*** the expression of AVP-V2R , ***AQP2*** , and AQP3 mRNAs in vitro .	positive	1
2792	10322639	551;360	AVP;AQP3	***AVP*** ***upregulates*** the expression of AVP-V2R , AQP2 , and ***AQP3*** mRNAs in vitro .	positive	1
2793	10322639	551;554	AVP;V2R	***AVP*** ***upregulates*** the expression of ***AVP-V2R*** , AQP2 , and AQP3 mRNAs in vitro .	positive	1
2794	10322947	6750;2353	somatostatin;c-fos	[ ***somatostatin*** and electroacupuncture ***inhibited*** ***c-fos*** expression in spinal cord of arthritic rats ] .	negative	1
2795	10323452	3596;3605	IL-13;IL-17	Addition of both IL-4 and ***IL-13*** completely ***inhibited*** the production of ***IL-17*** , whereas IL-10 had no effect .	negative	1
2796	10323452	3565;3605	IL-4;IL-17	Addition of both ***IL-4*** and IL-13 completely ***inhibited*** the production of ***IL-17*** , whereas IL-10 had no effect .	negative	1
2797	10323670	2099;4846	ERalpha;eNOS	These findings indicate that the acute effects of estrogen on both endothelial and airway epithelial ***eNOS*** are ***mediated*** by ***ERalpha*** functioning in a novel , nongenomic manner to activate the enzyme via calcium-dependent , MAP kinase-dependent mechanisms .	target	0
2798	10323791	5054;7040	PAI-1;TGF-beta	***PAI-1*** production by adipose tissue was ***correlated*** with those of TNF-alpha ( r = 0.5 , P = 0.01 ) and ***TGF-beta*** ( r = 0 .	parallel	0
2799	10323868	1017;5715	Cdk2;p27	Furthermore , another p27 mutant [ ***p27*** ( CK - ) ] that can be ***phosphorylated*** by cyclin ***E/Cdk2*** but can not bind this kinase complex , is refractory to ubiquitination .	target	1
2800	10323868	983;5715	Cdk1;p27	In fact , cyclin ***B/Cdk1*** which can ***phosphorylate*** ***p27*** efficiently , but can not form a stable complex with it , is unable to stimulate p27 ubiquitination by G1 extracts .	target	1
2801	10325225	2475;10243	RAFT1;gephyrin	***Interaction*** of ***RAFT1*** with ***gephyrin*** required for rapamycin-sensitive signaling .	parallel	1
2802	10325225	2475;10243	RAFT1;gephyrin	In mammalian cells ***RAFT1*** ***interacted*** with ***gephyrin*** , a widely expressed protein necessary for the clustering of glycine receptors at the cell membrane of neurons .	parallel	1
2803	10325244	183;5972	angiotensinogen;renin	To test whether prorenin might be enzymatically active in these tissues , transgenic mice expressing the human ***renin*** ***substrate*** ( ***angiotensinogen*** ) exclusively in the pituitary gland were mated to mice expressing either active human renin or prorenin in the same tissue .	parallel	1
2804	10325245	183;1956	Angiotensin II;epidermal growth factor receptor	***Angiotensin II-induced*** ***transactivation*** of ***epidermal growth factor receptor*** regulates fibronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms .	positive	1
2805	10325245	2353;3725	c-fos;c-jun	We concluded that Ang II-induced expression of fibronectin and TGF-beta is mediated by downstream signaling of EGF-R transactivated by Ca2 + - dependent tyrosine kinase and that Ang II-induced fibronectin mRNA expression is regulated by 2 different mechanisms , which are transcriptional control by binding of the ******c-fos/c-jun****** ***complex*** to the AP-1 site and posttranscriptional control by mRNA stabilization due to autocrine or paracrine effects of TGF-beta .	parallel	1
2806	10325247	5970;4790	p65;p50	The mobility of the NF-kappaB DNA complex was shifted by anti-p65 and anti-p50 antibodies but not by anti-c-Rel antibodies , indicating that the subunits of NF-kappaB involved in gene activation after ischemic PC consist of ******p65-p50****** ***heterodimers*** .	parallel	1
2807	10325253	213;7422	albumin;vascular endothelial growth factor	Human ***albumin*** ***enhances*** expression of ***vascular endothelial growth factor*** in cultured human luteinizing granulosa cells : importance in ovarian hyperstimulation syndrome .	positive	0
2808	10325253	213;7422	albumin;VEGF	Here it is reported that in cultured human luteinizing granulosa cells , ***VEGF*** mRNA expression was ***enhanced*** by human ***albumin*** and maximum expression was observed in cultured granulosa cells obtained from patients with serum oestradiol concentrations > 2000 pg/ml on the day of human chorionic gonadotrophin injection ( P < 0 .	positive	0
2809	10326621	7042;920	transforming growth factor (TGF)-beta 2;CD4	Because ***transforming growth factor (TGF)-beta 2*** ***down-regulates*** ***CD4*** membrane expression , its contribution , as well as the contribution of TGF-beta 1 and prostaglandin ( PG ) E2 , to the modulation CD8 expression was studied using human peripheral blood lymphocytes ( PBLs ) .	negative	1
2810	10326761	7980;2159	TFPI-2;factor Xa	However , whereas wild-type ***TFPI-2*** is a relatively weak ***inhibitor*** of human ***factor Xa*** amidolytic activity ( IC50 approximately 1 microM ) , R24Q TFPI-2 exhibited enhanced inhibitory activity towards the amidolytic and coagulant activities of this proteinase with a Ki of 18 nM .	negative	1
2811	10326761	7980;2159	TFPI-2;factor Xa	While the molecular basis for the enhanced ***inhibition*** of human ***factor Xa*** by R24Q ***TFPI-2*** is unknown , these data provide suggestive evidence that murine TFPI-2 may function as a serine proteinase inhibitor in spite of the absence of a P1 Arg or Lys residue .	negative	1
2812	10326762	4018;4043	lipoprotein;39-kDa receptor associated protein	Low density ***lipoprotein*** receptor family members characteristically ***bind*** ***39-kDa receptor associated protein*** ( RAP ) .	parallel	1
2813	10326865	7422;3791	VEGF;VEGFR	Moreover , overexpression of ***VEGF*** was ***related*** to upregulation of ***VEGFR-1*** / Flt-1 and VEGFR-2 / Flk-1 expression in malignant and premalignant lung lesions .	parallel	0
2814	10327051	2033;3725	p300;c-jun	The N-terminal transactivation domain of ATF2 is a target for the co-operative ***activation*** of the ***c-jun*** promoter by ***p300*** and 12S E1A .	positive	1
2815	10327051	2033;3725	p300;AP1	***p300*** , a transcriptional ***coactivator*** of several ***AP1*** and ATF transcription factors has been postulated to play a role in this activation .	positive	1
2816	10327051	2033;2668	p300;ATF	***p300*** , a transcriptional ***coactivator*** of several AP1 and ***ATF*** transcription factors has been postulated to play a role in this activation .	positive	1
2817	10327051	2033;3725	p300;c-jun	Here , we present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2 : ( 1 ) Over-expression of ***p300*** was found to ***stimulate*** ***c-jun*** transcription both in the presence and absence of E1A .	positive	0
2818	10327051	2033;3725	p300;c-jun	Here , we present evidence that ***p300*** can ***control*** ***c-jun*** transcription by acting as a cofactor for ATF2 : ( 1 ) Over-expression of p300 was found to stimulate c-jun transcription both in the presence and absence of E1A .	target	0
2819	10327051	1387;2033	CBP;p300	We further demonstrate that the Stress-Activated-Protein-Kinase ( SAPK ) target sites of ATF2 , Thr69 and Thr71 are not required for the formation of the ******p300/CBP-GeneGene****** 3 multiprotein ***complex*** .	parallel	1
2820	10327058	7157;1026	p53;WAF1	We employ a tet-repressible system to show that , under conditions in which the ***WAF1*** mRNA steady-state level is ***upregulated*** fourfold by ***p53*** , the SCL mRNA level is not altered .	positive	1
2821	10327058	7157;6886	p53;SCL	This disparity prompted us to explore the differences between ***p53*** ***regulation*** of ***SCL*** CS activity in organized ( chromosomally integrated ) and disorganized ( non-replicating episomal plasmid ) chromatin .	target	1
2822	10327062	4193;7157	mdm-2;p53	In contrast to the Q22 , S23 double mutation , this latter mutation set does not alter ***mdm-2-mediated*** ***inhibition*** and degradation of ***p53*** .	negative	1
2823	10327073	3195;1489	HOX11;CTF1	***HOX11*** ***interacts*** with ***CTF1*** and mediates hematopoietic precursor cell immortalization .	parallel	1
2824	10327200	8851;1020	p35;cyclin-dependent kinase 5	Expression of ***cyclin-dependent kinase 5*** and its ***activator*** ***p35*** in rat brain after middle cerebral artery occlusion .	positive	1
2825	10328178	1437;3383	CSF;ICAM-1	Administration of ***rG-CSF*** prior to LPS exposure tended to ***increase*** NOS II , CINC , and ***ICAM-1*** mRNA transcripts in hepatocytes .	positive	0
2826	10328232	356;355	FasL;CD95	***CD95/APO-1*** ***ligand*** ( ***FasL*** ) is implicated in the maintenance of immune privileged sites by inducing apoptosis of activated infiltrating T lymphocytes .	parallel	1
2827	10328545	7157;1026	p53;p21	The Cdk inhibitor ***p21/WAF1*** can be transcriptionally ***activated*** by wild-type ***p53*** , not by mutant p53 , and functions to block cell-cycle progression in many human neoplasms .	positive	1
2828	10328578	356;355	hFasL;Fas	Employing these molecular processes in the treatment of RA , we have recently shown that ex vivo gene transfer of human ***Fas*** ***ligand*** ( ***hFasL*** ) induced apoptosis of synoviocytes and infiltrated mononuclear cells of RA synovial tissue through cell-to-cell interaction via the Fas/FasL system .	parallel	1
2829	10328873	3565;3569	interleukin 4;interleukin 6	***Interactions*** of noradrenalin and tumour necrosis factor alpha , ***interleukin 4*** and ***interleukin 6*** in the control of lipolysis from adipocytes around lymph nodes .	parallel	1
2830	10328918	9241;3549	Noggin;Ihh	***Interaction*** of ***Ihh*** and ***BMP/Noggin*** signaling during cartilage differentiation .	parallel	1
2831	10328918	3549;650	Indian hedgehog;BMP2	We further demonstrate that misexpression of ***Indian hedgehog*** appears to directly ***upregulate*** ***BMP2*** and BMP4 expression , independent of the differentiation state of the flanking chondrocytes .	positive	1
2832	10328918	3549;652	Indian hedgehog;BMP4	We further demonstrate that misexpression of ***Indian hedgehog*** appears to directly ***upregulate*** BMP2 and ***BMP4*** expression , independent of the differentiation state of the flanking chondrocytes .	positive	1
2833	10328953	375790;2247	agrin;FGF-2	Our data show that ***agrin*** ***binds*** ***FGF-2*** and thrombospondin by a heparan sulfate-dependent mechanism , merosin and laminin by both heparan sulfate-dependent and - independent mechanisms , and tenascin solely via agrin 's protein core .	parallel	1
2834	10328964	2247;4656	bFGF;myogenin	These results indicate that both TNF-alpha and ***bFGF*** ***inhibit*** ***myogenin*** expression but differentially influence myoblast proliferation .	negative	1
2835	10328964	7124;4656	TNF-alpha;myogenin	These results indicate that both ***TNF-alpha*** and bFGF ***inhibit*** ***myogenin*** expression but differentially influence myoblast proliferation .	negative	1
2836	10328964	7124;3479	TNF-alpha;IGF-I	We have examined the mechanisms by which ***TNF-alpha*** , in comparison to basic fibroblast growth factor ( bFGF ) , ***inhibits*** the insulin-like growth factor-I ( ***IGF-I*** ) - induced differentiation of C2C12 myoblasts .	negative	1
2837	10328964	7124;4656	TNF-alpha;myogenin	However , ***TNF-alpha*** ***inhibited*** ***myogenin*** mRNA and protein expression .	negative	1
2838	10329108	5595;5594	ERK-1;ERK	Phospho-specific ***ERK-1*** and ERK-2 mitogen-activated protein kinase ( MAPK ) antibody , which ***recognizes*** only activated ***ERK*** , was used to determine ERK activation status by Western blotting .	target	1
2839	10329190	5450;5451	Bob1;Oct-1	The expression of immunoglobulin genes is controlled in part by the DNA-binding protein ***Oct-1*** and the B cell-specific transcription co-activator , ***Bob1*** ( also known as OCA-B or OBF-1 ) that together form a ***complex*** on the Igkappa promoter .	parallel	1
2840	10329351	7124;5321	TNF-alpha;cPLA2	***TNF-alpha*** also ***increased*** the level of immunoreactive ***cPLA2*** protein in a time-dependent manner with the highest levels evident after 8 and 16 h.	positive	0
2841	10329371	2934;351	gelsolin;Abeta	We report here that ***gelsolin*** , a secretory protein , also ***binds*** to ***Abeta*** in a concentration-dependent manner .	parallel	1
2842	10329371	2934;351	gelsolin;Abeta	Abeta was found to co-immunoprecipitate along with gelsolin from the plasma , suggesting that ******gelsolin-Abeta****** ***complex*** exists under physiological conditions .	parallel	1
2843	10329371	2934;351	gelsolin;Abeta	The ******gelsolin-Abeta****** ***complex*** was sodium dodecyl sulfate ( SDS ) stable in the absence of reducing agent , but was dissociated when the SDS stop solution contained dithiothreitol ( reducing agent ) .	parallel	1
2844	10329371	2934;351	gelsolin;Abeta	This study suggests that the function of secretory ***gelsolin*** in the CSF and plasma is to ***bind*** and sequester ***Abeta*** .	parallel	1
2845	10329376	2885;6464	Grb2;Shc	It is also suggested that the phosphorylated p58 xShc may play a role unique to the egg activation process because we found that there was no increase of ******Shc-Grb2****** ***complex*** after fertilization .	parallel	1
2846	10329379	5617;672	Prolactin;BRCA1	***Prolactin-dependent*** ***up-regulation*** of ***BRCA1*** expression in human breast cancer cell lines .	positive	1
2847	10329393	4086;652	Smad1;BMP-4	Human , Drosophila , and Xenopus ***Smad1*** all have been shown to ***mediate*** the biological effects of ***BMP-4*** in Xenopus embryos .	target	0
2848	10329396	10307;351	Fe65L2;beta-amyloid precursor protein	Genome structure and chromosomal mapping of the gene for ***Fe65L2*** ***interacting*** with Alzheimer 's ***beta-amyloid precursor protein*** .	parallel	1
2849	10329396	10307;351	Fe65L2;beta-amyloid precursor protein	Recently we cloned the cDNA encoding human ***Fe65L2*** , which ***interacts*** with Alzheimer 's ***beta-amyloid precursor protein*** ( APP ) .	parallel	1
2850	10329404	7124;5054	Tumor necrosis factor alpha;PAI-1	***Tumor necrosis factor alpha*** ( TNF-alpha ) ***enhanced*** ***PAI-1*** secretion and mRNA expression by approximately 2-fold .	positive	0
2851	10329404	5468;5054	PPARgamma;PAI-1	These results suggest that ***PPARgamma*** may ***regulate*** ***PAI-1*** expression in HUVEC and that thiazolidinediones have a therapeutic potential for improving endothelial dysfunction observed in insulin resistance .	target	1
2852	10329406	7124;1432	tumor necrosis factor-alpha;p38 MAP kinase	Thioredoxin negatively regulates ***p38 MAP kinase*** ***activation*** and IL-6 production by ***tumor necrosis factor-alpha*** .	positive	1
2853	10329406	7295;1432	TRX;p38 MAP kinase	The results showed that TNF-alpha-induced ***p38 MAP kinase*** ***activation*** and interleukin-6 ( IL-6 ) production by ***TRX*** 14 were less than those by the parental L cells and the control transfected L cells ( Neo-1 ) .	positive	1
2854	10329406	1432;3569	p38 MAP kinase;IL-6	SB 203580 as the specific inhibitor for p38 MAP kinase activity inhibited TNF-alpha-induced IL-6 production by the parental L cells , indicating that TNF-alpha-activated ***p38 MAP kinase*** ***regulates*** ***IL-6*** production by the cell lines used in this study .	target	1
2855	10329406	7295;3569	TRX;IL-6	These results showed that overexpression of ***TRX*** negatively ***regulates*** p38 MAP kinase activation and p38 MAP kinase-mediated ***IL-6*** production by TNF-alpha-stimulated cells , indicating that TRX is critical for p38 MAP kinase activation which regulates cytokine expression .	negative	1
2856	10329406	7295;1432	TRX;p38 MAP kinase	These results showed that overexpression of ***TRX*** negatively ***regulates*** ***p38 MAP kinase*** activation and p38 MAP kinase-mediated IL-6 production by TNF-alpha-stimulated cells , indicating that TRX is critical for p38 MAP kinase activation which regulates cytokine expression .	negative	1
2857	10329410	5468;7352	PPARgamma;UCP3	Moreover , BRL49653 , a ligand for the nuclear hormone receptor PPARgamma induces expression of UCP3 mRNA suggesting that ***PPARgamma*** may ***regulate*** transcription of the ***UCP3*** gene .	target	1
2858	10329423	3931;57338	LCAT;HDL2	In this study the equilibrium dissociation constants ( Kds ) for the ***interaction*** of pure human plasma ***LCAT*** with LDL , ***HDL2*** , HDL3 , and a reconstituted discoidal HDL ( rHDL ) were determined by the activity-inhibition method .	parallel	1
2859	10329423	3931;53369	LCAT;HDL3	In this study the equilibrium dissociation constants ( Kds ) for the ***interaction*** of pure human plasma ***LCAT*** with LDL , HDL2 , ***HDL3*** , and a reconstituted discoidal HDL ( rHDL ) were determined by the activity-inhibition method .	parallel	1
2860	10329425	1950;6772	EGF;Stat1	***EGF-induced*** ***activation*** of ***Stat1*** , Stat3 , and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes .	positive	1
2861	10329425	1950;6774	EGF;Stat3	***EGF-induced*** ***activation*** of Stat1 , ***Stat3*** , and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes .	positive	1
2862	10329425	1950;6777	EGF;Stat5b	***EGF-induced*** ***activation*** of Stat1 , Stat3 , and ***Stat5b*** is unrelated to the stimulation of DNA synthesis in cultured hepatocytes .	positive	1
2863	10329425	1950;6772	EGF;Stat1	In freshly isolated hepatocytes , ***EGF*** ***activated*** ***Stat1*** , Stat3 , and , particularly , Stat5b .	positive	1
2864	10329425	1950;6774	EGF;Stat3	In freshly isolated hepatocytes , ***EGF*** ***activated*** Stat1 , ***Stat3*** , and , particularly , Stat5b .	positive	1
2865	10329425	1950;5594	EGF;Erk1/2	In these cells ***EGF*** did not detectably activate Stat1 , Stat3 , or Stat5b but markedly ***stimulated*** MAP kinase ( ***Erk1/2*** ) .	positive	0
2866	10329429	6774;3569	STAT3;interleukin-6	Although a reason for the overexpression in myeloma cells is not understood , very interestingly , the promoter region of the HM1 .24 gene has a tandem repeat of three cis elements for a transcription factor , ***STAT3*** , which ***mediates*** ***interleukin-6*** ( IL-6 ) response gene expression .	target	0
2867	10329429	6774;684	STAT3;HM1.24 antigen	Since IL-6 is a differentiation factor for B cells , and known as a paracrine/autocrine growth factor for multiple myeloma cells , the expression of ***HM1.24 antigen*** may be ***regulated*** by the activation of ***STAT3*** .	target	1
2868	10329444	2321;7422	FLT-1;VEGF	We conclude that VEGF may inhibit contraction of hepatic stellate cells appearing during activation by culture , probably through attenuation of smooth muscle alpha-actin expression via upregulated ***VEGF*** ***receptor*** , ***FLT-1*** .	parallel	1
2869	10329457	596;2246	BCL-2;FGF1	These results suggest that there is a ***link*** between the endogenous ***FGF1*** signaling pathway and ***BCL-2*** in neuronal survival modulation .	parallel	0
2870	10329539	3700;7852	gp120;CXCR4	Identification of determinants of ***interaction*** between ***CXCR4*** and ***gp120*** of a dual-tropic HIV-1DH12 isolate .	parallel	1
2871	10329539	7852;3700	CXCR4;gp120	In this study , chimeric CXCR4-CXCR2 chemokine receptors were employed to identify the determinants involved in the ***interaction*** between ***CXCR4*** and the dual-tropic HIV-1DH12 ***gp120*** .	parallel	1
2872	10329539	3700;7852	gp120;CXCR4	Our results indicate that ( i ) HIV-1DH12 gp120 interacts primarily with the extracellular domains 1 ( E1 ) and 2 ( E2 ) of CXCR4 , ( ii ) the V1/V2 and the V3 regions interact with different domains of CXCR4 , and ( iii ) the V1/V2 region plays a more critical role in the ***interaction*** between ***CXCR4*** and HIV-1DH12 ***gp120*** .	parallel	1
2873	10329593	729230;6347	chemokine receptor 2;MCP-1	C-C ***chemokine receptor 2*** ( CCR2 ) is considered the major G-protein coupled ***receptor*** for ***MCP-1/JE*** .	parallel	1
2874	10329593	729230;3458	CCR2;IFNgamma	In granulomatous lungs , ***CCR2*** knockout increased mRNA for CCR2 agonists , MCP-1 , MCP-3 , and MCP-5 , but ***reduced*** IL-4 and ***IFNgamma*** mRNA .	positive	1
2875	10329593	729230;3565	CCR2;IL-4	In granulomatous lungs , ***CCR2*** knockout increased mRNA for CCR2 agonists , MCP-1 , MCP-3 , and MCP-5 , but ***reduced*** ***IL-4*** and IFNgamma mRNA .	positive	1
2876	10329623	7040;7039	TGF-beta;TGF-alpha	***TGF-beta*** ***cooperates*** with ***TGF-alpha*** to induce the self-renewal of normal erythrocytic progenitors : evidence for an autocrine mechanism .	parallel	0
2877	10329626	5966;182	c-Rel;Jagged1	Both ***c-Rel*** and RelA ***induced*** ***Jagged1*** gene expression , whereas a mutant defective for transactivation did not .	target	1
2878	10329626	5970;182	RelA;Jagged1	Both c-Rel and ***RelA*** ***induced*** ***Jagged1*** gene expression , whereas a mutant defective for transactivation did not .	target	1
2879	10329626	4792;4790	IkappaBalpha;NF-kappaB	Importantly , Jagged1 transcripts were also upregulated by endogenous NF-kappaB activation and this effect was inhibited by a dominant mutant of ***IkappaBalpha*** , a physiological ***inhibitor*** of ***NF-kappaB*** .	negative	1
2880	10329626	4790;182	NF-kappaB;Jagged1	Importantly , ***Jagged1*** transcripts were also ***upregulated*** by endogenous ***NF-kappaB*** activation and this effect was inhibited by a dominant mutant of IkappaBalpha , a physiological inhibitor of NF-kappaB .	positive	1
2881	10329627	23414;2623	FOG-2;GATA-1	Recently , two new members of the FOG family have been identified : a mammalian protein , ***FOG-2*** , that also ***associates*** with ***GATA-1*** and other mammalian GATA factors ; and U-shaped , a Drosophila protein that interacts with the Drosophila GATA protein Pannier .	parallel	0
2882	10329628	2932;1499	GSK-3beta;beta-catenin	Axin promotes the ***phosphorylation*** of ***beta-catenin*** by ***GSK-3beta*** , leading to beta-catenin degradation .	target	1
2883	10329646	10392;842	Nod1;caspase-9	***Nod1*** , an Apaf-1-like ***activator*** of ***caspase-9*** and nuclear factor-kappaB .	positive	1
2884	10329646	10392;4790	Nod1;NF-kappaB	Unlike Apaf-1 , ***Nod1*** ***induced*** activation of nuclear factor-kappa-B ( ***NF-kappaB*** ) and bound RICK , a CARD-containing kinase that also induces NF-kappaB activation .	target	1
2885	10329646	10392;8767	Nod1;RICK	Unlike Apaf-1 , ***Nod1*** induced activation of nuclear factor-kappa-B ( NF-kappaB ) and ***bound*** ***RICK*** , a CARD-containing kinase that also induces NF-kappaB activation .	parallel	1
2886	10329646	10392;4790	Nod1;NF-kappaB	***Nod1*** mutants ***inhibited*** ***NF-kappaB*** activity induced by RICK , but not that resulting from tumor necrosis factor-alpha stimulation .	positive	1
2887	10329658	387;2822	RhoA;PLD	Here we report that ***stimulation*** of ***PLD*** activity , measured in the presence of phosphatidylinositol 4,5-bisphosphate , by ***RhoA*** in membranes of HEK-293 cells expressing the m3 muscarinic acetylcholine receptor ( mAChR ) is phosphorylation-dependent .	positive	0
2888	10329658	387;2822	RhoA;PLD	Recombinant Rho-kinase-CAT mimicked the phosphorylation-dependent ***PLD*** ***stimulation*** by ***RhoA*** in HEK-293 cell membranes .	positive	0
2889	10329665	5617;5706	prolactin;p44	Short term incubation ( < 60 min ) of prolactin-responsive Nb2 lymphoma cells at high density selectively blocked ***prolactin*** ***stimulation*** of ***p42/p44*** mitogen-activated protein kinases and transcription factors Stat1 and Stat3 but not prolactin activation of Stat5 or the tyrosine kinase Jak2 .	positive	0
2890	10329666	6714;5894	Src;Raf-1	In baculovirus-infected Sf9 insect cells , Tvl-1 potentiates the ***activation*** of ***Raf-1*** by ***Src*** and Ras while in COS-1 cells it potentiates the activation of Raf-1 by EGF .	positive	1
2891	10329676	7124;6385	TNF-alpha;syndecan-4	In vitro studies demonstrated that ***TNF-alpha*** ***induced*** endothelial cell ***syndecan-4*** expression by both increasing syndecan-4 gene expression in an NF-kappaB-dependent manner and by prolonging syndecan-4 mRNA half-life .	target	1
2892	10329689	2185;6714	Pyk2;Src	***Pyk2-induced*** ***activation*** of ***Src*** is necessary for phosphorylation of Shc and p130Cas and their association with Grb2 and Crk , respectively , and for the activation of ERK and JNK cascades .	positive	1
2893	10329689	2885;5594	Grb2;ERK	***Grb2*** with a deleted carboxyl-terminal Src homology 3 domain partially ***blocked*** Pyk2-induced ***ERK*** and JNK pathways , whereas expression of dominant interfering mutants of p130Cas or Crk specifically inhibited JNK but not ERK activation by Pyk2 .	negative	0
2894	10329689	2885;5599	Grb2;JNK	***Grb2*** with a deleted carboxyl-terminal Src homology 3 domain partially ***blocked*** Pyk2-induced ERK and ***JNK*** pathways , whereas expression of dominant interfering mutants of p130Cas or Crk specifically inhibited JNK but not ERK activation by Pyk2 .	negative	0
2895	10329719	1435;5599	CSF-1;JNK-1	We were not able to show that ***CSF-1*** ***enhanced*** BMM ***JNK-1*** activity to a significant extent ; again , no role could be found for JNK-1 activity in the BMM apoptosis occurring after CSF-1 removal .	positive	0
2896	10329721	722;5627	c4bp;protein S	In conclusion , beta-chain SCR-2 contributes to the ***interaction*** of ***c4bp*** with ***protein S*** .	parallel	1
2897	10329721	722;5627	c4bp;protein S	***Interaction*** between ***protein S*** and complement C4b-binding protein ( ***c4bp*** ) .	parallel	1
2898	10329721	722;5627	c4bp;protein S	***c4bp*** can ***bind*** anticoagulant ***protein S*** , resulting in a decreased cofactor function of protein S for activated protein C .	parallel	1
2899	10329733	7157;596	p53;Bcl-2	***p53*** ***suppresses*** the activation of the ***Bcl-2*** promoter by the Brn-3a POU family transcription factor .	negative	1
2900	10329733	5457;596	Brn-3a;Bcl-2	p53 suppresses the ***activation*** of the ***Bcl-2*** promoter by the ***Brn-3a*** POU family transcription factor .	positive	1
2901	10329733	5457;596	Brn-3a;Bcl-2	This ***activation*** of the ***Bcl-2*** promoter by ***Brn-3a*** is strongly inhibited by the p53 anti-oncogene protein .	positive	1
2902	10329736	3643;3480	insulin receptor;insulin-like growth factor-1 receptor	***Interaction*** of ***insulin receptor*** substrate 3 with insulin receptor , insulin receptor-related receptor , ***insulin-like growth factor-1 receptor*** , and downstream signaling proteins .	parallel	1
2903	10329736	3643;3645	insulin receptor;insulin receptor-related receptor	***Interaction*** of ***insulin receptor*** substrate 3 with insulin receptor , ***insulin receptor-related receptor*** , insulin-like growth factor-1 receptor , and downstream signaling proteins .	parallel	1
2904	10329737	4193;7157	MDM2;p53	The cleaved ***MDM2*** loses the ability to promote p53 degradation and may potentially function in a dominant-negative fashion to ***stabilize*** ***p53*** .	positive	0
2905	10329743	348;5663	apolipoprotein E;presenilin-1	We found no evidence for a possible ***association*** between the ***presenilin-1*** polymorphism and the ***apolipoprotein E*** epsilon4 allele .	parallel	0
2906	10329795	3337;3308	Hsp40;Hsp70	***Hsp40*** , bound by unfolded polypeptide , can ***interact*** directly with ***Hsp70*** to stimulate the ATPase activity of Hsp70 .	parallel	1
2907	10329795	3337;3308	Hsp40;Hsp70	***Hsp40*** , bound by unfolded polypeptide , can interact directly with Hsp70 to ***stimulate*** the ATPase activity of ***Hsp70*** .	positive	0
2908	10329845	4790;3725	NF-kappaB;AP-1	***Binding*** of NF-AT , ***NF-kappaB*** , and ***AP-1*** was induced by T-cell receptor ( TcR ) stimulation , although there was no significant upregulation of binding by IL-2 stimulation .	parallel	1
2909	10329846	5970;4790	p65;p50	The binding activity of NF-kappaB ******p50/p65****** ***heterodimer*** and RBP-Jkappa was enhanced in these clones .	parallel	1
2910	10329978	7124;3667	TNF-alpha;IRS-1	In addition , ***TNF-alpha*** ***decreased*** insulin-stimulated ***IRS-1*** tyrosine phosphorylation by 40 % ( P < 0.05 ) .	negative	0
2911	10329978	7124;5706	TNF-alpha;p42	Furthermore , ***TNF-alpha*** ***repressed*** insulin-induced ***p42*** ( MAPK ) and p44 ( MAPK ) tyrosine phosphorylation by 81 % ( P < 0.01 ) .	negative	1
2912	10329981	3667;2885	IRS1;Grb2	Contraction also resulted in an apparent increase in the association of Raf-1 with p21Ras , although stimulation of MAP kinase signaling occurred independent of Shc , IRS1 , and IRS2 tyrosine phosphorylation or the formation of Shc/Grb2 or ******IRS1/Grb2****** ***complexes*** .	parallel	1
2913	10329981	6464;2885	Shc;Grb2	Contraction also resulted in an apparent increase in the association of Raf-1 with p21Ras , although stimulation of MAP kinase signaling occurred independent of Shc , IRS1 , and IRS2 tyrosine phosphorylation or the formation of ******Shc/Grb2****** or IRS1/Grb2 ***complexes*** .	parallel	1
2914	10330020	7082;100506658	ZO-1;occludin	Loss of ***ZO-1*** was ***associated*** with the altered localization of ZO-2 and ***occludin*** .	parallel	0
2915	10330020	7082;9414	ZO-1;ZO-2	Loss of ***ZO-1*** was ***associated*** with the altered localization of ***ZO-2*** and occludin .	parallel	0
2916	10330040	1991;4586	Neutrophil elastase;MUC5AC	***Neutrophil elastase*** ***increased*** ***MUC5AC*** mRNA levels by enhancing mRNA stability .	positive	0
2917	10330040	1991;4586	Neutrophil elastase;MUC5AC	***Neutrophil elastase*** ***increases*** ***MUC5AC*** mRNA and protein expression in respiratory epithelial cells .	positive	0
2918	10330040	1991;4586	Neutrophil elastase;MUC5AC	***Neutrophil elastase*** ***increased*** ***MUC5AC*** mRNA levels in a time-dependent manner in both cell culture systems .	positive	0
2919	10330040	1991;4586	Neutrophil elastase;MUC5AC	***Neutrophil elastase*** treatment also ***increased*** ***MUC5AC*** protein levels in A549 cells .	positive	0
2920	10330050	213;5579	albumin;PKC-beta	Glycated ***albumin*** ***stimulation*** of ***PKC-beta*** activity is linked to increased collagen IV in mesangial cells .	positive	0
2921	10330148	1436;1435	CSF-1R;CSF-1	The separation of multimeric complexes of the ***CSF-1*** ***receptor*** ( ***CSF-1R*** ) by anion-exchange chromatography enabled the enrichment of low-stoichiometry complexes .	parallel	1
2922	10330148	1436;867	CSF-1R;Cbl	A small pool of ***CSF-1R*** formed a multimeric ***complex*** with phosphatidylinositol-3 kinase ( PI-3 kinase ) , SHP-1 , Grb2 , Shc , c-Src , ***Cbl*** , and a significant number of tyrosine-phosphorylated proteins in CSF-1-stimulated cells .	parallel	1
2923	10330148	1436;6714	CSF-1R;c-Src	A small pool of ***CSF-1R*** formed a multimeric ***complex*** with phosphatidylinositol-3 kinase ( PI-3 kinase ) , SHP-1 , Grb2 , Shc , ***c-Src*** , Cbl , and a significant number of tyrosine-phosphorylated proteins in CSF-1-stimulated cells .	parallel	1
2924	10330148	1436;2885	CSF-1R;Grb2	A small pool of ***CSF-1R*** formed a multimeric ***complex*** with phosphatidylinositol-3 kinase ( PI-3 kinase ) , SHP-1 , ***Grb2*** , Shc , c-Src , Cbl , and a significant number of tyrosine-phosphorylated proteins in CSF-1-stimulated cells .	parallel	1
2925	10330148	1436;6464	CSF-1R;Shc	A small pool of ***CSF-1R*** formed a multimeric ***complex*** with phosphatidylinositol-3 kinase ( PI-3 kinase ) , SHP-1 , Grb2 , ***Shc*** , c-Src , Cbl , and a significant number of tyrosine-phosphorylated proteins in CSF-1-stimulated cells .	parallel	1
2926	10330157	115708;51605	GCD14p;Gcd10p	***GCD14p*** , a repressor of GCN4 translation , ***cooperates*** with ***Gcd10p*** and Lhp1p in the maturation of initiator methionyl-tRNA in Saccharomyces cerevisiae .	parallel	0
2927	10330157	51605;115708	Gcd10p;GCD14p	A mutation in gcd10 or deletion of LHP1 exacerbated the defects in cell growth and expression of mature tRNAiMet in gcd14 mutants , consistent with functional ***interactions*** between ***GCD14p*** , ***Gcd10p*** , and Lhp1p in vivo .	parallel	1
2928	10330159	7421;3725	VDR;AP-1	Transfected ***FLAG-VDR*** ***bound*** to the ***NFAT1-AP-1*** DNA binding element can be selectively precipitated from nuclear extracts that are made from cells treated with activating agents in the presence of 1,25 ( OH ) 2D3 .	parallel	1
2929	10330159	7421;4773	VDR;NFAT1	Transfected ***FLAG-VDR*** ***bound*** to the ***NFAT1-AP-1*** DNA binding element can be selectively precipitated from nuclear extracts that are made from cells treated with activating agents in the presence of 1,25 ( OH ) 2D3 .	parallel	1
2930	10330159	3725;4773	AP-1;NFAT1	These two events mediated by VDR effectively block the ******NFAT1-AP-1****** activation ***complex*** , resulting in an attenuation of activated GM-CSF transcription .	parallel	1
2931	10330159	7421;3725	vitamin D receptor;c-Jun	A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene : ***vitamin D receptor*** competes for DNA binding with NFAT1 and ***stabilizes*** ***c-Jun*** .	positive	0
2932	10330159	2353;3725	Fos;Jun	Secondly , VDR stabilizes the binding of a ******Jun-Fos****** ***heterodimer*** to the adjacent AP-1 portion of the element .	parallel	1
2933	10330159	2353;3725	Fos;AP-1	Secondly , VDR stabilizes the ***binding*** of a ***Jun-Fos*** heterodimer to the adjacent ***AP-1*** portion of the element .	parallel	1
2934	10330159	3725;7421	c-Jun;VDR	This appears to occur through a direct ***interaction*** between ***VDR*** and ***c-Jun*** , as demonstrated in vitro by direct glutathione S-transferase coprecipitation assays .	parallel	1
2935	10330164	2033;2959	p300;TFIIB	In this report , we analyze the specific domains of p300 required for the ***binding*** of ***p300*** to cyclin E-Cdk2 , ***TFIIB*** , and E1A and the ability of these proteins to interact with p300 , alone or in combination .	parallel	1
2936	10330164	2959;2033	TFIIB;p300	In contrast , 13S E1A , a pleiotropic transcriptional activator , does not inhibit ***TFIIB*** ***binding*** to ***p300*** , although it enhances the interaction of cyclin E-Cdk2 with p300 .	parallel	1
2937	10330167	11200;1111	Cds1;Chk1	These and other data indicate that ***Cds1*** ***prevents*** ***Chk1*** phosphorylation in HU-arrested cells , which suggests that Cds1 actively suppresses a repair process that leads to Chk1 phosphorylation .	negative	0
2938	10330169	2885;6464	Grb2;Shc	The concentrations of EGF for which PI 3-kinase inhibitors block Ras activation induce formation of ******Shc-Grb2****** ***complexes*** but not detectable EGF receptor phosphorylation and do not activate PI 3-kinase .	parallel	1
2939	10330170	4205;3725	MEF2;c-jun	Subsequently , however , we obtained evidence that GPCRs can potently ***stimulate*** the activity of the ***c-jun*** promoter through ***MEF2*** transcription factors , which do not act downstream from JNK .	positive	0
2940	10330172	7538;7124	TTP;TNF-alpha	We show here that ***TTP*** ***binding*** to the ***TNF-alpha*** ARE is dependent upon the integrity of both zinc fingers , since mutation of a single cysteine residue in either zinc finger to arginine severely attenuated the binding of TTP to the TNF-alpha ARE .	parallel	1
2941	10330176	2626;2627	GATA-4;GATA-6	Cooperative ***interaction*** between ***GATA-4*** and ***GATA-6*** regulates myocardial gene expression .	parallel	1
2942	10330177	10951;10155	M31;KAP-1	We observed colocalization of KAP-1 with M31 and M32 in interphase nuclei , lending support to the biochemical evidence that ***M31*** and M32 directly ***interact*** with ***KAP-1*** .	parallel	1
2943	10330177	10155;55888	KAP-1;ZFP	This work suggests a mechanism for the recruitment of HP1-like gene products by the ******KRAB-ZFP-KAP-1****** ***complex*** to specific loci within the genome through formation of heterochromatin-like complexes that silence gene activity .	parallel	1
2944	10330178	84962;2885	Ajuba;Grb2	***Ajuba*** specifically ***associated*** with ***Grb2*** in vitro and in vivo .	parallel	0
2945	10330181	1855;1499	Dvl-1;beta-catenin	***Dvl-1*** ***inhibited*** Axin-promoted glycogen synthase kinase 3beta-dependent phosphorylation of ***beta-catenin*** , and the DIX domain of Dvl-1 was required for this inhibitory activity .	negative	1
2946	10330181	1855;1499	Dvl-1;beta-catenin	Expression of ***Dvl-1*** in L cells ***induced*** the nuclear accumulation of ***beta-catenin*** , and deletion of the DIX domain abolished this activity .	target	1
2947	10330188	161882;2623	FOG;GATA-1	***FOG*** is coexpressed with GATA-1 in developing erythroid and megakaryocyte cell lineages and ***cooperates*** with ***GATA-1*** to control erythropoiesis .	parallel	0
2948	10330188	2626;23414	GATA-4;FOG-2	FOG-2 interacts with GATA factors , and ***interaction*** of ***GATA-4*** and ***FOG-2*** results in either synergistic activation or repression of GATA-dependent cardiac promoters , depending on the specific promoter and the cell type in which they are tested .	parallel	1
2949	10330189	1499;51176	beta-catenin;LEF-1	Excess beta-catenin can squelch reporter gene activation by ******LEF-1-beta-catenin****** ***complexes*** but not activation by the transcription factor VP16 .	parallel	1
2950	10330191	207;6198	PKB;S6K1	The results demonstrate that ***PKB*** ***mediates*** ***S6K1*** activation only as a function of constitutive membrane localization , whereas the activation of PKB appears both necessary and sufficient to induce 4E-BP1 phosphorylation independently of its intracellular location .	target	0
2951	10330191	2185;1978	Protein kinase B;eukaryotic translation initiation factor 4E-binding protein 1	***Protein kinase B*** localization and activation differentially ***affect*** S6 kinase 1 activity and ***eukaryotic translation initiation factor 4E-binding protein 1*** phosphorylation .	target	0
2952	10330191	207;2932	PKBalpha;GSK-3beta	The results demonstrate that two activated ***PKBalpha*** mutants , whose basal activity is equivalent to that of insulin-induced wild-type PKB , ***inhibit*** ***GSK-3beta*** to the same extent as a highly active , constitutively membrane-targeted wild-type PKB allele .	positive	1
2953	10330191	207;6198	PKB;S6K1	However , of these two mutants , only the constitutively membrane-targeted allele of ***PKB*** ***induces*** ***S6K1*** activation .	target	1
2954	10330191	207;2932	PKB;GSK-3beta	Furthermore , an interfering mutant of ***PKB*** , which ***blocks*** insulin-induced PKB activation and ***GSK-3beta*** inactivation , has no effect on S6K1 activation .	positive	0
2955	10330191	207;1978	PKB;4E-BP1	Surprisingly , all the activated PKB mutants , regardless of constitutive membrane localization , induce 4E-BP1 phosphorylation and the interfering ***PKB*** mutant ***blocks*** insulin-induced ***4E-BP1*** phosphorylation .	positive	0
2956	10330191	207;1978	PKB;4E-BP1	Surprisingly , all the activated ***PKB*** mutants , regardless of constitutive membrane localization , ***induce*** ***4E-BP1*** phosphorylation and the interfering PKB mutant blocks insulin-induced 4E-BP1 phosphorylation .	target	1
2957	10330192	6767;3312	Hop;Hsc70	Hip and ***Hop*** ***interact*** with ***Hsc70*** via a tetratricopeptide repeat domain .	parallel	1
2958	10330231	3552;3162	IL-1alpha;HO-1	These results demonstrate that TNF-alpha and ***IL-1alpha*** ***induction*** of ***HO-1*** requires PKC-mediated phosphorylation and PLA2 activation as well as oxidant generation .	target	1
2959	10330231	7124;3162	TNF-alpha;HO-1	These results demonstrate that ***TNF-alpha*** and IL-1alpha ***induction*** of ***HO-1*** requires PKC-mediated phosphorylation and PLA2 activation as well as oxidant generation .	target	1
2960	10330231	3552;8398	IL-1alpha;PLA2	These results demonstrate that TNF-alpha and ***IL-1alpha*** induction of HO-1 ***requires*** PKC-mediated phosphorylation and ***PLA2*** activation as well as oxidant generation .	target	0
2961	10330231	7124;8398	TNF-alpha;PLA2	These results demonstrate that ***TNF-alpha*** and IL-1alpha induction of HO-1 ***requires*** PKC-mediated phosphorylation and ***PLA2*** activation as well as oxidant generation .	target	0
2962	10330231	3552;3162	IL-1alpha;heme oxygenase-1	TNF-alpha and ***IL-1alpha*** ***induce*** ***heme oxygenase-1*** via protein kinase C , Ca2 + , and phospholipase A2 in endothelial cells .	target	1
2963	10330231	7124;3162	TNF-alpha;heme oxygenase-1	***TNF-alpha*** and IL-1alpha ***induce*** ***heme oxygenase-1*** via protein kinase C , Ca2 + , and phospholipase A2 in endothelial cells .	target	1
2964	10330231	3552;3162	IL-1alpha;HO-1	However , prolonged exposure , which downregulates most PKC isoforms , blocked ***induction*** of ***HO-1*** mRNA by ***IL-1alpha*** and TNF-alpha .	target	1
2965	10330231	7124;3162	TNF-alpha;HO-1	However , prolonged exposure , which downregulates most PKC isoforms , blocked ***induction*** of ***HO-1*** mRNA by IL-1alpha and ***TNF-alpha*** .	target	1
2966	10330276	961;3558	IAP;IL-2	Ligation of ***IAP*** acted in synergy with TCR to ***induce*** ***IL-2*** transcription and synthesis , but failed to synergize with the signal generated by CD16-7-zeta , while CD28 was a potent co-stimulator with both TCR and CD16-7-zeta .	target	1
2967	10330285	3586;3135	IL-10;HLA-G	***IL-10*** selectively ***induces*** ***HLA-G*** expression in human trophoblasts and monocytes .	target	1
2968	10330285	3586;3135	IL-10;HLA-G	Using Northern blot , RNase protection assay and RT-PCR analysis , we demonstrated that ***IL-10*** ***enhances*** steady-state levels of ***HLA-G*** transcription in cultured trophoblast cells .	positive	0
2969	10330285	3586;3135	IL-10;HLA-G	We further tested the effect of IL-10 on HLA-G gene transcription and protein expression in peripheral blood monocytes , showing that ***IL-10*** can ***up-regulate*** ***HLA-G*** cell surface expression in this cell type .	positive	1
2970	10330285	3586;3135	IL-10;HLA-G	***Induction*** of ***HLA-G*** expression by ***IL-10*** on monocytes may thus play a role in down-regulation of the immune response .	target	1
2971	10330372	28514;388585	Dll1;Hes5	The ***Dll1*** , Notch1 and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , Jagged1 , Mesp1 , Mesp2 and ***Hes5*** in the PSM .	negative	0
2972	10330372	28514;182	Dll1;Jagged1	The ***Dll1*** , Notch1 and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , ***Jagged1*** , Mesp1 , Mesp2 and Hes5 in the PSM .	negative	0
2973	10330372	28514;55897	Dll1;Mesp1	The ***Dll1*** , Notch1 and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , Jagged1 , ***Mesp1*** , Mesp2 and Hes5 in the PSM .	negative	0
2974	10330372	28514;145873	Dll1;Mesp2	The ***Dll1*** , Notch1 and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , Jagged1 , Mesp1 , ***Mesp2*** and Hes5 in the PSM .	negative	0
2975	10330372	4851;388585	Notch1;Hes5	The Dll1 , ***Notch1*** and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , Jagged1 , Mesp1 , Mesp2 and ***Hes5*** in the PSM .	negative	0
2976	10330372	4851;182	Notch1;Jagged1	The Dll1 , ***Notch1*** and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , ***Jagged1*** , Mesp1 , Mesp2 and Hes5 in the PSM .	negative	0
2977	10330372	4851;55897	Notch1;Mesp1	The Dll1 , ***Notch1*** and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , Jagged1 , ***Mesp1*** , Mesp2 and Hes5 in the PSM .	negative	0
2978	10330372	4851;145873	Notch1;Mesp2	The Dll1 , ***Notch1*** and RBPJkappa mutations ***disrupt*** the expression of Lunatic fringe ( L-fng ) , Jagged1 , Mesp1 , ***Mesp2*** and Hes5 in the PSM .	negative	0
2979	10330396	5902;7514	RanBP1;CRM1	***RanBP1*** as well as Ran-binding domains of the cytoplasmic nucleoporin RanBP2 ***promote*** the release of ***CRM1*** from the NPC .	positive	0
2980	10330396	5903;7514	RanBP2;CRM1	RanBP1 as well as Ran-binding domains of the cytoplasmic nucleoporin ***RanBP2*** ***promote*** the release of ***CRM1*** from the NPC .	positive	0
2981	10330402	2247;5594	bFGF;ERK	In contrast to the IGF-I-triggered pathway , PDGF-BB , ***bFGF*** , and EGF coordinately ***activated*** ***ERK*** and p38MAPK pathways .	positive	1
2982	10330402	1950;5594	EGF;ERK	In contrast to the IGF-I-triggered pathway , PDGF-BB , bFGF , and ***EGF*** coordinately ***activated*** ***ERK*** and p38MAPK pathways .	positive	1
2983	10330402	207;5594	PKB;ERK	When the ***ERK*** and p38MAPK pathways were simultaneously ***blocked*** by their specific inhibitors or an active form of either PI3-K or ***PKB*** ( Akt ) was transfected , PDGF-BB in turn initiated to maintain the differentiated SMC phenotype .	negative	0
2984	10330403	8215;1499	Dsh;beta-catenin	Coexpression of hemagglutinin-tagged Dishevelled ( Dsh ) revealed strong colocalization with Axin , suggesting that ***Dsh*** can ***interact*** with the Axin/APC/GSK3 / ***beta-catenin*** complex , and may thus modulate its activity .	parallel	1
2985	10330431	925;3932	CD8;Lck	In naive cytotoxic T cells , only a few ***CD8*** molecules are ***associated*** with ***Lck*** and the kinase is homogeneously distributed inside the cell .	parallel	0
2986	10330435	3596;3565	IL-13;IL-4	We conclude that ***IL-4*** and ***IL-13*** ***cooperate*** to initiate rapid Th2 cell-driven responses , and that although their functions overlap , they perform additive roles .	parallel	0
2987	10330437	6610;3558	neutral sphingomyelinase;IL-2	Moreover , specific inactivation of ***neutral sphingomyelinase*** by antisense RNA ***inhibited*** ***IL-2*** production and mitogen-activated protein kinase activation after TCR triggering .	positive	1
2988	10330485	1499;51176	beta-catenin;LEF-1	The C-terminal transactivation domain of beta-catenin is necessary and sufficient for signaling by the ******LEF-1/beta-catenin****** ***complex*** in Xenopus laevis .	parallel	1
2989	10331406	3952;7351	leptin;UCP-2	In normal pancreatic islets , ***UCP-2*** is ***upregulated*** by ***leptin*** and is low in leptin-resistant islets of ZDF rats .	positive	1
2990	10331409	6750;2641	Somatostatin;Glucagon	***Somatostatin*** was infused ( 0.8 microg x kg ( -1 ) x min ( -1 ) ) to ***inhibit*** extrapancreatic ***Glucagon*** in dogs , and basal Glucagon was restored by intraportal infusion ( 0.65 ng x kg ( -1 ) x min ( -1 ) ) .	negative	1
2991	10331411	6517;3667	GLUT4;IRS-1	Overexpression of ***GLUT4*** in db / + TG6 mice markedly improved glucose-stimulated insulin secretion , by 250 % , and ***increased*** IRbeta , ***IRS-1*** , and p85alpha phosphorylation twofold , despite no change in concentration of these proteins .	positive	0
2992	10331411	6517;5295	GLUT4;p85alpha	Overexpression of ***GLUT4*** in db / + TG6 mice markedly improved glucose-stimulated insulin secretion , by 250 % , and ***increased*** IRbeta , IRS-1 , and ***p85alpha*** phosphorylation twofold , despite no change in concentration of these proteins .	positive	0
2993	10331420	7422;6347	Vascular endothelial growth factor;monocyte chemoattractant protein-1	***Vascular endothelial growth factor*** activates nuclear factor-kappaB and ***induces*** ***monocyte chemoattractant protein-1*** in bovine retinal endothelial cells .	target	1
2994	10331422	2247;3791	bFGF;KDR	These data suggest that ***bFGF*** ***stimulates*** ***KDR*** expression through a PKC and p44/p42 MAPK-dependent pathway not primarily involving the beta isoform of PKC , PKA , or PI-3 kinase .	positive	0
2995	10331422	2247;7422	bFGF;VEGF	Since ***bFGF*** ***induces*** ***VEGF*** expression and since increased KDR expression potentiates VEGF action , resulting in additional KDR expression and marked mitogenic activity , these data provide a novel mechanistic explanation for the angiogenic synergy between VEGF and bFGF .	target	1
2996	10331422	3791;7422	KDR;VEGF	Since bFGF induces VEGF expression and since increased ***KDR*** expression ***potentiates*** ***VEGF*** action , resulting in additional KDR expression and marked mitogenic activity , these data provide a novel mechanistic explanation for the angiogenic synergy between VEGF and bFGF .	positive	0
2997	10331424	3172;6927	HNF-4;HNF-1	On the other hand , in the presence of COUP TFII , the substitution impairs the enhancement of ***HNF-4-mediated*** ***activation*** of ***HNF-1*** promoter .	positive	1
2998	10331434	596;581	Bcl-2;Bax	Coimmunoprecipitation experiments showed that Bax-Bax interactions are greater in the mitochondrial-enriched membrane compartment of ALS motor cortex compared with controls , whereas ******Bax-Bcl-2****** ***interactions*** are lower in the membrane compartment of ALS motor cortex compared with controls .	parallel	1
2999	10331497	7124;6347	tumor necrosis factor alpha;MCP-1	Recombinant ***tumor necrosis factor alpha*** ( TNF-alpha ) ***induced*** a low level ***MCP-1*** mRNA accumulation in neutrophils , and addition of anti-TNF-alpha IgG blocked 30-70 % of MCP-1 mRNA expression induced with PHA-sup .	target	1
3000	10331507	356;355	Fas ligand;Fas	Fas , a member of the tumor necrosis receptor superfamily , is 36 kD surface protein containing a single transmembrane region and induces apoptosis by ******Fas-Fas ligand****** ***binding*** .	parallel	1
3001	10331605	2332;10146	FMRP;G3BP	Our results indicate that ***G3BP*** mRNA may be ***regulated*** by ***FMRP*** and supports the hypothesis that FMRP may modulate the transcription of specific transcripts .	target	1
3002	10331650	836;142	caspase-3;PARP	In intact human osteosarcoma cells undergoing spontaneous apoptosis , both PARP and PAR decreased after this early peak , concomitant with the ***inactivation*** and cleavage of ***PARP*** by ***caspase-3*** and the onset of substantial DNA and nuclear fragmentation .	negative	1
3003	10331651	142;5925	PARP;pRB	On the other hand , in a reconstituted reaction system , purified ***PARP*** from human placenta ***suppressed*** the ***pRB-phosphorylation*** activity in the presence of NAD and damaged DNA .	negative	1
3004	10331664	1382;5947	CRABP-II;CRABP-I	We examined the ligand protein ***interactions*** of two highly homologous cellular retinol binding proteins , CRBP and CRBP-II , and two highly homologous cellular retinoic acid binding proteins , ***CRABP-I*** and ***CRABP-II*** .	parallel	1
3005	10331664	1382;5948	CRABP-II;CRBP-II	We examined the ligand protein ***interactions*** of two highly homologous cellular retinol binding proteins , CRBP and ***CRBP-II*** , and two highly homologous cellular retinoic acid binding proteins , CRABP-I and ***CRABP-II*** .	parallel	1
3006	10331664	5947;5947	CRBP;CRABP-I	We examined the ligand protein ***interactions*** of two highly homologous cellular retinol binding proteins , ***CRBP*** and CRBP-II , and two highly homologous cellular retinoic acid binding proteins , ***CRABP-I*** and CRABP-II .	parallel	1
3007	10331664	5947;1382	CRBP;CRABP-II	We examined the ligand protein ***interactions*** of two highly homologous cellular retinol binding proteins , ***CRBP*** and CRBP-II , and two highly homologous cellular retinoic acid binding proteins , CRABP-I and ***CRABP-II*** .	parallel	1
3008	10331664	5947;5948	CRBP;CRBP-II	We examined the ligand protein ***interactions*** of two highly homologous cellular retinol binding proteins , ***CRBP*** and ***CRBP-II*** , and two highly homologous cellular retinoic acid binding proteins , CRABP-I and CRABP-II .	parallel	1
3009	10331664	5948;5947	CRBP-II;CRABP-I	We examined the ligand protein ***interactions*** of two highly homologous cellular retinol binding proteins , CRBP and ***CRBP-II*** , and two highly homologous cellular retinoic acid binding proteins , ***CRABP-I*** and CRABP-II .	parallel	1
3010	10331666	6278;2171	S100A7;E-FABP	Probable ***interaction*** between ***S100A7*** and ***E-FABP*** in the cytosol of human keratinocytes from psoriatic scales .	parallel	1
3011	10331666	6278;2171	S100A7;E-FABP	Finally , immunoprecipitations using antiserum against E-FABP revealed that ***S100A7*** ***co-immunoprecipitated*** with ***E-FABP*** from protein extracts of psoriatic scales .	parallel	1
3012	10331666	6278;2171	S100A7;E-FABP	These data indicate that ***E-FABP*** and ***S100A7*** might form a ***complex*** in the cytosol of human keratinocytes .	parallel	1
3013	10331987	650;3209	BMP-2;Hoxa-13	Administration of ***BMP-2*** at the anterior margin of the limb bud ***induced*** ectopic ***Hoxa-13*** expression in the anterior region of the muscle masses followed by ectopic muscle formation close to the source of exogenous BMP-2 .	target	1
3014	10332154	655;2247	OP-1;bFGF	This in vitro study showed that both bFGF and ***OP-1*** ***increased*** [ 3H ] thymidine incorporation , especially ***bFGF*** which stimulated it 3.5-fold at a dose of 30ng/ml .	positive	0
3015	10332738	30816;920	Env;CD4 molecule	The discovery that ***Env*** initially ***binds*** the ***CD4 molecule*** on the target cell surface and then makes subsequent interactions with one of several members of the chemokine receptor family has greatly enhanced the molecular understanding of HIV-1 entry .	parallel	1
3016	10332965	958;7124	CD40;tumor necrosis factor-alpha	Ligation of ***CD40*** ***induced*** ***tumor necrosis factor-alpha*** in rheumatoid arthritis : a novel mechanism of activation of synoviocytes .	target	1
3017	10332965	958;7124	CD40;TNF-alpha	Ligation of ***CD40*** on RA ST cells significantly ***increased*** the production of ***TNF-alpha*** in a dose dependent fashion .	positive	0
3018	10332965	3596;7124	IL-13;TNF-alpha	Interferon-gamma ( IFN-gamma ) , interleukin 4 ( IL-4 ) , or ***IL-13*** acted synergistically with CD40 ligation to ***enhance*** ***TNF-alpha*** production by ST cells .	positive	0
3019	10332965	3565;7124	IL-4;TNF-alpha	Interferon-gamma ( IFN-gamma ) , interleukin 4 ( ***IL-4*** ) , or IL-13 acted synergistically with CD40 ligation to ***enhance*** ***TNF-alpha*** production by ST cells .	positive	0
3020	10332965	3458;7124	Interferon-gamma;TNF-alpha	***Interferon-gamma*** ( IFN-gamma ) , interleukin 4 ( IL-4 ) , or IL-13 acted synergistically with CD40 ligation to ***enhance*** ***TNF-alpha*** production by ST cells .	positive	0
3021	10333295	590;7018	Butyrylcholinesterase;transferrin	***Butyrylcholinesterase*** is ***complexed*** with ***transferrin*** in chicken serum .	parallel	1
3022	10333295	7018;590	transferrin;BChE	The possible biomedical implications of a ***complex*** between ***transferrin*** and ***BChE*** which here has been shown to exist in chicken serum are briefly discussed .	parallel	1
3023	10333360	1435;1081	MCSF;HCG	***MCSF*** increased MMP-9 immunoreactivity ( P < 0.05 ) and moderately ***decreased*** ***HCG*** .	negative	0
3024	10333360	7040;1081	TGFbeta;HCG	***TGFbeta*** ***decreased*** ***HCG*** ( P < 0.041 ) and increased fFN ( P < 0.042 ) .	negative	0
3025	10333497	6927;2305	HNF-1;HNF-3	Sequences were inserted at position -21 , separating both HNF-3 binding sites from the HNF-1-HNF-6 binding site , and position -5 , separating the ******HNF-3-HNF-1-HNF-6****** ***complex*** from the transcription start site .	parallel	1
3026	10333497	6927;3175	HNF-1;HNF-6	Sequences were inserted at position -21 , separating both HNF-3 binding sites from the HNF-1-HNF-6 binding site , and position -5 , separating the ******HNF-3-HNF-1-HNF-6****** ***complex*** from the transcription start site .	parallel	1
3027	10333497	3175;2305	HNF-6;HNF-3	Sequences were inserted at position -21 , separating both HNF-3 binding sites from the HNF-1-HNF-6 binding site , and position -5 , separating the ******HNF-3-HNF-1-HNF-6****** ***complex*** from the transcription start site .	parallel	1
3028	10333542	5617;4313	prolactin;matrix metalloproteinase (MMP)-2	We previously reported that ***prolactin*** ( PRL ) ***stimulated*** ***matrix metalloproteinase (MMP)-2*** activity to degrade collagen type IV as a mechanism of structural luteolysis .	positive	0
3029	10333542	4323;4313	MT-MMP;MMP-2	***Activation*** of ***pro-MMP-2*** by membrane type-MMP ( ***MT-MMP*** ) is reported to be a rate-limiting step for catalytic function .	positive	1
3030	10334300	3952;5443	leptin;alpha-MSH	This ***alpha-MSH/MC4-R*** system may be ***inhibited*** by ***leptin*** and/or insulin .	negative	1
3031	10334300	3952;4160	leptin;MC4-R	This ***alpha-MSH/MC4-R*** system may be ***inhibited*** by ***leptin*** and/or insulin .	negative	1
3032	10334302	3953;3952	leptin receptor;leptin	Thus , the two ***leptin receptor*** isoforms , ObRa and ObRb , ***mediate*** ***leptin*** internalization by a coated pit-dependent mechanism , leptin degradation by a lysosomal pathway , and ligand-induced receptor downregulation .	target	0
3033	10334384	3439;3569	IFN-alpha;IL-6	In fact , ***IFN-alpha*** significantly ***stimulated*** the secretion of ***IL-6*** and TNF-alpha in CD40-activated B-CLL cells ( p < 0.01 ) .	positive	0
3034	10334384	3439;7124	IFN-alpha;TNF-alpha	In fact , ***IFN-alpha*** significantly ***stimulated*** the secretion of IL-6 and ***TNF-alpha*** in CD40-activated B-CLL cells ( p < 0.01 ) .	positive	0
3035	10334387	1508;3553	cathepsin B;IL-1beta	The present results suggest that ***cathepsin B*** , cathepsin L , and cathepsin D in kidney lysosomes are involved in the metabolic ***degradation*** of human ***IL-1beta*** .	negative	1
3036	10334387	1509;3553	cathepsin D;IL-1beta	The present results suggest that cathepsin B , cathepsin L , and ***cathepsin D*** in kidney lysosomes are involved in the metabolic ***degradation*** of human ***IL-1beta*** .	negative	1
3037	10334387	1514;3553	cathepsin L;IL-1beta	The present results suggest that cathepsin B , ***cathepsin L*** , and cathepsin D in kidney lysosomes are involved in the metabolic ***degradation*** of human ***IL-1beta*** .	negative	1
3038	10334392	3558;3458	IL-2;IFN-gamma	***IL-2*** or retinoids alone could ***induce*** low but significant levels of ***IFN-gamma*** .	target	1
3039	10334393	1436;1435	CSF-1R;CSF-1	In addition , ***CSF-1*** ***receptor*** ( ***CSF-1R*** ) blocking experiments indicated that a proportion of the GM-CSF-induced DNA synthesis is due to endogenous levels of CSF-1 .	parallel	1
3040	10334872	4353;23430	myeloperoxidase;mast cell tryptase	Neutrophil ***myeloperoxidase*** is a potent and selective ***inhibitor*** of ***mast cell tryptase*** .	negative	1
3041	10334872	4353;23430	MPO;mast cell tryptase	***MPO*** ***inhibits*** human ***mast cell tryptase*** in a time-dependent manner with an IC50 of 16 nM at 1 h.	negative	1
3042	10334922	650;5743	BMP-2;COX-2	Since ***BMP-2*** alone ***induced*** the expression of ***COX-2*** and ODF genes in osteoblast-like cells , it appears to be one of the regulating factors of osteoclastogenesis .	target	1
3043	10334922	650;8600	BMP-2;ODF	Since ***BMP-2*** alone ***induced*** the expression of COX-2 and ***ODF*** genes in osteoblast-like cells , it appears to be one of the regulating factors of osteoclastogenesis .	target	1
3044	10334922	650;5743	BMP-2;cyclooxygenase-2	Western blot analysis showed that a simultaneous addition of ***BMP-2*** and IL-1alpha synergistically ***enhanced*** ***cyclooxygenase-2*** ( COX-2 ) expression in osteoblast-like cells .	positive	0
3045	10334922	3552;5743	IL-1alpha;cyclooxygenase-2	Western blot analysis showed that a simultaneous addition of BMP-2 and ***IL-1alpha*** synergistically ***enhanced*** ***cyclooxygenase-2*** ( COX-2 ) expression in osteoblast-like cells .	positive	0
3046	10334923	4301;7082	AF-6;ZO-1	In vivo ***interaction*** of ***AF-6*** with activated Ras and ***ZO-1*** .	parallel	1
3047	10334923	4301;7082	AF-6;ZO-1	We previously showed that an ***AF-6*** fragment containing the amino-terminal ( N-terminal ) RA domain directly ***binds*** to activated Ras and ***ZO-1*** in vitro .	parallel	1
3048	10334923	4301;7082	AF-6;ZO-1	Moreover , we showed that ***AF-6*** was ***coimmunoprecipitated*** with ***ZO-1*** from Rat1 cells .	parallel	1
3049	10334923	4301;7082	AF-6;ZO-1	Taken together , these results indicate that the Ras-interacting region on AF-6 is structurally similar to that on Raf-1 and on RalGDS and that ***AF-6*** ***interacts*** with activated Ras and ***ZO-1*** in vivo .	parallel	1
3050	10335401	3700;920	gp120;CD4	Furthermore , RD6-Y664 did not show any inhibition of ******gp120-CD4****** ***interaction*** , or binding of anti-CXCR4 antibody to CXCR4 .	parallel	1
3051	10335944	596;581	Bcl-2;Bax	The ***interaction*** of ***Bcl-2*** and ***Bax*** regulates apoptosis in biliary epithelial cells of rats with obstructive jaundice .	parallel	1
3052	10335944	596;581	Bcl-2;Bax	The ***interaction*** between ***Bcl-2*** and ***Bax*** triggers apoptosis in BEC and acts as a cell rheostat in BEC hyperplasia and its involution after biliary decompression .	parallel	1
3053	10336054	3265;351	p21ras;Abeta	We previously reported on the elevated expression of ***p21ras*** ***associated*** with paired helical filament formation and ***Abeta-deposits*** .	parallel	0
3054	10336116	627;2890	Brain-derived neurotrophic factor;GluR1	***Brain-derived neurotrophic factor*** treatment specifically ***increased*** the protein levels of ***GluR1*** ( 193 + / -22 % ) and GluR2/3 ( 182 + / -11 % ) in cultured rat neocortical neurons .	positive	0
3055	10336116	627;2892	Brain-derived neurotrophic factor;GluR2/3	***Brain-derived neurotrophic factor*** treatment specifically ***increased*** the protein levels of GluR1 ( 193 + / -22 % ) and ***GluR2/3*** ( 182 + / -11 % ) in cultured rat neocortical neurons .	positive	0
3056	10336162	3952;4852	leptin;neuropeptide Y	***leptin*** is secreted by adipocytes in proportion to fat content , exhibits a daily rhythm in plasma that is synchronized to feeding time , and ***inhibits*** activity of arcuate ***neuropeptide Y*** neurons that stimulate feeding behavior and regulate metabolism .	negative	1
3057	10336162	3952;4852	leptin;neuropeptide Y	If the effects of obesity on food-entrained rhythms are mediated by ***leptin*** ***inhibition*** of ***neuropeptide Y*** neurons , then these rhythms may be enhanced in leptin-insensitive Zucker obese rats .	negative	1
3058	10336187	51052;5617	PrRP;prolactin	prolactin-releasing peptide ( ***PrRP*** ) , a novel peptide identified as the endogenous ligand for an orphan receptor isolated from the pituitary , is a potent ***stimulator*** of ***prolactin*** release .	positive	0
3059	10336256	348;4137	apolipoprotein E;tau	***Regulation*** of ***tau*** phosphorylation in microtubule fractions by ***apolipoprotein E*** .	target	1
3060	10336256	348;4137	apoE;tau	We found that ***apoE*** ***attenuates*** ***tau*** hyperphosphorylation in the fractions , but the pattern was indistinguishable for the different isoforms .	negative	0
3061	10336413	4792;4790	IkappaBalpha;NF-kappaB	The Tax oncoprotein of human T cell leukemia virus type 1 constitutively activates transcription factor NF-kappaB by a mechanism involving Tax-induced phosphorylation of ***IkappaBalpha*** , a labile cytoplasmic ***inhibitor*** of ***NF-kappaB*** .	negative	1
3062	10336416	2280;6261	FKBP12;RyR1	FK506-binding protein ( ***FKBP12*** ) has been found to be ***associated*** with the skeletal muscle ryanodine receptor ( ***RyR1*** ) ( calcium release channel ) , whereas FKBP12.6 , a novel isoform of FKBP , is selectively associated with the cardiac ryanodine receptor ( RyR2 ) .	parallel	0
3063	10336416	2281;6262	FKBP12.6;RyR2	FK506-binding protein ( FKBP12 ) has been found to be associated with the skeletal muscle ryanodine receptor ( RyR1 ) ( calcium release channel ) , whereas ***FKBP12.6*** , a novel isoform of FKBP , is selectively ***associated*** with the cardiac ryanodine receptor ( ***RyR2*** ) .	parallel	0
3064	10336416	2281;6262	FKBP12.6;RyR2	Although FKBP12.6 differs from FKBP12 by only 18 of 108 amino acids , ***FKBP12.6*** selectively ***binds*** to ***RyR2*** and exchanges with bound FKBP12.6 of RyR2 , whereas both FKBP isoforms bind to RyR1 and exchange with bound FKBP12 of RyR1 .	parallel	1
3065	10336432	8575;5610	PACT;PKR	RAX has a high sequence homology to human ***PACT*** , which ***activates*** ***PKR*** in the absence of dsRNA .	positive	1
3066	10336432	8575;5610	RAX;PKR	Although ***RAX*** also can directly ***activate*** ***PKR*** in vitro , overexpression of RAX does not induce PKR activation or inhibit growth of interleukin-3 ( IL-3 ) - dependent cells in the presence of IL-3 .	positive	1
3067	10336432	8575;5610	RAX;PKR	However , IL-3 deprivation as well as diverse cell stress treatments including arsenite , thapsigargin , and H2O2 , which are known to inhibit protein synthesis , induce the rapid phosphorylation of RAX followed by ******RAX-PKR****** ***association*** and activation of PKR .	parallel	0
3068	10336432	8575;5610	RAX;PKR	Therefore , cellular ***RAX*** may be a stress-activated , physiologic ***activator*** of ***PKR*** that couples transmembrane stress signals and protein synthesis .	positive	1
3069	10336433	5111;466	PCNA;ATF-1	Inducibility of the human PCNA promoter by E1A 243R is conferred by the cis-acting ***PCNA*** E1A-responsive element ( PERE ) , which ***associates*** with the ***ATF-1*** , cAMP response element-binding protein ( CREB ) , and RFX1 transcription factors and is modulated by cellular proteins such as the coactivator CREB-binding protein ( CBP ) and tumor suppressor p107 ( Labrie , C. , Lee , B.	parallel	0
3070	10336433	5111;1385	PCNA;CREB	Inducibility of the human PCNA promoter by E1A 243R is conferred by the cis-acting ***PCNA*** E1A-responsive element ( PERE ) , which ***associates*** with the ATF-1 , cAMP response element-binding protein ( ***CREB*** ) , and RFX1 transcription factors and is modulated by cellular proteins such as the coactivator CREB-binding protein ( CBP ) and tumor suppressor p107 ( Labrie , C. , Lee , B.	parallel	0
3071	10336433	5111;5989	PCNA;RFX1	Inducibility of the human PCNA promoter by E1A 243R is conferred by the cis-acting ***PCNA*** E1A-responsive element ( PERE ) , which ***associates*** with the ATF-1 , cAMP response element-binding protein ( CREB ) , and ***RFX1*** transcription factors and is modulated by cellular proteins such as the coactivator CREB-binding protein ( CBP ) and tumor suppressor p107 ( Labrie , C. , Lee , B.	parallel	0
3072	10336449	6285;3000	S100b;retGC-1	In addition to recombinant bovine GCAPs , constitutively active mutants of GCAPs that activate retGC-1 in a [ Ca2 + ] - independent manner and bovine brain ***S100b*** that ***activates*** ***retGC-1*** in the presence of approximately 10 microM [ Ca2 + ] were used to investigate whether these activations take place through a similar mechanism , and whether [ Ca2 + ] is directly involved in the dimerization .	positive	1
3073	10336453	1437;6774	CSF;STAT3	Notably , in the presence of GM-CSF , ***G-CSF*** induced the tyrosine phosphorylation of STAT3 but failed to ***induce*** the nuclear translocation of tyrosine-phosphorylated ***STAT3*** .	target	1
3074	10336453	1437;6774	CSF;STAT3	Notably , in the presence of GM-CSF , ***G-CSF*** ***induced*** the tyrosine phosphorylation of ***STAT3*** but failed to induce the nuclear translocation of tyrosine-phosphorylated STAT3 .	target	1
3075	10336453	1437;84959	GM-CSF;p70	***GM-CSF*** ***induced*** activation of not only ***p70*** S6 kinase , but also of MAP kinase .	target	1
3076	10336453	1437;6774	CSF;STAT3	PD98059 , an MEK1 inhibitor , inhibited the ***G-CSF-dependent*** serine727 ***phosphorylation*** of ***STAT3*** and blocked the inhibitory effect of GM-CSF on G-CSF-dependent nuclear translocation of STAT3 .	target	1
3077	10336453	1437;6774	CSF;STAT3	From the analysis of confocal laser scanning fluorescence microscopy and differential centrifugation , it was clearly demonstrated that ***G-CSF*** ***induced*** nuclear translocation of tyrosine-phosphorylated ***STAT3*** .	target	1
3078	10336463	7124;5970	TNF-alpha;p65	RAI protein appeared to be located in the nucleus and colocalized with NF-kappaB ***p65*** that was ***activated*** by ***TNF-alpha*** .	positive	1
3079	10336466	6722;6749	SRF;SSRP1	Using a modified yeast one-hybrid screen to identify potential SRF cofactors , we found that ***SRF*** ***interacts*** with the high mobility group factor ***SSRP1*** ( structure-specific recognition protein ) .	parallel	1
3080	10336466	6749;6722	SSRP1;SRF	SSRP1 does not bind the CArG box , but ***interaction*** of ***SSRP1*** with ***SRF*** dramatically increases the DNA binding activity of SRF , resulting in synergistic transcriptional activation of native and artificial SRF-dependent promoters .	parallel	1
3081	10336473	7422;285	vascular endothelial growth factor;angiopoietin-2	Hypoxia and ***vascular endothelial growth factor*** selectively ***up-regulate*** ***angiopoietin-2*** in bovine microvascular endothelial cells .	positive	1
3082	10336478	4486;4485	RON;MSP	The ***RON*** receptor-type tyrosine kinase , a member of the hepatocyte growth factor receptor family , is a ***receptor*** for macrophage-stimulating protein ( ***MSP*** ) .	parallel	1
3083	10336480	857;7422	caveolin-1;VEGF	Furthermore , we show that ***caveolin-1*** can function as a negative ***regulator*** of ***VEGF-R*** ( KDR ) signal transduction in vivo .	negative	1
3084	10336480	7422;857	VEGF;caveolin-1	***VEGF-induced*** ***down-regulation*** of ***caveolin-1*** expression also resulted in the morphological loss of cell surface caveolae organelles as seen by transmission electron microscopy .	negative	1
3085	10336480	7422;857	VEGF;caveolin-1	A variety of well characterized angiogenesis inhibitors ( including angiostatin , fumagillin , 2-methoxy estradiol , transforming growth factor-beta , and thalidomide ) effectively blocked ***VEGF-induced*** ***down-regulation*** of ***caveolin-1*** as seen by immunoblotting and immunofluorescence microscopy .	negative	1
3086	10336480	7422;857	VEGF;caveolin-1	PD98059 , a specific inhibitor of mitogen-activated protein kinase and a known angiogenesis inhibitor , also blocked the observed ***VEGF-induced*** ***down-regulation*** of ***caveolin-1*** .	negative	1
3087	10336493	1869;1719	E2F1;dihydrofolate reductase	***Activation*** of the murine ***dihydrofolate reductase*** promoter by ***E2F1*** .	positive	1
3088	10336495	5465;2033	PPARalpha;p300	In contrast to the ***interaction*** of ***PPARalpha*** with the coactivator protein , ***p300*** , association of the receptor with NCoR did not require any part of the PPARalpha ligand binding domain .	parallel	1
3089	10336516	4803;4804	NGF;p75	We have identified a novel nonpeptidic molecule , ALE-0540 , that inhibits the ***binding*** of ***NGF*** to tyrosine kinase ( Trk ) A or both ***p75*** and TrkA ( IC50 5.88 + / - 1 .	parallel	1
3090	10336516	4803;4914	NGF;Trk	We have identified a novel nonpeptidic molecule , ALE-0540 , that inhibits the ***binding*** of ***NGF*** to tyrosine kinase ( ***Trk*** ) A or both p75 and TrkA ( IC50 5.88 + / - 1 .	parallel	1
3091	10336668	321;351	Mint2;APP	In Mint2/APP-cotransfected cells , ***Mint2*** reorganizes the subcellular distribution of APP and also ***increases*** the steady-state levels of ***APP*** .	positive	0
3092	10336676	2912;5594	mGluR2;ERK2	In particular , mGluR1a and ***mGluR2*** preferentially ***mediated*** phosphorylation and activation of ***ERK2*** in a pertussis toxin ( PTX ) - sensitive and concentration-dependent manner .	target	0
3093	10336677	7025;2516	COUP-TFI;SF-1	Electrophoretic mobility shift assays confirmed specific ***binding*** of Sp1 , ***SF-1*** and ***COUP-TFI*** .	parallel	1
3094	10336726	7200;4842	TRH;NOS	The findings suggest that mobilization of intracellular Ca2 + by ***TRH*** stimulation ***activates*** Ca2 + - dependent ***NOS*** in GH3 cells .	positive	1
3095	10336827	3479;2690	IGF-I;GHR	The similar action of pGH and ***IGF-I*** on preadipocyte proliferation and differentiation , ***associated*** with the similar expression of ***GHR*** and IGF-IR mRNA in LW and MS pigs , suggests that the GH/IGF-I axis is not impaired in MS pigs .	parallel	0
3096	10336864	348;3949	apoE;LDLr	We are using this system to express a panel of 2E8 variant Fabs that will be used as probes to establish the structural features responsible for the ***binding*** of ***apoE*** to the ***LDLr*** .	parallel	1
3097	10337591	1019;1029	Cdk4;p16	The p16 level was found to be almost the same in both normal and transformed cells , a loss of ******p16-Cdk4****** ***interaction*** was observed in two of the three melanoma cell lines .	parallel	1
3098	10337864	949;4018	CD36 and LIMPII analogous-1;lipoprotein	***CD36 and LIMPII analogous-1*** ( CLA-1 ) , a human homolog of the rodent scavenger receptor B1 ( SR-B1 ) , ***binds*** high-density ***lipoprotein*** ( HDL ) and mediates the selective uptake of HDL cholesterol ester ( CE ) by cultured transfected cells .	parallel	1
3099	10337866	155;7350	beta3AR;UCP1	Our results suggest that the ***beta3AR*** mutation is ***associated*** with hypertriglyceridemia and the ***UCP1*** polymorphism may be a weak contributing factor to obesity in Japanese men .	parallel	0
3100	10337915	116;3458	PACAP;IFNgamma	***VIP/PACAP*** ***inhibit*** the production of IL-12 , IL-6 , tumor necrosis factor alpha ( TNFalpha ) , and interferon gamma ( ***IFNgamma*** ) in vivo in endotoxemic mice .	negative	1
3101	10337915	116;3569	PACAP;IL-6	***VIP/PACAP*** ***inhibit*** the production of IL-12 , ***IL-6*** , tumor necrosis factor alpha ( TNFalpha ) , and interferon gamma ( IFNgamma ) in vivo in endotoxemic mice .	negative	1
3102	10337915	116;7124	PACAP;tumor necrosis factor alpha	***VIP/PACAP*** ***inhibit*** the production of IL-12 , IL-6 , ***tumor necrosis factor alpha*** ( TNFalpha ) , and interferon gamma ( IFNgamma ) in vivo in endotoxemic mice .	negative	1
3103	10338	1442;5617	placental lactogen;prolactin	***Inhibition*** of pituitary ***prolactin*** secretion by human ***placental lactogen*** in rats .	negative	1
3104	10338369	1437;7040	GM-CSF;TGF-beta1	However , ***GM-CSF*** ( 1 ng / ml ) up-regulates its own protein expression , but does not effect TGF-beta1 mRNA protein expression in epithelial and stromal cells , and actually ***inhibits*** the cell-associated ***TGF-beta1*** protein in stromal cells ( P < 0.05 ) .	negative	1
3105	10338476	3553;1673	IL-1beta;HBD-2	Human beta-defensins are expressed in oral tissues , and the proteins are secreted in saliva ; HBD-1 expression was constitutive , while ***HBD-2*** expression was ***induced*** by ***IL-1beta*** and LPS .	target	1
3106	10339431	1677;1676	CAD;ICAD	***CAD*** is ***complexed*** with its inhibitor , ***ICAD*** , in growing , non-apoptotic cells [ 2 ] [ 7 ] .	parallel	1
3107	10339432	5883;11200	Rad9;Rad53	Rad9 hyperphosphorylation , which occurs after DNA damage [ 4 ] [ 5 ] [ 6 ] , was absent in the BRCT mutants , as was ***Rad9-dependent*** ***phosphorylation*** of the ***Rad53*** protein .	target	1
3108	10339433	8737;8772	RIP;FADD	The tumor necrosis factor receptor 1 ( TNFR1 ) and the Fas receptor recruit complexes formed by the ***interactions*** between ***RIP*** kinase , TRADD , ***FADD*** and RAIDD - adaptor proteins that contain death domains - which in turn recruit other proteins to initiate signaling [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] .	parallel	1
3109	10339433	8737;8717	RIP;TRADD	The tumor necrosis factor receptor 1 ( TNFR1 ) and the Fas receptor recruit complexes formed by the ***interactions*** between ***RIP*** kinase , ***TRADD*** , FADD and RAIDD - adaptor proteins that contain death domains - which in turn recruit other proteins to initiate signaling [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] .	parallel	1
3110	10339433	8717;8772	TRADD;FADD	The tumor necrosis factor receptor 1 ( TNFR1 ) and the Fas receptor recruit complexes formed by the ***interactions*** between RIP kinase , ***TRADD*** , ***FADD*** and RAIDD - adaptor proteins that contain death domains - which in turn recruit other proteins to initiate signaling [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] .	parallel	1
3111	10339475	4792;7124	IkappaB-alpha;TNF-alpha	We found that overexpression of ***IkappaB-alpha*** in endothelial cells using a recombinant adenovirus ***prevented*** tumor necrosis factor-alpha ( ***TNF-alpha*** ) - induced degradation of IkappaB-alpha and suppressed the upregulation of vascular cell adhesion molecule-1 ( VCAM-1 ) , intercellular adhesion molecule-1 ( ICAM-1 ) , and E-selectin mRNA and surface protein expression and the upregulation of transcripts for the chemokines monocyte chemoattractant protein 1 ( MCP-1 ) and growth-related activity-alpha ( GRO-alpha ) by TNF-alpha .	negative	0
3112	10339475	4792;3383	IkappaB-alpha;intercellular adhesion molecule-1	We found that overexpression of ***IkappaB-alpha*** in endothelial cells using a recombinant adenovirus prevented tumor necrosis factor-alpha ( TNF-alpha ) - induced degradation of IkappaB-alpha and ***suppressed*** the upregulation of vascular cell adhesion molecule-1 ( VCAM-1 ) , ***intercellular adhesion molecule-1*** ( ICAM-1 ) , and E-selectin mRNA and surface protein expression and the upregulation of transcripts for the chemokines monocyte chemoattractant protein 1 ( MCP-1 ) and growth-related activity-alpha ( GRO-alpha ) by TNF-alpha .	negative	1
3113	10339475	4792;7412	IkappaB-alpha;vascular cell adhesion molecule-1	We found that overexpression of ***IkappaB-alpha*** in endothelial cells using a recombinant adenovirus prevented tumor necrosis factor-alpha ( TNF-alpha ) - induced degradation of IkappaB-alpha and ***suppressed*** the upregulation of ***vascular cell adhesion molecule-1*** ( VCAM-1 ) , intercellular adhesion molecule-1 ( ICAM-1 ) , and E-selectin mRNA and surface protein expression and the upregulation of transcripts for the chemokines monocyte chemoattractant protein 1 ( MCP-1 ) and growth-related activity-alpha ( GRO-alpha ) by TNF-alpha .	negative	1
3114	10339478	2889;1399	C3G;CrkL	Taken together , these results indicate that the ******CrkL-C3G****** ***complex*** activates VLA-4 and VLA-5 in hematopoietic cells , possibly by activating the small GTP binding proteins , including R-Ras , through the guanine nucleotide exchange activity of C3G .	parallel	1
3115	10339478	2889;3678	C3G;VLA-5	Taken together , these results indicate that the ***CrkL-C3G*** complex ***activates*** VLA-4 and ***VLA-5*** in hematopoietic cells , possibly by activating the small GTP binding proteins , including R-Ras , through the guanine nucleotide exchange activity of C3G .	positive	1
3116	10339478	1399;3678	CrkL;VLA-5	Taken together , these results indicate that the ***CrkL-C3G*** complex ***activates*** VLA-4 and ***VLA-5*** in hematopoietic cells , possibly by activating the small GTP binding proteins , including R-Ras , through the guanine nucleotide exchange activity of C3G .	positive	1
3117	10339482	2056;2185	erythropoietin;Protein kinase B	***Protein kinase B*** ( c-Akt ) , phosphatidylinositol 3-kinase , and STAT5 are ***activated*** by ***erythropoietin*** ( EPO ) in HCD57 erythroid cells but are constitutively active in an EPO-independent , apoptosis-resistant subclone ( HCD57-SREI cells ) .	positive	1
3118	10339482	2056;6776	erythropoietin;STAT5	Protein kinase B ( c-Akt ) , phosphatidylinositol 3-kinase , and ***STAT5*** are ***activated*** by ***erythropoietin*** ( EPO ) in HCD57 erythroid cells but are constitutively active in an EPO-independent , apoptosis-resistant subclone ( HCD57-SREI cells ) .	positive	1
3119	10339482	2056;2185	erythropoietin;Protein kinase B	We found that ***erythropoietin*** ( EPO ) and stem cell factor ( SCF ) ***activated*** ***Protein kinase B*** ( PKB/Akt ) in EPO-dependent HCD57 erythroid cells .	positive	1
3120	10339482	4254;2185	SCF;Protein kinase B	We found that erythropoietin ( EPO ) and stem cell factor ( ***SCF*** ) ***activated*** ***Protein kinase B*** ( PKB/Akt ) in EPO-dependent HCD57 erythroid cells .	positive	1
3121	10339488	1958;2152	EGR-1;tissue factor	Vascular endothelial cell growth factor-induced ***tissue factor*** expression in endothelial cells is ***mediated*** by ***EGR-1*** .	target	0
3122	10339499	3458;4084	IFN-gamma;Mad1	In contrast , TPA + ***IFN-gamma*** costimulation neither ***increased*** the expression of ***Mad1*** or other Mad/mnt family genes nor altered heterodimerization or DNA-binding activity of Mad1 .	positive	0
3123	10339547	983;9013	cdc2;TAFI110	We have shown that transcription initiation factor ( TIF ) - IB/SL1 is inactivated during mitosis by ***cdc2/cyclin*** B-directed ***phosphorylation*** of ***TAFI110*** .	target	1
3124	10339564	990;1017	HsCdc6;Cdk2	***HsCdc6*** is an excellent ***substrate*** for ***Cdk2*** in vitro and is phosphorylated in vivo at three sites ( Ser-54 , Ser-74 , and Ser-106 ) that are phosphorylated by Cdk2 in vitro , strongly suggesting that HsCdc6 is an in vivo Cdk substrate .	parallel	1
3125	10339565	207;5728	Akt;PTEN	***Akt*** activation increased Bad phosphorylation and ***promoted*** ***PTEN*** - / - cell survival .	positive	0
3126	10339565	5728;207	PTEN;Akt	Our studies suggest that ***PTEN*** ***regulates*** the phosphatidylinositol 3,4 , 5,-trisphosphate and ***Akt*** signaling pathway and consequently modulates two critical cellular processes : cell cycle progression and cell survival .	target	1
3127	10339577	8945;1499	beta-Trcp;beta-catenin	Here we show that phosphorylated ***beta-catenin*** is specifically ***recognized*** by ***beta-Trcp*** , an F-box/WD40-repeat protein that also associates with Skp1 , an essential component of the ubiquitination apparatus .	target	1
3128	10339589	9467;695	Sab;Bruton's tyrosine kinase	***Bruton's tyrosine kinase*** activity is negatively ***regulated*** by ***Sab*** , the Btk-SH3 domain-binding protein .	negative	1
3129	10339592	3700;1234	gp120;CCR5	Substitution of the 8x V3 loop with that from the R5 virus strain BaL resulted in an Env ( 8x-V3BaL ) that mediated CD4-independent CCR5-dependent virus infection and a ***gp120*** that ***bound*** to ***CCR5*** in the absence of CD4 .	parallel	1
3130	10339592	30816;3700	Env;gp120	Substitution of the 8x V3 loop with that from the R5 virus strain BaL resulted in an ***Env*** ( 8x-V3BaL ) that ***mediated*** CD4-independent CCR5-dependent virus infection and a ***gp120*** that bound to CCR5 in the absence of CD4 .	target	0
3131	10339615	10681;9628	Gbeta5;RGS6	When RGS6 is coexpressed with different Gbeta subunits , only ***RGS6*** and ***Gbeta5*** ***interact*** .	parallel	1
3132	10339621	4881;10488	NPR1;basic leucine zipper protein	***Interaction*** of ***NPR1*** with ***basic leucine zipper protein*** transcription factors that bind sequences required for salicylic acid induction of the PR-1 gene .	parallel	1
3133	10339667	7124;1017	TNF-alpha;cdk2	***TNF-alpha*** ***reduced*** the expression of the cyclin ***E-cdk2*** complex .	negative	1
3134	10339667	1019;595	cdk4;cyclin D1	TNF-alpha did not affect the amount of cyclin D1 , cyclin E , cdk4 , cdk2 , and of ******cyclin D1-cdk4****** ***complex*** .	parallel	1
3135	10339667	3569;1026	IL-6;p21	***IL-6*** ***decreased*** ***p21*** expression and its complex with cdk2 , while it increased the cyclin E-cdk2 complex .	negative	0
3136	10339669	885;4318	CCK;MMP-9	These results suggest that ***CCK*** may ***regulate*** the invasiveness and the production of ***MMP-9*** via protein kinase C in human pancreatic cancer cell lines .	target	1
3137	10339675	3084;2065	Hrg;erbB-3	***Hrg*** beta1 treatment ***enhanced*** only ***erbB-3*** tyrosine phosphorylation ; however , the addition of Hrg in low serum did not stimulate ovarian cell growth , unlike all three breast cancer cell lines examined .	positive	0
3138	10340301	2891;9463	GluR2;PICK1	The PDZ domain of PICK1 is required for the interaction and the mutation of a single amino acid in this region ( Lys-27 to Glu ) prevents ***interaction*** between ***PICK1*** and ***GluR2*** in the yeast two-hybrid assay .	parallel	1
3139	10340301	9463;5578	PICK1;PKC alpha	A similar mutation has been reported to prevent the ***binding*** of ***PICK1*** to ***PKC alpha*** indicating that the same domain of PICK1 binds both PKC alpha and GluRs .	parallel	1
3140	10340301	9463;124454	PICK1;GluRs	A similar mutation has been reported to prevent the binding of PICK1 to PKC alpha indicating that the same domain of ***PICK1*** ***binds*** both PKC alpha and ***GluRs*** .	parallel	1
3141	10340301	9463;5578	PICK1;PKC alpha	A similar mutation has been reported to prevent the binding of PICK1 to PKC alpha indicating that the same domain of ***PICK1*** ***binds*** both ***PKC alpha*** and GluRs .	parallel	1
3142	10340301	2891;9463	GluR2;PICK1	Recombinant full length ***GluR2*** is ***coimmunoprecipitated*** with ***flag-PICK1*** using an anti-flag antibody and flag-PICK1 is coimmunoprecipitated with an N-terminal directed anti-GluR2 antibody .	parallel	1
3143	10340386	3725;203074	c-Jun;TSP1	We now demonstrate that the ***c-Jun-induced*** ***repression*** of ***TSP1*** does not occur directly and does not require binding of c-Jun to the TSP1 promoter .	negative	1
3144	10340386	3725;203074	c-Jun;TSP1	We now demonstrate that the c-Jun-induced repression of TSP1 does not occur directly and does not require ***binding*** of ***c-Jun*** to the ***TSP1*** promoter .	parallel	1
3145	10340394	1435;2056	Colony-stimulating factor-1;erythropoietin	***Colony-stimulating factor-1*** ***impairs*** both proliferation and differentiation signals of ***erythropoietin*** during the commitment of bipotential NFS-60 cell line to the monocytic lineage .	negative	0
3146	10340468	116;1621	PACAP;DBH	Taken together , the data suggests that ***PACAP*** is involved in the ***regulation*** of maintenance of the catecholamine synthesizing enzymes TH and ***DBH*** by utilizing the cAMP/PKA pathway .	target	1
3147	10340512	1394;1392	CRF1;corticotropin-releasing factor	Two different ***corticotropin-releasing factor*** ( CRF ) ***receptors*** , ***CRF1*** and CRF2 , have been identified in rat and human brain .	parallel	1
3148	10340512	1395;1392	CRF2;corticotropin-releasing factor	Two different ***corticotropin-releasing factor*** ( CRF ) ***receptors*** , CRF1 and ***CRF2*** , have been identified in rat and human brain .	parallel	1
3149	10340542	970;939	CD70;CD27	***CD70*** , a ***ligand*** of the T cell costimulatory receptor ***CD27*** , is expressed mainly on activated B cells and has been shown to increase cytotoxic activity and proliferation of preferentially unprimed T cells .	parallel	1
3150	10340552	4632;3630	myosin-light chain 1;proinsulin	Thus , C2C12 mouse myoblast cells were stably transfected with a chimeric gene obtained by ***linking*** the ***myosin-light chain 1*** ( MLC1 ) promoter to the human ***proinsulin*** gene , containing genetically engineered furin endoprotease cleavage sites ( MLC1/Insm ) .	parallel	0
3151	10340753	7422;2321	VEGF;VEGFR-1	Vascular endothelial growth factor B ( ***VEGF-B*** ) is structurally closely related to VEGF and ***binds*** one of its receptors , ***VEGFR-1*** .	parallel	1
3152	10340755	6469;5727	Shh;Ptc	However , in Msx1 mutant dental mesenchyme Shh-soaked beads were able to induce Gli1 but failed to induce Ptc expression , indicating a requirement for Msx1 in the ***induction*** of ***Ptc*** by ***Shh*** .	target	1
3153	10340755	652;5727	BMP4;Ptc	Moreover , we show that another signaling molecule , ***BMP4*** , was able to ***induce*** ***Ptc*** expression in wild-type dental mesenchyme , but induced a distinct expression pattern of Ptc in the Msx1 mutant molar mesenchyme .	target	1
3154	10340760	3569;627	IL-6;neurotrophin	In summary , our results indicate that ***IL-6*** in conjunction with sIL-6R ***regulates*** specific ***neurotrophin*** expression in astrocytes in a brain region dependent manner .	target	1
3155	10340812	7124;3952	TNFalpha;leptin	CONCLUSIONS : Our results are consistent with the hypothesis that the ***TNFalpha*** system could be involved in the ***regulation*** of plasma ***leptin*** concentrations in obese subjects .	target	1
3156	10340821	5443;551	ACTH;arginine vasopressin	***ACTH*** and cortisol ***response*** to combined ***corticotropin releasing hormone-arginine vasopressin*** stimulation in obese males and its relationship to body weight , fat distribution and parameters of the metabolic syndrome .	parallel	0
3157	10340821	5443;1392	ACTH;corticotropin releasing hormone	***ACTH*** and cortisol ***response*** to combined ***corticotropin releasing hormone-arginine vasopressin*** stimulation in obese males and its relationship to body weight , fat distribution and parameters of the metabolic syndrome .	parallel	0
3158	10340949	5879;5599	Rac1;JNK	In contrast , expression of a constitutively active Rac1 , an alternative guanosine triphosphatase involved in intracellular signaling , produced a high level of JNK1 activation , suggesting that ***Rac1*** is an important upstream ***activator*** of ***JNK*** in this system .	positive	1
3159	10340949	6416;5599	SEK1;JNK	Active Ras and MAPK/ ERK kinase-1 ( MEK1 ) ( the upstream activator of ERK ) each induced cyclin D1 promoter activity , whereas active stress-activated protein kinase/ERK kinase-1 ( ***SEK1*** ) , an upstream ***activator*** of ***JNK*** , did not .	positive	1
3160	10340964	959;958	CD40L;CD40	OBJECTIVE : The expression of CD40 and ***CD40*** ***ligand*** ( ***CD40L*** ) in mononuclear cells ( MNCs ) infiltrating the salivary glands of patients with Sjögren 's syndrome ( SS ) has recently been reported .	parallel	1
3161	10340997	5104;5327	PCI;tPA	Similarly , > 90 % of ******PCI-tPA****** ***complex*** was formed after 30 min of heparin stimulation in normal seminal plasma but no response was observed in the two patient samples .	parallel	1
3162	10341084	9173;4602	fit-1;MYB	The ***fit-1*** common integration locus in human and mouse is closely ***linked*** to ***MYB*** .	parallel	0
3163	10341204	3553;2252	IL-1;KGF	These data indicate a regulation of keratinocyte growth by a double paracrine mechanism through release of ***IL-1*** which ***induces*** ***KGF*** in cocultured fibroblasts .	target	1
3164	10341227	5663;1499	PS1;beta-catenin	Here , we show that both the full length and the C-terminal fragment of wild-type or FAD mutant ***PS1*** ***interact*** with ***beta-catenin*** from transfected cells and brains of transgenic mice , whereas E-cadherin and adenomatous polyposis coli ( APC ) are not detected in this complex .	parallel	1
3165	10341227	2932;1499	GSK-3beta;beta-catenin	Inducible overexpression of PS1 led to increased association of beta-catenin with glycogen synthase kinase-3beta ( ***GSK-3beta*** ) , a negative ***regulator*** of ***beta-catenin*** , and accelerated the turnover of endogenous beta-catenin .	negative	1
3166	10341227	1499;2932	beta-catenin;GSK-3beta	Inducible overexpression of PS1 led to increased ***association*** of ***beta-catenin*** with glycogen synthase kinase-3beta ( ***GSK-3beta*** ) , a negative regulator of beta-catenin , and accelerated the turnover of endogenous beta-catenin .	parallel	0
3167	10341227	5663;1499	PS1;beta-catenin	In support of this finding , the beta-catenin half-life was dramatically longer in fibroblasts deficient in PS1 , and this phenotype was completely rescued by replacement of PS1 , demonstrating that ***PS1*** normally ***stimulates*** the degradation of ***beta-catenin*** .	positive	0
3168	10341227	1499;2932	beta-catenin;GSK-3beta	In contrast , overexpression of FAD-linked PS1 mutants ( M146L and DeltaX9 ) failed to enhance the ***association*** between ***GSK-3beta*** and ***beta-catenin*** and interfered with the constitutive turnover of beta-catenin .	parallel	0
3169	10341227	5663;1499	PS1;beta-catenin	In vivo confirmation was demonstrated in the brains of transgenic mice in which the expression of the M146L mutant ***PS1*** was ***correlated*** with increased steady-state levels of endogenous ***beta-catenin*** .	parallel	0
3170	10341227	1499;5663	beta-catenin;PS1	Thus , our results indicate that PS1 normally promotes the turnover of beta-catenin , whereas PS1 mutants partially interfere with this process , possibly by failing to recruit GSK-3beta into the ******PS1-beta-catenin****** ***complex*** .	parallel	1
3171	10341227	1499;5663	beta-catenin;PS1	These findings raise the intriguing possibility that ******PS1-beta-catenin****** ***interactions*** and subsequent activities may be consequential for the pathogenesis of AD .	parallel	1
3172	10341229	5803;7143	phosphacan;TN-R	However , immunostaining for the chondroitin sulfate proteoglycan ***phosphacan*** , a high-affinity ***ligand*** for ***TN-R*** , is weak and diffuse in the mutant when compared with wild-type mice .	parallel	1
3173	10341341	7832;29883	BTG2;CAF1	***BTG2*** protein physically ***interacts*** with the protein ***CAF1*** , an element of a general transcription complex , and with a protein-arginine N-methyl transferase , PRMT1 .	parallel	1
3174	10341341	7832;3276	BTG2;PRMT1	***BTG2*** protein physically ***interacts*** with the protein CAF1 , an element of a general transcription complex , and with a protein-arginine N-methyl transferase , ***PRMT1*** .	parallel	1
3175	10341737	3623;213	inhibin alpha-subunit;albumin	In Expt 1 , during the breeding season , 30 ewes were subdivided into three groups : group I served as the non-immunized control ; group II was immunized against inhibin-like peptide ( 100 micrograms inhibin-like peptide equivalent , followed by three booster injections ) ; group III was immunized against pig ***inhibin alpha-subunit*** ***conjugated*** to human serum ***albumin*** ( 96 micrograms for the primary administration and 46 micrograms for the booster ) .	parallel	1
3176	10341860	5443;1392	POMC;CRH	In contrast , plasma ***POMC*** positively ***correlated*** with plasma ***CRH*** .	positive	0
3177	10342332	847;176	Catalase;Aggrecan	***Catalase*** significantly ***prevented*** the release of labeled ***Aggrecan*** in LPS-chondrocyte cultures , suggesting a role for chondrocyte-derived hydrogen peroxide in Aggrecan degradation .	negative	0
3178	10342375	3791;7422	KDR;VEGF	We investigated the transcription of ***VEGF*** and its ***receptor*** ***KDR/flk-1*** genes during the development of experimentally induced choroidal neovascularization .	parallel	1
3179	10342375	3791;7422	KDR;VEGF	CONCLUSIONS : Our findings demonstrate that expression of ***VEGF*** and its ***receptor*** ***KDR*** may play a role in the formation of experimentally induced choroidal neovascularization .	parallel	1
3180	10342402	4803;4852	NGF;NPY	The results of our studies show : ( a ) that NGF is present in the brain of these birds and it is higher in the HVC than in the other neostriatal tissues ; ( b ) that exogenous administration of NGF or NGF-antibody had no discernible effect on singing behavior ; and ( c ) that ***NGF*** ***enhances*** the ***NPY*** immunoreactivity in neurons and fibers localized in HVC and other areas of the neostriatum and hippocampus whereas anti-NGF decreased NPY stained cells in the hippocampus .	positive	0
3181	10342487	7040;4843	TGF-beta1;NOS2	These findings suggest that the ***interaction*** between ***TGF-beta1*** and ***NOS2*** might be important for angiogenesis after cerebral ischaemia and may indicate that TGF-beta1 is upregulated as a negative feedback response to elevated levels of NO .	parallel	1
3182	10342807	5465;7352	PPAR-alpha;UCP-3	It is proposed that the ***UCP-3*** gene is predominantly ***regulated*** in neonatal muscle by ***PPAR-alpha*** activation .	target	1
3183	10342810	3645;3667	Insulin receptor-related receptor;insulin receptor substrate-1	***Insulin receptor-related receptor*** is expressed in pancreatic beta-cells and ***stimulates*** tyrosine phosphorylation of ***insulin receptor substrate-1*** and -2 .	positive	0
3184	10342820	5054;213	PAI-1;albumin	Furthermore , ***PAI-1*** activity was positively ***correlated*** with urinary ***albumin*** excretion ( r = 0.48 , P < 0.01 ) and inversely correlated with the vasodilatory response to the highest ACh dose ( r = -0.37 , P < 0.05 ) .	positive	0
3185	10342828	7124;2908	TNF alpha;glucocorticoid receptor	Moreover , ***TNF alpha*** treatment only weakly ***inhibited*** ligand-dependent ***glucocorticoid receptor*** activity in the HOB-03-CE6 cells .	negative	1
3186	10342828	7124;4790	TNF alpha;NF-kappaB	Treatment of the cells with 17beta-E2 partially suppressed the ***activation*** of ***NF-kappaB*** by ***TNF alpha*** , but did not block cytokine-induced IL-6 secretion .	positive	1
3187	10342855	2100;5617	ER beta;PRL	We conclude that 1 ) both ER beta and TERP messenger RNAs in GH3 cells are increased by estradiol in a dose - and time-dependent manner , whereas ER alpha is not altered ; 2 ) a 58-kDa ER beta protein is expressed in both the pituitary and GH3 cells ; and 3 ) overexpression of ***ER beta*** ***increases*** estrogen-induced ***PRL*** gene expression .	positive	0
3188	10342861	2099;5241	ER-alpha;progesterone receptor	The results suggest that the stromal cell sensitivity to decidualization is critically dependent on P4-regulated events , and estrogenic ***induction*** of ***progesterone receptor*** via classical nuclear ***ER-alpha*** is not critical for this process .	target	1
3189	10342875	2691;2692	GHRH;growth hormone-releasing hormone (GHRH) receptor	Differential in vivo ***regulation*** of the pituitary ***growth hormone-releasing hormone (GHRH) receptor*** by ***GHRH*** in young and aged rats .	target	1
3190	10342884	4233;3082	c-Met;HGF	Both of these cells express ***c-Met*** , the ***receptor*** for ***HGF*** .	parallel	1
3191	10343075	5175;3685	PECAM-1;integrin alphavbeta3	As well as mediating homophilic ( PECAM-1/PECAM-1 ) adhesion , ***PECAM-1*** can also ***bind*** the ***integrin alphavbeta3*** .	parallel	1
3192	10344280	4792;4790	IkappaBalpha;NFkappaB	The model used in this study was a human lymphoblastoid cell line in which a functional repression of the transcription factors NFkappaB was obtained by induction of overexpression of ***IkappaBalpha*** , a physiological ***inhibitor*** of ***NFkappaB*** .	negative	1
3193	10344756	3845;3725	Ki-Ras;c-Jun	Activated ***Ki-Ras*** ***suppresses*** 12-O-tetradecanoylphorbol-13-acetate-induced activation of the ***c-Jun*** NH2-terminal kinase pathway in human colon cancer cells .	negative	1
3194	10344757	4605;596	B-Myb;bcl-2	Overexpression of ***B-Myb*** was ***associated*** with enhanced expression of ***bcl-2*** , which was dependent , at least in part , on increased transcription .	parallel	0
3195	10344757	4605;596	B-Myb;bcl-2	In transient transfection assays in T-lymphoblastic cells , ***B-Myb*** was able to ***stimulate*** the promoter activity of the ***bcl-2*** 5 ' flanking region linked to the chloramphenicol acetyltransferase reporter gene .	positive	0
3196	10344759	1029;4193	ARF;Mdm2	***ARF*** ***binds*** directly to ***Mdm2*** to prevent down-regulation of p53 and thereby promotes p53-dependent transcription and cell cycle arrest .	parallel	1
3197	10344759	1029;7157	ARF;p53	***ARF*** binds directly to Mdm2 to ***prevent*** down-regulation of ***p53*** and thereby promotes p53-dependent transcription and cell cycle arrest .	negative	0
3198	10346816	10111;4361	Rad50;Mre11	Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the ******Mre11/Rad50****** ***complex*** .	parallel	1
3199	10346816	4683;4361	Nbs1;Mre11	We show in this work that the triple ***complex*** of recombinant ***Nbs1*** , ***Mre11*** , and Rad50 proteins binds cooperatively to DNA and forms a distinct protein-DNA species .	parallel	1
3200	10346816	10111;4361	Rad50;Mre11	We show in this work that the triple ***complex*** of recombinant Nbs1 , ***Mre11*** , and ***Rad50*** proteins binds cooperatively to DNA and forms a distinct protein-DNA species .	parallel	1
3201	10346816	10111;4683	Rad50;Nbs1	We show in this work that the triple ***complex*** of recombinant ***Nbs1*** , Mre11 , and ***Rad50*** proteins binds cooperatively to DNA and forms a distinct protein-DNA species .	parallel	1
3202	10346816	4683;4361	Nbs1;Mre11	The ******Mre11/Rad50/Nbs1****** ***complex*** displays several enzymatic activities that are not seen without Nbs1 , including partial unwinding of a DNA duplex and efficient cleavage of fully paired hairpins .	parallel	1
3203	10346816	10111;4361	Rad50;Mre11	The ******Mre11/Rad50/Nbs1****** ***complex*** displays several enzymatic activities that are not seen without Nbs1 , including partial unwinding of a DNA duplex and efficient cleavage of fully paired hairpins .	parallel	1
3204	10346816	10111;4683	Rad50;Nbs1	The ******Mre11/Rad50/Nbs1****** ***complex*** displays several enzymatic activities that are not seen without Nbs1 , including partial unwinding of a DNA duplex and efficient cleavage of fully paired hairpins .	parallel	1
3205	10346818	7186;5599	TRAF2;JNK	Overexpressed ***TRAF2*** or TRAF6 ***activate*** ***JNK*** , p38 , or IKK in the absence of extracellular stimulation .	positive	1
3206	10346818	7186;5594	TRAF2;p38	Overexpressed ***TRAF2*** or TRAF6 ***activate*** JNK , ***p38*** , or IKK in the absence of extracellular stimulation .	positive	1
3207	10346818	7189;5599	TRAF6;JNK	Overexpressed TRAF2 or ***TRAF6*** ***activate*** ***JNK*** , p38 , or IKK in the absence of extracellular stimulation .	positive	1
3208	10346818	7189;5594	TRAF6;p38	Overexpressed TRAF2 or ***TRAF6*** ***activate*** JNK , ***p38*** , or IKK in the absence of extracellular stimulation .	positive	1
3209	10346818	7186;4214	TRAF2;MEKK1	TNF-alpha also enhances the ***binding*** of native ***TRAF2*** to ***MEKK1*** and stimulates the kinase activity of the latter .	parallel	1
3210	10346818	7124;7186	TNF-alpha;TRAF2	***TNF-alpha*** also ***enhances*** the binding of native ***TRAF2*** to MEKK1 and stimulates the kinase activity of the latter .	positive	0
3211	10346929	3700;920	gp120;CD4	The anti-HIV agent cosalane inhibits both the ***binding*** of ***gp120*** to ***CD4*** as well as an undefined postattachment event prior to reverse transcription .	parallel	1
3212	10347092	1998;7010	NERF2;Tie2	***NERF2*** can ***bind*** to the ***Tie2*** promoter Ets sites in electrophoretic mobility shift assays .	parallel	1
3213	10347094	7422;5747	Vascular endothelial growth factor;p125FAK	***Vascular endothelial growth factor*** ***induces*** activation and subcellular translocation of focal adhesion kinase ( ***p125FAK*** ) in cultured rat cardiac myocytes .	target	1
3214	10347094	3791;7422	Flk-1;VEGF	We found that the 2 ***VEGF*** ***receptors*** , ***KDR/Flk-1*** and Flt-1 , were expressed in cardiac myocytes and that KDR/Flk-1 was significantly tyrosine phosphorylated on VEGF stimulation .	parallel	1
3215	10347094	2321;7422	Flt-1;VEGF	We found that the 2 ***VEGF*** ***receptors*** , KDR/Flk-1 and ***Flt-1*** , were expressed in cardiac myocytes and that KDR/Flk-1 was significantly tyrosine phosphorylated on VEGF stimulation .	parallel	1
3216	10347113	3482;3481	M6P/IGF2R;insulin-like growth factor 2	Failure to detect genetic alteration of the mannose-6-phosphate / ***insulin-like growth factor 2*** ***receptor*** ( ***M6P/IGF2R*** ) gene in hepatocellular carcinomas in Japan .	parallel	1
3217	10347113	3482;3481	M6P/IGF2R;insulin-like growth factor 2	The mannose-6-phosphate / ***insulin-like growth factor 2*** ***receptor*** ( ***M6P/IGF2R*** ) suppresses cell growth through binding to the insulin-like growth factor 2 ( IGF2 ) and latent complex of the transforming growth factor-beta ( TGF-beta ) .	parallel	1
3218	10347117	3479;5594	IGF-1;ERK	Insulin and IGF-1 induced 70-kd S6 kinase phosphorylation in HSC , whereas ***IGF-1*** only ***induced*** ***ERK*** phosphorylation .	target	1
3219	10347160	7186;4790	TRAF2;NF-kappaB	Divergence of signals must , however , occur downstream of TRAF2 as a dominant negative ***TRAF2*** mutant that ***blocks*** LMP1-induced ***NF-kappaB*** activation also inhibited p38 signaling .	positive	0
3220	10347163	4436;2956	MSH2;MSH6	A mutation in the MSH6 subunit of the Saccharomyces cerevisiae ******MSH2-MSH6****** ***complex*** disrupts mismatch recognition .	parallel	1
3221	10347163	4436;2956	MSH2;MSH6	In yeast , ***MSH2*** ***interacts*** with ***MSH6*** to repair base pair mismatches and single nucleotide insertion/deletion mismatches and with MSH3 to recognize small loop insertion/deletion mismatches .	parallel	1
3222	10347163	4436;2956	MSH2;MSH6	In UV cross-linking , filter binding , and gel retardation assays , the ******MSH2-MSH6-F337A****** ***complex*** displayed a mismatch recognition defect .	parallel	1
3223	10347163	4436;2956	MSH2;MSH6	These observations , in conjunction with ATPase and dissociation rate analysis , suggested that ******MSH2-MSH6-F337A****** formed an unproductive ***complex*** that was unable to stably bind to mismatch DNA .	parallel	1
3224	10347167	8031;5468	ARA70;PPARgamma	Thus , ***ARA70*** can function as a ligand-enhanced ***coactivator*** of ***PPARgamma*** .	positive	1
3225	10347175	3937;7409	SLP-76;Vav	Surprisingly , we find also that the ***interaction*** between ***SLP-76*** and ***Vav*** is not required for their cooperation in augmenting IL-2 promoter activity , as the two molecules appear to function in different signaling pathways upstream of IL-2 gene expression .	parallel	1
3226	10347175	7409;3558	Vav;IL-2	Additionally , overexpression of ***Vav*** , but not SLP-76 , ***augments*** CD28-induced ***IL-2*** promoter activity .	positive	0
3227	10347184	7514;5902	Crm1;RanBP1	Second , RanBP1 ( or homologous proteins ) can displace Nup and form a ternary ******RanBP1/RanGTP/Crm1****** ***complex*** that can be disassembled by RanGAP via GTP hydrolysis .	parallel	1
3228	10347185	3576;3577	interleukin-8;CXCR1	While ***interleukin-8*** stimulation ***promoted*** ***CXCR1*** sequestration in RBL-2H3 cells , receptor internalization in HEK 293 cells required co-expression of G protein-coupled receptor kinase 2 and beta-arrestin proteins .	positive	0
3229	10347188	10845;8192	ClpX;ClpP	Recombinant ***ClpX*** can also ***interact*** with its putative partner protease subunit ***ClpP*** in overexpression experiments in 293T cells .	parallel	1
3230	10347196	10847;1387	SRCAP;CREB-binding protein	Identification of a novel SNF2/SWI2 protein family member , ***SRCAP*** , which ***interacts*** with ***CREB-binding protein*** .	parallel	1
3231	10347206	3350;820	5-HT1A;cAMP	Thus , ***5-HT1A*** and muscarinic M4 receptor may couple dominantly to Galphai1 and Galphai3 , respectively , to ***inhibit*** ***cAMP*** production .	negative	1
3232	10347209	5579;7299	PKC-beta;tyrosinase	We conclude that ***PKC-beta*** ***activates*** ***tyrosinase*** directly by phosphorylating serine residues at positions 505 and 509 in the cytoplasmic domain of this melanosome-associated protein .	positive	1
3233	10347209	5579;7299	Protein kinase C-beta;tyrosinase	***Protein kinase C-beta*** ***activates*** ***tyrosinase*** by phosphorylating serine residues in its cytoplasmic domain .	positive	1
3234	10347209	5579;7299	PKC-beta;tyrosinase	By immunoelectron microscopy , ***PKC-beta*** but not PKC-alpha was closely ***associated*** with ***tyrosinase*** on the outer surface of melanosomes .	parallel	0
3235	10347209	5579;7299	PKC-beta;tyrosinase	Only the cytoplasmic ( extra-melanosomal ) domain of ***tyrosinase*** , which contains two serines but no threonines , was ***phosphorylated*** by the serine/threonine kinase ***PKC-beta*** .	target	1
3236	10347215	3586;3716	IL-10;Jak1	Herein , we demonstrate that the ability of ***IL-10*** to inhibit tumor necrosis factor alpha ( TNFalpha ) production in lipopolysaccharide-stimulated macrophages ***requires*** the presence of Stat3 , ***Jak1*** , and two distinct regions of the IL-10 receptor intracellular domain .	target	0
3237	10347215	3586;6774	IL-10;Stat3	Herein , we demonstrate that the ability of ***IL-10*** to inhibit tumor necrosis factor alpha ( TNFalpha ) production in lipopolysaccharide-stimulated macrophages ***requires*** the presence of ***Stat3*** , Jak1 , and two distinct regions of the IL-10 receptor intracellular domain .	target	0
3238	10347215	3586;7124	IL-10;TNFalpha	These results thus demonstrate that ***IL-10-induced*** ***inhibition*** of ***TNFalpha*** production requires two distinct regions of the IL-10 receptor intracellular domain and thereby establish a distinctive molecular basis for the developmental versus the anti-inflammatory actions of IL-10 .	negative	1
3239	10347217	4193;7157	MDM2;p53	Oligomerization is required for ***p53*** to be efficiently ***ubiquitinated*** by ***MDM2*** .	target	1
3240	10347217	4193;7157	MDM2;p53	Recent studies indicate that ***MDM2*** can ***bind*** ***p53*** and promote its rapid degradation although the molecular basis for this degradation has not been clarified .	parallel	1
3241	10347217	4193;7157	MDM2;p53	This report demonstrates that ***MDM2*** can ***promote*** the ubiquitination of wild-type ***p53*** and cancer-derived p53 mutants in transiently transfected cells .	positive	0
3242	10347217	4193;7157	MDM2;p53	These results indicate that oligomerization is required for ***p53*** to efficiently bind and be ***ubiquitinated*** by ***MDM2*** .	target	1
3243	10347227	4215;9261	MEKK3;MAPKAPK2	Anisomycin , sorbitol , or the expression of ***MEKK3*** in HEK293 cells ***enhanced*** ***MAPKAPK2*** phosphorylation , whereas MEKK2 was less effective .	positive	0
3244	10347227	4215;5608	MEK kinase 3;MKK6	***MEK kinase 3*** directly ***activates*** ***MKK6*** and MKK7 , specific activators of the p38 and c-Jun NH2-terminal kinases .	positive	1
3245	10347227	4215;5609	MEK kinase 3;MKK7	***MEK kinase 3*** directly ***activates*** MKK6 and ***MKK7*** , specific activators of the p38 and c-Jun NH2-terminal kinases .	positive	1
3246	10347227	10746;5608	MEKK2;MKK6	***MEKK2*** , a closely related homologue of MEKK3 , also ***activated*** MKK7 and ***MKK6*** in COS-7 cells .	positive	1
3247	10347227	10746;5609	MEKK2;MKK7	***MEKK2*** , a closely related homologue of MEKK3 , also ***activated*** ***MKK7*** and MKK6 in COS-7 cells .	positive	1
3248	10347229	5159;867	PDGFRbeta;Cbl	Here , we show that , similar to PDGFRalpha , selective stimulation of ***PDGFRbeta*** ***induces*** ***Cbl*** phosphorylation , and its physical association with the receptor .	target	1
3249	10347244	185;183	AT1;angiotensin II	Relationship between internalization and mRNA decay in down-regulation of recombinant type 1 ***angiotensin II*** ***receptor*** ( ***AT1*** ) expression in smooth muscle cells .	parallel	1
3250	10347244	185;183	AT1;angiotensin II	In vascular smooth muscle cells , the hormone angiotensin II is thought to cause internalization of the seven-transmembrane domain type 1 ***angiotensin II*** ***receptor*** ( ***AT1-R*** ) but it also suppresses expression of the receptor mRNA .	parallel	1
3251	10347248	10203;796	calcitonin receptor-like receptor;calcitonin	The ***calcitonin receptor-like receptor*** ( CRLR ) can function as either a ***receptor*** for ***calcitonin*** gene-related peptide ( CGRP ) or for adrenomedullin ( ADM ) , depending upon the coexpression of a novel family of single transmembrane proteins , which we have called receptor activity modifying proteins or RAMPs .	parallel	1
3252	10348340	3558;6774	IL-2;STAT3	***IL-2*** ***induced*** the DNA binding activity of ***STAT3*** and STAT5 of a HTLV-1-transformed cell line and then stimulated its proliferation .	target	1
3253	10348343	7157;5610	p53;PKR	These novel findings raise the possibility of a functional ***interaction*** between ***PKR*** and ***p53*** in vivo , which may account , at least in part , for the ability of each protein to regulate gene expression at both the transcriptional and the translational levels .	parallel	1
3254	10348343	5610;7157	PKR;p53	The double-stranded RNA activated protein kinase ***PKR*** physically ***associates*** with the tumor suppressor ***p53*** protein and phosphorylates human p53 on serine 392 in vitro .	parallel	0
3255	10348343	5610;7157	PKR;p53	The double-stranded RNA activated protein kinase ***PKR*** physically associates with the tumor suppressor p53 protein and ***phosphorylates*** human ***p53*** on serine 392 in vitro .	target	1
3256	10348343	5610;7157	PKR;p53	Here we report that ***PKR*** physically ***associates*** with ***p53*** .	parallel	0
3257	10348343	5610;7157	PKR;p53	The ***interaction*** of ***PKR*** with ***p53*** is enhanced by IFNs and upon conditions that p53 acquires a wild type conformation .	parallel	1
3258	10348343	7157;5610	p53;PKR	***PKR/p53*** complex formation in vitro ***requires*** the N-terminal regulatory domain of ***PKR*** and the last 30 amino acids of the C-terminus of human p53 .	target	0
3259	10348343	7157;5610	p53;PKR	In addition , ***p53*** may function as a ***substrate*** of ***PKR*** since phosphorylation of human p53 on serine392 is induced by activated PKR in vitro .	parallel	1
3260	10348346	595;1017	cyclin D1;cdk2	The expression of cyclin A ( a regulatory subunit of cdk2 ) markedly decreased , while ***cyclin D1*** , the major cdk4 partner in fibroblasts , expressed at a slightly higher level and formed ***complexes*** with ***cdk2*** and cdk6 in addition to cdk4 .	parallel	1
3261	10348346	595;1021	cyclin D1;cdk6	The expression of cyclin A ( a regulatory subunit of cdk2 ) markedly decreased , while ***cyclin D1*** , the major cdk4 partner in fibroblasts , expressed at a slightly higher level and formed ***complexes*** with cdk2 and ***cdk6*** in addition to cdk4 .	parallel	1
3262	10348346	1029;7157	p19ARF;p53	Induction of ***p19ARF*** ***activated*** ***p53*** by increasing its stability , and allowed the expression of p21Cip1 , which bound to all of the cyclin D1-cdk complexes ( cyclin D1-cdk2 , - cdk4 , and - cdk6 ) thereby inhibiting their kinase activities .	positive	1
3263	10348349	1630;836	DCC;caspase-3	In the present study , we demonstrated that expression of ***DCC*** ***activated*** ***caspase-3*** and programmed cell death , or induced G2/M cell cycle arrest in tumor cells .	positive	1
3264	10348828	7039;5595	TGF-alpha;ERK1	RESULTS : ***TGF-alpha*** ***stimulated*** activation of ***ERK1*** / -2 , which was dependent on MEK-1 , but independent of PKC activity .	positive	0
3265	10349617	8928;7040	Fast1;TGF beta	We propose that mouse ***Fast1*** , like Xenopus FAST-1 , ***mediates*** ***TGF beta*** superfamily signals specifying developmental fate during early embryogenesis .	target	0
3266	10349699	6351;5617	CCl4;PRL	Serum ***PRL*** levels were ***reduced*** by E + or ***CCl4*** on all 3 dates of PRL evaluation .	negative	1
3267	10349800	3952;1588	Leptin;aromatase	***Leptin*** ***regulation*** of ***aromatase*** activity in adipose stromal cells from regularly cycling women .	target	1
3268	10349800	3952;1588	Leptin;aromatase	The aromatase gene promoter in adipose stromal cells contains a functional STAT binding region , leading to the hypothesis that ***Leptin*** may ***regulate*** ***aromatase*** activity in fat tissue .	target	1
3269	10349817	5328;5329	uPA;uPAR	Particular attention has been given to the effects of plasmin proteolysis which is generated in the extracellular matrix by urokinase plasminogen activator ( ***uPA*** ) ***complexed*** with its receptor ( ***uPAR*** ) .	parallel	1
3270	10349838	4803;836	NGF;caspase-3	***NGF*** ***regulated*** several members of the bcl-2 family and ***caspase-3*** in a manner consistent with its effect on apoptosis in PC12 cells .	target	1
3271	10349838	4803;598	NGF;bcl-xs	Levels of bcl-xl , ***bcl-xs*** , and caspase-3 mRNAs were ***increased*** by ***NGF*** treatment .	positive	0
3272	10349844	3458;3162	interferon-gamma;heme oxygenase-1	***Suppression*** of ***heme oxygenase-1*** mRNA expression by ***interferon-gamma*** in human glioblastoma cells .	negative	1
3273	10349844	3458;3162	interferon-gamma;heme oxygenase-1	These findings raise the possibility that the expression of ***heme oxygenase-1*** is ***down-regulated*** by ***interferon-gamma*** in the nervous system .	negative	1
3274	10349867	831;5579	calpain inhibitor;PKC-beta	A ***calpain inhibitor*** , acetylleucylleucylnorleucinal , ***inhibited*** the down-regulation of ***PKC-beta*** , through intravenous injection .	negative	1
3275	10349994	7248;7249	hamartin;tuberin	This is consistent with the recent finding that ***tuberin*** and ***hamartin*** ***interact*** and with the clinical similarity between TSC1 - and TSC2-linked disease .	parallel	1
3276	10350046	5609;6777	MEK;Stat5b	***MEK*** is a negative ***regulator*** of ***Stat5b*** in PDGF-stimulated cells .	negative	1
3277	10350046	5609;6777	MEK;Stat5b	These observations indicate that ***MEK*** is a negative ***modulator*** of PDGF-induced ***Stat5b*** activation through a mechanism not involving direct phosphorylation of Stat5b .	negative	0
3278	10350061	5335;5781	PLC-gamma1;SHP-2	Using two phosphopeptides , NSDVQpY663TEVQV and DTETVpY686SEVRK , we demonstrate differential ***binding*** of SHP-1 , ***SHP-2*** , SHIP and ***PLC-gamma1*** .	parallel	1
3279	10350210	983;55968	p34cdc2;p47	***Phosphorylation*** of p97 ( VCP ) and ***p47*** in vitro by ***p34cdc2*** kinase .	target	1
3280	10350210	983;7415	p34cdc2;p97	***Phosphorylation*** of ***p97*** ( VCP ) and p47 in vitro by ***p34cdc2*** kinase .	target	1
3281	10350210	983;7415	p34cdc2;p97	Monomeric , but not hexameric , ***p97*** was ***phosphorylated*** by ***p34cdc2*** kinase , as was the p97-associated protein p47 .	target	1
3282	10350216	4926;636	structural nuclear protein;BICD	In a yeast two-hybrid screen we identified an ***interaction*** between Drosophila lamin Dm0 , a ***structural nuclear protein*** , and ***BICD*** , a protein involved in oocyte development .	parallel	1
3283	10350489	2745;5770	thioltransferase;PTP1B	In addition , inactivated ***PTP1B*** is ***reactivated*** enzymatically by the glutathione-specific dethiolase enzyme ***thioltransferase*** ( glutaredoxin ) , indicating that the inactivated form of the phosphatase is a glutathionyl mixed disulfide .	positive	1
3284	10350617	1956;5335	EGFR;PLC-gamma1	The ***EGFR*** specifically ***activates*** phospholipase C-gamma1 ( ***PLC-gamma1*** ) .	positive	1
3285	10350623	1369;3827	kininase I;Bradykinin	Furthermore , the cortex homogenate expresses a ***kininase I*** activity that ***cleaves*** ***Bradykinin*** to des-Arg9-Bradykinin .	target	1
3286	10350644	2033;1387	p300;CBP	Mammalian two hybrid assays indicated that the ***interaction*** between C/ATF and ******CBP/p300****** can occur in mammalian cells , and that the p300 CH1 domain is critical for the interaction .	parallel	1
3287	10350652	2950;2729	GSTP1;GCS	GSH homeostasis thus appears to be maintained by an ***interaction*** between ***GSTP1*** and ***GCS*** in human hepatic cells resistant to the GSH poison .	parallel	1
3288	10351940	6037;6348	ECP;MIP-1-alpha	Eosinophil cationic protein ( ECP ) and eosinophil-derived neurotoxin ( EDN ) , the eosinophil secretory ribonucleases , were detected in lower airway secretions from RSV-infected patients ; ***ECP*** concentrations ***correlated*** with ***MIP-1-alpha*** concentrations ( r = 0.93 ) .	parallel	0
3289	10352239	3558;4915	IL-2;trkB	The Th1 cytokine ***IL-2*** ***stimulated*** production of ***trkB*** mRNA but not of trkC , whereas the Th2 cytokine IL-4 enhanced NT-3 but not BDNF mRNA expression .	positive	0
3290	10352239	3558;4916	IL-2;trkC	The Th1 cytokine ***IL-2*** ***stimulated*** production of trkB mRNA but not of ***trkC*** , whereas the Th2 cytokine IL-4 enhanced NT-3 but not BDNF mRNA expression .	positive	0
3291	10352240	7186;958	TRAF2;CD40	We find that ***binding*** of ***TRAF2*** and TRAF3 to ***CD40*** is not required for the induction of Ab secretion , but that both TRAF molecules can regulate the activation process .	parallel	1
3292	10352240	7187;958	TRAF3;CD40	We find that ***binding*** of TRAF2 and ***TRAF3*** to ***CD40*** is not required for the induction of Ab secretion , but that both TRAF molecules can regulate the activation process .	parallel	1
3293	10352242	3439;596	IFN-alpha;Bcl-2	Instead , ***IFN-alpha*** and IFN-beta , but not IFN-gamma , significantly ***increase*** the levels of the survival protein ***Bcl-2*** , and to a lesser extent , Bcl-xL expression .	positive	0
3294	10352242	3456;596	IFN-beta;Bcl-2	Instead , IFN-alpha and ***IFN-beta*** , but not IFN-gamma , significantly ***increase*** the levels of the survival protein ***Bcl-2*** , and to a lesser extent , Bcl-xL expression .	positive	0
3295	10352244	6693;3586	CD43;IL-10	In parallel , ***CD43*** cross-linking ***induced*** synthesis and release of IL-1beta , IL-6 , TNF-alpha , IL-12 , and ***IL-10*** .	target	1
3296	10352244	6693;3553	CD43;IL-1beta	In parallel , ***CD43*** cross-linking ***induced*** synthesis and release of ***IL-1beta*** , IL-6 , TNF-alpha , IL-12 , and IL-10 .	target	1
3297	10352244	6693;3569	CD43;IL-6	In parallel , ***CD43*** cross-linking ***induced*** synthesis and release of IL-1beta , ***IL-6*** , TNF-alpha , IL-12 , and IL-10 .	target	1
3298	10352244	6693;7124	CD43;TNF-alpha	In parallel , ***CD43*** cross-linking ***induced*** synthesis and release of IL-1beta , IL-6 , ***TNF-alpha*** , IL-12 , and IL-10 .	target	1
3299	10352245	356;355	CD95L;CD95	Two distinct forms of short-term cytolysis have been described for CD8 + CTLs , the perforin/granzyme - and Fas ligand/Fas ( ***CD95*** ***ligand*** ( ***CD95L*** ) / CD95 ) - mediated pathways .	parallel	1
3300	10352248	356;355	Fas ligand;Fas	Thus , the increased sensitivity of mev T cells to apoptosis following TCR restimulation appears to reflect a TCR-driven phenomenon mediated through up-regulation of ******Fas-Fas ligand****** ***interaction*** and induction of the Fas signaling cascade .	parallel	1
3301	10352257	959;958	CD40L;CD40	In the APC-Th cell interaction , p40 mRNA accumulation in APC was shown to be up-regulated by stimulation with ***CD40*** ***ligand*** ( ***CD40L*** ) on Th cells .	parallel	1
3302	10352257	959;958	CD40L;CD40	However , the ******CD40-CD40L****** ***interaction*** scarcely induced p35 mRNA accumulation in APC .	parallel	1
3303	10352257	959;3592	CD40L;p35	However , the ***CD40-CD40L*** interaction scarcely ***induced*** ***p35*** mRNA accumulation in APC .	target	1
3304	10352257	958;3592	CD40;p35	However , the ***CD40-CD40L*** interaction scarcely ***induced*** ***p35*** mRNA accumulation in APC .	target	1
3305	10352267	973;974	Ig alpha;Ig beta	Furthermore , ******Ig alpha/Ig beta****** ***complexes*** in which the immunoreceptor tyrosine-based activation motif tyrosines of Ig alpha were mutated were also incapable of accessing the MIIC or of facilitating the presentation of Ag .	parallel	1
3306	10352279	940;3558	CD28;IL-2	***CD28*** costimulation ***augments*** ***IL-2*** secretion of activated lamina propria T cells by increasing mRNA stability without enhancing IL-2 gene transactivation .	positive	0
3307	10352284	4261;942	CIITA;CD86	These data suggest that if ***CIITA*** and ***CD86*** ***cooperate*** , enhanced tumor immunity could be achieved .	parallel	0
3308	10352287	959;958	CD40 ligand;CD40	******CD40-CD40 ligand****** ***interaction*** is central to cell-mediated immunity against Toxoplasma gondii : patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer .	parallel	1
3309	10352287	958;959	CD40;CD40L	We demonstrate that ******CD40-CD40L****** ***interaction*** in humans is critical for generation of the IL-12 / IFN-gamma immune response against Toxoplasma gondii .	parallel	1
3310	10352287	958;959	CD40;CD40L	******CD40-CD40L****** ***signaling*** was required for optimal T cell production of IFN-gamma in response to T. gondii .	parallel	0
3311	10352287	959;958	CD40L;CD40	Not only was IL-12 production in response to T. gondii dependent on ******CD40-CD40L****** ***signaling*** , but also , patients with HIGM syndrome exhibited deficient in vitro secretion of this cytokine in response to the parasite .	parallel	0
3312	10352303	958;7124	CD40;TNF-alpha	By also measuring TNF-alpha levels , specificity of cytokine regulation was observed ; while ***anti-CD40*** and CTLA-4-Fc ***reduced*** IL-10 and ***TNF-alpha*** levels , anti-CD23 did not affect TNF-alpha while attenuating IL-10 generation .	negative	1
3313	10352342	7157;578	p53;BAK	Thus , wild-type ***p53*** ***induces*** ***BAK*** and CD95 expression in human glioma cells without enhancing their susceptibility to CD95-mediated apoptosis , and mutant p53 modulates CD95L-evoked apoptotic signalling in a gain-of-function fashion up-stream and down-stream of caspase 3 activation .	target	1
3314	10352342	7157;355	p53;CD95	Thus , wild-type ***p53*** ***induces*** BAK and ***CD95*** expression in human glioma cells without enhancing their susceptibility to CD95-mediated apoptosis , and mutant p53 modulates CD95L-evoked apoptotic signalling in a gain-of-function fashion up-stream and down-stream of caspase 3 activation .	target	1
3315	10352342	7157;578	p53;BAK	***p53*** ***enhances*** ***BAK*** and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis .	positive	0
3316	10352342	7157;355	p53;CD95	***p53*** ***enhances*** BAK and ***CD95*** expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis .	positive	0
3317	10352342	356;355	CD95L;CD95	The temperature-sensitive murine p53val135 mutant was introduced into 3 human malignant glioma cell lines to examine the effects of the p53 status on BCL-2 family protein expression , CD95 expression , and sensitivity to ***CD95*** ***ligand*** ( ***CD95L*** ) - induced apoptosis .	parallel	1
3318	10352357	3553;7124	IL-1beta;TNFalpha	The addition of ***IL-1beta*** resulted in an increase in the release of IL-6 and MCP-1 , similar to that observed with LPS stimulation , but failed to ***increase*** the production of ***TNFalpha*** .	positive	0
3319	10352357	3553;6348	IL-1beta;MIP-1alpha	***MIP-1alpha*** production was only marginally ***enhanced*** by ***IL-1beta*** .	positive	0
3320	10353405	2208;3565	CD23;IL-4	The upregulation of ***CD23*** ***correlates*** with greater ***IL-4*** activity in the culture supernatant of MCNS peripheral blood lymphocytes ( PBLs ) than normal PBLs stimulated by mitogens , as assessed by the CD23-inducing effect of the PBL supernatant on tonsillar B cells .	parallel	0
3321	10353468	3596;7412	IL-13;VCAM-1	In this study we found IL-4 to induce both intercellular cell adhesion molecule-1 ( ICAM-1 ) and VCAM-1 expression , whereas ***IL-13*** ***induced*** ***VCAM-1*** only .	target	1
3322	10353474	308;5321	Annexin V;cPLA2	We report that ***Annexin V*** ***modulates*** the activity of cPKCs as well as of ***cPLA2*** by interfering with their ability to bind to negatively charged phospholipids and calcium .	target	0
3323	10353605	2885;6464	Grb2;Shc	We also found that ShcdeltaCH1 could associate with p185 * ; however , this association did not interfere with the endogenous Shc-p185 * interaction or the ******Shc-Grb2****** ***interaction*** .	parallel	1
3324	10353694	1437;2822	GM-CSF;PLD	Taken together the data indicate that ***GM-CSF*** rapidly ***activates*** ***PLD*** in adherent cells , which is responsible for the generation of PA .	positive	1
3325	10353695	6776;3960	Stat5a;Gal4	A fusion protein ( Gal4-Stat5 ( 695 ) ) , containing the C-terminal domain of ***Stat5a*** ( amino acids 695-794 ) ***linked*** to the DNA-binding domain of ***Gal4*** ( Gal4 DBD ) , strongly activated transcription of a luciferase reporter gene .	parallel	0
3326	10353724	811;5551	Calreticulin;perforin	These observations open the possibilities that membrane-bound ***Calreticulin*** ***prevents*** hydrophobic entry of ***perforin*** into membranes and ( or ) prevents perforin from assembling into polyperforin pores .	negative	0
3327	10353724	811;5551	Calreticulin;perforin	The calcium-independent ***association*** of ***perforin*** and ***Calreticulin*** prompted our evaluation of Calreticulin 's potential to function as a regulatory molecule that protects cytotoxic lymphocytes from their own perforin .	parallel	0
3328	10353724	5551;811	perforin;Calreticulin	Previously , we found that millimolar levels of calcium in the hemolytic assays dissociate high-affinity perforin-Calreticulin complexes , which makes it unlikely that ***perforin*** ***associates*** with ***Calreticulin*** in solution when hemolysis is blocked .	parallel	0
3329	10353724	811;5551	Calreticulin;perforin	Previously , we found that millimolar levels of calcium in the hemolytic assays dissociate high-affinity ******perforin-Calreticulin****** ***complexes*** , which makes it unlikely that perforin associates with Calreticulin in solution when hemolysis is blocked .	parallel	1
3330	10353724	811;5551	Calreticulin;perforin	***Calreticulin*** may ***affect*** ***perforin*** at the erythrocyte membrane .	target	0
3331	10353729	1029;1019	p16;Cdk4	The ***p16*** protein ***associates*** exclusively with ***Cdk4*** and Cdk6 , inhibiting their complexation with D-type cyclins and the consequent phosphorylation of pRb .	parallel	0
3332	10353729	1029;1021	p16;Cdk6	The ***p16*** protein ***associates*** exclusively with Cdk4 and ***Cdk6*** , inhibiting their complexation with D-type cyclins and the consequent phosphorylation of pRb .	parallel	0
3333	10353845	1475;1508	cystatin A;cathepsin B	In contrast , the N-terminal region is required also for an initial ***binding*** of ***cystatin A*** to ***cathepsin B*** , presumably by promoting the displacement of the occluding loop and allowing facile interaction of the rest of the inhibiting wedge with the active-site cleft of the enzyme .	parallel	1
3334	10354271	3303;596	HSP 72;Bcl2	***HSP 72*** , a known cytoprotectant , ***co-immunoprecipitated*** with ***Bcl2*** , an anti-apoptotic protein .	parallel	1
3335	10354271	3303;596	HSP 72;Bcl2	Prior heat stress markedly increased the ***interaction*** between ***HSP 72*** and ***Bcl2*** .	parallel	1
3336	10354271	3303;596	HSP 72;Bcl2	Novel ***interactions*** between ***HSP 72*** and ***Bcl2*** may be responsible , at least in part , for the protection afforded by prior heat stress against ATP depletion injury .	parallel	1
3337	10354273	3458;941	IFN-gamma;B7-1	***IFN-gamma*** and LPS differentially ***modulate*** class II MHC and ***B7-1*** expression on murine renal tubular epithelial cells .	target	0
3338	10354352	3600;3458	IL-15;interferon gamma	Further , the CTL response to parasite infected target cells as well as the production of ***interferon gamma*** was ***enhanced*** by ***IL-15/TLA*** administration in the alpha - / - mice .	positive	0
3339	10354362	1508;3818	cysteine protease;plasma prekallikrein	On endothelial cells , ***plasma prekallikrein*** is ***activated*** by a membrane-associated ***cysteine protease*** .	positive	1
3340	10354373	6737;973	Ro52;IgA	***Ro52*** ***interacted*** with IgG1 and IgG4 , but not with IgG2 , IgG3 , ***IgA*** or IgM .	parallel	1
3341	10354373	6737;3502	Ro52;IgG3	***Ro52*** ***interacted*** with IgG1 and IgG4 , but not with IgG2 , ***IgG3*** , IgA or IgM .	parallel	1
3342	10354379	3439;4599	IFN-alpha;MxA	The ***IFN-alpha*** produced by cells of patients infected with HIV-1 was able to ***induce*** ***MxA*** protein in human amnions WISH cells but was unable to protect these cells against Vesicular Stomatitis Virus ( VSV ) - induced cytopathic effects .	target	1
3343	10354480	5015;5949	OTX2;IRBP	Here we demonstrate that the human homeodomain protein ***OTX2*** is present in nuclear extracts of IRBP expressing cells and specifically ***interacts*** with the ***IRBP*** A promoter element in vitro .	parallel	1
3344	10354480	1406;5949	CRX;IRBP	OTX2 , as well as ***CRX*** , a homeodomain protein very similar to OTX2 , ***activates*** the human ***IRBP*** promoter in co-transfection experiments .	positive	1
3345	10354480	5015;5949	OTX2;IRBP	***OTX2*** , as well as CRX , a homeodomain protein very similar to OTX2 , ***activates*** the human ***IRBP*** promoter in co-transfection experiments .	positive	1
3346	10354513	3667;3643	IRS-1;insulin receptor	In this model , we have shown that : ( 1 ) lipids were incorporated in treated HepG2 cells , but redistributed differently when compared to treated ZHC cells ; ( 2 ) that insulin signaling events , such as insulin receptor autophosphorylation and the phosphorylation of the major ***insulin receptor*** ***substrate*** ( ***IRS-1*** ) were altered in response to the addition of membrane lipids or cholesterol derived components ; and ( 3 ) different lipids affected insulin receptor signaling differently .	parallel	1
3347	10355595	7124;836	TNF-alpha;caspase-3	DbcAMP also inhibited the ***TNF-alpha/cycloheximide-induced*** ***activation*** of ***caspase-3*** , but it had no effect on the activation of caspase-8 in human neutrophils .	positive	1
3348	10355597	133;1432	adrenomedullin;P38	These results indicate that : ( a ) In rat mesangial cells adrenomedullin-mediated inhibition of [ 3H ] thymidine incorporation and stimulation of nucleosome-associated cytoplasmic DNA fragmentation are sensitive to SB203580 , and ( b ) ***adrenomedullin*** ***activates*** a ***P38*** MAPK through a wortmannin-sensitive kinase .	positive	1
3349	10355597	133;820	adrenomedullin;cAMP	In cultured rat glomerular mesangial cells ***adrenomedullin*** ***increases*** ***cAMP*** , decreases proliferation and increases apoptosis .	positive	0
3350	10355629	1605;1756	beta-dystroglycan;dystrophin	Targeted mutagenesis of conserved WW domain residues reveals that the ******dystrophin/beta-dystroglycan****** ***interaction*** occurs primarily through the WW domain of dystrophin .	parallel	1
3351	10355633	3553;351	IL-1beta;PN-II	Neither serum depletion - nor ***IL-1beta-induced*** ***stimulation*** of extracellular ***PN-II*** accumulation were accompanied by obvious alteration of the levels of APP mRNA and cellular APP holoprotein , suggesting that the enhanced extracellular accumulation of PN-II might result from up-regulation of the secretory pathway of APP .	positive	0
3352	10355820	83992;7124	ORF4;TNF-alpha	End-phosphorothioated ***ORF4*** ( ORF4-PE ) significantly ***reduced*** ***TNF-alpha*** mRNA levels by greater than 80 % ( p < 0.001 ) and protein levels by 60 % ( p < 0.001 ) in U937 cells .	negative	1
3353	10355820	83992;7124	ORF4;TNF-alpha	***ORF4-PE*** ***reduced*** newly synthesized ***TNF-alpha*** protein levels by > 80 % in lipopolysaccharide ( LPS ) - stimulated human macrophages , by greater than 60 % in phorbol myristate acetate/phyto-hemagglutinin ( PMA/PHA ) - stimulated human peripheral blood mononuclear cells ( PBMC ) , and by approximately 50 % in LPS-stimulated murine monocytes .	negative	1
3354	10355881	796;796	CGRP;calcitonin	Quantitative receptor autoradiography was used to evaluate potential alterations in substance P ( SP ) and ***calcitonin*** gene-related peptide ( ***CGRP*** ) ***binding*** in the L4 spinal segment of rats following unilateral poisoning of the sciatic nerve with pronase .	parallel	1
3355	10356288	847;5595	catalase;ERK1	Addition of extracellular ***catalase*** during ZAS stimulation significantly ***reduced*** the tyrosine phosphorylation response and the activation of ***ERK1*** and ERK2 and their activator MEK1/2 while it did not affect that of p38 MAPK and MKK3/MKK6 .	negative	1
3356	10356288	847;5594	catalase;ERK2	Addition of extracellular ***catalase*** during ZAS stimulation significantly ***reduced*** the tyrosine phosphorylation response and the activation of ERK1 and ***ERK2*** and their activator MEK1/2 while it did not affect that of p38 MAPK and MKK3/MKK6 .	negative	1
3357	10356288	847;5605	catalase;MEK1/2	Addition of extracellular ***catalase*** during ZAS stimulation significantly ***reduced*** the tyrosine phosphorylation response and the activation of ERK1 and ERK2 and their activator ***MEK1/2*** while it did not affect that of p38 MAPK and MKK3/MKK6 .	negative	1
3358	10356295	4902;1103	neurturin;choline acetyltransferase	Here , we report that ***neurturin*** , like GDNF , ***increases*** the ***choline acetyltransferase*** activity of normal postnatal motor neurons , induces neurite outgrowth in spinal cord , and potently protects motor neurons from chronic glutamate-mediated degeneration .	positive	0
3359	10356298	1000;5594	N-cadherin;ERK	We have found that ***N-cadherin*** , as well as laminin ( LN ) and basic fibroblast growth factor ( bFGF ) , can ***activate*** ***ERK*** in embryonic chick retinal neurons .	positive	1
3360	10356298	1000;5594	N-cadherin;ERK	We conclude ( 1 ) that ***N-cadherin*** and LN can ***activate*** ***ERK*** in retinal neurons and ( 2 ) that activation of ERK is required for full neurite outgrowth induced by these proteins .	positive	1
3361	10356322	4790;3659	NF-kappaB;IRF-1	We conclude that ***IRF-1*** and ***NF-kappaB*** ***interact*** in vivo , and that this interaction physically bends the indicible nitric oxide synthase promoter DNA .	parallel	1
3362	10356322	4790;3659	NF-kappaB;IRF-1	Co-immunoprecipitation experiments show that ***IRF-1*** and ***NF-kappaB*** ***interact*** in stimulated but not resting cells .	parallel	1
3363	10356322	4790;3659	NF-kappaB;IRF-1	Super-shift experiments show that ***IRF-1*** and ***NF-kappaB*** ***interact*** while binding to their respective DNA binding sites .	parallel	1
3364	10356322	4790;3659	NF-kappaB;IRF-1	These results demonstrate the existence of a physical ***interaction*** between ***IRF-1*** and ***NF-kappaB*** proteins in vivo .	parallel	1
3365	10356322	4790;3659	NF-kappaB;IRF-1	We next suggested that this ***interaction*** between ***IRF-1*** and ***NF-kappaB*** bends the DNA of the iNOS promoter region .	parallel	1
3366	10356357	1437;6776	GM-CSF;STAT5	***Activation*** of a functionally distinct 80-kDa ***STAT5*** isoform by IL-5 and ***GM-CSF*** in human eosinophils and neutrophils .	positive	1
3367	10356357	3567;6776	IL-5;STAT5	***Activation*** of a functionally distinct 80-kDa ***STAT5*** isoform by ***IL-5*** and GM-CSF in human eosinophils and neutrophils .	positive	1
3368	10356357	1437;6776	GM-CSF;STAT5	We show that different ***STAT5*** isoforms are ***activated*** by IL-5 and ***GM-CSF*** in eosinophils , neutrophils , and differentiated eosinophilic HL-60 cells .	positive	1
3369	10356357	3567;6776	IL-5;STAT5	We show that different ***STAT5*** isoforms are ***activated*** by ***IL-5*** and GM-CSF in eosinophils , neutrophils , and differentiated eosinophilic HL-60 cells .	positive	1
3370	10356357	3567;6776	IL-5;STAT5A	Whereas ***IL-5*** ***activated*** the wild-type ***STAT5A*** and STAT5B proteins in HL60-eos cells , a carboxyl-terminally truncated 80-kDa STAT5 isoform was activated in mature eosinophils and neutrophils .	positive	1
3371	10356357	3567;6777	IL-5;STAT5B	Whereas ***IL-5*** ***activated*** the wild-type STAT5A and ***STAT5B*** proteins in HL60-eos cells , a carboxyl-terminally truncated 80-kDa STAT5 isoform was activated in mature eosinophils and neutrophils .	positive	1
3372	10356358	3192;3643	pp120;insulin receptor	Cell adhesion properties and effects on receptor-mediated insulin endocytosis are independent properties of ***pp120*** , a ***substrate*** of the ***insulin receptor*** tyrosine kinase .	parallel	1
3373	10356359	5008;5594	oncostatin M;MAPK2	***Activation*** of Jak-Stat and ***MAPK2*** pathways by ***oncostatin M*** leads to growth inhibition of human glioma cells .	positive	1
3374	10356360	650;4684	bone morphogenetic protein-2;NCAM	Homeobox proteins as signal transduction intermediates in ***regulation*** of ***NCAM*** expression by recombinant human ***bone morphogenetic protein-2*** in osteoblast-like cells .	target	1
3375	10356361	5371;1026	PML;p21	Transcriptional ***activation*** of the cyclin-dependent kinase inhibitor ***p21*** by ***PML/RARalpha*** .	positive	1
3376	10356361	5914;1026	RARalpha;p21	Transcriptional ***activation*** of the cyclin-dependent kinase inhibitor ***p21*** by ***PML/RARalpha*** .	positive	1
3377	10356364	1435;6774	CSF-1;STAT3	***CSF-1-mediated*** ***activation*** of ***STAT3*** was also abrogated in the M1/Y559F cell line .	positive	1
3378	10356400	8878;8737	p62;RIP	The ***interaction*** of ***p62*** with ***RIP*** links the atypical PKCs to NF-kappaB activation .	parallel	1
3379	10356400	3551;4790	IKKbeta;NF-kappaB	The two members of the atypical protein kinase C ( aPKC ) subfamily of isozymes ( zetaPKC and lambda/iotaPKC ) are involved in the ***control*** of nuclear factor kappaB ( ***NF-kappaB*** ) through ***IKKbeta*** activation .	target	0
3380	10356400	8878;8737	p62;RIP	Here we show that the previously described aPKC-binding protein , ***p62*** , selectively ***interacts*** with ***RIP*** but not with TRAF2 in vitro and in vivo .	parallel	1
3381	10356400	7124;4790	TNFalpha;NF-kappaB	Together , these results demonstrate that the interaction of p62 with RIP serves to link the atypical PKCs to the ***activation*** of ***NF-kappaB*** by the ***TNFalpha*** signaling pathway .	positive	1
3382	10356400	8878;8737	p62;RIP	Together , these results demonstrate that the ***interaction*** of ***p62*** with ***RIP*** serves to link the atypical PKCs to the activation of NF-kappaB by the TNFalpha signaling pathway .	parallel	1
3383	10357258	1392;5443	CRF;adrenocorticotropin	***CRF*** ***increased*** ***adrenocorticotropin*** ( ACTH ) secretion from AtT-20 cells , and CRA1000 and CRA1001 inhibited CRF-induced ACTH secretion , concentration-dependently , as did other CRF1 receptor antagonists .	positive	0
3384	10357466	6387;1234	SDF-1;CCR5	All group O isolates tested were efficiently inhibited by ***SDF-1*** or RANTES , the natural ***ligands*** of CXCR4 and ***CCR5*** , respectively .	parallel	1
3385	10357466	6387;7852	SDF-1;CXCR4	All group O isolates tested were efficiently inhibited by ***SDF-1*** or RANTES , the natural ***ligands*** of ***CXCR4*** and CCR5 , respectively .	parallel	1
3386	103576	12;1511	alpha-1-antichymotrypsin;cathepsin G	***Complexes*** of ***alpha-1-antichymotrypsin*** with human chymotrypsin and human leukocyte ***cathepsin G*** are stable in sodium dodecyl sulfate and have molecular weights near 90,000 suggesting 1:1 complex formation on a molar basis between inhibitor and enzyme .	parallel	1
3387	10357789	5320;324	Pla2g2a;Apc	In an attempt to determine the genetic factors implicated in the susceptibility to formation of ACFs , a possible involvement of the adenomatous polyposis gene ( ***Apc*** ) and its ***modifier*** secretory phospholipase A2 ( ***Pla2g2a*** ) was analyzed .	target	0
3388	10357807	965;914	CD58;CD2	The new structural information supports a ' hand-shake ' model of ******CD2-CD58****** ***interaction*** involving the GFCC ' C " faces of both CD2 and CD58 adhesion domains .	parallel	1
3389	10357817	1499;7157	beta-catenin;p53	Excess ***beta-catenin*** ***promotes*** accumulation of transcriptionally active ***p53*** .	positive	0
3390	10357823	2081;610	Ire1p;HAC1	In the yeast Saccharomyces cerevisiae , the bifunctional transmembrane kinase/endoribonuclease ***Ire1p*** ***cleaves*** ***HAC1*** mRNA at both splice junctions and tRNA ligase joins the two exons together .	target	1
3391	10357833	3458;4018	IFN-gamma;lipoprotein	***IFN-gamma*** ***increased*** low density ***lipoprotein*** ( LDL ) - induced cellular CE 2-fold compared to LDL alone .	positive	0
3392	10357834	3949;348	LDL receptor;apoE	***LDL receptor*** ***binds*** newly synthesized ***apoE*** in macrophages .	parallel	1
3393	10357834	348;3949	apoE;LDL receptor	The results of these studies indicated that nascent macrophage-derived ***apoE*** ***binds*** to the ***LDL receptor*** , and that this apoE served as a precursor pool for apoE released into the medium .	parallel	1
3394	10357837	6347;729230	MCP-1;CCR2	The accumulation of monocytes is mediated by the ***interaction*** of locally produced chemoattractant protein-1 ( ***MCP-1*** ) with its receptor ***CCR2*** .	parallel	1
3395	10357838	336;3990	ApoA-II;hepatic lipase	In summary , these results strongly suggest that ***ApoA-II*** is a physiological ***inhibitor*** of ***hepatic lipase*** and that this is at least part of the mechanism whereby ApoA-II maintains HDL cholesterol levels .	negative	1
3396	10357844	5360;4018	PLTP;lipoprotein	The plasma phospholipid transfer protein ( ***PLTP*** ) is an important ***regulator*** of high density ***lipoprotein*** ( HDL ) metabolism .	target	1
3397	10357875	3952;969	leptin;CD69	Moreover , ***leptin*** ***increases*** the expression of the early activation marker ***CD69*** in monocytes but not in lymphocytes .	positive	0
3398	10357879	820;5599	cAMP;JNK	***DB-cAMP*** also ***blocked*** PMA-induced ***JNK*** activation .	negative	0
3399	10357882	355;5599	Fas;JNK	We recently observed that in T lymphocytes ***Fas*** strongly ***induced*** activation of ***JNK*** ( c-Jun N-terminal kinase ) but not of second messengers leading to activation of ERK ( extracellular regulated kinase ) .	target	1
3400	10357882	5604;5594	MEK1;ERK	This was confirmed in the current study by showing that activation of ***MEK1*** , the upstream ***regulator*** of ***ERK*** , reduces Fas-mediated apoptosis , whereas inhibition of MEK1 augments apoptosis by Fas .	target	1
3401	10357921	356;355	Fas ligand;Fas	CONCLUSIONS : These results strongly suggest that ******Fas/Fas ligand****** ***interaction*** mediates the liver injury during allograft rejection .	parallel	1
3402	10358028	7421;85329	VDR;GRIP-1	Compared with the ***interaction*** of ***VDR*** with RXR or ***GRIP-1*** , the differentiation dose-response most closely correlated to the ligand-dependent recruitment of the DRIP coactivator complex to VDR and to the ability of the receptor to activate transcription in a cell-free system .	parallel	1
3403	10358032	8737;4790	RIP;NF-kappaB	Previous studies have shown that ***RIP*** ***mediates*** TNF-induced activation of the anti-apoptotic ***NF-kappaB*** pathway .	target	0
3404	10358044	328;3725	Redox factor-1;AP-1	***Redox factor-1*** ( Ref-1 ) ***mediates*** the activation of ***AP-1*** in HeLa and NIH 3T3 cells in response to heat shock .	target	0
3405	10358044	328;3725	Ref-1;AP-1	Electrophoretic mobility shift assay extracts immunodepleted of Ref-1 protein demonstrated that the increase in AP-1 DNA-binding activity following heating was dependent upon the presence of Ref-1 and that ***Ref-1*** ***regulates*** inducible , but not basal , ***AP-1*** DNA-binding activity .	target	1
3406	10358045	3815;4254	c-Kit;SCF	Stem cell factor ( ***SCF*** ) and its tyrosine kinase ***receptor*** , ***c-Kit*** , play a crucial role in regulating migration and proliferation of melanoblasts , germ cells , and hemopoietic cell progenitors by activating a number of intracellular signaling molecules .	parallel	1
3407	10358050	8178;7157	ELL;p53	Our observations indicate the existence of a mutually inhibitory interaction between p53 and a general transcription elongation factor ELL and raise the possibility that an aberrant ***interaction*** between ***p53*** and ***ELL*** may play a role in the genesis of leukemias carrying MLL-ELL gene translocations .	parallel	1
3408	10358050	7157;8178	p53;ELL	Physical ***interaction*** and functional antagonism between the RNA polymerase II elongation factor ***ELL*** and ***p53*** .	parallel	1
3409	10358050	8178;7157	ELL;p53	Thus , ***ELL*** acts as a negative ***regulator*** of ***p53*** in transcription .	negative	1
3410	10358050	7157;8178	p53;ELL	Conversely , ***p53*** ***inhibits*** the transcription elongation activity of ***ELL*** , suggesting that p53 is capable of regulating general transcription by RNA polymerase II through controlling the ELL activity .	negative	1
3411	10358050	7157;1026	p53;p21	Elevated levels of ELL in cells resulted in the inhibition of ***p53-dependent*** ***induction*** of endogenous ***p21*** and substantially protected cells from p53-mediated apoptosis that is induced by genotoxic stress .	target	1
3412	10358067	8839;632	CTGF-L;osteocalcin	In addition , recombinant human ***CTGF-L*** ***inhibits*** ***osteocalcin*** production in rat osteoblast-like Ros 17/2 .8 cells .	negative	1
3413	10358076	2308;3484	FKHR;insulin-like growth factor-binding protein-1	Reporter gene studies in HepG2 hepatoma cells show that ***FKHR*** ***stimulates*** ***insulin-like growth factor-binding protein-1*** promoter activity through an IRS , and introduction of IRSs confers this effect on a heterologous promoter .	positive	0
3414	10358076	2308;207	FKHR;PKB	Antisense studies indicate that ***FKHR*** contributes to basal promoter function and is required to ***mediate*** effects of insulin and ***PKB*** on promoter activity via an IRS .	target	0
3415	10358076	207;2308	PKB;FKHR	To our knowledge , these results provide the first report that FKHR stimulates promoter activity through an IRS and that ***phosphorylation*** of ***FKHR*** by ***PKB*** mediates effects of insulin on gene expression .	target	1
3416	10358077	3458;836	IFN-gamma;caspase-3	In addition , IFN-gamma/TNF-alpha and ***IL-1alpha/IFN-gamma/TNF-alpha*** ***stimulate*** activation of caspase-8 and ***caspase-3*** , which IL-13 pretreatment was able to partially inhibit and delay .	positive	0
3417	10358077	3458;841	IFN-gamma;caspase-8	In addition , IFN-gamma/TNF-alpha and ***IL-1alpha/IFN-gamma/TNF-alpha*** ***stimulate*** activation of ***caspase-8*** and caspase-3 , which IL-13 pretreatment was able to partially inhibit and delay .	positive	0
3418	10358077	3552;836	IL-1alpha;caspase-3	In addition , IFN-gamma/TNF-alpha and ***IL-1alpha/IFN-gamma/TNF-alpha*** ***stimulate*** activation of caspase-8 and ***caspase-3*** , which IL-13 pretreatment was able to partially inhibit and delay .	positive	0
3419	10358077	3552;841	IL-1alpha;caspase-8	In addition , IFN-gamma/TNF-alpha and ***IL-1alpha/IFN-gamma/TNF-alpha*** ***stimulate*** activation of ***caspase-8*** and caspase-3 , which IL-13 pretreatment was able to partially inhibit and delay .	positive	0
3420	10358077	7124;836	TNF-alpha;caspase-3	In addition , IFN-gamma/TNF-alpha and ***IL-1alpha/IFN-gamma/TNF-alpha*** ***stimulate*** activation of caspase-8 and ***caspase-3*** , which IL-13 pretreatment was able to partially inhibit and delay .	positive	0
3421	10358077	7124;841	TNF-alpha;caspase-8	In addition , IFN-gamma/TNF-alpha and ***IL-1alpha/IFN-gamma/TNF-alpha*** ***stimulate*** activation of ***caspase-8*** and caspase-3 , which IL-13 pretreatment was able to partially inhibit and delay .	positive	0
3422	10358077	3596;2185	IL-13;protein kinase B	***IL-13*** also ***stimulates*** activation of the major PI 3-kinase effector , ***protein kinase B*** .	positive	0
3423	10358077	3596;2185	IL-13;protein kinase B	The PI 3-kinase inhibitors wortmannin and LY294002 inhibit ***IL-13*** ***stimulation*** of ***protein kinase B*** as well as the cell survival effects of IL-13 .	positive	0
3424	10358078	5321;118460	cPLA2;p11	In order to determine if increased p11 protein expression resulted in increased interaction between p11 and cPLA2 , anti-cPLA2 antibodies were used to immunoprecipitate ******p11.cPLA2****** ***complexes*** and Western blots of the immunoprecipitate were used to detect p11 .	parallel	1
3425	10358078	5321;118460	cPLA2;p11	In order to determine if increased p11 protein expression resulted in increased ***interaction*** between ***p11*** and ***cPLA2*** , anti-cPLA2 antibodies were used to immunoprecipitate p11.cPLA2 complexes and Western blots of the immunoprecipitate were used to detect p11 .	parallel	1
3426	10358079	2064;2066	ErbB2;ErbB4	However , neu differentiation factor-induced ***heterodimers*** of ***ErbB2*** and ***ErbB4*** activated Stat5 .	parallel	1
3427	10358079	2064;6777	ErbB2;Stat5	However , neu differentiation factor-induced heterodimers of ***ErbB2*** and ErbB4 ***activated*** ***Stat5*** .	positive	1
3428	10358079	2066;6777	ErbB4;Stat5	However , neu differentiation factor-induced heterodimers of ErbB2 and ***ErbB4*** ***activated*** ***Stat5*** .	positive	1
3429	10358079	6772;1956	Stat1;ErbB1	In A431 cells , ***Stat1*** , Stat3 , and Stat5 , were constitutively ***complexed*** with ***ErbB1*** and rapidly phosphorylated on tyrosine in response to EGF .	parallel	1
3430	10358079	6774;1956	Stat3;ErbB1	In A431 cells , Stat1 , ***Stat3*** , and Stat5 , were constitutively ***complexed*** with ***ErbB1*** and rapidly phosphorylated on tyrosine in response to EGF .	parallel	1
3431	10358079	6777;1956	Stat5;ErbB1	In A431 cells , Stat1 , Stat3 , and ***Stat5*** , were constitutively ***complexed*** with ***ErbB1*** and rapidly phosphorylated on tyrosine in response to EGF .	parallel	1
3432	10358079	5617;6776	prolactin;Stat5a	In contrast to ***prolactin*** , which ***induced*** only Tyr694 phosphorylation of ***Stat5a*** , EGF promoted phosphorylation on Tyr694 and additional tyrosine residue ( s ) .	target	1
3433	10358083	2626;2248	GATA-4;fgf-3	In undifferentiated F9 cells , ***GATA-4*** expression ***stimulates*** the ***fgf-3*** promoter , whereas in differentiated F9 cells already expressing GATA-4 , no further increase in promoter activity was observed .	positive	0
3434	10358088	1956;322	Mena;FE65	Although this single substitution in YAP WW1 domain is sufficient to precipitate the two protein isoforms of ***Mena*** , an in vivo ***ligand*** of ***FE65*** , we showed that an additional substitution , histidine 192 ( betaB7 ) to glycine , significantly increased the ability of YAP to mimic FE65 .	parallel	1
3435	10358091	11097;7514	NLP-1;CRM-1	We show here that ***NLP-1*** , like the previously described Rev-interacting protein hRIP/Rab and several nucleoporins , also ***interacts*** with ***CRM-1*** both in yeast and mammalian cells .	parallel	1
3436	10358095	2033;2113	p300;ets-1	Two regions of ***p300/CBP*** between amino acids ( a.a. ) 328 and 596 and a. a. 1678 and 2370 independently can ***interact*** with ***ets-1*** and ets-2 in vitro and in vivo .	parallel	1
3437	10358095	2033;2114	p300;ets-2	Two regions of ***p300/CBP*** between amino acids ( a.a. ) 328 and 596 and a. a. 1678 and 2370 independently can ***interact*** with ets-1 and ***ets-2*** in vitro and in vivo .	parallel	1
3438	10358095	2114;2033	ets-2;p300	The LXXLL sequence , reported to be important in receptor-coactivator interactions , does not appear to play a role in the ***interaction*** of ***ets-2*** with ***p300/CBP*** .	parallel	1
3439	10358137	3821;3824	NKG2A;CD94	Taken together , these results suggest that the ******CD94/NKG2A****** receptor ***complex*** is the major known inhibitory receptor for class I ( Qa1b ) molecules on developing fetal NK cells .	parallel	1
3440	10358138	3824;4068	NK cell receptor;SAP	Cutting edge : human 2B4 , an activating ***NK cell receptor*** , ***recruits*** the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein ***SAP*** .	target	0
3441	10358138	3824;5781	NK cell receptor;SHP-2	Cutting edge : human 2B4 , an activating ***NK cell receptor*** , ***recruits*** the protein tyrosine phosphatase ***SHP-2*** and the adaptor signaling protein SAP .	target	0
3442	10358144	959;3458	CD40L;IFN-gamma	The expression of ***CD40L*** inversely ***correlates*** with the secretion of ***IFN-gamma*** after target cell contact ( p = 0.0001 ) , but correlations of CD40L expression and failure to secrete IFN-gamma with EC-selective killing did not reach statistical significance .	negative	0
3443	10358149	3574;3565	IL-7;IL-4	***IL-7*** ***up-regulates*** ***IL-4*** production by splenic NK1 .1 + and NK1 .1 - MHC class I-like/CD1-dependent CD4 + T cells .	positive	1
3444	10358150	3458;5696	IFN-gamma;LMP7	Consistent with these observations we show that ***up-regulation*** of ***LMP7*** by ***IFN-gamma*** enhances presentation of the VIYQYMDDL epitope .	positive	1
3445	10358152	4067;930	Lyn;CD19	Subsequently , Src-family PTKs , particularly ***Lyn*** , are proposed to ***phosphorylate*** and bind ***CD19*** , a cell-surface costimulatory molecule that regulates mature B cell activation .	target	1
3446	10358152	930;4067	CD19;Lyn	In wild-type B cells , ***CD19*** was constitutively ***complexed*** with Vav , ***Lyn*** , and other Src-family PTKs , with CD19 phosphorylation and its associations with Lyn and Vav increased after BCR ligation .	parallel	1
3447	10358152	930;4067	CD19;Lyn	Constitutive ******CD19/Lyn/Vav****** complex ***signaling*** may therefore be responsible for the establishment of baseline signaling thresholds in B cells before Ag receptor ligation , in addition to accelerating signaling following BCR engagement or other transmembrane signals .	parallel	0
3448	10358152	930;4067	CD19;Lyn	Thus , constitutive and induced ******CD19/Lyn****** ***complexes*** are likely to regulate basal signaling thresholds and BCR signaling by amplifying the kinase activity of Lyn and other Src-family PTKs .	parallel	1
3449	10358153	867;1399	Cbl;CrkL	A specific protein kinase C ( PKC ) inhibitor ( GF-109203X ) reversed the effect of PMA on tyrosine phosphorylation of Cbl and restored the activation-dependent ***association*** of ***Cbl*** with PI3-K and ***CrkL*** .	parallel	0
3450	10358153	5578;867	PKCalpha;Cbl	We also provide evidence that ***PKCalpha*** and PKCtheta can physically ***associate*** with ***Cbl*** and are able to phosphorylate it in vitro and in vivo .	parallel	0
3451	10358155	940;1432	CD28;p38 alpha	In both Th1 and Th2 cells , ***CD28*** signaling ***activated*** ***p38 alpha*** and was required for cytokine production .	positive	1
3452	10358155	940;1432	CD28;p38 alpha	Using purified human CD4 + peripheral blood T cells , we show that ***CD28*** stimulation alone ***activates*** p38 alpha mitogen-activated protein kinase ( ***p38 alpha*** ) .	positive	1
3453	10358157	3700;7852	gp120;chemokine receptor 4	Inhibition of tyrosine kinase activation blocks the ***down-regulation*** of CXC ***chemokine receptor 4*** by HIV-1 ***gp120*** in CD4 + T cells .	negative	1
3454	10358158	7535;27040	ZAP-70;LAT	These findings provide evidence that c-Cbl is involved in the negative ***regulation*** of the phosphorylation of ***LAT*** and SLP-76 by ***ZAP-70*** .	negative	1
3455	10358158	7535;3937	ZAP-70;SLP-76	These findings provide evidence that c-Cbl is involved in the negative ***regulation*** of the phosphorylation of LAT and ***SLP-76*** by ***ZAP-70*** .	negative	1
3456	10358158	867;27040	c-Cbl;LAT	These findings provide evidence that ***c-Cbl*** is involved in the negative ***regulation*** of the phosphorylation of ***LAT*** and SLP-76 by ZAP-70 .	negative	1
3457	10358158	867;3937	c-Cbl;SLP-76	These findings provide evidence that ***c-Cbl*** is involved in the negative ***regulation*** of the phosphorylation of LAT and ***SLP-76*** by ZAP-70 .	negative	1
3458	10358159	356;355	FasL;Fas	In summary , our data suggest the important regulatory role of cytokine-controlled ******Fas/FasL****** ***interaction*** in the cross-talk between keratinocytes and skin-infiltrating T cells for maintenance of homeostasis in inflammatory skin processes .	parallel	1
3459	10358159	356;355	Fas ligand;Fas	Crosstalk between keratinocytes and T lymphocytes via ******Fas/Fas ligand****** ***interaction*** : modulation by cytokines .	parallel	1
3460	10358159	356;355	FasL;Fas	Apoptosis mediated by ******Fas/FasL****** ***interaction*** plays an important role during many inflammatory skin disorders .	parallel	1
3461	10358159	3586;356	IL-10;FasL	Stimulation of the cells with IL-6 , IL-10 , IL-12 , TGF-beta1 , and GM-CSF did not modulate the constitutive FasL expression , but IFN-gamma-mediated ***FasL*** up-regulation was significantly ***diminished*** by ***IL-10*** and TGF-beta1 , respectively .	negative	0
3462	10358159	7040;356	TGF-beta1;FasL	Stimulation of the cells with IL-6 , IL-10 , IL-12 , TGF-beta1 , and GM-CSF did not modulate the constitutive FasL expression , but IFN-gamma-mediated ***FasL*** up-regulation was significantly ***diminished*** by IL-10 and ***TGF-beta1*** , respectively .	negative	0
3463	10358163	973;974	Igalpha;Igbeta	The BCR enters the class II-containing compartment as an intact ******mIg/Igalpha/Igbeta****** ***complex*** bound to Ag .	parallel	1
3464	10358164	3821;3824	NKG2-A;CD94	******CD94/NKG2-A****** inhibitory ***complex*** blocks CD16-triggered Syk and extracellular regulated kinase activation , leading to cytotoxic function of human NK cells .	parallel	1
3465	10358164	3821;3824	NKG2-A;CD94	The ******CD94/NKG2-A****** ***complex*** is the inhibitory receptor for the nonclassical MHC class I molecule HLA-E on human NK cells .	parallel	1
3466	10358164	3821;3824	NKG2-A;CD94	Both tyrosine phosphorylation and activation of Syk kinase together with tyrosine phosphorylation of CD16 receptor zeta subunit are markedly inhibited by the coengagement of ******CD94/NKG2-A****** ***complex*** .	parallel	1
3467	10358164	6464;2885	Shc;Grb-2	The block of ERK activation is exerted at an early , PTK-dependent stage in the events leading to p21ras activation , as the CD16-induced tyrosine phosphorylation of Shc adaptor protein and the formation of ******Shc/Grb-2****** ***complex*** are abrogated by CD94/NKG2-A simultaneous engagement .	parallel	1
3468	10358169	2534;10657	Fyn;Sam68	***Fyn*** membrane localization is necessary to ***induce*** the constitutive tyrosine phosphorylation of ***Sam68*** in the nucleus of T lymphocytes .	target	1
3469	10358173	3558;3659	IL-2;IRF-1	Furthermore , ***IL-2*** and IL-12 synergistically ***induced*** ***IRF-1*** , whereas IFN-alpha and IL-12 did not .	target	1
3470	10358173	6775;3659	STAT4;IRF-1	First , STAT4 was required for the IL-12-dependent transactivation of an IRF-1 reporter construct , and second , ***STAT4*** ***binding*** to the ***IRF-1*** promoter was shown using EMSA .	parallel	1
3471	10358186	356;355	CD95L;APO-1	Induction of antitumor immunity with ***Fas/APO-1*** ***ligand*** ( ***CD95L*** ) - transfected neuroblastoma neuro-2a cells .	parallel	1
3472	10358186	356;355	FasL;Fas	Fas/APO-1 ( CD95 ) - ***Fas*** ***ligand*** ( ***FasL*** ) system has been implicated in the suppression and stimulation of immune responses .	parallel	1
3473	10358194	728;719	C5aR;C3aR	***C3aR*** internalization is a rapid negative control mechanism and is ***influenced*** by the ***C5aR*** pathway .	target	0
3474	10358194	719;718	C3aR;C3a	The ***C3a*** ***receptor*** ( ***C3aR*** ) is expressed on most human peripheral blood leukocytes with the exception of resting lymphocytes , implying a much higher pathophysiological relevance of the anaphylatoxin C3a as a proinflammatory mediator than previously thought .	parallel	1
3475	10358195	3458;3394	IFN-gamma;ICSBP	Like induction of leishmaniacidal activity , LPS and ***IFN-gamma*** synergize to ***induce*** ***ICSBP*** mRNA and protein .	target	1
3476	10358195	3458;3394	IFN-gamma;ICSBP	These findings extend in a significant way our understanding of the ***regulation*** of ***ICSBP*** by LPS and ***IFN-gamma*** and provide important clues as to its role in macrophage activation .	target	1
3477	10358200	3929;929	LBP;CD14	Class 1 mAbs blocked the binding of LPS to LBP ; class 2 mAbs blocked the ***binding*** of ***LPS/LBP*** complexes to ***CD14*** ; class 3 mAbs bound LBP but did not suppress LBP activity .	parallel	1
3478	10358200	3929;929	LBP;CD14	These results show that the neutralization of LBP accomplished by blocking either the binding of LPS to LBP or the ***binding*** of ***LPS/LBP*** complexes to ***CD14*** protects the host from LPS-induced toxicity , confirming that LBP is a critical component of innate immunity .	parallel	1
3479	10358206	3558;7852	IL-2;CXCR4	Progesterone treatment had no effect on constitutive expression of CCR5 and CXCR4 by nonactivated T cells and macrophages , but significantly inhibited ***IL-2-induced*** ***up-regulation*** of CCR5 and ***CXCR4*** on activated T cells ( p < 0.05 ) .	positive	1
3480	10358762	4049;7132	LT-alpha;CD120a	Four members of the tumor necrosis factor ( TNF ) ligand family , TNF-alpha , ***LT-alpha*** , LT-beta , and LIGHT , ***interact*** with four receptors of the TNF/nerve growth factor family , the p55 TNF receptor ( ***CD120a*** ) , the p75 TNF receptor ( CD120b ) , the lymphotoxin beta receptor ( LT beta R ) , and herpes virus entry mediator ( HVEM ) to control a wide range of innate and adaptive immune response functions .	parallel	1
3481	10358762	4049;8764	LT-alpha;HVEM	Four members of the tumor necrosis factor ( TNF ) ligand family , TNF-alpha , ***LT-alpha*** , LT-beta , and LIGHT , ***interact*** with four receptors of the TNF/nerve growth factor family , the p55 TNF receptor ( CD120a ) , the p75 TNF receptor ( CD120b ) , the lymphotoxin beta receptor ( LT beta R ) , and herpes virus entry mediator ( ***HVEM*** ) to control a wide range of innate and adaptive immune response functions .	parallel	1
3482	10358762	4049;4055	LT-alpha;LT beta R	Four members of the tumor necrosis factor ( TNF ) ligand family , TNF-alpha , ***LT-alpha*** , LT-beta , and LIGHT , ***interact*** with four receptors of the TNF/nerve growth factor family , the p55 TNF receptor ( CD120a ) , the p75 TNF receptor ( CD120b ) , the lymphotoxin beta receptor ( ***LT beta R*** ) , and herpes virus entry mediator ( HVEM ) to control a wide range of innate and adaptive immune response functions .	parallel	1
3483	10358762	7124;7132	TNF-alpha;CD120a	Four members of the tumor necrosis factor ( TNF ) ligand family , ***TNF-alpha*** , LT-alpha , LT-beta , and LIGHT , ***interact*** with four receptors of the TNF/nerve growth factor family , the p55 TNF receptor ( ***CD120a*** ) , the p75 TNF receptor ( CD120b ) , the lymphotoxin beta receptor ( LT beta R ) , and herpes virus entry mediator ( HVEM ) to control a wide range of innate and adaptive immune response functions .	parallel	1
3484	10358762	7124;8764	TNF-alpha;HVEM	Four members of the tumor necrosis factor ( TNF ) ligand family , ***TNF-alpha*** , LT-alpha , LT-beta , and LIGHT , ***interact*** with four receptors of the TNF/nerve growth factor family , the p55 TNF receptor ( CD120a ) , the p75 TNF receptor ( CD120b ) , the lymphotoxin beta receptor ( LT beta R ) , and herpes virus entry mediator ( ***HVEM*** ) to control a wide range of innate and adaptive immune response functions .	parallel	1
3485	10358762	7124;4055	TNF-alpha;LT beta R	Four members of the tumor necrosis factor ( TNF ) ligand family , ***TNF-alpha*** , LT-alpha , LT-beta , and LIGHT , ***interact*** with four receptors of the TNF/nerve growth factor family , the p55 TNF receptor ( CD120a ) , the p75 TNF receptor ( CD120b ) , the lymphotoxin beta receptor ( ***LT beta R*** ) , and herpes virus entry mediator ( HVEM ) to control a wide range of innate and adaptive immune response functions .	parallel	1
3486	10359010	4790;4609	NF-kappaB;c-Myc	Thus , ***NF-kappaB*** ***cooperates*** with ***c-Myc*** in promoting murine hepatocyte survival in a manner independent of p53 tumor suppressor activity .	parallel	0
3487	10359014	3725;2355	c-Jun;Fra-2	Here , we report that the transcriptional activity of ******Fra-2/c-Jun****** ***heterodimer*** was greatly enhanced by cotransfecting a constitutively active mutant of MEK1 gene ( MEK-DD ) into F9 cells , indicating that Fra-2 was converted into an active transactivator after phosphorylation by MAPK .	parallel	1
3488	10359075	351;43	Abeta;AChE	Stable ******AChE-Abeta****** ***complexes*** were found to be more toxic than those formed without the enzyme , for Abeta1-40 and Abeta1-42 , but not for amyloid fibrils formed with AbetaVal18-Ala , a synthetic variant of the Abeta1-40 peptide .	parallel	1
3489	10359075	351;43	Abeta;AChE	Of all the ******AChE-Abeta****** ***complexes*** tested the one containing the Abeta1-40 peptide was the most toxic .	parallel	1
3490	10359100	5788;3577	CD45;CXCR1	***CD45*** ***modulation*** of ***CXCR1*** and CXCR2 in human polymorphonuclear leukocytes .	target	0
3491	10359100	5788;3579	CD45;CXCR2	***CD45*** ***modulation*** of CXCR1 and ***CXCR2*** in human polymorphonuclear leukocytes .	target	0
3492	10359104	3565;3456	interleukin-4;IFN-beta	Its expression could be blocked in the presence of either anti-IFN-beta or ***interleukin-4*** , which ***down-regulates*** the endogenous ***IFN-beta*** production .	negative	1
3493	10359140	1029;1019	CDKN2;Cyclin-dependent kinase 4	***Cyclin-dependent kinase 4*** ***inhibitor*** ( ***CDKN2/p16*** ) is a cell cycle regulatory protein that has been demonstrated to be inactivated by mutations , deletions or transcriptional silencing during pathogenesis of a variety of human malignancies .	negative	1
3494	10359205	940;941	CD28;B7-1	Human natural killer cells were found to express ***CD28*** , a ***receptor*** for ***B7-1*** .	parallel	1
3495	10359315	5080;6908	Pax-6;TBP	In the present study it was shown that ***Pax-6*** ***interacted*** with the ***TBP*** , the DNA-binding subunit of general transcription complex TFIID .	parallel	1
3496	10359324	3557;3383	IL-1ra;ICAM-1	***IL-1ra-induced*** ***suppression*** of ***ICAM-1*** expression was accompanied by a profound decrease in corneal leukocytic infiltration by 44.6 % at day 1 ( P < 0.003 ) , 71.8 % at day 3 ( P < 0.001 ) , 60.1 % at day 7 ( P < 0.001 ) , and 63.8 % at day 14 ( P < 0.001 ) , compared with control corneas .	negative	1
3497	10359333	356;355	FasL;Fas	The role of ***Fas*** ***ligand*** ( ***FasL*** ) molecule in HFRPE-mediated apoptosis was assessed by using a mutant Jkt cell line ( DD3 ) , which is deficient in Fas-mediated signaling .	parallel	1
3498	10359456	4790;5966	NF-kappaB;Rel	Transient expression assays with NF-kappaB/Rel binding sites linked to the chloramphenicol acetyltransferase gene suggest that the PWM-induced increase in transcription is mediated by the ******NF-kappaB/Rel****** transcription factor ***complex*** .	parallel	1
3499	10359565	387;373156	RhoA;GST	Constitutively activated ***RhoA*** , loaded with [ gamma-32P ] GTP , directly ***interacted*** with ***GST-IL-1Rcd*** in a filter-binding assay .	parallel	1
3500	10359574	2885;7132	Grb2;TNFR-I	The ******TNFR-I/Grb2****** ***interaction*** is essential for the TNF-alpha-dependent activation of c-Raf-1 kinase ; activation of c-Raf-1 kinase by TNF-alpha can be blocked by coexpression of Grb2 mutants harboring inactivating point mutations in the NH2 - or COOH-terminal SH3 domain , cell-permeable peptides that disrupt the Grb2/TNFR-I interaction or transdominant negative Ras .	parallel	1
3501	10359574	2885;7132	Grb2;TNFR-I	Functionality of the ******TNFR-I/Grb2/SOS****** / Ras ***interaction*** is a prerequisite but not sufficient for TNF-alpha-dependent activation of c-Raf-1 kinase .	parallel	1
3502	10359574	7124;6610	TNF-alpha;neutral sphingomyelinase	Inhibition of the TNFR-I/FAN ( factor associated with neutral sphingomyelinase ) interaction , which is essential for ***TNF-alpha-dependent*** ***activation*** of the ***neutral sphingomyelinase*** , either by cell-permeable peptides or by deletion of the FAN binding domain , prevents activation of c-Raf-1 kinase .	positive	1
3503	10359574	2885;7132	Grb2;TNFR-I	In conclusion , ***binding*** of the ***Grb2*** adapter protein via its COOH-terminal SH3 domain to the nontyrosine kinase receptor ***TNFR-I*** results in activation of a signaling cascade known so far to be initiated , in the case of the tyrosine kinase receptors , by binding of the SH2 domain of Grb2 to phosphotyrosine .	parallel	1
3504	10359574	7124;7132	TNF-alpha;TNFR-I	Recently , c-Raf-1 kinase was identified as an intracellular target of a signal transduction cascade initiated by ***binding*** of ***TNF-alpha*** to ***TNFR-I*** .	parallel	1
3505	10359575	2204;973	FcalphaRI;hIgA	Nevertheless , they are functionally distinct in that ***FcalphaRI*** ***binds*** human IgA ( ***hIgA*** ) but not bovine IgG2 ( bIgG2 ) , whereas bFcgamma2R binds bIgG2 but not hIgA .	parallel	1
3506	10359581	23643;7099	MD-2;TLR4	***MD-2*** is physically ***associated*** with ***TLR4*** on the cell surface and confers responsiveness to LPS .	parallel	0
3507	10359610	5883;3364	hRAD9;hHUS1	We show here that the human checkpoint control protein ***hRAD9*** physically ***associates*** with two other checkpoint control proteins , hRAD1 and ***hHUS1*** .	parallel	0
3508	10359610	5883;5810	hRAD9;hRAD1	We show here that the human checkpoint control protein ***hRAD9*** physically ***associates*** with two other checkpoint control proteins , ***hRAD1*** and hHUS1 .	parallel	0
3509	10359611	5524;7431	PP2A;Vimentin	Taken together these data show that , in mammalian fibroblasts , the intermediate filament protein ***Vimentin*** is ***dephosphorylated*** by ***PP2A*** , an event targeted by B55 .	target	1
3510	10359611	5515;7431	PP2Ac;Vimentin	Both biochemical fractionation and immunofluorescence analysis of detergent-extracted cells revealed that fractions of ***PP2Ac*** , PR65 , and B55 were tightly ***associated*** with ***Vimentin*** .	parallel	0
3511	10359616	2078;7402	ets-related;utrophin	Using this region of the utrophin promoter for DNA affinity purification , immunoblots , in vitro kinase assays , electrophoretic mobility shift assays , and in vitro expression in cultured muscle cells , we demonstrate that ***ets-related*** GA-binding protein alpha/beta transcription factors are ***activators*** of the ***utrophin*** promoter .	positive	1
3512	10359656	196;1543	aryl hydrocarbon receptor;CYP1A1	Dietary flavonols quercetin and kaempferol are ligands of the ***aryl hydrocarbon receptor*** that ***affect*** ***CYP1A1*** transcription differentially .	target	0
3513	10359657	4843;859	NOS;caveolin 3	The ***association*** of ***NOS*** II with ***caveolin 3*** might have implications for the regulation of contraction of , and/or glucose uptake by , slow-twitch muscle fibres .	parallel	0
3514	10359664	1017;4082	Cdk2;MARCKS	In contrast , ***phosphorylation*** of ***MARCKS*** by ***Cdk2*** did not significantly affect further phosphorylation by PKC .	target	1
3515	10359664	983;4082	Cdk1;MARCKS	We established that Cdk2 , Cdk4 and , to a smaller extent , ***Cdk1*** that have been immunoprecipitated from cellular extracts ***phosphorylate*** ***MARCKS*** .	target	1
3516	10359668	4311;821	neprilysin;calnexin	***Interaction*** of mammalian ***neprilysin*** with binding protein and ***calnexin*** in Schizosaccharomyces pombe .	parallel	1
3517	10359668	4311;3309	NEP;BiP	The ***interactions*** of ***NEP*** with ***BiP*** and Cnx1p were , however , more refractive to the same stresses .	parallel	1
3518	10359698	4838;5308	Nodal;Pitx2	This indicates a gene cascade relationship in the propagation of left-right information , whereby ***Nodal*** ***activates*** ***Pitx2*** on the left through a double-negative mechanism involving the repression of SnR 's repressor role on Pitx2 .	positive	1
3519	10359702	207;4790	Akt;NF-kappaB	***Induction*** of ***NF-kappaB*** by the ***Akt/PKB kinase*** .	target	1
3520	10359702	5170;4790	PKB kinase;NF-kappaB	***Induction*** of ***NF-kappaB*** by the ***Akt/PKB kinase*** .	target	1
3521	10359735	2152;7035	tissue factor;tissue factor pathway inhibitor	Heightened ***tissue factor*** ***associated*** with ***tissue factor pathway inhibitor*** and prognosis in patients with unstable angina .	parallel	0
3522	10359792	4084;4149	Mad;Max	A specific histone deacetylase , Rpd3 , interacts with a variety of sequence-specific transcriptional repressors , including ******Mad-Max****** ***heterodimers*** and members of the nuclear receptor superfamily .	parallel	1
3523	10359806	3627;2833	IP-10;CXCR3	In the brain , the CCR5 ligand , MIP-1alpha , was strongly associated with microglia/macrophages , and the ***CXCR3*** ***ligand*** , ***IP-10*** , was expressed by astrocytes in MS lesions but not unaffected white matter of control or MS subjects .	parallel	1
3524	10359809	4067;207	Lyn;Akt	***Lyn*** ***inhibited*** ***Akt/PKB*** additively with an okadaic acid-sensitive endogenous phosphatase ( s ) .	negative	1
3525	10359809	4067;207	Lyn;Akt	Negative ***regulation*** of ***Akt/PKB*** by ***Lyn*** was not dependent on the protein phosphatases SHP-1 , SHP-2 , or SHIP .	negative	1
3526	10359817	1029;7157	P19;p53	Taken together , ***P19*** ( ARF ) could ***stabilize*** ***p53*** by inhibiting the nuclear export of Mdm2 .	positive	0
3527	10359817	1029;7157	P19;p53	***P19*** ( ARF ) ***stabilizes*** ***p53*** by blocking nucleo-cytoplasmic shuttling of Mdm2 .	positive	0
3528	10359817	4193;7157	Mdm2;p53	Whereas p16 ( INK4a ) restrains cell growth through preventing phosphorylation of the retinoblastoma protein , P19 ( ARF ) acts by attenuating ***Mdm2-mediated*** ***degradation*** of ***p53*** , thereby stabilizing p53 .	negative	1
3529	10359817	1029;4193	P19;Mdm2	We show here that coexpression of ***P19*** ( ARF ) ***blocks*** the nucleo-cytoplasmic shuttling of ***Mdm2*** .	negative	0
3530	10359821	5663;4851	presenilin-1;Notch-1	Proteolytic release and nuclear translocation of ***Notch-1*** are ***induced*** by ***presenilin-1*** and impaired by pathogenic presenilin-1 mutations .	target	1
3531	10359822	6772;9021	STAT-1;SOCS-3	Thus , LIF-stimulated ***SOCS-3*** gene expression is at least in part ***mediated*** by STAT-3 and ***STAT-1*** .	target	0
3532	10359822	6774;9021	STAT-3;SOCS-3	Thus , LIF-stimulated ***SOCS-3*** gene expression is at least in part ***mediated*** by ***STAT-3*** and STAT-1 .	target	0
3533	10359822	9021;3976	SOCS-3;LIF	Pituitary corticotroph ***SOCS-3*** is a novel intracellular ***regulator*** of leukemia inhibitory factor ( ***LIF*** ) - mediated proopiomelanocortin gene expression and adrenocorticotropic hormone ( ACTH ) secretion , inhibiting LIF-activated Janus kinase-signal transducers and activators of transcription ( STAT ) signaling in a negative autoregulatory loop .	target	1
3534	10359822	3976;9021	LIF;SOCS-3	A STAT-1/STAT-3 binding element , located at nucleotides -72 to -64 , was essential for ***LIF*** ***stimulation*** of ***SOCS-3*** promoter activity .	positive	0
3535	10359836	3553;3952	IL-1;Leptin	***Leptin*** actions on food intake and body temperature are ***mediated*** by ***IL-1*** .	target	0
3536	10359895	5451;3567	Oct1;IL-5	CONCLUSION : We suggest that ***Oct1*** , YY1 , and octamer-like factors binding to the -90 / -79 sequence within the proximal IL-5 promoter are involved in ***suppression*** of ***IL-5*** transcription in T cells .	negative	1
3537	10359895	3567;5451	hIL-5;Oct1	We show that the BR3 sequence contains a novel negative regulatory element located at positions -90 to -79 of the ***hIL-5*** promoter , which ***binds*** ***Oct1*** , octamer-like , and YY1 nuclear factors .	parallel	1
3538	10360183	1024;3960	CDK8;GAL4	***GAL4*** is ***regulated*** by the RNA polymerase II holoenzyme-associated cyclin-dependent protein kinase ***SRB10/CDK8*** .	target	1
3539	10360378	2623;7490	transcription factor GATA-1;WT1	***WT1*** transcription is ***regulated*** in erythroid and myeloid lineages by the ***transcription factor GATA-1*** .	target	1
3540	10360383	7066;4352	thrombopoietin;Mpl	The recently defined ligand for the ***Mpl*** ***receptor*** , ***thrombopoietin*** ( TPO ) , has been found to be the principal regulatory cytokine of megakaryocytopoiesis .	parallel	1
3541	10360579	998;10188	Cdc42;ACK	Structure of the small G protein ***Cdc42*** ***bound*** to the GTPase-binding domain of ***ACK*** .	parallel	1
3542	10360628	3458;811	interferon-gamma;cC1qR	The results demonstrate that the expression of both ***cC1qR*** and gC1qR by bone marrow vascular endothelial cells is ***up-regulated*** by inflammatory mediators , ***interferon-gamma*** , tumor necrosis factor-alpha , and lipopolysaccharide ( Escherichia coli , 055 : B5 ) in a dose - and time-dependent manner , as detected by enzyme-linked immunosorbent assay .	positive	1
3543	10360628	3458;708	interferon-gamma;gC1qR	The results demonstrate that the expression of both cC1qR and ***gC1qR*** by bone marrow vascular endothelial cells is ***up-regulated*** by inflammatory mediators , ***interferon-gamma*** , tumor necrosis factor-alpha , and lipopolysaccharide ( Escherichia coli , 055 : B5 ) in a dose - and time-dependent manner , as detected by enzyme-linked immunosorbent assay .	positive	1
3544	10360628	7124;811	tumor necrosis factor-alpha;cC1qR	The results demonstrate that the expression of both ***cC1qR*** and gC1qR by bone marrow vascular endothelial cells is ***up-regulated*** by inflammatory mediators , interferon-gamma , ***tumor necrosis factor-alpha*** , and lipopolysaccharide ( Escherichia coli , 055 : B5 ) in a dose - and time-dependent manner , as detected by enzyme-linked immunosorbent assay .	positive	1
3545	10360628	7124;708	tumor necrosis factor-alpha;gC1qR	The results demonstrate that the expression of both cC1qR and ***gC1qR*** by bone marrow vascular endothelial cells is ***up-regulated*** by inflammatory mediators , interferon-gamma , ***tumor necrosis factor-alpha*** , and lipopolysaccharide ( Escherichia coli , 055 : B5 ) in a dose - and time-dependent manner , as detected by enzyme-linked immunosorbent assay .	positive	1
3546	10360640	3569;8731	HGF;Met	***Activation*** of ***Met*** by its ligand ***HGF*** has been shown to elicit both mitogenic and motogenic responses in thyrocytes in vitro .	positive	1
3547	10360643	25;4609	v-abl;c-myc	Exogenous ALA induced the accumulation of substantial concentrations of PpIX in fibrosarcoma cells , and in immortalized fibroblasts transfected with the oncogene ***c-myc*** , IGF-1 receptor , IGF-1 and its ***receptor*** , v-fos , v-raf , v-Ki-ras , ***v-abl*** , or polyomavirus middle T antigen with G418 resistance selection .	parallel	1
3548	10360653	7157;1026	p53;p21	Ectopic expression of wild-type ***p53*** also ***induces*** ***p21*** , and facilitates boswellic acid-induced apoptosis .	target	1
3549	10360671	3569;7422	IL-6;VEGF	***IL-6*** , besides its thrombopoietic effect , also seems to ***affect*** the amount of ***VEGF*** stored in the platelets .	target	0
3550	10360671	3569;7422	interleukin-6;VEGF	Platelet number and ***interleukin-6*** ***correlate*** with ***VEGF*** but not with bFGF serum levels of advanced cancer patients .	parallel	0
3551	10360671	3569;7422	IL-6;VEGF	Serum ***IL-6*** levels ***correlated*** with platelet count ( r = 0.36 ; P < 10 ( -3 ) ) , with serum ***VEGF*** levels ( r = 0.55 ; P < 10 ( -4 ) ) and with the calculated load of VEGF per platelet ( r = 0.4 ; P = 3 x 10 ( -4 ) ) .	parallel	0
3552	10360681	3297;3308	HSF1;hsp70	Because the heat shock transcription factor ***HSF1*** ***mediates*** the heat-induced transcription of ***hsp70*** , the effect of age on HSF1 was also studied .	target	0
3553	10360790	5970;4790	Rela;Nfkb1	The gel supershift assay with Nfkb1 , Rela and/or Rel antibodies revealed that the specific molecular forms of NF-kappaB activated by radiation in the spleen were Nfkb1 homodimers and ******Nfkb1/Rela****** ***heterodimers*** .	parallel	1
3554	10360829	4804;627	p75NTR;neurotrophin	The low-affinity p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) , a cysteine-rich transmembrane glycoprotein , is frequently expressed in advanced stages of human melanoma , but the biological consequences of this expression are unknown .	parallel	1
3555	10360829	10457;627	transmembrane glycoprotein;neurotrophin	The low-affinity p75 ***neurotrophin*** ***receptor*** ( p75NTR ) , a cysteine-rich ***transmembrane glycoprotein*** , is frequently expressed in advanced stages of human melanoma , but the biological consequences of this expression are unknown .	parallel	1
3556	10360829	10457;4804	transmembrane glycoprotein;p75	The low-affinity ***p75*** neurotrophin ***receptor*** ( p75NTR ) , a cysteine-rich ***transmembrane glycoprotein*** , is frequently expressed in advanced stages of human melanoma , but the biological consequences of this expression are unknown .	parallel	1
3557	10360829	627;4803	neurotrophin;NGF	We also examined these cell lines for presence of TrkA receptor , the high-affinity ***receptor*** for nerve growth factor ( ***NGF*** ) , the prototypic ***neurotrophin*** .	parallel	1
3558	10360838	10531;5173	hMP1;leumorphin	***hMP1*** ***cleaved*** a prodynorphin-derived peptide , ***leumorphin*** , N-terminal to Arg in the monobasic processing site , as evidenced by MALDI-TOF mass spectrometry .	target	1
3559	10360965	952;695	CD38;Bruton's tyrosine kinase	***CD38*** ligation on mouse B cells by CS/2 , an anti-mouse CD38 mAb , ***induces*** proliferation , IL-5 receptor alpha chain expression and tyrosine phosphorylation of ***Bruton's tyrosine kinase*** .	target	1
3560	10360975	3458;6356	IFN-gamma;eotaxin	Although the protective effect of IFN-gamma against allergic inflammation has been assumed to result from its sole regulation of the proliferation of Th2-type T lymphocytes , these results imply that ***IFN-gamma*** can also directly act on stromal cells to ***inhibit*** ***eotaxin*** production and consequently intervene in eosinophil recruitment .	negative	1
3561	10360975	3458;6356	IFN-gamma;eotaxin	Th1-derived cytokine ***IFN-gamma*** is a potent ***inhibitor*** of ***eotaxin*** synthesis in vitro .	negative	1
3562	10360975	3565;6356	IL-4;eotaxin	Inasmuch as Th2-derived cytokine ***IL-4*** has been shown to ***stimulate*** ***eotaxin*** generation , we investigated here the effect of Th1-derived cytokine IFN-gamma on human eotaxin production .	positive	0
3563	10360983	4790;5970	p50;p65	Construction , expression , purification and functional analysis of recombinant NFkappaB ******p50/p65****** ***heterodimer*** .	parallel	1
3564	10360983	4790;5970	p50;p65	The ******p50/p65****** ***heterodimer*** is the most abundant form of the NFkappaB dimers and plays a more elaborate role in gene regulation .	parallel	1
3565	10360983	4790;5970	p50;p65	We report two methods for the large scale expression and purification of recombinant NFkappaB ******p50/p65****** ***heterodimer*** .	parallel	1
3566	10360983	4790;5970	p50;p65	The first utilizes a bacterial double expression vector which contains two ribosomal binding sites to facilitate the coexpression of the polypeptides in the ******p50/p65****** NFkappaB ***heterodimer*** .	parallel	1
3567	10361118	7066;896	Mpl ligand;cyclin D3	***Mpl ligand*** ***enhances*** the transcription of the ***cyclin D3*** gene : a potential role for Sp1 transcription factor .	positive	0
3568	10361130	3578;4790	Interleukin-9;NF-kappaB	***Interleukin-9*** ***regulates*** ***NF-kappaB*** activity through BCL3 gene induction .	target	1
3569	10361130	602;4790	BCL3;NF-kappaB	***BCL3*** encodes a protein with close homology to IkappaB proteins and ***interacts*** with p50 ***NF-kappaB*** homodimers .	parallel	1
3570	10361130	602;958	BCL3;p50	***BCL3*** encodes a protein with close homology to IkappaB proteins and ***interacts*** with ***p50*** NF-kappaB homodimers .	parallel	1
3571	10361130	3578;602	IL-9;BCL3	***BCL3*** ***induction*** by ***IL-9*** was detected as soon as 4 hours after stimulation and appeared to be dependent on the Jak/STAT pathway .	target	1
3572	10361231	3565;3458	IL-4;IFN-gamma	***IL-4*** and IL-10 ***reduced*** the effects of ***IFN-gamma*** on monocytic cells , and both cytokines were additively antagonistic to IFN-gamma in PBMC and THP-1 cells .	negative	1
3573	10361428	185;183	AT1;angiotensin II	The gene encoding ***angiotensin II*** type 1 ***receptor*** ( ***AT1*** ) is mapped on 3q21-q25 region , and a polymorphism , A1166C , is located at 3 ' untranslated region ( UTR ) .	parallel	1
3574	10361858	213;4790	albumin;NFkappaB	Therefore , ***albumin*** ***increased*** ***NFkappaB*** and reduced IkappaB levels in PTC , and MCP-1 expression was dependent on NFkappaB activation .	positive	0
3575	10361858	213;6347	albumin;monocyte chemoattractant protein-1	***Induction*** of ***monocyte chemoattractant protein-1*** by ***albumin*** is mediated by nuclear factor kappaB in proximal tubule cells .	target	1
3576	10361858	213;4790	albumin;NFkappaB	***Activation*** of ***NFkappaB*** by delipidated bovine serum ***albumin*** ( 15 mg/ml ) was detectable within 2 h , maximal after 8 h , and maintained for at least 16 h of continuous exposure .	positive	1
3577	10362102	4790;3383	NF-kappaB;ICAM-1	Synergistic ***induction*** of ***ICAM-1*** expression by cisplatin and 5-fluorouracil in a cancer cell line via a ***NF-kappaB*** independent pathway .	target	1
3578	10362250	3439;5925	IFN-alpha;pRb	Furthermore , we found that ***IFN-alpha*** not only ***suppresses*** the phosphorylation of ***pRb*** , but also alters the phosphorylation and expression of the other pocket proteins p130 and p107 .	negative	1
3579	10362250	5715;1017	p27;Cdk2	Moreover , elevated levels of ***p27*** ***correlated*** with a dissociation of cyclin ***E/Cdk2-GeneGene*** 1 or p107 complexes to yield cyclin E/Cdk2-GeneGene 4 complexes .	parallel	0
3580	10362253	5594;3725	Erk2;AP-1	Overexpression of wild-type Erk2 in Cl 30.7 b cells that contain small amounts of Erks caused a 46.6 - or 138.1-fold increase of AP-1 activity by UVB and UVC , respectively ; introduction of a dominant negative ***Erk2*** into Cl 41 cells significantly ***blocked*** the UV-induced Erks activation as well as the ***AP-1*** activation .	negative	0
3581	10362258	4803;2033	NGF;p300	Transcriptional activity of Sp1 , Sp3 and ***p300*** was specifically ***induced*** by ***NGF*** in a Gal4-fusion assay , indicating that induction of p21 during neuronal differentiation may involve regulation of the activity of these factors by NGF .	target	1
3582	10362258	4803;6670	NGF;Sp3	Transcriptional activity of Sp1 , ***Sp3*** and p300 was specifically ***induced*** by ***NGF*** in a Gal4-fusion assay , indicating that induction of p21 during neuronal differentiation may involve regulation of the activity of these factors by NGF .	target	1
3583	10362259	1499;4316	beta-catenin;matrilysin	Inactivation of the Tcf binding site increased promoter activity and overexpression of the Tcf factor , LEF-1 , significantly downregulated matrilysin promoter activity , suggesting that ***beta-catenin*** ***transactivates*** the ***matrilysin*** promoter by virtue of its ability to abrogate Tcf-mediated repression .	positive	1
3584	10362259	1499;4316	beta-catenin;matrilysin	Because genetic ablation of matrilysin decreases tumor formation in multiple intestinal neoplasia ( Min ) mice , we propose that ***regulation*** of ***matrilysin*** production by ***beta-catenin*** accumulation is a contributing factor to intestinal tumorigenesis .	target	1
3585	10362260	1647;983	Gadd45;Cdc2	Association with Cdc2 and ***inhibition*** of ***Cdc2/Cyclin B1*** kinase activity by the p53-regulated protein ***Gadd45*** .	negative	1
3586	10362260	1647;891	Gadd45;Cyclin B1	Association with Cdc2 and ***inhibition*** of ***Cdc2/Cyclin B1*** kinase activity by the p53-regulated protein ***Gadd45*** .	negative	1
3587	10362260	983;891	Cdc2;Cyclin B1	While inhibitory phosphorylation of Cdc2 and suppression of Cyclin B1 levels are known to be involved in G2 delays after genotoxic stress , Gadd45 has now been found to directly inhibit the activity of ******Cdc2/Cyclin B1****** ***complex*** , while it had no appreciable effect on Cdk2 / Cyclin E activity even at very high levels of Gadd45 .	parallel	1
3588	10362300	3976;51083	Leukemia inhibitory factor;galanin message-associated peptide	***Leukemia inhibitory factor*** ***regulates*** ***galanin/galanin message-associated peptide*** expression in cultured mouse dorsal root ganglia ; with a note on in situ hybridization methodology .	target	1
3589	10362300	3976;51083	Leukemia inhibitory factor;galanin message-associated peptide	These results support the hypothesis that ***Leukemia inhibitory factor*** is an important ***regulator*** of ***galanin/galanin message-associated peptide*** expression following axotomy , and may therefore be involved in the defence mechanisms against neuropathic pain at the level of dorsal root ganglion neurons .	target	1
3590	10362352	10524;602	Tip60;Bcl-3	Furthermore , the histone acetylase ***Tip60*** ***enhances*** ***Bcl-3-p50*** activated transcription through an NF-kappaB binding site , indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappaB driven gene expression .	positive	0
3591	10362352	10524;4790	Tip60;p50	Furthermore , the histone acetylase ***Tip60*** ***enhances*** ***Bcl-3-p50*** activated transcription through an NF-kappaB binding site , indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappaB driven gene expression .	positive	0
3592	10362354	2185;3717	protein kinase B;JAK2	Activation of ***protein kinase B*** ( PKB ) ***required*** ***JAK2*** and was inhibited by dominant-negative phosphatidylinositol 3-kinase ( P13K ) .	target	0
3593	10362354	3717;5595	JAK2;ERK1	Overexpression of ***JAK2*** was sufficient to ***activate*** both protein kinase B ( PKB ) and extracellular regulated kinase-1 ( ***ERK1*** ) .	positive	1
3594	10362354	3717;2185	JAK2;protein kinase B	Overexpression of ***JAK2*** was sufficient to ***activate*** both ***protein kinase B*** ( PKB ) and extracellular regulated kinase-1 ( ERK1 ) .	positive	1
3595	10362355	1399;25	CRKL;BCR/ABL	***CRKL*** ***binds*** directly to ***BCR/ABL*** through its N-terminal SH3 domain , suggesting it may be involved in BCR/ABL signal transduction .	parallel	1
3596	10362357	23624;1956	cbl-3;EGFR	These data demonstrate that ***cbl-3*** , a novel mammalian cbl protein , is a ***regulator*** of ***EGFR*** mediated signal transduction .	target	1
3597	10362515	6667;6688	Sp1;PU.1	This transactivation is mediated through adjacent binding sites rather than through the more distant Sp binding site , suggesting a possible direct ***interaction*** between ***PU.1*** and ***Sp1/3*** .	parallel	1
3598	10362515	6670;695	Sp3;Btk	Expression of Btk was found in ES cells and levels of expression were the same as in ES cells with a targeted deletion of the Sp1 gene , suggesting that ***Sp3*** acts as a positive ***regulator*** of ***Btk*** in vivo , in the absence of Sp1 .	positive	1
3599	10362518	51738;6750	growth hormone releasing peptide;somatostatin	Chimeric peptides consisting of ***growth hormone releasing peptide*** ( GHRP-6 ) ***linked*** to ***somatostatin*** ( 6-11 ) via an amide bond to provide the effector parts of both the peptides were synthesized .	parallel	0
3600	10362531	2357;1432	fMLP;p38	The concentration of SB 203580 that suppresses activation of NADPH oxidase is similar to that which inhibits SAPK2/p38 in vitro , and both ***fMLP*** and PMA ***induce*** an extremely rapid and potent activation of ***SAPK2/p38*** in neutrophils .	target	1
3601	10362531	2357;5600	fMLP;SAPK2	The concentration of SB 203580 that suppresses activation of NADPH oxidase is similar to that which inhibits SAPK2/p38 in vitro , and both ***fMLP*** and PMA ***induce*** an extremely rapid and potent activation of ***SAPK2/p38*** in neutrophils .	target	1
3602	10362533	3553;623	IL-1beta;BDKRB1	***BDKRB1*** mRNA expression in MH-S cells was ***increased*** by ***IL-1beta*** ( 1 , 3 , and 10 ng/ml ) in a time-dependent manner , peaking at 3-4 h by 100-1000 fold .	positive	0
3603	10362540	3316;2670	HSP27;glial fibrillary acidic protein	Here we report that ***HSP27*** like alphaB-crystallin is ***associated*** with ***glial fibrillary acidic protein*** and vimentin intermediate filament networks in unstressed U373MG astrocytoma cells .	parallel	0
3604	10362540	3316;7431	HSP27;vimentin	Here we report that ***HSP27*** like alphaB-crystallin is ***associated*** with glial fibrillary acidic protein and ***vimentin*** intermediate filament networks in unstressed U373MG astrocytoma cells .	parallel	0
3605	10362540	3316;2670	HSP27;GFAP	The transient transfection of GFAP into MCF7 cells was used to show that the induction of a completely separate network of intermediate filaments resulted in the specific ***association*** of the endogenous ***HSP27*** with these new ***GFAP*** filaments .	parallel	0
3606	10362602	7124;5502	TNF-alpha;inhibitor-1	***TNF-alpha*** and insulin , alone and synergistically , ***induce*** plasminogen activator ***inhibitor-1*** expression in adipocytes .	target	1
3607	10362652	2885;6464	Grb2;Shc	***Grb2*** ***association*** with ***Shc*** was demonstrated by blotting Grb2 immunoprecipitates with an anti-Shc antibody .	parallel	0
3608	10362694	3479;5294	IGF-I;PI3K	***IGF-I*** ***activated*** a wortmannin-sensitive ***PI3K*** and its purported effector , the atypical protein kinase C (PKC)-zeta .	positive	1
3609	10362694	3479;5590	IGF-I;protein kinase C (PKC)-zeta	***IGF-I*** ***activated*** a wortmannin-sensitive PI3K and its purported effector , the atypical ***protein kinase C (PKC)-zeta*** .	positive	1
3610	10362713	7124;3569	tumor necrosis factor (TNF)-alpha;IL-6	In contrast , ***tumor necrosis factor (TNF)-alpha*** ( 200 U/ml ) ***induced*** ***IL-6*** at the protein and mRNA levels in both airway epithelial cells and lung fibroblasts .	target	1
3611	10362723	7124;6347	TNF-alpha;MCP-1	The results support the hypothesis that ***TNF-alpha*** ***mediates*** cristobalite-induced ***MCP-1*** and MIP-2 expression through the generation of ROS .	target	0
3612	10362723	7124;2920	TNF-alpha;MIP-2	The results support the hypothesis that ***TNF-alpha*** ***mediates*** cristobalite-induced MCP-1 and ***MIP-2*** expression through the generation of ROS .	target	0
3613	10362724	2017;4638	cortactin;myosin light chain kinase	***Regulation*** of endothelial cell ***myosin light chain kinase*** by Rho , ***cortactin*** , and p60 ( src ) .	target	1
3614	10362724	7984;4638	p60;myosin light chain kinase	***Regulation*** of endothelial cell ***myosin light chain kinase*** by Rho , cortactin , and ***p60*** ( src ) .	target	1
3615	10362724	91807;2017	MLCK;cortactin	Immunoprecipitation of EC MLCK after DPV challenge revealed dramatic time-dependent tyrosine phosphorylation of the kinase in association with increased MLCK activity and a stable ***association*** of ***MLCK*** with the p85 actin-binding protein ***cortactin*** and p60 ( src ) .	parallel	0
3616	10362724	91807;7984	MLCK;p60	Immunoprecipitation of EC MLCK after DPV challenge revealed dramatic time-dependent tyrosine phosphorylation of the kinase in association with increased MLCK activity and a stable ***association*** of ***MLCK*** with the p85 actin-binding protein cortactin and ***p60*** ( src ) .	parallel	0
3617	10362724	7984;2017	p60;cortactin	These studies indicate that DPV activates the endothelial contractile apparatus in a Rho GTPase-dependent fashion and suggests that ***p60*** ( src ) - induced tyrosine ***phosphorylation*** of MLCK and ***cortactin*** may be important features of contractile complex assembly .	target	1
3618	10362724	7984;91807	p60;MLCK	These studies indicate that DPV activates the endothelial contractile apparatus in a Rho GTPase-dependent fashion and suggests that ***p60*** ( src ) - induced tyrosine ***phosphorylation*** of ***MLCK*** and cortactin may be important features of contractile complex assembly .	target	1
3619	10362800	7124;1520	TNF-alpha;cathepsin S	***TNF-alpha*** ***induced*** ***cathepsin S*** , MMP-1 , -3 , and -9 mRNA expression in a dose-dependent manner : the maximal effect was observed at a concentration of 10 ng/ml , with appreciable increases observed at concentrations of 0.1 to 1.0 ng/ml .	target	1
3620	10363677	3659;3456	interferon regulatory factor-1;IFN-beta	***IFN-beta*** expression can be ***activated*** by ***interferon regulatory factor-1*** ( IRF-1 ) and interferon-stimulated gene factor 3gamma ( ISGF3gamma ) .	positive	1
3621	10363677	3659;3620	IRF-1;IDO	It has been described that ***IRF-1*** can ***induce*** ***IDO*** gene expression .	target	1
3622	10363677	7124;3620	TNF-alpha;IDO	Infection of synovial fibroblasts alone in the absence of exogenous cytokine induced the expression of ***IDO*** mRNA which was ***enhanced*** by ***TNF-alpha*** treatment .	positive	0
3623	10363755	5054;3952	PAI-1;leptin	In postmenopausal females , a significant ***association*** between ***leptin*** and low tPA activity/high ***PAI-1*** activity was seen after adjustment for age and BMI ( P < 0.05 ) .	parallel	0
3624	10363755	5054;5327	PAI-1;tPA	In postmenopausal females , a significant ***association*** between leptin and low ***tPA*** activity/high ***PAI-1*** activity was seen after adjustment for age and BMI ( P < 0.05 ) .	parallel	0
3625	10363755	5327;3952	tPA;leptin	In postmenopausal females , a significant ***association*** between ***leptin*** and low ***tPA*** activity/high PAI-1 activity was seen after adjustment for age and BMI ( P < 0.05 ) .	parallel	0
3626	10363899	356;7124	FasL;TNF-alpha	Bacterial translocation and systemic endotoxemia have been reported after a burn injury , and Caspase-3 activation due to ***TNF-alpha*** and Fas ***ligand*** ( ***FasL*** ) are presumed to initiate apoptosis .	parallel	1
3627	10363928	7432;51083	VIP;Galanin	Addition of ***VIP*** or forskolin to the culture medium reduced Galanin mRNA expression by 75 % and 77 % , respectively , and ***reduced*** ***Galanin*** peptide expression by 76 % and 82 % , respectively , compared with ganglia cultured in control medium .	negative	1
3628	10363971	5728;207	PTEN;Akt	***Regulation*** of ***Akt/PKB*** activity , cellular growth , and apoptosis in prostate carcinoma cells by ***MMAC/PTEN*** .	target	1
3629	10363976	1029;1021	p16INK4a;Cdk4/6	To address this , we synthesized a peptidyl mimetic of the ***Cdk4/6*** ***inhibitor*** , ***p16INK4a*** that contained an NH2-terminal TAT protein transduction domain .	negative	1
3630	10363999	4087;4088	Smad2;Smad3	TGF-beta1-mediated receptor activation ***induces*** phosphorylation of ***Smad2*** and ***Smad3*** , which form complexes with Smad4 , that translocate to the nucleus to regulate transcription of target genes .	target	1
3631	10363999	4088;4087	Smad3;Smad2	TGF-beta1-mediated receptor activation ***induces*** phosphorylation of ***Smad2*** and ***Smad3*** , which form complexes with Smad4 , that translocate to the nucleus to regulate transcription of target genes .	target	1
3632	10364070	4023;7124	LPL;TNFalpha	Taken together , these data suggest that ( 1 ) differentiation of human monocytes to MDMs is associated with increased LPL-induced TNFalpha mRNA expression and production , ( 2 ) a protein kinase C-dependent pathway is involved in the ***induction*** of ***TNFalpha*** by ***LPL*** in these cells , and ( 3 ) LPL effect is mediated by cell surface proteoglycans .	target	1
3633	10364072	3565;6778	IL-4;Stat6	***IL-4*** also ***induced*** prolonged activation of ***Stat6*** , which was contingent on the continuous presence of IL-4 .	target	1
3634	10364076	6720;336	SREBP-1;ApoA-II	***SREBP-1*** mutants lacking the activation domain bind to their cognate sites and directly ***repress*** the ***ApoA-II*** promoter whereas mutants defective in DNA binding indirectly repress the ApoA-II promoter activity , possibly by a squelching mechanism .	positive	1
3635	10364076	6720;336	SREBP-1;ApoA-II	SREBP-1 binds to multiple sites and transactivates the human ApoA-II promoter in vitro : ***SREBP-1*** mutants defective in DNA binding or transcriptional activation ***repress*** ***ApoA-II*** promoter activity .	positive	1
3636	10364076	6720;336	SREBP-1;ApoA-II	***SREBP-1*** binds to multiple sites and ***transactivates*** the human ***ApoA-II*** promoter in vitro : SREBP-1 mutants defective in DNA binding or transcriptional activation repress ApoA-II promoter activity .	positive	1
3637	10364076	6720;336	SREBP-1;ApoA-II	Transient cotransfection experiments in HepG2 cells showed that ***SREBP-1*** ***transactivated*** the -911 / 29 ***ApoA-II*** promoter 3.5-fold as well as truncated ApoA-II promoter segments that contain 1 , 2 , 3 , or 4 SREBP binding sites .	positive	1
3638	10364076	6720;336	SREBP-1;ApoA-II	Despite the strong ***transactivation*** of the ***ApoA-II*** promoter by ***SREBP-1*** we could not demonstrate significant changes on the endogenous ApoA-II mRNA levels of HepG2 cells after cotransfection with SREBP-1 or in the presence or absence of cholesterol and 25-OH-cholesterol .	positive	1
3639	10364076	6720;336	SREBP-1;ApoA-II	An ***SREBP-1*** mutant lacking the amino-terminal activation domain bound normally to its cognate sites and ***repressed*** the ***ApoA-II*** promoter activity .	positive	1
3640	10364076	6720;336	SREBP-1;ApoA-II	Overall , the findings suggest that the wild-type ***SREBP-1*** can ***bind*** and transactivate efficiently the ***ApoA-II*** promoter in cell culture .	parallel	1
3641	10364093	4018;5054	lipoprotein;PAI-1	The consistent positive correlation between triglyceride and plasminogen activator inhibitor-1 ( PAI-1 ) levels in plasma and the fact that very low density ***lipoprotein*** ( VLDL ) ***induces*** secretion of ***PAI-1*** from cultured human umbilical vein endothelial cells ( HUVECs ) and human hepatoblastoma cells have raised the question of whether fibrate treatment , the main effect of which is a profound lowering of plasma concentrations of VLDL , might improve fibrinolytic function by reducing the plasma levels of PAI-1 .	target	1
3642	10364155	355;355	CD95;Fas	Both p53 and ******CD95/Fas****** ***signaling*** have been implicated in c-Myc-induced apoptosis but neither was required for c-Myc-induced cytochrome c release .	parallel	0
3643	10364157	6688;2623	PU.1;GATA-1	We find that ***PU.1*** ***interacts*** directly with ***GATA-1*** , a zinc finger transcription factor required for erythroid differentiation .	parallel	1
3644	10364157	6688;2623	PU.1;GATA-1	***Interaction*** between ***PU.1*** and ***GATA-1*** requires intact DNA-binding domains in both proteins .	parallel	1
3645	10364159	2475;1978	mTOR;4E-BP1	Taken together , our results suggest that ***4E-BP1*** ***phosphorylation*** by ***FRAP/mTOR*** on Thr-37 and Thr-46 is a priming event for subsequent phosphorylation of the carboxy-terminal serum-sensitive sites .	target	1
3646	10364159	2475;1978	mTOR;4E-BP1	***FRAP/mTOR*** has been reported to ***phosphorylate*** ***4E-BP1*** directly in vitro .	target	1
3647	10364159	2475;1978	mTOR;4E-BP1	To address these questions , a recombinant ***FRAP/mTOR*** protein and a FRAP/mTOR immunoprecipitate were utilized in in vitro kinase assays to ***phosphorylate*** ***4E-BP1*** .	target	1
3648	10364170	9267;375	sec7;ARF1	Physical ***interaction*** of the ***sec7*** domain with an ***ARF1*** mutant was demonstrated , but it was much weaker than that of the cytohesin-1 sec7 domain with the same ARF protein .	parallel	1
3649	10364173	4792;4790	IkappaB-alpha;NF-kappaB	Moreover , IGF-II induced , through a PI 3-kinase-dependent pathway , a decrease in IkappaB-alpha protein content that correlated with a decrease in the amount of ***IkappaB-alpha*** ***associated*** with p65 ***NF-kappaB*** .	parallel	0
3650	10364179	836;637	caspase-3;Bid	caspase-8 and ***caspase-3*** ***cleaved*** ***Bid*** , a proapoptotic Bcl-2 family member , which gains cytochrome c releasing activity in response to caspase cleavage .	target	1
3651	10364179	841;637	caspase-8;Bid	***caspase-8*** and caspase-3 ***cleaved*** ***Bid*** , a proapoptotic Bcl-2 family member , which gains cytochrome c releasing activity in response to caspase cleavage .	target	1
3652	10364184	6550;4036	NHE3;megalin	When immunoprecipitations were performed using either 10A3 or anti-NHE3 mAb 2B9 after separation of solubilized renal proteins by sucrose velocity gradient centrifugation , we found that NHE3 exists in two states with distinct sedimentation coefficients , a 9.6 S megalin-free form and a 21 S megalin-bound form , and that when ***NHE3*** ***assembles*** with ***megalin*** , epitopes within the carboxyl-terminal 131 amino acids of NHE3 are blocked .	parallel	1
3653	10364187	3952;5465	leptin;peroxisome proliferator-activated receptor (PPAR)-alpha	***leptin*** significantly lowered the mRNA of leptin and fatty acid synthase of adipocytes ( FAS ) ( p < 0.05 ) , and ***up-regulated*** the mRNA of ***peroxisome proliferator-activated receptor (PPAR)-alpha*** , carnitine palmitoyl transferase-1 , ( CPT-1 ) , and acyl CoA oxidase ( ACO ) ( p < 0.05 ) .	positive	1
3654	10364189	6532;821	SERT;calnexin	Functional expression of the unglycosylated SERT mutant , SERT-QQ , was also increased on co-expression of calnexin , suggesting that the ***interaction*** between ***calnexin*** and ***SERT*** is not entirely dictated by the N-glycan .	parallel	1
3655	10364189	821;811	calnexin;calreticulin	A physical ***interaction*** between ***Myc-SERT-calnexin*** and ***Myc-SERT-calreticulin*** was demonstrated by co-immunoprecipitation .	parallel	1
3656	10364189	821;6532	calnexin;SERT	A physical ***interaction*** between ***Myc-SERT-calnexin*** and ***Myc-SERT-calreticulin*** was demonstrated by co-immunoprecipitation .	parallel	1
3657	10364189	6532;811	SERT;calreticulin	A physical ***interaction*** between Myc-SERT-calnexin and ******Myc-SERT-calreticulin****** was demonstrated by co-immunoprecipitation .	parallel	1
3658	10364201	821;6521	Calnexin;AE1	The results show that the ***interaction*** of ***Calnexin*** with the polytopic membrane glycoprotein ***AE1*** was dependent on the presence but not the location of the oligosaccharide .	parallel	1
3659	10364201	821;6521	Calnexin;AE1	Furthermore , ***Calnexin*** was ***associated*** with ***AE1*** after release of AE1 from the translocation machinery .	parallel	0
3660	10364219	10928;5898	RLIP76;Ral	The Ral effector protein ***RLIP76*** ( also called RIP/RalBP1 ) ***binds*** to ***Ral.GTP*** via a region that shares no sequence homology with the Ras-binding domains of the Ser/Thr kinase c-Raf-1 and the Ral-specific guanine nucleotide exchange factors .	parallel	1
3661	10364242	8915;4790	CLAP;NF-kappaB	***CLAP*** , a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway , ***regulates*** ***NF-kappaB*** activation and apoptosis .	target	1
3662	10364245	1401;1432	CRP;p38 MAP kinase	Impressively , ***CRP-mediated*** ***inhibition*** of ***p38 MAP kinase*** activity correlated with CRP-mediated inhibition of fMLP-induced chemotaxis ( r = -0.7144 ) .	negative	1
3663	10364245	1401;1432	C-reactive protein;p38 mitogen-activated protein kinase	***C-reactive protein*** ***inhibits*** chemotactic peptide-induced ***p38 mitogen-activated protein kinase*** activity and human neutrophil movement .	negative	1
3664	10364245	1401;1432	CRP;p38 MAP kinase	More importantly , ***CRP*** ***inhibited*** fMLP-induced ***p38 MAP kinase*** activity in a concentration-dependent manner as measured by an in vitro kinase assay .	negative	1
3665	10364250	5915;3486	RARbeta;IGFBP-3	By using an RARalpha-selective antagonist ( Ro 41-5253 ) , we demonstrated that RARbeta expression was induced by atRA through an RARalpha-dependent signaling pathway and that ***RARbeta*** induction was ***correlated*** with ***IGFBP-3*** induction .	parallel	0
3666	10364250	5915;3486	RARbeta;IGFBP-3	On the other hand , antisense ***RARbeta*** cDNA transfection of MCF-7 cells ***blocked*** atRA-induced ***IGFBP-3*** expression , indicating that RARbeta is directly involved in the mediation of IGFBP-3 induction by atRA .	negative	0
3667	10364250	3486;5915	IGFBP-3;RARbeta	By ***linking*** ***IGFBP-3*** to ***RARbeta*** , our experiments define the signal intersection between the retinoid and IGF systems in cell growth regulation and explain why loss of RARbeta might be critical in breast cancer carcinogenesis/progression .	parallel	0
3668	10364266	5864;115827	Rab3a;Rab3c	Binding constants for the ***interaction*** of the GTP-bound forms of ***Rab3a*** , Rab3b , ***Rab3c*** , and Rab3d with Rabphilin3 were comparable ( Kd = 10-20 nM ) .	parallel	1
3669	10364266	5865;5864	Rab3b;Rab3a	Binding constants for the ***interaction*** of the GTP-bound forms of ***Rab3a*** , ***Rab3b*** , Rab3c , and Rab3d with Rabphilin3 were comparable ( Kd = 10-20 nM ) .	parallel	1
3670	10364266	5865;115827	Rab3b;Rab3c	Binding constants for the ***interaction*** of the GTP-bound forms of Rab3a , ***Rab3b*** , ***Rab3c*** , and Rab3d with Rabphilin3 were comparable ( Kd = 10-20 nM ) .	parallel	1
3671	10364266	9545;5864	Rab3d;Rab3a	Binding constants for the ***interaction*** of the GTP-bound forms of ***Rab3a*** , Rab3b , Rab3c , and ***Rab3d*** with Rabphilin3 were comparable ( Kd = 10-20 nM ) .	parallel	1
3672	10364266	9545;5865	Rab3d;Rab3b	Binding constants for the ***interaction*** of the GTP-bound forms of Rab3a , ***Rab3b*** , Rab3c , and ***Rab3d*** with Rabphilin3 were comparable ( Kd = 10-20 nM ) .	parallel	1
3673	10364266	9545;115827	Rab3d;Rab3c	Binding constants for the ***interaction*** of the GTP-bound forms of Rab3a , Rab3b , ***Rab3c*** , and ***Rab3d*** with Rabphilin3 were comparable ( Kd = 10-20 nM ) .	parallel	1
3674	10364284	79966;920	sCD4;CD4	A soluble form of the ***CD4*** ***receptor*** ( ***sCD4*** ) can either enhance or inhibit the infection of cells by simian immunodeficiency virus ( SIV ) and human immunodeficiency virus .	parallel	1
3675	10364288	10044;1981	NSP3;eIF4GI	***NSP3*** also ***interacts*** with the translation initiation factor ***eIF4GI*** and competes with the poly ( A ) binding protein .	parallel	1
3676	10364292	1025;904	CDK9;cyclin T1	Rodent ( mouse and Chinese hamster ) cyclin T1 is defective in Tat binding and transactivation , but hamster ***CDK9*** ***interacts*** with human ***cyclin T1*** to give active TAK in hybrid cells containing human chromosome 12 .	parallel	1
3677	10364318	4049;8764	lymphotoxin-alpha;HveA	Inhibition of herpes simplex virus gD and ***lymphotoxin-alpha*** ***binding*** to ***HveA*** by peptide antagonists .	parallel	1
3678	10364318	8764;4049	HveA;LT-alpha	When we analyzed these peptides for the ability to interfere with ***HveA*** ***binding*** to its natural ligand ***LT-alpha*** , we found that BP-1 inhibited the interaction of cellular LT-alpha with HveA .	parallel	1
3679	10364318	4049;8764	LT-alpha;HveA	When we analyzed these peptides for the ability to interfere with HveA binding to its natural ligand LT-alpha , we found that BP-1 inhibited the ***interaction*** of cellular ***LT-alpha*** with ***HveA*** .	parallel	1
3680	10364318	1978;4049	BP-1;LT-alpha	When we analyzed these peptides for the ability to interfere with HveA binding to its natural ligand LT-alpha , we found that ***BP-1*** ***inhibited*** the interaction of cellular ***LT-alpha*** with HveA .	negative	1
3681	10364370	821;811	calnexin;calreticulin	Stable ***complexes*** between G1-G2 and ***calnexin*** or ***calreticulin*** could be immunoprecipitated after solubilization of virus-infected BHK21 cells with the detergents digitonin or Triton X-100 .	parallel	1
3682	10364424	5075;2303	PAX1;MFH1	Notochord-dependent expression of ***MFH1*** and ***PAX1*** ***cooperates*** to maintain the proliferation of sclerotome cells during the vertebral column development .	parallel	0
3683	10364424	2303;5075	MFH1;PAX1	Thus , both the ***MFH1*** and the ***PAX1*** gene products ***cooperate*** to mediate Sonic hedgehog-dependent proliferation of sclerotome cells .	parallel	0
3684	10364428	4254;3815	stem cell factor;c-kit	The Sl locus encodes ***stem cell factor*** ( SCF ) , which is the ***ligand*** of ***c-kit*** , a receptor tyrosine kinase encoded by the W locus .	parallel	1
3685	10364447	5443;4792	alpha-melanocyte-stimulating hormone;IkappaBalpha	***alpha-melanocyte-stimulating hormone*** ***inhibits*** NF-kappaB activation and ***IkappaBalpha*** degradation in human glioma cells and in experimental brain inflammation .	negative	1
3686	10364447	5443;4790	alpha-melanocyte-stimulating hormone;NF-kappaB	***alpha-melanocyte-stimulating hormone*** ***inhibits*** ***NF-kappaB*** activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation .	negative	1
3687	10364447	5443;4790	alpha-MSH;NF-kappaB	Electrophoretic mobility shift assays of nuclear extracts from A-172 cells and whole mouse brains stimulated with LPS revealed that ***alpha-MSH*** does ***suppress*** ***NF-kappaB*** activation .	negative	1
3688	10364455	7040;5706	TGFbeta;p44	***TGFbeta*** ***induced*** ***p42/p44*** MAP kinase activities .	target	1
3689	10364461	7341;989	Smt3;Cdc3	***Smt3*** , a SUMO-1 homolog , is ***conjugated*** to ***Cdc3*** , a component of septin rings at the mother-bud neck in budding yeast .	parallel	1
3690	10364461	7341;989	Smt3;Cdc3	Thus , we conclude that ***Smt3*** was ***conjugated*** to ***Cdc3*** in septin rings localized at the mother-bud neck .	parallel	1
3691	10364466	4145;4067	CHK;Lyn	***CHK*** ***down-regulates*** SCF/KL-activated ***Lyn*** kinase activity in Mo7e megakaryocytic cells .	negative	1
3692	10364466	4145;4067	CHK;Lyn	Taken together , these findings show that ***CHK*** is able to ***down-regulate*** SCF/KL-stimulated ***Lyn*** activity in megakaryocytes .	negative	1
3693	10364477	10544;5624	protein C receptor;protein C	The endothelial cell ***protein C receptor*** ( EPCR ) functions as a primary ***receptor*** for ***protein C*** activation on endothelial cells in arteries , veins , and capillaries .	parallel	1
3694	10364477	10544;5624	EPCR;protein C	These results indicate that ***EPCR*** functions as an important ***regulator*** for the ***protein C*** pathway in various types of vessels .	target	1
3695	10364484	7852;920	CXCR4;CD4	A mechanism of resistance to HIV-1 entry : inefficient ***interactions*** of ***CXCR4*** with ***CD4*** and gp120 in macrophages .	parallel	1
3696	10364484	7852;3700	CXCR4;gp120	A mechanism of resistance to HIV-1 entry : inefficient ***interactions*** of ***CXCR4*** with CD4 and ***gp120*** in macrophages .	parallel	1
3697	10364484	7852;920	CXCR4;CD4	To test the hypothesis that inefficient ***interactions*** of ***CXCR4*** with ***CD4*** and gp120 could affect HIV-1 entry , we incubated macrophages , monocytes , and lymphocytes with gp120 and coimmunoprecipitated CD4 by using anti-CXCR4 antibodies .	parallel	1
3698	10364484	7852;3700	CXCR4;gp120	To test the hypothesis that inefficient ***interactions*** of ***CXCR4*** with CD4 and ***gp120*** could affect HIV-1 entry , we incubated macrophages , monocytes , and lymphocytes with gp120 and coimmunoprecipitated CD4 by using anti-CXCR4 antibodies .	parallel	1
3699	10364484	920;7852	CD4;CXCR4	Overexpression of CD4 in macrophages resulted in detection of CD4-CXCR4 and ******gp120-CD4-CXCR4****** ***complexes*** in parallel with the restoration of macrophage fusion susceptibility .	parallel	1
3700	10364484	3700;920	gp120;CD4	Overexpression of CD4 in macrophages resulted in detection of CD4-CXCR4 and ******gp120-CD4-CXCR4****** ***complexes*** in parallel with the restoration of macrophage fusion susceptibility .	parallel	1
3701	10364484	3700;7852	gp120;CXCR4	Overexpression of CD4 in macrophages resulted in detection of CD4-CXCR4 and ******gp120-CD4-CXCR4****** ***complexes*** in parallel with the restoration of macrophage fusion susceptibility .	parallel	1
3702	10364543	7401;4647	USH3;USH1B	Possible ***interaction*** between ***USH1B*** and ***USH3*** gene products as implied by apparent digenic deafness inheritance .	parallel	1
3703	10364571	6714;3717	c-Src;Jak2	The angiotensin II-dependent ***association*** of ***Jak2*** and ***c-Src*** requires the N-terminus of Jak2 and the SH2 domain of c-Src .	parallel	0
3704	10364571	183;185	angiotensin II;AT1	The ***binding*** of ***angiotensin II*** ( Ang II ) to ***AT1*** is known to increase the kinase activity of several nonreceptor tyrosine kinases including Jak2 and c-Src .	parallel	1
3705	10364571	3717;6714	Jak2;c-Src	In the present study , we demonstrate that treatment of vascular smooth muscle cells with Ang II results in a rapid and transient ***association*** of ***Jak2*** and ***c-Src*** .	parallel	0
3706	10364571	3717;6714	Jak2;c-Src	Lastly , using transiently transfected COS-7 cells , we found that Ang II treatment induced an ***association*** between ***c-Src*** and wild-type Jak2 but not between c-Src and the ***Jak2*** molecule that lacks the initial 240 amino acids .	parallel	0
3707	10364571	3717;6714	Jak2;c-Src	Thus , our data suggest that in addition to increasing the kinase activities Jak2 and c-Src , treatment of cells with Ang II results in the physical ***association*** of ***Jak2*** and ***c-Src*** ; an association that is mediated by the SH2 domain of c-Src and the N-terminus of Jak2 .	parallel	0
3708	10364692	3479;6750	IGF-I;somatostatin	There were no significant alterations in hypothalamic IR growth hormone releasing factor content , although IR ***somatostatin*** ( SRIH ) content was ***increased*** by ***IGF-I-Ab*** .	positive	0
3709	10364693	3953;4852	leptin receptor;NPY	Full-length ***leptin receptor*** expression in the arcuate nucleus was negatively ***correlated*** with neuropeptide Y ( ***NPY*** ) expression ( r = 0.447 , p < 0 .	negative	0
3710	10364831	7124;4790	TNF-alpha;NF-kappa B	Here we show that micromolar concentrations of hypericin inhibited the PMA - and ***TNF-alpha-induced*** ***activation*** of ***NF-kappa B*** in HeLa and TC10 cells , respectively .	positive	1
3711	10365089	999;1956	E-cadherin;epidermal growth factor receptor	The ******E-cadherin/epidermal growth factor receptor****** ***interaction*** : a hypothesis of reciprocal and reversible control of intercellular adhesion and cell proliferation .	parallel	1
3712	10365096	7157;7153	p53;topoisomerase II alpha	Both ***p53*** and c-erbB-2 were significantly ***associated*** with high tumour grade , large tumour size , DNA aneuploidy , lack of steroid hormone receptors , young age , and increased ***topoisomerase II alpha*** and Ki-67 expression levels .	parallel	0
3713	10365570	4314;1401	MMP-3;C-reactive protein	In JRA , MMP-3 levels of patients with arthritis were statistically higher than those of patients without arthritis ( P < 0.05 ) and ***MMP-3*** levels were ***correlated*** with ***C-reactive protein*** ( rs = 0.465 , P < 0.05 ) , while TIMP-1 did not ( rs = 0.340 ) .	parallel	0
3714	10365667	959;958	CD40 ligand;CD40	***CD40 ligand*** ( CD40L ) , the ***ligand*** for ***CD40*** on antigen-presenting cells , is essential for the initiation of antigen-specific T cell responses , an important component of the immune response to tumors .	parallel	1
3715	10365830	3569;213	IL-6;albumin	High concentrations of CRP ( > or = 60mg/L ) were associated with low albumin concentrations ( 33 [ 5 ] g/L ) ; high alpha-1 antitrypsin concentrations ( > or = 4.0 g/L ) were associated with low albumin concentrations ( 34 [ 6 ] g/L ) ; and high ***IL-6*** concentrations ( > or = 4pg/ml ) were ***associated*** with low ***albumin*** concentrations ( 37 [ 6 ] g/L ) compared with a mean ( SD ) albumin concentration of 40 ( 5 ) g/L in patients who had no evidence of an acute phase response .	parallel	0
3716	10365917	5747;5829	FAK;paxillin	Surprisingly , the ***association*** between ***FAK*** and ***paxillin*** was enhanced in B104-1-1 cells , suggesting reorganization of protein-protein interaction modulated by protein phosphorylation .	parallel	0
3717	10366100	7157;3569	p53;IL-6	The mutant ***p53*** genes also ***increased*** ***IL-6*** gene expression .	positive	0
3718	10366107	3596;4322	IL-13;Collagenase 3	***IL-13*** ***inhibited*** ***Collagenase 3*** production , IL-4 had little effect , and IL-10 had none .	negative	1
3719	10366413	7039;3479	transforming growth factor-alpha;IGF-I	***IGF-I*** production by adult rat hepatocytes is ***stimulated*** by ***transforming growth factor-alpha*** and transforming growth factor-beta1 .	positive	0
3720	10366413	7039;3479	TGF-alpha;IGF-I	Our results demonstrate that ***TGF-alpha*** and TGF-beta1 significantly ***stimulate*** ***IGF-I*** and IGFBP secretion by cultured hepatocytes but no change in the abundance of IGF-I and IGFBP mRNAs was observed with respect to controls .	positive	0
3721	10366413	7040;3479	TGF-beta1;IGF-I	Our results demonstrate that TGF-alpha and ***TGF-beta1*** significantly ***stimulate*** ***IGF-I*** and IGFBP secretion by cultured hepatocytes but no change in the abundance of IGF-I and IGFBP mRNAs was observed with respect to controls .	positive	0
3722	10366414	5617;4312	prolactin;MMP-1	However , an intraperitoneal injection of bovine ***prolactin*** at the time when the preovulatory prolactin surge occurs normally , ***increased*** ***MMP-1*** and TIMP-1 gene expression ( P < 0.01 ) .	positive	0
3723	10366414	5617;7076	prolactin;TIMP-1	However , an intraperitoneal injection of bovine ***prolactin*** at the time when the preovulatory prolactin surge occurs normally , ***increased*** MMP-1 and ***TIMP-1*** gene expression ( P < 0.01 ) .	positive	0
3724	10366442	1020;595	Cdk5;cyclin D1	Active or inactive ***Cdk5*** was ***associated*** with ***cyclin D1*** , but only active Cdk5 exhibited threonine phosphorylation .	parallel	0
3725	10366588	23534;10921	TRN-SR;SR protein	These findings strongly suggest that ***TRN-SR*** is a nuclear import ***receptor*** for the ***SR protein*** family .	parallel	1
3726	10366609	8801;8802	Gbeta;Galpha	In conclusion , coupling specificity in signal transduction is unlikely to arise as a result of restricted ******Galpha/Gbeta****** gamma ***interaction*** .	parallel	1
3727	10366611	10497;6812	UNC-13;UNC-18	***Regulation*** of the ***UNC-18-Caenorhabditis*** elegans syntaxin complex by ***UNC-13*** .	target	1
3728	10366611	10497;6812	UNC-13;UNC-18	We show that ***UNC-13*** transiently ***interacts*** with the ***UNC-18-Ce*** syntaxin complex , resulting in rapid displacement of UNC-18 from the complex .	parallel	1
3729	10366624	7099;6103	TOLL;RP3	***TOLL*** and FAS3 , putative " negative " and " positive " recognition molecules , respectively , ***affect*** ***RP3*** antagonistically .	target	0
3730	10366627	4917;1630	Netrin-3;DCC	Unlike chick netrin-1 , however , murine ***Netrin-3*** ***binds*** to ***DCC*** with lower affinity than to the other four receptors .	parallel	1
3731	10366629	1942;2043	Ephrin-A1;EphA4	Ligand-receptor binding assays indicate that ***Ephrin-A1*** and ephrin-A4 selectively ***bind*** ***EphA4*** but not EphA7 in the lysates of striatal tissue .	parallel	1
3732	10366629	1945;2043	ephrin-A4;EphA4	Ligand-receptor binding assays indicate that Ephrin-A1 and ***ephrin-A4*** selectively ***bind*** ***EphA4*** but not EphA7 in the lysates of striatal tissue .	parallel	1
3733	10366629	1943;2045	ephrin-A2;EphA7	Conversely , ***ephrin-A2*** , ephrin-A3 , and ephrin-A5 ***bind*** ***EphA7*** but not EphA4 .	parallel	1
3734	10366629	1944;2045	ephrin-A3;EphA7	Conversely , ephrin-A2 , ***ephrin-A3*** , and ephrin-A5 ***bind*** ***EphA7*** but not EphA4 .	parallel	1
3735	10366629	1946;2045	ephrin-A5;EphA7	Conversely , ephrin-A2 , ephrin-A3 , and ***ephrin-A5*** ***bind*** ***EphA7*** but not EphA4 .	parallel	1
3736	10366647	627;2353	BDNF;c-fos	***BDNF*** , localized in primary sensory neuron cell bodies and central terminals , potentiates nociceptive spinal reflex responses in an in vitro spinal cord preparation and ***induces*** ***c-fos*** expression in dorsal horn neurons .	target	1
3737	10366647	4803;627	NGF;BDNF	Systemic ***NGF*** treatment , a procedure that mimics peripheral inflammatory states , ***raises*** ***BDNF*** levels in sensory neurons and increases nociceptive spinal reflex excitability .	positive	0
3738	10366690	7124;3383	TNF-alpha;ICAM-1	Tumour necrosis factor-alpha ( ***TNF-alpha*** ) , which is elevated in MS and CM , decreased the integrity of the barrier in co-cultured endothelial cells and ***upregulated*** the expression of ***ICAM-1*** nine-fold .	positive	1
3739	10366699	4915;627	TrkB;BDNF	These results suggest that ***TrkB*** , a functional high-affinity ***receptor*** of ***BDNF*** and NT-4 / 5 , and LIFR beta , a receptor component contained in CNTF and LIF receptor complex , might be involved in the observed synergistic effects .	parallel	1
3740	10366699	1270;4909	CNTF;neurotrophin-4	***CNTF*** also ***enhanced*** the ***neurotrophin-4*** / 5-mediated increase of ChAT activity , but not the nerve growth factor ( NGF ) - mediated one .	positive	0
3741	10366730	1471;1514	cystatin C;cathepsin L	Notably , the affinity of bovine cystatin C for cathepsin H was somewhat weaker than that of human cystatin C , and bovine ***cystatin C*** ***bound*** to ***cathepsin L*** with about a four-fold higher association rate constant than the human inhibitor .	parallel	1
3742	10366748	5663;4851	presenilin 1;notch 1	The Alzheimer-related gene ***presenilin 1*** ***facilitates*** ***notch 1*** in primary mammalian neurons .	positive	0
3743	10366748	5663;4851	PS1;Notch1	Furthermore , we present evidence demonstrating that there is a functional ***interaction*** between ***PS1*** and ***Notch1*** in mammalian neurons , analogous to the sel-12 / lin-12 interaction in vulval development in C. elegans [ D.	parallel	1
3744	10366748	5663;4851	PS1;Notch1	These data suggest that ***PS1*** ***facilitates*** ***Notch1*** function in mammalian neurons , and support the hypothesis that a functional interaction exists between PS1 and Notch1 in postmitotic mammalian neurons .	positive	0
3745	10366761	2520;3030	gastrin;GBP	In order to investigate the structural requirements for binding to the GBP , 26 analogues of sulindac sulphide and sulindac sulphoxide were tested for their ability to inhibit the ***binding*** of iodinated ***gastrin*** to the ***GBP*** .	parallel	1
3746	10366775	4018;338	lipoprotein;apoB-100	***lipoprotein*** ( a ) [ Lp ( a ) ] is a ***heterodimer*** of apolipoprotein ( a ) [ Apo ( a ) ] and apolipoprotein B-100 ( ***apoB-100*** ) of low density lipoprotein linked by a disulfide bond .	parallel	1
3747	10366852	10645;207	CaMKK;PKB	***Activation*** of ***PKB*** by ***CaMKK*** appears to be important in protection of neurons from programmed cell death during development .	positive	1
3748	10367743	596;581	Bcl-2;Bax	Surprisingly , ***Bcl-2*** also ***blocked*** ***Bax*** membrane insertion .	negative	0
3749	10367887	672;1647	BRCA1;GADD45	The p53-independent ***induction*** of ***GADD45*** by ***BRCA1*** and its activation of JNK/SAPK suggest a pathway for BRCA1-induced apoptosis .	target	1
3750	10367898	3574;207	IL-7;PKB	We show that ***IL-7*** ***activates*** ***PKB*** and STAT5 in human thymocytes .	positive	1
3751	10368124	5502;5327	inhibitor-1;tPA	Plasminogen activator ***inhibitor-1*** ( PAI-1 ) , a rapid ***inhibitor*** of ***tPA*** , may contribute to arterial thrombolysis resistance .	negative	1
3752	10368277	4790;4792	NFkappaB;IkappaBalpha	A firm hand on NFkappaB : structures of the ******IkappaBalpha-NFkappaB****** ***complex*** .	parallel	1
3753	10368775	8792;8600	RANK;RANKL	Osteoclast precursors express ***RANK*** , a TNF receptor family member , ***recognize*** ***RANKL*** through cell-to-cell interaction with osteoblasts/stromal cells , and differentiate into pOCs in the presence of M-CSF .	target	1
3754	10368775	4982;8600	OPG;RANKL	***OPG*** , which has also been called OCIF or TR1 , is a soluble ***receptor*** for ***RANKL*** and acts as a decoy receptor in the RANK-RANKL signaling system ( Fig .	parallel	1
3755	10369079	596;4609	Bcl-2;c-Myc	Synergistic ***cooperation*** between ***c-Myc*** and ***Bcl-2*** in lymph node progression of T1 human breast carcinomas .	parallel	0
3756	10369126	3956;5788	Galectin-1;CD45	***Galectin-1*** , a natural ***ligand*** for the receptor-type protein tyrosine phosphatase ***CD45*** .	parallel	1
3757	10369126	3956;5788	Galectin-1;CD45	In the present work , placental ***Galectin-1*** has been identified to be a natural ***ligand*** for the receptor-type protein tyrosine phosphatase ***CD45*** .	parallel	1
3758	10369126	3956;5788	Galectin-1;CD45	The ***binding*** of ***Galectin-1*** to ***CD45*** was detected by affinity chromatography of NP 40 solubilized Jurkat T cell membranes on Galectin-1 agarose followed by immunoblotting of the Galectin-1 agarose bound fraction applying monoclonal antibodies to CD45 isoforms .	parallel	1
3759	10369131	3553;4254	IL-1;SCF	TNF + ***IL-1*** significantly ***decreased*** the secretion of ***SCF*** by AFb .	negative	0
3760	10369418	6778;4790	STAT6;NF-kappaB	In addition , activation of the promoter by IL-4 was blocked by mutation of all three NF-kappaB sites and similarly reduced by mutation of site 1 , suggesting that ******NF-kappaB-STAT6****** ***interactions*** may be necessary for STAT6-mediated transactivation of the germline gamma1 promoter .	parallel	1
3761	10369419	3566;653361	interleukin-4 receptor alpha chain;p47phox	***Association*** of the ***interleukin-4 receptor alpha chain*** with ***p47phox*** , an activator of the phagocyte NADPH oxidase in B cells .	parallel	0
3762	10369455	4843;5320	inducible NO-synthase;group IIA-phospholipase A2	***Cross-talk*** between ***group IIA-phospholipase A2*** and ***inducible NO-synthase*** in rat renal mesangial cells .	parallel	0
3763	10369472	728;8288	C5a;eosinophil peroxidase	In the presence of cytochalasin B ( CB ) , ***C5a*** ***induced*** a dose-dependent release of the granular ***eosinophil peroxidase*** ( EPO ) , but not O2 - , whereas in the absence of CB O2 - , but not EPO , was released .	target	1
3764	10369675	2065;2064	ErbB-3;ErbB-2	Consistent with the possibility that this domain recruits a relatively potent signaling pathway ( s ) , the mitogenic signals generated by the recombinant fusion protein were superior to those generated by ErbB-1 homodimers and comparable to the proliferative activity of ******ErbB-2/ErbB-3****** ***heterodimers*** .	parallel	1
3765	10369680	10107;84733	Zn finger protein;M33	We have identified a new ***Zn finger protein*** , RYBP , which ***interacts*** directly with both Ring1 proteins ( Ring1A and Ring1B ) and with ***M33*** , two mutually interacting sets of proteins of the mammalian Polycomb complex .	parallel	1
3766	10369680	10107;6015	Zn finger protein;Ring1	We have identified a new ***Zn finger protein*** , RYBP , which ***interacts*** directly with both ***Ring1*** proteins ( Ring1A and Ring1B ) and with M33 , two mutually interacting sets of proteins of the mammalian Polycomb complex .	parallel	1
3767	10369680	23429;84733	RYBP;M33	Ring1 binds RYBP and M33 through the same C-terminal domain , whereas the ******RYBP-M33****** ***interaction*** takes place through an M33 domain not involved in Ring1 binding .	parallel	1
3768	10369680	6015;84733	Ring1;M33	***Ring1*** ***binds*** RYBP and ***M33*** through the same C-terminal domain , whereas the RYBP-M33 interaction takes place through an M33 domain not involved in Ring1 binding .	parallel	1
3769	10369680	6015;23429	Ring1;RYBP	***Ring1*** ***binds*** ***RYBP*** and M33 through the same C-terminal domain , whereas the RYBP-M33 interaction takes place through an M33 domain not involved in Ring1 binding .	parallel	1
3770	10369680	23429;7528	RYBP;YY1	***RYBP*** also ***interacts*** directly with ***YY1*** , a transcription factor partially related to the product of the Drosophila pleiohomeotic gene .	parallel	1
3771	10369681	3558;22806	IL-2;Aiolos	Indirect immunofluorescence shows that ***IL-2*** ***controls*** the cellular distribution of ***Aiolos*** and induces its tyrosine phosphorylation , required for dissociation from Ras .	target	0
3772	10369681	22806;596	Aiolos;Bcl-2	Mutation of Aiolos-binding sites within the Bcl-2 promoter inhibits transactivation of the reporter gene luciferase , suggesting direct ***control*** of ***Bcl-2*** expression by ***Aiolos*** .	target	0
3773	10369681	22806;596	Aiolos;Bcl-2	Co-transfection experiments confirm that ***Aiolos*** ***induces*** ***Bcl-2*** expression and prevents apoptosis in IL-2-deprived cells .	target	1
3774	10369681	22806;596	Aiolos;Bcl-2	We propose a model for the ***regulation*** of ***Bcl-2*** expression via ***Aiolos*** .	target	1
3775	10369682	5307;2516	Ptx1;SF-1	***Ptx1*** ***regulates*** ***SF-1*** activity by an interaction that mimics the role of the ligand-binding domain .	target	1
3776	10369682	5307;2516	Ptx1;SF-1	The ***interaction*** between the C-terminus of ***Ptx1*** and the N-terminal half of ***SF-1*** results in transcriptional enhancement that equals the activity of a constitutively active SF-1 mutant and that may mimic the effect of a still unidentified SF-1 ligand .	parallel	1
3777	10369783	3329;3336	GroEL;GroES	To achieve this , the ***cooperation*** of ***GroEL*** and ***GroES*** , the two protein components of the chaperone system , is an essential requirement .	parallel	0
3778	10369785	3077;7037	HFE;transferrin receptor	***HFE*** ***binds*** tightly to ***transferrin receptor*** ( TfR ) , the receptor that mediates uptake of iron-loaded transferrin .	parallel	1
3779	10369785	7037;3077	TfR;HFE	A biosensor-derived pH-dependent affinity profile for the ******HFE-TfR****** ***interaction*** is discussed in terms of HFE 's hypothesized role in intracellular trafficking .	parallel	1
3780	10370370	3586;1234	IL-10;CCR5	Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines : ***CCR5*** expression is ***downregulated*** by ***IL-10*** in CD4-positive lymphocytes .	negative	1
3781	10370370	3586;1234	IL-10;CCR5	The type 2 cytokine ***IL-10*** ***downregulated*** both ***CCR5*** mRNA and protein expression in wt/wt and wt/del individuals .	negative	1
3782	10370375	940;941	CD28;B7-1	***CD28*** , a ***receptor*** for ***B7-1*** which activates T cells , is upregulated in B6/lpr and B6/gld mice , while CTLA4 , a negative regulator of T cells which binds B7-1 , is not .	parallel	1
3783	10371193	5170;207	3-phosphoinositide-dependent protein kinase-1;AKT	Arabidopsis ***3-phosphoinositide-dependent protein kinase-1*** is able to ***activate*** human protein kinase B alpha ( ***PKB/AKT*** ) in the presence of PtdIns ( 3,4,5 ) P3 .	positive	1
3784	10371251	581;596	Bax;Bcl-2	The function of the Bax-Bax dimer in active cell death is antagonized by ******Bax-Bcl-2****** ***heterodimers*** .	parallel	1
3785	10371349	3791;7422	KDR;vascular endothelial growth factor	In this study , we examined the protein expression of ***vascular endothelial growth factor*** ( VEGF ) and its specific and functional ***receptor*** ***KDR*** in human breast tissue .	parallel	1
3786	10371394	6855;3667	Syp;IRS-1	In addition , ethanol exposure may preferentially inhibit downstream signaling that requires ***interaction*** between ***Syp*** and ***PY-IRS-1*** .	parallel	1
3787	10371508	959;958	CD154;CD40	***CD154*** is the ***ligand*** for the receptor ***CD40*** .	parallel	1
3788	10371521	3456;3458	Interferon beta;IFNgamma	***Interferon beta-1b*** treatment ***modulates*** TNFalpha and ***IFNgamma*** spontaneous gene expression in MS.	target	0
3789	10371521	3456;7124	Interferon beta;TNFalpha	***Interferon beta-1b*** treatment ***modulates*** ***TNFalpha*** and IFNgamma spontaneous gene expression in MS.	target	0
3790	10372132	1437;3717	GM-CSF;JAK2	Binding of ***GM-CSF*** ***activates*** at least one receptor-associated tyrosine kinase , ***JAK2*** , and rapidly induces tyrosine phosphorylation of the GMR beta c chain ( GMR beta ) , but not the GMR alpha chain ( GMR alpha ) .	positive	1
3791	10372132	1437;5781	GM-CSF;SHP2	Tyrosine 577 was found to be sufficient to regenerate GM-CSF-dependent phosphorylation of SHC , and any of Y577 , Y612 , or Y695 were sufficient to regenerate ***GM-CSF-inducible*** ***phosphorylation*** of ***SHP2*** .	target	1
3792	10372738	5443;1392	adrenocorticotropin;corticotropin-releasing hormone	Desmopressin normalizes the blunted ***adrenocorticotropin*** ***response*** to ***corticotropin-releasing hormone*** in melancholic depression : evidence of enhanced vasopressinergic responsivity .	parallel	0
3793	10372803	4690;867	Nck;Cbl	By means of affinity purification with the Nck-binding phosphopeptide EPGPY ( P ) AQPSV , we could also detect the ***association*** of endogenous ***Nck*** with the proto-oncogene product ***Cbl*** .	parallel	0
3794	10372806	342897;3717	NCCRP-1;JAK2	To determine if ***NCCRP-1*** was physically ***associated*** with ***JAK2*** kinase , chemical cross-linking experiments were conducted .	parallel	0
3795	10372815	2150;4790	PAR-2;NFkappaB	***Activation*** of ***NFkappaB*** via either PAR-1 or ***PAR-2*** does not predict mitogenesis .	positive	1
3796	10372835	7421;5741	vitamin D receptor;PTH	Different ***vitamin D receptor*** genotypes may be ***associated*** with higher levels of serum ***PTH*** and a predisposition to autonomous hyperplasia .	parallel	0
3797	10372988	5015;5949	OTX2;IRBP	Since no clones for the homeodomain protein CRX were found , and since OTX2 can transcriptionally activate IRBP in normally non-expressing HeLa cells , it is possible that ***OTX2*** rather than CRX is the transcriptional ***activator*** for ***IRBP*** in human photoreceptors .	positive	1
3798	10372988	5015;5949	OTX2;IRBP	Since no clones for the homeodomain protein CRX were found , and since ***OTX2*** can transcriptionally ***activate*** ***IRBP*** in normally non-expressing HeLa cells , it is possible that OTX2 rather than CRX is the transcriptional activator for IRBP in human photoreceptors .	positive	1
3799	10372988	8517;5015	IP1;OTX2	The core promoter element ***IP1*** ***binds*** to ***OTX2*** in the yeast one-hybrid system .	parallel	1
3800	10372988	5015;5949	OTX2;IRBP	By cotransfecting HeLa cells , ***OTX2*** could ***transactivate*** the ***IRBP*** promoter .	positive	1
3801	10372988	5015;5949	OTX2;IRBP	The region containing the HeLa cell-specific footprint IP4 ( from -202 to -180 ) could silence the ***OTX2*** ***transactivation*** of the ***IRBP*** promoter .	positive	1
3802	10372996	3553;6347	IL-1beta;MCP-1	HRPE IL-8 and ***MCP-1*** gene expression and protein production are ***stimulated*** by ***IL-1beta*** or TNF-alpha through pathways differentially modulated by IL-4 and GM-CSF .	positive	0
3803	10372996	7124;6347	TNF-alpha;MCP-1	HRPE IL-8 and ***MCP-1*** gene expression and protein production are ***stimulated*** by IL-1beta or ***TNF-alpha*** through pathways differentially modulated by IL-4 and GM-CSF .	positive	0
3804	10372996	1437;6347	granulocyte/macrophage-colony-stimulating factor;MCP-1	***Modulation*** of IL-8 and ***MCP-1*** production by interleukin-4 ( IL-4 ) , a important mediator in Th2-mediated immunity , and ***granulocyte/macrophage-colony-stimulating factor*** ( GM-CSF ) , one of the cytokines secreted by HRPE has been reported in non-ocular cells .	target	0
3805	10372996	3565;6347	interleukin-4;MCP-1	***Modulation*** of IL-8 and ***MCP-1*** production by ***interleukin-4*** ( IL-4 ) , a important mediator in Th2-mediated immunity , and granulocyte/macrophage-colony-stimulating factor ( GM-CSF ) , one of the cytokines secreted by HRPE has been reported in non-ocular cells .	target	0
3806	10373014	5915;3214	RARbeta;Hoxb4	***RARbeta*** ***mediates*** the response of Hoxd4 and ***Hoxb4*** to exogenous retinoic acid .	target	0
3807	10373014	5915;3233	RARbeta;Hoxd4	***RARbeta*** ***mediates*** the response of ***Hoxd4*** and Hoxb4 to exogenous retinoic acid .	target	0
3808	10373018	3791;7422	FLK-1;vascular endothelial growth factor	These studies indicate that all factors examined , including ***vascular endothelial growth factor*** and its ***receptor*** ***FLK-1*** , Flt-3 ligand and its receptor STK-1 , and stem cell leukemia transcription factor , are expressed by both hematopoietic cells in the cluster and endothelial cells .	parallel	1
3809	10373018	2322;7422	STK-1;vascular endothelial growth factor	These studies indicate that all factors examined , including ***vascular endothelial growth factor*** and its receptor FLK-1 , Flt-3 ligand and its ***receptor*** ***STK-1*** , and stem cell leukemia transcription factor , are expressed by both hematopoietic cells in the cluster and endothelial cells .	parallel	1
3810	10373219	183;3082	angiotensin II;HGF	***HGF*** production is ***downregulated*** by ***angiotensin II*** ( Ang II ) in vitro .	negative	1
3811	10373228	3827;5327	Bradykinin;tPA	***Bradykinin*** ***increased*** ***tPA*** release across the forearm in the absence of systemic effects .	positive	0
3812	10373228	3827;5327	Bradykinin;tPA	These data demonstrate that ***Bradykinin*** ***stimulates*** ***tPA*** release in the human vasculature .	positive	0
3813	10373228	3827;5327	Bradykinin;tPA	The present study tests the hypothesis that ***Bradykinin*** ***increases*** ***tPA*** release in humans through local effects on the vasculature .	positive	0
3814	10373309	6676;4956	Spag4;Odf1	***Spag4*** , a novel sperm protein , ***binds*** outer dense-fiber protein ***Odf1*** and localizes to microtubules of manchette and axoneme .	parallel	1
3815	10373309	6676;4956	Spag4;Odf1	Spag4 mRNA is spermatid specific , and the 49-kDa ***Spag4*** protein ***complexes*** specifically with ***Odf1*** , but not Odf2 , mediated by a leucine zipper .	parallel	1
3816	10373410	5317;1832	plakophilin-1;desmoplakin	In transient expression assays , ***plakophilin-1*** formed ***complexes*** with a ***desmoplakin*** amino-terminal domain and enhanced its recruitment to cell-cell borders ; this recruitment was not dependent on the equimolar expression of desmosomal cadherins .	parallel	1
3817	10373410	1832;5317	desmoplakin;plakophilin-1	In contrast to desmoplakin-plakoglobin interactions , the ***interaction*** between ***desmoplakin*** and ***plakophilin-1*** was not mediated by the armadillo repeat domain of plakophilin-1 but by the non-armadillo head domain , as assessed by yeast two-hybrid and recruitment assays .	parallel	1
3818	10373412	6750;22941	somatostatin;cortactin-binding protein 1	Agonist-dependent ***interaction*** of the rat ***somatostatin*** receptor subtype 2 with ***cortactin-binding protein 1*** .	parallel	1
3819	10373416	10849;916	CAST;CD3epsilon	***CAST*** specifically ***interacts*** in vivo and in vitro with ***CD3epsilon*** but not with CD3zeta or FcRgamma via a unique membrane-proximal region of CD3epsilon .	parallel	1
3820	10373416	10849;2207	CAST;FcRgamma	***CAST*** specifically ***interacts*** in vivo and in vitro with CD3epsilon but not with CD3zeta or ***FcRgamma*** via a unique membrane-proximal region of CD3epsilon .	parallel	1
3821	10373426	718;5141	ASP;PDE4	Phosphodiesterase 3 ( PDE3 ) activity was stimulated by ASP and insulin , whereas ***PDE4*** activity was slightly ***increased*** by ***ASP*** only .	positive	0
3822	10373445	6464;2885	Shc;Grb2	Our results also show that shear stress induced an association of alphavbeta3 and beta1 integrins with Shc , and an attendant ***association*** of ***Shc*** with ***Grb2*** .	parallel	0
3823	10373445	6464;3725	Shc;c-Jun	***Shc-SH2*** , an expression plasmid encoding the SH2 domain of Shc , ***attenuated*** shear stress activation of extracellular signal-regulated kinases and ***c-Jun*** N-terminal kinases , and the gene transcription mediated by the activator protein-1 / 12-O-tetradecanoylphorbol-13-acetate-responsive element complex .	negative	0
3824	10373468	9091;5277	GPI1;PIG-A	In mammalian cells , this reaction is mediated by a ***complex*** of ***PIG-A*** , PIG-H , PIG-C , and ***GPI1*** .	parallel	1
3825	10373468	9091;5283	GPI1;PIG-H	In mammalian cells , this reaction is mediated by a ***complex*** of PIG-A , ***PIG-H*** , PIG-C , and ***GPI1*** .	parallel	1
3826	10373468	5279;9091	PIG-C;GPI1	In mammalian cells , this reaction is mediated by a ***complex*** of PIG-A , PIG-H , ***PIG-C*** , and ***GPI1*** .	parallel	1
3827	10373468	5279;5277	PIG-C;PIG-A	In mammalian cells , this reaction is mediated by a ***complex*** of ***PIG-A*** , PIG-H , ***PIG-C*** , and GPI1 .	parallel	1
3828	10373468	5279;5283	PIG-C;PIG-H	In mammalian cells , this reaction is mediated by a ***complex*** of PIG-A , ***PIG-H*** , ***PIG-C*** , and GPI1 .	parallel	1
3829	10373468	5283;5277	PIG-H;PIG-A	In mammalian cells , this reaction is mediated by a ***complex*** of ***PIG-A*** , ***PIG-H*** , PIG-C , and GPI1 .	parallel	1
3830	10373468	5283;5277	PIG-H;PIG-A	A complex of PIG-A , PIG-H , and PIG-C decreased to a nearly undetectable level , whereas a ***complex*** of ***PIG-A*** and ***PIG-H*** was easily detected .	parallel	1
3831	10373468	5279;5277	PIG-C;PIG-A	A ***complex*** of ***PIG-A*** , PIG-H , and ***PIG-C*** decreased to a nearly undetectable level , whereas a complex of PIG-A and PIG-H was easily detected .	parallel	1
3832	10373468	5283;5279	PIG-H;PIG-C	A ***complex*** of PIG-A , ***PIG-H*** , and ***PIG-C*** decreased to a nearly undetectable level , whereas a complex of PIG-A and PIG-H was easily detected .	parallel	1
3833	10373468	5283;5277	PIG-H;PIG-A	Therefore , GPI1 stabilizes the enzyme by tying up PIG-C with a ***complex*** of ***PIG-A*** and ***PIG-H*** .	parallel	1
3834	10373476	5757;1938	prothymosin alpha;eEF-2	Recently , Vega et al. proposed that exogenous ***prothymosin alpha*** can specifically ***increase*** the phosphorylation of eukaryotic elongation factor 2 ( ***eEF-2*** ) in extracts of NIH3T3 cells ( Vega , F.	positive	0
3835	10373477	5594;2885	ERK;Grb2	Although treatment with the phorbol myristate acetate resulted in ***ERK*** ***activation*** and complete dissociation of the ***Grb2-SOS*** complex , there was no effect on subsequent insulin-stimulated Ras activation .	positive	1
3836	10373483	7124;84959	TNFalpha;p70	***TNFalpha*** ***inhibited*** ***p70*** ( s6k ) activation by glucose-stimulated beta-cells of the islets of Langerhans in a dose - and time-dependent manner , with maximal inhibition observed at approximately 20-50 ng/ml , detected after 24 and 48 h of exposure .	negative	1
3837	10373483	7124;84959	TNFalpha;p70	Exogenous insulin failed to prevent ***TNFalpha-induced*** ***inhibition*** of ***p70*** ( s6k ) , suggesting a defect in the insulin signaling pathway .	negative	1
3838	10373483	7124;84959	TNFalpha;p70	Furthermore , the ability of IL-1 receptor antagonist protein , IRAP , to block ***TNFalpha-induced*** ***inhibition*** of ***p70*** ( s6k ) indicated that activation of intra-islet macrophages and the release of IL-1 that induces inos expression in beta-cells was responsible for the inhibitory effects of TNFalpha .	negative	1
3839	10373483	3553;4843	IL-1;inos	Furthermore , the ability of IL-1 receptor antagonist protein , IRAP , to block TNFalpha-induced inhibition of p70 ( s6k ) indicated that activation of intra-islet macrophages and the release of ***IL-1*** that ***induces*** ***inos*** expression in beta-cells was responsible for the inhibitory effects of TNFalpha .	target	1
3840	10373493	5294;933	PI3K;CD22	This finding suggests that PLCgamma and ***PI3K*** may be ***recruited*** to ***CD22*** either through a direct interaction with Tyr863 or indirectly through an association with one or more intermediate proteins .	target	0
3841	10373501	4790;4792	NF-kappaB;IkappaBalpha	In most cases , constitutive ***NF-kappaB*** DNA binding ***correlated*** with reduced levels of either ***IkappaBalpha*** or IkappaBbeta isoforms .	parallel	0
3842	10373512	7979;675	DSS1;BRCA2	Yeast and mammalian two-hybrid assays showed that ***DSS1*** can ***associate*** with ***BRCA2*** in the region of amino acids 2472 to 2957 in the C terminus of the protein .	parallel	0
3843	10373512	675;7979	BRCA2;DSS1	Furthermore , endogenous ***BRCA2*** could be ***coimmunoprecipitated*** with endogenous ***DSS1*** in MCF7 cells , demonstrating an in vivo association .	parallel	1
3844	10373514	1965;4790	eIF-2alpha;NF-kappaB	The translation initiation factor ***eIF-2alpha*** ( alpha subunit of eukaryotic translation initiation factor 2 ) and IkappaBalpha , the ***inhibitor*** of the transcription factor ***NF-kappaB*** , have been proposed as downstream mediators of PKR effects .	negative	1
3845	10373514	5610;4790	PKR;NF-kappaB	Biochemical analysis and transient assays revealed that ***PKR*** expression by a VV vector ***induced*** ***NF-kappaB*** binding and transactivation .	target	1
3846	10373516	4609;1019	c-Myc;Cdk4	***c-Myc*** ***regulates*** cyclin ***D-Cdk4*** and - Cdk6 activity but affects cell cycle progression at multiple independent points .	target	1
3847	10373517	3667;3643	IRS1;insulin receptor	This inhibition of insulin-stimulated downstream signaling occurred without any significant effect on insulin receptor autophosphorylation or tyrosine phosphorylation of ***insulin receptor*** ***substrate*** 1 ( ***IRS1*** ) .	parallel	1
3848	10373527	1022;902	MO15;cyclin H	This finding provides in vivo support for the previous biochemical observation that ******MO15-cyclin H****** ***complexes*** can be activated either by activating phosphorylation of MO15 or by binding to MAT1 .	parallel	1
3849	10373529	3556;9139	IL-1 receptor accessory protein;p85	We have found that IL-1 stimulates ***interaction*** of the ***IL-1 receptor accessory protein*** with the ***p85*** regulatory subunit of PI3K , leading to the activation of the p110 catalytic subunit .	parallel	1
3850	10373529	3553;3556	IL-1;IL-1 receptor accessory protein	We have found that ***IL-1*** ***stimulates*** interaction of the ***IL-1 receptor accessory protein*** with the p85 regulatory subunit of PI3K , leading to the activation of the p110 catalytic subunit .	positive	0
3851	10373529	3553;4792	IL-1;IkappaBalpha	Specific PI3K inhibitors strongly inhibit both PI3K activation and NF-kappaB-dependent gene expression but have no effect on the ***IL-1-stimulated*** ***degradation*** of ***IkappaBalpha*** , the nuclear translocation of NF-kappaB , or the ability of NF-kappaB to bind to DNA .	negative	1
3852	10373529	3553;4790	IL-1;NF-kappaB	In contrast , PI3K inhibitors block the ***IL-1-stimulated*** ***phosphorylation*** of ***NF-kappaB*** itself , especially the p65/RelA subunit .	target	1
3853	10373529	5290;4790	PI3K;NF-kappaB	Therefore , IL-1 stimulates the ***PI3K-dependent*** ***phosphorylation*** and transactivation of ***NF-kappaB*** , a process quite distinct from the liberation of NF-kappaB from its cytoplasmic inhibitor IkappaB .	target	1
3854	10373529	3553;4790	IL-1;NF-kappaB	Therefore , ***IL-1*** ***stimulates*** the PI3K-dependent phosphorylation and transactivation of ***NF-kappaB*** , a process quite distinct from the liberation of NF-kappaB from its cytoplasmic inhibitor IkappaB .	positive	0
3855	10373531	993;5894	Cdc25A;Raf-1	***Cdc25A*** was found to ***dephosphorylate*** ***Raf-1*** on tyrosines that resulted in a significant decrease in Raf-1 kinase activity .	target	1
3856	10373534	672;1017	BRCA1;CDK2	Furthermore , ***BRCA1*** ***coimmunoprecipitates*** with ***CDK2*** and cyclin A.	parallel	1
3857	10373539	9099;7398	USP-2;USP-1	When cell extracts were used , the EcR-B1-USP-2 heterodimer showed no binding to EcRE1 , and the presence of excess ***USP-2*** ***prevented*** the binding of ***EcR-B1-USP-1*** to this element .	negative	0
3858	10373541	6304;1523	SATB1;CDP	***SATB1*** ***interacted*** with ***CDP*** through its DNA-binding domain , as demonstrated by glutathione S-transferase ( GST ) pull-down assays .	parallel	1
3859	10373541	1523;6304	CDP;SATB1	GST pull-down assays also showed that ***CDP*** ***associated*** with ***SATB1*** through three of its four DNA-binding domains ( CR1 , CR2 , and the homeodomain ) .	parallel	0
3860	10373541	1523;6304	CDP;SATB1	Far-Western blotting detected ***interaction*** of ***SATB1*** and ***CDP*** in several different tissue extracts .	parallel	1
3861	10373541	1523;6304	CDP;SATB1	***Association*** of purified ***SATB1*** and ***CDP*** in vitro resulted in the inability of each protein to bind to DNA in gel retardation assays .	parallel	0
3862	10373544	9328;9330	hTFIIIC63;hTFIIIC102	These include novel ***interactions*** of ***hTFIIIC63*** with ***hTFIIIC102*** , with hTFIIIB90 , and with hRPC62 , in addition to the hTFIIIC102-hTFIIIB90 and hTFIIIB90-hRPC39 interactions that parallel the previously described interactions in yeast .	parallel	1
3863	10373548	3558;6777	IL-2;STAT5b	Additionally , in lymphocytes expressing SOCS-3 but not CIS , ***IL-2-induced*** tyrosine ***phosphorylation*** of ***STAT5b*** was markedly reduced , while there was only a weak effect on IL-3-mediated STAT5b tyrosine phosphorylation .	target	1
3864	10373548	3558;9021	IL-2;SOCS-3	The findings suggest that when ***SOCS-3*** is rapidly ***induced*** by ***IL-2*** in T cells , it acts to inhibit IL-2 responses in a classical negative feedback loop .	target	1
3865	10373548	9021;3716	SOCS-3;Jak1	In these experiments , ***SOCS-3*** ***associated*** with ***Jak1*** and inhibited Jak1 phosphorylation , and this inhibition was markedly enhanced by the presence of IL-2 receptor beta chain ( IL-2Rbeta ) .	parallel	0
3866	10373551	695;2969	Btk;TFII-I	Thus , mutations impairing the physical and/or functional ***association*** between ***TFII-I*** and ***Btk*** may result in diminished TFII-I-dependent transcription and contribute to defective B-cell development and/or function .	parallel	0
3867	10373551	695;2969	Bruton's tyrosine kinase;TFII-I	***Regulation*** of nuclear localization and transcriptional activity of ***TFII-I*** by ***Bruton's tyrosine kinase*** .	target	1
3868	10373551	2969;695	TFII-I;Btk	***TFII-I*** ***associates*** constitutively in vivo with wild-type Btk and kinase-inactive ***Btk*** but not xid Btk .	parallel	0
3869	10373555	5170;2185	3-phosphoinositide-dependent protein kinase 1;protein kinase B	Domain swapping used to investigate the mechanism of ***protein kinase B*** ***regulation*** by ***3-phosphoinositide-dependent protein kinase 1*** and Ser473 kinase .	target	1
3870	10373559	6772;6773	Stat1;Stat2	In response to IFN-alpha , ***Stat1*** ***binds*** to ***Stat2*** in a heterodimer that recruits p48 , an IRF family member , to activate transcription .	parallel	1
3871	10373560	891;983	cyclin B1;Cdc2	Overproduction of human Myt1 kinase induces a G2 cell cycle delay by interfering with the intracellular trafficking of ******Cdc2-cyclin B1****** ***complexes*** .	parallel	1
3872	10373560	9088;983	Myt1;Cdc2	The ***Myt1*** protein kinase functions to negatively ***regulate*** ***Cdc2-cyclin*** B complexes by phosphorylating Cdc2 on threonine 14 and tyrosine 15 .	negative	1
3873	10373560	983;891	Cdc2;cyclin B1	Throughout interphase , human Myt1 localizes to the endoplasmic reticulum and Golgi complex , whereas ******Cdc2-cyclin B1****** ***complexes*** shuttle between the nucleus and the cytoplasm .	parallel	1
3874	10373560	983;891	Cdc2;cyclin B1	Myt1 mutants lacking this domain no longer bound cyclin B1 and did not efficiently phosphorylate ******Cdc2-cyclin B1****** ***complexes*** in vitro .	parallel	1
3875	10373560	9088;983	Myt1;Cdc2	These results suggest that the docking of Cdc2-cyclin B1 complexes to the COOH terminus of Myt1 facilitates the ***phosphorylation*** of ***Cdc2*** by ***Myt1*** and that overproduction of Myt1 perturbs cell cycle progression by sequestering Cdc2-cyclin B1 complexes in the cytoplasm .	target	1
3876	10373560	983;891	Cdc2;cyclin B1	These results suggest that the docking of Cdc2-cyclin B1 complexes to the COOH terminus of Myt1 facilitates the phosphorylation of Cdc2 by Myt1 and that overproduction of Myt1 perturbs cell cycle progression by sequestering ******Cdc2-cyclin B1****** ***complexes*** in the cytoplasm .	parallel	1
3877	10373563	4214;367	MEKK1;androgen receptor	***MEKK1*** also ***stimulates*** the transcriptional activity of the ***androgen receptor*** in the presence or absence of ligand , whereas a dominant negative mutant of MEKK1 impairs activation of the androgen receptor by androgen .	positive	0
3878	10373563	4214;367	MEKK1;androgen receptor	MEKK1 also stimulates the transcriptional activity of the androgen receptor in the presence or absence of ligand , whereas a dominant negative mutant of ***MEKK1*** ***impairs*** activation of the ***androgen receptor*** by androgen .	positive	0
3879	10373567	1600;351	Dab1;APP	***Dab1*** ***associates*** with the ***APP*** cytoplasmic domain in transfected cells and is coexpressed with APP in hippocampal neurons .	parallel	0
3880	10373581	1432;4205	p38 MAP kinase;MEF2A	Subsequent phosphopeptide mapping and phosphoamino acid analysis indicated the appearance of several phoshopeptides due to ***p38 MAP kinase*** ***activation*** of ***MEF2A*** which were due to phosphorylation on serine and threonine residues .	positive	1
3881	10373589	1387;6778	CBP;Stat6	***p300/CBP*** is required for transcriptional induction by interleukin-4 and ***interacts*** with ***Stat6*** .	parallel	1
3882	10373589	2033;6778	p300;Stat6	***p300/CBP*** is required for transcriptional induction by interleukin-4 and ***interacts*** with ***Stat6*** .	parallel	1
3883	10373589	3565;6778	interleukin-4;Stat6	***interleukin-4*** ( IL-4 ) ***induces*** tyrosine phosphorylation of the latent transcription factor ***Stat6*** , which mediates the transcriptional responses of IL-4 .	target	1
3884	10373589	6778;3565	Stat6;IL-4	interleukin-4 ( IL-4 ) induces tyrosine phosphorylation of the latent transcription factor ***Stat6*** , which ***mediates*** the transcriptional responses of ***IL-4*** .	target	0
3885	10373597	3516;3569	CBF1;IL-6	By transfection analyses performed in HeLa cells , we demonstrate that overexpressed ***CBF1*** acts as a negative ***regulator*** of ***IL-6*** gene transcription and is unable to elicit Notch-dependent activation of this gene .	negative	1
3886	10373597	3516;3569	CBF1;IL-6	This finding suggests that ***CBF1*** may ***influence*** ***IL-6*** gene transcription by determining a specific conformation of the promoter region .	target	0
3887	10373662	7157;7422	p53;VEGF	The ***association*** between MVD , ***VEGF*** expression , ***p53*** mutations and preinvasive lesions of the bronchial tree suggests that neoangiogenesis is early in non-small cell lung cancer ( NSCLC ) development and that p53 may have an important role in promoting angiogenesis in this human model of carcinogenesis .	parallel	0
3888	10374073	925;6647	CD8;homodimer	The ratio of T cell subsets expressing CD8 alpha alpha ******homodimer/CD8****** alpha beta ***heterodimer*** was found to be higher in the dark period than that in the light period .	parallel	1
3889	10374333	7157;4193	p53;MDM2	There was a striking ***association*** between ***MDM2*** and ***p53*** overexpressions .	parallel	0
3890	10374718	133;5594	adrenomedullin;ERK2	Associated with the changes in proliferation and apoptosis , ***adrenomedullin*** ***decreased*** ***ERK2*** activity , and increased JNK1 and P38 MAPK activities .	negative	0
3891	10374718	133;5599	adrenomedullin;JNK1	Associated with the changes in proliferation and apoptosis , ***adrenomedullin*** decreased ERK2 activity , and ***increased*** ***JNK1*** and P38 MAPK activities .	positive	0
3892	10374718	133;5594	adrenomedullin;P38	Associated with the changes in proliferation and apoptosis , ***adrenomedullin*** decreased ERK2 activity , and ***increased*** JNK1 and ***P38*** MAPK activities .	positive	0
3893	10374772	2208;3497	CD23;IgE	***CD23*** functions as the ***receptor*** for ***IgE*** and also appears to play a role in controlling the growth and proliferation of lymphocytes .	parallel	1
3894	10374812	3458;3586	interferon-gamma;IL-10	The T helper 1-type cytokine ***interferon-gamma*** ( IFN-gamma ) induced TNF transcripts , but not TNF secretion , and ***suppressed*** LPS-induced ***IL-10*** mRNA and secretion by microglia .	negative	1
3895	10374817	43;351	AChE;Abeta	Our results suggest that Neuro 2a cells are less susceptible to exposure to ******AChE-Abeta****** ***complexes*** , Abeta25-35 fragment , glutamate and H2O2 than PC12 cells , due to higher intracellular levels of antioxidant defense factors .	parallel	1
3896	10374837	6670;4953	Sp3;ODC	We have shown that the transcription factor Sp1 is one of the regulators of ODC expression and that ***Sp3*** ***antagonizes*** this Sp1-mediated activation of ***ODC*** expression .	negative	1
3897	10374846	356;355	FasL;Fas	Co-treatment did not significantly alter Bcl2 , Bcl-xL , Bax or Fas receptor ( FasR ) , but modestly increased ***Fas*** ***ligand*** ( ***FasL*** ) protein .	parallel	1
3898	10374859	947;1791	CD34;TdT	***CD34*** positivity was highly ***correlated*** with ***TdT*** expression ( P < 0.0001 ) .	parallel	0
3899	10374878	6774;581	Stat3;Bax	Inhibition of constitutively activated ***Stat3*** ***correlates*** with altered ***Bcl-2/Bax*** expression and induction of apoptosis in mycosis fungoides tumor cells .	parallel	0
3900	10374878	6774;596	Stat3;Bcl-2	Inhibition of constitutively activated ***Stat3*** ***correlates*** with altered ***Bcl-2/Bax*** expression and induction of apoptosis in mycosis fungoides tumor cells .	parallel	0
3901	10374879	836;5371	caspase-3;PML	In acute promyelocytic leukemia NB4 cells , the synthetic retinoid CD437 induces contemporaneously apoptosis , a ***caspase-3-mediated*** ***degradation*** of ***PML/RARalpha*** protein and the PML retargeting on PML-nuclear bodies .	negative	1
3902	10374879	836;5914	caspase-3;RARalpha	In acute promyelocytic leukemia NB4 cells , the synthetic retinoid CD437 induces contemporaneously apoptosis , a ***caspase-3-mediated*** ***degradation*** of ***PML/RARalpha*** protein and the PML retargeting on PML-nuclear bodies .	negative	1
3903	10374881	3717;10603	Janus kinase-2;APS	Here , we report that ***APS*** was tyrosine ***phosphorylated*** by ***Janus kinase-2*** ( JAK2 ) at its C-terminal tyrosine residue and interacted with c-Cbl .	target	1
3904	10374908	2641;5443	glucagon;ACTH	In contrast , ***glucagon*** and GLP-1 partially ( 40 % ) ***inhibited*** ***ACTH*** ( 10 ( -9 ) M ) - enhanced corticosterone secretion of inner cells , maximal effective concentration being 10 ( -7 ) M.	negative	1
3905	10374915	6750;5443	somatostatin;beta-endorphin	Our results showed that ***somatostatin*** treatment significantly ***increased*** ***beta-endorphin*** levels in the blood and lymphocytes from popliteal lymph nodes .	positive	0
3906	10375014	2353;3484	c-fos;IGFBP-1	Co-expression of ***c-fos*** or c-jun in rat hepatocytes , individually or together , ***suppresses*** ***IGFBP-1*** promoter activity by approximately 60 % .	negative	1
3907	10375014	3725;3484	c-jun;IGFBP-1	Co-expression of c-fos or ***c-jun*** in rat hepatocytes , individually or together , ***suppresses*** ***IGFBP-1*** promoter activity by approximately 60 % .	negative	1
3908	10375033	2494;1588	FTZ-F1;aromatase	Medaka ( Oryzias latipes ) ***FTZ-F1*** potentially ***regulates*** the transcription of P-450 ***aromatase*** in ovarian follicles : cDNA cloning and functional characterization .	target	1
3909	10375532	6500;8454	Skp1;Cul-1	Skp2-dependent ***associations*** between ***Skp1*** or ***Cul-1*** and the p27 phosphopeptide were also detected .	parallel	0
3910	10375961	3553;5443	IL-1 beta;ACTH	Intravenous administrations of ***IL-1 beta*** ***increased*** AVP , atrial natriuretic hormone ( ANH ) and ***ACTH*** .	positive	0
3911	10375961	3553;551	IL-1 beta;AVP	Intravenous administrations of ***IL-1 beta*** ***increased*** ***AVP*** , atrial natriuretic hormone ( ANH ) and ACTH .	positive	0
3912	10376217	834;3606	ICE;interleukin-18	caspase-1 , or interleukin-1 beta converting enzyme ( ***ICE*** ) , ***promotes*** maturation of interleukin-1 beta ( IL-1 beta ) and ***interleukin-18*** ( IL-18 ) by proteolytic cleavage of precursor forms to generate biologically active peptides .	positive	0
3913	10376217	834;3553	ICE;interleukin-1 beta	caspase-1 , or interleukin-1 beta converting enzyme ( ***ICE*** ) , ***promotes*** maturation of ***interleukin-1 beta*** ( IL-1 beta ) and interleukin-18 ( IL-18 ) by proteolytic cleavage of precursor forms to generate biologically active peptides .	positive	0
3914	10376217	3553;3606	interleukin-1 beta;interleukin-18	caspase-1 , or ***interleukin-1 beta*** converting enzyme ( ICE ) , ***promotes*** maturation of interleukin-1 beta ( IL-1 beta ) and ***interleukin-18*** ( IL-18 ) by proteolytic cleavage of precursor forms to generate biologically active peptides .	positive	0
3915	10376266	1392;5443	corticotropin-releasing factor;ACTH	The addition of ***corticotropin-releasing factor*** to primary trophoblast cell cultures ***stimulates*** ***ACTH*** secretion in a dose-dependent manner , and its action is mediated by cyclic adenosine monophosphate as second messenger .	positive	0
3916	10376522	3084;2064	NDF;ErbB2	Neu differentiation factor ( ***NDF*** ) / heregulin ***activates*** ***ErbB2*** via heterodimerization with the NDF receptors ErbB3 and ErbB4 .	positive	1
3917	10376522	2064;2065	ErbB2;ErbB3	G1 progression was associated with ***ErbB2*** ***transactivation*** of ***ErbB3*** and subsequent stimulation of the phosphatidylinositol 3-kinase ( PI3K ) pathway whereas apoptosis was dependent on p38 MAPK .	positive	1
3918	10376524	4342;3308	c-Mos;Hsp70	Based on our identification of ******c-Mos-Hsp70****** ***interaction*** , one of the roles of ATP may be to assist the regulation of c-Mos via ATP involvement in the protein-folding function of Hsp70 and possibly other molecular chaperones .	parallel	1
3919	10376524	4342;3308	c-Mos;Hsp70	We also detected by coimmunoprecipitation a physical ***association*** between endogenous ***c-Mos*** and ***Hsp70*** in Xenopus eggs .	parallel	0
3920	10376524	4342;3308	c-Mos;Hsp70	We provide evidence that mouse ***c-Mos*** ***binds*** to ***Hsp70*** , a molecular chaperone .	parallel	1
3921	10376527	11016;5601	ATFa;JNK2	Role of the ******ATFa/JNK2****** ***complex*** in Jun activation .	parallel	1
3922	10376527	11016;5601	ATFa;JNK2	We also show that the N-terminal domain of ***ATFa*** which stably ***binds*** the Jun N-terminal kinase-2 ( ***JNK2*** ) ( Bocco et al. , 1996 ) , is not a substrate for this kinase in vivo but , instead , serves as a JNK2-docking site for ATFa-associated partners like JunD , allowing them to be phosphorylated by the bound kinase .	parallel	1
3923	10376594	317;112752	CED-4;CED-3	Furthermore , analysis of homologues from Caenorhabditis elegans indicates that ***recruitment*** of ***CED-3*** by ***CED-4*** is probably mediated by the same set of conserved structural motifs , with a corresponding change in the specificity-determining residues .	target	0
3924	10376604	9044;6908	Mot1;TBP	Using mutant yeast strains , we show that ***Mot1*** ***prevents*** the binding of ***TBP*** to inactive promoters and that activator-mediated stimulation of TBP binding requires additional GTFs , including TFIIB and Srb4 .	negative	0
3925	10376794	2950;2944	GSTP1;GSTM1	The potential ***interaction*** of ***GSTM1*** and ***GSTP1*** genotypes in pulmonary carcinogenesis was assessed in 382 male Japanese lung cancer patients ( 127 squamous cell carcinoma , 78 small cell carcinoma , 177 adenocarcinoma ) and 257 controls .	parallel	1
3926	10376794	2950;2944	GSTP1;GSTM1	The estimated relative risk of the GSTM1 null genotype for lung cancer was 2.58 ( 95 % CI = 1.26-5 .30 ) in smokers with the GSTP1 mutant allele while it was 1.17 ( 95 % CI = 0.77-1 .79 ) in those without , suggesting that mutated ***GSTM1*** and ***GSTP1*** genotypes ***interact*** to potentiate the risk of lung cancers in Japanese smokers .	parallel	1
3927	10376804	3576;5706	NaF;p44	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate ( TPA ) , a protein kinase C ( PKC ) activator , or NaF , an activator of heterotrimeric GTP-binding protein , as well as the ***p42/p44*** MAP kinase ***activation*** by TPA or ***NaF*** .	positive	1
3928	10376805	3562;6777	IL-3;STAT5	Here we show that , in IFN-alpha-responsive Ba/F3 cells , this cytokine stimulates the DNA-binding of STAT5A and B but that ***IL-3*** is a much more potent ***activator*** of both ***STAT5*** isoforms .	positive	1
3929	10376805	3562;5292	IL-3;pim-1	Northern blots revealed that ***IL-3*** strongly ***induced*** the expression of two STAT5-regulated genes , ***pim-1*** and oncostatin-M , whereas IFN-alpha had a weak stimulatory effect on pim-1 expression only .	target	1
3930	10376811	5970;3725	p65;AP-1	Evidence that PDTC induced AP-1 DNA binding and AP-1 reporter gene activity , raised the hypothesis that the effect of PDTC was mediated by an ***interaction*** between the ***AP-1*** pathway and ***p65*** ( RelA ) .	parallel	1
3931	10376933	7040;3576	TGF beta;IL-8	In contrast , transforming growth factor beta ( ***TGF beta*** ) , appeared to down ***modulate*** tat-induced ***IL-8*** production .	target	0
3932	10376964	1026;1019	p21;cdk4	Co-immunoprecipitation with anti-cdk4 antibody showed that induced ***p21*** ***associates*** with ***cdk4*** and that its kinase activity is reduced by TGF-beta , which kinetically correlates closely with G1 arrest following TGF-beta treatment of both cell lines .	parallel	0
3933	10376969	1029;595	p16INK4a;cyclin D1	Our findings support the hypothesis that ***cyclin D1*** and ***p16INK4a*** can ***cooperate*** to dysregulate the cell cycle , but that loss of Rb protein abolishes the G1 checkpoint completely , removing any selective advantage for cells that alter additional cell cycle proteins .	parallel	0
3934	10376986	595;7157	Cyclin D1;p53	We found that : ( 1 ) Cyclin D1 was expressed in 13 ( 11.7 % ) of 111 NSCLCs ; ( 2 ) the Cyclin D1 gene was neither significantly amplified nor rearranged ; ( 3 ) ***Cyclin D1*** expression significantly ***correlated*** with altered ***p53*** protein expression ( P = 0.04 ) , whereas it did not correlate with p16 and RB protein status ; ( 4 ) proliferative activity tended to be higher in Cyclin D1-positive ( + ) tumours than in Cyclin D1-negative ( - ) tumours , although this difference was not statistically significant ( P = 0.08 ) ; and ( 5 ) patients with Cyclin D1 + tumours survived longer than patients with Cyclin D1 - tumours ( 5-year survival rates , 89 % and 64 % respectively , by the Kaplan-Meier method ; P = 0.045 by the log-rank test ) , and Cyclin D1 expression tended to be a favourable prognostic factor ( P = 0.08 in univariate analysis ) .	parallel	0
3935	10377033	356;355	FasL;Fas	The Fas system has been implicated as a possible key regulator of apoptosis in various cells : binding of ***Fas*** ***ligand*** ( ***FasL*** ) , a type II transmembrane protein , to Fas , a type I transmembrane receptor protein , triggers apoptosis in cells expressing Fas .	parallel	1
3936	10377033	356;355	FasL;Fas	The Fas system has been implicated as a possible key regulator of apoptosis in various cells : ***binding*** of Fas ligand ( ***FasL*** ) , a type II transmembrane protein , to ***Fas*** , a type I transmembrane receptor protein , triggers apoptosis in cells expressing Fas .	parallel	1
3937	10377139	958;959	CD40;CD40L	These results indicate that ******CD40-CD40L****** ***signaling*** may be an important step in host immune response against M. avium infection .	parallel	0
3938	10377182	3565;3557	IL-4;IL-1Ra	In M. tuberculosis-stimulated peripheral blood mononuclear cells , the addition of ***IL-4*** ***increased*** ***IL-1Ra*** secretion , whereas interferon gamma increased and IL-10 decreased IL-1beta production , indicative of a differential influence on the IL-1Ra/IL-1beta ratio by cytokines .	positive	0
3939	10377182	3458;3553	interferon gamma;IL-1beta	In M. tuberculosis-stimulated peripheral blood mononuclear cells , the addition of IL-4 increased IL-1Ra secretion , whereas ***interferon gamma*** ***increased*** and IL-10 decreased ***IL-1beta*** production , indicative of a differential influence on the IL-1Ra/IL-1beta ratio by cytokines .	positive	0
3940	10377183	958;959	CD40;CD40 ligand	Induction of cytotoxic T lymphocyte ( CTL ) responses against minor histocompatibility antigens is dependent upon the presence of T cell help and requires the ***interaction*** of ***CD40*** on dendritic cells ( DCs ) with ***CD40 ligand*** on activated T helper cells ( Th ) .	parallel	1
3941	10377195	6348;1437	MIP-1alpha;CSF	Moreover , ***MIP-1alpha*** did not mobilize MPCs to the blood or ***synergize*** with ***G-CSF*** in this effect in CCR1 ( - / - ) mice .	parallel	0
3942	10377223	1432;7124	p38 MAP kinase;TNF-alpha	This work led to identification of 48 , a potent ( ***p38 MAP kinase*** inhibition IC50 0.24 nM ) and selective p38 MAP kinase inhibitor which ***inhibits*** lipopolysaccharide-stimulated release of ***TNF-alpha*** from human blood with an IC50 2.2 nM , shows good oral bioavailability in rat and rhesus monkey , and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model .	negative	1
3943	10377245	3075;7124	Factor H;TNF-alpha	Pretreatment of ***Factor H*** with sialidase ***reduced*** both the binding of L-selectin to Factor H and the Factor H-induced L-selectin-mediated ***TNF-alpha*** secretion by leukocytes .	negative	1
3944	10377265	183;4690	Angiotensin II;Nck	***Angiotensin II*** ***stimulates*** serine phosphorylation of the adaptor protein ***Nck*** : physical association with the serine/threonine kinases Pak1 and casein kinase I.	positive	0
3945	10377265	183;4690	Angiotensin II;Nck	We report here that ***Angiotensin II*** , working through the AT1 receptor subtype , ***stimulates*** the phosphorylation of ***Nck*** in rat aortic smooth muscle cells .	positive	0
3946	10377335	5008;7124	OSM;TNF-alpha	Oncostatin M ( ***OSM*** ) induced IL-6 alone and ***synergized*** with ***TNF-alpha*** for enhanced expression .	parallel	0
3947	10377335	5008;3569	OSM;IL-6	Oncostatin M ( ***OSM*** ) ***induced*** ***IL-6*** alone and synergized with TNF-alpha for enhanced expression .	target	1
3948	10377336	2247;4137	fibroblast growth factor-2;tau	Dynamic regulation of expression and ***phosphorylation*** of ***tau*** by ***fibroblast growth factor-2*** in neural progenitor cells from adult rat hippocampus .	target	1
3949	10377336	2247;4137	fibroblast growth factor-2;tau	We have found that neural progenitor cells from adult rat hippocampus express adult isoforms of tau and that the expression and the phosphorylation of ***tau*** are ***regulated*** by ***fibroblast growth factor-2*** ( FGF-2 ) .	target	1
3950	10377346	5663;207	presenilin-1;Akt	Mutant ***presenilin-1*** induces apoptosis and ***downregulates*** ***Akt/PKB*** .	negative	1
3951	10377349	4803;627	NGF;BDNF	In this report , we provide evidence that NGF and BDNF have functionally antagonistic actions on sympathetic neuron growth and target innervation , with ***NGF*** acting via TrkA to ***promote*** growth and ***BDNF*** via p75NTR to inhibit growth .	positive	0
3952	10377389	81570;3308	ClpB;Hsp70	Functional chaperone ***cooperation*** between ***Hsp70*** ( DnaK ) and Hsp104 ( ***ClpB*** ) was demonstrated in vitro .	parallel	0
3953	10377395	3553;5743	IL-1beta;cyclooxygenase-2	A549 cells have been used as a model system to study ***cyclooxygenase-2*** ***induction*** by ***IL-1beta*** .	target	1
3954	10377409	7430;54776	Ezrin;p85	While investigating the mechanism responsible for this apoptosis , we found that ***Ezrin*** ***interacts*** with ***p85*** , the regulatory subunit of phosphatidylinositol 3-kinase ( PI 3-kinase ) .	parallel	1
3955	10377410	991;6790	Cdc20;aurora2	***Cdc20*** ***associates*** with the kinase ***aurora2/Aik*** .	parallel	0
3956	10377410	991;6790	Cdc20;aurora2	In HeLa cells , ***Cdc20*** is ***associated*** with the kinase ***aurora2/Aik*** .	parallel	0
3957	10377410	991;6790	Cdc20;aurora2	The demonstration that ***Cdc20*** is ***associated*** with ***aurora2/Aik*** suggests that some function of Cdc20 is carried out or regulated through its association with aurora2/Aik .	parallel	0
3958	10377422	10111;4361	Rad50;Mre11	The ******Mre11/Rad50****** protein ***complex*** functions in diverse aspects of the cellular response to double-strand breaks ( DSBs ) , including the detection of DNA damage , the activation of cell cycle checkpoints , and DSB repair .	parallel	1
3959	10377422	10111;4361	Rad50;Mre11	We established mRad50 mutant mice to examine the role of the mammalian ******Mre11/Rad50****** protein ***complex*** in the DNA damage response .	parallel	1
3960	10377422	10111;4361	Rad50;Mre11	However , the null mrad50 mutation is lethal in cultured embryonic stem cells and in early developing embryos , indicating that the mammalian ******Mre11/Rad50****** protein ***complex*** mediates functions in normally growing cells that are essential for viability .	parallel	1
3961	10377438	7329;2120	UBC9;TEL	Based on our data , we conclude that ***UBC9*** physically ***interacts*** with ***TEL*** through the HLH domain and that the interaction leads to modulation of the transcription activity of TEL .	parallel	1
3962	10377438	7329;2120	UBC9;TEL	We show that a protein , ***UBC9*** , ***interacts*** specifically with ***TEL*** in vitro and in vivo .	parallel	1
3963	10377438	2120;7329	TEL;UBC9	These enzymes usually are involved in proteosome-mediated degradation ; however , our data suggest that ***interaction*** of ***TEL*** with ***UBC9*** does not lead to TEL degradation .	parallel	1
3964	10377438	7329;2120	UBC9;TEL	Our studies show that ***UBC9*** ***binds*** to ***TEL*** exclusively through the HLH domain of TEL .	parallel	1
3965	10377443	920;1234	CD4;CCR5	Constitutive cell surface ***association*** between ***CD4*** and ***CCR5*** .	parallel	0
3966	10377443	920;1234	CD4;CCR5	Here , we provide evidence that ***CD4*** is specifically ***associated*** with ***CCR5*** in the absence of gp120 or any other receptor-specific ligand .	parallel	0
3967	10377443	920;1234	CD4;CCR5	The amount of ***CD4*** ***coimmunoprecipitated*** with ***CCR5*** was significantly higher than that with the other major HIV coreceptor , CXCR4 , and in contrast to CXCR4 the CD4-CCR5 coimmunoprecipitation was not significantly increased by gp120 .	parallel	1
3968	10377443	920;1234	CD4;CCR5	The ******CD4-CCR5****** ***interaction*** probably takes place via the second extracellular loop of CCR5 and the first two domains of CD4 .	parallel	1
3969	10377443	920;1234	CD4;CCR5	These findings suggest a possible pathway of HIV-1 evolution and development of immunopathogenicity , a potential new target for antiretroviral drugs and a tool for development of vaccines based on ******Env-CD4-CCR5****** ***complexes*** .	parallel	1
3970	10377443	30816;1234	Env;CCR5	These findings suggest a possible pathway of HIV-1 evolution and development of immunopathogenicity , a potential new target for antiretroviral drugs and a tool for development of vaccines based on ******Env-CD4-CCR5****** ***complexes*** .	parallel	1
3971	10377443	30816;920	Env;CD4	These findings suggest a possible pathway of HIV-1 evolution and development of immunopathogenicity , a potential new target for antiretroviral drugs and a tool for development of vaccines based on ******Env-CD4-CCR5****** ***complexes*** .	parallel	1
3972	10377452	351;7157	APP;p53	Wild-type ***APP*** also strongly ***inhibited*** ***p53*** DNA-binding activity and p53-mediated gene transactivation , whereas FAD-mutant APP did not .	negative	1
3973	10377478	3659;3456	IRF1;IFNbeta	***IRF1*** ***enhances*** the synthesis of ***IFNbeta*** but other pathways may be involved as well .	positive	0
3974	10377880	959;958	CD154;CD40	The ***interaction*** between B-cell molecule ***CD40*** and T-helper surface molecule ***CD154*** is the key event of B-cell (and other antigen-presenting cell) activation .	parallel	1
3975	10377945	10111;4361	hRad50;hMre11	This protein is a component of the ******hMre11/hRad50****** protein ***complex*** , suggesting a defect in DNA double-strand break ( DSB ) repair and/or cell cycle checkpoint function in NBS cells .	parallel	1
3976	10378690	4609;1017	c-Myc;cyclin-dependent kinase 2	Recent work suggests that ***c-Myc*** may ***stimulate*** the activity of cyclin ***E/cyclin-dependent kinase 2*** ( Cdk2 ) complexes and antagonize the action of the Cdk inhibitor p27KIP1 .	positive	0
3977	10378690	4609;1027	c-Myc;p27KIP1	Recent work suggests that ***c-Myc*** may stimulate the activity of cyclin E/cyclin-dependent kinase 2 ( Cdk2 ) complexes and ***antagonize*** the action of the Cdk inhibitor ***p27KIP1*** .	negative	1
3978	10378709	3565;2208	IL-4;CD23	Twelve patients had detectable levels of IL-4 in plasma and 10 in SF ( nine patients in both samples ) ; the absence of ***IL-4*** was ***related*** to a higher expression of ***CD23*** on CD5 + B cells and with higher levels of sCD23 .	parallel	0
3979	10378896	6464;2885	Shc;Grb2	Among upstream signaling molecules of ERK , ***Shc*** was constitutively ***associated*** with ***Grb2*** and was not tyrosine-phosphorylated by GM-CSF and FMLP , and Sos1 and c-Raf-1 were not phosphorylated by GM-CSF , IL-3 , TNF , and FMLP in monocytes , whereas all these signaling molecules were affected and/or utilized by GM-CSF in MO7e cells .	parallel	0
3980	10378898	4254;3815	SCF;c-Kit	******SCF/c-Kit****** ***interaction*** is one factor required for their maintenance , but involvement of other factor ( s ) in the conditioned medium of TBR59 stromal cells was suggested .	parallel	1
3981	10379702	1828;1830	Dsg1;Dsg3	In herpetiform pemphigus ( HP ) most sera recognize ***Dsg1*** and the rest of them ***recognize*** ***Dsg3*** , indicating that HP is a clinical variant of PF or PV .	target	1
3982	10379742	7157;581	p53;Bax	***p53*** mutations in bladder tumors ***inactivate*** the transactivation of the p21 and ***Bax*** genes , and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy .	positive	1
3983	10379742	7157;1026	p53;p21	***p53*** mutations in bladder tumors ***inactivate*** the transactivation of the ***p21*** and Bax genes , and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy .	positive	1
3984	10379742	7157;581	p53;Bax	CONCLUSIONS : The ***p53*** mutations , using functional assay in yeast , ***inactivate*** the transcription of p21 and ***Bax*** genes , and based on these preliminary results could have a useful predictive value for BCG therapy response in bladder cancer .	positive	1
3985	10379742	7157;1026	p53;p21	CONCLUSIONS : The ***p53*** mutations , using functional assay in yeast , ***inactivate*** the transcription of ***p21*** and Bax genes , and based on these preliminary results could have a useful predictive value for BCG therapy response in bladder cancer .	positive	1
3986	10379900	2661;3037	GDF-9;hyaluronan synthase 2	We find that recombinant ***GDF-9*** ***induces*** ***hyaluronan synthase 2*** ( HAS2 ) , cyclooxygenase 2 ( COX-2 ) , and steroidogenic acute regulator protein ( StAR ) mRNA synthesis but suppresses urokinase plasminogen activator ( uPA ) and LHR mRNA synthesis .	target	1
3987	10379900	2661;960	GDF-9;LHR	We find that recombinant ***GDF-9*** induces hyaluronan synthase 2 ( HAS2 ) , cyclooxygenase 2 ( COX-2 ) , and steroidogenic acute regulator protein ( StAR ) mRNA synthesis but ***suppresses*** urokinase plasminogen activator ( uPA ) and ***LHR*** mRNA synthesis .	negative	1
3988	10379900	2661;5328	GDF-9;uPA	We find that recombinant ***GDF-9*** induces hyaluronan synthase 2 ( HAS2 ) , cyclooxygenase 2 ( COX-2 ) , and steroidogenic acute regulator protein ( StAR ) mRNA synthesis but ***suppresses*** urokinase plasminogen activator ( ***uPA*** ) and LHR mRNA synthesis .	negative	1
3989	10379911	3574;596	IL-7;Bcl-2	This protection is partly mediated by ***IL-7*** ***induction*** of ***Bcl-2*** , however other IL-7-induced events are probably also involved in the trophic response .	target	1
3990	10380079	8829;10371	neuropilin-1;collapsin-1	These results together indicate that ***neuropilin-1*** ***mediates*** ***collapsin-1*** action on axoplasmic transport .	target	0
3991	10380079	10371;8829	collapsin-1;neuropilin-1	To visualize ***collapsin-1*** ***binding*** to endogenous ***neuropilin-1*** , we used a truncated collapsin-1-alkaline phosphatase fusion protein ( CAP-4 ) .	parallel	1
3992	10380878	274;4609	Bin1;Myc	***Bin1*** functionally ***interacts*** with ***Myc*** and inhibits cell proliferation via multiple mechanisms .	parallel	1
3993	10380878	4609;274	Myc;Bin1	These findings supported functional ***interaction*** between ***Myc*** and ***Bin1*** in cells and indicated that Bin1 could inhibit malignant cell growth through multiple mechanisms .	parallel	1
3994	10380881	7039;1956	TGFalpha;EGFR	ErbB2 transgene induction was accompanied by increased expression of ***TGFalpha*** , a ***ligand*** of epidermal growth factor receptor ( ***EGFR*** ) , and to a lesser extent , EGFR , further enhancing RTK signal transduction .	parallel	1
3995	10380882	7157;30008	p53;MBP1	Specific ***interaction*** between ***MBP1*** and mutant ***p53*** was illustrated by both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells .	parallel	1
3996	10380884	1432;3725	p38 MAP kinase;AP-1	Inhibition of ***p38 MAP kinase*** ***increases*** okadaic acid mediated ***AP-1*** expression and DNA binding but has no effect on TRE dependent transcription .	negative	0
3997	10380904	3586;4790	IL-10;NF-kappaB	Anti-inflammatory cytokines , ***IL-10*** , and transforming growth factor ( TGF ) - beta sequentially ***inhibited*** LPS - and cytokine-induced microglial cell ***NF-kappaB*** activation , RANTES mRNA expression , and protein release .	negative	1
3998	10380912	3385;3689	ICAM-3;LFA-1	***ICAM-3*** ***binds*** to ***LFA-1*** on antigen-presenting cells ( APC ) stabilizing the T cell-APC interaction , facilitating signaling through the CD3/TCR complex .	parallel	1
3999	10380930	965;914	CD58;CD2	***Interaction*** between ***CD2*** and its counterreceptor , ***CD58*** ( LFA-3 ) , on opposing cells optimizes immune recognition , facilitating contacts between helper T lymphocytes and antigen-presenting cells as well as between cytolytic effectors and target cells .	parallel	1
4000	10380930	914;965	CD2;CD58	Here , we report the crystal structure of the heterophilic adhesion ***complex*** between the amino-terminal domains of human ***CD2*** and ***CD58*** .	parallel	1
4001	10380930	914;965	CD2;CD58	These features explain ******CD2-CD58****** dynamic ***binding*** , offering insights into interactions of related immunoglobulin superfamily receptors .	parallel	1
4002	10381050	3586;3553	IL-10;IL-1beta	***IL-10*** ***correlated*** negatively with ***IL-1beta*** ( p = 0.013 ) and TNF-alpha ( p = 0.039 ) .	negative	0
4003	10381050	3586;7124	IL-10;TNF-alpha	***IL-10*** ***correlated*** negatively with IL-1beta ( p = 0.013 ) and ***TNF-alpha*** ( p = 0.039 ) .	negative	0
4004	10381168	3558;596	IL-2;Bcl-2	***Bcl-2*** downregulation and spontaneous apoptosis of T lymphocytes from HIV-infected individuals can be partially ***prevented*** by the exogeneous addition of ***IL-2*** , but not of IL-12 , IL-4 , or antibodies that prevent the CD95/CD95 ligand pathway of apoptosis .	negative	0
4005	10381168	3565;596	IL-4;Bcl-2	***Bcl-2*** downregulation and spontaneous apoptosis of T lymphocytes from HIV-infected individuals can be partially ***prevented*** by the exogeneous addition of IL-2 , but not of IL-12 , ***IL-4*** , or antibodies that prevent the CD95/CD95 ligand pathway of apoptosis .	negative	0
4006	10381170	373156;4899	GST;NRF1	Glutathione S-transferase ( GST ) pull-down experiments showed ***association*** of ***GST-Tax*** fusion protein with ***NRF1*** in vitro .	parallel	0
4007	10381257	10651;4580	metaxin 2;Metaxin 1	Metaxin 1 bound to a Ni2 + - chelate affinity column only in the presence of metaxin 2 , indicating that ***Metaxin 1*** and ***metaxin 2*** ***interact*** when overexpressed in insect cells .	parallel	1
4008	10381257	4580;10651	Metaxin 1;metaxin 2	***Metaxin 1*** ***interacts*** with ***metaxin 2*** , a novel related protein associated with the mammalian mitochondrial outer membrane .	parallel	1
4009	10381361	5617;356	PRL;FasL	These data suggest that the CD3-positive T lymphocyte in the CL is at least one of the PRL-effector cell species during the process of luteolysis in rats , and that ***FasL*** expression of these cells is ***upregulated*** by ***PRL*** .	positive	1
4010	10381377	6464;2885	Shc;Grb2	Although overexpression of SHIP2 did not affect insulin-induced tyrosine phosphorylation of the insulin receptor beta-subunit and Shc , subsequent ***association*** of ***Shc*** with ***Grb2*** was inhibited , possibly by competition between the SH2 domains of SHIP2 and Grb2 for the Shc phosphotyrosine .	parallel	0
4011	10381382	10163;10096	WAVE2;Arp2/3	Further , ***WAVE2*** and WAVE3 ***associate*** with the ***Arp2/3*** complex as does WAVE1 .	parallel	0
4012	10381382	10810;10096	WAVE3;Arp2/3	Further , WAVE2 and ***WAVE3*** ***associate*** with the ***Arp2/3*** complex as does WAVE1 .	parallel	0
4013	10381392	1984;7514	eIF-5A;CRM1	We are able to show that ***eIF-5A*** ***interacts*** with the general nuclear export receptor , ***CRM1*** .	parallel	1
4014	10381393	990;983	CDC6;Cdc2	The ***CDC6*** protein ***interacts*** in vivo with ***Cdc2*** kinase complexes .	parallel	1
4015	10381393	990;983	CDC6;Cdc2	Interestingly , ***CDC6*** is an in vitro ***substrate*** for ***Cdc13/Cdc2*** and Cig1/Cdc2 , but not for Cig2/Cdc2-associated kinases .	parallel	1
4016	10381499	6387;7852	SDF-1;CXCR4	These results suggest that ***CXCR4*** and its ***ligand*** ***SDF-1*** expressed in CD34 ( + ) progenitors may play an important role in regulating the local and systemic trafficking of these cells .	parallel	1
4017	10381499	3700;920	gp120;CD4	Moreover , these findings suggest multiple and potentially synergistic mechanisms at the basis of the resistance of CD34 ( + ) cells to X4 HIV infection , including their ability to produce SDF-1 , and the lack of CXCR4 internalization following ***gp120*** ***binding*** to ***CD4*** .	parallel	1
4018	10381499	6387;7852	stromal cell-derived factor-1;CXCR4	Human CD34 ( + ) cells express ***CXCR4*** and its ***ligand*** ***stromal cell-derived factor-1*** .	parallel	1
4019	10381499	6387;7852	stromal cell-derived factor-1;CXCR4	Human CD34 ( + ) hematopoietic progenitor cells obtained from bone marrow ( BM ) , umbilical cord blood ( UCB ) , and mobilized peripheral blood ( MPB ) were purified and investigated for the expression of the chemokine receptor ***CXCR4*** and its ***ligand*** , ***stromal cell-derived factor-1*** ( SDF-1 ) .	parallel	1
4020	10381501	2623;2056	GATA-1;erythropoietin	***GATA-1*** and ***erythropoietin*** ***cooperate*** to promote erythroid cell survival by regulating bcl-xL expression .	parallel	0
4021	10381501	2623;598	GATA-1;bcl-xL	Here we report that in erythroid cells , ***GATA-1*** strongly ***induces*** the expression of the anti-apoptotic protein ***bcl-xL*** , but not the related proteins bcl-2 and mcl-1 .	target	1
4022	10381501	2056;2623	erythropoietin;GATA-1	In addition , we show that ***erythropoietin*** , which is also required for erythroid cell survival , ***cooperates*** with ***GATA-1*** to stimulate bcl-xL gene expression and to maintain erythroid cell viability during terminal maturation .	parallel	0
4023	10381501	2056;598	erythropoietin;bcl-xL	In addition , we show that ***erythropoietin*** , which is also required for erythroid cell survival , cooperates with GATA-1 to ***stimulate*** ***bcl-xL*** gene expression and to maintain erythroid cell viability during terminal maturation .	positive	0
4024	10381534	4869;238	NPM;ALK	The tumor cells in both cases gave positive immunohistochemical labeling for ALK protein ( with both monoclonal and polyclonal antibodies ) , demonstrating that these translocations induce aberrant expression of this kinase and suggesting that genes other than ***NPM*** can ***activate*** the ***ALK*** gene in ALCL .	positive	1
4025	10381535	4352;7066	Mpl;thrombopoietin	The ***thrombopoietin*** ***receptor*** , ***Mpl*** , is a member of the cytokine receptor superfamily .	parallel	1
4026	10381539	627;2904	Brain-derived neurotrophic factor;NR2B	Our recent studies revealed that ***Brain-derived neurotrophic factor*** ( BDNF ) rapidly ***enhances*** tyrosine phosphorylation and dephosphorylation of the NMDA receptor subunit , ***NR2B*** , in the postsynaptic density ( PSD ) , potentially regulating synaptic plasticity .	positive	0
4027	10381546	5595;4741	Erk1;NF-M	In a previous study , we have demonstrated that a constitutively active form of MEK1 activates ***Erk1*** and Erk2 kinases , which ***phosphorylate*** co-transfected ***NF-M*** in NIH 3T3 cells .	target	1
4028	10381546	5594;4741	Erk2;NF-M	In a previous study , we have demonstrated that a constitutively active form of MEK1 activates Erk1 and ***Erk2*** kinases , which ***phosphorylate*** co-transfected ***NF-M*** in NIH 3T3 cells .	target	1
4029	10381547	3553;3557	IL-1beta;IL-1Ra	In both young and old rats , ***IL-1beta*** ***induced*** a significant up-regulation of cerebellar ***IL-1Ra*** , IL-1RI , and TGF-beta1 mRNAs ; hippocampal TGF-beta1 mRNA ; hypothalamic IL-1beta , IL-1Ra , TGF-beta1 , and gp 130 mRNAs ; and midbrain IL-1beta and TGF-beta1 mRNAs .	target	1
4030	10381566	4613;10397	N-myc;ndr1	***N-myc-dependent*** ***repression*** of ***ndr1*** , a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant .	negative	1
4031	10381566	10397;4613	ndr1;N-myc	To establish the direct ***link*** between ***N-myc*** activity and the ***ndr1*** regulation , the ndr1 gene was cloned and analyzed .	parallel	0
4032	10381566	4613;10397	N-myc;ndr1	The ***ndr1*** promoter activity was ***down-regulated*** by ***N-myc*** , and more strongly by the combination of N-myc and Max in the cotransfection assay .	negative	1
4033	10381567	5316;3211	PREP1;HOXB1	Human ***PREP1*** , a novel homeodomain protein of the TALE super-family , forms a stable DNA-binding complex with PBX proteins in solution , a ternary ***complex*** with PBX and ***HOXB1*** on DNA , and is able to act as a co-activator in the transcription of PBX-HOXB1 activated promoters ( Berthelsen , J. , Zappavigna , V. , Ferretti , E. , Mavilio , F. , Blasi , F. , 1998b .	parallel	1
4034	10381625	7157;355	p53;Fas	Recent evidence suggests an intriguing ***link*** between ***p53*** and the ***Fas*** pathway .	parallel	0
4035	10381630	356;355	CD95L;CD95	IAP proteins were not cleaved during ***CD95*** ***ligand*** ( ***CD95L*** ) - induced apoptosis , and loss of IAP protein expression was not responsible for the potentiation of CD95L-induced apoptosis when protein synthesis was inhibited .	parallel	1
4036	10381630	331;841	XIAP;caspase 8	However , ***XIAP*** failed to ***block*** ***caspase 8*** processing in LN-229 cells in the presence of CHX .	negative	0
4037	10381633	2247;836	bFGF;caspase-3	***bFGF*** ***inhibits*** the activation of ***caspase-3*** and apoptosis of P19 embryonal carcinoma cells during neuronal differentiation .	negative	1
4038	10381633	2247;836	bFGF;caspase-3	Basic fibroblast growth factor ( ***bFGF*** ) inhibited more than 90 % of the caspase-3-like activity , ***inhibited*** processing of ***caspase-3*** into its active form , and inhibited DNA fragmentation .	negative	1
4039	10381635	142;836	PARP;CPP32	In addition , poly - ( ADP-ribose ) polymerase ( ***PARP*** ) , a cellular ***substrate*** for ***CPP32*** protease was degraded to generate apoptotic fragments in Mn2 + - treated B cell lines .	parallel	1
4040	10381639	598;356	Bcl-XL;CD95-L	In addition , overexpression of ***Bcl-XL*** in CEM cells ***blocked*** doxorubicin-triggered ROS and ***CD95-L*** expression .	negative	0
4041	10381646	599;578	Bcl-w;Bak	Mutation of A1 at a highly conserved glycine within the BH1 domain prevented binding , but the comparable ***Bcl-w*** mutant still ***bound*** ***Bak*** , Bad and Bik , indicating that the glycine is not essential for all heterodimerization .	parallel	1
4042	10381646	599;638	Bcl-w;Bik	Mutation of A1 at a highly conserved glycine within the BH1 domain prevented binding , but the comparable ***Bcl-w*** mutant still ***bound*** Bak , Bad and ***Bik*** , indicating that the glycine is not essential for all heterodimerization .	parallel	1
4043	10381651	1019;595	cdk4;cyclin D1	Here we show that during early phase G1 arrest which occurs in UV-irradiated human U343 glioblastoma cells , there are ( 1 ) decreases in cyclin D1 and cdk4 levels which parallel a loss of S-phase promoting ******cyclin D1/cdk4****** ***complexes*** , and ( 2 ) increases in p53 and p21 protein levels .	parallel	1
4044	10381651	1019;595	cdk4;cyclin D1	We also show that the late phase UV-induced apoptosis of U343 cells occurs after cell cycle re-entry and parallels the reappearance of cyclin D1 and cdk4 and ******cyclin D1/cdk4****** ***complexes*** .	parallel	1
4045	10381819	355;356	Fas;Fas ligand	******Fas-Fas ligand****** ( FasL ) ***interactions*** play a significant role in the immune privilege status of certain cell populations , and several cytokines and growth factors can modulate their expression .	parallel	1
4046	10381821	6590;1991	Secretory leukocyte protease inhibitor;leukocyte elastase	***Secretory leukocyte protease inhibitor*** ( SLPI ) is a potent ***inhibitor*** of human ***leukocyte elastase*** .	negative	1
4047	10382071	11144;5888	DMC1;RAD51	The behaviour of ATR at meiotic prophase sets it apart from the distribution of the ******RAD51/DMC1****** recombinase ***complex*** and our electron microscope observations confirm that they do not co-localize .	parallel	1
4048	10382071	472;11144	Atm;DMC1	ATR , ***Atm*** and RAD1 , are ***associated*** with ***RAD51/DMC1*** recombination sites where DNA breaks are expected to be present , is therefore not supported by our observations .	parallel	0
4049	10382071	472;5888	Atm;RAD51	ATR , ***Atm*** and RAD1 , are ***associated*** with ***RAD51/DMC1*** recombination sites where DNA breaks are expected to be present , is therefore not supported by our observations .	parallel	0
4050	10382071	545;11144	ATR;DMC1	***ATR*** , Atm and RAD1 , are ***associated*** with ***RAD51/DMC1*** recombination sites where DNA breaks are expected to be present , is therefore not supported by our observations .	parallel	0
4051	10382071	545;5888	ATR;RAD51	***ATR*** , Atm and RAD1 , are ***associated*** with ***RAD51/DMC1*** recombination sites where DNA breaks are expected to be present , is therefore not supported by our observations .	parallel	0
4052	10382071	5810;11144	RAD1;DMC1	ATR , Atm and ***RAD1*** , are ***associated*** with ***RAD51/DMC1*** recombination sites where DNA breaks are expected to be present , is therefore not supported by our observations .	parallel	0
4053	10382071	5810;5888	RAD1;RAD51	ATR , Atm and ***RAD1*** , are ***associated*** with ***RAD51/DMC1*** recombination sites where DNA breaks are expected to be present , is therefore not supported by our observations .	parallel	0
4054	10382239	551;6647	antidiuretic hormone;ALS	Based on these findings , the patient was diagnosed as having the syndrome of inappropriate secretion of ***antidiuretic hormone*** ( SIADH ) ***associated*** with amyotrophic lateral sclerosis ( ***ALS*** ) .	parallel	0
4055	10382266	1634;7040	decorin;TGF-beta	***decorin*** ***binds*** to ***TGF-beta*** , thus inhibiting its bioactivity , and is a direct or indirect negative modulator of TGF-beta synthesis .	parallel	1
4056	10382266	1634;7040	decorin;TGF-beta	Here , we discuss ***interactions*** of ***decorin*** with ***TGF-beta*** and with p21 , both of which are relevant to carcinogenesis and tumor progression .	parallel	1
4057	10382302	6603;5705	BAF60b;thyroid hormone receptor interacting protein-1	Evidence for evolutionary conservation of a physical ***linkage*** between the human ***BAF60b*** , a subunit of SWI/SNF complex , and ***thyroid hormone receptor interacting protein-1*** genes on chromosome 17 .	parallel	0
4058	10382539	4149;4609	MAX;MYC	Repression mediated by MAD is thought to antagonize the transcriptional activation and proliferation-promoting functions of ******MYC-MAX****** ***heterodimers*** .	parallel	1
4059	10382588	7351;3952	UCP2;leptin	Although no association was found between the UCP2 exon 8 variant and overt obesity in British subjects , the ***UCP2*** genotype of obese women ( n = 83 ) ***correlated*** with fasting serum ***leptin*** concentration ( p = 0.006 ) in the presence of extreme obesity .	parallel	0
4060	10382740	8742;3725	TWEAK;c-jun	In contrast to TNF , ***TWEAK*** does only modestly ***activate*** NF-kappaB or ***c-jun*** N-terminal kinase ( JNK ) in Kym-1 cells .	positive	1
4061	10382740	8742;5599	TWEAK;JNK	In contrast to TNF , ***TWEAK*** does only modestly ***activate*** NF-kappaB or c-jun N-terminal kinase ( ***JNK*** ) in Kym-1 cells .	positive	1
4062	10382740	8742;4790	TWEAK;NF-kappaB	In contrast to TNF , ***TWEAK*** does only modestly ***activate*** ***NF-kappaB*** or c-jun N-terminal kinase ( JNK ) in Kym-1 cells .	positive	1
4063	10382744	7852;6387	CXCR4;stromal cell-derived factor-1	Expression of ***CXCR4*** , the ***receptor*** for ***stromal cell-derived factor-1*** on fetal and adult human lympho-hematopoietic progenitors .	parallel	1
4064	10382744	7852;6387	CXCR4;SDF-1	We investigated the expression of ***CXCR4*** , the ***receptor*** for ***SDF-1*** , on CD34 + cells from different hematopoietic sites and developmental stages .	parallel	1
4065	10382746	7006;3558	Tec;IL-2	***Tec*** kinase is involved in transcriptional ***regulation*** of ***IL-2*** and IL-4 in the CD28 pathway .	target	1
4066	10382746	7006;3565	Tec;IL-4	***Tec*** kinase is involved in transcriptional ***regulation*** of IL-2 and ***IL-4*** in the CD28 pathway .	target	1
4067	10382746	3932;7006	Lck;Tec	Here , we show in heterologous COS-7 cells that co-expression of Src family kinases such as Lck increases Tec activation or CD28-mediated Tec activation , whereas co-expression of kinase-dead ***Lck*** ***blocks*** Tec activation or CD28-mediated ***Tec*** activation .	negative	0
4068	10382746	940;7006	CD28;Tec	These data suggest that ***CD28*** ***activates*** ***Tec*** via Src family PTK .	positive	1
4069	10382758	718;1378	C3b;CR1	When compared to full-length ( 30 SCR ) soluble CR1 ( sCR1 ) , SCR ( 1-3 ) was significantly less potent in accord with a model involving multi-valent ***binding*** of ***C3b/C4b*** to ***CR1*** .	parallel	1
4070	10382758	721;1378	C4b;CR1	When compared to full-length ( 30 SCR ) soluble CR1 ( sCR1 ) , SCR ( 1-3 ) was significantly less potent in accord with a model involving multi-valent ***binding*** of ***C3b/C4b*** to ***CR1*** .	parallel	1
4071	10383008	3990;5741	hepatic lipase;parathormone	Uraemic hypertriglyceridaemia is due , in part , to lipoprotein lipase and ***hepatic lipase*** deficiencies , which are causally ***linked*** to excess ***parathormone*** ( PTH ) .	parallel	0
4072	10383008	4023;5741	lipoprotein lipase;parathormone	Uraemic hypertriglyceridaemia is due , in part , to ***lipoprotein lipase*** and hepatic lipase deficiencies , which are causally ***linked*** to excess ***parathormone*** ( PTH ) .	parallel	0
4073	10383053	1437;3717	GM-CSF;Jak2	In addition , ***GM-CSF*** ***induced*** ***Jak2*** , STAT5A , and STAT5B in BV-2 cells , as it does in monocytes and macrophages .	target	1
4074	10383053	1437;6776	GM-CSF;STAT5A	In addition , ***GM-CSF*** ***induced*** Jak2 , ***STAT5A*** , and STAT5B in BV-2 cells , as it does in monocytes and macrophages .	target	1
4075	10383053	1437;6777	GM-CSF;STAT5B	In addition , ***GM-CSF*** ***induced*** Jak2 , STAT5A , and ***STAT5B*** in BV-2 cells , as it does in monocytes and macrophages .	target	1
4076	10383054	5660;5594	Prosaposin;ERK	Recently , we demonstrated that ***Prosaposin*** and prosaptides ( peptides encompassing the neurotrophic sequence in Prosaposin ) ***prevent*** cell death and increase extracellular regulated kinase ( ***ERK*** ) phosphorylation and sulfatide content in primary Schwann cells or oligodendrocytes ( Hiraiwa et al. , 1997a ) .	negative	0
4077	10383113	4803;4914	NGF;TrkA	In this review , we will overview the evidence implicating specific signaling cascades in aspects of the cellular response to the neurotrophins , specifically in response to ***activation*** of ***TrkA*** by ***NGF*** .	positive	1
4078	10383128	8743;8795	TRAIL;KILLER/DR5	Molecular cloning and functional analysis of the mouse homologue of the ***KILLER/DR5*** tumor necrosis factor-related apoptosis-inducing ***ligand*** ( ***TRAIL*** ) death receptor .	parallel	1
4079	10383130	8626;7157	p63;p53	We found that ***p51/p63*** ***trans-activated*** the previously identified ***p53*** target genes , but the degree of the transactivation by p51/p63 differed from that by p53 .	positive	1
4080	10383144	3084;5829	HRG;paxillin	Because the process of cell migration must involve dynamic changes in the formation of new focal adhesions at the leading edge and dissolution of preexisting focal points , we explored the potential ***HRG*** ***regulation*** of ***paxillin*** , a major component of focal adhesion .	target	1
4081	10383144	3084;5829	HRG;paxillin	The observed HRG stimulation of paxillin mRNA expression was completely blocked by actinomycin D ( a transcriptional inhibitor ) as well as by cycloheximide ( a protein synthesis inhibitor ) , suggesting the involvement of an inducible protein factor ( s ) and transcriptional ***regulation*** of ***paxillin*** mRNA by ***HRG*** .	target	1
4082	10383144	3084;5829	HRG;paxillin	The observed ***HRG*** ***stimulation*** of ***paxillin*** mRNA expression was completely blocked by actinomycin D ( a transcriptional inhibitor ) as well as by cycloheximide ( a protein synthesis inhibitor ) , suggesting the involvement of an inducible protein factor ( s ) and transcriptional regulation of paxillin mRNA by HRG .	positive	0
4083	10383148	1464;373156	NG2;GST	In addition , direct ***binding*** between GST-TAASGVRSMH and ***GST-LTLRWVGLMS*** fusion proteins and ***NG2*** was demonstrated in solid-phase binding assays .	parallel	1
4084	10383163	1051;3553	NF-IL6;IL-1beta	Treatment with the FTase inhibitors resulted in a concentration-dependent decrease in both ***NF-IL6/CREB*** ***binding*** to the ***IL-1beta*** promoter and IL-1beta protein levels , without a significant change in total cellular protein levels .	parallel	1
4085	10383394	960;3458	CD44;interferon-gamma	***CD44*** , a cell surface chondroitin sulfate proteoglycan , ***mediates*** binding of ***interferon-gamma*** and some of its biological effects on human vascular smooth muscle cells .	target	0
4086	10383403	5590;10818	PKC zeta;FRS2	***PKC zeta*** , the other member of the atypical PKC subfamily , could also ***bind*** ***FRS2*** .	parallel	1
4087	10383426	1471;115209	cystatin C;peptidase	We have investigated the ***inhibition*** of the recently identified family C13 cysteine ***peptidase*** , pig legumain , by human ***cystatin C*** .	negative	1
4088	10383426	5641;1471	legumain;cystatin C	A ternary ***complex*** between ***legumain*** , ***cystatin C*** , and papain was demonstrated by gel filtration supported by immunoblotting .	parallel	1
4089	10383427	3949;4018	LDLR;lipoprotein	To evaluate the contribution of the macrophage low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) to atherosclerotic lesion formation , we performed bone marrow transplantation studies in different mouse strains .	parallel	1
4090	10383440	6774;5008	STAT3;oncostatin M	Moreover , ***dn-STAT3*** ***blocked*** the ability of either IL-6 + soluble IL-6 receptor or ***oncostatin M*** to induce RANKL .	negative	0
4091	10383452	973;959	Igalpha;IgM	Finally , the ***Igalpha/Igbeta*** heterodimers ***associated*** with fully assembled ***IgM*** molecules as a terminal event in B cell receptor assembly .	parallel	0
4092	10383452	974;959	Igbeta;IgM	Finally , the ***Igalpha/Igbeta*** heterodimers ***associated*** with fully assembled ***IgM*** molecules as a terminal event in B cell receptor assembly .	parallel	0
4093	10383452	974;973	Igbeta;Igalpha	Finally , the ******Igalpha/Igbeta****** ***heterodimers*** associated with fully assembled IgM molecules as a terminal event in B cell receptor assembly .	parallel	1
4094	10383460	7329;367	Ubc9;androgen receptor	***Ubc9*** ***interacts*** with the ***androgen receptor*** and activates receptor-dependent transcription .	parallel	1
4095	10383609	2353;3725	C-fos;c-jun	We investigated the role of ***C-fos*** ***dimerizing*** with ***c-jun*** in controlling the induction of maternal behaviour , altered peptide gene expression , and oxytocin and amino acid release in this region at birth .	parallel	1
4096	10383816	959;836	IgM;CPP32	In each instance where microfilament assembly is inhibited , ***anti-IgM-induced*** ***activation*** of the protease ***CPP32*** ( caspase ) is also inhibited .	positive	1
4097	10383823	3558;3001	interleukin 2;granzyme A	***interleukin 2*** ***increased*** ***granzyme A*** protein expression independent of alcohol consumption ; however , this increase was associated with decreased enzyme activity .	positive	0
4098	10383894	3077;7037	HFE;TFR	The HFE wild-type gene product complexes with the transferrin receptor ( TF ) and two different ***HFE*** mutations ( Cys282Tyr and His63Asp ) have been found to ***increase*** the affinity of ***TFR*** for TF and increase cellular iron uptake .	negative	0
4099	10383894	7037;3077	TFR;HFE	In a recent study we found no associations for HFE and TFR separately , but an ***interaction*** between ***HFE*** and ***TFR*** genotypes in multiple myeloma .	parallel	1
4100	10383894	7037;3077	TFR;HFE	Thus , an ***interaction*** between ***HFE*** and ***TFR*** alleles may increase the risk for different neoplastic disorders .	parallel	1
4101	10383941	960;2885	CD44;Grb2	We found that ***CD44*** cross-linking by mAb in CD4 ( + ) peripheral blood T cells ***promotes*** formation of a trimeric complex of ***Grb2*** , phospholipase ( PLC ) - gamma1 and a 36-38 kDa phosphoprotein , and the activation of PLC-gamma1 .	positive	0
4102	10383941	2885;5335	Grb2;PLC-gamma1	We found that CD44 cross-linking by mAb in CD4 ( + ) peripheral blood T cells promotes formation of a trimeric ***complex*** of ***Grb2*** , phospholipase ( PLC ) - gamma1 and a 36-38 kDa phosphoprotein , and the activation of ***PLC-gamma1*** .	parallel	1
4103	10383941	960;920	CD44;CD4	Co-capping , co-immunoprecipitation and fluorescence resonance energy transfer experiments showed that ***CD44*** ***associates*** with ***CD4*** and CD3 on the cell surface .	parallel	0
4104	10383941	920;960	CD4;CD44	This association suggests functional ***interplay*** between the ***CD4-TCR*** complex and ***CD44*** .	parallel	1
4105	10383941	3700;920	gp120;CD4	In line with this possibility , we found that CD4 triggering by ***gp120*** , a natural ***ligand*** of ***CD4*** , potentiates CD44-mediated adhesion to hyaluronic acid .	parallel	1
4106	10384100	940;941	CD28;B7.1	In this study , we have evaluated the potential of human ******B7.1-CD28****** ***interaction*** as an activating trigger for human blood NK cells .	parallel	1
4107	10384102	958;959	CD40;CD40 ligand	We conclude that CD4 + T cells play a critical role in the generation of antitumor immune responses through their capacity to induce the activation of DC via ******CD40/CD40 ligand****** ***interaction*** , and thus maximize CD8 + T cell responses .	parallel	1
4108	10384104	959;958	CD40L;CD40	This study demonstrates that Ag-activated CD4 + NKT cells express ***CD40*** ***ligand*** ( ***CD40L*** ) ( CD154 ) , which engages CD40 on APC and stimulates them to produce IL-12 .	parallel	1
4109	10384107	940;3558	CD28;IL-2	We find that ***CD28*** signaling acts transiently to ***stabilize*** the ***IL-2*** mRNA following T cell activation .	positive	0
4110	10384135	7295;4792	TRX;IkappaBalpha	Consistent with these findings , the ***IkappaBalpha*** phosphorylation at Ser32 and its subsequent degradation in response to TNF-alpha was ***facilitated*** by ***TRX*** .	positive	0
4111	10384135	1401;7124	C-reactive protein;TNF-alpha	Multiple regression analysis revealed that the serum ***C-reactive protein*** value was better ***correlated*** with the linear combination of SF ***TNF-alpha*** and SF TRX values than with SF TNF-alpha alone , suggesting that TRX might play a subsidiary role in the rheumatoid inflammation .	parallel	0
4112	10384140	653509;929	SP-A;CD14	These results demonstrate the different actions of SP-A upon distinct serotypes of LPS and indicate that the direct ***interaction*** of ***SP-A*** with ***CD14*** constitutes a likely mechanism by which SP-A modulates LPS-elicited cellular responses .	parallel	1
4113	10384140	653509;7124	SP-A;TNF-alpha	In the macrophage-like cell line U937 , ***SP-A*** ***inhibited*** mRNA expression and secretion of ***TNF-alpha*** induced by smooth LPS , but rough LPS-induced TNF-alpha expression was unaffected by SP-A .	negative	1
4114	10384140	653509;929	SP-A;CD14	To clarify the mechanism by which SP-A modulates LPS-elicited cellular responses , we further examined the ***interaction*** of ***SP-A*** with ***CD14*** , which is known as a major LPS receptor .	parallel	1
4115	10384140	653509;929	SP-A;CD14	In addition , ***SP-A*** directly ***bound*** to recombinant soluble ***CD14*** ( rsCD14 ) .	parallel	1
4116	10384144	5747;1234	FAK;CCR5	HIV envelope-induced cellular ***association*** of ***FAK*** and ***CCR5*** was also demonstrated , suggesting that ligation of CD4 and CCR5 leads to the formation of an activation complex composed of FAK and CCR5 .	parallel	0
4117	10384145	3551;4790	IKK-2;NF-kappa B	This is the first demonstration that ***IKK-2*** is a pivotal ***regulator*** of ***NF-kappa B*** in primary human cells .	target	1
4118	10384146	4982;8600	osteoclastogenesis inhibitory factor;ODF	A soluble form of RANK as well as ***osteoprotegerin/osteoclastogenesis inhibitory factor*** , a decoy ***receptor*** of ***ODF*** , blocked OCL formation and prevented the survival , multinucleation , and pit-forming activity of pOCs induced by sODF .	parallel	1
4119	10384149	3567;241	IL-5;FLAP	We hypothesized that ***IL-5*** ***induces*** the expression of 5-LO and/or its activating protein ***FLAP*** in eosinophils , and that this might be modulated by anti-inflammatory corticosteroids .	target	1
4120	10384149	3567;241	IL-5;FLAP	Compared with control cultures , ***IL-5*** increased the proportion of normal blood eosinophils immunostaining for FLAP ( 65 + / - 4 vs 34 + / - 4 % ; p < 0.0001 ) , ***enhanced*** immunoblot levels of ***FLAP*** by 51 + / - 14 % ( p = 0.03 ) , and quadrupled ionophore-stimulated leukotriene C4 synthesis from 5.7 to 20.8 ng/106 cells ( p < 0.02 ) .	positive	0
4121	10384149	3567;241	IL-5;FLAP	Thus , ***IL-5*** ***increases*** ***FLAP*** expression and translocates 5-LO to the nucleus in normal blood eosinophils in vitro .	positive	0
4122	10384156	958;941	CD40;B7-1	Neither IFN-gamma plus TNF-alpha nor ***CD40*** stimulation significantly ***induced*** ***B7-1*** or up-regulated B7-2 on human myeloma cell line or primary myeloma cells from six of seven patients .	target	1
4123	10384156	958;942	CD40;B7-2	Neither IFN-gamma plus TNF-alpha nor ***CD40*** stimulation significantly ***induced*** B7-1 or up-regulated ***B7-2*** on human myeloma cell line or primary myeloma cells from six of seven patients .	target	1
4124	10384156	3458;941	IFN-gamma;B7-1	Neither ***IFN-gamma*** plus TNF-alpha nor CD40 stimulation significantly ***induced*** ***B7-1*** or up-regulated B7-2 on human myeloma cell line or primary myeloma cells from six of seven patients .	target	1
4125	10384156	3458;942	IFN-gamma;B7-2	Neither ***IFN-gamma*** plus TNF-alpha nor CD40 stimulation significantly ***induced*** B7-1 or up-regulated ***B7-2*** on human myeloma cell line or primary myeloma cells from six of seven patients .	target	1
4126	10384156	7124;941	TNF-alpha;B7-1	Neither IFN-gamma plus ***TNF-alpha*** nor CD40 stimulation significantly ***induced*** ***B7-1*** or up-regulated B7-2 on human myeloma cell line or primary myeloma cells from six of seven patients .	target	1
4127	10384156	7124;942	TNF-alpha;B7-2	Neither IFN-gamma plus ***TNF-alpha*** nor CD40 stimulation significantly ***induced*** B7-1 or up-regulated ***B7-2*** on human myeloma cell line or primary myeloma cells from six of seven patients .	target	1
4128	10384404	796;54826	CGRP;Gin-1	When cells were pretreated with PD98059 , a selective inhibitor of MAPK kinase ( also known as MEK ) , ***CGRP*** not only failed to induce phosphorylation of MAPK but also failed to ***stimulate*** ***Gin-1*** cell proliferation .	positive	0
4129	10384879	7124;3398	TNF alpha;Id2	***TNF alpha*** also ***increased*** ***Id2*** mRNA expression in the caudate putamen and hippocampus at the injection site .	positive	0
4130	10384880	4916;4908	TrkC;Neurotrophin-3	***Neurotrophin-3*** ( NT-3 ) and its ***receptor*** ***TrkC*** are known to be important for neuronal survival .	parallel	1
4131	10384911	7432;3458	VIP;interferon gamma	***VIP*** , at 10 ( -5 ) mol/l and serotonin at 10 ( -4 ) mol/l ***stimulated*** the secretion of ***interferon gamma*** .	positive	0
4132	10384959	3329;3336	GroEL;GroES	The dynamic ***interaction*** of ***GroEL*** and ***GroES*** is regulated by the GroEL ATPase and involves the formation of asymmetrical GroEL : GroES1 and symmetrical GroEL : GroES2 complexes .	parallel	1
4133	10384959	3329;3336	GroEL;GroES	The dynamic interaction of GroEL and ***GroES*** is ***regulated*** by the ***GroEL*** ATPase and involves the formation of asymmetrical GroEL : GroES1 and symmetrical GroEL : GroES2 complexes .	target	1
4134	10385244	4363;3569	MRP1;IL-6	These results indicate that the membrane transporter ***MRP1*** is involved in the ***regulation*** of ***IL-6*** expression in activated human peripheral blood monocytes .	target	1
4135	10385249	2056;4843	erythropoietin;iNOS	Recombinant human ***erythropoietin*** ***inhibits*** ***iNOS*** activity and reverts vascular dysfunction in splanchnic artery occlusion shock .	negative	1
4136	10385397	7124;3939	Tumor necrosis factor-alpha;lactate dehydrogenase A	***Tumor necrosis factor-alpha*** ***stimulates*** ***lactate dehydrogenase A*** expression in porcine cultured sertoli cells : mechanisms of action .	positive	0
4137	10385398	7124;4155	TNF-alpha;MBP	While ***TNF-alpha*** ***decreased*** ***MBP*** and PLP mRNA abundance by 5 - to 6-fold , IGF-I abrogated TNF-alpha-induced reductions in a dose - and time-dependent manner .	negative	0
4138	10385398	7124;5354	TNF-alpha;PLP	While ***TNF-alpha*** ***decreased*** MBP and ***PLP*** mRNA abundance by 5 - to 6-fold , IGF-I abrogated TNF-alpha-induced reductions in a dose - and time-dependent manner .	negative	0
4139	10385400	3479;3485	IGF-I;IGFBP-2	Affinity cross-linking of [ 125I ] IGF-I to neuroblastoma cell membranes followed by immunoprecipitation revealed a approximately 38 kDa [ 125I ] ******IGF-I/IGFBP-2****** ***complex*** .	parallel	1
4140	10385409	5741;5744	PTH;PTHrP	Similarly , ***PTH*** ( 1-34 ) treatment for 48 h ***abolished*** ***PTHrP*** binding to cell surface receptors ; however , neither the PTH analogs nor the cAMP regulating agents altered PTH binding or numbers of binding sites on osteoblastic cells .	negative	0
4141	10385409	5741;632	PTH;OCN	THFA and PTH ( 7-34 ) - treated cultures had increased OCN expression ; whereas , ***PTH*** ( 1-34 ) and forskolin ***reduced*** ***OCN*** expression .	negative	1
4142	10385410	5594;3480	ERK2;insulin-like growth factor 1 receptor	Prolonged activation of ***ERK2*** by epidermal growth factor and other growth factors ***requires*** a functional ***insulin-like growth factor 1 receptor*** .	target	0
4143	10385413	4852;3952	NPY;leptin	It was found that the combined i.c.v. infusion of ***NPY*** and dexamethasone in ADX rats ***increased*** food intake , body weight , plasma insulin , ***leptin*** , and triglyceride levels relative to vehicle-infused ADX controls .	positive	0
4144	10385418	3458;834	IFNgamma;caspase 1	Apoptosis in NIT-1 cells was increased by coincubation with ***IFNgamma*** , which also ***increased*** ***caspase 1*** expression .	positive	0
4145	10385423	7200;5443	thyrotropin-releasing hormone;alpha-melanocyte-stimulating hormone	Involvement of protein kinase C and protein tyrosine kinase in ***thyrotropin-releasing hormone-induced*** ***stimulation*** of ***alpha-melanocyte-stimulating hormone*** secretion in frog melanotrope cells .	positive	0
4146	10385500	6868;7124	TACE;TNF-alpha	CONCLUSIONS : This study has shown that increased myocardial ***TACE*** expression is ***associated*** with elevated myocardial ***TNF-alpha*** expression in both mRNA and protein levels in clinically advanced DCM .	parallel	0
4147	10385525	5747;5599	FAK;JNK	******FAK-JNK****** ***signaling*** was necessary for proper progression through the G1 phase of the cell cycle .	parallel	0
4148	10385526	7128;4790	A20;NF-kappaB	Moreover , ***NF-kappaB*** activation induced by overexpression of the TNF receptor-associated proteins TNF receptor-associated death domain protein ( TRADD ) , receptor interacting protein ( RIP ) , and TNF recep - tor-associated factor 2 ( TRAF2 ) was also ***inhibited*** by expression of ***A20*** , whereas NF-kappaB activation induced by overexpression of NF-kappaB-inducing kinase ( NIK ) or the human T cell leukemia virus type 1 ( HTLV-1 ) Tax was unaffected .	negative	1
4149	10385551	7157;3308	p53;HSP70	Wild-type ***p53*** has been reported to ***repress*** ***HSP70*** gene expression .	negative	1
4150	10385551	3308;7157	HSP70;p53	It has been shown that mutant ******p53-HSP70****** ***complex*** is highly expressed in cancer .	parallel	1
4151	10385598	3553;5743	IL-1beta;COX-2	Moreover , ***IL-1beta*** ***induced*** ***COX-2*** expression in both cell types .	target	1
4152	10385598	3553;4843	IL-1beta;iNOS	By contrast , ***IL-1beta*** ***stimulated*** the expression of ***iNOS*** protein in rat cells only .	positive	0
4153	10385599	10724;5706	beta-hexosaminidase;p44	***beta-hexosaminidase-induced*** ***activation*** of ***p44/42*** mitogen-activated protein kinase is dependent on p21Ras and protein kinase C and mediates bovine airway smooth-muscle proliferation .	positive	1
4154	10385613	3952;3725	Leptin;c-Jun	In addition , ***Leptin*** ***activated*** the NH2-terminal ***c-Jun*** kinase/stress-activated protein kinase pathway as demonstrated by enhanced JNK activity and AP-1 DNA binding .	positive	1
4155	10385613	3952;4790	Leptin;NF-kappaB	***NF-kappaB*** , another redox-sensitive transcription factor , was also ***activated*** by ***Leptin*** stimulation in an oxidant-dependent manner .	positive	1
4156	10385613	3725;6347	AP-1;monocyte chemoattractant protein-1	Finally , activation of both ***AP-1*** and NF-kappaB was ***associated*** with an enhanced expression of the ***monocyte chemoattractant protein-1*** in HUVEC .	parallel	0
4157	10385613	4790;6347	NF-kappaB;monocyte chemoattractant protein-1	Finally , activation of both AP-1 and ***NF-kappaB*** was ***associated*** with an enhanced expression of the ***monocyte chemoattractant protein-1*** in HUVEC .	parallel	0
4158	10385629	23462;997	Hrt1;Cdc34	***Hrt1*** assembles into recombinant SCF complexes and individually ***binds*** Cdc4 , Cdc53 and ***Cdc34*** , but not Skp1 .	parallel	1
4159	10385629	23462;55294	Hrt1;Cdc4	***Hrt1*** assembles into recombinant SCF complexes and individually ***binds*** ***Cdc4*** , Cdc53 and Cdc34 , but not Skp1 .	parallel	1
4160	10385629	23462;6500	Hrt1;Skp1	***Hrt1*** assembles into recombinant SCF complexes and individually ***binds*** Cdc4 , Cdc53 and Cdc34 , but not ***Skp1*** .	parallel	1
4161	10385629	23462;4254	Hrt1;SCF	***Hrt1*** ***stimulates*** the E3 activity of recombinant ***SCF*** potently and enables the reconstitution of Cln2 ubiquitination by recombinant SCFGrr1 .	positive	0
4162	10385629	23493;8454	HRT2;CUL-1	The highly conserved human Hrt1 complements the lethality of hrt1Delta , and human ***HRT2*** ***binds*** ***CUL-1*** .	parallel	1
4163	10385651	3082;598	HGF;Bcl-xL	Moreover , ***HGF*** strongly ***induced*** ***Bcl-xL*** expression and blocked apoptotic signal transduction upstream of CPP32 ( caspase-3 ) in the liver , thereby leading to inhibition of massive hepatocyte apoptosis .	target	1
4164	10385656	7040;356	TGF-beta;CD95L	***TGF-beta*** and TNF-alpha significantly ***reduced*** expression of ***CD95L*** in activated HSCs , whereas CD95 expression remained unchanged .	negative	1
4165	10385656	7124;356	TNF-alpha;CD95L	TGF-beta and ***TNF-alpha*** significantly ***reduced*** expression of ***CD95L*** in activated HSCs , whereas CD95 expression remained unchanged .	negative	1
4166	10385657	3586;2920	IL-10;MIP-2	***IL-10*** ***suppressed*** NFkappaB activation as well as messenger RNA expression of tumor necrosis factor-alpha ( TNF-alpha ) and macrophage inflammatory protein-2 ( ***MIP-2*** ) .	negative	1
4167	10385657	3586;7124	IL-10;TNF-alpha	***IL-10*** ***suppressed*** NFkappaB activation as well as messenger RNA expression of tumor necrosis factor-alpha ( ***TNF-alpha*** ) and macrophage inflammatory protein-2 ( MIP-2 ) .	negative	1
4168	10385657	3586;4790	IL-10;NFkappaB	***IL-10*** ***suppressed*** ***NFkappaB*** activation as well as messenger RNA expression of tumor necrosis factor-alpha ( TNF-alpha ) and macrophage inflammatory protein-2 ( MIP-2 ) .	negative	1
4169	10385657	3586;2920	IL-10;MIP-2	In addition , ***IL-10*** ***reduced*** serum levels of TNF-alpha and ***MIP-2*** .	negative	1
4170	10385657	3586;7124	IL-10;TNF-alpha	In addition , ***IL-10*** ***reduced*** serum levels of ***TNF-alpha*** and MIP-2 .	negative	1
4171	10385700	4804;627	p75;neurotrophin	L-753 ,000 was effective at nanomolar concentrations in a Chinese hamster ovary cell line that expressed TrkA but was devoid of ***p75*** , the low-affinity ***neurotrophin*** ***receptor*** .	parallel	1
4172	10385700	4908;4914	NT-3;TrkA	Because L-753 , 000 selectively potentiates the ***NT-3-induced*** ***stimulation*** of ***TrkA*** without inhibiting Trks and other protein kinases , it represents a novel class of selective modifiers of neurotrophin actions .	positive	0
4173	10385702	2247;5594	FGF-2;mitogen-activated protein kinase-1	Moreover , the polysulfonates PSS and PAS inhibited ***FGF-2-induced*** ***activation*** of ***mitogen-activated protein kinase-1/2*** , involved in FGF-2 signal transduction .	positive	1
4174	10385702	2247;2260	FGF-2;FGFR-1	The antiproliferative activity of these compounds was associated with the abrogation of ***FGF-2-induced*** tyrosine ***phosphorylation*** of ***FGFR-1*** .	target	1
4175	10385705	10267;3375	RAMP 1;amylin	Cotransfection of ***RAMP 1*** or RAMP 3 with the human CT receptor lacking the 16-amino acid insert in intracellular domain 1 ( hCTRI1 - ) into COS-7 cells ***induced*** specific 125I-labeled rat ***amylin*** binding .	target	1
4176	10385705	10268;3375	RAMP 3;amylin	Cotransfection of RAMP 1 or ***RAMP 3*** with the human CT receptor lacking the 16-amino acid insert in intracellular domain 1 ( hCTRI1 - ) into COS-7 cells ***induced*** specific 125I-labeled rat ***amylin*** binding .	target	1
4177	10386007	5972;183	renin;angiotensinogen	These results suggest the possibility that CG ***renin*** is transferred to the uterine epithelium at mating and temporarily ***activates*** the expression of ***angiotensinogen*** in the uterus .	positive	1
4178	10386600	1017;6502	Cdk2;Skp2	In addition , cyclin ***A/Cdk2*** complexes from regenerating liver clearly ***interacted*** with ***Skp2*** .	parallel	1
4179	10386606	183;5594	angiotensin II;extracellular signal-regulated kinase 1/2	***Activation*** of ***extracellular signal-regulated kinase 1/2*** by ***angiotensin II*** is a multistep process involving both its phosphorylation by mitogen-activated protein kinase extracellular signal-regulated kinase kinase in the cytoplasm and a subsequent translocation to the nucleus .	positive	1
4180	10386606	183;5594	angiotensin II;extracellular signal-regulated kinase 1/2	In contrast , ***angiotensin II-induced*** ***activation*** of protein kinase Czeta and ***extracellular signal-regulated kinase 1/2*** in the nucleus were both inhibited by troglitazone .	positive	1
4181	10386610	7124;6352	tumor necrosis factor-alpha;RANTES	In A549 cells , interleukin-1beta and ***tumor necrosis factor-alpha*** ***induced*** endogenous ***RANTES*** protein secretion , mRNA expression , and promoter activity .	target	1
4182	10386612	5266;1991	Elafin;neutrophil elastase	***Elafin*** ( elastase-specific inhibitor ) is a low molecular weight ***inhibitor*** of ***neutrophil elastase*** which is secreted in the lung .	negative	1
4183	10386854	1051;4790	NF-IL-6;NF-kappaB	AP-1 and ***NF-IL-6*** physically ***interact*** with ***NF-kappaB*** , and functional cooperativity among the factors appears to be critical for optimal IL-8 promoter activity in different cell types .	parallel	1
4184	10386953	627;5781	BDNF;Shp2	In PC12 cells stably expressing TrkB , both ***BDNF*** and nerve growth factor ***stimulated*** ***Shp2*** signaling similarly to that by BDNF in cultured cortical neurons .	positive	0
4185	10386953	4803;5781	nerve growth factor;Shp2	In PC12 cells stably expressing TrkB , both BDNF and ***nerve growth factor*** ***stimulated*** ***Shp2*** signaling similarly to that by BDNF in cultured cortical neurons .	positive	0
4186	10386953	5781;627	Shp2;BDNF	These results indicated that Shp2 shows cross-talk with various signaling molecules including Grb2 and PI3-K in BDNF-induced signaling and that ***Shp2*** may be involved in the ***regulation*** of various actions of ***BDNF*** in CNS neurons .	target	1
4187	10386953	5781;2885	Shp2;Grb2	Brain-derived neurotrophic factor stimulates ***interactions*** of ***Shp2*** with phosphatidylinositol 3-kinase and ***Grb2*** in cultured cerebral cortical neurons .	parallel	1
4188	10386953	627;5781	Brain-derived neurotrophic factor;Shp2	***Brain-derived neurotrophic factor*** ***stimulates*** interactions of ***Shp2*** with phosphatidylinositol 3-kinase and Grb2 in cultured cerebral cortical neurons .	positive	0
4189	10386953	627;4915	BDNF;TrkB	This BDNF-stimulated Shp2 signaling was markedly sustained as well as ***BDNF-induced*** ***phosphorylation*** of ***TrkB*** and mitogen-activated protein kinases .	target	1
4190	10386956	2668;7054	GDNF;tyrosine hydroxylase	NTN was found to be as potent as GDNF at preventing the death of nigral dopaminergic neurons , but only ***GDNF*** ***induced*** ***tyrosine hydroxylase*** staining , sprouting , or hypertrophy of dopaminergic neurons .	target	1
4191	10386963	6714;5179	Src;proenkephalin	We have found that the inhibition of Src-related nonreceptor tyrosine kinases blocks forskolin-induced proenkephalin gene expression without having any effect on serine-133-phosphorylated CREB levels and that constitutively activated ***Src*** kinase can ***activate*** the ***proenkephalin*** promoter .	positive	1
4192	10387086	7018;7037	transferrin;hTfR	The dissociation constant for the equilibrium ***binding*** of TMR-labeled ***ferri-transferrin*** to ***hTfR*** in detergent free solution was determined to be 7 + / - 3 nM .	parallel	1
4193	10387091	6590;1511	mucus proteinase inhibitor;cathepsin G	***Inhibition*** of neutrophil ***cathepsin G*** by oxidized ***mucus proteinase inhibitor*** .	negative	1
4194	10387091	1511;6590	cathepsin G;MPI	The Ki of the oxidized ******MPI-cathepsin G****** ***complex*** ( 1.2 microM ) is probably too high to be compatible with significant inhibition of cathepsin G in inflammatory lung secretions .	parallel	1
4195	10387091	6590;1511	MPI;cathepsin G	Stopped-flow kinetics shows that , within the inhibitor concentration range used , the mechanism of ***inhibition*** of ***cathepsin G*** and chymotrypsin by oxidized ***MPI*** is consistent with a one-step reaction , [ equation in text ] whereas the inhibition of elastase takes place in two steps , [ equation in text ] .	negative	1
4196	10387091	6590;1511	MPI;cathepsin G	In the presence of heparin , oxidized ***MPI*** ***inhibits*** ***cathepsin G*** via a two-step reaction characterized by Ki = 0.22 microM , k2 = 0.1 s-1 , k-2 = 0.023 s-1 , and Ki = 42 nM .	negative	1
4197	10387976	3716;1441	JAK-1;G-CSF receptor	The ***G-CSF receptor*** signal is ***mediated*** by the ***JAK-1*** and JAK-2 tyrosine kinases .	target	0
4198	10387976	3717;1441	JAK-2;G-CSF receptor	The ***G-CSF receptor*** signal is ***mediated*** by the JAK-1 and ***JAK-2*** tyrosine kinases .	target	0
4199	10388012	5777;3717	SH-PTP1;JAK2	Conversely , the tyrosine phosphatase ***SH-PTP1*** ( also called HCP ) that has an SH2 domain and is specific to blood cells associates with the tyrosine phosphorylation site of the receptor and ***promotes*** the dephosphorylation of ***JAK2*** .	positive	0
4200	10388523	3082;4233	HGF;c-met	These findings suggest a model in which ***HGF*** ***binding*** to luminally accessible ***c-met*** stimulates gtk activity .	parallel	1
4201	10388534	841;836	Caspase-8;caspase-3	***Caspase-8*** ***mediates*** ***caspase-3*** activation and cytochrome c release during singlet oxygen-induced apoptosis of HL-60 cells .	target	0
4202	10388534	841;836	Caspase-8;caspase-3	In addition , blockade of ***Caspase-8*** by Z-IETD-FMK ***inhibited*** cleavage of ***pro-caspase-3*** and prevented loss of mitochondrial cytochrome c.	positive	1
4203	10388534	841;836	Caspase-8;caspase-3	These results suggest that ***Caspase-8*** ***mediates*** ***caspase-3*** activation and cytochrome c release during singlet oxygen-induced apoptosis in HL-60 cells .	target	0
4204	10388535	7040;4790	TGF-beta1;NF-kappaB	***TGF-beta1*** ***inhibits*** ***NF-kappaB*** activity through induction of IkappaB-alpha expression in human salivary gland cells : a possible mechanism of growth suppression by TGF-beta1 .	negative	1
4205	10388535	7040;4790	TGF-beta;NF-kappaB	Although accumulated evidence indicates the mechanisms of the antimitogenic effect of TGF-beta in a variety of cell types , the signal transduction mechanism underlying the ***regulation*** of ***NF-kappaB*** transcription factor by ***TGF-beta*** is largely unknown .	target	1
4206	10388535	7040;4790	TGF-beta1;NF-kappaB	These results indicate that ***TGF-beta1*** ***downregulates*** ***NF-kappaB*** activity through the induction of IkappaB-alpha expression in human salivary gland cells and that inhibition of NF-kappaB activity suppresses the growth rate of these cells .	negative	1
4207	10388747	3598;3596	IL-13R;IL-13	To understand the mechanisms of interaction between IL-13 and ***IL-13*** ***receptors*** ( ***IL-13R*** ) , and the role of the IL-2 receptor common gamma chain ( gammac ) in IL-13 binding and processing , we have examined IL-13 binding kinetics , dissociation/shedding , and internalization in renal cell carcinoma ( RCC ) cell lines .	parallel	1
4208	10388747	3598;3596	IL-13R;IL-13	To understand the mechanisms of ***interaction*** between ***IL-13*** and IL-13 receptors ( ***IL-13R*** ) , and the role of the IL-2 receptor common gamma chain ( gammac ) in IL-13 binding and processing , we have examined IL-13 binding kinetics , dissociation/shedding , and internalization in renal cell carcinoma ( RCC ) cell lines .	parallel	1
4209	10389198	5054;5327	PAI-1;tPA	An impaired fibrinolytic function , as evidenced by increased plasma concentrations of PAI-1 , tPA antigen and ******tPA/PAI-1****** ***complex*** , or a decreased capacity to release active tPA on exercise , is more common in individuals suffering from myocardial infarction .	parallel	1
4210	10389198	5054;5327	PAI-1;tPA	There is a highly statistically significant correlation between ******tPA/PAI-1****** ***complex*** and both PAI-1 and tPA antigen .	parallel	1
4211	10389210	7139;7137	cTnT;cTnI	With recombinant or in vitro formed ternary ******cTnI-cTnT-TnC****** ***complexes*** the differences were smaller ( 3-fold ) .	parallel	1
4212	10389210	7139;7134	cTnT;TnC	With recombinant or in vitro formed ternary ******cTnI-cTnT-TnC****** ***complexes*** the differences were smaller ( 3-fold ) .	parallel	1
4213	10389210	7134;7137	TnC;cTnI	With recombinant or in vitro formed ternary ******cTnI-cTnT-TnC****** ***complexes*** the differences were smaller ( 3-fold ) .	parallel	1
4214	10389215	338;335	apolipoprotein B;apo	More precisely , being working on 119 families we have showed that : a ) The apolipoprotein E ( apo E ) common polymorphism is involved in the total cholesterol , low density lipoprotein cholesterol ( LDL-Chol ) , apo E , apo B levels variability , b ) the apolipoprotein A-IV gene had no effect on lipid metabolism parameters variability , apo A-IV levels included , c ) the ***apolipoprotein B*** gene was ***associated*** with total cholesterol , high density lipoprotein cholesterol , LDL-Chol , triglycerides and ***apo*** B levels genetic variability , d ) the lipoproteine lipase ( LPL ) gene was responsible for 6.5 % of the triglycerides variability , e ) the apo E and LPL 447 polymorphisms influence in conjunction lipid parameters .	parallel	0
4215	10389759	7124;3569	tumor necrosis factor-alpha;IL-6	The CAOV-3 cell line spontaneously secreted ***IL-6*** , which was ***enhanced*** by ***tumor necrosis factor-alpha*** ( 877 + / - 89 vs. 8,452 + / - 1,762 pg/ml , x + / - sd , p < 0.01 ) .	positive	0
4216	10389762	374;4318	amphiregulin;MMP-9	In a previous study , we have shown that EGF and ***amphiregulin*** ***upregulate*** ***MMP-9*** in metastatic SKBR-3 cells but have no effect on MMP-2 secretion .	positive	1
4217	10389762	1950;4318	EGF;MMP-9	In a previous study , we have shown that ***EGF*** and amphiregulin ***upregulate*** ***MMP-9*** in metastatic SKBR-3 cells but have no effect on MMP-2 secretion .	positive	1
4218	10389763	3082;4313	hepatocyte growth factor;matrix metalloproteinase-2	***Regulation*** of ***matrix metalloproteinase-2*** ( MMP-2 ) by ***hepatocyte growth factor/scatter factor*** ( HGF/SF ) in human glioma cells : HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP .	target	1
4219	10389764	4233;3569	c-MET;HGF	Moreover , these cells express mRNA for both ***HGF*** and its ***receptor*** ***c-MET*** , suggesting that this autocrine loop might contribute to the invasiveness of the tumour from which CAL 72 originated .	parallel	1
4220	10389906	7048;7040	TbetaR-II;TGF-beta	TGF-beta exerts its antiproliferative effect via the ***TGF-beta*** type II ***receptor*** ( ***TbetaR-II*** ) .	parallel	1
4221	10389937	1948;4914	EFNB2;TrkA	High-level expression of EPHB6 , ***EFNB2*** , and EFNB3 is ***associated*** with low tumor stage and high ***TrkA*** expression in human neuroblastomas .	parallel	0
4222	10389937	1949;4914	EFNB3;TrkA	High-level expression of EPHB6 , EFNB2 , and ***EFNB3*** is ***associated*** with low tumor stage and high ***TrkA*** expression in human neuroblastomas .	parallel	0
4223	10389937	2051;4914	EPHB6;TrkA	High-level expression of ***EPHB6*** , EFNB2 , and EFNB3 is ***associated*** with low tumor stage and high ***TrkA*** expression in human neuroblastomas .	parallel	0
4224	10389937	4914;1948	TrkA;EFNB2	Expression of ***TrkA*** , a well-established prognostic marker of favorable NB , was positively ***correlated*** with EPHB6 , ***EFNB2*** , and EFNB3 expression ( P < 0.0001 , P = 0.0019 , and P = 0.0001 , respectively ) .	positive	0
4225	10389937	4914;1949	TrkA;EFNB3	Expression of ***TrkA*** , a well-established prognostic marker of favorable NB , was positively ***correlated*** with EPHB6 , EFNB2 , and ***EFNB3*** expression ( P < 0.0001 , P = 0.0019 , and P = 0.0001 , respectively ) .	positive	0
4226	10389937	4914;2051	TrkA;EPHB6	Expression of ***TrkA*** , a well-established prognostic marker of favorable NB , was positively ***correlated*** with ***EPHB6*** , EFNB2 , and EFNB3 expression ( P < 0.0001 , P = 0.0019 , and P = 0.0001 , respectively ) .	positive	0
4227	10389988	3458;6275	IFN-gamma;S100A4	The present study demonstrates that interferon gamma ( ***IFN-gamma*** ) , but not IFN-alpha and IFN-beta , ***down-regulates*** the ***S100A4*** mRNA level in colon adenocarcinoma WiDr cells in time - and dose-dependent manners .	negative	1
4228	10389988	3458;6275	IFN-gamma;S100A4	***IFN-gamma*** also strongly ***suppressed*** the ***S100A4*** mRNA expression in HT-29 cells , but weakly in Colo201 cells .	negative	1
4229	10389988	3458;6275	IFN-gamma;S100A4	Flow cytometric analysis revealed that the level of the IFN-gamma receptor expression in Colo201 cells was lower than that in WiDr and HT-29 cells , suggesting that the ***suppression*** of the ***S100A4*** expression by ***IFN-gamma*** depends on the amount of cell surface IFN-gamma receptor protein .	negative	1
4230	10390120	308;2152	annexin V;Tissue factor	The phosphatidylserine-binding protein ***annexin V*** ***decreased*** ***Tissue factor*** activity on both ionophore-treated and untreated cells , reflecting the role of phosphatidylserine in Tissue factor activity .	negative	0
4231	10390359	7320;5610	E2 protein;PKR	***Inhibition*** of the interferon-inducible protein kinase ***PKR*** by HCV ***E2 protein*** .	negative	1
4232	10390537	5896;5897	RAG1;RAG2	Previous studies have shown that RAG1 alone is capable of binding to the RSS , whereas RAG2 only binds as a ******RAG1/RAG2****** ***complex*** .	parallel	1
4233	10390537	3148;5896	HMG2;RAG1	The high mobility group protein ***HMG2*** is stably incorporated into the recombinant RAG1/RSS complex and can ***increase*** the affinity of ***RAG1*** for the RSS in the absence of RAG2 .	positive	0
4234	10390541	6732;5619	SR protein-specific kinase 1;protamine 1	***SR protein-specific kinase 1*** is highly expressed in testis and ***phosphorylates*** ***protamine 1*** .	target	1
4235	10390548	1520;2247	cathepsin S;bFGF	Also , when expressed in endothelial cells , ***cathepsin S*** autocrinely ***attenuates*** the basic fibroblast growth factor ( ***bFGF*** ) - mediated binding of FGF receptor containing cells to endothelial cells , by acting on basement membrane proteoglycans .	negative	0
4236	10390549	4803;1520	NGF;cathepsin S	RESULTS : Basic FGF and ***NGF*** treatment of macrophages and microglia significantly ***increased*** the levels of ***cathepsin S*** , B , and L mRNAs ( 2 - to 5-fold ) .	positive	0
4237	10390549	1520;4155	cathepsin S;myelin basic protein	Recombinant human ***cathepsin S*** was able to ***degrade*** ***myelin basic protein*** and monomeric and dimeric amyloid beta peptide at both acidic and neutral pH , as well as to process human amyloid precursor protein generating amyloidogenic fragments .	negative	0
4238	10391095	3553;3569	IL-1beta;IL-6	In the conditioned medium , marked ***IL-6*** secretion was ***induced*** from WI-38 cells by ***IL-1beta*** or TNF-alpha .	target	1
4239	10391095	7124;3569	TNF-alpha;IL-6	In the conditioned medium , marked ***IL-6*** secretion was ***induced*** from WI-38 cells by IL-1beta or ***TNF-alpha*** .	target	1
4240	10391125	847;4790	catalase;NF-kappaB	This activation of ***NF-kappaB*** was ***decreased*** by a metal chelator , diethylene triaminepentaacetic acid or a H2O2 scavenger , ***catalase*** , but was increased by superoxide dismutase .	negative	0
4241	10391247	6885;51701	TAK1;NLK	Here we show that ***TAK1*** activation ***stimulates*** ***NLK*** activity and downregulates transcriptional activation mediated by beta-catenin and TCF .	positive	0
4242	10391249	25;7161	c-Abl;p73	The tyrosine kinase ***c-Abl*** ***regulates*** ***p73*** in apoptotic response to cisplatin-induced DNA damage .	target	1
4243	10391249	25;7161	c-Abl;p73	The half-life of p73 is prolonged by cisplatin and by co-expression with c-Abl tyrosine kinase ; the apoptosis-inducing function of ***p73*** is also ***enhanced*** by the ***c-Abl*** kinase .	positive	0
4244	10391250	7161;25	p73;c-Abl	We find that ***p73*** is a ***substrate*** of the ***c-Abl*** kinase and that the ability of c-Abl to phosphorylate p73 is markedly increased by gamma-irradiation .	parallel	1
4245	10391251	25;7161	c-Abl;p73	***p73*** is ***regulated*** by tyrosine kinase ***c-Abl*** in the apoptotic response to DNA damage .	target	1
4246	10391251	25;7161	c-Abl;p73	Here we show that ***c-Abl*** ***binds*** to ***p73*** in cells , interacting through its SH3 domain with the carboxy-terminal homo-oligomerization domain of p73 .	parallel	1
4247	10391251	25;7161	c-Abl;p73	This ***regulation*** of ***p73*** by ***c-Abl*** in response to DNA damage is also demonstrated by a failure of ionizing-radiation-induced apoptosis after disruption of the c-Abl-p73 interaction .	target	1
4248	10391251	7161;25	p73;c-Abl	This regulation of p73 by c-Abl in response to DNA damage is also demonstrated by a failure of ionizing-radiation-induced apoptosis after disruption of the ******c-Abl-p73****** ***interaction*** .	parallel	1
4249	10391282	3082;4233	hepatocyte growth factor;c-Met	BACKGROUND : ***hepatocyte growth factor*** ( HGF ) , a ***ligand*** for the ***c-Met*** receptor tyrosine kinase , plays a role as organotrophic factor for regeneration of various organs .	parallel	1
4250	10391366	4915;627	trkB;brain-derived neurotrophic factor	Recent studies have suggested that ***brain-derived neurotrophic factor*** ( BNDF ) and its ***receptor*** , ***trkB*** , may provide neuroprotection following injury to the central nervous system .	parallel	1
4251	10391562	5627;7301	protein S;Tyro3	***protein S*** also acts as a mitogen on distinct cell types and is a ***ligand*** for ***Tyro3*** , a member of the Axl family of oncogenic receptor tyrosine kinases .	parallel	1
4252	10391675	1111;995	hChk1;Cdc25C	Taken together with the findings that phosphorylation of Cdc25C on serine 216 is increased at the S to M phase , it is suggested that at this particular phase of the cell cycle , even in the absence of DNA damage , ***hChk1*** ***phosphorylates*** ***Cdc25C*** on serine 216 , which is considered to be a prerequisite for the G2/M checkpoint .	target	1
4253	10391681	355;5601	Fas;JNK2	***Fas*** ligation in the presence of cycloheximide ***induced*** Jun N-terminal kinase 1 ( JNK1 ) and ***JNK2*** phosphorylation , caspase activation and cell death in the IL-3-dependent cell line BAF3 .	target	1
4254	10391681	355;5599	Fas;Jun N-terminal kinase	***Fas*** ligation in the presence of cycloheximide ***induced*** ***Jun N-terminal kinase*** 1 ( JNK1 ) and JNK2 phosphorylation , caspase activation and cell death in the IL-3-dependent cell line BAF3 .	target	1
4255	10391681	355;5599	Fas;JNK	M3/6 prevented ***Fas*** ***stimulation*** of ***JNK*** , but did not affect Fas-mediated caspase activation or cell death , demonstrating that JNK activation is not required for these processes .	positive	0
4256	10391843	356;355	FasL;Fas	***Fas*** ***ligand*** ( ***FasL*** ) induces apoptotic death of activated lymphocytes that express its cell surface receptor , FasR ( CD95/APO-1 ) .	parallel	1
4257	10391889	1432;1958	p38;egr-1	We conclude that ***egr-1*** induction by anisomycin is ***mediated*** by ***p38/SAPK2*** and probably by MSK1 .	target	0
4258	10391889	5600;1958	SAPK2;egr-1	We conclude that ***egr-1*** induction by anisomycin is ***mediated*** by ***p38/SAPK2*** and probably by MSK1 .	target	0
4259	10391889	1432;1958	p38;egr-1	Using mutants of the egr-1 promoter , we demonstrate that a distal cAMP-responsive element ( CRE ; nucleotides -134 to -126 ) is necessary to control ***egr-1*** ***induction*** by ***p38/SAPK2*** .	target	1
4260	10391889	5600;1958	SAPK2;egr-1	Using mutants of the egr-1 promoter , we demonstrate that a distal cAMP-responsive element ( CRE ; nucleotides -134 to -126 ) is necessary to control ***egr-1*** ***induction*** by ***p38/SAPK2*** .	target	1
4261	10391891	6667;6596	Sp1;helicase-like transcription factor	Functional ***interactions*** between ***Sp1*** or Sp3 and the ***helicase-like transcription factor*** mediate basal expression from the human plasminogen activator inhibitor-1 gene .	parallel	1
4262	10391896	7124;4790	tumor necrosis factor alpha;NF-kappaB	***NF-kappaB*** ***activation*** by ***tumor necrosis factor alpha*** ( TNFalpha ) provides a survival signal that impairs the TNFalpha-induced apoptotic response .	positive	1
4263	10391896	5074;5970	Par-4;p65	We show here that expression of ***Par-4*** ***inhibits*** the TNFalpha-induced nuclear translocation of ***p65*** as well as the kappaB-dependent promoter activity .	negative	1
4264	10391900	4831;4609	NDPK-B;c-myc	We propose a mechanism through which human ***NDPK-B*** could ***stimulate*** transcription of ***c-myc*** or possibly other genes involved in cellular differentiation .	positive	0
4265	10391903	9846;2885	Gab2;Grb2	Upon tyrosine phosphorylation , ***Gab2*** physically ***interacts*** with Shp2 tyrosine phosphatase and ***Grb2*** adapter protein .	parallel	1
4266	10391903	9846;5781	Gab2;Shp2	Upon tyrosine phosphorylation , ***Gab2*** physically ***interacts*** with ***Shp2*** tyrosine phosphatase and Grb2 adapter protein .	parallel	1
4267	10391919	10612;4644	BERP;myosin Va	This interaction was confirmed by immunoprecipitation , which also demonstrated that ***BERP*** could ***associate*** with ***myosin Va*** , the product of the dilute gene .	parallel	0
4268	10391928	652;3726	BMP2/4;JunB	***BMP2/4*** rapidly ***induced*** transcript levels of the homeobox genes Msx-1 and Msx-2 and the proto-oncogene ***JunB*** , whereas c-jun transcripts displayed delayed albeit prolonged increase .	target	1
4269	10391928	652;3725	BMP2/4;c-jun	***BMP2/4*** rapidly ***induced*** transcript levels of the homeobox genes Msx-1 and Msx-2 and the proto-oncogene JunB , whereas ***c-jun*** transcripts displayed delayed albeit prolonged increase .	target	1
4270	10391928	652;3397	BMP4;Id1	Besides Id3 , also the ***Id1*** and Id2 genes were ***activated*** by ***BMP4*** in both ES cells and a range of different cell lines .	positive	1
4271	10391928	652;3398	BMP4;Id2	Besides Id3 , also the Id1 and ***Id2*** genes were ***activated*** by ***BMP4*** in both ES cells and a range of different cell lines .	positive	1
4272	10391929	183;6774	angiotensin II;STAT3	Regulation of ***angiotensin II-induced*** ***phosphorylation*** of ***STAT3*** in vascular smooth muscle cells .	target	1
4273	10391929	6714;6774	c-Src;STAT3	In the present study , using specific enzyme inhibitors and antisense oligonucleotides , we show that Ang II-induced tyrosine phosphorylation and nuclear translocation of ***STAT3*** in VSMCs is ***mediated*** by p60 ***c-Src*** , whereas tyrosine dephosphorylation is mediated by calcineurin .	target	0
4274	10391929	5524;6774	PP2A;STAT3	***PP2A*** translocates to the nucleus in response to Ang II stimulation of VSMCs and forms a ***complex*** with ***STAT3*** in an Ang II-dependent manner .	parallel	1
4275	10391939	177;3146	RAGE;amphoterin	Moreover , dominant negative Rac and Cdc42 but not dominant negative Ras inhibit the extension of neurites induced by ******RAGE-amphoterin****** ***interaction*** .	parallel	1
4276	10391943	11221;5594	MKP-5;p38	***MKP-5*** ***binds*** to ***p38*** and SAPK/JNK , but not to MAPK/ERK , and inactivates p38 and SAPK/JNK , but not MAPK/ERK .	parallel	1
4277	10391943	11221;5599	MKP-5;JNK	***MKP-5*** binds to p38 and SAPK/JNK , but not to MAPK/ERK , and ***inactivates*** p38 and ***SAPK/JNK*** , but not MAPK/ERK .	negative	1
4278	10391943	11221;5594	MKP-5;p38	***MKP-5*** binds to p38 and SAPK/JNK , but not to MAPK/ERK , and ***inactivates*** ***p38*** and SAPK/JNK , but not MAPK/ERK .	negative	1
4279	10391943	11221;5601	MKP-5;SAPK	***MKP-5*** binds to p38 and SAPK/JNK , but not to MAPK/ERK , and ***inactivates*** p38 and ***SAPK/JNK*** , but not MAPK/ERK .	negative	1
4280	10391950	7048;7040	TbetaR-II;TGF-beta	TGF-beta stimulated Man-6-P / IGF-II receptor-mediated uptake ( approximately 2-fold after 12 h treatment ) of exogenous beta-glucuronidase in Mv1Lu cells and type II ***TGF-beta*** ***receptor*** ( ***TbetaR-II*** ) - defective mutant cells ( DR26 cells ) but not in type I TGF-beta receptor ( TbetaR-I ) - defective mutant cells ( R-1B cells ) and human colorectal carcinoma cells ( RII-37 cells ) expressing TbetaR-I and TbetaR-II but lacking TbetaR-V .	parallel	1
4281	10392359	3486;3479	IGFBP-3;IGF-I	***IGFBP-3*** levels ***correlated*** positively with ***IGF-I*** ( r = 0.44 , p < 0.005 ) , and free IGF-I levels ( r = 0.37 , p = 0.05 ) in the obese children .	positive	0
4282	10392633	4193;7157	mdm-2;p53	***mdm-2*** expression ***correlates*** with wild-type ***p53*** status in esophageal adenocarcinoma .	parallel	0
4283	10392758	3586;1234	IL-10;CCR5	***IL-10*** ***up-regulates*** ***CCR5*** gene expression in human monocytes .	positive	1
4284	10392758	3586;1234	IL-10;CCR5	Pretreatment of monocytes with actinomycin D prevented the IL-10-induced effect , suggesting a transcriptional mechanism for ***CCR5*** ***up-regulation*** by ***IL-10*** .	positive	1
4285	10392758	3586;1234	IL-10;CCR5	Taken together , our data indicate that ***IL-10*** can ***modulate*** ***CCR5*** expression and function .	target	0
4286	10392899	1958;5243	EGR1;MDR1	We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate ( TPA ) increases transcription of the MDR1 gene and activates the MDR1 promoter , and that promoter activation by TPA requires ***binding*** of the zinc finger transcription factor ***EGR1*** to specific ***MDR1*** promoter sequences ( C.	parallel	1
4287	10392899	5243;1958	MDR1;EGR1	Inhibition is likely a direct effect of WT1 binding to the MDR1 promoter because : ( a ) WT1 expression does not inhibit the increase in EGR1 after TPA treatment ; ( b ) inhibition by WT1 requires the zinc finger domain ; ( c ) WT1 binds to ***MDR1*** promoter sequences that ***bind*** ***EGR1*** and are responsive to TPA ; and ( d ) there is an inverse correlation between WT1 protein expression and MDR1 expression and promoter activity .	parallel	1
4288	10392899	1958;5243	EGR1;MDR1	These results suggest that the MDR1 gene is a target for regulation by WT1 and suggest mechanisms by which ***MDR1*** may be ***regulated*** by WT1 and ***EGR1*** during normal and aberrant hematopoiesis .	target	1
4289	10392902	1027;983	p27Kip1;CDK1	Cyclin/cyclin-dependent kinase ( CDK ) complexes immunoprecipitated with p27Kip1 are differentially modified by DXM addition : ( a ) G1 kinasic complexes ( cyclin D/CDK4 or CDK6 ) associated with p27Kip1 are strongly decreased by DXM , ( b ) S-phase complexes ( CDK2/cyclin E and A ) remained stable or increased , and ( c ) the ***association*** of ***p27Kip1*** with the phosphorylated forms of ***CDK1*** is increased by DXM .	parallel	0
4290	10392903	993;1017	cdc25A;cdk2	Rather , expression of cyclin A , which regulates cdk2 activity , and the ***cdc25A*** and cdc25B phosphatases , which are thought to ***activate*** ***cdk2*** , was significantly reduced at both the RNA and protein levels in response to E2 expression .	positive	1
4291	10392903	993;1017	cdc25A;cdk2	Rather , expression of cyclin A , which ***regulates*** ***cdk2*** activity , and the ***cdc25A*** and cdc25B phosphatases , which are thought to activate cdk2 , was significantly reduced at both the RNA and protein levels in response to E2 expression .	target	1
4292	10392903	7320;993	E2 protein;cdc25A	The ***E2 protein*** ***reduced*** expression of ***cdc25A*** and cdc25B in both HT-3 and HeLa cells , but not in cells that were not growth-inhibited by the E2 protein .	negative	1
4293	10392903	7320;994	E2 protein;cdc25B	The ***E2 protein*** ***reduced*** expression of cdc25A and ***cdc25B*** in both HT-3 and HeLa cells , but not in cells that were not growth-inhibited by the E2 protein .	negative	1
4294	10393052	7422;3383	VEGF;ICAM-1	***VEGF*** ***increases*** retinal vascular ***ICAM-1*** expression in vivo .	positive	0
4295	10393052	7422;3383	VEGF;ICAM-1	RESULTS : ***VEGF*** ***increased*** capillary endothelial cell ***ICAM-1*** levels in a dose - and time-dependent manner ( 6-24 hours , plateau after 6 hours ; EC50 , 25 ng/ml ) .	positive	0
4296	10393052	7422;3383	VEGF;ICAM-1	CONCLUSIONS : ***VEGF*** ***increases*** retinal vascular ***ICAM-1*** expression .	positive	0
4297	10393079	1535;1536	p22phox;gp91phox	It is commonly assumed that activation of the superoxide-generating NADPH oxidase requires the formation of a stable complex between flavocytochrome b-245 ( the ******gp91phox/p22phox****** ***heterodimer*** ) and the cytosolic cofactors p47phox , p67phox and Rac2 .	parallel	1
4298	10393085	6418;3725	I2PP2A;c-Jun	Expression of ***I2PP2A*** , an inhibitor of protein phosphatase 2A , ***induces*** ***c-Jun*** and AP-1 activity .	target	1
4299	10393085	6418;5524	I2PP2A;PP2A	Transient expression of ***I2PP2A*** , a potent ***inhibitor*** of protein phosphatase 2A ( ***PP2A*** ) , in HEK-293 cells increased the concentration and DNA binding of the proto-oncogene c-Jun .	negative	1
4300	10393085	6418;3725	I2PP2A;proto-oncogene c-Jun	Transient expression of ***I2PP2A*** , a potent inhibitor of protein phosphatase 2A ( PP2A ) , in HEK-293 cells ***increased*** the concentration and DNA binding of the ***proto-oncogene c-Jun*** .	positive	0
4301	10393113	4916;4908	TrkC;neurotrophin-3	***neurotrophin-3*** and its ***receptor*** ***TrkC*** are expressed during the development of the mammalian cerebral cortex .	parallel	1
4302	10393114	392255;9241	GDF6;noggin	We demonstrate that ***GDF6*** ***binds*** directly to the neural inducer ***noggin*** .	parallel	1
4303	10393114	650;392255	BMP2;GDF6	Furthermore , we find that ***GDF6*** and ***BMP2*** can form ***heterodimers*** and the process seems to require cotranslation of the proteins in the same cells .	parallel	1
4304	10393175	836;317	procaspase-3;Apaf-1	We also show that procaspase-9 can ***recruit*** ***procaspase-3*** to the ***Apaf-1-procaspase-9*** complex .	target	0
4305	10393178	1435;1436	CSF-1;CSF-1R	Colony-stimulating factor-1 ( ***CSF-1*** ) ***activation*** of the CSF-1 receptor ( ***CSF-1R*** ) causes Cbl protooncoprotein tyrosine phosphorylation , Cbl-CSF-1R association and their simultaneous multiubiquitination at the plasma membrane .	positive	1
4306	10393178	1435;1436	CSF-1;CSF-1R	Their CSF-1Rs fail to exhibit multiubiquitination and a second wave of tyrosine phosphorylation previously suggested to be involved in preparation of the ******CSF-1-CSF-1R****** ***complex*** for endocytosis .	parallel	1
4307	10393178	1435;1436	CSF-1;CSF-1R	Consistent with this result , Cbl - / - macrophage cell surface ******CSF-1-CSF-1R****** ***complexes*** are internalized more slowly , yet are still lysosomally degraded , and the CSF-1 utilization by Cbl - / - macrophages is reduced approximately 2-fold .	parallel	1
4308	10393181	5595;821	extracellular-signal regulated kinase-1;calnexin	Analysis by two-dimensional phosphopeptide maps revealed that ***calnexin*** was in vitro ***phosphorylated*** in isolated microsomes by casein kinase 2 ( CK2 ) and ***extracellular-signal regulated kinase-1*** ( ERK-1 ) at sites corresponding to those for in vivo phosphorylation .	target	1
4309	10393181	821;5595	calnexin;ERK-1	Taken together with studies revealing ***calnexin*** ***association*** with CK2 and ***ERK-1*** , a model is proposed whereby phosphorylation of calnexin leads to a potential increase in glycoprotein folding close to the translocon .	parallel	0
4310	10393185	1616;5077	Daxx;Pax3	In this report we demonstrate that human ***Daxx*** ( hDaxx ) ***interacts*** with ***Pax3*** in vivo and with DNA-bound Pax3 in vitro .	parallel	1
4311	10393198	7374;5111	UNG2;PCNA	PCNA and replication protein A ( RPA ) co-localize with UNG2 in replication foci , and a direct molecular ***interaction*** of ***UNG2*** with ***PCNA*** ( one binding site ) and RPA ( two binding sites ) was demonstrated using two-hybrid assays , a peptide SPOT assay and enzyme-linked immunosorbent assays .	parallel	1
4312	10393217	6646;338	ACAT;ApoB	We conclude that inhibition of hepatic ***ACAT*** by avasimibe ***reduces*** both plasma VLDL and LDL ***ApoB*** concentrations , primarily by decreasing ApoB secretion .	positive	1
4313	10393217	6646;338	ACAT;apolipoprotein B	Inhibition of ***ACAT*** by avasimibe ***decreases*** both VLDL and LDL ***apolipoprotein B*** production in miniature pigs .	positive	0
4314	10393248	1457;5435	CKII;RPB6	In this study , we investigated in vitro ***phosphorylation*** of rat ***RPB6*** by casein kinase II ( ***CKII*** ) , a pleiotropic regulator of numerous cellular proteins .	target	1
4315	10393248	1457;5435	CKII;RPB6	Therefore , ***RPB6*** was implied to be ***phosphorylated*** by ***CKII*** in the nucleus .	target	1
4316	10393530	2353;3725	c-fos;c-jun	The ***association*** between ***c-fos*** and ***c-jun*** expression and estrogen and progesterone receptors is lost in human endometrial cancer .	parallel	0
4317	10393558	5914;6257	RARalpha;retinoid X receptor beta	In gel mobility shift assays , ***heterodimers*** of retinoic acid receptor alpha ( ***RARalpha*** ) and ***retinoid X receptor beta*** ( RXRbeta ) bound specifically to this element .	parallel	1
4318	10393698	6348;1234	MIP-1alpha;CCR5	Moreover , macrophage inflammatory protein-1alpha ( ***MIP-1alpha*** ) , one of the ***ligands*** for ***CCR5*** , was selectively expressed on intralobular bile duct epithelial cells , endothelial cells , and infiltrating macrophages and lymphocytes .	parallel	1
4319	10393810	885;9112	cholecystokinin;mta1	The expression of ***mta1*** was ***up-regulated*** in the pancreas by endogenous ***cholecystokinin*** release and in AR4-2J after induction of cellular differentiation by dexamethasone .	positive	1
4320	10393857	3606;3458	IL-18;IFN-gamma	***IL-18*** , primarily a monocyte product , ***promotes*** the secretion of ***IFN-gamma*** , which stimulates Mig and RANTES expression .	positive	0
4321	10393857	3458;4283	IFN-gamma;Mig	IL-18 , primarily a monocyte product , promotes the secretion of ***IFN-gamma*** , which ***stimulates*** ***Mig*** and RANTES expression .	positive	0
4322	10393857	3458;6352	IFN-gamma;RANTES	IL-18 , primarily a monocyte product , promotes the secretion of ***IFN-gamma*** , which ***stimulates*** Mig and ***RANTES*** expression .	positive	0
4323	10393859	4792;4790	IkappaBalpha;NF-kappaB	In addition , NO attenuates signal-initiated degradation of ***IkappaBalpha*** , an intracellular ***inhibitor*** of ***NF-kappaB*** , and blocks the DNA binding activity of the NF-kappaB p50/p50 homodimer and p50/p65 heterodimer .	negative	1
4324	10393859	4790;5970	p50;p65	In addition , NO attenuates signal-initiated degradation of IkappaBalpha , an intracellular inhibitor of NF-kappaB , and blocks the DNA binding activity of the NF-kappaB p50/p50 homodimer and ******p50/p65****** ***heterodimer*** .	parallel	1
4325	10393926	983;891	Cdc2;cyclin B1	Mitosis is triggered in vertebrate cells by the ******cyclin B1-Cdc2****** ***complex*** .	parallel	1
4326	10393932	836;356	caspase-3;CD95L	Inhibition of ***caspase-3*** , a downstream protease in the CD95 signaling pathway , ***blocked*** both ***CD95L*** and UVB-induced apoptosis , whereas blockage of caspase-8 , the most proximal caspase , inhibited CD95L-mediated apoptosis completely , but UVB-induced apoptosis only partially .	positive	0
4327	10393933	999;1500	E-cadherin;p120	Expression of exogenous ***E-cadherin*** ***down-regulated*** nuclear ***p120*** ( ctn ) whereas activation of protein kinase C increased the level of nuclear p120 ( ctn ) .	negative	1
4328	10393935	596;11083	Bcl-2;DIO-1	***DIO-1*** apoptotic induction is ***prevented*** by caspase inhibitors and ***Bcl-2*** overexpression .	negative	0
4329	10393951	3565;3567	IL-4;IL-5	Moreover , ***IL-4*** , which by itself had no visible effect on human MC , ***enhanced*** the release of histamine , leukotriene C4 , and ***IL-5*** in MC triggered by IgE receptor crosslinking .	positive	0
4330	10393956	962;7124	CD48;tumor necrosis factor alpha	The mast cell ***tumor necrosis factor alpha*** response to FimH-expressing Escherichia coli is ***mediated*** by the glycosylphosphatidylinositol-anchored molecule ***CD48*** .	target	0
4331	10393958	7408;58	VASP;ActA	***VASP*** , which is expressed in most cell types and in particularly high levels in human platelets , ***binds*** to profilin , zyxin , vinculin , F-actin , and the Listeria monocytogenes surface protein ***ActA*** .	parallel	1
4332	10393958	7408;7414	VASP;vinculin	***VASP*** , which is expressed in most cell types and in particularly high levels in human platelets , ***binds*** to profilin , zyxin , ***vinculin*** , F-actin , and the Listeria monocytogenes surface protein ActA .	parallel	1
4333	10393958	7408;7791	VASP;zyxin	***VASP*** , which is expressed in most cell types and in particularly high levels in human platelets , ***binds*** to profilin , ***zyxin*** , vinculin , F-actin , and the Listeria monocytogenes surface protein ActA .	parallel	1
4334	10393981	5741;1594	PTH;CYP27B1	***PTH*** ***increased*** the expression of renal ***CYP27B1*** mRNA only in vitamin D-deficient hypocalcemic TPTX rats .	positive	0
4335	10394054	3600;3586	IL-15;IL-10	As to immunoglobulin secretion , ***IL-15*** was able to ***potentiate*** the stimulatory effect of ***IL-10*** .	positive	0
4336	10394363	6844;6810	VAMP2;syntaxin 4	Insulin-stimulated glucose transport and GLUT4 translocation require regulated ***interactions*** between the v-SNARE , ***VAMP2*** , and the t-SNARE , ***syntaxin 4*** .	parallel	1
4337	10394363	10490;6810	v-SNARE;syntaxin 4	Insulin-stimulated glucose transport and GLUT4 translocation require regulated ***interactions*** between the ***v-SNARE*** , VAMP2 , and the t-SNARE , ***syntaxin 4*** .	parallel	1
4338	10394363	10490;6844	v-SNARE;VAMP2	Insulin-stimulated glucose transport and GLUT4 translocation require regulated ***interactions*** between the ***v-SNARE*** , ***VAMP2*** , and the t-SNARE , syntaxin 4 .	parallel	1
4339	10394363	6814;6810	syntaxin 4-binding protein;syntaxin 4	We have isolated a novel ***syntaxin 4-binding protein*** , Synip , which specifically ***interacts*** with ***syntaxin 4*** .	parallel	1
4340	10395064	183;1958	angiotensin II;Egr-1	***Induction*** of ***Egr-1*** mRNA and protein by endothelin 1 , ***angiotensin II*** and norepinephrine in neonatal cardiac myocytes .	target	1
4341	10395064	1906;1958	endothelin 1;Egr-1	***Induction*** of ***Egr-1*** mRNA and protein by ***endothelin 1*** , angiotensin II and norepinephrine in neonatal cardiac myocytes .	target	1
4342	10395089	1230;6348	CC-CKR1;MIP-1 alpha	Identification of amino acids involved in the binding of hMIP-1 alpha to ***CC-CKR1*** , a ***MIP-1 alpha*** ***receptor*** found on neutrophils .	parallel	1
4343	10395179	196;1543	Ah receptor;CYP1	Expression of the ***Ah receptor*** and Arnt which are involved in the transcriptional ***activation*** of the ***CYP1*** genes was also studied .	positive	1
4344	10395179	405;1543	Arnt;CYP1	Expression of the Ah receptor and ***Arnt*** which are involved in the transcriptional ***activation*** of the ***CYP1*** genes was also studied .	positive	1
4345	10395199	652070;3265	scFv;p21Ras	Primers designed for rat Vlambda amplification allowed the cloning of a functional ***scFv*** that could ***bind*** ***p21Ras*** .	parallel	1
4346	10395199	652070;3265	scFv;p21Ras	The kinetics of ***interaction*** of purified Y238 ***scFv*** with the ***p21Ras*** protein was evaluated by BIAcore with a NTA sensor chip and gave an apparent affinity constant in the nanomolar range ( K ( D ) = 4.58 + / -0.63 nM ) .	parallel	1
4347	10395217	3782;3738	hSKCa3;potassium channel	A possible ***association*** between the small conductance calcium-regulated ***potassium channel*** gene , ***hSKCa3*** , and schizophrenia has recently been described by Chandy et al using a case-control design with patients with schizophrenia ( n = 141 ) and matched controls ( n = 158 ) .	parallel	0
4348	10395289	3949;4018	LDLR;lipoprotein	This study examines the effect of mutation of the low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) on cholesterol metabolism , and especially lipoprotein-derived cholesteryl ester uptake , in murine ovarian granulosa cells .	parallel	1
4349	10395292	2822;5329	GPI-PLD;uPAR	We show that ***uPAR*** release is ***catalyzed*** by cellular GPI-specific phospholipase D ( ***GPI-PLD*** ) , an enzyme cleaving the GPI anchor of the receptor .	positive	1
4350	10395292	2822;5329	GPI-PLD;uPAR	We found that ***GPI-PLD*** also ***regulated*** ***uPAR*** expression , possibly by releasing a GPI-anchored growth factor .	target	1
4351	10395322	958;959	CD40;CD40 ligand	The action of T helper cells in CTL priming is mediated by ******CD40-CD40 ligand****** ***interactions*** .	parallel	1
4352	10395405	4883;2981	guanylate cyclase-C;uroguanylin	Membrane ***guanylate cyclase-C*** is an intestinal ***receptor*** for guanylin and ***uroguanylin*** that is responsible for stimulation of Cl - and HCO3 - secretion into the intestinal lumen .	parallel	1
4353	10395457	3336;3329	GroES;GroEL	The observed variations in sulfhydryl accessibility are consistent with mechanisms that suggest ***binding*** of ***GroES*** to ***GroEL*** differs from the binding of substrate protein to GroEL , and that the binding of Mg2 + or Mg-adenine nucleotides results in conformational changes in GroEL .	parallel	1
4354	10395644	355;3606	Fas;IL-18	Since IL-18 enhances Fas ligand ( FasL ) expression on NK cell lines , the ***IL-18*** antitumor effects could be ***mediated*** by FasL-induced cross-linking of ***Fas*** and subsequent tumor apoptosis .	target	0
4355	10395644	3606;356	IL-18;Fas ligand	Since ***IL-18*** ***enhances*** ***Fas ligand*** ( FasL ) expression on NK cell lines , the IL-18 antitumor effects could be mediated by FasL-induced cross-linking of Fas and subsequent tumor apoptosis .	positive	0
4356	10395651	959;1440	CD40 ligand;G-CSF	Both the soluble form of ***CD40 ligand*** ( sCD40L ) and TNF ***increased*** the level of M-CSF and ***G-CSF*** mRNA .	positive	0
4357	10395651	959;1435	CD40 ligand;M-CSF	Both the soluble form of ***CD40 ligand*** ( sCD40L ) and TNF ***increased*** the level of ***M-CSF*** and G-CSF mRNA .	positive	0
4358	10395652	7097;929	TLR2;CD14	We show that ***TLR2*** ***associates*** with the high-affinity LPS binding protein membrane ***CD14*** to serve as an LPS receptor complex , and that LPS treatment enhances the oligomerization of TLR2 .	parallel	0
4359	10395652	7189;4790	TNF receptor-associated factor 6;NF-kappaB	DN constructs of myeloid differentiation protein , IRAK , ***TNF receptor-associated factor 6*** , and NF-kappaB-inducing kinase , when coexpressed with TLR2 , ***abrogate*** TLR2-mediated ***NF-kappaB*** activation .	negative	0
4360	10395655	959;958	CD40L;CD40	In vivo Ig responses to soluble , haptenated polysaccharide ( PS ) Ags are T cell independent and do not require ***CD40*** ***ligand*** ( ***CD40L*** ) .	parallel	1
4361	10395656	3383;7124	ICAM-1;TNF-alpha	Using rat astrocytes in culture , we report that ***ICAM-1*** binding by specific Abs ***induces*** ***TNF-alpha*** secretion together with phosphorylation of the transcription factor cAMP response element-binding protein .	target	1
4362	10395661	3558;2353	IL-2;c-fos	Herein , we demonstrate that diacylglycerol kinase inhibition has a profound effect on the ***induction*** of the protooncogenes c-myc , ***c-fos*** , and c-raf by ***IL-2*** , whereas expression of bcl-2 and bcl-xL are not affected .	target	1
4363	10395661	3558;4609	IL-2;c-myc	Herein , we demonstrate that diacylglycerol kinase inhibition has a profound effect on the ***induction*** of the protooncogenes ***c-myc*** , c-fos , and c-raf by ***IL-2*** , whereas expression of bcl-2 and bcl-xL are not affected .	target	1
4364	10395661	3558;5894	IL-2;c-raf	Herein , we demonstrate that diacylglycerol kinase inhibition has a profound effect on the ***induction*** of the protooncogenes c-myc , c-fos , and ***c-raf*** by ***IL-2*** , whereas expression of bcl-2 and bcl-xL are not affected .	target	1
4365	10395661	3558;896	IL-2;cyclin D3	When the IL-2-regulated cell cycle control checkpoints are examined in detail , we demonstrate that inhibition of diacylglycerol kinase activation prevents ***IL-2*** ***induction*** of ***cyclin D3*** without affecting p27 down-regulation .	target	1
4366	10395669	3454;3439	hIFNAR;IFN	The human ***IFN-alpha*** ***receptor*** ( ***hIFNAR*** ) is a complex composed of at least two chains , hIFNAR1 and hIFNAR2 .	parallel	1
4367	10395669	3455;3439	hIFNAR2;hIFN	To confirm that residues important for ligand binding are indeed important for IFN signal transduction , we determined the ability of mouse L929 cells expressing ***hIFNAR2*** extracellular domain mutants to ***mediate*** ***hIFN*** signal .	target	0
4368	10395671	958;959	CD40;CD40 ligand	******CD40/CD40 ligand****** ***interactions*** play a key role in the immune responses of B lymphocytes , monocytes , and dendritic cells .	parallel	1
4369	10395671	3718;958	Janus kinase 3;CD40	In contrast , although the ***Janus kinase 3*** tyrosine kinase was ***associated*** with ***CD40*** molecules in both monocytes and resting B cells , Janus kinase 3 phosphorylation induction was observed only in CD40-activated monocytes , with subsequent induction of STAT5a DNA binding activity in the nucleus .	parallel	0
4370	10395673	7409;5879	Vav;Rac1	This was dependent on ***Vav-mediated*** ***activation*** of ***Rac1*** as a Dbl domain-mutated Vav , inactive Rac N17 , and inactive JNK1 down-regulated the Vav-induced JNK1 or IL-6 responses .	positive	1
4371	10395673	7409;3569	Vav;IL-6	***Vav*** expression , but not expression of domain-mutated Vav , ***increased*** ***IL-6*** secretion from nonimmortalized bone marrow-derived mast cells upon FcepsilonRI engagement .	positive	0
4372	10395678	940;5879	CD28;Rac-1	Here , we show that ***TCR/CD28*** costimulation synergistically ***induces*** ***Rac-1*** GDP/GTP exchange .	target	1
4373	10395678	7535;7409	ZAP-70;Vav	Our findings , obtained by using ZAP-70-negative Jurkat T cells , indicate that CD28 costimulation augments TCR-mediated T cell activation by increasing the ***ZAP-70-mediated*** Tyr ***phosphorylation*** of ***Vav*** .	target	1
4374	10395678	7409;27040	Vav;linker for activation of T cells	CD28 amplifies TCR-induced ZAP-70 activity and ***association*** of ***Vav*** with ZAP-70 and ***linker for activation of T cells*** ( LAT ) .	parallel	0
4375	10395678	7409;7535	Vav;ZAP-70	CD28 amplifies TCR-induced ZAP-70 activity and ***association*** of ***Vav*** with ***ZAP-70*** and linker for activation of T cells ( LAT ) .	parallel	0
4376	10395688	3458;8743	IFN-gamma;TRAIL	CMV infection increased the expression of TRAIL-R1 and -R2 , whereas ***IFN-gamma*** ***down-regulated*** the expression of ***TRAIL-Rs*** on uninfected fibroblasts .	negative	1
4377	10395688	3458;4790	IFN-gamma;NF-kappaB	Moreover , ***IFN-gamma*** significantly ***decreased*** the basal level of ***NF-kappaB*** activation , a known survival factor that inhibits apoptosis .	negative	0
4378	10395791	5727;2735	Ptc;Gli1	We find that excess ***Ptc*** is sufficient to ***inhibit*** expression of ***Gli1*** and ptc1 , suggesting that Sonic hedgehog ( Shh ) can not signal effectively .	negative	1
4379	10395798	8929;1621	NBPhox;DBH	However , ***NBPhox*** substantially ***enhances*** second messenger-mediated activation of the ***DBH*** promoter by forskolin and/or phorbol ester .	positive	0
4380	10395798	8929;2353	NBPhox;c-fos	Furthermore , we found that ***NBPhox*** can also ***enhance*** second messenger-mediated activation of the ***c-fos*** promoter and several enhancers , including cyclic AMP-response element , the binding site for activator protein 1 , and serum-response element .	positive	0
4381	10395864	4018;948	lipoprotein;CD36	Plasmodium falciparum-infected erythrocytes and oxidized low-density ***lipoprotein*** ***bind*** to separate domains of ***CD36*** .	parallel	1
4382	10395864	948;4018	CD36;lipoprotein	The cytoadherence of erythrocytes ( red blood cells ) infected with Plasmodium falciparum ( pRBCs ) to endothelial cells and the uptake of oxidized low-density ***lipoprotein*** ( oxLDL ) by macrophages are both ***mediated*** , in part , by the glycoprotein receptor ***CD36*** .	target	0
4383	10395923	10102;7284	EF-Ts;EF-Tu	The activity of E. coli ***EF-Tu*** but not of EF-Tumt is ***stimulated*** by E. coli ***EF-Ts*** .	positive	0
4384	10395932	6373;2833	CXCL 11;CXCR3	***CXCL 11*** , encoded by the cDNA sequences designated beta-R1 , H-174 , or I-TAC , is a CXC chemokine ***ligand*** for ***CXCR3*** and assumed to be involved in inflammatory diseases characterized by the presence of activated T-cells .	parallel	1
4385	10395955	7124;1435	TNF-alpha;M-CSF	By using a specific ELISA we found that their constitutive secretion of ***M-CSF*** is ***enhanced*** by tumour necrosis factor-alpha ( ***TNF-alpha*** ) .	positive	0
4386	10395972	5443;4160	alpha-melanocyte-stimulating hormone;MC4-R	POMC is the precursor of ***alpha-melanocyte-stimulating hormone*** ( alpha-MSH ) , which ***binds*** to the melanocortin receptor ***MC4-R*** in the brain , decreases appetite , and activates lipid metabolism .	parallel	1
4387	10396029	5617;3479	PRL;IGF-I	***PRL*** completely ***abolished*** the ***IGF-I*** stimulation of alpha-mRNA levels , suggesting a desensitisation of the gill tissue to IGF-I , which may explain the overall anti-SW adaptive effect of PRL .	negative	0
4388	10396036	960;4233	CD44;c-Met	***Cross-talk*** between ***CD44*** and ***c-Met*** in B cells .	parallel	0
4389	10396366	3484;5054	IGFBP-1;PAI-1	RESULTS : After correcting for age , sex and body mass index , concentrations of ***IGFBP-1*** , ***correlated*** with those of HDL-cholesterol ( r = 0.40 ; P < 0.001 ) , triglycerides ( r = -0.24 ; P = 0.04 ) , insulin ( r = -0.39 ; P < 0.001 ) , intact proinsulin ( r = -0.32 ; P = 0.006 ) , des 31,32 proinsulin ( r = -0.40 ; P = 0.001 ) , and with insulin sensitivity ( r = 0.38 ; P = 0.001 ) and ***PAI-1*** activity ( r = -0.24 ; P = 0.05 ) ; IGF-1 levels only correlated with those of HDL-cholesterol ( r = -0.33 ; P = 0.005 ) , and this was not explained by IGFBP-1 or insulin sensitivity .	parallel	0
4390	10396366	3484;5054	IGFBP-1;PAI-1	***IGFBP-1*** concentrations were ***related*** to ***PAI-1*** activity , and this may be explained by insulin , which regulates the production of IGFBP-1 and PAI-1 .	parallel	0
4391	10397152	5781;6464	SHP-2;Shc	The P-ITIM-compelled multi-phosphoprotein complex binds to and activates ***SHP-2*** , which in turn ***dephosphorylates*** SHIP and ***Shc*** and probably other substrates .	target	1
4392	10397171	4689;7295	p40phox;TRX	These results showed that ***p40phox*** ***interacts*** with ***TRX*** and indicated the possibility of TRX-dependent regulation of phagocyte oxidase activity .	parallel	1
4393	10397175	7076;4602	Epo;c-myb	In spite of this , we demonstrated in this paper that in ELM-I-1 cells the ***Epo-induced*** ***down-regulation*** of ***c-myb*** expression and hemoglobin production can be effectively enhanced by the simultaneously added [ Ca2 + ] i-increasing agent , cyclopiazonic acid ( CPA ) .	negative	1
4394	10397248	842;836	caspase-9;procaspase-3	Because the ***activation*** of ***procaspase-3*** by ***caspase-9*** requires the release of cytochrome c into the cytoplasm , we determined the level of cytoplasmic cytochrome c in each cell line in response to cisplatin treatment .	positive	1
4395	10397252	356;355	FasL;Fas	We report the preferential expression of Fas on CD4 + T cells and ***Fas*** ***ligand*** ( ***FasL*** ) on monocytes and their potential role in the selective loss of CD4 + T cells in breast cancer patients undergoing high-dose chemotherapy and peripheral blood stem cell transplantation ( PSCT ) .	parallel	1
4396	10397252	355;356	Fas;FasL	The prevention of CD4 + T-cell apoptosis and improved immune reconstitution by the manipulation of PB stem cell products , blockade of ******Fas-FasL****** ***interactions*** , or cytokine support after transplantation may be important adjuvant immunotherapeutic strategies in patients undergoing high-dose chemotherapy and PSCT .	parallel	1
4397	10397263	6760;6756	SYT;SSX1	There was a significant ***association*** between ******SYT-SSX1****** and a high tumor proliferation rate ( P = 0.02 ) .	parallel	0
4398	10397275	3480;355	insulin-like growth factor 1 receptor;Fas	The ***insulin-like growth factor 1 receptor*** induces transformation and tumorigenicity of ovarian mesothelial cells and ***down-regulates*** their ***Fas-receptor*** expression .	negative	1
4399	10397405	3553;5743	IL-1beta;PGHS-2	These results suggest that CRE may mediate the ***induction*** of ***PGHS-2*** by ***IL-1beta*** and PMA as well as the suppression of expression by dexamethasone in amnion-derived cells .	target	1
4400	10397699	7035;2152	TFPI;tissue factor	Finally , chemical modification of lysine and arginine residues reduced the overall ***inhibition*** of ***tissue factor*** by ***TFPI*** .	negative	1
4401	10397699	7035;2152	TFPI;tissue factor	We propose that ***TFPI*** and LDL act separately to ***inhibit*** ***tissue factor*** in vivo .	negative	1
4402	10397715	7066;5054	TPO;PAI-1	***TPO*** also differentiated human cord blood CD34 ( + ) / CD41 ( - ) cells to CD34 ( - ) / CD41 ( + ) cells , generated morphologically mature megakaryocytes , and ***induced*** the expression of ***PAI-1*** mRNA .	target	1
4403	10397715	7066;5054	TPO;PAI-1	However , ***induction*** of ***PAI-1*** mRNA in UT-7 / EPO-Mpl cells by ***TPO*** required at least 14-days stimulation .	target	1
4404	10397721	10076;3815	PTP-RO;c-Kit	The results demonstrated that ***PTP-RO*** ***associates*** with ***c-Kit*** but not with the tyrosine kinase receptor FGF-R and that PTP-RO is tyrosine-phosphorylated after SCF stimulation of Mo7e and CMK cells .	parallel	0
4405	10397721	10076;4254	PTP-RO;Kit ligand	***PTP-RO*** was found to be ***associated*** with the c-Kit receptor in these transfected cells and the ***SCF/Kit ligand*** induced a rapid tyrosine phosphorylation of PTP-RO .	parallel	0
4406	10397721	10076;3815	PTP-RO;c-Kit	In addition , we assessed the ***association*** of ***PTP-RO*** with ***c-Kit*** in vivo .	parallel	0
4407	10397722	2908;3815	glucocorticoid receptor;c-Kit	The ***glucocorticoid receptor*** ***cooperates*** with the erythropoietin receptor and ***c-Kit*** to enhance and sustain proliferation of erythroid progenitors in vitro .	parallel	0
4408	10397722	2908;2057	glucocorticoid receptor;erythropoietin receptor	The ***glucocorticoid receptor*** ***cooperates*** with the ***erythropoietin receptor*** and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro .	parallel	0
4409	10397723	1440;6688	granulocyte colony-stimulating factor;PU.1	C/EBPalpha bypasses ***granulocyte colony-stimulating factor*** signals to rapidly ***induce*** ***PU.1*** gene expression , stimulate granulocytic differentiation , and limit proliferation in 32D cl3 myeloblasts .	target	1
4410	10397723	1050;6688	C/EBPalpha;PU.1	C/EBPalphaWT-ER induced endogenous PU.1 mRNA within 8 hours in both 32D cl3 and Ba/F3 cells , even in the presence of cycloheximide , indicating that ***C/EBPalpha*** directly ***activates*** the ***PU.1*** gene .	positive	1
4411	10397725	2247;7035	bFGF;TFPI	Our study also suggests that ***control*** of ***TFPI*** expression by serum or ***bFGF*** occurs via translational rather than transcriptional regulation .	target	0
4412	10397731	961;3673	CD47;collagen receptor	We test here the possibility that ***CD47*** may also ***modulate*** the function of platelet integrin alpha2beta1 , a ***collagen receptor*** .	target	0
4413	10397744	5715;896	p27;cyclin D3	These results could support the hypothesis that there are ******cyclin D3/p27****** ***complexes*** in a subset of aggressive B-cell lymphomas in which p27 lacks the inhibitory activity found when it is bound to cyclin E/CDK2 complexes .	parallel	1
4414	10397744	1027;896	KIP1;cyclin D3	Anomalous high ***p27/KIP1*** expression in a subset of aggressive B-cell lymphomas is ***associated*** with ***cyclin D3*** overexpression .	parallel	0
4415	10397744	5715;896	p27;cyclin D3	Anomalous high ***p27/KIP1*** expression in a subset of aggressive B-cell lymphomas is ***associated*** with ***cyclin D3*** overexpression .	parallel	0
4416	10397744	5715;896	p27;cyclin D3	A statistically significant ***association*** between ***p27*** and ***cyclin D3*** expression was found for the group as a whole .	parallel	0
4417	10397744	5715;896	p27;cyclin D3	Additional evidence in favor of p27 sequestration by cyclin D3 was provided by coimmunoprecipitation studies in a Burkitt 's cell line ( Raji ) showing the existence of ******cyclin D3/p27****** ***complexes*** and the absence of CDK2/p27 complexes .	parallel	1
4418	10397744	1017;5715	CDK2;p27	Additional evidence in favor of p27 sequestration by cyclin D3 was provided by coimmunoprecipitation studies in a Burkitt 's cell line ( Raji ) showing the existence of cyclin D3/p27 complexes and the absence of ******CDK2/p27****** ***complexes*** .	parallel	1
4419	10397753	1026;5111	p21;PCNA	We further demonstrate that the inhibition of DNA repair is mediated via ***binding*** of ***p21*** to ***PCNA*** .	parallel	1
4420	10397776	100287932;10440	Tim23;Tim17	Preproteins carrying amino-terminal signals mainly use Tom20 , the general import pore ( GIP ) complex and the ******Tim23-Tim17****** ***complex*** .	parallel	1
4421	10397789	3725;2353	Jun;Fos	GKH-Fos ( 139-211 ) / Jun ( 248-334 ) ( GKH : glycine-lysine-histidine ) is a modified ******Fos/Jun****** ***heterodimer*** designed to contain a metal binding motif in the form of a GKH tripeptide at the amino terminus of Fos bZIP domain dimerized with the Jun basic region leucine zipper ( bZIP ) domain .	parallel	1
4422	10397789	3725;2353	Jun;Fos	However , due to the presence of the positively charged GKH motif on Fos , the degree of the induced bend by GKH - Fos ( 139-211 ) / Jun ( 248-334 ) is greater than that induced by the unmodified ******Fos/Jun****** ***heterodimer*** .	parallel	1
4423	10398121	7157;1026	TP53;p21	Furthermore , there may be an ***association*** between ***TP53*** and ***p21*** ( p = 0 .	parallel	0
4424	10398149	3458;941	IFN-gamma;B7-1	The expression of ***B7-1/B7-2*** on cardiac myocytes could be ***induced*** by ***IFN-gamma*** in vitro .	target	1
4425	10398149	3458;942	IFN-gamma;B7-2	The expression of ***B7-1/B7-2*** on cardiac myocytes could be ***induced*** by ***IFN-gamma*** in vitro .	target	1
4426	10398149	942;941	B7-2;B7-1	In vivo anti-B7-1 MAb treatment significantly prolonged the survival of mice with myocarditis , whereas ***anti-B7-2*** MAb treatment ***abrogated*** the protective effect of ***anti-B7-1*** .	negative	0
4427	10398158	1499;999	beta-catenin;E-cadherin	The common denominator is impaired ***beta-catenin*** ***association*** with either ***E-cadherin*** ( PaTuII ) or alpha-catenin ( BxPc3 and T3M4 ) .	parallel	0
4428	10398299	7132;7124	TNFR-I;TNFalpha	NGF also binds to the common neurotrophin receptor ( p75 ( NTR ) ) , a member of the ***TNFalpha*** ***receptor*** ( ***TNFR-I*** ) superfamily , whose function may be to modulate apoptosis via the release of ceramide and the activation of the transcription factor nuclear factor kappa B ( NFkappaB ) .	parallel	1
4429	10398438	675;5599	BRCA2;JNK	However , unlike JUN , we have determined that this region of ***BRCA2*** neither interacts with nor serves as a ***substrate*** for ***JNK*** , or any other kinase that can be detected in extracts from either fibroblasts or epithelial cells .	parallel	1
4430	10398604	3458;10673	interferon-gamma;BLyS	***BLyS*** expression on human monocytes could be ***up-regulated*** by ***interferon-gamma*** .	positive	1
4431	10398686	196;5715	Ah receptor;p27	***p27*** ( Kip1 ) ***induction*** and inhibition of proliferation by the intracellular ***Ah receptor*** in developing thymus and hepatoma cells .	target	1
4432	10398851	7040;3308	TGF-beta1;HSP70	The results indicate that : ( 1 ) UVB irradiation stimulates HSP70 expression in a dose - and time-dependent manner , ( 2 ) constitutive expression of TGF-beta1 mRNA is detected after UVB irradiation , the level of which peaks at 4 h after 10 mJ cm-2 of UVB irradiation , ( 3 ) ***HSP70*** expression is ***induced*** by ***TGF-beta1*** without UVB irradiation , and ( 4 ) HSP70 expression induction with UVB irradiation is inhibited by preincubation of the cells with the anti-TGF-beta type II receptor antibody .	target	1
4433	10399074	10859;2209	LIR-1;Fc gamma RI	Upon tyrosine phosphorylation , ***LIR-1*** and LIR-2 associate with the tyrosine phosphatase , SHP-1 , and have been shown to ***inhibit*** ***Fc gamma RI*** signalling when co-crosslinked in monocytes .	negative	1
4434	10399349	1636;5972	Angiotensin-I-converting enzyme;renin	***Angiotensin-I-converting enzyme*** ( ACE ) has been classically ***associated*** with the ***renin-angiotensin*** system which regulates peripheral blood pressure .	parallel	0
4435	10399627	596;7157	Bcl-2;p53	***Bcl-2*** immunoreactivity correlated with estrogen receptor ( ER ) and progesterone receptor ( PgR ) positivity and was inversely ***correlated*** with ***p53*** accumulation .	negative	0
4436	10399751	7124;7133	TNF-alpha;TNF-R75	***TNF-alpha*** acts via two different ***receptors*** of 55 ( TNF-R55 ) and 75 kD ( ***TNF-R75*** ) .	parallel	1
4437	10399920	1630;9423	DCC;netrin-1	To test whether these proteins form a receptor complex for repulsion , we studied the attractive responses of Xenopus spinal axons to ***netrin-1*** , which are ***mediated*** by ***DCC*** .	target	0
4438	10399920	9423;1630	netrin-1;DCC	We show that attraction is converted to repulsion by expression of UNC5 proteins in these cells , that this repulsion requires DCC function , that the UNC5 cytoplasmic domain is sufficient to effect the conversion , and that repulsion can be initiated by ***netrin-1*** ***binding*** to either UNC5 or ***DCC*** .	parallel	1
4439	10399941	4905;2891	NSF;GluR2	These data suggest that the ******NSF-GluR2****** ***interaction*** is required for the surface expression of GluR2-containing AMPA receptors and that disruption of the interaction leads to the functional elimination of AMPA receptors at synapses .	parallel	1
4440	10400034	11318;133	AM-R;adrenomedullin	OBJECTIVE : To determine the expression and localization of ***adrenomedullin*** ( AM ) and its ***receptor*** ( ***AM-R*** ) in portal hypertensive ( PHT ) gastric mucosa after intragastric ethanol administration .	parallel	1
4441	10400038	7040;1490	TGF-beta;Connective tissue growth factor	BACKGROUND : ***Connective tissue growth factor*** ( CTGF ) , which is ***regulated*** by transforming growth factor beta ( ***TGF-beta*** ) , has recently been implicated in skin fibrosis and atherosclerosis .	target	1
4442	10400038	7048;7040	TbetaR-II;TGF-beta	In the present study , the authors analyzed the concomitant presence of TGF-beta1 and its signaling receptors-TGF-beta receptor I , subtype ALK5 ( TbetaR-I ( ALK5 ) ) , and ***TGF-beta*** ***receptor*** II ( ***TbetaR-II*** ) - as well as CTGF and collagen type I in the pancreatic tissue of patients undergoing surgery for chronic pancreatitis .	parallel	1
4443	10400186	558;2621	UFO;GAS6	Since the transforming activity of the ***GAS6*** ***receptor*** ( ***AXL/UFO*** ) was documented , GAS6 might stimulate rather than inhibit proliferation .	parallel	1
4444	10400250	348;4137	ApoE;tau	The ***ApoE*** epsilon4 allele accelerates the progression of dementia and ***increases*** the levels of CSF ***tau*** in AD patients .	positive	0
4445	10400313	5610;1965	PKR;eIF-2alpha	In the presence of 0.25 microM staurosporine ( a concentration which completely inhibits a wide range of Ser/Thr protein kinases ) , the ***phosphorylation*** of ***eIF-2alpha*** by HRI and ***PKR*** was not inhibited .	target	1
4446	10400317	5921;309	p120GAP;annexin VI	The GTPase activating protein , p120GAP , contains an amino acid sequence motif called the Ca2 + - dependent lipid binding domain ( CaLB ) which mediates a protein-protein ***interaction*** between ***p120GAP*** and ***annexin VI*** and also binds to negatively charged phospholipids .	parallel	1
4447	10400318	2885;1956	GRB2;EGFR	We also demonstrated the ability of the peptides to block the ***binding*** of the ***GRB2*** SH2 domain to ***EGFR*** in a mammalian cell-based binding assay .	parallel	1
4448	10400418	4214;596	MEKK1;Bcl-2	***MEKK1*** and Ras , upstream activators of JNK and ERK MAPK , also fail to ***induce*** ***Bcl-2*** hyperphosphorylation .	target	1
4449	10400625	7186;4790	TRAF2;NF-kappaB	Expression of c-E10 under the control of a doxycycline-dependent transcriptional transactivator results in ***NF-kappaB*** activation , which is ***inhibited*** by dominant negative forms of ***TRAF2*** and NIK kinase .	negative	1
4450	10400627	6464;5599	Shc;JNK	***Shc*** ***regulates*** epidermal growth factor-induced activation of the ***JNK*** signaling pathway .	target	1
4451	10400627	2885;5594	Grb2;ERK	Here we show that the EGF-mediated ***ERK*** activation is ***abolished*** by loss of ***Grb2*** , whereas this response is not affected by loss of Shc .	positive	0
4452	10400632	3329;3336	GroEL;GroES	During encapsulation of non-native protein inside ******GroEL.GroES****** ***complexes*** , a folding reaction takes place , generating association-competent monomeric intermediates that are no longer recognized by GroEL .	parallel	1
4453	10400639	3303;5599	HSP72;JNK	The major inducible heat shock protein ***HSP72*** has previously been demonstrated to ***inhibit*** activation of ***JNK*** in cells exposed to heat shock and other protein-damaging agents , thus suppressing apoptosis .	negative	1
4454	10400639	3303;5599	HSP72;JNK	We show that ***HSP72*** ***suppresses*** activation of ***JNK*** induced by non-protein-damaging stimuli , interleukin-1 and UV irradiation , as well as by constitutively active components of the JNK signaling cascade Cdc42 and MEKK1 .	negative	1
4455	10400639	3303;5599	HSP72;JNK	Furthermore , ***HSP72*** strongly ***reduced*** activation of ***JNK*** by phosphatase inhibitors .	negative	1
4456	10400647	207;6513	Akt1;GLUT1	***Regulation*** of ***GLUT1*** gene transcription by the serine/threonine kinase ***Akt1*** .	target	1
4457	10400647	207;6513	Akt1;GLUT1	Our studies reveal that stimulation of ***MER-Akt1*** by hydroxytamoxifen ***induces*** ***GLUT1*** mRNA and protein accumulation to levels comparable to that induced by insulin ; therefore , activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system .	target	1
4458	10400647	2852;6513	MER;GLUT1	Our studies reveal that stimulation of ***MER-Akt1*** by hydroxytamoxifen ***induces*** ***GLUT1*** mRNA and protein accumulation to levels comparable to that induced by insulin ; therefore , activation of the Akt cascade suffices to induce GLUT1 gene expression in this cell system .	target	1
4459	10400647	207;6513	Akt;GLUT1	Additional studies reveal that the ***induction*** of ***GLUT1*** mRNA by ***Akt*** and by insulin reflects increased mRNA synthesis and not decreased mRNA degradation .	target	1
4460	10400650	5524;596	PP2A;Bcl2	These findings indicate that in cells expressing functional Bcl2 , the mechanism of death action for ceramide may involve , at least in part , a mitochondrial ***PP2A*** that ***dephosphorylates*** and inactivates ***Bcl2*** .	target	1
4461	10400652	3551;4792	IKKbeta;IkappaBalpha	Inactive ***IKKbeta*** was able to ***block*** vanadate-induced degradation of ***IkappaBalpha*** , yet it was unable to influence the activation of JNK by vanadate .	negative	0
4462	10400659	135;7422	A2AR;vascular endothelial growth factor	We further found that activation of ***A2AR*** enhances cell viability during hypoxia and also ***inhibits*** ***vascular endothelial growth factor*** expression in PC12 cells .	negative	1
4463	10400669	5610;3609	PKR;DRBP76	***DRBP76*** , a double-stranded RNA-binding nuclear protein , is ***phosphorylated*** by the interferon-induced protein kinase , ***PKR*** .	target	1
4464	10400669	5610;3609	PKR;DRBP76	DsRNA and ***PKR*** ***interactions*** of ***DRBP76*** were confirmed by analysis of in vitro translated and purified native proteins .	parallel	1
4465	10400669	3609;5610	DRBP76;PKR	Finally , purified ***DRBP76*** was shown to be a ***substrate*** of ***PKR*** in vitro , indicating that this protein 's cellular activities may be regulated by PKR-mediated phosphorylation .	parallel	1
4466	10400671	176;2192	aggrecan;Fibulin-1	Surface plasmon resonance measurements confirmed that ***aggrecan*** and versican lectin domains ***bind*** ***Fibulin-1*** , whereas brevican and neurocan do not .	parallel	1
4467	10400671	1462;2192	versican;Fibulin-1	Surface plasmon resonance measurements confirmed that aggrecan and ***versican*** lectin domains ***bind*** ***Fibulin-1*** , whereas brevican and neurocan do not .	parallel	1
4468	10400673	885;886	CCK;CCK-AR	This study also allowed us to demonstrate that ( i ) the identified interactions are crucial for stabilizing the high affinity phospholipase C-coupled state of the ******CCK-AR.CCK****** ***complex*** , ( ii ) Arg-336 and Asn-333 are directly involved in interactions with nonpeptide antagonists SR-27 ,897 and L-364 ,718 , and ( iii ) Arg-336 but not Asn-333 is directly involved in the binding of the peptide antagonist JMV 179 and the peptide partial agonist JMV 180 .	parallel	1
4469	10400682	2534;5913	Fyn;rapsyn	Three Src class kinases , ***Fyn*** , Fyk , and Src , each formed a ***complex*** with the endplate-specific cytoskeletal protein ***rapsyn*** .	parallel	1
4470	10400682	5913;2534	rapsyn;Fyn	Most importantly , ***rapsyn*** ***regulation*** of ***Fyn*** , Fyk , and Src resulted in phosphorylation of the nicotinic acetylcholine receptor beta and delta subunits and anchoring of the receptor to the cytoskeleton .	target	1
4471	10400692	207;1978	Akt;4E-BP1	Insulin-induced phosphorylation of ***4E-BP1*** was ***inhibited*** by ***Akt-AA*** in Chinese hamster ovary cells .	negative	1
4472	10400699	4792;4790	IkappaBalpha;NF-kappaB	Our data show that ***DeltaN-IkappaBalpha*** can ***bind*** ***NF-kappaB*** , suppress NF-kappaB activation , and sensitize cells to death .	parallel	1
4473	10400699	4792;4790	IkappaBalpha;NF-kappaB	Our data show that ***DeltaN-IkappaBalpha*** can bind NF-kappaB , ***suppress*** ***NF-kappaB*** activation , and sensitize cells to death .	negative	1
4474	10400732	387923;3002	Serp2;granzyme B	Myxoma virus ***Serp2*** is a weak ***inhibitor*** of ***granzyme B*** and interleukin-1beta-converting enzyme in vitro and unlike CrmA can not block apoptosis in cowpox virus-infected cells .	negative	1
4475	10400757	920;30816	CD4;Env	The delineation of the critical regions involved in the interactions within the ******Env-CD4-coreceptor****** ***complex*** are presently under intensive investigation , and the use of chimeras of coreceptor molecules has provided valuable information .	parallel	1
4476	10400792	6387;7852	SDF-1;CXCR4	Infection was blocked by ***SDF-1*** , the ***ligand*** for ***CXCR4*** , by antibody to CD4 and by HIV-neutralizing antibody .	parallel	1
4477	10400814	1385;4790	transactivator protein;NF-kappaB	The ***transactivator protein*** of human immunodeficiency virus type 1 ( HIV-1 ) ( Tat ) is a powerful ***activator*** of nuclear factor-kappaB ( ***NF-kappaB*** ) , acting through degradation of the inhibitor IkappaB-alpha ( F.	positive	1
4478	10400853	355;7124	Fas;TNF-alpha	***Anti-Fas*** had little effect on spontaneous eosinophil apoptosis but significantly ***reduced*** the inhibitory effects of PGE2 , cyclic AMP , and ***TNF-alpha*** .	negative	1
4479	10400998	3753;3757	minK;HERG	***minK*** assembles with KvLQT1 to produce the slow delayed rectifier K + current IKs and may ***assemble*** with ***HERG*** to modulate the rapid delayed rectifier IKr .	parallel	1
4480	10400998	3753;3784	minK;KvLQT1	***minK*** ***assembles*** with ***KvLQT1*** to produce the slow delayed rectifier K + current IKs and may assemble with HERG to modulate the rapid delayed rectifier IKr .	parallel	1
4481	10401538	1392;3557	CRH;IL-1ra	During gestation , symptoms of maternal depression were found to be associated with lower levels of CRH ; lower levels of ***CRH*** were ***associated*** with lower levels of ***IL-1ra*** .	parallel	0
4482	10401538	1392;3557	CRH;IL-1ra	Maternal symptoms of depression during gestation may attenuate the ***association*** between ***CRH*** and ***IL-1ra*** .	parallel	0
4483	10401555	5368;4987	Nociceptin;ORL1	***Nociceptin*** , also known as orphanin FQ , is an endogenous ***ligand*** for the orphan opioid receptor-like receptor 1 ( ***ORL1*** ) and involves in various functions in the central nervous system ( CNS ) .	parallel	1
4484	10401575	4214;5594	MEKK1;p38	The serine/threonine protein kinase ***MEKK1*** is an upstream ***activator*** of the MAP kinases c-Jun N-terminal kinase/stress-activated protein kinase ( JNK/SAPK ) , extracellular signal-regulated kinase ( ERK ) , and ***p38*** as well as NF-kappa B .	positive	1
4485	10401666	7849;6528	Pax-8;NIS	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , thyroid transcription factor (TTF)-1 , TTF-2 , and ***Pax-8*** , which coordinately ***regulate*** ***NIS*** , TPO , TG , and the TSHR .	target	1
4486	10401666	7849;7173	Pax-8;TPO	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , thyroid transcription factor (TTF)-1 , TTF-2 , and ***Pax-8*** , which coordinately ***regulate*** NIS , ***TPO*** , TG , and the TSHR .	target	1
4487	10401666	7849;7253	Pax-8;TSHR	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , thyroid transcription factor (TTF)-1 , TTF-2 , and ***Pax-8*** , which coordinately ***regulate*** NIS , TPO , TG , and the ***TSHR*** .	target	1
4488	10401666	7080;6528	thyroid transcription factor (TTF)-1;NIS	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , ***thyroid transcription factor (TTF)-1*** , TTF-2 , and Pax-8 , which coordinately ***regulate*** ***NIS*** , TPO , TG , and the TSHR .	target	1
4489	10401666	7080;7173	thyroid transcription factor (TTF)-1;TPO	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , ***thyroid transcription factor (TTF)-1*** , TTF-2 , and Pax-8 , which coordinately ***regulate*** NIS , ***TPO*** , TG , and the TSHR .	target	1
4490	10401666	7080;7253	thyroid transcription factor (TTF)-1;TSHR	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , ***thyroid transcription factor (TTF)-1*** , TTF-2 , and Pax-8 , which coordinately ***regulate*** NIS , TPO , TG , and the ***TSHR*** .	target	1
4491	10401666	2304;6528	TTF-2;NIS	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , thyroid transcription factor (TTF)-1 , ***TTF-2*** , and Pax-8 , which coordinately ***regulate*** ***NIS*** , TPO , TG , and the TSHR .	target	1
4492	10401666	2304;7173	TTF-2;TPO	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , thyroid transcription factor (TTF)-1 , ***TTF-2*** , and Pax-8 , which coordinately ***regulate*** NIS , ***TPO*** , TG , and the TSHR .	target	1
4493	10401666	2304;7253	TTF-2;TSHR	TSH does this by modulating the expression and activity of the thyroid-specific transcription factors , thyroid transcription factor (TTF)-1 , ***TTF-2*** , and Pax-8 , which coordinately ***regulate*** NIS , TPO , TG , and the ***TSHR*** .	target	1
4494	10402201	3739;1742	Kv1.4;PSD-95	When domains that mediate the ***interaction*** of ***Kv1.4*** and ***PSD-95*** were disrupted , Kv1.4 localized nonspecifically .	parallel	1
4495	10402242	1748;4609	DLX-7;c-myc	***DLX-7*** homeobox gene ***regulates*** ***c-myc*** and GATA-1 gene expression in different stages respectively .	target	1
4496	10402242	1748;2623	DLX-7;GATA-1	***DLX-7*** homeobox gene ***regulates*** c-myc and ***GATA-1*** gene expression in different stages respectively .	target	1
4497	10402242	1748;4609	DLX-7;c-myc	These results suggest that ***DLX-7*** may ***regulate*** ***c-myc*** and GATA-1 genes at transcriptional and post-transcriptional levels .	target	1
4498	10402242	1748;2623	DLX-7;GATA-1	These results suggest that ***DLX-7*** may ***regulate*** c-myc and ***GATA-1*** genes at transcriptional and post-transcriptional levels .	target	1
4499	10402473	8829;10371	Neuropilin-1;semaphorin III	***Neuropilin-1*** ***mediates*** ***collapsin-1/semaphorin III*** inhibition of endothelial cell motility : functional competition of collapsin-1 and vascular endothelial growth factor-165 .	target	0
4500	10402475	2719;3481	GPC3;IGF-II	Since BWS has been associated with biallelic expression of insulin-like growth factor II ( IGF-II ) , it has been proposed that ***GPC3*** is a negative ***regulator*** of ***IGF-II*** .	negative	1
4501	10402475	3482;3481	IGF2R;IGF-II	The degree of developmental overgrowth of the GPC3-deficient mice is similar to that of mice deficient in IGF receptor type 2 ( ***IGF2R*** ) , a well characterized negative ***regulator*** of ***IGF-II*** .	negative	1
4502	10402478	367;5304	Androgen receptor;GCDFP-15	***Androgen receptor*** ( AR ) mediated ***regulation*** of ***GCDFP-15*** expression was investigated in the AR-positive human mammary cancer cell lines MFM-223 and ZR-75-1 .	target	1
4503	10403376	8835;8651	SOCS-2;SOCS-1	In cotransfection studies , ***SOCS-2*** was able to ***block*** the inhibitory effect of ***SOCS-1*** but not that of SOCS-3 on GH signaling .	negative	0
4504	10403393	4214;5599	MEKK1;JNK	Activation of ***JNK*** and cell death by cisplatin is ***mediated*** by the ***MEKK1/SEK1*** cascade , since expression of dominant negative expression vectors of these kinases blocked both processes .	target	0
4505	10403393	6416;5599	SEK1;JNK	Activation of ***JNK*** and cell death by cisplatin is ***mediated*** by the ***MEKK1/SEK1*** cascade , since expression of dominant negative expression vectors of these kinases blocked both processes .	target	0
4506	10403397	2885;6464	Grb2;Shc	Actinomycin D as a novel SH2 domain ligand inhibits ******Shc/Grb2****** ***interaction*** in B104-1-1 ( neu * - transformed NIH3T3 ) and SAA ( hEGFR-overexpressed NIH3T3 ) cells .	parallel	1
4507	10403397	6464;2885	Shc;Grb2	Actinomycins , a family of bicyclic chromopeptide lactones with strong antineoplastic activity , were screened as inhibitors of ******Shc/Grb2****** ***interaction*** in in vitro assay systems .	parallel	1
4508	10403397	2885;6464	Grb2;Shc	To investigate the effects of actinomycin D on Shc/Grb2 interaction in cell-based experiments , we used SAA ( normal hEGFR-overexpressed NIH3T3 ) cells and B104-1-1 ( neu * - transformed NIH3T3 ) cells , because a large number of the ******Shc/Grb2****** ***complexes*** were detected .	parallel	1
4509	10403397	2885;6464	Grb2;Shc	To investigate the effects of actinomycin D on ******Shc/Grb2****** ***interaction*** in cell-based experiments , we used SAA ( normal hEGFR-overexpressed NIH3T3 ) cells and B104-1-1 ( neu * - transformed NIH3T3 ) cells , because a large number of the Shc/Grb2 complexes were detected .	parallel	1
4510	10403397	6464;2885	Shc;Grb2	The result of the immunoblotting experiment revealed that actinomycin D inhibited ******Shc/Grb2****** ***interaction*** in a dose-dependent manner in both B104-1-1 and EGF-stimulated SAA cells .	parallel	1
4511	10403397	6464;2885	Shc;Grb2	The inhibition of ******Shc/Grb2****** ***interaction*** by actinomycin D in B104-1-1 cells also reduced tyrosine phosphorylation of MAP kinase ( Erk1/Erk2 ) , one of the major components in the Ras-MAP kinase signaling pathway .	parallel	1
4512	10403482	7040;2200	TGF-beta;Fbn-1	We also demonstrate for the first time that ***TGF-beta*** , which plays a crucial role in skin fibrosis , ***binds*** to both wild-type and mutated ***Fbn-1*** .	parallel	1
4513	10403485	940;3725	CD28;c-jun	***CD28-mediated*** ***regulation*** of the ***c-jun*** promoter involves the MEF2 transcription factor in Jurkat T cells .	target	1
4514	10403509	6750;2520	somatostatin;gastrin	***somatostatin*** ***suppresses*** ***gastrin*** and somatostatin secretion via somatostatin receptors ( SSTRs ) .	negative	1
4515	10403529	7124;1545	TNF-alpha;Cyp1B1	Interestingly , ***TNF-alpha*** is a potent ***stimulator*** of the ***Cyp1B1*** gene in HSCs and acts in concert with DMBA .	positive	0
4516	10403529	7124;1545	TNF-alpha;Cyp1B1	The inflammatory cytokine ***TNF-alpha*** ***enhanced*** the ***Cyp1B1*** gene expression in HSCs , either when administered alone or in addition to DMBA , while TGFbeta1 did not affect Cyp1B1 expression , even after DMBA induction .	positive	0
4517	10403545	7157;581	p53;Bax	Positive expression of ***p53*** was related to poor prognosis ( P = 0.0445 ) and was ***associated*** with negative expression of ***Bax*** ( P = 0.0439 ) .	parallel	0
4518	10403560	7124;834	TNF alpha;Caspase 1	Interestingly , ***TNF alpha*** levels measured by immunohistochemistry ***correlated*** with the net increase in Caspase 3 activity after 4 h ( p = 0.517 , n = 13 , P = 0.07 ) and the starting levels of ***Caspase 1*** at 0 h correlated with the Caspase 3 levels attained at 4 h ( p = 0.593 , n = 13 , P = 0.033 ) .	parallel	0
4519	10403569	2247;2697	bFGF;Cx43	Basic fibroblast growth factor ( ***bFGF*** ) , known to be important in wound healing , has been found to ***increase*** ***Cx43*** expression and intercellular communication in endothelial cells and cardiac fibroblasts .	positive	0
4520	10403649	4094;3565	c-Maf;interleukin-4	The transcription factor ***c-Maf*** ***controls*** the production of ***interleukin-4*** but not other Th2 cytokines .	target	0
4521	10403730	7124;3458	TNF-alpha;IFN-gamma	***TNF-alpha*** also ***enhanced*** ***IFN-gamma*** dependent changes in cell morphology but did not induce cell death .	positive	0
4522	10403735	356;355	FasL;Fas	AIMS : To investigate which of the two most investigated inductors of apoptosis ( ***Fas*** ***ligand*** ( ***FasL*** ) and tumour necrosis factor alpha ( TNF-alpha ) ) is responsible for the induction of apoptosis in this animal model .	parallel	1
4523	10403735	355;356	Fas;FasL	CONCLUSIONS : The ******FasL-Fas****** ***interaction*** is not involved in the induction of apoptosis during acute GVHD .	parallel	1
4524	10403737	3553;834	IL-1beta;Caspase 1	CONCLUSIONS : The demonstration that the human colonic epithelial barrier is able to express ***Caspase 1*** and its ***substrate*** ***IL-1beta*** reinforces the concept that , under certain conditions , the epithelium could trigger an inflammatory reaction .	parallel	1
4525	10403766	613;2071	BCR;XPB	We have previously shown that P210 ***BCR-ABL*** ***binds*** to the xeroderma pigmentosum group B protein ( ***XPB*** ) through the portion of BCR that is homologous to the catalytic domain of GDP-GTP exchangers such as yeast CDC24 and Dbl .	parallel	1
4526	10403766	2071;613	XPB;BCR	The ***binding*** of endogenous ***BCR*** and ***XPB*** proteins was also detected in Hela cells , and this was inhibited by a blocking peptide .	parallel	1
4527	10403766	373156;613	GST;BCR	***GST-XPB*** ( 203-782 ) was localized predominantly in the cytoplasm and ***bound*** to ***BCR*** but not to p62 , one of the other components in TFIIH .	parallel	1
4528	10403766	2071;613	XPB;BCR	***GST-XPB*** ( 203-782 ) was localized predominantly in the cytoplasm and ***bound*** to ***BCR*** but not to p62 , one of the other components in TFIIH .	parallel	1
4529	10403766	373156;613	GST;BCR	***GST-XPB*** ( 1-782 ) was largely in the nucleus and ***bound*** to p62 and ***BCR*** .	parallel	1
4530	10403766	373156;2965	GST;p62	***GST-XPB*** ( 1-782 ) was largely in the nucleus and ***bound*** to ***p62*** and BCR .	parallel	1
4531	10403766	2071;613	XPB;BCR	***GST-XPB*** ( 1-782 ) was largely in the nucleus and ***bound*** to p62 and ***BCR*** .	parallel	1
4532	10403766	2071;2965	XPB;p62	***GST-XPB*** ( 1-782 ) was largely in the nucleus and ***bound*** to ***p62*** and BCR .	parallel	1
4533	10403766	613;2965	BCR;p62	Although the biological significance of the binding remains to be uncovered , ***BCR*** ***binds*** to the ***XPB/p62*** complex .	parallel	1
4534	10403766	613;2071	BCR;XPB	Although the biological significance of the binding remains to be uncovered , ***BCR*** ***binds*** to the ***XPB/p62*** complex .	parallel	1
4535	10403766	2071;2965	XPB;p62	Although the biological significance of the binding remains to be uncovered , BCR binds to the ******XPB/p62****** ***complex*** .	parallel	1
4536	10403788	1594;10294	VDR;DnaJ	All ***VDR*** constructs bound DnaK in amounts greater than GST alone and ***bound*** smaller amounts of ***DnaJ*** or GrpE .	parallel	1
4537	10403788	1594;80273	VDR;GrpE	All ***VDR*** constructs bound DnaK in amounts greater than GST alone and ***bound*** smaller amounts of DnaJ or ***GrpE*** .	parallel	1
4538	10403788	3329;1594	GroEL;VDR	***GroEL*** ***bound*** only to ***FL-VDR*** .	parallel	1
4539	10403788	3320;1594	hsp90;VDR	***Binding*** of ***hsp90*** to ***VDR*** was not detected .	parallel	1
4540	10403802	80150;1978	L-Asparaginase;4E-BP1	Here we demonstrate that addition of ***L-Asparaginase*** to human leukemic cells ***inhibits*** activity of p70 ( s6k ) and phosphorylation of ***4E-BP1*** , but not activities of other cell growth-related serine/threonine kinases .	negative	1
4541	10403802	80150;84959	L-Asparaginase;p70	Here we demonstrate that addition of ***L-Asparaginase*** to human leukemic cells ***inhibits*** activity of ***p70*** ( s6k ) and phosphorylation of 4E-BP1 , but not activities of other cell growth-related serine/threonine kinases .	negative	1
4542	10403808	3458;3569	IFN-gamma;IL-6	LPS and ***IFN-gamma*** ***induced*** ***IL-6*** gene expression with a similar qualitative profile in both cell types .	target	1
4543	10403828	5970;4792	RelA;IkappaBalpha	***RelA*** and ***IkappaBalpha*** formed a stable ***complex*** that could be purified to > 95 % homogeneity .	parallel	1
4544	10403845	9994;112752	Ced-4;Ced-3	***Ced-4*** ***facilitates*** the proteolytic activation of the caspase , ***Ced-3*** , while Ced-9 opposes Ced-3/Ced-4 killing .	positive	0
4545	10403910	720;213	C4A;albumin	We report here the ***binding*** of ***C4A*** and C4B to an immune complex of bovine serum ***albumin*** ( BSA ) anti-BSA as it occurs in serum .	parallel	1
4546	10403926	3558;3565	IL-2;IL-4	OvAg did not stimulate ***IL-2*** and none of the mitogens or antigens ***induced*** production of ***IL-4*** in neonates .	target	1
4547	10403929	959;958	CD40L;CD40	***CD40*** and its ***ligand*** ***CD40L*** are key players in T cell-B cell interaction and T cell-antigen-presenting cell ( APC ) interaction .	parallel	1
4548	10403929	958;959	CD40;CD40L	Inhibition of ******CD40-CD40L****** ***interaction*** leads to severe humoral and cellular immunodeficiency .	parallel	1
4549	10403929	959;958	CD40L;CD40	The highly elevated levels of sCD40 may point to the involvement of ***CD40*** and its ***ligand*** ***CD40L*** in the clinical manifestation of uraemic immunodeficiency .	parallel	1
4550	10403932	7124;7422	TNF-alpha;VEGF	RA PBMC ***VEGF*** production was ***up-regulated*** by TGF-beta isoforms and ***TNF-alpha*** and down-regulated by IL-4 and IL-10 , with no effect observed with IL-1beta , IL-6 and IL-8 .	positive	1
4551	10403932	7124;7422	TNF-alpha;VEGF	Antibody blocking experiments confirmed that ***TNF-alpha*** and not TGF-beta isoforms in SF ***increased*** ***VEGF*** secretion by RA PBMC .	positive	0
4552	10404006	796;7124	CGRP;tumor necrosis factor alpha	***CGRP*** inhibits osteoclasts , stimulates insulin-like growth factor I and ***inhibits*** ***tumor necrosis factor alpha*** production by osteoblasts in vitro .	negative	1
4553	10404014	4087;7040	Smad2;TGF-beta	Smad1 and Smad5 mediate intracellular signaling of bone morphogenetic protein ( BMP ) , whereas ***Smad2*** and Smad3 ***transduce*** ***TGF-beta*** signaling .	positive	1
4554	10404014	4088;7040	Smad3;TGF-beta	Smad1 and Smad5 mediate intracellular signaling of bone morphogenetic protein ( BMP ) , whereas Smad2 and ***Smad3*** ***transduce*** ***TGF-beta*** signaling .	positive	1
4555	10404027	7040;10631	TGF-beta;periostin	By Western blot analysis , ***TGF-beta*** ***increased*** ***periostin*** expression in primary osteoblast cells .	positive	0
4556	10404056	3565;3458	IL-4;IFN-gamma	Increased IL-4 production by HIV-1 p24-activated immunocompetent cells of patients and a predominant ***IL-4*** ***response*** to HIV-1 p24 ( with ***IL-4/IFN-gamma*** > 1 ) were positively correlated with an increased viral load .	parallel	0
4557	10404062	1499;999	beta-catenin;E-cadherin	Immunoprecipitation studies showed that the truncated ***beta-catenin*** proteins only ***bound*** weakly to ***E-cadherin*** and beta-catenin compared with non-truncated beta-catenin .	parallel	1
4558	10404183	23139;1756	MAST205;dystrophin	Our data suggest that ***MAST205*** and SAST ***link*** the ***dystrophin/utrophin*** network with microtubule filaments via the syntrophins .	parallel	0
4559	10404183	23139;7402	MAST205;utrophin	Our data suggest that ***MAST205*** and SAST ***link*** the ***dystrophin/utrophin*** network with microtubule filaments via the syntrophins .	parallel	0
4560	10404183	22983;1756	SAST;dystrophin	Our data suggest that MAST205 and ***SAST*** ***link*** the ***dystrophin/utrophin*** network with microtubule filaments via the syntrophins .	parallel	0
4561	10404183	22983;7402	SAST;utrophin	Our data suggest that MAST205 and ***SAST*** ***link*** the ***dystrophin/utrophin*** network with microtubule filaments via the syntrophins .	parallel	0
4562	10404213	1387;1385	CBP;CREB	Electrostatic contribution of phosphorylation to the stability of the ******CREB-CBP****** activator-coactivator ***complex*** .	parallel	1
4563	10404391	3458;3659	IFN gamma;IRF-1	Our results also suggest that the ***induction*** of ***IRF-1*** mRNA by ***IFN gamma*** and TNF alpha is not the cellular mechanism involved in the synergistic effect of these cytokines on thyroid function .	target	1
4564	10404391	7124;3659	TNF alpha;IRF-1	Our results also suggest that the ***induction*** of ***IRF-1*** mRNA by IFN gamma and ***TNF alpha*** is not the cellular mechanism involved in the synergistic effect of these cytokines on thyroid function .	target	1
4565	10404391	3458;3659	interferon-gamma;interferon regulatory factor-1	***Induction*** of transcription factor ***interferon regulatory factor-1*** by ***interferon-gamma*** ( IFN gamma ) and tumor necrosis factor-alpha ( TNF alpha ) in FRTL-5 cells .	target	1
4566	10404391	7124;3659	tumor necrosis factor-alpha;interferon regulatory factor-1	***Induction*** of transcription factor ***interferon regulatory factor-1*** by interferon-gamma ( IFN gamma ) and ***tumor necrosis factor-alpha*** ( TNF alpha ) in FRTL-5 cells .	target	1
4567	10404396	4803;5595	NGF;ERK-1	The inhibition of tyrosine phosphorylation by ethanol was not a general effect , however , as we found that ethanol increased basal and ***NGF-induced*** tyrosine ***phosphorylation*** of extracellular signal-activated protein kinase-1 ( ***ERK-1*** ) .	target	1
4568	10404396	5617;3659	PRL;IRF-1	These data indicate that ethanol inhibits PRL-induced tyrosine phosphorylation of the JAK/STAT pathway resulting in decreased nuclear GAS DNA ***binding*** and inhibition of the ***PRL*** inducible gene , ***IRF-1*** .	parallel	1
4569	10404403	7124;3458	TNF-alpha;IFN-gamma	However , the ***TNF-alpha*** secreting CD3 cell percentage is ***correlated*** with the ***IFN-gamma*** and IL-2 secreting CD3 cell percentages in multiple sclerosis patients .	parallel	0
4570	10404403	7124;3458	TNF-alpha;IFN-gamma	In the controls , only the ***TNF-alpha*** secreting CD3 cell percentage is ***correlated*** with ***IFN-gamma*** .	parallel	0
4571	10404439	2209;2064	Fc gamma RI;erbB-2	MDX-H210 is a chemically , cross-linked , half-humanized bispecific antibody composed of F ( ab ' ) fragment from monoclonal antibody ( mAb ) H22 that binds to the high-affinity receptor ***Fc gamma RI*** and F ( ab ' ) of mAb 520C9 that ***recognizes*** the ***erbB-2*** ( HER2/neu ) oncoprotein .	target	1
4572	10404760	7035;2152	TFPI;tissue factor	Thrombin-antithrombin complexes ( TAT ) , tissue factor ( TF ) , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , thrombomodulin ( TM ) and von Willebrand factor antigen ( vWF : Ag ) were analyzed before and during the orthopaedic surgery .	negative	1
4573	10404768	5624;2153	protein C;factor V Leiden	Activated ***protein C*** ( APC ) resistance , defined as a low APC ratio , is ***associated*** with the factor V mutation R506Q ( ***factor V Leiden*** ) .	parallel	0
4574	10404822	4036;7038	megalin;thyroglobulin	We recently showed that ***megalin*** is a high-affinity ***receptor*** for ***thyroglobulin*** .	parallel	1
4575	10405182	2475;1978	mTOR;PHAS-I	Mutational analysis of sites in the translational regulator , ***PHAS-I*** , that are selectively ***phosphorylated*** by ***mTOR*** .	target	1
4576	10405182	1978;1977	PHAS-I;eIF4E	Phosphorylation of Thr36 only slightly attenuated ***binding*** of ***PHAS-I*** to ***eIF4E*** , while phosphorylation of Thr45 markedly inhibited binding .	parallel	1
4577	10405323	7066;1432	Thrombopoietin;p38 mitogen-activated protein kinase	***Thrombopoietin*** ***potentiates*** agonist-stimulated activation of ***p38 mitogen-activated protein kinase*** in human platelets .	positive	0
4578	10405323	7066;1432	TPO;p38	TPO did not activate p38 by itself , whereas ***TPO*** pretreatment ***potentiated*** the agonist-induced activation of ***p38*** .	positive	0
4579	10405329	4638;4633	myosin light chain kinase;regulatory light chain of myosin	***myosin light chain kinase*** ( MLCK ) ***phosphorylates*** the ***regulatory light chain of myosin*** in the presence of Ca ( 2 + ) and calmodulin ( Ca ( 2 + ) - CaM ) so that myosin can interact with actin filaments .	target	1
4580	10405333	2641;890	glucagon;cyclin A2	***glucagon*** indeed ***upregulated*** cyclin A2 and ***cyclin A2-associated*** kinase while cyclin E-associated kinase was unmodified .	positive	1
4581	10405348	3569;1588	IL-6;aromatase	Both paclitaxel and 2-meOE2 also inhibited ***stimulation*** of ***aromatase*** activity by ***IL-6*** plus its soluble receptor and PGE ( 2 ) .	positive	0
4582	10405761	613;2885	Bcr;Grb-2	Previous work in our laboratory established that Bcr is a major transformation-related substrate for the v-Fps tyrosine kinase , and tyrosine phosphorylation of Bcr induces ******Bcr-Grb-2****** / SOS ***association*** in vivo through the Src homology 2 ( SH2 ) domain of Grb-2 .	parallel	0
4583	10405761	2242;613	Fes;Bcr	Tyrosine ***phosphorylation*** of ***Bcr*** by ***Fes*** greatly enhanced the binding of Bcr to the SH2 domains of multiple signalling molecules in vitro , including Grb-2 , Ras GTPase activating protein , phospholipase C-gamma , the 85,000 M ( r ) subunit of phosphatidylinositol 3 ' - kinase , and the Abl tyrosine kinase .	target	1
4584	10405785	186;185	AT2;AT1	***AT2*** ***inhibits*** ***AT1*** ( growth factor-stimulated cell growth ) , AT2 attenuates the vasoconstriction induced by AT1 .	negative	1
4585	10406004	3485;3481	insulin-like growth factor binding protein-2;IGF-II	***insulin-like growth factor binding protein-2*** ( IGFBP-2 ) , one of the six carrier proteins for IGFs , is also thought to be released from the choroid plexus , ***bind*** to ***IGF-II*** in the cerebrospinal fluid ( CSF ) and modulate the action of this growth factor .	parallel	1
4586	10406074	355;356	Fas;FasL	This review initially provides background information and updates aspects of the Fas/FasL signaling system , including the role of caspases and molecules recruited to the ******FasL/Fas****** signaling ***complex*** and the revised functions ascribed to membrane and soluble forms of FasL .	parallel	1
4587	10406188	4313;7077	MMP-2;tissue inhibitor of metalloproteinases-2	The chromatography of serum revealed a single peak at the position of about 90 kDa corresponding to an ***MMP-2*** ***complexed*** with ***tissue inhibitor of metalloproteinases-2*** .	parallel	1
4588	10406461	7200;5617	TRH;PRL	The hypothalamic hormone , ***TRH*** , ***stimulates*** ***PRL*** secretion and gene transcription .	positive	0
4589	10406461	7200;5617	TRH;PRL	A kinase-defective , interfering MAPK kinase ( MAPKK ) mutant reduced ***TRH*** ***induction*** of the ***PRL*** promoter .	target	1
4590	10406461	7200;5617	TRH;PRL	Treatment with the MAPKK inhibitor , PD98059 , blocked TRH-induced activation of MAPK and also reduced ***TRH*** ***induction*** of a ***PRL-luciferase*** reporter gene , confirming that MAPK activation is necessary for TRH effects on PRL gene expression .	target	1
4591	10406465	1387;5617	CBP;PRL	Furthermore , ***CBP*** also ***increases*** the activation of the ***PRL*** promoter by GHF-1 and the ligand-independent activation by both wild-type and mutant VDR .	positive	0
4592	10406465	5449;5617	GHF-1;PRL	Furthermore , CBP also increases the ***activation*** of the ***PRL*** promoter by ***GHF-1*** and the ligand-independent activation by both wild-type and mutant VDR .	positive	1
4593	10406465	5449;5617	GHF-1;prolactin	Synergistic ***activation*** of the ***prolactin*** promoter by vitamin D receptor and ***GHF-1*** : role of the coactivators , CREB-binding protein and steroid hormone receptor coactivator-1 ( SRC-1 ) .	positive	1
4594	10406465	7421;5617	vitamin D receptor;prolactin	Synergistic ***activation*** of the ***prolactin*** promoter by ***vitamin D receptor*** and GHF-1 : role of the coactivators , CREB-binding protein and steroid hormone receptor coactivator-1 ( SRC-1 ) .	positive	1
4595	10406465	7421;5617	VDR;PRL	We found that ***VDR*** ***activates*** the ***PRL*** promoter both in a ligand-dependent and - independent manner through a sequence located between positions -45 / -27 in the proximal 5 ' - flanking region .	positive	1
4596	10406465	7421;5449	VDR;GHF-1	In the context of the PRL gene , ***VDR*** ***requires*** the presence of ***GHF-1*** to activate the promoter .	target	0
4597	10406466	9611;4654	N-CoR;MyoD	This work demonstrates that the corepressor ***N-CoR*** is a key ***regulator*** of ***MyoD*** activity and mammalian differentiation , and that N-CoR has a multifaceted role in myogenesis .	target	1
4598	10406466	9611;4654	N-CoR;MyoD	The nuclear receptor corepressor N-CoR regulates differentiation : ***N-CoR*** directly ***interacts*** with ***MyoD*** .	parallel	1
4599	10406466	4654;9611	MyoD;N-CoR	The mechanism involves direct ***interactions*** between ***MyoD*** and ***N-CoR*** ; moreover , the interaction was dependent on the amino-terminal repression domain ( RD1 ) of N-CoR and the bHLH region of MyoD .	parallel	1
4600	10406469	3439;6773	IFN;STAT-1 (signal transducer and activator of transcription-1) and -2	***IFN-tau*** ***activated*** ***STAT-1 (signal transducer and activator of transcription-1) and -2*** by 0.5 h , and IRF-1 by 2 h in BEND cells .	positive	1
4601	10406469	4137;6773	tau;STAT-1 (signal transducer and activator of transcription-1) and -2	***IFN-tau*** ***activated*** ***STAT-1 (signal transducer and activator of transcription-1) and -2*** by 0.5 h , and IRF-1 by 2 h in BEND cells .	positive	1
4602	10406811	1977;1981	eIF4E;eIF4G	We show that the 4E-BPs 1 and 2 block the ***interaction*** between ***eIF4G*** and ***eIF4E*** by competing for binding to a dorsal site on eIF4E .	parallel	1
4603	10406811	1978;1977	4E-BP1;eIF4E	The binding contacts and affinities for the ***interactions*** between ***4E-BP1/2*** and ***eIF4E*** are distinct ( estimated K ( d ) values of 10 ( -8 ) and 3x10 ( -9 ) for 4E-BP1 and 2 , respectively ) , and the differences in these properties are determined by three amino acids within an otherwise conserved motif .	parallel	1
4604	10406830	5743;5972	COX-2;renin	In summary , these studies indicate that the selective COX-2 inhibitor SC58236 decreases renin production and release in RVH and suggest an important role for ***COX-2*** ***regulation*** of the ***renin-angiotensin*** system .	target	1
4605	10406830	5743;5972	Cyclooxygenase-2;renin	***Cyclooxygenase-2*** inhibition ***decreases*** ***renin*** content and lowers blood pressure in a model of renovascular hypertension .	positive	0
4606	10406834	183;3569	angiotensin II;interleukin-6	***Induction*** of ***interleukin-6*** expression by ***angiotensin II*** in rat vascular smooth muscle cells .	target	1
4607	10406964	7040;1191	TGFbeta;clusterin	Transforming growth factor-beta ( ***TGFbeta*** ) ***induces*** gene expression of the glycoprotein ***clusterin*** in a variety of cell types via a consensus AP-1 binding site .	target	1
4608	10406964	7040;1191	TGFbeta;clusterin	Further , we demonstrate that in stable c-Fos-overexpressing cell lines , ***TGFbeta*** ***induction*** of endogenous ***clusterin*** mRNA , as well as clusterin promoter transactivation are blocked .	target	1
4609	10406964	7040;2353	TGFbeta;c-Fos	The results suggest that the c-Fos represses clusterin gene expression , maintaining a low basal level in the absence of TGFbeta , and that ***TGFbeta*** , presumably through its effects on c-Fos protein synthesis and/or stability , ***abrogates*** the repression of ***c-Fos*** , thereby resulting in gene expression .	negative	0
4610	10406964	2353;1191	c-Fos;clusterin	The results suggest that the ***c-Fos*** ***represses*** ***clusterin*** gene expression , maintaining a low basal level in the absence of TGFbeta , and that TGFbeta , presumably through its effects on c-Fos protein synthesis and/or stability , abrogates the repression of c-Fos , thereby resulting in gene expression .	negative	1
4611	10407014	3791;7422	flk-1;VEGF	Immunostaining showed that the ***VEGF*** receptor fetal liver kinase ***receptor*** ( ***flk-1*** ) was found on nerve cell bodies in DRG and to a lesser extent on neurons in SCG .	parallel	1
4612	10407040	627;4915	BDNF;TrkB	Thus , the impaired AMPA receptor function in the stg mutant GC is not likely to result from the reduced ******BDNF-TrkB****** ***signaling*** .	parallel	0
4613	10407185	7040;351	TGF-beta;amyloid precursor protein	The transforming growth factor , ***TGF-beta*** ( 1 ) , has been found to be increased in the central nervous system of Alzheimer 's disease ( AD ) patients , ***elevates*** ***amyloid precursor protein*** ( APP ) mRNA levels in rat primary astrocytes , and may initiate or promote the deposition of amyloid-beta ( Abeta ) peptide in AD .	positive	0
4614	10407185	7040;351	TGF-beta;APP	Here , we report that ***TGF-beta*** ( 1 ) treatment of human astrocytes markedly ***elevated*** ***APP*** mRNA levels , and also increased the half-life of APP message by at least five-fold .	positive	0
4615	10407222	5539;6343	pancreatic polypeptide;secretin	Plasma ***pancreatic polypeptide*** ***response*** to ***secretin*** .	parallel	0
4616	10407222	6343;5539	secretin;pancreatic polypeptide	OBJECTIVE : Intravenously administered ***secretin*** ***stimulates*** ***pancreatic polypeptide*** ( PP ) release in patients with endocrine enteropancreatic tumors , but data in patients with nontumorous disorders are controversial .	positive	0
4617	10407496	3552;2353	IL-1 alpha;AP-1	***IL-1 alpha*** at this dose ( which activates NF-kappa B , but not AP-1 ) also ***enhanced*** LDL-activated ***AP-1*** binding .	positive	0
4618	10407498	3552;3589	IL-1 alpha;IL-11	Furthermore , ***IL-1 alpha*** , TGF beta , and TNF alpha ***induced*** ***IL-11*** gene expression in VSMC .	target	1
4619	10407498	7040;3589	TGF beta;IL-11	Furthermore , IL-1 alpha , ***TGF beta*** , and TNF alpha ***induced*** ***IL-11*** gene expression in VSMC .	target	1
4620	10407498	7124;3589	TNF alpha;IL-11	Furthermore , IL-1 alpha , TGF beta , and ***TNF alpha*** ***induced*** ***IL-11*** gene expression in VSMC .	target	1
4621	10407498	7040;3589	TGF beta;IL-11	IL-1 alpha , transforming growth factor-beta ( ***TGF beta*** ) and , to a lesser extent , tumor necrosis factor-alpha ( TNF alpha ) ***stimulated*** the ***IL-11*** production by VSMC , and the stimulatory effects of IL-1 alpha and TGF beta on IL-11 production were dose-dependent .	positive	0
4622	10407498	7124;3589	TNF alpha;IL-11	IL-1 alpha , transforming growth factor-beta ( TGF beta ) and , to a lesser extent , tumor necrosis factor-alpha ( ***TNF alpha*** ) ***stimulated*** the ***IL-11*** production by VSMC , and the stimulatory effects of IL-1 alpha and TGF beta on IL-11 production were dose-dependent .	positive	0
4623	10407498	3552;3589	IL-1 alpha;IL-11	***IL-1 alpha*** and TNF alpha synergistically ***augmented*** TGF beta-stimulated ***IL-11*** production by VSMC .	positive	0
4624	10407498	7124;3589	TNF alpha;IL-11	IL-1 alpha and ***TNF alpha*** synergistically ***augmented*** TGF beta-stimulated ***IL-11*** production by VSMC .	positive	0
4625	10407627	7124;3383	TNF-alpha;ICAM-1	Alternatively , endogenous ***TNF-alpha*** might ***upregulate*** M phi ***ICAM-1*** expression even at very low concentrations .	positive	1
4626	10408258	2056;7422	erythropoietin;vascular endothelial growth factor	Recombinant human ***erythropoietin*** ***stimulates*** ***vascular endothelial growth factor*** release by glomerular endothelial cells .	positive	0
4627	10408347	4233;3082	c-Met;Hepatocyte growth factor	KS cells synthesize and secrete HGF and express the ***Hepatocyte growth factor*** ***receptor*** ( ***c-Met*** ) , thus providing an autocrine loop for tumor proliferation and neovascularization which can be enhanced by proinflammatory cytokines .	parallel	1
4628	10408363	1380;2208	CD21;CD23	In a similar fashion to IgE complexes , another ***ligand*** of ***CD23*** , the soluble ***CD21*** was shown to efficiently trigger CD23-signalling pathways in human monocytes .	parallel	1
4629	10408379	3716;5595	JAK1;ERK1	Therefore , ***JAK1*** activity may be involved in ***activation*** of Raf-1 and ***ERK1*** via G proteins activated by C5b-9 .	positive	1
4630	10408379	3716;5894	JAK1;Raf-1	Therefore , ***JAK1*** activity may be involved in ***activation*** of ***Raf-1*** and ERK1 via G proteins activated by C5b-9 .	positive	1
4631	10408722	6352;3458	RANTES;interferon gamma	***Aminooxypentane-RANTES*** , an inhibitor of R5 human immunodeficiency virus type 1 , ***increases*** the ***interferon gamma*** to interleukin 10 ratio without impairing cellular proliferation .	positive	0
4632	10408842	2668;5979	GDNF;RET	Mutation and deletion analysis of GFR alpha-1 , encoding the co-receptor for the ******GDNF/RET****** ***complex*** , in human brain tumours .	parallel	1
4633	10408981	3553;3557	IL-1beta;IL-1ra	***IL-1beta*** ***stimulated*** IL-6 and ***IL-1ra*** release into peripheral blood , the stimulation was much more profound after i.c.v. injection ( p < 0.001 ) .	positive	0
4634	10408982	959;958	CD40L;CD40	We also find that ***ligation*** of microglial ***CD40*** by ***CD40L*** triggers a significant production of TNF-alpha .	parallel	1
4635	10408982	958;7124	CD40;TNF-alpha	We also find that ligation of microglial ***CD40*** by CD40L ***triggers*** a significant production of ***TNF-alpha*** .	positive	0
4636	10409110	885;3627	Cholecystokinin;mob-1	***Cholecystokinin*** ***induction*** of ***mob-1*** chemokine expression in pancreatic acinar cells requires NF-kappaB activation .	target	1
4637	10409110	885;4790	Cholecystokinin;NF-kappaB	***Cholecystokinin*** induction of mob-1 chemokine expression in pancreatic acinar cells ***requires*** ***NF-kappaB*** activation .	target	0
4638	10409110	2922;4792	bombesin;IkappaB-alpha	Neither ***bombesin*** nor carbachol significantly ***increased*** mob-1 mRNA or induced ***IkappaB-alpha*** degradation .	positive	0
4639	10409110	2922;3627	bombesin;mob-1	Neither ***bombesin*** nor carbachol significantly ***increased*** ***mob-1*** mRNA or induced IkappaB-alpha degradation .	positive	0
4640	10409110	4790;3627	NF-kappaB;mob-1	Inhibition of ***NF-kappaB*** with pharmacological agents or by adenovirus-mediated expression of the inhibitory protein IkappaB-alpha also ***inhibited*** ***mob-1*** gene expression .	positive	1
4641	10409120	6804;1080	Syntaxin 1A;CFTR	***Syntaxin 1A*** ***inhibits*** regulated ***CFTR*** trafficking in xenopus oocytes .	negative	1
4642	10409120	6804;1080	Syntaxin 1A;CFTR	***Inhibition*** of plasma membrane ***CFTR*** content by ***Syntaxin 1A*** is consistent with the concept that syntaxin and other components of the SNARE machinery are involved in regulated trafficking of CFTR .	negative	1
4643	10409128	551;2641	AVP;glucagon	***AVP*** and OT ( 3 pM-3 nM ) ***increased*** ***glucagon*** release in a concentration-dependent manner .	positive	0
4644	10409128	551;2641	AVP;glucagon	Because ***AVP*** and OT at physiological concentrations ( 3-30 pM ) ***increased*** ***glucagon*** release , we conclude that AVP and OT increase glucagon release under the physiological condition through the activation of V ( 1b ) and OT receptors , respectively .	positive	0
4645	10409129	3484;3479	IGFBP-1;IGF-I	It is concluded that free ***IGF-I*** concentration , which may be ***regulated*** by ***IGFBP-1*** through a direct effect of AAs on the liver , may have an important role in regulating anabolism in visceral and possibly skeletal tissue during PN .	target	1
4646	10409166	7039;5045	TGF-alpha;furin	***TGF-alpha*** ***stimulated*** the ***furin*** promoter activity highly in a mouse GSM cell line GSM06 .	positive	0
4647	10409230	958;959	CD40;CD40 ligand	Enhancement of tumoricidal activity of alveolar macrophages via ******CD40-CD40 ligand****** ***interaction*** .	parallel	1
4648	10409230	958;959	CD40;CD40 ligand	******CD40-CD40 ligand****** ( CD40L ) ***interaction*** was originally defined as important molecules for the development of humoral immunity .	parallel	1
4649	10409230	958;959	CD40;CD40L	Here we investigated the antitumor activity of murine alveolar macrophages through ******CD40-CD40L****** ***interaction*** .	parallel	1
4650	10409230	959;958	CD40L;CD40	On the other hand , interleukin-6 production by alveolar macrophages did not depend on ******CD40-CD40L****** ***interaction*** .	parallel	1
4651	10409231	3565;3383	IL-4;ICAM-1	We conclude that 1 ) IL-4 augments epithelial cell ICAM-1 expression , 2 ) IL-4 potentiates the adhesion of THP-1 monocyte/macrophage cells to epithelial cells , and 3 ) ***modulation*** of epithelial cell ***ICAM-1*** expression by ***IL-4*** may play a role in the immunopathology of bronchial asthma .	target	0
4652	10409231	3565;3383	IL-4;ICAM-1	We conclude that 1 ) ***IL-4*** ***augments*** epithelial cell ***ICAM-1*** expression , 2 ) IL-4 potentiates the adhesion of THP-1 monocyte/macrophage cells to epithelial cells , and 3 ) modulation of epithelial cell ICAM-1 expression by IL-4 may play a role in the immunopathology of bronchial asthma .	positive	0
4653	10409231	3565;3383	IL-4;ICAM-1	***IL-4*** ***induces*** ***ICAM-1*** expression in human bronchial epithelial cells and potentiates TNF-alpha .	target	1
4654	10409231	3565;7124	IL-4;TNF-alpha	***IL-4*** induces ICAM-1 expression in human bronchial epithelial cells and ***potentiates*** ***TNF-alpha*** .	positive	0
4655	10409231	3565;3383	IL-4;CD54	This study evaluated if ***IL-4*** either alone or together with TNF-alpha costimulation might ***modulate*** ***CD54*** expression by human bronchial epithelial cells ( HBECs ) .	target	0
4656	10409231	7124;3565	TNF-alpha;IL-4	***TNF-alpha*** ***increased*** ***IL-4*** mRNA , and IL-4 potentiated this .	positive	0
4657	10409431	8087;2332	FXR1P;FMRP	Efforts to understand the function of FMRP have led to the identification of two autosomal homologs , ***FXR1P*** and FXR2P , that may ***interact*** with ***FMRP*** in some tissues .	parallel	1
4658	10409431	9513;2332	FXR2P;FMRP	Efforts to understand the function of FMRP have led to the identification of two autosomal homologs , FXR1P and ***FXR2P*** , that may ***interact*** with ***FMRP*** in some tissues .	parallel	1
4659	10409502	2737;6469	Gli3;Shh	However , expression of ***Shh*** , which is negatively ***regulated*** by ***Gli3*** in the spinal cord , is not affected in the Xt ( J ) / Xt ( J ) forebrain .	negative	1
4660	10409614	1676;1677	DFF45;DFF40	Functional ***interaction*** of DFF35 and ***DFF45*** with caspase-activated DNA fragmentation nuclease ***DFF40*** .	parallel	1
4661	10409620	595;5715	cyclin D1;p27	Immunoprecipitation-Western blotting analysis of p27 ( Kip1 ) showed serum stimulation of the vascular endothelial cell line resulted in increased amounts of ***cyclin D1*** ***bound*** to ***p27*** ( Kip1 ) .	parallel	1
4662	10409620	595;5715	cyclin D1;p27	In the PKCdeltaEC line , serum did not increase the amount of ***cyclin D1*** ***bound*** to ***p27*** ( Kip1 ) .	parallel	1
4663	10409622	3716;6294	JAK1;glutathione S-transferase fusion protein	A ***glutathione S-transferase fusion protein*** of the cytoplasmic domain of IL-13Ralpha was ***phosphorylated*** on tyrosine in vitro by ***JAK1*** , JAK3 , and Tyk2 , although the tyrosine phosphorylation events mediated by Tyk2 and JAK3 were not detectable using anti-phosphotyrosine antibodies .	target	1
4664	10409622	3718;6294	JAK3;glutathione S-transferase fusion protein	A ***glutathione S-transferase fusion protein*** of the cytoplasmic domain of IL-13Ralpha was ***phosphorylated*** on tyrosine in vitro by JAK1 , ***JAK3*** , and Tyk2 , although the tyrosine phosphorylation events mediated by Tyk2 and JAK3 were not detectable using anti-phosphotyrosine antibodies .	target	1
4665	10409622	7297;6294	Tyk2;glutathione S-transferase fusion protein	A ***glutathione S-transferase fusion protein*** of the cytoplasmic domain of IL-13Ralpha was ***phosphorylated*** on tyrosine in vitro by JAK1 , JAK3 , and ***Tyk2*** , although the tyrosine phosphorylation events mediated by Tyk2 and JAK3 were not detectable using anti-phosphotyrosine antibodies .	target	1
4666	10409622	3596;6774	IL-13;STAT3	These data , together with the demonstration that IL-13Ralpha associates constitutively with Tyk2 and that Tyr-402 is involved in ***IL-13-induced*** ***phosphorylation*** of ***STAT3*** , suggest that the latter is mediated by Tyk2 .	target	1
4667	10409627	317;842	Apaf-1;caspase-9	Here we show that Apaf-1 can dimerize via the CED-4 homologous and linker domains of the molecule providing a means by which ***Apaf-1*** can ***promote*** the clustering of ***caspase-9*** and facilitate its activation .	positive	0
4668	10409629	2516;8431	steroidogenic factor-1;SHP	Among these , the orphan receptor ***steroidogenic factor-1*** ( SF-1 ) was found to potently ***transactivate*** the ***SHP*** promoter .	positive	1
4669	10409629	2494;8431	FTF;SHP	However , liver expresses a close relative of SF-1 , the orphan fetoprotein transcription factor ( FTF ) , and ***FTF*** can also ***transactivate*** the ***SHP*** promoter .	positive	1
4670	10409632	2668;2353	GDNF;c-fos	In a motorneuron-derived cell line expressing Ret and GFRalphas , ***GDNF*** ***stimulated*** sustained activation of the Ras/ERK and phosphatidylinositol 3-kinase/Akt pathways , cAMP response element-binding protein phosphorylation , and increased ***c-fos*** expression .	positive	0
4671	10409632	2668;2534	GDNF;Src-like kinase	***GDNF*** treatment did not activate the Ras/ERK pathway in these cells , but ***stimulated*** a GFRalpha1-associated ***Src-like kinase*** activity in detergent-insoluble membrane compartments , rapid phosphorylation of cAMP response element-binding protein , up-regulation of c-fos mRNA , and cell survival .	positive	0
4672	10409636	1445;6714	Csk;c-Src	A decreased Csk/c-Src ratio in GEM may cause activation of c-Src because ***Csk*** is a negative ***regulator*** of ***c-Src*** .	negative	1
4673	10409643	2520;3067	gastrin;histidine decarboxylase	***Activation*** of human ***histidine decarboxylase*** gene promoter activity by ***gastrin*** is mediated by two distinct nuclear factors .	positive	1
4674	10409643	2520;3067	gastrin;histidine decarboxylase	The human ***histidine decarboxylase*** gene is ***regulated*** by ***gastrin*** through a cis-acting element known as the gastrin response element ( GAS-RE ) that was initially localized to a site ( +2 to +24 ) downstream of the transcriptional start site .	target	1
4675	10409643	2520;3067	gastrin;histidine decarboxylase	Hence , ***activation*** of ***histidine decarboxylase*** gene promoter activity by ***gastrin*** is most likely mediated by two separate nuclear factors .	positive	1
4676	10409647	3827;2353	bradykinin;c-fos	Although both depolarization-induced calcium influx and ***bradykinin*** stimulation of PC12 cells were found to ***induce*** ***c-fos*** transcription through EGFR activation , the former signal is CaM kinase-dependent and the latter was shown to be independent .	target	1
4677	10409650	5664;351	presenilin-1 and -2;Abeta	Two other FAD genes , ***presenilin-1 and -2*** , have also been shown to ***regulate*** ***Abeta*** production ; however , studies examining the biological role of these FAD genes suggest an alternative theory for the pathogenesis of AD .	target	1
4678	10409669	596;836	Bcl-2;Caspase-3	These results demonstrate that in these models of apoptosis , specific cleavage of ***Bcl-2*** ***requires*** activation of ***Caspase-3*** .	target	0
4679	10409669	836;596	Caspase-3;Bcl-2	Therefore , ***Caspase-3-dependent*** ***cleavage*** of ***Bcl-2*** appears to promote further caspase activation as part of a positive feedback loop for executing the cell .	target	1
4680	10409669	836;596	Caspase-3;Bcl-2	***Caspase-3-dependent*** ***cleavage*** of ***Bcl-2*** promotes release of cytochrome c.	target	1
4681	10409671	3937;2533	SLP-76;FYB	******FYN-T-FYB-SLP-76****** ***interactions*** define a T-cell receptor zeta/CD3-mediated tyrosine phosphorylation pathway that up-regulates interleukin 2 transcription in T-cells .	parallel	1
4682	10409671	2533;3558	FYB;lymphokine	These findings document the existence of a T-cell receptor-regulated ***FYN-T-FYB*** pathway that interfaces with the adaptor SLP-76 and ***up-regulates*** ***lymphokine*** production in T-cells .	positive	1
4683	10409677	7423;8829	vascular endothelial growth factor B;neuropilin-1	Differential ***binding*** of ***vascular endothelial growth factor B*** splice and proteolytic isoforms to ***neuropilin-1*** .	parallel	1
4684	10409677	8829;7422	NRP1;VEGF	The ***NRP1*** ***binding*** of ***VEGF-B*** could be competed by an excess of VEGF ( 165 ) .	parallel	1
4685	10409677	7422;8829	VEGF;NRP1	The ***NRP1*** binding of VEGF-B could be ***competed*** by an excess of ***VEGF*** ( 165 ) .	negative	0
4686	10409677	7422;8829	VEGF;NRP1	The binding of VEGF-B ( 167 ) was mediated by the heparin binding domain , whereas the ***binding*** of ***VEGF-B*** ( 186 ) to ***NRP1*** was regulated by exposure of a short COOH-terminal proline-rich peptide upon its proteolytic processing .	parallel	1
4687	10409689	207;5106	Akt;PEPCK	Although a constitutively active mutant of ***Akt*** ( protein kinase B ) ***inhibited*** ***PEPCK-CAT*** gene transcription induced by dexamethasone and cAMP , a mutant Akt ( Akt-AA ) in which the phosphorylation sites targeted by insulin are replaced by alanine did not affect the ability of insulin to inhibit transcription of the fusion gene .	positive	1
4688	10409708	4804;627	p75NTR;neurotrophin	The p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) alters tumor necrosis factor-mediated NF-kappaB activity under physiological conditions , but direct p75NTR-mediated NF-kappaB activation requires cell stress .	parallel	1
4689	10409708	4804;627	p75NTR;neurotrophin	The p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) has been linked to activation of the NF-kappaB transcriptional complex in oligodendrocytes , Schwann cells , and PCNA cells .	parallel	1
4690	10409708	627;4790	neurotrophin;NF-kappaB	All cell types showed TNF-mediated activation of NF-kappaB , but direct ***neurotrophin-dependent*** ***activation*** of ***NF-kappaB*** was never observed under normal growth conditions .	positive	1
4691	10409708	4803;4792	NGF;IkappaBalpha	The increase in NF-kappaB activity mediated by NGF correlated with reduced levels of IkappaBalpha ; NGF added alone had no effect on IkappaBalpha levels , but when added with TNF , ***NGF*** treatment significantly ***reduced*** ***IkappaBalpha*** levels .	negative	1
4692	10409713	128209;2322	novel zinc finger protein;Flt3	Fiz1 , a ***novel zinc finger protein*** ***interacting*** with the receptor tyrosine kinase ***Flt3*** .	parallel	1
4693	10409713	84922;2322	Fiz1;Flt3	***Fiz1*** ***binds*** to the catalytic domain of ***Flt3*** but not to the structurally related receptor tyrosine kinases Kit , Fms , and platelet-derived growth factor receptor .	parallel	1
4694	10409713	2322;84922	Flt3;Fiz1	The ***interaction*** between ***Flt3*** and ***Fiz1*** detected in yeast was confirmed by in vitro and in vivo coprecipitation assays .	parallel	1
4695	10409724	5781;3569	SHP-2;IL-6	These results suggest that ***IL-6*** regulation of APP genes is ***affected*** by ***SHP-2*** in two ways : SHP-2 acts as a phosphatase on the JAK/STAT pathway and serves as linker to the MAP kinase pathway , which in turn moderates APP production .	target	0
4696	10409724	3572;5594	gp130;ERK1/2	This study shows that in hepatoma cells , the recruitment and tyrosine phosphorylation of SHP-2 , but not SHC , is the primary signaling event associated with the ***activation*** of MAP kinases ( ***ERK1/2*** ) by ***gp130*** .	positive	1
4697	10409724	3569;5594	IL-6;ERK	Overexpression of truncated SHP-2 that lacks Grb2-interacting sites , but not the full-length catalytically inactive SHP-2 , reduces ***ERK*** ***activation*** by ***IL-6*** , confirming the signal-mediating role of SHP-2 .	positive	1
4698	10409724	5781;5594	SHP-2;ERK	Overexpression of truncated ***SHP-2*** that lacks Grb2-interacting sites , but not the full-length catalytically inactive SHP-2 , ***reduces*** ***ERK*** activation by IL-6 , confirming the signal-mediating role of SHP-2 .	negative	1
4699	10409727	1655;1387	p68;CBP	We also show that the RNA helicase activity previously ascribed to p68 is dispensable for the ERalpha AF-1 coactivator activity and that ***p68*** ***binds*** to ***CBP*** in vitro .	parallel	1
4700	10409732	10403;8243	hsHEC1;SMC1	Overexpression of either ***hsHEC1*** or scHEC1 ***suppressed*** the lethal phenotype of ***SMC1-2*** and smc2-6 at nonpermissive temperatures , suggesting that the interactions between Hec1p and Smc1p and -2 p are biologically significant .	negative	1
4701	10409739	7555;5468	sterol regulatory element binding protein;peroxisome proliferator-activated receptor gamma	***Regulation*** of ***peroxisome proliferator-activated receptor gamma*** expression by adipocyte differentiation and determination factor ***1/sterol regulatory element binding protein*** 1 : implications for adipocyte differentiation and metabolism .	target	1
4702	10409740	1869;3065	E2F1;HDAC1	Coexpression of ***E2F1*** ***interferes*** with ***HDAC1*** binding to Sp1 and abolishes Sp1-mediated transcriptional repression .	negative	0
4703	10409741	991;7986	Cdc20;Pds1	However , they are thought to act at two different stages of the cell cycle : Cdc4 is involved in the proteolysis of the Cdk inhibitor , Sic1 , necessary for G ( 1 ) / S transition , while ***Cdc20*** ***mediates*** anaphase-promoting complex-dependent degradation of anaphase inhibitor ***Pds1*** , a process necessary for the onset of chromosome segregation .	target	0
4704	10409742	8844;5609	Kinase suppressor of Ras;MEK	***Kinase suppressor of Ras*** forms a multiprotein signaling complex and ***modulates*** ***MEK*** localization .	target	0
4705	10409742	8844;5609	KSR;MEK	However , ******KSR-MEK****** ***binding*** shifts the apparent molecular mass of MEK from 44 to > 700 kDa , and this results in the appearance of MEK in membrane-associated fractions .	parallel	1
4706	10409744	6873;891	CIF150;cyclin B1	***CIF150*** ( hTAF ( II ) 150 ) directly ***stimulated*** ***cyclin B1*** and cyclin A transcription in cotransfection assays and in vitro assays , suggesting that the expression of these genes is dependent on CIF150 ( hTAF ( II ) 150 ) function .	positive	0
4707	10409745	1973;1977	eIF4A;eIF4F	The ***association*** of ***eIF4A*** with Saccharomyces cerevisiae ***eIF4F*** has not yet been demonstrated , and therefore the degree to which eIF4A 's conserved function relies upon this association has remained unclear .	parallel	0
4708	10409755	6416;5599	SEK1;JNK	Transient expression of a dominant negative mutant ***SEK1*** ( Lys -- > Arg ) , an upstream kinase of JNK , ***prevented*** both TG-induced ***JNK*** activation and apoptosis .	negative	0
4709	10409763	8717;4790	TRADD;NF-kappaB	LMP1 is partially blocked for ***NF-kappaB*** ***activation*** by a ***TRADD*** mutant consisting of residues 122 to 293 .	positive	1
4710	10409765	4790;595	NF-kappaB;cyclin D1	An analysis of cell cycle markers revealed that ***NF-kappaB*** ***activates*** ***cyclin D1*** expression , and the results showed that this regulatory pathway is one mechanism by which NF-kappaB inhibits myogenesis .	positive	1
4711	10409765	4790;595	NF-kappaB;cyclin D1	***NF-kappaB*** ***regulation*** of ***cyclin D1*** occurs at the transcriptional level and is mediated by direct binding of NF-kappaB to multiple sites in the cyclin D1 promoter .	target	1
4712	10409765	4790;595	NF-kappaB;cyclin D1	Using diploid fibroblasts , we demonstrate that ***NF-kappaB*** is required to ***induce*** ***cyclin D1*** expression and pRb hyperphosphorylation and promote G ( 1 ) - to-S progression .	target	1
4713	10409765	4790;5925	NF-kappaB;pRb	Using diploid fibroblasts , we demonstrate that ***NF-kappaB*** is required to ***induce*** cyclin D1 expression and ***pRb*** hyperphosphorylation and promote G ( 1 ) - to-S progression .	target	1
4714	10410140	324;1499	APC;beta-catenin	The ***APC*** gene is a negative ***regulator*** of ***beta-catenin*** and is considered to play the role of gatekeeper in the adenoma carcinoma sequence .	negative	1
4715	10410979	719;718	C3aR;C3a	Employing this method , a recombinant C3a (rC3a) anaphylatoxin with a His-tag at its N-terminus could be shown to bind to ***C3a*** ***receptor*** ( ***C3aR*** ) - expressing RBL-2H3 transfectants with a half-maximal effective concentration ( EC50 ) of about 3 nM which is well within the range of published affinity constants .	parallel	1
4716	10410979	728;727	C5aR;C5a	Furthermore , aminoterminally tagged C5a molecules of rat or human origin could be shown to bind to the human ***C5a*** ***receptor*** ( ***C5aR*** ) .	parallel	1
4717	10410997	3458;941	IFN-gamma;CD80	Almost pure ( > 99 % ) cord blood-derived MC ( CBMC ) were shown to express class II Ags ( HLA-DR and HLA-DQ ) and ***CD80*** , which were ***up-regulated*** by ***IFN-gamma*** treatment and , to a lesser extent , by interleukin-4 ( IL-4 ) and granulocyte-macrophage colony-stimulating factor ( GM-CSF ) .	positive	1
4718	10411003	3589;3383	IL-11;ICAM-1	These in vivo anti-inflammatory effects of ***IL-11*** were ***associated*** with reduced NF-kappaB activation in lung , reduced levels of tumor necrosis factor alpha ( TNF-alpha ) in bronchoalveolar lavage ( BAL ) fluids , and diminished up-regulation of lung vascular ***ICAM-1*** .	parallel	0
4719	10411003	3589;4790	IL-11;NF-kappaB	These in vivo anti-inflammatory effects of ***IL-11*** were ***associated*** with reduced ***NF-kappaB*** activation in lung , reduced levels of tumor necrosis factor alpha ( TNF-alpha ) in bronchoalveolar lavage ( BAL ) fluids , and diminished up-regulation of lung vascular ICAM-1 .	parallel	0
4720	10411003	3589;7124	IL-11;tumor necrosis factor alpha	These in vivo anti-inflammatory effects of ***IL-11*** were ***associated*** with reduced NF-kappaB activation in lung , reduced levels of ***tumor necrosis factor alpha*** ( TNF-alpha ) in bronchoalveolar lavage ( BAL ) fluids , and diminished up-regulation of lung vascular ICAM-1 .	parallel	0
4721	10411089	958;909	CD40;CD1a	Expression of ***CD40*** ***correlated*** with expression of ***CD1a*** on CD83 + TiDCs .	parallel	0
4722	10411089	3383;942	CD54;CD86	Expression of ***CD54*** ( ICAM-1 ) ***correlated*** with a lower expression of ***CD86*** ( B7.2 ) as well as a decrease in CD3 + and CD8 + TiLs .	parallel	0
4723	10411321	6195;5594	p90rsk;ERK	This review describes the family of 90 kDa ribosomal S6 kinases ( RSK ; also known as ***p90rsk*** or MAPK-activated protein kinase-1 , MAPKAP-K1 ) , which were among the first ***substrates*** of ***ERK*** to be discovered and which has proven to be a ubiquitous and versatile mediator of ERK signal transduction .	parallel	1
4724	10411533	1081;5241	hCG;progesterone receptor	Both in vivo and in vitro , ***hCG*** ***induced*** expression of the ***progesterone receptor*** and the prostaglandin endoperoxide synthase-2 ( PGS-2 ) gene within 3 h.	target	1
4725	10411533	1081;5743	hCG;prostaglandin endoperoxide synthase-2	Both in vivo and in vitro , ***hCG*** ***induced*** expression of the progesterone receptor and the ***prostaglandin endoperoxide synthase-2*** ( PGS-2 ) gene within 3 h.	target	1
4726	10411633	1584;1583	CYP11B1;CYP11A1	***Interaction*** of ***CYP11B1*** ( cytochrome P-45011 beta ) with ***CYP11A1*** ( cytochrome P-450scc ) in COS-1 cells .	parallel	1
4727	10411633	1584;1583	CYP11B1;CYP11A1	The ***interactions*** of ***CYP11B1*** ( cytochrome P-45011beta ) , CYP11B2 ( cytochrome P-450aldo ) and ***CYP11A1*** ( cytochrome P-450scc ) were investigated by cotransfection of their cDNA into COS-1 cells .	parallel	1
4728	10411633	1585;1583	CYP11B2;CYP11A1	The ***interactions*** of CYP11B1 ( cytochrome P-45011beta ) , ***CYP11B2*** ( cytochrome P-450aldo ) and ***CYP11A1*** ( cytochrome P-450scc ) were investigated by cotransfection of their cDNA into COS-1 cells .	parallel	1
4729	10411633	1585;1584	CYP11B2;CYP11B1	The ***interactions*** of ***CYP11B1*** ( cytochrome P-45011beta ) , ***CYP11B2*** ( cytochrome P-450aldo ) and CYP11A1 ( cytochrome P-450scc ) were investigated by cotransfection of their cDNA into COS-1 cells .	parallel	1
4730	10411633	1583;1584	CYP11A1;CYP11B1	These results suggest that the ***interactions*** of ***CYP11A1*** with ***CYP11B1*** and CYP11B2 do not have an identical regulatory function in human and in bovine adrenal tissue .	parallel	1
4731	10411633	1583;1585	CYP11A1;CYP11B2	These results suggest that the ***interactions*** of ***CYP11A1*** with CYP11B1 and ***CYP11B2*** do not have an identical regulatory function in human and in bovine adrenal tissue .	parallel	1
4732	10411679	1234;6352	CCR5;RANTES	***CCR5*** is a ***receptor*** for the C-C chemokine ***RANTES*** , which is expressed in inflammatory kidney diseases and transplant rejection .	parallel	1
4733	10411682	7040;2247	TGF-beta1;bFGF	This decrease in intracellular bFGF was associated with a 15 % reduction in anti-bFGF antibody binding to fixed permeabilized cells , following the addition of 10 ng/ml of recombinant TGF-beta1 ( N = 9 , P = 0.0007 ) , suggesting that the mechanism of ***stimulation*** of ***bFGF*** by ***TGF-beta1*** involved the release of preformed bFGF from within the cells .	positive	0
4734	10411682	7040;2247	TGF-beta1;bFGF	CONCLUSION : The data presented suggest that the main mechanism by which ***TGF-beta1*** ***stimulates*** ***bFGF*** generation by proximal tubular epithelial cells is by stimulation of the secretion of preformed cytokine from within the cells .	positive	0
4735	10411682	7040;2247	TGF-beta1;bFGF	***TGF-beta1*** ***stimulates*** the release of pre-formed ***bFGF*** from renal proximal tubular cells .	positive	0
4736	10411794	5020;5743	Oxytocin;cyclooxygenase-2	***Oxytocin*** activates mitogen-activated protein kinase and ***up-regulates*** ***cyclooxygenase-2*** and prostaglandin production in human myometrial cells .	positive	1
4737	10411939	3725;6688	c-Jun;PU.1	We demonstrate further that GATA inhibits binding of PU.1 to ***c-Jun*** , a critical ***coactivator*** of ***PU.1*** transactivation of myeloid promoters .	positive	1
4738	10411939	6688;3725	PU.1;c-Jun	We demonstrate further that GATA inhibits ***binding*** of ***PU.1*** to ***c-Jun*** , a critical coactivator of PU.1 transactivation of myeloid promoters .	parallel	1
4739	10411939	6688;2623	PU.1;GATA-1	Finally , ***PU.1*** protein can ***inhibit*** both ***GATA-1*** and GATA-2 transactivation function .	negative	1
4740	10411939	6688;2624	PU.1;GATA-2	Finally , ***PU.1*** protein can ***inhibit*** both GATA-1 and ***GATA-2*** transactivation function .	negative	1
4741	10412029	4803;1103	Nerve growth factor;ChAT	In the present study , ***Nerve growth factor*** ( NGF ; 100 ng/ml ) was shown to ***enhance*** expression of VAChT and ***ChAT*** mRNA in primary cultured rat embryonic septal cells .	positive	0
4742	10412030	3553;4790	IL-1beta;NF-kappaB	Co-localization of IL-1beta and NF-kappaB suggests an ***association*** between ***IL-1beta*** and ***NF-kappaB*** induction .	parallel	0
4743	10412039	3439;650	IFNalpha;BMP-2	In contrast , ***IFNalpha*** significantly ***inhibited*** ***BMP-2*** mRNA expression in the absence of ascorbate and dexamethasone .	negative	1
4744	10412039	3439;650	IFNalpha;BMP-2	In conclusion , ***IFNalpha*** inhibits human osteoprogenitor cell proliferation , CFU - F formation , HOP-26 expression , and alkaline phosphatase specific activity and ***modulates*** ***BMP-2*** gene expression .	target	0
4745	10412046	5241;3320	progesterone receptor;Hsp90	Only a small portion of the cytoplasmic ***progesterone receptor*** is ***associated*** with ***Hsp90*** in vivo .	parallel	0
4746	10412048	2247;3569	bFGF;interleukin-6	We previously showed that basic fibroblast growth factor ( ***bFGF*** ) - induced activation of protein kinase C ( PKC ) via phosphatidylinositol-hydrolyzing phospholipase C and phosphatidylcholine-hydrolyzing phospholipase D ***suppresses*** ***interleukin-6*** ( IL-6 ) synthesis by bFGF itself in osteoblast-like MC3T3-E1 cells .	negative	1
4747	10412048	2247;1432	bFGF;p38 MAP kinase	The ***phosphorylation*** of ***p38 MAP kinase*** by ***bFGF*** was suppressed by TMB-8 , an inhibitor of intracellular Ca ( 2 + ) mobilization , or the depletion of extracellular Ca ( 2 + ) with EGTA .	target	1
4748	10412058	4804;627	p75NTR;neurotrophin	To determine the role of the p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) in sympathetic neuron development , we crossed transgenic mice with mutations in p75NTR , nerve growth factor ( NGF ) and neurotrophin-3 ( NT-3 ) .	parallel	1
4749	10412150	6347;2152	MCP-1;tissue factor	***MCP-1*** , a CC-chemokine , ***enhances*** ***tissue factor*** production by macrophages and increases ICAM-1 expression on endothelial cells .	positive	0
4750	10412150	6347;3383	MCP-1;ICAM-1	***MCP-1*** , a CC-chemokine , enhances tissue factor production by macrophages and ***increases*** ***ICAM-1*** expression on endothelial cells .	positive	0
4751	10412376	3952;7352	Leptin;uncoupling protein-3	***Leptin*** , but not a beta 3-adrenergic agonist , ***upregulates*** muscle ***uncoupling protein-3*** messenger RNA expression : short-term thermogenic interactions .	positive	1
4752	10412376	3952;7352	Leptin;UCP3	The present study provides evidence , for the first time , of the ***induction*** of ***UCP3*** mRNA expression in skeletal muscle by ***Leptin*** in nongenetically obese animals .	target	1
4753	10412736	3689;3383	LFA-1;ICAM-1	Many of the infiltrating glomerular M phi expressed lymphocyte function-associated antigen-1 ( ***LFA-1*** ) and very late antigen-4 ( VLA-4 ) , which are ***ligands*** for ***ICAM-1*** and VCAM-1 , respectively .	parallel	1
4754	10412736	3689;7412	LFA-1;VCAM-1	Many of the infiltrating glomerular M phi expressed lymphocyte function-associated antigen-1 ( ***LFA-1*** ) and very late antigen-4 ( VLA-4 ) , which are ***ligands*** for ICAM-1 and ***VCAM-1*** , respectively .	parallel	1
4755	10412822	7412;338	VCAM-1;apoB	In children , soluble ***VCAM-1*** levels were ***correlated*** with the levels of triglyceride ( in boys ) and ***apoB*** , the ratio of apoB to apoA-I and FER ( HDL ) ( in girls ) .	parallel	0
4756	10412857	183;359	Angiotensin I;AQP2	***Angiotensin I*** , infused for 3 days at 115-120 days ' gestation , ***increased*** the ***AQP2/GAPDH*** mRNA ratios by twofold ( major transcript ) and sixfold ( minor transcript ) , which were highly significant ( P < 0.001 ) .	positive	0
4757	10412868	718;3075	C3b;factor H	These convertase-related nephritides are seen in association with heterozygous absence of a binding site for factor H on ***C3b*** ( Marder disease ) , homozygous factor H deficiency , circulating ***factor H*** ***inhibitor*** , and with the nephritic factors , one of the amplification loop and the other of the terminal pathway , found in membranoproliferative glomerulonephritis ( MPGN ) types II and III , respectively .	negative	1
4758	10412986	10891;4899	PGC-1;NRF-1	***PGC-1*** ***stimulates*** a powerful induction of ***NRF-1*** and NRF-2 gene expression ; in addition , PGC-1 binds to and coactivates the transcriptional function of NRF-1 on the promoter for mitochondrial transcription factor A ( mtTFA ) , a direct regulator of mitochondrial DNA replication/transcription .	positive	0
4759	10412986	10891;2551	PGC-1;NRF-2	***PGC-1*** ***stimulates*** a powerful induction of NRF-1 and ***NRF-2*** gene expression ; in addition , PGC-1 binds to and coactivates the transcriptional function of NRF-1 on the promoter for mitochondrial transcription factor A ( mtTFA ) , a direct regulator of mitochondrial DNA replication/transcription .	positive	0
4760	10413089	7124;6347	tumor necrosis factor-alpha;monocyte chemoattractant protein-1	In human vascular endothelial cells , interleukin-1beta and ***tumor necrosis factor-alpha*** ***induced*** endogenous ***monocyte chemoattractant protein-1*** protein secretion , mRNA expression and promoter activity .	target	1
4761	10413094	192668;5587	cys1;Protein kinase D	We found that deletion of ***cys1*** , cys2 or the entire cysteine-rich domain ***increases*** the basal activity of ***Protein kinase D*** leading to a constitutively active form of this enzyme .	negative	0
4762	10413101	377;27236	ARF3;Arfaptin 1	However , addition of myristoylated ***ARF3*** ( myrARF3 ) ***increases*** the association of ***Arfaptin 1*** with the membranes , suggesting that Arfaptin 1 and ARF form a complex on the Golgi .	positive	0
4763	10413107	6011;6010	GRK1;rhodopsin	***GRK1*** ***phosphorylates*** photoactivated ***rhodopsin*** ( Rho * ) , initiating steps in its deactivation .	target	1
4764	10413115	2932;4137	GSK-3beta;tau	***Phosphorylation*** of ***tau*** protein by recombinant ***GSK-3beta*** : pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain .	target	1
4765	10413455	627;4915	BDNF;TrkB	***BDNF*** and NT4/5 also ***increased*** ***TrkB*** mRNA levels in BPN neurons .	positive	0
4766	10413464	196;3320	AhR;hsp90	Characterization of the ******AhR-hsp90-XAP2****** core ***complex*** and the role of the immunophilin-related protein XAP2 in AhR stabilization .	parallel	1
4767	10413464	9049;196	XAP2;AhR	Characterization of the ******AhR-hsp90-XAP2****** core ***complex*** and the role of the immunophilin-related protein XAP2 in AhR stabilization .	parallel	1
4768	10413464	9049;3320	XAP2;hsp90	Characterization of the ******AhR-hsp90-XAP2****** core ***complex*** and the role of the immunophilin-related protein XAP2 in AhR stabilization .	parallel	1
4769	10413464	9049;3320	XAP2;hsp90	Mapping studies indicate that ***XAP2*** ***requires*** the PAS , ***hsp90*** , and ligand binding domain ( s ) of the AhR for binding , and that both proteins directly interact in the absence of hsp90 .	target	0
4770	10413465	348;351	apoE;Abeta	These findings suggest that the amino - and carboxy-terminal residues of apoE are required for SDS-stable ***binding*** of ***apoE*** to ***Abeta*** and that the presence of at least one cysteine contributes to the efficient Abeta binding .	parallel	1
4771	10413465	348;351	apoE;Abeta	This analysis showed that a mutation in the O-glycosylation site of apoE2 ( Thr194-Ala ) did not affect the SDS-stable ***binding*** of ***apoE*** to ***Abeta*** .	parallel	1
4772	10413465	348;351	apoE;Abeta	In contrast , introduction of cysteine at position 158 of apoE4 ( Arg112 , Cys158 ) increased the SDS-stable ***binding*** of ***apoE*** to ***Abeta*** to the levels similar to those observed in apoE2 .	parallel	1
4773	10413516	920;3700	CD4;gp120	Conformational changes of ***gp120*** in epitopes near the CCR5 binding site are ***induced*** by ***CD4*** and a CD4 miniprotein mimetic .	target	1
4774	10413517	2072;2067	XPF;ERCC1	During nucleotide excision repair , one of the two incisions necessary for removal of a broad spectrum of DNA adducts is made by the human ******XPF/ERCC1****** protein ***complex*** .	parallel	1
4775	10413522	1583;2232	P450SCC;adrenodoxin reductase	In contrast , no evidence was found for the existence of ******adrenodoxin reductase-P450SCC****** ***complexes*** or a ternary complex of all three proteins .	parallel	1
4776	10413589	8200;5594	GDF-5;ERK	***GDF-5*** ***induced*** phosphorylation of p38 MAP kinase and extracellular signal-regulated kinase ( ***ERK*** ) but not that of c-Jun N-terminal kinase ( JNK ) .	target	1
4777	10413589	8200;1432	GDF-5;p38 MAP kinase	***GDF-5*** ***induced*** phosphorylation of ***p38 MAP kinase*** and extracellular signal-regulated kinase ( ERK ) but not that of c-Jun N-terminal kinase ( JNK ) .	target	1
4778	10413589	650;1432	BMP-2;p38 MAP kinase	The phosphorylation of ***p38 MAP kinase*** was also ***induced*** by ***BMP-2*** and TGF-beta1 .	target	1
4779	10413589	7040;1432	TGF-beta1;p38 MAP kinase	The phosphorylation of ***p38 MAP kinase*** was also ***induced*** by BMP-2 and ***TGF-beta1*** .	target	1
4780	10413589	8200;5594	GDF-5;ERK	On the other hand , although an inhibitor of MAP/ERK kinase , PD98059 , inhibited the rapid ***phosphorylation*** of ***ERK*** by ***GDF-5*** , it inhibited neither ALP activity nor cartilage nodule formation induced by GDF-5 .	target	1
4781	10413591	1432;3315	p38 MAP kinase;HSP27	These results indicate that sphingosine 1-phosphate stimulates the ***induction*** of ***HSP27*** via ***p38 MAP kinase*** activation in aortic smooth muscle cells .	target	1
4782	10413594	2547;7520	Ku70;Ku80	Ku protein is a ***complex*** of two subunits , ***Ku70*** and ***Ku80*** .	parallel	1
4783	10414325	2892;23426	GluR2/3;GRIP	NMDA receptor NR2 subunits bind to the PSD-95 family of proteins , whereas AMPA receptor subunits ***GluR2/3*** ***bind*** to ***GRIP*** .	parallel	1
4784	10414464	3606;3458	IL-18;IFNgamma	***IL-18*** and IL-12 synergistically ***augment*** ***IFNgamma*** production reportedly because IL-12 enhances IL-18 receptor ( IL-18R ) expression .	positive	0
4785	10414464	3606;3586	IL-18;IL-10	We now show that ***IL-18*** also ***synergizes*** with ***IL-10*** to augment murine splenic NK activity against Yac-1 cells in a standard 4-h chromium-release assay , but IFNgamma production is only slightly enhanced .	parallel	0
4786	10414468	356;355	FasL;Fas	These results indicate that ******Fas/FasL****** ***interactions*** are involved in the down-regulation of IL-2-activated human NK cells .	parallel	1
4787	10414748	3486;3479	IGFBP-3;IGF-1	Since ***IGFBP-3*** can ***control*** ***IGF-1*** bioavailability , the lowered IGFBP-3 could explain in part the increased risk of prostate cancer in AA men .	target	0
4788	10414969	7402;1756	utrophin;dystrophin	These results show first that aneural myotubes contain preassembled AChR protein complexes that may function in the assembly of the postsynaptic apparatus , and second that rapsyn , in addition to its role in AChR phosphorylation , mediates selected protein interactions with the AChR and serves as a link between the AChR and the ******dystrophin/utrophin****** glycoprotein ***complex*** .	parallel	1
4789	10414969	7402;1756	utrophin;dystrophin	These results show first that aneural myotubes contain preassembled AChR protein complexes that may function in the assembly of the postsynaptic apparatus , and second that rapsyn , in addition to its role in AChR phosphorylation , mediates selected protein interactions with the AChR and serves as a ***link*** between the AChR and the ******dystrophin/utrophin****** glycoprotein complex .	parallel	0
4790	10414980	8829;10371	neuropilin-1;semaphorin III	***neuropilin-1*** ( Npn-1 ) , a ***receptor*** for ***semaphorin III*** , mediates the guidance of growth cones on extending neurites .	parallel	1
4791	10414981	2892;23426	GluR2/3;GRIP	A majority of detergent-extractable ***GluR2/3*** was ***complexed*** with ***GRIP*** in the brain .	parallel	1
4792	10414982	859;351	Caveolin-3;amyloid precursor protein	***Caveolin-3*** upregulation ***activates*** beta-secretase-mediated cleavage of the ***amyloid precursor protein*** in Alzheimer 's disease .	positive	1
4793	10414982	859;351	Caveolin-3;APP	Interestingly , recombinant overexpression of ***Caveolin-3*** in cultured cells ***stimulated*** beta-secretase-mediated processing of ***APP*** .	positive	0
4794	10414984	4908;4916	NT3;trkC	Selective ***regulation*** of ***trkC*** expression by ***NT3*** in the developing peripheral nervous system .	target	1
4795	10414984	4908;4916	NT3;trkC	This demonstrates that endogenous ***NT3*** ***regulates*** ***trkC*** expression in trigeminal neurons independently of changes in population size .	target	1
4796	10414997	2230;551	ADX;AVP	In gonadal-intact rats , ***ADX*** ***increased*** corticotropin-releasing factor ( CRH ) and vasopressin ( ***AVP*** ) mRNA in hypothalamic parvocellular paraventricular nuclei ( PVN ) and ACTH in pituitary and plasma .	positive	0
4797	10414997	2230;1392	ADX;CRH	In gonadal-intact rats , ***ADX*** ***increased*** corticotropin-releasing factor ( ***CRH*** ) and vasopressin ( AVP ) mRNA in hypothalamic parvocellular paraventricular nuclei ( PVN ) and ACTH in pituitary and plasma .	positive	0
4798	10415001	6352;356	RANTES;Fas ligand	Cutting edge : ***RANTES*** ***regulates*** ***Fas ligand*** expression and killing by HIV-specific CD8 cytotoxic T cells .	target	1
4799	10415001	6352;356	RANTES;FasL	Accordingly , ***RANTES*** ***enhanced*** the expression of ***FasL*** in a concentration - and time-dependent manner in HIV-specific CTLs , whereas anti-RANTES Ab decreased markedly FasL expression .	positive	0
4800	10415001	6356;1232	eotaxin;CCR3	Finally , cell surface expression of FasL protein in HIV-specific CTLs was also up-regulated by ***eotaxin*** , a selective ***ligand*** for ***CCR3*** .	parallel	1
4801	10415001	6352;356	RANTES;FasL	Our observations show that the action of ***RANTES*** via CCR3 is necessary to ***regulate*** ***FasL*** expression on HIV-specific CD8 + T cells that kill through the Fas/FasL pathway .	target	1
4802	10415024	8743;8797	APO2L;APO2	Two known mediators of activation-induced cell death are Fas ( CD95 ) ligand ( FasL ) and ***APO2*** ***ligand*** ( ***APO2L*** ) / TNF-related apoptosis-inducing ligand ( TRAIL ) .	parallel	1
4803	10415025	10076;5594	PTP;ERK	Thus , the complex ***formation*** of ***LC-PTP*** with ***ERK*** is the essential mechanism for the suppression .	parallel	0
4804	10415025	5604;5594	MEK1;ERK2	Expression of wild-type LC-PTP in 293T cells suppressed the ***phosphorylation*** of ***ERK2*** by a mutant ***MEK1*** , which was constitutively active regardless of upstream activation signals .	target	1
4805	10415025	10076;5594	PTP;ERK2	Expression of wild-type ***LC-PTP*** in 293T cells ***suppressed*** the phosphorylation of ***ERK2*** by a mutant MEK1 , which was constitutively active regardless of upstream activation signals .	negative	1
4806	10415025	10076;5594	PTP;ERK	In Jurkat cells , ***LC-PTP*** ***suppressed*** the ***ERK*** and p38 mitogen-activated protein kinase cascades .	negative	1
4807	10415025	10076;1432	PTP;p38 mitogen-activated protein kinase	In Jurkat cells , ***LC-PTP*** ***suppressed*** the ERK and ***p38 mitogen-activated protein kinase*** cascades .	negative	1
4808	10415026	2323;2322	Flt3L;fms-like tyrosine kinase 3	Daily treatment of mice with ***fms-like tyrosine kinase 3*** ***ligand*** ( ***Flt3L*** ) leads to a significant increase in the number of dendritic cells and induces antitumor immunity .	parallel	1
4809	10415026	958;959	CD40;CD40L	In addition , we demonstrate that endogenous CD40L plays a critical role in antitumor immunity , since blockade of ******CD40-CD40L****** ***interactions*** in vivo prevents the generation of antitumor immunity in therapeutic and vaccination protocols .	parallel	1
4810	10415027	940;1493	CD28;CD152	T cell activation is known to be regulated by the ***interactions*** between CD86/CD80 and ******CD28/CD152****** , although it remains unclear whether the B7 isoforms have distinct roles .	parallel	1
4811	10415027	941;1493	CD80;CD152	T cell activation is known to be regulated by the ***interactions*** between ***CD86/CD80*** and ***CD28/CD152*** , although it remains unclear whether the B7 isoforms have distinct roles .	parallel	1
4812	10415027	941;940	CD80;CD28	T cell activation is known to be regulated by the ***interactions*** between ***CD86/CD80*** and ***CD28/CD152*** , although it remains unclear whether the B7 isoforms have distinct roles .	parallel	1
4813	10415027	941;942	CD80;CD86	T cell activation is known to be regulated by the ***interactions*** between ******CD86/CD80****** and CD28/CD152 , although it remains unclear whether the B7 isoforms have distinct roles .	parallel	1
4814	10415027	942;1493	CD86;CD152	T cell activation is known to be regulated by the ***interactions*** between ***CD86/CD80*** and ***CD28/CD152*** , although it remains unclear whether the B7 isoforms have distinct roles .	parallel	1
4815	10415027	942;940	CD86;CD28	T cell activation is known to be regulated by the ***interactions*** between ***CD86/CD80*** and ***CD28/CD152*** , although it remains unclear whether the B7 isoforms have distinct roles .	parallel	1
4816	10415032	940;3932	CD28;Lck	TCR alpha beta-independent ***CD28*** signaling and costimulation ***require*** non-CD4-associated ***Lck*** .	target	0
4817	10415060	356;355	FasL;Fas	To address this , pancreatic islets from NOD mice were analyzed by flow cytometry to directly identify which cells express Fas and ***Fas*** ***ligand*** ( ***FasL*** ) ex vivo and after in vitro culture with cytokines .	parallel	1
4818	10415061	356;355	CD95L;CD95	Upon microbial Ag recognition , gamma delta cells secrete cytokines and chemokines and undergo apoptosis via ***CD95/CD95*** ***ligand*** ( ***CD95L*** ) interaction , possibly influencing the outcome of infection and the characteristics of the disease .	parallel	1
4819	10415061	355;356	CD95;CD95L	NO left unaffected the expression of CD95 and CD95L , suggesting interference with an event ensuing ******CD95/CD95L****** ***interaction*** .	parallel	1
4820	10415065	10344;6356	eotaxin-3;eotaxin	***eotaxin-3*** ***inhibited*** the binding of ***125I-eotaxin*** , but not 125I-macrophage inflammatory protein-1alpha , to eosinophils and acted on cell lines transfected with CCR-3 , suggesting that eotaxin-3 recognized CCR-3 .	negative	1
4821	10415065	10344;1232	eotaxin-3;CCR-3	eotaxin-3 inhibited the binding of 125I-eotaxin , but not 125I-macrophage inflammatory protein-1alpha , to eosinophils and acted on cell lines transfected with CCR-3 , suggesting that ***eotaxin-3*** ***recognized*** ***CCR-3*** .	target	1
4822	10415065	3596;10344	IL-13;eotaxin-3	***IL-13*** as well as IL-4 ***up-regulated*** ***eotaxin-3*** mRNA in HUVEC , whereas neither TNF-alpha , IL-1beta , IFN-gamma , nor TNF-alpha plus IFN-gamma did .	positive	1
4823	10415065	3565;10344	IL-4;eotaxin-3	IL-13 as well as ***IL-4*** ***up-regulated*** ***eotaxin-3*** mRNA in HUVEC , whereas neither TNF-alpha , IL-1beta , IFN-gamma , nor TNF-alpha plus IFN-gamma did .	positive	1
4824	10415068	3553;6376	IL-1beta;fractalkine	Molecular analyses of the chemokine fractalkine and its receptor CX3C-R1 in the rat brain have revealed a striking polarization : ***fractalkine*** is expressed constitutively in neurons and is ***up-regulated*** by TNF-alpha and ***IL-1beta*** in astrocytes .	positive	1
4825	10415068	7124;6376	TNF-alpha;fractalkine	Molecular analyses of the chemokine fractalkine and its receptor CX3C-R1 in the rat brain have revealed a striking polarization : ***fractalkine*** is expressed constitutively in neurons and is ***up-regulated*** by ***TNF-alpha*** and IL-1beta in astrocytes .	positive	1
4826	10415075	4790;5970	NF-kappa B;p65	Abnormal ***NF-kappa B*** activity in T lymphocytes from patients with systemic lupus erythematosus is ***associated*** with decreased ***p65-RelA*** protein expression .	parallel	0
4827	10415108	196;405	AhR;ARNT	KLE cells expressed higher levels of aryl hydrocarbon receptor ( AhR ) than RL95-2 and gel mobility shift assay also identified more liganded ******AhR-ARNT****** ***complex*** bound to xenobiotic response elements ( XRE ) .	parallel	1
4828	10415163	7124;5829	TNF-alpha;paxillin	Concurrently , ***TNF-alpha*** rapidly ***induced*** tyrosine phosphorylation of both ***paxillin*** and focal adhesion kinase , without affecting the expression levels of these two proteins .	target	1
4829	10415163	7124;5829	TNF-alpha;paxillin	These effects occur simultaneously , with a prompt ***TNF-alpha-induced*** tyrosine ***phosphorylation*** of ***paxillin*** and focal adhesion kinase , indicating that these proteins , known to regulate actin polymerization and formation of focal adhesions , may be directly involved in the mechanism controlling the observed actin redistribution .	target	1
4830	10415333	10111;4361	RAD50;Mre11	Human ***RAD50*** is physically ***associated*** with human ***Mre11*** : Identification of a conserved multiprotein complex implicated in recombinational DNA repair .	parallel	0
4831	10415336	5728;4609	PTEN;c-myc	***PTEN*** transcriptionally ***modulates*** ***c-myc*** gene expression in human breast carcinoma cells and is involved in cell growth regulation .	target	0
4832	10415402	5443;4790	alpha-MSH;NF-kappaB	Electrophoretic mobility shift assays of nuclear extracts demonstrated that parenteral ***alpha-MSH*** ***inhibited*** ***NF-kappaB*** activation .	negative	1
4833	10415402	5443;4790	alpha-MSH;NF-kappaB	These findings indicate that ***alpha-MSH*** peptides given systemically can ***inhibit*** ***NF-kappaB*** activation induced in acute brain inflammation even in the absence of MC1R .	negative	1
4834	10415422	5743;3725	COX-2;c-Jun	The induction of ***COX-2*** ***correlated*** more closely with the induction of ***c-Jun*** than with that of c-Fos .	parallel	0
4835	10415525	1906;488	endothelin-1;SERCA2	Liposome-based transfection of cells with a 1.9 kb SERCA2 promoter fragment directed expression of a reporter gene identical to the ***downregulation*** of genomic ***SERCA2*** expression by ***endothelin-1*** .	negative	1
4836	10415613	3458;3553	IFN-gamma;IL-1 beta	It is conceivable that ***IFN-gamma*** , or other cytokines secreted by infiltrating T-lymphocytes , are able to ***promote*** ***IL-1 beta*** secretion by TFC .	positive	0
4837	10415716	4314;7076	MMP-3;TIMP-1	Differences in proteinase susceptibility between free TIMP-1 and the ******TIMP-1-MMP-3****** ***complex*** and mutagenesis studies suggested that the residues around the disulfide bond between Cys1 and Cys70 in TIMP-1 may interact with MMPs .	parallel	1
4838	10415853	3569;4233	HGF;c-met	Interestingly , hollow-spheres showed intensive immunoreactivity for the HGF-receptor ( ***c-met*** ) and its ***ligand*** ( ***HGF*** ) .	parallel	1
4839	10415871	4914;627	Trk;neurotrophin	Based on these data we have evaluated the therapeutic potential of inhibiting ******neurotrophin-Trk****** ***interactions*** using a selective Trk tyrosine kinase inhibitor ( CEP-701 ) on subcutaneous ( s.c. ) and tracheal xenografts derived from the poorly differentiated PDAC cell line , Panc1 .	parallel	1
4840	10416616	7124;4790	TNF-alpha;NF-kappaB	The increased cytokine expression was associated with an increase in constitutive and ***TNF-alpha-inducible*** ***activation*** of ***NF-kappaB*** as demonstrated by electrophoretic mobility shift assay and luciferase-reporter gene assay .	positive	1
4841	10416616	7124;4790	TNF-alpha;NF-kappaB	***Induction*** of ***NF-kappaB*** by ***TNF-alpha*** was inhibited by the addition of protease inhibitors calpain inhibitor I and N-tosyl-phechloromethyl ketone and antioxidant 1-pyrrolidinecarbodithioic acid , whereas constitutive activation of NF-kappaB and cytokine KC mRNA expression was inhibited by N-tosyl-phechloromethyl ketone alone .	target	1
4842	10416616	7124;4790	TNF-alpha;NF-kappaB	These data indicate that activation of NF-kappaB contributes to increased expression of proinflammatory cytokines during metastatic tumor progression of squamous cell carcinoma , and that distinct mechanisms may be involved in the regulation of constitutive and ***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** in squamous cell carcinoma .	positive	1
4843	10416957	7124;7157	TNF-alpha;p53	In addition , it has been established that tumor necrosis factor-alpha ( ***TNF-alpha*** ) can ***activate*** the expression of wild type ***p53*** in concert with the nuclear transcription factor , NF-kappa B .	positive	1
4844	10417139	1493;941	CTLA-4;CD80	We sought to enhance the protective immune response induced during Mycobacterium bovis BCG infection by administering an antibody that blocks the ***interaction*** of ***CTLA-4*** with its ligands , ***CD80*** and CD86 .	parallel	1
4845	10417139	1493;942	CTLA-4;CD86	We sought to enhance the protective immune response induced during Mycobacterium bovis BCG infection by administering an antibody that blocks the ***interaction*** of ***CTLA-4*** with its ligands , CD80 and ***CD86*** .	parallel	1
4846	10417151	4792;4790	IkappaBalpha;NF-kappaB	Furthermore , nitrite reductase induced the degradation of ***IkappaBalpha*** , the major cytoplasmic ***inhibitor*** of ***NF-kappaB*** , and the expression of IkappaBalpha mRNA .	negative	1
4847	10417181	7124;355	tumor necrosis factor alpha;Fas	A provocative injection of ***tumor necrosis factor alpha*** into LPS-sensitized mice ***augmented*** ***Fas*** and Fas ligand expression and the apoptosis of renal tubular epithelial cells .	positive	0
4848	10417181	7124;356	tumor necrosis factor alpha;Fas ligand	A provocative injection of ***tumor necrosis factor alpha*** into LPS-sensitized mice ***augmented*** Fas and ***Fas ligand*** expression and the apoptosis of renal tubular epithelial cells .	positive	0
4849	10417322	811;4583	CRT;MUC2	MUC2 co-precipitated with CRT at zero time and 0.5 h was endo-beta-N-acetylglucosaminidase-sensitive ; therefore ***CRT*** must have ***associated*** with ***MUC2*** in the ER .	parallel	0
4850	10417322	4583;811	MUC2;CRT	Treatment with tunicamycin ( TUN ) diminished the ***binding*** of ***MUC2*** to ***CRT*** , suggesting a requirement for initial N-glycan addition during this process .	parallel	1
4851	10417327	335;635	apo;BHMT	Results suggest that ***apo*** B-mRNA abundance in McA cells is ***related*** to the expression of ***BHMT*** , an enzyme important in homocysteine metabolism .	parallel	0
4852	10417330	10603;3643	APS;insulin receptor	***APS*** , an adapter protein with a PH and SH2 domain , is a ***substrate*** for the ***insulin receptor*** kinase .	parallel	1
4853	10417330	10603;3643	APS;insulin receptor	Here we show that ***APS*** ***interacts*** with the ***insulin receptor*** kinase activation loop through its SH2 domain and insulin stimulates the tyrosine-phosphorylation of APS .	parallel	1
4854	10417350	8503;3667	p55PIK;insulin receptor substrate-1	Interestingly , when C57MG cells were treated with insulin , only ***p55PIK*** , but not p50PIK , ***bound*** to ***insulin receptor substrate-1*** protein , providing evidence that different forms of p55PIKs may have specific distinct roles in signal transduction pathways .	parallel	1
4855	10417351	5524;5140	PP2A;PDE3B	In summary , ***PP2A*** seems to be involved in the ***regulation*** of ***PDE3B*** in vivo and can act as a PDE3B phosphatase in vitro .	target	1
4856	10417394	1869;1026	E2F-1;p21CIP1	***E2F-1*** overexpression in cardiomyocytes ***induces*** downregulation of ***p21CIP1*** and p27KIP1 and release of active cyclin-dependent kinases in the presence of insulin-like growth factor I.	target	1
4857	10417394	1869;1027	E2F-1;p27KIP1	***E2F-1*** overexpression in cardiomyocytes ***induces*** downregulation of p21CIP1 and ***p27KIP1*** and release of active cyclin-dependent kinases in the presence of insulin-like growth factor I.	target	1
4858	10417394	1869;1026	E2F-1;p21	Furthermore , overexpression of ***E2F-1*** in the presence of IGF-I ***induced*** the specific downregulation of total ***p21*** ( CIP1 ) and p27 ( KIP1 ) protein levels and their dissociation from cyclin-dependent kinases ( cdks ) .	target	1
4859	10417394	1026;1017	p21;cdk2	The dissociation of ***p21*** ( CIP1 ) and p27 ( KIP1 ) from their cdk complexes ***correlated*** well with the activation of ***cdk2*** , cdk4 , and cdk6 and the release from cell cycle arrest .	parallel	0
4860	10417394	1026;1019	p21;cdk4	The dissociation of ***p21*** ( CIP1 ) and p27 ( KIP1 ) from their cdk complexes ***correlated*** well with the activation of cdk2 , ***cdk4*** , and cdk6 and the release from cell cycle arrest .	parallel	0
4861	10417394	1026;1021	p21;cdk6	The dissociation of ***p21*** ( CIP1 ) and p27 ( KIP1 ) from their cdk complexes ***correlated*** well with the activation of cdk2 , cdk4 , and ***cdk6*** and the release from cell cycle arrest .	parallel	0
4862	10417394	5715;1017	p27;cdk2	The dissociation of p21 ( CIP1 ) and ***p27*** ( KIP1 ) from their cdk complexes ***correlated*** well with the activation of ***cdk2*** , cdk4 , and cdk6 and the release from cell cycle arrest .	parallel	0
4863	10417394	5715;1019	p27;cdk4	The dissociation of p21 ( CIP1 ) and ***p27*** ( KIP1 ) from their cdk complexes ***correlated*** well with the activation of cdk2 , ***cdk4*** , and cdk6 and the release from cell cycle arrest .	parallel	0
4864	10417394	5715;1021	p27;cdk6	The dissociation of p21 ( CIP1 ) and ***p27*** ( KIP1 ) from their cdk complexes ***correlated*** well with the activation of cdk2 , cdk4 , and ***cdk6*** and the release from cell cycle arrest .	parallel	0
4865	10417395	183;5972	angiotensin II;renin	Mechanical stretch and ***angiotensin II*** differentially ***upregulate*** the ***renin-angiotensin*** system in cardiac myocytes In vitro .	positive	1
4866	10417450	356;355	FasL;Fas	In lichenoid tissue reactions , the Civatte body or colloid body is a form of apoptotic keratinocytes which is mediated by T lymphocytes via ******Fas-FasL****** ***interaction*** or through the perforin-granzyme B pathway .	parallel	1
4867	10417772	3458;355	IFN-gamma;CD95	Here we show that ***IFN-gamma*** , but not IFN-alpha , is able to increase the susceptibility of sensitive cell lines and to ***induce*** ***CD95*** sensitivity in resistant melanoma cell lines , accompanied by up-regulation of the protein expression level of CD95 and/or bcl-xS .	target	1
4868	10417825	596;5829	bcl-2;paxillin	Utilizing the kidney as a model of an organ that undergoes three-dimensional development we demonstrate that ***bcl-2*** directly ***associates*** with ***paxillin*** .	parallel	0
4869	10417825	5829;596	paxillin;bcl-2	The ***interaction*** of ***paxillin*** with ***bcl-2*** during nephrogenesis may provide an alternative to integrin ( s ) signaling through paxillin/FAK thus bypassing the need for adhesion-mediated survival during three dimensional morphogenesis .	parallel	1
4870	10418800	7056;5624	thrombomodulin;protein C	At inhibitor concentrations well below the achieved plasma levels in major clinical trials , the ***thrombin-thrombomodulin-mediated*** ***activation*** of ***protein C*** was inhibited by all the studied inhibitors in a dose-dependent manner , but , contrary to our hypothesis , to a greater extent by unfractionated heparin + antithrombin and dalteparin + antithrombin than by the direct thrombin inhibitors , hirudin and inogatran .	positive	1
4871	10418851	3667;3643	IRS-1;insulin receptor	Studies of the mechanisms by which free fatty acids ( FFA ) cause insulin resistance in humans indicate that increased FFA levels inhibit glucose transport , which may be a consequence of decreased ***insulin receptor*** ***substrate*** ( ***IRS-1*** ) - associated phosphatidylinositol 3-kinase activity .	parallel	1
4872	10418988	6770;1583	Steroidogenic Acute Regulatory (StAR) protein;P450scc	The ***Steroidogenic Acute Regulatory (StAR) protein*** , which ***mediates*** cholesterol delivery to the inner mitochondrial membrane and the ***P450scc*** enzyme , has been shown to require a mitochondrial electrochemical gradient for its activity in vitro .	target	0
4873	10419452	8802;5909	Galpha;Rap1 GTPase-activating protein	Modulation of rap activity by direct ***interaction*** of ***Galpha*** ( o ) with ***Rap1 GTPase-activating protein*** .	parallel	1
4874	10419452	5909;8802	Rap1GAP;Galpha	This study focuses on ***Rap1GAP*** , which selectively ***interacts*** with Galpha ( o ) and Galpha ( i ) but not with Galpha ( s ) or ***Galpha*** ( q ) .	parallel	1
4875	10419452	5909;8802	Rap1GAP;Galpha	***Rap1GAP*** ***interacts*** more avidly with the unactivated ***Galpha*** ( o ) as compared with the mutant ( Q205L ) - activated Galpha ( o ) .	parallel	1
4876	10419452	5909;5906	Rap1GAP;Rap1	Expression of chick ***Rap1GAP*** in PC-12 cells ***inhibited*** activation of ***Rap1*** by forskolin .	negative	1
4877	10419455	7535;1398	ZAP-70;Crk	T cell activation stimulates the ***association*** of enzymatically active tyrosine-phosphorylated ***ZAP-70*** with the ***Crk*** adapter proteins .	parallel	0
4878	10419455	7535;1398	ZAP-70;Crk	Incubation of various glutathione S-transferase fusion proteins with a lysate of activated Jurkat cells resulted in selective ***association*** of ***ZAP-70*** with ***Crk*** , but not Grb2 or Nck , adapter proteins .	parallel	0
4879	10419455	7535;1398	ZAP-70;Crk	In addition , tyrosine-phosphorylated ***ZAP-70*** ***co-immunoprecipitated*** with ***Crk*** from a lysate of activated Jurkat cells , and ZAP-70 association with GST-Crk was observed in a lysate of activated human peripheral blood T cells .	parallel	1
4880	10419455	7535;1398	ZAP-70;Crk	In addition , tyrosine-phosphorylated ZAP-70 co-immunoprecipitated with Crk from a lysate of activated Jurkat cells , and ***ZAP-70*** ***association*** with ***GST-Crk*** was observed in a lysate of activated human peripheral blood T cells .	parallel	0
4881	10419455	7535;373156	ZAP-70;GST	In addition , tyrosine-phosphorylated ZAP-70 co-immunoprecipitated with Crk from a lysate of activated Jurkat cells , and ***ZAP-70*** ***association*** with ***GST-Crk*** was observed in a lysate of activated human peripheral blood T cells .	parallel	0
4882	10419473	7295;387332	TRX;TBP-2	The ***association*** of ***TRX*** with ***TBP-2/VDUP1*** was observed in vitro and in vivo .	parallel	0
4883	10419473	7295;10628	TRX;VDUP1	The ***association*** of ***TRX*** with ***TBP-2/VDUP1*** was observed in vitro and in vivo .	parallel	0
4884	10419473	387332;7295	TBP-2;TRX	***TBP-2/VDUP1*** ***bound*** to reduced TRX but not to oxidized TRX nor to mutant ***TRX*** , in which two redox active cysteine residues are substituted by serine .	parallel	1
4885	10419473	10628;7295	VDUP1;TRX	***TBP-2/VDUP1*** ***bound*** to reduced TRX but not to oxidized TRX nor to mutant ***TRX*** , in which two redox active cysteine residues are substituted by serine .	parallel	1
4886	10419475	4437;4436	hMSH3;hMSH2	To examine the biochemical basis of this repair specificity , we characterized the mispair ***binding*** and ATPase activity of ******hMSH2-hMSH3****** .	parallel	1
4887	10419506	283489;1080	cAMP;CFTR	Other mutations impair the ***cAMP-dependent*** ***activation*** or the ion conductance of ***CFTR*** chloride channel .	positive	1
4888	10419510	5595;5801	ERK1;PTP-SL	***ERK1*** and ERK2 ***associate*** with the tyrosine phosphatase ***PTP-SL*** through a kinase interaction motif ( KIM ) located in the juxtamembrane region of PTP-SL .	parallel	0
4889	10419510	5594;5801	ERK2;PTP-SL	ERK1 and ***ERK2*** ***associate*** with the tyrosine phosphatase ***PTP-SL*** through a kinase interaction motif ( KIM ) located in the juxtamembrane region of PTP-SL .	parallel	0
4890	10419510	5967;5594	PTP;ERK2	Furthermore , tyrosine ***dephosphorylation*** of ***ERK2*** by the ***PTP-SLDeltaKIM*** mutant was impaired .	target	1
4891	10419510	5595;373156	ERK1;GST	The in vitro ***association*** of ***ERK1/2*** with ***GST-PTP-SL*** was highly stable ; however , low concentrations of nucleotides partially dissociated the ERK1/2 .	parallel	0
4892	10419510	5595;5801	ERK1;PTP-SL	The in vitro ***association*** of ***ERK1/2*** with ***GST-PTP-SL*** was highly stable ; however , low concentrations of nucleotides partially dissociated the ERK1/2 .	parallel	0
4893	10419510	5801;5595	PTP-SL;ERK1	Partial deletions of the KIM abrogated the ***association*** of ***PTP-SL*** with ***ERK1/2*** , indicating that KIM integrity is required for interaction .	parallel	0
4894	10419513	5467;5468	PPARdelta;PPARgamma	Expression of peroxisome proliferator-activated receptor ***PPARdelta*** ***promotes*** induction of ***PPARgamma*** and adipocyte differentiation in 3T3C2 fibroblasts .	positive	0
4895	10419515	841;637	Casp-8;BID	When full-length ***BID*** was ***cleaved*** by ***Casp-8*** , it too demonstrated channel activity similar to that seen with BIDDelta1-55 .	target	1
4896	10419521	11267;8178	EAP30;ELL	Remarkably , ***EAP30*** can ***interact*** with ***ELL*** and derepress ELL 's inhibitory activity in vitro .	parallel	1
4897	10419551	3553;623	IL-1beta;B1R	DesArg ( 10 ) KD and BK synergistically increased ***B1R*** ( 9-fold ) , which was further ***increased*** by inclusion of ***IL-1beta*** ( 36-fold ) .	positive	0
4898	10419551	3553;623	IL-1beta;B1R	Interleukin-1beta ( ***IL-1beta*** ; 500 pg/ml ) also ***increased*** ***B1R*** ( 4 - to 6-fold ) .	positive	0
4899	10419646	3458;4023	IFN-gamma;LPL	The action of the inhibitors on the ***IFN-gamma-dependent*** ***reduction*** of ***LPL*** activity was mediated at the level of LPL mRNA metabolism , with translational and/or post-translational levels of regulation being involved in the action of all the other mediators tested .	negative	0
4900	10419648	970;939	CD70;CD27	***CD27*** and its cellular ***ligand*** , ***CD70*** , have been implicated in the regulation of T cell and B cell interactions that lead to cellular activation and regulation of immunoglobulin expression .	parallel	1
4901	10419732	1435;1436	CSF-1;CSF-1R	CONCLUSION : In contradistinction to endometrial adenocarcinomas , in which ***CSF-1/CSF-1R*** is strongly ***correlated*** with tumor progression , CSF-1 and ***CSF-1R*** overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas .	parallel	0
4902	10419732	1436;1435	CSF-1R;CSF-1	CONCLUSION : In contradistinction to endometrial adenocarcinomas , in which ***CSF-1/CSF-1R*** is strongly ***correlated*** with tumor progression , ***CSF-1*** and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas .	parallel	0
4903	10419732	1436;1435	CSF-1R;Colony-stimulating factor-1	OBJECTIVE : Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor ***Colony-stimulating factor-1*** ( CSF-1 ) and its ***receptor*** ( ***CSF-1R*** ) in breast , ovarian , and endometrial adenocarcinomas , and their expression in each of these cancers is strongly correlated with poor prognosis .	parallel	1
4904	10419769	4843;5743	iNOS;COX-2	***Interactions*** between the inducible cyclooxygenase ( ***COX-2*** ) and nitric oxide synthase ( ***iNOS*** ) pathways : implications for therapeutic intervention in osteoarthritis .	parallel	1
4905	10419777	6868;7124	TACE;TNFalpha	These experiments demonstrate a functional paracrine/autocrine role of ***TNFalpha*** in OA-affected cartilage that is ***modulated*** by upregulated levels of chondrocyte-derived ***TACE*** .	target	0
4906	10419886	1440;6774	hG-CSF;STAT3	In addition , ***hG-CSF*** ***induced*** phosphorylation of ***STAT3*** but not Jak2 or STAT5 , while TPO induced phosphorylation of both .	target	1
4907	10419890	5196;2247	platelet factor-4;fibroblast growth factor-2	In this study , we examined in detail the ***interaction*** of ***platelet factor-4*** ( PF-4 ) with ***fibroblast growth factor-2*** ( FGF-2 ) and vascular endothelial growth factor ( VEGF ) and the effect of PF-4-derived synthetic peptides .	parallel	1
4908	10419890	5196;7422	platelet factor-4;VEGF	In this study , we examined in detail the ***interaction*** of ***platelet factor-4*** ( PF-4 ) with fibroblast growth factor-2 ( FGF-2 ) and vascular endothelial growth factor ( ***VEGF*** ) and the effect of PF-4-derived synthetic peptides .	parallel	1
4909	10419890	5196;2247	PF-4;FGF-2	This is based on the following observations : PF-4 peptide 47-70 inhibited FGF-2 or VEGF binding to endothelial cells ; it inhibited FGF-2 or VEGF binding to FGFRs or VEGFRs in heparan sulfate-deficient CHO cells transfected with FGFR1 ( CHOFGFR1 ) or VEGFR2 ( CHOmVEGFR2 ) cDNA ; it blocked proliferation or tube formation in three-dimensional angiogenesis assays ; and , finally , it competed with the direct ***association*** of ( 125 ) ***I-PF-4*** with ***FGF-2*** or VEGF , respectively , and inhibited heparin-induced FGF-2 dimerization .	parallel	0
4910	10419890	5196;7422	PF-4;VEGF	This is based on the following observations : PF-4 peptide 47-70 inhibited FGF-2 or VEGF binding to endothelial cells ; it inhibited FGF-2 or VEGF binding to FGFRs or VEGFRs in heparan sulfate-deficient CHO cells transfected with FGFR1 ( CHOFGFR1 ) or VEGFR2 ( CHOmVEGFR2 ) cDNA ; it blocked proliferation or tube formation in three-dimensional angiogenesis assays ; and , finally , it competed with the direct ***association*** of ( 125 ) ***I-PF-4*** with FGF-2 or ***VEGF*** , respectively , and inhibited heparin-induced FGF-2 dimerization .	parallel	0
4911	10419890	5196;2247	PF-4;FGF-2	This is based on the following observations : ***PF-4*** peptide 47-70 ***inhibited*** ***FGF-2*** or VEGF binding to endothelial cells ; it inhibited FGF-2 or VEGF binding to FGFRs or VEGFRs in heparan sulfate-deficient CHO cells transfected with FGFR1 ( CHOFGFR1 ) or VEGFR2 ( CHOmVEGFR2 ) cDNA ; it blocked proliferation or tube formation in three-dimensional angiogenesis assays ; and , finally , it competed with the direct association of ( 125 ) I-PF-4 with FGF-2 or VEGF , respectively , and inhibited heparin-induced FGF-2 dimerization .	negative	1
4912	10419890	5196;7422	PF-4;VEGF	This is based on the following observations : ***PF-4*** peptide 47-70 ***inhibited*** FGF-2 or ***VEGF*** binding to endothelial cells ; it inhibited FGF-2 or VEGF binding to FGFRs or VEGFRs in heparan sulfate-deficient CHO cells transfected with FGFR1 ( CHOFGFR1 ) or VEGFR2 ( CHOmVEGFR2 ) cDNA ; it blocked proliferation or tube formation in three-dimensional angiogenesis assays ; and , finally , it competed with the direct association of ( 125 ) I-PF-4 with FGF-2 or VEGF , respectively , and inhibited heparin-induced FGF-2 dimerization .	negative	1
4913	10420084	3565;7040	IL-4;TGF-beta	IL-12 enhanced production of IL-10 and IFN-gamma by the CD8alphabeta + alphabeta iIEL significantly but only marginally affected the CD8alphaalpha + subset , whereas ***IL-4*** induced IL-4 , IL-5 , and IL-10 production and ***augmented*** ***TGF-beta*** production by both subsets .	positive	0
4914	10420084	3565;3586	IL-4;IL-10	IL-12 enhanced production of IL-10 and IFN-gamma by the CD8alphabeta + alphabeta iIEL significantly but only marginally affected the CD8alphaalpha + subset , whereas ***IL-4*** ***induced*** IL-4 , IL-5 , and ***IL-10*** production and augmented TGF-beta production by both subsets .	target	1
4915	10420084	3565;3567	IL-4;IL-5	IL-12 enhanced production of IL-10 and IFN-gamma by the CD8alphabeta + alphabeta iIEL significantly but only marginally affected the CD8alphaalpha + subset , whereas ***IL-4*** ***induced*** IL-4 , ***IL-5*** , and IL-10 production and augmented TGF-beta production by both subsets .	target	1
4916	10420089	1392;5443	corticotropin-releasing hormone;ACTH	***corticotropin-releasing hormone*** ( CRH ) is a potent ***stimulator*** of ***ACTH*** secretion .	positive	0
4917	10420185	7039;7040	TGF-alpha;TGF-beta1	PDGF-BB and ***TGF-alpha*** slightly ***increased*** ***TGF-beta1*** mRNA .	positive	0
4918	10420846	7157;3308	P53;HSP70	Finally , a ***P53*** protein increase was detected in UVC-treated HepG2 cells and could be ***coimmunoprecipitated*** with ***HSP70*** after a thermal stress treatment .	parallel	1
4919	10421222	3952;3486	leptin;IGFBP-3	In simple regression analysis , the serum ***leptin*** concentration was positively ***correlated*** with the body mass index ( [ BMI ] men , r = .51 , P = .005 ; women , r = .71 , P < .001 ) , ***IGFBP-3*** ( men , r = .20 , P = nonsignificant ; women , r = .41 , P < .025 ) , and AIRG ( men , r = .73 , P < .001 ; women , r = .62 , P < .01 ) .	positive	0
4920	10421367	5367;2847	MCH;SLC-1	Here we show that the 353-amino-acid human orphan G-protein-coupled receptor ***SLC-1*** expressed in HEK293 cells binds MCH with sub-nanomolar affinity , and is ***stimulated*** by ***MCH*** to mobilize intracellular Ca2 + and reduce forskolin-elevated cyclic AMP levels .	positive	0
4921	10421367	2847;5367	SLC-1;MCH	Here we show that the 353-amino-acid human orphan G-protein-coupled receptor ***SLC-1*** expressed in HEK293 cells ***binds*** ***MCH*** with sub-nanomolar affinity , and is stimulated by MCH to mobilize intracellular Ca2 + and reduce forskolin-elevated cyclic AMP levels .	parallel	1
4922	10421433	1394;1392	CRHR1;corticotropin-releasing hormone	Antalarmin is a pyrrolopyrimidine compound that antagonizes ***corticotropin-releasing hormone*** ( CRH ) type 1 ***receptors*** ( ***CRHR1*** ) .	parallel	1
4923	10421436	43;8292	AChE;ColQ	In the collagen-tailed forms , ***AChE*** ( T ) subunits are ***associated*** with a specific collagen , ***ColQ*** , which is encoded by a single gene in mammals .	parallel	0
4924	10421578	8936;10096	Scar1;Arp2/3	We interfered with the targeting of the Arp2/3 complex to Listeria by using carboxy-terminal fragments of ***Scar1*** that ***bind*** the ***Arp2/3*** complex [ 11 ] .	parallel	1
4925	10421641	3458;942	IFN-gamma;B7-2	***IFN-gamma*** significantly reduced B7-1 expression in some lines and significantly ***increased*** ***B7-2*** expression in others .	positive	0
4926	10421641	3458;941	IFN-gamma;B7-1	***IFN-gamma*** significantly ***reduced*** ***B7-1*** expression in some lines and significantly increased B7-2 expression in others .	negative	1
4927	10421649	355;356	Fas;FasL	However , less attention has been paid to the role of ******Fas/FasL****** ***interaction*** in vivo .	parallel	1
4928	10421655	4313;4323	MMP2;MT1-MMP	Treatment of cells with concanavalin A resulted in a marked activation of ***MMP2*** that ***correlated*** with the proteolytic processing of ***MT1-MMP*** , the MMP2 activator , from a Mr = 60 kd toward a Mr = 43 kd polypeptide .	parallel	0
4929	10421655	7077;4313	tissue inhibitor of metalloproteinase-2;MMP2	Recombinant ***tissue inhibitor of metalloproteinase-2*** and the MMP inhibitor BB-3103 , but not PMSF , ***blocked*** ***MMP2*** activation induced by collagen I or concanavalin A , and MT1-MMP processing to its Mr-43 kd form .	negative	0
4930	10421786	3565;6777	IL-4;STAT5	***Activation*** of ***STAT5*** by ***IL-4*** relies on Janus kinase function but not on receptor tyrosine phosphorylation , and can contribute to both cell proliferation and gene regulation .	positive	1
4931	10421786	3565;6777	IL-4;STAT5	However , disruption of a membrane-proximal proline-rich sequence motif ( ' box1 ' ) in either subunit of the bipartite IL-4R abolished not only ligand-induced tyrosine phosphorylation of Janus kinases JAK1 and JAK3 , but also ***IL-4-triggered*** ***activation*** of ***STAT5*** and concomitant cell proliferation .	positive	1
4932	10421792	3824;3133	CD94;HLA-E	This HLA-G-mediated inhibition of antigen-specific CTL lysis was ( i ) peptide dose dependent , ( ii ) reversed by blocking HLA-G with a specific mAb and ( iii ) still observed despite the blockade of ******HLA-E/CD94/NKG2A****** ***interaction*** .	parallel	1
4933	10421792	3824;3821	CD94;NKG2A	This HLA-G-mediated inhibition of antigen-specific CTL lysis was ( i ) peptide dose dependent , ( ii ) reversed by blocking HLA-G with a specific mAb and ( iii ) still observed despite the blockade of ******HLA-E/CD94/NKG2A****** ***interaction*** .	parallel	1
4934	10421792	3133;3821	HLA-E;NKG2A	This HLA-G-mediated inhibition of antigen-specific CTL lysis was ( i ) peptide dose dependent , ( ii ) reversed by blocking HLA-G with a specific mAb and ( iii ) still observed despite the blockade of ******HLA-E/CD94/NKG2A****** ***interaction*** .	parallel	1
4935	10421795	4233;3082	c-met;HGF	Transcription of ***HGF*** and its ***receptor*** , ***c-met*** , was detected by reverse transcription-polymerase chain reaction ( RT-PCR ) .	parallel	1
4936	10421795	3082;1081	HGF;HCG	Concentrations of ***HGF*** in FF were positively ***correlated*** with those of progesterone ( r = 0.649 , P < 0.0001 ) and ***HCG*** ( r = 0.264 , P = 0.026 ) concentrations in FF .	positive	0
4937	10421796	3952;1588	Leptin;aromatase	***Leptin*** directly ***stimulates*** ***aromatase*** activity in human luteinized granulosa cells .	positive	0
4938	10421804	6667;2697	Sp1;Cx43	Promoter mutagenesis and transient transfection analyses combined with Sp1 and c-Jun/c-Fos over-expression studies indicate that both ***Sp1*** and c-Jun are required for maximal promoter activity and , therefore , may positively ***regulate*** transcription of myometrial ***Cx43*** during the initiation of labour .	positive	1
4939	10421844	7189;958	TRAF6;CD40	BACKGROUND : TRAF6 , a member of the tumour necrosis factor receptor-associated factor family , was first identified as a transducer of CD40 and interleukin-1 receptor ( IL-1R ) signals based on the ***interaction*** of ***TRAF6*** with the cytoplasmic tail of ***CD40*** and with the IL-1R associated kinase in vitro .	parallel	1
4940	10421844	7189;958	TRAF6;CD40	BACKGROUND : ***TRAF6*** , a member of the tumour necrosis factor receptor-associated factor family , was first identified as a ***transducer*** of ***CD40*** and interleukin-1 receptor ( IL-1R ) signals based on the interaction of TRAF6 with the cytoplasmic tail of CD40 and with the IL-1R associated kinase in vitro .	positive	1
4941	10422145	3439;3567	IFN-alpha;IL-5	***IL-5*** production by these cells was markedly increased and was ***inhibited*** by ***IFN-alpha*** and IFN-beta in vitro .	negative	1
4942	10422145	3456;3567	IFN-beta;IL-5	***IL-5*** production by these cells was markedly increased and was ***inhibited*** by IFN-alpha and ***IFN-beta*** in vitro .	negative	1
4943	10422218	1636;3827	ACE;bradykinin	Angiotensin converting enzyme ( ***ACE*** ) is involved in the ***degradation*** of ***bradykinin*** , an inflammatory mediator , and in the regulation of blood pressure .	negative	1
4944	10422564	6347;941	hMCP-1;B7-1	Expression of ***B7-1*** in 24h-cultured LC of BA LB/c mice was ***augmented*** by addition of recombinant ***hMCP-1*** in a dose-dependent manner .	positive	0
4945	10422564	6347;941	MCP-1;B7-1	These findings suggest that ***MCP-1*** accelerates LC migration from epidermis into the DLN and ***up-regulates*** I-Ad and ***B7-1*** expressions on the LC , which eventually enhances CHR .	positive	1
4946	10422733	3952;4852	Leptin;NPY	Decreased ***Leptin*** signaling in the arcuate nucleus is hypothesized to ***increase*** the expression of ***NPY*** and AGRP .	positive	0
4947	10422768	3952;885	Leptin;CCK	We conclude that : ( 1 ) exogenous Leptin or that released endogenously by CCK or meal exerts a potent gastroprotective action depending upon vagal activity , and involving hyperemia probably mediated by NO and sensory nerves but unrelated to endogenous prostaglandins ; ( 2 ) ***Leptin*** mimics the gastroprotective effect of CCK and probably ***mediates*** the protective and hyperemic actions of ***CCK*** in the rat stomach .	target	0
4948	10422773	1524;6376	CX3CR1;fractalkine	Functional expression of ***CX3CR1*** , a recently discovered ***receptor*** for the chemokine ***fractalkine*** , was investigated in cultured rat microglia .	parallel	1
4949	10422804	3949;4018	LDLR;lipoprotein	A cohort of 236 apparently unrelated patients with clinical features of FH was screened for a common mutation causing familial defective apolipoprotein B-100 ( FDB ) and seven low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) gene defects known to be relatively common in South Africans with FH .	parallel	1
4950	10423033	4982;8600	OPG;ODF	Recent analyses of ODF receptor demonstrated that RANK , a member of the TNF receptor family , is the signaling receptor for ODF in osteoclastogenesis , and that ***OPG/OCIF*** acts as a decoy ***receptor*** for ***ODF*** to compete against RANK .	parallel	1
4951	10423033	8792;8600	RANK;ODF	Recent analyses of ODF receptor demonstrated that ***RANK*** , a member of the TNF receptor family , is the signaling ***receptor*** for ***ODF*** in osteoclastogenesis , and that OPG/OCIF acts as a decoy receptor for ODF to compete against RANK .	parallel	1
4952	10423035	4221;3727	Menin;junD	Menin is principally a nuclear protein ; ***Menin*** ***interacts*** with ***junD*** .	parallel	1
4953	10423162	79109;3162	SIN-1;heme oxygenase-1	A combination of ***SIN-1*** plus SNP or GSNO additively ***increased*** ***heme oxygenase-1*** mRNA expression , whereas synergistic induction was seen with SNP plus GSNO .	positive	0
4954	10423165	1457;4609	CKII;Myc	In our current study , we showed that the Km values for purified CKII were similar for casein and Myc oncoprotein under a variety of assay conditions , and that specific natural and synthetic polyamines stimulated ***CKII*** ***phosphorylation*** of ***Myc*** oncoprotein 2 - to 20-fold via increases in Vmax .	target	1
4955	10423165	4609;1457	Myc;CKII	Because the Myc oncoprotein transactivates several genes for key proteins involved in the regulation of cellular proliferation , including the omithine decarboxylase gene ( rate-limiting enzyme of polyamine synthesis ) , we suggest that there may be ***linkages*** between polyamines , ***CKII*** , and ***Myc*** in the control of cellular proliferation .	parallel	0
4956	10423273	4744;4747	NF-H;NF-L	These data extend earlier cell-free demonstrations that ***NF-H*** preferentially ***associates*** with ***NF-L*** rather than alpha-IN .	parallel	0
4957	10423400	7124;2006	tumor necrosis factor-alpha;tropoelastin	Fibroblast ***tropoelastin*** and alpha-smooth-muscle actin expression are ***repressed*** by particulate-activated macrophage-derived ***tumor necrosis factor-alpha*** in experimental silicosis .	negative	1
4958	10423406	5553;3576	eosinophil granule major basic protein;interleukin-8	***Stimulation*** of neutrophil ***interleukin-8*** production by ***eosinophil granule major basic protein*** .	positive	0
4959	10423408	5265;5284	A1AT;pIgR	The recombinant ***scFv-A1AT*** fusion protein ***bound*** specifically to the ***pIgR*** on the basolateral surface of an epithelial cell monolayer , and was transported and released into the apical medium where the A1AT domain was capable of forming an inactivation complex with NE .	parallel	1
4960	10423413	728;727	C5aR;C5a	Previously , we have shown that ***C5a*** ***receptors*** ( ***C5aR*** ) are constitutively expressed on human bronchial epithelial cells ( HBECs ) grown in culture .	parallel	1
4961	10424279	3569;3565	IL-6;IL-4	***IL-6*** , but neither IL-10 nor IL-12 pretreatment ***suppressed*** Con-A-induced ***IL-4*** production and hepatitis .	negative	1
4962	10424441	3811;2207	KIR;FcR gamma	This implies that KIR may function in the immediate vicinity of activating molecules , and previous studies have shown that p58 ***KIR*** is ***associated*** with TCR zeta - and ***FcR gamma-chain*** in NK cells .	parallel	0
4963	10424441	3811;919	KIR;TCR zeta-chain	To better understand the molecular ***interaction*** between ***KIR*** and ***TCR zeta-chain*** , we generated a His-tag fusion protein of a p70 KIR cytoplasmic tail ( His-CytKIR ) and used this protein to coprecipitate TCR zeta-chain from Jurkat T cells .	parallel	1
4964	10424442	7409;3937	Vav;SLP-76	In addition , co-immunoprecipitation experiments demonstrated that ***Vav*** is ***associated*** with ***SLP-76*** upon FcgammaRIIa1 activation .	parallel	0
4965	10424683	4908;6863	neurotrophic factor;substance P	Glial cell line derived ***neurotrophic factor*** ( GDNF ) ***regulates*** VR1 and ***substance P*** in cultured sensory neurons .	target	1
4966	10424683	4908;7442	neurotrophic factor;VR1	Glial cell line derived ***neurotrophic factor*** ( GDNF ) ***regulates*** ***VR1*** and substance P in cultured sensory neurons .	target	1
4967	10424760	3479;207	IGF-I;AKT1	***AKT1*** activity was ***increased*** by either estradiol or ***IGF-I*** in estrogen-dependent MCF-7 cells , and both factors acted synergistically to increase AKT1 activity and promote cell proliferation .	positive	0
4968	10424760	3479;207	IGF-I;AKT1	***Stimulation*** of ***AKT1*** activity by estradiol and ***IGF-I*** was blocked by the antiestrogen ICI 182780 and by the phosphatidylinositol-3-kinase inhibitor wortmannin .	positive	0
4969	10425190	3312;871	HSC70;gp46	Here we showed that ***HSC70*** directly ***binds*** to ***gp46*** by co-immunoprecipitation of HSC70 and gp46 from HTLV-I-producing human T-cell lysate .	parallel	1
4970	10425198	4233;999	HGF/SF receptor;E-cadherin	***Association*** of the ***HGF/SF receptor*** , c-met , with the cell-surface adhesion molecule , ***E-cadherin*** , and catenins in human tumor cells .	parallel	0
4971	10425201	3952;7054	Leptin;tyrosine hydroxylase	***Leptin*** ( 1 , 10 , 100 nM ) significantly ***increased*** ***tyrosine hydroxylase*** ( TH ) ( a rate-limiting enzyme in the biosynthesis of catecholamine ) mRNA levels in a concentration-dependent manner .	positive	0
4972	10425206	5468;2167	PPARgamma;adipocyte fatty acid binding protein	***PPARgamma*** activation ***induces*** the expression of the ***adipocyte fatty acid binding protein*** gene in human monocytes .	target	1
4973	10425208	7157;1432	p53;p38	Moreover , ***p53*** ***bound*** to ***p38*** as revealed by immunoprecipitation with anti-p53 antibodies from UV-treated F9 cells .	parallel	1
4974	10425270	7124;3383	TNFalpha;ICAM-1	In contrast , the pro-inflammatory cytokine ***TNFalpha*** , whose activity is dependent on the generation of intracellular ROS , ***induces*** IL-8 and ***ICAM-1*** in both cell types .	target	1
4975	10425270	7124;3383	TNFalpha;ICAM-1	The differential ***induction*** of IL-8 and ***ICAM-1*** by H2O2 and ***TNFalpha*** suggest that the two inflammatory stimuli target distinct redox responsive signaling pathways to activate cell type-specific gene expression .	target	1
4976	10425271	959;958	CD40L;CD40	CD40 , a cell surface molecule found on B lymphocytes and other antigen presenting cells , can , when engaged by ***CD40*** ***ligand*** ( ***CD40L*** ) , induce gene rearrangements and isotype switching .	parallel	1
4977	10426315	7124;6000	tumor necrosis factor (TNF)-alpha;RGS7	Here we demonstrate that ***tumor necrosis factor (TNF)-alpha*** , an essential mediator of endotoxin-induced sepsis , ***prevents*** the proteasome-dependent degradation of ***RGS7*** , a regulator of G-protein signaling .	negative	0
4978	10426315	6000;1432	RGS7;p38	The stabilization of ***RGS7*** by TNF-alpha ***requires*** activation of the stress-activated protein kinase ***p38*** and the presence of candidate mitogen-activated protein kinase phosphorylation sites .	target	0
4979	10426565	949;4018	CLA-1;lipoprotein	***CLA-1*** , a human homologue of rodent scavenger receptor class B1 ( SR-B1 ) , has been identified as a ***receptor*** for high density ***lipoprotein*** ( HDL ) and is highly expressed in the adrenal gland .	parallel	1
4980	10426565	5443;949	ACTH;CLA-1	In this study , we show that ***ACTH*** and its second messenger cAMP ***stimulated*** ***CLA-1*** protein expression in a human adrenocortical cell line .	positive	0
4981	10426565	5443;949	ACTH;CLA-1	These findings demonstrated for the first time that ***ACTH*** ***increased*** ***CLA-1*** protein in cultured human adrenocortical cells , and that cortisol - and aldosterone-secreting adenomas had high CLA-1 proteins in their cell surfaces .	positive	0
4982	10426789	7157;7150	p53;topoisomerase I	PolyADP-ribose-mediated regulation of ***p53*** ***complexed*** with ***topoisomerase I*** following ionizing radiation .	parallel	1
4983	10426789	7157;7150	p53;topoisomerase I	This investigation demonstrates that the ***p53*** and ***topoisomerase I*** ( topo I ) proteins which form a molecular ***complex*** in vivo are polyADP ribosylated following 1 Gy of gamma irradiation .	parallel	1
4984	10426994	22914;10870	NKG2D;DAP10	Thus , ******NKG2D-DAP10****** receptor ***complexes*** may activate NK and T cell responses against MICA-bearing tumors .	parallel	1
4985	10426999	10111;4361	hRad50;hMre11	Association of BRCA1 with the ******hRad50-hMre11-p95****** ***complex*** and the DNA damage response .	parallel	1
4986	10426999	10111;4683	hRad50;p95	Association of BRCA1 with the ******hRad50-hMre11-p95****** ***complex*** and the DNA damage response .	parallel	1
4987	10426999	4683;4361	p95;hMre11	Association of BRCA1 with the ******hRad50-hMre11-p95****** ***complex*** and the DNA damage response .	parallel	1
4988	10426999	672;4361	BRCA1;hMre11	***Association*** of ***BRCA1*** with the ***hRad50-hMre11-p95*** complex and the DNA damage response .	parallel	0
4989	10426999	672;10111	BRCA1;hRad50	***Association*** of ***BRCA1*** with the ***hRad50-hMre11-p95*** complex and the DNA damage response .	parallel	0
4990	10426999	672;4683	BRCA1;p95	***Association*** of ***BRCA1*** with the ***hRad50-hMre11-p95*** complex and the DNA damage response .	parallel	0
4991	10426999	672;10111	BRCA1;hRad50	Here , it is shown that ***BRCA1*** ***interacts*** in vitro and in vivo with ***hRad50*** , which forms a complex with hMre11 and p95/nibrin .	parallel	1
4992	10426999	10111;4361	hRad50;hMre11	Here , it is shown that BRCA1 interacts in vitro and in vivo with ***hRad50*** , which forms a ***complex*** with ***hMre11*** and p95/nibrin .	parallel	1
4993	10426999	10111;4683	hRad50;p95	Here , it is shown that BRCA1 interacts in vitro and in vivo with ***hRad50*** , which forms a ***complex*** with hMre11 and ***p95/nibrin*** .	parallel	1
4994	10426999	10111;4361	hRad50;hMre11	These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the ******hRad50-hMre11-p95****** ***complex*** .	parallel	1
4995	10426999	10111;4683	hRad50;p95	These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the ******hRad50-hMre11-p95****** ***complex*** .	parallel	1
4996	10426999	4683;4361	p95;hMre11	These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the ******hRad50-hMre11-p95****** ***complex*** .	parallel	1
4997	10427095	8215;1499	Dsh;beta-catenin	Finally , we demonstrate that overexpression of ***Dsh*** can ***stabilize*** ***beta-catenin*** in Xenopus .	positive	0
4998	10427134	1956;7039	EGFR;TGFalpha	In stratified squamous epithelial cells , these receptors include epidermal growth factor receptor ( ***EGFR*** ) that ***binds*** both EGF and transforming growth factor alpha ( ***TGFalpha*** ) , and c-met whose ligand is hepatocyte growth factor/scatter factor ( HGF/SF ) .	parallel	1
4999	10427159	3484;3479	IGFBP-1;IGF-I	CONCLUSIONS : The results of this study suggest that , while overexpression of ***IGFBP-1*** ***attenuates*** ***IGF-I*** action in vitro , it enhances thyroid growth in vivo , presumably as a result of perturbations in thyroid function at multiple levels .	negative	0
5000	10427504	8651;6774	SOCS-1;STAT3	The expression of the SOCS proteins had no effect on CSF-1 mediated STAT3 tyrosine phosphorylation ; however , ***SOCS-1*** and SOCS-3 ***reduced*** the tyrosine phosphorylation of ***STAT3*** in response to IL-6 but did not abolish it .	negative	1
5001	10427504	9021;6774	SOCS-3;STAT3	The expression of the SOCS proteins had no effect on CSF-1 mediated STAT3 tyrosine phosphorylation ; however , SOCS-1 and ***SOCS-3*** ***reduced*** the tyrosine phosphorylation of ***STAT3*** in response to IL-6 but did not abolish it .	negative	1
5002	10427963	274;55607	Bin1;Neurabin-I	We suggest that Bau may ***link*** ***Bin1*** to the ***Neurabin-I/p70S6K*** system in muscle and other cells , perhaps providing a mechanism to influence adhesion-dependent signals which affect cell fate .	parallel	0
5003	10427971	3596;6778	IL-13;STAT6	Analysis of cell lines Daudi and THP-1 that differentially express gamma ( c ) and IL-13R alpha1 showed that ***IL-13*** can ***activate*** ***STAT6*** in IL-13R alpha1-positive THP-1 cells but not in gamma ( c ) - positive , IL-13R alpha1-negative Daudi cells .	positive	1
5004	10427971	3596;6778	IL-13;STAT6	***IL-13*** ***activation*** of ***STAT6*** was reduced in MDMac which was associated with diminished IL-13-induced expression of CD23 and MHC class II .	positive	1
5005	10427974	922;921	CD5L;CD5	To date only ***CD5*** ***ligands*** ( ***CD5L*** ) compatible with a T-B co-stimulatory role have been described ( CD72 , gp40-80 and IgV ( H ) framework region ) so the existence of alternative CD5L involved in other aspects of T cell biology warrants further exploration .	parallel	1
5006	10427974	923;214	CD6;ALCAM	These results imply a novel CD5/CD5L interaction model recalling some aspects of the ***interaction*** of ***CD6*** with activated leukocyte cell adhesion molecule ( ***ALCAM*** ) .	parallel	1
5007	10427988	3384;7124	ICAM-2;TNF-alpha	In contrast , ***ICAM-2*** and ICAM-3 ***induced*** a much stronger secretion of the Th1 cytokine ***TNF-alpha*** compared to LFA-1/ICAM-1 induced co-stimulation , despite the lower proliferation rate .	target	1
5008	10427988	3385;7124	ICAM-3;TNF-alpha	In contrast , ICAM-2 and ***ICAM-3*** ***induced*** a much stronger secretion of the Th1 cytokine ***TNF-alpha*** compared to LFA-1/ICAM-1 induced co-stimulation , despite the lower proliferation rate .	target	1
5009	10427990	695;867	Btk;c-Cbl	Previous work using Btk-derived fusion proteins has shown that the ***Btk*** SH3 domain ***binds*** to ***c-Cbl*** and Wiskott-Aldrich syndrome protein ( WASP ) in vitro .	parallel	1
5010	10427990	695;867	Btk;c-Cbl	Although the phosphorylated ***Btk*** SH3 domain still ***binds*** ***c-Cbl*** , it no longer binds WASP and instead acquires a high affinity for kinase-active Syk .	parallel	1
5011	10427998	940;27040	CD28;LAT	Thus , ***CD28*** ligation appears to ***induce*** tyrosine phosphorylation of ***LAT*** by mechanisms that are independent of ZAP-70 and Syk .	target	1
5012	10427998	940;27040	CD28;LAT	***CD28*** ligation ***induces*** rapid tyrosine phosphorylation of the linker molecule ***LAT*** in the absence of Syk and ZAP-70 tyrosine phosphorylation .	target	1
5013	10427998	940;27040	CD28;LAT	We show in the present report that ***CD28*** ligation ***induces*** tyrosine phosphorylation of ***LAT*** .	target	1
5014	10427998	940;27040	CD28;LAT	***CD28-induced*** tyrosine ***phosphorylation*** of ***LAT*** was rapid , as it was apparent within 1 min of CD28 ligation , reached a peak by 5 min , and declined thereafter .	target	1
5015	10428053	79969;2932	Tat;GSK-3beta	Coprecipitation experiments revealed that ***Tat*** can ***associate*** with ***GSK-3beta*** , but direct addition of Tat to purified GSK-3beta had no effect on enzyme activity , suggesting that Tat 's effects might be mediated indirectly .	parallel	0
5016	10428060	5539;4852	pancreatic polypeptide;NPY	The Y2 receptor agonists NPY ( 13-36 ) and N-acetyl [ Leu28 , Leu31 ] NPY ( 24-36 ) , the Y4 agonist rat ***pancreatic polypeptide*** ( rPP ) , and the Y4/Y5 agonist human pancreatic polypeptide ( hPP ) significantly ***reduced*** both basal and stimulated ***NPY*** release .	negative	1
5017	10428063	5594;2353	Erk;Fos	As extracellular signal-regulated kinase ( ***Erk*** ) and stress-activated protein kinase/c-GeneGene 6 N-terminal kinase ( SAPK/JNK ) phosphorylation may ***induce*** ***Fos*** and Jun gene transcription and activator protein-1 ( AP-1 ) DNA binding , the activation of Erk1 , Erk2 , p38 , and SAPK/JNK was examined in the nucleus tractus solitarii and neocortex during hypoxia and following administration of MK-801 .	target	1
5018	10428063	5594;3725	Erk;Jun	As extracellular signal-regulated kinase ( ***Erk*** ) and stress-activated protein kinase/c-GeneGene 6 N-terminal kinase ( SAPK/JNK ) phosphorylation may ***induce*** Fos and ***Jun*** gene transcription and activator protein-1 ( AP-1 ) DNA binding , the activation of Erk1 , Erk2 , p38 , and SAPK/JNK was examined in the nucleus tractus solitarii and neocortex during hypoxia and following administration of MK-801 .	target	1
5019	10428080	3552;3339	IL-1alpha;perlecan	These results show an increase in perlecan biosynthesis after injury and suggest a specific ***regulation*** of ***perlecan*** mRNA by ***IL-1alpha*** , which depends on brain area .	target	1
5020	10428080	3552;3339	IL-1alpha;perlecan	We thus studied ***perlecan*** ***regulation*** by ***IL-1alpha*** , in vivo .	target	1
5021	10428300	10855;2719	heparanase;heparan sulphate proteoglycan	Previous studies from this laboratory have shown that ***degradation*** of ***heparan sulphate proteoglycan*** by both living macrophages and macrophage lysosomal ***heparanase*** induces phenotypic change of vascular smooth muscle cells ( SMC ) from a high volume fraction of myofilaments ( V ( v ) myo ) to a low V ( v ) myo [ Campbell et al .	negative	1
5022	10428302	729230;6347	CCR2;monocyte chemotactic protein-1	***monocyte chemotactic protein-1*** ( MCP-1 ) and its ***receptor*** ***CCR2*** are important for monocyte extravasation and formation of atherosclerotic lesions .	parallel	1
5023	10428302	7124;729230	TNF-alpha;CCR2	Notably , oxLDL counteracted the ***TNF-alpha-mediated*** ***downregulation*** of ***CCR2*** and CCR2-dependent transendothelial chemotaxis .	negative	1
5024	10428479	1471;1514	cystatin C;Cathepsin L	One of them appeared whether E-64 or PMSF was added or not , evidently representing a ******cystatin C/Cathepsin L****** ***complex*** .	parallel	1
5025	10428479	1514;1471	Cathepsin L;cystatin C	N-terminal sequencing after separation by HPLC showed that ***cystatin C*** is ***cleaved*** by ***Cathepsin L*** at the Gly11-Gly12 bond .	target	1
5026	10428482	7039;239	transforming growth factor-alpha;12-lipoxygenase	***Induction*** of ***12-lipoxygenase*** expression by ***transforming growth factor-alpha*** in human epidermoid carcinoma A431 cells .	target	1
5027	10428482	7039;239	transforming growth factor-alpha;12-lipoxygenase	***transforming growth factor-alpha*** ( TGF-alpha ) ***increased*** the expression of ***12-lipoxygenase*** activity in a time-dependent manner in human epidermoid carcinoma A431 cells .	positive	0
5028	10428756	7040;5054	TGF-beta1;PAI-1	Moreover , by using semiquantitative RT-PCR and Western blotting , we observed that only the expression of ***PAI-1*** was ***modulated*** by ***TGF-beta1*** treatment via a TGF-beta-inducible element contained in the PAI-1 promoter ( CAGA box ) .	target	0
5029	10428756	7040;5054	TGF-beta;PAI-1	These data show that ***TGF-beta*** and activin were able to ***induce*** the overexpression of ***PAI-1*** in astrocytes , but that bone morphogenetic proteins , glial cell line-derived neutrophic factor , and neurturin did not .	target	1
5030	10428779	8204;196	RIP140;AhR	The signature motif , LXXLL , which is responsible for binding of several coactivators to nuclear receptors , is not required for ***RIP140*** ***binding*** to ***AhR*** .	parallel	1
5031	10428779	8204;196	RIP140;AhR	In addition , the data suggest that there are distinct motif ( s ) for the ***recruitment*** of ***RIP140*** to ***AhR*** and possibly other non-steroid receptors/transcription factors .	target	0
5032	10428779	8204;196	RIP140;AhR	Co-immunoprecipitation and co-localization assays revealed that ***RIP140*** ***interacted*** with ***AhR*** , but not with ARNT , both in vitro and in cells .	parallel	1
5033	10428779	196;8204	AhR;RIP140	Mapping of the interaction sites revealed that ***RIP140*** was ***recruited*** by the ***AhR*** transactivation domain via the Q-rich subdomain .	target	0
5034	10428779	8204;196	RIP140;AhR	The ***RIP140*** domain that ***interacts*** with the ***AhR*** was mapped to a location between amino acid residues 154 and 350 , which is distinct from those involved in estrogen receptor binding .	parallel	1
5035	10428780	2056;598	Erythropoietin;bcl-x	***Erythropoietin*** can ***induce*** the expression of ***bcl-x*** ( L ) through Stat5 in Erythropoietin-dependent progenitor cell lines .	target	1
5036	10428782	5609;3725	MKK7;c-Jun	However , ***MKK7*** ( D ) , a constitutive ***activator*** of ***c-Jun*** N-terminal kinases , failed to inhibit these TNF actions .	positive	1
5037	10428782	1432;4790	p38;NF-kappaB	Thus , sustained ***p38*** activation by various stimuli ***inhibits*** TNF-induced IkappaB phosphorylation and ***NF-kappaB*** activation .	negative	1
5038	10428782	1432;4790	p38 MAP kinase;NF-kappaB	Cell stress and MKK6b-mediated ***p38 MAP kinase*** activation ***inhibit*** tumor necrosis factor-induced IkappaB phosphorylation and ***NF-kappaB*** activation .	negative	1
5039	10428799	376267;7037	Rab15;transferrin receptor	Our biochemical and confocal immunofluorescence studies demonstrate that ***Rab15*** ***associates*** with the ***transferrin receptor*** , a marker for the early endocytic pathway , but not with Rab7 or the cation-independent mannose 6-phosphate receptor , markers for late endosomal membranes .	parallel	0
5040	10428807	5511;5499	NIPP-1;PP1alpha	Deletion of C-terminal sequences that included the beta12-beta13 loop attenuated the ***inhibition*** of the resulting ***PP1alpha*** catalytic core by I-1 , I-2 , ***NIPP-1*** , and several toxins , including tautomycin , microcystin-LR , calyculin A , and okadaic acid .	negative	1
5041	10428811	28964;8874	Cat-1;p85	***Cat-1*** and Cat-2 both ***bind*** to the COOH-terminal region of ***p85*** ( Cool-1 ) and p85 ( Cool-2 ) but do not bind to p50 ( Cool-1 ) .	parallel	1
5042	10428811	9815;8874	Cat-2;p85	Cat-1 and ***Cat-2*** both ***bind*** to the COOH-terminal region of ***p85*** ( Cool-1 ) and p85 ( Cool-2 ) but do not bind to p50 ( Cool-1 ) .	parallel	1
5043	10428812	3458;3717	interferon-gamma;Jak2	The ***interferon-gamma-activated*** tyrosine ***phosphorylation*** of ***Jak2*** and Stat3 was independent of the extracellular matrix .	target	1
5044	10428812	3458;6774	interferon-gamma;Stat3	The ***interferon-gamma-activated*** tyrosine ***phosphorylation*** of Jak2 and ***Stat3*** was independent of the extracellular matrix .	target	1
5045	10428814	958;5599	CD40;Jun N-terminal kinase	Differential requirements for tumor necrosis factor receptor-associated factor family proteins in ***CD40-mediated*** ***induction*** of NF-kappaB and ***Jun N-terminal kinase*** activation .	target	1
5046	10428814	958;4790	CD40;NF-kappaB	Differential requirements for tumor necrosis factor receptor-associated factor family proteins in ***CD40-mediated*** ***induction*** of ***NF-kappaB*** and Jun N-terminal kinase activation .	target	1
5047	10428814	9618;958	TRAF4;CD40	In contrast to TRAF2 and TRAF3 , direct ***binding*** of TRAF1 , ***TRAF4*** , TRAF5 , or TRAF6 to ***CD40*** was not detected .	parallel	1
5048	10428814	7188;958	TRAF5;CD40	In contrast to TRAF2 and TRAF3 , direct ***binding*** of TRAF1 , TRAF4 , ***TRAF5*** , or TRAF6 to ***CD40*** was not detected .	parallel	1
5049	10428814	7189;958	TRAF6;CD40	In contrast to TRAF2 and TRAF3 , direct ***binding*** of TRAF1 , TRAF4 , TRAF5 , or ***TRAF6*** to ***CD40*** was not detected .	parallel	1
5050	10428814	7188;958	TRAF5;CD40	However , ***TRAF5*** could be ***recruited*** to wild-type ***CD40*** in a TRAF3-dependent manner but not to a CD40 mutant ( Q263A ) that selectively fails to bind TRAF3 .	target	0
5051	10428814	958;4790	CD40;NF-kappaB	A carboxyl-truncation mutant of CD40 lacking the last 32 amino acids required for TRAF2 and TRAF3 binding , ***CD40*** ( Delta32 ) , ***mediated*** ***NF-kappaB*** induction through a mechanism that was suppressible by co-expression of TRAF6 ( DeltaN ) , a dominant-negative version of TRAF6 , but not by TRAF2 ( DeltaN ) , implying that while TRAF6 does not directly bind CD40 , it can participate in CD40 signaling .	target	0
5052	10428814	958;5599	CD40;JNK	Taken together , these findings reveal redundancy in the involvement of TRAF family proteins in CD40-mediated NF-kappaB induction and suggest that the membrane-proximal region of ***CD40*** may ***stimulate*** the ***JNK*** pathway through a TRAF-independent mechanism .	positive	0
5053	10428824	6776;6777	STAT5A;STAT5B	In this study , DNA ***binding*** and tyrosine phosphorylation of ***STAT5A*** and ***STAT5B*** were compared with their subcellular localization determined using indirect immunofluorescence microscopy .	parallel	1
5054	10428824	5617;6776	prolactin;STAT5A	Furthermore , overexpression of a dominant negative kinase-inactive mutant of JAK2 prevented ***prolactin-induced*** tyrosine ***phosphorylation*** and nuclear translocation of ***STAT5A*** and STAT5B but did not block src kinase activation and nuclear translocation of STAT5B .	target	1
5055	10428824	5617;6777	prolactin;STAT5B	Furthermore , overexpression of a dominant negative kinase-inactive mutant of JAK2 prevented ***prolactin-induced*** tyrosine ***phosphorylation*** and nuclear translocation of STAT5A and ***STAT5B*** but did not block src kinase activation and nuclear translocation of STAT5B .	target	1
5056	10428824	5617;6777	prolactin;STAT5B	In co-transfection assays , ***prolactin-mediated*** ***activation*** but not src kinase-mediated activation of ***STAT5B*** resulted in the induction of a beta-casein promoter-driven reporter construct .	positive	1
5057	10428835	627;5594	brain-derived neurotrophic factor;ERK	Here , we report that ***brain-derived neurotrophic factor*** ( BDNF ) protects cortical neurons against apoptosis induced by camptothecin or serum deprivation and ***activates*** the extracellular-signal-regulated kinase ( ***ERK*** ) and the phosphatidylinositol 3-kinase ( PI 3-kinase ) pathways .	positive	1
5058	10428842	10499;2104	GRIP1;ERR3	The ERR3 AF-2 domain bound GRIP1 in a ligand-independent manner both in vitro and in vivo , through the LXXLL motifs of GRIP1 , and ***GRIP1*** functioned as a transcriptional ***coactivator*** for ***ERR3*** in both yeast and mammalian cells .	positive	1
5059	10428842	2104;10499	ERR3;GRIP1	The ***ERR3*** AF-2 domain ***bound*** ***GRIP1*** in a ligand-independent manner both in vitro and in vivo , through the LXXLL motifs of GRIP1 , and GRIP1 functioned as a transcriptional coactivator for ERR3 in both yeast and mammalian cells .	parallel	1
5060	10428849	1958;4323	Egr-1;membrane type 1 matrix metalloproteinase	***Egr-1*** ***mediates*** extracellular matrix-driven transcription of ***membrane type 1 matrix metalloproteinase*** in endothelium .	target	0
5061	10428849	1958;4323	Egr-1;MT1-MMP	Increased ***binding*** of ***Egr-1*** to the ***MT1-MMP*** promoter correlates with enhanced transcriptional activity , whereas mutations in the Egr-1 binding site abrogate the increased transcription of MT1-MMP in the stimulated cells .	parallel	1
5062	10428850	317;842	apoptotic protease-activating factor;caspase-9	In mammals , ***apoptotic protease-activating factor*** 1 ( Apaf-1 ) , cytochrome c , and dATP ***activate*** ***caspase-9*** , which initiates the postmitochondrial-mediated caspase cascade by proteolytic cleavage/activation of effector caspases to form active approximately 60-kDa heterotetramers .	positive	1
5063	10428852	183;207	angiotensin II;Akt	Reactive oxygen species mediate the ***activation*** of ***Akt/protein kinase B*** by ***angiotensin II*** in vascular smooth muscle cells .	positive	1
5064	10428852	183;2185	angiotensin II;protein kinase B	Reactive oxygen species mediate the ***activation*** of ***Akt/protein kinase B*** by ***angiotensin II*** in vascular smooth muscle cells .	positive	1
5065	10428852	183;207	angiotensin II;Akt	Both ***angiotensin II*** and H ( 2 ) O ( 2 ) ***stimulation*** of ***Akt/PKB*** are abrogated by the phosphatidylinositol 3-kinase ( PI3-K ) inhibitors wortmannin and LY294002 ( 2 ( 4-morpholinyl ) -8 - phenyl-4H-1-benzopyran-4-one ) , suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs .	positive	0
5066	10428863	7020;9892	AP-2;AP180	We find that there is a direct , clathrin-independent interaction between AP180 and AP-2 and that the ******AP180-AP-2****** ***complex*** is more efficient at assembling clathrin under physiological conditions than is either protein alone .	parallel	1
5067	10428863	7020;9892	AP-2;AP180	We find that there is a direct , clathrin-independent ***interaction*** between ***AP180*** and ***AP-2*** and that the AP180-AP-2 complex is more efficient at assembling clathrin under physiological conditions than is either protein alone .	parallel	1
5068	10428863	9892;7020	AP180;AP-2	We find that recombinant AP180 is a substrate for casein kinase II in vitro and that its phosphorylation weakens both the ***binding*** of ***AP-2*** by ***AP180*** and the cooperative clathrin assembly activity of these proteins .	parallel	1
5069	10428863	7020;9892	AP-2;AP180	The AP180/AP-2 interaction can be disrupted by a recombinant AP180 fragment containing the AP-2 binding site , and this fragment also disrupts the cooperative clathrin assembly activity of the ******AP180-AP-2****** ***complex*** .	parallel	1
5070	10428863	7020;9892	AP-2;AP180	The ******AP180/AP-2****** ***interaction*** can be disrupted by a recombinant AP180 fragment containing the AP-2 binding site , and this fragment also disrupts the cooperative clathrin assembly activity of the AP180-AP-2 complex .	parallel	1
5071	10428863	9892;7020	AP180;AP-2	The ***AP180/AP-2*** interaction can be ***disrupted*** by a recombinant ***AP180*** fragment containing the AP-2 binding site , and this fragment also disrupts the cooperative clathrin assembly activity of the AP180-AP-2 complex .	negative	0
5072	10428863	7020;9892	AP-2;AP180	These results indicate that ***AP180*** and ***AP-2*** ***interact*** directly to form a complex that assembles clathrin more efficiently than either protein alone .	parallel	1
5073	10428867	4831;4609	NM23-H2;c-MYC	Most NM23 proteins have phosphotransferase ( nucleoside diphosphate kinase ) activity , and the second human isoform , ***NM23-H2*** , also ***binds*** to a nuclease-hypersensitive ***c-MYC*** promoter element through which it activates c-MYC transcription .	parallel	1
5074	10428876	9970;5465	Orphan nuclear hormone receptor;PPARalpha	Here we demonstrate that the ***Orphan nuclear hormone receptor*** , RevErbalpha , ***modulates*** ***PPARalpha/RXRalpha*** - dependent transactivation in a response element-specific manner .	target	0
5075	10428961	8312;51176	Axin;LEF-1	The observation that the Dvl-binding domain of either Frat1 or ***Axin*** was able to ***inhibit*** Wnt-1-induced ***LEF-1*** activation suggests that the interactions between Dvl and Axin and between Dvl and Frat may be important for this signaling pathway .	negative	1
5076	10428961	10023;51176	Frat1;LEF-1	The observation that the Dvl-binding domain of either ***Frat1*** or Axin was able to ***inhibit*** Wnt-1-induced ***LEF-1*** activation suggests that the interactions between Dvl and Axin and between Dvl and Frat may be important for this signaling pathway .	negative	1
5077	10428961	10023;8312	Frat1;Axin	Furthermore , Wnt-1 appeared to promote the disintegration of the ******Frat1-Dvl-GSK-Axin****** ***complex*** , resulting in the dissociation of GSK from Axin .	parallel	1
5078	10428963	3821;3824	NKG2-A;CD94	Kinetics and peptide dependency of the ***binding*** of the inhibitory NK receptor ******CD94/NKG2-A****** and the activating receptor CD94/NKG2-C to HLA-E .	parallel	1
5079	10428963	3824;3133	CD94;HLA-E	We show first that these interactions have very fast association and dissociation rate constants , secondly , that the inhibitory CD94/NKG2-A receptor has a higher binding affinity for HLA-E than the activating CD94/NKG2-C receptor and , finally , that ***recognition*** of ***HLA-E*** by both CD94/NKG2-A and ***CD94/NKG2-C*** is peptide dependent .	target	1
5080	10428963	3821;3133	NKG2-A;HLA-E	We show first that these interactions have very fast association and dissociation rate constants , secondly , that the inhibitory CD94/NKG2-A receptor has a higher binding affinity for HLA-E than the activating CD94/NKG2-C receptor and , finally , that ***recognition*** of ***HLA-E*** by both ***CD94/NKG2-A*** and CD94/NKG2-C is peptide dependent .	target	1
5081	10428963	3822;3133	NKG2-C;HLA-E	We show first that these interactions have very fast association and dissociation rate constants , secondly , that the inhibitory CD94/NKG2-A receptor has a higher binding affinity for HLA-E than the activating CD94/NKG2-C receptor and , finally , that ***recognition*** of ***HLA-E*** by both CD94/NKG2-A and ***CD94/NKG2-C*** is peptide dependent .	target	1
5082	10428965	2101;6696	ERRalpha;osteopontin	Accordingly , the ***osteopontin*** gene promoter is ***stimulated*** through SFRE sequences , by ***ERRalpha*** as well as by ERalpha , but not by ERbeta .	positive	0
5083	10428966	1869;990	E2F-1;p62	We demonstrate that TFIIH is responsible for the E2F-1 phosphorylation observed in cell extracts and that endogenous ***E2F-1*** ***interacts*** in vivo with ***p62*** , a component of TFIIH , during S phase .	parallel	1
5084	10428982	3931;1071	LCAT;CETP	Plasma ***CETP*** and PLTP activity levels were ***increased*** by 34.8 + / - 30.4 % ( P < 0.02 ) and by 15.9 + / - 6.4 % ( P < 0.02 ) , respectively , but ***LCAT*** activity was then unaltered .	positive	0
5085	10428982	3931;5360	LCAT;PLTP	Plasma CETP and ***PLTP*** activity levels were ***increased*** by 34.8 + / - 30.4 % ( P < 0.02 ) and by 15.9 + / - 6.4 % ( P < 0.02 ) , respectively , but ***LCAT*** activity was then unaltered .	positive	0
5086	10429185	7037;7018	TfR;transferrin	These results were compared to the expression of ***transferrin*** ***receptor*** ( ***TfR*** ) mRNA which also has IREs in its 3 ' - UTR and is regulated by Fe and NO via the binding of iron-regulatory proteins ( IRPs ) to its IREs .	parallel	1
5087	10429446	7035;2152	TFPI;tissue factor	Vascular endothelial cells play a critical role in the regulation of coagulation and fibrinolysis by controlling the expression of tissue factor ( TF ) , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , plasminogen activator inhibitor-1 ( PAI-1 ) , and tissue type plasminogen activator ( TPA ) .	negative	1
5088	10429668	914;962	CD2;CD48	Although the interaction of CD2 on T cells with wild-type or shortened forms of CD48 on APCs enhances T cell antigen recognition , the ***interaction*** of ***CD2*** with elongated forms of ***CD48*** is strongly inhibitory .	parallel	1
5089	10429668	914;962	CD2;CD48	Further experiments indicated that elongation of the ******CD2/CD48****** ***complex*** inhibited TCR engagement of peptide-MHC , presumably by preventing the formation of sufficiently intimate contacts at the T cell/APC interface .	parallel	1
5090	10429761	355;356	Fas;Fas ligand	Localization of the Th2 cytokines IL-3 , IL-4 , IL-10 at the fetomaternal interface during human and murine pregnancy and lack of requirement for ******Fas/Fas ligand****** ***interaction*** for a successful allogeneic pregnancy .	parallel	1
5091	10429761	355;356	Fas;Fas ligand	PROBLEM : Th2 cytokines and ******Fas/Fas ligand****** ***interactions*** are proposed to be part of the placental barrier that contribute to the success of allogeneic pregnancy .	parallel	1
5092	10429761	355;356	Fas;Fas ligand	We also need to assess the requirement for ******Fas/Fas ligand****** ***interaction*** in facilitating a successful allogeneic pregnancy .	parallel	1
5093	10429761	355;356	Fas;Fas ligand	We used mice that are genetically deficient in ******Fas/Fas ligand****** ***interactions*** and raised specific anti-paternal CTLs by anti-paternal immunization of the mother before mating .	parallel	1
5094	10429761	355;356	Fas;Fas ligand	CONCLUSIONS : The success of allopregnancy in mice with circulating anti-paternal CTLs and deficient ******Fas/Fas ligand****** ***interactions*** rules out a mandatory role for such a mechanism in ensuring the success of allogeneic pregnancy .	parallel	1
5095	10429946	4605;1278	B-Myb;alpha 2(V) collagen	Ectopic expression of ***B-Myb*** ***decreased*** alpha 2 ( V ) promoter activity and endogenous ***alpha 2(V) collagen*** mRNA levels .	negative	0
5096	10429981	7157;5111	p53;PCNA	In actinic keratosis , only half of the specimens showed overexpression of ***p53*** ***associated*** with moderate or intense expression of ***PCNA*** .	parallel	0
5097	10430035	3458;10379	interferon-gamma;ISGF3	***Activation*** of the transcription factor ***ISGF3*** by ***interferon-gamma*** .	positive	1
5098	10430082	5225;5241	PepC;progesterone receptor	Statistically significant ***associations*** of ***PepC*** concentration with patient age and estrogen receptor and ***progesterone receptor*** status were not observed .	parallel	0
5099	10430177	5443;7077	ACTH;Tissue inhibitor of metalloproteinase-2	***Tissue inhibitor of metalloproteinase-2*** ( TIMP-2 ) expression is strongly ***induced*** by ***ACTH*** in adrenocortical cells .	target	1
5100	10430177	5443;7077	ACTH;TIMP-2	The ***induction*** of ***TIMP-2*** by ***ACTH*** required transcription , was mimicked by 8-bromo cyclic 3 ' -5 ' adenosine monophosphate , but was not observed in response to angiotensin II , IGF-1 , fibroblast growth factor-2 , transforming growth factor-beta1 , or cortisol treatments .	target	1
5101	10430177	5443;7077	ACTH;TIMP-2	***ACTH*** ***stimulated*** ***TIMP-2*** mRNA levels by a factor 4 , whereas TIMP-1 mRNA levels were not affected and TIMP-3 mRNA remained undetectable .	positive	0
5102	10430178	3565;7412	IL-4;vascular cell adhesion molecule-1	***Induction*** of ***vascular cell adhesion molecule-1*** expression by ***IL-4*** in human aortic smooth muscle cells is not associated with increased nuclear NF-kappaB levels .	target	1
5103	10430178	7124;3383	TNF-alpha;ICAM-1	Tumor necrosis factor-alpha ( ***TNF-alpha*** ) ***induced*** both VCAM-1 and ***ICAM-1*** expression in human umbilical vein endothelial cells ( HUVECs ; ED50 approximately 300 and 30 U/ml , respectively ) .	target	1
5104	10430178	7124;7412	TNF-alpha;VCAM-1	Tumor necrosis factor-alpha ( ***TNF-alpha*** ) ***induced*** both ***VCAM-1*** and ICAM-1 expression in human umbilical vein endothelial cells ( HUVECs ; ED50 approximately 300 and 30 U/ml , respectively ) .	target	1
5105	10430178	3553;3383	IL-1beta;ICAM-1	TNF-alpha and interleukin-1beta ( ***IL-1beta*** ) ***stimulated*** cell surface ***ICAM-1*** expression , but not VCAM-1 expression , in human aortic smooth muscle cells ( HASMCs ) .	positive	0
5106	10430178	7124;3383	TNF-alpha;ICAM-1	***TNF-alpha*** and interleukin-1beta ( IL-1beta ) ***stimulated*** cell surface ***ICAM-1*** expression , but not VCAM-1 expression , in human aortic smooth muscle cells ( HASMCs ) .	positive	0
5107	10430178	3553;4790	IL-1beta;NF-kappaB	***IL-1beta*** and TNF-alpha ***stimulated*** nuclear ***NF-kappaB*** levels by about fourfold and fivefold , respectively , in HASMCs .	positive	0
5108	10430178	7124;4790	TNF-alpha;NF-kappaB	IL-1beta and ***TNF-alpha*** ***stimulated*** nuclear ***NF-kappaB*** levels by about fourfold and fivefold , respectively , in HASMCs .	positive	0
5109	10430489	627;4804	brain-derived neurotrophic factor;p75	The possibility that MC192 or ***brain-derived neurotrophic factor*** might ***activate*** ***p75*** signaling directly ( and potentially antagonize TrkA signaling ) was also investigated .	positive	1
5110	10430489	4914;4804	TrkA;p75	Our results demonstrate that both TrkA and p75 play a role in neurite growth response to nerve growth factor , and further suggest that any alteration in optimal ******TrkA-p75****** ***interactions*** , or direct activation of p75 at the expense of TrkA , results in an inhibition of nerve growth factor-dependent neurite growth in adult sensory neurons .	parallel	1
5111	10430489	4803;4804	nerve growth factor;p75	brain-derived neurotrophic factor and the anti-p75 monoclonal antibody MC192 have been shown to interfere with the ***binding*** of ***nerve growth factor*** to ***p75*** .	parallel	1
5112	10430489	4803;4914	nerve growth factor;TrkA	brain-derived neurotrophic factor , which binds p75 but not TrkA , competes with nerve growth factorforp75 , while the anti-p75 antibody MC192 has been shown to decrease the ***interaction*** of ***nerve growth factor*** with ***TrkA*** .	parallel	1
5113	10430489	627;4804	brain-derived neurotrophic factor;p75	***brain-derived neurotrophic factor*** , which ***binds*** ***p75*** but not TrkA , competes with nerve growth factorforp75 , while the anti-p75 antibody MC192 has been shown to decrease the interaction of nerve growth factor with TrkA .	parallel	1
5114	10430606	2587;51083	Gal1-R;galanin	We have shown previously that ***galanin-1*** ***receptors*** ( ***Gal1-R*** ) are expressed by epithelial cells lining the human GI tract , and upon activation cause Cl - secretion .	parallel	1
5115	10430606	4790;5970	p50;p65	Pathogenic Escherichia coli , but not nonpathogenic E. coli , activate a ******p50/p65****** NF-kappa B ***complex*** that binds to oligonucleotides corresponding to a recognition site located within the 5 ' flanking region of the human GAL1R gene .	parallel	1
5116	10430608	3553;7099	IL-1beta;TLR4	***TLR4*** expression levels in cardiac myocytes and in coronary microvascular endothelial cells could be ***enhanced*** by either LPS or ***IL-1beta*** , an effect inhibited by the oxygen radical scavenger PDTC .	positive	0
5117	10430620	115209;2191	peptidase;DPPIV	Reexpression of either wild-type or mutant DPPIV rescued expression of a second putative cell surface serine ***peptidase*** , fibroblast activation protein alpha , which can form a ***heterodimer*** with ***DPPIV*** .	parallel	1
5118	10430621	3502;3565	IgG3;IL-4	Splenic B cells from mice deficient in Msh2 , Mlh1 , Pms2 , or Mlh1 and Pms2 were stimulated in culture with lipopolysaccharide ( LPS ) to induce immunoglobulin ( Ig ) G2b and ***IgG3*** , LPS and interleukin ( IL ) -4 to ***induce*** IgG1 , or LPS , anti-delta-dextran , ***IL-4*** , IL-5 , and transforming growth factor ( TGF ) - beta1 to induce IgA .	target	1
5119	10430621	3502;3567	IgG3;IL-5	Splenic B cells from mice deficient in Msh2 , Mlh1 , Pms2 , or Mlh1 and Pms2 were stimulated in culture with lipopolysaccharide ( LPS ) to induce immunoglobulin ( Ig ) G2b and ***IgG3*** , LPS and interleukin ( IL ) -4 to ***induce*** IgG1 , or LPS , anti-delta-dextran , IL-4 , ***IL-5*** , and transforming growth factor ( TGF ) - beta1 to induce IgA .	target	1
5120	10430626	940;3932	CD28;Lck	Supporting a role for Lck in CD28 signaling , we demonstrate that ***CD28*** signaling in both transformed and primary T cells ***requires*** ***Lck*** as well as proline residues in CD28 .	target	0
5121	10430748	4790;5970	p50;p65	Endotoxin increased NF-kappaB ******p50/p65****** heterodimer ***binding*** .	parallel	1
5122	10430771	93210;718	CAB-2;C3a	***CAB-2*** , a chimeric protein constructed from genes encoding the complement regulatory proteins CD46 and CD55 , inactivates the C3/C5 convertases and ***blocks*** in vitro generation of ***C3a*** , C5a , and C5b-9 .	negative	0
5123	10430771	93210;727	CAB-2;C5a	***CAB-2*** , a chimeric protein constructed from genes encoding the complement regulatory proteins CD46 and CD55 , inactivates the C3/C5 convertases and ***blocks*** in vitro generation of C3a , ***C5a*** , and C5b-9 .	negative	0
5124	10430771	93210;718	CAB-2;C3a	***CAB-2*** at both doses significantly ***inhibited*** formation of ***C3a*** and C5b-9 during SECC .	negative	1
5125	10430771	93210;3684	CAB-2;CD11b	High-dose ***CAB-2*** significantly ***blocked*** monocyte and PMN ***CD11b*** upregulation and PMN elastase release .	negative	0
5126	10430771	93210;1991	CAB-2;PMN elastase	High-dose ***CAB-2*** significantly ***blocked*** monocyte and PMN CD11b upregulation and ***PMN elastase*** release .	negative	0
5127	10430786	5054;5328	PAI-1;uPA	BACKGROUND : The complex between urokinase ( ***uPA*** ) and its type-1 ***inhibitor*** ( ***PAI-1*** ) is formed exclusively from the active forms of these components ; thus , the complex concentration in a biological sample may reflect the ongoing degree of plasminogen activation .	negative	1
5128	10430786	5328;5054	uPA;PAI-1	BACKGROUND : The ***complex*** between urokinase ( ***uPA*** ) and its type-1 inhibitor ( ***PAI-1*** ) is formed exclusively from the active forms of these components ; thus , the complex concentration in a biological sample may reflect the ongoing degree of plasminogen activation .	parallel	1
5129	10430878	3175;2908	HNF-6;glucocorticoid receptor	In vitro and in vivo experiments suggest that this inhibition is mediated by a direct ******HNF-6/glucocorticoid receptor****** ***interaction*** involving the amino-terminal domain of HNF-6 and the DNA-binding domain of the receptor .	parallel	1
5130	10430888	5747;5335	FAK;PLC-gamma1	Overexpression of ***FAK*** and PLC-gamma1 in COS-7 cells ***increases*** ***PLC-gamma1*** enzymatic activity and tyrosine phosphorylation , also dependent on FAK Tyr-397 .	positive	0
5131	10430890	6924;6921	elongin A;elongin C	Binding of ***elongin A*** or a von Hippel-Lindau peptide ***stabilizes*** the structure of yeast ***elongin C*** .	positive	0
5132	10430890	6921;6924	elongin C;elongin A	Mammalian ***elongin C*** ***interacts*** with both ***elongin A*** and elongin B , as well as with the von Hippel-Lindau tumor suppressor protein VHL .	parallel	1
5133	10430890	6921;7428	elongin C;VHL	Mammalian ***elongin C*** ***interacts*** with both elongin A and elongin B , as well as with the von Hippel-Lindau tumor suppressor protein ***VHL*** .	parallel	1
5134	10430899	11135;998	MSE55;Cdc42	Using glutathione S-transferase-capture experiments , we show that ***MSE55*** ***binds*** to ***Cdc42*** in a GTP-dependent manner .	parallel	1
5135	10430899	11135;998	MSE55;Cdc42	***MSE55*** ***binding*** to ***Cdc42*** required an intact CRIB domain , because a MSE55 CRIB domain mutant no longer interacted with Cdc42 .	parallel	1
5136	10430908	4790;598	NF-kappaB;Bcl-x	***NF-kappaB-mediated*** ***up-regulation*** of ***Bcl-x*** and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes .	positive	1
5137	10430908	4790;597	NF-kappaB;Bfl-1	***NF-kappaB-mediated*** ***up-regulation*** of Bcl-x and ***Bfl-1/A1*** is required for CD40 survival signaling in B lymphocytes .	positive	1
5138	10430908	958;598	CD40;Bcl-x	Inhibition of the NF-kappaB pathway by overexpression of a dominant-active inhibitor of NF-kappaB abolished ***CD40-induced*** ***up-regulation*** of both the Bfl-1 and ***Bcl-x*** genes and also eliminated the ability of CD40 to rescue Fas-induced cell death .	positive	1
5139	10430908	958;597	CD40;Bfl-1	Inhibition of the NF-kappaB pathway by overexpression of a dominant-active inhibitor of NF-kappaB abolished ***CD40-induced*** ***up-regulation*** of both the ***Bfl-1*** and Bcl-x genes and also eliminated the ability of CD40 to rescue Fas-induced cell death .	positive	1
5140	10430952	4915;627	TrkB;BDNF	***Sequestration*** of endogenous ***BDNF/neurotrophin 4*** by intraspinal ***TrkB-Fc*** fusion protein administration does not , in noninflamed animals , change basal pain sensitivity nor the mechanical hypersensitivity induced by peripheral capsaicin administration , a measure of C fiber-mediated central sensitization .	negative	0
5141	10430952	4915;4909	TrkB;neurotrophin 4	***Sequestration*** of endogenous ***BDNF/neurotrophin 4*** by intraspinal ***TrkB-Fc*** fusion protein administration does not , in noninflamed animals , change basal pain sensitivity nor the mechanical hypersensitivity induced by peripheral capsaicin administration , a measure of C fiber-mediated central sensitization .	negative	0
5142	10430956	4792;4790	IkappaB-alpha;NF-kappaB	Overexpression of a transdominant negative ***IkappaB-alpha*** ***blocks*** ***NF-kappaB*** activation and potentiates Abeta-mediated neuronal apoptosis .	negative	0
5143	10431249	6736;55534	Sry;CAG repeat domain	***Sry*** ***requires*** a ***CAG repeat domain*** for male sex determination in Mus musculus .	target	0
5144	10431389	1581;3156	cholesterol 7 alpha-hydroxylase;3-hydroxy-3-methylglutaryl coenzyme A reductase	In vivo and in vitro studies on the regulatory ***link*** between ***3-hydroxy-3-methylglutaryl coenzyme A reductase*** and ***cholesterol 7 alpha-hydroxylase*** in rat liver .	parallel	0
5145	10431850	4233;3082	c-met;HGF	Immunoperoxidase studies of hepatocyte growth factor ( ***HGF*** ) and its ***receptor*** , ***c-met*** , were positive .	parallel	1
5146	10431997	3569;4312	IL-6;MMP-1	The increased ***IL-6*** production may ***induce*** ***MMP-1*** , leading to tissue organ injury .	target	1
5147	10432118	3565;246	Interleukin-4;12/15-lipoxygenase	In monocytes and macrophages , 13-HODE and 15-HETE can be generated from linoleic and arachidonic acids , respectively , by a ***12/15-lipoxygenase*** that is ***upregulated*** by the TH2-derived cytokine ***Interleukin-4*** .	positive	1
5148	10432118	3565;5468	Interleukin-4;PPAR-gamma	Here we show that ***Interleukin-4*** also ***induces*** the expression of ***PPAR-gamma*** and provide evidence that the coordinate induction of PPAR-gamma and 12/15-lipoxygenase mediates Interleukin-4-dependent transcription of the CD36 gene in macrophages .	target	1
5149	10432219	4879;1392	BNP;CRF	Atrial natriuretic peptide ( ANP ) , brain natriuretic peptide ( ***BNP*** ) and C-type natriuretic peptide ( CNP ) all ***inhibited*** ***CRF*** ( 10 ( -9 ) M ) - evoked ACTH secretion over a concentration range of 10 ( -12 ) -10 ( -10 ) M and also stimulated cyclic GMP accumulation over a concentration range of 10 ( -8 ) -10 ( -5 ) M.	negative	1
5150	10432219	4880;1392	CNP;CRF	Atrial natriuretic peptide ( ANP ) , brain natriuretic peptide ( BNP ) and C-type natriuretic peptide ( ***CNP*** ) all ***inhibited*** ***CRF*** ( 10 ( -9 ) M ) - evoked ACTH secretion over a concentration range of 10 ( -12 ) -10 ( -10 ) M and also stimulated cyclic GMP accumulation over a concentration range of 10 ( -8 ) -10 ( -5 ) M.	negative	1
5151	10432227	2492;3973	FSHR;LHR	Its ability to distinguish ***LHR*** and follitropin ***receptors*** ( ***FSHR*** ) is controlled by 20 beta-subunit ' seatbelt ' residues that surround alpha-subunit loop 2 .	parallel	1
5152	10432231	2113;2078	c-Ets-1;Ets-related	Expression of the DNA-binding domain of ***c-Ets-1*** , which acts as a dominant negative ***inhibitor*** of ***Ets-related*** transcription factors , reduces EGF-increased prolactin-CAT expression 65 % in GH4 cells .	negative	1
5153	10432236	5744;2252	PTHrP;KGF	N-terminal ***PTHrP*** ( 1-36 ) ***increased*** ***KGF*** secretion , protein expression and mRNA expression by NHDF in a dose-dependent manner , however , KGF did not regulate PTHrP expression and secretion by NHFK .	positive	0
5154	10432236	5744;2252	PTHrP;KGF	Our results indicate that ***PTHrP*** produced by keratinocytes is a potential paracrine ***regulator*** of ***KGF*** expression by dermal fibroblasts in vivo .	target	1
5155	10432301	836;1965	caspase-3;eIF-2alpha	In addition , ***eIF-2alpha*** was ***cleaved*** by recombinant active ***caspase-3*** in vitro .	target	1
5156	10432301	5610;1965	PKR;eIF-2alpha	***PKR*** ***phosphorylates*** ***eIF-2alpha*** on Ser ( 51 ) , resulting in the suppression of protein synthesis .	target	1
5157	10432304	1906;1432	Endothelin-1;p38 MAP kinase	***Endothelin-1*** ***stimulated*** ***p38 MAP kinase*** activity in a time - and concentration-dependent manner , and these effects were mediated through the endothelin-A receptor subtype .	positive	0
5158	10432304	1906;1432	Endothelin-1;p38 MAP kinase	The protein kinase C ( PKC ) inhibitor , RO 31-8220 , had no inhibitory effect on Endothelin-1-induced p38 MAP kinase activation , suggesting that ***Endothelin-1*** ***activation*** of ***p38 MAP kinase*** is independent of PKC .	positive	1
5159	10432313	4254;4067	SCF;Lyn	These findings demonstrate that ***SCF*** ***activates*** the Src family member ***Lyn*** before the G ( 1 ) / S transition of the cell cycle and suggest that Lyn is involved in SCF-induced cell cycle progression .	positive	1
5160	10432313	4254;3815	SCF;c-Kit	Stem cell factor ( ***SCF*** ) ***binds*** the receptor tyrosine kinase ***c-Kit*** and is critical in haemopoiesis .	parallel	1
5161	10432313	4067;3815	Lyn;c-Kit	Recently we found that the Src family member ***Lyn*** is highly expressed in SCF-responsive cells , ***associates*** with ***c-Kit*** and is activated within minutes of the addition of SCF .	parallel	0
5162	10432313	4254;4067	SCF;Lyn	Here we show that ***SCF*** ***activates*** ***Lyn*** a second time , hours later , during SCF-induced cell cycle progression .	positive	1
5163	10432313	4067;1017	Lyn;Cdk2	***Lyn*** was ***associated*** with ***Cdk2*** ; Cdk2-associated Lyn was heavily phosphorylated on serine and threonine residues both in vitro and in situ during S-phase .	parallel	0
5164	10432383	3172;213	HNF-4;albumin	***HNF-4*** mRNA was increased approximately twofold in both NS groups and ***correlated*** with ***albumin*** ( R = 0.881 , P < 0.001 ) , transferrin ( R = 0.563 , P = 0.012 ) and apo A-1 ( R = 0.644 , P = 0 .	parallel	0
5165	10432395	5741;6550	PTH;NHE-3	Parathyroid hormone ( ***PTH*** ) induced a tenfold increase in cAMP and ***reduced*** the Na-dependent phosphate uptake and ***NHE-3*** activity , as observed in proximal tubule cells .	negative	1
5166	10432398	5734;820	EP4;cAMP	CONCLUSION : The increase in DNA synthesis in MCs under high-glucose conditions can be explained , at least in part , by the high-glucose-induced ***inhibition*** of ***cAMP*** production via ***EP4*** , which augments EP1 function in conjunction with the overproduction of PGE2 .	negative	1
5167	10432398	5734;5731	EP4;EP1	CONCLUSION : The increase in DNA synthesis in MCs under high-glucose conditions can be explained , at least in part , by the high-glucose-induced inhibition of cAMP production via ***EP4*** , which ***augments*** ***EP1*** function in conjunction with the overproduction of PGE2 .	positive	0
5168	10433070	3553;2572	IL-1beta;GAD-65	We have previously demonstrated that ***IL-1beta*** ***inhibits*** glutamic acid decarboxylase-65 ( ***GAD-65*** ) and increases heat shock protein-70 ( HSP-70 ) expression in islet cells .	negative	1
5169	10433070	3553;2572	IL-1beta;GAD-65	We found that ( 1 ) ***IL-1beta*** at 10 U/ml increased nitrite production , inhibited insulin release , increased HSP-70 expression and ***decreased*** ***GAD-65*** expression .	negative	0
5170	10433070	3553;3308	IL-1beta;HSP-70	We found that ( 1 ) ***IL-1beta*** at 10 U/ml increased nitrite production , inhibited insulin release , ***increased*** ***HSP-70*** expression and decreased GAD-65 expression .	positive	0
5171	10433081	3606;3553	IL-18;IL-1beta	It was also tested if ***IL-18*** ( 10 nM ) could ***affect*** ***IL-1beta*** ( 25 U/ml ) induced suppression of the glucose oxidation rate , but this was not the case .	target	0
5172	10433177	1392;5443	corticotropin-releasing hormone;adrenocorticotropic hormone	In the corticotroph-like murine pituitary tumor cell line , AtT-20 , ***adrenocorticotropic hormone*** release is ***triggered*** by ***corticotropin-releasing hormone*** and is attenuated by the synthetic adrenal steroid dexamethasone .	positive	0
5173	10433204	3553;3488	IL-1beta;IGFBP-4 and -5	Our findings also suggest , by inference , that the ***IL-1beta-mediated*** ***inhibition*** of ***IGFBP-4 and -5*** transcripts is due in part to a decrease in the rate of transcription of the corresponding genes and not to a change in the stability of the relevant messenger RNAs .	negative	1
5174	10433211	5741;4982	PTH;OPG	After 6 h , ***PTH*** completely ***inhibited*** ***OPG*** mRNA .	negative	1
5175	10433211	5741;4982	PTH;OPG	***PTH*** treatment of calvaria ***decreased*** ***OPG*** expression by 30 % at 6 h.	negative	0
5176	10433211	5741;4982	PTH;OPG	In primary osteoblastic cells , ***PTH*** stimulated TRANCE mRNA expression 4-fold at 2 h and ***inhibited*** ***OPG*** mRNA expression by 46 % .	negative	1
5177	10433211	5741;4982	Parathyroid hormone;osteoprotegerin	***Parathyroid hormone*** stimulates TRANCE and ***inhibits*** ***osteoprotegerin*** messenger ribonucleic acid expression in murine bone marrow cultures : correlation with osteoclast-like cell formation .	negative	1
5178	10433211	5741;4982	PTH;OPG	Reciprocal ***regulation*** of TRANCE and ***OPG*** mRNA by ***PTH*** preceded its effects on OCL formation by 18-23 h.	target	1
5179	10433211	5741;4982	PTH;OPG	In contrast , ***OPG*** mRNA expression was ***decreased*** by 0.1 ng/ml ***PTH*** ( 40 % ) and completely abolished by 1 ng/ml .	negative	0
5180	10433214	6750;2691	somatostatin;GHRH	These observations suggest ***GHRH-R*** mRNA is tonically ***suppressed*** by ***somatostatin*** .	negative	1
5181	10433214	2691;2692	Growth hormone (GH)-releasing hormone;GHRH receptor	***Growth hormone (GH)-releasing hormone*** ( GHRH ) and the GH secretagogue ( GHS ) , L692 ,585 , differentially ***modulate*** rat pituitary GHS receptor and ***GHRH receptor*** messenger ribonucleic acid levels .	target	0
5182	10433215	2798;2796	GnRH-R;GnRH	As previous studies suggest that the pituitary actions of testosterone ( T ) and estradiol ( E ) differ in male primates and rodents , we compared the effects of 10 nM T , 0.1 nM E , and 10 nM dihydrotestosterone ( DHT ) on the LH response to hourly pulses of GnRH as well as the ***GnRH*** ***receptor*** ( ***GnRH-R*** ) and LH subunit messenger RNA ( mRNA ) levels in dispersed pituitary cells from intact male monkeys and rats .	parallel	1
5183	10433224	6513;3479	GLUT1;IGF-I	Northern and Western analysis of GLUT1 in granulosa cells following 24 h coincubation with FSH and IGF-I revealed up-regulation of GLUT1 at both the messenger RNA and protein levels ( 1.6 - and 1.3-fold of control , respectively ) , suggesting that the stimulatory effects of FSH and ***IGF-I*** on DHAA transport are ***mediated*** by the induction of ***GLUT1*** .	target	0
5184	10433233	4803;7425	nerve growth factor;VGF	Furthermore , ***nerve growth factor*** failed to ***stimulate*** ***VGF*** gene expression .	positive	0
5185	10433240	6750;2641	somatostatin;glucagon	***somatostatin*** , also known as somatotropin release-inhibiting factor ( SRIF ) , is secreted by pancreatic delta-cells and ***inhibits*** the secretion of both insulin and ***glucagon*** .	negative	1
5186	10433268	1742;9229	PSD-95;GKAP	Shank , a novel family of postsynaptic density proteins that binds to the NMDA ******receptor/PSD-95/GKAP****** ***complex*** and cortactin .	parallel	1
5187	10433268	9229;1742	GKAP;PSD-95	A ternary ***complex*** of ******Shank/GKAP/PSD-95****** assembles in heterologous cells and can be coimmunoprecipitated from rat brain .	parallel	1
5188	10433268	22941;9229	Shank;GKAP	A ternary ***complex*** of ******Shank/GKAP/PSD-95****** assembles in heterologous cells and can be coimmunoprecipitated from rat brain .	parallel	1
5189	10433268	22941;1742	Shank;PSD-95	A ternary ***complex*** of ******Shank/GKAP/PSD-95****** assembles in heterologous cells and can be coimmunoprecipitated from rat brain .	parallel	1
5190	10433269	22941;9456	Shank;Homer	Here , we report that ***Shank*** proteins also ***bind*** to ***Homer*** .	parallel	1
5191	10433356	3586;3587	IL-10;IL-10R1	***Binding*** of ***IL-10*** to the extracellular domain of ***IL-10R1*** activates phosphorylation of the receptor-associated Janus tyrosine kinases , JAK1 and Tyk2 .	parallel	1
5192	10433365	356;355	FasL;Fas	Significant increases in intrapancreatic mRNA levels of TNF-alpha , ***Fas*** ***ligand*** ( ***FasL*** ) , and IL-1beta-converting enzyme ( ICE ) were observed from day 3 after PDL with the appearance of acinar cell apoptosis .	parallel	1
5193	10433520	2922;5706	bombesin;p42	In PANC-1 cells , EGF and ***bombesin*** ***stimulated*** ***p42*** in gel activation ; p44 remained highly activated and unresponsive to stimuli and p38 did not respond .	positive	0
5194	10433555	3558;6375	IL-2;lymphotactin	Expression of ***SCM-1alpha/lymphotactin*** and SCM-1beta in natural killer cells is ***upregulated*** by ***IL-2*** and IL-12 .	positive	1
5195	10433815	4803;4790	NGF;NF-kappaB	***NGF*** treatment also ***activated*** ***NF-kappaB*** , and preventing this activation with superrepressor IkappaB-alpha reduced the NGF survival response .	positive	1
5196	10433823	3791;7422	Flk-1;VEGF	The expression of ***VEGF*** and its two ***receptors*** , ***Flk-1*** and Flt-1 , is pivotal for the proper formation of blood vessels in embryogenesis as shown by gene-targeting experiments .	parallel	1
5197	10433823	2321;7422	Flt-1;VEGF	The expression of ***VEGF*** and its two ***receptors*** , Flk-1 and ***Flt-1*** , is pivotal for the proper formation of blood vessels in embryogenesis as shown by gene-targeting experiments .	parallel	1
5198	10433828	993;983	Cdc25A;Cdc2	These results indicate that periodic phosphorylation of Cdc2/Cdk2 on tyr15 occurs in each pre-MBT cell cycle , and ***dephosphorylation*** of ***Cdc2/Cdk2*** by ***Cdc25A*** controls at least in part the length of the cell cycle and the timing of cleavage in pre-MBT embryos .	target	1
5199	10433828	993;1017	Cdc25A;Cdk2	These results indicate that periodic phosphorylation of Cdc2/Cdk2 on tyr15 occurs in each pre-MBT cell cycle , and ***dephosphorylation*** of ***Cdc2/Cdk2*** by ***Cdc25A*** controls at least in part the length of the cell cycle and the timing of cleavage in pre-MBT embryos .	target	1
5200	10433873	3562;5580	Interleukin-3;protein kinase C delta	***Interleukin-3*** or immunoglobulin E ***promotes*** expression of ***protein kinase C delta*** gene in murine mast cells .	positive	0
5201	10433921	196;405	Ahr;Arnt	This suggests that the interaction of Ss and Tgo does not require additional signals , unlike the ligand-dependent ***interaction*** of ***Ahr*** and ***Arnt*** .	parallel	1
5202	10433937	7057;948	TSP-1;CD36	However , ***TSP-1*** overexpression ***up-regulated*** the TSP-1 receptor ***CD36*** , leading to enhanced adhesion of A431 cells to TSP-1 .	positive	1
5203	10433995	4803;207	NGF;Akt	To understand this discrepancy , we investigated more closely the ***regulation*** of ***PKB/Akt*** activity by ***NGF*** .	target	1
5204	10433997	5443;5617	beta-endorphin;PRL	During this period , ***beta-endorphin*** ***stimulates*** ***PRL*** secretion by regulation of dopaminergic neurons in the hypothalamus .	positive	0
5205	10434033	23645;7247	GADD34;Translin	Evidence for the ***interaction*** between ***Translin*** and ***GADD34*** in mammalian cells .	parallel	1
5206	10434033	23645;7247	GADD34;Translin	The ***interaction*** between ***GADD34*** and ***Translin*** was also confirmed by an in vitro binding assay and in vivo two-hybrid analysis in NIH 3T3 cells .	parallel	1
5207	10434034	2033;7392	p300;USF2	Here , we demonstrate that the coactivator ***p300*** ***interacts*** functionally with ***USF2*** proteins to potentiate the activation of the ATPA initiator element by USF2 .	parallel	1
5208	10434040	5552;960	serglycin;CD44	***serglycin*** has been shown to be a ***ligand*** for ***CD44*** , a membrane protein expressed in endothelial cells .	parallel	1
5209	10434309	6310;8125	ataxin-1;leucine-rich acidic nuclear protein	Mutant ***ataxin-1*** ***interacts*** preferentially with a ***leucine-rich acidic nuclear protein*** that is abundantly expressed in cerebellar Purkinje cells and other brain regions affected in SCA1 .	parallel	1
5210	10434309	3301;6310	HSDJ;ataxin-1	Moreover , overexpression of the chaperone HDJ-2 / ***HSDJ*** in HeLa cells ***decreased*** ***ataxin-1*** aggregation , suggesting that protein misfolding might underlie NI formation .	negative	0
5211	10434348	958;959	CD40;CD40 ligand	Tumor cell counter-attack against effector T-cells has also been described , using either inhibitory cytokines ( IL-10 ) , apoptosis induction ( via Fas signalling ) , functional inactivation ( disruption of normal ******CD40/CD40 ligand****** ***interactions*** ) , or induction of anergy .	parallel	1
5212	10434569	3596;3497	IL-13;IgE	Both IL-4 and ***IL-13*** ***induce*** ***IgE*** synthesis in B cells by binding to their functional receptors on target cells .	target	1
5213	10434569	3565;3497	IL-4;IgE	Both ***IL-4*** and IL-13 ***induce*** ***IgE*** synthesis in B cells by binding to their functional receptors on target cells .	target	1
5214	10434935	5617;1081	prolactin;hCG	In the oviduct , there was little competition for receptor occupancy between hCG and pig FSH , bovine thyroid-stimulating hormone ( TSH ) , pig growth hormone ( GH ) and pig ***prolactin*** ( 1.2 , 0.1 , 0.01 and < 0.001 % , respectively ) but pig LH could completely ***inhibit*** the binding of [ 125I ] ***hCG*** .	negative	1
5215	10434941	5617;3479	prolactin;IGF-I	The results revealed that ***prolactin*** ***upregulates*** the expression of ***IGF-I*** mRNA in luteal cells , but not that of its receptor .	positive	1
5216	10434941	5617;3479	prolactin;IGF-I	Collectively , the results indicate that ***prolactin*** ***stimulates*** luteal ***IGF-I*** production , which in turn acts on the luteal cell to stimulate expression of oestrogen receptor beta .	positive	0
5217	10435043	3479;5706	IGF-I;p44	While PDGF-BB stimulation of FAK tyrosine phosphorylation is not dependent on p42/p44 MAP kinase activation , PDGF-BB and ***IGF-I*** both ***stimulate*** ***p42/p44*** MAP kinase activity and the chemotactic response to these factors is partially dependent on MAP kinase activation .	positive	0
5218	10435048	3553;2643	IL-1 beta;GTP cyclohydrolase-1	CONCLUSION : The simplest explanation of these results is that ***IL-1 beta*** ***induces*** expression of ***GTP cyclohydrolase-1*** which leads to increased generation of BH4 and activation of eNOS .	target	1
5219	10435158	4193;7157	MDM2;p53	The hallmark of the study was the significant ***association*** of ***MDM2*** expression with the ***p53*** protein accumulation in 16/33 ( 49 % ) oral premalignant lesions ( p = 0.001 ) and 39/65 ( 60 % ) malignant lesions ( p = 0.021 ) , suggesting an active role for MDM2 in binding and inactivating p53 in oral tumorigenesis .	parallel	0
5220	10435158	7157;4193	p53;MDM2	Further , significant ***association*** of ******MDM2/p53****** co-expression was observed with advanced tumour stage ( p = 0.0009 ) , as well as lymph node metastasis ( p = 0.0325 ) features associated with aggressive tumour behaviour and poor prognosis .	parallel	0
5221	10435471	958;3497	CD40;IgE	CONCLUSIONS : This study demonstrates that appropriate targeting of ***CD40*** can ***modulate*** ***IgE*** synthesis either positively or negatively .	negative	0
5222	10435471	2208;3497	CD23;IgE	We have asked about the interplay between CD40L and CD40 mAb that recognize distinct epitopes in delivering signals for regulating IL-4-dependent IgE synthesis and the expression of ***CD23*** , the low-affinity ***IgE*** ***receptor*** , in resting B cells .	parallel	1
5223	10435471	959;958	CD40L;CD40	RESULTS : With regard to both induction of CD23 and IgE production , soluble CD40L trimer ( sCD40LT ) showed synergistic interaction with two mAb to CD40 which bind to epitopes located outside the ligand binding site ( EA5 and 5C3 ) , but not with a mAb ( G28-5 ) which effectively competes for ***CD40L*** ***binding*** to ***CD40*** .	parallel	1
5224	10435576	1879;5079	EBF;Pax5	We also show that ***EBF*** directly ***binds*** and activates the ***Pax5*** promoter .	parallel	1
5225	10435586	861;596	AML1;Bcl-2	The chimeric gene , ***AML1/ETO*** ( MTG8 ) , generated in t ( 8 ; 21 ) acute myeloid leukemia ***enhances*** the expression of ***Bcl-2*** .	positive	0
5226	10435586	862;596	ETO;Bcl-2	The chimeric gene , ***AML1/ETO*** ( MTG8 ) , generated in t ( 8 ; 21 ) acute myeloid leukemia ***enhances*** the expression of ***Bcl-2*** .	positive	0
5227	10435591	373156;6714	GST;c-Src	Further , a ***GST-p58gag*** fusion protein ***bound*** full length ***c-Src*** from either platelets or c-Src-expressing insect cells .	parallel	1
5228	10435591	373156;6714	GST;c-Src	The ***binding*** of ***GST-p58gag*** to ***c-Src*** was almost completely abolished by a 50-fold excess of the GST-SH3 domain of Src , and a parallel decrease in tyrosine phosphorylation of p58gag was observed .	parallel	1
5229	10435597	7157;8794	p53;TRID	Consistent with these results , exogenous wild-type ***p53*** also ***upregulates*** the expression of endogenous ***TRID*** in p53-null cells .	positive	1
5230	10435622	545;7157	ATR;p53	The ataxia-telangiectasia related protein ***ATR*** ***mediates*** DNA-dependent phosphorylation of ***p53*** .	target	0
5231	10435624	3217;1387	HOXB7;CREB-binding protein	***HOXB7*** physically ***interacted*** both in vitro and in vivo with the coactivator ***CREB-binding protein*** ( CBP ) .	parallel	1
5232	10435630	7161;1647	p73;GADD45	For example , ***p73*** ***activates*** the ***GADD45*** gene more efficiently than p53 , whereas the reverse situation was apparent for the p21 gene .	positive	1
5233	10435631	8887;7128	TXBP151;A20	Moreover , transfection of antisense ***TXBP151*** partially ***abolished*** the anti-apoptotic effect of ***A20*** .	negative	0
5234	10435632	6777;598	STAT5;Bcl-xL	IL-3 dependent ***regulation*** of ***Bcl-xL*** gene expression by ***STAT5*** in a bone marrow derived cell line .	target	1
5235	10435632	3562;598	IL-3;Bcl-x	***IL-3*** ***regulation*** of ***Bcl-x*** expression at protein and mRNA levels was impaired in these cells while that of Bcl-2 expression was unaffected .	target	1
5236	10435632	6777;598	STAT5;Bcl-x	***Transactivation*** of a ***Bcl-x*** gene promoter reporter construct by ***STAT5*** was observed in Ba/F3 cells .	positive	1
5237	10435635	2621;558	Gas6;Axl	***Gas6*** was identified as the ***ligand*** for ***Axl*** tyrosine kinase receptor family .	parallel	1
5238	10435635	6714;2621	Src;Gas6	We have previously demonstrated that both ***Gas6*** mitogenic and survival effects are ***mediated*** by ***Src*** and the phosphatidylinositol3-OH kinase ( PI3K ) .	target	0
5239	10435757	3458;7124	Interferon gamma;TNF-alpha	***Interferon gamma*** significantly ***increased*** ***TNF-alpha*** release and cotinine significantly increased NO release .	positive	0
5240	10436007	7039;1956	transforming growth factor alpha;EGFR	Addition of a neutralizing monoclonal antibody versus ***transforming growth factor alpha*** ( TGFalpha ) had no effect on the primary activation of either the EGFR or the MAPK and JNK pathways after irradiation but ***abolished*** the secondary activation of ***EGFR*** , MAPK , and JNK .	negative	0
5241	10436007	7039;5599	transforming growth factor alpha;JNK	Addition of a neutralizing monoclonal antibody versus ***transforming growth factor alpha*** ( TGFalpha ) had no effect on the primary activation of either the EGFR or the MAPK and JNK pathways after irradiation but ***abolished*** the secondary activation of EGFR , MAPK , and ***JNK*** .	negative	0
5242	10436013	2923;811	ERp57;calreticulin	This result was confirmed by a specific ***interaction*** between in vitro synthesized ***calreticulin*** and ***ERp57*** prepared in solution in the absence of other ER components .	parallel	1
5243	10436013	2923;821	ERp57;calnexin	We conclude that ***ERp57*** forms ***complexes*** with both ***calnexin*** and calreticulin and propose that it is these complexes that can specifically modulate glycoprotein folding within the ER lumen .	parallel	1
5244	10436013	2923;811	ERp57;calreticulin	We conclude that ***ERp57*** forms ***complexes*** with both calnexin and ***calreticulin*** and propose that it is these complexes that can specifically modulate glycoprotein folding within the ER lumen .	parallel	1
5245	10436013	2923;811	ERp57;calreticulin	Specific ******ERp57/calreticulin****** ***complexes*** exist in canine pancreatic microsomes , as demonstrated by SDS-PAGE after cross-linking , and by native electrophoresis in the absence of cross-linking .	parallel	1
5246	10436016	8379;4085	Mad1;Mad2	The spindle checkpoint of budding yeast depends on a tight ***complex*** between the ***Mad1*** and ***Mad2*** proteins .	parallel	1
5247	10436160	355;356	Fas;FasL	Thus , FasL-mediated apoptosis is important for skin homeostasis , suggesting that the dysregulation of ******Fas-FasL****** ***interactions*** may be central to the development of skin cancer .	parallel	1
5248	10436170	7124;4012	TNF-alpha;AT(1) receptor	The present findings provide evidence for ***TNF-alpha*** ***regulation*** of ***AT(1) receptor*** density on cardiac fibroblasts .	target	1
5249	10436255	3569;3570	interleukin-6;interleukin-6 receptor	Circulating levels of interleukin-6 , its soluble receptor and ******interleukin-6/interleukin-6 receptor****** ***complexes*** in patients with type 2 diabetes mellitus .	parallel	1
5250	10436400	3725;2353	AP-1;c-fos	Our findings suggested that osteocalcin , a bone formation marker , ***c-fos*** and c-jun genes , and family protein products ( ***AP-1*** ) ***interacted*** to restore the normal cell function which deteriorated in the low calcium environment .	parallel	1
5251	10436400	3725;632	AP-1;osteocalcin	Our findings suggested that ***osteocalcin*** , a bone formation marker , c-fos and c-jun genes , and family protein products ( ***AP-1*** ) ***interacted*** to restore the normal cell function which deteriorated in the low calcium environment .	parallel	1
5252	10436400	2353;632	c-fos;osteocalcin	Our findings suggested that ***osteocalcin*** , a bone formation marker , ***c-fos*** and c-jun genes , and family protein products ( AP-1 ) ***interacted*** to restore the normal cell function which deteriorated in the low calcium environment .	parallel	1
5253	10436400	3725;3725	c-jun;AP-1	Our findings suggested that osteocalcin , a bone formation marker , c-fos and ***c-jun*** genes , and family protein products ( ***AP-1*** ) ***interacted*** to restore the normal cell function which deteriorated in the low calcium environment .	parallel	1
5254	10437653	1440;4843	G-CSF;iNOS	Qualitative and quantitative analyses of iNOS cDNA revealed that ***G-CSF*** significantly ***reduced*** interferon-gamma/lipopolysaccharide ( IFN-gamma/LPS ) dependent ***iNOS*** gene expression ( P < 0.05 ) following 6 , 18 , 24 , and 48 h incubation periods .	negative	1
5255	10437777	1437;6745	granulocyte-macrophage colony-stimulating factor;Translocon-associated protein alpha	***Translocon-associated protein alpha*** transcripts are ***induced*** by ***granulocyte-macrophage colony-stimulating factor*** and exhibit complex alternative polyadenylation .	target	1
5256	10437794	6714;3643	Src;insulin receptor	We have found that ***Src*** associated in mitosis 68 is a ***substrate*** of the ***insulin receptor*** both in vivo and in vitro .	parallel	1
5257	10437913	5451;3122	Oct-1;HLA-DRA	***Oct-1*** , a POU domain transcription factor , was identified as a ***repressor*** of ***HLA-DRA*** promoter activity in the Rb-defective cells .	negative	1
5258	10437913	5451;3576	Oct-1;interleukin 8	***Oct-1*** has also been shown to ***repress*** ***interleukin 8*** promoter activity .	negative	1
5259	10437983	4352;7066	TPOr;thrombopoietin	GW395058 is a PEGylated peptide ***thrombopoietin*** ***receptor*** ( ***TPOr*** ) agonist being evaluated for the treatment of chemotherapy-induced thrombocytopenia .	parallel	1
5260	10438351	919;920	CD3zeta;CD4	***CD3zeta*** expression ***correlated*** significantly with ***CD4*** cell counts and HIV-1 RNA levels ; impaired expression of CD3zeta molecules appeared to be reversible upon virus load reduction following highly active antiretroviral treatment ( HAART ) .	parallel	0
5261	10438454	8517;4790	IKKgamma;NF-kappaB	In this report , we show that Tax physically interacts with a regulatory component of the IKK complex , the ***NF-kappaB*** essential ***modulator*** or ***IKKgamma*** ( NEMO/IKKgamma ) .	target	0
5262	10438459	2113;4249	Ets-1;GnT-V	***Regulation*** of the ***GnT-V*** promoter by transcription factor ***Ets-1*** in various cancer cell lines .	target	1
5263	10438459	2113;3725	Ets-1;c-Jun	Although ***Ets-1*** ***cooperates*** with ***c-Jun*** in certain gene expressions , this was not the case in the regulation of the GnT-V gene .	parallel	0
5264	10438468	207;3569	Akt;IL-6	Thus , concomitant activation of the PI ***3-kinase/Akt*** and the STAT3 pathways ***mediates*** the anti-apoptotic effect of ***IL-6*** against TGF-beta , with the former likely playing a major role in this anti-apoptosis .	target	0
5265	10438468	3569;7045	Interleukin-6;transforming growth factor-beta-induced	***Interleukin-6*** ***inhibits*** ***transforming growth factor-beta-induced*** apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways .	negative	1
5266	10438468	7040;836	TGF-beta;caspase-3	Addition of IL-6 blocked ***TGF-beta-induced*** ***activation*** of ***caspase-3*** while showing no effect on the induction of plasminogen activator inhibitor-1 and p15 ( INK4B ) genes , indicating that IL-6 interferes with only a subset of TGF-beta activities .	positive	1
5267	10438468	3569;836	IL-6;caspase-3	Addition of ***IL-6*** ***blocked*** TGF-beta-induced activation of ***caspase-3*** while showing no effect on the induction of plasminogen activator inhibitor-1 and p15 ( INK4B ) genes , indicating that IL-6 interferes with only a subset of TGF-beta activities .	negative	0
5268	10438498	7040;929	TGF-beta;CD14	Furthermore , with stably transfected cell lines , we demonstrate that the C/EBP binding site in the CD14 promoter plays a critical role for mediating TGF-beta signaling in the synergistic ***activation*** of ***CD14*** expression by vitamin D ( 3 ) and ***TGF-beta*** during U937 differentiation .	positive	1
5269	10438509	3483;3486	ALS;IGFBP-3	However , little is known about how ***ALS*** ***binds*** to ***IGFBP-3*** or -5 , which link the IGFs to ALS .	parallel	1
5270	10438509	3486;3483	IGFBP-3;ALS	However , little is known about how ALS binds to ***IGFBP-3*** or -5 , which ***link*** the IGFs to ***ALS*** .	parallel	0
5271	10438525	7422;7082	VEGF;ZO-1	In conclusion , ***VEGF*** rapidly ***increases*** occludin phosphorylation as well as the tyrosine phosphorylation of ***ZO-1*** .	positive	0
5272	10438525	7422;100506658	VEGF;occludin	In conclusion , ***VEGF*** rapidly ***increases*** ***occludin*** phosphorylation as well as the tyrosine phosphorylation of ZO-1 .	positive	0
5273	10438529	3700;920	gp120;CD4	Infections by human immunodeficiency virus type 1 ( HIV-1 ) involve ***interactions*** of the viral envelope glycoprotein ***gp120*** with ***CD4*** and then with a coreceptor .	parallel	1
5274	10438530	3493;2204	IgA1;CD89	Although a tailpiece-deleted ***IgA1*** was able to ***bind*** and trigger ***CD89*** , antibodies featuring CH3 domain exchanges between human IgA1 and IgG1 could not , indicating that both domains but not the tailpiece are required for FcalphaR recognition .	parallel	1
5275	10438530	3493;2204	IgA1;CD89	In contrast , bovine ***IgA1*** , identical to human IgA1 within these interdomain loops despite numerous differences elsewhere in the Fc region , did ***bind*** ***CD89*** .	parallel	1
5276	10438536	149371;10640	Exo84p;Sec10p	The assembly of ***Exo84p*** into the exocyst complex ***requires*** two other subunits , Sec5p and ***Sec10p*** .	target	0
5277	10438536	149371;55770	Exo84p;Sec5p	The assembly of ***Exo84p*** into the exocyst complex ***requires*** two other subunits , ***Sec5p*** and Sec10p .	target	0
5278	10438536	149371;10640	Exo84p;Sec10p	***Exo84p*** ***interacts*** with both Sec5p and ***Sec10p*** in a two-hybrid assay .	parallel	1
5279	10438536	149371;55770	Exo84p;Sec5p	***Exo84p*** ***interacts*** with both ***Sec5p*** and Sec10p in a two-hybrid assay .	parallel	1
5280	10438538	1432;595	p38alpha;cyclin D1	Overexpression of a kinase-inactive form of p38gamma was also able to reverse in part the effect of hypoxia on cyclin D1 levels , suggesting that ***p38alpha*** and p38gamma converge to ***regulate*** ***cyclin D1*** during hypoxia .	target	1
5281	10438538	6300;595	p38gamma;cyclin D1	Overexpression of a kinase-inactive form of p38gamma was also able to reverse in part the effect of hypoxia on cyclin D1 levels , suggesting that p38alpha and ***p38gamma*** converge to ***regulate*** ***cyclin D1*** during hypoxia .	target	1
5282	10438543	2017;6850	cortactin;Syk	Tyrosine phosphorylation of ***cortactin*** ***associated*** with ***Syk*** accompanies thromboxane analogue-induced platelet shape change .	parallel	0
5283	10438543	2017;6850	cortactin;Syk	Since tyrosine kinase Syk was activated early during platelet activation , we examined the possibility that ***cortactin*** is a potential ***substrate*** of ***Syk*** in TxA ( 2 ) - induced platelet shape change .	parallel	1
5284	10438543	2017;6850	cortactin;Syk	Furthermore , ***cortactin*** was ***associated*** with ***Syk*** , and this association increases along with the level of phosphorylation .	parallel	0
5285	10438543	6850;2017	Syk;cortactin	These data suggest a novel pathway for a G protein-coupled TxA ( 2 ) high affinity receptor to the protein-tyrosine kinase ***Syk*** , which is ***associated*** with ***cortactin*** in the very early steps of platelet activation .	parallel	0
5286	10438566	3082;999	HGF;E-cadherin	***HGF/SF*** ***decreased*** the expression of ***E-cadherin*** and increased the percentage of cells with N-cadherin and sarcomeric myosin .	negative	0
5287	10438580	1191;3482	clusterin;cation-independent mannose 6-phosphate (M6P) receptor	***Binding*** of ***clusterin*** to the immobilized ***cation-independent mannose 6-phosphate (M6P) receptor*** indicated that part of the phosphate label was contained in M6P moieties .	parallel	1
5288	10438583	596;835	Bcl-2;caspase-2	When all the clones were treated with anti-Fas the processing of ***caspase-2*** , -3 , and -7 but not -8 was ***inhibited*** in the resistant clones to a similar extent by the differential overexpression of ***Bcl-2*** .	negative	1
5289	10438723	1026;1017	p21;CDK2	Thus , retinoic acid induced a rapid , but transient increased ***binding*** of ***p21*** ( Cip1 ) to ***CDK2*** .	parallel	1
5290	10438731	2623;1051	GATA-1;C/EBPbeta	In addition , GST pull-down experiments demonstrated a physical ***interaction*** between human ***GATA-1*** and ***C/EBPbeta*** .	parallel	1
5291	10438731	161882;2623	FOG;GATA-1	Expression of ***FOG*** ( riend ATA ) , which ***binds*** to ***GATA-1*** and acts as a cofactor for GATA-binding proteins , decreased transactivation activity of GATA-1 for the MBP promoter in a dose-dependent manner .	parallel	1
5292	10438731	1051;5553	C/EBPbeta;eosinophil granule major basic protein	***C/EBPbeta*** and GATA-1 synergistically ***regulate*** activity of the ***eosinophil granule major basic protein*** promoter : implication for C/EBPbeta activity in eosinophil gene expression .	target	1
5293	10438731	2623;5553	GATA-1;eosinophil granule major basic protein	C/EBPbeta and ***GATA-1*** synergistically ***regulate*** activity of the ***eosinophil granule major basic protein*** promoter : implication for C/EBPbeta activity in eosinophil gene expression .	target	1
5294	10438822	2033;3661	p300;IRF-3	While no binding between the full-size IRF-3 and vIRF-1 could be detected by the same assay , we show that vIRF-1 also targets the carboxy-terminal region ( aa 1623 to 2414 ) of the transcriptional coactivator ***p300*** which could also ***bind*** ***IRF-3*** and IRF-1 .	parallel	1
5295	10438843	958;5970	p50;p65	TNF is the major inducer of NF-kappaB and particularly of the ******p50-p65****** ***complex*** , whereas IL-7 acts as a cofactor by sustaining the expression of the p75 TNF receptor .	parallel	1
5296	10438849	4193;7157	mdm2;p53	Normally , ***mdm2*** protein ***inhibits*** ***p53*** function in an autoregulatory loop .	negative	1
5297	10438849	4193;7157	mdm2;p53	***Regulation*** of ***p53*** by ***mdm2*** is required for murine development as well as for proliferation of cultured human fibroblasts .	target	1
5298	10438870	3700;920	Gp120;CD4	***Gp120*** on HIV-1 virions ***binds*** ***CD4*** on the cell surface , triggering conformational rearrangements that create or expose a binding site for a seven-transmembrane ( 7TM ) coreceptor .	parallel	1
5299	10438898	6890;5698	Tap1;Lmp2	To localize the MHC-linked diabetogenic genes in the nonobese diabetic ( NOD ) mouse , a recombinational hotspot from the B10.A ( R209 ) mouse was introduced to the region between the MHC class I K and class II A of the NOD mouse with the recombinational site centromeric to the ******Lmp2/Tap1****** ***complex*** by breeding the two strains .	parallel	1
5300	10438903	3558;6774	IL-2;Stat3	Moreover , we provide evidence that TCR/CD3 and ***IL-2*** ***induce*** ***Stat3*** activation via distinct signaling pathways .	target	1
5301	10438904	5336;29760	phospholipase C-gamma 2;BLNK	Cutting edge : ***association*** of ***phospholipase C-gamma 2*** Src homology 2 domains with ***BLNK*** is critical for B cell antigen receptor signaling .	parallel	0
5302	10438904	5336;29760	PLC-gamma 2;BLNK	A possible explanation for the SH2 ( N ) requirement was provided by findings that this mutation abrogates the ***association*** of ***PLC-gamma 2*** with an adaptor protein ***BLNK*** .	parallel	0
5303	10438919	7535;27040	ZAP-70;linker for activation of T cells	Coordinate activation of these pathways is dependent on Lck - and ***ZAP-70-mediated*** tyrosine ***phosphorylation*** of a 36-kDa ***linker for activation of T cells*** and subsequent recruitment of phospholipase C-gamma1 , Grb2-SOS , and SLP-76-vav .	target	1
5304	10438925	8743;356	TRAIL;FasL	We recently showed that ***TRAIL*** ***mediates*** perforin - and Fas ligand ( ***FasL*** ) - independent cytotoxic activity of human CD4 + T cell clones .	target	0
5305	10438925	5551;356	perforin;FasL	In addition to ***perforin*** ***inactivation*** and neutralization of ***FasL*** by anti-FasL mAb , neutralization of TRAIL by anti-TRAIL mAb was needed for the complete inhibition of IL-2 - or IL-15-activated NK cell cytotoxicity against mouse fibrosarcoma L929 target cells , which were susceptible to both FasL and TRAIL .	negative	1
5306	10438935	3383;3683	ICAM-1;CD11a	The trafficking of leukocytes through tissues is supported by an interaction between the beta 2 ( CD18 ) integrins ***CD11a/CD18*** ( LFA-1 ) and CD11b/CD18 ( Mac-1 ) and their ***ligand*** ***ICAM-1*** .	parallel	1
5307	10438935	3383;3689	ICAM-1;CD18	The trafficking of leukocytes through tissues is supported by an interaction between the beta 2 ( CD18 ) integrins ***CD11a/CD18*** ( LFA-1 ) and CD11b/CD18 ( Mac-1 ) and their ***ligand*** ***ICAM-1*** .	parallel	1
5308	10438935	3683;3684	CD11a;CD11b	The trafficking of leukocytes through tissues is supported by an ***interaction*** between the beta 2 ( CD18 ) integrins ***CD11a/CD18*** ( LFA-1 ) and ***CD11b/CD18*** ( Mac-1 ) and their ligand ICAM-1 .	parallel	1
5309	10438935	3683;3689	CD11a;CD18	The trafficking of leukocytes through tissues is supported by an ***interaction*** between the beta 2 ( CD18 ) integrins ***CD11a/CD18*** ( LFA-1 ) and ***CD11b/CD18*** ( Mac-1 ) and their ligand ICAM-1 .	parallel	1
5310	10438935	3683;3383	CD11a;ICAM-1	The trafficking of leukocytes through tissues is supported by an ***interaction*** between the beta 2 ( CD18 ) integrins ***CD11a/CD18*** ( LFA-1 ) and CD11b/CD18 ( Mac-1 ) and their ligand ***ICAM-1*** .	parallel	1
5311	10438935	3684;3689	CD11b;CD18	The trafficking of leukocytes through tissues is supported by an ***interaction*** between the beta 2 ( CD18 ) integrins CD11a/CD18 ( LFA-1 ) and ******CD11b/CD18****** ( Mac-1 ) and their ligand ICAM-1 .	parallel	1
5312	10438935	3684;3383	CD11b;ICAM-1	The trafficking of leukocytes through tissues is supported by an ***interaction*** between the beta 2 ( CD18 ) integrins CD11a/CD18 ( LFA-1 ) and ***CD11b/CD18*** ( Mac-1 ) and their ligand ***ICAM-1*** .	parallel	1
5313	10438935	3689;3383	CD18;ICAM-1	The trafficking of leukocytes through tissues is supported by an ***interaction*** between the beta 2 ( CD18 ) integrins CD11a/CD18 ( LFA-1 ) and ***CD11b/CD18*** ( Mac-1 ) and their ligand ***ICAM-1*** .	parallel	1
5314	10438937	3394;3606	ICSBP;IL-18	Furthermore , cotransfection of ***ICSBP*** or PU.1 expression vector ***increased*** p1 promoter activity or ***IL-18*** expression , respectively .	positive	0
5315	10438937	6688;3606	PU.1;IL-18	Furthermore , cotransfection of ICSBP or ***PU.1*** expression vector ***increased*** p1 promoter activity or ***IL-18*** expression , respectively .	positive	0
5316	10438945	914;965	CD2;CD58	Unlike many other CD2 Abs , M1 and M2 do not interfere with TCR/CD3 triggering nor do they inhibit ***binding*** of ***CD2*** to its ligand ***CD58*** , thus preserving the physiological functions of these important effector cell molecules .	parallel	1
5317	10438951	3553;4790	IL-1;NF-kappa B	However , dexamethasone failed to induce I kappa B or inhibit ***activation*** of ***NF-kappa B*** by ***IL-1*** in the two cell types .	positive	1
5318	10438951	4790;3553	NF-kappa B;IL-1	The lack of effect of dexamethasone on the capacity of IL-1 to activate ***NF-kappa B*** ***correlated*** with its inability to induce I kappa B and the ability of ***IL-1*** to cause degradation of I kappa B , even in the presence of dexamethasone .	parallel	0
5319	10438953	7124;3383	TNF-alpha;ICAM-1	Although dexamethasone partially inhibited IL-1 beta - and ***TNF-alpha-induced*** ***up-regulation*** of ***ICAM-1*** at 4 h , dexamethasone had no effect on cytokine-induced ICAM-1 expression at 18-24 h.	positive	1
5320	10438958	3553;6347	IL-1 beta;MCP-1	Simultaneous neutralization of soluble TNF-alpha and ***IL-1 beta*** ***decreased*** ***MCP-1*** production by 55 % in membrane-separated cocultures of MC/CD40L-activated monocytes .	negative	0
5321	10438958	7124;6347	TNF-alpha;MCP-1	Simultaneous neutralization of soluble ***TNF-alpha*** and IL-1 beta ***decreased*** ***MCP-1*** production by 55 % in membrane-separated cocultures of MC/CD40L-activated monocytes .	negative	0
5322	10438961	3458;729230	IFN-gamma;CCR2	IL-4 treatment enhanced CCR2 protein in Th1 - and Th2-type fibroblasts whereas ***IFN-gamma*** treatment ***augmented*** ***CCR2*** protein in normal and Th1-type fibroblasts .	positive	0
5323	10438961	3565;729230	IL-4;CCR2	***IL-4*** treatment ***enhanced*** ***CCR2*** protein in Th1 - and Th2-type fibroblasts whereas IFN-gamma treatment augmented CCR2 protein in normal and Th1-type fibroblasts .	positive	0
5324	10438973	942;7040	B7.2;TGF-beta	In addition , ***anti-B7.2*** , but not anti-B7.1 , ***inhibited*** secretion of ***TGF-beta*** , one of the primary cytokines that mediates low-dose oral tolerance .	negative	1
5325	10438997	7422;3553	VEGF;IL-1 beta	Levels of ***VEGF*** were significantly ***correlated*** with levels of ***IL-1 beta*** , IL-8 , and TNF-alpha , as well as progesterone concentrations , hematocrit , and white blood cell counts .	parallel	0
5326	10438997	7422;3576	VEGF;IL-8	Levels of ***VEGF*** were significantly ***correlated*** with levels of IL-1 beta , ***IL-8*** , and TNF-alpha , as well as progesterone concentrations , hematocrit , and white blood cell counts .	parallel	0
5327	10438997	7422;7124	VEGF;TNF-alpha	Levels of ***VEGF*** were significantly ***correlated*** with levels of IL-1 beta , IL-8 , and ***TNF-alpha*** , as well as progesterone concentrations , hematocrit , and white blood cell counts .	parallel	0
5328	10439226	23430;2150	mast cell tryptase;PAR-2	We localized PAR-2 in human skin by immunohistochemistry , examined PAR-2 expression by RT-PCR and RNA blotting , and investigated ***PAR-2*** ***activation*** by ***mast cell tryptase*** .	positive	1
5329	10440099	183;3265	angiotensin II;p21ras	***angiotensin II*** ***activates*** ***p21ras*** , and mediates cardiac hypertrophic growth through the type 1 angiotensin II receptor in cardiac myocytes .	positive	1
5330	10440099	183;3265	angiotensin II;p21ras	***angiotensin II*** ***increased*** ***p21ras*** activity and membrane association , and lovastatin inhibited them .	positive	0
5331	10440129	2641;2645	Glucagon-like peptide-1;glucokinase	***Glucagon-like peptide-1*** also ***increased*** the expression of PDX-1 , glucose transporter 2 , ***glucokinase*** and insulin mRNAs .	positive	0
5332	10440129	2641;3651	Glucagon-like peptide-1;PDX-1	***Glucagon-like peptide-1*** also ***increased*** the expression of ***PDX-1*** , glucose transporter 2 , glucokinase and insulin mRNAs .	positive	0
5333	10440230	2648;100	GCN5;Ada	We propose that activation of Ire1p induces splicing of HACl mRNA as well as engages and targets the ******GCN5/Ada/Hac1****** protein ***complex*** to genes that are transcriptionally activated in response to unfolded protein in the ER .	parallel	1
5334	10440232	3569;3320	interleukin-6;Hsp90	We have previously demonstrated that ***interleukin-6*** ( IL-6 ) ***increases*** the levels of the heat shock protein 90 ( ***Hsp90*** ) and activates the Hsp90beta promoter via the IL-6-activated transcription factors NF-IL6 and STAT-3 .	positive	0
5335	10440232	3569;3326	interleukin-6;Hsp90beta	We have previously demonstrated that ***interleukin-6*** ( IL-6 ) increases the levels of the heat shock protein 90 ( Hsp90 ) and ***activates*** the ***Hsp90beta*** promoter via the IL-6-activated transcription factors NF-IL6 and STAT-3 .	positive	1
5336	10440232	3458;3308	interferon-gamma;Hsp70	In addition , ***interferon-gamma*** ( IFN-gamma ) treatment increases the levels of Hsp70 and Hsp90 and also ***enhances*** the activity of the ***Hsp70*** and Hsp90beta promoters with these effects being dependent on activation of the STAT-1 transcription factor by IFN-gamma .	positive	0
5337	10440232	3458;3326	interferon-gamma;Hsp90beta	In addition , ***interferon-gamma*** ( IFN-gamma ) treatment increases the levels of Hsp70 and Hsp90 and also ***enhances*** the activity of the Hsp70 and ***Hsp90beta*** promoters with these effects being dependent on activation of the STAT-1 transcription factor by IFN-gamma .	positive	0
5338	10440232	3458;3308	interferon-gamma;Hsp70	In addition , ***interferon-gamma*** ( IFN-gamma ) treatment ***increases*** the levels of ***Hsp70*** and Hsp90 and also enhances the activity of the Hsp70 and Hsp90beta promoters with these effects being dependent on activation of the STAT-1 transcription factor by IFN-gamma .	positive	0
5339	10440232	3458;3320	interferon-gamma;Hsp90	In addition , ***interferon-gamma*** ( IFN-gamma ) treatment ***increases*** the levels of Hsp70 and ***Hsp90*** and also enhances the activity of the Hsp70 and Hsp90beta promoters with these effects being dependent on activation of the STAT-1 transcription factor by IFN-gamma .	positive	0
5340	10440232	3458;6772	IFN-gamma;STAT-1	In addition , interferon-gamma ( IFN-gamma ) treatment increases the levels of Hsp70 and Hsp90 and also enhances the activity of the Hsp70 and Hsp90beta promoters with these effects being dependent on ***activation*** of the ***STAT-1*** transcription factor by ***IFN-gamma*** .	positive	1
5341	10440232	3308;1051	Hsp70;NF-IL6	The effect of IL-6/STAT-3 and IFN-gamma/STAT-1 was mediated via a short region of the ***Hsp70/Hsp90*** promoters , which also ***mediates*** the effects of ***NF-IL6*** .	target	0
5342	10440232	3320;1051	Hsp90;NF-IL6	The effect of IL-6/STAT-3 and IFN-gamma/STAT-1 was mediated via a short region of the ***Hsp70/Hsp90*** promoters , which also ***mediates*** the effects of ***NF-IL6*** .	target	0
5343	10440232	6774;3308	STAT-3;Hsp70	In contrast , ***STAT-3*** and HSF-1 antagonize one another and ***reduce*** the activation of both the ***Hsp70*** and Hsp90 promoters .	negative	1
5344	10440232	6774;3320	STAT-3;Hsp90	In contrast , ***STAT-3*** and HSF-1 antagonize one another and ***reduce*** the activation of both the Hsp70 and ***Hsp90*** promoters .	negative	1
5345	10440232	6772;3297	STAT-1;HSF-1	However , ***STAT-1*** or STAT-3 ***interact*** differently with ***HSF-1*** to regulate Hsp promoter activity .	parallel	1
5346	10440232	6774;3297	STAT-3;HSF-1	However , STAT-1 or ***STAT-3*** ***interact*** differently with ***HSF-1*** to regulate Hsp promoter activity .	parallel	1
5347	10440243	285;7422	Ang2;VEGF	CONCLUSIONS : Present findings that Ang2 and VEGF are co-upregulated and that Tie2 is expressed in a variety of cell types in CNVMs further support a crucial role of the ***interaction*** between ***VEGF*** and ***Ang2*** in pathologic angiogenesis of CNVM formation .	parallel	1
5348	10440249	7040;5829	TGFbeta;paxillin	Immunoprecipitation of cell proteins with 4G10 or PY20 identified the ***TGFbeta-associated*** tyrosine ***phosphorylation*** of ***paxillin*** , pp125fak , p130 , PLCgamma , and tensin , which was blocked by addition of GRGDdSP .	target	1
5349	10440249	7040;5747	TGFbeta;pp125fak	Immunoprecipitation of cell proteins with 4G10 or PY20 identified the ***TGFbeta-associated*** tyrosine ***phosphorylation*** of paxillin , ***pp125fak*** , p130 , PLCgamma , and tensin , which was blocked by addition of GRGDdSP .	target	1
5350	10440249	7040;7145	TGFbeta;tensin	Immunoprecipitation of cell proteins with 4G10 or PY20 identified the ***TGFbeta-associated*** tyrosine ***phosphorylation*** of paxillin , pp125fak , p130 , PLCgamma , and ***tensin*** , which was blocked by addition of GRGDdSP .	target	1
5351	10440512	356;355	FasL;Fas	***Fas*** ***ligand*** ( ***FasL*** ) is a lethal cytokine that promotes apoptosis through cross-linking of the Fas receptor , although it also has other , less well understood functions .	parallel	1
5352	10440698	7251;2033	Tumor susceptibility gene 101;p300	***Tumor susceptibility gene 101*** protein represses androgen receptor transactivation and ***interacts*** with ***p300*** .	parallel	1
5353	10440698	7251;367	Tumor susceptibility gene 101;androgen receptor	***Tumor susceptibility gene 101*** protein ***represses*** ***androgen receptor*** transactivation and interacts with p300 .	negative	1
5354	10440698	2033;7251	p300;tsg101	In addition , a direct ***association*** between ***tsg101*** and the transcriptional co-factor ***p300*** was demonstrated in vitro and in vivo .	parallel	0
5355	10440900	348;351	ApoE;Abeta	In contrast , lipidated ApoJ and ***ApoE*** ***decreased*** the degradation of ***Abeta*** , and the effects were ApoE isoform-dependent .	negative	0
5356	10440927	596;176	Bcl-2;aggrecan	***Bcl-2*** ***regulates*** chondrocyte morphology and ***aggrecan*** gene expression independent of caspase activation and full apoptosis .	target	1
5357	10440927	596;176	Bcl-2;aggrecan	In this article , we report that ***Bcl-2*** affects the morphology and ***regulates*** the expression of ***aggrecan*** in a rat chondrocyte cell line ( IRC ) .	target	1
5358	10441098	958;959	CD40;CD40L	METHODS AND RESULTS : To study the role of ******CD40L-CD40****** ***interaction*** in coronary disease , we analyzed levels of soluble ( s ) and membrane-bound CD40L in the peripheral blood from 29 patients with stable angina , 26 with unstable angina , and 19 controls .	parallel	1
5359	10441098	958;959	CD40;CD40L	CONCLUSIONS : This first demonstration of enhanced levels of soluble and membrane-bound forms of CD40L in angina patients , with particularly high levels in patients with unstable angina , suggests that ******CD40L-CD40****** ***interaction*** may play a pathogenic role in both the long-term atherosclerotic process and in the triggering and propagation of acute coronary syndromes .	parallel	1
5360	10441128	5578;5337	PKCalpha;PLD1	In the presence of PMA , purified ***PLD1*** from rat brain was also found to be ***phosphorylated*** by ***PKCalpha*** in vitro at multiple sites generating seven distinct tryptic phosphopeptides .	target	1
5361	10441128	5578;5337	PKCalpha;PLD1	Four phosphopeptides generated in vivo and in vitro correlated well with each other , suggesting direct ***phosphorylation*** of ***PLD1*** by ***PKCalpha*** in the cells .	target	1
5362	10441134	7448;462	vitronectin;antithrombin	Protein disulfide isomerase catalyzes the ***formation*** of disulfide-linked complexes of ***vitronectin*** with ***thrombin-antithrombin*** .	parallel	0
5363	10441134	5034;7448	PDI;vitronectin	In this study , purified preparations of platelet protein disulfide isomerase ( PDI ) , vitronectin , alpha-thrombin , and antithrombin ( AT ) were used to demonstrate that ***PDI*** ***catalyzes*** formation of ***vitronectin-thrombin-AT*** complexes .	positive	1
5364	10441483	4780;2729	Nrf2;GCS	These studies demonstrate that ***Nrf2*** proteins ***recognize*** and bind the ***GCS*** ( l ) EpRE sequence to affect transactivation of the gene .	target	1
5365	10441514	2353;239	c-Fos;arachidonate 12-lipoxygenase	Overexpression of ***c-Fos*** ***enhances*** the transcription of human ***arachidonate 12-lipoxygenase*** in A431 cells .	positive	0
5366	10441524	6908;23066	TBP;TIP120B	Pull-down assay using GST-fused TBP demonstrated that ***TBP*** specifically ***associated*** with ***TIP120B*** in the nuclear extract .	parallel	0
5367	10441524	23066;6908	TIP120B;TBP	These results indicate that ***TIP120B*** is a muscle-specific TIP120 family protein and can also ***interact*** with ***TBP*** .	parallel	1
5368	10441525	5970;4790	p65;p50	When liver was subjected to ischemia followed by reperfusion , but not ischemia alone , an NF-kappaB complex composed of ******p50/p65****** ***heterodimer*** and p50 homodimer was rapidly activated within 1 h and remained elevated for up to 3 h , and then tended to decline after 5 h of reperfusion .	parallel	1
5369	10442402	3572;3717	gp130;JAK2	Both the phosphorylation of gp130 and the ***association*** of ***gp130*** with JAK1 and ***JAK2*** were increased after pressure overload .	parallel	0
5370	10442405	4914;4803	trkA;NGF	Most of the biological effects of nerve growth factor ( NGF ) are mediated by ***trkA*** , the high affinity ***receptor*** for ***NGF*** .	parallel	1
5371	10442405	4803;4914	NGF;trkA	Despite the decline in trkA mRNA in the ganglion , 3000 injured DRG neurons sustain trkA immunoreactivity , suggesting that exogenous ***NGF*** can still ***influence*** these ***trkA*** expressing neurons , even though they are isolated from the periphery .	target	0
5372	10442483	8288;4586	eosinophil peroxidase;mucin	Two eosinophil granule proteins , ***eosinophil peroxidase*** and major basic protein , ***inhibit*** ***mucin*** release from hamster tracheal surface epithelial cells in primary culture .	negative	1
5373	10442483	6037;4586	eosinophil cationic protein;mucin	RESULTS : ( 1 ) Neither ***eosinophil cationic protein*** nor eosinophil-derived neurotoxin ***affected*** ***mucin*** release at concentrations up to 10 ( -6 ) M ; ( 2 ) both major basic protein ( MBP ) and eosinophil peroxidase ( EPO ) inhibited mucin release in a dose-dependent fashion , and the inhibitory effect by these proteins appeared to be reversible ; ( 3 ) neither MBP nor EPO caused any apparent cytotoxicity at concentrations up to 10 ( -6 ) M.	target	0
5374	10442483	8288;4586	eosinophil peroxidase;mucin	RESULTS : ( 1 ) Neither eosinophil cationic protein nor eosinophil-derived neurotoxin affected mucin release at concentrations up to 10 ( -6 ) M ; ( 2 ) both major basic protein ( MBP ) and ***eosinophil peroxidase*** ( EPO ) ***inhibited*** ***mucin*** release in a dose-dependent fashion , and the inhibitory effect by these proteins appeared to be reversible ; ( 3 ) neither MBP nor EPO caused any apparent cytotoxicity at concentrations up to 10 ( -6 ) M.	negative	1
5375	10442483	5553;4586	MBP;mucin	RESULTS : ( 1 ) Neither eosinophil cationic protein nor eosinophil-derived neurotoxin affected mucin release at concentrations up to 10 ( -6 ) M ; ( 2 ) both major basic protein ( ***MBP*** ) and eosinophil peroxidase ( EPO ) ***inhibited*** ***mucin*** release in a dose-dependent fashion , and the inhibitory effect by these proteins appeared to be reversible ; ( 3 ) neither MBP nor EPO caused any apparent cytotoxicity at concentrations up to 10 ( -6 ) M.	negative	1
5376	10442490	3600;7422	IL-15;VPF	CONCLUSION : These results indicate that ***IL-15*** plus IL-12 acted additively to ***augment*** ***VPF*** release .	positive	0
5377	10442549	5054;2152	PAI-1;tissue factor	The expression of ***tissue factor*** ( TF ) , tissue factor pathway inhibitor ( TFPI ) , von Willebrand factor ( vWF ) , endothelial nitric oxide (NO) synthase ( eNOS ) , tissue plasminogen activator ( tPA ) , its ***inhibitor*** ( ***PAI-1*** ) , and myosin , an indicator of local shear stress , was examined in the endothelium of cerebral vessels according to vessel size and location in human autopsy brains , using immunohistochemistry .	negative	1
5378	10442549	7035;2152	TFPI;tissue factor	The expression of tissue factor ( TF ) , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , von Willebrand factor ( vWF ) , endothelial nitric oxide (NO) synthase ( eNOS ) , tissue plasminogen activator ( tPA ) , its inhibitor ( PAI-1 ) , and myosin , an indicator of local shear stress , was examined in the endothelium of cerebral vessels according to vessel size and location in human autopsy brains , using immunohistochemistry .	negative	1
5379	10442631	841;8772	FLICE;FADD	At least in part , this function may involve displacement of ******FADD-FLICE****** ***binding*** through the death effector domain of PED/PEA-15 .	parallel	1
5380	10442631	8682;356	PED;FasL	In MCF-7 and HeLa cells , a fivefold overexpression of ***PED/PEA-15*** ***blocked*** ***FasL*** and TNFalpha apoptotic effects .	negative	0
5381	10442631	8682;7124	PED;TNFalpha	In MCF-7 and HeLa cells , a fivefold overexpression of ***PED/PEA-15*** ***blocked*** FasL and ***TNFalpha*** apoptotic effects .	negative	0
5382	10442631	8682;8682	PED;PEA-15	******PED/PEA-15-GeneGene****** 2 ***association*** was inhibited by overexpression of the wild-type but not of a DED-deletion mutant of FADD .	parallel	0
5383	10442631	8682;8772	PED;FADD	TNFalpha , in turn , reduces ***PED*** ***association*** with the endogenous ***FADD*** and FLICE of the cells .	parallel	0
5384	10442631	8682;841	PED;FLICE	TNFalpha , in turn , reduces ***PED*** ***association*** with the endogenous FADD and ***FLICE*** of the cells .	parallel	0
5385	10442631	7124;8682	TNFalpha;PED	***TNFalpha*** , in turn , ***reduces*** ***PED*** association with the endogenous FADD and FLICE of the cells .	negative	1
5386	10442632	613;25	Bcr;Abl	Importantly , the phosphotyrosine content of total P160 Bcr ( induced plus endogenous ) was strongly reduced by inducing expression of Bcr , indicating that the induced ***Bcr*** protein was not a target of the tyrosine kinase activity of Bcr-Abl but instead functioned as an ***inhibitor*** of ***Bcr-Abl*** .	negative	1
5387	10442632	613;25	Bcr;Abl	These results show that the ***Bcr*** protein can function as a negative ***regulator*** of ***Bcr-Abl*** , but that the inhibitory effects of Bcr are dependent on achieving an elevated level of Bcr expression relative to Bcr-Abl .	negative	1
5388	10442633	387;5599	RhoA;JNK	The activation of ***JNK*** by Galpha12Q229L was ***inhibited*** by dominant-negative ***RhoA*** ( T19N ) , and botulinum C3 exoenzyme which specifically inactivates Rho .	negative	1
5389	10442633	387;5599	RhoA;JNK	Interestingly , the v-Src-induced activation of ***JNK*** was ***inhibited*** by dominant-negative ***RhoA*** ( T19N ) .	negative	1
5390	10442637	2099;283120	ERalpha;H19	We demonstrated that ***ERalpha*** ***up-regulated*** the ***H19*** promoter in MCF-7 and in HBL-100 , whereas PR-A did not have any effect per se .	positive	1
5391	10442638	7786;1385	ZPK;CREB	Furthermore ***ZPK*** ***phosphorylates*** both Myc and ***CREB*** .	target	1
5392	10442768	2155;2152	coagulation factor VII;tissue factor	***coagulation factor VII*** ***bound*** to its cofactor ***tissue factor*** is the physiological initiator of blood coagulation .	parallel	1
5393	10442768	2155;2152	factor VII;tissue factor	The ***interaction*** between ***factor VII*** and ***tissue factor*** involves all four of the structural modules found in factor VII , with the most significant contribution coming from the first EGF-like domain .	parallel	1
5394	10443613	7124;4353	TNF-alpha;myeloperoxidase	***Anti-TNF-alpha*** treatment ***reduced*** protein permeability and ***myeloperoxidase*** activity and increased blood oxygenation in the groups exposed to only acid .	negative	1
5395	10443687	2690;3483	GH receptor;ALS	IGFBP-3 complexes measured by ELISA-1 and -2 in samples from normal individuals and subjects with GH deficiency , acromegaly , and ***GH receptor*** deficiency more tightly ***correlated*** with IGF-I , IGFBP-3 , and ***ALS*** than IGF-II .	parallel	0
5396	10443687	2690;3486	GH receptor;IGFBP-3	IGFBP-3 complexes measured by ELISA-1 and -2 in samples from normal individuals and subjects with GH deficiency , acromegaly , and ***GH receptor*** deficiency more tightly ***correlated*** with IGF-I , ***IGFBP-3*** , and ALS than IGF-II .	parallel	0
5397	10443695	3569;3976	IL-6;LIF	Dexamethasone ( 1 micromol/L ) inhibited basal LIF concentration by 83 % ( P < 0.05 ) , whereas TSH and ***IL-6*** ***stimulated*** ***LIF*** by 52 % ( P = 0.04 ) and 42 % ( P = 0.03 ) , respectively .	positive	0
5398	10443709	7040;3486	TGF-beta1;IGFBP-3	The changes in IGFBP-3 protein levels correlated well with its mRNA , indicating that ***TGF-beta1*** is able to ***up-regulate*** ***IGFBP-3*** synthesis in chondrocytes .	positive	1
5399	10443709	7040;3486	TGF-beta1;IGFBP-3	Thus , we conclude that even though ***TGF-beta1*** is able to ***up-regulate*** ***IGFBP-3*** , the growth inhibitory action produced by TGF-beta1 is not mediated by IGFBP-3 increase and appears to be mainly a direct TGF-beta1 effect on HFEC .	positive	1
5400	10444000	942;940	B7-2;CD28	In contrast , the same cells can be induced by BCL1-C11 tumor cells that express high amounts of the ***CD28*** ***ligand*** , ***B7-2*** .	parallel	1
5401	10444309	4852;2691	NPY;GHRH	***NPY*** significantly stimulated SS and ***inhibited*** basal and potassium-stimulated ***GHRH*** release , while potentiating potassium-evoked AVP secretion .	negative	1
5402	10444389	6780;10989	staufen;motor protein	Although the mechanism underlying mRNA localization is unknown , mRNA-staufen complexes have been shown to move in a microtubule-dependent manner , and it has been suggested that ***staufen*** ***associates*** with a ***motor protein*** which generates the movement .	parallel	0
5403	10444422	1981;1977	eIF4G;eIF4E	Compared with control values , muscle from alcohol-fed rats demonstrated 1 ) an increased binding of the translational repressor 4E-binding protein 1 ( 4E-BP1 ) with eIF4E , 2 ) a decrease in the phosphorylated gamma-form of 4E-BP1 , and 3 ) a decrease in ***eIF4G*** ***associated*** with ***eIF4E*** .	parallel	0
5404	10444422	1978;1977	4E-BP1;eIF4E	Compared with control values , muscle from alcohol-fed rats demonstrated 1 ) an increased ***binding*** of the translational repressor 4E-binding protein 1 ( ***4E-BP1*** ) with ***eIF4E*** , 2 ) a decrease in the phosphorylated gamma-form of 4E-BP1 , and 3 ) a decrease in eIF4G associated with eIF4E .	parallel	1
5405	10444459	7432;5578	VIP;PKC-alpha	Our results indicate that 1 ) translocation of Raf-1 to the membrane when stimulated with ceramide is inhibited by vasoactive intestinal peptide ( VIP ) , a relaxant neuropeptide ; 2 ) PKC-alpha and mitogen-activated protein kinase translocate and colocalize on the membrane in response to ceramide , and ***PKC-alpha*** translocation is ***inhibited*** by ***VIP*** ; 3 ) HSP27 colocalizes with actin when contraction occurs ; and 4 ) HSP27 immunoprecipitates with actin and with the contractile proteins myosin , tropomyosin , and caldesmon .	negative	1
5406	10444461	3320;4846	Hsp90;endothelial nitric oxide synthase	***Hsp90*** ***regulation*** of ***endothelial nitric oxide synthase*** contributes to vascular control in portal hypertension .	target	1
5407	10444476	551;1017	AVP;cdk2	***AVP*** and ANG II ***enhanced*** the expression and activity of ***cdk2*** , cyclin E , and proliferating cell nuclear antigen but did not induce expression of cdc2/cyclin B complex , a critical regulator of G ( 2 ) / M transition .	positive	0
5408	10444476	551;5111	AVP;proliferating cell nuclear antigen	***AVP*** and ANG II ***enhanced*** the expression and activity of cdk2 , cyclin E , and ***proliferating cell nuclear antigen*** but did not induce expression of cdc2/cyclin B complex , a critical regulator of G ( 2 ) / M transition .	positive	0
5409	10444476	1869;983	E2F-1;cdc2	***Binding*** of free ***E2F-1*** to the ***cdc2*** promoter did not occur in hormone-treated VSMC , which may account for the defective induction of cdc2 .	parallel	1
5410	10444531	3552;3383	IL-1alpha;ICAM-1	Both ***IL-1alpha*** and IL-1beta ***upregulated*** ***ICAM-1*** mRNA expression and increased susceptibility to RV infection , whereas other cytokines failed to alter ICAM-1 mRNA expression .	positive	1
5411	10444531	3553;3383	IL-1beta;ICAM-1	Both IL-1alpha and ***IL-1beta*** ***upregulated*** ***ICAM-1*** mRNA expression and increased susceptibility to RV infection , whereas other cytokines failed to alter ICAM-1 mRNA expression .	positive	1
5412	10444536	1634;6440	decorin;surfactant protein C	Additionally , exogenous TGF-beta-induced antiproliferative effects as well as the downregulation of ***surfactant protein C*** were ***abrogated*** by ***decorin*** in cultured embryonic lungs .	negative	0
5413	10444536	1634;7040	decorin;TGF-beta	Our findings suggest that ***decorin*** can ***antagonize*** bioactive ***TGF-beta*** during lung growth and differentiation , establishing the rationale for decorin as a candidate therapeutic approach to ameliorate excessive levels of TGF-beta signaling in the developing lung .	negative	1
5414	10444573	3479;5594	IGF-I;ERK	In PT cells , ***activation*** of the ***ERK*** pathway by insulin-like growth factor I ( ***IGF-I*** ) increased survival by threefold ( P < 0.001 ) , and this IGF-I-enhanced cell survival was inhibited by PD-098059 .	positive	1
5415	10444591	53615;9219	MBD3;MTA2	***MBD3*** ***mediates*** the association of ***MTA2*** with the core histone deacetylase complex .	target	0
5416	10444591	53615;8932	MBD3;MBD2	***MBD3*** does not directly bind methylated DNA but is highly ***related*** to ***MBD2*** , a polypeptide that binds to methylated DNA and has been reported to possess demethylase activity .	parallel	0
5417	10445106	7432;107	vasoactive intestinal peptide;adenyl cyclase	In target tissues , ***vasoactive intestinal peptide*** ( VIP ) ***stimulates*** ***adenyl cyclase*** activity , which elevates intracellular cAMP levels and activates protein kinase activity .	positive	0
5418	10445608	356;355	FasL;Fas	In the immune system , Fas antigen ( Fas ) and ***Fas*** ***ligand*** ( ***FasL*** ) are involved in the down regulation of immune reactions by inducing apoptosis .	parallel	1
5419	10445612	1432;3576	p38 Mitogen-activated protein kinase;IL-8	***p38 Mitogen-activated protein kinase*** ***regulates*** ***IL-8*** expression in human pulmonary vascular endothelial cells .	target	1
5420	10445851	6416;5599	MKK4;JNK	Expression of a dominant negative mutant of mitogen-activated protein kinase kinase 4 ( ***MKK4*** ) , a direct ***activator*** of ***JNK/SAPK*** , prevented T/P-induced JNK/SAPK activation .	positive	1
5421	10445851	6416;5601	MKK4;SAPK	Expression of a dominant negative mutant of mitogen-activated protein kinase kinase 4 ( ***MKK4*** ) , a direct ***activator*** of ***JNK/SAPK*** , prevented T/P-induced JNK/SAPK activation .	positive	1
5422	10445852	3569;5601	interleukin-6;jun kinase	We analysed the involvement of MAPK homologues in IL-6 transduction pathways and found that ***interleukin-6*** ***triggered*** activation of p38 stress-activated protein kinase ( p38 ) but not of ***jun kinase*** .	positive	0
5423	10445852	3569;1432	interleukin-6;p38	We analysed the involvement of MAPK homologues in IL-6 transduction pathways and found that ***interleukin-6*** ***triggered*** activation of p38 stress-activated protein kinase ( ***p38*** ) but not of jun kinase .	positive	0
5424	10445852	6774;3240	STAT3;haptoglobin	Using a reporter gene construct containing a 190 bp promoter fragment of the acute phase protein haptoglobin we found that p38 is involved in transcriptional ***activation*** of the ***haptoglobin*** promoter by ***STAT3*** but not by NF-IL6 .	positive	1
5425	10445852	1432;3240	p38;haptoglobin	Using a reporter gene construct containing a 190 bp promoter fragment of the acute phase protein haptoglobin we found that ***p38*** is involved in transcriptional ***activation*** of the ***haptoglobin*** promoter by STAT3 but not by NF-IL6 .	positive	1
5426	10446085	283489;7408	cAMP;VASP	Clopidogrel abolishes the inhibitory P2Y(AC) receptor-mediated ADP effects on prostaglandin E ( 1 ) - stimulated , ***cAMP-dependent*** ***phosphorylation*** of ***VASP*** without affecting epinephrine , thrombin , and thromboxane signaling .	target	1
5427	10446124	841;637	caspase-8;BID	Upon activation of the Fas apoptotic signaling pathway , ***BID*** , a " BH3 domain-only " pro-apoptotic molecule , is ***cleaved*** by ***caspase-8*** into a 6.5-kDa N-terminal and a 15-kDa BH3 domain-containing C-terminal fragment , referred to as t ( n ) - BID and t ( c ) - BID , respectively .	target	1
5428	10446132	2157;4035	FVIII;LRP	More detailed analysis revealed that ***FVIII*** light chain ***interacts*** with ***LRP*** with moderate affinity ( k ( on ) approximately 5 x 10 ( 4 ) M ( -1 ) s ( -1 ) ; k ( off ) approximately 2.5 x 10 ( -3 ) s ( -1 ) ; K ( d ) approximately 50 nM ) .	parallel	1
5429	10446132	4035;2157	LRP;FVIII	Collectively , our data demonstrate that in vitro ***LRP*** is able to ***bind*** ***FVIII*** at the cell surface and to mediate its transport to the intracellular degradation pathway .	parallel	1
5430	10446132	4035;2157	LRP;FVIII	******FVIII-LRP****** ***interaction*** involves the FVIII light chain , and FVIII-vWF complex formation plays a regulatory role in LRP binding .	parallel	1
5431	10446132	2157;9902	FVIII;endocytic receptor	In the present study , the ***interaction*** between the ***endocytic receptor*** low density lipoprotein receptor-related protein ( LRP ) and coagulation factor VIII ( ***FVIII*** ) was investigated .	parallel	1
5432	10446132	2157;4035	FVIII;LRP	In the present study , the ***interaction*** between the endocytic receptor low density lipoprotein receptor-related protein ( ***LRP*** ) and coagulation factor VIII ( ***FVIII*** ) was investigated .	parallel	1
5433	10446132	4035;9902	LRP;endocytic receptor	In the present study , the ***interaction*** between the ***endocytic receptor*** low density lipoprotein receptor-related protein ( ***LRP*** ) and coagulation factor VIII ( FVIII ) was investigated .	parallel	1
5434	10446132	2157;4035	FVIII;LRP	The interaction appeared to be specific because the LRP antagonist receptor-associated protein readily inhibited ***binding*** of ***FVIII*** to ***LRP*** ( IC ( 50 ) approximately 1 nM ) .	parallel	1
5435	10446132	4035;2157	LRP;FVIII	The interaction appeared to be specific because the ***LRP*** antagonist receptor-associated protein readily ***inhibited*** binding of ***FVIII*** to LRP ( IC ( 50 ) approximately 1 nM ) .	negative	1
5436	10446132	2157;4035	FVIII;LRP	In addition , a 12-fold molar excess of the physiological carrier of FVIII , i.e. von Willebrand factor ( vWF ) , reduced the ***binding*** of ***FVIII*** to ***LRP*** by over 90 % .	parallel	1
5437	10446132	2157;4035	FVIII;LRP	In ligand blotting experiments , ***binding*** of ***FVIII*** light chain to ***LRP*** could be visualized .	parallel	1
5438	10446136	4880;4882	CNP;NPR-B	***Activation*** of ***NPR-B*** by ***CNP*** in human mHSC leads to inhibition of both growth and contraction .	positive	1
5439	10446149	22808;4301	M-Ras;AF6	***M-Ras/R-Ras*** 3 , a transforming ras protein regulated by Sos1 , GRF1 , and p120 Ras GTPase-activating protein , ***interacts*** with the putative Ras effector ***AF6*** .	parallel	1
5440	10446149	22808;4301	M-Ras;AF6	Although ***M-Ras*** ***coimmunoprecipitated*** with ***AF6*** , a putative regulator of cell junction formation , overexpression of AF6 did not contribute to fibroblast transformation , suggesting the possibility of novel effector proteins .	parallel	1
5441	10446169	5663;598	presenilin-1;Bcl-X	***Interaction*** of Alzheimer 's ***presenilin-1*** and presenilin-2 with ***Bcl-X*** ( L ) .	parallel	1
5442	10446169	5664;598	presenilin-2;Bcl-X	***Interaction*** of Alzheimer 's presenilin-1 and ***presenilin-2*** with ***Bcl-X*** ( L ) .	parallel	1
5443	10446176	6773;6772	Stat2;Stat1	Urokinase induces activation and formation of Stat4 and ******Stat1-Stat2****** ***complexes*** in human vascular smooth muscle cells .	parallel	1
5444	10446176	6772;6773	Stat1;Stat2	Analysis of Stat complexes formed in response to uPA revealed a ******Stat2-Stat1****** ***heterodimer*** , which lacks p48 , a DNA-binding protein known to combine with Stat1-Stat2 .	parallel	1
5445	10446176	6773;6772	Stat2;Stat1	This new uPA-induced ******Stat2-Stat1****** ***heterodimer*** binds to GAS ( the interferon-gamma activation site ) distinct from the interferon-stimulated response element to which the p48 protein containing complexes generally bind .	parallel	1
5446	10446203	4802;4609	CBF-C;c-Myc	***CBF-C/NF-YC*** directly ***bound*** to ***c-Myc*** in vitro and in vivo in cultured cells .	parallel	1
5447	10446212	183;2185	angiotensin II;proline-rich tyrosine kinase 2	Nitric oxide inhibits ***angiotensin II-induced*** ***activation*** of the calcium-sensitive tyrosine kinase ***proline-rich tyrosine kinase 2*** without affecting epidermal growth factor receptor transactivation .	positive	1
5448	10446212	183;5594	angiotensin II;ERK	We contrasted the effects of nitric oxide on ***ERK*** ***activation*** by ***angiotensin II*** and epidermal growth factor ( EGF ) , since the transactivation of the EGF receptor has been implicated as a response to angiotensin II .	positive	1
5449	10446212	2885;6464	Grb2;Shc	The tyrphostin AG1478 , known to inhibit EGF receptor phosphorylation , also inhibited the angiotensin II and EGF-induced activation of ERK , the phosphorylation of the EGF receptor , and the subsequent ***association*** of ***Shc*** and ***Grb2*** .	parallel	0
5450	10446216	7124;5599	TNF-alpha;JNK	Similarly , LY294002 significantly diminished ***TNF-alpha-induced*** ***activation*** of ***JNK*** , suggesting that nuclear signaling triggered by TNF-alpha is dependent on PI 3-kinase-mediated activation of both c-fos SRE and JNK .	positive	1
5451	10446219	5580;6774	Protein kinase C delta;Stat3	***Protein kinase C delta*** ***associates*** with and phosphorylates ***Stat3*** in an interleukin-6-dependent manner .	parallel	0
5452	10446219	3569;6774	IL-6;Stat3	In this study , we investigated whether protein kinase C ( PKC ) is the kinase that is induced and responsible for ***Stat3*** serine ***phosphorylation*** by ***IL-6*** stimulation and which isoform of PKCs is likely to be involved .	target	1
5453	10446222	2817;6385	glypican-1;syndecan-4	To determine the role played by syndecan-4 cytoplasmic domain in the mediation of basic fibroblast growth factor ( bFGF ) signaling , immortalized human cells ( ECV ) were used to generate cell lines expressing constructs encoding full-length sequences for syndecan-4 ( S4 ) , syndecan-1 ( S1 ) , glypican-1 ( G1 ) , or chimeric proteins consisting of the ectoplasmic domain of ***glypican-1*** ***linked*** to the transmembrane/cytoplasmic domain of syndecan-4 ( G1-S4c ) and the ectoplasmic domain of ***syndecan-4*** linked to the glypican-1 glycosylphosphatidylinositol ( GPI ) anchor sequence ( S4-GPI ) .	parallel	0
5454	10446223	5747;2886	FAK;Grb7	This interaction is cell adhesion-dependent , suggesting that the ******FAK-Grb7****** ***complex*** is involved in integrin signaling .	parallel	1
5455	10446223	5747;2886	FAK;Grb7	Taken together , these results suggest that the ******FAK-Grb7****** ***complex*** plays a role in cell migration stimulated by integrin signaling through FAK .	parallel	1
5456	10446255	1050;5934	C/EBPalpha;p130	Our data suggest that ***induction*** of ***p130/E2F*** complexes by ***C/EBPalpha*** occurs via up-regulation of p21 , which , in turn , leads to association with and inhibition of , cdk2 kinase activity .	target	1
5457	10446255	1050;5934	C/EBPalpha;p130	E2F/p107 and ***E2F/p130*** complexes are ***regulated*** by ***C/EBPalpha*** in 3T3-L1 adipocytes .	target	1
5458	10446267	649;8646	BMP1;chordin	Here we show that Xenopus ***BMP1*** ***blocks*** the dorsalising activity of ***chordin*** , but not noggin or DeltaxBMPR , when coexpressed in the ventral marginal zone and degrades chordin protein in vitro .	negative	0
5459	10446271	2246;2255	FGF-1;FGF-10	Our data show that ***FGF-10*** and FGF-7 , important for patterning and growth of the lung bud , are differentially ***regulated*** by ***FGF-1*** , -2 and Shh .	target	1
5460	10446271	2246;2252	FGF-1;FGF-7	Our data show that FGF-10 and ***FGF-7*** , important for patterning and growth of the lung bud , are differentially ***regulated*** by ***FGF-1*** , -2 and Shh .	target	1
5461	10446271	6469;2255	Shh;FGF-10	Our data show that ***FGF-10*** and FGF-7 , important for patterning and growth of the lung bud , are differentially ***regulated*** by FGF-1 , -2 and ***Shh*** .	target	1
5462	10446271	6469;2252	Shh;FGF-7	Our data show that FGF-10 and ***FGF-7*** , important for patterning and growth of the lung bud , are differentially ***regulated*** by FGF-1 , -2 and ***Shh*** .	target	1
5463	10446313	7432;6348	VIP;MIP-1alpha	These studies suggest that the neuroprotective action of ***VIP*** is ***linked*** in part to its release of ***MIP-1alpha*** .	parallel	0
5464	10446331	1270;4804	Ciliary neurotrophic factor;NGF receptor	***Ciliary neurotrophic factor*** ***enhances*** the expression of NGF and p75 low-affinity ***NGF receptor*** in astrocytes .	positive	0
5465	10446348	598;836	Bcl-xL;caspase-3	***Bcl-xL*** is a negative ***regulator*** of ***caspase-3*** activation in immature neurons during development .	negative	1
5466	10446393	4790;3558	NFkappaB;interleukin-2	These data implicate IRAK and TRAF-6 in transcriptional ***regulation*** of ***interleukin-2*** gene expression via ***NFkappaB*** , and provide direct evidence that IRAK lies upstream from TRAF-6 .	target	1
5467	10446393	7189;3558	TRAF-6;interleukin-2	Interleukin-1 receptor-associated kinase and ***TRAF-6*** ***mediate*** the transcriptional regulation of ***interleukin-2*** by interleukin-1 via NFkappaB but unlike interleukin-1 are unable to stabilise interleukin-2 mRNA .	target	0
5468	10446393	3654;4790	IRAK;NFkappaB	Interleukin-1 receptor-associated kinase , ***IRAK*** , has been shown to ***activate*** ***NFkappaB*** in response to interleukin-1 .	positive	1
5469	10446393	3654;3558	IRAK;interleukin-2	***IRAK*** was unable , however , to ***increase*** ***interleukin-2*** protein production .	positive	0
5470	10446393	7189;3558	TRAF-6;interleukin-2	Overexpression of ***TRAF-6*** induced similar responses and again failed to ***increase*** ***interleukin-2*** protein production .	positive	0
5471	10446393	7189;3558	TRAF-6;interleukin-2	A dominant negative ***TRAF-6*** ***inhibited*** reporter gene expression and ***interleukin-2*** protein production in response to both interleukin-1 and IRAK transfection .	negative	1
5472	10446393	3654;3558	IRAK;interleukin-2	Interleukin-1 treatment and ***IRAK*** or TRAF-6 transfection ***increased*** ***interleukin-2*** mRNA production .	positive	0
5473	10446393	7189;3558	TRAF-6;interleukin-2	Interleukin-1 treatment and IRAK or ***TRAF-6*** transfection ***increased*** ***interleukin-2*** mRNA production .	positive	0
5474	10446410	627;4852	brain-derived neurotrophic factor;neuropeptide Y	Mathis , ***brain-derived neurotrophic factor*** ***induces*** functional expression and phenotypic differentiation of cultured fetal ***neuropeptide Y*** producing neurons , J.	target	1
5475	10446446	4335;4149	MNT;Max	These experiments demonstrated that ***MNT*** ***interacts*** with ***Max*** , and that this heterodimer binds DNA specifically , suggesting a functional bHLHZip domain of MB-derived MNT .	parallel	1
5476	10446747	1476;1508	cystatin B;cysteine protease	The underlying gene encodes ***cystatin B*** , a ***cysteine protease*** ***inhibitor*** .	negative	1
5477	10446818	3308;4049	HSP70;tumor necrosis factor-beta	Furthermore , we investigated a possible ***linkage*** between ***HSP70*** gene polymorphisms and the previously reported and mortality-related ***tumor necrosis factor-beta*** ( TNF-beta ) NcoI gene polymorphism .	parallel	0
5478	10446818	3308;4049	HSP70;TNF-beta	Analysis of a possible ***linkage*** between ***HSP70*** and ***TNF-beta*** genotypes resulted in a significant association ( odds ratio , 4.15 ; p < .01 ) of the HSP70-2 A/A homozygous genotype and the TNFB2/B2 homozygous genotype , which is reported to be a genomic marker for a poor prognosis in severe sepsis .	parallel	0
5479	10446857	4282;7124	MIF;TNFalpha	Peripheral blood mononuclear cell TNFalpha release was induced by culture in RA FLS-conditioned medium , and this induction was significantly abrogated by monoclonal anti-MIF antibody , suggesting that ***MIF*** is an upstream ***regulator*** of ***TNFalpha*** release .	target	1
5480	10446867	356;355	CD95L;CD95	METHODS : Two-color cytometric analysis was used to study the phenotype of freshly separated mononuclear cells , while Western blotting was used to detect ***CD95*** ***ligand*** ( ***CD95L*** ) expression in total homogenates of isolated CD4 + T lymphocytes .	parallel	1
5481	10446902	2516;190	SF-1;Dax-1	Taken together , our findings indicate that ***Ad4BP/SF-1*** ***controls*** the transcription of the ***Dax-1*** gene .	target	0
5482	10446902	190;2516	Dax-1;SF-1	In recent studies , ***Dax-1*** was reported to function as a transcriptional ***suppressor*** of ***Ad4BP/SF-1*** , a critical transcription factor in gonadal and adrenal differentiation .	negative	1
5483	10446907	2796;1385	GnRH;CREB	In alphaT3 gonadotrope cells , estradiol had no direct effect on CREB phosphorylation , whereas ***GnRH*** ***increased*** ***CREB*** phosphorylation 4 - to 5-fold within 5 min .	positive	0
5484	10446908	133;4609	adrenomedullin;c-Myc	Neither ***adrenomedullin*** nor CGRP ***affected*** ***c-Myc*** expression .	target	0
5485	10446908	796;4609	CGRP;c-Myc	Neither adrenomedullin nor ***CGRP*** ***affected*** ***c-Myc*** expression .	target	0
5486	10446912	7020;6667	AP-2;Sp1	***AP-2*** ***associated*** directly with ***Sp1*** in vitro requiring the AP-2 basic region and the Sp1 carboxy terminus .	parallel	0
5487	10446912	7020;6667	AP-2;Sp1	***AP-2*** ***induced*** ***Sp1/Sp3*** activity independently of AP-2 binding to DNA using a GAL4 paradigm .	target	1
5488	10446912	6667;3960	Sp1;GAL4	The ***Sp1*** and Sp3 transactivation domains were ***linked*** to the DNA-binding domain of ***GAL4*** , and their activity was assessed using a luciferase reporter gene containing only the GAL4 DNA-binding sites linked to the minimal TATA site .	parallel	0
5489	10446912	7020;3960	AP-2;GAL4	***AP-2*** ***induced*** Sp1 / ***Sp3-GAL4*** activity 3 - to 4-fold , requiring both the amino and extreme carboxy terminus of AP-2 .	target	1
5490	10446912	7020;6667	AP-2;Sp1	***AP-2*** ***induced*** ***Sp1*** / Sp3-GAL4 activity 3 - to 4-fold , requiring both the amino and extreme carboxy terminus of AP-2 .	target	1
5491	10446912	7020;6667	AP-2;Sp1	We conclude that ***AP-2*** can ***bind*** to and stimulate ***Sp1*** activity and induces the ovine CYP11A1 promoter through conserved Sp1/Sp3-binding sites in JEG-3 cells .	parallel	1
5492	10446912	7020;1583	AP-2;CYP11A1	We conclude that ***AP-2*** can bind to and stimulate Sp1 activity and ***induces*** the ovine ***CYP11A1*** promoter through conserved Sp1/Sp3-binding sites in JEG-3 cells .	target	1
5493	10446912	7020;6667	AP-2;Sp1	The ***induction*** of ***Sp1*** activity by ***AP-2*** may contribute to the induction of other genes that bind Sp1 .	target	1
5494	10446912	7020;1583	Activator protein-2;CYP11A1	***Activator protein-2*** ***mediates*** transcriptional activation of the ***CYP11A1*** gene by interaction with Sp1 rather than binding to DNA .	target	0
5495	10446912	7020;1583	AP-2;CYP11A1	In the current studies , ***AP-2*** ***induced*** the ovine ***CYP11A1*** promoter 4.5-fold in JEG-3 cells with full induction requiring the previously defined cAMP-responsive elements .	target	1
5496	10446912	7020;1583	AP-2;CYP11A1	***AP-2*** ***induction*** of the ***CYP11A1*** promoter required the basic region ( N165-N278 ) and the carboxy terminus of AP-2 ( N413-N437 ) .	target	1
5497	10446912	7020;6667	AP-2;Sp1	***AP-2*** did not bind OF5 or OF3 directly but rather formed a multiprotein ***complex*** with ***Sp1*** in JEG-3 cells .	parallel	1
5498	10446920	3456;6352	IFN-beta;RANTES	This effect of ***IFN-beta*** was ***correlated*** with an overexpression of ***RANTES*** and completely abrogated by RANTES-blocking antibody .	parallel	0
5499	10446930	60412;11336	sec8;sec6	It seems that newly synthesized vesicular stomatitis virus G is preferentially delivered into the cell processes of the podocytes , where it is colocalized with known regulators of vesicular transport from the Golgi apparatus to the plasma membrane , such as the small GTPase rab8 and the ******sec6/sec8****** ***complex*** .	parallel	1
5500	10446957	5591;7157	DNA-PK catalytic subunit;p53	Our observation clearly indicates that ***DNA-PK catalytic subunit*** does not phosphorylate p53 Ser-18 in vivo or ***control*** the transactivation of ***p53*** in response to DNA damage , and these results further emphasize the different pathways in which ataxia telangiectasia-mutated ( ATM ) and DNA-PK operate following radiation damage .	target	0
5501	10446958	672;5888	BRCA1;Rad51	Both ***BRCA1*** and BRCA2 have been reported to ***bind*** ***Rad51*** , a protein essential for homologous recombination and the recombinational repair of DNA double-strand breaks .	parallel	1
5502	10446958	675;5888	BRCA2;Rad51	Both BRCA1 and ***BRCA2*** have been reported to ***bind*** ***Rad51*** , a protein essential for homologous recombination and the recombinational repair of DNA double-strand breaks .	parallel	1
5503	10446965	2475;595	FRAP;cyclin D1	***Regulation*** of cell growth and ***cyclin D1*** expression by the constitutively active ***FRAP-p70s6K*** pathway in human pancreatic cancer cells .	target	1
5504	10446979	7157;4134	p53;microtubule-associated protein 4	DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through ***p53-dependent*** ***repression*** of ***microtubule-associated protein 4*** .	negative	1
5505	10446979	7157;4134	p53;MAP4	Expression of ***MAP4*** is transcriptionally ***repressed*** by wild-type ***p53*** .	negative	1
5506	10446984	3605;3569	IL-17;IL-6	We showed that in vitro , ***IL-17*** ***increases*** ***IL-6*** and IL-8 secretion by cervical carcinoma cell lines at both protein and mRNA levels .	positive	0
5507	10446990	10620;5925	Bdp;pRb	Like MyoD , ***Bdp*** ***binds*** to the COOH-terminal region of pRb through its conserved region and to hypophosphorylated ***pRb*** .	parallel	1
5508	10446996	1029;7422	p16;vascular endothelial growth factor	Restoration of wild-type ***p16*** ***down-regulates*** ***vascular endothelial growth factor*** expression and inhibits angiogenesis in human gliomas .	negative	1
5509	10447004	472;7157	ATM;p53	As a protein kinase , ***ATM*** then directly ***phosphorylates*** ***p53*** and interacts with many other molecules involved in homologous and nonhomologous DSB repair , as well as in cell signalling .	target	1
5510	10447088	6751;2353	SSTR1;c-fos	These data indicate that leukemia cells express ***SSTR1*** and SS ***reduce*** ***c-fos*** gene expression with resultant suppression of leukemia cell growth , possibly mediated by the SSTRI .	negative	1
5511	10447100	7200;4157	Thyrotropin releasing hormone;melanocortin 1 receptor	***Thyrotropin releasing hormone*** ( TRH ) selectively ***binds*** and activates the ***melanocortin 1 receptor*** .	parallel	1
5512	10447100	7200;820	TRH;cAMP	Moreover , ***TRH*** also ***stimulated*** ***cAMP*** production in murine B16 melanoma cells reaching the same maximum level of cAMP as found for alpha-MSH .	positive	0
5513	10447224	213;1401	albumin;C-reactive protein	The ***associations*** between serum ***C-reactive protein*** , serum ***albumin*** and white blood cells in blood were studied amongst hypophosphataemic patients .	parallel	0
5514	10447519	3586;3329	IL-10;hsp60	The ***IL-10*** ***response*** to ***hsp60*** was higher in twins at low disease risk ( islet cell antibody-negative ) than in their diabetic cotwins ( p < 0.01 ) , as was the IL-4 response to phytohaemagglutinin ( p < 0.05 ) .	parallel	0
5515	10447591	834;596	caspase-1;Bcl-2	However , ***Bcl-2*** is itself ***cleaved*** by both ***caspase-1*** and caspase-3 at two adjacent recognition sites , YEWD ( 31 ' ) A and DAGD ( 34 ' ) V respectively , immediately downstream from the N-terminal BH4 domain , a region of Bcl-2 which is essential for its anti-apoptotic activity ; similar cleavage of Bcl-2 by caspases has been demonstrated in mammalian cells .	target	1
5516	10447591	836;596	caspase-3;Bcl-2	However , ***Bcl-2*** is itself ***cleaved*** by both caspase-1 and ***caspase-3*** at two adjacent recognition sites , YEWD ( 31 ' ) A and DAGD ( 34 ' ) V respectively , immediately downstream from the N-terminal BH4 domain , a region of Bcl-2 which is essential for its anti-apoptotic activity ; similar cleavage of Bcl-2 by caspases has been demonstrated in mammalian cells .	target	1
5517	10447714	2534;4739	Fyn;CasL	We show here that an ***association*** between ***CasL*** and two types of Src family PTKs , ***Fyn*** and Lck , is induced by anti-CD3 cross-linking of human H9 T cells .	parallel	0
5518	10447714	3932;4739	Lck;CasL	We show here that an ***association*** between ***CasL*** and two types of Src family PTKs , Fyn and ***Lck*** , is induced by anti-CD3 cross-linking of human H9 T cells .	parallel	0
5519	10447714	3932;2534	Lck;Fyn	We show here that an ***association*** between CasL and two types of Src family PTKs , ***Fyn*** and ***Lck*** , is induced by anti-CD3 cross-linking of human H9 T cells .	parallel	0
5520	10447714	4739;2534	CasL;Fyn	These results strongly suggest that ***CasL*** is a ***substrate*** for ***Fyn*** and Lck PTKs in TCR signal transduction .	parallel	1
5521	10447728	719;718	C3aR;C3a	To better characterize the cellular distribution of ***C3a*** ***receptor*** ( ***C3aR*** ) expression , monoclonal antibodies against two different epitopes on the third extracellular domain of the human C3aR were generated .	parallel	1
5522	10447736	3569;3320	IL-6;hsp 90	Recent studies have shown that the cytokine ***IL-6*** ***activates*** ***hsp 90*** gene expression via specific transcription factors that include STAT-3 ( signal transducer and activator of transcription 3 ) .	positive	1
5523	10447736	3586;3320	IL-10;hsp 90	Here we report that ***IL-10*** ***enhances*** the expression of ***hsp 90*** in both a human hepatoma cell line ( HepG2 ) stably expressing the human IL-10 receptor and peripheral blood mononuclear cells ( PBMC ) .	positive	0
5524	10447738	3603;920	interleukin-16;CD4 receptor	***interleukin-16*** ( IL-16 ) , a natural ***ligand*** for the ***CD4 receptor*** , has been found to modulate T-lymphocyte function and to inhibit human immunodeficiency virus type 1 ( HIV-1 ) replication .	parallel	1
5525	10447747	4790;2920	NF-kappaB;MIP-2	Gel-mobility shift assays revealed ***NF-kappaB*** ***binding*** to the ***MIP-2*** promoter/enhancer sequence was induced by H2O2 .	parallel	1
5526	10447768	3458;3565	IFN-gamma;IL-4	***IFN-gamma*** cDNA ***increased*** the serum IgG2a but ***IL-4*** cDNA had no affect .	positive	0
5527	10447936	959;3700	IgM;gp120	A panel of monovalent antigen-binding fragments ( Fab ) selected from IgM and IgG isotype libraries generated from peripheral blood mononuclear cells ( PBMC ) of a healthy , HIV-1 noninfected individual was analysed , reflecting that only ***IgM*** , but not IgG , Fab were able to ***recognize*** HIV-1 ***gp120*** .	target	1
5528	10448008	3383;356	ICAM-1;Fas ligand	Moreover , inhibition of ***ICAM-1*** ***modulated*** the activity of membrane-associated ***Fas ligand*** so that its cellular specificity was similar to that of soluble Fas ligand .	target	0
5529	10448015	959;958	CD154;CD40	***Binding*** of ***CD40*** by ***CD154*** expressed on activated T cells is a pivotal event in T cell help to B cells , macrophages , and other antigen-presenting cells .	parallel	1
5530	10448033	5087;3211	pbx1;HoxB1	The crystal structure of a human ******HoxB1-pbx1-DNA****** ternary ***complex*** revealed that interactions between the two proteins are mediated by the HoxB1 hexapeptide , which inserts into a hydrophobic pocket in pbx1 .	parallel	1
5531	10448033	5087;3211	pbx1;HoxB1	This study suggests a model for the assembly of a stable ******HoxB1-pbx1-DNA****** ternary ***complex*** .	parallel	1
5532	10448081	23529;4790	CLC;NFkappaB	Purified recombinant ***CLC*** ***induced*** the activation of ***NFkappaB*** and SRE reporter constructs in the TF-1 , U937 , and M1 cell lines .	target	1
5533	10448092	1457;4150	CKII;MAZ	***Phosphorylation*** of ***MAZ*** by ***CKII*** at this serine residue was required for maximum binding of MAZ to the pyrimidine-rich DNA of the nuclease-hypersensitive element ( NHE ) in the 5 ' - end promoter region of the c-myc gene .	target	1
5534	10448095	5468;6776	PPARgamma;STAT5A	***PPARgamma*** ligand-dependent ***induction*** of STAT1 , ***STAT5A*** , and STAT5B during adipogenesis .	target	1
5535	10448095	5468;6777	PPARgamma;STAT5B	***PPARgamma*** ligand-dependent ***induction*** of STAT1 , STAT5A , and ***STAT5B*** during adipogenesis .	target	1
5536	10448186	3077;7018	HFE;transferrin	AIM : To determine if there is an ***association*** between high ***transferrin*** saturation and the C282Y ***HFE*** gene mutation in very low birthweight ( VLBW ) infants .	parallel	0
5537	10448271	7040;1026	TGF-beta;p21	***TGF-beta*** upregulated p21 promoter activity by approximately 2-fold of the control and concurrently ***increased*** ***p21*** mRNA expression , except in OSC-8 and -9 .	positive	0
5538	10448271	7040;1026	TGF-beta;p21	***TGF-beta*** ***upregulated*** ***p21*** promoter activity by approximately 2-fold of the control and concurrently increased p21 mRNA expression , except in OSC-8 and -9 .	positive	1
5539	10448271	7040;1026	TGF-beta;p21	In parallel with the messenger expression , ***p21*** protein expression was strongly ***increased*** by ***TGF-beta*** , but only weakly increased by gamma-rays .	positive	0
5540	10448305	3458;3592	IFN gamma;p35	***IFN gamma*** IL-10 mRNA were ***associated*** with the presence of the IL-12 ***p35*** and p40 transcripts ( P = 0.008 and P < 0.00001 , respectively ) .	parallel	0
5541	10448305	3586;3592	IL-10;p35	IFN gamma ***IL-10*** mRNA were ***associated*** with the presence of the IL-12 ***p35*** and p40 transcripts ( P = 0.008 and P < 0.00001 , respectively ) .	parallel	0
5542	10448520	4035;4018	LRP;lipoprotein	The LDL-R is the prototype of this family , which also contains very-low-density ***lipoprotein*** ***receptors*** ( VLDL-R ) , apolipoprotein E receptor 2 , ***LRP*** , and megalin .	parallel	1
5543	10448520	4036;4018	megalin;lipoprotein	The LDL-R is the prototype of this family , which also contains very-low-density ***lipoprotein*** ***receptors*** ( VLDL-R ) , apolipoprotein E receptor 2 , LRP , and ***megalin*** .	parallel	1
5544	10448599	834;3553	ICE;IL-1 beta	The presence of IL-1Ra or antisense ***ICE*** also ***suppressed*** the endogenous ***IL-1 beta*** production of AML cells , at both the level of pro-IL-1 beta and mature IL-1 beta .	negative	1
5545	10448599	3557;3553	IL-1Ra;IL-1 beta	The presence of ***IL-1Ra*** or antisense ICE also ***suppressed*** the endogenous ***IL-1 beta*** production of AML cells , at both the level of pro-IL-1 beta and mature IL-1 beta .	negative	1
5546	10448730	7048;7040	TbetaR-II;TGF-beta	The marked reduction of membranous ***TbetaR-II*** and their predominant cytoplasmic location ***diminishes*** ***TGF-beta*** growth inhibition and may contribute to the transformation of VC into the more aggressive SqCC .	positive	0
5547	10448889	1906;5743	endothelin-1;cyclooxygenase 2	Our previous report showed that ***endothelin-1*** at concentrations above 10 ( -11 ) M ***induced*** ***cyclooxygenase 2*** expression through mainly endothelin ET ( B ) receptors and that an endothelin ET ( B ) receptor-mediated process was not involved in cyclooxygenase 2 activation in macrophages stimulated by lipopolysaccharide for 4 h.	target	1
5548	10448889	1906;5743	endothelin-1;cyclooxygenase 2	From these results , we conclude that ***endothelin-1*** ***promotes*** lipopolysaccharide-induced ***cyclooxygenase 2*** activation in the delayed phase through endothelin ET ( B ) receptors up-regulated by lipopolysaccharide .	positive	0
5549	10448894	1392;1393	CRF;CRF-BP	The association rates of [ 125I ] [ Tyr0 ] Urocortin or [ 125I ] [ Tyr0 ] ***CRF*** ***binding*** to the ***CRF-BP*** were similar .	parallel	1
5550	10448894	7349;1393	Urocortin;CRF-BP	The association rates of [ 125I ] [ Tyr0 ] ***Urocortin*** or [ 125I ] [ Tyr0 ] CRF ***binding*** to the ***CRF-BP*** were similar .	parallel	1
5551	10449034	7039;598	TGF-alpha;bcl-X	***TGF-alpha*** inhibited apoptosis and ***increased*** ***bcl-X*** ( L ) and decreased bak protein levels in c-myc hepatocytes but not in wild-type hepatocytes .	positive	0
5552	10449168	7124;958	Tumor necrosis factor alpha;CD40	***Tumor necrosis factor alpha*** ( TNF-alpha ) ***enhanced*** ***CD40*** expression on LC during culture .	positive	0
5553	10449168	7124;958	TNF-alpha;CD40	***TNF-alpha*** , which ***up-regulated*** ***CD40*** expression on LC during culture , did not modulate CD40L .	positive	1
5554	10449265	3308;3329	hsp70;hsp60	OBJECTIVE : The relationship between pregnancy outcome and expression of the heat shock proteins ( hsps ) or hsp-antibody ***complexes*** of 60kD ( ***hsp60*** ) , 70kD ( ***hsp70*** ) , and 90kD ( hsp90 ) in placental tissue and circulating antibodies to hsps was evaluated .	parallel	1
5555	10449265	3308;3320	hsp70;hsp90	OBJECTIVE : The relationship between pregnancy outcome and expression of the heat shock proteins ( hsps ) or hsp-antibody ***complexes*** of 60kD ( hsp60 ) , 70kD ( ***hsp70*** ) , and 90kD ( ***hsp90*** ) in placental tissue and circulating antibodies to hsps was evaluated .	parallel	1
5556	10449265	3320;3329	hsp90;hsp60	OBJECTIVE : The relationship between pregnancy outcome and expression of the heat shock proteins ( hsps ) or hsp-antibody ***complexes*** of 60kD ( ***hsp60*** ) , 70kD ( hsp70 ) , and 90kD ( ***hsp90*** ) in placental tissue and circulating antibodies to hsps was evaluated .	parallel	1
5557	10449420	7536;11338	SF1;U2AF65	PKG phosphorylates SF1 at Ser20 , which inhibits the ******SF1-U2AF65****** ***interaction*** leading to a block of pre-spliceosome assembly .	parallel	1
5558	10449420	5592;7536	PKG;SF1	***PKG*** ***phosphorylates*** ***SF1*** at Ser20 , which inhibits the SF1-U2AF65 interaction leading to a block of pre-spliceosome assembly .	target	1
5559	10449420	5592;7536	PKG;SF1	***SF1*** is ***phosphorylated*** in vitro by ***PKG*** , but not by cAMP-dependent protein kinase A ( PKA ) .	target	1
5560	10449420	7536;11338	SF1;U2AF65	These results suggest a new role for PKG in mammalian pre-mRNA splicing by regulating in a phosphorylation-dependent manner the ***association*** of ***SF1*** with ***U2AF65*** and spliceosome assembly .	parallel	0
5561	10449526	942;3558	CD86;IL-2	Addition of ***anti-CD86*** but not anti-CD80 monoclonal antibodies to cocultures ***inhibited*** ***IL-2*** production and the proliferation of CD4 ( + ) T cells to allogeneic donor human umbilical vein ECs ( HUVECs ) , as well as to skin and lung microvascular ECs .	negative	1
5562	10449752	2277;3791	Figf;VEGFR-2	In vitro ***Figf/Vegf-D*** ***induces*** tyrosine phosphorylation of ***VEGFR-2*** and VEGFR-3 in primary human umbilical cord vein endothelial cells ( HUVECs ) and in an immortal cell line derived from Kaposi 's sarcoma lesion ( KS-IMM ) .	target	1
5563	10449752	2277;2324	Figf;VEGFR-3	In vitro ***Figf/Vegf-D*** ***induces*** tyrosine phosphorylation of VEGFR-2 and ***VEGFR-3*** in primary human umbilical cord vein endothelial cells ( HUVECs ) and in an immortal cell line derived from Kaposi 's sarcoma lesion ( KS-IMM ) .	target	1
5564	10449753	3953;5781	Leptin receptor;SHP-2	These data suggest that ***activation*** of ***SHP-2*** by the ***Leptin receptor*** results in a decreased phosphorylation of JAK2 and may act to attenuate Leptin signal transduction .	positive	1
5565	10449753	3952;3953	Leptin;Leptin receptor	***Leptin*** ***binding*** to the Ob-Rb form of the ***Leptin receptor*** leads to tyrosyl phosphorylation of the cytoplasmic domain of its receptor .	parallel	1
5566	10449770	867;6503	Cbl;SLAP	N-terminal ***Cbl*** ***interacts*** with ***SLAP*** in vivo and in vitro in a tyrosine phosphorylation-independent manner .	parallel	1
5567	10449770	6503;27040	SLAP;LAT	We observed that SLAP is expressed in T cells , and upon TCR activation , ***SLAP*** ***interacts*** with ZAP-70 , Syk , ***LAT*** , and TCRzeta chain in Jurkat T cells .	parallel	1
5568	10449770	6503;6850	SLAP;Syk	We observed that SLAP is expressed in T cells , and upon TCR activation , ***SLAP*** ***interacts*** with ZAP-70 , ***Syk*** , LAT , and TCRzeta chain in Jurkat T cells .	parallel	1
5569	10449770	6503;7535	SLAP;ZAP-70	We observed that SLAP is expressed in T cells , and upon TCR activation , ***SLAP*** ***interacts*** with ***ZAP-70*** , Syk , LAT , and TCRzeta chain in Jurkat T cells .	parallel	1
5570	10449773	7305;23601	DAP12;MDL-1	Crosslinking of ******MDL-1/DAP12****** ***complexes*** in J774 mouse macrophage cells resulted in calcium mobilization .	parallel	1
5571	10449773	7305;23601	DAP12;MDL-1	These findings suggest that signaling via ******MDL-1/DAP12****** ***complexes*** may constitute a significant activation pathway in myeloid cells .	parallel	1
5572	10449788	7124;3479	TNF-alpha;IGF-I	Here we show that concentrations of ***TNF-alpha*** as low as 10 pg/ml markedly ***reduce*** the capacity of ***IGF-I*** to promote survival of primary murine cerebellar granule neurons .	negative	1
5573	10449788	3479;8660	IGF-I;IRS-2	TNF-alpha suppresses ***IGF-I-induced*** tyrosine ***phosphorylation*** of insulin receptor substrate 2 ( ***IRS-2*** ) and inhibits IRS-2-precipitable phosphatidylinositol 3 ' - kinase activity .	target	1
5574	10449788	7124;8660	TNF-alpha;IRS-2	***TNF-alpha*** ***suppresses*** IGF-I-induced tyrosine phosphorylation of insulin receptor substrate 2 ( ***IRS-2*** ) and inhibits IRS-2-precipitable phosphatidylinositol 3 ' - kinase activity .	negative	1
5575	10449788	7124;3480	TNF-alpha;IGF-I receptor	These experiments indicate that ***TNF-alpha*** promotes IGF-I receptor resistance in neurons and ***inhibits*** the ability of the ***IGF-I receptor*** to tyrosine-phosphorylate the IRS-2 docking molecule and to subsequently activate the critical downstream enzyme phosphatidylinositol 3 ' - kinase .	negative	1
5576	10449788	7124;3480	TNF-alpha;IGF-I receptor	These experiments indicate that ***TNF-alpha*** ***promotes*** ***IGF-I receptor*** resistance in neurons and inhibits the ability of the IGF-I receptor to tyrosine-phosphorylate the IRS-2 docking molecule and to subsequently activate the critical downstream enzyme phosphatidylinositol 3 ' - kinase .	positive	0
5577	10450836	3952;183	leptin;angiotensinogen	Moreover , plasma ***leptin*** was significantly ***correlated*** with plasma ***angiotensinogen*** levels .	parallel	0
5578	10450836	3952;5972	leptin;renin	Plasma ***leptin*** levels strongly ***correlate*** with plasma ***renin*** activity in patients with essential hypertension .	parallel	0
5579	10451345	6809;8773	syntaxin 3;SNAP23	***syntaxin 3*** is present on the apical membrane and forms a ***complex*** with ***SNAP23*** which is also localized on the basolateral membrane where it forms a complex with syntaxin 4 .	parallel	1
5580	10451350	7422;3791	VEGF;VEGFR-1 and -2	This may reflect the different binding properties of VEGFs to VEGFRs , in that ***VEGF-A*** ***binds*** to ***VEGFR-1 and -2*** , whereas VEGF-C acts through VEGFR-3 , whose expression becomes restricted to lymphatics and certain veins during development .	parallel	1
5581	10451350	7422;3791	VEGF;VEGFR-2	However , the finding that ***VEGF-C*** also binds to and ***activates*** ***VEGFR-2*** may explain why it induces angiogenesis under certain conditions , which makes it relevant to experimental or clinical settings in which one would wish to block or to stimulate angiogenesis .	positive	1
5582	10451362	23013;4488	MINT;Msx2	In toto , these data indicate that the novel nuclear protein ***MINT*** ***binds*** the homeoprotein ***Msx2*** and coregulates OC during craniofacial development .	parallel	1
5583	10452106	3586;3553	IL-10;IL-1 beta	TNF alpha , ***IL-1 beta*** , and IL-6 secretions were ***inhibited*** by recombinant ***IL-10*** , but the cytokines release was upregulated by anti-IL-10 monoclonal antibody .	negative	1
5584	10452106	3586;7124	IL-10;TNF alpha	***TNF alpha*** , IL-1 beta , and IL-6 secretions were ***inhibited*** by recombinant ***IL-10*** , but the cytokines release was upregulated by anti-IL-10 monoclonal antibody .	negative	1
5585	10452124	3586;3558	IL-10;IL-2	***IL-10*** and trichosanthin dramatically ***inhibited*** T-cell proliferation and ***IL-2*** production .	negative	1
5586	10452533	6714;52	Src;low molecular weight phosphotyrosine protein phosphatase	The ***low molecular weight phosphotyrosine protein phosphatase*** ( LMW-PTP ) is ***phosphorylated*** by ***Src*** and Src-related kinases both in vitro and in vivo ; in Jurkat cells , and in NIH-3T3 cells , it becomes tyrosine-phosphorylated upon stimulation by PDGF .	target	1
5587	10452537	4313;1462	MMP-2;versican	Large chondroitinsulphate-containing proteoglycan ( ***versican*** ) isolated from rabbit lung was ***cleaved*** by purified gelatinase A ( ***MMP-2*** ) and gelatinase B ( MMP-9 ) , as well as by crude enzyme extract from rabbit lung with hydraulic edema .	target	1
5588	10452548	6667;5327	Sp1;t-PA	Transient co-transfections of Drosophila SL2 and human HT1080 fibrosarcoma cells with t-PA reporter constructs showed that ***Sp1*** and Sp3 ***activate*** the ***t-PA*** promoter .	positive	1
5589	10452548	6670;5327	Sp3;t-PA	Transient co-transfections of Drosophila SL2 and human HT1080 fibrosarcoma cells with t-PA reporter constructs showed that Sp1 and ***Sp3*** ***activate*** the ***t-PA*** promoter .	positive	1
5590	10452684	3082;7039	HGF;TGF alpha	Expression of ***TGF alpha*** was ***enhanced*** by ***HGF*** treatment only in AsPC-1 cells .	positive	0
5591	10452684	3082;7039	Hepatocyte growth factor;transforming growth factor alpha	***Hepatocyte growth factor*** stimulates cell growth and ***enhances*** the expression of ***transforming growth factor alpha*** mRNA in AsPC-1 human pancreatic cancer cells .	positive	0
5592	10452765	728;727	C5aR;C5a	We have studied the genomic sequence of the ***C5a*** ***receptor*** ( ***C5aR*** ) in 2 of the subjects to determine whether this unresponsiveness was due to a genetic mutation or to aberrant complement activation associated with the MBL deficiency .	parallel	1
5593	10452968	7852;6387	CXCR4;stromal cell-derived factor-1	Human ***CXCR4*** is a specific ***receptor*** for the CXC chemokine ***stromal cell-derived factor-1*** ( SDF-1 ) and a coreceptor for T cell line tropic strains of HIV-1 .	parallel	1
5594	10452980	1843;5594	mitogen-activated protein kinase phosphatase-1;ERK-1/2	M-CSF induces the transient expression of ***mitogen-activated protein kinase phosphatase-1*** ( MKP-1 ) , which ***correlates*** with the inactivation of ***ERK-1/2*** .	parallel	0
5595	10452980	1435;1843	M-CSF;mitogen-activated protein kinase phosphatase-1	***M-CSF*** ***induces*** the transient expression of ***mitogen-activated protein kinase phosphatase-1*** ( MKP-1 ) , which correlates with the inactivation of ERK-1/2 .	target	1
5596	10452980	1435;1843	M-CSF;MKP-1	Because the time course of ERK activation must be finely controlled to induce cell proliferation , we studied the mechanisms involved in the ***induction*** of ***MKP-1*** by ***M-CSF*** .	target	1
5597	10452980	1435;5594	M-CSF;ERK-1/2	Therefore , ***M-CSF*** ***activates*** ***ERK-1/2*** and induces MKP-1 expression through different pathways .	positive	1
5598	10452980	1435;1843	M-CSF;MKP-1	Therefore , ***M-CSF*** activates ERK-1/2 and ***induces*** ***MKP-1*** expression through different pathways .	target	1
5599	10452980	1435;1843	M-CSF;MKP-1	The use of two protein kinase C ( PKC ) inhibitors ( GF109203X and calphostin C ) revealed that ***M-CSF*** ***induces*** ***MKP-1*** expression through a PKC-dependent pathway .	target	1
5600	10452982	959;958	CD154;CD40	These results suggest that the generation of allograft immunity is dependent on the ***interaction*** of ***CD154*** with ***CD40*** but not primarily for the activation of APCs .	parallel	1
5601	10452982	959;958	CD154;CD40	***CD154*** ( CD40 ligand , gp39 ) ***interaction*** with its receptor ***CD40*** has been shown to be critically important for the generation of cell-mediated as well as humoral immunity .	parallel	1
5602	10452987	7535;5788	ZAP70;CD45	Furthermore , unlike Syk , ***ZAP70*** ***required*** ***CD45*** to display receptor-induced increase in kinase activity .	target	0
5603	10452987	7535;5788	ZAP70;CD45	Therefore , in mast cells , ***ZAP70*** , but not Syk , ***requires*** ***CD45*** for Ag receptor-induced signaling .	target	0
5604	10452990	3586;3815	IL-10;Kit	***Inhibition*** of ***Kit*** expression by IL-4 and ***IL-10*** in murine mast cells : role of STAT6 and phosphatidylinositol 3 ' - kinase .	negative	1
5605	10452990	3815;6778	Kit;STAT6	Using mouse bone marrow-derived mast cells , we demonstrate that IL-4-mediated ***Kit*** down-regulation ***requires*** ***STAT6*** expression and phosphotidylinositide-3 ' - kinase activation .	target	0
5606	10452990	3586;3815	IL-10;Kit	We also find that the Th2 cytokine ***IL-10*** potently ***down-regulates*** ***Kit*** expression .	negative	1
5607	10452990	3586;3815	IL-10;Kit	***Inhibition*** of ***Kit*** expression by IL-4 and ***IL-10*** resulted in a loss of Kit-mediated signaling , as evidenced by reduced IL-13 and TNF-alpha mRNA induction after stem cell factor stimulation .	negative	1
5608	10452990	3586;3815	IL-10;Kit	These data offer a role for STAT6 and phosphotidylinositide-3 ' - kinase in IL-4-mediated Kit down-regulation , coupled with the novel observation that ***IL-10*** is a potent ***inhibitor*** of ***Kit*** expression and function .	negative	1
5609	10453004	3717;6776	JAK2;Stat5	Further consistent with inhibitory activity of SOCS3 , LPS also inhibited the ***JAK2-dependent*** ***activation*** of ***Stat5*** by GM-CSF .	positive	1
5610	10453004	1437;6776	GM-CSF;Stat5	Further consistent with inhibitory activity of SOCS3 , LPS also inhibited the JAK2-dependent ***activation*** of ***Stat5*** by ***GM-CSF*** .	positive	1
5611	10453005	2323;2322	flt3L;flt3	To delineate factors involved in NK cell development , we established an in vitro system in which lineage marker ( Lin ) - , c-kit + , Sca2 + bone marrow cells differentiate into lytic NK1 .1 + but Ly49 - cells upon culture in IL-7 , stem cell factor ( SCF ) , and ***flt3*** ***ligand*** ( ***flt3L*** ) , followed by IL-15 alone .	parallel	1
5612	10453010	3458;6772	IFN-gamma;STAT1	In this paper , we also show that the higher expression of Ia protein in B10R cells is associated with higher I-Abeta mRNA expression , which correlates with a higher level of ***IFN-gamma-induced*** ***phosphorylation*** of the ***STAT1-alpha*** protein and subsequently with elevated expression of class II transactivator ( CIITA ) mRNA , compared with B10S .	target	1
5613	10453013	3394;3553	ICSBP;IL-1beta	Furthermore , both IRF4 and ***ICSBP*** ***activated*** transcription of the ***IL-1beta*** promoter in both cell types .	positive	1
5614	10453013	3662;3553	IRF4;IL-1beta	Furthermore , both ***IRF4*** and ICSBP ***activated*** transcription of the ***IL-1beta*** promoter in both cell types .	positive	1
5615	10453013	6688;3553	PU.1;IL-1beta	Synergistic ***activation*** of the ***IL-1beta*** promoter by these IRF proteins and ***PU.1*** was found to require PU.1 serine 148 .	positive	1
5616	10453013	3394;6688	ICSBP;PU.1	In NIH-3T3 fibroblasts , IRF4 and ***ICSBP*** also ***synergized*** with exogenous ***PU.1*** to activate transcription of a PU.1/IRF-dependent promoter .	parallel	0
5617	10453013	3662;6688	IRF4;PU.1	In NIH-3T3 fibroblasts , ***IRF4*** and ICSBP also ***synergized*** with exogenous ***PU.1*** to activate transcription of a PU.1/IRF-dependent promoter .	parallel	0
5618	10453032	3727;5743	AP-1;cyclooxygenase-2	Superoxide attenuates macrophage apoptosis by NF-kappa B and ***AP-1*** activation that ***promotes*** ***cyclooxygenase-2*** expression .	positive	0
5619	10453032	4790;5743	NF-kappa B;cyclooxygenase-2	Superoxide attenuates macrophage apoptosis by ***NF-kappa B*** and AP-1 activation that ***promotes*** ***cyclooxygenase-2*** expression .	positive	0
5620	10453034	6356;3565	Eotaxin;IL-4	***Eotaxin*** ***potentiates*** antigen-dependent basophil ***IL-4*** production .	positive	0
5621	10453034	6356;3565	Eotaxin;IL-4	***Eotaxin*** alone had no effect on basophil IL-4 production , but further ***increased*** allergen-stimulated ***IL-4*** expression .	positive	0
5622	10453034	6356;3565	Eotaxin;IL-4	***Eotaxin*** also ***enhanced*** ***IL-4*** release from purified basophils 2 - to 4-fold , as determined by ELISA ( p < 0.01 ) .	positive	0
5623	10453034	6356;3562	Eotaxin;IL-3	Additionally , ***Eotaxin*** ***augmented*** ***IL-3*** priming of basophil IL-4 production in a synergistic manner ( p < 0.01 ) .	positive	0
5624	10453053	3725;2908	c-Jun;glucocorticoid receptor	The ***c-Jun*** protein ***inhibits*** the transcriptional activity of the ***glucocorticoid receptor*** and thus represses glutamine synthetase expression .	negative	1
5625	10453053	3725;2752	c-Jun;glutamine synthetase	The ***c-Jun*** protein inhibits the transcriptional activity of the glucocorticoid receptor and thus ***represses*** ***glutamine synthetase*** expression .	negative	1
5626	10453054	2066;2064	erbB-4;erbB-2	They stimulate LHRH secretion indirectly , via activation of erbB-1 / erbB-2 and ******erbB-4/erbB-2****** receptor ***complexes*** also located on astrocytes .	parallel	1
5627	10453074	7124;355	TNF-alpha;Fas	Another cell death induction system : ***TNF-alpha*** acts as a ***ligand*** for ***Fas*** in vaginal cells .	parallel	1
5628	10453074	7124;355	TNF-alpha;Fas	Here , we propose that ***TNF-alpha*** acts for the ***ligand*** for ***Fas*** in vaginal cells , suggesting a new cell death induction system .	parallel	1
5629	10453076	356;355	CD95L;CD95	We describe induction of apoptosis by IFNgamma through the expression of ***CD95*** and its ***ligand*** ( ***CD95L*** ) in human neuroblastoma cell lines .	parallel	1
5630	10453076	356;355	CD95L;CD95	Our results demonstrated that cytokine-mediated apoptosis was mediated through the activation of the CD95/CD95L autocrine circuit since : ( i ) cell death occurred following CD95/CD95L expression and correlated with CD95 and CD95L expression levels , ( ii ) failed to occur in a clone which weakly upregulated CD95 and lacked CD95L induction after IFNgamma stimulation , ( iii ) was at least partially inhibited by using blocking F ( ab ' ) 2 anti-CD95 antibody fragments and the recombinant Fas-Fc protein , that prevented the ***interaction*** between ***CD95*** and ***CD95L*** .	parallel	1
5631	10453520	5443;3458	beta-endorphin;IFN-gamma	[ ***beta-endorphin*** ***enhances*** IL-2 and ***IFN-gamma*** gene expression in human blood mononuclear cells ] .	positive	0
5632	10453520	5443;3558	beta-endorphin;IL-2	[ ***beta-endorphin*** ***enhances*** ***IL-2*** and IFN-gamma gene expression in human blood mononuclear cells ] .	positive	0
5633	10453553	3126;3630	DR4;IDDM	[ Study on the ***association*** of ***HLA-DR4*** with ***IDDM*** susceptibility in a Chinese population ] .	parallel	0
5634	10453553	3126;3630	DR4;IDDM	As an additional evidence , the findings above mentioned may account for the different ***association*** of different ***DR4*** subtypes with ***IDDM*** in various ethnic groups .	parallel	0
5635	10453562	632;7421	osteocalcin;vitamin D receptor	[ The ***association*** between ***vitamin D receptor*** gene polymorphisms , bone mineral density and ***osteocalcin*** in Chinese women ] .	parallel	0
5636	10453739	10726;5048	NUDC;NudF	In both Aspergillus nidulans and the mouse , studies of the nuclear distribution gene C ( NUDC ) have strongly suggested that the ***NUDC*** protein ***interacts*** with ***NudF*** , which is the product of NudF , a homologue of human LIS1 ( also know as PAFAH1B1 ) , one of the causative genes for classical lissencephaly .	parallel	1
5637	10453987	3479;3725	IGF-I;c-Jun	We have characterized ***IGF-I*** ***stimulated*** phosphorylation of IRS-1 , activation of Ras cycle and phosphorylation of ***c-Jun*** in this cell line .	positive	0
5638	10453987	3479;3667	IGF-I;IRS-1	We have characterized ***IGF-I*** ***stimulated*** phosphorylation of ***IRS-1*** , activation of Ras cycle and phosphorylation of c-Jun in this cell line .	positive	0
5639	10454161	5979;2668	Ret;GDNF	We propose that the neuroprotective effect of ***GDNF*** on 6-OHDA-treated dopaminergic neurons in vitro is most likely ***mediated*** by functional ***Ret*** receptor signaling pathways .	target	0
5640	10454258	1543;1571	CYP1A1;CYP2E1	Many investigators have reported an ***association*** between genetic polymorphisms of cytochromes P-450 ***CYP2E1*** , ***CYP1A1*** or glutathione S-transferase Mu ( GSTM1 ) and susceptibility to lung cancer .	parallel	0
5641	10454343	7124;3458	Tumor necrosis factor-alpha;interferon-gamma	We describe a novel mechanism of signaling interaction through which ***Tumor necrosis factor-alpha*** ( TNF-alpha ) treatment ***augments*** ***interferon-gamma*** ( IFN-gamma ) - induced Stat1alpha DNA-binding complexes and transcriptional activation of a Stat-binding element .	positive	0
5642	10454343	3458;3717	IFN-gamma;Jak2	In TNF-alpha-treated cells , ***IFN-gamma-induced*** ***phosphorylation*** of ***Jak2*** kinase is increased , Jak2 kinase activity is enhanced , and genetic studies indicate that TNF-alpha requires Jak2 kinase activity to enhance Stat1alpha tyrosine phosphorylation .	target	1
5643	10454343	7124;3717	TNF-alpha;Jak2	In TNF-alpha-treated cells , IFN-gamma-induced phosphorylation of Jak2 kinase is increased , Jak2 kinase activity is enhanced , and genetic studies indicate that ***TNF-alpha*** ***requires*** ***Jak2*** kinase activity to enhance Stat1alpha tyrosine phosphorylation .	target	0
5644	10454343	3458;7124	IFN-gamma;TNF-alpha	Thus , there exists a direct signaling ***interaction*** between ***TNF-alpha*** and ***IFN-gamma*** , independent of cooperating enhancer elements , that may be relevant for cytokine action during immune-mediated host defense and inflammatory processes .	parallel	1
5645	10454352	3458;355	interferon-gamma;Fas	In the present study , we showed that ***Fas-L*** expression on AK-5 cells is ***regulated*** by ***interferon-gamma*** ( IFN-gamma ) and tumor necrosis factor-alpha ( TNF-alpha ) , as injection of antibodies against IFN-gamma downregulated the expression of Fas-L by tumor cells as determined by immunostaining and Northern hybridizations .	target	1
5646	10454352	7124;355	TNF-alpha;Fas	In the present study , we showed that ***Fas-L*** expression on AK-5 cells is ***regulated*** by interferon-gamma ( IFN-gamma ) and tumor necrosis factor-alpha ( ***TNF-alpha*** ) , as injection of antibodies against IFN-gamma downregulated the expression of Fas-L by tumor cells as determined by immunostaining and Northern hybridizations .	target	1
5647	10454435	3816;3827	Tissue kallikrein;kininogen	***Tissue kallikrein*** ***cleaves*** ***kininogen*** substrate to produce vasoactive kinin peptides that have been implicated in the proliferation of vascular smooth muscle cells ( VSMCs ) .	target	1
5648	10454532	3066;5928	RPD3;RbAp48	We show that ***RPD3*** ***associates*** with ***RbAp48*** through N - and C-terminal contacts and that RbAp48 also interacts with SIN3 .	parallel	0
5649	10454533	3312;27102	Hsc70;HRI	Clofibric acid disrupted the ***interaction*** of ***Hsc70*** with transformed ***HRI*** that had been matured and transformed in the absence of the drug .	parallel	1
5650	10454533	3312;27102	Hsc70;HRI	Disruption of ***Hsc70*** ***interaction*** with transformed ***HRI*** in heme-deficient RRL resulted in its hyperactivation .	parallel	1
5651	10454533	3312;27102	Hsc70;HRI	Furthermore , activation of HRI in response to heat shock or denatured proteins also resulted in a similar blockage of ***Hsc70*** ***interaction*** with transformed ***HRI*** .	parallel	1
5652	10454533	3312;27102	Hsc70;HRI	Recently , we have demonstrated that the heat shock cognate protein ***Hsc70*** negatively ***modulates*** the activation of ***HRI*** in RRL in response to these environmental conditions .	negative	0
5653	10454533	3312;27102	Hsc70;HRI	Like Hsp90 , ***Hsc70*** ***interacted*** with nascent HRI and ***HRI*** that was matured to a state which was competent to undergo stimulus-induced activation ( mature-competent HRI ) .	parallel	1
5654	10454533	27102;3312	HRI;Hsc70	***Interaction*** of ***HRI*** with ***Hsc70*** was required for the transformation of HRI , as the Hsc70 antagonist clofibric acid inhibited the folding of HRI into a mature-competent conformation .	parallel	1
5655	10454533	3312;27102	Hsc70;HRI	Unlike Hsp90 , ***Hsc70*** also ***interacted*** with transformed ***HRI*** .	parallel	1
5656	10454534	7157;983	p53;CDC2	Down regulation was mediated by ***p53-dependent*** transcriptional ***repression*** of the ***CDC2*** and cyclin B promoters .	negative	1
5657	10454536	207;4790	Rac;NF-kappaB	The ability of ***Rac*** to suppress Ras-induced apoptosis is dependent on effector pathway ( s ) controlled by the insert region and is ***linked*** to the activation of ***NF-kappaB*** .	parallel	0
5658	10454538	4609;7040	c-Myc;TGF-beta	The evidence suggests that ***c-Myc*** ***interferes*** with ***TGF-beta*** activation of the p15 G ( 1 ) arrest pathway .	negative	0
5659	10454538	7040;4609	TGF-beta;c-Myc	***TGF-beta*** must therefore ***downregulate*** ***c-Myc*** in order to activate this pathway .	negative	1
5660	10454538	4609;1030	c-Myc;p15	We show that ***c-Myc*** ***prevents*** induction of the cdk4 inhibitor ***p15*** ( Ink4b ) and the subsequent inhibition of G ( 1 ) cdks by TGF-beta .	negative	0
5661	10454539	4790;597	NF-kappaB;Bfl-1	***NF-kappaB*** ***induces*** expression of the Bcl-2 homologue ***A1/Bfl-1*** to preferentially suppress chemotherapy-induced apoptosis .	target	1
5662	10454539	4790;841	NF-kappaB;caspase 8	For example , it was shown that ***NF-kappaB*** activation ***suppresses*** the activation of ***caspase 8*** , the apical caspase in tumor necrosis factor ( TNF ) receptor family signaling cascades , through the transcriptional regulation of certain TRAF and IAP proteins .	negative	1
5663	10454543	27336;2963	Tat-SF1;RAP30	***Tat-SF1*** protein ***associates*** with ***RAP30*** and human SPT5 proteins .	parallel	0
5664	10454543	27336;6829	Tat-SF1;SPT5	***Tat-SF1*** protein ***associates*** with RAP30 and human ***SPT5*** proteins .	parallel	0
5665	10454543	6829;27336	hSPT5;Tat-SF1	In nuclear extracts , small fractions of both ***hSPT5*** and Pol II are ***associated*** with ***Tat-SF1*** protein .	parallel	0
5666	10454543	2963;27336	RAP30;Tat-SF1	Surprisingly , the ***RAP30*** protein of the heterodimeric transcription TFIIF factor is ***associated*** with ***Tat-SF1*** , while the RAP74 subunit of TFIIF is not coimmunoprecipitated with Tat-SF1 .	parallel	0
5667	10454547	5594;595	ERK;cyclin D1	Taken together , these results show that ( i ) early induction of the MEK/ERK cascade is restricted to hepatocytes from hepatectomized animals , allowing an early distinction of primed hepatocytes from those returning to quiescence , and ( ii ) mid-late G ( 1 ) ***MEK/ERK*** activation is mainly ***associated*** with ***cyclin D1*** accumulation which leads to mitogen-independent progression of hepatocytes to S phase .	parallel	0
5668	10454547	5609;595	MEK;cyclin D1	Taken together , these results show that ( i ) early induction of the MEK/ERK cascade is restricted to hepatocytes from hepatectomized animals , allowing an early distinction of primed hepatocytes from those returning to quiescence , and ( ii ) mid-late G ( 1 ) ***MEK/ERK*** activation is mainly ***associated*** with ***cyclin D1*** accumulation which leads to mitogen-independent progression of hepatocytes to S phase .	parallel	0
5669	10454554	472;545	TEL1;MEC1	***Interactions*** of TLC1 ( which encodes the RNA subunit of telomerase ) , ***TEL1*** , and ***MEC1*** in regulating telomere length in the yeast Saccharomyces cerevisiae .	parallel	1
5670	10454555	472;836	ATM;caspase 3	We establish that ATM cleavage in vivo is dependent on caspases , reveal that ***ATM*** is an efficient ***substrate*** for ***caspase 3*** but not caspase 6 in vitro , and show that the in vitro caspase 3 cleavage pattern mirrors that in cells undergoing apoptosis .	parallel	1
5671	10454561	4790;4792	NF-kappaB;IkappaBalpha	Identification by in vivo genomic footprinting of a transcriptional switch containing ***NF-kappaB*** and Sp1 that ***regulates*** the ***IkappaBalpha*** promoter .	target	1
5672	10454561	6667;4792	Sp1;IkappaBalpha	Identification by in vivo genomic footprinting of a transcriptional switch containing NF-kappaB and ***Sp1*** that ***regulates*** the ***IkappaBalpha*** promoter .	target	1
5673	10454561	4790;4792	NF-kappaB;IkappaBalpha	***IkappaBalpha*** gene expression is also ***regulated*** by an ***NF-kappaB*** autoregulatory mechanism , via NF-kappaB binding sites in the IkappaBalpha promoter .	target	1
5674	10454561	4792;5970	IkappaBalpha;RelA	In the present study , we demonstrate that expression of TD-IkappaBalpha blocked phorbol myristate acetate-phytohemagglutinin or tumor necrosis factor alpha-induced IkappaBalpha gene transcription and abolished NF-kappaB DNA binding activity , due to the continued cytoplasmic ***sequestration*** of ***RelA*** ( p65 ) by ***TD-IkappaBalpha*** .	negative	0
5675	10454561	4792;4790	IkappaBalpha;NF-kappaB	In the present study , we demonstrate that expression of ***TD-IkappaBalpha*** blocked phorbol myristate acetate-phytohemagglutinin or tumor necrosis factor alpha-induced IkappaBalpha gene transcription and ***abolished*** ***NF-kappaB*** DNA binding activity , due to the continued cytoplasmic sequestration of RelA ( p65 ) by TD-IkappaBalpha .	negative	0
5676	10454561	4790;5966	p50;c-Rel	Prolonged NF-kappaB binding and a temporal switch in the composition of NF-kappaB complexes bound to the -63 to -53 kappaB1 site of the IkappaBalpha promoter were also observed ; with time after induction , decreased levels of transcriptionally active p50-p65 and increased ******p50-c-Rel****** ***heterodimers*** were detected at the kappaB1 site .	parallel	1
5677	10454563	1387;2033	CBP;p300	We identified a new highly conserved motif in the AD1 region which is important for ******CBP/p300****** ***binding*** .	parallel	1
5678	10454566	3562;4170	IL-3;mcl-1	Reporter gene assays further showed that the PI3-K/Akt signaling pathway was involved in ***IL-3*** ***activation*** of ***mcl-1*** gene transcription .	positive	1
5679	10454566	3562;4170	IL-3;mcl-1	Analysis of the mcl-1 promoter revealed that both promoter elements , SIE at position -87 and CRE-2 at -70 , contribute to ***IL-3*** ***stimulation*** of ***mcl-1*** gene expression .	positive	0
5680	10454566	3562;4170	IL-3;mcl-1	Lastly , we showed that CREB was one component of the CRE-2 binding complex and played a role in ***IL-3*** ***activation*** of the ***mcl-1*** reporter gene .	positive	1
5681	10454566	3562;4170	IL-3;mcl-1	Taken together , our results suggest that both PI3-K/Akt-dependent and - independent pathways contribute to the ***IL-3*** ***activation*** of ***mcl-1*** gene expression .	positive	1
5682	10454570	2114;1386	Ets-2;ATF-2	Role of distinct mitogen-activated protein kinase pathways and ***cooperation*** between ***Ets-2*** , ***ATF-2*** , and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate .	parallel	0
5683	10454570	2114;3725	Ets-2;Jun	Role of distinct mitogen-activated protein kinase pathways and ***cooperation*** between ***Ets-2*** , ATF-2 , and ***Jun*** family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate .	parallel	0
5684	10454570	3725;1386	Jun;ATF-2	Role of distinct mitogen-activated protein kinase pathways and ***cooperation*** between Ets-2 , ***ATF-2*** , and ***Jun*** family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate .	parallel	0
5685	10454570	3725;1386	c-Jun;ATF-2	Both the IL-1 and the TPA-mediated induction result in a drastic increase of AP-1 binding to the downstream site of the enhancer ( uPA 3 ' TPA-responsive element ) , while a mostly qualitative change , resulting from the interplay between ATF-2 homodimers and ******c-Jun-ATF-2****** ***heterodimers*** , takes place at the upstream AP-1 element .	parallel	1
5686	10454570	3725;1386	c-Jun;ATF-2	Both the IL-1 and the TPA-mediated induction result in a drastic increase of AP-1 binding to the downstream site of the enhancer ( uPA 3 ' TPA-responsive element ) , while a mostly qualitative change , resulting from the ***interplay*** between ATF-2 homodimers and ******c-Jun-ATF-2****** heterodimers , takes place at the upstream AP-1 element .	parallel	1
5687	10454582	6929;3205	E2A;Hoxa9	The results obtained demonstrated a strong synergistic ***interaction*** between ***E2A-Pbx1a*** and ***Hoxa9*** in inducing growth factor-independent proliferation of transduced bone marrow cells in vitro and leukemic growth in vivo in only 39 + / - 2 days .	parallel	1
5688	10454591	5925;1869	pRb;E2F-1	***Complexes*** between the retinoblastoma protein ( ***pRb*** ) and the transcription factor ***E2F-1*** are thought to be important for regulating cell proliferation .	parallel	1
5689	10454591	5925;1869	pRb;E2F-1	These data suggest that an important role for ******pRb-E2F-1****** ***complex*** during fiber cell differentiation is to negatively regulate cell cycle progression , thereby allowing completion of the differentiation program to occur .	parallel	1
5690	10454619	4149;4609	Max;c-Myc	Specificity of DNA ***binding*** of the ******c-Myc/Max****** and ARNT/ARNT dimers at the CACGTG recognition site .	parallel	1
5691	10454619	4609;4149	c-Myc;Max	Basic helix-loop-helix proteins that interact with the DNA recognition site CACGTG include the ******c-Myc/Max****** ***heterodimer*** and the ARNT ( Ahreceptornucleartranslocator ) homodimer .	parallel	1
5692	10454619	4149;4609	Max;c-Myc	These flanking sequences also regulate the ability of ARNT to competitively displace the ******c-Myc/Max****** ***heterodimer*** from a CACGTG-containing sequence .	parallel	1
5693	10454739	7040;23552	TGF-beta 1;p42	***TGF-beta 1*** delayed EGF - or PDGF-induced cyclin D1 expression and ***blocked*** the induction of active ***p42/p44MAPK*** .	negative	0
5694	10454739	7040;5595	TGF-beta 1;p44MAPK	***TGF-beta 1*** delayed EGF - or PDGF-induced cyclin D1 expression and ***blocked*** the induction of active ***p42/p44MAPK*** .	negative	0
5695	10454739	595;1019	cyclin D1;cdk4	The current study is concerned with the evaluation of a key cyclin ( ***cyclin D1*** ) which ***activates*** ***cdk4*** and p27KIP1 which in turn inhibit cdk2 in the proliferative responses of epidermal growth factor ( EGF ) and platelet-derived growth factor ( PDGF ) and their modulation by TGF-beta 1 .	positive	1
5696	10454739	595;1027	cyclin D1;p27KIP1	The current study is concerned with the evaluation of a key cyclin ( ***cyclin D1*** ) which ***activates*** cdk4 and ***p27KIP1*** which in turn inhibit cdk2 in the proliferative responses of epidermal growth factor ( EGF ) and platelet-derived growth factor ( PDGF ) and their modulation by TGF-beta 1 .	positive	1
5697	10454739	1019;1017	cdk4;cdk2	The current study is concerned with the evaluation of a key cyclin ( cyclin D1 ) which activates ***cdk4*** and p27KIP1 which in turn ***inhibit*** ***cdk2*** in the proliferative responses of epidermal growth factor ( EGF ) and platelet-derived growth factor ( PDGF ) and their modulation by TGF-beta 1 .	negative	1
5698	10454739	1027;1017	p27KIP1;cdk2	The current study is concerned with the evaluation of a key cyclin ( cyclin D1 ) which activates cdk4 and ***p27KIP1*** which in turn ***inhibit*** ***cdk2*** in the proliferative responses of epidermal growth factor ( EGF ) and platelet-derived growth factor ( PDGF ) and their modulation by TGF-beta 1 .	negative	1
5699	10454749	6670;6667	Sp3;Sp1	One of the elements responsible for the oncogene-mediated downregulation of mouse RECK gene is the Sp1 site , where the ***Sp1*** and ***Sp3*** factors ***bind*** .	parallel	1
5700	10454826	7124;7852	Tumor necrosis factor alpha;chemokine receptor	***Tumor necrosis factor alpha*** ***regulates*** CXC ***chemokine receptor*** expression and function .	target	1
5701	10454826	7124;3579	TNFalpha;CXCR-2	In flow cytometry experiments , ***TNFalpha*** pretreatment substantially ***decreased*** cell surface ***CXCR-2*** receptor levels but showed partial recovery at 120 min .	negative	0
5702	10454832	3553;4050	IL-1;LTB	Plasma ***LTB*** , and TNF were ***reduced*** by ***IL-1*** blockade , compared with septic controls .	positive	1
5703	10455015	1270;1103	CNTF;ChAT	We previously reported that ciliary neurotrophic factor ( ***CNTF*** ) ***upregulates*** the expression of ***ChAT*** and VAChT , as well as ACh production , in SN56 cells .	positive	1
5704	10455016	1586;4519	CYP17;cytochrome b	That the defect could be essentially reversed by lysine mutagenesis has led to the conclusion that the cationic charges on all three residues ( at the positions of Arg ( 347 ) , Arg ( 358 ) , Arg ( 449 ) ) are vital for the functional ***interaction*** of ***CYP17*** with ***cytochrome b*** ( 5 ) and that the loss of any one of these cationic charges is catastrophic .	parallel	1
5705	10455033	2822;2353	GPI-PLD;c-Fos	We also confirmed that the phosphorylation of ***c-Fos*** as well as PKCalpha itself was greatly ***enhanced*** by the expression of ***GPI-PLD*** .	positive	0
5706	10455060	1026;1017	p21;cdk2	However , ***p21*** ***blocked*** ***cdk2*** kinase activity induced by both E1A pathways equally .	negative	0
5707	10455089	7124;3952	TNFalpha;leptin	***TNFalpha*** ***increases*** secretion of ***leptin*** , a hormone which decreases food intake and increases energy expenditure .	positive	0
5708	10455112	5617;3717	prolactin;Janus kinase 2	***prolactin*** ( PRL ) has been shown to ***activate*** the cytoplasmic tyrosine kinase ***Janus kinase 2*** ( Jak2 ) and the subsequent recruitment of various signaling molecules including members of the signal transducer and activator of transcription family of transcription factors .	positive	1
5709	10455112	8651;3717	SOCS-1;Jak2	Constitutive expression of ***SOCS-1*** and SOCS-3 ***suppressed*** PRL-induced signal transducer and activator of transcription 5-dependent gene transcription , and ***Jak2*** tyrosine kinase activity was greatly reduced in the presence of SOCS-1 or SOCS-3 .	negative	1
5710	10455112	9021;3717	SOCS-3;Jak2	Constitutive expression of SOCS-1 and ***SOCS-3*** ***suppressed*** PRL-induced signal transducer and activator of transcription 5-dependent gene transcription , and ***Jak2*** tyrosine kinase activity was greatly reduced in the presence of SOCS-1 or SOCS-3 .	negative	1
5711	10455112	8835;5618	SOCS-2;prolactin receptor	SOCS-1 was shown to associate with Jak2 , whereas ***SOCS-2*** was ***associated*** with the ***prolactin receptor*** .	parallel	0
5712	10455112	8835;8651	SOCS-2;SOCS-1	***SOCS-2*** was shown to ***suppress*** the inhibitory effect of ***SOCS-1*** by restoring Jak2 kinase activity but did not affect the inhibitory effect of SOCS-3 on PRL signaling .	negative	1
5713	10455128	8517;4790	IKK-gamma;NF-kappaB	This study compared the effect of these stimuli on endogenous IkappaB kinase ( IKK ) signalsome activation and IkappaB phosphorylation/proteolysis in human monocytic cells and investigated the role of the signalsome proteins IKK-alpha , IKK-beta , NF-kappaB-inducing kinase ( NIK ) , ***IKK-gamma*** ( ***NF-kappaB*** essential ***modulator*** ) , and IKK complex-associated protein .	target	0
5714	10455128	1147;4792	IKK-alpha;IkappaB-alpha	Furthermore , our studies showed ***association*** of the ***IKK-alpha/beta*** heterodimer with NIK , ***IkappaB-alpha*** and - epsilon in unstimulated cells .	parallel	0
5715	10455128	1147;9020	IKK-alpha;NIK	Furthermore , our studies showed ***association*** of the ***IKK-alpha/beta*** heterodimer with ***NIK*** , IkappaB-alpha and - epsilon in unstimulated cells .	parallel	0
5716	10455134	861;640	AML1;BLK	Physical interaction of AML1 with BSAP correlates with functional cooperativity in transfection studies where ***AML1*** and BSAP synergistically ***activate*** ***BLK*** promoter transcription by more than 50-fold .	positive	1
5717	10455139	7555;4547	Sterol regulatory element-binding protein;microsomal triglyceride transfer protein	***Sterol regulatory element-binding protein*** negatively ***regulates*** ***microsomal triglyceride transfer protein*** gene transcription .	negative	1
5718	10455189	796;5829	calcitonin;paxillin	***calcitonin*** also ***induced*** the tyrosine phosphorylation of ***paxillin*** and focal adhesion kinase , and the association of these two proteins with HEF1 .	target	1
5719	10455189	796;4739	calcitonin;HEF1	In conclusion , the ***calcitonin-stimulated*** tyrosine ***phosphorylation*** of ***HEF1*** is mediated by calcium - and protein kinase C-dependent mechanisms and requires the integrity of the actin cytoskeleton .	target	1
5720	10455189	796;4739	calcitonin;HEF1	The ***calcitonin-induced*** tyrosine ***phosphorylation*** of ***HEF1*** increased in a time - and dose-dependent manner .	target	1
5721	10455189	796;4739	calcitonin;HEF1	Increasing cytosolic Ca ( 2 + ) with ionomycin stimulated HEF1 phosphorylation and preventing any calcitonin-induced change in cytosolic calcium by a combination of BAPTA and extracellular EGTA completely blocked the ***calcitonin-induced*** tyrosine ***phosphorylation*** of ***HEF1*** .	target	1
5722	10455190	7038;7849	thyroglobulin;Pax-8	Follicular ***thyroglobulin*** ( TG ) ***decreases*** expression of the thyroid-restricted transcription factors , thyroid transcription factor (TTF)-1 , TTF-2 , and ***Pax-8*** , thereby suppressing expression of the sodium iodide symporter , thyroid peroxidase , TG , and thyrotropin receptor genes ( Suzuki , K. , Lavaroni , S. , Mori , A. , Ohta , M. , Saito , J. , Pietrarelli , M. , Singer , D.	negative	0
5723	10455190	7038;7080	thyroglobulin;thyroid transcription factor (TTF)-1	Follicular ***thyroglobulin*** ( TG ) ***decreases*** expression of the thyroid-restricted transcription factors , ***thyroid transcription factor (TTF)-1*** , TTF-2 , and Pax-8 , thereby suppressing expression of the sodium iodide symporter , thyroid peroxidase , TG , and thyrotropin receptor genes ( Suzuki , K. , Lavaroni , S. , Mori , A. , Ohta , M. , Saito , J. , Pietrarelli , M. , Singer , D.	negative	0
5724	10455190	7038;2304	thyroglobulin;TTF-2	Follicular ***thyroglobulin*** ( TG ) ***decreases*** expression of the thyroid-restricted transcription factors , thyroid transcription factor (TTF)-1 , ***TTF-2*** , and Pax-8 , thereby suppressing expression of the sodium iodide symporter , thyroid peroxidase , TG , and thyrotropin receptor genes ( Suzuki , K. , Lavaroni , S. , Mori , A. , Ohta , M. , Saito , J. , Pietrarelli , M. , Singer , D.	negative	0
5725	10455211	596;7157	Bcl-2;p53	***Bcl-2*** expression was correlated with positive ER ( P < 0.001 ) and PgR ( P < 0.001 ) status and inversely ***correlated*** with ***p53*** ( P = 0.0036 ) , Ki-67 ( P = 0.0073 ) , and nuclear cytologic grade ( P < 0.001 ) .	negative	0
5726	10455211	596;5241	Bcl-2;PgR	***Bcl-2*** expression was ***correlated*** with positive ER ( P < 0.001 ) and ***PgR*** ( P < 0.001 ) status and inversely correlated with p53 ( P = 0.0036 ) , Ki-67 ( P = 0.0073 ) , and nuclear cytologic grade ( P < 0.001 ) .	parallel	0
5727	10455260	3553;6356	IL-1beta;eotaxin	***Induction*** of ***eotaxin*** expression and release from human airway smooth muscle cells by ***IL-1beta*** and TNFalpha : effects of IL-10 and corticosteroids .	target	1
5728	10455260	7124;6356	TNFalpha;eotaxin	***Induction*** of ***eotaxin*** expression and release from human airway smooth muscle cells by IL-1beta and ***TNFalpha*** : effects of IL-10 and corticosteroids .	target	1
5729	10455361	3553;2322	IL-1beta;flt-3	In the presence of early acting cytokines interleukin-1beta ( ***IL-1beta*** ) , IL-3 , IL-6 , stem cell factor ( SCF ) , ***flt-3*** ***ligand*** with and without thrombopoietin ( Tpo ) , we compared the expansion capacity of CD34 + enriched cells from CB , NB and bone marrow ( BM ) .	parallel	1
5730	10455886	3576;2919	IL-8;GRO-alpha	***IL-8*** and ***GRO-alpha*** ***interact*** to modulate these PMN [ Ca2 + ] i responses .	parallel	1
5731	10455887	1432;7124	p38 map kinase;tumor necrosis factor alpha	Evidence of a central role for ***p38 map kinase*** ***induction*** of ***tumor necrosis factor alpha*** in pancreatitis-associated pulmonary injury .	target	1
5732	10455907	7040;5328	TGF-beta 1;uPA	***TGF-beta 1*** ***upregulated*** ***uPA*** production only in the RIE-S cells .	positive	1
5733	10455916	2247;5594	FGF-2;ERK-1 and -2	CONCLUSIONS : ***ERK-1 and -2*** are ***activated*** by ***FGF-2*** released from endothelial cells in response to injury .	positive	1
5734	10455994	7040;567	TGF-beta 1;beta 2-microglobulin	***TGF-beta 1*** ***inhibits*** HLA-DR and ***beta 2-microglobulin*** expression in HeLa cells induced with r-IFN .	negative	1
5735	10456033	51176;1499	Lef1;beta-catenin	What is the structural basis of specific protein-protein interactions , such as those between homeodomain proteins and ******beta-catenin-Lef1****** ***interactions*** , and how are these determinants altered in transcriptional regulation in oncogenesis and in genetic diseases ?	parallel	1
5736	10456457	5104;5624	protein C inhibitor;protein C	***Inhibition*** of activated ***protein C*** ( APC ) by ***protein C inhibitor*** ( PCI ) is stimulated by heparin , whereas inhibition by alpha1-antitrypsin ( AAT ) is heparin-independent .	negative	1
5737	10456458	5627;2159	protein S;prothrombinase	***Regulation*** of ***prothrombinase*** activity by ***protein S*** .	target	1
5738	10456672	596;947	Bcl-2;CD34	***Bcl-2*** over-expression is ***associated*** with ***CD34*** positivity , poor response to chemotherapy and reduced overall survival in AML patients .	parallel	0
5739	10456775	5478;811	cyclophilin A;calreticulin	Identification of simian cyclophilin A as a calreticulin-binding protein in yeast two-hybrid screen and demonstration of ***cyclophilin A*** ***interaction*** with ***calreticulin*** .	parallel	1
5740	10456882	942;1493	B7.2;CTLA-4	In addition , decreased expression of CD28 and increased expression of B7.2 on T cells would favor ***B7.2*** ***interaction*** with ***CTLA-4*** on T cells , and this could provide a negative signal to developing Th2 cells .	parallel	1
5741	10457011	4929;7054	Nurr1;tyrosine hydroxylase	***Nurr1*** , an orphan nuclear receptor , is a transcriptional ***activator*** of endogenous ***tyrosine hydroxylase*** in neural progenitor cells derived from the adult brain .	positive	1
5742	10457011	4929;7054	Nurr1;tyrosine hydroxylase	In gain-of-function experiments , ***Nurr1*** is able to ***activate*** transcription of the ***tyrosine hydroxylase*** gene by binding a response element within a region of the tyrosine hydroxylase promoter necessary for midbrain-specific expression .	positive	1
5743	10457107	3497;3115	IgE;HLA-DPB	RESULTS : Significant linkage of mite-specific ***IgE*** ***response*** to ***HLA-DPB*** ( P = 0.00001 ) , HLA-DRB ( 0.02 ) and HLA-DQB ( P = 0.001 ) was revealed by sibpair analysis of MHC class II alleles and confirmed by the extended transmission disequilibrium test for HLA-DRB ( P = 0.01 ) and HLA-DPB ( P = 0.04 ) .	parallel	0
5744	10457217	5747;2885	FAK;Grb2	***FAK*** in MRL-lpr glomeruli is highly tyrosine phosphorylated and is ***associated*** with adapter protein ***Grb2*** .	parallel	0
5745	10457260	5741;250	PTH;ALP	In this system , ***PTH/PTHrP*** was found to ***repress*** type X collagen synthesis , ***ALP*** expression , and cartilage matrix mineralization .	negative	1
5746	10457260	5744;250	PTHrP;ALP	In this system , ***PTH/PTHrP*** was found to ***repress*** type X collagen synthesis , ***ALP*** expression , and cartilage matrix mineralization .	negative	1
5747	10457260	5741;250	PTH;ALP	In this system , ***PTH*** addition to culture completely ***inhibited*** the expression of ***ALP*** and matrix mineralization , whereas cell proliferation and expression of type I collagen were not affected .	negative	1
5748	10457261	7040;7422	TGF-beta1;vascular endothelial growth factor	Moreover , virally produced ***TGF-beta1*** was functionally active and ***regulated*** the expression of collagen IalphaI ( 5-fold increase ) and the ***vascular endothelial growth factor*** ( 2.5-fold increase ) .	target	1
5749	10457348	5055;5340	PAI-2;plasmin	In addition , the activation of ***plasmin*** from plasminogen was ***inhibited*** by anti-E-cadherin antibodies and ***PAI-2*** , consistent with a role for uPA .	negative	1
5750	10457352	3458;355	IFNgamma;FAS	In colonic organ cultures , ***IFNgamma*** and TNFalpha also ***enhanced*** colonocyte ***FAS*** expression , resulting in a markedly increased apoptotic response to stimulation of this receptor , as shown by in situ terminal deosyuridine triphosphate nick-end staining .	positive	0
5751	10457352	7124;355	TNFalpha;FAS	In colonic organ cultures , IFNgamma and ***TNFalpha*** also ***enhanced*** colonocyte ***FAS*** expression , resulting in a markedly increased apoptotic response to stimulation of this receptor , as shown by in situ terminal deosyuridine triphosphate nick-end staining .	positive	0
5752	10457352	355;356	FAS;FAS ligand	******FAS-FAS ligand****** ***interaction*** has been implicated in increased enterocyte apoptosis seen in immune-mediated bowel injury .	parallel	1
5753	10457352	3458;355	IFNgamma;FAS	The sensitizing effect to FAS-induced apoptosis was mediated via TNFalpha - and ***IFNgamma-induced*** ***upregulation*** of ***FAS*** expression ( maximally 348 % ) .	positive	1
5754	10457364	5813;4155	Puralpha;myelin basic protein	***Regulation*** of ***myelin basic protein*** gene transcription by Sp1 and ***Puralpha*** : evidence for association of Sp1 and Puralpha in brain .	target	1
5755	10457364	5813;4155	Puralpha;MBP	Results from cotransfection studies revealed that ectopic expression of ***Puralpha*** and Sp1 synergistically ***stimulates*** ***MBP*** promoter activity in CNS cells .	positive	0
5756	10457893	3558;3458	IL-2;IFN-gamma	We conclude that , upon antigenic stimulation , the initially mounted immune response ( increased IL-6 ) is somehow blocked/switched off in patients , resulting in an immunologic tolerance/unresponsiveness to MA ( ***IL-2*** ***decreased*** , ***IFN-gamma*** unchanged ) .	negative	0
5757	10458758	940;6375	CD28;lymphotactin	Transcript destabilization can be ruled out as a mechanism by which ***CD28*** ***down-regulates*** ***lymphotactin*** expression .	negative	1
5758	10458759	6750;3458	somatostatin;IFN-gamma	Macrophages secrete the immunoregulatory peptide ***somatostatin*** ( SOM ) that ***inhibits*** ***IFN-gamma*** release by splenocytes and granuloma cells of schistosome-infected mice .	negative	1
5759	10458769	6850;5777	Syk;SHP1	Taken together , our findings support the notion that ZAP-70 and ***Syk*** can be direct ***substrates*** for ***SHP1*** in intact cells .	parallel	1
5760	10458769	7535;5777	ZAP-70;SHP1	Taken together , our findings support the notion that ***ZAP-70*** and Syk can be direct ***substrates*** for ***SHP1*** in intact cells .	parallel	1
5761	10458775	3456;836	IFN-beta;caspase 3	***IFN-beta*** also ***inhibited*** ***caspase 3*** and the proteolytic activation of PKC-delta .	negative	1
5762	10458911	9181;998	GEF;Cdc42	FGD1 encodes a guanine nucleotide exchange factor ( ***GEF*** ) that specifically ***activates*** the Rho GTPase ***Cdc42*** .	positive	1
5763	10458914	8878;3434	p62;p56	The amino acid sequence homology search also reveals that STAP is identical to a mouse oxidative stress protein , A170 , and has 90 % homology with a human ***p62*** protein that ***binds*** to the tyrosine kinase ***p56*** ( lck ) SH2 domain .	parallel	1
5764	10458926	4352;7066	c-mpl;TPO	We have previously shown that specific murine liver EC ( LEC-1 ) located in the hepatic sinusoids coexpress ***TPO*** and its ***receptor*** , ***c-mpl*** .	parallel	1
5765	10458928	3791;7422	KDR;VEGF	Reverse transcriptase-polymerase chain reaction analysis demonstrated the presence of both ***KDR*** and flt mRNA , two known ***VEGF*** ***receptors*** , in SMC cultures .	parallel	1
5766	10459014	991;51343	Cdc20;Cdh1	We found that not only the ***binding*** of the activators ***Cdc20*** and ***Cdh1*** and the inhibitor Mad2 to APC , but also the phosphorylation of Cdc20 and Cdh1 by Cdc2-Cyclin B and that of APC by Polo-like kinase and cAMP-dependent protein kinase , regulate APC activity .	parallel	1
5767	10459014	991;4085	Cdc20;Mad2	We found that not only the ***binding*** of the activators ***Cdc20*** and Cdh1 and the inhibitor ***Mad2*** to APC , but also the phosphorylation of Cdc20 and Cdh1 by Cdc2-Cyclin B and that of APC by Polo-like kinase and cAMP-dependent protein kinase , regulate APC activity .	parallel	1
5768	10459014	51343;4085	Cdh1;Mad2	We found that not only the ***binding*** of the activators Cdc20 and ***Cdh1*** and the inhibitor ***Mad2*** to APC , but also the phosphorylation of Cdc20 and Cdh1 by Cdc2-Cyclin B and that of APC by Polo-like kinase and cAMP-dependent protein kinase , regulate APC activity .	parallel	1
5769	10459017	5357;7431	fimbrin;vimentin	A 1:4 stoichiometry of fimbrin binding to vimentin and a low percentage ( 1 % ) of the extracted vimentin suggest that ***fimbrin*** ***interacts*** with a ***vimentin*** subunit .	parallel	1
5770	10459017	5357;7431	fimbrin;vimentin	A 1:4 stoichiometry of ***fimbrin*** ***binding*** to ***vimentin*** and a low percentage ( 1 % ) of the extracted vimentin suggest that fimbrin interacts with a vimentin subunit .	parallel	1
5771	10459017	5357;7431	fimbrin;vimentin	Based on these observations , we propose that a ******fimbrin-vimentin****** ***complex*** may be involved in directing the assembly of the vimentin cytoskeleton at cell adhesion sites .	parallel	1
5772	10459018	960;302	CD44;annexin II	Taken together , our data indicate that in mammary epithelial cells the vast majority of ***CD44*** ***interacts*** with ***annexin II*** in lipid rafts in a cholesterol-dependent manner .	parallel	1
5773	10459018	960;302	CD44;annexin II	These basolateral ******CD44/annexin II-lipid****** raft ***complexes*** were stabilized by addition of GTPgammaS or phalloidin in a semipermeabilized and cholesterol-depleted cell system .	parallel	1
5774	10459021	7076;3486	TIMP-1;IGFBP-3	Ligand blotting showed that IGFBP-3 protein levels were increased in TIMP-1-overexpressing double transgenic littermates , whereas IGFBP-3 mRNA levels were not different , suggesting that ***TIMP-1*** ***affects*** ***IGFBP-3*** at a posttranscriptional level .	target	0
5775	10459500	4292;1647	MLH1;GADD45	In the group of fibromatous naevi , ***MLH1*** ***correlated*** significantly with ***GADD45*** and highly significant with GADD34 expression .	parallel	0
5776	10459548	958;941	CD40;CD80	***CD40*** ligation ***induced*** phenotypic and functional expression of ***CD80*** by human cardiac microvascular endothelial cells .	target	1
5777	10459548	958;959	CD40;CD40L	BACKGROUND : ******CD40/CD40L****** ( gp39 ) ***interactions*** are known to play a central role in the function of the immune system ( 1 ) .	parallel	1
5778	10459548	959;958	CD40L;CD40	RESULTS : ******CD40-CD40L****** ***interactions*** induced the expression of the adhesion molecules VCAM-1 and E-selectin and the costimulatory molecule CD80 but not CD86 ( B7-2 ) on the MECs .	parallel	1
5779	10459548	958;941	CD40;CD80	RESULTS : ***CD40-CD40L*** interactions ***induced*** the expression of the adhesion molecules VCAM-1 and E-selectin and the costimulatory molecule ***CD80*** but not CD86 ( B7-2 ) on the MECs .	target	1
5780	10459548	959;941	CD40L;CD80	RESULTS : ***CD40-CD40L*** interactions ***induced*** the expression of the adhesion molecules VCAM-1 and E-selectin and the costimulatory molecule ***CD80*** but not CD86 ( B7-2 ) on the MECs .	target	1
5781	10459631	7039;1956	TGF-alpha;EGFR	Although the ratios of TGF-alpha , EGFR and PCNA mRNA to beta-actin mRNA were not significantly different among the diseases , the ***TGF-alpha/beta-actin*** ratio ***correlated*** with ***EGFR/beta-actin*** and PCNA/beta-actin ratios ( p < 0.001 and p < 0.0001 , respectively ) , and EGFR/beta-actin ratio was related to PCNA/beta-actin ratio in all patients , especially with HCC .	parallel	0
5782	10459631	1956;5111	EGFR;PCNA	Although the ratios of TGF-alpha , EGFR and PCNA mRNA to beta-actin mRNA were not significantly different among the diseases , the TGF-alpha/beta-actin ratio correlated with EGFR/beta-actin and PCNA/beta-actin ratios ( p < 0.001 and p < 0.0001 , respectively ) , and ***EGFR/beta-actin*** ratio was ***related*** to ***PCNA/beta-actin*** ratio in all patients , especially with HCC .	parallel	0
5783	10459843	3586;3558	interleukin-10;IL-2	This results in the synthesis of ***interleukin-10*** ( IL-10 ) , which ***suppresses*** the formation of interferon-gamma ( INF-gamma ) and ***IL-2*** , and of IL-6 , which suppresses T-cell responses .	negative	1
5784	10459843	3586;3458	interleukin-10;interferon-gamma	This results in the synthesis of ***interleukin-10*** ( IL-10 ) , which ***suppresses*** the formation of ***interferon-gamma*** ( INF-gamma ) and IL-2 , and of IL-6 , which suppresses T-cell responses .	negative	1
5785	10459849	5241;3484	progesterone receptor;insulin-like growth factor binding protein-1	***Activation*** of the ***insulin-like growth factor binding protein-1*** promoter by ***progesterone receptor*** in decidualized human endometrial stromal cells .	positive	1
5786	10459859	655;7422	Osteogenic protein-1;vascular endothelial growth factor	***Osteogenic protein-1*** ***increases*** gene expression of ***vascular endothelial growth factor*** in primary cultures of fetal rat calvaria cells .	positive	0
5787	10459859	655;7422	OP-1;VEGF	***OP-1*** ***increased*** the steady-state level of ***VEGF*** mRNA by about 3-fold in an OP-1 concentration - and time-dependent manner .	positive	0
5788	10459866	1387;3960	CBP;GAL4	Also , ***CBP*** ***potentiated*** the transcriptional activity of ***GAL4-SF-1*** in the presence of PKA .	positive	0
5789	10459866	1387;2516	CBP;SF-1	Also , ***CBP*** ***potentiated*** the transcriptional activity of ***GAL4-SF-1*** in the presence of PKA .	positive	0
5790	10460227	3815;4254	c-kit;stem cell factor	The potential role of ***stem cell factor*** and its ***receptor*** ***c-kit*** in the mouse blastocyst implantation .	parallel	1
5791	10460227	3815;4254	c-kit;stem cell factor	***stem cell factor*** ( SCF ) and its ***receptor*** ***c-kit*** regulate the proliferation and survival of germ cells and play an important role in follicular development .	parallel	1
5792	10460232	8448;23025	Doc2alpha;Munc13-1	Furthermore , presynaptic loading of a synthetic peptide with the sequence of the N-terminal domain of ***Doc2alpha*** ***interacting*** with ***Munc13-1*** ( Mid peptide ) significantly attenuated PESP , whereas mutated Mid peptide had no effect .	parallel	1
5793	10460245	375790;2353	agrin;c-fos	Here we show , in cultured cortical neurons , that ***agrin*** ***induces*** expression of the immediate early gene ***c-fos*** in a concentration-dependent and saturable manner , as expected for a signal transduction pathway activated by a cell surface receptor .	target	1
5794	10460248	8573;6382	CASK;syndecan	The ******syndecan-CASK****** ***interaction*** may be involved in intercellular signaling and/or cell adhesion .	parallel	1
5795	10460248	8573;9672	CASK;syndecan-3	In support of this , we were able to coimmunoprecipitate a ***complex*** of ***CASK*** and ***syndecan-3*** from brain extracts .	parallel	1
5796	10460257	1600;333	Dab1;APLP1	The ***association*** of ***Dab1*** with ***APLP1*** was confirmed in biochemical assays , and the site of interaction was localized to a cytoplasmic region of APLP1 containing the amino acid sequence motif Asn-Pro-x-Tyr ( NPxY ) .	parallel	0
5797	10460257	1600;351	Dab1;amyloid precursor protein	Indeed , we found that ***Dab1*** also ***interacts*** with ***amyloid precursor protein*** ( APP ) and APLP2 in biochemical association experiments .	parallel	1
5798	10460257	1600;334	Dab1;APLP2	Indeed , we found that ***Dab1*** also ***interacts*** with amyloid precursor protein ( APP ) and ***APLP2*** in biochemical association experiments .	parallel	1
5799	10460591	2322;5781	flt3;CFC	In addition , ***flt3-L*** ***increased*** the detection of ***HPP-CFC*** , both immediately after cell selection , and after 7 and 14 d of cultures .	positive	0
5800	10460607	2056;6776	Epo;STAT5	***Epo*** was able to ***stimulate*** ***STAT5*** DNA binding activity in all normal and 12/24 MDS marrows tested , with no correlation between the level of STAT5 activation and the development of erythroid colonies in response to Epo .	positive	0
5801	10460611	970;939	CD70;CD27	In normal lymphoid tissues the tumour necrosis factor-receptor family member ***CD27*** and its ***ligand*** ***CD70*** have a restricted expression pattern .	parallel	1
5802	10460756	3557;3553	IRAP;IL-1	We conclude that IL-8 is produced by virus vector-infected cells , partly through ***IL-1*** activation that can be ***downregulated*** by ***IRAP*** .	negative	1
5803	10460756	3557;3576	Interleukin-1 receptor antagonist;interleukin-8	***Interleukin-1 receptor antagonist*** ***inhibits*** ***interleukin-8*** expression in A549 respiratory epithelial cells infected in vitro with a replication-deficient recombinant adenovirus vector .	negative	1
5804	10460756	3557;3553	IRAP;IL-1	We tested the hypothesis that the induction of IL-8 by the AV1LacZ4 adenovirus is accomplished by means of the ***IL-1/IL-8*** activation pathway , which could be ***blocked*** by IL-1 receptor antagonist ( ***IRAP*** ) .	negative	0
5805	10460756	3557;3576	IRAP;IL-8	We tested the hypothesis that the induction of IL-8 by the AV1LacZ4 adenovirus is accomplished by means of the ***IL-1/IL-8*** activation pathway , which could be ***blocked*** by IL-1 receptor antagonist ( ***IRAP*** ) .	negative	0
5806	10460779	7124;3576	TNF-alpha;IL-8	RESULTS : Simultaneous addition of IL-4 inhibited ***TNF-alpha*** ***induced*** ***IL-8*** production in both corneal epithelial cells and keratocytes .	target	1
5807	10460779	3565;6352	IL-4;RANTES	TNF-alpha and ***IL-4*** synergistically ***stimulated*** the production of ***RANTES*** in keratocytes .	positive	0
5808	10460779	7124;6352	TNF-alpha;RANTES	***TNF-alpha*** and IL-4 synergistically ***stimulated*** the production of ***RANTES*** in keratocytes .	positive	0
5809	10461428	5340;5345	plasmin;alpha 2-antiplasmin	METHODS : Plasma thrombin-antithrombin III ( TAT ) and ******plasmin-alpha 2-antiplasmin****** ( PAP ) ***complexes*** were measured using ELISA methods in 32 patients with sepsis and 20 controls and were analyzed according to the APACHE III scores and survival of the patients .	parallel	1
5810	10461887	323;351	hFE65L;amyloid precursor protein	***hFE65L*** ***influences*** ***amyloid precursor protein*** maturation and secretion .	target	0
5811	10461980	551;5443	AVP;ACTH	As in other species , it seems that ***AVP*** ***enhances*** the release of ***ACTH*** and cortisol .	positive	0
5812	10462036	7422;3791	VEGF;KDR	In HCAEC , ***VEGF*** ***stimulates*** phosphorylation of ***KDR*** in a concentration-dependent manner proving that KDDR is a functional receptor tyrosine kinase .	positive	0
5813	10462040	7124;3576	tumor necrosis factor-alpha;interleukin-8	Redox-dependent ***regulation*** of ***interleukin-8*** by ***tumor necrosis factor-alpha*** in lung epithelial cells .	target	1
5814	10462047	7040;5599	TGF-beta1;JNK	These results demonstrate that ***TGF-beta1*** ***inhibits*** LPS-stimulated ***JNK*** activity in mouse macrophages .	negative	1
5815	10462168	7124;1401	TNF-alpha;CRP	The concentration of ***TNF-alpha*** was positively ***correlated*** with the concentrations of plasma IL-6 , sTNFR-II , and ***CRP*** .	positive	0
5816	10462226	7040;1634	TGF-beta1;decorin	***TGF-beta1*** ***decreased*** ***decorin*** mRNA expression in the cells dose dependently , but did not affect their biglycan mRNA expression .	negative	0
5817	10462226	7040;1634	TGF-beta1;decorin	Both rhBMP-2 and ***TGF-beta1*** ***inhibit*** ***decorin*** mRNA expression in osteoblasts at varying stages of differentiation , but their effects on biglycan mRNA expression and alkaline phosphatase are different .	negative	1
5818	10462278	1401;7139	CRP;cTnT	A logistic multivariate analysis revealed that age and ***CRP*** significantly ***influenced*** ***cTnT*** .	target	0
5819	10462445	200879;2159	phospholipase A;factor Xa	Targeting of venom phospholipases : the strongly anticoagulant ***phospholipase A*** ( 2 ) from Naja nigricollis venom ***binds*** to coagulation ***factor Xa*** to inhibit the prothrombinase complex .	parallel	1
5820	10462445	200879;2159	phospholipase A;prothrombinase	Targeting of venom phospholipases : the strongly anticoagulant ***phospholipase A*** ( 2 ) from Naja nigricollis venom binds to coagulation factor Xa to ***inhibit*** the ***prothrombinase*** complex .	negative	1
5821	10462445	200879;2159	phospholipase A;prothrombinase	The strongly anticoagulant basic ***phospholipase A*** ( 2 ) ( CM-IV ) from Naja nigricollis venom has previously been shown to ***inhibit*** the ***prothrombinase*** complex of the coagulation cascade by a novel nonenzymatic mechanism ( S.	negative	1
5822	10462502	3458;185	IFN-gamma;AT1	These results suggest that ***IFN-gamma*** can ***inhibit*** ***AT1*** receptor expression at gene transcription level , and that the transcription suppression is dependent on MAP kinase and Jak-2 .	negative	1
5823	10462506	6416;3297	SEK1;HSF1	Furthermore , the dominant-negative mutant of ***SEK1*** ***blocked*** the phosphorylation of ***HSF1*** and up-regulation of mitochondrial HSP75 in response to vincristine or vinblastine .	positive	0
5824	10462506	5599;3329	JNK;HSP60	These data suggest that anticancer drugs regulate the HSF1 transcriptional activity differently from heat shock , and ***JNK/SAPK*** pathway appears to be involved in anticancer drug-induced HSF1 phosphorylation and consequently differential ***regulation*** of mitochondrial HSP75 and ***HSP60*** and cytoplasmic HSP70 .	target	1
5825	10462506	5599;10131	JNK;HSP75	These data suggest that anticancer drugs regulate the HSF1 transcriptional activity differently from heat shock , and ***JNK/SAPK*** pathway appears to be involved in anticancer drug-induced HSF1 phosphorylation and consequently differential ***regulation*** of mitochondrial ***HSP75*** and HSP60 and cytoplasmic HSP70 .	target	1
5826	10462506	5601;3329	SAPK;HSP60	These data suggest that anticancer drugs regulate the HSF1 transcriptional activity differently from heat shock , and ***JNK/SAPK*** pathway appears to be involved in anticancer drug-induced HSF1 phosphorylation and consequently differential ***regulation*** of mitochondrial HSP75 and ***HSP60*** and cytoplasmic HSP70 .	target	1
5827	10462506	5601;10131	SAPK;HSP75	These data suggest that anticancer drugs regulate the HSF1 transcriptional activity differently from heat shock , and ***JNK/SAPK*** pathway appears to be involved in anticancer drug-induced HSF1 phosphorylation and consequently differential ***regulation*** of mitochondrial ***HSP75*** and HSP60 and cytoplasmic HSP70 .	target	1
5828	10462517	7422;1499	VEGF;beta-catenin	Here we show that : ( 1 ) vascular endothelial growth factor ( ***VEGF*** ) ***induces*** ***beta-catenin*** tyrosine phosphorylation in a time - , and dose-dependent manner and that VEGF receptors co-localize to areas of endothelial cell-cell contact in vitro and in vivo .	target	1
5829	10462524	7430;1499	Ezrin;beta-catenin	Furthermore , coprecipitation studies revealed an ***association*** of ***Ezrin*** with E-cadherin and ***beta-catenin*** .	parallel	0
5830	10462524	7430;999	Ezrin;E-cadherin	Furthermore , coprecipitation studies revealed an ***association*** of ***Ezrin*** with ***E-cadherin*** and beta-catenin .	parallel	0
5831	10462524	3082;7430	hepatocyte growth factor;Ezrin	***Induction*** of the phosphorylation of ***Ezrin*** by orthovanadate and ***hepatocyte growth factor/scatter factor*** resulted in changes similar to those seen with antisense treatment , together with a marked decrease in the association of Ezrin with both beta-catenin and E-cadherin .	target	1
5832	10462524	7430;1499	Ezrin;beta-catenin	Induction of the phosphorylation of Ezrin by orthovanadate and hepatocyte growth factor/scatter factor resulted in changes similar to those seen with antisense treatment , together with a marked decrease in the ***association*** of ***Ezrin*** with both ***beta-catenin*** and E-cadherin .	parallel	0
5833	10462524	7430;999	Ezrin;E-cadherin	Induction of the phosphorylation of Ezrin by orthovanadate and hepatocyte growth factor/scatter factor resulted in changes similar to those seen with antisense treatment , together with a marked decrease in the ***association*** of ***Ezrin*** with both beta-catenin and ***E-cadherin*** .	parallel	0
5834	10462686	1435;1436	CSF-1;CSF-1R	We demonstrated that in cultures the ligand ***CSF-1*** ***binds*** to its receptor ( ***CSF-1R*** ) in neurons and that reduction of the number of apoptotic neurons and potentiation of neuron survival is CSF-1 dose dependent .	parallel	1
5835	10462686	1435;1436	CSF-1;CSF-1R	We propose that ******CSF-1/CSF-1R****** ***signaling*** is an important regulatory pathway between neurons , microglia , and astrocytes .	parallel	0
5836	10462715	4609;3308	c-myc;HSP70	We report on the identification of a third ***c-myc*** binding site ( between -158 and -162 ) that is an important ***regulator*** of magnetic field-induced ***HSP70*** expression .	target	1
5837	10463072	6261;5860	RyR1;DHPR	In E-C coupling of skeletal muscle ( DICR ) , the reciprocal tight ***interactions*** between ***DHPR*** and ***RyR1*** are critically required .	parallel	1
5838	10463146	348;338	apolipoprotein E;apolipoprotein B	The interaction between genetic and environmental factors is further illustrated with results from the ***association*** of ***apolipoprotein E*** polymorphism with the level of ***apolipoprotein B*** and a variety of other determinants of apolipoprotein B level .	parallel	0
5839	104634	5617;7200	Prolactin;thyrotropin-releasing factor	***Prolactin*** ***responses*** to provocative ***thyrotropin-releasing factor*** ( TRH ) stimulation were evaluated in 43 chronic alcoholic men were divided into groups for analysis based on the presence or absence of gynecomastia and the histologic appearance of their livers as determined by percutaneous liver biopsy .	parallel	0
5840	10463569	1786;5111	DNMT1;proliferating cell nuclear antigen	The polypeptide p21 , which has been reported to undermine ***DNMT1*** ***binding*** to ***proliferating cell nuclear antigen*** at DNA replication sites , was not expressed by normal colonic cells containing DNMT1 and other cell proliferation markers .	parallel	1
5841	10463582	3481;3091	IGF-2;HIF-1alpha	We demonstrate that insulin , insulin-like growth factor (IGF)-1 , and ***IGF-2*** ***induce*** expression of ***HIF-1alpha*** , which is required for expression of genes encoding IGF-2 , IGF-binding protein (IGFBP)-2 and IGFBP-3 .	target	1
5842	10463582	3479;3091	insulin-like growth factor (IGF)-1;HIF-1alpha	We demonstrate that insulin , ***insulin-like growth factor (IGF)-1*** , and IGF-2 ***induce*** expression of ***HIF-1alpha*** , which is required for expression of genes encoding IGF-2 , IGF-binding protein (IGFBP)-2 and IGFBP-3 .	target	1
5843	10463585	9622;5269	kallikrein;protease inhibitor-6	Identification of a novel ***complex*** between human ***kallikrein*** 2 and ***protease inhibitor-6*** in prostate cancer tissue .	parallel	1
5844	10463621	3958;595	galectin-3;cyclin D1	Interestingly , ***galectin-3*** ***induces*** ***cyclin D1*** expression ( an early G1 cyclin ) and its associated kinase activity in the absence of cell anchorage .	target	1
5845	10463774	3557;3553	Interleukin-1 receptor antagonist;IL-1	***Interleukin-1 receptor antagonist*** ( IL-1ra ) , an endogeneous ***inhibitor*** of ***IL-1*** , plays an immunosuppressive role in vivo by blocking the proinflammatory effects of IL-1 .	negative	1
5846	10463949	3600;4792	IL-15;IkappaBalpha	Most important , binding of ***IL-15*** to IL-15Ralpha successfully competes with the TNFR1 complex for TRAF2 binding , which may impede assembly of key adaptor proteins to the TNFR1 complex , and ***induces*** ***IkappaBalpha*** phosphorylation .	target	1
5847	10463960	3576;213	interleukin-8;albumin	***interleukin-8*** ***correlated*** with neutrophils ( rho = 0.72 , P < 0.001 ) , fibrinogen ( rho = 0.65 , P < 0.001 ) , ***albumin*** ( rho = 0.67 , P = 0 .	parallel	0
5848	10463960	6863;213	substance P;albumin	***substance P*** ***correlated*** with ***albumin*** ( rho = 0.60 , P = 0.006 ) .	parallel	0
5849	10464055	7422;2321	VEGF;Flt-1	***VEGF*** ***binds*** to two cell surface tyrosine-kinase receptors , KDR ( kinase domain region ) and ***Flt-1*** ( fms-like tyrosine kinase-1 ) .	parallel	1
5850	10464143	3553;2875	IL-1beta;alanine aminotransferase	Both serum ***alanine aminotransferase*** value and hepatic DNA fragmentation were significantly ***suppressed*** by ***IL-1beta*** pretreatment .	negative	1
5851	10464169	1432;7124	p38 mitogen-activated protein kinase;TNF-alpha	The ***p38 mitogen-activated protein kinase*** ( MAPK ) is involved in ***control*** of ***TNF-alpha*** translation in human macrophages .	target	0
5852	10464169	5594;7124	p38;TNF-alpha	Therefore , both PI 3-K and ***p38*** MAPK signaling pathways ***control*** ***TNF-alpha*** production in T cells .	target	0
5853	10464238	121512;5599	frabin;JNK	Full-length ***frabin*** ***induces*** microspike formation and c-Jun N-terminal kinase ( ***JNK*** ) activation .	target	1
5854	10464245	4790;595	NF-kappaB;cyclin D1	Stable overexpression of Rac ( Leu-61 ) increased ***binding*** of Rel A and ***NF-kappaB*** ( 1 ) to the ***cyclin D1*** promoter NF-kappaB site .	parallel	1
5855	10464245	207;4790	Rac;NF-kappaB	Stable overexpression of ***Rac*** ( Leu-61 ) ***increased*** binding of Rel A and ***NF-kappaB*** ( 1 ) to the cyclin D1 promoter NF-kappaB site .	positive	0
5856	10464245	5879;595	Rac1;cyclin D1	Activation of ***Rac1*** in NIH 3T3 cells induces both NF-kappaB binding and activity and ***enhances*** expression of ***cyclin D1*** through an NF-kappaB and ATF-2 site in the proximal promoter , suggesting a critical role for NF-kappaB in cell cycle regulation through cyclin D1 and Rac1 .	positive	0
5857	10464245	5879;4790	Rac1;NF-kappaB	Activation of ***Rac1*** in NIH 3T3 cells ***induces*** both ***NF-kappaB*** binding and activity and enhances expression of cyclin D1 through an NF-kappaB and ATF-2 site in the proximal promoter , suggesting a critical role for NF-kappaB in cell cycle regulation through cyclin D1 and Rac1 .	target	1
5858	10464245	207;595	Rac;cyclin D1	Integration of ***Rac-dependent*** ***regulation*** of ***cyclin D1*** transcription through a nuclear factor-kappaB-dependent pathway .	target	1
5859	10464245	5879;595	Rac1;cyclin D1	In the current studies , activating mutants of ***Rac1*** ( Rac ( Leu-61 ) , Rac ( Val-12 ) ) ***induced*** cyclin D1 expression and the ***cyclin D1*** promoter in NIH 3T3 cells .	target	1
5860	10464245	5879;595	Rac1;cyclin D1	***Induction*** of ***cyclin D1*** by ***Rac1*** required both an NF-kappaB and an ATF-2 binding site .	target	1
5861	10464245	595;4790	cyclin D1;NF-kappaB	Induction of ***cyclin D1*** by Rac1 ***required*** both an ***NF-kappaB*** and an ATF-2 binding site .	target	0
5862	10464245	4792;4790	IkappaBalpha;NF-kappaB	Inhibiting NF-kappaB by overexpression of an ***NF-kappaB*** trans-dominant ***inhibitor*** ( nonphosphorylatable ***IkappaBalpha*** ) reduced cyclin D1 promoter activation by the Rac1 mutants , placing NF-kappaB in a pathway of Rac1 activation of cyclin D1 .	negative	1
5863	10464245	4790;595	NF-kappaB;cyclin D1	The ***NF-kappaB*** factors Rel A ( p65 ) and NF-kappaB ( 1 ) ( p50 ) ***induced*** the ***cyclin D1*** promoter , requiring both the NF-kappaB binding site and the ATF-2 site .	target	1
5864	10464250	207;1843	Rac;mitogen-activated protein kinase (MAPK) phosphatase 1	Cyclic strain stress-induced ***mitogen-activated protein kinase (MAPK) phosphatase 1*** expression in vascular smooth muscle cells is ***regulated*** by ***Ras/Rac-MAPK*** pathways .	target	1
5865	10464253	6283;6280	S100A12;MRP14	However , no evidence for direct protein-protein ***interactions*** of ***S100A12*** with either MRP8 or ***MRP14*** or the heterodimer was found by chemical cross-linking , density gradient centrifugation , mass spectrometric measurements , or yeast two hybrid detection .	parallel	1
5866	10464253	6283;6279	S100A12;MRP8	However , no evidence for direct protein-protein ***interactions*** of ***S100A12*** with either ***MRP8*** or MRP14 or the heterodimer was found by chemical cross-linking , density gradient centrifugation , mass spectrometric measurements , or yeast two hybrid detection .	parallel	1
5867	10464254	382;1675	ARF6;adipsin	In contrast , the secretion of ***adipsin*** , a serine protease specifically expressed in adipocytes , was ***increased*** by the expression of wild-type ***ARF6*** and was inhibited by the expression of D125N .	positive	0
5868	10464270	65108;89782	MRP;gp63	MARCKS-related protein ( ***MRP*** ) is a ***substrate*** for the Leishmania major surface protease leishmanolysin ( ***gp63*** ) .	parallel	1
5869	10464270	89782;65108	gp63;MRP	***MRP*** was similarly ***degraded*** by purified leishmanolysin ( ***gp63*** ) , a Leishmania surface metalloprotease .	negative	0
5870	10464278	1440;6774	G-CSF;STAT 3	***G-CSF-induced*** tyrosine ***phosphorylation*** of ***STAT 3*** in Trf-R ( - ) cells much more than in Trf-R ( + ) cells .	target	1
5871	10464279	6622;4137	alpha-synuclein;Tau	***alpha-synuclein*** ***binds*** to ***Tau*** and stimulates the protein kinase A-catalyzed Tau phosphorylation of serine residues 262 and 356 .	parallel	1
5872	10464279	6622;4137	alpha-synuclein;Tau	***alpha-synuclein*** binds to Tau and ***stimulates*** the protein kinase A-catalyzed ***Tau*** phosphorylation of serine residues 262 and 356 .	positive	0
5873	10464279	4137;6622	Tau;alpha-synuclein	High concentrations of tubulin inhibited the ***binding*** between ***Tau*** and ***alpha-synuclein*** .	parallel	1
5874	10464279	6622;4137	alpha-synuclein;Tau	We propose that ***alpha-synuclein*** ***modulates*** the phosphorylation of soluble axonal ***Tau*** and thereby indirectly affects the stability of axonal microtubules .	target	0
5875	10464283	54521;8766	Rabphilin-11;rab11	***Rabphilin-11*** ***bound*** ***GTP-rab11*** more preferentially than GDP-rab11 at the N-terminal region and was specific for rab11 and inactive for other Rab and Rho small G proteins .	parallel	1
5876	10464309	858;857	caveolin-2;caveolin-1	Conversely , transient expression of ***caveolin-2*** in CHO cells is sufficient to ***up-regulate*** endogenous ***caveolin-1*** expression .	positive	1
5877	10464309	857;858	caveolin-1;caveolin-2	Interestingly , we also show that expression of ***caveolin-1*** in K562 cells dramatically ***up-regulates*** the expression of endogenous ***caveolin-2*** .	positive	1
5878	10464309	857;858	caveolin-1;caveolin-2	Northern blot analysis reveals that caveolin-2 mRNA levels remain constant under these conditions , suggesting that the expression of ***caveolin-1*** ***stabilizes*** the ***caveolin-2*** protein .	positive	0
5879	10464310	2260;1398	FGFR-1;Crk	Transient tyrosine phosphorylation of Crk in fibroblast growth factor-2-stimulated endothelial cells was dependent on the juxtamembrane tyrosine residue 463 in FGFR-1 , and a Crk SH2 domain precipitated FGFR-1 via phosphorylated Tyr-463 , indicating direct complex ***formation*** between ***Crk*** and ***FGFR-1*** .	parallel	0
5880	10464310	1398;2889	Crk;C3G	Furthermore , ***Crk*** SH2 and SH3 domains formed ligand-independent ***complexes*** with Shc , ***C3G*** , and the Crk-associated substrate ( Cas ) .	parallel	1
5881	10464310	1398;6464	Crk;Shc	Furthermore , ***Crk*** SH2 and SH3 domains formed ligand-independent ***complexes*** with ***Shc*** , C3G , and the Crk-associated substrate ( Cas ) .	parallel	1
5882	10464324	5906;673	rap1;B-raf	In spite of the close homology between p21 ( ras ) and rap1 , the S17N mutant of rap1 was not dominant negative because ( i ) overexpression of rap1 ( S17N ) failed to inhibit A ( 2A ) receptor-dependent MAP kinase activation , ( ii ) rap1 ( S17N ) was recovered in the active form with a GST fusion protein comprising the rap1-binding domain of ralGDS after A ( 2A ) receptor activation , and ( iii ) A ( 2A ) agonists promoted the ***association*** of ***rap1*** ( S17N ) with the 68-kDa isoform of ***B-raf*** in CHO cells .	parallel	0
5883	10464329	2353;10531	AP-1;metalloprotease-1	Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the ***AP-1-mediated*** ***induction*** of matrix-degrading ***metalloprotease-1*** .	target	1
5884	10464330	4043;7436	RAP;VLDL receptor	Using intracellular cross-linking techniques , we found that ***RAP*** is ***associated*** with newly synthesized ***VLDL receptor*** .	parallel	0
5885	10464378	84260;581	tumor-suppressor protein;Bax	In using immunocytochemistry to seek putative death factors , we observed that squamous epithelial cells of the tongue were negative for Bax , a death factor in the Bcl-2 family of survival/death factors , and were also negative for p53 , a ***tumor-suppressor protein*** ***linked*** to apoptosis and ***Bax*** transcription .	parallel	0
5886	10464393	6863;2922	substance P;gastrin-releasing peptide	***Interaction*** between ***substance P*** and ***gastrin-releasing peptide*** on thyrotropin secretion by rat pituitary in vitro .	parallel	1
5887	10464565	5329;7448	u-PAR;vitronectin	Direct ***interactions*** of ***u-PAR*** with ***vitronectin*** and integrins further regulate cell invasion .	parallel	1
5888	10464779	6900;1463	TAG-1;neurocan	Although both L1 and ***TAG-1*** have been reported to ***bind*** both ***neurocan*** and phosphacan in vitro , interactions between NCAMs and CSPGs in vivo indicate more complicated patterns than previously thought .	parallel	1
5889	10464779	6900;5803	TAG-1;phosphacan	Although both L1 and ***TAG-1*** have been reported to ***bind*** both neurocan and ***phosphacan*** in vitro , interactions between NCAMs and CSPGs in vivo indicate more complicated patterns than previously thought .	parallel	1
5890	10465056	3592;5594	p35;p40	IL-12 levels ( measured with an ELISA that detects both the ******p35/p40****** ***heterodimer*** and free p40 ) were comparable between AE patients and controls and showed a similar distribution pattern to IL-10 with regard to disease progression .	parallel	1
5891	10465067	905;1025	cyclin T2;CDK9	***cyclin T2*** ***binds*** to ***CDK9*** but not to Tat .	parallel	1
5892	10465277	7039;5697	TGF-alpha;PYY	***TGF-alpha*** also ***increased*** intestinal expression of NT and ***PYY*** peptide , but not mRNA levels .	positive	0
5893	10465281	1392;1393	CRH;CRH-BP	***CRH*** can also positively ***regulate*** ***CRH-BP*** gene expression to 6.1 times control levels .	positive	1
5894	10465281	1392;1393	CRH;CRH-BP	These results demonstrate that ***CRH*** , glucocorticoids , and the protein kinase A and protein kinase C signaling pathways are involved in ***regulation*** of ***CRH-BP*** gene expression in astrocyte cultures , and that this regulation is caused , at least in part , by altered transcription of the gene .	target	1
5895	10465290	3485;3487	IGFBP-2;IGFBP-4	The addition of an excess of IGF-I enhanced IGFBP-4 proteolytic degradation , whereas addition of ***IGFBP-2*** or -3 or monoclonal antibodies against IGF-I and - II dose dependently ***inhibited*** ***IGFBP-4*** proteolytic degradation .	negative	1
5896	10465290	3486;3487	IGFBP-3;IGFBP-4	So , in ovine preovulatory follicles , ***IGFBP-4*** proteolytic degradation both 1 ) depends on IGFs , and 2 ) is ***inhibited*** by ***IGFBP-3*** via its C-terminal heparin-binding domain as well as by heparin-binding domain containing peptides .	negative	1
5897	10465296	3479;207	IGF-I;Akt	These inhibitors also suppressed ***IGF-I-induced*** ***phosphorylation*** of protein kinase B ***PKB/Akt*** at Ser437 using concentrations that also inhibited cell motility .	target	1
5898	10465299	5745;5741	PTH1R;PTH	Previous studies in which PTH analogs were cross-linked to human ***PTH/PTHrP*** ***receptor*** ( ***PTH1R*** ) identified Met425 and Phe173-Met189 as the contact sites for Bpa1-PTH and K13 , respectively .	parallel	1
5899	10465304	7040;4087	TGF-beta1;Smad2	Both ***TGF-beta1*** and activin A , but not BMP-7 , ***increased*** the phosphorylation of ***Smad2*** , induced nuclear translocation of Smad2 , Smad3 , and Smad4 , and inhibited thyrocyte cell growth as well as TSH-stimulated cAMP response .	positive	0
5900	10465304	7040;4087	TGF-beta1;Smad2	Both ***TGF-beta1*** and activin A , but not BMP-7 , increased the phosphorylation of Smad2 , ***induced*** nuclear translocation of ***Smad2*** , Smad3 , and Smad4 , and inhibited thyrocyte cell growth as well as TSH-stimulated cAMP response .	target	1
5901	10465304	7040;4088	TGF-beta1;Smad3	Both ***TGF-beta1*** and activin A , but not BMP-7 , increased the phosphorylation of Smad2 , ***induced*** nuclear translocation of Smad2 , ***Smad3*** , and Smad4 , and inhibited thyrocyte cell growth as well as TSH-stimulated cAMP response .	target	1
5902	10465304	7040;4089	TGF-beta1;Smad4	Both ***TGF-beta1*** and activin A , but not BMP-7 , increased the phosphorylation of Smad2 , ***induced*** nuclear translocation of Smad2 , Smad3 , and ***Smad4*** , and inhibited thyrocyte cell growth as well as TSH-stimulated cAMP response .	target	1
5903	10465306	2100;6647	ERbeta;homodimer	Collectively , these results show that ***ERbeta*** protein is preferentially expressed in immature granulosa cells , is functionally active ( binds DNA ) , can ***transactivate*** ( either as a ***homodimer*** or heterodimer with ERalpha ) ERE-containing promoter constructs , and might be associated with increased expression of the endogenous gene encoding c-Jun .	positive	1
5904	10465513	5367;5443	MCH;alpha-MSH	***Effects*** and interactions between ***alpha-MSH*** and ***MCH/NEI*** upon striatal cAMP levels .	parallel	0
5905	10465513	5367;5443	MCH;alpha-MSH	In this study we examined : a ) the effect of other neuropeptides : MCH and NEI , on this cyclic nucleotide ; b ) if the effects of ***alpha-MSH*** on cAMP production can be ***modulated*** by addition of ***MCH*** or NEI to the incubation medium .	target	0
5906	10465582	356;355	Fas ligand;Fas	***Fas ligand*** ( FasL ) , a cell surface molecule belonging to the tumour necrosis factor family , ***binds*** to its receptor ***Fas*** and thus induces apoptosis of Fas-bearing cells such as activated lymphocytes .	parallel	1
5907	10465586	356;355	FasL;Fas	Immunohistochemistry using monoclonal antibodies directed against HLA molecules , HMB45 , P53 , ***Fas*** ***ligand*** ( ***FasL*** ) , Fas , Bcl-2 and tumour-infiltrating cells was applied to sections of an enucleated eye containing a uveal melanoma that received TTT 1 week before enucleation .	parallel	1
5908	10465695	2668;847	GDNF;catalase	Results indicated that acute ***GDNF*** infusion significantly ***increased*** glutathione peroxidase , superoxide dismutase and ***catalase*** activities .	positive	0
5909	10465754	2922;5443	bombesin;beta-endorphin	The ***interaction*** of three bioactive peptides , ***bombesin*** , ***beta-endorphin*** , and glucagon with a phosphatidylcholine monolayer that was immobilized to porous silica particles and packed into a stainless steel column cartridge , has been studied using dynamic elution techniques .	parallel	1
5910	10465754	2641;5443	glucagon;beta-endorphin	The ***interaction*** of three bioactive peptides , bombesin , ***beta-endorphin*** , and ***glucagon*** with a phosphatidylcholine monolayer that was immobilized to porous silica particles and packed into a stainless steel column cartridge , has been studied using dynamic elution techniques .	parallel	1
5911	10465754	2641;2922	glucagon;bombesin	The ***interaction*** of three bioactive peptides , ***bombesin*** , beta-endorphin , and ***glucagon*** with a phosphatidylcholine monolayer that was immobilized to porous silica particles and packed into a stainless steel column cartridge , has been studied using dynamic elution techniques .	parallel	1
5912	10465786	1039;4609	cdr2;c-Myc	The cytoplasmic Purkinje onconeural antigen ***cdr2*** ***down-regulates*** ***c-Myc*** function : implications for neuronal and tumor cell survival .	negative	1
5913	10465786	1039;4609	cdr2;c-Myc	Disease antisera from six of six PCD patients specifically blocked the ***interaction*** between ***cdr2*** and ***c-Myc*** in vitro .	parallel	1
5914	10465792	10926;8317	Dbf4;Cdc7	An active Clb/Cdc28 kinase complex , or its vertebrate equivalent , is required in trans to stimulate initiation in G ( 1 ) - phase nuclei , whereas the ******Dbf4/Cdc7****** kinase ***complex*** must be provided by the template nuclei themselves .	parallel	1
5915	10466040	356;355	FasL;Fas	Fas ( CD95/Apo -1 ) receptor ( FasR ) is a cell-surface receptor that mediates apoptotic cell death upon triggering by ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
5916	10466077	796;3458	Calcitonin;IFN-gamma	***Calcitonin*** gene-related peptide ***enhanced*** ***IFN-gamma*** secretion in susceptible mouse splenocytes at 10 ( -6 ) , 10 ( -7 ) and 10 ( -9 ) M , as did VIP at 10 ( -10 ) M and NPY at 10 ( -7 ) M.	positive	0
5917	10466583	2208;3497	CD23;IgE	***CD23*** , the low affinity ***receptor*** for ***IgE*** , is a 45 kilodalton molecule belonging to the C-type lectin family , some members of which have been identified as adhesion molecules .	parallel	1
5918	10466583	1437;2208	GM-CSF;CD23	Moreover , we found that in our experimental conditions the presence of IFN-g or ***GM-CSF*** alone or in combination with IL-4 ***inhibited*** ***CD23*** expression during the 24 h incubation .	negative	1
5919	10466743	133;1621	PAMP;DBH	***PAMP*** ( > or = 1 microM ) significantly ***inhibited*** the nicotine-induced increases of TH - and ***DBH*** mRNA expression in a concentration-dependent manner .	negative	1
5920	10467177	5045;5046	furin;PACE4	These results show that ***PACE4*** activity can be ***inhibited*** by alpha1-PDX as well as ***furin*** ( SPC1 ) and suggest that the inhibition of PACE4-mediated activation of factors such as BMPs by alpha1-PDX causes abnormal embryogenic development .	negative	1
5921	10467256	5609;5595	MEK;ERK1	Inhibition of ***MEK*** with the specific inhibitor , PD98059 , ***blocked*** the phosphorylation of ***ERK1*** and 2 and increased Mn ( 2 + ) toxicity .	positive	0
5922	10467351	3439;5599	IFNalpha;JNK-1	We have also found that ***IFNalpha*** enhanced the expression of heat shock proteins ( HSP ) HSP-70 , HSP-90 and HSP-27 and ***activated*** the NH2-terminal Jun kinase-1 ( ***JNK-1*** ) and p38 mitogen activated protein kinase , the target enzymes of a stress-dependent intracellular transduction pathway .	positive	1
5923	10467351	3439;1432	IFNalpha;p38 mitogen activated protein kinase	We have also found that ***IFNalpha*** enhanced the expression of heat shock proteins ( HSP ) HSP-70 , HSP-90 and HSP-27 and ***activated*** the NH2-terminal Jun kinase-1 ( JNK-1 ) and ***p38 mitogen activated protein kinase*** , the target enzymes of a stress-dependent intracellular transduction pathway .	positive	1
5924	10467396	596;598	Bcl-2;Bcl-xL	***Bcl-2/E1B*** 19 kDa-interacting protein 3-like protein ( Bnip3L ) ***interacts*** with ***Bcl-2/Bcl-xL*** and induces apoptosis by altering mitochondrial membrane permeability .	parallel	1
5925	10467396	665;596	Bnip3L;Bcl-2	Bcl-2/E1B 19 kDa-interacting protein 3-like protein ( ***Bnip3L*** ) ***interacts*** with ***Bcl-2/Bcl-xL*** and induces apoptosis by altering mitochondrial membrane permeability .	parallel	1
5926	10467396	665;598	Bnip3L;Bcl-xL	Bcl-2/E1B 19 kDa-interacting protein 3-like protein ( ***Bnip3L*** ) ***interacts*** with ***Bcl-2/Bcl-xL*** and induces apoptosis by altering mitochondrial membrane permeability .	parallel	1
5927	10467396	665;596	Bnip3L;Bcl-2	Here we show that Bnip3L contains a motif similar to the BH3 domain which is conserved in Bcl-2 family proteins as well as containing a membrane-anchoring domain , and that ***Bnip3L*** ***interacts*** with ***Bcl-2*** and Bcl-xL .	parallel	1
5928	10467396	665;598	Bnip3L;Bcl-xL	Here we show that Bnip3L contains a motif similar to the BH3 domain which is conserved in Bcl-2 family proteins as well as containing a membrane-anchoring domain , and that ***Bnip3L*** ***interacts*** with Bcl-2 and ***Bcl-xL*** .	parallel	1
5929	10467398	7320;7157	E2 protein;p53	We have previously shown that expression of the papillomavirus ***E2 protein*** in HeLa cells ***induces*** ***p53*** accumulation and causes both cell cycle arrest and apoptosis .	target	1
5930	10467399	7157;573	p53;BAG-1	Most importantly , functional characterization of the BAG-1 promoter in vivo demonstrated that gain-of-function ***p53*** mutants derived from human tumors ***upregulated*** the transcription of ***BAG-1*** RNA and the expression of a reporter gene from the BAG-1 promoter .	negative	1
5931	10467404	1025;904	CDK9;Cyclin T1	The ******Cyclin T1/CDK9****** ***complex*** is implicated in Tat transactivation , and it has been suggested that Tat functions by recruiting this complex to RNAPII through cooperative binding to RNA .	parallel	1
5932	10467404	1025;904	CDK9;Cyclin T1	Here , we demonstrate that targeted recruitment of ******Cyclin T1/CDK9****** kinase ***complex*** to specific promoters , through fusion to a DNA-binding domain of either Cyclin T1 or CDK9 kinase , stimulates transcription in vivo .	parallel	1
5933	10467411	6714;10657	Src;Sam68	Mutation of Sam68 SH3 binding sites further indicated that the Src SH3 domain mediates ***binding*** of ***Src*** to unphosphorylated ***Sam68*** .	parallel	1
5934	10467411	6714;10657	Src;Sam68	***Phosphorylation*** of ***Sam68*** by ***Src*** kinase was inhibited when the Src SH3 binding site of Sam68 was mutated or when corresponding peptides were added to in vitro kinase reactions indicating that binding of the Src SH3 domain to a specific site near the amino-terminus of Sam68 ( including residues 38 - 45 : PPLPHRSR ) facilitates phosphorylation of Sam68 by the Src kinase domain .	target	1
5935	10467415	7157;2068	p53;TFIIH	The tumor suppressor gene product ***p53*** can bind to and ***inhibit*** the helicase activity of the multisubunit transcription-repair factor ***TFIIH*** .	negative	1
5936	10467419	5898;4318	RalA;MMP-2 and 9	The dominant negative ***RalA*** mutant ***blocked*** increased MMP-2 and 9 overproduction induced by v-Src , but not the increased activity of ***MMP-2 and 9*** induced by v-Ras .	positive	0
5937	10468518	4973;4018	LOX-1;lipoprotein	Angiotensin II induces ***LOX-1*** , the human endothelial ***receptor*** for oxidized low-density ***lipoprotein*** .	parallel	1
5938	10468518	183;4973	Angiotensin II;LOX-1	***Angiotensin II*** ***induces*** ***LOX-1*** , the human endothelial receptor for oxidized low-density lipoprotein .	target	1
5939	10468518	4012;4973	AT(1) receptor;LOX-1	CONCLUSIONS : We conclude that LOX-1 is regulated by Ang II in vitro and in vivo , that induction of ***LOX-1*** is ***mediated*** by the ***AT(1) receptor*** , and that repression of LOX-1 by long-term ACE inhibitor treatment may contribute to the antiatherosclerotic potential of this therapy .	target	0
5940	10468529	5350;488	phospholamban;SERCA2	***phospholamban*** ( PLB ) ***inhibits*** ***SERCA2*** activity and is therefore a potential target to improve the cardiac performance in heart failure .	negative	1
5941	10468560	10661;3043	EKLF;beta-globin	Based on these results , we present a model that illustrates how ***EKLF*** may be ***recruited*** to the ***beta-globin*** locus .	target	0
5942	10468612	7157;7153	p53;DNA topoisomerase	The ***interaction*** between ***p53*** and ***DNA topoisomerase*** I is regulated differently in cells with wild-type and mutant p53 .	parallel	1
5943	10468612	7150;7157	topoisomerase I;p53	Previous studies have shown that ***topoisomerase I*** ***interacts*** directly with the tumor-suppressor protein ***p53*** .	parallel	1
5944	10468612	7157;7150	p53;topoisomerase I	We now report that ***topoisomerase I*** can be ***stimulated*** by both latent and activated wild-type ***p53*** as well as by several mutant and truncated p53 proteins in vitro , indicating that sequence-specific DNA-binding and stimulation of topoisomerase I are distinct properties of p53 .	positive	0
5945	10468612	7157;7150	p53;topoisomerase I	In living cells , the ***interaction*** between ***p53*** and ***topoisomerase I*** is strongly dependent on p53 status .	parallel	1
5946	10468946	5617;2691	PRL;GHRH	MEASUREMENTS : AND RESULTS The GH and PRL responses to TRH ( 200 microg iv ) , and the GH and ***PRL*** ***responses*** to ***GHRH*** ( 50 microg iv ) were evaluated , respectively , on the days 1 and 16 and on days 2 , 7and 15 after admission .	parallel	0
5947	10468946	5617;2691	PRL;GHRH	We found a significant ***PRL*** ***response*** to ***GHRH*** during the whole period of observation .	parallel	0
5948	10469058	3586;3458	IL-10;IFN-gamma	In a similar vein , exogenous ***IL-10*** in turn ***inhibited*** ***IFN-gamma*** secretion as well as proliferation when used at low/medium concentrations , but at high concentrations this effect was abolished and replaced by the simultaneous detection of IFN-gamma , IL-10 and proliferation .	negative	1
5949	10469124	5336;6850	PLC-gamma2;Syk	The absence of an in vivo ***association*** between ***Syk*** and ***PLC-gamma2*** in platelets is in contrast with that for PLC-gamma1 and Syk in B cells .	parallel	0
5950	10469140	7124;5055	TNFalpha;PAI-2	While no evidence was found for ***TNFalpha*** ***regulation*** of the ***PAI-2*** gene through either of these two sites , one of the NF-kappaB-like motifs , transcriptional regulatory motif ( TRM ) , present at position -400 was found to be essential for constitutive PAI-2 transcription , as mutation of this motif abolished basal PAI-2 promoter activity in both monocyte-like U937 cells and HT1080 fibrosarcoma cells .	target	1
5951	10469171	6477;2911	Siah-1A;mGluR1	Following coexpression in COS-7 cells , myc-tagged ***Siah-1A*** was ***coimmunoprecipitated*** with the flag-tagged ***ct-mGluR1*** by anti-flag antibody .	parallel	1
5952	10469228	7040;6404	TGF-beta;CLA	Levels of alphaebeta7 and ***CLA*** were ***up-regulated*** on peripheral blood lymphocytes ( PBL ) by transforming growth factor-beta ( ***TGF-beta*** ) and interleukin-12 ( IL-12 ) , respectively , and both groups of lymphocytes adhered onto oral and skin keratinocytes .	positive	1
5953	10469232	3604;355	CD137;CD95	Here , we show that immobilized ***CD137*** protein ***induces*** expression of ***CD95*** in resting primary T and B lymphocytes .	target	1
5954	10469273	1232;6356	CCR3;Eotaxin	Eotaxin and ***Eotaxin*** ***receptor*** ( ***CCR3*** ) expression in Sephadex particle-induced rat lung inflammation .	parallel	1
5955	10469273	1232;6356	CCR3;Eotaxin	The time course of Eotaxin expression in lung at various time points after Sephadex administration was related to the appearance of eosinophils in the bronchoalveolar lavage fluid and tissue distribution of ***Eotaxin*** ***receptor*** ( ***CCR3*** ) positive cells .	parallel	1
5956	10469276	3553;4982	IL-1beta;OCIF	Interleukin-1beta ( ***IL-1beta*** ) and tumor necrosis factor-alpha ( TNF-alpha ) ***increased*** ***OPG/OCIF*** mRNA levels in a dose-and time-dependent manner in HPDL .	positive	0
5957	10469276	7124;4982	TNF-alpha;OCIF	Interleukin-1beta ( IL-1beta ) and tumor necrosis factor-alpha ( ***TNF-alpha*** ) ***increased*** ***OPG/OCIF*** mRNA levels in a dose-and time-dependent manner in HPDL .	positive	0
5958	10469276	3553;4982	IL-1beta;OCIF	After 12 h of treatment , ***IL-1beta*** at 3 ng/ml and TNF-alpha at 3 ng/ml ***increased*** ***OPG/OCIF*** mRNA expression by 190 % and 110 % , respectively , with a maximal effect .	positive	0
5959	10469278	820;5741	cAMP;PTH	In contrast to the relatively stable PTH1R mRNA expression , the ***cAMP*** ***response*** to ***PTH*** varies markedly with no response at day 5 and a marked response ( 80-fold versus control ) by day 10 .	parallel	0
5960	10469279	3605;3552	IL-17;IL-1alpha	In addition , ***IL-17*** ***increased*** TNF-alpha-induced ***IL-1alpha*** , IL-1beta , and IL-6 mRNA expression in fetal mouse metatarsals and IL-1alpha and IL-6 mRNA expression in MC3T3-E1 cells .	positive	0
5961	10469279	3605;3553	IL-17;IL-1beta	In addition , ***IL-17*** ***increased*** TNF-alpha-induced IL-1alpha , ***IL-1beta*** , and IL-6 mRNA expression in fetal mouse metatarsals and IL-1alpha and IL-6 mRNA expression in MC3T3-E1 cells .	positive	0
5962	10469280	650;860	bone morphogenetic protein-2;CBFA1	Differentiation of human marrow stromal precursor cells : ***bone morphogenetic protein-2*** ***increases*** ***OSF2/CBFA1*** , enhances osteoblast commitment , and inhibits late adipocyte maturation .	positive	0
5963	10469280	650;10631	bone morphogenetic protein-2;OSF2	Differentiation of human marrow stromal precursor cells : ***bone morphogenetic protein-2*** ***increases*** ***OSF2/CBFA1*** , enhances osteoblast commitment , and inhibits late adipocyte maturation .	positive	0
5964	10469303	3552;2006	interleukin-1 alpha;tropoelastin	We previously reported that tropoelastin gene expression in vivo decreases with acute ultraviolet B exposure , and ***interleukin-1 alpha-mediated*** ***upregulation*** of ***tropoelastin*** is blocked in vitro after ultraviolet B radiation .	positive	1
5965	10469303	3552;7124	interleukin-1 alpha;tumor necrosis factor-alpha	Ultraviolet B and ***interleukin-1 alpha*** synergistically ***increased*** ***tumor necrosis factor-alpha*** secretion by fibroblasts , a finding not seen with ultraviolet B alone nor with ultraviolet A or ultraviolet A1 combined with interleukin-1 alpha .	positive	0
5966	10469333	3606;3458	interleukin-18;interferon-gamma	In this study , we demonstrated by enzyme-linked immunosorbent assay that ***interleukin-18*** and interleukin-12 synergistically ***upregulated*** ***interferon-gamma*** production by dendritic epidermal T cells in short-term cultures .	positive	1
5967	10469333	3606;3458	interleukin-18;interferon-gamma	Thus , this study suggests that ***interleukin-18*** and interleukin-12 produced by keratinocytes and Langerhans cells ***regulate*** ***interferon-gamma*** production by dendritic epidermal T cells and thus may play important parts in the regulation of immune responses in skin-associated lymphoid tissues .	target	1
5968	10469355	3952;7040	Leptin;TGF-beta1	Short-term ***Leptin*** infusion ( 72 hr ) into naive rats induced a significant proliferation , mainly restricted to glomerular endothelial cells , and ***enhanced*** glomerular ***TGF-beta1*** mRNA levels .	positive	0
5969	10469355	3952;7040	Leptin;TGF-beta	***Leptin*** ***stimulates*** proliferation and ***TGF-beta*** expression in renal glomerular endothelial cells : potential role in glomerulosclerosis [ seecomments ] .	positive	0
5970	10469356	5966;6347	c-Rel;MCP-1	CONCLUSIONS : This study demonstrates for the first time that the ***c-Rel*** oncoprotein can ***enhance*** ***MCP-1*** transcription in mesangial cells and suggests that it may have an important role in amplifying gene expression in the inflamed glomerulus .	positive	0
5971	10469356	5966;6347	Rel;MCP-1	Specific members of the nuclear factor ***kappaB/Rel*** ( NF-kappaB ) proteins may ***regulate*** ***MCP-1*** expression in a stimulus - and tissue-specific manner .	target	1
5972	10469356	5970;6347	p65;MCP-1	IL-1 induced c-Rel to form a complex with ***p65*** , which ***bound*** the ***MCP-1*** A2 site but not the A1 or IL-6 NF-kappaB sites in vitro .	parallel	1
5973	10469356	5970;6347	p65;MCP-1	Cotransfer of the MCP-1 enhancer together with individual members of the NF-kappaB family showed that the heterodimer c-relp65 or ( ***p65*** ) 2 can selectively ***trans-activate*** the ***MCP-1*** gene via its A1 and A2 sites in mesangial cells .	positive	1
5974	10469359	999;3082	E-cadherin;HGF	BACKGROUND : ***E-cadherin*** ***mediated*** cell-cell adhesion and hepatocyte growth factor ( ***HGF*** ) are important for renal epithelial morphogenesis .	target	0
5975	10469359	3082;999	HGF;E-cadherin	RESULTS : Surface immunoprecipitation experiments showed that ***HGF*** ***increased*** the amount of cell surface ***E-cadherin*** associated with gamma-catenin .	positive	0
5976	10469366	7040;941	TGF-beta1;B7-1	***TGF-beta1*** ***down-regulates*** induced expression of both class II MHC and ***B7-1*** on primary murine renal tubular epithelial cells .	negative	1
5977	10469366	7040;941	TGF-beta1;B7-1	Our studies revealed that ***B7-1*** mRNA and cell-surface expression in IFN-gamma + LPS-treated F1K were ***decreased*** by ***TGF-beta1*** pretreatment .	negative	0
5978	10469372	5972;6347	Renin;monocyte chemoattractant protein-1	To test the hypothesis that overexpression of ***monocyte chemoattractant protein-1*** ( MCP-1 ) , a monocyte chemoattractant , is ***attenuated*** by ***Renin-angiotensin*** system ( RAS ) inhibition , we assessed expression of genes regulating monocyte transmigration in the glomeruli of diabetic rats .	negative	0
5979	10469565	5594;6195	ERK;rsk1	Nevertheless , ***activation*** of full-length ***rsk1*** in the absence of serum required activation by both PDK1 and ***ERK*** .	positive	1
5980	10469565	5170;6195	PDK1;rsk1	Nevertheless , ***activation*** of full-length ***rsk1*** in the absence of serum required activation by both ***PDK1*** and ERK .	positive	1
5981	10469565	5170;6195	PDK1;rsk1	CONCLUSIONS : ***rsk1*** is ***phosphorylated*** by ***PDK1*** in the amino-terminal kinase-activation loop , and by ERK in the carboxy-terminal kinase-activation loop .	target	1
5982	10469565	5594;6195	ERK;rsk1	***rsk1*** activation is therefore ***regulated*** by both the mitogen-stimulated ***ERK/MAP*** kinase pathway and a PDK1-dependent pathway .	target	1
5983	10469565	5594;6195	ERK;rsk1	***ERK*** ***activation*** and subsequent phosphorylation of the ***rsk1*** carboxy-terminal catalytic loop stimulates phosphotransferase activity in the rsk1 amino-terminal kinase domain .	positive	1
5984	10469565	5170;6195	PDK1;rsk1	In vitro kinase assays established that ERK phosphorylates rsk1 within the carboxy-terminal kinase domain , and the phosphoinositide-dependent kinase 1 ( ***PDK1*** ) ***phosphorylates*** ***rsk1*** within the amino-terminal kinase domain .	target	1
5985	10469565	5594;6195	ERK;rsk1	In vitro kinase assays established that ***ERK*** ***phosphorylates*** ***rsk1*** within the carboxy-terminal kinase domain , and the phosphoinositide-dependent kinase 1 ( PDK1 ) phosphorylates rsk1 within the amino-terminal kinase domain .	target	1
5986	10469565	5170;6195	PDK1;rsk1	In transiently transfected HEK 293E cells , ***PDK1*** alone ***stimulated*** phosphotransferase activity of an isolated ***rsk1*** amino-terminal kinase domain .	positive	0
5987	10469568	4193;7157	MDM2;p53	These differences between the ***regulation*** of ***p53*** and p73 by ***MDM2/MDMX*** may highlight a physiological difference in their action .	target	1
5988	10469568	4193;7161	MDM2;p73	These differences between the ***regulation*** of p53 and ***p73*** by ***MDM2/MDMX*** may highlight a physiological difference in their action .	target	1
5989	10469568	4194;7157	MDMX;p53	These differences between the ***regulation*** of ***p53*** and p73 by ***MDM2/MDMX*** may highlight a physiological difference in their action .	target	1
5990	10469568	4194;7161	MDMX;p73	These differences between the ***regulation*** of p53 and ***p73*** by ***MDM2/MDMX*** may highlight a physiological difference in their action .	target	1
5991	10469568	4193;7161	MDM2;p73	***MDM2*** and MDMX ***bind*** and stabilize the p53-related protein ***p73*** .	parallel	1
5992	10469568	4194;7161	MDMX;p73	MDM2 and ***MDMX*** ***bind*** and stabilize the p53-related protein ***p73*** .	parallel	1
5993	10469568	7157;4193	p53;MDM2	***Interaction*** between ***MDM2*** and ***p53*** represents a key step in the regulation of p53 , as MDM2 promotes the degradation of p53 .	parallel	1
5994	10469568	4193;7157	MDM2;p53	Interaction between MDM2 and p53 represents a key step in the regulation of p53 , as ***MDM2*** ***promotes*** the degradation of ***p53*** .	positive	0
5995	10469568	4194;7161	protein MDMX;p73	Like MDM2 , the MDM2-related ***protein MDMX*** also bound p73 and ***stabilized*** the level of ***p73*** .	positive	0
5996	10469568	4194;7161	protein MDMX;p73	Like MDM2 , the MDM2-related ***protein MDMX*** also ***bound*** ***p73*** and stabilized the level of p73 .	parallel	1
5997	10469599	2185;140885	PYK2;SHPS-1	Recruitment of FYB/SLAP-130 to SHPS-1 required SKAP55hom/R , whereas ***PYK2*** ***associated*** with ***SHPS-1*** independently .	parallel	0
5998	10469599	2533;140885	SLAP-130;SHPS-1	***Recruitment*** of ***FYB/SLAP-130*** to ***SHPS-1*** required SKAP55hom/R , whereas PYK2 associated with SHPS-1 independently .	target	0
5999	10469600	2253;579	FGF8;NKX3.2	Ectopic application of ***FGF8*** on the left side ***blocked*** ***NKX3.2*** expression , whereas the FGF receptor-1 ( FGFR-1 ) antagonist SU5402 , implanted on the right side , resulted in bilateral NKX3.2 expression in the LPM , suggesting that FGF8 is an important negative determinant of asymmetric NKX3.2 expression .	negative	0
6000	10469655	602;4790	Bcl-3;p50	NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of ******Bcl-3-p50****** ***complexes*** .	parallel	1
6001	10469655	3553;602	IL-1beta;Bcl-3	We show that TNFalpha , ***IL-1beta*** or phorbolester ( PMA ) ***trigger*** rapid formation of ***Bcl-3-p50*** complexes with the same kinetics as activation of p50-p65 complexes .	positive	0
6002	10469655	3553;4790	IL-1beta;p50	We show that TNFalpha , ***IL-1beta*** or phorbolester ( PMA ) ***trigger*** rapid formation of ***Bcl-3-p50*** complexes with the same kinetics as activation of p50-p65 complexes .	positive	0
6003	10469655	7124;602	TNFalpha;Bcl-3	We show that ***TNFalpha*** , IL-1beta or phorbolester ( PMA ) ***trigger*** rapid formation of ***Bcl-3-p50*** complexes with the same kinetics as activation of p50-p65 complexes .	positive	0
6004	10469655	7124;4790	TNFalpha;p50	We show that ***TNFalpha*** , IL-1beta or phorbolester ( PMA ) ***trigger*** rapid formation of ***Bcl-3-p50*** complexes with the same kinetics as activation of p50-p65 complexes .	positive	0
6005	10469655	4790;602	p50;Bcl-3	We show that TNFalpha , IL-1beta or phorbolester ( PMA ) trigger rapid formation of ******Bcl-3-p50****** ***complexes*** with the same kinetics as activation of p50-p65 complexes .	parallel	1
6006	10469655	4790;5970	p50;p65	We show that TNFalpha , IL-1beta or phorbolester ( PMA ) trigger rapid formation of Bcl-3-p50 complexes with the same kinetics as activation of ******p50-p65****** ***complexes*** .	parallel	1
6007	10469655	4790;5970	p50;p65	Thus , the known NF-kappaB stimuli not only cause nuclear accumulation of ******p50-p65****** ***heterodimers*** but also of Bcl-3-p50 and perhaps further transcription activator complexes which are formed upon IKK-mediated p105 degradation .	parallel	1
6008	10470105	7124;4843	TNF alpha;iNOS	Simultaneously , ***TNF alpha*** ***stimulated*** induction of ***iNOS*** and generation of NO .	positive	0
6009	10470133	1029;1021	p16;CDK4/6	The ***p16*** protein is encoded by the CDKN2 gene , and functions as an ***inhibitor*** of cyclin-dependent kinase 4 and 6 ( ***CDK4/6*** ) .	negative	1
6010	10470133	1029;1019	p16;cyclin-dependent kinase 4	The ***p16*** protein is encoded by the CDKN2 gene , and functions as an ***inhibitor*** of ***cyclin-dependent kinase 4*** and 6 ( CDK4/6 ) .	negative	1
6011	10470151	7157;4193	p53;Mdm2	***Interaction*** of ***p53*** with ***Mdm2*** is hindered if either protein is phosphorylated by DNA-dependent protein kinase ( DNAPK ) , which may account for the activation of p53 in response to double-stranded DNA breaks .	parallel	1
6012	10470151	7157;4193	p53;Mdm2	Here we report that unlike the ******p53/Mdm2****** ***complex*** , p53/T antigen complex remains intact following phosphorylation by DNAPK , indicating that the effect of phosphorylation upon p53 interaction is dependent on the protein partner .	parallel	1
6013	10470286	4601;4609	Mxi1;Myc	***Mxi1*** is thought to negatively ***regulate*** ***Myc*** function and may therefore be a potential tumor suppressor gene .	negative	1
6014	10470412	5104;5624	protein C inhibitor;protein C	***protein C inhibitor*** ***inhibits*** activated ***protein C*** and other coagulation factors .	negative	1
6015	10470438	355;356	Fas;FasL	The ***interaction*** of ***Fas*** with ***FasL*** has been demonstrated to be implicated in the pathogenesis of several autoimmune and liver diseases .	parallel	1
6016	10470853	4790;5966	NF-kappaB;Rel	The decreased growth of Hs578T and MCF7 breast cancer cell lines on TGF-beta1 treatment correlated with a drop in ******NF-kappaB/Rel****** ***binding*** .	parallel	1
6017	10470853	4790;5966	NF-kappaB;Rel	Ectopic expression of c-Rel in Hs578T cells led to the maintenance of ******NF-kappaB/Rel****** ***binding*** and resistance to TGF-beta1-mediated inhibition of proliferation .	parallel	1
6018	10470855	6251;5594	RSU-1;Erk2	Using RSU-1 transfectants of the pheochromocytoma cell line PC12 , we demonstrated previously that ***RSU-1*** expression inhibited Jun kinase activation but ***enhanced*** ***Erk2*** activation in response to epidermal growth factor .	positive	0
6019	10470855	6251;5601	RSU-1;Jun kinase	Using RSU-1 transfectants of the pheochromocytoma cell line PC12 , we demonstrated previously that ***RSU-1*** expression ***inhibited*** ***Jun kinase*** activation but enhanced Erk2 activation in response to epidermal growth factor .	negative	1
6020	10470856	2122;4133	Evi1;microtubule-associated protein-2	Enforced expression of ***Evi1*** in P19 cells ***induced*** neuron-specific microtubule-associated protein-2 ***microtubule-associated protein-2*** and TrkA expression in the absence of RA under monolayer culture .	target	1
6021	10470857	3558;993	IL-2;Cdc25A	Furthermore , our data indicate that IFN-alpha has selective effects on the pathways that emerge from the IL-2 receptor because IFN-alpha treatment does not block ***IL-2-induced*** ***up-regulation*** of c-myc or ***Cdc25A*** .	positive	1
6022	10470857	3558;4609	IL-2;c-myc	Furthermore , our data indicate that IFN-alpha has selective effects on the pathways that emerge from the IL-2 receptor because IFN-alpha treatment does not block ***IL-2-induced*** ***up-regulation*** of ***c-myc*** or Cdc25A .	positive	1
6023	10470858	5617;596	PRL;Bcl-2	When stimulated with PRL , the PRL-R transfectants underwent some changes characteristic of B-cell differentiation : ( a ) IL-2R alpha chain became positively controlled by PRL ; ( b ) antiapoptotic ***Bcl-2*** protein was ***induced*** by ***PRL*** in a dose-dependent manner ; and ( c ) transcription of the pre-B cell receptor encoding the lambda5 gene was strongly up-regulated .	target	1
6024	10470871	3643;7124	insulin receptor;TNFalpha	Neither the insulin-binding capacity nor ***insulin receptor*** affinity were ***related*** to this ***TNFalpha*** increase in these tissues .	parallel	0
6025	10471036	834;836	ICE;CPP32	The observation that inhibition of either ICE or CPP32 could suppress acidic stress-induced apoptosis suggested that ***ICE*** ***activates*** ***pro-CPP32*** , which then cleaves PARP .	positive	1
6026	10471036	836;1302	CPP32;PARP	The observation that inhibition of either ICE or CPP32 could suppress acidic stress-induced apoptosis suggested that ICE activates ***pro-CPP32*** , which then ***cleaves*** ***PARP*** .	target	1
6027	10471065	1565;1557	CYP2D6;CYP2C19	***Association*** between different NAT2 , ***CYP2D6*** , ***CYP2C19*** and GSTP1 genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals .	parallel	0
6028	10471065	1565;2950	CYP2D6;GSTP1	***Association*** between different NAT2 , ***CYP2D6*** , CYP2C19 and ***GSTP1*** genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals .	parallel	0
6029	10471065	1565;10	CYP2D6;NAT2	***Association*** between different ***NAT2*** , ***CYP2D6*** , CYP2C19 and GSTP1 genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals .	parallel	0
6030	10471065	2950;1557	GSTP1;CYP2C19	***Association*** between different NAT2 , CYP2D6 , ***CYP2C19*** and ***GSTP1*** genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals .	parallel	0
6031	10471065	10;1557	NAT2;CYP2C19	***Association*** between different ***NAT2*** , CYP2D6 , ***CYP2C19*** and GSTP1 genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals .	parallel	0
6032	10471065	10;2950	NAT2;GSTP1	***Association*** between different ***NAT2*** , CYP2D6 , CYP2C19 and ***GSTP1*** genotypes and prostate cancer was studied in a Swedish and Danish case-control study comprising 850 individuals .	parallel	0
6033	10471085	5443;8620	met-enkephalin;NPFF	These data provide the first direct demonstration that ***met-enkephalin*** ( among other opioid peptides ) can ***mediate*** the antinociceptive action of ***NPFF*** at the spinal level in rats .	target	0
6034	10471171	1544;1576	CYP1A2;CYP3A	Fluvoxamine is a potent inhibitor of ***CYP1A2*** , a moderate ***inhibitor*** of ***CYP3A*** and a mild inhibitor of CYP2D6 .	negative	1
6035	10471171	1544;1565	CYP1A2;CYP2D6	Fluvoxamine is a potent inhibitor of ***CYP1A2*** , a moderate inhibitor of CYP3A and a mild ***inhibitor*** of ***CYP2D6*** .	negative	1
6036	10471331	5594;3265	Erk;p21ras	Cytokine signal transduction in P19 embryonal carcinoma cells : regulation of Stat3-mediated transactivation occurs independently of ******p21ras-Erk****** ***signaling*** .	parallel	0
6037	10471383	5747;6464	FAK;Shc	We found that CSR induced the activation of FAK and Src and the ***association*** of ***FAK*** and ***Shc*** , a signaling molecule linking growth factor receptor tyrosine kinase and Grb2 .	parallel	0
6038	10471390	847;5594	catalase;ERK	Silica-induced ***ERK*** phosphorylation was also effectively ***attenuated*** by ***catalase*** and DPI .	negative	0
6039	10471394	7422;2321	VEGF;Flt-1	In addition , Flt-1 amino acid residues Arg-224 and Asp-231 were not essential for high-affinity ***binding*** of ***VEGF*** to membrane-bound ***Flt-1*** .	parallel	1
6040	10471440	335;4524	apo;MTHFR	The ***association*** of ***MTHFR*** and ***apo*** ( a ) was greater in the younger subjects .	parallel	0
6041	10471495	3643;3479	Insulin receptor;Igf-1	***Insulin receptor*** substrates ( Irs proteins ) ***mediate*** the pleiotropic effects of insulin and ***Igf-1*** ( insulin-like growth factor-1 ) , including regulation of glucose homeostasis and cell growth and survival .	target	0
6042	10471521	3949;4018	LDLr;lipoprotein	Since the low-density ***lipoprotein*** ***receptor*** ( ***LDLr*** ) is involved in the uptake of essential fatty acids , we studied the effect of LDL on growth and gene regulation in colorectal cancer cells .	parallel	1
6043	10471533	2885;6464	GRB2;SHC	Accordingly , CGP78850 blocks epidermal growth factor receptor ( EGFR ) - GRB2 and ******SHC-GRB2****** ***interactions*** in living cells .	parallel	1
6044	10471535	7040;595	TGF-beta-1;cyclin D1	***TGF-beta-1*** ***up-regulates*** ***cyclin D1*** expression in COLO-357 cells , whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor .	positive	1
6045	10471535	7040;595	TGF-beta1;cyclin D1	***TGF-beta1*** ***increased*** ***cyclin D1*** mRNA and protein levels .	positive	0
6046	10471536	7040;3611	TGF-beta1;integrin-linked kinase	Our data further illustrate the ***TGF-beta1-dependent*** ***up-regulation*** of ***integrin-linked kinase*** and the nuclear translocation of beta-catenin , 2 intracellular proteins involved in integrin and cadherin signaling .	positive	1
6047	10471611	3606;3458	IL-18;IFN-gamma	The administration of ***IL-18*** ***enhanced*** antigen-induced ***IFN-gamma*** and TNF-alpha production , but not IL-5 production , in the BALF and lungs of sensitized mice .	positive	0
6048	10471611	3606;7124	IL-18;TNF-alpha	The administration of ***IL-18*** ***enhanced*** antigen-induced IFN-gamma and ***TNF-alpha*** production , but not IL-5 production , in the BALF and lungs of sensitized mice .	positive	0
6049	10471746	5316;6929	Prep1;E2a	Here , we report that Pbx-Meis1 / ***Prep1*** ***binds*** DNA cooperatively with heterodimers of ***E2a*** and MyoD , myogenin , Mrf-4 or Myf-5 .	parallel	1
6050	10471746	5316;4618	Prep1;Mrf-4	Here , we report that Pbx-Meis1 / ***Prep1*** ***binds*** DNA cooperatively with heterodimers of E2a and MyoD , myogenin , ***Mrf-4*** or Myf-5 .	parallel	1
6051	10471746	5316;4617	Prep1;Myf-5	Here , we report that Pbx-Meis1 / ***Prep1*** ***binds*** DNA cooperatively with heterodimers of E2a and MyoD , myogenin , Mrf-4 or ***Myf-5*** .	parallel	1
6052	10471746	5316;4654	Prep1;MyoD	Here , we report that Pbx-Meis1 / ***Prep1*** ***binds*** DNA cooperatively with heterodimers of E2a and ***MyoD*** , myogenin , Mrf-4 or Myf-5 .	parallel	1
6053	10471746	5316;4656	Prep1;myogenin	Here , we report that Pbx-Meis1 / ***Prep1*** ***binds*** DNA cooperatively with heterodimers of E2a and MyoD , ***myogenin*** , Mrf-4 or Myf-5 .	parallel	1
6054	10471746	6929;4618	E2a;Mrf-4	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of ***E2a*** and MyoD , myogenin , ***Mrf-4*** or Myf-5 .	parallel	1
6055	10471746	6929;4617	E2a;Myf-5	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of ***E2a*** and MyoD , myogenin , Mrf-4 or ***Myf-5*** .	parallel	1
6056	10471746	6929;4654	E2a;MyoD	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of ***E2a*** and ***MyoD*** , myogenin , Mrf-4 or Myf-5 .	parallel	1
6057	10471746	6929;4656	E2a;myogenin	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of ***E2a*** and MyoD , ***myogenin*** , Mrf-4 or Myf-5 .	parallel	1
6058	10471746	4618;4654	Mrf-4;MyoD	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of E2a and ***MyoD*** , myogenin , ***Mrf-4*** or Myf-5 .	parallel	1
6059	10471746	4618;4656	Mrf-4;myogenin	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of E2a and MyoD , ***myogenin*** , ***Mrf-4*** or Myf-5 .	parallel	1
6060	10471746	4617;4618	Myf-5;Mrf-4	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of E2a and MyoD , myogenin , ***Mrf-4*** or ***Myf-5*** .	parallel	1
6061	10471746	4617;4654	Myf-5;MyoD	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of E2a and ***MyoD*** , myogenin , Mrf-4 or ***Myf-5*** .	parallel	1
6062	10471746	4617;4656	Myf-5;myogenin	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of E2a and MyoD , ***myogenin*** , Mrf-4 or ***Myf-5*** .	parallel	1
6063	10471746	4654;4656	MyoD;myogenin	Here , we report that Pbx-Meis1 / Prep1 binds DNA cooperatively with ***heterodimers*** of E2a and ***MyoD*** , ***myogenin*** , Mrf-4 or Myf-5 .	parallel	1
6064	10471781	3552;56052	IL-1alpha;MT-1	We found that ***IL-1alpha*** , IL-1beta and IL-6 ***increased*** both metallothionein-1 ( ***MT-1*** ) and metallothionein-2 ( MT-2 ) mRNA in HepG2 cells .	positive	0
6065	10471781	3552;4502	IL-1alpha;MT-2	We found that ***IL-1alpha*** , IL-1beta and IL-6 ***increased*** both metallothionein-1 ( MT-1 ) and metallothionein-2 ( ***MT-2*** ) mRNA in HepG2 cells .	positive	0
6066	10471781	3553;56052	IL-1beta;MT-1	We found that IL-1alpha , ***IL-1beta*** and IL-6 ***increased*** both metallothionein-1 ( ***MT-1*** ) and metallothionein-2 ( MT-2 ) mRNA in HepG2 cells .	positive	0
6067	10471781	3553;4502	IL-1beta;MT-2	We found that IL-1alpha , ***IL-1beta*** and IL-6 ***increased*** both metallothionein-1 ( MT-1 ) and metallothionein-2 ( ***MT-2*** ) mRNA in HepG2 cells .	positive	0
6068	10471781	3569;56052	IL-6;MT-1	We found that IL-1alpha , IL-1beta and ***IL-6*** ***increased*** both metallothionein-1 ( ***MT-1*** ) and metallothionein-2 ( MT-2 ) mRNA in HepG2 cells .	positive	0
6069	10471781	3569;4502	IL-6;MT-2	We found that IL-1alpha , IL-1beta and ***IL-6*** ***increased*** both metallothionein-1 ( MT-1 ) and metallothionein-2 ( ***MT-2*** ) mRNA in HepG2 cells .	positive	0
6070	10471781	3569;56052	IL-6;MT-1	***IL-6*** ***induced*** only low levels of both ***MT-1*** and MT-2 mRNA .	target	1
6071	10471781	3569;4502	IL-6;MT-2	***IL-6*** ***induced*** only low levels of both MT-1 and ***MT-2*** mRNA .	target	1
6072	10471813	4214;5599	MEK kinase 1;JNK	A novel Jun N-terminal kinase ( JNK ) - binding protein that enhances the ***activation*** of ***JNK*** by ***MEK kinase 1*** and TGF-beta-activated kinase 1 .	positive	1
6073	10471813	6885;5599	TGF-beta-activated kinase 1;JNK	A novel Jun N-terminal kinase ( JNK ) - binding protein that enhances the ***activation*** of ***JNK*** by MEK kinase 1 and ***TGF-beta-activated kinase 1*** .	positive	1
6074	10471813	4214;5599	MEK kinase 1;JNK	However , the ***activation*** of ***JNK*** by ***MEK kinase 1*** and TGF-beta-activated kinase 1 was significantly enhanced in the presence of JNKBP1 .	positive	1
6075	10471813	6885;5599	TGF-beta-activated kinase 1;JNK	However , the ***activation*** of ***JNK*** by MEK kinase 1 and ***TGF-beta-activated kinase 1*** was significantly enhanced in the presence of JNKBP1 .	positive	1
6076	10471993	1756;1605	dystrophin;beta-dystroglycan	We have established that ***dystrophin*** is exclusively ***associated*** with ***beta-dystroglycan*** and both alpha - and delta-sarcoglycans in cardiac muscle cell membranes .	parallel	0
6077	10472212	5340;5345	plasmin;alpha 2-antiplasmin	We have investigated the consequences of NHD on haemostasis by comparing conventional global tests ( prothrombin time ( PT ) , activated partial thromboplastin time ( aPTT ) with more specific measures of coagulation ( prothrombin fragment 1 + 2 ( F 1 + 2 ) , thrombin-antithrombin III complex ( TAT ) and fibrinolysis ( D-dimer ( DD ) , ******plasmin-alpha 2-antiplasmin****** ***complex*** ( PAP ) ) .	parallel	1
6078	10473039	2057;2056	Epo-R;erythropoietin	***erythropoietin*** ***receptors*** ( ***Epo-R*** ) are expressed on cells in the small bowel of human fetuses , but their function has not been defined .	parallel	1
6079	10473083	4953;1509	ODC;cathepsin D	***ODC*** activity ***correlated*** with histological grade , peritumoral lymphatic or blood vessel invasion , S-phase fraction , and ***cathepsin D*** .	parallel	0
6080	10473107	4914;627	Trk;neurotrophin	On the basis of these data , we have evaluated the therapeutic potential of inhibiting ******neurotrophin-Trk****** ***interactions*** using a selective and potent Trk tyrosine kinase inhibitor ( CEP-701 ) in several preclinical models of human PDAC .	parallel	1
6081	10473112	4193;7157	oncoprotein MDM2;p53	The ***oncoprotein MDM2*** ***binds*** and inactivates ***p53*** .	parallel	1
6082	10473112	4193;1869	MDM2;E2F-1	***MDM2*** also ***binds*** to the tumor suppressor pRB , as well as ***E2F-1*** .	parallel	1
6083	10473112	4193;5925	MDM2;pRB	***MDM2*** also ***binds*** to the tumor suppressor ***pRB*** , as well as E2F-1 .	parallel	1
6084	10473114	958;959	CD40;CD40L	The important role of ******CD40-CD40L****** ***interactions*** in the regulation of immune cells in the lymph node and the unique high-level expression of CD40L by these immune cells lend support to the hypothesis that this ligand/receptor pair is an important mediator of cell growth in SCCHN .	parallel	1
6085	10473114	959;958	CD40L;CD40	CD40 ligation by trimeric ***CD40*** ***ligand*** ( ***CD40L*** ) resulted in a 20-45 % inhibition of tumor cell growth in three of seven cell lines tested .	parallel	1
6086	10473114	959;958	CD40L;CD40	***CD40*** ***ligation*** by trimeric CD40 ligand ( ***CD40L*** ) resulted in a 20-45 % inhibition of tumor cell growth in three of seven cell lines tested .	parallel	1
6087	10473116	7291;129685	Twist;TAF	Gene dosage assays imply that an ***interplay*** of Dorsal and ***Twist*** with ***TAF*** ( II ) 110 is critically required for the activation of mesoderm-determining gene expression in the Drosophila embryo .	parallel	1
6088	10473550	5618;5617	hPRLR;prolactin	Zinc increases the affinity of human growth hormone ( hGH ) for the human ***prolactin*** ***receptor*** ( ***hPRLR*** ) due to the coordination of one zinc ion involving Glu-174 ( hGH ) and His-18 ( hGH ) .	parallel	1
6089	10473551	8826;1499	IQGAP1;beta-catenin	These results indicate that Cdc42 and Rac1 negatively regulate the IQGAP1 function by inhibiting the ***interaction*** of ***IQGAP1*** with ***beta-catenin*** , leading to stabilization of the cadherin-catenin complex .	parallel	1
6090	10473551	998;8826	Cdc42;IQGAP1	These results indicate that ***Cdc42*** and Rac1 negatively ***regulate*** the ***IQGAP1*** function by inhibiting the interaction of IQGAP1 with beta-catenin , leading to stabilization of the cadherin-catenin complex .	negative	1
6091	10473551	5879;8826	Rac1;IQGAP1	These results indicate that Cdc42 and ***Rac1*** negatively ***regulate*** the ***IQGAP1*** function by inhibiting the interaction of IQGAP1 with beta-catenin , leading to stabilization of the cadherin-catenin complex .	negative	1
6092	10473551	8826;1499	IQGAP1;beta-catenin	Cdc42 and Rac1 regulate the ***interaction*** of ***IQGAP1*** with ***beta-catenin*** .	parallel	1
6093	10473551	998;8826	Cdc42;IQGAP1	***Cdc42*** and Rac1 ***regulate*** the interaction of ***IQGAP1*** with beta-catenin .	target	1
6094	10473551	5879;8826	Rac1;IQGAP1	Cdc42 and ***Rac1*** ***regulate*** the interaction of ***IQGAP1*** with beta-catenin .	target	1
6095	10473551	998;8826	Cdc42;IQGAP1	Here we investigated how ***Cdc42*** and Rac1 ***regulate*** the ***IQGAP1*** function .	target	1
6096	10473551	5879;8826	Rac1;IQGAP1	Here we investigated how Cdc42 and ***Rac1*** ***regulate*** the ***IQGAP1*** function .	target	1
6097	10473551	8826;1499	IQGAP1;beta-catenin	GST-Rac1 inhibited the ***binding*** of ***IQGAP1*** to ***beta-catenin*** in a dose-dependent manner in vitro , whereas neither GDP.GST-Cdc42 , GDP .	parallel	1
6098	10473551	373156;8826	GST;IQGAP1	***GST-Rac1*** ***inhibited*** the binding of ***IQGAP1*** to beta-catenin in a dose-dependent manner in vitro , whereas neither GDP.GST-Cdc42 , GDP .	negative	1
6099	10473551	5879;8826	Rac1;IQGAP1	***GST-Rac1*** ***inhibited*** the binding of ***IQGAP1*** to beta-catenin in a dose-dependent manner in vitro , whereas neither GDP.GST-Cdc42 , GDP .	negative	1
6100	10473580	5788;925	gp180;CD8	This process appears to relate in part to a 180-kDa IEC surface glycoprotein , ***gp180*** , which ***binds*** to ***CD8*** and activates CD8-associated p56 ( lck ) .	parallel	1
6101	10473580	912;5788	CD1d;gp180	Because the class Ib molecule CD1d is expressed by IECs and monoclonal antibodies ( mAbs ) against CD1d inhibit IEC-induced proliferation of CD8 ( + ) T cells , co-immunoprecipitation and enzyme-linked immunosorbent assay studies were performed , which demonstrated an ***association*** of ***gp180*** and ***CD1d*** on the IEC surface .	parallel	0
6102	10473580	912;5788	CD1d;gp180	These data suggest that the ******CD1d-gp180****** ***complex*** on the surface of IECs can be recognized by the TCR-CD8 co-receptor , resulting in the activation of CD8 ( + ) T cells .	parallel	1
6103	10473597	207;842	Akt;caspase-9	These data suggest that M-CSF may induce cell survival through ***Akt-induced*** ***suppression*** of ***caspase-9*** activation .	negative	1
6104	10473597	1435;207	M-CSF;Akt	These ***M-CSF*** receptor events ***correlated*** with activation of the serine/threonine kinase ***Akt*** .	parallel	0
6105	10473597	1435;207	M-CSF;Akt	In normal human monocytes , ***M-CSF*** increased the levels of tyrosine-phosphorylated proteins and ***induced*** ***Akt*** activation in a PI3K-dependent manner .	target	1
6106	10473611	650;1432	BMP-2;p38 MAP kinase	In contrast , ***BMP-2*** characteristically ***induced*** the sustained activation of the ***p38 MAP kinase*** pathway .	target	1
6107	10473611	650;1432	BMP-2;p38 MAP kinase	Pretreatment of PC12 cells with SB203580 inhibited the BMP-2-induced neurite outgrowth formation in a dose-dependent manner ; this inhibition coincided well with the ability of SB203580 to inihibit the ***BMP-2-induced*** ***activation*** of the ***p38 MAP kinase*** pathway .	positive	1
6108	10473611	650;1432	BMP-2;p38 MAP kinase	Overexpression in PC12 cells of wild-type MAP kinase kinase ( MKK ) -6 enhanced the ***BMP-2-induced*** ***activation*** of ***p38 MAP kinase*** , whose activation correlated well with the ability of these cells to induce neurite outgrowth in response to BMP-2 .	positive	1
6109	10473612	4760;7143	beta2;TN-R	We hypothesized that ***beta2*** may ***interact*** with tenascin-R ( ***TN-R*** ) , an extracellular matrix molecule that is secreted by oligodendrocytes during myelination and that binds F3-contactin .	parallel	1
6110	10473620	4803;5598	nerve growth factor;ERK5	Here we have found that ***ERK5*** is strongly ***activated*** by epidermal growth factor and ***nerve growth factor*** , whose receptors are tyrosine kinases .	positive	1
6111	10473620	5607;5598	MEK5;ERK5	The reporter assays demonstrated that the serum-induced enhancement of transcription from serum response element was significantly inhibited by expression of a dominant-negative form of ***MEK5*** , which was a direct and specific ***activator*** for ***ERK5*** and that transcription from serum response element mediated by the Ets-domain transcription factor Sap1a , but not by Elk1 , was stimulated by coexpression of ERK5 and active MEK5 .	positive	1
6112	10473620	5607;2353	MEK5;c-Fos	Moreover , the serum-induced ***c-Fos*** expression was markedly ***inhibited*** by expression of dominant-negative ***MEK5*** .	negative	1
6113	10473671	6262;6546	RyR2;Na(+)-Ca2+ exchanger	Immunolabeling experiments demonstrated overlapping distributions of the ***Na(+)-Ca2+ exchanger*** and ryanodine ***receptors*** ( ***RyR2*** ) in AD myocytes .	parallel	1
6114	10473809	958;959	CD40;CD40L	Generation of protective immunity against an immunogenic carcinoma requires ******CD40/CD40L****** and B7/CD28 ***interactions*** but not CD4 ( + ) T cells .	parallel	1
6115	10473809	958;959	CD40;CD40L	***Interactions*** between ***CD40*** and ***CD40L*** play a central role in the regulation of both humoral and cellular immunity .	parallel	1
6116	10474052	3557;3553	IL-1ra;IL-1beta	Two hours , the effect of LPS on ACTH output was not modified by pretreatment with anti-IL-1beta IgG , anti-IL-6 IgG , anti-TNF-alpha IgG nor with IL-1ra , although ***IL-1ra*** treatment was able to fully ***block*** the ***IL-1beta*** ( 35 microg/kg body weight ) - stimulated HPA axis function , 1 and 2 h after cytokine administration .	negative	0
6117	10474056	5443;3557	proopiomelanocortin;interleukin-1 receptor antagonist	Differential ***regulation*** of ***interleukin-1 receptor antagonist*** by ***proopiomelanocortin*** peptides adrenocorticotropic hormone and beta-endorphin .	target	1
6118	10474056	1392;3557	corticotropin-releasing hormone;interleukin-1 receptor antagonist (IL-1ra) protein	We have previously described the ***regulation*** of ***interleukin-1 receptor antagonist (IL-1ra) protein*** secretion and expression by IL-1 , glucocorticoids and ***corticotropin-releasing hormone*** in monocytes in culture .	target	1
6119	10474080	5970;4790	p65;p50	Treatment with H. pylori resulted in the activation of two species of NF-kappa B dimers ( a ******p50/p65****** ***heterodimer*** and a p50 homodimer ) .	parallel	1
6120	10474686	595;1026	cyclin D1;p21	CONCLUSION : Overexpression of the cyclin D1 gene seems to lead to growth arrest in a variety of human cancers , possibly through the ***induction*** of ***p21*** by ***cyclin D1*** .	target	1
6121	10475063	3725;5578	c-jun;protein kinase C alpha	The molecular association of p300 and ATF-2 enhances the transcription of the ***c-jun*** gene , which ***requires*** ***protein kinase C alpha*** mediated phosphorylation of Ser-121 of ATF-2 within its p300 interaction domain .	target	0
6122	10475092	7040;6347	TGF-beta1;MCP-1	***TGF-beta1*** in cotreatment with either TNF alpha or IL-1beta , but not IFN gamma , significantly ***decreased*** ***MCP-1*** mRNA and protein expression , as compared to TNF alpha or IL-1beta treatment alone .	negative	0
6123	10475115	596;355	bcl-2;Fas	METHODS : Apoptosis and the expression of its related proteins , Fas , ***Fas*** ***ligand*** ( FasL ) , ***bcl-2*** and p53 , in epithelial cells of human ovarian tumors of different histological grades , were determined immunohistochemically and morphometrically .	parallel	1
6124	10475115	356;355	FasL;Fas	METHODS : Apoptosis and the expression of its related proteins , Fas , ***Fas*** ***ligand*** ( ***FasL*** ) , bcl-2 and p53 , in epithelial cells of human ovarian tumors of different histological grades , were determined immunohistochemically and morphometrically .	parallel	1
6125	10475115	7157;355	p53;Fas	METHODS : Apoptosis and the expression of its related proteins , Fas , ***Fas*** ***ligand*** ( FasL ) , bcl-2 and ***p53*** , in epithelial cells of human ovarian tumors of different histological grades , were determined immunohistochemically and morphometrically .	parallel	1
6126	10476062	5111;7150	PCNA;topoisomerase I	***Suppression*** of pea nuclear ***topoisomerase I*** enzyme activity by pea ***PCNA*** .	negative	1
6127	10476215	941;940	CD80;CD28	Here , in vitro propagated DC were transduced using an adenoviral ( Ad ) vector to express the gene encoding cytotoxic T lymphocyte antigen 4-immunoglobulin ( CTLA4lg ) , which blocks ***interaction*** of ***CD80*** and CD86 on DC with ***CD28*** on T cells .	parallel	1
6128	10476215	942;940	CD86;CD28	Here , in vitro propagated DC were transduced using an adenoviral ( Ad ) vector to express the gene encoding cytotoxic T lymphocyte antigen 4-immunoglobulin ( CTLA4lg ) , which blocks ***interaction*** of CD80 and ***CD86*** on DC with ***CD28*** on T cells .	parallel	1
6129	10476217	7852;2920	chemokine receptor;MIP-2	However , AdMIP-2 infection in mice lacking the CXC ***chemokine receptor*** that ***binds*** ***MIP-2*** , CXCR2 , did not attenuate any of the markers of liver injury after adenovirus and acetaminophen challenge .	parallel	1
6130	10476693	3811;3804	KIR;p58	RESULTS : We found no difference between the RM and control couples in the degree of paternal incompatibility for maternal HLA-C alleles and the distribution of the two HLA-C supertypic specificities that are recognized differently by ***p58*** killer cell inhibitory ***receptor*** ( ***KIR*** ) positive natural killer ( NK ) cells was similar in the two groups .	parallel	1
6131	10476693	3811;3107	KIR;HLA-C	RESULTS : We found no difference between the RM and control couples in the degree of paternal incompatibility for maternal HLA-C alleles and the distribution of the two ***HLA-C*** supertypic specificities that are ***recognized*** differently by p58 killer cell inhibitory receptor ( ***KIR*** ) positive natural killer ( NK ) cells was similar in the two groups .	target	1
6132	10476927	3439;3458	IFN-alpha;IFN-gamma	We have proposed a unifying hypothesis of the origin of autoimmunity as a type I IFN immunodeficiency syndrome involving inadequate ***regulation*** of the acquired immune system product ***IFN-gamma*** by the ***IFN-alpha/beta*** innate immune system .	target	1
6133	10476935	3439;3659	IFN-alpha;IRF-1	The daily administration of ***IFN-alpha*** ( 0.1 , 1 , 10 , and 100 IU/body ) for 1 week ***augmented*** ***IRF-1*** and 2-5 ( A ) synthetase mRNA expression levels , as well as 2-5 ( A ) synthetase enzymatic activity in spleen cells but not in cervical lymph nodes .	positive	0
6134	10476939	3439;9636	IFN-alpha;ISG-15	***IFN-alpha*** ***augmented*** BEC ***ISG-15*** gene expression in a concentration dependent manner both in vivo and in vitro .	positive	0
6135	10476940	3439;362	IFN-alpha;AQP5	***IFN-alpha*** ***augmented*** ***AQP5*** transcription and protein production in a concentration-dependent manner , and increased the size of intensity of staining of AQP5-containing cytoplasmic vesicles in acinar cells .	positive	0
6136	10476940	3439;362	IFN-alpha;AQP5	We conclude that ***IFN-alpha*** ***upregulates*** ***AQP5*** gene expression in human parotid acinar cells in vitro .	positive	1
6137	10477081	116;1621	pituitary adenylate cyclase-activating polypeptide;dopamine beta-hydroxylase	Roles of protein kinase A ( PKA ) and protein kinase C ( PKC ) in ***regulation*** of tyrosine hydroxylase , ***dopamine beta-hydroxylase*** , and phenylethanolamine N-methyltransferase expression by ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) were determined in primary cultured bovine chromaffin cells .	target	1
6138	10477081	116;5409	pituitary adenylate cyclase-activating polypeptide;phenylethanolamine N-methyltransferase	Roles of protein kinase A ( PKA ) and protein kinase C ( PKC ) in ***regulation*** of tyrosine hydroxylase , dopamine beta-hydroxylase , and ***phenylethanolamine N-methyltransferase*** expression by ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) were determined in primary cultured bovine chromaffin cells .	target	1
6139	10477081	116;7054	pituitary adenylate cyclase-activating polypeptide;tyrosine hydroxylase	Roles of protein kinase A ( PKA ) and protein kinase C ( PKC ) in ***regulation*** of ***tyrosine hydroxylase*** , dopamine beta-hydroxylase , and phenylethanolamine N-methyltransferase expression by ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) were determined in primary cultured bovine chromaffin cells .	target	1
6140	10477081	116;1621	PACAP;DBH	***DBH*** ***up-regulation*** by ***PACAP*** was reduced by H-89 and not further increased by forskolin showing involvement of cAMP/PKA .	positive	1
6141	10477081	116;7054	PACAP;tyrosine hydroxylase	***tyrosine hydroxylase*** ***induction*** by ***PACAP*** was mediated by both kinases .	target	1
6142	10477081	116;1621	PACAP;dopamine beta-hydroxylase	***PACAP*** ***increased*** tyrosine hydroxylase and ***dopamine beta-hydroxylase*** activities , but slightly lowered phenylethanolamine N-methyltransferase activity , resulting in a preferential rise in norepinephrine over epinephrine .	positive	0
6143	10477081	116;7054	PACAP;tyrosine hydroxylase	***PACAP*** ***increased*** ***tyrosine hydroxylase*** and dopamine beta-hydroxylase activities , but slightly lowered phenylethanolamine N-methyltransferase activity , resulting in a preferential rise in norepinephrine over epinephrine .	positive	0
6144	10477262	1981;1977	eIF4G;eIF4E	We have shown previously that the stimulation of cultured Xenopus kidney cells with serum resulted in the activation of protein synthesis , enhanced phosphorylation of eIF4E and increased ***binding*** of the adapter protein , ***eIF4G*** , and poly ( A ) - binding protein ( PABP ) to ***eIF4E*** to form the functional initiation factor complex , eIF4F/PABP .	parallel	1
6145	10477262	26986;1981	PABP;eIF4G	We now show that cellular stresses such as arsenite , anisomycin and heat shock also result in increased phosphorylation of eIF4E , eIF4F complex formation and the ***association*** of ***PABP*** with ***eIF4G*** , in conditions under which the rate of protein synthesis is severely inhibited .	parallel	0
6146	10477262	1981;1977	eIF4G;eIF4E	These results indicate that cellular stresses activate multiple signalling pathways that converge at the level of eIF4F complex formation to influence the ***interactions*** between ***eIF4E*** , ***eIF4G*** and PABP .	parallel	1
6147	10477262	1981;26986	eIF4G;PABP	These results indicate that cellular stresses activate multiple signalling pathways that converge at the level of eIF4F complex formation to influence the ***interactions*** between eIF4E , ***eIF4G*** and ***PABP*** .	parallel	1
6148	10477262	26986;1977	PABP;eIF4E	These results indicate that cellular stresses activate multiple signalling pathways that converge at the level of eIF4F complex formation to influence the ***interactions*** between ***eIF4E*** , eIF4G and ***PABP*** .	parallel	1
6149	10477277	834;5272	Caspase-1;PI9	The ***complexes*** of ***Caspase-1*** and caspase-4 with ***PI9*** can be immunoprecipitated but no complex with caspase-3 can be detected .	parallel	1
6150	10477277	837;5272	caspase-4;PI9	The ***complexes*** of Caspase-1 and ***caspase-4*** with ***PI9*** can be immunoprecipitated but no complex with caspase-3 can be detected .	parallel	1
6151	10477277	5272;834	PI9;Caspase-1	These results show that ***PI9*** is an ***inhibitor*** of ***Caspase-1*** and to a smaller extent caspase-4 and caspase-8 , but not of the more distantly related caspase-3 .	negative	1
6152	10477279	2254;1026	FGF9;p21	***FGF9*** also ***stimulated*** expression of the mitotic inhibitor ***p21*** to a greater extent than FGF2 .	positive	0
6153	10477283	6812;6804	nSec-1;syntaxin 1A	***nSec-1*** ( munc-18 ) ***interacts*** with both primed and unprimed ***syntaxin 1A*** and associates in a dimeric complex on adrenal chromaffin granules .	parallel	1
6154	10477283	6812;6804	nSec-1;syntaxin 1A	It has been demonstrated that ***nSec-1*** , a regulatory protein also involved in neuronal exocytosis , ***binds*** ***syntaxin 1A*** with high affinity in vitro , although evidence for this physical interaction occurring in vivo has proven elusive .	parallel	1
6155	10477283	6812;6804	nSec-1;syntaxin 1A	The results of this study therefore suggest the possibility of ***nSec-1*** ***interactions*** with primed ***syntaxin 1A*** and demonstrate a potentially significant interaction of syntaxin 1A and nSec-1 on the membranes of chromaffin granules .	parallel	1
6156	10477283	6812;6804	nSec-1;syntaxin 1A	The results of this study therefore suggest the possibility of nSec-1 interactions with primed syntaxin 1A and demonstrate a potentially significant ***interaction*** of ***syntaxin 1A*** and ***nSec-1*** on the membranes of chromaffin granules .	parallel	1
6157	10477397	3553;6992	IL-1beta;inhibitor-3	***IL-1beta*** ***induced*** serine protease ***inhibitor-3*** ( SPI-3 ; a putative cellular " defense " protein ) mRNA expression in both wt and IRF-1 - / - islets or beta-cells .	target	1
6158	10477397	3458;5269	IFN-gamma;SPI-3	***IFN-gamma*** ***decreased*** the IL-1beta-induced ***SPI-3*** expression in wt islets or beta-cells , but induced a 5-fold increase in the expression of this mRNA in IRF-1 - / - islets cells , suggesting that IRF-1 mediates an inhibitory effect of IFN-gamma on SPI-3 expression .	negative	0
6159	10477520	3738;5590	potassium channel;PKCzeta	Two alternatively spliced ZIP1 and ZIP2 proteins are described , which bind to both Kvbeta2 subunits of potassium channel and protein kinase C (PKC) zeta , thereby acting as a physical link in the assembly of ******PKCzeta-ZIP-potassium channel****** ***complexes*** .	parallel	1
6160	10477523	580;1477	BARD1;CstF-50	Functional ***interaction*** of BRCA1-associated ***BARD1*** with polyadenylation factor ***CstF-50*** .	parallel	1
6161	10477523	580;1477	BARD1;CstF-50	The ******BARD1-CstF-50****** ***interaction*** inhibits polyadenylation in vitro .	parallel	1
6162	10477549	355;356	Fas;Fas ligand	This demonstrates a novel developmental step at which intact ******Fas-Fas ligand****** ***signaling*** is required to regulate B cells in order to prevent autoimmunity .	parallel	0
6163	10477563	7292;2353	gp34;c-fos	Intracellular signaling of gp34 , the OX40 ligand : ***induction*** of c-jun and ***c-fos*** mRNA expression through ***gp34*** upon binding of its receptor , OX40 .	target	1
6164	10477563	7292;3725	gp34;c-jun	Intracellular signaling of gp34 , the OX40 ligand : ***induction*** of ***c-jun*** and c-fos mRNA expression through ***gp34*** upon binding of its receptor , OX40 .	target	1
6165	10477563	7292;7293	gp34;OX40	We investigated the intracellular signaling events of ***OX40*** ***ligand*** ( ***gp34*** ) , a member of the TNF family .	parallel	1
6166	10477563	7293;3725	OX40;c-jun	Furthermore , ***OX40*** binding ***induced*** ***c-jun*** mRNA expression also in HUVECs , which in our previous study have been shown to express gp34 and interact with activated T cells through the OX40/gp34 pathway .	target	1
6167	10477567	6352;1234	RANTES;CCR5	In this report , we show that RANTES and its derivative , aminooxypentane ( AOP ) - ***RANTES*** , a potent RANTES antagonist as well as an inhibitor of HIV-1 infection , both ***promote*** ***CCR5*** desensitization involving G protein-coupled receptor kinases-2 and beta-arrestin equally well .	positive	0
6168	10477571	7432;7124	Vasoactive intestinal peptide;TNF-alpha	***Vasoactive intestinal peptide*** ***synergizes*** with ***TNF-alpha*** in inducing human dendritic cell maturation .	parallel	0
6169	10477576	7124;4790	TNF-alpha;NF-kappa B	***TNF-alpha*** rapidly ***induced*** marked activation of nuclear transcription factor ***NF-kappa B*** in all 4 cell lines .	target	1
6170	10477577	959;958	CD40L;CD40	Neutralizing Abs against ***CD40*** ***ligand*** ( ***CD40L*** ) , but not against IL-4 or IL-15 , abrogated IgM-RF production .	parallel	1
6171	10477577	958;959	CD40;CD40L	The results suggest that selective induction of apoptosis in high-affinity RF B cells may be achieved by blockade of ******CD40L-CD40****** ***interaction*** .	parallel	1
6172	10477578	3603;1234	IL-16;CCR5	Reciprocal desensitization of ***CCR5*** and CD4 is ***mediated*** by ***IL-16*** and macrophage-inflammatory protein-1 beta , respectively .	target	0
6173	10477578	3603;920	IL-16;CD4	Reciprocal desensitization of CCR5 and ***CD4*** is ***mediated*** by ***IL-16*** and macrophage-inflammatory protein-1 beta , respectively .	target	0
6174	10477578	6351;1234	macrophage-inflammatory protein-1 beta;CCR5	Reciprocal desensitization of ***CCR5*** and CD4 is ***mediated*** by IL-16 and ***macrophage-inflammatory protein-1 beta*** , respectively .	target	0
6175	10477578	6351;920	macrophage-inflammatory protein-1 beta;CD4	Reciprocal desensitization of CCR5 and ***CD4*** is ***mediated*** by IL-16 and ***macrophage-inflammatory protein-1 beta*** , respectively .	target	0
6176	10477578	920;3603	CD4;IL-16	These studies demonstrate that ******IL-16/CD4****** ***signaling*** in T lymphocytes results in a selective loss of macrophage-inflammatory protein ( MIP ) -1 beta/CCR5-induced chemotaxis .	parallel	0
6177	10477578	6351;1234	MIP-1 beta;CCR5	Desensitization of CCR5 by IL-16 required at least 10 min of pretreatment ; no modulation of CCR5 expression was observed , nor was ***MIP-1 beta*** ***binding*** to ***CCR5*** altered .	parallel	1
6178	10477579	356;355	FasL;Fas	IL-2 up-regulated ***Fas*** ***ligand*** ( ***FasL*** ) and down-regulated gamma c expression on activated 2C cells in vitro and in vivo .	parallel	1
6179	10477579	3558;356	IL-2;FasL	***IL-2*** ***up-regulated*** Fas ligand ( ***FasL*** ) and down-regulated gamma c expression on activated 2C cells in vitro and in vivo .	positive	1
6180	10477581	3937;3932	SLP-76;p56lck	***SLP-76*** ***binding*** to ***p56lck*** : a role for SLP-76 in CD4-induced desensitization of the TCR/CD3 signaling complex .	parallel	1
6181	10477584	3439;355	IFN-alpha;CD95	Recombinant ***IFN-alpha*** ( 2b ) ***increases*** the expression of apoptosis receptor ***CD95*** and chemokine receptors CCR1 and CCR3 in monocytoid cells .	positive	0
6182	10477584	3439;355	IFN-alpha;CD95	We also provide evidence that , under these conditions , ***IFN-alpha*** treatment ***increased*** the expression of ***CD95*** ( Fas , Apo1 ) , resulting in enhanced susceptibility to apoptosis .	positive	0
6183	10477587	958;959	CD40;CD40L	This study highlights the importance of ******CD40-CD40L****** ***interactions*** in generating virus-specific CD4 T cell responses and in resolving chronic viral infection .	parallel	1
6184	10477591	3606;3458	IL-18;IFN-gamma	***IL-18*** , a recently identified cytokine synthesized by different cell types , including Kupffer cells , activated macrophages , and keratinocytes , ***induces*** ***IFN-gamma*** production by T cells and NK cells .	target	1
6185	10477595	7422;4790	VEGF;NF-kappaB	***VEGF*** ***inhibited*** FL-inducible activation of transcription factor ***NF-kappaB*** .	negative	1
6186	10477597	7186;11183	TRAF2;GCKR	Here we show that ***TRAF2*** ***interacts*** with ***GCKR*** .	parallel	1
6187	10477597	7186;11183	TRAF2;GCKR	The full ***activation*** of ***GCKR*** by ***TRAF2*** required the TRAF2 RING finger domain .	positive	1
6188	10477597	11183;7186	GCKR;TRAF2	The full activation of ***GCKR*** by TRAF2 ***required*** the ***TRAF2*** RING finger domain .	target	0
6189	10477597	7186;11183	TRAF2;GCKR	These findings are consistent with a model whereby TNF signaling results in the ***recruitment*** and activation of ***GCKR*** by ***TRAF2*** , which leads to SAPK activation .	target	0
6190	10477599	4773;6375	NF-ATp;SCM-1	One-hybrid assays in yeast isolated NF-ATp as an E1 binding protein , and transfection of ***NF-ATp*** into T and B cell lines strongly ***enhanced*** the activation-dependent ***SCM-1*** promoter activity .	positive	0
6191	10477604	958;959	CD40;CD40 ligand	Analysis of the immune response of acutely infected CD28 - / - mice revealed that IL-12 was required for T cell production of IFN-gamma and this was independent of the ******CD40/CD40 ligand****** ***interaction*** .	parallel	1
6192	10477616	3565;7412	IL-4;VCAM-1	***IL-4*** ***increased*** ***VCAM-1*** expression , but P-selectin and E-selectin remained at constitutive levels .	positive	0
6193	10477681	3553;3091	IL-1beta;HIF-1alpha	Only ***IL-1beta*** ***increased*** ***HIF-1alpha*** protein levels .	positive	0
6194	10477689	5464;6850	PP1;Syk	The Src family-specific inhibitor ***PP1*** dose-dependently ***inhibits*** phosphorylation of ***Syk*** , its association with tyrosine-phosphorylated gamma-chain , phosphorylation of PLCgamma2 , platelet aggregation , and 5-HT release .	negative	1
6195	10477695	3578;22808	IL-9;M-Ras	***M-Ras*** expression was found to be ***induced*** by ***IL-9*** but not IL-2 or IL-4 in various murine T-helper-cell clones , and this induction seems to be dependent on the JAK/STAT pathway .	target	1
6196	10477697	3458;3383	IFN-gamma;CD54	LPS preincubation in this experimental setting did not result in a general hyporesponsiveness of the monocytes , as IL-6 production as well as ***IFN-gamma-induced*** ***upregulation*** of ***CD54*** did not decline .	positive	1
6197	10477698	3002;836	granzyme B;caspase-3	The apoptotic pathway distal to the DISC is intact because ceramide analogs , staurosporine , and ***granzyme B*** ***activate*** ***caspase-3*** and induce apoptosis .	positive	1
6198	10477698	841;8837	caspase-8;FLIP	In addition , ***modification*** of the ***caspase-8/FLIP*** ( L ) ratio by ***caspase-8*** or FLIP ( L ) overexpression was able to alter the susceptibility status of the cell lines tested .	target	0
6199	10477698	8837;841	FLIP;caspase-8	In addition , ***modification*** of the ***caspase-8/FLIP*** ( L ) ratio by caspase-8 or ***FLIP*** ( L ) overexpression was able to alter the susceptibility status of the cell lines tested .	target	0
6200	10477703	1029;1030	p16;p15	Our results suggest a role for p15 and p16 gene methylation during lymphomagenesis and a possible ***association*** between ***p15*** and ***p16*** inactivation and aggressive transformation in B-cell and T-cell lymphomas .	parallel	0
6201	10477704	3458;942	interferon-gamma;B7-2	***interferon-gamma*** ( IFN-gamma ) ***enhances*** ***B7-2*** protein expression in monocytic cells .	positive	0
6202	10477716	7124;3576	tumor necrosis factor alpha;interleukin-8	Nuclear factor-kappaB-dependent ***induction*** of ***interleukin-8*** gene expression by ***tumor necrosis factor alpha*** : evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation .	target	1
6203	10477717	1233;6367	CCR4;MDC	MDC-responsive murine thymocytes express mRNA for ***CCR4*** , a recently identified ***receptor*** for ***MDC*** .	parallel	1
6204	10477718	6351;1234	MIP-1beta;CCR5	Among these ligands , MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , MCP-3 could also inhibit the ***activation*** of ***CCR5*** by ***MIP-1beta*** and may therefore be considered as a natural antagonist for CCR5 .	positive	1
6205	10477718	6354;1234	MCP-3;CCR5	Among these ligands , MCP-3 had the remarkable property of binding CCR5 with high affinity without eliciting a functional response , ***MCP-3*** could also ***inhibit*** the activation of ***CCR5*** by MIP-1beta and may therefore be considered as a natural antagonist for CCR5 .	negative	1
6206	10477725	7040;7066	TGF-beta1;thrombopoietin	Transforming growth factor-beta1 ( ***TGF-beta1*** ) ***induces*** ***thrombopoietin*** from bone marrow stromal cells , which stimulates the expression of TGF-beta receptor on megakaryocytes and , in turn , renders them susceptible to suppression by TGF-beta itself with high specificity .	target	1
6207	10477736	7124;6356	TNF-alpha;eotaxin	Production of tumor necrosis factor-alpha ( TNF-alpha ) by Hodgkin/Reed-Sternberg cells appears to be responsible for this induction , because blocking of ***TNF-alpha*** by neutralizing antibodies ***prevented*** fibroblast ***eotaxin*** expression .	positive	0
6208	10477738	3569;4313	IL-6;MMP-2	Moreover , in human lymphoid cell lines of B - and T-cell origin ( Raji , Jurkat , and NC-37 ) , ***IL-6*** ***stimulated*** production of MMP-9 and ***MMP-2*** but not TIMP-1 .	positive	0
6209	10477738	3569;4318	IL-6;MMP-9	Moreover , in human lymphoid cell lines of B - and T-cell origin ( Raji , Jurkat , and NC-37 ) , ***IL-6*** ***stimulated*** production of ***MMP-9*** and MMP-2 but not TIMP-1 .	positive	0
6210	10477741	2885;1399	Grb2;CrkL	Stimulation of FcalphaRI induced the tyrosine phosphorylation of Shc and increased the ***association*** of ***Grb2*** with Shc and ***CrkL*** .	parallel	0
6211	10477741	2885;6464	Grb2;Shc	Stimulation of FcalphaRI induced the tyrosine phosphorylation of Shc and increased the ***association*** of ***Grb2*** with ***Shc*** and CrkL .	parallel	0
6212	10477741	2204;2885	FcalphaRI;Grb2	Stimulation of ***FcalphaRI*** induced the tyrosine phosphorylation of Shc and ***increased*** the association of ***Grb2*** with Shc and CrkL .	positive	0
6213	10477752	5295;1499	p85alpha;beta-catenin	Interestingly , a strong association of p85alpha and p110alpha subunits of PI3K with beta-catenin is induced in V12Ras-expressing keratinocytes , and in vitro binding assays show a direct ***interaction*** between ***beta-catenin*** and ***p85alpha*** .	parallel	1
6214	10477752	5290;5295	p110alpha;p85alpha	Interestingly , a strong ***association*** of ***p85alpha*** and ***p110alpha*** subunits of PI3K with beta-catenin is induced in V12Ras-expressing keratinocytes , and in vitro binding assays show a direct interaction between beta-catenin and p85alpha .	parallel	0
6215	10477752	5290;1499	p110alpha;beta-catenin	Overexpression of either V12Ras or constitutively active ***p110alpha*** ***induces*** metabolic stabilization of ***beta-catenin*** and promotes its accumulation in cytoplasmic and nuclear pools .	target	1
6216	10477765	375790;4593	Agrin;MuSK	***Agrin*** released from motor nerve terminals ***activates*** a muscle-specific receptor tyrosine kinase ( ***MuSK*** ) in muscle cells to trigger formation of the skeletal neuromuscular junction .	positive	1
6217	10477765	4593;375790	MuSK;Agrin	Together , our results indicate that the ectodomain of ***MuSK*** ***mediates*** both ***Agrin*** - dependent activation of a complex signal transduction pathway and Agrin-independent association of the kinase with other postsynaptic components .	target	0
6218	10477767	3569;952	IL-6;CD38	***IL-6*** , in turn , ***enhanced*** ***CD38*** mRNA expression .	positive	0
6219	10478798	3815;92086	c-kit;gamma-glutamyl transpeptidase	In addition , the cell line expressed the anti-human epithelial-related antigen ( MOC-31 ) , the human epithelial antigen ( HEA ) , and the ***gamma-glutamyl transpeptidase*** , the hematopoietic growth factor , stem cell factor , and also its ***receptor*** , ***c-kit*** .	parallel	1
6220	10478798	3815;4072	c-kit;MOC-31	In addition , the cell line expressed the anti-human epithelial-related antigen ( ***MOC-31*** ) , the human epithelial antigen ( HEA ) , and the gamma-glutamyl transpeptidase , the hematopoietic growth factor , stem cell factor , and also its ***receptor*** , ***c-kit*** .	parallel	1
6221	10478838	2516;949	SF-1;SR-BI	We now provide in vivo evidence that ***SF-1*** ***regulates*** ***SR-BI*** .	target	1
6222	10478845	10499;6095	GRIP-1;RORalpha	***GRIP-1*** functioned as a ***coactivator*** for the ***RORalpha*** both in yeast and in mammalian cells .	positive	1
6223	10478845	10499;6095	GRIP-1;RORalpha	Thus , ***GRIP-1*** is the first proven ***coactivator*** for ***RORalpha*** .	positive	1
6224	10479057	3458;3135	IFN-gamma;HLA-G	These results suggest that both post-transcriptional and transcriptional mechanisms implicating IFN-responsive regulatory sequences outside the 1.4 kb-region are involved in ***IFN-gamma*** gene ***activation*** of the ***HLA-G*** gene .	positive	1
6225	10479057	3458;3135	IFN-gamma;HLA-G	***HLA-G*** cell surface expression was ***enhanced*** by ***IFN-gamma*** treatment in JEG-3 and U937 cell lines and peripheral blood monocytes while no effect was observed in tera-2 teratocarcinoma cell line .	positive	0
6226	10479400	3553;3558	IL-1;IL-2	These results indicate that p42/p44 MAP kinase is involved in the ***regulation*** of ***IL-2*** gene transcription by ***IL-1*** , whilst p38 MAP kinase has a post-transcriptional target .	target	1
6227	10479400	5706;3558	p42;IL-2	These results indicate that ***p42/p44*** MAP kinase is involved in the ***regulation*** of ***IL-2*** gene transcription by IL-1 , whilst p38 MAP kinase has a post-transcriptional target .	target	1
6228	10479400	3553;3558	IL-1;IL-2	Distinct roles for p42/p44 and p38 mitogen-activated protein kinases in the ***induction*** of ***IL-2*** by ***IL-1*** .	target	1
6229	10479400	3553;5594	IL-1;p38	Interleukin 1 ( ***IL-1*** ) ***activates*** p42/p44 and ***p38*** mitogen-activated protein kinases ( MAP kinases ) in target cells .	positive	1
6230	10479400	3553;5706	IL-1;p42	Interleukin 1 ( ***IL-1*** ) ***activates*** ***p42/p44*** and p38 mitogen-activated protein kinases ( MAP kinases ) in target cells .	positive	1
6231	10479400	3553;3558	IL-1;IL-2	Here we have used two specific inhibitors , PD98059 which inhibits MAP kinase kinase ( MEK ) , and SB203580 which inhibits p38 MAP kinase to explore the involvement of these kinases in the ***induction*** of ***IL-2*** by ***IL-1*** in the murine thymoma cell line EL4.NOB-1 .	target	1
6232	10479411	5663;4035	presenilin-1;LRP	Aberrant ***presenilin-1*** expression ***downregulates*** LDL receptor-related protein ( ***LRP*** ) : is LRP central to Alzheimer 's disease pathogenesis ?	negative	1
6233	10479411	5663;4035	presenilin-1;LRP	Here we report that aberrant ***presenilin-1*** expression in vivo and in vitro ***downregulates*** ***LRP*** .	negative	1
6234	10479448	649;8646	BMP-1;Chordin	***BMP-1*** and mTLL-1 are shown to ***cleave*** ***Chordin*** , at sites similar to procollagen C-propeptide cleavage sites , and to counteract dorsalizing effects of Chordin upon overexpression in Xenopus embryos .	target	1
6235	10479460	7852;6387	CXCR4;SDF-1	Embryonic expression and function of the chemokine ***SDF-1*** and its ***receptor*** , ***CXCR4*** .	parallel	1
6236	10479529	3848;3827	Cytokeratin 1;high molecular weight kininogen	***Cytokeratin 1*** and gC1qR ***mediate*** ***high molecular weight kininogen*** binding to endothelial cells .	target	0
6237	10479529	708;3827	gC1qR;high molecular weight kininogen	Cytokeratin 1 and ***gC1qR*** ***mediate*** ***high molecular weight kininogen*** binding to endothelial cells .	target	0
6238	10479532	6504;3458	SLAM;interferon-gamma	***SLAM*** engagement ***augments*** T cell expansion and ***interferon-gamma*** ( IFN-gamma ) production independently of CD28 .	positive	0
6239	10479532	4068;6504	SLAM-associated protein;SLAM	***SLAM*** signaling is ***regulated*** by the ***SLAM-associated protein*** .	target	1
6240	10479532	6504;3458	SLAM;IFN-gamma	Results showed that : ( 1 ) SLAM-expressing CD4 ( + ) and CD8 ( + ) lymphocytes diminish in group A patients compared to both group B patients and HC ; ( 2 ) SLAM expression on CD4 ( + ) lymphocytes is preferentially associated with the lack of CD7 on cell surface ( CD4 ( + ) CD7 ( - ) produce IL-10 but not IFN-gamma ) ; ( 3 ) SLAM engagement increases HIV env peptide-stimulated , but neither tetanus toxoid - nor PHA-stimulated proliferation of peripheral blood mononuclear cells ( PBMC ) in patients but not in HC ; and ( 4 ) ***SLAM*** engagement ***augments*** ***IFN-gamma*** and reduces IL-10 production by env peptide-stimulated PBMC of HIV-infected individuals .	positive	0
6241	10479532	6504;3586	SLAM;IL-10	Results showed that : ( 1 ) SLAM-expressing CD4 ( + ) and CD8 ( + ) lymphocytes diminish in group A patients compared to both group B patients and HC ; ( 2 ) SLAM expression on CD4 ( + ) lymphocytes is preferentially associated with the lack of CD7 on cell surface ( CD4 ( + ) CD7 ( - ) produce IL-10 but not IFN-gamma ) ; ( 3 ) SLAM engagement increases HIV env peptide-stimulated , but neither tetanus toxoid - nor PHA-stimulated proliferation of peripheral blood mononuclear cells ( PBMC ) in patients but not in HC ; and ( 4 ) ***SLAM*** engagement augments IFN-gamma and ***reduces*** ***IL-10*** production by env peptide-stimulated PBMC of HIV-infected individuals .	negative	1
6242	10479645	7040;6722	TGF-beta;serum response factor	Electrophoretic mobility shift assays showed that ***TGF-beta*** ***enhanced*** binding of a ***serum response factor*** to the CArG elements and the binding of an as-yet-unidentified factor to the TCE in endothelial cells and fibroblasts , but to a much lesser extent compared with SMCs .	positive	0
6243	10479645	7040;6876	TGF-beta;SM22alpha	***TGF-beta*** also ***stimulated*** expression of the SMC differentiation marker ***SM22alpha*** in non-SMCs .	positive	0
6244	10479648	2353;3383	c-Fos;intercellular adhesion molecule-1	Adenovirus-mediated overexpression of c-Jun and ***c-Fos*** ***induces*** ***intercellular adhesion molecule-1*** and monocyte chemoattractant protein-1 in human endothelial cells .	target	1
6245	10479648	2353;6347	c-Fos;monocyte chemoattractant protein-1	Adenovirus-mediated overexpression of c-Jun and ***c-Fos*** ***induces*** intercellular adhesion molecule-1 and ***monocyte chemoattractant protein-1*** in human endothelial cells .	target	1
6246	10479648	3725;3383	c-Jun;intercellular adhesion molecule-1	Adenovirus-mediated overexpression of ***c-Jun*** and c-Fos ***induces*** ***intercellular adhesion molecule-1*** and monocyte chemoattractant protein-1 in human endothelial cells .	target	1
6247	10479648	3725;6347	c-Jun;monocyte chemoattractant protein-1	Adenovirus-mediated overexpression of ***c-Jun*** and c-Fos ***induces*** intercellular adhesion molecule-1 and ***monocyte chemoattractant protein-1*** in human endothelial cells .	target	1
6248	10479651	5468;5465	PPARgamma;PPAR	Other peroxisome proliferator activated receptor ( ***PPAR*** ) ***ligands*** , 15d-PGJ ( 2 ) and troglitazone ( ***PPARgamma*** ) , Wy14 ,643 ( PPARalpha ) , and PD195599 ( PPARbeta ) inhibited the induction of MCP-1 by RA .	parallel	1
6249	10479651	5465;6347	PPARalpha;MCP-1	Other peroxisome proliferator activated receptor ( PPAR ) ligands , 15d-PGJ ( 2 ) and troglitazone ( PPARgamma ) , Wy14 ,643 ( ***PPARalpha*** ) , and PD195599 ( PPARbeta ) ***inhibited*** the induction of ***MCP-1*** by RA .	negative	1
6250	10479651	5467;6347	PPARbeta;MCP-1	Other peroxisome proliferator activated receptor ( PPAR ) ligands , 15d-PGJ ( 2 ) and troglitazone ( PPARgamma ) , Wy14 ,643 ( PPARalpha ) , and PD195599 ( ***PPARbeta*** ) ***inhibited*** the induction of ***MCP-1*** by RA .	negative	1
6251	10479652	820;5741	cAMP;parathyroid hormone	Dex also enhanced several phenotypic markers of osteoblasts , such as alkaline phosphatase activity , procollagen type I carboxy-terminal peptide production , and ***cAMP*** ***responses*** to ***parathyroid hormone*** in BVSMCs .	parallel	0
6252	10479652	820;5741	cAMP;parathyroid hormone	The effects of Dex on alkaline phosphatase activity and the ***cAMP*** ***response*** to ***parathyroid hormone*** in BVSMCs were less prominent than those in Saos-2 cells .	parallel	0
6253	10479653	183;3480	Angiotensin II;insulin-like growth factor 1 receptor	***Angiotensin II*** ***activation*** of ***insulin-like growth factor 1 receptor*** transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism .	positive	1
6254	10479653	183;3480	Angiotensin II;insulin-like growth factor 1 receptor	We have recently shown that ***Angiotensin II*** ***activation*** of ***insulin-like growth factor 1 receptor*** ( IGF-1R ) transcription is a critical requirement for angiotensin-stimulated vascular smooth muscle cell growth ; therefore , we examined the signaling pathway involved .	positive	1
6255	10479671	7035;2152	Tissue factor pathway inhibitor;Tissue factor	***Tissue factor pathway inhibitor*** ***attenuates*** procoagulant activity and upregulation of ***Tissue factor*** at the site of balloon-induced arterial injury in pigs .	negative	0
6256	10479717	4803;1386	nerve growth factor;activating transcription factor-2	Axonal transport of ***activating transcription factor-2*** is ***modulated*** by ***nerve growth factor*** in nociceptive neurons .	target	0
6257	10480138	1636;4018	ACE;lipoprotein	The II ***ACE*** genotype was ***associated*** with higher ***lipoprotein*** ( a ) ( Lp [ a ] ) levels and greater cerebrovascular disease family history and the MT AGT genotype with lower total cholesterol ( TC ) and triglycerides ( TG ) levels .	parallel	0
6258	10480313	213;4023	albumin;lipoprotein lipase	A vanadyl sulfate-bovine serum ***albumin*** complex ***stimulates*** the release of ***lipoprotein lipase*** activity from isolated rat fat pads through an increase in the cellular content of cAMP and myo-inositol 1,4,5-trisphosphate .	positive	0
6259	10480327	5054;5327	PAI-1;t-PA	It is known that angiotensin II ( Ang II ) exerts an antifibrinolytic effect by stimulating synthesis of plasminogen activator inhibitor type-1 ( ***PAI-1*** ) , a specific ***inhibitor*** of tissue plasminogen activator ( ***t-PA*** ) .	negative	1
6260	10480339	3977;3976	LIFR;LIF	Therefore , in vivo and in vitro expression of LIF , IL-6 and their signal transducer genes encoding ***LIF*** ***receptor*** ( ***LIFR*** ) , IL-6 receptor ( IL-6R ) and gp130 in human medulloblastoma cells were investigated by multiple cellular and molecular biology approaches .	parallel	1
6261	10480633	6387;7852	SDF-1;CXCR4	While ***SDF-1*** , the ***ligand*** for ***CXCR4*** , blocked entry of R5X4 viruses to a similar extent in EUdelta32 and UUdelta32 , there was a differential production of soluble factors by EUdelta32 .	parallel	1
6262	10480866	11196;5111	p125;PCNA	These studies provide an unequivocal demonstration that the ***p125*** subunit of pol delta ***interacts*** with ***PCNA*** .	parallel	1
6263	10480866	5111;11196	proliferating cell nuclear antigen;p125	Direct ***interaction*** of ***proliferating cell nuclear antigen*** with the ***p125*** catalytic subunit of mammalian DNA polymerase delta .	parallel	1
6264	10480866	11196;5111	p125;PCNA	Thus , rigorous evidence was sought for a direct ***interaction*** of the ***p125*** catalytic subunit and ***PCNA*** .	parallel	1
6265	10480866	11196;5111	p125;PCNA	An ***interaction*** between ***p125*** and ***PCNA*** could also be demonstrated in the yeast two hybrid system .	parallel	1
6266	10480866	11196;5111	p125;PCNA	Overlay experiments using biotinylated PCNA showed that the free ***p125*** subunit ***interacts*** with ***PCNA*** .	parallel	1
6267	10480869	2956;4436	MSH6;MSH2	Biochemical characterization of the interaction between the Saccharomyces cerevisiae ******MSH2-MSH6****** ***complex*** and mispaired bases in DNA .	parallel	1
6268	10480869	2956;4436	MSH6;MSH2	Biochemical characterization of the ***interaction*** between the Saccharomyces cerevisiae ******MSH2-MSH6****** complex and mispaired bases in DNA .	parallel	1
6269	10480869	2956;4436	MSH6;MSH2	The interaction of the Saccharomyces cerevisiae ******MSH2-MSH6****** ***complex*** with mispaired bases was analyzed using gel mobility shift assays and surface plasmon resonance methods .	parallel	1
6270	10480869	2956;4436	MSH6;MSH2	Differential effects of ATP on the stability of ******MSH2-MSH6-mispair****** ***complexes*** suggested that base-base mispairs and the smaller IDL mispairs were recognized by a different binding mode than larger IDL mispairs , consistent with genetic experiments indicating that MSH2-MSH6 functions primarily in the repair of base-base and small IDL mispairs .	parallel	1
6271	10480893	1387;2033	CBP;p300	E1A mutants defective in ******CBP/p300****** ***binding*** only weakly inhibited HS2-mediated transactivation , whereas a mutant defective in retinoblastoma protein binding strongly inhibited transactivation .	parallel	1
6272	10480898	4286;7306	Mitf;tyrosinase-related protein-1	Previous work has established that the melanocyte-specific ***tyrosinase-related protein-1*** ( TRP-1 ) promoter is ***regulated*** positively by the microphthalmia-associated transcription factor ***Mitf*** , acting through the conserved M box and negatively by the T-box factor Tbx2 , which can bind two " melanocyte-specific elements " termed the MSEu and MSEi .	positive	1
6273	10480898	5077;7306	Pax3;TRP-1	Consistent with ***Pax3*** being able to ***bind*** the ***TRP-1*** promoter , Pax3 is expressed in melanocytes and melanomas , and TRP-1 promoter activity is up-regulated by Pax3 .	parallel	1
6274	10480898	5077;7306	Pax3;TRP-1	Consistent with Pax3 being able to bind the TRP-1 promoter , Pax3 is expressed in melanocytes and melanomas , and ***TRP-1*** promoter activity is ***up-regulated*** by ***Pax3*** .	positive	1
6275	10480903	7750;2260	FIM;FGFR1	The t ( 8 ; 13 ) translocation found in a rare type of stem cell myeloproliferative disorder generates a constitutively activated tyrosine kinase containing N-terminal sequence encoded by the ***FIM*** gene ***linked*** to the ***FGFR1*** kinase domain .	parallel	0
6276	10480921	3482;3481	CI-MPR;IGF-II	However , the ***CI-MPR*** from the opossum has been reported to ***bind*** bovine ***IGF-II*** with low affinity ( Dahms , N.	parallel	1
6277	10480921	3481;3482	IGF-II;CI-MPR	To examine the ***binding*** of ***IGF-II*** to a marsupial ***CI-MPR*** in a homologous system , we have previously purified kangaroo IGF-II ( Yandell , C.	parallel	1
6278	10480921	3482;3481	CI-MPR;IGF-II	The ***interaction*** of the kangaroo ***CI-MPR*** with ***IGF-II*** has been examined by ligand blotting , radioreceptor assay , and real-time biomolecular interaction analysis .	parallel	1
6279	10480932	5608;1432	MKK6;p38 mitogen-activated protein kinase	We have found that ***p38 mitogen-activated protein kinase*** , and its direct ***activator*** ***MKK6*** are rapidly activated in response to TGF-beta .	positive	1
6280	10480932	5608;1432	MKK6;p38	Expression of dominant negative ***MKK6*** or dominant negative TAK1 ***inhibited*** the TGF-beta-induced transcriptional activation as well as the ***p38*** activation .	negative	1
6281	10480932	6885;1432	TAK1;p38	Expression of dominant negative MKK6 or dominant negative ***TAK1*** ***inhibited*** the TGF-beta-induced transcriptional activation as well as the ***p38*** activation .	negative	1
6282	10480932	7040;1432	TGF-beta;p38	These results show that the ***p38*** pathway is ***activated*** by ***TGF-beta*** and is involved in the TGF-beta-induced transcriptional activation by regulating the Smad-mediated pathway .	positive	1
6283	10480933	5170;6197	PDK1;RSK2	Here , we show that the isolated N-terminal kinase of ***RSK2*** ( amino acids 1-360 ) is ***phosphorylated*** at Ser ( 227 ) by ***PDK1*** , a constitutively active kinase , leading to 100-fold stimulation of kinase activity .	target	1
6284	10480933	5170;6197	PDK1;RSK2	In COS7 cells , ectopic ***PDK1*** ***induced*** the phosphorylation of full-length ***RSK2*** at Ser ( 227 ) and Ser ( 386 ) , without involvement of ERK , leading to partial activation of RSK2 .	target	1
6285	10480933	5170;6195	PDK1;RSK1	Similarly , two other members of the RSK family , ***RSK1*** and RSK3 , were partially ***activated*** by ***PDK1*** in COS7 cells .	positive	1
6286	10480933	5170;6196	PDK1;RSK3	Similarly , two other members of the RSK family , RSK1 and ***RSK3*** , were partially ***activated*** by ***PDK1*** in COS7 cells .	positive	1
6287	10480933	5170;5594	PDK1;ERK	Finally , our data indicate that full activation of RSK2 by growth factor requires the ***cooperation*** of ***ERK*** and ***PDK1*** through phosphorylation of Ser ( 227 ) , Ser ( 369 ) , and Ser ( 386 ) .	parallel	0
6288	10480933	6197;5594	RSK2;ERK	Finally , our data indicate that full activation of ***RSK2*** by growth factor ***requires*** the cooperation of ***ERK*** and PDK1 through phosphorylation of Ser ( 227 ) , Ser ( 369 ) , and Ser ( 386 ) .	target	0
6289	10480933	6197;5170	RSK2;PDK1	Finally , our data indicate that full activation of ***RSK2*** by growth factor ***requires*** the cooperation of ERK and ***PDK1*** through phosphorylation of Ser ( 227 ) , Ser ( 369 ) , and Ser ( 386 ) .	target	0
6290	10482243	3952;4852	Leptin;NPY	***Leptin*** differentially ***regulates*** ***NPY*** and POMC neurons projecting to the lateral hypothalamic area .	target	1
6291	10482243	3952;5443	Leptin;POMC	***Leptin*** differentially ***regulates*** NPY and ***POMC*** neurons projecting to the lateral hypothalamic area .	target	1
6292	10482243	3952;9021	Leptin;SOCS-3	In contrast , ***Leptin*** ***induced*** both Fos and ***SOCS-3*** expression in POMC neurons , many of which also innervated the LHA .	target	1
6293	10482262	7076;4318	TIMP-1;MMP-9	For both high-migratory groups , migration could be reduced to control levels after the exogenous addition of ***TIMP-1*** , a relatively specific ***inhibitor*** of the ***MMP-9*** , implicating this protease in the process of T-cell migration .	negative	1
6294	10482306	7124;355	TNF-alpha;Fas	***TNF-alpha*** ***augmented*** both ***Fas*** expression and Fas-mediated apoptosis more efficiently than did IL-1beta .	positive	0
6295	10482544	958;920	CD40;CD4	***CD40-Mediated*** ***induction*** of ***CD4*** and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection : potential role of B lymphocytes as a viral reservoir .	target	1
6296	10482544	958;7852	CD40;CXCR4	***CD40-Mediated*** ***induction*** of CD4 and ***CXCR4*** on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection : potential role of B lymphocytes as a viral reservoir .	target	1
6297	10482544	958;959	CD40;CD40L	We used one of the major pathways of immune activation , namely , ******CD40-CD40L****** ***interactions*** , to study the infectability of B lymphocytes isolated from peripheral blood mononuclear cells .	parallel	1
6298	10482545	4790;598	NF-kappaB;Bcl-x	***Induction*** of ***Bcl-x*** ( L ) expression by human T-cell leukemia virus type 1 Tax through ***NF-kappaB*** in apoptosis-resistant T-cell transfectants with Tax .	target	1
6299	10482545	4792;4790	IkappaBalpha;NF-kappaB	Furthermore , Tax-induced transactivation of the Bcl-x promoter was also diminished by the mutant ***IkappaBalpha*** , which specifically ***inhibits*** ***NF-kappaB*** activity .	negative	1
6300	10482561	3700;7852	gp120;chemokine receptor	Primary , clinical HIV-1 isolates require interaction with CD4 to allow ***gp120*** to ***bind*** the CCR5 ***chemokine receptor*** efficiently .	parallel	1
6301	10482562	5818;2532	HveC;glycoprotein D	We previously demonstrated direct ***binding*** of the purified ***HveC*** ectodomain to purified HSV type 1 ( HSV-1 ) and HSV-2 ***glycoprotein D*** ( gD ) .	parallel	1
6302	10482593	9479;5599	JIP-1;JNK	The yield of virus in NIH 3T3 cells stably expressing ***JIP-1*** , an ***inhibitor*** of ***JNK*** translocation to the nucleus , was reduced 70 % compared to that of control cells , in single-step growth experiments .	negative	1
6303	10482594	3586;100616496	interleukin-2 and -10;pol	***Regulation*** of bovine leukemia virus tax and ***pol*** mRNA levels by ***interleukin-2 and -10*** .	target	1
6304	10482594	3586;100616496	IL-10;pol	***IL-10*** ***inhibited*** BLV tax and ***pol*** mRNA levels in BLV-infected PBMCs ; however , the inhibitory effect of IL-10 was prevented in PBMCs depleted of monocytes and/or macrophages ( monocyte/macrophages ) .	negative	1
6305	10482594	3558;100616496	IL-2;pol	In contrast , ***IL-2*** ***increased*** BLV tax and ***pol*** mRNA and p24 protein production .	positive	0
6306	10482599	7124;4790	tumor necrosis factor alpha;NF-kappaB	By contrast , ***tumor necrosis factor alpha-induced*** ***activation*** of the transcription factor ***NF-kappaB*** was not affected .	positive	1
6307	10482630	355;356	Fas;FasL	Our results suggest that ******Fas-FasL****** ***interaction*** was not involved in NS-1 - or B19-induced apoptosis in erythroid cells .	parallel	1
6308	10482694	7057;5054	TSP-1;PAI-1	We conclude that ***TSP-1*** , in a receptor-mediated process that involves the activation of TGF-beta1 , ***upregulates*** ***PAI-1*** expression in pancreatic cancer without an effect on uPA production .	positive	1
6309	10482694	7057;5340	Thrombospondin-1;plasmin	We have shown that ***Thrombospondin-1*** ( TSP-1 ) , through activation of transforming growth factor beta-1 ( TGF-beta1 ) , ***regulates*** the ***plasminogen/plasmin*** protease system in breast cancer .	target	1
6310	10482697	4922;2641	neurotensin;glucagon-like peptide 2	Enterotrophic effects of ***glucagon-like peptide 2*** are ***enhanced*** by ***neurotensin*** .	positive	0
6311	10482985	558;596	Axl;Bcl-2	The ***association*** between Axl and ***Bcl-2*** and ***Axl*** and CD34 expression in de novo AML needs further investigation .	parallel	0
6312	10482985	947;558	CD34;Axl	The ***association*** between Axl and Bcl-2 and ***Axl*** and ***CD34*** expression in de novo AML needs further investigation .	parallel	0
6313	10482985	947;596	CD34;Bcl-2	The ***association*** between Axl and ***Bcl-2*** and Axl and ***CD34*** expression in de novo AML needs further investigation .	parallel	0
6314	10482985	558;596	Axl;Bcl-2	***Axl*** expression is ***associated*** with adverse prognosis and with expression of ***Bcl-2*** and CD34 in de novo acute myeloid leukemia ( AML ) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research ( SAKK ) .	parallel	0
6315	10482985	558;947	Axl;CD34	***Axl*** expression is ***associated*** with adverse prognosis and with expression of Bcl-2 and ***CD34*** in de novo acute myeloid leukemia ( AML ) : results from a multicenter trial of the Swiss Group for Clinical Cancer Research ( SAKK ) .	parallel	0
6316	10483070	1469;1470	cystatin SN;cystatin SA	RESULTS AND CONCLUSIONS : Salivary ***cystatin SN*** was found to ***inhibit*** the human lysosomal cathepsins B , H and L and salivary ***cystatin SA*** was found to inhibit human lysosomal cathepsin L in vitro .	negative	1
6317	10483906	1803;2641	dipeptidyl peptidase IV;GLP-2	***GLP-2*** is rapidly ***degraded*** by the enzyme ***dipeptidyl peptidase IV*** ( DPP-IV ) to produce the biologically inactive form GLP-2 ( 3-33 ) , however , GLP-2 analogs that confer resistance to DPP-IV exhibit enhanced biologic activity in vivo .	negative	0
6318	10484325	818;5350	CaMK;phospholamban	The SR CaMK and CaMK-stimulated Ca2 + uptake activities , as well as ***CaMK*** ***phosphorylation*** of Ca2 + pump ATPase ( SERCA2a ) and ***phospholamban*** ( PLB ) , were significantly decreased in both I and I/R hearts .	target	1
6319	10484385	356;355	FasL;Fas	Both caspase protease inhibitors and neutralizing antibodies to either Fas receptor ( Fas ) and ***Fas*** ***ligand*** ( ***FasL*** ) inhibited this process ; neutralizing antibodies to other apoptotic cytokines [ interleukin-1beta ( IL-1beta ) , tumor necrosis factor-alpha ( TNF-alpha ) , and transforming growth factor-beta ( TGF-beta ) ] had no effect .	parallel	1
6320	10484389	5706;5706	p44;p42	We found that inhibition of the ******p42/p44****** MAPK ***signaling*** by the PD-98059 compound or by ectopic expression of the MAPK phosphatase-1 strongly attenuated E2F-dependent transcriptional activity in Caco-2 / 15 cells .	parallel	0
6321	10484397	356;355	CD95L;Fas	***Fas*** ***ligand*** ( ***CD95L*** ) and tumor necrosis factor-alpha ( TNF-alpha ) are pivotal inducers of hepatocyte apoptosis .	parallel	1
6322	10484433	1026;1017	p21;cdk2	Moreover , addition of A4 .1 antibody to VSMCs markedly increased the level of ***p21*** ***bound*** to ***cdk2*** .	parallel	1
6323	10484511	2641;5697	GLP-1;PYY	In addition , the release of ***PYY*** into the circulation is ***inhibited*** by ***GLP-1*** infusion , suggesting a negative feedback of GLP-1 on the function of the L-cell .	negative	1
6324	10484511	2641;5697	GLP-1;PYY	***GLP-1*** slows solid gastric emptying and ***inhibits*** insulin , glucagon , and ***PYY*** release in humans .	negative	1
6325	10484543	959;958	CD40L;CD40	A cell surface cytokine ***CD40*** ***ligand*** ( ***CD40L*** ) enhances TF expression in vitro .	parallel	1
6326	10484544	183;7412	Angiotensin II;vascular cell adhesion molecule-1	***Angiotensin II*** ***induces*** ***vascular cell adhesion molecule-1*** expression in rat vasculature : A potential link between the renin-angiotensin system and atherosclerosis .	target	1
6327	10484544	4792;7412	IkappaB-alpha;VCAM-1	***IkappaB-alpha*** overexpression in RASMCs ***inhibited*** Ang II-induced ***VCAM-1*** promoter transactivation .	negative	1
6328	10484681	3586;7124	Interleukin 10;TNF-alpha	***Interleukin 10*** ***inhibits*** ***TNF-alpha*** production in human monocytes independently of interleukin 12 and interleukin 1 beta .	negative	1
6329	10484681	3586;7124	IL-10;TNF-alpha	Similarly to its effects on T-cells , ***IL-10*** ***inhibited*** monocyte ***TNF-alpha*** production by about half .	negative	1
6330	10484767	5979;6464	RET;Shc	Finally , we provide evidence that these effects are partly mediated via the disruption of the ******RET/Shc****** ***interaction*** .	parallel	1
6331	10485270	7040;3553	TGF-beta1;IL-1beta	Moreover , supernatants from patients ' LTBMCs had increased concentrations of IL-6 and ***TGF-beta1*** , which strongly ***correlated*** with serum ***IL-1beta*** .	parallel	0
6332	10485332	3303;3297	hsp72;HSF1	Since H-7 is known to be a potent inhibitor of some PKs , especially calcium-dependent PK ( PKC ) , cyclicAMP-dependent PK ( PKA ) and cyclicGMP-dependent PK ( PKG ) , it is possible that the ***activation*** of ***HSF1*** by phosphorylation and subsequent ***hsp72*** gene expression are dependent on some of those PKs .	positive	1
6333	10485390	6590;1991	SLPI;leukocyte elastase	Since ***SLPI*** is a strong ***inhibitor*** of ***leukocyte elastase*** , we also focused on the function of elastase in allergic rhinitis .	negative	1
6334	10485470	6670;1026	Sp3;WAF1	***Sp3*** , but not Sp1 , ***mediates*** the transcriptional activation of the ***p21/WAF1/Cip1*** gene promoter by histone deacetylase inhibitor .	target	0
6335	10485493	960;4233	CD44;c-Met	Our results showed the following novel features of CD44 on the cells : ( a ) colon cancer cells express high levels of CD44 ; ( b ) stimulation of cancer cells by CD44 cross-linking or fragmented hyaluronan markedly induces the expression of LFA-1s , some of which reveal an activation epitope on the cells ; ( c ) CD44 cross-linking induces F-actin polymerization in the cell cortex ; ( d ) fragmented hyaluronan induces up-regulation of the activation epitope of LFA-1 , which is mediated through protein kinase C ; ( e ) stimulation of CD44 augments the LFA-1-mediated adhesion of cancer cells to endothelial cells and intercellular adhesion molecule 1-transfected cells and facilitates transendothelial migration ; ( f ) stimulation of ***CD44*** also ***induces*** expression of the hepatocyte growth factor (HGF) receptor ***c-Met*** on cancer cells ; and ( g ) HGF further amplifies the LFA-1-mediated adhesion of cells prestimulated by CD44-derived signaling .	target	1
6336	10485496	958;5970	p50;p65	These results indicate that an active NF-kappaB complex , such as the ******p50-p65****** ***heterodimer*** , plays a crucial role in the progression of cell cycle in malignant glioma cells .	parallel	1
6337	10485496	5970;958	p65;p50	Electrophoretic mobility-shift assay showed that TNF-alpha strongly activated a subtype of NF-kappaB , the ******p50-p65****** ***heterodimer*** , in all of the resistant cell lines tested .	parallel	1
6338	10485496	7124;4790	TNF-alpha;NF-kappaB	Electrophoretic mobility-shift assay showed that ***TNF-alpha*** strongly ***activated*** a subtype of ***NF-kappaB*** , the p50-p65 heterodimer , in all of the resistant cell lines tested .	positive	1
6339	10485496	7124;958	TNF-alpha;p50	Electrophoretic mobility-shift assay showed that ***TNF-alpha*** strongly ***activated*** a subtype of NF-kappaB , the ***p50-p65*** heterodimer , in all of the resistant cell lines tested .	positive	1
6340	10485496	7124;5970	TNF-alpha;p65	Electrophoretic mobility-shift assay showed that ***TNF-alpha*** strongly ***activated*** a subtype of NF-kappaB , the ***p50-p65*** heterodimer , in all of the resistant cell lines tested .	positive	1
6341	10485496	7124;4790	TNF-alpha;NF-kappaB	***Activation*** of ***NF-kappaB*** by ***TNF-alpha*** in the resistant cell lines resulted in a significant increase of a reporter gene expression driven by NF-kappaB site , suggesting a possibility that activation of p50-p65 confers resistance to TNF-alpha .	positive	1
6342	10485496	5970;958	p65;p50	In the established clone , induction of p65 DN protein decreased TNF-alpha-dependent increase in the DNA binding of ******p50-p65****** ***heterodimer*** and NF-kappaB-dependent reporter gene activity .	parallel	1
6343	10485496	5970;958	p65;p50	In the established clone , induction of p65 DN protein decreased TNF-alpha-dependent increase in the DNA ***binding*** of ******p50-p65****** heterodimer and NF-kappaB-dependent reporter gene activity .	parallel	1
6344	10485595	3082;7124	HGF;TNF-alpha	***RhGH/HGF*** ***increased*** serum ***TNF-alpha*** on day 2 after burn , while it decreased serum IL-1beta on day 1 after burn compared with placebo ( P < 0.05 ) .	positive	0
6345	10485654	930;933	CD19;CD22	These data collectively suggest that ***CD19*** ***activates*** the ***CD22/SHP1*** inhibitory pathway that then acts primarily on CD19 .	positive	1
6346	10485654	930;5777	CD19;SHP1	These data collectively suggest that ***CD19*** ***activates*** the ***CD22/SHP1*** inhibitory pathway that then acts primarily on CD19 .	positive	1
6347	10485710	4790;207	NF-kappaB;Akt	***NF-kappaB*** activation by tumour necrosis factor ***requires*** the ***Akt*** serine-threonine kinase .	target	0
6348	10485710	207;4790	Akt;NF-kappaB	Here we show that the ***Akt*** serine-threonine kinase is involved in the ***activation*** of ***NF-kappaB*** by tumour necrosis factor ( TNF ) .	positive	1
6349	10485710	207;4790	Akt;NF-kappaB	Wortmannin ( a PI ( 3 ) K inhibitor ) , dominant-negative PI ( 3 ) K or kinase-dead ***Akt*** ***inhibits*** TNF-mediated ***NF-kappaB*** activation .	negative	1
6350	10485710	207;4790	Akt;NF-kappaB	Constitutively active ***Akt*** ***induces*** ***NF-kappaB*** activity and this effect is blocked by dominant-negative NIK .	target	1
6351	10485710	9020;4790	NIK;NF-kappaB	Conversely , ***NIK*** ***activates*** ***NF-kappaB*** and this is blocked by kinase-dead Akt .	positive	1
6352	10485710	207;1147	Akt;IKKalpha	***Akt*** ***mediates*** ***IKKalpha*** phosphorylation at threonine 23 .	target	0
6353	10485843	6497;7040	Ski oncoprotein;TGFbeta	The ***Ski oncoprotein*** interacts with the Smad proteins to ***repress*** ***TGFbeta*** signaling .	negative	1
6354	10485843	6497;4087	Ski;Smad2	Here we show that a nuclear oncoprotein , ***Ski*** , can ***interact*** directly with ***Smad2*** , Smad3 , and Smad4 on a TGFbeta-responsive promoter element and repress their abilities to activate transcription through recruitment of the nuclear transcriptional corepressor N-CoR and possibly its associated histone deacetylase complex .	parallel	1
6355	10485843	6497;4088	Ski;Smad3	Here we show that a nuclear oncoprotein , ***Ski*** , can ***interact*** directly with Smad2 , ***Smad3*** , and Smad4 on a TGFbeta-responsive promoter element and repress their abilities to activate transcription through recruitment of the nuclear transcriptional corepressor N-CoR and possibly its associated histone deacetylase complex .	parallel	1
6356	10485843	6497;4089	Ski;Smad4	Here we show that a nuclear oncoprotein , ***Ski*** , can ***interact*** directly with Smad2 , Smad3 , and ***Smad4*** on a TGFbeta-responsive promoter element and repress their abilities to activate transcription through recruitment of the nuclear transcriptional corepressor N-CoR and possibly its associated histone deacetylase complex .	parallel	1
6357	10485844	7291;7157	Twist;p53	Thus , ***Twist*** may play multiple roles in the formation of rhabdomyosarcomas , halting terminal differentiation , inhibiting apoptosis , and ***interfering*** with the ***p53*** tumor-suppressor pathway .	negative	0
6358	10485844	7291;7157	Twist;p53	Thus , ***Twist*** may ***affect*** ***p53*** indirectly through modulation of the ARF/MDM2/p53 pathway .	target	0
6359	10485849	983;10051	Cdc2;SMC4	Fission yeast condensin complex : essential roles of non-SMC subunits for condensation and ***Cdc2*** ***phosphorylation*** of ***Cut3/SMC4*** .	target	1
6360	10485905	1755;6441	gp-340;lung surfactant protein D	Cloning of ***gp-340*** , a putative opsonin ***receptor*** for ***lung surfactant protein D*** .	parallel	1
6361	10485905	1755;6441	gp-340;SP-D	A 340-kDa glycoprotein ( ***gp-340*** ) has been shown to ***bind*** ***SP-D*** in the presence of calcium but does so independently of carbohydrate recognition .	parallel	1
6362	10485906	3565;6778	IL-4;STAT6	These findings demonstrate that IFNs inhibit ***IL-4-induced*** ***activation*** of ***STAT6*** and STAT6-dependent gene expression , at least in part , by inducing expression of SOCS-1 .	positive	1
6363	10485906	3565;6778	interleukin 4;STAT6	Interferons inhibit ***activation*** of ***STAT6*** by ***interleukin 4*** in human monocytes by inducing SOCS-1 gene expression .	positive	1
6364	10485906	3565;6778	IL-4;STAT6	Pretreatment of monocytes with IFN-beta or IFN-gamma , but not IL-1 , IL-2 , macrophage colony-stimulating factor , granulocyte/macrophage colony-stimulating factor , IL-6 , or transforming growth factor beta suppressed ***activation*** of ***STAT6*** by ***IL-4*** .	positive	1
6365	10485906	8651;3458	SOCS-1;IFN-gamma	Forced expression of ***SOCS-1*** in a macrophage cell line , RAW264 , markedly ***suppressed*** trans-activation of an IL-4-inducible reporter as well as IL-6 - and ***IFN-gamma-induced*** reporter gene activity .	negative	1
6366	10485914	5469;2099	peroxisome proliferator-activated receptor binding protein;ERalpha	***peroxisome proliferator-activated receptor binding protein*** ( PBP ) , a nuclear receptor coactivator , ***interacts*** with estrogen receptor alpha ( ***ERalpha*** ) in the absence of estrogen .	parallel	1
6367	10485917	3576;4318	IL-8;MMP-9	In summary , ***IL-8*** ***induces*** the rapid systemic release of ***MMP-9*** with concurrent mobilization of HPC that is prevented by pretreatment with an inhibitory anti-gelatinase B antibody , indicating that MMP-9 is involved as a mediator of the IL-8-induced mobilization of HPC .	target	1
6368	10486154	3606;3458	Interleukin-18;interferon-gamma	***Interleukin-18*** ***induces*** ***interferon-gamma*** production through NF-kappaB and NFAT activation in murine T helper type 1 cells .	target	1
6369	10486154	3606;3458	Interleukin-18;interferon-gamma	***Interleukin-18*** ( IL-18 ) combined with anti-CD3 monoclonal antibody ( mAb ) ***induced*** ***interferon-gamma*** ( IFN-gamma ) production by T helper type 1 ( Th1 ) cells .	target	1
6370	10486154	3606;3458	IL-18;IFN-gamma	Neither ***IL-18*** nor anti-CD3 mAb alone ***induced*** production of ***IFN-gamma*** .	target	1
6371	10486154	3606;4790	IL-18;NF-kappaB	In these cells , ***activation*** of ***NF-kappaB*** and production of IFN-gamma by ***IL-18*** were suppressed .	positive	1
6372	10486198	627;4915	BDNF;TrkB	Using TrkB-expressing cells , we found that ***BDNF*** and NT-4 individually ***induced*** tyrosine phosphorylation of ***TrkB*** in a dose-dependent fashion .	target	1
6373	10486198	4909;4915	NT-4;TrkB	Using TrkB-expressing cells , we found that BDNF and ***NT-4*** individually ***induced*** tyrosine phosphorylation of ***TrkB*** in a dose-dependent fashion .	target	1
6374	10486198	627;4915	BDNF;TrkB	At maximally effective concentrations , ***BDNF*** or NT-4 ***induced*** robust ***TrkB*** tyrosine phosphorylation at 5 min ; this progressively declined at 15 , 30 , and 60 min .	target	1
6375	10486198	4909;4915	NT-4;TrkB	At maximally effective concentrations , BDNF or ***NT-4*** ***induced*** robust ***TrkB*** tyrosine phosphorylation at 5 min ; this progressively declined at 15 , 30 , and 60 min .	target	1
6376	10486203	2932;4137	GSK-3beta;microtubule-associated protein tau	Recent studies have shown that ***GSK-3beta*** ***phosphorylates*** the ***microtubule-associated protein tau*** in vitro and in cell culture .	target	1
6377	10486249	1033;84260	cyclin-dependent kinase inhibitor;tumor suppressor protein	Direct ***interaction*** of p21 ***cyclin-dependent kinase inhibitor*** with the retinoblastoma ***tumor suppressor protein*** .	parallel	1
6378	10486249	1028;5925	p57;pRb	Among p21 family members , ***p57*** , but not p27 , ***associated*** with ***pRb*** .	parallel	0
6379	10486249	1026;5925	p21;pRb	Overexpression of cyclin D1 , Cdk4 , and E2F1 in the cells expressing pRb and p21 did not perturb the ***interaction*** between ***p21*** and ***pRb*** .	parallel	1
6380	10486249	1026;5925	p21;pRb	Coexpression of ***p21*** in cells expressing pRb , cyclin D1 , and Cdk4 ***prevented*** ***pRb*** hyperphosphorylation by cyclin D1/Cdk4 .	negative	0
6381	10486249	5925;1026	pRb;p21	On the other hand , hyperphosphorylation of ***pRb*** by an excess amount of cyclin/Cdk ***disrupted*** ***pRb/p21*** complex formation in vitro .	negative	0
6382	10486249	1026;5925	p21;pRb	These findings suggest that ***pRb*** may be dynamically ***regulated*** by the relative binding and activities of ***p21*** and Cdks .	target	1
6383	10486263	4689;4688	p40phox;p67phox	Rac1 disrupts ******p67phox/p40phox****** ***binding*** : a novel role for Rac in NADPH oxidase activation .	parallel	1
6384	10486263	5879;4689	Rac1;p40phox	***Rac1*** ***disrupts*** ***p67phox/p40phox*** binding : a novel role for Rac in NADPH oxidase activation .	negative	0
6385	10486263	5879;4688	Rac1;p67phox	***Rac1*** ***disrupts*** ***p67phox/p40phox*** binding : a novel role for Rac in NADPH oxidase activation .	negative	0
6386	10486263	4688;4689	p67phox;p40phox	We investigated binding interactions between p40phox , p67phox , and Rac and found that Rac1-GTP displaced ***p67phox*** ***bound*** to ***p40phox*** .	parallel	1
6387	10486263	4689;4688	p40phox;p67phox	We investigated binding ***interactions*** between ***p40phox*** , ***p67phox*** , and Rac and found that Rac1-GTP displaced p67phox bound to p40phox .	parallel	1
6388	10486263	4689;207	p40phox;Rac	We investigated binding ***interactions*** between ***p40phox*** , p67phox , and ***Rac*** and found that Rac1-GTP displaced p67phox bound to p40phox .	parallel	1
6389	10486263	207;4688	Rac;p67phox	We investigated binding ***interactions*** between p40phox , ***p67phox*** , and ***Rac*** and found that Rac1-GTP displaced p67phox bound to p40phox .	parallel	1
6390	10486263	4689;4688	p40phox;p67phox	A synthetic peptide corresponding to p67phox amino acids 170-199 , a region identified previously as a Rac binding domain , significantly reduced the ability of Rac1-GTP to disrupt ******p67phox/p40phox****** ***binding*** .	parallel	1
6391	10486263	207;4688	Rac;p67phox	We hypothesize that ***Rac-GTP*** ***binds*** the ***p67phox*** N-terminal domain encompassing amino acids 170-199 that transmits a conformational change which causes p40phox to dissociate from its binding site in the p67phox C-terminus .	parallel	1
6392	10486269	3581;3578	IL-9R;IL-9	interleukin-9 ( IL-9 ) exerts its pleiotropic effects through the ***IL-9*** ***receptor*** ( ***IL-9R*** ) complex that consists of the ligand specific IL-9R alpha-chain , and the IL-2R gamma-chain .	parallel	1
6393	10486281	3569;3700	interleukin-6;ITIH4	***ITIH4*** serum concentration increases during acute-phase processes in human patients and is ***up-regulated*** by ***interleukin-6*** in hepatocarcinoma HepG2 cells .	positive	1
6394	10486285	5443;7124	Alpha-MSH;tumor necrosis factor-alpha	***Alpha-MSH*** peptides ***inhibit*** production of nitric oxide and ***tumor necrosis factor-alpha*** by microglial cells activated with beta-amyloid and interferon gamma .	negative	1
6395	10486441	3562;967	IL-3;CD63	***IL-3-preincubation*** ***increases*** the spontaneous expression of ***CD63*** even at low concentrations ( 0.1 ng/ml ) on the basophils of 2 patients out of 20 .	positive	0
6396	10486558	1991;5266	neutrophil elastase;elastase-specific inhibitor	Human ***neutrophil elastase*** ***regulates*** the expression and secretion of elafin ( ***elastase-specific inhibitor*** ) in type II alveolar epithelial cells .	target	1
6397	10486559	6908;79828	TBP;TIP	BIAcore analyses for the ***interaction*** between recombinant ***Pk-TIP*** and recombinant ***Pk-TBP*** indicated that they interact with each other with an equilibrium dissociation constant , KD , of 1.24-1 .46 microM .	parallel	1
6398	10486569	9771;5906	GFR;Rap1	We demonstrated that ***GFR*** can ***activate*** ***Rap1*** but not H-Ras in 293T cells and that the cdc25 domain of GFR is required for the activation of Rap1 .	positive	1
6399	10486571	4804;4803	P75NTR;NGF	These results support the hypothesis that the survival response to NGF depends on its binding to TrkA without any involvement of ***P75NTR*** which in turn selectively ***mediates*** the pro-apoptotic activity of ***NGF*** with no contribution of TrkA and show that , depending on the growth state of the cells , NGF exhibits dual pro- or anti-apoptotic properties via P75NTR and TrkA , respectively .	target	0
6400	10486777	2796;2798	GnRH;GnRHR	At the level of the anterior pituitary , ***GnRH*** ***binds*** to the GnRH receptor ( ***GnRHR*** ) on the cell surface of pituitary gonadotropes .	parallel	1
6401	10486777	2798;2796	GnRHR;GnRH	At the level of the anterior pituitary , GnRH binds to the ***GnRH*** ***receptor*** ( ***GnRHR*** ) on the cell surface of pituitary gonadotropes .	parallel	1
6402	10486970	3700;1234	gp120;CCR5	When compared with CCR5 sequences from humans and other primates , our results demonstrate that : ( 1 ) nucleotide and amino acid sequences of CCR5 among primates are highly homologous , with variations slightly concentrated on the amino and carboxyl termini ; and ( 2 ) site Asp13 , which is critical for CD4-independent ***binding*** of SIV ***gp120*** to Macaca mulatta ***CCR5*** , was also present in all other nonhuman primates tested here , suggesting that those nonhuman primate CCR5s might also bind SIV gp120 without the presence of CD4 .	parallel	1
6403	10487137	7124;3600	TNF-alpha;IL-15	***TNF-alpha*** production in SLE patients was unlikely to be ***related*** with ***IL-15*** .	parallel	0
6404	10487493	5360;335	PLTP;apolipoprotein A-I	Serum ***PLTP*** activity ***correlated*** negatively ( r = -0.20 , P < 0.001 ) with levels of ***apolipoprotein A-I*** in HDL particles that contained only apo A-I [ Lp ( A-I ) particles ] .	negative	0
6405	10487520	4089;7040	DPC4;TGFbeta	***DPC4*** tumor-suppressive function has been implicated to ***mediate*** the transforming growth factor-beta ( ***TGFbeta*** ) - suppressive pathway ; however , in a DPC4-null pancreatic cancer cell line , TGFbeta growth-inhibitory and transcriptional responses were found to be DPC4-independent .	target	0
6406	10487521	7157;1026	p53;Cip1	Northern blot hybridization of the HSC3 cells possessing an inducible function of p53 as well as a luciferase assay for the p21Waf1/Cip1/Sdi1 promoter showed that only wt ***p53*** could ***induce*** ***p21Waf1/Cip1/Sdi1*** transcription .	target	1
6407	10487611	4233;3082	c-MET;HGF	***HGF/SF*** and its ***receptor*** ***c-MET*** play a minor role in the dissemination of human B-lymphoma cells in SCID mice .	parallel	1
6408	10487624	1026;7020	p21;AP-2	There was a significant positive ***association*** between ***p21*** and ***AP-2*** expression levels ( P = 0.01 ) .	parallel	0
6409	10487691	7124;5054	Tumor necrosis factor alpha;PAI-1	***Tumor necrosis factor alpha*** significantly ***decreased*** ***PAI-1*** production in a concentration-dependent manner in both visceral and sc cultures , whereas transforming growth factor beta significantly elevated PAI-1 production , but only in sc preadipocytes from obese individuals .	negative	0
6410	10487693	4233;3082	c-met;HGF	Papillary thyroid cancer ( PTC ) , but neither the follicular nor the anaplastic histotype [ follicular thyroid cancer ( FTC ) , anaplastic thyroid cancer ( ATC ) ] , overexpresses simultaneously the protooncogene ***HGF*** ( hepatocyte growth factor ) and its ***receptor*** HGF-R ( or ***c-met*** ) .	parallel	1
6411	10487712	1081;5743	hCG;COX-2	In summary , we conclude that ***hCG*** and LH treatment can ***increase*** expression of the ***COX-2*** gene in human endometrial gland epithelial cells .	positive	0
6412	10487747	26003;2801	GRASP55;GM130	***GRASP55*** ***binding*** to ***GM130*** , could not be detected using biochemical methods , although a weak interaction was detected with the yeast two-hybrid system .	parallel	1
6413	10487749	1432;4214	p38 MAP kinase;MEKK1	A dominant-negative mutant of ***p38 MAP kinase*** ***interfered*** with ***MEKK1*** and also IL-1-induced stabilization .	positive	0
6414	10487751	958;831	CD40;calpastatin	Furthermore , calpain activation is associated with decreased expression levels of ***calpastatin*** , which is ***upregulated*** by ***CD40*** ligation .	positive	1
6415	10487760	9734;4205	MITR;MEF-2	***MEF-2*** function is ***modified*** by a novel co-repressor , ***MITR*** .	target	0
6416	10487760	9734;4205	MEF-2 interacting transcription repressor (MITR) protein;MEF-2	The ***MEF-2 interacting transcription repressor (MITR) protein*** ***binds*** to the N-terminal ***MADS/MEF-2*** region of the MEF-2 proteins but does not bind to the related Xenopus MADS protein serum response factor .	parallel	1
6417	10487760	9734;3065	MITR;HDAC1	In functional assays , MITR negatively regulates MEF-2-dependent transcription and we show that this repression is mediated by direct ***binding*** of ***MITR*** to the histone deacetylase ***HDAC1*** .	parallel	1
6418	10487761	9759;4205	HDAC4;MEF2	***HDAC4*** deacetylase associates with and ***represses*** the ***MEF2*** transcription factor .	negative	1
6419	10487761	9759;4205	HDAC4;MEF2A	In the nucleus , ***HDAC4*** ***associates*** with the myocyte enhancer factor ***MEF2A*** .	parallel	0
6420	10487761	9759;4205	HDAC4;MEF2A	***Binding*** of ***HDAC4*** to ***MEF2A*** results in the repression of MEF2A transcriptional activation , a function that requires the deacetylase domain of HDAC4 .	parallel	1
6421	10487780	3567;3553	IL-5;IL-1beta	Autocrine ***interaction*** between ***IL-5*** and ***IL-1beta*** mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle .	parallel	1
6422	10487780	3567;3553	IL-5;IL-1beta	Taken together , these observations provide new evidence that ( a ) the Th2 cytokine IL-5 and the pleiotropic proinflammatory cytokine IL-1beta are endogenously released by atopic asthmatic sensitized ASM and mechanistically interact to mediate the proasthmatic perturbations in ASM responsiveness ; and ( b ) the nature of this interaction is given by an initial endogenous release of ***IL-5*** , which then acts to ***induce*** the autologous release of ***IL-1beta*** by the sensitized ASM itself , resulting in its autocrine manifestation of the proasthmatic phenotype .	target	1
6423	10487979	7057;948	TSP-1;CD36	Furthermore , the ***association*** of ***TSP-1/L-GeneGene*** 1 complex with ***CD36*** is necessary to the activation of L-TGF-beta1 because antibodies to CD36 prevent the colocalization of TGF-beta1 with CD36 as observed by immunofluorescence and inhibit activation of the L-TGF-beta1 by explanted alveolar macrophages .	parallel	0
6424	10487979	5340;7040	plasmin;TGF-beta1	These findings suggest that ***activation*** of ***L-TGF-beta1*** by ***plasmin*** occurs at the cell surface of activated alveolar macrophages and requires a TSP-1/CD36 interaction .	positive	1
6425	10487979	948;7057	CD36;TSP-1	These findings suggest that activation of L-TGF-beta1 by plasmin occurs at the cell surface of activated alveolar macrophages and requires a ******TSP-1/CD36****** ***interaction*** .	parallel	1
6426	10487979	7040;948	TGF-beta1;CD36	These findings suggest that activation of ***L-TGF-beta1*** by plasmin occurs at the cell surface of activated alveolar macrophages and ***requires*** a ***TSP-1/CD36*** interaction .	target	0
6427	10487979	7040;7057	TGF-beta1;TSP-1	These findings suggest that activation of ***L-TGF-beta1*** by plasmin occurs at the cell surface of activated alveolar macrophages and ***requires*** a ***TSP-1/CD36*** interaction .	target	0
6428	10487979	5340;7040	plasmin;transforming growth factor beta-1	***Activation*** of rat alveolar macrophage-derived latent ***transforming growth factor beta-1*** by ***plasmin*** requires interaction with thrombospondin-1 and its cell surface receptor , CD36 .	positive	1
6429	10487979	7040;7057	TGF-beta1;TSP-1	However , in the presence of plasmin both latency-associated peptide and TGF-beta1 were decreased in the same cell lysates , indicating that ***L-TGF-beta1*** ***associated*** with ***TSP-1*** is released by plasmin .	parallel	0
6430	10487979	7040;7057	TGF-beta1;TSP-1	Using immunofluorescence and antibodies to ***TGF-beta1*** and CD36 , a ***receptor*** for ***TSP-1*** , there was colocalization of TGF-beta1 with CD36 .	parallel	1
6431	10487979	7057;948	TSP-1;CD36	Because TSP-1 but not TGF-beta1 is a natural ligand for CD36 , these findings suggest that the L-TGF-beta1 in a complex with TSP-1 localizes to the macrophage cell surface when ***TSP-1*** ***interacts*** with its receptor , ***CD36*** .	parallel	1
6432	10487979	7057;948	TSP-1;CD36	Because ***TSP-1*** but not TGF-beta1 is a natural ***ligand*** for ***CD36*** , these findings suggest that the L-TGF-beta1 in a complex with TSP-1 localizes to the macrophage cell surface when TSP-1 interacts with its receptor , CD36 .	parallel	1
6433	10488069	2934;2822	gelsolin;PLD	Our results suggest that ***gelsolin*** ***modulates*** bradykinin-mediated ***PLD*** activation via suppression of PLC and PKC activities but did not affect S1P-mediated PLD activation .	target	0
6434	10488069	2934;5337	gelsolin;PLD1	Here we showed in in vitro experiments that ***gelsolin*** ***inhibited*** recombinant phospholipase D1 ( ***PLD1*** ) and PLD2 activities but not the oleate-dependent PLD and that this inhibition was not reversed by increasing PIP ( 2 ) concentration .	negative	1
6435	10488069	2934;5338	gelsolin;PLD2	Here we showed in in vitro experiments that ***gelsolin*** ***inhibited*** recombinant phospholipase D1 ( PLD1 ) and ***PLD2*** activities but not the oleate-dependent PLD and that this inhibition was not reversed by increasing PIP ( 2 ) concentration .	negative	1
6436	10488069	3827;2822	bradykinin;PLD	gelsolin overexpression suppressed ***bradykinin-induced*** ***activation*** of phospholipase C ( PLC ) and ***PLD*** .	positive	1
6437	10488069	2934;2822	gelsolin;PLD	***gelsolin*** overexpression ***suppressed*** bradykinin-induced activation of phospholipase C ( PLC ) and ***PLD*** .	negative	1
6438	10488079	9229;1742	GKAP;PSD-95	***GKAP/SAPAP/DAP*** ***recruits*** ***PSD-95/SAP90*** and its interacting protein , brain-enriched guanylate kinase-interacting protein , into the Triton X-100-insoluble fraction in transfected cells , suggesting that GKAP/SAPAP/DAP may link several PSD components to the Triton X-100-insoluble structures in the PSD .	target	0
6439	10488079	50944;9229	Synamon;GKAP	***Synamon*** ***interacts*** with the COOH-terminal region of ***GKAP/SAPAP/DAP*** via the middle region containing a PSD-95/Dlg-A/ZO -1 domain .	parallel	1
6440	10488081	4193;7157	Mdm2;p53	The ***Mdm2*** oncoprotein ***mediates*** ***p53*** degradation at cytoplasmic proteasomes and is the principal regulator for maintaining low , often undetectable levels of p53 in unstressed cells .	target	0
6441	10488081	7157;4193	p53;Mdm2	This resistance is not due to a lack of Mdm2 expression in NB cells or a lack of ******p53-Mdm2****** ***interaction*** , nor is it due to a deficiency in the ubiquitination state of p53 or proteasome dysfunction .	parallel	1
6442	10488088	3479;5600	IGF-I;p38beta	***IGF-I*** ***increased*** the activity of ***p38beta*** MAPK introduced into the cells by adenoviral infection .	positive	0
6443	10488088	3479;596	IGF-I;bcl-2	Thus , we have characterized a novel signaling pathway ( MAPK kinase 6/p38beta MAPK/MAPKAP-K3 ) that defines a transcriptional mechanism for the ***induction*** of the antiapoptotic protein ***bcl-2*** by ***IGF-I*** through the nuclear transcription factor cAMP-response element-binding protein in PC12 cells .	target	1
6444	10488091	23568;402	BART;ARL2	Recombinant ***BART*** was found to ***bind*** ***ARL2.GTP*** in a manner indistinguishable from native BART .	parallel	1
6445	10488091	402;23568	ARL2;BART	The lack of detectable membrane ***association*** of ***ARL2*** or ***BART*** upon activation of ARL2 is suggestive of actions quite distinct from those of the ARFs .	parallel	0
6446	10488092	8802;5743	Galpha;cyclooxygenase-2	***Galpha*** ( 13 ) ***stimulates*** Rho-dependent activation of the ***cyclooxygenase-2*** promoter .	positive	0
6447	10488092	8802;5743	Galpha;COX-2	Co-expression of Clostridium botulinum C3 toxin specifically blocked ***induction*** of the ***COX-2*** promoter by either ***Galpha*** ( 13 ) Q226L or RhoQ63L but did not prevent the activation of this promoter by Ras , Rac , v-src , or forskolin .	target	1
6448	10488096	5777;23368	SHP-1;p85	In this study , we demonstrate that ***SHP-1*** ***co-immunoprecipitates*** with the ***p85*** regulatory subunit of PI3K in Jurkat T cells , and that this association is increased by ligation of the TCR complex .	parallel	1
6449	10488096	5777;23368	SHP-1;p85	By contrast , a truncated ***SHP-1*** mutant lacking the Lck phosphorylation site ( Tyr ( 564 ) ) failed to ***bind*** ***p85*** .	parallel	1
6450	10488096	5777;23368	SHP-1;p85	Wild-type but not catalytically inactive ***SHP-1*** ***induced*** dephosphorylation of ***p85*** .	target	1
6451	10488096	5777;5291	SHP-1;PI3K	Furthermore , expression of ***SHP-1*** ***decreased*** ***PI3K*** enzyme activity in anti-phosphotyrosine immunoprecipitates and phosphorylation of serine 473 in Akt , a process dependent on PI3K activity .	negative	0
6452	10488096	5291;5777	PI3K;SHP-1	These results indicate the presence of a functional ***interaction*** between ***PI3K*** and ***SHP-1*** and suggest that PI3K signaling , which has been implicated in cell proliferation , apoptosis , cytoskeletal reorganization , and many other biological activities , can be regulated by SHP-1 in T lymphocytes .	parallel	1
6453	10488096	5777;5291	SHP-1;PI3K	These results indicate the presence of a functional interaction between PI3K and SHP-1 and suggest that ***PI3K*** signaling , which has been implicated in cell proliferation , apoptosis , cytoskeletal reorganization , and many other biological activities , can be ***regulated*** by ***SHP-1*** in T lymphocytes .	target	1
6454	10488101	3791;7422	VEGFR-2;VEGF-A	In vitro , VEGF-C induces the tyrosine phosphorylation of ***VEGFR-2*** , a ***receptor*** also for ***VEGF-A*** , as well as that of VEGFR-3 .	parallel	1
6455	10488109	8312;1499	Axin;beta-catenin	***Axin*** , a Wnt signal negative regulator , ***enhances*** glycogen synthase kinase ( GSK ) -3 beta-dependent phosphorylation of ***beta-catenin*** and stimulates the degradation of beta-catenin .	positive	0
6456	10488109	8312;1499	Axin;beta-catenin	***Axin*** , a Wnt signal negative regulator , enhances glycogen synthase kinase ( GSK ) -3 beta-dependent phosphorylation of beta-catenin and ***stimulates*** the degradation of ***beta-catenin*** .	positive	0
6457	10488136	7295;4790	TRX;NF-kappaB	This two-step ***TRX-dependent*** ***regulation*** of the ***NF-kappaB*** complex may be a novel activation mechanism of redox-sensitive transcription factors .	target	1
6458	10488136	7295;4790	TRX;p50	In our in vitro diamide-induced cross-linking study , we showed that ***TRX*** can ***associate*** directly with NF-kappaB ***p50*** .	parallel	0
6459	10488136	7295;4790	TRX;NF-kappaB	In the nucleus , however , ***TRX*** ***enhances*** ***NF-kappaB*** transcriptional activities by enhancing its ability to bind DNA .	positive	0
6460	10488140	335;348	Apolipoprotein A-I;apolipoprotein E	***Apolipoprotein A-I*** ***stimulates*** secretion of ***apolipoprotein E*** by foam cell macrophages .	positive	0
6461	10488142	23533;5294	p101;p110gamma	This finding implies that the intracellular localization of ***p110gamma*** is ***regulated*** by ***p101*** as well as Gbetagamma .	target	1
6462	10488144	4690;25	Nck;Abl	A myristoylated ***Nck*** SH3 domain construct , which is expected to localize to membranes , potently ***activated*** ***Abl*** when expressed at low levels .	positive	1
6463	10488144	4690;25	Nck;Abl	An unmyristoylated ***Nck*** SH3 domain construct , which localizes to the cytosol and nucleus , also ***activated*** ***Abl*** but only at high levels of expression .	positive	1
6464	10488144	4690;25	Nck;c-Abl	***Activation*** of ***c-Abl*** by ***Nck*** SH3 domains provides a robust experimental system for analyzing the mechanisms that normally repress Abl activity and how that normal regulation can be perturbed .	positive	1
6465	10488146	3716;3667	JAK1;insulin receptor substrate-1	***JAK1-dependent*** ***phosphorylation*** of ***insulin receptor substrate-1*** ( IRS-1 ) is inhibited by IRS-1 serine phosphorylation .	target	1
6466	10488146	3439;3667	IFN-alpha;IRS-1	We found that treatment of U266 cells with OA induced serine phosphorylation of IRS-1 and completely blocked ***IFN-alpha-dependent*** tyrosine ***phosphorylation*** of IRS-1 and IFN-alpha-dependent ***IRS-1/PI3K*** association .	target	1
6467	10488146	3439;5290	IFN-alpha;PI3K	We found that treatment of U266 cells with OA induced serine phosphorylation of IRS-1 and completely blocked ***IFN-alpha-dependent*** tyrosine ***phosphorylation*** of IRS-1 and IFN-alpha-dependent ***IRS-1/PI3K*** association .	target	1
6468	10488146	3667;5290	IRS-1;PI3K	We found that treatment of U266 cells with OA induced serine phosphorylation of IRS-1 and completely blocked IFN-alpha-dependent tyrosine phosphorylation of IRS-1 and IFN-alpha-dependent ******IRS-1/PI3K****** ***association*** .	parallel	0
6469	10488146	3439;3667	IFN-alpha;IRS-1	Chronic treatment of U266 cells with insulin led to a 50 % reduction in ***IFN-alpha-dependent*** tyrosine ***phosphorylation*** of IRS-1 and ***IRS-1/PI3K*** association .	target	1
6470	10488146	3439;5290	IFN-alpha;PI3K	Chronic treatment of U266 cells with insulin led to a 50 % reduction in ***IFN-alpha-dependent*** tyrosine ***phosphorylation*** of IRS-1 and ***IRS-1/PI3K*** association .	target	1
6471	10488146	3667;5290	IRS-1;PI3K	Chronic treatment of U266 cells with insulin led to a 50 % reduction in IFN-alpha-dependent tyrosine phosphorylation of IRS-1 and ******IRS-1/PI3K****** ***association*** .	parallel	0
6472	10488147	10344;1232	eotaxin-3;CCR3	Collectively , ***eotaxin-3*** is yet another functional ***ligand*** for ***CCR3*** .	parallel	1
6473	10488147	10344;1232	eotaxin-3;CC chemokine receptor 3	Molecular cloning of a novel human CC chemokine ( ***eotaxin-3*** ) that is a functional ***ligand*** of ***CC chemokine receptor 3*** .	parallel	1
6474	10488147	10344;6356	eotaxin-3;eotaxin	***eotaxin-3*** ***competed*** the binding of ( 125 ) ***I-eotaxin*** to CCR3-expressing L1 .2 cells with an IC ( 50 ) of 13 nM .	negative	0
6475	10488148	3725;4790	AP-1;NF-kappaB	ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative ***interaction*** of ***AP-1*** and ***NF-kappaB*** .	parallel	1
6476	10488148	3725;4790	AP-1;NF-kappaB	These studies suggest that MAPK acts by stimulating AP-1 and a subsequent physical and functional ***interaction*** of ***AP-1*** with ***NF-kappaB*** , resulting in a complex that synergistically transactivates the HIV-1 LTR .	parallel	1
6477	10488153	5887;5710	hHR23B;S5a	Here we demonstrate that the human NER factor ***hHR23B*** as well as another human homolog of RAD23 , hHR23A , ***interact*** specifically with ***S5a*** , a subunit of the human 26 S proteasome using the yeast two-hybrid system .	parallel	1
6478	10488157	6461;2885	Shb;Grb2	We have recently investigated the role of the adaptor protein Shb in the early events of T cell signaling and observed that ***Shb*** ***associates*** with ***Grb2*** , linker for activation of T cells ( LAT ) and the TCR zeta-chain in Jurkat cells .	parallel	0
6479	10488157	6461;27040	Shb;linker for activation of T cells	We have recently investigated the role of the adaptor protein Shb in the early events of T cell signaling and observed that ***Shb*** ***associates*** with Grb2 , ***linker for activation of T cells*** ( LAT ) and the TCR zeta-chain in Jurkat cells .	parallel	0
6480	10488157	6461;919	Shb;TCR zeta-chain	We have recently investigated the role of the adaptor protein Shb in the early events of T cell signaling and observed that ***Shb*** ***associates*** with Grb2 , linker for activation of T cells ( LAT ) and the ***TCR zeta-chain*** in Jurkat cells .	parallel	0
6481	10488157	6461;5335	Shb;PLC-gamma1	We now report that ***Shb*** also ***associates*** with phospholipase C-gamma1 ( ***PLC-gamma1*** ) in these cells .	parallel	0
6482	10488157	6461;5335	Shb;PLC-gamma1	In addition , the ***Shb*** mutant also ***blocked*** phosphorylation of ***PLC-gamma1*** and the increase in cytoplasmic Ca ( 2 + ) following TCR stimulation .	positive	0
6483	10488243	10152;10006	abi2;abi1	Conversely , stomatal opening assays indicated different ***interactions*** of ***abi1*** and ***abi2*** , with Ca ( 2 ) + - dependent signal transduction pathways controlling stomatal closing versus stomatal opening .	parallel	1
6484	10488332	983;286204	Cdc2;Crb2	***Cdc2*** ***phosphorylation*** of ***Crb2*** is required for reestablishing cell cycle progression after the damage checkpoint .	target	1
6485	10488343	4638;10984	kinase-related protein;LIT-1	MOM-4 , a MAP kinase kinase ***kinase-related protein*** , ***activates*** WRM-1 / ***LIT-1*** kinase to transduce anterior/posterior polarity signals in C. elegans .	positive	1
6486	10488687	196;1543	Ah receptor;CYP1A1	The ***Ah receptor*** which ***controls*** the expression of ***CYP1A1/1A2*** and CYP1B1 , was detected in cytosolic fractions from these tissues as a 104 kDa and a minor level of the 106 kDa form .	target	0
6487	10488687	196;1545	Ah receptor;CYP1B1	The ***Ah receptor*** which ***controls*** the expression of CYP1A1/1A2 and ***CYP1B1*** , was detected in cytosolic fractions from these tissues as a 104 kDa and a minor level of the 106 kDa form .	target	0
6488	10488949	7436;4018	VLDLR;lipoprotein	Mouse very low-density ***lipoprotein*** ***receptor*** ( ***VLDLR*** ) : gene structure , tissue-specific expression and dietary and developmental regulation .	parallel	1
6489	10488949	7436;4018	VLDLR;lipoprotein	The very low density ***lipoprotein*** ***receptor*** ( ***VLDLR*** ) is a multifunctional apolipoprotein (apo) E receptor that shares a common structural feature as well as some ligand specificity to apo E with members of the low density lipoprotein receptor gene family .	parallel	1
6490	10488956	5972;4524	renin;methylenetetrahydrofolate reductase	The genotype ***interactions*** of ***methylenetetrahydrofolate reductase*** and ***renin-angiotensin*** system genes are associated with myocardial infarction .	parallel	1
6491	10488956	185;183	AT1R;angiotensin II	We analyzed the evolution with age of the frequencies of the I/D polymorphism of the angiotensin I-converting enzyme ( ACE ) , a1166c of the ***angiotensin II*** AT1 ***receptor*** ( ***AT1R*** ) , M235T of the angiotensinogen ( AGT ) and A225V of their methylenetetrahydrofolate reductase ( MTHFR ) gene in a healthy ( H ) population and the subsequent comparison to age - and sex-matched groups of myocardial infarction ( MI ) subjects .	parallel	1
6492	10488968	26;213	DAO;albumin	The ***DAO*** activity 30 min after the heparin injection significantly ***correlated*** with either the glycated ***albumin*** ( GA ) concentration or the plant sterol levels in all subjects .	parallel	0
6493	10489101	2057;2056	EpoR;erythropoietin	METHODS : Reverse transcription-polymerase chain reaction ( RT-PCR ) was performed to identify a specific ***erythropoietin*** ***receptor*** ( ***EpoR*** ) .	parallel	1
6494	10489112	3082;2321	HGF;Flt-1	We also confirmed the presence of ***Flt-1*** , KDR/FIk -1 , and their ligand vascular endothelial growth factor , c-Met and its ***ligand*** hepatocyte growth factor ( ***HGF*** ) , and Tie-1 , Tie-2 / Tek by immunohistochemistry and RT-PCR .	parallel	1
6495	10489112	3082;4233	HGF;c-Met	CONCLUSION : These findings suggest that ******HGF/c-Met****** ***interactions*** may play an important role in cardiac hypertrophy and remodeling , probably as a result of the activation of the local renin-angiotensin system .	parallel	1
6496	10489401	183;5743	angiotensin II;COX-2	Because macula densa-derived prostaglandins are considered stimulators of renin secretion and renin synthesis , ***inhibition*** of macula densa ***COX-2*** by ***angiotensin II*** could form a novel indirect negative feedback control of the renin system .	negative	1
6497	10489401	5743;5972	COX-2;renin	These data indicate that endogenous angiotensin II apparently inhibits COX-2 expression in the macula densa via AT ( 1 ) receptors and can therefore not account for the stimulation of ***COX-2*** expression ***associated*** with an activated ***renin-angiotensin*** system .	parallel	0
6498	10489401	183;5743	angiotensin II;COX-2	These data indicate that endogenous ***angiotensin II*** apparently ***inhibits*** ***COX-2*** expression in the macula densa via AT ( 1 ) receptors and can therefore not account for the stimulation of COX-2 expression associated with an activated renin-angiotensin system .	negative	1
6499	10489445	387;396	RhoA;RhoGDI	The functional human ******RhoA-RhoGDI****** ***complex*** has been expressed in yeast and crystallized ( P6 ( 5 ) 22 , unit-cell parameters a = b = 139 , c = 253 A , two complexes in the asymmetric unit ) .	parallel	1
6500	10490027	5037;5894	RKIP;Raf-1	***Suppression*** of ***Raf-1*** kinase activity and MAP kinase signalling by ***RKIP*** .	negative	1
6501	10490027	5894;5604	Raf-1;MEK-1	***Raf-1*** ***phosphorylates*** and activates ***MEK-1*** , a kinase that activates the extracellular signal regulated kinases ( ERK ) .	target	1
6502	10490027	5037;5894	RKIP;Raf-1	In vitro , ***RKIP*** ***binds*** to ***Raf-1*** , MEK and ERK , but not to Ras .	parallel	1
6503	10490027	5037;5609	RKIP;MEK	***RKIP*** ***co-immunoprecipitates*** with Raf-1 and ***MEK*** from cell lysates and colocalizes with Raf-1 when examined by confocal microscopy .	parallel	1
6504	10490027	5037;5894	RKIP;Raf-1	***RKIP*** ***co-immunoprecipitates*** with ***Raf-1*** and MEK from cell lysates and colocalizes with Raf-1 when examined by confocal microscopy .	parallel	1
6505	10490027	5037;5609	RKIP;MEK	***RKIP*** overexpression ***interferes*** with the activation of ***MEK*** and ERK , induction of AP-1-dependent reporter genes and transformation elicited by an oncogenically activated Raf-1 kinase .	negative	0
6506	10490027	5037;3725	RKIP;AP-1	Downregulation of endogenous ***RKIP*** by expression of antisense RNA or antibody microinjection ***induces*** the activation of MEK - , ERK - and ***AP-1-dependent*** transcription .	target	1
6507	10490099	8651;3458	SOCS1;interferon gamma	***SOCS1*** is a critical ***inhibitor*** of ***interferon gamma*** signaling and prevents the potentially fatal neonatal actions of this cytokine .	negative	1
6508	10490099	8651;3458	SOCS1;IFNgamma	Our data indicate that ***SOCS1*** is a key ***modulator*** of ***IFNgamma*** action , allowing the protective effects of this cytokine to occur without the risk of associated pathological responses .	target	0
6509	10490106	1387;8202	CBP;ACTR	In exploring the underlying mechanism , we found that the acetylase ***ACTR*** can be ***acetylated*** by ***p300/CBP*** .	target	1
6510	10490106	2033;8202	p300;ACTR	In exploring the underlying mechanism , we found that the acetylase ***ACTR*** can be ***acetylated*** by ***p300/CBP*** .	target	1
6511	10490589	1628;1548	DBP;coumarin 7-hydroxylase	Circadian expression of the steroid 15 alpha-hydroxylase ( Cyp2a4 ) and ***coumarin 7-hydroxylase*** ( Cyp2a5 ) genes in mouse liver is ***regulated*** by the PAR leucine zipper transcription factor ***DBP*** .	target	1
6512	10490593	5897;5896	RAG2;RAG1	V ( D ) J recombination is initiated by the specific binding of the ******RAG1-RAG2****** ( RAG1/2 ) ***complex*** to the heptamer-nonamer recombination signal sequences ( RSS ) .	parallel	1
6513	10490598	148170;5601	Borg3;Jun kinase	***Borg3*** also ***inhibited*** ***Jun kinase*** activity by a mechanism that was independent of Cdc42 binding .	negative	1
6514	10490598	10435;998	Borg1;Cdc42	***Borg1*** , Borg2 , Borg4 , and Borg5 ***bind*** both TC10 and ***Cdc42*** in a GTP-dependent manner .	parallel	1
6515	10490598	10435;23433	Borg1;TC10	***Borg1*** , Borg2 , Borg4 , and Borg5 ***bind*** both ***TC10*** and Cdc42 in a GTP-dependent manner .	parallel	1
6516	10490598	10602;998	Borg2;Cdc42	Borg1 , ***Borg2*** , Borg4 , and Borg5 ***bind*** both TC10 and ***Cdc42*** in a GTP-dependent manner .	parallel	1
6517	10490598	10602;23433	Borg2;TC10	Borg1 , ***Borg2*** , Borg4 , and Borg5 ***bind*** both ***TC10*** and Cdc42 in a GTP-dependent manner .	parallel	1
6518	10490598	23580;998	Borg4;Cdc42	Borg1 , Borg2 , ***Borg4*** , and Borg5 ***bind*** both TC10 and ***Cdc42*** in a GTP-dependent manner .	parallel	1
6519	10490598	23580;23433	Borg4;TC10	Borg1 , Borg2 , ***Borg4*** , and Borg5 ***bind*** both ***TC10*** and Cdc42 in a GTP-dependent manner .	parallel	1
6520	10490598	11135;998	Borg5;Cdc42	Borg1 , Borg2 , Borg4 , and ***Borg5*** ***bind*** both TC10 and ***Cdc42*** in a GTP-dependent manner .	parallel	1
6521	10490598	11135;23433	Borg5;TC10	Borg1 , Borg2 , Borg4 , and ***Borg5*** ***bind*** both ***TC10*** and Cdc42 in a GTP-dependent manner .	parallel	1
6522	10490598	148170;998	Borg3;Cdc42	Surprisingly , ***Borg3*** ***bound*** only to ***Cdc42*** .	parallel	1
6523	10490601	100;2648	ADA;Gcn5	The SAGA ( ******Spt-ADA-Gcn5-acetyltransferase****** ) ***complex*** contains several subunits which also function as part of other protein complexes , including a subset of TATA box binding protein-associated factors ( TAFIIs ) and Tra1 .	parallel	1
6524	10490603	9337;23019	CAF1;NOT1	The CAF1 protein was found to be absolutely required for CCR4 association with the NOT proteins , and CCR4 and ***CAF1*** , in turn , physically ***interacted*** with ***NOT1*** through its central amino acid region from positions 667 to 1152 .	parallel	1
6525	10490603	57472;23019	CCR4;NOT1	The CAF1 protein was found to be absolutely required for CCR4 association with the NOT proteins , and ***CCR4*** and CAF1 , in turn , physically ***interacted*** with ***NOT1*** through its central amino acid region from positions 667 to 1152 .	parallel	1
6526	10490603	4848;23019	NOT2;NOT1	In contrast , the ***NOT2*** , NOT4 , and NOT5 ***interacted*** with the C-terminal region ( residues 1490 to 2108 ) of ***NOT1*** in which NOT2 and NOT5 physically associated in the absence of CAF1 , NOT3 , and NOT4 .	parallel	1
6527	10490603	4850;23019	NOT4;NOT1	In contrast , the NOT2 , ***NOT4*** , and NOT5 ***interacted*** with the C-terminal region ( residues 1490 to 2108 ) of ***NOT1*** in which NOT2 and NOT5 physically associated in the absence of CAF1 , NOT3 , and NOT4 .	parallel	1
6528	10490604	867;7535	c-Cbl;ZAP-70	The oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding domain-dependent negative ***regulation*** of ***ZAP-70*** by ***c-Cbl*** in Jurkat T cells .	negative	1
6529	10490605	958;11183	CD40;GCKR	In addition , ***CD40*** ***activated*** endogenous ***GCKR*** in primary B cells , implicating GCK family proteins in CD40-mediated B-cell functions .	positive	1
6530	10490613	5609;5599	MKK7;JNK	Constitutively active MAP kinase kinase 7 ( ***MKK7*** ) , an ***activator*** of the stress-activated protein kinase/c-Jun N-terminal kinase ( ***SAPK/JNK*** ) pathway , induced IL-8 synthesis and transcription from a minimal IL-8 promoter .	positive	1
6531	10490613	5609;5601	MKK7;SAPK	Constitutively active MAP kinase kinase 7 ( ***MKK7*** ) , an ***activator*** of the stress-activated protein kinase/c-Jun N-terminal kinase ( ***SAPK/JNK*** ) pathway , induced IL-8 synthesis and transcription from a minimal IL-8 promoter .	positive	1
6532	10490620	10736;2138	Six2;Eya1	Coexpression of ***Six2*** , Six4 , or Six5 ***induced*** nuclear translocation of ***Eya1*** , Eya2 , and Eya3 , which were otherwise distributed in the cytoplasm .	target	1
6533	10490620	10736;2139	Six2;Eya2	Coexpression of ***Six2*** , Six4 , or Six5 ***induced*** nuclear translocation of Eya1 , ***Eya2*** , and Eya3 , which were otherwise distributed in the cytoplasm .	target	1
6534	10490620	10736;2140	Six2;Eya3	Coexpression of ***Six2*** , Six4 , or Six5 ***induced*** nuclear translocation of Eya1 , Eya2 , and ***Eya3*** , which were otherwise distributed in the cytoplasm .	target	1
6535	10490620	51804;2138	Six4;Eya1	Coexpression of Six2 , ***Six4*** , or Six5 ***induced*** nuclear translocation of ***Eya1*** , Eya2 , and Eya3 , which were otherwise distributed in the cytoplasm .	target	1
6536	10490620	51804;2139	Six4;Eya2	Coexpression of Six2 , ***Six4*** , or Six5 ***induced*** nuclear translocation of Eya1 , ***Eya2*** , and Eya3 , which were otherwise distributed in the cytoplasm .	target	1
6537	10490620	51804;2140	Six4;Eya3	Coexpression of Six2 , ***Six4*** , or Six5 ***induced*** nuclear translocation of Eya1 , Eya2 , and ***Eya3*** , which were otherwise distributed in the cytoplasm .	target	1
6538	10490620	147912;2138	Six5;Eya1	Coexpression of Six2 , Six4 , or ***Six5*** ***induced*** nuclear translocation of ***Eya1*** , Eya2 , and Eya3 , which were otherwise distributed in the cytoplasm .	target	1
6539	10490620	147912;2139	Six5;Eya2	Coexpression of Six2 , Six4 , or ***Six5*** ***induced*** nuclear translocation of Eya1 , ***Eya2*** , and Eya3 , which were otherwise distributed in the cytoplasm .	target	1
6540	10490620	147912;2140	Six5;Eya3	Coexpression of Six2 , Six4 , or ***Six5*** ***induced*** nuclear translocation of Eya1 , Eya2 , and ***Eya3*** , which were otherwise distributed in the cytoplasm .	target	1
6541	10490620	2139;51804	Eya2;Six4	A specific ***interaction*** between the Six domain and homeodomain of ***Six4*** and ***Eya2*** was observed by yeast two-hybrid analysis .	parallel	1
6542	10490621	1543;4782	CYP1A1;NFI	Using an NFI/CTF-GeneGene 2 fusion , we show that ***NFI/CTF*** transactivating function is ***decreased*** by a high activity of ***CYP1A1*** .	negative	0
6543	10490622	3192;2967	hnRNP U;TFIIH	We showed that ***hnRNP U*** can ***bind*** ***TFIIH*** in vivo under certain conditions and inhibit TFIIH-mediated CTD phosphorylation in vitro .	parallel	1
6544	10490623	1956;2064	ErbB1;ErbB2	Using rapamycin-inducible heterodimerization we show that c-Cbl is unable to associate with ErbB1 in a ******ErbB1-ErbB2****** ***heterodimer*** most likely because ErbB2 is unable to phosphorylate the c-Cbl binding site on ErbB1 .	parallel	1
6545	10490623	1956;867	ErbB1;c-Cbl	However , only ErbB1 homodimers were internalized upon AP1510 stimulation , and only ***ErbB1*** homodimers were able to ***associate*** with and induce phosphorylation of ***c-Cbl*** .	parallel	0
6546	10490629	25;207	c-Abl;Akt	In addition , we found that DeltaSH3 ***c-Abl*** ***induced*** less activation of ***Akt*** and STAT5 than did Bcr-Abl , suggesting that activation of these pathways plays a critical role in inducing a CML-like disease .	target	1
6547	10490629	25;6777	c-Abl;STAT5	In addition , we found that DeltaSH3 ***c-Abl*** ***induced*** less activation of Akt and ***STAT5*** than did Bcr-Abl , suggesting that activation of these pathways plays a critical role in inducing a CML-like disease .	target	1
6548	10490632	2885;6464	Grb2;Shc	Coexpression of Cas with v-Src enhanced the ***association*** of ***Grb2*** with the adapter protein ***Shc*** and the protein tyrosine phosphatase Shp-2 ; coexpression of Shc or Shp-2 mutants significantly reduced SRE activation by Cas and v-Src .	parallel	0
6549	10490632	2885;5781	Grb2;Shp-2	Coexpression of Cas with v-Src enhanced the ***association*** of ***Grb2*** with the adapter protein Shc and the protein tyrosine phosphatase ***Shp-2*** ; coexpression of Shc or Shp-2 mutants significantly reduced SRE activation by Cas and v-Src .	parallel	0
6550	10490632	2885;6464	Grb2;Shc	Cas-induced ***Grb2*** ***association*** with Shp-2 and ***Shc*** may account for the Cas-dependent activation of the Ras/Mek/Erk pathway and SRE-dependent transcription .	parallel	0
6551	10490632	2885;5781	Grb2;Shp-2	Cas-induced ***Grb2*** ***association*** with ***Shp-2*** and Shc may account for the Cas-dependent activation of the Ras/Mek/Erk pathway and SRE-dependent transcription .	parallel	0
6552	10490634	5707;5430	RPN2;Rpb1	The 26S proteasome is also required ; a mutation of ***SEN3/RPN2*** ( SEN3-1 ) , which encodes an essential regulatory subunit of the 26S proteasome , partially ***blocks*** 4-NQO-induced degradation of ***Rpb1*** .	positive	0
6553	10490634	6410;5430	SEN3;Rpb1	The 26S proteasome is also required ; a mutation of ***SEN3/RPN2*** ( SEN3-1 ) , which encodes an essential regulatory subunit of the 26S proteasome , partially ***blocks*** 4-NQO-induced degradation of ***Rpb1*** .	positive	0
6554	10490634	23327;5430	Rsp5;Rpb1	These results suggest that ***Rsp5-mediated*** ***ubiquitination*** and degradation of ***Rpb1*** are components of the response to DNA damage .	target	1
6555	10490636	1195;10921	Clk/Sty;SR protein	The protein kinase ***Clk/Sty*** directly ***modulates*** ***SR protein*** activity : both hyper - and hypophosphorylation inhibit splicing .	target	0
6556	10490636	1195;10921	Clk/Sty;SR protein	These findings indicate that ***Clk/Sty*** directly and specifically ***influences*** the activity of ***SR protein*** splicing factors and , importantly , show that both under - and overphosphorylation of SR proteins can modulate splicing .	target	0
6557	10490637	5308;5617	Pitx2;prolactin	We have previously shown that ***Pitx2*** ( also called Ptx2 and RIEG ) transactivates a reporter gene containing a bicoid enhancer and synergistically ***transactivates*** the ***prolactin*** promoter in the presence of the POU homeodomain protein Pit-1 .	positive	1
6558	10490637	5308;5449	Pitx2;Pit-1	Deletion analysis of Pitx2 revealed that the C-terminal 39-amino-acid tail represses DNA binding activity and is required for ******Pitx2-Pit-1****** ***interaction*** and Pit-1 synergism .	parallel	1
6559	10490637	5449;5308	Pit-1;Pitx2	***Pit-1*** ***interaction*** with the ***Pitx2*** C terminus masks the inhibitory effect and promotes increased DNA binding activity .	parallel	1
6560	10490642	4297;23645	HRX;GADD34	Using the yeast two-hybrid system and human cell culture coimmunoprecipitation experiments , we show here that ***HRX*** proteins ***interact*** directly with the ***GADD34*** protein .	parallel	1
6561	10490642	23645;6598	GADD34;INI1	We also show here that ***GADD34*** ***binds*** the human ***SNF5/INI1*** protein , a member of the SNF/SWI complex that can remodel chromatin and activate transcription .	parallel	1
6562	10490645	4790;5970	p50;RelA	Interestingly , expression of ***p50*** ***prevents*** the cytoplasmic expression of ***RelA*** , leading to the nuclear accumulation of both RelA and p50 .	negative	0
6563	10490645	4790;5970	p50;RelA	Together , these results suggest that the nuclear and cytoplasmic shuttling of ***RelA*** is ***regulated*** by both an intrinsic NES-like sequence and the ***p50*** subunit of NF-kappaB .	target	1
6564	10490645	4790;5970	p50;RelA	***Regulation*** of ***RelA*** subcellular localization by a putative nuclear export signal and ***p50*** .	target	1
6565	10490645	4792;4790	IkappaBalpha;NF-kappaB	Signal-mediated ***IkappaBalpha*** degradation ***triggers*** the release and subsequent nuclear translocation of ***NF-kappaB*** .	negative	0
6566	10490649	6774;3725	Stat3;c-Jun	In addition , a physical ***interaction*** of ***Stat3*** with ***c-Jun*** , based on yeast two-hybrid interaction experiments , has been reported .	parallel	1
6567	10490649	6774;3725	Stat3;c-Jun	Here we confirm the existence of an ***interaction*** between ***Stat3*** and ***c-Jun*** both in vitro , with recombinant proteins , and in vivo , during transient transfection .	parallel	1
6568	10490649	6774;3725	Stat3;c-Jun	Point mutations of Stat3 within the interacting domains blocked both physical ***interaction*** of ***Stat3*** with ***c-Jun*** and their cooperation in IL-6-induced transcription directed by the alpha ( 2 ) - macroglobulin enhancer .	parallel	1
6569	10490649	6772;3725	Stat1;c-Jun	While the amino acid sequences and the three-dimensional structures of Stat3 and Stat1 cores are very similar , fragments of ***Stat1*** failed to ***bind*** ***c-Jun*** in vitro .	parallel	1
6570	10490649	6772;3725	Stat1;c-Jun	Although Stat1 binds in vitro to the gamma interferon gene response ( GAS ) element in the alpha ( 2 ) - macroglobulin enhancer , Stat1 did not stimulate transcription , nor did ***Stat1*** and ***c-Jun*** ***cooperate*** in driving transcription controlled by the alpha ( 2 ) - macroglobulin enhancer .	parallel	0
6571	10490652	6285;7157	S100B;p53	Concerted ***regulation*** of wild-type ***p53*** nuclear accumulation and activation by ***S100B*** and calcium-dependent protein kinase C.	target	1
6572	10490652	6285;7157	S100B;p53	We first confirmed that ***S100B*** expression in mouse embryo fibroblasts ***enhanced*** specific nuclear accumulation of wild-type ***p53*** .	positive	0
6573	10490653	1051;3858	C/EBPbeta;keratin 10	Forced expression of ***C/EBPbeta*** in BALB/MK2 keratinocytes inhibited growth , induced morphological changes consistent with a more differentiated phenotype , and ***upregulated*** two early markers of differentiation , keratin 1 ( K1 ) and ***keratin 10*** ( K10 ) but had a minimal effect on the expression of late-stage markers , loricrin and involucrin .	positive	1
6574	10490653	1051;3848	C/EBPbeta;keratin 1	Forced expression of ***C/EBPbeta*** in BALB/MK2 keratinocytes inhibited growth , induced morphological changes consistent with a more differentiated phenotype , and ***upregulated*** two early markers of differentiation , ***keratin 1*** ( K1 ) and keratin 10 ( K10 ) but had a minimal effect on the expression of late-stage markers , loricrin and involucrin .	positive	1
6575	10490661	604;3565	BCL-6;IL-4	Thus , ***BCL-6*** can ***modulate*** the transcription of selective Stat6-dependent ***IL-4*** responses , including IgE class switching in B cells .	target	0
6576	10490661	3565;2208	IL-4;CD23	Expression of BCL-6 can repress the IL-4-dependent induction of immunoglobulin ( Ig ) germ line epsilon transcripts , but does not repress the ***IL-4*** ***induction*** of ***CD23*** transcripts .	target	1
6577	10490710	6532;1813	SERT;DRD2	Previously reported positive ***associations*** between ***DRD2*** or ***SERT*** and bipolar disorder were conceivably due to stratification dependent on the case-control design , even though our sample might have failed to detect small associations due to limited power .	parallel	0
6578	10490793	7124;3952	TNF-alpha;leptin	***TNF-alpha*** at concentrations of 0.24 to 24 ng/ml significantly ***inhibited*** ***leptin*** secretion over 96 h by 19-60 % .	negative	1
6579	10490793	7124;3952	TNF-alpha;leptin	***TNF-alpha*** at concentrations of 0.024 to 24 ng/ml significantly ***decreased*** steady-state levels of ***leptin*** mRNA after 96 h by 32-95 % .	negative	0
6580	10490823	26060;5290	APPL;p110alpha	APPL interacts with the inactive form of AKT2 ; moreover , ***APPL*** ***binds*** to the PI3K catalytic subunit , ***p110alpha*** .	parallel	1
6581	10490823	26060;208	APPL;AKT2	***APPL*** ***interacts*** with the inactive form of ***AKT2*** ; moreover , APPL binds to the PI3K catalytic subunit , p110alpha .	parallel	1
6582	10490825	4803;3479	NGF;IGF-I	Furthermore , ***NGF*** does not stimulate [ 3H ] thymidine incorporation and ***inhibits*** ***IGF-I*** mediated DNA synthesis in CHO/TrkA cells .	negative	1
6583	10490825	3479;5594	IGF-I;ERK2	NGF and ***IGF-I*** ***induce*** extracellular-signal regulated kinase 1 ( ERK1 ) and ***ERK2*** activation , but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I .	target	1
6584	10490825	3479;5595	IGF-I;extracellular-signal regulated kinase 1	NGF and ***IGF-I*** ***induce*** ***extracellular-signal regulated kinase 1*** ( ERK1 ) and ERK2 activation , but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I .	target	1
6585	10490825	4803;5594	NGF;ERK2	***NGF*** and IGF-I ***induce*** extracellular-signal regulated kinase 1 ( ERK1 ) and ***ERK2*** activation , but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I .	target	1
6586	10490825	4803;5595	NGF;extracellular-signal regulated kinase 1	***NGF*** and IGF-I ***induce*** ***extracellular-signal regulated kinase 1*** ( ERK1 ) and ERK2 activation , but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I .	target	1
6587	10490825	4803;5335	NGF;PLC-gamma1	***NGF*** , but not IGF-I , ***stimulates*** tyrosine phosphorylation and activation of ***PLC-gamma1*** which can be inhibited in a dose-dependent manner by phosphoinositide-specific phospholipase C ( PI-PLC ) inhibitor U73122 ( IC50 = 4 microM ) .	positive	0
6588	10490830	2033;6886	p300;SCL	***p300*** functions as a transcriptional ***coactivator*** for the ***TAL1/SCL*** oncoprotein .	positive	1
6589	10490830	6886;2033	TAL1;p300	Deletion analysis identified the bHLH domain of TAL1 and amino-terminal sequences of p300 as necessary for p300-stimulated transactivation and ******TAL1-p300****** ***interaction*** in vitro .	parallel	1
6590	10490831	1326;5241	Tpl-2;progesterone receptor	Furthermore , overexpression of ***Tpl-2*** was ***associated*** with positive ***progesterone receptor*** status of the samples .	parallel	0
6591	10490837	324;1499	APC;beta-catenin	CDX2 is mutated in a colorectal cancer with normal ******APC/beta-catenin****** ***signaling*** .	parallel	0
6592	10490847	5170;6198	PDK1;S6K1	Differences between ***activation*** of ***S6K1*** and S6K2 by ***PDK1*** were observed , suggesting potential differences in the regulation of these homologs .	positive	1
6593	10490847	5170;6199	PDK1;S6K2	Differences between ***activation*** of S6K1 and ***S6K2*** by ***PDK1*** were observed , suggesting potential differences in the regulation of these homologs .	positive	1
6594	10490953	1436;1435	c-fms;M-CSF	The transition from B lymphocyte to B/M phi cell was marked by the kinetic appearance of mRNA for the ***M-CSF*** ***receptor*** , ***c-fms*** , at day 3 following culture initiation .	parallel	1
6595	10490953	3458;1435	IFN-gamma;M-CSF	Interestingly , the presence of ***IFN-gamma*** in splenic B lymphocyte cultures ***abrogated*** the effect of fibroblast-conditioned medium or ***M-CSF*** on outgrowth of B/M phi cells .	negative	0
6596	10490955	7057;3725	TSP1;AP-1	This ***TSP1*** peptide-dependent ***activation*** of ***AP-1*** was inhibited by both heparin and the MAP/ERK kinase inhibitor PD98059 , providing a functional link between adhesion molecule interaction and nuclear transactivation events via the MAP kinase pathways .	positive	1
6597	10490959	7124;7852	TNF-alpha;chemokine receptor	As ***TNF-alpha*** has been shown to ***increase*** the production of C-C ***chemokine receptor*** ( CCR5 ) - binding chemokines under certain circumstances , we hypothesized that TNF-alpha inhibits HIV-1 replication by increasing the expression of these HIV-suppressive factors .	positive	0
6598	10490959	7124;1234	TNF-alpha;CCR5	In addition , we found that ***TNF-alpha*** treatment ***reduces*** ***CCR5*** expression on PBM and AM .	negative	1
6599	10490966	3586;942	IL-10;B7-2	Ribavirin-mediated suppression of ***IL-10*** in BALB/c mice was ***associated*** with increased ***B7-2*** expression and enhanced CHS responses , whereas enhanced IL-10 levels , following ribavirin administration , led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice .	parallel	0
6600	10490982	3439;6778	IFN-alpha;Stat6	***IFN-alpha*** ***activates*** ***Stat6*** and leads to the formation of Stat2 : Stat6 complexes in B cells .	positive	1
6601	10490982	3439;6772	IFN-alpha;Stat1	In most cell types , ***activation*** of ***Stat1*** and Stat2 by ***IFN-alpha*** leads to the formation of either STAT homo - / heterodimers or of the IFN-stimulated gene factor 3 complex composed of Stat1 , Stat2 , and p48 , a non-STAT protein .	positive	1
6602	10490982	3439;6773	IFN-alpha;Stat2	In most cell types , ***activation*** of Stat1 and ***Stat2*** by ***IFN-alpha*** leads to the formation of either STAT homo - / heterodimers or of the IFN-stimulated gene factor 3 complex composed of Stat1 , Stat2 , and p48 , a non-STAT protein .	positive	1
6603	10490982	3439;6778	IFN-alpha;Stat6	***Induction*** of ***Stat6*** complexes by ***IFN-alpha*** appears to be cell type specific , given that tyrosine phosphorylation of Stat6 in response to IFN-alpha is predominantly detected in B cells .	target	1
6604	10490982	3439;6778	IFN-alpha;Stat6	***Activation*** of ***Stat6*** by ***IFN-alpha*** in B cells is accompanied by the formation of novel Stat2 : Stat6 complexes , including an IFN-stimulated gene factor 3-like complex containing Stat2 , Stat6 , and p48 .	positive	1
6605	10490982	3439;6778	IFN-alpha;Stat6	B cell lines resistant to the antiproliferative effects of IFN-alpha display a decrease in the ***IFN-alpha-mediated*** ***activation*** of ***Stat6*** .	positive	1
6606	10490984	2208;4790	CD23;NF kappa B	Investigation of the second messengers mediating the ***CD23-dependent*** ***activation*** of ***NF kappa B*** demonstrates that I kappa B kinases ( IKKs ) but not p90rsk are selectively activated following CD23 cross-linking and mediates the phosphorylation of I kappa B alpha .	positive	1
6607	10490984	2208;4790	CD23;NF kappa B	Cotransfection experiments with an IKK beta negative dominant completely inhibit ***CD23*** ***induced*** ***NF kappa B*** activation .	target	1
6608	10490990	6772;2033	STAT1;p300	In contrast , there is a marked decrease in IFN-gamma-induced ***association*** of ***STAT1*** with the transcriptional coactivators CREB binding protein and ***p300*** in M. tuberculosis-infected macrophages , indicating that M. tuberculosis directly or indirectly disrupts this protein-protein interaction that is essential for transcriptional responses to IFN-gamma .	parallel	0
6609	10490995	4790;3576	p50;IL-8	CoMTB stimulated nuclear ***binding*** of p65 , ***p50*** , and c-Rel subunits of NF-kappa B to ***IL-8*** promoter sequences .	parallel	1
6610	10490995	5970;3576	p65;IL-8	CoMTB stimulated nuclear ***binding*** of ***p65*** , p50 , and c-Rel subunits of NF-kappa B to ***IL-8*** promoter sequences .	parallel	1
6611	10490995	4790;3576	NF-kappa B;IL-8	Transient transfections with IL-8 promoter reporter constructs showed ***NF-kappa B*** binding-site mutations ***abolished*** ***IL-8*** promoter activity while NF-IL-6 binding-site mutations decreased promoter activity to 50.2 + / - 6.3 % of wild-type activity .	positive	0
6612	10490995	3553;3576	IL-1 beta;IL-8	Recombinant ***IL-1 beta*** ( 2 ng/ml ) ***induced*** similar levels of ***IL-8*** secretion to CoMTB in both A549 cells and NHBE .	target	1
6613	10490997	1401;3075	CRP;factor H	In this study , we examined the ***interaction*** of ***CRP*** with ***factor H*** ( FH ) , a key regulator of the alternative pathway ( AP ) of complement .	parallel	1
6614	10490997	3075;1401	FHL-1;CRP	Also FH-like protein 1 ( ***FHL-1*** ) , an alternatively spliced product of the FH gene , ***bound*** to ***CRP*** with its most C-terminal domain ( SCR 7 ) .	parallel	1
6615	10491002	7124;3383	TNF-alpha;ICAM-1	***TNF-alpha*** and IL-1 sequentially ***induce*** endothelial ***ICAM-1*** and VCAM-1 expression in MRL/lpr lupus-prone mice .	target	1
6616	10491002	7124;7412	TNF-alpha;VCAM-1	***TNF-alpha*** and IL-1 sequentially ***induce*** endothelial ICAM-1 and ***VCAM-1*** expression in MRL/lpr lupus-prone mice .	target	1
6617	10491003	7852;6387	CXCR4;SDF-1	This chemokine was able to directly activate p85/p110 PI3-kinase in whole human PBL and to induce the association of PI3-kinase to the ***SDF-1*** alpha ***receptor*** , ***CXCR4*** , in a pertussis toxin-sensitive manner .	parallel	1
6618	10491009	958;959	CD40;CD40L	These findings suggest that CD40L up-regulation is involved in pathogenic cytokine production in inflammatory bowel disease and that blockade of ******CD40-CD40L****** ***interactions*** may have therapeutic effects for these patients .	parallel	1
6619	10491012	3439;4760	IFN-alpha;beta 2	In PBL from six of seven SS patients tested , beta 2 message was expressed at low to undetectable levels and its expression could not be stimulated by either ***IFN-alpha*** or IFN - gamma , which ***stimulated*** ***beta 2*** expression in control PBL .	positive	0
6620	10491020	4323;4313	MT1-MMP;MMP-2	***MT1-MMP*** has proteolytic activity against components of the extracellular matrix and ***activates*** progelatinase A ( ***MMP-2*** ) at the cell surface .	positive	1
6621	10491027	2056;3558	erythropoietin;interleukin 2	Recombinant human ***erythropoietin*** ***stimulates*** production of ***interleukin 2*** by whole blood cell cultures of hemodialysis patients .	positive	0
6622	10491082	100506658;57530	occludin;cingulin	Furthermore , nothing is known about the ***interaction*** of ***occludin*** with ***cingulin*** , a cytoplasmic plaque component of tight junctions .	parallel	1
6623	10491082	100506658;57530	occludin;cingulin	Here we report the isolation and sequencing of a complete X. laevis occludin cDNA , and experiments aimed at mapping X. laevis occludin in vitro phosphorylation site ( s ) and characterizing ***occludin*** ***interaction*** with ***cingulin*** .	parallel	1
6624	10491082	57530;100506658	cingulin;occludin	GST pull-down experiments using in vitro translated , full-length Xenopus cingulin indicated that ***cingulin*** ***interacts*** directly with the C-terminal region of ***occludin*** .	parallel	1
6625	10491089	6625;683	SNP-1;BST-1	Inhibitor peptide ***SNP-1*** ***binds*** to a soluble form of ***BST-1/CD157*** at a 2:2 stoichiometry .	parallel	1
6626	10491089	6625;683	SNP-1;BST-1	***SNP-1*** ***inhibits*** ***BST-1*** ADP-ribosyl cyclase activity uncompetitively with a Ki value of 180 + / - 40 nM .	negative	1
6627	10491115	3476;5524	alpha4;PP2A	A murine ***alpha4*** , identified in lymphocytes , ***binds*** to protein phosphatase 2A ( ***PP2A*** ) .	parallel	1
6628	10491115	3476;5524	alpha4;PP2A	The ***alpha4-b*** protein ***associates*** with the catalytic subunit of ***PP2A*** ( PP2Ac ) , suggesting that the alpha4-b protein is involved in the regulation of phosphatase activity in neuronal cells .	parallel	0
6629	10491170	7879;1121	Rab7;REP-1	Characterization of the ternary ***complex*** between ***Rab7*** , ***REP-1*** and Rab geranylgeranyl transferase .	parallel	1
6630	10491170	7879;1121	Rab7;REP-1	We demonstrate that the state of the nucleotide bound to Rab7 does not influence the affinity of RabGGTase for the ******Rab7-REP-1****** ***complex*** .	parallel	1
6631	10491170	7879;1121	Rab7;REP-1	Experiments using Rab7 mutants in which the last 16 amino acids were either mutated or truncated revealed that the distal part of the C-terminus makes only a limited contribution to the binding affinity between RabGGTase and the ******Rab7-REP-1****** ***complex*** .	parallel	1
6632	10491172	1457;5048	CKII;LIS1	In vitro , ***LIS1*** was ***phosphorylated*** by protein kinase ***CKII*** ( casein kinase II ) , but not many other kinases that were tested .	target	1
6633	10491174	5321;6300	cPLA2;SAPK3	SAPK2b and SAPK4 incorporated less phosphate , and ***cPLA2*** was a poor ***substrate*** for ***SAPK3*** .	parallel	1
6634	10491182	5328;5329	uPA;uPAR	Taken together , our findings indicate that ***uPA*** ***binds*** to ***uPAR*** and stimulates the production of Ins ( 1,4,5 ) P3 via a G-protein - and phospholipase C-dependent mechanism .	parallel	1
6635	10491182	5328;5329	uPA;uPAR	We used the patch-clamp technique to demonstrate that urokinase ( ***uPA*** ) ***binds*** to ***uPAR*** and thereby stimulates Ca ( 2 + ) - activated K + channels in U937 cells .	parallel	1
6636	10491193	5868;8411	Rab5a;EEA1	Although EEA1-CT and EEA1-NT interacted strongly with wild-type Rab5b in the two-hybrid system , we detected no interaction with wild-type Rab5a , even though GTPase-deficient mutants of both ***Rab5a*** and Rab5b ***interacted*** equally well with ***EEA1*** .	parallel	1
6637	10491193	5869;8411	Rab5b;EEA1	Although EEA1-CT and EEA1-NT interacted strongly with wild-type Rab5b in the two-hybrid system , we detected no interaction with wild-type Rab5a , even though GTPase-deficient mutants of both Rab5a and ***Rab5b*** ***interacted*** equally well with ***EEA1*** .	parallel	1
6638	10491193	8411;5869	EEA1;Rab5b	Although EEA1-CT and ***EEA1-NT*** ***interacted*** strongly with wild-type ***Rab5b*** in the two-hybrid system , we detected no interaction with wild-type Rab5a , even though GTPase-deficient mutants of both Rab5a and Rab5b interacted equally well with EEA1 .	parallel	1
6639	10491193	8411;5868	EEA1;Rab5a	These data provide evidence that ***EEA1*** ***interacts*** with both ***Rab5a*** and Rab5b , and that the GTPase activities of the two proteins are differentially regulated in vivo .	parallel	1
6640	10491193	8411;5869	EEA1;Rab5b	These data provide evidence that ***EEA1*** ***interacts*** with both Rab5a and ***Rab5b*** , and that the GTPase activities of the two proteins are differentially regulated in vivo .	parallel	1
6641	10491193	8411;5869	EEA1;Rab5b	Direct ***interaction*** of ***EEA1*** with ***Rab5b*** .	parallel	1
6642	10491194	7150;7153	topoisomerase I;DNA topoisomerase	One conformation is in the form of a ***topoisomerase I-ATP*** complex , which ***inhibits*** DNA relaxation activity of human ***DNA topoisomerase*** I , and the other , a topoisomerase I-DNA complex , which exerts DNA relaxation activity .	negative	1
6643	10491221	650;6662	bone morphogenetic protein-2;Sox9	We investigated the ***regulation*** of ***Sox9*** , a transcription factor known to play a role in chondrogenesis , by ***bone morphogenetic protein-2*** ( BMP-2 ) and hedgehog proteins in order to better understand their signaling function in endochondral bone formation .	target	1
6644	10491223	3553;1000	IL-1beta;N-cadherin	TNF-alpha and ***IL-1beta*** ***suppress*** ***N-cadherin*** expression in MC3T3-E1 cells .	negative	1
6645	10491223	7124;1000	TNF-alpha;N-cadherin	***TNF-alpha*** and IL-1beta ***suppress*** ***N-cadherin*** expression in MC3T3-E1 cells .	negative	1
6646	10491223	3553;1000	IL-1beta;N-cadherin	TNF-alpha ( 10-100 U/ml ) and ***IL-1beta*** ( 10-100 ng/ml ) ***suppressed*** ***N-cadherin*** without changing OB-cadherin expression , while PTH ( 1-100 ng/ml ) had no effect on cadherin expression .	negative	1
6647	10491223	7124;1000	TNF-alpha;N-cadherin	***TNF-alpha*** ( 10-100 U/ml ) and IL-1beta ( 10-100 ng/ml ) ***suppressed*** ***N-cadherin*** without changing OB-cadherin expression , while PTH ( 1-100 ng/ml ) had no effect on cadherin expression .	negative	1
6648	10491296	940;941	CD28;CD80	Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking ***interaction*** of ***CD28*** with ***CD80/CD86*** .	parallel	1
6649	10491296	940;942	CD28;CD86	Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking ***interaction*** of ***CD28*** with ***CD80/CD86*** .	parallel	1
6650	10491296	941;80381	CD80;costimulatory molecule	Interestingly , both a major ***costimulatory molecule*** , CD28 , and its ***ligands*** , ***CD80/CD86*** , were coexpressed on the immortalized T cells .	parallel	1
6651	10491296	942;80381	CD86;costimulatory molecule	Interestingly , both a major ***costimulatory molecule*** , CD28 , and its ***ligands*** , ***CD80/CD86*** , were coexpressed on the immortalized T cells .	parallel	1
6652	10491296	940;941	CD28;CD80	The treatment of the cells with a neutralizing monoclonal antibody against CD28 , which blocks ***interaction*** of ***CD28*** with ***CD80/CD86*** , resulted in retarded cell growth and in induction of apoptosis .	parallel	1
6653	10491296	940;942	CD28;CD86	The treatment of the cells with a neutralizing monoclonal antibody against CD28 , which blocks ***interaction*** of ***CD28*** with ***CD80/CD86*** , resulted in retarded cell growth and in induction of apoptosis .	parallel	1
6654	10491296	940;941	CD28;CD80	These findings demonstrate the requirement of ***interaction*** of ***CD28*** with ***CD80/CD86*** for the optimal growth of HVS-immortalized T cells .	parallel	1
6655	10491296	940;942	CD28;CD86	These findings demonstrate the requirement of ***interaction*** of ***CD28*** with ***CD80/CD86*** for the optimal growth of HVS-immortalized T cells .	parallel	1
6656	10491299	6667;3973	Sp1;LHR	***Activation*** of the human ***LHR*** promoter through ***Sp1/3*** factors is negatively regulated through EREhs and upstream sequences to exert control of gene expression .	positive	1
6657	10491309	3458;2206	IFNgamma;Atopy	However , neither murine nor human variants of ***IFNgamma*** ***associate*** with ***Atopy*** .	parallel	0
6658	10491337	3565;1906	interleukin-4;endothelin-1	***Downregulation*** of ***endothelin-1*** by ***interleukin-4*** during gastric ulcer healing .	negative	1
6659	10491379	4790;5743	NF-kappaB;COX-2	***Conclusions-NF-kappaB*** activation ***correlates*** with LPS-induced expression of TNF-alpha , ***COX-2*** , CINC , and ICAM-1 genes in vivo .	parallel	0
6660	10491379	4790;7124	NF-kappaB;TNF-alpha	***Conclusions-NF-kappaB*** activation ***correlates*** with LPS-induced expression of ***TNF-alpha*** , COX-2 , CINC , and ICAM-1 genes in vivo .	parallel	0
6661	10491389	5594;1026	ERK;p21	In contrast to the induction of cyclin D1 , the induction of ***p21*** ( cip1 ) is ***mediated*** by transient ***ERK*** activity .	target	0
6662	10491392	3925;8201	Op18;MTs	However , the NH ( 2 ) - and COOH-terminal-truncated ***Op18*** mutants ***regulate*** ***MTs*** by distinct mechanisms as evidenced by morphological analysis of microinjected newt lung cells .	target	1
6663	10491394	8976;10096	N-WASP;Arp2/3	Dramatic stimulation of actin assembly is linked to the formation of a ternary ******IcsA-N-WASP-Arp2/3****** ***complex*** , which nucleates actin polymerization .	parallel	1
6664	10491411	3606;3458	IL-18;IFN-gamma	Both neutralization of ***IL-18*** and ICE deficiency significantly ***reduced*** induction of circulating ***IFN-gamma*** in mice receiving IL-12 .	negative	1
6665	10491411	3606;3458	IL-18;IFN-gamma	Extracellular levels of ***IL-18*** significantly ***correlated*** with IL-12-induced ***IFN-gamma*** and were reduced in cells obtained from ICE-deficient mice .	parallel	0
6666	10491431	4233;3082	c-met;scatter factor	BACKGROUND : Expression of ***scatter factor*** ( SF ) , also known as hepatocyte growth factor ( HGF ) , and its ***receptor*** , ***c-met*** , is often associated with malignant progression of human tumors , including gliomas .	parallel	1
6667	10491635	7124;3479	TNF-alpha;IGF-I	***TNF-alpha*** ***potentiated*** effects of insulin and ***IGF-I*** in a dose-dependent and additive fashion ( up to 6.7-fold ; P < 0.001 ) .	positive	0
6668	10491639	7124;1906	TNFalpha;endothelin-1	Furthermore , ***TNFalpha*** significantly ***stimulated*** prostaglandin E ( 2 ) and ***endothelin-1*** secretion by both CS and TS cells ( P < 0.05 or lower ) .	positive	0
6669	10491647	5069;5553	PAPP-A;eosinophil major basic protein	PAPP-A/proMBP , the ***complex*** of pregnancy-associated plasma protein-A ( ***PAPP-A*** ) and the proform of ***eosinophil major basic protein*** ( proMBP ) , circulates at increasing levels during pregnancy .	parallel	1
6670	10491647	5069;3487	PAPP-A;insulin-like growth factor (IGF) binding protein-4	Recently , however , it has been shown that ***PAPP-A*** specifically ***cleaves*** ***insulin-like growth factor (IGF) binding protein-4*** in an IGF-dependent manner .	target	1
6671	10491650	3952;7040	Leptin;TGF-beta	***Leptin*** ***abolished*** the ***TGF-beta*** effect on P450 ( arom ) mRNA expression , and it decreased P450 ( arom ) activity by approximately 27 % .	negative	0
6672	10491650	3952;7040	Leptin;TGF-beta	These data support the hypothesis that ***Leptin*** ***antagonizes*** the stimulatory effects of ***TGF-beta*** on FSH-dependent estrogen production by a mechanism involving the Leptin-induced attenuation of P450 ( arom ) activity and mRNA expression in GC .	negative	1
6673	10491650	3952;7040	Leptin;TGF-beta	However , ***Leptin*** ***suppressed*** the effect of ***TGF-beta*** on FSH-dependent E ( 2 ) and E ( 1 ) production by 39 % and 29 % , respectively .	negative	1
6674	10492013	7048;7040	TbetaR-II;TGF-beta1	In addition , 5-HT-induced facilitation was blocked by application of a soluble fragment of the extracellular portion of the ***TGF-beta1*** type II ***receptor*** ( ***TbetaR-II*** ) , which presumably acted by scavenging an endogenous TGF-beta1-like molecule .	parallel	1
6675	10492041	598;596	Bcl-X;bcl-2	A new apoptosis ***inhibitor*** of the ***bcl-2*** gene family , ***Bcl-X*** ( L ) , was recently found in some types human neoplasia but not in normal tissue .	negative	1
6676	10492068	3815;4254	c-Kit;SCF	Activating mutations in ***c-Kit*** , the ***receptor*** for Stem Cell Factor ( ***SCF*** ) , have been identified in dysplasias and leukaemias of the mast cell lineage and have been shown to contribute to transformation in model systems .	parallel	1
6677	10492081	3383;3683	CD54;CD11a	Lymphoma cells express CD11a and CD49d ( VLA-4 ) , while endothelial cells expressed ***CD54*** ( ***CD11a*** ***ligand*** ) and CD106 ( CD49d ligand ) .	parallel	1
6678	10492081	7412;3676	CD106;CD49d	Lymphoma cells express CD11a and CD49d ( VLA-4 ) , while endothelial cells expressed CD54 ( CD11a ligand ) and ***CD106*** ( ***CD49d*** ***ligand*** ) .	parallel	1
6679	10492400	4193;84260	mdm-2;tumor-suppressor protein	Because ***mdm-2*** protein ***blocks*** the growth-suppressive activity of the p53 ***tumor-suppressor protein*** through similar activities , we examined the expression patterns of mdmx to determine how MdmX expression correlates with p53 protein levels .	negative	0
6680	10492400	7157;4193	p53;mdm-2	Because p53 transactivation is critical following a genotoxic stress , we examined p53 : MdmX complexes after in vitro DNA-PK phosphorylation , a posttranslational modification that blocks ***p53*** ***association*** with ***mdm-2*** .	parallel	0
6681	10492402	3553;6648	IL-1;MnSOD	We found that the 5 ' and 3 ' flanking regions containing several NF-kappaB-binding sites do not mediate ***MnSOD*** ***induction*** by TNF or ***IL-1*** .	target	1
6682	10492523	351;5332	Abeta;PI-PLC	A neurotoxic fragment of amyloid , ***Abeta*** 25-35 , incubated in the presence of endogenous Ca2 + , ***increased*** significantly the ***PI-PLC*** activity of normoxic brain .	positive	0
6683	10493212	2159;7035	factor Xa;tissue factor pathway inhibitor	Monoclonal antibody specific for ******tissue factor pathway inhibitor-factor Xa****** ***complex*** : its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation .	parallel	1
6684	10493264	2944;1543	GSTM1;CYP1A1	Considerable amounts of data have focused on the ***interaction*** between ***CYP1A1*** and ***GSTM1*** , particularly in Japanese patients with lung cancer .	parallel	1
6685	10493496	324;1499	APC;beta-catenin	These and previous data from our laboratory suggest that ***activation*** of the ***beta-catenin-Tcf*** signaling pathway , through either beta-catenin or ***APC*** mutation , contributes to HNPCC colorectal carcinogenesis in approximately 65 % of cases .	positive	1
6686	10493501	7507;2067	XPA;ERCC1	Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair : association with attenuation of the ***interaction*** of ***XPA*** and ***ERCC1*** nucleotide excision repair proteins .	parallel	1
6687	10493501	7507;2067	XPA;ERCC1	A pull-down assay using the MBP-XPA fusion protein showed a significant reduction in the binding of ERCC1 to XPA in nuclear extracts from UCN-01-treated cells compared with untreated cells , suggesting that UCN-01 reduced the ******XPA-ERCC1****** ***interaction*** .	parallel	1
6688	10493501	2067;7507	ERCC1;XPA	A pull-down assay using the MBP-XPA fusion protein showed a significant reduction in the ***binding*** of ***ERCC1*** to ***XPA*** in nuclear extracts from UCN-01-treated cells compared with untreated cells , suggesting that UCN-01 reduced the XPA-ERCC1 interaction .	parallel	1
6689	10493501	7507;2067	XPA;ERCC1	Taken together , these data demonstrate the NER-inhibitory action of UCN-01 , which is associated with the inhibition of the ******XPA-ERCC1****** ***interaction*** by UCN-01 and with the effect of UCN-01 on the phosphorylation/dephosphorylation of an XPA-bound , 52-kDa protein , the identity of which remains to be determined .	parallel	1
6690	10493508	5888;672	Rad51;BRCA1	Human ***Rad51*** ( hRad51 ) has been found to be ***associated*** with ***BRCA1*** , BRCA2 , and p53 either directly or indirectly and is one of at least eight human genes that are members of the Escherichia coli RecA/Saccharomyces cerevisiae Rad51 family thought to affect genomic stability through DNA recombination/repair processes .	parallel	0
6691	10493508	5888;675	Rad51;BRCA2	Human ***Rad51*** ( hRad51 ) has been found to be ***associated*** with BRCA1 , ***BRCA2*** , and p53 either directly or indirectly and is one of at least eight human genes that are members of the Escherichia coli RecA/Saccharomyces cerevisiae Rad51 family thought to affect genomic stability through DNA recombination/repair processes .	parallel	0
6692	10493508	5888;7157	Rad51;p53	Human ***Rad51*** ( hRad51 ) has been found to be ***associated*** with BRCA1 , BRCA2 , and ***p53*** either directly or indirectly and is one of at least eight human genes that are members of the Escherichia coli RecA/Saccharomyces cerevisiae Rad51 family thought to affect genomic stability through DNA recombination/repair processes .	parallel	0
6693	10493588	3454;3455	IFNAR1;IFNAR2	The ability to produce the IFN-beta-1a / IFNAR2 and IFN-beta-1a / ******IFNAR1/IFNAR2****** ***complexes*** make them attractive candidates for X-ray crystallography studies aimed at determining the molecular interactions between IFN-beta-1a and its receptor .	parallel	1
6694	10493665	3553;3383	IL-1beta;intercellular adhesion molecule 1	RESULTS : TNF-alpha , ***IL-1beta*** , and concanavalin A activated PBMC ***increased*** the expression of vascular cellular adhesion molecule 1 and ***intercellular adhesion molecule 1*** significantly on vessels and nonvascular synovial cells compared with injection of medium only .	positive	0
6695	10493665	7124;3383	TNF-alpha;intercellular adhesion molecule 1	RESULTS : ***TNF-alpha*** , IL-1beta , and concanavalin A activated PBMC ***increased*** the expression of vascular cellular adhesion molecule 1 and ***intercellular adhesion molecule 1*** significantly on vessels and nonvascular synovial cells compared with injection of medium only .	positive	0
6696	10493721	4804;627	p75NTR;neurotrophin	The p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) binds all known neurotrophins and has been suggested to either function as a coreceptor for the trk receptor tyrosine kinases or be involved in independent signaling leading to cell death .	parallel	1
6697	10493725	8682;841	PEA-15;caspase-8	In vitro assays evidence that ***PEA-15*** may ***bind*** to DED-containing protein FADD and ***caspase-8*** known to be apical adaptors of the TNF apoptotic signaling .	parallel	1
6698	10493725	8682;8772	PEA-15;FADD	In vitro assays evidence that ***PEA-15*** may ***bind*** to DED-containing protein ***FADD*** and caspase-8 known to be apical adaptors of the TNF apoptotic signaling .	parallel	1
6699	10493726	43;8292	AChE;ColQ	***Interaction*** of ***AChE*** ( T ) subunits with the complete collagen tail ***ColQ*** increased enzyme activity in cultured cells , as well as in muscle fibers in vivo .	parallel	1
6700	10493726	8292;43	ColQ;AChE	Truncated ***ColQ*** subunits , presenting more or less extensive C-terminal deletions , also ***increased*** ***AChE*** activity and secretion in C2C12 cells , although the triple helix could not form in the case of the larger deletion .	positive	0
6701	10493740	2911;9455	mGluR1;Cupidin	In keeping with this , F-actin immunocytochemically colocalized with Cupidin in cultured cerebellar granule cells , and a ******Cupidin-mGluR1-actin****** ***complex*** was immunoprecipitated from crude cerebellar lysates using an anti-Cupidin antibody .	parallel	1
6702	10493740	9455;998	Cupidin;Cdc42	On the other hand , the C-terminal portion of ***Cupidin*** ***bound*** to ***Cdc42*** , a member of Rho family small GTPases , in a GTP-dependent manner in vitro , and Cupidin functionally interacted with activated-Cdc42 in a heterologous expression system .	parallel	1
6703	10493740	9455;998	Cupidin;Cdc42	On the other hand , the C-terminal portion of Cupidin bound to Cdc42 , a member of Rho family small GTPases , in a GTP-dependent manner in vitro , and ***Cupidin*** functionally ***interacted*** with ***activated-Cdc42*** in a heterologous expression system .	parallel	1
6704	10493815	9829;3312	auxilin;Hsc70	We previously found that , in the presence of ATP , DnaJ homologues catalytically induce formation of a metastable Hsc70 polymer and , similarly , the DnaJ homologue ***auxilin*** catalytically ***induces*** formation of a metastable ***Hsc70-clathrin*** basket complex .	target	1
6705	10493815	3312;10294	Hsc70;DnaJ	Surprisingly , however , under certain conditions the rate of polymerization appears to be independent of Hsc70 concentration , suggesting that polymerization is a first-order reaction , perhaps occurring when two ***Hsc70*** molecules ***bind*** to a single ***DnaJ*** molecule and then shift their binding to each other .	parallel	1
6706	10493821	79109;5742	SIN-1;PGHS-1	To this end , we show that 3-morpholinosydnonimine hydrochloride ( ***SIN-1*** ) , a compound capable of generating peroxynitrite , ***activates*** purified ***PGHS-1*** and also stimulates PGE ( 2 ) production in arterial smooth muscle cells in the presence of exogenous arachidonic acid .	positive	1
6707	10493852	3689;3383	LFA-1;intercellular adhesion molecule-1	We report here that lovastatin , a drug clinically used for lowering cholesterol levels , inhibits the ***interaction*** of human ***LFA-1*** with its counter-receptor ***intercellular adhesion molecule-1*** .	parallel	1
6708	10493920	7040;7048	TGF-beta;TGF-beta type II receptor	We show that there is an antagonist present in normal human serum which inhibits the ***binding*** of active ***TGF-beta*** to the extracellular domain of the ***TGF-beta type II receptor*** when it is coated on the well of an ELISA plate .	parallel	1
6709	10493945	4193;84260	MDM2;tumor suppressor protein	The ***MDM2*** oncoprotein ***binds*** to the p53 ***tumor suppressor protein*** and serves as a negative regulator of p53 .	parallel	1
6710	10493945	4193;7157	MDM2;p53	The ***MDM2*** oncoprotein binds to the p53 tumor suppressor protein and serves as a negative ***regulator*** of ***p53*** .	negative	1
6711	10493945	4193;7157	MDM2;p53	Therefore , the negative ***regulation*** of ***p53*** by ***MDM2*** may limit the magnitude of p53 activation by DNA damaging agents , thereby limiting their therapeutic effectiveness .	negative	1
6712	10493945	4193;7157	MDM2;p53	The investigators hypothesize that , by inhibiting MDM2 expression , the MDM2 oncoprotein level will be reduced and the ***MDM2*** negative feedback ***inhibition*** of ***p53*** will be diminished , resulting in a significant increase of functional p53 levels that will modulate p53-mediated therapeutic effects .	negative	1
6713	10493968	1401;3569	CRP;IL-6	***CRP*** production in vitro ***correlated*** with ***IL-6*** production by PBMC from patients with pancreatic cancer ( r = 0.76 , p < 0.0001 ) .	parallel	0
6714	10493969	356;355	CD95L;CD95	Tu-2449 and SRB-10 cells that showed low CD95 expression were resistant to ***CD95*** ***ligand*** ( ***CD95L*** ) - induced apoptosis unless coexposed to CD95L and inhibitors of RNA or protein synthesis .	parallel	1
6715	10494025	7157;1026	p53;p21	Although proteasome inhibitors induced p53 accumulation in a cell line retaining wild-type p53 activity , p53 activity was dispensable for apoptosis since transdominant-negative ***p53*** ***abrogated*** p53-dependent ***p21*** induction but did not modulate apoptosis .	negative	0
6716	10494776	5328;2736	u-PA;THP-1	***Binding*** of human single chain ***u-PA*** ( scu-PA ) to human ***THP-1*** and HT 1080 cells amounted to 2.5 x10 ( 6 ) and 7.1 x10 ( 6 ) molecules per cell , respectively .	parallel	1
6717	10494776	4314;5340	MMP-3;plasmin	These data indicate that ***MMP-3*** may ***downregulate*** cell-associated ***plasmin*** activity by decreasing the amount of activatible plasminogen , without affecting cell-bound u-PA activity .	negative	1
6718	10494798	356;355	Fas ligand;CD95	Other molecules that have been directly implicated in the mechanism of deletion of graft reactive T cells by BMC include the CD8 accessory molecule , major histocompatibility class I gene products , ***CD95/CD95*** ***ligand*** ( ***Fas/Fas ligand*** ) , and transforming growth factor-beta .	parallel	1
6719	10494829	1270;3569	CNTF;IL-6	A tetramer would be the simplest model to describe such a receptor complex , but present orthodoxy describes the active ***complexes*** of ***IL-6*** and ciliary neurotrophic factor ( ***CNTF*** ) as hexamers .	parallel	1
6720	10494847	142;4790	PARP;NF-kappaB	Finally , we show that both ***NF-kappaB*** and ***PARP*** formed a stable immunoprecipitable nuclear ***complex*** .	parallel	1
6721	10494849	6654;2885	Sos1;Grb2	The activation of many hematopoietic cells via cytokine receptors , as well as B and T cell receptors , leads to the tyrosine phosphorylation of Shc and its association with both ******Grb2-Sos1****** ***complexes*** and with a 145 kDa protein referred to as the SH2 containing inositol 5-phosphatase ( SHIP1 ) .	parallel	1
6722	10494862	889;5906	Krit1;Krev-1	The third has homology , with transcriptional or processing variations , to a human genomic sequence , a positional candidate for a tumour suppressor gene , encoding the ***Krit1*** protein which ***interacts*** with the Ras-family GTPase ***Krev-1*** .	parallel	1
6723	10495128	7124;8600	tumor necrosis factor-alpha;osteoprotegerin ligand	Interleukin-1beta and ***tumor necrosis factor-alpha*** , but not interleukin-6 , ***stimulate*** ***osteoprotegerin ligand*** gene expression in human osteoblastic cells .	positive	0
6724	10495128	3553;4982	IL-1beta;OPG	***IL-1beta*** and TNF-alpha ***increased*** ***OPG-L*** mRNA steady-state levels in the normal MS cells and the hMS cell line in a time - and dose-dependent fashion by up to 4.1-fold and up to 2.6-fold , respectively .	positive	0
6725	10495128	7124;4982	TNF-alpha;OPG	IL-1beta and ***TNF-alpha*** ***increased*** ***OPG-L*** mRNA steady-state levels in the normal MS cells and the hMS cell line in a time - and dose-dependent fashion by up to 4.1-fold and up to 2.6-fold , respectively .	positive	0
6726	10495268	1499;2020	beta-catenin;engrailed-2	An ***engrailed-2*** promoter luciferase reporter construct containing these LEF/TCF sites is ***induced*** in embryo explant assays by the combination of Xwnt-3a or ***beta-catenin*** and noggin .	target	1
6727	10495286	2034;7422	HIF-2alpha;vascular endothelial growth factor	Unlike HIF-1alpha - the founding member of the HIF family - which is expressed more or less ubiquitously , ***HIF-2alpha*** ( also called HRF , HLF and EPAS1 ) is highly expressed by vascular endothelial cells and was shown to ***activate*** the transcription of endothelial cell-specific receptor tyrosine kinases ( tie-2 and flk-1 / VEGF receptor 2 ) and of ***vascular endothelial growth factor*** ( VEGF ) .	positive	1
6728	10496070	3172;3091	HNF-4;HIF-1	Transitional change in ***interaction*** between ***HIF-1*** and ***HNF-4*** in response to hypoxia .	parallel	1
6729	10496172	1634;7040	decorin;TGF-beta	Interestingly , the ***reduction*** of ***TGF-beta*** levels in the tumors by ***decorin*** is associated with the de novo expression of inducible nitric oxide synthase ( iNOS ) in a minority of microglial cells .	negative	0
6730	10496178	116;7124	PACAP;TNF alpha	We reported previously that VIP and ***PACAP*** ***inhibit*** IL-6 , IL-12 , ***TNF alpha*** and NO production , and enhance IL-10 production , from lipopolysaccharide ( LPS ) - stimulated macrophages .	negative	1
6731	10496178	7432;7124	VIP;TNF alpha	We reported previously that ***VIP*** and PACAP ***inhibit*** IL-6 , IL-12 , ***TNF alpha*** and NO production , and enhance IL-10 production , from lipopolysaccharide ( LPS ) - stimulated macrophages .	negative	1
6732	10496178	116;7124	PACAP;TNF alpha	The ***VIP/PACAP*** ***inhibition*** of ***TNF alpha*** and NO occurs through both CD14-dependent and - independent mechanisms , whereas the inhibition of IL-6 production appears to be strictly CD14-dependent .	negative	1
6733	10496178	7432;7124	VIP;TNF alpha	The ***VIP/PACAP*** ***inhibition*** of ***TNF alpha*** and NO occurs through both CD14-dependent and - independent mechanisms , whereas the inhibition of IL-6 production appears to be strictly CD14-dependent .	negative	1
6734	10496316	6366;7852	SLC;chemokine receptor	We examined the chemotactic activity of CXCR3 ligands on CD34 + HPC because it has been reported that ***SLC*** is a potential ***ligand*** of CXC ***chemokine receptor*** , CXCR3 , in addition to a CC chemokine receptor , CCR7 .	parallel	1
6735	10496320	7124;729230	TNF-alpha;CCR2	***TNF-alpha*** ***down-regulated*** CC chemokine receptor (CCR)1 , ***CCR2*** , and CCR5 and up-regulated CCR7 mRNA levels , in agreement with functional data .	negative	1
6736	10496320	7124;1234	TNF-alpha;CCR5	***TNF-alpha*** ***down-regulated*** CC chemokine receptor (CCR)1 , CCR2 , and ***CCR5*** and up-regulated CCR7 mRNA levels , in agreement with functional data .	negative	1
6737	10496320	7124;1230	TNF-alpha;chemokine receptor (CCR)1	***TNF-alpha*** ***down-regulated*** CC ***chemokine receptor (CCR)1*** , CCR2 , and CCR5 and up-regulated CCR7 mRNA levels , in agreement with functional data .	negative	1
6738	10496320	7124;1236	TNF-alpha;CCR7	***TNF-alpha*** down-regulated CC chemokine receptor (CCR)1 , CCR2 , and CCR5 and ***up-regulated*** ***CCR7*** mRNA levels , in agreement with functional data .	positive	1
6739	10496322	3458;6355	IFN-gamma;MCP-2	Transcriptional ***control*** of the human ***MCP-2*** gene promoter by ***IFN-gamma*** and IL-1beta in connective tissue cells .	target	0
6740	10496322	3553;6355	IL-1beta;MCP-2	Transcriptional ***control*** of the human ***MCP-2*** gene promoter by IFN-gamma and ***IL-1beta*** in connective tissue cells .	target	0
6741	10496322	3458;6355	IFN-gamma;MCP-2	These results show that ***IFN-gamma*** , produced by lymphocytes and NK cells , ***induces*** the transcription of the ***MCP-2*** gene in fibroblasts and thereby can indirectly contribute to recruitment of various leukocyte cell types to inflammatory sites .	target	1
6742	10496535	5174;1244	PDZK1;cMOAT	***PDZK1*** , a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21 , ***interacts*** with ***cMOAT*** ( MRP2 ) , the multidrug resistance-associated protein .	parallel	1
6743	10496535	5174;1244	PDZK1;cMOAT	Using the yeast two-hybrid system , we have also determined that ***PDZK1*** ***interacts*** with the carboxy-terminal portion of ***cMOAT*** ( MRP2 ) , the canalicular multispecific organic anion transporter associated with multidrug resistance .	parallel	1
6744	10496535	5174;10257	PDZK1;canalicular multispecific organic anion transporter	Using the yeast two-hybrid system , we have also determined that ***PDZK1*** ***interacts*** with the carboxy-terminal portion of cMOAT ( MRP2 ) , the ***canalicular multispecific organic anion transporter*** associated with multidrug resistance .	parallel	1
6745	10496535	1244;5174	cMOAT;PDZK1	Therefore , the protein cluster formed by the ***association*** of ***cMOAT*** , ***PDZK1*** , and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance , and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents .	parallel	0
6746	10496535	10158;1244	MAP17;cMOAT	Therefore , the protein cluster formed by the ***association*** of ***cMOAT*** , PDZK1 , and ***MAP17*** could play an important role in the cellular mechanisms associated with multidrug resistance , and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents .	parallel	0
6747	10496535	10158;5174	MAP17;PDZK1	Therefore , the protein cluster formed by the ***association*** of cMOAT , ***PDZK1*** , and ***MAP17*** could play an important role in the cellular mechanisms associated with multidrug resistance , and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents .	parallel	0
6748	10496679	1499;999	beta-catenin;E-cadherin	Additionally , a decrease in ***beta-catenin*** ***interactions*** with ***E-cadherin*** and alpha-catenin , as assessed by immunoprecipitation and Western blot analysis , was seen .	parallel	1
6749	10496903	958;959	CD40;CD40 ligand	Taken together , these studies strongly suggest that ******CD40-CD40 ligand****** ***interactions*** in normal mice play an important protective role in immune responses against the gram-negative , intracellular pathogen S. dublin .	parallel	1
6750	10496903	958;959	CD40;CD40 ligand	******CD40-CD40 ligand****** ***interactions*** augment survival of normal mice , but not CD40 ligand knockout mice , challenged orally with Salmonella dublin .	parallel	1
6751	10496903	958;959	CD40;CD40 ligand	We demonstrate here that ******CD40-CD40 ligand****** ***interactions*** are significant events in the protective response against the intracellular pathogen Salmonella dublin in normal mice but not for animals genetically deficient in CD40 ligand expression .	parallel	1
6752	10496903	958;959	CD40;CD40 ligand	Conversely , in vivo administration of a monoclonal antibody against CD40 ligand to block endogenous ******CD40-CD40 ligand****** ***interactions*** resulted in a decreased resistance to salmonellosis .	parallel	1
6753	10496903	958;959	CD40;CD40 ligand	In vitro treatment of Salmonella-infected macrophages from BALB/c mice with soluble trimeric CD40 ligand resulted in an elevated production of interleukin 12p70 by these cells , suggesting a mechanism whereby ******CD40-CD40 ligand****** ***interactions*** might enhance protective immune responses to this pathogen .	parallel	1
6754	10496974	1594;632	VDR;osteocalcin	Furthermore , we observed that 1,25 ( OH ) ( 2 ) D ( 3 ) -3 - BE significantly decreased the ***binding*** of ***VDR*** to human ***osteocalcin*** vitamin D responsive element ( hOCVDRE ) , as well as the dissociation rate of VDR from hOCVDRE , compared with 1,25 ( OH ) ( 2 ) D ( 3 ) in COS-1 cells , transiently transfected with a VDR construct .	parallel	1
6755	10496984	7980;1511	tissue factor pathway inhibitor-2;cathepsin G	Human ***tissue factor pathway inhibitor-2*** ( TFPI-2 ) / matrix-associated serine protease inhibitor ( MSPI ) , a Kunitz-type serine protease inhibitor , ***inhibits*** plasmin , trypsin , chymotrypsin , plasma kallikrein , ***cathepsin G*** , and factor VIIa-tissue factor complex .	negative	1
6756	10496984	7980;9622	tissue factor pathway inhibitor-2;kallikrein	Human ***tissue factor pathway inhibitor-2*** ( TFPI-2 ) / matrix-associated serine protease inhibitor ( MSPI ) , a Kunitz-type serine protease inhibitor , ***inhibits*** plasmin , trypsin , chymotrypsin , plasma ***kallikrein*** , cathepsin G , and factor VIIa-tissue factor complex .	negative	1
6757	10496984	7980;5340	tissue factor pathway inhibitor-2;plasmin	Human ***tissue factor pathway inhibitor-2*** ( TFPI-2 ) / matrix-associated serine protease inhibitor ( MSPI ) , a Kunitz-type serine protease inhibitor , ***inhibits*** ***plasmin*** , trypsin , chymotrypsin , plasma kallikrein , cathepsin G , and factor VIIa-tissue factor complex .	negative	1
6758	10496984	7980;2152	tissue factor pathway inhibitor-2;tissue factor	Human ***tissue factor pathway inhibitor-2*** ( TFPI-2 ) / matrix-associated serine protease inhibitor ( MSPI ) , a Kunitz-type serine protease inhibitor , ***inhibits*** plasmin , trypsin , chymotrypsin , plasma kallikrein , cathepsin G , and factor ***VIIa-tissue factor*** complex .	negative	1
6759	10497156	3439;3659	IFN-alpha;interferon regulatory factor-1	***IFN-alpha*** ***induces*** transcription factors , interferon-stimulated gene factor 3 ( ISGF3 ) , and ***interferon regulatory factor-1*** ( IRF-1 ) , which activate interferon-inducible gene expression through binding to the interferon-stimulated regulatory element ( ISRE ) " AGTTTCNNTTTCNC " in the gene promoters .	target	1
6760	10497156	3439;10379	IFN-alpha;ISGF3	***IFN-alpha*** ***induces*** transcription factors , interferon-stimulated gene factor 3 ( ***ISGF3*** ) , and interferon regulatory factor-1 ( IRF-1 ) , which activate interferon-inducible gene expression through binding to the interferon-stimulated regulatory element ( ISRE ) " AGTTTCNNTTTCNC " in the gene promoters .	target	1
6761	10497156	3659;10379	IRF-1;p48	Gel mobility shift assay showed ***binding*** of in vitro translated ***IRF-1*** and in vitro translated ***p48*** ( ISGF3-gamma ) , which is a component of ISGF3 to this sequence .	parallel	1
6762	10497158	81570;10049	ClpB;DnaJ	***ClpB*** ***cooperates*** with DnaK , ***DnaJ*** , and GrpE in suppressing protein aggregation .	parallel	0
6763	10497158	81570;80273	ClpB;GrpE	***ClpB*** ***cooperates*** with DnaK , DnaJ , and ***GrpE*** in suppressing protein aggregation .	parallel	0
6764	10497159	2185;6517	Protein kinase B;GLUT4	***Protein kinase B*** ***stimulates*** the translocation of ***GLUT4*** but not GLUT1 or transferrin receptors in 3T3-L1 adipocytes by a pathway involving SNAP-23 , synaptobrevin-2 , and/or cellubrevin .	positive	0
6765	10497159	8773;9341	SNAP-23;cellubrevin	An ***interaction*** of ***SNAP-23*** and syntaxin 4 on the plasma membrane with vesicle-associated synaptobrevin-2 and/or ***cellubrevin*** , known as SNAP ( soluble N-ethyl-maleimide-sensitive factor attachment protein ) receptors or SNAREs , has been proposed to provide the targeting and/or fusion apparatus for insulin-stimulated translocation of the GLUT4 isoform of glucose transporter to the plasma membrane .	parallel	1
6766	10497159	8773;6844	SNAP-23;synaptobrevin-2	An ***interaction*** of ***SNAP-23*** and syntaxin 4 on the plasma membrane with vesicle-associated ***synaptobrevin-2*** and/or cellubrevin , known as SNAP ( soluble N-ethyl-maleimide-sensitive factor attachment protein ) receptors or SNAREs , has been proposed to provide the targeting and/or fusion apparatus for insulin-stimulated translocation of the GLUT4 isoform of glucose transporter to the plasma membrane .	parallel	1
6767	10497159	6810;9341	syntaxin 4;cellubrevin	An ***interaction*** of SNAP-23 and ***syntaxin 4*** on the plasma membrane with vesicle-associated synaptobrevin-2 and/or ***cellubrevin*** , known as SNAP ( soluble N-ethyl-maleimide-sensitive factor attachment protein ) receptors or SNAREs , has been proposed to provide the targeting and/or fusion apparatus for insulin-stimulated translocation of the GLUT4 isoform of glucose transporter to the plasma membrane .	parallel	1
6768	10497159	6810;6844	syntaxin 4;synaptobrevin-2	An ***interaction*** of SNAP-23 and ***syntaxin 4*** on the plasma membrane with vesicle-associated ***synaptobrevin-2*** and/or cellubrevin , known as SNAP ( soluble N-ethyl-maleimide-sensitive factor attachment protein ) receptors or SNAREs , has been proposed to provide the targeting and/or fusion apparatus for insulin-stimulated translocation of the GLUT4 isoform of glucose transporter to the plasma membrane .	parallel	1
6769	10497159	2185;6517	Protein kinase B;GLUT4	By contrast , a constitutively active ***Protein kinase B*** ( PKB-DD ) only ***stimulated*** a translocation of ***GLUT4*** and not GLUT1 or the transferrin receptor .	positive	0
6770	10497177	2159;2152	factor Xa;tissue factor	***Inhibition*** of ***tissue factor-factor*** VIIa-catalyzed factor X activation by ***factor Xa-tissue factor pathway inhibitor*** .	negative	1
6771	10497177	7035;2152	tissue factor pathway inhibitor;tissue factor	***Inhibition*** of ***tissue factor-factor*** VIIa-catalyzed factor X activation by ***factor Xa-tissue factor pathway inhibitor*** .	negative	1
6772	10497177	2159;7035	FXa;TFPI	FXa generation at a rotating disc coated with TF embedded in a membrane composed of pure phosphatidylcholine ( TF.PC ) or 25 % phosphatidylserine and 75 % phosphatidylcholine ( TF.PSPC ) was measured in the presence of preformed ***complexes*** of ******FXa.TFPI****** ( FL ) or FXa.TFPI ( 1-161 ) ( TFPI lacking the third Kunitz domain and C terminus ) .	parallel	1
6773	10497187	5777;7535	SHP-1L;ZAP70	COS cell-expressed glutathione ***S-transferase-SHP-1L*** can ***dephosphorylate*** tyrosine-phosphorylated ***ZAP70*** .	target	1
6774	10497197	3827;5747	Bradykinin;FAK	***Bradykinin*** , endothelin , and lysophosphatidic acid also ***stimulated*** ***FAK-Src*** complex formation .	positive	0
6775	10497197	2922;5747	Bombesin;FAK	***Bombesin*** ***stimulated*** ***FAK/Src*** association through a Ca ( 2 + ) and phosphatidylinositol 3 ' - kinase-independent pathway that requires the integrity of the actin filament network and is partly dependent on functional protein kinase C.	positive	0
6776	10497198	840;142	caspase-7;PARP	In vitro experiments showed that ***PARP*** ***cleavage*** by ***caspase-7*** , but not by caspase-3 , was stimulated by its automodification by long and branched poly ( ADP-ribose ) .	target	1
6777	10497212	602;6647	Bcl3;homodimer	***Bcl3*** was subsequently shown to ***associate*** tightly with and transactivate the NFkappaB p50 or p52 ***homodimer*** .	parallel	0
6778	10497212	602;4790	Bcl3;p50	***Bcl3*** was subsequently shown to ***associate*** tightly with and transactivate the NFkappaB ***p50*** or p52 homodimer .	parallel	0
6779	10497212	602;2353	Bcl3;AP-1	In addition , anti-HA antibody co-precipitated c-Jun from HeLa cells co-expressing c-Jun and HA-tagged Bcl3 , consistent with the idea that ***Bcl3*** directly ***associates*** with ***AP-1*** in vivo .	parallel	0
6780	10497215	7040;3381	TGF-beta1;bone sialoprotein	Northern analysis showed that both fetuin and high dose ***TGF-beta1*** ***suppressed*** expression of the bone-associated transcripts alkaline phosphatase , osteopontin , collagen type I , and ***bone sialoprotein*** .	negative	1
6781	10497215	7040;6696	TGF-beta1;osteopontin	Northern analysis showed that both fetuin and high dose ***TGF-beta1*** ***suppressed*** expression of the bone-associated transcripts alkaline phosphatase , ***osteopontin*** , collagen type I , and bone sialoprotein .	negative	1
6782	10497236	5663;4851	Presenilin-1;Notch1	***Presenilin-1*** ( PS1 ) ***facilitates*** gamma-secretase cleavage of the beta-amyloid precursor protein and the intramembraneous cleavage of ***Notch1*** .	positive	0
6783	10497238	5020;5594	oxytocin;ERK-2	We previously showed that the rat oxytocin receptor transfected into Chinese hamster ovary cells was coupled to both G ( q/11 ) and G ( i/o ) , and that ***oxytocin*** ***stimulated*** ***ERK-2*** phosphorylation and prostaglandin E ( 2 ) synthesis via protein kinase C activity .	positive	0
6784	10497239	6929;3399	E2A;Id3	***E2A*** ( 505-513 ) ***interacted*** with mUbc9 but not with human Ubc5 , MyoD , ***Id3*** , or the polymyositis-scleroderma autoantigen .	parallel	1
6785	10497239	6929;4654	E2A;MyoD	***E2A*** ( 505-513 ) ***interacted*** with mUbc9 but not with human Ubc5 , ***MyoD*** , Id3 , or the polymyositis-scleroderma autoantigen .	parallel	1
6786	10497240	3569;3726	Interleukin-6;JunB	***Interleukin-6*** and leukemia inhibitory factor ***induction*** of ***JunB*** is regulated by distinct cell type-specific cis-acting elements .	target	1
6787	10497240	3976;3726	leukemia inhibitory factor;JunB	Interleukin-6 and ***leukemia inhibitory factor*** ***induction*** of ***JunB*** is regulated by distinct cell type-specific cis-acting elements .	target	1
6788	10497242	4088;2033	Smad3;p300	E1A inhibits the ***interaction*** of ***Smad3*** with a ***p300*** mutant that contains SID but lacks the E1A binding domain .	parallel	1
6789	10497252	199699;4601	Sp1;MXI1	Expression of ***MXI1*** , a Myc antagonist , is ***regulated*** by ***Sp1*** and AP2 .	target	1
6790	10497254	3553;7412	IL-1beta;vascular cell adhesion molecule-1	Adenovirus-mediated overexpression of a dominant-negative IkappaBalpha ( inhibitor of kappaB ) mutant blocked NF-kappaB activation by gel shift assay and blocked ***induction*** of ***vascular cell adhesion molecule-1*** protein by TNF-alpha , ***IL-1beta*** , and LPS , a NF-kappaB-dependent response .	target	1
6791	10497254	7124;7412	TNF-alpha;vascular cell adhesion molecule-1	Adenovirus-mediated overexpression of a dominant-negative IkappaBalpha ( inhibitor of kappaB ) mutant blocked NF-kappaB activation by gel shift assay and blocked ***induction*** of ***vascular cell adhesion molecule-1*** protein by ***TNF-alpha*** , IL-1beta , and LPS , a NF-kappaB-dependent response .	target	1
6792	10497254	4792;4790	IkappaBalpha;NF-kappaB	Adenovirus-mediated overexpression of a dominant-negative ***IkappaBalpha*** ( inhibitor of kappaB ) mutant ***blocked*** ***NF-kappaB*** activation by gel shift assay and blocked induction of vascular cell adhesion molecule-1 protein by TNF-alpha , IL-1beta , and LPS , a NF-kappaB-dependent response .	negative	0
6793	10497255	2185;3667	protein kinase B;insulin receptor substrate-1	***Phosphorylation*** of ***insulin receptor substrate-1*** ( IRS-1 ) by ***protein kinase B*** positively regulates IRS-1 function .	target	1
6794	10497255	207;3667	PKB;IRS-1	Furthermore , ***PKB*** and ***IRS-1*** formed stable ***complexes*** in vivo , and overexpression of PKB enhanced Ser phosphorylation of IRS-1 .	parallel	1
6795	10497307	3565;4254	interleukin-4;SCF	Leukemia inhibitory factor ( LIF ) or ***interleukin-4*** ( IL-4 ) moderately ***increased*** ***SCF*** mRNA in all cell lines , but IL-3 did not .	positive	0
6796	10497307	3976;4254	LIF;SCF	Leukemia inhibitory factor ( ***LIF*** ) or interleukin-4 ( IL-4 ) moderately ***increased*** ***SCF*** mRNA in all cell lines , but IL-3 did not .	positive	0
6797	10497307	7040;4254	TGF-beta1;SCF	The dot-blot enzyme-linked immunosorbent assay ( ELISA ) further confirmed that ***SCF*** protein production in these cell lines and bone marrow stromal cells was markedly ***enhanced*** by ***TGF-beta1*** , although TGF-beta1 suppressed the proliferation of all these cells .	positive	0
6798	10497311	3082;100506658	Hepatocyte growth factor;occludin	***Hepatocyte growth factor/scatter factor*** ***decreases*** the expression of ***occludin*** and transendothelial resistance ( TER ) and increases paracellular permeability in human vascular endothelial cells .	negative	0
6799	10497311	3082;100506658	HGF;occludin	Western blotting revealed that ***HGF/SF*** ***decreased*** the level of ***occludin*** in the cells , a primary tight junction forming protein .	negative	0
6800	10497311	3082;100506658	HGF;occludin	It is concluded that ***HGF/SF*** ***decreases*** the expression of ***occludin*** , resulting in the functional change of tight junction .	negative	0
6801	10497315	3458;3627	IFN-gamma;IP-10	***IFN-gamma*** ***induced*** the expression of ***IP-10*** ; however unlike in macrophages , it did not selectively inhibit that of JE and KC .	target	1
6802	10498401	595;1543	CCND1;CYP1A1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , GSTP1 , CYP2D6 , ***CYP1A1*** , CYP2E1 , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6803	10498401	595;1565	CCND1;CYP2D6	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , GSTP1 , ***CYP2D6*** , CYP1A1 , CYP2E1 , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6804	10498401	595;1571	CCND1;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , GSTP1 , CYP2D6 , CYP1A1 , ***CYP2E1*** , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6805	10498401	595;2944	CCND1;GSTM1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , GSTT1 , GSTM3 , GSTP1 , CYP2D6 , CYP1A1 , CYP2E1 , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6806	10498401	595;2947	CCND1;GSTM3	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , ***GSTM3*** , GSTP1 , CYP2D6 , CYP1A1 , CYP2E1 , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6807	10498401	595;2950	CCND1;GSTP1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , ***GSTP1*** , CYP2D6 , CYP1A1 , CYP2E1 , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6808	10498401	595;2952	CCND1;GSTT1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , ***GSTT1*** , GSTM3 , GSTP1 , CYP2D6 , CYP1A1 , CYP2E1 , and ***CCND1*** genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6809	10498401	1543;1571	CYP1A1;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , GSTP1 , CYP2D6 , ***CYP1A1*** , ***CYP2E1*** , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6810	10498401	1543;2947	CYP1A1;GSTM3	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , ***GSTM3*** , GSTP1 , CYP2D6 , ***CYP1A1*** , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6811	10498401	1565;1543	CYP2D6;CYP1A1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , GSTP1 , ***CYP2D6*** , ***CYP1A1*** , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6812	10498401	1565;1571	CYP2D6;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , GSTP1 , ***CYP2D6*** , CYP1A1 , ***CYP2E1*** , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6813	10498401	1565;2947	CYP2D6;GSTM3	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , ***GSTM3*** , GSTP1 , ***CYP2D6*** , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6814	10498401	1565;2950	CYP2D6;GSTP1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , ***GSTP1*** , ***CYP2D6*** , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6815	10498401	2944;1543	GSTM1;CYP1A1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , GSTT1 , GSTM3 , GSTP1 , CYP2D6 , ***CYP1A1*** , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6816	10498401	2944;1565	GSTM1;CYP2D6	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , GSTT1 , GSTM3 , GSTP1 , ***CYP2D6*** , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6817	10498401	2944;1571	GSTM1;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , GSTT1 , GSTM3 , GSTP1 , CYP2D6 , CYP1A1 , ***CYP2E1*** , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6818	10498401	2944;2947	GSTM1;GSTM3	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , GSTT1 , ***GSTM3*** , GSTP1 , CYP2D6 , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6819	10498401	2944;2950	GSTM1;GSTP1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , GSTT1 , GSTM3 , ***GSTP1*** , CYP2D6 , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6820	10498401	2944;2952	GSTM1;GSTT1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between ***GSTM1*** , ***GSTT1*** , GSTM3 , GSTP1 , CYP2D6 , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6821	10498401	2947;1571	GSTM3;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , ***GSTM3*** , GSTP1 , CYP2D6 , CYP1A1 , ***CYP2E1*** , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6822	10498401	2950;1543	GSTP1;CYP1A1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , ***GSTP1*** , CYP2D6 , ***CYP1A1*** , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6823	10498401	2950;1571	GSTP1;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , GSTM3 , ***GSTP1*** , CYP2D6 , CYP1A1 , ***CYP2E1*** , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6824	10498401	2950;2947	GSTP1;GSTM3	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , GSTT1 , ***GSTM3*** , ***GSTP1*** , CYP2D6 , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6825	10498401	2952;1543	GSTT1;CYP1A1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , ***GSTT1*** , GSTM3 , GSTP1 , CYP2D6 , ***CYP1A1*** , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6826	10498401	2952;1565	GSTT1;CYP2D6	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , ***GSTT1*** , GSTM3 , GSTP1 , ***CYP2D6*** , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6827	10498401	2952;1571	GSTT1;CYP2E1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , ***GSTT1*** , GSTM3 , GSTP1 , CYP2D6 , CYP1A1 , ***CYP2E1*** , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6828	10498401	2952;2947	GSTT1;GSTM3	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , ***GSTT1*** , ***GSTM3*** , GSTP1 , CYP2D6 , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6829	10498401	2952;2950	GSTT1;GSTP1	Accordingly , we have examined , in patients with one squamous cell carcinoma ( SCC ) of the head and neck , ***associations*** between GSTM1 , ***GSTT1*** , GSTM3 , ***GSTP1*** , CYP2D6 , CYP1A1 , CYP2E1 , and CCND1 genotypes and the outcome parameters , tumor extension , histological grade , and presence of nodes .	parallel	0
6830	10498586	7035;2152	TFPI;tissue factor	We have investigated the influence of alterations in plasma coagulation factor levels between 50 % and 150 % of their mean values for prothrombin , factor X , factor XI , factor IX , factor VII , factor VIII , factor V , protein C , protein S , antithrombin III ( AT-III ) , and ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) as well as combinations of extremes , eg , 50 % anticoagulants and 150 % procoagulants or 50 % procoagulants and 150 % anticoagulants in a synthetic " plasma " system .	negative	1
6831	10498589	3439;25	IFN-alpha;BCR/ABL	In cell culture experiments , ***IFN-alpha*** priming significantly ***reduced*** the levels of ***BCR/ABL*** hybrid transcripts in a dose-dependent manner in Ph + bone marrow precursors obtained at diagnosis from patients who subsequently responded to IFN-alpha treatment ( P < .005 ) .	negative	1
6832	10498600	2323;2322	FLT3L;FLT-3	In 2 animals , cells of the different fractions were transduced in the presence of human ***FLT-3*** ***ligand*** ( ***FLT3L*** ) , canine stem cell factor ( cSCF ) , and human megakaryocyte growth and development factor ( MGDF ) , and in 2 other dogs , transduction was performed in the presence of FLT3L , cSCF , and canine granulocyte-colony stimulating factor ( cG-CSF ) .	parallel	1
6833	10498602	10371;8829	semaphorin III;Neuropilin-1	Two ***Neuropilin-1*** ***ligands*** , ***semaphorin III*** and VEGF 165 , can bind to these cells , and the addition of VEGF 165 to MS-5 cells increases expression of 2 cytokines known to regulate early hematopoiesis , Tpo and Flt3-L .	parallel	1
6834	10498602	7422;8829	VEGF;Neuropilin-1	Two ***Neuropilin-1*** ***ligands*** , semaphorin III and ***VEGF*** 165 , can bind to these cells , and the addition of VEGF 165 to MS-5 cells increases expression of 2 cytokines known to regulate early hematopoiesis , Tpo and Flt3-L .	parallel	1
6835	10498610	7037;7018	TfR;transferrin	To elucidate the pathways by which nitric oxide ( NO ) influences macrophage iron metabolism , the uptake , release , and intracellular distribution of iron in the murine macrophage cell line J774 has been investigated , together with ***transferrin*** ***receptor*** ( ***TfR*** ) expression and iron-regulatory protein ( IRP1 and IRP2 ) activity .	parallel	1
6836	10498610	3458;3658	IFN-gamma;IRP2	Finally , although NO released by IFN-gamma/LPS-activated macrophages increased the iron-responsive element ( IRE ) - binding activity of both IRP1 and IRP2 , ***IFN-gamma*** treatment ***decreased*** ***IRP2*** activity in an NO-independent manner .	negative	0
6837	10498611	3815;4318	c-kit;Matrix metalloproteinase-9	***Matrix metalloproteinase-9*** production , a newly identified function of mast cell progenitors , is ***downregulated*** by ***c-kit*** receptor activation .	negative	1
6838	10498611	4254;4318	stem cell factor;MMP-9	Thus , the present results suggest that mast cell precursors are able to produce MMP-9 , which may be essential for mast cell migration into tissues , and that ***stem cell factor*** may ***downregulate*** the ***MMP-9*** production , resulting in engagement of mast cells to matrix components .	negative	1
6839	10498628	10803;6370	GPR-9-6;thymus-expressed chemokine	Here we report that ***GPR-9-6*** , now called CC chemokine receptor 9 ( CCR9 ) , is a ***receptor*** for ***thymus-expressed chemokine*** , TECK .	parallel	1
6840	10498628	10803;6370	CCR9;TECK	Our data suggest that ******TECK/CCR9****** ***interaction*** may play a pivotal role in T-cell migration in the thymus .	parallel	1
6841	10498643	3458;958	IFN-gamma;CD40	We have shown that 6 HCC cell lines constitutively expressed ***CD40*** mRNA and membrane-bound CD40 antigen , which was slightly ***up-regulated*** by interferon gamma ( ***IFN-gamma*** ) .	positive	1
6842	10498647	3725;6772	AP-1;STAT1	In the presence of the ERK inhibitor , ***binding*** of the ***AP-1*** complex and of ***STAT1*** to the related regulatory elements was inhibited .	parallel	1
6843	10498648	4790;7124	NF-kappaB;TNF-alpha	The aim of this study is to investigate how PAF participates in the LPS-induced and ***NF-kappaB-mediated*** ***regulation*** of ***TNF-alpha*** and CINC in regenerating rat livers .	target	1
6844	10498650	4323;7077	MT-MMP;tissue inhibitor of metalloproteinases (TIMP)-2	Progelatinase A activation requires its binding to a ***complex*** of membrane-type matrix metalloproteinase ( ***MT-MMP*** ) and ***tissue inhibitor of metalloproteinases (TIMP)-2*** .	parallel	1
6845	10498679	5727;6469	ptc1;Shh	The polydactyly was preceded by unexpected anterior limb bud transcription of Shh , so one function of ***ptc1*** is to ***repress*** ***Shh*** expression in the anterior limb bud .	negative	1
6846	10498691	7075;7010	TIE;TEK	***Interaction*** of the ***TEK*** and ***TIE*** receptor tyrosine kinases during cardiovascular development .	parallel	1
6847	10498824	2260;2247	FGFR1;bFGF	Consistent with its growth-suppressive effect , ***FGFR1*** antisense oligonucleotides markedly ***reduced*** expression of both FGFR1 mRNA and high-affinity ***bFGF*** binding sites , whereas FGFR1 reverse antisense control oligonucleotide had no effect .	negative	1
6848	10498853	4880;5350	CNP;phospholamban	Addition of ***CNP*** to isolated adult rat cardiomyocytes , induced a 25 fold increase in guanosine 3 ' ,5 ' cyclic monophosphate ( cGMP ) levels and ***stimulated*** the phosphorylation of ***phospholamban*** and troponin I , two proteins involved in the regulation of cardiac contractility .	positive	0
6849	10498870	1027;1017	p27Kip1;Cdk2	Overexpression of ***p27Kip1*** allowed accumulation of the inhibitor in the nucleus but ***inhibited*** entry of ***Cdk2*** into the nucleus following serum stimulation .	negative	1
6850	10498872	3082;4233	HGF;Met	We have investigated the role of hepatocyte growth factor ( ***HGF*** ) , the high-affinity ***ligand*** for ***Met*** , in mutant Met-mediated cell transformation .	parallel	1
6851	10498890	4091;4087	Smad6;Smad2	Phosphorylation of ***Smad2/Smad3*** by activated TbetaRI is ***inhibited*** by two newly discovered members of the Smad family , ***Smad6*** and Smad7 .	negative	1
6852	10498890	4091;4088	Smad6;Smad3	Phosphorylation of ***Smad2/Smad3*** by activated TbetaRI is ***inhibited*** by two newly discovered members of the Smad family , ***Smad6*** and Smad7 .	negative	1
6853	10498890	4092;4087	Smad7;Smad2	Phosphorylation of ***Smad2/Smad3*** by activated TbetaRI is ***inhibited*** by two newly discovered members of the Smad family , Smad6 and ***Smad7*** .	negative	1
6854	10498890	4092;4088	Smad7;Smad3	Phosphorylation of ***Smad2/Smad3*** by activated TbetaRI is ***inhibited*** by two newly discovered members of the Smad family , Smad6 and ***Smad7*** .	negative	1
6855	10498893	3479;5915	insulin-like growth factor 1;RARbeta	In this study we show that ***insulin-like growth factor 1*** ( IGF-1 ) and tetradecanoyl phorbol acetate ( TPA ) ***induce*** ***RARbeta*** gene expression in neuroblastoma SH-SY5Y cells .	target	1
6856	10498895	2534;2046	Fyn;EphA8	Additionally , a high level of EphA8 was detected in Fyn immunoprecipitates in intact cells , indicating that ***EphA8*** and ***Fyn*** can physically ***associate*** in vivo .	parallel	0
6857	10498895	2534;2046	Fyn;EphA8	In contrast , the ***association*** of full-length ***Fyn*** to ***EphA8*** containing mutation at either Tyr-615 or Tyr-838 was greatly reduced .	parallel	0
6858	10498896	1029;1019	p16INK4a;CDK4	Among the 17 sequence variants analysed , three distinct categories can be distinguished : those that abrogate the ***binding*** of ***p16INK4a*** to ***CDK4*** and CDK6 , those that alter the properties of the protein without preventing it from interacting with CDKs , and those that have no discernible effect on protein function .	parallel	1
6859	10498896	1029;1021	p16INK4a;CDK6	Among the 17 sequence variants analysed , three distinct categories can be distinguished : those that abrogate the ***binding*** of ***p16INK4a*** to CDK4 and ***CDK6*** , those that alter the properties of the protein without preventing it from interacting with CDKs , and those that have no discernible effect on protein function .	parallel	1
6860	10498899	3659;6590	IRF-1;SLPI	Furthermore , co-transfection studies demonstrated that ***SLPI*** expression was ***inhibited*** by ***IRF-1*** co-expression .	negative	1
6861	10499166	6469;3670	Shh;Isl-1	In contrast , purified ***Shh*** ***induced*** ***Isl-1*** expression in neural tube explants , suggesting that additional neural tube-derived factors are required to induce motoneuron differentiation .	target	1
6862	10499422	3952;4852	leptin;Neuropeptide Y	Hypothalamic ***Neuropeptide Y*** ( NPY ) neurons are ***influenced*** by circulating levels of insulin and ***leptin*** and are thought to be involved in mediating hunger following underfeeding .	target	0
6863	10499490	183;6770	Angiotensin II;steroidogenic acute regulatory protein	***Angiotensin II*** and cyclic adenosine 3 ' ,5 ' - monophosphate ***induce*** human ***steroidogenic acute regulatory protein*** transcription through a common steroidogenic factor-1 element .	target	1
6864	10499492	2520;3952	gastrin;leptin	We therefore propose that ***gastrin*** is involved in long term ***regulation*** of ***leptin*** expression and secretion in rat fat tissues through activation of an adipocyte gastrin/CCK-B receptor .	target	1
6865	10499494	5741;5746	PTH;PTH2 receptor	The human ***PTH2 receptor*** , expressed in tissue culture cells , is selectively ***activated*** by ***PTH*** .	positive	1
6866	10499494	5741;5746	PTH;PTH2 receptor	This suggests that ***PTH*** is unlikely to be a physiologically important endogenous ***ligand*** for the ***PTH2 receptor*** .	parallel	1
6867	10499497	5617;3569	PRL;IL-6	***PRL*** ***inhibition*** of ***IL-6*** expression was totally reversed by tyrphostin AG490 , a JAK2 inhibitor .	negative	1
6868	10499497	5617;3569	PRL;IL-6	This inhibition is induced by ***PRL*** and estradiol , which ***down-regulate*** not only ***IL-6*** expression , but also the expression of IL-6 receptor and signaling proteins .	negative	1
6869	10499497	5617;3569	PRL;IL-6	Progesterone showed no effect , whereas estradiol and ***PRL*** ***reduced*** the level of ***IL-6*** mRNA expression .	negative	1
6870	10499502	367;7358	androgen receptor;UDPGDH	The increase in UDPGDH messenger RNA was completely prevented by coincubation with the pure antiandrogen hydroxyflutamide , but not by cycloheximide , indicating that ***UDPGDH*** is directly ***regulated*** by the ***androgen receptor*** .	target	1
6871	10499509	1050;5617	CCAAT/enhancer-binding protein alpha;prolactin	***CCAAT/enhancer-binding protein alpha*** is a physiological ***regulator*** of ***prolactin*** gene expression .	target	1
6872	10499509	1649;1050	Chop10;C/EBP alpha	Expression of C/EBP alpha increased basal PRL gene expression almost 6-fold , whereas expression of ***Chop10*** that can act as an ***inhibitor*** of ***C/EBP alpha*** reduced the basal activity of the PRL promoter 60-75 % .	negative	1
6873	10499509	1050;5617	C/EBP alpha;PRL	Expression of ***C/EBP alpha*** ***increased*** basal ***PRL*** gene expression almost 6-fold , whereas expression of Chop10 that can act as an inhibitor of C/EBP alpha reduced the basal activity of the PRL promoter 60-75 % .	positive	0
6874	10499512	1052;3488	C/EBPdelta;IGFBP-5	Overexpression of ***C/EBPdelta*** ***stimulated*** basal ***IGFBP-5*** promoter activity , and this effect was eliminated by mutating the C/EBP-binding site .	positive	0
6875	10499513	3565;6778	IL-4;Stat6	Our data also demonstrates that the stimulatory effect of ***IL-4*** was always ***associated*** with the activation of ***Stat6*** , thus supporting the essential role of Stat6 in this induction of 3beta-HSD type 1 gene expression .	parallel	0
6876	10499514	6464;2885	Shc;Grb2	Insulin stimulation of ***Shc*** ***association*** with ***Grb2*** , which is important for p21ras-MAP kinase activation , was decreased by overexpression of WT - and 2F-SHIP .	parallel	0
6877	10499514	6464;2885	Shc;Grb2	In accordance with the extent of ***Shc*** ***association*** with ***Grb2*** , insulin-induced MAP kinase activation was relatively decreased in both WT-SHIP and 2F-SHIP cells , but not in deltaSH2-SHIP cells .	parallel	0
6878	10499517	5550;2796	prolyl endopeptidase;GnRH	Early prepubertal ontogeny of pulsatile gonadotropin-releasing hormone ( GnRH ) secretion : I. Inhibitory autofeedback control through ***prolyl endopeptidase*** ***degradation*** of ***GnRH*** .	negative	1
6879	10499518	3479;3488	IGF-I;IGF binding protein-5	***IGF-I*** ***stimulates*** the synthesis of ***IGF binding protein-5*** by these cells .	positive	0
6880	10499522	7124;7849	TNF-alpha;Pax-8	These results indicate that ***TNF-alpha*** ***suppresses*** the activity of TTF-1 and ***Pax-8*** by different mechanisms , which , in part , seem to be involved in TNF-alpha-induced decrease in TG gene expression .	negative	1
6881	10499522	7124;7849	Tumor necrosis factor-alpha;Pax-8	***Tumor necrosis factor-alpha*** ***regulation*** of thyroid transcription factor-1 and ***Pax-8*** in rat thyroid FRTL-5 cells .	target	1
6882	10499522	7124;7080	Tumor necrosis factor-alpha;thyroid transcription factor-1	***Tumor necrosis factor-alpha*** ***regulation*** of ***thyroid transcription factor-1*** and Pax-8 in rat thyroid FRTL-5 cells .	target	1
6883	10499522	7124;7849	TNF-alpha;Pax-8	In the present study , we show that ***TNF-alpha*** ***suppresses*** DNA-binding activity of thyroid transcription factors , ***Pax-8*** and thyroid transcription factor-1 ( TTF-1 ) , which is , in part , involved in TNF-alpha-induced decrease in TG gene expression .	negative	1
6884	10499522	7124;7080	TNF-alpha;thyroid transcription factor-1	In the present study , we show that ***TNF-alpha*** ***suppresses*** DNA-binding activity of thyroid transcription factors , Pax-8 and ***thyroid transcription factor-1*** ( TTF-1 ) , which is , in part , involved in TNF-alpha-induced decrease in TG gene expression .	negative	1
6885	10499524	3827;2796	Bradykinin;GnRH	In a previous publication we provided evidence of a novel neuronal pathway for the ***control*** of ***GnRH*** secretion by ***Bradykinin*** .	target	0
6886	10499524	3827;2796	Bradykinin;GnRH	***Bradykinin*** ***stimulation*** of ***GnRH*** secretion from GT1-7 cells appears to involve activation of the phospholipase C signaling pathway and mobilization of extracellular and intracellular calcium stores .	positive	0
6887	10499537	3952;7350	leptin;uncoupling protein 1	***leptin*** also ***increases*** ***uncoupling protein 1*** ( UCP1 ) expression in brown adipose tissue ( BAT ) , but the neurotransmitter that mediates this effect has not been established .	positive	0
6888	10499541	5241;5617	Progesterone receptor;decidual prolactin	***Progesterone receptor*** ***regulates*** ***decidual prolactin*** expression in differentiating human endometrial stromal cells .	target	1
6889	10499550	2641;3651	Glucagon-like peptide-1;PDX-1	***Glucagon-like peptide-1*** ***regulates*** the beta cell transcription factor , ***PDX-1*** , in insulinoma cells .	target	1
6890	10499550	2641;2645	Glucagon-like peptide-1;glucokinase	***Glucagon-like peptide-1*** ( GLP-1 ) ***enhances*** insulin biosynthesis and secretion as well as transcription of the insulin , GLUT2 and ***glucokinase*** genes .	positive	0
6891	10499550	2641;6514	Glucagon-like peptide-1;GLUT2	***Glucagon-like peptide-1*** ( GLP-1 ) ***enhances*** insulin biosynthesis and secretion as well as transcription of the insulin , ***GLUT2*** and glucokinase genes .	positive	0
6892	10499580	2253;10637	FGF-8;Lefty-1	Our results define a complex network of antagonistic molecular ***interactions*** between Activin , ***FGF-8*** , ***Lefty-1*** , Nodal , BMPs and Car that cooperate to control left-right asymmetry in the chick embryo .	parallel	1
6893	10499580	4838;2253	Nodal;FGF-8	Our results define a complex network of antagonistic molecular ***interactions*** between Activin , ***FGF-8*** , Lefty-1 , ***Nodal*** , BMPs and Car that cooperate to control left-right asymmetry in the chick embryo .	parallel	1
6894	10499580	4838;10637	Nodal;Lefty-1	Our results define a complex network of antagonistic molecular ***interactions*** between Activin , FGF-8 , ***Lefty-1*** , ***Nodal*** , BMPs and Car that cooperate to control left-right asymmetry in the chick embryo .	parallel	1
6895	10499587	10911;2837	U-II;GPR14	Goby and human ***U-II*** ***bind*** to recombinant human ***GPR14*** with high affinity , and the binding is functionally coupled to calcium mobilization .	parallel	1
6896	10499626	284;7010	angiopoietin-1;Tie2	Enhanced expression of ***Tie2*** , its ***ligand*** ***angiopoietin-1*** , vascular endothelial growth factor , and CD31 in human non-small cell lung carcinomas .	parallel	1
6897	10499815	7329;3329	P18;hsp60	In addition we analyzed ***binding*** of ***P18*** , a soluble gp41 fragment harboring the extracellular domain ( Env aa539-684 ) , to recombinant ***hsp60*** .	parallel	1
6898	10499826	355;356	Fas;FasL	***Interaction*** between ***Fas*** and ***FasL*** is a crucial mechanism for clonal deletion and immune tolerance and privilege , control of T cell expansion during immune responses and killing by cytotoxic T lymphocytes .	parallel	1
6899	10499882	5167;3643	PC-1;insulin receptor	Membrane glycoprotein ***PC-1*** ( plasma cell antigen-1 ) , which ***inhibits*** ***insulin receptor*** tyrosine kinase activity , was isolated from fibroblasts of NIDDM patients .	negative	1
6900	10499915	1493;3558	CTLA-4;interleukin 2	Upon T cell activation by cross-linking with anti-CD3 and anti-CD28 antibodies , ***CTLA-4*** engagement ***inhibited*** both proliferation and ***interleukin 2*** production in tyrosine mutants as well as in wild-type CTLA-4 transfectants .	negative	1
6901	10499915	1493;3558	CTLA-4;interleukin 2	Furthermore , the mutant ***CTLA-4*** lacking most of the cytoplasmic region strongly ***suppressed*** ***interleukin 2*** production as well .	negative	1
6902	10499915	1493;5781	CTLA-4;SHP-2	These data suggest that negative signals by CTLA-4 could be mediated through the membrane-proximal region of CTLA-4 but not through the YVKM motif and that the ***association*** of ***CTLA-4*** with ***SHP-2*** is not required for CTLA-4-mediated suppression of T cell activation .	parallel	0
6903	10500035	5054;2152	PAI-1;tissue factor	BACKGROUND : Recent reports link C. pneumoniae infection of arteriosclerotic lesions to the precipitation of acute coronary syndromes , which also feature ***tissue factor*** and plasminogen activator ***inhibitor*** 1 ( ***PAI-1*** ) overexpression .	negative	1
6904	10500044	7057;2247	TSP-1;FGF-2	They also identify 2 independent pathways by which ***TSP-1*** can ***block*** ***FGF-2*** and VEGF angiogenic signals on endothelial cells .	negative	0
6905	10500044	7057;7422	TSP-1;VEGF	They also identify 2 independent pathways by which ***TSP-1*** can ***block*** FGF-2 and ***VEGF*** angiogenic signals on endothelial cells .	negative	0
6906	10500079	6590;4790	SLPI;NF-kappaB	***SLPI*** also ***suppressed*** activation of the transcription factor ***NF-kappaB*** in liver .	negative	1
6907	10500113	6469;5727	Shh;Ptc	We favor the alternative , that ***Shh-N*** functions primarily as a ***ligand*** for the putative receptor Patched ( ***Ptc*** ) .	parallel	1
6908	10500113	6469;5727	Shh;Ptc	This possibility is supported by new evidence for direct ***binding*** of ***Shh-N*** to ***Ptc*** and by a strong correlation between the affinity of Ptc-binding and the signaling potency of Shh-N protein variants carrying alterations of conserved residues in a particular region of the protein surface .	parallel	1
6909	10500113	6469;5727	Shh;Ptc	These results together suggest that direct ***Shh-N*** ***binding*** to ***Ptc*** is a critical event in transduction of the Shh-N signal .	parallel	1
6910	10500146	8851;1020	p25;cdk5	Like other members of the cdk family , ***cdk5*** catalytic activity is ***influenced*** by both ***p25*** binding and phosphorylation .	target	0
6911	10500157	1386;595	ATF-2;cyclin D1	Both c-Jun and ***ATF-2*** ***transactivated*** the ***cyclin D1*** promoter in transient transfection experiments , and a clear additional increase was detected when ER was cotransfected with either c-Jun or with c-Jun and ATF-2 but not with ATF-2 alone .	positive	1
6912	10500157	3725;595	c-Jun;cyclin D1	Both ***c-Jun*** and ATF-2 ***transactivated*** the ***cyclin D1*** promoter in transient transfection experiments , and a clear additional increase was detected when ER was cotransfected with either c-Jun or with c-Jun and ATF-2 but not with ATF-2 alone .	positive	1
6913	10500157	1386;3725	ATF-2;c-Jun	We show that ATF-2 homodimers and ******ATF-2/c-Jun****** ***heterodimers*** , but not c-Jun homodimers , were able to bind the CRE of the cyclin D1 promoter .	parallel	1
6914	10500157	1386;595	ATF-2;cyclin D1	To interpret these results , we propose a mechanism in which ***ATF-2/c-Jun*** heterodimers bind to the CRE-D1 element and ***mediate*** the activation of ***cyclin D1*** promoter by the ER .	target	0
6915	10500157	3725;595	c-Jun;cyclin D1	To interpret these results , we propose a mechanism in which ***ATF-2/c-Jun*** heterodimers bind to the CRE-D1 element and ***mediate*** the activation of ***cyclin D1*** promoter by the ER .	target	0
6916	10500157	1386;3725	ATF-2;c-Jun	To interpret these results , we propose a mechanism in which ******ATF-2/c-Jun****** ***heterodimers*** bind to the CRE-D1 element and mediate the activation of cyclin D1 promoter by the ER .	parallel	1
6917	10500165	317;842	Apaf-1;caspase-9	Direct ***recruitment*** and activation of ***caspase-9*** by ***Apaf-1*** through the homophilic CARD/CARD ( Caspase Recruitment Domain ) interaction is critical for the activation of caspases downstream of mitochondrial damage in apoptosis .	target	0
6918	10500165	317;842	Apaf-1;caspase-9	On the basis of the identified functional residues of Apaf-1 CARD and the surface charge complementarity , we propose a model of CARD/CARD ***interaction*** between ***Apaf-1*** and ***caspase-9*** .	parallel	1
6919	10500180	7157;891	p53;cyclin B1	The detailed model could be used to explain various experiments relevant to G2DDC reported recently , including the nuclear export of 14-3-3-bound Cdc25 , the ***down-regulation*** of ***cyclin B1*** expression by ***p53*** , the effect of Chk1 and p53 on Cdc25 levels , and Wee1 degradation .	negative	1
6920	10500198	23529;3572	BSF-3;gp130	NNT-1 / ***BSF-3*** ***induces*** tyrosine phosphorylation of glycoprotein 130 ( ***gp130*** ) , leukemia inhibitory factor receptor beta , and signal transducer and activator of transcription 3 in the SK-N-MC human neuroblastoma cells .	target	1
6921	10500198	23529;6774	BSF-3;signal transducer and activator of transcription 3	NNT-1 / ***BSF-3*** ***induces*** tyrosine phosphorylation of glycoprotein 130 ( gp130 ) , leukemia inhibitory factor receptor beta , and ***signal transducer and activator of transcription 3*** in the SK-N-MC human neuroblastoma cells .	target	1
6922	10500199	6929;51384	E2A;WNT-16	Here , we show that the ***E2A-Pbx1*** fusion protein ***activates*** the expression of a novel WNT gene , ***WNT-16*** .	positive	1
6923	10500199	5087;51384	Pbx1;WNT-16	Here , we show that the ***E2A-Pbx1*** fusion protein ***activates*** the expression of a novel WNT gene , ***WNT-16*** .	positive	1
6924	10500210	387;7040	RhoA;TGFbeta	These data support the conclusion that ***TGFbeta*** signaling is ***regulated*** by ***RhoA*** GTPase and demonstrate a relationship between cholesterol metabolism and TGFbeta signaling .	target	1
6925	10500212	3606;3458	IL-18;interferon gamma	***IL-18*** ***binding*** and inhibition of ***interferon gamma*** induction by human poxvirus-encoded proteins .	parallel	1
6926	10500217	1387;4609	CREB-binding protein;MYC	The coadaptor ***CREB-binding protein*** ( CBP ) binds vIRF and ***synergizes*** transactivation of ***MYC*** , but , unexpectedly , closely related histone acetyltransferases p300 and P/CAF potently suppress vIRF transactivation .	parallel	0
6927	10500222	1393;1392	CRH-BP;CRH	The biological activity of ***CRH*** and other mammalian CRH-like peptides , such as urocortin , may be ***modulated*** by CRH-binding protein ( ***CRH-BP*** ) .	target	0
6928	10500232	6863;6869	substance P;NK1R	Although it is well established that ***substance P*** ( SP ) ***interacts*** with the neurokinin 1 receptor ( ***NK1R*** ) to initiate neurogenic inflammation , the mechanisms that terminate inflammation are unknown .	parallel	1
6929	10500258	1760;3552	DMPK;IL-1alpha	These results suggest that overexpression of ***DMPK*** in C2C12 cultures may ***up-regulate*** ***IL-1alpha*** expression , resulting in the induction of FN-H expression .	positive	1
6930	10500481	3667;3643	IRS-1;insulin receptor	Upon binding of insulin to cell-surface insulin receptor , the receptor phosphorylates tyrosine residues of ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) in the cell .	parallel	1
6931	10500494	4602;6667	MYB;Sp1	We observed no inhibition of the ***binding*** of ***Sp1*** , Maf , ***MYB*** and MYC .	parallel	1
6932	10500494	4609;4602	MYC;MYB	We observed no inhibition of the ***binding*** of Sp1 , Maf , ***MYB*** and ***MYC*** .	parallel	1
6933	10500494	4609;6667	MYC;Sp1	We observed no inhibition of the ***binding*** of ***Sp1*** , Maf , MYB and ***MYC*** .	parallel	1
6934	10501190	3827;3569	Bradykinin;interleukin-6	***Bradykinin*** ***induces*** ***interleukin-6*** expression in astrocytes through activation of nuclear factor-kappaB .	target	1
6935	10501190	3827;4790	Bradykinin;NF-kappaB	***Bradykinin*** ***activated*** ***NF-kappaB*** in primary astrocytes as shown by increased DNA binding of NF-kappaB .	positive	1
6936	10501191	497258;4760	BDNF;beta2	In neurons maintained in low K + medium ( 5 mM K + ) that will enter apoptosis , ***BDNF*** ***increases*** beta2-AR and ***beta2-AR*** transcripts .	positive	0
6937	10501212	836;1676	caspase-3;DFF45	DFF40 is typically bound to the 45-kDa subunit of DFF ( DFF45 ) , and activation of DFF40 may occur as a result of ***caspase-3-mediated*** ***cleavage*** of ***DFF45*** into 30 - and 11-kDa fragments .	target	1
6938	10501221	6285;4099	S100beta;myelin-associated glycoprotein	Calcium-dependent ***interaction*** between the large ***myelin-associated glycoprotein*** and ***S100beta*** .	parallel	1
6939	10501415	51056;2875	LAP;alanine aminotransferase	***LAP*** levels ***correlated*** positively with levels of lactate dehydrogenase , aspartate aminotransferase , ***alanine aminotransferase*** and gamma-glutamyl transpeptidase , and negatively with the total serum haemolytic complement and leucocyte , neutrophil and lymphocyte counts , but showed no correlation with alkaline phosphatase , gamma-globulin , beta2-microglobulin or C-reactive protein levels , or platelet count .	positive	0
6940	10501415	51056;92086	LAP;gamma-glutamyl transpeptidase	***LAP*** levels ***correlated*** positively with levels of lactate dehydrogenase , aspartate aminotransferase , alanine aminotransferase and ***gamma-glutamyl transpeptidase*** , and negatively with the total serum haemolytic complement and leucocyte , neutrophil and lymphocyte counts , but showed no correlation with alkaline phosphatase , gamma-globulin , beta2-microglobulin or C-reactive protein levels , or platelet count .	positive	0
6941	10502048	2321;7422	flt-1;vascular endothelial growth factor	***Vascular permeability factor/vascular endothelial growth factor*** ( VPF/VEGF ) and its ***receptor*** ***flt-1*** in microcystic meningiomas .	parallel	1
6942	10502286	348;351	apoE4;Abeta	The dissociation constant ( Kd ) values obtained for the specific ***binding*** of recombinant apoE2 , apoE3 , and ***apoE4*** to ***Abeta*** ( 1-42 ) were 48.1 + / - 2.2 nM , 63.7 + / - 2.1 nM , and 75.9 + / - 1.8 nM , respectively .	parallel	1
6943	10502286	348;351	apoE;Abeta	No basic difference was observed between lipidated and nonlipidated apoE in terms of the characteristics of the ***binding*** of ***apoE*** isoforms to ***Abeta*** ( 1-42 ) ; however , lipidation reduced the binding capacity of each isoform in a dose-dependent manner .	parallel	1
6944	10502297	7157;7153	p53;topoisomerase IIalpha	These results suggest that an epitope for topoisomerase IIalpha is concealed in cells expressing wild-type p53 and that a ***complex*** between ***topoisomerase IIalpha*** and ***p53*** may be disrupted by the addition of antitumor drugs .	parallel	1
6945	10502299	6464;1499	Shc;beta-catenin	However , ***Shc*** binding to cadherin did negatively ***influence*** ***beta-catenin*** binding to the same molecule .	negative	0
6946	10502410	4233;3082	c-met;HGF	Recently , much attention has been focused upon the role of hepatocyte growth factor ( ***HGF*** ) and its ***receptor*** ***c-met*** in the induction of tubulogenesis by epithelial cells .	parallel	1
6947	10502453	3458;3486	IFN-gamma;IGFBP-3	Previous studies have demonstrated that these inhibitory effects of RA , and the combination of TNFalpha and ***IFN-gamma*** are ***associated*** with increased accumulation of ***IGFBP-3*** in the culture medium of HSG cells .	parallel	0
6948	10502453	7124;3486	TNFalpha;IGFBP-3	Previous studies have demonstrated that these inhibitory effects of RA , and the combination of ***TNFalpha*** and IFN-gamma are ***associated*** with increased accumulation of ***IGFBP-3*** in the culture medium of HSG cells .	parallel	0
6949	10502458	2690;3716	growth hormone receptor;Jak1	The ***growth hormone receptor*** ***associates*** with ***Jak1*** , Jak2 and Tyk2 in human liver .	parallel	0
6950	10502458	2690;3717	growth hormone receptor;Jak2	The ***growth hormone receptor*** ***associates*** with Jak1 , ***Jak2*** and Tyk2 in human liver .	parallel	0
6951	10502458	2690;7297	growth hormone receptor;Tyk2	The ***growth hormone receptor*** ***associates*** with Jak1 , Jak2 and ***Tyk2*** in human liver .	parallel	0
6952	10502458	3716;2690	Jak1;GHR	Immunoprecipitation by an antibody against the GHR ( Mab 263 ) followed by immunoblotting with specific antibodies against Jak proteins showed that ***Jak1*** , Jak2 and Tyk2 were ***associated*** with the ***GHR*** in this tissue .	parallel	0
6953	10502458	3717;2690	Jak2;GHR	Immunoprecipitation by an antibody against the GHR ( Mab 263 ) followed by immunoblotting with specific antibodies against Jak proteins showed that Jak1 , ***Jak2*** and Tyk2 were ***associated*** with the ***GHR*** in this tissue .	parallel	0
6954	10502458	7297;2690	Tyk2;GHR	Immunoprecipitation by an antibody against the GHR ( Mab 263 ) followed by immunoblotting with specific antibodies against Jak proteins showed that Jak1 , Jak2 and ***Tyk2*** were ***associated*** with the ***GHR*** in this tissue .	parallel	0
6955	10502458	2690;3716	GHR;Jak1	We conclude that the ***GHR*** ***associates*** with ***Jak1*** , Jak2 and Tyk2 in human liver .	parallel	0
6956	10502458	2690;3717	GHR;Jak2	We conclude that the ***GHR*** ***associates*** with Jak1 , ***Jak2*** and Tyk2 in human liver .	parallel	0
6957	10502458	2690;7297	GHR;Tyk2	We conclude that the ***GHR*** ***associates*** with Jak1 , Jak2 and ***Tyk2*** in human liver .	parallel	0
6958	10502559	3458;4233	Interferon-gamma;hepatocyte growth factor receptor	***Interferon-gamma*** ***upregulates*** the ***c-Met/hepatocyte growth factor receptor*** expression in alveolar epithelial cells .	positive	1
6959	10502559	3458;4233	IFN-gamma;c-Met	We analyzed the mechanism of this upregulation and found that ***IFN-gamma*** ***enhances*** the transcription of the ***c-Met*** proto-oncogene , and that it does not prolong the stability of the c-Met mRNA .	positive	0
6960	10502560	940;941	CD28;CD80	***CD28*** ***interactions*** with either ***CD80*** or CD86 are sufficient to induce allergic airway inflammation in mice .	parallel	1
6961	10502560	940;942	CD28;CD86	***CD28*** ***interactions*** with either CD80 or ***CD86*** are sufficient to induce allergic airway inflammation in mice .	parallel	1
6962	10502561	7124;2920	TNF-alpha;MIP-2	These results suggest that LPS-induced ***MIP-2*** release from alveolar epithelial cells may be ***mediated*** in part by ***TNF-alpha*** from the same cell type .	target	0
6963	10502561	7124;2920	TNF-alpha;MIP-2	***TNF-alpha*** also ***induced*** ***MIP-2*** production from alveolar epithelial cells .	target	1
6964	10502725	1029;1019	p16;cdk4	On the other hand , high cdk4 levels in p16-positive tumors as compared with p16-negative tumors resulted in a positive ***association*** between ***p16*** and ***cdk4*** expression ( Chi squared = 5.98 ; p = 0.01 ) .	parallel	0
6965	10503767	1906;2353	Endothelin-1;c-fos	***Endothelin-1*** ***stimulates*** ***c-fos*** mRNA expression in C6 glioma cells via MAP kinase pathway .	positive	0
6966	10503877	4869;4691	B23;C23	In vivo ***interaction*** of ***nucleophosmin/B23*** and protein ***C23*** during cell cycle progression in HeLa cells .	parallel	1
6967	10503877	4869;4691	B23;C23	The ***association*** between ***nucleophosmin/B23*** and protein ***C23*** while being observed at interphase and cytokinesis , was not detected in prometaphase and metaphase cells .	parallel	0
6968	10503877	4869;4691	B23;C23	***Interactions*** of ***nucleophosmin/B23*** with ***C23*** not only could be found in cells in which nucleophosmin/B23 and C23 were both mainly localized to the nucleolus , but also in cells in which nucleophosmin/B23 and C23 had translocated from the nucleolus to the nucleoplasm during actinomycin D-induced cell growth inhibition .	parallel	1
6969	10503877	983;4869	cdc2;B23	The purified recombinant ***GST-B23*** being ***phosphorylated*** by prometaphase cell extracts ( nocodazole-arrested cells ) or ***cdc2*** kinase could still be co-immunoprecipitated with C23 .	target	1
6970	10503948	7040;1437	TGF-beta;GM-CSF	On the other hand , ***TGF-beta*** ***stimulated*** the expression of both MCP-I and ***GM-CSF*** , but suppressed M-CSF expression .	positive	0
6971	10503948	7040;1435	TGF-beta;M-CSF	On the other hand , ***TGF-beta*** stimulated the expression of both MCP-I and GM-CSF , but ***suppressed*** ***M-CSF*** expression .	negative	1
6972	10504052	4893;596	N-ras;Bcl-2	Mutated ***N-ras*** ***upregulates*** ***Bcl-2*** in human melanoma in vitro and in SCID mice .	positive	1
6973	10504052	4893;596	N-ras;Bcl-2	We found that mutated ***N-ras*** specifically ***upregulates*** the expression of the anti-apoptosis gene ***Bcl-2*** in two human melanoma cell lines in vitro and in SCID mice .	positive	1
6974	10504115	958;959	CD40;CD154	An important co-stimulatory pathway for most immune responses is mediated by the ***interaction*** of ***CD40*** on antigen-presenting cells with ***CD154*** ( CD40L ) on host T cells .	parallel	1
6975	10504200	814;627	CaM kinase IV;BDNF	This signaling pathway , which links calcium influx to the ***induction*** of ***BDNF*** via ***CaM kinase IV*** and CREB , is likely to be centrally involved in mediating long-term activity-dependent plasticity .	target	1
6976	10504230	2978;3000	GCAP;ROS-GC1	There are two GCAPs , 1 and 2 , which link the cyclase with phototransduction , and one ***CD-GCAP*** , which is predicted to ***link*** ***ROS-GC1*** with its retinal synaptic activity .	parallel	0
6977	10504261	5557;5558	p49;p58	Regulation of the ******p49-p58****** primase ***complex*** during primer synthesis and the interaction of the primase subunits with DNA were examined .	parallel	1
6978	10504261	5557;5558	p49;p58	This occurs within both the context of the four-subunit pol alpha-primase complex and in the ******p49-p58****** primase ***complex*** , indicating that the newly generated primer-template species need not interact with pol alpha to regulate further primase activity .	parallel	1
6979	10504261	5557;5558	p49;p58	Photo-cross-linking of single-stranded DNA-primase complexes revealed that whereas the isolated p49 and p58 subunits both reacted with DNA upon photolysis , only the p58 subunit reacted with the DNA when photolysis was performed using the ******p49-p58****** primase ***complex*** .	parallel	1
6980	10504300	654;90	BMP-6;ALK-2	These findings indicate that in the process of differentiation to osteoblasts , ***BMP-6*** ***binds*** to ***ALK-2*** as well as other type I receptors , and transduces signals mainly through Smad5 and possibly through Smad1 .	parallel	1
6981	10504300	654;90	BMP-6;activin receptor-like kinase (ALK)-2	The profile of binding of BMP-6 to type I and type II receptors was similar to that of OP-1 / BMP-7 in C2C12 cells and MC3T3-E1 cells ; ***BMP-6*** strongly ***bound*** to ***activin receptor-like kinase (ALK)-2*** ( also termed ActR-I ) , together with type II receptors , i.e.	parallel	1
6982	10504300	650;657	BMP-2;ALK-3	In addition , BMP-6 weakly bound to BMPR-IA ( ***ALK-3*** ) , to which ***BMP-2*** also ***bound*** .	parallel	1
6983	10504300	654;657	BMP-6;ALK-3	In addition , ***BMP-6*** weakly ***bound*** to BMPR-IA ( ***ALK-3*** ) , to which BMP-2 also bound .	parallel	1
6984	10504300	654;658	BMP-6;ALK-6	In contrast , ***binding*** of ***BMP-6*** to BMPR-IB ( ***ALK-6*** ) , and less efficiently to ALK-2 and BMPR-IA , together with BMPR-II was detected in ROB-C26 cells .	parallel	1
6985	10504300	654;4090	BMP-6;Smad5	Among the receptor-regulated Smads activated by BMP receptors , ***BMP-6*** strongly ***induced*** phosphorylation and nuclear accumulation of ***Smad5*** , and less efficiently those of Smad1 .	target	1
6986	10504338	3646;5987	Int-6;Ret finger protein	***Interaction*** between the ***Ret finger protein*** and the ***Int-6*** gene product and co-localisation into nuclear bodies .	parallel	1
6987	10504338	5987;3646	Rfp;Int-6	The ***interaction*** of ***Rfp*** with ***Int-6*** is mediated through a region in Rfp designated ' Rfp domain ' , distinct from that involved in the interaction with PML .	parallel	1
6988	10504338	5987;3646	Rfp;Int-6	Int-6 and Rfp are co-localised in certain PML nuclear bodies in lymphocytes and transfection studies in HeLa cells strongly suggest that ***Rfp*** ***triggers*** translocation of ***Int-6*** to nuclear bodies .	positive	0
6989	10504341	9088;983	Myt1;Cdc2	In conclusion , we propose that Myt1 can negatively regulate Cdc2/cyclin B1 and inhibit G ( 2 ) / M progression by two means , both of which require the C-terminal domain ; first , ***Myt1*** can ***bind*** and sequester ***Cdc2/cyclin B1*** in the cytoplasm preventing entry into the nucleus , and , second , it can phosphorylate associated Cdc2/cyclin B1 at Thr14 and Tyr15 thus inhibiting its catalytic activity .	parallel	1
6990	10504341	9088;891	Myt1;cyclin B1	In conclusion , we propose that Myt1 can negatively regulate Cdc2/cyclin B1 and inhibit G ( 2 ) / M progression by two means , both of which require the C-terminal domain ; first , ***Myt1*** can ***bind*** and sequester ***Cdc2/cyclin B1*** in the cytoplasm preventing entry into the nucleus , and , second , it can phosphorylate associated Cdc2/cyclin B1 at Thr14 and Tyr15 thus inhibiting its catalytic activity .	parallel	1
6991	10504341	9088;983	Myt1;Cdc2	In conclusion , we propose that ***Myt1*** can negatively ***regulate*** ***Cdc2/cyclin B1*** and inhibit G ( 2 ) / M progression by two means , both of which require the C-terminal domain ; first , Myt1 can bind and sequester Cdc2/cyclin B1 in the cytoplasm preventing entry into the nucleus , and , second , it can phosphorylate associated Cdc2/cyclin B1 at Thr14 and Tyr15 thus inhibiting its catalytic activity .	negative	1
6992	10504341	9088;891	Myt1;cyclin B1	In conclusion , we propose that ***Myt1*** can negatively ***regulate*** ***Cdc2/cyclin B1*** and inhibit G ( 2 ) / M progression by two means , both of which require the C-terminal domain ; first , Myt1 can bind and sequester Cdc2/cyclin B1 in the cytoplasm preventing entry into the nucleus , and , second , it can phosphorylate associated Cdc2/cyclin B1 at Thr14 and Tyr15 thus inhibiting its catalytic activity .	negative	1
6993	10504341	9088;983	Myt1;Cdc2	The C-terminal domain of the Cdc2 inhibitory kinase ***Myt1*** ***interacts*** with ***Cdc2*** complexes and is required for inhibition of G ( 2 ) / M progression .	parallel	1
6994	10504383	392;5921	RhoGAP;RasGAP	The ***interaction*** of ***RasGAP*** and p190 ***RhoGAP*** in two multiprotein complexes could constitute an additional level of Rho regulation during morphogenetic events of gastrulation .	parallel	1
6995	10504384	344148;2159	NAP5;factor Xa	***NAP5*** and NAP6 ***inhibit*** ***factor Xa*** by binding to its active site , whereas NAPc2 binds to factor Xa at a different , as yet unidentified , site and the resultant binary complex inhibits the tissue factor-factor VIIa complex .	negative	1
6996	10504438	3565;7133	IL-4;TNF-RII	After pretreating Langerhans cells with TNF-alpha , ***IL-4*** ***inhibited*** both the migration of Langerhans cells and the expression of ***TNF-RII*** in a time dependent manner .	negative	1
6997	10504441	5443;4790	Alpha-melanocyte-stimulating hormone;NF-kappaB	***Alpha-melanocyte-stimulating hormone*** ***inhibits*** ***NF-kappaB*** activation in human melanocytes and melanoma cells .	negative	1
6998	10504441	5970;4790	p65;p50	The transcription factor complex was positively identified as the ******p50/p65****** ***heterodimer*** , recognized to have transcriptional activating potential .	parallel	1
6999	10504447	3569;7020	interleukin-6;Activator protein-2	The ***interleukin-6-dependent*** ***induction*** of ***Activator protein-2*** mRNA was completely blocked by adding actinomycin D , whereas it was approximately 50 % affected by cycloheximide .	target	1
7000	10504447	3569;7020	interleukin-6;Activator protein-2	Furthermore , a gel mobility shift assay using the nuclear extracts from interleukin-6-treated cells showed that ***interleukin-6*** ***induced*** the functional ***Activator protein-2*** protein for the gene activation .	target	1
7001	10504456	3603;3559	interleukin-16;CD25	***interleukin-16*** expression ***correlated*** positively with the expression of interleukin-2 and its receptor ***CD25*** in individual skin lesions .	positive	0
7002	10504456	3603;3558	interleukin-16;interleukin-2	***interleukin-16*** expression ***correlated*** positively with the expression of ***interleukin-2*** and its receptor CD25 in individual skin lesions .	positive	0
7003	10504456	3559;3558	CD25;interleukin-2	interleukin-16 expression correlated positively with the expression of ***interleukin-2*** and its ***receptor*** ***CD25*** in individual skin lesions .	parallel	1
7004	10504469	6885;595	TAK1;cyclin D1	The ***cyclin D1*** protein level is ***reduced*** by the ***TAK1*** pathway .	negative	1
7005	10504469	5604;595	MKK1;cyclin D1	In contrast , overexpression of the active form of MKK1 , the classic MAPK-activator , ***MKK1*** ***increased*** ***cyclin D1*** promoter activity and protein level , as well as the percentages of S and G2/M phases .	positive	0
7006	10504483	355;356	Fas;Fas ligand	The data suggest that up-regulated RTC ***Fas*** ***binds*** to ***Fas ligand*** on adjacent RTCs , which then leads to RTC death by fratricide .	parallel	1
7007	10504487	7421;5741	Vitamin D receptor;parathyroid hormone	***Vitamin D receptor*** genotype ***influences*** ***parathyroid hormone*** and calcitriol levels in predialysis patients .	target	0
7008	10504488	7040;4088	TGF-beta1;Smad3	***TGF-beta1*** ***down-regulated*** ***Smad3*** mRNA and protein expression , respectively , after 4 and 24 hours of treatment , whereas Smad2 and Smad4 were less affected .	negative	1
7009	10504489	7124;5594	TNF-alpha;p38	Pretreatment with SB203580 ( 10 microM ) had no effect on basal or ***TNF-alpha-stimulated*** ***phosphorylation*** of ***p38*** MAPK but completely abolished TNF-alpha-stimulated p38 MAPK activity .	target	1
7010	10504490	5608;595	MKK6;cyclin D1	***cyclin D1*** and A promoter activity and cell cycle progression in renal tubular cells are negatively ***regulated*** by the ***TAK1-MKK6-p38K*** pathway and positively regulated by the MKK1-p42 / 44MAPK pathway .	negative	1
7011	10504490	5608;7040	MKK6;TGF-beta	CONCLUSION : The growth-inhibitory effects of ***TGF-beta*** are at least partially ***mediated*** by the ***TAK1-MKK6-p38K*** pathway .	target	0
7012	10504548	596;581	Bcl-2;Bax	These results imply that ***Bcl-2*** is ***associated*** with good prognostic markers and the regulation of ***Bax*** is complex and does not necessarily correlate with mutant p53 status in breast cancers .	parallel	0
7013	10505654	4914;4803	TrkA;nerve growth factor	Tyrosine kinase A ( ***TrkA*** ) , a high affinity ***receptor*** for ***nerve growth factor*** ( NGF ) , is activated during differentiation and regeneration of selective neuronal population .	parallel	1
7014	10505674	920;355	CD4;CD95	In a previous work , we found by co-capping that gp120 ( 451 ) and gp120MN , but not gp120 ( IIIB ) , induce lateral ***association*** of ***CD4*** with ***CD95*** on the T cell surface .	parallel	0
7015	10505674	3700;920	gp120;CD4	In a previous work , we found by co-capping that ***gp120*** ( 451 ) and gp120MN , but not gp120 ( IIIB ) , ***induce*** lateral association of ***CD4*** with CD95 on the T cell surface .	target	1
7016	10505674	355;920	CD95;CD4	In this work , we used fluorescence resonance energy transfer to confirm that ******CD4/CD95****** lateral ***association*** is induced by gp120 ( 451 ) , but not gp120 ( IIIB ) .	parallel	0
7017	10505674	3700;920	gp120;CD4	In this work , we used fluorescence resonance energy transfer to confirm that ***CD4/CD95*** lateral association is ***induced*** by ***gp120*** ( 451 ) , but not gp120 ( IIIB ) .	target	1
7018	10505674	3700;355	gp120;CD95	In this work , we used fluorescence resonance energy transfer to confirm that ***CD4/CD95*** lateral association is ***induced*** by ***gp120*** ( 451 ) , but not gp120 ( IIIB ) .	target	1
7019	10505674	3700;355	gp120;CD95	CD95 involvement in gp120-induced cell death was confirmed by showing that ***gp120*** ( 451 ) and gp120MN did not induce death in CD4 + T cells derived from patients with autoimmune/lymphoproliferative disease ( ALD ) and ***decreased*** ***CD95*** function .	negative	0
7020	10505674	920;355	CD4;CD95	These data suggest that the gp120-induced ******CD4/CD95****** ***association*** exerts a dual effect : an early effect that is independent of CD95L and may be due to direct triggering of CD95 by gp120 , and a late effect that may be due to sensitization of CD95 to triggering by CD95L .	parallel	0
7021	10505687	7040;7052	TGF-beta1;tissue transglutaminase	This study suggests that in the IPRK and in the absence of other exogenous growth factors , ***TGF-beta1*** selectively ***increases*** the synthesis of ECM and ***tissue transglutaminase*** without changes that would result in the reduction of ECM degradation .	positive	0
7022	10505688	624;623	B2R;B1R	In this study , the ***association*** between ***B1R*** and ***B2R*** polymorphisms and ESRD was examined using a family-based study design : transmission/disequilibrium test .	parallel	0
7023	10505689	7422;3791	VEGF;Flk-1	***VEGF*** ***induced*** upregulation of ***Flk-1*** and Flt-1 expression , as assessed by Western blot analysis .	target	1
7024	10505689	7422;2321	VEGF;Flt-1	***VEGF*** ***induced*** upregulation of Flk-1 and ***Flt-1*** expression , as assessed by Western blot analysis .	target	1
7025	10505717	4087;4089	Smad2;Smad4	Activated TbetaRI phosphorylates ***Smad2*** , which then ***heterodimerizes*** with ***Smad4*** , translocates into the nucleus , and subsequently effects gene transcription .	parallel	1
7026	10505717	7040;4087	TGF-beta1;Smad2	Furthermore , ***TGF-beta1*** ***increases*** steady-state levels of ***Smad2*** mRNA in the TGF-beta1-sensitive pancreatic cancer cell line COLO-357 .	positive	0
7027	10505738	4254;3815	stem cell factor;CD117	The c-kit receptor ( ***CD117*** ) and its ***ligand*** ***stem cell factor*** ( SCF ) play an important role in the development , differentiation , and survival of normal and malignant hematopoietic cells .	parallel	1
7028	10505744	3458;3455	IFN-gamma;interferon receptor	***Upregulation*** of type I ***interferon receptor*** by ***IFN-gamma*** .	positive	1
7029	10505751	885;6343	CCK;secretin	To examine the synergistic ***effect*** between ***CCK*** and ***secretin*** , the effect of CCK during a background secretin infusion was examined in LETO rats .	parallel	0
7030	10505752	3953;885	leptin receptor;CCK	These data demonstrate that the rat pancreatic tumor cell line AR42J expresses a functional form of the ***leptin receptor*** that ***modulates*** the action of ***CCK*** in calcium mobilization and amylase release .	target	0
7031	10505975	3458;4261	IFN-gamma;CIITA	Here we demonstrate that ***IFN-gamma*** treatment of rat astrocytes ***induces*** only ***CIITA*** promoter IV activity in contrast to the murine macrophage cell line RAW 264.7 that uses both IFN-gamma-inducible promoters .	target	1
7032	10505977	5443;4790	alpha-MSH;NF-kappaB	Electrophoretic mobility shift assays of nuclear extracts from the murine foot pad injected with TNF-alpha demonstrated that centrally administered ***alpha-MSH*** does ***inhibit*** ***NF-kappaB*** activation .	negative	1
7033	10505977	5443;4792	alpha-MSH;IkappaBalpha	Centrally administered ***alpha-MSH*** ***inhibited*** peripheral NF-kappaB activation and ***IkappaBalpha*** degradation even in mice with nonfunctional melanocortin 1 receptors ( MC1R ) .	negative	1
7034	10505977	5443;4790	alpha-MSH;NF-kappaB	Centrally administered ***alpha-MSH*** ***inhibited*** peripheral ***NF-kappaB*** activation and IkappaBalpha degradation even in mice with nonfunctional melanocortin 1 receptors ( MC1R ) .	negative	1
7035	10505977	5443;4790	alpha-MSH;NF-kappaB	These findings indicate that ***alpha-MSH*** can act centrally to ***inhibit*** ***NF-kappaB*** activation in peripheral acute inflammation via a descending neural pathway .	negative	1
7036	10506124	6519;11136	rBAT;BAT1	In the nonreducing condition , a 125-kDa band , which seems to correspond to the heterodimeric ***complex*** of ***BAT1*** and ***rBAT*** , was detected in rat kidney with anti-BAT1 antibody .	parallel	1
7037	10506127	8411;10228	EEA1;syntaxin-6	The Rab5 effector ***EEA1*** ***interacts*** directly with ***syntaxin-6*** .	parallel	1
7038	10506141	1045;2033	cdx-2;p300	In the present study , we investigated the ***interaction*** of ***cdx-2*** and pax-6 with ***p300*** , a co-activator coupled to the basal transcription machinery .	parallel	1
7039	10506141	5080;2033	pax-6;p300	In the present study , we investigated the ***interaction*** of cdx-2 and ***pax-6*** with ***p300*** , a co-activator coupled to the basal transcription machinery .	parallel	1
7040	10506141	2033;1045	p300;cdx-2	In transient transfection-expression experiments , we found that the transactivating effects of ***cdx-2*** and pax-6 on the Glucagon gene were greatly ***enhanced*** by the additional expression of ***p300*** .	positive	0
7041	10506141	2033;5080	p300;pax-6	In transient transfection-expression experiments , we found that the transactivating effects of cdx-2 and ***pax-6*** on the Glucagon gene were greatly ***enhanced*** by the additional expression of ***p300*** .	positive	0
7042	10506141	5080;2033	pax-6;p300	Further , we found that the presence of cdx-2 enhanced the ***interaction*** of ***pax-6*** with ***p300*** , thus establishing a molecular complex of transcription factors implicated in tissue-specific Glucagon gene expression with the basal transcriptional machinery .	parallel	1
7043	10506141	1045;5080	cdx-2;pax-6	Further , we found that the presence of ***cdx-2*** ***enhanced*** the interaction of ***pax-6*** with p300 , thus establishing a molecular complex of transcription factors implicated in tissue-specific Glucagon gene expression with the basal transcriptional machinery .	positive	0
7044	10506143	5599;3725	JNK1;c-Jun	Transient transfection assays demonstrated that the ***JNKK2-JNK1*** fusion protein was sufficient to ***stimulate*** ***c-Jun*** transcriptional activity in the absence of any stimulus .	positive	0
7045	10506143	5609;3725	JNKK2;c-Jun	Transient transfection assays demonstrated that the ***JNKK2-JNK1*** fusion protein was sufficient to ***stimulate*** ***c-Jun*** transcriptional activity in the absence of any stimulus .	positive	0
7046	10506143	5601;3725	Jun kinase;c-Jun	The JNKK2-JNK1 fusion protein acts as a constitutively active ***c-Jun kinase*** that ***stimulates*** ***c-Jun*** transcription activity .	positive	0
7047	10506143	5609;5599	JNKK2;JNK1	Immunoblotting analysis indicated that ***JNK1*** was ***phosphorylated*** by ***JNKK2*** in the fusion protein on both Thr ( 183 ) and Tyr ( 185 ) residues .	target	1
7048	10506145	7124;3383	TNF-alpha;ICAM-1	To determine which MAPK signaling pathway is required for ***TNF-alpha*** ***induction*** of ***ICAM-1*** expression , we have utilized the protein kinase inhibitor dimethylaminopurine , demonstrating that treatment of Sertoli cells with such compound significantly reduced ICAM-1 expression and JNK/SAPK activation .	target	1
7049	10506145	7124;3383	TNF-alpha;ICAM-1	Altogether our results demonstrate that ***TNF-alpha*** ***up-regulates*** ***ICAM-1*** expression through the activation of the JNK/SAPK transduction pathway mediated by the p55 receptor .	positive	1
7050	10506155	2534;4684	Fyn;NCAM	In the rafts , ***Fyn*** kinase is tightly ***associated*** with ***NCAM*** 120 and F3 .	parallel	0
7051	10506168	6670;6667	Sp3;Sp1	Electrophoretic gel shift analysis demonstrates binding of specific DNA-protein complexes to the Sp1 and AP-2 sites : Sp1 and ***Sp3*** ***bind*** to the ***Sp1*** site , while the AP-2 transcription factor binds the AP-2 element .	parallel	1
7052	10506169	3458;5743	interferon gamma;cyclooxygenase-2	***Regulation*** of ***cyclooxygenase-2*** by ***interferon gamma*** and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells .	target	1
7053	10506169	7039;5743	transforming growth factor alpha;cyclooxygenase-2	***Regulation*** of ***cyclooxygenase-2*** by interferon gamma and ***transforming growth factor alpha*** in normal human epidermal keratinocytes and squamous carcinoma cells .	target	1
7054	10506169	3458;5743	IFN-gamma;COX-2	Activation of the epidermal growth factor receptor ( EGFR ) signaling pathway due to the enhanced transforming growth factor alpha ( TGFalpha ) expression plays an important role in the ***induction*** of ***COX-2*** by ***IFN-gamma*** .	target	1
7055	10506169	5594;5743	p38;COX-2	These results suggest that the ***p38*** MAPK signaling pathway ***controls*** ***COX-2*** at the level of mRNA stability , while the ERK signaling pathway regulates COX-2 at the level of transcription .	target	0
7056	10506169	5594;5743	ERK;COX-2	These results suggest that the p38 MAPK signaling pathway controls COX-2 at the level of mRNA stability , while the ***ERK*** signaling pathway ***regulates*** ***COX-2*** at the level of transcription .	target	1
7057	10506190	23533;5294	p101;p110gamma	Gbetagamma efficiently and potently ( EC ( 50 ) , 5 nM ) activated the ******p101/p110gamma****** ***heterodimer*** but negligibly stimulated the p110gamma monomer to form PI-3,4,5-trisphosphate .	parallel	1
7058	10506190	5294;5266	PI3K;PI-3	This finding is in accordance with the in vivo situation , where activated ***PI3K*** ***catalyzes*** the formation of ***PI-3,4,5-trisphosphate*** but not PI-3-phosphate .	positive	1
7059	10506192	27040;7535	Lat;ZAP-70	***Lat*** , a prominent in vivo ***substrate*** of ***ZAP-70*** that mediates assembly of multimolecular signaling complexes at the plasma membrane of T cells was also found to be required for TCR-stimulated Itk activation .	parallel	1
7060	10506207	1999;2346	ESE-1;PSMA	In contrast , ***ESE-1*** ***transactivates*** the keratinocyte-specific SPRR2A promoter Ets site and the prostate-specific ***PSMA*** promoter significantly better than ESE-2 .	positive	1
7061	10506207	1999;6700	ESE-1;SPRR2A	In contrast , ***ESE-1*** ***transactivates*** the keratinocyte-specific ***SPRR2A*** promoter Ets site and the prostate-specific PSMA promoter significantly better than ESE-2 .	positive	1
7062	10506207	2001;140683	ESE-2;PSP	Thus , ***ESE-2*** , but not ESE-1 , ***transactivates*** the parotid gland-specific ***PSP*** promoter and the prostate-specific PSA promoter .	positive	1
7063	10506210	5499;5925	PP1alpha;pRB	In conjunction with earlier studies , these results indicate that ***PP1alpha*** may ***control*** ***pRB*** function throughout the cell cycle .	target	0
7064	10506210	5499;5925	PP1alpha;pRB	In addition , our new results suggest that different subpopulations of PP1alpha regulate the G ( 1 ) / S and G ( 2 ) / M transitions and that ***PP1alpha*** ***complexed*** to ***pRB*** requires inhibitory phosphorylation by G ( 1 ) - specific Cdks in order to prevent untimely reactivation of pRB and permit transition from G ( 1 ) - to S-phase and/or complete S-phase .	parallel	1
7065	10506210	1017;5499	Cdk2;PP1alpha	Inhibition of ***Cdk2*** led to a small increase in PP1 activity and also ***prevented*** ***PP1alpha*** phosphorylation .	positive	0
7066	10506210	5499;1017	PP1alpha;Cdk2	In vitro , ***PP1alpha*** was a ***substrate*** for ***Cdk2*** but not Cdk4 .	parallel	1
7067	10506213	23336;1674	synemin;desmin	Molecular interaction studies demonstrate that purified ***synemin*** ***interacts*** with ***desmin*** , the major IF protein in mature muscle cells , and with alpha-actinin , an integral myofibrillar Z-line protein .	parallel	1
7068	10506215	4792;596	IkappaBalpha;Bcl-2	Furthermore , adenovirus-mediated delivery of an ***IkappaBalpha*** mutant to prevent NFkappaB activation ***impaired*** the ability of ***Bcl-2*** to suppress apoptosis provoked by TNFalpha plus cycloheximide in ventricular myocytes .	negative	0
7069	10506215	596;4792	Bcl-2;IkappaBalpha	The data provide the first evidence for the ***regulation*** of ***IkappaBalpha*** by ***Bcl-2*** through a mechanism that requires the conserved BH4 domain that links Bcl-2 to the NFkappaB signaling pathway for suppression of apoptosis .	target	1
7070	10506215	596;4790	Bcl-2;NFkappaB	The data provide the first evidence for the regulation of IkappaBalpha by Bcl-2 through a mechanism that requires the conserved BH4 domain that ***links*** ***Bcl-2*** to the ***NFkappaB*** signaling pathway for suppression of apoptosis .	parallel	0
7071	10506216	22941;9229	Shank;GKAP	***Shank*** directly ***interacts*** with ***GKAP*** and Homer , thus potentially bridging the N-methyl-D-aspartate receptor-PSD-95-GKAP complex and the mGluR-Homer complex in synapses ( Naisbitt , S. , Kim , E. , Tu , J.	parallel	1
7072	10506216	22941;9456	Shank;Homer	***Shank*** directly ***interacts*** with GKAP and ***Homer*** , thus potentially bridging the N-methyl-D-aspartate receptor-PSD-95-GKAP complex and the mGluR-Homer complex in synapses ( Naisbitt , S. , Kim , E. , Tu , J.	parallel	1
7073	10506216	9229;1742	GKAP;PSD-95	Shank directly interacts with GKAP and Homer , thus potentially bridging the N-methyl-D-aspartate ******receptor-PSD-95-GKAP****** ***complex*** and the mGluR-Homer complex in synapses ( Naisbitt , S. , Kim , E. , Tu , J.	parallel	1
7074	10506221	7157;581	p53;Bax	Overexpression of the anti-apoptotic protein Bcl-2 in MCF-7 cells inhibited SST-induced apoptosis upstream of acidification by inhibiting ***p53-dependent*** ***induction*** of ***Bax*** as well as by raising the resting pH ( i ) and attenuating SST-induced decrease in pH ( i ) .	target	1
7075	10506225	3725;1026	c-Jun;p21	By utilizing the same assay , we found that the glutamine-rich segment of the B domain of Sp1 ( Bc , amino acids 424-542 ) was sufficient for ***c-Jun-induced*** ***transactivation*** of the ***p21*** promoter .	positive	1
7076	10506225	3725;1026	c-Jun;p21	***c-Jun*** ***transactivates*** the promoter of the human ***p21*** ( WAF1/Cip1 ) gene by acting as a superactivator of the ubiquitous transcription factor Sp1 .	positive	1
7077	10506225	3725;1026	c-Jun;p21	In the present study we show that the Sp1-occupied promoter region mediates ***transactivation*** of the ***p21*** promoter by ***c-Jun*** and the related proteins JunB , JunD , and ATF-2 .	positive	1
7078	10506481	183;5155	Angiotensin II;platelet-derived growth factor-B chain	***Angiotensin II*** ***stimulates*** ***platelet-derived growth factor-B chain*** expression in newborn rat vascular smooth muscle cells and neointimal cells through Ras , extracellular signal-regulated protein kinase , and c-Jun N-terminal protein kinase mechanisms .	positive	0
7079	10506481	183;5155	Angiotensin II;PDGF-B chain	In the present study , we demonstrate that ***Angiotensin II*** ( Ang II ) , which is also implicated in vascular stenosis after angioplasty and atherosclerosis , markedly ***stimulates*** ***PDGF-B chain*** mRNA expression in cultured newborn rat medial VSMCs and neointimal VSMCs via an AT ( 1 ) , but not in adult rat VSMCs .	positive	0
7080	10506521	1634;7040	Decorin;TGF-beta	In this study , we aimed to demonstrate significant inhibition of fibrogenesis , glial scarring , and inflammation in penetrating incisional wounds of the rat brain using the proteoglycan ***Decorin*** , which effectively ***inhibits*** ***TGF-beta*** activity .	negative	1
7081	10506573	8802;7852	Galpha;CXCR4	Here we demonstrate that SDF-1alpha activation promotes the physical ***association*** of ***Galpha*** ( i ) with the ***CXCR4*** .	parallel	0
7082	10506573	3717;7852	JAK2;CXCR4	After SDF-1alpha binding , ***JAK2*** and JAK3 ***associate*** with ***CXCR4*** and are activated , probably by transphosphorylation , in a Galpha ( i ) - independent manner .	parallel	0
7083	10506580	1490;7045	Connective tissue growth factor;transforming growth factor beta-induced	***Connective tissue growth factor*** ***mediates*** ***transforming growth factor beta-induced*** collagen synthesis : down-regulation by cAMP .	target	0
7084	10506632	3479;3486	insulin-like growth factor 1;insulin-like growth factor-binding protein 3	PURPOSE : To evaluate and quantify the ***association*** between consumption of specific food groups/macronutrients and concentrations of serum ***insulin-like growth factor 1*** ( IGF-1 ) and ***insulin-like growth factor-binding protein 3*** ( IGFBP-3 ) .	parallel	0
7085	10506696	5054;1508	PAI-1;Cathepsin B	BACKGROUND : ***Cathepsin B*** ( CATB ) and cathepsin L ( CATL ) , which are cysteine proteases , urokinase - ( UPA ) and tissue-type plasminogen activator ( TPA ) , both serine proteases , and their ***inhibitor*** type-1 ( ***PAI-1*** ) are believed to play an important role in colorectal carcinoma ( CRC ) invasion and metastasis .	negative	1
7086	10506696	1514;5054	CATL;PAI-1	CATB and ***CATL*** significantly ***correlated*** with UPA and ***PAI-1*** .	parallel	0
7087	10506722	3791;7422	KDR;VEGF	***KDR*** is a ***receptor*** for the various ***VEGF*** isoforms and for VEGF-C ; Flt-1 is a receptor for the various isoforms .	parallel	1
7088	10506725	7035;2152	TFPI;Tissue factor	***Tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) is a strong biologic inhibitor of TF .	negative	1
7089	10506927	960;5925	CD44;pRb	In the group of invasive carcinomas , ***CD44*** expression was statistically ***correlated*** with ***pRb*** ( p = 0.011 ) , while in preinvasive lesions it was correlated with PCNA ( p = 0.016 ) .	parallel	0
7090	10507321	3383;3689	ICAM-1;Mac-1	***ICAM-1*** ***binds*** to leukocyte function-associated antigen ( LFA-1 ) or macrophage-1 antigen ( ***Mac-1*** ) .	parallel	1
7091	10507550	627;5594	Brain-Derived Neurotrophic Factor;ERK	***Brain-Derived Neurotrophic Factor*** ( BDNF ) was used to ***stimulate*** ***ERK*** in hippocampal slices prepared from PN5 pups and activation and cellular localization was determined with immunofluorescence combined with confocal microscopy .	positive	0
7092	10507603	1401;7124	CRP;TNF-alpha	MEASUREMENTS AND MAIN RESULTS : ***CRP*** and PCT were both significantly ***correlated*** with ***TNF-alpha*** and IL-6 .	parallel	0
7093	10508165	4609;894	Myc;cyclin D2	Direct ***induction*** of ***cyclin D2*** by ***Myc*** contributes to cell cycle progression and sequestration of p27 .	target	1
7094	10508165	5715;1017	p27;Cdk2	Ectopic expression of Myc induces Cdk2 kinase activity in quiescent cells and antagonizes ***association*** of ***p27*** ( kip1 ) with ***Cdk2*** .	parallel	0
7095	10508165	4609;5715	Myc;p27	Ectopic expression of ***Myc*** induces Cdk2 kinase activity in quiescent cells and ***antagonizes*** association of ***p27*** ( kip1 ) with Cdk2 .	negative	1
7096	10508165	4609;1017	Myc;Cdk2	Ectopic expression of ***Myc*** ***induces*** ***Cdk2*** kinase activity in quiescent cells and antagonizes association of p27 ( kip1 ) with Cdk2 .	target	1
7097	10508165	1019;894	Cdk4;cyclin D2	We now show that p27 is rapidly and transiently sequestered by ******cyclin D2-Cdk4****** ***complexes*** upon activation of Myc and that cyclin D2 is a direct target gene of Myc .	parallel	1
7098	10508165	4149;4084	Max;Mad	The cyclin D2 promoter is repressed by ******Mad-Max****** ***complexes*** and de-repressed by Myc via a single highly conserved E-box element .	parallel	1
7099	10508165	4084;894	Mad;cyclin D2	The ***cyclin D2*** promoter is ***repressed*** by ***Mad-Max*** complexes and de-repressed by Myc via a single highly conserved E-box element .	negative	1
7100	10508165	4149;894	Max;cyclin D2	The ***cyclin D2*** promoter is ***repressed*** by ***Mad-Max*** complexes and de-repressed by Myc via a single highly conserved E-box element .	negative	1
7101	10508179	910;821	CD1b;calnexin	In beta ( 2 ) m-deficient FO-1 cells , we found ***CD1b*** heavy chains ( HC ) ***complexed*** with the chaperones ***calnexin*** and calreticulin , while MHC class I HC associated only with calnexin .	parallel	1
7102	10508179	910;811	CD1b;calreticulin	In beta ( 2 ) m-deficient FO-1 cells , we found ***CD1b*** heavy chains ( HC ) ***complexed*** with the chaperones calnexin and ***calreticulin*** , while MHC class I HC associated only with calnexin .	parallel	1
7103	10508199	949;4018	SR-BI;lipoprotein	Scavenger receptor BI ( ***SR-BI*** ) ***mediates*** selective uptake of high density ***lipoprotein*** ( HDL ) cholesteryl ester in the liver and adrenal gland .	target	0
7104	10508199	5443;949	ACTH;SR-BI	By contrast , uncontrolled stress or supplemental ***ACTH*** treatment ***increased*** ***SR-BI*** levels but narrowed the difference in SR-BI expression between apoA-I0 and wild-type .	positive	0
7105	10508211	5604;3949	Mek-1;LDL receptor	Critical role of p42/44 ( MAPK ) activation in anisomycin and hepatocyte growth factor-induced LDL receptor expression : activation of ***Raf-1/Mek-1/p42*** / 44 ( MAPK ) cascade alone is sufficient to ***induce*** ***LDL receptor*** expression .	target	1
7106	10508211	5894;3949	Raf-1;LDL receptor	Critical role of p42/44 ( MAPK ) activation in anisomycin and hepatocyte growth factor-induced LDL receptor expression : activation of ***Raf-1/Mek-1/p42*** / 44 ( MAPK ) cascade alone is sufficient to ***induce*** ***LDL receptor*** expression .	target	1
7107	10508219	7057;961	thrombospondin-1;integrin-associated protein	Co-expression of ***integrin-associated protein*** ( IAP/CD47 ) and its ***ligand*** ***thrombospondin-1*** on human granulosa and large luteal cells .	parallel	1
7108	10508219	7057;961	thrombospondin-1;IAP	The expression of ***thrombospondin-1*** ( TSP-1 ) , which is a ***ligand*** for ***IAP*** , was also observed in human GC by immunocytochemistry and RT-PCR .	parallel	1
7109	10508240	3586;3458	IL-10;IFN-gamma	***IL-10*** ***enhances*** NK cell proliferation , cytotoxicity and production of ***IFN-gamma*** when combined with IL-18 .	positive	0
7110	10508268	6367;1233	ABCD-1;CCR4	Both ***ABCD-1*** and ABCD-2 ***bind*** to the same receptor ( ***CCR4*** ) .	parallel	1
7111	10508268	6361;1233	ABCD-2;CCR4	Both ABCD-1 and ***ABCD-2*** ***bind*** to the same receptor ( ***CCR4*** ) .	parallel	1
7112	10508269	356;4790	FasL;NF-kappaB	Our results demonstrate the essential role of NF-kappaB for the expression of the death receptor ligand FasL , and suggest a direct ***link*** between ***NF-kappaB*** activation and the expression of ***FasL*** .	parallel	0
7113	10508274	958;5599	CD40;JNK	In human B cells , antigen receptor ligation and ***CD40*** ligation are known to ***activate*** the extracellular-regulated kinases ( ERK ) and c-Jun N-terminal kinase ( ***JNK*** ) pathways , which in turn regulate many important B cell functions .	positive	1
7114	10508274	958;5594	CD40;p38	Here , we demonstrate that another SAPK , ***p38/Hog1*** , is ***activated*** by both antigen receptor ligation or ***CD40*** ligation in a human B-lymphoblastoid cell line and tonsillar B cells .	positive	1
7115	10508274	958;5599	CD40;JNK1	Wortmannin , an inhibitor of phosphatidylinositol 3-kinase , partially inhibited ERK2 and p38 activation triggered through the B cell receptor whereas ***activation*** of ***JNK1*** and p38 through ***CD40*** was not affected .	positive	1
7116	10508274	958;5594	CD40;p38	Wortmannin , an inhibitor of phosphatidylinositol 3-kinase , partially inhibited ERK2 and p38 activation triggered through the B cell receptor whereas ***activation*** of JNK1 and ***p38*** through ***CD40*** was not affected .	positive	1
7117	10508274	958;5599	CD40;JNK	Thus , the B cell receptor and ***CD40*** ***recruit*** the ERK , ***JNK*** and p38 pathways by using different upstream effectors .	target	0
7118	10508274	958;5594	CD40;p38	Thus , the B cell receptor and ***CD40*** ***recruit*** the ERK , JNK and ***p38*** pathways by using different upstream effectors .	target	0
7119	10508278	156;719	GRK2;C3aR	Overexpression of ***GRK2*** , GRK3 , GRK5 or GRK6 together with C3aR in COS-7 cells ***enhanced*** the C3a-induced ***C3aR*** phosphorylation 1.5 - 1.9-fold ( p < 0.05 ) , but each kinase reduced ligand-stimulated phospholipase C activity differently .	positive	0
7120	10508278	157;719	GRK3;C3aR	Overexpression of GRK2 , ***GRK3*** , GRK5 or GRK6 together with C3aR in COS-7 cells ***enhanced*** the C3a-induced ***C3aR*** phosphorylation 1.5 - 1.9-fold ( p < 0.05 ) , but each kinase reduced ligand-stimulated phospholipase C activity differently .	positive	0
7121	10508278	2869;719	GRK5;C3aR	Overexpression of GRK2 , GRK3 , ***GRK5*** or GRK6 together with C3aR in COS-7 cells ***enhanced*** the C3a-induced ***C3aR*** phosphorylation 1.5 - 1.9-fold ( p < 0.05 ) , but each kinase reduced ligand-stimulated phospholipase C activity differently .	positive	0
7122	10508278	2870;719	GRK6;C3aR	Overexpression of GRK2 , GRK3 , GRK5 or ***GRK6*** together with C3aR in COS-7 cells ***enhanced*** the C3a-induced ***C3aR*** phosphorylation 1.5 - 1.9-fold ( p < 0.05 ) , but each kinase reduced ligand-stimulated phospholipase C activity differently .	positive	0
7123	10508278	156;719	GRK2;C3aR	Conversely , antibody-mediated inhibition of endogenous ***GRK2*** and GRK3 significantly ***inhibited*** ***C3aR*** phosphorylation in permeabilized cells .	positive	1
7124	10508278	157;719	GRK3;C3aR	Conversely , antibody-mediated inhibition of endogenous GRK2 and ***GRK3*** significantly ***inhibited*** ***C3aR*** phosphorylation in permeabilized cells .	positive	1
7125	10508279	22853;9625	lmr2;lmr1	Employing a strategy to identify loci that interact , we show here that ***lmr1*** and ***lmr2*** ***interact*** synergistically , and we describe a new locus lmr3 , lying on the X chromosome , whose effect depends on a specific lmr1 haplotype .	parallel	1
7126	10508403	8811;51083	GalR2;galanin	Membrane cholesterol modulates ******galanin-GalR2****** ***interaction*** .	parallel	1
7127	10508403	8811;51083	GalR2;galanin	The role that membrane cholesterol plays in modulating the ***interaction*** between ***galanin*** and one of the three cloned galanin receptor subtypes ( ***GalR2*** ) expressed in Chinese hamster ovary ( CHO ) cells was examined .	parallel	1
7128	10508403	51083;8811	galanin;GalR2	The inability of some of these analogues to rescue the binding activity also suggests that ***binding*** of ***galanin*** to ***GalR2*** is independent of membrane fluidity as , like cholesterol , cholesterol analogues generally rigidize membranes .	parallel	1
7129	10508403	51083;8811	galanin;GalR2	In addition , treatment of the membranes with other modulators of membrane fluidity , e.g. ethanol , did not affect ***galanin*** ***binding*** to the ***GalR2*** .	parallel	1
7130	10508486	999;3479	E-cadherin;IGF-I	Integrins and ***E-cadherin*** ***cooperate*** with ***IGF-I*** to induce migration of epithelial colonic cells .	parallel	0
7131	10508488	7040;1026	TGF-beta;p21	In gastric-cancer cells , SNU16 , ***TGF-beta*** treatment ***induced*** enhanced expression of ***p21*** ( WAF1/CIP1 ) ( p21 ) , which inhibited the kinase activity of cyclin-D - and cyclin-E-associated Cdks and blocked p130 phosphorylation .	target	1
7132	10508488	7040;5934	TGF-beta;p130	***TGF-beta*** also ***enhanced*** the stability of ***p130*** , suggesting that hypophosphorylation of p130 and increased stability of p130 contribute to p130-mediated G ( 1 ) arrest in gastric-cancer cells .	positive	0
7133	10508495	1956;6774	ErbB-1;stat 3	In this report , we demonstrate that ***stat 3*** is constitutively ***activated*** in these cells by the TGF-alpha-stimulated ***ErbB-1*** / -2 heterodimer complex .	positive	1
7134	10508515	889;5906	KRIT1;RAP1A	Here we report a physical and transcriptional map of this interval and that CCM1 , a gene whose protein product , ***KRIT1*** , ***interacts*** with ***RAP1A*** ( also known as KREV1 ; ref .	parallel	1
7135	10508522	2130;7040	EWSR1;TGF-beta	Introduction of ***EWSR1-FLI1*** into cells lacking the EWSR1-FLI1 fusion ***suppresses*** ***TGF-beta*** RII expression , whereas antisense to EWSR1-FLI1 in ES cell lines positive for this gene fusion restores TGF-beta RII expression .	negative	1
7136	10508522	2313;7040	FLI1;TGF-beta	Introduction of ***EWSR1-FLI1*** into cells lacking the EWSR1-FLI1 fusion ***suppresses*** ***TGF-beta*** RII expression , whereas antisense to EWSR1-FLI1 in ES cell lines positive for this gene fusion restores TGF-beta RII expression .	negative	1
7137	10508588	388;5585	rhoB;PRK1	We have recently demonstrated that ***rhoB*** ***binds*** the RhoA effector , ***PRK1*** and targets it to the endosomal compartment [ 7 ] .	parallel	1
7138	10508588	388;1956	rhoB;epidermal growth factor receptor	***Regulation*** of ***epidermal growth factor receptor*** traffic by the small GTPase ***rhoB*** .	target	1
7139	10508646	8826;1499	IQGAP1;beta-catenin	***IQGAP1*** , an effector of Cdc42 and Rac1 , ***interacts*** with cadherin and ***beta-catenin*** and induces the dissociation of alpha-catenin from the cadherin-catenins complex leading to disruption of cell-cell adhesion : activated Cdc42 and Rac1 counteract the effect of IQGAP1 .	parallel	1
7140	10508857	2066;6777	ErbB4;Stat5	When expressed transiently in 293T cells , ***ErbB4*** ***induced*** phosphorylation of ***Stat5*** .	target	1
7141	10508858	5328;5329	uPA;uPAR	These results indicate that dormancy of low uPAR cells may be the consequence of insufficient ******uPA/uPAR/alpha5beta1****** ***complexes*** , which can not induce ERK1/2 activity above a threshold needed to sustain tumor growth in vivo .	parallel	1
7142	10508860	5663;3725	Presenilin 1;c-Jun	***Presenilin 1*** ***suppresses*** the function of ***c-Jun*** homodimers via interaction with QM/Jif -1 .	negative	1
7143	10508920	6502;6500	Skp2;Skp1	The F-box protein ***Skp2*** is important for S phase entry and ***binds*** to ***Skp1*** and the cyclin A-Cdk2 complex .	parallel	1
7144	10509034	3815;4254	c-kit;Stem cell factor	BACKGROUND AND OBJECTIVE : ***Stem cell factor*** ( SCF ) , and its ***receptor*** ( ***c-kit*** ) play key roles in the expansion and differentiation of hematopoietic progenitor cells , in melanoblasts and primordial germ cells , making it possible that SCF and c-kit are involved in neoplastic processes deriving from these cells .	parallel	1
7145	10509034	4254;3815	SCF;c-kit	RESULTS : In vitro ***SCF*** stimulation ***induces*** ***c-kit*** down-regulation ; this phenomenon could be connected with receptor internalization , and new protein synthesis is necessary for its re-expression .	target	1
7146	10509378	1020;4744	Cyclin dependent kinase-5;neurofilament heavy	***Cyclin dependent kinase-5*** ( cdk-5 ) ***phosphorylates*** ***neurofilament heavy*** ( NF-H ) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis ( ALS ) and is present in affected motor neurones in ALS .	target	1
7147	10509807	7040;3486	TGF-beta1;IGFBP-3	IGF-I increased IGFBP-3 , IGFBP-2 and decreased IGFBP-4 , while ***TGF-beta1*** ***decreased*** ***IGFBP-3*** and apparently increased IGFBP-4 .	negative	0
7148	10509807	7040;3487	TGF-beta1;IGFBP-4	IGF-I increased IGFBP-3 , IGFBP-2 and decreased IGFBP-4 , while ***TGF-beta1*** decreased IGFBP-3 and apparently ***increased*** ***IGFBP-4*** .	positive	0
7149	10509807	3479;3485	IGF-I;IGFBP-2	***IGF-I*** ***increased*** IGFBP-3 , ***IGFBP-2*** and decreased IGFBP-4 , while TGF-beta1 decreased IGFBP-3 and apparently increased IGFBP-4 .	positive	0
7150	10509807	3479;3486	IGF-I;IGFBP-3	***IGF-I*** ***increased*** ***IGFBP-3*** , IGFBP-2 and decreased IGFBP-4 , while TGF-beta1 decreased IGFBP-3 and apparently increased IGFBP-4 .	positive	0
7151	10509807	3479;3487	IGF-I;IGFBP-4	***IGF-I*** ***increased*** IGFBP-3 , IGFBP-2 and decreased ***IGFBP-4*** , while TGF-beta1 decreased IGFBP-3 and apparently increased IGFBP-4 .	positive	0
7152	10509819	1378;718	CR1;C3b	We have determined that ( 1 ) VCP requires all four SCRs to bind C3b , ( 2 ) whereas ***CR1*** ***binds*** ***C3b*** and iC3b , VCP binds C3b but not iC3b , and ( 3 ) although normally secreted , if expressed on the membrane of mammalian cells , VCP effectively protects the cells from complement-mediated lysis .	parallel	1
7153	10510146	966;5972	min-1;renin	Phenylephrine 0.5 microg kg-1 ***min-1*** produced very similar haemodynamic effects to L-NMMA , and also ***suppressed*** the ***renin*** response to frusemide ( 1.43 + / -0.290 vs 2.67 + / -0.342 ng ml-1 h-1 P < 0 .	negative	1
7154	10510187	1839;2066	heparin-binding epidermal growth factor;ErbB4	***heparin-binding epidermal growth factor*** ( HB-EGF ) ***interacts*** with both EGF-R and a related receptor , ***ErbB4*** , whereas transforming growth factor alpha ( TGFalpha ) interacts only with EGF-R .	parallel	1
7155	10510252	6271;6285	S100A1;S100B	***Binding*** of ***S100A1*** and ***S100B*** results in inhibition of desmin and GFAP assemblies into IFs and stimulation of the disassembly of preformed desmin and GFAP IFs .	parallel	1
7156	10510289	183;1958	Angiotensin II;egr-1	***Angiotensin II*** ***inhibits*** insulin-induced ***egr-1*** expression in mesangial cells .	negative	1
7157	10510289	183;1958	Angiotensin II;egr-1	***Angiotensin II*** ***inhibited*** insulin-induced ***egr-1*** expression but not c-fos expression , and the decrease in egr-1 expression was concurrent with a decrease in insulin receptor substrate-1 ( IRS-1 ) tyrosine phosphorylation .	negative	1
7158	10510299	4023;4018	lipoprotein lipase;lipoprotein	Endogenously produced ***lipoprotein lipase*** ***enhances*** the binding and cell association of native , mildly oxidized and moderately oxidized low-density ***lipoprotein*** in mouse peritoneal macrophages .	positive	0
7159	10510314	2246;3313	Fibroblast growth factor-1;GRP75	***Fibroblast growth factor-1*** ***interacts*** with the glucose-regulated protein ***GRP75/mortalin*** .	parallel	1
7160	10510314	2246;3313	FGF-1;GRP75	The ***interaction*** of ***FGF-1*** and ***GRP75/mortalin*** in vivo was confirmed by co-immunoprecipitation , immunohistochemical co-localization in Rat-1 fibroblasts and by using the yeast two-hybrid system .	parallel	1
7161	10510327	10671;1017	p27;cyclin-dependent kinase-2	The majority of thyroid carcinomas maintain the expression of the cell growth suppressor ***p27*** , an ***inhibitor*** of ***cyclin-dependent kinase-2*** ( Cdk2 ) .	negative	1
7162	10510327	896;10671	cyclin D3;p27	In thyroid tumors and cell lines , ***cyclin D3*** expression was ***associated*** with cytoplasmic localization of ***p27*** .	parallel	0
7163	10510327	896;10671	cyclin D3;p27	Moreover , expression of ***cyclin D3*** in thyroid carcinoma cells ***induced*** cytoplasmic retention of cotransfected ***p27*** and rescued p27-imposed growth arrest .	target	1
7164	10510327	896;10671	cyclin D3;p27	In these cells , ***cyclin D3*** ***induced*** the formation of cytoplasmic ***p27-cyclin D3-Cdk*** complexes , which titrated p27 away from intranuclear complexes that contain cyclins A-E and Cdk2 .	target	1
7165	10510327	10671;896	p27;cyclin D3	In these cells , cyclin D3 induced the formation of cytoplasmic ******p27-cyclin D3-Cdk****** ***complexes*** , which titrated p27 away from intranuclear complexes that contain cyclins A-E and Cdk2 .	parallel	1
7166	10510329	566;836	HBP;caspase-3	Internalized ***HBP*** markedly ***reduced*** growth factor deprivation-induced ***caspase-3*** activation and protected endothelial cells from apoptosis , suggesting that uptake and intracellular routing of exogenous HBP to mitochondria contributes to the sustained viability of endothelial cells in the context of locally activated neutrophils .	negative	1
7167	10510333	186;3827	AT2;bradykinin	Our results suggest that ***AT2*** in aortic VSM cells ***stimulates*** the production of ***bradykinin*** , which stimulates the NO/cGMP system in a paracrine manner to promote vasodilation .	positive	0
7168	10510346	355;356	CD95;CD95 ligand	CD95-sensitive cells were used to reveal that death occurred independently of ******CD95-CD95 ligand****** ***interactions*** .	parallel	1
7169	10510351	3565;3558	IL-4;IL-2	In this study , we have investigated in detail the cytokine requirements for the generation of allospecific CD8 + CTL in vitro and have found that ***IL-4*** can ***augment*** the generation of anti-CD8-sensitive but not anti-CD8-resistant CTL , whereas ***IL-2*** or IL-12 can augment the generation of both anti-CD8-sensitive and anti-CD8-resistant CTL .	positive	0
7170	10510358	116;942	PACAP;B7.2	VIP and ***PACAP*** ***up-regulate*** ***B7.2*** , but not B7.1 , expression and induce the capacity to stimulate the proliferation of naive T cells in response to soluble anti-CD3 or allogeneic stimulation .	positive	1
7171	10510358	7432;942	VIP;B7.2	***VIP*** and PACAP ***up-regulate*** ***B7.2*** , but not B7.1 , expression and induce the capacity to stimulate the proliferation of naive T cells in response to soluble anti-CD3 or allogeneic stimulation .	positive	1
7172	10510363	7535;3689	ZAP-70;LFA-1	This suggested that LFA-1 engagement triggers a signal that amplifies a weak chemokine signal and that dominant-negative ***ZAP-70*** ***blocks*** this ***LFA-1*** signal .	negative	0
7173	10510363	831;3689	calpain inhibitor;LFA-1	The chemokine and the ***LFA-1*** signal were both ***blocked*** by a phospholipase C inhibitor and a ***calpain inhibitor*** , suggesting that one of the amplified signals is the phospholipase C-dependent activation of calpain .	negative	0
7174	10510372	940;959	CD28;CD40 ligand	Ligation of ***CD28*** in vivo ***induces*** ***CD40 ligand*** expression and promotes B cell survival .	target	1
7175	10510372	940;958	CD28;CD40	Among these accessory molecules , ***interactions*** between ***CD28/CTLA-4*** with B7 family members ( CD80 and CD86 ) and ***CD40*** with CD40 ligand ( CD40L ) play a decisive role in regulating the progression of balanced immune responses .	parallel	1
7176	10510372	1493;940	CTLA-4;CD28	Among these accessory molecules , ***interactions*** between ******CD28/CTLA-4****** with B7 family members ( CD80 and CD86 ) and CD40 with CD40 ligand ( CD40L ) play a decisive role in regulating the progression of balanced immune responses .	parallel	1
7177	10510372	1493;958	CTLA-4;CD40	Among these accessory molecules , ***interactions*** between ***CD28/CTLA-4*** with B7 family members ( CD80 and CD86 ) and ***CD40*** with CD40 ligand ( CD40L ) play a decisive role in regulating the progression of balanced immune responses .	parallel	1
7178	10510379	6778;4790	STAT6;NF kappa B	The data demonstrate that ***cooperation*** of ***STAT6*** with at least PU.1 or ***NF kappa B/rel*** is necessary for IL-4-induced activation of IgE germline gene transcription .	parallel	0
7179	10510379	6778;6688	STAT6;PU.1	The data demonstrate that ***cooperation*** of ***STAT6*** with at least ***PU.1*** or NF kappa B/rel is necessary for IL-4-induced activation of IgE germline gene transcription .	parallel	0
7180	10510379	6688;4790	PU.1;NF kappa B	Transient transfection experiments using IgE germline promoter reporter gene constructs demonstrated that mutations affecting DNA ***binding*** of ***PU.1*** or ***NF kappa B/rel*** had no or little effect on IL-4 inducibility of these plasmids .	parallel	1
7181	10510468	836;4780	caspase-3;NRF2	***NRF2*** was ***cleaved*** at two sites by recombinant ***caspase-3*** in vitro as well as in HeLa cells during TNFalpha-mediated apoptosis .	target	1
7182	10510469	7157;581	p53;Bax	Our findings exclude a direct transcriptional ***transactivation*** of the ***Bax*** gene by ***p53*** in murine cells suggesting a dominance of p53 independent mechanisms for the regulation of Bax protein expression .	positive	1
7183	10510470	7157;23360	p53;FBP-30	WW domain-containing ***FBP-30*** is ***regulated*** by ***p53*** .	target	1
7184	10510470	7157;23360	p53;FBP-30	While the kinetics of its induction are rapid , the observed increased expression of FBP-30 in the presence of protein synthesis inhibitors suggests that ***FBP-30*** gene expression is indirectly ***regulated*** by ***p53*** , through downregulation of a labile inhibitor of FBP-30 expression .	target	1
7185	10510472	2113;1649	ETS1;GADD153	Our results also demonstrate how ***ETS1*** and FLI-1 specifically ***regulate*** ***GADD153*** expression .	target	1
7186	10510472	2313;1649	FLI-1;GADD153	Our results also demonstrate how ETS1 and ***FLI-1*** specifically ***regulate*** ***GADD153*** expression .	target	1
7187	10510672	5340;5345	plasmin;alpha 2-antiplasmin	Hemostasis markers measured thrombin-antithrombin complexes ( TAT ) , fibrinogen , ******plasmin-alpha 2-antiplasmin****** ***complexes*** ( PAP ) , plasminogen activator inhibitor ( PAI-1 ) , and D-dimer .	parallel	1
7188	10511312	2247;1026	fibroblast growth factor-2;p21Cip1/Waf1	Ras - and mitogen-activated protein kinase kinase-dependent and - independent pathways in ***p21Cip1/Waf1*** ***induction*** by ***fibroblast growth factor-2*** , platelet-derived growth factor , and transforming growth factor-beta1 .	target	1
7189	10511313	999;1969	E-cadherin;EphA2	***E-cadherin*** ***regulates*** the function of the ***EphA2*** receptor tyrosine kinase .	target	1
7190	10511313	999;1969	E-cadherin;EphA2	We report here the ***regulation*** of ***EphA2*** by ***E-cadherin*** .	target	1
7191	10511313	999;1969	E-cadherin;EphA2	***Activation*** of ***EphA2*** , either by ***E-cadherin*** expression or antibody-mediated aggregation , decreased cell-extracellular matrix adhesion and cell growth .	positive	1
7192	10511426	1499;2932	beta-catenin;GSK-3beta	Nuclear localization of ***beta-catenin*** in adult mouse thalamus ***correlates*** with low levels of ***GSK-3beta*** .	parallel	0
7193	10511545	10923;29101	Sub1;Ssu72	This collection of sua7 alleles , including the initial sua7 alleles , was used to investigate the allele specificity of ***interactions*** between ***Ssu72*** and ***Sub1*** , both of which were initially identified as either suppressors ( Sub1 2mu ) or enhancers ( sub1Delta , Ssu72-1 ) of sua7 mutations .	parallel	1
7194	10511594	3479;3486	IGF-I;IGFBP3	Dissociation of the ******IGF-I-IGFBP3****** ***complex*** renders IGF-I available to bind to its receptor and stimulates cellular proliferation .	parallel	1
7195	10511594	3479;3486	IGF-I;IGFBP3	CONCLUSIONS : These results are consistent with the idea that PSA can modulate in vitro ***interactions*** between ***IGF-I*** and ***IGFBP3*** and suggest that PSA may play a role in the regulation of human prostatic fibromuscular cell growth .	parallel	1
7196	10511596	356;355	FasL;Fas	BACKGROUND : ***Fas*** ***ligand*** ( ***FasL*** ) is a transmembrane protein that induces apoptosis ( programmed cell death ) in susceptible cells by interacting with its receptor , Fas .	parallel	1
7197	10511705	998;10096	Cdc42;Arp2/3	In this pathway , the GTPase ***Cdc42*** acts in concert with WASP family proteins to ***activate*** the ***Arp2/3*** complex .	positive	1
7198	10512200	6670;5460	Sp3;Oct-4	***Binding*** of Sp1 and ***Sp3*** transcription factors to the ***Oct-4*** gene promoter .	parallel	1
7199	10512369	181;3952	AGRP;leptin	This study provides the first direct evidence that ***AGRP*** is a negative ***regulator*** of ***leptin*** action , and leptin downregulates hypothalamic AGRP production .	negative	1
7200	10512369	3952;181	leptin;AGRP	This study provides the first direct evidence that AGRP is a negative regulator of leptin action , and ***leptin*** ***downregulates*** hypothalamic ***AGRP*** production .	negative	1
7201	10512369	3952;5443	leptin;alpha-melanocyte stimulating hormone	Because ***leptin*** is shown to ***increase*** hypothalamic ***alpha-melanocyte stimulating hormone*** ( alpha-MSH ) production , our data suggest that its action via the hypothalamic melanocortin system is determined by the balance between the levels of its agonist and antagonist , alpha-MSH and AGRP .	positive	0
7202	10512373	177;213	RAGE;albumin	These results strongly suggest that in experimental diabetes the interaction of circulating AGEs and endothelial ***RAGE*** ***mediates*** ***albumin*** micro-vascular leakage , possibly via AGE-RAGE-dependent enhanced oxidant stress .	target	0
7203	10512629	30816;920	envelope glycoprotein;CD4	The initial event in infection by the human immunodeficiency virus type 1 ( HIV-1 ) is the ***interaction*** of the viral ***envelope glycoprotein*** ( HIV-gp120 ) with its primary cellular receptor , the glycoprotein ***CD4*** .	parallel	1
7204	10512690	1511;3488	cathepsin G;IGFBP-5	Under similar experimental conditions , ***cathepsin G*** preferentially ***cleaved*** ***IGFBP-5*** , followed by BP-2 , BP-3 , BP-4 , BP-1 , and BP-6 .	target	1
7205	10512728	2249;2263	FGF4;FGFR-2	Chemical crosslinking of radiolabeled FGF4 to the soluble FGF receptors confirms the preferential formation of ******FGF4-FGFR-2****** ***complexes*** under restricted heparin availability , with maximal ligand-receptor interactions at almost 20-fold lower heparin concentrations then those required for the affinity labeling of FGFR-1 .	parallel	1
7206	10512728	2263;2249	FGFR-2;FGF4	We suggest that ***FGFR-2*** is the preferred ***receptor*** for ***FGF4*** under restricted HS conditions and that the bioavailability of structurally distinct HS motifs may differentially control receptor specificity of FGF4 in vivo .	parallel	1
7207	10512746	5468;3383	PPARgamma;ICAM-1	In addition , ligand-dependent ***PPARgamma*** activation ***increased*** ***ICAM-1*** protein expression and enhanced adherence of monocytes to ECV304 cells by two - to threefold .	positive	0
7208	10512750	1457;9616	CKII;SAG	Protein kinase ***CKII*** interacts with and ***phosphorylates*** the ***SAG*** protein containing ring-H2 finger motif .	target	1
7209	10512750	1457;9616	CKII;SAG	Recombinant ***SAG*** can be ***phosphorylated*** by ***CKII*** in vitro , providing evidence that the beta subunit mediates the interaction of CKII enzyme with substrate proteins .	target	1
7210	10512750	1457;9616	CKII;SAG	Overlay experiment shows that SAG and the beta subunit of CKII associate directly in vitro and that ***CKII-mediated*** ***phosphorylation*** of ***SAG*** does not affect the interaction between SAG and the beta subunit of CKII .	target	1
7211	10512856	998;5599	Cdc42;JNK	Activation of c-Jun N-terminal kinase ( JNK ) appears not to be essential for block of differentiation because , although Rac1 and ***Cdc42*** GTPases modestly ***activate*** ***JNK*** in quail myoblasts , a Rac1 mutant defective for JNK activation can still inhibit myogenic differentiation .	positive	1
7212	10512856	5879;5599	Rac1;JNK	Activation of c-Jun N-terminal kinase ( JNK ) appears not to be essential for block of differentiation because , although ***Rac1*** and Cdc42 GTPases modestly ***activate*** ***JNK*** in quail myoblasts , a Rac1 mutant defective for JNK activation can still inhibit myogenic differentiation .	positive	1
7213	10512857	7471;1499	Wnt-1;beta-catenin	Although cnxPg and ***Wnt-1*** ***stabilize*** ***beta-catenin*** to similar extents , cnxPg activates OT to 10 - to 20-fold higher levels than Wnt-1 .	positive	0
7214	10512857	51176;1499	LEF1;beta-catenin	Moreover , although ***LEF1*** and TCF4 ***synergize*** with ***beta-catenin*** and plakoglobin to activate OT , both suppress the signaling activity of cnxPg .	parallel	0
7215	10512857	6934;1499	TCF4;beta-catenin	Moreover , although LEF1 and ***TCF4*** ***synergize*** with ***beta-catenin*** and plakoglobin to activate OT , both suppress the signaling activity of cnxPg .	parallel	0
7216	10513602	1392;627	Corticotropin-releasing factor;brain-derived neurotrophic factor	***Corticotropin-releasing factor*** ***enhances*** ***brain-derived neurotrophic factor*** gene expression to facilitate memory retention in rats .	positive	0
7217	10513602	627;1392	BDNF;CRF	***BDNF*** antisense oligonucleotide treatment , at a concentration which did not affect retention performance alone ( 0.5 mM ) , ***blocked*** the memory-enhancing effect of ***CRF*** .	negative	0
7218	10513808	959;958	CD154;CD40	One pathway is T cell dependent , predominantly through a ******CD40-CD154****** ***interaction*** , while the other is T cell independent , mediated through TNFalpha .	parallel	1
7219	10513808	959;958	CD154;CD40	Inhibition of IL-12 production by interference with ******CD40-CD154****** ***interaction*** and TNFalpha production may be a potential therapeutic strategy for treating RA .	parallel	1
7220	10513808	958;959	CD40;CD154	OBJECTIVE : To investigate the roles of tumor necrosis factor alpha ( TNFalpha ) and the ******CD40-CD154****** ***interaction*** in interleukin-12 ( IL-12 ) production by rheumatoid synovial cells ( SC ) .	parallel	1
7221	10513896	338;821	apolipoprotein B;calnexin	***Interaction*** of newly synthesized ***apolipoprotein B*** with ***calnexin*** and calreticulin requires glucose trimming in the endoplasmic reticulum .	parallel	1
7222	10513896	338;811	apolipoprotein B;calreticulin	***Interaction*** of newly synthesized ***apolipoprotein B*** with calnexin and ***calreticulin*** requires glucose trimming in the endoplasmic reticulum .	parallel	1
7223	10513983	3320;196	HSP90;AhR	Taken together , these results demonstrate that ***HSP90*** can ***regulate*** ***AhR*** activity in vivo , and that Ah-responsiveness is dependent upon cellular ER content through a mechanism that involves HSP90 .	target	1
7224	10514006	356;355	FasL;Fas	Activation of Stat5 by IL-2 was found to be involved in T cell proliferation and promoted ***Fas*** ***ligand*** ( ***FasL*** ) expression and AICD .	parallel	1
7225	10514014	356;3606	FasL;IL-18	Administration of recombinant soluble ***FasL*** ( rFasL ) after P. acnes priming ***induced*** comparable elevation of serum ***IL-18*** in parallel with elevated serum liver enzyme levels .	target	1
7226	10514378	23607;4868	CD2AP;nephrin	Supporting a role for CD2AP in the specialized cell junction known as the slit diaphragm , ***CD2AP*** ***associated*** with ***nephrin*** , the primary component of the slit diaphragm .	parallel	0
7227	10514384	1499;4316	beta-catenin;matrix metalloproteinase-7	***beta-catenin*** ***regulates*** the expression of the ***matrix metalloproteinase-7*** in human colorectal cancer .	target	1
7228	10514388	3596;6778	IL-13;STAT6	***IL-13*** ***activates*** ***STAT6*** and inhibits liver injury induced by ischemia/reperfusion .	positive	1
7229	10514388	3596;7124	IL-13;TNFalpha	Administration of ***IL-13*** ***reduced*** the production of ***TNFalpha*** and MIP-2 mRNA and protein .	negative	1
7230	10514388	3596;6778	IL-13;STAT6	Administration of ***IL-13*** had no effect on liver NFkappaB activation , but greatly ***increased*** the activation of ***STAT6*** .	positive	0
7231	10514391	1674;5159	desmin;PDGFRbeta	In the rat model , ***desmin*** staining was ***associated*** with ***PDGFRbeta*** in areas of fibrosis .	parallel	0
7232	10514402	1232;6356	CCR3;eotaxin	Eosinophils , basophils , and Th2 cells express the chemokine receptor ***CCR3*** , which ***binds*** ***eotaxin*** , RANTES , and some other chemokines .	parallel	1
7233	10514402	1232;6352	CCR3;RANTES	Eosinophils , basophils , and Th2 cells express the chemokine receptor ***CCR3*** , which ***binds*** eotaxin , ***RANTES*** , and some other chemokines .	parallel	1
7234	10514424	8945;4793	beta-TrCP;IkappaBbeta	***beta-TrCP*** ***mediates*** the signal-induced ubiquitination of ***IkappaBbeta*** .	target	0
7235	10514424	8945;4793	beta-TrCP;IkappaBbeta	We demonstrate that ***beta-TrCP*** ***interacts*** specifically with ***IkappaBbeta*** , and such interaction is dependent on prior phosphorylation of IkappaBbeta on serines 19 and 23 .	parallel	1
7236	10514426	1432;5599	p38;JNK	Recent studies have implicated gadd45 and two related proteins , MyD118/Gadd45beta and CR6/Gadd45gamma , as initiators of ******JNK/p38****** ***signaling*** via their interaction with an upstream kinase MTK1 .	parallel	0
7237	10514433	8945;6500	FWD1;Skp1	***FWD1*** ***associates*** with ***Skp1*** through the F-box domain and also recognizes the conserved DSGXXS motif of IkappaBalpha .	parallel	0
7238	10514433	8945;4792	FWD1;IkappaBalpha	The structural requirements for the ***interactions*** of ***FWD1*** with ***IkappaBalpha*** and with Skp1 have now been investigated further .	parallel	1
7239	10514433	4792;8945	IkappaBalpha;FWD1	The D31A mutation ( but not the G33A mutation ) in the DSGXXS motif of IkappaBalpha abolished the ***binding*** of ***IkappaBalpha*** to ***FWD1*** and its subsequent ubiquitination without affecting the phosphorylation of IkappaBalpha .	parallel	1
7240	10514433	8945;4792	FWD1;IkappaBalpha	These results suggest that , in addition to site-specific phosphorylation at Ser ( 32 ) and Ser ( 36 ) , an acidic amino acid at position 31 is required for ***FWD1-mediated*** ***ubiquitination*** of ***IkappaBalpha*** .	target	1
7241	10514438	7157;983	p53;cdc2	These results suggest that ***p53*** negatively ***regulates*** ***cdc2*** transcription and that the NF-Y transcription factor is required for the p53-mediated regulation .	negative	1
7242	10514438	7157;983	p53;cdc2	***p53*** negatively ***regulates*** ***cdc2*** transcription via the CCAAT-binding NF-Y transcription factor .	negative	1
7243	10514438	7157;983	p53;cdc2	In this study , we investigated the mechanism by which ***p53*** ***regulates*** transcription of the ***cdc2*** gene .	target	1
7244	10514438	7157;983	p53;cdc2	An adenovirus oncoprotein , E1B-55K inhibits the ***p53-mediated*** ***repression*** of the ***cdc2*** promoter , while E1B-19K does not .	negative	1
7245	10514457	2796;2353	GnRH;c-Fos	These observations suggest that calcium influx through L-type channels is required for ***GnRH-induced*** ***activation*** of ERK and ***c-Fos*** and that the influence of calcium lies downstream of protein kinase C.	positive	1
7246	10514457	2796;5594	GnRH;ERK	These observations suggest that calcium influx through L-type channels is required for ***GnRH-induced*** ***activation*** of ***ERK*** and c-Fos and that the influence of calcium lies downstream of protein kinase C.	positive	1
7247	10514468	6777;5465	STAT5b;peroxisome proliferator-activated receptor alpha	***STAT5b*** ***down-regulates*** ***peroxisome proliferator-activated receptor alpha*** transcription by inhibition of ligand-independent activation function region-1 trans-activation domain .	negative	1
7248	10514468	5465;6777	PPAR;STAT5b	This inhibitory ***cross-talk*** between ***STAT5b*** and ***PPAR*** is now reported for PPAR forms gamma and delta and for thyroid hormone receptor , indicating a more general potential for inhibitory cross-talk between JAK/STAT and nuclear receptor signaling pathways .	parallel	0
7249	10514468	9021;6777	SOCS-3;STAT5b	Further investigations revealed that ***SOCS-3*** , a growth hormone-inducible negative regulator of cytokine signaling to STAT5b , ***abolished*** the ***STAT5b*** inhibitory response .	negative	0
7250	10514468	6777;5465	STAT5b;PPARalpha	A constitutively active ***STAT5b*** mutant failed to ***inhibit*** ***PPARalpha*** activity , indicating that STAT5b does not induce synthesis of a more proximal PPARalpha inhibitor .	positive	1
7251	10514479	1021;1029	cdk6;INK4	Furthermore , a mutation that prevents ***cdk6*** ***interaction*** with ***INK4*** proteins ( cdk6R31C ) was found to inactivate the proliferative effect of cdk6 and increase cytoplasmic localization , despite the fact that this mutant could phosphorylate the retinoblastoma protein in vitro .	parallel	1
7252	10514481	5074;4790	Par-4;NF-kappaB	***Par-4*** ***abrogates*** oncogenic Ras-inducible ***NF-kappaB*** transcription activity but does not interfere with cytoplasmic activation , or the DNA binding activity , of NF-kappaB .	negative	0
7253	10514492	3717;9021	JAK2;SOCS-3	Finally , ***JAK2*** ***co-immunoprecipitates*** with ***SOCS-3*** in lysates from leptin-treated COS cells .	parallel	1
7254	10514492	9021;3952	SOCS-3;leptin	These results suggest that ***SOCS-3*** is a leptin-regulated ***inhibitor*** of proximal ***leptin*** signaling in vivo .	negative	1
7255	10514492	3952;9021	leptin;SOCS-3	We earlier demonstrated that ***leptin*** ***induces*** expression of ***SOCS-3*** mRNA in the hypothalamus .	target	1
7256	10514492	9021;3952	SOCS-3;leptin	Furthermore , transfection data suggest that ***SOCS-3*** is an ***inhibitor*** of ***leptin*** signaling .	negative	1
7257	10514492	3952;9021	leptin;SOCS-3	However , little is known about the ***regulation*** of ***SOCS-3*** expression by ***leptin*** and the mechanism by which SOCS-3 inhibits leptin action .	target	1
7258	10514492	9021;3952	SOCS-3;leptin	However , little is known about the regulation of SOCS-3 expression by leptin and the mechanism by which ***SOCS-3*** ***inhibits*** ***leptin*** action .	negative	1
7259	10514492	3952;3717	leptin;JAK2	In transfected COS cells , forced expression of SOCS-3 results in inhibition of ***leptin-induced*** tyrosine ***phosphorylation*** of ***JAK2*** .	target	1
7260	10514494	10618;57619	TGN38;F-actin binding protein	Direct ***interaction*** of the trans-Golgi network membrane protein , ***TGN38*** , with the ***F-actin binding protein*** , neurabin .	parallel	1
7261	10514498	7428;8988	pVHL;protein 3	Whereas wild type hpVHL represses levels of TH mRNA and protein 5-fold , a truncated pVHL mutant , ***pVHL*** ( 1-115 ) , ***induces*** accumulation of TH mRNA and ***protein 3-fold*** .	target	1
7262	10514501	3455;1432	interferon receptor;p38	Thus , the ***p38*** kinase signaling cascade is ***activated*** by the Type I ***interferon receptor*** and plays a critical role in interferon signaling and interferon-dependent transcriptional regulation .	positive	1
7263	10514505	2889;1399	C3G;CrkL	These data indicate that the ******CrkL-C3G****** ***complex*** plays a role in Epo - or IL-3-induced , Ras-dependent activation of the Raf/ERK pathway leading to the activation of Elk-1 and the c-fos gene transcription .	parallel	1
7264	10514505	2056;5595	Epo;ERK1	Moreover , the ***Epo-induced*** ***activation*** of ***ERK1*** and ERK2 was augmented and prolonged in cells inducibly overexpressing CrkL .	positive	1
7265	10514505	2056;5594	Epo;ERK2	Moreover , the ***Epo-induced*** ***activation*** of ERK1 and ***ERK2*** was augmented and prolonged in cells inducibly overexpressing CrkL .	positive	1
7266	10514505	2056;5599	Epo;JNK	A moderate increase in ***Epo-induced*** ***activation*** of ***JNK*** was also observed in cells overexpressing CrkL .	positive	1
7267	10514505	2889;2002	C3G;Elk-1	Overexpression of ***C3G*** ***enhanced*** the ***Elk-1*** activation synergistically with CrkL , while a C3G mutant lacking the guanine nucleotide exchange domain showed an inhibitory effect .	positive	0
7268	10514505	2056;5594	Epo;ERK2	Most importantly , a CrkL mutant defective in the SH2 or N-terminal SH3 domain showed an inhibitory effect on the ***Epo-induced*** ***activation*** of ***ERK2*** .	positive	1
7269	10514511	7186;7133	TRAF2;p75	Furthermore , TRAF4 interacted with dimeric p75 ( NTR ) , whereas ***TRAF2*** ***interacted*** preferentially with monomeric ***p75*** ( NTR ) .	parallel	1
7270	10514511	9618;7133	TRAF4;p75	Furthermore , ***TRAF4*** ***interacted*** with dimeric ***p75*** ( NTR ) , whereas TRAF2 interacted preferentially with monomeric p75 ( NTR ) .	parallel	1
7271	10514511	7133;7189	p75;TRAF6	TRAF2-p75 ( NTR ) , TRAF4-p75 ( NTR ) , and ******TRAF6-p75****** ( NTR ) ***interactions*** modulated p75 ( NTR ) - induced cell death and NF-kappaB activation with contrasting effects .	parallel	1
7272	10514511	7186;7133	TRAF2;p75	******TRAF2-p75****** ( NTR ) , TRAF4-p75 ( NTR ) , and TRAF6-p75 ( NTR ) ***interactions*** modulated p75 ( NTR ) - induced cell death and NF-kappaB activation with contrasting effects .	parallel	1
7273	10514511	9618;7133	TRAF4;p75	TRAF2-p75 ( NTR ) , ******TRAF4-p75****** ( NTR ) , and TRAF6-p75 ( NTR ) ***interactions*** modulated p75 ( NTR ) - induced cell death and NF-kappaB activation with contrasting effects .	parallel	1
7274	10514511	7186;7133	TRAF2;p75	***TRAF2-p75*** ( NTR ) , TRAF4-p75 ( NTR ) , and TRAF6-p75 ( NTR ) interactions ***modulated*** ***p75*** ( NTR ) - induced cell death and NF-kappaB activation with contrasting effects .	target	0
7275	10514511	9618;7133	TRAF4;p75	TRAF2-p75 ( NTR ) , ***TRAF4-p75*** ( NTR ) , and TRAF6-p75 ( NTR ) interactions ***modulated*** ***p75*** ( NTR ) - induced cell death and NF-kappaB activation with contrasting effects .	target	0
7276	10514511	7189;7133	TRAF6;p75	TRAF2-p75 ( NTR ) , TRAF4-p75 ( NTR ) , and ***TRAF6-p75*** ( NTR ) interactions ***modulated*** ***p75*** ( NTR ) - induced cell death and NF-kappaB activation with contrasting effects .	target	0
7277	10514511	7186;7133	TRAF2;p75	TRAF4 also inhibited the NF-kappaB response , whereas ***TRAF2*** and TRAF6 ***enhanced*** ***p75*** ( NTR ) - induced NF-kappaB activation .	positive	0
7278	10514511	7189;7133	TRAF6;p75	TRAF4 also inhibited the NF-kappaB response , whereas TRAF2 and ***TRAF6*** ***enhanced*** ***p75*** ( NTR ) - induced NF-kappaB activation .	positive	0
7279	10514511	9618;4790	TRAF4;NF-kappaB	***TRAF4*** also ***inhibited*** the ***NF-kappaB*** response , whereas TRAF2 and TRAF6 enhanced p75 ( NTR ) - induced NF-kappaB activation .	negative	1
7280	10514513	3479;3486	IGF-I;IGFBP-3	IGF-I does not compete for IGFBP-3 binding ; instead , ***IGF-I*** ***binds*** immobilized ***IGFBP-3.fibrinogen*** and IGFBP-3.fibrin complexes with affinity similar to that of IGF-I for the type I IGF receptor .	parallel	1
7281	10514513	3486;3479	IGFBP-3;IGF-I	IGFBP-3 also binds specifically to native fibrin clots , and addition of exogenous ***IGFBP-3*** ***increases*** ***IGF-I*** binding .	positive	0
7282	10514514	5608;1432	mitogen-activated protein kinase kinase 6;p38 mitogen-activated protein kinase	Overexpression of wild-type ***p38 mitogen-activated protein kinase*** and its upstream ***activator*** ***mitogen-activated protein kinase kinase 6*** ( MKK6 ) resulted in an enhanced STAT1 tyrosine phosphorylation upon osmotic shock .	positive	1
7283	10514516	3667;5781	insulin receptor substrate 1;SHP-2	On examining two lines of Tg mice identified by Southern blot , the transgene product was expressed in skeletal muscle , liver , and adipose tissues , and insulin-induced ***association*** of ***insulin receptor substrate 1*** with endogenous ***SHP-2*** was inhibited , confirming that DeltaPTP has a dominant negative property .	parallel	0
7284	10514518	64145;4843	110-kDa protein;NOS2	We show that murine macrophages express a ***110-kDa protein*** that ***interacts*** with ***NOS2*** , which we call NOS-associated protein-110 kDa ( NAP110 ) .	parallel	1
7285	10514520	1154;3560	CIS;interleukin-2 receptor beta	***CIS*** ***associates*** with the ***interleukin-2 receptor beta*** chain and inhibits interleukin-2-dependent signaling .	parallel	0
7286	10514520	1154;3558	CIS;IL-2	We now demonstrate that ***CIS*** also ***interacts*** with the ***IL-2*** receptor beta chain ( IL-2Rbeta ) .	parallel	1
7287	10514520	3558;6777	IL-2;Stat5	Correspondingly , CIS inhibits functions associated with both of these kinases : Lck-mediated phosphorylation of IL-2Rbeta and ***IL-2-mediated*** ***activation*** of ***Stat5*** .	positive	1
7288	10514520	1154;3558	CIS;IL-2	Thus , we demonstrate that ***CIS*** can negatively ***control*** at least two independent ***IL-2*** signaling pathways .	negative	0
7289	10514521	5894;1026	Raf-1;p21	The ***Raf-1/MEK/ERK*** pathway ***regulates*** the expression of the ***p21*** ( Cip1/Waf1 ) gene in chondrocytes .	target	1
7290	10514527	1432;859	p38;caveolin-3	Taken together , these results support the idea that caveolin-3 expression is required for myoblast fusion and myotube formation , and suggest that ***p38*** is an upstream ***regulator*** of ***caveolin-3*** expression .	target	1
7291	10514551	3717;5617	Janus kinase 2;prolactin	In addition , l-oPRLR and s-oPRLR both responded to ***prolactin*** ***stimulation*** by ( 1 ) ***Janus kinase 2*** ( Jak2 ) tyrosine phosphorylation , ( 2 ) DNA-binding activation of signal transducer and activator of transcription 5 ( STAT5 ) , ( 3 ) stimulation of transcription from a promoter made of six repeats of STAT5-responsive sequence .	positive	0
7292	10514828	1476;1508	cystatin B;cysteine protease	Unverricht-Lundborg disease has been shown to be caused by mutations in the gene that codes for ***cystatin B*** , an ***inhibitor*** of ***cysteine protease*** .	negative	1
7293	10515226	960;6696	CD44;osteopontin	In addition , on nonastrocytic cell types it has been shown that an integrin receptor and the cell surface proteoglycan ***CD44*** ***recognize*** the same ECM ligand ***osteopontin*** , and thus modulate each others function ( 77 , 86 ) .	target	1
7294	10515254	4915;627	TrkB;BDNF	Quantitative in situ hybridization demonstrates that running increases the expression of mRNA coding for ***BDNF*** and its high affinity ***receptor*** ***TrkB*** in hippocampus in a running length dependent manner .	parallel	1
7295	10515388	5175;5781	CD31;SHP2	Tyrosine-phosphorylated ***CD31*** ***complexed*** with ***SHP2*** and other unidentified phosphoproteins .	parallel	1
7296	10515437	4233;3082	c-met;HGF	Moreover , the presence of a local HGF system ( ***HGF*** and its specific ***receptor*** , ***c-met*** ) has been demonstrated in vascular cells both in vitro and in vivo .	parallel	1
7297	10515439	7040;551	TGF-beta1;AVP	These results indicate that ***TGF-beta1*** ***inhibits*** the cellular signaling of ***AVP*** at steps beyond the AVP receptors and prior to the phospholipase C activation , and that TGF-beta1 may participate in a negative feedback regulation on the cellular action of AVP in glomerular mesangial cells .	negative	1
7298	10515502	5054;5327	PAI-1;tPA	The tPA activity , tPA antigen and ***tPA*** ***inhibitor*** 1 ( ***PAI-1*** ) antigen were determined in the supernatant of transduced ( BBEC/tPA ) cell cultures by an immunoassay .	negative	1
7299	10515814	3576;718	IL-8;C3a	IL-8 release by PMNL from persons with early-stage infection and from healthy donors was similar ; however , PMNL from persons with late-stage HIV infection had significantly impaired IL-8 production , which correlated with reduced ***IL-8*** ***response*** to ***C3a*** and C5a proteins and decreased CD88 expression .	parallel	0
7300	10515814	3576;727	IL-8;C5a	IL-8 release by PMNL from persons with early-stage infection and from healthy donors was similar ; however , PMNL from persons with late-stage HIV infection had significantly impaired IL-8 production , which correlated with reduced ***IL-8*** ***response*** to C3a and ***C5a*** proteins and decreased CD88 expression .	parallel	0
7301	10515814	3576;728	IL-8;CD88	IL-8 release by PMNL from persons with early-stage infection and from healthy donors was similar ; however , PMNL from persons with late-stage HIV infection had significantly impaired ***IL-8*** production , which correlated with reduced IL-8 response to C3a and C5a proteins and ***decreased*** ***CD88*** expression .	negative	0
7302	10515828	355;356	Fas;FasL	******Fas-FasL****** ***interactions*** modulate host defense against systemic Candida albicans infection .	parallel	1
7303	10515828	355;356	Fas;FasL	This study found that ******Fas-FasL****** ***interactions*** are involved in host defense against lethal infection with Candida albicans .	parallel	1
7304	10515828	355;356	Fas;FasL	Absence of ******Fas-FasL****** ***interactions*** leads to increased cytokine production after C. albicans stimulation , protecting mice against disseminated candidiasis .	parallel	1
7305	10515865	355;356	Fas;FasL	Similar changes occurred in C57BL/6-gld/gld mice , indicating that they resulted from ******Fas/FasL****** ***interactions*** .	parallel	1
7306	10515865	356;355	FasL;Fas	Yet , the incidence of CFU-S decreased after Fas cross-linking on normal bone marrow cells in the presence of interferon gamma , consistent with a regulatory function of ******Fas/FasL****** ***interactions*** in early progenitor cell development .	parallel	1
7307	10515879	4323;4313	MT1-MMP;MMP-2	Fibronectin upregulates gelatinase B ( MMP-9 ) and induces coordinated expression of gelatinase A ( ***MMP-2*** ) and its ***activator*** ***MT1-MMP*** ( MMP-14 ) by human T lymphocyte cell lines .	positive	1
7308	10515879	4312;4313	matrix metalloproteinase-1;MMP-2	MMP-2 activation was likely achieved by inducing a coordinated expression of membrane-type ***matrix metalloproteinase-1*** ( MMP-14 ) , a major ***activator*** of ***MMP-2*** .	positive	1
7309	10515888	3553;4790	IL-1beta;NF-kappaB	Because PAO inhibits activation of the transcription factor NF-kappaB and because NF-kappaB modulates an array of signals controlling cellular survival , proliferation , and cytokine production , we also studied the effect of PAO on NF-kappaB activation in AML cells and found that PAO suppressed the ***IL-1beta-induced*** ***activation*** of ***NF-kappaB*** .	positive	1
7310	10515892	3586;9021	IL-10;CIS3	Collectively , our data suggest that , in neutrophils , the activation of STAT1 and STAT3 phosphorylation is neither required for ***CIS3/SOCS3*** ***induction*** by ***IL-10*** nor involved in the regulatory effects of IL-10 on cytokine production .	target	1
7311	10515892	3586;9021	Interleukin-10;CIS3	***Interleukin-10*** ( IL-10 ) selectively ***enhances*** ***CIS3/SOCS3*** mRNA expression in human neutrophils : evidence for an IL-10-induced pathway that is independent of STAT protein activation .	positive	0
7312	10516092	7040;7422	TGF-beta1;VEGF	Blockade of TGF-beta1 signal transduction via a dominant-negative receptor II adenovirus significantly decreased ***TGF-beta1*** ***induction*** of ***VEGF*** mRNA .	target	1
7313	10516205	7124;4843	TNF-alpha;iNOS	However , the addition of ***TNF-alpha*** to IL-1beta significantly ***enhanced*** ***iNOS*** mRNA expression , iNOS protein synthesis , and NO production ( NO ( - ) ( 2 ) ) .	positive	0
7314	10516208	1956;2353	epidermal growth factor receptor;c-fos	Asbestos-induced phosphorylation of ***epidermal growth factor receptor*** is ***linked*** to ***c-fos*** and apoptosis .	parallel	0
7315	10516221	811;4846	calreticulin;endothelial NOS	Increased expression of ***calreticulin*** is ***linked*** to ANG IV-mediated activation of lung ***endothelial NOS*** .	parallel	0
7316	10516287	3082;207	HGF;Akt	***HGF*** ***induced*** rapid phosphorylation of ***Akt*** in HKC cells , which was immediately followed by phosphorylation and resultant inactivation of Bad , a pro-apoptotic member of the Bcl-2 family .	target	1
7317	10516287	3082;207	HGF;Akt	Pretreatment of the HKC cells with 10 nM wortmannin completely abolished ***HGF-induced*** ***phosphorylation*** of ***Akt*** and Bad , suggesting that this pathway is dependent on phosphoinositide ( PI ) 3-kinase .	target	1
7318	10516394	3484;3486	IGFBP-1;IGFBP-3	***Associations*** of IGF-I , ***IGFBP-1*** and ***IGFBP-3*** on intrauterine growth and early catch-up growth .	parallel	0
7319	10516394	3484;3479	IGFBP-1;IGF-I	***Associations*** of ***IGF-I*** , ***IGFBP-1*** and IGFBP-3 on intrauterine growth and early catch-up growth .	parallel	0
7320	10516394	3479;3486	IGF-I;IGFBP-3	***Associations*** of ***IGF-I*** , IGFBP-1 and ***IGFBP-3*** on intrauterine growth and early catch-up growth .	parallel	0
7321	10516478	1395;1392	CRHR-2;CRH	Changes in type 2 ***CRH*** ***receptor*** ( ***CRHR-2*** ) mRNA in the ventromedial hypothalamus ( VMH ) , a possible target of anorectic CRH effect , were also examined .	parallel	1
7322	10516478	1395;3952	CRHR-2;leptin	These results provide additional evidence ***linking*** VMH ***CRHR-2*** mRNA levels to plasma ***leptin*** concentration .	parallel	0
7323	10516480	2230;1392	ADX;CRH	***ADX*** ***increased*** ***CRH*** mRNA in the PVN , as did LPS , but no enhancement of this response was seen in LPS/ADX animals .	positive	0
7324	10516485	3952;5617	Leptin;prolactin	***Leptin*** ( 116-130 ) ***stimulates*** ***prolactin*** and luteinizing hormone secretion in fasted adult male rats .	positive	0
7325	10516485	3952;5617	Leptin;PRL	***Leptin*** ***stimulates*** in vivo LH secretion in fasted female rats and in vitro ***PRL*** secretion .	positive	0
7326	10516485	3952;5617	Leptin;PRL	In conclusion , these data show that ***Leptin*** ( 116-130 ) ***stimulates*** LH and ***PRL*** secretion in fasted adult male rats .	positive	0
7327	10516598	356;355	FasL;Fas	When the membrane receptor Fas binds its ligand , ***Fas*** ***ligand*** ( ***FasL*** ) , an apoptotic cascade is initiated in the cell bearing the Fas receptor .	parallel	1
7328	10516598	7124;7132	TNF-alpha;TNFR1	The same can be said about the tumor necrosis factor receptor-1 ( ***TNFR1*** ) and its ***ligand*** , ***TNF-alpha*** .	parallel	1
7329	10516626	728;727	C5aR;C5a	In vitro ***C5a*** ***receptor*** ( ***C5aR*** ) binding experiments showed that YSFKPMPLaR and YSFKD ( NMeNle ) PlaR had similar affinities for the macrophage C5aR ( IC50 0.2 , 0.1 microM respectively ) .	parallel	1
7330	10516719	3586;168400	IL-10;CT26	These results demonstrate that ***IL-10*** ***affects*** ***CT26*** tumor cell growth by both inhibiting the malignant phenotype and by recruiting and activating a T cell-mediated antitumor response .	target	0
7331	10516755	3458;355	interferon-gamma;CD95	***Regulation*** of ***CD95*** expression and CD95-mediated cell death by ***interferon-gamma*** in acute lymphoblastic leukemia with chromosomal translocation t ( 4 ; 11 ) .	target	1
7332	10516755	3458;355	IFNgamma;CD95	Addition of ***IFNgamma*** markedly ***upregulated*** ***CD95*** expression in SEM ( 8-9-fold ) , RS4 ; 11 ( 2-3-fold ) , and MV4 ; 11 ( 2-3-fold ) lines .	positive	1
7333	10517338	3479;5266	IGF-I;PI-3	Recent work has shown that mitogen-activated protein kinase ( MAPK ) and phosphotidylinositol-3 ( ***PI-3*** ) kinase are ***activated*** by ***IGF-I*** in these cells .	positive	1
7334	10517496	7066;4352	Thrombopoietin;Mpl	The ***interaction*** of ***Thrombopoietin*** ( TPO ) with its receptor , ***Mpl*** , triggers growth and differentiation of megakaryocytes and their progenitors .	parallel	1
7335	10517667	8031;367	RFG;androgen receptor	***RFG*** ( ARA70 , ELE1 ) ***interacts*** with the human ***androgen receptor*** in a ligand-dependent fashion , but functions only weakly as a coactivator in cotransfection assays .	parallel	1
7336	10517671	10902;5468	p120;PPARgamma	Furthermore , the yeast three-hybrid assay clearly revealed a significant ***interaction*** between ***p120*** and ***PPARgamma*** via RXR of PPARgamma/RXR heterodimer only in the presence of 9-cis-RA .	parallel	1
7337	10517679	3667;3643	IRS-1;insulin receptor	The presence of tyrosine-phosphorylated ***IRS-1*** appears to ***increase*** ***insulin receptor*** tyrosine phosphorylation and potentially tyrosine kinase activity via inhibition of protein-tyrosine phosphatase ( s ) .	positive	0
7338	10517737	183;3383	Angiotensin II;ICAM-1	***Angiotensin II*** stimulates intercellular adhesion molecule-1 ( ICAM-1 ) expression by human vascular endothelial cells and ***increases*** soluble ***ICAM-1*** release in vivo .	positive	0
7339	10517737	183;3383	Angiotensin II;intercellular adhesion molecule-1	***Angiotensin II*** ***stimulates*** ***intercellular adhesion molecule-1*** ( ICAM-1 ) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo .	positive	0
7340	10517807	94274;5578	CPI-17;PKCalpha	In in vitro experiments , ***CPI-17*** was a much better ***substrate*** for ***PKCalpha*** than calponin , caldesmon , MLC and myosin .	parallel	1
7341	10517851	353;7915	AMP;SSADH	***AMP*** , ADP , and ATP ***inhibited*** the activity of ***SSADH*** ( Ki = 2.5-8 mM ) .	negative	1
7342	10517906	3553;3383	IL-1beta;ICAM-1	RESULTS : Dexamethasone greatly reduced ***IL-1beta*** ***induced*** leucocyte adhesion , endothelial expression of ***ICAM-1*** in the postcapillary venule , and release of the mast cell derived chemokine KC .	target	1
7343	10517960	7124;627	TNF-alpha;BDNF	These findings indicate that ***TNF-alpha*** significantly ***influences*** ***BDNF*** and NGF synthesis , most probably in a dose-dependent manner .	target	0
7344	10517960	7124;4803	TNF-alpha;NGF	These findings indicate that ***TNF-alpha*** significantly ***influences*** BDNF and ***NGF*** synthesis , most probably in a dose-dependent manner .	target	0
7345	10518011	983;9113	Cdc2;h-warts	Furthermore , ***h-warts*** is specifically ***phosphorylated*** in cells at mitotic phase , most likely by ***Cdc2*** kinase .	target	1
7346	10518217	133746;2033	JMY;p300	JMY and p300 associate in physiological conditions , and , during the cellular stress response , the ******p300/JMY****** ***complex*** is recruited to activated p53 .	parallel	1
7347	10518217	133746;7157	JMY;p53	JMY and p300 associate in physiological conditions , and , during the cellular stress response , the ***p300/JMY*** complex is ***recruited*** to activated ***p53*** .	target	0
7348	10518217	2033;7157	p300;p53	JMY and p300 associate in physiological conditions , and , during the cellular stress response , the ***p300/JMY*** complex is ***recruited*** to activated ***p53*** .	target	0
7349	10518217	133746;2033	JMY;p300	The results provide compelling evidence that the ******p300/JMY****** coactivator ***complex*** plays a central role in facilitating the p53 response .	parallel	1
7350	10518221	1948;2050	ephrin-B2;EphB4	Symmetrical mutant phenotypes of the receptor ***EphB4*** and its specific transmembrane ***ligand*** ***ephrin-B2*** in cardiovascular development .	parallel	1
7351	10518221	2050;1948	EphB4;ephrin-B2	Here we show that ***EphB4*** , a specific ***receptor*** for ***ephrin-B2*** , is exclusively expressed by vascular endothelial cells in embryos and is preferentially expressed on veins .	parallel	1
7352	10518221	2050;1948	EphB4;ephrin-B2	These data indicate that ******ephrin-B2-EphB4****** ***interactions*** are intrinsically required in vascular endothelial cells and are consistent with the idea that they mediate bidirectional signaling essential for angiogenesis .	parallel	1
7353	10518225	2956;4436	MSH6;MSH2	Consistent with this , ******MSH2-MSH6****** ***complex*** bound to GO : A mispairs and GO : C base pairs with high affinity and specificity .	parallel	1
7354	10518225	2956;4436	MSH6;MSH2	Consistent with this , ******MSH2-MSH6****** complex ***bound*** to GO : A mispairs and GO : C base pairs with high affinity and specificity .	parallel	1
7355	10518492	652;9241	BMP4;Noggin	Hence , we hypothesized that an ***interplay*** between ***Noggin*** and ***BMP4*** in the dorsal tube generates graded concentrations of the latter that in turn triggers the delamination of neural crest progenitors .	parallel	1
7356	10518499	2253;2637	FGF8;Gbx2	***FGF8*** can ***activate*** ***Gbx2*** and transform regions of the rostral mouse brain into a hindbrain fate .	positive	1
7357	10518505	8829;7422	neuropilin-1;VEGF	***neuropilin-1*** is also expressed in endothelial cells and shown to ***bind*** vascular endothelial growth factor ( ***VEGF*** ) , a potent regulator for vasculogenesis and angiogenesis .	parallel	1
7358	10518526	2908;5054	Glucocorticoid receptor;PAI-1	Here we report that ***Glucocorticoid receptor*** ( GR ) ***represses*** TGF-beta transcriptional activation of the type-1 plasminogen activator inhibitor ( ***PAI-1*** ) gene in a ligand-dependent manner .	negative	1
7359	10518526	7040;5054	TGF-beta;PAI-1	Here we report that Glucocorticoid receptor ( GR ) represses ***TGF-beta*** transcriptional ***activation*** of the type-1 plasminogen activator inhibitor ( ***PAI-1*** ) gene in a ligand-dependent manner .	positive	1
7360	10518526	2908;7040	Glucocorticoid receptor;TGF-beta	Here we report that ***Glucocorticoid receptor*** ( GR ) ***represses*** ***TGF-beta*** transcriptional activation of the type-1 plasminogen activator inhibitor ( PAI-1 ) gene in a ligand-dependent manner .	negative	1
7361	10518537	2185;4303	protein kinase B;AFX	***Regulation*** of nuclear translocation of forkhead transcription factor ***AFX*** by ***protein kinase B*** .	target	1
7362	10518537	2185;4303	protein kinase B;AFX	***AFX*** was ***phosphorylated*** in vitro by ***protein kinase B*** ( PKB ) , a downstream target of PI 3-kinase , but a mutant protein in which three putative phosphorylation sites of PKB had been replaced by Ala was not recognized by PKB .	target	1
7363	10518542	672;7157	BRCA1;p53	Although it has been reported that ***BRCA1*** ***interacts*** with ***p53*** , we find the p53 status did not affect the ability of BRCA1 to suppress colony formation .	parallel	1
7364	10518542	672;5925	BRCA1;pRb	We further found that the ***BRCA1*** protein ***complexes*** with the hypophosphorylated form of ***pRb*** .	parallel	1
7365	10518547	2255;2263	Fgf10;Fgfr2	Highly similar lung and limb phenotypes were detected recently in the loss of function mutation of ***Fgf10*** , a ***ligand*** of ***Fgfr2*** .	parallel	1
7366	10518561	695;26228	Btk;BRDG1	In 293 cells expressing recombinant BRDG1 and various PTKs , Tec and Pyk2 , but not ***Btk*** , Bmx , Lyn , Syk , or c-Abl , ***induced*** marked phosphorylation of ***BRDG1*** on tyrosine residues .	target	1
7367	10518561	2185;26228	Pyk2;BRDG1	In 293 cells expressing recombinant BRDG1 and various PTKs , Tec and ***Pyk2*** , but not Btk , Bmx , Lyn , Syk , or c-Abl , ***induced*** marked phosphorylation of ***BRDG1*** on tyrosine residues .	target	1
7368	10518561	7006;26228	Tec;BRDG1	In 293 cells expressing recombinant BRDG1 and various PTKs , ***Tec*** and Pyk2 , but not Btk , Bmx , Lyn , Syk , or c-Abl , ***induced*** marked phosphorylation of ***BRDG1*** on tyrosine residues .	target	1
7369	10518561	7006;26228	Tec;BRDG1	***BRDG1*** was also ***phosphorylated*** by ***Tec*** directly in vitro .	target	1
7370	10518561	7006;26228	Tec;BRDG1	Efficient ***phosphorylation*** of ***BRDG1*** by ***Tec*** required the PH and SH2 domains as well as the kinase domain of the latter .	target	1
7371	10518574	949;4018	SR-BI;lipoprotein	Scavenger receptor BI ( ***SR-BI*** ) ***mediates*** the selective uptake of high density ***lipoprotein*** ( HDL ) cholesteryl esters ( CE ) by cells , i.e. , the uptake of CE without degradation of HDL protein .	target	0
7372	10518614	3091;7037	HIF-1;transferrin receptor	***HIF-1-mediated*** ***activation*** of ***transferrin receptor*** gene transcription by iron chelation .	positive	1
7373	10518827	7528;3567	YY1;hIL-5	CONCLUSION : We report the novel combination of ***YY1*** and nuclear factor of activated T cells transcription factors ***binding*** to a distal ***hIL-5*** promoter element where both factors are involved in down-regulation of hIL-5 gene expression in human T cell .	parallel	1
7374	10518934	112755;6844	syntaxin 1A and 1B;synaptobrevin 1 and 2	The results show that although both ***syntaxin 1A and 1B*** may ***interact*** with ***synaptobrevin 1 and 2*** , this interaction is not uniform , showing different affinity patterns depending on the syntaxin 1/synaptobrevin isoform combination .	parallel	1
7375	10519161	4879;4881	BNP;NPR-A	ANP and ***BNP*** ***bind*** to the natriuretic peptide-A receptor ( ***NPR-A*** ) , which , via 3 ' ,5 ' - cyclic guanosine monophosphate ( cGMP ) , mediates natriuresis , vasodilation , renin inhibition , antimitogenesis , and lusitropic properties .	parallel	1
7376	10519366	3077;3105	HFE;HLA-A	Hereditary haemochromatosis ( HH ) is an autosomal recessive disease involving mutations in the recently characterised ***HFE*** gene ***linked*** to ***HLA-A*** in the major histocompatibility complex .	parallel	0
7377	10519414	3265;7378	c-H-ras;UPase	***UPase*** expression is ***affected*** by the ***c-H-ras*** oncogene and various cytokines through unknown mechanisms .	target	0
7378	10519551	25805;7040	BAMBI;TGF-beta	The results indicate that ***BAMBI*** negatively ***regulates*** ***TGF-beta-family*** signalling by a regulatory mechanism involving the interaction of signalling receptors with a pseudoreceptor .	negative	1
7379	10519552	56993;10452	Tom22;Tom40	The central receptor ***Tom22*** binds preproteins through both its cytosolic domain and its intermembrane space domain and is stably ***associated*** with the channel protein ***Tom40*** ( refs 11-13 ) .	parallel	0
7380	10519912	1393;1392	CRF binding protein;CRF	Besides the two receptors , a 37 kD ***CRF binding protein*** ( CRF-BP ) ***binds*** several ***CRF*** peptides with high affinity .	parallel	1
7381	10519915	5741;2822	PTH;PLD	***PTH*** and PTHrP receptor activation ***stimulates*** adenylyl cyclase ( AC ) , phospholipase C ( PLC ) , and phospholipase D ( ***PLD*** ) in target cells .	positive	0
7382	10519970	1910;1907	ETB;ET2	ETs bind to at least two subtypes of receptors : the ETA subtype is ET1 selective whereas the ***ETB*** subtype ***binds*** ET1 , ***ET2*** and ET3 .	parallel	1
7383	10520003	959;958	CD40L;CD40	***CD40L*** ***stimulated*** increases in the surface expression of CD40 , CD54 , CD69 , CD70 , CD80 and CD95 , whereas Bryostatin induced expression of ***CD40*** , CD54 , CD69 and CD95 but not the co-stimulatory molecules CD70 and CD80 .	positive	0
7384	10520003	959;355	CD40L;CD95	***CD40L*** ***stimulated*** increases in the surface expression of CD40 , CD54 , CD69 , CD70 , CD80 and CD95 , whereas Bryostatin induced expression of CD40 , CD54 , CD69 and ***CD95*** but not the co-stimulatory molecules CD70 and CD80 .	positive	0
7385	10520066	3497;3586	IgE;IL-10	***Anti-IgE*** ( 1 microg/mL ) ***induced*** a median ***IL-10*** release of 301.7 ( 7.8-1532 .4 ) pg/106 mast cells/24 h.	target	1
7386	10520177	3683;3383	LFA-1;intercellular adhesion molecule-1	We have investigated the intercellular ***cross-talk*** between lymphocyte function-associated antigen-1 ( ***LFA-1*** ) and its counter-receptor , ***intercellular adhesion molecule-1*** ( ICAM-1 ) .	parallel	0
7387	10520231	820;7045	cAMP;betaig-h3	***cAMP-dependent*** ***phosphorylation*** of ***betaig-h3*** protein in human corneal endothelial cells .	target	1
7388	10520410	7037;7018	transferrin receptor;transferrin	Classically , four major proteins are involved in iron metabolism : ( a ) transferrin which is implicated in its plasmatic transport , ( b ) ***transferrin receptor*** which ***regulates*** ***iron-transferrin*** uptake , ( c ) ferritin , the major iron storage protein , and ( d ) IRP ( Iron Regulatory Protein ) which regulates both the entry and storage of iron by linking to the IRE ( Iron Responsive Element ) , a nucleotidic sequence found on transferrin receptor and ferritin mRNA .	target	1
7389	10520779	7035;2152	TFPI;tissue factor	OBJECTIVES : We investigated the effects of enalapril therapy on plasma tissue factor ( TF ) , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) and monocyte chemoattractant protein-1 ( MCP-1 ) levels in patients with acute myocardial infarction .	negative	1
7390	10520809	1636;5054	ACE;PAI-1	The impact of moderately increased ***ACE*** and PAI-1 activities ***associated*** with the ACE D/D and ***PAI-1*** 4G/4G genotypes is too small to affect mortality in the general population .	parallel	0
7391	10520993	9383;7503	Tsix;Xist	We have hypothesized that the antisense gene , ***Tsix*** , ***controls*** ***Xist*** expression .	target	0
7392	10520993	9383;7503	Tsix;Xist	We conclude that ***Tsix*** ***regulates*** ***Xist*** in cis and determines X chromosome choice without affecting silencing .	target	1
7393	10520994	10154;8829	Plexin;neuropilin-1	******Plexin-neuropilin-1****** ***complexes*** form functional semaphorin-3A receptors .	parallel	1
7394	10520994	5361;8829	plexin 1;neuropilin-1	We find that the two known semaphorin-binding proteins , ***plexin 1*** ( Plex 1 ) and ***neuropilin-1*** ( NP-1 ) , form a stable ***complex*** .	parallel	1
7395	10520995	10154;8482	plexin;Sema7A	Plexin-B1 is a receptor for the transmembrane semaphorin Sema4D ( CD100 ) , and ***plexin-C1*** is a ***receptor*** for the GPI-anchored semaphorin ***Sema7A*** ( Sema-K1 ) .	parallel	1
7396	10520995	5364;10507	Plexin-B1;Sema4D	***Plexin-B1*** is a ***receptor*** for the transmembrane semaphorin ***Sema4D*** ( CD100 ) , and plexin-C1 is a receptor for the GPI-anchored semaphorin Sema7A ( Sema-K1 ) .	parallel	1
7397	10521084	4792;4790	IkappaB-alpha;NF-kappaB	We examined ***NF-kappaB*** and its ***inhibitors*** , ***IkappaB-alpha*** and IkappaB-beta , in the colitis of interleukin-2 deficient ( IL-2 - / - ) mice at the ages of 5 , 10 , and 15 weeks and compared them with those of age-matched wild-type mice .	negative	1
7398	10521084	4793;4790	IkappaB-beta;NF-kappaB	We examined ***NF-kappaB*** and its ***inhibitors*** , IkappaB-alpha and ***IkappaB-beta*** , in the colitis of interleukin-2 deficient ( IL-2 - / - ) mice at the ages of 5 , 10 , and 15 weeks and compared them with those of age-matched wild-type mice .	negative	1
7399	10521116	3977;3976	LIF-R;leukemia inhibitory factor	OBJECTIVE : To examine the expression of ***leukemia inhibitory factor*** ( LIF ) and its ***receptor*** ( ***LIF-R*** ) transcripts in human and murine preimplantation embryos .	parallel	1
7400	10521240	6714;2697	c-Src;connexin43	We , therefore , conclude that during the progression of cardiac dysfunction in the cardiomyopathic heart , gap junctional communication is reduced via ***c-Src-mediated*** tyrosine ***phosphorylation*** of ***connexin43*** .	target	1
7401	10521245	183;285335	angiotensin II;NHE	This reflects an autocrine-paracrine mechanism whereby stretch triggers the release of ***angiotensin II*** , which in turn releases endothelin and ***activates*** the ***NHE*** through ET ( A ) receptors .	positive	1
7402	10521347	6364;1235	LARC;CCR6	The binding of iodinated ***LARC*** , the chemokine ***ligand*** for ***CCR6*** , to CCR6-transfected cells was competitively displaced by beta-defensin .	parallel	1
7403	10521388	7035;2152	TFPI;tissue factor	The intimal thickening that follows vascular injury is inhibited by periprocedural ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) treatment in animal models .	negative	1
7404	10521388	7035;2159	TFPI;factor Xa	To examine the structural requirements for the inhibition of neointimal formation by TFPI , several TFPI-related proteins were tested in the rat carotid angioplasty model : 1 ) XK ( 1 ) , a hybrid protein containing the N-terminal portion of factor X and the first Kunitz domain of TFPI that directly inhibits factor VIIa/TF ; 2 ) TFPI ( WT ) , the full-length TFPI molecule that inhibits factor Xa and factor VIIa/TF and binds cell surfaces ; 3 ) TFPI ( K36I ) , an altered form of TFPI that inhibits factor Xa , but not factor VIIa/TF , and binds cell surfaces ; 4 ) TFPI ( 13-161 ) , a truncated form of ***TFPI*** that inhibits factor VIIa/TF but ***interacts*** with ***factor Xa*** poorly and does not bind to cell surfaces .	parallel	1
7405	10521388	7035;2159	TFPI;factor Xa	To examine the structural requirements for the inhibition of neointimal formation by TFPI , several TFPI-related proteins were tested in the rat carotid angioplasty model : 1 ) XK ( 1 ) , a hybrid protein containing the N-terminal portion of factor X and the first Kunitz domain of TFPI that directly inhibits factor VIIa/TF ; 2 ) TFPI ( WT ) , the full-length TFPI molecule that inhibits factor Xa and factor VIIa/TF and binds cell surfaces ; 3 ) TFPI ( K36I ) , an altered form of ***TFPI*** that ***inhibits*** ***factor Xa*** , but not factor VIIa/TF , and binds cell surfaces ; 4 ) TFPI ( 13-161 ) , a truncated form of TFPI that inhibits factor VIIa/TF but interacts with factor Xa poorly and does not bind to cell surfaces .	negative	1
7406	10521392	3091;405	HIF-1;ARNT	This pathway requires ***HIF-1*** ( ***HIF-1alpha/ARNT*** ***heterodimers*** ) because ARNT ( - / - ) embryoid bodies fail to exhibit hypoxia-mediated progenitor proliferation .	parallel	1
7407	10521392	405;3091	ARNT;HIF-1alpha	This pathway requires HIF-1 ( ******HIF-1alpha/ARNT****** ***heterodimers*** ) because ARNT ( - / - ) embryoid bodies fail to exhibit hypoxia-mediated progenitor proliferation .	parallel	1
7408	10521396	841;84268	caspase-8;RIP	***Cleavage*** of the death domain kinase ***RIP*** by ***caspase-8*** prompts TNF-induced apoptosis .	target	1
7409	10521396	841;84268	caspase-8;RIP	We report here that the death domain kinase ***RIP*** , a key component of the TNF signaling complex , was ***cleaved*** by ***caspase-8*** in TNF-induced apoptosis .	target	1
7410	10521396	8772;8772	FADD;MORT1	RIPc , one of the cleavage products , enhanced ***interaction*** between TRADD and ******FADD/MORT1****** and increased cells ' sensitivity to TNF .	parallel	1
7411	10521396	8717;8772	TRADD;MORT1	RIPc , one of the cleavage products , enhanced ***interaction*** between ***TRADD*** and ***FADD/MORT1*** and increased cells ' sensitivity to TNF .	parallel	1
7412	10521419	7471;51176	Wnt-1;LEF-1	On the contrary , coexpressed ***Wnt-1*** and Frat ***activated*** ***LEF-1*** but did not show significant inhibition of GSK-mediated phosphorylation of a peptide substrate .	positive	1
7413	10521425	2641;2353	GLP-2;c-fos	Although ***GLP-2*** ***stimulated*** the expression of ***c-fos*** , c-jun , junB , and zif268 , and transiently increased p70 S6 kinase in quiescent BHK-GLP-2R cells , GLP-2 also inhibited extracellular signal-regulated kinase 1/2 and reduced serum-stimulated Elk-1 activity .	positive	0
7414	10521425	2641;3725	GLP-2;c-jun	Although ***GLP-2*** ***stimulated*** the expression of c-fos , ***c-jun*** , junB , and zif268 , and transiently increased p70 S6 kinase in quiescent BHK-GLP-2R cells , GLP-2 also inhibited extracellular signal-regulated kinase 1/2 and reduced serum-stimulated Elk-1 activity .	positive	0
7415	10521425	2641;3726	GLP-2;junB	Although ***GLP-2*** ***stimulated*** the expression of c-fos , c-jun , ***junB*** , and zif268 , and transiently increased p70 S6 kinase in quiescent BHK-GLP-2R cells , GLP-2 also inhibited extracellular signal-regulated kinase 1/2 and reduced serum-stimulated Elk-1 activity .	positive	0
7416	10521425	2641;5594	GLP-2;extracellular signal-regulated kinase 1/2	Although GLP-2 stimulated the expression of c-fos , c-jun , junB , and zif268 , and transiently increased p70 S6 kinase in quiescent BHK-GLP-2R cells , ***GLP-2*** also ***inhibited*** ***extracellular signal-regulated kinase 1/2*** and reduced serum-stimulated Elk-1 activity .	negative	1
7417	10521430	5170;5590	PDK-1;PKC-zeta	Further , insulin effects on ERK were inhibited by kinase-inactive 3-phosphoinositide-dependent protein kinase-1 ( PDK-1 ) , and by mutation of Thr-410 in the activation loop of PKC-zeta , which is the target of PDK-1 and is essential for ***PI3K/PDK-1-dependent*** ***activation*** of ***PKC-zeta*** .	positive	1
7418	10521430	5294;5590	PI3K;PKC-zeta	Further , insulin effects on ERK were inhibited by kinase-inactive 3-phosphoinositide-dependent protein kinase-1 ( PDK-1 ) , and by mutation of Thr-410 in the activation loop of PKC-zeta , which is the target of PDK-1 and is essential for ***PI3K/PDK-1-dependent*** ***activation*** of ***PKC-zeta*** .	positive	1
7419	10521432	10522;3181	NUDR;heterogeneous nuclear ribonucleoprotein A2/B1	Nuclear DEAF-1-related ( ***NUDR*** ) protein contains a novel DNA binding domain and ***represses*** transcription of the ***heterogeneous nuclear ribonucleoprotein A2/B1*** promoter .	negative	1
7420	10521443	7186;4790	TRAF2;NF-kappaB	Along with its protective effect , overexpressed ***TRAF2*** ***increased*** basal and insulin-stimulated ***NF-kappaB*** activities .	positive	0
7421	10521443	7186;4790	TRAF2;NF-kappaB	All effects were inhibited by IkappaB-alpha ( A32/36 ) , suggesting that an amplification loop involving ***TRAF2*** ***activation*** of ***NF-kappaB*** is implicated in insulin antiapoptotic signaling .	positive	1
7422	10521444	8743;4790	TRAIL;NF-kappaB	***TRAIL-R1*** and TRAIL-R2 can induce apoptosis of cancer cells and ***activate*** the transcription factor ***NF-kappaB*** .	positive	1
7423	10521444	8793;4790	TRAIL-R4;NF-kappaB	***TRAIL-R4*** can ***activate*** ***NF-kappaB*** and protect cells from TRAIL-induced apoptosis .	positive	1
7424	10521444	9020;4790	NIK;NF-kappaB	Here we show that TRAIL-R1 - , TRAIL-R2 - , and TRAIL-R4-induced ***NF-kappaB*** activation are ***mediated*** by a ***TRAF2-NIK-IkappaB*** kinase alpha/beta signaling cascade but is MEKK1 independent .	target	0
7425	10521444	9020;8743	NIK;TRAIL	Here we show that TRAIL-R1 - , ***TRAIL-R2*** - , and TRAIL-R4-induced NF-kappaB activation are ***mediated*** by a ***TRAF2-NIK-IkappaB*** kinase alpha/beta signaling cascade but is MEKK1 independent .	target	0
7426	10521444	7186;4790	TRAF2;NF-kappaB	Here we show that TRAIL-R1 - , TRAIL-R2 - , and TRAIL-R4-induced ***NF-kappaB*** activation are ***mediated*** by a ***TRAF2-NIK-IkappaB*** kinase alpha/beta signaling cascade but is MEKK1 independent .	target	0
7427	10521444	7186;8743	TRAF2;TRAIL	Here we show that TRAIL-R1 - , ***TRAIL-R2*** - , and TRAIL-R4-induced NF-kappaB activation are ***mediated*** by a ***TRAF2-NIK-IkappaB*** kinase alpha/beta signaling cascade but is MEKK1 independent .	target	0
7428	10521444	8743;5599	TRAIL;JNK	***JNK*** ***activation*** by ***TRAIL-R1*** is mediated by a TRAF2-MEKK1-MKK4 but not the TRAF2-NIK / IkappaB kinase alpha/beta signaling pathway .	positive	1
7429	10521444	4214;5599	MEKK1;JNK	***JNK*** activation by TRAIL-R1 is ***mediated*** by a ***TRAF2-MEKK1-MKK4*** but not the TRAF2-NIK / IkappaB kinase alpha/beta signaling pathway .	target	0
7430	10521444	6416;5599	MKK4;JNK	***JNK*** activation by TRAIL-R1 is ***mediated*** by a ***TRAF2-MEKK1-MKK4*** but not the TRAF2-NIK / IkappaB kinase alpha/beta signaling pathway .	target	0
7431	10521444	7186;5599	TRAF2;JNK	***JNK*** activation by TRAIL-R1 is ***mediated*** by a ***TRAF2-MEKK1-MKK4*** but not the TRAF2-NIK / IkappaB kinase alpha/beta signaling pathway .	target	0
7432	10521444	4792;4790	IkappaBalpha;NF-kappaB	Moreover , ***inhibition*** of ***NF-kappaB*** by ***IkappaBalpha*** sensitizes cells to tumor necrosis factor - but not TRAIL-induced apoptosis .	negative	1
7433	10521451	839;1676	caspase-6;DFF45	Strikingly , only the DEVD cleaving caspases , Caspase-3 and caspase-7 , inactivated DFF45/ICAD and promoted DNA fragmentation in an in vitro DFF40/CAD assay , suggesting that granzyme B , ***caspase-6*** , and caspase-8 ***promote*** ***DFF45/ICAD*** inactivation and DNA fragmentation indirectly by activating Caspase-3 and/or caspase-7 .	positive	0
7434	10521451	841;1676	caspase-8;DFF45	Strikingly , only the DEVD cleaving caspases , Caspase-3 and caspase-7 , inactivated DFF45/ICAD and promoted DNA fragmentation in an in vitro DFF40/CAD assay , suggesting that granzyme B , caspase-6 , and ***caspase-8*** ***promote*** ***DFF45/ICAD*** inactivation and DNA fragmentation indirectly by activating Caspase-3 and/or caspase-7 .	positive	0
7435	10521451	3002;1676	granzyme B;DFF45	Strikingly , only the DEVD cleaving caspases , Caspase-3 and caspase-7 , inactivated DFF45/ICAD and promoted DNA fragmentation in an in vitro DFF40/CAD assay , suggesting that ***granzyme B*** , caspase-6 , and caspase-8 ***promote*** ***DFF45/ICAD*** inactivation and DNA fragmentation indirectly by activating Caspase-3 and/or caspase-7 .	positive	0
7436	10521451	836;1676	Caspase-3;DFF45	In vitro , however , ***Caspase-3*** ***inactivated*** ***DFF45/ICAD*** and promoted DNA fragmentation more effectively than caspase-7 and endogenous levels of caspase-7 failed to inactivate DFF45/ICAD in Caspase-3 null MCF7 cells and extracts .	negative	1
7437	10521462	23043;2934	TNIK;Gelsolin	Furthermore , ***TNIK*** can ***phosphorylate*** ***Gelsolin*** in vitro .	target	1
7438	10521463	5747;5599	FAK;JNK	We show here that the activation of ***FAK*** by anchoring to the cell membrane is itself sufficient to ***stimulate*** potently both ERK and ***JNK*** .	positive	0
7439	10521463	5747;207	FAK;Akt	These effects were found to be phosphatidylinositol 3-kinase-independent , as ***FAK*** effectively ***stimulated*** ***Akt*** , and wortmannin suppressed Akt but not ERK or JNK activation .	positive	0
7440	10521463	5747;5599	FAK;JNK	Instead , we provide evidence that ***FAK*** may ***stimulate*** ***JNK*** through a novel pathway involving the recruitment of paxillin to the plasma membrane and the subsequent activation of a biochemical route dependent on small GTP-binding proteins of the Rho family .	positive	0
7441	10521466	5663;596	Presenilin 1;Bcl-2	***Presenilin 1*** protein directly ***interacts*** with ***Bcl-2*** .	parallel	1
7442	10521466	596;5663	Bcl-2;Presenilin 1	We describe a direct ***interaction*** between ***Presenilin 1*** ( PS1 ) and ***Bcl-2*** , a key factor in the regulation of apoptosis , by yeast two-hybrid interaction system , by co-immunoprecipitation , and by cross-linking experiments .	parallel	1
7443	10521470	998;3725	Cdc42;AP-1	In addition , we have shown that LAMPf stimulate Cdc42 and that inhibition of ***Cdc42*** or Rac by dominant negative mutants ***abrogates*** LAMPf-mediated activation of JNK and transactivation of NF-kappaB and ***AP-1*** in the murine macrophage cell line RAW 264.7 .	positive	0
7444	10521470	998;5599	Cdc42;JNK	In addition , we have shown that LAMPf stimulate Cdc42 and that inhibition of ***Cdc42*** or Rac by dominant negative mutants ***abrogates*** LAMPf-mediated activation of ***JNK*** and transactivation of NF-kappaB and AP-1 in the murine macrophage cell line RAW 264.7 .	positive	0
7445	10521470	998;4790	Cdc42;NF-kappaB	In addition , we have shown that LAMPf stimulate Cdc42 and that inhibition of ***Cdc42*** or Rac by dominant negative mutants ***abrogates*** LAMPf-mediated activation of JNK and transactivation of ***NF-kappaB*** and AP-1 in the murine macrophage cell line RAW 264.7 .	positive	0
7446	10521470	207;3725	Rac;AP-1	In addition , we have shown that LAMPf stimulate Cdc42 and that inhibition of Cdc42 or ***Rac*** by dominant negative mutants ***abrogates*** LAMPf-mediated activation of JNK and transactivation of NF-kappaB and ***AP-1*** in the murine macrophage cell line RAW 264.7 .	positive	0
7447	10521470	207;5599	Rac;JNK	In addition , we have shown that LAMPf stimulate Cdc42 and that inhibition of Cdc42 or ***Rac*** by dominant negative mutants ***abrogates*** LAMPf-mediated activation of ***JNK*** and transactivation of NF-kappaB and AP-1 in the murine macrophage cell line RAW 264.7 .	positive	0
7448	10521470	207;4790	Rac;NF-kappaB	In addition , we have shown that LAMPf stimulate Cdc42 and that inhibition of Cdc42 or ***Rac*** by dominant negative mutants ***abrogates*** LAMPf-mediated activation of JNK and transactivation of ***NF-kappaB*** and AP-1 in the murine macrophage cell line RAW 264.7 .	positive	0
7449	10521474	6626;213	U1A;albumin	A ***U1A*** protein peptide ***conjugated*** to ***albumin*** completely inhibited the polyadenylation of a SV40 mRNA by HeLa cell nuclear extract in vitro ; however , the 3 ' - end adenylation of human SRP RNA or Alu RNA , which corresponds to 5 ' and 3 ' - ends of SRP RNA , was not affected by this U1A peptide conjugate .	parallel	1
7450	10521474	6726;6470	SRP 9;14-kDa protein	In addition , binding of ******SRP 9/14-kDa protein****** ***heterodimer*** was required for adenylation of Alu RNA in vitro .	parallel	1
7451	10521474	6726;6470	SRP 9;14-kDa protein	In addition , ***binding*** of ******SRP 9/14-kDa protein****** heterodimer was required for adenylation of Alu RNA in vitro .	parallel	1
7452	10521475	2626;4205	GATA-4;MEF2	In vitro translated ***GATA-4*** , MEF2C , SRF , and Oct-1 ***bound*** to consensus GATA , ***MEF2*** , SRE , and Oct-1 elements , respectively , but not to the betaA/T-rich element .	parallel	1
7453	10521475	4208;4205	MEF2C;MEF2	In vitro translated GATA-4 , ***MEF2C*** , SRF , and Oct-1 ***bound*** to consensus GATA , ***MEF2*** , SRE , and Oct-1 elements , respectively , but not to the betaA/T-rich element .	parallel	1
7454	10521475	6722;4205	SRF;MEF2	In vitro translated GATA-4 , MEF2C , ***SRF*** , and Oct-1 ***bound*** to consensus GATA , ***MEF2*** , SRE , and Oct-1 elements , respectively , but not to the betaA/T-rich element .	parallel	1
7455	10521479	3667;3643	IRS-1;insulin receptor	The wild-type insulin receptor chimera mediated approximately 2-fold greater phosphorylation of ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) , association of IRS-1 with phosphoinositide 3-kinase , stimulation of glucose uptake , and GLUT4 translocation , compared with the IGF-I receptor chimera .	parallel	1
7456	10521479	3643;3667	insulin receptor;IRS-1	The wild-type ***insulin receptor*** chimera ***mediated*** approximately 2-fold greater phosphorylation of insulin receptor substrate 1 ( ***IRS-1*** ) , association of IRS-1 with phosphoinositide 3-kinase , stimulation of glucose uptake , and GLUT4 translocation , compared with the IGF-I receptor chimera .	target	0
7457	10521479	6464;2885	Shc;Grb2	In contrast , the IGF-I receptor chimera mediated more effective Shc phosphorylation , ***association*** of ***Shc*** with ***Grb2*** , and activation of mitogen-activated protein kinase compared with the insulin receptor chimera .	parallel	0
7458	10521479	3480;6464	IGF-I receptor;Shc	In contrast , the ***IGF-I receptor*** chimera ***mediated*** more effective Shc phosphorylation , association of ***Shc*** with Grb2 , and activation of mitogen-activated protein kinase compared with the insulin receptor chimera .	target	0
7459	10521481	1432;1386	p38;ATF-2	Consistent with these findings , TNFR1 engagement results in increased p38 MAP kinase activity and ***p38-dependent*** ***phosphorylation*** of ***ATF-2*** .	target	1
7460	10521483	2888;7010	Grb14;Tek	Using this approach , we demonstrate that five molecules , Grb2 , Grb7 , ***Grb14*** , Shp2 , and the p85 subunit of phosphatidylinositol 3-kinase can ***interact*** with ***Tek*** in a phosphotyrosine-dependent manner through their SH2 domains .	parallel	1
7461	10521483	2885;7010	Grb2;Tek	Using this approach , we demonstrate that five molecules , ***Grb2*** , Grb7 , Grb14 , Shp2 , and the p85 subunit of phosphatidylinositol 3-kinase can ***interact*** with ***Tek*** in a phosphotyrosine-dependent manner through their SH2 domains .	parallel	1
7462	10521483	2886;7010	Grb7;Tek	Using this approach , we demonstrate that five molecules , Grb2 , ***Grb7*** , Grb14 , Shp2 , and the p85 subunit of phosphatidylinositol 3-kinase can ***interact*** with ***Tek*** in a phosphotyrosine-dependent manner through their SH2 domains .	parallel	1
7463	10521483	5781;7010	Shp2;Tek	Using this approach , we demonstrate that five molecules , Grb2 , Grb7 , Grb14 , ***Shp2*** , and the p85 subunit of phosphatidylinositol 3-kinase can ***interact*** with ***Tek*** in a phosphotyrosine-dependent manner through their SH2 domains .	parallel	1
7464	10521483	2885;7010	Grb2;Tek	Mutation of this site abrogates ***binding*** of ***Grb2*** and Grb7 to ***Tek*** in vivo , and this site is required for tyrosine phosphorylation of Grb7 and p85 in vivo .	parallel	1
7465	10521483	2886;7010	Grb7;Tek	Mutation of this site abrogates ***binding*** of Grb2 and ***Grb7*** to ***Tek*** in vivo , and this site is required for tyrosine phosphorylation of Grb7 and p85 in vivo .	parallel	1
7466	10521486	3569;4322	IL-6;MMP-13	We show that ***IL-6*** ***increased*** ***MMP-13-mRNA*** and MMP-13 protein .	positive	0
7467	10521486	3569;3725	IL-6;AP1	Mobility shift assays demonstrated that ***IL-6*** ***induced*** the DNA binding activity of ***AP1*** .	target	1
7468	10521486	3569;4322	IL-6;MMP-13	We conclude that ***IL-6*** ***increases*** interstitial ***MMP-13*** gene expression at the promoter level .	positive	0
7469	10521487	2185;5209	protein kinase B;PFK-2	Previous studies have shown that ( i ) the insulin-induced activation of heart 6-phosphofructo-2-kinase ( PFK-2 ) is wortmannin-sensitive , but is insensitive to rapamycin , suggesting the involvement of phosphatidylinositol 3-kinase ; and ( ii ) ***protein kinase B*** ( PKB ) ***activates*** ***PFK-2*** in vitro by phosphorylating Ser-466 and Ser-483 .	positive	1
7470	10521487	5170;5209	PDK-1;PFK-2	However , the insulin-induced activation of ***PFK-2*** was ***prevented*** only by KD ***PDK-1*** , but not by KD PKB .	negative	0
7471	10521488	2261;5744	fgfr3;PTHrP	Furthermore , these results provide a possible ***link*** between ***PTHrP*** signaling and ***fgfr3*** gene expression during the process of endochondral ossification .	parallel	0
7472	10521497	2159;2157	FXa;FVIII	The anti-C2 monoclonal antibody ESH8 , which recognizes residues 2248-2285 and does not inhibit FVIII binding to von Willebrand factor or phospholipid , inhibited ***FVIII*** ***activation*** by ***FXa*** in a clotting assay .	positive	1
7473	10521497	2159;2157	FXa;FVIII	Our results provide the first evidence for a direct role of the C2 domain in the ***association*** between ***FVIII*** and ***FXa*** .	parallel	0
7474	10521505	5599;6774	JNK;Stat3	Serine ***phosphorylation*** and negative regulation of ***Stat3*** by ***JNK*** .	target	1
7475	10521505	5594;6774	ERK;Stat3	Recently , serine ***phosphorylation*** of ***Stat3*** on Ser-727 by ***ERK*** has been identified in response to epidermal growth factor ( EGF ) .	target	1
7476	10521505	5599;6774	JNK1;Stat3	We further demonstrate that ***JNK1*** , activated by its upstream kinase MKK7 , negatively ***regulated*** the tyrosine phosphorylation and DNA binding and transcriptional activities of ***Stat3*** stimulated by EGF .	negative	1
7477	10521508	156;7852	GRK2;CXCR4	Expression of ***GRK2*** and/or arrestins ***promoted*** modest additional ***CXCR4*** internalization in response to both PMA and SDF .	positive	0
7478	10521509	9628;10681	RGS6;gbeta5	After expression in Sf9 cells , ***complexes*** of both ***RGS6*** and RGS7 with the ***gbeta5*** subunit ( but not Gbetas 1-4 ) are found in the cytosol .	parallel	1
7479	10521509	6000;10681	RGS7;gbeta5	After expression in Sf9 cells , ***complexes*** of both RGS6 and ***RGS7*** with the ***gbeta5*** subunit ( but not Gbetas 1-4 ) are found in the cytosol .	parallel	1
7480	10521509	9628;8802	RGS6;Galpha	Unlike conventional G ( betagamma ) complexes , ***RGS6/beta5*** and RGS7/beta5 do not form heterotrimeric ***complexes*** with either ***Galpha*** ( o ) - GDP or Galpha ( q ) - GDP .	parallel	1
7481	10521509	6000;8802	RGS7;Galpha	Unlike conventional G ( betagamma ) complexes , RGS6/beta5 and ***RGS7/beta5*** do not form heterotrimeric ***complexes*** with either ***Galpha*** ( o ) - GDP or Galpha ( q ) - GDP .	parallel	1
7482	10521536	3569;6480	IL-6;ST6Gal I	These results indicate that ***ST6Gal I*** induction in mouse liver during the acute phase reaction is ***mediated*** predominantly by the ***IL-6*** pathway , and results in the induction of the Exon H-containing class of ST6Gal I mRNA that is specific to the liver .	target	0
7483	10521569	27087;6863	NK-1;Neurokinin-1	Recent behavioral studies using pharmacological techniques have demonstrated that the high affinity substance P ( SP ) receptor , ***Neurokinin-1*** ***receptor*** ( ***NK-1*** ) , in the medial hypothalamus could be important in mediating defensive rage behavior in the cat .	parallel	1
7484	10521570	57126;351	cell surface receptor;Abeta	The receptor for advanced glycation end products ( RAGE ) has been proposed as a ***cell surface receptor*** that ***binds*** amyloid-beta protein ( ***Abeta*** ) , thereby triggering its cytotoxic effects [ S.D.	parallel	1
7485	10521570	177;351	RAGE;Abeta	To investigate the ***interaction*** between ***Abeta*** and ***RAGE*** and another scavenger receptor , SRA , under physiological conditions , they were co-expressed with human betaAPP ( 695 ) - SFAD in a human cell and the level of Abeta in the condition medium was assessed by immunoprecipitation and enzyme-linked immunosorbent assay ( ELISA ) analysis .	parallel	1
7486	10521570	57126;351	cell surface receptor;Abeta	A nearly 100 % reduction of Abeta from the conditioned medium of hRAGE cells and approximately 40 % reduction from the SRA-cells implied that hRAGE could be a prominent ***cell surface receptor*** ***interacting*** with ***Abeta*** .	parallel	1
7487	10521580	3084;4908	glial growth factor 2;neurotrophin-3	Transforming growth factor-beta1 and ***glial growth factor 2*** ***reduce*** ***neurotrophin-3*** mRNA expression in cultured Schwann cells via a cAMP-dependent pathway .	negative	1
7488	10521580	3084;4908	GGF;NT-3	Transforming growth factor-beta1 ( TGF-beta1 ) and glial growth factor 2 ( ***GGF*** ( 2 ) ) also ***reduced*** the levels of ***NT-3*** mRNA in a dose and time-dependent manner .	negative	1
7489	10521580	7040;4908	TGF-beta1;NT-3	Transforming growth factor-beta1 ( ***TGF-beta1*** ) and glial growth factor 2 ( GGF ( 2 ) ) also ***reduced*** the levels of ***NT-3*** mRNA in a dose and time-dependent manner .	negative	1
7490	10521598	5803;1742	PTPzeta;SAP90	We performed yeast two-hybrid screening using the intracellular region of PTPzeta as a bait , and found that the C-terminal sequence of ***PTPzeta*** ***binds*** to the PSD-95 / ***SAP90*** family through the second PDZ domain .	parallel	1
7491	10521684	2944;1565	GSTM1;CYP2D6	The data did not suggest a substantial interaction ***effect*** between ***GSTM1*** and ***CYP2D6*** polymorphisms and the risk of lung cancer .	parallel	0
7492	10521702	3596;5321	IL-13;cPLA2	***IL-13*** induces serine phosphorylation of cPLA2 in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and ***blocks*** the zymosan-induced serine phosphorylation of ***cPLA2*** and eicosanoid production .	negative	0
7493	10521702	3596;5321	IL-13;cPLA2	***IL-13*** ***induces*** serine phosphorylation of ***cPLA2*** in mouse peritoneal macrophages leading to arachidonic acid and PGE2 production and blocks the zymosan-induced serine phosphorylation of cPLA2 and eicosanoid production .	target	1
7494	10521801	3082;5747	HGF;FAK	***HGF*** ***induces*** ***FAK*** activation and integrin-mediated adhesion in MTLn3 breast carcinoma cells .	target	1
7495	10521801	4233;3082	c-Met;HGF	Expression of hepatocyte growth factor ( ***HGF*** ) and its tyrosine kinase ***receptor*** , ***c-Met*** , is positively correlated with breast carcinoma progression .	parallel	1
7496	10521801	3082;4233	HGF;c-Met	In MTLn3 cells , ***HGF*** ***induced*** rapid tyrosine phosphorylation and activation of both ***c-Met*** and focal adhesion kinase ( FAK ) .	target	1
7497	10521801	3082;5747	HGF;FAK	In MTLn3 cells , ***HGF*** ***induced*** rapid tyrosine phosphorylation and activation of both c-Met and focal adhesion kinase ( ***FAK*** ) .	target	1
7498	10521801	3082;5747	HGF;FAK	Cell anchorage and adhesion to the ECM substrates was required for HGF-induced FAK activation , since ***HGF*** failed to ***trigger*** tyrosine phosphorylation of ***FAK*** in suspended cells .	positive	0
7499	10521801	4233;5747	c-Met;FAK	Our results provide evidence that the 2 signaling pathways , integrin/ECM and ***c-Met/HGF*** , cooperate synergistically to ***induce*** ***FAK*** activation in an adhesion-dependent manner , leading to enhanced cell adhesion and motility .	target	1
7500	10521801	3082;5747	HGF;FAK	Our results provide evidence that the 2 signaling pathways , integrin/ECM and ***c-Met/HGF*** , cooperate synergistically to ***induce*** ***FAK*** activation in an adhesion-dependent manner , leading to enhanced cell adhesion and motility .	target	1
7501	10521801	3082;4233	HGF;c-Met	Our results provide evidence that the 2 signaling pathways , integrin/ECM and ******c-Met/HGF****** , ***cooperate*** synergistically to induce FAK activation in an adhesion-dependent manner , leading to enhanced cell adhesion and motility .	parallel	0
7502	10521809	1000;1499	N-cadherin;beta-catenin	We conclude that E-cadherin-negative anaplastic thyroid-carcinoma cell lines display functional ******N-cadherin/beta-catenin****** ***complexes*** , partial or complete loss of gamma-catenin , and isoform shift of p120 ( ctn ) .	parallel	1
7503	10522058	7157;1026	p53;p21	BACKGROUND/AIMS : When the DNA of cells is damaged , wild-type ***p53*** protein ***induces*** the expression of ***p21*** ( Waf1/Cip1/Sdi1 ) , and regulates the progression of the cell cycle by inducing G1 arrest .	target	1
7504	10523005	5167;3643	PC-1;insulin receptor	An increased tissue content of ***PC-1*** , an ***inhibitor*** of ***insulin receptor*** signaling , may play a role in insulin resistance .	negative	1
7505	10523022	1392;1586	CRH;P450c17	Thus , ***CRH*** is coupled to the phospholipase C-inositol phosphate second messenger system and preferentially ***induces*** the expression of ***P450c17*** and DHEAS , suggesting a unique role of CRH regulating human fetal adrenal function via PKC .	target	1
7506	10523035	2798;2796	GnRH-R;GnRH	This patient bore a novel point mutation ( T for A ) at codon 168 of the gene encoding the ***GnRH*** ***receptor*** ( ***GnRH-R*** ) , resulting in a serine to arginine change in the fourth transmembrane domain of the receptor .	parallel	1
7507	10523313	10926;8317	Dbf4;Cdc7	Mammalian ******Cdc7-Dbf4****** protein kinase ***complex*** is essential for initiation of DNA replication .	parallel	1
7508	10523313	8317;4171	HsCdc7;MCM2	Purified baculovirus-expressed ***HsCdc7-HsDbf4*** selectively ***phosphorylates*** the ***MCM2*** subunit of the minichromosome maintenance ( MCM ) protein complex isolated by immunoprecipitation with MCM7 antibodies in vitro .	target	1
7509	10523409	3553;5743	IL-1beta;COX-2	***Induction*** of ***COX-2*** by ***IL-1beta*** in HMSMCs provides support for the hypothesis that autocrine prostaglandin signalling in the myometrium , initiated by elevated intrauterine cytokine concentrations , plays a role in regulating myometrial contractility during labour .	target	1
7510	10523409	3553;1432	IL-1beta;p38 mitogen-activated protein kinase	***IL-1beta*** ***induced*** a transient ( 5-30 min ) activation of p42/44 and ***p38 mitogen-activated protein kinase*** ( MAPK ) enzymes in HMSMCs .	target	1
7511	10523501	7013;8658	TRF1;tankyrase	These data indicate that the subcellular localization of ***tankyrase*** can be ***regulated*** by both the cell cycle and ***TRF1*** .	target	1
7512	10523510	983;995	Cdc2;cdc25	Suc1-dependent ******cdc25/Cdc2****** ***interaction*** is required for this process .	parallel	1
7513	10523510	983;995	Cdc2;cdc25	This first step occurs independently of PP2A or Suc1/Cks-dependent ******cdc25/Cdc2****** ***association*** .	parallel	0
7514	10523516	6422;7471	frizzled related protein;Wnt-1	A secreted ***frizzled related protein*** , FrzA , selectively ***associates*** with ***Wnt-1*** protein and regulates Wnt-1 signaling .	parallel	0
7515	10523516	6422;7471	frizzled related protein;Wnt-1	A secreted ***frizzled related protein*** , FrzA , selectively associates with Wnt-1 protein and ***regulates*** ***Wnt-1*** signaling .	target	1
7516	10523516	6422;7471	FrzA;Wnt-1	Here we demonstrate that ***FrzA*** , a sFRP that is highly expressed in vascular endothelium and a variety of epithelium , specifically ***binds*** to ***Wnt-1*** protein , but not Wnt-5a protein , and modulates Wnt-1 signaling .	parallel	1
7517	10523516	6422;7471	FrzA;Wnt-1	Here we demonstrate that ***FrzA*** , a sFRP that is highly expressed in vascular endothelium and a variety of epithelium , specifically binds to Wnt-1 protein , but not Wnt-5a protein , and ***modulates*** ***Wnt-1*** signaling .	target	0
7518	10523516	6422;7471	FrzA;Wnt-1	***FrzA*** ***associated*** with ***Wnt-1*** either when expressed in the same cell or when soluble FrzA was incubated with Wnt-1-expressing cells .	parallel	0
7519	10523516	6422;7471	FrzA;Wnt-1	***FrzA*** efficiently ***inhibited*** the ***Wnt-1*** mediated increase in cytoplasmic ( beta ) - catenin levels as well as the Wnt-1 induction of transcription from a Lef/tcf reporter gene .	negative	1
7520	10523516	6422;7471	FrzA;Wnt-1	These data demonstrate the existence of a negative regulatory mechanism mediated by the selective ***binding*** of ***FrzA*** to ***Wnt-1*** protein .	parallel	1
7521	10523620	7040;2006	TGF-beta1;tropoelastin	Binding activity increased as tropoelastin expression dropped , being low in neonatal fibroblasts and high in adult cells , and treatment with transforming growth factor beta1 ( ***TGF-beta1*** ) , which ***stimulates*** ***tropoelastin*** expression by stabilizing its mRNA , reduced mRNA-binding activity .	positive	0
7522	10523627	5335;29760	PLCgamma1;BLNK	Tyrosine phosphorylation did not require the SH2 ( C ) or SH3 domains but depended exclusively on a functional SH2 ( N ) domain , which mediated the ***association*** of ***PLCgamma1*** with the adapter protein , ***BLNK*** .	parallel	0
7523	10523630	3611;2185	ILK;protein kinase B	***ILK*** ***activates*** ***protein kinase B*** and inhibits the glycogen synthase kinase 3 ( GSK-3 ) activity in a phosphatidylinositol-3-kinase ( PI 3-kinase ) - dependent manner .	positive	1
7524	10523633	5245;1869	prohibitin;E2F1	Agents such as E1A , p38 kinase , and cyclins D and E had no effect on ***prohibitin-mediated*** ***repression*** of ***E2F1*** , but all of these molecules could reverse Rb function .	negative	1
7525	10523640	6714;6774	Src;Stat3	Although the ***Src*** tyrosine kinase ***induces*** constitutive ***Stat3*** phosphorylation on tyrosine , activation of Stat3-mediated gene regulation requires both tyrosine and serine phosphorylation of Stat3 .	target	1
7526	10523640	5599;6774	JNK;Stat3	Furthermore , inhibition of p38 and ***JNK*** activities ***suppresses*** constitutive ***Stat3*** serine phosphorylation and Stat3-mediated gene regulation .	positive	1
7527	10523640	5594;6774	p38;Stat3	Furthermore , inhibition of ***p38*** and JNK activities ***suppresses*** constitutive ***Stat3*** serine phosphorylation and Stat3-mediated gene regulation .	positive	1
7528	10523640	5599;6774	JNK;Stat3	In vitro kinase assays with purified full-length Stat3 as the substrate show that both ***JNK*** and p38 can ***phosphorylate*** ***Stat3*** on serine .	target	1
7529	10523640	5594;6774	p38;Stat3	In vitro kinase assays with purified full-length Stat3 as the substrate show that both JNK and ***p38*** can ***phosphorylate*** ***Stat3*** on serine .	target	1
7530	10523642	4214;23162	MEKK1;JSAP1	Although JSAP1 coprecipitated with MEK1 MAPKK and Raf-1 MAPKKK , and not MKK6 or MKK7 MAPKK , in cotransfected COS-7 cells , MEK1 and Raf-1 do not interfere with the ***binding*** of SEK1 and ***MEKK1*** to ***JSAP1*** , respectively .	parallel	1
7531	10523642	6416;23162	SEK1;JSAP1	Although JSAP1 coprecipitated with MEK1 MAPKK and Raf-1 MAPKKK , and not MKK6 or MKK7 MAPKK , in cotransfected COS-7 cells , MEK1 and Raf-1 do not interfere with the ***binding*** of ***SEK1*** and MEKK1 to ***JSAP1*** , respectively .	parallel	1
7532	10523642	23162;5599	JSAP1;JNK	The regions of ***JSAP1*** that ***bound*** ***JNK*** , SEK1 , and MEKK1 were distinct from one another .	parallel	1
7533	10523642	23162;4214	JSAP1;MEKK1	The regions of ***JSAP1*** that ***bound*** JNK , SEK1 , and ***MEKK1*** were distinct from one another .	parallel	1
7534	10523642	23162;6416	JSAP1;SEK1	The regions of ***JSAP1*** that ***bound*** JNK , ***SEK1*** , and MEKK1 were distinct from one another .	parallel	1
7535	10523642	5599;23162	JNK;JSAP1	***JNK*** and MEKK1 also ***bound*** ***JSAP1*** in vitro , suggesting that these interactions are direct .	parallel	1
7536	10523642	4214;23162	MEKK1;JSAP1	JNK and ***MEKK1*** also ***bound*** ***JSAP1*** in vitro , suggesting that these interactions are direct .	parallel	1
7537	10523642	6416;23162	SEK1;JSAP1	In contrast , only the activated form of ***SEK1*** ***associated*** with ***JSAP1*** in cotransfected COS-7 cells .	parallel	0
7538	10523642	6416;4214	SEK1;MEKK1	The unstimulated ***SEK1*** ***bound*** to ***MEKK1*** ; thus , SEK1 might indirectly associate with JSAP1 through MEKK1 .	parallel	1
7539	10523642	6416;23162	SEK1;JSAP1	The unstimulated SEK1 bound to MEKK1 ; thus , ***SEK1*** might indirectly ***associate*** with ***JSAP1*** through MEKK1 .	parallel	0
7540	10523647	1649;2353	CHOP;c-Fos	Here we show that ***CHOP*** ***interacts*** with members of the immediate-early response , growth-promoting AP-1 transcription factor family , JunD , c-Jun , and ***c-Fos*** , to activate promoter elements in the somatostatin , JunD , and collagenase genes .	parallel	1
7541	10523647	1649;3725	CHOP;c-Jun	Here we show that ***CHOP*** ***interacts*** with members of the immediate-early response , growth-promoting AP-1 transcription factor family , JunD , ***c-Jun*** , and c-Fos , to activate promoter elements in the somatostatin , JunD , and collagenase genes .	parallel	1
7542	10523647	1649;3727	CHOP;JunD	Here we show that ***CHOP*** ***interacts*** with members of the immediate-early response , growth-promoting AP-1 transcription factor family , ***JunD*** , c-Jun , and c-Fos , to activate promoter elements in the somatostatin , JunD , and collagenase genes .	parallel	1
7543	10523647	1649;3725	CHOP;AP-1	Analyses by electrophoretic mobility shift assays and by an in vivo mammalian two-hybrid system for protein-protein interactions indicate that ***CHOP*** ***interacts*** with ***AP-1*** proteins inside cells and suggest that it is recruited to the AP-1 complex by a tethering mechanism rather than by direct binding of DNA .	parallel	1
7544	10523647	1649;3725	CHOP;AP-1	Thus , ***CHOP*** not only is a negative or a positive regulator of C/EBP target genes but also , when tethered to AP-1 factors , can ***activate*** ***AP-1*** target genes .	positive	1
7545	10523650	1017;4654	Cdk2;MyoD	Taken together , our data suggest that repression of cyclin ***E-Cdk2-mediated*** ***phosphorylation*** of ***MyoD*** by p57 ( Kip2 ) could play an important role in the accumulation of MyoD at the onset of myoblast differentiation .	target	1
7546	10523650	1028;4654	p57;MyoD	***p57*** ( Kip2 ) ***stabilizes*** the ***MyoD*** protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts .	positive	0
7547	10523650	1029;4654	p16;MyoD	In addition , p57 ( Kip2 ) , p21 ( Cip1 ) , and p27 ( Kip1 ) but not ***p16*** ( Ink4a ) ***induced*** an increased level of ***MyoD*** protein , and we show that MyoD , an unstable nuclear protein , was stabilized by p57 ( Kip2 ) .	target	1
7548	10523650	5715;4654	p27;MyoD	In addition , p57 ( Kip2 ) , p21 ( Cip1 ) , and ***p27*** ( Kip1 ) but not p16 ( Ink4a ) ***induced*** an increased level of ***MyoD*** protein , and we show that MyoD , an unstable nuclear protein , was stabilized by p57 ( Kip2 ) .	target	1
7549	10523650	1028;4654	p57;MyoD	In addition , ***p57*** ( Kip2 ) , p21 ( Cip1 ) , and p27 ( Kip1 ) but not p16 ( Ink4a ) ***induced*** an increased level of ***MyoD*** protein , and we show that MyoD , an unstable nuclear protein , was stabilized by p57 ( Kip2 ) .	target	1
7550	10523650	1028;4654	p57;MyoD	In addition , p57 ( Kip2 ) , p21 ( Cip1 ) , and p27 ( Kip1 ) but not p16 ( Ink4a ) induced an increased level of MyoD protein , and we show that ***MyoD*** , an unstable nuclear protein , was ***stabilized*** by ***p57*** ( Kip2 ) .	positive	0
7551	10523650	1017;4654	Cdk2;MyoD	Furthermore , ***phosphorylation*** of ***MyoD*** by purified cyclin ***E-Cdk2*** complexes was inhibited by p57 ( Kip2 ) .	target	1
7552	10523650	1028;4654	p57;MyoD	Furthermore , phosphorylation of ***MyoD*** by purified cyclin E-Cdk2 complexes was ***inhibited*** by ***p57*** ( Kip2 ) .	negative	1
7553	10523656	10111;4361	Rad50;Mre11	The ******Mre11-Rad50-Xrs2****** protein ***complex*** facilitates homologous recombination-based double-strand break repair in Saccharomyces cerevisiae .	parallel	1
7554	10523656	10111;4361	Rad50;Mre11	Saccharomyces cerevisiae mre11Delta mutants are profoundly deficient in double-strand break ( DSB ) repair , indicating that the ******Mre11-Rad50-Xrs2****** protein ***complex*** plays a central role in the cellular response to DNA DSBs .	parallel	1
7555	10523656	10111;4361	Rad50;Mre11	Since a nuclease-deficient Mre11 mutant was not impaired in these assays , it appears that the role of the S. cerevisiae ******Mre11-Rad50-Xrs2****** protein ***complex*** in facilitating homologous recombination is independent of its nuclease activities .	parallel	1
7556	10523657	5971;4792	RelB;IkappaBalpha	***RelB*** ***modulation*** of ***IkappaBalpha*** stability as a mechanism of transcription suppression of interleukin-1alpha ( IL-1alpha ) , IL-1beta , and tumor necrosis factor alpha in fibroblasts .	target	0
7557	10523670	9759;4208	HDAC4;MEF2C	Through a small region located at its N-terminal domain , ***HDAC4*** ***interacts*** with the MADS-box transcription factor ***MEF2C*** .	parallel	1
7558	10523828	11184;1147	Hematopoietic progenitor kinase-1;IKK-alpha	***Hematopoietic progenitor kinase-1*** ( HPK1 ) stress response signaling pathway ***activates*** IkappaB kinases ( ***IKK-alpha/beta*** ) and IKK-beta is a developmentally regulated protein kinase .	positive	1
7559	10523828	11184;3551	Hematopoietic progenitor kinase-1;IKK-beta	***Hematopoietic progenitor kinase-1*** ( HPK1 ) stress response signaling pathway ***activates*** IkappaB kinases ( IKK-alpha/beta ) and ***IKK-beta*** is a developmentally regulated protein kinase .	positive	1
7560	10523828	11184;1147	Hematopoietic progenitor kinase-1;IKK-alpha	Moreover , both ***IKK-alpha*** and - beta were ***activated*** by ***Hematopoietic progenitor kinase-1*** ( HPK1 ) and MAPK/ERK kinase kinase-1 ( MEKK1 ) specifically , suggesting that IkappaB/NF-kappaB is regulated through the HPK1-MEKK1 stress response signaling pathway .	positive	1
7561	10523828	4214;1147	MAPK/ERK kinase kinase-1;IKK-alpha	Moreover , both ***IKK-alpha*** and - beta were ***activated*** by Hematopoietic progenitor kinase-1 ( HPK1 ) and ***MAPK/ERK kinase kinase-1*** ( MEKK1 ) specifically , suggesting that IkappaB/NF-kappaB is regulated through the HPK1-MEKK1 stress response signaling pathway .	positive	1
7562	10523846	4609;999	c-myc;E-cadherin	***E-cadherin*** expression was previously shown to be ***activated*** by RB and ***c-myc*** specifically in epithelial cells , through interaction with the AP-2 transcription factor .	positive	1
7563	10523846	4609;999	c-myc;E-cadherin	Here we show that only a wild type ***c-myc*** gene , coding for the two c-myc proteins c-Myc2 and c-Myc1 , was able to ***transactivate*** the ***E-cadherin*** promoter , in contrast to c-Myc2 or c-Myc1 alone which strongly repressed E-cadherin in both epithelial cells and fibroblasts .	positive	1
7564	10523853	3454;3439	IFNAR1;IFN-alpha	The E6/Tyk2 interaction requires the JH6-JH7 domains of Tyk2 , which are important for Tyk2 binding to the cytoplasmic portion of ***IFN-alpha*** ***receptor*** 1 ( ***IFNAR1*** ) .	parallel	1
7565	10523862	4217;5601	ASK1;SAPK	We report that TRAF2 , TRAF5 and TRAF6 associate with apoptosis signal-regulating kinase 1 ( ASK1 ) , and a catalytically-inactive ***ASK1*** mutant ***blocks*** stress-activated protein kinase ( ***SAPK*** ) / Jun NH2-terminal kinase ( JNK ) activation by these TRAFs .	positive	0
7566	10523862	7186;4217	TRAF2;ASK1	A truncated derivative of ***TRAF2*** , which inhibits SAPK activation by TNF , ***blocks*** TNF-induced ***ASK1*** activation .	negative	0
7567	10523862	7186;5601	TRAF2;SAPK	A truncated derivative of ***TRAF2*** , which ***inhibits*** ***SAPK*** activation by TNF , blocks TNF-induced ASK1 activation .	negative	1
7568	10524205	2623;57602	GATA-1;DUB-1	Furthermore , we demonstrated that ***GATA-1*** constitutively ***binds*** to the ***DUB-1*** enhancer element .	parallel	1
7569	10524211	10856;2040	ECP-51;stomatin	The ***interaction*** of ***ECP-51*** and ECP-54 with the ***stomatin*** peptide and the localization to the nucleus and cytoplasm suggest an additional function for these proteins as chaperone components .	parallel	1
7570	10524211	8607;2040	ECP-54;stomatin	The ***interaction*** of ECP-51 and ***ECP-54*** with the ***stomatin*** peptide and the localization to the nucleus and cytoplasm suggest an additional function for these proteins as chaperone components .	parallel	1
7571	10524239	2247;8714	bFGF;mrp3	Although the three cloned mrp/plf gene promoters are over 97 % identical , only ***mrp3*** is transcriptionally ***activated*** by ***bFGF*** .	positive	1
7572	10524251	23648;1278	SSDP;alpha 2(I) collagen	Chicken ***SSDP*** has been proposed to be involved in the transcriptional ***regulation*** of the ***alpha 2(I) collagen*** gene .	target	1
7573	10524342	4804;627	p75;neurotrophin	Neurotrophins exert effects on sensory neurons through receptor tyrosine kinases ( trks ) and a common ***neurotrophin*** ***receptor*** ( ***p75*** ) .	parallel	1
7574	10524563	5617;7200	PRL;TRH	The ***response*** of ***PRL*** to ***TRH*** was lower in patients versus control group ( 30 minutes : 3.9 + / - 3.4 and 12.0 + / - 2.8 ng/mL , p < 0.01 ) .	parallel	0
7575	10524628	6469;2249	Sonic hedgehog;fibroblast growth factor (FGF)4	***Sonic hedgehog*** ( SHH ) signalling by the polarizing region ***modulates*** ***fibroblast growth factor (FGF)4*** signalling by the posterior AER , which in turn maintains the polarizing region ( SHH/FGF4 feedback loop ) .	target	0
7576	10524628	26585;2249	Gremlin;FGF4	This study uncovers the cascade by which the SHH signal is relayed from the posterior mesenchyme to the AER and establishes that Formin-dependent activation of the BMP antagonist ***Gremlin*** is sufficient to ***induce*** ***FGF4*** and establish the SHH/FGF4 feedback loop .	target	1
7577	10524682	3479;5328	IGF-1;uPA	Interestingly , ***IGF-1*** ***enhanced*** basal ***uPA*** activity in OA specimens in a dose-dependent manner .	positive	0
7578	10524682	3479;5340	IGF-1;Plasmin	***IGF-1*** also ***reduced*** ***Plasmin*** activity in OA osteoblasts while it did not modify this activity in normal osteoblasts .	negative	1
7579	10524682	3479;5328	IGF-1;uPA	Addition of ***IGF-1*** to osteoblasts significantly ***reduced*** ***uPA*** protein levels only in OA patients ( P < 0.05 ) .	negative	1
7580	10525037	3827;186	bradykinin;angiotensin II type 2 receptor	The ***interaction*** of nitric oxide , ***bradykinin*** , and the ***angiotensin II type 2 receptor*** : lessons learned from transgenic mice .	parallel	1
7581	10525042	959;3627	CD40 ligand;IP-10	In vitro experiments supported these results and showed that IL-1beta , TNF-alpha , and ***CD40 ligand*** ***potentiated*** ***IP-10*** expression from IFN-gamma-stimulated ECs .	positive	0
7582	10525042	3553;3627	IL-1beta;IP-10	In vitro experiments supported these results and showed that ***IL-1beta*** , TNF-alpha , and CD40 ligand ***potentiated*** ***IP-10*** expression from IFN-gamma-stimulated ECs .	positive	0
7583	10525042	7124;3627	TNF-alpha;IP-10	In vitro experiments supported these results and showed that IL-1beta , ***TNF-alpha*** , and CD40 ligand ***potentiated*** ***IP-10*** expression from IFN-gamma-stimulated ECs .	positive	0
7584	10525042	3458;3627	IFN-gamma;IP-10	In addition , nitric oxide ( NO ) treatment decreased ***IFN-gamma*** ***induction*** of ***IP-10*** .	target	1
7585	10525082	3553;2247	IL-1;bFGF	These results indicate that ***IL-1*** , expressed in macrophages/monocytes and fibroblasts in the ulcer base , might ***up-regulate*** the mRNA expression of COX-2 , iNOS , CINC-1 , HGF , and ***bFGF*** , thereby contributing to gastric ulcer healing in rats .	positive	1
7586	10525082	3553;5743	IL-1;COX-2	These results indicate that ***IL-1*** , expressed in macrophages/monocytes and fibroblasts in the ulcer base , might ***up-regulate*** the mRNA expression of ***COX-2*** , iNOS , CINC-1 , HGF , and bFGF , thereby contributing to gastric ulcer healing in rats .	positive	1
7587	10525082	3553;3082	IL-1;HGF	These results indicate that ***IL-1*** , expressed in macrophages/monocytes and fibroblasts in the ulcer base , might ***up-regulate*** the mRNA expression of COX-2 , iNOS , CINC-1 , ***HGF*** , and bFGF , thereby contributing to gastric ulcer healing in rats .	positive	1
7588	10525082	3553;4843	IL-1;iNOS	These results indicate that ***IL-1*** , expressed in macrophages/monocytes and fibroblasts in the ulcer base , might ***up-regulate*** the mRNA expression of COX-2 , ***iNOS*** , CINC-1 , HGF , and bFGF , thereby contributing to gastric ulcer healing in rats .	positive	1
7589	10525082	3557;4843	IL-1RA;iNOS	***IL-1RA*** dose-dependently ***reduced*** prostaglandin E ( 2 ) production , total and ***iNOS*** activities , neutrophil chemotactic activity , and growth-promoting activity toward gastric epithelial cells in the ulcer base .	negative	1
7590	10525157	8862;187	Apelin;APJ	***Apelin*** , the natural ***ligand*** of the orphan receptor ***APJ*** , is abundantly secreted in the colostrum .	parallel	1
7591	10525311	3439;356	IFN-alpha;FasL	***IFN-alpha*** ***upregulated*** mRNA expression of Fas and ***FasL*** in activated PBMC .	positive	1
7592	10525313	3565;6356	IL-4;eotaxin	The ***eotaxin*** generation was ***induced*** by tumour necrosis factor alpha ( TNF-alpha ) or ***IL-4*** , and the production was drastically increased by combined use of these cytokines .	target	1
7593	10525313	7124;6356	TNF-alpha;eotaxin	The ***eotaxin*** generation was ***induced*** by tumour necrosis factor alpha ( ***TNF-alpha*** ) or IL-4 , and the production was drastically increased by combined use of these cytokines .	target	1
7594	10525320	3458;3592	IFN-gamma;p35	SAC-stimulated IL-12 ***p35*** and p40 mRNAs were significantly ***augmented*** by interferon gamma ( ***IFN-gamma*** ) .	positive	0
7595	10525320	3458;3578	IFN-gamma;p40	SAC-stimulated IL-12 p35 and ***p40*** mRNAs were significantly ***augmented*** by interferon gamma ( ***IFN-gamma*** ) .	positive	0
7596	10525320	3458;3586	IFN-gamma;IL-10	Exogenous IL-12 or ***IFN-gamma*** significantly ***inhibited*** ***IL-10*** gene expression , without affecting IL-6 mRNA or other proinflammatory cytokine mRNA levels .	negative	1
7597	10525354	6469;650	Shh;BMP2	Our observations suggest that ***Shh-N*** selectively promotes the elaboration of both neuronal and oligodendroglial lineage species and ***inhibits*** the effects of ***BMP2*** on progenitor cell proliferation and astroglial differentiation .	negative	1
7598	10525372	3558;3458	IL-2;IFNgamma	***IL-2*** ***enhances*** standard ***IFNgamma/LPS*** activation of macrophage cytotoxicity to human ovarian carcinoma in vitro : a potential for adoptive cellular immunotherapy .	positive	0
7599	10525409	4322;176	collagenase-3;aggrecan	***collagenase-3*** ( MMP-13 ) is a member of this family and preferentially ***cleaves*** type II collagen , cartilage , fibronectin and ***aggrecan*** .	target	1
7600	10525423	1756;4842	dystrophin;nNOS	In skeletal muscle , ***dystrophin*** is normally ***associated*** with neuronal nitric oxide synthase ( ***nNOS*** ) at the sarcolemma .	parallel	0
7601	10525448	7189;4790	TRAF-6;NFkappaB	The IL-18R complex recruits the IL-1R-activating kinase ( IRAK ) and TNFR-associated factor-6 ( ***TRAF-6*** ) which ***phosphorylates*** nuclear factor kappaB ( ***NFkappaB*** ) - inducing kinase ( NIK ) with subsequent activation of NFkappaB .	target	1
7602	10525448	3606;356	IL-18;Fas ligand	***IL-18*** ***induces*** gene expression and synthesis of tumor necrosis factor ( TNF ) , IL-1 , ***Fas ligand*** , and several chemokines .	target	1
7603	10525448	3606;3553	IL-18;IL-1	***IL-18*** ***induces*** gene expression and synthesis of tumor necrosis factor ( TNF ) , ***IL-1*** , Fas ligand , and several chemokines .	target	1
7604	10525667	8660;3643	IRS-2;insulin receptor	The variant did not affect the ***binding*** of ***IRS-2*** to the ***insulin receptor*** or p85alpha of phosphatidylinositol 3-kinase when measured in the yeast two-hybrid system .	parallel	1
7605	10525667	8660;5295	IRS-2;p85alpha	The variant did not affect the ***binding*** of ***IRS-2*** to the insulin receptor or ***p85alpha*** of phosphatidylinositol 3-kinase when measured in the yeast two-hybrid system .	parallel	1
7606	10526095	5972;183	renin;angiotensin (ANG) II	Most of the biological actions of the circulating ( a.k.a. , the systemic or blood-borne ) ***renin-angiotensin*** system ***require*** the generation of the octapeptide ***angiotensin (ANG) II*** from the decapeptide ANG I.	target	0
7607	10526127	351;836	Abeta;caspase-3	We here report on ***caspase-3*** ***activation*** by ***Abeta-treatment*** of cultured neurons .	positive	1
7608	10526127	351;1302	Abeta;PARP	Caspase inhibitor of broad specificity , Z-VAD-CH ( 2 ) - DCB , additionally prevented ***Abeta-induced*** ***cleavage*** of ***PARP*** and some early loss of cell membrane integrity measured by LDH release .	target	1
7609	10526130	1019;5925	Cdk4;pRb	***pRb*** phosphorylation is ***regulated*** differentially by cyclin-dependent kinase (Cdk) 2 and ***Cdk4*** in retinoic acid-induced neuronal differentiation of P19 cells .	target	1
7610	10526130	1017;5925	cyclin-dependent kinase (Cdk) 2;pRb	***pRb*** phosphorylation is ***regulated*** differentially by ***cyclin-dependent kinase (Cdk) 2*** and Cdk4 in retinoic acid-induced neuronal differentiation of P19 cells .	target	1
7611	10526130	1017;5925	Cdk2;pRb	These observations suggest that ***Cdk2*** and Cdk4 may ***phosphorylate*** different sites of ***pRb*** in vivo and that the two sites of pRb examined here are newly phosphorylated during RA-induced neuronal differentiation in P19 cells .	target	1
7612	10526130	1019;5925	Cdk4;pRb	These observations suggest that Cdk2 and ***Cdk4*** may ***phosphorylate*** different sites of ***pRb*** in vivo and that the two sites of pRb examined here are newly phosphorylated during RA-induced neuronal differentiation in P19 cells .	target	1
7613	10526166	4018;2621	lipoprotein;Gas6	Furthermore , the atherogenic ***lipoprotein*** , oxidized LDL , ***induced*** ***Gas6*** production in these cells .	target	1
7614	10526178	112950;3099	Med8;HXK2	Analysis by atomic force microscopy of ***Med8*** ***binding*** to cis-acting regulatory elements of the SUC2 and ***HXK2*** genes of saccharomyces cerevisiae .	parallel	1
7615	10526183	5008;5743	OSM;COX-2	We conclude that ***induction*** of ***COX-2*** by ***OSM*** is necessary for its angiogenic activity , but is not sufficient since IL-1beta , which also induces COX-2 in HMEC-1 , has only a poor proliferative effect .	target	1
7616	10526183	3553;5743	IL-1beta;COX-2	We conclude that induction of COX-2 by OSM is necessary for its angiogenic activity , but is not sufficient since ***IL-1beta*** , which also ***induces*** ***COX-2*** in HMEC-1 , has only a poor proliferative effect .	target	1
7617	10526212	7336;5980	MMS2;rev3	The synergistic effects of MMS2 and rev3 mutations towards killing by a variety of DNA-damaging agents ruled out the possibility that ***MMS2*** simply acts to ***suppress*** ***rev3*** activity and favored the hypothesis that MMS2 and rev3 form two alternative subpathways within the RAD6 DNA repair pathway .	negative	1
7618	10526239	5705;6908	SUG1;TBP	Previous studies have demonstrated that ***SUG1*** is ***associated*** with ***TBP*** .	parallel	0
7619	10526239	5705;6908	SUG1;TBP	In this study , we investigated the ***association*** of mammalian ***SUG1*** with ***TBP*** in more detail .	parallel	0
7620	10526239	5705;5701	SUG1;MSS1	We present evidence that TBP and at least ***SUG1*** , ***MSS1*** , and S4 form a ***complex*** in the cell .	parallel	1
7621	10526239	5705;6908	SUG1;TBP	We present evidence that ***TBP*** and at least ***SUG1*** , MSS1 , and S4 form a ***complex*** in the cell .	parallel	1
7622	10526239	6908;5701	TBP;MSS1	We present evidence that ***TBP*** and at least SUG1 , ***MSS1*** , and S4 form a ***complex*** in the cell .	parallel	1
7623	10526261	7040;3952	TGF-beta1;leptin	Similarly , ***TGF-beta1*** ***decreased*** ***leptin*** mRNA expression in newly differentiated human adipocytes to 77 + / - 12 % after 24h and to 54 + / - 8 % after 48h compared with control cultures .	negative	0
7624	10526314	5458;5080	Brn-3B;Pax-6	Evidence that POU factor ***Brn-3B*** ***regulates*** expression of ***Pax-6*** in neuroretina cells .	target	1
7625	10526316	627;5816	brain-derived neurotrophic factor;Parvalbumin	***Parvalbumin*** immunoreactivity is ***enhanced*** by ***brain-derived neurotrophic factor*** in organotypic cultures of rat retina .	positive	0
7626	10526337	5045;9445	Furin;ABri	***Furin*** ***mediates*** enhanced production of fibrillogenic ***ABri*** peptides in familial British dementia .	target	0
7627	10526409	8721;2516	MBF1;Ad4BP	Human ***MBF1*** ( hMBF1 ) can ***bind*** to TBP and to the nuclear receptor ***Ad4BP*** , and is suggested to mediate Ad4BP-dependent transcriptional activation .	parallel	1
7628	10526409	8721;6908	MBF1;TBP	Human ***MBF1*** ( hMBF1 ) can ***bind*** to ***TBP*** and to the nuclear receptor Ad4BP , and is suggested to mediate Ad4BP-dependent transcriptional activation .	parallel	1
7629	10526628	29953;7200	TRH-DE;TRH	Vice versa it also holds true that ***TRH*** is selectively ***inactivated*** only by ***TRH-DE*** and thus , this enzyme might be considered to be the terminator of TRH signals .	negative	1
7630	10527265	5624;5627	protein C;protein S	***Interaction*** of the ******protein C/protein S****** anticoagulant system , the endothelium and pregnancy .	parallel	1
7631	10527398	3123;3122	DRB1;HLA-DRA	The complete ***linkage*** between ***DRB1*** * 1501 and the ***HLA-DRA*** promoter A allele indicates that the MS susceptibility haplotype ( DRB1 * 1501-HLA-DQB1 * 0602-HLA-DQA1 * 0102 ) can be extended out to promoter of the HLA-DRA locus .	parallel	0
7632	10527398	3122;3109	HLA-DRA;HLA-DMB	***Interactions*** between both ***HLA-DMB*** and the ***HLA-DRA*** promoter and other reported MS susceptibility loci were examined ( TCRBV polymorphisms , HLA-DQA1 and HLA-DQB1 ) .	parallel	1
7633	10527453	7124;5320	TNF-alpha;sPLA2	On the other hand , C-2 ceramide ( 0.3 microM ) as well as other lipid mediators , such as lysophosphatidylcholine and arachidonic acid , were able to elicit a small increase in sPLA2 and potentiate the ***induction*** of ***sPLA2*** by ***TNF-alpha*** .	target	1
7634	10527519	1147;373156	IKK-1;GST	The assay provided a convenient way to compare IKK protein and peptide substrate preferences ; biotinylated ***GST-IkappaBalpha*** ( 1-54 ) was more readily ***phosphorylated*** by both ***IKK-1*** and IKK-2 compared to biotinylated myelin basic protein or a 20-mer biotinylated peptide containing serines 32 and 36 of IkappaBalpha .	target	1
7635	10527519	1147;4792	IKK-1;IkappaBalpha	The assay provided a convenient way to compare IKK protein and peptide substrate preferences ; biotinylated ***GST-IkappaBalpha*** ( 1-54 ) was more readily ***phosphorylated*** by both ***IKK-1*** and IKK-2 compared to biotinylated myelin basic protein or a 20-mer biotinylated peptide containing serines 32 and 36 of IkappaBalpha .	target	1
7636	10527519	3551;373156	IKK-2;GST	The assay provided a convenient way to compare IKK protein and peptide substrate preferences ; biotinylated ***GST-IkappaBalpha*** ( 1-54 ) was more readily ***phosphorylated*** by both IKK-1 and ***IKK-2*** compared to biotinylated myelin basic protein or a 20-mer biotinylated peptide containing serines 32 and 36 of IkappaBalpha .	target	1
7637	10527519	3551;4792	IKK-2;IkappaBalpha	The assay provided a convenient way to compare IKK protein and peptide substrate preferences ; biotinylated ***GST-IkappaBalpha*** ( 1-54 ) was more readily ***phosphorylated*** by both IKK-1 and ***IKK-2*** compared to biotinylated myelin basic protein or a 20-mer biotinylated peptide containing serines 32 and 36 of IkappaBalpha .	target	1
7638	10527633	2064;2065	ErbB2;ErbB3	We analyzed the ***formation*** of homo - and heterodimers between EGFR , ***ErbB2*** , and ***ErbB3*** ( members of the EGF receptor family ) in the human skin keratinocyte cell line HaCaT , in dependence of the added ligand .	parallel	0
7639	10527638	5339;1674	plectin;desmin	These data were supplemented with in vitro binding assays showing direct ***interaction*** of ***plectin*** with ***desmin*** via its carboxy-terminal IF-binding domain .	parallel	1
7640	10527639	1019;896	CDK4;cyclin D3	This implies that even after induction of stable nuclear ******cyclin D3-CDK4****** ***complexes*** , dog thyrocytes still depend on cAMP for RB phosphorylation and commitment to DNA synthesis , which suggests that a key labile event responsible for a last control of restriction point passage remains to be uncovered , in the cAMP-dependent cell cycle of dog thyrocytes and possibly other systems .	parallel	1
7641	10527687	970;939	CD70;CD27	***CD70*** , which is expressed on activated B and T cells , but not on resting lymphocytes , is a ***ligand*** for ***CD27*** .	parallel	1
7642	10527687	970;939	CD70;CD27	Most AIDS-NHL cell lines and primary AIDS-NHL tumor specimens expressed both ***CD27*** and its ***ligand*** , ***CD70*** .	parallel	1
7643	10527714	1803;2641	dipeptidyl peptidase IV;GLP-2	The intestinal brush-border protease ***dipeptidyl peptidase IV*** ( DPP IV ) ***cleaves*** ***GLP-2*** to an inactive form .	target	1
7644	10527715	3486;7040	IGFBP-3;TGF-beta	In some systems , ***IGFBP-3*** ***mediates*** the effects of ***TGF-beta*** .	target	0
7645	10527766	7010;284	Tie-2;Ang-1	These findings are consistent with the view that ******Ang-1/Tie-2****** ***signaling*** is essential for both angiogenesis and endothelial cell survival .	parallel	0
7646	10527766	7010;284	Tie-2;Angiopoietin-1	***Angiopoietin-1*** and its ***receptor*** ***Tie-2*** participate in the regulation of capillary-like tubule formation and survival of endothelial cells .	parallel	1
7647	10527766	7010;284	Tie-2;Angiopoietin-1	***Angiopoietin-1*** ( Ang-1 ) and its ***receptor*** ***Tie-2*** , a trans-membrane tyrosine kinase uniquely expressed by endothelial cells , are shown by null mutation studies to be essential to developmental angiogenesis .	parallel	1
7648	10527766	284;7010	Ang-1;Tie-2	Although recombinant ***Ang-1*** , which ***induces*** ***Tie-2*** phosphorylation , has no effect on the proliferation of endothelial cells , treatment of confluent adult bovine aortic endothelial cells ( ABAE ) cells grown on collagen gels with Ang-1 ( 100 ng/ml ) causes the cells to migrate into the collagen gel and form capillary-like tubules .	target	1
7649	10527802	2668;1103	glial-derived neurotrophic factor;choline acetyltransferase	Using organotypic spinal cord cultures from postnatal rats , we have demonstrated that insulin-like growth factor-I ( IGF-I ) and ***glial-derived neurotrophic factor*** ( GDNF ) significantly ***increase*** ***choline acetyltransferase*** ( ChAT ) activity , but brain-derived neurotrophic factor ( BDNF ) , neurotrophin-4 ( NT-4/5 ) , and neurotrophin-3 ( NT-3 ) do not .	positive	0
7650	10527802	3479;1103	IGF-I;choline acetyltransferase	Using organotypic spinal cord cultures from postnatal rats , we have demonstrated that insulin-like growth factor-I ( ***IGF-I*** ) and glial-derived neurotrophic factor ( GDNF ) significantly ***increase*** ***choline acetyltransferase*** ( ChAT ) activity , but brain-derived neurotrophic factor ( BDNF ) , neurotrophin-4 ( NT-4/5 ) , and neurotrophin-3 ( NT-3 ) do not .	positive	0
7651	10527803	3479;836	IGF-I;caspase-3	In contrast , addition of ***IGF-I*** , even at physiological concentrations , ***prevents*** activation of ***caspase-3*** and neuronal apoptosis in vitro .	negative	0
7652	10527805	5663;5689	presenilin 1;HC5	Alzheimer 's disease associated ***presenilin 1*** ***interacts*** with ***HC5*** and ZETA , subunits of the catalytic 20S proteasome .	parallel	1
7653	10527805	5689;5663	HC5;PSEN1	Here we demonstrate the direct physical ***interaction*** between ***PSEN1*** and two subunits , ***HC5*** and ZETA , of the 20S proteasome .	parallel	1
7654	10527818	3481;6541	IGF-II;CAT1	These data indicate that an excess level of GH stimulates GLT1 ( EAAT2 ) expression and that a normal level of IGF-II is required for typical expression of GLT1 ( EAAT2 ) , GLAST1 ( EAAT1 ) and EAAC1 ( EAAT3 ) , but that ***IGF-II*** ***downregulates*** the expression of EAAT4 and ***CAT1*** .	negative	1
7655	10527818	3481;6511	IGF-II;EAAT4	These data indicate that an excess level of GH stimulates GLT1 ( EAAT2 ) expression and that a normal level of IGF-II is required for typical expression of GLT1 ( EAAT2 ) , GLAST1 ( EAAT1 ) and EAAC1 ( EAAT3 ) , but that ***IGF-II*** ***downregulates*** the expression of ***EAAT4*** and CAT1 .	negative	1
7656	10527851	2114;4314	ETS-2;stromelysin-1	EHF protein represses the ***ETS-2*** ***induced*** activity of both ***stromelysin-1*** and collagenase-1 promoters .	target	1
7657	10527858	2268;1232	c-fgr;CCR3	Novel ***association*** of the src family kinases , hck and ***c-fgr*** , with ***CCR3*** receptor stimulation : A possible mechanism for eotaxin-induced human eosinophil chemotaxis .	parallel	0
7658	10527858	6356;1232	eotaxin;CCR3	Coimmunoprecipitation studies revealed that ***binding*** of ***eotaxin*** to ***CCR3*** greatly enhanced association of the Src family kinases , Hck and c-fgr , with CCR3 after internalization of CCR3 .	parallel	1
7659	10527858	2268;1232	c-fgr;CCR3	Coimmunoprecipitation studies revealed that binding of eotaxin to CCR3 greatly enhanced ***association*** of the Src family kinases , Hck and ***c-fgr*** , with ***CCR3*** after internalization of CCR3 .	parallel	0
7660	10527858	2268;1232	c-fgr;CCR3	These results may indicate that ***recruitment*** of Hck and ***c-fgr*** to ***CCR3*** in a compartment triggers tyrosine phosphorylation , leading to rapid cell shape changes required for cell migration .	target	0
7661	10527860	1676;1677	DFF45;DFF40	Either D1 or D2 , as an isolated domain , is capable of inhibiting DFF40 nuclease activity while double domain fragments D1-2 and D2-3 , as well as full-length ***DFF45*** , ***bind*** to ***DFF40*** with high affinity and are much more effective inhibitors .	parallel	1
7662	10527861	1676;1677	DFF45;DFF40	Multiple domains of ***DFF45*** ***bind*** synergistically to ***DFF40*** : roles of caspase cleavage and sequestration of activator domain of DFF40 .	parallel	1
7663	10527861	1676;1677	DFF45;DFF40	This allows us to show that DFF40/45 interaction is mediated by ***binding*** of three functional domains ( D1 , D2 , and D3 ) of ***DFF45*** to two domains ( activator and catalytic ) of ***DFF40*** .	parallel	1
7664	10527909	5606;5594	MKK3;p38	SEK1 phosphorylates and activates both p38 and c-Jun NH ( 2 ) - terminal kinase ( JNK ) , whereas ***MKK3*** and MKK6 selectively ***phosphorylate*** and activate ***p38*** .	target	1
7665	10527909	5608;5594	MKK6;p38	SEK1 phosphorylates and activates both p38 and c-Jun NH ( 2 ) - terminal kinase ( JNK ) , whereas MKK3 and ***MKK6*** selectively ***phosphorylate*** and activate ***p38*** .	target	1
7666	10527913	355;356	Fas;Fas ligand	Role of ******Fas-Fas ligand****** ***interactions*** in 2,3,7,8-tetrachlorodibenzo - p-dioxin ( TCDD ) - induced immunotoxicity : increased resistance of thymocytes from Fas-deficient ( lpr ) and Fas ligand-defective ( gld ) mice to TCDD-induced toxicity .	parallel	1
7667	10527913	355;356	Fas;Fas ligand	Together , the current study demonstrates that ******Fas-Fas ligand****** ***interactions*** play an important role in TCDD-mediated induction of apoptosis and immunotoxicity .	parallel	1
7668	10527940	2056;6886	erythropoietin;SCL	Mitogen-activated protein kinase mediates ***erythropoietin-induced*** ***phosphorylation*** of the ***TAL1/SCL*** transcription factor in murine proerythroblasts .	target	1
7669	10527940	2056;6886	erythropoietin;TAL1	We reported previously that ***TAL1*** phosphorylation is ***stimulated*** by ***erythropoietin*** in splenic proerythroblasts isolated from mice infected with the anaemia-inducing strain of Friend virus and show here the signalling pathway responsible .	positive	0
7670	10527951	3320;1431	HSP90;citrate synthase	Although ***HSP90*** ***inhibited*** the aggregation of ***citrate synthase*** as a molecular chaperone in vitro , the activity was suppressed almost completely in the presence of CDDP .	negative	1
7671	10528162	317;842	Apaf-1;caspase-9	We have found both caspases-3 and -9 , but not caspase-8 , to be involved in the BCR apoptotic pathway , thus supporting the notion that initiation of the caspase cascade could be under the control of the ******caspase-9/Apaf-1/cytochrome****** c multimolecular ***complex*** .	parallel	1
7672	10528163	3565;3458	IL-4;IFN-gamma	While the molecular mechanisms for IL-4-mediated transcription activation have been extensively studied , little is known about molecular mechanisms required for ***IL-4*** ***inhibition*** of ***IFN-gamma*** signaling .	negative	1
7673	10528169	6363;3586	Macrophage inflammatory protein-3 beta;IL-10	***Macrophage inflammatory protein-3 beta*** ***enhances*** ***IL-10*** production by activated human peripheral blood monocytes and T cells .	positive	0
7674	10528169	6363;1236	MIP-3 beta;CCR7	The ability of ***MIP-3 beta*** to augment IL-10 production ***correlated*** with ***CCR7*** mRNA expression and stimulation of intracellular calcium mobilization in both monocytes and T cells .	parallel	0
7675	10528175	1432;3567	p38 mitogen-activated protein kinase;IL-5	***p38 mitogen-activated protein kinase*** ***regulates*** human T cell ***IL-5*** synthesis .	target	1
7676	10528180	958;959	CD40;CD40 ligand	The ******CD40-CD40 ligand****** ( CD40L ) ***interaction*** is a key event in the initiation of an adaptive immune response , and as such the therapeutic value of CD40L blockade has been studied in many experimental models of tissue transplantation and autoimmune disease .	parallel	1
7677	10528182	941;3565	B7-1;IL-4	However , whereas B7-1 expression on APCs can promote IL-4 production , ***IL-4*** production is ***inhibited*** by ***B7-1*** on T cells .	negative	1
7678	10528182	941;3565	B7-1;IL-4	However , whereas ***B7-1*** expression on APCs can ***promote*** ***IL-4*** production , IL-4 production is inhibited by B7-1 on T cells .	positive	0
7679	10528182	3565;941	IL-4;B7-1	In addition , we found that ***IL-4*** ***inhibits*** ***B7-1*** expression by wild-type DO11 .10 T cells .	negative	1
7680	10528182	941;3565	B7-1;IL-4	The studies presented here demonstrate that ***B7-1*** on T cells as well as on APCs ***regulates*** ***IL-4*** production .	target	1
7681	10528187	3604;8744	CD137;4-1BB ligand	BB ( ***CD137*** ) is a costimulatory molecule expressed on activated T cells and ***interacts*** with ***4-1BB ligand*** ( 4-1BBL ) on APCs .	parallel	1
7682	10528187	959;958	CD40L;CD40	Altogether , these results indicate that T cells have distinct costimulatory requirements : optimal CD8 responses require 4-1BBL-dependent interactions , whereas CD4 responses are minimally affected by 4-1BB costimulation , but require ******CD40-CD40L****** and B7-dependent ***interactions*** .	parallel	1
7683	10528192	4609;7412	c-Myc;VCAM-1	A novel role for H-Ras in the ***regulation*** of very late antigen-4 integrin and ***VCAM-1*** via ***c-Myc-dependent*** and - independent mechanisms .	target	1
7684	10528193	836;596	caspase-3;Bcl-2	This study thus provides novel in vivo evidence that ***caspase-3*** , conventionally known for its downstream effector function in apoptosis , also ***modifies*** ***Bcl-2*** and other upstream proteins involved in the regulation of Fas-mediated apoptosis .	target	0
7685	10528193	836;596	caspase-3;Bcl-2	Western blotting confirmed the lack of ***caspase-3-mediated*** ***cleavage*** of ***Bcl-2*** .	target	1
7686	10528195	6416;5599	SEK1;JNK	Dominant-negative ***SEK1*** can ***block*** ***JNK*** activation by LPS , but not by Salmonella .	negative	0
7687	10528211	721;1378	C4b;CR1	C1q and ***C4b*** ***bind*** simultaneously to ***CR1*** and additively support erythrocyte adhesion .	parallel	1
7688	10528214	5594;5599	ERK;JNK1	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7689	10528214	5594;6714	ERK;Src	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ******Src/ERK****** and Syk/JNK1 cascades that are both necessary to sustain IL-1 synthesis .	target	0
7690	10528214	5594;6850	ERK;Syk	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7691	10528214	5599;5594	JNK1;ERK	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7692	10528214	5599;6714	JNK1;Src	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7693	10528214	5599;6850	JNK1;Syk	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent Src/ERK and ******Syk/JNK1****** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7694	10528214	6714;5594	Src;ERK	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ******Src/ERK****** and Syk/JNK1 cascades that are both necessary to sustain IL-1 synthesis .	target	0
7695	10528214	6714;5599	Src;JNK1	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7696	10528214	6714;6850	Src;Syk	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7697	10528214	6850;5594	Syk;ERK	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7698	10528214	6850;5599	Syk;JNK1	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent Src/ERK and ******Syk/JNK1****** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7699	10528214	6850;6714	Syk;Src	Our data support a model where the status of microtubule polymerization influences the activity of Go or Gi proteins that ***control*** , in turn , two independent ***Src/ERK*** and ***Syk/JNK1*** cascades that are both necessary to sustain IL-1 synthesis .	target	0
7700	10528224	672;1026	BRCA1;p21	***BRCA1*** has intrinsic transactivation activity and is able to ***activate*** the ***p21*** promoter .	positive	1
7701	10528224	672;10111	BRCA1;Rad50	In human cells , ***BRCA1*** ***binds*** to both ***Rad50*** and Rad51 and colocalizes with these proteins at repair foci .	parallel	1
7702	10528224	672;5888	BRCA1;Rad51	In human cells , ***BRCA1*** ***binds*** to both Rad50 and ***Rad51*** and colocalizes with these proteins at repair foci .	parallel	1
7703	10528229	2621;558	gas6;Axl	Administration of the ***Axl*** ***ligand*** , ***gas6*** , to peripheral transgenic blood samples eliminated excessive TNF-alpha production in response to LPS stimulation .	parallel	1
7704	10528232	1432;3315	p38 MAP kinase;HSP25	Because phosphorylation of HSP25 is essential for its actin-modulating function , we suppressed the activity of ***p38 MAP kinase*** , the major upstream ***activator*** of ***HSP25*** phosphorylation , with the specific inhibitor SB 203580 .	positive	1
7705	10528890	958;3569	CD40;interleukin-6	***CD40*** activation of myeloma cells changes their cell surface phenotype , ***triggers*** autocrine ***interleukin-6*** secretion , and can regulate myeloma cell cycle in a p53-dependent fashion .	positive	0
7706	10528999	1387;2908	CREB-binding protein;glucocorticoid receptor	Conditional ***modulation*** of ***glucocorticoid receptor*** activities by ***CREB-binding protein*** ( CBP ) and p300 .	target	0
7707	10528999	2033;2908	p300;glucocorticoid receptor	Conditional ***modulation*** of ***glucocorticoid receptor*** activities by CREB-binding protein ( CBP ) and ***p300*** .	target	0
7708	10528999	2033;1387	p300;CBP	In fact , ***p300*** completely ***antagonized*** the suppressive effects of ***CBP*** in a dose-dependent fashion , probably by competing with this protein at the level of the transcription complex .	negative	1
7709	10529123	941;942	B7-1;B7-2	CD28 responsive complex was detected in nuclear extracts of freshly isolated lymphocytes from RA synovial tissues , but not those from osteoarthritis synovial tissues or normal peripheral blood , suggesting in vivo activation of T cells by the ******CD28/B7-1/B7-2****** ***interactions*** .	parallel	1
7710	10529123	941;940	B7-1;CD28	CD28 responsive complex was detected in nuclear extracts of freshly isolated lymphocytes from RA synovial tissues , but not those from osteoarthritis synovial tissues or normal peripheral blood , suggesting in vivo activation of T cells by the ******CD28/B7-1/B7-2****** ***interactions*** .	parallel	1
7711	10529123	940;942	CD28;B7-2	CD28 responsive complex was detected in nuclear extracts of freshly isolated lymphocytes from RA synovial tissues , but not those from osteoarthritis synovial tissues or normal peripheral blood , suggesting in vivo activation of T cells by the ******CD28/B7-1/B7-2****** ***interactions*** .	parallel	1
7712	10529148	7422;1401	VEGF;CRP	***VEGF*** levels ***correlated*** statistically with C-reactive protein ( ***CRP*** ) in patients with both infectious diseases and polyarticular JRA , but the regression slope ( VEGF/CRP ) was much steeper in polyarticular JRA than in infectious diseases .	parallel	0
7713	10529171	6347;729230	MCP-1;CCR2	To identify the regions of ***MCP-1*** that ***contact*** its receptor , ***CCR2*** , we substituted all surface-exposed residues with alanine .	parallel	0
7714	10529237	6285;3000	S100beta;ROS-GC1	However , at micromolar concentrations of Ca ( 2 + ) , ***ROS-GC1*** is ***stimulated*** by ***S100beta*** [ also named calcium-dependent ( CD ) GCAP ] .	positive	0
7715	10529267	348;4018	apolipoprotein E;lipoprotein	Analysis of expression of genes involved in apolipoprotein E-based lipoprotein metabolism in pregnant mice deficient in the receptor-associated protein , the low density ***lipoprotein*** ***receptor*** , or ***apolipoprotein E*** .	parallel	1
7716	10529267	3949;4018	LDLR;lipoprotein	To attempt to determine the reason for this , we analyzed the regulation of expression of genes involved in apolipoprotein E ( apoE ) - based mechanisms in RAP-deficient mice and compared this to results in mice deficient in low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) or apoE .	parallel	1
7717	10529369	2033;7157	p300;p53	The coactivator ***p300*** , which ***binds*** to both ERalpha and ***p53*** , does not prevent this loss of hERalpha function .	parallel	1
7718	10529385	25792;1026	ciz1;p21	However , coexpression of ***ciz1*** ***induced*** cytoplasmic distribution of ***p21*** ( Cip1/Waf1 ) .	target	1
7719	10529400	207;842	Akt;caspase-9	Recently , it was shown that human ***caspase-9*** is ***phosphorylated*** by ***Akt*** and that its protease activity is reduced .	target	1
7720	10529402	4792;4790	IkappaBalpha;NF-kappaB	Adenovirus mediated overexpression of ***IkappaBalpha*** , the ***inhibitor*** of ***NF-kappaB*** , completely suppresses MMP-1 and -3 protein and mRNA expression .	negative	1
7721	10529415	4487;5077	Msx1;Pax3	***Msx1*** ***antagonizes*** the myogenic activity of ***Pax3*** in migrating limb muscle precursors .	negative	1
7722	10529415	4487;4654	Msx1;MyoD	We find that ectopic expression of ***Msx1*** in the forelimb and somites of chicken embryos ***inhibits*** ***MyoD*** expression as well as muscle differentiation .	negative	1
7723	10529415	5077;4654	Pax3;MyoD	Conversely , ectopic expression of ***Pax3*** ***activates*** ***MyoD*** expression , while co-ectopic expression of Msx1 and Pax3 neutralizes their effects on MyoD .	positive	1
7724	10529415	5077;4654	Pax3;MyoD	Moreover , we find that Msx1 represses and ***Pax3*** ***activates*** ***MyoD*** regulatory elements in cell culture , while in combination , Msx1 and Pax3 oppose each other 's trancriptional actions on MyoD .	positive	1
7725	10529415	4487;5077	Msx1;Pax3	Finally , we show that the ***Msx1*** protein ***interacts*** with ***Pax3*** in vitro , thereby inhibiting DNA binding by Pax3 .	parallel	1
7726	10529415	4487;5077	Msx1;Pax3	Thus , we propose that ***Msx1*** ***antagonizes*** the myogenic activity of ***Pax3*** in migrating limb muscle precursors via direct protein-protein interaction .	negative	1
7727	10529597	3565;6356	IL-4;eotaxin	***IL-4*** ***induces*** ***eotaxin*** in human dermal fibroblasts .	target	1
7728	10529597	7124;6356	TNF-alpha;eotaxin	***TNF-alpha*** markedly ***enhances*** ***eotaxin*** mRNA expression and release of the protein product from IL-4-stimulated fibroblasts .	positive	0
7729	10529597	3565;6356	IL-4;eotaxin	As mast cells and Th2 cells produce both cytokines , it is probable that Eo recruitment into sites of allergen-induced , Th2-mediated skin reactions is , at least in part , due to ***IL-4-stimulated*** ***induction*** of ***eotaxin*** in dermal fibroblasts .	target	1
7730	10529600	3458;6402	Interferon-gamma;CD62L	***Interferon-gamma*** ***increases*** ***CD62L*** expression on human eosinophils .	positive	0
7731	10529600	1437;6402	GM-CSF;CD62L	RESULTS : IL-5 or ***GM-CSF*** ***downregulated*** ***CD62L*** and upregulated CD11b expression on eosinophils after 30 min stimulation .	negative	1
7732	10529600	3567;6402	IL-5;CD62L	RESULTS : ***IL-5*** or GM-CSF ***downregulated*** ***CD62L*** and upregulated CD11b expression on eosinophils after 30 min stimulation .	negative	1
7733	10529600	3458;6402	IFN-gamma;CD62L	Conversely , ***IFN-gamma*** ***upregulated*** ***CD62L*** after 12 h stimulation in a time - and dose-dependent manner , and had no effect on CD11b expression .	positive	1
7734	10529603	6356;1232	eotaxin;CCR3	METHODS : In this study , we used RT-PCR to investigate the kinds of cells that express mRNA for CCR3 , a common receptor of these chemokines , and ***eotaxin*** , a ***ligand*** for ***CCR3*** .	parallel	1
7735	10529607	3689;6037	CD18;ECP	***Anti-CD18*** , CD49d , and alpha4beta7 antibodies significantly ***suppressed*** ***ECP*** levels in the serum .	negative	1
7736	10529607	3676;6037	CD49d;ECP	Anti-CD18 , ***CD49d*** , and alpha4beta7 antibodies significantly ***suppressed*** ***ECP*** levels in the serum .	negative	1
7737	10531052	23621;351	BACE;amyloid precursor protein	Beta-secretase ***cleavage*** of Alzheimer 's ***amyloid precursor protein*** by the transmembrane aspartic protease ***BACE*** .	target	1
7738	10531061	1407;406	CRY1;BMAL1	Mammalian ***CRY1*** and CRY2 are here shown to act as light-independent ***inhibitors*** of ***CLOCK-BMAL1*** , the activator driving Per1 transcription .	negative	1
7739	10531061	1408;406	CRY2;BMAL1	Mammalian CRY1 and ***CRY2*** are here shown to act as light-independent ***inhibitors*** of ***CLOCK-BMAL1*** , the activator driving Per1 transcription .	negative	1
7740	10531062	6498;7040	SnoN;TGF-beta	Negative feedback ***regulation*** of ***TGF-beta*** signaling by the ***SnoN*** oncoprotein .	negative	1
7741	10531062	4088;6498	Smad3;SnoN	Immediately after TGF-beta stimulation , ***SnoN*** is rapidly ***degraded*** by the nuclear accumulation of ***Smad3*** , allowing the activation of TGF-beta target genes .	negative	0
7742	10531067	4205;3164	MEF2;Nur77	***Nur77*** expression is ***controlled*** by the transcription factor myocyte enhancer factor 2 ( ***MEF2*** ) , but how MEF2 is activated by calcium signaling is still obscure .	target	0
7743	10531067	23523;4205	Cabin1;MEF2	***Cabin1*** , a calcineurin inhibitor , was found to ***regulate*** ***MEF2*** .	target	1
7744	10531067	4205;23523	MEF2;Cabin1	The ***interplay*** between ***Cabin1*** , ***MEF2*** , and calmodulin defines a distinct signaling pathway from the TCR to the Nur77 promoter during T cell apoptosis .	parallel	1
7745	10531202	4790;5970	NF-kappaB;p65	The DNA-bindable ***NF-kappaB*** was identified as a ***heterodimer*** of ***p65*** and p50 .	parallel	1
7746	10531222	7040;3586	TGF-beta1;interleukin-10	Here we examined the ***interaction*** of transforming growth factor beta1 ( ***TGF-beta1*** ) and ***interleukin-10*** ( IL-10 ) in purified protein derivative ( PPD ) - stimulated human mononuclear cell cultures in vitro .	parallel	1
7747	10531222	7040;3586	TGF-beta1;IL-10	***TGF-beta1*** ***induced*** monocyte ***IL-10*** ( but not tumor necrosis factor alpha ) production ( by 70-fold , P < 0.02 ) and mRNA expression in the absence but not in the presence of PPD .	target	1
7748	10531222	3586;3458	IL-10;IFN-gamma	Both exogenous recombinant ( r ) ***IL-10*** and rTGF-beta1 independently ***suppressed*** the production of PPD-induced gamma interferon ( ***IFN-gamma*** ) in mononuclear cells from PPD skin test-positive individuals .	negative	1
7749	10531222	3586;3458	IL-10;IFN-gamma	Also , neutralization of endogenous TGF-beta1 and ***IL-10*** together ***enhanced*** PPD-induced ***IFN-gamma*** in PBMC in a synergistic manner .	positive	0
7750	10531222	7040;3458	TGF-beta1;IFN-gamma	Also , neutralization of endogenous ***TGF-beta1*** and IL-10 together ***enhanced*** PPD-induced ***IFN-gamma*** in PBMC in a synergistic manner .	positive	0
7751	10531222	7040;3586	TGF-beta1;IL-10	Thus , TGF-beta1 and IL-10 together potentiate the downmodulatory effect on M. tuberculosis-induced T-cell production of IFN-gamma , and ***TGF-beta1*** alone ***enhances*** ***IL-10*** production .	positive	0
7752	10531300	472;3065	ATM;HDAC1	Binding and immunoprecipitation assays have now shown that ***ATM*** ***interacts*** with the histone deacetylase ***HDAC1*** both in vitro and in vivo , and that the extent of this association is increased after exposure of MRC5CV1 human fibroblasts to ionizing radiation .	parallel	1
7753	10531320	3553;5743	IL-1beta;cyclooxygenase-2	Since we recently observed that ***IL-1beta*** ***induces*** ***cyclooxygenase-2*** ( COX-2 ) gene expression and PGE ( 2 ) synthesis in islet beta cells , we have reassessed the possibility that PGE ( 2 ) mediates IL-1beta effects on beta function .	target	1
7754	10531323	2185;2185	PYK2;CAKbeta	Moreover CCK stimulation causes a rapid formation of both PYK2/CAKbeta-GeneGene 2 and ******PYK2/CAKbeta-GeneGene****** 5 ***complexes*** .	parallel	1
7755	10531323	885;2185	CCK;CAKbeta	These results demonstrate that ***PYK2/CAKbeta*** and p125 ( FAK ) are ***regulated*** differently by ***CCK*** ( A ) receptor stimulation and that PYK2/CAKbeta is probably an important mediator of downstream signals by CCK-8 , especially in its ability to activate the MAPK signaling pathway , which possibly mediates CCK growth effects in normal and neoplastic tissues .	target	1
7756	10531323	885;2185	Cholecystokinin;PYK2	***Cholecystokinin*** ***activates*** ***PYK2/CAKbeta*** by a phospholipase C-dependent mechanism and its association with the mitogen-activated protein kinase signaling pathway in pancreatic acinar cells .	positive	1
7757	10531323	885;2185	CCK;CAKbeta	In rat pancreatic acini , ***CCK-8*** ( 10 nM ) rapidly ***stimulated*** tyrosine phosphorylation and activation of ***PYK2/CAKbeta*** by both activation of high affinity and low affinity CCK ( A ) receptor states .	positive	0
7758	10531329	4043;4035	RAP;LRP	Finally , we show that one RAP molecule can bind to different clusters simultaneously , supporting a model in which ***RAP*** ***binding*** to ***LRP*** induces a conformational change in the receptor that is incompatible with ligand binding .	parallel	1
7759	10531348	7157;11200	p53;hCds1	In addition , transfection of normal human fibroblasts with SV40 T antigen or human papilloma viruses E6 or E7 causes a marked induction of hCds1 mRNA , and the introduction of functional p53 into SV40 T antigen - and E6 - , but not E7 - , transfected cells decreases the hCds1 level , suggesting that ***p53*** negatively ***regulates*** the expression of ***hCds1*** .	negative	1
7760	10531356	10419;4155	JBP1;myelin basic protein	***JBP1*** can be cross-linked to radiolabeled S-adenosylmethionine ( AdoMet ) and ***methylates*** histones ( H2A and H4 ) and ***myelin basic protein*** .	target	1
7761	10531360	2034;7422	EPAS1;VEGF	Our results suggest that ***EPAS1*** is an important ***regulator*** of ***VEGF*** gene expression .	target	1
7762	10531360	2034;7422	EPAS1;VEGF	In this report , we show that ***EPAS1*** ***increased*** ***VEGF*** gene expression through the HIF-1-binding site .	positive	0
7763	10531360	2034;7422	EPAS1;VEGF	Deletion analysis of EPAS1 revealed a potent activation domain ( amino acids 486-639 ) essential for ***EPAS1*** to ***transactivate*** the ***VEGF*** promoter .	positive	1
7764	10531360	2034;7422	EPAS1;VEGF	Because a truncated EPAS1 protein lacking the transactivation domain at amino acids 486-639 eliminated ***induction*** of the ***VEGF*** promoter by wild-type ***EPAS1*** , the truncated protein functions as a dominant-negative mutant .	target	1
7765	10531362	864;4088	CBFA3;Smad3	Among them , ***PEBP2alphaC/CBFA3/AML2*** forms a ***complex*** with ***Smad3*** and stimulates transcription of the germline Ig Calpha promoter in a cooperative manner , for which binding of both factors to their specific binding sites is essential .	parallel	1
7766	10531364	5894;5598	Raf-1;ERK5	A clue to the mechanism of action of Raf-1 on ERK5 comes from the observation that endogenous ***Raf-1*** ***binds*** to endogenous ***ERK5*** , suggesting the involvement of regulatory protein-protein interactions .	parallel	1
7767	10531364	5894;5598	Raf-1;ERK5	This interaction is specific because ***Raf-1*** ***binds*** only to ***ERK5*** and not ERK2 or SAPK .	parallel	1
7768	10531366	1051;1052	C/EBPbeta;C/EBPdelta	Electrophoretic mobility shift assays with nuclear extracts from 3T3-F442A cells indicate that GH rapidly ( 2-5 min ) increases ***binding*** of ***C/EBPbeta*** and ***C/EBPdelta*** , to the c-fos C/EBP binding site .	parallel	1
7769	10531372	5585;8802	PAK1;Galpha	In transfected cells , ***Galpha*** ( z ) was ***phosphorylated*** both by wild-type ***PAK1*** when stimulated by the GTP-binding protein Rac1 and by constitutively active PAK1 mutants .	target	1
7770	10531372	5585;8802	PAK1;Galpha	***PAK1*** thus ***regulates*** ***Galpha*** ( z ) function by attenuating the inhibitory effects of both GAPs and Gbetagamma .	target	1
7771	10531373	5594;5599	ERK;JNK	A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor , PD98059 , had no effect on the cisplatin-induced JNK activity , suggesting an absence of ***cross-talk*** between the ***ERK*** and ***JNK*** cascades .	parallel	0
7772	10531381	867;7332	c-Cbl;UbcH7	Ligand-induced ubiquitination of the epidermal growth factor receptor involves the ***interaction*** of the ***c-Cbl*** RING finger and ***UbcH7*** .	parallel	1
7773	10531381	867;7332	c-Cbl;UbcH7	We demonstrate here , using the yeast two-hybrid system and an in vitro binding assay , that the ***c-Cbl*** RING finger domain ***interacts*** with ***UbcH7*** , a ubiquitin-conjugating enzyme ( E2 ) .	parallel	1
7774	10531381	7332;867	UbcH7;c-Cbl	***UbcH7*** ***interacted*** with the wild-type ***c-Cbl*** RING finger domain but not with a RING finger domain that lacks the amino acids that are deleted in 70Z-Cbl , an oncogenic mutant of c-Cbl .	parallel	1
7775	10531381	7332;1956	UbcH7;EGFR	In contrast , 70Z-Cbl markedly reduced the ligand-induced , ***UbcH7-mediated*** ***ubiquitination*** of the ***EGFR*** .	target	1
7776	10531398	7157;1026	p53;p21	Tumor suppressor ***p53*** but not cGMP ***mediates*** NO-induced expression of ***p21*** ( Waf1/Cip1/Sdi1 ) in vascular smooth muscle cells .	target	0
7777	10531399	4804;4803	p75;NGF	While the physiological role of the low affinity ***NGF*** ***receptor*** ( ***p75*** ) has not been clearly defined , this receptor promotes activation of nuclear factor ( NF ) kappaB in Schwann cells .	parallel	1
7778	10531402	7157;596	p53;bcl-2	Under lower serum ( 0.1-1 % ) but not normal serum conditions , ***p53*** induction ***correlated*** with selective down-regulation of ***bcl-2*** , an inhibitor of apoptosis .	parallel	0
7779	10531446	5781;2064	SHP2;ErbB2	We found that ***SHP2*** ***interacted*** with ***ErbB2*** and ErbB3 after neuregulin stimulation of muscle cells .	parallel	1
7780	10531446	5781;2065	SHP2;ErbB3	We found that ***SHP2*** ***interacted*** with ErbB2 and ***ErbB3*** after neuregulin stimulation of muscle cells .	parallel	1
7781	10532402	7124;4790	TNF-alpha;NF-kappaB	***TNF-alpha*** ***stimulated*** ***NF-kappaB*** activation was partially inhibited by preincubation with the antioxidants alpha-lipoic acid and butylated hydroxyanisol ( BHA ) .	positive	0
7782	10532591	728;727	C5aR;C5a	A direct action of C5a on hepatocytes would require their expression of the specific ***C5a*** ***receptor*** ( ***C5aR*** ) .	parallel	1
7783	10532634	1508;3553	cysteine protease;IL-1beta	Interleukin-1 ( IL-1 ) converting enzyme ( ICE ) is a ***cysteine protease*** that ***cleaves*** inactive ***pro-IL-1beta*** to active IL-1beta .	target	1
7784	10532946	1958;688	Egr-1;transcription factor BTEB2	Transcriptional ***activation*** of the zinc finger ***transcription factor BTEB2*** gene by ***Egr-1*** through mitogen-activated protein kinase pathways in vascular smooth muscle cells .	positive	1
7785	10533051	3553;5743	Interleukin-1 beta;cyclooxygenase-2	***Interleukin-1 beta*** ***activates*** expression of ***cyclooxygenase-2*** and inducible nitric oxide synthase in primary hippocampal neuronal culture : platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression .	positive	1
7786	10533284	861;1378	AML1;CR1	***AML1*** , the target of chromosomal rearrangements in human leukemia , ***regulates*** the expression of human complement receptor type 1 ( ***CR1*** ) gene .	target	1
7787	10533284	861;1378	AML1;CR1	We show that the ***AML1*** binds specifically to this site and ***activates*** the human ***CR1*** promoter .	positive	1
7788	10533319	958;959	CD40;CD154	******CD40-CD154****** ***interactions*** in B-cell signaling .	parallel	1
7789	10533474	4363;7157	MRP;p53	***MRP*** overexpression ***correlated*** with aberrant ***p53*** accumulation in CRCs and CIAs ( chi 2 test , P < = or 0.01 ) .	parallel	0
7790	10533610	2260;2247	FGFR-1;fibroblast growth factor-2	OBJECTIVE : The type 1 fibroblast growth factor receptor ( ***FGFR-1*** ) is the only high affinity ***receptor*** for ***fibroblast growth factor-2*** ( FGF-2 ) in the rat myocardium , and is essential for normal growth and development of the heart .	parallel	1
7791	10533983	4915;627	TrkB;BDNF	The ***TrkB*** protein tyrosine kinase is a high affinity ***receptor*** for brain derived neurotrophic factor ( ***BDNF*** ) and neurotrophin-4 ( NT-4 ) .	parallel	1
7792	10533983	4915;4909	TrkB;neurotrophin-4	The ***TrkB*** protein tyrosine kinase is a high affinity ***receptor*** for brain derived neurotrophic factor ( BDNF ) and ***neurotrophin-4*** ( NT-4 ) .	parallel	1
7793	10533984	185;183	AT1R;angiotensin II	The type 1 ***angiotensin II*** ***receptor*** ( ***AT1R*** ) which is a G-protein-coupled receptor , also activates tyrosine kinases and undergoes endocytosis .	parallel	1
7794	10533985	4923;4922	NTR;neurotensin	In the absence of Na + , 125I-neurotensin ( 125I-NT ) binding to the ***neurotensin*** ***receptor*** ( ***NTR*** ) produces a stable noncovalent 125I-NT-NTR complex whose dissociation rate is extremely low even after the addition of 1 microM NT , 100 microM SR48692 ( antagonist ) , 100 microM GPPNHP or 100 mM NaCl .	parallel	1
7795	10533985	4922;4923	neurotensin;NTR	In the absence of Na + , ***125I-neurotensin*** ( 125I-NT ) ***binding*** to the neurotensin receptor ( ***NTR*** ) produces a stable noncovalent 125I-NT-NTR complex whose dissociation rate is extremely low even after the addition of 1 microM NT , 100 microM SR48692 ( antagonist ) , 100 microM GPPNHP or 100 mM NaCl .	parallel	1
7796	10534012	1636;28	ACE;ABO blood group	An association was found between the ***interaction*** of I/D ***ACE*** gene polymorphism and ***ABO blood group*** system on the one hand and mean values of systolic ( p = 0.016 ) or mean arterial ( p = 0.027 ) blood pressures and the phase shift of 24-h BP rhythm ( p = 0.036 ) on the other hand .	parallel	1
7797	10534343	7040;598	TGF-beta1;Bcl-xL	Our results also showed that ***down-regulation*** of the expression of ***Bcl-xL*** and XIAP by ***TGF-beta1*** may facilitate activation of caspase-3 in these cells .	negative	1
7798	10534343	356;355	FasL;Fas	***Fas/Fas*** ***ligand*** ( ***FasL*** ) interactions in HuH-7 cells were not involved in the apoptotic process .	parallel	1
7799	10534922	5345;5340	Alpha-2-antiplasmin;plasmin	***Alpha-2-antiplasmin*** is a main ***inhibitor*** of ***plasmin*** and play a crucial role in regulation of intravascular fibrinolysis .	negative	1
7800	10535305	886;6714	CCK-AR;Src	The low-affinity ***CCK-AR*** is coupled to both the Galphaq/11/PLCbeta1 / inositol 1,4,5-trisphosphate ( IP3 ) to ***evoke*** intracellular Ca2 + release and the ***Src/PTK*** pathway to mediate extracellular Ca2 + influx .	positive	0
7801	10535358	4609;4953	c-myc;ODC	Ornithine decarboxylase ( ***ODC*** ) , a key enzyme involved in polyamine biosynthesis , is ***regulated*** by ***c-myc*** , which is a transcriptional activator implicated not only in the control of cell proliferation and differentiation but also in programmed cell death .	target	1
7802	10535409	7432;3586	VIP;IL-10	Previous reports indicate that ***VIP*** and the structurally related peptide PACAP , ***inhibit*** IL-2 and ***IL-10*** production in antigen-stimulated T lymphocytes .	negative	1
7803	10535409	7432;3558	VIP;IL-2	Previous reports indicate that ***VIP*** and the structurally related peptide PACAP , ***inhibit*** ***IL-2*** and IL-10 production in antigen-stimulated T lymphocytes .	negative	1
7804	10535455	3952;3953	leptin;OB-R	LEP - ( 116-130 ) was unable to compete the ***binding*** of alkaline ***phosphatase-leptin*** fusion protein to ***OB-R*** .	parallel	1
7805	10535459	3791;7422	VEGFR-2;vascular endothelial growth factor	Increased renal expression of ***vascular endothelial growth factor*** ( VEGF ) and its ***receptor*** ***VEGFR-2*** in experimental diabetes .	parallel	1
7806	10535569	4193;7157	mdm2;p53 tumor suppressor	The ***p53 tumor suppressor*** gene product is ***regulated*** by ***mdm2*** and both gene products influence cell cycle progression through the cyclin-dependent kinase inhibitor p21 .	target	1
7807	10535609	3558;920	IL-2;CD4	***IL-2*** therapy induced moderate effects on CD4 T cell recovery and ***increased*** ***CD4/CD25*** + cells and sCD25 levels after 2 weeks , while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point .	positive	0
7808	10535680	5741;6550	parathyroid hormone;NHE3	In proximal tubules , PKC-induced inhibition of ***NHE3*** and Na + , Pi cotransporter can be ***triggered*** by ***parathyroid hormone*** .	positive	0
7809	10535925	7341;28996	SUMO-1;HIPK2	Covalent ***modification*** of the homeodomain-interacting protein kinase 2 ( ***HIPK2*** ) by the ubiquitin-like protein ***SUMO-1*** .	target	0
7810	10535925	7341;28996	SUMO-1;HIPK2	Here , we show that ***HIPK2*** is ***regulated*** by a ubiquitin-like protein , ***SUMO-1*** .	target	1
7811	10535925	7341;28996	SUMO-1;HIPK2	In cultured cells , HIPK2 is covalently modified by SUMO-1 , and the ***SUMO-1*** ***modification*** of ***HIPK2*** correlates with its localization to nuclear speckles ( dots ) .	target	0
7812	10535925	7341;28996	SUMO-1;HIPK2	In cultured cells , ***HIPK2*** is covalently ***modified*** by ***SUMO-1*** , and the SUMO-1 modification of HIPK2 correlates with its localization to nuclear speckles ( dots ) .	target	0
7813	10535925	7341;28996	SUMO-1;HIPK2	Thus , our results provide firm evidence that the nuclear protein kinase ***HIPK2*** can be covalently ***modified*** by ***SUMO-1*** , which directs its localization to nuclear speckles ( dots ) .	target	0
7814	10535940	9978;8453	Rbx1;CUL-2	The protein ***Rbx1/ROC1*** ***enhances*** ligase activity of ***VBC-CUL-2*** as it does in the SKP1-CUL-1-F-box protein ligase complex .	positive	0
7815	10535940	6500;8454	SKP1;CUL-1	The protein Rbx1/ROC1 enhances ligase activity of VBC-CUL-2 as it does in the ******SKP1-CUL-1-F-box****** protein ligase ***complex*** .	parallel	1
7816	10535940	7428;57186	pVHL;p220	We also found that ***pVHL*** ***associates*** with two proteins , p100 and ***p220*** , which migrate at a similar molecular weight as two major bands in the ubiquitination assay .	parallel	0
7817	10535941	7040;4088	TGF-beta;Smad3	Some TGF-beta-initiated signals are conveyed through Smad3 ; ***TGF-beta*** binding to its receptors ***induces*** phosphorylation of ***Smad3*** , which then migrates to the nucleus where it functions as a transcription factor .	target	1
7818	10535941	4088;6498	Smad3;SnoN	We describe here the ***association*** of ***Smad3*** with the nuclear protooncogene protein ***SnoN*** .	parallel	0
7819	10535960	5320;324	Pla2g2a;Apc	Aggregation chimeras were formed between C57BL/6 mice heterozygous for the Apc ( min ) ( Min ) mutation and wild-type SWR mice , that differ in their ***Pla2g2a*** status , a ***modifier*** of ***Apc*** ( min ) , and also in their resistance to intestinal polyp formation .	target	0
7820	10535980	8772;355	FADD;Fas	Furthermore LFG does not inhibit ***binding*** of ***FADD*** to ***Fas*** .	parallel	1
7821	10535997	4018;3949	lipoprotein;LDL receptor	Endocytosis of the Flaviviridae viruses , hepatitis C virus , GB virus C/hepatitis G virus , and bovine viral diarrheal virus ( BVDV ) was shown to be mediated by low density lipoprotein ( LDL ) receptors on cultured cells by several lines of evidence : by the demonstration that endocytosis of these virus correlated with LDL receptor activity , by complete inhibition of detectable endocytosis by anti-LDL receptor antibody , by inhibition with anti-apolipoprotein E and - apolipoprotein B antibodies , by chemical methods abrogating ******lipoprotein/LDL receptor****** ***interactions*** , and by inhibition with the endocytosis inhibitor phenylarsine oxide .	parallel	1
7822	10536205	5368;4987	nociceptin;ORL1	***nociceptin*** ( NOC ) , an endogenous ***ligand*** for the orphan opioid receptor ***ORL1*** ( ORL1 ) , has recently been recognized as a neuropeptide .	parallel	1
7823	10536372	3958;2006	Galectin-3;tropoelastin	Furthermore we demonstrated by immunoprecipitation that endogenous ***Galectin-3*** in breast carcinoma cells is ***associated*** with ***tropoelastin*** .	parallel	0
7824	10536660	5972;1906	renin;endothelin-1	***Interactions*** between ***endothelin-1*** and the ***renin-angiotensin-aldosterone*** system .	parallel	1
7825	10536818	6279;6280	MRP8;MRP14	Calcium-induced stabilization of the ******MRP8/MRP14****** ***complexes*** was confirmed by DSC studies .	parallel	1
7826	10536968	7040;1306	TGF-beta;COL15A1	***TGF-beta*** ***enhanced*** the expression of the type XV collagen gene ( ***COL15A1*** ) in a time-dependent manner , up to 4.3-fold after 24 h of incubation , whereas TNF-alpha and IL-1beta reduced the mRNA steady-state levels by 32 and 80 % , respectively .	positive	0
7827	10536983	4157;5443	MC1-R;MSH	To elucidate the mechanism of this upregulation , the expression of genes encoding corticotropin-releasing hormone ( CRH ) and its receptor , CRH-R , as well as POMC and the ***MSH*** ***receptor*** ( ***MC1-R*** ) , was evaluated by reverse transcriptase-polymerase chain reaction using cultured human melanoma cells , nevus cells , and normal melanocytes .	parallel	1
7828	10536986	5077;4286	PAX3;MITF	By analyzing the genes for Waardenburg syndrome , we showed that ***PAX3*** , the gene responsible for Waardenburg syndrome type 1 , ***regulates*** ***MITF*** , the gene responsible for Waardenburg syndrome type 2 .	target	1
7829	10537043	5970;4790	RelA;p50	Our data indicate that the constitutive neuronal kappaB-binding factor ( NKBF ) is distinct from bona fide NF-kappaB ( ******RelA/p50****** ***heterodimer*** ) .	parallel	1
7830	10537045	7052;4137	tissue transglutaminase;Tau	***Tau*** is ***modified*** by ***tissue transglutaminase*** in situ : possible functional and metabolic effects of polyamination .	target	0
7831	10537060	3569;6774	IL-6;STAT3	***IL-6-induced*** ***activation*** and translocation of ***STAT3*** and to a lesser degree STAT1 but not STAT5 are demonstrated .	positive	1
7832	10537068	5594;836	ERK;caspase-3	These PI 3-kinase inhibitors also inhibited the activation of ERK in response to MK , demonstrating a ***link*** between ***ERK*** and the ***caspase-3*** pathway that is modulated by the PI 3-kinase activation .	parallel	0
7833	10537117	3953;3952	OB-R;leptin	To probe this hypothesis , we first analyzed the expression of ***leptin*** ***receptors*** ( ***OB-R*** ) in rodent Leydig cells in culture .	parallel	1
7834	10537119	51083;5617	galanin;PRL	We conclude that overexpression of ***galanin*** in lactotrophs ***stimulates*** ***PRL*** synthesis and secretion and acts as a growth factor resulting in the formation of pituitary hyperplasia and hyperprolactinemia .	positive	0
7835	10537123	183;186	angiotensin II;angiotensin II type 2 receptor	Transcriptional and translational ***regulation*** of ***angiotensin II type 2 receptor*** by ***angiotensin II*** and growth factors .	target	1
7836	10537140	3552;5706	IL-1alpha;p42	***IL-1alpha*** time-dependently ***stimulated*** the phosphorylation of both ***p42/p44*** mitogen-activated protein ( MAP ) kinase and p38 MAP kinase .	positive	0
7837	10537140	3552;5706	IL-1alpha;p42	Calphostin C , a specific inhibitor of PKC , or D-609 , a specific inhibitor of PC-PLC , significantly enhanced the ***IL-1alpha-induced*** ***phosphorylation*** of ***p42/p44*** MAP kinase without affecting the phosphorylation of p38 MAP kinase .	target	1
7838	10537140	3552;5706	IL-1alpha;p44	The ***phosphorylation*** of ***p42/p44*** MAP kinase by ***IL-1alpha*** was markedly increased in PKC-down-regulated MC3T3-E1 cells .	target	1
7839	10537143	5617;3952	Prolactin;leptin	***Prolactin*** ***stimulates*** ***leptin*** secretion by rat white adipose tissue .	positive	0
7840	10537143	5617;3952	PRL;leptin	It was found that increased serum ***PRL*** levels , obtained by pituitary graft or exogenous injected ovine PRL ( oPRL , 5 mg/kg ) , significantly ***stimulate*** serum ***leptin*** concentration .	positive	0
7841	10537143	5617;3952	PRL;leptin	Moreover , in vivo , ***PRL*** was able to ***induce*** ***leptin*** messenger RNA levels in several areas of rat white adipose tissue .	target	1
7842	10537146	4852;2796	neuropeptide Y;LHRH	A large body of evidence indicates that ***neuropeptide Y*** ( NPY ) is involved in ***stimulation*** of basal and cyclic release of hypothalamic ***LHRH*** and pituitary LH .	positive	0
7843	10537164	4323;4322	MT1-MMP;collagenase-3	In conclusion , our data suggest that gelatinase A , collagenase-3 , and MT1-MMP may have separate functions during the CL life span : gelatinase A mainly takes part in CL formation , whereas collagenase-3 mainly takes part in luteal regression ; ***MT1-MMP*** is constitutively expressed during the CL life span and may therefore serve as an in vivo ***activator*** of both gelatinase A and ***collagenase-3*** .	positive	1
7844	10537276	4193;7157	MDM2;p53	***MDM2*** , a key negative ***regulator*** of ***p53*** , has recently been shown to suppress TGF-beta-induced growth arrest in a p53-independent manner .	negative	1
7845	10537276	4193;4086	MDM2;SMAD1	Here we show that ***MDM2*** and the structurally related protein MDMX can ***inhibit*** the transcriptional activity of ectopically expressed ***SMAD1*** , SMAD2 , SMAD3 , and SMAD4 .	negative	1
7846	10537276	4193;4087	MDM2;SMAD2	Here we show that ***MDM2*** and the structurally related protein MDMX can ***inhibit*** the transcriptional activity of ectopically expressed SMAD1 , ***SMAD2*** , SMAD3 , and SMAD4 .	negative	1
7847	10537276	4193;4088	MDM2;SMAD3	Here we show that ***MDM2*** and the structurally related protein MDMX can ***inhibit*** the transcriptional activity of ectopically expressed SMAD1 , SMAD2 , ***SMAD3*** , and SMAD4 .	negative	1
7848	10537276	4193;4089	MDM2;SMAD4	Here we show that ***MDM2*** and the structurally related protein MDMX can ***inhibit*** the transcriptional activity of ectopically expressed SMAD1 , SMAD2 , SMAD3 , and ***SMAD4*** .	negative	1
7849	10537276	4194;4086	protein MDMX;SMAD1	Here we show that MDM2 and the structurally related ***protein MDMX*** can ***inhibit*** the transcriptional activity of ectopically expressed ***SMAD1*** , SMAD2 , SMAD3 , and SMAD4 .	negative	1
7850	10537276	4194;4087	protein MDMX;SMAD2	Here we show that MDM2 and the structurally related ***protein MDMX*** can ***inhibit*** the transcriptional activity of ectopically expressed SMAD1 , ***SMAD2*** , SMAD3 , and SMAD4 .	negative	1
7851	10537276	4194;4088	protein MDMX;SMAD3	Here we show that MDM2 and the structurally related ***protein MDMX*** can ***inhibit*** the transcriptional activity of ectopically expressed SMAD1 , SMAD2 , ***SMAD3*** , and SMAD4 .	negative	1
7852	10537276	4194;4089	protein MDMX;SMAD4	Here we show that MDM2 and the structurally related ***protein MDMX*** can ***inhibit*** the transcriptional activity of ectopically expressed SMAD1 , SMAD2 , SMAD3 , and ***SMAD4*** .	negative	1
7853	10537276	4089;4193	SMAD4;MDM2	We have no evidence that ***SMAD4*** ***binds*** directly to ***MDM2*** or MDMX ; hence , the inactivation and nuclear exclusion of SMAD4 by MDM2/MDMX may involve other indirect mechanisms .	parallel	1
7854	10537276	4089;4194	SMAD4;MDMX	We have no evidence that ***SMAD4*** ***binds*** directly to MDM2 or ***MDMX*** ; hence , the inactivation and nuclear exclusion of SMAD4 by MDM2/MDMX may involve other indirect mechanisms .	parallel	1
7855	10537276	4193;4089	MDM2;SMAD4	We have no evidence that SMAD4 binds directly to MDM2 or MDMX ; hence , the ***inactivation*** and nuclear exclusion of ***SMAD4*** by ***MDM2/MDMX*** may involve other indirect mechanisms .	negative	1
7856	10537276	4194;4089	MDMX;SMAD4	We have no evidence that SMAD4 binds directly to MDM2 or MDMX ; hence , the ***inactivation*** and nuclear exclusion of ***SMAD4*** by ***MDM2/MDMX*** may involve other indirect mechanisms .	negative	1
7857	10537344	4363;1244	MRP1;MRP2	Expression of ***MRP1*** was ***related*** to ***MRP2*** ( P < 0.0001 ) and P-gp ( P < 0.001 ) expression , whereas LRP expression was more frequently observed in patients with early stage ( P < 0.01 ) , lower grade ( P < 0.05 ) , and smaller residual tumor ( P < 0.05 ) .	parallel	0
7858	10537344	4363;5243	MRP1;P-gp	Expression of ***MRP1*** was ***related*** to MRP2 ( P < 0.0001 ) and ***P-gp*** ( P < 0.001 ) expression , whereas LRP expression was more frequently observed in patients with early stage ( P < 0.01 ) , lower grade ( P < 0.05 ) , and smaller residual tumor ( P < 0.05 ) .	parallel	0
7859	10537344	4363;1244	MRP1;MRP2	In conclusion , in ovarian carcinoma , ***MRP1*** expression is ***associated*** with ***MRP2*** and P-gp expression , whereas LRP expression is associated with favorable clinicopathological characteristics .	parallel	0
7860	10537344	4363;5243	MRP1;P-gp	In conclusion , in ovarian carcinoma , ***MRP1*** expression is ***associated*** with MRP2 and ***P-gp*** expression , whereas LRP expression is associated with favorable clinicopathological characteristics .	parallel	0
7861	10537354	598;596	Bcl-X;Bcl-2	Furthermore , a strong association was found between the expression of Bcl-2 and Bcl-X , suggesting that ***Bcl-X*** ***potentiates*** rather than replaces the effect of ***Bcl-2*** in NHL .	positive	0
7862	10537356	685;2065	betacellulin;c-erbB-3	The objective of this study was to determine the immunohistochemical expression of the ***c-erbB-3*** and c-erbB-4 growth factor receptors and their principal ***ligands*** , the neuregulins and ***betacellulin*** , in normal endometrium and determine whether there was evidence of under - or overexpression in endometrial adenocarcinoma .	parallel	1
7863	10540152	958;942	CD40;B7.2	As ***CD40*** is known to ***up-regulate*** ***B7.2*** expression on B cells , the mechanism of B7.2 down-regulation by CsA and dexamethasone was further studied by investigating the effect of these agents on CD40 expression on B cells .	positive	1
7864	10540155	7124;1051	TNF-alpha;CCAAT/enhancer-binding protein (C/EBP)beta	The EMSAs indicated that sodium butyrate suppressed TNF-alpha-induced nuclear factor ( NF ) - kappaB - and activation protein ( AP ) -1 - DNA binding activity , but enhanced ***TNF-alpha-induced*** ***activation*** of ***CCAAT/enhancer-binding protein (C/EBP)beta*** ( NF-IL-6 ) - DNA binding activity .	positive	1
7865	10540157	3553;6347	IL-1beta;MCP-1	In contrast , ***IL-1beta*** strongly ***induced*** ***MCP-1*** secretion preferentially into the basal compartment of all RPE monolayers tested .	target	1
7866	10540162	3439;5551	IFN-alpha;perforin	Our data suggest that ***up-regulation*** of ***perforin*** by ***IFN-alpha*** results in elevated cytotoxicity , suggesting that IFN-alpha might support elimination of virally infected cells via this pathway .	positive	1
7867	10540162	3439;356	IFN-alpha;FasL	We have recently shown that ***IFN-alpha*** ***up-regulates*** ***FasL*** expression in T cells isolated from healthy volunteers and augments activation-induced T cell death .	positive	1
7868	10540162	3439;356	IFN-alpha;FasL	***IFN-alpha*** ***up-regulates*** ***FasL*** mRNA and protein synthesis in mitogen-activated PBMC of HCV + individuals , as previously found in healthy subjects .	positive	1
7869	10540167	356;355	FasL;Fas	To determine the mechanisms responsible for the impaired lymphocyte-mediated cytotoxicity in Chediak-Higashi syndrome ( CHS ) , we investigated the killing ability of peripheral blood lymphocytes ( PBL ) from three patients with CHS using several kinds of target cells that were sensitive to perforin , ***Fas*** ***ligand*** ( ***FasL*** ) , and/or tumour necrosis factor-alpha ( TNF-alpha ) .	parallel	1
7870	10540168	3565;3458	IL-4;IFN-gamma	These results indicate that nasal administration of ***IL-4*** promotes activation of DC and ***induces*** production of ***IFN-gamma*** and IL-10 by DC .	target	1
7871	10540168	3565;3586	IL-4;IL-10	These results indicate that nasal administration of ***IL-4*** promotes activation of DC and ***induces*** production of IFN-gamma and ***IL-10*** by DC .	target	1
7872	10540172	959;958	CD40L;CD40	It was recently shown that one immunological abnormality found in male BXSB mice encompasses B cell expression of ***CD40*** ***ligand*** ( ***CD40L*** ) by an expanded population of large B cells .	parallel	1
7873	10540190	3458;4843	IFN-gamma;iNOS	Semiquantification of gene expression for inducible nitric oxide synthase ( iNOS ) showed that BZL completely inhibited ***iNOS*** gene ***induction*** by ***IFN-gamma*** , and resulted in respective inhibitions of 30 % and 50 % with LPS - and LPS + IFN-gamma-stimulated cells .	target	1
7874	10540194	3458;6347	IFN-gamma;MCP-1	***IFN-gamma*** however was only able to ***up-regulate*** ***MCP-1*** production .	positive	1
7875	10540194	3553;6374	IL-1;ENA-78	Maximal production of MCP-1 in LMVEC was achieved with TNF-alpha ( 28.4 ng/ml , P < 0.01 ) , whereas ***IL-1*** was the most potent ***stimulator*** of ***ENA-78*** ( 2.78 ng/ml , P < 0.001 ) and Groalpha ( 29.2 ng/ml , P < 0.001 ) .	positive	0
7876	10540215	959;958	CD40L;CD40	Monoclonal antibodies ( mAb ) to ***CD40*** ***ligand*** ( ***CD40L*** ) and human leucocyte antigen ( HLA ) - DR , but not lymphocyte function-associated antigen-1 ( LFA-1 ) , LFA-3 or HLA-class I , significantly inhibited the T-lymphocyte induction of DC costimulator expression .	parallel	1
7877	10540222	1437;3502	GM-CSF;IgG3	Among the macrophage cytokines , TNF-alpha and ***GM-CSF*** which have not been shown to play a role in B-cell activation were positively ***associated*** with IgG1 ( TNF-alpha , P = 0.0005 ; GM-CSF , P = 0.001 ) and ***IgG3*** ( TNF-alpha , P = 0.001 ; GM-CSF , P = 0.021 ) antibodies .	positive	0
7878	10540222	7124;3502	TNF-alpha;IgG3	Among the macrophage cytokines , ***TNF-alpha*** and GM-CSF which have not been shown to play a role in B-cell activation were positively ***associated*** with IgG1 ( TNF-alpha , P = 0.0005 ; GM-CSF , P = 0.001 ) and ***IgG3*** ( TNF-alpha , P = 0.001 ; GM-CSF , P = 0.021 ) antibodies .	positive	0
7879	10540223	396;5880	RhoGDI;Rac2	We proposed that eosinophils translate and express ***Rac2*** and its GDP-dissociation ***inhibitor*** , ***RhoGDI*** .	negative	1
7880	10540228	3458;3586	IFN-gamma;IL-10	Using reverse transcriptase-polymerase chain reaction , significant increases in Th2 [ interleukin-4 ( IL-4 ) , IL-5 and IL-10 ] , and IFN-gamma cytokine mRNA were found in the lungs of sensitized and OA-exposed animals , while exogenous ***IFN-gamma*** significantly ***suppressed*** IL-4 , IL-5 and ***IL-10*** mRNA expression , and anti-IFN-gamma antibody increased IL-4 and IL-5 mRNA expression .	negative	1
7881	10540228	3458;3565	IFN-gamma;IL-4	Using reverse transcriptase-polymerase chain reaction , significant increases in Th2 [ interleukin-4 ( IL-4 ) , IL-5 and IL-10 ] , and IFN-gamma cytokine mRNA were found in the lungs of sensitized and OA-exposed animals , while exogenous ***IFN-gamma*** significantly ***suppressed*** ***IL-4*** , IL-5 and IL-10 mRNA expression , and anti-IFN-gamma antibody increased IL-4 and IL-5 mRNA expression .	negative	1
7882	10540228	3458;3567	IFN-gamma;IL-5	Using reverse transcriptase-polymerase chain reaction , significant increases in Th2 [ interleukin-4 ( IL-4 ) , IL-5 and IL-10 ] , and IFN-gamma cytokine mRNA were found in the lungs of sensitized and OA-exposed animals , while exogenous ***IFN-gamma*** significantly ***suppressed*** IL-4 , ***IL-5*** and IL-10 mRNA expression , and anti-IFN-gamma antibody increased IL-4 and IL-5 mRNA expression .	negative	1
7883	10540229	941;940	CD80;CD28	These observations suggested that the presence of low levels of CD80 on monocytes may partially inhibit CD27 expression due to inefficient delivery of positive signals via ******CD28/CD80****** ***interaction*** , and that the increased levels of CD80 enhance the inhibition through interactions with CD152 which is expressed at the highest levels after 48 hr of activation .	parallel	1
7884	10540231	1604;976	DAF;CD97	The ***interaction*** of ***CD97*** and ***DAF*** was found to be species-restrictive in that human erythrocytes were unable to bind to mouse CD97-transfected HEK cells .	parallel	1
7885	10540231	1604;976	DAF;CD97	These results indicate that the general structure , membrane association property and DAF-binding ability of CD97 are conserved and that the adhesive ***interaction*** between ***CD97*** and ***DAF*** is independent of the RGD motif .	parallel	1
7886	10540231	1604;976	DAF;CD97	To understand further the ***interaction*** between ***CD97*** and ***DAF*** , as well as the structure and function of CD97 in general , we have cloned the mouse CD97 cDNA and studied the encoded protein for its membrane association property and ability to interact specifically with the murine decay-accelerating factor .	parallel	1
7887	10540317	959;958	CD40 ligand;CD40	Microglia became professional APC only after a multistep activation process involving both stimulation through cytokines [ granulocyte-macrophage colony-stimulating factor ( GM-CSF ) and IFN-gamma ] and cognate signaling ( B7-CD28 and ******CD40-CD40 ligand****** ***interactions*** ) .	parallel	1
7888	10540317	958;959	CD40;CD40 ligand	******CD40-CD40 ligand****** ***interaction*** significantly enhanced microglial ability to prime TCR-transgenic T cells and was essential for presentation of MBP to in vivo primed non-transgenic T cells .	parallel	1
7889	10540332	6346;1237	I-309;CCR8	These results provide strong evidence that , at physiologically relevant concentrations , ***I-309*** is the only known human ***ligand*** for ***CCR8*** .	parallel	1
7890	10540350	1874;7027	E2F4;DP1	We find that ***E2F4*** and ***DP1*** form the predominant E2F ***heterodimers*** in the G0 and G1 phases of the cell cycle , complexed with hypophosphorylated p130 .	parallel	1
7891	10540352	973;959	IgA;IgM	In this study we made deletions of the human pIgR D2 and D3 ( pIgRDelta2 ,3 ) , or D4 and D5 ( pIgRDelta4 ,5 ) , to investigate the influence of these domains in receptor ***binding*** and transport of dimeric ***IgA*** and pentameric ***IgM*** across MDCK cells transfected with the truncated receptors .	parallel	1
7892	10540352	973;5284	IgA;pIgR	Moreover , our studies imply that dimeric human ***IgA*** ***binds*** differently to ***pIgR*** from various species .	parallel	1
7893	10541301	7035;2152	TFPI;tissue factor	Dialysis was associated with a striking increase in circulating levels of ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , a physiologic inhibitor of the TF/VIIa complex .	negative	1
7894	10541313	3569;2252	IL-6;KGF	Both cAMP and ***IL-6*** significantly ***increased*** expression of ***KGF*** but not KGF receptor during a 48-h experiment .	positive	0
7895	10541317	4352;7066	c-mpl;TPO	To exclude the possible role of ***TPO*** and its ***receptor*** ***c-mpl*** in the etiology of this condition , linkage analysis was performed using microsatellite markers close to the TPO and c-mpl genes on chromosomes 3q26.3-q27 and 1p34 , respectively .	parallel	1
7896	10541432	1956;5594	erbB;ERK	Kinase-deficient ***erbB*** proteins reduced epidermal growth factor ( EGF ) - induced tyrosine phosphorylation of endogenous Shc proteins and also ***reduced*** immediate and sustained EGF-induced ***ERK*** MAPK activities in human glioblastoma cells , although basal ERK MAPK activities were unaffected .	negative	1
7897	10541434	5970;1281	p65;alpha1(I) collagen	Nuclear run-on assays showed that NF-kappaB ***p65*** ***inhibited*** transcription of the endogenous ***alpha1(I) collagen*** gene .	negative	1
7898	10541434	4790;1281	NF-kappaB;alpha1(I) collagen	Together , these results demonstrate that ***NF-kappaB*** ***decreases*** transcription of the ***alpha1(I) collagen*** gene .	negative	0
7899	10541434	4790;1281	NF-kappaB;alpha1(I) collagen	***NF-kappaB*** ***inhibits*** expression of the ***alpha1(I) collagen*** gene .	negative	1
7900	10541552	4609;4193	c-Myc;Mdm2	In cultured primary mouse embryo fibroblasts , ***c-Myc*** ***activates*** the p19 ( ARF ) - ***Mdm2-p53*** tumor suppressor pathway , enhancing p53-dependent apoptosis but ultimately selecting for surviving immortalized cells that have sustained either p53 mutation or biallelic ARF deletion .	positive	1
7901	10541552	4609;1029	c-Myc;p19	In cultured primary mouse embryo fibroblasts , ***c-Myc*** ***activates*** the ***p19*** ( ARF ) - Mdm2-p53 tumor suppressor pathway , enhancing p53-dependent apoptosis but ultimately selecting for surviving immortalized cells that have sustained either p53 mutation or biallelic ARF deletion .	positive	1
7902	10541552	4609;7157	c-Myc;p53	In cultured primary mouse embryo fibroblasts , ***c-Myc*** ***activates*** the p19 ( ARF ) - ***Mdm2-p53*** tumor suppressor pathway , enhancing p53-dependent apoptosis but ultimately selecting for surviving immortalized cells that have sustained either p53 mutation or biallelic ARF deletion .	positive	1
7903	10541554	648;1029	Bmi-1;INK4a	Here we demonstrate that ***down-regulation*** of ***INK4a-ARF*** by ***Bmi-1*** underlies its ability to cooperate with Myc in tumorigenesis .	negative	1
7904	10541554	4609;1029	Myc;p19arf	Furthermore , Bmi-1 collaborates with Myc in enhancing proliferation and transformation of primary embryo fibroblasts ( MEFs ) in an INK4a-ARF dependent manner , by prohibiting ***Myc-mediated*** ***induction*** of ***p19arf*** and apoptosis .	target	1
7905	10541569	3586;4318	IL-10;matrix metalloproteinase (MMP)-9	Furthermore , ***IL-10*** dramatically ***reduces*** the synthesis of ***matrix metalloproteinase (MMP)-9*** and the invasivity of cytotrophoblast cells in vitro , suggesting that an autocrine regulatory role in vivo is also possible .	negative	1
7906	10541762	5741;2353	PTH;c-fos	We conclude that during the immediate early phase of the anabolic response , ***PTH*** ***regulates*** ***c-fos*** , c-jun , and IL-6 expression in osteoblasts , osteocytes , megakaryocytes , and selected bone marrow hematopoietic cells in bone .	target	1
7907	10541762	5741;3725	PTH;c-jun	We conclude that during the immediate early phase of the anabolic response , ***PTH*** ***regulates*** c-fos , ***c-jun*** , and IL-6 expression in osteoblasts , osteocytes , megakaryocytes , and selected bone marrow hematopoietic cells in bone .	target	1
7908	10541762	5741;3569	PTH;IL-6	We conclude that during the immediate early phase of the anabolic response , ***PTH*** ***regulates*** c-fos , c-jun , and ***IL-6*** expression in osteoblasts , osteocytes , megakaryocytes , and selected bone marrow hematopoietic cells in bone .	target	1
7909	10541969	2321;7422	FLT-1;vascular endothelial growth factor	The expression patterns of ***vascular endothelial growth factor*** ( VEGF ) and its two ***receptors*** , ***FLT-1*** and KDR , were assessed in normal human melanocytes , transformed melanocytes expressing the simian virus 40 Tgene ( SV40T ) , and melanoma cells derived from primary and metastatic lesions .	parallel	1
7910	10541969	3791;7422	KDR;vascular endothelial growth factor	The expression patterns of ***vascular endothelial growth factor*** ( VEGF ) and its two ***receptors*** , FLT-1 and ***KDR*** , were assessed in normal human melanocytes , transformed melanocytes expressing the simian virus 40 Tgene ( SV40T ) , and melanoma cells derived from primary and metastatic lesions .	parallel	1
7911	10542098	8795;8743	DR5;TRAIL	Structure of the ******TRAIL-DR5****** ***complex*** reveals mechanisms conferring specificity in apoptotic initiation .	parallel	1
7912	10542098	8795;8743	DR5;TRAIL	Here we report the crystal structure at 2.2 A resolution of a ***complex*** between ***TRAIL*** and the extracellular region of ***DR5*** .	parallel	1
7913	10542132	116;4914	PACAP;TrkA	The PACAP38-selective antagonist ***PACAP*** 6-38 ***blocked*** ***TrkA*** receptor upregulation elicited by PACAP38 .	negative	0
7914	10542132	4803;4914	NGF;TrkA	PACAP38 provoked an increase in basal and ***NGF-stimulated*** ***phosphorylation*** of ***TrkA*** .	target	1
7915	10542135	2034;405	HIF-2alpha;aryl hydrocarbon receptor nuclear translocator	As well as HIF-1alpha , ***HIF-2alpha*** forms a heterodimeric ***complex*** with the ***aryl hydrocarbon receptor nuclear translocator*** and upregulates hypoxia-inducible genes such as vascular endothelial growth factor .	parallel	1
7916	10542161	9212;3005	Stk1;histone H1	The ***Stk1*** kinase is 39 kDa and undergoes autophosphorylation and can ***phosphorylate*** eukaryotic ***histone H1*** .	target	1
7917	10542211	2185;5599	RAFTK;JNK	Expression of wild-type ***RAFTK*** ***enhanced*** GPCR-mediated ***JNK/SAPK*** activation , whereas dominant-negative mutant constructs of RAFTK , such as K457A ( which lacks kinase activity ) and Y402F ( a Src-binding mutant ) , inhibited KSHV-GPCR-mediated activation of JNK/SAPK .	positive	0
7918	10542211	2185;5601	RAFTK;SAPK	Expression of wild-type ***RAFTK*** ***enhanced*** GPCR-mediated ***JNK/SAPK*** activation , whereas dominant-negative mutant constructs of RAFTK , such as K457A ( which lacks kinase activity ) and Y402F ( a Src-binding mutant ) , inhibited KSHV-GPCR-mediated activation of JNK/SAPK .	positive	0
7919	10542211	2185;5599	RAFTK;JNK	Expression of wild-type RAFTK enhanced GPCR-mediated JNK/SAPK activation , whereas dominant-negative mutant constructs of ***RAFTK*** , such as K457A ( which lacks kinase activity ) and Y402F ( a Src-binding mutant ) , ***inhibited*** KSHV-GPCR-mediated activation of ***JNK/SAPK*** .	negative	1
7920	10542211	2185;5601	RAFTK;SAPK	Expression of wild-type RAFTK enhanced GPCR-mediated JNK/SAPK activation , whereas dominant-negative mutant constructs of ***RAFTK*** , such as K457A ( which lacks kinase activity ) and Y402F ( a Src-binding mutant ) , ***inhibited*** KSHV-GPCR-mediated activation of ***JNK/SAPK*** .	negative	1
7921	10542212	4790;5970	p50;p65	In its inactive state , NF-kappaB is constitutively present in the cytoplasm as a ******p50-p65****** ***heterodimer*** bound to its inhibitory protein IkappaB .	parallel	1
7922	10542221	116;7124	PACAP;tumor necrosis factor-alpha	We showed previously that VIP and ***PACAP*** ***inhibit*** the production of macrophage-derived ***tumor necrosis factor-alpha*** , interleukin ( IL ) -6 , nitric oxide , and IL-12 .	negative	1
7923	10542221	7432;7124	VIP;tumor necrosis factor-alpha	We showed previously that ***VIP*** and PACAP ***inhibit*** the production of macrophage-derived ***tumor necrosis factor-alpha*** , interleukin ( IL ) -6 , nitric oxide , and IL-12 .	negative	1
7924	10542222	10044;5906	SHEP1;Rap1A	***SHEP1*** also contains a domain similar to Ras guanine nucleotide exchange factor domains and ***binds*** to the GTPases R-Ras and ***Rap1A*** , but not Ha-Ras or RalA .	parallel	1
7925	10542237	5465;3725	PPARalpha;c-Jun	Finally , glutathione S-transferase pull-down experiments demonstrate that ***PPARalpha*** physically ***interacts*** with ***c-Jun*** , p65 , and CBP .	parallel	1
7926	10542237	5465;5970	PPARalpha;p65	Finally , glutathione S-transferase pull-down experiments demonstrate that ***PPARalpha*** physically ***interacts*** with c-Jun , ***p65*** , and CBP .	parallel	1
7927	10542237	5465;5970	PPARalpha;p65	Furthermore , activation of ***PPARalpha*** ***represses*** both c-Jun - and ***p65-induced*** transcription of the human IL-6 promoter .	negative	1
7928	10542237	3725;5465	c-Jun;PPAR	Transcriptional interference between PPARalpha and both c-Jun and p65 occurs reciprocally , since ***c-Jun*** and p65 also ***inhibit*** PPARalpha-mediated activation of a ***PPAR*** response element-driven promoter .	negative	1
7929	10542237	5970;5465	p65;PPAR	Transcriptional interference between PPARalpha and both c-Jun and p65 occurs reciprocally , since c-Jun and ***p65*** also ***inhibit*** PPARalpha-mediated activation of a ***PPAR*** response element-driven promoter .	negative	1
7930	10542237	5465;3725	PPARalpha;c-Jun	Overexpression of the transcriptional coactivator cAMP-responsive element-binding protein-binding protein ( CBP ) does not relieve ***PPARalpha-mediated*** transcriptional ***repression*** of p65 and ***c-Jun*** .	negative	1
7931	10542237	5465;5970	PPARalpha;p65	Overexpression of the transcriptional coactivator cAMP-responsive element-binding protein-binding protein ( CBP ) does not relieve ***PPARalpha-mediated*** transcriptional ***repression*** of ***p65*** and c-Jun .	negative	1
7932	10542243	2033;3569	p300;IL-6	At the cofactor level , cAMP-responsive element-binding protein-binding protein ( CBP ) or ***p300*** ***potentiate*** basal and induced ***IL-6*** promoter activation via multiple protein-protein interactions with all transcription factors bound to the promoter DNA .	positive	0
7933	10542250	6678;7040	SPARC;TGF-beta1	We conclude that ***SPARC*** ***regulates*** the expression of collagen type I and ***TGF-beta1*** in kidney mesangial cells .	target	1
7934	10542258	1741;1741	SAP102;NE-dlg	A novel NE-dlg/SAP102-associated protein , p51-nedasin , related to the amidohydrolase superfamily , interferes with the ***association*** between ******NE-dlg/SAP102****** and N-methyl-D-aspartate receptor .	parallel	0
7935	10542261	6441;4239	SP-D;MFAP4	No binding was seen to recombinant SP-D composed of the neck region and carbohydrate recognition domain of SP-D , indicating that the ***interaction*** between ***MFAP4*** and ***SP-D*** is mediated via the collagen region of SP-D .	parallel	1
7936	10542264	4092;7040	Smad7;TGF-beta	***Smad7*** has been identified as a negative ***regulator*** of transforming growth factor beta ( ***TGF-beta*** ) signaling by interfering with the phosphorylation of other Smad proteins by TGF-beta receptor type I ( TbetaRI ) .	negative	1
7937	10542264	4092;7040	Smad7;TGF-beta	Importantly , the expression of recombinant ***Smad7*** differentially ***inhibited*** ***TGF-beta*** signaling pathways .	negative	1
7938	10542266	5290;672	PI3K;BRCA1	Heregulin-induced phosphorylation of ***BRCA1*** was ***abrogated*** by phosphatidylinositol 3-kinase ( ***PI3K*** ) inhibitors and by a dominant-negative AKT .	negative	0
7939	10542266	207;672	AKT;BRCA1	We have also shown that the ***phosphorylation*** of ***BRCA1*** by ***AKT*** occurs on the residue Thr-509 , which is located in the nuclear localization signal .	target	1
7940	10542273	145258;60529	Gsc;Alx4	We demonstrate that Alx4 homodimers , Gsc homodimers , and ******Alx4/Gsc****** ***heterodimers*** each have distinct DNA binding properties , and each can discriminate between highly related palindromic elements .	parallel	1
7941	10542278	5378;4292	hPMS1;hMLH1	Identification of hMutLbeta , a ***heterodimer*** of ***hMLH1*** and ***hPMS1*** .	parallel	1
7942	10542291	10116;355	F1Aalpha;Fas	***F1Aalpha*** ***associates*** with the cytoplasmic domains of ***Fas*** and tumor necrosis factor receptor 1 , two prototype members of the " death receptor " family .	parallel	0
7943	10542297	3456;6774	interferon-beta;STAT3	Catalytically active TYK2 is essential for ***interferon-beta-mediated*** ***phosphorylation*** of ***STAT3*** and interferon-alpha receptor-1 ( IFNAR-1 ) but not for activation of phosphoinositol 3-kinase .	target	1
7944	10542297	3456;3454	IFN-beta;IFNAR-1	Additionally , ***IFN-beta-mediated*** ***phosphorylation*** of interferon-alpha receptor-1 ( ***IFNAR-1*** ) was defective in IFN-beta treated U1.KR930 cells , but evident in U1.wt cells .	target	1
7945	10542297	9733;3454	p110;IFNAR-1	In U1A-derived cells , the ***p85/p110*** phosphoinositol 3-kinase isoform was ***associated*** with ***IFNAR-1*** but not STAT3 , and the association was ligand-independent .	parallel	0
7946	10542297	5295;3454	p85;IFNAR-1	In U1A-derived cells , the ***p85/p110*** phosphoinositol 3-kinase isoform was ***associated*** with ***IFNAR-1*** but not STAT3 , and the association was ligand-independent .	parallel	0
7947	10542297	3456;3454	IFN-beta;IFNAR-1	Our results indicate that catalytically active TYK2 is required for ***IFN-beta-mediated*** tyrosine ***phosphorylation*** of STAT3 and ***IFNAR-1*** in intact cells .	target	1
7948	10542297	3456;6774	IFN-beta;STAT3	Our results indicate that catalytically active TYK2 is required for ***IFN-beta-mediated*** tyrosine ***phosphorylation*** of ***STAT3*** and IFNAR-1 in intact cells .	target	1
7949	10542322	914;962	CD2;CD48	We have also shown 2B4 to interact with CD48 with nine times more affinity than that of ******CD2-CD48****** ***interaction*** .	parallel	1
7950	10542365	5054;5328	PAI-1;u-PA	Urokinase plasminogen activator ( ***u-PA*** ) and its fast acting type-1 ***inhibitor*** ( ***PAI-1*** ) localize to cellular focal adhesive structures and the adjoining proximal undersurface region , respectively ( Kutz et al. , J.	negative	1
7951	10542982	3565;3586	IL-4;IL-10	***IL-4*** failed to ***suppress*** LPS-induced production of ***IL-10*** by AMs both in control patients and in lung cancer patients .	negative	1
7952	10543213	5340;5345	plasmin;Alpha 2-plasmin inhibitor	[ ******Alpha 2-plasmin inhibitor-plasmin****** ***complex*** ] .	parallel	1
7953	10543214	5327;5054	t-PA;PAI-1	[ ******t-PA-PAI-1****** ***complex*** ] .	parallel	1
7954	10543327	7037;2056	transferrin receptor;erythropoietin	Soluble ***transferrin receptor*** is ***correlated*** with ***erythropoietin*** sensitivity in dialysis patients .	parallel	0
7955	10543395	217;1571	ALDH2;CYP2E1	Moreover , a borderline significant ***interaction*** between the ***ALDH2*** and ***CYP2E1*** genotypes on excessive alcohol consumption was observed , i.e. , the group of subjects having the c2 allele of CYP2E1 had a higher frequency of EAC than those having c1/c1 genotypes in the genotype subgroup ALDH2 ( 1 ) / ALDH2 ( 1 ) , whereas these were not found in the heterozygote and homozygote subgroups of the ALDH2 ( 2 ) allele .	parallel	1
7956	10543448	4325;4326	MT3-MMP;MT4-MMP	TIMP-1 , a poor inhibitor of MT1 - , MT2 - and ***MT3-MMP*** , ***suppresses*** ***MT4-MMP*** activity effectively .	negative	1
7957	10543448	7076;4326	TIMP-1;MT4-MMP	***TIMP-1*** , a poor inhibitor of MT1 - , MT2 - and MT3-MMP , ***suppresses*** ***MT4-MMP*** activity effectively .	negative	1
7958	10543448	7077;4326	TIMP-2;MT4-MMP	The progelatinase ***A/TIMP-2*** complex that usually reacts like TIMP-2 also ***inhibits*** ***MT4-MMP*** .	negative	1
7959	10543448	7077;4326	TIMP-2;MT4-MMP	***TIMP-2*** , a strong inhibitor of other MT-MMPS , ***inhibits*** ***MT4-MMP*** at low concentrations .	negative	1
7960	10543451	4084;4609	Mad;Myc	DNA binding of ******Myc/Max/Mad****** network ***complexes*** to oligonucleotides containing two E box elements : c-Myc/Max heterodimers do not bind DNA cooperatively .	parallel	1
7961	10543451	4149;4084	Max;Mad	DNA binding of ******Myc/Max/Mad****** network ***complexes*** to oligonucleotides containing two E box elements : c-Myc/Max heterodimers do not bind DNA cooperatively .	parallel	1
7962	10543451	4149;4609	Max;Myc	DNA binding of ******Myc/Max/Mad****** network ***complexes*** to oligonucleotides containing two E box elements : c-Myc/Max heterodimers do not bind DNA cooperatively .	parallel	1
7963	10543451	4149;4609	Max;c-Myc	DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements : ******c-Myc/Max****** ***heterodimers*** do not bind DNA cooperatively .	parallel	1
7964	10543451	4149;4609	Max;c-Myc	To extend this finding we analyzed DNA binding of ******c-Myc/Max****** ***complexes*** using a transient COS-7 expression system .	parallel	1
7965	10543451	4149;4609	Max;c-Myc	To extend this finding we analyzed DNA ***binding*** of ******c-Myc/Max****** complexes using a transient COS-7 expression system .	parallel	1
7966	10543451	4149;4609	Max;c-Myc	In both competition and titration experiments no cooperative binding of ******c-Myc/Max****** ***heterodimers*** to probes with two E boxes was observed .	parallel	1
7967	10543488	5340;5345	plasmin;alpha 2 plasmin inhibitor	Blood was obtained for the measurement of thrombin-antithrombin III complexes , fibrinopeptide A , ******plasmin-alpha 2 plasmin inhibitor****** ***complexes*** , and D-dimer preoperatively ; after heparin administration ; 10 , 60 , and 90 minutes after the start of bypass ; after protamine administration ; and 1 , 3 , 6 , 12 , and 24 hours after the end of bypass .	parallel	1
7968	10543727	5328;3725	ATF;AP-1	Here we demonstrate that latter element is bound by at least two distinct ***heterodimers*** of the ******AP-1/ATF****** transcription factor family , namely c-Jun/ATF-2 and c-Jun/Fra2 .	parallel	1
7969	10543731	183;8548	angiotensin II;cytoplasmic protein	SM-20 encodes a ***cytoplasmic protein*** , which is ***induced*** by platelet-derived growth factor and ***angiotensin II*** in cultured SMC and is upregulated in intimal SMC of atherosclerotic plaques and injured arteries .	target	1
7970	10543954	5327;5054	t-PA;PAI-1	We propose that the length , flexibility and different charge architecture of the VR1 loop of t-PA invoke an induced fit of the reactive center loop of PAI-1 , thereby enhancing the rate of acylation in the Michaelis ***complex*** between thrombin-VR1 ( ***t-PA*** ) and ***PAI-1*** by more than two orders of magnitude .	parallel	1
7971	10543959	10728;3320	p23;Hsp90	This unstructured region is dispensible for ***interaction*** of ***p23*** with ***Hsp90*** , since truncated p23 can still form complexes with Hsp90 .	parallel	1
7972	10543991	3553;5595	IL-1beta;ERK1	We found that KS cell growth factors oncostatin M , sIL-6R / IL-6 , TNFalpha , and ***IL-1beta*** all ***activate*** ***ERK1/2*** , and selective blockage of this kinase by PD98059 resulted in a profound inhibition of the cytokine-induced KS cell growth .	positive	1
7973	10543991	3569;5595	IL-6;ERK1	We found that KS cell growth factors oncostatin M , sIL-6R / ***IL-6*** , TNFalpha , and IL-1beta all ***activate*** ***ERK1/2*** , and selective blockage of this kinase by PD98059 resulted in a profound inhibition of the cytokine-induced KS cell growth .	positive	1
7974	10543991	7124;5595	TNFalpha;ERK1	We found that KS cell growth factors oncostatin M , sIL-6R / IL-6 , ***TNFalpha*** , and IL-1beta all ***activate*** ***ERK1/2*** , and selective blockage of this kinase by PD98059 resulted in a profound inhibition of the cytokine-induced KS cell growth .	positive	1
7975	10544014	3458;356	interferon-gamma;Fas ligand	Tumor necrosis factor-alpha and ***interferon-gamma*** ***induce*** expression of functional ***Fas ligand*** on HT29 and MCF7 adenocarcinoma cells .	target	1
7976	10544014	7124;356	Tumor necrosis factor-alpha;Fas ligand	***Tumor necrosis factor-alpha*** and interferon-gamma ***induce*** expression of functional ***Fas ligand*** on HT29 and MCF7 adenocarcinoma cells .	target	1
7977	10544014	7124;356	Tumor necrosis factor-alpha;FasL	Here we show that ***Tumor necrosis factor-alpha*** ( TNF-alpha ) in addition to interferon-gamma ( IFN-gamma ) ***induces*** cell surface expression of functional ***FasL*** in human HT29 colon and MCF7 breast adenocarcinoma cells that constitutively lack cell surface expression of FasL .	target	1
7978	10544014	3458;356	IFN-gamma;FasL	These results demonstrate that TNF-alpha and ***IFN-gamma*** ***induce*** expression of functional ***FasL*** in adenocarcinoma cells which thereby can kill T lymphocytes by the FasL/Fas pathway .	target	1
7979	10544014	7124;356	TNF-alpha;FasL	These results demonstrate that ***TNF-alpha*** and IFN-gamma ***induce*** expression of functional ***FasL*** in adenocarcinoma cells which thereby can kill T lymphocytes by the FasL/Fas pathway .	target	1
7980	10544021	4193;7157	MDM2;p53	Overexpressed ***MDM2*** ***inactivates*** wild-type ( wt ) ***p53*** in various human tumors .	negative	1
7981	10544021	7157;4193	p53;MDM2	This p53 was co-immunoprecipitated with MDM2 , but ***p53*** activated by etoposide or doxorubicin barely ***complexed*** with ***MDM2*** .	parallel	1
7982	10544021	7157;4193	p53;MDM2	This ***p53*** was ***co-immunoprecipitated*** with ***MDM2*** , but p53 activated by etoposide or doxorubicin barely complexed with MDM2 .	parallel	1
7983	10544028	2885;8661	Grb2;p185	Peptide 14 also inhibited ******Grb2/p185****** ( erb ) ( B-2 ) protein ***association*** in cell homogenates of erbB-2-overexpressing MDA-MA-453 cancer cells at near one micromolar concentrations .	parallel	0
7984	10544141	7128;5599	A20;JNK	***A20*** , which is induced by LMP1 through NF-kB , can block NF-kB activation from both domains of LMP1 and ***inhibit*** ***JNK*** activation from CTAR2 .	negative	1
7985	10544141	7185;7186	TRAF1;TRAF2	A20 did not affect the ***association*** of ***TRAF1*** with ***TRAF2*** but did displace TRAF1 from the LMP1 complex .	parallel	0
7986	10544199	958;959	CD40;CD40 ligand	A critical role for ******CD40-CD40 ligand****** ***interactions*** in amplification of the mucosal CD8 T cell response .	parallel	1
7987	10544199	958;959	CD40;CD40L	Appearance of virus-specific mucosal , but not splenic , CD8 cells also relied heavily on ******CD40-CD40L****** ***interactions*** .	parallel	1
7988	10544233	5783;7133	FAP-1;p75	Thus , ***FAP-1*** may ***regulate*** ***p75*** ( NTR ) - mediated signal transduction by physiological interaction through its third PDZ domain .	target	1
7989	10544233	5783;7133	FAP-1;p75	Functional ***interaction*** of Fas-associated phosphatase-1 ( ***FAP-1*** ) with ***p75*** ( NTR ) and their effect on NF-kappaB activation .	parallel	1
7990	10544233	5783;355	FAP-1;Fas	***FAP-1*** ( Fas-associated phosphatase-1 ) , which ***binds*** to the cytoplasmic tail of ***Fas*** , was originally identified as a negative regulator of Fas-mediated apoptosis .	parallel	1
7991	10544233	5783;7133	FAP-1;p75	Here we have shown by co-immunoprecipitation that ***FAP-1*** also ***binds*** to the ***p75*** ( NTR ) cytoplasmic domain in vivo through the interaction between the third PDZ domain of FAP-1 and C-terminal Ser-Pro-Val residues of p75 ( NTR ) .	parallel	1
7992	10544233	5783;4790	FAP-1;NF-kappaB	The results revealed that TRAF6-mediated NF-kappaB activation was suppressed by p75 ( NTR ) and that the p75 ( NTR ) - mediated ***NF-kappaB*** suppression was ***reduced*** by ***FAP-1*** expression .	negative	1
7993	10544233	7133;4790	p75;NF-kappaB	The results revealed that TRAF6-mediated ***NF-kappaB*** activation was ***suppressed*** by ***p75*** ( NTR ) and that the p75 ( NTR ) - mediated NF-kappaB suppression was reduced by FAP-1 expression .	negative	1
7994	10544245	3320; 3091	Hsp90;HIF-1alpha	Hypoxia-induced activation of HIF-1 : role of ******HIF-1alpha-Hsp90****** ***interaction*** .	parallel	1
7995	10544250	2006;22795	Tropoelastin;nidogen-2	***Tropoelastin*** ***binding*** to fibulins , ***nidogen-2*** and other extracellular matrix proteins .	parallel	1
7996	10544256	7124;4790	TNF-alpha;NF-kappaB	***Activation*** of ***NF-kappaB*** by ***TNF-alpha*** was reproduced in primary hOBs .	positive	1
7997	10544264	5923;207	Ras-GRF1;Rac	CDC25 ( Mm ) / ***Ras-GRF1*** ***regulates*** both Ras and ***Rac*** signaling pathways .	target	1
7998	10544264	5923;2353	Ras-GRF1;c-fos	We found that a ***Ras-GRF1*** mutant lacking PH1 and IQ domains is sufficient to ***activate*** ***c-fos*** promoter in response to lysophosphatidic acid ( LPA ) .	negative	1
7999	10544283	1977;1979	eIF4E;4E-BP2	***Interaction*** between X. laevis ***eIF4E*** and ***4E-BP2*** was analyzed by affinity column chromatography , gel permeation chromatography ( GPC ) , and surface plasmon resonance ( SPR ) .	parallel	1
8000	10544283	1979;1977	4E-BP2;eIF4E	Furthermore , the SPR analysis showed that the eIF4E-cap-analogue interaction was very weak regardless of complex ***formation*** of ***4E-BP2*** with ***eIF4E*** ; the dissociation constant of eIF4E for the cap-analogue was estimated to be 10 ( -2 ) -10 ( -4 ) M.	parallel	0
8001	10544657	7409;7535	Vav;Zap-70	Upon stimulation of TCR by antigenic peptides , ***Vav*** ***associates*** with ***Zap-70*** in TCR/CD3 signaling complex and becomes phosphorylated on Tyr-174 by tyrosine kinase Lck .	parallel	0
8002	10544657	940;7409	CD28;Vav	It seems that ***Vav*** functions in key point of TCR-mediated signaling pathway , which is ***regulated*** by costimulatory molecule ( ***CD28*** ) necessary for negative selection .	target	1
8003	10544917	7124;5624	TNF-alpha;protein C	Both quantitative reverse transcription-PCR assay and in situ hybridization analysis revealed that ***TNF-alpha*** ***decreased*** ***protein C*** mRNA expression in the liver , kidney , and testis .	negative	0
8004	10544960	1906;1432	Endothelin-1;p38 mitogen-activated protein kinase	***Endothelin-1*** ***activates*** ***p38 mitogen-activated protein kinase*** via endothelin-A receptor in rat myocardial cells .	positive	1
8005	10544965	1843;356	MKP-1;Fas ligand	***MKP-1*** overexpression in DU-145 cells was also found to ***inhibit*** ***Fas ligand*** ( FasL ) - induced apoptosis , as well as block the activation of caspases by Fas engagement .	negative	1
8006	10544965	1843;356	MKP-1;FasL	***MKP-1*** ***blocked*** the ability of ***FasL*** to induce loss of mitochondrial transmembrane potential ( delta Psi ( m ) ) , suggesting that MKP-1 acts upstream of mitochondrial pro-apoptotic events induced by FasL and that the SAPK/JNK pathway may form the signaling link between Fas receptor and mitochondrial dysfunction .	negative	0
8007	10545030	10153;2042	CBF2;EphA3	Ectopic expression of CBF1 using in ovo electroporation repressed the expression of CBF2 , and misexpression of ***CBF2*** ***influenced*** the graded localization of ***EphA3*** in the retina , albeit imperfectly .	target	0
8008	10545030	3516;10153	CBF1;CBF2	Ectopic expression of ***CBF1*** using in ovo electroporation ***repressed*** the expression of ***CBF2*** , and misexpression of CBF2 influenced the graded localization of EphA3 in the retina , albeit imperfectly .	negative	1
8009	10545161	8851;1020	p35;cdk5	Mice lacking ***p35*** , an ***activator*** of ***cdk5*** in the central nervous system ( CNS ) , exhibit defects in a variety of CNS structures , most prominently characterized by a disruption in the laminar structure of the neocortex ( Chae et al. , 1997 ) .	positive	1
8010	10545217	7048;7040	TbetaR-II;TGFbeta	Resistance to the growth inhibitory effects of transforming growth factor beta ( TGFbeta ) has been associated with decreased levels of the ***TGFbeta*** type II ***receptor*** ( ***TbetaR-II*** ) and has been correlated with tumorigenicity .	parallel	1
8011	10545217	1523;7048	CDP/Cut;TbetaR-II	In this study , we show that the ***CDP/Cut*** ( CCAAT displacement protein ) transcription factor , a transcriptional repressor , ***binds*** both the wild type and the mutant ***TbetaR-II*** promoter .	parallel	1
8012	10545285	4829;4828	NMBR;neuromedin B	Using the reverse transcription-polymerase chain reaction ( RT-PCR ) , we have detected mRNA for the ***neuromedin B*** ***receptor*** ( ***NMBR*** ) in all 14 of the NSCLC cell lines examined .	parallel	1
8013	10545285	2925;2922	GRPR;GRP	***GRP*** ***receptor*** ( ***GRPR*** ) mRNA was also expressed in the majority of NSCLC cell lines ( nine of 14 ) .	parallel	1
8014	10545482	4790;5970	p50;p65	We show here for the first time that alcohol inhibits lipopolysaccharide ( LPS ) - induced NFkappaB activation in human monocytes by decreasing DNA binding of the ******p65/p50****** ***heterodimer*** as seen in electrophoretic mobility shift and supershift assays .	parallel	1
8015	10545482	4790;5970	p50;p65	We show here for the first time that alcohol inhibits lipopolysaccharide ( LPS ) - induced NFkappaB activation in human monocytes by decreasing DNA ***binding*** of the ******p65/p50****** heterodimer as seen in electrophoretic mobility shift and supershift assays .	parallel	1
8016	10545488	1380;2208	CD21;CD23	***CD21*** , the ***C3d/CD23/Epstein-Barr*** virus ( EBV ) , ***receptor*** is expressed at low density on cells of the T lineage .	parallel	1
8017	10545507	1838;1756	beta-Dystrobrevin;dystrophin	Furthermore , ***beta-Dystrobrevin*** forms a specific ***complex*** with ***dystrophin*** and syntrophin .	parallel	1
8018	10545526	9021;3717	SOCS-3;JAK2	Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation : dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase , and ***SOCS-3-dependent*** ***inactivation*** of ***JAK2*** .	negative	1
8019	10545526	5777;3717	SHP-1;JAK2	Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation : ***dephosphorylation*** of ***JAK2*** and STAT3 by the ***SHP-1*** tyrosine phosphatase , and SOCS-3-dependent inactivation of JAK2 .	target	1
8020	10545526	5777;6774	SHP-1;STAT3	Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation : ***dephosphorylation*** of JAK2 and ***STAT3*** by the ***SHP-1*** tyrosine phosphatase , and SOCS-3-dependent inactivation of JAK2 .	target	1
8021	10545526	3976;5443	leukemia inhibitory factor;proopiomelanocortin	Inhibitory roles for SHP-1 and SOCS-3 following pituitary ***proopiomelanocortin*** ***induction*** by ***leukemia inhibitory factor*** .	target	1
8022	10545526	3976;5777	LIF;SHP-1	***LIF*** ***activates*** the SH2 domain-containing tyrosine phosphatase , ***SHP-1*** , with maximal stimulation observed at 30 minutes .	positive	1
8023	10545526	5777;3717	SHP-1;JAK2	***SHP-1*** is constitutively ***associated*** with ***JAK2*** , and LIF induces recruitment of phosphorylated STAT3 to this complex .	parallel	0
8024	10545526	3976;6774	LIF;STAT3	SHP-1 is constitutively associated with JAK2 , and ***LIF*** ***induces*** recruitment of phosphorylated ***STAT3*** to this complex .	target	1
8025	10545526	9021;3717	SOCS-3;JAK2	In addition , ***SOCS-3*** , a negative regulator of LIF signaling , ***binds*** to ***JAK2*** after 60 minutes of LIF stimulation , after which the complex is degraded by the proteasome .	parallel	1
8026	10545526	9021;3976	SOCS-3;LIF	In addition , ***SOCS-3*** , a negative ***regulator*** of ***LIF*** signaling , binds to JAK2 after 60 minutes of LIF stimulation , after which the complex is degraded by the proteasome .	negative	1
8027	10545526	9021;3717	SOCS-3;JAK2	***SOCS-3*** overexpression ***blocks*** LIF-induced ***JAK2*** tyrosine phosphorylation , confirming a role for SOCS-3 in deactivating JAK2 by direct association .	negative	0
8028	10545594	2132;11227	EXT2;GalNAc-T5	The ******EXT2-GalNAc-T5****** ***interaction*** provides the first direct physical link between EXT proteins and known components of glycosamino-glycan synthesis .	parallel	1
8029	10545793	7039;1956	transforming growth factor-alpha;EGFR	***transforming growth factor-alpha*** ( TGF-alpha ) is a ***ligand*** for epidermal growth factor receptor ( ***EGFR*** ) and it is overexpressed in various malignancies including lung , esophageal , colorectal , ovarian and gastric carcinomas .	parallel	1
8030	10545955	1786;1788	Dnmt1;Dnmt3a	When co-expressed , ***Dnmt1*** and ***Dnmt3a*** ***cooperated*** to establish and maintain methylation patterns .	parallel	0
8031	10545997	958;959	CD40;CD40 ligand	Blocking both CD28-B7 and ******CD40-CD40 ligand****** ***interactions*** ( co-stimulation blockade ) inhibited proliferation of alloreactive T cells in vivo while allowing cell cycle-dependent T-cell apoptosis of proliferating T cells , with permanent engraftment of cardiac allografts but not skin allografts .	parallel	1
8032	10546000	958;959	CD40;CD154	Increasing evidence supports the importance of ******CD40-CD154****** ***interactions*** in atherosclerosis , interactions originally known to be essential in major immune reactions and autoimmune diseases .	parallel	1
8033	10546000	958;2152	CD40;tissue factor	Ligation of ***CD40*** on atheroma-associated cells in vitro ***activates*** the production of chemokines , cytokines , matrix metalloproteinases , adhesion molecules and ***tissue factor*** , substances responsible for lesion progression and plaque destabilization .	positive	1
8034	10546000	958;959	CD40;CD154	These data indicate that ******CD40-CD154****** ***signaling*** is important in late atherosclerotic changes , such as lipid core formation and plaque destabilization .	parallel	0
8035	10546001	2247;9232	bFGF;PTTG	We also demonstrate that ***PTTG*** expression is ***induced*** by ***bFGF*** , and show concordant PTTG and bFGF expression in experimental and human pituitary adenomas .	target	1
8036	10546932	5327;7422	TPA;VEGF	Vitreous concentrations of ***TPA*** and plasminogen activator inhibitor are ***associated*** with ***VEGF*** in proliferative diabetic vitreoretinopathy .	parallel	0
8037	10547059	1432;3315	p38 MAP kinase;Hsp27	Selective ***stimulation*** of ***Hsp27*** and alphaB-crystallin but not Hsp70 expression by ***p38 MAP kinase*** activation .	positive	0
8038	10547073	959;4609	CD40L;c-Myc	This down-regulation of ***c-Myc*** is ***prevented*** by ***CD40L*** , which rescues cells from anti-IgM-induced apoptosis .	negative	0
8039	10547073	959;1027	CD40L;p27Kip1	***CD40L*** , the calcium chelator 1,2-bis ( 2-aminophenoxy ) ethane-N , N , N ' , N ' - tetraacetic acid-acetoxymethyl ester , and cyclosporin A all ***prevented*** anti-IgM-induced ***p27Kip1*** accumulation , suggesting that both the decrease in c-Myc expression and an increase in free calcium are necessary for p27Kip1 up-regulation .	negative	0
8040	10547074	7040;598	TGF-beta;Bcl-X	***TGF-beta*** dose-dependently increased the expression of Bcl-2 and Bad and ***decreased*** the expression of ***Bcl-X*** ( L ) in U937 cells .	negative	0
8041	10547074	7040;596	TGF-beta;Bcl-2	***TGF-beta*** dose-dependently ***increased*** the expression of ***Bcl-2*** and Bad and decreased the expression of Bcl-X ( L ) in U937 cells .	positive	0
8042	10547095	3586;7124	interleukin-10;tumor necrosis factor-alpha	Systemically administered ***interleukin-10*** ***reduces*** ***tumor necrosis factor-alpha*** production and significantly improves functional recovery following traumatic spinal cord injury in rats .	negative	1
8043	10547154	3921;3592	p40;p35	Biologically active interleukin-12 ( IL-12 ) , comprising a 40 kDa subunit ( ***p40*** ) covalently ***linked*** to a 35 kDa subunit ( ***p35*** ) , is produced in response to a range of infectious stimuli .	parallel	0
8044	10547157	3606;3458	IL-18;IFN-gamma	Human recombinant ***IL-18*** ( rHuIL-18 ) ***induced*** ***IFN-gamma*** production by PHA-stimulated peripheral blood mononuclear cells ( PBMC ) , which was potentiated by rHuIL-12 .	target	1
8045	10547161	3553;4318	IL-1beta;MMP-9	Moreover , nuclear run-on analysis has revealed that ***IL-1beta*** significantly ***increased*** ***MMP-9*** gene transcription in GCT stromal cells .	positive	0
8046	10547194	6750;3375	somatostatin;islet amyloid polypeptide	Differential ***inhibition*** of insulin and ***islet amyloid polypeptide*** secretion by intraislet ***somatostatin*** in the isolated perfused human pancreas .	negative	1
8047	10547201	5320;6343	PLA2;secretin	Commercially available porcine pancreatic ***PLA2*** dose-dependently ***stimulated*** ***secretin*** release from STC-1 cells .	positive	0
8048	10547201	5320;6343	PLA2;secretin	Porcine pancreatic ***PLA2*** also ***stimulated*** ***secretin*** release from a secretin-producing cells-enriched preparation isolated from rat duodenal mucosa .	positive	0
8049	10547272	2056;596	Erythropoietin;BCL-2	***Erythropoietin*** ( Epo ) ***induced*** the expression of ***BCL-2*** and MCL-1 protein in TF-1 cells , however it did not support their long term proliferation , further demonstrating that upregulation of these anti-apoptotic genes is insufficient for the long term proliferation of TF-1 cells .	target	1
8050	10547272	2056;4170	Erythropoietin;MCL-1	***Erythropoietin*** ( Epo ) ***induced*** the expression of BCL-2 and ***MCL-1*** protein in TF-1 cells , however it did not support their long term proliferation , further demonstrating that upregulation of these anti-apoptotic genes is insufficient for the long term proliferation of TF-1 cells .	target	1
8051	10547275	632;3553	osteocalcin;IL-1beta	Plasma ***osteocalcin*** levels were positively ***correlated*** with spontaneous production of ***IL-1beta*** , IL-6 and TNF-alpha .	positive	0
8052	10547275	632;7124	osteocalcin;TNF-alpha	Plasma ***osteocalcin*** levels were positively ***correlated*** with spontaneous production of IL-1beta , IL-6 and ***TNF-alpha*** .	positive	0
8053	10547363	2547;7520	Ku70;Ku80	The Ku protein is a ***complex*** of two subunits , ***Ku70*** and ***Ku80*** .	parallel	1
8054	10547573	1026;595	CIP1;cyclin D1	Expression of cell-cycle regulatory proteins ***cyclin D1*** , cyclin E , and their ***inhibitor*** p21 ***WAF1/CIP1*** in gastric cancer .	negative	1
8055	10547574	1019;595	cdk4;cyclin D1	***cdk4*** overexpression was ***linked*** to ***cyclin D1*** , but not Cyclin D2 overexpression .	parallel	0
8056	10547600	355;356	CD95;CD95L	The target cells underwent apoptosis when cultured on breast cancer sections , but could be rescued when ***CD95L*** was specifically ***blocked*** by a ***CD95-Fc*** fusion molecule .	negative	0
8057	10547603	1029;1030	p16;p15	These deletions encompass the ******p15/p16****** ***complex*** and two additional putative tumour suppressor loci .	parallel	1
8058	10547604	356;355	FasL;Fas	The mechanisms of apoptosis in neuroblastomas have been investigated by examining the expression profiles of Fas , ***Fas*** ***ligand*** ( ***FasL*** ) , and caspase 3 in 42 primary tumour tissues .	parallel	1
8059	10548050	6356;1232	eotaxin;CCR3	***eotaxin*** ***binds*** the CC chemokine receptor ***CCR3*** that is highly expressed by eosinophils , and it is considered important in the pathology of chronic respiratory disorders such as asthma .	parallel	1
8060	10548110	1017;51343	Cdk2;Cdh1	These results implicate an E2F-dependent , cyclin ***A/Cdk2-mediated*** ***phosphorylation*** of ***Cdh1*** in the timely accumulation of cyclin B1 and the coordination of cell-cycle progression during the post-restriction point period .	target	1
8061	10548204	3458;7124	IFN-gamma;TNF-alpha	IFN-gamma , IL-1beta , or LPS alone did not induce TNF-alpha production , whereas ***IFN-gamma*** and IL-1beta in combination were able to ***induce*** ***TNF-alpha*** production to some extent , and the production could be further increased with LPS .	target	1
8062	10548204	3553;7124	IL-1beta;TNF-alpha	IFN-gamma , IL-1beta , or LPS alone did not induce TNF-alpha production , whereas IFN-gamma and ***IL-1beta*** in combination were able to ***induce*** ***TNF-alpha*** production to some extent , and the production could be further increased with LPS .	target	1
8063	10548280	627;4852	BDNF;NPY	Results showed that ***BDNF*** ***upregulated*** cortical ***NPY-immunoreactivity*** ( ir ) and SOM-ir , upregulated hippocampal NPY-ir , and downregulated hippocampal DYN-ir in both aged and young rats .	positive	1
8064	10548435	7422;3791	VEGF;KDR	Our data indicate that NX1838 inhibits binding of VEGF to HUVECs ( human umbilical vein endothelial cells ) and dose-dependently prevents ***VEGF-mediated*** ***phosphorylation*** of ***KDR*** and PLCgamma , calcium flux , and ultimately VEGF-induced cell proliferation .	target	1
8065	10548481	1029;7157	ARF;p53	***ARF*** ***induces*** ***p53*** in response to oncogene activation by preventing its degradation .	target	1
8066	10548488	2247;4982	bFGF;OCIF	Enzyme-linked immunosorbent assay showed that ***bFGF*** hardly ***affected*** ***OCIF*** production in the treated ST2 cells .	target	0
8067	10548503	2022;7040	endoglin;TGF-beta	This was purified and identified by peptide sequencing analysis and mass spectrometry as ***endoglin*** ( CD105 ) , the ***TGF-beta*** ***receptor*** III present on endothelial cells , syncytiotrophoblasts , macrophages , and connective tissue stromal cells .	parallel	1
8068	10548505	10329;4790	type II membrane protein;NF-kappaB	Osteoblastic stromal cells produce receptor activator of ***NF-kappaB*** ***ligand*** ( RANKL ) , a ***type II membrane protein*** of the TNF ligand family , in response to these agents .	parallel	1
8069	10548507	2247;4982	bFGF;OCIF	Northern blot analysis revealed that ***bFGF*** up-regulated the expression of osteoclast differentiation factor ( ODF ) and COX-2 and ***down-regulated*** the expression of ***OCIF*** in primary osteoblastic cells .	negative	1
8070	10548507	2247;5743	bFGF;COX-2	Northern blot analysis revealed that ***bFGF*** ***up-regulated*** the expression of osteoclast differentiation factor ( ODF ) and ***COX-2*** and down-regulated the expression of OCIF in primary osteoblastic cells .	positive	1
8071	10548507	2247;8600	bFGF;osteoclast differentiation factor	Northern blot analysis revealed that ***bFGF*** ***up-regulated*** the expression of ***osteoclast differentiation factor*** ( ODF ) and COX-2 and down-regulated the expression of OCIF in primary osteoblastic cells .	positive	1
8072	10548507	2247;4982	bFGF;OCIF	Enzyme-linked immunosorbent assay showed that ***bFGF*** ***inhibited*** ***OCIF*** production by osteoblastic cells , and the inhibition was not affected by NS-398 .	negative	1
8073	10548518	4205;4617	MEF2;myf5	The importance of MEF2 activity was further demonstrated by expression of antisense ***MEF2*** RNA which ***repressed*** MEF2 and ***myf5-mediated*** MEF2 site-dependent reporter gene activation and the synergistic transactivation of a myogenin CAT reporter by myf5 and MEF2 .	negative	1
8074	10548518	4205;4617	MEF2;myf5	Consistently , coimmunoprecipitation studies revealed impaired ******MEF2/myf5****** protein-protein ***interactions*** .	parallel	1
8075	10548519	7040;54	TGF-beta;TRAP	In cocultures of hematopoietic cells and BALC cells ( a calvarial-derived cell line ) , ***TGF-beta*** ***inhibited*** tartrate-resistant acid phosphatase ( ***TRAP*** ) - positive multinucleated cell formation .	negative	1
8076	10548521	7040;2353	TGF-beta1;c-fos	Transforming growth factor-beta1 ( ***TGF-beta1*** ) stimulated cell proliferation in early passage cells and ***induced*** ***c-fos*** expression , while it inhibited proliferation in late passage cells .	target	1
8077	10548550	5170;10110	PDK1;SGK2	***SGK2*** and SGK3 are ***activated*** in vitro by ***PDK1*** , albeit more slowly than SGK1 , and their activation is accompanied by the phosphorylation of Thr ( 193 ) and Thr ( 253 ) respectively , the residues equivalent to the Thr in the ' activation loop ' of PKB that is targeted by PDK1 .	positive	1
8078	10548550	5170;23678	PDK1;SGK3	SGK2 and ***SGK3*** are ***activated*** in vitro by ***PDK1*** , albeit more slowly than SGK1 , and their activation is accompanied by the phosphorylation of Thr ( 193 ) and Thr ( 253 ) respectively , the residues equivalent to the Thr in the ' activation loop ' of PKB that is targeted by PDK1 .	positive	1
8079	10548550	5170;10110	PDK1;SGK2	The ***PDK1-catalysed*** ***phosphorylation*** and activation of ***SGK2*** and SGK3 , like SGK1 , is greatly potentiated by mutating Ser ( 356 ) and Ser ( 419 ) respectively to Asp , these residues being equivalent to the C-terminal phosphorylation site of PKB .	target	1
8080	10548550	5170;23678	PDK1;SGK3	The ***PDK1-catalysed*** ***phosphorylation*** and activation of SGK2 and ***SGK3*** , like SGK1 , is greatly potentiated by mutating Ser ( 356 ) and Ser ( 419 ) respectively to Asp , these residues being equivalent to the C-terminal phosphorylation site of PKB .	target	1
8081	10548550	3479;10110	insulin-like growth factor-1;SGK2	***SGK2*** and SGK3 are ***activated*** to a smaller extent by ***insulin-like growth factor-1*** ( 2-fold ) than SGK1 ( 5-fold ) .	positive	1
8082	10548550	3479;23678	insulin-like growth factor-1;SGK3	SGK2 and ***SGK3*** are ***activated*** to a smaller extent by ***insulin-like growth factor-1*** ( 2-fold ) than SGK1 ( 5-fold ) .	positive	1
8083	10548879	356;355	FasL;Fas	The mutation of the Fas or ***Fas*** ***ligand*** ( ***FasL*** ) has been observed in a minority of patients with autoimmune disease .	parallel	1
8084	10548885	4221;3727	Menin;JunD	***Menin*** ***binds*** to ***JunD*** , an AP-1 transcription factor , inhibiting JunD 's activation of transcription .	parallel	1
8085	10549282	6497;4088	Ski oncoprotein;Smad3	***Interaction*** of the ***Ski oncoprotein*** with ***Smad3*** regulates TGF-beta signaling .	parallel	1
8086	10549282	6497;7040	Ski oncoprotein;TGF-beta	Interaction of the ***Ski oncoprotein*** with Smad3 ***regulates*** ***TGF-beta*** signaling .	target	1
8087	10549282	7040;4088	TGF-beta;Smad3	***TGF-beta*** ***induces*** phosphorylation and nuclear translocation of ***Smad3*** .	target	1
8088	10549288	8797;8743	DR4;Apo2L	Formation of a complex between ***Apo2L*** ( also called TRAIL ) and its signaling ***receptors*** , ***DR4*** and DR5 , triggers apoptosis by inducing the oligomerization of intracellular death domains .	parallel	1
8089	10549288	8795;8743	DR5;Apo2L	Formation of a complex between ***Apo2L*** ( also called TRAIL ) and its signaling ***receptors*** , DR4 and ***DR5*** , triggers apoptosis by inducing the oligomerization of intracellular death domains .	parallel	1
8090	10549288	8797;8743	DR4;Apo2L	Formation of a ***complex*** between ***Apo2L*** ( also called TRAIL ) and its signaling receptors , ***DR4*** and DR5 , triggers apoptosis by inducing the oligomerization of intracellular death domains .	parallel	1
8091	10549288	8795;8743	DR5;Apo2L	Formation of a ***complex*** between ***Apo2L*** ( also called TRAIL ) and its signaling receptors , DR4 and ***DR5*** , triggers apoptosis by inducing the oligomerization of intracellular death domains .	parallel	1
8092	10549288	8795;8797	DR5;DR4	Formation of a ***complex*** between Apo2L ( also called TRAIL ) and its signaling receptors , ***DR4*** and ***DR5*** , triggers apoptosis by inducing the oligomerization of intracellular death domains .	parallel	1
8093	10549288	8795;8743	DR5;Apo2L	We report the crystal structure of the ***complex*** between ***Apo2L*** and the ectodomain of ***DR5*** .	parallel	1
8094	10549354	6934;1499	Tcf-4;beta-catenin	A proportion of APC wild-type colon carcinomas and melanomas also contains constitutive nuclear ******Tcf-4/beta-catenin****** ***complexes*** as a result of dominant mutations in the N terminus of beta-catenin that render it insensitive to downregulation by APC , GSK3 beta , and Axin/Conductin .	parallel	1
8095	10549354	1499;6934	beta-catenin;Tcf-4	In APC-deficient colon carcinoma cell lines , ***beta-catenin*** accumulates and is constitutively ***complexed*** with nuclear ***Tcf-4*** .	parallel	1
8096	10549415	3931;335	lecithin:cholesterol acyltransferase;apoA1	Plasma ***lecithin:cholesterol acyltransferase*** activity was positively ***correlated*** with ***h-apoA1*** levels in transgenic mice ( r = 0.43 ; P < 0.01 ) .	positive	0
8097	10549596	472;7157	ATM;p53	***ATM*** ***binds*** to ***p53*** in a complex fashion and activates the molecule in response to breaks in DNA by phosphorylating it at serine 15 close to the N-terminus and by controlling other phosphorylation and dephosphorylation changes on the molecule .	parallel	1
8098	10549623	10746;5594	MEKK2;ERK	Biochemical activation of MEKK2 follows TCR stimulation , and expression of a dominant-negative ***MEKK2*** ***inhibits*** TCR-mediated conjugate stabilization and ***ERK*** and p38 MAP kinase phosphorylation .	negative	1
8099	10549623	10746;1432	MEKK2;p38 MAP kinase	Biochemical activation of MEKK2 follows TCR stimulation , and expression of a dominant-negative ***MEKK2*** ***inhibits*** TCR-mediated conjugate stabilization and ERK and ***p38 MAP kinase*** phosphorylation .	negative	1
8100	10549631	971;5777	CD72;SHP-1	***CD72*** , a B cell surface protein of the C-type lectin superfamily , ***recruits*** the tyrosine phosphatase ***SHP-1*** through its ITIM motif ( s ) .	target	0
8101	10549650	3458;5949	IFN-gamma;IRBP	Unlike the B10.A strain in which appreciable disease did not develop without PTX , B10.RIII mice mounted a high ***IFN-gamma*** ***response*** to ***IRBP*** in the absence of PTX treatment .	parallel	0
8102	10549664	627;835	BDNF;caspase-2	***BDNF*** ***diminishes*** ***caspase-2*** but not c-Jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia .	negative	0
8103	10549664	834;3725	caspase-1;c-Jun	The purpose of this study was to examine the ***association*** of ***c-Jun*** , ***caspase-1*** , -2 , and -3 immunoreactivities and neuronal apoptosis in the retinal ganglion cell layer ( GCL ) and to study the effects of intravitreal brain-derived neurotrophic factor ( BDNF ) on the expression of these gene products in a rat model of retinal ischemia-reperfusion injury .	parallel	0
8104	10549816	728;727	C5aR;C5a	We recently reported that not only lymphoid cells , but cells of neuronal origin may harbor ***C5a*** ***receptors*** ( ***C5aR*** ) as suggested by results of RT-PCR testing and that an apoptotic pathway is associated with the C5aR .	parallel	1
8105	10550055	472;672	ATM;brca1	Requirement of ***ATM-dependent*** ***phosphorylation*** of ***brca1*** in the DNA damage response to double-strand breaks .	target	1
8106	10550055	472;672	ATM;brca1	Thus , ***phosphorylation*** of ***brca1*** by the checkpoint kinase ***ATM*** may be critical for proper responses to DNA double-strand breaks and may provide a molecular explanation for the role of ATM in breast cancer .	target	1
8107	10550315	6387;7852	SDF-1;CXCR4	CXCR4 was also detected in many different normal cell types , including endothelial and epithelial cells , which points to a role for ******SDF-1/CXCR4****** cell ***signaling*** in vascular and epithelial homeostasis .	parallel	0
8108	10550322	4803;4914	NGF;TrkA	The growth inhibition induced by blocking the insulin-like growth factor-I receptor suggests that IGF-II is a component of the effector mechanism of ***TrkA*** ***activation*** by ***NGF*** in TrkA-transfected cells .	positive	1
8109	10550413	1906;2641	endothelin-1;glucagon	***endothelin-1*** - ( 100 nmol/l ) ***increased*** , however , both insulin and ***glucagon*** secretion from a mixture of purified beta and non-beta cells indicating that alpha cells seem to have a key role for the action of ET-1 on insulin secretion .	positive	0
8110	10550413	2641;1906	glucagon;endothelin-1	The insulinotropic effect of ***endothelin-1*** is ***mediated*** by ***glucagon*** release from the islet alpha cells .	target	0
8111	10550416	1803;2641	dipeptidyl peptidase IV;GLP-1	Inhibition of ***dipeptidyl peptidase IV*** with NVP-DPP728 ***increases*** plasma ***GLP-1*** ( 7-36 amide ) concentrations and improves oral glucose tolerance in obese Zucker rats .	negative	0
8112	10551777	1154;2690	suppressor of cytokine signaling;growth hormone receptor	Mechanism of ***inhibition*** of ***growth hormone receptor*** signaling by ***suppressor of cytokine signaling*** proteins .	negative	1
8113	10551777	8651;6777	SOCS-1;STAT5	Both ***SOCS-1*** and SOCS-3 were able to ***inhibit*** GH-induced ***STAT5*** ( signal transducer and activator of transcription ) activation .	negative	1
8114	10551777	9021;6777	SOCS-3;STAT5	Both SOCS-1 and ***SOCS-3*** were able to ***inhibit*** GH-induced ***STAT5*** ( signal transducer and activator of transcription ) activation .	negative	1
8115	10551777	8651;3717	SOCS-1;Janus kinase 2	***SOCS-1*** ***inhibited*** the tyrosine kinase activity of ***Janus kinase 2*** ( JAK2 ) directly , while SOCS-3 only inhibited JAK2 when stimulated by the GH receptor .	negative	1
8116	10551777	9021;3717	SOCS-3;JAK2	SOCS-1 inhibited the tyrosine kinase activity of Janus kinase 2 ( JAK2 ) directly , while ***SOCS-3*** only ***inhibited*** ***JAK2*** when stimulated by the GH receptor .	negative	1
8117	10551783	4149;4609	Max;Myc	These studies , in conjunction with mutational analysis and reporter gene assays with dominant negative Myc and Max expression vectors , showed that Myc and ***Max*** ***interaction*** with a ***Myc*** consensus site is required for androgen regulation of the 350-bp fragment .	parallel	1
8118	10551785	8648;7157	SRC-1;p53	These results suggest that ***SRC-1*** and its family members may differentially ***modulate*** the ***p53*** transactivation in vivo .	target	0
8119	10551811	5599;4609	JNK;c-Myc	These results indicate that the JNK pathway is selectively involved in the c-Myc-mediated apoptosis and that the apoptotic function of ***c-Myc*** is directly ***regulated*** by ***JNK*** pathway through phosphorylation at Ser-62 and Ser-71 .	target	1
8120	10551813	847;84959	catalase;p70	Exposure of JB6 cells to platelet-derived growth factor or epidermal growth factor led to a rapid increase in H ( 2 ) O ( 2 ) , phosphorylation , and activation of ***p70*** ( S6k ) , which were ***antagonized*** by the pretreatment of ***catalase*** .	negative	1
8121	10551814	6261;2280	RyR1;FKBP12	A structure-activity model is proposed by which substitutions on the Eastern and Western hemispheres of the bastarane macrocycle may confer specificity toward the ******RyR1-FKBP12****** ***complex*** to stabilize either the closed or open channel conformation .	parallel	1
8122	10551814	6261;2280	RyR1;FKBP12	These results indicate that ******RyR1-FKBP12****** ***complexes*** possesses a novel binding domain for phenoxycatechols and raise the possibility of molecular recognition of an endogenous ligand .	parallel	1
8123	10551816	7040;4052	TGF-beta1;LTBP-1	However , since ***TGF-beta1*** failed to ***stimulate*** the transcription of ***LTBP-1*** reporter gene constructs , TGF-beta1 may mediate the induction of the isoforms by post-transcriptional mechanisms .	positive	0
8124	10551817	5706;3091	p42;HIF-1alpha	This ***interaction*** between ***HIF-1alpha*** and ***p42/p44*** MAPK suggests a cooperation between hypoxic and growth factor signals that ultimately leads to the increase in HIF-1-mediated gene expression .	parallel	1
8125	10551817	5706;5706	p44;p42	This ***interaction*** between HIF-1alpha and ******p42/p44****** MAPK suggests a cooperation between hypoxic and growth factor signals that ultimately leads to the increase in HIF-1-mediated gene expression .	parallel	1
8126	10551817	5706;3091	p42;HIF-1	***p42/p44*** mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha ( HIF-1alpha ) and ***enhance*** the transcriptional activity of ***HIF-1*** .	positive	0
8127	10551817	5706;3091	p42;HIF-1alpha	***p42/p44*** mitogen-activated protein kinases ***phosphorylate*** hypoxia-inducible factor 1alpha ( ***HIF-1alpha*** ) and enhance the transcriptional activity of HIF-1 .	target	1
8128	10551817	5706;3091	p42;HIF-1alpha	In vitro , ***HIF-1alpha*** is ***phosphorylated*** by ***p42*** and p44 mitogen-activated protein kinases ( MAPKs ) and not by p38 MAPK or c-Jun N-terminal kinase .	target	1
8129	10551817	5706;3091	p44;HIF-1alpha	Interestingly , ***p42/p44*** MAPK stoichiometrically ***phosphorylate*** ***HIF-1alpha*** in vitro , as judged by a complete upper shift of HIF-1alpha .	target	1
8130	10551817	5706;3091	p42;HIF-1	Finally , we found that in a vascular endothelial growth factor promoter mutated at sites previously shown to be MAPK-sensitive ( SP1/AP2 -88 -66 site ) , ***p42/p44*** MAPK activation is sufficient to ***promote*** the transcriptional activity of ***HIF-1*** .	positive	0
8131	10551821	5295;4067	p85;LYN	This process has been proposed to be mediated by an ***interaction*** between the Src family kinase ***LYN*** and the ***p85*** subunit of PI3K and/or through p85 membrane recruitment mediated by CBL and/or CD19 .	parallel	1
8132	10551821	6850;867	SYK;CBL	Whereas CD19 does not appear to be involved in this SYK-dependent pathway , the SYK substrate CBL is likely involved as the dominant negative ***SYK*** markedly ***attenuates*** ***CBL*** tyrosine phosphorylation and completely blocks the BCR-dependent association of CBL with p85 PI3K .	negative	0
8133	10551821	6850;867	SYK;CBL	Whereas CD19 does not appear to be involved in this SYK-dependent pathway , the SYK substrate CBL is likely involved as the dominant negative ***SYK*** markedly attenuates CBL tyrosine phosphorylation and completely ***blocks*** the BCR-dependent association of ***CBL*** with p85 PI3K .	negative	0
8134	10551832	215;225	ALDP;ALDRP	Co-immunoprecipitation demonstrated the homodimerization of ALDP , the ***heterodimerization*** of ***ALDP*** with PMP70 or ***ALDRP*** , and the heterodimerization of ALDRP with PMP70 .	parallel	1
8135	10551840	1958;2152	Egr-1;tissue factor	Our data show for the first time that both low density lipoprotein and oxidized low density lipoprotein induce tissue factor gene expression in smooth muscle cells and that this ***tissue factor*** gene expression is ***mediated*** by both ***Egr-1*** and Sp1 transcription factors .	target	0
8136	10551840	4018;2152	lipoprotein;tissue factor	Our data show for the first time that both low density ***lipoprotein*** and oxidized low density lipoprotein ***induce*** ***tissue factor*** gene expression in smooth muscle cells and that this tissue factor gene expression is mediated by both Egr-1 and Sp1 transcription factors .	target	1
8137	10551840	4018;2152	lipoprotein;tissue factor	Native and oxidized low density ***lipoprotein*** ***induction*** of ***tissue factor*** gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1 .	target	1
8138	10551840	1958;4018	Egr-1;lipoprotein	Native and oxidized low density ***lipoprotein*** induction of tissue factor gene expression in smooth muscle cells is ***mediated*** by both ***Egr-1*** and Sp1 .	target	0
8139	10551840	4018;2152	lipoprotein;tissue factor	By using lipid extracts of low density lipoprotein or methylation of the intact lipoprotein to block receptor recognition , we showed that this ***lipoprotein*** ***induced*** ***tissue factor*** mRNA via both receptor-independent and receptor-augmented pathways .	target	1
8140	10551845	2549;5295	Gab1;p85	By using a specific chemical inhibitor of the epidermal growth factor receptor ( EGFR ) and expression of a dominant negative mutant , we have observed that recruitment of p85/p110 PI3Ks occurs through transactivation of the EGFR by LPA and downstream mobilization of the docking protein ***Gab1*** that ***associates*** with ***p85*** upon LPA stimulation .	parallel	0
8141	10551859	5888;675	Rad51;BRCA2	Expression of BRC repeats in breast cancer cells disrupts the ******BRCA2-Rad51****** ***complex*** and leads to radiation hypersensitivity and loss of G ( 2 ) / M checkpoint control .	parallel	1
8142	10551859	675;5888	BRCA2;Rad51	***BRCA2*** ***binds*** to ***Rad51*** through its BRC repeats .	parallel	1
8143	10551859	5888;675	Rad51;BRCA2	In support of the biological significance of this interaction , we found that the ***complex*** of ***BRCA2*** and ***Rad51*** in breast cancer MCF-7 cells was diminished upon conditional expression of a wild-type , but not a mutated , BRC4 repeat using the tetracycline-inducible system .	parallel	1
8144	10551859	5888;675	Rad51;BRCA2	These results strongly suggest that the ***interaction*** between ***BRCA2*** and ***Rad51*** mediated by BRC repeats is critical for the cellular response to DNA damage .	parallel	1
8145	10551875	7422;4846	Vascular endothelial growth factor;endothelial nitric-oxide synthase	The mechanism by which ***Vascular endothelial growth factor*** ( VEGF ) ***regulates*** ***endothelial nitric-oxide synthase*** ( eNOS ) expression is presently unclear .	target	1
8146	10551878	2185;1978	protein kinase b;4E-BP1	Because phosphatidylinositol 3-kinase ( PI3K ) and ***protein kinase b*** ( PKB ) , in concert with mTOR , ***inactivate*** ***4E-BP1*** , we explored their role in GLUT1 protein expression .	negative	1
8147	10551883	2260;663	fibroblast growth factor receptor-1;BNIP-2	Tyrosine ***phosphorylation*** of the Bcl-2-associated protein ***BNIP-2*** by ***fibroblast growth factor receptor-1*** prevents its binding to Cdc42GAP and Cdc42 .	target	1
8148	10551883	2260;663	Flg;BNIP-2	In addition , the recombinant ***BNIP-2*** expressed in bacteria could be ***phosphorylated*** by active ***Flg*** in vitro .	target	1
8149	10551883	663;998	BNIP-2;Cdc42	Unexpectedly , ***BNIP-2*** , either produced as a bacterial recombinant protein or expressed in 293T cells , could ***stimulate*** the intrinsic GTPase activity of ***Cdc42*** .	positive	0
8150	10551884	183;2534	angiotensin II;Fyn	A catalytically active Jak2 is required for the ***angiotensin II-dependent*** ***activation*** of ***Fyn*** .	positive	1
8151	10551884	183;4012	angiotensin II;AT(1) receptor	Here we demonstrate that ***activation*** of the seven-transmembrane ***AT(1) receptor*** by ***angiotensin II*** induces a physical association between Jak2 and Fyn , in vivo .	positive	1
8152	10551884	2534;3717	Fyn;Jak2	Here we demonstrate that activation of the seven-transmembrane AT(1) receptor by angiotensin II induces a physical ***association*** between ***Jak2*** and ***Fyn*** , in vivo .	parallel	0
8153	10551884	3717;2534	Jak2;Fyn	Deletion studies indicate that the region of ***Jak2*** that ***binds*** ***Fyn*** is located between amino acids 1 and 240 .	parallel	1
8154	10551884	2534;3717	Fyn;Jak2	Studies of the Fyn SH2 and SH3 domains demonstrate that the SH2 domain plays the primary role in ******Jak2/Fyn****** ***association*** .	parallel	0
8155	10551888	595;1019	cyclin D1;CDK4	The cyclin-dependent kinase (CDK) inhibitor p21 ( Cip1 ) has a dual role in the regulation of the cell cycle ; it is an activator of ******cyclin D1-CDK4****** ***complexes*** and an inhibitor of cyclins E/A-CDK 2 activity .	parallel	1
8156	10552211	7124;3569	TNF-alpha;IL-6	The production of ***IL-6*** in the fibroblast cultures was ***stimulated*** by ***TNF-alpha*** ( 0.01-10 nm/ml medium ) in a dose-dependent way .	positive	0
8157	10552654	4897;2746	Bravo;GDH	Basagran , Sevin , and ***Bravo*** ***increased*** the amination activities of ***GDH*** from 30.0 + / - 2.8 units in the control assay to 479.0 + / - 20.7 , 63.0 + / - 5.8 , and 35.2 + / - 2.2 units , respectively , therefore indicating a direct GDH-pesticide interaction .	positive	0
8158	10552899	1017;1017	CDK2;cyclin-dependent kinase 2	This article demonstrates the application of FP in a miniaturized HTS format , using 1536-well plates , to measure direct ***binding*** between ***cyclin-dependent kinase 2/cyclin*** E complex ( ***CDK2/E*** ) and an 8-mer-peptide kinase inhibitor .	parallel	1
8159	10552932	10370;1387	p35srj;CBP	***p35srj*** ***interferes*** with the recruitment of ***p300/CBP*** by the transcription factor HIF-1alpha , a process that is essential for the transcriptional response to hypoxia .	negative	0
8160	10552932	10370;2033	p35srj;p300	***p35srj*** ***interferes*** with the recruitment of ***p300/CBP*** by the transcription factor HIF-1alpha , a process that is essential for the transcriptional response to hypoxia .	negative	0
8161	10552932	3091;1387	HIF-1alpha;CBP	p35srj interferes with the ***recruitment*** of ***p300/CBP*** by the transcription factor ***HIF-1alpha*** , a process that is essential for the transcriptional response to hypoxia .	target	0
8162	10552932	3091;2033	HIF-1alpha;p300	p35srj interferes with the ***recruitment*** of ***p300/CBP*** by the transcription factor ***HIF-1alpha*** , a process that is essential for the transcriptional response to hypoxia .	target	0
8163	10552962	974;973	CD79b;Igalpha	The B-cell antigen receptor ( BCR ) comprises membrane Igs ( mIgs ) and a ***heterodimer*** of ***Igalpha*** ( CD79a ) and Igbeta ( ***CD79b*** ) transmembrane proteins , encoded by the mb-1 and B29 genes , respectively .	parallel	1
8164	10552962	974;974	Igbeta;CD79b	The B-cell antigen receptor ( BCR ) comprises membrane Igs ( mIgs ) and a ***heterodimer*** of Igalpha ( CD79a ) and ***Igbeta*** ( ***CD79b*** ) transmembrane proteins , encoded by the mb-1 and B29 genes , respectively .	parallel	1
8165	10553038	4790;5970	p50;p65	NF-kappa B inhibitors blocked the ability of toxin A to induce IL-8 secretion , and supershift analysis indicated that the major isoform of NF-kappa B activated by the toxin is a ******p50-p65****** ***heterodimer*** .	parallel	1
8166	10553046	958;959	CD40;CD154	During T-APC interactions in vivo , interfering with ******CD40-CD154****** ***interactions*** leads to reduced T cell priming , defects in effector function , and , in some cases , T cell tolerance .	parallel	1
8167	10553046	958;959	CD40;CD154	Thus , the requirement for ******CD40-CD154****** ***interactions*** appears to be strongly influenced by the type of APC involved .	parallel	1
8168	10553070	3551;940	IKK beta;CD28	Moreover , ***IKK beta*** , but not IKK alpha , overexpression ***enhanced*** transcriptional activation of the ***CD28*** response element in the IL-2 promoter .	positive	0
8169	10553071	1879;640	EBF;Blk	EMSA indicated that recombinant and cellular EBF interact physically with this site ; furthermore , transient transfections indicated that ectopic expression of ***EBF*** in nonlymphoid HeLa cells ***activate*** a ***Blk*** promoter-controlled reporter construct 9-fold .	positive	1
8170	10553089	3586;324	IL-10;APC	***IL-10*** ***down-regulates*** the ***APC*** function of many dendritic cells ( DC ) , including human peripheral blood ( PB ) DC .	negative	1
8171	10553089	3587;3586	IL-10R1;IL-10	Whereas the effects of ***IL-10*** on PB DC were shown to be ***mediated*** by ***IL-10R1*** , neither PB nor RA SF DC constitutively expressed IL-10R1 mRNA or detectable surface protein .	target	0
8172	10553091	7124;3551	TNF-alpha;IKK beta	This study shows that the sesquiterpene lactone parthenolide inhibits a common step in NF-kappa B activation by preventing the ***TNF-alpha-induced*** ***induction*** of I kappa B kinase ( IKK ) and ***IKK beta*** , without affecting the activation of p38 and c-Jun N-terminal kinase .	target	1
8173	10553092	3458;6352	IFN-gamma;RANTES	IL-4 and IFN-gamma had selective effects on chemokine expression ; IL-4 selectively up-regulated the expression of eotaxin and MCP-4 and potentiated TNF-alpha-induced eotaxin , while ***IFN-gamma*** markedly ***potentiated*** only the TNF-alpha-induced expression of ***RANTES*** .	positive	0
8174	10553092	3565;6356	IL-4;eotaxin	IL-4 and IFN-gamma had selective effects on chemokine expression ; ***IL-4*** selectively ***up-regulated*** the expression of ***eotaxin*** and MCP-4 and potentiated TNF-alpha-induced eotaxin , while IFN-gamma markedly potentiated only the TNF-alpha-induced expression of RANTES .	positive	1
8175	10553092	3565;6357	IL-4;MCP-4	IL-4 and IFN-gamma had selective effects on chemokine expression ; ***IL-4*** selectively ***up-regulated*** the expression of eotaxin and ***MCP-4*** and potentiated TNF-alpha-induced eotaxin , while IFN-gamma markedly potentiated only the TNF-alpha-induced expression of RANTES .	positive	1
8176	10553092	3565;6356	IL-4;eotaxin	IL-4 and IFN-gamma had selective effects on chemokine expression ; ***IL-4*** selectively up-regulated the expression of eotaxin and MCP-4 and ***potentiated*** TNF-alpha-induced ***eotaxin*** , while IFN-gamma markedly potentiated only the TNF-alpha-induced expression of RANTES .	positive	0
8177	10553496	2321;7422	Flt-1;VPF	Dysregulation of ***Flt-1*** , a major ***receptor*** for vascular permeability factor ( ***VPF*** ) , may provide a mechanism for the development of proteinuria in minimal change nephropathy ( MCN ) .	parallel	1
8178	10554025	388;1026	RhoB;p21	***RhoB-GG*** ***induced*** the cell cycle kinase inhibitor ***p21*** ( WAF1 ) in a p53-dependent manner , similar to FTI treatment , but this event was dispensable because RhoB-GG could still inhibit the growth of p53-null cells that lacked p21WAF1 activation .	target	1
8179	10554028	3439;356	IFN-alpha;CD95 ligand	***IFN-alpha*** did not up-regulate CD95 in BL or PEL but did ***induce*** expression of the death receptor ligand , ***CD95 ligand*** .	target	1
8180	10554029	3621;7157	p33ING1;p53	The ***p33ING1*** gene ***cooperates*** with ***p53*** to block cell proliferation .	parallel	0
8181	10554171	3684;3689	CD11b;CD18	A cocktail of blocking MAbs to CD62P , CD15 , GPIIb/IIIa and the ******CD11b/CD18****** ***complex*** had no effect on unstimulated samples , whilst totally inhibiting aggregation induced by 10 ( -5 ) M ADP , suggesting that the PLAs in unstimulated blood were preformed in vivo .	parallel	1
8182	10554406	3605;3383	IL-17;ICAM-1	However , ***IL-17*** synergistically ***enhanced*** ***ICAM-1*** expression induced by IFN-gamma .	positive	0
8183	10554801	5328;5329	uPA;uPAR	The finding of uPA , uPAR , PAI-1 and PAI-2 synthesized by leukaemic cells suggests that plasminogen activation may contribute to the invasive behaviour of these cells , the fibrinolytic imbalance observed in leukaemic patients and the differentiation and proliferation of M4-M5 by ***interaction*** of ***uPA*** with ***uPAR*** .	parallel	1
8184	10554809	7124;941	TNF-alpha;CD80	Addition of ***TNF-alpha*** or LPS ***induced*** both normal and CMML Mo-DC to express prominent dendritic processes , the CMRF44 + and CD83 + antigens and high levels of HLA-DR , ***CD80*** and CD86 .	target	1
8185	10554809	7124;942	TNF-alpha;CD86	Addition of ***TNF-alpha*** or LPS ***induced*** both normal and CMML Mo-DC to express prominent dendritic processes , the CMRF44 + and CD83 + antigens and high levels of HLA-DR , CD80 and ***CD86*** .	target	1
8186	10554816	4352;7066	c-Mpl;thrombopoietin	Human dendritic cells express the ***thrombopoietin*** ***receptor*** , ***c-Mpl*** .	parallel	1
8187	10554816	4352;7066	c-Mpl;TPO	However , ***c-Mpl*** , the ***TPO*** ***receptor*** , has been detected in human leukaemic cell lines with a myelomonocytic phenotype .	parallel	1
8188	10554819	4352;7066	c-mpl;thrombopoietin	The presence of the ***thrombopoietin*** ( TPO ) ***receptor*** , ***c-mpl*** , did not correlate with inducibility of the gpIIbIIIa complex since essentially all CD34 + progenitors , including the earliest identifiable human haemopoietic progenitors ( CD34 + CD38 - cells ) , expressed c-mpl mRNA detectable by PCR regardless of their ultimate fate .	parallel	1
8189	10554988	8851;1020	p35;cdk5	reelin , an extracellular glycoprotein found in layer I , and a cyclin-dependent kinase ( ***cdk5*** ) and its neuronal-specific ***activator*** ( ***p35*** ) may have played key roles in the generation of the inside-out gradient .	positive	1
8190	10554988	8851;5649	p35;reelin	***reelin*** , an extracellular glycoprotein found in layer I , and a cyclin-dependent kinase ( cdk5 ) and its neuronal-specific ***activator*** ( ***p35*** ) may have played key roles in the generation of the inside-out gradient .	positive	1
8191	10555036	3605;5604	IL-17;mitogen-activated protein kinase kinase-1	Within minutes , ***IL-17*** ***induced*** the phosphorylation of ***mitogen-activated protein kinase kinase-1/2*** ( MEK-1/2 ) , -3 / 6 ( MKK-3/6 ) , p44/42 , p38 , and inhibitor of nuclear factor kappaB ( I kappaB ) - alpha , as well as the activation of mitogen-activated protein kinase-activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 ) .	target	1
8192	10555036	3605;5594	IL-17;p38	Within minutes , ***IL-17*** ***induced*** the phosphorylation of mitogen-activated protein kinase kinase-1/2 ( MEK-1/2 ) , -3 / 6 ( MKK-3/6 ) , p44/42 , ***p38*** , and inhibitor of nuclear factor kappaB ( I kappaB ) - alpha , as well as the activation of mitogen-activated protein kinase-activated protein kinase-1 and -2 ( MAPKAPK-1 and -2 ) .	target	1
8193	10555036	3605;5599	IL-17;JNK	Interestingly , ***IL-17*** ***induced*** phosphorylation of the stress-activated protein kinase/Jun N-terminal kinase ( ***SAPK/JNK*** ) ( p54/46 ) only when PKA was inhibited .	target	1
8194	10555036	3605;5601	IL-17;SAPK	Interestingly , ***IL-17*** ***induced*** phosphorylation of the stress-activated protein kinase/Jun N-terminal kinase ( ***SAPK/JNK*** ) ( p54/46 ) only when PKA was inhibited .	target	1
8195	10555036	3605;4792	IL-17;IkappaB-alpha	Inhibiting MAPK , including MEK-1/2 and p38 , had no effect on the ***IL-17-induced*** ***activation*** of ***IkappaB-alpha*** , but reversed the IL-17 activation of MAPKAPK-1 and -2 , respectively .	positive	1
8196	10555038	796;820	CGRP;cAMP	***CGRP*** and VIP ***inhibited*** nuclear translocation and phosphorylation of the transcription factor ***cAMP*** response element binding protein in RA synovial cells .	negative	1
8197	10555038	7432;820	VIP;cAMP	CGRP and ***VIP*** ***inhibited*** nuclear translocation and phosphorylation of the transcription factor ***cAMP*** response element binding protein in RA synovial cells .	negative	1
8198	10555566	155;3952	beta3AR;leptin	Because beta3AR signal transduction is impaired with age in BAT and WAT , ***beta3AR-mediated*** ***regulation*** of ***leptin*** , feeding behavior , and adiposity may also be impaired with age .	target	1
8199	10555568	183;5972	angiotensin II;renin	Chloride channel blockers attenuate the ***inhibition*** of ***renin*** secretion by ***angiotensin II*** .	negative	1
8200	10555784	4803;2353	NGF;c-Fos	While ***NGF*** somewhat ***increased*** ***c-Fos*** and c-Jun protein levels transiently , it had a more robust and persistent stimulatory effect on Jun B protein levels .	positive	0
8201	10555784	4803;3725	NGF;c-Jun	While ***NGF*** somewhat ***increased*** c-Fos and ***c-Jun*** protein levels transiently , it had a more robust and persistent stimulatory effect on Jun B protein levels .	positive	0
8202	10555956	480;477	Atp1a4;Atp1a2	The Na,K-ATPase alpha4 gene ( ***Atp1a4*** ) encodes a ouabain-resistant alpha subunit and is tightly ***linked*** to the alpha2 gene ( ***Atp1a2*** ) on mouse chromosome 1 .	parallel	0
8203	10555993	355;356	Fas;Fas ligand	Effect of graft-versus-host disease ( GVHD ) on host hematopoietic progenitor cells is mediated by ******Fas-Fas ligand****** ***interactions*** but this does not explain the effect of GVHD on donor cells .	parallel	1
8204	10555993	355;356	Fas;FasL	This suggests that ******Fas-FasL****** ***interactions*** may regulate suppression of host hematopoietic cells but not of donor hematopoietic cells .	parallel	1
8205	10555993	355;356	Fas;FasL	Hematopoietic dysfunctions caused by the reconstituted donor cells are independent to ******Fas-FasL****** ***interactions*** and persisted for a long time during parental-induced acute GVHD .	parallel	1
8206	10556042	3077;7037	HFE;transferrin receptor	***HFE*** ***binds*** to ***transferrin receptor*** ( TfR ) , the receptor used by cells to obtain iron in the form of diferric transferrin ( Fe-Tf ) .	parallel	1
8207	10556042	3077;7037	HFE;TfR	Previous studies demonstrated that ***HFE*** and Fe-Tf can ***bind*** simultaneously to ***TfR*** to form a ternary complex , and that membrane-bound or soluble HFE binding to cell surface TfR results in a reduction in the affinity of TfR for Fe-Tf .	parallel	1
8208	10556042	3077;7037	HFE;TfR	Previous studies demonstrated that HFE and Fe-Tf can bind simultaneously to TfR to form a ternary complex , and that membrane-bound or soluble ***HFE*** ***binding*** to cell surface ***TfR*** results in a reduction in the affinity of TfR for Fe-Tf .	parallel	1
8209	10556042	3077;7037	HFE;TfR	The results demonstrate that ***HFE*** ***inhibits*** the ***TfR*** : Fe-Tf interaction by binding at or near the Fe-Tf binding site on TfR , and that the Fe-Tf : TfR : HFE ternary complex consists of one Fe-Tf and one HFE bound to a TfR homodimer .	negative	1
8210	10556046	4086;90	Smad1;ALK2	Moreover , ectopic expression of ***Smad1*** or Smad7 identified two downstream ***modulators*** of the ***BMP/ALK2*** signaling pathway that also can regulate cardiac orientation .	target	0
8211	10556046	4092;90	Smad7;ALK2	Moreover , ectopic expression of Smad1 or ***Smad7*** identified two downstream ***modulators*** of the ***BMP/ALK2*** signaling pathway that also can regulate cardiac orientation .	target	0
8212	10556076	3211;2624	Hoxb1;GATA2	Ubiquitous expression of ***Hoxb1*** in the hindbrain ***induces*** ectopic expression of ***GATA2*** and GATA3 in ventral r2 and r3 .	target	1
8213	10556076	3211;2625	Hoxb1;GATA3	Ubiquitous expression of ***Hoxb1*** in the hindbrain ***induces*** ectopic expression of GATA2 and ***GATA3*** in ventral r2 and r3 .	target	1
8214	10556323	1437;5008	GM-CSF;OSM	***GM-CSF*** , phorbol-12-myristate-13-acetate ( PMA ) , and lipopolysaccharide ( LPS ) ***induce*** ***OSM*** expression .	target	1
8215	10556423	4439;4438	Msh5;hMSH4	Yeast two-hybrid analysis indicated that the mouse ***Msh5*** protein positively ***interacted*** with the human ***hMSH4*** protein-suggesting that Msh5 shares common functional properties with its human counterpart .	positive	1
8216	10556578	5272;3002	PI9;granzyme B	***PI9*** has been shown to be a fast-acting ***inhibitor*** of ***granzyme B*** in vitro , presumably through the utilization of Glu ( 340 ) as the P ( 1 ) inhibitory residue in its reactive site loop .	negative	1
8217	10556578	5272;1991	PI9;neutrophil elastase	In this report , we describe the ***inhibition*** of human ***neutrophil elastase*** by recombinant human ***PI9*** .	negative	1
8218	10556640	3952;1392	leptin;corticotropin-releasing hormone	Administration of ***leptin*** also ***prevented*** the fasting-induced reductions of thyrotropin-releasing hormone ( TRH ) and ***corticotropin-releasing hormone*** ( CRH ) mRNAs in the parvocellular division of the PVN .	negative	0
8219	10556640	3952;7200	leptin;thyrotropin-releasing hormone	Administration of ***leptin*** also ***prevented*** the fasting-induced reductions of ***thyrotropin-releasing hormone*** ( TRH ) and corticotropin-releasing hormone ( CRH ) mRNAs in the parvocellular division of the PVN .	negative	0
8220	10556640	3952;1392	leptin;CRH	These results suggest that ***leptin*** is ***associated*** with fasting-induced reduction of nNOS mRNA in the PVN and SON as well as TRH and ***CRH*** mRNAs in the PVN .	parallel	0
8221	10556640	3952;7200	leptin;TRH	These results suggest that ***leptin*** is ***associated*** with fasting-induced reduction of nNOS mRNA in the PVN and SON as well as ***TRH*** and CRH mRNAs in the PVN .	parallel	0
8222	10556646	4914;627	TrkA;neurotrophin	The presence of the ***neurotrophin*** ***receptor*** , ***TrkA*** , in neurochemically identified vagal and glossopharyngeal sensory neurons of the adult rat was examined .	parallel	1
8223	10556646	4803;4914	NGF;TrkA	These data show distinct colocalizations of TrkA with specific neurochemicals in vagal and glossopharyngeal sensory neurons , and suggest that nerve growth factor ( ***NGF*** ) , the neurotrophin ***ligand*** for ***TrkA*** , plays a role in functions of specific neurochemically defined subpopulations of mature vagal and glossopharyngeal sensory neurons .	parallel	1
8224	10556798	945;5777	CD33;SHP-1	Co-immunoprecipitation studies demonstrate that ***CD33*** ***associates*** with the SH2-containing tyrosine phosphatase ***SHP-1*** in monocytes .	parallel	0
8225	10556800	3558;356	IL-2;FasL	***FasL*** promoter ***activation*** by ***IL-2*** through SP1 and NFAT but not Egr-2 and Egr-3 .	positive	1
8226	10556801	962;51744	CD48;NAIL	Taken together these results indicate that the ******NAIL-CD48****** ***interaction*** may be an important mechanism regulating a variety of immune responses .	parallel	1
8227	10556805	941;940	B7.1;CD28	In this study , we demonstrate using the murine T cell hybridoma DC27 .1 , that SHIP is strongly tyrosine phosphorylated after ***ligation*** of ***CD28*** by either mAb or the natural ligand ***B7.1*** .	parallel	1
8228	10556811	1437;3689	GM-CSF;LFA-1	Furthermore , ***GM-CSF*** ***up-regulated*** and activated ***LFA-1*** , as assessed by NKI-L16 neoepitope expression .	positive	1
8229	10556832	1991;1378	HNE;CR1	Purified human neutrophil elastase ( ***HNE*** ) ***cleaved*** ***CR1*** from erythrocytes and urinary vesicles originating from podocytes and enhanced tenfold the cleavage of CR1 from activated PMN .	target	1
8230	10556976	9479;5599	JIP-1;JNK	Furthermore , the TNFalpha-activated ***JNK*** activity in H9c2 cells was completely ***abolished*** by dnJNKK2 and ***JIP-1*** .	negative	0
8231	10556986	7037;7018	TfR;transferrin	DESIGN : In this self-selected sample , haemoglobin , haematocrit , red cell indices , serum ferritin , serum iron , serum transferrin , and serum ***transferrin*** ***receptor*** ( ***TfR*** ) were measured .	parallel	1
8232	10557071	1029;4193	P14ARF;MDM2	Recent evidence has shown that ***P14ARF*** ***binds*** to ***MDM2*** leading to an increased availability of wild type TP53 protein .	parallel	1
8233	10557076	3458;4261	IFN-gamma;CIITA	***IFN-gamma*** ***induced*** ***CIITA*** transcription in many cell types is directed by the CIITA Type IV promoter .	target	1
8234	10557076	3659;4261	IRF-1;CIITA	In addition , we found that ***IRF-1*** and IRF-2 synergistically ***activate*** the ***CIITA*** Type IV promoter .	positive	1
8235	10557076	3660;4261	IRF-2;CIITA	In addition , we found that IRF-1 and ***IRF-2*** synergistically ***activate*** the ***CIITA*** Type IV promoter .	positive	1
8236	10557076	3458;4261	IFN-gamma;CIITA	Finally , ***CIITA*** ***induction*** by ***IFN-gamma*** does not occur in a pancreatic tumor cell line that expresses a mutated IRF-2 , representing the first IRF-2 mutation identified in a human tumor cell line .	target	1
8237	10557082	5787;7010	vascular endothelial-protein-tyrosine phosphatase;Tie-2	Functional ***interaction*** of ***vascular endothelial-protein-tyrosine phosphatase*** with the angiopoietin receptor ***Tie-2*** .	parallel	1
8238	10557082	5787;7010	VE-PTP;Tie-2	In addition , ***VE-PTP*** ***dephosphorylates*** ***Tie-2*** but not VEGFR-2 .	target	1
8239	10557082	5787;7010	VE-PTP;Tie-2	We conclude that VE-PTP is a Tie-2 specific phosphatase expressed in ECs , and ***VE-PTP*** phosphatase activity serves to specifically ***modulate*** ***Angiopoietin/Tie-2*** function .	target	0
8240	10557084	7472;8321	Wnt-2;Hfz1	While Wnt-3a , -3 , -1 and to a lesser extent ***Wnt-2*** ***cooperated*** with ***Hfz1*** in the paracrine assay for TCF dependent signaling , neither Wnt-4 , -5 a , -5 b , -6 , -7 a nor -7 b did so , despite similar levels of expression .	parallel	0
8241	10557085	1739;324	hDLG;APC	The C-terminal peptide of Tax prevented the ***binding*** of ***hDLG*** to ***APC*** tumor suppressor gene product , suggesting inhibition of hDLG function by Tax .	parallel	1
8242	10557088	596;581	Bcl-2;Bax	***Bax*** membrane insertion during Fas ( CD95 ) - induced apoptosis precedes cytochrome c release and is ***inhibited*** by ***Bcl-2*** .	negative	1
8243	10557089	7391;1997	USF-1;Elf-1	We propose that ***interactions*** between ***USF-1*** , USF-2 and ***Elf-1*** play an important role in the transcriptional regulation of the BRCA2 gene .	parallel	1
8244	10557089	7391;7392	USF-1;USF-2	We propose that ***interactions*** between ***USF-1*** , ***USF-2*** and Elf-1 play an important role in the transcriptional regulation of the BRCA2 gene .	parallel	1
8245	10557089	7392;1997	USF-2;Elf-1	We propose that ***interactions*** between USF-1 , ***USF-2*** and ***Elf-1*** play an important role in the transcriptional regulation of the BRCA2 gene .	parallel	1
8246	10557092	1263;995	Prk;Cdc25C	Co-immunoprecipitation and affinity column chromatography experiments demonstrate that ***GST-Prk*** and native ***Cdc25C*** ***interact*** .	parallel	1
8247	10557092	1263;995	Prk;Cdc25C	Moreover , phosphopeptide mapping shows that ***His6-Prk*** ***phosphorylates*** ***His6-Cdc25C*** at two sites in vitro and that the major phosphorylation site co-migrates with the one that is phosphorylated in vivo in asynchonized cells .	target	1
8248	10557092	1263;995	Prk;Cdc25C	Further studies reveal that ***His6-Prk*** ***phosphorylates*** ***Cdc25C*** on serine216 , a residue also phosphorylated by Chk1 and Chk2 .	target	1
8249	10557095	3725;3726	Jun;junB	Overexpression of ***Jun*** causes significant alterations in the composition of AP-1 , ***decreased*** ***junB*** and increased fra-1 expression and results in an increased biologic aggressiveness .	negative	0
8250	10557095	3725;8061	Jun;fra-1	Overexpression of ***Jun*** causes significant alterations in the composition of AP-1 , decreased junB and ***increased*** ***fra-1*** expression and results in an increased biologic aggressiveness .	positive	0
8251	10557278	920;30816	CD4;envelope glycoprotein	Rational engineering of a miniprotein that reproduces the core of the ***CD4*** site ***interacting*** with HIV-1 ***envelope glycoprotein*** .	parallel	1
8252	10557278	920;3700	CD4;gp120	In competition experiments , the resulting 27-amino acid miniprotein inhibited ***binding*** of ***CD4*** to ***gp120*** with a 40 microM IC ( 50 ) .	parallel	1
8253	10557285	57126;4087	cell surface receptor;Smad2	TGF-beta signals through its ***cell surface receptor*** serine kinases that ***phosphorylate*** ***Smad2*** or Smad3 proteins .	target	1
8254	10557285	57126;4088	cell surface receptor;Smad3	TGF-beta signals through its ***cell surface receptor*** serine kinases that ***phosphorylate*** Smad2 or ***Smad3*** proteins .	target	1
8255	10557285	4088;7030	Smad3;TFE3	Whereas an isolated ***Smad3*** MH1 domain ***binds*** to ***TFE3*** , TGF-beta receptor-mediated phosphorylation of full-length Smad3 enhances its binding to TFE3 .	parallel	1
8256	10557333	64006;7514	K-Rev;Crm1	Like HIV-1 Rev , ***K-Rev*** ***binds*** to both the ***Crm1*** nuclear export factor and to a cis-acting viral RNA target to activate nuclear export of unspliced RNAs .	parallel	1
8257	10557343	5715;1029	p27;p19	Therefore , ***p19*** ( Ink4d ) and ***p27*** ( Kip1 ) ***cooperate*** to maintain differentiated neurons in a quiescent state that is potentially reversible .	parallel	0
8258	10558879	1026;983	p21;cdc2	Furthermore , treatment of As ( 2 ) O ( 3 ) markedly enhanced the ***binding*** of ***p21*** with ***cdc2*** , and the activity of cdc2 kinase was decreased in a time-dependent manner .	parallel	1
8259	10558884	3700;920	gp120;CD4	During HIV entry or resulting cell to cell fusion , the envelope glycoprotein ***gp120*** ***binds*** first to the ***CD4*** membrane distal domain and second to a chemokine receptor as coreceptor .	parallel	1
8260	10558884	920;3700	CD4;gp120	This finding demonstrates that the ******gp120-CD4****** ***interaction*** induces local and specific conformational changes of CD4 and constitutes functional evidence for hinge regions that could confer to this molecule the flexibility required for its various functions .	parallel	1
8261	10558884	3700;920	gp120;CD4	This finding demonstrates that the ***gp120-CD4*** interaction ***induces*** local and specific conformational changes of ***CD4*** and constitutes functional evidence for hinge regions that could confer to this molecule the flexibility required for its various functions .	target	1
8262	10558886	6667;8091	Sp1;Hmgi-c	We demonstrate that this tract is a multiple binding site for the transcription factors Sp1 and Sp3 and that in Drosophila SL2 cells , ***Sp1*** ***activates*** the ***Hmgi-c*** promoter .	positive	1
8263	10558888	5468;4233	PPARgamma;c-MET	***PPARgamma*** ***inhibits*** the expression of ***c-MET*** in human gastric cancer cells through the suppression of Ets .	negative	1
8264	10558888	4233;5468	c-MET;PPARgamma	Two days after the ***activation*** of ***PPARgamma*** by troglitazone , a potent and selective PPARgamma ligand , a dramatic reduction of c-MET transcripts and the ***c-MET*** protein in MKN45 cells was observed .	positive	1
8265	10558888	5468;4233	PPARgamma;c-MET	The luciferase assay showed that the activation of ***PPARgamma*** ***suppressed*** -249 to +330 ***c-MET*** promoter activity , driven by cotransfection of ETS-1 expression vector .	negative	1
8266	10558893	8743;8797	Apo2L;Apo2	Here , we report that the locoregional application of ***Apo2*** ***ligand*** ( ***Apo2L*** ) exerts strong antitumor activity on preestablished intracranially growing human U87MG glioma xenografts in athymic mice .	parallel	1
8267	10558944	3600;3458	IL-15;IFN-gamma	Production of ***IFN-gamma*** is ***stimulated*** by synergistic effects of interleukin ( IL ) -18 , IL-12 , and ***IL-15*** .	positive	0
8268	10558944	3600;3458	IL-15;IFN-gamma	These data suggest that during gram-negative sepsis , ***IFN-gamma*** production is ***controlled*** at least in part by endogenous IL-18 , IL-12 , and ***IL-15*** .	target	0
8269	10558944	3606;3458	IL-18;IFN-gamma	These data suggest that during gram-negative sepsis , ***IFN-gamma*** production is ***controlled*** at least in part by endogenous ***IL-18*** , IL-12 , and IL-15 .	target	0
8270	10558993	10891;5468	PGC-1;peroxisome proliferator-activated receptor gamma	The ***docking*** of ***PGC-1*** to ***peroxisome proliferator-activated receptor gamma*** ( PPARgamma ) stimulates an apparent conformational change in PGC-1 that permits binding of SRC-1 and CBP/p300 , resulting in a large increase in transcriptional activity .	parallel	1
8271	10558993	1387;2033	CBP;p300	The docking of PGC-1 to peroxisome proliferator-activated receptor gamma ( PPARgamma ) stimulates an apparent conformational change in PGC-1 that permits ***binding*** of SRC-1 and ******CBP/p300****** , resulting in a large increase in transcriptional activity .	parallel	1
8272	10558993	1387;8648	CBP;SRC-1	The docking of PGC-1 to peroxisome proliferator-activated receptor gamma ( PPARgamma ) stimulates an apparent conformational change in PGC-1 that permits ***binding*** of ***SRC-1*** and ***CBP/p300*** , resulting in a large increase in transcriptional activity .	parallel	1
8273	10558993	8648;2033	SRC-1;p300	The docking of PGC-1 to peroxisome proliferator-activated receptor gamma ( PPARgamma ) stimulates an apparent conformational change in PGC-1 that permits ***binding*** of ***SRC-1*** and ***CBP/p300*** , resulting in a large increase in transcriptional activity .	parallel	1
8274	10559006	4018;4312	lipoprotein;MMP-1	In the present study , we found that oxidized low density ***lipoprotein*** ( LDL ) ***stimulated*** ***MMP-1*** release from both human umbilical vein and aortic endothelial cells .	positive	0
8275	10559014	3990;4018	hepatic lipase;lipoprotein	High ***hepatic lipase*** ( HL ) activity is ***associated*** with an atherogenic ***lipoprotein*** profile of small , dense LDL particles and lower HDL ( 2 ) - C.	parallel	0
8276	10559031	7035;2152	TFPI;tissue factor	The initiating mechanism for blood coagulation is the tissue factor ( TF ) dependent pathway , which is inhibited by ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) .	negative	1
8277	10559031	7035;2152	TFPI;tissue factor	The initiating mechanism for blood coagulation is the ***tissue factor*** ( TF ) dependent pathway , which is ***inhibited*** by tissue factor pathway inhibitor ( ***TFPI*** ) .	negative	1
8278	10559090	7124;5327	TNF-alpha;tPA	Pleural inflammation caused by TB may enhance the release of proinflammatory cytokines , particularly ***TNF-alpha*** , which subsequently may increase PAI-1 and ***decrease*** ***tPA*** in pleural fluid .	negative	0
8279	10559090	7124;5054	TNF-alpha;PAI-1	Pleural inflammation caused by TB may enhance the release of proinflammatory cytokines , particularly ***TNF-alpha*** , which subsequently may ***increase*** ***PAI-1*** and decrease tPA in pleural fluid .	positive	0
8280	10559134	3479;3716	IGF-1;JAK1	***JAK1*** , but not JAK2 or Tyk2 , was ***phosphorylated*** by ***IGF-1*** as early as 2 minutes and peaked at 5 minutes .	target	1
8281	10559134	3479;3716	IGF-1;JAK1	These results indicated that ( 1 ) ***IGF-1*** ***activated*** ***JAK1*** but not JAK2 or Tyk2 in rat cardiomyocytes ; ( 2 ) IGF-1 induced both tyrosine and serine phosphorylation of STAT1 and STAT3 ; and ( 3 ) the tyrosine phosphorylation of STAT3 was not caused by JAK1 alone , and protein kinase C and intracellular Ca ( 2 + ) were required for phosphorylation .	positive	1
8282	10559137	7077;4313	TIMP-2;matrix metalloproteinase-2	***matrix metalloproteinase-2*** ( MMP-2 , gelatinase A ) and its tissue ***inhibitor*** ( ***TIMP-2*** ) are mainly known for their roles in the ( patho ) physiological remodeling of the vasculature , angiogenesis , tissue repair , tumor invasion , inflammation , and atherosclerotic plaque rupture .	negative	1
8283	10559191	26086;8802	AGS3;Galpha	In protein interaction studies , AGS2 selectively associated with Gbetagamma , whereas ***AGS3*** ***bound*** ***Galpha*** and exhibited a preference for GalphaGDP versus GalphaGTPgammaS .	parallel	1
8284	10559204	51347;5599	JIK;JNK	The ***inhibition*** of ***JNK/SAPK*** signaling pathway by ***JIK*** was found to occur between the EGF receptor and the small GTP-binding proteins Rac1 and Cdc42Hs .	negative	1
8285	10559204	51347;5601	JIK;SAPK	The ***inhibition*** of ***JNK/SAPK*** signaling pathway by ***JIK*** was found to occur between the EGF receptor and the small GTP-binding proteins Rac1 and Cdc42Hs .	negative	1
8286	10559222	4088;4092	Smad3;Smad7	Taken together , these data provided the first evidence that Smad7 transcription is regulated by TGF-beta and activin signaling through direct ***binding*** of ***Smad3*** and Smad4 to the ***Smad7*** promoter .	parallel	1
8287	10559222	4089;4092	Smad4;Smad7	Taken together , these data provided the first evidence that Smad7 transcription is regulated by TGF-beta and activin signaling through direct ***binding*** of Smad3 and ***Smad4*** to the ***Smad7*** promoter .	parallel	1
8288	10559222	7040;4092	TGF-beta;Smad7	Taken together , these data provided the first evidence that ***Smad7*** transcription is ***regulated*** by ***TGF-beta*** and activin signaling through direct binding of Smad3 and Smad4 to the Smad7 promoter .	target	1
8289	10559222	4092;4088	Smad7;Smad3	A 33-bp ***Smad7*** promoter fragment containing this SBE was able to ***bind*** ***Smad3*** and Smad4 .	parallel	1
8290	10559222	4092;4089	Smad7;Smad4	A 33-bp ***Smad7*** promoter fragment containing this SBE was able to ***bind*** Smad3 and ***Smad4*** .	parallel	1
8291	10559225	2247;2006	bFGF;elastin	Previous studies demonstrated that basic fibroblast growth factor ( ***bFGF*** ) ***decreases*** ***elastin*** gene transcription in pulmonary fibroblasts .	negative	0
8292	10559225	2247;2006	bFGF;elastin	Overall the results suggest that ***bFGF*** ***represses*** ***elastin*** gene transcription by increasing the amount of the Fra 1 that subsequently binds to the -564 - to -558 - bp as a heterodimer with c-Jun to form an inhibitory complex .	negative	1
8293	10559225	2247;2006	bFGF;elastin	We propose that the identified ***bFGF*** response element can serve to ***down-regulate*** ***elastin*** transcription in elastogenic cells and , conversely , can serve to up-regulate elastogenesis in cells where endogenous bFGF signaling is attenuated or altered .	negative	1
8294	10559227	3084;2064	HRG;ErbB2	Immunoprecipitation/Western blot studies revealed that ***HRG*** ( 100 ng/ml ) ***stimulated*** tyrosine phosphorylation and dimerization of ErbB3 and ***ErbB2*** , but had no effect on phosphorylation of the EGFR .	positive	0
8295	10559227	3084;2065	HRG;ErbB3	Immunoprecipitation/Western blot studies revealed that ***HRG*** ( 100 ng/ml ) ***stimulated*** tyrosine phosphorylation and dimerization of ***ErbB3*** and ErbB2 , but had no effect on phosphorylation of the EGFR .	positive	0
8296	10559227	5295;2064	p85;ErbB2	HRG also stimulated ***recruitment*** of the ***p85*** subunit of PI3-K to ***ErbB3/ErbB2*** receptor dimers , while the PI3-K inhibitor , wortmannin ( 50 nM ) , completely reversed the inhibitory effect of HRG on CCh-stimulated secretion .	target	0
8297	10559227	5295;2065	p85;ErbB3	HRG also stimulated ***recruitment*** of the ***p85*** subunit of PI3-K to ***ErbB3/ErbB2*** receptor dimers , while the PI3-K inhibitor , wortmannin ( 50 nM ) , completely reversed the inhibitory effect of HRG on CCh-stimulated secretion .	target	0
8298	10559227	5295;2064	p85;ErbB2	EGF , but not CCh , stimulated the formation of EGFR/ErbB2 receptor dimers and the ***recruitment*** of ***p85*** to ***ErbB2*** .	target	0
8299	10559228	960;7124	CD44;TNFalpha	Ligation of certain cell surface receptors , namely CD45 , ***CD44*** , and CD58 , can ***induce*** the production of ***TNFalpha*** in monocytes .	target	1
8300	10559228	5788;7124	CD45;TNFalpha	Ligation of certain cell surface receptors , namely ***CD45*** , CD44 , and CD58 , can ***induce*** the production of ***TNFalpha*** in monocytes .	target	1
8301	10559228	965;7124	CD58;TNFalpha	Ligation of certain cell surface receptors , namely CD45 , CD44 , and ***CD58*** , can ***induce*** the production of ***TNFalpha*** in monocytes .	target	1
8302	10559235	1956;310	epidermal growth factor receptor;Annexin VII	In vitro phosphorylation assays showed that PDGF receptor , calcium-dependent tyrosine kinase ( CADTK/Pyk-2 ) , Src kinase , and ***epidermal growth factor receptor*** all were able to ***phosphorylate*** purified ***Annexin VII*** and XI on tyrosine residues .	target	1
8303	10559240	959;958	CD154;CD40	X-linked hyper-IgM syndrome is a rare immunodeficiency disorder resulting from mutations in the gene encoding the ***CD40*** ***ligand*** ( ***CD154*** ) molecule .	parallel	1
8304	10559241	857;2099	Caveolin-1;ERalpha	Interestingly , ***Caveolin-1*** expression also ***synergized*** with a constitutively active , ligand-independent ***ERalpha*** mutant , dramatically illustrating the potent stimulatory effect of Caveolin-1 in this receptor system .	parallel	0
8305	10559241	857;2099	Caveolin-1;ERalpha	***Caveolin-1-mediated*** ***activation*** of ***ERalpha*** was sensitive to a well known ER antagonist , 4-hydroxytamoxifen .	positive	1
8306	10559246	23229;998	hPEM-2;Cdc42	Employing biochemical activity assays for Rho-like GTPases we found that ***hPEM-2*** specifically ***activates*** ***Cdc42*** and not Rac or RhoA .	positive	1
8307	10559251	4780;2729	Nrf2;gamma-glutamylcysteine synthetase	***Regulation*** of ***gamma-glutamylcysteine synthetase*** subunit gene expression by the transcription factor ***Nrf2*** .	target	1
8308	10559251	4780;2729	Nrf2;GCS	***Nrf2*** overexpression ***increased*** the activity of ***GCS*** ( h ) and GCS ( l ) promoter/reporter transgenes .	positive	0
8309	10559251	4780;2729	Nrf2;GCS	Overexpression of an MafK dominant negative mutant decreased ***Nrf2*** ***binding*** to ***GCS*** EpRE sequences , inhibited the inducible expression of GCS ( h ) and GCS ( l ) promoter/reporter transgenes , and reduced endogenous GCS gene induction .	parallel	1
8310	10559254	10749;7532	KIF1C;14-3-3gamma	Serine 1092 was a substrate for the protein kinase casein kinase II in vitro , and inhibition of casein kinase II in cells diminished the ***association*** of ***KIF1C*** with ***14-3-3gamma*** .	parallel	0
8311	10559258	8767;5594	RIP2;ERK2	***RIP2*** directly ***phosphorylates*** and activates ***ERK2*** in vivo and in vitro .	target	1
8312	10559258	7124;5594	TNFalpha;ERK2	Kinase-defective point and deletion variants of RIP2 also significantly blocked the ***activation*** of ***ERK2*** by ***TNFalpha*** but not epidermal growth factor .	positive	1
8313	10559259	8802;6517	Galpha;GLUT4	ET-1-stimulated ***GLUT4*** translocation was markedly ***decreased*** by 70 or 75 % by microinjection of ***Galpha*** ( q/11 ) antibody or RGS2 protein , respectively .	negative	0
8314	10559259	5290;6517	p110alpha;GLUT4	ET-1 stimulated the PI 3-kinase activity of the p110alpha subunit ( 5.5-fold ) , and microinjection of ***anti-p110alpha*** or PKC-lambda antibodies ***inhibited*** ET-stimulated ***GLUT4*** translocation .	negative	1
8315	10559267	7157;1026	p53;p21	In contrast to Saos-2 cells in which p53 activated both the p21 and bax promoters , in MDA-MB-453 cells ***p53*** ***activated*** the ***p21*** promoter , but failed to activate the bax promoter .	positive	1
8316	10559267	7157;1026	p53;p21	Together , these data suggest a potential mechanism for the differential regulation of ***p53-dependent*** ***transactivation*** of the bax and ***p21*** genes .	positive	1
8317	10559276	6464;2885	Shc;Grb2	Tyrosine phosphorylation of caldesmon is required for binding to the ******Shc.Grb2****** ***complex*** .	parallel	1
8318	10559276	6464;2885	Shc;Grb2	Our studies also show that the tyrosine phosphorylation of CaD enhances its binding to the ******Shc.Grb2****** ***complex*** .	parallel	1
8319	10559276	6464;2885	Shc;Grb2	Together , these studies demonstrate that the major sites of tyrosine phosphorylation on CaD are located in the myosin and actin binding domains of CaD and that Tyr-27 is the major tyrosine phosphorylation site through which CaD interacts with the ******Shc.Grb2****** ***complex*** .	parallel	1
8320	10559283	9961;1017	LRP;Cdk2	LR gene products inhibit cell cycle progression , perhaps as a result of ***LRP*** ***interacting*** with ***Cdk2/cyclin*** complexes .	parallel	1
8321	10559304	894;1021	cyclin D2;cdk6	This is in contrast to uninfected T cells , where ***cyclin D2*** ***associates*** only with ***cdk6*** .	parallel	0
8322	10559330	4904;6862	YB-1;protein T	Taken together , these data demonstrate that the cellular factor ***YB-1*** and the viral regulatory ***protein T-antigen*** ***interact*** both physically and functionally and that this interaction modulates transcription from the JCV promoters .	parallel	1
8323	10559349	920;7852	CD4;chemokine receptor	Although infection by human immunodeficiency virus ( HIV ) typically requires an ***interaction*** between the viral envelope glycoprotein ( Env ) , ***CD4*** , and a ***chemokine receptor*** , CD4-independent isolates of HIV and simian immunodeficiency virus have been described .	parallel	1
8324	10559353	1234;3700	CCR5;gp120	Here we use the kinetics of ***interaction*** between ***CCR5*** and ***gp120*** to understand temporal and structural changes that occur during viral fusion .	parallel	1
8325	10559353	1234;3700	CCR5;gp120	Using saturation binding and homologous competition analysis , we estimated the K ( d ) of ***interaction*** between ***CCR5*** and ***gp120*** from the macrophage tropic HIV-1 strain JRFL to be 4 nM .	parallel	1
8326	10559353	3700;1234	gp120;CCR5	Unlike Env-mediated fusion , ***gp120*** ***binding*** to ***CCR5*** did not require divalent cations or elevated temperatures .	parallel	1
8327	10559378	4914;4803	TrkA;NGF	We have exploited a new monoclonal antibody against the tyrosine kinase A ( TrkA ) nerve growth factor (NGF) receptor to block the ******NGF-TrkA****** ***interaction*** in the rat basal forebrain .	parallel	1
8328	10559378	4803;4914	NGF;TrkA	The monoclonal antibody MNAC13 is a potent antagonist that prevents the ***binding*** of ***NGF*** to ***TrkA*** in a variety of systems .	parallel	1
8329	10559391	1026;2056	p21;erythropoietin	Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA ***binding*** of hypoxia-inducible factor-1 and ATF-1 / CREB and increased expression of glycolytic enzymes , ***p21*** ( waf1/cip1 ) , and ***erythropoietin*** .	parallel	1
8330	10559391	3091;466	HIF-1;activating transcription factor 1	The protective effects of iron chelators are correlated with their ability to enhance DNA ***binding*** of ***HIF-1*** and ***activating transcription factor 1*** ( ATF-1 ) / cAMP response element-binding protein ( CREB ) to the hypoxia response element in cortical cultures and the H19-7 hippocampal neuronal cell line .	parallel	1
8331	10559400	2066;2064	erbB-4;erbB-2	Neuregulins signaling via a glial ******erbB-2-erbB-4****** receptor ***complex*** contribute to the neuroendocrine control of mammalian sexual development .	parallel	1
8332	10559400	2066;2064	erbB-4;erbB-2	Thus , activation of the ******erbB-2-erbB-4****** receptor ***complex*** appears to be a critical component of the signaling process by which astrocytes facilitate the acquisition of female reproductive capacity in mammals .	parallel	1
8333	10559401	4915;627	trkB;Brain-derived neurotrophic factor	Expression of the neurotrophin ***Brain-derived neurotrophic factor*** ( BDNF ) and its ***receptor*** ***trkB*** in the ganglion cell layer of the Xenopus retina during retinal ganglion cell ( RGC ) dendritic arborization indicates that BDNF is spatially and temporally available to influence RGC morphological differentiation ( ; ) .	parallel	1
8334	10559471	1794;5879	DOCK2;Rac1	***DOCK2*** ***bound*** to and activated ***Rac1*** , as did DOCK180 ; however , DOCK2 did not bind to CrkII , which transduces signals at focal adhesions .	parallel	1
8335	10559471	1793;207	DOCK180;Rac	Thus , ***DOCK180*** and DOCK2 are ***regulators*** of ***Rac*** and function in adherent and non-adherent cells , respectively .	target	1
8336	10559471	1794;207	DOCK2;Rac	Thus , DOCK180 and ***DOCK2*** are ***regulators*** of ***Rac*** and function in adherent and non-adherent cells , respectively .	target	1
8337	10559484	324;8312	APC;Axin	Although the connection between XAPC and the VCC dorsal factor is not yet clear , the fact that ***APC*** ***binds*** ***Axin*** suggests that the VCC dorsal factor could act on Axin rather than XGSK3 .	parallel	1
8338	10559506	729230;6347	CCR2;MCP-1	In this review , we will discuss our present knowledge about ***MCP-1*** and its ***receptor*** ***CCR2*** and their role in atherogenesis .	parallel	1
8339	10559511	183;4790	Angiotensin II;NF-kappaB	***Angiotensin II*** ( Ang II ) and tumor necrosis factor alpha ( TNF-alpha ) ***increased*** ***NF-kappaB*** activity in VSMC ( 2 and 5-fold , respectively ) .	positive	0
8340	10559511	7124;4790	tumor necrosis factor alpha;NF-kappaB	Angiotensin II ( Ang II ) and ***tumor necrosis factor alpha*** ( TNF-alpha ) ***increased*** ***NF-kappaB*** activity in VSMC ( 2 and 5-fold , respectively ) .	positive	0
8341	10559511	7124;3627	TNF-alpha;IP-10	Ang II and ***TNF-alpha*** ***induced*** the expression of ***IP-10*** ( 1.5 and 3.4-fold ) and MCP-1 ( 2.4 and 4-fold ) in VSMC .	target	1
8342	10559511	7124;6347	TNF-alpha;MCP-1	Ang II and ***TNF-alpha*** ***induced*** the expression of IP-10 ( 1.5 and 3.4-fold ) and ***MCP-1*** ( 2.4 and 4-fold ) in VSMC .	target	1
8343	10559665	5443;1584	ACTH;CYP11B1	***CYP11B1*** , the gene encoding 11beta-hydroxylase ( P450c11 ) , is expressed on high levels in the zona fasciculata and is ***regulated*** by ***ACTH*** .	target	1
8344	10559781	6347;6348	MCP-1;MIP-1alpha	***Binding*** of labeled ***MCP-1*** and of labeled ***MIP-1alpha*** was antagonized by the respective unlabeled homologue but not by the unlabeled heterologous chemokine .	parallel	1
8345	10559781	6354;6347	MCP-3;MCP-1	Binding of labeled ***MCP-1*** was also ***inhibited*** by unlabeled ***MCP-3*** , both of which are ligands for CCR2 .	negative	1
8346	10559781	6352;6348	RANTES;MIP-1alpha	In a parallel manner , binding of labeled ***MIP-1alpha*** was first shown to be ***attenuated*** by unlabeled ***RANTES*** , both of which recognize CCR1 and CCR5 , and then separately antagonized by MCP-3 and MIP-1beta , which bind to CCR1 and CCR5 , respectively .	negative	0
8347	10559858	1869;6502	E2F-1;p45SKP2	This event is linked to a specific ***interaction*** of ***E2F-1*** with the F-box-containing protein ***p45SKP2*** , which is the cell-cycle-regulated component of the ubiquitin-protein ligase SCFSKP2 that recognizes substrates for this ligase .	parallel	1
8348	10559858	1869;6502	E2F-1;p45SKP2	Disruption of the ***interaction*** between ***E2F-1*** and ***p45SKP2*** results in a reduction in ubiquitination of E2F-1 and the stabilization and accumulation of transcriptionally active E2F-1 protein .	parallel	1
8349	10559859	1029;7157	Arf;p53	Nucleolar ***Arf*** sequesters Mdm2 and ***activates*** ***p53*** .	positive	1
8350	10559859	4193;7157	Mdm2;p53	Here we show that Arf binds to the product of the Mdm2 gene and sequesters it into the nucleolus , thereby preventing negative-feedback ***regulation*** of ***p53*** by ***Mdm2*** and leading to the activation of p53 in the nucleoplasm .	target	1
8351	10559861	273;1759	amphiphysin;dynamin-1	Moreover , ***amphiphysin-1*** ***assembles*** with ***dynamin-1*** into ring-like structures around the tubules and enhances the liposome-fragmenting activity of dynamin-1 in the presence of GTP .	parallel	1
8352	10559861	273;1759	amphiphysin;dynamin-1	Moreover , ***amphiphysin-1*** assembles with dynamin-1 into ring-like structures around the tubules and ***enhances*** the liposome-fragmenting activity of ***dynamin-1*** in the presence of GTP .	positive	0
8353	10559918	6502;1027	p45SKP2;p27Kip1	***p45SKP2*** ***promotes*** ***p27Kip1*** degradation and induces S phase in quiescent cells .	positive	0
8354	10559918	6502;1027	p45SKP2;p27Kip1	Expression of ***p45SKP2*** in quiescent fibroblasts ***promotes*** ***p27Kip1*** degradation , allows the generation of cyclin-A-dependent kinase activity and induces S phase .	positive	0
8355	10559921	5970;4790	p65;NF-kappa B	The truncated ***p65*** acts as a dominant-negative ***inhibitor*** of ***NF-kappa B*** , promoting apoptosis , whereas an uncleavable , caspase-resistant p65 protects the cells from apoptosis .	negative	1
8356	10559936	5058;1072	Pak1;cofilin	Here we show that p21-activated kinase ( ***Pak1*** ) phosphorylates LIM-kinase at threonine residue 508 within LIM-kinase 's activation loop , and ***increases*** LIM-kinase-mediated phosphorylation of the actin-regulatory protein ***cofilin*** tenfold in vitro .	positive	0
8357	10559945	51684;2735	SUFUH;Gli-1	These results show that ***SUFUH*** is a conserved negative ***regulator*** of ***Gli-1*** signalling that may affect nuclear-cytoplasmic shuttling of Gli-1 or the activity of Gli-1 in the nucleus and thereby modulate cellular responses .	negative	1
8358	10559965	885;857	cholecystokinin;caveolin-1	Secretion of ***caveolin-1*** from pancreatic acinar cells and a transfected exocrine cell line , but not from Chinese hamster ovary cells , is ***stimulated*** by the secretagogues secretin , ***cholecystokinin*** and dexamethasone .	positive	0
8359	10559965	6343;857	secretin;caveolin-1	Secretion of ***caveolin-1*** from pancreatic acinar cells and a transfected exocrine cell line , but not from Chinese hamster ovary cells , is ***stimulated*** by the secretagogues ***secretin*** , cholecystokinin and dexamethasone .	positive	0
8360	10560661	3553;5743	IL-1beta;COX-2	Microinjection of IFN-gamma did not alter COX-2-ir , whereas TNF-alpha or ***IL-1beta*** injection ***induced*** a moderate ***COX-2-ir*** in the perivascular cells of a few blood vessels close to the injection site , and in very few of the infiltrating neutrophils .	target	1
8361	10560661	7124;5743	TNF-alpha;COX-2	Microinjection of IFN-gamma did not alter COX-2-ir , whereas ***TNF-alpha*** or IL-1beta injection ***induced*** a moderate ***COX-2-ir*** in the perivascular cells of a few blood vessels close to the injection site , and in very few of the infiltrating neutrophils .	target	1
8362	10560912	1436;1435	c-fms;M-CSF	They expressed transcripts for ***c-fms*** , the ***receptor*** for macrophage-colony stimulating factor ( ***M-CSF*** ) , and were able to develop into macrophages at high numbers , but not to other myeloid cells .	parallel	1
8363	10560922	4803;4914	NGF;trkA	The data also indicate that ***NGF*** ***increased*** phosphorylation of ***trkA*** and the mitogen-activated protein kinase extracellular signal-regulated kinase ( ERK ) in dentate gyrus in vitro .	positive	0
8364	10560922	4803;5594	NGF;ERK	The data also indicate that ***NGF*** ***increased*** phosphorylation of trkA and the mitogen-activated protein kinase extracellular signal-regulated kinase ( ***ERK*** ) in dentate gyrus in vitro .	positive	0
8365	10561024	3458;931	interferon-gamma;CD20	Our studies further suggest that ***interferon-gamma*** may ***enhance*** ***CD20*** expression on MM plasma cells , thereby increasing their susceptibility to anti-CD20 monoclonal antibody therapies .	positive	0
8366	10561084	4914;4803	TrkA;Nerve growth factor	***Nerve growth factor*** ( NGF ) and its high-affinity tyrosine kinase ***receptor*** A ( ***TrkA*** ) are involved in neural development and survival and growth of central and peripheral nerves .	parallel	1
8367	10561278	3439;596	IFNalpha;bcl-2	***CRA/IFNalpha*** can ***modulate*** ***bcl-2*** expression in vitro and demonstrates similar biologic activity in patients .	target	0
8368	10561278	3439;596	IFNalpha;bcl-2	***CRA/IFNalpha*** ***decreased*** ***bcl-2*** expression in vitro and in PBMCs .	negative	0
8369	10561305	4914;4803	TrkA;Nerve growth factor	***Nerve growth factor*** ( NGF ) and its high-affinity ***receptor*** ***TrkA*** are involved in stimulating epithelial cancer cell growth and perineural invasion , as well as in pain generation in chronic benign disorders .	parallel	1
8370	10561498	695;5587	Bruton's tyrosine kinase;protein kinase C mu	***Bruton's tyrosine kinase*** ( Btk ) ***associates*** with ***protein kinase C mu*** .	parallel	0
8371	10561505	4654;4342	MyoD;Mos	***MyoD*** ***binds*** to ***Mos*** and inhibits the Mos/MAP kinase pathway .	parallel	1
8372	10561505	4654;4342	MyoD;Mos	***MyoD*** binds to Mos and ***inhibits*** the ***Mos/MAP*** kinase pathway .	negative	1
8373	10561528	3684;3383	Mac-1;ICAM-1	E-selectin , an adhesion molecule classically upregulated during inflammation , as well as ***Mac-1*** , a ***ligand*** for ***ICAM-1*** , were not expressed on human Schwann cells at basal condition or after treatment with cytokines .	parallel	1
8374	10561590	4193;1457	mdm2;protein kinase CK2	Recently , we have shown that ***mdm2*** is a good ***substrate*** for ***protein kinase CK2*** at least in vitro .	parallel	1
8375	10561590	7157;4193	p53;mdm2	Binding studies revealed that phosphorylation of mdm2 at S269 does not have any influence on the ***binding*** of ***p53*** to ***mdm2*** .	parallel	1
8376	10561691	322;351	FE65;beta-amyloid peptide	The ***FE65*** protein binds to an intracellular domain of the beta-amyloid precursor protein ( betaPP ) and may ***modulate*** the production of ***beta-amyloid peptide*** ( AP ) .	target	0
8377	10561696	5443;4790	alpha-melanocyte-stimulating hormone;NF-kappaB	Autocrine ***alpha-melanocyte-stimulating hormone*** ***inhibits*** ***NF-kappaB*** activation in human glioma .	negative	1
8378	10561943	3569;5743	interleukin-6;cyclooxygenase-2	The induction of ***cyclooxygenase-2*** ( COX-2 ) in cultured endothelial cells treated with serum from preeclampsia is ***mediated*** by ***interleukin-6*** .	target	0
8379	10561943	3569;5743	IL-6;COX-2	Thus , the induction of ***COX-2*** in pSerum treated nHUVEC was ***mediated*** by ***IL-6*** .	target	0
8380	10562279	5193;5192	PEX12;PEX10	***PEX12*** ***interacts*** with PEX5 and ***PEX10*** and acts downstream of receptor docking in peroxisomal matrix protein import .	parallel	1
8381	10562279	5193;5830	PEX12;PEX5	***PEX12*** ***interacts*** with ***PEX5*** and PEX10 and acts downstream of receptor docking in peroxisomal matrix protein import .	parallel	1
8382	10562279	5193;5192	PEX12;PEX10	Using two-hybrid studies , blot overlay assays , and coimmunoprecipitation experiments , we observed that the zinc-binding domain of ***PEX12*** ***binds*** both PEX5 , the PTS1 receptor , and ***PEX10*** , another integral peroxisomal membrane protein required for peroxisomal matrix protein import .	parallel	1
8383	10562279	5193;5830	PEX12;PEX5	Using two-hybrid studies , blot overlay assays , and coimmunoprecipitation experiments , we observed that the zinc-binding domain of ***PEX12*** ***binds*** both ***PEX5*** , the PTS1 receptor , and PEX10 , another integral peroxisomal membrane protein required for peroxisomal matrix protein import .	parallel	1
8384	10562279	5193;5192	PEX12;PEX10	Furthermore , we identified a patient with a missense mutation in the PEX12 zinc-binding domain , S320F , and observed that this mutation reduces the ***binding*** of ***PEX12*** to PEX5 and ***PEX10*** .	parallel	1
8385	10562279	5193;5830	PEX12;PEX5	Furthermore , we identified a patient with a missense mutation in the PEX12 zinc-binding domain , S320F , and observed that this mutation reduces the ***binding*** of ***PEX12*** to ***PEX5*** and PEX10 .	parallel	1
8386	10562279	5192;5193	PEX10;PEX12	Overexpression of either PEX5 or ***PEX10*** can ***suppress*** this ***PEX12*** mutation , providing genetic evidence that these interactions are biologically relevant .	negative	1
8387	10562279	5830;5193	PEX5;PEX12	Overexpression of either ***PEX5*** or PEX10 can ***suppress*** this ***PEX12*** mutation , providing genetic evidence that these interactions are biologically relevant .	negative	1
8388	10562297	1080;9368	CFTR;ezrin-radixin-moesin-binding phosphoprotein 50	We also demonstrate that ***CFTR*** ***binds*** to ***ezrin-radixin-moesin-binding phosphoprotein 50*** ( EBP50 ) , an apical membrane PDZ domain-containing protein .	parallel	1
8389	10562299	3578;4586	IL-9;mucin	Allergen-induced ***IL-9*** directly ***stimulates*** ***mucin*** transcription in respiratory epithelial cells .	positive	0
8390	10562300	116;6750	PACAP;somatostatin	***PACAP*** and VIP ***stimulated*** calcium signaling and ***somatostatin*** release from D cells with almost equal efficacy .	positive	0
8391	10562301	3606;3458	IL-18;IFN-gamma	Together with IL-12 or IL-15 , ***IL-18*** ***induced*** significant ***IFN-gamma*** production by synovial tissues in vitro .	target	1
8392	10562301	3606;1437	IL-18;GM-CSF	***IL-18*** independently ***promoted*** ***GM-CSF*** and nitric oxide production , and it induced significant TNF-alpha synthesis by CD14 ( + ) macrophages in synovial cultures ; the latter effect was potentiated by IL-12 or IL-15 .	positive	0
8393	10562301	3586;3458	IL-10;IFN-gamma	TNF-alpha and ***IFN-gamma*** synthesis was ***suppressed*** by ***IL-10*** and TGF-beta .	negative	1
8394	10562301	3586;7124	IL-10;TNF-alpha	***TNF-alpha*** and IFN-gamma synthesis was ***suppressed*** by ***IL-10*** and TGF-beta .	negative	1
8395	10562301	7040;3458	TGF-beta;IFN-gamma	TNF-alpha and ***IFN-gamma*** synthesis was ***suppressed*** by IL-10 and ***TGF-beta*** .	negative	1
8396	10562301	7040;7124	TGF-beta;TNF-alpha	***TNF-alpha*** and IFN-gamma synthesis was ***suppressed*** by IL-10 and ***TGF-beta*** .	negative	1
8397	10562310	643;10563	CXCR5;BCA-1	High-level expression of ***BCA-1*** and its ***receptor*** , ***CXCR5*** , was observed in all mucosal lymphoid aggregates and in the mantle zone of all secondary lymphoid follicles in Hp-induced gastric mucosa-associated lymphoid tissue ( MALT ) .	parallel	1
8398	10562320	3574;6772	IL-7;STAT1	These loss of function studies demonstrate an essential role of endogenous IFN and activated STAT1 for constitutive MHC class I expression in normal mice and define ***IL-7-dependent*** but IFN-independent ***regulation*** of ***STAT1*** restricted to T lymphocytes .	target	1
8399	10562324	259197;9436	NKp30;NKp44	***NKp30*** ***cooperates*** with NKp46 and/or ***NKp44*** in the induction of NK-mediated cytotoxicity against the majority of target cells , whereas it represents the major triggering receptor in the killing of certain tumors .	parallel	0
8400	10562324	259197;9437	NKp30;NKp46	***NKp30*** ***cooperates*** with ***NKp46*** and/or NKp44 in the induction of NK-mediated cytotoxicity against the majority of target cells , whereas it represents the major triggering receptor in the killing of certain tumors .	parallel	0
8401	10562325	27040;920	LAT;CD4	Here we show that ***LAT*** ***associates*** with surface ***CD4*** and CD8 coreceptors and that its association is promoted by the same coreceptor cysteine motif that mediates Lck binding .	parallel	0
8402	10562360	4838;5154	Nodal;PDGF-A	RESULTS : ***Nodal*** involvement ***correlated*** with ***PDGF-A*** and TGF-beta1 mRNA expression in early and advanced carcinomas , respectively .	parallel	0
8403	10562360	4838;7040	Nodal;TGF-beta1	RESULTS : ***Nodal*** involvement ***correlated*** with PDGF-A and ***TGF-beta1*** mRNA expression in early and advanced carcinomas , respectively .	parallel	0
8404	10562431	6513;2040	Glut1;stomatin	Likewise , employing anti-stomatin antibody , we found that ***Glut1*** ***coimmunoprecipitated*** with ***stomatin*** from samples of RBC membranes .	parallel	1
8405	10562431	6513;2040	Glut1;stomatin	However , neither band 3 , which is the most abundant integral membrane protein in the RBC , nor actin coimmunoprecipitated with Glut1 , indicating a specific ***interaction*** between ***Glut1*** and ***stomatin*** .	parallel	1
8406	10562431	2040;6513	stomatin;Glut1	The above results suggest that ***stomatin*** is closely ***associated*** with ***Glut1*** in the plasma membrane and that overexpression of stomatin results in a depression in the basal rate of glucose transport .	parallel	0
8407	10562550	8805;23468	TIF1alpha;HP1	However , in vitro , both ***TIF1alpha*** and TIF1beta interact with and ***phosphorylate*** the ***HP1*** proteins .	target	1
8408	10562553	55922;4790	NRF;NF-kappaB	Our data strongly suggest that the ***NRF-mediated*** ***inhibition*** of ***NF-kappaB*** is a critical component of the IFN-beta gene silencing prior to viral infection .	negative	1
8409	10562553	55922;4790	NRF;NF-kappaB	Constitutive silencing of IFN-beta promoter is mediated by ***NRF*** ( NF-kappaB-repressing factor ) , a nuclear ***inhibitor*** of ***NF-kappaB*** .	negative	1
8410	10562553	4790;55922	NF-kappaB;NRF	In vitro , ***NF-kappaB*** proteins ***bind*** to purified ***NRF*** by a direct protein-protein interaction .	parallel	1
8411	10562557	7341;7157	SUMO-1;p53	***SUMO-1*** modification ***activates*** the transcriptional response of ***p53*** .	positive	1
8412	10562557	7341;7157	SUMO-1;p53	Here we show that ***p53*** is ***modified*** by the small ubiquitin-like protein ***SUMO-1*** at a single site , K386 , in the C-terminus of the protein .	target	0
8413	10562557	7341;7157	SUMO-1;p53	Overexpression of ***SUMO-1*** ***activates*** the transcriptional activity of wild-type ***p53*** , but not K386R p53 where the SUMO-1 acceptor site has been mutated .	positive	1
8414	10562557	7341;7157	SUMO-1;p53	The ***SUMO-1*** modification pathway therefore acts as a potential ***regulator*** of the ***p53*** response and may represent a novel target for the development of therapeutically useful modulators of the p53 response .	target	1
8415	10562568	11200;5884	Rad53;Rad24	Activation of ***Rad53*** in response to DNA damage in G ( 1 ) ***requires*** the Rad9 , Mec3 , Ddc1 , Rad17 and ***Rad24*** checkpoint factors , while this dependence is greatly reduced in S phase cells .	target	0
8416	10562568	11200;5883	Rad53;Rad9	Activation of ***Rad53*** in response to DNA damage in G ( 1 ) ***requires*** the ***Rad9*** , Mec3 , Ddc1 , Rad17 and Rad24 checkpoint factors , while this dependence is greatly reduced in S phase cells .	target	0
8417	10562607	6416;5599	mitogen-activated protein kinase kinase 4;JNK	In contrast to the greater activation of JNK with eccentric exercise , the ***mitogen-activated protein kinase kinase 4*** , the immediate upstream ***regulator*** of ***JNK*** , was similarly activated by concentric and eccentric exercise .	target	1
8418	10563471	3458;3587	IFN-gamma;IL-10R1	Furthermore we could show that IL-4 , ***IFN-gamma*** , FK506 , loratadine and UVA ***enhance*** the mRNA levels of the ***IL-10R1*** in vitro in normal cultured keratinocytes .	positive	0
8419	10563471	3565;3587	IL-4;IL-10R1	Furthermore we could show that ***IL-4*** , IFN-gamma , FK506 , loratadine and UVA ***enhance*** the mRNA levels of the ***IL-10R1*** in vitro in normal cultured keratinocytes .	positive	0
8420	10563496	356;355	FasL;Fas	It has been suggested that ***Fas*** ***ligand*** ( ***FasL*** ) , expressed by several neoplastic cell lines and some tumors in vivo , is able to trigger the apoptotic process in activated T-lymphocytes and may constitute a key element of the immunological escape mechanisms used by many types of neoplasia .	parallel	1
8421	10563614	3456;3458	IFN-beta;IFN-gamma	Although the level of TNF-alpha and IFN-gamma was generally unaltered or decreased , ***IFN-beta*** appeared to ***enhance*** the production of ***IFN-gamma*** in PBMCs derived from some individuals with MS.	positive	0
8422	10563614	3456;4155	IFN-beta;myelin basic protein	CONCLUSION : Interferon beta la ( ***IFN-beta*** ) ***suppresses*** ***myelin basic protein*** ( MBP ) - reactive T cells and induces immune deviation toward the production of T-helper 2 cytokines , which may contribute to its therapeutic benefit in MS.	negative	1
8423	10563747	5617;7200	prolactin;thyrotropin-releasing hormone	Responses of plasma gonadotropin and corticotropin-cortisol levels to respective hypothalamic hormones were delayed or blunted , but the ***response*** of plasma ***prolactin*** to ***thyrotropin-releasing hormone*** was exaggerated .	parallel	0
8424	10564099	1906;4846	Endothelin-1;endothelial nitric oxide synthase	***Endothelin-1*** ***stimulation*** of ***endothelial nitric oxide synthase*** in the pathogenesis of hepatopulmonary syndrome .	positive	0
8425	10564100	5715;1017	p27;Cdk2	The ***p27*** ***complexed*** with ***Cdk2*** dissociated after 2 days , whereas p21 associated in a reverse fashion .	parallel	1
8426	10564114	7040;1281	TGF-beta1;alpha1(I) collagen	Therefore , stretch upregulates transcription for ***TGF-beta1*** , which ***stimulates*** ***alpha1(I) collagen*** gene expression in smooth muscle from developing gut .	positive	0
8427	10564160	3084;5706	NRG-1;p42	***NRG-1*** ***activated*** ***p42/p44*** mitogen-activated protein kinase ( MAPK ) [ extracellular signal-regulated kinase ( ERK ) -2 / ERK1 ] and ribosomal S6 kinase (RSK)-2 ( 90-kDa ribosomal S6 kinase ) , both of which could be inhibited by the MAPK/ERK kinase-1 antagonist PD-098059 .	positive	1
8428	10564160	3084;6197	NRG-1;ribosomal S6 kinase (RSK)-2	***NRG-1*** ***activated*** p42/p44 mitogen-activated protein kinase ( MAPK ) [ extracellular signal-regulated kinase ( ERK ) -2 / ERK1 ] and ***ribosomal S6 kinase (RSK)-2*** ( 90-kDa ribosomal S6 kinase ) , both of which could be inhibited by the MAPK/ERK kinase-1 antagonist PD-098059 .	positive	1
8429	10564161	7422;1499	VEGF;beta-catenin	***VEGF*** ***stimulates*** tyrosine phosphorylation of ***beta-catenin*** and small-pore endothelial barrier dysfunction .	positive	0
8430	10564168	7124;4353	TNF-alpha;myeloperoxidase	Similarly , ***TNF-alpha*** binding protein ( 175 mg/kg ) ***attenuated*** LPS-induced ***myeloperoxidase*** activity ( 6.04 + / - 0.14 U/g lung wet wt ; P < 0.05 ) .	negative	0
8431	10564168	3589;7124	IL-11;TNF-alpha	Therefore , ***IL-11*** ***prevents*** LPS-induced lung ***TNF-alpha*** production , neutrophil sequestration , and pulmonary vasomotor dysfunction .	negative	0
8432	10564176	3586;4790	Interleukin-10;NF-kappaB	***Interleukin-10*** ***inhibits*** pulmonary ***NF-kappaB*** activation and lung injury induced by hepatic ischemia-reperfusion .	negative	1
8433	10564176	3586;2920	IL-10;MIP-2	Administration of ***IL-10*** suppressed lung NF-kappaB activation , ***reduced*** TNF-alpha and ***MIP-2*** mRNA expression , and decreased pulmonary neutrophil recruitment and lung injury .	negative	1
8434	10564176	3586;7124	IL-10;TNF-alpha	Administration of ***IL-10*** suppressed lung NF-kappaB activation , ***reduced*** ***TNF-alpha*** and MIP-2 mRNA expression , and decreased pulmonary neutrophil recruitment and lung injury .	negative	1
8435	10564176	3586;4790	IL-10;NF-kappaB	Administration of ***IL-10*** ***suppressed*** lung ***NF-kappaB*** activation , reduced TNF-alpha and MIP-2 mRNA expression , and decreased pulmonary neutrophil recruitment and lung injury .	negative	1
8436	10564177	5605;2002	MEK1/2;Elk1	Finally , transfection assays showed that ***MEK1/2*** inhibition could ***inhibit*** trans-activation of ***Elk1*** , a transcription factor in the ERK pathway , in BEAS cells exposed to metals .	positive	1
8437	10564259	7157;983	p53;CDC2	Overexpression of ***p53*** may also ***interfere*** with the accumulation of ***CDC2/cyclin B1*** in the nucleus , required for cells to enter mitosis .	negative	0
8438	10564259	7157;891	p53;cyclin B1	Overexpression of ***p53*** may also ***interfere*** with the accumulation of ***CDC2/cyclin B1*** in the nucleus , required for cells to enter mitosis .	negative	0
8439	10564264	9341;6513	cellubrevin;GLUT1	GTPgammaS - and insulin-stimulated ***GLUT1*** translocation were both partially ***inhibited*** by ***GST-cellubrevin*** ( approximately 50 % ) but not by GST-vesicle-associated membrane protein-2 .	negative	1
8440	10564271	22926;3309	ATF6;GRP78	In contrast , mutant ***ATF6*** representing the cytoplasmic region translocates into the nucleus and ***activates*** transcription of the endogenous ***GRP78/BiP*** gene .	positive	1
8441	10564280	10657;91746	Sam68;YT521-B	The ***interaction*** and colocalization of ***Sam68*** with the splicing-associated factor ***YT521-B*** in nuclear dots is regulated by the Src family kinase p59 ( fyn ) .	parallel	1
8442	10564280	3611;10657	p59;Sam68	The interaction and colocalization of ***Sam68*** with the splicing-associated factor YT521-B in nuclear dots is ***regulated*** by the Src family kinase ***p59*** ( fyn ) .	target	1
8443	10564283	1437;207	GM-CSF;Akt	***GM-CSF*** ***activates*** phosphoinositide-3-OH kinase as well as ***Akt*** , and activation of both was suppressed by addition of wortmannin .	positive	1
8444	10564547	3569;1440	IL-6;G-CSF	The effect of the ***IL-6-induced*** ***suppression*** of ***G-CSF*** production differed from that of IL-4 and IL-10 in that it was much less pronounced and could be partially overridden by addition of functional IL-1 , yet it also appeared to involve the interference with IL-1 function and the suppression of IL-1-independent mechanisms .	negative	1
8445	10564547	3553;1440	IL-1;G-CSF	Here , ***IL-1*** was the main ***stimulator*** of ***G-CSF*** release , and the effect of IL-1 was neither affected by IL-10 nor IL-6 , while IL-4 had a stimulatory effect .	positive	0
8446	10564550	958;959	CD40;CD154	This shows that monocytes rescue of activated T cells from apoptosis is dependent upon ******CD40/CD154****** ***interaction*** .	parallel	1
8447	10564553	3439;942	IFN-alpha;CD86	An addition of ***IFN-alpha*** to the PBMC cultures greatly ***increased*** the HLA class II and the ***CD86*** expression on developing dendritic cells ( DCs ) during a 7-day culture period .	positive	0
8448	10564664	836;2620	Caspase-3;Gas2	***Caspase-3*** and caspase-7 but not caspase-6 ***cleave*** ***Gas2*** in vitro : implications for microfilament reorganization during apoptosis .	target	1
8449	10564664	840;2620	caspase-7;Gas2	Caspase-3 and ***caspase-7*** but not caspase-6 ***cleave*** ***Gas2*** in vitro : implications for microfilament reorganization during apoptosis .	target	1
8450	10564664	2620;836	Gas2;Caspase-3	We now demonstrate that ***Gas2*** is a ***substrate*** of ***Caspase-3*** but not of caspase-6 .	parallel	1
8451	10564681	2944;2952	GSTM1;GSTT1	This study was undertaken to evaluate the ***association*** between ***GSTM1*** and ***GSTT1*** gene polymorphisms and breast cancer risk .	parallel	0
8452	10564820	10657;6714	Sam68;Src	***Sam68*** , a nuclear RNA-binding protein , is a major ***substrate*** of the ***Src*** tyrosine kinase in mitotic cells .	parallel	1
8453	10564825	551;552	Arginine vasopressin;V1aR	***Arginine vasopressin*** ***interacts*** with the vasopressin type 1a receptor ( ***V1aR*** ) to initiate physiological effects such as vasoconstriction of blood vessels and glycogenolysis .	parallel	1
8454	10565013	51083;2796	GAL;LHRH	Both NPY and ***GAL*** ***stimulate*** feeding and ***LHRH*** secretion , but antisense oligodeoxynucleotides behaved differently in interrupting these two responses .	positive	0
8455	10565013	4852;2796	NPY;LHRH	Both ***NPY*** and GAL ***stimulate*** feeding and ***LHRH*** secretion , but antisense oligodeoxynucleotides behaved differently in interrupting these two responses .	positive	0
8456	10565161	3439;355	IFN-alpha;Fas	CONCLUSION : These data suggest that apoptosis via the Fas/FasL system is functional , and that preoperative ***IFN-alpha*** treatment may ***up-regulate*** the ***Fas/FasL*** system in RCC .	positive	1
8457	10565161	3439;356	IFN-alpha;FasL	CONCLUSION : These data suggest that apoptosis via the Fas/FasL system is functional , and that preoperative ***IFN-alpha*** treatment may ***up-regulate*** the ***Fas/FasL*** system in RCC .	positive	1
8458	10565567	3656;4790	IRAK-2;NF-kappaB	Antisense ***IRAK-2*** oligonucleotide ***blocks*** IL-1-stimulated ***NF-kappaB*** activation and ICAM-1 expression in cultured endothelial cells .	negative	0
8459	10565683	7157;4193	p53;mdm2	Biochemical uncovering of ******mdm2/p53****** ***complexes*** in liposarcomas parallels their immunohistochemical detection .	parallel	1
8460	10565683	7157;4193	p53;mdm2	A biochemical study of ******mdm2-p53****** ***association*** in 11 tumor samples characterized by the presence of different mdm2 and p53 immunophenotypes was performed .	parallel	0
8461	10565683	7157;4193	p53;mdm2	The findings in this study agree with the molecular data and they show the physical ***association*** of ***mdm2*** and ***p53*** in fresh liposarcoma surgical specimens .	parallel	0
8462	10565837	1386;1385	activating transcription factor (ATF)-2;CREB-1	PMA/Io induced two CRE DNA binding complexes , a major complex consisting of a cAMP response element-binding protein (CREB)-1 homodimer , and a minor ******CREB-1/activating transcription factor (ATF)-2****** ***complex*** .	parallel	1
8463	10566653	3553;3037	IL-1beta;HAS2	Here we report that ***IL-1beta*** can dramatically and consistently ***induce*** in orbital fibroblasts the expression of ***HAS2*** in the five orbital strains examined .	target	1
8464	10566682	5617;3659	prolactin;IRF-1	Localization of interferon regulatory factor-1 ( IRF-1 ) in nonpregnant human endometrium : expression of ***IRF-1*** is ***up-regulated*** by ***prolactin*** during the secretory phase of the menstrual cycle .	positive	1
8465	10566730	959;958	CD40L;CD40	Expression of ***CD40*** and its ***ligand*** , ***CD40L*** , in intestinal lesions of Crohn 's disease .	parallel	1
8466	10566890	3700;920	gp120;CD4	Our data indicate that ***binding*** of the HIV-1 ***gp120*** to either ***CD4*** or CXCR4 is sufficient to enable infection of human cells with SNV vector particles .	parallel	1
8467	10566890	3700;7852	gp120;CXCR4	Our data indicate that ***binding*** of the HIV-1 ***gp120*** to either CD4 or ***CXCR4*** is sufficient to enable infection of human cells with SNV vector particles .	parallel	1
8468	10566959	4804;627	p75NTR;neurotrophin	The low affinity ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) mediates apoptosis of a number of neuronal and non-neuronal cells but the signals leading to the apoptosis remain obscure .	parallel	1
8469	10567051	958;959	CD40;CD40L	These results show that IL-12 is sufficient to overcome CD40L blockade and suggest that , of the multiple consequences of the ******CD40L-CD40****** ***interaction*** , IL-12 induction is an essential one for induction of EAE .	parallel	1
8470	10567208	351;847	Abeta;catalase	Amyloid-beta ( ***Abeta*** ) specifically ***bound*** purified ***catalase*** with high affinity and inhibited catalase breakdown of H ( 2 ) O ( 2 ) .	parallel	1
8471	10567208	351;847	Abeta;catalase	Amyloid-beta ( ***Abeta*** ) specifically bound purified catalase with high affinity and ***inhibited*** ***catalase*** breakdown of H ( 2 ) O ( 2 ) .	negative	1
8472	10567218	1191;4036	apoJ;megalin	Although it is not known whether the structural changes observed are directly responsible for the higher receptor-binding affinity , the data suggest that the complement inhibition and amyloid beta-binding motifs are located in areas of the molecule different from those involved in the ******apoJ-megalin****** ***interaction*** .	parallel	1
8473	10567225	207;2475	PKB;mTOR	It has been suggested that PKB regulates mTOR function by phosphorylation although direct ***phosphorylation*** of ***mTOR*** by ***PKB*** has not been demonstrated previously .	target	1
8474	10567225	207;2475	PKB;mTOR	It has been suggested that ***PKB*** ***regulates*** ***mTOR*** function by phosphorylation although direct phosphorylation of mTOR by PKB has not been demonstrated previously .	target	1
8475	10567225	207;2475	PKB;mTOR	In the present work , we have found that ***PKB*** directly ***phosphorylates*** ***mTOR*** and , using phosphospecific antibodies , we have shown this phosphorylation occurs at Ser ( 2448 ) .	target	1
8476	10567230	5578;811	PKCalpha;calreticulin	The analysis of calreticulin immunoprecipitates from control or treated cells indicated that ***PKCalpha*** , PKCbeta , PKCtheta ; , PKCzeta and PKCmu , but not PKCdelta or PKCepsilon , ***co-immunoprecipitated*** with ***calreticulin*** .	parallel	1
8477	10567320	7040;3082	TGF-beta;HGF	Although active ***TGF-beta*** , a ***suppressor*** of ***HGF*** , was increased at 72 hours after hypoxic treatment , treatment of anti-TGF-beta antibody did not attenuate decreased HGF production .	negative	1
8478	10567356	28988;11184	HIP-55;hematopoietic progenitor kinase 1	A novel src homology 3 domain-containing adaptor protein , ***HIP-55*** , that ***interacts*** with ***hematopoietic progenitor kinase 1*** .	parallel	1
8479	10567356	11184;28988	HPK1;HIP-55	We found that ***HPK1*** ***bound*** to ***HIP-55*** both in vitro and in vivo .	parallel	1
8480	10567356	11184;5599	HPK1;JNK1	A dominant-negative ***HPK1*** mutant ***blocked*** activation of ***JNK1*** by HIP-55 showing that HIP-55 activates the JNK1 signaling pathway via HPK1 .	positive	0
8481	10567356	28988;5599	HIP-55;JNK1	A dominant-negative HPK1 mutant blocked ***activation*** of ***JNK1*** by ***HIP-55*** showing that HIP-55 activates the JNK1 signaling pathway via HPK1 .	positive	1
8482	10567356	28988;5599	HIP-55;JNK1	A dominant-negative HPK1 mutant blocked activation of JNK1 by HIP-55 showing that ***HIP-55*** ***activates*** the ***JNK1*** signaling pathway via HPK1 .	positive	1
8483	10567356	28988;11184	HIP-55;HPK1	Our results identify a novel protein , ***HIP-55*** , that ***binds*** to ***HPK1*** and regulates the JNK1 signaling cascade .	parallel	1
8484	10567356	28988;5599	HIP-55;JNK1	Our results identify a novel protein , ***HIP-55*** , that binds to HPK1 and ***regulates*** the ***JNK1*** signaling cascade .	target	1
8485	10567369	5594;5604	ERK2;MEK1	We examined the importance of this binding site in the feedback ***phosphorylation*** of ***MEK1*** on Thr ( 292 ) and Thr ( 386 ) by ***ERK2*** , the phosphorylation and activation of ERK2 by MEK1 , and the interaction of MEK1 with ERK2 and Raf-1 .	target	1
8486	10567369	5604;5594	MEK1;ERK2	We examined the importance of this binding site in the feedback phosphorylation of MEK1 on Thr ( 292 ) and Thr ( 386 ) by ERK2 , the ***phosphorylation*** and activation of ***ERK2*** by ***MEK1*** , and the interaction of MEK1 with ERK2 and Raf-1 .	target	1
8487	10567369	5604;5594	MEK1;ERK2	We examined the importance of this binding site in the feedback phosphorylation of MEK1 on Thr ( 292 ) and Thr ( 386 ) by ERK2 , the phosphorylation and activation of ERK2 by MEK1 , and the ***interaction*** of ***MEK1*** with ***ERK2*** and Raf-1 .	parallel	1
8488	10567369	5604;5894	MEK1;Raf-1	We examined the importance of this binding site in the feedback phosphorylation of MEK1 on Thr ( 292 ) and Thr ( 386 ) by ERK2 , the phosphorylation and activation of ERK2 by MEK1 , and the ***interaction*** of ***MEK1*** with ERK2 and ***Raf-1*** .	parallel	1
8489	10567369	4155;5604	myelin basic protein;MEK1	However , it did not affect ***MEK1*** ***phosphorylation*** by p21-activated protein kinase or ***myelin basic protein*** phosphorylation by ERK2 .	target	1
8490	10567378	2033;140628	p300;GATA-5	E1A markedly down-regulates endogenous atrial natriuretic factor expression , as well as disrupts the ***interaction*** between ***p300*** and ***GATA-5*** .	parallel	1
8491	10567384	573;10963	BAG-1;Hop	At low BAG-1 : hsp70/hsc70 ratios , ***BAG-1*** ***promoted*** the release of ***Hop*** from the hsp90-based chaperone system without inhibiting GR.hsp90 heterocomplex assembly .	positive	0
8492	10567384	573;3308	BAG-1;hsp70	These observations suggest that , at physiological concentrations , BAG-1 modulates assembly by promoting Hop release from the assembly complex ; but , at concentrations closer to those in transfected cells and some transformed cell lines , ***hsp70*** is continuously ***bound*** by ***BAG-1*** , and heterocomplex assembly is blocked .	parallel	1
8493	10567387	1438;1437	GMR;GM-CSF	The granulocyte-macrophage colony-stimulating factor ( ***GM-CSF*** ) ***receptor*** ( ***GMR*** ) is composed of two chains that belong to the superfamily of cytokine receptors typified by the growth hormone receptor .	parallel	1
8494	10567390	2033;595	E1A-associated protein p300;cyclin D1	***Activation*** of the ***cyclin D1*** gene by the ***E1A-associated protein p300*** through AP-1 inhibits cellular apoptosis .	positive	1
8495	10567391	2516;8721	Ad4BP;hMBF1	While hMBF1 was detected in the cytoplasm by immunostaining , coexpression of the nuclear protein ***Ad4BP/SF*** -1 with hMBF1 ***induced*** accumulation of ***hMBF1*** in the nucleus , suggesting that hMBF1 is localized in the nucleus through its binding to Ad4BP/SF -1 .	target	1
8496	10567406	5592;5609	PKG;MEK	The effects of PKG on ERK and JNK activity were additive with those of platelet-derived growth factor ( PDGF ) , suggesting that ***PKG*** ***activates*** ***MEK*** through a pathway not used by PDGF .	positive	1
8497	10567406	5592;2353	PKG;c-fos	Increased activation of these MAP kinase pathways may be one mechanism by which cGMP and ***PKG*** activation ***mediate*** ***c-fos*** induction and increased proliferation of contractile adult RASMC .	target	0
8498	10567409	6667;6670	Sp1;Sp3	Co-transfection experiments further established that ***Sp1*** ***antagonizes*** the activity of ***Sp3*** to transactivate the L2 promoter .	negative	1
8499	10567414	5966;4790	Rel;NF-kappaB	However , the IL-6 NF-kappaB sequence together with the IL-8 CD28RE and HIV-1 NF-kappaB sequence differed from the IL-2 CD28RE in the ***binding*** of ******NF-kappaB/Rel****** family proteins .	parallel	1
8500	10567423	3708;836	Inositol 1,4,5-trisphosphate receptor type 1;caspase-3	***Inositol 1,4,5-trisphosphate receptor type 1*** is a ***substrate*** for ***caspase-3*** and is cleaved during apoptosis in a caspase-3-dependent manner .	parallel	1
8501	10567430	8802;156	Galpha;GRK2	Additional studies revealed that bovine brain ***Galpha*** ( q/11 ) could also ***bind*** to an N-terminal construct of ***GRK2*** , while no binding of Galpha ( q/11 ) , Galpha ( s ) , Galpha ( i ) , or Galpha ( 12/13 ) to comparable constructs of GRK5 or GRK6 was observed .	parallel	1
8502	10567430	156;8802	GRK2;Galpha	Activation-dependent binding was also observed in both COS-1 and HEK293 cells as ***GRK2*** significantly ***co-immunoprecipitated*** constitutively active ***Galpha*** ( q ) ( R183C ) but not wild type Galpha ( q ) .	parallel	1
8503	10567430	156;8802	GRK2;Galpha	However , ***GRK2*** effectively ***inhibited*** ***Galpha*** ( q ) - mediated activation of phospholipase C-beta both in vitro and in cells , possibly through sequestration of activated Galpha ( q ) .	negative	1
8504	10567431	2475;6198	mammalian target of rapamycin;p70 S6 kinase alpha	Immunopurified ***mammalian target of rapamycin*** ***phosphorylates*** and activates ***p70 S6 kinase alpha*** in vitro .	target	1
8505	10567431	5170;6198	3-phosphoinositide-dependent protein kinase 1;p70alpha	Moreover , sequential ***phosphorylation*** of ***p70alpha*** by mTOR and ***3-phosphoinositide-dependent protein kinase 1*** in vitro resulted in a synergistic stimulation of p70alpha activity to levels similar to that attained by serum stimulation in vivo .	target	1
8506	10567431	2475;6198	mTOR;p70alpha	Moreover , sequential ***phosphorylation*** of ***p70alpha*** by ***mTOR*** and 3-phosphoinositide-dependent protein kinase 1 in vitro resulted in a synergistic stimulation of p70alpha activity to levels similar to that attained by serum stimulation in vivo .	target	1
8507	10567431	2475;84959	mTOR;p70	These results indicate that ***mTOR*** is likely to function as a direct ***activator*** of ***p70*** in vivo , although the relative contribution of mTOR-catalyzed p70 phosphorylation in each of the many circumstances that engender p70 activation remains to be defined .	positive	1
8508	10567521	55832;5434	TIP120;RPB5	Interestingly , ***TIP120*** also stimulates RNAP I - and III-driven transcription and ***binds*** to ***RPB5*** , one of the common subunits of the eukaryotic RNA polymerases , in vitro .	parallel	1
8509	10567531	5595;2353	ERK1;c-fos	Novel membrane-targeted ***ERK1*** and ERK2 chimeras which act as dominant negative , isotype-specific mitogen-activated protein kinase ***inhibitors*** of Ras-Raf-mediated transcriptional activation of ***c-fos*** in NIH 3T3 cells .	negative	1
8510	10567531	5594;2353	ERK2;c-fos	Novel membrane-targeted ERK1 and ***ERK2*** chimeras which act as dominant negative , isotype-specific mitogen-activated protein kinase ***inhibitors*** of Ras-Raf-mediated transcriptional activation of ***c-fos*** in NIH 3T3 cells .	negative	1
8511	10567531	5594;2353	ERK2;c-fos	The ***inhibition*** of the Ras-mediated ***c-fos*** induction by ***ERK2-CAAX*** can in part be rescued by coexpression of a wild-type ERK2 but not by wild-type ERK1 .	negative	1
8512	10567533	558;2621	Axl;gas6	******Axl-gas6****** ***interaction*** counteracts E1A-mediated cell growth suppression and proapoptotic activity .	parallel	1
8513	10567556	79930;25	DOKL;Abl	These results suggest that ***DOKL*** may ***modulate*** ***Abl*** function .	target	0
8514	10567556	25;79930	Abl;DOKL	***DOKL*** is ***phosphorylated*** by the ***Abl*** tyrosine kinase in vivo .	target	1
8515	10567563	8648;367	SRC1;androgen receptor	In contrast , mutants lacking the glutamine-rich region are inactive , indicating that this region is both necessary and sufficient for ***recruitment*** of ***SRC1*** to the ***androgen receptor*** .	target	0
8516	10567567	3320;440275	Hsp90;Gcn2	***Hsp90*** ***binds*** and regulates ***Gcn2*** , the ligand-inducible kinase of the alpha subunit of eukaryotic translation initiation factor 2 [ corrected ] .	parallel	1
8517	10567567	3320;440275	Hsp90;Gcn2	Using genetic and biochemical approaches , we show that ***Gcn2*** is ***regulated*** by the molecular chaperone ***Hsp90*** in budding yeast Saccharomyces cerevisiae .	target	1
8518	10567567	3320;440275	Hsp90;Gcn2	Specifically , we found that ( i ) several Hsp90 mutant strains exhibit constitutive expression of a GCN4-lacZ reporter plasmid ; ( ii ) ***Gcn2*** and ***Hsp90*** form a ***complex*** in vitro as well as in vivo ; ( iii ) the specific inhibitors of Hsp90 , geldanamycin and macbecin I , enhance the association of Gcn2 with Hsp90 and inhibit its kinase activity in vitro ; ( iv ) in vivo , macbecin I strongly reduces the levels of Gcn2 ; ( v ) in a strain expressing the temperature-sensitive Hsp90 mutant G170D , both the accumulation and activity of Gcn2 are abolished at the restrictive temperature ; and ( vi ) the Hsp90 cochaperones Cdc37 , Sti1 , and Sba1 are required for the response to amino acid starvation .	parallel	1
8519	10567567	440275;3320	Gcn2;Hsp90	Specifically , we found that ( i ) several Hsp90 mutant strains exhibit constitutive expression of a GCN4-lacZ reporter plasmid ; ( ii ) Gcn2 and Hsp90 form a complex in vitro as well as in vivo ; ( iii ) the specific inhibitors of Hsp90 , geldanamycin and macbecin I , enhance the ***association*** of ***Gcn2*** with ***Hsp90*** and inhibit its kinase activity in vitro ; ( iv ) in vivo , macbecin I strongly reduces the levels of Gcn2 ; ( v ) in a strain expressing the temperature-sensitive Hsp90 mutant G170D , both the accumulation and activity of Gcn2 are abolished at the restrictive temperature ; and ( vi ) the Hsp90 cochaperones Cdc37 , Sti1 , and Sba1 are required for the response to amino acid starvation .	parallel	0
8520	10567572	4217;596	ASK1;BCL-2	***BCL-2*** is ***phosphorylated*** and inactivated by an ***ASK1/Jun*** N-terminal protein kinase pathway normally activated at G ( 2 ) / M.	target	1
8521	10567572	3725;596	Jun;BCL-2	***BCL-2*** is ***phosphorylated*** and inactivated by an ***ASK1/Jun*** N-terminal protein kinase pathway normally activated at G ( 2 ) / M.	target	1
8522	10567572	4217;596	ASK1;BCL-2	Moreover , the combination of dominant negative ***ASK1*** , ( dnASK1 ) , dnMKK7 , and dnJNK1 ***inhibited*** paclitaxel-induced ***BCL-2*** phosphorylation .	negative	1
8523	10567583	4802;4801	NF-YC;NF-YB	In such assays , the ******NF-YB-NF-YC****** dimer forms ***complexes*** with H3-H4 , for whose formation the CCAAT box is not required .	parallel	1
8524	10567583	4801;4800	NF-YB;NF-YA	These results indicate that ( i ) the NF-Y histone fold dimer can efficiently associate DNA during nucleosome formation ; ( ii ) it has an intrinsic affinity for H3-H4 but does not form octamers ; and ( iii ) the ***interactions*** between ***NF-YA*** , ***NF-YB-NF-YC*** , and H3-H4 or nucleosomes are not mutually exclusive .	parallel	1
8525	10567583	4801;4802	NF-YB;NF-YC	These results indicate that ( i ) the NF-Y histone fold dimer can efficiently associate DNA during nucleosome formation ; ( ii ) it has an intrinsic affinity for H3-H4 but does not form octamers ; and ( iii ) the ***interactions*** between NF-YA , ******NF-YB-NF-YC****** , and H3-H4 or nucleosomes are not mutually exclusive .	parallel	1
8526	10567583	4802;4800	NF-YC;NF-YA	These results indicate that ( i ) the NF-Y histone fold dimer can efficiently associate DNA during nucleosome formation ; ( ii ) it has an intrinsic affinity for H3-H4 but does not form octamers ; and ( iii ) the ***interactions*** between ***NF-YA*** , ***NF-YB-NF-YC*** , and H3-H4 or nucleosomes are not mutually exclusive .	parallel	1
8527	10567629	355;356	Fas;FasL	CONCLUSION : ******Fas/FasL****** ***interaction*** is probably implicated in the human CF airway apoptotic pathway .	parallel	1
8528	10567901	7157;596	p53;bcl-2	The present study shows a cumulative prognostic value of simultaneous detection of bcl-2 over-expression and p53-gene aberration in some primary HNSCC treated with conventional RT , and provides further evidence for ***cross-talk*** between ***p53*** and ***bcl-2*** , suggesting that these genes are important determinants of radiation-induced apoptosis , thereby modulating resistance to RT .	parallel	0
8529	10567913	3479;836	IGF-I;caspase-3	***IGF-I*** ***blocks*** both the mitochondrial membrane depolarization and ***caspase-3*** activation normally induced by hyperosmotic treatment in neuroblastoma cells .	negative	0
8530	10568031	3005;10983	histone H1;Cyc1	***histone H1*** kinase activity ***associated*** with ***Cyc1*** reached a peak at PCD while Cyc2 showed maximal activity when about 75 % cells have completed cytokinesis .	parallel	0
8531	10568816	1499;999	beta-catenin;E-cadherin	In immunohistochemical analysis , beta-catenin protein in untreated cells showed diffuse cytoplasmic localization , whereas beta-catenin in treated cells was present in cytoplasm with a clear submembranous localization , indicating that increased ***beta-catenin*** mainly ***bound*** with ***E-cadherin*** , participating in cell-cell adhesion .	parallel	1
8532	10568836	3553;2099	IL-1beta;ERalpha	These results provide compelling evidence for direct transcriptional ***activation*** of ***ERalpha*** by ***IL-1beta*** .	positive	1
8533	10568836	3553;2099	IL-1beta;ERalpha	Evidence for transcriptional ***activation*** of ***ERalpha*** by ***IL-1beta*** in breast cancer cells .	positive	1
8534	10569131	1392;885	CRH;CCK	The present data suggest that ***interactions*** between ***CCK*** and ***CRH*** are significant in the human CNS , particularly perhaps in depressed and alcoholic patients , and that CSF samples may be used to assess elements of the relationship between these hormones .	parallel	1
8535	10569281	3952;5443	leptin;ACTH	***leptin*** participates in the expression of CRH in the hypothalamus , ***interacts*** at the adrenal level with ***ACTH*** , and is regulated by glucocorticoids .	parallel	1
8536	10569470	4488;632	MSX2;osteocalcin	***osteocalcin*** is upregulated by the transcription factor core-binding factor alpha 1 , which is responsible for commitment to the osteoblastic lineage , and is ***downregulated*** by ***MSX2*** , a homeobox-containing transcription factor expressed during the early proliferative phase of osteoblast differentiation .	negative	1
8537	10569698	3664;3458	LPS;IFNgamma	We found , that histamine inhibited the ***LPS*** ***induced*** transcription of ***IFNgamma*** gene and biosynthesis of IFNgamma protein in PMBC and also in CD19-depleted cell populations .	target	1
8538	10569731	7124;1803	tumor necrosis factor alpha;CD26	Interleukin-1alpha ( IL-1alpha ) ; ***tumor necrosis factor alpha*** ; gamma interferon ; lipopolysaccharide from Porphyromonas gingivalis , Prevotella intermedia , and Escherichia coli ; and Prevotella glycoprotein ***augmented*** ***CD26*** expression on gingival fibroblasts .	positive	0
8539	10569733	3606;3458	IL-18;IFN-gamma	As such , several different cytokines including , interleukin-12 ( IL-12 ) and ***IL-18*** , can ***induce*** ***IFN-gamma*** .	target	1
8540	10569753	959;958	CD40L;CD40	Isotype switching to immunoglobulin G ( IgG ) was abrogated in mice deficient in major histocompatibility complex ( MHC ) class II antigen (Ag)-T-cell receptor ( TCR ) , B7-CD28 , or ******CD40-CD40L****** ***interactions*** .	parallel	1
8541	10569753	958;959	CD40;CD40L	These data suggest that MHC class II Ag-TCR , B7-CD28 , and ******CD40-CD40L****** ***interactions*** are critical for immune responses to glycoconjugate vaccines in vivo .	parallel	1
8542	10569761	5340;7076	plasmin;Tissue inhibitor of metalloproteinase-1	***Tissue inhibitor of metalloproteinase-1*** was also ***degraded*** by the ***plasmin*** activity generated on the bacterial cells .	negative	0
8543	10569764	3586;941	IL-10;B7-1	***IL-10*** ***down-regulated*** major histocompatibility complex ( MHC ) class I , MHC class II , CD40 , ***B7-1*** , and B7-2 expression on M. tuberculosis-infected monocytes to a greater extent than TGF-beta .	negative	1
8544	10569764	3586;942	IL-10;B7-2	***IL-10*** ***down-regulated*** major histocompatibility complex ( MHC ) class I , MHC class II , CD40 , B7-1 , and ***B7-2*** expression on M. tuberculosis-infected monocytes to a greater extent than TGF-beta .	negative	1
8545	10569764	3586;958	IL-10;CD40	***IL-10*** ***down-regulated*** major histocompatibility complex ( MHC ) class I , MHC class II , ***CD40*** , B7-1 , and B7-2 expression on M. tuberculosis-infected monocytes to a greater extent than TGF-beta .	negative	1
8546	10569952	3931;4018	lecithin cholesterol acyltransferase;lipoprotein	***Binding*** of ***lecithin cholesterol acyltransferase*** ( LCAT ) to ***lipoprotein*** surfaces is a key step in the reverse cholesterol transport process , as the subsequent cholesterol esterification reaction drives the removal of cholesterol from tissues into plasma .	parallel	1
8547	10569952	3931;4018	LCAT;lipoprotein	In conclusion , the ***association*** of ***LCAT*** to ***lipoprotein*** surfaces is essentially independent of their composition but has a small electrostatic contribution , while dissociation of LCAT from lipoproteins is decreased due to the presence of apoA-I , suggesting protein-protein interactions .	parallel	0
8548	10570039	196;405	AHR;ARNT	Importantly , gel mobility shift analysis and Western blotting showed that the same level of ******AHR/ARNT****** ***complexes*** could be detected in cells treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin during hypoxia and normoxia .	parallel	1
8549	10570039	196;405	AHR;ARNT	These data suggest that the effects of hypoxia on AHR-mediated gene regulation occur distal to the formation of ******AHR/ARNT****** ***complexes*** and imply that functional interference between hypoxia and AHR-mediated signaling does not occur through competition for ARNT protein .	parallel	1
8550	10570062	8856;1576	pregnane X receptor;CYP3A4	The orphan human ***pregnane X receptor*** ***mediates*** the transcriptional activation of ***CYP3A4*** by rifampicin through a distal enhancer module .	target	0
8551	10570134	5978;3065	NRSF;histone deacetylase 1	Furthermore , ***NRSF*** and mSin3 formed a ***complex*** with ***histone deacetylase 1*** , suggesting that NRSF-mediated repression involves histone deacetylation .	parallel	1
8552	10570134	5978;3065	NRSF;histone deacetylase 1	These results indicate that ***NRSF*** ***recruits*** mSin3 and ***histone deacetylase 1*** to silence neural-specific genes and suggest further that repression of histone deacetylation is crucial for transcriptional activation of neural-specific genes during neuronal terminal differentiation .	target	0
8553	10570149	472;7157	ATM;p53	The ***ATM*** and ATR kinases , whose activation in response to ionizing radiation ( IR ) and UV light , respectively , is required for p53 stabilization , directly ***phosphorylate*** ***p53*** on Ser-15 .	target	1
8554	10570149	545;7157	ATR;p53	The ATM and ***ATR*** kinases , whose activation in response to ionizing radiation ( IR ) and UV light , respectively , is required for p53 stabilization , directly ***phosphorylate*** ***p53*** on Ser-15 .	target	1
8555	10570149	7157;4193	p53;Mdm2	Thus , whether any p53 modifications , and which , underlie disruption of the ******p53-Mdm2****** ***complex*** after DNA damage remains to be determined .	parallel	1
8556	10570149	7157;4193	p53;Mdm2	Furthermore , both IR and UV light induced phosphorylation of p53 on Ser-20 , which involved the majority of nuclear p53 protein and weakened the ***interaction*** of ***p53*** with ***Mdm2*** in vitro .	parallel	1
8557	10570156	25;1432	c-Abl;p38	We examined the effect of overexpression of c-Abl on the activation of mitogen-activated protein kinase pathways and found that overexpression of ***c-Abl*** selectively ***stimulated*** ***p38*** , while having no effect on c-Jun N-terminal kinase or on extracellular signal-regulated kinase .	positive	0
8558	10570156	25;5608	c-Abl;MKK6	Our study suggests that c-Abl is required for DNA damage-induced MKK6 and p38 activation , and that ***activation*** of ***MKK6*** by ***c-Abl*** is required for c-Abl-induced apoptosis but not c-Abl-induced cell cycle arrest .	positive	1
8559	10570177	912;3586	CD1d;IL-10	Ligation of intestinal epithelial ***CD1d*** ***induces*** bioactive ***IL-10*** : critical role of the cytoplasmic tail in autocrine signaling .	target	1
8560	10570177	912;3586	CD1d;IL-10	Subsequent studies revealed that ***anti-CD1d*** crosslinking specifically ***induces*** epithelial ***IL-10*** mRNA and protein and is blocked by the tyrosine kinase inhibitor genistein .	target	1
8561	10570177	912;3458	CD1d;IFN-gamma	Further studies addressing epithelial-derived IL-10 revealed that ***anti-CD1d*** crosslinking ***attenuates*** ***IFN-gamma*** signaling and that such attenuation is reversed by addition of functionally inhibitory IL-10 antibodies .	negative	0
8562	10570180	6772;1432	STAT1;p38 mitogen-activated protein kinase	Stress-induced phosphorylation of ***STAT1*** at Ser727 ***requires*** ***p38 mitogen-activated protein kinase*** whereas IFN-gamma uses a different signaling pathway .	target	0
8563	10570181	3606;3565	IL-18;IL-4	***IL-18*** , although antiallergic when administered with IL-12 , ***stimulates*** ***IL-4*** and histamine release by basophils .	positive	0
8564	10570190	4803;4804	NGF;NGF receptor	Human monocytes/macrophages ( M/M ) infected in vitro with HIV type 1 ( HIV-1 ) are able to produce substantial levels of ***NGF*** that are ***associated*** with enhanced expression of the high-affinity ***NGF receptor*** ( p140 trkA ) on the M/M surface .	parallel	0
8565	10570208	5327;9856	tPA;Neuronal migration	In the nervous system , ***tPA*** activity is ***correlated*** with neurite outgrowth , ***Neuronal migration*** , learning , and excitotoxic death .	parallel	0
8566	10570256	3937;2533	SLP-76;FYB	Cutting edge : SLP-76 cooperativity with FYB/FYN-T in the Up-regulation of TCR-driven IL-2 transcription requires ***SLP-76*** ***binding*** to ***FYB*** at Tyr595 and Tyr651 .	parallel	1
8567	10570256	2533;3558	FYB;IL-2	Coexpression of FYN-T , ***FYB*** , and SLP-76 can synergistically ***up-regulate*** ***IL-2*** production in T cells upon TCR ligation .	positive	1
8568	10570256	3937;3558	SLP-76;IL-2	Coexpression of FYN-T , FYB , and ***SLP-76*** can synergistically ***up-regulate*** ***IL-2*** production in T cells upon TCR ligation .	positive	1
8569	10570256	2533;3937	FYB;SLP-76	Furthermore , the synergistic up-regulation of IL-2 promoter activity in the FYN-T-FYB-SLP-76 pathway is contingent upon the ***interaction*** between ***FYB*** and ***SLP-76*** , but not the interaction between FYB and FYN-T .	parallel	1
8570	10570258	3458;6351	IFN-gamma;MIP-1beta	IL-4 , IL-10 , ***IFN-gamma*** , and IL-18 primarily ***inhibited*** ***MIP-1beta*** secretion and also weakly suppressed MIP-1alpha secretion .	negative	1
8571	10570258	3586;6351	IL-10;MIP-1beta	IL-4 , ***IL-10*** , IFN-gamma , and IL-18 primarily ***inhibited*** ***MIP-1beta*** secretion and also weakly suppressed MIP-1alpha secretion .	negative	1
8572	10570258	3606;6351	IL-18;MIP-1beta	IL-4 , IL-10 , IFN-gamma , and ***IL-18*** primarily ***inhibited*** ***MIP-1beta*** secretion and also weakly suppressed MIP-1alpha secretion .	negative	1
8573	10570258	3565;6351	IL-4;MIP-1beta	***IL-4*** , IL-10 , IFN-gamma , and IL-18 primarily ***inhibited*** ***MIP-1beta*** secretion and also weakly suppressed MIP-1alpha secretion .	negative	1
8574	10570261	958;9261	CD40;MAPKAPK-2	In DCs , as in B cells , ***CD40*** ligation ***activated*** p38 mitogen-activated protein kinase ( MAPK ) , its downstream target , ***MAPKAPK-2*** , and the c-Jun N-terminal kinase .	positive	1
8575	10570261	958;1432	CD40;p38 mitogen-activated protein kinase	In DCs , as in B cells , ***CD40*** ligation ***activated*** ***p38 mitogen-activated protein kinase*** ( MAPK ) , its downstream target , MAPKAPK-2 , and the c-Jun N-terminal kinase .	positive	1
8576	10570270	6504;4068	SLAM;SLAM-associated protein	Mouse ***SLAM*** also ***associates*** with the recently described human ***SLAM-associated protein*** .	parallel	0
8577	10570282	6387;2185	SDF-1;protein kinase B	The effects of ***SDF-1*** on D-3 phosphoinositide lipid accumulation ***correlated*** well with activation of the known PI 3-kinase effector ***protein kinase B*** , which was also inhibited by wortmannin and pertussis toxin .	parallel	0
8578	10570284	3574;6776	IL-7;stat5	Although TSLP and ***IL-7*** both ***induce*** tyrosine phosphorylation of the transcription factor ***stat5*** , only IL-7-mediated signal transduction could be associated with activation of Janus family kinases ( Jaks ) .	target	1
8579	10570284	85480;6776	TSLP;stat5	Although ***TSLP*** and IL-7 both ***induce*** tyrosine phosphorylation of the transcription factor ***stat5*** , only IL-7-mediated signal transduction could be associated with activation of Janus family kinases ( Jaks ) .	target	1
8580	10570284	85480;6776	TSLP;stat5	Herein , we demonstrate that ***TSLP*** ***induces*** a functional ***stat5*** transcription factor in that TSLP stimulation results in stat5-DNA complex formation and transcription of the stat5-responsive gene CIS .	target	1
8581	10570290	6464;2885	Shc;Grb2	High affinity IgG receptor activation of Src family kinases is required for modulation of the ******Shc-Grb2-Sos****** ***complex*** and the downstream activation of the nicotinamide adenine dinucleotide phosphate ( reduced ) oxidase .	parallel	1
8582	10570290	867;2885	Cbl;Grb2	Cross-linking of FcgammaRI induces the tyrosine phosphorylation of ***Cbl*** , which forms a ***complex*** with ***Grb2*** and Shc via the Cbl C terminus .	parallel	1
8583	10570290	867;6464	Cbl;Shc	Cross-linking of FcgammaRI induces the tyrosine phosphorylation of ***Cbl*** , which forms a ***complex*** with Grb2 and ***Shc*** via the Cbl C terminus .	parallel	1
8584	10570290	867;6464	Cbl;Shc	Kinetic experiments confirm that Cbl-Grb2 is relatively stable , whereas Grb2-Sos , Grb2-Shc , and ******Cbl-Shc****** ***interactions*** are highly inducible .	parallel	1
8585	10570290	6464;2885	Shc;Grb2	Kinetic experiments confirm that Cbl-Grb2 is relatively stable , whereas Grb2-Sos , ******Grb2-Shc****** , and Cbl-Shc ***interactions*** are highly inducible .	parallel	1
8586	10570290	2885;6464	Grb2;Shc	The Src family tyrosine kinase inhibitor , PP1 , was shown to completely ***inhibit*** ***Shc*** tyrosine phosphorylation , the ***Shc-Grb2*** interaction , and the FcgammaR-induced respiratory burst .	negative	1
8587	10570290	6464;2885	Shc;Grb2	The Src family tyrosine kinase inhibitor , PP1 , was shown to completely inhibit Shc tyrosine phosphorylation , the ******Shc-Grb2****** ***interaction*** , and the FcgammaR-induced respiratory burst .	parallel	1
8588	10570290	6464;2885	Shc;Grb2	Our results provide the first evidence that the upstream activation of Src kinases is required for the modulation of the ******Shc-Grb2****** ***interaction*** and the myeloid NADPH oxidase response .	parallel	1
8589	10570291	929;3569	CD14;IL-6	We show that 3 of 18 soluble mutants of human ***CD14*** failed to ***mediate*** the LPS-induced ***IL-6*** production in U373 cells .	target	0
8590	10570299	6688;1387	PU.1;CREB-binding protein	***Recruitment*** of ***CREB-binding protein*** by ***PU.1*** , IFN-regulatory factor-1 , and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression .	target	0
8591	10570299	1387;1536	CBP;CYBB	In these investigations , we determine that ***recruitment*** of a coactivator protein , ***CBP*** ( the CREBbinding protein ) , to the ***CYBB*** or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1 , IRF1 , and ICSBP .	target	0
8592	10570299	1387;4688	CBP;NCF2	In these investigations , we determine that ***recruitment*** of a coactivator protein , ***CBP*** ( the CREBbinding protein ) , to the CYBB or ***NCF2*** promoter is the molecular mechanism of transcriptional activation by PU.1 , IRF1 , and ICSBP .	target	0
8593	10570299	3458;1536	IFN-gamma;gp91phox	Because ***IFN-gamma*** ***induces*** simultaneous expression of p67phox and ***gp91phox*** , these investigations identify a molecular event that coordinates oxidase gene transcription during the inflammatory response .	target	1
8594	10570299	3458;4688	IFN-gamma;p67phox	Because ***IFN-gamma*** ***induces*** simultaneous expression of ***p67phox*** and gp91phox , these investigations identify a molecular event that coordinates oxidase gene transcription during the inflammatory response .	target	1
8595	10570299	3394;3659	ICSBP;IRF1	Also , these investigations identify CBP recruitment by ***cooperation*** between PU.1 , ***IRF1*** , and ***ICSBP*** as a novel molecular mechanism for IFN-gamma-induced activation of myeloid genes that are involved in the system of host defense .	parallel	0
8596	10570299	3394;6688	ICSBP;PU.1	Also , these investigations identify CBP recruitment by ***cooperation*** between ***PU.1*** , IRF1 , and ***ICSBP*** as a novel molecular mechanism for IFN-gamma-induced activation of myeloid genes that are involved in the system of host defense .	parallel	0
8597	10570299	6688;3659	PU.1;IRF1	Also , these investigations identify CBP recruitment by ***cooperation*** between ***PU.1*** , ***IRF1*** , and ICSBP as a novel molecular mechanism for IFN-gamma-induced activation of myeloid genes that are involved in the system of host defense .	parallel	0
8598	10570307	7040;6348	TGF-beta;Mip-1alpha	Apoptotic cell ingestion or ***TGF-beta*** also ***inhibited*** Mip-2 and ***Mip-1alpha*** gene expression in LPS-treated J774 cells , whereas TNF-alpha mRNA levels were unaffected .	negative	1
8599	10570307	7040;2920	TGF-beta;Mip-2	Apoptotic cell ingestion or ***TGF-beta*** also ***inhibited*** ***Mip-2*** and Mip-1alpha gene expression in LPS-treated J774 cells , whereas TNF-alpha mRNA levels were unaffected .	negative	1
8600	10570312	958;959	CD40;CD154	To understand the biological relevance of CD40 in vivo , KS cells were engineered to express and release a soluble form of CD40 ( KS-sCD40 ) able to disrupt ******CD40-CD154****** ***interaction*** .	parallel	1
8601	10570322	941;940	CD80;CD28	***CD80*** and CD86 ***interact*** with ***CD28*** and deliver costimulatory signals required for T cell activation .	parallel	1
8602	10570322	942;940	CD86;CD28	CD80 and ***CD86*** ***interact*** with ***CD28*** and deliver costimulatory signals required for T cell activation .	parallel	1
8603	10570322	941;3596	CD80;IL-13	Allergen-induced IL-5 and ***IL-13*** production by the asthmatic tissue was ***inhibited*** by ***anti-CD80*** and , to a lesser extent , by anti-CD86 mAbs .	negative	1
8604	10570322	941;3567	CD80;IL-5	Allergen-induced ***IL-5*** and IL-13 production by the asthmatic tissue was ***inhibited*** by ***anti-CD80*** and , to a lesser extent , by anti-CD86 mAbs .	negative	1
8605	10570324	3821;3824	NKG2;CD94	In addition , the engagement of HLA-E lead to the phosphorylation of the ******CD94/NKG2****** ***complex*** and the recruitment of SH2 domain-containing protein phosphatase 1 ( SHP-1 ) to the complex .	parallel	1
8606	10570325	3456;3439	IFN-beta;IFN-alpha	The ***IFN-alpha*** production was greatly ***enhanced*** by IFN-alpha2b and ***IFN-beta*** , and for SLE-IIF it was also enhanced by GM-CSF but inhibited by IL-10 .	positive	0
8607	10570465	2255;2253	FGF10;FGF8	Nature Genet 21:138 -141 ] , these results indicate that the product of the limbless gene is required for ***FGF10*** to ***induce*** expression of ***FGF8*** .	target	1
8608	10570482	1742;9419	PSD-95;CRIPT	Disrupting the ******CRIPT-PSD-95****** ***interaction*** in cultured hippocampal neurons with a PDZ3-specific peptide prevented the association of PSD-95 with microtubules and inhibited the synaptic clustering of PSD-95 , chapsyn-110/PSD-93 and GKAP ( a PSD-95-binding protein ) .	parallel	1
8609	10570913	718;8720	Asp;site-1 protease	Exons 15-23 encode the hydrophilic carboxyl-terminal domains containing four copies of a motif called the ***Trp-Asp*** ( WD ) repeats that ***interact*** with and regulate SREBP and the ***site-1 protease*** .	parallel	1
8610	10570927	1742;9229	PSD-95;guanylate kinase-associated protein	***PSD-95*** also ***interacts*** with ***guanylate kinase-associated protein*** ( GKAP ) through the guanylate kinase-like domain of PSD-95 .	parallel	1
8611	10570927	9229;1742	GKAP;PSD-95	Here we report that ***GKAP*** markedly ***potentiates*** the channel activity of the ***receptor-PSD-95*** complex .	positive	0
8612	10570944	3439;1113	IFN-alpha;CgA	To test the hypothesis that ***IFN-alpha*** can directly ***interfere*** with ***CgA*** gene transcription , we performed transient transfection studies in pancreatic neuroendocrine tumor cells employing CgA-luciferase reporter gene constructs showing that IFN-alpha inhibited basal and protein kinase C-dependent CgA promoter activity .	negative	0
8613	10570944	3439;1113	IFN-alpha;CgA	To test the hypothesis that IFN-alpha can directly interfere with CgA gene transcription , we performed transient transfection studies in pancreatic neuroendocrine tumor cells employing CgA-luciferase reporter gene constructs showing that ***IFN-alpha*** ***inhibited*** basal and protein kinase C-dependent ***CgA*** promoter activity .	negative	1
8614	10571054	7040;6414	TGF-beta1;SeP	The expression of a luciferase reporter construct under control of the human SeP promoter was downregulated by TGF-beta1 treatment in a dose-dependent fashion indicating a transcriptional ***regulation*** of the ***SeP*** gene by ***TGF-beta1*** .	target	1
8615	10571058	11244;4800	ZHX1;NF-YA	Amino acids located between 272 and 564 , a region that contains two homeodomains , are required for the ***interaction*** of ***ZHX1*** with ***NF-YA*** .	parallel	1
8616	10571067	5099;5499	BH-Pcdh;PP1alpha	***PP1alpha*** activity towards glycogen phosphorylase was ***inhibited*** by the intracellular domain of ***BH-Pcdh-c*** .	negative	1
8617	10571078	3077;7037	HFE;transferrin receptor	The findings indicate that ***HFE*** ***binding*** to ***transferrin receptor*** reduces cellular iron availability and regulates the balance between transferrin-mediated and non-transferrin-mediated cellular iron incorporation .	parallel	1
8618	10571080	5829;5335	paxillin;PLC-gamma1	Furthermore , immunoprecipitation analysis showed that ***paxillin*** forms a heteromeric ***complex*** with ***PLC-gamma1*** in cells grown on fibronectin .	parallel	1
8619	10571080	5829;5335	paxillin;PLC-gamma1	These results suggest that a complex ***formation*** between ***paxillin*** and ***PLC-gamma1*** may play a role in cell-substrate adhesion .	parallel	0
8620	10571081	5921;309	p120GAP;annexin VI	Mapping the site of ***interaction*** between ***annexin VI*** and the ***p120GAP*** C2 domain .	parallel	1
8621	10571232	4905;2891	NSF;GluR2	Hippocampal LTD expression involves a pool of AMPARs regulated by the ******NSF-GluR2****** ***interaction*** .	parallel	1
8622	10571232	4905;2891	NSF;GluR2	Blockade of the ******NSF-GluR2****** ***interaction*** by a specific peptide ( pep2m ) introduced into neurons prevented homosynaptic , de novo long-term depression ( LTD ) .	parallel	1
8623	10571232	4905;2891	NSF;GluR2	These results suggest that there is a pool of AMPARs dependent on the ******NSF-GluR2****** ***interaction*** and that LTD expression involves the removal of these receptors from synapses .	parallel	1
8624	10571233	4915;627	TrkB;Brain-derived neurotrophic factor	***Brain-derived neurotrophic factor*** ( BDNF ) and its ***receptor*** ***TrkB*** regulate both short-term synaptic functions and long-term potentiation ( LTP ) of brain synapses , raising the possibility that BDNF/TrkB may be involved in cognitive functions .	parallel	1
8625	10571240	5649;7436	Reelin;VLDLR	Furthermore , the CR-50 monoclonal antibody , which inhibits Reelin function , blocks the ***association*** of ***Reelin*** with ***VLDLR*** .	parallel	0
8626	10571240	5649;1600	Reelin;Dab1	In dissociated neurons , apoE reduces the level of ***Reelin-induced*** tyrosine ***phosphorylation*** of ***Dab1*** .	target	1
8627	10571241	5649;7804	Reelin;ApoE receptor 2	Direct ***binding*** of ***Reelin*** to VLDL receptor and ***ApoE receptor 2*** induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation .	parallel	1
8628	10571241	5649;7436	Reelin;VLDL receptor	Direct ***binding*** of ***Reelin*** to ***VLDL receptor*** and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation .	parallel	1
8629	10571241	5649;4137	Reelin;tau	Direct binding of ***Reelin*** to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and ***modulates*** ***tau*** phosphorylation .	target	0
8630	10571263	117;116	PACAPr;pituitary adenylate cyclase activating polypeptide	***pituitary adenylate cyclase activating polypeptide*** type I ***receptor*** ( ***PACAPr*** ) belongs to the novel subfamily of the G-protein coupled receptors with a long extracellular N-terminus , which functions as a major binding site for the PACAP .	parallel	1
8631	10571265	9588;3572	24-kDa protein;gp130	( GAM ) is a recently cloned ***24-kDa protein*** , which ***binds*** to ***gp130*** at its cytoplasmic membrane-proximal region and has high homology with the N-terminal of Groucho/TLE molecules , a transcription co-repressor family playing an essential role in Notch signaling .	parallel	1
8632	10571691	2254;2261	FGF9;FGFR3	The observations provide evidence that targeted , in vivo activation of endogenous FGFR3 inhibits bone growth and demonstrate that signals derived from ******FGF9-FGFR3****** ***interactions*** can physiologically block endochondral ossification to produce a phenotype characteristic of the achondroplasia group of human chondrodysplasias .	parallel	1
8633	10571771	183;7040	angiotensin II;TGF-beta	In turn , ***angiotensin II*** may further ***increase*** ***TGF-beta*** expression in both proximal tubular and interstitial cells , thus amplifying the stimulus to fibrogenesis in the renal tubulointerstitium .	positive	0
8634	10572039	4087;8928	Smad2;FAST-1	The ******FAST-1/Smad2/Smad4****** ***complex*** binds and activates a 50 bp activin responsive element identified in the promoter of the meso-endodermal marker Mix .2 .	parallel	1
8635	10572039	4087;4089	Smad2;Smad4	The ******FAST-1/Smad2/Smad4****** ***complex*** binds and activates a 50 bp activin responsive element identified in the promoter of the meso-endodermal marker Mix .2 .	parallel	1
8636	10572039	4089;8928	Smad4;FAST-1	The ******FAST-1/Smad2/Smad4****** ***complex*** binds and activates a 50 bp activin responsive element identified in the promoter of the meso-endodermal marker Mix .2 .	parallel	1
8637	10572062	7040;596	TGF-beta;bcl-2	IL-1beta-induced apoptosis was associated with a significant decline in expression of the antiapoptotic protein ***bcl-2*** , which was ***prevented*** by concomitant ***TGF-beta*** ( 1 ) treatment .	negative	0
8638	10572087	27033;2176	FAZF;FANCC	Our data suggest that the ******FAZF/FANCC****** ***interaction*** maps to a region of FANCC deleted in FA patients with a severe disease phenotype .	parallel	1
8639	10572088	1438;1437	GMRalpha;GM-CSF	The GM-CSF receptor consists of two subunits : ***GMRalpha*** , which ***binds*** ***GM-CSF*** with low affinity , and GMRbeta , which lacks intrinsic ligand-binding capability but complexes with GMRalpha to form a high-affinity receptor ( GMRalpha/beta ) .	parallel	1
8640	10572104	3553;3569	IL-1;HGF	Transforming growth factor beta1 and ***IL-1*** ***potentiated*** the effect of ***HGF*** on IL-11 secretion , whereas an additive effect was observed with tumor necrosis factor .	positive	0
8641	10572104	3082;3589	Hepatocyte growth factor;interleukin-11	***Hepatocyte growth factor*** ( HGF ) ***induces*** ***interleukin-11*** secretion from osteoblasts : a possible role for HGF in myeloma-associated osteolytic bone disease .	target	1
8642	10572104	3569;3589	HGF;IL-11	We now report that ***HGF*** ***induces*** ***IL-11*** secretion from human osteoblast-like cells and from the osteosarcoma cell lines Saos-2 and HOS .	target	1
8643	10572104	3569;3589	HGF;IL-11	Removal of surface-bound ***HGF*** on JJN-3 cells ***reduced*** ***IL-11*** production induced in cocultures .	positive	1
8644	10572108	3077;7037	HFE;transferrin receptor	A previously identified ***interaction*** of ***HFE*** and the ***transferrin receptor*** suggests a possible regulatory role of HFE in cellular iron absorption .	parallel	1
8645	10572111	3586;7124	interleukin-10;TNF-alpha	The antiinflammatory ***interleukin-10*** ( IL-10 ) ***antagonizes*** ***TNF-alpha*** and reduces GVHD .	negative	1
8646	10572168	11144;5888	Dmc1;Rad51	Using a two-hybrid screening to examine the interactions of the proteins encoded by the operon , we identified a specific ***interaction*** between the second subunit of PolD ( DP1 ) and a ******Rad51/Dmc1****** homologous protein ( RadB ) .	parallel	1
8647	10572244	5706;3315	p44;HSP27	These results indicate that PGF ( 2alpha ) stimulates the ***induction*** of ***HSP27*** via ***p42/p44*** MAP kinase activation , which depends on upstream PKC activation in osteoblasts .	target	1
8648	10572252	5925;595	pRb;cyclin D1	In a coprecipitation assay in T98G cells , a human glioblastoma cell line , the C-terminal domain of pRb2/p130 was able to interact solely with cyclin D3 , while the corresponding portion of ***pRb*** ***interacted*** with either cyclin D3 or ***cyclin D1*** .	parallel	1
8649	10572252	5925;896	pRb;cyclin D3	In a coprecipitation assay in T98G cells , a human glioblastoma cell line , the C-terminal domain of pRb2/p130 was able to interact solely with cyclin D3 , while the corresponding portion of ***pRb*** ***interacted*** with either ***cyclin D3*** or cyclin D1 .	parallel	1
8650	10572936	3565;632	interleukin-4;osteocalcin	We recently showed that ***interleukin-4*** ( IL-4 ) ***enhanced*** collagen and ***osteocalcin*** accumulation and caused mineralization in human periosteal osteoblast-like ( SaM-1 ) cells .	positive	0
8651	10573108	2247;596	FGF-2;Bcl-2	These data demonstrate that the expression of ***FGF-2*** ***downregulates*** ***Bcl-2*** and promotes programmed cell death in MCF-7 human breast cancer cells .	negative	1
8652	10573108	581;596	Bax;Bcl-2	Immunoprecipitation of Bax demonstrated a decreased ***association*** of ***Bax*** with ***Bcl-2*** in these cells .	parallel	0
8653	10573110	116;2353	PACAP;c-fos	***PACAP-27*** ***stimulated*** ***c-fos*** mRNA in T47D cells and the increase in c-fos gene expression caused by PACAP was reversed by PACAP ( 6-38 ) .	positive	0
8654	10573112	7037;7018	Transferrin receptor;Transferrin	***Transferrin receptor*** overexpression ***enhances*** ***Transferrin*** responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line .	positive	0
8655	10573217	3458;3383	interferon gamma;intercellular adhesion molecule-1	It is concluded that the Helper-1T-cell , type cytokine ***interferon gamma*** and the Helper-2 T-cell type cytokine interleukin-4 differentially ***regulate*** ***intercellular adhesion molecule-1*** and vascular cell adhesion molecule-1 expression on human lung fibroblasts .	target	1
8656	10573217	3458;7412	interferon gamma;vascular cell adhesion molecule-1	It is concluded that the Helper-1T-cell , type cytokine ***interferon gamma*** and the Helper-2 T-cell type cytokine interleukin-4 differentially ***regulate*** intercellular adhesion molecule-1 and ***vascular cell adhesion molecule-1*** expression on human lung fibroblasts .	target	1
8657	10573217	3565;3383	interleukin-4;intercellular adhesion molecule-1	It is concluded that the Helper-1T-cell , type cytokine interferon gamma and the Helper-2 T-cell type cytokine ***interleukin-4*** differentially ***regulate*** ***intercellular adhesion molecule-1*** and vascular cell adhesion molecule-1 expression on human lung fibroblasts .	target	1
8658	10573217	3565;7412	interleukin-4;vascular cell adhesion molecule-1	It is concluded that the Helper-1T-cell , type cytokine interferon gamma and the Helper-2 T-cell type cytokine ***interleukin-4*** differentially ***regulate*** intercellular adhesion molecule-1 and ***vascular cell adhesion molecule-1*** expression on human lung fibroblasts .	target	1
8659	10573217	3565;3383	interleukin-4;ICAM-1	Interferon-gamma and ***interleukin-4*** differentially ***regulate*** ***ICAM-1*** and VCAM-1 expression on human lung fibroblasts .	target	1
8660	10573217	3565;7412	interleukin-4;VCAM-1	Interferon-gamma and ***interleukin-4*** differentially ***regulate*** ICAM-1 and ***VCAM-1*** expression on human lung fibroblasts .	target	1
8661	10573217	3553;3383	IL-1beta;ICAM-1	***IL-1beta*** ( optimal concentration ( OC ) 1 U x mL ( -1 ) ) and TNFalpha ( OC 100 U x mL ( -1 ) ) both ***increased*** ***ICAM-1*** and VCAM-1 expression .	positive	0
8662	10573217	3553;7412	IL-1beta;VCAM-1	***IL-1beta*** ( optimal concentration ( OC ) 1 U x mL ( -1 ) ) and TNFalpha ( OC 100 U x mL ( -1 ) ) both ***increased*** ICAM-1 and ***VCAM-1*** expression .	positive	0
8663	10573514	444;3123	AAH;HLA-DRB1	In contrast to the class II associations in children , ***AAH*** was ***associated*** with ***HLA-DRB1*** * 0405 ( RR = 10.4 , Pc < .005 ) but not with HLA-DRB1 * 1301 or HLA-DRB1 * 0301 .	parallel	0
8664	10573518	8837;841	I-FLICE;FLICE	Our aims were to determine if altered expression of FasR and FasL or changes in expression of ***FLICE*** ***inhibitor*** ( ***I-FLICE*** ) allow cholangiocarcinoma cells to escape immune surveillance .	negative	1
8665	10573519	3082;5599	HGF;JNK	***HGF*** alone ***induced*** moderate levels of c-Jun-N-terminal kinase ( ***JNK*** ) and p44/p42 mitogen-activated protein kinase ( MAPK ) , resulting in moderate levels of AP-1-DNA binding activity .	target	1
8666	10573519	3082;5706	HGF;p44	***HGF*** alone ***induced*** moderate levels of c-Jun-N-terminal kinase ( JNK ) and ***p44/p42*** mitogen-activated protein kinase ( MAPK ) , resulting in moderate levels of AP-1-DNA binding activity .	target	1
8667	10573519	3082;3725	HGF;AP-1	The combination of LPS + ***HGF*** ***increased*** JNK and ***AP-1-DNA*** binding activity more than levels seen with LPS or HGF alone .	positive	0
8668	10573519	3082;5599	HGF;JNK	The combination of LPS + ***HGF*** ***increased*** ***JNK*** and AP-1-DNA binding activity more than levels seen with LPS or HGF alone .	positive	0
8669	10573531	1051;1244	C/EBPbeta;MRP2	This study suggests that ***C/EBPbeta*** ( -356 to -343 ) may ***regulate*** the liver expression of the ***MRP2*** gene .	target	1
8670	10574332	3439;2353	IFN-alpha;c-fos	This hypothesis was supported by the observation that ***IFN-alpha*** , even though it had no effect on the transcription of the c-fos gene , efficiently ***suppressed*** the IL-3-dependent expression of the ***c-fos*** protein .	negative	1
8671	10574364	5663;1499	PS1;beta-catenin	***PS1*** may ***regulate*** the function of ***beta-catenin*** , and mutant PS1 may disrupt this regulation .	target	1
8672	10574364	5663;1499	PS1;beta-catenin	In the present study , we confirm that PS1-WT , as well as mutant ***PS1*** , ***associates*** with ***beta-catenin*** , and that mutant PS1 expression decreases the stability and/or enhances the degradation of beta-catenin .	parallel	0
8673	10574364	5663;1499	PS1;beta-catenin	In the present study , we confirm that PS1-WT , as well as mutant PS1 , associates with beta-catenin , and that mutant ***PS1*** expression decreases the stability and/or ***enhances*** the degradation of ***beta-catenin*** .	positive	0
8674	10574372	9546;351	X11L2;beta-amyloid precursor protein	Recently we cloned a new member of the X11 protein family , ***X11L2*** ( gene symbol APBA3 ) which ***interacts*** with Alzheimer 's ***beta-amyloid precursor protein*** ( APP ) and has three protein-protein interaction domains , a phosphotyrosine interacting domain ( PID ) and two PDZ .	parallel	1
8675	10574471	1392;5443	Corticotropin releasing hormone;beta-endorphin	***Corticotropin releasing hormone*** ( CRH ) ***increases*** ***beta-endorphin*** ( beta-end like ) concentration in cerebrospinal fluid of rats with vasospasm following subarachnoid hemorrhage .	positive	0
8676	10574471	1392;5443	Corticotropin releasing hormone;beta-endorphin	***Corticotropin releasing hormone*** ( CRH ) ***induces*** the release of ***beta-endorphin*** ( beta-END ) from hypothalamic neurons and also from mononuclear white blood cells .	target	1
8677	10574472	4018;2643	lipoprotein;GTP cyclohydrolase I	Oxidized low density ***lipoprotein*** ***inhibits*** inducible nitric oxide synthase , ***GTP cyclohydrolase I*** and transforming growth factor beta gene expression in rat macrophages .	negative	1
8678	10574571	4982;8600	osteoprotegerin;ODF	The pit-forming activity of osteoclasts induced by sODF/sRANKL or osteoblasts was completely inhibited by simultaneous addition of ***osteoprotegerin/osteoclastogenesis inhibitory factor*** , a decoy ***receptor*** of ***ODF/RANKL*** .	parallel	1
8679	10574588	2152;7035	Tissue factor;TFPI	In conclusion , we demonstrated persistent elevation of the ***Tissue factor*** levels ***associated*** with low ***TFPI*** during and after CPR in patients with out-of-hospital cardiac arrest .	parallel	0
8680	10574615	941;940	B7-1;CD28	One is provided by T cell receptor ( TCR ) / CD3 in the context of the mayor histocompatibility complex ( MHC ) , and another signal is mediated by antigen-independent molecules , that is T cell membrane-bound ***CD28*** and its specific ***ligand*** ***B7-1*** ( CD80 ) present in APC .	parallel	1
8681	10574616	3430;9111	IFP 35;Nmi	Subcellular localization of interferon-inducible Myc/stat-interacting protein ***Nmi*** is ***regulated*** by a novel ***IFP 35*** homologous domain .	target	1
8682	10574698	3611;3987	ILK;PINCH	***ILK*** ***binds*** to ***PINCH*** through the N-terminal ankyrin ( ANK ) repeat domain and the PINCH binding is crucial for focal adhesion localization of ILK .	parallel	1
8683	10574698	3611;3987	ILK;PINCH	The ******ILK-PINCH****** ***interaction*** also connects ILK to Nck-2 , an SH2-SH3-containing adaptor protein that interacts with components of growth factor and small GTPase signaling pathways .	parallel	1
8684	10574699	998;8826	Cdc42;IQGAP1	Activated ***Cdc42*** and Rac1 ***inhibit*** ***IQGAP1*** , thereby stabilizing the cadherin-catenins complex .	negative	1
8685	10574699	5879;8826	Rac1;IQGAP1	Activated Cdc42 and ***Rac1*** ***inhibit*** ***IQGAP1*** , thereby stabilizing the cadherin-catenins complex .	negative	1
8686	10574705	655;90	BMP-7;ALK-2	Activin A bound to ActR-IB/ALK-4 and ActR-II , and ***BMP-7*** ***bound*** to ***ActR-I/ALK-2*** , BMP type I receptor ( BMPR-I ) / ALK-3 , ActR-II and BMPR-II .	parallel	1
8687	10574708	3987;3611	PINCH;ILK	We demonstrate in this study that the ******ILK-PINCH****** ***interaction*** requires the N-terminal-most ANK repeat ( ANK1 ) of ILK and one ( the C-terminal ) of the two zinc-binding modules within the LIM1 domain of PINCH .	parallel	1
8688	10574708	3611;3987	ILK;PINCH	The ***ILK*** ANK repeats domain , which is capable of interacting with PINCH in vitro , could also form a ***complex*** with ***PINCH*** in vivo .	parallel	1
8689	10574709	7430;10630	Ezrin;PA2.26	***Ezrin*** and moesin , but not radixin , can be ***coimmunoprecipitated*** together with ***PA2.26*** from cell lysates .	parallel	1
8690	10574709	4478;10630	moesin;PA2.26	Ezrin and ***moesin*** , but not radixin , can be ***coimmunoprecipitated*** together with ***PA2.26*** from cell lysates .	parallel	1
8691	10574717	2078;3384	Erg;ICAM-2	Furthermore , an ***Erg*** cDNA ***transactivated*** the ***ICAM-2*** promoter when transiently transfected into both HeLa cells and HUVEC .	positive	1
8692	10574767	6469;2735	Shh;GLI1	Much attention has been devoted to the expression pattern of Gli genes ; ***GLI1*** is ***induced*** by ***Shh*** , whereas GLI3 transcription appears to be repressed by Shh signalling [ 13 ] [ 14 ] [ 15 ] .	target	1
8693	10574767	6469;2737	Shh;GLI3	Much attention has been devoted to the expression pattern of Gli genes ; GLI1 is induced by Shh , whereas ***GLI3*** transcription appears to be ***repressed*** by ***Shh*** signalling [ 13 ] [ 14 ] [ 15 ] .	negative	1
8694	10574912	8812;1025	Cyclin K;CDK9	To identify additional factors involved in P-TEFb function we performed a yeast two-hybrid screen using CDK9 as bait and found that ***Cyclin K*** ***interacts*** with ***CDK9*** in vivo .	parallel	1
8695	10574912	8812;1025	Cyclin K;CDK9	The ******CDK9-Cyclin K****** ***complex*** phosphorylated the CTD of RNAPII and functionally substituted for P-TEFb comprised of CDK9 and cyclin T in in vitro transcription reactions .	parallel	1
8696	10574929	127933;5066	P-CIP2;PAM	Based on both in vitro binding experiments and co-immunoprecipitation from cell extracts , ***P-CIP2*** ***interacts*** with ***PAM*** proteins containing the wild type cytosolic domain , but not with mutant forms of PAM whose trafficking is disrupted .	parallel	1
8697	10574935	5898;2822	Ral;PLD	Taken together , strong evidence is provided that RTK-induced ***PLD*** stimulation in HEK-293 cells is ***mediated*** by PKC and a ***Ras/Ral*** signaling cascade .	target	0
8698	10574935	5898;2822	Ral;PLD	Moreover , recombinant ***Ral-GDS*** ***potentiated*** Ral-dependent PKC-induced ***PLD*** stimulation in membranes .	positive	0
8699	10574935	5898;2822	RalA;PLD	Second , expression of dominant-negative ***RalA*** and Ras mutants strongly ***reduced*** RTK-induced ***PLD*** stimulation .	negative	1
8700	10574939	1234;6355	CCR5;MCP-2	***CCR5*** is a functional ***receptor*** for MIP-1alpha , MIP-1beta , RANTES ( regulated on activation normal T cell expressed ) , ***MCP-2*** , and MCP-4 and constitutes the main coreceptor for macrophage tropic human and simian immunodeficiency viruses .	parallel	1
8701	10574939	1234;6357	CCR5;MCP-4	***CCR5*** is a functional ***receptor*** for MIP-1alpha , MIP-1beta , RANTES ( regulated on activation normal T cell expressed ) , MCP-2 , and ***MCP-4*** and constitutes the main coreceptor for macrophage tropic human and simian immunodeficiency viruses .	parallel	1
8702	10574939	1234;6348	CCR5;MIP-1alpha	***CCR5*** is a functional ***receptor*** for ***MIP-1alpha*** , MIP-1beta , RANTES ( regulated on activation normal T cell expressed ) , MCP-2 , and MCP-4 and constitutes the main coreceptor for macrophage tropic human and simian immunodeficiency viruses .	parallel	1
8703	10574939	1234;6351	CCR5;MIP-1beta	***CCR5*** is a functional ***receptor*** for MIP-1alpha , ***MIP-1beta*** , RANTES ( regulated on activation normal T cell expressed ) , MCP-2 , and MCP-4 and constitutes the main coreceptor for macrophage tropic human and simian immunodeficiency viruses .	parallel	1
8704	10574949	2261;2254	FGFR3;FGF9	In contrast , ***FGFR3*** ***bound*** well to FGF8 and ***FGF9*** but poorly to FGF2 .	parallel	1
8705	10574950	3667;3643	IRS-1;insulin receptor	Insulin-induced tyrosine phosphorylation of the insulin receptor , ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) , and IRS-2 was reduced by prestimulation of beta ( 3 ) - adrenergic receptors ( CL316243 ) .	parallel	1
8706	10574956	2057;2056	EpoR;erythropoietin	We constructed chimeric receptors wherein the extracellular domain of the ***erythropoietin*** ***receptor*** ( ***EpoR*** ) was fused to the transmembrane and intracellular domains of the interferon ( IFN ) type I receptor subunits , IFNaR1 or IFNaR2-2 .	parallel	1
8707	10574981	9046;920	p56;CD4	Furthermore , ***p56*** ( lck ) ***interaction*** with the intracytoplasmic tail of ***CD4*** markedly enhanced such induction .	parallel	1
8708	10574982	1051;5743	C/EBPbeta;PGHS-2	Thus , high levels of amino-terminal truncated USF-2 and ***C/EBPbeta*** in bovine granulosa cells prior to hCG treatment could repress gene expression , and be involved in the delayed ***induction*** of ***PGHS-2*** in species with a long ovulatory process .	target	1
8709	10574983	5340;1360	plasmin;procarboxypeptidase B	Characterization of ***plasmin-mediated*** ***activation*** of plasma ***procarboxypeptidase B*** .	positive	1
8710	10574984	4088;10923	SMAD3;p15	Infection of rat astrocytes by SMAD3 and SMAD4 adenoviruses failed to induce increased expression of p15 ( INK4B ) , implying indirect transcriptional ***regulation*** of ***p15*** ( INK4B ) by ***SMAD3*** .	target	1
8711	10574993	9479;5599	JIP-1;JNK	Jun amino-terminal kinase ( JNK ) interacting protein-1 ( ***JIP-1*** ) was originally identified as a cytoplasmic ***inhibitor*** of ***JNK*** .	negative	1
8712	10575001	100506658;7082	occludin;ZO-1	We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define ***interactions*** between ***ZO-1*** , ZO-2 , ZO-3 , ***occludin*** , and the actin cytoskeleton .	parallel	1
8713	10575001	100506658;9414	occludin;ZO-2	We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define ***interactions*** between ZO-1 , ***ZO-2*** , ZO-3 , ***occludin*** , and the actin cytoskeleton .	parallel	1
8714	10575001	100506658;27134	occludin;ZO-3	We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define ***interactions*** between ZO-1 , ZO-2 , ***ZO-3*** , ***occludin*** , and the actin cytoskeleton .	parallel	1
8715	10575001	7082;27134	ZO-1;ZO-3	We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define ***interactions*** between ***ZO-1*** , ZO-2 , ***ZO-3*** , occludin , and the actin cytoskeleton .	parallel	1
8716	10575001	9414;7082	ZO-2;ZO-1	We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define ***interactions*** between ***ZO-1*** , ***ZO-2*** , ZO-3 , occludin , and the actin cytoskeleton .	parallel	1
8717	10575001	9414;27134	ZO-2;ZO-3	We utilized in vitro binding assays with purified recombinant proteins and immunoprecipitation analyses to define ***interactions*** between ZO-1 , ***ZO-2*** , ***ZO-3*** , occludin , and the actin cytoskeleton .	parallel	1
8718	10575001	100506658;9414	occludin;ZO-2	The binding ***interactions*** of ***ZO-2*** , ZO-3 , and ***occludin*** were corroborated in vivo by immunofluorescence colocalization experiments which showed that all three proteins colocalized with actin aggregates at cell borders in cytochalasin D-treated Madin-Darby canine kidney cells .	parallel	1
8719	10575001	100506658;27134	occludin;ZO-3	The binding ***interactions*** of ZO-2 , ***ZO-3*** , and ***occludin*** were corroborated in vivo by immunofluorescence colocalization experiments which showed that all three proteins colocalized with actin aggregates at cell borders in cytochalasin D-treated Madin-Darby canine kidney cells .	parallel	1
8720	10575001	9414;27134	ZO-2;ZO-3	The binding ***interactions*** of ***ZO-2*** , ***ZO-3*** , and occludin were corroborated in vivo by immunofluorescence colocalization experiments which showed that all three proteins colocalized with actin aggregates at cell borders in cytochalasin D-treated Madin-Darby canine kidney cells .	parallel	1
8721	10575001	9414;100506658	ZO-2;occludin	Exploration of other tight junction protein interactions demonstrated that ***ZO-2*** ***binds*** directly to both ZO-1 and ***occludin*** .	parallel	1
8722	10575001	9414;7082	ZO-2;ZO-1	Exploration of other tight junction protein interactions demonstrated that ***ZO-2*** ***binds*** directly to both ***ZO-1*** and occludin .	parallel	1
8723	10575001	7082;27134	ZO-1;ZO-3	Contrary to previous beliefs , our immunoprecipitation results indicate that ZO-1 , ZO-2 , and ZO-3 exist in situ primarily as independent ZO-1.ZO-2 and ******ZO-1.ZO-3****** ***complexes*** rather than a trimeric ZO-1.ZO-2.ZO-3 grouping .	parallel	1
8724	10575002	196;1543	aryl hydrocarbon receptor;CYP1A1	However , DHEA did not inhibit CYP1A1 promoter-driven transcription , indicating that it did not affect the ***aryl hydrocarbon receptor*** , which ***regulates*** transcription of the ***CYP1A1*** gene .	target	1
8725	10575004	3458;5699	IFN-gamma;MECL1	These data indicate that the ***IFN-gamma*** ***induction*** of human ***MECL1*** is mediated by IFN-gamma-induced IRF-1 .	target	1
8726	10575004	3659;3458	IRF-1;IFN-gamma	These data indicate that the ***IFN-gamma*** induction of human MECL1 is ***mediated*** by IFN-gamma-induced ***IRF-1*** .	target	0
8727	10575004	3659;3458	Interferon regulatory factor 1;interferon-gamma	***Interferon regulatory factor 1*** ***mediates*** the ***interferon-gamma*** induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1 .	target	0
8728	10575004	3458;5699	IFN-gamma;MECL1	The importance of these elements for ***IFN-gamma*** ***induction*** of ***MECL1*** was addressed by transfecting an endothelial cell line with MECL1 promoter constructs .	target	1
8729	10575005	3725;355	AP-1;Fas	Transcriptional ***regulation*** of ***Fas*** gene expression by GA-binding protein and ***AP-1*** in T cell antigen receptor.CD3 complex-stimulated T cells .	target	1
8730	10575007	3949;4018	LDLR;lipoprotein	We have used adenovirus-mediated gene transfer in mice to investigate low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) and LDLR-related protein ( LRP ) - independent mechanisms that control the metabolism of chylomicron and very low density lipoprotein ( VLDL ) remnants in vivo .	parallel	1
8731	10575010	4792;4790	IkappaBalpha;NF-kappaB	In addition , the overexpression of ***IkappaBalpha*** completely ***inhibited*** ***NF-kappaB*** activation , p53 promoter transactivation and the stimulatory effect on p53 transcription induced by B [ a ] P.	negative	1
8732	10575010	4792;7157	IkappaBalpha;p53	In addition , the overexpression of ***IkappaBalpha*** completely ***inhibited*** NF-kappaB activation , ***p53*** promoter transactivation and the stimulatory effect on p53 transcription induced by B [ a ] P.	negative	1
8733	10575011	8312;4214	Axin;MEKK1	***Axin*** forms a ***complex*** with ***MEKK1*** and activates c-Jun NH ( 2 ) - terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling .	parallel	1
8734	10575011	8312;4214	Axin;MEKK1	***Axin*** forms a ***complex*** with ***MEKK1*** through a novel domain that we term MEKK1-interacting domain .	parallel	1
8735	10575011	8312;5599	Axin;JNK	Furthermore , Axin without the MEKK1-interacting domain has a dominant-negative effect on ***JNK*** ***activation*** by wild-type ***Axin*** .	positive	1
8736	10575633	3458;4843	IFN-gamma;iNOS	The ***iNOS*** gene was synergistically ***induced*** by LPS and ***IFN-gamma*** .	target	1
8737	10576546	2247;6531	bFGF;DA transporter	These results suggest the existence of Na ( + ) - dependent and Na ( + ) - independent DA uptake in cultured rat astrocytes , and that EGF or ***bFGF*** might ***stimulate*** the expression and translocation of the extraneuronal ***DA transporter*** .	positive	0
8738	10576620	7124;3383	TNF-alpha;ICAM-1	We demonstrate here that out of three compounds , viz diferuloylmethane , p-coumaroylferuloylmethane and di-p-coumaroylmethane , present in the ethyl acetate extract of Curcuma longa , diferuloylmethane is most potent in inhibiting ***TNF-alpha*** ***induced*** expression of ***ICAM-1*** , VCAM-1 and E-selectin on human umbilical vein endothelial cells .	target	1
8739	10576620	7124;7412	TNF-alpha;VCAM-1	We demonstrate here that out of three compounds , viz diferuloylmethane , p-coumaroylferuloylmethane and di-p-coumaroylmethane , present in the ethyl acetate extract of Curcuma longa , diferuloylmethane is most potent in inhibiting ***TNF-alpha*** ***induced*** expression of ICAM-1 , ***VCAM-1*** and E-selectin on human umbilical vein endothelial cells .	target	1
8740	10576657	5304;5241	PIP;progesterone receptor	Higher ***PIP*** mRNA levels ***correlated*** with ER + ( P = 0.0004 ) , ***progesterone receptor*** positive ( PR + ) ( P = 0.0167 ) , low-grade ( P = 0.0195 ) tumours , and also PIP protein levels assessed by immunohistochemistry ( n = 19 , P = 0.0319 ) .	parallel	0
8741	10576741	207;5594	Akt;ERK	Differentiation stage-specific ***inhibition*** of the ***Raf-MEK-ERK*** pathway by ***Akt*** .	negative	1
8742	10576741	207;5594	Akt;ERK	Furthermore , the ***PI3K-Akt*** pathway was shown to ***inhibit*** the ***Raf-MEK-ERK*** pathway ; this cross-regulation depended on the differentiation state of the cell : Akt activation inhibited the Raf-MEK-ERK pathway in differentiated myotubes , but not in their myoblast precursors .	negative	1
8743	10576768	3553;355	IL-1beta;Fas	There was no evidence that the expression of ***IL-1beta*** or other cytokines is ***related*** to the expression of ***Fas*** or its ligand .	parallel	0
8744	10577390	10926;8317	Dbf4;CDC7	***CDC7*** kinase and its ***activator*** ***Dbf4*** protein , originally identified in budding yeast Saccharomyces cerevisiae , are widely conserved in eukaryotes including fission yeast and human .	positive	1
8745	10577507	7133;7124	TNFR2;TNF-alpha	Evasion of apoptosis by this pathogen is achieved by enhanced release of sTNFR2 by H37Rv-infected macrophages and subsequent formation of inactive ******TNF-alpha-TNFR2****** ***complexes*** .	parallel	1
8746	10577511	941;940	B7-1;CD28	Because ***B7-1*** is not expressed at high enough levels on residual accessory cells in primary T cell cultures to be an effective ***ligand*** for ***CD28*** , we used LPS-stimulated B cells , which express substantial B7-1 , in addition to B7-2 , to determine the contribution of B7-1 to AK-T cell development .	parallel	1
8747	10577511	942;3002	B7-2;granzyme B	Blockade of ***B7-2*** / CD28 interactions with anti-B7-2 mAb strongly ***inhibited*** ***granzyme B*** , but not perforin or Fas ligand gene expression , suggesting an explanation for the inhibitory effect of anti-B7-2 mAb on AK-T cell development .	positive	1
8748	10577517	3565;1235	Interleukin-4;CCR6	***Interleukin-4*** was also able to ***decrease*** ***CCR6*** protein levels .	negative	0
8749	10577517	1235;6364	CCR6;MIP-3alpha	Our findings suggest that the ******MIP-3alpha/CCR6****** ***interaction*** plays an important role in the trafficking of immature DC to chemokine production sites such as injured or inflamed peripheral tissues , where DC undergo maturation on contact with antigens .	parallel	1
8750	10577519	4689;653361	p40-phox;p47-phox	Furthermore , purified protein kinase C but not casein kinase II directly phosphorylated p40-phox of ******p40-phox/p47-phox/p67-phox****** ***complex*** .	parallel	1
8751	10577519	4688;4689	p67-phox;p40-phox	Furthermore , purified protein kinase C but not casein kinase II directly phosphorylated p40-phox of ******p40-phox/p47-phox/p67-phox****** ***complex*** .	parallel	1
8752	10577519	4688;653361	p67-phox;p47-phox	Furthermore , purified protein kinase C but not casein kinase II directly phosphorylated p40-phox of ******p40-phox/p47-phox/p67-phox****** ***complex*** .	parallel	1
8753	10578139	5368;4987	Nociceptin;ORL-1	***Stimulation*** of the opioid receptor-like1 ( ***ORL-1*** ) receptor by ***Nociceptin*** ( NC ) produces hyperalgesia and reverses the antinociceptive effects induced by opioids .	positive	0
8754	10578152	6343;7432	secretin;VIP	We also studied the ***interaction*** between ***VIP*** and ***secretin*** on cholinergic mucus output .	parallel	1
8755	10578152	6343;7432	secretin;VIP	Similarly , ***secretin*** ( 1 microM ) ***potentiated*** ***VIP*** ( 1 microM ) - induced mucus output by 160 % .	positive	0
8756	10578180	652;842	BMP-4;caspase-9	***BMP-4*** and retinoic acid synergistically ***induce*** activation of ***caspase-9*** and cause apoptosis of P19 embryonal carcinoma cells cultured as a monolayer .	target	1
8757	10578180	598;842	Bcl-xL;caspase-9	***Bcl-xL*** ***inhibited*** processing of ***caspase-9*** , Ac-DEVD-MCA cleavage activity and DNA fragmentation induced by RA/BMP-4 treatment .	negative	1
8758	10578180	652;842	BMP-4;caspase-9	RA and ***BMP-4*** may ***activate*** ***caspase-9*** through an apoptotic pathway other than the Apaf-1/cytochrome c pathway .	positive	1
8759	10579222	1270;2596	Ciliary neurotrophic factor;growth-associated protein-43	In the axotomized retinas , ***Ciliary neurotrophic factor*** initiated sprouting of axon-like processes at 14 and 28 days post-axotomy and ***up-regulated*** the expression level of ***growth-associated protein-43*** messenger RNA at 7 , 14 and 28 days post-axotomy .	positive	1
8760	10579320	2100;2099	ERbeta;ERalpha	The estrogen receptor beta-isoform ( ***ERbeta*** ) of the human estrogen receptor ***modulates*** ***ERalpha*** transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens .	target	0
8761	10579320	2100;2099	ERbeta;ERalpha	The importance of these findings was revealed when it was determined that ***ERbeta*** functions as a transdominant ***inhibitor*** of ***ERalpha*** transcriptional activity at subsaturating hormone levels and that ERbeta decreases overall cellular sensitivity to estradiol .	negative	1
8762	10579320	2100;2099	ERbeta;ERalpha	In probing the mechanisms underlying ***ERbeta-mediated*** ***repression*** of ***ERalpha*** transcriptional activity we have determined that 1 ) ERalpha and ERbeta can form heterodimers within target cells ; and 2 ) ERbeta interacts with target gene promoters in a ligand-independent manner .	negative	1
8763	10579320	2100;2099	ERbeta;ERalpha	In probing the mechanisms underlying ERbeta-mediated repression of ERalpha transcriptional activity we have determined that 1 ) ***ERalpha*** and ***ERbeta*** can form ***heterodimers*** within target cells ; and 2 ) ERbeta interacts with target gene promoters in a ligand-independent manner .	parallel	1
8764	10579320	2100;2099	ERbeta;ERalpha	Cumulatively , these data indicate that one role of ***ERbeta*** is to ***modulate*** ***ERalpha*** transcriptional activity , and thus the relative expression level of the two isoforms will be a key determinant of cellular responses to agonists and antagonists .	target	0
8765	10579328	1392;5443	CRH;ACTH	***CRH*** and vasopressin ( VP ) , the main ***regulators*** of pituitary ***ACTH*** secretion , co-exist in parvocellular cells of the PVN , but their levels of expression are regulated differentially during manipulations of the hypothalamic pituitary adrenal ( HPA ) axis .	target	1
8766	10579331	2516;949	steroidogenic factor-1;SR-BI	Consistent with this fact , we have recently shown that ***steroidogenic factor-1*** ( SF-1 ) ***mediates*** cAMP activation of the HDL receptor ***SR-BI*** gene .	target	0
8767	10579331	2516;949	SF-1;SR-BI	The results confirm that indeed both ***SF-1*** and SREBP-1a synergize to ***induce*** HDL receptor ***SR-BI*** gene expression .	target	1
8768	10579338	3479;3082	insulin-like growth factor 1;hepatocyte growth factor	It has been shown recently that ***insulin-like growth factor 1*** ( IGF-1 ) ***increases*** both DNA synthesis and ***hepatocyte growth factor*** ( HGF ) production in cultured hepatic stellate cells .	positive	0
8769	10579343	5741;5706	PTH;p42	Immunoblot analysis with an activation - specific MAPK antibody indicated that ***PTH*** ***activated*** both ***p42*** and p44 MAPK .	positive	1
8770	10579343	5741;2966	PTH;p44	Immunoblot analysis with an activation - specific MAPK antibody indicated that ***PTH*** ***activated*** both p42 and ***p44*** MAPK .	positive	1
8771	10579348	2691;4254	GHRH;stem cell factor	GHRH-RP is a recently described peptide derived from proteolytic processing of ***pro-GHRH*** that ***activates*** ***stem cell factor*** , a factor known to be essential for hemopoiesis , spermatogenesis , and melanocyte function .	positive	1
8772	10579588	8851;1020	p35;Cyclin-dependent kinase-5	***Cyclin-dependent kinase-5*** ( cdk5 ) and its neuron-specific ***activator*** , ***p35*** , are essential for the proper migration of neurons .	positive	1
8773	10579721	7074;207	Tiam1;Rac	Using biochemical assays to determine the activation state of Rho-like GTPases , we show that the guanine nucleotide exchange factor ***Tiam1*** functions as a specific ***activator*** of ***Rac*** but not Cdc42 or Rho in NIH3T3 fibroblasts .	positive	1
8774	10579721	7074;207	Tiam1;Rac	***Activation*** of ***Rac*** by ***Tiam1*** induces an epithelial-like morphology with functional cadherin-based adhesions and inhibits migration of fibroblasts .	positive	1
8775	10579721	7074;207	Tiam1;Rac	Transient PDGF-induced as well as sustained ***Rac*** ***activation*** by ***Tiam1*** or V12Rac downregulate Rho activity .	positive	1
8776	10579724	8837;841	FLIP;caspase-8	Motoneurons resistant to Fas activation expressed high levels of FLICE-inhibitory protein ( ***FLIP*** ) , an endogenous ***inhibitor*** of ***caspase-8*** activation .	negative	1
8777	10579725	836;207	caspase 3;PKB	p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the ***caspase 3-dependent*** ***cleavage*** of ***AKT/PKB*** .	target	1
8778	10579726	23421;3693	TAP20;integrin beta5	Thus , the discovery of ***TAP20*** , which ***interacts*** with ***integrin beta5*** and modulates cell adhesion , migration , and tube formation , further defines a possible pathway to angiogenesis dependent on PKCtheta .	parallel	1
8779	10579747	183;1906	angiotensin II;endothelin-1	In addition , ***angiotensin II*** appears to ***facilitate*** sympathetic activation and the release of ***endothelin-1*** , and also to promote apoptosis .	positive	0
8780	10579830	6348;7852	MIP-1alpha;chemokine receptor	A novel series of 4-hydroxypiperidines has been discovered by high throughput screening ( HTS ) which potently inhibits the ***binding*** of ***MIP-1alpha*** and RANTES to the recombinant human CCR1 ***chemokine receptor*** .	parallel	1
8781	10579830	6352;7852	RANTES;chemokine receptor	A novel series of 4-hydroxypiperidines has been discovered by high throughput screening ( HTS ) which potently inhibits the ***binding*** of MIP-1alpha and ***RANTES*** to the recombinant human CCR1 ***chemokine receptor*** .	parallel	1
8782	10579912	4149;4609	Max;c-Myc	***Max*** also heterodimerizes with the Mad family of proteins to repress transcription , ***antagonize*** ***c-Myc*** , and promote cellular differentiation .	negative	1
8783	10580005	140628;1482	Gata5;nkx2.5	Together , these results implicate zebrafish Gata5 in controlling the growth , morphogenesis , and differentiation of the heart and endoderm and indicate that ***Gata5*** ***regulates*** the expression of the early myocardial gene ***nkx2.5*** .	target	1
8784	10580148	64343;4790	AZ2;NFkappaB	Overexpression of ***AZ2*** ***inhibited*** TNF alpha mediated ***NFkappaB*** activation .	negative	1
8785	10580148	64343;7124	AZ2;TNF alpha	Overexpression of ***AZ2*** ***inhibited*** ***TNF alpha*** mediated NFkappaB activation .	negative	1
8786	10580503	4982;8600	osteoprotegerin;osteoprotegerin ligand	Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule ***osteoprotegerin ligand*** ( OPGL ) and its decoy ***receptor*** ***osteoprotegerin*** ( OPG ) .	parallel	1
8787	10580503	8792;8600	RANK;OPGL	The ***OPGL*** ***receptor*** , ***RANK*** , is expressed on chondrocytes , osteoclast precursors and mature osteoclasts .	parallel	1
8788	10580548	7124;3383	TNF-alpha;ICAM-1	***Induction*** of intercellular adhesion molecule ( ***ICAM-1*** ) , vascular cell adhesion molecule ( VCAM-1 ) and E-selectin by ***TNF-alpha*** , measured by a radiometric technique , was similar in IVEC and HUVEC , while the induction of E-selectin by IL-1beta on IVEC was limited and significantly different from that observed on HUVEC ( p < 0.001 ) .	target	1
8789	10580548	7124;7412	TNF-alpha;VCAM-1	***Induction*** of intercellular adhesion molecule ( ICAM-1 ) , vascular cell adhesion molecule ( ***VCAM-1*** ) and E-selectin by ***TNF-alpha*** , measured by a radiometric technique , was similar in IVEC and HUVEC , while the induction of E-selectin by IL-1beta on IVEC was limited and significantly different from that observed on HUVEC ( p < 0.001 ) .	target	1
8790	10580588	7040;7431	TGF-beta1;vimentin	Western blotting analysis showed that ***TGF-beta1*** decreased cytokeratin and ***increased*** ***vimentin*** levels , while DMSO decreased both cytokeratin and vimentin .	positive	0
8791	10580710	2668;5594	GDNF;ERK1/2	Moreover , ***GDNF*** ***stimulated*** the phosphorylation of MAP kinase ( ***ERK1/2*** ) in the cells .	positive	0
8792	10580739	3557;3553	IL-1Ra;IL-1beta	The stimulatory effect of ***IL-1beta*** was ***reduced*** by IL-1 receptor antagonist ( ***IL-1Ra*** ) in a dose dependent manner .	negative	1
8793	10580747	7040;5594	TGF-beta1;ERK	These results indicate that ***TGF-beta1*** specifically ***activates*** MEK1 and subsequent ***ERK*** pathways in CRAC , and that the activation of this MAPK pathway plays a role in the mitogenic response to TGF-beta1 .	positive	1
8794	10580747	7040;5594	TGF-beta1;ERK	***TGF-beta1*** ***induced*** a rapid activation of extracellular signal regulated kinase ( ***ERK*** ) with a peak at 5 min , which decreased to basal levels within 240 min after TGF-beta1 stimulation .	target	1
8795	10580747	7040;5594	TGF-beta1;ERK	***ERK*** ***activation*** by ***TGF-beta1*** was also confirmed by in vivo phosphorylation assays of Elk1 .	positive	1
8796	10580796	23533;7124	P101;TNF-alpha	Moreover , SPA and ***P101*** also ***inhibit*** the release of histamine and ***TNF-alpha*** induced by dSP suggesting that a receptor-independent mechanism is involved .	negative	1
8797	10580807	3605;4792	Interleukin-17;IkappaB alpha	***Interleukin-17*** ***stimulates*** the expression of ***IkappaB alpha*** mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines .	positive	0
8798	10580807	3605;3569	Interleukin-17;IL-6	***Interleukin-17*** ***stimulates*** the expression of IkappaB alpha mRNA and the secretion of ***IL-6*** and IL-8 in glioblastoma cell lines .	positive	0
8799	10580807	3605;3576	Interleukin-17;IL-8	***Interleukin-17*** ***stimulates*** the expression of IkappaB alpha mRNA and the secretion of IL-6 and ***IL-8*** in glioblastoma cell lines .	positive	0
8800	10580807	3605;3569	IL-17;IL-6	Furthermore , ***IL-17*** ***stimulated*** the secretion of ***IL-6*** and IL-8 in glial cells , and IL-17 and IL-1beta in combination showed a superadditive effect .	positive	0
8801	10580807	3605;3576	IL-17;IL-8	Furthermore , ***IL-17*** ***stimulated*** the secretion of IL-6 and ***IL-8*** in glial cells , and IL-17 and IL-1beta in combination showed a superadditive effect .	positive	0
8802	10580833	6670;2520	Sp3;gastrin	The effect of Sp3 was cell-line dependent , since ***Sp3*** ***inhibited*** the ***gastrin*** promoter activity in AGS cells and caused a synergistic activation of the Sp1 stimulated gastrin promoter in Drosophila cells .	negative	1
8803	10580833	6667;2520	Sp1;gastrin	The effect of Sp3 was cell-line dependent , since Sp3 inhibited the gastrin promoter activity in AGS cells and caused a synergistic activation of the ***Sp1*** ***stimulated*** ***gastrin*** promoter in Drosophila cells .	positive	0
8804	10580837	5617;1978	Prolactin;PHAS-I	***Prolactin*** and insulin synergize to ***regulate*** the translation modulator ***PHAS-I*** via mitogen-activated protein kinase-independent but wortmannin - and rapamycin-sensitive pathway .	target	1
8805	10581001	3700;2353	gp120;c-fos	In addition , ***gp120*** protein at lower concentrations ***enhanced*** mRNA expression of ***c-fos*** and at higher concentrations promoted mRNA expression of c-jun .	positive	0
8806	10581001	3700;3725	gp120;c-jun	In addition , ***gp120*** protein at lower concentrations enhanced mRNA expression of c-fos and at higher concentrations ***promoted*** mRNA expression of ***c-jun*** .	positive	0
8807	10581025	26277;7013	TIN2;TRF1	***TIN2*** ***interacted*** with ***TRF1*** in vitro and in cells , and co-localized with TRF1 in nuclei and metaphase chromosomes .	parallel	1
8808	10581081	3479;7422	IGF-1;VEGF	***IGF-1*** receptor ***regulation*** of ***VEGF*** action is mediated at least in part through control of VEGF activation of p44/42 mitogen-activated protein kinase , establishing a hierarchical relationship between IGF-1 and VEGF receptors .	target	1
8809	10581151	2978;3000	GCAP-1;RetGC-1	The photoreceptor membrane guanylyl cyclases , ***RetGC-1*** and RetGC-2 ( also referred to as GC-E and GC-F ) , are ***regulated*** intracellularly by two Ca ( 2 + ) - binding proteins , ***GCAP-1*** and GCAP-2 .	target	1
8810	10581151	2978;2986	GCAP-1;RetGC-2	The photoreceptor membrane guanylyl cyclases , RetGC-1 and ***RetGC-2*** ( also referred to as GC-E and GC-F ) , are ***regulated*** intracellularly by two Ca ( 2 + ) - binding proteins , ***GCAP-1*** and GCAP-2 .	target	1
8811	10581151	2979;3000	GCAP-2;RetGC-1	The photoreceptor membrane guanylyl cyclases , ***RetGC-1*** and RetGC-2 ( also referred to as GC-E and GC-F ) , are ***regulated*** intracellularly by two Ca ( 2 + ) - binding proteins , GCAP-1 and ***GCAP-2*** .	target	1
8812	10581151	2979;2986	GCAP-2;RetGC-2	The photoreceptor membrane guanylyl cyclases , RetGC-1 and ***RetGC-2*** ( also referred to as GC-E and GC-F ) , are ***regulated*** intracellularly by two Ca ( 2 + ) - binding proteins , GCAP-1 and ***GCAP-2*** .	target	1
8813	10581160	1499;3172	beta-catenin;Tcf	Upon binding of a Wnt to its receptor , GSK3beta is inhibited through an unknown mechanism involving Dishevelled ( Dsh ) , resulting in the dephosphorylation and stabilization of ***beta-catenin*** , which translocates to the nucleus and ***interacts*** with ***Lef/Tcf*** transcription factors to activate target gene expression .	parallel	1
8814	10581185	2837;10911	GPR14;UII	We have now demonstrated that ***GPR14*** is a high affinity ***receptor*** for ***UII*** and designate it UII-R1a .	parallel	1
8815	10581191	4609;10397	c-myc;Ndr1	***Ndr1*** was isolated as a gene upregulated in N-myc mutant mouse embryos and is ***repressed*** by N-myc and ***c-myc*** .	negative	1
8816	10581191	4613;10397	N-myc;Ndr1	***Ndr1*** was isolated as a gene upregulated in N-myc mutant mouse embryos and is ***repressed*** by ***N-myc*** and c-myc .	negative	1
8817	10581192	2059;1855	EPS8;Dvl1	During the screening , we found that ***EPS8*** , which is a substrate for activated EGF receptor ( EGFR ) , specifically ***interacted*** with ***Dvl1*** .	parallel	1
8818	10581193	2705;100506658	connexin 32;occludin	Induction of tight junctions in human connexin 32 ( hCx32 ) - transfected mouse hepatocytes : ***connexin 32*** ***interacts*** with ***occludin*** .	parallel	1
8819	10581193	100506658;2705	occludin;Cx32	In Western blots , occludin protein was increased in the transfectants compared to parental cells , and ***binding*** of ***occludin*** to ***Cx32*** protein was demonstrated by immunoprecipitation .	parallel	1
8820	10581204	5594;7867	p38;MAPKAPK-2 and -3	However , ***p38*** ***phosphorylates*** ***MAPKAPK-2 and -3*** , whereas SAPK4 does not .	target	1
8821	10581206	1545;196	CYP1B1;AhR	Inhibition of ***CYP1B1*** was ***linked*** to enhanced ***AhR*** activation even at early stages prior to significant ligand depletion .	parallel	0
8822	10581234	6996;7374	TDG;uracil-DNA glycosylase	Despite low sequence homology , the ***MUG/TDG*** enzymes are structurally ***related*** to the ***uracil-DNA glycosylase*** enzymes , but have a very different mechanism for substrate recognition .	parallel	0
8823	10581242	4790;4792	NF-kappaB;IkappaBalpha	***NF-kappaB*** ( p65 ) ***association*** with ***IkappaBalpha*** affects steady-state localization but does not inhibit its shuttling .	parallel	0
8824	10581242	4790;4792	NF-kappaB;IkappaBalpha	Endogenous ***complexes*** of ******IkappaBalpha-NF-kappaB****** shuttle and will accumulate in the nucleus when CRM1 export is blocked .	parallel	1
8825	10581242	4790;4792	NF-kappaB;IkappaBalpha	We find TNFalpha can activate the nuclear ******IkappaBalpha-NF-kappaB****** ***complexes*** by the classical mechanism of proteasome-mediated degradation of IkappaBalpha .	parallel	1
8826	10581242	7124;4792	TNFalpha;IkappaBalpha	We find ***TNFalpha*** can ***activate*** the nuclear ***IkappaBalpha-NF-kappaB*** complexes by the classical mechanism of proteasome-mediated degradation of IkappaBalpha .	positive	1
8827	10581242	7124;4790	TNFalpha;NF-kappaB	We find ***TNFalpha*** can ***activate*** the nuclear ***IkappaBalpha-NF-kappaB*** complexes by the classical mechanism of proteasome-mediated degradation of IkappaBalpha .	positive	1
8828	10581243	10010;29110	TANK;TBK1	We find that ***TANK*** ***interacts*** with ***TBK1*** ( TANK-binding kinase 1 ) , a novel IKK-related kinase that can activate NF-kappaB in a kinase-dependent manner .	parallel	1
8829	10581243	10010;29110	TANK;TBK1	***TBK1*** , ***TANK*** and TRAF2 can form a ternary ***complex*** , and complex formation appears to be required for TBK1 activity .	parallel	1
8830	10581243	7186;10010	TRAF2;TANK	TBK1 , ***TANK*** and ***TRAF2*** can form a ternary ***complex*** , and complex formation appears to be required for TBK1 activity .	parallel	1
8831	10581243	7186;29110	TRAF2;TBK1	***TBK1*** , TANK and ***TRAF2*** can form a ternary ***complex*** , and complex formation appears to be required for TBK1 activity .	parallel	1
8832	10581243	29110;4790	TBK1;NF-kappaB	Kinase-inactive ***TBK1*** ***inhibits*** TANK-mediated ***NF-kappaB*** activation but does not block the activation mediated by TNF-alpha , IL-1 or CD40 .	negative	1
8833	10581243	10010;7186	TANK;TRAF2	The ******TBK1-TANK-TRAF2****** signaling ***complex*** functions upstream of NIK and the IKK complex and represents an alternative to the receptor signaling complex for TRAF-mediated activation of NF-kappaB .	parallel	1
8834	10581243	29110;10010	TBK1;TANK	The ******TBK1-TANK-TRAF2****** signaling ***complex*** functions upstream of NIK and the IKK complex and represents an alternative to the receptor signaling complex for TRAF-mediated activation of NF-kappaB .	parallel	1
8835	10581243	29110;7186	TBK1;TRAF2	The ******TBK1-TANK-TRAF2****** signaling ***complex*** functions upstream of NIK and the IKK complex and represents an alternative to the receptor signaling complex for TRAF-mediated activation of NF-kappaB .	parallel	1
8836	10581250	920;3700	CD4;gp120	In conclusion , HIV-1 attachment to target cells is a multi-step process that requires an initial CypA-heparan interaction followed by the ******gp120-CD4****** ***interaction*** .	parallel	1
8837	10581258	1432;7157	p38;p53	***Phosphorylation*** of human ***p53*** by ***p38*** kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation .	target	1
8838	10581258	1432;7157	p38;p53	In MCF-7 cells , ***p38*** kinase ***activated*** ***p53*** more effectively than other members of the ras pathway .	positive	1
8839	10581266	3320;983	Hsp90;Cdc2	Hsp90 complexes are required for CDK regulation ; the synergy found between the excess of Wos2 and a deficiency in Hsp90 activity suggests that Wos2 could specifically interfere with the ***Hsp90-dependent*** ***regulation*** of ***Cdc2*** .	target	1
8840	10581275	40;2040	degenerin;stomatin	A ***stomatin*** and a ***degenerin*** ***interact*** to control anesthetic sensitivity in Caenorhabditis elegans .	parallel	1
8841	10581359	19;6041	ABC1;RNAseL	At present the MDR/TAP , the ALD , the MRP/CFTR , the ***ABC1*** , the White , the ***RNAseL*** ***inhibitor*** , the ANSA , and the GCN20 subfamilies are identified .	negative	1
8842	10581359	215;6041	ALD;RNAseL	At present the MDR/TAP , the ***ALD*** , the MRP/CFTR , the ABC1 , the White , the ***RNAseL*** ***inhibitor*** , the ANSA , and the GCN20 subfamilies are identified .	negative	1
8843	10581359	1080;6041	CFTR;RNAseL	At present the MDR/TAP , the ALD , the ***MRP/CFTR*** , the ABC1 , the White , the ***RNAseL*** ***inhibitor*** , the ANSA , and the GCN20 subfamilies are identified .	negative	1
8844	10581359	4363;6041	MRP;RNAseL	At present the MDR/TAP , the ALD , the ***MRP/CFTR*** , the ABC1 , the White , the ***RNAseL*** ***inhibitor*** , the ANSA , and the GCN20 subfamilies are identified .	negative	1
8845	10581390	10379;3439	p48;IFN	Even after IFN treatment a drastic decrease in STAT-1alpha ( signal transducers and activators of transcription-1alpha ) , STAT-2 and ***p48*** ( ISGF-3gamma : IFN-stimulated gene factor-3gamma ) , which are closely ***correlated*** with the ***IFN-signaling*** pathway , was found in these persistently infected cells ( Akata-MP1 and K-MTP ) .	parallel	0
8846	10581390	6773;3439	STAT-2;IFN	Even after IFN treatment a drastic decrease in STAT-1alpha ( signal transducers and activators of transcription-1alpha ) , ***STAT-2*** and p48 ( ISGF-3gamma : IFN-stimulated gene factor-3gamma ) , which are closely ***correlated*** with the ***IFN-signaling*** pathway , was found in these persistently infected cells ( Akata-MP1 and K-MTP ) .	parallel	0
8847	10581407	9479;5599	JNK interacting protein-1;JNK	Expression of ***JNK interacting protein-1*** ( JIP-1 ) , which ***facilitates*** ***JNK*** signaling , remained unchanged in post-ischemic hippocampal neurons .	positive	0
8848	10582246	4792;7341	I kappa B alpha;SUMO-1	We have detected a modified form of ***I kappa B alpha*** , ***conjugated*** to the small ubiquitin-like protein ***SUMO-1*** , which is resistant to signal-induced degradation .	parallel	1
8849	10582246	10477;4792	Ubch9;I kappa B alpha	Reconstitution of the conjugation reaction with highly purified proteins demonstrated that in the presence of a novel E1 SUMO-1 activating enzyme , ***Ubch9*** directly ***conjugated*** SUMO-1 to ***I kappa B alpha*** on residues K21 and K22 , which are also used for ubiquitin modification .	parallel	1
8850	10582246	4790;4792	NF-kappa B;I kappa B alpha	An autoregulatory loop is established when ***NF-kappa B*** ***induces*** expression of the ***I kappa B alpha*** gene and newly synthesized I kappa B alpha accumulates in the nucleus where it negatively regulates NF-kappa B-dependent transcription .	target	1
8851	10582246	4792;4790	I kappa B alpha;NF-kappa B	As part of this post-induction repression , the nuclear export signal on I kappa B alpha mediates transport of ******NF-kappa B-I kappa B alpha****** ***complexes*** from the nucleus to the cytoplasm .	parallel	1
8852	10582338	3815;4254	C-kit;stem cell factor	The biology of ***stem cell factor*** and its ***receptor*** ***C-kit*** .	parallel	1
8853	10582338	4254;3815	stem cell factor;C-kit	The receptor tyrosine kinase ***C-kit*** and its ***ligand*** ***stem cell factor*** ( SCF ) are essential for haemopoiesis , melanogenesis and fertility .	parallel	1
8854	10582339	4254;3815	SCF;c-Kit	***Interaction*** of ***SCF*** with ***c-Kit*** rapidly induces receptor dimerization and increases in autophosphorylation activity .	parallel	1
8855	10582340	2057;2056	EpoR;erythropoietin	Biochemical and structural analysis of the ***erythropoietin*** ***receptor*** ( ***EpoR*** ) is revealing the molecular mechanisms of EpoR function , leading the way to the development of small molecule Epo mimetics .	parallel	1
8856	10582341	2056;2057	erythropoietin;EpoR	The proliferation and differentiation of erythroid cells is a highly regulated process that is controlled primarily at the level of ***interaction*** of ***erythropoietin*** ( Epo ) with its specific cell surface receptor ( ***EpoR*** ) .	parallel	1
8857	10582341	30816;2057	envelope glycoprotein;EpoR	The studies have revealed that SFFV encodes a unique ***envelope glycoprotein*** which ***interacts*** specifically with the ***EpoR*** at the cell surface , resulting in activation of the receptor and subsequent activation of erythroid signal transduction pathways .	parallel	1
8858	10582341	30816;2057	envelope glycoprotein;EpoR	While ***interaction*** of the SFFV ***envelope glycoprotein*** with the ***EpoR*** leads to Epo-independent erythroid hyperplasia , this is not sufficient to transform these cells .	parallel	1
8859	10582342	7018;7037	transferrin;transferrin receptor	Iron uptake from transferrin involves the ***binding*** of ***transferrin*** to the ***transferrin receptor*** , internalization of transferrin within an endocytic vesicle by receptor-mediated endocytosis and the release of iron from the protein by a decrease in endosomal pH.	parallel	1
8860	10582591	5781;2781	SHP-2;transducin-alpha	***Association*** of the tyrosine phosphatase ***SHP-2*** with ***transducin-alpha*** and a 97-kDa tyrosine-phosphorylated protein in photoreceptor rod outer segments .	parallel	0
8861	10582591	5781;2781	SHP-2;transducin-alpha	***SHP-2*** ***associated*** with ***transducin-alpha*** and a 97-kDa tyrosine-phosphorylated protein in ROS , suggesting the formation of a multimeric signaling complex .	parallel	0
8862	10582593	6387;7852	stromal cell-derived factor 1;CXCR4	Glial and neuronal cells express functional chemokine receptor ***CXCR4*** and its natural ***ligand*** ***stromal cell-derived factor 1*** .	parallel	1
8863	10582594	1956;6464	ErbB;Shc	Neuregulin-increased expression of acetylcholine receptor epsilon-subunit gene requires ***ErbB*** ***interaction*** with ***Shc*** .	parallel	1
8864	10582606	581;596	Bax;Bcl-2	Relevant to the neuroprotective effects of Bcl-2 in transgenic mSOD1 mice , overexpression of Bcl-2 ***increases*** the formation of ***Bcl-2*** : ***Bax*** heterodimers , which abolish the Bax proapoptotic property .	positive	0
8865	10582686	4074;3481	M6PR;IGF-II	The insulin-like growth factor-II/mannose -6 phosphate receptor ( ***IGF-II/M6PR*** ) is believed to ***bind*** and degrade the potent mitogen ***IGF-II*** , a growth factor for many tumors .	parallel	1
8866	10582705	3725;4790	AP-1;NF-kappaB	Point-mutated luciferase reporter studies indicated that AP-1 and NF-kappaB-like factor binding elements were mainly responsible for hypoxia-induced increase in IL-8 gene expression in human ovarian cancer cells , and that IL-8 transcription activation by hypoxia required the ***cooperation*** of ***NF-kappaB*** and ***AP-1*** binding sites .	parallel	0
8867	10582705	3576;3725	IL-8;AP-1	Point-mutated luciferase reporter studies indicated that AP-1 and NF-kappaB-like factor binding elements were mainly responsible for hypoxia-induced increase in IL-8 gene expression in human ovarian cancer cells , and that ***IL-8*** transcription activation by hypoxia ***required*** the cooperation of NF-kappaB and ***AP-1*** binding sites .	target	0
8868	10582705	3576;4790	IL-8;NF-kappaB	Point-mutated luciferase reporter studies indicated that AP-1 and NF-kappaB-like factor binding elements were mainly responsible for hypoxia-induced increase in IL-8 gene expression in human ovarian cancer cells , and that ***IL-8*** transcription activation by hypoxia ***required*** the cooperation of ***NF-kappaB*** and AP-1 binding sites .	target	0
8869	10582706	3091;7157	HIF-1alpha;p53	***HIF-1alpha*** expression was ***correlated*** with aberrant ***p53*** accumulation and cell proliferation .	parallel	0
8870	10582791	3815;4254	c-kit;SCF	The ***SCF*** and its ***receptor*** ***c-kit*** are an appropriate example to illustrate the role of signalling molecules in the physiology and pathology of spermatogenesis .	parallel	1
8871	10583160	7039;1956	transforming growth factor-alpha;EGFR	Among factors which may be related to hyperplasia of psoriatic keratinocytes is the persistent autocrine ***stimulation*** of the epidermal growth factor receptor ( ***EGFR*** ) by ***transforming growth factor-alpha*** .	positive	0
8872	10583368	174;596	AFP;Bcl-2	***AFP*** treatment of Raji cells ***increased*** ***Bcl-2*** protein , showing that AFP-induced apoptosis is not explained by downregulation of the Bcl-2 gene .	positive	0
8873	10583368	174;356	AFP;Fas ligand	***AFP*** notably ***decreased*** basal levels of soluble and membrane-bound ***Fas ligand*** .	negative	0
8874	10583401	2159;3817	factor Xa;hK2	The purified mutant ***hK2*** may be ***activated*** by either enterokinase or ***factor Xa*** to generate an enzyme for use in functional studies with the characteristics of the original wild-type protein .	positive	1
8875	10583422	183;2056	Angiotensin II;erythropoietin	***Angiotensin II*** ***increases*** ***erythropoietin*** production in healthy human volunteers .	positive	0
8876	10583479	4804;627	p75NTR;neurotrophin	Recent studies have demonstrated that Nerve growth factor ( NGF ) induces apoptosis of several cell types in the central nervous system through its low-affinity p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) .	parallel	1
8877	10583479	4803;4804	NGF;p75NTR	This pro-apoptotic effect was completely reversed by the blocking anti-p75NTR ( REX ) antibody which inhibits ***NGF*** ***binding*** to ***p75NTR*** .	parallel	1
8878	10583479	4804;4803	p75NTR;NGF	This pro-apoptotic effect was completely reversed by the blocking ***anti-p75NTR*** ( REX ) antibody which ***inhibits*** ***NGF*** binding to p75NTR .	negative	1
8879	10583502	3082;4233	HGF;c-met	Administration of ***HGF*** ***reduced*** this ***c-met*** upregulation almost to normal levels .	negative	1
8880	10583597	3606;3458	interleukin-18;IFN-gamma	Recent in vitro studies have demonstrated that interleukin-12 ( IL-12 ) and ***interleukin-18*** ( IL-18 ) synergistically ***up-regulate*** ***IFN-gamma*** secretion .	positive	1
8881	10583598	5617;3458	PRL;interferon-gamma	As ***PRL*** has been shown to ***up-regulate*** the production of ***interferon-gamma*** ( IFN-gamma ) by peripheral blood mononuclear cells , we studied its effect on IFN-gamma production by NK cells as a possible mechanism of autocrine activation of cytotoxicity .	positive	1
8882	10583598	5617;3458	PRL;IFN-gamma	Released and intracellular IFN-gamma , as well as ***IFN-gamma*** mRNA expression , were ***increased*** by pituitary and recombinant human ***PRL*** , which stimulated optimal NK and LAK cytotoxicity .	positive	0
8883	10583602	1493;941	CTLA-4;CD80	It is concluded that ***interaction*** of ***CTLA-4*** with its functional ligands , ***CD80*** or CD86 , can down-regulate human T-cell responses , probably by intracellular signalling events and independent of CD28 occupancy .	parallel	1
8884	10583602	1493;942	CTLA-4;CD86	It is concluded that ***interaction*** of ***CTLA-4*** with its functional ligands , CD80 or ***CD86*** , can down-regulate human T-cell responses , probably by intracellular signalling events and independent of CD28 occupancy .	parallel	1
8885	10583602	1493;941	CTLA-4;CD80	***Interaction*** of ***CTLA-4*** ( CD152 ) with ***CD80*** or CD86 inhibits human T-cell activation .	parallel	1
8886	10583602	1493;942	CTLA-4;CD86	***Interaction*** of ***CTLA-4*** ( CD152 ) with CD80 or ***CD86*** inhibits human T-cell activation .	parallel	1
8887	10583729	117;116	PAC1;pituitary adenylate cyclase-activating polypeptide	Three full-length cDNAs encoding functional splice variants of the ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) type 1 ***receptor*** ( ***PAC1*** ) were isolated from Y-79 retinoblastoma cells and human cerebellum .	parallel	1
8888	10583731	1393;1392	CRF-BP;CRF	corticotropin-releasing factor-binding protein ( ***CRF-BP*** ) is known to ***regulate*** the bioavailability of ***CRF*** and may also play a role in stress behaviours .	target	1
8889	10583731	3569;1393	IL6;CRF-BP	Twenty-four hour treatment with 30 microM forskolin , 1000 nM CRF , 50 nM TPA , 100 pM ***IL6*** or 100 nM dexamethasone significantly ***increased*** ***CRF-BP*** expression ( P < 0.05 , n = 3 for each treatment ) .	positive	0
8890	10584265	4915;627	TrkB;BDNF	This positive effect is probably dependent on the cross-signaling between ***BDNF*** and its specific ***receptor*** ***TrkB*** .	parallel	1
8891	10584701	4193;7157	mdm2;p53	Thus , altered p53 pathways , such as p53 gene mutation and ***mdm2-mediated*** ***inactivation*** of ***p53*** , may play a pathogenetic role in this form of tumor progression showing myxoid MFH-like morphology in liposarcoma , as has been suggested in dedifferentiated liposarcoma .	negative	1
8892	10585263	596;581	Bcl-2;Bax	Overexpression of ***Bcl-2*** not only suppressed apoptosis but also completely ***prevented*** induction of p21 and ***Bax*** caused by ceramide in SK-Hep-1 cells .	negative	0
8893	10585263	596;1026	Bcl-2;p21	Overexpression of ***Bcl-2*** not only suppressed apoptosis but also completely ***prevented*** induction of ***p21*** and Bax caused by ceramide in SK-Hep-1 cells .	negative	0
8894	10585263	1026;596	p21;Bcl-2	Furthermore , overexpression of ***p21*** ***antagonized*** the death-protective function of ***Bcl-2*** and upregulated expression of Bax protein .	negative	1
8895	10585263	1026;596	p21;Bcl-2	***p21*** promotes ceramide-induced apoptosis and ***antagonizes*** the antideath effect of ***Bcl-2*** in human hepatocarcinoma cells .	negative	1
8896	10585273	1017;595	Cdk2;cyclin D1	***Cdk2*** protein was dramatically decreased in senescent cells and ***complexed*** primarily with ***cyclin D1*** and p21 .	parallel	1
8897	10585273	1017;1026	Cdk2;p21	***Cdk2*** protein was dramatically decreased in senescent cells and ***complexed*** primarily with cyclin D1 and ***p21*** .	parallel	1
8898	10585273	1029;1019	p16;Cdk4	Thus , one of the underlying molecular events involved in replicative senescence is the impaired activation of Cdk4 and Cdk2 due to increased ***binding*** of ***p16*** to ***Cdk4*** and increased association of Cdk2 with cyclin D1 and p21 .	parallel	1
8899	10585273	1017;595	Cdk2;cyclin D1	Thus , one of the underlying molecular events involved in replicative senescence is the impaired activation of Cdk4 and Cdk2 due to increased binding of p16 to Cdk4 and increased ***association*** of ***Cdk2*** with ***cyclin D1*** and p21 .	parallel	0
8900	10585273	1017;1026	Cdk2;p21	Thus , one of the underlying molecular events involved in replicative senescence is the impaired activation of Cdk4 and Cdk2 due to increased binding of p16 to Cdk4 and increased ***association*** of ***Cdk2*** with cyclin D1 and ***p21*** .	parallel	0
8901	10585280	1029;1017	p16;CDK2	Here we present evidence that activation of a cAMP pathway correlates with multiple cellular changes in these cells : ( 1 ) increased expression of the transcription factor microphthalmia ; ( 2 ) increased melanogenesis ; ( 3 ) increased ***association*** of the cyclin-dependent kinase inhibitors ( CDK-Is ) p27 ( KIP1 ) and ***p16*** ( INK4 ) with ***CDK2*** and CDK4 , respectively ; ( 4 ) failure to phosphorylate the retinoblastoma protein ( pRB ) ; ( 5 ) decreased expression of E2F1 , E2F2 , and E2F4 proteins ; ( 6 ) loss of E2F DNA-binding activity ; and ( 7 ) phenotypic changes characteristic of senescent cells .	parallel	0
8902	10585280	1029;1019	p16;CDK4	Here we present evidence that activation of a cAMP pathway correlates with multiple cellular changes in these cells : ( 1 ) increased expression of the transcription factor microphthalmia ; ( 2 ) increased melanogenesis ; ( 3 ) increased ***association*** of the cyclin-dependent kinase inhibitors ( CDK-Is ) p27 ( KIP1 ) and ***p16*** ( INK4 ) with CDK2 and ***CDK4*** , respectively ; ( 4 ) failure to phosphorylate the retinoblastoma protein ( pRB ) ; ( 5 ) decreased expression of E2F1 , E2F2 , and E2F4 proteins ; ( 6 ) loss of E2F DNA-binding activity ; and ( 7 ) phenotypic changes characteristic of senescent cells .	parallel	0
8903	10585285	3481;1026	IGF-II;p21	The results show that the induction of ***p21*** by TSA can be ***modulated*** by additions of ***IGF-II*** whereas addition of TGFbeta1 affects its own expression but not p21 .	target	0
8904	10585285	3481;1026	IGF-II;p21	***IGF-II*** ***enhances*** trichostatin A-induced TGFbeta1 and ***p21*** ( Waf1 , Cip1 , sdi1 ) expression in Hep3B cells .	positive	0
8905	10585289	284;207	angiopoietin-1;Akt	Ceramide induced endothelial cell death and abolished ***angiopoietin-1-mediated*** ***activation*** of ***Akt*** and the effect on cell survival .	positive	1
8906	10585352	7018;7037	transferrin;transferrin receptor	Increased serum ***transferrin*** saturation is ***associated*** with lower serum ***transferrin receptor*** concentration .	parallel	0
8907	10585406	7040;1026	TGF-beta;p21	Constitutively active components in the MAPK pathway activate p21 expression , and inhibitors or dominant negative constructs for the MAPK pathway significantly decrease ***p21*** ***induction*** by ***TGF-beta*** .	target	1
8908	10585421	3569;6774	il-6;STAT3	The inhibitory effect of PE on ***il-6*** ***activation*** of ***STAT3*** was also abolished by the tyrosine phosphatase inhibitor sodium vanadate , indicating involvement of protein tyrosine phosphatases .	positive	1
8909	10585421	5604;6774	MEK1;STAT3	Furthermore , preincubation of the cells with the specific MEK1 inhibitor PD98059 or a dominant negative MEK1 reversed the inhibitory effect of PE , and expression of constitutively activated ***MEK1*** alone ***abolished*** il-6-activated ***STAT3*** .	negative	0
8910	10585421	3569;6774	il-6;STAT3	Taken together , these data indicate that PE inhibits ***il-6*** ***activation*** of ***STAT3*** in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism , and tyrosine phosphatases are involved .	positive	1
8911	10585426	5594;1848	ERK2;MKP3	The ***binding*** of ***ERK2*** to the N-terminal domain of ***MKP3*** facilitates the repositioning of active site residues and speeds up the loop closure in MKP3 such that chemistry becomes rate-limiting in the presence of ERK2 .	parallel	1
8912	10585427	1432;3661	p38;interferon regulatory factor 3	***p38-dependent*** ***activation*** of ***interferon regulatory factor 3*** by lipopolysaccharide .	positive	1
8913	10585430	8651;3717	SOCS-1;JAK2	SOCS-1 , SOCS-2 , SOCS-3 , and CIS each strongly inhibited the GH receptor ( GHR ) - dependent tyrosine phosphorylation of JAK2 seen at low levels of transfected JAK2 ; however , only ***SOCS-1*** strongly ***inhibited*** the GHR-independent tyrosine phosphorylation of ***JAK2*** seen at higher JAK2 levels .	negative	1
8914	10585430	1154;2690	CIS;GHR	SOCS-1 , SOCS-2 , SOCS-3 , and ***CIS*** each strongly ***inhibited*** the GH receptor ( ***GHR*** ) - dependent tyrosine phosphorylation of JAK2 seen at low levels of transfected JAK2 ; however , only SOCS-1 strongly inhibited the GHR-independent tyrosine phosphorylation of JAK2 seen at higher JAK2 levels .	negative	1
8915	10585430	8651;2690	SOCS-1;GHR	***SOCS-1*** , SOCS-2 , SOCS-3 , and CIS each strongly ***inhibited*** the GH receptor ( ***GHR*** ) - dependent tyrosine phosphorylation of JAK2 seen at low levels of transfected JAK2 ; however , only SOCS-1 strongly inhibited the GHR-independent tyrosine phosphorylation of JAK2 seen at higher JAK2 levels .	negative	1
8916	10585430	8835;2690	SOCS-2;GHR	SOCS-1 , ***SOCS-2*** , SOCS-3 , and CIS each strongly ***inhibited*** the GH receptor ( ***GHR*** ) - dependent tyrosine phosphorylation of JAK2 seen at low levels of transfected JAK2 ; however , only SOCS-1 strongly inhibited the GHR-independent tyrosine phosphorylation of JAK2 seen at higher JAK2 levels .	negative	1
8917	10585430	9021;2690	SOCS-3;GHR	SOCS-1 , SOCS-2 , ***SOCS-3*** , and CIS each strongly ***inhibited*** the GH receptor ( ***GHR*** ) - dependent tyrosine phosphorylation of JAK2 seen at low levels of transfected JAK2 ; however , only SOCS-1 strongly inhibited the GHR-independent tyrosine phosphorylation of JAK2 seen at higher JAK2 levels .	negative	1
8918	10585430	2690;3717	GHR;JAK2	SOCS/CIS proteins can thus inhibit GH signaling to STAT5b by three distinct mechanisms , distinguished by their molecular targets within the ******GHR-JAK2****** signaling ***complex*** , as exemplified by SOCS-1 ( direct JAK2 kinase inhibition ) , SOCS-3 ( inhibition of JAK2 signaling via membrane-proximal GHR tyrosines 333 and 338 ) , and CIS and SOCS-2 ( inhibition via membrane-distal tyrosine ( s ) ) .	parallel	1
8919	10585430	9021;3717	SOCS-3;JAK2	SOCS/CIS proteins can thus inhibit GH signaling to STAT5b by three distinct mechanisms , distinguished by their molecular targets within the GHR-JAK2 signaling complex , as exemplified by SOCS-1 ( direct JAK2 kinase inhibition ) , ***SOCS-3*** ( ***inhibition*** of ***JAK2*** signaling via membrane-proximal GHR tyrosines 333 and 338 ) , and CIS and SOCS-2 ( inhibition via membrane-distal tyrosine ( s ) ) .	negative	1
8920	10585435	5970;598	p65;bcl-x	Co-transfection experiment using a bcl-x promoter reporter construct and an expression vector for NF-kappaB p50 or p65 indicates that ***p65*** , but not p50 , ***up-regulates*** the promoter activity of the ***bcl-x*** gene .	positive	1
8921	10585438	4790;1385	NF-kappaB;CREB	Stimulation of Sertoli cells with tumor necrosis factor-alpha , an NF-kappaB-activating cytokine produced by round spermatids located adjacent to Sertoli cells , stimulated the elimination of IkappaB , the translocation of additional NF-kappaB to the nucleus , and increased ***NF-kappaB*** ***binding*** to ***CREB*** promoter kappaB enhancer elements .	parallel	1
8922	10585438	4790;1385	NF-kappaB;CREB	Furthermore , the CREB promoter is also inducible by NF-kappaB in NIH 3T3 cells suggesting that ***NF-kappaB*** may be a general ***regulator*** of ***CREB*** in non-testis tissues .	target	1
8923	10585443	7248;7249	hamartin;tuberin	Characterization of the cytosolic ******tuberin-hamartin****** ***complex*** .	parallel	1
8924	10585443	7248;7249	hamartin;tuberin	Previously , we demonstrated direct ***binding*** between ***tuberin*** and ***hamartin*** .	parallel	1
8925	10585446	2963;2967	TFIIF;TFIIH	We observe ( i ) that TFIIF suppresses the frequency of abortive transcription by very early RNA polymerase II elongation intermediates by increasing their processivity and ( ii ) that ***TFIIF*** ***cooperates*** with ***TFIIH*** to prevent premature arrest of early elongation intermediates .	parallel	0
8926	10585452	2887;5604	Grb10;MEK1	We have recently demonstrated that the ***Grb10*** SH2 domain ***interacts*** with both the Raf-1 and ***MEK1*** kinases .	parallel	1
8927	10585452	2887;5894	Grb10;Raf-1	We have recently demonstrated that the ***Grb10*** SH2 domain ***interacts*** with both the ***Raf-1*** and MEK1 kinases .	parallel	1
8928	10585456	183;5972	angiotensinogen;renin	***angiotensinogen*** ( ANG ) is the specific ***substrate*** of the ***renin-angiotensin*** system , a major participant in blood pressure control .	parallel	1
8929	10585464	7295;7157	TRX;p53	Hence , ***TRX-dependent*** redox ***regulation*** of ***p53*** activity indicates coupling of the oxidative stress response and p53-dependent repair mechanism .	target	1
8930	10585464	328;3725	redox factor 1;Jun	TRX also interacts with an intranuclear reducing molecule ***redox factor 1*** ( Ref-1 ) , which ***enhances*** the activity of ***Jun/Fos*** .	positive	0
8931	10585464	7295;7157	TRX;p53	Electrophoretic mobility shift assay showed that ***TRX*** ***augmented*** the DNA binding activity of ***p53*** and also further potentiated Ref-1-enhanced p53 activity .	positive	0
8932	10585464	7295;7157	TRX;p53	Electrophoretic mobility shift assay showed that ***TRX*** augmented the DNA binding activity of p53 and also further ***potentiated*** Ref-1-enhanced ***p53*** activity .	positive	0
8933	10585464	7295;1026	TRX;p21	Luciferase assay revealed that transfection of ***TRX*** ***enhanced*** p53-dependent expression of ***p21*** and further intensified Ref-1-mediated p53 activation .	positive	0
8934	10585464	7157;1026	p53;p21	Furthermore , Western blot analysis revealed that ***p53-dependent*** ***induction*** of ***p21*** protein was also facilitated by transfection with TRX .	target	1
8935	10585464	7295;328	TRX;Ref-1	Overexpression of transdominant negative mutant TRX ( mTRX ) suppressed the effects of TRX or Ref-1 , showing a functional ***interaction*** between ***TRX*** and ***Ref-1*** .	parallel	1
8936	10585464	7295;328	TRX;Ref-1	Overexpression of transdominant negative mutant ***TRX*** ( mTRX ) ***suppressed*** the effects of TRX or ***Ref-1*** , showing a functional interaction between TRX and Ref-1 .	negative	1
8937	10585470	5777;10657	SHP-1;p62	***SHP-1*** ***regulation*** of ***p62*** ( DOK ) tyrosine phosphorylation in macrophages .	target	1
8938	10585470	5777;10657	SHP-1;p62	In both cell types , the ***interaction*** of ***SHP-1*** with ***p62*** ( DOK ) occurred independently of p62 ( DOK ) tyrosine phosphorylation , but only the tyrosine-phosphorylated p62 ( DOK ) was bound by SHP-1 C453S in a far Western analysis .	parallel	1
8939	10585470	10657;5777	p62;SHP-1	These findings suggest a constitutive ***association*** of ***SHP-1*** and ***p62*** ( DOK ) that is either conformation-dependent or indirect as well as a direct , inducible association of the SHP-1 catalytic domain with tyrosine-phosphorylated p62 ( DOK ) .	parallel	0
8940	10585470	5777;10657	SHP-1;p62	These findings suggest a constitutive association of SHP-1 and p62 ( DOK ) that is either conformation-dependent or indirect as well as a direct , inducible ***association*** of the ***SHP-1*** catalytic domain with tyrosine-phosphorylated ***p62*** ( DOK ) .	parallel	0
8941	10585480	10174;7414	Vinexin;vinculin	***Vinexin*** , a novel protein that plays a key role in cell spreading and cytoskeletal organization , contains three SH3 domains and ***binds*** to ***vinculin*** through its first and second SH3 domains .	parallel	1
8942	10585480	10174;5599	vinexin beta;JNK	Exogenous expression of ***vinexin beta*** in NIH/3T3 cells ***enhanced*** ***JNK/SAPK*** activation but did not affect Erk activation .	positive	0
8943	10585480	10174;5601	vinexin beta;SAPK	Exogenous expression of ***vinexin beta*** in NIH/3T3 cells ***enhanced*** ***JNK/SAPK*** activation but did not affect Erk activation .	positive	0
8944	10585492	2690;3717	GHR;JAK2	The growth hormone receptor ( ***GHR*** ) , a cytokine receptor superfamily member , ***requires*** the ***JAK2*** tyrosine kinase for signaling .	target	0
8945	10585492	3976;2064	leukemia inhibitory factor;ErbB-2	Notably , ***leukemia inhibitory factor*** , but not interferon-gamma , also ***promoted*** ***ErbB-2*** shift and mitogen-activated protein kinase activation .	positive	0
8946	10585493	4738;8453	NEDD8;cullin-2	We have previously shown that human ***cullin-2*** ( Cul-2 ) is covalently ***modified*** at Lys-689 by ***NEDD8*** ( Wada , H. , Yeh , E.	target	0
8947	10585493	4738;8453	NEDD8;Cul-2	Furthermore , we used a pVHL-deficient cell line , 786-0 , to show that ***Cul-2*** is poorly but clearly ***conjugated*** by ***NEDD8*** , indicating that pVHL is not the only molecule that promotes NEDD8 conjugation to Cul-2 .	parallel	1
8948	10585493	4738;8453	NEDD8;Cul-2	Taken together , the VBC complex appears to have ligase activity in the ***conjugation*** of ***NEDD8*** to ***Cul-2*** .	parallel	1
8949	10585574	596;3308	bcl-2;HSP70	Our results suggest that HSP70 antisense oligomer treatment abrogates the expression of HSP70 protein that may disrupt ******HSP70-bcl-2****** ***interactions*** , in turn inhibiting cell proliferation and inducing apoptosis .	parallel	1
8950	10585574	3308;596	HSP70;bcl-2	Our results suggest that HSP70 antisense oligomer treatment abrogates the expression of ***HSP70*** protein that may ***disrupt*** ***HSP70-bcl-2*** interactions , in turn inhibiting cell proliferation and inducing apoptosis .	negative	0
8951	10585578	7422;2353	VEGF;c-fos	***VEGF*** also ***enhanced*** mitogen-activated protein kinase ( MAPK ) phosphorylation and ***c-fos*** induction in Capan-1 cells , whereas the MAPK kinase inhibitor PD98059 abolished the growth-stimulatory effect of VEGF .	positive	0
8952	10585590	7157;6648	p53;MnSOD	Interestingly , ***Ad-p53*** was able to ***inhibit*** TNF-induced ***MnSOD*** mRNA expression in MCF7/Adr cells , which might contribute to the sensitization of cells to the cytotoxic action of TNF .	negative	1
8953	10585616	2690;3485	GHBP;IGFBP-1 and -2	RESULTS : Non-diabetic obese subjects had increased free IGF-I and - II , total IGF-II , IGFBP-3 and ***GHBP*** , ***reduced*** ***IGFBP-1 and -2*** ( p < 0.05 ) , but normal total IGF-I , when compared to lean subjects .	negative	1
8954	10585616	3486;3485	IGFBP-3;IGFBP-1 and -2	RESULTS : Non-diabetic obese subjects had increased free IGF-I and - II , total IGF-II , ***IGFBP-3*** and GHBP , ***reduced*** ***IGFBP-1 and -2*** ( p < 0.05 ) , but normal total IGF-I , when compared to lean subjects .	negative	1
8955	10585767	26190;6500	Fwd2;Skp1	A coimmunoprecipitation assay has revealed the in vivo ***interaction*** between ***Skp1*** and ***Fwd2*** through the F-box domain .	parallel	1
8956	10585767	26190;8454	Fwd2;Cul1	***Fwd2*** also ***interacts*** with ***Cul1*** through Skp1 , suggesting that Skp1 , Cul1 , and the F-box protein Fwd2 form an SCF complex ( SCF ( Fwd2 ) ) .	parallel	1
8957	10585767	8454;26190	Cul1;Fwd2	Fwd2 also interacts with Cul1 through Skp1 , suggesting that Skp1 , ***Cul1*** , and the F-box protein ***Fwd2*** form an SCF ***complex*** ( SCF ( Fwd2 ) ) .	parallel	1
8958	10585767	8454;6500	Cul1;Skp1	Fwd2 also interacts with Cul1 through Skp1 , suggesting that ***Skp1*** , ***Cul1*** , and the F-box protein Fwd2 form an SCF ***complex*** ( SCF ( Fwd2 ) ) .	parallel	1
8959	10585767	6500;26190	Skp1;Fwd2	Fwd2 also interacts with Cul1 through Skp1 , suggesting that ***Skp1*** , Cul1 , and the F-box protein ***Fwd2*** form an SCF ***complex*** ( SCF ( Fwd2 ) ) .	parallel	1
8960	10585775	10891;5468	PPARGC1;peroxisome proliferator activated receptor gamma	Human ***peroxisome proliferator activated receptor gamma*** ***coactivator*** 1 ( ***PPARGC1*** ) gene : cDNA sequence , genomic organization , chromosomal localization , and tissue expression .	positive	1
8961	10585775	10891;7350	Pgc1;uncoupling protein-1	Mouse peroxisome proliferator activated receptor gamma coactivator 1 ( ***Pgc1*** ) has been reported to ***enhance*** the expression of ***uncoupling protein-1*** , a key mediator of thermogenesis in brown adipose tissue ( Puigserver et al. , 1998 , Cell 92 , 829-839 ) .	positive	0
8962	10585775	10891;5468	Pgc1;peroxisome proliferator activated receptor gamma	Mouse ***peroxisome proliferator activated receptor gamma*** ***coactivator*** 1 ( ***Pgc1*** ) has been reported to enhance the expression of uncoupling protein-1 , a key mediator of thermogenesis in brown adipose tissue ( Puigserver et al. , 1998 , Cell 92 , 829-839 ) .	positive	1
8963	10585851	3479;2305	insulin-like growth factor 1;INS-1	Moreover , glucose-dependent rGH-induced ***INS-1*** cell proliferation was ***increased*** further by addition of ***insulin-like growth factor 1*** ( IGF-1 ; 10 nM ) to > 90-fold at 12 mM glucose .	positive	0
8964	10585866	3458;3713	IFN-gamma;involucrin	In contrast , transfection of a STAT1 dominant-negative expression vector suppressed the ***IFN-gamma-dependent*** ***up-regulation*** of ***involucrin*** promoter activity .	positive	1
8965	10585866	3458;3713	IFN-gamma;involucrin	These results indicate that ***IFN-gamma*** ***stimulates*** expression of the human ***involucrin*** gene via the G1 ( -883 to -874 ) region of the involucrin gene promoter .	positive	0
8966	10585866	3458;3713	Interferon-gamma;involucrin	***Interferon-gamma-dependent*** ***stimulation*** of human ***involucrin*** gene expression : STAT1 ( signal transduction and activators of transcription 1 ) protein activates involucrin promoter activity .	positive	0
8967	10585866	3458;3713	IFN-gamma;involucrin	Northern blot analyses revealed that ***IFN-gamma*** ***increased*** the expression of ***involucrin*** mRNA .	positive	0
8968	10585866	3458;3713	IFN-gamma;involucrin	Deletion analyses of the p2463Luc vector revealed that the G1 region is critical for the ***IFN-gamma-dependent*** ***up-regulation*** of the ***involucrin*** gene .	positive	1
8969	10585876	6720;118	SREBP-1c;ADD1	Co-immunoprecipitation studies using in vitro-translated proteins demonstrated further the physical ***interaction*** of Id and ******ADD1/SREBP-1c****** proteins in the absence of DNA .	parallel	1
8970	10585878	4803;6714	NGF;Src	NE , UTP , EGF and ***NGF*** all ***increased*** tyrosine phosphorylation of ***Src*** , and this was inhibited by the Src inhibitor PP2 .	positive	0
8971	10585882	3458;6610	IFN-gamma;neutral sphingomyelinase	***IFN-gamma*** was found to ***increase*** selectively the activity of cytosolic , Mg ( 2 + ) - independent , ***neutral sphingomyelinase*** .	positive	0
8972	10586033	3702;3702	Itk;kinase Emt	Regulated ***association*** between the tyrosine ******kinase Emt/Itk/Tsk****** and phospholipase-C gamma 1 in human T lymphocytes .	parallel	0
8973	10586033	5335;3702	phospholipase-C gamma 1;kinase Emt	Regulated ***association*** between the tyrosine ***kinase Emt/Itk/Tsk*** and ***phospholipase-C gamma 1*** in human T lymphocytes .	parallel	0
8974	10586033	3702;5335	Itk;phospholipase-C gamma 1	***Modulation*** of TCR/CD3-induced ***phospholipase-C gamma 1*** ( PLC gamma 1 ) activity by the tyrosine ***kinase Emt/Itk/Tsk*** has been demonstrated based on studies of Itk-deficient murine T lymphocytes .	target	0
8975	10586038	3394;3659	ICSBP;IRF-1	In addition , ***ICSBP*** ***interacts*** with two IRF members , ***IRF-1*** and IRF-2 , which also have central roles in the regulation of cell-mediated immunity .	parallel	1
8976	10586038	3394;3660	ICSBP;IRF-2	In addition , ***ICSBP*** ***interacts*** with two IRF members , IRF-1 and ***IRF-2*** , which also have central roles in the regulation of cell-mediated immunity .	parallel	1
8977	10586038	6688;3662	PU.1;IRF-4	The IAD2 shares similar characteristics with the PEST domain that is essential for the ***interaction*** of ***PU.1*** with ***IRF-4*** .	parallel	1
8978	10586056	959;958	CD40 ligand;CD40	***Ligation*** of ***CD40*** by ***CD40 ligand*** on these cells results in microglial activation , as measured by TNF-alpha production and neuronal injury .	parallel	1
8979	10586056	958;7124	CD40;TNF-alpha	Taken together , these data show that ligation of microglial ***CD40*** ***triggers*** ***TNF-alpha*** release through the p44/42 MAPK pathway , an effect that can be opposed by TGF-beta1 and IL-10 .	positive	0
8980	10586058	1390;1385	CREM;CREB	The -180 site of the IL-2 promoter is the target of ******CREB/CREM****** ***binding*** in T cell anergy .	parallel	1
8981	10586058	1390;1385	CREM;CREB	However , the induction of anergy by prolonged stimulation through the TCR led to an increase in binding of only the ******CREB/CREM****** ***complex*** .	parallel	1
8982	10586058	1390;1385	CREM;CREB	However , the induction of anergy by prolonged stimulation through the TCR led to an increase in ***binding*** of only the ******CREB/CREM****** complex .	parallel	1
8983	10586058	1390;1385	CREM;CREB	Finally , an IL-2 promoter-driven reporter construct that contained a mutation that specifically reduced the binding of the ******CREB/CREM****** ***complex*** displayed a decreased ability to be affected by anergy , while a construct that contained a mutation that decreased the binding of the Jun-Jun/Oct complex was still susceptible to anergy .	parallel	1
8984	10586058	1390;1385	CREM;CREB	Finally , an IL-2 promoter-driven reporter construct that contained a mutation that specifically reduced the ***binding*** of the ******CREB/CREM****** complex displayed a decreased ability to be affected by anergy , while a construct that contained a mutation that decreased the binding of the Jun-Jun/Oct complex was still susceptible to anergy .	parallel	1
8985	10586060	3977;3976	LIFR;LIF	leukemia inhibitory factor ( LIF ) , cardiotrophin-1 , ciliary neurotrophic factor , and oncostatin M ( OSM ) lead to heterodimerization of ***LIF*** ***receptor*** ( ***LIFR*** ) or the OSM-specific receptor ( OSMR ) with glycoprotein ( gp ) 130 , the common receptor subunit for IL-6-type cytokines .	parallel	1
8986	10586060	6774;6772	STAT3;STAT1	The membrane-proximal region of LIFR or OSMR was crucial for the ability of such receptor complexes to induce DNA ***binding*** of ***STAT1*** and ***STAT3*** in COS-7 cells .	parallel	1
8987	10586069	3552;1673	IL-1alpha;hBD-2	However , ***hBD-2*** expression is rapidly ***induced*** by ***IL-1alpha*** stimulation or infection of those cells with enteroinvasive bacteria .	target	1
8988	10586083	4790;6347	NF-kappa B;Monocyte chemoattractant protein-1	***Monocyte chemoattractant protein-1*** , which is ***regulated*** by ***NF-kappa B*** , was decreased in allergen-treated c-Rel-deficient mice relative to wild-type controls .	target	1
8989	10586086	10747;5648	MASP-2;MASP-1	Upon activation of the MBL/MASPs/MAp19 complex , MASP-2 cleaves the fourth complement component C4 , while the role of MAp19 within the ******MBL/MASP-1/MASP-2****** / MAp19 ***complex*** remains to be clarified .	parallel	1
8990	10586086	10747;4153	MASP-2;MBL	Upon activation of the MBL/MASPs/MAp19 complex , MASP-2 cleaves the fourth complement component C4 , while the role of MAp19 within the ******MBL/MASP-1/MASP-2****** / MAp19 ***complex*** remains to be clarified .	parallel	1
8991	10586086	4153;5648	MBL;MASP-1	Upon activation of the MBL/MASPs/MAp19 complex , MASP-2 cleaves the fourth complement component C4 , while the role of MAp19 within the ******MBL/MASP-1/MASP-2****** / MAp19 ***complex*** remains to be clarified .	parallel	1
8992	10586089	3565;6356	IL-4;eotaxin	These results imply that TNF-alpha and ***IL-4*** ***stimulate*** expression of the ***eotaxin*** gene by activating NF-kappa B and STAT6 .	positive	0
8993	10586089	7124;6356	TNF-alpha;eotaxin	These results imply that ***TNF-alpha*** and IL-4 ***stimulate*** expression of the ***eotaxin*** gene by activating NF-kappa B and STAT6 .	positive	0
8994	10586089	4790;6356	NF-kappa B;eotaxin	***Activation*** of ***eotaxin*** gene transcription by ***NF-kappa B*** and STAT6 in human airway epithelial cells .	positive	1
8995	10586089	6778;6356	STAT6;eotaxin	***Activation*** of ***eotaxin*** gene transcription by NF-kappa B and ***STAT6*** in human airway epithelial cells .	positive	1
8996	10586089	3565;6356	IL-4;eotaxin	We focused on the molecular mechanisms of ***eotaxin*** gene ***regulation*** by TNF-alpha and ***IL-4*** in the airway epithelial cell line , BEAS-2B .	target	1
8997	10586089	7124;6356	TNF-alpha;eotaxin	We focused on the molecular mechanisms of ***eotaxin*** gene ***regulation*** by ***TNF-alpha*** and IL-4 in the airway epithelial cell line , BEAS-2B .	target	1
8998	10586089	3565;6356	IL-4;eotaxin	***eotaxin*** promoter activity was ***increased*** by TNF-alpha ( 2.5-fold ) and ***IL-4*** ( 1.5-fold ) , respectively .	positive	0
8999	10586089	7124;6356	TNF-alpha;eotaxin	***eotaxin*** promoter activity was ***increased*** by ***TNF-alpha*** ( 2.5-fold ) and IL-4 ( 1.5-fold ) , respectively .	positive	0
9000	10586107	3717;6772	Jak2;STAT1	Gene induction by type II IFN involves the ***phosphorylation*** of only ***STAT1*** by JAK1 and ***Jak2*** kinases .	target	1
9001	10586114	3562;5594	IL-3;p38	Despite the fact that ***IL-3*** did ***induce*** ***p38*** and ERK kinase activity , it was not able to enhance IL-6 protein secretion , which coincided with the inability of IL-3 to induce NFkappaB ( nuclear factor kappaB ) activation and IkappaB ( inhibitory protein kappaB ) degradation .	target	1
9002	10586290	7124;6347	Tumor necrosis factor-alpha;monocyte chemoattractant protein-1	***Tumor necrosis factor-alpha*** ***induces*** ***monocyte chemoattractant protein-1*** mRNA in a Schwann cell line .	target	1
9003	10586884	4211;5087	Meis1;Pbx1	We find that Meis1/2 expression is restricted to a proximal domain , coincident with the previously reported domain in which Pbx1 is localized to the nucleus , and resembling the distribution of the Drosophila homologues homothorax ( hth ) and extradenticle ( exd ) ; that ***Meis1*** ***regulates*** ***Pbx1*** activity by promoting nuclear import of the Pbx1 protein ; and that ectopic expression of Meis1 in chicken and hth in Drosophila disrupts distal limb development and induces distal-to-proximal transformations .	target	1
9004	10587185	940;3586	CD28;IL-10	Proliferation and production of interferon ( IFN ) - gamma , interleukin ( IL ) -2 , IL-4 , tumor necrosis factor ( TNF ) , and ***IL-10*** were ***stimulated*** by cross-linking of CD3 and ***CD28*** .	positive	0
9005	10587185	940;3565	CD28;IL-4	Proliferation and production of interferon ( IFN ) - gamma , interleukin ( IL ) -2 , ***IL-4*** , tumor necrosis factor ( TNF ) , and IL-10 were ***stimulated*** by cross-linking of CD3 and ***CD28*** .	positive	0
9006	10587343	3479;207	IGF-1;Akt	CONCLUSIONS : ***IGF-1*** ***activates*** PI 3-kinase and ***Akt*** in cardiomyocytes .	positive	1
9007	10587347	356;355	FasL;Fas	This regulation and/or elimination was dependent on T cells bearing alpha/beta type T cell receptor , especially on CD8 ( + ) T cells and independent of the ***Fas-Fas*** ***ligand*** ( ***FasL*** ) system .	parallel	1
9008	10587524	1432;4879	p38;hBNP	***Activation*** of the ***hBNP*** promoter by either ***p38*** or strain was mediated by DNA elements present in the 5 ' flanking sequence of the gene .	positive	1
9009	10587525	2321;7422	Flt-1;VEGF	Reduced tissue oxygen tension triggers VEGF expression , and increased protein and mRNA levels for ***VEGF*** and its ***receptors*** ( ***Flt-1*** , Flk-1 / KDR ) occur in the ischemic rat brain .	parallel	1
9010	10587587	4286;7299	MITF;tyrosinase	Glycogen synthase kinase 3 ( GSK3 ) was found to phosphorylate Ser298 in vitro , thereby enhancing the ***binding*** of ***MITF*** to the ***tyrosinase*** promoter .	parallel	1
9011	10588088	183;5972	Angiotensin II;renin	ARBs also block the ***Angiotensin II-induced*** feedback ***regulation*** of ***renin*** release , resulting in an increase in Angiotensin II levels .	target	1
9012	10588448	186;185	AT2;AT1	Brain ******AT1/AT2****** ***interactions*** may occur in selective cases as inter-neuron cross talk .	parallel	1
9013	10588510	3577;3576	CXCR1;IL-8	CXCR2 stimulation primes ***CXCR1*** [ Ca2 + ] i ***responses*** to ***IL-8*** in human neutrophils .	parallel	0
9014	10588510	2919;3576	GRO-alpha;IL-8	We evaluated the ***interactions*** of ***IL-8*** and ***GRO-alpha*** in priming human PMN calcium fluxes [ Ca2 + ] i within circulatory environments .	parallel	1
9015	10588510	3576;2919	IL-8;GRO-alpha	At physiologic concentrations , GRO-alpha primes PMN for IL-8 mediated [ Ca2 + ] i mobilization , whereas ***IL-8*** ***abolishes*** ***GRO-alpha*** responses .	negative	0
9016	10588510	2919;3576	GRO-alpha;IL-8	Repeated ***GRO-alpha*** exposures further ***enhance*** ***IL-8*** responses .	positive	0
9017	10588510	3577;3579	CXCR1;CXCR2	***CXCR1*** stimulation ***down-regulated*** ***CXCR2*** surface expression , whereas CXCR2 stimulation upregulated CXCR1 expression .	negative	1
9018	10588510	3579;3577	CXCR2;CXCR1	CXCR1 stimulation down-regulated CXCR2 surface expression , whereas ***CXCR2*** stimulation ***upregulated*** ***CXCR1*** expression .	positive	1
9019	10588510	3579;3576	CXCR2;IL-8	GRO-alpha / ***CXCR2*** signaling ***enhanced*** post-receptor ***IL-8*** initiated PMN [ Ca2 + ] i influx as well as efflux .	positive	0
9020	10588510	2919;3576	GRO-alpha;IL-8	***GRO-alpha*** / CXCR2 signaling ***enhanced*** post-receptor ***IL-8*** initiated PMN [ Ca2 + ] i influx as well as efflux .	positive	0
9021	10588576	2890;1739	GluR1;SAP97	Thus , the enhanced GluR1-like staining in Alzheimer 's disease might be ascribed to the hampered ***interaction*** between ***SAP97*** and ***GluR1*** leading to epitope unmasking of GluR1 on tissue sections .	parallel	1
9022	10588638	5884;5983	Rad17;rfc3	***Association*** of ***rfc3*** and ***Rad17*** in vivo and a significant reduction of the phosphorylated form of Chk1 in rfc3-1 cells after treatments with MMS and gamma or UV irradiation suggested that the checkpoint signal emitted by rfc3 is linked to the downstream checkpoint machinery via Rad17 and Chk1 .	parallel	0
9023	10588663	5141;4656	PDE4;myogenin	***PDE4*** inhibition ***prevented*** vasopressin-induced nuclear translocation of the muscle-specific transcription factor ***myogenin*** without affecting its overall expression level .	positive	0
9024	10588700	25;2130	c-Abl;EWS	Tyrosine ***phosphorylation*** of ***EWS/WT1*** by ***c-Abl*** negatively regulates its DNA binding properties .	target	1
9025	10588700	25;7490	c-Abl;WT1	Tyrosine ***phosphorylation*** of ***EWS/WT1*** by ***c-Abl*** negatively regulates its DNA binding properties .	target	1
9026	10588730	3574;581	IL-7;Bax	Withdrawal of ***IL-7*** ***induces*** ***Bax*** translocation from cytosol to mitochondria through a rise in intracellular pH.	target	1
9027	10588752	5592;1385	PKG;CREB	In contrast , ***PKG*** failed to ***phosphorylate*** ***CREB*** directly in vitro .	target	1
9028	10588860	8682;841	PEA-15;caspase-8	The phosphoprotein protein ***PEA-15*** inhibits Fas - but ***increases*** TNF-R1-mediated ***caspase-8*** activity and apoptosis .	positive	0
9029	10588860	8682;7132	15-kDa phosphoprotein enriched in astrocytes;TNF-R1	The ***15-kDa phosphoprotein enriched in astrocytes*** ( PEA-15 ) inhibits Fas-mediated apoptosis and ***increases*** tumor necrosis factor receptor-1 ( ***TNF-R1*** ) - mediated apoptosis in the same cell type in a ligand-dependent manner .	positive	0
9030	10588868	2263;2252	FGFR-2;KGF	Although no significant differences in the expression of adhesion molecules ( NCAM ) , selected morphogens ( TGFbeta-2 , HGF/SF , FGF-2 , KGF ) , or their receptors ( TGFbetaR-II , m-met , FGFR-1 ) were seen between DP of p75NTR knockout and wild-type mice , p75NTR mutants showed a prominent upregulation of ***FGFR-2*** , a high-affinity ***receptor*** for ***KGF*** , in both follicular DP and epithelium .	parallel	1
9031	10588868	2252;2263	KGF;FGFR-2	These observations suggest that p75NTR plays an important role during HF morphogenesis , functioning as a receptor that negatively controls HF development , most likely via alterations in DP fibroblast proliferation/differentiation and via downregulation of ******KGF/FGFR-2****** ***signaling*** in the HF .	parallel	0
9032	10588870	7020;1050	AP-2;C/EBPalpha	This novel regulatory scheme involves : ( 1 ) unique gradients of expression for each transcription factor , i.e. , C/EBPbeta and AP-2 most abundant in the lower epidermis , C/EBPalpha in the upper ; ( 2 ) C/EBP-binding sites in the ap-2alpha gene promoter , through which C/EBPbeta stimulates ap-2alpha ; and ( 3 ) AP-2 binding sites in the C/EBPalpha promoter , through which ***AP-2*** ***represses*** ***C/EBPalpha*** .	negative	1
9033	10588870	1051;7020	C/EBPbeta;ap-2alpha	This novel regulatory scheme involves : ( 1 ) unique gradients of expression for each transcription factor , i.e. , C/EBPbeta and AP-2 most abundant in the lower epidermis , C/EBPalpha in the upper ; ( 2 ) C/EBP-binding sites in the ap-2alpha gene promoter , through which ***C/EBPbeta*** ***stimulates*** ***ap-2alpha*** ; and ( 3 ) AP-2 binding sites in the C/EBPalpha promoter , through which AP-2 represses C/EBPalpha .	positive	0
9034	10588870	1051;7020	C/EBPbeta;AP-2	Promoter-analysis and gene-expression data presented herein support a regulatory model in which ***C/EBPbeta*** ***activates*** and maintains ***AP-2*** expression in basal keratinocytes , whereas AP-2 represses C/EBPalpha in those cells .	positive	1
9035	10588870	7020;1050	AP-2;C/EBPalpha	Promoter-analysis and gene-expression data presented herein support a regulatory model in which C/EBPbeta activates and maintains AP-2 expression in basal keratinocytes , whereas ***AP-2*** ***represses*** ***C/EBPalpha*** in those cells .	negative	1
9036	10588925	239;241	12-lipoxygenase;FLAP	These results suggest that the ***12-lipoxygenase*** of human platelets ***binds*** to ***FLAP*** or a similar protein , and OPC-29030 suppresses 12 ( S ) - HETE production by inhibiting a certain step of the 12-lipoxygenase translocation .	parallel	1
9037	10589103	183;4358	angiotensin II;glomerulosclerosis	Locally increased synthesis of ***angiotensin II*** ( ANG II ) in the kidney has been ***linked*** to glomerular hypertrophy , ***glomerulosclerosis*** and tubulo-interstitial fibrosis observed in chronic renal failure after subtotal nephrectomy .	parallel	0
9038	10589684	796;1594	Calcitonin;CYP27B1	The present data suggest that ***Calcitonin*** ***upregulates*** ***CYP27B1*** mRNA expression via the protein kinase C pathway in LLC-PK1 cells .	positive	1
9039	10589684	796;1594	Calcitonin;25-hydroxyvitamin D3 1alpha-hydroxylase	***Calcitonin*** ***induces*** ***25-hydroxyvitamin D3 1alpha-hydroxylase*** mRNA expression via protein kinase C pathway in LLC-PK1 cells .	target	1
9040	10589684	796;1594	Calcitonin;CYP27B1	***Calcitonin*** at 100 nmol/L significantly ***increased*** ***CYP27B1*** mRNA expression by 24 h ( 271 + / - 21 % of control ) .	positive	0
9041	10589688	558;2621	Axl;Gas6	In mesangial cells , ***Gas6*** and its ***receptor*** ***Axl*** were expressed .	parallel	1
9042	10589690	2833;3627	CXCR3;IP-10	Role for ***interactions*** between ***IP-10/Mig*** and ***CXCR3*** in proliferative glomerulonephritis .	parallel	1
9043	10589690	2833;4283	CXCR3;Mig	Role for ***interactions*** between ***IP-10/Mig*** and ***CXCR3*** in proliferative glomerulonephritis .	parallel	1
9044	10589690	4283;3627	Mig;IP-10	Role for ***interactions*** between ******IP-10/Mig****** and CXCR3 in proliferative glomerulonephritis .	parallel	1
9045	10589839	284119;7270	PTRF;TTF-I	We demonstrate that ***PTRF*** ***interacts*** with the largest subunit of murine Pol I , with ***TTF-I*** and Reb1p , but not the lac repressor .	parallel	1
9046	10589839	284119;7270	PTRF;TTF-I	The results imply that Pol I transcription termination in yeast and mouse is mediated by conserved ***interactions*** between Pol I , ***Reb1p/TTF-I*** and ***PTRF*** .	parallel	1
9047	10589939	1991;6347	Neutrophil elastase;MCP-1	CONCLUSIONS : ***MCP-1*** production by macrophages is ***stimulated*** by ***Neutrophil elastase*** and oxygen radicals generated by hypoxia , probably due to microthrombus formation after ischemia/reperfusion of the rat liver .	positive	0
9048	10589939	6347;2152	MCP-1;tissue factor	BACKGROUND : The monocyte chemoattractant protein-1 ( ***MCP-1*** ) is produced during reperfusion injury and ***induces*** ***tissue factor*** that is the initiator of the clotting cascade .	target	1
9049	10589939	1991;6347	Neutrophil elastase;MCP-1	RESULTS : Human ***Neutrophil elastase*** or oxygen radicals significantly ***enhanced*** in vitro ***MCP-1*** production by macrophage .	positive	0
9050	10590020	7049;7040	betaglycan;TGF-beta1	The receptor III ( or ***betaglycan*** ) ***binds*** and presents ***TGF-beta1*** or beta2 to receptor II .	parallel	1
9051	10590033	7035;2152	TFPI;tissue factor	In this work we have undertaken a comparative study of human umbilical vein endothelial cells ( HUVECs ) and human saphenous vein endothelial cells ( HSVECs ) with respect to functional and antigenic tissue factor ( TF ) , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , and TF mRNA .	negative	1
9052	10590034	3479;3569	IGF-I;IL-6	***IGF-I*** ***increases*** interferon-gamma and ***IL-6*** mRNA expression and protein production in neonatal mononuclear cells .	positive	0
9053	10590034	3479;3458	IGF-I;interferon-gamma	***IGF-I*** ***increases*** ***interferon-gamma*** and IL-6 mRNA expression and protein production in neonatal mononuclear cells .	positive	0
9054	10590034	3479;3569	IGF-I;IL-6	***IGF-I*** alone ***induced*** a high level of ***IL-6*** mRNA expression and protein production in neonatal MNC .	target	1
9055	10590034	3479;3569	IGF-I;IL-6	***IGF-I*** significantly ***increased*** mRNA expression and protein production of both ***IL-6*** and interferon-y but had no influence on that of IL-2 and IL-4 in PHA-stimulated neonatal MNC .	positive	0
9056	10590034	3479;3902	IGF-I;lymphocyte-activation gene 3	***IGF-I*** could further ***enhance*** the mRNA expression of ***lymphocyte-activation gene 3*** , which is associated with interferon-gamma production and differentiation of T-helper 1 lymphocytes , in PHA-stimulated neonatal MNC .	positive	0
9057	10590034	3902;3458	lymphocyte-activation gene 3;interferon-gamma	IGF-I could further enhance the mRNA expression of ***lymphocyte-activation gene 3*** , which is ***associated*** with ***interferon-gamma*** production and differentiation of T-helper 1 lymphocytes , in PHA-stimulated neonatal MNC .	parallel	0
9058	10590045	5196;7124	PF-4;TNF-alpha	In previous studies , we found that ***PF-4*** specifically binds to human polymorphonuclear granulocytes ( PMN ) , but ***requires*** tumor necrosis factor-alpha ( ***TNF-alpha*** ) as a costimulus for the induction of effector functions in suspended cells .	target	0
9059	10590050	5966;4790	Rel;NF-kappaB	In the nontumorigenic murine myeloid progenitor 32D cells incubated with amifostine , we detected a reduction of the IkappaBalpha cytoplasmic levels by Western blotting and a raising of nuclear ******NF-kappaB/Rel****** ***complexes*** by electrophoretic mobility shift assay .	parallel	1
9060	10590061	3673;7454	collagen receptor;WASp	***Regulation*** and function of ***WASp*** in platelets by the ***collagen receptor*** , glycoprotein VI .	target	1
9061	10590066	3600;3458	IL-15;IFN-gamma	Lastly , using highly purified cell population , we report that ***IL-15*** ***triggers*** the synthesis of ***IFN-gamma*** from both CD4 ( + ) and NK cells , which can act in both autocrine and paracrine fashion to modulate NK cells cytotoxic potential .	positive	0
9062	10590070	4602;8900	c-myb;cyclin A1	Taken together , ***c-myb*** can directly ***transactivate*** the promoter of ***cyclin A1*** , and c-myb might be involved in the high-level expression of cyclin A1 observed in acute myeloid leukemia .	positive	1
9063	10590070	4602;8900	c-myb;cyclin A1	***c-myb*** transactivates the human cyclin A1 promoter and ***induces*** ***cyclin A1*** gene expression .	target	1
9064	10590070	4602;8900	c-myb;cyclin A1	***c-myb*** ***transactivates*** the human ***cyclin A1*** promoter and induces cyclin A1 gene expression .	positive	1
9065	10590070	4602;8900	c-myb;cyclin A1	Gel-shift assays demonstrated that ***c-myb*** could ***bind*** to the ***cyclin A1*** promoter at a binding site located near the transcription start site .	parallel	1
9066	10590092	1054;1051	C/EBPgamma;NF-IL6	These findings reveal how the ***interplay*** of ***NF-IL6*** and ***C/EBPgamma*** , together with Sp1 and COUP-TF , regulates HIV-1 gene transcription in brain cells .	parallel	1
9067	10590105	3700;7852	gp120;CXCR4	Thus , therapeutic intervention targeting the ***interaction*** of HIV-1 ***gp120*** with ***CXCR4*** may be highly valuable for suppressing the pathogenic effects of late-stage viruses .	parallel	1
9068	10590121	920;30816	CD4;Env	Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function : soluble ***CD4*** ***activates*** ***Env*** for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120 .	positive	1
9069	10590121	3700;920	gp120;CD4	These findings provide direct functional evidence for a sequential two-step model of Env-receptor interactions , whereby ***gp120*** ***binds*** first to ***CD4*** and becomes activated for subsequent functional interaction with coreceptor , leading to membrane fusion .	parallel	1
9070	10590168	23569;51702	PAD4;PAD3	The expression of ***PAD3*** is tightly correlated with camalexin synthesis and is ***regulated*** by ***PAD4*** and PAD1 .	target	1
9071	10590179	1270;3976	CNTF;LIF	To investigate the role of ******CNTF/LIF****** ***signaling*** in regenerative responses of motoneurons , we studied the expression of the three receptor components , CNTF receptor alpha ( CNTFRalpha ) , LIF receptor beta ( LIFRbeta ) , and gp130 , and the activation of the STAT3 signal transduction pathway in the rat facial nucleus following peripheral nerve transection .	parallel	0
9072	10590234	7157;4255	p53;MGMT	Although these studies support a role for ***p53*** ***regulation*** of ***MGMT*** in neonatal mouse astrocytes , BCNU resistance in wild-type cells appears to be mediated by a non-MGMT mechanism .	target	1
9073	10590238	5008;5743	Oncostatin M;cyclooxygenase-2	***Oncostatin M*** ***induces*** interleukin-6 and ***cyclooxygenase-2*** expression in human vascular smooth muscle cells : synergy with interleukin-1beta .	target	1
9074	10590238	5008;3569	Oncostatin M;interleukin-6	***Oncostatin M*** ***induces*** ***interleukin-6*** and cyclooxygenase-2 expression in human vascular smooth muscle cells : synergy with interleukin-1beta .	target	1
9075	10590238	5008;3569	OSM;IL-6	***OSM*** ***stimulated*** the release of ***IL-6*** by hASMCs in a dose-dependent way ; after a 48-hour exposure , values were 8.5 + / -0.7 , 29.7 + / -3.5 , 50.9 + / -4.4 , and 73.8 + / -7.6 x10 ( 3 ) U/mL ( n = 6 ) at OSM concentrations of 0 , 1 , 10 , and 100 ng/mL , respectively .	positive	0
9076	10590238	5008;5743	OSM;COX-2	***OSM*** ***induced*** marked expression of ***COX-2*** protein and mRNA .	target	1
9077	10590243	6714;5598	Src;BMK1	In contrast , although ROS increase during reperfusion after ischemia , the activities of both ***BMK1*** and its upstream ***regulator*** , ***Src*** , were markedly attenuated by reperfusion after ischemia .	target	1
9078	10590243	6714;5598	Src;BMK1	Previously , we showed that ***Src*** ***regulates*** ***BMK1*** via a redox-sensitive signaling pathway .	target	1
9079	10590260	3848;4790	CK-1;NFkappaB	The GM-CSF ***CK-1*** element has been shown to ***bind*** ***NFkappaB*** proteins , in particular c-Rel , whose binding and function is dependent on the architectural transcription factor HMGI ( Y ) .	parallel	1
9080	10590260	1437;4790	GM-CSF;NFkappaB	The ***GM-CSF*** CK-1 element has been shown to ***bind*** ***NFkappaB*** proteins , in particular c-Rel , whose binding and function is dependent on the architectural transcription factor HMGI ( Y ) .	parallel	1
9081	10590260	4773;3848	NFATp;CK-1	The binding of ***NFATp*** and Rel proteins ***requires*** the same core ***CK-1*** sequences , and appears to be mutually exclusive .	target	0
9082	10590260	4773;3848	NFATp;CK-1	We investigated the functional significance of ***NFATp*** ***binding*** to ***CK-1*** by overexpressing the protein in Jurkat T cells and found that NFATp can not activate the CD28RR alone but can cooperate with signals generated by phorbol 12-myristate 13-acetate/calcium ionophore .	parallel	1
9083	10590270	928;3688	CD9;CD29	Immunoprecipitation of T cell lysates with anti-CD9 mAb followed by immunoblotting with mAb against various T cell molecules showed the ***association*** of ***CD9*** with CD3 , CD4 , CD5 , CD2 , ***CD29*** and CD44 .	parallel	0
9084	10590270	928;920	CD9;CD4	Immunoprecipitation of T cell lysates with anti-CD9 mAb followed by immunoblotting with mAb against various T cell molecules showed the ***association*** of ***CD9*** with CD3 , ***CD4*** , CD5 , CD2 , CD29 and CD44 .	parallel	0
9085	10590270	928;960	CD9;CD44	Immunoprecipitation of T cell lysates with anti-CD9 mAb followed by immunoblotting with mAb against various T cell molecules showed the ***association*** of ***CD9*** with CD3 , CD4 , CD5 , CD2 , CD29 and ***CD44*** .	parallel	0
9086	10590311	4880;4882	CNP;NPR-B	***CNP*** , a specific ***ligand*** for ***NPR-B*** lets ATDC5 cells accumulate great amounts of cGMP , revealing NPR-B as a dominant biological receptor through differentiation .	parallel	1
9087	10590316	1435;4318	M-CSF;MMP-9	Monocytes freshly isolated from human peripheral blood produced MMP-9 , but not urokinase , and ***M-CSF*** ***enhanced*** ***MMP-9*** production .	positive	0
9088	10590316	1435;4318	M-CSF;MMP-9	***M-CSF*** ***augmented*** production of ***MMP-9*** and urokinase in a dose-dependent manner .	positive	0
9089	10590316	1435;4312	M-CSF;MMP-1	***M-CSF*** also ***enhanced*** ***MMP-1*** production of macrophages , but not significantly .	positive	0
9090	10590366	4233;3082	Met;scatter factor	BACKGROUND : Activation of ***Met*** , the ***receptor*** for ***scatter factor/hepatocyte growth factor*** , is associated with mitogenesis , motogenesis , and decreased cell adhesion .	parallel	1
9091	10590480	652;4086	bmp2b;Smad1	Injection studies and mutant analyses suggest that the ventral ***Smad1*** expression is positively ***regulated*** by ***bmp2b*** , but not by Bmp4 signaling , whereas Smad5 expression is independent of bmp2b .	positive	1
9092	10591026	3553;4879	IL-1 beta;BNP	In the MC-NMC coculture , ***IL-1 beta*** and ET-1 each significantly ***augmented*** the secretion of ANP and ***BNP*** .	positive	0
9093	10591026	3553;4879	IL-1 beta;BNP	This study shows that ***IL-1 beta*** ***induces*** unique cardiac hypertrophy and the marked secretion of ANP and ***BNP*** , and that NMC is indispensable when treated with IL-1 beta .	target	1
9094	10591068	3827;4852	bradykinin;neuropeptide Y	These data do not support our original hypothesis that ***bradykinin*** ***mediates*** the renal effects of ***neuropeptide Y*** .	target	0
9095	10591213	23621;351	Asp2;APP	Solubilized ***Asp2*** protein ***cleaves*** a synthetic ***APP*** peptide substrate at the beta-secretase site , and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer 's disease in Sweden .	target	1
9096	10591629	54763;114822	Ropporin;rhophilin	These results suggest that ***rhophilin*** and ***Ropporin*** may form a ***complex*** in sperm flagella .	parallel	1
9097	10591629	54763;114822	Ropporin;rhophilin	Deletion analysis indicated that the carboxy-terminal four amino acids are essential for ***binding*** of ***Ropporin*** to ***rhophilin*** , and Ropporin and RhoV14 coprecipitated in the presence of rhophilin in vitro .	parallel	1
9098	10591631	5328;5329	uPA;uPAR	These studies demonstrate that ***binding*** of endogenously produced ***uPA*** to ***uPAR*** may serve as a major determinant of basal levels of activated ERK and , by this mechanism , regulate cellular migration and invasion .	parallel	1
9099	10591631	5328;5329	uPA;uPAR	Antibodies which block ***binding*** of endogenously produced ***uPA*** to ***uPAR*** reduced ERK phosphorylation and migration of LRP-deficient cells to the levels observed with control cells .	parallel	1
9100	10591661	4843;4790	inducible NO synthase;NF-kappaB	Augmented expression of ***inducible NO synthase*** in vascular smooth muscle cells during aging is ***associated*** with enhanced ***NF-kappaB*** activation .	parallel	0
9101	10591661	4790;3383	NF-kappaB;ICAM-1	Both iNOS and ***ICAM-1*** are transcriptionally ***regulated*** by nuclear factor kappaB ( ***NF-kappaB*** ) .	target	1
9102	10591662	4320;2006	MMP-11;elastin	The mechanisms by which ***MMP-11*** could ***impair*** ***elastin*** degradation and cellular migration in this model remain , however , unknown .	negative	0
9103	10592111	4018;5340	lipoprotein;plasmin	These data support the concept that ***lipoprotein*** ( a ) can ***inhibit*** plasminogen activation and ***plasmin*** formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent .	negative	1
9104	10592690	348;341	APOE;APOC1	In accordance with global trends in the distribution of human genetic variation , the European sample from Portugal presented more intense linkage disequilibrium between APOE and APOC1 than the African sample from São Tomé where , despite the short 4-kb distance that separates the 2 loci , the level of association ***between*** the APOC1 ***alleles*** and APOE ******* 4 was nonsignificant .	parallel	0
9105	10593335	6372;3577	GCP-2;CXCR-1	Only IL-8 and ***GCP-2*** ***bind*** ***CXCR-1*** with high affinity .	parallel	1
9106	10593335	6374;3577	ENA-78;CXCR-1	RESULTS : Flow cytometry and radioligand binding data indicate that IL-8 , GCP-2 , and ***ENA-78*** equivalently ***reduced*** ***CXCR-1*** and CXCR-2 cell surface expression by 34 % to 54 % .	negative	1
9107	10593335	6374;3579	ENA-78;CXCR-2	RESULTS : Flow cytometry and radioligand binding data indicate that IL-8 , GCP-2 , and ***ENA-78*** equivalently ***reduced*** CXCR-1 and ***CXCR-2*** cell surface expression by 34 % to 54 % .	negative	1
9108	10593335	6372;3577	GCP-2;CXCR-1	RESULTS : Flow cytometry and radioligand binding data indicate that IL-8 , ***GCP-2*** , and ENA-78 equivalently ***reduced*** ***CXCR-1*** and CXCR-2 cell surface expression by 34 % to 54 % .	negative	1
9109	10593335	6372;3579	GCP-2;CXCR-2	RESULTS : Flow cytometry and radioligand binding data indicate that IL-8 , ***GCP-2*** , and ENA-78 equivalently ***reduced*** CXCR-1 and ***CXCR-2*** cell surface expression by 34 % to 54 % .	negative	1
9110	10593375	3952;7422	leptin;VEGF	Follicular ***leptin*** levels ***correlated*** positively with ***VEGF*** levels ( r = 0.46 , P = .008 ) and with NO3/NO2 levels ( r = 0.39 , P = .006 ) .	positive	0
9111	10593431	7035;2152	TFPI;tissue factor	Monocytes are potent regulators of blood coagulation through the expression of tissue factor ( TF ) on stimulation and of ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , a selective inhibitor of TF pathway .	negative	1
9112	10593485	959;958	CD40 ligand;CD40	***CD40 ligand*** ( CD40L ) , expressed on activated T cells , ***binds*** its receptor , ***CD40*** , on dendritic cells , B cells , and monocytes / macrophages .	parallel	1
9113	10593617	3554;3553	IL-1R1;IL-1	The shape change and subsequent repair processes are IL-1beta activity-dependent , acting through the ***IL-1*** type 1 ***receptor*** ( ***IL-1R1*** ) , as co-application of the IL-1type 1 receptor antagonist protein ( IL-1ra ) blocks IL-1beta induced effects .	parallel	1
9114	10593650	4953;1017	ODC;Cdk2	Thus , ***ODC/polyamine-induced*** ***activation*** of cyclin ***E/Cdk2*** and cyclin A/Cdk2-associated kinase activity may cooperate with the ras induction of cyclin D/Cdk4/6-associated retinoblastoma protein phosphorylation to not only stimulate proliferation but ultimately contribute to tumor development .	positive	1
9115	10593866	3082;5743	HGF;COX-2	***HGF*** ***triggers*** activation of the ***COX-2*** gene in rat gastric epithelial cells : action mediated through the ERK2 signaling pathway .	positive	0
9116	10593866	3082;5743	HGF;COX-2	Thus , ***HGF*** ***triggers*** activation of the ***COX-2*** gene in gastric epithelial cells through phosphorylation of c-Met/HGF receptor and activation of the ERK2 signaling pathway.-Jones , M.	positive	0
9117	10593866	3082;5743	HGF;COX-2	S. ***HGF*** ***triggers*** activation of the ***COX-2*** gene in rat gastric epithelial cells : action mediated through the ERK2 signaling pathway .	positive	0
9118	10593883	4215;5607	MEKK3;MEK5	***MEKK3*** directly ***regulates*** ***MEK5*** activity as part of the big mitogen-activated protein kinase 1 ( BMK1 ) signaling pathway .	target	1
9119	10593883	4215;5598	MEKK3;BMK1	In addition , we show that a dominant active form of ***MEKK3*** ***stimulates*** ***BMK1*** activity through MEK5 .	positive	0
9120	10593896	2817;2252	glypican-1;FGF-7	In the present study , we investigated the ***modulation*** of ***FGF-7*** activities by heparin and ***glypican-1*** in HS-free background utilizing either HS-deficient cells expressing the FGF-7 receptor ( designated BaF/KGFR cells ) or soluble extracellular domain of the receptor .	target	0
9121	10593898	3551;4792	IKK-2;IkappaB-alpha	Moreover , the ***IKK-2*** ***catalyzes*** the phosphorylation of the full-length ***IkappaB-alpha*** and the amino acid 26-42 peptide with nearly equal efficiency , while the msIKK catalyzes the phosphorylation of the full-length IkappaB-alpha 25,000 times more efficiently than the 26-42 peptide .	positive	1
9122	10593898	3551;4793	IKK-2;IkappaB-beta	This is consistent with the observation that ***IKK-2*** is able to ***phosphorylate*** the ***IkappaB-beta*** and IkappaB-epsilon proteins , which have consensus phosphorylation sites nearly identical to that of amino acids 31-37 of IkappaB-alpha .	target	1
9123	10593898	3551;4794	IKK-2;IkappaB-epsilon	This is consistent with the observation that ***IKK-2*** is able to ***phosphorylate*** the IkappaB-beta and ***IkappaB-epsilon*** proteins , which have consensus phosphorylation sites nearly identical to that of amino acids 31-37 of IkappaB-alpha .	target	1
9124	10593900	10370;9355	MRG1;Lhx2	***MRG1*** was shown to ***bind*** ***Lhx2*** in vitro , and a co-immunoprecipitation assay provided evidence that endogenous MRG1 forms a complex with Lhx2 in alphaT3-1 cells .	parallel	1
9125	10593906	3553;5606	IL-1beta;MKK3	In previous studies we demonstrated that ***IL-1beta*** can ***activate*** MKK4/SEK1 , ***MKK3*** , and MKK6 in renal mesangial cells ; therefore , we examined the role of these MAPK kinases in the modulation of iNOS induced by IL-1beta .	positive	1
9126	10593906	3553;6416	IL-1beta;MKK4	In previous studies we demonstrated that ***IL-1beta*** can ***activate*** ***MKK4/SEK1*** , MKK3 , and MKK6 in renal mesangial cells ; therefore , we examined the role of these MAPK kinases in the modulation of iNOS induced by IL-1beta .	positive	1
9127	10593906	3553;5608	IL-1beta;MKK6	In previous studies we demonstrated that ***IL-1beta*** can ***activate*** MKK4/SEK1 , MKK3 , and ***MKK6*** in renal mesangial cells ; therefore , we examined the role of these MAPK kinases in the modulation of iNOS induced by IL-1beta .	positive	1
9128	10593906	5608;5594	MKK3/6;p38	Interestingly overexpression of wild type ***MKK3/6*** was ***associated*** with phosphorylation of ***p38*** ( MAPK ) ; however , in the absence of IL-1beta , iNOS expression was not enhanced .	parallel	0
9129	10593926	6945;4149	Max-like BHLHZip protein;Max	Mlx , a novel ***Max-like BHLHZip protein*** that ***interacts*** with the ***Max*** network of transcription factors .	parallel	1
9130	10593926	6945;4084	Mlx;Mad1	In contrast with Max , ***Mlx*** ***interacts*** only with ***Mad1*** and Mad4 .	parallel	1
9131	10593926	6945;10608	Mlx;Mad4	In contrast with Max , ***Mlx*** ***interacts*** only with Mad1 and ***Mad4*** .	parallel	1
9132	10593929	5594;2549	ERK2;GAB1	Activated ***ERK2*** ***interacts*** with and phosphorylates the docking protein ***GAB1*** .	parallel	1
9133	10593929	2549;5594	GAB1;ERK2	In vitro , both the MBD and full-length ***GAB1*** were found to be ***substrates*** for activated ***ERK2*** .	parallel	1
9134	10593929	2549;5594	GAB1;ERK2	Thus , it appears that ***GAB1*** can ***associate*** directly with phosphorylated ***ERK2*** via the MET-binding domain and that GAB1 then acts as a substrate for the enzyme .	parallel	0
9135	10593931	2160;2158	coagulation factor XI;factor IX	Activated ***coagulation factor XI*** ( factor XIa ) proteolytically ***cleaves*** its substrate , ***factor IX*** , in an interaction requiring the factor XI A3 domain ( Sun , Y. , and Gailani , D. ( 1996 ) J.	target	1
9136	10593935	348;3339	apoE;Perlecan	Analysis of the conditioned medium from apoE-stimulated cells revealed that the HSPG increase was in Perlecan and that ***apoE*** also ***stimulated*** ***Perlecan*** mRNA expression by > 2-fold .	positive	0
9137	10593935	3339;348	Perlecan;apoE	Thus , these data show that ***Perlecan*** is a potent inhibitor of SMC proliferation and is required to ***mediate*** the antiproliferative effect of ***apoE*** .	target	0
9138	10593935	3339;348	Perlecan;apolipoprotein E	***Perlecan*** ***mediates*** the antiproliferative effect of ***apolipoprotein E*** on smooth muscle cells .	target	0
9139	10593949	10084;51729	Npw38;NpwBP	***Association*** of two nuclear proteins , ***Npw38*** and ***NpwBP*** , via the interaction between the WW domain and a novel proline-rich motif containing glycine and arginine .	parallel	0
9140	10593949	51729;10084	NpwBP;Npw38	Coimmunoprecipitation experiments confirmed the ***association*** between ***Npw38*** and ***NpwBP*** , which were expressed as epitope-tagged forms in COS7 cells .	parallel	0
9141	10593949	51729;10084	NpwBP;Npw38	These results suggest that NpwBP is a physiological ligand of Npw38 and that the ******Npw38-NpwBP****** ***complex*** may function as a component of an mRNA factory in the nucleus .	parallel	1
9142	10593949	51729;10084	NpwBP;Npw38	These results suggest that ***NpwBP*** is a physiological ***ligand*** of ***Npw38*** and that the Npw38-NpwBP complex may function as a component of an mRNA factory in the nucleus .	parallel	1
9143	10593952	2920;5599	GRObeta;JNK1	We also show that , in addition to the known stimulation of a phosphoinositide-specific phospholipase C , ***GRObeta*** ***activates*** both neutral ( N - ) and acidic ( A - ) sphingomyelinases ( SMase ) and the stress-activated c-Jun N-terminal kinase 1 ( ***JNK1*** ) .	positive	1
9144	10593953	5884;4809	HRad17;NHP2L1	Using the yeast two-hybrid system , we determined that ***HRad17*** can ***interact*** with a nucleolar protein , ***NHP2L1*** .	parallel	1
9145	10593965	7124;4792	TNFalpha;IkappaBalpha	We show 5-ASA inhibits ***TNFalpha-stimulated*** ***phosphorylation*** of ***IkappaBalpha*** in intact YAMC cells .	target	1
9146	10593965	1147;4792	IKKalpha;IkappaBalpha	***Phosphorylation*** of a glutathione ***S-transferase-IkappaBalpha*** fusion protein by cellular extracts or immunoprecipitated ***IKKalpha*** isolated from cells treated with TNFalpha is inhibited by 5-ASA .	target	1
9147	10593970	5909;8802	Rap1GAP;Galpha	Functional ***interaction*** between ***Galpha*** ( z ) and ***Rap1GAP*** suggests a novel form of cellular cross-talk .	parallel	1
9148	10593970	8802;5909	Galpha;Rap1GAP	Biochemical analysis using purified recombinant proteins revealed that the physical ***interaction*** between ***Galpha*** ( z ) and ***Rap1GAP*** blocks the ability of RGSs ( regulators of G protein signaling ) to stimulate GTP hydrolysis of the alpha subunit , and also attenuates the ability of activated Galpha ( z ) to inhibit adenylyl cyclase .	parallel	1
9149	10593970	8802;5906	Galpha;Rap1	Co-precipitation assays revealed that ***Galpha*** ( z ) , Rap1GAP , and ***Rap1*** can form a stable ***complex*** .	parallel	1
9150	10593970	8802;5909	Galpha;Rap1GAP	Co-precipitation assays revealed that ***Galpha*** ( z ) , ***Rap1GAP*** , and Rap1 can form a stable ***complex*** .	parallel	1
9151	10593970	5906;5909	Rap1;Rap1GAP	Co-precipitation assays revealed that Galpha ( z ) , ***Rap1GAP*** , and ***Rap1*** can form a stable ***complex*** .	parallel	1
9152	10593973	5829;5747	paxillin;FAK	These results suggest that ***paxillin*** must ***bind*** ***FAK*** for maximal phosphorylation in response to cell adhesion and that FAK may function to direct tyrosine phosphorylation of paxillin in the process of transformation by the src oncogene .	parallel	1
9153	10593976	4803;4804	NGF;p75	Binding and cross-linking studies demonstrated that the ***NGF*** ***binding*** to both TrkA and ***p75*** ( NTR ) was considerably enriched in CLM and that about 90 % of high affinity binding to TrkA was present in CLM .	parallel	1
9154	10593976	4803;4914	NGF;TrkA	Binding and cross-linking studies demonstrated that the ***NGF*** ***binding*** to both ***TrkA*** and p75 ( NTR ) was considerably enriched in CLM and that about 90 % of high affinity binding to TrkA was present in CLM .	parallel	1
9155	10593976	4914;6464	TrkA;Shc	Remarkably , in NGF-treated cells , it was only in CLM that activated ***TrkA*** was ***coimmunoprecipitated*** with phosphorylated ***Shc*** and PLCgamma .	parallel	1
9156	10593980	999;1499	E-cadherin;beta-catenin	We have examined the role of this modification in these proteins in the control of ******beta-catenin/E-cadherin****** ***binding*** using in vitro assays with recombinant proteins .	parallel	1
9157	10593980	999;1499	E-cadherin;beta-catenin	However , a role for p120-catenin in the modulation of ******beta-catenin/E-cadherin****** ***binding*** was not observed , since addition of phosphorylated p120-catenin did not modify the affinity of phosphorylated ( or unphosphorylated ) beta-catenin for E-cadherin .	parallel	1
9158	10593980	1499;999	beta-catenin;E-cadherin	Transient transfections of different mutants demonstrated that Tyr-654 is phosphorylated in conditions in which adherens junctions are disrupted and evidenced that ***binding*** of ***beta-catenin*** to ***E-cadherin*** in vivo is controlled by phosphorylation of beta-catenin Tyr-654 .	parallel	1
9159	10593983	3308;3337	Hsp70;Hsp40	Likewise , the ***cooperation*** between ***Hsp40*** and ***Hsp70*** is lost by introduction of a point mutation in the conserved HPD motif of the Hsp40 J-domain or by deletion of the four C-terminal amino acids of Hsp70 ( EEVD motif ) .	parallel	0
9160	10594015	8471;2185	IRS-4;protein kinase B	***IRS-4*** ***mediates*** ***protein kinase B*** signaling during insulin stimulation without promoting antiapoptosis .	target	0
9161	10594015	2885;3667	Grb-2;IRS-1	Insulin promoted the ***association*** of ***Grb-2*** with ***IRS-1*** and IRS-4 , whereas IRS-2 weakly bound Grb-2 ; consequently , IRS-1 and IRS-4 enhanced insulin-stimulated mitogen-activated protein kinase activity .	parallel	0
9162	10594015	2885;8471	Grb-2;IRS-4	Insulin promoted the ***association*** of ***Grb-2*** with IRS-1 and ***IRS-4*** , whereas IRS-2 weakly bound Grb-2 ; consequently , IRS-1 and IRS-4 enhanced insulin-stimulated mitogen-activated protein kinase activity .	parallel	0
9163	10594015	8660;2885	IRS-2;Grb-2	Insulin promoted the association of Grb-2 with IRS-1 and IRS-4 , whereas ***IRS-2*** weakly ***bound*** ***Grb-2*** ; consequently , IRS-1 and IRS-4 enhanced insulin-stimulated mitogen-activated protein kinase activity .	parallel	1
9164	10594015	5295;207	p85alpha;Akt	During insulin stimulation , IRS-1 and IRS-2 strongly bound ***p85alpha/beta*** , which ***activated*** phosphatidylinositol ( PI ) 3-kinase , protein kinase B ( PKB ) / ***Akt*** , and p70 ( s6k ) , and promoted the phosphorylation of BAD .	positive	1
9165	10594015	5295;84959	p85alpha;p70	During insulin stimulation , IRS-1 and IRS-2 strongly bound ***p85alpha/beta*** , which ***activated*** phosphatidylinositol ( PI ) 3-kinase , protein kinase B ( PKB ) / Akt , and ***p70*** ( s6k ) , and promoted the phosphorylation of BAD .	positive	1
9166	10594015	3667;5295	IRS-1;p85alpha	During insulin stimulation , ***IRS-1*** and IRS-2 strongly ***bound*** ***p85alpha/beta*** , which activated phosphatidylinositol ( PI ) 3-kinase , protein kinase B ( PKB ) / Akt , and p70 ( s6k ) , and promoted the phosphorylation of BAD .	parallel	1
9167	10594015	8660;5295	IRS-2;p85alpha	During insulin stimulation , IRS-1 and ***IRS-2*** strongly ***bound*** ***p85alpha/beta*** , which activated phosphatidylinositol ( PI ) 3-kinase , protein kinase B ( PKB ) / Akt , and p70 ( s6k ) , and promoted the phosphorylation of BAD .	parallel	1
9168	10594015	8471;207	IRS-4;PKB	***IRS-4*** also ***promoted*** the activation of ***PKB/Akt*** and BAD phosphorylation during insulin stimulation ; however , it weakly bound or activated p85-associated PI 3-kinase and failed to mediate the activation of p70 ( s6k ) .	positive	0
9169	10594021	8431;3172	SHP;HNF-4	***SHP*** ***interacts*** with the same ***HNF-4*** surface recognized by transcriptional coactivators and competes with them for binding in vivo .	parallel	1
9170	10594022	4217;5599	apoptosis signal-regulating kinase 1;JNK	Recently , a new mitogen-activated protein (MAP) kinase kinase kinase , ***apoptosis signal-regulating kinase 1*** ( ASK1 ) which ***activates*** both the c-Jun N-terminal kinase ( ***JNK*** ) and p38 MAP kinase pathways and plays pivotal roles in tumor necrosis factor - and Fas-induced apoptosis , has been identified .	positive	1
9171	10594022	4217;1432	apoptosis signal-regulating kinase 1;p38 MAP kinase	Recently , a new mitogen-activated protein (MAP) kinase kinase kinase , ***apoptosis signal-regulating kinase 1*** ( ASK1 ) which ***activates*** both the c-Jun N-terminal kinase ( JNK ) and ***p38 MAP kinase*** pathways and plays pivotal roles in tumor necrosis factor - and Fas-induced apoptosis , has been identified .	positive	1
9172	10594022	355;5599	Fas;JNK	Recently , a new mitogen-activated protein (MAP) kinase kinase kinase , apoptosis signal-regulating kinase 1 ( ASK1 ) which ***activates*** both the c-Jun N-terminal kinase ( ***JNK*** ) and p38 MAP kinase pathways and plays pivotal roles in tumor necrosis factor - and ***Fas-induced*** apoptosis , has been identified .	positive	1
9173	10594022	355;1432	Fas;p38 MAP kinase	Recently , a new mitogen-activated protein (MAP) kinase kinase kinase , apoptosis signal-regulating kinase 1 ( ASK1 ) which ***activates*** both the c-Jun N-terminal kinase ( JNK ) and ***p38 MAP kinase*** pathways and plays pivotal roles in tumor necrosis factor - and ***Fas-induced*** apoptosis , has been identified .	positive	1
9174	10594022	4217;4803	ASK1;NGF	Finally , expression of a kinase-inactive ***ASK1*** significantly ***blocked*** both ***NGF*** withdrawal - and Cdc42-induced death and activation of c-jun .	negative	0
9175	10594040	6810;6814	syntaxin 4;Munc18c	To examine the functional role of the ***interaction*** between ***Munc18c*** and ***syntaxin 4*** in the regulation of GLUT4 translocation in 3T3L1 adipocytes , we assessed the effects of introducing three different peptide fragments ( 20 to 24 amino acids ) of Munc18c from evolutionarily conserved regions of the Sec1 protein family predicted to be solvent exposed .	parallel	1
9176	10594040	6814;6810	Munc18c;syntaxin 4	One peptide , termed 18c/pep3 , inhibited the ***binding*** of full-length ***Munc18c*** to ***syntaxin 4*** , whereas expression of the other two peptides had no effect .	parallel	1
9177	10594040	6810;6814	syntaxin 4;Munc18c	Together , these data suggest that the ***interaction*** between ***Munc18c*** and ***syntaxin 4*** is required for the integration of GLUT4 and IRAP storage vesicles into the plasma membrane but is not necessary for the insulin-stimulated trafficking to and association with the cell surface .	parallel	1
9178	10594042	8648;1387	SRC-1;CBP	Given the absence of cysteine residues in one of the Ref-1-regulated transactivation domains of HIF-1alpha , it is thus possible that Ref-1 functions in hypoxic cells by targeting critical steps in the recruitment of the ******CBP-SRC-1****** coactivator ***complex*** .	parallel	1
9179	10594043	7037;7018	TfR;transferrin	The lighter of the two peaks ( peak 2 ) was comprised of two overlapping peaks : peak 2b contained recycling endosomal markers such as the ***transferrin*** ***receptor*** ( ***TfR*** ) , cellubrevin , and Rab4 , and peak 2a was enriched in TGN markers ( syntaxin 6 , the cation-dependent mannose 6-phosphate receptor , sortilin , and sialyltransferase ) .	parallel	1
9180	10594167	4880;4882	CNP;GC-B	ANP and BNP have high affinities for GC-A , and ***CNP*** is the preferred ***ligand*** for ***GC-B*** .	parallel	1
9181	10594175	6667;3945	Sp1;Ldh-B	This Fundulus hepatocyte Sp1-like protein as well as the human ***Sp1*** protein ***binds*** the ***Ldh-B*** Sp1 sites .	parallel	1
9182	10594518	6750;2691	somatostatin;growth hormone-releasing hormone	OBJECTIVES : Pulsatile GH release in humans is thought to involve the coordinated ***interaction*** of ***growth hormone-releasing hormone*** ( GHRH ) and ***somatostatin*** ( SS ) .	parallel	1
9183	10594549	3458;969	IFN-gamma;CD69	***IFN-gamma*** significantly ***up-regulated*** survival and ***CD69*** expression in 24-48 h cultured eosinophils .	positive	1
9184	10594549	3458;3717	IFN-gamma;JAK2	Further , ***IFN-gamma*** ***induced*** tyrosine phosphorylation of ***JAK2*** in eosinophils , as indicated by Western blot analysis .	target	1
9185	10594549	3458;969	IFN-gamma;CD69	In conclusion , these results indicate that ***IFN-gamma*** ***induces*** eosinophil survival and ***CD69*** expression through the activation of JAK2 in peripheral eosinophils , suggesting that JAK2 may play a significant role in eosinophil regulation by IFN-gamma-IFN-gammaR interaction .	target	1
9186	10594556	3565;3458	IL-4;interferon-gamma	Endogenous ***IL-4*** activity in naive CD4 + T cell cultures ***modulates*** the production of ***interferon-gamma*** ( IFN-gamma ) on the one hand and IL-5 and IL-13 on the other hand in opposite directions , and it is partly responsible for the low IFN-gamma production by cord blood T cells .	target	0
9187	10594565	356;355	FasL;Fas	***Fas*** ***ligand*** ( ***FasL*** ) is a type II membrane protein which induces apoptosis by binding to its membrane receptor , Fas .	parallel	1
9188	10594681	3600;3576	IL-15;IL-8	These results show that ***IL-15*** can ***suppress*** ***IL-8*** and MCP-1 secretion by intestinal epithelial cells .	negative	1
9189	10594681	3600;6347	IL-15;MCP-1	These results show that ***IL-15*** can ***suppress*** IL-8 and ***MCP-1*** secretion by intestinal epithelial cells .	negative	1
9190	10594681	3600;3576	Interleukin-15;interleukin-8	***Interleukin-15*** strongly ***inhibits*** ***interleukin-8*** and monocyte chemoattractant protein-1 production in human colonic epithelial cells .	negative	1
9191	10594681	3600;6347	Interleukin-15;monocyte chemoattractant protein-1	***Interleukin-15*** strongly ***inhibits*** interleukin-8 and ***monocyte chemoattractant protein-1*** production in human colonic epithelial cells .	negative	1
9192	10594681	3600;3576	IL-15;IL-8	***IL-15*** ***down-regulates*** ***IL-8*** and MCP-1 production in Caco-2 cells as well as in freshly isolated human colonic epithelial cells in a dose-dependent manner .	negative	1
9193	10594681	3600;6347	IL-15;MCP-1	***IL-15*** ***down-regulates*** IL-8 and ***MCP-1*** production in Caco-2 cells as well as in freshly isolated human colonic epithelial cells in a dose-dependent manner .	negative	1
9194	10594689	7535;5747	Zap-70;p125FAK	Moreover , clustering of fibronectin receptors led to the detection of a ******p125FAK/Zap-70****** ***complex*** .	parallel	1
9195	10594689	7535;5747	Zap-70;p125FAK	Finally , while the complex between fak-B , another protein kinase localized to focal adhesion sites , and Zap-70 was detected in cells plated either on BSA or on fibronectin , the formation of the ******p125FAK/Zap-70****** ***complex*** appeared specifically induced following fibronectin-mediated integrin clustering .	parallel	1
9196	10594690	356;355	CD95L;CD95	Using superantigen-activated human T cells , we found that whilst T-cell receptor ( TCR ) signalling triggered up-regulation of ***CD95*** ***ligand*** ( ***CD95L*** ) , the majority of T cells were resistant to apoptosis induction , despite co-expressing high levels of CD95 .	parallel	1
9197	10594746	7124;941	TNF-alpha;B7-1	***TNF-alpha*** markedly ***upregulated*** CD40 and ***B7-1*** expression on Langerhans cells , but not B7-2 expression .	positive	1
9198	10594746	7124;958	TNF-alpha;CD40	***TNF-alpha*** markedly ***upregulated*** ***CD40*** and B7-1 expression on Langerhans cells , but not B7-2 expression .	positive	1
9199	10594746	1437;941	GM-CSF;B7-1	***GM-CSF*** moderately ***upregulated*** ***B7-1*** and B7-2 expression , and slightly upregulated CD40 expression .	positive	1
9200	10594746	1437;942	GM-CSF;B7-2	***GM-CSF*** moderately ***upregulated*** B7-1 and ***B7-2*** expression , and slightly upregulated CD40 expression .	positive	1
9201	10594746	1435;941	M-CSF;B7-1	***M-CSF*** moderately ***upregulated*** ***B7-1*** expression , but did not modulate CD40 or B7-2 expression .	positive	1
9202	10594750	7422;7424	Vascular endothelial growth factor;Vascular endothelial growth factor-C	In vitro , human dermal microvascular endothelial cells also expressed ***Vascular endothelial growth factor-C*** mRNA that was further ***upregulated*** by ***vascular permeability factor/Vascular endothelial growth factor*** .	positive	1
9203	10594752	3458;3586	IFN-gamma;IL-10	These findings suggest that UVA photoimmunoprotection is mediated via prevention of IL-10 release , and thus the maintenance of the Th1/Th2 balance , probably by upregulation of IL-12 and ***IFN-gamma*** , which are known to ***antagonize*** ***IL-10*** in numerous models .	negative	1
9204	10594786	6348;1234	MIP-1alpha;CCR-5	BACKGROUND : This study was designed to evaluate the role of the novel chemokine receptor antagonist amino-oxypentane RANTES ( AOP-RANTES ) , which blocks the ***binding*** of macrophage inflammatory protein-1alpha ( ***MIP-1alpha*** ) , MIP-1beta , and RANTES to the chemokine receptor-5 ( ***CCR-5*** ) on the infiltration of monocytes in experimental glomerulonephritis .	parallel	1
9205	10594786	388372;1234	MIP-1beta;CCR-5	BACKGROUND : This study was designed to evaluate the role of the novel chemokine receptor antagonist amino-oxypentane RANTES ( AOP-RANTES ) , which blocks the ***binding*** of macrophage inflammatory protein-1alpha ( MIP-1alpha ) , ***MIP-1beta*** , and RANTES to the chemokine receptor-5 ( ***CCR-5*** ) on the infiltration of monocytes in experimental glomerulonephritis .	parallel	1
9206	10594786	6352;1234	RANTES;CCR-5	BACKGROUND : This study was designed to evaluate the role of the novel chemokine receptor antagonist amino-oxypentane RANTES ( AOP-RANTES ) , which blocks the ***binding*** of macrophage inflammatory protein-1alpha ( MIP-1alpha ) , MIP-1beta , and ***RANTES*** to the chemokine receptor-5 ( ***CCR-5*** ) on the infiltration of monocytes in experimental glomerulonephritis .	parallel	1
9207	10594786	6352;388372	RANTES;MIP-1beta	BACKGROUND : This study was designed to evaluate the role of the novel chemokine receptor antagonist amino-oxypentane ***RANTES*** ( AOP-RANTES ) , which ***blocks*** the binding of macrophage inflammatory protein-1alpha ( MIP-1alpha ) , ***MIP-1beta*** , and RANTES to the chemokine receptor-5 ( CCR-5 ) on the infiltration of monocytes in experimental glomerulonephritis .	negative	0
9208	10594919	706;1622	MBR;DBI	Whereas the mitochondrial benzodiazepine/diazepam binding inhibitor ( ***DBI*** ) ***receptor*** ( ***MBR*** ) was below the immunohistochemical detection limit in normal mice ( except in the choroid plexus and ependyma cells ) , it was significantly expressed in many reactive astrocytes of jp and shi mice brains .	parallel	1
9209	10594926	3553;1051	IL-1beta;C/EBPbeta	Here we show that lipopolysaccharides ( LPS ) , ***IL-1beta*** , and TNFalpha ***induce*** the expression of the ***C/EBPbeta*** and - delta genes in mouse primary astrocytes .	target	1
9210	10594926	7124;1051	TNFalpha;C/EBPbeta	Here we show that lipopolysaccharides ( LPS ) , IL-1beta , and ***TNFalpha*** ***induce*** the expression of the ***C/EBPbeta*** and - delta genes in mouse primary astrocytes .	target	1
9211	10595511	627;387	Neurotrophin;RhoA	In transfected cells , p75NTR activated RhoA , and ***Neurotrophin*** binding ***abolished*** ***RhoA*** activation .	negative	0
9212	10595511	4804;387	p75NTR;RhoA	In transfected cells , ***p75NTR*** ***activated*** ***RhoA*** , and Neurotrophin binding abolished RhoA activation .	positive	1
9213	10595516	2891;4905	GluR2;NSF	Disrupting exocytosis or the ***interaction*** of ***GluR2*** with ***NSF*** caused a gradual reduction in the AMPAR EPSC , while inhibition of endocytosis caused a gradual increase in the AMPAR EPSC .	parallel	1
9214	10595525	627;4804	brain-derived neurotrophic factor;p75NTR	***Binding*** of four mammalian neurotrophins , nerve growth factor ( NGF ) , ***brain-derived neurotrophic factor*** ( BDNF ) , neurotrophin-3 ( NT-3 ) , and neurotrophin-4/5 ( NT-4 / 5 ) , to ***p75NTR*** is studied by molecular modeling based on X-ray structures of the neurotrophins and the extracellular domain of p55TNFR , a homologue of p75NTR .	parallel	1
9215	10595525	4803;4804	nerve growth factor;p75NTR	***Binding*** of four mammalian neurotrophins , ***nerve growth factor*** ( NGF ) , brain-derived neurotrophic factor ( BDNF ) , neurotrophin-3 ( NT-3 ) , and neurotrophin-4/5 ( NT-4 / 5 ) , to ***p75NTR*** is studied by molecular modeling based on X-ray structures of the neurotrophins and the extracellular domain of p55TNFR , a homologue of p75NTR .	parallel	1
9216	10595525	4908;4804	neurotrophin-3;p75NTR	***Binding*** of four mammalian neurotrophins , nerve growth factor ( NGF ) , brain-derived neurotrophic factor ( BDNF ) , ***neurotrophin-3*** ( NT-3 ) , and neurotrophin-4/5 ( NT-4 / 5 ) , to ***p75NTR*** is studied by molecular modeling based on X-ray structures of the neurotrophins and the extracellular domain of p55TNFR , a homologue of p75NTR .	parallel	1
9217	10595525	4909;4804	neurotrophin-4/5;p75NTR	***Binding*** of four mammalian neurotrophins , nerve growth factor ( NGF ) , brain-derived neurotrophic factor ( BDNF ) , neurotrophin-3 ( NT-3 ) , and ***neurotrophin-4/5*** ( NT-4 / 5 ) , to ***p75NTR*** is studied by molecular modeling based on X-ray structures of the neurotrophins and the extracellular domain of p55TNFR , a homologue of p75NTR .	parallel	1
9218	10595533	719;718	C3aR;C3a	The human ***C3a*** anaphylatoxin ***receptor*** ( ***C3aR*** ) is a G protein-coupled receptor ( GPCR ) composed of seven transmembrane alpha-helices connected by hydrophilic loops .	parallel	1
9219	10595583	5777;2057	SHP1;EPOR	It has been shown previously that ***SHP1*** ***associates*** with the activated erythropoietin receptor ( ***EPOR*** ) and negatively regulates mitogenic signaling .	parallel	0
9220	10595583	2057;2056	EPOR;erythropoietin	It has been shown previously that SHP1 associates with the activated ***erythropoietin*** ***receptor*** ( ***EPOR*** ) and negatively regulates mitogenic signaling .	parallel	1
9221	10595644	4879;183	BNP;angiotensin II	In the present study , we demonstrate that brain natriuretic peptide ( ***BNP*** ) and C-type natriuretic peptide ( CNP ) ***interact*** with ***angiotensin II*** ( Ang II ) in regulative blood coagulation and fibrinolysis by suppressing the expressions of both tissue factor ( TF ) and plasminogen activator inhibitor-1 ( PAI-1 ) induced by Ang II .	parallel	1
9222	10595644	4880;183	CNP;angiotensin II	In the present study , we demonstrate that brain natriuretic peptide ( BNP ) and C-type natriuretic peptide ( ***CNP*** ) ***interact*** with ***angiotensin II*** ( Ang II ) in regulative blood coagulation and fibrinolysis by suppressing the expressions of both tissue factor ( TF ) and plasminogen activator inhibitor-1 ( PAI-1 ) induced by Ang II .	parallel	1
9223	10595644	4879;5054	BNP;PAI-1	Both ***BNP*** and CNP ***suppressed*** the expressions of TF and ***PAI-1*** mRNA induced by Ang II in a time - and concentration-dependent manner via cGMP cascade , which suppressions were accompanied by respective decrease in activities of TF and PAI-1 .	negative	1
9224	10595644	4880;5054	CNP;PAI-1	Both BNP and ***CNP*** ***suppressed*** the expressions of TF and ***PAI-1*** mRNA induced by Ang II in a time - and concentration-dependent manner via cGMP cascade , which suppressions were accompanied by respective decrease in activities of TF and PAI-1 .	negative	1
9225	10595644	7035;2152	TFPI;tissue factor	However , neither the expression of ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) nor tissue-type plasminogen activator ( TPA ) mRNA was affected by the treatment of BNP and CNP .	negative	1
9226	10595647	7035;2152	TFPI;tissue factor	In this study , we investigated the effects of angiotensin metabolites on the mRNA expression of tissue factor ( TF ) , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , plasminogen activator inhibitor-1 ( PAI-1 ) , and tissue type plasminogen activator ( TPA ) in cultured rat aortic endothelial cells .	negative	1
9227	10595738	1398;1956	CrkII;EGFR	***CrkII-23*** mutant , which was isolated as a suppressor gene of the EGF-dependent transformation of NRK cells , ***binds*** constitutively to ***EGFR*** .	parallel	1
9228	10595738	1398;1956	CrkII;EGFR	We found that the ***CrkII*** proto-oncogene product was ***associated*** with the ***EGFR*** in human glioma cells in the absence of epidermal growth factor ( EGF ) .	parallel	0
9229	10595738	2885;1956	Grb2;EGFR	By contrast , Shc and ***Grb2*** were inducibly ***associated*** with the ***EGFR*** in response to EGF stimulation of glioma cells .	parallel	0
9230	10595738	6464;1956	Shc;EGFR	By contrast , ***Shc*** and Grb2 were inducibly ***associated*** with the ***EGFR*** in response to EGF stimulation of glioma cells .	parallel	0
9231	10595926	7422;285	VEGF;angiopoietin-2	In fact , we found a strong ***association*** between tumor size and high levels of ***VEGF*** and ***angiopoietin-2*** .	parallel	0
9232	10595927	3458;2247	interferon-gamma;bFGF	Neither tumor necrosis factor-alpha nor ***interferon-gamma*** ***affected*** ***bFGF*** synthesis by HPMCs .	target	0
9233	10595927	7124;2247	tumor necrosis factor-alpha;bFGF	Neither ***tumor necrosis factor-alpha*** nor interferon-gamma ***affected*** ***bFGF*** synthesis by HPMCs .	target	0
9234	10596380	5054;5327	PAI-1;tPA	In this prospective study , we measured tPA antigen , PAI-1 antigen and activity , as well as ******tPA/PAI-1****** ***complex*** in patients with acute stroke .	parallel	1
9235	10596854	3827;3848	high molecular weight kininogen;cytokeratin 1	***Interaction*** of factor XII and ***high molecular weight kininogen*** with ***cytokeratin 1*** and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer 's disease .	parallel	1
9236	10596857	3816;3827	tissue kallikrein;kininogen	The basic enzymatic ***cleavage*** of ***kininogen*** substrate by the serine protease ***tissue kallikrein*** to liberate kinins is regulated by a number of factors .	target	1
9237	10596908	1029;7157	INK4a;p53	In addition to the INK4a locus , other genes involved in melanoma development are discussed here , in particular those genes that participate in the same functional pathway , such as CDK4 and Rb , and ***p53*** , which is ***regulated*** by the alternative product of ***INK4a*** .	target	1
9238	10596981	6929;4654	E47;MyoD	******MyoD-E47****** covalent ***heterodimer*** binds DNA more tightly ( Kd = 1.8 nM ) than MyoD ( Kd = 14.2 nM ) or E47 ( Kd = 11.5 nM ) covalent homodimers .	parallel	1
9239	10597035	2908;4318	Glucocorticoid receptor;MMP-9	***Glucocorticoid receptor-induced*** ***down-regulation*** of ***MMP-9*** by ginseng components , PD and PT contributes to inhibition of the invasive capacity of HT1080 human fibrosarcoma cells .	negative	1
9240	10597047	2120;861	TEL;AML1	When TEL/AML1 and AML1 proteins are present in cells at the same time , the ***TEL/AML1*** protein ***inhibits*** the transactivation activities of ***AML1*** protein on the human CR1 promoter even though TEL/AML1 retains the transactivation domain of AML1 .	negative	1
9241	10597187	4904;7153	YB-1;topoisomerase II alpha	***YB-1*** expression ***correlated*** well with both DNA ***topoisomerase II alpha*** and PCNA expression .	parallel	0
9242	10597216	573;596	Bcl-2-binding protein;Bcl-2	Bis , a ***Bcl-2-binding protein*** that ***synergizes*** with ***Bcl-2*** in preventing cell death .	parallel	0
9243	10597216	9531;596	Bis;Bcl-2	Co-immunoprecipitation analysis confirmed that ***Bis*** ***interacted*** with ***Bcl-2*** in vivo .	parallel	1
9244	10597239	1027;896	p27kip1;cyclin D3	Interestingly , we observed that high level ***p27kip1*** expression often ***correlated*** with ***cyclin D3*** overexpression both in vivo and in BL cell lines .	parallel	0
9245	10597239	1027;896	p27kip1;cyclin D3	The majority of ***p27kip1*** in BL40 cells was ***complexed*** with ***cyclin D3*** indicating that overexpressed cyclin D3 may at least be part of the sequestering activity for the inhibitory function of p27kip1 .	parallel	1
9246	10597240	1869;5813	E2F-1;Pur alpha	***Association*** of ***Pur alpha*** and ***E2F-1*** suppresses transcriptional activity of E2F-1 .	parallel	0
9247	10597240	5813;1869	Pur alpha;E2F-1	Association of ***Pur alpha*** and E2F-1 ***suppresses*** transcriptional activity of ***E2F-1*** .	negative	1
9248	10597240	5925;1869	pRb;E2F-1	Evidently , the activity of this protein is modulated by its cellular partner , ***pRb*** , which in the hypophosphorylated form , ***binds*** to ***E2F-1*** and inactivates its transcriptional ability .	parallel	1
9249	10597240	23648;1869	sequence-specific single-stranded DNA binding protein;E2F-1	In this study , we have demonstrated that expression of a ***sequence-specific single-stranded DNA binding protein*** , Pur alpha , in cells ***decreases*** the ability of ***E2F-1*** to exert its transcriptional activity upon the responsive promoter derived from DHFR .	negative	0
9250	10597240	1869;5813	E2F-1;Pur alpha	Results from GST pull-down assays and the combined immunoprecipitation/Western blot analysis of nuclear extracts revealed a direct ***association*** of ***E2F-1*** with ***Pur alpha*** in the absence of the DNA molecule containing the E2F-1 binding site .	parallel	0
9251	10597240	5813;1869	Pur alpha;E2F-1	The ***association*** of ***Pur alpha*** with ***E2F-1*** may increase the stability of E2F-1 , as a higher level of E2F-1 was detected in cells coexpressing Pur alpha and E2F-1 .	parallel	0
9252	10597240	5813;1869	Pur alpha;E2F-1	The association of ***Pur alpha*** with E2F-1 may ***increase*** the stability of ***E2F-1*** , as a higher level of E2F-1 was detected in cells coexpressing Pur alpha and E2F-1 .	positive	0
9253	10597246	7157;1026	p53;p21	Additionally , AAF treatment induces strong nuclear ***p53*** expression which is ***associated*** with increased ***p21*** mRNA levels .	parallel	0
9254	10597247	6502;595	Skp2;cyclin D1	The F-box protein ***Skp2*** is a component of an SCF ubiquitin ligase complex and can ***associate*** with ***cyclin D1*** and the cdk inhibitor p21 ( Zhong-Kang et al. , 1998 ) .	parallel	0
9255	10597247	6502;1026	Skp2;p21	The F-box protein ***Skp2*** is a component of an SCF ubiquitin ligase complex and can ***associate*** with cyclin D1 and the cdk inhibitor ***p21*** ( Zhong-Kang et al. , 1998 ) .	parallel	0
9256	10597247	896;6502	cyclin D3;Skp2	We extend this observation and show that ***cyclin D3*** can also ***associate*** with ***Skp2*** suggesting that cyclins D1 , D3 and p21 may share the same SCF complex .	parallel	0
9257	10597251	8563;1436	Fms-interacting protein;Fms	Here we identified a novel ***Fms-interacting protein*** ( FMIP , MW 78 kDa ) which ***binds*** transiently via its N-terminal 144 residues to the cytoplasmic domain of activated ***Fms-molecules*** .	parallel	1
9258	10597252	9966;4790	VEGI;NF-kappa B	In this report , we show that in myeloid cells ***VEGI*** ***activated*** the transcription factor kappa B ( ***NF-kappa B*** ) as determined by the electrophoretic mobility shift assay , induced degradation of I kappa B alpha , and nuclear translocation of p65 subunit of NF-kappa B .	positive	1
9259	10597253	596;836	bcl-2;caspase-3	Apoptosis and activation of ***caspase-3*** by cisplatin , but not DCVC , was ***prevented*** by ***bcl-2*** .	negative	0
9260	10597253	596;836	bcl-2;caspase-3	Thus , ***caspase-3*** ***activation*** by ***bcl-2-dependent*** and - independent mechanisms is a terminal event in chemical-apoptosis of renal epithelial cells .	positive	1
9261	10597260	5578;207	PKC-alpha;Akt	Furthermore , ***activation*** of overexpressed ***Akt*** by ***PKC-alpha*** is consistent with their synergistic effect on suppressing apoptosis , providing the strong evidence of cross talk between Akt and PKC-alpha .	positive	1
9262	10597260	5578;207	Protein kinase C-alpha;Akt	***Protein kinase C-alpha*** overexpression ***stimulates*** ***Akt*** activity and suppresses apoptosis induced by interleukin 3 withdrawal .	positive	0
9263	10597260	3562;207	interleukin 3;Akt	Both basal and ***interleukin 3-stimulated*** ***phosphorylation*** of ***Akt*** on serine 473 was enhanced in the PKC-alpha and Akt contransfectants .	target	1
9264	10597261	3558;10912	IL2;CR6	The physiologic ***induction*** of ***CR6*** expression by ***IL2*** in quiescent normal human T cells occurs transiently in the first half of G1 , coordinately with the expression of p21 .	target	1
9265	10597265	672;7157	BRCA1;p53	We show here that ***BRCA1*** ***increases*** ***p53*** protein levels through a post-transcriptional mechanism .	positive	0
9266	10597265	672;7157	BRCA1;p53	Our results suggest that ***BRCA1*** may ***trigger*** the ***p53*** pathway through two potentially separate mechanisms : accumulation of p53 through a direct or indirect induction of p14ARF as well as direct transcriptional coactivation of p53 .	positive	0
9267	10597267	56163;4084	Mmip-2;mad1	The ******mad1-Mmip-2****** ***interaction*** is mediated by the ZIP domain in the former protein and by at least two regions in the latter which do not include the RING finger .	parallel	1
9268	10597267	1613;4084	ZIP;mad1	The ***mad1-Mmip-2*** interaction is ***mediated*** by the ***ZIP*** domain in the former protein and by at least two regions in the latter which do not include the RING finger .	target	0
9269	10597267	1613;56163	ZIP;Mmip-2	The ***mad1-Mmip-2*** interaction is ***mediated*** by the ***ZIP*** domain in the former protein and by at least two regions in the latter which do not include the RING finger .	target	0
9270	10597267	56163;4609	Mmip-2;Myc	These observations suggest a novel way by which ***Mmip-2*** can ***modulate*** the transcriptional activity of ***Myc*** oncoproteins .	target	0
9271	10597274	5458;672	Brn-3b;BRCA-1	The ***Brn-3b*** POU family transcription factor ***represses*** expression of the ***BRCA-1*** anti-oncogene in breast cancer cells .	negative	1
9272	10597274	5458;672	Brn-3b;BRCA-1	Moreover , ***Brn-3b*** but not Brn-3a can strongly ***repress*** the ***BRCA-1*** promoter approximately 20-fold in mammary tumour cells .	negative	1
9273	10597276	2246;2017	fibroblast growth factor 1;cortactin	***fibroblast growth factor 1*** ( FGF-1 ) is a potent chemotactic factor and ***induces*** tyrosine phosphorylation of a cortical actin-associated protein ( ***cortactin*** ) .	target	1
9274	10597276	2246;2017	FGF-1;cortactin	Morphological analysis further reveals that ***FGF-1*** fails to ***induce*** the formation of polarized lamellipodia and the translocation of ***cortactin*** into the leading edge of Src - / - cells .	target	1
9275	10597277	545;7157	ATR;p53	We show directly that , like ATM and DNA-PK , ***ATR*** ***phosphorylates*** the genome surveillance protein ***p53*** on serine 15 , a site which is up-regulated in response to DNA damage .	target	1
9276	10597280	5915;6772	RAR beta;STAT1	The induction and activation of ***STAT1*** by all-trans-retinoic acid are ***mediated*** by ***RAR beta*** signaling pathways in breast cancer cells .	target	0
9277	10597281	3569;2185	interleukin-6;RAFTK	Finally , ***interleukin-6*** ( IL-6 ) , a known survival factor for MM cells , ***inhibits*** both activation of ***RAFTK*** and apoptosis of MM .1 S cells triggered by Dex .	negative	1
9278	10597288	145258;6688	GSC;PU.1	We demonstrate an in vitro ***interaction*** between the oncogene ***PU.1*** , an ets family transcription factor thought to play a role in erythropoiesis , and the goosecoid protein ( ***GSC*** ) .	parallel	1
9279	10597290	9111;4613	Nmi;MycN	Therefore only a very small amount of MycN and Nmi is likely to be involved in ******MycN/Nmi****** ***interaction*** in vivo .	parallel	1
9280	10597290	4149;4613	Max;MycN	Both ***Max*** and Nmi also ***bind*** to ***MycN*** .	parallel	1
9281	10597290	9111;4613	Nmi;MycN	Both Max and ***Nmi*** also ***bind*** to ***MycN*** .	parallel	1
9282	10597290	4149;4609	Max;Myc	In contrast to the well defined ***binding*** of ***Max*** to ***Myc*** family proteins the interaction of Nmi with Myc or MycN is only poorly characterized .	parallel	1
9283	10597290	9111;4609	Nmi;Myc	In contrast to the well defined binding of Max to Myc family proteins the ***interaction*** of ***Nmi*** with ***Myc*** or MycN is only poorly characterized .	parallel	1
9284	10597290	9111;4613	Nmi;MycN	In contrast to the well defined binding of Max to Myc family proteins the ***interaction*** of ***Nmi*** with Myc or ***MycN*** is only poorly characterized .	parallel	1
9285	10597293	4738;8451	NEDD8;Cul-4A	Recently we found that ***NEDD8*** , a ubiquitin-like protein , was ***linked*** covalently to human cullin-4A ( abbreviated ***Cul-4A*** ) by a new ubiquitin-related pathway that is analogous to but distinct from the ligating system for SUMO1 , another ubiquitin-like protein .	parallel	0
9286	10597294	5879;5599	Rac1;JNK	***Rac1*** is a member of the Ras superfamily of small GTPases involved in signal transduction pathways that induce the formation of lamellipodia , stimulate cell proliferation and ***activate*** the ***JNK/SAPK*** protein kinase cascade .	positive	1
9287	10597294	5879;5601	Rac1;SAPK	***Rac1*** is a member of the Ras superfamily of small GTPases involved in signal transduction pathways that induce the formation of lamellipodia , stimulate cell proliferation and ***activate*** the ***JNK/SAPK*** protein kinase cascade .	positive	1
9288	10597303	7157;4193	p53;mdm2	We propose that mdm2 alpha expression may provide a mechanism for uncoupling ******mdm2-p53****** ***interaction*** in certain cell types and/or under specific conditions of cell growth .	parallel	1
9289	10597310	3087;5371	PRH;PML	The effect on cell growth by PML and the hematopoietic actions of PRH raises the possibility that the ***interaction*** between ***PML*** and ***PRH*** represents a link between growth control and hematopoiesis .	parallel	1
9290	10597310	5371;3087	PML;PRH	The promyelocytic leukemia protein ***PML*** ***interacts*** with the proline-rich homeodomain protein ***PRH*** : a RING may link hematopoiesis and growth control .	parallel	1
9291	10597310	5371;3087	PML;PRH	Using yeast 2-hybrid techniques , we found that ***PML*** and a related RING protein , Z , ***bind*** the proline rich homeodomain protein ( ***PRH*** ) through their RING domains .	parallel	1
9292	10597318	2922;2353	GRP;c-fos	In U-373MG glioblastoma cells , which also express BRS-1 , and U-87MG cells , cultured in vitro , ***GRP*** ( 14-27 ) ***induced*** the expression of ***c-fos*** mRNA , and some c-jun mRNA , in a time-dependent manner with the maximal effect occurring 2 h after the stimulation and a return to basal levels after 8 h.	target	1
9293	10597318	2922;2353	GRP;c-fos	Antagonist RC-3940-II inhibited the ***stimulation*** of ***c-fos*** by ***GRP*** ( 14-27 ) .	positive	0
9294	10597319	10572;939	Siva-2;CD27	Murine Siva-1 and ***Siva-2*** , alternate splice forms of the mouse Siva gene , both ***bind*** to ***CD27*** but differentially transduce apoptosis .	parallel	1
9295	10597896	3320;8349	Hsp90;H2B	In our present studies we used surface plasmon resonance measurements to demonstrate that ***Hsp90*** ***binds*** histones H1 , H2A , ***H2B*** , H3 and H4 with high affinity having dissociation constants in the submicromolar range .	parallel	1
9296	10598372	4193;7157	mdm2;p53	However , it would be also possible that p53 protein accumulation is not related to p53 mutation but to inhibition of ******p53/mdm2****** ***binding*** due to mdm2 defects and/or other events related to cell stress signals .	parallel	1
9297	10598578	857;3643	Caveolin-1;insulin receptor	***Caveolin-1*** ***interacts*** with the ***insulin receptor*** and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells .	parallel	1
9298	10598578	857;2002	Cav;Elk-1	Interestingly , overexpression of ***Cav-WT*** in Cos-7 cells significantly ***enhanced*** insulin-stimulated phosphorylation of ***Elk-1*** ( a mitogen-activated protein kinase-dependent pathway ) while overexpression of Cav-Mut was without effect .	positive	0
9299	10598578	857;5594	Cav;ERK2	In contrast , in adipose cells , overexpression of either Cav-WT or ***Cav-Mut*** did not affect insulin-stimulated phosphorylation of a cotransfected ERK2 ( but did significantly ***inhibit*** basal phosphorylation of ***ERK2*** ) .	negative	1
9300	10598578	4594;5594	Mut;ERK2	In contrast , in adipose cells , overexpression of either Cav-WT or ***Cav-Mut*** did not affect insulin-stimulated phosphorylation of a cotransfected ERK2 ( but did significantly ***inhibit*** basal phosphorylation of ***ERK2*** ) .	negative	1
9301	10598580	7040;3725	TGFbeta;c-Jun	Whereas both CRE-binding protein ( CREB ) and c-Jun present in extracts of unstimulated cells can complex with a CRE in gel-shift experiments , ***TGFbeta*** treatment ***increases*** the amount of ***c-Jun*** found in the complex .	positive	0
9302	10598580	3725;1385	c-Jun;CREB	Overexpression of ***c-Jun*** is sufficient to ***increase*** CRE and ***GAL4-CREB-dependent*** transcription and mimics the stimulatory effects of TGFbeta on transcription from either reporter gene .	positive	0
9303	10598580	3725;3960	c-Jun;GAL4	Overexpression of ***c-Jun*** is sufficient to ***increase*** CRE and ***GAL4-CREB-dependent*** transcription and mimics the stimulatory effects of TGFbeta on transcription from either reporter gene .	positive	0
9304	10598581	5617;6777	PRL;Stat5	Rather ***PRL*** ***activation*** of ***Stat5*** , principally Stat5b , occurred in association with luteinization .	positive	1
9305	10598587	8805;2099	hTIF1alpha;ERalpha	Finally , we show that , mainly in the absence of hormone , ***hTIF1alpha*** ***interacts*** better with ERbeta than with ***ERalpha*** independently of the presence of ERE .	parallel	1
9306	10598587	8805;2100	hTIF1alpha;ERbeta	Finally , we show that , mainly in the absence of hormone , ***hTIF1alpha*** ***interacts*** better with ***ERbeta*** than with ERalpha independently of the presence of ERE .	parallel	1
9307	10598880	3569;3240	IL-6;haptoglobin	SS was found effective in the blockade of the signaling cascade of IL-6 : phosphorylation of both gp130 and Stat3 was eliminated by SS treatment and the production of ***IL-6*** ***stimulated*** ***haptoglobin*** by the cells was abolished .	positive	0
9308	10598907	7039;1634	TGFalpha;decorin	In fact , in CLP fibroblasts , ***TGFalpha*** and TGFbeta1 ***down-regulated*** PG ***decorin*** transcript , TGFbeta1 increased collagen and GAG in both cellular and extracellular compartments , and TGFbeta3 promoted secretory processes of cells .	negative	1
9309	10599309	7039;1956	transforming growth factor-alpha;EGFR	Both ***transforming growth factor-alpha*** ( TGF-alpha ) and epidermal growth factor ***bind*** to and activate ***EGFR*** .	parallel	1
9310	10599310	595;5241	cyclin D1;progesterone receptor	Elevated levels of p27 , p21 and ***cyclin D1*** ***correlate*** with positive oestrogen and ***progesterone receptor*** status in node-negative breast carcinoma patients .	parallel	0
9311	10599310	1026;5241	p21;progesterone receptor	Elevated levels of p27 , ***p21*** and cyclin D1 ***correlate*** with positive oestrogen and ***progesterone receptor*** status in node-negative breast carcinoma patients .	parallel	0
9312	10599552	4852;3952	NPY;leptin	These results may suggest that the feedback system in the ***interaction*** between ***leptin*** and ***NPY*** is disturbed in PCOS .	parallel	1
9313	10599552	3952;4852	leptin;NPY	***leptin*** can ***modulate*** the activity of ***NPY*** and other peptides in the hypothalamus that are known to affect eating behavior .	target	0
9314	10599732	3586;7124	Interleukin-10;tumor necrosis factor-alpha	***Interleukin-10*** ***modifies*** the effects of interleukin-1beta and ***tumor necrosis factor-alpha*** on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells .	target	0
9315	10599732	3586;3553	IL-10;IL-1beta	The goals of this study were to evaluate the ***interaction*** of ***IL-10*** with ***IL-1beta*** and TNFalpha on PG synthesis and to determine the effects of IL-10 , IL-1beta , and TNFalpha on PG metabolism using purified cultures of villous trophoblast and chorion trophoblast cells prepared from placentas of patients at term .	parallel	1
9316	10599732	3586;7124	IL-10;TNFalpha	The goals of this study were to evaluate the ***interaction*** of ***IL-10*** with IL-1beta and ***TNFalpha*** on PG synthesis and to determine the effects of IL-10 , IL-1beta , and TNFalpha on PG metabolism using purified cultures of villous trophoblast and chorion trophoblast cells prepared from placentas of patients at term .	parallel	1
9317	10599732	3553;3248	IL-1beta;PGDH	***IL-1beta*** increased PGHS-2 mRNA and PGE2 output from villous and chorion trophoblasts and ***decreased*** ***PGDH*** mRNA in villous trophoblasts ( all P < 0.05 ) .	negative	0
9318	10599732	3553;5743	IL-1beta;PGHS-2	***IL-1beta*** ***increased*** ***PGHS-2*** mRNA and PGE2 output from villous and chorion trophoblasts and decreased PGDH mRNA in villous trophoblasts ( all P < 0.05 ) .	positive	0
9319	10599732	7124;3248	TNFalpha;PGDH	We found no change in PGHS-2 mRNA or PGE2 output in either trophoblast type treated with TNFalpha , but ***TNFalpha*** ***reduced*** ***PGDH*** mRNA in villous trophoblast , and this effect was reversed by IL-10 ( both P < 0.05 ) .	negative	1
9320	10599848	8851;8941	p35;p39	CDK5 ***requires*** either ***p39*** or ***p35*** to assume its active form in the mammalian CNS .	target	0
9321	10599848	8941;8851	p39;p35	CDK5 ***requires*** either ***p39*** or ***p35*** to assume its active form in the mammalian CNS .	target	0
9322	10599848	1020;8851	CDK5;p35	***CDK5*** ***requires*** either p39 or ***p35*** to assume its active form in the mammalian CNS .	target	0
9323	10599848	1020;8941	CDK5;p39	***CDK5*** ***requires*** either ***p39*** or p35 to assume its active form in the mammalian CNS .	target	0
9324	10600009	3135;3659	HLA-G;IRF-1	Excess unlabeled ***HLA-G-GAS*** oligonucleotide failed to ***inhibit*** binding of the ***IRF-1-GAS*** using the same nuclear extracts .	negative	1
9325	10600159	3725;3162	AP-1;heme oxygenase-1	Studies with mutated constructs showed that both an ***AP-1*** element and a metal responsive element are involved in the PAO-mediated ***induction*** of the ***heme oxygenase-1*** reporter construct .	target	1
9326	10600396	4609;2064	c-myc;HER-2/neu	Our objective was to evaluate the ***association*** between ***HER-2/neu*** , ***c-myc*** , p53 , and clinicopathologic variables in endometrial cancer using fluorescence in situ hybridization ( FISH ) cytogenetic analysis .	parallel	0
9327	10600472	27131;2175	SNX5;Fanconi anemia complementation group A	***SNX5*** , a new member of the sorting nexin family , ***binds*** to the ***Fanconi anemia complementation group A*** protein .	parallel	1
9328	10600500	1975;1974	eIF4B;eIF4A	In contrast to mammalian eIF4B and eIF4A , the combination of wheat eIF4B and eIF4A does not stimulate RNA-dependent ATP hydrolysis activity ; however , wheat ***eIF4B*** does ***stimulate*** eIF4F and ***eIF4A*** RNA-dependent ATP hydrolysis activity .	positive	0
9329	10600528	6714;6774	c-Src;Stat3	Here we report that ***c-Src*** ***activates*** the DNA binding activity of Stat3alpha , Stat3beta , and three ***Stat3*** mutants , one in which serine 727 was replaced by alanine ( Stat3alphaS727A ) and C-terminal truncated molecules Delta48 and Delta55 .	positive	1
9330	10600550	3184;4012	AUF1;AT(1) receptor	Characterization of the ***binding*** of the RNA-binding protein ***AUF1*** to the human ***AT(1) receptor*** mRNA .	parallel	1
9331	10600550	3184;4012	AUF1;AT(1) receptor	Our data demonstrate the presence of AUF1 in human vascular smooth muscle cells and its modulation by activation of the beta-adrenergic and the AT ( 1 ) pathways , a and specific ***binding*** of ***AUF1*** to the human ***AT(1) receptor*** mRNA , suggesting a role of this protein in the modulation of the AT(1) receptor expression .	parallel	1
9332	10600634	5617;6714	prolactin;c-Src	***Stimulation*** of ***c-Src*** by ***prolactin*** is independent of Jak2 .	positive	0
9333	10600634	5617;1445	PRL;c-Src kinase	In the present work , we studied the mechanisms underlying ***c-Src kinase*** ***activation*** by ***PRL*** and the role that Jak2 plays in this process .	positive	1
9334	10600634	5617;6714	PRL;c-Src	These findings indicate that ***PRL-mediated*** ***stimulation*** of ***c-Src*** was independent of Jak2 activation and of receptor phosphorylation .	positive	0
9335	10600748	959;958	CD40L;CD40	Microglial activation resulting from ******CD40-CD40L****** ***interaction*** after beta-amyloid stimulation .	parallel	1
9336	10600748	959;958	CD40L;CD40	Increased tumor necrosis factor alpha production and induction of neuronal injury occurred when Abeta-stimulated microglia were treated with ***CD40*** ***ligand*** ( ***CD40L*** ) .	parallel	1
9337	10600748	958;959	CD40;CD40L	Microglia from Tg APPsw mice deficient for CD40L demonstrated reduction in activation , suggesting that the ******CD40-CD40L****** ***interaction*** is necessary for Abeta-induced microglial activation .	parallel	1
9338	10600748	959;958	CD40L;CD40	Finally , abnormal tau phosphorylation was reduced in Tg APPsw animals deficient for CD40L , suggesting that the ******CD40-CD40L****** ***interaction*** is an early event in AD pathogenesis .	parallel	1
9339	10600750	4803;596	NGF;Bcl-2	Moreover , expression of ***Bcl-2*** was ***activated*** by ***NGF*** and other neurotrophins by a CREB-dependent transcriptional mechanism .	positive	1
9340	10600754	885;1432	CCK;p38 mitogen-activated protein (MAP) kinase	In these cells , as in rat acini , ***CCK*** ***activated*** ***p38 mitogen-activated protein (MAP) kinase*** and increased the phosphorylation of HSP27 .	positive	1
9341	10600759	958;5970	p50;p65	The cytokine triggers nuclear translocation of nuclear factor-kappaB ( NF-kappaB ) p50/p50 homodimers and ******p50/p65****** ***heterodimers*** , and an inhibitor of this transcriptional factor , pyrrolidinedithiocarbamate , can attenuate the PGHS-2 induction .	parallel	1
9342	10600759	4790;5743	NF-kappaB;PGHS-2	The cytokine triggers nuclear translocation of nuclear factor-kappaB ( ***NF-kappaB*** ) p50/p50 homodimers and p50/p65 heterodimers , and an inhibitor of this transcriptional factor , pyrrolidinedithiocarbamate , can ***attenuate*** the ***PGHS-2*** induction .	negative	0
9343	10600761	1080;6557	CFTR;Na(+)-K(+)-2Cl(-) cotransporter	***CFTR*** ***upregulates*** the expression of the basolateral ***Na(+)-K(+)-2Cl(-) cotransporter*** in cultured pancreatic duct cells .	positive	1
9344	10600769	2981;2984	uroguanylin;GC-C	***uroguanylin*** ( UGN ) and guanylin ( GN ) are the endogenous intestinal ***ligands*** for guanylyl cyclase C ( ***GC-C*** ) .	parallel	1
9345	10600794	1906;5706	Endothelin-1;p44	We previously reported that ***Endothelin-1*** ( ET-1 ) ***activates*** ***p42/p44*** mitogen-activated protein ( MAP ) kinase in osteoblast-like MC3T3-E1 cells and consequently induces synthesis of interleukin-6 .	positive	1
9346	10600798	1977;1978	eIF4E;4E-BP1	No changes were observed in eIF2B activity , in the amount of ***eIF4E*** ***associated*** with the eIF4E-binding protein ( ***4E-BP1*** ) , or in the phosphorylation of 4E-BP1 .	parallel	0
9347	10600798	1977;1981	eIF4E;eIF4G	The abundance of ***eIF4E*** ***bound*** to ***eIF4G*** and the extent of phosphorylation of eIF4E were increased by 800 and 20 % , respectively .	parallel	1
9348	10600798	1978;1977	4E-BP1;eIF4E	The fall in eIF4G binding to eIF4E was associated with increased ***4E-BP1*** ***bound*** to ***eIF4E*** and a reduced phosphorylation of 4E-BP1 .	parallel	1
9349	10600798	1981;1977	eIF4G;eIF4E	The fall in ***eIF4G*** ***binding*** to ***eIF4E*** was associated with increased 4E-BP1 bound to eIF4E and a reduced phosphorylation of 4E-BP1 .	parallel	1
9350	10600818	1019;595	Cdk4;cyclin D1	Although ******cyclin D1/Cdk4****** ***complexes*** were more abundant in the cytoplasmic fraction after partial hepatectomy , kinase activity was detected primarily in the nuclear fraction .	parallel	1
9351	10600818	1019;595	Cdk4;cyclin D1	Cytoplasmic ******cyclin D1/Cdk4****** ***complexes*** were activated by recombinant cyclin H/Cdk7 .	parallel	1
9352	10600818	1022;1019	Cdk7;Cdk4	Cytoplasmic ***cyclin D1/Cdk4*** complexes were ***activated*** by recombinant cyclin ***H/Cdk7*** .	positive	1
9353	10600818	1022;595	Cdk7;cyclin D1	Cytoplasmic ***cyclin D1/Cdk4*** complexes were ***activated*** by recombinant cyclin ***H/Cdk7*** .	positive	1
9354	10601018	5608;5594	MKK6;p38	Accordingly , a constitutively activated ***MKK6*** , a ***p38*** ***activator*** , activated TGF-alpha shedding in the absence of exogenous stimuli .	positive	1
9355	10601020	4654;1019	MyoD;cyclin-dependent kinase 4	Here we show that ***MyoD*** can ***interact*** with ***cyclin-dependent kinase 4*** ( cdk4 ) through a conserved 15 amino acid ( aa ) domain in the C-terminus of MyoD .	parallel	1
9356	10601022	4193;7157	MDM2;p53	The data also indicate that Ser15-dependent regulation of transactivation is independent of any involvement in modulating MDM2 binding , and that Ser15 phosphorylation alone is not sufficient to block the ******p53-MDM2****** ***interaction*** .	parallel	1
9357	10601023	5914;5371	RARalpha;PML	Here we report a novel RARalpha-independent signaling pathway that induces maturation of both ATRA-sensitive and ATRA-resistant APL NB4 cells , and does not invoke the ligand-induced alteration of ******PML-RARalpha****** ***signaling*** , stability or compartmentalization .	parallel	0
9358	10601036	11023;5080	Vax1;Pax6	This observation suggests that ***Vax1*** may ***interfere*** negatively with the expression of ***Pax6*** and Rx .	negative	0
9359	10601040	1499;652	beta-catenin;bmp4	Early expression of mouse wnt8 , Xwnt8 , ***beta-catenin*** , or dominant-negative GSK3 induces the expression of neural-specific markers and ***inhibits*** the expression of ***bmp4*** in Xenopus ectoderm .	negative	1
9360	10601091	1618;5940	Dazl1;Rbm	We mimicked human deletions of Rbm and DAZ in the mouse by crossing male mice with a deleted Y chromosome with a reduced number of Rbm genes ( Y ( d1 ) ) to heterozygote Dazl1 null female mice to study the ***interaction*** of the ***Dazl1*** and ***Rbm*** or other genes located in the Y ( d1 ) deletion interval .	parallel	1
9361	10601128	7124;5594	TNF-alpha;p38	Tumor necrosis factor-alpha ( ***TNF-alpha*** ) alone can ***induce*** extracellular signal-regulated kinase ( ERK ) , ***p38*** MAPK , and c-Jun N-terminal kinase activity in a rapid and transient manner , whereas interferon-gamma ( IFN-gamma ) can induce only ERK .	target	1
9362	10601234	995;983	Cdc25;Cdc2	In Xenopus egg extracts , the inhibitory phosphorylations of ***Cdc2*** on Tyr-15 and Thr-14 are ***controlled*** by the phosphatase ***Cdc25*** and the kinases Myt1 and Wee1 .	target	0
9363	10601234	5300;995	Pin1;Cdc25	Overexpression of the prolyl isomerase ***Pin1*** , which ***binds*** to the hyperphosphorylated forms of ***Cdc25*** , Myt1 , and Wee1 found at M-phase , is known to block the initiation of mitosis in egg extracts .	parallel	1
9364	10601234	5300;9088	Pin1;Myt1	Overexpression of the prolyl isomerase ***Pin1*** , which ***binds*** to the hyperphosphorylated forms of Cdc25 , ***Myt1*** , and Wee1 found at M-phase , is known to block the initiation of mitosis in egg extracts .	parallel	1
9365	10601234	5300;7465	Pin1;Wee1	Overexpression of the prolyl isomerase ***Pin1*** , which ***binds*** to the hyperphosphorylated forms of Cdc25 , Myt1 , and ***Wee1*** found at M-phase , is known to block the initiation of mitosis in egg extracts .	parallel	1
9366	10601239	6843;8673	Vamp1;Vamp8	To determine if this mechanism of targeting to the endoplasmic reticulum extends to other Vamps , we compared the membrane ***binding*** of ***Vamp1*** and Vamp2 with the distantly related ***Vamp8*** .	parallel	1
9367	10601239	6844;8673	Vamp2;Vamp8	To determine if this mechanism of targeting to the endoplasmic reticulum extends to other Vamps , we compared the membrane ***binding*** of Vamp1 and ***Vamp2*** with the distantly related ***Vamp8*** .	parallel	1
9368	10601253	2288;3320	FKBP52;hsp90	Immunoadsorption of FKBP52 from reticulocyte lysate also yields co-immunoadsorption of cytoplasmic dynein , and we show that co-immunoadsorption of dynein is competed by a fragment of FKBP52 containing its PPIase domain , but not by a TPR domain fragment that blocks ***FKBP52*** ***binding*** to ***hsp90*** .	parallel	1
9369	10601253	2288;2908	FKBP52;glucocorticoid receptor	Using purified proteins , we also show that ***FKBP52*** ***binds*** directly to the hsp90-free ***glucocorticoid receptor*** .	parallel	1
9370	10601253	2288;3320	FKBP52;hsp90	Because neither the PPIase fragment nor the TPR fragment affects the binding of FKBP52 to the glucocorticoid receptor under conditions in which they block ***FKBP52*** ***binding*** to dynein or ***hsp90*** , respectively , different regions of FKBP52 must determine its association with these three proteins .	parallel	1
9371	10601253	2288;2908	FKBP52;glucocorticoid receptor	Because neither the PPIase fragment nor the TPR fragment affects the ***binding*** of ***FKBP52*** to the ***glucocorticoid receptor*** under conditions in which they block FKBP52 binding to dynein or hsp90 , respectively , different regions of FKBP52 must determine its association with these three proteins .	parallel	1
9372	10601276	3479;207	IGF-I;PKB	These results suggest that the action of ***IGF-I*** on IGFBP-5 gene expression ***requires*** the activation of the PI ***3-kinase-PKB*** / Akt-p70 ( s6k ) pathway but not the MAPK pathway in vascular smooth muscle cells .	target	0
9373	10601277	7020;6288	AP-2;SAA1	Subsequent functional analysis showed that forced expression of ***AP-2*** in HepG2 cells could indeed ***inhibit*** conditioned medium-induced ***SAA1*** promoter activation .	negative	1
9374	10601280	1051;4320	C/EBPbeta;ST3	We demonstrate that ST3 gene induction is actually mediated by the second element , a C/EBP-binding site , by showing : ( i ) that this element becomes accessible in cells induced to express ST3 , ( ii ) that endogenous ***C/EBPbeta*** ***binds*** to the ***ST3*** promoter , and ( iii ) that this binding leads to ST3 transcriptional activation .	parallel	1
9375	10601289	8439;6610	factor associated with neutral sphingomyelinase activation;neutral sphingomyelinase	Stable expression of a dominant-negative form of the FAN protein ( ***factor associated with neutral sphingomyelinase activation*** ) , which has been reported to ***mediate*** tumor necrosis factor-induced activation of ***neutral sphingomyelinase*** , significantly inhibited CD40 ligand-induced sphingomyelinase stimulation and apoptosis of transformed human fibroblasts .	target	0
9376	10601289	8439;958	FAN;CD40	Finally , anti-CD40 antibodies were able to co-immunoprecipitate FAN in control fibroblasts but not in cells expressing the dominant-negative form of FAN , indicating ***interaction*** between ***CD40*** and ***FAN*** .	parallel	1
9377	10601295	7040;4322	TGF-beta1;MMP-13	Expression of ***MMP-13*** by human gingival fibroblasts cultured in monolayer or in collagen gel was ***induced*** by transforming growth factor-beta1 ( ***TGF-beta1*** ) .	target	1
9378	10601295	7040;4322	TGF-beta1;MMP-13	***Induction*** of ***MMP-13*** expression by ***TGF-beta1*** was blocked by SB203580 , a specific inhibitor of p38 MAPK , but not by PD98059 , a selective inhibitor of ERK1/2 activation .	target	1
9379	10601295	7040;4322	TGF-beta1;MMP-13	Adenovirus-mediated expression of dominant negative p38alpha and c-Jun potently inhibited ***induction*** of ***MMP-13*** expression in gingival fibroblasts by ***TGF-beta1*** .	target	1
9380	10601297	2549;207	Gab1;Akt	***HA-Gab1*** was constitutively tyrosine-phosphorylated in PC12 cells and ***induced*** the phosphorylation of ***Akt/protein kinase B*** and p44/42 mitogen-activated protein kinase .	target	1
9381	10601297	2549;2185	Gab1;protein kinase B	***HA-Gab1*** was constitutively tyrosine-phosphorylated in PC12 cells and ***induced*** the phosphorylation of ***Akt/protein kinase B*** and p44/42 mitogen-activated protein kinase .	target	1
9382	10601300	836;5580	caspase 3;protein kinase C-delta	Spontaneous neutrophil apoptosis involves ***caspase 3-mediated*** ***activation*** of ***protein kinase C-delta*** .	positive	1
9383	10601306	5879;3084	Rac1;neuregulin-1	Adenoviral delivery of dominant negative ***Rac1*** , which acts downstream of phosphatidylinositol 3-kinase , ***blocked*** the effect of combined ***neuregulin-1*** / insulin-like growth factor-I treatment .	negative	0
9384	10601307	7514;5903	exportin-1;RanBP2	The bovine RanBP2 transcript contained only five of the eight zinc fingers reported in the human counterpart and are sufficient for ***exportin-1*** ***association*** with ***RanBP2*** .	parallel	0
9385	10601307	7514;5903	exportin-1;RanBP2	In contrast to Ran interaction with ******RanBP2-exportin-1****** ***complex*** , exportin-1 binding to the zinc finger cluster domain of RanBP2 is insensitive to leptomycin B and nucleotide-bound state of Ran-GTPase .	parallel	1
9386	10601311	5170;84959	PDK1;p70	These observations indicate that PDK1 regulates the activation of p70 S6 kinase and provides evidence that ***PDK1*** ***mediates*** the phosphorylation of ***p70*** S6 kinase at Thr-412 .	target	0
9387	10601311	5170;84959	PDK1;p70	These observations indicate that ***PDK1*** ***regulates*** the activation of ***p70*** S6 kinase and provides evidence that PDK1 mediates the phosphorylation of p70 S6 kinase at Thr-412 .	target	1
9388	10601311	5170;84959	3-phosphoinositide-dependent protein kinase-1;p70	Evidence that ***3-phosphoinositide-dependent protein kinase-1*** ***mediates*** phosphorylation of ***p70*** S6 kinase in vivo at Thr-412 as well as Thr-252 .	target	0
9389	10601311	5170;5586	PDK1;protein kinase C-related kinase-2	Recent work has shown that ***PDK1*** ***interacts*** with a region of ***protein kinase C-related kinase-2*** , termed the PDK1 interacting fragment ( PIF ) .	parallel	1
9390	10601313	7040;5599	TGF-beta;JNK	We show that ***JNK*** is rapidly ***activated*** by ***TGF-beta*** in a SMAD-independent manner and phosphorylates Smad3 outside its - SSXS motif .	positive	1
9391	10601313	5599;4088	JNK;Smad3	We show that ***JNK*** is rapidly activated by TGF-beta in a SMAD-independent manner and ***phosphorylates*** ***Smad3*** outside its - SSXS motif .	target	1
9392	10601313	5599;4088	JNK;Smad3	***Smad3*** ***phosphorylation*** by ***JNK*** facilitates both its activation by the TGF-beta receptor complex and its nuclear accumulation .	target	1
9393	10601315	7137;5592	cTnI;cGK	Together with the observations that ***cTnI*** is a good ***substrate*** for ***cGK*** I and is effectively phosphorylated in the presence of cTnT in vitro , these findings suggest that TnT functions as an anchoring protein for cGK I and that cGK I may participate in the regulation of muscle contraction through phosphorylation of TnI .	parallel	1
9394	10601320	1490;596	CTGF;Bcl2	Finally , recombinant ***CTGF*** showed no effect on Bax protein expression but significantly ***reduced*** ***Bcl2*** protein expression .	negative	1
9395	10601322	7490;7015	Wilms' tumor 1;telomerase reverse transcriptase	The ***Wilms' tumor 1*** tumor suppressor gene ***represses*** transcription of the human ***telomerase reverse transcriptase*** gene .	negative	1
9396	10601328	5801;1432	PTP-SL;p38alpha	Upon phosphorylation of Ser ( 231 ) , ***PTP-SL*** ***binding*** and tyrosine dephosphorylation of the MAP kinases extracellular signal-regulated kinase ( ERK ) 1/2 and ***p38alpha*** were impaired .	parallel	1
9397	10601333	11218;6633	Gemin3;SmD2	***Gemin3*** ***interacts*** directly with SMN , as well as with SmB , ***SmD2*** , and SmD3 .	parallel	1
9398	10601333	11218;6634	Gemin3;SmD3	***Gemin3*** ***interacts*** directly with SMN , as well as with SmB , SmD2 , and ***SmD3*** .	parallel	1
9399	10601334	27230;821	RAMP4;calnexin	***SERP1/RAMP4*** ***interacted*** with Sec61alpha and Sec61beta , which are subunits of translocon , and a molecular chaperon ***calnexin*** .	parallel	1
9400	10601344	3559;387	IL2R;RhoA	In addition , using biochemical activity assays for Rho-like GTPases , we show that the expression of beta1A , beta1D , or ***IL2R-beta1A*** in GE11 or GD25 cells ***triggers*** activation of both ***RhoA*** and Rac1 , but not of Cdc42 .	positive	0
9401	10601346	7082;9414	ZO-1;ZO-2	We then examined the possible ***interactions*** between ******ZO-1/ZO-2/ZO-3****** and claudins .	parallel	1
9402	10601346	27134;7082	ZO-3;ZO-1	We then examined the possible ***interactions*** between ******ZO-1/ZO-2/ZO-3****** and claudins .	parallel	1
9403	10601346	27134;9414	ZO-3;ZO-2	We then examined the possible ***interactions*** between ******ZO-1/ZO-2/ZO-3****** and claudins .	parallel	1
9404	10601358	3662;3565	interferon regulatory factor 4;interleukin 4	Lineage-specific ***modulation*** of ***interleukin 4*** signaling by ***interferon regulatory factor 4*** .	target	0
9405	10601358	3662;6778	IRF-4;signal transducer and activator of transcription (Stat)6	Furthermore , we find that ***IRF-4*** can ***interact*** with ***signal transducer and activator of transcription (Stat)6*** and drive the expression of IL-4-inducible genes .	parallel	1
9406	10601358	604;3662	BCL-6;IRF-4	The transactivating ability of ***IRF-4*** is ***blocked*** by the repressor factor ***BCL-6*** .	negative	0
9407	10601562	1437;3569	GM-CSF;IL-6	Elevated ***GM-CSF*** levels in tumor bearing mice ***upregulate*** ***IL-6*** production by B cells via a mechanism independent of TNF-alpha .	positive	1
9408	10601562	1437;3569	GM-CSF;IL-6	Rather , ***GM-CSF*** ***activates*** ***IL-6*** production independently of TNF-alpha as demonstrated by neutralization studies using anti-TNF-alpha antibodies .	positive	1
9409	10601586	1471;1508	cystatin C;cathepsin B	The localization of ***cathepsin B*** , a potential promoter of prolactin ( PRL ) release via extra renal renin-angiotensin system in the adenohypophysis , and its ***inhibitor*** ***cystatin C*** in the human adenohypophysis and in pituitary adenomas were examined using single and dual immunohistochemical staining .	negative	1
9410	10601634	3976;677	LIF;cMG1	***LIF*** ***induced*** ***cMG1/ERF-1*** mRNA at 15 min , and levels peaked at 10-fold initial levels at 30 min .	target	1
9411	10601634	183;677	angiotensin II;cMG1	Phenylephrine , ***angiotensin II*** and endothelin-1 also ***induced*** ***cMG1/ERF-1*** expression .	target	1
9412	10601634	1906;677	endothelin-1;cMG1	Phenylephrine , angiotensin II and ***endothelin-1*** also ***induced*** ***cMG1/ERF-1*** expression .	target	1
9413	10601648	133;7124	Adrenomedullin;tumor necrosis factor-alpha	***Adrenomedullin*** ***suppresses*** interleukin-1beta-induced ***tumor necrosis factor-alpha*** production in Swiss 3T3 cells .	negative	1
9414	10601648	133;7124	Adrenomedullin;tumor necrosis factor-alpha	We demonstrated that ***Adrenomedullin*** ( AM ) ***inhibited*** interleukin-1beta-induced ***tumor necrosis factor-alpha*** ( TNF-alpha ) secretion and gene transcription in Swiss 3T3 fibroblasts maximally to 23 % and 18 % of control , while the other peptides elevating intracellular cAMP levels elicited much weaker effects .	negative	1
9415	10601865	4883;2981	guanylate cyclase C;uroguanylin	***guanylate cyclase C*** ( GCC ) serves as a ***receptor*** for the endogenous ligands , guanylin and ***uroguanylin*** , as well as the family of bacterial heat-stable enterotoxins ( ST ) , which are one of the major causes of diarrhoea the world over .	parallel	1
9416	10601960	3479;3484	IGF-I;IGFBP-1	CONCLUSION : The present study shows that both total and nonphosphorylated IGFBP-1 concentrations are decreased in obese children and the increased free ***IGF-I*** level in obese children is ***related*** to the reduced total ***IGFBP-1*** level , but unrelated to the change in the IGFBP-1 phosphorylation status .	parallel	0
9417	10601992	26191;5601	PEP;Jnk2	Expression of ***PEP*** also ***reduced*** activation of the N-terminal c-Jun kinase ***Jnk2*** in response to receptor ligation , but not in response to UV light .	negative	1
9418	10601992	26191;2353	PEP;c-fos	Finally , we observed that ***PEP*** ***reduced*** ***c-fos*** activation in a synergistic manner with Csk , supporting the notion that these two enzymes form a functional team acting on Src family kinases involved in TCR signaling .	negative	1
9419	10601993	959;3569	CD154;IL-6	Membrane-bound ***CD154*** , but not CD40-specific antibody , ***mediates*** NF-kappaB-independent ***IL-6*** production in B cells .	target	0
9420	10601993	958;3569	CD40;IL-6	Engagement of ***CD40*** on either a B cell line or normal mouse splenic B cells with a membrane-bound form of CD154 ( also known as CD40L or gp39 ) ***induced*** ***IL-6*** secretion as well as up-regulation of IL-6 mRNA , but cross-linking CD40 with agonistic anti-CD40 mAb did not , although these mAb induce many other CD40 activation events , including the nuclear translocation of the transcription factor NF-kappaB .	target	1
9421	10601993	958;3569	CD40;IL-6	Thus , CD40-mediated IL-6 induction is independent of NF-kappaB activation and the binding of TRAF2 and -3 , but ***CD40*** must be engaged by trimeric CD154 on cell membranes to ***activate*** production of ***IL-6*** .	positive	1
9422	10601999	940;2625	CD28;GATA-3	We suggest that ***CD28-dependent*** ***induction*** of ***GATA-3*** in concert with other transcription factors , which are preferentially induced by strong CD28-signals , primes CD4 T cells for IL-4-dependent Th2 differentiaton .	target	1
9423	10602002	3569;4170	IL-6;mcl-1	***IL-6*** ***up-regulates*** ***mcl-1*** in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway .	positive	1
9424	10602002	3569;4170	IL-6;mcl-1	In the current study , we demonstrate that ***IL-6*** , a survival factor for the human myeloma cell line MDN , rapidly ***up-regulates*** ***mcl-1*** whereas it has no effect on Bcl-2 protein level .	positive	1
9425	10602002	3569;6774	IL-6;STAT3	In MDN cells , ***IL-6*** ***induces*** both extracellular signal-regulated protein kinase ( ERK ) 1,2 and ***STAT3*** activation whereas STAT1 and STAT5 activation remains undetectable .	target	1
9426	10602003	5788;5790	CD45;CD45-associated protein	In lymphocytes , ***CD45*** ***interacts*** with ***CD45-associated protein*** ( CD45AP ) , a 32 000 Mr phosphoprotein , through their respective transmembrane domains .	parallel	1
9427	10602037	8837;841	c-FLIP;caspase-8	Moreover , transfection of ***c-FLIP*** ( L ) into A20 cells inhibited Fas-dependent apoptosis and ***suppressed*** recruitment of ***caspase-8*** to the DISC .	negative	1
9428	10602039	1051;5451	C/EBPbeta;Oct-1	We show that ***C/EBPbeta-3*** forms ternary ***complexes*** with ***Oct-1*** and Oct-2 on heavy and light chain promoters , and also interacts with both octamer-binding proteins in the absence of DNA .	parallel	1
9429	10602039	1051;5452	C/EBPbeta;Oct-2	We show that ***C/EBPbeta-3*** forms ternary ***complexes*** with Oct-1 and ***Oct-2*** on heavy and light chain promoters , and also interacts with both octamer-binding proteins in the absence of DNA .	parallel	1
9430	10602042	6367;3565	MDC;IL-4	In this study , we show in vitro ***MDC*** production also by activated T cells , which preferentially ***associate*** with the production of Th2 cytokines , ***IL-4*** , IL-5 , and IL-6 , and inversely correlate with the production of the Th1 cytokine , IFN-gamma .	parallel	0
9431	10602042	6367;3567	MDC;IL-5	In this study , we show in vitro ***MDC*** production also by activated T cells , which preferentially ***associate*** with the production of Th2 cytokines , IL-4 , ***IL-5*** , and IL-6 , and inversely correlate with the production of the Th1 cytokine , IFN-gamma .	parallel	0
9432	10602042	6367;3569	MDC;IL-6	In this study , we show in vitro ***MDC*** production also by activated T cells , which preferentially ***associate*** with the production of Th2 cytokines , IL-4 , IL-5 , and ***IL-6*** , and inversely correlate with the production of the Th1 cytokine , IFN-gamma .	parallel	0
9433	10602049	10803;6370	CCR9;thymus-expressed chemokine	In the process of searching for molecules specifically expressed at different stages of mouse thymic differentiation , we have characterized the cDNA coding for the ***thymus-expressed chemokine*** ( TECK ) and its ***receptor*** ***CCR9*** .	parallel	1
9434	10602049	10803;6370	CCR9;TECK	In conclusion , the interplay of ***TECK*** and its ***receptor*** ***CCR9*** is likely to have a significant role in the recruitment of developing thymocytes to discrete compartments of the thymus .	parallel	1
9435	10602049	10803;6370	CCR9;TECK	In conclusion , the ***interplay*** of ***TECK*** and its receptor ***CCR9*** is likely to have a significant role in the recruitment of developing thymocytes to discrete compartments of the thymus .	parallel	1
9436	10602073	7124;6347	TNFalpha;MCP-1	***TNFalpha*** ***induced*** EC expression and activity of ***MCP-1*** and tissue factor and suppressed that of thrombomodulin on all substrates .	target	1
9437	10602073	7124;2152	TNFalpha;tissue factor	***TNFalpha*** ***induced*** EC expression and activity of MCP-1 and ***tissue factor*** and suppressed that of thrombomodulin on all substrates .	target	1
9438	10602073	7124;6347	TNFalpha;MCP-1	***TNFalpha*** ***increased*** ***MCP-1*** secretion significantly in aortic and pulmonary artery EC but to a lesser extent in microvascular EC .	positive	0
9439	10602073	7124;7056	TNFalpha;thrombomodulin	Basal expression of thrombomodulin was largely comparable for all three cell types grown on different surfaces , but ***TNFalpha*** ***suppressed*** ***thrombomodulin*** to different extents depending on the origin of the EC .	negative	1
9440	10602092	961;140885	CD47;SHPS-1	Expression of a synapse-associated membrane protein , ***P84/SHPS-1*** , and its ***ligand*** , ***IAP/CD47*** , in mouse retina .	parallel	1
9441	10602092	140885;961	P84;IAP	Examination of transgenic IAP-null retinae revealed a failure of P84 to become associated with synaptic sites , suggesting the ***interaction*** of ***P84*** with ***IAP*** was necessary for P84 's synaptic localization .	parallel	1
9442	10602324	728;727	C5aR;C5a	Potent and highly selective small molecule antagonists have recently been developed by us for ***C5a*** ***receptors*** ( ***C5aR*** ) on human polymorphonuclear leukocytes ( PMN ) .	parallel	1
9443	10602409	1234;6348	CCR-5;MIP-1alpha	Based on the observation of CC chemokine induction in monocytes by Tat , we also examined the cellular localization of the CC chemokine Macrophage Inflammatory Protein-1alpha ( ***MIP-1alpha*** ) and its cognate ***receptor*** ***CCR-5*** in these samples .	parallel	1
9444	10602415	6387;7852	stromal cell-derived factor-1;CXCR4	The chemokine receptor ***CXCR4*** and its ***ligand*** ***stromal cell-derived factor-1*** ( SDF-1 ) play an important role in trafficking of normal lymphocytes , monocytes , as well as hematopoietic stem - and progenitor cells .	parallel	1
9445	10602416	3458;3659	IFNgamma;IRF-1	Unexpectedly , all primary acute promyelocytic leukemia ( APL ) samples lacked IRF-1 protein and most exhibited accelerated exon skipping ; furthermore , IRF-1 could not be induced by ***IFNgamma*** or all-trans retinoic acid ( ATRA ) which both ***induce*** ***IRF-1*** in the NB4 APL cell line .	target	1
9446	10602419	8548;3725	JEM-1;c-Jun	Interestingly , ***JEM-1-1*** ***increased*** substantially the transcriptional activity of ***c-Jun*** ( three-fold ) and more strongly that of ectopically co-expressed c-Fos and c-Jun ( five - to six-fold ) , as measured by a CAT reporter gene driven by a heterologous promoter containing the AP-1 binding site of the human collagenase gene .	positive	0
9447	10602469	4792;4790	IkappaBalpha;NF-kappaB	As reviewed here , Tax activates NF-kappaB primarily via a pathway leading to the chronic phosphorylation and degradation of ***IkappaBalpha*** , a cytoplasmic ***inhibitor*** of ***NF-kappaB*** .	negative	1
9448	10602478	58497;4830	PRUNE;nm23-H1	The data presented are consistent with the view that ***PRUNE*** acts as a negative ***regulator*** of the ***nm23-H1*** protein .	negative	1
9449	10602478	58497;4830	PRUNE;nm23-H1	We discuss how ***PRUNE*** ***regulates*** ***nm23-H1*** protein and postulate possible implications of PRUNE in neuroblastoma progression .	target	1
9450	10602480	5074;1613	Par-4;Dlk	Complex ***formation*** between ***Dlk*** and ***Par-4*** was confirmed by GST pull-down experiments and kinase reactions in vitro and coexpression experiments in vivo .	parallel	0
9451	10602491	1019;896	cdk4;Cyclin D3	The induction of cyclin A and cdc2 , the phosphorylation of cdk2 , the nuclear translocation of cdk4 and the assembly of ******Cyclin D3-cdk4****** ***complexes*** required the synergy of TSH and insulin .	parallel	1
9452	10602491	1019;896	cdk4;Cyclin D3	This inhibition was overridden by insulin , which markedly stimulated Cyclin D3 mRNA and protein accumulation , but failed to assemble ******Cyclin D3-cdk4****** ***complexes*** in the absence of TSH .	parallel	1
9453	10602493	355;5599	Fas;JNK	***Activation*** of c-Jun N-terminal kinase ( ***JNK*** ) by ***Fas*** ligation is caspase-dependent , suggesting that caspases may regulate activators of the JNK pathway .	positive	1
9454	10602496	4792;4790	IkappaB-alpha;NF-kappaB	The activity of the ***IkappaB-alpha*** kinase , IKKalpha , which ***mediates*** ***NF-kappaB*** activation , was also measured .	target	0
9455	10602496	1147;4790	IKKalpha;NF-kappaB	The activity of the IkappaB-alpha kinase , ***IKKalpha*** , which ***mediates*** ***NF-kappaB*** activation , was also measured .	target	0
9456	10602501	602;6647	Bcl-3;homodimer	It has been shown that nuclear IkappaB protein ***Bcl-3*** is able to ***increase*** p50/p50 ***homodimer*** binding to the different kappaB sites in mouse thymocytes .	positive	0
9457	10602501	602;4790	Bcl-3;p50	It has been shown that nuclear IkappaB protein ***Bcl-3*** is able to ***increase*** ***p50/p50*** homodimer binding to the different kappaB sites in mouse thymocytes .	positive	0
9458	10602505	5728;5925	PTEN;pRb	Finally , the hyperphosphorylation of transfected ***pRb*** is ***inhibited*** by ***PTEN*** co-expression and restored by PI-3K co-expression .	negative	1
9459	10602506	2353;3725	c-fos;AP-1	Since ***c-fos*** expression may play an important role in UVB ***induced*** ***AP-1*** activation , and AP-1 activation is known to play a role in tumor promotion , both p38 and ERK could be potential targets for chemoprevention of skin cancer .	target	1
9460	10602506	5594;2353	p38;c-fos	Suppression of both ***p38*** and ERK not only completely blocked UVB induced c-fos expression , but also ***decreased*** ***c-fos*** gene basal expression .	positive	0
9461	10602507	5609;1017	MEK;cdk2	Moreover , activated ***MEK*** ***inhibited*** E2-stimulated ***cdk2*** activity .	negative	1
9462	10602507	1436;1435	CSF-1R;CSF-1	The ***CSF-1*** ***receptor*** ( ***CSF-1R*** ) is expressed in > 50 % of human breast cancers .	parallel	1
9463	10602507	1435;1017	CSF-1;cdk2	Unexpectedly , ***CSF-1*** substantially inhibited estradiol ( E2 ) and insulin-dependent proliferation of MCF-7 transfectants ( MCF-7fms ) and ***prevented*** cyclin E/cdk2 and cyclin ***A/cdk2*** activation , consistent with a G1 arrest .	negative	0
9464	10602507	1435;5594	CSF-1;ERK	***ERK*** ***activation*** by ***CSF-1*** was robust and sustained in MCF-7fms and to a much lesser extent in T-47Dfms .	positive	1
9465	10602508	7520;2547	Ku80;Ku70	Ku antigen is a ***complex*** of ***Ku70*** and ***Ku80*** subunits and plays an important role in not only DNA double-strand breaks ( DSB ) repair and V ( D ) J recombination , but also in growth regulation .	parallel	1
9466	10602516	2534;3725	SLK;c-Jun	Biochemical characterization showed that ***SLK*** overexpression ***activates*** ***c-Jun*** amino-terminal kinase 1 ( JNK1 ) .	positive	1
9467	10602516	2534;5599	SLK;JNK1	Biochemical characterization showed that ***SLK*** overexpression ***activates*** c-Jun amino-terminal kinase 1 ( ***JNK1*** ) .	positive	1
9468	10602518	2247;598	FGF2;Bcl-xl	***FGF2*** also ***increased*** the de novo synthesis and the production of ***Bcl-xl*** before the onset of apoptosis .	positive	0
9469	10602518	598;2247	bcl-x;FGF2	Both inhibition of ERK2 activation , which decreased Bcl-xl synthesis , and downregulation of ***bcl-x*** by antisense oligonucleotide treatment ***inhibited*** the survival-promoting activity of ***FGF2*** .	positive	1
9470	10602522	7157;7078	p53;TIMP-3	***Inhibition*** of the putative tumor suppressor gene ***TIMP-3*** by tumor-derived ***p53*** mutants and wild type p53 .	negative	1
9471	10602562	5329;5340	uPAR;plasmin	Thus , local generation of ***plasmin*** and consequent degradation of fibrin are likely to be ***promoted*** by cell surface localization of uPA by ***uPAR*** in cellular constituents of the vessel wall .	positive	0
9472	10602890	4586;920	mucin;CD4	***Modulation*** of ***CD4*** cell cytokine production by colon cancer-associated ***mucin*** .	target	0
9473	10603087	7080;6469	NKX2.1;Shh	We found that expression of ***NKX2.1*** , NKX2.2 , and NKX2 .9 in neural domains ***requires*** ***Shh*** signaling , whereas NKX2.3 , NKX2.5 and NKX2 .6 expression in endoderm and mesoderm is independent of Shh .	target	0
9474	10603087	4821;6469	NKX2.2;Shh	We found that expression of NKX2.1 , ***NKX2.2*** , and NKX2 .9 in neural domains ***requires*** ***Shh*** signaling , whereas NKX2.3 , NKX2.5 and NKX2 .6 expression in endoderm and mesoderm is independent of Shh .	target	0
9475	10603309	3091;7422	HIF-1;VEGF	Hypoxia-dependent ***VEGF*** induction is ***mediated*** by hypoxia-inducible factor-1 ( ***HIF-1*** ) .	target	0
9476	10603340	2253;1746	FGF8;Dlx2	***FGF8*** also ***inhibits*** expression of ***Dlx2*** in the epithelium by a signalling pathway that requires the mesenchyme .	negative	1
9477	10603350	6469;7448	Shh;vitronectin	Here we show that ***N-Shh*** ***binds*** to the three forms of ***vitronectin*** ( 70 , 54 and 45 kDa ) isolated from embryonic tissue , although is preferentially associated with the 45 kDa form .	parallel	1
9478	10603357	3082;4233	Scatter Factor;c-Met	Previous studies have shown that Pax3 , together with the ***c-Met*** receptor tyrosine kinase and its ***ligand*** ***Scatter Factor*** ( SF ) are necessary for the migration of hypaxial muscle precursors in mice .	parallel	1
9479	10603935	5350;488	phospholamban;SERCA2	In addition , ***phospholamban*** mutants with changes of basic to acidic amino acids in the cytoplasmic domain ***increased*** ***SERCA2*** activity by 30-35 % .	negative	0
9480	10603943	2280;6261	FKBP12;RyR1	We propose that ***binding*** of one ***FKBP12*** to each ***RyR1*** lowers the energy of twisted-amide peptidyl-prolyl bonds and stabilizes RyR1 in a conformation that permits coordinated gating of the four RyR1 subunits .	parallel	1
9481	10603943	2280;6261	FKBP12;RyR1	We propose that binding of one ***FKBP12*** to each RyR1 lowers the energy of twisted-amide peptidyl-prolyl bonds and ***stabilizes*** ***RyR1*** in a conformation that permits coordinated gating of the four RyR1 subunits .	positive	0
9482	10603951	5350;488	phospholamban;SERCA2	The fact that the ***modulation*** of ***SERCA2*** activity by ***phospholamban*** is preserved in failing human myocardium offers an opportunity for improvement in the therapy of heart failure .	target	0
9483	10604385	796;27087	calcitonin;NK-1	PURPOSE : In bladder , sensory afferent nerve fibers contain the " sensory neuropeptides " substance P ( SP ) , neurokinin A ( NKA ) and ***calcitonin*** gene-related peptide ( CGRP ) , which ***interact*** with tachykinin ***NK-1*** and NK-2 receptors and CGRP receptors , respectively .	parallel	1
9484	10604385	6863;27087	neurokinin A;NK-1	PURPOSE : In bladder , sensory afferent nerve fibers contain the " sensory neuropeptides " substance P ( SP ) , ***neurokinin A*** ( NKA ) and calcitonin gene-related peptide ( CGRP ) , which ***interact*** with tachykinin ***NK-1*** and NK-2 receptors and CGRP receptors , respectively .	parallel	1
9485	10604389	2908;1958	glucocorticoid receptor;Egr-1	The ***glucocorticoid receptor*** expression was also ***correlated*** with PNMT expression in the tumors and the expression of ***Egr-1*** was also high in 3 of the 4 specimens .	parallel	0
9486	10604467	8851;1020	p25;Cdk5	Unlike p35 , p25 is not readily degraded , and ***binding*** of ***p25*** to ***Cdk5*** constitutively activates Cdk5 , changes its cellular location and alters its substrate specificity .	parallel	1
9487	10604467	8851;1020	p25;Cdk5	Unlike p35 , p25 is not readily degraded , and binding of ***p25*** to Cdk5 constitutively ***activates*** ***Cdk5*** , changes its cellular location and alters its substrate specificity .	positive	1
9488	10604467	8851;1020	p25;Cdk5	In vivo the ******p25/Cdk5****** ***complex*** hyperphosphorylates tau , which reduces tau 's ability to associate with microtubules .	parallel	1
9489	10604467	1020;8851	Cdk5;p25	Moreover , expression of the ******p25/Cdk5****** ***complex*** in cultured primary neurons induces cytoskeletal disruption , morphological degeneration and apoptosis .	parallel	1
9490	10604473	1020;84152	Cdk5;DARPP-32	***Phosphorylation*** of ***DARPP-32*** by ***Cdk5*** modulates dopamine signalling in neurons .	target	1
9491	10604473	1020;84152	Cdk5;DARPP-32	***Cdk5*** ***phosphorylates*** ***DARPP-32*** in vitro and in intact brain cells .	target	1
9492	10604537	3816;3827	Tissue kallikrein;kininogen	***Tissue kallikrein*** ***cleaves*** ***kininogen*** substrate to produce vasoactive kinin peptides that have been implicated to play a role in the proliferation of vascular smooth muscle cells ( VSMC ) .	target	1
9493	10604552	1432;6352	p38 MAP kinase;RANTES	***p38 MAP kinase*** ***regulates*** ***RANTES*** production by TNF-alpha-stimulated human pulmonary vascular endothelial cells .	target	1
9494	10604552	7124;1432	TNF-alpha;p38 MAP kinase	RESULTS : The results showed that ***TNF-alpha*** ***induced*** RANTES production and ***p38 MAP kinase*** activity in human pulmonary vascular endothelial cells .	target	1
9495	10604552	7124;6352	TNF-alpha;RANTES	RESULTS : The results showed that ***TNF-alpha*** ***induced*** ***RANTES*** production and p38 MAP kinase activity in human pulmonary vascular endothelial cells .	target	1
9496	10604883	9370;7412	adiponectin;VCAM-1	Physiological concentrations of ***adiponectin*** dose-dependently ***inhibited*** TNF-alpha-induced THP-1 adhesion and expression of ***VCAM-1*** , E-selectin , and ICAM-1 on HAECs .	negative	1
9497	10604958	5970;4790	p65;p50	Antibodies to NF-kappaB p65 ( Rel A ) and p50 ( but not normal rabbit IgG ) supershifted this retardation signal and verified the type of NF-kappaB species as the classical ******p50/p65****** ***heterodimer*** .	parallel	1
9498	10604986	929;3329	CD14;HSP60	Cutting edge : heat shock protein ( HSP ) 60 activates the innate immune response : ***CD14*** is an essential ***receptor*** for ***HSP60*** activation of mononuclear cells .	parallel	1
9499	10604988	3456;5594	IFN-beta;p40	We report that in our Th cell differentiation model , DC IL-12 secretion is dependent on the CD40L/CD40 accessory pathway , and , utilizing a Th cell-free system , we find that ***IFN-beta*** ***inhibits*** anti-CD40 mAb-induced DC secretion of the ***p40*** chain of the IL-12 heterodimer .	negative	1
9500	10604988	3456;958	IFN-beta;CD40	In addition , we show that ***IFN-beta-mediated*** ***inhibition*** of ***CD40*** signaling does not interfere with all signaling pathways emanating from CD40 , since anti-CD40 mAb-induced DC IL-6 secretion is augmented by IFN-beta .	negative	1
9501	10604988	3456;958	IFN-beta;CD40	In addition , we show that IFN-beta-mediated inhibition of CD40 signaling does not interfere with all signaling pathways emanating from CD40 , since ***anti-CD40*** mAb-induced DC IL-6 secretion is ***augmented*** by ***IFN-beta*** .	positive	0
9502	10604988	3456;3569	IFN-beta;IL-6	In addition , we show that IFN-beta-mediated inhibition of CD40 signaling does not interfere with all signaling pathways emanating from CD40 , since anti-CD40 mAb-induced DC ***IL-6*** secretion is ***augmented*** by ***IFN-beta*** .	positive	0
9503	10604994	3606;3458	IL-18;IFN-gamma	***IL-18*** produced by DCs and macrophages acts in an autocrine manner and ***augments*** IL-12-induced ***IFN-gamma*** production by DCs as also observed in T and NK cells .	positive	0
9504	10604994	3565;3458	IL-4;IFN-gamma	In addition , ***IL-4*** markedly ***enhances*** ***IFN-gamma*** production when DCs are stimulated through CD40 or MHC class II .	positive	0
9505	10604994	3606;1432	IL-18;p38 mitogen-activated protein kinase	***IL-18*** but not IL-4 or IL-12 further ***activates*** the ***p38 mitogen-activated protein kinase*** activity , suggesting that IL-4 and IL-18 enhance IFN-gamma production through distinct intracellular signal transduction pathways in DCs .	positive	1
9506	10604994	3606;3458	IL-18;IFN-gamma	IL-18 but not IL-4 or IL-12 further activates the p38 mitogen-activated protein kinase activity , suggesting that IL-4 and ***IL-18*** ***enhance*** ***IFN-gamma*** production through distinct intracellular signal transduction pathways in DCs .	positive	0
9507	10604994	3565;3458	IL-4;IFN-gamma	IL-18 but not IL-4 or IL-12 further activates the p38 mitogen-activated protein kinase activity , suggesting that ***IL-4*** and IL-18 ***enhance*** ***IFN-gamma*** production through distinct intracellular signal transduction pathways in DCs .	positive	0
9508	10604996	941;940	CD80;CD28	The individual ***CD28*** ***ligand*** , ***CD80*** , is important for some lung immune responses and can not always be compensated for by CD86 .	parallel	1
9509	10604996	940;941	CD28;CD80	In vivo treatment with CTLA4-Ig to block the ***interaction*** of ***CD28*** with ***CD80*** and CD86 reduced virus-specific cytotoxicity and IFN-gamma production by bronchoalveolar lavage fluid CD8 + T lymphocytes in vitro .	parallel	1
9510	10604996	940;942	CD28;CD86	In vivo treatment with CTLA4-Ig to block the ***interaction*** of ***CD28*** with CD80 and ***CD86*** reduced virus-specific cytotoxicity and IFN-gamma production by bronchoalveolar lavage fluid CD8 + T lymphocytes in vitro .	parallel	1
9511	10604996	940;942	CD28;CD86	Treatment with Y100F-Ig , a mutant form of CTLA4-Ig which selectively binds to CD80 and blocks the CD28-CD80 interaction leaving ******CD28-CD86****** ***binding*** intact , did not affect Ab production , spleen cytotoxic precursors , or clearance of virus .	parallel	1
9512	10604996	940;941	CD28;CD80	Treatment with Y100F-Ig , a mutant form of CTLA4-Ig which selectively binds to CD80 and blocks the ******CD28-CD80****** ***interaction*** leaving CD28-CD86 binding intact , did not affect Ab production , spleen cytotoxic precursors , or clearance of virus .	parallel	1
9513	10604999	942;941	CD86;CD80	Costimulation mediated by the ***interactions*** of the B7 Ags ( ******CD80/CD86****** ) on APC with CD28 on the responding T cell regulates the magnitude of the immune response and may influence Th1/Th2 development .	parallel	1
9514	10605004	941;940	B7-1;CD28	This study was designed to examine the roles of ***CD28*** and its individual ***ligands*** , ***B7-1*** and B7-2 , in experimental autoimmune encephalomyelitis ( EAE ) , a Th1-mediated inflammatory disease of the CNS .	parallel	1
9515	10605004	942;940	B7-2;CD28	This study was designed to examine the roles of ***CD28*** and its individual ***ligands*** , B7-1 and ***B7-2*** , in experimental autoimmune encephalomyelitis ( EAE ) , a Th1-mediated inflammatory disease of the CNS .	parallel	1
9516	10605018	959;958	CD40 ligand;CD40	Th2-dependent B cell responses in the absence of ******CD40-CD40 ligand****** ***interactions*** .	parallel	1
9517	10605021	3569;3589	IL-6;IL-11	Whereas the role of the three membrane-distal domains ( D1-D3 ) in ***binding*** of ***IL-6*** and ***IL-11*** is well established , the function of the membrane-proximal domains ( D4-D6 ) is unclear .	parallel	1
9518	10605026	3458;3134	IFN-gamma;HLA-F	We have found that ***IFN-gamma*** treatment ***induces*** expression of HLA-F mRNA and ***HLA-F*** protein , but that this does not result in concomitant cell surface expression .	target	1
9519	10605026	3134;811	HLA-F;calreticulin	***HLA-F*** ***associates*** with at least two components of the conventional class I assembly pathway , ***calreticulin*** and TAP .	parallel	0
9520	10605026	3134;10482	HLA-F;TAP	***HLA-F*** ***associates*** with at least two components of the conventional class I assembly pathway , calreticulin and ***TAP*** .	parallel	0
9521	10605041	3586;7124	IL-10;TNF-alpha	Human ***IL-10*** expression in the lung ***suppressed*** local ***TNF-alpha*** production following AdV/hIL -10 ( adenovirus construct expressing human IL-10 ) delivery , but did not lead to increased or prolonged transgene expression when coexpressed with beta-galactosidase .	negative	1
9522	10605044	356;355	FasL;Fas	The ***Fas/Fas*** ***ligand*** ( ***FasL*** ) pathway is involved in a variety of regulatory mechanisms that could be important for the development of graft-vs-host disease ( GVHD ) after bone marrow transplantation ( BMT ) , such as cytolysis of target cells by cytotoxic T cells , regulation of inflammatory responses , peripheral deletion of autoimmune cells , costimulation of T cells , and activation-induced cell death .	parallel	1
9523	10605054	2862;4295	motilin receptor;motilin	On the model of ***interaction*** between ***motilin*** and ***motilin receptor*** evolved from these results , the three points of interaction , due to Phe1 , Ile4 , and Tyr7 , and the presence of an open space were expected .	parallel	1
9524	10605929	3553;4790	IL-1beta;NF-kappaB	Our data thus indicate that ROIs are cell type-specific second messengers for ***NF-kappaB*** ***induction*** by ***IL-1beta*** .	target	1
9525	10606188	4193;7157	MDM2;P53	Additionally , the mechanism of ***MDM2-mediated*** ***degradation*** of ***P53*** protein , without involving stabilization and inactivation of P53 gene , should be considered for better understanding of all features of tumor progression processes .	negative	1
9526	10606245	1523;632	CCAAT displacement protein;osteocalcin	The ***CCAAT displacement protein/cut*** homeodomain protein ***represses*** ***osteocalcin*** gene transcription and forms complexes with the retinoblastoma protein-related protein p107 and cyclin A.	negative	1
9527	10606246	1958;3481	Egr-1;IGF-II	Cotransfection of HepG2 cells with an Egr-1 expression vector and an IGF-II P3 promoter-luciferase reporter plasmid showed that the transcription of ***IGF-II*** was ***activated*** by ***Egr-1*** in a dose-dependent manner .	positive	1
9528	10606246	1958;3481	Egr-1;IGF-II	***Egr-1*** ***mediates*** transcriptional activation of ***IGF-II*** gene in response to hypoxia .	target	0
9529	10606246	7490;3481	WT1;IGF-II	In contrast , the level of ***WT1*** , a ***repressor*** of ***IGF-II*** expression , was markedly decreased during hypoxia .	negative	1
9530	10606251	5744;5741	PTHrP;Parathyroid hormone	These cell lines did not demonstrate ******Parathyroid hormone/PTHrP****** receptor-mediated ***binding*** of iodinated PTHrP or steady-state receptor message by Northern blot analysis , but they did have a detectable receptor message by reverse transcription-PCR analysis .	parallel	1
9531	10606251	5741;5744	Parathyroid hormone;PTHrP	These cell lines did not demonstrate ***Parathyroid hormone/PTHrP*** receptor-mediated ***binding*** of iodinated ***PTHrP*** or steady-state receptor message by Northern blot analysis , but they did have a detectable receptor message by reverse transcription-PCR analysis .	parallel	1
9532	10606628	6387;7852	SDF-1;CXCR4	In contrast , ***SDF-1*** , a ***CXCR4*** ***ligand*** , was not detectable in the CD34 ( + ) KIT ( + ) cells , even by RT-PCR .	parallel	1
9533	10606650	7161;7157	p73;p53	The results suggest that ***p73*** can ***modulate*** ***p53*** function by inhibiting its DNA binding and that overexpression of p73 in tumors might be a novel mechanism of inactivation of p53 .	target	0
9534	10606656	6722;2313	SRF;Fli-1	The mechanism of complex ***formation*** between ***Fli-1*** and ***SRF*** transcription factors .	parallel	0
9535	10606656	2313;6722	Fli-1;SRF	In this study we have analysed how a different ETS-domain transcription factor ***Fli-1*** ***interacts*** with ***SRF*** to form ternary complexes with this element .	parallel	1
9536	10606656	6722;2313	SRF;Fli-1	By using Fli-1 derivatives with mutations in the N-terminal SRF binding motif , the significance of ******Fli-1-SRF****** ***interactions*** in recruitment of Fli-1 to the c - fos SRE in vivo has been demonstrated .	parallel	1
9537	10606656	2313;6722	Fli-1;SRF	Collectively our data provide a model of how ***Fli-1*** ***interacts*** with ***SRF*** that differs significantly from the mechanism used by a different ETS-domain protein , Elk-1 .	parallel	1
9538	10606664	333929;4760	Smuc;basic helix-loop-helix transcription factor	A novel snail-related transcription factor ***Smuc*** ***regulates*** ***basic helix-loop-helix transcription factor*** activities via specific E-box motifs .	target	1
9539	10606664	333929;4654	Smuc;MyoD	***Smuc*** inhibited the binding of a MyoD-E12 complex to the CACCTG E-box sequence in a dose-dependent manner and ***suppressed*** the transcriptional activity of ***MyoD-E12*** .	negative	1
9540	10606744	7157;4193	p53;MDM2	In this paper , we identify threonine 18 of p53 , a key site in regulating the ***interaction*** between ***p53*** and its regulatory partner ***MDM2*** , as a novel site phosphorylated in vitro by purified recombinant casein kinase 1 (CK1) delta .	parallel	1
9541	10606755	3569;6774	IL-6;STAT3	LPS and TNFalpha induce SOCS3 mRNA and inhibit ***IL-6-induced*** ***activation*** of ***STAT3*** in macrophages .	positive	1
9542	10606755	7124;9021	TNFalpha;SOCS3	LPS and ***TNFalpha*** ***induce*** ***SOCS3*** mRNA and inhibit IL-6-induced activation of STAT3 in macrophages .	target	1
9543	10606755	7124;6774	TNFalpha;STAT3	In this study we show that LPS and ***TNFalpha*** are potent ***inhibitors*** of IL-6-mediated ***STAT3*** activation in human monocyte derived macrophages , rat liver macrophages and RAW 264.7 mouse macrophages but not in human hepatoma cells ( HepG2 ) or in rat hepatocytes .	negative	1
9544	10606763	5054;7448	PAI-1;vitronectin	Moreover , removal of helix F strongly affects the ***binding*** of ***PAI-1*** to ***vitronectin*** .	parallel	1
9545	10606930	1432;6352	p38 MAP kinase;RANTES	***p38 MAP kinase*** ***regulates*** TNF alpha - , IL-1 alpha - and PAF-induced ***RANTES*** and GM-CSF production by human bronchial epithelial cells .	target	1
9546	10606930	5606;1432	MKK3;p38 MAP kinase	OBJECTIVE : In the present study , we examined serine phosphorylation of ***MKK3*** and MKK6 which is the upstream ***regulator*** of p38 MAP kinase and ***p38 MAP kinase*** activation in tumour necrosis factor ( TNF ) - alpha , interleukin (IL)-1 alpha and platelet-activating factor ( PAF ) - stimulated BECs and the effect of SB 203580 as the specific inhibitor for p38 MAP kinase activity on RANTES and GM-CSF expression in order to clarify the intracellular signal regulating RANTES and GM-CSF production by human BECs .	target	1
9547	10606930	5608;1432	MKK6;p38 MAP kinase	OBJECTIVE : In the present study , we examined serine phosphorylation of MKK3 and ***MKK6*** which is the upstream ***regulator*** of p38 MAP kinase and ***p38 MAP kinase*** activation in tumour necrosis factor ( TNF ) - alpha , interleukin (IL)-1 alpha and platelet-activating factor ( PAF ) - stimulated BECs and the effect of SB 203580 as the specific inhibitor for p38 MAP kinase activity on RANTES and GM-CSF expression in order to clarify the intracellular signal regulating RANTES and GM-CSF production by human BECs .	target	1
9548	10606930	3552;5606	IL-1 alpha;MKK3	RESULTS : The results showed that TNF alpha , ***IL-1 alpha*** and PAF ***induced*** serine phosphorylation of ***MKK3*** and MKK6 , and p38 MAP kinase activation in BECs .	target	1
9549	10606930	3552;5608	IL-1 alpha;MKK6	RESULTS : The results showed that TNF alpha , ***IL-1 alpha*** and PAF ***induced*** serine phosphorylation of MKK3 and ***MKK6*** , and p38 MAP kinase activation in BECs .	target	1
9550	10606930	7124;5606	TNF alpha;MKK3	RESULTS : The results showed that ***TNF alpha*** , IL-1 alpha and PAF ***induced*** serine phosphorylation of ***MKK3*** and MKK6 , and p38 MAP kinase activation in BECs .	target	1
9551	10606930	7124;5608	TNF alpha;MKK6	RESULTS : The results showed that ***TNF alpha*** , IL-1 alpha and PAF ***induced*** serine phosphorylation of MKK3 and ***MKK6*** , and p38 MAP kinase activation in BECs .	target	1
9552	10606960	940;941	CD28;CD80	The ***CD28*** and CTLA-4 molecules on T cells serve as ***receptors*** for the ***CD80*** and CD86 costimulatory antigens .	parallel	1
9553	10606960	1493;941	CTLA-4;CD80	The CD28 and ***CTLA-4*** molecules on T cells serve as ***receptors*** for the ***CD80*** and CD86 costimulatory antigens .	parallel	1
9554	10606964	3383;3689	ICAM-1;Mac-1	***ICAM-1*** ( CD54 ) , the ***ligand*** for LFA-1 and ***Mac-1*** , is up-regulated during inflammatory reaction on the activated vascular endothelium .	parallel	1
9555	10606975	3558;596	IL-2;Bcl-2	In addition , preliminary results suggest that ***Bcl-2*** expression and level of spontaneous apoptosis in patients can be ***modified*** by ***IL-2*** and interferon-gamma .	target	0
9556	10606975	3458;596	interferon-gamma;Bcl-2	In addition , preliminary results suggest that ***Bcl-2*** expression and level of spontaneous apoptosis in patients can be ***modified*** by IL-2 and ***interferon-gamma*** .	target	0
9557	10606981	7422;5228	VEGF;PlGF	******PlGF/VEGF****** ***heterodimers*** were detected in 21 % of RA samples and none of the control samples .	parallel	1
9558	10606981	7422;5228	VEGF;PlGF	This is the first report of the detection of PlGF and ******PlGF/VEGF****** ***heterodimers*** in the SF of patients with inflammatory arthropathies , and we have shown for the first time that PlGF up-regulates PBMC VEGF production .	parallel	1
9559	10606981	5228;7422	PlGF;VEGF	This is the first report of the detection of PlGF and PlGF/VEGF heterodimers in the SF of patients with inflammatory arthropathies , and we have shown for the first time that ***PlGF*** ***up-regulates*** PBMC ***VEGF*** production .	positive	1
9560	10606981	7422;5228	VEGF;PlGF	******PlGF/VEGF****** ***heterodimers*** were detected in 10.2 % of SF samples , most frequently in RA samples .	parallel	1
9561	10606983	3458;5806	interferon-gamma;PTX3	In contrast , ***interferon-gamma*** and transforming growth factor-beta ***inhibited*** ***PTX3*** constitutive expression in RA synoviocytes .	negative	1
9562	10607288	356;355	Fas ligand;Fas	The induction of apoptosis in Jurkat T cells by the hookworm secretions did not involve cell activation or the ******Fas/Fas ligand****** ***interaction*** .	parallel	1
9563	10607305	3493;2204	IgA1;FcalphaRI	***Binding*** of ***IgA1*** and IgA2 to ASGP-R and ***FcalphaRI*** was found to be sugar dependent because oversialylated IgA bound less than native or desialylated IgA .	parallel	1
9564	10607309	7040;3600	TGF-beta;IL-15	The mechanism by which ***TGF-beta*** may ***influence*** the effect of ***IL-15*** remains poorly understood , however .	target	0
9565	10607309	7040;3458	TGF-beta;IFN-gamma	In activated , IL-15-stimulated peripheral blood T lymphocytes , ***TGF-beta*** ***suppressed*** ***IFN-gamma*** mRNA and protein levels by approximately 75 % .	negative	1
9566	10607313	356;355	FasL;Fas	Using reverse transcriptase-polymerase chain reaction ( RT-PCR ) and specific primers , mRNA for the cytolytic molecules perforin , granzyme A and B , Fas and ***Fas*** ***ligand*** ( ***FasL*** ) were detected in both the gammadelta - and the alphabetaT cells .	parallel	1
9567	10607391	23229;10243	Collybistin;gephyrin	***Collybistin*** , a newly identified brain-specific GEF , ***induces*** submembrane clustering of ***gephyrin*** .	target	1
9568	10607425	940;5599	CD28;JNK	The c-Jun N-terminal kinase ( ***JNK*** ) can be ***activated*** in T-cells either by the combination of TCR and ***CD28*** costimulation or by a variety of stress-related stimuli including UV light , H ( 2 ) O ( 2 ) , and hyperosmolar sorbitol solutions .	positive	1
9569	10607425	940;5599	CD28;JNK	In T-lymphocytes , ***TCR/CD28*** ***stimulation*** of ***JNK*** leads to induction of new gene expression via c-Jun , ATF-2 , and Elk-1 .	positive	0
9570	10607425	940;5599	CD28;JNK	Here we show that the age-related decline in ***TCR/CD28*** ***activation*** of ***JNK*** reflects two effects of age : the accumulation of memory cells ( in which JNK stimulation is poor regardless of donor age ) and age-dependent declines in JNK activation within the naive subset .	positive	1
9571	10607425	940;5599	CD28;JNK	Cyclosporin A inhibits ***induction*** of ***JNK*** function by ***TCR/CD28*** , PMA/ionomycin , ceramide , or H ( 2 ) O ( 2 ) , but not induction by UV light or hyperosmolar sorbitol .	target	1
9572	10607425	6416;5599	MKK4;JNK	Finally , we show that the alterations in JNK function are not due to changes in the expression of ***MKK4*** , an upstream ***activator*** of ***JNK*** , and that another JNK kinase , MKK7 , is not expressed in splenic T-cells .	positive	1
9573	10607564	6504;4068	SLAM;SAP	The ******SAP-SLAM****** ***interaction*** can occur in a phosphorylation-independent manner .	parallel	1
9574	10607564	6504;4068	SLAM;SAP	RESULTS : To characterize the ***interaction*** between ***SAP*** and ***SLAM*** , we synthesized peptides corresponding to the SAP-binding site at residue Y281 in SLAM .	parallel	1
9575	10607564	4068;6504	SAP;SLAM	These results were confirmed by nuclear magnetic resonance ( NMR ) studies on ( 15 ) N - and ( 13 ) C-labeled ***SAP*** ***complexed*** with three ***SLAM*** peptides : an amino-terminally truncated phosphopeptide , a carboxy-terminally truncated phosphopeptide and a non-phosphorylated Tyr-containing full-length peptide .	parallel	1
9576	10607586	355;356	Fas;Fas ligand	BACKGROUND : The ***Fas ligand/Fas*** ***receptor*** ( ***FasL/Fas*** ) system is an important mediator of apoptosis in the immune system where the juxtaposition of cells expressing the cell-surface ligand induces the apoptotic pathway in Fas-expressing lymphocytes .	parallel	1
9577	10607586	356;355	FasL;Fas	BACKGROUND : The ***Fas ligand/Fas*** ***receptor*** ( ***FasL/Fas*** ) system is an important mediator of apoptosis in the immune system where the juxtaposition of cells expressing the cell-surface ligand induces the apoptotic pathway in Fas-expressing lymphocytes .	parallel	1
9578	10607586	4316;356	matrilysin;FasL	CONCLUSIONS : The results show that a functional form of sFasL was generated by the action of the metalloproteinase matrilysin , and suggest that ***matrilysin*** ***cleavage*** of ***FasL*** is an important mediator of epithelial cell apoptosis .	target	1
9579	10607589	5329;4691	uPAR;nucleolin	Immunoprecipitation experiments in combination with an in vitro kinase assay demonstrated a specific ***association*** of ***uPAR*** with ***nucleolin*** and casein kinase 2 and revealed a uPA-induced activation of casein kinase 2 , which presumably led to phosphorylation of nucleolin .	parallel	0
9580	10607597	8878;10121	p62;Arp1	***Interaction*** of the ***p62*** subunit of dynactin with ***Arp1*** and the cortical actin cytoskeleton .	parallel	1
9581	10607597	8878;10121	p62;Arp1	Deletion of the LIM domain abolished targeting of p62 to focal-adhesion sites but did not interfere with ***binding*** of ***p62*** to actin or ***Arp1*** .	parallel	1
9582	10607682	7040;6348	TGF-beta;MIP-1alpha	However , IL-12 significantly enhanced IPP-induced expression and release of ***MIP-1alpha*** that was ***down-regulated*** by ***TGF-beta*** whereas the induction of MIP-1beta by IPP+IL -12 was refractory to cotreatment with TGFbeta indicating that these chemokines are differentially regulated by these cytokines .	negative	1
9583	10607702	3725;7422	AP-1;VEGF	In addition , ***VEGF*** gene regulation by NO , as well as by hypoxia , is ***potentiated*** by the ***AP-1*** element of the gene .	positive	0
9584	10607707	3565;5473	IL-4;Tc1	In addition , IL-12 enhanced and ***IL-4*** ***inhibited*** the growth of ***Tc1*** but not Tc2/0 CD8 T-cell clones .	negative	1
9585	10607712	1440;7124	G-CSF;TNF-alpha	We conclude that the attenuation of IFN-gamma release from lymphocytes is not a direct effect of G-CSF on these cells but is rather due to the ***inhibition*** of monocytic IL-12 and ***TNF-alpha*** release by ***G-CSF*** .	negative	1
9586	10607712	1440;7124	G-CSF;TNF-alpha	***G-CSF*** in vitro also ***attenuated*** ***TNF-alpha*** release from elutriation-purified monocytes .	negative	0
9587	10607716	841;836	caspase-8;caspase-3	CD95 aggregation was associated with the recruitment of FADD and caspase-8 to the CD95 receptor to form the CD95 death-inducing signaling complex ( DISC ) , resulting in ***caspase-8*** ***activation*** and cleavage of the effector ***caspase-3*** and PARP .	positive	1
9588	10607716	355;841	CD95;caspase-8	***CD95*** aggregation was ***associated*** with the recruitment of FADD and ***caspase-8*** to the CD95 receptor to form the CD95 death-inducing signaling complex ( DISC ) , resulting in caspase-8 activation and cleavage of the effector caspase-3 and PARP .	parallel	0
9589	10607716	355;8772	CD95;FADD	***CD95*** aggregation was ***associated*** with the recruitment of ***FADD*** and caspase-8 to the CD95 receptor to form the CD95 death-inducing signaling complex ( DISC ) , resulting in caspase-8 activation and cleavage of the effector caspase-3 and PARP .	parallel	0
9590	10607746	3512;973	J chain;IgA	***J chain*** is ***associated*** with pentameric IgM and dimeric ***IgA*** via disulfide bonds involving the penultimate cysteine residue in the secretory tailpiece of the mu or the alpha heavy chain .	parallel	0
9591	10607757	5310;999	Polycystin-1;E-cadherin	***Polycystin-1*** ***interacts*** with ***E-cadherin*** and the catenins -- clues to the pathogenesis of cyst formation in ADPKD ?	parallel	1
9592	10607841	5663;351	PS-1;Abeta	This is in line with a role of ***PS-1*** in the regulation of protein trafficking in the ER/Golgi , which can ***modulate*** the production of ***Abeta*** .	target	0
9593	10607937	3952;3479	leptin;IGF-1	In addition , ***leptin*** abundance was highly ***correlated*** with adipose tissue ***IGF-1*** mRNA in GH-treated animals ( P > 0.001 ) .	parallel	0
9594	10608012	7040;5327	TGF-beta;t-PA	Transforming growth factor-beta ( ***TGF-beta*** ) ***decreased*** ***t-PA*** antigen production , increased PAI-1 activity , and decreased ECM degradation .	negative	0
9595	10608465	7040;5594	TGF-beta1;ERK	CONCLUSIONS : The results provide the first evidence that ***TGF-beta1*** ***activates*** ***ERK*** in vascular smooth muscle cells of both normotensive and hypertensive rats .	positive	1
9596	10608777	4018;1234	lipoprotein;CCR5	Virulent Treponema pallidum , ***lipoprotein*** , and synthetic lipopeptides ***induce*** ***CCR5*** on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1 .	target	1
9597	10608777	4018;1234	lipoprotein;CCR5	Reverse transcription-polymerase chain reaction for CCR5 gene transcripts , macrophage inflammatory protein ( MIP ) -1 beta binding assays , and flow cytometry revealed that either T. pallidum , a representative treponemal ***lipoprotein*** , or a corresponding synthetic lipopeptide ***induced*** ***CCR5*** on CD14 monocytes but not on CD3 lymphocytes .	target	1
9598	10608804	2889;867	C3G;Cbl	Interestingly , overexpression of C3G also enhanced migration , suggesting that a ******Cbl-Crkl-C3G****** ***complex*** may be involved in migration signaling in Ba/F3 cells .	parallel	1
9599	10608804	2889;1399	C3G;Crkl	Interestingly , overexpression of C3G also enhanced migration , suggesting that a ******Cbl-Crkl-C3G****** ***complex*** may be involved in migration signaling in Ba/F3 cells .	parallel	1
9600	10608804	867;1399	Cbl;Crkl	Interestingly , overexpression of C3G also enhanced migration , suggesting that a ******Cbl-Crkl-C3G****** ***complex*** may be involved in migration signaling in Ba/F3 cells .	parallel	1
9601	10608804	1399;25	Crkl;BCR/ABL	***Crkl*** ***binds*** to ***BCR/ABL*** through its N-terminal SH3 domain and is known to interact with several signaling proteins that have been implicated in integrin signaling , including Cbl , Cas , Hef-1 , and paxillin .	parallel	1
9602	10608806	545;675	ATR;Brca2	***Brca2*** , phosphatidylinositol 3-kinase , and DNA-5B peptides were ***phosphorylated*** specifically by ***ATR*** , and DNA Ligase IV is a specific in vitro substrate of DNA-PK .	target	1
9603	10608812	836;9135	caspase-3;rabaptin-5	Human ***rabaptin-5*** is selectively ***cleaved*** by ***caspase-3*** during apoptosis .	target	1
9604	10608826	4043;2157	39-kDa receptor-associated protein;fVIII	The specificity was confirmed by a complete ***inhibition*** of ***fVIII/LRP*** binding by ***39-kDa receptor-associated protein*** ( RAP ) , an antagonist of all LRP ligands .	negative	1
9605	10608826	4043;4035	39-kDa receptor-associated protein;LRP	The specificity was confirmed by a complete ***inhibition*** of ***fVIII/LRP*** binding by ***39-kDa receptor-associated protein*** ( RAP ) , an antagonist of all LRP ligands .	negative	1
9606	10608826	4035;2157	LRP;fVIII	The specificity was confirmed by a complete inhibition of ******fVIII/LRP****** ***binding*** by 39-kDa receptor-associated protein ( RAP ) , an antagonist of all LRP ligands .	parallel	1
9607	10608826	2157;4035	fVIII;LRP	The region of fVIII involved in its binding to LRP was localized within the A2 domain residues 484-509 , based on the ability of the isolated A2 domain and the synthetic A2 domain peptide 484-509 to prevent ***fVIII*** ***interaction*** with ***LRP*** .	parallel	1
9608	10608826	2157;4035	fVIII;LRP	Since vWf did not inhibit ***fVIII*** ***binding*** to ***LRP*** , we proposed that LRP receptor may internalize fVIII from its complex with vWf .	parallel	1
9609	10608826	2157;7450	fVIII;vWf	Consistent with this hypothesis , mouse embryonic fibroblasts that express LRP , but not fibroblasts genetically deficient in LRP , were able to catabolize ( 125 ) ***I-fVIII*** ***complexed*** with ***vWf*** , which was not internalized by the cells .	parallel	1
9610	10608854	8826;999	IQGAP1;E-cadherin	***IQGAP1*** and calmodulin ***modulate*** ***E-cadherin*** function .	target	0
9611	10608854	8826;999	IQGAP1;E-cadherin	***IQGAP1*** , a novel RasGAP-related protein that interacts with the cytoskeleton , ***binds*** to actin , members of the Rho family , and ***E-cadherin*** .	parallel	1
9612	10608863	3458;4790	IFN-gamma;NF-kappaB	While keratinocytes derived from psoriatic plaque resist apoptosis , and combination of TPA and ***IFN-gamma*** ***activates*** ***NF-kappaB*** , the molecular mechanism linking NF-kappaB activation and keratinocyte apoptosis resistance was unknown .	positive	1
9613	10608883	9693;5911	PDZ-GEF1;Rap2	Interestingly , ***PDZ-GEF1*** also ***activates*** ***Rap2*** , a close relative of Rap1 .	positive	1
9614	10608892	4193;4194	MDM2;MDMX	The results obtained in these studies provide evidence that C-terminal RING finger domains , contained within both of these proteins , play an important role in mediating the ***association*** between ***MDM2*** and ***MDMX*** .	parallel	0
9615	10608892	4194;7157	MDMX;p53	***MDMX*** also ***inhibits*** MDM2-mediated ***p53*** degradation , with subsequent accumulation of p53 .	negative	1
9616	10608894	660;595	Etk;cyclin D1	Furthermore , we demonstrated that ***Etk*** activation alone ***augmented*** ***cyclin D1*** promoter/enhancer activity via its STAT5 response element in both Pa-4DeltaEtk : ER and A549 cells .	positive	0
9617	10608902	5814;5813	Purbeta;Puralpha	Translational efficiency was restored by mutations that impaired mRNA ***binding*** of ***Puralpha*** , ***Purbeta*** , and MSY1 , implying that these proteins can also participate in messenger ribonucleoprotein formation in living cells .	parallel	1
9618	10609788	3660;3659	IRF-2;IRF-1	The structurally related ***IRF-2*** ***represses*** the effects of ***IRF-1*** by competitive binding to the same DNA sequence elements .	negative	1
9619	10609879	3554;3654	Interleukin-1 receptor type I;IRAK	Stimulation of the ***Interleukin-1 receptor type I*** ( IL-1-RI ) with IL-1 ***activates*** an associated serine/threonine kinase , ***IRAK*** , which phosphorylates downstream targets , resulting in NFkappaB activation .	positive	1
9620	10611067	356;355	FasL;Fas	The Fas antigen is a cell surface receptor that triggers apoptosis when bound to ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
9621	10611068	356;355	FasL;Fas	Fas antigen is a receptor that triggers apoptosis when bound by ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
9622	10611224	5898;1956	RalA;epidermal growth factor receptor	Phospholipase D and ***RalA*** ***cooperate*** with the ***epidermal growth factor receptor*** to transform 3Y1 rat fibroblasts .	parallel	0
9623	10611225	1973;1981	eIF4A;eIF4GI	These data indicate that the ***interaction*** of ***eIF4A*** with the middle region of ***eIF4GI*** is necessary for translation , whereas the interaction of eIF4A with the C-terminal region plays a modulatory role .	parallel	1
9624	10611232	9421;430	HAND1;Mash2	In vitro , ***HAND1*** could ***antagonize*** ***Mash2*** function by competing for E-factor binding .	negative	1
9625	10611234	2648;4609	hGCN5;c-Myc	The essential cofactor TRRAP ***recruits*** the histone acetyltransferase ***hGCN5*** to ***c-Myc*** .	target	0
9626	10611234	8295;2648	TRRAP;hGCN5	The essential cofactor ***TRRAP*** ***recruits*** the histone acetyltransferase ***hGCN5*** to c-Myc .	target	0
9627	10611236	356;355	CD95-L;CD95	Resistance to apoptosis was accompanied by impaired expression of ***CD95*** ***ligand*** ( ***CD95-L*** ) , a well-known inducer of apoptosis .	parallel	1
9628	10611247	836;2534	Caspase 3;SLK	***Caspase 3*** ***cleavage*** of the Ste20-related kinase ***SLK*** releases and activates an apoptosis-inducing kinase domain and an actin-disassembling region .	target	1
9629	10611247	836;9748	Caspase 3;Ste20-related kinase	***Caspase 3*** ***cleavage*** of the ***Ste20-related kinase*** SLK releases and activates an apoptosis-inducing kinase domain and an actin-disassembling region .	target	1
9630	10611247	836;2534	Caspase 3;SLK	***SLK*** was ***cleaved*** by ***Caspase 3*** in vitro and in vivo during c-Myc - , tumor necrosis factor alpha , and UV-induced apoptosis .	target	1
9631	10611258	7124;3569	TNFalpha;IL-6	Addition of the NFkappaB inhibitor SN50 ( 5 microg/ml ) to confluent cultures of endometrial epithelial cells inhibited interleukin ( IL ) -1 alpha ( 10 ng/ml ) and tumour necrosis factor alpha ( ***TNFalpha*** ) ( 10 ng/ml ) ***stimulated*** ***IL-6*** ( P < 0.001 and P < 0.01 respectively ) and LIF ( P < 0.01 and P < 0.05 respectively ) production .	positive	0
9632	10611265	285;7010	angiopoietin-2;Tie-2	Interaction between the endothelial cell receptor , ***Tie-2*** , and its recently discovered antagonist ***ligand*** , ***angiopoietin-2*** ( Ang-2 ) , has been implicated in the loosening of vessel structure .	parallel	1
9633	10611265	7010;285	Tie-2;angiopoietin-2	***Interaction*** between the endothelial cell receptor , ***Tie-2*** , and its recently discovered antagonist ligand , ***angiopoietin-2*** ( Ang-2 ) , has been implicated in the loosening of vessel structure .	parallel	1
9634	10611293	4193;129685	MDM2;TAF	The alpha-helical FXXPhiPhi motif in p53 : ***TAF*** ***interaction*** and discrimination by ***MDM2*** .	parallel	1
9635	10611293	4193;7157	MDM2;p53	***MDM2*** , the cellular attenuator of p53 , discriminates the FXXPhiPhi motif of p53 from those of NF-kappaB p65 and VP16 and specifically ***inhibits*** ***p53*** activity .	negative	1
9636	10611305	356;355	FasL;Fas	***Activation*** of ***Fas*** by ***FasL*** induces apoptosis by a mechanism that can not be blocked by Bcl-2 or Bcl-x ( L ) .	positive	1
9637	10611305	355;356	Fas;FasL	Comparison between physiological ligand and anti-Fas antibodies revealed that only extensive ***Fas*** aggregation , by membrane ***bound*** ***FasL*** or aggregated soluble FasL consistently triggered apoptosis , whereas antibodies could act as death agonists or antagonists .	parallel	1
9638	10611322	472;4193	ATM;MDM2	Rapid ***ATM-dependent*** ***phosphorylation*** of ***MDM2*** precedes p53 accumulation in response to DNA damage .	target	1
9639	10611322	4193;7157	MDM2;p53	Conceivably , ***p53*** function may be ***modulated*** by modifications of ***MDM2*** as well .	target	0
9640	10611322	472;4193	ATM;MDM2	Furthermore , ***MDM2*** is directly ***phosphorylated*** by ***ATM*** in vitro .	target	1
9641	10611322	472;7157	ATM;p53	These findings suggest that in response to DNA strand breaks , ***ATM*** may ***promote*** ***p53*** activity and stability by mediating simultaneous phosphorylation of both partners of the p53-MDM2 autoregulatory feedback loop .	positive	0
9642	10611345	5371;5914	promyelocytic leukemia;RARalpha	Acute ***promyelocytic leukemia*** ( APML ) most often is ***associated*** with the balanced reciprocal translocation t ( 15 ; 17 ) ( q22 ; q11 .2 ) and the expression of both the ***PML-RARalpha*** and RARalpha-PML fusion cDNAs that are formed by this translocation .	parallel	0
9643	10611347	5178;7422	PEG-3;VEGF	Furthermore , transient ectopic expression of ***PEG-3*** transcriptionally ***activates*** ***VEGF*** in transformed rodent and human cancer cells .	positive	1
9644	10611368	348;351	Apoe;Abeta	Because the absence of Apoe alters neither the transcription or translation of the APP ( V717F ) transgene nor its processing to Abeta peptide ( s ) , we postulate that ***Apoe*** ***promotes*** both the deposition and fibrillization of ***Abeta*** , ultimately affecting clearance of protease-resistant Abeta/Apoe aggregates .	positive	0
9645	10611455	1386;5594	activating transcription factor-2;p38	The phosphorylation of endogenous ***activating transcription factor-2*** , a ***substrate*** of ***p38*** MAPK , was also inhibited by wortmannin .	parallel	1
9646	10611490	3565;3716	IL-4;JAK1	In keratinocytes , ***IL-4*** ***induced*** ***JAK1*** and JAK2 phosphorylation but , unlike in immune cells , IL-4 did not involve JAK3 activation for its signaling .	target	1
9647	10611490	3565;3717	IL-4;JAK2	In keratinocytes , ***IL-4*** ***induced*** JAK1 and ***JAK2*** phosphorylation but , unlike in immune cells , IL-4 did not involve JAK3 activation for its signaling .	target	1
9648	10611490	3565;6778	IL-4;signal transducer and activator of transcription (STAT) 6	In both cell types , ***IL-4*** ***induced*** phosphorylation and DNA binding activation of the ***signal transducer and activator of transcription (STAT) 6*** protein .	target	1
9649	10611749	3458;7124	IFN-gamma;TNF-alpha	IL-12 produced by macrophages is an inducer of ***IFN-gamma*** production , which in turn activates the macrophage antibacterial activity and ***synergizes*** its effects with ***TNF-alpha*** .	parallel	0
9650	10611754	2122;4088	oncogene Evi-1;Smad3	Of these , specific roles have been ascribed to Smad3 in control of chemotaxis of neutrophils and macrophages and the ***inhibition*** of ***Smad3*** activity by the ***oncogene Evi-1*** suggests that it may play a role in leukemogenesis .	negative	1
9651	10611754	4092;4088	Smad7;Smad3	Other data , such as the induction by the inflammatory cytokine interferon-gamma of an inhibitory Smad , ***Smad7*** , which ***blocks*** the actions of ***Smad3*** , suggest that identification of the specific gene targets of Smad proteins in immune cells will provide new insight into the mechanisms of TGF-beta action on these cells .	negative	0
9652	10612393	941;3205	lab-7;Abd-B	The ***lab-7*** domain ***activates*** ***Abd-B*** in parasegment 12 ( ps12 ) , whereas lab-8 controls expression in ps13 .	positive	1
9653	10612423	5617;100506658	Prolactin;tight junction protein occludin	***Prolactin*** , alone or in combination with glucocorticoids , ***enhances*** tight junction formation and expression of the ***tight junction protein occludin*** in mammary cells .	positive	0
9654	10612430	6464;2885	Shc;Grb2	Insulin stimulates rapid tyrosine phosphorylation of the protein ***Shc*** , which subsequently ***binds*** to ***Grb2*** , resulting in the activation of a complex mitogenic signaling network .	parallel	1
9655	10612430	2885;6464	Grb2;Shc	In this study , we examined the levels of Shc protein , its phosphorylation state and ******Shc-Grb2****** ***association*** in liver , muscle and adipose tissue before and after insulin administration in three animal models of insulin resistance ( chronic dexamethasone treatment , 72-h starvation and aging ) .	parallel	0
9656	10612430	2885;6464	Grb2;Shc	Alterations in Shc phosphorylation correlated well with the level of ******Shc-Grb2****** ***association*** .	parallel	0
9657	10612430	2885;6464	Grb2;Shc	These results indicate that Shc tyrosyl phosphorylation and ******Shc-Grb2****** ***association*** are regulated in the different types of insulin resistance and that this regulation is apparently related to the animals ' plasma insulin levels .	parallel	0
9658	10612430	2885;6464	Grb2;Shc	The ******Shc-Grb2****** ***association*** is directly related to the insulin-induced tyrosyl phosphorylation of Shc .	parallel	0
9659	10612431	3479;3486	IGF-I;IGFBP-3	***IGF-I*** , but not [ LR3 ] IGF-I , ***reduced*** the proportion of phosphorylated ***IGFBP-3*** in Hs578T conditioned medium , consistent with increased release of non-phosphorylated , cell-associated IGFBP-3 .	negative	1
9660	10612445	7349;1394	urocortin;CRFR1	High-affinity ***binding*** of ***urocortin*** and astressin but not CRF to G protein-uncoupled ***CRFR1*** .	parallel	1
9661	10612638	51052;5020	PrRP;oxytocin	This observation indicates that ***PrRP*** may ***regulate*** ***oxytocin*** secretion .	target	1
9662	10612638	51052;5020	PrRP;oxytocin	Our results show that central administration of ***PrRP*** ***increased*** the plasma ***oxytocin*** and vasopressin levels in female rats , but in male rats only oxytocin was increased .	positive	0
9663	10612703	3952;4852	leptin;neuropeptide Y	The candidate site for the brain 's detection of leptin adiposity signaling is the hypothalamic arcuate nucleus , where ***leptin*** ***inhibits*** expression ***neuropeptide Y*** and increases expression of the pro-opiomelanocortin ( POMC ) precursor of alphaMSH .	negative	1
9664	10613355	7040;7421	TGF-beta1;Vitamin D receptor	***Vitamin D receptor*** ( VDR ) expression was ***increased*** by ***TGF-beta1*** , suggesting synergistic action of TGF-beta1 and EB1089 .	positive	0
9665	10613355	7040;10671	TGF-beta1;p27	***Up-regulation*** of ***p27*** protein expression by either ***TGF-beta1*** or EB1089 was reduced by anti-TGF-beta1 .	positive	1
9666	10613356	3572;3569	gp130;IL-6	Our findings suggest that ******IL-6/gp130****** ***signaling*** may be involved in the regulation of the megakaryocytic differentiation of K562 cells .	parallel	0
9667	10613622	1557;1548	CYP2C19;CYP2A6	***Association*** between ***CYP2A6*** and ***CYP2C19*** mutant alleles .	parallel	0
9668	10613644	4792;4790	IkappaBalpha;NF-kappaB	Transcriptional activation of the TF gene was assessed by analysis of the transcription factor ***NF-kappaB*** and its ***inhibitor*** molecule ***IkappaBalpha*** .	negative	1
9669	10613650	7035;2155	TFPI;factor VII	Thus by enhancing lipase activity , full length ***TFPI*** may ***facilitate*** hydrolysis of triglyceride and concomitantly lower ***factor VII*** coagulant activity as demonstrated earlier , particularly after heparin injection when both TFPI and LPL are released in circulation .	positive	0
9670	10613896	2060;3268	eps15;Hrbl	In this study , we demonstrate that ***eps15*** and Eps15R , two EH-containing proteins , ***synergize*** with Hrb and ***Hrbl*** to enhance the function of Rev in the export pathway .	parallel	0
9671	10613896	58513;3268	Eps15R;Hrbl	In this study , we demonstrate that eps15 and ***Eps15R*** , two EH-containing proteins , ***synergize*** with Hrb and ***Hrbl*** to enhance the function of Rev in the export pathway .	parallel	0
9672	10613909	998;3985	Cdc42;LIMK2	***LIMK2*** activity toward Cofilin phosphorylation was ***stimulated*** by coexpression of activated Rho and ***Cdc42*** , but not Rac .	positive	0
9673	10613909	207;3985	Rac;LIMK2	***LIMK2*** activity toward Cofilin phosphorylation was ***stimulated*** by coexpression of activated Rho and Cdc42 , but not ***Rac*** .	positive	0
9674	10613913	57530;7082	Cingulin;ZO-1	***Cingulin*** contains globular and coiled-coil domains and ***interacts*** with ***ZO-1*** , ZO-2 , ZO-3 , and myosin .	parallel	1
9675	10613913	57530;9414	Cingulin;ZO-2	***Cingulin*** contains globular and coiled-coil domains and ***interacts*** with ZO-1 , ***ZO-2*** , ZO-3 , and myosin .	parallel	1
9676	10613913	57530;27134	Cingulin;ZO-3	***Cingulin*** contains globular and coiled-coil domains and ***interacts*** with ZO-1 , ZO-2 , ***ZO-3*** , and myosin .	parallel	1
9677	10613913	57530;7082	Cingulin;ZO-1	Pull-down assays from epithelial , insect cell , and reticulocyte lysates show that an NH ( 2 ) - terminal fragment of ***Cingulin*** ( 1-378 ) ***interacts*** in vitro with ***ZO-1*** ( K ( d ) approximately 5 nM ) , ZO-2 , ZO-3 , myosin , and AF-6 , but not with symplekin , and a COOH-terminal fragment ( 377-1 ,368 ) interacts with myosin and ZO-3 .	parallel	1
9678	10613985	5327;5054	t-PA;PAI-1	In this study we determined the effect of endotoxin on ***PAI-1*** and tissue plasminogen ***activator*** ( ***t-PA*** ) production by aortic SMCs in vivo in two animal species , and in culture .	positive	1
9679	10614620	5741;5997	PTH;RGS2	These findings demonstrate that ***RGS2*** is ***regulated*** by ***PTH*** , prostaglandin E2 , and PTHrP and that regulation by PTH in bone occurs via the cAMP pathway .	target	1
9680	10614620	5744;5997	PTHrP;RGS2	These findings demonstrate that ***RGS2*** is ***regulated*** by PTH , prostaglandin E2 , and ***PTHrP*** and that regulation by PTH in bone occurs via the cAMP pathway .	target	1
9681	10614629	6750;2641	Somatostatin;glucagon	***Somatostatin*** ***inhibits*** insulin and ***glucagon*** secretion via two receptors subtypes : an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice .	negative	1
9682	10614629	6750;2641	Somatostatin;glucagon	***Somatostatin*** ( SST ) potently ***inhibits*** insulin and ***glucagon*** release from pancreatic islets .	negative	1
9683	10614646	1392;7349	corticotropin-releasing hormone;Urocortin	***Urocortin*** expression in the Edinger-Westphal nucleus is ***up-regulated*** by stress and ***corticotropin-releasing hormone*** deficiency .	negative	1
9684	10614647	1490;176	Hcs24;aggrecan	Moreover , RT-PCR analysis revealed that the recombinant ***CTGF/Hcs24*** ***stimulated*** gene expression of ***aggrecan*** and collagen types II and X in RGC cells in culture .	positive	0
9685	10614651	2798;2796	GnRH-R;GnRH	This study examined the mechanism underlying the rat ***GnRH*** ***receptor*** ( ***GnRH-R*** ) internalization pathway by investigating the role of added/extended C-terminal tails and the effect of beta-arrestins and dynamin .	parallel	1
9686	10614663	10203;796	CRLR;calcitonin	RDC1 and ***CRLR*** in the presence of particular modifying proteins can also ***bind*** ***calcitonin*** gene-related peptide ( CGRP ) .	parallel	1
9687	10614663	7433;796	RDC1;calcitonin	***RDC1*** and CRLR in the presence of particular modifying proteins can also ***bind*** ***calcitonin*** gene-related peptide ( CGRP ) .	parallel	1
9688	10614670	3488;3483	IGFBP-5;ALS	Like insulin-like growth factor binding protein-3 ( IGFBP-3 ) , ***IGFBP-5*** forms a ternary ***complex*** with insulin-like growth factor ( IGF ) - I or IGF-II , and the acid-labile subunit ( ***ALS*** ) .	parallel	1
9689	10614670	3488;3483	IGFBP-5;ALS	An IGFBP-6 chimeric protein containing the central domain of IGFBP-5 complexed efficiently with ALS , and a carboxy-terminally truncated IGFBP-5 mutant , ***IGFBP-5*** ' ( 1-169 ) , also ***bound*** to ***ALS*** in the presence of IGFs , although with much less potency than full length rhIGFBP-5 .	parallel	1
9690	10614670	3489;3483	IGFBP-6;ALS	An ***IGFBP-6*** chimeric protein containing the central domain of IGFBP-5 ***complexed*** efficiently with ***ALS*** , and a carboxy-terminally truncated IGFBP-5 mutant , IGFBP-5 ' ( 1-169 ) , also bound to ALS in the presence of IGFs , although with much less potency than full length rhIGFBP-5 .	parallel	1
9691	10614768	3383;3683	ICAM-1;CD11a	***ICAM-1*** ***interactions*** with the beta2 integrins ***CD11a/CD18*** ( LFA-1 ) and CD11b/CD18 ( MAC-1 ) on the surface of leukocytes are important for their transendothelial migration to sites of inflammation and their function as costimulatory molecules for T cell activation .	parallel	1
9692	10614768	3383;3684	ICAM-1;CD11b	***ICAM-1*** ***interactions*** with the beta2 integrins CD11a/CD18 ( LFA-1 ) and ***CD11b/CD18*** ( MAC-1 ) on the surface of leukocytes are important for their transendothelial migration to sites of inflammation and their function as costimulatory molecules for T cell activation .	parallel	1
9693	10614768	3383;3689	ICAM-1;CD18	***ICAM-1*** ***interactions*** with the beta2 integrins CD11a/CD18 ( LFA-1 ) and ***CD11b/CD18*** ( MAC-1 ) on the surface of leukocytes are important for their transendothelial migration to sites of inflammation and their function as costimulatory molecules for T cell activation .	parallel	1
9694	10615005	3827;3816	kininogen;tissue kallikrein	Little is known about the species specificity of ******tissue kallikrein-kininogen****** ***interaction*** since the kinetic parameters for Lys-bradykinin release from kininogen by tissue kallikreins from different animal species have not been reported .	parallel	1
9695	10615055	9372;4087	Smad anchor for receptor activation;Smad2	Structural basis of ***Smad2*** ***recognition*** by the ***Smad anchor for receptor activation*** .	target	1
9696	10615065	7124;4790	TNF-alpha;NF-kappaB	In accord with promoter analyses , an electrophoretic mobility shift assay showed that CAM repressed AP-1 binding in TNF-alpha-treated BET-1A cells ; however , ***TNF-alpha*** ***induced*** both AP-1 and ***NF-kappaB*** binding activities in BET-1A cells .	target	1
9697	10615072	79109;3725	SIN-1;AP-1	***SIN-1*** ( 1 mM , a peroxynitrite agonist ) ***increased*** DNA-binding activity of ***AP-1*** .	positive	0
9698	10615255	3439;5020	IFN;oxytocin	The presence of IFN receptors in the hypothalamus and posterior pituitary and the ***IFN-induced*** ***suppression*** of extra-ovarian ***oxytocin*** secretion provides tentative evidence of an involvement of the central nervous system in maternal recognition of pregnancy in deer .	negative	1
9699	10615944	5167;3643	PC-1;insulin receptor	Membrane glycoprotein ***PC-1*** ***inhibition*** of ***insulin receptor*** function occurs via direct interaction with the receptor alpha-subunit .	negative	1
9700	10615944	5167;3643	Plasma cell membrane glycoprotein-1;insulin receptor	***Plasma cell membrane glycoprotein-1*** ( PC-1 ) ***inhibits*** ***insulin receptor*** ( IR ) tyrosine kinase activity and subsequent cellular signaling .	negative	1
9701	10615948	356;355	FasL;Fas	The lack of NO production partially protected islets from cytokine-induced apoptosis but had no effect on cell death induced by cell surface cross-linking of Fas with soluble ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
9702	10615989	650;3549	BMP2;Ihh	Because the effects of Shh-N on chondrocyte differentiation in this culture system differed from those of bone morphogenetic protein-2 ( BMP2 ) and PTH , in terms of proteoglycan synthesis and ALPase activity , it is unlikely that ***BMP2*** or PTH/PTH-related protein ***mediates*** the direct effects of ***Ihh*** in chondrocytes .	target	0
9703	10615989	5741;3549	PTH;Ihh	Because the effects of Shh-N on chondrocyte differentiation in this culture system differed from those of bone morphogenetic protein-2 ( BMP2 ) and PTH , in terms of proteoglycan synthesis and ALPase activity , it is unlikely that BMP2 or ***PTH/PTH-related protein*** ***mediates*** the direct effects of ***Ihh*** in chondrocytes .	target	0
9704	10615989	5744;3549	PTH-related protein;Ihh	Because the effects of Shh-N on chondrocyte differentiation in this culture system differed from those of bone morphogenetic protein-2 ( BMP2 ) and PTH , in terms of proteoglycan synthesis and ALPase activity , it is unlikely that BMP2 or ***PTH/PTH-related protein*** ***mediates*** the direct effects of ***Ihh*** in chondrocytes .	target	0
9705	10616194	960;3569	CD44;interleukin 6	Crosslinking of ***CD44*** on rheumatoid synovial cells ***augment*** ***interleukin 6*** production .	positive	0
9706	10616208	6348;3458	MIP-1alpha;IFN-gamma	***MIP-1alpha*** can ***promote*** macrophage chemotaxis and ***IFN-gamma*** promotes macrophage activation .	positive	0
9707	10616214	7040;1490	TGF-beta1;connective tissue growth factor	***Regulation*** of lysyl oxidase , collagen , and ***connective tissue growth factor*** by ***TGF-beta1*** and detection in human gingiva .	target	1
9708	10616214	7040;4015	TGF-beta1;lysyl oxidase	***Regulation*** of ***lysyl oxidase*** , collagen , and connective tissue growth factor by ***TGF-beta1*** and detection in human gingiva .	target	1
9709	10616214	7040;1490	TGF-beta1;connective tissue growth factor	In addition , ***TGF-beta1*** ***regulation*** of ***connective tissue growth factor*** ( CTGF ) was assessed in human gingival cells and tissues .	target	1
9710	10616214	7040;4015	TGF-beta1;lysyl oxidase	The results show that ***TGF-beta1*** ***increases*** ***lysyl oxidase*** enzyme activity and mRNA levels for lysyl oxidase and alpha-1-type I collagen , but not elastin , in a dose - and time-dependent manner .	positive	0
9711	10616214	7040;1490	TGF-beta1;CTGF	This study shows for the first time that ***CTGF*** mRNA and protein are strongly and rapidly ***induced*** by ***TGF-beta1*** in human gingival fibroblasts .	target	1
9712	10616757	3329;3576	HSP60;IL-8	Reactivity of monoclonal antibody to HSP60 homologue of Helicobacter pylori with human gastric epithelial cells and ***induction*** of ***IL-8*** from these cells by purified H. pylori ***HSP60*** .	target	1
9713	10616757	3329;3576	HSP60;interleukin-8	In addition , affinity-purified ***HSP60*** from H. pylori by H20 mAb ***induced*** ***interleukin-8*** ( IL-8 ) secretion from PHGE cells ( in one of four cases ) .	target	1
9714	10616757	3329;3576	HSP60;IL-8	These results indicate that H. pylori ***HSP60*** ***induces*** ***IL-8*** secretion from human gastric cells , and the levels of IL-8 differ among the various prepared PHGE cells .	target	1
9715	10616903	4149;4609	MAX;MYC	The switch from ******MYC-MAX****** ***complexes*** to MAD-MAX complexes has been postulated to couple cell-cycle arrest with differentiation .	parallel	1
9716	10616903	4149;4084	MAX;MAD	The switch from MYC-MAX complexes to ******MAD-MAX****** ***complexes*** has been postulated to couple cell-cycle arrest with differentiation .	parallel	1
9717	10616904	355;835	Fas;caspase-2	***Fas*** ***activation*** of ***caspase-2*** , caspase-3 , caspase-7 , and caspase-8 and the proteolytic cleavage of substrates such as BID , protein kinase Cdelta , and poly ( ADP-ribose ) polymerase were completely defective in the FADD mutant cell lines .	positive	1
9718	10616904	355;836	Fas;caspase-3	***Fas*** ***activation*** of caspase-2 , ***caspase-3*** , caspase-7 , and caspase-8 and the proteolytic cleavage of substrates such as BID , protein kinase Cdelta , and poly ( ADP-ribose ) polymerase were completely defective in the FADD mutant cell lines .	positive	1
9719	10616904	355;840	Fas;caspase-7	***Fas*** ***activation*** of caspase-2 , caspase-3 , ***caspase-7*** , and caspase-8 and the proteolytic cleavage of substrates such as BID , protein kinase Cdelta , and poly ( ADP-ribose ) polymerase were completely defective in the FADD mutant cell lines .	positive	1
9720	10616904	355;841	Fas;caspase-8	***Fas*** ***activation*** of caspase-2 , caspase-3 , caspase-7 , and ***caspase-8*** and the proteolytic cleavage of substrates such as BID , protein kinase Cdelta , and poly ( ADP-ribose ) polymerase were completely defective in the FADD mutant cell lines .	positive	1
9721	10616965	3586;3458	IL-10;IFN-gamma	It is suggested that increased ***IL-10*** production down ***regulates*** ***IFN-gamma*** secretion and T cell proliferative responses .	target	1
9722	10617103	8862;187	apelin;APJ receptor	Characterization of ***apelin*** , the ***ligand*** for the ***APJ receptor*** .	parallel	1
9723	10617103	8862;187	apelin;APJ	The ***apelin*** peptide was recently discovered and demonstrated to be the endogenous ***ligand*** for the G protein-coupled receptor , ***APJ*** .	parallel	1
9724	10617104	3725;3726	AP-1;JunB	The compositional changes of ***AP-1*** were ***associated*** with an elevation of c-Jun and ***JunB*** protein levels and the appearance of phosphorylated c-Jun and ATF-2 at 15-40 h posttreatment .	parallel	0
9725	10617108	4914;4803	TrkA;NGF	To investigate further its possible mode of action , the ability of monoamine-activated alpha1M and normal alpha1M to bind and to activate the ***NGF*** ***receptor*** ( ***TrkA*** ) was investigated .	parallel	1
9726	10617115	6285;3569	S100beta;interleukin-6	***S100beta*** ***induction*** of the proinflammatory cytokine ***interleukin-6*** in neurons .	target	1
9727	10617115	6285;3569	S100beta;IL-6	We used RT-PCR and electrophoretic mobility shift assay to assess ***S100beta*** ***induction*** of ***IL-6*** expression and the role of kappaB-dependent transcription in this induction in neuron-enriched cultures and in neuron-glia mixed cultures from fetal rat cortex .	target	1
9728	10617115	6285;3569	S100beta;IL-6	***S100beta*** ( 10 or 100 ng/ml x 24 h ) ***increased*** ***IL-6*** mRNA levels two - and fivefold , respectively ( p < 0.05 in each case ) , and S100beta ( 100-1 ,000 ng/ml ) induced increases in medium levels of biologically active IL-6 ( 30-80 % ) .	positive	0
9729	10617115	6285;3569	S100beta;IL-6	***S100beta*** ***induction*** of ***IL-6*** expression correlated with an increase in DNA binding activity specific for a KB element and was inhibited ( 75 % ) by suppression of kappaB binding with double-stranded " decoy " oligonucleotides .	target	1
9730	10617115	6285;3569	S100beta;IL-6	The low levels of S100beta required to induce IL-6 overexpression in neurons , shown here , suggest that overexpression of ***S100beta*** ***induces*** neuronal expression of ***IL-6*** and of IL-6-induced neurodegenerative cascades in Alzheimer 's disease .	target	1
9731	10617118	2903;1742	NR2A;PSD-95	The ***association*** between ***PSD-95*** and ***NR2A*** and NR2B , as indicated by coimmunoprecipitation , was less in postischemic samples than in sham-operated controls .	parallel	0
9732	10617207	7307;11338	U2AF35;U2AF65	Our results suggest that the ******U2AF65-U2AF35****** ***complex*** identifies the U4CAG/R , with U2AF35 being responsible for recognition of the canonical AG .	parallel	1
9733	10617281	3932;6774	Lck;STAT3	The Src-family kinase ***Lck*** can ***induce*** ***STAT3*** phosphorylation and DNA binding activity .	target	1
9734	10617281	3932;6774	Lck;STAT3	Moreover , the ***activation*** of ***STAT3*** by exogenous ***Lck*** could be attenuated by the Lck-specific inhibitor PP1 .	positive	1
9735	10617281	3932;6774	Lck;STAT3	These data provide strong evidence that , like v-Src , ***Lck*** can also directly ***activate*** ***STAT3*** , which contributes to the transformation process .	positive	1
9736	10617282	2885;6464	Grb2;Shc	As previously reported , insulin induced Shc phosphorylation , ******Shc-Grb2****** ***association*** , MAP kinase activation , and BrdU incorporation .	parallel	0
9737	10617282	2885;6464	Grb2;Shc	Interestingly , preincubation of okadaic acid potentiated insulin stimulation of tyrosine phosphorylation of Shc ( 213 % of control ) , ******Shc-Grb2****** ***association*** ( 150 % ) , MAP kinase activity ( 152 % ) , and BrdU incorporation ( 148 % ) .	parallel	0
9738	10617286	836;5580	caspase-3;protein kinase C delta	Proteolytic ***activation*** of ***protein kinase C delta*** and epsilon by ***caspase-3*** in U937 cells during chemotherapeutic agent-induced apoptosis .	positive	1
9739	10617286	836;5581	caspase-3;nPKCepsilon	Furthermore , ***nPKCepsilon*** in non-treated U937 cell lysates was ***cleaved*** by purified recombinant ***caspase-3*** to generate the 43-kDa fragment , identical in size to the fragment observed in vivo .	target	1
9740	10617286	836;5581	caspase-3;nPKCepsilon	These results suggest that ***caspase-3*** specifically ***cleaves*** ***nPKCepsilon*** .	target	1
9741	10617572	117154;2139	Dach2;Eya2	Although Dach2 alone is unable to induce myogenesis , ***Dach2*** can ***synergize*** with ***Eya2*** ( a vertebrate homolog of the Drosophila gene eyes absent ) to regulate myogenic differentiation .	parallel	0
9742	10617572	2139;6495	Eya2;Six1	Moreover , ***Eya2*** can also ***synergize*** with ***Six1*** ( a vertebrate homolog of the Drosophila gene sine oculis ) to regulate myogenesis .	parallel	0
9743	10617572	2139;117154	Eya2;Dach2	This synergistic regulation is explained by direct physical ***interactions*** between ***Dach2*** and ***Eya2*** , and Eya2 and Six1 proteins , analogous to interactions observed between the Drosophila proteins .	parallel	1
9744	10617579	5744;5741	PTHrP;PTH	The comparison between PTHrP analogs substituted by Bpa at two consecutive positions and across PTH and PTHrP reveals insights into the ******PTH/PTHrP****** ligand-receptor bimolecular ***interaction*** at the level of a single amino acid .	parallel	1
9745	10617583	4208;4656	MEF2C;myogenin	***MEF2C*** induced myogenesis in P19 cells and ***up-regulated*** the expression of ***myogenin*** with 25-fold greater efficiency than that of MyoD .	positive	1
9746	10617583	4656;4205	myogenin;MEF2	The MRF , ***myogenin*** , can ***activate*** ***MEF2*** DNA binding activity when transfected into fibroblasts and , in turn , the myogenin promoter contains essential MEF2 DNA binding elements .	positive	1
9747	10617583	4656;4208	myogenin;MEF2C	***myogenin*** expression , and not MyoD , was found to ***up-regulate*** ***MEF2C*** expression .	positive	1
9748	10617585	7080;6439	TTF-1;hSP-B	***TTF-1*** protein synergistically ***stimulated*** the ***hSP-B*** promoter with RARalpha , CBP , and nuclear receptor coactivators in H441 cells .	positive	0
9749	10617585	7080;5914	TTF-1;RARalpha	In addition , ***TTF-1*** ***interacted*** directly with ***RARalpha*** and TIF2 in the mammalian two-hybrid system .	parallel	1
9750	10617585	7080;10499	TTF-1;TIF2	In addition , ***TTF-1*** ***interacted*** directly with RARalpha and ***TIF2*** in the mammalian two-hybrid system .	parallel	1
9751	10617585	1387;7080	CBP;TTF-1	These findings support a model in which RAR/retinoid X receptor , ***TTF-1*** , coactivators , and ***CBP*** form a transcription activation ***complex*** in the upstream enhancer region of the hSP-B gene .	parallel	1
9752	10617585	6439;5914	hSP-B;RARalpha	Deletion and site-specific mutagenesis analysis identified clustered retinoic acid-responsive element sites in the 5 ' - flanking enhancer region of the ***hSP-B*** gene that ***bound*** ***RARalpha*** proteins .	parallel	1
9753	10617585	8202;6439	ACTR;SP-B	RAR coactivators ***ACTR*** , SRC-1 , and transcriptional intermediary factor 2 ( TIF2 ) ***stimulated*** human ( h ) ***SP-B*** promoter activity in a dose-dependent fashion in pulmonary adenocarcinoma H441 cells .	positive	0
9754	10617585	10499;6439	TIF2;SP-B	RAR coactivators ACTR , SRC-1 , and transcriptional intermediary factor 2 ( ***TIF2*** ) ***stimulated*** human ( h ) ***SP-B*** promoter activity in a dose-dependent fashion in pulmonary adenocarcinoma H441 cells .	positive	0
9755	10617585	1387;5914	CREB-binding protein;RAR	In addition , an RAR-associated protein , ***CREB-binding protein*** ( CBP ) , ***potentiated*** the effects of ***RAR*** on hSP-B promoter activity in H441 cells .	positive	0
9756	10617598	694;3219	Btg1;Hoxb9	The leukemia-associated protein ***Btg1*** and the p53-regulated protein Btg2 ***interact*** with the homeoprotein ***Hoxb9*** and enhance its transcriptional activation .	parallel	1
9757	10617598	7832;3219	Btg2;Hoxb9	The leukemia-associated protein Btg1 and the p53-regulated protein ***Btg2*** ***interact*** with the homeoprotein ***Hoxb9*** and enhance its transcriptional activation .	parallel	1
9758	10617598	7832;3219	Btg2;Hoxb9	We further show that Btg1 and Btg2 enhance Hoxb9-mediated transcription in transfected cells , and we report the formation of a ******Hoxb9.Btg2****** ***complex*** on a Hoxb9-responsive target , and the fact that this interaction facilitates the binding of Hoxb9 to DNA .	parallel	1
9759	10617607	5663;351	presenilin 1;amyloid precursor protein	***Regulation*** of ***amyloid precursor protein*** processing by ***presenilin 1*** ( PS1 ) and PS2 in PS1 knockout cells .	target	1
9760	10617607	5664;351	PS2;amyloid precursor protein	***Regulation*** of ***amyloid precursor protein*** processing by presenilin 1 ( PS1 ) and ***PS2*** in PS1 knockout cells .	target	1
9761	10617615	7186;4790	TRAF2;NF-kappaB	TRAF2 is required for TNF-induced activation of c-Jun N-terminal kinase/stress-activated protein kinase ( JNK/SAPK ) , and ***TRAF2*** can also ***mediate*** activation of ***NF-kappaB*** .	target	0
9762	10617615	7186;5599	TRAF2;JNK	Overexpressed Filamin inhibits ***TRAF2-induced*** ***activation*** of ***JNK/SAPK*** and of NF-kappaB .	positive	1
9763	10617615	7186;5601	TRAF2;SAPK	Overexpressed Filamin inhibits ***TRAF2-induced*** ***activation*** of ***JNK/SAPK*** and of NF-kappaB .	positive	1
9764	10617616	904;1025	cyclin T1;Cdk9	Requirement for a kinase-specific chaperone pathway in the production of a ******Cdk9/cyclin T1****** ***heterodimer*** responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription .	parallel	1
9765	10617616	1025;11140	Cdk9;Cdc37	In addition to forming a heterodimer with cyclin T1 , ***Cdk9*** ***interacted*** with the molecular chaperone Hsp70 or a kinase-specific chaperone complex , ***Hsp90/Cdc37*** , to form two separate chaperone-Cdk9 complexes .	parallel	1
9766	10617616	1025;3308	Cdk9;Hsp70	In addition to forming a heterodimer with cyclin T1 , ***Cdk9*** ***interacted*** with the molecular chaperone ***Hsp70*** or a kinase-specific chaperone complex , Hsp90/Cdc37 , to form two separate chaperone-Cdk9 complexes .	parallel	1
9767	10617616	1025;3320	Cdk9;Hsp90	In addition to forming a heterodimer with cyclin T1 , ***Cdk9*** ***interacted*** with the molecular chaperone Hsp70 or a kinase-specific chaperone complex , ***Hsp90/Cdc37*** , to form two separate chaperone-Cdk9 complexes .	parallel	1
9768	10617616	904;1025	cyclin T1;Cdk9	Several lines of evidence indicate the ***heterodimer*** of ******Cdk9/cyclin T1****** to be the mature , active form of P-TEFb responsible for phosphorylation of the C-terminal domain of RNA polymerase II interaction with the Tat activation domain , and mediation of Tat activation of HIV-1 transcription .	parallel	1
9769	10617616	1025;904	Cdk9;cyclin T1	Our data suggest a previously unrecognized chaperone-dependent pathway involving the sequential actions of Hsp70 and Hsp90/Cdc37 in the stabilization/folding of Cdk9 as well as the assembly of an active ******Cdk9/cyclin T1****** ***complex*** responsible for P-TEFb-mediated Tat transactivation .	parallel	1
9770	10617621	5601;598	SAPK;Bcl-x	***SAPK*** ***phosphorylates*** ***Bcl-x*** ( L ) on threonine 47 ( Thr-47 ) and threonine 115 ( Thr-115 ) in vitro and in vivo .	target	1
9771	10617627	867;1956	Cbl;epidermal growth factor receptor	The evolutionarily conserved N-terminal region of ***Cbl*** is sufficient to ***enhance*** down-regulation of the ***epidermal growth factor receptor*** .	positive	0
9772	10617634	207;5879	Akt;Rac1	***Akt*** protein kinase ***inhibits*** ***Rac1-GTP*** binding through phosphorylation at serine 71 of Rac1 .	negative	1
9773	10617634	207;5879	Akt;Rac1	***Phosphorylation*** of ***Rac1*** by ***Akt*** kinase was assayed with recombinant Rac1 protein and the fluorescein-labeled Rac1 peptide .	target	1
9774	10617634	207;5879	Akt;Rac1	It was shown that the ***Rac1*** peptide and the recombinant protein were ***phosphorylated*** by the activated recombinant ***Akt*** kinase and the lysate of SK-MEL28 cells , a human melanoma cell line .	target	1
9775	10617634	207;5879	Akt;Rac1	Thus , the results suggest that ***Akt*** kinase of the phosphoinositide 3-kinase signal transduction pathway phosphorylates serine 71 of Rac1 as one of its authentic substrates and ***modulates*** the ***Rac1*** signal transduction pathway through phosphorylation .	target	0
9776	10617637	4282;7076	MIF;Tissue inhibitor of metalloproteinase (TIMP)-1	***Tissue inhibitor of metalloproteinase (TIMP)-1*** , a common inhibitor of these proteases , was slightly ***up-regulated*** by ***MIF*** .	positive	1
9777	10617648	860;4760	Cbfa1;basic helix loop helix transcription factor	Here we provide the first demonstration that ***Cbfa1*** ( as well as the related protein , Cbfa2/AML1 ) physically ***interacts*** with the ***basic helix loop helix transcription factor*** , HES-1 , a mammalian counterpart of the Drosophila Hairy and Enhancer of split proteins .	parallel	1
9778	10617648	3280;860	HES-1;Cbfa1	Our studies also show that ***HES-1*** can ***antagonize*** the binding of ***Cbfa1*** to mammalian transcriptional corepressors of the Groucho family .	negative	1
9779	10617653	6047;367	SNURF;androgen receptor	Collectively , ***SNURF*** ***modulates*** the transcriptional activities of ***androgen receptor*** and Sp1 via different domains , and it may act as a functional link between steroid - and Sp1-regulated transcription .	target	0
9780	10617676	3553;5743	IL-1beta;COX-2	These results indicate that in human pulmonary epithelial cells , ***IL-1beta*** might activate phosphatidylcholine-phospholipase C through an upstream tyrosine phosphorylation to elicit PKC activation , which in turn initiates NF-kappaB activation , and finally ***induces*** ***COX-2*** expression and PGE ( 2 ) release .	target	1
9781	10617682	3320;196	HSP90;AhR	Because sodium molybdate stabilizes the ******AhR-HSP90****** ***interaction*** and inhibits the gene activation of a number of steroid receptors , we reasoned that molybdate would be a useful tool in delineating the role of HSP90 dissociation in AhR nuclear translocation .	parallel	1
9782	10617865	6774;3569	STAT3;IL-6	CONCLUSIONS : ***STAT3*** transcriptional activation ***correlates*** with the growth-inhibitory signal of ***IL-6*** in LNCaP , suggesting that STAT3 transcriptional activity is an important determinant in the different phenotypic responses to IL-6 in prostate cancer .	parallel	0
9783	10617865	3569;6774	IL-6;STAT3	RESULTS : ***IL-6*** ***induced*** transcriptional activity of ***STAT3*** only in LNCaP .	target	1
9784	10617950	7124;836	TNF-alpha;caspase-3	RESULTS : Our results indicated that linoleic acid and ***TNF-alpha*** independently , but more markedly in concert , ***up-regulated*** ***caspase-3*** activity and induced annexin V binding and DNA fragmentation .	positive	1
9785	10618379	7157;9518	p53;PTGF-beta	The ***p53*** ***binding*** and transactivation of the ***PTGF-beta*** promoter was enhanced by etoposide , a p53 activator , and was largely blocked by a dominant negative p53 mutant .	parallel	1
9786	10618391	7410;1956	vav-2;EGFR	We demonstrate that ***vav-2*** is phosphorylated on tyrosine residues in response to EGF and ***associates*** with the ***EGFR*** in vivo .	parallel	0
9787	10618391	7410;1956	vav-2;EGFR	***Binding*** of ***vav-2*** to the ***EGFR*** is mediated by the SH2 domain of vav-2 .	parallel	1
9788	10618411	3126;1116	DR4;gp39	Similar results were obtained with the ******gp39-DR4****** ***complex*** for nearly all RA patients .	parallel	1
9789	10618435	8850;2033	PCAF;p300	Through its intrinsic HAT activity , ***PCAF*** can further ***potentiate*** the ***p300*** effect .	positive	0
9790	10618488	6667;47	Sp1;ATP citrate-lyase	Transcriptional ***regulation*** of fatty acid synthase gene and ***ATP citrate-lyase*** gene by ***Sp1*** and Sp3 in rat hepatocytes ( 1 ) .	target	1
9791	10618488	6667;2194	Sp1;fatty acid synthase	Transcriptional ***regulation*** of ***fatty acid synthase*** gene and ATP citrate-lyase gene by ***Sp1*** and Sp3 in rat hepatocytes ( 1 ) .	target	1
9792	10618488	6670;47	Sp3;ATP citrate-lyase	Transcriptional ***regulation*** of fatty acid synthase gene and ***ATP citrate-lyase*** gene by Sp1 and ***Sp3*** in rat hepatocytes ( 1 ) .	target	1
9793	10618488	6670;2194	Sp3;fatty acid synthase	Transcriptional ***regulation*** of ***fatty acid synthase*** gene and ATP citrate-lyase gene by Sp1 and ***Sp3*** in rat hepatocytes ( 1 ) .	target	1
9794	10618500	10142;2902	Yotiao;NR1	***Yotiao*** ***interacts*** with the ***NR1*** subunit of the NMDA receptor .	parallel	1
9795	10618500	10142;2902	Yotiao;NR1	Co-assembly of ***Yotiao/PKAII*** ***complexes*** with ***NR1*** subunits may promote cAMP-dependent modulation of NMDA receptor activity at synapses , thereby influencing brain development and synaptic plasticity .	parallel	1
9796	10618692	3586;3553	IL-10;IL-1beta	Earlier , we reported an ***association*** between low in vitro and in vivo IL-1 and IL-6 production , decreased ***IL-1beta*** and ***IL-10*** mRNA expression and B cell chronic lymphocytic leukemia ( B-CLL ) disease progression .	parallel	0
9797	10618706	4193;7157	MDM2;p53	Central to the activation process , by whichever route , is the destabilization of the ******p53-MDM2****** ***interaction*** .	parallel	1
9798	10618706	4193;7157	MDM2;p53	The second is that activation involves not just a single molecular event such as disruption of the ******p53-MDM2****** ***interaction*** , but a series of sequential events the nature of which is governed by the type of activating stimulus .	parallel	1
9799	10618708	7157;4193	p53;mdm2	Beginning with the properties of the ******Rb-mdm2-p53****** trimeric ***complex*** , we shall review the propounding evidence suggesting that the apoptotic function of p53 is linked to its transrepression function .	parallel	1
9800	10618713	1029;25	p19ARF;v-Abl	***Inhibition*** of ***v-Abl*** transformation by p53 and ***p19ARF*** .	negative	1
9801	10618713	7157;25	p53;v-Abl	***Inhibition*** of ***v-Abl*** transformation by ***p53*** and p19ARF .	negative	1
9802	10618714	7157;6890	p53;TAP1	***p53*** ***induces*** ***TAP1*** and enhances the transport of MHC class I peptides .	target	1
9803	10618714	7157;6890	p53;TAP1	Here we found that ***TAP1*** is strongly ***induced*** by ***p53*** and DNA-damaging agents through a p53-responsive element .	target	1
9804	10618714	7161;7157	p73;p53	We also found that ***p73*** , which is homologous to p53 , is capable of inducing TAP1 and ***cooperates*** with ***p53*** to activate TAP1 .	parallel	0
9805	10618714	7161;6890	p73;TAP1	We also found that ***p73*** , which is homologous to p53 , is capable of inducing TAP1 and cooperates with p53 to ***activate*** ***TAP1*** .	positive	1
9806	10618714	7157;3458	p53;interferon gamma	Furthermore , we found that by inducing TAP1 , ***p53*** enhances the transport of MHC class I peptides and expression of surface MHC-peptide complexes , and ***cooperates*** with ***interferon gamma*** to activate the MHC class I pathway .	parallel	0
9807	10618716	6667;3371	Sp1;TN-C	In conclusion , this study shows for the first time that the TN-C gene is regulated by Ets proteins , which together with ***Sp1*** act as potent ***activators*** of ***TN-C*** expression .	positive	1
9808	10618716	2313;6667	Fli1;Sp1	The studies performed in Drosophila cells demonstrate that either ***Fli1*** or GABPalpha + beta1 functionally ***interact*** with ***Sp1*** resulting in a synergistic stimulation of the TN-C promoter activity .	parallel	1
9809	10618718	5599;1398	JNK;Crk	Met-induced ***JNK*** activation is mediated by the adapter protein Crk and ***correlates*** with the Gab1 - ***Crk*** signaling complex formation .	parallel	0
9810	10618718	1398;5599	Crk;JNK	Met-induced ***JNK*** activation is ***mediated*** by the adapter protein ***Crk*** and correlates with the Gab1 - Crk signaling complex formation .	target	0
9811	10618718	4233;2549	Met;Gab1	Our studies show that activated ***Met*** ***associates*** with , and phosphorylates , the docking protein ***Gab1*** , which in turn binds to the src homology 2 ( SH2 ) - domain of the adapter protein Crk and recruits Crk to the Met signaling complex .	parallel	0
9812	10618718	1398;4233	Crk;Met	Our studies show that activated Met associates with , and phosphorylates , the docking protein Gab1 , which in turn binds to the src homology 2 ( SH2 ) - domain of the adapter protein Crk and ***recruits*** ***Crk*** to the ***Met*** signaling complex .	target	0
9813	10618718	4233;5599	Met;JNK	Formation of the Gab1 - Crk complex correlates with Met-induced JNK activation , and mutant forms of ***Met*** that fail to induce the complex formation also fail to ***activate*** ***JNK*** .	positive	1
9814	10618718	4233;5599	Met;JNK	Importantly , expression of a loss-of-function mutant of Crk severely impairs ***activation*** of the ***JNK*** pathway by ***Met*** .	positive	1
9815	10618718	4233;4312	Met;matrix metalloproteinase-1	We also show here that ***Met*** ***controls*** the transcription of the ***matrix metalloproteinase-1*** ( MMP-1 ) gene in carcinoma cells and that this transcriptional regulation occurs in a Crk - JNK-dependent manner through an AP-1 element in the MMP-1 promoter .	target	0
9816	10618719	4168;998	DBL;CDC42	However , since this inhibitor could sequester many GDP-dissociation stimulators ( GDSs ) , such as ***DBL*** , OST and Tiam-1 which ***activate*** not only ***CDC42*** , but also Rho or Rac , in fact it is not a specific inhibitor that inactivates only CDC42 .	positive	1
9817	10618719	23263;998	OST;CDC42	However , since this inhibitor could sequester many GDP-dissociation stimulators ( GDSs ) , such as DBL , ***OST*** and Tiam-1 which ***activate*** not only ***CDC42*** , but also Rho or Rac , in fact it is not a specific inhibitor that inactivates only CDC42 .	positive	1
9818	10618719	7074;998	Tiam-1;CDC42	However , since this inhibitor could sequester many GDP-dissociation stimulators ( GDSs ) , such as DBL , OST and ***Tiam-1*** which ***activate*** not only ***CDC42*** , but also Rho or Rac , in fact it is not a specific inhibitor that inactivates only CDC42 .	positive	1
9819	10618719	10188;998	ACK-1;CDC42	Thus , we have taken the minimum CDC42-binding domain ( residues 504 - 545 , called ACK42 ) of the Tyr-kinase ***ACK-1*** that ***binds*** only ***CDC42*** in the GTP-bound form , and thereby blocking the interactions of CDC42-GTP with its downstream effectors such as ACKs , PAKs and N-WASP .	parallel	1
9820	10618720	4215;5599	MEKK3;JNK	Of the four MEKKs tested , only ***MEKK3*** and MEKK4 are involved in arsenate-mediated ***activation*** of ***JNK*** .	positive	1
9821	10618720	4216;5599	MEKK4;JNK	Of the four MEKKs tested , only MEKK3 and ***MEKK4*** are involved in arsenate-mediated ***activation*** of ***JNK*** .	positive	1
9822	10618720	5599;10746	JNK;MEKK2	In contrast , arsenite-mediated ***JNK*** activation ***requires*** ***MEKK2*** , MEKK3 and MEKK4 .	target	0
9823	10618720	5599;4215	JNK;MEKK3	In contrast , arsenite-mediated ***JNK*** activation ***requires*** MEKK2 , ***MEKK3*** and MEKK4 .	target	0
9824	10618720	5599;4216	JNK;MEKK4	In contrast , arsenite-mediated ***JNK*** activation ***requires*** MEKK2 , MEKK3 and ***MEKK4*** .	target	0
9825	10619020	8850;4654	PCAF;MyoD	Here , we provide a molecular explanation of this phenomenon and report that ***MyoD*** is directly ***acetylated*** by ***PCAF*** at evolutionarily conserved lysines .	target	1
9826	10619025	1605;375790	alpha-dystroglycan;agrin	The crystal structure of a laminin G-like module reveals the molecular basis of ***alpha-dystroglycan*** ***binding*** to laminins , perlecan , and ***agrin*** .	parallel	1
9827	10619025	1605;3339	alpha-dystroglycan;perlecan	The crystal structure of a laminin G-like module reveals the molecular basis of ***alpha-dystroglycan*** ***binding*** to laminins , ***perlecan*** , and agrin .	parallel	1
9828	10619187	7124;3952	tumor necrosis factor-alpha;leptin	Protein kinase C mediates ***tumor necrosis factor-alpha-induced*** ***inhibition*** of obese gene expression and ***leptin*** secretion in brown adipocytes .	negative	1
9829	10619187	7124;4023	tumor necrosis factor-alpha;lipoprotein lipase	Previously we showed that ***tumor necrosis factor-alpha*** ( TNF-alpha ) ***inhibits*** ***lipoprotein lipase*** ( LPL ) activity and its gene expression , an early marker of adipocyte differentiation , in cultured brown adipocytes .	negative	1
9830	10619187	7124;3952	TNF-alpha;leptin	Time-course study showed that ***TNF-alpha*** significantly ***suppressed*** ***leptin*** secretion during incubation for 16 , 24 and 48 h.	negative	1
9831	10619187	7124;3952	TNF-alpha;leptin	Since some effect of TNF-alpha is mediated by activation of protein kinase C ( PKC ) , the role of PKC in ***TNF-alpha-induced*** ***downregulation*** of ob gene expression and ***leptin*** secretion was studied .	negative	1
9832	10619403	3952;6774	Leptin;STAT3	***Leptin*** ***enhanced*** the DNA-binding activity of the transcription factor ***STAT3*** and extracellular signal-regulated kinase 2 ( ERK2 ) activity was stimulated by Leptin after 15 min .	positive	0
9833	10619492	1017;1027	cdk2;p27Kip1	The key components of the network that generate a dynamic switching behaviour associated with the R-point include a positive feedback loop between cyclin-E/cdk2 and Cdc25A , along with the mutually negative ***interaction*** between the cdk inhibitor ***p27Kip1*** and ***cyclin-E/cdk2*** .	parallel	1
9834	10619552	2321;2670	flt-1;GFAP	The spatial and temporal immunoexpression of the intermediate filament (IF) protein nestin and its relationship to glial fibrillary acidic protein ( ***GFAP*** ) , vascular endothelial growth factor ( VEGF ) , and its ***receptor*** ***flt-1*** ( VEGF-R1 ) in reactive astroglia was examined following stab wounds or transplants of fetal CNS tissue into the adult brain .	parallel	1
9835	10619564	4915;627	trkB;BDNF	We have previously demonstrated that following experimental brain trauma of moderate severity ( 2.0-2 .1 atm ) , mRNA levels of ***BDNF*** and its high-affinity ***receptor*** , ***trkB*** , are increased bilaterally in the hippocampus for several hours , whereas NT-3 mRNA expression is decreased .	parallel	1
9836	10619573	183;5502	Angiotensin II;inhibitor 1	***Angiotensin II*** ***stimulates*** plasminogen activator ***inhibitor 1*** and directly causes endothelial dysfunction .	positive	0
9837	10619603	7027;1875	DP-1;E2F-5	Detailed analysis using a two-hybrid approach in mammalian cells indicated lack of physical ***interaction*** between p53 and ***E2F-5*** , ***DP-1*** , or E2F-1 .	parallel	1
9838	10619603	7027;7157	DP-1;p53	Detailed analysis using a two-hybrid approach in mammalian cells indicated lack of physical ***interaction*** between ***p53*** and E2F-5 , ***DP-1*** , or E2F-1 .	parallel	1
9839	10619603	1869;7027	E2F-1;DP-1	Detailed analysis using a two-hybrid approach in mammalian cells indicated lack of physical ***interaction*** between p53 and E2F-5 , ***DP-1*** , or ***E2F-1*** .	parallel	1
9840	10619603	1869;1875	E2F-1;E2F-5	Detailed analysis using a two-hybrid approach in mammalian cells indicated lack of physical ***interaction*** between p53 and ***E2F-5*** , DP-1 , or ***E2F-1*** .	parallel	1
9841	10619603	1869;7157	E2F-1;p53	Detailed analysis using a two-hybrid approach in mammalian cells indicated lack of physical ***interaction*** between ***p53*** and E2F-5 , DP-1 , or ***E2F-1*** .	parallel	1
9842	10619603	7157;1875	p53;E2F-5	Detailed analysis using a two-hybrid approach in mammalian cells indicated lack of physical ***interaction*** between ***p53*** and ***E2F-5*** , DP-1 , or E2F-1 .	parallel	1
9843	10619603	1869;7027	E2F-1;DP-1	Reciprocal analysis revealed that whereas ***E2F-1*** dramatically ***inhibited*** p53-activated transcription , E2F-5 or ***DP-1*** did not .	negative	1
9844	10619603	1869;1875	E2F-1;E2F-5	Reciprocal analysis revealed that whereas ***E2F-1*** dramatically ***inhibited*** p53-activated transcription , ***E2F-5*** or DP-1 did not .	negative	1
9845	10619820	4790;3553	NF-kappaB;IL-1beta	Inhibition of ***NF-kappaB*** by pyrrolidine dithiocarbamate ***attenuated*** ***IL-1beta*** and TNF-alpha synthesis .	positive	0
9846	10619820	4790;7124	NF-kappaB;TNF-alpha	Inhibition of ***NF-kappaB*** by pyrrolidine dithiocarbamate ***attenuated*** IL-1beta and ***TNF-alpha*** synthesis .	positive	0
9847	10619845	375790;4593	agrin;MuSK	***agrin*** ***activates*** ***MuSK*** and stimulates phosphorylation and clustering of acetylcholine receptors ( AChRs ) at synaptic sites .	positive	1
9848	10619853	339287;84148	MSL1;MOF	Furthermore , the ***MSL1*** C-terminal domain ***binds*** specifically to a ***GST-MOF*** fusion protein and co-immunoprecipitates with HA-tagged MSL3 .	parallel	1
9849	10620011	571;4094	Bach1;Maf	***Bach1*** forms heterodimers with small Maf proteins through its leucine zipper and ***binds*** to ***Maf*** recognition elements ( MARE ) .	parallel	1
9850	10620011	7975;571	MafK;Bach1	RESULTS : Using atomic force microscopy we visualized large looped DNA structures between MAREs located in different regulatory elements within the human beta-globin LCR that were mediated by ******Bach1/MafK****** ***heterodimers*** .	parallel	1
9851	10620017	3312;3320	Hsc70;Hsp90	The third factor may be required for the loading of ***Hsc70*** on to the substrate protein ***bound*** to ***Hsp90*** .	parallel	1
9852	10620020	8239;1499	Fam;beta-catenin	CONCLUSION : These results indicate that ***Fam*** interacts with and ***stabilizes*** ***beta-catenin*** in vivo , presumably through the deubiquitination of beta-catenin .	positive	0
9853	10620020	8239;1499	Fam;beta-catenin	The deubiquitinating enzyme ***Fam*** interacts with and ***stabilizes*** ***beta-catenin*** .	positive	0
9854	10620020	8239;4301	Fam;AF-6	We have previously found that the deubiquitinating enzyme ***Fam*** is colocalized with AF-6 , one of the effectors of the Ras small GTPase , at cell-cell contact sites in epithelial cells and ***interacts*** with ***AF-6*** in vivo and in vitro .	parallel	1
9855	10620020	8239;4301	Fam;AF-6	***Fam*** has deubiquitinating activity in vitro and ***prevents*** the ubiquitination of ***AF-6*** in intact cells .	negative	0
9856	10620020	8239;1499	Fam;beta-catenin	These observations prompted us to examine the possible ***Fam*** ***regulation*** of the stabilization of ***beta-catenin*** .	target	1
9857	10620020	8239;1499	Fam;beta-catenin	RESULTS : We found that ***Fam*** ***interacted*** with ***beta-catenin*** both in vivo and in vitro .	parallel	1
9858	10620065	655;6662	BMP-7;sox9	***BMP-7*** also ***induced*** type II collagen and ***sox9*** mRNAs in the same cell population , indicating that noggin induction occurred in the chondrogenic precursor cells .	target	1
9859	10620065	655;9241	BMP-7;noggin	Coordinated expression of noggin and bone morphogenetic proteins ( BMPs ) during early skeletogenesis and ***induction*** of ***noggin*** expression by ***BMP-7*** .	target	1
9860	10620139	4049;3596	TNF-beta;IL-13	Compared with medium control , ***TNF-beta*** significantly ***decreased*** IL-5 ( p = 0.0004 ) and ***IL-13*** ( p = 0.008 ) but increased IFN-gamma ( p = 0.001 ) production .	negative	0
9861	10620139	4049;3567	TNF-beta;IL-5	Compared with medium control , ***TNF-beta*** significantly ***decreased*** ***IL-5*** ( p = 0.0004 ) and IL-13 ( p = 0.008 ) but increased IFN-gamma ( p = 0.001 ) production .	negative	0
9862	10620193	6678;7040	SPARC;TGF-beta1	***Induction*** of ***TGF-beta1*** by the matricellular protein ***SPARC*** in a rat model of glomerulonephritis .	target	1
9863	10620193	6678;7040	SPARC;TGF-beta1	UNLABELLED : ***Induction*** of ***TGF-beta1*** by the matricellular protein ***SPARC*** in a rat model of glomerulonephritis .	target	1
9864	10620194	729230;6347	CCR2;MCP-1	***CCR2*** is a prominent ***receptor*** for monocyte chemoattractant protein-1 ( ***MCP-1*** ) .	parallel	1
9865	10620194	6347;729230	MCP-1;CCR2	It has been suggested that ***CCR2*** and its ***ligand*** , ***MCP-1*** , play a role in the pathogenesis of glomerulonephritis .	parallel	1
9866	10620287	3784;3753	KCNQ1;KCNE1	The voltage-gated potassium channel ***KCNQ1*** ***associates*** with the small ***KCNE1*** subunit to form the cardiac IKs delayed rectifier potassium current and mutations in both genes can lead to the long QT syndrome .	parallel	0
9867	10620355	5617;7498	prolactin;XOR	***prolactin*** and cortisol ***increased*** ***XOR*** protein and mRNA in the presence of epidermal growth factor , which blocked the stimulation of beta-casein synthesis by these hormones .	positive	0
9868	10620499	820;796	cAMP;calcitonin	Distinct signalling pathways mediate the cAMP response element ( CRE ) - dependent ***activation*** of the ***calcitonin*** gene-related peptide gene promoter by ***cAMP*** and nerve growth factor .	positive	1
9869	10620499	4803;796	nerve growth factor;calcitonin	Distinct signalling pathways mediate the cAMP response element ( CRE ) - dependent ***activation*** of the ***calcitonin*** gene-related peptide gene promoter by cAMP and ***nerve growth factor*** .	positive	1
9870	10620503	6300;4137	SAPK3;tau	Taken together , these results suggest that osmotic stress activates at least two tau-directed protein kinases , one proline-directed and one non-proline-directed , that ***SAPK3*** can ***phosphorylate*** ***tau*** on Ser/Thr-Pro residues in situ , and that Ser-262 / 356 phosphorylation only partially regulates tau localization in the cell .	target	1
9871	10620507	5590;5894	protein kinase C-zeta;Raf-1	We found previously that ***protein kinase C-zeta*** ( PKC-zeta ) can ***phosphorylate*** and activate ***Raf-1*** in a signalling complex [ van Dijk , Hilkmann and van Blitterswijk ( 1997 ) Biochem .	target	1
9872	10620507	5894;5590	Raf-1;PKC-zeta	We report now that ******PKC-zeta-Raf-1****** ***interaction*** is mediated by 14-3-3 proteins in vitro and in vivo .	parallel	1
9873	10620507	5894;5590	Raf-1;PKC-zeta	Co-immunoprecipitation experiments in COS cells revealed that complex ***formation*** between ***PKC-zeta*** and ***Raf-1*** is mediated strongly by the 14-3-3beta and - theta ; isotypes , but not by 14-3-3zeta .	parallel	0
9874	10620510	221937;23309	MNF;sin3B	The winged-helix/forkhead protein myocyte nuclear factor beta ( ***MNF-beta*** ) forms a co-repressor ***complex*** with mammalian ***sin3B*** .	parallel	1
9875	10620516	867;5594	Cbl;ERK2	The expression of wild-type ***Cbl*** or the 70Z/3 Cbl mutant ***enhances*** basal ***ERK2*** activity in transfectants with a minimal effect on alpha4 integrin-mediated ERK2 activity .	positive	0
9876	10620570	5327;5054	tPA;PAI-1	BACKGROUND : We evaluated assays to measure both total tissue plasminogen activator ( tPA ) and the three principle forms of tPA in plasma : active tPA , ***tPA*** ***complexed*** with plasminogen activator inhibitor type 1 ( ***PAI-1*** ) , and tPA complexed with C1-inhibitor .	parallel	1
9877	10620570	5054;5327	PAI-1;tPA	For measurement of ******tPA/PAI-1****** ***complex*** , polyclonal anti-PAI-1 conjugates recovered 112 % + / - 20 % of the expected tPA/PAI-1 vs recovery of only 38 % + / - 16 % when monoclonal anti-PAI-1 conjugates were used .	parallel	1
9878	10620615	6346;1237	I-309;CCR8	Because of its pharmacological selectivity , the MC148 protein could be a useful tool in the delineation of the role played by ***CCR8*** and its endogenous ***ligand*** , ***I-309*** .	parallel	1
9879	10620618	8772;8772	MORT1;FADD	Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or ******FADD/MORT1****** ***signaling*** .	parallel	0
9880	10620618	356;355	FasL;Fas	It has been reported that tumor cells treated with anticancer drugs increase surface expression of ***Fas*** ***ligand*** ( ***FasL*** ) and are killed by autocrine or paracrine apoptosis signaling through Fas ( Friesen , C. , I.	parallel	1
9881	10620629	598;581	Bcl-X;Bax	Bax conformation and ******Bax-Bcl-X****** ( L ) ***interactions*** were monitored by immunofluorescence and immunoprecipitation , respectively .	parallel	1
9882	10620629	958;598	CD40;Bcl-X	Activation of surface protein ***CD40*** ***increased*** ***Bcl-X*** ( L ) protein levels via an ( E ) - capsaicin-inhibitable activation of NF-kappaB ; i.e. , ( E ) - capsaicin restored etoposide sensitivity .	positive	0
9883	10620629	598;958	Bcl-X;CD40	interleukin 4 had no effect on Bcl-X ( L ) protein levels but accelerated the increase in ***Bcl-X*** ( L ) protein ***associated*** with ***CD40*** activation .	parallel	0
9884	10620629	3565;581	interleukin 4;Bax	VCAM-1 - and ***interleukin 4-mediated*** signals diminished conformational changes in Bax protein and ***prevented*** the etoposide-induced disruption of constitutive ***Bax-Bcl-X*** ( L ) binding .	negative	0
9885	10620629	3565;598	interleukin 4;Bcl-X	VCAM-1 - and ***interleukin 4-mediated*** signals diminished conformational changes in Bax protein and ***prevented*** the etoposide-induced disruption of constitutive ***Bax-Bcl-X*** ( L ) binding .	negative	0
9886	10620662	1020;4137	cyclin-dependent kinase (cdk) 5;tau	As previously reported , ***cyclin-dependent kinase (cdk) 5*** can ***phosphorylate*** ***tau*** at the site of abnormally phosphorylated in PHF .	target	1
9887	10620702	2932;4137	GSK-3beta;tau	These findings suggest that ***GSK-3beta*** ***modulates*** in a graded manner the ability of ***tau*** to control the microtubule-dependent induction of cell processes .	target	0
9888	10622416	4288;3479	MIB-1;IGF-1	Women on HC displayed a higher breast tissue proliferation ( p = 0.05 ) expressed as Ki-67 , ***MIB-1*** positivity , which was ***correlated*** with ***IGF-1*** mRNA ( r ( s ) = 0.82 , p = 0.04 ) .	parallel	0
9889	10622714	596;836	Bcl-2;caspase-3	Nevertheless , synthesis of the anti-apoptotic protein ***Bcl-2*** appears to delay the subsequent time course of PS exposure and to ***reduce*** ***caspase-3*** activation and the fraction of cells which become hypoploid .	negative	1
9890	10622723	10878;718	FHR-3;C3b	The apparent K ( A ) values for the ***interactions*** of ***FHR-3*** and FHR-4 with ***C3b*** are 7.5 x 10 ( 6 ) M ( -1 ) and 2.9 x 10 ( 6 ) M ( -1 ) , respectively .	parallel	1
9891	10622723	10877;718	FHR-4;C3b	The apparent K ( A ) values for the ***interactions*** of FHR-3 and ***FHR-4*** with ***C3b*** are 7.5 x 10 ( 6 ) M ( -1 ) and 2.9 x 10 ( 6 ) M ( -1 ) , respectively .	parallel	1
9892	10623425	3579;5473	CXCR2;NAP-2	Moreover , although ***CXCR2*** ***bound*** IL-8 and ***NAP-2*** with similarly high affinity , IL-8 functionally competed with and displaced NAP-2 , and prompted high levels of internalization , similar to those induced by IL-8 alone .	parallel	1
9893	10623436	3553;100507436	IL-1beta;HLA-class I antigen	The ***HLA-class I antigen*** expression of PC-9 was ***augmented*** by either TNF-alpha or ***IL-1beta*** .	positive	0
9894	10623436	7124;100507436	TNF-alpha;HLA-class I antigen	The ***HLA-class I antigen*** expression of PC-9 was ***augmented*** by either ***TNF-alpha*** or IL-1beta .	positive	0
9895	10623463	5890;4155	Rad51L1;myelin basic protein	Here , we report that ***hsRec2/Rad51L1*** can ***phosphorylate*** kemptide , as well as ***myelin basic protein*** , p53 , cyclin E , and cdk2 , but not a peptide substrate containing tyrosine only .	target	1
9896	10623464	3439;5610	IFN;PKR	However , ***PKR*** enzymatic activity was significantly ***induced*** by ***IFN*** only in C2-NEO cells , while it was hardly detected in both clones 17 and 22 , even after IFN treatment .	target	1
9897	10623469	1052;1050	C/EBPdelta;C/EBPalpha	These data demonstrate that Myc specifically inhibits the terminal stages of the adipogenic program and suggest that Myc may act by blocking C/EBPbeta - and ***C/EBPdelta-directed*** ***activation*** of ***C/EBPalpha*** and PPARgamma2 expression , although the precise molecular mechanism is not understood .	positive	1
9898	10623575	5015;3170	OTX2;HNF-3beta	***OTX2*** directly ***interacts*** with LIM1 and ***HNF-3beta*** .	parallel	1
9899	10623575	5015;3975	OTX2;LIM1	***OTX2*** directly ***interacts*** with ***LIM1*** and HNF-3beta .	parallel	1
9900	10623575	5015;3170	OTX2;HNF-3beta	Several transcription factors are expressed in these tissues , and mutant mice analyses have suggested the ***interactions*** of the ***OTX2*** gene cascade with the LIM1 or ***HNF-3beta*** cascade .	parallel	1
9901	10623575	5015;3975	OTX2;LIM1	Several transcription factors are expressed in these tissues , and mutant mice analyses have suggested the ***interactions*** of the ***OTX2*** gene cascade with the ***LIM1*** or HNF-3beta cascade .	parallel	1
9902	10623575	5015;3170	OTX2;HNF-3beta	Here we show that ***OTX2*** directly ***associates*** with LIM1 and ***HNF-3beta*** ; OTX2 binds to the LIM1 homeodomain ( HD ) with its C-terminal region , whereas both HD and C-terminal regions of OTX2 bind to the HNF-3beta fork head domain or OTX2 HD .	parallel	0
9903	10623575	5015;3975	OTX2;LIM1	Here we show that ***OTX2*** directly ***associates*** with ***LIM1*** and HNF-3beta ; OTX2 binds to the LIM1 homeodomain ( HD ) with its C-terminal region , whereas both HD and C-terminal regions of OTX2 bind to the HNF-3beta fork head domain or OTX2 HD .	parallel	0
9904	10623575	5015;3170	OTX2;HNF-3beta	Direct ***interactions*** of ***OTX2*** with LIM1 or ***HNF-3beta*** may play important roles in anterior visceral endoderm and/or anterior mesendoderm to constitute transcriptional regulatory networks for head development .	parallel	1
9905	10623575	5015;3975	OTX2;LIM1	Direct ***interactions*** of ***OTX2*** with ***LIM1*** or HNF-3beta may play important roles in anterior visceral endoderm and/or anterior mesendoderm to constitute transcriptional regulatory networks for head development .	parallel	1
9906	10623590	9463;375	PICK1;ARF1	Thus , ***PICK1*** specifically ***interacts*** with ***ARF1/3*** in the GTP-bound state , suggesting that PICK1 participates in ARF1/3-mediated cellular processes .	parallel	1
9907	10623615	387;2822	RhoA;PLD	***RhoA*** , which is known to be a plasma membrane ***activator*** of ***PLD*** , was dissociated from PKA-treated plasma membrane by addition of cytosol .	positive	1
9908	10623622	5465;4318	PPARalpha;matrix metalloproteinase 9	Activation of ***PPARalpha*** or gamma ***reduces*** secretion of ***matrix metalloproteinase 9*** but not interleukin 8 from human monocytic THP-1 cells .	negative	1
9909	10623629	1019;595	Cdk4;cyclin D1	Following CSF-1 stimulation , ***Cdk4*** ***bound*** to ***cyclin D1*** and then to p21 , concomitant with the dissociation of p15 from the complexes .	parallel	1
9910	10623629	1019;1026	Cdk4;p21	The activation of ***Cdk4*** ***correlated*** well with ***p21*** binding to the complexes , and the majority of active Cdk4 complexes contained p21 .	parallel	0
9911	10623629	1019;595	Cdk4;cyclin D1	Using the baculovirus expression system , we succeeded in reconstituting a capacity for Cdk4 activation in insect cells , forming an active ******cyclin D1/Cdk4/p21****** ternary ***complex*** .	parallel	1
9912	10623629	1019;1026	Cdk4;p21	Using the baculovirus expression system , we succeeded in reconstituting a capacity for Cdk4 activation in insect cells , forming an active ******cyclin D1/Cdk4/p21****** ternary ***complex*** .	parallel	1
9913	10623629	1026;595	p21;cyclin D1	Using the baculovirus expression system , we succeeded in reconstituting a capacity for Cdk4 activation in insect cells , forming an active ******cyclin D1/Cdk4/p21****** ternary ***complex*** .	parallel	1
9914	10623629	595;1019	cyclin D1;Cdk4	Taken together , it is suggested that p21 and ***cyclin D1*** act cooperatively as ***activators*** of ***Cdk4*** through the release of CKIs of the INK4 family .	positive	1
9915	10623629	1026;1019	p21;Cdk4	Taken together , it is suggested that ***p21*** and cyclin D1 act cooperatively as ***activators*** of ***Cdk4*** through the release of CKIs of the INK4 family .	positive	1
9916	10623647	958;2152	CD40;tissue factor	***CD40*** ligation ***induces*** ***tissue factor*** expression in human vascular smooth muscle cells .	target	1
9917	10623647	959;958	CD40L;CD40	In cultured vascular SMC , ligation of CD40 with native ***CD40*** ***ligand*** ( ***CD40L*** ) derived from activated T lymphocytes or recombinant human CD40L ( rCD40L ) induced the transient expression of TF on the cell surface ( as determined by FACS analysis ) in a concentration - and time-dependent manner and enhanced total cell-associated TF ( as determined by ELISA ) .	parallel	1
9918	10623647	959;958	CD40L;CD40	Because TF and CD40 colocalize on lesional SMC in human atheroma , ******CD40/CD40L****** ***signaling*** may contribute to the TF expression and hence to increased thrombogenicity of plaques during the inflammatory responses of atherogenesis and arterial injury .	parallel	0
9919	10623731	920;30816	CD4;envelope glycoprotein	Since the ***interaction*** between the viral ***envelope glycoprotein*** and ***CD4*** and the chemokine receptor mediates fusion and plays a key role in tropism , we have analyzed the HIV-1 ( BORI-15 ) env as a fusogen and in recombinant and pseudotyped viruses .	parallel	1
9920	10623731	7852;920	chemokine receptor;CD4	Since the ***interaction*** between the viral envelope glycoprotein and ***CD4*** and the ***chemokine receptor*** mediates fusion and plays a key role in tropism , we have analyzed the HIV-1 ( BORI-15 ) env as a fusogen and in recombinant and pseudotyped viruses .	parallel	1
9921	10623731	7852;30816	chemokine receptor;envelope glycoprotein	Since the ***interaction*** between the viral ***envelope glycoprotein*** and CD4 and the ***chemokine receptor*** mediates fusion and plays a key role in tropism , we have analyzed the HIV-1 ( BORI-15 ) env as a fusogen and in recombinant and pseudotyped viruses .	parallel	1
9922	10623743	5829;5955	paxillin;E6BP	To determine which BE6 interactions are necessary for transformation by BE6 , we used a novel selection strategy for temperature-sensitive BE6 mutants in yeast that could discriminate in their ***interaction*** between E6AP , ***E6BP*** , and ***paxillin*** .	parallel	1
9923	10623756	3054;10488	HCF;luman	We hypothesize that similar ******luman-HCF****** ***interactions*** in sensory neurons in trigeminal ganglia result in the suppression of viral replication and the establishment of latency .	parallel	1
9924	10623756	10488;27040	luman;LAT	Interestingly , ***luman*** could ***activate*** the promoters of IE110 and ***LAT*** , two genes that are critical for reactivation of HSV-1 from latency .	positive	1
9925	10623756	10488;3054	luman;HCF	In this respect VP16 mimics the host basic leucine zipper (bZIP) protein ***luman*** , which also ***requires*** ***HCF*** for activating transcription .	target	0
9926	10623756	3054;10488	HCF;luman	Our objective is to explore ***interactions*** between ***luman*** and ***HCF*** and to determine if they play a role in the biology of herpesviruses .	parallel	1
9927	10623756	3054;10488	HCF;luman	This cytoplasmic ***association*** of ***luman*** and ***HCF*** could also be demonstrated in neurons in trigeminal ganglia removed from cattle soon after death .	parallel	0
9928	10623764	1509;3700	cathepsin D;gp120	***cathepsin D*** may ***induce*** conformational modification of viral ***gp120*** , allowing direct interaction with a coreceptor .	target	1
9929	10623771	3791;7422	flk-1;VEGF	In particular , KS-SM enhanced the expression of ***KDR/flk-1*** , a ***receptor*** for vascular endothelial growth factor ( ***VEGF*** ) , in cotransfection studies .	parallel	1
9930	10623794	7099;3329	Tlr4;hsp60	We conclude that ***Tlr4*** ***mediates*** ***hsp60*** signaling .	target	0
9931	10623799	3700;3596	gp120;IL-13	These results indicate that ***gp120*** , which acts as a viral superantigen , interacts with the VH3 region of IgE to ***induce*** the release of IL-4 and ***IL-13*** from human Fc epsilon RI + cells .	target	1
9932	10623799	3700;3565	gp120;IL-4	These results indicate that ***gp120*** , which acts as a viral superantigen , interacts with the VH3 region of IgE to ***induce*** the release of ***IL-4*** and IL-13 from human Fc epsilon RI + cells .	target	1
9933	10623799	3700;3596	gp120;IL-13	HIV-1 ***gp120*** ***induces*** IL-4 and ***IL-13*** release from human Fc epsilon RI + cells through interaction with the VH3 region of IgE .	target	1
9934	10623799	3700;3565	gp120;IL-4	HIV-1 ***gp120*** ***induces*** ***IL-4*** and IL-13 release from human Fc epsilon RI + cells through interaction with the VH3 region of IgE .	target	1
9935	10623803	958;4790	CD40;NF-kappaB	Interestingly , however , although we could show TRAF6-dependent ***CD40-mediated*** ***activation*** of ***NF-kappaB*** in 293 kidney epithelial cells , no such effect was seen in B cells , suggesting that TRAF6 has cell-type-specific functions .	positive	1
9936	10623803	7189;4790	TRAF6;NF-kappaB	Interestingly , however , although we could show ***TRAF6-dependent*** CD40-mediated ***activation*** of ***NF-kappaB*** in 293 kidney epithelial cells , no such effect was seen in B cells , suggesting that TRAF6 has cell-type-specific functions .	positive	1
9937	10623803	7189;958	TRAF6;CD40	Using both molecules , we found that ***TRAF6*** ***association*** with ***CD40*** is important for CD40-induced IL-6 and Ig secretion , and that TRAF6 mediates its effects on CD40-stimulated Ig secretion principally through its effects on IL-6 production by the B cell .	parallel	0
9938	10623803	7189;958	TRAF6;CD40	***TRAF6*** ***association*** with ***CD40*** was also found to be important for B7-1 up-regulation , but not for up-regulation of other surface molecules .	parallel	0
9939	10623805	6370;10803	TECK;GPR-9-6	Furthermore we show that ***TECK*** ( thymus-expressed chemokine ) , a chemokine produced by thymic medullary dendritic cells , is a functional ***ligand*** for ***GPR-9-6*** .	parallel	1
9940	10623811	959;958	CD40 ligand;CD40	Induction of B7-1 ( CD80 ) and increased or sustained expression of CD44H , ICAM-1 ( CD54 ) , and B7-2 ( CD86 ) are dependent on the ***interaction*** of ***CD40 ligand*** with ***CD40*** .	parallel	1
9941	10623814	6348;5328	MIP-1alpha;uPA	Interestingly , MIP-1alpha was also capable of preventing the decreased matrix invasion observed by blocking uPAR , suggesting that the ***uPA/uPAR*** system and ***MIP-1alpha*** ***cooperate*** in driving immature DC migration through the subendothelial matrix .	parallel	0
9942	10623814	6348;5329	MIP-1alpha;uPAR	Interestingly , MIP-1alpha was also capable of preventing the decreased matrix invasion observed by blocking uPAR , suggesting that the ***uPA/uPAR*** system and ***MIP-1alpha*** ***cooperate*** in driving immature DC migration through the subendothelial matrix .	parallel	0
9943	10623814	5328;5329	uPA;uPAR	Interestingly , MIP-1alpha was also capable of preventing the decreased matrix invasion observed by blocking uPAR , suggesting that the ******uPA/uPAR****** system and MIP-1alpha ***cooperate*** in driving immature DC migration through the subendothelial matrix .	parallel	0
9944	10623820	3558;4363	IL-2;mrp1	Like the Fluo-3 pump , ***mrp1*** protein expression was ***enhanced*** by ***IL-2*** .	positive	0
9945	10623825	5970;4790	p65;p50	Moreover , although the rabbit kappaB site binds murine NF-kappaB p50/p50 and ******p50/p65****** ***complexes*** with high affinity , this site is not capable of mediating transcriptional activation of transient transfection reporter constructs in mouse B lineage cells .	parallel	1
9946	10623830	3592;3458	P35;IFN-gamma	Because of its crucial function during immune responses , IL-12 production is stringently regulated , in part through transcriptional control of its ***P35*** subunit , which ***requires*** the differentiative effects of ***IFN-gamma*** for expression .	target	0
9947	10623834	7124;7039	TNF-alpha;transforming growth factor-alpha	***TNF-alpha*** ***regulates*** ***transforming growth factor-alpha*** expression in regenerating murine liver and isolated hepatocytes .	target	1
9948	10623834	7124;7039	TNF-alpha;TGF-alpha	***TNF-alpha*** directly ***up-regulates*** ***TGF-alpha*** mRNA by up to 7-fold in isolated mouse hepatocytes , whereas neutralization of TNF-alpha significantly decreased liver mRNA and protein expression of TGF-alpha following chemical-induced hepatotoxicity .	positive	1
9949	10623834	7124;7039	TNF-alpha;TGF-alpha	Using cells transfected with the TGF-alpha promoter , and an RNA polymerase inhibitor , it was shown that ***TNF-alpha*** ***modulates*** ***TGF-alpha*** expression through both pre - and posttranscriptional events .	target	0
9950	10623843	958;5970	p50;p65	The molecular mechanism of action of this CpG motif was associated with the sustained induction of the NF-kappaB ******p50/p65****** ***heterodimer*** and of the transcription-factor complex AP-1 .	parallel	1
9951	10623855	7124;5468	TNF-alpha;PPARgamma	Although 15-deoxy-Delta12 ,14 - prostaglandin J2 ( 15d-PGJ2 ) at micromolar concentrations significantly inhibited the production of ***TNF-alpha*** and IL-6 , four other high affinity ***PPARgamma*** ***ligands*** failed to affect cytokine production .	parallel	1
9952	10623861	3606;6356	IL-18;eotaxin	***IL-18*** was subsequently shown to ***induce*** ***eotaxin*** production from bronchial epithelial cells and isolated macrophages in in vitro assays .	target	1
9953	10623878	1950;1956	EGF;HER1	Ligand-dependent ***activation*** of ***HER1*** , HER3 , and HER4 by ***EGF*** or heregulin results in heterodimerization and , thereby , HER2 activation .	positive	1
9954	10623878	1950;2065	EGF;HER3	Ligand-dependent ***activation*** of HER1 , ***HER3*** , and HER4 by ***EGF*** or heregulin results in heterodimerization and , thereby , HER2 activation .	positive	1
9955	10623878	1950;2066	EGF;HER4	Ligand-dependent ***activation*** of HER1 , HER3 , and ***HER4*** by ***EGF*** or heregulin results in heterodimerization and , thereby , HER2 activation .	positive	1
9956	10623888	650;652	BMP-2;BMP-4	***BMP-2*** and BMP-6 also ***inhibited*** ***BMP-4*** mRNA levels .	negative	1
9957	10623888	654;652	BMP-6;BMP-4	BMP-2 and ***BMP-6*** also ***inhibited*** ***BMP-4*** mRNA levels .	negative	1
9958	10623888	9241;652	noggin;BMP-4	***noggin*** ***increased*** ***BMP-4*** transcripts , suggesting autocrine control of BMP-4 expression .	positive	0
9959	10623891	5054;5340	PAI-1;plasmin	Induced expression of plasminogen activator inhibitor type-1 ( ***PAI-1*** ) , a major negative ***regulator*** of pericellular ***plasmin*** generation , accompanies wound repair in vitro and in vivo .	negative	1
9960	10624298	796;4353	CGRP;myeloperoxidase	On the other hand , 5 x 10 ( -9 ) mol ***CGRP*** i.p. significantly ***reduced*** the marked surgery-induced accumulation of flap ***myeloperoxidase*** ( a marker for neutrophil recruitment ) without affecting the circulating neutrophil count .	negative	1
9961	10624965	26047;3736	Caspr2;Kv1.1	We further show that ***Caspr2*** specifically ***associates*** with ***Kv1.1*** , Kv1.2 , and their Kvbeta2 subunit .	parallel	0
9962	10624965	26047;3737	Caspr2;Kv1.2	We further show that ***Caspr2*** specifically ***associates*** with Kv1.1 , ***Kv1.2*** , and their Kvbeta2 subunit .	parallel	0
9963	10625107	7048;7040	TbetaR-II;TGF-beta1	To test this hypothesis , we examined the steady-state mRNA level of TGF-beta1 and the protein localization of ***TGF-beta1*** and its type II ***receptor*** ( ***TbetaR-II*** ) during experimental tooth movement .	parallel	1
9964	10625200	5054;5327	PAI-1;t-PA	Fibrinolytic factors such as tissue plasminogen activator ( t-PA ) , plasminogen activator inhibitor type 1 ( PAI-1 ) , and ******t-PA-PAI-1****** ***complex*** ( PAI-C ) of specimens were measured by enzyme-linked immunoassay .	parallel	1
9965	10625299	1958;488	Egr-1;SERCA2	In addition , Egr-1 antisense oligonucleotides blocked the DOX-induced reduction in SERCA2 mRNA , suggesting that ***Egr-1*** is a transcriptional ***inhibitor*** of the ***SERCA2*** gene in DOX-induced cardiomyopathy .	negative	1
9966	10625301	284;7010	Ang1;Tie2	***Ang1*** ***induced*** phosphorylation of ***Tie2*** and the p85 subunit of phosphatidylinositol 3 ' - kinase ( PI 3 ' - kinase ) and increased PI 3 ' - kinase activity in a dose-dependent manner .	target	1
9967	10625301	284;207	Ang1;Akt	***Ang1*** ***induced*** phosphorylation of the serine-threonine kinase ***Akt*** at Ser473 in a PI 3 ' - kinase-dependent manner .	target	1
9968	10625534	2022;7040	Endoglin;TGFbeta	***Endoglin*** , an ancillary ***TGFbeta*** ***receptor*** , is required for extraembryonic angiogenesis and plays a key role in heart development .	parallel	1
9969	10625534	2022;7040	Endoglin;TGFbeta	***Endoglin*** ( CD105 ) is expressed on the surface of endothelial and haematopoietic cells in mammals and ***binds*** ***TGFbeta*** isoforms 1 and 3 in combination with the signaling complex of TGFbeta receptors types I and II .	parallel	1
9970	10625549	3172;1499	TCF;beta-catenin	We show that the transactivational activity of endogenous sea urchin TCF is potentiated by LiCl treatment , which vegetalizes embryos by inhibiting GSK3 , consistent with an in vivo ***interaction*** between endogenous ***beta-catenin*** and ***TCF*** .	parallel	1
9971	10625552	9464;50805	dHand;Irx4	Cardiac expression of the ventricle-specific homeobox gene ***Irx4*** is ***modulated*** by Nkx2-5 and ***dHand*** .	target	0
9972	10625552	1482;50805	Nkx2-5;Irx4	Cardiac expression of the ventricle-specific homeobox gene ***Irx4*** is ***modulated*** by ***Nkx2-5*** and dHand .	target	0
9973	10625609	7132;7124	CD120a;tumor necrosis factor alpha	Cross-linking of ***CD120a*** ( p55 ) , a ***receptor*** for ***tumor necrosis factor alpha*** ( TNFalpha ) , initiates downstream events , including the activation of protein Ser/Thr kinases .	parallel	1
9974	10625618	9669;1431	IF2;citrate synthase	EF-G and ***IF2*** ***promote*** the functional folding of ***citrate synthase*** and alpha-glucosidase after urea denaturation .	positive	0
9975	10625620	3458;4609	IFN-gamma;c-Myc	Interestingly , both IL-3 and ***IFN-gamma*** ***induce*** expression of the ***c-Myc*** gene that is not dependent on the Stat1 activity .	target	1
9976	10625620	3562;4609	IL-3;c-Myc	Interestingly , both ***IL-3*** and IFN-gamma ***induce*** expression of the ***c-Myc*** gene that is not dependent on the Stat1 activity .	target	1
9977	10625622	7124;4790	tumor necrosis factor (TNF)-alpha;NF-kappaB	In contrast , although ***tumor necrosis factor (TNF)-alpha*** ***activated*** ***NF-kappaB*** transcription , E5510 had no effect on TNF-alpha-induced activation .	positive	1
9978	10625622	2247;4790	bFGF;NF-kappaB	These results indicate that TRAP and ***bFGF*** ***induced*** I-kappaB degradation and ***NF-kappaB*** activation through a distinct pathway from TNF-alpha and that ERK1/2 may play an important role in NF-kappaB activation induced by TRAP and bFGF .	target	1
9979	10625627	59269;1029	KRC;mts1	These data indicate that ***KRC*** positively ***regulates*** transcription of ***S100A4/mts1*** .	positive	1
9980	10625627	59269;6275	KRC;S100A4	These data indicate that ***KRC*** positively ***regulates*** transcription of ***S100A4/mts1*** .	positive	1
9981	10625627	59269;1029	KRC;mts1	The kappaB and V ( D ) J recombination signal sequence binding protein ***KRC*** ***regulates*** transcription of the mouse metastasis-associated gene ***S100A4/mts1*** .	target	1
9982	10625627	59269;6275	KRC;S100A4	The kappaB and V ( D ) J recombination signal sequence binding protein ***KRC*** ***regulates*** transcription of the mouse metastasis-associated gene ***S100A4/mts1*** .	target	1
9983	10625627	1523;1029	p200;mts1	Site-directed mutagenesis in conjunction with transient transfections indicate that ***p200*** , but not the NF-kappaB/Rel proteins , ***transactivates*** ***S100A4/mts1*** .	positive	1
9984	10625627	1523;6275	p200;S100A4	Site-directed mutagenesis in conjunction with transient transfections indicate that ***p200*** , but not the NF-kappaB/Rel proteins , ***transactivates*** ***S100A4/mts1*** .	positive	1
9985	10625638	5741;632	PTH;osteocalcin	***osteocalcin*** expression is ***modulated*** by parathyroid hormone ( ***PTH*** ) and a variety of other factors .	target	0
9986	10625647	4086;3224	Smad1;Hoxc-8	***Smad1*** domains ***interacting*** with ***Hoxc-8*** induce osteoblast differentiation .	parallel	1
9987	10625647	4086;6696	Smad1;osteopontin	Previously , we have reported that ***Smad1*** ***activates*** ***osteopontin*** gene expression in response to bone morphogenetic protein simulation through an interaction with a homeodomain transcription factor , Hoxc-8 .	positive	1
9988	10625647	4086;3224	Smad1;Hoxc-8	Our data suggest that the ***interaction*** of amino-terminal ***Smad1*** with ***Hoxc-8*** mimics bone morphogenetic protein signaling and is sufficient to induce osteoblast differentiation and bone cell formation .	parallel	1
9989	10625663	6616;80725	SNAP-25;SNIP	By using deletion analysis , we have mapped the binding domains of SNIP and SNAP-25 , and we have demonstrated that the ******SNIP-SNAP-25****** ***association*** is mediated via coiled-coil interactions .	parallel	0
9990	10625666	25803;367	PDEF;androgen receptor	***PDEF*** , a novel prostate epithelium-specific ets transcription factor , ***interacts*** with the ***androgen receptor*** and activates prostate-specific antigen gene expression .	parallel	1
9991	10625668	2028;836	gp160;caspase 3	Increasing expression of wild type ***gp160*** , but not gp160A835W , ***correlates*** with increased calmodulin levels , increased apoptosis , and ***caspase 3*** activation in response to anti-FAS treatment .	parallel	0
9992	10625669	7040;948	TGF-beta1;CD36	TGF-beta1/TGF-beta2 also inhibited CD36 mRNA expression induced by oxidized low density lipoprotein and 15-deoxyDelta ( 12,14 ) prostaglandin J ( 2 ) , a peroxisome proliferator-activated receptor ( PPAR ) - gamma ligand , suggesting that the ***TGF-beta1/TGF-beta2*** ***down-regulated*** ***CD36*** expression by inactivating PPAR-gamma-mediated signaling .	negative	1
9993	10625669	7042;948	TGF-beta2;CD36	TGF-beta1/TGF-beta2 also inhibited CD36 mRNA expression induced by oxidized low density lipoprotein and 15-deoxyDelta ( 12,14 ) prostaglandin J ( 2 ) , a peroxisome proliferator-activated receptor ( PPAR ) - gamma ligand , suggesting that the ***TGF-beta1/TGF-beta2*** ***down-regulated*** ***CD36*** expression by inactivating PPAR-gamma-mediated signaling .	negative	1
9994	10625669	7040;948	TGF-beta1;CD36	***TGF-beta1/TGF-beta2*** also ***inhibited*** ***CD36*** mRNA expression induced by oxidized low density lipoprotein and 15-deoxyDelta ( 12,14 ) prostaglandin J ( 2 ) , a peroxisome proliferator-activated receptor ( PPAR ) - gamma ligand , suggesting that the TGF-beta1/TGF-beta2 down-regulated CD36 expression by inactivating PPAR-gamma-mediated signaling .	negative	1
9995	10625669	7042;948	TGF-beta2;CD36	***TGF-beta1/TGF-beta2*** also ***inhibited*** ***CD36*** mRNA expression induced by oxidized low density lipoprotein and 15-deoxyDelta ( 12,14 ) prostaglandin J ( 2 ) , a peroxisome proliferator-activated receptor ( PPAR ) - gamma ligand , suggesting that the TGF-beta1/TGF-beta2 down-regulated CD36 expression by inactivating PPAR-gamma-mediated signaling .	negative	1
9996	10625669	7040;5468	TGF-beta1;PPAR-gamma	***TGF-beta1/TGF-beta2*** ***increased*** phosphorylation of both mitogen-activated protein ( MAP ) kinase and ***PPAR-gamma*** , whereas MAP kinase inhibitors reversed suppression of CD36 and inhibited PPAR-gamma phosphorylation induced by TGF-beta1/TGF-beta2 .	positive	0
9997	10625669	7042;5468	TGF-beta2;PPAR-gamma	***TGF-beta1/TGF-beta2*** ***increased*** phosphorylation of both mitogen-activated protein ( MAP ) kinase and ***PPAR-gamma*** , whereas MAP kinase inhibitors reversed suppression of CD36 and inhibited PPAR-gamma phosphorylation induced by TGF-beta1/TGF-beta2 .	positive	0
9998	10625669	7040;948	TGF-beta1;CD36	Our data demonstrate for the first time that ***TGF-beta1*** and TGF-beta2 ***decrease*** expression of ***CD36*** by a mechanism involving phosphorylation of MAP kinase , subsequent MAP kinase phosphorylation of PPAR-gamma , and a decrease in CD36 gene transcription by phosphorylated PPAR-gamma .	negative	0
9999	10625669	7042;948	TGF-beta2;CD36	Our data demonstrate for the first time that TGF-beta1 and ***TGF-beta2*** ***decrease*** expression of ***CD36*** by a mechanism involving phosphorylation of MAP kinase , subsequent MAP kinase phosphorylation of PPAR-gamma , and a decrease in CD36 gene transcription by phosphorylated PPAR-gamma .	negative	0
10000	10625680	4790;2908	NF-kappaB;glucocorticoid receptor	We argue that negative ***cross-talk*** between the ***glucocorticoid receptor*** and ***NF-kappaB*** may provide a basis for the molecular mechanism underlying the negative action of corticosteroids on serotonin signaling in the brain .	parallel	0
10001	10625687	1026;2033	p21;p300	The evidence supporting the ***linkage*** between ***p300*** and TSA-induced ***p21*** promoter activation were realized from the following findings : 1 ) cotransfection of p300 elevated p21 promoter activity , and this elevation was dependent on TSA-responsive GC-box ; 2 ) TSA-induced promoter activation was blocked by the introduction of p300 dominant-negative mutant into cells ; and 3 ) Sp1 - or Sp3-mediated activation was also suppressed by this p300 dominant-negative mutant .	parallel	0
10002	10625692	5829;5782	paxillin;PTP-PEST	These results demonstrate that paxillin can serve as a PTP-PEST substrate in vivo and support the model that a noncatalytic domain interaction ***recruits*** ***paxillin*** to ***PTP-PEST*** to facilitate its dephosphorylation .	target	0
10003	10625696	664;596	BNIP3;Bcl-2	***BNIP3*** ***heterodimerizes*** with ***Bcl-2/Bcl-X*** ( L ) and induces cell death independent of a Bcl-2 homology 3 ( BH3 ) domain at both mitochondrial and nonmitochondrial sites .	parallel	1
10004	10625696	664;598	BNIP3;Bcl-X	***BNIP3*** ***heterodimerizes*** with ***Bcl-2/Bcl-X*** ( L ) and induces cell death independent of a Bcl-2 homology 3 ( BH3 ) domain at both mitochondrial and nonmitochondrial sites .	parallel	1
10005	10625696	598;596	Bcl-X;Bcl-2	Typically , the BH3 domain of pro-apoptotic Bcl-2 homologues mediates ******Bcl-2/Bcl-X****** ( L ) ***heterodimerization*** and confers pro-apoptotic activity .	parallel	1
10006	10625698	9252;5594	MSK1;p38	Stimulation of ***MSK1*** in contracting skeletal muscle ***required*** the activation of both ERK and ***p38*** ( MAPK ) .	target	0
10007	10625699	7040;633	TGF-beta;biglycan	The present data suggest that ***TGF-beta*** ( 1 ) ***promotes*** the synthesis of both perlecan and ***biglycan*** when endothelial cell density is high , whereas only biglycan synthesis is stimulated when the cell density is low .	positive	0
10008	10625699	7040;3339	TGF-beta;perlecan	The present data suggest that ***TGF-beta*** ( 1 ) ***promotes*** the synthesis of both ***perlecan*** and biglycan when endothelial cell density is high , whereas only biglycan synthesis is stimulated when the cell density is low .	positive	0
10009	10625711	5327;5054	tPA;PAI-1	This study was designed to test whether plasma levels of tissue plasminogen activator ( tPA ) , plasminogen activator inhibitor-1 ( PAI-1 ) , and ******tPA/PAI-1****** ***complex*** could predict a first-ever stroke .	parallel	1
10010	10625711	5054;5327	PAI-1;tPA	The mean plasma concentration of ******tPA/PAI-1****** ***complex*** was higher for the stroke cases than for the controls ( 3.9 versus 3.0 microgram/L ) .	parallel	1
10011	10625711	5054;5327	PAI-1;tPA	In univariate regression analysis , significantly higher odds ratios were found for the ******tPA/PAI-1****** ***complex*** as continuous variable .	parallel	1
10012	10625711	5054;5327	PAI-1;tPA	In the multivariate model , the ******tPA/PAI-1****** ***complex*** remained an independent predictor for stroke .	parallel	1
10013	10625711	5054;5327	PAI-1;tPA	In subgroup analysis of cerebral hemorrhage ( n = 18 ) , the mean tPA/PAI-1 complex level was higher for the cases than for the controls ( 4.8 versus 3.0 microgram/L ) , and in multivariate analysis including all controls ( n = 216 ) , only ******tPA/PAI-1****** ***complex*** remained significant .	parallel	1
10014	10625711	5054;5327	PAI-1;tPA	CONCLUSIONS : This prospective study shows that ******tPA/PAI-1****** ***complex*** , a novel fibrinolytic marker , is independently associated with the development of a first-ever stroke , especially hemorrhagic stroke .	parallel	1
10015	10626036	348;1	APOE;A1BG	A tight ***linkage*** between the ***A1BG*** and the ***APOE*** loci was documented ( theta = 0.038 ) .	parallel	0
10016	10626139	3553;3569	interleukin-1 beta;IL-6	***interleukin-1 beta*** has potent OAF activity , can increase the expression of adhesion molecules , and can ***induce*** paracrine ***IL-6*** production ( see Fig. 1 ) .	target	1
10017	10626247	356;355	FasL;Fas	Studies on lpr ( lymphoproliferation ) and gld ( generalized lymphoproliferative disease ) mice , which are loss-of-function mutant mice of Fas and ***Fas*** ***ligand*** ( ***FasL*** ) , respectively , show that these mutations are responsible for the early onset of systemic autoimmune disease in MRL mice , suggesting that autoreactive immunocytes are eliminated by the function of Fas/FasL system ( " physiological function " of Fas ) .	parallel	1
10018	10626249	356;355	FasL;Fas	Fas ( Apo-1 , CD95 ) cell surface antigen belongs to the tumor necrosis factor receptor family and mediates apoptosis of a variety of cell types , including lymphocytes , after ligation with ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
10019	10626249	356;355	FasL;Fas	Recent studies on the role of ******Fas/FasL****** ***interaction*** in the immune responses strongly suggest the relevance of dysregulation in Fas-mediated apoptosis as a cause of autoimmune disorders .	parallel	1
10020	10626681	4790;3107	p50;HLA-C	Among these receptors , p58 and ***p50*** ***bind*** to ***HLA-C*** .	parallel	1
10021	10626681	3804;3107	p58;HLA-C	Among these receptors , ***p58*** and p50 ***bind*** to ***HLA-C*** .	parallel	1
10022	10626812	1634;1956	decorin;epidermal growth factor receptor	No decorin-induced up-regulation of c-myc was seen , although ***decorin*** was reported to ***activate*** the ***epidermal growth factor receptor*** .	positive	1
10023	10626822	596;7076	bcl-2;TIMP-1	We have found that ***bcl-2*** overexpression ***induces*** ***TIMP-1*** expression in breast epithelial cell lines ( MCF10A , MCF10AneoT.TG3B , and MCF-7 ) , whereas it has no effect on TIMP-2 expression .	target	1
10024	10626893	3572;6774	gp130;STAT3	The ***activation*** of ***STAT3*** by the cytokine receptor ***gp130*** is required for both the G1 to S cell cycle transition and antiapoptosis .	positive	1
10025	10626899	1027;5897	p27Kip1;RAG-2	Here cyclin A/CDK2 is shown to oppose RAG-2 accumulation ; conversely , ***RAG-2*** is ***induced*** by ***p27Kip1*** and related CDK inhibitors .	target	1
10026	10626900	7132;4790	TNFR1;NF-kappaB	We show that in T cells , TNFR2 ( TNFRSF1B ) signaling is dramatically affected by the intracellular mediator RIP , a protein Ser/Thr kinase required for ***NF-kappaB*** ***activation*** by ***TNFR1*** ( TNFRSF1A ) .	positive	1
10027	10626900	3267;7133	RIP;TNFR2	We show that in T cells , ***TNFR2*** ( TNFRSF1B ) signaling is dramatically ***affected*** by the intracellular mediator ***RIP*** , a protein Ser/Thr kinase required for NF-kappaB activation by TNFR1 ( TNFRSF1A ) .	target	0
10028	10626900	7133;4790	TNFR2;NF-kappaB	In the presence of RIP , TNFR2 triggers cell death , whereas in the absence of RIP , ***TNFR2*** ***activates*** ***NF-kappaB*** .	positive	1
10029	10626910	965;914	LFA-3;CD2	The low affinity LFA-3 / IgG1 binding to T cells is consistent with binding to CD2 only , and is in agreement with the low affinity reported for ***interactions*** between soluble forms of ***LFA-3*** and ***CD2*** by surface plasmon resonance technology .	parallel	1
10030	10627280	2022;7040	CD105;TGFbeta	***CD105*** ( endoglin ) , a ***receptor*** for transforming growth factor beta ( ***TGFbeta*** ) , is highly expressed in tissue-cultured , activated endothelial cells in vitro and in tissues undergoing angiogenesis in vivo .	parallel	1
10031	10627290	2099;5617	ERalpha;PRL	Overall , the data indicate that plasma membrane ***ERalpha*** proteins ***mediate*** estrogen-stimulated ***PRL*** release from GH ( 3 ) / B6/F10 cells .	target	0
10032	10627454	3565;6778	IL-4;stat6	Phospho-amino acid analysis and tryptic phosphopeptide maps revealed that ***IL-4*** ***induced*** phosphorylation of ***stat6*** on serine and tyrosine residues in Ramos cells and in 32D cells lacking endogenous IRS proteins .	target	1
10033	10627455	3589;3562	interleukin-11;interleukin-3	Recombinant human ***interleukin-11*** ***synergizes*** with steel factor and ***interleukin-3*** to promote directly the early stages of murine megakaryocyte development in vitro .	parallel	0
10034	10627455	3589;4254	interleukin-11;steel factor	Recombinant human ***interleukin-11*** ***synergizes*** with ***steel factor*** and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro .	parallel	0
10035	10627465	7448;5054	vitronectin;PAI-1	***vitronectin*** ( VN ) , an abundant plasma and matrix glycoprotein , ***binds*** ***PAI-1*** and stabilizes its active conformation .	parallel	1
10036	10627472	4283;2833	Mig;CXCR3	We also report that the ***CXCR3*** ***ligand*** , ***Mig*** , is coexpressed on tumor cells in many cases of CLL/SLL ( 10 of 13 cases examined ) with Mig expression less frequently seen in other B-cell lymphoma subtypes .	parallel	1
10037	10627472	4283;2833	Mig;CXCR3	Coexpression of ***CXCR3*** and its ***ligand*** , ***Mig*** , may be an important functional interaction in B-CLL , as well as a useful diagnostic marker for the differential diagnosis of small cell lymphomas .	parallel	1
10038	10627478	653361;4519	p47-phox;cytochrome b	Thus , the introduction or reversal of charge at residues 369 , 408 , and 568 in gp91-phox destroys the correct ***binding*** of ***p47-phox*** and p67-phox to ***cytochrome b*** ( 558 ) .	parallel	1
10039	10627478	4688;4519	p67-phox;cytochrome b	Thus , the introduction or reversal of charge at residues 369 , 408 , and 568 in gp91-phox destroys the correct ***binding*** of p47-phox and ***p67-phox*** to ***cytochrome b*** ( 558 ) .	parallel	1
10040	10627496	7026;1581	COUP-TFII;CYP7A1	HNF4 and ***COUP-TFII*** interact to ***modulate*** transcription of the cholesterol 7alpha-hydroxylase gene ( ***CYP7A1*** ) .	target	0
10041	10627496	3172;1581	HNF4;CYP7A1	***HNF4*** and COUP-TFII interact to ***modulate*** transcription of the cholesterol 7alpha-hydroxylase gene ( ***CYP7A1*** ) .	target	0
10042	10627496	3172;7026	HNF4;COUP-TFII	***HNF4*** and ***COUP-TFII*** ***interact*** to modulate transcription of the cholesterol 7alpha-hydroxylase gene ( CYP7A1 ) .	parallel	1
10043	10627496	7026;1581	COUP-TFII;CYP7A1	Hepatocyte nuclear factor 4 ( HNF4 ) and chicken ovalbumin upstream promoter transcription factor II ( ***COUP-TFII*** ) synergistically ***activate*** transcription of the ***CYP7A1*** promoter .	positive	1
10044	10627496	3172;1581	HNF4;CYP7A1	Hepatocyte nuclear factor 4 ( ***HNF4*** ) and chicken ovalbumin upstream promoter transcription factor II ( COUP-TFII ) synergistically ***activate*** transcription of the ***CYP7A1*** promoter .	positive	1
10045	10627496	3172;1581	HNF4;CYP7A1	***Transactivation*** of ***CYP7A1*** by ***HNF4*** in the human hepatoma cell line , HepG2 , was enhanced by cotransfection with COUP-TFII or the basal transcription element binding protein ( BTEB ) .	positive	1
10046	10627535	3439;3458	IFN-alpha;IFN-gamma	Taken together , these findings suggest that expression of human CD46 in mouse macrophages enhances production of IFN-alpha/beta in response to MV infection , and ***IFN-alpha/beta*** ***synergizes*** with ***IFN-gamma*** to enhance NO production and restrict viral protein synthesis and virus replication .	parallel	0
10047	10627535	4179;3439	CD46;IFN-alpha	Taken together , these findings suggest that expression of human ***CD46*** in mouse macrophages ***enhances*** production of ***IFN-alpha/beta*** in response to MV infection , and IFN-alpha/beta synergizes with IFN-gamma to enhance NO production and restrict viral protein synthesis and virus replication .	positive	0
10048	10627535	4179;3439	CD46;IFN-alpha	These cells produced much lower levels of NO and IFN-alpha/beta upon infection by MV , suggesting the ***CD46*** cytoplasmic domains ***enhanced*** ***IFN-alpha/beta*** production .	positive	0
10049	10627560	4851;9260	NOTCH1;LMP1	We have demonstrated that intracellular forms of ***NOTCH1*** ***transactivate*** two major Epstein-Barr virus ( EBV ) latent promoters , the ***LMP1*** and Cp1 promoters in an EBV-negative B-cell line , BJAB .	positive	1
10050	10627560	4851;9260	NOTCH1;LMP1	Truncated intracellular ***NOTCH1*** associated with the nuclear membrane ( DeltaE ) ***transactivates*** the ***LMP1*** promoter fivefold ; however , the intranucleus localized form of NOTCH1 ( ICN ) transactivates this promoter approximately twofold in chloroamphenicol acetyltransferase ( CAT ) reporter assays in BJAB cells .	positive	1
10051	10627560	4851;9260	NOTCH1;LMP1	Similarly , another truncated form of ***NOTCH1*** , referred to as ICNW , which contains the tryptophan residue W ( 1767 ) within one of the RBP-Jkappa interacting domains , ***repressed*** the ***LMP1*** promoter approximately twofold .	negative	1
10052	10627592	1742;3761	PSD-95;Kir2.3	When coexpressed in a bicistronic internal ribosome entry site expression vector in HEK-293 cells macroscopic and elementary current analysis revealed that ***PSD-95*** ***suppressed*** the activity of ***Kir2.3*** channels by > 50 % .	negative	1
10053	10627600	4803;5329	nerve growth factor;UPAR	The urokinase plasminogen activator receptor ( ***UPAR*** ) is preferentially ***induced*** by ***nerve growth factor*** in PC12 pheochromocytoma cells and is required for NGF-driven differentiation .	target	1
10054	10627863	6363;1236	ELC;CCR7	This observation is intriguing given that ***CCR7*** and its ***ligand*** EBI1-Ligand Chemokine ( ***ELC*** ) , may play a role in the migration and homing of normal lymphocytes .	parallel	1
10055	10628325	5594;207	ERK;Akt	These results suggest that ***ERK*** , JNK , p38 and ***PI3-K/Akt*** signaling pathways ***interact*** to form an integrated network , and the induction of apoptosis requires coordinated changes in these signaling pathways .	parallel	1
10056	10628325	5599;207	JNK;Akt	These results suggest that ERK , ***JNK*** , p38 and ***PI3-K/Akt*** signaling pathways ***interact*** to form an integrated network , and the induction of apoptosis requires coordinated changes in these signaling pathways .	parallel	1
10057	10628325	5599;5594	JNK;ERK	These results suggest that ***ERK*** , ***JNK*** , p38 and PI3-K/Akt signaling pathways ***interact*** to form an integrated network , and the induction of apoptosis requires coordinated changes in these signaling pathways .	parallel	1
10058	10628325	5594;5594	p38;ERK	These results suggest that ***ERK*** , JNK , ***p38*** and PI3-K/Akt signaling pathways ***interact*** to form an integrated network , and the induction of apoptosis requires coordinated changes in these signaling pathways .	parallel	1
10059	10628325	5594;5599	p38;JNK	These results suggest that ERK , ***JNK*** , ***p38*** and PI3-K/Akt signaling pathways ***interact*** to form an integrated network , and the induction of apoptosis requires coordinated changes in these signaling pathways .	parallel	1
10060	10628334	943;2026	CD30;NSE	CONCLUSIONS : Our results suggest that a ***link*** between ***NSE*** and ***CD30*** expression exists in malignant lymphomas .	parallel	0
10061	10628429	3952;1050	leptin;C/EBP-alpha	These results suggest that 1 ) ***leptin*** expression is positively ***correlated*** with ***C/EBP-alpha*** expression , and 2 ) the maintenance of leptin expression after insulin deprivation in 850 nM insulin-treated cultures on Day 9 may be associated with the presence of C/EBP-alpha expression and/or activation .	positive	0
10062	10628656	920;3700	CD4;gp120	Some of these polyanionic proteins have been shown to interfere also with the ******gp120-CD4****** mediated virus/cell ***binding*** .	parallel	1
10063	10628744	8554;2908	PIAS1;glucocorticoid receptor	***PIAS1*** also ***enhanced*** ***glucocorticoid receptor*** transactivation in response to dexamethasone but inhibited progesterone-induced progesterone receptor transactivation in the same assay system .	positive	0
10064	10628744	8554;5241	PIAS1;progesterone receptor	***PIAS1*** also enhanced glucocorticoid receptor transactivation in response to dexamethasone but ***inhibited*** progesterone-induced ***progesterone receptor*** transactivation in the same assay system .	negative	1
10065	10628748	1385;3623	CREB;inhibin alpha	The ***binding*** of SF-1 and CRE binding protein ( ***CREB*** ) to the ***inhibin alpha*** regulatory elements was relatively weak in gel mobility shift assays , consistent with their deviation from consensus binding sites .	parallel	1
10066	10628748	2516;3623	SF-1;inhibin alpha	The ***binding*** of ***SF-1*** and CRE binding protein ( CREB ) to the ***inhibin alpha*** regulatory elements was relatively weak in gel mobility shift assays , consistent with their deviation from consensus binding sites .	parallel	1
10067	10628748	1385;2516	CREB;SF-1	We propose a model in which direct ***interactions*** of ***SF-1*** , ***CREB*** , and associated coactivators like CBP induce strongly cooperative transactivation by pathways that individually have relatively weak effects on transcription .	parallel	1
10068	10628748	2516;3623	steroidogenic factor-1;inhibin alpha	Synergistic ***activation*** of the ***inhibin alpha-promoter*** by ***steroidogenic factor-1*** and cyclic adenosine 3 ' ,5 ' - monophosphate .	positive	1
10069	10628748	2516;3623	SF-1;inhibin alpha	Because this pattern of expression corresponds to that of the orphan nuclear receptor , steroidogenic factor-1 ( SF-1 ) , we hypothesized that the ***inhibin alpha*** promoter might be ***regulated*** by ***SF-1*** .	target	1
10070	10628750	7124;5966	TNFalpha;Rel	In contrast to the ***TNFalpha*** mechanism , which strongly ***induces*** ***Rel*** A x NF-kappaB1 binding , Sar1 AII selectively activates a heterogenous pattern of NF-kappaB1 binding .	target	1
10071	10628751	6777;7124	Stat5b;tumor necrosis factor-alpha	Further , PRL-inducible ***Stat5b*** ***inhibits*** ***tumor necrosis factor-alpha*** signaling presumably by inhibiting endogenous NFkappaB .	negative	1
10072	10628754	4790;1392	NF-kappaB;CRH	These data demonstrate a novel cytoprotective effect of ***CRH*** that is ***mediated*** by CRH-R1 and downstream by suppression of ***NF-kappaB*** and indicate CRH as an endogenous protective neuropeptide against oxidative cell death in addition to its function in the HPA-system .	target	0
10073	10628754	4792;4790	IkappaB-alpha;NF-kappaB	Suppression of NF-kappaB by overexpression of a super-repressor mutant form of ***IkappaB-alpha*** , a specific ***inhibitor*** of ***NF-kappaB*** , led to protection of the cells against oxidative stress .	negative	1
10074	10628797	1026;7157	p21;p53	The expression of ***p21*** in human neoplasms is heterogeneous , and may be ***related*** to ***p53*** functional status .	parallel	0
10075	10628835	3313;7157	mot-2;p53	NIH 3T3 cells malignantly transformed by ***mot-2*** show ***inactivation*** and cytoplasmic sequestration of the ***p53*** protein .	negative	1
10076	10628835	3313;7157	mot-2;p53	The data suggests that ***mot-2*** ***mediated*** cytoplasmic sequestration and inactivation of ***p53*** may operate , at least in part , for malignant phenotype of NIH 3T3/mot-2 cells .	target	0
10077	10628969	51362;51362	PRP17;CDC40	Extensive genetic ***interactions*** between PRP8 and ******PRP17/CDC40****** , two yeast genes involved in pre-mRNA splicing and cell cycle progression .	parallel	1
10078	10628969	51362;10594	PRP17;PRP8	Extensive genetic ***interactions*** between ***PRP8*** and ***PRP17/CDC40*** , two yeast genes involved in pre-mRNA splicing and cell cycle progression .	parallel	1
10079	10628969	10594;51362	PRP8;CDC40	Extensive genetic ***interactions*** between ***PRP8*** and ***PRP17/CDC40*** , two yeast genes involved in pre-mRNA splicing and cell cycle progression .	parallel	1
10080	10628969	51362;51362	PRP17;CDC40	In this report we describe extensive genetic ***interactions*** between ******PRP17/CDC40****** and the PRP8 gene .	parallel	1
10081	10628969	51362;10594	PRP17;PRP8	In this report we describe extensive genetic ***interactions*** between ***PRP17/CDC40*** and the ***PRP8*** gene .	parallel	1
10082	10628969	10594;51362	PRP8;CDC40	In this report we describe extensive genetic ***interactions*** between ***PRP17/CDC40*** and the ***PRP8*** gene .	parallel	1
10083	10628969	10594;51362	PRP8;PRP17	On the basis of these findings , we propose a model for the mode of ***interaction*** between the ***PRP8*** and ***PRP17*** proteins during the second catalytic step of the splicing reaction .	parallel	1
10084	10629029	25;7157	c-Abl;p53	***Stimulation*** of ***p53*** DNA binding by ***c-Abl*** requires the p53 C terminus and tetramerization .	positive	0
10085	10629029	25;7157	c-Abl;p53	Growth suppressor ***c-Abl*** ***interacts*** with ***p53*** in response to DNA damage and overexpression of c-Abl leads to G ( 1 ) growth arrest in a p53-dependent manner .	parallel	1
10086	10629029	25;7157	c-Abl;p53	Here , we show that ***c-Abl*** ***binds*** directly to the carboxyl-terminal regulatory domain of ***p53*** and that this interaction requires tetramerization of p53 .	parallel	1
10087	10629029	25;7157	c-Abl;p53	Importantly , we demonstrate that ***c-Abl*** ***stimulates*** the DNA-binding activity of wild-type ***p53*** but not of a carboxyl-terminally truncated p53 ( p53Delta363C ) .	positive	0
10088	10629029	25;7157	c-Abl;p53	To investigate the mechanism for this activation , we have also shown that ***c-Abl*** ***stabilizes*** the ***p53-DNA*** complex .	positive	0
10089	10629029	25;7157	c-Abl;p53	These results led us to hypothesize that the interaction of ***c-Abl*** with the C terminus of p53 may ***stabilize*** the ***p53*** tetrameric conformation , resulting in a more stable p53-DNA complex .	positive	0
10090	10629030	11140;1022	Cdc37;Cak1	In addition , ***Cdc37*** ***promotes*** the production of ***Cak1*** , but not that of Cdc28 , when coexpressed in insect cells .	positive	0
10091	10629032	1994;1026	HuR;p21	***HuR*** ***regulates*** ***p21*** mRNA stabilization by UV light .	target	1
10092	10629033	7157;1026	p53;p21	All p53 mutants examined were recessive to wild-type ***p53*** ***transactivation*** of ***p21*** ( WAF1/CIP1 ) but dominant-negative for transactivation of Bax .	positive	1
10093	10629042	867;2534	Cbl proto-oncogene;Fyn	The ***Cbl proto-oncogene*** product negatively ***regulates*** the Src-family tyrosine kinase ***Fyn*** by enhancing its degradation .	negative	1
10094	10629042	867;2534	Cbl;Fyn	Importantly , a ***Fyn*** mutant ( FynY528F ) relieved of intramolecular repression was still negatively ***regulated*** by ***Cbl*** .	negative	1
10095	10629042	867;2534	Cbl;Fyn	The ***Cbl-dependent*** negative ***regulation*** of ***Fyn*** did not appear to be mediated by inhibition of Fyn kinase activity but was correlated with enhanced protein turnover .	negative	1
10096	10629047	6929;4009	E47;Lmx1.1	***Cooperation*** between ***Lmx1.1*** and ***E47/Pan1*** results not only in the aggregation of multiple activation domains but also in the unmasking of a potent activation domain on E47/Pan1 that is normally silent in non-beta cells .	parallel	0
10097	10629047	55655;6929	Pan1;E47	***Cooperation*** between Lmx1.1 and ******E47/Pan1****** results not only in the aggregation of multiple activation domains but also in the unmasking of a potent activation domain on E47/Pan1 that is normally silent in non-beta cells .	parallel	0
10098	10629047	55655;4009	Pan1;Lmx1.1	***Cooperation*** between ***Lmx1.1*** and ***E47/Pan1*** results not only in the aggregation of multiple activation domains but also in the unmasking of a potent activation domain on E47/Pan1 that is normally silent in non-beta cells .	parallel	0
10099	10629049	10488;3054	LZIP;HCF-1	Whether the ***interaction*** between ***HCF-1*** and ***LZIP*** is required for cell proliferation remains to be determined .	parallel	1
10100	10629050	637;581	Bid;Bax	***Bid*** ***induces*** the oligomerization and insertion of ***Bax*** into the outer mitochondrial membrane .	target	1
10101	10629053	5914;1387	RARalpha;CREB binding protein	The binding of COUP-TF to the DR-8 element synergistically increases the RA-dependent RARalpha transactivation function by enhancing the ***interaction*** of ***RARalpha*** with its coactivator ***CREB binding protein*** .	parallel	1
10102	10629055	4803;10818	NGF;FRS2alpha	In addition , ***NGF-induced*** tyrosine ***phosphorylation*** of ***FRS2alpha*** is diminished in cells that overexpress a kinase-inactive mutant of FGFR1 .	target	1
10103	10629055	2260;10818	FGFR1;FRS2	While ***FGFR1*** ***interacts*** with ***FRS2*** constitutively , independent of ligand stimulation and tyrosine phosphorylation , NGF receptor ( TrkA ) binding to FRS2 is strongly dependent on receptor activation .	parallel	1
10104	10629055	4804;10818	NGF receptor;FRS2	While FGFR1 interacts with FRS2 constitutively , independent of ligand stimulation and tyrosine phosphorylation , ***NGF receptor*** ( TrkA ) ***binding*** to ***FRS2*** is strongly dependent on receptor activation .	parallel	1
10105	10629057	4194;7157	MdmX;p53	Like Mdm2 , ***MdmX*** is able to ***bind*** ***p53*** and inhibit p53 transactivation ; however , the ability of MdmX to degrade p53 has yet to be examined .	parallel	1
10106	10629057	4194;7157	MdmX;p53	Like Mdm2 , ***MdmX*** is able to bind p53 and ***inhibit*** ***p53*** transactivation ; however , the ability of MdmX to degrade p53 has yet to be examined .	negative	1
10107	10629057	4194;7157	MdmX;p53	One domain requires ***MdmX*** ***interaction*** with ***p53*** and results in the retention of both proteins within the nucleus and repression of p53 transactivation .	parallel	1
10108	10629059	28227;990	PR48;Cdc6	***PR48*** , a novel regulatory subunit of protein phosphatase 2A , ***interacts*** with ***Cdc6*** and modulates DNA replication in human cells .	parallel	1
10109	10629059	28227;990	PR48;Cdc6	***PR48*** ***binds*** specifically to an amino-terminal segment of ***Cdc6*** and forms functional holoenzyme complexes with A and C subunits of PP2A .	parallel	1
10110	10629059	5524;990	PP2A;Cdc6	These results suggest that ***dephosphorylation*** of ***Cdc6*** by ***PP2A*** , mediated by a specific interaction with PR48 , is a regulatory event controlling initiation of DNA replication in mammalian cells .	target	1
10111	10629060	23162;5599	JIP3;JNK	Here we describe the molecular cloning of a putative molecular scaffold protein , ***JIP3*** , that binds the protein kinase components of a JNK signaling module and ***facilitates*** ***JNK*** activation in cultured cells .	positive	0
10112	10629065	573;3308	Bag1;Hsp70	These results provide the first formal evidence that ***Bag1*** functions in vivo as a ***regulator*** of ***Hsp70*** and suggest an intriguing complexity for Hsp70-regulatory events .	target	1
10113	10629065	573;3308	Bag1;Hsp70	***Bag1*** functions in vivo as a negative ***regulator*** of ***Hsp70*** chaperone activity .	negative	1
10114	10629065	573;3308	Bag1;Hsp70	Additional protein cofactors include Hip and ***Bag1*** , identified in protein interaction assays , which ***bind*** to and modulate ***Hsp70*** chaperone activity in vitro .	parallel	1
10115	10629065	6767;3308	Hip;Hsp70	Additional protein cofactors include ***Hip*** and Bag1 , identified in protein interaction assays , which ***bind*** to and modulate ***Hsp70*** chaperone activity in vitro .	parallel	1
10116	10629065	573;3308	Bag1;Hsp70	***Bag1*** , originally identified as an antiapoptotic protein , forms a stoichiometric ***complex*** with ***Hsp70*** and inhibits completely Hsp70-dependent in vitro protein refolding of an unfolded polypeptide .	parallel	1
10117	10629074	7077;4313	TIMP-2;MMP-2	We also show that H-ras-mediated invasiveness is significantly inhibited when the expression of MMP-2 is down-regulated , using an oligodeoxyribonucleotide complementary to the MMP-2 mRNA , or when ***MMP-2*** activity is ***blocked*** by its inhibitor ***TIMP-2*** ( tissue inhibitors of matrix metalloproteinase-2 ) .	negative	0
10118	10629089	1026;1017	p21;CDK2	An inhibitory effect of UCN-01 on ***CDK2*** activity , which is ***mediated*** by ***p21*** ( Cip1 ) / CDK2 complex formation upon UCN-01 treatment , was observed in SBC-3 but not in SBC-3 / UCN cells .	target	0
10119	10629161	3479;3485	IGF-I;IGFBP-2	***IGF-I*** stimulated the cells to grow to a high cellular density and ***inhibited*** ***IGFBP-2*** secretion in a concentration-dependent fashion .	negative	1
10120	10629162	3485;3479	IGFBP-2;IGF-I	As this IGF-I analogue has lower affinity for IGFBPs , we believe that in this cell culture system , activity of ***IGF-I*** may be ***attenuated*** in the long and short term by the accumulation of ***IGFBP-2*** in conditioned medium and by the presence of IGFBP-2 associated with the cell membrane and/or ECM .	negative	0
10121	10629228	1500;999	p120;E-cadherin	We have generated minimal mutations in this region that uncouple the ******E-cadherin-p120****** ***interaction*** , but do not affect interactions with other catenins .	parallel	1
10122	10629451	355;356	Fas;Fas ligand	CONCLUSION : These findings indicate that in vivo IL-18 not only inhibited antigen-specific T ( H2 ) development but also affected apoptosis through ******Fas-Fas ligand****** ***interactions*** .	parallel	1
10123	10629451	3606;3458	IL-18;IFN-gamma	Although ***IL-18*** and IL-12 act on T cells synergistically to ***induce*** ***IFN-gamma*** production , the contribution of IL-18 T ( H1 ) / T ( H2 ) imbalance and to subsequent asthmatic response has not been elucidated in vivo .	target	1
10124	10629460	3581;3578	IL-9R;IL-9	OBJECTIVE : To investigate the contribution of IL-9 to the pathogenesis of asthma , we examined the expression of ***IL-9*** and its ***receptor*** ( ***IL-9R*** ) in bronchial tissue from subjects with atopic asthma ( n = 10 ) , chronic bronchitis ( n = 11 ) , and sarcoidosis ( n = 9 ) and from atopic ( n = 7 ) and nonatopic ( n = 10 ) healthy control subjects .	parallel	1
10125	10629462	7124;6356	TNF-alpha;eotaxin	RESULTS : ***TNF-alpha*** ***induced*** production of ***eotaxin*** , IL-8 , and RANTES in a concentration-dependent manner .	target	1
10126	10629462	7124;6352	TNF-alpha;RANTES	RESULTS : ***TNF-alpha*** ***induced*** production of eotaxin , IL-8 , and ***RANTES*** in a concentration-dependent manner .	target	1
10127	10629462	3596;6356	IL-13;eotaxin	Both IL-4 and ***IL-13*** synergistically ***enhanced*** TNF-alpha-induced ***eotaxin*** production , whereas IL-8 production induced by TNF-alpha was significantly down-regulated by the T ( H ) 2-derived cytokines .	positive	0
10128	10629462	3458;6352	IFN-gamma;RANTES	***RANTES*** production by TNF-alpha was not affected by IL-4 and IL-13 but was markedly ***enhanced*** by ***IFN-gamma*** .	positive	0
10129	10629465	3458;999	IFN-gamma;E-cadherin	In contrast , ***IFN-gamma*** was found to ***suppress*** the ***E-cadherin*** expression and to be a strong antagonist of IL-4 by inhibiting the production of CD1a ( + ) cells .	negative	1
10130	10629565	4254;3815	stem cell factor;c-kit	It was of interest that the aberrant expression of ***stem cell factor*** ( SCF ) , a ***ligand*** of ***c-kit*** , was demonstrated on biliary epithelia of the dilated and stenotic bile ducts showing periductal fibrosis and inflammation and also of the proliferated peribiliary glands in hepatolithiasis and PSC , while no such expression was seen in non-affected bile ducts in hepatolithiasis or in the bile ducts in normal livers .	parallel	1
10131	10629618	328;3315	HAP1;HSP27	However , UDG and human AP endonuclease ( ***HAP1*** ) were ***associated*** with HSP70 and ***HSP27*** , which are present in 150-180-kDa and 30-70-kDa proteins of cell sonicates .	parallel	0
10132	10629618	328;3308	HAP1;HSP70	However , UDG and human AP endonuclease ( ***HAP1*** ) were ***associated*** with ***HSP70*** and HSP27 , which are present in 150-180-kDa and 30-70-kDa proteins of cell sonicates .	parallel	0
10133	10629618	7374;3315	UDG;HSP27	However , ***UDG*** and human AP endonuclease ( HAP1 ) were ***associated*** with HSP70 and ***HSP27*** , which are present in 150-180-kDa and 30-70-kDa proteins of cell sonicates .	parallel	0
10134	10629618	7374;3308	UDG;HSP70	However , ***UDG*** and human AP endonuclease ( HAP1 ) were ***associated*** with ***HSP70*** and HSP27 , which are present in 150-180-kDa and 30-70-kDa proteins of cell sonicates .	parallel	0
10135	10629626	356;355	FasL;Fas	These data suggest that ******Fas/FasL****** mediated ***signaling*** may play a general role in the cytotoxicity of anticancer drugs .	parallel	0
10136	10629645	3669;3558	CD25;IL-2	We designed a prospective pilot study to evaluate in vivo effects of low dose IL-2 and IFN-alpha combination on expression of Bcl-2 , Fas ( APO-1/CD 95 ) , Fas ligand , ***IL-2*** ***receptor*** ( ***CD25*** ) , and HLA-DR on peripheral lymphocytes in patients with advanced renal cell carcinoma .	parallel	1
10137	10629645	3669;3558	CD25;IL-2	After initiation of the immunomodulating therapy , Bcl-2 expressing lymphocytes increased significantly on day 3 ( p < 0.025 ) , Fas ( APO-1/CD95 ) expressing lymphocyte increased significantly on day 5 ( p < 0.003 ) , Fas ligand expressing lymphocytes increased significantly on day 3 ( p < 0.004 ) , HLA-DR expressing lymphocytes increased significantly on day 5 ( p < 0.003 ) , and ***IL-2*** ***receptor*** ( ***CD25*** ) expressing cells increased significantly on day 5 ( p < 0.01 ) .	parallel	1
10138	10629859	156;207	GRK2;Akt	Expression of ***GRK2-ct*** inhibited the H2O2-induced activation of ERK by 70 % and also ***inhibited*** the activation of ***Akt*** by 30 % .	negative	1
10139	10629859	156;5594	GRK2;ERK	Expression of ***GRK2-ct*** ***inhibited*** the H2O2-induced activation of ***ERK*** by 70 % and also inhibited the activation of Akt by 30 % .	negative	1
10140	10629876	23430;2150	mast cell tryptase;PAR-2	Amongst four distinct PARs that have been cloned , PARs 1 , 3 and 4 are activated by thrombin , but ***PAR-2*** is ***activated*** by trypsin or ***mast cell tryptase*** .	positive	1
10141	10630404	5618;3717	PRLR;Jak2	Overexpression of SOCS-1 led to a significant reduction in ***PRLR-mediated*** tyrosyl ***phosphorylation*** of ***Jak2*** , PRLR , Stat5 and the cytoplasmic protein tyrosine phosphatase SHP2 .	target	1
10142	10630404	5618;5781	PRLR;SHP2	Overexpression of SOCS-1 led to a significant reduction in ***PRLR-mediated*** tyrosyl ***phosphorylation*** of Jak2 , PRLR , Stat5 and the cytoplasmic protein tyrosine phosphatase ***SHP2*** .	target	1
10143	10630404	5618;6777	PRLR;Stat5	Overexpression of SOCS-1 led to a significant reduction in ***PRLR-mediated*** tyrosyl ***phosphorylation*** of Jak2 , PRLR , ***Stat5*** and the cytoplasmic protein tyrosine phosphatase SHP2 .	target	1
10144	10630404	5618;3717	PRLR;Jak2	Overexpression of SOCS-3 however , led to selective inhibition in ***PRLR-mediated*** tyrosyl ***phosphorylation*** of ***Jak2*** , the PRLR as well as SHP2 .	target	1
10145	10630404	8651;5618	SOCS-1;PRLR	Unlike SOCS-2 , both ***SOCS-1*** and SOCS-3 ***abolished*** the ability of the ***PRLR*** to induce beta-casein gene promoter activation .	negative	0
10146	10630404	9021;5618	SOCS-3;PRLR	Unlike SOCS-2 , both SOCS-1 and ***SOCS-3*** ***abolished*** the ability of the ***PRLR*** to induce beta-casein gene promoter activation .	negative	0
10147	10630406	3458;5610	IFN-gamma;PKR	The addition of ***IFN-gamma*** to culture medium ***increased*** the ***PKR*** mRNA level in a dose-dependent manner in cultured endometrial stromal cells .	positive	0
10148	10630411	6777;8835	STAT5b;SOCS-2	***STAT5b*** ***mediates*** the GH-induced expression of ***SOCS-2*** and SOCS-3 mRNA in the liver .	target	0
10149	10630411	6777;9021	STAT5b;SOCS-3	***STAT5b*** ***mediates*** the GH-induced expression of SOCS-2 and ***SOCS-3*** mRNA in the liver .	target	0
10150	10630414	3569;5443	interleukin 6;ACTH	Leukemia inhibitory factor ( LIF ) and ***interleukin 6*** ( IL-6 ) , two cytokines sharing the common gp130 receptor subunit and functioning through activation of the intracellular JAK/STAT pathway , ***induce*** POMC synthesis and ***ACTH*** release .	target	1
10151	10630414	3976;5443	LIF;ACTH	Leukemia inhibitory factor ( ***LIF*** ) and interleukin 6 ( IL-6 ) , two cytokines sharing the common gp130 receptor subunit and functioning through activation of the intracellular JAK/STAT pathway , ***induce*** POMC synthesis and ***ACTH*** release .	target	1
10152	10630414	3976;5122	LIF;PC1	A significant time-dependent ***up-regulation*** of both ***PC1*** protein and mRNA by ***LIF*** and IL-6 was seen in mouse corticotroph AtT-20 cells .	positive	1
10153	10630642	672;5888	BRCA1;RAD51	The ***association*** of ***BRCA1*** with ***RAD51*** has led to the hypothesis that BRCA1 is involved in DNA repair .	parallel	0
10154	10630990	6767;3312	HIP;HSC70	Using threading and comparative model building methods , a structural model of a segment of HIP involved in HSC70 binding has been constructed and potential sites of ***interaction*** between ***HIP*** and ***HSC70*** are proposed on the basis of electrostatic as well as shape complementarity .	parallel	1
10155	10631078	7852;3458	LCR1;IFN-gamma	Previous studies demonstrated that the L. chagasi antigen ***LCR1*** ***stimulates*** ***IFN-gamma*** production from T cells of infected BALB/c mice , and immunization with recombinant LCR1 partially protects against L. chagasi infection .	positive	0
10156	10631093	3565;6778	IL-4;STAT6	In this report , we provide evidence that interleukin 4 ( ***IL-4*** ) ***induced*** JAK2-mediated ***STAT6*** tyrosine phosphorylation and DNA binding in 3T3-L1 preadipocytes but not in 3T3-L1 adipocytes .	target	1
10157	10631107	11127;23645	KIF3A;GADD34	The ***interaction*** between ***GADD34*** and ***KIF3A*** was confirmed in the NIH3T3 cells by in vivo two-hybrid analysis .	parallel	1
10158	10631112	3375;4018	islet amyloid polypeptide;lipoprotein	Fibrillar ***islet amyloid polypeptide*** differentially ***affects*** oxidative mechanisms and ***lipoprotein*** uptake in correlation with cytotoxicity in two insulin-producing cell lines .	target	0
10159	10631114	4982;8600	OCIF;ODF	Moreover , the coculture with cancer cells inhibited secretion of osteoprotegerin/osteoclastogenesis inhibitory factor ( ***OPG/OCIF*** ) , an inhibitory decoy ***receptor*** for ***ODF*** , from BMCs .	parallel	1
10160	10631115	1363;6750	carboxypeptidase E;somatostatin	***carboxypeptidase E*** deficiency as seen in the fat/fat mice is ***associated*** with reduced antral ***somatostatin*** content but tripling of the progastrin product .	parallel	0
10161	10631175	3549;5744	Ihh;PTHrP	***Ihh*** positively ***regulates*** ***PTHrP*** , which is sufficient to prevent chondrocyte hypertrophy and maintain a normal domain of cells competent to undergo proliferation .	positive	1
10162	10631312	3315;3312	hsp25;hsc70	The potential function of the ******hsp110-hsc70-hsp25****** ***complex*** is discussed .	parallel	1
10163	10631313	7124;5743	tumor necrosis factor alpha;cyclooxygenase-2	In murine osteoblastic MC3T3-E1 cells which produced prostaglandin E2 as a bone resorption factor , the ***cyclooxygenase-2*** ***induction*** by ***tumor necrosis factor alpha*** ( TNFalpha ) was suppressed by dexamethasone with an IC ( 50 ) of 1 nM .	target	1
10164	10631319	325;813	SAP;Calumenin	Furthermore , we verified and characterized the ******Calumenin-SAP****** ***interaction*** by the surface plasmon resonance technique .	parallel	1
10165	10631812	7040;4629	TGF-beta;SMMHC	We also examined ***regulation*** of ***SMMHC*** gene expression by ***TGF-beta*** , a cytokine known to be involved in the differentiation process .	target	1
10166	10631974	4909;627	neurotrophin 4;brain-derived neurotrophic factor	The structures of the neurotrophin 4 homodimer and the ******brain-derived neurotrophic factor/neurotrophin 4****** ***heterodimer*** reveal a common Trk-binding site .	parallel	1
10167	10632112	1906;5476	Endothelin-1;protective protein/cathepsin A	***Endothelin-1*** is a peptidic ***substrate*** in vitro of lysosomal ***protective protein/cathepsin A*** ( PPCA ) with serine carboxypeptidase activity .	parallel	1
10168	10632347	4323;4313	Membrane type 1-matrix metalloproteinase;MMP-2	***Membrane type 1-matrix metalloproteinase*** ( MT1-MMP ) is a known ***activator*** of latent ***MMP-2*** ( pro-MMP-2 ) , and increased MMP-2 expression has been associated with tumor aggressiveness in prostate cancer .	positive	1
10169	10632361	7157;1026	p53;p21	Wild-type ***p53*** can ***induce*** ***p21*** and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated .	target	1
10170	10632361	7157;1026	p53;p21	This work demonstrates that ***p53*** is expressed in the nucleus of neuroblastoma cells and can ***mediate*** induction of ***p21*** .	target	0
10171	10632363	2348;3458	FBP;IFN-gamma	Furthermore , ***FBP*** peptides ***induced*** E39-specific CTLs and E39 - and E41-specific ***IFN-gamma*** and IP-10 secretion in certain healthy donors .	target	1
10172	10632444	3565;1437	Interleukin-4;granulocyte-macrophage colony-stimulating factor	***Interleukin-4*** ***inhibits*** ***granulocyte-macrophage colony-stimulating factor*** , interleukin-6 , and tumor necrosis factor-alpha expression by human monocytes in response to polymethylmethacrylate particle challenge in vitro .	negative	1
10173	10632444	3565;3569	Interleukin-4;interleukin-6	***Interleukin-4*** ***inhibits*** granulocyte-macrophage colony-stimulating factor , ***interleukin-6*** , and tumor necrosis factor-alpha expression by human monocytes in response to polymethylmethacrylate particle challenge in vitro .	negative	1
10174	10632444	3565;7124	Interleukin-4;tumor necrosis factor-alpha	***Interleukin-4*** ***inhibits*** granulocyte-macrophage colony-stimulating factor , interleukin-6 , and ***tumor necrosis factor-alpha*** expression by human monocytes in response to polymethylmethacrylate particle challenge in vitro .	negative	1
10175	10632444	3565;1437	Interleukin-4;granulocyte-macrophage colony-stimulating factor	***Interleukin-4*** ***inhibited*** the expression of ***granulocyte-macrophage colony-stimulating factor*** , interleukin-6 , and tumor necrosis factor-alpha at 48 hours in a dose-dependent manner .	negative	1
10176	10632444	3565;3569	Interleukin-4;interleukin-6	***Interleukin-4*** ***inhibited*** the expression of granulocyte-macrophage colony-stimulating factor , ***interleukin-6*** , and tumor necrosis factor-alpha at 48 hours in a dose-dependent manner .	negative	1
10177	10632444	3565;7124	Interleukin-4;tumor necrosis factor-alpha	***Interleukin-4*** ***inhibited*** the expression of granulocyte-macrophage colony-stimulating factor , interleukin-6 , and ***tumor necrosis factor-alpha*** at 48 hours in a dose-dependent manner .	negative	1
10178	10632476	3827;3569	bradykinin;interleukin-6	In cultured decidua-derived cells , ***bradykinin*** ***stimulates*** the release of arachidonic acid , ***interleukin-6*** ( IL-6 ) , and interleukin-8 ( IL-8 ) .	positive	0
10179	10632476	3827;3576	bradykinin;interleukin-8	In cultured decidua-derived cells , ***bradykinin*** ***stimulates*** the release of arachidonic acid , interleukin-6 ( IL-6 ) , and ***interleukin-8*** ( IL-8 ) .	positive	0
10180	10632478	4282;7124	macrophage migration inhibitory factor;tumor necrosis factor-alpha	***Induction*** of T-kininogen and ***tumor necrosis factor-alpha*** by ***macrophage migration inhibitory factor*** in vivo .	target	1
10181	10632479	4282;5502	MIF;inhibitor-1	Moreover , human recombinant ***MIF*** ***upregulated*** the expression of urokinase plasminogen activator ***inhibitor-1*** ( PAI-1 ) precursor mRNA in human osteoblastic Saos-2 cells .	positive	1
10182	10632538	355;356	Fas;Fas ligand	The ***interaction*** of ***Fas*** ( APO-1 / CD95 ) and the ***Fas ligand*** system induces apoptosis .	parallel	1
10183	10632583	5327;4035	tPA;LRP	Finally , we found that ***tPA*** ***binding*** to ***LRP*** in hippocampal neurons enhances the activity of cyclic AMP-dependent protein kinase , a key molecule that is known to be involved in L-LTP .	parallel	1
10184	10632583	4035;5327	LRP;tPA	Taken together , our results demonstrate that ***interactions*** between ***tPA*** and cell surface ***LRP*** are important for hippocampal L-LTP .	parallel	1
10185	10632583	57126;5327	cell surface receptor;tPA	Metabolic labeling and ligand binding analyses showed that both tPA and LRP are synthesized by hippocampal neurons and that LRP is the major ***cell surface receptor*** that ***binds*** ***tPA*** .	parallel	1
10186	10632593	27344;5122	proSAAS;prohormone convertase 1	Purified ***proSAAS*** ***inhibits*** ***prohormone convertase 1*** activity with an IC ( 50 ) of 590 nM but does not inhibit prohormone convertase 2 .	negative	1
10187	10632606	4915;627	TrkB;BDNF	Thus , ******BDNF-TrkB****** ***signaling*** does not protect 5-HT neurons from axonal injury , but has a fundamental role in promoting the structural plasticity of these neurons in the adult brain .	parallel	0
10188	10632670	356;355	FasL;Fas	Dysregulation of apoptosis , particularly in the ***Fas/Fas*** ***ligand*** ( ***FasL*** ) pathway , is considered to be involved in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus ( SLE ) .	parallel	1
10189	10632677	728;727	C5aR;C5a	In the treatment groups , soluble CR1 ( sCR1 ) or ***C5a*** ***receptor*** ( ***C5aR*** ) antagonist was administered intra-articularly or intravenously and effects on the course of the acute synovitis were monitored .	parallel	1
10190	10632726	6280;6279	S100A9;S100A8	Recombinantly expressed murine ***S100A9*** ***interacts*** in vitro with murine and human ***S100A8*** in an in vitro glutathione S-transferase pull-down assay .	parallel	1
10191	10632975	3565;3558	IL-4;IL-2	IL-10 was suppressive on all the investigated cytokines , while ***IL-4*** ***interfered*** with ***IL-2*** induced IFN-gamma and IL-12 production , but was additive to IL-2 in its effect on IL-5 and IL-13 .	negative	0
10192	10632975	3558;3596	interleukin-2;interleukin-13	Regulation of ***interleukin-2*** ***induced*** interleukin-5 and ***interleukin-13*** production in human peripheral blood mononuclear cells .	target	1
10193	10632975	3558;3567	interleukin-2;interleukin-5	Regulation of ***interleukin-2*** ***induced*** ***interleukin-5*** and interleukin-13 production in human peripheral blood mononuclear cells .	target	1
10194	10632975	3558;3596	IL-2;IL-13	We therefore investigated the regulation of ***IL-2*** ***induced*** production of IL-5 and ***IL-13*** ( which , similarly to IL-5 , is a mediator of allergy-like symptoms ) .	target	1
10195	10632975	3558;3567	IL-2;IL-5	We therefore investigated the regulation of ***IL-2*** ***induced*** production of ***IL-5*** and IL-13 ( which , similarly to IL-5 , is a mediator of allergy-like symptoms ) .	target	1
10196	10632975	3558;3596	IL-2;IL-13	In anti-CD3-treated peripheral blood mononuclear cells , ***IL-2*** ***induced*** IL-5 and ***IL-13*** alongside IFN-gamma , IL-10 and IL-12 .	target	1
10197	10632975	3558;3567	IL-2;IL-5	In anti-CD3-treated peripheral blood mononuclear cells , ***IL-2*** ***induced*** ***IL-5*** and IL-13 alongside IFN-gamma , IL-10 and IL-12 .	target	1
10198	10632976	3458;355	IFN-gamma;CD95	From these findings we conclude that the combination of ***IFN-gamma*** and TNF-alpha ***enhances*** ***CD95*** expression , which results in an increase in FasL-mediated apoptosis of eosinophils in vitro .	positive	0
10199	10632976	7124;355	TNF-alpha;CD95	From these findings we conclude that the combination of IFN-gamma and ***TNF-alpha*** ***enhances*** ***CD95*** expression , which results in an increase in FasL-mediated apoptosis of eosinophils in vitro .	positive	0
10200	10632976	356;355	FasL;Fas	Many cells , including eosinophils , express CD95 ( Fas ) , a surface receptor that mediates apoptosis when ligated by specific antibodies or its natural ligand , ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
10201	10632976	3458;355	interferon-gamma;CD95	It has previously been shown that ***interferon-gamma*** ( IFN-gamma ) and tumour necrosis factor-alpha ( TNF-alpha ) together ***increase*** ***CD95*** surface expression on eosinophils .	positive	0
10202	10632976	7124;355	TNF-alpha;CD95	It has previously been shown that interferon-gamma ( IFN-gamma ) and tumour necrosis factor-alpha ( ***TNF-alpha*** ) together ***increase*** ***CD95*** surface expression on eosinophils .	positive	0
10203	10633078	3082;650	HGF;BMP-2	A current model proposes ***HGF*** ***inhibits*** ***BMP-2*** signaling at the level of Smad1 in a common target cell .	negative	1
10204	10633078	3082;650	HGF;BMP-2	We examined the ***interactions*** between ***BMP-2*** and ***HGF*** in the mIMCD-3 model of collecting duct morphogenesis .	parallel	1
10205	10633078	657;650	ALK3;BMP-2	During tubule formation , HGF rescued the inhibitory effects of BMP-2 and of a constitutive active form of the ***BMP-2*** ***receptor*** , ***ALK3*** , stably expressed in mIMCD-3 cells .	parallel	1
10206	10633078	657;650	ALK3;BMP-2	To determine whether the effect of HGF occurs through known mediators which act downstream of the ******BMP-2/ALK3****** ***complex*** , we examined the effect of HGF on BMP-2-induced Smad1 phosphorylation , Smad1/Smad4 complex formation , and Smad1 nuclear translocation .	parallel	1
10207	10633078	3082;4086	HGF;Smad1	Neither ***HGF*** nor other receptor tyrosine kinase ligands ( EGF , FGF-4 ) ***induced*** phosphorylation of endogenous ***Smad1*** in mIMCD-3 cells or in Mv1Lu , MC3T3-E1 or P19 cells .	target	1
10208	10633084	1436;1435	c-fms;M-CSF	Immunofluorescence showed that the ***M-CSF*** ***receptor*** ( ***c-fms*** ) associated with the small vesicles and also the larger phase-bright vesicles .	parallel	1
10209	10633084	5266;9733	PI-3;p110	The inhibition of vesicle trafficking and maturation correlated with ablation of M-CSF-induced ***PI-3*** kinase activity ***associated*** with ***p110*** ( alpha ) .	parallel	0
10210	10633457	5745;5741	PTHR1;PTH	In order to examine the cellular abnormalities in renal bone disease we have performed a series of in situ hybridization studies to examine renal bone cell expression of genes for ***PTH*** ***receptor*** ( ***PTHR1*** ) , transforming growth factor beta ( TGF-beta ) and insulin growth factor 1 ( IGF-I ) .	parallel	1
10211	10634137	5444;4018	PON1;lipoprotein	Human serum paraoxonase ( ***PON1*** ) is ***associated*** with high density ***lipoprotein*** ( HDL ) particles .	parallel	0
10212	10634413	3481;3486	IGF-II;IGFBP-3	In contrast , IGF-II at an equimolar dose had little effect on proteolysis of recombinant human IGFBP-3 , whereas excess ***IGF-II*** reproducibly ***inhibited*** recombinant human ***IGFBP-3*** proteolysis by pregnancy serum .	negative	1
10213	10634413	3481;3487	IGF-II;IGFBP-4	Although ***IGF-II*** ***enhanced*** ***IGFBP-4*** proteolysis , results from N-terminal sequence and mass spectrometric analyses of IGFBP-4 proteolytic fragments demonstrate that the cleavage site ( Met135-Lys136 ) in human IGFBP-4 was not altered by IGF-II .	positive	0
10214	10634512	1950;207	EGF;Akt	Assessment of PI3K pathway activation using antiphospho-Akt antibodies revealed that ***EGF*** was a poor ***activator*** of ***Akt*** ; activation of this pathway was markedly enhanced by the addition of SCF .	positive	1
10215	10634512	4254;3791	stem cell factor;tyrosine kinase growth factor receptor	Kit , a ***tyrosine kinase growth factor receptor*** , and its ***ligand*** , ***stem cell factor*** ( SCF ) , are commonly coexpressed in breast cancer .	parallel	1
10216	10634581	9313;265	enamelysin;amelogenin	Furthermore , recombinant porcine ***enamelysin*** was demonstrated to ***cleave*** recombinant porcine ***amelogenin*** at virtually all of the sites that have previously been described in vivo .	target	1
10217	10634619	7039;631	TGF-alpha;filensin	Finally , ***TGF-alpha*** treatment ***induced*** increased expression of the beaded filament protein ***filensin*** when compared with control cells .	target	1
10218	10634792	6714;5599	Src;JNK	***Regulation*** of ***JNK*** by ***Src*** during Drosophila development .	target	1
10219	10634792	5599;6714	JNK;Src	This work confirms mammalian studies that demonstrated a physiological ***link*** between ***Src*** and ***JNK*** .	parallel	0
10220	10634821	6927;338	HNF1A;apolipoprotein (apo) B	In Oji-Cree subjects with type 2 diabetes , we found that the ***HNF1A*** G319S genotype was significantly ***associated*** with lower plasma concentrations of total cholesterol , low density lipoprotein cholesterol , and ***apolipoprotein (apo) B*** .	parallel	0
10221	10634826	7035;4023	tissue factor pathway inhibitor;lipoprotein lipase	Intravascular free ***tissue factor pathway inhibitor*** is inversely ***correlated*** with HDL cholesterol and postheparin ***lipoprotein lipase*** but proportional to apolipoprotein A-II .	negative	0
10222	10634912	2959;6908	TFIIB;TBP	The requirement for ******TBP-TFIIB****** ***interactions*** was evaluated in maize cells by introducing mutations into the Arabidopsis TBP ( AtTBP2 ) within the C-terminal stirrup .	parallel	1
10223	10634912	2959;6908	TFIIB;TBP	******TBP-TFIIB****** ***interactions*** were dispensable for basal transcription but were required for activated transcription .	parallel	1
10224	10634932	4899;1869	alpha-pal;E2F-1	Transcriptional ***regulation*** of ***E2F-1*** and eIF-2 genes by ***alpha-pal*** : a potential mechanism for coordinated regulation of protein synthesis , growth , and the cell cycle .	target	1
10225	10634932	4899;1965	alpha-pal;eIF-2	Transcriptional ***regulation*** of E2F-1 and ***eIF-2*** genes by ***alpha-pal*** : a potential mechanism for coordinated regulation of protein synthesis , growth , and the cell cycle .	target	1
10226	10634963	2641;2695	glucagon;GIP	CONCLUSIONS : Exogenous ***glucagon*** in addition to its well-documented action of increasing glucose and insulin concentrations and delaying gastric emptying also markedly ***reduces*** ***GIP*** and GLP-1 secretion .	negative	1
10227	10635057	1636;2152	ACE;tissue factor	***ACE*** catalyzes the conversion of Ang I to Ang II , which in turn stimulates the production of PAI-1 , sensitizes platelets , promotes the production of superoxide radicals that scavenge free NO , and ***induces*** the expression of ***tissue factor*** .	target	1
10228	10635057	1636;3827	ACE;bradykinin	Conversely , ***ACE*** ***catalyzes*** the breakdown of ***bradykinin*** , a potent stimulus to t-PA secretion .	positive	1
10229	10635315	5663;1499	PS1;beta-catenin	***PS1*** fragments form ***complexes*** with E-cadherin , ***beta-catenin*** , and alpha-catenin , all components of adherens junctions .	parallel	1
10230	10635315	5663;999	PS1;E-cadherin	***PS1*** fragments form ***complexes*** with ***E-cadherin*** , beta-catenin , and alpha-catenin , all components of adherens junctions .	parallel	1
10231	10635315	999;5663	E-cadherin;PS1	In confluent MDCK cells , PS1 forms complexes with cell surface E-cadherin ; disruption of Ca ( 2 + ) - dependent cell-cell contacts reduces surface PS1 and the levels of ******PS1-E-cadherin****** ***complexes*** .	parallel	1
10232	10635315	5663;999	PS1;E-cadherin	In confluent MDCK cells , ***PS1*** forms ***complexes*** with cell surface ***E-cadherin*** ; disruption of Ca ( 2 + ) - dependent cell-cell contacts reduces surface PS1 and the levels of PS1-E-cadherin complexes .	parallel	1
10233	10635319	5897;5896	RAG2;RAG1	The ******RAG1/RAG2****** ***complex*** constitutes a 3 ' flap endonuclease : implications for junctional diversity in V ( D ) J and transpositional recombination .	parallel	1
10234	10635328	7189;6714	TRAF6;c-Src	***TRAF6*** , in turn , ***enhances*** the kinase activity of ***c-Src*** leading to tyrosine phosphorylation of downstream signaling molecules such as c-Cbl .	positive	0
10235	10635456	4233;3082	c-met;scatter factor	Myogenic precursor cells for the limb bud are recruited from the dermomyotome by the ***interaction*** of ***c-met*** with its ligand ***scatter factor*** ( SF/HGF ) .	parallel	1
10236	10636070	2520;302	gastrin;LPC 2	***LPC 2*** , 6 , and 7 were ***stimulated*** by CCK-8S , ***gastrin-17*** , and their antagonists .	positive	0
10237	10636485	6863;4790	Substance P;NF-kappaB	***Substance P*** ***activates*** ***NF-kappaB*** independent of elevations in intracellular calcium in murine macrophages and dendritic cells .	positive	1
10238	10636485	6863;4790	Substance P;NF-kappaB	While no increases in intracellular calcium concentration were detected in macrophages or dendritic cells using sensitive fluorimetric techniques , ***Substance P*** did ***induce*** rapid enhanced activation of ***NF-kappaB*** , a transcriptional activator known to regulate pro-inflammatory cytokines .	target	1
10239	10636848	6892;6890	Tapasin;TAP1	***Tapasin*** is a subunit of the TAP complex and ***binds*** both to ***TAP1*** and MHC class I.	parallel	1
10240	10636855	3956;3929	GBP;LBP	***GBP*** also ***binds*** to PAP and ***LBP*** with K ( D ) values of 1.25 x 10 ( -7 ) and 1.43 x 10 ( -8 ) M , respectively , and this binding is enhanced about 10-fold upon the addition of SpA and LPS to form the GBP.PAP.SpA and GBP.LBP.LPS complexes , respectively .	parallel	1
10241	10636855	3929;3956	LBP;GBP	GBP also binds to PAP and LBP with K ( D ) values of 1.25 x 10 ( -7 ) and 1.43 x 10 ( -8 ) M , respectively , and this binding is enhanced about 10-fold upon the addition of SpA and LPS to form the GBP.PAP.SpA and ******GBP.LBP.LPS****** ***complexes*** , respectively .	parallel	1
10242	10636859	728;727	CD88;C5a	Human complement 5a ( ***C5a*** ) anaphylatoxin ***receptor*** ( ***CD88*** ) phosphorylation sites and their specific role in receptor phosphorylation and attenuation of G protein-mediated responses .	parallel	1
10243	10636863	3932;952	Lck;CD38	Direct ***interaction*** of the ***CD38*** cytoplasmic tail and the ***Lck*** SH2 domain .	parallel	1
10244	10636882	960;7074	CD44;tiam1	***CD44*** ***interaction*** with ***tiam1*** promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration .	parallel	1
10245	10636882	960;5879	CD44;Rac1	***CD44*** interaction with tiam1 ***promotes*** ***Rac1*** signaling and hyaluronic acid-mediated breast tumor cell migration .	positive	0
10246	10636882	960;7074	CD44;tiam1	In this study we have explored the ***interaction*** between ***CD44*** ( the hyaluronic acid ( HA ) - binding receptor ) and ***tiam1*** ( a guanine nucleotide exchange factor ) in metastatic breast tumor cells ( SP1 cell line ) .	parallel	1
10247	10636882	960;7074	CD44;tiam1	Using an Escherichia coli-derived calmodulin-binding peptide-tagged tiam1 fragment ( i.e. the NH ( 2 ) - terminal pleckstrin homology ( PHn ) domain and an adjacent protein interaction domain designated as PHn-CC-Ex , amino acids 393-738 of tiam1 ) and an in vitro binding assay , we have detected a specific binding ***interaction*** between the ***tiam1*** PHn-CC-Ex domain and ***CD44*** .	parallel	1
10248	10636882	7074;960	tiam1;CD44	Co-transfection of SP1 cells with PHn-CC-Ex cDNA and tiam1 cDNA effectively inhibits ***tiam1*** ***association*** with ***CD44*** and efficiently blocks tumor behaviors .	parallel	0
10249	10636889	5243;4790	mdr1;NF-kappaB	Moreover , cadmium - and ROS-associated ***mdr1*** up-regulation was ***linked*** to activation of the transcription factor ***NF-kappaB*** ; N-acetylcysteine , pyrrolidine dithiocarbamate , and the IkappaB-alpha kinase inhibitor Bay 11-7082 ( 20 microM ) prevented both , mdr1 overexpression and degradation of the inhibitory NF-kappaB subunit , IkappaB-alpha , induced by cadmium .	parallel	0
10250	10636891	10539;3725	PICOT;AP-1	***Inhibition*** of the c-Jun N-terminal ***kinase/AP-1*** and NF-kappaB pathways by ***PICOT*** , a novel protein kinase C-interacting protein with a thioredoxin homology domain .	negative	1
10251	10636891	10539;4790	PICOT;NF-kappaB	***Inhibition*** of the c-Jun N-terminal kinase/AP-1 and ***NF-kappaB*** pathways by ***PICOT*** , a novel protein kinase C-interacting protein with a thioredoxin homology domain .	negative	1
10252	10636906	6856;6844	Pantophysin;vesicle-associated membrane protein 2	Consistent with the interaction of synaptophysin with vesicle-associated membrane protein 2 in neuroendocrine tissues , ***Pantophysin*** ***associated*** with ***vesicle-associated membrane protein 2*** in adipocytes .	parallel	0
10253	10636906	6855;6844	synaptophysin;vesicle-associated membrane protein 2	Consistent with the ***interaction*** of ***synaptophysin*** with ***vesicle-associated membrane protein 2*** in neuroendocrine tissues , Pantophysin associated with vesicle-associated membrane protein 2 in adipocytes .	parallel	1
10254	10636912	2956;4436	hMSH6;hMSH2	In human cells , binding of base/base mismatches and small insertion/deletion loops is mediated by hMutSalpha , a ***heterodimer*** of ***hMSH2*** and ***hMSH6*** .	parallel	1
10255	10636915	3717;1432	Janus kinase 2;p38 mitogen-activated protein kinase	***Janus kinase 2-dependent*** ***activation*** of ***p38 mitogen-activated protein kinase*** by growth hormone .	positive	1
10256	10636920	3569;6774	IL-6;Stat3	Thus , in PC12-E2 cells , ***Stat3*** homodimers are preferentially ***activated*** by ***IL-6*** , indicating a role for Stat3 in the regulation of cellular differentiation .	positive	1
10257	10636921	8802;5587	Galpha;PKD	Our results show that ***Galpha*** ( q ) activation is sufficient to ***stimulate*** sustained ***PKD*** activation via protein kinase C and indicate that the endogenous Galpha ( q ) mediates PKD activation in response to acute bombesin receptor stimulation .	positive	0
10258	10636921	8802;5587	Galpha;PKD	Our results show that Galpha ( q ) activation is sufficient to stimulate sustained PKD activation via protein kinase C and indicate that the endogenous ***Galpha*** ( q ) ***mediates*** ***PKD*** activation in response to acute bombesin receptor stimulation .	target	0
10259	10636924	3932;7409	Lck;Vav1	This ***Lck-mediated*** ***phosphorylation*** of ***Vav1*** has been reported to depend upon Tyr-174 in Vav1 , a site implicated in Vav1 function by other studies as well .	target	1
10260	10637092	958;959	CD40;CD40L	The CD28-B7 and ******CD40L-CD40****** ***interaction*** is required during the primary immune response to AChR .	parallel	1
10261	10637095	3458;6347	IFN-gamma;MCP-1	Since interferon-gamma ( IFN-gamma ) has been reported to have a likely role in determining the severity of symptoms in the neuromuscular autoimmune disease experimental myasthenia gravis ( EAMG ) , the hypothesis tested and proven true in these studies was that ***IFN-gamma*** would ***up-regulate*** the production of ***MCP-1*** in LE1 cells .	positive	1
10262	10637098	3458;3600	IFN-gamma;IL-15	Furthermore , the level of ***IL-15*** also can be ***regulated*** by ***IFN-gamma*** itself .	target	1
10263	10637230	3458;4609	IFN-gamma;c-myc	Both agents abrogated the ***IFN-gamma-dependent*** ***induction*** of ***c-myc*** expression in Stat1-null cells .	target	1
10264	10637230	3458;4609	IFN-gamma;c-myc	***Regulation*** of ***c-myc*** expression by ***IFN-gamma*** through Stat1-dependent and - independent pathways .	target	1
10265	10637230	6772;4609	Stat1;c-myc	***Regulation*** of ***c-myc*** expression by IFN-gamma through ***Stat1-dependent*** and - independent pathways .	target	1
10266	10637230	3458;4609	IFN-gamma;c-myc	***IFN-gamma*** ***suppresses*** ***c-myc*** in wild-type mouse embryo fibroblasts , but not in Stat1-null cells , where IFNs induce c-myc mRNA rapidly and transiently , thus revealing a novel signaling pathway .	negative	1
10267	10637231	25;3725	Abl;c-Jun	We found that active nuclear ***Abl*** efficiently ***phosphorylate*** ***c-Jun*** , a transcription factor not previously known to be tyrosine phosphorylated .	target	1
10268	10637231	25;3725	Abl;c-Jun	After ***phosphorylation*** of ***c-Jun*** by ***Abl*** on Tyr170 , both proteins interacted via the SH2 domain of Abl .	target	1
10269	10637272	4982;8600	OCIF;RANKL	Osteoclast formation induced by TNF-alpha was inhibited by the addition of respective antibodies against TNF receptor 1 ( TNFR1 ) or TNFR2 , but not by osteoclastogenesis inhibitory factor ( ***OCIF*** , also called OPG , a decoy ***receptor*** of ***ODF/RANKL*** ) , nor the Fab fragment of anti-RANK ( ODF/RANKL receptor ) antibody .	parallel	1
10270	10637286	1111;995	Chk1;Cdc25	***Chk1*** ***regulates*** the activity and localization of ***Cdc25*** , the tyrosine phosphatase that activates the cdk Cdc2 .	target	1
10271	10637290	1500;7525	p120;c-Yes	Like E - and P-cadherin , Ca ( 2 + ) treatment of normal and tumor-derived human keratinocytes resulted in ***c-Yes*** ( and c-Src and Fyn ) , as well as their putative ***substrate*** ***p120*** ( CTN ) , being recruited to cell-cell contacts .	parallel	1
10272	10637430	8626;7161	p51;p73	However , the protein-protein ***interactions*** analyzed by a yeast two-hybrid assay between p51 and p53 , between ***p51*** and ***p73*** , and between p51 and oncoproteins showed that p51 is functionally rather distant from p53 .	parallel	1
10273	10637439	4804;627	p75NTR;Neurotrophin	In order to dissect the potential role of ***p75NTR*** , the common ***Neurotrophin*** ***receptor*** , in Neurotrophin dependence , we expressed wild-type and mutant p75NTR in cells that do not express endogenous p75NTR or Trk family members ( NIH3T3 ) .	parallel	1
10274	10637480	9612;7704	SMRT;PLZF	The difference in response to ATRA therapy between acute promyelocytic leukemia ( APL ) patients with PML-RARalpha fusion and PLZF-RARalpha fusion has recently been found to be partially due to the strong ***association*** of the transcriptional co-repressor , ***SMRT/N-CoR*** , with ***PLZF*** domain .	parallel	0
10275	10637494	1029;1019	p16;CDK4	The ***p16*** gene competes with cyclin D for binding to CDK4/CDK6 and therefore ***inhibits*** ***CDK4/6*** complex kinase activity , resulting in dephosphorylation of pRb and related G1 growth arrest .	negative	1
10276	10637505	5594;2002	ERK;Elk-1	***ERK*** activation ***induces*** phosphorylation of ***Elk-1*** at multiple S/T-P motifs to high stoichiometry .	target	1
10277	10638662	3553;4790	IL-1beta;NF-kappaB	***IL-1beta*** ***induction*** of ***NF-kappaB*** activation in human intestinal epithelial cells is independent of oxyradical signaling .	target	1
10278	10638704	3458;1026	IFN-gamma;p21	***IFN-gamma*** ***induction*** of ***p21*** ( WAF1 ) is required for cell cycle inhibition and suppression of apoptosis .	target	1
10279	10638704	3458;1017	IFN-gamma;cyclin-dependent kinase 2	***IFN-gamma*** upregulated p21 ( WAF1 ) expression in a p53-independent manner , ***decreased*** ***cyclin-dependent kinase 2*** activity , and inhibited entry into the S phase of the cell cycle in p21 + / + but not in p21 - / - HCT116 cells .	negative	0
10280	10638705	3725;4790	AP-1;NF-kappaB	***Cooperation*** between transcription factor ***AP-1*** and ***NF-kappaB*** in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia .	parallel	0
10281	10638705	3725;4790	AP-1;NF-kappaB	These data suggest that hypoxic environments upregulate the IL-8 gene via ***cooperation*** of ***NF-kappaB*** and ***AP-1*** and contribute to the progression and metastasis of human pancreatic cancer .	parallel	0
10282	10638746	3077;7037	HFE;transferrin receptor	Crystal structure of the hereditary haemochromatosis protein ***HFE*** ***complexed*** with ***transferrin receptor*** .	parallel	1
10283	10638746	3077;7037	HFE;TfR	***HFE*** ***binds*** to the transferrin receptor ( ***TfR*** ) , a receptor by which cells acquire iron-loaded transferrin .	parallel	1
10284	10638746	7037;3077	TfR;HFE	The 2.8 A crystal structure of a ***complex*** between the extracellular portions of ***HFE*** and ***TfR*** shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .	parallel	1
10285	10638746	3077;7037	HFE;TfR	The ******HFE-TfR****** ***complex*** suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .	parallel	1
10286	10638962	4792;4790	IkappaB-alpha;NF-kappaB	The activation and regulation of ***NF-kappaB*** are tightly ***controlled*** by ***IkappaB-alpha*** , a cellular inhibitory protein of NF-kappaB .	target	0
10287	10639137	2132;2131	EXT2;EXT1	Instead , it appears that ***EXT1*** and ***EXT2*** form a hetero-oligomeric ***complex*** in vivo that leads to the accumulation of both proteins in the Golgi apparatus .	parallel	1
10288	10639137	2132;2131	EXT2;EXT1	Remarkably , the Golgi-localized ******EXT1/EXT2****** ***complex*** possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone , which suggests that the complex represents the biologically relevant form of the enzyme ( s ) .	parallel	1
10289	10639148	3606;7412	IL-18;VCAM-1	The ***IL-18*** cytokine ***increases*** expression of ***VCAM-1*** and the adherence of melanoma cells .	positive	0
10290	10639155	27190;3553	IL-17B;IL-1beta	In a survey of cytokine induction , ***IL-17B*** and IL-17C ***stimulate*** the release of tumor necrosis factor alpha and ***IL-1beta*** from the monocytic cell line , THP-1 , whereas IL-17 has only a weak effect in this system .	positive	0
10291	10639155	27190;7124	IL-17B;tumor necrosis factor alpha	In a survey of cytokine induction , ***IL-17B*** and IL-17C ***stimulate*** the release of ***tumor necrosis factor alpha*** and IL-1beta from the monocytic cell line , THP-1 , whereas IL-17 has only a weak effect in this system .	positive	0
10292	10639155	27189;3553	IL-17C;IL-1beta	In a survey of cytokine induction , IL-17B and ***IL-17C*** ***stimulate*** the release of tumor necrosis factor alpha and ***IL-1beta*** from the monocytic cell line , THP-1 , whereas IL-17 has only a weak effect in this system .	positive	0
10293	10639155	27189;7124	IL-17C;tumor necrosis factor alpha	In a survey of cytokine induction , IL-17B and ***IL-17C*** ***stimulate*** the release of ***tumor necrosis factor alpha*** and IL-1beta from the monocytic cell line , THP-1 , whereas IL-17 has only a weak effect in this system .	positive	0
10294	10639175	581;472	Bax;Atm	***Atm*** and ***Bax*** ***cooperate*** in ionizing radiation-induced apoptosis in the central nervous system .	parallel	0
10295	10639175	581;836	Bax;caspase-3	Further , Atm - and ***Bax-dependent*** apoptosis in the CNS also ***required*** ***caspase-3*** activation .	target	0
10296	10639190	5617;50	prolactin;Mitochondrial aconitase	***Mitochondrial aconitase*** gene expression is ***regulated*** by testosterone and ***prolactin*** in prostate epithelial cells .	target	1
10297	10639461	3493;3916	IgA1;LAMP1	We previously demonstrated that the Neisseria ***IgA1*** protease ***cleaves*** ***LAMP1*** ( lysosome-associated membrane protein 1 ) , a major integral membrane glycoprotein of lysosomes , thereby accelerating its degradation rate in infected A431 human epidermoid carcinoma cells and resulting in the alteration of lysosomes in these cells .	target	1
10298	10639461	3493;3916	IgA1;LAMP1	We report that N. gonorrhoeae infection of T84 monolayers , grown on a solid substrate or polarized on semiporous membranes , also results in ***IgA1*** protease-mediated ***reduction*** of ***LAMP1*** .	negative	0
10299	10639493	1056;7184	BSDL;Grp94	We have also shown that the ******Grp94-BSDL****** ***complexes*** , which are insensitive to denaturing conditions , are present in pancreatic homogenate but not in duodenal lysate .	parallel	1
10300	10639493	1056;7184	BSDL;Grp94	In previous studies , we have shown that the bile salt-dependent lipase ( ***BSDL*** ) ***associates*** with the ***Grp94*** molecular chaperone , an association that appears to play essential roles in the folding of BSDL .	parallel	0
10301	10639493	1056;7184	BSDL;Grp94	The ******Grp94-BSDL****** ***complex*** is secreted with the pancreatic juice into the acinar lumen and reaches the duodenal lumen , where it is internalized by enterocytes .	parallel	1
10302	10639513	9564;5241	p130Cas;progesterone receptor	RESULTS : ***Bcar1/p130Cas*** levels in primary tumors were ***associated*** with age/menopausal status and the levels of estrogen receptor and ***progesterone receptor*** .	parallel	0
10303	10639565	4609;4953	c-Myc;ODC	Since ***ODC*** expression is ***regulated*** by ***c-Myc*** oncoprotein , this model could be useful to monitor in vivo the effects of new anti-neoplastic molecules , specific inhibitors of c-Myc .	target	1
10304	10639567	7422;3791	VEGF;flk-1	The ***VEGF*** isoforms ***bind*** with two tyrosine-kinase receptors , ***KDR/flk-1*** and flt-1 .	parallel	1
10305	10639567	7422;2321	VEGF;flt-1	The ***VEGF*** isoforms ***bind*** with two tyrosine-kinase receptors , KDR/flk-1 and ***flt-1*** .	parallel	1
10306	10639570	3479;7040	IGF-I;TGF-beta1	In order to examine the hypothesis that ***IGF-I*** ***suppresses*** ***TGF-beta1*** expression in the mammary gland , we studied the effect of various manipulations of the growth hormone - IGF-I axis on TGF-beta1 mRNA abundance .	negative	1
10307	10639570	3479;7040	IGF-I;TGF-beta1	Administration of ***IGF-I*** to intact animal ***suppressed*** ***TGF-beta1*** mRNA levels in a dose-dependent manner to approximately 20 % of control levels .	negative	1
10308	10639576	836;4214	caspase-3;MEKK1	Analysis of the defective apoptotic pathway in 2008/C13 cells indicates that these cells are deficient in the proteolytic ***activation*** of ***MEKK1*** by ***caspase-3*** .	positive	1
10309	10639579	26292;4609	c-Myc binding protein;c-Myc	We have reported that a novel ***c-Myc binding protein*** , AMY-1 , ***stimulated*** the transcription activity of ***c-Myc*** and was translocated from cytoplasm to nuclei in a c-Myc-dependent manner .	positive	0
10310	10639593	2887;3643	Grb10;insulin receptor	In the present review the focus is on the ***interaction*** between ***Grb10*** proteins and the insulin-like growth factor ***receptor/insulin receptor*** , and the role of Grb10 in IGF-I/insulin-induced mitogenesis is discussed , considering that the data available are also partially discordant .	parallel	1
10311	10640274	4193;3091	Mdm2;HIF-1alpha	We find that p53 promotes ***Mdm2-mediated*** ***ubiquitination*** and proteasomal degradation of the ***HIF-1alpha*** subunit of hypoxia-inducible factor 1 ( HIF-1 ) , a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation .	target	1
10312	10640274	3091;7422	HIF-1;VEGF	Loss of p53 in tumor cells enhances HIF-1alpha levels and augments ***HIF-1-dependent*** transcriptional ***activation*** of the vascular endothelial growth factor ( ***VEGF*** ) gene in response to hypoxia .	positive	1
10313	10640274	7157;3091	p53;HIF-1alpha	Loss of ***p53*** in tumor cells ***enhances*** ***HIF-1alpha*** levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor ( VEGF ) gene in response to hypoxia .	negative	0
10314	10640274	3091;7422	HIF-1alpha;VEGF	Forced expression of ***HIF-1alpha*** in p53-expressing tumor cells ***increases*** hypoxia-induced ***VEGF*** expression and augments neovascularization and growth of tumor xenografts .	positive	0
10315	10640350	4193;7157	HDM2;p53	***Binding*** of ***p53*** by ***HDM2*** traffics p53 from the nucleus to the cytoplasm where it is recognized and targeted for ubiquitin-mediated degradation ( D.	parallel	1
10316	10640350	4193;7157	HDM2;p53	A homogeneous time-resolved fluorescence ( HTRF ) assay has been developed to monitor ******p53/HDM2****** ***binding*** .	parallel	1
10317	10640350	7157;4193	p53;HDM2	***Binding*** of ***p53*** to ***HDM2*** brings the fluorophores into close proximity , allowing fluorescence resonance energy transfer to occur .	parallel	1
10318	10640351	2056;2057	erythropoietin;erythropoietin receptor	***erythropoietin*** ***induces*** dimerization of the ***erythropoietin receptor*** on the surface of erythroid progenitor cells , promoting the differentiation of these cells into mature red blood cells .	target	1
10319	10640423	891;9793	cyclin B1;TOG	Finally , we demonstrated ***interaction*** between ***TOG/XMAP215*** and ***cyclin B1*** by co-immunoprecipitation assays .	parallel	1
10320	10640425	7039;2670	TGF-alpha;GFAP	***TGF-alpha*** differentially ***regulates*** ***GFAP*** , vimentin , and nestin gene expression in U-373 MG glioblastoma cells : correlation with cell shape and motility .	target	1
10321	10640425	7039;10763	TGF-alpha;nestin	***TGF-alpha*** differentially ***regulates*** GFAP , vimentin , and ***nestin*** gene expression in U-373 MG glioblastoma cells : correlation with cell shape and motility .	target	1
10322	10640425	7039;7431	TGF-alpha;vimentin	***TGF-alpha*** differentially ***regulates*** GFAP , ***vimentin*** , and nestin gene expression in U-373 MG glioblastoma cells : correlation with cell shape and motility .	target	1
10323	10640427	643;5594	blr1;ERK2	Retinoic acid-induced ***blr1*** expression ***promotes*** ***ERK2*** activation and cell differentiation in HL-60 cells .	positive	0
10324	10640438	3553;3725	IL-1 beta;c-Jun	These data illustrate that some of the pathological effects of IL-1 beta and TNF alpha may be mediated through the MAPK cascades , and that the ERK cascade , rather than JNKs or p38-MAPKs , are implicated in the ***upregulation*** of ***c-Jun*** by ***IL-1 beta*** .	positive	1
10325	10640438	3553;1386	IL-1 beta;ATF2	***IL-1 beta*** and TNF alpha ***stimulated*** the phosphorylation of c-Jun and ***ATF2*** .	positive	0
10326	10640438	3553;3725	IL-1 beta;c-Jun	***IL-1 beta*** and TNF alpha ***stimulated*** the phosphorylation of ***c-Jun*** and ATF2 .	positive	0
10327	10640438	7124;1386	TNF alpha;ATF2	IL-1 beta and ***TNF alpha*** ***stimulated*** the phosphorylation of c-Jun and ***ATF2*** .	positive	0
10328	10640438	7124;3725	TNF alpha;c-Jun	IL-1 beta and ***TNF alpha*** ***stimulated*** the phosphorylation of ***c-Jun*** and ATF2 .	positive	0
10329	10640627	5524;4133	PP2A;MAP2	The inhibition of ***PP2A*** but not of PP2B also ***induced*** phosphorylation of ***MAP2*** at multiple sites and impaired its microtubule binding activity .	target	1
10330	10640633	2934;351	Gelsolin;Abeta	We recently reported that ***Gelsolin*** , a secretory protein , ***binds*** to ***Abeta*** , and that Gelsolin/Abeta complex is present in the plasma [ V.P.S.	parallel	1
10331	10640633	351;2934	Abeta;Gelsolin	We recently reported that Gelsolin , a secretory protein , binds to Abeta , and that ******Gelsolin/Abeta****** ***complex*** is present in the plasma [ V.P.S.	parallel	1
10332	10640633	2934;351	Gelsolin;Abeta	Congo red staining and electron microscopic examination in negative staining of aged samples of Abeta alone and Abeta incubated with Gelsolin showed that ***Gelsolin*** ***inhibits*** the fibrillization of synthetic ***Abeta*** 1-40 and Abeta 1-42 at Gelsolin to Abeta molar ratio of 1:40 .	negative	1
10333	10640682	5457;1958	Brn-3a;NGFI-A	***Regulation*** of ***NGFI-A*** ( Egr-1 ) gene expression by the POU domain transcription factor ***Brn-3a*** .	target	1
10334	10640682	5457;1958	Brn-3a;NGFI-A	We report here that ***Brn-3a*** ***activates*** the ***NGFI-A*** promoter in neurons ( both primary and cell lines ) .	positive	1
10335	10640687	4929;6531	nurr1;hDAT	The transcription factor ***nurr1*** ***increases*** the transcriptional activity of several larger ***hDAT*** constructs , consistent with the presence of several putative NGFI-B response elements ( NBRE ) .	positive	0
10336	10640727	5829;6714	paxillin;Src	Furthermore , VEGF induction enhanced the complex ***formation*** between ***Src*** kinase and ***paxillin*** .	parallel	0
10337	10640731	116;356	PACAP;FasL	***VIP/PACAP-mediated*** ***inhibition*** of both AICD and ***FasL*** expression is mediated through the specific receptors VPAC1 and VPAC2 .	negative	1
10338	10640731	7432;356	VIP;FasL	***VIP/PACAP-mediated*** ***inhibition*** of both AICD and ***FasL*** expression is mediated through the specific receptors VPAC1 and VPAC2 .	negative	1
10339	10640741	356;355	FasL;Fas	Fas or ***Fas*** ***ligand*** ( ***FasL*** ) - deficient mice are relatively resistant to the induction of experimental allergic encephalomyelitis , implying the involvement of Fas/FasL in this disease process .	parallel	1
10340	10640741	3458;355	IFN-gamma;Fas	In microglia , Fas expression is regulated at the level of mRNA expression ; TNF-alpha and ***IFN-gamma*** ***induced*** ***Fas*** mRNA by approximately 20-fold .	target	1
10341	10640741	7124;355	TNF-alpha;Fas	In microglia , Fas expression is regulated at the level of mRNA expression ; ***TNF-alpha*** and IFN-gamma ***induced*** ***Fas*** mRNA by approximately 20-fold .	target	1
10342	10640741	7040;355	TGF-beta;Fas	The cytokine ***TGF-beta*** ***inhibits*** basal expression of ***Fas*** as well as cytokine-mediated Fas expression by microglia .	negative	1
10343	10640744	959;958	CD40 ligand;CD40	T cells can induce somatic mutation in B cell receptor-engaged BL2 Burkitt 's lymphoma cells independently of ******CD40-CD40 ligand****** ***interactions*** .	parallel	1
10344	10640752	4790;5175	NF-kappa B;PECAM-1	Mobility shifts assays identified a specific NF-kappa B-binding element at +110 / +120 , whose mutation abolished the basal promoter activity of PECAM-1 and decreased ***NF-kappa B-dependent*** ***responses*** of the ***PECAM-1*** gene promoter .	parallel	0
10345	10640752	4790;5175	NF-kappa B;PECAM-1	These results demonstrate that ***NF-kappa B*** can ***regulate*** the transcriptional activity of ***PECAM-1*** .	target	1
10346	10640769	2209;1401	Fc gamma RI;CRP	Further analysis of CRP binding to macrophages , neutrophils , and lymphocytes provides direct evidence that Fc gamma RIIb1 , Fc gamma RIIb2 , and ***Fc gamma RI*** are the ***receptors*** for ***CRP*** on mouse leukocytes .	parallel	1
10347	10640770	5777;7124	SHP-1;TNF-alpha	Positive ***regulation*** of c-Jun N-terminal kinase and ***TNF-alpha*** production but not histamine release by ***SHP-1*** in RBL-2H3 mast cells .	positive	1
10348	10640773	7039;4586	TGF-alpha;MUC5AC	In contrast , the EGFR ligand , ***TGF-alpha*** , ***increased*** EGFR tyrosine phosphorylation , activation of p44/42mapk , and subsequent ***MUC5AC*** synthesis , but these effects were not inhibited by antioxidants .	positive	0
10349	10640779	4790;7124	NF-kappa B;TNF-alpha	***NF-kappa B*** ***modulates*** ***TNF-alpha*** production by alveolar macrophages in asymptomatic HIV-seropositive individuals .	target	0
10350	10640791	959;958	CD40L;CD40	The ******CD40-CD40L****** ***interaction*** , which was initially shown to have important roles in the T cell-mediated activation of B cells during humoral immune responses , is now known to have roles in activation of endothelial cells , smooth muscle cells , and macrophages within atherosclerotic plaques .	parallel	1
10351	10640976	1029;1019	p16;CDK4	This was not the case for CDK4 protein , although ***p16*** protein expression ***correlated*** significantly with ***CDK4*** protein expression in BPH ( Spearman rank correlation [ R ( S ) ] = 0.63 ) and carcinoma ( R ( S ) = 0.78 ) .	parallel	0
10352	10640990	7157;7299	p53;tyrosinase	This study shows that the promoters of the genes coding for the enzymes crucial in melanin biosynthesis , namely ***tyrosinase*** and tyrosinase-related protein-1 ( TRP-1 ) , are ***activated*** by wild-type ***p53*** .	positive	1
10353	10640990	7157;7306	p53;tyrosinase-related protein-1	This study shows that the promoters of the genes coding for the enzymes crucial in melanin biosynthesis , namely tyrosinase and ***tyrosinase-related protein-1*** ( TRP-1 ) , are ***activated*** by wild-type ***p53*** .	positive	1
10354	10641575	7133;7124	TNFR-2;TNF-alpha	Transfection of lymphocytes led to selective decrease in ***CD120b/TNF-alpha*** ***receptor*** II ( ***TNFR-2*** ) - positive cells .	parallel	1
10355	10641591	1437;7852	Granulocyte macrophage colony-stimulating factor;chemokine receptor	***Granulocyte macrophage colony-stimulating factor*** and interleukin-3 ***regulate*** chemokine and ***chemokine receptor*** expression in bone marrow macrophages .	target	1
10356	10641591	3562;7852	interleukin-3;chemokine receptor	Granulocyte macrophage colony-stimulating factor and ***interleukin-3*** ***regulate*** chemokine and ***chemokine receptor*** expression in bone marrow macrophages .	target	1
10357	10641597	238;943	ALK;CD30	The tyrosine kinase ***NPM-ALK*** , associated with anaplastic large cell lymphoma , ***binds*** the intracellular domain of the surface receptor ***CD30*** but is not activated by CD30 stimulation .	parallel	1
10358	10641597	4869;943	NPM;CD30	The tyrosine kinase ***NPM-ALK*** , associated with anaplastic large cell lymphoma , ***binds*** the intracellular domain of the surface receptor ***CD30*** but is not activated by CD30 stimulation .	parallel	1
10359	10641597	238;943	ALK;cytokine receptor CD30	We demonstrate that ***NPM-ALK*** specifically ***binds*** to the intracellular domain of the ***cytokine receptor CD30*** .	parallel	1
10360	10641597	4869;943	NPM;cytokine receptor CD30	We demonstrate that ***NPM-ALK*** specifically ***binds*** to the intracellular domain of the ***cytokine receptor CD30*** .	parallel	1
10361	10641711	847;5594	catalase;ERK1/2	Overexpression of ***catalase*** strongly ***inhibited*** UVB-induced ***EGFR/ERK1/2*** pathway activation .	negative	1
10362	10641752	581;596	Bax;Bcl-2	These patients are being followed-up to look for any ***association*** between clinical outcome , ******Bcl-2/Bax****** ratio and apoptosis .	parallel	0
10363	10641752	7157;581	p53;Bax	Both ***Bax*** and Bcl-2 are ***regulated*** by the tumour-suppressor protein ***p53*** .	target	1
10364	10641752	7157;596	p53;Bcl-2	Both Bax and ***Bcl-2*** are ***regulated*** by the tumour-suppressor protein ***p53*** .	target	1
10365	10642089	4908;4744	NT-3;NFH	Reductions in sural nerve axonal caliber were associated with a tendency for elevation of both phosphorylated NFH levels in large fibers and the ratio of phosphorylated to nonphosphorylated ***NFH*** that was ***attenuated*** by ***NT-3*** .	negative	0
10366	10642277	183;5743	angiotensin II;cyclooxygenase-2	***Induction*** of ***cyclooxygenase-2*** by ***angiotensin II*** in cultured rat vascular smooth muscle cells .	target	1
10367	10642297	4790;3383	NF-kappaB;ICAM-1	PDTC also prevented the ***NF-kappaB-dependent*** ***transactivation*** of the intercellular adhesion molecule ***ICAM-1*** and inducible nitric oxide synthase .	positive	1
10368	10642313	3553;4879	IL-1beta;hBNP	Thus , Ca ( 2 + ) and Ca ( 2 + ) - dependent pathways are critical to ***IL-1beta*** ***regulation*** of the ***hBNP*** promoter .	target	1
10369	10642313	3553;4879	IL-1beta;hBNP	We questioned whether Ca ( 2 + ) and Ca ( 2 + ) - dependent pathways mediate ***IL-1beta*** ***regulation*** of the ***hBNP*** promoter in cardiac myocytes .	target	1
10370	10642313	3553;4879	IL-1beta;hBNP	These data suggest that ( 1 ) Ca ( 2 + ) activates the hBNP promoter ; ( 2 ) release of Ca ( 2 + ) from intracellular stores is important to ***IL-1beta*** ***regulation*** of the ***hBNP*** promoter , but transport via voltage-sensitive Ca ( 2 + ) channels is not ; ( 3 ) protein kinase C and Ca ( 2 + ) / calmodulin-dependent kinase II mediate the action of IL-1beta ; and ( 4 ) the phosphatase calcineurin is not involved in IL-1beta regulation of the hBNP promoter .	target	1
10371	10642333	5972;183	renin;angiotensin II	However , the hypertensive and hypertrophic effects of subpressor ***angiotensin II*** are at least in part ***mediated*** by the brain ***renin-angiotensin*** system .	target	0
10372	10642432	3479;5982	insulin-like growth factor-1;activator-1	The ***insulin-like growth factor-1*** ***elevates*** urokinase-type plasminogen ***activator-1*** in human breast cancer cells : a new avenue for breast cancer therapy .	positive	0
10373	10642500	6722;2353	serum response factor;c-fos	***serum response factor*** ( SRF ) is a key transcriptional ***activator*** of the ***c-fos*** gene and of muscle-specific gene expression .	positive	1
10374	10642509	7077;4323	TIMP-2;MT1-MMP	In addition , the pro-MMP-2 in the ******MT1-MMP-TIMP-2-pro-MMP-2****** ternary ***complex*** was not activated without external activator , but readily by addition of sMT1-MMP .	parallel	1
10375	10642509	7077;4323	TIMP-2;MT1-MMP	These results demonstrate that the TM domain of MT1-MMP is not required for the ability to activate pro-MMP-2 , but is required for the enhancing effect of TIMP-2 on pro-MMP-2 activation by recruiting pro-MMP-2 to the ******MT1-MMP-TIMP-2****** ***complex*** as a cell-surface pro-MMP-2 receptor .	parallel	1
10376	10642518	5274;5327	Neuroserpin;tPA	A higher-molecular-mass ******tPA-Neuroserpin****** ***complex*** was also observed in AtT-20-cell conditioned culture medium .	parallel	1
10377	10642518	5274;5327	Neuroserpin;tPA	There was no accumulation of a ******tPA-Neuroserpin****** ***complex*** .	parallel	1
10378	10642518	5274;5327	Neuroserpin;tPA	As ***Neuroserpin*** ***inhibits*** tissue plasminogen activator ( ***tPA*** ) in vitro , we measured plasminogen-activator levels .	negative	1
10379	10642522	8878;3320	p60;hsp90	Binding of p23 to hsp90 did not change the affinity of the ******hsp90-p60****** ***complex*** and the stabilizing effect of ATP .	parallel	1
10380	10642522	10728;3320	p23;hsp90	***Binding*** of ***p23*** to ***hsp90*** did not change the affinity of the hsp90-p60 complex and the stabilizing effect of ATP .	parallel	1
10381	10642522	3308;6767	hsp70;p48	Saturation of the ******p48-hsp70****** ***interaction*** could not be achieved , suggesting multiple binding sites .	parallel	1
10382	10642536	3581;3578	IL-9R;IL-9	interleukin 9 ( IL-9 ) exerts its pleiotropic effects through the ***IL-9*** ***receptor*** ( ***IL-9R*** ) complex , which consists of the IL-9R alpha-chain , which determines the cytokine specificity , and the IL-2 receptor gamma-chain .	parallel	1
10383	10642580	1232;6356	CCR3;eotaxin	Expression of the chemokine ***eotaxin*** and its ***receptor*** , ***CCR3*** , in human endometrium .	parallel	1
10384	10642580	1232;6356	CCR3;eotaxin	The expression of the eosinophil chemoattractant , ***eotaxin*** , and its ***receptor*** , ***CCR3*** , within the human endometrium were investigated by immunohistochemical analysis of tissue sections spanning the entire menstrual cycle .	parallel	1
10385	10642594	7471;2697	Wnt-1;connexin43	***Wnt-1*** ***regulation*** of ***connexin43*** in cardiac myocytes .	target	1
10386	10642598	3667;3643	IRS-1;insulin receptor	To analyze the role of the insulin signaling pathway in these processes , we have generated mice with combined heterozygous null mutations in insulin receptor ( ir ) , ***insulin receptor*** ***substrate*** ( ***IRS-1*** ) , and/or IRS-2 .	parallel	1
10387	10642787	3572;6774	gp130;Stat3	***Activation*** of ***Stat3*** by cytokine receptor ***gp130*** ventralizes Xenopus embryos independent of BMP-4 .	positive	1
10388	10642827	4233;3082	c-Met;hepatocyte growth factor	Differential expression of ***hepatocyte growth factor*** and its ***receptor*** , ***c-Met*** in the rat retina during development .	parallel	1
10389	10642827	4233;3082	c-Met;HGF	In this study , we examined spatial and temporal expression of ***HGF*** and its ***receptor*** , ***c-Met*** , during retinal development at RNA or protein levels .	parallel	1
10390	10642889	4654;9935	MyoD;mafB	It was also suggested that ***MyoD*** ***transactivated*** the mouse ***mafB*** promoter and this gene was positively autoregulated by its product , mafB .	positive	1
10391	10643146	4352;7066	c-MPL;TPO	Surface ***c-MPL*** , the ***receptor*** for ***TPO*** , defines a phenotype of hematopoietic stem cells with long-term repopulating ability .	parallel	1
10392	10643294	7422;2152	VEGF;tissue factor	The expression of ***tissue factor*** ( TF ) , an initiator of extrinsic blood coagulation , was ***upregulated*** by ***VEGF*** in retinal vascular endothelial cells ( REC ) .	positive	1
10393	10643713	7124;4254	TNFalpha;SCF	Furthermore , ***TNFalpha*** was found to ***augment*** ***SCF*** expression in SFB .	positive	0
10394	10643713	7124;4254	Tumor necrosis factor alpha;stem cell factor	***Tumor necrosis factor alpha*** ***promotes*** the expression of ***stem cell factor*** in synovial fibroblasts and their capacity to induce mast cell chemotaxis .	positive	0
10395	10643717	655;176	OP-1;aggrecan	RESULTS : ***OP-1*** ***stimulated*** the expression of HAS-2 , CD44 , and ***aggrecan*** mRNA in a time-dependent manner , resulting in increased expression of HA , CD44 , and aggrecan .	positive	0
10396	10643717	655;960	OP-1;CD44	RESULTS : ***OP-1*** ***stimulated*** the expression of HAS-2 , ***CD44*** , and aggrecan mRNA in a time-dependent manner , resulting in increased expression of HA , CD44 , and aggrecan .	positive	0
10397	10643885	367;3725	androgen receptor;c-Jun	Here we show that the size of this polyglutamine tract influences both c-Jun regulation of androgen receptor-mediated transcription and ***androgen receptor*** ***regulation*** of ***c-Jun*** activity .	target	1
10398	10643887	8851;1020	p35;cyclin-dependent kinase 5	Insulin-like growth factor-1 affects expressions of ***cyclin-dependent kinase 5*** and its ***activator*** ***p35*** in reperfused rat brain .	positive	1
10399	10643887	3479;1020	Insulin-like growth factor-1;cyclin-dependent kinase 5	***Insulin-like growth factor-1*** ***affects*** expressions of ***cyclin-dependent kinase 5*** and its activator p35 in reperfused rat brain .	target	0
10400	10643887	3479;8851	Insulin-like growth factor-1;p35	***Insulin-like growth factor-1*** ***affects*** expressions of cyclin-dependent kinase 5 and its activator ***p35*** in reperfused rat brain .	target	0
10401	10643887	8851;1020	p35;cdk5	The present results suggest that IGF-1 has a significant effect on ameliorating brain injury after transient focal brain ischemia with affecting the expressions of ***cdk5*** and its ***activator*** ***p35*** .	positive	1
10402	10644003	5443;7299	alpha-MSH;tyrosinase	Independent ***regulation*** of ***tyrosinase*** by the hypopigmenting cytokines TGF beta1 and TNF alpha and the melanogenic hormone ***alpha-MSH*** in B16 mouse melanocytes .	target	1
10403	10644003	5443;7299	alpha-MSH;tyrosinase	In B16 melanocytes , ***tyrosinase*** activity and melanin formation are ***upregulated*** by ***alpha-MSH*** and downregulated by TGF beta1 and TNF alpha .	positive	1
10404	10644003	5443;7299	alpha-MSH;tyrosinase	Since TGF beta1 or TNF alpha block the differentiation programs induced by throphic hormones in other cell types , we studied ***tyrosinase*** ***regulation*** by ***alpha-MSH*** in the presence of the hypopigmenting cytokines , as well as the effects of the cytokines on several aspects of alpha-MSH signaling .	target	1
10405	10644013	5443;4157	Alpha melanocyte-stimulating hormone;MC1-R	***Alpha melanocyte-stimulating hormone*** ( MSH ) and related proopiomelanocortin-derived ( POMC ) peptides ***bind*** to the melanocortin 1 receptor ( ***MC1-R*** ) of mammalian melanocytes and stimulate proliferation and melanogenesis .	parallel	1
10406	10644332	3725;4790	AP1;NF-kappaB	We postulate that a Tat-mediated increase in SP1 binding activities augments the ***binding*** of ***AP1*** and ***NF-kappaB*** , leading to synergistic activation of the MCP-1 promoter .	parallel	1
10407	10644362	3646;3434	Int6;P56	Characterization of the ***interaction*** between the interferon-induced protein ***P56*** and the ***Int6*** protein encoded by a locus of insertion of the mouse mammary tumor virus .	parallel	1
10408	10644363	3458;7037	IFN-gamma;CD71	Neither ***IFN-gamma*** treatment nor VZV infection ***affected*** the expression of transferrin receptor ( ***CD71*** ) .	target	0
10409	10644368	7852;3700	CXCR4;gp120	Consistent with the binding of polyanions to the coreceptor binding surface , dextran sulfate interfered with the ******gp120-CXCR4****** ***association*** while having no detectable effect on the gp120-CD4 interaction .	parallel	0
10410	10644368	920;3700	CD4;gp120	Consistent with the binding of polyanions to the coreceptor binding surface , dextran sulfate interfered with the gp120-CXCR4 association while having no detectable effect on the ******gp120-CD4****** ***interaction*** .	parallel	1
10411	10644447	246;10514	ALOX15;MYBBP1A	A P1 artificial chromosome clone containing the 5 ' region of MYBBP1A was isolated and indicates a physical ***linkage*** between ***MYBBP1A*** and the 15-lipoxygenase gene ( ***ALOX15*** ) .	parallel	0
10412	10644537	1977;1978	eIF4E;4E-BP1	IGF-I did not alter either the amount of ***eIF4E*** ***associated*** with the eIF4E binding protein ***4E-BP1*** or the phosphorylation state of 4E-BP1 .	parallel	0
10413	10644537	1977;1981	eIF4E;eIF4G	In contrast , the amount of ***eIF4E*** ***bound*** to ***eIF4G*** was increased threefold by IGF-I .	parallel	1
10414	10644539	1977;1978	eIF4E;4E-BP1	Furthermore , translation initiation factor ***eIF4E*** preferred ***association*** with its endogenous inhibitor ***4E-BP1*** rather than eIF4G .	parallel	0
10415	10644570	6343;116	secretin;PACAP	The effect of ***PACAP-27*** is ***mediated*** by local release of ***secretin*** , somatostatin , and PGE ( 2 ) in isolated perfused rat stomach .	target	0
10416	10644570	116;6343	PACAP;secretin	***PACAP-27*** at 10 microg/h significantly ***increased*** concentrations of ***secretin*** , somatostatin , and PGE ( 2 ) in basal or pentagastrin-stimulated state .	positive	0
10417	10644570	116;6750	PACAP;somatostatin	***PACAP-27*** at 10 microg/h significantly ***increased*** concentrations of secretin , ***somatostatin*** , and PGE ( 2 ) in basal or pentagastrin-stimulated state .	positive	0
10418	10644648	3553;4790	IL-1beta;NF-kappaB	These data suggest that constitutive ***NF-kappaB*** p65 protein synthesis is ***regulated*** by ***IL-1beta*** , particularly during pregnancy .	target	1
10419	10644648	3553;5970	IL-1beta;p65	These data suggest that constitutive NF-kappaB ***p65*** protein synthesis is ***regulated*** by ***IL-1beta*** , particularly during pregnancy .	target	1
10420	10644670	23643;7099	MD-2;TLR4	These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the ******TLR4.MD-2****** ***complex*** is the shared molecule in Taxol and LPS signal transduction in mice .	parallel	1
10421	10644687	998;5062	Cdc42;PAK2	***Regulation*** of Xenopus p21-activated kinase ( ***X-PAK2*** ) by ***Cdc42*** and maturation-promoting factor controls Xenopus oocyte maturation .	target	1
10422	10644687	998;902	Cdc42;p34	We hypothesize that the X-PAK2 / ***Cdc42*** pathway could ***link*** ***p34*** ( cdc2 ) activity to the major cytoskeleton rearrangements leading to spindle migration and anchorage to the animal pole cortex .	parallel	0
10423	10644687	5062;902	PAK2;p34	We hypothesize that the ***X-PAK2*** / Cdc42 pathway could ***link*** ***p34*** ( cdc2 ) activity to the major cytoskeleton rearrangements leading to spindle migration and anchorage to the animal pole cortex .	parallel	0
10424	10644693	8556;7157	Cdc14;p53	The human ***Cdc14*** phosphatases interact with and ***dephosphorylate*** the tumor suppressor protein ***p53*** .	target	1
10425	10644693	8556;7157	hCDC14A;p53	Here we report that the ***hCDC14A*** and hCdc14B proteins ***interact*** with the tumor suppressor protein ***p53*** both in vitro and in vivo .	parallel	1
10426	10644693	8555;7157	hCdc14B;p53	Here we report that the hCDC14A and ***hCdc14B*** proteins ***interact*** with the tumor suppressor protein ***p53*** both in vitro and in vivo .	parallel	1
10427	10644693	8556;7157	hCdc14;p53	Furthermore , the ***hCdc14*** phosphatases were found to ***dephosphorylate*** ***p53*** specifically at the p34 ( Cdc2 ) / clb phosphorylation site ( p53-phosphor-Ser ( 315 ) ) .	target	1
10428	10644693	8556;7157	hCdc14;p53	Furthermore , the identification of p53 as a substrate for hCdc14 indicates that ***hCdc14*** may ***regulate*** the function of ***p53*** .	target	1
10429	10644716	348;4018	apolipoprotein E;lipoprotein	The region of ***apolipoprotein E*** ( apoE ) that ***interacts*** directly with the low density ***lipoprotein*** ( LDL ) receptor lies in the vicinity of residues 136-150 , where lysine and arginine residues are crucial for full binding activity .	parallel	1
10430	10644717	27429;1432	Omi;Mxi2	***Omi*** ***interacts*** with ***Mxi2*** , an alternatively spliced form of the p38 stress-activated kinase .	parallel	1
10431	10644727	4318;7076	MMP-9;TIMP-1	Gel filtration and surface plasmon resonance analyses demonstrated that the ***pro-MMP-9*** monomeric and dimeric forms ***bind*** ***TIMP-1*** with similar affinities .	parallel	1
10432	10644727	4314;4318	stromelysin 1;MMP-9	Kinetic analyses of the ***activation*** of monomeric and dimeric ***pro-MMP-9*** by ***stromelysin 1*** revealed K ( m ) values in the nanomolar range and relative low k ( cat ) values ( 1.9 x 10 ( -3 ) and 4.1 x 10 ( -4 ) s ( -1 ) , for the monomer and dimer , respectively ) consistent with a faster rate ( 1 order of magnitude ) of activation of the monomeric form by stromelysin 1 .	positive	1
10433	10644731	6775;3455	Stat4;human interferon-alpha/beta receptor	***Recruitment*** of ***Stat4*** to the ***human interferon-alpha/beta receptor*** requires activated Stat2 .	target	0
10434	10644731	6775;6773	Stat4;Stat2	Recruitment of ***Stat4*** to the human interferon-alpha/beta receptor ***requires*** activated ***Stat2*** .	target	0
10435	10644731	6775;6773	Stat4;Stat2	Expression of murine Stat4 in the Stat1-deficient U3A and the Stat2-deficient U6A cell lines shows that IFN-alpha-induced ***Stat4*** phosphorylation ***requires*** the presence of activated ***Stat2*** but not Stat1 .	target	0
10436	10644749	2804;8615	giantin;p115	The amino-terminal domain of the golgi protein ***giantin*** ***interacts*** directly with the vesicle-tethering protein ***p115*** .	parallel	1
10437	10644752	3929;1583	LBP;P450scc	Cloning of factors related to HIV-inducible ***LBP*** proteins that ***regulate*** steroidogenic factor-1-independent human placental transcription of the cholesterol side-chain cleavage enzyme , ***P450scc*** .	target	1
10438	10644752	29842;7342	LBP-9;LBP-1b	When the -155 / -131 fragment was linked to a minimal promoter , co-expression of LBP-1b increased transcription 21-fold in a dose-dependent fashion , but addition of ***LBP-9*** ***suppressed*** the stimulatory effect of ***LBP-1b*** .	negative	1
10439	10644755	6647;4792	Homodimer;IkappaBalpha	***Homodimer*** of two F-box proteins betaTrCP1 or betaTrCP2 ***binds*** to ***IkappaBalpha*** for signal-dependent ubiquitination .	parallel	1
10440	10644756	3717;2690	JAK2;GHR	Activated ***JAK2*** ***phosphorylates*** itself and ***GHR*** , thus initiating multiple signaling pathways .	target	1
10441	10644760	401;1621	Arix;dopamine beta-hydroxylase	The homeodomain protein ***Arix*** ***promotes*** protein kinase A-dependent activation of the ***dopamine beta-hydroxylase*** promoter through multiple elements and interaction with the coactivator cAMP-response element-binding protein-binding protein .	positive	0
10442	10644770	26298;4233	ESE-3;c-MET	A potential role in branching morphogenesis is suggested , since ***ESE-3*** ***transactivates*** the ***c-MET*** promoter via three high affinity binding sites .	positive	1
10443	10644890	356;355	FasL;Fas	In this report , the involvement of Fas and ***Fas*** ***ligand*** ( ***FasL*** ) in PCF-induced apoptosis was investigated .	parallel	1
10444	10644890	355;356	Fas;FasL	Caspase-3 is one of the proteolytic enzymes that can be activated by the ******Fas-FasL****** ***interaction*** .	parallel	1
10445	10644890	356;355	FasL;Fas	Therefore , PCF-treated plasmacytoma cells might undergo apoptosis via ***interaction*** between ***Fas*** and ***FasL*** .	parallel	1
10446	10644908	5159;5155	PDGF-Rbeta;platelet-derived growth factor B chain	The mRNA of the fibrogenic cytokine transforming growth factor beta 1 ( TGF-beta1 ) is increased two - to threefold during the time course , whereas the mRNAs of ***platelet-derived growth factor B chain*** ( PDGF-B ) and its ***receptor*** beta ( ***PDGF-Rbeta*** ) increase after UUO , reaching their maxima on days 10-15 .	parallel	1
10447	10644982	140885;5781	SHPS-1;SHP-2	Overexpression of the SHP-2 mutant also increased the strength of cell-substratum adhesion and resulted in hyperphosphorylation of ***SHPS-1*** , a ***substrate*** of ***SHP-2*** that contributes to cell adhesion-induced signaling .	parallel	1
10448	10644984	1440;6464	G-CSF;Shc	While G-CSF stimulated Ras activity in all cell lines , ***G-CSF*** failed to ***induce*** the tyrosine phosphorylation of ***Shc*** in Lyn-deficient cells .	target	1
10449	10644984	1440;5595	G-CSF;Erk1	***G-CSF*** ***induced*** a statistically significant activation of ***Erk1/Erk2*** Kinase or p90Rsk only in the wt cells .	target	1
10450	10644984	1440;5594	G-CSF;Erk2	***G-CSF*** ***induced*** a statistically significant activation of ***Erk1/Erk2*** Kinase or p90Rsk only in the wt cells .	target	1
10451	10644984	1440;6195	G-CSF;p90Rsk	***G-CSF*** ***induced*** a statistically significant activation of Erk1/Erk2 Kinase or ***p90Rsk*** only in the wt cells .	target	1
10452	10644984	1440;867	G-CSF;Cbl	***G-CSF*** ***induced*** the tyrosine phosphorylation of ***Cbl*** and increased activity of PI 3-kinase in wild-type and Syk-deficient , but non in Lyn-deficient , cells .	target	1
10453	10644987	3082;6714	HGF;Src	Indeed , TGF beta2 inhibited HGF effects because it prevented ***HGF-induced*** MAP kinase ***activation*** and tyrosine phosphorylation of ***Src*** .	positive	1
10454	10644988	2623;4602	GATA-1;c-Myb	Inhibitory ***interaction*** of ***c-Myb*** and ***GATA-1*** via transcriptional co-activator CBP .	parallel	1
10455	10644988	4602;1387	c-Myb;CBP	The exclusive ***binding*** of GATA-1 and ***c-Myb*** to ***CBP*** is probably the molecular basis for the mutual inhibition of their transcriptional activity .	parallel	1
10456	10644988	2623;1387	GATA-1;CBP	The exclusive ***binding*** of ***GATA-1*** and c-Myb to ***CBP*** is probably the molecular basis for the mutual inhibition of their transcriptional activity .	parallel	1
10457	10644990	1999;7040	ELF3;TGF-beta	The epithelium-specific transcription factor , ERT/ESX/ESE-1 / ***ELF3*** , ***binds*** to the ***TGF-beta*** RII promoter in a sequence specific manner and regulates its expression .	parallel	1
10458	10644996	7157;1877	p53;p120E4F	Here we demonstrate that ***p53*** ***binds*** to the E1A-regulated transcription factor ***p120E4F*** , a transcriptional repressor of the adenovirus E4 promoter .	parallel	1
10459	10644996	1877;7157	p120E4F;p53	Although ***p120E4F*** can also ***bind*** to mutant ***p53*** , the growth suppression induced by overexpression of the protein is severely reduced in a cell line that contains mutant p53 .	parallel	1
10460	10644997	5728;3611	MMAC1;integrin-linked kinase	In addition , we show that ***MMAC1*** expression ***inhibits*** ***integrin-linked kinase*** activity .	negative	1
10461	10644997	5728;3611	MMAC1;integrin-linked kinase	The ***MMAC1*** tumor suppressor phosphatase ***inhibits*** phospholipase C and ***integrin-linked kinase*** activity .	negative	1
10462	10644998	22924;10297	EB3;APCL	Since APCL is also expressed highly and specifically in the central nervous system , ******APCL-EB3****** ***interaction*** may be specific to the CNS , possibly involving stability and/or extension of microtubules during neuritogenesis .	parallel	1
10463	10645001	7157;4193	p53;MDM2	Nuclear exclusion of ***p53*** in a subset of tumors ***requires*** ***MDM2*** function .	target	0
10464	10645001	1029;4193	ARF;MDM2	Inhibition of MDM2 expression using antisense oligonucleotide , ***inhibition*** of ***MDM2*** function by the tumor suppressor ***ARF*** or a MDM2 deletion mutant result in the accumulation of nuclear p53 .	negative	1
10465	10645003	3458;4322	interferon-gamma;collagenase-3	***Inhibition*** of ***collagenase-3*** ( MMP-13 ) expression in transformed human keratinocytes by ***interferon-gamma*** is associated with activation of extracellular signal-regulated kinase-1 ,2 and STAT1 .	negative	1
10466	10645003	4322;6772	collagenase-3;STAT1	Inhibition of ***collagenase-3*** ( MMP-13 ) expression in transformed human keratinocytes by interferon-gamma is ***associated*** with activation of extracellular signal-regulated kinase-1 ,2 and ***STAT1*** .	parallel	0
10467	10645003	3458;4322	interferon-gamma;MMP-13	Here , we show , that ***interferon-gamma*** ( IFN-gamma ) markedly ***inhibits*** expression of ***MMP-13*** by human cutaneous SCC cells ( UT-SCC-7 ) and by ras-transformed human epidermal keratinocytes ( A-5 cells ) at the transcriptional level .	negative	1
10468	10645003	3458;4312	IFN-gamma;MMP-1	***IFN-gamma*** ***abolished*** the enhancement of MMP-13 and ***MMP-1*** expression by transforming growth factor-beta ( TGF-beta ) and tumor necrosis factor-alpha ( TNF-alpha ) , and inhibited invasion of A-5 cells through type I collagen .	negative	0
10469	10645003	3458;4322	IFN-gamma;MMP-13	***IFN-gamma*** ***abolished*** the enhancement of ***MMP-13*** and MMP-1 expression by transforming growth factor-beta ( TGF-beta ) and tumor necrosis factor-alpha ( TNF-alpha ) , and inhibited invasion of A-5 cells through type I collagen .	negative	0
10470	10645003	3458;4322	IFN-gamma;MMP-13	These observations identify a novel role for IFN-gamma as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells , and show that ***inhibition*** of ***MMP-13*** expression by ***IFN-gamma*** involves activation of ERK1 ,2 and STAT1 .	negative	1
10471	10645009	595;4605	cyclin D1;B-Myb	***Regulation*** of ***B-Myb*** activity by ***cyclin D1*** .	target	1
10472	10645009	595;4605	cyclin D1;B-Myb	Here , we show that ***cyclin D1*** , in contrast to cyclin A , strongly ***inhibits*** the activity of ***B-Myb*** .	negative	1
10473	10645009	595;4605	cyclin D1;B-Myb	This inhibitory effect does not involve increased phosphorylation of B-Myb but seems to rely on the formation of a specific ***complex*** of ***B-Myb*** and ***cyclin D1*** .	parallel	1
10474	10645009	595;4605	cyclin D1;B-Myb	Our work identifies B-Myb as an interacting partner for cyclin D1 and suggest that the activity of ***B-Myb*** during the cell cycle is ***controlled*** by the antagonistic effects of ***cyclin D1*** and A.	target	0
10475	10645402	7157;4193	p53;MDM2	A p53-independent pathway of p21 induction is supported by the results ; ***p53*** suppression may be ***associated*** with ***MDM2*** protein expression in a subset of cancers .	parallel	0
10476	10645925	7035;2159	tissue factor pathway inhibitor;factor Xa	BACKGROUND : ***tissue factor pathway inhibitor*** ( TFPI ) is an endogenous ***inhibitor*** of ***factor Xa*** and the coagulant initiator complex tissue factor/factor VIIa .	negative	1
10477	10646113	8548;6714	cytoplasmic protein;c-src	The csk ( C-terminal Src family kinase ) gene encodes a ***cytoplasmic protein-tyrosine*** kinase that specifically ***phosphorylates*** the negative regulatory site of ***c-src*** ( Tyr-527 ) , thereby inhibiting its kinase activity .	target	1
10478	10646500	4803;116	nerve growth factor;pituitary adenylate cyclase-activating polypeptide	Synergistic ***induction*** of ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) gene expression by ***nerve growth factor*** and PACAP in PC12 cells .	target	1
10479	10646500	4803;116	NGF;PACAP	***PACAP*** gene transcription was also ***induced*** by ***NGF*** .	target	1
10480	10646501	7124;4318	TNFalpha;MMP-9	The addition of ***TNFalpha*** or PMA ***potentiated*** RA-induced ***MMP-9*** expression with a synergic maximal effect at day 14 of RA exposure .	positive	0
10481	10646503	3725;4790	c-Jun;NF-kappaB	Together , these studies demonstrate a functional ***interaction*** between ***NF-kappaB*** and ***c-Jun*** and suggest a novel mechanism of NF-kappaB-mediated neuroprotection .	parallel	1
10482	10646512	183;4843	Angiotensin II;iNOS	We demonstrated previously that ***Angiotensin II*** ( Ang II ) ***decreases*** the expression of ***iNOS*** produced by bacterial endotoxin or cytokines in cultured astroglia prepared from adult rat brain .	negative	0
10483	10646517	627;4915	BDNF;TrkB	***BDNF*** ***binds*** to ***TrkB*** , a receptor tyrosine kinase , which results in the activation of a variety of signaling molecules to exert the various functions of BDNF .	parallel	1
10484	10646604	3784;3753	KCNQ1;KCNE1	***KCNQ1*** ( KvLQT1 ) ***interacts*** with the beta-subunit ***KCNE1*** ( IsK , minK ) to form the slow , depolarization-activated potassium current I ( Ks ) that is affected in some forms of cardiac arrhythmia .	parallel	1
10485	10646645	941;3458	B7-1;IFN-gamma	This may be related to the fact that ***B7-1*** changes the mechanisms of antitumor immunity and ***inhibits*** ***IFN-gamma*** production induced by IL-12 in vivo .	negative	1
10486	10646796	2255;2253	FGF10;Fgf8	***FGF10*** can ***induce*** ***Fgf8*** expression concomitantly with En1 and R-fng expression in chick limb ectoderm , independent of its dorsoventral specification .	target	1
10487	10646796	2253;2255	Fgf8;FGF10	A secreted molecule fibroblast growth factor (FGF)10 is involved in inducing Fgf8 expression in the prospective AER and mutual ***interaction*** between mesenchymal ***FGF10*** and ***Fgf8*** in the AER is essential for limb outgrowth .	parallel	1
10488	10646796	2255;2253	FGF10;Fgf8	It was found that ***FGF10*** is sufficient to ***induce*** ***Fgf8*** expression in the ectoderm of the foil-inserted limb bud , concomitantly with R-fng and En1 expression .	target	1
10489	10646796	2019;2253	En1;Fgf8	Thus , it is suggested that epithelial factors of ***En1*** and R-fng can ***induce*** ***Fgf8*** expression in the limb ectoderm in cooperation with a mesenchymal factor FGF10 .	target	1
10490	10646854	3479;4613	IGF-I;N-Myc	Our results demonstrate that ***IGF-I*** ***induces*** ***N-Myc*** in the KP-N-RT neuroblastoma cell line at the RNA level and establishes a clear correlation between N-Myc induction and activation of p44/42 MAPK signaling .	target	1
10491	10646854	3479;4613	IGF-I;N-Myc	We found that ***IGF-I*** ***induces*** ***N-Myc*** mRNA and protein in the KP-N-RT with maximums of four and six times more than the basal level at 2 and 3 h after stimulation , respectively .	target	1
10492	10646860	10297;1499	APCL;beta-catenin	***APCL*** , a central nervous system-specific sequence homologue of the adenomatous polyposis coli tumor suppressor , can ***regulate*** the cytoplasmic level of ***beta-catenin*** as the adenomatous polyposis coli tumor suppressor does , but its overall biological function remains unclear .	target	1
10493	10646861	5324;3481	PLAG1;IGF-II	***PLAG1*** , the main translocation target in pleomorphic adenoma of the salivary glands , is a positive ***regulator*** of ***IGF-II*** .	positive	1
10494	10646861	5324;3481	PLAG1;IGF-II	We show that ***PLAG1*** ***binds*** ***IGF-II*** promoter 3 and stimulates its activity .	parallel	1
10495	10646863	29128;7153	ICBP90;topoisomerase IIalpha	Overexpression of ***ICBP90*** in COS-1-transfected cells ***induced*** an enhanced expression of endogenous ***topoisomerase IIalpha*** .	target	1
10496	10646865	2113;4249	ets-1;GnT-V	GnT-V mRNA expression was increased by the induction of c-ets-1 , suggesting that the ***ets-1*** transcription factor directly ***regulates*** the transcription of ***GnT-V*** .	target	1
10497	10646865	2113;4249	c-ets-1;GnT-V	***GnT-V*** mRNA expression was ***increased*** by the induction of ***c-ets-1*** , suggesting that the ets-1 transcription factor directly regulates the transcription of GnT-V .	positive	0
10498	10646866	4609;7422	c-Myc;vascular endothelial growth factor	***c-Myc*** suppresses the tumorigenicity of lung cancer cells and ***down-regulates*** ***vascular endothelial growth factor*** expression .	negative	1
10499	10646893	3481;4313	IGF-II;matrix metalloproteinase-2	Quantitative gelatin-based zymography identified that ***matrix metalloproteinase-2*** ( MMP-2 ) activity generated from HUVECs was ***increased*** by ***IGF-II*** .	positive	0
10500	10646893	3481;4313	IGF-II;MMP-2	This induction of MMP-2 activity was correlated with Northern blot analysis , showing in HUVECs that ***IGF-II*** ***increased*** the expression of ***MMP-2*** mRNA , while it did not affect that of TIMP-2 , a tissue inhibitor of MMP-2 .	positive	0
10501	10647992	959;958	CD40-L;CD40	Therefore it is now thought that ******CD40-CD40-L****** ***interactions*** play a more general role in immune regulation .	parallel	1
10502	10647992	959;958	CD40-L;CD40	This article reviews recent developments in this field of research , with main emphasis on ( 1 ) structure and expression of CD40 and its ligand ; ( 2 ) CD40 signal transduction ; ( 3 ) in vitro function of CD40 on different cell types ; and ( 4 ) in vivo functions of ******CD40/CD40-L****** ***interactions*** .	parallel	1
10503	10647993	7124;3458	tumor necrosis factor alpha;IFN-gamma	In addition , these components synergistically induce secretion of ***tumor necrosis factor alpha*** ( TNF-alpha ) , which also ***synergizes*** strongly with ***IFN-gamma*** .	parallel	0
10504	10648003	3569;9332	IL-6;CD163	CD163 expression is also suppressed by proinflammatory mediators like lipopolysaccharide ( LPS ) , interferon-gamma ( IFN-gamma ) , and tumor necrosis factor alpha , whereas ***IL-6*** and the antiinflammatory cytokine interleukin-10 ( IL-10 ) strongly ***up-regulate*** ***CD163*** mRNA in monocytes and macrophages .	positive	1
10505	10648003	3586;9332	interleukin-10;CD163	CD163 expression is also suppressed by proinflammatory mediators like lipopolysaccharide ( LPS ) , interferon-gamma ( IFN-gamma ) , and tumor necrosis factor alpha , whereas IL-6 and the antiinflammatory cytokine ***interleukin-10*** ( IL-10 ) strongly ***up-regulate*** ***CD163*** mRNA in monocytes and macrophages .	positive	1
10506	10648121	960;6402	CD44;CD62L	We show that , unlike many other stimuli such as B cell mitogens , cytokines , and surrogate antigen , alone or in combination , an alloreactive Th2 clonal line ***induces*** splenic B cells to become cell surface peanut agglutinin ( PNA ) ( hi ) , Ig ( lo ) , ***CD62L*** ( lo ) , and ***CD44*** ( hi ) to produce mRNA for M17 and to express a GC-specific transgene even without B cell receptor ligation .	target	1
10507	10648121	6402;960	CD62L;CD44	We show that , unlike many other stimuli such as B cell mitogens , cytokines , and surrogate antigen , alone or in combination , an alloreactive Th2 clonal line ***induces*** splenic B cells to become cell surface peanut agglutinin ( PNA ) ( hi ) , Ig ( lo ) , ***CD62L*** ( lo ) , and ***CD44*** ( hi ) to produce mRNA for M17 and to express a GC-specific transgene even without B cell receptor ligation .	target	1
10508	10648122	958;959	CD40;CD154	Finally , we present evidence that the effects of ******CD154-CD40****** ***interactions*** on HUVEC chemokine production are independent of IL-1beta production .	parallel	1
10509	10648122	958;959	CD40;CD154	These findings demonstrate that ******CD154-CD40****** ***interactions*** induce endothelial cells to produce specific neutrophil and mononuclear cell chemoattractants .	parallel	1
10510	10648122	958;959	CD40;CD154	******CD154-CD40****** ***interactions*** play key roles in humoral and cellular immune responses .	parallel	1
10511	10648241	100506658;7082	occludin;ZO-1	We propose that the phosphorylation of one form of occludin ( band 2 , 65-67 kDa ) during late cleavage , which leads to its exclusive conversion from a Triton X-100-soluble to - insoluble pool , may regulate ***occludin*** ***association*** with ***ZO-1*** ( & agr ;) + and membrane assembly , and thereby act to control completion of TJ biogenesis and the timing of blastocyst formation .	parallel	0
10512	10648383	7852;6387	CXCR-4;stromal cell-derived factor-1	The chemokine ***stromal cell-derived factor-1*** ( SDF-1 ) , and its ***receptor*** , ***CXCR-4*** , have been implicated in the homing and mobilization of human CD34 ( + ) cells .	parallel	1
10513	10648383	6387;952	SDF-1;CD38	In synergy with cytokines , ***SDF-1*** ***increased*** PB CD34 ( + ) and CD34 ( high ) ***CD38*** ( low ) cell expansion and colony formation .	positive	0
10514	10648385	11183;1399	GCKR;CRKL	Detection of the ******CRKL-GCKR****** ***interaction*** required the SH3 domains of CRKL and 2 regions in GCKR-1 between amino acids 387 and 395 that contains a consensus SH3 binding motif and the other between amino acids 599 and 696 .	parallel	1
10515	10648385	1398;11183	CRK;GCKR	***CRK*** or CRKL overexpression ***increased*** ***GCKR*** catalytic activity .	positive	0
10516	10648385	1399;11183	CRKL;GCKR	CRK or ***CRKL*** overexpression ***increased*** ***GCKR*** catalytic activity .	positive	0
10517	10648395	3562;3692	IL3;p27	Supraphysiological concentrations of ***IL3*** or SCF ***prevent*** ***p27*** ( KIP1 ) elevation and override the integrin-mediated inhibition of entry into S phase .	negative	0
10518	10648395	4254;3692	SCF;p27	Supraphysiological concentrations of IL3 or ***SCF*** ***prevent*** ***p27*** ( KIP1 ) elevation and override the integrin-mediated inhibition of entry into S phase .	negative	0
10519	10648403	3684;3683	CD11b;CD11a	Sequential ***binding*** of ***CD11a/CD18*** and ***CD11b/CD18*** defines neutrophil capture and stable adhesion to intercellular adhesion molecule-1 .	parallel	1
10520	10648403	3684;3689	CD11b;CD18	Sequential ***binding*** of CD11a/CD18 and ******CD11b/CD18****** defines neutrophil capture and stable adhesion to intercellular adhesion molecule-1 .	parallel	1
10521	10648403	3689;3683	CD18;CD11a	Sequential ***binding*** of ***CD11a/CD18*** and ***CD11b/CD18*** defines neutrophil capture and stable adhesion to intercellular adhesion molecule-1 .	parallel	1
10522	10648409	79581;998	PAR-1;cdc42	***PAR-1*** stimulation also rapidly and extensively ***activates*** ***cdc42*** , though , in contrast to rac , some cdc42 associates with the actin cytoskeleton in resting platelets , and the bound fraction increases during stimulation .	positive	1
10523	10648410	5967;10507	PTP;CD100	Immunodepletion and Western blotting experiments demonstrated that CD45 was the ***PTP*** ***associated*** with ***CD100*** in cell lines displaying pre-B , activated B , and pre-plasma cell phenotypes .	parallel	0
10524	10648410	10507;5967	CD100;PTP	CD148 , the other transmembrane PTP known to be implicated in lymphocyte signaling pathways , was either only partly involved in the CD100-associated PTP activity or not expressed in plasma cell lines , indicating the ***association*** of ***CD100*** with another main ***PTP*** .	parallel	0
10525	10648413	4254;3815	SCF;c-kit	We conclude that ******c-kit/SCF****** ***interactions*** in vivo are dispensable for the commitment of HSC to the NK lineage , but they provide essential signals for generating normal numbers of fully mature NK cells .	parallel	1
10526	10648414	2261;3569	FGFR3;interleukin-6	To investigate the mechanism by which ***FGFR3*** overexpression ***promotes*** MM development , ***interleukin-6*** ( IL-6 ) - dependent murine B9 cells were transduced with retroviruses expressing functional wild-type or constitutively activated mutant FGFR3 .	positive	0
10527	10648420	958;7157	CD40;p53	Using p21-luciferase reporter assays , we confirmed that ***CD40*** ***induces*** ***p53*** transactivation in RPMI 8226 and HS Sultan cells cultured under permissive , but not restrictive , conditions .	target	1
10528	10648420	958;1026	CD40;p21	Furthermore , ***CD40*** activation of these MM cells under permissive , but not restrictive , temperatures ***increased*** the expression of p53 and ***p21*** mRNA and protein .	positive	0
10529	10648420	958;7157	CD40;p53	Furthermore , ***CD40*** activation of these MM cells under permissive , but not restrictive , temperatures ***increased*** the expression of ***p53*** and p21 mRNA and protein .	positive	0
10530	10648444	351;3458	Abeta;IFN-gamma	These findings , taken together , indicate that the ***association*** of ***Abeta*** with ***IFN-gamma*** stimulates NO ( 2 ) ( - ) production via induction of iNOS gene expression in skeletal muscle cells , with occasional evidence for nuclear changes suggesting apoptotic morphology .	parallel	0
10531	10648469	3606;3458	IL-18;IFN-gamma	***IL-18*** immunoneutralization ***prevented*** ***IFN-gamma*** release and protected from liver injury induced by con A.	negative	0
10532	10648469	3606;51497	IL-18;Th1-like	CONCLUSIONS : ***Th1-like*** response induced by con A is ***mediated*** by ***IL-18*** and requires activation of multiple caspases .	target	0
10533	10648566	3552;5594	IL-1alpha;ERK	Interleukin 1alpha ( ***IL-1alpha*** ) strongly ***induced*** ***ERK*** activation as well as NF-kappaB activation .	target	1
10534	10648571	2064;1398	ErbB2;Crk	Overexpression of ***ErbB2*** in cells devoid of other ErbB receptor members is sufficient to ***promote*** ERK activation and ***CAS/Crk*** coupling , leading to cell migration .	positive	0
10535	10648571	2064;5594	ErbB2;ERK	Overexpression of ***ErbB2*** in cells devoid of other ErbB receptor members is sufficient to ***promote*** ***ERK*** activation and CAS/Crk coupling , leading to cell migration .	positive	0
10536	10648599	5594;2969	ERK;TFII-I	Serum stimulation enhances complex ***formation*** between ***TFII-I*** and ***ERK*** , and dominant-negative Ras abrogates this interaction .	parallel	0
10537	10648599	5594;2969	ERK;TFII-I	In addition , TFII-I can be phosphorylated in vitro by ERK and mutation of consensus MAP kinase substrate sites at serines 627 and 633 impairs the ***phosphorylation*** of ***TFII-I*** by ***ERK*** and its activity on the c-fos promoter .	target	1
10538	10648599	5594;2969	ERK;TFII-I	In addition , ***TFII-I*** can be ***phosphorylated*** in vitro by ***ERK*** and mutation of consensus MAP kinase substrate sites at serines 627 and 633 impairs the phosphorylation of TFII-I by ERK and its activity on the c-fos promoter .	target	1
10539	10648599	5594;2969	ERK;TFII-I	These results suggest that ***ERK*** ***regulates*** the activity of ***TFII-I*** by direct phosphorylation .	target	1
10540	10648599	2969;2353	TFII-I;c-fos	We have previously shown that ***TFII-I*** ***enhances*** transcriptional activation of the ***c-fos*** promoter through interactions with upstream elements in a signal-dependent manner .	positive	0
10541	10648599	387;2969	RhoA;TFII-I	Here we demonstrate that activated Ras and ***RhoA*** ***synergize*** with ***TFII-I*** for c-fos promoter activation , whereas dominant-negative Ras and RhoA inhibit these effects of TFII-I .	parallel	0
10542	10648599	387;2969	RhoA;TFII-I	Here we demonstrate that activated Ras and RhoA synergize with TFII-I for c-fos promoter activation , whereas dominant-negative Ras and ***RhoA*** ***inhibit*** these effects of ***TFII-I*** .	negative	1
10543	10648599	2969;5594	TFII-I;ERK	Consistent with this , we have found that ***TFII-I*** forms an in vivo ***complex*** with extracellular signal-related kinase ( ***ERK*** ) .	parallel	1
10544	10648599	5594;2969	ERK;TFII-I	Moreover , the ***interaction*** between ***TFII-I*** and ***ERK*** can be regulated .	parallel	1
10545	10648601	5608;1432	MKK6;p38 mitogen-activated protein kinase	We have investigated the signaling pathways that are involved in this response , and cotransfection with plasmids which harbor either wild-type or constitutively active ***MKK6*** , a specific immediate upstream ***activator*** of ***p38 mitogen-activated protein kinase*** ( MAPK ) , increases IRES-mediated translation .	positive	1
10546	10648602	1147;3551	IKKalpha;IKKbeta	Activation of the heterodimeric IkappaB kinase alpha ( IKKalpha ) - IKKbeta complex is directional : ***IKKalpha*** ***regulates*** ***IKKbeta*** under both basal and stimulated conditions .	target	1
10547	10648602	1147;3551	IKKalpha;IKKbeta	Here we demonstrate that assembly of IKKalpha with IKKbeta in the heterodimeric signalsome serves two important functions : ( i ) in unstimulated cells , ***IKKalpha*** ***inhibits*** the constitutive IkappaB kinase activity of ***IKKbeta*** ; ( ii ) in activated cells , IKKalpha kinase activity is required for the induction of IKKbeta .	negative	1
10548	10648602	1147;9020	IKKalpha;NIK	The introduction of kinase-inactive ***IKKalpha*** , activation loop mutants of IKKalpha , or IKKalpha antisense RNA into 293 or HeLa cells ***blocks*** ***NIK*** ( NF-kappaB-inducing kinase ) - induced phosphorylation of the IKKbeta activation loop occurring in functional signalsomes .	negative	0
10549	10648602	9020;1147	NIK;IKKalpha	In contrast , catalytically inactive mutants of IKKbeta do not block ***NIK-mediated*** ***phosphorylation*** of ***IKKalpha*** in these macromolecular signaling complexes .	target	1
10550	10648606	10036;5111	p150;PCNA	The largest subunit ( ***p150*** ) of this factor ***interacts*** directly with proliferating cell nuclear antigen ( ***PCNA*** ) , and critical regions for this interaction on both proteins have been mapped .	parallel	1
10551	10648610	4193;7157	Mdm2;p53	The ***binding*** of ***Mdm2*** to ***p53*** is required for targeting p53 for degradation .	parallel	1
10552	10648611	5884;5810	Rad17;Rad1	However , two-hybrid interaction , in vitro association and in vivo overexpression experiments suggest a transient ***interaction*** between ***Rad1*** and ***Rad17*** .	parallel	1
10553	10648611	3364;5810	Hus1;Rad1	The ******Rad1-Rad9-Hus1-B****** ***complex*** is readily detectable , but upon cofractionation of soluble extracts , the majority of each protein is not present in this complex .	parallel	1
10554	10648611	3364;5883	Hus1;Rad9	The ******Rad1-Rad9-Hus1-B****** ***complex*** is readily detectable , but upon cofractionation of soluble extracts , the majority of each protein is not present in this complex .	parallel	1
10555	10648611	5883;5810	Rad9;Rad1	The ******Rad1-Rad9-Hus1-B****** ***complex*** is readily detectable , but upon cofractionation of soluble extracts , the majority of each protein is not present in this complex .	parallel	1
10556	10648614	5610;4790	PKR;NF-kappaB	Taken together , these results demonstrate that ***PKR-dependent*** dsRNA ***induction*** of ***NF-kappaB*** is mediated by NIK and IKK activation .	target	1
10557	10648614	5610;4790	double-stranded-RNA-activated protein kinase;NF-kappaB	***NF-kappaB*** ***activation*** by ***double-stranded-RNA-activated protein kinase*** ( PKR ) is mediated through NF-kappaB-inducing kinase and IkappaB kinase .	positive	1
10558	10648614	5610;4790	PKR;NF-kappaB	The mechanism by which ***PKR*** ***mediates*** activation of ***NF-kappaB*** is unknown .	target	0
10559	10648614	5610;4790	PKR;NF-kappaB	Moreover , ***PKR*** was required to establish a sustained response to tumor necrosis factor alpha ( TNF-alpha ) and to ***potentiate*** activation of ***NF-kappaB*** by cotreatment with TNF-alpha and IFN-gamma .	positive	0
10560	10648616	7161;2033	p73;p300	The ******p73-p300****** ***interaction*** was confirmed in vitro by glutathione S-transferase-protein association assays and in vivo by coimmunoprecipitating the overexpressed p300 and p73 in human p53-free small-cell lung carcinoma H1299 or osteosarcoma Saos-2 cells .	parallel	1
10561	10648629	2549;1956	Gab1;EGFR	We show that ***Gab1*** ***associates*** with the ***EGFR*** in vivo and in vitro via pTyr sites 1068 and 1086 in the carboxy-terminal tail of the receptor and that overexpression of Gab1 potentiates EGF-induced activation of the mitogen-activated protein kinase and Jun kinase signaling pathways .	parallel	0
10562	10648730	2903;1742	NR2A;PSD-93/95	These studies suggest that there is a preference for ***complexes*** of ******NR2A/PSD-93/95****** and NR2B/SAP-102 .	parallel	1
10563	10648730	2904;2903	NR2B;NR2A	These studies suggest that there is a preference for ***complexes*** of ***NR2A/PSD-93/95*** and ***NR2B/SAP-102*** .	parallel	1
10564	10648730	2904;1742	NR2B;PSD-93/95	These studies suggest that there is a preference for ***complexes*** of ***NR2A/PSD-93/95*** and ***NR2B/SAP-102*** .	parallel	1
10565	10648730	2904;1741	NR2B;SAP-102	These studies suggest that there is a preference for ***complexes*** of NR2A/PSD-93/95 and ******NR2B/SAP-102****** .	parallel	1
10566	10648730	1741;2903	SAP-102;NR2A	These studies suggest that there is a preference for ***complexes*** of ***NR2A/PSD-93/95*** and ***NR2B/SAP-102*** .	parallel	1
10567	10648730	1741;1742	SAP-102;PSD-93/95	These studies suggest that there is a preference for ***complexes*** of ***NR2A/PSD-93/95*** and ***NR2B/SAP-102*** .	parallel	1
10568	10648788	5432;5437	rpb3;Rpb8	Coexpression of various combinations of a few subunits revealed that Rpb11 enhances ******rpb3-Rpb8****** ***interaction*** and consequently Rpb8 enhances Rpb1-rpb3 interaction to some extent .	parallel	1
10569	10648788	5430;5432	Rpb1;rpb3	Coexpression of various combinations of a few subunits revealed that Rpb11 enhances rpb3-Rpb8 interaction and consequently Rpb8 enhances ******Rpb1-rpb3****** ***interaction*** to some extent .	parallel	1
10570	10648788	5439;5432	Rpb11;rpb3	Coexpression of various combinations of a few subunits revealed that ***Rpb11*** ***enhances*** ***rpb3-Rpb8*** interaction and consequently Rpb8 enhances Rpb1-rpb3 interaction to some extent .	positive	0
10571	10648788	5439;5437	Rpb11;Rpb8	Coexpression of various combinations of a few subunits revealed that ***Rpb11*** ***enhances*** ***rpb3-Rpb8*** interaction and consequently Rpb8 enhances Rpb1-rpb3 interaction to some extent .	positive	0
10572	10648816	3336;3329	GroES;GroEL	The affinity of the ******GroEL/GroES****** ***complex*** for peptides under conditions of protein folding .	parallel	1
10573	10648816	3336;3329	GroES;GroEL	We further report that the ******GroEL/GroES****** ***complex*** has a high affinity for peptides during ATP hydrolysis when protein substrates would undergo repeated cycles of assisted folding .	parallel	1
10574	10648820	867;1436	Cbl;Fms	***Association*** of ***Cbl*** with ***Fms*** and p85 in response to macrophage colony-stimulating factor .	parallel	0
10575	10648820	867;23368	Cbl;p85	***Association*** of ***Cbl*** with Fms and ***p85*** in response to macrophage colony-stimulating factor .	parallel	0
10576	10648820	1436;1435	Fms;M-CSF	Tyrosine phosphorylation of Cbl and its association with signal-transducing molecules in response to macrophage colony-stimulating factor ( M-CSF ) were analyzed by using cell lines which express the wild-type and a mutant ***M-CSF*** ***receptor*** , ***Fms*** .	parallel	1
10577	10648820	1436;867	Fms;Cbl	We found that in a clone , F723 TF-1 cells expressing mutant Fms in which tyrosine 723 had been substituted with phenylalanine , the M-CSF stimulation-dependent ***association*** between ***Cbl*** and ***Fms*** was markedly impaired .	parallel	0
10578	10648830	9255;840	endothelial monocyte-activating polypeptide II;caspase-7	The ***endothelial monocyte-activating polypeptide II*** ( EMAP II ) is a ***substrate*** for ***caspase-7*** .	parallel	1
10579	10648835	1948;2051	Ephrin-B2;EphB6	***Ephrin-B2*** is a candidate ***ligand*** for the Eph receptor , ***EphB6*** .	parallel	1
10580	10648883	7857;1385	SgII;CREB	***SgII*** promoter activities in the neuroblastoma cell lines ***correlated*** not only with the levels of SgII but also the levels of the cyclic AMP response element-binding protein ***CREB*** which were highest in BE ( 2 ) - M17 cells and lowest in SH-SY5Y cells .	parallel	0
10581	10649249	4352;7066	c-mpl;thrombopoietin	Expression of ***thrombopoietin*** and its ***receptor*** ( ***c-mpl*** ) in chronic myelogenous leukemia : correlation with disease progression and response to therapy .	parallel	1
10582	10649249	4352;7066	c-mpl;thrombopoietin	***thrombopoietin*** ( TPO ) and its ***receptor*** , ***c-mpl*** , support the proliferation of multiple types of immature hematopoietic progenitor cells , and induce clonal growth of leukemic cells .	parallel	1
10583	10649432	2247;1278	FGF-2;type I procollagen	Extracellular-signal regulated kinase signaling pathway mediates ***downregulation*** of ***type I procollagen*** gene expression by ***FGF-2*** , PDGF-BB , and okadaic acid in osteoblastic cells .	negative	1
10584	10649441	4790;5970	p50;p65	Two PMA-inducible nuclear protein complexes were found to bind to a putative NF-kappaB site at -41 and were identified as a ******p65/p50****** ***heterodimer*** and a p50/50 homodimer of NF-kappaB family .	parallel	1
10585	10649441	4790;5970	p50;p65	Mutations in the -41 NF-kappaB site attenuated the ***p50-mediated*** ***suppression*** of the ***p65*** transactivation of the FN promoter .	negative	1
10586	10649446	2274;4176	FHL2;hCDC47	Protein-protein ***interaction*** of ***FHL2*** , a LIM domain protein preferentially expressed in human heart , with ***hCDC47*** .	parallel	1
10587	10649717	1437;6347	GM-CSF;MCP-1	Recombinant ***GM-CSF*** at concentrations found during CAPD peritonitis in vivo significantly ***increased*** the release of IL-8 and ***MCP-1*** in a time - and dose-dependent manner .	positive	0
10588	10650002	7186;5599	TRAF2;JNK	Dominant-negative ***TRAF2*** ***inhibited*** activation of ***JNK*** by IRE1 .	negative	1
10589	10650928	1392;5443	CRF;ACTH	Finally , in cultured rat pituitary cells that express native CRF1 receptors , ***CRF-SAP*** ***suppressed*** CRF-induced ( 1 nM ) ***ACTH*** release .	negative	1
10590	10650928	4068;5443	SAP;ACTH	Finally , in cultured rat pituitary cells that express native CRF1 receptors , ***CRF-SAP*** ***suppressed*** CRF-induced ( 1 nM ) ***ACTH*** release .	negative	1
10591	10650935	4881;4878	NPR-A;ANP	The expression of ***ANP*** and CNP as well as their cognate guanylyl cyclase ***receptors*** ( ***NPR-A*** and NPR-B , respectively ) have been detected in the rat ovary .	parallel	1
10592	10650935	4882;4878	NPR-B;ANP	The expression of ***ANP*** and CNP as well as their cognate guanylyl cyclase ***receptors*** ( NPR-A and ***NPR-B*** , respectively ) have been detected in the rat ovary .	parallel	1
10593	10650939	2118;3248	PEA3;PGDH	Cotransfection of A-CREB , a dominant negative to CREB , inhibited ***stimulation*** of ***PGDH-2368*** / luc3 by ***PEA3*** in myometrial SMC , whereas treatment with 8-bromo-cAMP moderately enhanced promoter activity .	positive	0
10594	10650939	1385;3248	CREB;PGDH	Cotransfection of ***A-CREB*** , a dominant negative to CREB , ***inhibited*** stimulation of ***PGDH-2368*** / luc3 by PEA3 in myometrial SMC , whereas treatment with 8-bromo-cAMP moderately enhanced promoter activity .	negative	1
10595	10650943	3643;5781	insulin receptor;Shp-2	We were interested in finding a new molecule ( s ) , tyrosine phosphorylated by the ***insulin receptor*** ( IR ) , that could ***interact*** with ***Shp-2*** .	parallel	1
10596	10650943	10818;5781	FRS2;Shp-2	After cloning the entire cDNA , we found that 1 ) in the yeast two-hybrid system , ***FRS2*** ***interacts*** with ***Shp-2*** in a fashion dependent on the presence of the IR ; and 2 ) in the PC12/IR cell-line , insulin leads to an increase in FRS2 association with the phosphatase .	parallel	1
10597	10650962	9607;1392	CART;CRH	***CART*** ***activates*** central ***CRH*** neurons as well as both magnocellular ( presumably neurohypophysial ) and parvicellular ( presumably descending ) oxytocinergic neurons of the PVN .	positive	1
10598	10650967	7038;5172	thyroglobulin;Pendrin	***Pendrin*** , the protein encoded by the Pendred syndrome gene ( PDS ) , is an apical porter of iodide in the thyroid and is ***regulated*** by ***thyroglobulin*** in FRTL-5 cells .	target	1
10599	10651020	8743;8797	APO2L;APO2	***APO2*** ***ligand*** ( ***APO2L*** ) / TRAIL is a novel member of the tumor necrosis factor cytokine family and a potent inducer of apoptosis in tumor cell lines .	parallel	1
10600	10651065	887;3067	gastrin receptor;HDC	Thus ***CCK-B/gastrin receptor*** blockade of hypergastrinemic animals ***reduces*** the ***HDC*** mRNA expression in normal mucosa but not in ECL cell carcinoids .	positive	1
10601	10651223	1380;930	CD21;CD19	The ******CD19/CD21****** ***complex*** is categorized among the ' response regulator ' class of receptors which determine the magnitude and outcomes of B cell receptor signals .	parallel	1
10602	10651223	1380;930	CD21;CD19	Since CD19 serves as a central regulator of signaling thresholds in B cells , the ******CD19/CD21****** ***complex*** may be an appropriate target for suppressing the development of autoimmunity .	parallel	1
10603	10651245	23468;3930	HP1;LBR	These include interactions between nuclear lamins and core histones , Lamina Associated Polypeptide 2 ( LAP2 ) , and the Barrier to Autointegration Factor ( BAF ) and ***interactions*** between lamin B receptor ( ***LBR*** ) and the chromodomain protein ***HP1*** .	parallel	1
10604	10651629	1029;1021	p19;CDK6	The important results are summarized as follows : ( a ) some residues at loops 1 and 2 , but not 3 , are important for the inhibitory function of p18 , similar to the results for p16 ; ( b ) two residues at the first helix-turn-helix motif and two at the third are important for inhibition ; ( c ) while the results generally agree with the prediction based on the crystal structures of p16-CDK6 and ******p19-CDK6****** binary ***complexes*** , there are significant differences in a few residues , suggesting that the interactions in the binary complexes may not accurately represent the interactions in the ternary complexes ( in the presence of cyclin D2 ) ; ( d ) most importantly , the extra loop of p18 appears to contribute to the function of p18 , even though the crystal structure of the p19INK4D-CDK6 complex indicates no interactions involving this loop ; ( e ) detailed analyses of the crystal structures and the functional results suggest that there are notable differences in the interactions between different members of the INK4 family and CDKs .	parallel	1
10605	10651739	3689;3385	LFA-1;ICAM-3	******ICAM-3/LFA-1****** ***binding*** during a lymphocyte-mediated cellular immune response has been well established ; however , its role in the marrow compartment is unclear .	parallel	1
10606	10651751	6750;2688	somatostatin;pituitary growth hormone	OBJECTIVE : ***somatostatin*** , acting via specific receptors in the anterior pituitary , tonically ***inhibits*** ***pituitary growth hormone*** secretion and somatotroph proliferation .	negative	1
10607	10651761	3952;3569	leptin;IL-6	***leptin*** was strongly ***correlated*** with BMI ( r = 0.61 , P < 0.001 ) , but also with sialic acid ( r = 0.40 , P = 0.01 ) and ***IL-6*** ( r = 0.38 , P = 0.04 ) .	parallel	0
10608	10651811	10049;3308	DnaJ;Hsp70	The membrane-bound ***DnaJ*** protein located at the cytosolic site of glyoxysomes specifically ***binds*** the cytosolic isoform 1 of ***Hsp70*** but not other Hsp70 species .	parallel	1
10609	10651866	7852;6387	CXCR4;stromal cell-derived factor 1	***CXCR4*** is the Gi protein-linked seven-transmembrane ***receptor*** for the alpha chemokine ***stromal cell-derived factor 1*** ( SDF-1 ) , a chemoattractant for lymphocytes .	parallel	1
10610	10651889	3553;1432	IL-1beta;p38	The data described indicate that ***IL-1beta*** and H2O2 ***increase*** the activity of two stress-activated mitogen-activated protein kinases , c-Jun NH2-terminal kinase ( JNK ) and ***p38*** in vitro , while age-related increases in both kinases were observed .	positive	0
10611	10651905	10254;9146	Hbp;hrs	***Hbp*** was ***co-immunoprecipitated*** with ***hrs*** , and its intracellular localization was similar to that of hrs .	parallel	1
10612	10651905	9146;10254	hrs;Hbp	The ***association*** between ***Hbp*** and ***hrs*** was mediated through the coiled coil motifs in Hbp and hrs .	parallel	0
10613	10651905	10254;9146	Hbp;hrs	CONCLUSIONS : ***Hbp*** is thought to be closely ***associated*** with ***hrs*** on early endosomes .	parallel	0
10614	10651941	959;958	CD40 ligand;CD40	A polymorphic ***CD40 ligand*** ( CD154 ) molecule mediates CD40-dependent signalling but ***interferes*** with the ability of soluble ***CD40*** to functionally block CD154 : CD40 interactions .	negative	0
10615	10651941	958;959	CD40;CD154	In contrast , we found that the 5c8 mAb , which recognized the polymorphic molecule to a similar extent as wild-type CD154 , effectively blocked the ***interaction*** between ***CD154/G219R*** and ***CD40*** as measured by CD80 expression .	parallel	1
10616	10651943	3458;356	interferon-gamma;CD95L	In four breast cancer cell lines , ***CD95L*** expression was ***increased*** by ***interferon-gamma*** ( IFN-gamma ) , which resulted in higher levels of CD95L-specific apoptosis in co-cultured Jurkat T cells .	positive	0
10617	10651950	3586;3553	IL-10;IL-1beta	***IL-10*** also ***inhibited*** the production of interleukin-1beta ( ***IL-1beta*** ) and the expression of mRNA for IL-1beta , indicating that this cytokine has a broad anti-inflammatory effect .	negative	1
10618	10651992	4914;627	TrkA;brain-derived neurotrophic factor	Here , we show that , during hair follicle morphogenesis in C57BL/6 mice , nerve growth factor , ***brain-derived neurotrophic factor*** and their corresponding high-affinity tyrosine kinase ***receptors*** , ***TrkA*** and TrkB , show stringently controlled spatiotemporal expression patterns in the follicular epithelium and mesenchyme .	parallel	1
10619	10651992	4915;627	TrkB;brain-derived neurotrophic factor	Here , we show that , during hair follicle morphogenesis in C57BL/6 mice , nerve growth factor , ***brain-derived neurotrophic factor*** and their corresponding high-affinity tyrosine kinase ***receptors*** , TrkA and ***TrkB*** , show stringently controlled spatiotemporal expression patterns in the follicular epithelium and mesenchyme .	parallel	1
10620	10652041	5972;5340	renin;plasmin	Evidence also suggested that the ***PA/plasmin*** system and the ***renin-angiotensin*** system ( RAS ) ***interact*** together to affect the risk of fibrosis and thrombosis .	parallel	1
10621	10652041	5054;1636	PAI-1;ACE	Hence , we also studied the synergistic ***effect*** between ***PAI-1*** and angiotensin-converting enzyme ( ***ACE*** ) gene polymorphisms .	parallel	0
10622	10652049	7040;7124	TGF-beta1;TNF-alpha	The addition of exogenous ***TGF-beta1*** ( 0.1 to 10 ng/mL ) ***decreased*** AGE-beta2m-induced ***TNF-alpha*** production and increased IL-1Ra production in a dose-dependent fashion .	negative	0
10623	10652049	7040;3557	TGF-beta1;IL-1Ra	The addition of exogenous ***TGF-beta1*** ( 0.1 to 10 ng/mL ) decreased AGE-beta2m-induced TNF-alpha production and ***increased*** ***IL-1Ra*** production in a dose-dependent fashion .	positive	0
10624	10652160	6288;4018	serum amyloid A protein;lipoprotein	Acute phase ***serum amyloid A protein*** ***increases*** high density ***lipoprotein*** binding to human peripheral blood mononuclear cells and an endothelial cell line .	positive	0
10625	10652160	4018;2736	lipoprotein;THP-1	Incorporation of SAA into HDL at concentrations equivalent to those found physiologically in moderate inflammation mediated a 1.5-fold increase in the binding of HDL to adherent peripheral blood mononuclear cells but had no effect on ***binding*** of the ***lipoprotein*** to the monocyte cell lines , U937 or ***THP-1*** .	parallel	1
10626	10652192	5972;5054	renin;PAI-1	These findings suggest that the local ***renin-angiotensin*** system ***regulates*** ***PAI-1*** expression , and that the increased PAI-1 levels may contribute to the cardiovascular remodeling in this model .	target	1
10627	10652192	183;5054	Angiotensin II;PAI-1	***Angiotensin II*** has been shown to ***stimulate*** ***PAI-1*** in vitro .	positive	0
10628	10652211	3565;6464	IL-4;Shc	***IL-4*** ***induced*** the association of tyrosine-phosphorylated ***Shc*** with the IL-4Ralpha , whereas no detectable tyrosine phosphorylation of IRS-1 or IRS-2 was induced .	target	1
10629	10652211	6464;5335	Shc;PLCgamma1	We further found the ***association*** of ***Shc*** with ***PLCgamma1*** .	parallel	0
10630	10652215	2189;2176	FANCG;FANCC	We used the yeast two-hybrid assay to test for ***interactions*** of the FANCA , ***FANCC*** , and ***FANCG*** proteins .	parallel	1
10631	10652218	181;5443	agouti-related protein;alpha-melanocyte-stimulating hormone	Agouti protein and ***agouti-related protein*** ( AGRP ) ***antagonize*** ***alpha-melanocyte-stimulating hormone*** that binds to and activates the melanocortin-4 receptor ( MC4-R ) in the hypothalamus , thereby stimulating food intake .	negative	1
10632	10652218	5443;4160	alpha-melanocyte-stimulating hormone;MC4-R	Agouti protein and agouti-related protein ( AGRP ) antagonize ***alpha-melanocyte-stimulating hormone*** that ***binds*** to and activates the melanocortin-4 receptor ( ***MC4-R*** ) in the hypothalamus , thereby stimulating food intake .	parallel	1
10633	10652220	5970;4790	p65;p50	In DNA binding assays performed with nuclear extracts from blood MO , p50/p50 homodimers were mainly detected , whereas complexes containing p50/RelB and ******p50/p65****** ***heterodimers*** were less abundant .	parallel	1
10634	10652220	5971;4790	RelB;p50	In DNA binding assays performed with nuclear extracts from blood MO , p50/p50 homodimers were mainly detected , whereas complexes containing ******p50/RelB****** and p50/p65 ***heterodimers*** were less abundant .	parallel	1
10635	10652224	4087;4089	Smad2;Smad4	Here , we showed that TGF-beta phosphorylated Smad2 and induced ***interaction*** between ***Smad2*** and ***Smad4*** in primary T cells and the Jurkat T cell line .	parallel	1
10636	10652224	4089;4087	Smad4;Smad2	Interestingly , ligation of the T cell receptor ( TCR ) / CD3 complex with anti-CD3 mAb also phosphorylated Smad2 , but failed to induce ***interaction*** between ***Smad2*** and ***Smad4*** in the Jurkat T cell line .	parallel	1
10637	10652228	10188;4168	ACK-1;Dbl	Moreover , accumulation of the GTP-bound form of Rho and Rac within the cell paralleled ***ACK-1-dependent*** tyrosine ***phosphorylation*** of ***Dbl*** .	target	1
10638	10652228	10188;4168	ACK1;Dbl	Collectively , these findings suggest that the tyrosine kinase ***ACK1*** may act as a ***regulator*** of ***Dbl*** , which in turn activates Rho family proteins .	target	1
10639	10652241	207;5599	Rac;JNK	However , the signaling events that mediate the ***activation*** of ***JNK*** by ***Rac*** are not yet well characterized .	positive	1
10640	10652241	207;5599	Rac;JNK	To broaden our understanding of downstream mediators that ***link*** ***Rac*** signals to the ***JNK*** pathway , we investigated whether cytosolic phospholipase A ( 2 ) ( cPLA ( 2 ) ) is involved in Rac activation of JNK .	parallel	0
10641	10652241	207;5599	Rac;JNK	To broaden our understanding of downstream mediators that link Rac signals to the JNK pathway , we investigated whether cytosolic phospholipase A ( 2 ) ( cPLA ( 2 ) ) is involved in ***Rac*** ***activation*** of ***JNK*** .	positive	1
10642	10652241	207;5599	Rac;JNK	Together , our findings suggest that cPLA ( 2 ) mediates , at least partly , the signaling cascade by which ***Rac*** ***stimulates*** ***JNK*** .	positive	0
10643	10652249	2923;5610	P58;PKR	In addition to GRP78 , mRNA expression of the cochaperone ***P58*** ( IPK ) , which is the 58-kDa cellular ***inhibitor*** of the double-stranded RNA-regulated protein kinase ( ***PKR*** ) , was also shown to be suppressed by VT-treatment .	negative	1
10644	10652265	391;998	rhoG;Cdc42Hs	These data demonstrate that Trio controls a signaling cascade that activates ***rhoG*** , which in turn ***activates*** Rac1 and ***Cdc42Hs*** .	positive	1
10645	10652265	391;5879	rhoG;Rac1	These data demonstrate that Trio controls a signaling cascade that activates ***rhoG*** , which in turn ***activates*** ***Rac1*** and Cdc42Hs .	positive	1
10646	10652271	4318;7040	matrix metalloproteinase-9;TGF-beta	Cell surface-localized ***matrix metalloproteinase-9*** proteolytically ***activates*** ***TGF-beta*** and promotes tumor invasion and angiogenesis .	positive	1
10647	10652271	4313;7040	MMP-2;TGF-beta	Our observations also indicate that MMP-9 , as well as ***MMP-2*** , proteolytically ***cleaves*** latent ***TGF-beta*** , providing a novel and potentially important mechanism for TGF-beta activation .	target	1
10648	10652271	4318;7040	MMP-9;TGF-beta	Our observations also indicate that ***MMP-9*** , as well as MMP-2 , proteolytically ***cleaves*** latent ***TGF-beta*** , providing a novel and potentially important mechanism for TGF-beta activation .	target	1
10649	10652271	4318;7040	MMP-9;TGF-beta	In addition , we show that ***MMP-9*** localization to the surface of normal keratinocytes is CD44 dependent and can ***activate*** latent ***TGF-beta*** .	positive	1
10650	10652273	4790;7040	NF-kappa B;TGF-beta	A mechanism of ***suppression*** of ***TGF-beta/SMAD*** signaling by ***NF-kappa B/RelA*** .	negative	1
10651	10652273	5970;7040	RelA;TGF-beta	A mechanism of ***suppression*** of ***TGF-beta/SMAD*** signaling by ***NF-kappa B/RelA*** .	negative	1
10652	10652273	3553;4092	IL-1beta;Smad7	Following stimulation with bacterial lipopolysaccharide ( LPS ) , or the proinflammatory cytokines TNF-alpha and interleukin-1beta ( ***IL-1beta*** , NF-kappaB/RelA ***induces*** ***Smad7*** synthesis through activation of Smad7 gene transcription .	target	1
10653	10652273	4790;4092	NF-kappaB;Smad7	These results suggest a mechanism of suppression of TGF-beta/SMAD signaling by opposing stimuli mediated through the ***activation*** of inhibitory ***Smad7*** by ***NF-kappaB/RelA*** .	positive	1
10654	10652273	5970;4092	RelA;Smad7	These results suggest a mechanism of suppression of TGF-beta/SMAD signaling by opposing stimuli mediated through the ***activation*** of inhibitory ***Smad7*** by ***NF-kappaB/RelA*** .	positive	1
10655	10652277	1437;598	GM-CSF;Bcl-x	The antiapoptotic protein ***Bcl-x*** was ***induced*** by ***GM-CSF*** and IL-3 in a Stat5-dependent fashion .	target	1
10656	10652277	3562;598	IL-3;Bcl-x	The antiapoptotic protein ***Bcl-x*** was ***induced*** by GM-CSF and ***IL-3*** in a Stat5-dependent fashion .	target	1
10657	10652289	7124;5054	TNFalpha;PAI-1	In conclusion , we showed that during the induction of monocyte/macrophage differentiation , TNFalpha and PAI-1 gene expressions are activated and that synthesized ***TNFalpha*** ***up-regulates*** and prolongs , in an autocrine manner , the synthesis of ***PAI-1*** .	positive	1
10658	10652292	2113;5449	Ets-1;Pit-1	By using a series of Pit-1 internal-deletion constructs in a transient transfection protocol to reconstitute rPRL promoter activity in HeLa cells , we have determined that the functional and physical ***interaction*** of ***Pit-1*** and ***Ets-1*** is mediated via the POU homeodomain , which is common to both Pit-1 and Pit-1beta .	parallel	1
10659	10652293	1051;5743	NF-IL6;COX-2	Although mutating the two NF-IL6 sites individually did not affect COX-2 promoter activity , mutating both ***NF-IL6*** sites substantially ***inhibits*** ***COX-2*** promoter activity .	negative	1
10660	10652293	1051;5743	CCAAT/enhancer-binding protein-beta;COX-2	Moreover , overexpression of wild type ***CCAAT/enhancer-binding protein-beta*** ( C/EBPbeta ) ***augments*** ***COX-2*** promoter activity in activated mast cells and cotransfection of a dominant negative C/EBPbeta construct completely blocks COX-2 promoter/luciferase expression .	positive	0
10661	10652293	1051;5743	C/EBPbeta;COX-2	Our data suggest that in activated mast cells , a Ras/MEKK1/c-Jun NH ( 2 ) - terminal kinase signal transduction pathway activating c-Jun , a Ras/Raf-1/extracellular signal-regulated kinase pathway , and activated ***C/EBPbeta*** ***facilitate*** ***COX-2*** induction via the cyclic AMP response element and NF-IL6 sites of the COX-2 promoter .	positive	0
10662	10652293	3725;5743	c-Jun;COX-2	Our data suggest that in activated mast cells , a Ras/MEKK1/c-Jun NH ( 2 ) - terminal kinase signal transduction pathway activating ***c-Jun*** , a Ras/Raf-1/extracellular signal-regulated kinase pathway , and activated C/EBPbeta ***facilitate*** ***COX-2*** induction via the cyclic AMP response element and NF-IL6 sites of the COX-2 promoter .	positive	0
10663	10652294	3552;5879	IL1;Rac1	***IL1*** ***induced*** a rapid and sustained activation of ***Rac1*** in the thymoma cell line EL4.NOB-1 .	target	1
10664	10652318	10131;10963	TRAP1;Hop	***TRAP1*** did not form stable ***complexes*** with the classic hsp90 co-chaperones p23 and ***Hop*** ( p60 ) .	parallel	1
10665	10652318	10131;10728	TRAP1;p23	***TRAP1*** did not form stable ***complexes*** with the classic hsp90 co-chaperones ***p23*** and Hop ( p60 ) .	parallel	1
10666	10652320	462;2159	antithrombin;FXa	***antithrombin*** ***inactivated*** ***FXa*** derivatives with a similar second-order association rate constant ( k ( 2 ) ) in both the absence and presence of pentasaccharide .	negative	1
10667	10652322	5741;3479	PTH;insulin-like growth factor-1	In cyclically stretched osteocytes on flexible-bottomed plates , ***PTH*** also synergistically ***elevated*** the ***insulin-like growth factor-1*** mRNA level .	positive	0
10668	10652325	29843;5371	SENP1;PML	In addition , sentrinized ***PML*** , a tumor suppressor protein that resides in the nucleus , was selectively ***affected*** by ***SENP1*** , whereas sentrinized RanGAP1 , which is associated with the cytoplasmic fibrils of the nuclear pore complex , remained intact .	target	0
10669	10652326	6833;3767	SUR1;Kir6.2	We conclude that the glibenclamide-binding site includes amino acid residues from both halves of the molecule , that there is strong interaction between different regions of SUR1 , that NBD2 is not essential for glibenclamide binding , and that ***interactions*** between ***Kir6.2*** and ***SUR1*** participate in ATP-sensitive potassium channel assembly .	parallel	1
10670	10652336	6398;3559	K12;CD25	Human ***K12-Fc*** ***stimulated*** the up-regulation of ***CD25*** , CD54 , and CD69 on human NK cells in vitro .	positive	0
10671	10652336	6398;3383	K12;CD54	Human ***K12-Fc*** ***stimulated*** the up-regulation of CD25 , ***CD54*** , and CD69 on human NK cells in vitro .	positive	0
10672	10652336	6398;969	K12;CD69	Human ***K12-Fc*** ***stimulated*** the up-regulation of CD25 , CD54 , and ***CD69*** on human NK cells in vitro .	positive	0
10673	10652338	10499;7025	GRIP1;COUP-TFI	Furthermore , we show that ***GRIP1*** and SRC-1 ***potentiate*** the activity of ***COUP-TFI*** and that COUP-TFI associates with these coactivators in vivo using the same region required for transcription activation .	positive	0
10674	10652338	8648;7025	SRC-1;COUP-TFI	Furthermore , we show that GRIP1 and ***SRC-1*** ***potentiate*** the activity of ***COUP-TFI*** and that COUP-TFI associates with these coactivators in vivo using the same region required for transcription activation .	positive	0
10675	10652349	5599;4772	JNK;NFATc	We show that ***JNK*** , ERK , and p38 physically ***associate*** with the ***NFATc*** N-terminal regulatory domain and can directly phosphorylate functionally important residues involved in regulating NFATc subcellular localization , namely Ser ( 172 ) and the conserved NFATc Ser-Pro repeats .	parallel	0
10676	10652349	5594;4772	p38;NFATc	We show that JNK , ERK , and ***p38*** physically ***associate*** with the ***NFATc*** N-terminal regulatory domain and can directly phosphorylate functionally important residues involved in regulating NFATc subcellular localization , namely Ser ( 172 ) and the conserved NFATc Ser-Pro repeats .	parallel	0
10677	10652349	5599;4772	JNK;NFATc	Moreover , we found that overexpression of ***JNK*** , ERK , or p38 is able to ***block*** ionomycin-induced ***NFATc*** nuclear translocation , whereas treatment of cells with both PD98059 and SB202190 , which inhibit MAPK/SAPK signaling pathways , is sufficient to trigger NFATc nuclear localization .	negative	0
10678	10652349	5594;4772	p38;NFATc	Moreover , we found that overexpression of JNK , ERK , or ***p38*** is able to ***block*** ionomycin-induced ***NFATc*** nuclear translocation , whereas treatment of cells with both PD98059 and SB202190 , which inhibit MAPK/SAPK signaling pathways , is sufficient to trigger NFATc nuclear localization .	negative	0
10679	10652350	7046;7040	ALK-5;TGF-beta	***TGF-beta*** type 1 ***receptor*** ( ***ALK-5*** ) , activin type IB receptor ( ALK-4 ) , and the " orphan " ALK-7 trans-activate the Ialpha1 promoter , thus raising the possibility that other members of the TGF-beta superfamily can also modulate IgA synthesis .	parallel	1
10680	10652352	207;5979	AKT;MEN2A	Furthermore , infection of rat fibroblasts with a retrovirus expressing a dominant-interfering form of PI3K suppresses RET-MEN2A-dependent transformation , whereas overexpression of ***AKT*** ***enhances*** the ***RET-MEN2A*** oncogenic potential .	positive	0
10681	10652353	3984;1072	LIMK1;cofilin	LIM-kinase 1 ( ***LIMK1*** ) ***phosphorylates*** ***cofilin*** , an actin-depolymerizing factor , and regulates actin cytoskeletal reorganization .	target	1
10682	10652353	5058;3984	PAK1;LIMK1	Together with the recent finding that ***PAK1*** , a downstream effector of Rac , also ***activates*** ***LIMK1*** by phosphorylation at Thr-508 , these results suggest that activation of LIMK1 is one of the common targets for Rho and Rac to reorganize the actin cytoskeleton .	positive	1
10683	10652362	1080;7020	CFTR;AP-2	In vivo cross-linking and in vitro pull-down assays show that full-length ***CFTR*** ***binds*** to the endocytic adaptor complex ***AP-2*** .	parallel	1
10684	10652364	51052;5594	PrRP;ERK	These results suggest that ***PrRP*** differentially ***activates*** ***ERK*** and JNK , and both cascades are necessary to elicit rPRL promoter activity in an Ets-dependent mechanism .	positive	1
10685	10652364	51052;5599	PrRP;JNK	These results suggest that ***PrRP*** differentially ***activates*** ERK and ***JNK*** , and both cascades are necessary to elicit rPRL promoter activity in an Ets-dependent mechanism .	positive	1
10686	10652367	7124;6662	tumor necrosis factor-alpha;Sox9	Potent ***inhibition*** of the master chondrogenic factor ***Sox9*** gene by interleukin-1 and ***tumor necrosis factor-alpha*** .	negative	1
10687	10652367	7124;1280	TNF-alpha;Col2a1	This role was further supported by the ability of a dominant-negative mutant of IkappaBalpha to block the IL-1 and ***TNF-alpha*** ***inhibition*** of Sox9-dependent ***Col2a1*** enhancer elements .	negative	1
10688	10652367	7124;6662	TNF-alpha;Sox9	Because Sox9 is essential for chondrogenesis , the marked ***down-regulation*** of the ***Sox9*** gene by IL-1 and ***TNF-alpha*** in chondrocytes is sufficient to account for the inhibition of the chondrocyte phenotype by these cytokines .	negative	1
10689	10652369	5868;8411	Rab5;EEA1	The importance of Rab5 in membrane binding of EEA1 is underscored by the finding that the increased expression of wild-type ***Rab5*** ***increases*** endosomal binding of ***EEA1*** and decreases its dependence on PtdIns3P .	positive	0
10690	10652372	673;5906	B-Raf;Rap1	Furthermore , depolarization also induced the PKA-dependent stimulation of Rap1 and led to the formation of a ******Rap1/B-Raf****** signaling ***complex*** .	parallel	1
10691	10652372	673;5906	B-Raf;Rap1	The major action of PKA-dependent ******Rap1/B-Raf****** ***signaling*** in neuronal cells is the activation of ERKs .	parallel	0
10692	10652434	7040;5054	TGF-beta1;PAI-1	***TGF-beta1*** ***induces*** uPA and ***PAI-1*** secretion and promotes binding of uPA at the external plasma membrane with increased membrane-associated plasmin activity .	target	1
10693	10652441	6376;7124	Fractalkine;TNF-alpha	***Fractalkine*** ***modulates*** ***TNF-alpha*** secretion and neurotoxicity induced by microglial activation .	target	0
10694	10652447	3569;2353	IL-6;c-fos	***IL-6*** ***induced*** higher levels of STAT3 phosphorylation and STAT3-responsive ***c-fos*** gene expression in pure oligodendrocyte cultures of motheaten compared with normal littermate mice .	target	1
10695	10652447	3569;6774	IL-6;STAT3	***IL-6*** ***induced*** higher levels of ***STAT3*** phosphorylation and STAT3-responsive c-fos gene expression in pure oligodendrocyte cultures of motheaten compared with normal littermate mice .	target	1
10696	10652570	7157;581	p53;Bax	Consistent with this result , ***Bax*** , which is ***regulated*** by ***p53*** and is able to promote apoptosis , was also found to increase in a same kinetic manner as p53 .	target	1
10697	10652592	960;1509	CD44;cathepsin D	The ***association*** between ***cathepsin D*** expression and ***CD44*** , p53 , Rb proteins and proliferation indices ( Ki-67 , PCNA ) was assessed by univariate analysis .	parallel	0
10698	10653164	1475;1508	stefin A;Cathepsin B	***Cathepsin B*** and its ***inhibitor*** ***stefin A*** in brain tumors .	negative	1
10699	10653164	1475;1508	stefin A;Cathepsin B	Cysteine protease ***Cathepsin B*** ( CatB ) and its endogenous ***inhibitor*** ***stefin A*** ( StA ) play an important role in tumor progression .	negative	1
10700	10653388	356;355	FasL;Fas	Fas or ***Fas*** ***ligand*** ( ***FasL*** ) expression was tested by surface staining with specific mAbs .	parallel	1
10701	10653389	3586;3458	IL-10;IFN-gamma	Addition of ***IL-10*** significantly ***inhibited*** the production of TNF-alpha , ***IFN-gamma*** , IL-5 , and IL-6 by 76 , 96 , 100 , and 93 % , respectively , in xeno-MLC .	negative	1
10702	10653389	3586;3567	IL-10;IL-5	Addition of ***IL-10*** significantly ***inhibited*** the production of TNF-alpha , IFN-gamma , ***IL-5*** , and IL-6 by 76 , 96 , 100 , and 93 % , respectively , in xeno-MLC .	negative	1
10703	10653389	3586;3569	IL-10;IL-6	Addition of ***IL-10*** significantly ***inhibited*** the production of TNF-alpha , IFN-gamma , IL-5 , and ***IL-6*** by 76 , 96 , 100 , and 93 % , respectively , in xeno-MLC .	negative	1
10704	10653389	3586;7124	IL-10;TNF-alpha	Addition of ***IL-10*** significantly ***inhibited*** the production of ***TNF-alpha*** , IFN-gamma , IL-5 , and IL-6 by 76 , 96 , 100 , and 93 % , respectively , in xeno-MLC .	negative	1
10705	10653389	3586;3458	IL-10;IFN-gamma	Addition of ***IL-10*** also significantly ( P < 0.05 ) ***inhibited*** the production of TNF-alpha , ***IFN-gamma*** , IL-5 , and IL-6 by 88 , 91 , 100 , and 96 % , respectively , in MILC .	negative	1
10706	10653389	3586;3567	IL-10;IL-5	Addition of ***IL-10*** also significantly ( P < 0.05 ) ***inhibited*** the production of TNF-alpha , IFN-gamma , ***IL-5*** , and IL-6 by 88 , 91 , 100 , and 96 % , respectively , in MILC .	negative	1
10707	10653389	3586;3569	IL-10;IL-6	Addition of ***IL-10*** also significantly ( P < 0.05 ) ***inhibited*** the production of TNF-alpha , IFN-gamma , IL-5 , and ***IL-6*** by 88 , 91 , 100 , and 96 % , respectively , in MILC .	negative	1
10708	10653389	3586;7124	IL-10;TNF-alpha	Addition of ***IL-10*** also significantly ( P < 0.05 ) ***inhibited*** the production of ***TNF-alpha*** , IFN-gamma , IL-5 , and IL-6 by 88 , 91 , 100 , and 96 % , respectively , in MILC .	negative	1
10709	10653592	6318;1511	SCCA2;cathepsin G	Paradoxically , SCCA1 is an inhibitor of papain-like cysteine proteinases , such as cathepsins L , S , and K , whereas ***SCCA2*** ***inhibits*** chymotrypsin-like serine proteinases , ***cathepsin G*** , and mast cell chymase .	negative	1
10710	10653592	6318;1215	SCCA2;chymase	Paradoxically , SCCA1 is an inhibitor of papain-like cysteine proteinases , such as cathepsins L , S , and K , whereas ***SCCA2*** ***inhibits*** chymotrypsin-like serine proteinases , cathepsin G , and mast cell ***chymase*** .	negative	1
10711	10653854	7124;3569	TNF-alpha;IL-6	It is well known that ***TNF-alpha*** ***induces*** ***IL-6*** production from synovial cells as well as their proliferation .	target	1
10712	10653854	7124;3569	TNF-alpha;IL-6	In addition , the IL-6-sIL-6R complex reduced the TNF-alpha-induced proliferation of synovial cells while ***TNF-alpha*** ***induced*** their ***IL-6*** production .	target	1
10713	10653872	4582;213	MUC1;albumin	MATERIALS AND METHODS : We measured immunoglobulin G ( IgG ) and immunoglobulin M ( IgM ) antibodies to MUC1 with an enzyme-linked immunoassay ( PEM.CIg ) , which uses a ***MUC1*** triple-tandem repeat peptide ***conjugated*** to bovine serum ***albumin*** , in pretreatment serum samples obtained from 154 breast cancer patients ( 52 with stage I disease and 102 with stage II ) and 302 controls .	parallel	1
10714	10653975	6421;5725	PSF;PTB	These ******PTB/PSF****** ***complexes*** as well as the observed PSF-PTB interaction may reflect the previously reported presence of PTB and PSF in spliceosomal complexes during RNA processing .	parallel	1
10715	10653975	5725;6421	PTB;PSF	These PTB/PSF complexes as well as the observed ******PSF-PTB****** ***interaction*** may reflect the previously reported presence of PTB and PSF in spliceosomal complexes during RNA processing .	parallel	1
10716	10653975	6421;5725	PSF;PTB	The present data , however , point to different cellular distribution and nuclear matrix ***association*** of the majority of ***PSF*** and ***PTB*** .	parallel	0
10717	10653980	2099;3479	ER-alpha;IGF-I	Protein kinase A and phosphatidylinositol 3-kinase inhibitors blocked the IGF-I effects on ER-alpha expression and activity , suggesting that these kinases may be involved in the ***cross-talk*** between the ***IGF-I*** and ***ER-alpha*** pathways .	parallel	0
10718	10653980	2099;3479	ER-alpha;IGF-I	The pure antiestrogen ICI-164 , 384 blocked this induction , suggesting that ***ER-alpha*** ***mediates*** the effects of ***IGF-I*** .	target	0
10719	10654195	941;940	CD80;CD28	The co-stimulatory signal provided by the interaction between ***CD28*** and its ***ligands*** , ***CD80*** and CD86 , is critical for T cell activation .	parallel	1
10720	10654195	942;940	CD86;CD28	The co-stimulatory signal provided by the interaction between ***CD28*** and its ***ligands*** , CD80 and ***CD86*** , is critical for T cell activation .	parallel	1
10721	10654195	940;942	CD28;CD86	The co-stimulatory signal provided by the ***interaction*** between ***CD28*** and its ligands , CD80 and ***CD86*** , is critical for T cell activation .	parallel	1
10722	10654195	941;940	CD80;CD28	The co-stimulatory signal provided by the ***interaction*** between ***CD28*** and its ligands , ***CD80*** and CD86 , is critical for T cell activation .	parallel	1
10723	10654195	941;942	CD80;CD86	The co-stimulatory signal provided by the ***interaction*** between CD28 and its ligands , ***CD80*** and ***CD86*** , is critical for T cell activation .	parallel	1
10724	10654331	359;551	aquaporin-2;ADH	The secretion of antidiuretic hormone ( ADH ) was decreased , and urinary excretion of aquaporin-2 , a vasopressin-sensitive water channel protein , was suppressed under basal conditions , but the ***response*** of ***aquaporin-2*** to ***ADH*** was essentially preserved .	parallel	0
10725	10654915	355;356	Fas;Fas ligand	Soluble Fas ( sFas ) , generated by alternative splicing , has been reported to antagonize the ***interaction*** of cell-surface ***Fas*** with ***Fas ligand*** .	parallel	1
10726	10654929	1027;7040	p27kip1;TGF-beta	More recently , the posttranslational reduction of levels of the cyclin-dependent kinase inhibitor ( CKI ) , ***p27kip1*** , which ***mediates*** ***TGF-beta*** growth inhibition , provides an additional means for cancer cells to escape negative growth regulation by TGF-beta .	target	0
10727	10654935	2274;367	FHL2;androgen receptor	***FHL2*** , a novel tissue-specific ***coactivator*** of the ***androgen receptor*** .	positive	1
10728	10655067	8600;8061	Rankl;Fosl1	The osteoclast differentiation factor ***Rankl*** ( also known as TRANCE , ODF and OPGL ; refs 8-11 ) ***induces*** transcription of ***Fosl1*** in a c-Fos-dependent manner , thereby establishing a link between Rank signalling and the expression of Ap-1 proteins in osteoclast differentiation .	target	1
10729	10655069	19;335	Abc1;apo-AI	***Abc1*** is expressed on the plasma membrane and the Golgi complex , ***mediates*** ***apo-AI*** associated export of cholesterol and phospholipids from the cell , and is regulated by cholesterol flux .	target	0
10730	10655102	23430;2150	mast cell tryptase;proteinase-activated receptor 2	Trypsin and ***mast cell tryptase*** ***cleave*** ***proteinase-activated receptor 2*** and , by unknown mechanisms , induce widespread inflammation .	target	1
10731	10655108	2118;2064	PEA3;HER-2/neu	The ets protein ***PEA3*** ***suppresses*** ***HER-2/neu*** overexpression and inhibits tumorigenesis .	negative	1
10732	10655476	4792;4790	IkappaBalpha;NF-kappaB	A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive ******NF-kappaB/IkappaBalpha****** ***complexes*** .	parallel	1
10733	10655476	4792;4790	IkappaBalpha;NF-kappaB	The nuclear export inhibitor leptomycin B ( LMB ) sequestered ******NF-kappaB/IkappaBalpha****** ***complexes*** in the nucleus .	parallel	1
10734	10655476	4792;4790	IkappaBalpha;NF-kappaB	These results suggest that ******NF-kappaB/IkappaBalpha****** ***complexes*** shuttle between the cytoplasm and nucleus by a nuclear localization signal-dependent nuclear import and a CRM1-dependent nuclear export .	parallel	1
10735	10655477	672;1385	BRCA1;CREB	***BRCA1*** ***interacts*** with the cAMP response element binding protein ( ***CREB*** ) domain of p300/CBP via both its amino and carboxyl termini .	parallel	1
10736	10655504	5747;836	FAK;caspase-3	Focal adhesion kinase ( ***FAK*** ) is a ***substrate*** of both ***caspase-3*** and caspase-6 , and inactivation of FAK by these caspases promotes apoptosis .	parallel	1
10737	10655504	5747;839	FAK;caspase-6	Focal adhesion kinase ( ***FAK*** ) is a ***substrate*** of both caspase-3 and ***caspase-6*** , and inactivation of FAK by these caspases promotes apoptosis .	parallel	1
10738	10655506	10068;3458	IL-18BP;IFN-gamma	A novel , constitutively expressed and secreted IL-18 binding protein ( ***IL-18BP*** ) neutralizes IL-18 and thereby ***suppresses*** the production of ***IFN-gamma*** , resulting in reduced T-helper type 1 immune responses .	negative	1
10739	10655506	3606;3458	IL-18;IFN-gamma	A novel , constitutively expressed and secreted ***IL-18*** binding protein ( IL-18BP ) neutralizes IL-18 and thereby ***suppresses*** the production of ***IFN-gamma*** , resulting in reduced T-helper type 1 immune responses .	negative	1
10740	10655584	1969;5747	EphA2;FAK	Moreover , ***EphA2*** is constitutively ***associated*** with focal-adhesion kinase ( ***FAK*** ) in resting cells .	parallel	0
10741	10655584	5747;1969	FAK;EphA2	Within one minute after stimulation of EphA2 with its ligand , ephrin-A1 , the protein tyrosine phosphatase SHP2 is recruited to EphA2 ; this is followed by dephosphorylation of FAK and paxillin , and dissociation of the ******FAK-EphA2****** ***complex*** .	parallel	1
10742	10655584	5781;1969	SHP2;EphA2	Within one minute after stimulation of EphA2 with its ligand , ephrin-A1 , the protein tyrosine phosphatase ***SHP2*** is ***recruited*** to ***EphA2*** ; this is followed by dephosphorylation of FAK and paxillin , and dissociation of the FAK-EphA2 complex .	target	0
10743	10655614	396;207	RhoGDI;Rac	The ******Rac-RhoGDI****** ***complex*** and the structural basis for the regulation of Rho proteins by RhoGDI .	parallel	1
10744	10656172	5340;7040	plasmin;TGF-beta 1	A high Lp ( a ) level has also been shown to be an independent genetic risk factor , while its inverse relationship with TGF-beta 1 has suggested that it may interfere with ***plasmin-mediated*** ***activation*** of ***TGF-beta 1*** and result in increased endothelial activation , as well as migration and proliferation of vascular smooth muscle cells .	positive	1
10745	10656256	10468;796	Follistatin;CGRP	***Follistatin*** ***blocked*** ***CGRP*** expression induced by serum or skin-conditioned medium , implicating transforming growth factor beta ( TGFbeta ) family members .	negative	0
10746	10656438	7852;6387	chemokine receptor 4;SDF1	Identification and localization of the cytokine ***SDF1*** and its ***receptor*** , CXC ***chemokine receptor 4*** , to regions of necrosis and angiogenesis in human glioblastoma .	parallel	1
10747	10656440	332;961	survivin;IAP	The expression of a novel ***IAP*** apoptosis ***inhibitor*** , ***survivin*** , in breast cancer and its association with tumor cell apoptosis and overall prognosis were examined in this study .	negative	1
10748	10656451	355;356	Fas;FasL	Interestingly , caspase-8 activation was observed upon drug exposure , independently from ******Fas/FasL****** ***signaling*** .	parallel	0
10749	10656457	1027;1017	p27Kip1;CDK2	Compatible with the effects on the cell cycle , treatment with mAb ID5 decreased levels of cyclin-dependent kinase (CDK) 2 , cyclin E , and CDK6 proteins and reduced cyclin E-CDK2-associated kinase activity ; mAb HD5-treated cells had increased p27Kip1 expression and an increased ***association*** of ***p27Kip1*** with ***CDK2*** .	parallel	0
10750	10656623	7124;4843	TNF-alpha;inducible NOS	The ***TNF-alpha*** mRNA expression was ***correlated*** with the ***inducible NOS*** ( iNOS ) level , which was high in adenocarcinomas and low in normal tissues .	parallel	0
10751	10656678	1026;5111	p21;PCNA	The resultant amino acid substitution from aspartate to glycine may have vital implication in ***PCNA*** mediated cell cycle ***regulation*** by ***p21*** ( waf1/cip1 ) .	target	1
10752	10656679	293;581	ANT;Bax	Our data are compatible with a ménage à trois model of mitochondrial apoptosis regulation in which ***ANT*** , the likely pore forming protein within the PTPC , ***interacts*** with ***Bax*** or Bcl-2 which influence its pore forming potential in opposing manners .	parallel	1
10753	10656679	293;596	ANT;Bcl-2	Our data are compatible with a ménage à trois model of mitochondrial apoptosis regulation in which ***ANT*** , the likely pore forming protein within the PTPC , ***interacts*** with Bax or ***Bcl-2*** which influence its pore forming potential in opposing manners .	parallel	1
10754	10656679	293;581	ANT;Bax	Bcl-2 prevents channel formation by Atr-treated ANT and neutralizes the ***cooperation*** between ***Bax*** and ***ANT*** .	parallel	0
10755	10656682	4193;7157	HDM2;p53	Phosphorylation at serine 15 prevents the binding of ***HDM2*** , a negative ***regulator*** of ***p53*** .	negative	1
10756	10656682	4193;7157	HDM2;p53	Phosphorylation by DNA-PK , that modifies serines 15 and 37 , inhibits ***HDM2*** ***binding*** to ***p53*** but does not induce the DNA-binding activity of p53 .	parallel	1
10757	10656684	4605;1025	B-Myb;CDK9	Physical ***interaction*** between ***CDK9*** and ***B-Myb*** results in suppression of B-Myb gene autoregulation .	parallel	1
10758	10656693	2033;4602	p300;c-Myb	***c-Myb*** ***acetylation*** at the carboxyl-terminal conserved domain by transcriptional co-activator ***p300*** .	target	1
10759	10656693	2033;4602	histone acetyltransferase p300;c-Myb	Here we demonstrate that ***c-Myb*** is ***acetylated*** at the carboxyl-terminal conserved domain by ***histone acetyltransferase p300*** both in vitro and in vivo .	target	1
10760	10656693	2033;4602	p300;c-Myb	Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that ***acetylation*** of ***c-Myb*** in vitro by ***p300*** causes dramatic increase in DNA binding activity .	target	1
10761	10656759	5594;3315	p38;Hsp25	The ***phosphorylation*** of ***Hsp25*** by the ***p38/SAPK2*** pathway is known to be important for certain of its functions .	target	1
10762	10656759	5600;3315	SAPK2;Hsp25	The ***phosphorylation*** of ***Hsp25*** by the ***p38/SAPK2*** pathway is known to be important for certain of its functions .	target	1
10763	10656807	4193;7157	Mdm2;p53	Over-expression of ***Mdm2*** in either tumor ( which do express endogenous functional Mdm2 ) or in p53 null cells ***decreased*** the stability of mutant ***p53*** suggesting that , despite its expression , Mdm2/JNK are insufficient ( amount/affinity ) for targeting mutant p53 degradation .	negative	0
10764	10656877	1371;1080	CPX;CFTR	***CPX*** also ***activates*** mutant ***CFTR*** channels .	positive	1
10765	10657017	3002;3458	granzyme B;interferon gamma	***granzyme B*** mRNA levels ***correlated*** with ***interferon gamma*** mRNA levels in Crohn 's disease .	parallel	0
10766	10657375	1471;261727	cystatin C;CrCl	RESULTS : ***cystatin C*** and creatinine ***correlated*** significantly ( P = 0.001 ) with ***CrCl*** .	parallel	0
10767	10657498	1991;4586	HNE;mucin	***HNE*** ***increased*** ***mucin*** release four to five fold in both cell types .	positive	0
10768	10657511	5443;2922	alpha-melanocyte stimulating hormone;bombesin	Neuropeptide Y ( alpha-melanocyte stimulating hormone0 ) , melanin concentrating hormone ( MCH ) , orexins A and B , galanin , and agouti - related peptide ( AgRP ) all act to stimulate feeding while ***alpha-melanocyte stimulating hormone*** ( alphaMSH ) , corticotropin releasing hormone ( CRH ) , cholecystokinin ( CCK ) , cocaine and amphetamine ***regulated*** transcript ( CART ) , neurotensin , glucagon-like peptide 1 ( GLP 1 ) , and ***bombesin*** have anorectic actions .	target	1
10769	10657511	5443;9607	alpha-melanocyte stimulating hormone;CART	Neuropeptide Y ( alpha-melanocyte stimulating hormone0 ) , melanin concentrating hormone ( MCH ) , orexins A and B , galanin , and agouti - related peptide ( AgRP ) all act to stimulate feeding while ***alpha-melanocyte stimulating hormone*** ( alphaMSH ) , corticotropin releasing hormone ( CRH ) , cholecystokinin ( CCK ) , cocaine and amphetamine ***regulated*** transcript ( ***CART*** ) , neurotensin , glucagon-like peptide 1 ( GLP 1 ) , and bombesin have anorectic actions .	target	1
10770	10657511	5443;2641	alpha-melanocyte stimulating hormone;GLP 1	Neuropeptide Y ( alpha-melanocyte stimulating hormone0 ) , melanin concentrating hormone ( MCH ) , orexins A and B , galanin , and agouti - related peptide ( AgRP ) all act to stimulate feeding while ***alpha-melanocyte stimulating hormone*** ( alphaMSH ) , corticotropin releasing hormone ( CRH ) , cholecystokinin ( CCK ) , cocaine and amphetamine ***regulated*** transcript ( CART ) , neurotensin , glucagon-like peptide 1 ( ***GLP 1*** ) , and bombesin have anorectic actions .	target	1
10771	10657511	5443;4922	alpha-melanocyte stimulating hormone;neurotensin	Neuropeptide Y ( alpha-melanocyte stimulating hormone0 ) , melanin concentrating hormone ( MCH ) , orexins A and B , galanin , and agouti - related peptide ( AgRP ) all act to stimulate feeding while ***alpha-melanocyte stimulating hormone*** ( alphaMSH ) , corticotropin releasing hormone ( CRH ) , cholecystokinin ( CCK ) , cocaine and amphetamine ***regulated*** transcript ( CART ) , ***neurotensin*** , glucagon-like peptide 1 ( GLP 1 ) , and bombesin have anorectic actions .	target	1
10772	10657527	116;7054	pituitary adenylate cyclase-activating polypeptide;tyrosine hydroxylase	We previously demonstrated that ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) coordinately ***upregulates*** the expression of the ***tyrosine hydroxylase*** ( TH ) and dopamine beta-hydroxylase ( DBH ) genes by activating the cyclic AMP ( cAMP ) and protein kinase C ( PKC ) signaling pathways .	positive	1
10773	10657527	116;2353	PACAP;c-fos	***PACAP*** potently ***stimulated*** the expression of ***c-fos*** , fosB junB and junD , but not c-jun mRNAs , at doses of 0.1-10 nM , as revealed by Northern blot analysis .	positive	0
10774	10657527	116;3726	PACAP;junB	***PACAP*** potently ***stimulated*** the expression of c-fos , fosB ***junB*** and junD , but not c-jun mRNAs , at doses of 0.1-10 nM , as revealed by Northern blot analysis .	positive	0
10775	10657527	116;3727	PACAP;junD	***PACAP*** potently ***stimulated*** the expression of c-fos , fosB junB and ***junD*** , but not c-jun mRNAs , at doses of 0.1-10 nM , as revealed by Northern blot analysis .	positive	0
10776	10657527	116;2353	PACAP;c-fos	***PACAP*** administration ***induced*** maximum expression of ***c-fos*** , fosB and junB mRNA after 60 min , and of junD mRNA after 8 h.	target	1
10777	10657527	116;2354	PACAP;fosB	***PACAP*** administration ***induced*** maximum expression of c-fos , ***fosB*** and junB mRNA after 60 min , and of junD mRNA after 8 h.	target	1
10778	10657527	116;3726	PACAP;junB	***PACAP*** administration ***induced*** maximum expression of c-fos , fosB and ***junB*** mRNA after 60 min , and of junD mRNA after 8 h.	target	1
10779	10657530	116;7054	Pituitary adenylate cyclase-activating polypeptide;tyrosine hydroxylase	***Pituitary adenylate cyclase-activating polypeptide*** ( PACAP-27 ) ***enhances*** ***tyrosine hydroxylase*** activity in the nucleus accumbens of the rat .	positive	0
10780	10657533	351;4018	Abeta;lipoprotein	Fibrillar Alzheimer 's amyloid peptide ***Abeta*** ( 1-42 ) ***stimulates*** low density ***lipoprotein*** binding and cell association , free radical production and cell cytotoxicity in PC12 cells .	positive	0
10781	10657533	351;4018	Abeta;lipoprotein	Fibrillar ***Abeta*** ( 1-42 ) at micromol concentrations ***increased*** low-density ***lipoprotein*** ( LDL ) binding and cell association by 460 % and 200 % respectively , and LDL degradation by about 62 % .	positive	0
10782	10657541	2520;3030	gastrin;gastrin-binding protein	Benzotript analogues were therefore tested for their ability to inhibit the ***binding*** of iodinated ***gastrin*** to the ***gastrin-binding protein*** .	parallel	1
10783	10657541	2520;3030	gastrin;gastrin-binding protein	In order to isolate more potent binding inhibitors , several selective CCK receptor antagonists were also tested as inhibitors of the ***binding*** of ***gastrin*** to the ***gastrin-binding protein*** .	parallel	1
10784	10657569	348;335	apolipoprotein (Apo)E;apo	***Association*** of ***apolipoprotein (Apo)E*** genotype with plasma ***apo*** E levels .	parallel	0
10785	10657578	4018;7124	lipoprotein;TNF-alpha	In contrast , the study suggests that very-low-density ***lipoprotein*** ( VLDL ) in hypertriglyceridemic patients ***augments*** ***TNF-alpha*** production .	positive	0
10786	10657592	6387;7852	SDF-1;CXCR4	Thus , our findings indicate : ( 1 ) that CXCR4 is widely expressed on human endothelial cells ; ( 2 ) the ***CXCR4*** ***ligand*** , ***SDF-1*** , can evoke a wide variety of responses from human endothelial cells ; and ( 3 ) CXCR4 on endothelial cells can serve as a receptor for isolates of HIV that can utilize chemokine receptors in the absence of CD4 .	parallel	1
10787	10657593	3553;1080	IL-1beta;CFTR	We conclude that the ***CFTR*** mRNA and protein levels are ***modulated*** by ***IL-1beta*** , this cytokine being the first extracellular protein known to up-regulate CFTR gene expression .	target	0
10788	10657604	3600;3458	IL-15;IFN-gamma	Supporting this , IL-12 and ***IL-15*** synergized to ***induce*** murine NK cell ***IFN-gamma*** production in vitro .	target	1
10789	10657611	356;355	FasL;Fas	We studied the possible role of two prominent nerve growth factor ( NGF-TNF ) family member systems , ***Fas*** ***ligand*** ( ***FasL*** ) - Fas receptor ( FasR ) and TNF-alpha-TNFR , in apoptosis of murine CD8 +4 + double-positive ( DP ) thymocytes induced via TCR-CD3 - and cAMP-mediated signaling .	parallel	1
10790	10657616	7124;3578	TNF-alpha;p40	***TNF-alpha*** is a potent ***inhibitor*** of IL-12 ***p40*** and p70 secretion from human macrophages induced by LPS or S. aureus .	negative	1
10791	10657616	7124;3578	TNF-alpha;p40	***TNF-alpha*** selectively ***inhibits*** IL-12 ***p40*** steady-state mRNA , but not those of IL-12 p35 , IL-1alpha , IL-1beta , or IL-6 .	negative	1
10792	10657616	3458;3578	IFN-gamma;p40	The major transcriptional factors identified to be involved in the ***regulation*** of IL-12 ***p40*** gene expression by LPS and ***IFN-gamma*** , i.e. , c-Rel , NF-kappaB p50 and p65 , IFN regulatory factor-1 , and ets-2 , were not affected by TNF-alpha when examined by nuclear translocation and DNA binding .	target	1
10793	10657618	3565;3458	IL-4;IFN-gamma	We examined the possibilities that ***IL-4*** ***stimulation*** of ***IFN-gamma*** production , suppression of IL-1 or IL-2 production , or induction of TNF-alpha or Fas-mediated apoptosis could account for IL-4 's suppressive effect .	positive	0
10794	10657619	970;939	CD70;CD27	Stimulation with immobilized anti-CD27 mAb or murine ***CD27*** ***ligand*** ( ***CD70*** ) transfectans solely could induce proliferation and IFN-gamma production of freshly isolated NK cells and enhanced the proliferation and IFN-gamma production of anti-NK1 .1 - sutimulated NK cells .	parallel	1
10795	10657620	3600;3458	IL-15;IFN-gamma	Furthermore , both IL-2 and ***IL-15*** ***induced*** ***IFN-gamma*** production of these T cells , which is strikingly augmented by the presence of IL-12 .	target	1
10796	10657621	941;958	CD80;CD40	In such DC-PBL cocultures , inhibition of ***CD80*** and CD86 expression on DCs was shown to ***require*** both MV replication and ***CD40*** triggering .	target	0
10797	10657621	942;958	CD86;CD40	In such DC-PBL cocultures , inhibition of CD80 and ***CD86*** expression on DCs was shown to ***require*** both MV replication and ***CD40*** triggering .	target	0
10798	10657627	3458;2889	IFN-gamma;C3G	***IFN-gamma*** ***activates*** the ***C3G/Rap1*** signaling pathway .	positive	1
10799	10657627	3458;27342	IFN-gamma;Rap1	***IFN-gamma*** ***activates*** the ***C3G/Rap1*** signaling pathway .	positive	1
10800	10657627	1399;2889	CrkL;C3G	***CrkL*** then ***regulates*** activation of the guanine exchange factor ***C3G*** , with which it interacts constitutively via its N terminus src homology 3 domain .	target	1
10801	10657627	3458;27342	IFN-gamma;Rap1	This results in the ***IFN-gamma-dependent*** ***activation*** of ***Rap1*** , a protein known to exhibit tumor suppressor activity and mediate growth inhibitory responses .	positive	1
10802	10657627	3439;1399	IFN-alpha;CrkL	On the other hand , IFN-gamma does not induce formation of nuclear ***CrkL-Stat5*** DNA-binding complexes , which are ***induced*** by ***IFN-alpha*** and IFN-beta , indicating that pathways downstream of CrkL are differentially regulated by different IFN subtypes .	target	1
10803	10657627	3456;1399	IFN-beta;CrkL	On the other hand , IFN-gamma does not induce formation of nuclear ***CrkL-Stat5*** DNA-binding complexes , which are ***induced*** by IFN-alpha and ***IFN-beta*** , indicating that pathways downstream of CrkL are differentially regulated by different IFN subtypes .	target	1
10804	10657629	50616;3578	IL-TIF;IL-9	Further studies will have to address the possibility that some of the ***IL-9*** activities may be ***mediated*** by ***IL-TIF*** .	target	0
10805	10657646	3574;3575	IL-7;IL-7R alpha	Murine pro-B cells require ***IL-7*** and its receptor complex to ***up-regulate*** ***IL-7R alpha*** , terminal deoxynucleotidyltransferase , and c mu expression .	positive	1
10806	10657646	3574;1791	IL-7;terminal deoxynucleotidyltransferase	Murine pro-B cells require ***IL-7*** and its receptor complex to ***up-regulate*** IL-7R alpha , ***terminal deoxynucleotidyltransferase*** , and c mu expression .	positive	1
10807	10657651	7040;1493	TGF-beta;CTLA-4	***TGF-beta*** ***mediates*** ***CTLA-4*** suppression of cellular immunity in murine kalaazar .	target	0
10808	10657651	1493;3458	CTLA-4;IFN-gamma	Production of TGF-beta1 accounted for the reciprocal ***regulation*** of ***IFN-gamma*** production by ***CTLA-4*** engagement .	target	1
10809	10657655	1785;2185	cytoskeletal protein;Pyk2	Proline-rich tyrosine kinase 2 ( Pyk2 ) , a tyrosine kinase related to focal adhesion kinase , and paxillin , a ***cytoskeletal protein*** that ***interacts*** with ***Pyk2*** , were both tyrosine phosphorylated in response to LPS in monocytes and macrophages .	parallel	1
10810	10657657	3596;6778	IL-13;Stat6	Studies in mice infected with the gastrointestinal nematode parasite Nippostrongylus brasiliensis demonstrated that ***IL-4/IL-13*** ***activation*** of ***Stat6*** suppresses development of intestinal mastocytosis and does not contribute to IL-4/IL-13 production , but is still essential for parasite expulsion .	positive	1
10811	10657657	3565;6778	IL-4;Stat6	Studies in mice infected with the gastrointestinal nematode parasite Nippostrongylus brasiliensis demonstrated that ***IL-4/IL-13*** ***activation*** of ***Stat6*** suppresses development of intestinal mastocytosis and does not contribute to IL-4/IL-13 production , but is still essential for parasite expulsion .	positive	1
10812	10657657	3596;6778	IL-13;Stat6	Instead , we find that ***Stat6*** ***activation*** by ***IL-4/IL-13*** is required in T. spiralis-infected mice for the mast cell responses that induce worm expulsion and for the cytokine responses that induce intestinal mastocytosis .	positive	1
10813	10657657	3565;6778	IL-4;Stat6	Instead , we find that ***Stat6*** ***activation*** by ***IL-4/IL-13*** is required in T. spiralis-infected mice for the mast cell responses that induce worm expulsion and for the cytokine responses that induce intestinal mastocytosis .	positive	1
10814	10657661	5610;4793	PKR;IkappaBbeta	Activation of this pathway requires the ***PKR-dependent*** ***degradation*** of the ***IkappaBbeta*** protein .	negative	1
10815	10657675	958;959	CD40;CD154	The data support the development of novel therapies based on blocking the ******CD154-CD40****** ***interaction*** in CLL .	parallel	1
10816	10657675	959;958	CD154;CD40	Based on observations that in some CLL cases , the tumor cells express both ***CD40*** and its ***ligand*** , ***CD154*** ( CD40 ligand ) , we proposed a model for CLL pathogenesis due to CD40 ligation within the tumor .	parallel	1
10817	10657675	958;4790	CD40;NF-kappaB	In each case examined , ***CD40*** ligation further ***augmented*** ***NF-kappaB*** activity and prolonged CLL cell survival in vitro .	positive	0
10818	10657679	3553;4790	IL-1 beta;NF-kappa B	However , when the ***IL-1 beta-dependent*** ***induction*** of ***NF-kappa B*** was inhibited , the antiapoptotic effect of IL-1 beta was partially reversed , suggesting that NF-kappa B-mediated gene activation is part of the protective mechanism .	target	1
10819	10657679	3553;596	IL-1 beta;Bcl-2	In addition , ***IL-1 beta*** significantly ***increased*** the expression of ***Bcl-2*** .	positive	0
10820	10657679	3553;355	IL-1 beta;CD95	These findings suggest that ***IL-1 beta*** ***modulates*** the ***CD95*** death cascade in chondrocytes by mechanisms that involve tyrosine phosphorylation events and NF-kappa B-dependent gene activation .	target	0
10821	10657699	9241;652	Noggin;BMP-2/4	***Noggin*** ***binds*** to ***BMP-2/4*** with high affinity , and prevents binding to cell surface receptors .	parallel	1
10822	10657730	3952;5443	leptin;proopiomelanocortin	***Regulation*** of hypothalamic ***proopiomelanocortin*** by ***leptin*** in lean and obese rats .	target	1
10823	10657738	3553;1392	IL-1beta;CRH	We have found that ***IL-1beta*** ***increased*** the activity of ***CRH*** gene promoter , in a time - and dose-dependent manner .	positive	0
10824	10657857	7040;3486	TGF-beta1;IGFBP-3	IGFBP-3 mRNA levels detected by Northern blotting of total RNA extracted from similar cultures showed the ***induction*** of ***IGFBP-3*** expression by ***TGF-beta1*** in normal PC-S and its lack of induction in BPH PC-S .	target	1
10825	10657857	3486;7040	IGFBP-3;TGF-beta1	In conclusion , BPH PC-S had a reduced ***IGFBP-3*** ***response*** to ***TGF-beta1*** and demonstrated decreased TGF-beta1-induced growth inhibition relative to normal PC-S .	parallel	0
10826	10657898	694;3276	BTG1;PRMT1	It has been previously described that recombinant ***BTG1*** and BTG2/TIS21 can physically ***interact*** with ***PRMT1*** , an arginine methyl transferase , suggesting that BTG1 and BTG2/TIS21 induction may lead to posttranslational modifications of cellular proteins .	parallel	1
10827	10657898	7832;3276	TIS21;PRMT1	It has been previously described that recombinant BTG1 and ***BTG2/TIS21*** can physically ***interact*** with ***PRMT1*** , an arginine methyl transferase , suggesting that BTG1 and BTG2/TIS21 induction may lead to posttranslational modifications of cellular proteins .	parallel	1
10828	10657901	4609;790	c-Myc;CAD	Previous studies suggest that hamster and rat carbamoyl phosphate synthase , aspartate transcarbamylase , dihydroorotase ***CAD*** genes are ***regulated*** by ***c-Myc*** .	target	1
10829	10657935	7124;7185	TNF-alpha;TRAF1	We demonstrate for the first time ***TNF-alpha*** dose-dependent ***induction*** of ***TRAF1*** protein and messenger RNA ( mRNA ) in human H441 and A549 pulmonary adenocarcinoma cell lines , as well as in lung cells of C57BL/6J mice after intratracheal administration of TNF-alpha .	target	1
10830	10657935	7124;330	TNF-alpha;cIAP2	Similarly , ***cIAP2*** mRNA was ***induced*** by ***TNF-alpha*** in both H441 and A549 pulmonary epithelial cells but not in U937 cells .	target	1
10831	10657944	3565;246	IL-4;12/15-lipoxygenase	The ***induction*** of the human ***12/15-lipoxygenase*** by ***IL-4*** suggests that the signal transducer and activator of transcription (Stat)-6 protein is critical for its expression .	target	1
10832	10658975	3824;3821	CD94;NKG2-A	The major described inhibitory pathways begin either with the recognition of a target cell classical class I HLA molecule by a killer cell immunologlobulin-like receptor ( KIR ) or the binding of the non-classical class I molecule HLA-E to the ******CD94/NKG2-A****** ***heterodimer*** .	parallel	1
10833	10659499	7051;4014	TGK;loricrin	Involucrine and ***loricrin*** , the building materials of the marginal band whose-cross-linking is ***mediated*** by ***TGK*** , were normally stained in the upper epidermis .	target	0
10834	10659697	84268;2908	RIP;glucocorticoid receptor	The nuclear-receptor interacting protein ( ***RIP*** ) 140 ***binds*** to the human ***glucocorticoid receptor*** and modulates hormone-dependent transactivation .	parallel	1
10835	10659855	1964;10209	eIF1A;eIF1	The resulting complex ***requires*** ***eIF1*** , ***eIF1A*** , eIF4A , eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10836	10659855	1964;1974	eIF1A;eIF4A	The resulting complex ***requires*** eIF1 , ***eIF1A*** , ***eIF4A*** , eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10837	10659855	1964;1975	eIF1A;eIF4B	The resulting complex ***requires*** eIF1 , ***eIF1A*** , eIF4A , ***eIF4B*** and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10838	10659855	1964;1981	eIF1A;eIF4F	The resulting complex ***requires*** eIF1 , ***eIF1A*** , eIF4A , eIF4B and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10839	10659855	10209;1964	eIF1;eIF1A	The resulting complex ***requires*** ***eIF1*** , ***eIF1A*** , eIF4A , eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10840	10659855	10209;1974	eIF1;eIF4A	The resulting complex ***requires*** ***eIF1*** , eIF1A , ***eIF4A*** , eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10841	10659855	10209;1975	eIF1;eIF4B	The resulting complex ***requires*** ***eIF1*** , eIF1A , eIF4A , ***eIF4B*** and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10842	10659855	10209;1981	eIF1;eIF4F	The resulting complex ***requires*** ***eIF1*** , eIF1A , eIF4A , eIF4B and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10843	10659855	1974;10209	eIF4A;eIF1	The resulting complex ***requires*** ***eIF1*** , eIF1A , ***eIF4A*** , eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10844	10659855	1974;1964	eIF4A;eIF1A	The resulting complex ***requires*** eIF1 , ***eIF1A*** , ***eIF4A*** , eIF4B and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10845	10659855	1974;1975	eIF4A;eIF4B	The resulting complex ***requires*** eIF1 , eIF1A , ***eIF4A*** , ***eIF4B*** and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10846	10659855	1974;1981	eIF4A;eIF4F	The resulting complex ***requires*** eIF1 , eIF1A , ***eIF4A*** , eIF4B and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10847	10659855	1975;10209	eIF4B;eIF1	The resulting complex ***requires*** ***eIF1*** , eIF1A , eIF4A , ***eIF4B*** and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10848	10659855	1975;1964	eIF4B;eIF1A	The resulting complex ***requires*** eIF1 , ***eIF1A*** , eIF4A , ***eIF4B*** and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10849	10659855	1975;1974	eIF4B;eIF4A	The resulting complex ***requires*** eIF1 , eIF1A , ***eIF4A*** , ***eIF4B*** and eIF4F to bind to a messenger RNA and to scan to the initiation codon .	target	0
10850	10659855	1975;1981	eIF4B;eIF4F	The resulting complex ***requires*** eIF1 , eIF1A , eIF4A , ***eIF4B*** and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10851	10659855	1981;10209	eIF4F;eIF1	The resulting complex ***requires*** ***eIF1*** , eIF1A , eIF4A , eIF4B and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10852	10659855	1981;1964	eIF4F;eIF1A	The resulting complex ***requires*** eIF1 , ***eIF1A*** , eIF4A , eIF4B and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10853	10659855	1981;1974	eIF4F;eIF4A	The resulting complex ***requires*** eIF1 , eIF1A , ***eIF4A*** , eIF4B and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10854	10659855	1981;1975	eIF4F;eIF4B	The resulting complex ***requires*** eIF1 , eIF1A , eIF4A , ***eIF4B*** and ***eIF4F*** to bind to a messenger RNA and to scan to the initiation codon .	target	0
10855	10659960	2688;3486	somatotropin;IGF-binding protein-3	***somatotropin*** tended to ***increase*** abundance of ***IGF-binding protein-3*** ( 40 to 43 kD ) in mammary extracts .	positive	0
10856	10659996	3082;5595	HGF;Erk1	Experiments performed with LY294002 indicated that phosphatidylinositol 3-kinase contributed to the ***HGF-stimulated*** ***phosphorylation*** of ***Erk1/Erk2*** .	target	1
10857	10659996	3082;5594	HGF;Erk2	Experiments performed with LY294002 indicated that phosphatidylinositol 3-kinase contributed to the ***HGF-stimulated*** ***phosphorylation*** of ***Erk1/Erk2*** .	target	1
10858	10660302	5982;5884	Rfc2;Rad24	These experiments showed that the small RFC proteins , ***Rfc2*** , Rfc3 , Rfc4 and Rfc5 , ***interacted*** with ***Rad24*** , whereas the Rfc1 subunit did not .	parallel	1
10859	10660302	5983;5884	Rfc3;Rad24	These experiments showed that the small RFC proteins , Rfc2 , ***Rfc3*** , Rfc4 and Rfc5 , ***interacted*** with ***Rad24*** , whereas the Rfc1 subunit did not .	parallel	1
10860	10660302	5984;5884	Rfc4;Rad24	These experiments showed that the small RFC proteins , Rfc2 , Rfc3 , ***Rfc4*** and Rfc5 , ***interacted*** with ***Rad24*** , whereas the Rfc1 subunit did not .	parallel	1
10861	10660302	5985;5884	Rfc5;Rad24	These experiments showed that the small RFC proteins , Rfc2 , Rfc3 , Rfc4 and ***Rfc5*** , ***interacted*** with ***Rad24*** , whereas the Rfc1 subunit did not .	parallel	1
10862	10660302	5981;5884	RFC;Rad24	These experiments showed that the small ***RFC*** proteins , Rfc2 , Rfc3 , Rfc4 and Rfc5 , ***interacted*** with ***Rad24*** , whereas the Rfc1 subunit did not .	parallel	1
10863	10660320	2175;2189	FANCA;FANCG	***FANCA*** protein ***binds*** ***FANCG*** proteins in an intracellular complex .	parallel	1
10864	10660521	8411;9135	EEA1;Rabaptin-5	Several Rab5 effectors are required in homotypic endosome fusion , including ***EEA1*** , which ***mediates*** endosome membrane docking , as well as ***Rabaptin-5*** x Rabex-5 complex and phosphatidylinositol 3-kinase hVPS34 .	target	0
10865	10660521	8411;27342	EEA1;Rabex-5	Several Rab5 effectors are required in homotypic endosome fusion , including ***EEA1*** , which ***mediates*** endosome membrane docking , as well as Rabaptin-5 x ***Rabex-5*** complex and phosphatidylinositol 3-kinase hVPS34 .	target	0
10866	10660524	2934;842	Gelsolin;caspase-3 and -9	***Gelsolin*** in complex with phosphatidylinositol 4,5-bisphosphate ***inhibits*** ***caspase-3 and -9*** to retard apoptotic progression .	negative	1
10867	10660524	836;2934	caspase-3;Gelsolin	Here we show that phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3 , 4-bisphosphate in pure micelles or mixed vesicles prevent ***caspase-3*** ***cleavage*** of ***Gelsolin*** .	target	1
10868	10660524	2934;842	Gelsolin;caspase-3 and -9	Moreover , phosphatidylinositol 4 , ***5-bisphosphate-Gelsolin*** strongly ***inhibits*** ***caspase-3 and -9*** activity through the formation of a stable phosphatidylinositol 4 , 5-bisphosphate-Gelsolin-caspase complex .	negative	1
10869	10660524	836;2934	caspase-3;Gelsolin	In addition , phosphatidylinositol 4,5-bisphosphate-Gelsolin prevents apoptotic progression mediated by caspase-3 in a cell-free system , and phosphatidylinositol 4,5-bisphosphate-Gelsolin-caspase-9 and phosphatidylinositol ******4,5-bisphosphate-Gelsolin-caspase-3****** ***complexes*** form in mouse embryonic fibroblasts during apoptosis induction when stimulated with fibronectin , to delay cell death .	parallel	1
10870	10660524	2934;836	Gelsolin;caspase-3	The results suggest that ***Gelsolin*** can act as both an effector and an ***inhibitor*** of ***caspase-3*** , the latter in concert with phosphatidylinositol 4 , 5-bisphosphate , and other membrane phospholipids to regulate the onset and progression of apoptosis .	negative	1
10871	10660533	1803;2641	Dipeptidyl peptidase IV;glucagon	***Dipeptidyl peptidase IV*** ( DPIV/CD26 ) ***degradation*** of ***glucagon*** .	negative	1
10872	10660534	7294;3937	Rlk;SLP-76	In this study , we identify a pathway in which ***Rlk*** ***phosphorylates*** ***SLP-76*** leading to the phosphorylation of PLCgamma1 , activation of ERKs , and the synergistic up-regulation of TcR-driven IL-2 NFAT/AP -1 transcription .	target	1
10873	10660535	3553;9021	IL-1beta;SOCS3	We conclude that the ***induction*** of ***SOCS3*** by ***IL-1beta*** contributes to the development of GH resistance in liver , and represents a mechanism by which cytokines such as IL-1beta cross-talk with cytokines using the JAK-STAT pathway .	target	1
10874	10660535	3553;9021	IL-1beta;SOCS3	In contrast , ***IL-1beta*** ***increased*** ***SOCS3*** mRNA by 8-fold after 24 h of treatment , whereas GH had no effect .	positive	0
10875	10660538	7157;355	p53;Fas	We propose that ***p53-dependent*** ***up-regulation*** of ***Fas*** does not induce apoptosis per se but sensitizes the cell to other pro-apoptotic signal ( s ) .	positive	1
10876	10660586	3082;9315	hepatocyte growth factor;P311	***Regulation*** of ***P311*** expression by ***Met-hepatocyte growth factor*** / scatter factor and the ubiquitin/proteasome system .	target	1
10877	10660586	8731;9315	Met;P311	***Regulation*** of ***P311*** expression by ***Met-hepatocyte growth factor*** / scatter factor and the ubiquitin/proteasome system .	target	1
10878	10660590	8900;983	cyclin A1;Cdc2	This kinase activity also copurifies with ORC over several fractionation steps and was identified as a ***complex*** of the ***Cdc2*** catalytic subunit and ***cyclin A1*** .	parallel	1
10879	10660591	885;1390	cholecystokinin;ICER	Here we show that ***ICER*** gene expression is ***induced*** by gastrin , ***cholecystokinin*** ( CCK ) , and epidermal growth factor in AR42J cells .	target	1
10880	10660591	2520;1390	gastrin;ICER	Here we show that ***ICER*** gene expression is ***induced*** by ***gastrin*** , cholecystokinin ( CCK ) , and epidermal growth factor in AR42J cells .	target	1
10881	10660591	886;1390	CCK-A receptor;ICER	The specific CCK-B receptor antagonist L740 ,093 blocks the gastrin but not the CCK response , indicating that both the CCK-B and the ***CCK-A receptor*** can ***mediate*** ***ICER*** gene activation .	target	0
10882	10660591	887;1390	CCK-B;ICER	The specific CCK-B receptor antagonist L740 ,093 blocks the gastrin but not the CCK response , indicating that both the ***CCK-B*** and the CCK-A receptor can ***mediate*** ***ICER*** gene activation .	target	0
10883	10660596	2885;3667	Grb2;IRS-1	These results provide new insight into novel molecular interactions involving PTP1B and ***Grb2*** that may ***influence*** the steady-state capacity of ***IRS-1*** to function as a phosphotyrosine scaffold and possibly affect the balance of postreceptor insulin signaling .	target	0
10884	10660596	5770;3667	PTP1B;IRS-1	These results provide new insight into novel molecular interactions involving ***PTP1B*** and Grb2 that may ***influence*** the steady-state capacity of ***IRS-1*** to function as a phosphotyrosine scaffold and possibly affect the balance of postreceptor insulin signaling .	target	0
10885	10660596	5770;3667	protein-tyrosine phosphatase 1B;insulin receptor substrate-1	Tyrosine ***dephosphorylation*** and deactivation of ***insulin receptor substrate-1*** by ***protein-tyrosine phosphatase 1B*** .	target	1
10886	10660596	1398;5781	Crk;SHP-2	Overlay blots with recombinant Src homology 2 domains of IRS-1 adaptor proteins showed that the loss of IRS-1 ***binding*** of ***Crk*** , Grb2 , ***SHP-2*** , and the p85 subunit of phosphatidylinositol 3 ' - kinase paralleled the rate of overall IRS-1 dephosphorylation .	parallel	1
10887	10660596	2885;1398	Grb2;Crk	Overlay blots with recombinant Src homology 2 domains of IRS-1 adaptor proteins showed that the loss of IRS-1 ***binding*** of ***Crk*** , ***Grb2*** , SHP-2 , and the p85 subunit of phosphatidylinositol 3 ' - kinase paralleled the rate of overall IRS-1 dephosphorylation .	parallel	1
10888	10660596	2885;5781	Grb2;SHP-2	Overlay blots with recombinant Src homology 2 domains of IRS-1 adaptor proteins showed that the loss of IRS-1 ***binding*** of Crk , ***Grb2*** , ***SHP-2*** , and the p85 subunit of phosphatidylinositol 3 ' - kinase paralleled the rate of overall IRS-1 dephosphorylation .	parallel	1
10889	10660596	5770;3667	PTP1B;IRS-1	Further studies revealed that the adaptor protein Grb2 strongly promoted the formation of a stable protein ***complex*** between tyrosine-phosphorylated ***IRS-1*** and catalytically inactive ***PTP1B*** , increasing their co-immunoprecipitation from an equimolar solution by 13.5 + / - 3.3-fold ( n = 7 ; p < 0.01 ) .	parallel	1
10890	10660600	9344;6416	PSK;MKK4	Immunoprecipitated PSK phosphorylates myelin basic protein and transfected ***PSK*** ***stimulates*** ***MKK4*** and MKK7 and activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway .	positive	0
10891	10660600	9344;5609	PSK;MKK7	Immunoprecipitated PSK phosphorylates myelin basic protein and transfected ***PSK*** ***stimulates*** MKK4 and ***MKK7*** and activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway .	positive	0
10892	10660609	5970;166	p65;AES	Using the yeast two-hybrid system , we have identified the protein-protein ***interaction*** between ***AES*** and the ***p65*** ( RelA ) subunit of the transcription factor nuclear factor kappaB ( NF-kappaB ) , which activates various target genes involved in inflammation , apoptosis , and embryonic development .	parallel	1
10893	10660609	5970;166	p65;AES	The ***interaction*** between ***AES*** and ***p65*** was confirmed by in vitro glutathione S-transferase pull down assay and by in vivo co-immunoprecipitation study .	parallel	1
10894	10660610	10459;4087	REV7 homolog;hMAD2	A human ***REV7 homolog*** that ***interacts*** with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein ***hMAD2*** .	parallel	1
10895	10660610	10459;5980	REV7 homolog;hREV3	A human ***REV7 homolog*** that ***interacts*** with the polymerase zeta catalytic subunit ***hREV3*** and the spindle assembly checkpoint protein hMAD2 .	parallel	1
10896	10660610	4087;10459	hMAD2;hREV7	In addition , we have identified an ***interaction*** between ***hREV7*** and ***hMAD2*** but not hMAD1 .	parallel	1
10897	10660611	3635;2057	Ship1;erythropoietin receptor	The SH2 inositol 5-phosphatase ***Ship1*** is ***recruited*** in an SH2-dependent manner to the ***erythropoietin receptor*** .	target	0
10898	10660611	3635;2057	Ship1;EPO-R	***Ship1*** is ***recruited*** to the ***EPO-R*** in an SH2-dependent manner .	target	0
10899	10660618	860;632	Cbfa1;osteocalcin	The bone-specific transcription factor , ***Cbfa1*** , ***regulates*** expression of the ***osteocalcin*** ( OCN ) gene and is essential for bone formation .	target	1
10900	10660618	5609;860	MEK;Cbfa1	Furthermore , ( 32 ) P metabolic labeling studies demonstrated that ***MEK*** ( SP ) clearly ***enhanced*** phosphorylation of ***Cbfa1*** in intact cells , while MEK ( DN ) decreased phosphorylation .	positive	0
10901	10660619	2237;5423	FEN1;DNA polymerase beta	***FEN1*** ***stimulation*** of ***DNA polymerase beta*** mediates an excision step in mammalian long patch base excision repair .	positive	0
10902	10660629	1019;672	Cdk4;BRCA1	Moreover , ectopic expression of cyclin D1 and ***Cdk4*** can ***stimulate*** the ***BRCA1*** promoter in an E2F-dependent manner , and this is inhibited by coexpression of the p16 ( INK4a ) cyclin-dependent kinase inhibitor .	positive	0
10903	10660629	595;672	cyclin D1;BRCA1	Moreover , ectopic expression of ***cyclin D1*** and Cdk4 can ***stimulate*** the ***BRCA1*** promoter in an E2F-dependent manner , and this is inhibited by coexpression of the p16 ( INK4a ) cyclin-dependent kinase inhibitor .	positive	0
10904	10660629	1869;672	E2F1;BRCA1	The human ***BRCA1*** promoter also contains a conserved E2F site and is similarly ***regulated*** by ***E2F1*** and Rb .	target	1
10905	10660833	5594;3576	ERK2;interleukin 8	Activation of ***ERK2*** by respiratory syncytial virus in A549 cells is ***linked*** to the production of ***interleukin 8*** .	parallel	0
10906	10661401	5594;3576	P38;interleukin-8	***RAC1/P38*** MAPK signaling pathway ***controls*** beta1 integrin-induced ***interleukin-8*** production in human natural killer cells .	target	0
10907	10661401	5879;3576	RAC1;interleukin-8	***RAC1/P38*** MAPK signaling pathway ***controls*** beta1 integrin-induced ***interleukin-8*** production in human natural killer cells .	target	0
10908	10661401	207;5594	Rac;P38	Finally , we provide direct evidence that p95 Vav and ***Rac*** ***control*** the activation of ***P38*** MAPK triggered by beta1 integrins .	target	0
10909	10661401	7409;5594	Vav;P38	Finally , we provide direct evidence that p95 ***Vav*** and Rac ***control*** the activation of ***P38*** MAPK triggered by beta1 integrins .	target	0
10910	10661402	3399;6929	Id3;E2A	Finally , we show that ***E2A*** and ***Id3*** ***interact*** genetically to regulate thymocyte development .	parallel	1
10911	10661405	1493;941	CTLA-4;B7-1	The structural data suggest a mechanism whereby the avidity-enhanced ***binding*** of ***B7-1*** and ***CTLA-4*** homodimers , along with the relatively high affinity of these interactions , favors the formation of very stable inhibitory signaling complexes .	parallel	1
10912	10661502	1392;5443	CRF;ACTH	***CRF*** ( 10 ng/ml ) significantly ***increased*** ***ACTH*** secretion in pituitary cultures from OLETF compared to LETO rats .	positive	0
10913	10661504	627;367	BDNF;androgen receptor	***BDNF*** ***regulation*** of ***androgen receptor*** expression in axotomized SNB motoneurons of adult male rats .	target	1
10914	10661576	4478;3385	moesin;ICAM-3	Chemokines induce ***moesin*** ***interaction*** with ***ICAM-3*** .	parallel	1
10915	10661874	2321;7422	Flt-1;VEGF	The ***VEGF*** ***receptor*** 1 ( ***Flt-1*** ) shows the same alternative splicing in humans and dogs and is overexpressed in the majority of tumors in both species .	parallel	1
10916	10661913	3953;3952	LEPR;leptin	Other studies have identified mutations within the genes that code for ***leptin*** ( LEP ) and its ***receptor*** ( ***LEPR*** ) , which have been linked to obesity in mice and humans .	parallel	1
10917	10662507	1270;3082	CNTF;HGF	***Cooperation*** between ***HGF*** and ***CNTF*** in promoting the survival and growth of sensory and parasympathetic neurons .	parallel	0
10918	10662507	3082;1270	HGF;CNTF	These results show that ***HGF*** ***cooperates*** with ***CNTF*** in promoting the survival and growth of parasympathetic and proprioceptive neurons and that within the same neurons , the effects of HGF on survival and growth are selectively dependent on which other signaling pathways are concurrently activated .	parallel	0
10919	10662555	9939;4116	RBM8;MAGOH	The ***interaction*** between ***MAGOH*** and ***RBM8*** was demonstrated by both yeast two-hybrid and GST fusion protein pull-down assays .	parallel	1
10920	10662616	3456;3434	IFN-beta;P56	***P56*** synthesis was rapidly ***induced*** by ***IFN-beta*** , and the protein had a half-life of 6 h.	target	1
10921	10662635	655;652	bmp7;bmp2b	Furthermore , overexpression experiments reveal that bmp2b and bmp7 synergize in the ventralization of wild-type embryos through a cell-autonomous mechanism , suggesting that ******bmp2b/bmp7****** ***heterodimers*** may act in vivo to specify ventral cell fates in the zebrafish embryo .	parallel	1
10922	10662728	5741;1184	PTH;ClC-5	***PTH*** ***regulates*** expression of ***ClC-5*** chloride channel in the kidney .	target	1
10923	10662728	5741;1184	PTH;ClC-5	Our results suggest that ***PTH*** ***modulates*** the expression of ***ClC-5*** in the kidney cortex and that neither 1alpha ,25 ( OH ) ( 2 ) vitamin D ( 3 ) nor PTH regulates ClC-5 expression in the medulla .	target	0
10924	10662774	5335;998	PLCgamma1;Cdc42	Finally , we are able to detect an in vitro ***interaction*** between ***Cdc42*** and ***PLCgamma1*** , the enzyme immediately upstream of IP ( 3 ) formation .	parallel	1
10925	10662783	928;7039	CD9;TGF-alpha	These data reveal that the ***association*** of ***CD9*** with transmembrane ***TGF-alpha*** regulates ligand-induced activation of the EGFR , and results in altered cell proliferation .	parallel	0
10926	10662783	928;7039	CD9;TGF-alpha	The tetraspanin ***CD9*** ***associates*** with transmembrane ***TGF-alpha*** and regulates TGF-alpha-induced EGF receptor activation and cell proliferation .	parallel	0
10927	10662783	928;1950	CD9;EGF	The tetraspanin ***CD9*** associates with transmembrane TGF-alpha and ***regulates*** TGF-alpha-induced ***EGF*** receptor activation and cell proliferation .	target	1
10928	10662783	7039;928	TGF-alpha;CD9	We now demonstrate that transmembrane ***TGF-alpha*** physically ***interacts*** with ***CD9*** , a protein with four membrane spanning domains that is frequently coexpressed with TGF-alpha in carcinomas .	parallel	1
10929	10662785	4323;4313	MT1-MMP;MMP2	These results suggest a model whereby expression of MT1-MMP is the primary trigger for migration over Ln-5 , whereas ***MMP2*** , which is ***activated*** by ***MT1-MMP*** , may play an ancillary role , perhaps by amplifying the MT1-MMP effects .	positive	1
10930	10662844	3952;7200	leptin;TRH	Because agouti-related protein ( AGRP ) , a leptin-regulated , arcuate nucleus-derived peptide with alpha-MSH antagonist activity , is contained in axon terminals that terminate on TRH neurons in the PVN , we raised the possibility that alpha-MSH may also participate in the mechanism by which ***leptin*** ***influences*** ***pro-TRH*** gene expression .	target	0
10931	10664460	397;7409	Ly-GDI;Vav	The ***interaction*** between ***Vav*** and ***Ly-GDI*** is not dependent on the tyrosine phosphorylation status of Vav .	parallel	1
10932	10664463	2886;27289	Grb7 adapter protein;Rnd1	***Interaction*** of the ***Grb7 adapter protein*** with ***Rnd1*** , a new member of the Rho family .	parallel	1
10933	10664463	2886;27289	Grb7;Rnd1	The contribution of the ***interaction*** between ***Rnd1*** and ***Grb7*** to their respective functions and properties is discussed .	parallel	1
10934	10664470	7046;7040	ALK-5;TGF-beta	We have identified in rat vascular smooth muscle cells ( SMCs ) the simultaneous expression of two ***TGF-beta*** type I ***receptor*** ( ***ALK-5*** ) cDNAs , occurring as a consequence of alternate usage of AG splice acceptor motifs separated by 12 nucleotides located at an intron-exon junction .	parallel	1
10935	10664857	93974;9551	ATPase inhibitor protein;F1Fo-ATPase	Mitochondrial ATP synthase ( ***F1Fo-ATPase*** ) is ***regulated*** by an intrinsic ***ATPase inhibitor protein*** .	target	1
10936	10665474	3791;7422	KDR;VEGF	We have produced a panel of antibodies directed against the ***VEGF*** ***receptor*** 2 , ***KDR/F1k*** -1 .	parallel	1
10937	10665474	3791;7422	KDR;VEGF	These antibodies potently block ******VEGF/KDR/F1k****** -1 ***interaction*** , and inhibit VEGF-stimulated activation of the receptor and proliferation of human endothelial cells .	parallel	1
10938	10665922	1029;4193	p14ARF;MDM2	The ***p14ARF*** gene product can ***complex*** with and sequester the ***MDM2*** protein within the nucleus , thus modulating the activity of the p53 protein .	parallel	1
10939	10665926	4043;4036	RAP;megalin	***RAP*** also ***binds*** to the related 600-kD multiligand endocytic receptor ***megalin*** expressed in many absorptive epithelia including renal proximal tubule .	parallel	1
10940	10666028	4953;6774	ODC;STAT3	We found that inhibition of ***ODC*** rapidly ***induces*** ***STAT3*** activation as determined by STAT3 tyrosine phosphorylation , translocation of STAT3 from the cytoplasm into the nucleus , and the presence of STAT3 in SIE-dependent DNA-protein complexes .	target	1
10941	10666030	885;3627	CCK;mob-1	Therefore , ***activation*** of NF-kappaB and ***mob-1*** expression by supraphysiological ***CCK*** is likely mediated by both PKC activation and elevated intracellular Ca ( 2 + ) .	positive	1
10942	10666030	885;4790	CCK;NF-kappaB	Therefore , ***activation*** of ***NF-kappaB*** and mob-1 expression by supraphysiological ***CCK*** is likely mediated by both PKC activation and elevated intracellular Ca ( 2 + ) .	positive	1
10943	10666030	885;3627	CCK;mob-1	***CCK*** ***stimulates*** ***mob-1*** expression and NF-kappaB activation via protein kinase C and intracellular Ca ( 2 + ) .	positive	0
10944	10666030	885;4790	CCK;NF-kappaB	***CCK*** ***stimulates*** mob-1 expression and ***NF-kappaB*** activation via protein kinase C and intracellular Ca ( 2 + ) .	positive	0
10945	10666030	885;3627	CCK;mob-1	***CCK*** ***induction*** of ***mob-1*** expression in isolated rat pancreatic acini was blocked by the protein kinase C ( PKC ) inhibitors GF-109203X and Ro-32-0432 and by the intracellular Ca ( 2 + ) chelator BAPTA .	target	1
10946	10666030	885;4790	CCK;NF-kappaB	***CCK*** ***induced*** ***NF-kappaB*** nuclear translocation , and DNA binding was also blocked by GF-109203X and BAPTA .	target	1
10947	10666084	1956;2885	EGFR;Grb2	The stretch rapidly ( within 2 min ) induced ***association*** of tyrosine-phosphorylated ***EGFR*** with adaptor proteins ( ***Shc/Grb2*** ) as revealed by coprecipitation with glutathione-S-transferase-Grb2 fusion protein coupled with immunoblotting with anti-phosphotyrosine , anti-EGFR , and anti-Shc antibodies .	parallel	0
10948	10666084	1956;6464	EGFR;Shc	The stretch rapidly ( within 2 min ) induced ***association*** of tyrosine-phosphorylated ***EGFR*** with adaptor proteins ( ***Shc/Grb2*** ) as revealed by coprecipitation with glutathione-S-transferase-Grb2 fusion protein coupled with immunoblotting with anti-phosphotyrosine , anti-EGFR , and anti-Shc antibodies .	parallel	0
10949	10666108	7124;3576	TNF-alpha;IL-8	Hyperoxia alone had a minimal effect on IL-8 gene expression , and ***TNF-alpha*** alone ***increased*** ***IL-8*** gene expression in a time-dependent manner .	positive	0
10950	10666108	7124;3576	TNF-alpha;IL-8	In contrast , the combination of ***TNF-alpha*** and hyperoxia synergistically ***increased*** ***IL-8*** gene expression as measured by ELISA ( TNF-alpha alone for 24 h = 769 + / - 89 pg/ml vs. hyperoxia + TNF-alpha for 24 h = 1 , 189 + / - 89 pg/ml ) and Northern blot analyses .	positive	0
10951	10666108	7124;3576	TNF-alpha;IL-8	Experiments involving IL-8 promoter-reporter assays , electromobility shift assays , and Western blot analyses demonstrated that hyperoxia augmented ***TNF-alpha-mediated*** ***activation*** of the ***IL-8*** promoter by a nuclear factor ( NF ) - kappaB-dependent mechanism and increased the duration of NF-kappaB nuclear translocation after concomitant treatment with TNF-alpha .	positive	1
10952	10666152	4852;7350	NPY;uncoupling protein (UCP)-1	Neuropeptide Y ( ***NPY*** ) injected into the hypothalamic paraventricular nucleus ( PVN ) stimulates feeding and ***decreases*** ***uncoupling protein (UCP)-1*** mRNA in brown adipose tissue ( BAT ) .	negative	0
10953	10666152	4852;7350	NPY;UCP-1	***NPY*** in the PVN stimulated feeding and ***decreased*** ***UCP-1*** mRNA in BAT independent of NPY-induced feeding .	negative	0
10954	10666152	4852;7352	NPY;UCP-3	In acromiotrapezius muscle , ***NPY*** ***decreased*** ***UCP-3*** mRNA , but this was reversed by restricting food intake to control levels .	negative	0
10955	10666158	7124;3952	Tumor necrosis factor (TNF)-alpha;leptin	***Tumor necrosis factor (TNF)-alpha*** ***induces*** ***leptin*** production through the p55 TNF receptor .	target	1
10956	10666158	7124;3952	Tumor necrosis factor (TNF)-alpha;leptin	***Tumor necrosis factor (TNF)-alpha*** acts directly on adipocytes to ***increase*** production of the lipostatic factor , ***leptin*** .	positive	0
10957	10666158	7124;3952	TNF-alpha;leptin	The results using all four strategies show that the ***induction*** of ***leptin*** production by ***TNF-alpha*** requires activation of the p55 TNFR and that although activation of the p75 TNFR alone can not cause leptin production , its presence affects the capability of TNF-alpha to induce leptin production through the p55 TNFR .	target	1
10958	10666192	943;944	CD30;CD30L	The activation of TRAF2 , followed by NF-kappaB , which occurs on ******CD30L/CD30****** ***binding*** , may explain the neoplastic proliferation and apoptosis protection of HD cells .	parallel	1
10959	10666198	959;941	CD40L;B7-1	After confirming that human ***CD40L*** can ***up-regulate*** expression of Fas , ***B7-1*** , and B7-2 molecules on murine BCL cells in vitro , we transfected the human CD40L gene into S typhimurium mutant ( ST40L ) , which was administrated orally to determine whether it was able to prevent the growth of BCL in mice .	positive	1
10960	10666198	959;942	CD40L;B7-2	After confirming that human ***CD40L*** can ***up-regulate*** expression of Fas , B7-1 , and ***B7-2*** molecules on murine BCL cells in vitro , we transfected the human CD40L gene into S typhimurium mutant ( ST40L ) , which was administrated orally to determine whether it was able to prevent the growth of BCL in mice .	positive	1
10961	10666198	959;355	CD40L;Fas	After confirming that human ***CD40L*** can ***up-regulate*** expression of ***Fas*** , B7-1 , and B7-2 molecules on murine BCL cells in vitro , we transfected the human CD40L gene into S typhimurium mutant ( ST40L ) , which was administrated orally to determine whether it was able to prevent the growth of BCL in mice .	positive	1
10962	10666199	2623;3569	GATA-1;IL-6	These results suggested that ***GATA-1*** may not only reprogram the lineage phenotype of M1 cells but also ***disrupt*** the biologic effects of ***IL-6*** through the sustained expression of cyclin D1 and bcl-2 .	negative	0
10963	10666199	3569;595	IL-6;cyclin D1	During IL-6-induced macrophage differentiation of M1 cells , ***IL-6*** ***down-regulated*** ***cyclin D1*** expression and induced p19 ( INK4D ) expression , leading to reduction in cdk4 activities .	negative	1
10964	10666199	3569;5967	IL-6;p19	During IL-6-induced macrophage differentiation of M1 cells , ***IL-6*** down-regulated cyclin D1 expression and ***induced*** ***p19*** ( INK4D ) expression , leading to reduction in cdk4 activities .	target	1
10965	10666199	3569;596	IL-6;bcl-2	Furthermore , although ***bcl-2*** expression was severely ***reduced*** by ***IL-6*** in M1 cells , it was sustained in GATA-1-introduced M1 cells during the culture with IL-6 .	negative	1
10966	10666204	1316;5328	Zf9;uPA	***Zf9*** transcriptionally ***activates*** urokinase plasminogen activator ( ***uPA*** ) .	positive	1
10967	10666204	1316;5328	Zf9;uPA	***Transactivation*** of ***uPA*** by ***Zf9*** is also supported in Drosophila S2 cells .	positive	1
10968	10666204	1316;5328	Zf9;uPA	Most importantly , transiently transfected ***Zf9*** ***up-regulates*** endogenous ***uPA*** messenger RNA and activity in BAECs , resulting in increased bioactive transforming growth factor-beta ( TGF-beta ) via enhancement of proteolytic activation of the latent molecule .	positive	1
10969	10666207	2155;2159	factor VII;factor Xa	The ***inhibition*** of ***factor Xa*** generation by ***factor VII*** is consistent with its competition with factor VIIa for TF .	negative	1
10970	10666220	7295;7124	Trx;TNF-alpha	In conclusion , we have found that human recombinant ***Trx*** ***induced*** ***TNF-alpha*** secretion , maintained Bcl-2 , and reduced apoptosis in B-CLL cells .	target	1
10971	10666222	332;836	survivin;caspase-3	Predictably , only recombinant survivin ( 140 ) and ***survivin*** ( 121 ) ***inhibited*** ***caspase-3*** activity .	negative	1
10972	10666243	920;3700	CD4;gp120	The drug resistance of NDK was partially overcome by preincubating virus with soluble ***CD4*** , a ***gp120*** ***ligand*** inducing conformational changes in the Env complex .	parallel	1
10973	10666284	3439;7297	IFN-alpha;Tyk2	In contrast to Jak1 , ***IFN-alpha-stimulated*** tyrosine ***phosphorylation*** of ***Tyk2*** was partially inhibited .	target	1
10974	10666336	7040;2596	TGFbeta;GAP43	***TGFbeta*** treatment further ***increased*** the synthesis of NF200 and ***GAP43*** in the transfected clones as revealed by Western blot analysis .	positive	0
10975	10666337	8940;7157	topoisomerase IIalpha and IIbeta;p53	Human ***topoisomerase IIalpha and IIbeta*** ***interact*** with the C-terminal region of ***p53*** .	parallel	1
10976	10666339	60312;6714	AFAP-110;Src	Thus , ***AFAP-110*** may be positioned to ***modulate*** the effects of ***Src*** upon actin filaments .	target	0
10977	10666367	332;836	survivin;caspase-3	Recombinant expression of green fluorescent protein ***survivin*** in endothelial cells ***reduced*** ***caspase-3*** activity and counteracted apoptosis induced by tumor necrosis factor alpha/cycloheximide .	negative	1
10978	10666388	898;1017	CCNE;CDK2	The results indicate that CCND2 cytoplasmic localization might reflect an important physiological role in tumor progression , whereas CCNE overexpression correlates with differentiation and a good prognosis , possibly because of accumulation of inactive forms of ******CCNE-CDK2****** ***complexes*** .	parallel	1
10979	10666414	1019;5925	cdk4;pRb	Shear stress inhibited the phosphorylation of a retinoblastoma protein ( pRb ) and the activity of cyclin-dependent kinase (cdk) 2 and ***cdk4*** , which ***phosphorylate*** ***pRb*** .	target	1
10980	10666414	1017;5925	cyclin-dependent kinase (cdk) 2;pRb	Shear stress inhibited the phosphorylation of a retinoblastoma protein ( pRb ) and the activity of ***cyclin-dependent kinase (cdk) 2*** and cdk4 , which ***phosphorylate*** ***pRb*** .	target	1
10981	10666414	1026;1017	p21;cdk2	The level of cdk inhibitor p21 ( Sdi1/Cip1/Waf1 ) protein , but not that of p27 ( Kip1 ) , increased as a result of shear stress , and the amount of ***p21*** protein ***associated*** with ***cdk2*** also increased , although the protein level of cdk2 was unchanged .	parallel	0
10982	10666420	3458;4012	Interferon-gamma;AT(2) receptor	***Interferon-gamma*** ***induces*** ***AT(2) receptor*** expression in fibroblasts by Jak/STAT pathway and interferon regulatory factor-1 .	target	1
10983	10666420	3458;4012	IFN-gamma;AT(2) receptor	We examined the effect of interferon ( IFN ) - gamma on AT(2) receptor expression in mouse fibroblast R3T3 cells and demonstrated that ***IFN-gamma*** treatment ***increased*** the expression of ***AT(2) receptor*** mRNA as well as its binding .	positive	0
10984	10666420	6772;3659	STAT1;IRF-1	Electrophoretic mobility shift assay with the GAS probe revealed increased ***STAT1*** ***binding*** to the ***IRF-1*** gene promoter in response to IFN-gamma stimulation .	parallel	1
10985	10666420	3458;4012	IFN-gamma;AT(2) receptor	Taken together , our data show that ***IFN-gamma*** ***upregulates*** ***AT(2) receptor*** expression in R3T3 cells via the activation of the intracellular Jak/STAT pathway and production of IRF-1 .	positive	1
10986	10666456	7341;5888	UBL1;RAD51	It was previously reported that a ubiquitin-like protein , ***UBL1*** , ***associates*** with ***RAD51*** in the yeast two-hybrid system .	parallel	0
10987	10666456	7341;5888	UBL1;RAD51	In the present study we found that non-conjugated ***UBL1*** forms a ***complex*** with ***RAD51*** and RAD52 proteins in human cells .	parallel	1
10988	10666456	7341;5893	UBL1;RAD52	In the present study we found that non-conjugated ***UBL1*** forms a ***complex*** with RAD51 and ***RAD52*** proteins in human cells .	parallel	1
10989	10666475	6426;6732	SF2;SRPK1	Functional coexpression of serine protein kinase ***SRPK1*** and its ***substrate*** ***ASF/SF2*** in Escherichia coli .	parallel	1
10990	10666614	29098;5901	MOG1;gsp1	Overexpression of ***MOG1*** is able to ***suppress*** temperature-sensitive ***gsp1*** mutants in yeast ; Deltamog1 null mutants display temperature-sensitive defects in nuclear trafficking .	negative	1
10991	1066663	9622;2161	kallikrein;Hageman factor	By studying separately some of the surface-dependent reactions involving Hageman factor , it was found that HMrK accelerated by at least an order of magnitude the following reactions : ( i ) the activation of factor XI by activated Hageman factor ; ( ii ) the activation of prekallikrein by activated Hageman factor ; and ( iii ) the ***activation*** of ***Hageman factor*** by ***kallikrein*** .	positive	1
10992	10666843	3077;567	HFE;beta 2-microglobulin	The Cys282Tyr-mutation disrupts a disulfid bond and thus abrogates ***binding*** of the mutant ***HFE-protein*** to ***beta 2-microglobulin*** and its presentation on the cell surface .	parallel	1
10993	10666843	7018;7037	transferrin;transferrin receptor	The His63Asp-mutation seems to play a role in pH-regulated dissociation of the ******transferrin receptor/transferrin****** ***complex*** in the lysosome .	parallel	1
10994	10667205	4088;4087	Smad3;Smad2	The mutant , ***Smad3*** ( DE ) , ***blocked*** the activation of wild-type ***Smad2*** and Smad3 .	positive	0
10995	10667217	84260;672	tumor suppressor protein;BRCA1	BAP1 , a candidate ***tumor suppressor protein*** that ***interacts*** with ***BRCA1*** .	parallel	1
10996	10667303	5594;5743	p38;cyclooxygenase-2	***Regulation*** of ***cyclooxygenase-2*** by the activated ***p38*** MAPK signaling pathway .	target	1
10997	10667306	5320;5743	sPLA2;COX-2	For instance , sPLA2 acts as an enhancer of COX-2 expression in rat mast cells , functional cPLA2 is required for sPLA2 induction in rat fibroblasts , and ***sPLA2*** ***augments*** cPLA2 and ***COX-2*** expression in mouse osteoblasts via endogenous PGE1 .	positive	0
10998	10667574	3552;3576	IL-1alpha;IL-8	In these cocultures , ***IL-8*** was ***induced*** by ***IL-1alpha*** and an additional , as yet unidentified , soluble factor .	target	1
10999	10667586	3082;5328	HGF;uPA	***HGF/SF*** ***induces*** the expression of urokinase plasminogen activator ( ***uPA*** ) and the uPA receptor ( uPAR ) , important mediators of cell invasion and metastasis .	target	1
11000	10667594	5599;3725	JNK;AP-1	Furthermore , ***JNK*** activation ***correlates*** with the induction of c-Jun expression , c-Jun phosphorylation on serines 63 and 73 , and increased ***AP-1*** activity .	parallel	0
11001	10667597	7422;7678	vascular endothelial growth factor;ZK7	***ZK7*** , a novel zinc finger gene , is ***induced*** by ***vascular endothelial growth factor*** and inhibits apoptotic death in hematopoietic cells .	target	1
11002	10668496	3725;5743	c-Jun;COX-2	Resveratrol inhibited PMA-mediated activation of protein kinase C and the ***induction*** of ***COX-2*** promoter activity by ***c-Jun*** .	target	1
11003	10668641	2796;2798	GnRH;GnRH-R	These results indicate that the duration of GnRH treatment is critical for ***upregulation*** of ***GnRH-R*** mRNA by continuous ***GnRH*** .	positive	1
11004	10668641	2796;2798	GnRH;GnRH-R	Collectively , our data provide strong evidence that continuous ***GnRH*** application is able to ***upregulate*** pituitary ***GnRH-R*** mRNA levels , if treated for a relatively short period ( 6 h ) .	positive	1
11005	10668641	2796;2798	GnRH;GnRH receptor	Homologous ***upregulation*** of ***GnRH receptor*** mRNA by continuous ***GnRH*** in cultured rat pituitary cells .	positive	1
11006	10668709	2;348	A2M;APOE	In one of our three samples there was an ***interaction*** between the ***A2M*** and ***APOE-epsilon4*** genes , but the other two samples showed no interaction between the two risk factors .	parallel	1
11007	10668711	2;351	A2M;Abeta	BACKGROUND : alpha2-Macroglobulin ( ***A2M*** ) forms the complex with amyloid beta-protein ( Abeta ) and is ***associated*** with degradation of ***Abeta*** .	parallel	0
11008	10668719	3456;355	IFN-beta;CD95	We report that ***IFN-beta*** moderately ***enhances*** the expression of the death receptor , ***CD95*** , at the surface of human antigen-specific T cells .	positive	0
11009	10668799	6738;6084	Ro60;hY1	Human Ro ribonucleoproteins ( RNPs ) are autoantigenic particles of unknown function ( s ) that consist of a 60-kDa protein ( ***Ro60*** ) ***associated*** with one hY RNA ( ***hY1-5*** ) .	parallel	0
11010	10668851	3586;1576	IL-10;CYP3A	***IL-10*** significantly ( P < or = .02 ) ***decreased*** ***CYP3A*** activity 12 % + / - 17 % , as reflected by midazolam clearance .	negative	0
11011	10668976	3214;3215	Hoxb-4;Hoxb-5	We found that ***induction*** of Hoxb-4 and ***Hoxb-5*** by ***Hoxb-4*** can be direct , whereas induction of Hoxb-7 is indirect , suggesting the possibility of an activating cascade .	target	1
11012	10669089	7057;7040	TSP-1;TGF-beta	***TSP-1*** is a major ***activator*** of ***TGF-beta*** in vivo and has been localized in head mesenchyme , including palates .	positive	1
11013	10669089	7058;7057	TSP-2;TSP-1	***TSP-2*** appears to ***inhibit*** ***TSP-1*** activation of latent TGF-beta by competitively binding the latent TGF-beta .	negative	1
11014	10669089	7058;7040	TSP-2;TGF-beta	***TSP-2*** appears to ***inhibit*** TSP-1 activation of latent ***TGF-beta*** by competitively binding the latent TGF-beta .	negative	1
11015	10669089	7057;7040	TSP-1;TGF-beta	TSP-2 appears to inhibit ***TSP-1*** ***activation*** of latent ***TGF-beta*** by competitively binding the latent TGF-beta .	positive	1
11016	10669103	9076;7082	Claudin-1;ZO-1	Immunoblot analysis revealed that overexpression of ***Claudin-1*** ***increased*** expression of ***ZO-1*** but not of occludin or ZO-2 .	positive	0
11017	10669103	9076;9414	Claudin-1;ZO-2	Immunoblot analysis revealed that overexpression of ***Claudin-1*** ***increased*** expression of ZO-1 but not of occludin or ***ZO-2*** .	positive	0
11018	10669116	3586;7124	IL-10;TNF-alpha	Both IL-4 and ***IL-10*** ***inhibited*** the production of ***TNF-alpha*** , which has been shown to play a crucial role in NO production .	negative	1
11019	10669116	3565;7124	IL-4;TNF-alpha	Both ***IL-4*** and IL-10 ***inhibited*** the production of ***TNF-alpha*** , which has been shown to play a crucial role in NO production .	negative	1
11020	10669345	3586;6348	IL-10;MIP-1alpha	In whole blood in vitro , the ***IL-10-induced*** ***inhibition*** of ***MIP-1alpha*** and MIP-1beta release was equally potent in the presence or absence of an anti-tumor necrosis factor ( TNF ) antibody .	negative	1
11021	10669370	3589;3458	IL-11;interferon-gamma	Plasma IL-6 , IL-1beta , and TNF-alpha levels were not different between rhIL-11-treated animals and the control group ; however , ***interferon-gamma*** levels were significantly ***reduced*** by ***IL-11*** treatment ( 2477 vs. 0 pg/mL , P < .01 ) .	negative	1
11022	10669540	958;959	B cell surface antigen CD40;CD40L	The second signal is delivered by ***interaction*** of the ***B cell surface antigen CD40*** with its ligand ( ***CD40L*** ) expressed on activated T cells .	parallel	1
11023	10669611	1762;6117	gene 59;single-stranded DNA binding protein	T4 ***gene 59*** helicase assembly protein ***binds*** to both T4 gene 41 helicase and T4 gene 32 ***single-stranded DNA binding protein*** , and to single and double-stranded DNA .	parallel	1
11024	10669624	356;7412	FasL;vascular cell adhesion molecule-1	Expression of ***FasL*** in arterial endothelium in this model ***decreased*** T-cell infiltration and expression of ***vascular cell adhesion molecule-1*** but did not affect expression of intercellular adhesion molecule-1 .	negative	0
11025	10669632	183;3487	angiotensin II;Insulin-like growth factor binding protein-4	***Insulin-like growth factor binding protein-4*** expression is ***decreased*** by ***angiotensin II*** and thrombin in rat aortic vascular smooth muscle cells .	negative	0
11026	10669632	3487;3479	IGFBP-4;IGF-I	To obtain further insight into the IGF-I system and to specifically study changes in ***IGFBP-4*** , a known ***inhibitor*** of ***IGF-I*** action , VSMCs were incubated with Ang II or thrombin .	negative	1
11027	10669633	1958;2321	Egr-1;Flt-1	Zinc finger transcription factor ***Egr-1*** ***activates*** ***Flt-1*** gene expression in THP-1 cells on induction for macrophage differentiation .	positive	1
11028	10669634	7124;5594	TNF-alpha;extracellular signal-regulated kinase 1/2	In this study , we show that ***TNF-alpha*** ***induces*** a parallel phosphorylation of ***extracellular signal-regulated kinase 1/2*** ( ERK1/2 ) and p38 mitogen-activated protein kinase ( p38MAPK ) and increases MCP-1 mRNA expression in cultured VSMCs .	target	1
11029	10669634	7124;1432	TNF-alpha;p38 mitogen-activated protein kinase	In this study , we show that ***TNF-alpha*** ***induces*** a parallel phosphorylation of extracellular signal-regulated kinase 1/2 ( ERK1/2 ) and ***p38 mitogen-activated protein kinase*** ( p38MAPK ) and increases MCP-1 mRNA expression in cultured VSMCs .	target	1
11030	10669634	7124;6347	TNF-alpha;MCP-1	In this study , we show that ***TNF-alpha*** induces a parallel phosphorylation of extracellular signal-regulated kinase 1/2 ( ERK1/2 ) and p38 mitogen-activated protein kinase ( p38MAPK ) and ***increases*** ***MCP-1*** mRNA expression in cultured VSMCs .	positive	0
11031	10669635	5579;6648	PKCbeta;Mn-SOD	Furthermore , the ***Mn-SOD*** promoter was ***activated*** either by overexpression of Sp1 or the constitutively activated form of ***PKCbeta*** in an Sp1 site-dependent manner .	positive	1
11032	10669637	3552;7124	IL-1alpha;TNF-alpha	LPS and ***IL-1alpha*** ***induced*** expression of ***TNF-alpha*** mRNA in HUVEC .	target	1
11033	10669637	3552;7124	IL-1alpha;TNF-alpha	***IL-1alpha*** ***induced*** expression and secretion of ***TNF-alpha*** protein , but LPS did not induce production of TNF-alpha protein .	target	1
11034	10669642	1050;3952	C/EBP-alpha;Leptin	Furthermore , our results suggest that ***C/EBP-alpha*** ***enhances*** ***Leptin*** expression in vivo and that PPARgamma mRNA expression is inversely associated with cardiovascular risk factors .	positive	0
11035	10669650	6667;1071	Sp1;CETP	These results indicate that ***Sp1*** and/or Sp3 ***repress*** ***CETP*** promoter activity , whereas nuclear factors binding the C allele are without effect on promoter expression .	negative	1
11036	10669650	6670;1071	Sp3;CETP	These results indicate that Sp1 and/or ***Sp3*** ***repress*** ***CETP*** promoter activity , whereas nuclear factors binding the C allele are without effect on promoter expression .	negative	1
11037	10669660	473;2155	Arg;Factor VII	In the Framingham Heart Study , the ***Arg/Gln*** polymorphism was significantly ***associated*** with ***Factor VII*** antigen levels .	parallel	0
11038	10669727	8802;5706	Galpha;p44	This approach identified Galpha ( i ) 2 and Galpha ( i ) 3 as mediators of the D2S receptor-mediated inhibition of forskolin-stimulated adenylyl cyclase activity ; ***Galpha*** ( i ) 2-mediated D2S-induced ***stimulation*** of p42 and ***p44*** mitogen-activated kinase ( MAPK ) and DNA synthesis , whereas Galpha ( i ) 3 was required for formation of transformed foci .	positive	0
11039	10669731	4690;9448	Nck;NIK	Taken together , these findings support a model in which the ***recruitment*** of the Ste20 kinase ***NIK*** to phosphotyrosine-containing proteins by ***Nck*** is an important proximal step in the signaling cascade downstream of EphRs .	target	0
11040	10669731	2047;9448	EphB1;NIK	EphB1 kinase activity and phosphorylation of a juxtamembrane tyrosine ( Y594 ) , conserved in all Eph receptors , are both critical for ***NIK*** ***activation*** by ***EphB1*** .	positive	1
11041	10669731	4690;9448	Nck;NIK	Although pY594 in the EphB1R has previously been shown to bind the SH2 domain of Nck , we found that stimulation of EphB1 and EphB2 led predominantly to a ***complex*** between ******NIK/Nck****** , p62 ( dok ) , RasGAP , and an unidentified 145-kDa tyrosine-phosphorylated protein .	parallel	1
11042	10669731	4690;8878	Nck;p62	Although pY594 in the EphB1R has previously been shown to bind the SH2 domain of Nck , we found that stimulation of EphB1 and EphB2 led predominantly to a ***complex*** between ***NIK/Nck*** , ***p62*** ( dok ) , RasGAP , and an unidentified 145-kDa tyrosine-phosphorylated protein .	parallel	1
11043	10669731	4690;5921	Nck;RasGAP	Although pY594 in the EphB1R has previously been shown to bind the SH2 domain of Nck , we found that stimulation of EphB1 and EphB2 led predominantly to a ***complex*** between ***NIK/Nck*** , p62 ( dok ) , ***RasGAP*** , and an unidentified 145-kDa tyrosine-phosphorylated protein .	parallel	1
11044	10669731	9448;8878	NIK;p62	Although pY594 in the EphB1R has previously been shown to bind the SH2 domain of Nck , we found that stimulation of EphB1 and EphB2 led predominantly to a ***complex*** between ***NIK/Nck*** , ***p62*** ( dok ) , RasGAP , and an unidentified 145-kDa tyrosine-phosphorylated protein .	parallel	1
11045	10669731	5921;9448	RasGAP;NIK	Although pY594 in the EphB1R has previously been shown to bind the SH2 domain of Nck , we found that stimulation of EphB1 and EphB2 led predominantly to a ***complex*** between ***NIK/Nck*** , p62 ( dok ) , ***RasGAP*** , and an unidentified 145-kDa tyrosine-phosphorylated protein .	parallel	1
11046	10669731	5921;8878	RasGAP;p62	Although pY594 in the EphB1R has previously been shown to bind the SH2 domain of Nck , we found that stimulation of EphB1 and EphB2 led predominantly to a ***complex*** between NIK/Nck , ***p62*** ( dok ) , ***RasGAP*** , and an unidentified 145-kDa tyrosine-phosphorylated protein .	parallel	1
11047	10669731	2047;5599	EphB1;JNK	We found that NIK activation is also critical for coupling EphB1R to biological responses that include the ***activation*** of integrins and ***JNK*** by ***EphB1*** .	positive	1
11048	10669732	1387;1385	CBP;CREB	Thus , ***recruitment*** of ***CBP*** to ***CREB*** is sufficient for transcriptional activation .	target	0
11049	10669740	207;4790	Akt;NF-kappaB	Our work demonstrates that , unlike activated Ras , which can stimulate parallel pathways to activate both DNA binding and the transcriptional activity of NF-kappaB , ***Akt*** ***stimulates*** ***NF-kappaB*** predominantly by upregulating of the transactivation potential of p65 .	positive	0
11050	10669740	207;5290	Akt;PI3K	In this study , we show that oncogenic H-Ras ***requires*** ***PI3K*** and ***Akt*** to stimulate the transcriptional activity of NF-kappaB .	target	0
11051	10669740	5290;207	PI3K;Akt	In this study , we show that oncogenic H-Ras ***requires*** ***PI3K*** and ***Akt*** to stimulate the transcriptional activity of NF-kappaB .	target	0
11052	10669740	207;4790	Akt;NF-kappaB	In this study , we show that oncogenic H-Ras requires PI3K and ***Akt*** to ***stimulate*** the transcriptional activity of ***NF-kappaB*** .	positive	0
11053	10669740	5290;4790	PI3K;NF-kappaB	In this study , we show that oncogenic H-Ras requires ***PI3K*** and Akt to ***stimulate*** the transcriptional activity of ***NF-kappaB*** .	positive	0
11054	10669743	7013;7014	TRF1;TRF2	Consistent with their role in measuring telomere length , indirect immunofluorescence indicated that both ***TRF1*** and ***TRF2*** ***bind*** to duplex telomeric DNA in vivo and are more abundant on telomeres with long TTAGGG repeat tracts .	parallel	1
11055	10669747	29970;4771	SCHIP-1;schwannomin	In attempt to shed light on schwannomin function , we have identified a novel coiled-coil protein , ***SCHIP-1*** , that specifically ***associates*** with ***schwannomin*** in vitro and in vivo .	parallel	0
11056	10669747	29970;4771	SCHIP-1;schwannomin	Our observations suggest that ***SCHIP-1*** ***interaction*** with ***schwannomin*** is regulated by conformational changes in schwannomin , possibly induced by posttranslational modifications , alternative splicing , or mutations .	parallel	1
11057	10669750	23598;4609	MAZR;c-myc	Unlike MAZ , ***MAZR*** functioned as a strong ***activator*** of the ***c-myc*** promoter in transfection assays with B cells .	positive	1
11058	10669751	5598;5599	ERK5;JNK	Furthermore , the use of dominant interfering molecules revealed that Cot ***requires*** ***JNK*** , p38s , and ***ERK5*** to stimulate the c-jun promoter fully and to induce neoplastic transformation .	target	0
11059	10669751	5599;5598	JNK;ERK5	Furthermore , the use of dominant interfering molecules revealed that Cot ***requires*** ***JNK*** , p38s , and ***ERK5*** to stimulate the c-jun promoter fully and to induce neoplastic transformation .	target	0
11060	10669751	5598;3725	ERK5;c-jun	Furthermore , the use of dominant interfering molecules revealed that Cot requires JNK , p38s , and ***ERK5*** to ***stimulate*** the ***c-jun*** promoter fully and to induce neoplastic transformation .	positive	0
11061	10669751	5599;3725	JNK;c-jun	Furthermore , the use of dominant interfering molecules revealed that Cot requires ***JNK*** , p38s , and ERK5 to ***stimulate*** the ***c-jun*** promoter fully and to induce neoplastic transformation .	positive	0
11062	10669754	5371;1616	PML;Daxx	***PML*** , but not its oncogenic fusion PML-RARalpha , ***inhibits*** the repressor function of ***Daxx*** .	negative	1
11063	10669754	7341;5371	SUMO-1;PML	In addition , ***SUMO-1*** ***modification*** of ***PML*** is required for sequestration of Daxx to the PODs and for efficient inhibition of Daxx-mediated transcriptional repression .	target	0
11064	10669755	7832;595	PC3;cyclin D1	Taken together , these findings indicate that PC3 impairs G ( 1 ) - S transition by inhibiting pRb function in consequence of a reduction of cyclin D1 levels and that ***PC3*** acts , either directly or indirectly , as a transcriptional ***regulator*** of ***cyclin D1*** .	target	1
11065	10669759	29974;335	ACF;apo	By UV cross-linking and immunoprecipitation , we show that ***ACF*** ***binds*** to ***apo-B*** mRNA in vitro and in vivo .	parallel	1
11066	10669759	339;29974	apobec-1;ACF	Coimmunoprecipitation experiments identified an ******ACF-apobec-1****** ***complex*** in transfected cells .	parallel	1
11067	10669761	10891;5465	PGC-1;PPARalpha	These results identify PGC-1 as a coactivator of PPARalpha in the transcriptional control of mitochondrial FAO capacity , define separable PPARalpha interaction and transactivation domains within the PGC-1 molecule , and demonstrate that certain features of the ******PPARalpha-PGC-1****** ***interaction*** are distinct from that of PPARgamma-PGC-1 .	parallel	1
11068	10669761	10891;5465	PGC-1;peroxisome proliferator-activated receptor alpha	The coactivator ***PGC-1*** ***cooperates*** with ***peroxisome proliferator-activated receptor alpha*** in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes .	parallel	0
11069	10669761	10891;3960	PGC-1;Gal4	***PGC-1*** also ***enhanced*** the transactivation activity of a ***PPARalpha-Gal4*** DNA binding domain fusion protein .	positive	0
11070	10669761	10891;5465	PGC-1;PPARalpha	***PGC-1*** also ***enhanced*** the transactivation activity of a ***PPARalpha-Gal4*** DNA binding domain fusion protein .	positive	0
11071	10669761	10891;5465	PGC-1;PPARalpha	Retroviral vector-mediated expression studies performed in 3T3-L1 cells demonstrated that PPARalpha and ***PGC-1*** cooperatively ***induced*** the expression of ***PPARalpha*** target genes and increased cellular palmitate oxidation rates .	target	1
11072	10669761	10891;5465	PGC-1;PPARalpha	Glutathione S-transferase " pulldown " studies revealed that in contrast to the previously reported ligand-independent interaction with PPARgamma , ***PGC-1*** ***binds*** ***PPARalpha*** in a ligand-influenced manner .	parallel	1
11073	10669761	5465;10891	PPARalpha;PGC-1	Protein-protein interaction studies and mammalian cell hybrid experiments demonstrated that the ******PGC-1-PPARalpha****** ***interaction*** involves an LXXLL domain in PGC-1 and the PPARalpha AF2 region , consistent with the observed ligand influence .	parallel	1
11074	10669763	7124;596	TNF-alpha;Bcl-2	Moreover , we show that oxidative stress mediates ***TNF-alpha-stimulated*** proteolytic ***degradation*** of ***Bcl-2*** by reducing MAP kinase activity .	negative	1
11075	10669763	7124;596	tumor necrosis factor alpha;Bcl-2	In endothelial cells , ***tumor necrosis factor alpha*** ( TNF-alpha ) ***induces*** dephosphorylation and subsequent ubiquitin-dependent degradation of the antiapoptotic protein ***Bcl-2*** .	target	1
11076	10669854	3458;3497	IFN-gamma;IgE	BACKGROUND : Although IL-4 , IL-13 , and ***IFN-gamma*** are known to ***affect*** ***IgE*** synthesis , it remains unclear which one plays the most important role in in vivo IgE synthesis in atopic patients .	target	0
11077	10669854	3596;3497	IL-13;IgE	BACKGROUND : Although IL-4 , ***IL-13*** , and IFN-gamma are known to ***affect*** ***IgE*** synthesis , it remains unclear which one plays the most important role in in vivo IgE synthesis in atopic patients .	target	0
11078	10669854	3565;3497	IL-4;IgE	BACKGROUND : Although ***IL-4*** , IL-13 , and IFN-gamma are known to ***affect*** ***IgE*** synthesis , it remains unclear which one plays the most important role in in vivo IgE synthesis in atopic patients .	target	0
11079	10670188	185;1636	AT1R;ACE	[ The C1166 allele of the ***AT1R*** gene ***associated*** with ***ACE*** DD phenotype increases the risk for deep venous thrombosis ] .	parallel	0
11080	10670449	6863;2353	neurokinin-1;c-Fos	The ***neurokinin-1*** , but not the neurokinin-2 , receptor antagonist ***attenuated*** the formalin-induced activation of ***c-Fos*** in the paraventricular nucleus of the hypothalamus .	negative	0
11081	10670451	3479;1103	insulin-like growth factor-1;choline acetyltransferase	***insulin-like growth factor-1*** markedly ***prevented*** the loss of calbindin-28kd ( n = 7 , P < 0.05 ) , ***choline acetyltransferase*** ( n = 7 , P < 0.05 ) , neuropeptide Y ( n = 7 , P < 0.05 ) , neuronal nitric oxide synthase ( n = 8 , P < 0.05 ) and glutamate acid decarboxylase ( n = 9 , P < 0.05 ) immunopositive neurons , but failed to protect parvalbumin ( n = 6 ) immunopositive neurons .	negative	0
11082	10670451	3479;4852	insulin-like growth factor-1;neuropeptide Y	***insulin-like growth factor-1*** markedly ***prevented*** the loss of calbindin-28kd ( n = 7 , P < 0.05 ) , choline acetyltransferase ( n = 7 , P < 0.05 ) , ***neuropeptide Y*** ( n = 7 , P < 0.05 ) , neuronal nitric oxide synthase ( n = 8 , P < 0.05 ) and glutamate acid decarboxylase ( n = 9 , P < 0.05 ) immunopositive neurons , but failed to protect parvalbumin ( n = 6 ) immunopositive neurons .	negative	0
11083	10670648	3458;7431	IFN-gamma;vimentin	Northern blot analysis and reporter gene assays reveal that ***IFN-gamma*** ***induces*** ***vimentin*** gene transcription in HeLa cells .	target	1
11084	10670648	3458;7431	IFN-gamma;vimentin	Band shift analysis shows that the Stat1alpha protein mediates ***vimentin*** ***induction*** by ***IFN-gamma*** .	target	1
11085	10670756	7040;4087	TGF-beta1;Smad2	Northern blot analysis showed that ***TGF-beta1*** significantly ***increased*** the mRNA level of ***Smad2*** but not of Smad4 in a dose - and time-dependent manner , suggesting that the augmentation of TGF-beta1 action is caused by increasing the expression of the downstream signalling molecule .	positive	0
11086	10670873	3557;3553	interleukin-1 receptor antagonist;IL-1beta	BACKGROUND : Soluble tumor necrosis factor receptor ( sTNFr ) and ***interleukin-1 receptor antagonist*** ( IL-1ra ) have been identified as endogenous ***inhibitors*** of TNF-alpha and ***IL-1beta*** .	negative	1
11087	10670873	3557;7124	interleukin-1 receptor antagonist;TNF-alpha	BACKGROUND : Soluble tumor necrosis factor receptor ( sTNFr ) and ***interleukin-1 receptor antagonist*** ( IL-1ra ) have been identified as endogenous ***inhibitors*** of ***TNF-alpha*** and IL-1beta .	negative	1
11088	10671193	3586;3567	IL-10;IL-5	***IL-10*** deficiency ***prevents*** ***IL-5*** overproduction and eosinophilic inflammation in a murine model of asthma-like reaction .	positive	0
11089	10671194	8744;920	4-1BBL;CD4	In addition , ***4-1BBL*** synergizes with B7 and ICAM to ***enhance*** naive ***CD4*** proliferation when antigen is limiting .	positive	0
11090	10671197	3458;3592	IFN-gamma;p35	Gal-lectin plus ***IFN-gamma*** ***stimulated*** IL-12 p40 and ***p35*** gene transcription with stable mRNA transcripts and a differential requirement for protein synthesis .	positive	0
11091	10671197	3458;5594	IFN-gamma;p40	Gal-lectin plus ***IFN-gamma*** ***stimulated*** IL-12 ***p40*** and p35 gene transcription with stable mRNA transcripts and a differential requirement for protein synthesis .	positive	0
11092	10671204	3383;959	CD54;CD154	An increased percentage of the T cells expressed activation molecules like HLA-DR , CD25 , CD26 , CD69 as well as adhesion and co-stimulatory molecules like ***CD54*** , ***CD154*** / 40 ***ligand*** .	parallel	1
11093	10671222	3824;5594	CD94;ERK	CD69-triggered ***ERK*** activation and functions are negatively ***regulated*** by ***CD94*** / NKG2-A inhibitory receptor .	negative	1
11094	10671224	4790;356	NF-kappaB;CD95L	Our studies provide evidence that Tat-enhanced ***CD95L*** expression is ***regulated*** at least in part by the ***NF-kappaB*** sites of the promoter .	target	1
11095	10671224	356;355	CD95L;CD95	***CD95*** ( APO-1 / Fas ) ***ligand*** ( ***CD95L*** ) gene expression is critically involved in activation-induced T cell apoptosis .	parallel	1
11096	10671227	7132;355	TNFR1;CD95	To evaluate ***cooperation*** between ***CD95*** and another TNFR family molecule , ***TNFR1*** , we generated mice deficient for both CD95 and TNFR1 .	parallel	0
11097	10671297	4352;7066	Mpl;Tpo	In single-point binding studies , both ***Mpl-WT*** and Y462A cells were able to ***bind*** [ ( 125 ) I ] ***Tpo*** in a specific manner .	parallel	1
11098	10671483	3569;3572	interleukin-6;gp130	The individual antibodies inhibit activation of the signal transducer by interleukin-6 and interfere with ***binding*** of ***interleukin-6*** to ***gp130*** .	parallel	1
11099	10671488	3312;3308	Hsc70;Hsp70	The ubiquitin-related BAG-1 provides a ***link*** between the molecular chaperones ******Hsc70/Hsp70****** and the proteasome .	parallel	0
11100	10671488	573;3312	BAG-1;Hsc70	The ***BAG-1*** protein ***modulates*** the chaperone activity of ***Hsc70*** and Hsp70 in the mammalian cytosol and nucleus .	target	0
11101	10671488	573;3308	BAG-1;Hsp70	The ***BAG-1*** protein ***modulates*** the chaperone activity of Hsc70 and ***Hsp70*** in the mammalian cytosol and nucleus .	target	0
11102	10671488	3312;3308	Hsc70;Hsp70	The presented findings reveal a role of BAG-1 as a physical ***link*** between the ******Hsc70/Hsp70****** chaperone system and the proteasome .	parallel	0
11103	10671503	1958;4790	Egr-1;NF-kappaB	***Inhibition*** of the RelA ( p65 ) ***NF-kappaB*** subunit by ***Egr-1*** .	negative	1
11104	10671503	1958;5970	Egr-1;p65	***Inhibition*** of the RelA ( ***p65*** ) NF-kappaB subunit by ***Egr-1*** .	negative	1
11105	10671503	1958;5970	Egr-1;RelA	In this study we demonstrate that the early growth response transcription factor ***Egr-1*** , whose DNA-binding domain shares a high degree of homology with that of Sp1 , can also ***interact*** with ***RelA*** in vitro and regulate NF-kappaB transcriptional activity in vivo .	parallel	1
11106	10671503	1958;4790	Egr-1;NF-kappaB	In this study we demonstrate that the early growth response transcription factor ***Egr-1*** , whose DNA-binding domain shares a high degree of homology with that of Sp1 , can also interact with RelA in vitro and ***regulate*** ***NF-kappaB*** transcriptional activity in vivo .	target	1
11107	10671503	1958;5970	Egr-1;RelA	Surprisingly , and in contrast to Sp1 , ***Egr-1*** specifically ***represses*** ***RelA*** transcriptional activity through its zinc finger domain .	negative	1
11108	10671503	5970;1958	RelA;Egr-1	Moreover , the ***interaction*** between ***RelA*** and the ***Egr-1*** zinc fingers is mutually exclusive with DNA binding suggesting a model in which Egr-1 directly sequesters NF-kappaB from its target promoters .	parallel	1
11109	10671514	3479;207	IGF-I;Akt-1	Although increasing the intracellular Ca ( 2 + ) concentration with the ionophore A23187 inhibited the ***activation*** of ***Akt-1*** by ***IGF-I*** , Ca ( 2 + ) does not appear to play a role in the phenylephrine-mediated inhibition of the PI 3-kinase/Akt pathway .	positive	1
11110	10671518	51164;10121	p62;Arp1	Affinity chromatography experiments demonstrate that ***p62*** ***binds*** directly to the ***Arp1*** subunit of dynactin .	parallel	1
11111	10671521	7124;54	TNF-alpha;TRAP	This study revealed that ***TNF-alpha*** directly ***induced*** the formation of tartrate-resistant acid phosphatase ( ***TRAP*** ) - positive multinucleated cells ( MNCs ) , which produced resorption pits on bone in vitro in the presence of M-CSF .	target	1
11112	10671526	5592;80318	cGK;GKAP42	Endogenous cGK-I is co-immunoprecipitated with anti-GKAP42 antibody from mouse testis tissue , suggesting that ***cGK-I*** physiologically ***interacts*** with ***GKAP42*** .	parallel	1
11113	10671526	5592;80318	cGK;GKAP42	Finally , we demonstrated that the kinase-deficient mutant of ***cGK-Ialpha*** stably ***associates*** with ***GKAP42*** and that binding of cGMP to cGK-Ialpha facilitates their release from GKAP42 .	parallel	0
11114	10671533	4790;5743	NF-kappaB;COX-2	Several lines of evidence suggest that the ***induction*** of ***COX-2*** by B [ a ] P is mediated , at least in part , by ***NF-kappaB*** .	target	1
11115	10671544	836;3192	caspase-3;scaffold attachment factor A	Apoptotic ***cleavage*** of ***scaffold attachment factor A*** ( SAF-A ) by ***caspase-3*** occurs at a noncanonical cleavage site .	target	1
11116	10671545	5741;860	PTH;Cbfa1	Thus , we demonstrate that ***PTH*** ***induces*** a PKA-dependent transactivation of ***Cbfa1*** , and this transactivation is required for collagenase-3 promoter activity in UMR cells .	target	1
11117	10671552	1499;999	beta-catenin;E-cadherin	Casein kinase II phosphorylation of E-cadherin increases ******E-cadherin/beta-catenin****** ***interaction*** and strengthens cell-cell adhesion .	parallel	1
11118	10671552	1499;999	beta-catenin;E-cadherin	***beta-catenin*** , a member of the Armadillo repeat protein family , ***binds*** directly to the cytoplasmic domain of ***E-cadherin*** , linking it via alpha-catenin to the actin cytoskeleton .	parallel	1
11119	10671552	1499;999	beta-catenin;E-cadherin	Here we report that in vitro this region is indeed phosphorylated by CKII and GSK-3beta , which results in an increased ***binding*** of ***beta-catenin*** to ***E-cadherin*** .	parallel	1
11120	10671552	1457;999	CKII;E-cadherin	Thus , ***phosphorylation*** of the ***E-cadherin*** cytoplasmic domain by ***CKII*** and GSK-3beta appears to modulate the affinity between beta-catenin and E-cadherin , ultimately modifying the strength of cell-cell adhesion .	target	1
11121	10671552	2932;999	GSK-3beta;E-cadherin	Thus , ***phosphorylation*** of the ***E-cadherin*** cytoplasmic domain by CKII and ***GSK-3beta*** appears to modulate the affinity between beta-catenin and E-cadherin , ultimately modifying the strength of cell-cell adhesion .	target	1
11122	10671553	5228;2321	placental growth factor;Flt1	Neither ***placental growth factor*** , which ***activates*** ***Flt1*** , epidermal growth factor ( EGF ) , or fibroblast growth factor ( FGF ) induced tyrosine phosphorylation of PLCgamma , indicating that KDR is uniquely important to PLCgamma activation in HUVEC .	positive	1
11123	10671560	3937;2533	SLP-76;SLAP-130	Functional ***association*** between ***SLAP-130*** and ***SLP-76*** in Jurkat T cells .	parallel	0
11124	10671560	2533;3937	SLAP-130;SLP-76	By generating both deletion and point mutants of SLAP-130 , we identified tyrosine 559 as critical for the ***interaction*** between ***SLP-76*** and ***SLAP-130*** .	parallel	1
11125	10671560	3937;2533	SLP-76;SLAP-130	These data suggest that the ******SLAP-130/SLP-76****** ***association*** is important for the negative regulatory role that SLAP-130 appears to play in T cell signaling .	parallel	0
11126	10671572	7124;4792	tumor necrosis factor-alpha;IkappaBalpha	***tumor necrosis factor-alpha*** ( TNF-alpha ) induced normal phosphorylation of IkappaBalpha but failed to ***induce*** degradation of phosphorylated ***IkappaBalpha*** .	target	1
11127	10671572	7124;4792	tumor necrosis factor-alpha;IkappaBalpha	***tumor necrosis factor-alpha*** ( TNF-alpha ) ***induced*** normal phosphorylation of ***IkappaBalpha*** but failed to induce degradation of phosphorylated IkappaBalpha .	target	1
11128	10671942	3952;2690	leptin;GHBP	Perhaps ***leptin*** , through increased insulin secretion , might ***induce*** ***GHBP/GH*** secretion , explaining the normal to high insulin-like growth factor ( IGF ) - I levels found in overnutrition .	target	1
11129	10672008	7124;5054	TNFalpha;PAI-1	In contrast to exogenously released NO that significantly reduced mostly basal PAI-1 expression , endogenously generated NO by NOS potentiated ***TNFalpha-induced*** ***upregulation*** of ***PAI-1*** expression .	positive	1
11130	10672014	4689;4688	p40-phox;p67-phox	Complementation of NADPH oxidase in p67-phox-deficient CGD patients ******p67-phox/p40-phox****** ***interaction*** .	parallel	1
11131	10672017	836;1981	caspase-3;eIF4GI	We have shown previously that polypeptide chain initiation factor ***eIF4GI*** is rapidly ***cleaved*** by ***caspase-3*** , whereas other components of the eIF4F complex are much more stable during apoptosis in BJAB and Jurkat cells .	target	1
11132	10672017	836;8661	caspase-3;eIF3	Purified recombinant ***caspase-3*** is able to ***degrade*** eIF4B and ***eIF3*** ( p35 ) in vitro , producing fragments of the same sizes as those seen in intact cells .	negative	0
11133	10672017	836;1975	caspase-3;eIF4B	Purified recombinant ***caspase-3*** is able to ***degrade*** ***eIF4B*** and eIF3 ( p35 ) in vitro , producing fragments of the same sizes as those seen in intact cells .	negative	0
11134	10672017	1978;1977	4E-BP1;eIF4E	Induction of apoptosis also results in a biphasic change in the ***association*** of ***4E-BP1*** with ***eIF4E*** .	parallel	0
11135	10672043	5937;4609	MSSP-2;c-Myc	RESULTS : We report that MSSP-1 and ***MSSP-2*** ***bound*** directly to the C-terminal portion of ***c-Myc*** , along with Max , side by side .	parallel	1
11136	10672043	4149;4609	Max;c-Myc	MSSP , ***c-Myc*** and ***Max*** formed a ternary ***complex*** in vivo , although MSSP did not directly associate with Max .	parallel	1
11137	10672043	5937;4609	MSSP;c-Myc	***MSSP*** , ***c-Myc*** and Max formed a ternary ***complex*** in vivo , although MSSP did not directly associate with Max .	parallel	1
11138	10672043	5937;4149	MSSP;Max	***MSSP*** , c-Myc and ***Max*** formed a ternary ***complex*** in vivo , although MSSP did not directly associate with Max .	parallel	1
11139	10672043	4149;5937	Max;MSSP	The ******MSSP/Myc/Max****** ternary ***complex*** lost the binding activity to the E-box sequence-the recognition sequence of c-Myc/Max complex-thereby abrogating the E-box-dependent transcription activity of c-Myc .	parallel	1
11140	10672043	5937;4609	MSSP;c-Myc	***MSSP*** specifically ***stimulated*** the cooperative transforming activity of ***c-Myc*** with ras , in a manner dependent upon the RNP sequences , while MSSP itself showed no transforming activity in mouse NIH3T3 cells .	positive	0
11141	10672043	5937;4609	MSSP;c-Myc	CONCLUSIONS : MSSP is a modulator of c-Myc and the ******c-Myc/MSSP****** ***complex*** may deregulate cell cycle controls and lead cells towards transforming pathways .	parallel	1
11142	10672043	5937;4609	MSSP;c-Myc	CONCLUSIONS : ***MSSP*** is a ***modulator*** of ***c-Myc*** and the c-Myc/MSSP complex may deregulate cell cycle controls and lead cells towards transforming pathways .	target	0
11143	10672044	4067;1437	Lyn;GM-CSF	***Association*** of ***Lyn*** tyrosine kinase to the ***GM-CSF*** and IL-3 receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosis .	parallel	0
11144	10672044	4067;3562	Lyn;IL-3	***Association*** of ***Lyn*** tyrosine kinase to the GM-CSF and ***IL-3*** receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosis .	parallel	0
11145	10672193	942;3567	CD86;IL-5	***IL-5*** production by MLN cells stimulated with somatic antigen was significantly ***reduced*** by addition of ***anti-CD86*** but not by anti-CD80 mAb .	negative	1
11146	10672319	2674;2668	GFR-alpha 1;Glial cell line-derived neurotrophic factor	***Glial cell line-derived neurotrophic factor*** ( GDNF ) and its ***receptor*** ( ***GFR-alpha 1*** ) are strongly expressed in human gliomas .	parallel	1
11147	10672496	355;356	Fas;FasL	In certain diseases , such as in HIV-infection and some autoimmune disorders , the functional activity of CD4 + CTL is disturbed preferentially at the level of ******FasL-Fas****** ***interaction*** , further emphasizing their important immunoregulatory role .	parallel	1
11148	10672498	356;355	FasL;Fas	Molecular and cellular mechanisms regulating T and B cell apoptosis through ******Fas/FasL****** ***interaction*** .	parallel	1
11149	10672498	356;355	FasL;Fas	Fas ( CD95 ) and ***Fas*** ***ligand*** ( ***FasL*** ) are a receptor/ligand pair critically involved in lymphocyte homeostasis and peripheral tolerance such that genetic defect in either Fas or FasL results in an autoimmune lymphoproliferative syndrome .	parallel	1
11150	10672498	356;355	FasL;Fas	***Binding*** of ***Fas*** by ***FasL*** induces apoptosis of the Fas-expressing cells .	parallel	1
11151	10672498	356;355	FasL;Fas	In the past few years , ******Fas/FasL****** ***interaction*** has been connected to a series of important phenomena previously viewed as independent immune processes .	parallel	1
11152	10672500	356;355	Fas ligand;Fas	Involvement of ******Fas-Fas ligand****** ***interactions*** in graft rejection .	parallel	1
11153	10672500	356;355	FasL;Fas	In addition to a deleterious role in destruction of graft tissue , ******Fas/FasL****** ***interactions*** may have a beneficial role in transplantation .	parallel	1
11154	10672830	4233;3082	c-met;HGF	The aim of this study is to ascertain the clinical significance of the expression of ***HGF*** and its ***receptor*** ( ***c-met*** ) during the course of gastric ulcer healing .	parallel	1
11155	10672833	7124;836	TNF-alpha;caspase-3	The addition of ***TNF-alpha*** and the soluble form of FasL , produced by neutrophils , significantly ***increased*** H. pylori-infected cell apoptosis and ***caspase-3*** activation .	positive	0
11156	10672910	2520;1113	gastrin;pancreastatin	Exogenous ***gastrin*** ( 4-h infusion ) ***raised*** microdialysate histamine and ***pancreastatin*** dose-dependently .	positive	0
11157	10672911	4879;820	BNP;cAMP	***BNP*** inhibited the contractile response produced by CCK-8 in a dose-response manner , with an IC50 value of 8.5 nM , and ***stimulated*** the production of ***cAMP*** .	positive	0
11158	10673036	4086;4089	Smad1;Smad4	***Smad1*** becomes phosphorylated by the cognate BMP transmembrane receptor protein kinases , ***associates*** with the common mediator ***Smad4*** and translocates to the nucleus where it is involved in regulation of gene transcription .	parallel	0
11159	10673036	4086;2033	Smad1;p300	In this report we demonstrate that ***Smad1*** ***interacts*** with the paralogous coactivators ***p300*** and CBP both in vitro and in vivo .	parallel	1
11160	10673290	7031;4586	TFF1;mucin	The TFF1 complex was present in the adherent mucus gel layer but while its interaction with mucin was destabilised by caesium chloride , the ***interaction*** between ***mucin*** and the ***TFF1*** dimer was resistant to caesium chloride .	parallel	1
11161	10673353	7297;7409	Tyk2;Vav	Earlier studies have shown that IFN-activated ***Tyk2*** kinase physical ***associates*** with p95Vav ( ***Vav*** ) , a proto-oncogene gene product expressed in hematopoietic cells .	parallel	0
11162	10673353	3439;7409	IFN-alpha;Vav	Using biochemical assays and in situ confocal microscopy , we demonstrate that ***IFN-alpha*** treatment ***triggers*** a rapid ( 10 min ) translocation of ***Vav*** from the nuclear compartment to the cytoplasm .	positive	0
11163	10673353	7520;7297	Ku80;Tyk2	In addition , we also show the existence of IFN-alpha-induced physical ***interaction*** between Vav and Ku80 , ***Ku80*** , and ***Tyk2*** , and among Vav , Ku80 , and Tyk2 in the cytoplasmic compartment of IFN-stimulated cells .	parallel	1
11164	10673353	7520;7409	Ku80;Vav	In addition , we also show the existence of IFN-alpha-induced physical ***interaction*** between ***Vav*** and Ku80 , ***Ku80*** , and Tyk2 , and among Vav , Ku80 , and Tyk2 in the cytoplasmic compartment of IFN-stimulated cells .	parallel	1
11165	10673353	7409;7297	Vav;Tyk2	In addition , we also show the existence of IFN-alpha-induced physical ***interaction*** between ***Vav*** and Ku80 , Ku80 , and ***Tyk2*** , and among Vav , Ku80 , and Tyk2 in the cytoplasmic compartment of IFN-stimulated cells .	parallel	1
11166	10673353	7409;5879	Vav;Rac1	Since recently ***Vav*** has been shown to ***promote*** the GDP/GTP exchange activity of the cytoskeleton signaling molecule small GTPase ***Rac1*** and activates its downstream signaling , our present findings raise the possibility of involvement of the small GTPase in IFN signaling leading to its biological effects , including cytoskeleton reorganization .	positive	0
11167	10673379	3336;3329	GroES;GroEL	E238 contributes to rapid ***GroES*** ***binding*** to ***GroEL*** because GroEL ( E238A ) is extremely sluggish in GroES binding .	parallel	1
11168	10673382	3569;4602	IL-6;c-myb	Protein synthesis inhibitors do not block the ***IL-6-stimulated*** ***repression*** of ***c-myb*** , or c-myc , mRNA , yet they do block the repression of Flt3 and CD24 mRNA , demonstrating the existence of both protein synthesis-independent and - dependent mechanisms of cytokine-triggered rapid gene repression during differentiation .	negative	1
11169	10673382	3569;4609	IL-6;c-myc	Protein synthesis inhibitors do not block the ***IL-6-stimulated*** ***repression*** of c-myb , or ***c-myc*** , mRNA , yet they do block the repression of Flt3 and CD24 mRNA , demonstrating the existence of both protein synthesis-independent and - dependent mechanisms of cytokine-triggered rapid gene repression during differentiation .	negative	1
11170	10673384	5196;4905	PF4;N-ethylmaleimide-sensitive factor	Antibody inhibition studies show that ***PF4*** release ***requires*** the general membrane fusion protein ***N-ethylmaleimide-sensitive factor*** ( NSF ) and well as the target membrane SNAP receptors ( t-SNAREs ) , syntaxin 2 , 4 , and SNAP-23 .	target	0
11171	10673384	5196;8773	PF4;SNAP-23	Antibody inhibition studies show that ***PF4*** release ***requires*** the general membrane fusion protein N-ethylmaleimide-sensitive factor ( NSF ) and well as the target membrane SNAP receptors ( t-SNAREs ) , syntaxin 2 , 4 , and ***SNAP-23*** .	target	0
11172	10673384	5196;2054	PF4;syntaxin 2	Antibody inhibition studies show that ***PF4*** release ***requires*** the general membrane fusion protein N-ethylmaleimide-sensitive factor ( NSF ) and well as the target membrane SNAP receptors ( t-SNAREs ) , ***syntaxin 2*** , 4 , and SNAP-23 .	target	0
11173	10673397	23421;5925	beta3-endonexin;pRB	In an in vitro kinase assay , ***beta3-endonexin*** ***inhibits*** ***pRB*** kinase activity associated with cyclin A-Cdk2 while leaving its histone H1 kinase activity unaffected .	negative	1
11174	10673399	3458;3606	Interferon-gamma;IL-18	***Interferon-gamma*** ***mediates*** gene expression of ***IL-18*** binding protein in nonleukocytic cells .	target	0
11175	10673399	10068;3606	Interleukin-18 (IL-18) binding protein;IL-18	***Interleukin-18 (IL-18) binding protein*** is a soluble decoy ***receptor*** for ***IL-18*** which efficiently antagonizes biological functions of IL-18 in vitro and in vivo .	parallel	1
11176	10673436	302;6281	annexin II;p11	The structure is surprisingly close to that of the ******p11-annexin II****** N-terminal peptide ***complex*** solved previously .	parallel	1
11177	10673500	11200;995	hCds1;Cdc25C	Like its yeast homologs , the ***Chk2/hCds1*** protein ***phosphorylates*** ***Cdc25C*** in vitro , suggesting that it arrests cells in G ( 2 ) in response to DNA damage .	target	1
11178	10673500	11200;84260	Chk2;tumor suppressor protein	Thus , in response to DNA damage , ***Chk2/hCds1*** ***stabilizes*** the p53 ***tumor suppressor protein*** leading to cell cycle arrest in G ( 1 ) .	positive	0
11179	10673501	1111;7157	hCHK1;p53	We confirmed that recombinant ***hCHK1*** , but not a kinase-defective version of hCHK1 , can ***phosphorylate*** ***p53*** in vitro at S20 .	target	1
11180	10673738	2952;2944	GSTT1;GSTM1	Moreover , a logistic regression analysis of possible predictors for myeloid malignancies , controlling for gender and race , did not reveal an ***association*** of ***GSTM1*** or ***GSTT1*** null genotypes ( P = 0.62 and 0.11 , respectively ) with treatment-related malignancies .	parallel	0
11181	10673742	5371;5914	PML;RARA	A mutated ***PML/RARA*** found in the retinoid maturation resistant NB4 subclone , NB4-R2 , ***blocks*** RARA and wild-type ***PML/RARA*** transcriptional activities .	negative	0
11182	10673742	5914;5371	RARA;PML	A mutated ***PML/RARA*** found in the retinoid maturation resistant NB4 subclone , NB4-R2 , ***blocks*** RARA and wild-type ***PML/RARA*** transcriptional activities .	negative	0
11183	10673742	5914;5371	RARA;promyelocytic leukemia	The fusion protein ***PML/RARA*** , ***associated*** with acute ***promyelocytic leukemia*** behaves as an abnormal retinoic acid ( RA ) receptor with altered transactivation properties but is still inducible by RA .	parallel	0
11184	10673775	6532;1815	5-HTTLPR;DRD4	The current results are consistent with two earlier reports in which we demonstrated an ***interaction*** between the ***5-HTTLPR*** and ***DRD4*** polymorphisms in 2-week-old neonates , in the same children assessed again at 2 months of age and in adults .	parallel	1
11185	10674268	7123;5327	tetranectin;tPA	To study this supposition , we investigated immunohistochemically the expression of ***tPA*** , uPA and its ***receptor*** , the plasminogen activator inhibitors PAI-1 and PAI-2 , ***tetranectin*** as well as the laminin breakdown as an event of secondary brain injury .	parallel	1
11186	10674277	3977;3572	LIFR;gp130	Serum concentrations of interleukin-6 ( IL-6 ) , IL-6 receptor ( IL-6R ) , ***gp130*** ( the IL-6 signaling protein ) , IL-1R antagonist ( IL-1RA ) and leukemia inhibitory factor ***receptor*** ( ***LIFR*** ) were assayed in 22 nonpregnant women and in 91 pregnant women before delivery and 1 and 3 days after delivery .	parallel	1
11187	10674277	3977;3557	LIFR;IL-1RA	Serum concentrations of interleukin-6 ( IL-6 ) , IL-6 receptor ( IL-6R ) , gp130 ( the IL-6 signaling protein ) , IL-1R antagonist ( ***IL-1RA*** ) and leukemia inhibitory factor ***receptor*** ( ***LIFR*** ) were assayed in 22 nonpregnant women and in 91 pregnant women before delivery and 1 and 3 days after delivery .	parallel	1
11188	10674277	3977;3569	LIFR;interleukin-6	Serum concentrations of ***interleukin-6*** ( IL-6 ) , IL-6 receptor ( IL-6R ) , gp130 ( the IL-6 signaling protein ) , IL-1R antagonist ( IL-1RA ) and leukemia inhibitory factor ***receptor*** ( ***LIFR*** ) were assayed in 22 nonpregnant women and in 91 pregnant women before delivery and 1 and 3 days after delivery .	parallel	1
11189	10674396	3667;3565	IRS-1;IL-4	This mechanism would involved the phosphorylation of ***IRS-1*** and IRS-2 , which ***transduce*** the ***IL-4*** signal through a PI 3-kinase - and MAPK-dependent signaling pathway .	positive	1
11190	10674396	8660;3565	IRS-2;IL-4	This mechanism would involved the phosphorylation of IRS-1 and ***IRS-2*** , which ***transduce*** the ***IL-4*** signal through a PI 3-kinase - and MAPK-dependent signaling pathway .	positive	1
11191	10674396	3565;6778	IL-4;Stat6	In fact , we have shown that ***Stat6*** was ***activated*** by ***IL-4*** in all cell lines studied where IL-4 induced 3beta-HSD expression , but not in those that failed to respond to IL-4 .	positive	1
11192	10674396	3565;3667	IL-4;IRS-1	***IL-4*** rapidly ***induced*** ***IRS-1*** and IRS-2 phosphorylation in ZR-75-1 human breast cancer cell lines .	target	1
11193	10674396	3565;8660	IL-4;IRS-2	***IL-4*** rapidly ***induced*** IRS-1 and ***IRS-2*** phosphorylation in ZR-75-1 human breast cancer cell lines .	target	1
11194	10674397	5999;156	Regulator of G protein signaling 4;GRK2	***Regulator of G protein signaling 4*** ( RGS4 ) ( an inhibitor of the activity of the alpha-subunit of Gq ) ***suppressed*** apoptotic signaling by the PTHR , whereas the C-terminal fragment of ***GRK2*** ( an inhibitor of the activity of the beta ( gamma ) - subunits of G proteins ) was without effect .	negative	1
11195	10674397	5745;5741	PTHR;PTH	The present studies were carried out to evaluate the mechanisms by which ***PTH/PTHrP*** ***receptor*** ( ***PTHR*** ) activation influences cell viability .	parallel	1
11196	10674397	5745;5744	PTHR;PTHrP	The present studies were carried out to evaluate the mechanisms by which ***PTH/PTHrP*** ***receptor*** ( ***PTHR*** ) activation influences cell viability .	parallel	1
11197	10674398	5449;6750	pit-1;somatostatin	Dual ***regulation*** of ***somatostatin*** receptor subtype 1 gene expression by ***pit-1*** in anterior pituitary GH3 cells .	target	1
11198	10674400	3172;3175	HNF-4;hnf6	Using transfection experiments and site-directed mutagenesis , we found that STAT5 and ***HNF-4*** ***stimulated*** transcription of an ***hnf6*** gene promoter-reporter construct .	positive	0
11199	10674400	6776;3175	STAT5;hnf6	Using transfection experiments and site-directed mutagenesis , we found that ***STAT5*** and HNF-4 ***stimulated*** transcription of an ***hnf6*** gene promoter-reporter construct .	positive	0
11200	10674400	3175;3172	HNF-6;hnf4	Consistent with our earlier finding that ***HNF-6*** ***stimulates*** the ***hnf4*** and hnf3beta gene promoters , GH treatment of hypophysectomized rats increased the liver concentration of HNF-4 and HNF-3beta mRNAs .	positive	0
11201	10674401	5617;3659	PRL;IRF-1	In the presence of PRL , OAS inhibited ***PRL*** ***induction*** of the immediate early ***IRF-1*** ( interferon-regulatory factor 1 ) promoter , but not PRL induction of the differentiation-specific beta-casein promoter , suggesting that OAS exerts specific effects on immediate early gene promoters .	target	1
11202	10674402	5617;1051	Prolactin;CCAAT enhancer-binding protein-beta	***Prolactin*** ***enhances*** ***CCAAT enhancer-binding protein-beta*** ( C/EBP beta ) and peroxisome proliferator-activated receptor gamma ( PPAR gamma ) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells .	positive	0
11203	10674402	5617;5468	Prolactin;peroxisome proliferator-activated receptor gamma	***Prolactin*** ***enhances*** CCAAT enhancer-binding protein-beta ( C/EBP beta ) and ***peroxisome proliferator-activated receptor gamma*** ( PPAR gamma ) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells .	positive	0
11204	10674402	5617;1051	PRL;C/EBPbeta	In this report we demonstrate that ***PRL*** , a lactogenic hormone , ***enhances*** ***C/EBPbeta*** and PPARbeta mRNA expression and augments adipogenic conversion of NIH-3T3 cells .	positive	0
11205	10674402	5617;5467	PRL;PPARbeta	In this report we demonstrate that ***PRL*** , a lactogenic hormone , ***enhances*** C/EBPbeta and ***PPARbeta*** mRNA expression and augments adipogenic conversion of NIH-3T3 cells .	positive	0
11206	10674402	6776;2167	Stat5;aP2	We further demonstrate that signal transducer and activator of transcription 5 ( ***Stat5*** ) , a PRL signal transducer , ***activates*** ***aP2*** promoter in a PRL-dependent manner .	positive	1
11207	10674403	3667;3643	IRS1;insulin receptor	These treatments had no effect on insulin receptor autophosphorylation or tyrosine phosphorylation of ***insulin receptor*** ***substrate*** 1 ( ***IRS1*** ) .	parallel	1
11208	10674492	7124;2670	tumor necrosis factor alpha;glial fibrillary acidic protein	On GL-15 cells , RA and ***tumor necrosis factor alpha*** ( TNFalpha ) both ***reduced*** the ***glial fibrillary acidic protein*** level and DNA synthesis and induced apoptotic pathways , but they were significantly more effective when used together .	negative	1
11209	10674496	7124;2670	TNF-alpha;GFAP	***TNF-alpha*** ***induced*** over-expression of ***GFAP*** is associated with MAPKs .	target	1
11210	10674496	7124;2670	TNF-alpha;GFAP	We conclude that ***TNF-alpha*** may ***upregulate*** ***GFAP*** through the MAPK signaling pathway .	positive	1
11211	10674712	1489;5706	CT-1;p44	Like other members of the interleukin-6 family of cytokines , ***CT-1*** ***stimulates*** both the ***p42/p44*** mitogen-activated protein kinase pathway and the Janus-activated kinase/signal transducers and activators of transcription pathway .	positive	0
11212	10674822	3458;355	IFN-gamma;CD95	In this report , we demonstrated that murine epidermal LC constitutively express the Fas antigen ( ***CD95*** ) and the expression was ***up-regulated*** by the addition of ***IFN-gamma*** in cultures .	positive	1
11213	10674822	3458;355	IFN-gamma;Fas	These results suggest that LC may acquire the susceptibility to Fas-mediated apoptosis through ***up-regulation*** of the ***Fas*** expression by ***IFN-gamma*** derived from activated T cells and that the elimination of LC may be important for preventing excess cutaneous inflammatory diseases .	positive	1
11214	10674826	958;3569	CD40;IL-6	***CD40*** ligation inhibits trichilemmoma cell proliferation and ***induces*** ***IL-6*** production .	target	1
11215	10674999	5788;3956	CD45;GAL1	Our results demonstrate that the tyrosine phosphatase CD45 is the receptor for GAL1 , and that the src-type tyrosine kinase Lyn is a target for the effects of ******GAL1/CD45****** ***interactions*** in B-cells .	parallel	1
11216	10674999	5788;3956	CD45;GAL1	Our results demonstrate that the tyrosine phosphatase ***CD45*** is the ***receptor*** for ***GAL1*** , and that the src-type tyrosine kinase Lyn is a target for the effects of GAL1/CD45 interactions in B-cells .	parallel	1
11217	10675027	7200;4082	TRH;MARCKS	***TRH*** ***stimulates*** the release of ***MARCKS*** from the membrane/cytoskeletal fraction to the cytosol fraction .	positive	0
11218	10675041	862;9139	AML1-MTG8;MTG8-like protein	We previously showed that ectopically expressed ***AML1-MTG8*** fusion protein is ***associated*** with an ***MTG8-like protein*** in the mouse myeloid precursor cell line L-G , and this association seemed to be required for AML1-MTG8 to stimulate proliferation .	parallel	0
11219	10675223	4314;4318	MMP-3;MMP-9	Using enzyme linked immunosorbent assay ( ELISA ) ***MMP-3*** ( which can ***activate*** ***MMP-9*** ) was detected in low concentrations in the CSF of 13 of 29 patients with neuroborreliosis , but not in controls .	positive	1
11220	10675242	3557;3552	IL-1ra;IL-1alpha	The effects of ***IL-1alpha*** were completely ***inhibited*** by its specific receptor antagonist ***IL-1ra*** .	negative	1
11221	10675270	1236;6363	CCR7;Exodus-2 and -3	Expression of message for ***CCR7*** , a shared ***receptor*** for ***Exodus-2 and -3*** , was detected in activated polyclonal NK cells and NKL cells but not resting NK cells .	parallel	1
11222	10675270	6363;4684	Exodus-2 and -3;CD56	Nevertheless , ***Exodus-2 and -3*** significantly ***augmented*** IL-2-induced proliferation of normal human ***CD56*** ( dim ) NK cells .	positive	0
11223	10675271	3952;969	leptin;CD69	***leptin*** dose-dependently ***enhanced*** stimulated ***CD69*** expression .	positive	0
11224	10675333	1956;6655	EGFR;Sos2	A sos1 ( - / - ) cell line , which expressed readily detectable levels of the closely related Sos2 protein , formed ***complexes*** between ***Sos2*** , epidermal growth factor receptor ( ***EGFR*** ) and Shc efficiently , gave normal Ras.GTP and ERK responses when treated with EGF for < or = 10 min and was transformed readily by activated Ras .	parallel	1
11225	10675335	8850;1869	P/CAF;E2F1	We show that the p300/CBP-associated factor ***P/CAF*** , and to a lesser extent p300/CBP itself , can ***acetylate*** ***E2F1*** in vitro and that intracellular E2F1 is acetylated .	target	1
11226	10675336	2957;6908	TFIIA;TBP	Biochemical characterization indicated that mutant ( mt ) - Toa1 dimerizes well with Toa2 ; it supports specific recognition of the TATA box by TBP but forms less stable ******TBP-TFIIA-DNA****** ***complexes*** .	parallel	1
11227	10675363	2209;1401	FcgammaRIa;CRP	***FcgammaRIa*** , the high-affinity IgG receptor , ***binds*** ***CRP*** with low affinity , whereas FcgammaRIIa , the low-affinity IgG receptor , binds CRP with high affinity .	parallel	1
11228	10675364	6804;1080	Syntaxin 1A;CFTR	Reagents that disrupt the ******CFTR-Syntaxin 1A****** ***interaction*** , including soluble Syntaxin 1A cytosolic domain and recombinant Munc-18 , augmented cAMP-dependent CFTR Cl ( - ) currents by more than 2 - to 4-fold in mouse tracheal epithelial cells and cells derived from human nasal polyps , but these reagents did not affect CaMK II-activated Cl ( - ) currents in these cells .	parallel	1
11229	10675482	7157;7422	p53;VEGF	Recently , it was reported that a mutant p53 in #duced the expression of VEGF mRNA , and that wild-type ***p53*** ***down-regulated*** endogenous ***VEGF*** mRNA levels .	negative	1
11230	10675485	5891;6714	renal cell carcinoma antigen;c-Src	***Association*** of ***renal cell carcinoma antigen*** , disialylgalactosylgloboside , with ***c-Src*** and Rho A in clustered domains at the surface membrane .	parallel	0
11231	10675486	1019;5925	CDK4;pRb	These findings suggest that ***phosphorylation*** of ***pRb*** by ***CDK4*** is not critical in the carcinogenesis or in the establishment of HPV-positive cervical cancer cell lines , since HPV E6 or E7 viral-transforming proteins inactivate p53 and pRb tumor suppressor protein function , resulting in deregulated progression of the cell cycle .	target	1
11232	10675494	7157;596	p53;Bcl-2	These data demonstrate that both the loss of ***p53*** and carcinogen stimulation are ***associated*** with altered expression of Fas-R , ***Bcl-2*** and FAP-1 , although the loss of p53 is sufficient for altered expression of Bax .	parallel	0
11233	10675494	7157;5783	p53;FAP-1	These data demonstrate that both the loss of ***p53*** and carcinogen stimulation are ***associated*** with altered expression of Fas-R , Bcl-2 and ***FAP-1*** , although the loss of p53 is sufficient for altered expression of Bax .	parallel	0
11234	10675494	7157;355	p53;Fas	These data demonstrate that both the loss of ***p53*** and carcinogen stimulation are ***associated*** with altered expression of ***Fas-R*** , Bcl-2 and FAP-1 , although the loss of p53 is sufficient for altered expression of Bax .	parallel	0
11235	10675528	840;5757	caspase-3 and -7;Prothymosin alpha	In vitro , ***Prothymosin alpha*** could be ***cleaved*** at D ( 99 ) by ***caspase-3 and -7*** .	target	1
11236	10675530	6885;4790	TAK1;NF-kappaB	A kinase-negative mutant of ***TAK1*** ***inhibited*** the LPS-induced ***NF-kappaB*** activation both in a macrophage-like cell line , RAW 264.7 , and in human embryonic kidney 293 cells expressing toll-like receptor 2 or 4 .	positive	1
11237	10675563	857;5338	caveolin-1;PLD2	These data identify the PLD activity in caveolin-rich membranes as PLD2 and provide in vivo evidence suggesting that ***caveolin-1*** ***regulates*** ***PLD2*** activity .	target	1
11238	10675611	28987;5714	Nob1p;Nin1p	***Nob1p*** , which ***interacts*** with ***Nin1p/Rpn12*** , a subunit of the 19S regulatory particle ( RP ) of the yeast 26S proteasome , has been identified by two-hybrid screening .	parallel	1
11239	10675770	2668;5601	Glial-derived neurotrophic factor;JUN kinase	***Glial-derived neurotrophic factor*** ( GDNF ) ***prevents*** ethanol-induced apoptosis and ***JUN kinase*** phosphorylation .	negative	0
11240	10675770	2668;5599	GDNF;JNK	***GDNF*** , in turn , ***prevented*** both ethanol-induced apoptosis and the activation of the death-associated ***JNK*** cascade .	negative	0
11241	10676633	7157;983	p53;cdc2	Biochemical analysis showed that ***p53*** ***inhibits*** cell cycle-dependent expression of ***cdc2*** and cyclin B1 and consequently inhibits cdc2 kinase .	negative	1
11242	10676633	7157;891	p53;cyclin B1	Biochemical analysis showed that ***p53*** ***inhibits*** cell cycle-dependent expression of cdc2 and ***cyclin B1*** and consequently inhibits cdc2 kinase .	negative	1
11243	10676633	891;983	cyclin B1;cdc2	Therefore , ***inactivation*** of ***cdc2*** kinase through cdc2 and ***cyclin B1*** repression is an essential step in p53-mediated G2-M arrest .	negative	1
11244	10676638	1111;995	Chk1;dual specificity phosphatase cdc25C	***Chk1*** ***phosphorylates*** the ***dual specificity phosphatase cdc25C*** on Ser-216 , and this may be involved in preventing cdc25 from activating cdc2/cyclinB and initiating mitosis .	target	1
11245	10676714	183;5502	angiotensin II;inhibitor-1	***angiotensin II*** has been shown to ***influence*** the actions of plasminogen activator ***inhibitor-1*** and , consequently , its thrombotic and sclerotic effects .	target	0
11246	10676816	396;998	RhoGDI;Cdc42	The 2.6 A X-ray crystallographic structure of the ******Cdc42/RhoGDI****** ***complex*** reveals two important sites of interaction between GDI and Cdc42 .	parallel	1
11247	10676844	2057;2056	EPOR;EPO	In this study we focused on the functional importance of STAT5 docking sites in the intracellular ***EPO*** ***receptor*** ( ***EPOR*** ) domain for the mediation of antiapoptotic activities .	parallel	1
11248	10676846	1906;2822	endothelin-1;PLD	Lysophosphatidic acid ( LPA ) and ***endothelin-1*** ( ET-1 ) ***activate*** phospholipase D ( ***PLD*** ) in many cell types .	positive	1
11249	10677040	8802;10497	Galpha;UNC-13	Serotonin inhibition of synaptic transmission : ***Galpha*** ( 0 ) ***decreases*** the abundance of ***UNC-13*** at release sites .	negative	0
11250	10677043	4803;4915	nerve growth factor;TrkB	***Activation*** of ***TrkB*** by brain-derived ***nerve growth factor*** ( BDNF ) led to production of a PLC-dependent , nonselective cation conductance in pontine neurons .	positive	1
11251	10677208	4052;7040	LTBP-1;TGF-beta	Covalent ***association*** of ***LTBP-1*** ( latent TGF-beta binding protein-1 ) to latent ***TGF-beta*** is mediated by the third eight-cysteine ( also referred to as TB ) module of LTBP-1 , a domain designated as CR3 .	parallel	0
11252	10677219	1432;4790	p38 MAP kinase;NF-kappa B	However , ***p38 MAP kinase*** is not involved in ***activation*** of ***NF-kappa B*** , a key transcriptional activator of HIV gene expression , in response to UV , suggesting that NF-kappa B acts independently of p38 MAP kinase .	positive	1
11253	10677219	7124;1432	TNF-alpha;p38 MAP kinase	Treatment of cells with sorbitol ( hyperosmotic shock ) strongly activates p38 MAP kinase , whereas the cytokine ***TNF-alpha*** is a poor ***activator*** of ***p38 MAP kinase*** .	positive	1
11254	10677219	7124;4790	TNF-alpha;NF-kappa B	On the other hand , ***TNF-alpha*** is a strong ***activator*** of ***NF-kappa B*** whereas sorbitol is not .	positive	1
11255	10677246	355;356	Fas;FasL	Since Fas ligand ( FasL ) can induce apoptosis of Fas-bearing cells , ******Fas/FasL****** ***interactions*** can play a critical role in maintaining self-tolerance .	parallel	1
11256	10677246	356;355	FasL;Fas	******Fas/FasL****** ***interactions*** in lupus-like autoimmune disease have been well characterized in studies using either Fas or FasL mutant mice .	parallel	1
11257	10677246	356;355	FasL;Fas	These results indicate that ******Fas/FasL****** ***interactions*** not only regulate IgG-type autoantibody production , but also influence the development of lupus nephritis in B/W F1 mice .	parallel	1
11258	10677261	6469;8403	sonic hedgehog;Sox14	The HMG box transcription factor gene ***Sox14*** marks a novel subset of ventral interneurons and is ***regulated*** by ***sonic hedgehog*** .	target	1
11259	10677261	6469;8403	sonic hedgehog;Sox14	Furthermore , expression of ***Sox14*** in spinal cord explants was found to be ***regulated*** by ***sonic hedgehog*** in a dose-dependent manner .	target	1
11260	10677388	213;5706	Albumin;p42	***Albumin*** ***stimulates*** ***p44/p42*** extracellular-signal-regulated mitogen-activated protein kinase in opossum kidney proximal tubular cells .	positive	0
11261	10677388	213;5594	Albumin;ERK	In addition , recombinant human ***Albumin*** ***activated*** ***ERK*** in a time-dependent ( maximal after 5 min ) and dose-dependent ( maximal at 1 mg/ml ) fashion .	positive	1
11262	10677500	8600;4982	osteoprotegerin ligand;osteoprotegerin	We have generated RANK ( receptor activator of NF-kappaB ) nullizygous mice to determine the molecular genetic ***interactions*** between ***osteoprotegerin*** , ***osteoprotegerin ligand*** , and RANK during bone resorption and remodeling processes .	parallel	1
11263	10677502	581;596	Bax;Bcl2	In addition , although the mechanism of regulation of Bcl2 by phosphorylation is not yet clear , our results indicate that phosphorylation may functionally stabilize the ******Bcl2-Bax****** ***heterodimerization*** .	parallel	1
11264	10677503	472;7157	Atm;p53	Taken together , our results support a model in which the upstream effectors DNA-PKcs and ***Atm*** selectively ***activate*** ***p53*** to differentially regulate cell-cycle and apoptotic responses .	positive	1
11265	10677503	5591;7157	DNA-PKcs;p53	Taken together , our results support a model in which the upstream effectors ***DNA-PKcs*** and Atm selectively ***activate*** ***p53*** to differentially regulate cell-cycle and apoptotic responses .	positive	1
11266	10677567	5663;824	presenilin-1;m-calpain	Molecular interactions between presenilin and calpain : ***inhibition*** of ***m-calpain*** protease activity by ***presenilin-1*** , 2 and cleavage of presenilin-1 by m - , mu-calpain .	negative	1
11267	10677567	824;5663	m-calpain;PS1	On the other hand , ***PS1*** was ***cleaved*** by ***m-calpain*** and mu-calpain at a different site from those already reported ( constitutive cleavage or alternative cleavage ) .	target	1
11268	10678165	6714;6722	Src;SRF	Inhibition of ***Src*** also ***blocked*** cytokinesis , ***SRF*** induction by activated DRFs , and cooperative stress fiber formation with active ROCK .	positive	0
11269	10678172	5897;5896	RAG2;RAG1	Identification of two catalytic residues in RAG1 that define a single active site within the ******RAG1/RAG2****** protein ***complex*** .	parallel	1
11270	10678544	133;183	Adrenomedullin;angiotensin II	OBJECTIVE : ***Adrenomedullin*** ***inhibits*** ***angiotensin II*** stimulated aldosterone production in vitro and in vivo in experimental animals .	negative	1
11271	10678544	133;183	Adrenomedullin;angiotensin II	RESULTS : ***Adrenomedullin*** significantly ***inhibited*** ***angiotensin II*** stimulated aldosterone production : the increment in aldosterone on the placebo day was 691 pmol/l compared with 552 pmol/l on the Adrenomedullin day ( P < 0.004 ) .	negative	1
11272	10678570	4233;3082	c-met;HGF	In Kupffer cell-depleted mice , the number of HGF-expressing cells decreased in the regenerating liver , and expressions of ***HGF*** and its ***receptor*** ( ***c-met*** ) as well as other growth factors/cytokines were less prominent than in control mice .	parallel	1
11273	10678579	3569;3240	interleukin-6;haptoglobin	COX-2 synthesizes prostaglandin E2 ( PGE2 ) which stimulates bcl-2 and inhibits apoptosis , and induces ***interleukin-6*** ( IL-6 ) which ***enhances*** ***haptoglobin*** synthesis .	positive	0
11274	10678585	6647;4790	SOD;NF-kappaB	Exogenous superoxide dismutase ( ***SOD*** ) ***enhanced*** the ***NF-kappaB*** activation by PMA , while catalase blocked it .	positive	0
11275	10678754	4914;4803	trkA;NGF	RT-PCR analysis revealed the presence of p75 and trkB transcripts in cortical cultures , but did not detect transcripts of ***trkA*** , a high-affinity ***receptor*** for ***NGF*** .	parallel	1
11276	10678776	4852;627	NPY;BDNF	These observations suggest that the role of BDNF and the ***interaction*** of ******BDNF-NPY****** may differ between species .	parallel	1
11277	10678911	5594;6556	p38;NRAMP1	Blockage of either ***p38*** or p42/44 MAPK pathways ***suppressed*** the expression of ***NRAMP1*** to basal levels .	positive	1
11278	10678917	7124;7412	TNF-alpha;VCAM-1	Expression of ***VCAM-1*** was ***mediated*** not only by ***TNF-alpha*** but also by IL-1alpha and IL-1beta , all of which were synthesized by endothelial cells in response to C. albicans .	target	0
11279	10678925	3553;355	interleukin 1beta;Fas	Tumor necrosis factor alpha and ***interleukin 1beta*** ***up-regulate*** gastric mucosal ***Fas*** antigen expression in Helicobacter pylori infection .	positive	1
11280	10678925	7124;355	Tumor necrosis factor alpha;Fas	***Tumor necrosis factor alpha*** and interleukin 1beta ***up-regulate*** gastric mucosal ***Fas*** antigen expression in Helicobacter pylori infection .	positive	1
11281	10678925	3553;355	interleukin 1beta;Fas	Of various inflammatory cytokines tested , only ***interleukin 1beta*** and Tumor necrosis factor alpha ***induced*** ***Fas*** Ag expression , and removal of either of these from the conditioned medium abrogated the response .	target	1
11282	10678925	7124;355	Tumor necrosis factor alpha;Fas	Of various inflammatory cytokines tested , only interleukin 1beta and ***Tumor necrosis factor alpha*** ***induced*** ***Fas*** Ag expression , and removal of either of these from the conditioned medium abrogated the response .	target	1
11283	10678943	959;958	CD40 ligand;CD40	The ******CD40/CD40 ligand****** ***interaction*** is required for resistance to toxoplasmic encephalitis .	parallel	1
11284	10678943	958;959	CD40;CD40 ligand	Since the ******CD40/CD40 ligand****** ( CD40L ) ***interaction*** is involved in the regulation of macrophage production of interleukin 12 ( IL-12 ) and T-cell production of gamma interferon ( IFN-gamma ) , effector cell functions associated with resistance to Toxoplasma gondii , the role of CD40L in immunity to this parasite was assessed .	parallel	1
11285	10678943	959;958	CD40L;CD40	Together , these results identify an important role for the ******CD40/CD40L****** ***interaction*** in resistance to T. gondii .	parallel	1
11286	10679013	983;324	cdc2;APC	At the end of G1 , the balance is reversed and ***cdc2/cyclin*** activity ***down-regulates*** both rum1 and the cyclin-degrading activity of the ***APC*** .	negative	1
11287	10679027	3643;596	insulin receptor;Bcl-2	***Association*** of ***insulin receptor*** substrate proteins with ***Bcl-2*** and their effects on its phosphorylation and antiapoptotic function .	parallel	0
11288	10679027	8660;596	IRS-2;Bcl-2	***IRS-2*** but not IRS-3 ***binds*** to ***Bcl-2*** , and IRS-1 associates with Bcl-XL but not with Bax or Bik .	parallel	1
11289	10679027	3667;598	IRS-1;Bcl-XL	IRS-2 but not IRS-3 binds to Bcl-2 , and ***IRS-1*** ***associates*** with ***Bcl-XL*** but not with Bax or Bik .	parallel	0
11290	10679027	3667;596	IRS-1;Bcl-2	Overexpression of ***IRS-1*** ***suppresses*** phosphorylation of ***Bcl-2*** induced by stimulation with insulin , and the hypophosphorylation may lead to its enhanced antiapoptotic activity .	negative	1
11291	10679028	7037;7018	TfR;transferrin	The decrease of the surface ***transferrin*** ***receptor*** ( ***TfR*** ) was correlated with expression levels of the mutant protein .	parallel	1
11292	10679062	7124;1230	TNF-alpha;CCR-1	Stimulation of mature DCs with TGF-beta 1 also enhanced ***TNF-alpha-induced*** ***down-regulation*** of the expressions of ***CCR-1*** , CCR-3 , CCR-5 , CCR-6 , and CXCR-4 , and chemotaxis to their respective ligands , while this stimulation suppressed TNF-alpha-induced expression of CCR-7 and chemotactic migratory ability to MIP-3 beta .	negative	1
11293	10679062	7124;1232	TNF-alpha;CCR-3	Stimulation of mature DCs with TGF-beta 1 also enhanced ***TNF-alpha-induced*** ***down-regulation*** of the expressions of CCR-1 , ***CCR-3*** , CCR-5 , CCR-6 , and CXCR-4 , and chemotaxis to their respective ligands , while this stimulation suppressed TNF-alpha-induced expression of CCR-7 and chemotactic migratory ability to MIP-3 beta .	negative	1
11294	10679062	7124;1234	TNF-alpha;CCR-5	Stimulation of mature DCs with TGF-beta 1 also enhanced ***TNF-alpha-induced*** ***down-regulation*** of the expressions of CCR-1 , CCR-3 , ***CCR-5*** , CCR-6 , and CXCR-4 , and chemotaxis to their respective ligands , while this stimulation suppressed TNF-alpha-induced expression of CCR-7 and chemotactic migratory ability to MIP-3 beta .	negative	1
11295	10679062	7124;1235	TNF-alpha;CCR-6	Stimulation of mature DCs with TGF-beta 1 also enhanced ***TNF-alpha-induced*** ***down-regulation*** of the expressions of CCR-1 , CCR-3 , CCR-5 , ***CCR-6*** , and CXCR-4 , and chemotaxis to their respective ligands , while this stimulation suppressed TNF-alpha-induced expression of CCR-7 and chemotactic migratory ability to MIP-3 beta .	negative	1
11296	10679062	7124;7852	TNF-alpha;CXCR-4	Stimulation of mature DCs with TGF-beta 1 also enhanced ***TNF-alpha-induced*** ***down-regulation*** of the expressions of CCR-1 , CCR-3 , CCR-5 , CCR-6 , and ***CXCR-4*** , and chemotaxis to their respective ligands , while this stimulation suppressed TNF-alpha-induced expression of CCR-7 and chemotactic migratory ability to MIP-3 beta .	negative	1
11297	10679064	6778;3565	Stat6;IL-4	***Stat6*** ***regulation*** of in vivo ***IL-4*** responses .	target	1
11298	10679064	6778;3565	Stat6;IL-4	Thus , ***Stat6*** signaling ***enhances*** primary ***IL-4*** responses that are made as part of a type 0 cytokine response ( mixed type 1 and type 2 ) and is required for normal development or survival of Th2 memory cells .	positive	0
11299	10679065	1432;820	p38 mitogen-activated protein kinase;cAMP	Identification of a membrane Ig-induced ***p38 mitogen-activated protein kinase*** module that ***regulates*** ***cAMP*** response element binding protein phosphorylation and transcriptional activation in CH31 B cell lymphomas .	target	1
11300	10679075	7852;6352	chemokine receptor;RANTES	***RANTES*** ***binding*** and down-regulation by a novel human herpesvirus-6 beta ***chemokine receptor*** .	parallel	1
11301	10679078	3586;3458	IL-10;IFN-gamma	Furthermore , IL-6 also up-regulates ***IL-10*** production which , together with IL-6 , negatively ***regulates*** IL-12 and ***IFN-gamma*** production .	negative	1
11302	10679090	356;355	FasL;Fas	Evidence for Fas-mediated lysis of beta cells in the pathogenesis of IDDM in nonobese diabetic ( NOD ) mice includes : 1 ) Fas-deficient NOD mice bearing the lpr mutation ( NOD-lpr/lpr ) fail to develop IDDM ; 2 ) transgenic expression of ***Fas*** ***ligand*** ( ***FasL*** ) on beta cells in NOD mice may result in accelerated IDDM ; and 3 ) irradiated NOD-lpr/lpr mice are resistant to adoptive transfer of diabetes by cells from NOD mice .	parallel	1
11303	10679090	356;355	FasL;Fas	Here we present novel evidence for the role of ******Fas/FasL****** ***interactions*** in the progression of NOD diabetes using two newly derived mouse strains .	parallel	1
11304	10679093	5452;5451	Oct-2;Oct-1	Oct-1/Oct-2 binding was required for the inhibitory activity of this sequence because mutations that blocked ******Oct-1/Oct-2****** ***binding*** also eliminated inhibition of the B29 promoter .	parallel	1
11305	10679111	3606;3458	IL-18;IFN-gamma	In another experiment , IL-18 administered only with allergic sensitization increased BAL eosinophilia and lung expression of IL-5 and IFN-gamma , while ***IL-18*** administered only with RW challenge decreased BAL eosinophilia and ***increased*** lung ***IFN-gamma*** expression , while lung expression of IL-5 remained unchanged .	positive	0
11306	10679127	3600;3605	IL-15;IL-17	High levels of IL-17 in rheumatoid arthritis patients : ***IL-15*** ***triggers*** in vitro ***IL-17*** production via cyclosporin A-sensitive mechanism .	positive	0
11307	10679205	1571;3952	CYP2E1;leptin	The present data indicate that while CYP2E1 is still inducible in obese mice by xenobiotics and fasting , full constitutive expression of ***CYP2E1*** ***requires*** ***leptin*** to be present .	target	0
11308	10679259	405;3091	HIF-1beta;HIF-1	In this study , we found that zinc induced the accumulation and nuclear translocation of hypoxia-inducible factor ( HIF ) -1 alpha but inhibited the nuclear translocation of ***HIF-1beta*** , which ***inactivated*** ***HIF-1*** and suppressed EPO mRNA induction in hypoxic cells .	negative	1
11309	10679268	26228;1436	STAP-1;c-fms	A two-hybrid assay indicated that ***STAP-1*** ***bound*** not only to c-kit but also to ***c-fms*** but not to JAK2 or Pyk2 .	parallel	1
11310	10679268	26228;3815	STAP-1;c-kit	A two-hybrid assay indicated that ***STAP-1*** ***bound*** not only to ***c-kit*** but also to c-fms but not to JAK2 or Pyk2 .	parallel	1
11311	10679277	213;351	albumin;Abeta	Human serum ***albumin*** ***bound*** ***Abeta*** peptides rapidly with a 1:1 stoichiometry and at physiological concentrations was capable of binding over 95 % of an input of 5 ng/ml Abeta .	parallel	1
11312	10679277	351;213	Abeta;albumin	Incubation of 5 ng/ml of Abeta in plasma revealed that about 30 % of the peptides were still detectable by immunoassay , presumably reflecting the ***binding*** of ***Abeta*** peptides with ***albumin*** and other plasma molecules .	parallel	1
11313	10679296	2132;2131	EXT2;EXT1	***Association*** of ***EXT1*** and ***EXT2*** , hereditary multiple exostoses gene products , in Golgi apparatus .	parallel	0
11314	10679298	3479;4313	hIGF-I;MMP-2	After 4 days of rabbit bone cell culture , hGH and ***hIGF-I*** significantly ***modulated*** cathepsin , MMP-9 ( latent form ) and ***MMP-2*** ( active form ) activities .	target	0
11315	10679298	3479;4318	hIGF-I;MMP-9	After 4 days of rabbit bone cell culture , hGH and ***hIGF-I*** significantly ***modulated*** cathepsin , ***MMP-9*** ( latent form ) and MMP-2 ( active form ) activities .	target	0
11316	10679298	3479;4313	hIGF-I;MMP-2	However , ***hIGF-I*** but not hGH ***increased*** ***MMP-2*** and MMP-9 activities released by purified osteoclasts .	positive	0
11317	10679298	3479;4318	hIGF-I;MMP-9	However , ***hIGF-I*** but not hGH ***increased*** MMP-2 and ***MMP-9*** activities released by purified osteoclasts .	positive	0
11318	10679324	207;79837	Rac;phosphatidylinositol-4-phosphate 5-kinase	We previously demonstrated that ***Rac*** ***interacts*** with a type I ***phosphatidylinositol-4-phosphate 5-kinase*** ( PIP 5-kinase ) in a GTP-independent manner [ 12 ] [ 13 ] .	parallel	1
11319	10679386	1499;595	beta-catenin;cyclin D1	For instance the discovery that ***cyclin D1*** is ***regulated*** by ***beta-catenin/Tcf*** -4 allows us to tie the APC pathway to the RB pathway and cell cycle control .	target	1
11320	10679516	551;3315	AVP;HSP27	Dissociation of the aggregated ***HSP27*** to the dissociated HSP27 was ***induced*** by ***AVP*** .	target	1
11321	10679516	551;3315	AVP;HSP27	These results strongly suggest that p38 MAP kinase takes part in the pathway of the ***AVP-stimulated*** ***induction*** of ***HSP27*** in vascular smooth muscle cells .	target	1
11322	10679516	551;1432	AVP;p38 MAP kinase	***AVP*** ***stimulated*** the phosphorylation of p42/p44 MAP kinase and ***p38 MAP kinase*** .	positive	0
11323	10679516	551;5706	AVP;p42	***AVP*** ***stimulated*** the phosphorylation of ***p42/p44*** MAP kinase and p38 MAP kinase .	positive	0
11324	10679771	25;4804	c-Abl;NGF receptor	These results suggest that ***c-Abl*** may be ***recruited*** to the ***NGF receptor*** complex and be involved in regulating specific phosphorylation events that occur during neuronal differentiation .	target	0
11325	10679771	25;4914	c-Abl;TrkA	The ***interaction*** of ***c-Abl*** with ***TrkA*** was also observed in differentiated pheochromocytoma PC12 cells .	parallel	1
11326	10679773	4915;627	TrkB;brain-derived neurotrophic factor	Because mRNAs encoding ***brain-derived neurotrophic factor*** ( BDNF ) and its ***receptor*** tyrosine kinase ***TrkB*** are detectable in subsets of sensory neurons from the earliest stages of their development , we investigated whether a BDNF autocrine loop is responsible for sustaining the survival of these neurons during this early stage in their development .	parallel	1
11327	10679787	3082;207	HGF;Akt	***HGF-induced*** ***phosphorylation*** of ***Akt*** and pretreatment of the cells with wortmannin completely impaired Akt activation .	target	1
11328	10679926	285;7010	Ang-1 and -2;Tie-2	RNA analysis demonstrates transcripts for the vascular endothelial growth factor receptors R1 and R2 , the receptor tyrosine kinases , Tie-1 and Tie-2 , as well as the ***Tie-2*** ***ligands*** , ***Ang-1 and -2*** .	parallel	1
11329	10680041	4018;5468	lipoprotein;peroxisome-proliferator-activated receptor gamma	Oxidized low-density ***lipoprotein*** , which plays a central role in lesion development , can ***activate*** ***peroxisome-proliferator-activated receptor gamma*** by providing the cell with oxidized fatty acid ligands of the receptor .	positive	1
11330	10681407	5360;4018	PLTP;lipoprotein	***PLTP*** activity was significantly and positively ***correlated*** with low density ***lipoprotein*** ( LDL ) cholesterol ( r ( s ) = 0.53 ) , apoB ( r ( s ) = 0.44 ) , glucose ( r ( s ) = 0.40 ) , HDL cholesterol ( r ( s ) = 0.38 ) , HDL ( 3 ) cholesterol ( r ( s ) = 0.37 ) , lipoprotein lipase activity ( r ( s ) = 0.36 ) , insulin ( r ( s ) = 0.33 ) , subcutaneous abdominal fat ( r ( s ) = 0.36 ) , intra-abdominal fat ( r ( s ) = 0.29 ) , and body mass index ( r ( s ) = 0.29 ) .	parallel	0
11331	10681407	5360;4023	PLTP;lipoprotein lipase	***PLTP*** activity was significantly and positively ***correlated*** with low density lipoprotein ( LDL ) cholesterol ( r ( s ) = 0.53 ) , apoB ( r ( s ) = 0.44 ) , glucose ( r ( s ) = 0.40 ) , HDL cholesterol ( r ( s ) = 0.38 ) , HDL ( 3 ) cholesterol ( r ( s ) = 0.37 ) , ***lipoprotein lipase*** activity ( r ( s ) = 0.36 ) , insulin ( r ( s ) = 0.33 ) , subcutaneous abdominal fat ( r ( s ) = 0.36 ) , intra-abdominal fat ( r ( s ) = 0.29 ) , and body mass index ( r ( s ) = 0.29 ) .	parallel	0
11332	10681424	5178;6477	Peg3;Siah1a	***Pw1/Peg3*** is a potential cell death mediator and ***cooperates*** with ***Siah1a*** in p53-mediated apoptosis .	parallel	0
11333	10681432	7124;3606	TNF-alpha;IL-18	Neutralization of ***TNF-alpha*** ***reduced*** induction of ***IL-18*** by either Con A ( 70 % reduction ) or PEA ( 40 % reduction ) .	negative	1
11334	10681439	10068;3606	IL-18BP;IL-18	These studies demonstrate that ***IL-18BP*** ***decreases*** endogenous ***IL-18*** activity by reducing IFN-gamma-mediated responses .	negative	0
11335	10681439	10068;3606	IL-18BP;IL-18	IL-18 binding protein ( ***IL-18BP*** ) is a naturally occurring and specific ***inhibitor*** of ***IL-18*** .	negative	1
11336	10681496	5524;29966	PP2A;SG2NA	In addition to CaM and PP2A , several unidentified proteins stably associate with the striatin-PP2A and ******SG2NA-PP2A****** ***complexes*** .	parallel	1
11337	10681496	5524;6801	PP2A;striatin	In addition to CaM and PP2A , several unidentified proteins stably associate with the ******striatin-PP2A****** and SG2NA-PP2A ***complexes*** .	parallel	1
11338	10681511	5961;5630	Rds;Peripherin	These results indicate that ******Peripherin/Rds****** and Rom-1 ***associate*** noncovalently to form multisubunit core complexes .	parallel	0
11339	10681511	6094;5630	Rom-1;Peripherin	These results indicate that ***Peripherin/Rds*** and ***Rom-1*** ***associate*** noncovalently to form multisubunit core complexes .	parallel	0
11340	10681511	6094;5961	Rom-1;Rds	These results indicate that ***Peripherin/Rds*** and ***Rom-1*** ***associate*** noncovalently to form multisubunit core complexes .	parallel	0
11341	10681513	4803;8661	Nerve growth factor;p185	***Nerve growth factor*** ***cooperates*** with ***p185*** ( HER2 ) in activating growth of human breast carcinoma cells .	parallel	0
11342	10681513	4803;8661	NGF;p185	Indeed , ***NGF*** ***induced*** tyrosine phosphorylation and stimulated kinase activity of ***p185*** ( HER2 ) , a kinase receptor of the HER family .	target	1
11343	10681520	6714;5923	Src;Ras-GRF1	Herein , we show that the nonreceptor tyrosine kinase ***Src*** ***phosphorylates*** ***Ras-GRF1*** , thereby inducing Rac-GEF activity .	target	1
11344	10681521	10544;5624	protein C receptor;protein C	Mechanisms by which soluble endothelial cell ***protein C receptor*** ***modulates*** ***protein C*** and activated protein C function .	target	0
11345	10681521	10544;5624	protein C receptor;protein C	The endothelial cell ***protein C receptor*** ( EPCR ) functions as an important ***regulator*** of the ***protein C*** anticoagulant pathway by binding protein C and enhancing activation by the thrombin-thrombomodulin complex .	target	1
11346	10681521	10544;5624	EPCR;protein C	***EPCR*** ***binds*** to both protein C and activated ***protein C*** ( APC ) with high affinity .	parallel	1
11347	10681527	9863;4088	ARIP1;Smad3	Interestingly , ***ARIP1*** also ***interacted*** with ***Smad3*** , which is an activin/transforming growth factor beta intracellular signaling molecule .	parallel	1
11348	10681529	5592;1466	cGKI;CRP2	The co-localization together with the specific ***phosphorylation*** of ***CRP2*** by ***cGKI*** in vitro and in vivo suggests that CRP2 is a novel substrate of cGKI in neurons and smooth muscle of the small intestine .	target	1
11349	10681529	1466;5592	CRP2;cGKI	The co-localization together with the specific phosphorylation of CRP2 by cGKI in vitro and in vivo suggests that ***CRP2*** is a novel ***substrate*** of ***cGKI*** in neurons and smooth muscle of the small intestine .	parallel	1
11350	10681548	5008;3572	OSM;gp130	The present study demonstrates that positions 189-192 of gp130 cytokine binding domain are essential for ***OSM*** ***binding*** to both gp130/LIF receptor beta and ***gp130/OSM*** receptor beta heterocomplexes .	parallel	1
11351	10681559	4193;83987	mdm2;p90	p76 ( ***mdm2*** ) ***inhibits*** the ability of ***p90*** ( mdm2 ) to destabilize p53 .	negative	1
11352	10681559	83987;84260	p90;tumor suppressor protein	The mdm2 oncogene encodes ***p90*** ( mdm2 ) , which ***binds*** to and inactivates the p53 ***tumor suppressor protein*** .	parallel	1
11353	10681561	2069;374	Epiregulin;amphiregulin	***Epiregulin*** ***up-regulated*** the mRNA levels of heparin-binding EGF-like growth factor ( HB-EGF ) , ***amphiregulin*** , and TGF-alpha .	positive	1
11354	10681561	2069;1839	Epiregulin;heparin-binding EGF-like growth factor	***Epiregulin*** ***up-regulated*** the mRNA levels of ***heparin-binding EGF-like growth factor*** ( HB-EGF ) , amphiregulin , and TGF-alpha .	positive	1
11355	10681561	2069;7039	Epiregulin;TGF-alpha	***Epiregulin*** ***up-regulated*** the mRNA levels of heparin-binding EGF-like growth factor ( HB-EGF ) , amphiregulin , and ***TGF-alpha*** .	positive	1
11356	10681561	374;2069	amphiregulin;Epiregulin	In turn , the addition of EGF , HB-EGF , ***amphiregulin*** , and TGF-alpha ***increased*** ***Epiregulin*** mRNA levels .	positive	0
11357	10681561	7039;2069	TGF-alpha;Epiregulin	In turn , the addition of EGF , HB-EGF , amphiregulin , and ***TGF-alpha*** ***increased*** ***Epiregulin*** mRNA levels .	positive	0
11358	10681572	6294;4803	glutathione S-transferase fusion protein;NGF	A ***glutathione S-transferase fusion protein*** containing amino acids 591-774 ( FP3 ) ***bound*** PDGF-BB and ***NGF-beta*** in ligand blotting assays whereas five other fusion proteins , which collectively include amino acids 99-590 and 775-1451 did not .	parallel	1
11359	10681572	7040;4803	TGF-beta;NGF	These results support the hypothesis that either a single linear sequence in human alpha ( 2 ) M or overlapping sequences are responsible for the ***binding*** of ***TGF-beta*** , PDGF-BB , and ***NGF-beta*** , even though there is minimal sequence identity between these three growth factors .	parallel	1
11360	10681578	5272;3002	PI-9;granzyme B	***PI-9*** is a potent ***inhibitor*** of ***granzyme B*** and of granzyme B-mediated apoptosis .	negative	1
11361	10681579	10204;5901	NTF2;GTPase Ran	We have used a range of complementary biochemical and biophysical methods to investigate the ***interactions*** between nuclear transport factor 2 ( ***NTF2*** ) , the Ras family ***GTPase Ran*** , and XFXFG nucleoporin repeats that are crucial for nuclear trafficking .	parallel	1
11362	10681587	4331;2967	Tfb3;Tfb4	A comprehensive pairwise two-hybrid analysis between yeast TFIIH subunits identified novel ***interactions*** between Rad3 and ***Tfb3*** , ***Tfb4*** and Ssl1 , as well as Ssl2 and Tfb2 .	parallel	1
11363	10681589	2023;4609	MBP-1;c-myc	***MBP-1*** ***binds*** to the ***c-myc*** P2 promoter and down-regulates c-myc expression .	parallel	1
11364	10681589	2023;4609	MBP-1;c-myc	***MBP-1*** binds to the c-myc P2 promoter and ***down-regulates*** ***c-myc*** expression .	negative	1
11365	10681590	2885;7535	Grb-2;ZAP-70	The subsequent tyrosine phosphorylation of LAT ( linker for activation of T cell ) by ZAP-70 leads to a shift in equilibrium from the ******ZAP-70.Grb-2.SOS****** ( Vav ) ***complex*** to the ( Vav ) SOS.Grb-2.LAT complex .	parallel	1
11366	10681592	5781;1003	SHP2;VE-cadherin	***SHP2*** ***association*** with ***VE-cadherin*** complexes in human endothelial cells is regulated by thrombin .	parallel	0
11367	10681592	5781;1499	SHP2;beta-catenin	Ligand-binding blots using a SHP2-glutathione S-transferase fusion peptide established that ***SHP2*** ***associates*** selectively with ***beta-catenin*** in VE-cadherin complexes .	parallel	0
11368	10681592	5781;1003	SHP2;VE-cadherin	We propose that thrombin regulates the tyrosine phosphorylation of VE-cadherin-associated beta-catenin , gamma-catenin , and p120-catenin by modulating the quantity of ***SHP2*** ***associated*** with ***VE-cadherin*** complexes .	parallel	0
11369	10682669	596;7157	bcl-2;p53	We looked for ***associations*** between spontaneous apoptosis , p53 gene mutation , ***p53*** protein accumulation , growth fraction , ***bcl-2*** expression and histological parameters in 64 ovarian , four tubal and three peritoneal carcinomas .	parallel	0
11370	10682675	3569;1401	IL-6;C-reactive protein	Ovarian carcinoma PCF ***IL-6*** activities were ***correlated*** with serum ***C-reactive protein*** levels ( r = 0.65 , P = 0.0000 , n = 25 ) .	parallel	0
11371	10682681	2064;5747	ERBB-2;FAK	In addition ***ERBB-2*** ***co-immunoprecipitates*** with focal adhesion kinase ( ***FAK*** ) in these cells .	parallel	1
11372	10682683	5036;2065	PA2G4;ErbB-3	***Interaction*** of the ***PA2G4*** ( Ebp1 ) protein with ***ErbB-3*** and regulation of this binding by heregulin .	parallel	1
11373	10682683	5036;2065	Ebp1;ErbB-3	The ***interaction*** of ***Ebp1*** with ***ErbB-3*** was examined in vitro and in vivo .	parallel	1
11374	10682843	356;355	FasL;Fas	We have previously shown that this luteolytic action of PRL is mediated by the ***Fas/Fas*** ***ligand*** ( ***FasL*** ) system .	parallel	1
11375	10682843	356;5617	FasL;PRL	We have previously shown that this luteolytic action of ***PRL*** is ***mediated*** by the Fas/Fas ligand ( ***FasL*** ) system .	target	0
11376	10683140	6885;51701	TAK1;NLK	Moreover , ***TAK1*** ***activates*** ***NLK*** , which phosphorylates TCFs bound to ( beta ) - catenin .	positive	1
11377	10683145	5339;5339	HD1;plectin	In ( & bgr ; ) 4-deficient keratinocytes , expression of an interleukin 2 receptor ( IL2R ) transmembrane chimera containing the ( beta ) 4 cytoplasmic tail with the mutation R1281W , which abrogates ******HD1/plectin****** ***binding*** , resulted in a diffuse distribution of the chimeric receptor .	parallel	1
11378	10683145	5339;5339	HD1;plectin	Intriguingly , we found that IL2R / ( beta ) 4 chimeras become localized in pre-existing hemidesmosomes of HD1/plectin-deficient keratinocytes , and that this localization requires a domain in the ( beta ) 4 cytoplasmic tail that is also required for ******HD1/plectin****** ***binding*** ( residues 1115-1356 ) .	parallel	1
11379	10683146	1020;3725	cdk5;p39	Finally , disruption of the actin cytoskeleton alters p39 subcellular localization as well as kinase activity of the ******p39/cdk5****** ***complex*** .	parallel	1
11380	10683146	1020;3725	cdk5;p39	Therefore , our results reveal the existence of the ******p39/cdk5****** ***complex*** in vivo and suggest that it might play a role in regulating actin cytoskeletal dynamics in cells .	parallel	1
11381	10683146	3725;1020	p39;cdk5	***p39*** ***activates*** ***cdk5*** in neurons , and is associated with the actin cytoskeleton .	positive	1
11382	10683146	3725;1020	p39;cdk5	We show here that ***p39*** ***associates*** with ***cdk5*** in brain lysates , and that this complex is active in phosphorylation of histone H1 .	parallel	0
11383	10683153	627;1020	BDNF;CDK5	On the other hand , ***BDNF*** ***stimulated*** the kinase activity of ***CDK5*** and induced appearance of an active form of ERK transiently .	positive	0
11384	10683153	627;1020	BDNF;CDK5	These results suggest a possibility that synapse formation induces NF-H phosphorylation , at least in part , through ***activation*** of ***CDK5*** by ***BDNF*** .	positive	1
11385	10683337	5818;2532	HveC;glycoprotein D	Several human and animal alphaherpesviruses can enter cells via human herpesvirus entry mediator C ( ***HveC*** ) , a ***receptor*** for viral ***glycoprotein D*** ( gD ) .	parallel	1
11386	10683442	64006;7514	cORF;Crm1	Like Rev , ***cORF*** ***binds*** to ***Crm1*** and cORF-mediated RNA export depends on Crm1 activity .	parallel	1
11387	10683463	3458;3606	IFN-gamma;IL-18	Considered collectively , our results indicated that host protection against C. neoformans induced by IL-12 involved endogenously synthesized IL-18 and that the production of ***IL-18*** was ***mediated*** at least in part by endogenous ***IFN-gamma*** .	target	0
11388	10683509	3458;7124	IFN-gamma;TNF-alpha	Furthermore , evidence for a synergistic ***interaction*** of both ***TNF-alpha*** and ***IFN-gamma*** was observed in the BN strain .	parallel	1
11389	10683516	116;3726	PACAP;JunB	***VIP/PACAP*** downregulate c-Jun , and ***upregulate*** ***JunB*** mRNA and protein .	positive	1
11390	10683516	7432;3726	VIP;JunB	***VIP/PACAP*** downregulate c-Jun , and ***upregulate*** ***JunB*** mRNA and protein .	positive	1
11391	10684111	5578;5894	PKC-alpha;Raf-1	It is reported that ***PKC-alpha*** can directly ***phosphorylate*** or activate ***Raf-1*** in NIH3 T3 cells .	target	1
11392	10684260	633;1605	biglycan;alpha-dystroglycan	The small leucine-rich repeat proteoglycan ***biglycan*** ***binds*** to ***alpha-dystroglycan*** and is upregulated in dystrophic muscle .	parallel	1
11393	10684260	633;1605	biglycan;alpha-dystroglycan	***biglycan*** ***binding*** to ***alpha-dystroglycan*** was confirmed by coimmunoprecipitation with both native and recombinant alpha-dystroglycan .	parallel	1
11394	10684270	940;5594	CD28;ERK	Inhibition of ***CD3/CD28-mediated*** ***activation*** of the ***MEK/ERK*** signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4 ( + ) T lymphocytes .	positive	1
11395	10684270	940;5609	CD28;MEK	Inhibition of ***CD3/CD28-mediated*** ***activation*** of the ***MEK/ERK*** signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4 ( + ) T lymphocytes .	positive	1
11396	10684270	5594;5609	ERK;MEK	Since the importance of MEK/ERK in the initial steps of viral replication is poorly understood , we have examined the role of ******MEK/ERK****** ***signaling*** in the CD3 - and CD28 ( CD3/CD28 ) - mediated activation of HIV-1 replication in resting peripheral blood CD4 ( + ) T lymphocytes infected with X4 or R5 HIV-1 .	parallel	0
11397	10684270	5594;5609	ERK;MEK	Inhibition of the CD3/CD28-stimulated MEK/ERK pathway did not affect the formation of the early proviral transcripts in cells infected with either X4 or R5 HIV-1 , indicating that virus reverse transcription is not affected in the absence of ******MEK/ERK****** ***signaling*** .	parallel	0
11398	10684602	10188;998	ACK;Cdc42	These mutations are interpreted using the structures of the ******Cdc42/ACK****** and Cdc42/WASP ***complexes*** to give insight into how effectors can specifically recognize Cdc42 .	parallel	1
11399	10684602	7454;998	WASP;Cdc42	These mutations are interpreted using the structures of the Cdc42/ACK and ******Cdc42/WASP****** ***complexes*** to give insight into how effectors can specifically recognize Cdc42 .	parallel	1
11400	10684622	1191;335	clusterin;apolipoprotein A-I	We found by affinity chromatography and ELISA that the ***binding*** of ***clusterin*** to glutathione-S-transferase , IgG , ***apolipoprotein A-I*** , and complement protein C9 was enhanced at mildly acidic compared to physiological pH.	parallel	1
11401	10684699	672;4288	BRCA1;MIB-1	***BRCA1*** expression was highly ***correlated*** with ***MIB-1*** expression in cystadenomas and borderline tumors .	parallel	0
11402	10684725	1499;1003	beta-catenin;VE-cadherin	Currently , a CAM endothelial ******VE-cadherin/beta-catenin****** ***complex*** was identified , and phosphotyrosine labeling of beta-catenin was decreased concurrently with the abrupt increase in CAM endothelial selectivity between Day 4.5 and Day 5.0 .	parallel	1
11403	10684855	1616;5371	Daxx;PML	Here , we show that upon mitogenic activation of mature splenic lymphocytes , Daxx is dramatically upregulated and accumulates in the PML nuclear body ( NB ) where ***PML*** and ***Daxx*** physically ***interact*** .	parallel	1
11404	10684856	867;29760	Cbl;BLNK	As a consequence of the ***interaction*** between ***Cbl*** and ***BLNK*** , the BCR-induced recruitment of PLC-gamma2 to BLNK and the subsequent PLC-gamma2 tyrosine phosphorylation were inhibited .	parallel	1
11405	10684856	5336;29760	PLC-gamma2;BLNK	As a consequence of the interaction between Cbl and BLNK , the BCR-induced ***recruitment*** of ***PLC-gamma2*** to ***BLNK*** and the subsequent PLC-gamma2 tyrosine phosphorylation were inhibited .	target	0
11406	10684856	5336;29760	PLC-gamma2;BLNK	Thus , our data suggest that Cbl negatively regulates the PLC-gamma2 pathway by inhibiting the ***association*** of ***PLC-gamma2*** with ***BLNK*** .	parallel	0
11407	10684856	867;5336	Cbl;PLC-gamma2	Thus , our data suggest that ***Cbl*** negatively ***regulates*** the ***PLC-gamma2*** pathway by inhibiting the association of PLC-gamma2 with BLNK .	negative	1
11408	10684857	959;3559	CD40L;CD25	Coligation of CD3 and ***CD40L*** ***increased*** expression of CD69 , ***CD25*** , and CD54 on CD4 ( + ) T cells .	positive	0
11409	10684857	959;3383	CD40L;CD54	Coligation of CD3 and ***CD40L*** ***increased*** expression of CD69 , CD25 , and ***CD54*** on CD4 ( + ) T cells .	positive	0
11410	10684857	959;969	CD40L;CD69	Coligation of CD3 and ***CD40L*** ***increased*** expression of ***CD69*** , CD25 , and CD54 on CD4 ( + ) T cells .	positive	0
11411	10684867	3416;351	IDE;Abeta	Overexpression of ***IDE*** in mammalian cells markedly ***reduced*** the steady-state levels of extracellular ***Abeta*** ( 40 ) and Abeta ( 42 ) , and the catalytic site mutation ( E111Q ) abolished this effect .	negative	1
11412	10684936	55342;5610	p74;PKR	We have found that ***p74*** also ***interacts*** with ***PKR*** , both the wild-type enzyme and a catalytically defective mutant ( K296R ) .	parallel	1
11413	10684975	6667;5329	Sp1;urokinase type plasminogen activator receptor	***Sp1*** ***mediates*** constitutive and transforming growth factor beta-inducible expression of ***urokinase type plasminogen activator receptor*** gene in human monocyte-like U937 cells .	target	0
11414	10684975	6667;5329	Sp1 transcription factor;huPAR	These results led us to conclude that ***Sp1 transcription factor*** ***mediates*** constitutive and TGF-beta-inducible expression of the ***huPAR*** gene in U937 cells through binding to the sequence located at -70 .	target	0
11415	10684977	2627;7032	GATA-6;TFF2	In MKN45 , KATOIII and LS174T , cotransfection with TFF reporter genes and GATA-6 expression vectors revealed that ***GATA-6*** ***activates*** TFF1 and ***TFF2*** 4-6-fold , without an effect on TFF3 .	positive	1
11416	10684997	2208;3497	CD23;IgE	***CD23*** , the low affinity ***receptor*** for ***IgE*** ( FcvarepsilonRII ) , is involved in regulation of IgE synthesis by B-lymphocytes .	parallel	1
11417	10684997	2208;3497	CD23;IgE	***CD23*** , the low affinity receptor for IgE ( FcvarepsilonRII ) , is involved in ***regulation*** of ***IgE*** synthesis by B-lymphocytes .	target	1
11418	10685027	3949;4018	LDLr;lipoprotein	To visualize the contribution of apolipoprotein conformation and/or the number of ' active ' lipid-bound apoE molecules in the reaction of binding to the low density ***lipoprotein*** ***receptor*** ( ***LDLr*** ) by solid-phase binding assay , the complexes of human plasma apolipoprotein or recombinant ( rec ) apoE3 with dipalmitoylphosphatidylcholine ( DPPC ) or palmitoyloleoylphosphatidylcholine ( POPC ) varying in size were used .	parallel	1
11419	10685029	7124;7351	TNF-alpha;UCP2	Although ***TNF-alpha*** has been shown to acutely ***increase*** ***UCP2*** mRNA levels in liver and WAT , and is overexpressed in adipose tissue in obesity , deletion of the genes for both TNF receptors in ob/ob mice produces a further increase in UCP2 mRNA expression in liver and adipose tissue indicating a paradoxical inhibitory role .	positive	0
11420	10685516	7124;3569	tumor necrosis factor-alpha;IL-6	***tumor necrosis factor-alpha*** ***increased*** the expression of ***IL-6*** messenger RNA in endometriotic cells in a dose-dependent manner .	positive	0
11421	10685631	596;598	Bcl-2;bcl-XL	***Bcl-2*** and mcl-1 are ***inhibitors*** of apoptosis , bcl-X , probably ***bcl-XL*** in biliary epithelial cells , an inhibitor , and bax , a promoter of apoptosis .	negative	1
11422	10685631	4170;598	mcl-1;bcl-XL	Bcl-2 and ***mcl-1*** are ***inhibitors*** of apoptosis , bcl-X , probably ***bcl-XL*** in biliary epithelial cells , an inhibitor , and bax , a promoter of apoptosis .	negative	1
11423	10685632	4233;3082	c-MET;HGF	Our results suggest that ******HGF/c-MET****** paracrine ***signaling*** may contribute to tumorigenesis and progression in synovial sarcoma .	parallel	0
11424	10685632	4233;3082	c-MET;scatter factor	Expression of hepatocyte growth factor ( HGF ) / ***scatter factor*** and its ***receptor*** ***c-MET*** correlates with poor prognosis in synovial sarcoma .	parallel	1
11425	10685632	4233;3082	c-MET;HGF	We investigated the expression of ***HGF*** and its ***receptor*** ***c-MET*** by immunohistochemistry ( IHC ) in 69 cases of synovial sarcoma and compared the findings with clinicopathologic parameters , proliferating activities evaluated by MIB-1 labeling index ( MIB-1 LI ) , and patients ' prognosis .	parallel	1
11426	10685665	3558;3718	IL-2;JAK3	Moreover , downstream events in ***IL-2*** receptor signaling ***linked*** to ***JAK3*** were impaired in T cells treated with tumor supernatants .	parallel	0
11427	10686343	4803;4842	nerve growth factor;nNOS	Neuronal nitric oxide synthase ( ***nNOS*** ) is ***induced*** by ***nerve growth factor*** ( NGF ) in pheochromocytoma PC12 cells .	target	1
11428	10686344	51673;5264	brain specific protein;phytanoyl-CoA alpha-hydroxylase	Identification of a ***brain specific protein*** that ***associates*** with a refsum disease gene product , ***phytanoyl-CoA alpha-hydroxylase*** .	parallel	0
11429	10686344	9796;5264	PAHX-AP #1;phytanoyl-CoA alpha-hydroxylase	We have identified a novel protein ( ***PAHX-AP #1*** ) ***associated*** with ***phytanoyl-CoA alpha-hydroxylase*** ( PAHX ) , a Refsum disease gene product , using the yeast-based two-hybrid assay .	parallel	0
11430	10686520	4790;5970	NF-kappaB;RelA	Caffeic acid phenethyl ester ( CAPE ) is a compound that modulates nuclear ***binding*** of the ***NF-kappaB*** p65 subunit ( ***RelA*** ) .	parallel	1
11431	10686520	5970;5970	p65;RelA	Caffeic acid phenethyl ester ( CAPE ) is a compound that modulates nuclear ***binding*** of the NF-kappaB ***p65*** subunit ( ***RelA*** ) .	parallel	1
11432	10686578	7124;348	TNF-alpha;apoE	After 48 h of incubation , ***apoE*** secretion was ***inhibited*** by ***TNF-alpha*** but not affected by IL-1beta and IFN-gamma .	negative	1
11433	10686595	6387;7852	Stromal cell-derived factor-1;CXCR4	***Stromal cell-derived factor-1*** , the ***ligand*** for ***CXCR4*** , and HIV gp120 neurotoxicity was attenuated by FGF1 in a dose-dependent manner in vitro , further supporting physiological relevance .	parallel	1
11434	10686595	2246;6387	FGF1;Stromal cell-derived factor-1	***Stromal cell-derived factor-1*** , the ligand for CXCR4 , and HIV gp120 neurotoxicity was ***attenuated*** by ***FGF1*** in a dose-dependent manner in vitro , further supporting physiological relevance .	negative	0
11435	10686978	4323;4313	membrane type-1 matrix metalloproteinase;Matrix metalloproteinase-2	We have previously reported that ***membrane type-1 matrix metalloproteinase*** ( MT1-MMP ) cooperates with neutrophil-derived serine proteinases ( NDPs ; elastase , cathepsin G , protease-3 ) to ***activate*** ***Matrix metalloproteinase-2*** .	positive	1
11436	10687139	355;356	CD95;CD95 ligand	The tumor cell-induced T-cell apoptosis can be blocked by an inhibitory anti-CD95 ( Apo-1/Fas ) antibody , indicating that tumor cells induce apoptosis of CTLs through ******CD95-CD95 ligand****** ***interaction*** .	parallel	1
11437	10687315	3827;6517	bradykinin;GLUT4	Platelet-derived growth factor ( PDGF ) , norepinephrine and ***bradykinin*** also ***triggered*** ***GLUT4*** translocation in CHO-GLUT4myc cells stably expressing each receptor .	positive	0
11438	10687854	7124;3952	TNF-alpha;leptin	***TNF-alpha*** ***blocked*** ***leptin*** synthesis during differentiation .	negative	0
11439	10687854	7124;3952	TNF-alpha;leptin	We conclude that ***TNF-alpha*** ***stimulates*** the release of preformed ***leptin*** from human mature adipocytes and existing differentiated preadipocytes , which may contribute to obesity/infection-linked hyperleptinemia , and that TNF-alpha inhibits leptin synthesis via inhibition of preadipocyte differentiation and induction of adipocyte dedifferentiation .	positive	0
11440	10687854	7124;3952	TNF-alpha;leptin	We conclude that TNF-alpha stimulates the release of preformed leptin from human mature adipocytes and existing differentiated preadipocytes , which may contribute to obesity/infection-linked hyperleptinemia , and that ***TNF-alpha*** ***inhibits*** ***leptin*** synthesis via inhibition of preadipocyte differentiation and induction of adipocyte dedifferentiation .	negative	1
11441	10687940	3553;6356	IL-1beta;Eotaxin	Using primary nasal polyp tissue-derived fibroblast lines , we demonstrated that LPS , ***IL-1beta*** and TNF-alpha ***induced*** the gene expression and protein production of ***Eotaxin*** in nasal polyp fibroblasts .	target	1
11442	10687940	7124;6356	TNF-alpha;Eotaxin	Using primary nasal polyp tissue-derived fibroblast lines , we demonstrated that LPS , IL-1beta and ***TNF-alpha*** ***induced*** the gene expression and protein production of ***Eotaxin*** in nasal polyp fibroblasts .	target	1
11443	10688034	367;4824	Androgen receptor;NKX3.1	***Androgen receptor*** ( AR ) expression in prostate tumor and normal tissue was ***correlated*** with ***NKX3.1*** expression .	parallel	0
11444	10688374	6865;6863	NK-2R;Substance P	***Substance P*** induction of murine keratinocyte PAM 212 interleukin 1 production is ***mediated*** by the neurokinin 2 receptor ( ***NK-2R*** ) .	target	0
11445	10688432	3567;960	IL-5;CD44	***IL-5*** also ***induces*** the expression of ***CD44*** on eosinophils in vitro .	target	1
11446	10688605	4609;1576	c-Myc;CYP3A	Furthermore , inhibition of ***c-Myc*** may indirectly ***influence*** the expression of ***CYP3A*** .	target	0
11447	10688614	3596;7076	IL-13;tissue inhibitor of metalloproteinase (TIMP)-1	Finally , ***IL-13*** inhibited IL-1beta-induced matrix metalloproteinase (MMP)-1 and MMP-3 production and ***enhanced*** ***tissue inhibitor of metalloproteinase (TIMP)-1*** generation from NF ; although similar effects were observed with IL-4 , TGF-beta ( 1 ) transiently enhanced MMP-1 and MMP-3 generation without effecting TIMP-1 .	positive	0
11448	10688614	3596;4312	IL-13;matrix metalloproteinase (MMP)-1	Finally , ***IL-13*** ***inhibited*** IL-1beta-induced ***matrix metalloproteinase (MMP)-1*** and MMP-3 production and enhanced tissue inhibitor of metalloproteinase (TIMP)-1 generation from NF ; although similar effects were observed with IL-4 , TGF-beta ( 1 ) transiently enhanced MMP-1 and MMP-3 generation without effecting TIMP-1 .	negative	1
11449	10688614	3596;4314	IL-13;MMP-3	Finally , ***IL-13*** ***inhibited*** IL-1beta-induced matrix metalloproteinase (MMP)-1 and ***MMP-3*** production and enhanced tissue inhibitor of metalloproteinase (TIMP)-1 generation from NF ; although similar effects were observed with IL-4 , TGF-beta ( 1 ) transiently enhanced MMP-1 and MMP-3 generation without effecting TIMP-1 .	negative	1
11450	10688614	7040;4314	TGF-beta;MMP-3	In KF , IL-13 and IL-4 inhibited MMP-3 , whereas ***TGF-beta*** ( 1 ) ***enhanced*** ***MMP-3*** ; TIMP-1 was unaffected by any of the three cytokines .	positive	0
11451	10688614	3596;4314	IL-13;MMP-3	In KF , ***IL-13*** and IL-4 ***inhibited*** ***MMP-3*** , whereas TGF-beta ( 1 ) enhanced MMP-3 ; TIMP-1 was unaffected by any of the three cytokines .	negative	1
11452	10688614	3565;4314	IL-4;MMP-3	In KF , IL-13 and ***IL-4*** ***inhibited*** ***MMP-3*** , whereas TGF-beta ( 1 ) enhanced MMP-3 ; TIMP-1 was unaffected by any of the three cytokines .	negative	1
11453	10688639	6688;5079	PU.1;BSAP	We also show that ***PU.1*** can ***inhibit*** ***BSAP*** transactivation and that this repression requires PU.1 amino acids 7 to 30 .	negative	1
11454	10688639	6688;5079	PU.1;BSAP	Transfection of p300 resulted in only a partial reversal of ***PU.1-mediated*** ***repression*** of ***BSAP*** .	negative	1
11455	10688639	5079;6688	BSAP;PU.1	When PU.1 function is assayed in the context of the immunoglobulin kappa chain 3 ' enhancer and associated binding proteins , ***BSAP*** ***represses*** ***PU.1*** function by a distinct mechanism .	negative	1
11456	10688643	207;3689	Rac;LFA-1	H-Ras and ***Rac*** ***activated*** ***LFA-1*** in a PI 3-kinase-dependent manner , whereas Rho and R-Ras had little effect .	positive	1
11457	10688643	5906;3689	Rap1;LFA-1	Unexpectedly , ***Rap1*** was demonstrated to function as the most potent ***activator*** of ***LFA-1*** .	positive	1
11458	10688643	5906;3689	Rap1;LFA-1	Furthermore , a dominant negative form of ***Rap1*** ( Rap1N17 ) ***inhibited*** T-cell receptor-mediated ***LFA-1*** activation in Jurkat T cells and LFA-1/ICAM-1-dependent cell aggregation upon differentiation of HL-60 cells into macrophages , suggesting that Rap1 is critically involved in physiological processes .	negative	1
11459	10688648	1869;5502	E2F1;inhibitor 1	Pocket protein-independent ***repression*** of urokinase-type plasminogen activator and plasminogen activator ***inhibitor 1*** gene expression by ***E2F1*** .	negative	1
11460	10688649	7157;4193	p53;MDM2	The requirement for a stimulus to activate ***p53-dependent*** ***regulation*** of ***MDM2*** expression in vivo appeared to differ from the situation in early-passage mouse embryo fibroblasts , where MDM2 expression is enhanced by the presence of p53 .	target	1
11461	10688649	7157;4193	p53;MDM2	The requirement for a stimulus to activate p53-dependent regulation of MDM2 expression in vivo appeared to differ from the situation in early-passage mouse embryo fibroblasts , where ***MDM2*** expression is ***enhanced*** by the presence of ***p53*** .	positive	0
11462	10688649	4193;84260	MDM2;tumor suppressor protein	***MDM2*** is an important ***regulator*** of the p53 ***tumor suppressor protein*** .	target	1
11463	10688649	4193;7157	MDM2;p53	***MDM2*** ***inhibits*** ***p53*** by binding to it , physically blocking its ability to transactivate gene expression , and stimulating its degradation .	negative	1
11464	10688649	7157;4193	p53;MDM2	In cultured cells , ***MDM2*** expression can be ***regulated*** by ***p53*** .	target	1
11465	10688649	7157;4193	p53;MDM2	Hence , ***MDM2*** and ***p53*** can ***interact*** to form an autoregulatory loop in which p53 activates expression of its own inhibitor .	parallel	1
11466	10688649	7157;4193	p53;MDM2	The p53/MDM2 autoregulatory loop has been elucidated within cultured cells ; however , ***regulation*** of ***MDM2*** expression by ***p53*** has not been demonstrated within intact tissues .	target	1
11467	10688649	7157;4193	p53;MDM2	Transcription of MDM2 is induced in a p53-dependent manner following gamma irradiation , indicating that ***p53*** ***regulates*** ***MDM2*** expression in vivo following a stimulus .	target	1
11468	10688650	2033;8648	p300;SRC-1	***p300*** ***requires*** its histone acetyltransferase activity and ***SRC-1*** interaction domain to facilitate thyroid hormone receptor activation in chromatin .	target	0
11469	10688651	6714;6774	Src;STAT3	Etk , a Btk family tyrosine kinase , mediates cellular transformation by ***linking*** ***Src*** to ***STAT3*** activation .	parallel	0
11470	10688651	6774;660	STAT3;Etk	***STAT3*** , which was previously shown to be activated by Etk , ***associated*** with ***Etk*** in vivo .	parallel	0
11471	10688651	660;6774	Etk;STAT3	***STAT3*** , which was previously shown to be ***activated*** by ***Etk*** , associated with Etk in vivo .	positive	1
11472	10688651	660;6774	Etk;STAT3	Dominant-negative inactivation of ***Etk*** not only ***blocked*** v-Src-induced tyrosine phosphorylation and activation of ***STAT3*** but also caused a great reduction in the transforming activity of v-Src .	positive	0
11473	10688660	8648;1387	SRC-1;CBP	Most importantly , we noted that binding of E1A to CBP prevented the assembly of a coactivation complex containing PR , CBP , and SRC-1/p160 , presumably by disrupting the ***interaction*** between ***CBP*** and ***SRC-1/p160*** .	parallel	1
11474	10688665	4193;7157	hDM2;p53	However , the domains in hDM2 required for the regulation of E2F activity can be distinguished from those necessary for p53 degradation , suggesting that ***control*** of E2F and ***p53*** by ***hDM2*** may be mechanistically distinct .	target	0
11475	10688666	4217;7295	ASK1;Trx	Thus , activation of ***ASK1*** by TNF ***requires*** the ROS-mediated dissociation of ***Trx*** possibly followed by the binding of TRAF2 and consequent ASK1 homo-oligomerization .	target	0
11476	10688666	7186;4217	TNF receptor (TNFR) associated factor 2;ASK1	Here we show that ***TNF receptor (TNFR) associated factor 2*** ( TRAF2 ) , an adapter protein that couples TNFRs to the SAPKs and p38s , can ***activate*** ***ASK1*** in vivo and can interact in vivo with the amino - and carboxyl-terminal noncatalytic domains of the ASK1 polypeptide .	positive	1
11477	10688666	7295;4217	Trx;ASK1	TNF can stimulate the production of reactive oxygen species ( ROS ) , and the redox-sensing enzyme thioredoxin ( ***Trx*** ) is an endogenous ***inhibitor*** of ***ASK1*** .	negative	1
11478	10688666	7186;4217	TRAF2;ASK1	We demonstrate that Trx significantly inhibits TRAF2 activation of SAPK and blocks the ******ASK1-TRAF2****** ***interaction*** in a reaction reversed by oxidants .	parallel	1
11479	10688666	7295;4217	Trx;ASK1	We demonstrate that ***Trx*** significantly inhibits TRAF2 activation of SAPK and ***blocks*** the ***ASK1-TRAF2*** interaction in a reaction reversed by oxidants .	negative	0
11480	10688666	7295;7186	Trx;TRAF2	We demonstrate that ***Trx*** significantly inhibits TRAF2 activation of SAPK and ***blocks*** the ***ASK1-TRAF2*** interaction in a reaction reversed by oxidants .	negative	0
11481	10688666	7295;7186	Trx;TRAF2	We demonstrate that ***Trx*** significantly ***inhibits*** ***TRAF2*** activation of SAPK and blocks the ASK1-TRAF2 interaction in a reaction reversed by oxidants .	negative	1
11482	10688670	6667;3725	Sp1;c-jun	Strikingly , ***Sp1*** functionally ***synergizes*** with NFAT and ATF-2 / ***c-jun*** in the activation of TNF-alpha gene transcription and selectively associates with the TNF-alpha promoter upon virus infection but not upon ionophore stimulation in vivo .	parallel	0
11483	10688671	6886;3065	TAL1;HDAC1	Further , ***TAL1*** ***association*** with mSin3A and ***HDAC1*** declined during dimethyl sulfoxide-induced differentiation of MEL cells in parallel with a decrease in mSin3A abundance .	parallel	0
11484	10688673	7514;5970	CRM1;p65	In mammalian cells , inhibition of ***CRM1*** by leptomycin B resulted in nuclear localization of cotransfected p65 and IkappaBalpha in COS cells and ***enhanced*** nuclear relocation of endogenous ***p65*** in T cells .	negative	0
11485	10688673	4792;5970	IkappaBalpha;p65	We propose that the nucleus is the major site of ******p65-IkappaBalpha****** ***association*** , from where these complexes must be exported in order to create the cytoplasmic pool .	parallel	0
11486	10688807	6372;3577	GCP-2;CXCR1	Although ***GCP-2*** has been considered an effective ***ligand*** for both ***CXCR1*** and CXCR2 , our findings demonstrated that it was a potent inducer of CXCR2 internalization only .	parallel	1
11487	10688807	6372;3579	GCP-2;CXCR2	Although ***GCP-2*** has been considered an effective ***ligand*** for both CXCR1 and ***CXCR2*** , our findings demonstrated that it was a potent inducer of CXCR2 internalization only .	parallel	1
11488	10688817	3562;3717	IL-3;Jak2	The target for this inhibition was Jak2 , and the activation of PKC by 12-O-tetradecanoyl-phorbol-13-acetate treatment also abrogated ***IL-3-induced*** tyrosine ***phosphorylation*** of ***Jak2*** in Ba/F3 cells .	target	1
11489	10688824	5624;10544	protein C;EPCR	Animals were treated with 4 separate protocols for survival studies and analysis of physiologic and biochemical parameters : ( 1 ) monoclonal antibody ( mAb ) that blocks protein C/activated ***protein C*** ***binding*** to ***EPCR*** plus sublethal numbers of E coli ( SLEC ) ( n = 4 ) ; ( 2 ) mAb to EPCR that does not block binding plus SLEC ( n = 3 ) ; ( 3 ) SLEC alone ( n = 4 ) ; and ( 4 ) blocking mAB alone ( n = 1 ) .	parallel	1
11490	10688824	5624;10544	protein C;EPCR	We conclude that protein C/activated ***protein C*** ***binding*** to ***EPCR*** contributes to the negative regulation of the coagulopathic and inflammatory response to E coli and that EPCR provides an additional critical step in the host defense against E coli .	parallel	1
11491	10688825	10544;5624	protein C receptor;protein C	The endothelial cell ***protein C receptor*** ( EPCR ) ***facilitates*** ***protein C*** activation by the thrombin-thrombomodulin complex .	positive	0
11492	10688825	7124;10544	TNF-alpha;EPCR	In cell culture , tumor necrosis factor-alpha ( ***TNF-alpha*** ) ***down-regulates*** ***EPCR*** expression , raising the possibility that EPCR might be down-regulated in septic shock .	negative	1
11493	10688880	8829;7422	neuropilin-1;vascular endothelial growth factor	Identification of a natural soluble ***neuropilin-1*** that ***binds*** ***vascular endothelial growth factor*** : In vivo expression and antitumor activity .	parallel	1
11494	10688886	5921;10657	RasGAP;p62	Here we have investigated the ***interaction*** between ***p62*** ( dok ) and ***RasGAP*** and the consequences of p62 ( dok ) tyrosine phosphorylation on the activity of RasGAP .	parallel	1
11495	10688886	10657;5921	p62;RasGAP	We have identified five tyrosine residues that are involved in in vitro RasGAP binding and have found that tyrosine-phosphorylated ***p62*** ( dok ) ***inhibits*** ***RasGAP*** activity .	negative	1
11496	10688901	6850;29760	Syk;BASH	The B cell-restricted adaptor protein ***BASH*** ( also termed BLNK/SLP-65 ) is rapidly ***phosphorylated*** by the tyrosine kinase ***Syk*** after BCR ligation and binds to various signaling proteins .	target	1
11497	10688965	51083;2587	galanin;GalR1	IC3 loop peptides also inhibited the ***binding*** of ( 125 ) ***I-galanin*** to ***GalR1*** in membranes from Rin m5F cells .	parallel	1
11498	10688970	4852;78986	Neuropeptide Y;DSP-4	The effect of ***DSP-4*** on time spent in social interaction was completely ***antagonized*** by intracerebroventricular administration of ***Neuropeptide Y*** ( NPY ) ( 1 microg ) which had no effect of its own on this measure .	negative	1
11499	10688975	796;5594	calcitonin;P38	Thus , these data suggest that activation of ERK by calcitonin gene-related peptide involves a H89-sensitive protein kinase A and a wortmannin-sensitive PI3-kinase while ***activation*** of ***P38*** MAPK by ***calcitonin*** gene-related peptide involves only the H89 sensitive pathway and is independent of PI3 kinase .	positive	1
11500	10688975	796;5594	calcitonin;ERK	Preincubation of the cells with the cAMP-dependent protein kinase inhibitor , H89 [ ¿ N - [ 2 - ( ( p-bromocinnamyl ) amino ) ethyl ] -5 - isoquinolinesulfonamide , hydrochloride ¿ ***]*** inhibited calcitonin ***gene-related*** peptide-mediated ***activation*** of ERK and P38 kinases .	positive	1
11501	10689110	925;920	CD8;CD4	They may reflect direct ***interactions*** between ***CD4*** or ***CD8*** and CD3 and/or interregulation of CD3 expression with expression of these coreceptor molecules .	parallel	1
11502	10689144	7535;919	Zap-70;CD3zeta chain	***Zap-70*** kinase ***associated*** with the ***CD3zeta chain*** shows a 2-fold increase with age in resting CD4 T cells , despite a three-fold decline with age in the levels of tyrosine phosphorylation of CD3zeta ; nonetheless , there is no effect of aging on Zap-70 kinase function in activated T cells as measured by in vitro kinase methods .	parallel	0
11503	10690190	963;7040	transmembrane glycoprotein;TGF-beta 1	endoglin is a ***transmembrane glycoprotein*** that ***binds*** ***TGF-beta 1*** and - beta 3 and interacts with TGF-beta signalling receptors to modulate many effects of this growth factor in different types of cell .	parallel	1
11504	10690190	2022;7040	endoglin;TGF-beta 1	Affinity labelling of these cells with 125I-labelled TGF-beta followed by immunoprecipitation with endoglin-specific polyclonal 1256:4 b antiserum indicated that ***endoglin*** expressed at the surface of uterine stromal cells ***binds*** ***TGF-beta 1*** and interacts with TGF-beta signalling receptors .	parallel	1
11505	10690503	7037;7018	transferrin receptor;Transferrin	The ***interaction*** between ***Transferrin*** and ***transferrin receptor*** appears to serve this function in the blood-brain , blood-CSF , and cellular-plasmalemma barriers .	parallel	1
11506	10690664	7040;4317	TGF-beta1;MMP-8	The expression of ***MMP-8*** in human odontoblasts and dental pulp cells is ***down-regulated*** by ***TGF-beta1*** .	negative	1
11507	10690664	7040;4317	TGF-beta;MMP-8	***TGF-beta*** ***down-regulated*** the ***MMP-8*** mRNA and concentration of secreted protein in both cultures .	negative	1
11508	10690804	3484;3481	IGFBP-1;IGF-II	Abundant decidual ***IGFBP-1*** may ***interact*** with the ***IGF-II-expressing*** , protease-secreting trophoblast to modulate invasion .	parallel	1
11509	10690850	7124;3952	Tumor necrosis factor-alpha;leptin	***Tumor necrosis factor-alpha*** ***inhibits*** ***leptin*** production in subcutaneous and omental adipocytes from morbidly obese humans .	negative	1
11510	10690850	7124;3952	Tumor necrosis factor-alpha;leptin	This study was undertaken to examine the ***regulation*** of ***leptin*** production from human adipocytes by ***Tumor necrosis factor-alpha*** ( TNFalpha ) .	target	1
11511	10690850	7124;3952	TNFalpha;leptin	Anti-TNFalpha antibody completely blocked ***TNFalpha*** ***inhibition*** of ***leptin*** release .	negative	1
11512	10690897	7124;3576	TNFalpha;IL-8	***TNFalpha*** ***induced*** the gene and protein expression of ***IL-8*** in endometriotic stromal cells in a dose-dependent fashion .	target	1
11513	10690937	51083;5617	GAL;prolactin	In rats , ***GAL*** is able to ***stimulate*** ***prolactin*** ( PRL ) release , but this effect is not clear in humans .	positive	0
11514	10690939	7124;6347	TNF-alpha;MCP-1	We found that ***TNF-alpha*** ***increased*** the secretion of ***MCP-1*** by 55-fold versus the control and troglitazone significantly inhibited this TNF-alpha-induced increase in MCP-1 secretion ( 49.3 % ) .	positive	0
11515	10691099	462;2159	antithrombin;factor Xa	We investigate the ***inhibition*** of clot-associated ***factor Xa*** and thrombin activities by purified human ***antithrombin*** either alone or as combination with a low molecular weight heparin ( enoxaparin ) as compared with unfractionated heparin ( UFH ) .	negative	1
11516	10691102	5054;5327	PAI-1;t-PA	To better understand the regulation of tissue plasminogen activator ( t-PA ) and plasminogen activator inhibitor 1 ( PAI-1 ) during liver transplantation , we used a computer model of the human circulatory system to simultaneously evaluate the effect of t-PA secretion , ***t-PA*** ***inhibition*** by ***PAI-1*** , hepatic clearance of t-PA , blood loss , transfusion and hemodynamics on t-PA and PAI-1 levels during liver transplantation in three patients that differed in severity of liver disease , blood loss and anhepatic changes in t-PA .	negative	1
11517	10691736	4089;4087	Smad4;Smad2	The results show that paired-like homeodomain transcription factors of the Mix family , Mixer and Milk , but not Mix .1 , mediate activin/TGF-beta-induced transcription through the DE by interacting with the effector domain of Smad2 , thereby recruiting active ******Smad2/Smad4****** ***complexes*** to the Mixer/Milk-binding site .	parallel	1
11518	10691779	5743;5972	COX-2;renin	In summary , these studies indicate that ***COX-2*** from macula densa/cTALH is a ***regulator*** of ***renin*** production and release .	target	1
11519	10691779	183;5743	Angiotensin II;COX-2	***Angiotensin II*** may be a negative ***regulator*** of cTALH/macula densa ***COX-2*** expression , and NO may mediate increased renal cortical COX-2 expression seen in volume depletion .	negative	1
11520	10691783	207;4846	Akt;eNOS	These data suggest that shear stress activates a pathway involving PI3K and the serine/threonine kinase ***Akt*** , which ***phosphorylates*** ***eNOS*** .	target	1
11521	10691892	3596;6356	IL-13;eotaxin	RESULTS : ***IL-13*** as well as IL-4 dose-dependently ***induced*** ***eotaxin*** expression in HNMFs .	target	1
11522	10691892	3565;6356	IL-4;eotaxin	RESULTS : IL-13 as well as ***IL-4*** dose-dependently ***induced*** ***eotaxin*** expression in HNMFs .	target	1
11523	10691892	3596;6356	IL-13;eotaxin	Furthermore , ***IL-13*** and TNFalpha synergistically ***induced*** ***eotaxin*** expression in HNMFs , while they hardly induced eotaxin expression in endothelial cells , epithelial cells or eosinophils .	target	1
11524	10691892	7124;6356	TNFalpha;eotaxin	Furthermore , IL-13 and ***TNFalpha*** synergistically ***induced*** ***eotaxin*** expression in HNMFs , while they hardly induced eotaxin expression in endothelial cells , epithelial cells or eosinophils .	target	1
11525	10691965	7037;7018	TfR;transferrin	In contrast to ***transferrin*** ***receptor*** ( ***TfR*** ) mRNA that increased after exposure to DFO and decreased after incubation with FAC , there was no change in MTf mRNA levels .	parallel	1
11526	10691970	248;249	IAP;TNAP	***TNAP*** activity was ***induced*** only by retinoic acid and ***IAP*** activity was induced only by dexamethasone .	target	1
11527	10692048	3586;3553	IL-10;IL-1beta	IL-10 production was similar in Th1/monocyte and Th2/monocyte co-cultures , thus arguing against preferential ***down-regulation*** of ***IL-1beta*** production by anti-inflammatory ***IL-10*** in Th2 co-cultures .	negative	1
11528	10692048	958;959	CD40;CD40 ligand	Blockade of the ******CD40-CD40 ligand****** ***interaction*** resulted in inhibition of IL-1beta-inducing capacity while IL-1Ra induction was unaffected , a result previously unknown .	parallel	1
11529	10692080	7124;3952	TNF-alpha;leptin	Median ***TNF-alpha*** levels for the first two days after stroke also ***correlated*** to median ***leptin*** levels at the end of the week ( P < 0.05 ) .	parallel	0
11530	10692092	4018;7040	lipoprotein;TGF-beta1	Lp ( a ) ***lipoprotein*** may ***block*** the activation of latent ***TGF-beta1*** .	negative	0
11531	10692100	5443;7299	alpha-melanocyte stimulating hormone;tyrosinase	Recently , it has been shown that ***alpha-melanocyte stimulating hormone*** can directly ***activate*** ***tyrosinase*** by removing the allosteric regulator 6 ( R ) - L-erythro 5,6,7,8 tetrahydrobiopterin resulting in a stable alpha-melanocyte stimulating hormone/6 ( R ) - L-erythro 5,6,7,8 tetrahydrobiopterin complex .	positive	1
11532	10692108	3458;7421	Interferon-gamma;vitamin D receptor	***Interferon-gamma*** and the phorbolester 12-O-tetradecanoyl phorbol 13-acetate , two well-known inducers of keratinocyte differentiation , both ***inhibited*** ***vitamin D receptor*** expression but only Interferon-gamma induced retinoid X receptor alpha .	negative	1
11533	10692113	5443;4988	beta-endorphin;mu-opiate receptor	***beta-endorphin*** stimulates cytokeratin 16 expression and ***downregulates*** ***mu-opiate receptor*** expression in human epidermis .	negative	1
11534	10692113	5443;3868	beta-endorphin;cytokeratin 16	***beta-endorphin*** ***stimulates*** ***cytokeratin 16*** expression and downregulates mu-opiate receptor expression in human epidermis .	positive	0
11535	10692113	5443;4988	beta-endorphin;mu-opiate receptor	Firstly , we demonstrate that ***beta-endorphin*** concentrations between 16 and 1000 nM significantly ***downregulate*** ***mu-opiate receptor*** expression in epidermis of cultured human skin after 48 h.	negative	1
11536	10692113	5443;3868	beta-endorphin;cytokeratin 16	Secondly , we show that ***beta-endorphin*** ***regulates*** ***cytokeratin 16*** expression in the epidermis of skin organ cultures exposed to 41-125 nM beta-endorphin for 48 h , leading to elevated cytokeratin 16 production .	target	1
11537	10692113	5443;4988	beta-endorphin;mu-opiate receptor	These results suggest that the ***mu-opiate receptor*** system and its ***ligand*** ***beta-endorphin*** are involved in the pathogenesis of psoriasis , especially in terms of differentiation .	parallel	1
11538	10692121	958;959	CD40;CD40 ligand	******CD40-CD40 ligand****** ***interactions*** , in the presence or absence of interferon-gamma , neither enhanced spontaneous keratinocyte apoptosis , nor did it enhance apoptosis induced by various agents .	parallel	1
11539	10692159	375757;22823	Swi5;Pcl2	We performed both biochemical and genetic tests to discover the biological significance of the ***interaction*** between ***Pcl2*** and ***Swi5*** seen in the two-hybrid assay .	parallel	1
11540	10692237	4773;4790	NFAT1;NFkappaB	Two sets of NFAT binding sites were identified in the HIV-1 long terminal repeat ( LTR ) promoter by in vitro footprinting with full-length recombinant NFAT protein , and gel shift analysis of nuclear protein from polyclonally activated primary CD4 T cells revealed specific ***binding*** of ***NFAT1*** to the ***NFkappaB*** binding sites of the HIV-1 LTR .	parallel	1
11541	10692240	3569;3486	Interleukin-6;insulin-like growth factor binding protein-3	***Interleukin-6*** release by cultured peripheral blood mononuclear cells inversely ***correlates*** with height velocity , bone age , insulin-like growth factor-I , and ***insulin-like growth factor binding protein-3*** serum levels in children with perinatal HIV-1 infection .	negative	0
11542	10692390	7157;5268	p53;maspin	***p53*** ***regulates*** the expression of the tumor suppressor gene ***maspin*** .	target	1
11543	10692392	9047;3791	VRAP;KDR	In HUVEC , VEGF promotes ***association*** of ***VRAP*** with ***KDR*** .	parallel	0
11544	10692395	10923;983	PC4;cdk-1	Here , we show that ***PC4*** , a naturally occurring transcriptional coactivator , competitively ***inhibits*** ***cdk-1*** , -2 , and -7 - mediated phosphorylation of the largest subunit of RNA polymerase II ( RNAPII ) , but it does not inhibit phosphorylation of other substrates of the same kinases .	negative	1
11545	10692396	4086;4091	Smad1;Smad6	These results indicate that the expression of ***Smad6*** is ***regulated*** by the effects of BMP-activated ***Smad1/5*** on the Smad6 promoter .	target	1
11546	10692406	9049;196	ARA9;AHR	To better understand the mechanism by which ***ARA9*** ***modifies*** ***AHR*** signal transduction , we performed a series of coexpression experiments in yeast and mammalian cells .	target	0
11547	10692406	9049;196	ARA9;AHR	Using receptor photoaffinity labeling experiments , we were able to show that ***ARA9*** ***enhances*** ***AHR*** signal transduction by increasing the available AHR binding sites within the cytosolic compartment of the cell .	positive	0
11548	10692406	9049;196	ARA9;AHR	Our evidence suggests that ARA9 's effects are related to its role as a cellular chaperone ; i.e. we observed that expression of ***ARA9*** ***increases*** the fraction of ***AHR*** in the cytosol and also stabilized the receptor under heat stress .	positive	0
11549	10692416	3658;3458	iron regulatory protein 2;interferon-gamma	Effects of ***interferon-gamma*** and lipopolysaccharide on macrophage iron metabolism are ***mediated*** by nitric oxide-induced degradation of ***iron regulatory protein 2*** .	target	0
11550	10692422	1051;5743	C/EBPbeta;COX-2	Overexpression of c-Jun , C/EBPbeta , and C/EBPdelta enhances induction of the COX-2 reporter , while overexpression of cyclic AMP-response element-binding protein or " dominant negative " ***C/EBPbeta*** ***represses*** ***COX-2*** induction .	negative	1
11551	10692427	5618;5617	PRLR;prolactin	These findings were documented using both surface plasmon resonance and gel filtration experiments and show that ovine placental lactogen ( PL ) heterodimerizes the extracellular domains ( ECDs ) of ruminant growth hormone receptor ( GHR ) and ***prolactin*** ***receptor*** ( ***PRLR*** ) .	parallel	1
11552	10692429	3667;3643	IRS-1;insulin receptor	Protein-tyrosine phosphatases ( PTPases ) play a key role in maintaining the steady-state tyrosine phosphorylation of the insulin receptor ( IR ) and its substrate proteins such as ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) .	parallel	1
11553	10692430	3665;3439	IRF-7;IFNA1	Using various IFNA reporter constructs in transient transfection assay we found that overexpression of IRF-3 in virus infected 2FTGH cells selectively activated IFNA1 VRE , whereas ***IRF-7*** was able to ***activate*** ***IFNA1*** , A2 , and A4 .	positive	1
11554	10692438	5327;5054	t-PA;PAI-1	Both antibodies bound to ******PAI-1-wt/t-PA****** ***complexes*** with a similar affinity as to PAI-1-wt ( K ( A ) = 4-5 x 10 ( 9 ) M ( -1 ) ) .	parallel	1
11555	10692442	10044;4739	Chat;HEF1	Chat is associated with Cas in brain , and ***Chat-H*** is ***associated*** with ***HEF1*** in splenocytes .	parallel	0
11556	10692445	4792;355	IkappaBalpha;Fas	Reporter gene experiments in hepatoma cell lines with a Fas promoter-luciferase construct indicated that the ***repression*** of ***Fas*** ( CD95 ) mRNA by ***IkappaBalpha*** was transcriptionally mediated .	negative	1
11557	10692449	27094;3778	hKCNMB3;Hslo	Although we found that ***hKCNMB3*** does ***interact*** with ***Hslo*** channels , its effects on Hslo1 channel properties were slight , increasing Hslo1 activation rates .	parallel	1
11558	10692452	29924;1213	epsin 1;clathrin heavy chain	This sequence , related to the known clathrin-binding sequences in the adaptor beta subunits , amphiphysin , and beta-arrestin , facilitates the ***association*** of ***epsin 1*** with the terminal domain of the ***clathrin heavy chain*** .	parallel	0
11559	10692454	4603;596	A-Myb;Bcl-2	***A-Myb*** ***up-regulates*** ***Bcl-2*** through a Cdx binding site in t ( 14 ; 18 ) lymphoma cells .	positive	1
11560	10692454	4603;596	A-Myb;Bcl-2	We showed that ***A-Myb*** ***up-regulates*** ***Bcl-2*** promoter activity .	positive	1
11561	10692454	4603;596	A-Myb;Bcl-2	In t ( 14 ; 18 ) cells and mature B cells , ***A-Myb*** ***up-regulated*** ***Bcl-2*** expression , whereas B - and c-Myb had little effect on Bcl-2 gene expression .	positive	1
11562	10692462	6764;5594	p126;ERK2	Furthermore , expression of p70 in COS-7 cells suppresses ***activation*** of mitogen activated protein kinase ***MAPK/ERK2*** by the largest ST5 product , ***p126*** , in response to epidermal growth factor stimulation .	positive	1
11563	10692462	84959;5594	p70;ERK2	Furthermore , expression of ***p70*** in COS-7 cells ***suppresses*** activation of mitogen activated protein kinase ***MAPK/ERK2*** by the largest ST5 product , p126 , in response to epidermal growth factor stimulation .	negative	1
11564	10692462	84959;5594	p70;ERK2	Analysis of signaling leading to MAPK/ERK2 stimulation revealed that in COS-7 cells , expression of either ***p70-DeltaC1*** or p70-DeltaC2 markedly ***enhanced*** ***ERK2*** activity in a growth factor-independent manner .	positive	0
11565	10692462	5605;5594	MEK2;ERK2	Whereas wild-type p70 slightly inhibited ***ERK2*** ***activation*** by RAS and ***MEK2*** , co-expression or p70-DeltaC1 or p70-DeltaC2 with either protein stimulated ERK2 cooperatively .	positive	1
11566	10692462	84959;5594	p70;ERK2	Whereas wild-type p70 slightly inhibited ***ERK2*** ***activation*** by RAS and MEK2 , co-expression or ***p70-DeltaC1*** or p70-DeltaC2 with either protein stimulated ERK2 cooperatively .	positive	1
11567	10692462	84959;5594	p70;ERK2	Whereas wild-type ***p70*** slightly ***inhibited*** ***ERK2*** activation by RAS and MEK2 , co-expression or p70-DeltaC1 or p70-DeltaC2 with either protein stimulated ERK2 cooperatively .	negative	1
11568	10692465	2155;2152	Factor VII;tissue factor	***Binding*** of the zymogen serine protease ***Factor VII*** ( FVII ) to its cellular cofactor ***tissue factor*** ( TF ) triggers blood coagulation .	parallel	1
11569	10692471	7040;5743	TGF-beta1;COX-2	The addition of ***TGF-beta1*** further ***stabilized*** the ***COX-2*** mRNA ( t1/2 > 50 min ) .	positive	0
11570	10692474	472;2547	ataxia-telangiectasia-mutated;Ku70	Ionizing radiation exposure results in ***up-regulation*** of ***Ku70*** via a ***p53/ataxia-telangiectasia-mutated*** protein-dependent mechanism .	positive	1
11571	10692474	7157;2547	p53;Ku70	Ionizing radiation exposure results in ***up-regulation*** of ***Ku70*** via a ***p53/ataxia-telangiectasia-mutated*** protein-dependent mechanism .	positive	1
11572	10692488	4609;10642	c-myc;CRD-BP	The correlation between ODN effects on RNA-protein interactions in vitro and those observed in cells supports the hypothesis that CRD-ODN4 inhibits the ***interaction*** between the ***CRD-BP*** and the ***c-myc*** mRNA and that disrupting this RNA-protein interaction reduces c-myc expression in cells .	parallel	1
11573	10692524	3569;1401	IL-6;CRP	***IL-6*** levels at t ( 180 ) were significantly ***correlated*** with ***CRP*** ( r = 0.50 , P < 0.01 ) and sPLA ( 2 ) ( r = 0.47 , P = 0.01 ) values at t ( 1440 ) .	parallel	0
11574	10692570	3569;3572	interleukin-6;gp130	Different epitopes are required for ***gp130*** ***activation*** by ***interleukin-6*** , oncostatin M and leukemia inhibitory factor .	positive	1
11575	10692570	3976;3572	leukemia inhibitory factor;gp130	Different epitopes are required for ***gp130*** ***activation*** by interleukin-6 , oncostatin M and ***leukemia inhibitory factor*** .	positive	1
11576	10692570	5008;3572	oncostatin M;gp130	Different epitopes are required for ***gp130*** ***activation*** by interleukin-6 , ***oncostatin M*** and leukemia inhibitory factor .	positive	1
11577	10692570	3589;3572	IL-11;gp130	IL-6 and ***IL-11*** ***induce*** ***gp130*** homodimerization whereas the others lead to the formation of heterodimers with LIFR or OSMR .	target	1
11578	10692570	3569;3572	IL-6;gp130	***IL-6*** and IL-11 ***induce*** ***gp130*** homodimerization whereas the others lead to the formation of heterodimers with LIFR or OSMR .	target	1
11579	10692570	9180;3572	OSMR;gp130	Thus , epitopes involved in gp130 homodimerization are distinct from those leading to the formation of gp130/LIFR or ******gp130/OSMR****** ***heterodimers*** .	parallel	1
11580	10692865	3659;3439	interferon regulatory factor 1;IFN	The action of ***IFN-tau*** is ***mediated*** by induction of signal transducer and activator of transcription 1 ( STAT-1 ) , STAT-2 and ***interferon regulatory factor 1*** ( IRF-1 ) transcription factors .	target	0
11581	10692865	6773;3439	STAT-2;IFN	The action of ***IFN-tau*** is ***mediated*** by induction of signal transducer and activator of transcription 1 ( STAT-1 ) , ***STAT-2*** and interferon regulatory factor 1 ( IRF-1 ) transcription factors .	target	0
11582	10693152	5443;1392	ACTH;CRH	Preclinical findings on the role of corticotropin releasing hormone ( CRH ) in stress and anxiety , on the interaction of CRH and cholecystokinin ( CCK ) in modulating anxiety , as well as the blunted corticotropin ( ***ACTH*** ) ***response*** to ***CRH*** in panic disorder suggest that CRH may play a role in panic disorder .	parallel	0
11583	10693152	1392;885	CRH;cholecystokinin	Preclinical findings on the role of corticotropin releasing hormone ( CRH ) in stress and anxiety , on the ***interaction*** of ***CRH*** and ***cholecystokinin*** ( CCK ) in modulating anxiety , as well as the blunted corticotropin ( ACTH ) response to CRH in panic disorder suggest that CRH may play a role in panic disorder .	parallel	1
11584	10693698	7039;1956	transforming growth factor-alpha;EGFR	Although it has been assumed that the major ligand for the EGFR during adaptation is EGF , the role for ***transforming growth factor-alpha*** ( TGF-alpha ) , another major ***ligand*** for the ***EGFR*** is unknown .	parallel	1
11585	10693698	7039;1956	TGF-alpha;EGFR	The purpose of this study was to test the hypothesis that ***TGF-alpha*** is an important ***ligand*** for the ***EGFR*** during intestinal adaptation .	parallel	1
11586	10693808	1499;4089	beta-catenin;Smad4	Here we show that ***beta-catenin*** and Lef1/Tcf , which are downstream components of the Wnt signalling cascade , form a ***complex*** with ***Smad4*** , an essential mediator of signals initiated by members of the TGF-beta growth factor superfamily .	parallel	1
11587	10693808	51176;4089	Lef1;Smad4	Here we show that beta-catenin and ***Lef1/Tcf*** , which are downstream components of the Wnt signalling cascade , form a ***complex*** with ***Smad4*** , an essential mediator of signals initiated by members of the TGF-beta growth factor superfamily .	parallel	1
11588	10693867	7124;176	TNFalpha;aggrecan	CONCLUSION : This in vivo study suggests that ***TNFalpha*** and other proinflammatory cytokines are involved in the ***up-regulation*** of the coordinated degradation of cartilage ***aggrecan*** and collagen in RA .	positive	1
11589	10693928	2066;3084	ErbB-4;NDF	***NDF*** and its ***receptor*** ***ErbB-4*** are highly expressed in neurons , implying important roles in neuronal cell functions .	parallel	1
11590	10693931	348;4018	apoE;lipoprotein	In contrast , the efflux of both cholesterol and phosphatidylcholine promoted by apoE was abolished following treatment with heparinase or lactoferrin , which block the ***interaction*** of ***apoE*** with heparan sulfate proteoglycans ( HSPGs ) or low-density ***lipoprotein*** receptor-related protein ( LRP ) , respectively .	parallel	1
11591	10693955	3952;4160	leptin;MC4-R	It is striking that plasma ***leptin*** levels at 1 week were inversely ***correlated*** with ***MC4-R*** density in the VMH , suggesting that this is a key site of leptin action .	negative	0
11592	10694365	5443;3479	ACTH;IGF-I	***ACTH*** treatment ***disrupts*** ovarian ***IGF-I*** and steroid hormone production .	negative	0
11593	10694373	3952;7351	leptin;UCP2	***leptin*** ( 0.9 mg/day for 3 days ) ***increased*** both ***UCP2*** and UCP3 mRNA by 30 % in the innervated and , surprisingly , in the denervated BAT .	positive	0
11594	10694373	3952;7352	leptin;UCP3	***leptin*** ( 0.9 mg/day for 3 days ) ***increased*** both UCP2 and ***UCP3*** mRNA by 30 % in the innervated and , surprisingly , in the denervated BAT .	positive	0
11595	10694373	3952;7351	leptin;UCP2	The present findings indicate that : sympathetic innervation is necessary to maintain basal levels of UCP3 mRNA ; beta ( 3 ) - adrenergic agonist stimulation induces UCP3 mRNA ; ***leptin*** ***induces*** ***UCP2*** and UCP3 mRNA and this induction is not dependent on sympathetic innervation ; RA increases UCP1 but decreases UCP2 and UCP3 mRNA ; and methylprednisolone suppresses UCP1 , UCP2 , and UCP3 mRNA equally .	target	1
11596	10694373	3952;7352	leptin;UCP3	The present findings indicate that : sympathetic innervation is necessary to maintain basal levels of UCP3 mRNA ; beta ( 3 ) - adrenergic agonist stimulation induces UCP3 mRNA ; ***leptin*** ***induces*** UCP2 and ***UCP3*** mRNA and this induction is not dependent on sympathetic innervation ; RA increases UCP1 but decreases UCP2 and UCP3 mRNA ; and methylprednisolone suppresses UCP1 , UCP2 , and UCP3 mRNA equally .	target	1
11597	10694416	116;820	PACAP;cAMP	Since ***PACAP*** potently ***activated*** ***cAMP*** and PI pathways and increased intracellular Ca ( 2 + ) , the peptide may interact with other developmental signals .	positive	1
11598	10694430	4286;7329	MITF;hUBC9	The ***association*** of ***MITF*** with ***hUBC9*** was further confirmed by an in vitro GST pull-down assay .	parallel	0
11599	10694434	983;51343	Cdk1;Fzr	We further show that ***Fzr*** activation of the cyclosome is negatively ***regulated*** by ***Cdk1*** .	negative	1
11600	10694436	5624;1499	APC;armadillo	Rod formation was prevented by coexpression of N-cadherin , ***APC*** , and Tcf-4 , which ***bind*** to the ***armadillo*** repeats of beta-catenin , but not by coexpression of alpha-catenin , although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus .	parallel	1
11601	10694436	1000;1499	N-cadherin;armadillo	Rod formation was prevented by coexpression of ***N-cadherin*** , APC , and Tcf-4 , which ***bind*** to the ***armadillo*** repeats of beta-catenin , but not by coexpression of alpha-catenin , although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus .	parallel	1
11602	10694436	6934;1499	Tcf-4;armadillo	Rod formation was prevented by coexpression of N-cadherin , APC , and ***Tcf-4*** , which ***bind*** to the ***armadillo*** repeats of beta-catenin , but not by coexpression of alpha-catenin , although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus .	parallel	1
11603	10694436	1499;6934	beta-catenin;Tcf-4	These results indicate that ***binding*** of ***beta-catenin*** to ***Tcf-4*** overrides the function of alpha-catenin to sequester beta-catenin in the cytoplasm and suggest that alpha-catenin can regulate beta-catenin signaling in the nucleus .	parallel	1
11604	10694474	3952;3060	Leptin;orexin	***Leptin*** ***regulation*** of prepro-orexin and ***orexin*** receptor mRNA levels in the hypothalamus .	target	1
11605	10694485	8945;1499	betaTRCP;Beta-catenin	***Beta-catenin*** , IkappaBalpha , and HIV Vpu are ***recruited*** to the ubiquitin-proteasome degradation pathway by ***betaTRCP*** , one of the components of the ubiquitin ligase complex .	target	0
11606	10694485	8945;4792	betaTRCP;IkappaBalpha	Beta-catenin , ***IkappaBalpha*** , and HIV Vpu are ***recruited*** to the ubiquitin-proteasome degradation pathway by ***betaTRCP*** , one of the components of the ubiquitin ligase complex .	target	0
11607	10694513	1493;5781	CTLA-4;SHP-2	***CTLA-4*** ***associates*** with the phosphatidylinositol 3-kinase , the phosphatase ***SHP-2*** and the clathrin adaptor complexes AP-1 and AP-2 .	parallel	0
11608	10694513	5781;1493	SHP-2;CTLA-4	***SHP-2*** SH2 domain ***binding*** to ***CTLA-4*** is unusual given the absence of a I/VxYxxI/V / L motif .	parallel	1
11609	10694513	5781;1493	SHP-2;CTLA-4	At the same time , we could confirm that ***SHP-2*** can ***associate*** with ***CTLA-4*** in murine T-cells indicating that the interaction between the phosphatase and CTLA-4 is an indirect event , possibly mediated by PI 3-kinase/SHP-2 binding .	parallel	0
11610	10694572	9973;6647	Copper chaperone for superoxide dismutase;Cu/Zn superoxide dismutase	***Copper chaperone for superoxide dismutase*** is essential to ***activate*** mammalian ***Cu/Zn superoxide dismutase*** .	positive	1
11611	10695480	5328;5329	uPA;uPAR	The ***binding*** of the urokinase plasminogen activator ( ***uPA*** ) to its receptor ( ***uPAR*** ) regulates cell adhesion , surface proteolysis , chemotaxis and cell extravasation in a number of experimental systems .	parallel	1
11612	10695724	3586;1392	IL-10;corticotropin releasing factor	***IL-10*** ***enhances*** ***corticotropin releasing factor*** ( CRF ) and corticotropin ( ACTH ) production in hypothalamic and pituitary tissues , respectively .	positive	0
11613	10695733	2064;3084	erbB2;glial growth factor-2	Human white matter from non-neurologic cases , multiple sclerosis ( MS ) and other neurologic diseases ( OND , inflammatory and non-inflammatory ) , was subjected to immunocytochemistry and Western blotting for expression of the neuregulin , ***glial growth factor-2*** ( GGF2 ) , and its ***receptors*** , ***erbB2*** , erbB3 and erbB4 .	parallel	1
11614	10695733	2065;3084	erbB3;glial growth factor-2	Human white matter from non-neurologic cases , multiple sclerosis ( MS ) and other neurologic diseases ( OND , inflammatory and non-inflammatory ) , was subjected to immunocytochemistry and Western blotting for expression of the neuregulin , ***glial growth factor-2*** ( GGF2 ) , and its ***receptors*** , erbB2 , ***erbB3*** and erbB4 .	parallel	1
11615	10695733	2066;3084	erbB4;glial growth factor-2	Human white matter from non-neurologic cases , multiple sclerosis ( MS ) and other neurologic diseases ( OND , inflammatory and non-inflammatory ) , was subjected to immunocytochemistry and Western blotting for expression of the neuregulin , ***glial growth factor-2*** ( GGF2 ) , and its ***receptors*** , erbB2 , erbB3 and ***erbB4*** .	parallel	1
11616	10695825	2153;5627	Factor V Leiden;protein S	The remaining four showed combined abnormalities ( ***Factor V Leiden*** mutation ***associated*** with inherited ***protein S*** deficiency , 1 patient ; acquired antithrombin deficiency , 2 patients and inherited antithrombin deficiency , 1 patient ) .	parallel	0
11617	10695940	5745;5744	PTH1R;PTHrP	These cells also expressed type I and XII collagen and type I ***PTH/PTHrP*** ***receptor*** ( ***PTH1R*** ) .	parallel	1
11618	10695998	3569;3572	IL-6;gp130	Furthermore , ***activation*** of the RA-induced ***gp130*** by exogenous ***IL-6*** potentiated the differentiating effects of RA .	positive	1
11619	10695998	3572;3569	gp130;IL-6	Our findings suggest that the differentiating effects of RA may partially be mediated by the up-regulation of ******IL-6/gp130****** ***signaling*** in HL-60 and HL-60 / S4 cells .	parallel	0
11620	10696064	3552;6440	IL-1alpha;SP-C	In contrast , at 27 to 30 d of gestation and in newborns , ***IL-1alpha*** ***decreased*** ***SP-C*** , - B , and - A mRNA by means of 64 to 67 % , 48 to 59 % , and 12 to 15 % , respectively .	negative	0
11621	10696146	3456;6346	IFNbeta;I-309	The monocyte chemoattractant beta-chemokine ***I-309*** mRNA was ***induced*** in human astrocytes and microglia by ***IFNbeta*** or IFNgamma , or by LPS in microglia , showing a tight co-regulation with IP-10 mRNA expression .	target	1
11622	10696146	3458;6346	IFNgamma;I-309	The monocyte chemoattractant beta-chemokine ***I-309*** mRNA was ***induced*** in human astrocytes and microglia by IFNbeta or ***IFNgamma*** , or by LPS in microglia , showing a tight co-regulation with IP-10 mRNA expression .	target	1
11623	10696146	3456;6352	IFNbeta;RANTES	The ***induction*** of ***RANTES*** mRNA in microglia by ***IFNbeta*** , IL-1beta or TNFalpha was variable , showing no to low level expression depending on the case , whereas LPS provided a consistent inducing signal .	target	1
11624	10696146	3553;6352	IL-1beta;RANTES	The ***induction*** of ***RANTES*** mRNA in microglia by IFNbeta , ***IL-1beta*** or TNFalpha was variable , showing no to low level expression depending on the case , whereas LPS provided a consistent inducing signal .	target	1
11625	10696146	7124;6352	TNFalpha;RANTES	The ***induction*** of ***RANTES*** mRNA in microglia by IFNbeta , IL-1beta or ***TNFalpha*** was variable , showing no to low level expression depending on the case , whereas LPS provided a consistent inducing signal .	target	1
11626	10696146	3664;3627	LPS;IP-10	In this study , we determined the pattern of ***IP-10*** gene ***induction*** in primary human microglia and astrocytes by cytokines and ***LPS*** using ribonuclease protection assay .	target	1
11627	10696146	3456;3627	IFNbeta;IP-10	The results showed that in human microglia , ***IP-10*** expression was ***induced*** equally potently by LPS , ***IFNbeta*** or IFNgamma .	target	1
11628	10696146	3458;3627	IFNgamma;IP-10	The results showed that in human microglia , ***IP-10*** expression was ***induced*** equally potently by LPS , IFNbeta or ***IFNgamma*** .	target	1
11629	10696146	3664;3627	LPS;IP-10	The results showed that in human microglia , ***IP-10*** expression was ***induced*** equally potently by ***LPS*** , IFNbeta or IFNgamma .	target	1
11630	10696424	5610;1965	PKR;eIF-2 alpha	***PKR*** ***phosphorylates*** ***eIF-2 alpha*** and shuts off protein synthesis .	target	1
11631	10696460	355;7157	Fas;p53	In a p53-positive cell line ( DU145 ) , ***p53*** was ***repressed*** by 70 % and ***Fas*** elevated sixfold with 10 mM PB .	negative	1
11632	10696907	7040;3458	TGF-beta1;IFN-gamma	IFN-gamma is a potent inducer of MHC-II gene and this induction was further elevated in microglia by TGF-beta1 , while ***TGF-beta1*** ***inhibited*** ***IFN-gamma*** , induction in macrophages .	negative	1
11633	10696916	3456;3586	IFNbeta;IL-10	We did not record increased numbers of IL-4 mRNA-expressing CSF-MC or PBMC , increased plasma IL-10 levels , increased numbers of IgG , A or M secreting plasma cells or in vitro ***induction*** of ***IL-10*** production by ***IFNbeta-1a*** .	target	1
11634	10697273	9260;598	LMP-1;BCL-XL	***LMP-1*** , EBV latent protein , has been shown to ***upregulate*** BCL-2 and ***BCL-XL*** .	positive	1
11635	10697503	5159;5295	PDGFR-beta;p85	PDGF-stimulated the ***association*** of ***PDGFR-beta*** with ***p85*** , ras GTPase-activating protein and PLC gamma .	parallel	0
11636	10697547	356;355	CD95L;CD95	Irradiation induced clonogenic cell death of human malignant glioma cells does not require ******CD95/CD95L****** ***interactions*** .	parallel	1
11637	10697547	356;355	CD95L;CD95	CONCLUSIONS : We conclude that endogenous ******CD95/CD95L****** ***interactions*** are not involved in radiation-induced clonogenic cell death and that the killing cascades of CD95L and irradiation are independent in human malignant glioma cells .	parallel	1
11638	10697802	7040;6654	TGF-beta 1;HGF	These patterns of expression and production suggest that enhanced ***TGF-beta 1*** production ***reduce*** the proteolytic activities of ***HGF*** fibroblasts , which favor the accumulation of ECM .	negative	1
11639	10698034	3552;3557	IL-1alpha;IL-1ra	The presence of ***IL-1alpha*** in the CM was negatively ***associated*** with embryonic development and the presence of ***IL-1ra*** in the CM was positively associated with embryonic development .	negative	0
11640	10698041	3458;7422	IFN-gamma;VEGF	RESULTS : ***IFN-gamma*** ***inhibited*** ***VEGF*** mRNA and protein expression by ES cells in a dose-dependent manner .	negative	1
11641	10698041	3458;7422	IFN-gamma;VEGF	***IFN-gamma*** also ***suppressed*** ***VEGF*** mRNA expression by ES cells .	negative	1
11642	10698046	2252;1081	KGF;hCG	***KGF*** significantly ***stimulated*** ***hCG*** secretion in cultured BeWo cells but did not affect [ 3H ] - thymidine incorporation .	positive	0
11643	10698169	156;2696	GRK2;GIPR	Overexpression of ***GRK2*** ***enhanced*** agonist-induced ***GIPR*** phosphorylation , but receptor endocytosis was not affected by cotransfection with GRKs or beta-arrestin-1 .	positive	0
11644	10698182	4804;4803	NGFR;NGF	Injection of the steroid resulted in increased intraovarian synthesis of ***NGF*** and its low affinity ***receptor*** , p75 ***NGFR*** .	parallel	1
11645	10698186	3488;3479	IGFBP-5;IGF-I	When the smooth muscle cell growth response to these components was assessed , IGF-I plus ***IGFBP-5*** or the combination of TSP-1 or OPN with IGF-I ***potentiated*** the ***IGF-I*** effect .	positive	0
11646	10698186	6696;3479	OPN;IGF-I	When the smooth muscle cell growth response to these components was assessed , IGF-I plus IGFBP-5 or the combination of TSP-1 or ***OPN*** with IGF-I ***potentiated*** the ***IGF-I*** effect .	positive	0
11647	10698186	7057;3479	TSP-1;IGF-I	When the smooth muscle cell growth response to these components was assessed , IGF-I plus IGFBP-5 or the combination of ***TSP-1*** or OPN with IGF-I ***potentiated*** the ***IGF-I*** effect .	positive	0
11648	10698186	6696;3488	OPN;IGFBP-5	Both ***OPN*** and TSP-1 specifically ***bind*** to ***IGFBP-5*** with high affinity .	parallel	1
11649	10698186	7057;3488	TSP-1;IGFBP-5	Both OPN and ***TSP-1*** specifically ***bind*** to ***IGFBP-5*** with high affinity .	parallel	1
11650	10698186	6696;3488	osteopontin;insulin-like growth factor (IGF)-binding protein-5	Thrombospondin and ***osteopontin*** ***bind*** to ***insulin-like growth factor (IGF)-binding protein-5*** leading to an alteration in IGF-I-stimulated cell growth .	parallel	1
11651	10698186	3488;7057	IGFBP-5;TSP-1	As TSP-1 binds avidly to heparin , as does IGFBP-5 , the effect of glycosaminoglycans on the ******TSP-1/IGFBP-5****** ***interaction*** was analyzed .	parallel	1
11652	10698186	3488;6696	IGFBP-5;OPN	In contrast , both heparin and heparan sulfate significantly inhibited the ******OPN-IGFBP-5****** ***interaction*** and chondroitin sulfate A , B , and C had no effect .	parallel	1
11653	10698193	7433;116	VPAC1;PACAP	Pituitary adenylate cyclase-activating polypeptide ( PACAP ) , the new hypophysiotropic factor member of the vasoactive intestinal peptide ( VIP ) / secretin/glucagon/GHRH family of neuropeptides , exerts its biological action by interacting with both PACAP-selective type I receptors ( PAC1 ) and type II receptors ( ***VPAC1*** ) , which ***bind*** both ***PACAP*** and VIP .	parallel	1
11654	10698193	7433;7432	VPAC1;VIP	Pituitary adenylate cyclase-activating polypeptide ( PACAP ) , the new hypophysiotropic factor member of the vasoactive intestinal peptide ( VIP ) / secretin/glucagon/GHRH family of neuropeptides , exerts its biological action by interacting with both PACAP-selective type I receptors ( PAC1 ) and type II receptors ( ***VPAC1*** ) , which ***bind*** both PACAP and ***VIP*** .	parallel	1
11655	10698261	1514;836	cathepsin L;caspase-3	Furthermore , the activation of ***caspase-3*** was ***enhanced*** by addition of purified ***cathepsin L*** only in the presence of the supernatant of the digitonin-treated ML .	positive	0
11656	10698343	728;727	CD88;C5a	Cytokine priming was shown to be accompanied by a down-regulation of ***C5a*** ***receptors*** ( ***CD88*** ) whereas vitamin D binding protein had no impact on the level of neutrophil C5a receptors .	parallel	1
11657	10698346	3075;718	factor H;C3b	The 5th loop of certain gonococcal PorlAs binds ***factor H*** , which efficiently ***inactivates*** ***C3b*** to iC3b .	negative	1
11658	10698346	721;722	C4b;C4bp	Purified ***C4b*** can ***inhibit*** binding of ***C4bp*** to Por 1B , but not Por1A , suggesting different binding sites on C4bp for the two Por types .	negative	1
11659	10698346	7417;3075	Por;factor H	Meningococcal strains with Class 3 Por preferentially bind factor H , suggesting Class 3 ***Por*** acts as a ***receptor*** for ***factor H*** .	parallel	1
11660	10698490	7157;4790	p53;NF-kappaB	A Western blot analysis of nuclear extracts demonstrated that ***NF-kappaB*** protein levels in the nuclei were ***suppressed*** by the transient expression of the ***wt-p53*** in a dose-dependent manner .	negative	1
11661	10698492	1616;2113	EAP1;ETS1	***Interaction*** of ***EAP1/Daxx*** with ***ETS1*** causes the repression of transcriptional activation of the MMP1 and BCL2 genes .	parallel	1
11662	10698492	1616;2113	EAP1;ETS1	***EAP1/Daxx*** ***interacts*** with ***ETS1*** and represses transcriptional activation of ETS1 target genes .	parallel	1
11663	10698492	1616;2113	EAP1;ETS1	***EAP1/Daxx*** interacts with ETS1 and ***represses*** transcriptional activation of ***ETS1*** target genes .	negative	1
11664	10698492	1616;2113	EAP1;ETS1	The region in ***EAP1/Daxx*** which specifically ***binds*** to ***ETS1*** is located within its carboxy terminal 173 amino acid region .	parallel	1
11665	10698492	1616;2113	EAP1;ETS1	The ***EAP1/Daxx*** ***interacts*** with both isoforms of ETS1 , p51-ETS1 and ***p42-ETS1*** .	parallel	1
11666	10698492	1616;5706	EAP1;p42	The ***EAP1/Daxx*** ***interacts*** with both isoforms of ETS1 , p51-ETS1 and ***p42-ETS1*** .	parallel	1
11667	10698492	1616;8626	EAP1;p51	The ***EAP1/Daxx*** ***interacts*** with both isoforms of ETS1 , ***p51-ETS1*** and p42-ETS1 .	parallel	1
11668	10698509	3082;3084	HGF;NDF	These results reveal that mesenchymally-derived ***HGF*** and KGF can ***activate*** autocrine ***NDF*** signaling in their epithelial targets , and suggest that this mechanism contributes to the coordination of stages of wound repair , and possibly development , where these growth factors act in concert to direct epithelial proliferation , morphogenesis and differentiation .	positive	1
11669	10698511	1026;5715	p21;p27	Anti-sense oligonucleotide of ***p21*** ( waf1/cip1 ) ***prevents*** interleukin 4-mediated elevation of ***p27*** ( kip1 ) in low grade astrocytoma cells .	negative	0
11670	10698511	3565;1026	IL-4;p21	***IL-4*** ***increased*** ***p21*** ( waf1/cip1 ) but not p27 ( kip1 ) mRNA levels , and stimulated luciferase activity of a p21 ( waf1/cip1 ) promoter-luciferase reporter .	positive	0
11671	10698511	3565;6778	IL-4;STAT6	***STAT6*** ***phosphorylation*** by ***IL-4*** , however , occurred in both p53-mutant WITG3 and p53-functional RTLGA cells .	target	1
11672	10698512	1027;1017	p27Kip1;cdk2	The ***inhibition*** of cyclin ***E/cdk2*** by ***p27Kip1*** contributes to G1 arrest of LNCaP following high dose DHT .	negative	1
11673	10698514	4893;1017	N-Ras;cdk2	This may be due to the fact that although association of cdk2 with cyclin E and the translocation of those complexes to the nucleus were achieved , [ Lys61 ] ***N-Ras*** expression was not sufficient to ***induce*** ***cdk2*** activation .	target	1
11674	10698514	5925;1017	pRb;cdk2	In consequence , oncogenic alterations that lead to a decrease in p27kip1 bound to cyclin E may cooperate with Ras to ***induce*** full ***cdk2*** activation , ***pRb*** inactivation and thus cell proliferation .	target	1
11675	10698514	4893;1019	N-Ras;Cdk4	[ Lys61 ] ***N-Ras*** is able to ***induce*** full activation and nuclear accumulation of ***Cdk4*** in NIH3T3 cells .	target	1
11676	10698514	4893;1019	N-Ras;Cdk4	We demonstrate that [ Lys61 ] ***N-Ras*** expression is able to ***induce*** full ***Cdk4*** activation .	target	1
11677	10698519	1499;999	beta-catenin;E-cadherin	Membranous ***beta-catenin*** localization was preserved only in fetal-type tumoral hepatocytes and was ***associated*** with ***E-cadherin*** expression .	parallel	0
11678	10698523	1499;8312	beta-catenin;Axin	GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by ***beta-catenin*** and protein phosphatase 2A ***complexed*** with ***Axin*** .	parallel	1
11679	10698523	8312;1499	Axin;beta-catenin	***Axin*** forms a ***complex*** with adenomatous polyposis coli gene product ( APC ) , glycogen synthase kinase-3beta ( GSK-3beta ) , and ***beta-catenin*** through different binding sites and downregulates beta-catenin .	parallel	1
11680	10698523	8312;2932	Axin;GSK-3beta	***Axin*** forms a ***complex*** with adenomatous polyposis coli gene product ( APC ) , glycogen synthase kinase-3beta ( ***GSK-3beta*** ) , and beta-catenin through different binding sites and downregulates beta-catenin .	parallel	1
11681	10698523	8312;1499	Axin;beta-catenin	***Axin*** forms a complex with adenomatous polyposis coli gene product ( APC ) , glycogen synthase kinase-3beta ( GSK-3beta ) , and beta-catenin through different binding sites and ***downregulates*** ***beta-catenin*** .	negative	1
11682	10698523	1499;8312	beta-catenin;Axin	Taken together , these results suggest that GSK-3beta-dependent phosphorylation of APC can be modulated by ***beta-catenin*** and PP2A ***complexed*** with ***Axin*** .	parallel	1
11683	10698527	1437;598	hGM-CSF;bcl-X	As expected , gamma irradiation increased p53 protein and bax mRNA levels and the presence of ***hGM-CSF*** dramatically ***modulated*** ***bax/bcl-X*** ( L ) ratio .	target	0
11684	10698527	3717;6776	JAK2;STAT5	Furthermore ***GyrB/JAK2*** , which can ***activate*** ***STAT5*** but not the MAPK cascade nor survival of BA/F3 cells , also could not prevent gamma irradiation-induced apoptosis .	positive	1
11685	10698621	356;355	CD95L;CD95	Stimulation of T cells with DCs at an S/R ratio of 5 induced a higher level of expression of ***CD95*** ***ligand*** ( ***CD95L*** ) than stimulation of T cells cultured with DCs at an S/R ratio of 0.5 , whereas similar levels of expression of CD28 and CD154 were observed in both cells .	parallel	1
11686	10698684	9135;5867	Rabaptin4;rab4a	***Rabaptin4*** preferentially ***interacts*** with ***rab4a-GTP*** and to a lesser extent with rab5aGTP .	parallel	1
11687	10698690	142;4790	PARP;NF-kappaB	Taken together , these results strongly suggest that ***PARP*** is involved in the ***regulation*** of ***NF-kappaB*** through the protein modification .	target	1
11688	10698706	836;397	caspase-3;Rho-GDI 2	GDP dissociation inhibitor D4-GDI ( ***Rho-GDI 2*** ) , but not the homologous rho-GDI 1 , is ***cleaved*** by ***caspase-3*** during drug-induced apoptosis .	target	1
11689	10698712	56925;1357	Latexin;CPA	Although ***Latexin*** also ***inhibits*** mast-cell ***CPA*** ( MCCPA ) , the expression of Latexin in rat mast cells has not previously been confirmed .	negative	1
11690	10698938	5786;6714	Protein tyrosine phosphatase alpha;Src	***Protein tyrosine phosphatase alpha*** ( PTPalpha ) is believed to ***dephosphorylate*** physiologically the ***Src*** proto-oncogene at phosphotyrosine ( pTyr ) 527 , a critical negative-regulatory residue .	target	1
11691	10698949	1978;1977	4E-BP1;eIF4E	As shown for serum , phosphorylation of 4E-BP1 by PKCdelta inhibits the ***interaction*** between ***4E-BP1*** and ***eIF4E*** and stimulates cap-dependent translation .	parallel	1
11692	10698951	996;3741	Cdc27;Pcn1	This motif is both necessary and sufficient for ***binding*** of ***Pcn1*** by ***Cdc27*** in vitro and is essential for Cdc27 function in vivo .	parallel	1
11693	10698951	996;3741	Cdc27;Pcn1	We also show that the Pcn1 binding motif in Cdc27 is distinct from its binding site for Cdc1 , the 55 kDa B-subunit of polymerase delta , and present evidence that ***Cdc27*** can ***bind*** to ***Pcn1*** and Cdc1 simultaneously .	parallel	1
11694	10698972	3458;3659	IFN-gamma;IRF-1	We found that IFN-gamma binding and signaling were attenuated in psoriasis : The IFN-gamma receptor , the signal transducer and activator of transcription STAT-1 , and the interferon regulatory factor ***IRF-1*** were strongly ***up-regulated*** by ***IFN-gamma*** in normal keratinocytes , but not in psoriatic ones .	positive	1
11695	10699162	3091;7422	HIF-1;VEGF	Hypoxia-inducible factor 1 ( ***HIF-1*** ) is a transcriptional ***activator*** of vascular endothelial growth factor ( ***VEGF*** ) and is critical for initiating early cellular responses to hypoxia .	positive	1
11696	10699463	7124;4353	TNFalpha;MPO	HL60 cells produce tumor necrosis factor alpha ( TNFalpha ) , and irradiation markedly increased the TNFalpha production in these cells ; in turn , ***TNFalpha*** ***decreased*** the levels of ***MPO*** transcripts in these cells .	negative	0
11697	10699930	2247;5054	FGF-2;PAI-1	***FGF-2*** isoforms of 18 and 22.5 kDa differentially ***modulate*** t-PA and ***PAI-1*** expressions on the pancreatic carcinoma cells AR4-2J : consequences on cell spreading and invasion .	target	0
11698	10699930	2247;5327	FGF-2;t-PA	***FGF-2*** isoforms of 18 and 22.5 kDa differentially ***modulate*** ***t-PA*** and PAI-1 expressions on the pancreatic carcinoma cells AR4-2J : consequences on cell spreading and invasion .	target	0
11699	10699930	2247;5054	FGF-2;PAI-1	The 22.5 kDa ***FGF-2*** ***reduced*** t-PA and ***PAI-1*** synthesis 2-fold .	negative	1
11700	10699930	2247;5327	FGF-2;t-PA	The 22.5 kDa ***FGF-2*** ***reduced*** ***t-PA*** and PAI-1 synthesis 2-fold .	negative	1
11701	10699948	356;355	FasL;Fas	In human lymphoid leukemic cells , ET-18-OCH ( 3 ) does not promote Fas or FasL expression and ET-18-OCH ( 3 ) - induced apoptosis is not inhibited by pre-incubation with an anti-Fas blocking antibody that abrogates cell killing mediated by ******Fas/FasL****** ***interactions*** .	parallel	1
11702	10699948	355;356	Fas;FasL	Our data indicate that ET-18-OCH ( 3 ) induces apoptosis via Fas after the ether lipid is inside the cell , and this Fas activation is independent of the ***interaction*** of ***Fas*** with its natural ligand ***FasL*** .	parallel	1
11703	10699973	1000;860	N-cadherin;Cbfa1	Furthermore , ***anti-N-cadherin*** or anti-E-cadherin antibodies markedly decreased Osf2/Cbfa1 mRNA levels and ***abolished*** the rhBMP-2-induced increased ***Osf2/Cbfa1*** expression , and reduced the increased osteocalcin mRNA levels induced by rhBMP-2 .	negative	0
11704	10699973	999;860	E-cadherin;Cbfa1	Furthermore , anti-N-cadherin or ***anti-E-cadherin*** antibodies markedly ***decreased*** ***Osf2/Cbfa1*** mRNA levels and abolished the rhBMP-2-induced increased Osf2/Cbfa1 expression , and reduced the increased osteocalcin mRNA levels induced by rhBMP-2 .	negative	0
11705	10699973	1000;860	N-cadherin;Cbfa1	Furthermore , ***anti-N-cadherin*** or anti-E-cadherin antibodies markedly ***decreased*** ***Osf2/Cbfa1*** mRNA levels and abolished the rhBMP-2-induced increased Osf2/Cbfa1 expression , and reduced the increased osteocalcin mRNA levels induced by rhBMP-2 .	negative	0
11706	10699973	1000;632	N-cadherin;osteocalcin	Furthermore , ***anti-N-cadherin*** or anti-E-cadherin antibodies markedly decreased Osf2/Cbfa1 mRNA levels and abolished the rhBMP-2-induced increased Osf2/Cbfa1 expression , and ***reduced*** the increased ***osteocalcin*** mRNA levels induced by rhBMP-2 .	negative	1
11707	10699981	2048;1947	EphB2;ephrin-B1	These results indicate that the ***interaction*** between ***ephrin-B1*** and ***EphB2*** is not required for patterning spinal motor axon segmentation .	parallel	1
11708	10699991	7422;1956	VEGF;EGFR	An inverse relationship ( p = 0.0006 ) was noted between VEGF and EGFR , with high ***VEGF*** expression ***correlating*** with low ***EGFR*** levels .	parallel	0
11709	10700046	1950;8513	EGF;HGL	Furthermore , ***EGF*** ***downregulates*** ***HGL*** expression at the mRNA level via the p42/44 ( MAPK ) pathway without affecting Pg5 .	negative	1
11710	10700143	2159;2155	Factor Xa;Factor VII	Once inside , the ***Factor VII*** is ***cleaved*** to Factor VIIa by the immobilized ***Factor Xa*** or XIIa .	target	1
11711	10700180	161882;2623	FOG-1;GATA-1	We show that the V205M mutation abrogates the ***interaction*** between ***GATA-1*** and ***FOG-1*** , inhibiting the ability of GATA-1 to rescue erythroid differentiation in an erythroid cell line deficient for GATA-1 ( G1E ) .	parallel	1
11712	10700188	2033;7157	EP300;TP53	***EP300*** ***acetylation*** of ***TP53*** in response to DNA damage regulates its DNA-binding and transcription functions .	target	1
11713	10700190	4215;4208	Mekk3;Mef2c	Moreover , ***Mekk3*** ***activated*** myocyte-specific enhancer factor 2C ( ***Mef2c*** ) , a transcription factor crucial for early embryonic cardiovascular development through the p38 mitogen-activated protein kinase ( Mapk ) cascade .	positive	1
11714	10700231	1027;10987	p27kip1;JAB1	Moreover , in anergic cells , ***p27kip1*** ***associates*** with the c-Jun co-activator ***JAB1*** , resulting in defective transactivation of AP-1 and interleukin 2 transcription .	parallel	0
11715	10700282	991;4085	Cdc20;Mad2	***Mad2*** and ***Cdc20*** form a tight 1:1 heterodimeric ***complex*** in which the C-terminal segment of Mad2 becomes folded .	parallel	1
11716	10700427	959;958	CD154;CD40	Increased expression of ***CD40*** ***ligand*** ( ***CD154*** ) on CD4 + T cells as a marker of disease activity in rheumatoid arthritis .	parallel	1
11717	10700460	1432;3458	p38;IFN-gamma	Since the ***p38*** MAPK recently has been shown to be critically involved in ***regulation*** of ***IFN-gamma*** production from T ( h ) 1 cells , we propose that A6H co-stimulation induces a specific pathway , mediated via p38 and AP-1 activation , for induction of a T ( h ) 1 profile in human CD4 ( + ) T cells .	target	1
11718	10700460	3932;7535	Lck;ZAP-70	The proximal signaling events associated with A6H ligation include protein tyrosine kinase phosphorylation and ***association*** of p56 ***Lck*** , ***ZAP-70*** and the TCR zeta chain .	parallel	0
11719	10700460	919;3932	TCR zeta chain;Lck	The proximal signaling events associated with A6H ligation include protein tyrosine kinase phosphorylation and ***association*** of p56 ***Lck*** , ZAP-70 and the ***TCR zeta chain*** .	parallel	0
11720	10700460	919;7535	TCR zeta chain;ZAP-70	The proximal signaling events associated with A6H ligation include protein tyrosine kinase phosphorylation and ***association*** of p56 Lck , ***ZAP-70*** and the ***TCR zeta chain*** .	parallel	0
11721	10700471	356;355	FasL;Fas	While the TCR-triggered signaling initiates both perforin - and ***Fas*** ***ligand*** ( ***FasL*** ) - Fas-mediated mechanisms of cytotoxicity , it was not clear which mechanism was utilized by Thy-1-triggered signals and which pathway of cytotoxicity was triggered at low levels of antigen expression .	parallel	1
11722	10700471	7070;356	Thy-1;FasL	It is shown that glycophosphatidylinositol-linked surface glycoprotein ***Thy-1*** preferentially ***activates*** ***FasL-Fas*** - but not perforin-mediated cytotoxicity .	positive	1
11723	10700555	596;836	Bcl-2;CPP32	In addition , overexpression of wild-type ***Bcl-2*** ***inhibited*** DNA laddering and ***CPP32*** activation induced by the insults , while that of mutant Bcl-2 did not .	negative	1
11724	10700616	1000;5594	N-cadherin;ERK2	For example , we have previously shown that laminin ( LN ) and ***N-cadherin*** ***activate*** ***ERK2*** in chick retinal neurons , and that pharmacological inhibition of MAPK/ERK kinase ( MEK ) , the major upstream ERK2 activator , severely impairs neurite growth induced by these proteins .	positive	1
11725	10701183	4803;7018	NGF;transferrin	The present investigation examined the pharmacokinetic behavior of nerve growth factor ( ***NGF*** ) , which was ***conjugated*** to ***transferrin*** by the avidin/biotin technology , especially its brain-uptake efficiency .	parallel	1
11726	10701774	2113;1508	Ets1;cathepsin B	Cotransfection experiments demonstrated that Spl and ***Ets1*** could ***trans-activate*** ***cathepsin B*** transcription , whereas Ets2 could not .	positive	1
11727	10701774	8879;1508	Spl;cathepsin B	Cotransfection experiments demonstrated that ***Spl*** and Ets1 could ***trans-activate*** ***cathepsin B*** transcription , whereas Ets2 could not .	positive	1
11728	10701810	185;183	AT1;angiotensin II	We used the following four candidate gene polymorphisms : angiotensin converting enzyme ( ACE ) / Insertion ( I ) - Deletion ( D ) , angiotensinogen ( AGT ) / M235T , ***angiotensin II*** type 1 ***receptor*** ( ***AT1*** ) / A1166C , type 2 receptor ( AT2 ) / C3123A , to examine the association between polymorphisms and the severity of lacunar infarction .	parallel	1
11729	10701841	80273;10049	GrpE;DnaJ	Therefore , both GST-SStp and His-S-SStp can be used as affinity-tagged substrates to study prokaryotic chaperone/transit peptide interactions as well as to provide a novel functional probe to study the dynamics of ******DnaK/DnaJ/GrpE****** ***interactions*** in vivo .	parallel	1
11730	10702203	4792;4790	IkappaB-alpha;p50	Degradation of the IkappaB-gamma component of p105 and partial reduction ***IkappaB-alpha*** selectively ***activate*** ***p50/p50*** dimers .	positive	1
11731	10702213	3553;4843	IL-1beta;iNOS	METHODS : Using rat hepatocytes in primary culture , ***iNOS*** gene transcription was ***induced*** by ***IL-1beta*** .	target	1
11732	10702222	5910;387	SmgGDS;RhoA	Our findings indicate that the expression of RhoA ( Asn-19 ) may specifically inhibit signaling pathways that rely upon the ***SmgGDS-dependent*** ***activation*** of ***RhoA*** .	positive	1
11733	10702230	5594;1848	ERK;MKP3	( Camps , M. , Nichols , A. , Gillieron , C. , Antonsson , B. , Muda , M. , Chabert , C. , Boschert , U. , and Arkinstall , S. ( 1998 ) Science 280 , 1262-1265 ) had demonstrated that ***ERK*** ***binding*** to the noncatalytic amino-terminal domain of ***MKP3*** can dramatically activate the phosphatase catalytic domain .	parallel	1
11734	10702230	5594;1848	ERK;MKP3	Here , we provide detailed biochemical evidence that ***ERK*** ***activates*** ***MKP3*** through the stabilization of the active phosphatase conformation , inducing closure of the catalytic " general acid " loop .	positive	1
11735	10702232	3659;3456	IRF-1;IFN-beta	Transient co-expression of E7 significantly inhibits the ***IRF-1-mediated*** ***activation*** of ***IFN-beta*** promoter in NIH-3T3 cells .	positive	1
11736	10702240	1511;9002	Cathepsin G;protease-activated receptor-4	***Cathepsin G*** ***activates*** ***protease-activated receptor-4*** in human platelets .	positive	1
11737	10702240	9002;1511	PAR4;Cathepsin G	We now report that this action of ***Cathepsin G*** is ***mediated*** by ***PAR4*** .	target	0
11738	10702246	3576;3577	IL-8;CXCR-1	***Stimulation*** of the ***CXCR-1*** / 2 receptors by human interleukin 8 ( ***IL-8*** ) rapidly activated the p44/42 mitogen-activated protein ( extracellular signal-regulated kinase ( Erk1/2 ) ) kinase pathway .	positive	0
11739	10702246	3576;5595	IL-8;Erk1	Treatment of SK-OV-3 cells with the inhibitors genestein and herbimycin A indicated that tyrosine kinases were involved in the ***IL-8*** ***activation*** of ***Erk1*** and Erk2 .	positive	1
11740	10702246	3576;5594	IL-8;Erk2	Treatment of SK-OV-3 cells with the inhibitors genestein and herbimycin A indicated that tyrosine kinases were involved in the ***IL-8*** ***activation*** of Erk1 and ***Erk2*** .	positive	1
11741	10702249	3337;3308	Hsp40;Hsp70	Hop binds independently to Hsp90 and to Hsp70 to form a ******Hsp90.Hop.Hsp70.Hsp40****** ***complex*** that is sufficient to convert the GR to its steroid binding form , and this four-protein complex will form stable GR.Hsp90 heterocomplexes if p23 is added to the system ( Dittmar , K.	parallel	1
11742	10702249	3337;3320	Hsp40;Hsp90	Hop binds independently to Hsp90 and to Hsp70 to form a ******Hsp90.Hop.Hsp70.Hsp40****** ***complex*** that is sufficient to convert the GR to its steroid binding form , and this four-protein complex will form stable GR.Hsp90 heterocomplexes if p23 is added to the system ( Dittmar , K.	parallel	1
11743	10702249	3320;3308	Hsp90;Hsp70	Hop binds independently to Hsp90 and to Hsp70 to form a ******Hsp90.Hop.Hsp70.Hsp40****** ***complex*** that is sufficient to convert the GR to its steroid binding form , and this four-protein complex will form stable GR.Hsp90 heterocomplexes if p23 is added to the system ( Dittmar , K.	parallel	1
11744	10702263	7124;7132	tumor necrosis factor-alpha;CD120a	The ***interaction*** of ***tumor necrosis factor-alpha*** with its receptor ***CD120a*** ( p55 ) initiates downstream signaling cascades that include the activation of the mitogen-activated protein kinase ( MAPK ) , p42 ( mapk/erk2 ) .	parallel	1
11745	10702271	2185;3716	Pyk2;Jak1	***Pyk2*** was found to be physically ***associated*** with ***Jak1*** prior to IL-7 stimulation and to increase its association with IL-7Ralpha chain following IL-7 stimulation .	parallel	0
11746	10702272	6850;6464	Syk;Shc	Upstream events such as the ***Syk-dependent*** ***phosphorylation*** of ***Shc*** , the engagement of Shc with the adapter protein , Grb2 , and the activation of Ras itself are unaffected .	target	1
11747	10702276	2252;3339	fibroblast growth factor-7;perlecan	We have recently discovered that ***fibroblast growth factor-7*** ( FGF7 ) ***binds*** to ***perlecan*** protein core and that exogenous perlecan efficiently reconstitutes FGF7 mitogenic activity in perlecan-deficient cells .	parallel	1
11748	10702276	3339;2252	perlecan;FGF7	Thus , ***perlecan*** protein core should be considered a novel biological ***ligand*** for ***FGF7*** , an interaction that could influence cancer growth and tissue remodeling .	parallel	1
11749	10702278	3949;4018	LDLR;lipoprotein	Monoclonal antibody 2E8 is specific for an epitope that coincides with the binding site of the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) on human apoE .	parallel	1
11750	10702306	3558;4609	interleukin-2;c-myc	***Regulation*** of ***c-myc*** transcription by ***interleukin-2*** ( IL-2 ) .	target	1
11751	10702306	3558;4609	IL-2;c-myc	Our results propose participation of Jak2 and STAT4 in ***IL-2-induced*** ***up-regulation*** of ***c-myc*** .	positive	1
11752	10702308	6885;10454	TAK1;TAB1	We show here that endogenous ***TAK1*** is constitutively ***associated*** with ***TAB1*** and phosphorylated following IL-1 stimulation .	parallel	0
11753	10702308	10454;6885	TAB1;TAK1	These results suggest that IL-1 and ectopic expression of ***TAB1*** both ***activate*** ***TAK1*** via autophosphorylation of Ser-192 .	positive	1
11754	10702315	4035;351	LRP;beta-amyloid precursor protein	***Modulation*** of ***beta-amyloid precursor protein*** processing by the low density lipoprotein receptor-related protein ( ***LRP*** ) .	target	0
11755	10702317	3184;5741	AUF1;PTH	Added recombinant ***AUF1*** also ***stabilized*** the ***PTH*** transcript in the in vitro degradation assay .	positive	0
11756	10702317	3184;5741	AUF1;PTH	Recombinant ***AUF1*** ***bound*** the full-length ***PTH*** mRNA and the 3 ' - UTR .	parallel	1
11757	10702390	4982;8600	OPG;OPGL	Using fluorescence in situ hybridization , we sought to determine mRNA expression of ***OPGL*** , its receptor RANK , and its decoy ***receptor*** ***OPG*** in three major cell types of GCT .	parallel	1
11758	10702399	4233;3569	Met;HGF	The possibility that ******HGF/Met****** ***interaction*** has a biological role in vivo was investigated in serial sections of six tumors immunostained for CD1a + , Met protein , and HGF .	parallel	1
11759	10702410	6405;7422	SEMA3F;vascular endothelial growth factor	In all tumors , an exclusive cytoplasmic localization of ***SEMA3F*** ***correlated*** with high levels of ***vascular endothelial growth factor*** and was related to the grade and aggressiveness .	parallel	0
11760	10702411	10971;348	protein tau;ApoE4	In three independent transgenic lines from two different promoter constructs , increased phosphorylation of ***protein tau*** was ***correlated*** with ***ApoE4*** expression levels .	parallel	0
11761	10702420	2674;2668	GDNF family receptor alpha-1;glial cell line-derived neurotrophic factor	***glial cell line-derived neurotrophic factor*** ( GDNF ) , neurturin ( NTN ) , and their ***receptors*** , ***GDNF family receptor alpha-1*** ( GFRalpha-1 ) and GDNF family receptor alpha-2 ( GFRalpha-2 ) , are critically important for kidney and nervous system development .	parallel	1
11762	10702420	2675;2668	GDNF family receptor alpha-2;glial cell line-derived neurotrophic factor	***glial cell line-derived neurotrophic factor*** ( GDNF ) , neurturin ( NTN ) , and their ***receptors*** , GDNF family receptor alpha-1 ( GFRalpha-1 ) and ***GDNF family receptor alpha-2*** ( GFRalpha-2 ) , are critically important for kidney and nervous system development .	parallel	1
11763	10702794	5778;5594	HePTP;ERK2	Together , these data identify ERK2 as a specific and direct target of HePTP and are consistent with a model in which ***HePTP*** negatively ***regulates*** ***ERK2*** activity as part of a feedback mechanism .	negative	1
11764	10702794	5594;5778	ERK2;HePTP	The MAP-kinase ***ERK2*** is a specific ***substrate*** of the protein tyrosine phosphatase ***HePTP*** .	parallel	1
11765	10702794	5594;5778	ERK2;HePTP	Tyrosine phosphorylated ***ERK2*** , but not ERK1 , p38 , or JNK1 , efficiently ***bound*** to catalytically inactive ***HePTP*** mutants in which the active site cysteine ( HePTP-C/S ) or the conserved aspartic acid residue ( HePTP-D/A ) had been exchanged for serine and alanine , respectively .	parallel	1
11766	10702794	5594;5778	ERK2;HePTP	Moreover , the ***interaction*** of ***ERK2*** with ***HePTP*** trapping mutants was dependent on ERK2 tyrosine phosphorylation , indicating that HePTP is specifically targeted to activated ERK2 .	parallel	1
11767	10702796	2065;1956	ErbB-3;ErbB-1	We show here that activation of ErbB-3/ErbB-2 heterodimeric receptors triggers PI3-kinase-dependent lamellipodia formation and spreading , while individual ErbB-receptor homodimers as well as ******ErbB-3/ErbB-1****** ***heterodimers*** are much less effective .	parallel	1
11768	10702797	3479;7157	IGF-I;p53	Cooperative ***interaction*** between mutant ***p53*** and des ( 1-3 ) ***IGF-I*** accelerates mammary tumorigenesis .	parallel	1
11769	10702802	5871;5599	GCK;JNK	Comparing early - and late-stage melanoma cells revealed low expression of TRAF2 and GCK in early-stage melanoma , which coincided with poor resistance to UV-induced , TNF-mediated apoptosis ; forced expression of ***GCK*** alone or in combination with TRAF2 efficiently ***increased*** ***JNK*** and NF-kappaB activities , which coincided with increased protection against apoptosis .	positive	0
11770	10702802	5871;4790	GCK;NF-kappaB	Comparing early - and late-stage melanoma cells revealed low expression of TRAF2 and GCK in early-stage melanoma , which coincided with poor resistance to UV-induced , TNF-mediated apoptosis ; forced expression of ***GCK*** alone or in combination with TRAF2 efficiently ***increased*** JNK and ***NF-kappaB*** activities , which coincided with increased protection against apoptosis .	positive	0
11771	10702805	1869;1026	E2F1;p21	We recently reported that ***E2F1*** could ***transactivate*** the ***p21*** promoter via cis-acting elements between -119 to +16 bp of the p21 gene .	positive	1
11772	10703604	23526;3105	minor histocompatibility antigen HA-1;HLA-A	Molecular modeling of the ***minor histocompatibility antigen HA-1*** peptides ***binding*** to ***HLA-A*** alleles .	parallel	1
11773	10703604	23526;3105	HA-1;HLA-A	In order to understand the ***interaction*** of ***HA-1*** peptides with other ***HLA-A*** alleles , we have used the LOOK interface to construct molecular models of both HA-1H peptide ( VLHDDLLEA ) and HA-1R peptide ( VLRDDLLEA ) binding with 103 HLA-A alleles .	parallel	1
11774	10704068	959;5199	IgM;properdin	Each lung was biopsied serially during perfusion , and assessed using an immunohistochemical technique , with vWF staining as an internal control to quantitate ***binding*** of human ***IgM*** , IgG , C3 , C5b-9 , ***properdin*** , and C1q .	parallel	1
11775	10704203	3456;3454	IFN-beta;ifnar1	The results suggest that the binding energy from interaction of IFN-beta with ifnar2 serves mainly to stabilize the bound IFN/receptor complex , whereas the binding energy generated by ***interaction*** of certain regions of ***IFN-beta*** with ***ifnar1*** is not fully expressed in the observed affinity of binding but instead serves to selectively stabilize activated states of the receptor .	parallel	1
11776	10704203	3456;3455	IFN-beta;ifnar2	The results suggest that the binding energy from ***interaction*** of ***IFN-beta*** with ***ifnar2*** serves mainly to stabilize the bound IFN/receptor complex , whereas the binding energy generated by interaction of certain regions of IFN-beta with ifnar1 is not fully expressed in the observed affinity of binding but instead serves to selectively stabilize activated states of the receptor .	parallel	1
11777	10704240	8548;7124	cytoplasmic protein;TNFalpha	Microfilament-dependent modulation of ***cytoplasmic protein*** ***binding*** to ***TNFalpha*** mRNA AU-rich instability element in human lymphoid cells .	parallel	1
11778	10704248	1437;6347	GM-CSF;MCP-1	In contrast , MIP-1alpha and ***MCP-1/JE*** were ***induced*** by IL-3 or ***GM-CSF*** at 48 h and this induction was inhibited by IL-4 .	target	1
11779	10704248	1437;6348	GM-CSF;MIP-1alpha	In contrast , ***MIP-1alpha*** and MCP-1/JE were ***induced*** by IL-3 or ***GM-CSF*** at 48 h and this induction was inhibited by IL-4 .	target	1
11780	10704248	3562;6347	IL-3;MCP-1	In contrast , MIP-1alpha and ***MCP-1/JE*** were ***induced*** by ***IL-3*** or GM-CSF at 48 h and this induction was inhibited by IL-4 .	target	1
11781	10704248	3562;6348	IL-3;MIP-1alpha	In contrast , ***MIP-1alpha*** and MCP-1/JE were ***induced*** by ***IL-3*** or GM-CSF at 48 h and this induction was inhibited by IL-4 .	target	1
11782	10704248	1437;113246	granulocyte-macrophage colony-stimulating factor;C10	Interferon gamma , a Th ( 1 ) - specific product , abolished the ***induction*** of ***C10*** mRNA and protein by either IL-3 or ***granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) in either bone marrow-derived or peritoneal macrophages .	target	1
11783	10704248	3562;113246	IL-3;C10	Interferon gamma , a Th ( 1 ) - specific product , abolished the ***induction*** of ***C10*** mRNA and protein by either ***IL-3*** or granulocyte-macrophage colony-stimulating factor ( GM-CSF ) in either bone marrow-derived or peritoneal macrophages .	target	1
11784	10704248	3458;113246	Interferon gamma;C10	The ***inhibition*** of ***C10*** production by ***Interferon gamma*** was not NO dependent .	negative	1
11785	10704248	1437;113246	GM-CSF;C10	Finally the ***GM-CSF-mediated*** ***induction*** of ***C10*** in peritoneal macrophages was eliminated when these cells presented antigen to established T cells of Th ( 1 ) phenotype .	target	1
11786	10704249	3553;6610	IL-1beta;neutral sphingomyelinase	***Activation*** of ***neutral sphingomyelinase*** by ***IL-1beta*** requires the type 1 interleukin 1 receptor .	positive	1
11787	10704249	3553;6610	IL-1beta;neutral sphingomyelinase	The cytokine interleukin 1beta ( IL-1beta ) plays an important role in host defence reactions and neuro-immune interactions but it is still not clear which of the two interleukin 1 receptor subtypes is coupled to ***activation*** of ***neutral sphingomyelinase*** ( nSMase ) by ***IL-1beta*** .	positive	1
11788	10704249	3553;6610	IL-1beta;nSMase	***IL-1beta*** ( human , recombinant ) was shown to ***activate*** , in a dose-dependent manner , ***nSMase*** in the P ( 2 ) brain fraction of the wild-type mice while in the knock-out mice the stimulatory effect of IL-1beta on nSMase was absent .	positive	1
11789	10704250	3439;3429	IFN-alpha;ISG12	In all cell lines ***ISG12*** is strongly ***induced*** by ***IFN-alpha*** and only slightly by IFNgamma .	target	1
11790	10704251	4790;3576	NF-kappaB;interleukin 8	Because activation of ***NF-kappaB*** is involved in the ***regulation*** of the chemokine ***interleukin 8*** ( IL-8 ) , we hypothesized that the sesquiterpene lactones , isohelenin and parthenolide , would inhibit IL-8 gene expression in cultured human respiratory epithelium .	target	1
11791	10704251	7124;4790	TNF-alpha;NF-kappaB	In addition , pretreatment with isohelenin or parthenolide inhibited ***TNF-alpha-mediated*** ***degradation*** of the ***NF-kappaB*** inhibitory protein , I-kappaBalpha .	negative	1
11792	10704255	3815;4254	c-kit;Stem cell factor	Murine intraepithelial lymphocytes ( IEL ) express ***c-kit*** , the ***receptor*** for ***Stem cell factor*** ( SCF ) .	parallel	1
11793	10704255	3815;4254	c-kit;SCF	SCF-induced proliferation was dependent upon ******SCF-c-kit****** ***interactions*** , since antibody to c-kit blocked this response , and IEL obtained from c-kit mutant ( W/W ( v ) ) mice failed to respond to SCF .	parallel	1
11794	10704255	3815;4254	c-kit;SCF	These data suggest that ******SCF-c-kit****** ***interactions*** play an important role in regulating IEL expansion and activation .	parallel	1
11795	10704285	7020;11278	AP-2alpha;AP-2rep	Human ***AP-2rep*** repressed both reporter expression from a transiently transfected AP-2alpha promoter and the endogenous AP-2alpha gene and inversely was negatively ***regulated*** by ***AP-2alpha*** .	negative	1
11796	10704285	11278;7020	AP-2rep;AP-2alpha	Human ***AP-2rep*** ***repressed*** both reporter expression from a transiently transfected AP-2alpha promoter and the endogenous ***AP-2alpha*** gene and inversely was negatively regulated by AP-2alpha .	negative	1
11797	10704341	920;3700	CD4;gp120	The specificity of this process was analyzed using several inhibitors of ******gp120-CD4-CXCR4****** ***interaction*** .	parallel	1
11798	10704341	7852;920	CXCR4;CD4	The specificity of this process was analyzed using several inhibitors of ******gp120-CD4-CXCR4****** ***interaction*** .	parallel	1
11799	10704341	7852;3700	CXCR4;gp120	The specificity of this process was analyzed using several inhibitors of ******gp120-CD4-CXCR4****** ***interaction*** .	parallel	1
11800	10704352	920;3700	CD4;gp120	The mutation occurring in the C4 region is localized near two amino acid residues critical for ******gp120/CD4****** ***interaction*** .	parallel	1
11801	10704352	920;3700	CD4;gp120	The possibilities that the establishment of latent infections can be directly related to the continuous expression of CD4 on the infected cell surface and that the occurrence of mutations in amino acid nearby residues critical for ******gp120/CD4****** ***interaction*** can restore the fully productive infectious process are discussed .	parallel	1
11802	10704357	3383;3683	ICAM-1;LFA-1	These results suggest that the ***interaction*** between virally embedded host ***ICAM-1*** and target cell surface ***LFA-1*** should be considered a factor modulating neutralization sensitivity of HIV-1 by human sera from HIV-1-infected individuals .	parallel	1
11803	10704365	4803;4804	NGF;p75	During their early postmitotic life , a proportion of the nascent retinal ganglion cells ( RGCs ) are induced to die as a result of the ***interaction*** of nerve growth factor ( ***NGF*** ) with the neurotrophin receptor ***p75*** .	parallel	1
11804	10704377	7430;6383	Ezrin;syndecan-2	In vitro assays indicated a direct ***association*** between the amino-terminal domain of ***Ezrin*** and the cytoplasmic domain of ***syndecan-2*** .	parallel	0
11805	10704377	7430;6383	Ezrin;syndecan-2	The ******syndecan-2/Ezrin****** protein ***complex*** was resistant to 0.2 % Triton X-100 extraction but the syndecan-2/amino-terminal domain of Ezrin complex was not , which indicated that carboxi-terminal domain of Ezrin is involved in the cytoskeleton anchorage of this protein complex .	parallel	1
11806	10704377	7430;6383	Ezrin;syndecan-2	Additionally we observed that the activation of rhoA GTPase increased syndecan-2 insolubility in 0.2 % Triton X-100 and ******syndecan-2/Ezrin****** ***association*** .	parallel	0
11807	10704383	9423;6900	Netrin 1;TAG-1	***Netrin 1*** promotes the exit of postmitotic migrating neurons from the embryonic lower rhombic lip and ***upregulates*** the expression of ***TAG-1*** in these neurons .	positive	1
11808	10704389	652;6469	BMP4;Shh	We further demonstrated that this ***regulation*** of ***Shh*** expression by ***BMP4*** is conserved in the mouse developing limb bud .	target	1
11809	10704389	652;6469	BMP4;Shh	In addition , Shh expression was unaffected in the developing limb buds of the transgenic mice in which a constitutively active Bmpr-IB is ectopically expressed in the forelimb posterior mesenchyme and throughout the hindlimb mesenchyme , suggesting that the ***repression*** of ***Shh*** expression by ***BMP4*** may not be mediated by BMP receptor-IB .	negative	1
11810	10704389	9241;652	noggin;BMP4	***Inhibition*** of ***BMP4*** activity by ***noggin*** resulted in repression of Shh and Bmp2 in wild-type dental epithelium .	negative	1
11811	10704389	652;6469	BMP4;Shh	Ectopic expression of human ***BMP4*** to the dental mesenchyme driven by the mouse Msx1 promoter restored Shh expression in the Msx1 mutant dental epithelium but ***repressed*** ***Shh*** in the wild-type tooth germ in vivo .	negative	1
11812	10704446	1398;5829	CRK;paxillin	Mutations in both tyrosine 31 and 118 diminished the phosphotyrosine content of paxillin and prevented the formation of the ******paxillin-CRK****** ***complex*** , suggesting that this association is necessary for collagen-mediated NBT-II cell migration .	parallel	1
11813	10704446	1398;5829	CRK;paxillin	These results demonstrate the important role of the ******paxillin-CRK****** ***complex*** in the collagen-induced cell motility .	parallel	1
11814	10704453	11252;6853	SdpII;synapsin I	***SdpII*** ***binds*** dynamin I , synaptojanin , ***synapsin I*** , and the neural Wiskott-Aldrich syndrome protein ( N-WASP ) , a stimulator of Arp2/3 induced actin filament nucleation .	parallel	1
11815	10704465	3565;3458	IL-4;IFN-gamma	These studies show that IL-4-driven Th2 differentiation can occur in the presence of persistent IL-12 signaling and that ***IL-4*** ***inhibits*** ***IFN-gamma*** production under these circumstances .	negative	1
11816	10704466	1432;9261	p38alpha;MAPKAP kinase 2	Therefore , these studies demonstrate that ***p38alpha*** is a major upstream ***activator*** of ***MAPKAP kinase 2*** and a key component of the IL-1 signaling pathway .	positive	1
11817	10704717	4852;1392	Neuropeptide Y;corticotropin-releasing factor	***Neuropeptide Y*** ***blocks*** anxiogenic-like behavioral action of ***corticotropin-releasing factor*** in an operant conflict test and elevated plus maze .	negative	0
11818	10704717	4852;1392	NPY;CRF	***NPY*** [ ( 1 microg , intracerebroventricularly ( i.c.v. ) ] significantly ***antagonized*** the response-suppressing effects of ***CRF*** ( 0.75 microg , i.c.v. ) on punished responding in the conflict test at doses that produced little or no behavioral effect when administered alone .	negative	1
11819	10704717	4852;1392	NPY;CRF	***NPY*** also ***antagonized*** the " anxiogenic-like " behavioral effects of ***CRF*** in the elevated plus maze .	negative	1
11820	10704718	3952;4852	leptin;neuropeptide Y	***Regulation*** of ***neuropeptide Y*** release from hypothalamic slices by melanocortin-4 agonists and ***leptin*** .	target	1
11821	10704718	5443;4852	alpha-MSH;NPY	However , the melanocortin-4 agonists , ***alpha-MSH*** and MT-II , significantly ***inhibited*** potassium-stimulated ***NPY*** release ( p < 0.01 ) without significantly altering basal NPY release .	negative	1
11822	10704718	4502;4852	MT-II;NPY	However , the melanocortin-4 agonists , alpha-MSH and ***MT-II*** , significantly ***inhibited*** potassium-stimulated ***NPY*** release ( p < 0.01 ) without significantly altering basal NPY release .	negative	1
11823	10704720	5697;7432	peptide YY;VIP	***peptide YY*** ***decreased*** the secretory effect of ***VIP*** in a dose-related fashion .	negative	0
11824	10704725	3375;133	amylin;PAMP	Specific ( 125 ) ***I-PAMP*** binding was ***inhibited*** by PAMP ( IC ( 50 ) of 100 nM ) but not ADM , calcitonin gene-related peptide ( CGRP ) , or ***amylin*** .	negative	1
11825	10704725	133;2353	ADM;c-fos	***ADM*** ( 100 nM ) ***stimulated*** transiently ***c-fos*** mRNA , whereas PAMP ( 1000 nM ) had little effect ; however , PAMP inhibited the increase in c-fos mRNA caused by ADM .	positive	0
11826	10704825	6464;9846	Shc;Gab2	***Shc*** ***associates*** with the IL-3 receptor beta subunit , SHIP and ***Gab2*** following IL-3 stimulation .	parallel	0
11827	10704825	6464;3562	Shc;IL-3	***Shc*** ***associates*** with the ***IL-3*** receptor beta subunit , SHIP and Gab2 following IL-3 stimulation .	parallel	0
11828	10704825	3562;6464	IL-3;Shc	The ***interaction*** between ***Shc*** and the ***IL-3*** receptor beta chains was direct , mediated by both the SH2 and PTB domains .	parallel	1
11829	10704829	2637;5015	Gbx2;Otx2	***Interaction*** between ***Otx2*** and ***Gbx2*** defines the organizing center for the optic tectum .	parallel	1
11830	10704829	2637;5015	Gbx2;Otx2	***Otx2*** and ***Gbx2*** ***interacted*** to repress each other 's expression .	parallel	1
11831	10704829	2637;2253	Gbx2;Fgf8	Ectopic Otx2 and ***Gbx2*** ***repressed*** endogenous expression of ***Fgf8*** in the isthmus , but induced Fgf8 expression at the interface between Otx2 and Gbx2 expression .	negative	1
11832	10704829	5015;2253	Otx2;Fgf8	Ectopic ***Otx2*** and Gbx2 ***repressed*** endogenous expression of ***Fgf8*** in the isthmus , but induced Fgf8 expression at the interface between Otx2 and Gbx2 expression .	negative	1
11833	10704829	5015;2253	Otx2;Fgf8	Ectopic ***Otx2*** and Gbx2 repressed endogenous expression of Fgf8 in the isthmus , but ***induced*** ***Fgf8*** expression at the interface between Otx2 and Gbx2 expression .	target	1
11834	10704829	2637;5015	Gbx2;Otx2	Thus , it is suggested that ***interaction*** between ***Otx2*** and ***Gbx2*** determines the site of Fgf8 expression and the posterior limit of the tectum .	parallel	1
11835	10704847	1499;1747	beta-catenin;Dlx3	***Regulation*** of early expression of ***Dlx3*** , a Xenopus anti-neural factor , by ***beta-catenin*** signaling .	target	1
11836	10704847	1499;8646	beta-catenin;chordin	The repression of Dlx3 is mediated by signaling though beta-catenin , but is probably not dependent on the ***induction*** of the Xnr3 or ***chordin*** genes by ***beta-catenin*** .	target	1
11837	10704849	51176;1499	LEF-1;beta-catenin	Two TCF binding sites located in a 500 bp Brachyury promoter fragment bind the ******LEF-1/beta-catenin****** ***complex*** and respond specifically to beta-catenin-dependent transactivation .	parallel	1
11838	10704850	9241;2626	Noggin;GATA4	***GATA4*** expression was also ***blocked*** by ***Noggin*** at stage 4 , however increased at stages 5 , 6 and 7 .	negative	0
11839	10704947	551;6197	AVP;RSK2	However , ***AVP-induced*** ***activation*** of ***RSK2*** , a downstream substrate of ERK1 and ERK2 , was PKC-dependent and PI 3-kinase-independent .	positive	1
11840	10704947	6197;5595	RSK2;ERK1	However , AVP-induced activation of ***RSK2*** , a downstream ***substrate*** of ***ERK1*** and ERK2 , was PKC-dependent and PI 3-kinase-independent .	parallel	1
11841	10704947	6197;5594	RSK2;ERK2	However , AVP-induced activation of ***RSK2*** , a downstream ***substrate*** of ERK1 and ***ERK2*** , was PKC-dependent and PI 3-kinase-independent .	parallel	1
11842	10704998	4804;4914	p75;Trk	Negative ***modulation*** of ***Trk*** signalling by ***p75*** could account for part of the pro-apoptotic effect , but is unlikely to be a major component .	negative	0
11843	10705081	7018;7124	Transferrin;tumor necrosis factor-alpha	***Transferrin*** ***modulates*** ***tumor necrosis factor-alpha*** secretion by cultured human mononuclear cells : influence of iron status .	target	0
11844	10705225	3565;6356	IL-4;eotaxin	***IL-4*** ***induces*** ***eotaxin*** production in corneal keratocytes but not in epithelial cells .	target	1
11845	10705225	3565;6356	IL-4;eotaxin	RESULTS : ***IL-4*** ***induced*** ***eotaxin*** production in keratocytes in a dose - and time-dependent manner which was enhanced by TNF-alpha .	target	1
11846	10705260	2321;7422	flt-1;vascular endothelial growth factor	Co-expression of ***vascular endothelial growth factor*** and its ***receptor*** ***flt-1*** in malignant pleural mesothelioma .	parallel	1
11847	10705260	2321;7422	flt-1;VEGF	Coexpression of ***VEGF*** and its ***receptor*** ***flt-1*** has been reported in different types of malignant tumors .	parallel	1
11848	10705304	5327;3082	tPA;HGF	Results obtained from in vitro experiments showed that urokinase-type plasminogen activator ( uPA ) and tissue-type plasminogen activator ( ***tPA*** ) can ***cleave*** single-chain ***HGF*** .	target	1
11849	10705306	3439;3458	IFN-alpha;IFN-gamma	In addition , ***IFN-alpha*** can ***induce*** ***IFN-gamma*** secretion by CD4 + Th cells , and both types of IFN may stimulate macrophage activities .	target	1
11850	10705382	7422;8829	VEGF;nrp1	Crosslinking experiments showed that ( 125 ) ***I-VEGF*** ( 165 ) ***binds*** to both ***nrp1*** and VEGFR2 present in decidual endothelial cells .	parallel	1
11851	10705382	7422;3791	VEGF;VEGFR2	Crosslinking experiments showed that ( 125 ) ***I-VEGF*** ( 165 ) ***binds*** to both nrp1 and ***VEGFR2*** present in decidual endothelial cells .	parallel	1
11852	10705382	8829;7422	neuropilin-1;VEGF	Recent evidence suggests that ***neuropilin-1*** ( nrp1 ) , a receptor involved in neuronal cell guidance , is expressed in endothelial cells , ***binds*** to ***VEGF*** ( 165 ) and enhances the binding of VEGF ( 165 ) to VEGFR2 .	parallel	1
11853	10705382	7422;3791	VEGF;VEGFR2	Recent evidence suggests that neuropilin-1 ( nrp1 ) , a receptor involved in neuronal cell guidance , is expressed in endothelial cells , binds to VEGF ( 165 ) and enhances the ***binding*** of ***VEGF*** ( 165 ) to ***VEGFR2*** .	parallel	1
11854	10705382	8829;7422	neuropilin-1;VEGF	Recent evidence suggests that ***neuropilin-1*** ( nrp1 ) , a receptor involved in neuronal cell guidance , is expressed in endothelial cells , binds to VEGF ( 165 ) and ***enhances*** the binding of ***VEGF*** ( 165 ) to VEGFR2 .	positive	0
11855	10705575	3479;7040	IGF-1;TGF-beta 1	These findings suggest that ***IGF-1*** ***induces*** latent ***TGF-beta 1*** and that the matrix-modulating autocrine effects of LTGF-beta 1 on dermal fibroblasts are facilitated by M6P/IGF-II receptors on these cells .	target	1
11856	10705575	3479;7040	insulin-like growth factor-1;transforming growth factor beta 1	We have previously shown that ***insulin-like growth factor-1*** ( IGF-1 ) ***induces*** the expression of latent ***transforming growth factor beta 1*** ( LTGF-beta 1 ) through activation of c-fos and c-jun oncogenes .	target	1
11857	10705576	658;655	ALK-6;OP-1	We therefore propose that the effects of ***OP-1*** on these cells in vitro are ***mediated*** by ***ALK-6/BMPR-IB*** .	target	0
11858	10705577	1027;595	p27Kip1;cyclin D1	Both TM and alpha IR-3 decreased the ***binding*** of ***p27Kip1*** to ***cyclin D1*** , whose expression was drastically reduced .	parallel	1
11859	10706084	4437;2956	Msh3;Msh6	These results suggest that ***Msh3*** ***cooperates*** with ***Msh6*** in tumor suppression .	parallel	0
11860	10706087	356;355	FasL;Fas	Programmed cell death ( apoptosis ) is primarily mediated by ***Fas*** ***ligand*** ( ***FasL*** ; CD95L ) and the Fas receptor ( Fas ; CD95 ) .	parallel	1
11861	10706100	682;4312	EMMPRIN;interstitial collagenase	***EMMPRIN*** ( CD147 ) , an inducer of matrix metalloproteinase synthesis , also ***binds*** ***interstitial collagenase*** to the tumor cell surface .	parallel	1
11862	10706100	682;4312	EMMPRIN;interstitial collagenase	In this study , we have found that ***EMMPRIN*** not only ***stimulates*** the production of ***interstitial collagenase*** ( MMP-1 ) but also forms a complex with MMP-1 at the tumor cell surface .	positive	0
11863	10706102	7157;1977	p53;CBP	We have compared the ***association*** of DNA-bound and overall pools of ***p53*** with murine double minute 2 ( Mdm2 ) , c-Jun NH2-terminal kinase ( JNK ) , ***p300/CBP*** , and p14ARF during cell cycle progression .	parallel	0
11864	10706102	7157;3725	p53;c-Jun	We have compared the ***association*** of DNA-bound and overall pools of ***p53*** with murine double minute 2 ( Mdm2 ) , ***c-Jun*** NH2-terminal kinase ( JNK ) , p300/CBP , and p14ARF during cell cycle progression .	parallel	0
11865	10706102	7157;5599	p53;JNK	We have compared the ***association*** of DNA-bound and overall pools of ***p53*** with murine double minute 2 ( Mdm2 ) , c-Jun NH2-terminal kinase ( ***JNK*** ) , p300/CBP , and p14ARF during cell cycle progression .	parallel	0
11866	10706102	7157;4193	p53;Mdm2	We have compared the ***association*** of DNA-bound and overall pools of ***p53*** with murine double minute 2 ( ***Mdm2*** ) , c-Jun NH2-terminal kinase ( JNK ) , p300/CBP , and p14ARF during cell cycle progression .	parallel	0
11867	10706102	7157;1029	p53;p14ARF	We have compared the ***association*** of DNA-bound and overall pools of ***p53*** with murine double minute 2 ( Mdm2 ) , c-Jun NH2-terminal kinase ( JNK ) , p300/CBP , and ***p14ARF*** during cell cycle progression .	parallel	0
11868	10706102	7157;2033	p53;p300	We have compared the ***association*** of DNA-bound and overall pools of ***p53*** with murine double minute 2 ( Mdm2 ) , c-Jun NH2-terminal kinase ( JNK ) , ***p300/CBP*** , and p14ARF during cell cycle progression .	parallel	0
11869	10706102	7157;5599	p53;JNK	Whereas DNA-bound ***p53*** ***associates*** with ***JNK*** at G0-G1 and with Mdm2 and p300 during S and G2-M phases , the general pool of p53 was found in complex with JNK and Mdm2 almost throughout the cell cycle .	parallel	0
11870	10706104	196;1543	aryl hydrocarbon receptor;CYP1A1	Procarcinogenic polycyclic aromatic hydrocarbons ( PAHs ) induce their own metabolism and activation by binding to the cytosolic ***aryl hydrocarbon receptor*** ( AhR ) , which then translocates to the nucleus and ***activates*** ***CYP1A1*** gene transcription via xenobiotic response elements ( XREs ) .	positive	1
11871	10706128	5320;5743	sPLA2;COX-2	Pancreatic secretory PLA2 ( ***sPLA2*** ) , via its receptor ( sPLA2R ) , transcriptionally ***activates*** ***COX-2*** gene expression in several cell types , although a specific transcription factor mediating COX-2 expression has not yet been identified .	positive	1
11872	10706380	183;5972	angiotensin II;renin	In isolated mesenteric arteries from 1K1C RHR and 2K1C RHR , ***angiotensin II*** ( Ang II ) , angiotensin I ( Ang I ) and tetradecapeptide ( TDP ) , a physiologically active ***renin*** ***substrate*** , produced concentration-dependent vasoconstriction .	parallel	1
11873	10706444	970;939	CD70;CD27	Plasma cell generation from B-lymphocytes via ******CD27/CD70****** ***interaction*** .	parallel	1
11874	10706557	356;355	FasL;Fas	Following this infection , induction of ***Fas*** ***ligand*** ( ***FasL*** ) , tumor necrosis factor alpha ( TNF-alpha ) , and perforin mRNA are all demonstrable in the liver , pointing to a role of respective pathways in liver injury .	parallel	1
11875	10706604	5803;5764	RPTP beta;PTN	The results also suggest that ***RPTP beta/zeta*** is a functional ***receptor*** for ***PTN*** ; PTN signals through ligand-dependent receptor inactivation of RPTP beta/zeta to increase levels of tyrosine phosphorylation of beta-catenin to initiate downstream signaling .	parallel	1
11876	10706604	5764;1499	Pleiotrophin;beta-catenin	***Pleiotrophin*** signals ***increased*** tyrosine phosphorylation of beta ***beta-catenin*** through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta .	positive	0
11877	10706604	5764;5803	PTN;RPTP beta	Our results suggest that ***PTN*** is a natural ***ligand*** for ***RPTP beta/zeta*** .	parallel	1
11878	10706604	5764;5803	PTN;RPTP beta	We have found that ***PTN*** ***binds*** to and functionally inactivates the catalytic activity of ***RPTP beta/zeta*** .	parallel	1
11879	10706604	5803;1499	RPTP beta;beta-catenin	We also have found that an active site-containing domain of ***RPTP beta/zeta*** both ***binds*** ***beta-catenin*** and functionally reduces its levels of tyrosine phosphorylation when added to lysates of pervanidate-treated cells .	parallel	1
11880	10706604	5803;1499	RPTP beta;beta-catenin	In contrast , an ( inactivating ) active-site mutant of ***RPTP beta/zeta*** also ***binds*** ***beta-catenin*** but fails to reduce tyrosine phosphorylation of beta-catenin .	parallel	1
11881	10706604	5764;1499	PTN;beta-catenin	Finally , in parallel to its ability to inactivate endogenous RPTP beta/zeta , ***PTN*** sharply ***increases*** tyrosine phosphorylation of ***beta-catenin*** in PTN-treated cells .	positive	0
11882	10706605	10661;3043	EKLF;beta-globin	We used the in vivo PIN * POINT assay to show that ***EKLF*** is ***recruited*** to the ***beta-globin*** promoter but not to the gamma-globin promoter .	target	0
11883	10706605	10661;3043	EKLF;beta-globin	The repeat , when inserted in the beta-globin promoter , decreases ***EKLF*** ***recruitment*** to and activity of the ***beta-globin*** promoter , suggesting that the repeat functions as a suppressor element .	target	0
11884	10706614	8851;1020	p25;cdk5	Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human ***p25*** , an ***activator*** of ***cdk5*** .	positive	1
11885	10706614	8851;1020	p25;cdk5	Here we show that tau and neurofilament are hyperphosphorylated in transgenic mice that overexpress human ***p25*** , an ***activator*** of ***cdk5*** .	positive	1
11886	10706625	7101;5076	Tlx;Pax2	The orphan nuclear receptor ***Tlx*** ***regulates*** ***Pax2*** and is essential for vision .	target	1
11887	10706629	2100;4085	ERbeta;MAD2	Here we show a direct and specific ***interaction*** between ***ERbeta*** and the cell cycle mitotic spindle assembly checkpoint protein , ***MAD2*** ( mitosis arrest-deficient 2 ) .	parallel	1
11888	10706629	4085;2100	MAD2;ERbeta	The ******ERbeta-MAD2****** ***interaction*** was identified by screening of a yeast two-hybrid system vascular endothelial cell library with ERbeta and confirmed with glutathione S-transferase-fusion protein interaction studies .	parallel	1
11889	10706629	4085;2100	MAD2;ERbeta	These data identify a ***link*** between ***ERbeta*** and ***MAD2*** of potential importance to regulation of the cell cycle and support a function of ERbeta distinct from the established role of ERs as transcription factors .	parallel	0
11890	10706653	4478;3385	moesin;ICAM-3	Chemokines induce ***moesin*** ***interaction*** with ***ICAM-3*** .	parallel	1
11891	10706670	4760;3458	beta 2;IFN-gamma	Cutting edge : ectopic expression of the IL-12 ***receptor-beta 2*** in developing and committed Th2 cells does not affect the production of IL-4 or ***induce*** the production of ***IFN-gamma*** .	target	1
11892	10706675	8743;8797	TRAIL;Apo2	***TRAIL*** ( ***Apo2*** ***ligand*** ) and TWEAK ( Apo3 ligand ) mediate CD4 + T cell killing of antigen-presenting macrophages .	parallel	1
11893	10706675	356;355	Fas ligand;Fas	Previous reports indicate that ******Fas-Fas ligand****** ***interactions*** are the principle molecules mediating this response .	parallel	1
11894	10706675	8743;8797	TRAIL;Apo2	Recent reports demonstrate that TNF-related apoptosis-inducing ligand ( ***TRAIL*** ) , ***interacting*** with ***Apo2*** , and TNF-like weak inducer of apoptosis ( TWEAK ) , interacting with Apo3 , will induce apoptosis in some cells .	parallel	1
11895	10706675	8743;8718	TRAIL;Apo3	Recent reports demonstrate that TNF-related apoptosis-inducing ligand ( ***TRAIL*** ) , interacting with Apo2 , and TNF-like weak inducer of apoptosis ( TWEAK ) , ***interacting*** with ***Apo3*** , will induce apoptosis in some cells .	parallel	1
11896	10706681	948;7057	CD36;TSP	However , ***TSP*** and its ***receptor*** ***CD36*** are abundantly expressed in chronically inflamed tissues such as the rheumatoid synovium .	parallel	1
11897	10706681	948;961	CD36;CD47	We propose that a ******CD47-TSP-CD36****** trimolecular ***complex*** is a novel costimulatory pathway that significantly decreases the threshold of T cell activation .	parallel	1
11898	10706681	948;7057	CD36;TSP	We propose that a ******CD47-TSP-CD36****** trimolecular ***complex*** is a novel costimulatory pathway that significantly decreases the threshold of T cell activation .	parallel	1
11899	10706681	7057;961	TSP;CD47	We propose that a ******CD47-TSP-CD36****** trimolecular ***complex*** is a novel costimulatory pathway that significantly decreases the threshold of T cell activation .	parallel	1
11900	10706702	7409;930	Vav;CD19	***Vav*** ***associated*** with ***CD19*** constitutively in unstimulated cells by a tyrosine-independent mechanism requiring the portion of CD19 encoded by exons 9-12 .	parallel	0
11901	10706714	1432;6352	p38 mitogen-activated protein kinase;RANTES	***p38 mitogen-activated protein kinase*** and c-jun-NH2-terminal kinase ***regulate*** ***RANTES*** production by influenza virus-infected human bronchial epithelial cells .	target	1
11902	10706714	5599;6352	JNK;RANTES	These results indicate that p38 MAP kinase and ***JNK*** , at least in part , ***regulate*** ***RANTES*** production by bronchial epithelial cells .	target	1
11903	10706714	1432;6352	p38 MAP kinase;RANTES	These results indicate that ***p38 MAP kinase*** and JNK , at least in part , ***regulate*** ***RANTES*** production by bronchial epithelial cells .	target	1
11904	10706717	3606;3458	IL-18;IFN-gamma	***IL-18*** ***induces*** ***IFN-gamma*** and NK cell cytotoxicity , making it a logical target for viral antagonism of host defense .	target	1
11905	10706719	1050;4602	C/EBPalpha;c-Myb	Gel mobility shift assay demonstrated that ***C/EBPalpha*** predominantly ***bound*** to the ***C/EBP/c-Myb*** sites using HL-60 nuclear extracts .	parallel	1
11906	10706725	4794;3383	I kappa B-epsilon;ICAM-1	These findings indicate that c-Rel-associated ***I kappa B-epsilon*** is involved in the ***induction*** of ***ICAM-1*** expression .	target	1
11907	10706730	7124;2520	TNF-alpha;gastrin	In accordance with this activity , G cells were shown to express high levels of the NF-kappa B target cytokine ***TNF-alpha*** , a well-documented ***stimulator*** of ***gastrin*** production .	positive	0
11908	10706733	4792;4790	I kappa B alpha;NF-kappa B	Because many proinflammatory cytokines are transcriptionally regulated by the NF-kappa B , we investigated whether an elevated extracellular NaCl content in airway fluids significantly impaired the regulation of the ******NF-kappa B/I kappa B alpha****** ***complex*** and the chemokine IL-8 production in primary non-CF and CF human bronchial gland epithelial cells .	parallel	1
11909	10706733	4790;4792	NF-kappa B;I kappa B alpha	Exposure of non-CF gland cells to hypotonic ( 85 mM ) NaCl solution , compared with isotonic ( 115 mM ) NaCl and hypertonic ( 170 mM ) NaCl solutions , resulted in a significant decrease in IL-8 production that was paralleled by a strong inhibition of activated ***NF-kappa B*** ***associated*** with an increased cytosolic expression of ***I kappa B alpha*** and a decrease in the I kappa B kinase alpha protein level .	parallel	0
11910	10706739	6351;1234	macrophage inflammatory protein 1 beta;CCR5	We analyzed sera from ESN , their HIV-infected sexual partners ( HIV + ) , and healthy controls ( USN ) searching for CCR5-specific Abs , studying whether incubation of PBMC with sera could prevent ***macrophage inflammatory protein 1 beta*** ( Mip1 beta ) ( natural ligand of CCR5 ) ***binding*** to ***CCR5*** .	parallel	1
11911	10706854	6356;5594	Eotaxin;ERK2	We conclude that ***Eotaxin*** ***induces*** a rapid concentration-dependent activation of ***ERK2*** and p38 in eosinophils and that the activation of these MAP kinases is required for Eotaxin-stimulated degranulation and directed locomotion .	target	1
11912	10706861	3976;3977	LIF;LIF receptor	Because the action of LIF is indirect and mediated by stromal cells , we hypothesized that ***LIF*** ***binds*** to the ***LIF receptor*** on AC6 .21 stromal cells , leading to up-regulated production of stem cell expansion promoting factor ( SCEPF ) and/or down-regulated production of stem cell expansion inhibitory factor ( SCEIF ) .	parallel	1
11913	10706872	3562;2204	IL-3;CD89	We show that ***IL-3-mediated*** ***activation*** of FcalphaR ( ***CD89*** ) requires the activation of PI3K , independent of p21ras activation .	positive	1
11914	10706873	356;355	Fas ligand;Fas	Mechanistically , AICD has been largely attributed to the ***interaction*** of ***Fas ligand*** ( Fas-L ) with its cell surface receptor ***Fas*** in activated T cells .	parallel	1
11915	10706874	4914;4803	TrkA;NGF	Because PMCs constitutively express the ***NGF*** high-affinity ***receptor*** ( ***TrkA*** ) with a tyrosine kinase domain , we focused on downstream effectors in signaling cascades following the TrkA .	parallel	1
11916	10706877	25;6777	ABL;Stat5	Because the ***BCR-ABL*** and TEL-PDGFbetaR oncoproteins also ***activate*** ***Stat5*** , activation of this factor should be a crucial step in activated tyrosine kinase-mediated leukemogenesis .	positive	1
11917	10706885	1440;207	G-CSF;Akt	***G-CSF*** stimulation of cells expressing the G-CSFR truncation mutant ***induces*** sustained activation of ***Akt*** and prolonged phosphorylation of the pro-apoptotic protein Bad , resulting in enhanced cell survival .	target	1
11918	10707082	1793;57539	ced-5;CED-2	We provide evidence that CED-2 and CED-10 function in engulfing rather than dying cells to control the phagocytosis of cell corpses , that ***CED-2*** and ***ced-5*** physically ***interact*** , and that ced-10 probably functions downstream of CED-2 and ced-5 .	parallel	1
11919	10707555	7124;3643	TNF-alpha;insulin receptor	For example , ***TNF-alpha*** from adipocytes ***reduces*** tyrosine kinase activity of the ***insulin receptor*** in obesity .	negative	1
11920	10707928	3553;7040	IL-1beta;TGF-beta1	In PANC-1 cells , ***IL-1beta*** and TNF-alpha ***induced*** a rapid activation of nuclear factor ( NF ) - kappaB , and ***TGF-beta1*** enhanced this activation slightly .	target	1
11921	10707928	7124;7040	TNF-alpha;TGF-beta1	In PANC-1 cells , IL-1beta and ***TNF-alpha*** ***induced*** a rapid activation of nuclear factor ( NF ) - kappaB , and ***TGF-beta1*** enhanced this activation slightly .	target	1
11922	10707959	8856;8204	PXR;receptor interacting protein 140	In the yeast two-hybrid protein interaction assay , ***PXR*** ***interacted*** with two nuclear receptor coactivator proteins , steroid hormone receptor coactivator-1 and ***receptor interacting protein 140*** , in the presence of phthalic acid or nonylphenol .	parallel	1
11923	10707960	1270;7432	ciliary neurotrophic factor;VIP	In addition , ***ciliary neurotrophic factor*** ( CNTF ) , a neuropoietic cytokine , synergizes with activin to ***increase*** ***VIP*** mRNA expression and transcription through the VIP CyRE .	positive	0
11924	10707961	9021;3716	SOCS-3;JAK1	In addition , we found that ***SOCS-3*** was ***associated*** with ***JAK1*** and JAK2 and that these associations were stimulated by TSH .	parallel	0
11925	10707961	9021;3717	SOCS-3;JAK2	In addition , we found that ***SOCS-3*** was ***associated*** with JAK1 and ***JAK2*** and that these associations were stimulated by TSH .	parallel	0
11926	10707961	3458;8651	IFN-gamma;SOCS-1	***IFN-gamma*** ***up-regulated*** ***SOCS-1*** and SOCS-3 RNA and protein in FRTL-5 cells , as reported previously for nonthyroid cells .	positive	1
11927	10707961	3458;9021	IFN-gamma;SOCS-3	***IFN-gamma*** ***up-regulated*** SOCS-1 and ***SOCS-3*** RNA and protein in FRTL-5 cells , as reported previously for nonthyroid cells .	positive	1
11928	10707962	7030;7299	TFE3;tyrosinase	***TFE3*** , a transcription factor homologous to microphthalmia , is a potential transcriptional ***activator*** of ***tyrosinase*** and TyrpI genes .	positive	1
11929	10707962	7030;7299	TFE3;tyrosinase	We show in this report that overexpression of ***TFE3*** ***stimulates*** the ***tyrosinase*** and TyrpI promoter activities , while TFEB acts only on the TyrpI promoter .	positive	0
11930	10707981	4914;4803	TrkA;NGF	Blocking the ******NGF-TrkA****** ***interaction*** rescues the developmental loss of LTP in the rat visual cortex : role of the cholinergic system .	parallel	1
11931	10708100	3559;3558	CD25;IL-2	The current study was designed to compare efficacy and tolerability of a combination of low-dose CsA and high-dose SDZ RAD ( CTL group ) to triple therapy using the chimeric anti-interleukin-2 ( ***IL-2*** ) ***receptor*** ( ***CD25*** ) monoclonal antibody ( mAb ) basiliximab ( anti-IL-2 receptor mAb ) for induction therapy ( basiliximab : 5 mg intravenously on days 0 and 4 ) plus low-dose CsA and low-dose SDZ RAD for maintenance immunosuppression ( CD25 group ) .	parallel	1
11932	10708136	1440;7124	G-CSF;TNFalpha	As a potential mechanism of the reduction in TNFalpha , we demonstrate ***G-CSF*** ***decreased*** dendritic cells ***TNFalpha*** , and interleukin-12 production to lipopolysaccharide .	negative	0
11933	10708181	5340;5345	plasmin;alpha 2-antiplasmin	MEASUREMENTS AND MAIN RESULTS : Standard coagulation data and molecular markers of coagulation activation and fibrinolytic activity ( soluble thrombomodulin , protein C , free protein S , thrombin/antithrombin III complex , ******plasmin-alpha 2-antiplasmin****** ***complex*** , tissue plasminogen activator , platelet factor 4 , beta-thromboglobulin were measured from arterial blood samples on the day of admission to the intensive care unit ( trauma/neurosurgery patients ) or on the day of diagnosis of sepsis ( baseline value ) and serially during the next 5 days .	parallel	1
11934	10708418	7076;3643	Epo;insulin receptor	We further show that in SFFV-infected erythroid cells grown in the absence of ***Epo*** , PI 3-kinase ***associates*** with the ***insulin receptor*** substrate ( IRS ) - related adapter molecules IRS-2 , Gab1 , and Gab2 , which are constitutively tyrosine phosphorylated in SFFV-infected cells .	parallel	0
11935	10708423	8548;10399	cytoplasmic protein;RACK1	The protein product of another CST ORF , A73 , is shown to be a ***cytoplasmic protein*** which can ***interact*** with the cell ***RACK1*** protein .	parallel	1
11936	10708452	959;958	CD40 ligand;CD40	Readministration of adenovirus vector in nonhuman primate lungs by blockade of ******CD40-CD40 ligand****** ***interactions*** .	parallel	1
11937	10708481	1026;1017	p21;Cdk2	Although p53 and p21 ( waf1/cip1 ) were induced by AAF , the ***binding*** of ***p21*** to cyclin E and ***Cdk2*** was not increased in growth arrested liver .	parallel	1
11938	10708552	3952;2641	leptin;GLP-1	Intraperitoneal ***leptin*** administration also ***increased*** hypothalamic ***GLP-1*** peptide in food-restricted mice ( P < 0 .	positive	0
11939	10708552	2641;2796	GLP-1;LHRH	Reduced CNS ***GLP-1*** neuronal activity during food deprivation may act to stimulate feeding behaviour , and perhaps also ***inhibit*** hypothalamic ***LHRH*** neurons , as part of the neuroendocrine response to starvation .	negative	1
11940	10708557	7124;285	Tumor necrosis factor-alpha;angiopoietin-2	***Tumor necrosis factor-alpha*** ***upregulates*** ***angiopoietin-2*** in human umbilical vein endothelial cells .	positive	1
11941	10708557	7124;285	TNF-alpha;Ang2	Reverse transcriptase-polymerase chain reaction and Northern blot analyses indicated that ***TNF-alpha*** ***induced*** ***Ang2*** mRNA expression in a time - and dose-dependent manner .	target	1
11942	10708557	7124;285	TNF-alpha;Ang2	Western blot analyses revealed that ***TNF-alpha*** treatment ***increased*** cellular ***Ang2*** protein .	positive	0
11943	10708557	7124;285	TNF-alpha;Ang2	***TNF-alpha*** ***induced*** less ***Ang2*** mRNA expression in the presence of nuclear factor-kappaB ( NF-kappaB ) inhibitor .	target	1
11944	10708567	1387;1406	CBP;cone-rod homeobox	***p300/CBP*** acts as a ***coactivator*** of the ***cone-rod homeobox*** transcription factor .	positive	1
11945	10708567	2033;1406	p300;cone-rod homeobox	***p300/CBP*** acts as a ***coactivator*** of the ***cone-rod homeobox*** transcription factor .	positive	1
11946	10708605	9622;3827	kallikrein;kininogen	In blood coagulation , HMW ***kininogen*** is considered to be ***cleaved*** by a specific enzyme ***kallikrein*** .	target	1
11947	10708669	5741;2353	PTH;c-fos	Both ***PTH*** ( 1-34 ) and PTHrP ( 1-34 ) ***increased*** cAMP and ***c-fos*** mRNA in CM/PDL cells .	positive	0
11948	10708669	5744;2353	PTHrP;c-fos	Both PTH ( 1-34 ) and ***PTHrP*** ( 1-34 ) ***increased*** cAMP and ***c-fos*** mRNA in CM/PDL cells .	positive	0
11949	10708710	7132;1906	CD120a;endothelin-1	The p55 tumor necrosis factor receptor ( ***CD120a*** ) ***induces*** ***endothelin-1*** synthesis in endothelial and epithelial cells .	target	1
11950	10708710	7124;1906	tumor necrosis factor alpha;endothelin-1	Synthesis of the vasoconstrictor peptide ***endothelin-1*** by endothelial and epithelial cells is strongly ***induced*** by ***tumor necrosis factor alpha*** ( TNF-alpha ) .	target	1
11951	10708710	7124;1906	TNF-alpha;endothelin-1	These results establish the p55 TNF receptor as the main receptor involved in the ***induction*** of ***endothelin-1*** synthesis by ***TNF-alpha*** .	target	1
11952	10708755	967;3689	CD63;CD18	***CD63*** ***associates*** with ***CD11/CD18*** in large detergent-resistant complexes after translocation to the cell surface in human neutrophils .	parallel	0
11953	10708755	3689;967	CD18;CD63	Gel permeation chromatography demonstrated that all of the cell surface ***CD11/CD18*** ***associated*** with ***CD63*** eluted in the void volume , indicating that they were present in large detergent-resistant complexes .	parallel	0
11954	10708759	4804;25	nerve growth factor receptor;c-Abl	Direct ***interaction*** of ***nerve growth factor receptor*** , TrkA , with non-receptor tyrosine kinase , ***c-Abl*** , through the activation loop .	parallel	1
11955	10708762	2534;309	Fyn;annexin VI	In addition , in vitro binding assays indicate that ***Fyn*** , but not Pyk2 ***binds*** directly to ***annexin VI*** .	parallel	1
11956	10708762	309;2534	annexin VI;Fyn	Finally , co-immunoprecipitation studies in Rat-1 fibroblasts confirm that ***Fyn*** , Pyk2 , ***annexin VI*** and RasGAP can form a protein ***complex*** in mammalian cells .	parallel	1
11957	10708762	309;2185	annexin VI;Pyk2	Finally , co-immunoprecipitation studies in Rat-1 fibroblasts confirm that Fyn , ***Pyk2*** , ***annexin VI*** and RasGAP can form a protein ***complex*** in mammalian cells .	parallel	1
11958	10708762	309;5921	annexin VI;RasGAP	Finally , co-immunoprecipitation studies in Rat-1 fibroblasts confirm that Fyn , Pyk2 , ***annexin VI*** and ***RasGAP*** can form a protein ***complex*** in mammalian cells .	parallel	1
11959	10708762	2534;5921	Fyn;RasGAP	Finally , co-immunoprecipitation studies in Rat-1 fibroblasts confirm that ***Fyn*** , Pyk2 , annexin VI and ***RasGAP*** can form a protein ***complex*** in mammalian cells .	parallel	1
11960	10708762	2185;2534	Pyk2;Fyn	Finally , co-immunoprecipitation studies in Rat-1 fibroblasts confirm that ***Fyn*** , ***Pyk2*** , annexin VI and RasGAP can form a protein ***complex*** in mammalian cells .	parallel	1
11961	10708762	2185;5921	Pyk2;RasGAP	Finally , co-immunoprecipitation studies in Rat-1 fibroblasts confirm that Fyn , ***Pyk2*** , annexin VI and ***RasGAP*** can form a protein ***complex*** in mammalian cells .	parallel	1
11962	10708937	999;7157	E-cadherin;p53	Loss of ***E-cadherin*** and beta-catenin immunoreactivity was found in 14 ( 35 % ) and 17 ( 43 % ) tumours , respectively , and was significantly ***associated*** with invasiveness , high grade and ***p53*** overexpression .	parallel	0
11963	10708950	5594;5609	Erk;MEK	This ***cross-talk*** between the ******MEK/Erk****** and Smad1 pathways was mediated through the four Erk consensus phosphorylation sites in the linker region of Smad1 .	parallel	0
11964	10708950	4086;5594	Smad1;Erk	This ***cross-talk*** between the ***MEK/Erk*** and ***Smad1*** pathways was mediated through the four Erk consensus phosphorylation sites in the linker region of Smad1 .	parallel	0
11965	10708950	4086;5609	Smad1;MEK	This ***cross-talk*** between the ***MEK/Erk*** and ***Smad1*** pathways was mediated through the four Erk consensus phosphorylation sites in the linker region of Smad1 .	parallel	0
11966	10708950	4086;4089	Smad1;Smad4	Mutation of these sites resulted in a loss of the ligand-dependence of both ******Smad1-Smad4****** ***interactions*** and nuclear accumulation of Smad1 , as well as a loss of the ability of Smad1 to enhance TGFbeta-mediated SBE activation .	parallel	1
11967	10708950	5594;4086	Erk;Smad1	Our results provide evidence that ***Erk-mediated*** ***phosphorylation*** of ***Smad1*** in response to TGFbeta is critical for regulating Smad1 subcellular localization ; this may be a key determinant in maintaining TGFbeta-dependent transcriptional activation .	target	1
11968	10708950	6416;7040	MKK4;TGFbeta	Expression of either RasN17 or dominant-negative ( DN ) ***MKK4*** , or addition of the MEK1 inhibitor PD98059 , can ***block*** the ability of ***TGFbeta*** to induce AP-1 complex formation at the TGFbeta ( 1 ) promoter and to autoinduce its own production .	negative	0
11969	10708950	4088;7040	Smad3;TGFbeta	In contrast , TGFbeta autoinduction is Smad3-dependent , as DN ***Smad3*** ***inhibits*** the ability of ***TGFbeta*** to stimulate TGFbeta ( 1 ) promoter activity .	negative	1
11970	10708950	5594;5609	Erk;MEK	Our results indicate that TGFbeta can ***activate*** both the MKK4/Sapk and ******MEK/Erk****** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11971	10708950	5594;6416	Erk;MKK4	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11972	10708950	5594;5601	Erk;Sapk	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11973	10708950	5609;5594	MEK;Erk	Our results indicate that TGFbeta can ***activate*** both the MKK4/Sapk and ******MEK/Erk****** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11974	10708950	5609;6416	MEK;MKK4	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11975	10708950	5609;5601	MEK;Sapk	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11976	10708950	6416;5594	MKK4;Erk	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11977	10708950	6416;5609	MKK4;MEK	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11978	10708950	6416;5601	MKK4;Sapk	Our results indicate that TGFbeta can ***activate*** both the ******MKK4/Sapk****** and MEK/Erk pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11979	10708950	5601;5594	Sapk;Erk	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11980	10708950	5601;5609	Sapk;MEK	Our results indicate that TGFbeta can ***activate*** both the ***MKK4/Sapk*** and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11981	10708950	5601;6416	Sapk;MKK4	Our results indicate that TGFbeta can ***activate*** both the ******MKK4/Sapk****** and MEK/Erk pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11982	10708950	5594;7040	Erk;TGFbeta	Our results indicate that TGFbeta can activate both the MKK4/Sapk and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to ***induce*** ***TGFbeta*** ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	target	1
11983	10708950	5609;7040	MEK;TGFbeta	Our results indicate that TGFbeta can activate both the MKK4/Sapk and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to ***induce*** ***TGFbeta*** ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	target	1
11984	10708950	6416;7040	MKK4;TGFbeta	Our results indicate that TGFbeta can activate both the ***MKK4/Sapk*** and MEK/Erk pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to ***induce*** ***TGFbeta*** ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	target	1
11985	10708950	5601;7040	Sapk;TGFbeta	Our results indicate that TGFbeta can activate both the ***MKK4/Sapk*** and MEK/Erk pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to ***induce*** ***TGFbeta*** ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	target	1
11986	10708950	7040;5594	TGFbeta;Erk	Our results indicate that ***TGFbeta*** can ***activate*** both the MKK4/Sapk and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11987	10708950	7040;5609	TGFbeta;MEK	Our results indicate that ***TGFbeta*** can ***activate*** both the MKK4/Sapk and ***MEK/Erk*** pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11988	10708950	7040;6416	TGFbeta;MKK4	Our results indicate that ***TGFbeta*** can ***activate*** both the ***MKK4/Sapk*** and MEK/Erk pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11989	10708950	7040;5601	TGFbeta;Sapk	Our results indicate that ***TGFbeta*** can ***activate*** both the ***MKK4/Sapk*** and MEK/Erk pathways , through Ras and TGFbeta R ( I ) and R ( II ) , to induce TGFbeta ( 1 ) production ; Smad4 does not appear to be involved , and Smad3 appears to function independently of this Smad4 .	positive	1
11990	10708950	4086;7040	Smad1;TGFbeta	In addition , ***Smad1*** could ***enhance*** ***TGFbeta*** activation of the SBE reporter SBE-luc and this effect could be blocked by co-expression of a DN TGFbeta R ( I ) receptor or by the MEK1 inhibitor PD98059 .	positive	0
11991	10708953	7057;7040	thrombospondin-1;TGF-beta	***Activation*** of latent ***TGF-beta*** by ***thrombospondin-1*** : mechanisms and physiology .	positive	1
11992	10708953	7057;7040	TSP-1;TGF-beta	Specific sequences in TSP-1 and in the precursor portion ( the latency associate peptide-LAP ) have been determined to be essential for ***activation*** of latent ***TGF-beta*** by ***TSP-1*** .	positive	1
11993	10708953	7057;7040	TSP-1;LAP	It is thought that binding of ***TSP-1*** to the latent complex ***induces*** a conformational rearrangement of the ***LAP*** in such a manner as to prevent the LAP from conferring latency on the mature domain of TGF-beta .	target	1
11994	10709629	57678;1374	GPAT;CPT I	Reciprocal ***interaction*** of ***CPT I*** and ***GPAT*** was discussed with regard to the balance existing between fatty acid oxidation and esterification metabolic pathways .	parallel	1
11995	10709860	23552;1026	p42;p21	Instead , ***p42/44*** mitogen activated protein kinase activation by NO results in reduced cellular proliferation and ***increased*** ***p21*** expression , suggesting NO inhibits intimal hyperplasia through cell cycle arrest as mediated by p21 and the signaling pathway involved in p21 upregulation may be regulated by p42/44 mitogen activated protein kinase .	positive	0
11996	10709997	7040;3569	TGF-beta;IL-6	In this paper , we report that ***TGF-beta*** ***stimulates*** ***IL-6*** transcripts in a time - and dose-dependent manner in primary rat osteoblasts isolated from 22-day-old calvariae ( Ob cells ) .	positive	0
11997	10709997	7040;3569	TGF-beta;IL-6	The mechanisms of IL-6 stimulation by TGF-beta is at least partially transcriptional because ***TGF-beta*** ***induces*** ***IL-6*** heterogenous nuclear RNA , and , to a lesser extent , IL-6 transcription rate as determined by a nuclear run-on assay .	target	1
11998	10710290	186;2065	AT2;ErbB3	Studies using mutated and chimeric AT2 receptors showed that replacing the third intracellular loop ( ICL ) of the AT2 receptor with that of the AT1 abolishes the ***interaction*** between the ***ErbB3*** and the ***AT2*** in yeast Two-Hybrid protein-protein interaction assay .	parallel	1
11999	10710310	11200;7157	Chk2;p53	DNA damage-induced ***activation*** of ***p53*** by the checkpoint kinase ***Chk2*** .	positive	1
12000	10710437	1995;7422	HuC;VEGF	With this assay , I demonstrate that ***HuC*** and HuD ***bind*** to the ***VEGF*** 3 ' - UTR regulatory segment ( VRS ) and to the c - myc 3 ' - UTR in a specific and concentration-dependent pattern , with both proteins showing a greater affinity for the VRS .	parallel	1
12001	10710437	1996;7422	HuD;VEGF	With this assay , I demonstrate that HuC and ***HuD*** ***bind*** to the ***VEGF*** 3 ' - UTR regulatory segment ( VRS ) and to the c - myc 3 ' - UTR in a specific and concentration-dependent pattern , with both proteins showing a greater affinity for the VRS .	parallel	1
12002	10710506	2247;3082	fibroblast growth factor-2;HGF	Cortisol decreased HGF/SF mRNA levels and diminished the ***induction*** of ***HGF/SF*** transcripts by ***fibroblast growth factor-2*** ( FGF-2 ) and platelet-derived growth factor BB ( PDGF BB ) .	target	1
12003	10710527	7040;3486	TGF-beta;IGFBP-3	***TGF-beta*** ***stimulates*** ***IGFBP-3*** mRNA and peptide expression in several cell types , and TGF-beta-induced growth inhibition and apoptosis have been shown to be mediated through the induction of IGFBP-3 .	positive	0
12004	10710535	7124;355	TNF-alpha;Fas	Surface ***Fas*** decreased partially during prolonged serum deprivation of cultured HASM cells and was ***upregulated*** by ***TNF-alpha*** stimulation .	positive	1
12005	10710543	551;359	AVP;AQP2	Using a phosphorylation state-specific AQP2 antibody , we demonstrated that ***AVP*** ***stimulates*** ***AQP2*** phosphorylation at the Ser ( 256 ) protein kinase A consensus site in a time - and dose-dependent manner .	positive	0
12006	10710543	551;359	AVP;AQP2	In parallel studies using a differential centrifugation technique , we demonstrated that ***AVP*** ***induced*** translocation of ***AQP2*** from an intracellular vesicle-enriched fraction to a plasma membrane-enriched fraction .	target	1
12007	10711600	3383;3683	CD54;CD11a	The antigens recognized by R1-73 , R2-40 and R1-34 mAbs were defined by immunoprecipitation and Western blot analyses as CD11a , CD18 and CD11b , respectively ; and the allografts expressed ***CD54*** , a ***ligand*** of ***CD11a*** or CD11b , suggesting leukocyte integrin-dependent killing .	parallel	1
12008	10711600	3383;3684	CD54;CD11b	The antigens recognized by R1-73 , R2-40 and R1-34 mAbs were defined by immunoprecipitation and Western blot analyses as CD11a , CD18 and CD11b , respectively ; and the allografts expressed ***CD54*** , a ***ligand*** of CD11a or ***CD11b*** , suggesting leukocyte integrin-dependent killing .	parallel	1
12009	10711683	627;5595	BDNF;ERK 1	In epithelium , predominantly ***ERK 1*** was ***activated*** by NGF , GDNF , and ***BDNF*** .	positive	1
12010	10711683	2668;5595	GDNF;ERK 1	In epithelium , predominantly ***ERK 1*** was ***activated*** by NGF , ***GDNF*** , and BDNF .	positive	1
12011	10711683	4803;5595	NGF;ERK 1	In epithelium , predominantly ***ERK 1*** was ***activated*** by ***NGF*** , GDNF , and BDNF .	positive	1
12012	10711692	4915;627	TrkB;BDNF	Obstructed axonal transport of ***BDNF*** and its ***receptor*** ***TrkB*** in experimental glaucoma .	parallel	1
12013	10711696	356;355	FasL;Fas	PURPOSE : To investigate the role of apoptosis in immunopathogenic mechanisms of experimental autoimmune uveoretinitis ( EAU ) , the kinetics of apoptotic cells and expression of Fas and ***Fas*** ***ligand*** ( ***FasL*** ) in the eye with EAU were studied .	parallel	1
12014	10711711	2006;7078	elastin;TIMP-3	There is also a correspondence between TIMP-3 and elastin immunoreactivies , which invites speculation as to a ***link*** between the SFD ***TIMP-3*** mutation and altered ***elastin*** processing .	parallel	0
12015	10712202	2720;2006	EBP;tropoelastin	Because the normal ***association*** between ***EBP*** and ***tropoelastin*** can be disrupted on contact with galactosugar-bearing moieties , and the fibroblasts from patients with Costello syndrome revealed an unusual accumulation of chondroitin sulfate-bearing proteoglycans ( CD44 and biglycan ) , we postulate that a chondroitin sulfate may be responsible for shedding EBP from Costello cells and in turn for their impaired elastogenesis .	parallel	0
12016	10712203	4771;9368	merlin;EBP-50	Although not correlated to the cell-adhesion phenotype , four missense mutations decreased the ***binding*** of ***merlin*** to the ERM-interacting protein ***EBP-50*** , implicating this interaction in merlin inhibition of cell growth .	parallel	1
12017	10712238	5594;2353	ERK;c-fos	Inhibition of the Na ( + ) / Ca ( 2 + ) exchanger by KB-R7943 and of protein kinase C ( PKC ) by Ro-31-8220 suppressed ***ERK*** ***activation*** and gene expressions of ***c-fos*** and IL-1 beta .	positive	1
12018	10712238	5594;3553	ERK;IL-1 beta	Inhibition of the Na ( + ) / Ca ( 2 + ) exchanger by KB-R7943 and of protein kinase C ( PKC ) by Ro-31-8220 suppressed ***ERK*** ***activation*** and gene expressions of c-fos and ***IL-1 beta*** .	positive	1
12019	10712262	2641;6476	Glucagon-like peptide-2;sucrase-isomaltase	***Glucagon-like peptide-2*** ***increases*** ***sucrase-isomaltase*** but not caudal-related homeobox protein-2 gene expression .	positive	0
12020	10712344	6352;5594	RANTES;Erk	PAF-induced ***RANTES*** production by human airway smooth muscle cells ***requires*** both p38 MAP kinase and ***Erk*** .	target	0
12021	10712344	6352;1432	RANTES;p38 MAP kinase	PAF-induced ***RANTES*** production by human airway smooth muscle cells ***requires*** both ***p38 MAP kinase*** and Erk .	target	0
12022	10712344	7124;5594	TNF-alpha;Erk	***TNF-alpha*** ***induced*** p38 MAP kinase and ***Erk*** phosphorylation , but neither SB 203580 nor PD 98059 inhibited RANTES production .	target	1
12023	10712344	7124;1432	TNF-alpha;p38 MAP kinase	***TNF-alpha*** ***induced*** ***p38 MAP kinase*** and Erk phosphorylation , but neither SB 203580 nor PD 98059 inhibited RANTES production .	target	1
12024	10712348	2208;3497	CD23;IgE	These changes were associated with increases in IFN-gamma and decreases in IL-4 production , suggesting that ***CD23*** binding may ***affect*** not only ***IgE*** production but also the Th1/Th2 imbalance during the development of allergic AHR .	target	0
12025	10712386	183;7412	Angiotensin II;vascular cell adhesion molecule-1	***Angiotensin II*** ***stimulates*** endothelial ***vascular cell adhesion molecule-1*** via nuclear factor-kappaB activation induced by intracellular oxidative stress .	positive	0
12026	10712388	3553;4843	IL-1beta;iNOS	***IL-1beta*** ***induced*** ***iNOS*** expression and NO generation and significantly upregulated VEGF mRNA expression and protein synthesis .	target	1
12027	10712390	5743;1437	Cyclooxygenase-2;granulocyte-macrophage colony-stimulating factor	***Cyclooxygenase-2*** ***regulates*** ***granulocyte-macrophage colony-stimulating factor*** , but not interleukin-8 , production by human vascular cells : role of cAMP .	target	1
12028	10712390	5743;1437	COX-2;GM-CSF	Under the same conditions , we found that ***COX-2*** activity ***suppressed*** ***GM-CSF*** , but not IL-8 , release by both types of human vascular cells .	negative	1
12029	10712390	5743;1437	COX-2;GM-CSF	These observations suggest that ***COX-2*** activity ***suppresses*** ***GM-CSF*** release via a cAMP-dependent pathway in human vascular cells and illustrates a novel mechanism by which this enzyme can modulate immune and inflammatory events .	negative	1
12030	10712415	9934;5054	P2Y receptor;PAI-1	***P2Y receptor*** ***regulation*** of ***PAI-1*** expression in vascular smooth muscle cells .	target	1
12031	10712416	7035;2152	tissue factor pathway inhibitor;tissue factor	Endothelial and tumor cells synthesize ***tissue factor pathway inhibitor*** ( TFPI-1 ) , which ***regulates*** ***tissue factor*** ( TF ) function by TF .	target	1
12032	10712420	207;5594	Rac;p38	***Ras/Rac-Dependent*** ***activation*** of ***p38*** mitogen-activated protein kinases in smooth muscle cells stimulated by cyclic strain stress	positive	1
12033	10712435	5617;3973	prolactin;LHR	We suggest that , in intact TG females , enhanced ovarian estrogen synthesis causes increased secretion of ***prolactin*** ( PRL ) , which ***elevates*** ***LHR*** expression .	positive	0
12034	10712436	1493;941	CTLA4;B7.1	T-cell costimulation is provided by ligation of CD28 with either B7.1 ( CD80 ) or B7.2 ( CD86 ) on antigen-presenting cells , and can be inhibited by a soluble form of ***CTLA4*** ( CTLA4-Ig ) that ***binds*** to both ***B7.1*** and B7.2 .	parallel	1
12035	10712436	1493;942	CTLA4;B7.2	T-cell costimulation is provided by ligation of CD28 with either B7.1 ( CD80 ) or B7.2 ( CD86 ) on antigen-presenting cells , and can be inhibited by a soluble form of ***CTLA4*** ( CTLA4-Ig ) that ***binds*** to both B7.1 and ***B7.2*** .	parallel	1
12036	10712436	1493;941	CTLA4;B7.1	We examined the effect of CD28-B7 blockade on the development of EAG using native ***CTLA4-Ig*** or mutant CTLA4-Ig ( Y100F-Ig ) , which selectively ***blocks*** ***B7.1*** .	negative	0
12037	10712507	5609;983	MEK;Cdc2	Finally , we present evidence that the negative ***regulation*** of ***Cdc2*** by ***Mos/MEK/p42*** MAPK contributes to the presence of an unusually long G2 phase in the first mitotic cell cycle .	negative	1
12038	10712507	4342;983	Mos;Cdc2	Finally , we present evidence that the negative ***regulation*** of ***Cdc2*** by ***Mos/MEK/p42*** MAPK contributes to the presence of an unusually long G2 phase in the first mitotic cell cycle .	negative	1
12039	10712507	23552;983	p42;Cdc2	Finally , we present evidence that the negative ***regulation*** of ***Cdc2*** by ***Mos/MEK/p42*** MAPK contributes to the presence of an unusually long G2 phase in the first mitotic cell cycle .	negative	1
12040	10712507	23552;7465	p42;Wee1	***Activation*** of ***Wee1*** by ***p42*** MAPK in vitro and in cycling xenopus egg extracts .	positive	1
12041	10712507	23552;7465	p42;Wee1	Purified recombinant ***p42*** MAPK was found to ***phosphorylate*** recombinant ***Wee1*** in vitro at sites that are phosphorylated in extracts .	target	1
12042	10712510	836;9564	caspase-3;p130cas	We investigated the changes in focal adhesion proteins during etoposide-induced apoptosis in Rat-1 cells and found that during apoptosis , ***p130cas*** ( Crk-associated substrate [ Cas ] ) is ***cleaved*** by ***caspase-3*** .	target	1
12043	10712520	1019;896	cdk4;cyclin D3	This study dissociates the assembly of ******cyclin D3-cdk4****** ***complexes*** from their nuclear localization and association with p27 ( kip1 ) .	parallel	1
12044	10712520	1019;3692	cdk4;p27	Transforming growth factor beta ( 1 ) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the ***association*** of ***cyclin D3-cdk4*** with nuclear ***p27*** ( kip1 ) .	parallel	0
12045	10712520	896;3692	cyclin D3;p27	Transforming growth factor beta ( 1 ) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the ***association*** of ***cyclin D3-cdk4*** with nuclear ***p27*** ( kip1 ) .	parallel	0
12046	10712520	7040;5933	TGFbeta;p107	***TGFbeta*** ***inhibited*** the phosphorylation of Rb , ***p107*** , and p130 induced by TSH , but it weakly affected the phosphorylation state of Rb-related proteins in EGF + serum-treated cells .	negative	1
12047	10712520	7040;5934	TGFbeta;p130	***TGFbeta*** ***inhibited*** the phosphorylation of Rb , p107 , and ***p130*** induced by TSH , but it weakly affected the phosphorylation state of Rb-related proteins in EGF + serum-treated cells .	negative	1
12048	10712520	1019;896	cdk4;cyclin D3	In TSH-stimulated cells , TGFbeta did not affect the expression of cyclin D3 , cdk4 , and p27 ( kip1 ) , nor the induced formation of ******cyclin D3-cdk4****** ***complexes*** , but it prevented the TSH-induced relocalization of p27 ( kip1 ) from cdk2 to cyclin D3-cdk4 .	parallel	1
12049	10712520	1019;896	cdk4;cyclin D3	It prevented the nuclear translocations of cdk4 and cyclin D3 without altering the assembly of ******cyclin D3-cdk4****** ***complexes*** probably formed in the cytoplasm , where they were prevented from sequestering nuclear p27 ( kip1 ) away from cdk2 .	parallel	1
12050	10712588	22974;3725	p100;c-Jun	Taken together , it is concluded that okadaic acid induces the expression of p100 RasGAP protein in JEG-3 cells preceded by activation of ERK and AP-1 cascade , and that this okadaic acid-induced ***p100*** RasGAP expression is independent of protein kinase C-mediated pathway but ***requires*** ***c-Jun/AP-1*** function .	target	0
12051	10712588	5921;3725	RasGAP;c-Jun	Taken together , it is concluded that okadaic acid induces the expression of p100 RasGAP protein in JEG-3 cells preceded by activation of ERK and AP-1 cascade , and that this okadaic acid-induced p100 ***RasGAP*** expression is independent of protein kinase C-mediated pathway but ***requires*** ***c-Jun/AP-1*** function .	target	0
12052	10712639	627;4852	BDNF;neuropeptide Y	Conversely , ***BDNF*** ***induces*** a long-lasting increase of ***neuropeptide Y*** ( NPY ) in the hippocampus , measured by immunohistochemistry and radioimmunoassay , outlasting the end of the infusion by at least 7 days .	target	1
12053	10712670	3586;7852	interleukin-10;chemokine receptor 4	CXC ***chemokine receptor 4*** expression and stromal cell-derived factor-1alpha-induced chemotaxis in CD4 + T lymphocytes are ***regulated*** by interleukin-4 and ***interleukin-10*** .	target	1
12054	10712670	3565;7852	interleukin-4;chemokine receptor 4	CXC ***chemokine receptor 4*** expression and stromal cell-derived factor-1alpha-induced chemotaxis in CD4 + T lymphocytes are ***regulated*** by ***interleukin-4*** and interleukin-10 .	target	1
12055	10712670	3586;7852	IL-10;CXCR4	The ***regulation*** of ***CXCR4*** expression in CD4 + T lymphocytes by IL-4 and ***IL-10*** could be blocked by a selective inhibitor of protein kinase ( staurosporine ) or by a selective inhibitor of cAMP - and cGMP-dependent protein kinase ( H-8 ) , indicating that these cytokines regulate CXCR4 on CD4 + T lymphocytes via both cAMP and cGMP signalling pathways .	target	1
12056	10712670	3565;7852	IL-4;CXCR4	The ***regulation*** of ***CXCR4*** expression in CD4 + T lymphocytes by ***IL-4*** and IL-10 could be blocked by a selective inhibitor of protein kinase ( staurosporine ) or by a selective inhibitor of cAMP - and cGMP-dependent protein kinase ( H-8 ) , indicating that these cytokines regulate CXCR4 on CD4 + T lymphocytes via both cAMP and cGMP signalling pathways .	target	1
12057	10712674	3815;4254	c-kit;SCF	These results indicate that mast cells enhance fibroblast-mediated contraction of collagen lattices via direct cell-cell contact , mediated in part by ******SCF/c-kit****** ***interactions*** .	parallel	1
12058	10712676	356;355	CD95 ligand;CD95	Evidence for multiple ******CD95-CD95 ligand****** ***interactions*** in anteriorchamber-associated immune deviation induced by soluble protein antigen .	parallel	1
12059	10712676	356;355	CD95L;CD95	The capacity of in vitro generated regulatory T cells to suppress DH expression to OVA in vivo was not governed by ******CD95-CD95L****** ***interactions*** .	parallel	1
12060	10712676	356;355	CD95L;CD95	We conclude that CD95-CD95L interactions are required in ACAID for the initial stage of APC presentation of eye-derived antigens to T cells , and that ******CD95-CD95L****** ***interactions*** participate at one or more additional step in the process by which ACAID is induced by soluble protein antigens .	parallel	1
12061	10712776	8725;2959	RMP;TF2B	RMP specifically disrupts the binding between TF2B and HBX protein , vice versa HBX protein also disrupt the ***interaction*** of ******TF2B-RMP****** as demonstrated by the in vitro protein binding competition assay .	parallel	1
12062	10712905	998;5894	Cdc42;Raf-1	***Regulation*** of the protein kinase ***Raf-1*** by oncogenic Ras through phosphatidylinositol 3-kinase , ***Cdc42/Rac*** and Pak .	target	1
12063	10712905	207;5894	Rac;Raf-1	***Regulation*** of the protein kinase ***Raf-1*** by oncogenic Ras through phosphatidylinositol 3-kinase , ***Cdc42/Rac*** and Pak .	target	1
12064	10712905	5063;5894	p21-activated kinase 3;Raf-1	We have reported previously that ***p21-activated kinase 3*** ( Pak3 ) ***upregulates*** ***Raf-1*** through direct phosphorylation on Ser338 [ 2 ] .	positive	1
12065	10712905	5063;5894	Pak3;Raf-1	***Pak3*** acted synergistically with either Cdc42V12 or Rac1V12 to ***stimulate*** the activities of ***Raf-1*** , Raf-CX , a membrane-localized Raf-1 mutant , and Raf-1 mutants defective in Ras binding .	positive	0
12066	10713049	25;5580	c-Abl;protein kinase C delta	***Interaction*** between ***protein kinase C delta*** and the ***c-Abl*** tyrosine kinase in the cellular response to oxidative stress .	parallel	1
12067	10713055	4547;338	microsomal triglyceride transfer protein;apolipoprotein B	A deficiency of ***microsomal triglyceride transfer protein*** ***reduces*** ***apolipoprotein B*** secretion .	positive	1
12068	10713055	338;4547	apoB;MTP	microsomal triglyceride transfer protein ( MTP ) transfers lipids to apolipoprotein B ( apoB ) within the endoplasmic reticulum , a process that involves direct ***interactions*** between ***apoB*** and the large subunit of ***MTP*** .	parallel	1
12069	10713055	4547;338	MTP;apoB	Recent studies with heterozygous MTP knockout mice have suggested that half-normal levels of ***MTP*** in the liver ***reduce*** ***apoB*** secretion .	negative	1
12070	10713055	4547;338	MTP;apoB	We hypothesized that reduced apoB secretion in the setting of half-normal MTP levels might be caused by a reduced MTP : apoB ratio in the endoplasmic reticulum , which would reduce the number of ******apoB-MTP****** ***interactions*** .	parallel	1
12071	10713062	4803;4790	NGF;NF-kappaB	These results suggest that ***NGF*** ***activation*** of ***NF-kappaB*** through the p75 receptor promotes survival , counterbalancing the pro-apoptotic signal .	positive	1
12072	10713062	4803;4804	NGF;p75	In contrast to its trophic actions through TrkA , ***NGF*** ***binding*** to ***p75*** has been shown to activate programmed cell death through a mechanism involving the stress kinase JNK .	parallel	1
12073	10713062	4803;5599	NGF;JNK	***NGF*** also ***stimulated*** ***JNK*** in the cells ( detected by in vitro kinase assays ) with a similar time course .	positive	0
12074	10713066	6189;1649	S3a;CHOP	Novel ***interaction*** between the transcription factor ***CHOP*** ( GADD153 ) and the ribosomal protein ***FTE/S3a*** modulates erythropoiesis .	parallel	1
12075	10713066	1649;1051	CHOP;C/EBPbeta	The transcription factor ***CHOP*** ( GADD153 ) ***heterodimerizes*** with other C/EBP family members , especially ***C/EBPbeta*** , thus preventing their homodimerization and binding to DNA sequences specific for the homodimers .	parallel	1
12076	10713066	6189;1649	S3a;CHOP	The in vivo ***interaction*** of ***CHOP*** and ***FTE/S3a*** was also demonstrated in cells overexpressing FTE/S3a but with endogenous expression levels of CHOP .	parallel	1
12077	10713070	5970;4790	p65;p50	To understand the relationship between the DNA binding properties of the dimer forms and transcriptional activation , the physical properties of the ***complexes*** of ***p50*** and ***p65*** with DNA have been analyzed .	parallel	1
12078	10713072	8802;5599	Galpha;JNK	Constitutively activated mutants of Galpha ( i1 ) , ***Galpha*** ( i2 ) , and Galpha ( i3 ) ***increased*** ***JNK*** activity .	negative	0
12079	10713072	8802;5599	Galpha;JNK	To examine the mechanism of ***JNK*** ***activation*** by ***Galpha*** ( i ) , kinase-deficient mutants of mitogen-activated protein kinase kinase 4 (MKK4) and 7 ( MKK7 ) , which are known to be JNK activators , were transfected into the cells .	positive	1
12080	10713072	8802;5599	Galpha;JNK	Furthermore , ***JNK*** ***activation*** by ***Galpha*** ( i ) was inhibited by dominant-negative Rho and Cdc42 and tyrosine kinase inhibitors , but not dominant-negative Rac and phosphatidylinositol 3-kinase inhibitors .	positive	1
12081	10713072	207;5599	Rac;JNK	Furthermore , ***JNK*** activation by Galpha ( i ) was ***inhibited*** by dominant-negative Rho and Cdc42 and tyrosine kinase inhibitors , but not dominant-negative ***Rac*** and phosphatidylinositol 3-kinase inhibitors .	negative	1
12082	10713072	8802;5599	Galpha;JNK	These results indicate that ***Galpha*** ( i ) ***regulates*** ***JNK*** activity dependent on small GTPases Rho and Cdc42 and on tyrosine kinase but not on MKK4 and MKK7 .	target	1
12083	10713076	9318;190	Alien;DAX-1	***Interaction*** of the corepressor ***Alien*** with ***DAX-1*** is abrogated by mutations of DAX-1 involved in adrenal hypoplasia congenita .	parallel	1
12084	10713076	190;9318	DAX-1;Alien	Interaction of the corepressor ***Alien*** with DAX-1 is ***abrogated*** by mutations of ***DAX-1*** involved in adrenal hypoplasia congenita .	positive	0
12085	10713076	190;9318	DAX-1;Alien	Here , we show that ***DAX-1*** ***interacts*** with the corepressor ***Alien*** but not with the corepressor SMRT .	parallel	1
12086	10713076	9318;190	Alien;DAX-1	Because the silencing domain of DAX-1 is unusual for NHRs , we mapped the ***interaction*** of ***Alien*** with ***DAX-1*** and with TR .	parallel	1
12087	10713077	9474;836	Asp;caspase-3	Moreover , a synthetic tetrapeptide , ***acetyl-Asp-Met-Gln-Asp-aldehyde*** ( DMQD-CHO ) , which ***inhibited*** the formation of active form of ***caspase-3*** more efficiently than those of caspase-4 , -6 , -7 , and -8 , blocked both caspase-3 like activity , c-jun expression and apoptosis induced by HS or C ( 2 ) - ceramide , although DMQD-CHO did not affect HS-induced ceramide generation .	negative	1
12088	10713077	9474;836	Asp;caspase-3	Moreover , a synthetic tetrapeptide , ***acetyl-Asp-Met-Gln-Asp-aldehyde*** ( DMQD-CHO ) , which inhibited the formation of active form of caspase-3 more efficiently than those of caspase-4 , -6 , -7 , and -8 , ***blocked*** both ***caspase-3*** like activity , c-jun expression and apoptosis induced by HS or C ( 2 ) - ceramide , although DMQD-CHO did not affect HS-induced ceramide generation .	negative	0
12089	10713077	9474;3725	Asp;c-jun	Moreover , a synthetic tetrapeptide , ***acetyl-Asp-Met-Gln-Asp-aldehyde*** ( DMQD-CHO ) , which inhibited the formation of active form of caspase-3 more efficiently than those of caspase-4 , -6 , -7 , and -8 , ***blocked*** both caspase-3 like activity , ***c-jun*** expression and apoptosis induced by HS or C ( 2 ) - ceramide , although DMQD-CHO did not affect HS-induced ceramide generation .	negative	0
12090	10713090	2888;2260	Grb14;FGFR1	These data demonstrate an ***interaction*** between activated ***FGFR1*** and ***Grb14*** and suggest a role for Grb14 in FGF signaling .	parallel	1
12091	10713090	2260;2888	fibroblast growth factor receptor 1;Grb14	***Association*** of ***fibroblast growth factor receptor 1*** with the adaptor protein ***Grb14*** .	parallel	0
12092	10713090	2888;2260	Grb14;FGFR1	Deletion of the C-tail or mutation of both C-tail tyrosine residues of FGFR1 to phenylalanine abolished binding , and deletion of the juxtamembrane domain of the receptor reduced binding , suggesting that ***Grb14*** ***binds*** to ***FGFR1*** at multiple sites .	parallel	1
12093	10713090	2888;2260	Grb14;FGFR1	Co-immunoprecipitation and in vitro binding assays demonstrated that ***binding*** of ***Grb14*** to ***FGFR1*** in mammalian cells was dependent on receptor activation by fibroblast growth factor-2 ( FGF-2 ) .	parallel	1
12094	10713090	2888;2260	Grb14;FGFR1	The SH2 domain alone bound both FGFR1 and platelet-derived growth factor receptor , whereas full-length ***Grb14*** ***bound*** only ***FGFR1*** , suggesting that regions upstream of the SH2 domain confer specificity for FGFR1 .	parallel	1
12095	10713097	2646;2645	glucokinase regulatory protein;glucokinase	The ***glucokinase regulatory protein*** ( GKRP ) ***inhibits*** ***glucokinase*** competitively with respect to glucose by forming a protein-protein complex with this enzyme .	negative	1
12096	10713097	2646;2645	GKRP;glucokinase	Interestingly , when assayed under conditions to promote the ***association*** between ***glucokinase*** and ***GKRP*** , liver glucokinase activity in wild-type and null mice displayed comparable glucose phosphorylation capacities at physiological glucose concentrations ( 5 mM ) .	parallel	0
12097	10713104	3059;4067	HS1;Lyn	***HS1*** ***interacts*** with ***Lyn*** and is critical for erythropoietin-induced differentiation of erythroid cells .	parallel	1
12098	10713104	4067;2057	Lyn;erythropoietin receptor	Previously we have shown that the tyrosine kinase ***Lyn*** ***associates*** with the ***erythropoietin receptor*** and is essential for hemoglobin synthesis in three erythroleukemic cell lines .	parallel	0
12099	10713105	23598;6047	PATZ;RNF4	A novel member of the BTB/POZ family , ***PATZ*** , ***associates*** with the ***RNF4*** RING finger protein and acts as a transcriptional repressor .	parallel	0
12100	10713105	23598;6047	PATZ;RNF4	We have identified a novel human gene encoding a 59-kDa POZ-AT hook-zinc finger protein ( ***PATZ*** ) that ***interacts*** with ***RNF4*** , a mediator of androgen receptor activity , and acts as a transcriptional repressor .	parallel	1
12101	10713105	23598;6047	PATZ;RNF4	In vitro and in vivo ***interaction*** between ***RNF4*** and ***PATZ*** was demonstrated by protein-protein affinity chromatography and coimmunoprecipitation experiments .	parallel	1
12102	10713105	23598;6047	PATZ;RNF4	When both proteins were overexpressed a strong repression of the basal transcription was observed , indicating that the ***association*** of ***PATZ*** with ***RNF4*** switches activation to repression .	parallel	0
12103	10713107	5284;9341	polymeric immunoglobulin receptor;Cellubrevin	Interestingly , only in those isolated endosomal fractions , endosomes enriched in transcytotic structures ( of livers loaded with IgA ) , the ***polymeric immunoglobulin receptor*** specifically ***co-immunoprecipitated*** with ***Cellubrevin*** .	parallel	1
12104	10713108	351;4843	Abeta;iNOS	Our data suggest that ***Abeta*** ***stimulation*** of astrocyte ***iNOS*** is mediated in part by IL-1beta and TNFalpha , and involves a TRAF6 - , TRAF2 - , and NIK-dependent signaling mechanism .	positive	0
12105	10713122	2064;4790	HER-2/neu;NF-kappaB	Here we report that ***HER-2/neu*** ***activates*** Akt and ***NF-kappaB*** without extracellular stimulation .	positive	1
12106	10713122	2064;4790	HER-2/neu;NF-kappaB	Our results suggested that ***HER-2/neu*** constitutively ***activates*** the ***Akt/NF-kappaB*** anti-apoptotic cascade to confer resistance to TNF on cancer cells and reduce host defenses against neoplasia .	positive	1
12107	10713127	30968;2040	SLP-2;stomatin	We hypothesize that ***SLP-2*** may ***link*** ***stomatin*** or other integral membrane proteins to the peripheral cytoskeleton and thereby play a role in regulating ion channel conductances or the organization of sphingolipid and cholesterol-rich lipid rafts .	parallel	0
12108	10713133	6777;2908	Stat5;glucocorticoid receptor	The glucocorticoid receptor was also present in GHINF , and ***Stat5*** ***co-immunoprecipitates*** with ***glucocorticoid receptor*** in hepatic nuclear extracts from rats treated with GH .	parallel	1
12109	10713136	2247;6550	bFGF;NHE3	In contrast , basic fibroblast growth factor ( ***bFGF*** ) ***increased*** PM expression of ***NHE3*** , which was associated with a 2-fold increase in rate constant for exit of the exchanger from the recycling compartment .	positive	0
12110	10713136	2247;6550	bFGF;NHE3	These data suggest that : ( i ) ***bFGF*** ***stimulates*** ***NHE3*** by increasing PM expression of the exchanger ; ( ii ) PI3-K mediates PM expression of NHE3 in both basal and bFGF-stimulated conditions , and ( iii ) not all of the effects of bFGF on NHE3 expression are mediated by PI3-K , suggesting additional regulatory mechanisms .	positive	0
12111	10713150	10490;6810	v-SNARE;syntaxin4	Together , these results demonstrate that SNAP23 contributes to insulin-dependent trafficking of GLUT4 to the plasma membrane in 3T3-L1 adipocytes by mediating the ***interaction*** between t-SNARE ( ***syntaxin4*** ) and ***v-SNARE*** ( VAMP2 ) .	parallel	1
12112	10713150	6844;6810	VAMP2;syntaxin4	Wild-type SNAP23 ( SNAP23-WT ) promoted the ***interaction*** between ***syntaxin4*** and ***VAMP2*** both in vitro and in vivo .	parallel	1
12113	10713150	8773;6810	SNAP23;syntaxin4	Although SNAP23-DeltaC49 bound to neither syntaxin4 nor VAMP2 , the ***SNAP23-DeltaC8*** mutant ***bound*** to ***syntaxin4*** but not to VAMP2 .	parallel	1
12114	10713150	8773;6810	SNAP23;syntaxin4	In addition , although ***SNAP23-DeltaC8*** ***bound*** to ***syntaxin4*** , it did not mediate the interaction between syntaxin4 and VAMP2 .	parallel	1
12115	10713150	6844;6810	VAMP2;syntaxin4	In addition , although SNAP23-DeltaC8 bound to syntaxin4 , it did not mediate the ***interaction*** between ***syntaxin4*** and ***VAMP2*** .	parallel	1
12116	10713150	8773;6517	SNAP23;GLUT4	Moreover , overexpression of ***SNAP23-DeltaC8*** in 3T3-L1 adipocytes by adenovirus-mediated gene transfer ***inhibited*** insulin-induced translocation of ***GLUT4*** but not that of GLUT1 .	negative	1
12117	10713156	4738;8454	Nedd8;cul-1	***Nedd8*** ***modification*** of ***cul-1*** activates SCF ( beta ( TrCP ) ) - dependent ubiquitination of IkappaBalpha .	target	0
12118	10713156	4738;8454	Nedd8;cul-1	Here we show that ***Nedd8*** ***modification*** of the ***cul-1*** component of SCF ( beta ( TrCP ) ) is important for function of SCF ( beta ( TrCP ) ) in ubiquitination of IkappaBalpha .	target	0
12119	10713156	8454;1499	cul-1;beta-catenin	In cells , Nedd8-conjugated ***cul-1*** was ***complexed*** with two substrates of SCF ( beta ( TrCP ) ) , phosphorylated IkappaBalpha and ***beta-catenin*** , indicating that Nedd8-cul-1 conjugates are part of SCF ( beta ( TrCP ) ) in vivo .	parallel	1
12120	10713156	8454;4792	cul-1;IkappaBalpha	In cells , Nedd8-conjugated ***cul-1*** was ***complexed*** with two substrates of SCF ( beta ( TrCP ) ) , phosphorylated ***IkappaBalpha*** and beta-catenin , indicating that Nedd8-cul-1 conjugates are part of SCF ( beta ( TrCP ) ) in vivo .	parallel	1
12121	10713156	8454;8945	cul-1;betaTrCP	Although only a minute fraction of total cellular cul-1 is modified by Nedd8 , the ***cul-1*** ***associated*** with ectopically expressed ***betaTrCP*** was highly enriched for the Nedd8-conjugated form .	parallel	0
12122	10713156	4738;8454	Nedd8;cul-1	The site of Nedd8 ligation to cul-1 is essential , as SCF ( beta ( TrCP ) ) containing a K720R mutant of cul-1 only weakly supported IkappaBalpha ubiquitination compared to SCF ( beta ( TrCP ) ) containing WT cul-1 , suggesting that the ***Nedd8*** ***ligation*** of ***cul-1*** affects the ubiquitination activity of SCF ( beta ( TrCP ) ) .	parallel	1
12123	10713157	5599;5609	JNK1;c-Jun N-terminal kinase (JNK) kinase 2	Synergistic ***interaction*** of MEK kinase 2 , ***c-Jun N-terminal kinase (JNK) kinase 2*** , and ***JNK1*** results in efficient and specific JNK1 activation .	parallel	1
12124	10713157	10746;5609	MEK kinase 2;c-Jun N-terminal kinase (JNK) kinase 2	Synergistic ***interaction*** of ***MEK kinase 2*** , ***c-Jun N-terminal kinase (JNK) kinase 2*** , and JNK1 results in efficient and specific JNK1 activation .	parallel	1
12125	10713157	10746;5599	MEK kinase 2;JNK1	Synergistic ***interaction*** of ***MEK kinase 2*** , c-Jun N-terminal kinase (JNK) kinase 2 , and ***JNK1*** results in efficient and specific JNK1 activation .	parallel	1
12126	10713157	10746;5599	MEKK2;JNK	Investigating the molecular basis of ***activation*** of the c-Jun N-terminal kinase ( ***JNK*** ) subgroup of MAPK by the MAPKKK ***MEKK2*** , we found that strong and specific JNK1 activation by MEKK2 was mediated by the MAPKK JNK kinase 2 ( JNKK2 ) rather than by JNKK1 through formation of a tripartite complex consisting of MEKK2 , JNKK2 , and JNK1 .	positive	1
12127	10713157	5599;10746	JNK1;MEKK2	Expression of JNK1 , JNKK2 , and MEKK2 significantly augmented the coprecipitation of , respectively , MEKK2-JNKK2 , MEKK2-JNK1 , and JNKK2-JNK1 , indicating that the ***interaction*** of ***MEKK2*** , JNKK2 , and ***JNK1*** is synergistic .	parallel	1
12128	10713157	5609;5599	JNKK2;JNK1	Expression of JNK1 , JNKK2 , and MEKK2 significantly augmented the coprecipitation of , respectively , MEKK2-JNKK2 , MEKK2-JNK1 , and JNKK2-JNK1 , indicating that the ***interaction*** of MEKK2 , ***JNKK2*** , and ***JNK1*** is synergistic .	parallel	1
12129	10713157	5609;10746	JNKK2;MEKK2	Expression of JNK1 , JNKK2 , and MEKK2 significantly augmented the coprecipitation of , respectively , MEKK2-JNKK2 , MEKK2-JNK1 , and JNKK2-JNK1 , indicating that the ***interaction*** of ***MEKK2*** , ***JNKK2*** , and JNK1 is synergistic .	parallel	1
12130	10713157	5599;10746	JNK1;MEKK2	Finally , the JNK1 was activated more efficiently in the ******MEKK2-JNKK2-JNK1****** ***complex*** than was the JNK1 excluded from the complex .	parallel	1
12131	10713157	5609;5599	JNKK2;JNK1	Finally , the JNK1 was activated more efficiently in the ******MEKK2-JNKK2-JNK1****** ***complex*** than was the JNK1 excluded from the complex .	parallel	1
12132	10713157	5609;10746	JNKK2;MEKK2	Finally , the JNK1 was activated more efficiently in the ******MEKK2-JNKK2-JNK1****** ***complex*** than was the JNK1 excluded from the complex .	parallel	1
12133	10713164	3516;22938	CBF1;SKIP	Both CBF1 and SKIP are highly conserved evolutionarily , and the ******SKIP-CBF1****** ***interaction*** is also conserved in assays using the Caenorhabditis elegans and Drosophila melanogaster SKIP homologs .	parallel	1
12134	10713164	9612;22938	SMRT;SKIP	Protein-protein interaction assays demonstrated ***interaction*** between ***SKIP*** and the corepressor ***SMRT*** .	parallel	1
12135	10713168	2067;2072	ERCC1;XPF	In addition , in this study , we showed that the structure-specific endonuclease , the ******XPF-ERCC1****** ***heterodimer*** , acted as a 3 ' - to-5 ' exonuclease on cross-linked DNA in the presence of RPA .	parallel	1
12136	10713174	440275;1965	GCN2;eIF2	Induction of GCN4 translation in amino acid-starved cells involves the inhibition of initiator tRNA ( Met ) binding to eukaryotic translation initiation factor 2 ( eIF2 ) in response to ***eIF2*** ***phosphorylation*** by protein kinase ***GCN2*** .	target	1
12137	10713175	4193;1029	mdm2;ARF	The mdm2 NrLS is unmasked upon ARF binding , and its deletion prevents import of the ******ARF-mdm2****** ***complex*** into nucleoli .	parallel	1
12138	10713175	1029;4193	ARF;mdm2	Collectively , the results suggest that ***ARF*** ***binding*** to ***mdm2*** induces a conformational change that facilitates nucleolar import of the ARF-mdm2 complex and p53-dependent cell cycle arrest .	parallel	1
12139	10713175	1029;4193	ARF;mdm2	Collectively , the results suggest that ARF binding to mdm2 induces a conformational change that facilitates nucleolar import of the ******ARF-mdm2****** ***complex*** and p53-dependent cell cycle arrest .	parallel	1
12140	10713175	4193;1029	mdm2;ARF	Hence , the ******ARF-mdm2****** ***interaction*** can be viewed as bidirectional , with each protein being capable of regulating the subnuclear localization of the other .	parallel	1
12141	10713175	4193;1029	mdm2;ARF	Cooperative signals governing ******ARF-mdm2****** ***interaction*** and nucleolar localization of the complex .	parallel	1
12142	10713175	84260;7157	tumor suppressor protein;p53	The ARF ***tumor suppressor protein*** ***stabilizes*** ***p53*** by antagonizing its negative regulator , mdm2 ( Hdm2 in humans ) .	positive	0
12143	10713175	1029;4193	ARF;mdm2	Although a nucleolar localization signal ( NrLS ) maps within a different segment ( residues 82 to 101 ) of the human p14 ( ***ARF*** ) protein , ***binding*** to ***mdm2*** and nucleolar import of ARF-mdm2 complexes are both required for cell cycle arrest induced by either the mouse or human ARF proteins .	parallel	1
12144	10713175	1029;4193	ARF;mdm2	Although a nucleolar localization signal ( NrLS ) maps within a different segment ( residues 82 to 101 ) of the human p14 ( ARF ) protein , binding to mdm2 and nucleolar import of ******ARF-mdm2****** ***complexes*** are both required for cell cycle arrest induced by either the mouse or human ARF proteins .	parallel	1
12145	10713176	3725;1017	Jun;cdk2	Despite this , ***v-Jun*** does not stimulate D-cyclin-cdk activity but does ***induce*** a marked deregulation of cyclin ***E-cdk2*** .	target	1
12146	10713178	4296;4214	MLK3;MEKK1	***MLK3*** ***cooperated*** with the other two IKKKs , ***MEKK1*** and NF-kappaB-inducing kinase , in the induction of IKK activity .	parallel	0
12147	10713180	1031;1019	p18;Cdk4	These results suggest a concerted model of progestin action whereby p27 ( Kip1 ) and ***p18*** ( INK4c ) cooperate to ***inhibit*** cyclin E-Cdk2 and ***Cdk4*** .	negative	1
12148	10713180	10519;102157402	Kip;Cip	Since similar models have been developed for growth inhibition by transforming growth factor beta and during adipogenesis , ***interaction*** between the ******Cip/Kip****** and INK4 families of inhibitors may be a common theme in physiological growth arrest and differentiation .	parallel	1
12149	10713181	639;4609	blimp-1;c-myc	In this study , we have explored the mechanism by which blimp-1 represses transcription by using Gal4-fusion protein assays and assays in which ***blimp-1*** ***represses*** the natural ***c-myc*** promoter .	negative	1
12150	10713181	639;4609	blimp-1;c-myc	The results show that ***blimp-1*** ***represses*** the ***c-myc*** promoter by an active mechanism that is independent of the adjacently bound activator YY1 .	negative	1
12151	10713181	639;4609	blimp-1;c-myc	The functional importance of recruiting HDAC for ***blimp-1-dependent*** ***repression*** of ***c-myc*** transcription is supported by two experiments .	negative	1
12152	10713264	250;207	PALP;Akt	The mitogenic effects of ***PALP*** are ***associated*** with the activation of c-Raf-1 , p42/p44 mitogen-activated protein kinases , p70 S6 kinase , ***Akt/PKB kinase*** and phosphatidylinositol 3 ' - kinase .	parallel	0
12153	10713264	250;5170	PALP;PKB kinase	The mitogenic effects of ***PALP*** are ***associated*** with the activation of c-Raf-1 , p42/p44 mitogen-activated protein kinases , p70 S6 kinase , ***Akt/PKB kinase*** and phosphatidylinositol 3 ' - kinase .	parallel	0
12154	10713325	356;355	FasL;fas	Both of the studied subclones expressed the fas receptor ( FasR ) , but only the ER cell line expressed the ***fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
12155	10713330	6772;6778	STAT1;STAT6	For example , ***STAT1*** which is induced by IFN-gamma and ***binds*** to the classical ***STAT6*** site .	parallel	1
12156	10713330	3458;6772	IFN-gamma;STAT1	For example , ***STAT1*** which is ***induced*** by ***IFN-gamma*** and binds to the classical STAT6 site .	target	1
12157	10713330	3565;6778	IL-4;STAT6	***IL-4*** ***induced*** the translocation of ***STAT6*** in B-CLL cells from all 22 patients investigated .	target	1
12158	10713344	2208;3497	CD23;IgE	Molecular cloning and sequencing of the low-affinity ***IgE*** ***receptor*** ( ***CD23*** ) for horse and cattle .	parallel	1
12159	10713344	2208;3497	CD23;IgE	Expression of the low-affinity ***IgE*** ***receptor*** ( ***CD23*** ) on the surface of mononuclear cells is a critical event in the development of IgE-mediated immunologic responses .	parallel	1
12160	10713367	3553;6352	IL-1beta;RANTES	The formation of a higher order nucleoprotein complex , or ' enhanceosome ' , may be critical for ***IL-1beta*** ***induction*** of the ***RANTES*** promoter .	target	1
12161	10713392	348;2099	apolipoprotein E;ESR1	In logistic regression analysis , a significantly increased risk of familial AD due to ***interaction*** between the ***ESR1*** xx genotype and the ***apolipoprotein E*** epsilon4 allele was observed in women in a Swedish clinic-based sample , taking subjects who had neither the xx genotype nor epsilon4 as reference ( OR 11.3 , 95 % CI 2.9-43 .8 ) .	parallel	1
12162	10713454	1950;10451	EGF;VAV3	TGF-beta and ***EGF*** reversibly ***down-regulate*** the abundance of the ***VAV3*** .	negative	1
12163	10713454	7040;10451	TGF-beta;VAV3	***TGF-beta*** and EGF reversibly ***down-regulate*** the abundance of the ***VAV3*** .	negative	1
12164	10713512	2280;6262	FKBP12;RyR2	FKBP12.6 is a novel isoform of ***FKBP12*** , which selectively ***binds*** to the cardiac ryanodine receptor ( ***RyR2*** ) .	parallel	1
12165	10713667	1111;994	CHK1;CDC25B	This interaction is not increased upon ***phosphorylation*** of ***CDC25B*** by ***CHK1*** and is not abolished by dephosphorylation .	target	1
12166	10713672	4609;890	c-Myc;cyclin A2	These results suggest that E2F1 and ***cyclin A2*** may be ***induced*** by ***c-Myc*** to mediate the onset of mammary cancer , whereas overexpression of cyclins D1 and E may occur later to facilitate tumor progression .	target	1
12167	10713672	4609;1869	c-Myc;E2F1	These results suggest that ***E2F1*** and cyclin A2 may be ***induced*** by ***c-Myc*** to mediate the onset of mammary cancer , whereas overexpression of cyclins D1 and E may occur later to facilitate tumor progression .	target	1
12168	10713673	392;5921	RhoGAP;RasGAP	RAFTK/Pyk2 tyrosine kinase mediates the ***association*** of p190 ***RhoGAP*** with ***RasGAP*** and is involved in breast cancer cell invasion .	parallel	0
12169	10713673	2185;392	Pyk2;RhoGAP	***RAFTK/Pyk2*** tyrosine kinase ***mediates*** the association of p190 ***RhoGAP*** with RasGAP and is involved in breast cancer cell invasion .	target	0
12170	10713673	2185;392	RAFTK;RhoGAP	Analyses of the members of the HRG-stimulated complex revealed that ***RAFTK*** is ***associated*** with p190 ***RhoGAP*** ( p190 ) , RasGAP and ErbB-2 , and plays an essential role in mediating the tyrosine phosphorylation of p190 by Src .	parallel	0
12171	10713673	2064;2185	ErbB-2;RAFTK	In addition , upon HRG stimulation of T47D cells , ***association*** of ***ErbB-2*** with ***RAFTK*** was observed and found to be indirect and mediated by Src .	parallel	0
12172	10713676	1026;836	p21;procaspase 3	As a result of Survivin/Cdk4 complex formation , ***p21*** is released from its complex with Cdk4 and ***interacts*** with mitochondrial ***procaspase 3*** to suppress Fas-mediated cell death .	parallel	1
12173	10713692	5618;5617	PRLR;prolactin	In the human , GH can activate both the ***prolactin*** ***receptor*** ( ***PRLR*** ) and the growth hormone receptor ( GHR ) .	parallel	1
12174	10713694	7039;1956	TGFalpha;EGFR	***Binding*** of ***TGFalpha*** to the epidermal growth factor receptor ( ***EGFR*** ) , activates the EGFRs ' endogenous tyrosine kinase activity and stimulates growth of the epithelium in the virgin and pregnant mouse mammary gland .	parallel	1
12175	10713700	3725;4233	AP-1;c-Met	We found that ***transactivation*** of the ***c-Met*** promoter by ***AP-1*** can be blocked by Curcumin , an inhibitor of AP-1 .	positive	1
12176	10713700	4233;3082	c-Met;hepatocyte growth factor	Transcriptional activation of the ***hepatocyte growth factor*** ***receptor*** ( ***c-Met*** ) gene by its ligand ( hepatocyte growth factor ) is mediated through AP-1 .	parallel	1
12177	10713700	3082;4233	hepatocyte growth factor;c-Met	Transcriptional ***activation*** of the hepatocyte growth factor receptor ( ***c-Met*** ) gene by its ligand ( ***hepatocyte growth factor*** ) is mediated through AP-1 .	positive	1
12178	10713700	4233;3725	c-Met;AP-1	The ***c-Met*** AP-1 element ***binds*** specifically to ***AP-1*** protein as verified by supershift assays .	parallel	1
12179	10713702	1019;595	cdk4;cyclin D1	Using an in vitro competition/association assay , we demonstrate that cyclin D1 alone , cdk4 alone and/or ******cyclin D1/cdk4****** ***complexes*** do not compete for the p57Kip2 homodimers formation .	parallel	1
12180	10713702	1019;595	cdk4;cyclin D1	However , a mutation in the alpha-helix domain of p57Kip2 ( R33L ) strongly reduced homodimer formation but did not modify interaction with ******cyclin D1-cdk4****** ***complexes*** .	parallel	1
12181	10713702	1028;1019	p57Kip2;cdk4	Also , increasing amounts of p57Kip2 lead in vivo to a significant augmentation in the level of ***p57Kip2*** homodimerization ***associated*** with ***cyclin D1-cdk4*** complexes and to a marked inhibition of the cyclin D1-cdk4 kinase activity .	parallel	0
12182	10713702	1028;595	p57Kip2;cyclin D1	Also , increasing amounts of p57Kip2 lead in vivo to a significant augmentation in the level of ***p57Kip2*** homodimerization ***associated*** with ***cyclin D1-cdk4*** complexes and to a marked inhibition of the cyclin D1-cdk4 kinase activity .	parallel	0
12183	10713702	1019;595	cdk4;cyclin D1	Also , increasing amounts of p57Kip2 lead in vivo to a significant augmentation in the level of p57Kip2 homodimerization associated with ******cyclin D1-cdk4****** ***complexes*** and to a marked inhibition of the cyclin D1-cdk4 kinase activity .	parallel	1
12184	10713702	1019;595	cdk4;cyclin D1	Altogether , these data suggest a model whereby p57Kip2 associates with itself by using the NH2 domain to form a homodimeric species which interacts with and inhibits the ******cyclin D1-cdk4****** ***complexes*** .	parallel	1
12185	10713704	6776;598	STAT5;Bcl-x	Analysis of the expression of the Bcl-2 members indicated that phosphorylation of Bad and ***Bcl-x*** expression which are respectively ***regulated*** by the PI 3-kinase/Akt pathway and ***STAT5*** probably explain this cooperation .	target	1
12186	10713704	3562;6776	IL-3;STAT5	These results indicate that the ***activations*** of ***STAT5*** and the PI 3-kinase by ***IL-3*** in Ba/F3 cells are tightly connected and cooperate to mediate IL-3-dependent suppression of apoptosis by modulating Bad phosphorylation and Bcl-x expression .	positive	1
12187	10713713	4792;4790	I kappa B alpha;NF-kappa B	***I kappa B alpha*** is a dual ***regulator*** of ***Rel/NF-kappa B*** transcription factors .	target	1
12188	10713713	4792;5966	I kappa B alpha;c-Rel	These data define a region of I kappa B alpha that may be required for optimal masking of the c-Rel NLS , or for the nuclear export of ******c-Rel/I kappa B alpha****** ***complexes*** .	parallel	1
12189	10713716	25;7157	c-Abl;p53	In this respect the ***interaction*** of ***c-Abl*** with ***p53*** and p73 has attracted particular attention .	parallel	1
12190	10713716	25;7161	c-Abl;p73	In this respect the ***interaction*** of ***c-Abl*** with p53 and ***p73*** has attracted particular attention .	parallel	1
12191	10713722	836;6625	caspase-3;U1-70K	During apoptosis , the ***U1-70K*** protein , a component of the spliceosomal U1 snRNP complex , is specifically ***cleaved*** by the enzyme ***caspase-3*** , converting it into a C-terminally truncated 40-kDa fragment .	target	1
12192	10713725	596;581	Bcl-2;Bax	***Bcl-2*** ***inhibits*** ***Bax*** translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells .	negative	1
12193	10713736	2033;2353	p300;c-Fos	Apoptotic response to growth factor deprivation involves cooperative ***interactions*** between ***c-Fos*** and ***p300*** .	parallel	1
12194	10713736	2033;2353	p300;c-Fos	We report that induction of apoptosis in sup + I cells is tightly correlated with the formation of ******c-Fos/p300****** ***complexes*** , which were not present in the non-apoptotic sup-II cells under the same conditions .	parallel	1
12195	10714219	8878;3932	p62;p56lck	Identification of ***p62*** , a phosphotyrosine independent ***ligand*** of ***p56lck*** kinase , as a major component of intracytoplasmic hyaline bodies in hepatocellular carcinoma .	parallel	1
12196	10714235	356;355	Fas ligand;Fas	The ******Fas-Fas ligand****** ***complex*** might , at least in part , account for the antiproliferative action of the hormone .	parallel	1
12197	10714241	4319;2252	stromelysin-2;keratinocyte growth factor	We demonstrate that the proinflammatory cytokines interleukin-1 alpha and - beta , tumor necrosis factor alpha , ***keratinocyte growth factor*** , transforming growth factors beta 1 , beta 2 , and beta 3 and their receptors , platelet-derived growth factors and their ***receptors*** , tenascin-C , ***stromelysin-2*** , macrophage metalloelastase , and enzymes involved in the generation of nitric oxide are targets of glucocorticoid action in wounded skin .	parallel	1
12198	10714241	4319;7124	stromelysin-2;tumor necrosis factor alpha	We demonstrate that the proinflammatory cytokines interleukin-1 alpha and - beta , ***tumor necrosis factor alpha*** , keratinocyte growth factor , transforming growth factors beta 1 , beta 2 , and beta 3 and their receptors , platelet-derived growth factors and their ***receptors*** , tenascin-C , ***stromelysin-2*** , macrophage metalloelastase , and enzymes involved in the generation of nitric oxide are targets of glucocorticoid action in wounded skin .	parallel	1
12199	10714392	5829;5747	paxillin;pp125FAK	In addition , twice as much ***paxillin*** ***associated*** with ***pp125FAK*** in OE adherent cells as in vector controls , but this difference was also lost in suspended cells .	parallel	0
12200	10714558	3606;3458	IL-18;interferon-gamma	However , it has also been demonstrated that simultaneous administration of ***IL-18*** and IL-12 to mice ***induces*** extraordinarily large amounts of ***interferon-gamma*** ( IFN-gamma ) in the serum .	target	1
12201	10714679	2288;3662	FKBP52;IRF-4	Posttranslational ***regulation*** of ***IRF-4*** activity by the immunophilin ***FKBP52*** .	target	1
12202	10714679	2288;3662	FKBP52;IRF-4	In this study , we characterize a novel ***interaction*** between ***IRF-4*** and the FK506-binding protein 52 ( ***FKBP52*** ) , a 59 kDa member of the immunophilin family with peptidyl-prolyl isomerase activity ( PPIase ) .	parallel	1
12203	10714679	2288;3662	FKBP52;IRF-4	******IRF-4-FKBP52****** ***association*** inhibited IRF4-PU.1 binding to the immunoglobulin light chain enhancer E ( lambda2-4 ) as well as IRF-4-PU.1 transactivation , effects that were dependent on functional PPIase activity .	parallel	0
12204	10714679	6688;3662	PU.1;IRF4	IRF-4-FKBP52 association inhibited ******IRF4-PU.1****** ***binding*** to the immunoglobulin light chain enhancer E ( lambda2-4 ) as well as IRF-4-PU.1 transactivation , effects that were dependent on functional PPIase activity .	parallel	1
12205	10714679	2288;3662	FKBP52;IRF4	***IRF-4-FKBP52*** association ***inhibited*** ***IRF4-PU.1*** binding to the immunoglobulin light chain enhancer E ( lambda2-4 ) as well as IRF-4-PU.1 transactivation , effects that were dependent on functional PPIase activity .	negative	1
12206	10714679	2288;6688	FKBP52;PU.1	***IRF-4-FKBP52*** association ***inhibited*** ***IRF4-PU.1*** binding to the immunoglobulin light chain enhancer E ( lambda2-4 ) as well as IRF-4-PU.1 transactivation , effects that were dependent on functional PPIase activity .	negative	1
12207	10714679	3662;6688	IRF-4;PU.1	***IRF-4-FKBP52*** association ***inhibited*** ***IRF4-PU.1*** binding to the immunoglobulin light chain enhancer E ( lambda2-4 ) as well as IRF-4-PU.1 transactivation , effects that were dependent on functional PPIase activity .	negative	1
12208	10714681	940;5599	CD28;JNK	Here , we report that PKCtheta function was selectively required in a Vav signaling pathway that mediates the ***TCR/CD28-induced*** ***activation*** of ***JNK*** and the IL-2 gene and the upregulation of CD69 expression .	positive	1
12209	10714681	7409;5599	Vav;JNK	Here , we report that PKCtheta function was selectively required in a ***Vav*** signaling pathway that ***mediates*** the TCR/CD28-induced activation of ***JNK*** and the IL-2 gene and the upregulation of CD69 expression .	target	0
12210	10714681	7409;3558	Vav;IL-2	Here , we report that PKCtheta function was selectively required in a ***Vav*** signaling pathway that ***mediates*** the TCR/CD28-induced activation of JNK and the ***IL-2*** gene and the upregulation of CD69 expression .	target	0
12211	10714814	5104;5624	protein C inhibitor;protein C	***protein C inhibitor*** ( PCI ) , a plasma serine protease ***inhibitor*** of activated ***protein C*** , is present at high concentrations in the seminal plasma of normal subjects and is decreased in some infertile patients .	negative	1
12212	10714817	1471;1508	cystatin C;cysteine protease	A study was performed to correlate the expression of junctional-complex components ( such as zonula occludens-1 [ ZO-1 ] , a tight-junction component protein ) and nonjunctional complex components ( such as urokinase-type plasminogen activator [ uPA ] , a serine protease ; cathepsin L , a cysteine protease ; alpha2-macroglobulin , a nonspecific protease inhibitor ; and ***cystatin C*** , a ***cysteine protease*** ***inhibitor*** ) at the time when inter-Sertoli tight junctions were established in vitro .	negative	1
12213	10714940	335;4018	apo;lipoprotein	Since ***apo*** A-IV synthesis in the enterocytes is ***linked*** to the intracellular assembly of ***lipoprotein*** , it is likely that in addition to lymphatic transport , production of chylomicrons is not impaired in ageing rats .	parallel	0
12214	10715104	5104;5624	PCI;protein C	Inhibition of recombinant APC molecules by the serpin ***protein C*** ***inhibitor*** ( ***PCI*** ) in the presence and absence of heparin was also investigated .	negative	1
12215	10715157	2885;2064	Grb2;erbB-2	Pmf-containing inhibitors show inhibition constants as low as 8 nM in extracellular Grb2 binding assays and in whole cell systems , effective blockade of both endogenous ***Grb2*** ***binding*** to cognate ***erbB-2*** , and downstream MAP kinase activation .	parallel	1
12216	10715321	6916;9181	Cyp5;GEF	Our results suggest that ***Cyp5*** may ***regulate*** the ARF ***GEF*** function of the GNOM protein during embryogenesis .	target	1
12217	10715546	7040;1588	TGF-beta1;aromatase	***TGF-beta1*** ***stimulates*** expression of the ***aromatase*** ( CYP19 ) gene in human osteoblast-like cells and THP-1 cells .	positive	0
12218	10715546	7040;1588	TGF-beta1;aromatase	***TGF-beta1*** ***increased*** IL-1beta + DEX - induced ***aromatase*** activity in osteoblast-like cells , while it inhibited activity in skin fibroblasts .	positive	0
12219	10715546	7040;1588	TGF-beta1;aromatase	In THP-1 cells , ***TGF-beta1*** ***enhanced*** DEX-induced ***aromatase*** activity almost linearly by 12 h and thereafter .	positive	0
12220	10715552	7020;1442	Activator protein-2;placental lactogen	***Activator protein-2*** ***regulates*** human ***placental lactogen*** gene expression .	target	1
12221	10715553	3552;1435	IL-1alpha;MCSF	TNFalpha ( 1 ng/ml ) , PTH ( 5x10 ( -8 ) M ) , and ***IL-1alpha*** ( 100 pg/ml ) , which ***increased*** ***MCSF*** protein secretion , failed to enhance the transcriptional rate of the full-length promoter .	positive	0
12222	10715553	7124;1435	TNFalpha;MCSF	***TNFalpha*** ( 1 ng/ml ) , PTH ( 5x10 ( -8 ) M ) , and IL-1alpha ( 100 pg/ml ) , which ***increased*** ***MCSF*** protein secretion , failed to enhance the transcriptional rate of the full-length promoter .	positive	0
12223	10715573	4790;5970	NF-kappaB;p65	Here , we demonstrate that activation of NF-kappaB in basal forebrain primary culture via treatment with hydrogen peroxide or TNF-alpha is predominantly restricted to CBFNs , and that ***NF-kappaB*** activation appears to mostly ***affect*** ***p65*** translocation to the nucleus , but not the p50 subunit .	target	0
12224	10715992	941;940	B7.1;CD28	The ***interaction*** of the costimulatory molecule ***B7.1*** ( CD80 ) with its receptor ***CD28*** provides a strong positive signal to T cells .	parallel	1
12225	10716190	396;387	RhoGDI;RhoA	Human ******RhoA/RhoGDI****** ***complex*** expressed in yeast : GTP exchange is sufficient for translocation of RhoA to liposomes .	parallel	1
12226	10716190	396;387	RhoGDI;RhoA	The ******RhoA/RhoGDI****** ***complex*** , purified to greater than 98 % at high yield from the yeast cytosolic fraction , could be stoichiometrically ADP-ribosylated by Clostridium botulinum C3 exoenzyme , contained stoichiometric GDP , and could be nucleotide exchanged fully with [ 3H ] GDP or partially with GTP in the presence of submicromolar Mg2 + .	parallel	1
12227	10716190	396;387	RhoGDI;RhoA	These results show that GTP-triggered translocation of RhoA from RhoGDI to a membrane , where it carries out its signaling function , is an intrinsic property of the ******RhoA/RhoGDI****** ***complex*** that does not require other protein factors or membrane receptors .	parallel	1
12228	1071628	9622;5972	kallikrein;Renin	Rats given a sodium load ( NaCl solution , 20 g/l , to drink ) for 28 days showed acute and prolonged significant falls in urinary ***kallikrein*** excretion ***associated*** with suppression of plasma ***Renin*** and angiotensin .	parallel	0
12229	1071652	183;1312	angiotensin II;catechol-O-methyltransferase	Intravenous administration of ***angiotensin II*** reduced the adrenaline content , ***increased*** the ***catechol-O-methyltransferase*** activity , and decreased the monoamine oxidase activity of rat hypothalamus .	positive	0
12230	10716623	3553;3586	IL-1beta;IL-10	Moreover , they provide original evidence that PDL cells secrete ***IL-10*** , which can be ***suppressed*** by ***IL-1beta*** .	negative	1
12231	10716639	2475;472	FRAP;ATM	Also , PHAS-1 , another ***FRAP*** target , may also be a ***substrate*** for ***ATM*** .	parallel	1
12232	10716693	8115;207	Tcl1;Akt1	Interestingly , Akt1 was also found in the nucleus when Akt1 was cotransfected with Tcl1 , suggesting that ***Tcl1*** ***promotes*** the transport of ***Akt1*** to the nucleus .	positive	0
12233	10716693	8115;207	Tcl1;Akt	***Tcl1*** ***enhances*** ***Akt*** kinase activity and mediates its nuclear translocation .	positive	0
12234	10716693	207;8115	Akt1;Tcl1	We further demonstrated that , in 293 cells transfected with Tcl1 , the endogenous ***Akt1*** ***bound*** to ***Tcl1*** is 5-10 times more active compared with Akt1 not bound to Tcl1 .	parallel	1
12235	10716710	1029;7157	p19ARF;p53	We used p19ARF knockout mouse embryo fibroblasts to show that DNA damage and microtubule disruption require ***p19ARF*** to ***induce*** ***p53*** responses , whereas ribonucleotide depletion and inhibition of RNA synthesis by low doses of actinomycin D do not .	target	1
12236	10716728	5588;4790	protein kinase C-theta;NF-kappa B	***NF-kappa B*** activation induced by T cell receptor/CD28 costimulation is ***mediated*** by ***protein kinase C-theta*** .	target	0
12237	10716737	3611;2185	integrin-linked kinase;protein kinase B	Inhibition of ***integrin-linked kinase*** ( ILK ) ***suppresses*** activation of ***protein kinase B/Akt*** and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells .	positive	1
12238	10716737	5728;3611	PTEN;ILK	We now demonstrate that the activity of ILK is constitutively elevated in a serum - and anchorage-independent manner in PTEN-mutant cells , and transfection of wild-type ( WT ) ***PTEN*** into these cells ***inhibits*** ***ILK*** activity .	negative	1
12239	10716929	4915;627	TrkB;BDNF	***BDNF*** and its tyrosine kinase ***receptor*** , ***TrkB*** , are expressed in hypothalamic nuclei associated with satiety and locomotor activity .	parallel	1
12240	10716937	899;891	Cyclin F;cyclin B1	***Cyclin F*** ***regulates*** the nuclear localization of ***cyclin B1*** through a cyclin-cyclin interaction .	target	1
12241	10716937	899;891	Cyclin F;cyclin B1	We exploited the yeast two-hybrid screen to find protein ( s ) potentially mediating localization of cyclin B1 and identified a novel ***interaction*** between ***cyclin B1*** and ***Cyclin F*** .	parallel	1
12242	10716937	983;891	cdc2;cyclin B1	We found that ***cdc2*** , ***cyclin B1*** and Cyclin F form a ***complex*** that exhibits histone H1 kinase activity .	parallel	1
12243	10716937	899;983	Cyclin F;cdc2	We found that ***cdc2*** , cyclin B1 and ***Cyclin F*** form a ***complex*** that exhibits histone H1 kinase activity .	parallel	1
12244	10716937	899;891	Cyclin F;cyclin B1	We found that cdc2 , ***cyclin B1*** and ***Cyclin F*** form a ***complex*** that exhibits histone H1 kinase activity .	parallel	1
12245	10716937	899;891	Cyclin F;cyclin B1	The ***interaction*** between ***cyclin B1*** and ***Cyclin F*** represents the first example of direct cyclin-cyclin binding , and elucidates a novel mechanism that regulates MPF localization and function .	parallel	1
12246	10716943	1676;1677	ICAD;CAD	Transgenic mice that ubiquitously express a caspase-resistant form of the ***CAD*** ***inhibitor*** ( ***ICAD*** ) were generated .	negative	1
12247	10716946	1499;8840	beta-catenin;WISP-1	The promoter of ***WISP-1*** was cloned and shown to be ***activated*** by both Wnt-1 and ***beta-catenin*** expression .	positive	1
12248	10716946	7471;8840	Wnt-1;WISP-1	The promoter of ***WISP-1*** was cloned and shown to be ***activated*** by both ***Wnt-1*** and beta-catenin expression .	positive	1
12249	10716965	5915;5947	retinoic acid receptor beta;CRBP	Preliminary experiments did not find an ***association*** between ***CRBP*** and ***retinoic acid receptor beta*** loss , but most ( four of five ) CRBP-negative tumors were also retinoic acid receptor beta negative .	parallel	0
12250	10716993	7048;7040	TbetaR-II;TGF-beta	The blood vessel defects in ALK1-deficient mice are reminiscent of mice lacking TGF-beta1 , ***TGF-beta*** type II ***receptor*** ( ***TbetaR-II*** ) , or endoglin , suggesting that ALK1 may mediate TGF-beta1 signal in endothelial cells .	parallel	1
12251	10716993	94;7040	ALK1;TGF-beta1	The blood vessel defects in ALK1-deficient mice are reminiscent of mice lacking TGF-beta1 , TGF-beta type II receptor ( TbetaR-II ) , or endoglin , suggesting that ***ALK1*** may ***mediate*** ***TGF-beta1*** signal in endothelial cells .	target	0
12252	10716993	94;7048	ALK1;TbetaR-II	Consistent with this hypothesis , we demonstrate that ***ALK1*** in endothelial cells ***binds*** to TGF-beta1 and ***TbetaR-II*** .	parallel	1
12253	10716993	94;7040	ALK1;TGF-beta1	Consistent with this hypothesis , we demonstrate that ***ALK1*** in endothelial cells ***binds*** to ***TGF-beta1*** and TbetaR-II .	parallel	1
12254	10716993	7046;7040	ALK5;TGF-beta1	Furthermore , the ALK1 signaling pathway can inhibit TGF-beta1-dependent transcriptional activation mediated by the known ***TGF-beta1*** type I ***receptor*** , ***ALK5*** .	parallel	1
12255	10716998	7124;729230	tumor necrosis factor-alpha;CCR2	We have shown previously that in human monocytes , bacterial lipopolysaccharide , IL-1 , and ***tumor necrosis factor-alpha*** ***induce*** a rapid down-regulation of the monocyte chemotactic protein-1 receptor ***CCR2*** ( CC chemokine receptor-2 ) .	target	1
12256	10716998	7124;1234	tumor necrosis factor-alpha;CCR5	In contrast , xanthine/xanthine oxidase opposed the bacterial lipopolysaccharide - and ***tumor necrosis factor-alpha-mediated*** ***inhibition*** of ***CCR5*** and CXCR4 mRNA expression and increased both the CCR5 surface expression and the cell migration ( 3-fold ) in response to macrophage inflammatory protein-1beta .	negative	1
12257	10716998	7124;7852	tumor necrosis factor-alpha;CXCR4	In contrast , xanthine/xanthine oxidase opposed the bacterial lipopolysaccharide - and ***tumor necrosis factor-alpha-mediated*** ***inhibition*** of CCR5 and ***CXCR4*** mRNA expression and increased both the CCR5 surface expression and the cell migration ( 3-fold ) in response to macrophage inflammatory protein-1beta .	negative	1
12258	10717003	3301;367	HDJ-2;androgen receptor	Previous studies suggested that HSPs might protect against inclusion formation , because overexpression of ***HDJ-2/HSDJ*** ( a human HSP40 homologue ) ***reduced*** ataxin-1 ( SCA1 ) and ***androgen receptor*** ( SBMA ) aggregate formation in HeLa cells .	negative	1
12259	10717003	3301;6310	HDJ-2;ataxin-1	Previous studies suggested that HSPs might protect against inclusion formation , because overexpression of ***HDJ-2/HSDJ*** ( a human HSP40 homologue ) ***reduced*** ***ataxin-1*** ( SCA1 ) and androgen receptor ( SBMA ) aggregate formation in HeLa cells .	negative	1
12260	10718114	7124;3383	TNFalpha;ICAM-1	***TNFalpha*** significantly ***increased*** ***ICAM-1*** expression in all cell types whereas SI elicited an increase in peritoneal macrophages ( PM ) and the cell line , MH-S .	positive	0
12261	10718114	7124;3383	TNFalpha;ICAM-1	Both ***anti-TNFalpha*** and NAC , but not L-NAME , ***inhibited*** elicited ( TNFalpha , SI ) as well as constitutive ( media ) ***ICAM-1*** expression .	negative	1
12262	10718175	183;3688	angiotensin II;Integrin beta1	***Integrin beta1*** ***upregulation*** in MCF-7 breast cancer cells by ***angiotensin II*** .	positive	1
12263	10718206	6757;6760	SSX;SYT	Strong ***association*** of ******SYT-SSX****** fusion type and morphologic epithelial differentiation in synovial sarcoma .	parallel	0
12264	10718206	6757;6760	SSX;SYT	There was a strong ***association*** between ******SYT-SSX****** fusion type and histologic subtype .	parallel	0
12265	10718212	4193;7157	mdm2;p53	Tumor suppressor protein p53 is a positive regulator of mdm2 gene expression and the ***mdm2*** protein can ***bind*** to ***p53*** , preventing the transactivation of p53 responsive genes , thus mimicking TP53 mutation .	parallel	1
12266	10718212	7157;4193	p53;mdm2	Tumor suppressor protein ***p53*** is a positive ***regulator*** of ***mdm2*** gene expression and the mdm2 protein can bind to p53 , preventing the transactivation of p53 responsive genes , thus mimicking TP53 mutation .	positive	1
12267	10718318	6469;5727	Shh;Ptc1	Treatment of murine brain primary cultures and a human teratoma cell line with the N-terminal activated form of Shh ( ShhNT ) , a ******Ptc1-Shh****** ***complex*** was observed in lysosomes .	parallel	1
12268	10718374	814;7124	CaMK IV;TNFalpha	Inhibition of ***CaMK IV*** , both after adherence and in non-adherent monocytes , significantly inhibited LPS-induced ERK 1/2 activation and ***abrogated*** ***TNFalpha*** production by up to 75 % .	positive	0
12269	10718374	814;5594	CaMK IV;ERK 1/2	Inhibition of ***CaMK IV*** , both after adherence and in non-adherent monocytes , significantly ***inhibited*** LPS-induced ***ERK 1/2*** activation and abrogated TNFalpha production by up to 75 % .	positive	1
12270	10718383	2919;836	Gro-alpha;Caspase 3	***Caspase 3*** activity was markedly ***suppressed*** at 24 h by the inclusion of either IL-8 and ***Gro-alpha*** .	negative	1
12271	10718488	5481;2099	cyclophilin 40;ER alpha	The immunophilins , ***cyclophilin 40*** ( CyP40 ) and FKBP52 , are ***associated*** with ***ER alpha*** and other steroid receptors in mutually exclusive heterocomplexes and may differentially modulate receptor activity .	parallel	0
12272	10718488	2288;2099	FKBP52;ER alpha	The immunophilins , cyclophilin 40 ( CyP40 ) and ***FKBP52*** , are ***associated*** with ***ER alpha*** and other steroid receptors in mutually exclusive heterocomplexes and may differentially modulate receptor activity .	parallel	0
12273	10719060	3458;7124	IFN-gamma;TNF-alpha	Similarly , IL-6 and ***IFN-gamma*** potently ***enhanced*** IL-1beta - or ***TNF-alpha-induced*** C3 and factor B secretion , respectively .	positive	0
12274	10719060	3569;7124	IL-6;TNF-alpha	Similarly , ***IL-6*** and IFN-gamma potently ***enhanced*** IL-1beta - or ***TNF-alpha-induced*** C3 and factor B secretion , respectively .	positive	0
12275	10719303	958;959	CD40;CD40 ligand	OBJECTIVE : We sought to delineate and compare the rescue of B-cell apoptosis through ******CD40 ligand-CD40****** ***interaction*** and cyclic adenosine monophosphate ( cAMP ) - dependent protein kinase A in human B cells .	parallel	1
12276	10719303	958;959	CD40;CD40 ligand	RESULTS : Both ******CD40 ligand-CD40****** ***interaction*** and activation of intracellular cAMP rescue B cells from apoptosis after antigen receptor ligation .	parallel	1
12277	10719303	959;836	IgM;CPP32	Although these pathways do not overlap , they converge by preventing the ***anti-IgM-induced*** ***activation*** of ***CPP32*** ( caspase 3 ) , a member of the IL-1beta-converting enzyme protease family .	positive	1
12278	10719355	3586;7124	IL-10;TNF-alpha	***IL-10*** ( 10 and 100 ng/ml ) and IL-4 ( 5 and 50 U/ml ) ***suppressed*** the LPS-induced production of NO , IL-6 , and ***TNF-alpha*** in a dose-dependent manner , whereas TGF-beta1/beta2 ( 2 and 20 ng/ml ) only suppressed NO production .	negative	1
12279	10719355	3586;3553	IL-10;IL-1beta	LPS-induced levels of ***IL-1beta*** were ***suppressed*** by ***IL-10*** , but not by IL-4 and TGF-beta1/beta2 .	negative	1
12280	10719389	213;7173	albumin;Thyroid peroxidase	Normal in vitro ***Thyroid peroxidase*** ( TPO ) iodide oxidation activity was completely ***inhibited*** by a hydrolyzed TPO preparation ( 0.15 mg/ml ) or hydrolyzed bovine serum ***albumin*** ( BSA , 0.2 mg/ml ) .	negative	1
12281	10719667	6441;653509	SP-D;SP-A	In addition , complementary or cooperative ***interactions*** between ***SP-A*** , ***SP-D*** and other host defense lectins could contribute to the efficiency of this defense system .	parallel	1
12282	10719752	3082;7066	Hepatocyte growth factor;thrombopoietin	***Hepatocyte growth factor/scatter factor*** ***enhances*** the ***thrombopoietin*** mRNA expression in rat hepatocytes and cirrhotic rat livers .	positive	0
12283	10719752	3082;7066	Hepatocyte growth factor;TPO	RESULTS : Among them , only ***Hepatocyte growth factor/scatter factor*** ( HGF/SF ) ***enhanced*** ***TPO*** mRNA expression ; other growth factors ( epidermal growth factor and transforming growth factor-beta ) and cytokines ( erythropoietin , granulocyte-colony stimulating factor , granulocyte-macrophage-colony stimulating factor , interleukin ( IL ) -3 , IL-6 and interferon-gamma ) did not .	positive	0
12284	10719839	5697;337	Peptide YY;apolipoprotein A-IV	***Peptide YY*** ***stimulates*** the expression of ***apolipoprotein A-IV*** gene in Caco-2 intestinal cells .	positive	0
12285	10719839	5697;337	Peptide YY;apolipoprotein A-IV	Western blotting revealed that the exogenous ***Peptide YY*** ***increased*** the intracellular concentration of ***apolipoprotein A-IV*** .	positive	0
12286	10719839	5697;337	Peptide YY;apolipoprotein A-IV	The present results suggest that ***Peptide YY*** ***modulates*** ***apolipoprotein A-IV*** gene expression , likely via the Y1-receptor subtype in intestinal epithelial cells .	target	0
12287	10719890	4914;4803	TrkA;NGF	Development of sensory neurons in the absence of ******NGF/TrkA****** ***signaling*** in vivo .	parallel	0
12288	10719890	4914;4803	TrkA;NGF	All dorsal root ganglion ( DRG ) neurons that normally die in the absence of ******NGF/TrkA****** ***signaling*** survive if BAX is also eliminated .	parallel	0
12289	10719890	4914;4803	TrkA;NGF	These findings establish that ******NGF/TrkA****** ***signaling*** regulates peripheral target field innervation and is required for the full phenotypic differentiation of sensory neurons .	parallel	0
12290	10720046	5741;250	PTH;ALP	***PTH*** was also significantly ***correlated*** with ***ALP*** , but not with OC .	parallel	0
12291	10720069	1392;5443	CRH;ACTH	***CRH*** , the principal neuropeptide ***regulator*** of pituitary ***ACTH*** secretion , is also expressed in placenta .	target	1
12292	10720133	5265;5970	alpha-1 antitrypsin;p65	Degradation of ***p65*** and other proteins in ALL samples could be specifically ***suppressed*** by ***alpha-1 antitrypsin*** .	negative	1
12293	10720160	1977;1978	eIF4E;4E-BP1	Concomitant with lower rates of protein synthesis , phosphorylation of the translational repressor , eukaryotic initiation factor ( eIF ) 4E-binding protein 1 ( 4E-BP1 ) , was less in S , leading to greater ***association*** of ******4E-BP1.eIF4E****** , and reduced formation of the active eIF4G.eIF4E complex compared with F ( P < 0.01 ) .	parallel	0
12294	10720167	3569;1401	interleukin 6;C-reactive protein	The concentration of ***interleukin 6*** was consistent with an appropriate proinflammatory response and ***correlated*** directly with the concentrations of ***C-reactive protein*** ( r = 0.67 , P < 0.01 ) and alpha1-antitrypsin ( r = 0.40 , P < 0.05 ) .	parallel	0
12295	10720179	7037;7018	TfR;transferrin	This study was designed to evaluate the effects of dietary ID and iron excess on rat brain iron and the iron metabolism proteins , transferrin ( Tf ) , ***transferrin*** ***receptor*** ( ***TfR*** ) and ferritin .	parallel	1
12296	10720441	335;5054	Apo;PAI-1	In addition , we observed a gene-gene ***interaction*** between the ***PAI-1*** and ***Apo*** ( a ) polymorphisms with respect to the risk of CAD .	parallel	1
12297	10720453	566;3569	HBP;IL-6	***HBP*** ***potentiates*** the endotoxin-induced release of tumor necrosis factor (TNF) alpha , interleukin ( IL ) -1 , and ***IL-6*** from isolated monocytes .	positive	0
12298	10720453	566;7124	HBP;tumor necrosis factor (TNF) alpha	***HBP*** ***potentiates*** the endotoxin-induced release of ***tumor necrosis factor (TNF) alpha*** , interleukin ( IL ) -1 , and IL-6 from isolated monocytes .	positive	0
12299	10720463	307;302	protein II;protein I	Optimization of the lipid composition in the liposomes allowed the efficient ***binding*** of both coat ***protein I*** and coat ***protein II*** ( COPII ) coat subunits .	parallel	1
12300	10720480	4922;4923	Neurotensin;NTR	***Neurotensin*** ( NT ) , a gastrointestinal ( GI ) hormone , ***binds*** its receptor ( ***NTR*** ) to stimulate proliferation of normal and neoplastic GI tissues ; the molecular mechanisms remain largely undefined .	parallel	1
12301	10720489	10524;1385	Tip60;CREB	***Tip60*** ***inhibits*** activation of ***CREB*** protein by protein kinase A.	negative	1
12302	10720489	10524;1385	Tip;CREB	This inhibition appears to be mediated through direct interaction of Tip and CREB , since ***Tip*** directly ***binds*** to ***CREB*** protein in vitro .	parallel	1
12303	10720489	1385;10524	CREB;Tip	This inhibition appears to be mediated through direct ***interaction*** of ***Tip*** and ***CREB*** , since Tip directly binds to CREB protein in vitro .	parallel	1
12304	10720489	10524;1385	Tip;CREB	***Inhibition*** of ***CREB*** activation by ***Tip*** is not diminished in a HAT negative Tip mutant , indicating that Tip can negatively regulate gene expression independent of HAT activity .	negative	1
12305	10720489	10524;1385	Tip;CREB	Recently , Tip has also been shown to be a transcriptional coactivator of nuclear hormone receptors ; therefore , ***Tip*** can both activate transcription factors of one signaling pathway ( nuclear hormone receptors ) and ***bind*** to a different transcription factor ( ***CREB*** ) and inhibit activation of another signaling pathway .	parallel	1
12306	10720495	183;6774	angiotensin II;STAT3	We recently reported that ***angiotensin II*** ( AngII ) biphasically activates the JAK/STAT pathway and ***induces*** delayed phosphorylation of ***STAT3*** in the late stage ( 120 min ) in cardiomyocytes .	target	1
12307	10720497	958;4321	CD40;matrix metalloproteinase-12	***Induction*** and regulation of ***matrix metalloproteinase-12*** by cytokines and ***CD40*** signaling in monocyte/macrophages .	target	1
12308	10720497	1437;4321	GM-CSF;MMP-12	By contrast , both U937-derived macrophages and human peripheral blood monocyte-derived macrophages showed spontaneous ***MMP-12*** expression , which was significantly ***increased*** by the addition of either ***GM-CSF*** or anti-CD40Ab .	positive	0
12309	10720515	3558;1234	Interleukin-2;CCR5	***Interleukin-2*** ***up-regulates*** expression of the human immunodeficiency virus fusion coreceptor ***CCR5*** by CD4 + lymphocytes in vivo .	positive	1
12310	10720515	3558;1234	IL-2;CCR5	***IL-2*** therapy ***induced*** ***CCR5*** expression in > 90 % of circulating memory CD4 + T cells , determined to be a long-term reservoir of HIV , suggesting significant activation of these cells .	target	1
12311	10720581	5972;1585	renin;CYP11B2	We detected an ***association*** between the ***CYP11B2*** gene polymorphisms and ***low-renin*** hypertension with inappropriate elevation of aldosterone .	parallel	0
12312	10720581	1636;5972	ACE;renin	The ***association*** between ***low-renin*** hypertension and angiotensin I-converting enzyme ( ***ACE*** ) gene was also analyzed .	parallel	0
12313	10720581	1636;1636	angiotensin I-converting enzyme;ACE	The ***association*** between low-renin hypertension and ***angiotensin I-converting enzyme*** ( ***ACE*** ) gene was also analyzed .	parallel	0
12314	10720688	3562;1437	IL-3;GM-CSF	We discuss these findings with regard to the stoichiometry , activation , and signalling of the normal ******GM-CSF/IL-3/IL-5****** receptor ***complexes*** .	parallel	1
12315	10720688	3567;1437	IL-5;GM-CSF	We discuss these findings with regard to the stoichiometry , activation , and signalling of the normal ******GM-CSF/IL-3/IL-5****** receptor ***complexes*** .	parallel	1
12316	10720688	3567;3562	IL-5;IL-3	We discuss these findings with regard to the stoichiometry , activation , and signalling of the normal ******GM-CSF/IL-3/IL-5****** receptor ***complexes*** .	parallel	1
12317	10720689	3569;355	IL-6;Fas	The addition of ***IL-6*** further ***increased*** the expression of ***Fas*** , but not that of c-Myc .	positive	0
12318	10720694	7066;6772	Thrombopoietin;Stat1	***Thrombopoietin*** ***induces*** the generation of distinct ***Stat1*** , Stat3 , Stat5a and Stat5b homo - and heterodimeric complexes with different kinetics in human platelets .	target	1
12319	10720694	7066;6774	Thrombopoietin;Stat3	***Thrombopoietin*** ***induces*** the generation of distinct Stat1 , ***Stat3*** , Stat5a and Stat5b homo - and heterodimeric complexes with different kinetics in human platelets .	target	1
12320	10720694	7066;6776	Thrombopoietin;Stat5a	***Thrombopoietin*** ***induces*** the generation of distinct Stat1 , Stat3 , ***Stat5a*** and Stat5b homo - and heterodimeric complexes with different kinetics in human platelets .	target	1
12321	10720694	6774;6777	Stat3;Stat5	RESULTS : We found homodimers of Stat1alpha , Stat3 , Stat5a , and Stat5b , as well as heterodimers of Stat1/Stat3 and Stat5a/Stat5b , but no Stat1/Stat5 or ******Stat3/Stat5****** ***heterodimers*** are formed in platelets in response to TPO .	parallel	1
12322	10720694	6772;6774	Stat1;Stat3	RESULTS : We found homodimers of Stat1alpha , Stat3 , Stat5a , and Stat5b , as well as ***heterodimers*** of ******Stat1/Stat3****** and Stat5a/Stat5b , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12323	10720694	6772;6776	Stat1;Stat5a	RESULTS : We found homodimers of Stat1alpha , Stat3 , Stat5a , and Stat5b , as well as ***heterodimers*** of ***Stat1/Stat3*** and ***Stat5a/Stat5b*** , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12324	10720694	6772;6777	Stat1;Stat5b	RESULTS : We found homodimers of Stat1alpha , Stat3 , Stat5a , and Stat5b , as well as ***heterodimers*** of ***Stat1/Stat3*** and ***Stat5a/Stat5b*** , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12325	10720694	6776;6774	Stat5a;Stat3	RESULTS : We found homodimers of Stat1alpha , Stat3 , Stat5a , and Stat5b , as well as ***heterodimers*** of ***Stat1/Stat3*** and ***Stat5a/Stat5b*** , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12326	10720694	6776;6777	Stat5a;Stat5b	RESULTS : We found homodimers of Stat1alpha , Stat3 , Stat5a , and Stat5b , as well as ***heterodimers*** of Stat1/Stat3 and ******Stat5a/Stat5b****** , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12327	10720694	6774;6776	Stat3;Stat5a	RESULTS : We found ***homodimers*** of Stat1alpha , ***Stat3*** , ***Stat5a*** , and Stat5b , as well as heterodimers of Stat1/Stat3 and Stat5a/Stat5b , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12328	10720694	6777;6774	Stat5b;Stat3	RESULTS : We found ***homodimers*** of Stat1alpha , ***Stat3*** , Stat5a , and ***Stat5b*** , as well as heterodimers of Stat1/Stat3 and Stat5a/Stat5b , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12329	10720694	6777;6776	Stat5b;Stat5a	RESULTS : We found ***homodimers*** of Stat1alpha , Stat3 , ***Stat5a*** , and ***Stat5b*** , as well as heterodimers of Stat1/Stat3 and Stat5a/Stat5b , but no Stat1/Stat5 or Stat3/Stat5 heterodimers are formed in platelets in response to TPO .	parallel	1
12330	10720694	1399;6777	CrkL;Stat5b	The adapter protein ***CrkL*** is present in DNA-bound Stat5 complexes and predominantly ***bound*** to ***Stat5b*** .	parallel	1
12331	10720941	3479;7431	IGF-1;vimentin	However , in the obstructed kidney , ***IGF-1*** ***reduced*** tubular expression of ***vimentin*** , apoptosis , and tubular atrophy by 38 to 50 % ( P < 0.05 ) .	negative	1
12332	10720953	6347;7040	MCP-1;TGF-beta	In cultured macrophages ***MCP-1*** ***raised*** the secretion of ***TGF-beta*** , which in turn increased the expression of collagen type I and III as well as fibronectin in renal interstitial myofibroblasts about 2.5 to 4-fold .	positive	0
12333	10721062	3458;3620	IFN-gamma;IDO	The results indicated that the ***IDO*** expression is ***mediated*** by ***IFN-gamma*** .	target	0
12334	10721095	7124;3458	TNF-alpha;IFN-gamma	For example we have found that TNF-alpha enhances IFN-gamma induced IDO activity and antimicrobial effect in human glioblastoma cells whereas both ***IFN-gamma*** mediated effects were ***blocked*** by ***TNF-alpha*** as well as by IL-1 in a human uroepithelial cell line .	negative	0
12335	10721099	3458;3620	IFN-gamma;IDO	The results revealed that i ) the expression of ***IDO*** in the large intestine or in the cecum is ***mediated*** by ***IFN-gamma*** , ii ) for the systemic IDO induction under endotoxin shock , IFN-gamma is a dominant inducer but not essential , and an IFN-gamma-independent mechanism is also operative , iii ) the systemic induction of IDO caused by IL-12 or Pokeweed mitogen is mediated by IFN-gamma , and iv ) the constitutive IDO expression in the epididymis is IFN-gamma-independent .	target	0
12336	10721693	4193;7157	MDM2;p53	In normal cells the ***MDM2*** protein ***binds*** to the ***p53*** protein and maintains p53 at low levels by increasing its susceptibility to proteolysis by the 26S proteosome .	parallel	1
12337	10721701	2057;2056	EpoR;erythropoietin	Endothelial cells express ***erythropoietin*** ***receptor*** ( ***EpoR*** ) and are responsive to erythropoietin ( Epo ) .	parallel	1
12338	10721717	9181;998	GEF;Cdc42	FGD1 encodes a guanine nucleotide exchange factor ( ***GEF*** ) that specifically ***activates*** the Rho GTPase ***Cdc42*** .	positive	1
12339	10721722	8851;1020	p35nck5a;Cdk5	The bacterially expressed glutathione S-transferase ( GST ) - fusion forms of these three proteins were able to co-precipitate ***p35nck5a*** ***complexed*** with ***Cdk5*** from insect cell lysate .	parallel	1
12340	10721723	3725;7020	AP-1;AP-2	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of ***AP-1*** , ***AP-2*** , C/EBPbeta , CRE , Egr-1 , Ets , NF-AT , NF-kappaB and SP-1 transcription factors .	parallel	1
12341	10721723	3725;1051	AP-1;C/EBPbeta	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of ***AP-1*** , AP-2 , ***C/EBPbeta*** , CRE , Egr-1 , Ets , NF-AT , NF-kappaB and SP-1 transcription factors .	parallel	1
12342	10721723	3725;1958	AP-1;Egr-1	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of ***AP-1*** , AP-2 , C/EBPbeta , CRE , ***Egr-1*** , Ets , NF-AT , NF-kappaB and SP-1 transcription factors .	parallel	1
12343	10721723	3725;4790	AP-1;NF-kappaB	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of ***AP-1*** , AP-2 , C/EBPbeta , CRE , Egr-1 , Ets , NF-AT , ***NF-kappaB*** and SP-1 transcription factors .	parallel	1
12344	10721723	7020;1051	AP-2;C/EBPbeta	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of AP-1 , ***AP-2*** , ***C/EBPbeta*** , CRE , Egr-1 , Ets , NF-AT , NF-kappaB and SP-1 transcription factors .	parallel	1
12345	10721723	1958;7020	Egr-1;AP-2	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of AP-1 , ***AP-2*** , C/EBPbeta , CRE , ***Egr-1*** , Ets , NF-AT , NF-kappaB and SP-1 transcription factors .	parallel	1
12346	10721723	1958;1051	Egr-1;C/EBPbeta	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of AP-1 , AP-2 , ***C/EBPbeta*** , CRE , ***Egr-1*** , Ets , NF-AT , NF-kappaB and SP-1 transcription factors .	parallel	1
12347	10721723	4790;7020	NF-kappaB;AP-2	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of AP-1 , ***AP-2*** , C/EBPbeta , CRE , Egr-1 , Ets , NF-AT , ***NF-kappaB*** and SP-1 transcription factors .	parallel	1
12348	10721723	4790;1051	NF-kappaB;C/EBPbeta	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of AP-1 , AP-2 , ***C/EBPbeta*** , CRE , Egr-1 , Ets , NF-AT , ***NF-kappaB*** and SP-1 transcription factors .	parallel	1
12349	10721723	4790;1958	NF-kappaB;Egr-1	The woodchuck TNF gene promoter contains consensus sequences for ***binding*** of AP-1 , AP-2 , C/EBPbeta , CRE , ***Egr-1*** , Ets , NF-AT , ***NF-kappaB*** and SP-1 transcription factors .	parallel	1
12350	10721793	3815;4254	c-kit;SCF	Activating mutations in ***c-kit*** , the ***receptor*** for Stem Cell Factor ( ***SCF*** ) , have been identified in dysplasias and leukaemias of the mast cell lineage and have been shown to contribute to transformation in model systems .	parallel	1
12351	10721994	30835;3385	DC-SIGN;ICAM-3	Identification of ***DC-SIGN*** , a novel dendritic cell-specific ***ICAM-3*** ***receptor*** that supports primary immune responses .	parallel	1
12352	10721994	30835;3385	DC-SIGN;ICAM-3	We discovered that instead of the common ICAM-3 receptors LFA-1 and alphaDbeta2 , a novel DC-specific C-type lectin , ***DC-SIGN*** , ***binds*** ***ICAM-3*** with high affinity .	parallel	1
12353	10721995	30835;3700	DC-SIGN;gp120	Here , we describe the properties of a DC-specific C-type lectin , ***DC-SIGN*** , that is highly expressed on DC present in mucosal tissues and ***binds*** to the HIV-1 envelope glycoprotein ***gp120*** .	parallel	1
12354	10722053	8660;207	IRS-2;PKB	We have examined the insulin-stimulated ***IRS-2*** ***association*** with PI 3-kinase and the phosphorylation of ***AKT/PKB*** , which is functionally located downstream of the PI 3-kinase , in aged ( obese ) rats .	parallel	0
12355	10722567	4790;5970	p50;p65	An inducible nuclear protein complex bound to the ICAM-1 NF-kappaB site and was identified as the NF-kappaB ******p50-p65****** ***heterodimer*** .	parallel	1
12356	10722567	4792;4790	IkappaB-alpha;NF-kappaB	H. pylori induced the degradation of ***IkappaB-alpha*** , a major cytoplasmic ***inhibitor*** of ***NF-kappaB*** , and stimulated the expression of IkappaB-alpha mRNA .	negative	1
12357	10722591	3586;3458	IL-10;IFN-gamma	Addition of anti-IL-4 MAbs to splenocyte cultures from infected WT 129/J , BALB/c , or C57BL/6 mice failed to modify IFN-gamma synthesis levels ; in contrast , ***IL-10*** neutralization ***increased*** ***IFN-gamma*** production and addition of rIL-4 and/or rIL-10 diminished IFN-gamma synthesis .	positive	0
12358	10722591	3565;3458	IL-4;IFN-gamma	We conclude that endogenous IL-4 is not a major determinant of susceptibility to Y strain T. cruzi infection but that ***IL-4*** can , in association with IL-10 , ***modulate*** ***IFN-gamma*** production and resistance .	target	0
12359	10722610	3856;157680	CK8;COH1	***CK8*** ***bound*** to ***COH1-13*** , an acapsular mutant of COH1 , demonstrating that adherence is not mediated by capsular polysaccharide .	parallel	1
12360	10722613	3565;3558	IL-4;interleukin-2	We report the identification of a large gene present in enteropathogenic strains of Escherichia coli ( EPEC ) that encodes a toxin that specifically ***inhibits*** lymphocyte proliferation and ***interleukin-2*** ( IL-2 ) , ***IL-4*** , and gamma interferon production in response to a variety of stimuli .	negative	1
12361	10722614	7124;5329	tumor necrosis factor alpha;uPAR	Although ***tumor necrosis factor alpha*** ( TNF ) ***upregulated*** monocyte ***uPAR*** expression , anti-TNF did not influence the endotoxin-induced increase in monocyte uPAR expression .	positive	1
12362	10722651	1385;1387	CREB;CREB-binding protein	The second messenger , cAMP , for example , promotes cellular gene expression via the protein kinase A-mediated phosphorylation of cAMP-response element-binding protein ( CREB ) at Ser ( 133 ) , and this modification in turn stimulates the ***association*** of ***CREB*** with the co-activator , ***CREB-binding protein*** ( CBP ) .	parallel	0
12363	10722652	4091;3224	Smad6;homeobox (Hox) c-8	Here we show that ***Smad6*** ***interacts*** with ***homeobox (Hox) c-8*** as a transcriptional corepressor , inhibiting BMP signaling in the nucleus .	parallel	1
12364	10722652	3224;4091	Hoxc-8;Smad6	The ***interaction*** between ***Smad6*** and ***Hoxc-8*** was identified by a yeast two-hybrid approach and further demonstrated by co-immunoprecipitation assays in cells .	parallel	1
12365	10722652	4091;3205	Smad6;Hoxa-9	Gel shift assays show that ***Smad6*** , but not Smad7 , ***interacts*** with both Hoxc-8 and ***Hoxa-9*** as a heterodimer when binding to DNA .	parallel	1
12366	10722652	4091;3224	Smad6;Hoxc-8	Gel shift assays show that ***Smad6*** , but not Smad7 , ***interacts*** with both ***Hoxc-8*** and Hoxa-9 as a heterodimer when binding to DNA .	parallel	1
12367	10722652	4091;4086	Smad6;Smad1	More importantly , the ***Smad6-Hoxc-8*** complex ***inhibits*** interaction of ***Smad1*** with Hoxc-8 - and Smad1-induced transcription activity .	negative	1
12368	10722671	183;2185	angiotensin II;Pyk2	***Regulation*** of calcium-sensitive tyrosine kinase ***Pyk2*** by ***angiotensin II*** in endothelial cells .	target	1
12369	10722671	183;2185	angiotensin II;Pyk2	In this study , we have investigated the ***regulation*** of ***Pyk2*** by ***angiotensin II*** ( Ang II ) in pulmonary vein endothelial cells .	target	1
12370	10722671	5781;2185	SHP-2;Pyk2	***SHP-2*** ***interacts*** with ***Pyk2*** through a region other than its SH2 domains .	parallel	1
12371	10722671	2185;5781	Pyk2;SHP-2	Finally , the SHP-2-mediated dephosphorylation of ***Pyk2*** ***correlates*** with the negative effect of ***SHP-2*** on the Ang II-induced activation of extracellular signal-regulated kinase and c-Jun NH ( 2 ) - terminal kinase .	parallel	0
12372	10722671	5781;2185	SHP-2;Pyk2	Finally , the ***SHP-2-mediated*** ***dephosphorylation*** of ***Pyk2*** correlates with the negative effect of SHP-2 on the Ang II-induced activation of extracellular signal-regulated kinase and c-Jun NH ( 2 ) - terminal kinase .	target	1
12373	10722677	196;405	AhR;Arnt	Inhibition of proteasomal degradation of AhR increases the amount of the nuclear ******AhR.Arnt****** ***complex*** and " superinduces " the expression of endogenous CYP1A1 gene by TCDD , indicating that the proteasomal degradation of AhR serves as a mechanism for controlling the activity of the activated receptor .	parallel	1
12374	10722682	156;6010	GRK2;rhodopsin	In addition , the recombinant proteins that represent the C-terminal domain and the conserved region of GRK2 could inhibit ***GRK2-mediated*** ***phosphorylation*** of ***rhodopsin*** and receptor-mediated activation of GRK2 but not GRK2-mediated phosphorylation of the peptide substrate .	target	1
12375	10722692	10987;5241	JAB1;progesterone receptor	***JAB1*** ***interacts*** with both the ***progesterone receptor*** and SRC-1 .	parallel	1
12376	10722692	10987;8648	JAB1;SRC-1	***JAB1*** ***interacts*** with both the progesterone receptor and ***SRC-1*** .	parallel	1
12377	10722692	10987;8648	JAB1;SRC-1	We show here , by yeast and mammalian two-hybrid analyses and by pull-down experiments , that ***JAB1*** also ***interacts*** with both the progesterone receptor ( PR ) and the steroid receptor coactivator 1 ( ***SRC-1*** ) and that it stabilizes PR-SRC-1 complexes .	parallel	1
12378	10722693	4792;4790	IkappaBalpha;NF-kappaB	Like TNF , however , PV induced phosphorylation and degradation of IkappaBalpha , and subsequent NF-kappaB activation , which could be blocked by N-tosyl-L-phenylalanine chloromethyl ketone , calpeptin , and pyrrolidine dithiocarbomate , suggesting a close ***link*** between PV-induced ***NF-kappaB*** activation and ***IkappaBalpha*** degradation .	parallel	0
12379	10722700	7124;836	TNF-alpha;caspase-3	The effector caspases-6 and -7 , and to a lesser extent ***caspase-3*** , were ***activated*** by ***TNF-alpha*** , but not by anti-Fas antibody .	positive	1
12380	10722711	860;4322	Cbfa1;MMP13	Retrovirally forced expression of either type I or type II ***Cbfa1*** in chick immature chondrocytes ***induced*** type X collagen and ***MMP13*** expression , alkaline phosphatase activity , and extensive cartilage-matrix mineralization .	target	1
12381	10722720	836;4155	caspase-3;MBP	In cytotrienin A-sensitive cell lines , we observed a strong ***activation*** of p36 ***MBP*** kinase by cleavage of the C-terminal regulatory domain of full-length MST/Krs proteins by ***caspase-3*** .	positive	1
12382	10722722	10274;10735	SA1;SA2	The ***SA1*** domain of one phragmoplastin molecule also ***binds*** to ***SA2*** of another as confirmed in vitro by using radiolabeled peptides .	parallel	1
12383	10722725	4233;1956	c-Met;EGFR	We conclude that ***c-Met*** ***associates*** with ***EGFR*** in tumor cells , and this association facilitates the phosphorylation of c-Met in the absence of hepatocyte growth factor .	parallel	0
12384	10722725	1956;4233	EGFR;c-Met	This ***cross-talk*** between ***c-Met*** and ***EGFR*** may have significant implications for altered growth control in tumorigenesis .	parallel	0
12385	10722725	4233;1956	c-Met;epidermal growth factor receptor	***Cross-talk*** between ***epidermal growth factor receptor*** and ***c-Met*** signal pathways in transformed cells .	parallel	0
12386	10722725	4233;1956	c-Met;EGFR	We found that ***c-Met*** in tumor cells ***co-immunoprecipitates*** with ***EGFR*** regardless of the existence of their ligands in tumor cells , but not in normal human hepatocytes .	parallel	1
12387	10722728	4435;2033	MSG1;p300	We also found that the Hsc70 heat-shock cognate protein also forms complex with MSG1 in vivo , suppressing both ***binding*** of ***MSG1*** to ***p300/CBP*** and enhancement of Smad-mediated transcription by MSG1 .	parallel	1
12388	10722731	5609;5594	MEK;ERK	For instance , Ras participates in the activation of Raf , which phosphorylates and activates mitogen-activated protein kinase kinase ( ***MEK*** ) , which then ***phosphorylates*** and activates extracellular signal-regulated kinase ( ***ERK*** ) , a mitogen-activated protein ( MAP ) kinase .	target	1
12389	10722740	8883;351	APP-BP1;amyloid precursor protein	***APP-BP1*** ***binds*** to the ***amyloid precursor protein*** ( APP ) carboxyl-terminal domain .	parallel	1
12390	10722740	8883;9039	APP-BP1;hUba3	We show here that , in vivo in mammalian cells , ***APP-BP1*** ***interacts*** with ***hUba3*** , its presumptive partner in the NEDD8 activation pathway , and that the APP-BP1 binding site for hUba3 is within amino acids 443-479 .	parallel	1
12391	10722742	4193;7157	Mdm2;p53	***Mdm2*** has been shown to ***regulate*** ***p53*** stability by targeting the p53 protein for proteasomal degradation .	target	1
12392	10722743	902;1025	cyclin H;cdc2-related kinase	***Activation*** of a Plasmodium falciparum ***cdc2-related kinase*** by heterologous p25 and ***cyclin H*** .	positive	1
12393	10722743	8851;1025	p25;cdc2-related kinase	***Activation*** of a Plasmodium falciparum ***cdc2-related kinase*** by heterologous ***p25*** and cyclin H .	positive	1
12394	10722744	6670;3681	Sp3;CD11d	In contrast , overexpression of ***Sp3*** in IM9 and Jurkat cells ***down-regulated*** ***CD11d*** promoter expression .	negative	1
12395	10722755	5599;3667	JNK;IRS-1	Endogenous ***JNK*** ***associates*** with ***IRS-1*** in Chinese hamster ovary cells .	parallel	0
12396	10722755	5599;3667	JNK;IRS-1	Anisomycin , a strong activator of JNK in these cells , stimulates the activity of ***JNK*** ***bound*** to ***IRS-1*** and inhibits the insulin-stimulated tyrosine phosphorylation of IRS-1 .	parallel	1
12397	10722755	5599;3667	JNK;IRS-1	Mutation of serine 307 to alanine eliminates ***phosphorylation*** of ***IRS-1*** by ***JNK*** and abrogates the inhibitory effect of TNFalpha on insulin-stimulated tyrosine phosphorylation of IRS-1 .	target	1
12398	10722757	4602;490	c-Myb;PMCA1	Overexpression of wild-type ***c-Myb*** severely ***repressed*** ***PMCA1*** promoter activity at both G ( 0 ) and G ( 1 ) / S while co-transfection of a dominant negative c-Myb , or a construct encoding an anti-c-Myb neutralizing antibody , completely abolished the repression seen at G ( 1 ) / S.	negative	1
12399	10723061	3458;836	Interferon-gamma;CPP32	***Interferon-gamma*** ***augmented*** the activation of ***CPP32*** by TNF-alpha in HOG cells and O2A ( + ) oligodendrocyte precursor cells but had no effect on mature oligodendrocytes .	positive	0
12400	10723061	7124;836	TNF-alpha;CPP32	Interferon-gamma augmented the ***activation*** of ***CPP32*** by ***TNF-alpha*** in HOG cells and O2A ( + ) oligodendrocyte precursor cells but had no effect on mature oligodendrocytes .	positive	1
12401	10723068	10681;6000	Gbeta5;RGS7	Coimmunoprecipitation studies confirmed the selective protein-protein ***interaction*** between ***RGS7*** and ***Gbeta5*** within brain regions that displayed immunohistochemical colocalization .	parallel	1
12402	10723084	7040;7045	TGF-beta;betaig-h3	The expression of ***betaig-h3*** was ***induced*** by ***TGF-beta*** in both affected and normal fibroblasts .	target	1
12403	10723089	4790;5970	p50;p65	This rel/bZIP heteromer complex activated by PGG-Glucan is different from the ******p65/p50****** rel/rel ***complex*** induced in these cells by lipopolysaccharide ( LPS ) .	parallel	1
12404	10723095	7124;633	TNF-alpha;biglycan	decorin production was inhibited by about 34 % by all treatments , while ***biglycan*** was ***upregulated*** 1.3-fold by ***TNF-alpha*** .	positive	1
12405	10723095	3553;1462	IL-1beta;versican	***versican*** was ***upregulated*** by ***IL-1beta*** ( 1.7-fold ) , whereas TNF-alpha was without effect .	positive	1
12406	10723098	142;5599	PARP;JNK	***Inhibition*** of ***JNK*** activity by a JNK inhibitor , curcumin , remarkably reduced MG-induced caspase-3 activation , ***PARP*** cleavage , and apoptosis .	negative	1
12407	10723127	5610;4790	PKR;NF-kappa B	We have recently described that ***induction*** of ***NF-kappa B*** by ***PKR*** is involved in apoptosis commitment .	target	1
12408	10723127	5610;4790	PKR;NF-kappa B	To define how ***PKR*** ***mediates*** ***NF-kappa B*** activation by dsRNA , we have used two different approaches , one based on expression of PKR by a vaccinia virus ( VV ) recombinant and the other based on induction of endogenous PKR by poly I : C ( pIC ) treatment .	target	0
12409	10723127	4790;5970	p50;p65	We found that NF-kappa B complexes induced by PKR are composed primarily of ******p50-p65****** ***heterodimers*** and also of c-rel-p50 heterodimers .	parallel	1
12410	10723127	4790;5966	p50;c-rel	We found that NF-kappa B complexes induced by PKR are composed primarily of p50-p65 heterodimers and also of ******c-rel-p50****** ***heterodimers*** .	parallel	1
12411	10723127	5610;4792	PKR;I kappa B alpha	As described for other stimuli , following pIC treatment , ***PKR*** ***phosphorylates*** the NF-kappa B inhibitor ***I kappa B alpha*** at serine 32 before degradation .	target	1
12412	10723128	5783;466	FAP1;ATF1	We further find that the ***FAP1*** site ***binds*** ***ATF1*** and CREB from HeLa nuclear extracts and that the phosphorylation of these factors is induced by TPA .	parallel	1
12413	10723128	5783;1385	FAP1;CREB	We further find that the ***FAP1*** site ***binds*** ATF1 and ***CREB*** from HeLa nuclear extracts and that the phosphorylation of these factors is induced by TPA .	parallel	1
12414	10723128	6197;466	Rsk2;ATF1	***ATF1*** and CREB can be ***phosphorylated*** by ***Rsk2*** which is a protein kinase directly activated by Erk MAP kinases .	target	1
12415	10723128	6197;1385	Rsk2;CREB	ATF1 and ***CREB*** can be ***phosphorylated*** by ***Rsk2*** which is a protein kinase directly activated by Erk MAP kinases .	target	1
12416	10723129	472;7157	ATM;p53	Though downstream targets of the ATM kinase are still being elucidated , it has been demonstrated that ***ATM*** acts upstream of p53 in a signal transduction pathway initiated by IR and can ***phosphorylate*** ***p53*** at serine 15 .	target	1
12417	10723244	551;3553	antidiuretic hormone;interleukin-1 beta	[ Syndrome of inappropriate ***antidiuretic hormone*** secretion ***associated*** with meningeal infiltration of tumor cells and elevated ***interleukin-1 beta*** and interleukin-6 in cerebrospinal fluid of a patient with adult T-cell leukemia ] .	parallel	0
12418	10723580	3563;3562	CD123;IL-3	***CD123*** ( ***IL-3*** ***receptor*** ) expression is similar in the three sources of hematopoietic cells at day 0 and after 48-h culture .	parallel	1
12419	10723580	3815;4254	CD117;SCF	***CD117*** ( ***SCF*** ***receptor*** ) expression , although very heterogeneous according to the subpopulations and the sources of progenitors evaluated , seems not to correlate with the difference of progenitor cell sensitivity to SCF nor with their proliferative capacity .	parallel	1
12420	10723580	4254;3815	SCF;c-kit	Considering the importance of the ******c-kit/SCF****** ***complex*** in the adhesion of stem cells to the microenvironment , several observations are relevant .	parallel	1
12421	10724175	11200;672	hCds1;BRCA1	***hCds1-mediated*** ***phosphorylation*** of ***BRCA1*** regulates the DNA damage response .	target	1
12422	10724175	11200;672	hCds1;BRCA1	Here we report that the human Cds1 kinase ( ***hCds1/Chk2*** ) ***regulates*** ***BRCA1*** function after DNA damage by phosphorylating serine 988 of BRCA1 .	target	1
12423	10724195	6741;6737	SS-B;SS-A	CONCLUSIONS : These findings indicate that photosensitivity and the presence and titer of circulating anti-SS-A / Ro and ***anti-SS-B*** / La antibodies are both directly ***correlated*** with the expression of accessible and immunoreactive ***SS-A/Ro*** and SS-B/La antigens in the skin specimens of patients with LE .	parallel	0
12424	10725230	421;999	ARVCF;E-cadherin	Using new ARVCF monoclonal antibodies , we have found that ***ARVCF*** ***associates*** with ***E-cadherin*** and competes with p120 for interaction with the E-cadherin juxtamembrane domain .	parallel	0
12425	10725236	2735;6469	GLI;SHH	Based on analogy to the Drosophila Hh pathway , the multiple ***GLI*** transcription factors in vertebrates are likely to both ***transduce*** ***SHH*** signaling and repress SHH transcription .	positive	1
12426	10725247	10146;387	G3BP;RhoA	Although ***rin/G3BP*** ***interacts*** genetically with ***RhoA*** , affecting both photoreceptor differentiation and polarity , it does not interact with the gain-of-function genotypes of fz and dsh .	parallel	1
12427	10725328	5175;5906	CD31;Rap1	Importantly , ***CD31*** selectively ***activated*** the small Ras-related GTPase , ***Rap1*** , but not Ras , R-Ras , or Rap2 .	positive	1
12428	10725331	50628;11218	Gemin4;Gemin3	The tight ***interaction*** of ***Gemin4*** with ***Gemin3*** suggests that it could serve as a cofactor of this DEAD box protein .	parallel	1
12429	10725395	1742;2066	PSD-95;ErbB-4	Using coimmunoprecipitation assays , we confirmed the direct ***interactions*** between ***ErbB-4*** and ***PSD-95*** in transfected heterologous cells , as well as in vivo , where both proteins are coimmunoprecipitated from brain lysates .	parallel	1
12430	10725410	119016;6714	Arf GTPase-activating protein;Src	An ***Arf GTPase-activating protein*** of the centaurin beta family , ASAP1 ( also known as centaurin beta4 ) , ***binds*** Arf and two other known regulators of the actin cytoskeleton , the tyrosine kinase ***Src*** and phosphatidylinositol 4,5-bisphosphate .	parallel	1
12431	10725413	1604;3383	DAF;intercellular adhesion molecule-1	Coxsackievirus A21 ( CAV-21 ) employs a cell receptor ***complex*** of decay-accelerating factor ( ***DAF*** ) and ***intercellular adhesion molecule-1*** ( ICAM-1 ) for cell infectivity .	parallel	1
12432	10725413	1604;3383	DAF;ICAM-1	In this study , the nature of potential extra - and/or intracellular ***interactions*** between ***DAF*** and ***ICAM-1*** involved in picornaviral cell entry was investigated .	parallel	1
12433	10725413	1604;3383	DAF;ICAM-1	Firstly , it was shown that intracellular interplay between DAF and ICAM-1 is not required for CAV-21 infection , as CAV-21 lytic infection mediated via the ******DAF/ICAM-1****** receptor ***complex*** is not inhibited by replacement of the transmembrane and cytoplasmic domains of ICAM-1 with those from an unrelated cell surface molecule , CD36 .	parallel	1
12434	10725413	1604;3383	DAF;ICAM-1	Firstly , it was shown that intracellular ***interplay*** between ***DAF*** and ***ICAM-1*** is not required for CAV-21 infection , as CAV-21 lytic infection mediated via the DAF/ICAM-1 receptor complex is not inhibited by replacement of the transmembrane and cytoplasmic domains of ICAM-1 with those from an unrelated cell surface molecule , CD36 .	parallel	1
12435	10725413	3383;1604	ICAM-1;DAF	By immunoprecipitation , chemical cross-linking and picornaviral binding assays , the existence of a close spatial ***association*** between ***DAF*** and ***ICAM-1*** on the surface of ICAM-1-transfected RD cells was confirmed .	parallel	0
12436	10725413	1604;3383	DAF;ICAM-1	Furthermore , it was shown that potential extracellular ******DAF/ICAM-1****** ***interactions*** are likely to occur in an area on or proximal to DAF SCR3 and may influence the route of CAV-21 cell entry .	parallel	1
12437	10725433	2668;1385	ATF;CREB	The activity of the Epstein-Barr virus BamHI W promoter in B cells is dependent on the ***binding*** of ******CREB/ATF****** factors .	parallel	1
12438	10725611	5617;3553	prolactin;IL-1beta	Neither adrenocorticotrophic hormone ( ACTH ) , ***prolactin*** , serum interleukin-1beta ( IL-1beta ) nor mitogen ***stimulated*** ***IL-1beta*** production was influenced at any time .	positive	0
12439	10725696	51554;10850	CCR10;ESkine	Cutting edge : identification of the orphan receptor G-protein-coupled receptor 2 as ***CCR10*** , a specific ***receptor*** for the chemokine ***ESkine*** .	parallel	1
12440	10725696	2826;10850	GPR2;ESkine	These results provide evidence that ***GPR2*** is a specific ***receptor*** for ***ESkine*** .	parallel	1
12441	10725697	2826;10850	G protein-coupled receptor-2;CCL27	Cutting edge : the orphan chemokine receptor ***G protein-coupled receptor-2*** ( GPR-2 , CCR10 ) ***binds*** the skin-associated chemokine ***CCL27*** ( CTACK/ALP/ILC ) .	parallel	1
12442	10725697	10850;2826	CCL27;GPR-2	We report that ***CCL27*** ***binds*** the previously orphan chemokine receptor ***GPR-2*** , as detected by calcium flux and chemotactic responses of GPR-2 transfectants .	parallel	1
12443	10725698	23643;7099	MD-2;toll-like receptor 4	Cutting edge : cell surface expression and lipopolysaccharide signaling via the ******toll-like receptor 4-MD-2****** ***complex*** on mouse peritoneal macrophages .	parallel	1
12444	10725698	23643;7099	MD-2;toll-like receptor 4	The human ***MD-2*** molecule is ***associated*** with the extracellular domain of human ***toll-like receptor 4*** ( TLR4 ) and greatly enhances its LPS signaling .	parallel	0
12445	10725698	23643;7099	MD-2;TLR4	The human ******TLR4-MD-2****** ***complex*** thus signals the presence of LPS .	parallel	1
12446	10725698	23643;7099	MD-2;TLR4	Little is known , however , about cell surface expression and LPS signaling of the ******TLR4-MD-2****** ***complex*** in vivo .	parallel	1
12447	10725698	23643;4790	MD-2;NF-kappaB	Mouse ***MD-2*** expression in TLR4-expressing cells ***enhanced*** LPS-induced ***NF-kappaB*** activation , which was clearly inhibited by MTS510 .	positive	0
12448	10725698	23643;7099	MD-2;TLR4	Collectively , the ******TLR4-MD-2****** ***complex*** is expressed on macrophages in vivo and senses and signals the presence of LPS .	parallel	1
12449	10725701	3565;356	IL-4;FasL	Analysis of FasL expression by flow cytometry showed that ***IL-4*** ***increased*** cell surface ***FasL*** expression on CD4 + and CD8 + splenocytes , with peak expression on day 4 after infection .	positive	0
12450	10725701	3565;356	IL-4;FasL	These data demonstrate that ***IL-4*** ***increases*** ***FasL*** expression on T cells , resulting in a shift of the mechanism of CTL killing from a dominant perforin-mediated cytolytic pathway to a dominant FasL-mediated cytolytic pathway .	positive	0
12451	10725702	796;942	Calcitonin;CD86	***Calcitonin*** gene-related peptide ***decreases*** expression of HLA-DR and ***CD86*** by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I Calcitonin gene-related peptide receptor .	negative	0
12452	10725703	3600;959	IL-15;CD154	IL-2 and ***IL-15*** ***regulate*** ***CD154*** expression on activated CD4 T cells .	target	1
12453	10725703	3558;959	IL-2;CD154	***IL-2*** and IL-15 ***regulate*** ***CD154*** expression on activated CD4 T cells .	target	1
12454	10725705	3659;356	IRF-1;FasL	EMSAs demonstrate specific ***FasL*** promoter ***binding*** by ***IRF-1*** and IRF-2 .	parallel	1
12455	10725705	3660;356	IRF-2;FasL	EMSAs demonstrate specific ***FasL*** promoter ***binding*** by IRF-1 and ***IRF-2*** .	parallel	1
12456	10725710	1493;7040	CTLA-4;TGF-beta1	The ***CTLA-4*** costimulation during priming ***augmented*** ***TGF-beta1*** mRNA accumulation in naive CD4 + T cells , and the inclusion of anti-TGF-beta in cultures for priming suppressed the effect of CTLA-4 costimulation on the Th1 polarization .	positive	0
12457	10725710	1493;3565	CTLA-4;IL-4	The ***CTLA-4*** costimulation was also shown to ***suppress*** ***IL-4*** production of naive CD4 + T cells upon priming .	negative	1
12458	10725717	3600;3458	IL-15;IFN-gamma	Moreover , lamina propria T cells ( LP-T ) from IBD patients were more responsive to IL-15 as compared with controls , and ***IL-15*** alone without a primary T cell stimulus ***induced*** ***IFN-gamma*** and TNF production by isolated IBD LP-T cells , especially by LP-T cells from patients with Crohn 's disease .	target	1
12459	10725717	959;958	CD40L;CD40	LP-T cells from IBD patients could induce ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) interaction-dependent TNF and IL-12 production by monocytes in a coculture system .	parallel	1
12460	10725720	3717;2353	Jak2;c-fos	Although phosphorylation of Jak1 but not of Jak2 occurred with stimulation of hGM-CSF , the dominant-negative ***Jak2*** but not the dominant-negative Jak1 ***suppresses*** ***c-fos*** promoter activation .	negative	1
12461	10725722	961;140885	CD47;SHPS-1	Because erythrocytes do not express integrins , this result suggested that ******SHPS-1-CD47****** ***interactions*** can take place in the absence of a CD47-integrin association .	parallel	1
12462	10725724	4261;4760	CIITA;beta2	Similarly , ***CIITA-mediated*** ***induction*** of MHC class I , ***beta2-microglobulin*** , and invariant chain genes was also found in these RFX-B-deficient fibroblasts .	target	1
12463	10725727	959;958	CD40L;CD40	Thus , our results demonstrate that the importance of ******CD40/CD40L****** ***interaction*** for activation of CD8 + T cells varies between viruses and over time .	parallel	1
12464	10725738	718;719	C3a;C3aR	In addition , synthetic ***C3a*** analogue peptides ***induced*** ***C3aR*** internalization , led to transient changes of intracellular Ca2 + concentration , and did release reactive oxygen species in human eosinophils indicating the in vivo relevance of C3a-related sequences .	target	1
12465	10725740	3689;3385	LFA-1;ICAM-3	We report that 1 ) ***LFA-1*** ***binds*** ***ICAM-3*** as its primary ligand supporting homotypic adhesion , although the possibility of other ligands was also detected .	parallel	1
12466	10725741	3553;3603	IL-1beta;IL-16	The ***induction*** of ***IL-16*** protein by ***IL-1beta*** can be attenuated with specific inhibition of caspase-3 , which could be detected in IL-1beta-treated fibroblasts .	target	1
12467	10725741	3553;6352	IL-1beta;RANTES	***IL-1beta*** also ***induces*** ***RANTES*** mRNA , protein , and activity , and most of the chemoattractant activity released from fibroblasts not derived from IL-16 can be attributed to RANTES .	target	1
12468	10725742	3458;4486	IFN-gamma;RON	TNF-alpha plus ***IFN-gamma*** ***abrogated*** macrophage ***RON*** expression , although individual cytokines had no significant effect .	negative	0
12469	10725742	7124;4486	TNF-alpha;RON	***TNF-alpha*** plus IFN-gamma ***abrogated*** macrophage ***RON*** expression , although individual cytokines had no significant effect .	negative	0
12470	10725744	7409;5588	Vav;protein kinase C theta	***Vav*** ***synergizes*** with ***protein kinase C theta*** to mediate IL-4 gene expression in response to CD28 costimulation in T cells .	parallel	0
12471	10725744	7409;3565	Vav;IL-4	***Vav*** synergizes with protein kinase C theta to ***mediate*** ***IL-4*** gene expression in response to CD28 costimulation in T cells .	target	0
12472	10725744	7409;3565	Vav;IL-4	The ***Vav/PKC*** theta-mediated synergistic ***activation*** of ***IL-4*** transcription was not inhibited by cyclosporin A.	positive	1
12473	10725745	3589;6772	IL-11;STAT1	***IL-11*** at 0.1 and 10 ng/ml ***induces*** tyrosine phosphorylation of STAT3 and ***STAT1*** , respectively , although maximal responses require 50 ng/ml .	target	1
12474	10725745	3589;6774	IL-11;STAT3	***IL-11*** at 0.1 and 10 ng/ml ***induces*** tyrosine phosphorylation of ***STAT3*** and STAT1 , respectively , although maximal responses require 50 ng/ml .	target	1
12475	10725748	3596;7852	IL-13;chemokine receptor	***IL-13*** and IL-4 strongly ***increased*** CXCR1 and CXCR2 ***chemokine receptor*** expression in human monocytes , macrophages , and dendritic cells .	positive	0
12476	10725748	3596;3577	IL-13;CXCR1	***IL-13*** and IL-4 strongly ***increased*** ***CXCR1*** and CXCR2 chemokine receptor expression in human monocytes , macrophages , and dendritic cells .	positive	0
12477	10725748	3596;3579	IL-13;CXCR2	***IL-13*** and IL-4 strongly ***increased*** CXCR1 and ***CXCR2*** chemokine receptor expression in human monocytes , macrophages , and dendritic cells .	positive	0
12478	10725748	3565;7852	IL-4;chemokine receptor	IL-13 and ***IL-4*** strongly ***increased*** CXCR1 and CXCR2 ***chemokine receptor*** expression in human monocytes , macrophages , and dendritic cells .	positive	0
12479	10725748	3565;3577	IL-4;CXCR1	IL-13 and ***IL-4*** strongly ***increased*** ***CXCR1*** and CXCR2 chemokine receptor expression in human monocytes , macrophages , and dendritic cells .	positive	0
12480	10725748	3565;3579	IL-4;CXCR2	IL-13 and ***IL-4*** strongly ***increased*** CXCR1 and ***CXCR2*** chemokine receptor expression in human monocytes , macrophages , and dendritic cells .	positive	0
12481	10725778	5368;7200	Nociceptin;TRH	The findings suggest that ***Nociceptin*** acts on the hypothalamus to ***stimulate*** ***TRH*** and TSH secretion .	positive	0
12482	10725797	1437;9332	GM-CSF;CD163	In contrast , dendritic differentiation in the presence of ***GM-CSF*** and IL-4 ***suppresses*** ***CD163*** mRNA and protein levels .	negative	1
12483	10725797	3565;9332	IL-4;CD163	In contrast , dendritic differentiation in the presence of GM-CSF and ***IL-4*** ***suppresses*** ***CD163*** mRNA and protein levels .	negative	1
12484	10725797	3586;9332	IL-10;CD163	Because an important function of CD163 in inflammation has been suggested , we investigated the influence of pro- and anti-inflammatory stimuli on CD163 expression and found a significant suppression by lipoposaccharide and IFN-gamma , whereas ***IL-10*** or dexamethasone strongly ***induced*** the expression of ***CD163*** .	target	1
12485	10725805	355;356	Fas;FasL	In this presentation we describe that human monocytes undergo spontaneous apoptosis in vitro which involves ******Fas/FasL****** ***interactions*** , and that proinflammatory cytokines such as tumor necrosis factor-alpha ( TNFalpha ) , interleukin-1beta and granulocyte-monocyte-colony-stimulating factor prevent spontaneous apoptosis .	parallel	1
12486	10725920	627;6853	brain-derived neurotrophic factor;synapsin I	In a synaptosomal preparation , ***brain-derived neurotrophic factor*** ( BDNF ) ***increased*** mitogen-activated protein ( MAP ) kinase-dependent ***synapsin I*** phosphorylation and acutely facilitated evoked glutamate release .	positive	0
12487	10726657	4193;7157	MDM2;p53 tumor suppressor	The ***p53 tumor suppressor*** is ***regulated*** by the ***MDM2*** oncoprotein through a negative feedback mechanism .	target	1
12488	10726657	4193;7157	MDM2;p53	***MDM2*** ***promotes*** the ubiquitination and proteasome-dependent degradation of ***p53*** , possibly by acting as a ubiquitin ligase .	positive	0
12489	10726657	4193;7157	MDM2;p53	In HPV-negative tumor cells , ***p53*** is ***activated*** by inhibition of ***MDM2*** but not E6-AP .	negative	1
12490	10726718	596;581	Bcl-2;Bax	CONCLUSIONS : The present work suggests that the presence of ******Bax-Bcl-2****** ***complexes*** in the left ventricle could be a more reliable marker of the apoptotic state than the determination of the absolute expression of Bcl-2 and Bax proteins .	parallel	1
12491	10726718	596;581	Bcl-2;Bax	We then determined the abundance of ******Bax-Bcl-2****** ***complexes*** in the left ventricle of the two groups of animals .	parallel	1
12492	10726718	596;581	Bcl-2;Bax	******Bax-Bcl-2****** ***complexes*** were more abundant in SHRs than WKY rats .	parallel	1
12493	10726718	581;596	Bax;Bcl-2	Doxazosin treatment reduced the formation of ******Bax-Bcl-2****** ***complexes*** in the left ventricle of SHRs , and this was accompanied by a decrease in the levels of 85kDa PARP and a reduction in apoptotic left ventricular cells .	parallel	1
12494	10726914	7040;213	TGF-beta1;albumin	Active ***TGF-beta1*** concentrations were ***correlated*** with urinary ***albumin*** excretion ( r = .49 , P < .003 ) and serum creatinine ( r = .55 , P < .01 ) .	parallel	0
12495	10726983	7040;581	TGF-beta1;Bax	***TGF-beta1*** ***increased*** ***Bax*** transcript level ( evaluated by Bax mRNA/GAPDH mRNA ratio ) and stimulated Bax protein movement from cytosol to organellar membranes , mainly mitochondrial , during 60 min .	positive	0
12496	10727020	596;4790	Bcl-2;NF-kappaB	***Suppression*** of transcription factor ***NF-kappaB*** activity by ***Bcl-2*** protein in NIH3T3 cells : implication of a novel NF-kappaB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2 .	negative	1
12497	10727020	4790;596	p50;Bcl-2	Suppression of transcription factor NF-kappaB activity by Bcl-2 protein in NIH3T3 cells : implication of a novel NF-kappaB ******p50-Bcl-2****** ***complex*** for the anti-apoptotic function of Bcl-2 .	parallel	1
12498	10727020	4790;596	NF-kappaB;Bcl-2	Surprisingly , we found that Bcl-2 delayed the release of IkB by formation of a ******Bcl-2-NF-kappaB****** ***complex*** ( p50-p65-IkappaB ) in the cytoplasm during cell apoptosis .	parallel	1
12499	10727020	4790;596	p50;Bcl-2	Furthermore , a novel ******Bcl-2-p50****** ***complex*** was found in the nucleus .	parallel	1
12500	10727020	596;4790	Bcl-2;NF-kappaB	Overexpression of ***Bcl-2*** suppressed the levels of c-myc , a target gene of NF-kappaB , and ***influenced*** the DNA-binding activity of ***NF-kappaB*** during GSNOinduced apoptosis .	target	0
12501	10727020	596;4609	Bcl-2;c-myc	Overexpression of ***Bcl-2*** ***suppressed*** the levels of ***c-myc*** , a target gene of NF-kappaB , and influenced the DNA-binding activity of NF-kappaB during GSNOinduced apoptosis .	negative	1
12502	10727020	4790;596	p50;Bcl-2	We suggest that the ******Bcl-2-p50****** ***complex*** inhibits NF-kappaB DNA-binding activity by competing with the p65-p50 heterodimer for the DNA-binding site in the nucleus .	parallel	1
12503	10727020	4790;5970	p50;p65	We suggest that the Bcl-2-p50 complex inhibits NF-kappaB DNA-binding activity by competing with the ******p65-p50****** ***heterodimer*** for the DNA-binding site in the nucleus .	parallel	1
12504	10727020	596;4790	Bcl-2;NF-kappaB	We suggest that the ***Bcl-2-p50*** complex ***inhibits*** ***NF-kappaB*** DNA-binding activity by competing with the p65-p50 heterodimer for the DNA-binding site in the nucleus .	negative	1
12505	10727212	2186;4150	Fetal Alz-50 clone 1 (FAC1) protein;ZF87	***Fetal Alz-50 clone 1 (FAC1) protein*** ***interacts*** with the Myc-associated zinc finger protein ( ***ZF87/MAZ*** ) and alters its transcriptional activity .	parallel	1
12506	10727212	4150;2186	MAZ;FAC1	These data demonstrate that ***interaction*** between ***FAC1*** and ***ZF87/MAZ*** alters the transactivation capacity of ZF87/MAZ .	parallel	1
12507	10727212	4150;4150	ZF87;MAZ	These data demonstrate that ***interaction*** between FAC1 and ******ZF87/MAZ****** alters the transactivation capacity of ZF87/MAZ .	parallel	1
12508	10727238	4023;344	LpL;apoC-II	We suggest that while the binding of apoC-II to the lipid surface promotes the formation of a high-affinity ***complex*** of ***apoC-II*** and ***LpL*** , activation occurs via direct helix-helix interactions between apoC-II39-62 and the loop covering the active site of LpL .	parallel	1
12509	10727296	7422;2321	vascular permeability factor;VEGFR-1	***vascular permeability factor/vascular endothelial growth factor*** ( VPF/VEGF ) ***interacts*** with two high-affinity tyrosine kinase receptors , ***VEGFR-1*** and VEGFR-2 , to increase microvascular permeability and induce angiogenesis .	parallel	1
12510	10727296	7422;3791	vascular permeability factor;VEGFR-2	***vascular permeability factor/vascular endothelial growth factor*** ( VPF/VEGF ) ***interacts*** with two high-affinity tyrosine kinase receptors , VEGFR-1 and ***VEGFR-2*** , to increase microvascular permeability and induce angiogenesis .	parallel	1
12511	10727401	284119;7707	polymerase I and transcript-release factor;BFCOL1	PTRF ( ***polymerase I and transcript-release factor*** ) is tissue-specific and ***interacts*** with the ***BFCOL1*** ( binding factor of a type-I collagen promoter ) zinc-finger transcription factor which binds to the two mouse type-I collagen gene promoters .	parallel	1
12512	10727406	3569;5595	IL-6;ERK-1	Although ***IL-6*** can ***activate*** ***ERK-1*** in HepG2 cells , STAT3 transactivation and Ser ( 727 ) phosphorylation were not reduced by using the MAP kinase/ERK kinase ( MEK ) inhibitor PD98059 or by overexpression of dominant-negative Raf .	positive	1
12513	10727406	6774;5599	STAT3;JNK-1	IL-6 did not activate JNK-1 in HepG2 cells and ***STAT3*** was a poor ***substrate*** for ***JNK-1*** activated by anisomycin , excluding a role for JNK1 in IL-6-induced STAT3 activation .	parallel	1
12514	10727406	5594;6774	p38;STAT3	Furthermore , inhibition of p38 kinase activity with the inhibitor SB203580 did not block STAT3 Ser ( 727 ) phosphorylation but rather increased both basal as well as IL-6-induced STAT3 transactivation , indicating that ***p38*** may act as a negative ***regulator*** of IL-6-induced ***STAT3*** transactivation through a presently unknown mechanism .	negative	1
12515	10727433	1435;1436	CSF-1;CSF-1R	Macrophage colony-stimulating factor ( ***CSF-1*** ) ***binds*** to a receptor ( ***CSF-1R*** ) encoded by the c-fms proto-oncogene and activates transcription of the urokinase plasminogen activator ( uPA ) gene in murine bone-marrow-derived macrophages .	parallel	1
12516	10727433	1435;5328	CSF-1;uPA	Macrophage colony-stimulating factor ( ***CSF-1*** ) binds to a receptor ( CSF-1R ) encoded by the c-fms proto-oncogene and ***activates*** transcription of the urokinase plasminogen activator ( ***uPA*** ) gene in murine bone-marrow-derived macrophages .	positive	1
12517	10727444	8803;211	SCS-betaA;ALAS	Using transient expression and coimmunoprecipitation , we verified that mitochodrially expressed ***SCS-betaA*** ***associates*** specifically with ***ALAS-E*** and not with ALAS-N .	parallel	0
12518	10727444	211;8803	ALAS;SCS-betaA	Furthermore , the ***ALAS-E*** mutants R411C and M426V ***associated*** with ***SCS-betaA*** , but the D190V mutant did not .	parallel	0
12519	10727444	211;8803	ALAS;SCS-betaA	Because the D190V mutant was identified in a patient with pyridoxine-refractory X-linked sideroblastic anemia , our findings suggest that appropriate ***association*** of ***SCS-betaA*** and ***ALAS-E*** promotes efficient use of succinyl CoA by ALAS-E or helps translocate ALAS-E into mitochondria .	parallel	0
12520	10727462	5934;1874	p130;E2F4	By gel shift analysis , we show that in mitogen-dependent normal melanocytes , external growth factors tightly controlled the levels of growth-promoting free E2F DNA binding activity , composed largely of E2F2 and E2F4 , and the growth-suppressive ******E2F4-p130****** ***complexes*** .	parallel	1
12521	10727463	3725;356	c-Jun;fas ligand	***Regulation*** of ***fas ligand*** expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and ***c-Jun*** NH2-terminal kinase .	target	1
12522	10727463	1432;356	p38 mitogen-activated protein kinase;fas ligand	***Regulation*** of ***fas ligand*** expression during activation-induced cell death in T cells by ***p38 mitogen-activated protein kinase*** and c-Jun NH2-terminal kinase .	target	1
12523	10727463	355;356	fas;fas ligand	Activation-induced cell death ( AICD ) is a mechanism of peripheral T cell tolerance that depends upon an ***interaction*** between ***fas*** and ***fas ligand*** ( FasL ) .	parallel	1
12524	10727463	5599;356	JNK;FasL	Thus , p38 MAPK and downstream ***JNK*** converge to ***regulate*** ***FasL*** expression at different times after T cell receptor stimulation to elicit maximum AICD .	target	1
12525	10727463	5594;356	p38;FasL	Thus , ***p38*** MAPK and downstream JNK converge to ***regulate*** ***FasL*** expression at different times after T cell receptor stimulation to elicit maximum AICD .	target	1
12526	10727853	4254;3815	Mgf;Kit	The tyrosine kinase receptor ***Kit*** and its ***ligand*** ***Mgf*** ( Steel Factor ) are essential for melanoblast survival and proliferation during their migration from the neural crest .	parallel	1
12527	10727856	652;7054	BMP 4;tyrosine hydroxylase	During differentiation of sympathetic neurons in chick embryos , ***tyrosine hydroxylase*** ( TH ) and dopamine beta-hydroxylase ( DBH ) mRNAs become detectable during the same developmental period and are both ***induced*** by ***BMP 4*** .	target	1
12528	10727952	23424;5128	Trap;PCTAIRE 2	***Trap*** ***associates*** with the N-terminal domain of ***PCTAIRE 2*** through its C-terminal domain , which contains two tudor-like domains .	parallel	0
12529	10727952	5127;23424	PCTAIRE 1;Trap	***PCTAIRE 1*** , but not PCTAIRE 3 , can also ***associate*** with ***Trap*** .	parallel	0
12530	10727981	3725;2099	c-jun;ERalpha	Although ***c-jun*** expression significantly ***correlated*** with ***ERalpha*** values for all squamous categories , it did not relate to pS2 status in either C-ACas or ISCCs .	parallel	0
12531	10727989	6347;729230	MCP-1;CCR2	The bronchiolar epithelial ***MCP-1*** mRNA expression ***correlated*** with both ***CCR2*** expression on macrophages and mast cells ( p < 0.05 ) and the numbers of intra-epithelial macrophages and mast cells ( p < 0.04 ) .	parallel	0
12532	10728028	5104;5624	protein C inhibitor;protein C	BACKGROUND : Since ***protein C inhibitor*** ( PCI ) ***inhibits*** activated ***protein C*** ( APC ) and a number of proteases , one would expect lower concentrations of PCI in a hypercoagulable state due to increased consumption of the inhibitor .	negative	1
12533	10728414	5997;2776	RGS2;G alpha q	RESULTS : The paired pre - and post-left ventricular assist device samples revealed that ***RGS2*** , a selective ***inhibitor*** of ***G alpha q*** , was decreased ( P < 0.01 ) , while the status of G alpha q , phospholipase C beta 1 , RGS3 and RGS4 were unchanged after left ventricular assist device implantation .	negative	1
12534	10728423	3753;3784	Isk;KvLQT1	The R243H , R533W and R539W mutations induced a positive voltage shift of the channel activation but only when co-expressed with Isk , pointing out the critical role of these positively charged residues in the ***modulation*** of the gating properties of ***KvLQT1*** by ***Isk*** .	target	0
12535	10728472	30816;1234	envelope glycoprotein;CCR5	Fusion of HIV with its host cell requires the ***interaction*** of the viral ***envelope glycoprotein*** 120 ( gp120 ) with the chemokine receptor CXCR4 [ T cell-tropic ( T-tropic ) or X4 HIV strains ] or ***CCR5*** [ macrophage-tropic ( M-tropic ) or R5 HIV strains ] followed by a ' spring-loaded ' action of the glycoprotein 41 ( gp41 ) that ensures fusion of the viral and cellular lipid membranes and permits the viral nucleocapsid to enter the cell .	parallel	1
12536	10728472	30816;7852	envelope glycoprotein;CXCR4	Fusion of HIV with its host cell requires the ***interaction*** of the viral ***envelope glycoprotein*** 120 ( gp120 ) with the chemokine receptor ***CXCR4*** [ T cell-tropic ( T-tropic ) or X4 HIV strains ] or CCR5 [ macrophage-tropic ( M-tropic ) or R5 HIV strains ] followed by a ' spring-loaded ' action of the glycoprotein 41 ( gp41 ) that ensures fusion of the viral and cellular lipid membranes and permits the viral nucleocapsid to enter the cell .	parallel	1
12537	10728593	2324;7424	VEGFR3;VEGFc	In adults , the ***interaction*** between ***VEGFc*** and ***VEGFR3*** ( previously FLT4 ) is more specifically involved in the biology of lymphatics .	parallel	1
12538	10728664	3725;3665	c-Jun;IRF7	Furthermore , ***IRF7*** was ***activated*** by the ***c-Jun*** NH2-terminal kinase ( JNK ) in response to DNA-damaging agents .	positive	1
12539	10728664	5599;3665	JNK;IRF7	Furthermore , ***IRF7*** was ***activated*** by the c-Jun NH2-terminal kinase ( ***JNK*** ) in response to DNA-damaging agents .	positive	1
12540	10728664	6416;5599	mitogen-activated protein kinase kinase-4;JNK	***Activation*** of ***JNK*** by ***mitogen-activated protein kinase kinase-4*** stimulated the transcriptional activity of IRF7 and induced its translocation into the nucleus .	positive	1
12541	10728664	5599;3665	JNK;IRF7	Activation of ***JNK*** by mitogen-activated protein kinase kinase-4 ***stimulated*** the transcriptional activity of ***IRF7*** and induced its translocation into the nucleus .	positive	0
12542	10728664	5599;3665	JNK;IRF7	Thus , ***activation*** of ***IRF7*** through the ***JNK*** signaling pathway may play a role in the transcriptional regulation of genes in response to DNA-damaging agents .	positive	1
12543	10728713	5728;207	PTEN;Akt	We postulate that negative ***regulation*** of the PI ***3-K/Akt*** pathway by ***PTEN*** may modulate the effects of the hyperactive epidermal growth factor receptor/mitogen-activated protein kinase pathway , contributing to the low proliferation and dysfunctional differentiation of laryngeal papillomas .	negative	1
12544	10728907	4915;627	TRKB;BDNF	***TRKB*** is the ***receptor*** for ***BDNF*** .	parallel	1
12545	10728932	3553;4586	IL-1beta;mucin	A mixture of TNF-alpha and ***IL-1beta*** synergistically ***increased*** secretion of ***mucin*** , IL-6 and IL-8 , but did not increase secretion of lysozyme .	positive	0
12546	10728932	7124;4586	TNF-alpha;mucin	A mixture of ***TNF-alpha*** and IL-1beta synergistically ***increased*** secretion of ***mucin*** , IL-6 and IL-8 , but did not increase secretion of lysozyme .	positive	0
12547	10729153	3661;6352	IRF-3;RANTES	Once activated , ***IRF-3*** transcriptionally up ***regulates*** alpha/beta interferon genes , the chemokine ***RANTES*** , and potentially other genes that inhibit viral infection .	target	1
12548	10729197	6046;1583	hFSH;P450scc	Moreover , ***hFSH*** ***induced*** ***P450scc*** gene expression in cells with and without a TIC gel overlay .	target	1
12549	10729302	7040;5054	TGF-beta;PAI-1	CONCLUSIONS : These data demonstrate that ***TGF-beta*** ***increases*** ***PAI-1*** and decreases cell associated lysis .	positive	0
12550	10729720	7124;1441	TNF-alpha;G-CSF receptor	***TNF-alpha*** , however , ***down-regulated*** ***G-CSF receptor*** expression .	negative	1
12551	10729720	1440;1441	G-CSF;G-CSF receptor	Furthermore , ***G-CSF receptor*** expression on neutrophils was ***modified*** not only by ***G-CSF*** itself , but also by TNF-alpha .	target	0
12552	10729921	7157;596	p53;bcl-2	Grade I and III tumors displayed an inverse ***association*** between the apoptotic index and ***bcl-2*** and ***p53*** protein expressions ; grade I tumors frequently expressed bcl-2 ( 19/28 ) , lacked p53 ( 20/28 ) , and presented a low number of apoptotic cells ( 18/28 ) , whereas grade III tumors tended to express p53 ( 12/17 ) , lacked bcl-2 ( 13/17 ) , and displayed a high number of apoptotic cells/10HPF ( 12/17 ) .	parallel	0
12553	10731036	1432;5321	p38 MAP kinase;cPLA2	The inhibition of ***p38 MAP kinase*** ***inhibited*** PGE2 synthesis , ***cPLA2*** phosphorylation and abolished Cox-2 expression .	positive	1
12554	10731102	3569;1588	IL-6;aromatase	PGE2 , TNFalpha and ***IL-6*** plus its soluble receptor ( IL-6sR ) all ***increased*** ***aromatase*** activity in these cells .	positive	0
12555	10731102	7124;1588	TNFalpha;aromatase	PGE2 , ***TNFalpha*** and IL-6 plus its soluble receptor ( IL-6sR ) all ***increased*** ***aromatase*** activity in these cells .	positive	0
12556	10731148	10207;2890	PDZ domain protein;GluR1	These results show that LTP and CaMKII activity drive AMPA-Rs to synapses by a mechanism that requires the ***association*** between ***GluR1*** and a ***PDZ domain protein*** .	parallel	0
12557	10731439	3553;5970	IL-1 beta;RelA	***IL-1 beta*** is a powerful ***stimulator*** of I kappaB alpha degradation , ***RelA*** nuclear import , and isoform specific NF kappaB enhancer binding in vitro , responses that are not detectable after P2Y receptor stimulation .	positive	0
12558	10731482	7124;3552	TNF-alpha;IL-1alpha	Since it is well established that ***TNF-alpha*** is able to ***induce*** the synthesis of ***IL-1alpha*** in endothelial cells and , as shown in the present study , TNF-alpha and IL-1alpha are themselves able to induce the synthesis of TNF-alpha in endothelial cells , an autocrine potentiation of cytokine release in sepsis can be proposed .	target	1
12559	10731482	3552;7124	IL-1alpha;TNF-alpha	Since it is well established that TNF-alpha is able to induce the synthesis of IL-1alpha in endothelial cells and , as shown in the present study , TNF-alpha and ***IL-1alpha*** are themselves able to ***induce*** the synthesis of ***TNF-alpha*** in endothelial cells , an autocrine potentiation of cytokine release in sepsis can be proposed .	target	1
12560	10731686	3553;3569	IL-1beta;IL-6	Moreover , exogenous ***IL-1beta*** ***stimulated*** ***IL-6*** mRNA expression in hepatocytes .	positive	0
12561	10731694	4192;596	Midkine;Bcl-2	Midkine rescues Wilms ' tumor cells from cisplatin-induced apoptosis : ***regulation*** of ***Bcl-2*** expression by ***Midkine*** .	target	1
12562	10731697	836;831	caspase-3;calpastatin	The full-length recombinant ***calpastatin*** was also ***cleaved*** by ***caspase-3*** or caspase-7 at Asp-233 into the same size fragment .	target	1
12563	10731697	840;831	caspase-7;calpastatin	The full-length recombinant ***calpastatin*** was also ***cleaved*** by caspase-3 or ***caspase-7*** at Asp-233 into the same size fragment .	target	1
12564	10731717	3565;2353	interleukin-4;c-fos	Suppression of prostaglandin E ( 2 ) - mediated ***c-fos*** mRNA ***induction*** by ***interleukin-4*** in murine macrophages .	target	1
12565	10731717	3565;2353	IL-4;c-fos	We also showed that the tyrosine phosphorylation of a Janus kinase , JAK3 , is enhanced by IL-4 treatment , suggesting that the PGE ( 2 ) - mediated ***c-fos*** mRNA induction is ***inhibited*** by ***IL-4*** through the tyrosine phosphorylation of JAK3 .	negative	1
12566	10731723	196;7514	AhR;CRM1	The ***interaction*** between chromosome region maintenance 1 ( ***CRM1*** ) and endogenous ***AhR*** was shown by immunoprecipitation with antibodies to AhR followed by immunoblot analysis with antibodies to CRM1 .	parallel	1
12567	10731724	4792;4790	IkappaBalpha;NF-kappaB	In the present study , we examined the effects of an overexpression of ***IkappaBalpha*** , a specific natural ***inhibitor*** of ***NF-kappaB*** , on CINC-1 production .	negative	1
12568	10731922	3953;3952	Ob-R;leptin	Expression of ***leptin*** ***receptor*** ( ***Ob-R*** ) in human atherosclerotic lesions : potential role in intimal neovascularization .	parallel	1
12569	10732316	3553;7422	interleukin-1 beta;vascular endothelial growth factor	Periovulatory and ***interleukin-1 beta-dependent*** ***up-regulation*** of intraovarian ***vascular endothelial growth factor*** ( VEGF ) in the rat : potential role for VEGF in the promotion of periovulatory angiogenesis and vascular permeability .	positive	1
12570	10732674	990;8556	CDC6;CDC14	We found genetic ***interactions*** between ***CDC14*** and the replication initiator gene ***CDC6*** , extending previous observations of interactions between the late mitotic function of Cdc14p and control of DNA replication .	parallel	1
12571	10732758	1543;6317	CYP1A1;SCC	A combination of susceptible ***CYP1A1*** and HYL1 genotypes was found to be highly ***associated*** with lung cancer , especially with ***SCC*** ( OR 6.76 ; 95 % CI 2.29-19 .10 ) .	parallel	0
12572	10732770	4233;3082	c-met;HGF	As a step to investigate mechanisms underlying subsequent intestinal repair , we have examined the expression profiles of hepatocyte growth factor ( ***HGF*** ) and its ***receptor*** ***c-met*** , two molecules previously implicated in tissue repair , in comparison to the histopathological and proliferative changes in a rat model of methotrexate-induced small intestinal mucositis .	parallel	1
12573	10732782	581;598	Bax;Bcl-XL	Etoposide diminished the ***binding*** between ***Bax*** and ***Bcl-XL*** but this was restored by IL-4 and VCAM-1 triggered signals .	parallel	1
12574	10732823	7852;6387	CXCR4;pre-B cell growth stimulating factor	This report reviews the physiological roles of chemokines and their receptors in the context of hematopoietic cell regulation , with particular focus on the involvement of stromal cell derived factor ( SDF ) -1 / ***pre-B cell growth stimulating factor*** ( PBSF ) and its ***receptor*** ***CXCR4*** .	parallel	1
12575	10733100	3458;5806	IFN-gamma;TSG-14	***Inhibition*** of LPS-induced ***TSG-14*** mRNA expression by ***IFN-gamma*** in macrophages was also observed in the presence of cycloheximide and in cells from STAT1 null mice , suggesting that IFN-gamma inhibits TSG-14 expression through an unconventional mechanism .	negative	1
12576	10733100	3458;5806	IFN-gamma;TSG-14	Inhibition of LPS-induced TSG-14 mRNA expression by IFN-gamma in macrophages was also observed in the presence of cycloheximide and in cells from STAT1 null mice , suggesting that ***IFN-gamma*** ***inhibits*** ***TSG-14*** expression through an unconventional mechanism .	negative	1
12577	10733100	3553;5806	IL-1;TSG-14	TNF and interleukin-1 ( ***IL-1*** ) potently ***induced*** ***TSG-14*** expression in 3T3 fibroblasts but not in peritoneal macrophages .	target	1
12578	10733100	3458;5806	interferon-gamma;TSG-14	Finally , ***interferon-gamma*** ( IFN-gamma ; but not IFN-alpha/beta ) ***inhibited*** LPS-induced ***TSG-14*** expression in macrophages and not in 3T3 fibroblasts .	negative	1
12579	10733345	3084;2065	HRG;HER3	Remarkably ***HER3*** ***activation*** by ***HRG*** could occurs independent of HER2 , and in one cell line almost no HER4 activation by HRG was detected despite high levels expression .	positive	1
12580	10733495	1440;3458	G-CSF;IFN-gamma	These results suggest that ***G-CSF*** ***decreases*** ***IFN-gamma*** and increases IL-4 production in vitro and in vivo and likely modulates a balance between TH1 and TH2 cells , an effect that may be important in PBSC transplantation .	negative	0
12581	10733495	1440;3565	G-CSF;IL-4	These results suggest that ***G-CSF*** decreases IFN-gamma and ***increases*** ***IL-4*** production in vitro and in vivo and likely modulates a balance between TH1 and TH2 cells , an effect that may be important in PBSC transplantation .	positive	0
12582	10733496	7422;652	Vascular endothelial growth factor;BMP-4	Here , we demonstrate that BMP-4 is essential for generating both erythro-myeloid colony-forming cells ( CFCs ) and lymphoid ( B and NK ) progenitor cells from ES cells and that ***Vascular endothelial growth factor*** ( VEGF ) ***synergizes*** with ***BMP-4*** .	parallel	0
12583	10733502	8888;4172	GANP;MCM3	A novel nuclear phosphoprotein , ***GANP*** , is up-regulated in centrocytes of the germinal center and ***associated*** with ***MCM3*** , a protein essential for DNA replication .	parallel	0
12584	10733502	8888;4172	GANP;MCM3	Remarkably , ***GANP*** is ***associated*** with MCM3 in B cells and ***MCM3*** is also up-regulated in the GC area .	parallel	0
12585	10733514	5594;85366	ERK2;MLCK	These results are consistent with the interpretation that MEK activates ERK , ***ERK2*** then ***activates*** ***MLCK*** , and MLCK activates myosin .	positive	1
12586	10733514	5594;4638	ERK;myosin light chain kinase	We hypothesized that ***myosin light chain kinase*** ( MLCK ) could be ***phosphorylated*** and activated by ***ERK*** , thereby linking the MAP kinase pathway to the activation of cytoskeletal components required for pseudopod formation .	target	1
12587	10733514	5594;85366	ERK;MLCK	To directly ***link*** ***ERK*** activation to ***MLCK*** activation , ERK2 was immunoprecipitated from PMNLs after EIgG ingestion .	parallel	0
12588	10733515	3385;4478	ICAM-3;moesin	Direct ***interaction*** of the cytoplasmic domains of ***ICAM-3*** and PSGL-1 with the amino-terminal domain of recombinant ***moesin*** was demonstrated by protein-protein binding assays .	parallel	1
12589	10733518	7292;7293	CD134L;CD134	We investigated the role of interaction between CD134 and ***CD134*** ***ligand*** ( ***CD134L*** ) in a murine model of acute GVHD by using a newly established monoclonal antibody ( mAb ) against murine CD134L .	parallel	1
12590	10733518	7292;7293	CD134L;CD134	We investigated the role of ***interaction*** between ***CD134*** and CD134 ligand ( ***CD134L*** ) in a murine model of acute GVHD by using a newly established monoclonal antibody ( mAb ) against murine CD134L .	parallel	1
12591	10733518	7292;7293	CD134L;CD134	These results suggest that ******CD134-CD134L****** ***interactions*** have an important role in the pathogenesis of acute GVHD .	parallel	1
12592	10733526	51343;991	Cdh1;Cdc20	Vertebrate ***Cdc20*** lacks a D box and therefore is ***recognized*** by ***Cdh1-APC*** through a different sequence .	target	1
12593	10733528	9575;1628	CLOCK;DBP	***CLOCK*** , an essential pacemaker component , ***controls*** expression of the circadian transcription factor ***DBP*** .	target	0
12594	10733528	1628;9575	DBP;CLOCK	Here we present evidence that circadian ***DBP*** transcription ***requires*** the basic helix-loop-helix-PAS protein ***CLOCK*** , an essential component of the negative-feedback circuitry generating circadian oscillations in mammals and fruit flies .	target	0
12595	10733528	9575;1628	CLOCK;DBP	Genetic and biochemical experiments suggest that ***CLOCK*** ***regulates*** ***DBP*** expression by binding to E-box motifs within putative enhancer regions located in the first and second introns .	target	1
12596	10733530	7157;64065	p53;PERP	Furthermore , analysis of the PERP promoter suggests that ***PERP*** is directly ***activated*** by ***p53*** .	positive	1
12597	10733556	125;126	ADH2;ADH3	Genetic polymorphism of alcohol dehydrogenase in europeans : the ***ADH2*** * 2 allele decreases the risk for alcoholism and is ***associated*** with ***ADH3*** * 1 .	parallel	0
12598	10733566	1147;3551	IKKalpha;IKKbeta	In contrast to IKKalpha , IKKalpha-DeltaLH failed to associate with either itself , IKKalpha , IKKbeta , or NEMO-IKKgamma-IKKAP1 , while ***IKKalpha-DeltaH*** ***complexed*** with ***IKKbeta*** and IKKalpha but not with NEMO .	parallel	1
12599	10733570	1026;2033	p21;p300	A novel transcriptional repression domain mediates ***p21*** ( WAF1/CIP1 ) ***induction*** of ***p300*** transactivation .	target	1
12600	10733570	1026;1319	p21;CRD1	Significantly ***p21*** ***regulation*** of ***CRD1*** is dependent on the nature of the core promoter .	target	1
12601	10733571	4790;598	NF-kappaB;Bcl-x	The ***Rel/NF-kappaB*** family directly ***activates*** expression of the apoptosis inhibitor ***Bcl-x*** ( L ) .	positive	1
12602	10733571	5966;598	Rel;Bcl-x	The ***Rel/NF-kappaB*** family directly ***activates*** expression of the apoptosis inhibitor ***Bcl-x*** ( L ) .	positive	1
12603	10733571	5966;598	c-Rel;Bcl-x	While ***Bcl-x*** ( L ) was significantly ***upregulated*** by ***c-Rel*** and RelA , Bcl-2 was not .	positive	1
12604	10733571	5970;598	RelA;Bcl-x	While ***Bcl-x*** ( L ) was significantly ***upregulated*** by c-Rel and ***RelA*** , Bcl-2 was not .	positive	1
12605	10733573	440275;1965	Gcn2;eIF-2alpha	In the yeast Saccharomyces cerevisiae , starvation for amino acids induces ***phosphorylation*** of ***eIF-2alpha*** by ***Gcn2*** protein kinase , leading to elevated translation of GCN4 , a transcriptional activator of more than 50 genes .	target	1
12606	10733575	5923;207	Cdc25;Rac	The DH and ***Cdc25*** domains possess guanine nucleotide exchange factor ( GEF ) activity and ***interact*** with ***Rac*** and Ras , respectively .	parallel	1
12607	10733577	79930;1445	Dok-3;Csk	This phosphorylation induces the ***binding*** of ***Dok-3*** to at least two inhibitory molecules , the 5 ' inositol phosphatase SHIP and the protein tyrosine kinase ***Csk*** .	parallel	1
12608	10733589	5819;4301	nectin-2;l-afadin	***nectin-2*** is a component of cell-cell adherens junctions and ***interacts*** with ***l-afadin*** , an F-actin-binding protein .	parallel	1
12609	10733668	5340;4312	Plasmin;MMP-1	Western blot analyses of conditioned medium demonstrated that fibroblasts in collagen lattices secreted the latent matrix metalloproteinase , ***MMP-1*** , which was subsequently ***cleaved*** by ***Plasmin*** .	target	1
12610	10733892	8833;471	glutamine amidotransferase;AICAR	Imidazole glycerol phosphate ( IGP ) synthase is a ***glutamine amidotransferase*** that ***catalyzes*** the formation of IGP and 5-aminoimidazole-4-carboxamide ribonucleotide ( ***AICAR*** ) from N ( 1 ) - [ ( 5 ' - phosphoribulosyl ) formimino ] -5 - aminoimidazole-4-car boxamide ribonucleotide ( PRFAR ) .	positive	1
12611	10733899	3659;1387	interferon regulatory factor 1;CREB-binding protein	Viral ***interferon regulatory factor 1*** of Kaposi 's sarcoma-associated herpesvirus ( human herpesvirus 8 ) binds to , and ***inhibits*** transactivation of , ***CREB-binding protein*** .	negative	1
12612	10733912	5594;7422	p38;vascular endothelial growth factor	Different ***regulation*** of ***vascular endothelial growth factor*** expression by the ERK and ***p38*** kinase pathways in v-ras , v-raf , and v-myc transformed cells .	target	1
12613	10733921	3479;207	IGF-1;Akt	***Akt*** was ***activated*** by insulin or ***IGF-1*** , but not IFNalpha , in the IFNalpha-sensitive U-266 myeloma cell line .	positive	1
12614	10733921	3479;207	IGF-1;Akt	Furthermore , the selective ***activation*** of ***Akt*** by ***insulin/IGF-1*** suggests the existence of distinct regulatory activities of PI3 ' - kinase in growth factor versus interferon signaling .	positive	1
12615	10733921	3439;3667	IFNalpha;IRS-1	Our data demonstrate that IFNalpha induces the interaction of p85 with IRS-1 or IRS-2 , but not Stat-3 , in various hematopoietic cell lines in which ***IRS-1*** and/or IRS-2 and Stat-3 are ***activated*** by ***IFNalpha*** .	positive	1
12616	10733921	3439;8660	IFNalpha;IRS-2	Our data demonstrate that IFNalpha induces the interaction of p85 with IRS-1 or IRS-2 , but not Stat-3 , in various hematopoietic cell lines in which IRS-1 and/or ***IRS-2*** and Stat-3 are ***activated*** by ***IFNalpha*** .	positive	1
12617	10733921	3439;6774	IFNalpha;Stat-3	Our data demonstrate that IFNalpha induces the interaction of p85 with IRS-1 or IRS-2 , but not Stat-3 , in various hematopoietic cell lines in which IRS-1 and/or IRS-2 and ***Stat-3*** are ***activated*** by ***IFNalpha*** .	positive	1
12618	10733938	399687;3718	MAJN;Jak3	A novel protein ***MAJN*** ***binds*** to ***Jak3*** and inhibits apoptosis induced by IL-2 deprival .	parallel	1
12619	10733938	399687;3718	MAJN;Jak3	The ***interaction*** between ***Jak3*** and ***MAJN*** was further confirmed by immunoprecipitation in BAF-B03 beta cells .	parallel	1
12620	10733939	953;3553	CD39;IL-1	***CD39*** ***modulates*** ***IL-1*** release from activated endothelial cells .	target	0
12621	10733939	953;3552	CD39;IL-1alpha	Overexpression of ***CD39*** following infection with recombinant CD39 adenoviral vectors ( AdCD39 ) abrogated the initial phase of ATP secretion and ***inhibited*** ***IL-1alpha*** release ; comparable results were obtained with soluble NTPDase .	negative	1
12622	10733939	953;3552	CD39;IL-1alpha	These data demonstrate that ***CD39/NTPDase*** ***modulates*** ***IL-1alpha*** release from LPS stimulated human EC .	target	0
12623	10733942	6647;652	homodimer;BMP-4	Previously we have shown that blocking bone morphogenetic protein ( BMP ) receptor signaling by a dominant negative BMP receptor causes neurogenesis in Xenopus animal caps ( ACs ) , whereas the physiological neural inducer noggin acts as a ***homodimer*** physically ***binding*** to ***BMP-4*** and disrupting its signaling at the ligand level .	parallel	1
12624	10733943	2150;4586	protease-activated receptor-2;mucin	Activation of ***protease-activated receptor-2*** ( PAR-2 ) ***triggers*** ***mucin*** secretion in the rat sublingual gland .	positive	0
12625	10733944	3725;1026	c-jun;p21	Previously , we found that ***c-jun*** ***represses*** the tumor suppressor ***p21*** ( ( Waf1/Cip1/Sdi1 ) ) ( p21 ) gene expression .	negative	1
12626	10733944	3725;1026	c-jun;p21	However , the data from electrophoretic mobility shift assay indicated that c-jun did not change the Sp1 DNA-binding affinity , suggesting that additional factors may be involved in the ***repression*** of ***p21*** by ***c-jun*** .	negative	1
12627	10733944	3725;1026	c-jun;p21	Furthermore , c-jun could inhibit butyrate-inducing p21 gene expression through Sp1 , indicating at least one common pathway whereby ***p21*** expression is ***affected*** by ***c-jun*** and butyrate in opposing actions .	target	0
12628	10733944	3725;1026	c-jun;p21	Furthermore , ***c-jun*** could ***inhibit*** butyrate-inducing ***p21*** gene expression through Sp1 , indicating at least one common pathway whereby p21 expression is affected by c-jun and butyrate in opposing actions .	negative	1
12629	10734051	4018;948	lipoprotein;CD36	The ***binding*** of oxidized low density ***lipoprotein*** to mouse ***CD36*** is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein .	parallel	1
12630	10734051	948;338	CD36;apoB	This model of an oxidized phospholipid was also an effective competitor for the ***CD36*** ***binding*** of both the resolubilized ***apoB*** and the lipid microemulsions from OxLDL .	parallel	1
12631	10734053	1437;6383	GM-CSF;Syndecan-2	Our results indicate functional ***interactions*** between ***Syndecan-2*** and ***GM-CSF*** in osteoblasts , and we propose that Syndecan-2 plays a role as a co-receptor for this cytokine .	parallel	1
12632	10734053	6383;1437	Syndecan-2;GM-CSF	***Syndecan-2*** also co-localized at the cell surface and ***co-immunoprecipitated*** with the ***GM-CSF*** receptor alpha chain , suggesting a strong interaction between the cytokine , its receptor , and Syndecan-2 .	parallel	1
12633	10734056	3576;3577	interleukin-8;CXCR1	***interleukin-8*** ***stimulation*** of ***CXCR1*** or CXCR2 cross-phosphorylated CCR1 and cross-desensitized its ability to stimulate GTPase activity and Ca ( 2 + ) mobilization .	positive	0
12634	10734056	3576;3579	interleukin-8;CXCR2	***interleukin-8*** ***stimulation*** of CXCR1 or ***CXCR2*** cross-phosphorylated CCR1 and cross-desensitized its ability to stimulate GTPase activity and Ca ( 2 + ) mobilization .	positive	0
12635	10734059	7124;338	Tumor necrosis factor-alpha;apolipoprotein B	***Tumor necrosis factor-alpha*** and interleukin-1beta ***inhibit*** ***apolipoprotein B*** secretion in CaCo-2 cells via the epidermal growth factor receptor signaling pathway .	negative	1
12636	10734059	3553;338	IL-1beta;apolipoprotein B	TNF-alpha and ***IL-1beta*** significantly ***decreased*** the basolateral secretion of ***apolipoprotein B*** ( apoB ) mass , with IL-1beta being more potent .	negative	0
12637	10734059	7124;338	TNF-alpha;apolipoprotein B	***TNF-alpha*** and IL-1beta significantly ***decreased*** the basolateral secretion of ***apolipoprotein B*** ( apoB ) mass , with IL-1beta being more potent .	negative	0
12638	10734067	4193;7157	Mdm2;p53	Stabilization is thought to involve disruption of the ***interaction*** between the ***p53*** protein and ***Mdm2*** , which targets p53 for degradation .	parallel	1
12639	10734067	4193;7157	Mdm2;p53	Here we show that the direct ***association*** between a ***p53*** N-terminal peptide and ***Mdm2*** is disrupted by phosphorylation of the peptide on Thr ( 18 ) but not by phosphorylation at other N-terminal sites , including Ser ( 15 ) and Ser ( 37 ) .	parallel	0
12640	10734073	836;1981	caspase 3;eIF4G	Recently , the ***cleavage*** of eukaryotic translation initiation factor 4G ( ***eIF4G*** ) by ***caspase 3*** was described as a possible event contributing to translation inhibition .	target	1
12641	10734073	836;1965	caspase 3;eIF2	The ***eIF2.GDP*** binary complex was ***cleaved*** much less efficiently by ***caspase 3*** .	target	1
12642	10734088	2624;2623	GATA-2;GATA-1	These results suggest that GATA-1 is an activator and that ***GATA-2*** is a relative competitive ***inhibitor*** of ***GATA-1*** in the expression of the gp91 ( phox ) gene in human eosinophils .	negative	1
12643	10734122	7124;5130	TNFalpha;CCTalpha	***TNFalpha-induced*** ***degradation*** of ***CCTalpha*** protein was partially blocked by ALLN or lactacystin .	negative	1
12644	10734125	355;836	Fas;caspase-3	Inhibition of actin polymerization using latrunculin A reduced the ability of constitutively active GTPase mutants to stimulate apoptosis and blocked ***Fas-induced*** ***activation*** of ***caspase-3*** .	positive	1
12645	10734128	1958;3972	NGFI-A;luteinizing hormone beta (LHbeta) subunit	The ***EGR1/NGFI-A*** transcription factor directly ***activates*** the ***luteinizing hormone beta (LHbeta) subunit*** promoter , and female mice lacking EGR1 are infertile due to LHbeta deficiency .	positive	1
12646	10734130	4609;356	c-Myc;Fas ligand	Expression of ***Fas ligand*** in activated T cells is ***regulated*** by ***c-Myc*** .	target	1
12647	10734130	4609;356	c-Myc;Fas ligand	Here we demonstrate that T cell activation-induced expression of ***Fas ligand*** ( FasL , CD95-L , APO-1-L ) , which can induce apoptotic cell death in many different cell types , is ***regulated*** by ***c-Myc*** .	target	1
12648	10734131	6688;7099	PU.1;Toll-like receptor 4	***PU.1*** and interferon consensus sequence-binding protein ***regulate*** the myeloid expression of the human ***Toll-like receptor 4*** gene .	target	1
12649	10734135	65268;5599	mitogen-activated protein kinase kinase kinase;JNK	Apoptosis signal-regulating kinase 1 ( ASK1 ) is a ubiquitously expressed ***mitogen-activated protein kinase kinase kinase*** that ***activates*** the c-Jun N-terminal kinase ( ***JNK*** ) and p38 mitogen-activated protein kinase signaling cascades .	positive	1
12650	10734135	65268;1432	mitogen-activated protein kinase kinase kinase;p38 mitogen-activated protein kinase	Apoptosis signal-regulating kinase 1 ( ASK1 ) is a ubiquitously expressed ***mitogen-activated protein kinase kinase kinase*** that ***activates*** the c-Jun N-terminal kinase ( JNK ) and ***p38 mitogen-activated protein kinase*** signaling cascades .	positive	1
12651	10734137	9066;10492	Syt-VII;SYNCRIP	Here , we report that ubiquitous isoforms of synaptotagmins , ***Syt-VII*** , Syt-VIII , and Syt-IX , ***interacted*** with a cytoplasmic RNA-binding protein , ***SYNCRIP*** ( Synaptotagmin-binding , cytoplasmic RNA-interacting protein ) , through their C2B domains .	parallel	1
12652	10734137	9066;10492	Syt-VII;SYNCRIP	Furthermore , the ***interaction*** between ***SYNCRIP*** and ***Syt-VII*** , - VIII , or - IX was revealed by co-immunoprecipitation experiments using COS cells transiently expressing each Syt isoform .	parallel	1
12653	10734140	6714;5335	c-Src;PLC-gamma1	Moreover , LTD ( 4 ) induced an increased ***association*** of ***c-Src*** with ***PLC-gamma1*** , and the selective Src family tyrosine kinase inhibitor PP1 blocked both LTD ( 4 ) - induced tyrosine phosphorylation of PLC-gamma1 and the association of PLC-gamma1 with Gbetagamma subunits .	parallel	0
12654	10734143	5887;7508	HR23B;XPC	We conclude that the ******XPC-HR23B****** protein ***complex*** plays a crucial role in the recruitment of TFIIH to damaged DNA in global genome repair .	parallel	1
12655	10734145	8517;4790	FIP3;NF-kappaB	***FIP3*** has also been shown to ***repress*** basal and tumor necrosis factor (TNF) alpha-induced ***NF-kappaB*** activity as well as to induce cell death when overexpressed .	negative	1
12656	10734145	8517;4790	FIP3;NF-kappaB	We also found that the carboxyl-terminal half of FIP3 blocked TNFalpha-induced IkappaB-alpha phosphorylation and subsequent degradation , which suggests that the stabilization of the cytoplasmic inhibitor of NF-kappaB underlies the ***FIP3*** ***inhibition*** of ***NF-kappaB*** activity .	negative	1
12657	10734145	8517;4792	FIP3;IkappaB-alpha	We also found that the carboxyl-terminal half of ***FIP3*** ***blocked*** TNFalpha-induced ***IkappaB-alpha*** phosphorylation and subsequent degradation , which suggests that the stabilization of the cytoplasmic inhibitor of NF-kappaB underlies the FIP3 inhibition of NF-kappaB activity .	negative	0
12658	10734145	8517;1147	FIP3;IKKalpha	The amino-terminal 119 amino acids were responsible for the FIP3-IKKbeta and ******FIP3-IKKalpha****** ***interaction*** , and the middle of the protein ( amino acids 201-300 ) appeared to be both the FIP3 self-association domain as well as the FIP3-Fas receptor-interacting protein interaction domain .	parallel	1
12659	10734145	8517;3551	FIP3;IKKbeta	The amino-terminal 119 amino acids were responsible for the ******FIP3-IKKbeta****** and FIP3-IKKalpha ***interaction*** , and the middle of the protein ( amino acids 201-300 ) appeared to be both the FIP3 self-association domain as well as the FIP3-Fas receptor-interacting protein interaction domain .	parallel	1
12660	10734218	820;627	cAMP;BDNF	The expression of ***BDNF*** was ***up-regulated*** by elevation of intracellular ***cAMP*** and down-regulated by Ca ( 2 + ) ionophore , bovine brain extract and laminar fluid shear stress .	positive	1
12661	10734227	1029;1019	INK4;CDK4	We report that the ***INK4*** proteins share the ability to arrest cells in G1 , and ***interact*** with ***CDK4*** or CDK6 with similar avidity .	parallel	1
12662	10734227	1029;1021	INK4;CDK6	We report that the ***INK4*** proteins share the ability to arrest cells in G1 , and ***interact*** with CDK4 or ***CDK6*** with similar avidity .	parallel	1
12663	10734230	2331;4060	Fibromodulin;lumican	Using a collagen fibril formation/sedimentation assay we show that ***Fibromodulin*** ***inhibits*** the binding of ***lumican*** , and vice versa .	negative	1
12664	10734230	4060;2331	lumican;Fibromodulin	Fibromodulin and lumican do not affect the binding of decorin to collagen , nor does decorin inhibit the ***binding*** of ***Fibromodulin*** or ***lumican*** .	parallel	1
12665	10734230	1634;2331	decorin;Fibromodulin	Fibromodulin and lumican do not affect the binding of decorin to collagen , nor does ***decorin*** ***inhibit*** the binding of ***Fibromodulin*** or lumican .	negative	1
12666	10734230	1634;4060	decorin;lumican	Fibromodulin and lumican do not affect the binding of decorin to collagen , nor does ***decorin*** ***inhibit*** the binding of Fibromodulin or ***lumican*** .	negative	1
12667	10734235	8880;6606	FBP;SMN	***FBP*** overexpressed in HEK293 cells or endogenously expressed in fetal and adult mouse brain ***bound*** specifically in vitro to recombinant ***SMN*** protein .	parallel	1
12668	10734310	4233;2549	HGF receptor;GRB2 Associated Binder-1	The ***HGF receptor*** directly activates PI3 kinase , Ras and STAT signalling pathways and ***phosphorylates*** the adaptator ***GRB2 Associated Binder-1*** ( Gab1 ) .	target	1
12669	10734310	3082;2549	HGF;Gab1	However , while both EGF and ***HGF*** ***induce*** rapid tyrosine phosphorylation of ***Gab1*** with a peak at 15 min , the phosphorylation persists for over 1 h , only in response to HGF .	target	1
12670	10734313	10771;9611	BS69;N-CoR	***BS69*** ***interacts*** with ***N-CoR*** through a MYND domain in its carboxyl terminus .	parallel	1
12671	10735599	3553;5021	Interleukin-1 beta;oxytocin receptor	***Interleukin-1 beta*** ***down-regulates*** the ***oxytocin receptor*** in cultured uterine smooth muscle cells .	negative	1
12672	10735617	7124;5599	TNFalpha;JNK	In quiescent cells ***TNFalpha*** ***stimulated*** p38 MAP kinase and ***JNK*** activities 12 - and 4-fold respectively and this was halved by 2-mercaptoethanol , an indirect antioxidant .	positive	0
12673	10735617	7124;1432	TNFalpha;p38 MAP kinase	In quiescent cells ***TNFalpha*** ***stimulated*** ***p38 MAP kinase*** and JNK activities 12 - and 4-fold respectively and this was halved by 2-mercaptoethanol , an indirect antioxidant .	positive	0
12674	10735617	7124;5599	TNFalpha;JNK	CONCLUSIONS : The ***activation*** of p38 MAP kinase and ***JNK*** by ***TNFalpha*** and endothelin , together with the inhibition of this activation by 2-mercaptoethanol , provides indirect evidence supporting their role in HSC transformation .	positive	1
12675	10735617	7124;1432	TNFalpha;p38 MAP kinase	CONCLUSIONS : The ***activation*** of ***p38 MAP kinase*** and JNK by ***TNFalpha*** and endothelin , together with the inhibition of this activation by 2-mercaptoethanol , provides indirect evidence supporting their role in HSC transformation .	positive	1
12676	10735917	23430;2150	mast cell tryptase;PAR-2	Four members of this family have been cloned , three of which are activated by thrombin ( PAR-1 , PAR-3 and PAR-4 ) while the fourth ( ***PAR-2*** ) is ***activated*** by trypsin or ***mast cell tryptase*** .	positive	1
12677	10736095	3565;3458	IL-4;IFN-gamma	Anti ***IL-4*** ***upregulated*** the binding of ***IFN-gamma*** and did not modify that of TNF-alpha so the low CTL activity could be as a result of IL-4 by a decrease of the IFN-gamma binding on MB cells .	positive	1
12678	10736095	3458;7124	IFN-gamma;TNF-alpha	Cells from those MB patients taking thalidomide ( MB-T ) did neither bind IFN-gamma nor TNF-alpha even when antigen or anti-IL-4 were added , demonstrating that thalidomide inhibits either the in vitro ***binding*** or receptor expression of both ***TNF-alpha*** and ***IFN-gamma*** .	parallel	1
12679	10736244	7124;5743	TNF-alpha;PGHS-2	***TNF-alpha*** ***increased*** PG output and ***PGHS-2*** expression independent of cell type .	positive	0
12680	10736563	4352;7066	MPL;thrombopoietin	Determination of interactions between human ***thrombopoietin*** and its ***receptor*** ***MPL*** by yeast two-hybrid system and affinity biosensor .	parallel	1
12681	10736563	4352;7066	MPL;thrombopoietin	Determination of ***interactions*** between human ***thrombopoietin*** and its receptor ***MPL*** by yeast two-hybrid system and affinity biosensor .	parallel	1
12682	10736563	7066;4352	thrombopoietin;MPL	The ***binding*** of human ***thrombopoietin*** to the extracellular domain of its receptor ***MPL*** prompts a cascade transduction of intracellular signals , leading to the development of megakaryocyte precursors and the production of circulating platelets .	parallel	1
12683	10736564	2264;2253	FGFR4;FGF-8	Immobilized ***FGFR4*** also ***bound*** ***FGF-8*** besides FGF-1 and FGF-2 .	parallel	1
12684	10736626	3439;1956	IFN alpha;epidermal growth factor receptor	We have found that ***IFN alpha*** ***increased*** ***epidermal growth factor receptor*** ( EGF-R ) expression , but reduced S phase and proliferative marker expression in human epidermoid KB cells and that this effect was antagonised by epidermal growth factor ( EGF ) .	positive	0
12685	10736753	3416;3630	IDE;Ins	Once Ins is internalized , Ins dissociates from the Ins receptor in the endosome , and is translocated to the cytoplasm , where most ***Ins*** is ***degraded*** by Ins-degrading enzyme ( ***IDE*** ) , although how the polypeptides cross the lipid bilayer is unknown .	negative	0
12686	10736969	914;965	CD2;CD58	***CD2*** ***binds*** to its primary ligand ***CD58*** ( LFA-3 ) on antigen presenting cells ( APC ) and stabilizes the T cell-APC interaction ; this stable interaction then optimizes Ag-specific T-cell activation .	parallel	1
12687	10737125	6647;348	ALS;APOE-4	Similarly , logistic regression analysis in the overall and stratified data set while controlling for sex showed no increase or decrease in risk of ***ALS*** ***associated*** with the ***APOE-4*** allele .	parallel	0
12688	10737606	3589;2670	IL-11;GFAP	This differentiation process is totally dependent on the gp130-mediated signal-transduction pathway involving activation of a latent cytoplasmic transcription factor , STAT3 ( for signal transducer and activator of transcription 3 ) , because ( a ) IL-11-induced astrocyte differentiation is not observed when neuroepithelial cells prepared from gp130-deficient mice were used , ( b ) stimulation of neuroepithelial cells by IL-11 rapidly induces tyrosine-phosphorylation of STAT3 , and ( c ) transfection of neuroepithelial cells with a dominant-negative form of STAT3 inhibits ***IL-11-induced*** ***activation*** of the ***GFAP*** gene promoter .	positive	1
12689	10737710	125;217	ADH2;ALDH2	In the present study , we attempted to examine ***associations*** between the ***ADH2*** and ***ALDH2*** polymorphisms , alcohol drinking and hepatocellular carcinoma ( HCC ) development in a case-control study in Japan .	parallel	0
12690	10737722	4193;7157	mdm2;p53	***mdm2*** functions as a negative feedback ***regulator*** of the tumor suppressor ***p53*** .	negative	1
12691	10737769	8553;4609	Stra13;c-Myc	Further , once induced , ***Stra13*** strongly ***represses*** the expression of the cell proliferation-associated gene ***c-Myc*** through an HDAC1-independent pathway that involves its interaction with the basal transcription factor TFIIB .	negative	1
12692	10737773	360;359	AQP3;AQP2	***AQP3*** deletion had little effect on AQP1 or AQP4 protein expression but ***decreased*** ***AQP2*** protein expression particularly in renal cortex .	positive	0
12693	10737893	7040;3486	TGF-beta1;IGFBP-3	Transforming growth factor-beta1 ( ***TGF-beta1*** ) ( 0.1 or 0.2 nM ) ***increased*** the expression and release of ***IGFBP-3*** , and caused an increase in mRNAs encoding IGFBP-2 and IGFBP-5 .	positive	0
12694	10737903	3486;3479	IGFBP-3;IGF-I	Basal DNA synthesis was unaffected by either an IGF neutralizing antibody or exogenous IGFBP3 , indicating the differences observed between + BP3 and Mock cells were not attributable to ***sequestration*** of endogenous ***IGF-I*** by ***IGFBP-3*** .	negative	0
12695	10737903	3486;3479	IGFBP-3;IGF-I	These results suggest that IGF-I regulation of IGFBP-3 represents a regulatory loop , the function of which is to increase IGF-I bioactivity , using a mechanism that does require an ******IGF-I-IGFBP-3****** ***interaction*** .	parallel	1
12696	10737903	3479;3486	IGF-I;IGFBP-3	These results suggest that ***IGF-I*** ***regulation*** of ***IGFBP-3*** represents a regulatory loop , the function of which is to increase IGF-I bioactivity , using a mechanism that does require an IGF-I-IGFBP-3 interaction .	target	1
12697	10737903	3486;3479	Insulin-like growth factor binding protein-3;IGF-I	***Insulin-like growth factor binding protein-3*** ***mediates*** ***IGF-I*** action in a bovine mammary epithelial cell line independent of an IGF interaction .	target	0
12698	10737903	3479;3486	IGF-I;IGFBP-3	In addition , ***IGF-I*** specifically ***upregulates*** ***IGFBP-3*** synthesis in these cells .	positive	1
12699	10737940	317;317	CED4;APAF-1	This prediction suggests a detailed molecular mechanism for the " induced proximity " hypothesis ( Salvesen and Dixit , Proc Natl Acad Sci USA 1999 ; 96:10964 -10967 ) for CED3/caspase-9 activation by ******CED4/APAF-1****** ***complex*** .	parallel	1
12700	10737940	317;842	APAF-1;caspase-9	This prediction suggests a detailed molecular mechanism for the " induced proximity " hypothesis ( Salvesen and Dixit , Proc Natl Acad Sci USA 1999 ; 96:10964 -10967 ) for ***CED3/caspase-9*** ***activation*** by ***CED4/APAF-1*** complex .	positive	1
12701	10737940	317;112752	APAF-1;CED3	This prediction suggests a detailed molecular mechanism for the " induced proximity " hypothesis ( Salvesen and Dixit , Proc Natl Acad Sci USA 1999 ; 96:10964 -10967 ) for ***CED3/caspase-9*** ***activation*** by ***CED4/APAF-1*** complex .	positive	1
12702	10737969	891;902	cyclin B1;p34	We detected the relative levels and ***association*** of ***p34*** ( cdc2 ) and ***cyclin B1*** .	parallel	0
12703	10738140	3082;8731	HGF;Met	The expression of Met/HGF by PEL cells may bear implications for the lymphoma proliferation and growth pattern , since ******Met/HGF****** ***interactions*** influence cell mitogenesis and motogenesis .	parallel	1
12704	10738185	3565;3458	IL-4;IFN-gamma	Exogenous IL-12 enhanced and exogenous ***IL-4*** ***diminished*** ***IFN-gamma*** production .	negative	0
12705	10738221	4084;4609	Mad1;Myc	***Mad1*** expression was closely linked to differentiation of the cancer cells and inversely ***correlated*** with ***Myc*** expression ( P = 0.042 ) .	negative	0
12706	10738221	4084;4609	Mad1;Myc	BACKGROUND : ***Mad1*** protein is known to ***repress*** ***Myc*** target genes and antagonize Myc function .	negative	1
12707	10738245	596;4790	bcl-2;NF-kappaB	***bcl-2*** over-expression ***enhances*** ***NF-kappaB*** activity and induces mmp-9 transcription in human MCF7 ( ADR ) breast-cancer cells .	positive	0
12708	10738245	596;4318	bcl-2;mmp-9	***bcl-2*** over-expression enhances NF-kappaB activity and ***induces*** ***mmp-9*** transcription in human MCF7 ( ADR ) breast-cancer cells .	target	1
12709	10738245	596;4790	bcl-2;NF-kappaB	The overall data indicate that ***bcl-2-mediated*** ***regulation*** of ***NF-kappaB-transcription-factor*** activity may represent an important mechanism for the promotion of malignant behavior in MCF-7 ( ADR ) cells .	target	1
12710	10738246	836;115209	caspase-3;peptidase	In A549/p16 -1 cells , cytosolic ***peptidase*** activities that cleaved Z-DEVD-7-amino-4-trifluoromethylcoumarin increased during CPT-11-induced apoptosis and were ***suppressed*** by a highly specific ***caspase-3*** and caspase-3-like inhibitor , Z-DEVD-fluoromethylketone .	negative	1
12711	10738944	4790;3383	NF-kappaB;ICAM-1	CONCLUSION : LPS inducibility of ICAM-1 mRNA in A549 cells is independent of TNF - and IL-1 in A549 cells , and the similar time course of mRNA induction and NF-kappaB activation suggest the induction of ***ICAM-1*** is ***mediated*** , in part , by ***NF-kappaB*** .	target	0
12712	10739375	185;183	AT1R;angiotensin II	Genetic polymorphisms of the renin angiotensin system ( the D/I polymorphism of the ACE gene and the A1166C polymorphism of the ***angiotensin II*** type 1 ***receptor*** [ ***AT1R*** ] ) and of haemostatic factors ( the -675 4G/5G polymorphism of the plasminogen-activator inhibitor 1 [ PAI-1 ] gene , and the G to T common point mutation in exon 2 , codon 34 of the Factor XIII A-subunit gene ) were examined .	parallel	1
12713	10739384	5104;5340	protein C inhibitor;plasmin	Bovine ***protein C inhibitor*** has a unique reactive site and can transiently ***inhibit*** ***plasmin*** .	negative	1
12714	10739384	5104;5624	protein C inhibitor;protein C	***protein C inhibitor*** ( PCI ) ***regulates*** the anticoagulant ***protein C*** pathway by neutralizing activated protein C and thrombin-thrombomodulin complex in the human hemostatic system .	target	1
12715	10739388	5327;5054	t-PA;PAI-1	The low density lipoprotein receptor-related protein ( LRP ) is a multiligand clearance receptor that removes free tissue-type plasminogen activator ( t-PA ) or ***complexes*** of ***t-PA*** with plasminogen activator inhibitor type 1 ( ***PAI-1*** ) from the blood circulation or the pericellular space .	parallel	1
12716	10739635	3458;355	Interferon-gamma;Fas	***Interferon-gamma*** ***modulation*** of the ***Fas*** pathway and apoptosis in microglia may be important in the pathogenesis of inflammatory CNS disease processes .	target	0
12717	10739635	3458;355	Interferon-gamma;Fas	***Interferon-gamma*** induces apoptosis and ***augments*** the expression of ***Fas*** and Fas ligand by microglia in vitro .	positive	0
12718	10739635	3458;356	Interferon-gamma;Fas ligand	***Interferon-gamma*** induces apoptosis and ***augments*** the expression of Fas and ***Fas ligand*** by microglia in vitro .	positive	0
12719	10739663	2263;632	FGFR-2;osteocalcin	Immunohistochemical analysis of the Apert calvaria suture showed that the Ser252Trp ***FGFR-2*** mutation ***increased*** type 1 collagen , ***osteocalcin*** , and osteopontin expression in preosteoblasts compared to normal , whereas cell growth was not affected .	negative	0
12720	10739663	2263;6696	FGFR-2;osteopontin	Immunohistochemical analysis of the Apert calvaria suture showed that the Ser252Trp ***FGFR-2*** mutation ***increased*** type 1 collagen , osteocalcin , and ***osteopontin*** expression in preosteoblasts compared to normal , whereas cell growth was not affected .	negative	0
12721	10739671	3659;4602	IRF-1;c-myb	Moreover , in vitro translated ***IRF-1*** or IRF-2 protein did ***interact*** with the 123-bp ***c-myb*** intron 1 fragment .	parallel	1
12722	10739671	3660;4602	IRF-2;c-myb	Moreover , in vitro translated IRF-1 or ***IRF-2*** protein did ***interact*** with the 123-bp ***c-myb*** intron 1 fragment .	parallel	1
12723	10739671	3659;4602	IRF-1;c-myb	Together , these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which ***IRF-1*** negatively ***regulates*** ***c-myb*** expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing .	negative	1
12724	10739674	4790;5970	p50;p65	For NF-kappaB complex the p50-p50 homodimer was activated before the ******p50-p65****** ***heterodimer*** , and c-Myc/Max DNA-binding activity increased thereafter .	parallel	1
12725	10739858	6810;8773	syntaxin-4;SNAP-23	These results suggest that the ***interaction*** between ***syntaxin-4*** , ***SNAP-23*** and VAMP-2 is fairly weak and their concentrations in the cell lysate are insufficient to make a readily detectable complex , and that bindings between these proteins are hindered by other proteins in parotid acinar cells .	parallel	1
12726	10739858	6810;6844	syntaxin-4;VAMP-2	These results suggest that the ***interaction*** between ***syntaxin-4*** , SNAP-23 and ***VAMP-2*** is fairly weak and their concentrations in the cell lysate are insufficient to make a readily detectable complex , and that bindings between these proteins are hindered by other proteins in parotid acinar cells .	parallel	1
12727	10739858	6844;8773	VAMP-2;SNAP-23	These results suggest that the ***interaction*** between syntaxin-4 , ***SNAP-23*** and ***VAMP-2*** is fairly weak and their concentrations in the cell lysate are insufficient to make a readily detectable complex , and that bindings between these proteins are hindered by other proteins in parotid acinar cells .	parallel	1
12728	10740816	7157;4193	p53;Mdm2	ARF has been shown to bind to the ******Mdm2-p53****** ***complex*** , resulting in stabilisation of both proteins , and a feedback loop exists through which ARF levels are negatively regulated by p53 .	parallel	1
12729	10740816	7157;1029	p53;ARF	ARF has been shown to bind to the Mdm2-p53 complex , resulting in stabilisation of both proteins , and a feedback loop exists through which ***ARF*** levels are negatively ***regulated*** by ***p53*** .	negative	1
12730	10741154	8862;187	apelin;APJ	Since ***apelin*** is an endogenous ***ligand*** for the HIV entry coreceptor ***APJ*** , we tested the effect of apelin on the entry of HIV in association with CD4 , and found that apelin blocked the entry of HIV-1 and HIV-2 .	parallel	1
12731	10741392	2355;4790	fra-2;p50	Chloramphenicol acetyltransferase ( CAT ) analysis , following transfection with a plasmid containing the regulatory sequence of MHC class I ( or its deletion derivatives ) with the CAT reporter gene , and electrophoretic mobility shift assay experiments demonstrated that the action of T ( alpha ) 1 was at the transcriptional level , and its mechanism of action is likely due to increased ***binding*** between the complex ******p50/fra-2****** and the enhancer A sequence of the 5 ' flanking region of a swine class I gene ( PD1 ) .	parallel	1
12732	10741396	7087;3689	Intercellular adhesion molecule-5;CD18	***Intercellular adhesion molecule-5*** ( ICAM-5 , telencephalin ) is a member of the immunoglobulin superfamily expressed on telencephalic neurons , and serves as a ***ligand*** for the leukocyte integrin CD11 ***a/CD18*** .	parallel	1
12733	10741396	3689;3683	CD18;CD11a	Protein constructs containing the first immunoglobulin domain of ICAM-5 were able to support ******CD11a/CD18****** ***interaction*** , while deletion of the first domain abolished binding .	parallel	1
12734	10741404	940;5599	CD28;JNK	Autonomous ***induction*** of proliferation , ***JNK*** and NF-alphaB activation in primary resting T cells by mobilized ***CD28*** .	target	1
12735	10741411	356;355	FasL;Fas	However , when these same cells revert to a resting phenotype and are subjected to restimulation with either SEB or anti-CD3 , the majority of these SEB-responsive cells undergo ***Fas*** ***ligand*** ( ***FasL*** ) - mediated activation-induced cell death ( AICD ) .	parallel	1
12736	10741459	1956;7039	epidermal growth factor receptor;TGF-alpha	The level of expression of ***epidermal growth factor receptor*** protein , the ***receptor*** for ***TGF-alpha*** , was also upregulated in the transgenics , indicating a role for the ErbB tyrosine kinase receptor family in the response to TGF-alpha in the olfactory epithelium .	parallel	1
12737	10741468	375790;4593	agrin;MuSK	Motor neuron-derived ***agrin*** ***induces*** the postsynaptic tyrosine phosphorylation of both a muscle-specific kinase ( ***MuSK*** ) and the AChR beta-subunit .	target	1
12738	10741631	1571;1576	CYP2E1;CYP3A4	METHODS : The involvement of ***CYP2E1*** was assessed through pretreatment of adult human volunteers with disulfiram to ***inhibit*** the enzyme and the role of ***CYP3A4*** through its induction in a second cohort of adults with rifampin ( INN , rifampicin ) .	negative	1
12739	10741643	983;891	p34cdc2;cyclin B1	The progression of cells from G2 into mitosis is mainly controlled by formation of the ******cyclin B1/p34cdc2****** ***complex*** .	parallel	1
12740	10741739	8031;5979	ELE1;RET	***ELE1/RET*** is ***related*** to the solid variant of PTC , ***H4/RET*** more frequently to typical papillary structures .	parallel	0
12741	10741750	3569;3572	hIL-6;gp130	Both ***hIL-6*** and vIL-6 ***activated*** ***gp130*** , Janus kinase 1 , signal transducers and activators of transcription-3 , and mitogen-activated protein kinase in both MH60 and B9 cells .	positive	1
12742	10741905	7124;3383	tumor necrosis factor alpha;ICAM-1	Previous studies showed that proinflammatory cytokines , interleukin 1 ( IL-1 ) and ***tumor necrosis factor alpha*** ( TNF alpha ) , ***induce*** surface expression of intercellular adhesion molecule 1 ( ***ICAM-1*** ) and the production of the chemokines interleukin 8 ( IL-8 ) and monocyte chemoattractant protein ( MCP-1 ) on pulmonary epithelial cell lines in vitro .	target	1
12743	10741905	3552;3383	IL-1alpha;ICAM-1	Both ***IL-1alpha*** and IL-1beta ***induced*** ***ICAM-1*** expression and IL-8 and MCP-1 production at lower doses than TNF alpha or TNF beta .	target	1
12744	10741905	3552;6347	IL-1alpha;MCP-1	Both ***IL-1alpha*** and IL-1beta ***induced*** ICAM-1 expression and IL-8 and ***MCP-1*** production at lower doses than TNF alpha or TNF beta .	target	1
12745	10741905	3553;3383	IL-1beta;ICAM-1	Both IL-1alpha and ***IL-1beta*** ***induced*** ***ICAM-1*** expression and IL-8 and MCP-1 production at lower doses than TNF alpha or TNF beta .	target	1
12746	10741905	3553;6347	IL-1beta;MCP-1	Both IL-1alpha and ***IL-1beta*** ***induced*** ICAM-1 expression and IL-8 and ***MCP-1*** production at lower doses than TNF alpha or TNF beta .	target	1
12747	10741909	2875;7422	alanine aminotransferase;VEGF	The histological grade of HCC and the level of ***alanine aminotransferase*** was ***related*** to ***VEGF*** expression in non-carcinoma liver cells and on endothelial cells in HCC areas .	parallel	0
12748	10742108	7349;1395	urocortin;Crhr2	Crh has a higher affinity for Crhr1 than for Crhr2 , and ***urocortin*** ( Ucn ) , a Crh-related peptide , is thought to be the endogenous ***ligand*** for ***Crhr2*** because it binds with almost 40-fold higher affinity than does Crh .	parallel	1
12749	10742109	1392;1394	corticotropin-releasing hormone;Crhr1	***corticotropin-releasing hormone*** ( Crh ) , a 41-residue polypeptide , ***activates*** two G-protein-coupled receptors , ***Crhr1*** and crhr2 , causing ( among other transductional events ) phosphorylation of the transcription factor Creb .	positive	1
12750	10742109	1392;1395	corticotropin-releasing hormone;crhr2	***corticotropin-releasing hormone*** ( Crh ) , a 41-residue polypeptide , ***activates*** two G-protein-coupled receptors , Crhr1 and ***crhr2*** , causing ( among other transductional events ) phosphorylation of the transcription factor Creb .	positive	1
12751	10742385	6387;7852	SDF-1;CXCR4	***SDF-1*** , a ***CXCR4*** ***ligand*** , induced calcium flux and phosphorylation of MAPK ( p42/44 ) and AKT in CD34 ( + ) KIT ( + ) bone marrow mononuclear cells which contain BFU-E , as well as chemotactic activity of both human CD34 ( + ) BFU-E progenitors and erythroid cells isolated from day 2-6 BFU-E colonies .	parallel	1
12752	10742385	6387;207	SDF-1;AKT	***SDF-1*** , a CXCR4 ligand , ***induced*** calcium flux and phosphorylation of MAPK ( p42/44 ) and ***AKT*** in CD34 ( + ) KIT ( + ) bone marrow mononuclear cells which contain BFU-E , as well as chemotactic activity of both human CD34 ( + ) BFU-E progenitors and erythroid cells isolated from day 2-6 BFU-E colonies .	target	1
12753	10742550	3565;5179	Interleukin-4;preproenkephalin	***Interleukin-4-dependent*** ***induction*** of ***preproenkephalin*** in antigen-specific T helper-type 2 ( Th2 ) cells .	target	1
12754	10742553	3569;3565	IL-6;IL-4	Administration of ***IL-6*** , which caused typical EAE in IL-6-deficient mice immunized with MOG , ***reduced*** ***IL-4*** production but did not restore IFN-gamma production in LNs of IL-6-deficient mice .	negative	1
12755	10742554	728;727	C5aR;C5a	Towards this aim , we have characterized a transgenic ***C5a*** ***receptor*** ( ***C5aR*** ) knockout ( KO ) mouse .	parallel	1
12756	10743860	3553;5055	interleukin 1beta;PAI-2	Our previous studies had demonstrated that in inflamed gingival tissues , tissue-type plasminogen activator ( t-PA ) is significantly increased in the extracellular matrix of the connective tissue and that ***interleukin 1beta*** ( IL-1beta ) can up ***regulate*** the level of t-PA and plasminogen activator inhibitor-2 ( ***PAI-2*** ) synthesis by human gingival fibroblasts .	target	1
12757	10743860	3553;5327	interleukin 1beta;t-PA	Our previous studies had demonstrated that in inflamed gingival tissues , tissue-type plasminogen activator ( t-PA ) is significantly increased in the extracellular matrix of the connective tissue and that ***interleukin 1beta*** ( IL-1beta ) can up ***regulate*** the level of ***t-PA*** and plasminogen activator inhibitor-2 ( PAI-2 ) synthesis by human gingival fibroblasts .	target	1
12758	10744059	3383;3162	ICAM-1;HO-1	Targeted disruption of ***ICAM-1*** or eNOS gene , but not the neuronal NOS gene , ***attenuated*** the TD-induced neurodegeneration and ***HO-1*** induction .	negative	0
12759	10744074	6714;999	c-Src;E-cadherin	We found that ***c-Src*** was ***coimmunoprecipitated*** with ***E-cadherin-catenin*** complex and was tyrosine-dephosphorylated and activated in the adherent cells .	parallel	1
12760	10744622	596;7422	Bcl-2;vascular endothelial growth factor	***Bcl-2*** overexpression and hypoxia synergistically act to ***modulate*** ***vascular endothelial growth factor*** expression and in vivo angiogenesis in a breast carcinoma line .	target	0
12761	10744645	976;1604	CD97;CD55	Remarkably , we found that the ***interaction*** between ***CD97*** and ***CD55*** is phylogenetically restricted , as indicated by the selective adhesion of primate erythrocytes to hCD97 transfectants , and of mouse and rat erythrocytes to mCD97 transfectants respectively .	parallel	1
12762	10744652	5788;1043	CD45;CD52	The ***CD45*** tyrosine phosphatase ***regulates*** Campath-1H ( ***CD52*** ) - induced TCR-dependent signal transduction in human T cells .	target	1
12763	10744656	4790;5970	p50;p65	Stimulation of Fc gamma R receptors induces monocyte chemoattractant protein-1 in the human monocytic cell line THP-1 by a mechanism involving I kappa B-alpha degradation and formation of ******p50/p65****** NF-kappa B/Rel ***complexes*** .	parallel	1
12764	10744656	5966;4790	Rel;NF-kappa B	Stimulation of Fc gamma R receptors induces monocyte chemoattractant protein-1 in the human monocytic cell line THP-1 by a mechanism involving I kappa B-alpha degradation and formation of p50/p65 ******NF-kappa B/Rel****** ***complexes*** .	parallel	1
12765	10744656	5970;4790	p65;p50	This was accompanied by a parallel activation of the transcription factor NF-kappaB as judged from both the appearance of kappaB-binding activity containing ******p50/p65****** NF-kappaB/Rel ***complexes*** in the nuclear extract and the disappearance of the NF-kappaB inhibitor IkappaB-alpha in the cell lysate .	parallel	1
12766	10744656	5966;4790	Rel;NF-kappaB	This was accompanied by a parallel activation of the transcription factor NF-kappaB as judged from both the appearance of kappaB-binding activity containing p50/p65 ******NF-kappaB/Rel****** ***complexes*** in the nuclear extract and the disappearance of the NF-kappaB inhibitor IkappaB-alpha in the cell lysate .	parallel	1
12767	10744656	4790;4792	NF-kappaB;IkappaB-alpha	Our findings suggest the existence in monocytic cells of a signaling mechanism initiated by cross-linking of low-affinity FcgammaR , most likely of the FcgammaRII family since THP-1 cells do not express FcgammaRIII receptors , that involves activation of ***NF-kappaB*** ***associated*** to the proteolytic degradation of ***IkappaB-alpha*** and leads to the transcriptional up-regulation of MCP-1 .	parallel	0
12768	10744659	116449;2885	MIST;Grb2	Upon FcepsilonRI cross-linking , ***MIST/Clnk*** is tyrosine phosphorylated and ***associates*** with signaling proteins , phospholipase Cgamma , Vav , ***Grb2*** and linker for activation of T cells ( LAT ) .	parallel	0
12769	10744659	116449;27040	MIST;linker for activation of T cells	Upon FcepsilonRI cross-linking , ***MIST/Clnk*** is tyrosine phosphorylated and ***associates*** with signaling proteins , phospholipase Cgamma , Vav , Grb2 and ***linker for activation of T cells*** ( LAT ) .	parallel	0
12770	10744659	116449;7409	MIST;Vav	Upon FcepsilonRI cross-linking , ***MIST/Clnk*** is tyrosine phosphorylated and ***associates*** with signaling proteins , phospholipase Cgamma , ***Vav*** , Grb2 and linker for activation of T cells ( LAT ) .	parallel	0
12771	10744662	7040;26585	TGF-beta1;gremlin	Mesangial cell ***gremlin*** mRNA levels were ***induced*** by high glucose , cyclic mechanical strain , and ***TGF-beta1*** in vitro , and gremlin mRNA levels were elevated in the renal cortex of rats with streptozotocin-induced diabetic nephropathy in vivo .	target	1
12772	10744676	3458;6772	interferon-gamma;STAT-1	Similarly , ***interferon-gamma*** , which is known to ***induce*** ***STAT-1*** activation , also induced apoptosis in cardiac cells .	target	1
12773	10744679	3725;356	AP-1;FasL	***Regulation*** of ***FasL*** by NF-kappaB and ***AP-1*** in Fas-dependent thymineless death of human colon carcinoma cells .	target	1
12774	10744679	4790;356	NF-kappaB;FasL	***Regulation*** of ***FasL*** by ***NF-kappaB*** and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells .	target	1
12775	10744679	356;355	FasL;Fas	During thymineless stress in TS ( - ) cells , ***Fas*** ***ligand*** ( ***FasL*** ) is expressed , and its promoter ( hFasLPr ) is activated .	parallel	1
12776	10744679	3725;356	AP-1;FasL	Transactivation of hFasLPr , dependent upon dThd deficiency , was inhibited following mutation of the binding sites for NF-kappaB or AP-1 and by preventing NF-kappaB or ***AP-1*** activation , which ***inhibited*** expression of ***FasL*** and enhanced clonogenic survival in stable transformants expressing IkappaBalphaM or DN-MEKK , respectively .	negative	1
12777	10744679	4790;356	NF-kappaB;FasL	Transactivation of hFasLPr , dependent upon dThd deficiency , was inhibited following mutation of the binding sites for NF-kappaB or AP-1 and by preventing ***NF-kappaB*** or AP-1 activation , which ***inhibited*** expression of ***FasL*** and enhanced clonogenic survival in stable transformants expressing IkappaBalphaM or DN-MEKK , respectively .	negative	1
12778	10744690	1104;3839	RCC1;karyopherin alpha3	The nuclear import of ***RCC1*** ***requires*** a specific nuclear localization sequence receptor , ***karyopherin alpha3/Qip*** .	target	0
12779	10744690	1104;3837	RCC1;karyopherin beta1	In addition to Kapalpha3 , we found that the nuclear import of ***pA-RCC1*** also ***required*** both ***karyopherin beta1*** and Ran .	target	0
12780	10744696	7410;998	Vav2;Cdc42	***Vav2*** is an ***activator*** of ***Cdc42*** , Rac1 , and RhoA .	positive	1
12781	10744696	7410;5879	Vav2;Rac1	***Vav2*** is an ***activator*** of Cdc42 , ***Rac1*** , and RhoA .	positive	1
12782	10744696	7410;387	Vav2;RhoA	***Vav2*** is an ***activator*** of Cdc42 , Rac1 , and ***RhoA*** .	positive	1
12783	10744704	2801;2804	GM130;giantin	These results question a simple tethering model involving a ternary ******giantin-p115-GM130****** ***complex*** and suggest that p115-giantin and p115-GM130 interactions might mediate independent membrane tethering events .	parallel	1
12784	10744704	2801;8615	GM130;p115	These results question a simple tethering model involving a ternary ******giantin-p115-GM130****** ***complex*** and suggest that p115-giantin and p115-GM130 interactions might mediate independent membrane tethering events .	parallel	1
12785	10744704	8615;2804	p115;giantin	These results question a simple tethering model involving a ternary ******giantin-p115-GM130****** ***complex*** and suggest that p115-giantin and p115-GM130 interactions might mediate independent membrane tethering events .	parallel	1
12786	10744704	8615;2804	p115;giantin	These results question a simple tethering model involving a ternary giantin-p115-GM130 complex and suggest that ******p115-giantin****** and p115-GM130 ***interactions*** might mediate independent membrane tethering events .	parallel	1
12787	10744704	8615;2801	p115;GM130	These results question a simple tethering model involving a ternary giantin-p115-GM130 complex and suggest that p115-giantin and ******p115-GM130****** ***interactions*** might mediate independent membrane tethering events .	parallel	1
12788	10744704	8615;2804	p115;giantin	The tether is proposed to involve the simultaneous ***binding*** of ***p115*** to ***giantin*** on one membrane and to GM130 on another membrane .	parallel	1
12789	10744704	2801;2804	GM130;giantin	To explore this model , we tested for the presence of the putative ******giantin-p115-GM130****** ternary ***complex*** .	parallel	1
12790	10744704	2801;8615	GM130;p115	To explore this model , we tested for the presence of the putative ******giantin-p115-GM130****** ternary ***complex*** .	parallel	1
12791	10744704	8615;2804	p115;giantin	To explore this model , we tested for the presence of the putative ******giantin-p115-GM130****** ternary ***complex*** .	parallel	1
12792	10744704	8615;2804	p115;giantin	Unexpectedly , GST fusions containing either the giantin or the GM130 p115 binding site efficiently bound p115 , but the ***p115*** ***bound*** to ***GST-giantin*** did not bind GM130 , and the p115 bound to GST-GM130 did not bind giantin .	parallel	1
12793	10744704	8615;373156	p115;GST	Unexpectedly , GST fusions containing either the giantin or the GM130 p115 binding site efficiently bound p115 , but the ***p115*** ***bound*** to ***GST-giantin*** did not bind GM130 , and the p115 bound to GST-GM130 did not bind giantin .	parallel	1
12794	10744704	8615;2801	p115;GM130	Unexpectedly , GST fusions containing either the giantin or the GM130 p115 binding site efficiently bound p115 , but the p115 bound to GST-giantin did not bind GM130 , and the ***p115*** ***bound*** to ***GST-GM130*** did not bind giantin .	parallel	1
12795	10744704	373156;8615	GST;p115	Unexpectedly , ***GST*** fusions containing either the giantin or the GM130 p115 binding site efficiently ***bound*** ***p115*** , but the p115 bound to GST-giantin did not bind GM130 , and the p115 bound to GST-GM130 did not bind giantin .	parallel	1
12796	10744705	7161;7490	p73;Wilms tumor 1	Physical ***interaction*** between ***Wilms tumor 1*** and ***p73*** proteins modulates their functions .	parallel	1
12797	10744705	7157;7490	p53;WT1	***Interaction*** between ***WT1*** and ***p53*** was shown to modulate their ability to regulate the transcription of their respective target genes .	parallel	1
12798	10744705	7490;7161	WT1;p73	Here , we report that all four isoforms of ***WT1*** ***bind*** to ***p73*** , a recently cloned homologue of p53 .	parallel	1
12799	10744705	7490;8626	WT1;KET	This , taken together with our finding that ***WT1*** also ***interacts*** with ***p63/KET*** , another p53 homologue , suggests that association between WT1 and the members of the p53 family of proteins may be an important determinant of their functions in cell growth and differentiation .	parallel	1
12800	10744706	3565;6772	IL-4;Stat1	Taken together , our data suggest that ***IL-4*** ***activates*** ***Stat1*** , leading to cell growth inhibition in colon cancer cells .	positive	1
12801	10744706	3565;6778	Interleukin-4;Stat6	***Interleukin-4*** ( IL-4 ) ***activates*** ***Stat6*** ( signal transducer and activator of transcription 6 ) and plays multiple roles in regulation of the immune system .	positive	1
12802	10744706	3565;3643	IL-4;insulin receptor	***IL-4*** also ***triggers*** phosphorylation of ***insulin receptor*** substrate ( IRS ) , leading to stimulation of cell growth .	positive	0
12803	10744706	3565;6772	IL-4;Stat1	Strikingly , ***IL-4*** ***activated*** ***Stat1*** in colon carcinoma cell lines but not in Burkitt 's lymphoma cell lines .	positive	1
12804	10744706	3565;6772	IL-4;Stat1	Therefore , these results suggest that ***IL-4*** ***induced*** ***Stat1*** activation , resulting in growth inhibition of colon carcinoma cell lines .	target	1
12805	10744718	3458;56300	interferon-gamma;IL-1H1	However , ***IL-1H1*** could be ***induced*** in vitro in keratinocytes by ***interferon-gamma*** and tumor necrosis factor-alpha and in vivo via a contact hypersensitivity reaction or herpes simplex virus infection .	target	1
12806	10744718	7124;56300	tumor necrosis factor-alpha;IL-1H1	However , ***IL-1H1*** could be ***induced*** in vitro in keratinocytes by interferon-gamma and ***tumor necrosis factor-alpha*** and in vivo via a contact hypersensitivity reaction or herpes simplex virus infection .	target	1
12807	10744719	53335;7026	CTIP1;ARP1	The ***interaction*** of ***CTIP1*** with ***ARP1*** was studied in detail , and CTIP1 was found to harbor two independent ARP1 interaction domains , ID1 and ID2 , whereas the putative AF-2 of ARP1 was required for interaction with CTIP1 .	parallel	1
12808	10744722	11200;995	Chk2;Cdc25C	***Chk2/Cds1*** is known to localize in the nucleus and to ***phosphorylate*** ***Cdc25C*** at serine 216 in vitro .	target	1
12809	10744730	4084;4609	Mad;Myc	***Mad*** proteins are thought to ***antagonize*** ***Myc*** functions at least in part by repressing gene transcription .	negative	1
12810	10744741	5111;2237	PCNA;FEN1	Overall , our results indicate that after FEN1 tracks to the cleavage site , ***PCNA*** ***enhances*** ***FEN1*** binding stability , allowing for greater cleavage efficiency .	positive	0
12811	10744741	5111;2237	proliferating cell nuclear antigen;FEN1	***proliferating cell nuclear antigen*** ( PCNA ) ***stimulates*** ***FEN1*** cleavage 5-50-fold .	positive	0
12812	10744741	5111;2237	PCNA;FEN1	***PCNA*** ***stimulates*** ***FEN1*** irrespective of the flap length .	positive	0
12813	10744750	1489;7422	Cardiotrophin-1;VEGF	***Cardiotrophin-1*** also ***enhanced*** ***VEGF*** mRNA expression in a dose-dependent manner .	positive	0
12814	10744750	3976;7422	LIF;VEGF	***VEGF*** protein production and secretion to the medium were also ***enhanced*** by ***LIF*** and Cardiotrophin-1 but not by interleukin-6 .	positive	0
12815	10744755	2646;2645	GKRP;glucokinase	Hepatic ***glucokinase*** is ***inhibited*** by a 68-kDa glucokinase regulatory protein ( ***GKRP*** ) that is expressed in molar excess .	negative	1
12816	10744755	2646;2645	GKRP;glucokinase	Adenovirus-mediated overexpression of ***GKRP*** ( by up to 2-fold above endogenous levels ) ***increased*** ***glucokinase*** binding and inhibited glucose phosphorylation , glycolysis , and glycogen synthesis over a wide range of concentrations of glucose and sorbitol .	positive	0
12817	10744766	64145;4605	110-kDa protein;B-MYB	We isolated a ***110-kDa protein*** ***associated*** endogenously with ***B-MYB*** in the nuclei of HL60 cells .	parallel	0
12818	10744766	142;4605	PARP;B-MYB	Transient transfection assays showed that ***PARP*** ***enhanced*** ***B-MYB*** transactivation and that PARP enzymatic activity is not required for B-MYB-dependent transactivation .	positive	0
12819	10744771	3172;1581	HNF-4;CYP7A1	This DR1 sequence was mapped previously as a binding site for the hepatocyte nuclear factor 4 ( ***HNF-4*** ) which ***stimulates*** ***CYP7A1*** transcription .	positive	0
12820	10744771	5465;3172	PPARalpha;HNF-4	However , Wy14 ,643 and ***PPARalpha/RXRalpha*** significantly ***reduced*** ***HNF-4*** expression in HepG2 cells .	negative	1
12821	10744771	3172;1581	HNF-4;CYP7A1	These results suggest that PPARalpha and agonist repress cholesterol 7alpha-hydroxylase activity by reducing the availability of HNF-4 for binding to the DR-1 sequence and therefore attenuates the ***transactivation*** of ***CYP7A1*** by ***HNF-4*** .	positive	1
12822	10744980	23308;29851	LICOS;ICOS	At 37 degrees C , ***LICOS*** ***binds*** only to ***ICOS*** but , at lower , non-physiological temperatures , it also binds weakly to CD28 and CTLA-4 .	parallel	1
12823	10745024	2064;2065	HER2;HER3	These data are consistent with an autocrine regulatory process mediated by NRG-1 activation of ******HER2/HER3****** ***heterodimers*** expressed on developing human fetal lung epithelial cells .	parallel	1
12824	10745024	3084;2064	NRG-1;HER2	These data are consistent with an autocrine regulatory process mediated by ***NRG-1*** ***activation*** of ***HER2/HER3*** heterodimers expressed on developing human fetal lung epithelial cells .	positive	1
12825	10745024	3084;2065	NRG-1;HER3	These data are consistent with an autocrine regulatory process mediated by ***NRG-1*** ***activation*** of ***HER2/HER3*** heterodimers expressed on developing human fetal lung epithelial cells .	positive	1
12826	10745028	1052;1050	C/EBPdelta;C/EBPalpha	Cotransfections with C/EBPalpha and C/EBPdelta together resulted in a superinduction of the CCSP promoter , indicating a regulatory role for the ******C/EBPalpha-C/EBPdelta****** ***heterodimers*** .	parallel	1
12827	10745028	1050;7356	C/EBPalpha;CCSP	Our findings demonstrate that ***C/EBPalpha*** and C/EBPdelta ***regulate*** the ***CCSP*** gene through a compound response element and suggest that these factors are important for the differentiation-dependent expression of CCSP .	target	1
12828	10745028	1052;7356	C/EBPdelta;CCSP	Our findings demonstrate that C/EBPalpha and ***C/EBPdelta*** ***regulate*** the ***CCSP*** gene through a compound response element and suggest that these factors are important for the differentiation-dependent expression of CCSP .	target	1
12829	10745028	1050;7356	C/EBPalpha;CCSP	Cotransfection studies in the lung epithelial cell line A549 showed that both ***C/EBPalpha*** and C/EBPdelta ***activate*** the murine ***CCSP*** gene and that a C/EBP-response element resides in the proximal CCSP promoter .	positive	1
12830	10745028	1052;7356	C/EBPdelta;CCSP	Cotransfection studies in the lung epithelial cell line A549 showed that both C/EBPalpha and ***C/EBPdelta*** ***activate*** the murine ***CCSP*** gene and that a C/EBP-response element resides in the proximal CCSP promoter .	positive	1
12831	10745028	1050;7356	C/EBPalpha;CCSP	Mutation of either site resulted in abolished or strikingly reduced ***transactivation*** of the ***CCSP*** promoter by ***C/EBPalpha*** and C/EBPdelta , as well as impaired binding of both factors , indicating that the two C/EBP-binding sites form a compound response element .	positive	1
12832	10745028	1052;7356	C/EBPdelta;CCSP	Mutation of either site resulted in abolished or strikingly reduced ***transactivation*** of the ***CCSP*** promoter by C/EBPalpha and ***C/EBPdelta*** , as well as impaired binding of both factors , indicating that the two C/EBP-binding sites form a compound response element .	positive	1
12833	10745028	1052;1050	C/EBPdelta;C/EBPalpha	Furthermore , electrophoretic mobility shift assays demonstrated that ***C/EBPalpha*** and ***C/EBPdelta*** preferentially form ***heterodimers*** at both binding sites .	parallel	1
12834	10745073	8548;3958	cytoplasmic protein;galectin-3	***Interaction*** of a novel cysteine and histidine-rich ***cytoplasmic protein*** with ***galectin-3*** in a carbohydrate-independent manner .	parallel	1
12835	10745081	867;5335	Cbl;PLCgamma1	These data indicate that Cbl and 70Z/3 ***Cbl*** differentially ***regulate*** ***PLCgamma1*** phosphorylation and activation .	target	1
12836	10746549	355;1437	Fas;GM-CSF	A ***Fas*** fusion protein ***inhibited*** tumor lysis and ***GM-CSF*** release by the CD4 + cells .	negative	1
12837	10746610	3303;7157	HSP72;p53	High levels of alphaBC and ***HSP72*** ***correlated*** with drug resistance and high ***p53*** levels in vitro .	parallel	0
12838	10746631	3667;6464	insulin receptor substrate-1;Shc	The two major ***substrates*** of the IGF-IR , ***insulin receptor substrate-1*** ( IRS-1 ) and the ***Shc*** proteins , are known to contribute to this activation .	parallel	1
12839	10746659	3552;3557	IL-1alpha;IL-1ra	Lipopolysaccharide , as well as ***IL-1alpha*** and - beta , were found to ***stimulate*** ***IL-1ra*** production in Sertoli cells .	positive	0
12840	10746663	5734;820	EP4;cAMP	These findings suggest that PGE2 stimulates bone resorption by a mechanism involving ***cAMP*** and ODF , which is ***mediated*** mainly by ***EP4*** and partially by EP2 .	target	0
12841	10746663	5734;8600	EP4;ODF	These findings suggest that PGE2 stimulates bone resorption by a mechanism involving cAMP and ***ODF*** , which is ***mediated*** mainly by ***EP4*** and partially by EP2 .	target	0
12842	10746663	5732;820	EP2;cAMP	Simultaneous addition of ***EP2*** and EP4 agonists cooperatively ***induced*** ***cAMP*** production and ODF mRNA expression .	target	1
12843	10746663	5732;8600	EP2;ODF	Simultaneous addition of ***EP2*** and EP4 agonists cooperatively ***induced*** cAMP production and ***ODF*** mRNA expression .	target	1
12844	10746715	6804;653677	syntaxin 1a;Sec1	Three-dimensional structure of the ******neuronal-Sec1-syntaxin 1a****** ***complex*** .	parallel	1
12845	10746715	653677;6804	Sec1;syntaxin 1a	***syntaxin 1a*** and neuronal ***Sec1*** ( nSec1 ) form an evolutionarily conserved ***heterodimer*** that is essential for vesicle trafficking and membrane fusion .	parallel	1
12846	10746715	6804;6812	syntaxin 1a;nSec1	The crystal structure of the ******nSec1-syntaxin 1a****** ***complex*** , determined at 2.6 A resolution , reveals that major conformational rearrangements occur in syntaxin relative to both the core SNARE complex and isolated syntaxin .	parallel	1
12847	10746730	6347;3565	monocyte chemoattractant protein-1;interleukin-4	The chemokine ***monocyte chemoattractant protein-1*** ( MCP-1 ) can ***stimulate*** ***interleukin-4*** production and its overexpression is associated with defects in cell-mediated immunity , indicating that it might be involved in T ( H ) 2 polarization .	positive	0
12848	10746933	196;1544	Ah receptor;CYP1A2	Induction requires transcriptional ***activation*** of the ***CYP1A2*** gene product by TCDD and the ***Ah receptor*** .	positive	1
12849	10747008	1634;200879	decorin;phospholipase A	Molecular basis for the ***association*** of group IIA ***phospholipase A*** ( 2 ) and ***decorin*** in human atherosclerotic lesions .	parallel	0
12850	10747014	708;2549	gC1q-R;Gab1	Furthermore , several experiments indicate that membrane recruitment and activation of PI 3-kinase involve an InlB-gC1q-R interaction and that ***gC1q-R*** ***associates*** with ***Gab1*** upon stimulation of Vero cells with InlB .	parallel	0
12851	10747018	11345;9527	GATE-16;GOS-28	***GATE-16*** , a membrane transport modulator , ***interacts*** with NSF and the Golgi v-SNARE ***GOS-28*** .	parallel	1
12852	10747020	4342;3308	Mos;Hsp70	We show that ***Mos*** ***interacts*** with both Hsp90 and ***Hsp70*** , and that there is an inverse relationship between association of Mos with these two chaperones .	parallel	1
12853	10747020	4342;3320	Mos;Hsp90	We show that ***Mos*** ***interacts*** with both ***Hsp90*** and Hsp70 , and that there is an inverse relationship between association of Mos with these two chaperones .	parallel	1
12854	10747021	3791;7422	KDR;VEGF	Since there is evidence that KDR plays an important role in tumor angiogenesis , we sought to identify peptides able to block the ******VEGF-KDR****** ***interaction*** .	parallel	1
12855	10747021	7422;3791	VEGF;KDR	Of the synthetic peptides corresponding to selected clones tested to determine their inhibitory activity , ATWLPPR completely abolished ***VEGF*** ***binding*** to cell-displayed ***KDR*** .	parallel	1
12856	10747026	3553;4790	IL-1;NF-kappaB	The atypical PKC-interacting protein p62 channels ***NF-kappaB*** ***activation*** by the ***IL-1-TRAF6*** pathway .	positive	1
12857	10747026	3553;8878	IL-1;p62	The atypical PKC-interacting protein ***p62*** channels NF-kappaB ***activation*** by the ***IL-1-TRAF6*** pathway .	positive	1
12858	10747026	7189;4790	TRAF6;NF-kappaB	The atypical PKC-interacting protein p62 channels ***NF-kappaB*** ***activation*** by the ***IL-1-TRAF6*** pathway .	positive	1
12859	10747026	7189;8878	TRAF6;p62	The atypical PKC-interacting protein ***p62*** channels NF-kappaB ***activation*** by the ***IL-1-TRAF6*** pathway .	positive	1
12860	10747026	7124;4790	tumor necrosis factor alpha;NF-kappaB	The atypical protein kinase C ( aPKC ) - interacting protein , p62 , has previously been shown to interact with RIP , linking these kinases to ***NF-kappaB*** ***activation*** by ***tumor necrosis factor alpha*** ( TNFalpha ) .	positive	1
12861	10747026	3553;4790	IL-1;NF-kappaB	Here we demonstrate that the inhibition of the aPKCs or the down-regulation of p62 severely abrogates ***NF-kappaB*** ***activation*** by ***IL-1*** and TRAF6 , suggesting that both proteins are critical intermediaries in this pathway .	positive	1
12862	10747026	7189;4790	TRAF6;NF-kappaB	Here we demonstrate that the inhibition of the aPKCs or the down-regulation of p62 severely abrogates ***NF-kappaB*** ***activation*** by IL-1 and ***TRAF6*** , suggesting that both proteins are critical intermediaries in this pathway .	positive	1
12863	10747026	8878;7189	p62;TRAF6	The ***binding*** of endogenous ***p62*** to ***TRAF6*** is stimulus dependent , reinforcing the notion that this is a physiologically relevant interaction .	parallel	1
12864	10747035	4173;4998	mcm4;orc1	Binding of ***mcm4*** to chromatin ***requires*** ***orc1*** and cdc18 ( homologous to Cdc6 in budding yeast ) .	target	0
12865	10747083	3875;7133	K18;TNFR2	K8 and ***K18*** both ***bind*** the cytoplasmic domain of ***TNFR2*** and moderate TNF-induced , Jun NH ( 2 ) - terminal kinase ( JNK ) intracellular signaling and NFkappaB activation .	parallel	1
12866	10747091	999;5310	E-cadherin;polycystin-1	Taken together with recent documentation of an ***association*** between ***polycystin-1*** and ***E-cadherin*** ( Huan and van Adelsberg 1999 ) , the data suggest that causal mutations disrupt E-cadherin-dependent cytoarchitecture , adversely affecting protein assemblies crucial for basolateral trafficking .	parallel	0
12867	10747096	55740;7408	Ena;VASP	Inhibition of ***binding*** between Fyb/SLAP and ******Ena/VASP****** proteins or WASP and the Arp2/3 complex impairs TCR-dependent actin rearrangement , suggesting that these interactions play a key role in linking T cell signaling to remodeling of the actin cytoskeleton .	parallel	1
12868	10747192	4915;627	TrkB;BDNF	An inhibitor for receptor tyrosine kinases , K252a , antagonised the action of BDNF , suggesting an involvement of ***BDNF*** ***receptors*** , ***TrkB*** .	parallel	1
12869	10747208	7138;7134	TnT;TnC	***TnT*** also ***interacts*** with ***TnC-TnI*** in a Ca ( 2 + ) - dependent manner .	parallel	1
12870	10747291	5970;4790	p65;p50	We have identified the nuclear NF-kappaB binding activity in mouse skin as composed of ******p50/p65****** ***heterodimers*** and p50 homodimers by supershift assays using different NF-kappaB-containing sequences .	parallel	1
12871	10747315	596;4288	bcl-2;MIB-1	MAIN OUTCOME MEASURES : Degree of ***association*** between histologic grading , ***MIB-1*** , p53 , and ***bcl-2*** immunoreactivity and carcinoid metastatic behavior .	parallel	0
12872	10747315	596;7157	bcl-2;p53	MAIN OUTCOME MEASURES : Degree of ***association*** between histologic grading , MIB-1 , ***p53*** , and ***bcl-2*** immunoreactivity and carcinoid metastatic behavior .	parallel	0
12873	10747315	7157;4288	p53;MIB-1	MAIN OUTCOME MEASURES : Degree of ***association*** between histologic grading , ***MIB-1*** , ***p53*** , and bcl-2 immunoreactivity and carcinoid metastatic behavior .	parallel	0
12874	10747844	4486;4485	RON;macrophage-stimulating protein	We investigated the pathway involved in integrin-mediated RTK activation , using ***RON*** , the ***receptor*** for ***macrophage-stimulating protein*** .	parallel	1
12875	10747844	6714;4486	c-Src;RON	This conclusion is based on these observations : 1 ) ECM-induced RON phosphorylation was inhibited in cells expressing kinase-inactive c-Src ; 2 ) active ***c-Src*** could ***phosphorylate*** immunoprecipitated ***RON*** from ECM-stimulated cells but not from unstimulated cells ; and 3 ) ECM did not cause RON phosphorylation in cells expressing kinase-dead RON , nor could active c-Src phosphorylate RON immunoprecipitated from these cells .	target	1
12876	10747851	8651;7409	Suppressor of cytokine signaling-1;VAV	***Suppressor of cytokine signaling-1*** ***inhibits*** ***VAV*** function through protein degradation .	negative	1
12877	10747851	8651;7409	SOCS1;VAV	***VAV*** and ***SOCS1*** form a protein ***complex*** through interactions between the VAV NH ( 2 ) - terminal regulatory region and the SH2 domain of SOCS1 in a phosphotyrosine-independent manner .	parallel	1
12878	10747851	8651;7409	SOCS1;VAV	***SOCS1*** ***decreases*** the steady state levels of cotransfected VAV and ***onco-VAV*** and reduces the focus forming activity of onco-VAV .	negative	0
12879	10747863	79837;375	phosphatidylinositol 4-phosphate 5-kinase;ADP-ribosylation factor 1	Type I ***phosphatidylinositol 4-phosphate 5-kinase*** directly ***interacts*** with ***ADP-ribosylation factor 1*** and is responsible for phosphatidylinositol 4,5-bisphosphate synthesis in the golgi compartment .	parallel	1
12880	10747867	2033;2099	p300;ERalpha	We found that neither any of the SRC-1 / TIF2 family coactivators nor TRAP220/DRIP205 is potent , whereas ***p300*** ***potentiates*** the AF-1 function of both human ***ERalpha*** and human ERbeta .	positive	0
12881	10747867	2033;2100	p300;ERbeta	We found that neither any of the SRC-1 / TIF2 family coactivators nor TRAP220/DRIP205 is potent , whereas ***p300*** ***potentiates*** the AF-1 function of both human ERalpha and human ***ERbeta*** .	positive	0
12882	10747870	998;5337	Cdc42;phospholipase D1	***Activation*** of ***phospholipase D1*** by ***Cdc42*** requires the Rho insert region .	positive	1
12883	10747870	998;5337	Cdc42;PLD1	In the present study , we demonstrate a physical ***association*** between a Rho family member , ***Cdc42*** , and ***PLD1*** .	parallel	0
12884	10747870	998;5337	Cdc42;PLD1	***Binding*** of ***Cdc42*** to ***PLD1*** and subsequent activation are GTP-dependent .	parallel	1
12885	10747870	998;5337	Cdc42;PLD1	Although ***binding*** of ***Cdc42*** to ***PLD1*** does not require geranylgeranylation , activation of PLD1 is dependent on this lipid modification of Cdc42 .	parallel	1
12886	10747870	998;5337	Cdc42;PLD1	Specific point mutations in the switch I region of Cdc42 abolish binding to and , therefore , ***activation*** of ***PLD1*** by ***Cdc42*** .	positive	1
12887	10747872	3716;6774	JAK1;STAT3	Dominant-negative ***JAK1*** or JAK2 was able to ***block*** the IGF-IR-mediated tyrosine phosphorylation of ***STAT3*** in 293T cells .	negative	0
12888	10747872	3717;6774	JAK2;STAT3	Dominant-negative JAK1 or ***JAK2*** was able to ***block*** the IGF-IR-mediated tyrosine phosphorylation of ***STAT3*** in 293T cells .	negative	0
12889	10747872	1154;6774	SOCS;STAT3	***Inhibition*** of ***STAT3*** activation by ***SOCS*** could be overcome by overexpression of native JAK1 and JAK2 .	negative	1
12890	10747872	3479;6774	IGF-I;STAT3	We conclude that ***IGF-I/IGF-IR*** is able to ***mediate*** activation of ***STAT3*** in vitro and in vivo and that JAKs are essential for the process of activation .	target	0
12891	10747874	51282;7753	SDP1;ZNF202	Biochemical binding studies confirmed the ***associations*** of ZNF191 and ***SDP1*** with ***ZNF202*** and established the SCAN domain as a selective hetero - and homotypic oligomerization domain .	parallel	0
12892	10747874	7572;7753	ZNF191;ZNF202	Biochemical binding studies confirmed the ***associations*** of ***ZNF191*** and SDP1 with ***ZNF202*** and established the SCAN domain as a selective hetero - and homotypic oligomerization domain .	parallel	0
12893	10747892	1647;983	GADD45;Cdc2	The ***GADD45*** ***inhibition*** of ***Cdc2*** kinase correlates with GADD45-mediated growth suppression .	negative	1
12894	10747892	1647;983	GADD45;Cdc2	Recent findings indicate that ***GADD45*** ***interacts*** with ***Cdc2*** protein and inhibits Cdc2 kinase activity .	parallel	1
12895	10747892	1647;983	GADD45;Cdc2	Recent findings indicate that ***GADD45*** interacts with Cdc2 protein and ***inhibits*** ***Cdc2*** kinase activity .	negative	1
12896	10747892	1647;983	GADD45;Cdc2	In the present study , a series of Myc-tagged GADD45 deletion mutants and a GADD45 overlapping peptide library were used to define the GADD45 domains that are involved in the ***interaction*** of ***GADD45*** with ***Cdc2*** .	parallel	1
12897	10747892	1647;983	GADD45;Cdc2	Both in vitro and in vivo studies indicate that the ***interaction*** of ***GADD45*** with ***Cdc2*** involves a central region of the GADD45 protein ( amino acids 65-84 ) .	parallel	1
12898	10747892	1647;983	GADD45;Cdc2	The Cdc2-binding domain of GADD45 is also required for ***GADD45*** ***inhibition*** of ***Cdc2*** kinase activity .	negative	1
12899	10747892	983;891	Cdc2;cyclin B1	The peptide containing the Cdc2-binding domain ( amino acids 65-84 ) disrupted the ******Cdc2-cyclin B1****** protein ***complex*** , suggesting that dissociation of this complex results from a direct interaction between the GADD45 and Cdc2 proteins .	parallel	1
12900	10747892	983;1647	Cdc2;GADD45	The peptide containing the Cdc2-binding domain ( amino acids 65-84 ) disrupted the Cdc2-cyclin B1 protein complex , suggesting that dissociation of this complex results from a direct ***interaction*** between the ***GADD45*** and ***Cdc2*** proteins .	parallel	1
12901	10747893	4792;5970	IkappaBalpha;p65	***GFP-p65*** was ***regulated*** by ***IkappaBalpha*** similar to wild type p65 and associated with its inhibitor even if both proteins were linked to a GFP protein .	target	1
12902	10747895	4846;7124	eNOS;tumor necrosis factor alpha	Here we show that ***eNOS*** ***regulates*** ***tumor necrosis factor alpha*** ( TNFalpha ) through a mechanism dependent on the production of O ( 2 ) and completely independent of NO .	target	1
12903	10747895	4846;7124	eNOS;TNFalpha	Expression of ***eNOS*** in transfected U937 cells ***increased*** phorbol 12-myristate 13-acetate-induced ***TNFalpha*** promoter activity and TNFalpha production .	positive	0
12904	10747897	7124;1432	tumor necrosis factor-alpha;p38 MAP kinase	Furthermore , we demonstrate that anisomycin - and ***tumor necrosis factor-alpha-induced*** phosphorylation of p53 at Ser-392 , which is important for the transcriptional activity of this growth suppressor protein , ***requires*** ***p38 MAP kinase*** and CK2 activities .	target	0
12905	10747899	857;595	caveolin-1;cyclin D1	The ***cyclin D1*** gene is transcriptionally ***repressed*** by ***caveolin-1*** .	negative	1
12906	10747899	857;595	caveolin-1;cyclin D1	We show here that ***caveolin-1*** expression levels inversely ***correlate*** with ***cyclin D1*** abundance levels in transformed cells .	negative	0
12907	10747899	857;595	caveolin-1;cyclin D1	Expression of antisense caveolin-1 increased cyclin D1 levels , whereas ***caveolin-1*** overexpression ***inhibited*** expression of the ***cyclin D1*** gene .	negative	1
12908	10747899	857;595	caveolin-1;cyclin D1	Expression of antisense ***caveolin-1*** ***increased*** ***cyclin D1*** levels , whereas caveolin-1 overexpression inhibited expression of the cyclin D1 gene .	positive	0
12909	10747899	857;595	caveolin-1;cyclin D1	***cyclin D1*** promoter activity was selectively ***repressed*** by ***caveolin-1*** , but not by caveolin-3 , and this repression required the caveolin-1 N terminus .	negative	1
12910	10747899	857;595	caveolin-1;cyclin D1	Maximal ***inhibition*** of the ***cyclin D1*** gene promoter by ***caveolin-1*** was dependent on the cyclin D1 promoter T-cell factor/lymphoid enhancer factor-1-binding site between -81 to -73 .	negative	1
12911	10747902	7975;4780	MafK;Nrf2	In this study , using in vitro binding assays , ******Nrf2/MafK****** ***heterodimers*** were found to interact with high affinity to the ARE .	parallel	1
12912	10747903	7157;6929	p53;transcription factor 3	***p53*** ***suppresses*** the c-Myb-induced activation of heat shock ***transcription factor 3*** .	negative	1
12913	10747925	4214;3661	MEKK1;IRF3	Consistent with this , ***MEKK1*** ***activates*** ***IRF3*** in addition to ATF2/c-JUN and NF-kappaB for the assembly of the IFN-beta enhanceosome .	positive	1
12914	10747925	4214;3661	MEKK1;IRF3	***MEKK1*** ***activates*** ***IRF3*** through the c-JUN amino-terminal kinase ( JNK ) pathway but not the p38 and IkappaB kinase ( IKK ) pathway .	positive	1
12915	10747925	4214;1386	MEKK1;ATF2	Taken together with previous observations , these results implicate that , for the assembly of an IFN-beta enhanceosome , ***MEKK1*** can ***induce*** IRF3 and ***ATF2/c-JUN*** through the JNK pathway , whereas it can induce NF-kappaB through the IKK pathway .	target	1
12916	10747925	4214;3725	MEKK1;c-JUN	Taken together with previous observations , these results implicate that , for the assembly of an IFN-beta enhanceosome , ***MEKK1*** can ***induce*** IRF3 and ***ATF2/c-JUN*** through the JNK pathway , whereas it can induce NF-kappaB through the IKK pathway .	target	1
12917	10747925	4214;3661	MEKK1;IRF3	Taken together with previous observations , these results implicate that , for the assembly of an IFN-beta enhanceosome , ***MEKK1*** can ***induce*** ***IRF3*** and ATF2/c-JUN through the JNK pathway , whereas it can induce NF-kappaB through the IKK pathway .	target	1
12918	10747947	6850;2185	Syk;RAFTK	***Syk*** was also activated upon MIP1beta stimulation of CCR5 L1.2 transfectants or T-cells and ***associated*** with ***RAFTK*** .	parallel	0
12919	10747947	2185;6850	RAFTK;Syk	Overexpression of a dominant-negative Src-binding mutant of RAFTK ( RAFTK ( m402 ) ) significantly attenuated Syk activation , whereas overexpression of wild-type ***RAFTK*** ***enhanced*** ***Syk*** activity , indicating that RAFTK acts upstream of CCR5-mediated Syk activation .	positive	0
12920	10747989	3075;3381	Factor H;bone sialoprotein	***Factor H*** ***binding*** to ***bone sialoprotein*** and osteopontin enables tumor cell evasion of complement-mediated attack .	parallel	1
12921	10747989	3075;6696	Factor H;osteopontin	***Factor H*** ***binding*** to bone sialoprotein and ***osteopontin*** enables tumor cell evasion of complement-mediated attack .	parallel	1
12922	10747989	3381;3075	BSP;complement Factor H	In this report , we show that ***BSP*** and OPN form rapid and tight ***complexes*** with ***complement Factor H*** .	parallel	1
12923	10747989	6696;3075	OPN;complement Factor H	In this report , we show that BSP and ***OPN*** form rapid and tight ***complexes*** with ***complement Factor H*** .	parallel	1
12924	10747998	26986;1975	PABP;eIF4B	In plants , ***PABP*** also ***interacts*** with ***eIF4B*** , a factor that assists eIF4F function .	parallel	1
12925	10748004	207;4790	Akt;NFkappaB	Although ***Akt*** has been reported to ***activate*** ***NFkappaB*** , LY294002 does not prevent TNF - or IL-1-induced degradation of IkappaBalpha , beta , or epsilon , transcription of NFkappaB-dependent E-selectin or ICAM-1 promoter-reporter genes , or surface expression of E-selectin or ICAM-1 in human EC .	positive	1
12926	10748018	5062;4638	PAK2;MLCK	These results demonstrate that ***PAK2*** can directly ***phosphorylate*** ***MLCK*** , inhibiting its activity and limiting the development of isometric tension .	target	1
12927	10748018	5062;4638	PAK2;myosin light chain kinase	***Phosphorylation*** of ***myosin light chain kinase*** by p21-activated kinase ***PAK2*** .	target	1
12928	10748018	5062;4638	PAK2;MLCK	Cdc42-activated placenta and recombinant , constitutively active ***PAK2*** ***phosphorylate*** ***MLCK*** in vitro with a stoichiometry of 1.71 + / - 0 .	target	1
12929	10748018	5062;4638	PAK2;MLCK	***PAK2*** ***catalyzes*** ***MLCK*** phosphorylation on serine residues 439 and 991 .	positive	1
12930	10748020	10891;2099	PGC-1;ERalpha	In this study we demonstrate that ***PGC-1*** is a ***coactivator*** of estrogen receptor-alpha ( ***ERalpha*** ) - dependent transcriptional activity .	positive	1
12931	10748020	10891;2099	PGC-1;ERalpha	However the mechanism by which ***PGC-1*** ***interacts*** with ***ERalpha*** is different from that of PPARgamma .	parallel	1
12932	10748026	836;1499	caspase-3;beta-catenin	Apoptosis-induced ***cleavage*** of ***beta-catenin*** by ***caspase-3*** results in proteolytic fragments with reduced transactivation potential .	target	1
12933	10748032	1385;2668	CREB;ATF	We report here that the TGF-beta-induced transcription from this promoter requires DNA ***binding*** of cAMP-response element-binding protein ( ***CREB*** ) to the nearby ***ATF/cAMP-response*** element site and of Smads to a nearby Smad binding sequence .	parallel	1
12934	10748032	4088;1385	Smad3;CREB	At these sites , ***Smad3/4*** ***cooperates*** with ***CREB*** to activate transcription in response to TGF-beta , and disruption of either binding sequence abolished TGF-beta-induced transcription .	parallel	0
12935	10748032	861;4088	AML1;Smad3	In addition , ***AML1*** or AML2 also binds to the promoter and ***cooperates*** with ***Smad3/4*** , and in this way further enhances the TGF-beta-induced transcriptional activation of the GL Ig alpha promoter .	parallel	0
12936	10748032	7040;973	TGF-beta;Ig alpha	In addition , AML1 or AML2 also binds to the promoter and cooperates with Smad3/4 , and in this way further enhances the ***TGF-beta-induced*** transcriptional ***activation*** of the GL ***Ig alpha*** promoter .	positive	1
12937	10748032	861;973	AML1;Ig alpha	In addition , ***AML1*** or AML2 also binds to the promoter and cooperates with Smad3/4 , and in this way further ***enhances*** the TGF-beta-induced transcriptional activation of the GL ***Ig alpha*** promoter .	positive	0
12938	10748033	6667;5315	Sp1;PKM	In addition , the overexpression of ***Sp1*** or Sp3 and NF-Y in Drosophila SL2 cells synergistically ***stimulated*** ***PKM*** gene distal promoter activity .	positive	0
12939	10748033	6670;5315	Sp3;PKM	In addition , the overexpression of Sp1 or ***Sp3*** and NF-Y in Drosophila SL2 cells synergistically ***stimulated*** ***PKM*** gene distal promoter activity .	positive	0
12940	10748033	6667;4800	Sp1;NF-YA	Using a mammalian two-hybrid system in HeLa cells , it was shown that both ***Sp1*** and Sp3 ***interacted*** with ***NF-YA*** but not NF-YB and NF-YC .	parallel	1
12941	10748033	6670;4800	Sp3;NF-YA	Using a mammalian two-hybrid system in HeLa cells , it was shown that both Sp1 and ***Sp3*** ***interacted*** with ***NF-YA*** but not NF-YB and NF-YC .	parallel	1
12942	10748033	4800;6667	NF-YA;Sp1	Moreover , glutathione S-transferase pull-down assays revealed that only in vitro translated ( 35 ) S-labeled ***NF-YA*** ***interacted*** with both ***Sp1*** and Sp3 in vitro .	parallel	1
12943	10748033	4800;6670	NF-YA;Sp3	Moreover , glutathione S-transferase pull-down assays revealed that only in vitro translated ( 35 ) S-labeled ***NF-YA*** ***interacted*** with both Sp1 and ***Sp3*** in vitro .	parallel	1
12944	10748033	6667;5315	Sp1;PKM	Thus , we conclude that ***Sp1*** , Sp3 , and NF-Y ***stimulate*** the transcription of the ***PKM*** gene via their interactions .	positive	0
12945	10748033	6670;5315	Sp3;PKM	Thus , we conclude that Sp1 , ***Sp3*** , and NF-Y ***stimulate*** the transcription of the ***PKM*** gene via their interactions .	positive	0
12946	10748034	3838;5079	importin alpha1;BSAP	Physical ***interaction*** between ***BSAP*** and ***importin alpha1*** was detected in vitro by a glutathione S-transferase ( GST ) pulldown assay .	parallel	1
12947	10748052	2885;4914	Grb2;TrkA	We demonstrate that the signaling adapter , ***Grb2*** , ***binds*** directly to the neurotrophin receptor tyrosine kinase , ***TrkA*** .	parallel	1
12948	10748052	2885;4914	Grb2;TrkA	***Grb2*** ***binding*** to ***TrkA*** is independent of Shc , FRS-2 , phospholipase Cgamma-1 , rAPS , and SH2B and is observed in in vitro binding assays , yeast two-hybrid assays , and in co-immunoprecipitation assays .	parallel	1
12949	10748052	2885;4914	Grb2;TrkA	***Grb2*** ***binding*** to ***TrkA*** is mediated by the central SH2 domain , requires a kinase-active TrkA , and is phosphotyrosine-dependent .	parallel	1
12950	10748052	2885;4914	Grb2;TrkA	***Grb2*** binding to TrkA is mediated by the central SH2 domain , ***requires*** a kinase-active ***TrkA*** , and is phosphotyrosine-dependent .	target	0
12951	10748052	2885;4914	Grb2;TrkA	By using acidic amino acid substitutions of the activation loop tyrosines on TrkA , we can stimulate constitutive kinase activity and TrkA-Shc interactions but , importantly , abolish ******TrkA/Grb2****** ***binding*** .	parallel	1
12952	10748052	6464;4914	Shc;TrkA	By using acidic amino acid substitutions of the activation loop tyrosines on TrkA , we can stimulate constitutive kinase activity and ******TrkA-Shc****** ***interactions*** but , importantly , abolish TrkA/Grb2 binding .	parallel	1
12953	10748052	2885;4914	Grb2;TrkA	Thus , in addition to providing the first evidence of direct ***Grb2*** ***binding*** to the neurotrophin receptor , ***TrkA*** , these data provide the first direct evidence that the activation loop tyrosines of a receptor tyrosine kinase , in addition to their essential role in kinase activation , also serve a direct role in the recruitment of intracellular signaling molecules .	parallel	1
12954	10748054	2885;933	Grb2;CD22	All three molecules were bound to CD22 when isolated from BCR-stimulated splenic B cells , indicating the formation of a ******CD22.Grb2.Shc.SHIP****** quaternary ***complex*** .	parallel	1
12955	10748054	2885;6464	Grb2;Shc	All three molecules were bound to CD22 when isolated from BCR-stimulated splenic B cells , indicating the formation of a ******CD22.Grb2.Shc.SHIP****** quaternary ***complex*** .	parallel	1
12956	10748054	6464;933	Shc;CD22	All three molecules were bound to CD22 when isolated from BCR-stimulated splenic B cells , indicating the formation of a ******CD22.Grb2.Shc.SHIP****** quaternary ***complex*** .	parallel	1
12957	10748061	5916;1022	RARgamma;cdk7	***RARgamma*** is more efficiently phosphorylated by TFIIH than by CAK and ***interacts*** not only with ***cdk7*** but also with several additional subunits of TFIIH .	parallel	1
12958	10748061	902;5916	CAK;RARgamma	***RARgamma*** is more efficiently ***phosphorylated*** by TFIIH than by ***CAK*** and interacts not only with cdk7 but also with several additional subunits of TFIIH .	target	1
12959	10748068	4884;5955	NP1;TCBP49	***NP1*** and NP2 are secreted , exist as higher order multimers ( probably pentamers ) , and ***interact*** with taipoxin and taipoxin-associated calcium-binding protein 49 ( ***TCBP49*** ) .	parallel	1
12960	10748079	3725;2353	c-Jun;c-Fos	Dexamethasone suppressed the abundance of the ******c-Fos/c-Jun****** ***complex*** in THP-1 cell nuclei , but there was no direct evidence for c-Fos/c-Jun transactivation through sites in the -172 to -52 bp region .	parallel	1
12961	10748082	3932;7409	Lck;Vav	Additionally , ***Lck*** ***phosphorylation*** of ***Vav*** , a known activating event , reduces the affinities between the Vav Dbl homology and pleckstrin homology domains and permits Rac binding .	target	1
12962	10748083	8454;9978	CUL1;ROC1	Consistent with this , these reagents also eliminate the ability of the ******Skp1-CUL1-HOS-ROC1****** E3 ligase ***complex*** to support the ubiquitination of IkappaBalpha .	parallel	1
12963	10748083	8454;6500	CUL1;Skp1	Consistent with this , these reagents also eliminate the ability of the ******Skp1-CUL1-HOS-ROC1****** E3 ligase ***complex*** to support the ubiquitination of IkappaBalpha .	parallel	1
12964	10748083	23291;8454	HOS;CUL1	Consistent with this , these reagents also eliminate the ability of the ******Skp1-CUL1-HOS-ROC1****** E3 ligase ***complex*** to support the ubiquitination of IkappaBalpha .	parallel	1
12965	10748083	23291;9978	HOS;ROC1	Consistent with this , these reagents also eliminate the ability of the ******Skp1-CUL1-HOS-ROC1****** E3 ligase ***complex*** to support the ubiquitination of IkappaBalpha .	parallel	1
12966	10748083	23291;6500	HOS;Skp1	Consistent with this , these reagents also eliminate the ability of the ******Skp1-CUL1-HOS-ROC1****** E3 ligase ***complex*** to support the ubiquitination of IkappaBalpha .	parallel	1
12967	10748083	6500;9978	Skp1;ROC1	Consistent with this , these reagents also eliminate the ability of the ******Skp1-CUL1-HOS-ROC1****** E3 ligase ***complex*** to support the ubiquitination of IkappaBalpha .	parallel	1
12968	10748095	3553;5599	IL-1beta;JNK	***Activation*** of ***JNK*** by interleukin 1 ( ***IL-1beta*** ) or by the upstream JNK constitutive activator DeltaMEKK1 promoted apoptosis in two pancreatic beta cell lines and decreased IB1 content by 50-60 % .	positive	1
12969	10748095	5599;9479	JNK;IB1	Activation of ***JNK*** by interleukin 1 ( IL-1beta ) or by the upstream JNK constitutive activator DeltaMEKK1 promoted apoptosis in two pancreatic beta cell lines and ***decreased*** ***IB1*** content by 50-60 % .	negative	0
12970	10748100	4091;1432	Smad6;p38	Interestingly , this ectopic expression of ***Smad6*** ***blocks*** BMP2-induced TAK1 activation and ***p38*** phosphorylation .	negative	0
12971	10748100	4091;6885	Smad6;TAK1	Interestingly , this ectopic expression of ***Smad6*** ***blocks*** BMP2-induced ***TAK1*** activation and p38 phosphorylation .	negative	0
12972	10748100	4091;6885	Smad6;TAK1	Moreover , ***Smad6*** can directly ***bind*** to ***TAK1*** .	parallel	1
12973	10748100	4091;6885	Smad6;TAK1	These findings suggest that ***Smad6*** is likely to function as a negative ***regulator*** of the ***TAK1*** pathway in the BMP2 signaling , in addition to the previously reported Smad pathway .	negative	1
12974	10748100	4091;1432	Smad6;p38	BMP2-induced apoptosis is mediated by activation of the ***TAK1-p38*** kinase pathway that is negatively ***regulated*** by ***Smad6*** .	negative	1
12975	10748100	4091;6885	Smad6;TAK1	BMP2-induced apoptosis is mediated by activation of the ***TAK1-p38*** kinase pathway that is negatively ***regulated*** by ***Smad6*** .	negative	1
12976	10748100	3569;6774	IL-6;STAT3	BMP2 has no inhibitory effect on the ***IL-6-induced*** tyrosine ***phosphorylation*** of ***STAT3*** , and the bcl-2 gene expression which is known to be regulated by STAT3 , suggesting that BMP2-induced apoptosis is not attributed to alteration of the IL-6-mediated bcl-2 pathway .	target	1
12977	10748100	6774;596	STAT3;bcl-2	BMP2 has no inhibitory effect on the IL-6-induced tyrosine phosphorylation of STAT3 , and the ***bcl-2*** gene expression which is known to be ***regulated*** by ***STAT3*** , suggesting that BMP2-induced apoptosis is not attributed to alteration of the IL-6-mediated bcl-2 pathway .	target	1
12978	10748100	650;1432	BMP2;p38	We demonstrate that ***BMP2*** ***induces*** activation of TGF-beta-activated kinase ( TAK1 ) and subsequent phosphorylation of ***p38*** stress-activated protein kinase .	target	1
12979	10748100	650;56911	BMP2;TGF-beta-activated kinase	We demonstrate that ***BMP2*** ***induces*** activation of ***TGF-beta-activated kinase*** ( TAK1 ) and subsequent phosphorylation of p38 stress-activated protein kinase .	target	1
12980	10748105	5378;4292	hPMS1;hMLH1	In this study , we describe the ***association*** of ***hPMS1*** with ***hMLH1*** as a heterodimer , in human cells .	parallel	0
12981	10748109	183;6772	angiotensin II;STAT1	After binding ligand , both the M5 and M6 AT ( 1 ) receptors trigger STAT1 tyrosine phosphorylation equivalent to that observed with the wild type receptor , indicating that ***angiotensin II-mediated*** ***phosphorylation*** of ***STAT1*** is independent of these receptor tyrosine residues .	target	1
12982	10748109	3717;6772	Jak2;STAT1	In response to angiotensin II , Jak2 autophosphorylates on tyrosine , and ***Jak2*** and ***STAT1*** physically ***associate*** , a process that depends on the SH2 domain of STAT1 in vitro .	parallel	0
12983	10748109	6772;4012	STAT1;AT(1) receptor	Immunodepletion of Jak2 virtually eliminated the ligand-dependent ***binding*** of ***STAT1*** to the ***AT(1) receptor*** .	parallel	1
12984	10748109	6772;4012	STAT1;AT(1) receptor	These data indicate that the association of STAT1 with the AT(1) receptor is not strictly bimolecular ; it requires Jak2 as both a STAT1 kinase and as a molecular bridge ***linking*** ***STAT1*** to the ***AT(1) receptor*** .	parallel	0
12985	10748109	6772;4012	STAT1;AT(1) receptor	These data indicate that the ***association*** of ***STAT1*** with the ***AT(1) receptor*** is not strictly bimolecular ; it requires Jak2 as both a STAT1 kinase and as a molecular bridge linking STAT1 to the AT(1) receptor .	parallel	0
12986	10748110	326;1387	autoimmune regulator;CREB-binding protein	The ***autoimmune regulator*** protein has transcriptional transactivating properties and ***interacts*** with the common coactivator ***CREB-binding protein*** .	parallel	1
12987	10748110	1387;326	CREB-binding protein;AIRE	In agreement , we show that the common transcriptional coactivator ***CREB-binding protein*** ( CBP ) ***interacts*** with ***AIRE*** in vitro and in yeast nuclei through the CH1 and CH3 conserved domains .	parallel	1
12988	10748114	1017;4173	Cdk2;Mcm4	The cyclin ***A/Cdk2*** mainly ***phosphorylated*** the amino-terminal region of ***Mcm4*** in the Mcm4 ,6,7 complex .	target	1
12989	10748114	1017;4173	Cdk2;Mcm4	These results raise the possibility that the ***inactivation*** of ***Mcm4*** ,6,7 helicase activity by ***Cdk2*** is a part of the system for regulating DNA replication .	negative	1
12990	10748121	8828;7422	Neuropilin-2;VEGF	***Neuropilin-2*** is a ***receptor*** for the vascular endothelial growth factor ( ***VEGF*** ) forms VEGF-145 and VEGF-165 [ corrected ] .	parallel	1
12991	10748126	5087;3211	PBX1;HOXB1	In the presence of all three nuclear factors , cooperative ***interactions*** between recombinant ***PBX1*** and PREP1 or PBX1 and ***HOXB1*** result in binding of the heterodimers to FPB in vitro .	parallel	1
12992	10748126	5316;3211	PREP1;HOXB1	In the presence of all three nuclear factors , cooperative ***interactions*** between recombinant PBX1 and ***PREP1*** or PBX1 and ***HOXB1*** result in binding of the heterodimers to FPB in vitro .	parallel	1
12993	10748126	5316;5087	PREP1;PBX1	In the presence of all three nuclear factors , cooperative ***interactions*** between recombinant ***PBX1*** and ***PREP1*** or PBX1 and HOXB1 result in binding of the heterodimers to FPB in vitro .	parallel	1
12994	10748131	6416;5599	SEK1;JNK	Overexpression of a dominant negative mutant form of ***SEK1*** , an upstream ***activator*** of ***JNK*** , likewise suppressed JNK activation and inhibited apoptosis .	positive	1
12995	10748139	958;7186	CD40;TRAF2	We show for the first time that engagement of ***CD40*** in intact B cells ***induces*** the rapid translocation of ***TRAF2*** from the cytoplasm to the plasma membrane .	target	1
12996	10748148	373;9267	ARD1;cytohesin-1	Specific functional ***interaction*** of human ***cytohesin-1*** and ADP-ribosylation factor domain protein ( ***ARD1*** ) .	parallel	1
12997	10748148	373;9267	ARD1;cytohesin-1	In this system , ***ARD1-GDP*** ***interacted*** well with ***cytohesin-1*** but very poorly with cytohesin-2 .	parallel	1
12998	10748151	5170;5058	PDK1;p21-activated kinase 1	In this study , we show that ***p21-activated kinase 1*** , the activity of which is regulated by the GTP-bound form of Cdc42 and Rac and by sphingosine , is ***phosphorylated*** by ***PDK1*** .	target	1
12999	10748151	998;5058	Cdc42;p21-activated kinase 1	In this study , we show that ***p21-activated kinase 1*** , the activity of which is ***regulated*** by the GTP-bound form of ***Cdc42*** and Rac and by sphingosine , is phosphorylated by PDK1 .	target	1
13000	10748151	207;5058	Rac;p21-activated kinase 1	In this study , we show that ***p21-activated kinase 1*** , the activity of which is ***regulated*** by the GTP-bound form of Cdc42 and ***Rac*** and by sphingosine , is phosphorylated by PDK1 .	target	1
13001	10748151	5170;5058	PDK1;p21-activated kinase 1	***Phosphorylation*** of ***p21-activated kinase 1*** by ***PDK1*** occurred only in the presence of sphingosine , which increased PDK1 autophosphorylation 25-fold .	target	1
13002	10748157	260425;207	MAGI3;PKB	Importantly , ***MAGI3*** and PTEN/MMAC cooperate to ***modulate*** the kinase activity of ***AKT/PKB*** .	target	0
13003	10748162	7157;624	p53;BK2	Furthermore , ***p53-mediated*** ***activation*** of the ***BK2*** promoter is augmented by the transcriptional co-activators , CBP/p300 .	positive	1
13004	10748162	7157;624	p53;BK2	Interestingly , removal of the P2 site by truncation or site-directed deletion amplifies ***p53-mediated*** ***activation*** of the ***BK2*** promoter .	positive	1
13005	10748162	624;3827	BK2;bradykinin	The ***bradykinin*** type 2 ***receptor*** ( ***BK2*** ) is a developmentally regulated G protein-coupled receptor that mediates diverse actions such as vascular reactivity , salt and water excretion , inflammatory responses , and cell growth .	parallel	1
13006	10748162	7157;624	p53;BK2	Transient transfection into HeLa cells of a CAT reporter construct driven by 1.2-kilobases of the BK2 gene 5 ' - flanking region demonstrated that the ***BK2*** promoter is dose dependently ***activated*** by co-expression of wild-type ***p53*** .	positive	1
13007	10748162	7157;624	p53;BK2	Co-expression of a dominant negative mutant p53 suppresses the ***activation*** of ***BK2*** by wild-type ***p53*** .	positive	1
13008	10748162	7157;624	p53;BK2	Co-expression of a dominant negative mutant ***p53*** ***suppresses*** the activation of ***BK2*** by wild-type p53 .	negative	1
13009	10748169	5664;6717	Presenilin 2;sorcin	***Presenilin 2*** ***interacts*** with ***sorcin*** , a modulator of the ryanodine receptor .	parallel	1
13010	10748169	5664;6717	PS2;sorcin	The ***association*** of endogenous ***sorcin*** and ***PS2*** was demonstrated in cultured cells and human brain tissues .	parallel	0
13011	10748169	5664;6717	PS2;sorcin	sorcin was found to interact with PS2 endoproteolytic fragments but not full-length PS2 , and the ******sorcin/PS2****** ***interaction*** was greatly enhanced by treatment with the Ca ( 2 + ) ionophore A23187 .	parallel	1
13012	10748187	5609;5594	MEK;ERK	ERK1b , a 46-kDa ***ERK*** isoform that is differentially ***regulated*** by ***MEK*** .	target	1
13013	10748198	166;2305	Grg5;HNF3	Overexpression of TLE1 in HepG2 and HeLa cells decreases transactivation mediated through the C-terminal domain of HNF3beta , and ***Grg5*** , a naturally occurring dominant negative form of Groucho/TLE , also ***increases*** the transcriptional activity of this region of ***HNF3*** .	positive	0
13014	10748202	5604;595	MEK1;cyclin D1	Wnt1 and ***MEK1*** cooperate to ***promote*** ***cyclin D1*** accumulation and cellular transformation .	positive	0
13015	10748202	7471;595	Wnt1;cyclin D1	***Wnt1*** and MEK1 cooperate to ***promote*** ***cyclin D1*** accumulation and cellular transformation .	positive	0
13016	10748202	5604;7471	MEK1;Wnt1	***Wnt1*** and ***MEK1*** ***cooperate*** to promote cyclin D1 accumulation and cellular transformation .	parallel	0
13017	10748203	5893;5888	Rad52;Rad51	Maximal restoration of pairing and strand exchange requires amounts of Rad52 substoichiometric to Rad51 and involves a stable , equimolar ***complex*** between ***Rad51*** and ***Rad52*** .	parallel	1
13018	10748203	5893;5888	Rad52;Rad51	The ******Rad51-Rad52****** ***complex*** efficiently utilizes a ssDNA template saturated with RPA for homologous pairing but does not appear to be more active than Rad51 when an RPA-free ssDNA template is used .	parallel	1
13019	10748204	4209;4205	MEF2D;MEF2A	These data strongly suggest that the ******MEF2A-MEF2D****** ***heterodimer*** is selectively decreased in insulin-deficient diabetes and is responsible for hormonally regulated expression of the GLUT4 gene .	parallel	1
13020	10748204	4209;4205	MEF2D;MEF2A	Co-immunoprecipitation with isoform-specific antibodies revealed that , in the basal state , essentially all of the MEF2A protein was presented as a ******MEF2A-MEF2D****** ***heterodimer*** without any detectable MEF2A-MEF2A homodimers or MEF2A-MEF2C and MEF2C-MEF2D heterodimers .	parallel	1
13021	10748204	4208;4205	MEF2C;MEF2A	Co-immunoprecipitation with isoform-specific antibodies revealed that , in the basal state , essentially all of the MEF2A protein was presented as a MEF2A-MEF2D heterodimer without any detectable MEF2A-MEF2A homodimers or ******MEF2A-MEF2C****** and MEF2C-MEF2D ***heterodimers*** .	parallel	1
13022	10748204	4209;4208	MEF2D;MEF2C	Co-immunoprecipitation with isoform-specific antibodies revealed that , in the basal state , essentially all of the MEF2A protein was presented as a MEF2A-MEF2D heterodimer without any detectable MEF2A-MEF2A homodimers or MEF2A-MEF2C and ******MEF2C-MEF2D****** ***heterodimers*** .	parallel	1
13023	10748204	4209;4205	MEF2D;MEF2A	Furthermore , immunodepletion of the ******MEF2A-MEF2D****** ***complex*** from control extracts abolished binding to the MEF2 element .	parallel	1
13024	10748217	5444;4018	PON1;lipoprotein	Serum paraoxonase ( ***PON1*** ) , present on high density lipoprotein , may ***inhibit*** low density ***lipoprotein*** ( LDL ) oxidation and protect against atherosclerosis .	negative	1
13025	10748218	5700;5688	PSMC1;PSMA7	Here we demonstrate that ***PSMC1*** , an ATPase-like subunit of the 19 S proteasome component , also ***interacts*** with HBX and ***PSMA7*** .	parallel	1
13026	10748219	29953;7200	TRH-DE;thyrotropin-releasing hormone	Evidence indicates that neuronally released ***thyrotropin-releasing hormone*** ( TRH ) is selectively ***inactivated*** by TRH-degrading ectoenzyme ( ***TRH-DE*** ) ( EC ) .	negative	1
13027	10748223	273;7020	amphiphysin;AP-2	Overexpression in Chinese hamster ovary cells of an ***amphiphysin*** 1 fragment that ***binds*** both ***AP-2*** and clathrin resulted in a segregation of clathrin , which acquired a diffuse distribution , from AP-2 , which accumulated at patches also positive for Eps15 .	parallel	1
13028	10748223	273;7020	amphiphysin;AP-2	The ***interaction*** of ***amphiphysin*** 1 with either clathrin or ***AP-2*** did not prevent its interaction with dynamin , supporting the existence of tertiary complexes between these proteins .	parallel	1
13029	10748234	6863;3738	substance P;Kv1.3	In support of this notion , we found that the proadhesive effects of the chemokine macrophage-inflammatory protein 1beta , the neuropeptide calcitonin gene-related peptide ( CGRP ) , as well as elevated [ K ( + ) ] ( o ) levels , are blocked by specific Kv1.3 channel blockers , and that the unique physiological ability of ***substance P*** to inhibit T cell adhesion ***correlates*** with ***Kv1.3*** inhibition .	parallel	0
13030	10748240	3605;5599	IL-17;JNK	In embryonic fibroblasts ( EFs ) derived from TRAF6 knockout mice , ***IL-17*** failed to ***activate*** the IkappaB kinases ( IKKs ) and ***JNK*** .	positive	1
13031	10748267	1490;836	hCTGF;caspase 3	These results suggest that ***r-hCTGF*** ***activates*** ***caspase 3*** and induces apoptosis .	positive	1
13032	10748276	3082;4586	Hepatocyte growth factor;mucin	***Hepatocyte growth factor*** region specifically ***activates*** ***mucin*** synthesis in rat stomach .	positive	1
13033	10748276	3082;4586	HGF;mucin	***HGF*** ***stimulated*** the ***mucin*** biosynthesis in the surface and gland mucus cells of corpus , but not in the antrum , without its trophic effects .	positive	0
13034	10748866	1471;1508	cystatin C;cysteine protease	To improve the current knowledge of the regulatory role of a major mammalian ***cysteine protease*** ***inhibitor*** , ***cystatin C*** , in such disease processes , a cystatin C deficient mouse was generated and characterized .	negative	1
13035	10749115	958;959	CD40;CD40L	The therapy was largely independent of CD8 + cells but required IFN-gamma and ******CD40-CD40L****** ***interactions*** , suggesting that tumor-specific Th1 cells eradicate established tumors by activating proinflammatory macrophages .	parallel	1
13036	10749118	675;701	BRCA2;hBUBR1	Here we report ***interaction*** of ***BRCA2*** with a mitotic checkpoint protein , ***hBUBR1*** , and its phosphorylation by hBUBR1 in vitro .	parallel	1
13037	10749135	842;841	caspase-9;caspase-8	This conclusion is supported by the observation that in HL-60 / Apaf-1 cells , ectopic expression of dominant negative ***caspase-9*** , its inhibitory short isoform caspase-9b , or XIAP or treatment with the caspase inhibitor zVAD ( 50 microM ) ***inhibited*** Apaf-1-induced ***caspase-8*** and Bid cleavage , mitochondrial deltapsim , release of cyt c , and apoptosis .	negative	1
13038	10749135	331;841	XIAP;caspase-8	This conclusion is supported by the observation that in HL-60 / Apaf-1 cells , ectopic expression of dominant negative caspase-9 , its inhibitory short isoform caspase-9b , or ***XIAP*** or treatment with the caspase inhibitor zVAD ( 50 microM ) ***inhibited*** Apaf-1-induced ***caspase-8*** and Bid cleavage , mitochondrial deltapsim , release of cyt c , and apoptosis .	negative	1
13039	10749144	7157;1647	p53;gadd45	A DNA damage signal is required for ***p53*** to ***activate*** ***gadd45*** .	positive	1
13040	10749144	7157;1647	p53;gadd45	We provide direct evidence that overexpression of p53 is not sufficient for robust ***p53-dependent*** ***activation*** of the endogenous ***gadd45*** gene .	positive	1
13041	10749215	8573;10716	CASK;Tbr-1	Here we report that , through its guanylate kinase domain , ***CASK*** ***interacts*** with ***Tbr-1*** , a T-box transcription factor that is involved in forebrain development .	parallel	1
13042	10749215	8573;10716	CASK;Tbr-1	***CASK*** acts as a ***coactivator*** of ***Tbr-1*** to induce transcription of T-element containing genes , including reelin , a gene that is essential for cerebrocortical development .	positive	1
13043	10749342	4790;5970	p50;p65	Treatment with H. pylori resulted in the activation of two species of NF-kappaB dimers ( a ******p50/p65****** ***heterodimer*** and a p50 homodimer ) .	parallel	1
13044	10749575	5122;2641	PC1;glucagon-like peptide 1	Regulation of pancreatic ***PC1*** and PC2 ***associated*** with increased ***glucagon-like peptide 1*** in diabetic rats .	parallel	0
13045	10749577	6348;3458	MIP-1alpha;IFN-gamma	***MIP-1alpha*** deficiency profoundly decreased resistance to MCMV and was ***associated*** with dramatically reduced NK cell accumulation and ***IFN-gamma*** production in liver .	parallel	0
13046	10749579	5443;7200	alpha-MSH;thyrotropin releasing hormone	In vitro , ***alpha-MSH*** ***increased*** ***thyrotropin releasing hormone*** ( TRH ) release from hypothalamic explants .	positive	0
13047	10749663	4018;4035	lipoprotein;apolipoprotein E receptor	Very-low-density ***lipoprotein*** ***binding*** to the ***apolipoprotein E receptor*** 2 is enhanced by lipoprotein lipase , and does not require apolipoprotein E .	parallel	1
13048	10749663	4023;4018	lipoprotein lipase;lipoprotein	Very-low-density ***lipoprotein*** binding to the apolipoprotein E receptor 2 is ***enhanced*** by ***lipoprotein lipase*** , and does not require apolipoprotein E .	positive	0
13049	10749663	4018;7804	lipoprotein;apoER2	In conclusion , ***lipoprotein*** ***binding*** of VLDL to the ***apoER2*** is enhanced in the presence of LPL , and is not restricted to apoE-containing lipoproteins .	parallel	1
13050	10749669	5609;1977	MEK;eIF4E	In serum-starved cells , activation of protein synthesis , phosphorylation of ***eIF4E*** , and formation of the eIF4F complex , were ***blocked*** by inhibition of ***MEK*** , a component of the extracellular regulated kinase ( ERK ) signalling pathway .	positive	0
13051	10749670	3082;3918	hepatocyte growth factor;laminin gamma2	Involvement of activator protein 1 complexes in the epithelium-specific ***activation*** of the ***laminin gamma2-chain*** gene promoter by ***hepatocyte growth factor*** ( scatter factor ) .	positive	1
13052	10749673	3827;5967	bradykinin;PTP	Although Src does not participate in ***bradykinin-induced*** ***stimulation*** of ***PTP*** activity , inhibition of Src by 4-amino-5 - ( 4-methylphenyl ) -7 - ( t-butyl ) pyrazolo ( 3,4-d ) pyrimidine leads to an increase in MAPK activation by bradykinin .	positive	0
13053	10749673	3827;5967	bradykinin;PTP	Three lines of evidence suggest the ***activation*** of a protein tyrosine phosphatase ( ***PTP*** ) by ***bradykinin*** : ( i ) treatment of A431 cells with bradykinin decreases both basal and EGF-induced EGFR tyrosine phosphorylation , ( ii ) this effect of bradykinin can be blocked by two different PTP inhibitors , and ( iii ) bradykinin significantly increased the PTP activity in total A431 cell lysates when measured in vitro .	positive	1
13054	10749673	3827;5967	bradykinin;PTP	Three lines of evidence suggest the activation of a protein tyrosine phosphatase ( PTP ) by bradykinin : ( i ) treatment of A431 cells with bradykinin decreases both basal and EGF-induced EGFR tyrosine phosphorylation , ( ii ) this effect of bradykinin can be blocked by two different PTP inhibitors , and ( iii ) ***bradykinin*** significantly ***increased*** the ***PTP*** activity in total A431 cell lysates when measured in vitro .	positive	0
13055	10749676	7057;3273	TSP1;histidine-rich glycoprotein	We conclude that TSP1 contains a high-affinity binding site for polyhistidine and this is likely to be the molecular basis for the observed ***binding*** of ***TSP1*** to ***histidine-rich glycoprotein*** .	parallel	1
13056	10749680	25759;2321	Sck;Flt1	Furthermore , we demonstrate that in the two-hybrid assay , both Shc and ***Sck*** SH2 domains can ***associate*** with the related receptor ***Flt1*** .	parallel	0
13057	10749696	7040;948	TGF-beta1;CD36	At initially low picomolar concentrations , ***TGF-beta1*** ***decreased*** ***CD36*** mRNA and protein surface expression and ScR-A mRNA levels in the human monocytic cell line THP-1 and in freshly isolated and cultivated human monocytes , whereas LOX-1 mRNA was increased .	negative	0
13058	10749698	1977;1981	eIF4E;eIF4G	Concomitant with this , insulin increased the ***binding*** of ***eIF4E*** to ***eIF4G*** .	parallel	1
13059	10749702	7124;3303	tumor necrosis factor-alpha;HSP72	Previously we have observed that the inflammatory cytokine ***tumor necrosis factor-alpha*** ***increases*** ***HSP72*** levels and postulated that dexamethasone might effect the heat shock response .	positive	0
13060	10749726	857;5594	Caveolin-1;ERK	We hypothesized that ***Caveolin-1*** ***regulates*** shear activation of ***ERK*** .	target	1
13061	10749759	7040;1889	TGF-beta1;ECE-1	***TGF-beta1*** ***downregulated*** ET-1-stimulated ppET-1 and ***ECE-1*** transcripts but only in L2 cells .	negative	1
13062	10749759	7040;1906	TGF-beta1;ppET-1	***TGF-beta1*** ***downregulated*** ET-1-stimulated ***ppET-1*** and ECE-1 transcripts but only in L2 cells .	negative	1
13063	10749781	8801;6550	Gbeta;NHE3	In contrast , Gbeta expression and the amount of ***Gbeta*** that ***coimmunoprecipitated*** with ***NHE3*** in BBMV was greatest in 2-wk-old rats and decreased with age .	parallel	1
13064	10749781	8801;6550	Gbeta;Na/H exchanger-3	***Gbeta*** ***regulation*** of ***Na/H exchanger-3*** activity in rat renal proximal tubules during development .	target	1
13065	10749790	356;355	FasL;Fas	However , little is known about the underlying mechanisms responsible for the increased apoptosis of lymphoid and parenchymal cells in solid organs and the role played by inflammatory mediators , such as tumor necrosis factor-alpha ( TNF-alpha ) and ***Fas*** ***ligand*** ( ***FasL*** ) , as well as by glucocorticoids .	parallel	1
13066	10749849	7157;1026	p53;p21	The physiological relevance of Gklf in mediating ***p53-dependent*** ***induction*** of ***p21*** ( WAF1/Cip1 ) is demonstrated by the ability of antisense Gklf oligonucleotides to block the production of p21 ( WAF1/Cip1 ) in response to p53 activation .	target	1
13067	10749849	9314;7157	Kruppel-like factor 4;p53	The gut-enriched Kruppel-like factor ( ***Kruppel-like factor 4*** ) ***mediates*** the transactivating effect of ***p53*** on the p21WAF1/Cip1 promoter .	target	0
13068	10749849	9314;1026	Gklf;p21	Moreover , during the first 30 min of methyl methanesulfonate treatment , the rise in Gklf mRNA level precedes that in p21 ( WAF1/Cip1 ) , suggesting that ***Gklf*** may be involved in the ***induction*** of ***p21*** ( WAF1/Cip1 ) .	target	1
13069	10749849	9314;1026	Gklf;p21	Indeed , ***Gklf*** ***activates*** ***p21*** ( WAF1/Cip1 ) through a specific Sp1-like cis-element in the p21 ( WAF1/Cip1 ) proximal promoter .	positive	1
13070	10749849	7157;9314	p53;Gklf	Potential mechanisms by which p53 activates the p21 ( WAF1/Cip1 ) promoter include a physical interaction between p53 and Gklf and the transcriptional ***induction*** of ***Gklf*** by ***p53*** .	target	1
13071	10749849	7157;9314	p53;Gklf	Potential mechanisms by which p53 activates the p21 ( WAF1/Cip1 ) promoter include a physical ***interaction*** between ***p53*** and Gklf and the transcriptional induction of ***Gklf*** by p53 .	parallel	1
13072	10749849	7157;1026	p53;p21	Potential mechanisms by which ***p53*** ***activates*** the ***p21*** ( WAF1/Cip1 ) promoter include a physical interaction between p53 and Gklf and the transcriptional induction of Gklf by p53 .	positive	1
13073	10749851	3609;3276	ILF3;PRMT1	***ILF3*** is a robust substrate for methylation by PRMT1 and can ***modulate*** ***PRMT1*** activity in in vitro methylation assays .	target	0
13074	10749851	3609;3276	ILF3;PRMT1	Deletion studies demonstrated that the COOH-terminal region of ILF3 , which is rich in arginine , glycine , and serine , is responsible for the strong ***interaction*** between ***PRMT1*** and ***ILF3*** and is the site of ILF3 methylation by PRMT1 .	parallel	1
13075	10749867	5889;5888	Rad51C;HsRad51	Previously we reported that HsRad51 interacts with XRCC3 , and ***Rad51C*** ***interacts*** with XRCC3 , Rad51B , and ***HsRad51*** .	parallel	1
13076	10749867	5889;5890	Rad51C;Rad51B	Previously we reported that HsRad51 interacts with XRCC3 , and ***Rad51C*** ***interacts*** with XRCC3 , ***Rad51B*** , and HsRad51 .	parallel	1
13077	10749867	5889;7517	Rad51C;XRCC3	Previously we reported that HsRad51 interacts with XRCC3 , and ***Rad51C*** ***interacts*** with ***XRCC3*** , Rad51B , and HsRad51 .	parallel	1
13078	10749867	5888;7517	HsRad51;XRCC3	Previously we reported that ***HsRad51*** ***interacts*** with ***XRCC3*** , and Rad51C interacts with XRCC3 , Rad51B , and HsRad51 .	parallel	1
13079	10749867	5892;5889	Rad51D;Rad51C	Here we report that in the yeast two-hybrid system , ***Rad51D*** ***interacts*** with XRCC2 and ***Rad51C*** .	parallel	1
13080	10749867	5892;7516	Rad51D;XRCC2	Here we report that in the yeast two-hybrid system , ***Rad51D*** ***interacts*** with ***XRCC2*** and Rad51C .	parallel	1
13081	10749867	5888;7517	Rad51;XRCC3	The yeast ***Rad51*** ***interacts*** with human Rad51 and ***XRCC3*** , suggesting Rad51 conservation since the human yeast divergence .	parallel	1
13082	10749867	5889;7517	Rad51C;XRCC3	For example , Rad51B expression enhances the ***binding*** of ***Rad51C*** to ***XRCC3*** and to HsRad51D , and Rad51C expression allows the indirect interaction of Rad51B with Rad51D .	parallel	1
13083	10749867	5890;5892	Rad51B;Rad51D	For example , Rad51B expression enhances the binding of Rad51C to XRCC3 and to HsRad51D , and Rad51C expression allows the indirect ***interaction*** of ***Rad51B*** with ***Rad51D*** .	parallel	1
13084	10749867	5890;5889	Rad51B;Rad51C	For example , ***Rad51B*** expression ***enhances*** the binding of ***Rad51C*** to XRCC3 and to HsRad51D , and Rad51C expression allows the indirect interaction of Rad51B with Rad51D .	positive	0
13085	10749867	5890;5892	Rad51B;Rad51D	Experiments using 6xHis-tagged proteins in the baculovirus system confirm several of our yeast results , including ***Rad51B*** ***interaction*** with ***Rad51D*** only when Rad51C is simultaneously expressed and Rad51C interaction with XRCC2 only when Rad51D is present .	parallel	1
13086	10749867	5889;7516	Rad51C;XRCC2	Experiments using 6xHis-tagged proteins in the baculovirus system confirm several of our yeast results , including Rad51B interaction with Rad51D only when Rad51C is simultaneously expressed and ***Rad51C*** ***interaction*** with ***XRCC2*** only when Rad51D is present .	parallel	1
13087	10749881	5328;5329	uPA;uPAR	Together , these findings indicate that uPA-induced chemotaxis is dependent on the binding of the uPA-kringle to the membrane surface of cells and the ***association*** of ***uPA*** with ***uPAR*** .	parallel	0
13088	10749881	5329;5328	uPAR;uPA	R-uPAwt-induced chemotaxis was dependent on an association with uPAR and a uPA-kringle domain-binding site , determined using a monoclonal uPAR antibody to prevent the ******uPA-uPAR****** ***interaction*** , and a monoclonal antibody to the uPA-kringle domain .	parallel	1
13089	10749886	5998;8802	RGS3;Galpha	Both ***RGS3*** and RGS3T ***bound*** to endogenous ***Galpha*** ( q/11 ) and inhibited endothelin-1-stimulated calcium mobilization and mitogen-activated protein kinase activity to a similar extent .	parallel	1
13090	10749919	8802;673	Galpha;B-Raf	The finding that ***Galpha*** ( o ) ***induces*** Ras-independent and protein kinase C - and phosphatidylinositol-3 kinase-dependent activation of ***B-Raf*** and conditionally stimulates MAPK activity provides direct evidence for intracellular signals connecting this G protein subunit to the MAPK pathway .	target	1
13091	10749919	2781;673	G(o) alpha chain;B-Raf	***Activation*** of ***B-Raf*** and regulation of the mitogen-activated protein kinase pathway by the ***G(o) alpha chain*** .	positive	1
13092	10749919	8802;673	Galpha;B-Raf	We found that expression of activated ***Galpha*** ( o ) ***stimulated*** ***B-Raf*** activity independently of the activation of the EGF receptor or Ras .	positive	0
13093	10749919	8802;673	Galpha;B-Raf	Inactivation of protein kinase C and inhibition of phosphatidylinositol-3 kinase abolished both ***B-Raf*** ***activation*** and EGF receptor-dependent MAPK stimulation by ***Galpha*** ( o ) .	positive	1
13094	10749928	107;55690	AC1;PACS-1	The membrane-proximal AC ( ***AC1*** ) directs TGN localization and ***interacts*** with the TGN sorting protein ***PACS-1*** .	parallel	1
13095	10749931	64151;5455	YCG1;BRN1	Temperature-sensitive mutations of ***BRN1*** can be ***suppressed*** by overexpression of a novel gene ***YCG1*** , which is homologous to another Xenopus condensin subunit , XCAP-G .	negative	1
13096	10749932	8853;5829	PAG3;paxillin	Moreover , overexpression of ***PAG3*** , but not its GAP-inactive mutant , ***inhibited*** ***paxillin*** recruitment to focal contacts and hampered cell migratory activities , whereas cell adhesion activities were almost unaffected .	negative	1
13097	10749932	8853;5829	PAG3;paxillin	***PAG3*** ***bound*** to all ***paxillin*** isoforms and was induced during monocyte maturation , at which time paxillin expression is also increased and integrins are activated .	parallel	1
13098	10749975	27316;6434	hnRNP G;Tra2beta	RBMY , a probable human spermatogenesis factor , and other ***hnRNP G*** proteins ***interact*** with ***Tra2beta*** and affect splicing .	parallel	1
13099	10749975	5940;6434	RBMY;Tra2beta	***RBMY*** , a probable human spermatogenesis factor , and other hnRNP G proteins ***interact*** with ***Tra2beta*** and affect splicing .	parallel	1
13100	10750020	3479;1509	IGF-I;cathepsin D	Insulin-like growth factor-I ( ***IGF-I*** ) , transforming growth factor alpha ( TGFalpha ) and epidermal growth factor ( EGF ) ***induced*** ***cathepsin D*** gene expression and reporter gene activity in MCF-7 human breast cancer cells transiently transfected with a construct ( pCD1 ) containing a -2576 to -124 cathepsin D gene promoter insert .	target	1
13101	10750020	7039;1509	TGFalpha;cathepsin D	Insulin-like growth factor-I ( IGF-I ) , transforming growth factor alpha ( ***TGFalpha*** ) and epidermal growth factor ( EGF ) ***induced*** ***cathepsin D*** gene expression and reporter gene activity in MCF-7 human breast cancer cells transiently transfected with a construct ( pCD1 ) containing a -2576 to -124 cathepsin D gene promoter insert .	target	1
13102	10750028	7124;1907	TNFalpha;ET-2	Combination of forskolin or dibutyryl cAMP with TNFalpha produced a significantly greater increase in ET-2 production than these agents alone , indicating that adenylate cyclase and ***TNFalpha*** ***induce*** ***ET-2*** synthesis by separate signalling pathways .	target	1
13103	10750028	1907;7124	ET-2;TNFalpha	Studies using receptor selective TNFalpha mutants , ( 125 ( I-TNFalpha binding and TNF receptor mRNA showed that type-1 TNF receptors mediate the ***ET-2*** ***response*** to ***TNFalpha*** .	parallel	0
13104	10750041	3479;3486	IGF-I;IGFBP-3	We conclude that EGF administration reduced serum IGFBP-3 whereas ***IGF-I*** administration ***increased*** the level of ***IGFBP-3*** and IGF-I and resulted in an increased body and kidney weight in adult female rats .	positive	0
13105	10750375	933;930	CD22;CD19	Reciprocally , ***CD22*** is a potent ***regulator*** of ***CD19*** function .	target	1
13106	10750554	3557;3553	IL-1ra;IL-1beta	IL-1 receptor antagonist ( ***IL-1ra*** ) is a competitive ***inhibitor*** of ***IL-1beta*** effects and the biological effects of IL-1beta are therefore proportional to the ratio IL-1beta/IL-1ra .	negative	1
13107	10750588	183;5594	angiotensin II;ERK	In cardiac fibroblasts , ***angiotensin II*** ***activated*** ***ERK*** via the G ( beta ) gamma subunit of Gi , Src , Shc , Grb2 , and Ras , whereas Gq and protein kinase C were critical in cardiomyocytes .	positive	1
13108	10751146	902;1022	cyclin H;CDK7	Notably , ******CDK7-cyclin H-Mat1****** ***complexes*** are known to accumulate in CBs .	parallel	1
13109	10751146	902;4331	cyclin H;Mat1	Notably , ******CDK7-cyclin H-Mat1****** ***complexes*** are known to accumulate in CBs .	parallel	1
13110	10751146	4331;1022	Mat1;CDK7	Notably , ******CDK7-cyclin H-Mat1****** ***complexes*** are known to accumulate in CBs .	parallel	1
13111	10751146	1017;8161	CDK2;coilin	Furthermore , we demonstrate that p80 ***coilin*** can be ***phosphorylated*** by purified ***CDK2-cyclin*** E complexes in vitro .	target	1
13112	10751173	650;3397	BMP2;Id1	Meanwhile , ***BMP2*** ***upregulated*** ***Id1*** .	positive	1
13113	10751174	7471;4010	Wnt1;Lmx1b	Furthermore , a similar phenotype is not observed in Wnt1/RCAS-infected brains , demonstrating that ectopic ***Wnt1*** is insufficient to ***mediate*** the effect of ectopic ***Lmx1b*** in our assay .	target	0
13114	10751181	2260;2247	fibroblast growth factor receptor-1;bFGF	Moreover , we have analyzed ES lines carrying targeted mutations for ***fibroblast growth factor receptor-1*** ( fgfr1 ) , a ***receptor*** for basic fibroblast growth factor ( ***bFGF*** ) , as well as scl , a transcription factor , for their potential to generate BL-CFCs and Flk1 ( + ) cells , to further define events leading to hemangioblast development .	parallel	1
13115	10751199	5579;5054	Protein kinase C-beta;PAI-1	***Protein kinase C-beta*** ***mediates*** lipoprotein-induced generation of ***PAI-1*** from vascular endothelial cells .	target	0
13116	10751199	5579;5054	PKC-beta;PAI-1	The results suggest that activation of ***PKC-beta*** may ***mediate*** the production of ***PAI-1*** in cultured arterial and venous EC induced by LDL , Lp ( a ) , or their oxidized forms .	target	0
13117	10751319	1956;2520	Epidermal growth factor (EGF) receptor;gastrin	***Epidermal growth factor (EGF) receptor*** activation ***stimulates*** ***gastrin*** gene expression through a GC-rich element called gastrin EGF response element ( gERE ) .	positive	0
13118	10751353	929;5743	CD14;Cox-2	Moreover , differential impact of plasma components was noted : for the large majority of cells , ***CD14*** surface expression ***correlated*** with ***Cox-2*** responsiveness to LPS independent of plasma , whereas the presence of plasma components was a prerequisite for the LPS response in CD14-negative cells .	parallel	0
13119	10751382	596;581	Bcl-2;Bax	Overexpression of the anti-apoptotic protein ***Bcl-2*** ***inhibited*** both the conformational change of ***Bax*** as well as its relocalization to the mitochondria .	negative	1
13120	10751382	596;581	Bcl-2;Bax	These results suggest that the mechanism by which ***Bcl-2*** ***inhibits*** ***Bax*** mitochondrial translocation and subsequent amplification of the apoptotic cascade is not by providing a physical barrier to Bax , but rather by inhibiting an upstream event necessary for Bax conformational change .	negative	1
13121	10751390	3651;6750	IDX1;somatostatin	Pancreatic homeodomain transcription factor ***IDX1/IPF1*** expressed in developing brain ***regulates*** ***somatostatin*** gene transcription in embryonic neural cells .	target	1
13122	10751390	3651;6750	IDX1;somatostatin	Electrophoretic mobility shift assays with nuclear extracts of embryonic brains indicated that ***IDX1/IPF1*** ***binds*** to two ***somatostatin*** promoter elements , SMS-UE-B and the recently discovered SMS-TAAT3 .	parallel	1
13123	10751390	3651;6750	IDX1;somatostatin	The requirement of these elements for ***IDX1/IPF1*** ***transactivation*** of the ***somatostatin*** gene in neural cells was confirmed in transfection studies using embryonic cerebral cortex-derived RC2.E10 cells .	positive	1
13124	10751398	5970;4790	p65;p50	Electrophoretic mobility shift assays characterized that the two NF-kappaB sites can be recognized and bound by the NF-kappaB ******p50/p65****** ***heterodimer*** .	parallel	1
13125	10751398	5970;4790	p65;NF-kappaB	Electrophoretic mobility shift assays characterized that the two ***NF-kappaB*** sites can be ***recognized*** and bound by the NF-kappaB ***p50/p65*** heterodimer .	target	1
13126	10751404	5536;2288	PP5;FKBP52	Mutation of Glu-651 and Asp-653 did not affect ***binding*** of ***FKBP52*** or ***PP5*** but inhibited both Hop binding and hsp90 chaperone activity .	parallel	1
13127	10751404	5536;3320	PP5;hsp90	We also found that a conserved Lys residue required for ***PP5*** ***binding*** to ***hsp90*** was critical for the binding of FKBP52 but not for the binding of Hop to hsp90 .	parallel	1
13128	10751406	7538;7124	TTP;TNFalpha	***TTP*** was then shown to ***destabilize*** ***TNFalpha*** mRNA after binding directly to the AU-rich region ( ARE ) of the 3 ' - untranslated region of the TNFalpha mRNA .	negative	0
13129	10751406	7538;7124	TTP;TNFalpha	We found that amino - and carboxyl-terminal truncated forms of ***TTP*** , as well as a 77 amino acid fragment that contained both zinc fingers , could ***bind*** to the ***TNFalpha*** ARE in cell-free cross-linking and gel shift assays .	parallel	1
13130	10751411	79663;3315	PASS1;hsp27	Ectopic expression of PASS1 in two cultured cell lines was observed to inhibit the ability of hsp27 to protect cells against heat shock , indicating that ***PASS1*** does ***interact*** with ***hsp27*** in the live cell .	parallel	1
13131	10751411	79663;3315	PASS1;hsp27	Ectopic expression of ***PASS1*** in two cultured cell lines was observed to ***inhibit*** the ability of ***hsp27*** to protect cells against heat shock , indicating that PASS1 does interact with hsp27 in the live cell .	negative	1
13132	10751411	79663;3315	PASS1;hsp27	In vitro , bacterially expressed glutathione ***S-transferase-PASS1*** fusion protein ***bound*** to ***hsp27*** , and hsp27 was co-immunoprecipitated with c-Myc-tagged PASS1 overexpressed in several cell lines .	parallel	1
13133	10751411	3315;79663	hsp27;PASS1	In vitro , bacterially expressed glutathione S-transferase-PASS1 fusion protein bound to hsp27 , and ***hsp27*** was ***co-immunoprecipitated*** with c-Myc-tagged ***PASS1*** overexpressed in several cell lines .	parallel	1
13134	10751420	10567;6844	PRA1;VAMP2	We have previously reported that prenylated Rab acceptor or ***PRA1*** ***interacts*** with Rab GTPases and vesicle-associated membrane protein ( ***VAMP2*** ) .	parallel	1
13135	10751420	10567;6844	PRA1;VAMP2	The binding of Rab and VAMP2 to PRA1 is mutually exclusive such that Rab3A can displace VAMP2 in a preformed ******VAMP2-PRA1****** ***complex*** .	parallel	1
13136	10751420	6844;10567	VAMP2;PRA1	The ***binding*** of Rab and ***VAMP2*** to ***PRA1*** is mutually exclusive such that Rab3A can displace VAMP2 in a preformed VAMP2-PRA1 complex .	parallel	1
13137	10751536	999;7040	E-cadherin;TGFbeta	CONCLUSION : The inhibition of ***TGFbeta*** ( 1 ) on the malignancy of colon cancer cell may partially be ***mediated*** by the up regulation of ***E-cadherin*** and catenins .	target	0
13138	10751555	4790;5970	NF-kappaB;p65	Furthermore , oroxylin A but not emodin blocked nuclear factor-kappaB ( ***NF-kappaB*** ) binding and transcriptional activation ***associated*** with decreased ***p65*** proteins in the nucleus induced by LPS .	parallel	0
13139	10751633	4193;7157	mdm2;p53	We hypothesize that point mutations at serine 17 could block its phosphorylation and thereby increase the ******p53-mdm2****** ***interaction*** .	parallel	1
13140	10752072	2691;6750	GHRH;somatostatin	This pattern is tightly controlled by the ***interplay*** of GH-releasing hormone ( ***GHRH*** ) and ***somatostatin*** ( SRIF ) , the primary hypothalamic factors that determine GH secretion from the somatotroph and which also regulate GH synthesis and secretory reserve .	parallel	1
13141	10752520	5972;7040	renin;TGF-beta1	Locally activated ***renin-angiotensin*** system ***associated*** with ***TGF-beta1*** as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats .	parallel	0
13142	10752545	3569;488	Interleukin-6;SERCA2	Leukemia Inhibitory Factor and ***Interleukin-6*** ***downregulate*** sarcoplasmic reticulum Ca2 + ATPase ( ***SERCA2*** ) in cardiac myocytes .	negative	1
13143	10752545	3976;488	Leukemia Inhibitory Factor;SERCA2	***Leukemia Inhibitory Factor*** and Interleukin-6 ***downregulate*** sarcoplasmic reticulum Ca2 + ATPase ( ***SERCA2*** ) in cardiac myocytes .	negative	1
13144	10752960	183;2353	Angiotensin II;c-fos	***Angiotensin II*** also ***increased*** the expression of ***c-fos*** and c-jun mRNA , and antisense oligonucleotides against c-fos blocked the AII-induced VEGF mRNA expression .	positive	0
13145	10752960	183;3725	Angiotensin II;c-jun	***Angiotensin II*** also ***increased*** the expression of c-fos and ***c-jun*** mRNA , and antisense oligonucleotides against c-fos blocked the AII-induced VEGF mRNA expression .	positive	0
13146	10753589	3479;3486	IGF-I;IGFBP-3	In conditioned media , ***IGF-I*** ***increased*** ***IGFBP-3*** accumulation by release of cell associated IGFBP-3 .	positive	0
13147	10753589	3479;3487	IGF-I;IGFBP-4	Northern blot analysis indicated that ***IGF-I*** ***increased*** ***IGFBP-4*** mRNA accumulation by stabilizing the mRNA while IGFBP-3 gene expression was slightly decreased .	positive	0
13148	10753589	3479;3487	IGF-I;IGFBP-4	The results demonstrate that ***IGF-I*** ***regulates*** ***IGFBP-4*** post-trancriptionally and post-translationally , whereas IGFBP-3 is only affected post-translationally .	target	1
13149	10753591	3479;3486	IGF-I;IGFBP-3	Taken together , these data suggest that the increase in serum IGFBP-3 by exogenous IGF-I may not be a receptor mediated event but may be the result of ***IGF-I*** ***binding*** to ***IGFBP-3*** and forming the binary and ternary complex , slowing IGFBP-3 degradation .	parallel	1
13150	10753591	3479;3486	IGF-I;IGFBP-3	***IGF-I*** but not the IGF-I variant long R ( 3 ) IGF-I ***increases*** serum ***IGFBP-3*** in adolescent monkeys .	positive	0
13151	10753594	3309;1540	BiP;SBs	The ER-specific chaperone ***BiP*** has been observed to be ***associated*** with developing ***SBs*** at all stages of this process , and it is postulated that its sequestration within these bodies may have consequences for host cell metabolism .	parallel	0
13152	10753660	22866;5894	membrane-associated guanylate kinase-interacting protein;Raf-1	***Association*** of ***membrane-associated guanylate kinase-interacting protein-1*** with ***Raf-1*** .	parallel	0
13153	10753660	3845;5894	Ki-Ras;Raf-1	However , in contrast to the dominant active mutant of ***Ki-Ras*** , which ***interacts*** with ***Raf-1*** , recruits it to the plasma membrane from the cytosol , and activates it , MAGUIN-1 neither activates Raf-1 nor recruits it to the plasma membrane .	parallel	1
13154	10753665	6285;3932	NEF;Lck	***NEF*** protein of HIV/SIV lentiviruses affects G-protein-mediated signaling , and physically ***associates*** to ***Lck*** , a myristoylated and palmitoylated Src-like tyrosine kinase .	parallel	0
13155	10753743	1000;1499	N-cadherin;beta-catenin	In addition , introduction of active p35-Cdk5 kinase into COS cells led to a decreased ******beta-catenin-N-cadherin****** ***interaction*** and loss of cell adhesion .	parallel	1
13156	10753743	1000;1020	N-cadherin;Cdk5	CONCLUSIONS : The ***association*** between ***p35-Cdk5*** and an ***N-cadherin*** adhesion complex in cortical neurons and the modulation of N-cadherin-mediated aggregation by p35-Cdk5 suggests that the p35-Cdk5 kinase is involved in the regulation of N-cadherin-mediated adhesion in cortical neurons .	parallel	0
13157	10753743	1000;8851	N-cadherin;p35	CONCLUSIONS : The ***association*** between ***p35-Cdk5*** and an ***N-cadherin*** adhesion complex in cortical neurons and the modulation of N-cadherin-mediated aggregation by p35-Cdk5 suggests that the p35-Cdk5 kinase is involved in the regulation of N-cadherin-mediated adhesion in cortical neurons .	parallel	0
13158	10753743	8851;1020	p35;Cdk5	CONCLUSIONS : The ***association*** between ******p35-Cdk5****** and an N-cadherin adhesion complex in cortical neurons and the modulation of N-cadherin-mediated aggregation by p35-Cdk5 suggests that the p35-Cdk5 kinase is involved in the regulation of N-cadherin-mediated adhesion in cortical neurons .	parallel	0
13159	10753743	8851;1499	p35;beta-catenin	In this study , we report the identification of a novel ***interaction*** between ***p35*** and the versatile cell adhesion signaling molecule ***beta-catenin*** .	parallel	1
13160	10753743	8851;1499	p35;beta-catenin	The ***p35*** and ***beta-catenin*** proteins ***interacted*** in vitro and colocalized in transfected COS cells .	parallel	1
13161	10753743	1000;1499	N-cadherin;beta-catenin	In addition , the p35-Cdk5 kinase was associated with a ******beta-catenin-N-cadherin****** ***complex*** in the cortex .	parallel	1
13162	10753743	1020;1499	Cdk5;beta-catenin	In addition , the ***p35-Cdk5*** kinase was ***associated*** with a ***beta-catenin-N-cadherin*** complex in the cortex .	parallel	0
13163	10753743	1020;1000	Cdk5;N-cadherin	In addition , the ***p35-Cdk5*** kinase was ***associated*** with a ***beta-catenin-N-cadherin*** complex in the cortex .	parallel	0
13164	10753743	8851;1499	p35;beta-catenin	In addition , the ***p35-Cdk5*** kinase was ***associated*** with a ***beta-catenin-N-cadherin*** complex in the cortex .	parallel	0
13165	10753743	8851;1000	p35;N-cadherin	In addition , the ***p35-Cdk5*** kinase was ***associated*** with a ***beta-catenin-N-cadherin*** complex in the cortex .	parallel	0
13166	10753833	2623;6688	GATA-1;PU.1	***GATA-1*** ***interacts*** with the myeloid ***PU.1*** transcription factor and represses PU.1-dependent transcription .	parallel	1
13167	10753834	1437;1958	GM-CSF;early growth response-1	We previously demonstrated that phosphorylation of the cyclic adenosine monophosphate ( cAMP ) response element-binding protein , CREB , occurs through a protein kinase A-independent pathway and is required for ***GM-CSF-induced*** transcriptional ***activation*** of the immediate early gene , ***early growth response-1*** ( egr-1 ) .	positive	1
13168	10753834	1437;1385	GM-CSF;CREB	We performed immune complex kinase assays in the human myeloid leukemic cell line , TF-1 , which revealed that ***GM-CSF*** ***induced*** pp90RSK activation and phosphorylation of ***CREB*** within 5 minutes of stimulation .	target	1
13169	10753834	1437;1385	GM-CSF;CREB	In this study , we report that ***GM-CSF*** ***induces*** ***CREB*** phosphorylation and egr-1 transcription by activating pp90RSK through an MEK-dependent signaling pathway .	target	1
13170	10753834	1437;1958	GM-CSF;egr-1	In this study , we report that ***GM-CSF*** ***induces*** CREB phosphorylation and ***egr-1*** transcription by activating pp90RSK through an MEK-dependent signaling pathway .	target	1
13171	10753837	3569;596	IL-6;Bcl-2	Moreover , ***IL-6-induced*** the ***up-regulation*** of ***Bcl-2*** and c-myc , and JunB was impaired in Ub-treated KT-3 cells , suggesting that the anti-apoptotic and mitogenic effects of IL-6 were disrupted by Ub .	positive	1
13172	10753837	3569;4609	IL-6;c-myc	Moreover , ***IL-6-induced*** the ***up-regulation*** of Bcl-2 and ***c-myc*** , and JunB was impaired in Ub-treated KT-3 cells , suggesting that the anti-apoptotic and mitogenic effects of IL-6 were disrupted by Ub .	positive	1
13173	10753839	3439;5359	IFN-alpha;PLSCR1	This study showed that the newly identified ***PLSCR1*** gene for phospholipid scramblase , previously implicated in remodeling of plasma membrane phospholipids , is ***regulated*** at the transcriptional level by ***IFN-alpha*** .	target	1
13174	10753851	4869;9612	NPM;SMRTe	Both ***NPM-RAR*** and PML-RAR ***interact*** with the co-repressor protein ***SMRTe*** in a manner that is less sensitive than RARalpha to dissociation by retinoic acid .	parallel	1
13175	10753851	84106;9612	PML-RAR;SMRTe	Both NPM-RAR and ***PML-RAR*** ***interact*** with the co-repressor protein ***SMRTe*** in a manner that is less sensitive than RARalpha to dissociation by retinoic acid .	parallel	1
13176	10753851	5914;9612	RAR;SMRTe	Both ***NPM-RAR*** and PML-RAR ***interact*** with the co-repressor protein ***SMRTe*** in a manner that is less sensitive than RARalpha to dissociation by retinoic acid .	parallel	1
13177	10753860	7421;29079	vitamin D receptor;vitamin D receptor interacting protein	***Binding*** of liganded ***vitamin D receptor*** to the ***vitamin D receptor interacting protein*** coactivator complex induces interaction with RNA polymerase II holoenzyme .	parallel	1
13178	10753864	6662;176	SOX9;aggrecan	These observations indicate that ***SOX9*** ***enhances*** ***aggrecan*** promoter activity and that its expression is up-regulated by RA in TC6 cells .	positive	0
13179	10753864	6662;176	SOX9;aggrecan	***SOX9*** ***enhances*** ***aggrecan*** gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line , TC6 .	positive	0
13180	10753867	207;596	Akt;Bcl-2	***Akt/protein kinase B*** ***up-regulates*** ***Bcl-2*** expression through cAMP-response element-binding protein .	positive	1
13181	10753867	2185;596	protein kinase B;Bcl-2	***Akt/protein kinase B*** ***up-regulates*** ***Bcl-2*** expression through cAMP-response element-binding protein .	positive	1
13182	10753867	1385;596	CREB;Bcl-2	In the present investigation , we define a second pathway contributing to ***CREB-dependent*** ***up-regulation*** of ***Bcl-2*** expression as a novel anti-apoptotic function of Akt signaling .	positive	1
13183	10753867	3479;596	IGF-I;Bcl-2	These data indicate that ***regulation*** of ***Bcl-2*** expression by ***IGF-I*** involves a signaling cascade mediated by PI 3-kinase/PDK1/Akt / CREB .	target	1
13184	10753869	4233;2549	c-Met;Gab1	Upon activation , the HGF-receptor ***c-Met*** ***binds*** and phosphorylates the multisite docking protein ***Gab1*** .	parallel	1
13185	10753870	25;2475	c-Abl;mammalian target of rapamycin	***Regulation*** of the rapamycin and FKBP-target ***1/mammalian target of rapamycin*** and cap-dependent initiation of translation by the ***c-Abl*** protein-tyrosine kinase .	target	1
13186	10753870	2475;1977	RAFT1;eIF4E	The rapamycin and FKBP-target 1 ( ***RAFT1*** ) , also known as FKBP12-rapamycin-associated protein ( FRAP , mTOR ) , ***regulates*** the p70S6 kinase ( p70 ( S6k ) ) and the eukaryotic initiation factor 4E ( ***eIF4E*** ) - binding protein 1 ( 4E-BP1 ) .	target	1
13187	10753870	25;2475	c-Abl;RAFT1	The present results demonstrate that ***c-Abl*** ***binds*** directly to ***RAFT1*** and phosphorylates RAFT1 in vitro and in vivo .	parallel	1
13188	10753870	25;2475	c-Abl;RAFT1	The present results demonstrate that ***c-Abl*** binds directly to RAFT1 and ***phosphorylates*** ***RAFT1*** in vitro and in vivo .	target	1
13189	10753870	25;2475	c-Abl;RAFT1	The functional significance of the ******c-Abl-RAFT1****** ***interaction*** is further supported by the finding that eIF4E-dependent translation in mouse embryo fibroblasts from Abl ( - / - ) mice is significantly higher than that compared in wild-type cells .	parallel	1
13190	10753870	1978;1977	4E-BP1;eIF4E	The results also demonstrate that exposure of cells to ionizing radiation is associated with c-Abl-mediated ***binding*** of ***4E-BP1*** to ***eIF4E*** and inhibition of translation .	parallel	1
13191	10753873	1432;9982	p38 mitogen-activated protein kinase;FGF-BP	Additionally , both EGF - and anisomycin-induced ***FGF-BP*** mRNA was ***abrogated*** by inhibition of ***p38 mitogen-activated protein kinase*** , demonstrating a role for p38 in the regulation of FGF-BP .	positive	0
13192	10753878	841;4790	caspase-8;NF-kappaB	These data indicate that FADD , Casper , and pro-caspase-8 are parts of the TNF-R1-induced NF-kappaB activation pathways , whereas activated ***caspase-8*** can negatively ***regulate*** TNF-R1-induced ***NF-kappaB*** activation by proteolytically inactivating NIK .	negative	1
13193	10753878	841;4790	caspase-8;NF-kappaB	***Activation*** of ***NF-kappaB*** by FADD , Casper , and ***caspase-8*** .	positive	1
13194	10753878	8837;4790	Casper;NF-kappaB	***Activation*** of ***NF-kappaB*** by FADD , ***Casper*** , and caspase-8 .	positive	1
13195	10753878	8772;4790	FADD;NF-kappaB	***Activation*** of ***NF-kappaB*** by ***FADD*** , Casper , and caspase-8 .	positive	1
13196	10753878	8837;4790	Casper;NF-kappaB	Here we show that overexpression of FADD and ***Casper*** potently ***activates*** ***NF-kappaB*** .	positive	1
13197	10753878	8772;4790	FADD;NF-kappaB	Here we show that overexpression of ***FADD*** and Casper potently ***activates*** ***NF-kappaB*** .	positive	1
13198	10753878	841;4790	caspase-8;NF-kappaB	In the presence of caspase inhibitors , overexpression of ***caspase-8*** also ***activates*** ***NF-kappaB*** .	positive	1
13199	10753878	841;4790	caspase-8;NF-kappaB	A caspase-inactive point mutant , ***caspase-8*** ( C360S ) , ***activates*** ***NF-kappaB*** as potently as wild-type caspase-8 , suggesting that caspase-8-induced apoptosis and NF-kappaB activation are uncoupled .	negative	1
13200	10753878	8837;4790	Casper;NF-kappaB	***NF-kappaB*** ***activation*** by FADD and ***Casper*** is inhibited by the caspase-specific inhibitors crmA and BD-fmk , suggesting that FADD - and Casper-induced NF-kappaB activation is mediated by caspase-8 .	positive	1
13201	10753878	841;8837	caspase-8;Casper	NF-kappaB activation by FADD and Casper is inhibited by the caspase-specific inhibitors crmA and BD-fmk , suggesting that FADD - and ***Casper-induced*** NF-kappaB activation is ***mediated*** by ***caspase-8*** .	target	0
13202	10753878	7186;8837	TRAF2;Casper	FADD , ***Casper*** , and caspase-8-induced NF-kappaB activation are ***inhibited*** by dominant negative mutants of ***TRAF2*** , NIK , IkappaB kinase alpha , and IkappaB kinase beta .	positive	1
13203	10753878	7186;8772	TRAF2;FADD	***FADD*** , Casper , and caspase-8-induced NF-kappaB activation are ***inhibited*** by dominant negative mutants of ***TRAF2*** , NIK , IkappaB kinase alpha , and IkappaB kinase beta .	positive	1
13204	10753878	7186;4790	TRAF2;NF-kappaB	FADD , Casper , and caspase-8-induced ***NF-kappaB*** activation are ***inhibited*** by dominant negative mutants of ***TRAF2*** , NIK , IkappaB kinase alpha , and IkappaB kinase beta .	positive	1
13205	10753878	8837;4790	Casper;NF-kappaB	A mutant of ***Casper*** and the caspase-specific inhibitors crmA and BD-fmk partially ***inhibit*** TNF-R1 - , TRADD , and TNF-induced ***NF-kappaB*** activation , suggesting that FADD , Casper , and caspase-8 function downstream of TRADD and contribute to TNF-R1-induced NF-kappaB activation .	positive	1
13206	10753878	8837;8717	Casper;TRADD	A mutant of ***Casper*** and the caspase-specific inhibitors crmA and BD-fmk partially ***inhibit*** TNF-R1 - , ***TRADD*** , and TNF-induced NF-kappaB activation , suggesting that FADD , Casper , and caspase-8 function downstream of TRADD and contribute to TNF-R1-induced NF-kappaB activation .	positive	1
13207	10753884	7124;4790	TNFalpha;NF-kappaB	Moreover , ***TNFalpha*** ***stimulated*** both the ***NF-kappaB*** and mitogen-activated protein ( MAP ) kinase ( extracellular signal-regulated kinase , c-Jun NH ( 2 ) - terminal kinase , and p38 MAP kinase ) signaling pathways in astrocytes .	positive	0
13208	10753885	2033;1869	p300;E2F-1	Here we report that ***E2F-1*** , -2 , and -3 , but not E2F-4 , -5 , and -6 , associate with and are ***acetylated*** by ***p300*** and cAMP-response element-binding protein acetyltransferases .	target	1
13209	10753901	6469;5727	Shh;Ptc	All other sites were sensitive to modification , indicating that the ***interaction*** of ***Shh*** with its primary receptor ***Ptc*** is mediated over a large surface of the Shh protein .	parallel	1
13210	10753901	5727;6469	Ptc;Shh	The structure-activity data provide a unique view of the ***interactions*** between ***Shh*** and ***Ptc*** that is not readily attainable by conventional mapping strategies .	parallel	1
13211	10753910	5170;5586	3-phosphoinositide-dependent protein kinase-1;PRK1/2	In analyzing the relationship between these inputs , it is shown that activation in vitro and in vivo involves the activation loop ***phosphorylation*** of ***PRK1/2*** by ***3-phosphoinositide-dependent protein kinase-1*** ( PDK1 ) .	target	1
13212	10753910	5586;5170	PRK1/2;PDK1	The ***interaction*** of ***PRK1/2*** with ***PDK1*** is shown to be dependent upon Rho .	parallel	1
13213	10753915	9124;81	CLP-36;actinin-4	***CLP-36*** PDZ-LIM protein ***associates*** with nonmuscle alpha-actinin-1 and ***alpha-actinin-4*** .	parallel	0
13214	10753915	9124;81	CLP-36;actinin-4	The high expression of alpha-actinin-4 in the colon , together with these results , suggests a specific function for the ******alpha-actinin-4-CLP-36****** ***complex*** in the colonic epithelium .	parallel	1
13215	10753918	5970;958	p65;p50	By contrast , truncation at Gly ( 359 ) created a dominant-negative mutant that inhibited ligand-induced cell death and activation of NF-kappaB ******p50/p65****** ***heterodimers*** .	parallel	1
13216	10753920	6285;6275	S100;S100A4	***Interaction*** in vivo and in vitro of the metastasis-inducing ***S100*** protein , ***S100A4*** ( p9Ka ) with S100A1 .	parallel	1
13217	10753920	6275;6285	S100A4;S100	Using the yeast two-hybrid system , a strong ***interaction*** between ***S100A4*** ( p9Ka ) and another ***S100*** protein , S100A1 , was detected .	parallel	1
13218	10753920	6275;6271	S100A4;S100A1	Using the yeast two-hybrid system , a strong ***interaction*** between ***S100A4*** ( p9Ka ) and another S100 protein , ***S100A1*** , was detected .	parallel	1
13219	10753920	6285;6271	S100;S100A1	Using the yeast two-hybrid system , a strong ***interaction*** between S100A4 ( p9Ka ) and another ***S100*** protein , ***S100A1*** , was detected .	parallel	1
13220	10753920	6271;6275	S100A1;S100A4	The ***interaction*** between ***S100A4*** and ***S100A1*** was also observed in vitro using affinity column chromatography and gel overlay techniques .	parallel	1
13221	10753938	4018;4846	lipoprotein;endothelial nitric-oxide synthase	High density lipoprotein prevents oxidized low density ***lipoprotein-induced*** ***inhibition*** of ***endothelial nitric-oxide synthase*** localization and activation in caveolae .	negative	1
13222	10753939	9261;5594	MAPKAPK2;p38	Arachidonic acid stimulated the phosphorylation of p38 , the activation of MAP kinase-activated protein kinase 2 ( ***MAPKAPK2*** , a downstream ***substrate*** of ***p38*** ) , and the phosphorylation of heat shock protein 27 ( a downstream substrate of MAP kinase-activated protein kinase 2 ) .	parallel	1
13223	10753943	6295;6714	arrestin1;c-SRC	***beta-arrestin1*** ***interacts*** with the catalytic domain of the tyrosine kinase ***c-SRC*** .	parallel	1
13224	10753943	6295;6714	arrestin1;c-SRC	We therefore hypothesized that a catalytically inactive mutant of the isolated catalytic subunit , SH1 ( kinase dead ) ( SH1 ( KD ) ) , would specifically block those cellular actions of ***c-SRC*** that are ***mediated*** by ***beta-arrestin1*** recruitment to the G-protein-coupled receptor .	target	0
13225	10753944	4088;4092	Smad3;Smad7	***Smad3*** and Smad4 ***mediate*** transcriptional activation of the human ***Smad7*** promoter by transforming growth factor beta .	target	0
13226	10753944	4089;4092	Smad4;Smad7	Smad3 and ***Smad4*** ***mediate*** transcriptional activation of the human ***Smad7*** promoter by transforming growth factor beta .	target	0
13227	10753944	4092;7040	Smad7;TGF-beta	***Smad7*** is an inducible intracellular ***inhibitor*** of transforming growth factor-beta ( ***TGF-beta*** ) signaling that is regulated by diverse stimuli including members of the TGF-beta superfamily .	negative	1
13228	10753944	7040;4092	TGF-beta;Smad7	A -303 to +672 Smad7 region contained a palindromic GTCTAGAC Smad binding element ( SBE ) between nucleotides -179 and -172 that was necessary for the ***induction*** of a ***Smad7*** promoter luciferase reporter gene by ***TGF-beta*** .	target	1
13229	10753944	7040;4092	TGF-beta;Smad7	Transfection assays in mouse embryonic fibroblasts ( MEFs ) , with targeted deletions of either Smad2 or Smad3 , and the Smad4-deficient cell line MD-MBA-468 revealed that both Smad3 and Smad4 , but not Smad2 , were absolutely required for ***induction*** of the ***Smad7*** promoter reporter gene by ***TGF-beta*** .	target	1
13230	10753944	7040;4092	TGF-beta;Smad7	Taken together , our data demonstrate that ***TGF-beta*** ***induces*** transcription of the human ***Smad7*** gene through activation of Smad3 and Smad4 transcription factor binding to its proximal promoter .	target	1
13231	10753945	7157;4322	p53;collagenase-3	Wild type and mutant ***p53*** differentially ***regulate*** the gene expression of human ***collagenase-3*** ( hMMP-13 ) .	target	1
13232	10753945	7157;4322	p53;hMMP-13	Here , we report that cotransfection of fibroblast-like synoviocytes with p53 expression and hMMP13CAT reporter plasmids revealed that ( i ) hMMP13 , another member of the human MMP family , was down-regulated by wild type p53 , whereas all six of the p53 mutants tested lost the wild type p53 repressor activity in fibroblast-like synoviocytes ; ( ii ) this ***repression*** of ***hMMP-13*** gene expression by wild type ***p53*** could be reversed by overexpression of p53 mutants p53-143A , p53-248W , p53-273H , and p53-281G ; ( iii ) the dominant effect of p53 mutants over wild type p53 appears to be a promoter - and mutant-specific effect .	negative	1
13233	10753945	7157;4322	p53;hMMP13	Here , we report that cotransfection of fibroblast-like synoviocytes with p53 expression and hMMP13CAT reporter plasmids revealed that ( i ) ***hMMP13*** , another member of the human MMP family , was ***down-regulated*** by wild type ***p53*** , whereas all six of the p53 mutants tested lost the wild type p53 repressor activity in fibroblast-like synoviocytes ; ( ii ) this repression of hMMP-13 gene expression by wild type p53 could be reversed by overexpression of p53 mutants p53-143A , p53-248W , p53-273H , and p53-281G ; ( iii ) the dominant effect of p53 mutants over wild type p53 appears to be a promoter - and mutant-specific effect .	negative	1
13234	10753945	7157;4322	p53;hMMP13	An intriguing finding was that p53 mutant ***p53-281G*** could conversely ***stimulate*** the promoter activity of ***hMMP13*** up to 2-4-fold and that it was dominant over wild type p53 .	positive	0
13235	10753946	5594;5829	ERK;paxillin	***Phosphorylation*** of ***paxillin*** via the ***ERK*** mitogen-activated protein kinase cascade in EL4 thymoma cells .	target	1
13236	10753946	5594;5829	ERK2;paxillin	***paxillin*** was ***phosphorylated*** in vitro by purified active ***ERK2*** .	target	1
13237	10753948	3952;5140	Leptin;phosphodiesterase 3B	One important function of this signaling pathway is to reduce levels of cAMP , because ***Leptin-mediated*** ***activation*** of both protein kinase B and ***phosphodiesterase 3B*** is most marked following elevation of cAMP by glucagon , and because Leptin suppresses glucagon-induced cAMP elevation in a PI3K-dependent manner .	positive	1
13238	10753948	3952;2185	Leptin;protein kinase B	One important function of this signaling pathway is to reduce levels of cAMP , because ***Leptin-mediated*** ***activation*** of both ***protein kinase B*** and phosphodiesterase 3B is most marked following elevation of cAMP by glucagon , and because Leptin suppresses glucagon-induced cAMP elevation in a PI3K-dependent manner .	positive	1
13239	10753948	3952;820	Leptin;cAMP	One important function of this signaling pathway is to reduce levels of cAMP , because Leptin-mediated activation of both protein kinase B and phosphodiesterase 3B is most marked following elevation of cAMP by glucagon , and because ***Leptin*** ***suppresses*** glucagon-induced ***cAMP*** elevation in a PI3K-dependent manner .	negative	1
13240	10753951	4323;7077	Membrane type 1 matrix metalloproteinase;tissue inhibitor of metalloproteinase 2	***Membrane type 1 matrix metalloproteinase-associated*** ***degradation*** of ***tissue inhibitor of metalloproteinase 2*** in human tumor cell lines .	negative	1
13241	10753951	4323;4313	Membrane type 1 matrix metalloproteinase;MMP-2	tissue inhibitor of metalloproteinase 2 ( TIMP-2 ) is required for the ***Membrane type 1 matrix metalloproteinase*** ( MT1-MMP ) - dependent ***activation*** of ***pro-MMP-2*** on the cell surface .	positive	1
13242	10753951	7077;4313	TIMP-2;MMP-2	MT1-MMP-bound ***TIMP-2*** has been shown to function as a ***receptor*** for secreted ***pro-MMP-2*** , resulting in the formation of a trimolecular complex .	parallel	1
13243	10753954	84959;5594	p70;ERK	A ***complex*** between ***ERK*** and ***p70*** ( S6k ) was documented by immunoprecipitation procedures .	parallel	1
13244	10753966	1958;6667	Egr-1;Sp1	Supershift assays excluded the direct ***association*** of ***Sp1*** , Sp3 , and ***Egr-1*** .	parallel	0
13245	10753966	1958;6670	Egr-1;Sp3	Supershift assays excluded the direct ***association*** of Sp1 , ***Sp3*** , and ***Egr-1*** .	parallel	0
13246	10753966	6667;6670	Sp1;Sp3	Supershift assays excluded the direct ***association*** of ***Sp1*** , ***Sp3*** , and Egr-1 .	parallel	0
13247	10753971	2033;3150	histone acetyltransferase p300;HMG-14	Here we show that the ***histone acetyltransferase p300*** specifically ***acetylates*** ***HMG-14*** , a nonhistone structural protein that binds to nucleosomes and reduces the compactness of the chromatin fiber .	target	1
13248	10753971	2033;3150	p300;HMG-14	We find that the nucleosomal binding domain is a major target for acetylation in vivo and that the specific ***acetylation*** of ***HMG-14*** by ***p300*** weakens its interaction with nucleosome cores .	target	1
13249	10753971	2033;3150	p300;HMG-14	Our results suggest that ***p300*** ***modulates*** the interaction of ***HMG-14*** with nucleosomes .	target	0
13250	10754199	2353;3725	Fos;Jun	Momordin I also showed the inhibitory action on the Jun/Jun homodimer , as well as on the ******Jun/Fos****** ***heterodimer*** .	parallel	1
13251	10754216	351;6347	Abeta;monocyte chemotactic protein (MCP)-1	Northern blot analysis and specific immunoassays demonstrate that Abeta [ 1-42 ] and ***Abeta*** [ 25-35 ] ***induce*** mRNA expression and release of ***monocyte chemotactic protein (MCP)-1*** but not of gamma-interferon inducible protein ( IP ) -10 by U373MG cells .	target	1
13252	10754216	351;6347	Abeta;MCP-1	The observation that ***Abeta*** ***induces*** astrocyte production of the potent microglia chemoattractant ***MCP-1*** contributes to understanding mechanism of damage exerted by Abeta in AD senile plaques .	target	1
13253	10754224	3953;3952	OB-R;leptin	One of its targets in the central nervous system appears to be the epithelial cells of the choroid plexus where ***leptin*** ***receptor*** ( ***OB-R*** ) expression is particularly high .	parallel	1
13254	10754226	2932;4137	GSK-3 beta;tau	The PSEN1 binding protein glycogen synthase kinase-3 beta ( GSK-3 beta ) has been considered as a key protein in AD pathogenesis since ***GSK-3 beta*** ***phosphorylates*** tau and hyperphosphorylated ***tau*** is a main component of neurofibrillary tangles associated to AD .	target	1
13255	10754293	940;7852	CD28;chemokine receptor 4	Engagement of ***CD28*** ***modulates*** CXC ***chemokine receptor 4*** surface expression in both resting and CD3-stimulated CD4 + T cells .	target	0
13256	10754295	355;355	Fas;CD95	******CD95/Fas****** ***signaling*** in T lymphocytes induces the cell cycle control protein p21cip-1 / WAF-1 , which promotes apoptosis .	parallel	0
13257	10754295	9474;836	Asp;caspase 3	This up-regulation was completely blocked by the cysteine protease inhibitor Z-VAD-fmk ( benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone ) , whereas DEVD-CHO ( ***succinyl-Asp-Glu-Val-Asp-aldehyde*** ) , a ***caspase 3*** ***inhibitor*** , had no effect .	negative	1
13258	10754297	6367;1233	macrophage-derived chemokine;CCR4	***macrophage-derived chemokine*** ( MDC ) , the ***ligand*** for ***CCR4*** , induces the phosphorylation of CCR4 within 0.5 min of activating IANK cells with this ligand .	parallel	1
13259	10754297	6367;1233	macrophage-derived chemokine;CCR4	***macrophage-derived chemokine*** ( MDC ) , the ligand for CCR4 , ***induces*** the phosphorylation of ***CCR4*** within 0.5 min of activating IANK cells with this ligand .	target	1
13260	10754298	1524;6376	CX3CR1;Fractalkine	Freshly separated NK cells expressed the ***Fractalkine*** ***receptor*** ( ***CX3CR1*** ) determined by FACS analysis and efficiently adhered to immobilized full-length Fractalkine , but not to the truncated forms of the chemokine domain or mucin domain , suggesting that Fractalkine functions as an adhesion molecule on the interaction between NK cells and ECs .	parallel	1
13261	10754303	7292;7293	CD134L;CD134	CD134L engagement enhances human B cell Ig production : CD154/CD40 , CD70/CD27 , and ******CD134/CD134L****** ***interactions*** coordinately regulate T cell-dependent B cell responses .	parallel	1
13262	10754303	958;959	CD40;CD154	We have previously reported that the CD70/CD27 interaction may be more important in the induction of plasma cell differentiation after the expansion phase induced by the ******CD154/CD40****** ***interaction*** has occurred .	parallel	1
13263	10754303	939;970	CD27;CD70	We have previously reported that the ******CD70/CD27****** ***interaction*** may be more important in the induction of plasma cell differentiation after the expansion phase induced by the CD154/CD40 interaction has occurred .	parallel	1
13264	10754310	811;5551	calreticulin;Perforin	***Perforin*** lytic activity is ***controlled*** by ***calreticulin*** .	target	0
13265	10754326	5970;4790	p65;p50	Although both the kappa B1 and kappa B3 sites bound transcriptionally active NF-kappa B ******p50/p65****** ***heterodimers*** , only the kappa B1 site contributed to down-regulation by NF-kappa B p50 homodimers .	parallel	1
13266	10754326	4790;7124	NF-kappa B;TNF-alpha	This study characterized the mechanism by which ***NF-kappa B*** family members interact to ***regulate*** the human ***TNF-alpha*** gene .	target	1
13267	10754326	3725;7124	c-Jun;TNF-alpha	Employing adenoviral vectors , dominant-negative versions of NF-kappa B p65 , and ***c-Jun*** , but not C/EBP beta , ***suppressed*** ( p < 0.05-0 .001 ) LPS-induced ***TNF-alpha*** secretion in primary human macrophages .	negative	1
13268	10754326	4790;3725	NF-kappa B;c-Jun	Following LPS stimulation , ***NF-kappa B*** p50/p65 heterodimers ***bound*** to the kappa B3 site and ***c-Jun*** to the -103 AP-1 site of the TNF-alpha promoter .	parallel	1
13269	10754326	5970;3725	p65;c-Jun	Following LPS stimulation , NF-kappa B ***p50/p65*** heterodimers ***bound*** to the kappa B3 site and ***c-Jun*** to the -103 AP-1 site of the TNF-alpha promoter .	parallel	1
13270	10754326	4790;5970	p50;p65	Following LPS stimulation , NF-kappa B ******p50/p65****** ***heterodimers*** bound to the kappa B3 site and c-Jun to the -103 AP-1 site of the TNF-alpha promoter .	parallel	1
13271	10754326	4790;7124	p50;TNF-alpha	By transient transfection , NF-kappa B p65 and ***p50*** synergistically ***activated*** the ***TNF-alpha*** promoter .	positive	1
13272	10754326	5970;7124	p65;TNF-alpha	By transient transfection , NF-kappa B ***p65*** and p50 synergistically ***activated*** the ***TNF-alpha*** promoter .	positive	1
13273	10754326	5970;4790	p65;p50	Following LPS stimulation , the kappa B1 site bound both NF-kappa B ******p50/p65****** ***heterodimers*** and p50 homodimers .	parallel	1
13274	10754327	1437;207	GM-CSF;Akt	***GM-CSF*** ***activated*** the PI ***3-kinase/Akt*** pathway as determined by phosphorylation of Akt and BAD .	positive	1
13275	10754333	3458;2209	IFN-gamma;Fc gamma RI	We next found that ***IFN-gamma*** ***up-regulated*** the expression of ***Fc gamma RI*** .	positive	1
13276	10754333	3458;2209	IFN-gamma;Fc gamma RI	This was confirmed by flow cytometry , where ***Fc gamma RI*** expression on human mast cells was ***increased*** from approximately 2 to 44 % by ***IFN-gamma*** exposure .	positive	0
13277	10754394	729230;6347	CCR2;MCP-1	Localisation of mRNA for ***JE/MCP-1*** and its ***receptor*** ***CCR2*** in atherosclerotic lesions of the ApoE knockout mouse .	parallel	1
13278	10754406	7035;2152	TFPI;tissue factor	In uremic patients , thrombomodulin and von Willebrand factor , activity of factor VII , ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) activity , TFPI and tissue factor ( TF ) concentrations , lipoprotein ( a ) level were significantly higher when compared to healthy volunteers .	negative	1
13279	10754489	356;355	FasL;Fas	The ***Fas*** ***ligand*** ( ***FasL*** ) and its receptor Fas ( APO-1 or CD95 ) are members , respectively , of the tumor necrosis factor family that , upon interaction with each other , play a key role in the initiation of one apoptotic pathway .	parallel	1
13280	10754489	355;356	Fas;FasL	The Fas ligand ( ***FasL*** ) and its ***receptor*** ***Fas*** ( APO-1 or CD95 ) are members , respectively , of the tumor necrosis factor family that , upon interaction with each other , play a key role in the initiation of one apoptotic pathway .	parallel	1
13281	10755382	4323;4313	membrane-type 1 matrix metalloproteinase;MMP-2	Northern blot analysis revealed a stronger expression of ***membrane-type 1 matrix metalloproteinase*** ( MT1-MMP ) , which is a specific ***activator*** of ***MMP-2*** , mRNA in HEp-2 cells than in fibroblasts .	positive	1
13282	10755407	3569;2099	IL-6;ERalpha	In conclusion , these results provide evidence for direct transcriptional ***activation*** of ***ERalpha*** by ***IL-6*** .	positive	1
13283	10755467	185;183	AT1;angiotensinogen	These data indicate that the expression of RAS by the rat epididymis at the levels of its precursor ***angiotensinogen*** and its ***receptor*** ***AT1*** , is subject to the regulation of testicular hormones and its expression appears to be predominantly testosterone-dependent .	parallel	1
13284	10755553	958;959	CD40;CD154	Significantly , there is conservation between pig and human at 5 residues shown by mutagenesis studies to be essential for ***binding*** of human ***CD40*** to ***CD154*** .	parallel	1
13285	10755617	7128;8517	A20;NEMO	Recruitment of the IKK signalosome to the p55 TNF receptor : RIP and ***A20*** ***bind*** to ***NEMO*** ( IKKgamma ) upon receptor stimulation .	parallel	1
13286	10755617	9730;8517	RIP;NEMO	Recruitment of the IKK signalosome to the p55 TNF receptor : ***RIP*** and A20 ***bind*** to ***NEMO*** ( IKKgamma ) upon receptor stimulation .	parallel	1
13287	10755617	9730;8517	RIP;NEMO	Here we show that triggering of the p55 TNF receptor induces ***binding*** of ***RIP*** to ***NEMO*** ( IKKgamma ) , a component of the I-kappa-B-kinase ( IKK ) " signalosome " complex , as well as recruitment of RIP to the receptor together with the three major signalosome components , NEMO , IKK1 and IKK2 , and some kind of covalent modification of the recruited RIP molecules .	parallel	1
13288	10755617	8517;7128	NEMO;A20	It also induces ***binding*** of ***NEMO*** to the signaling inhibitor ***A20*** , and recruitment of A20 to the receptor .	parallel	1
13289	10755617	8517;3725	NEMO;c-Jun	Enforced expression of NEMO in cells revealed that ***NEMO*** can both promote and block NF-kappaB activation and dramatically ***augments*** the phosphorylation of ***c-Jun*** .	positive	0
13290	10755617	8517;4790	NEMO;NF-kappaB	Enforced expression of NEMO in cells revealed that ***NEMO*** can both ***promote*** and block ***NF-kappaB*** activation and dramatically augments the phosphorylation of c-Jun .	positive	0
13291	10755617	8517;7128	NEMO;A20	The findings suggest that the signaling activities of the IKK signalosome are regulated through ***binding*** of ***NEMO*** to RIP and ***A20*** within the p55 TNF receptor complex .	parallel	1
13292	10755617	8517;9730	NEMO;RIP	The findings suggest that the signaling activities of the IKK signalosome are regulated through ***binding*** of ***NEMO*** to ***RIP*** and A20 within the p55 TNF receptor complex .	parallel	1
13293	10756005	3458;3627	interferon gamma;IP-10	The induction of IP-10 appeared to be direct because infection with adenovirus vectors failed to induce the expression of the potent ***IP-10*** ***stimulators*** , ***interferon gamma*** and tumor necrosis factor alpha .	positive	0
13294	10756005	7124;3627	tumor necrosis factor alpha;IP-10	The induction of IP-10 appeared to be direct because infection with adenovirus vectors failed to induce the expression of the potent ***IP-10*** ***stimulators*** , interferon gamma and ***tumor necrosis factor alpha*** .	positive	0
13295	10756023	3458;3620	IFN-gamma;IDO	The induction of ***IDO*** , while apparently independent of replication capacity , appears to be ***mediated*** by a transient production of ***IFN-gamma*** in MDM responding to the initial infection with selected strains of HIV-1 .	target	0
13296	10756032	7027;1874	DP-1;E2F-4	These results suggest that an altered ******E2F-4-DP-1-p130****** ***complex*** along with viral early gene expression may play a role in the transcriptional regulation of cyclin E mRNA during HCMV infection .	parallel	1
13297	10756032	5934;7027	p130;DP-1	These results suggest that an altered ******E2F-4-DP-1-p130****** ***complex*** along with viral early gene expression may play a role in the transcriptional regulation of cyclin E mRNA during HCMV infection .	parallel	1
13298	10756032	5934;1874	p130;E2F-4	These results suggest that an altered ******E2F-4-DP-1-p130****** ***complex*** along with viral early gene expression may play a role in the transcriptional regulation of cyclin E mRNA during HCMV infection .	parallel	1
13299	10756053	959;958	CD40L;CD40	Indeed , detailed studies of infectious MV release and intracellular MV nucleoprotein ( NP ) showed that inhibition of ******CD40-CD40L****** ligand ***interaction*** blocks NP synthesis .	parallel	1
13300	10756081	356;355	CD95L;CD95	Three colour flow cytometry indicated that B cells expressing CD95 ( Fas ) or ***CD95*** ***ligand*** ( ***CD95L*** ) were highly vulnerable to apoptosis , whereas B cells expressing Bcl-2 were relatively protected from apoptosis .	parallel	1
13301	10756081	356;355	CD95L;CD95	We propose that B cells are eliminated from the CNS by the ***interaction*** of ***CD95L*** and ***CD95*** on the same B cell and that this contributes to the spontaneous resolution of CNS inflammation and clinical recovery in acute EAE .	parallel	1
13302	10756100	23542;5599	IB2;JNK	***IB2*** ***interacts*** with both ***JNK*** and the JNK-kinase MKK7 .	parallel	1
13303	10756100	23542;5609	IB2;MKK7	***IB2*** ***interacts*** with both JNK and the JNK-kinase ***MKK7*** .	parallel	1
13304	10756201	10133;2971	TFIIIA-intP;TFIIIA	In vitro ***interaction*** of recombinant human ***TFIIIA-intP*** with recombinant Xenopus ***TFIIIA*** was demonstrated by immuno-precipitation of the complex using anti-TFIIIA-intP antibody .	parallel	1
13305	10756201	2971;10133	TFIIIA;TFIIIA-intP	***Interaction*** of rat ***TFIIIA*** with rat ***TFIIIA-intP*** was indicated by co-chromatography of the two proteins on DEAE-5PW following fractionation of a rat liver extract on cation , anion and gel filtration resins .	parallel	1
13306	10757782	6829;6827	SPT5;SPT4	We demonstrate that ***SPT5*** domains that ***bind*** ***SPT4*** and RNA polymerase II , in addition to a region in the C terminus of SPT5 that contains multiple heptad repeats and is designated CTR1 , are critical for in vitro transcriptional repression by DRB and activation by the Tat protein .	parallel	1
13307	10757792	5037;5609	RKIP;MEK	***RKIP*** ***interfered*** with ***MEK*** phosphorylation and activation by Raf-1 , resulting in the suppression of both Raf-1-induced transformation and AP-1-dependent transcription .	negative	0
13308	10757792	5894;5609	Raf-1;MEK	RKIP interfered with ***MEK*** ***phosphorylation*** and activation by ***Raf-1*** , resulting in the suppression of both Raf-1-induced transformation and AP-1-dependent transcription .	target	1
13309	10757792	5037;5609	RKIP;MEK	***RKIP*** can form ternary ***complexes*** with Raf-1 , ***MEK*** , and ERK .	parallel	1
13310	10757792	5037;5894	RKIP;Raf-1	***RKIP*** can form ternary ***complexes*** with ***Raf-1*** , MEK , and ERK .	parallel	1
13311	10757792	5609;5037	MEK;RKIP	However , whereas ***MEK*** and ERK can simultaneously ***associate*** with ***RKIP*** , Raf-1 binding to RKIP and that of MEK are mutually exclusive .	parallel	0
13312	10757792	5894;5037	Raf-1;RKIP	However , whereas MEK and ERK can simultaneously associate with RKIP , ***Raf-1*** ***binding*** to ***RKIP*** and that of MEK are mutually exclusive .	parallel	1
13313	10757792	5609;5894	MEK;Raf-1	RKIP is able to dissociate a ******Raf-1-MEK****** ***complex*** and behaves as a competitive inhibitor of MEK phosphorylation .	parallel	1
13314	10757792	5037;5609	RKIP;MEK	Both the Raf-1 and the MEK binding sites in RKIP need to be destroyed in order to relieve ***RKIP-mediated*** ***suppression*** of the ***Raf-1/MEK/ERK*** pathway , indicating that binding of either Raf-1 or MEK is sufficient for inhibition .	negative	1
13315	10757792	5037;5894	RKIP;Raf-1	Both the Raf-1 and the MEK binding sites in RKIP need to be destroyed in order to relieve ***RKIP-mediated*** ***suppression*** of the ***Raf-1/MEK/ERK*** pathway , indicating that binding of either Raf-1 or MEK is sufficient for inhibition .	negative	1
13316	10757792	5609;5894	MEK;Raf-1	Both the Raf-1 and the MEK binding sites in RKIP need to be destroyed in order to relieve RKIP-mediated suppression of the Raf-1/MEK/ERK pathway , indicating that ***binding*** of either ***Raf-1*** or ***MEK*** is sufficient for inhibition .	parallel	1
13317	10757795	6277;9612	hPRA;SMRT	Furthermore , our experiments indicate that ***hPRA*** ***interacts*** efficiently with the corepressor ***SMRT*** and that this activity permits it to function as a transdominant repressor .	parallel	1
13318	10757801	3717;6777	JAK2;Stat5B	DeltaC555 also blocks ***JAK2-mediated*** tyrosyl ***phosphorylation*** of ***Stat5B*** in COS cells and GH-stimulated nuclear accumulation of Stat5B in 3T3-F442A cells .	target	1
13319	10757802	128209;604	novel zinc finger protein;BCL6	Evi9 encodes a ***novel zinc finger protein*** that physically ***interacts*** with ***BCL6*** , a known human B-cell proto-oncogene product .	parallel	1
13320	10757813	50674;4760	neurogenin 3;BETA2	***Regulation*** of the pancreatic islet-specific gene ***BETA2*** ( neuroD ) by ***neurogenin 3*** .	target	1
13321	10757813	50674;4760	ngn3;BETA2	More importantly , overexpression of ***ngn3*** can ***induce*** the ectopic expression of ***BETA2*** in Xenopus embryos and stimulate the endogenous RNA of BETA2 in endocrine cell lines .	target	1
13322	10757813	50674;4760	ngn3;BETA2	More importantly , overexpression of ***ngn3*** can induce the ectopic expression of BETA2 in Xenopus embryos and ***stimulate*** the endogenous RNA of ***BETA2*** in endocrine cell lines .	positive	0
13323	10757813	6929;50674	E47;ngn3	Deletion and mutation analyses revealed that two proximal E box sequences , E1 and E3 , could bind to ******ngn3-E47****** ***heterodimer*** and mediate ngn3 activation .	parallel	1
13324	10757880	7402;1756	utrophin;dystrophin	As a remarquable source of cholinergic synapses , the Torpedo electrocyte model has served to identify the most important components involved in synaptic transmission such as the nicotinic acetylcholine receptor and the enzyme acetylcholinesterase , as well as proteins associated with the subsynaptic cytoskeleton and the extracellular matrix involved in the assembly of the postsynaptic membrane , namely the 43-kDa protein-rapsyn , the ******dystrophin/utrophin****** ***complex*** , agrin , and others .	parallel	1
13325	10757983	5443;2230	Adrenocorticotropin;adrenodoxin	***Adrenocorticotropin*** acting through cyclic adenosine monophosphate ( cAMP ) ***regulates*** transcription of the bovine ***adrenodoxin*** ( Adx ) gene in the adrenal cortex .	target	1
13326	10758163	17;7138	AAVS1;TNNT1	Here , we show that ***AAVS1*** is closely ***linked*** to the slow skeletal troponin T gene , ***TNNT1*** , which has been mapped previously to 19q13 .4 .	parallel	0
13327	10758165	4214;4790	MEKK1;NF-kappaB	Raf rather synergizes with another membrane shuttle kinase MEKK1 , and Raf-mediated activation of ***NF-kappaB*** is ***blocked*** by a dominant negative form of ***MEKK1*** .	negative	0
13328	10758170	3700;7852	gp120;CXCR4	Thus , the ***interaction*** of HIV-1 ***gp120*** with CCR5 or ***CXCR4*** evokes complex and distinct signaling responses in primary macrophages , and gp120-evoked signals differ from those activated by the coreceptors ' chemokine ligands .	parallel	1
13329	10758961	4018;102723508	Lipoprotein;spasm	BACKGROUND : Although elevated serum Lp ( a ) levels are known to be associated with coronary atherosclerosis and AMI , the ***association*** between the elevated level of this ***Lipoprotein*** and coronary ***spasm*** remains to be elucidated .	parallel	0
13330	10759003	5972;5054	renin;PAI-1	In vitro and in vivo studies indicate that the ***renin-angiotensin*** system is involved in the ***regulation*** of ***PAI-1*** .	target	1
13331	10759214	2520;5967	gastrin;Reg	***Reg*** protein production by ECL cells , as well as HB-EGF and AR production by parietal cells , is ***stimulated*** by ***gastrin*** and these growth factors are potent trophic agents of progenitor cells in the neck zone of the gastric fundic mucosa .	positive	0
13332	10759426	860;632	Cbfa1;osteocalcin	This interaction stimulates the ***binding*** of ***Osf2/Cbfa1*** to the ***osteocalcin*** promoter through an as-yet-undefined mechanism .	parallel	1
13333	10759505	51225;8988	abi3;HSP17	These data indicate that there is distinct developmental and stress regulation of HSP17 .4 , and imply that ***abi3*** ***activates*** ***HSP17*** .4 transcription during development .	positive	1
13334	10759526	57492;3308	CSS1;Hsp70	The ***interaction*** between SStp , the transit peptide of the precursor protein to the small subunit of Rubisco ( prSSU ) and two ***Hsp70*** molecular chaperones , Escherichia coli DnaK and pea ( Pisum sativum ) ***CSS1*** , was investigated in detail .	parallel	1
13335	10759547	1499;595	Beta-catenin;cyclin D1	Transactivation of ***Beta-catenin*** ***correlated*** significantly with ***cyclin D1*** expression both in eight breast cell lines in vitro and in 123 patient samples .	parallel	0
13336	10759720	4352;7066	c-mpl;TPO	Furthermore , an earlier induction of ***c-mpl*** protein , a ***receptor*** for ***TPO*** , was observed in the progenitors from bone marrow than in those from cord blood in the presence of SCF and IL-3 .	parallel	1
13337	10759890	10010;9641	I-TRAF;IKK-i	The association of IKK-i and I-TRAF is mediated via the ***interaction*** between the N-terminal domain of ***I-TRAF*** and the C-terminal portion of ***IKK-i*** .	parallel	1
13338	10759890	10010;9641	I-TRAF;IKK-i	The ***association*** of ***IKK-i*** and ***I-TRAF*** is mediated via the interaction between the N-terminal domain of I-TRAF and the C-terminal portion of IKK-i .	parallel	0
13339	10759890	9641;10010	IKK-i;I-TRAF	In vitro kinase assays demonstrate that ***IKK-i*** ***phosphorylates*** ***I-TRAF*** in the middle portion that associates with TRAF2 .	target	1
13340	10759890	10010;10010	TRAF2;I-TRAF	Interestingly , TRAF2 is freed from the ******I-TRAF/TRAF2****** ***complex*** after I-TRAF phosphorylation .	parallel	1
13341	10759890	9641;4790	IKK-i;NF-kappaB	***NF-kappaB*** ***activation*** by ***IKK-i*** is significantly blocked by coexpression of the N-terminal domain of I-TRAF , dominant negative TRAF2 , and dominant negative NIK and IKK-beta .	positive	1
13342	10759890	10010;4790	TRAF2;NF-kappaB	***NF-kappaB*** activation by IKK-i is significantly ***blocked*** by coexpression of the N-terminal domain of I-TRAF , dominant negative ***TRAF2*** , and dominant negative NIK and IKK-beta .	negative	0
13343	10759890	10010;9641	I-TRAF;IKK-i	These results show that ***I-TRAF*** is a ***substrate*** of ***IKK-i*** .	parallel	1
13344	10759890	9641;4790	IKK-i;NF-kappaB	***NF-kappaB*** ***activation*** by ***IKK-i*** may be mediated through phosphorylation of I-TRAF by IKK-i and subsequent liberation of TRAF2 .	positive	1
13345	10759890	9641;4790	IKK-i;NF-kappaB	CONCLUSION : These results indicate that ***NF-kappaB*** ***activation*** by ***IKK-i*** is mediated through phosphorylation of I-TRAF/TANK by IKK-i and subsequent liberation of TRAF2 .	positive	1
13346	10759890	9641;4790	IKK-i;NF-kappaB	***IKK-i*** significantly ***induced*** ***NF-kappaB*** activation upon over-expression , as did IKK-alpha and IKK-beta .	target	1
13347	10759890	9641;4790	IKK-i;NF-kappaB	Unlike IKK-alpha and IKK-beta , IKK-i phosphorylated Ser36 but not Ser32 in vitro , suggesting that ***IKK-i*** ***activates*** ***NF-kappaB*** by distinct mechanisms from the conventional IKKs .	positive	1
13348	10759945	4233;1499	c-met;beta-catenin	***c-met*** tyrosine kinase receptor expression is ***associated*** with abnormal ***beta-catenin*** expression and favourable prognostic factors in invasive breast carcinoma .	parallel	0
13349	10759945	4233;1499	c-met;beta-catenin	CONCLUSION : ***c-met*** immunohistochemical expression seems to be ***associated*** with abnormal ***beta-catenin*** expression , good prognostic and predictive factors and favourable outcome in breast cancer patients .	parallel	0
13350	10760083	4018;6347	lipoprotein;monocyte chemoattractant protein-1	Very low-density ***lipoprotein*** ***stimulates*** the expression of ***monocyte chemoattractant protein-1*** in mesangial cells .	positive	0
13351	10760093	1869;5934	E2F-1;p130	The suppression of ***E2F-1*** was ***associated*** with ( 1 ) dephosphorylation of retinoblastoma susceptibility gene proteins , pRB and p130 , and ( 2 ) accumulation of E2F-pRB and ***E2F-p130*** DNA binding complexes that bind to the E2F consensus sequence located in the E2F-1 promoter .	parallel	0
13352	10760093	1869;5925	E2F-1;pRB	The suppression of ***E2F-1*** was ***associated*** with ( 1 ) dephosphorylation of retinoblastoma susceptibility gene proteins , pRB and p130 , and ( 2 ) accumulation of ***E2F-pRB*** and E2F-p130 DNA binding complexes that bind to the E2F consensus sequence located in the E2F-1 promoter .	parallel	0
13353	10760215	4233;3082	c-Met;hepatocyte growth factor	Differential expression of ***hepatocyte growth factor*** and its ***receptor*** ( ***c-Met*** ) in a rat artificial anus model .	parallel	1
13354	10760215	4233;3082	c-Met;hepatocyte growth factor	It is mainly synthesized in mesenchymal cells and acts on epithelial cells , where its actions are dependent on binding to a specific cell-surface ***hepatocyte growth factor*** ***receptor*** ( ***c-Met*** ) .	parallel	1
13355	10760272	51573;6004	MIR16;RGS16	***MIR16*** , a putative membrane glycerophosphodiester phosphodiesterase , ***interacts*** with ***RGS16*** .	parallel	1
13356	10760273	2017;10456	cortactin;Hax-1	Furthermore we demonstrated an ***association*** between ***Hax-1*** and the F-actin-binding protein ***cortactin*** , which suggests a link between PKD2 and the actin cytoskeleton .	parallel	0
13357	10760291	5728;9863	PTEN;MAGI-2	***PTEN*** ***binds*** to ***MAGI-2*** through an interaction between the PDZ-binding motif of PTEN and the second PDZ domain of MAGI-2 .	parallel	1
13358	10760291	9863;5728	MAGI-2;PTEN	***MAGI-2*** ***enhances*** the ability of ***PTEN*** to suppress Akt activation .	positive	0
13359	10760298	4684;627	NCAM;BDNF	***PSA-NCAM*** , however , could directly ***interact*** with ***BDNF*** .	parallel	1
13360	10760302	5914;8648	RAR;SRC-1	These findings suggest that ligand-dependent transcriptional activities of the ***RAR*** and ER ***require*** concurrent or sequential recruitment of ***SRC-1*** and PBP-containing coactivator complexes .	target	0
13361	10760480	4023;4018	LPL;lipoprotein	Exogenous bovine ***LPL*** at a concentration of 1 microg/ml ***enhanced*** low density ***lipoprotein*** ( LDL ) - binding 10-fold .	positive	0
13362	10760758	7157;7422	p53;VEGF	CONCLUSIONS : The results of the current study demonstrated that angiogenesis develops in association with tumor progression from adenoma to noninvasive colorectal carcinoma , at least in part due to VEGF , and suggested that ***VEGF*** in m carcinomas is ***induced*** by mutant ***p53*** , although alternative mechanisms of VEGF up-regulation may exist in sm carcinomas .	target	1
13363	10760790	6361;1233	TARC;CCR4	TCR triggering of Th1 and Th2 cells leads to production of MDC and I-309 ( CCR4 and CCR8 ligands , respectively ) , whereas ***TARC*** ( ***CCR4*** ***ligand*** ) is selectively produced by Th2 cells .	parallel	1
13364	10760790	3439;6346	IFN-alpha;I-309	IL-12 and ***IFN-alpha*** , cytokines that promote the differentiation of human Th1 cells , selectively ***inhibit*** secretion and mRNA expression of MDC and ***I-309*** by Th1 cells .	negative	1
13365	10760790	3439;6367	IFN-alpha;MDC	IL-12 and ***IFN-alpha*** , cytokines that promote the differentiation of human Th1 cells , selectively ***inhibit*** secretion and mRNA expression of ***MDC*** and I-309 by Th1 cells .	negative	1
13366	10760796	966;8743	CD59;APO2L	The toxicity of these supernatants on Jurkat cells was fully prevented by the anti-APO2L blocking antibody , showing that ***CD59*** crosslinking ***induces*** the preferential release of ***APO2L*** also in normal T cells .	target	1
13367	10760816	1956;4318	epidermal growth factor receptor;matrix metalloproteinase-9	Overexpression of ***epidermal growth factor receptor*** in human head and neck squamous carcinoma cell lines ***correlates*** with ***matrix metalloproteinase-9*** expression and in vitro invasion .	parallel	0
13368	10760825	3458;3558	interferon-gamma;IL-2	IL-12 - and ***IL-2-induced*** tumor regression in a new murine model of oral squamous-cell carcinoma is ***promoted*** by expression of the CD80 co-stimulatory molecule and ***interferon-gamma*** .	positive	0
13369	10760953	7124;3383	TNF-alpha;ICAM-1	In the present report , we show that ***TNF-alpha*** ***increased*** ***ICAM-1*** mRNA levels in human astrocytoma cells and that ethanol markedly blocked TNF-alpha-induced increases in ICAM-1 mRNA levels .	positive	0
13370	10760955	5970;4790	p65;NF-kappaB	Electrophoretic mobility shift assays demonstrated that after TNF-alpha stimulation , p50 and ***p65*** NF-kappaB subunits ***bound*** specifically to the newly identified ***NF-kappaB*** transcription factor-binding site , distinct from the previously described NF-kappaB site , within the intronic enhancer region .	parallel	1
13371	10760955	4790;6648	NF-kappaB;Mn-SOD	In addition , site-directed mutagenesis and cotransfection studies demonstrated that the ***NF-kappaB*** p65 subunit ***enhanced*** the transcriptional activity of the ***Mn-SOD*** gene through the newly identified NF-kappaB site .	positive	0
13372	10760955	5970;6648	p65;Mn-SOD	In addition , site-directed mutagenesis and cotransfection studies demonstrated that the NF-kappaB ***p65*** subunit ***enhanced*** the transcriptional activity of the ***Mn-SOD*** gene through the newly identified NF-kappaB site .	positive	0
13373	10761054	3553;3569	IL-1-beta;IL-6	***IL-1-beta*** has potent osteoclast activating factor activity , can increase the expression of adhesion molecules , and can ***induce*** paracrine ***IL-6*** production .	target	1
13374	10761527	5443;3952	proopiomelanocortin;leptin	Rare mutations of the ***leptin*** gene and its ***receptor*** , ***proopiomelanocortin*** , or more frequently , melanocortin receptor 4 mutations , are evidence of the existence of an obesity gene .	parallel	1
13375	10761703	1026;983	p21;Cdc2	Following genistein treatment of cells , an increased ***binding*** of ***p21*** with Cdk2 and ***Cdc2*** paralleled a significant decrease in Cdc2 and Cdk2 kinase activity with no change in Cdk2 and Cdc2 expression .	parallel	1
13376	10761703	1026;1017	p21;Cdk2	Following genistein treatment of cells , an increased ***binding*** of ***p21*** with ***Cdk2*** and Cdc2 paralleled a significant decrease in Cdc2 and Cdk2 kinase activity with no change in Cdk2 and Cdc2 expression .	parallel	1
13377	10761922	27257;196513	Lsm1;Dcp1	In addition , the ***Lsm1-Lsm7*** proteins ***co-immunoprecipitate*** with the mRNA decapping enzyme ( ***Dcp1*** ) , a decapping activator ( Pat1/Mrt1 ) and with mRNA .	parallel	1
13378	10761922	51690;196513	Lsm7;Dcp1	In addition , the ***Lsm1-Lsm7*** proteins ***co-immunoprecipitate*** with the mRNA decapping enzyme ( ***Dcp1*** ) , a decapping activator ( Pat1/Mrt1 ) and with mRNA .	parallel	1
13379	10761931	30009;3458	T-bet;IFNgamma	***T-bet*** expression ***correlates*** with ***IFNgamma*** expression in Th1 and NK cells .	parallel	0
13380	10761931	30009;3458	T-bet;IFNgamma	Ectopic expression of ***T-bet*** both transactivates the IFNgamma gene and ***induces*** endogenous ***IFNgamma*** production .	target	1
13381	10761931	30009;3458	T-bet;IFNgamma	Ectopic expression of ***T-bet*** both ***transactivates*** the ***IFNgamma*** gene and induces endogenous IFNgamma production .	positive	1
13382	10761933	995;1111	Cdc25C;Chk1	Molecular modeling of the ***interaction*** of a ***Cdc25C*** peptide with ***Chk1*** has uncovered several conserved residues that are important for substrate selectivity .	parallel	1
13383	10762050	2885;6464	Grb2;Shc	They are capable to inhibit the ******Shc/Grb2****** ***interaction*** and MAP kinases ( ERK1 and ERK2 ) phosphorylation in cellular assay .	parallel	1
13384	10762075	3429;1019	p27;CDK4	An increase in the expression of ***p27/kipl*** , an ***inhibitor*** of ***CDK4*** , was observed in cells that were treated with both IFN and TM .	negative	1
13385	10762076	1432;3586	p38 MAP kinase;IL-10	These results indicate that macrophage ***IL-10*** and IL-6 expression is differentially ***regulated*** by PGE2 and ***p38 MAP kinase*** in murine inflammatory macrophages .	target	1
13386	10762077	3458;6356	IFN-gamma;eotaxin	Interleukin-4 and ***IFN-gamma*** differentially ***stimulate*** macrophage chemoattractant protein-1 ( MCP-1 ) and ***eotaxin*** production by intestinal epithelial cells .	positive	0
13387	10762077	3458;6347	IFN-gamma;MCP-1	Interleukin-4 and ***IFN-gamma*** differentially ***stimulate*** macrophage chemoattractant protein-1 ( ***MCP-1*** ) and eotaxin production by intestinal epithelial cells .	positive	0
13388	10762077	3565;6356	Interleukin-4;eotaxin	***Interleukin-4*** and IFN-gamma differentially ***stimulate*** macrophage chemoattractant protein-1 ( MCP-1 ) and ***eotaxin*** production by intestinal epithelial cells .	positive	0
13389	10762077	3565;6347	Interleukin-4;MCP-1	***Interleukin-4*** and IFN-gamma differentially ***stimulate*** macrophage chemoattractant protein-1 ( ***MCP-1*** ) and eotaxin production by intestinal epithelial cells .	positive	0
13390	10762077	3458;6347	IFN-gamma;MCP-1	Both ***IFN-gamma*** and IL-4 ***enhanced*** ***MCP-1*** mRNA levels but with different kinetics .	positive	0
13391	10762077	3565;6347	IL-4;MCP-1	Both IFN-gamma and ***IL-4*** ***enhanced*** ***MCP-1*** mRNA levels but with different kinetics .	positive	0
13392	10762077	3553;2920	IL-1beta;MIP-2	Finally , ***IL-1beta*** but not IFN-gamma or IL-4 ***enhanced*** ***MIP-2*** mRNA levels .	positive	0
13393	10762210	356;355	Fas ligand;Fas	Fas ligand has been suggested as a general underlying mechanism of immune privilege ; the human ***Fas ligand*** has been shown to ***ligate*** murine ***Fas*** in vitro .	parallel	1
13394	10762631	1029;595	p16INK4a;cyclin D1	The ***associations*** of p21 and nuclear ***cyclin D1*** , pRb , ***p16INK4a*** support the relevance of pathways linked to lung carcinogenesis that involve p21 but may act in addition to direct CDK inhibition .	parallel	0
13395	10762631	1029;1026	p16INK4a;p21	The ***associations*** of ***p21*** and nuclear cyclin D1 , pRb , ***p16INK4a*** support the relevance of pathways linked to lung carcinogenesis that involve p21 but may act in addition to direct CDK inhibition .	parallel	0
13396	10762631	1029;5925	p16INK4a;pRb	The ***associations*** of p21 and nuclear cyclin D1 , ***pRb*** , ***p16INK4a*** support the relevance of pathways linked to lung carcinogenesis that involve p21 but may act in addition to direct CDK inhibition .	parallel	0
13397	10762631	1026;595	p21;cyclin D1	The ***associations*** of ***p21*** and nuclear ***cyclin D1*** , pRb , p16INK4a support the relevance of pathways linked to lung carcinogenesis that involve p21 but may act in addition to direct CDK inhibition .	parallel	0
13398	10762631	5925;595	pRb;cyclin D1	The ***associations*** of p21 and nuclear ***cyclin D1*** , ***pRb*** , p16INK4a support the relevance of pathways linked to lung carcinogenesis that involve p21 but may act in addition to direct CDK inhibition .	parallel	0
13399	10762631	5925;1026	pRb;p21	The ***associations*** of ***p21*** and nuclear cyclin D1 , ***pRb*** , p16INK4a support the relevance of pathways linked to lung carcinogenesis that involve p21 but may act in addition to direct CDK inhibition .	parallel	0
13400	10762631	1026;595	p21;cyclin D1	***p21*** is ***associated*** with ***cyclin D1*** , p16INK4a and pRb expression in resectable non-small cell lung cancer .	parallel	0
13401	10762631	1026;1029	p21;p16INK4a	***p21*** is ***associated*** with cyclin D1 , ***p16INK4a*** and pRb expression in resectable non-small cell lung cancer .	parallel	0
13402	10762631	1026;5925	p21;pRb	***p21*** is ***associated*** with cyclin D1 , p16INK4a and ***pRb*** expression in resectable non-small cell lung cancer .	parallel	0
13403	10762631	1026;595	p21;cyclin D1	High ***p21*** expression was ***associated*** with well differentiated tumours ( p = 0.01 ) and ***cyclin D1*** nuclear staining ( p = 0.02 ) .	parallel	0
13404	10762646	2324;2277	VEGFR-3;VEGF-D	Another tyrosine kinase receptor , ***VEGFR-3*** ( flt-4 ) ***binds*** VEGF-C and ***VEGF-D*** and is more important in the development of lymphatic vessels .	parallel	1
13405	10762698	1020;4137	Cdk5;tau	In neurofilament and microtubule preparations from rat brain , we demonstrated by Western blot analysis that ***Cdk5*** , a neuronal cyclin dependent kinase and Erk1/2 were ***associated*** with complexes of NF proteins , tubulins and ***tau*** .	parallel	0
13406	10762708	1742;4842	PSD-95;nNOS	In addition , ***PSD-95*** ***binds*** with neuronal nitric oxide synthase ( ***nNOS*** ) , which is competitively inhibited by carboxy-terminal PDZ ligand of nNOS ( CAPON ) and , thereby , nNOS activity is thought to be regulated by PSD-95 and CAPON .	parallel	1
13407	10762708	1742;4842	PSD-95;nNOS	In addition , PSD-95 binds with neuronal nitric oxide synthase ( nNOS ) , which is competitively inhibited by carboxy-terminal PDZ ligand of nNOS ( CAPON ) and , thereby , ***nNOS*** activity is thought to be ***regulated*** by ***PSD-95*** and CAPON .	target	1
13408	10763147	1471;1508	cystatin C;cathepsin B	However , the ******cathepsin B/cystatin C****** ***complex*** was found to be less abundant in sera of patients with malignant tumors than in those with benign diseases or in healthy controls , suggesting an imbalance between the enzyme and its inhibitor in cancer patients .	parallel	1
13409	10763507	2246;598	FGF-1;bcl-X	In addition , ***FGF-1*** treatment also ***induces*** expression of the ***bcl-X*** anti-apoptotic protein in the same site of the media showing VSMC apoptosis .	target	1
13410	10763814	1991;4586	neutrophil elastase;mucin	Only 8-bromocyclic AMP and ***neutrophil elastase*** ***influenced*** ***mucin*** secretion .	target	0
13411	10763819	5371;595	promyelocytic leukemia (PML) protein;cyclin D1	The ***promyelocytic leukemia (PML) protein*** ***suppresses*** ***cyclin D1*** protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA .	negative	1
13412	10763819	1977;5371	eIF-4E;PML	Addition of eIF-4E overcomes PML induced retention and alters the morphology of PML bodies suggesting a mechanism by which ***eIF-4E*** can ***modulate*** ***PML*** function .	target	0
13413	10763821	4609;1027	c-Myc;p27Kip1	We propose that ***c-Myc*** is a primary effector of ErbB2-mediated oncogenicity and functions to ***prevent*** normal ***p27Kip1*** control of cyclinE/CDK2 .	negative	0
13414	10763821	1027;1017	p27Kip1;CDK2	We propose that c-Myc is a primary effector of ErbB2-mediated oncogenicity and functions to prevent normal ***p27Kip1*** ***control*** of ***cyclinE/CDK2*** .	target	0
13415	10763822	7538;7124	tristetraprolin;TNF-alpha	The immediate early protein ***tristetraprolin*** ( TTP ) is required to ***prevent*** inappropriate production of the cytokine ***TNF-alpha*** , and is a member of a zinc finger protein family that is associated with RNA binding .	negative	0
13416	10763822	7124;7538	TNF-alpha;TTP	***TTP*** expression is ***induced*** by ***TNF-alpha*** , and evidence indicates that TTP can bind and destabilize the TNF-alpha mRNA .	target	1
13417	10763822	7538;7124	TTP;TNF-alpha	TTP expression is induced by TNF-alpha , and evidence indicates that ***TTP*** can ***bind*** and destabilize the ***TNF-alpha*** mRNA .	parallel	1
13418	10763822	7538;7124	TTP;TNF-alpha	The data suggest that the TTP and TIS11 immediate early proteins have similar but distinct effects on growth or survival pathways , and that ***TTP*** might ***influence*** ***TNF-alpha*** regulation at multiple levels .	target	0
13419	10763825	25;207	Abl;Akt	The mitogenic MAPK/Erk kinases as well as ***Akt/PKB*** , a kinase implicated to negatively regulate apoptosis , were also constitutively ***activated*** by both Bcr-Abl and ***Tel-Abl*** .	positive	1
13420	10763828	6714;140885	Src;SHPS-1	***v-Src*** ***suppresses*** ***SHPS-1*** expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells .	negative	1
13421	10763828	6714;140885	Src;SHPS-1	While nontransforming Src kinases including c-Src , nonmyristoylated forms of v-Src had no inhibitory effect on SHPS-1 expression , transforming ***Src*** kinases including wild-type v-Src and chimeric mutant of c-Src bearing v-Src SH3 substantially ***suppressed*** the ***SHPS-1*** expression .	negative	1
13422	10763830	1030;1019	p15INK4B;CDK4	Both ***p15INK4B*** and p15 .5 INK4B ***bound*** to ***CDK4*** and CDK6 , inhibited DNA synthesis , and caused replicative senescence of a human glioma cell line .	parallel	1
13423	10763830	1030;1021	p15INK4B;CDK6	Both ***p15INK4B*** and p15 .5 INK4B ***bound*** to CDK4 and ***CDK6*** , inhibited DNA synthesis , and caused replicative senescence of a human glioma cell line .	parallel	1
13424	10764042	573;596	Bag-1;Bcl-2	In contrast to these ******Bcl-2/Bag-1****** ***interactions*** observed under serum starvation conditions , Bag-1 did not further enhance the strong protection from staurosporine - , CD95 ( Fas/Apo1 ) ligand - , Apo2 ligand ( TRAIL ) - or chemotherapeutic drug-induced apoptosis afforded by Bcl-2 .	parallel	1
13425	10764042	596;573	Bcl-2;Bag-1	Taken together , these results indicate a role for ******Bag-1/Bcl-2****** ***interactions*** in providing a survival advantage to cancer cells in a deprived microenvironment that may be characteristic of ischemic/hypoxic tumors such as human glioblastoma multiforme , and suggest that Bcl-2/Bag-1 interactions also modulate cell proliferation .	parallel	1
13426	10764042	573;596	Bag-1;Bcl-2	Taken together , these results indicate a role for Bag-1/Bcl-2 interactions in providing a survival advantage to cancer cells in a deprived microenvironment that may be characteristic of ischemic/hypoxic tumors such as human glioblastoma multiforme , and suggest that ******Bcl-2/Bag-1****** ***interactions*** also modulate cell proliferation .	parallel	1
13427	10764042	596;573	Bcl-2;Bag-1	Coexpressed ***Bcl-2*** ***abrogated*** these effects of ***Bag-1*** .	negative	0
13428	10764142	3563;3562	IL3R;interleukin-3	The DTLIL3 construct was more cytotoxic to ***interleukin-3*** ***receptor*** ( ***IL3R*** ) bearing human myeloid leukemia cell lines than receptor-negative cell lines based on assays of cytotoxicity using thymidine incorporation , growth in semi-solid medium and induction of apoptosis .	parallel	1
13429	10764144	10006;6455	Abi-1;EEN	The ***interaction*** between ***EEN*** and ***Abi-1*** , two MLL fusion partners , and synaptojanin and dynamin : implications for leukaemogenesis .	parallel	1
13430	10764157	2208;4843	CD23;iNOS	Ligation of ***CD23*** ( low affinity IgE receptor ) was found to ***increase*** ***iNOS*** expression in ESKOL and conversely to decrease the percentage of cells undergoing apoptosis , as measured by the percentage of cells expressing annexin V .	positive	0
13431	10764329	4790;5970	p50;p65	Unexpectedly , active NF - kappaB complexes found in BCs of heaves-affected horses were mainly p65 homodimers , rather than classic ******p65-p50****** ***heterodimers*** .	parallel	1
13432	10764405	185;5906	AT1R;Rap1	Activation of ERK1/ERK2 in AT1Rwt required Ras , whereas ***AT1R*** ( Del221/222 ) ***required*** ***Rap1*** .	target	0
13433	10764587	5590;4792	PKC-zeta;IkappaBalpha	***PKC-zeta*** has been shown to be ***associated*** with an ***IkappaBalpha*** kinase in resting cells .	parallel	0
13434	10764593	1457;4673	CKII;NAP-1	Here , we demonstrate that casein kinase 2 ( ***CKII*** ) from HeLa cell nuclear extracts interacts with immobilized NAP-II , and ***phosphorylates*** both NAP-2 and nucleosome assembly protein 1 ( ***NAP-1*** ) in vitro .	target	1
13435	10764593	1457;4676	CKII;NAP-2	Here , we demonstrate that casein kinase 2 ( ***CKII*** ) from HeLa cell nuclear extracts interacts with immobilized NAP-II , and ***phosphorylates*** both ***NAP-2*** and nucleosome assembly protein 1 ( NAP-1 ) in vitro .	target	1
13436	10764593	1457;4673	CKII;NAP-1	Addition of core histones can stimulate ***phosphorylation*** of ***NAP-1*** and NAP-2 by ***CKII*** .	target	1
13437	10764593	1457;4676	CKII;NAP-2	Addition of core histones can stimulate ***phosphorylation*** of NAP-1 and ***NAP-2*** by ***CKII*** .	target	1
13438	10764601	11214;5577	Ht31;RIIbeta	Surface competition assays with increasing concentrations of a competitor peptide covering amino acid residues 493 to 515 of the thyroid anchoring protein Ht31 , demonstrated that ***Ht31*** , but not a proline-substituted peptide , Ht31-P , ***competed*** binding of RIIalpha and ***RIIbeta*** to all the AKAPs examined ( EC ( 50 ) - values from 6 to 360 nM ) .	negative	0
13439	10764619	3824;3133	CD94;HLA-E	The ***CD94/NKG2*** and NKG2D lectin-like molecules , respectively , ***interact*** with ***HLA-E*** and MICA ; CD94/NKG2A functions as an inhibitory receptor , while CD94/NKG2C and NKG2D trigger NK cell activity .	parallel	1
13440	10764619	3824;100507436	CD94;MICA	The ***CD94/NKG2*** and NKG2D lectin-like molecules , respectively , ***interact*** with HLA-E and ***MICA*** ; CD94/NKG2A functions as an inhibitory receptor , while CD94/NKG2C and NKG2D trigger NK cell activity .	parallel	1
13441	10764619	22914;3133	NKG2D;HLA-E	The CD94/NKG2 and ***NKG2D*** lectin-like molecules , respectively , ***interact*** with ***HLA-E*** and MICA ; CD94/NKG2A functions as an inhibitory receptor , while CD94/NKG2C and NKG2D trigger NK cell activity .	parallel	1
13442	10764619	22914;100507436	NKG2D;MICA	The CD94/NKG2 and ***NKG2D*** lectin-like molecules , respectively , ***interact*** with HLA-E and ***MICA*** ; CD94/NKG2A functions as an inhibitory receptor , while CD94/NKG2C and NKG2D trigger NK cell activity .	parallel	1
13443	10764619	3821;3133	NKG2;HLA-E	The ***CD94/NKG2*** and NKG2D lectin-like molecules , respectively , ***interact*** with ***HLA-E*** and MICA ; CD94/NKG2A functions as an inhibitory receptor , while CD94/NKG2C and NKG2D trigger NK cell activity .	parallel	1
13444	10764619	3821;100507436	NKG2;MICA	The ***CD94/NKG2*** and NKG2D lectin-like molecules , respectively , ***interact*** with HLA-E and ***MICA*** ; CD94/NKG2A functions as an inhibitory receptor , while CD94/NKG2C and NKG2D trigger NK cell activity .	parallel	1
13445	10764649	5080;2018	Pax6;Emx2	These findings suggest that ***Emx2*** and ***Pax6*** ***cooperate*** to regulate arealization of the neocortex and to confer area identity to cortical cells .	parallel	0
13446	10764662	3458;4015	interferon-gamma;lysyl oxidase	***Regulation*** of ***lysyl oxidase*** by ***interferon-gamma*** in rat aortic smooth muscle cells .	target	1
13447	10764662	3458;4015	IFN-gamma;lysyl oxidase	***Downregulation*** of ***lysyl oxidase*** by ***IFN-gamma*** did not appear to require new protein synthesis .	negative	1
13448	10764662	3458;4015	IFN-gamma;lysyl oxidase	This study documents that ***IFN-gamma*** ***downregulates*** ***lysyl oxidase*** gene expression in rat aortic smooth muscle cells by transcriptional and posttranscriptional mechanisms .	negative	1
13449	10764682	4018;4973	lipoprotein;LOX-1	In this study , we examined the ***regulation*** of ***LOX-1*** by oxidized low density ***lipoprotein*** ( ox-LDL ) and determined the role of LOX-1 in ox-LDL-induced apoptosis of cultured human coronary artery endothelial cells ( HCAECs ) .	target	1
13450	10764682	4973;4790	LOX-1;NF-kappaB	The critical role of NF-kappaB activation became evident in experiments with antisense ***LOX-1*** , which ***abolished*** ox-LDL-mediated ***NF-kappaB*** activation .	negative	0
13451	10764685	7448;5054	vitronectin;PAI-1	Colocalization of thrombin , PAI-1 , and vitronectin in the atherosclerotic vessel wall : A potential regulatory mechanism of thrombin activity by ******PAI-1/vitronectin****** ***complexes*** .	parallel	1
13452	10764710	5816;3497	parvalbumin;IgE	Purified ***parvalbumin*** ***reacted*** with ***IgE*** of more than 95 % of individuals allergic to fish , induced dose-dependent basophil histamine release and contained , on average , 83 % of the IgE epitopes present in other fish species .	parallel	1
13453	10764711	4914;4803	TrkA;Nerve growth factor	***Nerve growth factor*** and Trk high affinity ***receptor*** ( ***TrkA*** ) gene expression in inflammatory bowel disease .	parallel	1
13454	10764727	27018;835	NADE;caspase-2	Co-expression of ***NADE*** and p75NTR ***induced*** ***caspase-2*** and caspase-3 activities and the fragmentation of nuclear DNA in 293T cells .	target	1
13455	10764727	27018;836	NADE;caspase-3	Co-expression of ***NADE*** and p75NTR ***induced*** caspase-2 and ***caspase-3*** activities and the fragmentation of nuclear DNA in 293T cells .	target	1
13456	10764727	4804;835	p75NTR;caspase-2	Co-expression of NADE and ***p75NTR*** ***induced*** ***caspase-2*** and caspase-3 activities and the fragmentation of nuclear DNA in 293T cells .	target	1
13457	10764727	4804;836	p75NTR;caspase-3	Co-expression of NADE and ***p75NTR*** ***induced*** caspase-2 and ***caspase-3*** activities and the fragmentation of nuclear DNA in 293T cells .	target	1
13458	10764727	27018;4804	NADE;p75NTR	Furthermore , p75NTR/NADE-induced cell death was dependent on NGF but not BDNF , NT-3 , or NT-4 / 5 , and the ***recruitment*** of ***NADE*** to ***p75NTR*** ( intracellular domain ) was dose-dependent .	target	0
13459	10764728	112752;317	CED-3;CED-4	The Caenorhabditis elegans sex determination protein FEM-1 is a ***CED-3*** substrate that ***associates*** with ***CED-4*** and mediates apoptosis in mammalian cells .	parallel	0
13460	10764738	4131;6622	Microtubule-associated protein 1B;alpha-synuclein	***Microtubule-associated protein 1B*** is a component of cortical Lewy bodies and ***binds*** ***alpha-synuclein*** filaments .	parallel	1
13461	10764744	7124;3725	TNF-alpha;AP-1	TNF-alpha signaling was not altered by the overexpression of catalase , as ***activation*** of nuclear factor kappaB and ***AP-1*** by ***TNF-alpha*** was similar in the three cell lines .	positive	1
13462	10764744	7124;841	TNF-alpha;caspase-3 and -8	The activities of ***caspase-3 and -8*** were ***increased*** by ***TNF-alpha*** , with the highest activities found in mC5 cells .	positive	0
13463	10764745	79719;9185	p34;POB1	***POB1*** and Epsin were ***phosphorylated*** by ***p34*** ( cdc2 ) kinase in vitro .	target	1
13464	10764746	7187;943	CD40-binding protein;CD30	We have identified a novel intracellular ***CD40-binding protein*** termed TRAF and TNF receptor-associated protein ( TTRAP ) that also ***interacts*** with TNF-R75 and ***CD30*** .	parallel	1
13465	10764746	7187;7133	CD40-binding protein;TNF-R75	We have identified a novel intracellular ***CD40-binding protein*** termed TRAF and TNF receptor-associated protein ( TTRAP ) that also ***interacts*** with ***TNF-R75*** and CD30 .	parallel	1
13466	10764746	51567;958	TTRAP;CD40	***Association*** of ***TTRAP*** with ***CD40*** increases profoundly in response to treatment of cells with CD40L .	parallel	0
13467	10764746	51567;4790	TTRAP;NF-kappaB	In transfected cells , ***TTRAP*** ***inhibits*** in a dose-dependent manner the transcriptional activation of a nuclear factor-kappaB ( ***NF-kappaB*** ) - dependent reporter mediated by CD40 , TNF-R75 or Phorbol 12-myristate 13-acetate ( PMA ) and to a lesser extent by TRAF2 , TRAF6 , TNF-alpha , or interleukin-1beta ( IL-1beta ) .	negative	1
13468	10764760	4296;5601	src-homology 3 domain-containing proline-rich kinase;SAPK	We found that the protein kinase mixed lineage kinase ***3/src-homology 3 domain-containing proline-rich kinase*** , a specific ***activator*** of the stress-activated protein kinase ( ***SAPK*** ) / JNK signaling pathway in T lymphocytes , induces high transcriptional activation of this promoter .	positive	1
13469	10764762	3903;5777	LAIR-1;SHP-1	Tyrosine-phosphorylated ***LAIR-1*** specifically ***interacts*** with ***SHP-1*** but not with SHP-2 , a structurally related tyrosine phosphatase .	parallel	1
13470	10764764	6667;7077	Sp1;TIMP-2	The NF-Y and the ***Sp1*** binding site are both involved in cAMP-dependent ***up-regulation*** of ***TIMP-2*** .	positive	1
13471	10764767	6774;1026	STAT3;SDI1	Functional ***interaction*** of ***STAT3*** transcription factor with the cell cycle inhibitor ***p21WAF1/CIP1/SDI1*** .	parallel	1
13472	10764767	1026;6774	p21;STAT3	In the present study , we show that the cyclin-dependent kinase inhibitor ***p21*** ( WAF1/CIP1/SDI1 ) ***inhibits*** ***STAT3*** transcriptional activation .	negative	1
13473	10764767	1026;6774	p21;STAT3	Interestingly , pull down experiments showed that p21 ( WAF1/CIP1/SDI1 ) could interact with the CREB-binding coactivator protein , and ***inhibition*** of ***STAT3*** activity by ***p21*** ( WAF1/CIP1/SDI1 ) did not occur when CREB-binding protein was overexpressed .	negative	1
13474	10764767	1026;6774	p21;STAT3	These results suggest a model by which ***p21*** ( WAF1/CIP1/SDI1 ) functions as an ***inhibitor*** of ***STAT3*** signaling and highlight a new activity for this cyclin-dependent kinase inhibitor .	negative	1
13475	10764778	6772;3659	stat1;IRF1	Adenovirus E1A down-regulates LMP2 transcription by interfering with the ***binding*** of ***stat1*** to ***IRF1*** .	parallel	1
13476	10764778	5698;3659	LMP2;IRF1	The ***LMP2*** gene , which encodes a protein required for efficient presentation of viral antigens , ***requires*** both unphosphorylated stat1 and ***IRF1*** for basal expression .	target	0
13477	10764778	5698;6772	LMP2;stat1	The ***LMP2*** gene , which encodes a protein required for efficient presentation of viral antigens , ***requires*** both unphosphorylated ***stat1*** and IRF1 for basal expression .	target	0
13478	10764778	6772;3659	stat1;IRF1	E1A interferes with the formation of this complex by occupying domains of ***stat1*** that ***bind*** to ***IRF1*** .	parallel	1
13479	10764786	7157;7153	p53 tumor suppressor;topoisomerase IIalpha	The ***p53 tumor suppressor*** ***stimulates*** the catalytic activity of human ***topoisomerase IIalpha*** by enhancing the rate of ATP hydrolysis .	positive	0
13480	10764786	7157;7153	p53;topoisomerase IIalpha	In this report , we have demonstrated that the catalytic activity of ***topoisomerase IIalpha*** , as measured by decatenation of kinetoplast DNA and by relaxation of negatively supercoiled DNA , was ***stimulated*** approximately 2-3-fold by the tumor suppressor ***p53*** protein .	positive	0
13481	10764786	7157;7153	p53;topoisomerase IIalpha	Clearly manifested in decatenation and relaxation assays , ***p53*** ***reduced*** the catalytic inhibition of ***topoisomerase IIalpha*** by ICRF-193 .	negative	1
13482	10764786	7157;7153	p53;topoisomerase IIalpha	Immunoprecipitation experiments revealed that ***p53*** physically ***interacts*** with ***topoisomerase IIalpha*** to form molecular complexes without a double-stranded DNA intermediary in vitro .	parallel	1
13483	10764798	3569;6774	interleukin-6;STAT3	Mitogen-activated protein ( MAP ) kinases stimulated by phorbol 13-myristate 12-acetate ( PMA ) have been shown to inhibit ***interleukin-6-induced*** ***activation*** of ***STAT3*** ( Sengupta , T.	positive	1
13484	10764799	3667;3643	IRS-1;insulin receptor	Treatment of the cells with high concentrations of glucose ( 15-33 mm ) caused phosphorylation of serine residues of the ***insulin receptor*** ***substrate*** 1 ( ***IRS-1*** ) , leading to reduced electrophoretic mobility of it .	parallel	1
13485	10764799	2885;6464	Grb2;Shc	In contrast , insulin-induced ***association*** of ***Shc*** and ***Grb2*** was not inhibited .	parallel	0
13486	10764802	1017;4654	Cdk2;MyoD	Recent data have demonstrated the role of Cdk1 - and ***Cdk2-dependent*** ***phosphorylation*** of ***MyoD*** ( Ser200 ) in the regulation of MyoD activity and protein turnover .	target	1
13487	10764802	1028;4654	p57;MyoD	Furthermore , ***p57*** ( Kip2 ) ***increases*** the levels of ***MyoD*** ( Ala200 ) in cotransfected cells .	positive	0
13488	10764802	1028;4654	p57;MyoD	This result implies that ***p57*** ( Kip2 ) may ***regulate*** ***MyoD*** through a process distinct from its function as a cyclin-dependent kinase inhibitors .	target	1
13489	10764803	7448;5054	vitronectin;PAI-1	These findings indicate that plasma ******PAI-1.vitronectin****** ***complexes*** can be localized to the surface of fibrin clots ; by this localization , they may modulate fibrinolysis and clot reorganization .	parallel	1
13490	10764803	5054;5327	PAI-1;t-PA	Type 1 plasminogen activator inhibitor ( ***PAI-1*** ) , the primary ***inhibitor*** of tissue-type plasminogen activator ( ***t-PA*** ) , circulates as a complex with the abundant plasma glycoprotein , vitronectin .	negative	1
13491	10764811	672;5932	BRCA1;CtIP	Finally , the ***interaction*** between ***CtIP*** and ***BRCA1*** is shown to be stable in the face of genotoxic stress elicited by treatment with UV light , adriamycin , or hydrogen peroxide .	parallel	1
13492	10764814	7124;5594	TNFalpha;ERK1/2	In contrast , ***TNFalpha*** transiently ***suppressed*** insulin-induced ***ERK1/2*** activation .	negative	1
13493	10764814	7124;6464	TNFalpha;Shc	Insulin-induced phosphorylation of ***Shc*** was ***inhibited*** by ***TNFalpha*** in a similar pattern .	negative	1
13494	10764815	4803;2185	NGF;RAFTK	***NGF*** ***induced*** the tyrosine phosphorylation of ***RAFTK*** in a time - and dose-dependent manner , whereas no change in the tyrosine phosphorylation of FAK was observed .	target	1
13495	10764815	5829;2185	paxillin;RAFTK	The focal adhesion molecule ***paxillin*** was ***co-immunoprecipitated*** with ***RAFTK*** , and its tyrosine phosphorylation was increased in a Ca ( 2 + ) - dependent manner upon NGF stimulation .	parallel	1
13496	10764953	3553;133	interleukin-1 (IL-1)beta;adrenomedullin	Interferon-gamma ( 100 U/ml ) increased the immunoreactive-endothelin levels , but not immunoreactive-adrenomedullin levels , whereas ***interleukin-1 (IL-1)beta*** ( 10 ng/ml ) ***increased*** ***immunoreactive-adrenomedullin*** levels , but not immunoreactive-endothelin levels .	positive	0
13497	10765004	6750;2641	somatostatin;glucagon	***somatostatin*** , which ***suppresses*** the secretion of ***glucagon*** and growth hormone , has been known to attenuate the rate of gluconeogesis and ketogenesis in insulin-dependent diabetes mellitus patients .	negative	1
13498	10765127	7421;2064	Vitamin D receptor;erbB-2	***Vitamin D receptor*** gene BsmI polymorphism ***correlates*** with ***erbB-2/HER-2*** expression in human rectal cancer .	parallel	0
13499	10765504	3949;4018	LDLR;lipoprotein	Long-term reversal of hypercholesterolemia in low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) - deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade .	parallel	1
13500	10765504	3949;4018	LDLR;lipoprotein	BACKGROUND : Deficiency of the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) results in abnormal elevation of cholesterol within the intermediate and low density plasma lipoproteins ( IDL/LDL ) , and predisposes to early onset atherosclerosis .	parallel	1
13501	10765928	355;356	Fas;Fas ligand	The suppressive effect was not mediated by ******Fas/Fas ligand****** ***interactions*** or by the chemokines macrophage inhibitory protein 1alpha or IL-8 .	parallel	1
13502	10765931	373156;6648	GST;MnSOD	However , ***interaction*** between ***MnSOD*** and ***GST*** genes appears to influence radiologic outcome independently of the SE .	parallel	1
13503	10765931	373156;6648	GST;MnSOD	We also examined whether radiologic outcome was influenced by ***interactions*** between ***MnSOD*** and glutathione S-transferase ( ***GST*** ) genes .	parallel	1
13504	10765931	2952;6648	GSTT1;MnSOD	There was evidence of ***interaction*** between the ***GSTT1*** and ***MnSOD*** genotypes , with the MnSOD VV/GSTT1-null combination being associated with the highest Larsen score ( 142.1 ; P = 0.007 after correction for the SE ) .	parallel	1
13505	10766162	4602;5743	c-MYB;Cyclooxygenase-2	***Cyclooxygenase-2*** , a colorectal cancer nonsteroidal anti-inflammatory drug target , is ***regulated*** by ***c-MYB*** .	target	1
13506	10766162	4602;5743	c-MYB;COX-2	On the basis of the coincident high levels of the transcription factor c-MYB and COX-2 in CRC , we hypothesized that ***c-MYB*** is a candidate ***activator*** of ***COX-2*** transcription .	positive	1
13507	10766162	4602;5743	c-MYB;COX-2	Promoter studies indicated that ***c-MYB*** can ***activate*** ***COX-2*** transcription , whereas dominant-negative Myb mediated repression .	positive	1
13508	10766163	2099;7157	ERalpha;p53	In this report , using the glutathione S-transferase pull-down methodology , we show the ligand-independent ***interaction*** of ***ERalpha*** with the NH2-terminal region of ***p53*** , a region known to bind the p300 and human double minute-2 ( hdm2 ) regulatory factors .	parallel	1
13509	10766163	7157;4193	p53;hdm2	The interaction of ERalpha and p53 does not interfere with the ***binding*** between ***p53*** and ***hdm2*** ; rather , these proteins form a ternary complex .	parallel	1
13510	10766163	7157;2099	p53;ERalpha	The ***interaction*** of ***ERalpha*** and ***p53*** does not interfere with the binding between p53 and hdm2 ; rather , these proteins form a ternary complex .	parallel	1
13511	10766182	3458;5698	IFN-gamma;LMP-2	***IFN-gamma*** ***induced*** surface class I MHC expression , as well as gene expression of TAP-1 , TAP-2 , ***LMP-2*** , and LMP-7 in the metastatic cells , yet the cells remained resistant to cell lysis induced by CTLs .	target	1
13512	10766182	3458;5696	IFN-gamma;LMP-7	***IFN-gamma*** ***induced*** surface class I MHC expression , as well as gene expression of TAP-1 , TAP-2 , LMP-2 , and ***LMP-7*** in the metastatic cells , yet the cells remained resistant to cell lysis induced by CTLs .	target	1
13513	10766182	3458;6890	IFN-gamma;TAP-1	***IFN-gamma*** ***induced*** surface class I MHC expression , as well as gene expression of ***TAP-1*** , TAP-2 , LMP-2 , and LMP-7 in the metastatic cells , yet the cells remained resistant to cell lysis induced by CTLs .	target	1
13514	10766182	3458;6891	IFN-gamma;TAP-2	***IFN-gamma*** ***induced*** surface class I MHC expression , as well as gene expression of TAP-1 , ***TAP-2*** , LMP-2 , and LMP-7 in the metastatic cells , yet the cells remained resistant to cell lysis induced by CTLs .	target	1
13515	10766245	472;4683	ATM;p95	***ATM*** ***phosphorylates*** ***p95/nbs1*** in an S-phase checkpoint pathway .	target	1
13516	10766245	472;4683	ATM;nbs1	Here , because of the similarities between AT and NBS , we evaluated the functional ***interactions*** between ***ATM*** and ***p95/nbs1*** .	parallel	1
13517	10766245	4683;472	p95;ATM	Here , because of the similarities between AT and NBS , we evaluated the functional ***interactions*** between ***ATM*** and ***p95/nbs1*** .	parallel	1
13518	10766245	4683;4683	p95;nbs1	Here , because of the similarities between AT and NBS , we evaluated the functional ***interactions*** between ATM and ******p95/nbs1****** .	parallel	1
13519	10766246	3689;10987	LFA-1;JAB1	Integrin ***LFA-1*** ***interacts*** with the transcriptional co-activator ***JAB1*** to modulate AP-1 activity .	parallel	1
13520	10766246	3689;3725	LFA-1;AP-1	Integrin ***LFA-1*** interacts with the transcriptional co-activator JAB1 to ***modulate*** ***AP-1*** activity .	target	0
13521	10766246	10987;3725	JAB1;c-Jun	This protein is ***JAB1*** ( Jun activation domain-binding protein 1 ) , a ***coactivator*** of the ***c-Jun*** transcription factor .	positive	1
13522	10766248	990;81620	Cdc6;Cdt1	Orr-Weaver , personal communication ) , suggesting that the ***cooperation*** of ***Cdc6/Cdc18*** with ***Cdt1*** to load MCM proteins onto chromatin may be a generally conserved feature of DNA licensing in eukaryotes .	parallel	0
13523	10766399	551;359	AVP;AQP-2	Urinary excretion of ***AQP-2*** was significantly ***increased*** by the single injection of ***AVP*** in patients with central diabetes insipidus .	positive	0
13524	10766449	6863;2641	neurokinin A;glucagon	substance P and ***neurokinin A*** infusion ***increased*** release of insulin , ***glucagon*** , and exocrine secretion , whereas somatostatin secretion was unaffected .	positive	0
13525	10766452	3375;6750	IAPP;somatostatin	***IAPP*** ( 10 microM ) ***enhanced*** the inhibitory effect of ***somatostatin*** on insulin secretion induced by L-arginine or forskolin .	positive	0
13526	10766741	8517;4790	NEMO;NF-kappaB	A novel , noncatalytic component of this kinase complex called ***NEMO*** ( ***NF-kappaB*** essential ***modulator*** ) / IKKgamma was identified recently .	target	0
13527	10766744	3488;3481	IGFBP-3 and -5;IGF-I and -II	Insulin-like growth factor-binding protein-3 and -5 ( ***IGFBP-3 and -5*** ) have been shown to ***bind*** insulin-like growth factor-I and - II ( ***IGF-I and -II*** ) with high affinity .	parallel	1
13528	10766744	3486;3481	Insulin-like growth factor-binding protein-3;IGF-I and -II	***Insulin-like growth factor-binding protein-3*** and -5 ( IGFBP-3 and -5 ) have been shown to ***bind*** insulin-like growth factor-I and - II ( ***IGF-I and -II*** ) with high affinity .	parallel	1
13529	10766756	983;596	CDC2;Bcl-2	***CDC2-mediated*** ***phosphorylation*** of ***Bcl-2*** may play some physiological roles in the negative regulatory events during mitosis .	target	1
13530	10766756	983;596	CDC2;Bcl-2	***Phosphorylation*** of ***Bcl-2*** protein by ***CDC2*** kinase during G2/M phases and its role in cell cycle regulation .	target	1
13531	10766757	3206;5087	HoxA10;Pbx1	A consensus sequence for ******Pbx1-HoxA10****** DNA ***binding*** has been derived , but genuine target genes have not been identified .	parallel	1
13532	10766765	7903;51046	ST8Sia IV;ST8Sia III	Polysialylation of NCAM was shown to be achieved by two alpha2,8-polysialyltransferases , ***ST8Sia IV*** ( PST ) and ST8Sia II ( STX ) , which are moderately ***related*** to another alpha2,8-sialyltransferase , ***ST8Sia III*** .	parallel	0
13533	10766818	7181;5914	TR2;RAR	The ***activation*** of ***RAR*** ( beta2 ) by ***TR2*** is mediated by the direct repeat-5 ( DR5 ) element located in the RAR ( beta2 ) promoter .	positive	1
13534	10766818	7181;5914	TR2;RAR	Furthermore , cAMP exerts an enhancing effect on the ***activation*** of ***RAR*** ( beta2 ) by ***TR2*** , which is mediated by the cAMP response element located in the 5 ' - flanking region of the DR5 .	positive	1
13535	10766822	857;8802	caveolin-1;Galpha	Furthermore , both anti-Trp1 and ***anti-caveolin-1*** antibodies ***co-immunoprecipitated*** hTrp1 , caveolin-1 , ***Galpha*** ( q/11 ) , and IP ( 3 ) receptor-type 3 ( IP ( 3 ) R3 ) .	parallel	1
13536	10766822	857;7220	caveolin-1;hTrp1	Furthermore , both anti-Trp1 and ***anti-caveolin-1*** antibodies ***co-immunoprecipitated*** ***hTrp1*** , caveolin-1 , Galpha ( q/11 ) , and IP ( 3 ) receptor-type 3 ( IP ( 3 ) R3 ) .	parallel	1
13537	10766822	7220;857	Trp1;caveolin-1	Furthermore , both ***anti-Trp1*** and anti-caveolin-1 antibodies ***co-immunoprecipitated*** hTrp1 , ***caveolin-1*** , Galpha ( q/11 ) , and IP ( 3 ) receptor-type 3 ( IP ( 3 ) R3 ) .	parallel	1
13538	10766822	7220;8802	Trp1;Galpha	Furthermore , both ***anti-Trp1*** and anti-caveolin-1 antibodies ***co-immunoprecipitated*** hTrp1 , caveolin-1 , ***Galpha*** ( q/11 ) , and IP ( 3 ) receptor-type 3 ( IP ( 3 ) R3 ) .	parallel	1
13539	10766831	8029;4036	cubilin;Megalin	Since ***cubilin*** has been reported to ***bind*** the endocytic receptor ***Megalin*** , we explored the possibility that Megalin acts in conjunction with cubilin to mediate HDL endocytosis .	parallel	1
13540	10766836	207;998	Rac;cdc42	In addition , these phenotypic changes were accompanied by a blockade of disassembly of focal adhesion points , stabilization of stress fibers , and enhanced cell spreading and were dependent on the presence of the kinase dead domain but independent of the presence of the Rac/cdc42 intact ( ******cdc42/Rac****** interactive ***binding*** ) domain of PAK1 .	parallel	1
13541	10766840	2932;595	GSK-3beta;cyclin D1	Our results demonstrate that free ***cyclin D1*** is ***ubiquitinated*** independently of its phosphorylation on threonine 286 by ***GSK-3beta*** , suggesting that , as has been shown for cyclin E , distinct pathways of ubiquitination lead to the degradation of free and CDK-bound cyclin D1 .	target	1
13542	10766841	7077;4323	TIMP-2;MT1-MMP	We show that ***TIMP-2*** ***regulates*** the amount of active ***MT1-MMP*** ( 57 kDa ) on the cell surface whereas in the absence of TIMP-2 MT1-MMP undergoes autocatalysis to a 44-kDa form , which displays a N terminus starting at Gly ( 285 ) and hence lacks the entire catalytic domain .	target	1
13543	10766841	4323;7077	MT1-MMP;TIMP-2	In contrast , active ***MT1-MMP*** ( N terminus Tyr ( 112 ) ) formed a ***complex*** with ***TIMP-2*** suggesting that regulation of MT1-MMP processing is mediated by a complex of TIMP-2 with the active enzyme .	parallel	1
13544	10766841	7077;4323	TIMP-2;MT1-MMP	Thus , under controlled conditions , ***TIMP-2*** may act as a positive ***regulator*** of ***MT1-MMP*** activity by promoting the availability of active MT1-MMP on the cell surface and consequently , may support pericellular proteolysis .	positive	1
13545	10766844	7189;4790	TRAF6;NFkappaB	By itself , DTRAF1 did not induce significant NFkappaB activation when overexpressed in mammalian cells , although it specifically increased ***NFkappaB*** ***induction*** by ***TRAF6*** .	target	1
13546	10766844	7186;4790	TRAF2;NFkappaB	Mutants of DTRAF1 lacking the N-terminal region inhibited ***NFkappaB*** ***induction*** by either ***TRAF2*** or TRAF6 .	target	1
13547	10766844	7189;4790	TRAF6;NFkappaB	Mutants of DTRAF1 lacking the N-terminal region inhibited ***NFkappaB*** ***induction*** by either TRAF2 or ***TRAF6*** .	target	1
13548	10766848	5350;488	phospholamban;SERCA2	To determine the levels of ***phospholamban*** which are ***associated*** with maximal inhibition of ***SERCA2*** , several lines of transgenic mice were generated which expressed increasing levels of a non-phosphorylatable form of phospholamban ( S16A , T17A ) specifically in the heart .	parallel	0
13549	10766859	183;1956	angiotensin II;epidermal growth factor receptor	The ***transactivation*** of the ***epidermal growth factor receptor*** by ***angiotensin II*** , a process required for the activation of ERK , was inhibited by N-acetylcysteine but not by nitric oxide .	positive	1
13550	10766859	183;1956	angiotensin II;epidermal growth factor receptor	The ***transactivation*** of the ***epidermal growth factor receptor*** by ***angiotensin II*** was shown to be independent of intracellular calcium increases .	positive	1
13551	10766865	5329;5328	uPAR;uPA	Overexpression of urokinase plasminogen activator ( ***uPA*** ) and its ***receptor*** ( ***uPAR*** ) has been well documented in a wide variety of tumor cells .	parallel	1
13552	10766865	1432;5328	p38;uPA	Treatment of highly invasive BT549 cells with a specific p38 MAPK inhibitor SB203580 diminished both uPA/uPAR mRNA and protein expression and abrogated the ability of these cells to invade matrigel , suggesting that ***p38*** MAPK signaling pathway is involved in the ***regulation*** of ***uPA/uPAR*** expression and breast cancer cell invasion .	target	1
13553	10766865	1432;5329	p38;uPAR	Treatment of highly invasive BT549 cells with a specific p38 MAPK inhibitor SB203580 diminished both uPA/uPAR mRNA and protein expression and abrogated the ability of these cells to invade matrigel , suggesting that ***p38*** MAPK signaling pathway is involved in the ***regulation*** of ***uPA/uPAR*** expression and breast cancer cell invasion .	target	1
13554	10766866	1050;265	C/EBPalpha;amelogenin	Transient transfection experiments showed that ***C/EBPalpha*** ***transactivated*** the mouse ***amelogenin*** reporter gene in Pa-4 cells , but not in Madin-Darby canine kidney cells .	positive	1
13555	10766866	1050;265	C/EBPalpha;amelogenin	Taken together , these data indicate that ***C/EBPalpha*** is a bona fide transcriptional ***activator*** of the mouse ***amelogenin*** gene in a cell type-specific manner .	positive	1
13556	10767105	5502;5327	inhibitor-1;t-PA	In this study we examined the effects of the T-cell lymphokine Interleukin-4 ( IL-4 ) on PDGF induction of human aortic SMC antigen levels of urokinase-type plasminogen activator ( u-PA ) and those of plasminogen activator ***inhibitor-1*** ( PAI-1 ) , the endogenous ***inhibitor*** of ***t-PA*** and u-PA , measured by enzyme-linked immunosorbent assays ( ELISAs ) .	negative	1
13557	10767123	1636;5054	ACE;PAI-1	In this study we investigated the ***association*** of the ***ACE*** gene polymorphism and plasma ***PAI-1*** levels in subjects with cerebral infarction .	parallel	0
13558	10767334	6606;11218	Smn;dp103	Direct ***interaction*** of ***Smn*** with ***dp103*** , a putative RNA helicase : a role for Smn in transcription regulation ?	parallel	1
13559	10767334	11218;6606	dp103;Smn	We suggest that the ***interaction*** between ***Smn*** and ***dp103*** is further evidence for a role for Smn in transcriptional regulation and that Smn may be involved in the regulation of neuron-specific genes essential in neuronal development .	parallel	1
13560	10767398	6318;1511	SCCA2;catG	Despite a high degree of similarity in their amino acid sequences , SCCA1 and SCCA2 have distinct biochemical properties : SCCA1 is an inhibitor of papain like cysteine proteinases , such as cathepsins ( cat ) L , S and K , whereas ***SCCA2*** ***inhibits*** chymotrypsin-like serine proteinases , ***catG*** and mast cell chymase .	negative	1
13561	10767398	6318;1215	SCCA2;chymase	Despite a high degree of similarity in their amino acid sequences , SCCA1 and SCCA2 have distinct biochemical properties : SCCA1 is an inhibitor of papain like cysteine proteinases , such as cathepsins ( cat ) L , S and K , whereas ***SCCA2*** ***inhibits*** chymotrypsin-like serine proteinases , catG and mast cell ***chymase*** .	negative	1
13562	10767413	133;10266	ADM;RAMP2	In conclusion , [ ( 125 ) I ] CGRP/rCRLR/RAMP1 and [ ( 125 ) I ] ******ADM/rCRLR/RAMP2****** ***complexes*** have been recognized in Drosophila S2 cells .	parallel	1
13563	10767416	3700;920	gp120;CD4	At the concentration of 100 nM , all RIPs appeared to enhance the ******CD4/gp120****** ***interaction*** by about 50 % .	parallel	1
13564	10767422	310;6717	annexin VII;sorcin	The ******sorcin-annexin VII****** calcium-dependent ***interaction*** requires the sorcin N-terminal domain .	parallel	1
13565	10767422	310;6717	annexin VII;sorcin	The ***sorcin-annexin VII*** calcium-dependent interaction ***requires*** the ***sorcin*** N-terminal domain .	target	0
13566	10767475	7040;1277	TGF-beta;alpha1(I) procollagen	CONCLUSIONS : Based on these findings , and on the fact that H ( 2 ) O ( 2 ) is produced during ***TGF-beta-induced*** ***upregulation*** of the ***alpha1(I) procollagen*** gene , we conclude that H ( 2 ) O ( 2 ) is one of the mediators of healing responses .	positive	1
13567	10767941	3952;5443	Leptin;proopiomelanocortin	***Leptin*** ***regulation*** of ***proopiomelanocortin*** .	target	1
13568	10767994	4363;1244	Mrp1;Mrp2	Expression of ***Mrp1*** was ***related*** to ***Mrp2*** ( p < 0.0001 ) and P-gp ( p < 0.001 ) expression , while Lrp expression was more frequently observed in patients with stage I/II versus stage III/IV tumors ( p < 0.01 ) , grade I/II versus III tumors ( p < 0.05 ) and residual tumor < 2 cm versus > 2 cm after laparotomy ( p < 0.05 ) .	parallel	0
13569	10767994	4363;5243	Mrp1;P-gp	Expression of ***Mrp1*** was ***related*** to Mrp2 ( p < 0.0001 ) and ***P-gp*** ( p < 0.001 ) expression , while Lrp expression was more frequently observed in patients with stage I/II versus stage III/IV tumors ( p < 0.01 ) , grade I/II versus III tumors ( p < 0.05 ) and residual tumor < 2 cm versus > 2 cm after laparotomy ( p < 0.05 ) .	parallel	0
13570	10768826	4878;5443	ANP;ACTH	Moreover , panic anxiety and concomitant ***ACTH*** and cortisol secretion elicited by stimulation with the panicogen cholecystokinin-tetrapeptide were also ***attenuated*** by ***ANP*** infusions in patients as well as in healthy volunteers .	negative	0
13571	10768840	944;943	CD30L;CD30	CD30 and its counter-receptor ***CD30*** ***ligand*** ( ***CD30L*** ) are members of the TNF-receptor/TNFalpha superfamily and function to regulate lymphocyte survival and differentiation .	parallel	1
13572	10768840	943;944	CD30;CD30L	***CD30L*** ***binding*** by ***CD30*** is blocked by MAb that recognize epitopes belonging to cluster Group A ( like Ber-H2 , Ber-H8 , and HRS-4 ) as well as cluster Group C ( like HeFi-1 and M44 ) .	parallel	1
13573	10768840	944;943	CD30L;CD30	Cluster Group B antibodies , including M67 and Ki-1 , do not affect ***CD30L*** ***binding*** to ***CD30*** .	parallel	1
13574	10768840	944;943	CD30L;CD30	Finally , we demonstrate that the anti-CD30L MAb M81 also completely inhibits ******CD30/CD30L****** ***interaction*** .	parallel	1
13575	10768865	2064;2065	HER-2;erbB-3	Heterodimer ***interactions*** between ***HER-2*** and HER-3 ( ***erbB-3*** ) are activated by neu differentiation factor/heregulin ( HRG ) , and HER-2/HER -3 heterodimers are constitutively activated in breast cancer cells with HER-2 gene amplification .	parallel	1
13576	10768865	3084;2064	HRG;HER-2	Dominant negative HER-3 inhibited the ***HRG-induced*** ***activation*** of ***HER-2/HER*** -3 and signaling in H16N-2 and 21 MT-1 cells as well as the constitutive activation of HER-2/HER -3 and signaling in 21 MT-1 cells .	positive	1
13577	10768872	4583;4582	MUC2;MUC1	However , there have been few reports about the ***associations*** between ***MUC1*** , ***MUC2*** and p53 expression and metastatic potential .	parallel	0
13578	10768872	4583;7157	MUC2;p53	However , there have been few reports about the ***associations*** between MUC1 , ***MUC2*** and ***p53*** expression and metastatic potential .	parallel	0
13579	10768872	7157;4582	p53;MUC1	However , there have been few reports about the ***associations*** between ***MUC1*** , MUC2 and ***p53*** expression and metastatic potential .	parallel	0
13580	10768925	3725;2353	AP-1;c-fos	Since TGF-beta1 pretreatment inhibited LPS-stimulated expression of c-fos and c-jun genes and also the binding of nuclear proteins to the consensus sequence of the binding site for activation protein 1 ( ***AP-1*** ) , a ***heterodimer*** of ***c-fos*** and c-jun , in the cells , TGF-beta1 inhibition of CD14 expression may be a consequence of downregulation of AP-1 .	parallel	1
13581	10768925	7040;2353	TGF-beta1;c-fos	Since ***TGF-beta1*** pretreatment ***inhibited*** LPS-stimulated expression of ***c-fos*** and c-jun genes and also the binding of nuclear proteins to the consensus sequence of the binding site for activation protein 1 ( AP-1 ) , a heterodimer of c-fos and c-jun , in the cells , TGF-beta1 inhibition of CD14 expression may be a consequence of downregulation of AP-1 .	negative	1
13582	10768925	7040;3725	TGF-beta1;c-jun	Since ***TGF-beta1*** pretreatment ***inhibited*** LPS-stimulated expression of c-fos and ***c-jun*** genes and also the binding of nuclear proteins to the consensus sequence of the binding site for activation protein 1 ( AP-1 ) , a heterodimer of c-fos and c-jun , in the cells , TGF-beta1 inhibition of CD14 expression may be a consequence of downregulation of AP-1 .	negative	1
13583	10768980	958;959	CD40;CD40L	Together , these results demonstrate that the CD28-B7 and ******CD40-CD40L****** ***interactions*** are involved in the development of infection-induced immunopathology in the absence of IL-10 .	parallel	1
13584	10768980	959;958	CD40L;CD40	Since costimulation is critical for T-cell activation , we investigated the role of the CD28-B7 and ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) interactions in this infection-induced immunopathology .	parallel	1
13585	10768980	958;959	CD40;CD40L	In vivo blockade of the CD28-B7 or ******CD40-CD40L****** ***interactions*** following infection of IL-10KO mice with T. gondii did not affect serum levels of IFN-gamma or IL-12 , nor did it prevent death in these mice .	parallel	1
13586	10768980	958;959	CD40;CD40L	Analysis of parasite-specific recall responses from infected IL-10KO mice revealed that blockade of the ******CD40-CD40L****** ***interaction*** had minimal effects on cytokine production , whereas blockade of the CD28-B7 interaction resulted in decreased production of IFN-gamma but not IL-12 .	parallel	1
13587	10768988	7124;1673	tumor necrosis factor alpha;hBD-2	***hBD-2*** mRNA was also ***induced*** by the proinflammatory cytokine ***tumor necrosis factor alpha*** ( TNF-alpha ) and phorbol myristate acetate ( PMA ) , an epithelial cell activator .	target	1
13588	10768988	7124;1673	TNF-alpha;hBD-2	Kinetic analysis indicates involvement of multiple distinct signaling pathways in the regulation of hBD-2 mRNA ; ***TNF-alpha*** and F. nucleatum cell wall ***induced*** ***hBD-2*** mRNA rapidly ( 2 to 4 h ) , while PMA stimulation was slower ( approximately 10 h ) .	target	1
13589	10769003	959;3458	CD40 ligand;IFN-gamma	Expression of ***CD40 ligand*** ( CD40L ) ***correlated*** directly with Mycobacterium tuberculosis-stimulated gamma interferon ( ***IFN-gamma*** ) production by peripheral blood mononuclear cells ( PBMC ) from tuberculosis patients and healthy tuberculin reactors .	parallel	0
13590	10769003	958;3458	CD40;IFN-gamma	The CD40L agonist increased M. tuberculosis-induced IFN-gamma production by PBMC , and ***anti-CD40*** or anti-CD40L antibodies ***reduced*** ***IFN-gamma*** production .	negative	1
13591	10769003	959;3458	CD40L;IFN-gamma	The CD40L agonist increased M. tuberculosis-induced IFN-gamma production by PBMC , and anti-CD40 or ***anti-CD40L*** antibodies ***reduced*** ***IFN-gamma*** production .	negative	1
13592	10769018	1387;1499	CBP;beta-catenin	The transcriptional coactivator ***CBP*** ***interacts*** with ***beta-catenin*** to activate gene expression .	parallel	1
13593	10769018	1499;1387	beta-catenin;CBP	Armadillo ( Arm ) repeat 10 to the COOH terminus of beta-catenin is involved in binding to CBP , whereas ***beta-catenin*** ***interacts*** directly with the CREB-binding domain of ***CBP*** .	parallel	1
13594	10769018	1499;1387	beta-catenin;CBP	***beta-catenin*** ***synergizes*** with ***CBP*** to stimulate the activity of a synthetic reporter in vivo .	parallel	0
13595	10769018	1387;1499	CBP;beta-catenin	These findings suggest that ***CBP*** provides a link between beta-catenin and the transcriptional machinery , and possibly ***mediates*** the oncogenic function of ***beta-catenin*** .	target	0
13596	10769033	9821;2185	FIP200;Pyk2	Together , these results suggest that ***FIP200*** functions as an ***inhibitor*** of ***Pyk2*** via binding to its kinase domain .	negative	1
13597	10769033	9821;2185	FIP200;Pyk2	***Suppression*** of ***Pyk2*** kinase and cellular activities by ***FIP200*** .	negative	1
13598	10769033	9821;5747	FIP200;FAK	In vitro binding assays and coimmunoprecipitation confirmed association of FIP200 with Pyk2 , and similar assays also showed ***FIP200*** ***binding*** to ***FAK*** .	parallel	1
13599	10769033	9821;2185	FIP200;Pyk2	In vitro binding assays and coimmunoprecipitation confirmed ***association*** of ***FIP200*** with ***Pyk2*** , and similar assays also showed FIP200 binding to FAK .	parallel	0
13600	10769033	9821;2185	FIP200;Pyk2	***FIP200*** also ***inhibited*** the kinase activity of the ***Pyk2*** isolated from SYF cells ( deficient in Src , Yes , and Fyn expression ) and the Pyk2 mutant lacking binding site for Src , suggesting that it regulated Pyk2 kinase directly rather than affecting the associated Src family kinases .	negative	1
13601	10769033	9821;2185	FIP200;Pyk2	Consistent with its inhibitory effect in vitro , ***FIP200*** ***inhibited*** activation of ***Pyk2*** and Pyk2-induced apoptosis in intact cells , which correlated with its binding to Pyk2 .	negative	1
13602	10769033	9821;2185	FIP200;Pyk2	Finally , activation of Pyk2 by several biological stimuli correlated with the dissociation of endogenous FIP200-Pyk2 complex , which provided further support for ***inhibition*** of ***Pyk2*** by ***FIP200*** in intact cells .	negative	1
13603	10769033	2185;9821	Pyk2;FIP200	Finally , activation of Pyk2 by several biological stimuli correlated with the dissociation of endogenous ******FIP200-Pyk2****** ***complex*** , which provided further support for inhibition of Pyk2 by FIP200 in intact cells .	parallel	1
13604	10769035	578;598	Bak;Bcl-X	We conclude that ras-induced resistance to anoikis in intestinal epithelial cells is mediated by at least two distinct mechanisms : one that triggers downregulation of ***Bak*** and another that ***stabilizes*** ***Bcl-X*** ( L ) expression in the absence of the ECM .	negative	0
13605	10769064	4790;3458	NF-kappaB;IFN-gamma	The ectromelia virus protein was found to block ***NF-kappaB*** ***activation*** and induction of ***IFN-gamma*** in response to IL-18 .	positive	1
13606	10769147	4547;338	MTP;ApoB	Experiments were then performed to study the effect of inhibition of ******ApoB-MTP****** ***binding*** on ApoB secretion in HepG2 cells .	parallel	1
13607	10769147	4547;338	MTP;ApoB	These studies indicate that AGI-S17 decreases ApoB secretion most likely by inhibiting ******ApoB-MTP****** ***interactions*** .	parallel	1
13608	10769147	4547;338	MTP;ApoB	Thus , the ***binding*** of ***MTP*** to ***ApoB*** may be important for the assembly and secretion of ApoB-containing lipoproteins and can be a potential target for the development of lipid-lowering drugs .	parallel	1
13609	10769147	4547;338	MTP;ApoB	Decreased secretion of ApoB follows inhibition of ******ApoB-MTP****** ***binding*** by a novel antagonist .	parallel	1
13610	10769147	4547;338	MTP;ApoB	To study the importance of ******ApoB-MTP****** ***binding*** in ApoB secretion , we have identified a compound , AGI-S17 , that inhibited ( 60-70 % at 40 microM ) the binding of various ApoB peptides to MTP but not to an anti-ApoB monoclonal antibody , 1D1 , whose epitope overlaps with an MTP binding site in ApoB .	parallel	1
13611	10769147	338;4547	ApoB;MTP	To study the importance of ApoB-MTP binding in ApoB secretion , we have identified a compound , AGI-S17 , that inhibited ( 60-70 % at 40 microM ) the ***binding*** of various ***ApoB*** peptides to ***MTP*** but not to an anti-ApoB monoclonal antibody , 1D1 , whose epitope overlaps with an MTP binding site in ApoB .	parallel	1
13612	10769147	4547;338	MTP;ApoB	In contrast , another antagonist , BMS-200150 , did not affect ******ApoB-MTP****** ***binding*** but inhibited MTP 's lipid transfer activity .	parallel	1
13613	10769147	4547;338	MTP;ApoB	These studies indicate that AGI-S17 inhibits ******ApoB-MTP****** ***binding*** but has no effect on MTP 's lipid transfer activity .	parallel	1
13614	10769163	8829;1601	transmembrane receptor;Dab2	Dab2 is the first intracellular ligand identified for gp600/megalin ; gp600/megalin is the first known ***transmembrane receptor*** that ***interacts*** with the cytosolic protein ***Dab2*** .	parallel	1
13615	10769164	7433;7432	VPAC1;vasoactive intestinal peptide	The human ***vasoactive intestinal peptide/pituitary*** adenylate cyclase-activating peptide ***receptor*** 1 ( ***VPAC1*** ) promoter : characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl .20 .	parallel	1
13616	10769191	151987;5531	PPP4R2;PPP4c	The ***interaction*** of ***PPP4R2*** with PPP4 catalytic subunit ( ***PPP4c*** ) was confirmed by co-sedimentation of PPP4c with PPP4R2 expressed in bacteria and human cells .	parallel	1
13617	10769191	151987;5531	PPP4R2;PPP4c	Native 450 kDa and 600 kDa PPP4 complexes are inactive , but can be activated by basic proteins , suggesting that ***PPP4R2*** may also ***regulate*** the activity of ***PPP4c*** at centrosomal microtubule organising centres .	target	1
13618	10769198	5592;10335	cGKI;IRAG	Phosphorylation of PP1M by cGKI ( alpha ) activates myosin phosphatase , whereas ***phosphorylation*** of ***IRAG*** by ***cGKI*** ( beta ) decreases Ins ( 1,4 , 5 ) P ( 3 ) - induced calcium release .	target	1
13619	10769211	1499;1825	beta-catenin;Dsc	In addition , ***beta-catenin*** was found to ***bind*** the endogenous ***Dsc*** in HaCaT cells .	parallel	1
13620	10769228	161882;2623	Friend of GATA-1;GATA-1	***Friend of GATA-1*** ( FOG-1 ) ***interacts*** with ***GATA-1*** and is expressed principally in hematopoietic lineages , whereas FOG-2 is expressed predominantly in heart and brain .	parallel	1
13621	10769232	6469;2735	Shh;Gli	***Shh*** and Wnt signaling pathways converge to ***control*** ***Gli*** gene activation in avian somites .	target	0
13622	10769236	4254;3815	SCF;c-kit	Regulation of proliferation and differentiation in spermatogonial stem cells : the role of ***c-kit*** and its ***ligand*** ***SCF*** .	parallel	1
13623	10769278	1401;2152	C-reactive protein;tissue factor	Interferon-gamma and lipopolysaccharide potentiate monocyte ***tissue factor*** ***induction*** by ***C-reactive protein*** : relationship with age , sex , and hormone replacement treatment .	target	1
13624	10769278	3458;2152	Interferon-gamma;tissue factor	***Interferon-gamma*** and lipopolysaccharide ***potentiate*** monocyte ***tissue factor*** induction by C-reactive protein : relationship with age , sex , and hormone replacement treatment .	positive	0
13625	10769644	4803;4914	nerve growth factor;TrkA	BACKGROUND : ***Binding*** of ***nerve growth factor*** ( NGF ) to its receptor ***TrkA*** leads to intracellular tyrosine kinase activation and regulates the growth and differentiation of various non-neuronal tumours .	parallel	1
13626	10769656	7012;7013	hTR;TRF	Quantitatively , the steady-state levels of ***hTR*** ***correlated*** with the ***TRF*** ( p < 0.05 ) .	parallel	0
13627	10769677	1029;595	p16;cyclin D1	Although ***p16*** and p21 expression significantly ***correlated*** with lymph node metastasis and ***cyclin D1*** overexpression , respectively , they were not related to Ki-67 LI .	parallel	0
13628	10769677	1026;595	p21;cyclin D1	Although p16 and ***p21*** expression significantly ***correlated*** with lymph node metastasis and ***cyclin D1*** overexpression , respectively , they were not related to Ki-67 LI .	parallel	0
13629	10770208	3479;3488	IGF-I;IGFBP-3 and -5	***IGF-I*** ***increased*** the abundance of both intact ***IGFBP-3 and -5*** in the culture medium .	positive	0
13630	10770208	3479;3487	IGF-I;IGFBP-4	Intact ***IGFBP-4*** was ***decreased*** by ***IGF-I*** , and the combination resulted in a similar reduction .	negative	0
13631	10770292	3553;6376	IL-1beta;fractalkine	***fractalkine*** was ***induced*** in rat aortic endothelial cells ( RAEC ) by interleukin-1beta ( ***IL-1beta*** ) , tumor necrosis factor alpha ( TNF-alpha ) , and lipopolysaccharide ( LPS ) transcriptionally and translationally .	target	1
13632	10770292	7124;6376	tumor necrosis factor alpha;fractalkine	***fractalkine*** was ***induced*** in rat aortic endothelial cells ( RAEC ) by interleukin-1beta ( IL-1beta ) , ***tumor necrosis factor alpha*** ( TNF-alpha ) , and lipopolysaccharide ( LPS ) transcriptionally and translationally .	target	1
13633	10770487	10951;2355	MOD-1;fra-2	TGF-beta1 reduces the interaction of a NF-kappaB ***p50/fra-2*** ***heterodimer*** ( ***MOD-1*** ) with Enhancer A while increasing its interaction with a NF-kappaB p50/p65 heterodimer .	parallel	1
13634	10770487	10951;4790	MOD-1;p50	TGF-beta1 reduces the interaction of a NF-kappaB ***p50/fra-2*** ***heterodimer*** ( ***MOD-1*** ) with Enhancer A while increasing its interaction with a NF-kappaB p50/p65 heterodimer .	parallel	1
13635	10770487	4790;5970	p50;p65	TGF-beta1 reduces the interaction of a NF-kappaB p50/fra-2 heterodimer ( MOD-1 ) with Enhancer A while increasing its interaction with a NF-kappaB ******p50/p65****** ***heterodimer*** .	parallel	1
13636	10770487	4790;2355	p50;fra-2	TGF-beta1 reduces the interaction of a NF-kappaB ******p50/fra-2****** ***heterodimer*** ( MOD-1 ) with Enhancer A while increasing its interaction with a NF-kappaB p50/p65 heterodimer .	parallel	1
13637	10770487	7040;3725	TGF-beta1;c-jun	Finally , we show that ***TGF-beta1*** ***increases*** ***c-jun*** RNA levels and induces the formation of new complexes involving c-jun , fra-2 , ATF-1 , and c-fos , which react with Enhancer A and the DRE .	positive	0
13638	10770492	8651;5617	SOCS-1;PRL	In summary , results of this study reveal that constitutive expression of ***SOCS-1*** can ***prevent*** ***PRL*** signaling and that the lack of PRL-induced expression of alpha2-macroglobulin in a defined decidual cell population is largely due to SOCS-1 expression in these cells .	negative	0
13639	10770527	1471;1508	cystatin C;cysteine protease	INTRODUCTION : ***cystatin C*** , a ***cysteine protease*** ***inhibitor*** , has been implicated in the neurodegenerative and repair processes of the nervous system , and the deposition of the same protein together with beta amyloid peptide was found as cerebral amyloid angiopathy ( CAA ) in different types of dementias .	negative	1
13640	10770536	356;355	CD95L;CD95	OBJECTIVE : To analyze the role of ***CD95/CD95*** ***ligand*** ( ***CD95L*** ) expression and functionality in peripheral blood lymphocytes ( PBL ) during primary , acute HIV syndrome ( AHS ) and in the subsequent period .	parallel	1
13641	10770798	10563;1234	B cell-attracting chemokine 1;chemokine receptor (CXCR)5	***B cell-attracting chemokine 1*** ( BCA-1 ) responses ***correlate*** with CXC ***chemokine receptor (CXCR)5*** expression , are first displayed by a pro-B cell subset , are lost in pre-B cells , and then are regained just before and after egress from the marrow .	parallel	0
13642	10770843	375790;4593	agrin;MuSK	Although the binding of agrin to basal lamina is tight , the ***binding*** of ***agrin*** to ***MuSK*** has yet to be shown ; therefore , basal lamina binding is critical for maintaining the presentation of agrin to MuSK .	parallel	1
13643	10770922	4286;6909	Mitf;Tbx2	Here we provide several lines of evidence to suggest that ***Mitf*** may ***regulate*** the expression of the ***Tbx2*** transcription factor , a member of the T-box family of proteins implicated in the maintenance of cell identity .	target	1
13644	10770922	4286;6909	Mitf;Tbx2	First , isolation and sequencing of the entire murine Tbx2 gene revealed that the Tbx2 promoter contains a full consensus Mitf recognition element ; second , ***Mitf*** could bind the promoter in vitro and ***activate*** ***Tbx2*** expression in vivo in an E box-dependent fashion ; and third , Tbx2 is expressed in melanoma cell lines expressing Mitf , but not in a line in which Mitf expression was not detectable .	positive	1
13645	10770926	4174;4173	Mcm3/5;Mcm4	Consistent with these results , the ***interaction*** of either Mcm2 or ***Mcm3/5*** with the ***Mcm4/6/7*** complex resulted in the disassembly of the dimeric complex of Mcm4/6/7 and the loss of DNA helicase activity .	parallel	1
13646	10770928	1571;5743	CYP2E1;COX-2	Incubation with NS-398 , a COX-2 inhibitor , blocked the effect of AA , but not of ethanol , on COL1A2 expression suggesting that ***CYP2E1*** ***activates*** ***COX-2*** expression , and the oxidation of AA by COX-2 is responsible for the increase in COL1A2 .	positive	1
13647	10770932	2247;995	bFGF;Cdc25C	We show that ***bFGF*** treatment inhibits Tyr-15 dephosphorylation of cdc2 and ***prevents*** activation of ***Cdc25C*** , similar to what is seen upon activation of the G ( 2 ) DNA damage checkpoint .	negative	0
13648	10770937	4605;1191	B-MYB;Clusterin	Direct ***transactivation*** of the anti-apoptotic gene apolipoprotein J ( ***Clusterin*** ) by ***B-MYB*** .	positive	1
13649	10770937	4605;1191	B-MYB;Clusterin	Here we show that the human ApoJ/Clusterin gene contains a Myb binding site in its 5 ' flanking region , which interacts with bacterially synthesized B-MYB protein and mediates ***B-MYB-dependent*** ***transactivation*** of the ***ApoJ/Clusterin*** promoter in transient transfection assays .	positive	1
13650	10770937	4605;1191	B-MYB;Clusterin	Thus , ***activation*** of ***ApoJ/Clusterin*** by ***B-MYB*** may be an important step in the regulation of apoptosis in normal and diseased cells .	positive	1
13651	10770943	6382;6386	syndecan;Syntenin	******Syntenin-syndecan****** ***binding*** requires syndecan-synteny and the co-operation of both PDZ domains of Syntenin .	parallel	1
13652	10770943	6386;6382	Syntenin;syndecan	***Syntenin-syndecan*** binding ***requires*** ***syndecan-synteny*** and the co-operation of both PDZ domains of Syntenin .	target	0
13653	10770943	6382;6386	syndecan;Syntenin	******Syntenin-syndecan****** ***binding*** involves the C-terminal part of Syntenin that contains a tandem of PDZ domains .	parallel	1
13654	10770943	6382;6386	syndecan;Syntenin	Isolated or combined mutations of the carboxylate binding lysines in the inter-betaAbetaB loops and of the alphaB1 residues in either one or both the PDZ domains of Syntenin all reduce ******Syntenin-syndecan****** ***binding*** in yeast two-hybrid , blot-overlay , and surface plasmon resonance assays .	parallel	1
13655	10770943	6382;6386	syndecan;Syntenin	PDZ2 mutations have more pronounced effects on binding than PDZ1 mutations , but complete abrogation of ******Syntenin-syndecan****** ***binding*** requires the combination of both the lysine and the alphaB1 mutations in both the PDZ domains of Syntenin .	parallel	1
13656	10770951	6714;5594	Src;Erk1/2	Here , the beta ( 3 ) signal is mediated classically via cAMP/protein kinase A. beta ( 3 ) and alpha ( 1 ) signals converge at ***Src*** , which thus ***mediates*** ***Erk1/2*** activation in both pathways .	target	0
13657	10770955	8743;8793	TRAIL;DcR2	In addition , ***TRAIL*** also ***binds*** to 3 " decoy " receptors , ***DcR2*** , a receptor with a truncated death domain , DcR1 , a glycosylphosphatidylinositol-anchored receptor , and OPG a secreted protein which is also known to bind to another member of the TNF family , RANKL .	parallel	1
13658	10770955	8743;4982	TRAIL;OPG	In addition , ***TRAIL*** also ***binds*** to 3 " decoy " receptors , DcR2 , a receptor with a truncated death domain , DcR1 , a glycosylphosphatidylinositol-anchored receptor , and ***OPG*** a secreted protein which is also known to bind to another member of the TNF family , RANKL .	parallel	1
13659	10770955	8743;8795	TRAIL;DR5	Preferentially enhanced ***binding*** of ***TRAIL*** to ***DR5*** was also observed at the cell surface .	parallel	1
13660	10771090	3077;7037	HFE;transferrin receptor	By co-immunoprecipitation and Western blotting , ***HFE-GFP*** protein formed a ***complex*** with endogenous ***transferrin receptor*** and beta ( 2 ) - microglobulin , suggesting that this fusion protein has the function of HFE reported previously .	parallel	1
13661	10771098	7184;1457	GRP94;protein kinase CK2	***GRP94*** has been reported to be a ***substrate*** for ***protein kinase CK2*** in vitro , although its phosphorylation in intact cells remains unreported .	parallel	1
13662	10771516	5915;3725	RARbeta1;AP1	The results demonstrate that ***RARbeta1*** , beta2 , and beta3 bind RA with a similar K ( d ) value , have a similar EC ( 50 ) value in RA-dependent transactivation assays and ***inhibit*** ***AP1*** activity to a similar level .	negative	1
13663	10771523	4313;4322	MMP-2;MMP-13	These results suggest that ***MMP-13*** is ***activated*** by ***MMP-2*** during chondrocyte maturation , and that the combination of both proteinases is required to prepare cartilage matrix for subsequent calcification , before endochondral ossification .	positive	1
13664	10771568	2247;7412	bFGF;VCAM-1	The data indicate that ***bFGF*** , but not VEGF , ***suppresses*** the production of ***VCAM-1*** by HUVEC under stimulation with TNF-alpha .	negative	1
13665	10772243	655;3037	Osteogenic protein-1;hyaluronan synthase-2	Of the two hyaluronan synthase genes expressed by chondrocytes , only ***hyaluronan synthase-2*** was ***upregulated*** by ***Osteogenic protein-1*** .	positive	1
13666	10772243	655;960	Osteogenic protein-1;CD44	CONCLUSIONS : These results demonstrate that ***Osteogenic protein-1*** ***stimulates*** not only the synthesis of the major cartilage extracellular matrix component aggrecan , but also two associated molecules necessary for the retention of aggrecan , namely hyaluronan and ***CD44*** .	positive	0
13667	10772338	1978;1977	4E-BP1;eIF4E	***Regulation*** of human ***eIF4E*** by ***4E-BP1*** : binding analysis using surface plasmon resonance .	target	1
13668	10772338	1978;1977	4E-BP1;eIF4E	The association rate of 4E-BP1 with eIF4E increased by about two orders of magnitude in the presence of m7GTP ( a model compound of mRNA cap structure ) , but the dissociation rate was scarcely affected , indicating the cap-dependent ***binding*** of ***4E-BP1*** to ***eIF4E*** .	parallel	1
13669	10772338	1978;1977	4E-BP1;eIF4E	However , phosphorylation of ***4E-BP1*** already ***associated*** with ***eIF4E*** or its m7GTP complex did not cause any change of the association , probably because of incomplete phosphorylation .	parallel	0
13670	10772387	4353;3596	myeloperoxidase;IL-13	In fact , significant correlations of blister fluid tryptase levels were observed with IL-3 , IL-4 , IL-5 , IL-6 , myeloperoxidase0 , IL-8 , VEGF , RANTES and sICAM-1 , while ***myeloperoxidase*** was ***correlated*** with IL-1beta , ***IL-13*** and IL-15 .	parallel	0
13671	10772387	4353;3600	myeloperoxidase;IL-15	In fact , significant correlations of blister fluid tryptase levels were observed with IL-3 , IL-4 , IL-5 , IL-6 , myeloperoxidase0 , IL-8 , VEGF , RANTES and sICAM-1 , while ***myeloperoxidase*** was ***correlated*** with IL-1beta , IL-13 and ***IL-15*** .	parallel	0
13672	10772387	4353;3553	myeloperoxidase;IL-1beta	In fact , significant correlations of blister fluid tryptase levels were observed with IL-3 , IL-4 , IL-5 , IL-6 , myeloperoxidase0 , IL-8 , VEGF , RANTES and sICAM-1 , while ***myeloperoxidase*** was ***correlated*** with ***IL-1beta*** , IL-13 and IL-15 .	parallel	0
13673	10772679	2064;3084	HER2;heregulin-alpha	Motility factor activities of heregulin-alpha are inhibited by monoclonal antibody AB2 , directed against the extracellular domain of ***HER2/NEU*** , which ***blocks*** the binding of ***heregulin-alpha*** .	negative	0
13674	10772681	4193;7157	MDM2;p53	BACKGROUND : The p14 ( ARF ) protein encoded by the INK4a/ARF locus promotes degradation of the MDM2 protein and thus prevents the ***MDM2-mediated*** ***inhibition*** of ***p53*** .	negative	1
13675	10772681	1029;7157	p14;p53	BACKGROUND : The ***p14*** ( ARF ) protein encoded by the INK4a/ARF locus promotes degradation of the MDM2 protein and thus ***prevents*** the MDM2-mediated inhibition of ***p53*** .	negative	0
13676	10772787	64506;891	CPEB;cyclin B1	These data indicate that ***CPEB*** is involved in both the repression and the ***stimulation*** of ***cyclin B1*** mRNA and suggest that the phosphorylation of this protein could be involved in regulating its activity .	positive	0
13677	10772826	3164;5914	Nur77;RARalpha	***Nur77*** ***bound*** ***RARalpha*** or RXRalpha in both yeast and mammalian two-hybrid tests , suggesting that direct protein-protein interaction between these receptors may mediate the inhibition .	parallel	1
13678	10772827	7040;5744	TGF-beta1;PTHrP	Both ***TGF-beta1*** and cis-retinoic acid stimulation markedly ***increased*** ***PTHrP*** mRNA levels , while BMP-2 and PTHrP stimulation decreased the expression of this transcript .	positive	0
13679	10772872	5777;3717	SHP-1;Jak2	SH2-Containing protein tyrosine phosphatase-1 ( ***SHP-1*** ) ***association*** with ***Jak2*** in UT-7 / Epo cells .	parallel	0
13680	10772872	3717;5777	Jak2;SHP-1	We have investigated the ***interaction*** of the SH2-containing protein tyrosine phosphatase-1 ( ***SHP-1*** ) and ***Jak2*** in an erythropoietin ( Epo ) - dependent human leukemia cell line , UT-7 / Epo , using reciprocal immunoprecipitation and immunoblotting .	parallel	1
13681	10772872	2057;2056	EpoR;Epo	Furthermore , immunoblotting with anti-Jak2 and anti-SHP-1 antibodies indicated that SHP-1 appeared to be constitutively associated with non-tyrosine-phosphorylated Jak2 in UT-7 / Epo cells in the absence of Epo and without phosphorylation of the ***Epo*** ***receptor*** ( ***EpoR*** ) .	parallel	1
13682	10772872	5777;3717	SHP-1;Jak2	Furthermore , immunoblotting with anti-Jak2 and anti-SHP-1 antibodies indicated that ***SHP-1*** appeared to be constitutively ***associated*** with non-tyrosine-phosphorylated ***Jak2*** in UT-7 / Epo cells in the absence of Epo and without phosphorylation of the Epo receptor ( EpoR ) .	parallel	0
13683	10772879	2120;2313	Tel;Fli-1	The ETS family member ***Tel*** ***antagonizes*** the ***Fli-1*** phenotype in hematopoietic cells .	negative	1
13684	10772879	2120;2313	Tel;Fli-1	In previous studies we demonstrated that ***Tel*** ***binds*** to ***Fli-1*** and blocks transactivation of megakaryocytic promoters by Fli-1 .	parallel	1
13685	10772879	2313;2120	Fli-1;Tel	Introduction of Tel blocked the megakaryocytic phenotype induced by Fli-1 , suggesting a biological correlation to the biochemical ***interaction*** of ***Tel*** and ***Fli-1*** reported previously .	parallel	1
13686	10772914	9436;4843	CD336;NOS2	The synthetic retinoid agonists ***CD336*** ( which specifically binds RARalpha ) and CD367 ( which binds all RARs ) but not agonists specific for RARbeta , RARgamma , or RXRs ***reduced*** IL-1beta-induced ***NOS2*** expression and NO production .	negative	1
13687	10772914	50856;4843	CD367;NOS2	The synthetic retinoid agonists CD336 ( which specifically binds RARalpha ) and ***CD367*** ( which binds all RARs ) but not agonists specific for RARbeta , RARgamma , or RXRs ***reduced*** IL-1beta-induced ***NOS2*** expression and NO production .	negative	1
13688	10772914	5914;4843	RARalpha;NOS2	These results indicate that retinoids modulate NO production in VSMC via ***RARalpha*** , which ***inhibits*** the transcription of the ***NOS2*** gene .	negative	1
13689	10772923	9223;1499	MAGI-1;beta-catenin	***MAGI-1*** ***interacts*** with ***beta-catenin*** and is associated with cell-cell adhesion structures .	parallel	1
13690	10772948	7040;5118	TGF-beta1;PCPE	Furthermore , transforming growth factor beta1 ( ***TGF-beta1*** ) , an important regulator of cellular proliferation in atheroma , ***increased*** the levels of the ***PCPE*** mRNA in cultured SMCs .	positive	0
13691	10772950	10203;10266	CRLR;RAMP2	A recent report has shown that in vitro the ******RAMP2/CRLR****** ***complex*** is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells .	parallel	1
13692	10772955	4738;8454	ubiquitin-like protein Nedd8;cullin-1	***Modification*** of ***cullin-1*** by ***ubiquitin-like protein Nedd8*** enhances the activity of SCF ( skp2 ) toward p27 ( kip1 ) .	target	0
13693	10772955	4738;8454	ubiquitin-like protein Nedd8;cullin-1	***cullin-1*** , a component of SCF , is ***modified*** by ***ubiquitin-like protein Nedd8*** .	target	0
13694	10772965	7026;595	COUP-TFII;cyclin D1	Interestingly , ***COUP-TFII*** ***increased*** the expression of ***cyclin D1*** and p21 ( WAF1/CIP1 ) in MDA-MB-435 cells .	positive	0
13695	10772965	7026;1026	COUP-TFII;p21	Interestingly , ***COUP-TFII*** ***increased*** the expression of cyclin D1 and ***p21*** ( WAF1/CIP1 ) in MDA-MB-435 cells .	positive	0
13696	10773004	1432;3576	p38 MAP kinase;IL-8	These results indicate that ***p38 MAP kinase*** ***regulates*** LPS-induced ***IL-8*** expression in pulmonary vascular endothelial cells .	target	1
13697	10773016	9568;2550	gb2;gb1	Direct evidence is lacking to show whether the gamma-aminobutyric acid ( GABA ) ( B ) ******gb1-gb2****** ***heterodimer*** is the signaling form of the receptor .	parallel	1
13698	10773016	9568;2550	gb2;gb1	Taken together with the truncated receptor studies , the data suggest that a high degree of structural specificity is required to form the functional GABA ( B ) receptor that is a ******gb1-gb2****** ***heterodimer*** .	parallel	1
13699	10773072	5423;7515	DNA polymerase beta;XRCC1	Domain specific interaction in the ******XRCC1-DNA polymerase beta****** ***complex*** .	parallel	1
13700	10773106	3553;5744	IL-1beta;PTHrP	Using a quantitative PCR-assay following reverse transcription of RNA , in situ hybridization , and a two-site immunofluorometric assay for PTHrP , we demonstrate that ***IL-1beta*** in a dose - and time-dependent manner ***increases*** PTHrP-mRNA expression and ***PTHrP-protein*** secretion .	positive	0
13701	10773106	3553;7040	IL-1beta;TGF-beta	In addition , ***IL-1beta*** ***decreased*** the ***TGF-beta*** protein concentration in conditioned medium .	negative	0
13702	10773107	8648;7421	SRC-1;VDR	The ***SRC-1*** ***binds*** the vitamin D receptor ( ***VDR*** ) in the presence of ligand in an activation function 2 ( AF-2 ) - dependent manner .	parallel	1
13703	10773213	7124;3383	TNFalpha;intercellular adhesion molecule 1	***TNFalpha*** ( 100 U/ml , 24 h ) ***upregulated*** ***intercellular adhesion molecule 1*** ( ICAM1 ) expression and fluid phase endocytosis ( FPE ) of horseradish peroxidase on brain microvascular endothelial cell ( BMEC ) culture .	positive	1
13704	10773351	3458;942	IFN-gamma;CD86	The ***induction*** of ***CD86*** expression by ***IFN-gamma*** on the surface of various antigen presenting cells has been previously reported .	target	1
13705	10773785	213;3569	albumin;HGF	RESULTS : CA19-9 / ***albumin*** levels in BALF significantly ***correlated*** with ***HGF/albumin*** , elastase/albumin , LDH/albumin , total number of alveolar macrophages , and total number of neutrophils .	parallel	0
13706	10773825	596;317	Bcl-2;Apaf-1	Previous reports have suggested at least two distinct mechanisms : ***Bcl-2*** and Bcl-xL may ***inhibit*** either the formation of the cytochrome ***c/Apaf-1/caspase-9*** apoptosome complex ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct interaction of Bcl-2 or Bcl-xL with Apaf-1 ) .	negative	1
13707	10773825	596;842	Bcl-2;caspase-9	Previous reports have suggested at least two distinct mechanisms : ***Bcl-2*** and Bcl-xL may ***inhibit*** either the formation of the cytochrome ***c/Apaf-1/caspase-9*** apoptosome complex ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct interaction of Bcl-2 or Bcl-xL with Apaf-1 ) .	negative	1
13708	10773825	598;317	Bcl-xL;Apaf-1	Previous reports have suggested at least two distinct mechanisms : Bcl-2 and ***Bcl-xL*** may ***inhibit*** either the formation of the cytochrome ***c/Apaf-1/caspase-9*** apoptosome complex ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct interaction of Bcl-2 or Bcl-xL with Apaf-1 ) .	negative	1
13709	10773825	598;842	Bcl-xL;caspase-9	Previous reports have suggested at least two distinct mechanisms : Bcl-2 and ***Bcl-xL*** may ***inhibit*** either the formation of the cytochrome ***c/Apaf-1/caspase-9*** apoptosome complex ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct interaction of Bcl-2 or Bcl-xL with Apaf-1 ) .	negative	1
13710	10773825	317;842	Apaf-1;caspase-9	Previous reports have suggested at least two distinct mechanisms : Bcl-2 and Bcl-xL may inhibit either the formation of the cytochrome ******c/Apaf-1/caspase-9****** apoptosome ***complex*** ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct interaction of Bcl-2 or Bcl-xL with Apaf-1 ) .	parallel	1
13711	10773825	596;317	Bcl-2;Apaf-1	Previous reports have suggested at least two distinct mechanisms : Bcl-2 and Bcl-xL may inhibit either the formation of the cytochrome c/Apaf-1/caspase-9 apoptosome complex ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct ***interaction*** of ***Bcl-2*** or Bcl-xL with ***Apaf-1*** ) .	parallel	1
13712	10773825	598;317	Bcl-xL;Apaf-1	Previous reports have suggested at least two distinct mechanisms : Bcl-2 and Bcl-xL may inhibit either the formation of the cytochrome c/Apaf-1/caspase-9 apoptosome complex ( by preventing cytochrome c release from mitochondria ) or the function of this apoptosome ( through a direct ***interaction*** of Bcl-2 or ***Bcl-xL*** with ***Apaf-1*** ) .	parallel	1
13713	10773875	1027;1017	p27Kip1;Cdk2	The importance of Cdk2 activity was demonstrated by ***p27Kip1*** , which ***attenuated*** ***Cdk2*** activity and inhibited cell cycle progression in C33A cells .	negative	0
13714	10773875	196;1017	AHR;Cdk2	Co-expression of ***AHR/BRG-1*** with PSM-RB ***attenuated*** Cyclin A and ***Cdk2*** expression as well as Cdk2-associated kinase activity , resulting in cell cycle inhibition of C33A cells .	negative	0
13715	10773875	6597;1017	BRG-1;Cdk2	Co-expression of ***AHR/BRG-1*** with PSM-RB ***attenuated*** Cyclin A and ***Cdk2*** expression as well as Cdk2-associated kinase activity , resulting in cell cycle inhibition of C33A cells .	negative	0
13716	10773884	1999;3851	ELF3;keratin 4	Interestingly , ***ELF3*** ***suppressed*** basal ***keratin 4*** promoter activity in both esophageal and cervical epithelial cancer cell lines , a novel result , while simultaneously activating the late-differentiation linked SPRR2A promoter .	negative	1
13717	10774955	5465;345	PPARalpha;apolipoprotein C-III	Upon fibrate activation , ***PPARalpha*** ***down-regulates*** hepatic ***apolipoprotein C-III*** and increases lipoprotein lipase gene expression , key players in triglyceride metabolism .	negative	1
13718	10774955	5465;4023	PPARalpha;lipoprotein lipase	Upon fibrate activation , ***PPARalpha*** down-regulates hepatic apolipoprotein C-III and ***increases*** ***lipoprotein lipase*** gene expression , key players in triglyceride metabolism .	positive	0
13719	10774955	5468;4023	PPARgamma;lipoprotein lipase	Glitazones exert a hypotriglyceridemic action via ***PPARgamma-mediated*** ***induction*** of ***lipoprotein lipase*** expression in adipose tissue .	target	1
13720	10775071	624;3827	B2R;bradykinin	Previous studies in rats have shown that blockade of ***bradykinin*** B2 ***receptors*** ( ***B2R*** ) in combination with a high-salt intake during gestation result in poor postnatal survival and long-term hypertension in the offspring .	parallel	1
13721	10775151	1906;5747	Endothelin-1;FAK	***Endothelin-1*** ( ET ) produces neonatal rat ventricular myocyte ( NRVM ) hypertrophy and ***activates*** focal adhesion kinase ( ***FAK*** ) in other cell types .	positive	1
13722	10775268	1977;1499	CBP;beta-catenin	The ***p300/CBP*** acetyltransferases function as transcriptional ***coactivators*** of ***beta-catenin*** in vertebrates .	positive	1
13723	10775268	2033;1499	p300;beta-catenin	The ***p300/CBP*** acetyltransferases function as transcriptional ***coactivators*** of ***beta-catenin*** in vertebrates .	positive	1
13724	10775272	440275;10985	GCN2;GCN1	***GCN2*** function in vivo also ***requires*** ***GCN1*** and GCN20 , but it was unknown whether these latter proteins act directly to promote the stimulation of GCN2 by uncharged tRNA .	target	0
13725	10775272	10985;440275	GCN1;GCN2	We found that the ***GCN1-GCN20*** complex physically ***interacts*** with ***GCN2*** , binding to the N-terminus of the protein .	parallel	1
13726	10775272	440275;10985	GCN2;GCN1	Overexpression of N-terminal GCN2 segments had a dominant-negative phenotype that correlated with their ability to interact with GCN1-GCN20 and impede ***association*** between ***GCN1*** and native ***GCN2*** .	parallel	0
13727	10775272	10985;440275	GCN1;GCN2	We conclude that ***binding*** of ***GCN1-GCN20*** to ***GCN2*** is required for its activation by uncharged tRNA .	parallel	1
13728	10775457	5578;2822	PKC-alpha;PLD	These results suggest that ***activation*** of the PtdEtn-hydrolyzing ***PLD*** enzyme by ***PKC-alpha*** is inhibited by p21 Ras .	positive	1
13729	10775461	4792;4790	IkappaBalpha;NF-kappaB	These studies demonstrate that high levels of arsenic may inhibit NF-kappaB-mediated gene transcription by specifically blocking IKK activity , thereby limiting the phosphorylation and subsequent degradation of the ***NF-kappaB*** ***inhibitor*** , ***IkappaBalpha*** .	negative	1
13730	10775502	3553;3569	IL-1 beta;IL-6	***IL-1 beta*** ***increases*** type 1 inositol trisphosphate receptor expression and ***IL-6*** secretory capacity in osteoblastic cell cultures .	positive	0
13731	10775502	3553;3569	IL-1 beta;IL-6	Acute ***IL-6*** secretion from osteosarcoma cells induced by the PI-linked hormones PTH ( 1-34 ) and endothelin-1 is ***potentiated*** by ***IL-1 beta*** .	positive	0
13732	10775566	3827;5706	bradykinin;p44	Preincubation of VSMCs with either N-acetyl-L-cysteine and/or alpha-lipoic acid significantly decreased ***bradykinin-induced*** cytosolic and nuclear ***phosphorylation*** of p42 ( mapk ) and ***p44*** ( mapk ) .	target	1
13733	10775592	3700;920	gp120;CD4	In this study , we show that CV-N blocked ***binding*** of ***gp120*** to cell-associated ***CD4*** .	parallel	1
13734	10775592	3700;1234	gp120;CCR5	Consistent with this , pretreatment of gp120 with CV-N inhibited soluble CD4 ( sCD4 ) - dependent ***binding*** of ***gp120*** to cell-associated ***CCR5*** .	parallel	1
13735	10775592	3700;920	gp120;CD4	Consistent with this , pretreatment of ***gp120*** with CV-N ***inhibited*** soluble ***CD4*** ( sCD4 ) - dependent binding of gp120 to cell-associated CCR5 .	negative	1
13736	10775592	79966;30816	sCD4;envelope glycoprotein	To investigate possible effects of CV-N at post-CD4 binding steps , we used an assay that measures ***sCD4*** ***activation*** of the HIV-1 ***envelope glycoprotein*** for fusion with CCR5-expressing cells .	positive	1
13737	10775608	10670;6993	FIP-1;TCTEL1	***FIP-1*** was able to ***bind*** both ***TCTEL1*** and Ad E3-14 .7 K simultaneously and was necessary to form a complex in which the viral protein was associated with a microtubule-binding motor protein .	parallel	1
13738	10776669	1978;1977	4E-BP1;eIF4E	However , acute alcohol intoxication increased ***binding*** of ***4E-BP1*** to ***eIF4E*** ( 113 % ) , decreased the amount of cIF4E bound to cIF4G ( 81 % ) , and decreased the amount of 4E-BP1 in the phosphorylated gamma-form ( 77 % ) .	parallel	1
13739	10777145	54681;3700	hpH4;gp120	The aim of this work was to evaluate the peripheral blood T cell expression of hpH4 in HIV-infected patients and the ***interplay*** between HIV ***gp120*** and ***hpH4*** , since both molecules interact with CD4 .	parallel	1
13740	10777207	7157;8795	p53;KILLER/DR5	These results suggest that the transactivation of ***KILLER/DR5*** is directly ***regulated*** by exogenous or endogenous ***wt-p53*** and establishes KILLER/DR5 as a p53 target gene that can signal apoptotic death .	target	1
13741	10777207	7157;8795	p53;KILLER/DR5	Wild-type ***p53*** ***transactivates*** the ***KILLER/DR5*** gene through an intronic sequence-specific DNA-binding site .	positive	1
13742	10777208	4298;10006	ENL;ABI1	***ENL*** , the MLL fusion partner in t ( 11 ; 19 ) , ***binds*** to the c-Abl interactor protein 1 ( ***ABI1*** ) that is fused to MLL in t ( 10 ; 11 ) + .	parallel	1
13743	10777208	4298;25	ENL;c-Abl	***ENL*** , the MLL fusion partner in t ( 11 ; 19 ) , ***binds*** to the ***c-Abl*** interactor protein 1 ( ABI1 ) that is fused to MLL in t ( 10 ; 11 ) + .	parallel	1
13744	10777208	10006;4298	ABI1;ENL	The ***interaction*** of ***ENL*** and ***ABI1*** could be verified in vitro by far-Western blot assays and GST-pulldown studies as well as in vivo by co-immunoprecipitation experiments .	parallel	1
13745	10777209	10538;2353	B-ATF;AP-1	***B-ATF*** functions as a negative ***regulator*** of ***AP-1*** mediated transcription and blocks cellular transformation by Ras and Fos .	negative	1
13746	10777209	10538;3725	B-ATF;Jun	B-ATF inhibits transcriptional activation of a reporter gene containing TRE sites in a dose-dependent manner , presumably by competing with Fos for Jun and forming transcriptionally inert ******Jun/B-ATF****** ***heterodimers*** .	parallel	1
13747	10777212	596;598	Bcl-2;Bcl-xS	The ***Bcl-2*** mutants deltaC22 , which lacks the transmembrane domain , and G145A ( mI-3 ) were able to ***inhibit*** the death-inducing effect of ***Bcl-xS*** .	positive	1
13748	10777217	7157;9540	p53;PIG3	Some tumor-derived ***p53-mutants*** , especially M246I , retained the ability to activate transcription of mdm2 but specifically failed to ***induce*** the ***PIG3*** promoter , thus resembling p53delta62-91 .	target	1
13749	10777218	22943;7157	Dkk-1;p53	Taken together , these results suggest that ***Dkk-1*** may ***mediate*** ***p53*** tumor suppression by antagonizing the Wnt signaling pathway .	target	0
13750	10777218	7157;22943	p53;Dkk-1	In this study , we found that ***Dkk-1*** is ***induced*** by wild-type ***p53*** but not mutant p53 ( R249S ) .	target	1
13751	10777219	1019;5925	CDK4;pRB	Most commonly , such mutations involve CDKN2A , a cyclin-dependent kinase inhibitor of two kinases , ***CDK4*** and CDK6 , which ***phosphorylate*** the retinoblastoma protein ( ***pRB*** ) and thereby promote passage through the G1/S cell-cycle restriction point .	target	1
13752	10777219	1021;5925	CDK6;pRB	Most commonly , such mutations involve CDKN2A , a cyclin-dependent kinase inhibitor of two kinases , CDK4 and ***CDK6*** , which ***phosphorylate*** the retinoblastoma protein ( ***pRB*** ) and thereby promote passage through the G1/S cell-cycle restriction point .	target	1
13753	10777220	1950;5598	EGF;erk-5	In contrast , BAPTA/AM prevented the ***EGF*** ***activation*** of ***erk-5*** in wild-type and Plcg1 - / - cells .	positive	1
13754	10777477	1387;7157	CREB-binding protein;p53	Down-regulation of p53 activity by HDACs is HDAC dosage-dependent , requires the deacetylase activity of HDACs , and depends on the region of ***p53*** that is ***acetylated*** by ***p300/CREB-binding protein*** ( CBP ) .	target	1
13755	10777477	2033;7157	p300;p53	Down-regulation of p53 activity by HDACs is HDAC dosage-dependent , requires the deacetylase activity of HDACs , and depends on the region of ***p53*** that is ***acetylated*** by ***p300/CREB-binding protein*** ( CBP ) .	target	1
13756	10777494	9771;5906	Repac;Rap1	A third member of the family , ***Repac*** ( GFR ) , which lacks the cAMP dependent regulatory sequences , is a constitutive ***activator*** of both ***Rap1*** and Rap2 .	positive	1
13757	10777494	9771;5911	Repac;Rap2	A third member of the family , ***Repac*** ( GFR ) , which lacks the cAMP dependent regulatory sequences , is a constitutive ***activator*** of both Rap1 and ***Rap2*** .	positive	1
13758	10777498	3309;64215	GRP78;MTJ1	***Interaction*** of murine ***BiP/GRP78*** with the DnaJ homologue ***MTJ1*** .	parallel	1
13759	10777498	64215;3309	MTJ1;GRP78	***J-MTJ1*** ***stimulates*** the ATPase activity of ***BiP/GRP78*** at stoichiometric concentrations .	positive	0
13760	10777498	3309;64215	BiP;MTJ1	Physical ***interactions*** between ***J-MTJ1*** and ***BiP/GRP78*** are stable and can be abolished by a single histidine -- > glutamine substitution in the highly conserved HPD motif shared by all DnaJ-like proteins .	parallel	1
13761	10777498	3309;3309	GRP78;BiP	Physical ***interactions*** between J-MTJ1 and ******BiP/GRP78****** are stable and can be abolished by a single histidine -- > glutamine substitution in the highly conserved HPD motif shared by all DnaJ-like proteins .	parallel	1
13762	10777503	3949;4018	LDLR;lipoprotein	To determine the role of ACAT-1 in atherogenesis , we crossed the ACAT-1 - / - mice with mice lacking apolipoprotein (apo) E or the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) , hyperlipidemic models susceptible to atherosclerosis .	parallel	1
13763	10777510	8862;187	apelin;APJ	Because pretreatment with apelin-36 but not [ < Glu ( 65 ) ] apelin-13 drastically reduced the ***binding*** of the labeled ***apelin*** to ***APJ*** , the different patterns of acidification induced by these two peptides appeared to reflect their dissociation rather than association with APJ .	parallel	1
13764	10777511	64132;6464	Sos;Shc	***Sos*** ***co-immunoprecipitated*** with ***Shc*** in cells that were treated with uPA for 1-2 .5 min , probably reflecting the formation of Shc-GRB2 / Sos complex ; however , by 10 min , co-immunoprecipitation of Sos with Shc was no longer observed .	parallel	1
13765	10777511	6464;2885	Shc;GRB2	Sos co-immunoprecipitated with Shc in cells that were treated with uPA for 1-2 .5 min , probably reflecting the formation of ******Shc-GRB2****** / Sos ***complex*** ; however , by 10 min , co-immunoprecipitation of Sos with Shc was no longer observed .	parallel	1
13766	10777512	7157;9518	p53;PTGF-beta	The ***PTGF-beta*** promoter is ***activated*** by ***p53*** and contains two p53 binding site motifs .	positive	1
13767	10777515	6647;5159	homodimer;PDGFR	In contrast , the PDGF A chain ***homodimer*** ( PDGF AA ) ***activates*** ***alpha-PDGFR*** only and fails to induce phenotypic transformation .	positive	1
13768	10777524	7056;1361	thrombomodulin;TAFI	In this study we followed ***TAFI*** ***activation*** and TAFIa inactivation by ***thrombin/thrombomodulin*** in time and characterized the cleavage pattern of TAFI using matrix-assisted laser desorption ionization mass spectrometry .	positive	1
13769	10777539	6927;8850	HNF-1;P/CAF	In exploring the molecular mechanism involved in HNF-1-dependent gene activation in the in vivo chromatin context , we found that ***HNF-1*** can physically ***interact*** with the histone acetyltransferases ( HATs ) CREB-binding protein ( CBP ) , p300/CBP-associated factor ( ***P/CAF*** ) , Src-1 , and RAC3 .	parallel	1
13770	10777539	6927;8202	HNF-1;RAC3	In exploring the molecular mechanism involved in HNF-1-dependent gene activation in the in vivo chromatin context , we found that ***HNF-1*** can physically ***interact*** with the histone acetyltransferases ( HATs ) CREB-binding protein ( CBP ) , p300/CBP-associated factor ( P/CAF ) , Src-1 , and ***RAC3*** .	parallel	1
13771	10777539	6927;8648	HNF-1;Src-1	In exploring the molecular mechanism involved in HNF-1-dependent gene activation in the in vivo chromatin context , we found that ***HNF-1*** can physically ***interact*** with the histone acetyltransferases ( HATs ) CREB-binding protein ( CBP ) , p300/CBP-associated factor ( P/CAF ) , ***Src-1*** , and RAC3 .	parallel	1
13772	10777539	1387;6927	CBP;HNF-1	The transcriptional activation potential of HNF-1 on a genome integrated promoter was strictly dependent on the synergistic action of ***CBP*** and P/CAF , which can independently ***interact*** with the N-terminal and C-terminal domain of ***HNF-1*** , respectively .	parallel	1
13773	10777539	8850;6927	P/CAF;HNF-1	The transcriptional activation potential of HNF-1 on a genome integrated promoter was strictly dependent on the synergistic action of CBP and ***P/CAF*** , which can independently ***interact*** with the N-terminal and C-terminal domain of ***HNF-1*** , respectively .	parallel	1
13774	10777539	1387;6927	CBP;HNF-1	***Interaction*** of ***CBP*** with the N-terminal domain of ***HNF-1*** greatly increased the binding affinity for P/CAF with the C-terminal activation domain , which may represent the molecular basis for the observed functional synergism .	parallel	1
13775	10777553	2185;1956	PYK-2;epidermal growth factor receptor	Carbachol-stimulated transactivation of ***epidermal growth factor receptor*** and mitogen-activated protein kinase in T ( 84 ) cells is ***mediated*** by intracellular Ca2 + , ***PYK-2*** , and p60 ( src ) .	target	0
13776	10777553	2185;1956	PYK-2;EGFR	The calmodulin inhibitor , fluphenazine ( 50 microM ) inhibited CCh-stimulated ***PYK-2*** ***association*** with the ***EGFR*** and phosphorylation of EGFR and ERK .	parallel	0
13777	10777554	3458;1051	IFN-gamma;C/EBP-beta	Interestingly , the expression of ***C/EBP-beta*** , not the other members of its family , is ***induced*** by ***IFN-gamma*** .	target	1
13778	10777555	4018;4790	lipoprotein;NF-kappaB	Oxidized low density ***lipoprotein*** ( ox-LDL ) binding to ox-LDL receptor-1 in endothelial cells ***induces*** the activation of ***NF-kappaB*** through an increased production of intracellular reactive oxygen species .	target	1
13779	10777558	3439;6772	IFNalpha;STAT1	Last , the ***IFNalpha-induced*** serine ***phosphorylation*** of ***STAT1*** and STAT3 is not inhibited by piceatannol but is sensitive to the Src kinase-specific inhibitor PP2 .	target	1
13780	10777558	3439;6774	IFNalpha;STAT3	Last , the ***IFNalpha-induced*** serine ***phosphorylation*** of STAT1 and ***STAT3*** is not inhibited by piceatannol but is sensitive to the Src kinase-specific inhibitor PP2 .	target	1
13781	10777559	2889;5599	C3G;JNK	Crk ***activation*** of ***JNK*** via ***C3G*** and R-Ras .	positive	1
13782	10777559	1398;5599	Crk;JNK	***Crk*** ***activation*** of ***JNK*** via C3G and R-Ras .	positive	1
13783	10777559	2889;1398	C3G;Crk	***C3G*** , a guanine nucleotide exchange factor (GEF) for Rap1 and R-Ras , is postulated to ***transduce*** the oncogenic signal of ***v-Crk*** to c-Jun kinase ( JNK ) .	positive	1
13784	10777559	1398;5599	Crk;JNK	We have found that R-Ras , but not Rap1 , mediates ***JNK*** ***activation*** by ***v-Crk*** in 293T and NIH 3T3 cells .	positive	1
13785	10777559	4296;5599	mixed lineage kinase 3;JNK	***JNK*** activation by R-Ras ( Val-38 ) was ***inhibited*** by a dominant-negative mutant of ***mixed lineage kinase 3*** .	positive	1
13786	10777560	5896;5897	RAG1;RAG2	This finding reinforces the biological significance of this predicted model and suggests that ***RAG1*** ***interacts*** with ***RAG2*** on one of the side of the scaffold formed by the beta-propeller .	parallel	1
13787	10777567	2906;25	NR2D;Abl	In contrast , the full-length ***NR2D*** subunit partially ***inhibited*** the autokinase activity of both DeltaSH3 Abl and ***Abl-PP*** , suggesting that NR2D and Abl may interact at multiple sites .	negative	1
13788	10777567	25;2906	Abl;NR2D	Taken together , the data in this report provide the first evidence for a novel inhibitory ***interaction*** between the ***NR2D*** subunit of the NMDA receptor and the ***Abl*** tyrosine kinase .	parallel	1
13789	10777567	2906;25	NR2D;c-Abl	***Interaction*** of the N-methyl-D-aspartic acid receptor ***NR2D*** subunit with the ***c-Abl*** tyrosine kinase .	parallel	1
13790	10777567	25;2906	Abl;NR2D	Co-immunoprecipitation of NR2D with Abl suggests stable ***association*** of ***NR2D*** and ***Abl*** in transfected cells .	parallel	0
13791	10777571	9522;7018	SCAMP1;transferrin	Expression of ***SCAMP1*** lacking the N-terminal NPF repeats potently ***inhibited*** ***transferrin*** uptake by endocytosis .	negative	1
13792	10777583	5781;9021	SHP2;SOCS3	Taken together , our results suggest differences in the function of SOCS1 and SOCS3 and a ***link*** between ***SHP2*** and ***SOCS3*** .	parallel	0
13793	10777591	3075;718	factor H;C3b	Antibody X13 .2 competes with C3b for association with factor H and strongly inhibits ***factor H/factor*** I-mediated ***cleavage*** of ***C3b*** , thereby evidently inactivating a negative regulator of complement ; yet , the antibody strongly inhibits complement-mediated lysis as well .	target	1
13794	10777610	4790;321	NF-kappaB;X11L	The amino acids 161-163 in Rel homology domain ( RHD ) of NF-kappaB/p65 is important in ***interaction*** of ***NF-kappaB/p65*** with ***X11L*** .	parallel	1
13795	10777610	5970;321	p65;X11L	The amino acids 161-163 in Rel homology domain ( RHD ) of NF-kappaB/p65 is important in ***interaction*** of ***NF-kappaB/p65*** with ***X11L*** .	parallel	1
13796	10777610	4790;351	NF-kappaB;Abeta	Our finding indicates ***NF-kappaB*** and X11L may , in novel way , ***regulate*** ***Abeta*** production in neuronal cells .	target	1
13797	10777610	321;351	X11L;Abeta	Our finding indicates NF-kappaB and ***X11L*** may , in novel way , ***regulate*** ***Abeta*** production in neuronal cells .	target	1
13798	10777617	1398;2889	CRKII;C3G	The ***association*** of ***CRKII*** with ***C3G*** can be regulated by integrins and defines a novel means to regulate the mitogen-activated protein kinases .	parallel	0
13799	10777617	2889;1398	C3G;CRKII	Consistent with the presence of a functional ******CRKII-C3G****** ***complex*** , we detected more GTP-loaded RAP1 in suspension than adherent lysates .	parallel	1
13800	10777617	2889;1398	C3G;CRKII	Finally , we have also observed that certain integrin alpha subunit cytoplasmic splice variants differentially regulate ERK1/2 but also in a manner that correlated with levels of a ******CRKII-C3G****** ***complex*** .	parallel	1
13801	10777675	7299;821	tyrosinase;calnexin	In addition , we show that tyrosinase degradation is sensitive to the proteasome inhibitor lactacystin and that ***tyrosinase*** ***associates*** with endogenous ***calnexin*** in COS-7 cells .	parallel	0
13802	10777696	116;4982	pituitary adenylate cyclase-activating polypeptide;osteoprotegerin	The inhibitory effects of vasoactive intestinal peptide and ***pituitary adenylate cyclase-activating polypeptide*** on osteoclast formation are ***associated*** with upregulation of ***osteoprotegerin*** and downregulation of RANKL and RANK .	parallel	0
13803	10777696	7432;4982	vasoactive intestinal peptide;osteoprotegerin	The inhibitory effects of ***vasoactive intestinal peptide*** and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are ***associated*** with upregulation of ***osteoprotegerin*** and downregulation of RANKL and RANK .	parallel	0
13804	10777699	4129;5594	MAO-B;ERK	These results show that ***MAO-B*** ***induces*** ***MAPK/ERK*** activation and cell mitogenesis through H ( 2 ) O ( 2 ) production .	target	1
13805	10777703	7040;3082	TGF-beta1;HGF	In MRC-5 cells , ***TGF-beta1*** ***modulates*** ***HGF/SF*** gene transcripts at the posttranscriptional level in order to favour expression of the 1.5-kb mRNA that encodes the truncated protein NK2 .	target	0
13806	10777774	5925;7027	pRb;DP1	Because Cdk4/6 phosphorylates retinoblastoma protein ( ***pRb*** ) family members that then ***modulate*** the transcriptional activity of ***E2F/DP1*** complexes , we examined the involvement of these components in DNA damage-evoked neuronal death .	target	0
13807	10777774	1021;5925	Cdk4/6;pRb	Because ***Cdk4/6*** ***phosphorylates*** retinoblastoma protein ( ***pRb*** ) family members that then modulate the transcriptional activity of E2F/DP1 complexes , we examined the involvement of these components in DNA damage-evoked neuronal death .	target	1
13808	1077784	2641;5972	glucagon;renin	Lanthanum prevented isoprenaline-induced and ***glucagon-induced*** ***stimulation*** of ***renin*** secretion .	positive	0
13809	10778531	3952;6517	leptin;GLUT-4	Hence , it is likely that there is a close ***interaction*** between ***GLUT-4*** , TNF-alpha , EFAs , daf-genes , melatonin and ***leptin*** that may have relevance to the development of insulin resistance , obesity , NIDDM , complications due to NIDDM , longevity and ageing .	parallel	1
13810	10778531	7124;6517	TNF-alpha;GLUT-4	Hence , it is likely that there is a close ***interaction*** between ***GLUT-4*** , ***TNF-alpha*** , EFAs , daf-genes , melatonin and leptin that may have relevance to the development of insulin resistance , obesity , NIDDM , complications due to NIDDM , longevity and ageing .	parallel	1
13811	10778531	7124;3952	TNF-alpha;leptin	Hence , it is likely that there is a close ***interaction*** between GLUT-4 , ***TNF-alpha*** , EFAs , daf-genes , melatonin and ***leptin*** that may have relevance to the development of insulin resistance , obesity , NIDDM , complications due to NIDDM , longevity and ageing .	parallel	1
13812	10778750	6500;9525	SKP1;Mig1	Interestingly , our data further indicate that A. thaliana ***SKP1*** ***inactivates*** ***Mig1*** by destabilising the yeast F-box protein Grr1 , which is required for cyclin degradation and is thus involved in control of the cell cycle , and for glucose-regulated gene repression .	negative	1
13813	10778944	1021;5925	CDK4/6;pRb	***Ds-CDK4/6*** ***mediated*** phosphorylation of ***pRb*** .	target	0
13814	10778946	7157;6667	p53;Sp1	These findings suggest that p53 repressed telomerase activity through down-regulation of hTERT transcription and that ***interaction*** of ***p53*** with ***Sp1*** or other transcription factors may be involved in this regulation .	parallel	1
13815	10778972	4436;4292	hMSH2;hMLH1	We sought ***associations*** between ***hMLH1*** and ***hMSH2*** protein expression and clinical parameters known to be of prognostic significance as well as response to treatment and overall survival .	parallel	0
13816	10778972	4292;94025	hMLH1;CA125	Expression of nuclear ***hMLH1*** and hMSH2 was positively ***correlated*** with pretreatment ***CA125*** level , and expression of nuclear hMSH2 was positively correlated with change in CA125 level after treatment .	positive	0
13817	10778972	4436;94025	hMSH2;CA125	Expression of nuclear hMLH1 and ***hMSH2*** was positively ***correlated*** with pretreatment ***CA125*** level , and expression of nuclear hMSH2 was positively correlated with change in CA125 level after treatment .	positive	0
13818	10778981	7027;1869	DP-1;E2F-1	Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the ******E2F-1/DP-1****** transcription factor ***complex*** .	parallel	1
13819	10779013	3458;4843	interferon-gamma;NOS-2	The ***NOS-2*** activity , assessed by nitrite accumulation , was absent from untreated cultures but was ***induced*** by interleukin-1beta and ***interferon-gamma*** acting synergistically .	target	1
13820	10779052	185;183	AT1R;Angiotensin II	Male SHRSPs were treated with hydralazine , captopril , or candesartan , an ***Angiotensin II*** type 1 ***receptor*** ( ***AT1R*** ) antagonist , from age 12 to 24 weeks .	parallel	1
13821	10779196	7422;7157	Vascular endothelial growth factor;p53	***Vascular endothelial growth factor*** expression ***correlates*** with ***p53*** mutation and angiogenesis in squamous cell carcinoma of the head and neck .	parallel	0
13822	10779323	2353;3725	c-Fos;Jun	A dominant negative form of c-Fos ( A-Fos ) that specifically disrupts ******c-Jun-c-Fos****** DNA ***binding*** inhibited synergistic activation of the alpha subunit .	parallel	1
13823	10779323	2353;3725	c-Fos;Jun	A dominant negative form of ***c-Fos*** ( A-Fos ) that specifically ***disrupts*** ***c-Jun-c-Fos*** DNA binding inhibited synergistic activation of the alpha subunit .	negative	0
13824	10779328	3717;6777	Jak2;Stat5	Deletion analysis of Jak2 showed that the pseudokinase domain but not JH domains 3 to 7 negatively regulated the catalytic activity of Jak2 as well as ***Jak2-mediated*** ***activation*** of ***Stat5*** .	positive	1
13825	10779328	3717;6777	Jak2;Stat5	***Phosphorylation*** of ***Stat5*** by wild-type ***Jak2*** was dependent on the SH2 domain of Stat5 ; however , this requirement was lost upon deletion of the pseudokinase domain of Jak2 .	target	1
13826	10779329	6503;6714	Slap;Src	We conclude that ***Slap*** is a negative ***regulator*** of ***Src*** during mitogenesis involving both the SH2 and the C terminus domains in a noncompetitive manner , but it does not regulate all Src function due to specific SH3 binding substrates .	negative	1
13827	10779329	6503;6714	Slap;Src	***Slap*** negatively ***regulates*** ***Src*** mitogenic function but does not revert Src-induced cell morphology changes .	negative	1
13828	10779330	3725;602	AP1;Bcl-3	***Bcl-3*** expression promotes cell survival following interleukin-4 deprivation and is ***controlled*** by ***AP1*** and AP1-like transcription factors .	target	0
13829	10779330	3565;602	IL-4;Bcl-3	To characterize the ***IL-4-induced*** ***regulation*** of murine ***Bcl-3*** expression , we cloned the promoter of this gene .	target	1
13830	10779330	3565;3725	IL-4;AP1	Retardation gels showed that ***IL-4*** specifically ***induces*** AP1 and ***AP1-like*** binding activity and that mutation of these binding sites abolishes the IL-4-induced Bcl-3 promoter activity , suggesting that these transcription factors are important in Bcl-3 promoter transactivation .	target	1
13831	10779339	4609;993	Myc;Cdc25A	The effect of ***Myc*** is ***associated*** with ***Cdc25A*** phosphatase and cyclin E-CDK2 kinase activation and abolished by antagonizing Myc activity with the dominant-negative ( dn ) MadMyc chimera .	parallel	0
13832	10779339	993;4609	Cdc25A;Myc	Finally , proper transcription of cyclin E and ***Cdc25A*** at the G ( 1 ) / S transition ***requires*** both ***Myc*** and E2F activities , and subthreshold levels of ectopic cyclin E and Cdc25A synergistically restore DNA synthesis in cells with silenced Myc and E2F activities .	target	0
13833	10779354	6929;1879	E47;EBF	Electrophoretic mobility shift assay analysis using the 5 ' part of the lambda5 promoter revealed ***formation*** of template-dependent heteromeric complexes between ***EBF*** and ***E47*** , suggesting that the synergistic mechanism involves cooperative binding to DNA .	parallel	0
13834	10779355	1147;3551	IKKalpha;IKKbeta	IkappaB kinase alpha ( ***IKKalpha*** ) ***regulation*** of ***IKKbeta*** kinase activity .	target	1
13835	10779355	7124;4790	tumor necrosis factor alpha;NF-kappaB	IKKbeta has a much higher level of kinase activity for the IkappaB proteins than does IKKalpha and is more critical than IKKalpha in modulating ***tumor necrosis factor alpha*** ***activation*** of the ***NF-kappaB*** pathway .	positive	1
13836	10779355	1147;3551	IKKalpha;IKKbeta	In the current study , we demonstrate that ***IKKalpha*** directly ***phosphorylates*** ***IKKbeta*** .	target	1
13837	10779355	1147;3551	IKKalpha;IKKbeta	Moreover , ***IKKalpha*** either directly or indirectly ***enhances*** ***IKKbeta*** kinase activity for IkappaBalpha .	positive	0
13838	10779355	1147;3551	IKKalpha;IKKbeta	These results indicate that ***IKKalpha*** , in addition to its previously described ability to phosphorylate IkappaBalpha , can ***increase*** the ability of ***IKKbeta*** to phosphorylate IkappaBalpha .	positive	0
13839	10779358	5997;382	RGS2;ARF6	The bombesin-elicited translocation of vesicular ***ARF6*** was mimicked by activated Galphaq and was partially ***inhibited*** by expression of ***RGS2*** , which down regulates Gq function .	negative	1
13840	10779380	3569;6772	IL-6;Stat1	Immunoprecipitation experiments showed that ***IL-6*** ***increased*** tyrosine phosphorylation of ***Stat1*** and Stat3 in PC12 cells , whereas NE caused a sustained increase in tyrosine phosphorylation of Stat1 .	positive	0
13841	10779380	3569;6774	IL-6;Stat3	Immunoprecipitation experiments showed that ***IL-6*** ***increased*** tyrosine phosphorylation of Stat1 and ***Stat3*** in PC12 cells , whereas NE caused a sustained increase in tyrosine phosphorylation of Stat1 .	positive	0
13842	10779392	196;7040	AHR;TGF-beta	Taken together , these results suggest that ***AHR*** ***influences*** ***TGF-beta*** production , leading to an alteration in cell cycle control .	target	0
13843	10779394	8802;112	Galpha;AC6	Studies to test whether the selective enhancement in beta-adrenergic receptor ( AR ) response might result from ***inhibition*** of ***AC6*** by ***Galpha*** ( i ) and Gbetagamma indicated that pertussis toxin-sensitive inhibition by the muscarinic cholinergic agonist carbachol was unaltered in myocytes overexpressing AC6 .	negative	1
13844	10779401	3586;1437	IL-10;GM-CSF	***IL-10*** is a potent ***inhibitor*** of LPS-stimulated ***GM-CSF*** production from healthy control alveolar macrophages .	negative	1
13845	10779415	598;8739	Bcl-x;Hrk	Expression of prosurvival ***Bcl-x*** ( L ) or Bcl-2 proteins ***blocked*** the induction of ***Hrk*** .	negative	0
13846	10779416	7341;5371	SUMO-1;PML	In addition , ***PML*** is , among other proteins , covalently ***modified*** by ***SUMO-1*** .	target	0
13847	10779444	397;5880	LyGDI;Rac2	In addition , ***association*** of ***Rac2*** and RhoGDI or ***LyGDI*** is abrogated or not detectable based on the low Rac2 expression in patients ' neutrophils .	parallel	0
13848	10779444	397;396	LyGDI;RhoGDI	In addition , ***association*** of Rac2 and ***RhoGDI*** or ***LyGDI*** is abrogated or not detectable based on the low Rac2 expression in patients ' neutrophils .	parallel	0
13849	10779444	5880;396	Rac2;RhoGDI	In addition , ***association*** of ***Rac2*** and ***RhoGDI*** or LyGDI is abrogated or not detectable based on the low Rac2 expression in patients ' neutrophils .	parallel	0
13850	10779465	4311;1889	NEP;ECE-1	***Inhibition*** of ***ECE-1*** by ***NEP-I*** represents a novel approach to interruption of the endothelin system in this cardiovascular disease state .	negative	1
13851	10779465	4311;1889	NEP;ECE-1	Our hypothesis was that chronic ***NEP-I*** , in association with augmented cGMP , would ***inhibit*** ***ECE-1*** conversion of big ET-1 to active ET-1 , thus reducing tissue ET-1 concentrations and associated atheroma formation .	negative	1
13852	10779468	2247;2152	bFGF;tissue factor	BACKGROUND : Basic fibroblast growth factor ( ***bFGF*** ) promotes vascular repair and angiogenesis and can ***induce*** in vitro ***tissue factor*** ( TF ) , a potent agent initiating thrombogenesis , which probably plays a role in angiogenesis .	target	1
13853	10779504	2033;367	p300;androgen receptor	***p300*** and p300/cAMP-response element-binding protein-associated factor ***acetylate*** the ***androgen receptor*** at sites governing hormone-dependent transactivation .	target	1
13854	10779506	2627;1601	GATA-6;Dab2	Cotransfection experiments demonstrate that the human ***Dab2*** promoter can be ***transactivated*** by forced expression of ***GATA-6*** in NIH-3T3 cells .	positive	1
13855	10779506	2627;1601	GATA-6;Dab2	Surprisingly , the specificity of ***GATA-6-induced*** ***transactivation*** of the ***Dab2*** promoter is not mediated through its zinc finger DNA-binding domain .	positive	1
13856	10779518	2353;4322	c-Fos;collagenase-3	Overexpression of both ***c-Fos*** and c-Jun in osteoblasts or core-binding factor a1 ***increased*** ***collagenase-3*** promoter activity .	positive	0
13857	10779518	3725;4322	c-Jun;collagenase-3	Overexpression of both c-Fos and ***c-Jun*** in osteoblasts or core-binding factor a1 ***increased*** ***collagenase-3*** promoter activity .	positive	0
13858	10779518	2353;4322	c-Fos;collagenase-3	Furthermore , overexpression of ***c-Fos*** , c-Jun , and core-binding factor a1 synergistically ***increased*** ***collagenase-3*** promoter activity .	positive	0
13859	10779518	3725;4322	c-Jun;collagenase-3	Furthermore , overexpression of c-Fos , ***c-Jun*** , and core-binding factor a1 synergistically ***increased*** ***collagenase-3*** promoter activity .	positive	0
13860	10779518	2355;4322	Fra-2;collagenase-3	Overexpression of ***Fra-2*** and JunD ***repressed*** core-binding factor a1-induced ***collagenase-3*** promoter activity .	negative	1
13861	10779518	3727;4322	JunD;collagenase-3	Overexpression of Fra-2 and ***JunD*** ***repressed*** core-binding factor a1-induced ***collagenase-3*** promoter activity .	negative	1
13862	10779525	998;4790	Cdc42hs;NFkappaB	Both Rac and ***Cdc42hs*** have been shown to ***regulate*** the activity of the transcription factor ***NFkappaB*** .	target	1
13863	10779525	207;4790	Rac;NFkappaB	Both ***Rac*** and Cdc42hs have been shown to ***regulate*** the activity of the transcription factor ***NFkappaB*** .	target	1
13864	10779525	5058;4790	PAK1;NFkappaB	Here we show that expression of active Ras , Raf-1 , or Rac1 in fibroblasts stimulates NFkappaB in a PAK1-dependent manner and that expression of active ***PAK1*** can ***stimulate*** ***NFkappaB*** on its own .	positive	0
13865	10779525	5879;4790	Rac1;NFkappaB	Here we show that expression of active Ras , Raf-1 , or ***Rac1*** in fibroblasts ***stimulates*** ***NFkappaB*** in a PAK1-dependent manner and that expression of active PAK1 can stimulate NFkappaB on its own .	positive	0
13866	10779525	5894;4790	Raf-1;NFkappaB	Here we show that expression of active Ras , ***Raf-1*** , or Rac1 in fibroblasts ***stimulates*** ***NFkappaB*** in a PAK1-dependent manner and that expression of active PAK1 can stimulate NFkappaB on its own .	positive	0
13867	10779549	3481;1028	IGF-II;p57kip2	Increased ***IGF-II*** protein ***affects*** ***p57kip2*** expression in vivo and in vitro : implications for Beckwith-Wiedemann syndrome .	target	0
13868	10779558	115708;51605	Gcd14p;Gcd10p	The ******Gcd10p/Gcd14p****** ***complex*** is the essential two-subunit tRNA ( 1-methyladenosine ) methyltransferase of Saccharomyces cerevisiae .	parallel	1
13869	10779558	115708;51605	Gcd14p;Gcd10p	These facts , plus our demonstration that gcd14Delta cells lacked m ( 1 ) A , strongly suggested that ******Gcd10p/Gcd14p****** ***complex*** is the yeast tRNA ( m ( 1 ) A ) methyltransferase [ ( m ( 1 ) A ) MTase ] .	parallel	1
13870	10779558	115708;51605	Gcd14p;Gcd10p	Supporting this prediction , affinity-purified ******Gcd10p/Gcd14p****** ***complexes*** used AdoMet as a methyl donor to synthesize m ( 1 ) A in either total tRNA or purified tRNA ( i ) ( Met ) lacking only this modification .	parallel	1
13871	10779747	355;356	CD95;CD95L	The ***interaction*** between ***CD95*** ( Fas ) and ***CD95L*** ( Fas ligand ) initiates apoptosis in a variety of cell types .	parallel	1
13872	10779765	867;7535	Cbl;ZAP-70	We have shown previously that ***Cbl*** ***binds*** to ***ZAP-70*** through its N-terminal tyrosine kinase binding ( TKB ) domain .	parallel	1
13873	10779765	867;7535	Cbl;ZAP-70	In this study , we demonstrate that overexpression of ***Cbl*** in Jurkat T cells ***decreases*** the TCR-induced phosphorylation of ***ZAP-70*** and other cellular phosphoproteins .	negative	0
13874	10779770	3586;6775	IL-10;Stat4	In contrast , the Th2 cytokines , IL-4 and ***IL-10*** , specifically ***down-regulate*** ***Stat4*** expression in activated monocytes , while having little effect on Stat6 expression .	negative	1
13875	10779770	3565;6775	IL-4;Stat4	In contrast , the Th2 cytokines , ***IL-4*** and IL-10 , specifically ***down-regulate*** ***Stat4*** expression in activated monocytes , while having little effect on Stat6 expression .	negative	1
13876	10779772	3569;3572	IL-6;gp130	IL-6 receptor independent ***stimulation*** of human ***gp130*** by viral ***IL-6*** .	positive	0
13877	10779772	3569;3572	IL-6;gp130	IL-6 binds to IL-6R , and the ***IL-6/IL*** -6 R complex ***associates*** with ***gp130*** which dimerizes and initiates intracellular signaling .	parallel	0
13878	10779773	3479;5140	IGF-1;PDE3B	In F/V cells , ***IGF-1*** ***increased*** PKB , ***PDE3B*** , and PDE4 activities approximately 2-fold .	positive	0
13879	10779773	3479;5141	IGF-1;PDE4	In F/V cells , ***IGF-1*** ***increased*** PKB , PDE3B , and ***PDE4*** activities approximately 2-fold .	positive	0
13880	10779773	3479;207	IGF-1;PKB	In F/V cells , ***IGF-1*** ***increased*** ***PKB*** , PDE3B , and PDE4 activities approximately 2-fold .	positive	0
13881	10779773	3479;5141	IGF-1;PDE4	In F/B - cells , ***IGF-1*** ***activated*** ***PDE4*** , not PDE3B , suggesting that kinase-inactive PKB behaved as a dominant negative with respect to PDE3B activation .	positive	1
13882	10779774	23308;29851	ICOSL;ICOS	We constructed a soluble-Ig fusion protein of the extracellular domain of human ICOS and used it as a probe to characterize expression patterns of the ***ICOS*** ***ligand*** ( ***ICOSL*** ) .	parallel	1
13883	10779774	3458;23308	IFN-gamma;ICOSL	Both ***ICOSL*** and CD152L were ***up-regulated*** on monocytes by ***IFN-gamma*** but by distinct signaling pathways .	positive	1
13884	10779802	3458;6279	IFN-gamma;S100A8	***IFN-gamma*** and TNF ***regulate*** macrophage expression of the chemotactic S100 protein ***S100A8*** .	target	1
13885	10779802	3458;6279	IFN-gamma;S100A8	We show that the kinetics of ***induction*** of ***S100A8*** mRNA in elicited murine macrophages ( Mac ) by LPS , ***IFN-gamma*** , and TNF were distinct from the C-C chemokines monocyte chemoattractant protein-1 ( MCP-1 ) , macrophage-inflammatory protein-1alpha ( MIP-1alpha ) , and RANTES .	target	1
13886	10780315	5054;5327	PAI-1;t-plasminogen activator	AIM OF THE STUDY : We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen , ***t-plasminogen activator*** ***inhibitor*** ( ***PAI-1*** ) and C reactive protein ( CRP ) in patients with coronary artery disease ( CAD ) and mixed hyperlipidaemia .	negative	1
13887	10780526	4254;3815	SCF;c-Kit	Stem cell factor ( ***SCF*** ) , the ***ligand*** for ***c-Kit*** , is known to regulate developmental and functional processes of haematopoietic stem cells , mast cells and melanocytes .	parallel	1
13888	10780664	356;355	Fas ligand;Fas	CD4 + T cell-mediated cytotoxicity toward thyrocytes : the importance of ******Fas/Fas ligand****** ***interaction*** inducing apoptosis of thyrocytes and the inhibitory effect of thyroid-stimulating hormone .	parallel	1
13889	10780664	355;356	Fas;Fas ligand	The ******Fas/Fas ligand****** ( FasL ) ***interaction*** between antigen-presenting cells and T cells regulates the apoptosis of the former cells triggered by the latter cells .	parallel	1
13890	10780664	356;355	FasL;Fas	We investigated the potential role of ******Fas/FasL****** ***interaction*** between thyrocytes and CD4 + T cells in the induction of Fas-mediated apoptosis of the former cells induced by the latter cells .	parallel	1
13891	10780664	355;356	Fas;FasL	In addition , a significant cytotoxicity of purified CD4 + T cells toward IFN-gamma-stimulated thyrocytes in the presence of SEB was induced , and the addition of anti-HLA-DR and - DQ monoclonal antibodies ( mAbs ) or blockade of the ******Fas/FasL****** ***interaction*** reduced this cytotoxicity .	parallel	1
13892	10780674	8539;1499	AAC-11;beta-catenin	These suggest that overexpressions of MMP-2 and MT1-MMP , loss of TIMP-2 expression , and ***up-regulation*** of ***beta-catenin*** by ***AAC-11*** transfection may contribute to the development of cervical cancer invasion .	positive	1
13893	10781016	796;10267	CGRP;RAMP-1	***CGRP*** binding ***correlates*** well with ***RAMP-1*** mRNA levels ( R = 1.0 , P = 0.007 ) , adrenomedullin binding shows a tendency to vary with RAMP-2 mRNA levels ( R = 0.85 , P = 0.14 ) and total binding is correlated with CRLR mRNA levels ( R = 0.94 , P = 0.03 ) .	parallel	0
13894	10781064	375790;4593	agrin;MuSK	Activation of ***MuSK*** is ***induced*** by ***agrin*** leading to clustering of several proteins , including acetylcholine receptors , at synaptic sites .	target	1
13895	10781372	2919;3579	Gro-alpha;CXCR2	However , ***CXCR2*** was ***downregulated*** by ***Gro-alpha*** and IL-8 to 71 + / - 7.5 and 79 + / - 6.3 % of control , respectively ( P < 0.05 ) .	negative	1
13896	10781376	3082;5594	HGF;ERK 1 and 2	CONCLUSION : ( i ) Both hypoosmotic cell swelling and ***HGF*** ***phosphorylate*** p38 , ***ERK 1 and 2*** , and SAPK/JNK , and ( ii ) HGF , but not hypoosmotic stress , activates NF-kappaB via p38 and ERK 1 and 2 phosphorylation .	target	1
13897	10781376	3082;5599	HGF;JNK	CONCLUSION : ( i ) Both hypoosmotic cell swelling and ***HGF*** ***phosphorylate*** p38 , ERK 1 and 2 , and ***SAPK/JNK*** , and ( ii ) HGF , but not hypoosmotic stress , activates NF-kappaB via p38 and ERK 1 and 2 phosphorylation .	target	1
13898	10781376	3082;5601	HGF;SAPK	CONCLUSION : ( i ) Both hypoosmotic cell swelling and ***HGF*** ***phosphorylate*** p38 , ERK 1 and 2 , and ***SAPK/JNK*** , and ( ii ) HGF , but not hypoosmotic stress , activates NF-kappaB via p38 and ERK 1 and 2 phosphorylation .	target	1
13899	10781423	7080;6440	TTF-1;SP-C	Cotransfection assays of the human 3.7-kb SP-C or -1,910 - to -215 - bp SP-C deletion construct with a TTF-1 expression plasmid demonstrates that ***TTF-1*** ***transactivates*** the human ***SP-C*** gene .	positive	1
13900	10781430	2252;3002	KGF;granzyme B	***KGF*** pretreatment ***decreases*** B7 and ***granzyme B*** expression and hastens repair in lungs of mice after allogeneic BMT .	negative	0
13901	10781581	335;3931	apolipoprotein A-I;Lecithin:Cholesterol acyltransferase	Identification of a sequence of ***apolipoprotein A-I*** ***associated*** with the activation of ***Lecithin:Cholesterol acyltransferase*** .	parallel	0
13902	10781582	5594;7157	p38;p53	ERKs and ***p38*** kinase ***phosphorylate*** ***p53*** protein at serine 15 in response to UV radiation .	target	1
13903	10781582	5594;7157	p38;p53	Here , we provide evidence that UVB-induced phosphorylation of ***p53*** at serine 15 is ***mediated*** directly by ERKs and ***p38*** kinase .	target	0
13904	10781582	5594;7157	p38;p53	Additionally , active recombinant ERK1/2 and ***p38*** kinase but not JNKs are also able to ***phosphorylate*** ***p53*** at serine 15 in vitro .	target	1
13905	10781586	3312;2571	HSC70;GAD	Third , in immunoprecipitation studies , again , ***HSC70*** was ***co-immunoprecipitated*** with ***GAD*** by a GAD ( 65 ) - specific monoclonal antibody .	parallel	1
13906	10781586	2571;3312	GAD;HSC70	Third , in immunoprecipitation studies , again , ***HSC70*** was ***co-immunoprecipitated*** with GAD by a ***GAD*** ( 65 ) - specific monoclonal antibody .	parallel	1
13907	10781587	56477;51554	CCL28;CCR10	Identification of a novel chemokine ( ***CCL28*** ) , which ***binds*** ***CCR10*** ( GPR2 ) .	parallel	1
13908	10781587	51554;56477	CCR10;CCL28	We report the identification and characterization of a novel CC chemokine designated ***CCL28*** and its ***receptor*** ***CCR10*** , known previously as orphan G-protein-coupled receptor GPR2 .	parallel	1
13909	10781591	29974;8570	ASP;KSRP	In rat liver , ***ASP*** is apparently ***associated*** with ***KSRP*** , which may confer stability to the editing enzyme-complex with its substrate apoB RNA serving as an additional auxiliary component .	parallel	0
13910	10781592	4133;2885	microtubule-associated protein 2;Grb2	Regulated ***association*** of ***microtubule-associated protein 2*** ( MAP2 ) with Src and ***Grb2*** : evidence for MAP2 as a scaffolding protein .	parallel	0
13911	10781592	4133;6714	microtubule-associated protein 2;Src	Regulated ***association*** of ***microtubule-associated protein 2*** ( MAP2 ) with ***Src*** and Grb2 : evidence for MAP2 as a scaffolding protein .	parallel	0
13912	10781592	6714;4133	Src;MAP2c	***Src*** ***bound*** primarily the soluble , non-microtubule-associated ***MAP2c*** in vitro .	parallel	1
13913	10781592	5594;4133	extracellular signal-regulated kinase 2;MAP2c	This specific MAP2/SH3 domain interaction was inhibited by ***phosphorylation*** of ***MAP2c*** by the mitogen-activated protein kinase ***extracellular signal-regulated kinase 2*** but not by protein kinase A.	target	1
13914	10781592	4133;4437	MAP2c;MAP2/SH3	This specific ***MAP2/SH3*** domain interaction was ***inhibited*** by phosphorylation of ***MAP2c*** by the mitogen-activated protein kinase extracellular signal-regulated kinase 2 but not by protein kinase A.	negative	1
13915	10781600	8802;5598	Galpha;ERK5	Using this system , as well as the expression of activated forms of G protein subunits , we show that the Galpha ( q ) and ***Galpha*** ( 12/13 ) families of heterotrimeric G proteins , but not the Galpha ( i ) , Galpha ( s ) , and betagamma subunits , are able to ***regulate*** ***ERK5*** .	target	1
13916	10781613	55872;5594	TOPK;p38	Gel precipitation study indicated that ***TOPK*** protein can be ***associated*** with ***p38*** in vitro .	parallel	0
13917	10781614	4790;3569	NF-kappa B;interleukin-6	p38 MAPK and ***NF-kappa B*** collaborate to ***induce*** ***interleukin-6*** gene expression and release .	target	1
13918	10781614	5594;3569	p38;interleukin-6	***p38*** MAPK and NF-kappa B collaborate to ***induce*** ***interleukin-6*** gene expression and release .	target	1
13919	10781614	5608;4790	MKK6;NF-kappaB	In cardiac myocytes , the stimulation of p38 MAPK by the MAPKK , ***MKK6*** , ***activates*** the transcription factor , ***NF-kappaB*** , and protects cells from apoptosis .	positive	1
13920	10781614	3569;4790	IL-6;NF-kappaB	Like ***IL-6*** , TNF-alpha , which ***activates*** both ***NF-kappaB*** and p38 , also induced p38-dependent IL-6 expression and release and protected myocytes from apoptotis .	positive	1
13921	10781614	3569;5594	IL-6;p38	Like ***IL-6*** , TNF-alpha , which ***activates*** both NF-kappaB and ***p38*** , also induced p38-dependent IL-6 expression and release and protected myocytes from apoptotis .	positive	1
13922	10781614	3569;6774	IL-6;STAT3	While TNF-alpha was relatively ineffective , ***IL-6*** ***activated*** myocardial cell ***STAT3*** by about 8-fold , indicating a probable role for this transcription factor in IL-6-mediated protection from apoptosis .	positive	1
13923	10781614	6885;4790	Tak1;NF-kappaB	TNF-alpha-mediated IL-6 induction was inhibited by a kinase-inactive form of the MAPKKK , TGF-beta activated protein kinase ( ***Tak1*** ) , which is known to ***activate*** p38 and ***NF-kappaB*** in other cell types .	positive	1
13924	10781614	6885;5594	Tak1;p38	TNF-alpha-mediated IL-6 induction was inhibited by a kinase-inactive form of the MAPKKK , TGF-beta activated protein kinase ( ***Tak1*** ) , which is known to ***activate*** ***p38*** and NF-kappaB in other cell types .	positive	1
13925	10781614	7040;4790	TGF-beta;NF-kappaB	TNF-alpha-mediated IL-6 induction was inhibited by a kinase-inactive form of the MAPKKK , ***TGF-beta*** activated protein kinase ( Tak1 ) , which is known to ***activate*** p38 and ***NF-kappaB*** in other cell types .	positive	1
13926	10781614	7040;5594	TGF-beta;p38	TNF-alpha-mediated IL-6 induction was inhibited by a kinase-inactive form of the MAPKKK , ***TGF-beta*** activated protein kinase ( Tak1 ) , which is known to ***activate*** ***p38*** and NF-kappaB in other cell types .	positive	1
13927	10781614	6885;7040	Tak1;TGF-beta	TNF-alpha-mediated IL-6 induction was ***inhibited*** by a kinase-inactive form of the MAPKKK , ***TGF-beta*** activated protein kinase ( ***Tak1*** ) , which is known to activate p38 and NF-kappaB in other cell types .	negative	1
13928	10781614	7040;6885	TGF-beta;Tak1	TNF-alpha-mediated IL-6 induction was ***inhibited*** by a kinase-inactive form of the MAPKKK , ***TGF-beta*** activated protein kinase ( ***Tak1*** ) , which is known to activate p38 and NF-kappaB in other cell types .	negative	1
13929	10781615	8538;1386	Barx2;ATF2	In GST pull-down experiments , ***Barx2*** ***bound*** to proteins of the CREB family , CREB1 and ***ATF2*** .	parallel	1
13930	10781615	8538;1385	Barx2;CREB1	In GST pull-down experiments , ***Barx2*** ***bound*** to proteins of the CREB family , ***CREB1*** and ATF2 .	parallel	1
13931	10781616	754;9232	PBF;PTTG	Glutathione S-transferase pull-down and co-immunoprecipitation assays demonstrate that ***PBF*** ***interacts*** specifically with ***PTTG*** under both in vitro and in vivo conditions .	parallel	1
13932	10781616	9232;754	PTTG;PBF	The ***interaction*** between ***PBF*** and ***PTTG*** facilitated PTTG translocation from the cytoplasm to the nucleus .	parallel	1
13933	10781757	338;1636	apolipoprotein B;ACE	The ***association*** between angiotensin-converting enzyme ( ***ACE*** ) as well as ***apolipoprotein B*** polymorphisms and dyslipidemia and coronary artery disease ( CAD ) is controversial .	parallel	0
13934	10781804	4208;429	Myocyte enhancer factor 2C;MASH-1	***Myocyte enhancer factor 2C*** ***upregulates*** ***MASH-1*** expression and induces neurogenesis in P19 cells .	positive	1
13935	10781804	4208;429	MEF2C;MASH-1	Our results indicate that ***MEF2C*** can directly or indirectly ***activate*** the expression of ***MASH-1*** , leading to neurogenesis .	positive	1
13936	10781812	4193;7157	Mdm2;p53	Biochemical characterisation of the ***interaction*** of ***Mdm2*** protein with ***p53*** protein has demonstrated that full-length Mdm2 does not bind stably to p53-DNA complexes , contrasting with C-terminal truncations of Mdm2 which do bind stably to p53-DNA complexes .	parallel	1
13937	10781812	4193;7157	Mdm2;p53	We investigated whether there was a second docking site on p53 for Mdm2 protein by examining the ***interaction*** of full-length ***Mdm2*** with ***p53*** lacking the BOX-I domain .	parallel	1
13938	10781812	4193;7157	Mdm2;p53	Although ***Mdm2*** protein did ***bind*** very weakly to ***p53*** protein lacking the BOX-I domain , addition of RNA activated Mdm2 protein binding to this truncated form of p53 .	parallel	1
13939	10781812	4193;7157	Mdm2;p53	Although Mdm2 protein did bind very weakly to p53 protein lacking the BOX-I domain , addition of RNA activated ***Mdm2*** protein ***binding*** to this truncated form of ***p53*** .	parallel	1
13940	10781817	6714;8506	c-Src;p190	***Phosphorylation*** of the ***p190*** RhoGAP N-terminal domain by ***c-Src*** results in a loss of GTP binding activity .	target	1
13941	10781817	6714;392	c-Src;RhoGAP	***Phosphorylation*** of the p190 ***RhoGAP*** N-terminal domain by ***c-Src*** results in a loss of GTP binding activity .	target	1
13942	10781837	23636;4790	p62;NF-kappaB	Over-expression of ***p62*** ( aa 336-522 ) induces NF-kappaB activation in resting cells and ***augments*** CD40-induced ***NF-kappaB*** activation , but has no effect on control STAT1 reporter activity , either at baseline or after IFN-gamma induction .	positive	0
13943	10781837	23636;4790	p62;NF-kappaB	Over-expression of ***p62*** ( aa 336-522 ) ***induces*** ***NF-kappaB*** activation in resting cells and augments CD40-induced NF-kappaB activation , but has no effect on control STAT1 reporter activity , either at baseline or after IFN-gamma induction .	target	1
13944	10781837	7187;23636	TRAF-3;p62	The finding that ***TRAF-3*** ***binds*** ***p62*** , suggests that TRAF-3 may serve as an adapter molecule at the nuclear membrane , in addition to its known adapter function at the plasma membrane .	parallel	1
13945	10781837	23636;7187	p62;TRAF-3	The ***interaction*** of ***p62*** with ***TRAF-3*** was specific , since p62 failed to interact with TRAF-2 , -4 , -5 , or -6 .	parallel	1
13946	10781838	7535;3932	ZAP-70;Lck	Furthermore , a close functional ***interplay*** between ***Lck*** and ***ZAP-70*** in intracellular signaling has been shown to occur in thymocytes .	parallel	1
13947	10781884	351;3028	Abeta;ERAB	The precise mechanism of cell death induction is unknown , however , Abeta inhibits ERAB activities and as a result of ******ERAB-Abeta****** ***interactions*** , enhanced formation of lipid peroxidation products occur .	parallel	1
13948	10781884	351;3028	Abeta;ERAB	The precise mechanism of cell death induction is unknown , however , ***Abeta*** ***inhibits*** ***ERAB*** activities and as a result of ERAB-Abeta interactions , enhanced formation of lipid peroxidation products occur .	negative	1
13949	10781932	4790;5966	p50;c-Rel	In WEHI-231 cells , anti-immunoglobulin ( anti-Ig ) treatment leads to both a decrease in the DNA-binding activity of ******p50/c-Rel/p53****** protein ***complexes*** and a transient enhancement in the DNA-binding activity of p50 homodimeric complexes .	parallel	1
13950	10781932	7157;5966	p53;c-Rel	In WEHI-231 cells , anti-immunoglobulin ( anti-Ig ) treatment leads to both a decrease in the DNA-binding activity of ******p50/c-Rel/p53****** protein ***complexes*** and a transient enhancement in the DNA-binding activity of p50 homodimeric complexes .	parallel	1
13951	10781932	7157;4790	p53;p50	In WEHI-231 cells , anti-immunoglobulin ( anti-Ig ) treatment leads to both a decrease in the DNA-binding activity of ******p50/c-Rel/p53****** protein ***complexes*** and a transient enhancement in the DNA-binding activity of p50 homodimeric complexes .	parallel	1
13952	10781941	4092;7040	Smad7;TGF-beta	We also demonstrated that Smad7 mRNA levels were rapidly and potently induced upon TGF-beta1 stimulation of lungs in culture , suggesting that ***Smad7*** ***regulates*** ***TGF-beta*** responses in a negative feedback loop .	target	1
13953	10781941	7040;4087	TGF-beta;Smad2	Smad7 was recently shown to antagonize ***TGF-beta-induced*** ***activation*** of signal-transducing ***Smad2*** and Smad3 proteins .	positive	1
13954	10781941	7040;4088	TGF-beta;Smad3	Smad7 was recently shown to antagonize ***TGF-beta-induced*** ***activation*** of signal-transducing Smad2 and ***Smad3*** proteins .	positive	1
13955	10781941	4092;4087	Smad7;Smad2	***Smad7*** was recently shown to ***antagonize*** TGF-beta-induced activation of signal-transducing ***Smad2*** and Smad3 proteins .	negative	1
13956	10781941	4092;7040	Smad7;TGF-beta	By immunocytochemistry , Smad7 protein was co-localized with both Smad2 and Smad3 in distal bronchial epithelial cells , supporting the concept that ***Smad7*** ***inhibits*** ***TGF-beta*** signaling by competing locally with Smad2 and Smad3 for TGF-beta receptor complex binding during lung morphogenesis .	negative	1
13957	10781942	1499;999	beta-catenin;E-cadherin	Our results suggest that Calpha is required for stabilization of ******E-cadherin/beta-catenin****** ***complexes*** at the plasma membrane .	parallel	1
13958	10781959	7471;1499	Wnt-1;beta-catenin	Upon ***Wnt-1/Wg*** signaling their members ***interact*** with ***beta-catenin*** and regulate the expression of Xenopus target genes siamois , twin , nodal related-3 or fibronectin .	parallel	1
13959	10782211	5310;7249	polycystic kidney disease 1;TSC2	There is close ***linkage*** between canine ***TSC2*** and the ***polycystic kidney disease 1*** gene ( PKD1 ) , as has been observed in humans and other mammalian species .	parallel	0
13960	10782669	1394;1392	CRHR1;corticotropin-releasing hormone	A series of fluoro-substituted 4 - ( dialkylamino ) pyrrolo [ 2,3-d ] pyrimidines was synthesized and their binding affinity for ***corticotropin-releasing hormone*** type 1 ***receptor*** ( ***CRHR1*** ) was investigated .	parallel	1
13961	10782807	1471;1508	cystatin C;Cathepsin B	***Cathepsin B*** and its endogenous ***inhibitor*** ***cystatin C*** in rheumatoid arthritis synovium .	negative	1
13962	10782807	1471;1508	cystatin C;Cathepsin B	OBJECTIVE : To compare the expression of ***Cathepsin B*** and its endogenous ***inhibitor*** ***cystatin C*** in synovial tissue of patients with rheumatoid arthritis ( RA ) and to determine the cell type expressing cystatin C .	negative	1
13963	10782811	4314;1401	MMP-3;CRP	RESULTS : ***MMP-3*** levels were significantly ***correlated*** with C-reactive protein ( ***CRP*** ) and interleukin 6 serum levels as well as with the disease activity score ( DAS ) , not only at start in untreated patients but also during the 12 month followup period in both treated groups .	parallel	0
13964	10782840	632;1401	Osteocalcin;C-reactive protein	In contrast , ***Osteocalcin*** levels were negatively ***correlated*** with ***C-reactive protein*** levels , both before and during treatment .	negative	0
13965	10782865	356;355	FasL;Fas	Also , ******Fas/FasL****** ***interactions*** may play an important role in the successful chemotherapy of FasL-bearing tumor .	parallel	1
13966	10782880	7157;1026	p53;p21	A highly significant ***association*** between ***p53*** accumulation and downregulation of ***p21*** ( WAF1/CIP1 ) was seen .	parallel	0
13967	10783130	3596;1437	IL-13;granulocyte macrophage colony-stimulating factor	Molecular ***regulation*** of ***granulocyte macrophage colony-stimulating factor*** in human lung epithelial cells by interleukin ( IL ) -1 beta , IL-4 , and ***IL-13*** involves both transcriptional and post-transcriptional mechanisms .	target	1
13968	10783130	3565;1437	IL-4;granulocyte macrophage colony-stimulating factor	Molecular ***regulation*** of ***granulocyte macrophage colony-stimulating factor*** in human lung epithelial cells by interleukin ( IL ) -1 beta , ***IL-4*** , and IL-13 involves both transcriptional and post-transcriptional mechanisms .	target	1
13969	10783130	3596;1437	IL-13;GM-CSF	IL-4 and ***IL-13*** both ***inhibited*** expression of ***GM-CSF*** mRNA and protein by 2 h after stimulation .	negative	1
13970	10783130	3565;1437	IL-4;GM-CSF	***IL-4*** and IL-13 both ***inhibited*** expression of ***GM-CSF*** mRNA and protein by 2 h after stimulation .	negative	1
13971	10783136	7124;5743	TNF-alpha;cyclooxygenase 2	We have also observed that the ability of ***TNF-alpha*** to induce PGE ( 2 ) was impaired in FF and was ***related*** to a reduced expression of ***cyclooxygenase 2*** .	parallel	0
13972	10783136	7124;4312	TNF-alpha;matrix metalloproteinase 1	Interestingly , unlike NF , ***TNF-alpha*** failed to ***increase*** ***matrix metalloproteinase 1*** levels in FF and did not cause any growth inhibition in these cells .	positive	0
13973	10783164	4176;55388	Mcm7;Mcm10	Furthermore , diminished ***interaction*** between ***Mcm10*** and ***Mcm7*** , a subunit of the MCM2-7 complex , by a mutation in either Mcm10 or Mcm7 inhibits replication initiation .	parallel	1
13974	10783164	4176;55388	Mcm7;Mcm10	Surprisingly , a double mutant containing both the Mcm10-1 and Mcm7-1 ( cdc47-1 ) alleles restores ***interaction*** between ***Mcm10*** and ***Mcm7*** and corrects all of the defects exhibited by each of the single mutants , including the stalling of replication forks at replication origins typically seen in Mcm10-1 cells .	parallel	1
13975	10783164	4176;55388	Mcm7;Mcm10	These results suggest that Mcm10 , like Mcm7 , is a critical component of the prereplication chromatin and that ***interaction*** between ***Mcm10*** and ***Mcm7*** is required for proper replication initiation and prompt release of origin-bound factors .	parallel	1
13976	10783165	4361;4683	MRE11;NBS1	This complex includes tumor suppressors and DNA damage repair proteins MSH2 , MSH6 , MLH1 , ATM , BLM , and the ******RAD50-MRE11-NBS1****** protein ***complex*** .	parallel	1
13977	10783165	4361;10111	MRE11;RAD50	This complex includes tumor suppressors and DNA damage repair proteins MSH2 , MSH6 , MLH1 , ATM , BLM , and the ******RAD50-MRE11-NBS1****** protein ***complex*** .	parallel	1
13978	10783165	4683;10111	NBS1;RAD50	This complex includes tumor suppressors and DNA damage repair proteins MSH2 , MSH6 , MLH1 , ATM , BLM , and the ******RAD50-MRE11-NBS1****** protein ***complex*** .	parallel	1
13979	10783165	4361;4683	MRE11;NBS1	We find that BRCA1 , the BLM helicase , and the ******RAD50-MRE11-NBS1****** ***complex*** colocalize to large nuclear foci that contain PCNA when cells are treated with agents that interfere with DNA synthesis .	parallel	1
13980	10783165	4361;10111	MRE11;RAD50	We find that BRCA1 , the BLM helicase , and the ******RAD50-MRE11-NBS1****** ***complex*** colocalize to large nuclear foci that contain PCNA when cells are treated with agents that interfere with DNA synthesis .	parallel	1
13981	10783165	4683;10111	NBS1;RAD50	We find that BRCA1 , the BLM helicase , and the ******RAD50-MRE11-NBS1****** ***complex*** colocalize to large nuclear foci that contain PCNA when cells are treated with agents that interfere with DNA synthesis .	parallel	1
13982	10783165	672;4436	BRCA1;MSH2	The ***association*** of ***BRCA1*** with ***MSH2*** and MSH6 , which are required for transcription-coupled repair , provides a possible explanation for the role of BRCA1 in this pathway .	parallel	0
13983	10783165	672;2956	BRCA1;MSH6	The ***association*** of ***BRCA1*** with MSH2 and ***MSH6*** , which are required for transcription-coupled repair , provides a possible explanation for the role of BRCA1 in this pathway .	parallel	0
13984	10783238	5663;351	PS1;Abeta	These data indicate that ***PS1*** may differentially ***facilitate*** gamma-secretase-mediated generation of ***Abeta*** and endoproteolysis of Notch .	positive	0
13985	10783306	5966;4790	Rel;NF-kappaB	In S-D rats , increased ******NF-kappaB/Rel****** ***binding*** was detected in nuclear extracts of mammary glands from 40 % of animals 3 weeks post-treatment with 15 mg/kg 7,12-dimethylbenz [ a ] anthracene ( DMBA ) ; this is prior to formation of tumors which normally begin to be detected after 7-9 weeks .	parallel	1
13986	10783318	3458;5743	Interferon gamma;COX-2	***Interferon gamma*** ***suppressed*** this ***COX-2*** promoter activity , while 12-O-tetradecanoylphorbol-13-acetate and transforming growth factor alpha ( TGFalpha ) exerted enhancing effects .	negative	1
13987	10783385	3309;1636	BiP;ACE	Overexpression of ***BiP*** ***inhibited*** ***ACE*** secretion , an effect accentuated by the expression of an enzymatically inactive mutant BiP .	negative	1
13988	10783389	10874;10316	neuromedin U;FM-3	In this paper , we demonstrate that ***neuromedin U*** is the cognate ***ligand*** for the orphan G protein-coupled receptor , ***FM-3*** , isolated originally as a homologue of neurotensin and growth hormone secretogogue receptors .	parallel	1
13989	10783838	3557;3553	IL-1ra;IL-1beta	AIMS : GCF levels of the cytokine ***IL-1beta*** and its ***receptor*** antagonist ***IL-1ra*** were analyzed with respect to smoking in patients with moderate to severe periodontal disease .	parallel	1
13990	10783893	5581;4790	protein kinase C-epsilon;NF-kappaB	Endogenous NAK is activated by phorbol ester tumour promoters and growth factors , whereas catalytically inactive NAK specifically inhibits ***activation*** of ***NF-kappaB*** by ***protein kinase C-epsilon*** ( PKCepsilon ) .	positive	1
13991	10783894	4303;1027	AFX;p27kip1	Indeed , ***AFX*** transcriptionally ***activates*** ***p27kip1*** , resulting in increased protein levels .	positive	1
13992	10784360	183;2056	angiotensin II;erythropoietin	Current evidence suggests that ***angiotensin II*** may be involved in the ***regulation*** of renal ***erythropoietin*** ( EPO ) production .	target	1
13993	10784377	4353;4018	myeloperoxidase;lipoprotein	We conclude that ***myeloperoxidase*** , which has been detected in atherosclerotic lesions , is able to ***modify*** low-density ***lipoprotein*** into the form which is taken up by macrophages in an uncontrolled manner .	target	0
13994	10784377	4353;4018	myeloperoxidase;lipoprotein	In summary , low-density ***lipoprotein*** modification is ***affected*** by the ***myeloperoxidase/hydrogen*** peroxide/chloride system in a similar manner to hypochlorous acid production .	target	0
13995	10784405	4914;4803	TrkA;NGF	We have recently reported that retinoic acid ( RA ) induced the expression of ***TrkA*** , the high affinity ***receptor*** for nerve growth factor ( ***NGF*** ) , in human myeloid leukemia KG-1 cells .	parallel	1
13996	10784412	820;5741	cAMP;PTH	A novel Van91 I polymorphism in the 1st intron of the parathyroid hormone ( PTH ) / PTH-related peptide ( PTHrP ) receptor gene and its effect on the urinary ***cAMP*** ***response*** to ***PTH*** .	parallel	0
13997	10784586	3600;3824	interleukin 15;CD94	Furthermore , expression of ***CD94*** could be selectively ***induced*** in vitro by T-cell receptor activation and/or ***interleukin 15*** , a cytokine produced by intestinal epithelial cells .	target	1
13998	10784592	2641;1843	Glucagon;MKP-1	***MKP-1*** ***induction*** by ***Glucagon*** was sensitive to inhibition of adenylate cyclase and protein kinase A.	target	1
13999	10784592	1843;2641	MKP-1;Glucagon	CONCLUSIONS : The ***MKP-1*** ***response*** to ***Glucagon*** produces an additional level of interaction with MAP kinase-dependent processes , which may contribute to the regulation of liver function by Glucagon or other cAMP-elevating agents .	parallel	0
14000	10784614	9547;2736	KS1;THP-1	***KS1*** ***bound*** specifically to B cells and macrophages , as well as two B cell lines , CESS and A20 , and a monocyte line , ***THP-1*** .	parallel	1
14001	10785355	6416;3725	Mitogen-activated protein kinase kinase 4;c-Jun	The ***Mitogen-activated protein kinase kinase 4*** ( MKK4 ) , a member of the MAP kinase kinase family , directly ***phosphorylates*** and activates the ***c-Jun*** NH2-terminal kinases ( JNK ) , in response to cellular stresses and proinflammatory cytokines .	target	1
14002	10785355	6416;5599	Mitogen-activated protein kinase kinase 4;JNK	The ***Mitogen-activated protein kinase kinase 4*** ( MKK4 ) , a member of the MAP kinase kinase family , directly ***phosphorylates*** and activates the c-Jun NH2-terminal kinases ( ***JNK*** ) , in response to cellular stresses and proinflammatory cytokines .	target	1
14003	10785360	1977;1978	eIF4E;4E-BP1	Moreover , the data show a significant dephosphorylation of 4E-BP1 in gastrointestinal tumours that correlated with an increase in the ***association*** of ***4E-BP1*** and ***eIF4E*** indicating a lower availability to eIF4E to recruit to the ribosomes .	parallel	0
14004	10785399	5592;8654	PKG;PDE5	The mechanism by which ***phosphorylation*** of ***PDE5*** by ***PKG*** could be involved in physiological negative-feedback regulation of cGMP levels is discussed .	target	1
14005	10785400	3439;3569	IFNalpha;IL-6	Interferon alpha ( IFNalpha ) by itself does not induce expression of IL-6 ; nonetheless , ***IFNalpha*** pretreatment dramatically ***enhances*** ***IL-6*** induction by dsRNA but not by IL-1beta .	positive	0
14006	10785400	3439;3569	IFNalpha;IL-6	These studies demonstrate that major differences exist in the induction of IL-6 at both the mRNA and protein levels by dsRNA compared to cytokines and that ***IFNalpha*** pretreatment selectively ***enhances*** ***IL-6*** induction by dsRNA but not by IL-1beta .	positive	0
14007	10785873	4023;4018	lipoprotein lipase;lipoprotein	Circulating ***lipoprotein*** profiles are ***modulated*** differently by ***lipoprotein lipase*** in obese humans .	target	0
14008	10785873	4023;4018	LpL;lipoprotein	In contrast , in some other studies ***LpL*** activity was positively ***correlated*** with plasma low-density ***lipoprotein*** ( LDL ) cholesterol concentrations .	positive	0
14009	10785873	3990;4018	hepatic lipase;lipoprotein	Moreover , in non-obese individuals , LpL activity correlated directly ( r = 0.40 ) and ***hepatic lipase*** activity ***correlated*** inversely ( r = -0.32 ) with high-density ***lipoprotein*** ( HDL ) cholesterol concentrations .	negative	0
14010	10786649	3815;4254	KIT;stem cell factor	***stem cell factor*** ( SCF ) and its ***receptor*** ***KIT*** play an important role in various biologic phases , such as hematopoiesis , reproduction , and regeneration .	parallel	1
14011	10786649	4254;3815	SCF;KIT	Although the significance of ***interaction*** of soluble ***SCF*** with soluble ***KIT*** has not yet been elucidated , in certain diseases proteins fluctuate in human sera .	parallel	1
14012	10786657	4352;7066	Mpl;thrombopoietin	In keeping with this function , megakaryocytes , platelets , and their precursors all express the ***thrombopoietin*** ***receptor*** , ***Mpl*** , on their cell surface .	parallel	1
14013	10786670	4193;7157	mdm2;p53	Recently , we demonstrated that the balance of the ******p53-mdm2****** ***interactions*** is disrupted in ICGTs .	parallel	1
14014	10786670	4193;7157	mdm2;p53	The p14ARF product , a tumor suppresser gene located on the INK4a/ARF locus , acts as one of the major factors affecting ******p53-mdm2****** ***interactions*** via its binding to mdm2 and the stimulation of mdm2 degradation .	parallel	1
14015	10786798	4790;7157	NF-kappaB;p53	Here we show that induction of p53 causes an activation of ***NF-kappaB*** that ***correlates*** with the ability of ***p53*** to induce apoptosis .	parallel	0
14016	10786798	7157;4790	p53;NF-kappaB	***Activation*** of ***NF-kappaB*** by ***p53*** was distinct from that mediated by tumour-necrosis factor-alpha and involved MEK1 and the activation of pp90rsk .	positive	1
14017	10786798	7157;4790	p53;NF-kappaB	Inhibition of MEK1 blocked ***activation*** of ***NF-kappaB*** by ***p53*** and completely abrogated p53-induced cell death .	positive	1
14018	10786798	5604;4790	MEK1;NF-kappaB	Inhibition of ***MEK1*** ***blocked*** activation of ***NF-kappaB*** by p53 and completely abrogated p53-induced cell death .	positive	0
14019	10786799	7518;7157	DNA-repair protein XRCC4;p53	***Interplay*** of ***p53*** and ***DNA-repair protein XRCC4*** in tumorigenesis , genomic stability and development .	parallel	1
14020	10786821	51083;5617	galanin;prolactin	Recent evidence suggests that ***galanin*** may ***regulate*** ***prolactin*** ( PRL ) secretion during lactation .	target	1
14021	10786835	3320;3308	Hsp90;Hsp70	The adaptor protein Hop mediates the ***association*** of the molecular chaperones ***Hsp70*** and ***Hsp90*** .	parallel	0
14022	10786835	10963;3308	Hop;Hsp70	The adaptor protein ***Hop*** ***mediates*** the association of the molecular chaperones ***Hsp70*** and Hsp90 .	target	0
14023	10786835	10963;3320	Hop;Hsp90	The adaptor protein ***Hop*** ***mediates*** the association of the molecular chaperones Hsp70 and ***Hsp90*** .	target	0
14024	10786835	3320;3308	Hsp90;Hsp70	These results explain how TPR domains participate in the ordered assembly of ******Hsp70-Hsp90****** multichaperone ***complexes*** .	parallel	1
14025	10786999	7852;6387	CXCR4;stromal cell derived factor-1	***CXCR4*** , the ***receptor*** of ***stromal cell derived factor-1*** ( SDF-1 ) and co-receptor for syncytium inducing HIVs , was comparably expressed in infected and uninfected astrocytic cells , whereas CCR5 was not detected in either cell line .	parallel	1
14026	10787174	8029;4018	Cubilin;lipoprotein	***Cubilin*** , a high-density ***lipoprotein*** ***receptor*** .	parallel	1
14027	10787416	3786;56479	KCNQ3;KCNQ5	This functional ***interaction*** between ***KCNQ5*** and ***KCNQ3*** , a component of the M-channel , suggests that KCNQ5 may contribute to a diversity of heteromeric channels underlying native neuronal M-currents .	parallel	1
14028	10787423	7157;5524	p53;PTPA	Thus , ***PTPA*** expression is negatively ***regulated*** by ***p53*** in normal conditions and in conditions where p53 is up-regulated , via an as yet unknown mechanism involving the negative control of YY1 .	negative	1
14029	10787423	7157;5524	p53;PTPA	Luciferase reporter assays in Saos-2 cells revealed that ***p53*** could ***down-regulate*** ***PTPA*** promoter activity in a dose-dependent manner , whereas four different p53 mutants could not .	negative	1
14030	10787423	7157;5524	p53;PTPA	***Inhibition*** of ***PTPA*** expression by endogenous ***p53*** was demonstrated in UVB-irradiated HepG2 cells , both on the mRNA and protein level .	negative	1
14031	10787423	7157;5524	p53;PTPA	Also basal PTPA levels are higher in p53-negative ( Saos-2 ) versus p53-positive ( HepG2 , U2OS ) cells , suggesting " latent " ***p53*** can ***control*** ***PTPA*** expression as well .	target	0
14032	10787429	3565;948	IL-4;CD36	***Induction*** of ***CD36*** expression by oxidized LDL and ***IL-4*** by a common signaling pathway dependent on protein kinase C and PPAR-gamma .	target	1
14033	10787429	948;4018	CD36;lipoprotein	***CD36*** , a class B scavenger receptor , is a macrophage ***receptor*** for oxidized low density ***lipoprotein*** ( OxLDL ) and may play a critical role in atherosclerotic foam cell formation .	parallel	1
14034	10787429	3565;948	interleukin-4;CD36	We have previously demonstrated that OxLDL , macrophage-colony stimulating factor ( M-CSF ) , and ***interleukin-4*** ( IL-4 ) ***enhanced*** expression of ***CD36*** .	positive	0
14035	10787429	1435;948	M-CSF;CD36	We have previously demonstrated that OxLDL , macrophage-colony stimulating factor ( ***M-CSF*** ) , and interleukin-4 ( IL-4 ) ***enhanced*** expression of ***CD36*** .	positive	0
14036	10787429	3565;948	IL-4;CD36	PKC inhibitors reduced basal expression of CD36 and blocked ***induction*** of ***CD36*** mRNA by 15d-PGJ ( 2 ) , OxLDL and ***IL-4*** .	target	1
14037	10787436	335;3931	apolipoprotein (apo) A-I;lecithin:cholesterol acyltransferase	In order to test the hypothesis that fish-eye disease ( FED ) is due to a deficient ***activation*** of ***lecithin:cholesterol acyltransferase*** ( LCAT ) by its co-factor ***apolipoprotein (apo) A-I*** , we overexpressed the natural mutants T123I , N131D , N391S , and other engineered mutants in Cos-1 cells .	positive	1
14038	10788429	9934;7124	P2Y receptor;tumor necrosis factor alpha	***P2Y receptor-mediated*** ***inhibition*** of ***tumor necrosis factor alpha*** - stimulated stress-activated protein kinase activity in EAhy926 endothelial cells .	negative	1
14039	10788439	7341;3725	SUMO-1;c-Jun	***c-Jun*** and p53 activity is ***modulated*** by ***SUMO-1*** modification .	target	0
14040	10788439	7341;7157	SUMO-1;p53	c-Jun and ***p53*** activity is ***modulated*** by ***SUMO-1*** modification .	target	0
14041	10788439	7341;4792	SUMO-1;IkappaBalpha	***SUMO-1*** modification was found to ***antagonize*** ***IkappaBalpha*** ubiquitination and protect it from degradation .	negative	1
14042	10788439	7341;7157	SUMO-1;p53	As with c-Jun , ***SUMO-1*** ***modification*** of ***p53*** is abrogated by phosphorylation but remains unaltered upon chemical damage to DNA or Mdm2-mediated ubiquitination .	target	0
14043	10788441	26160;8022	SLB;Lhx3	In this report we describe a novel gene product , ***SLB*** , that selectively ***interacts*** with ***Lhx3*** and the closely related LIM factor , Lhx4 .	parallel	1
14044	10788441	26160;89884	SLB;Lhx4	In this report we describe a novel gene product , ***SLB*** , that selectively ***interacts*** with Lhx3 and the closely related LIM factor , ***Lhx4*** .	parallel	1
14045	10788441	26160;8022	SLB;Lhx3	We demonstrate that ***SLB*** specifically ***binds*** to ***Lhx3*** and Lhx4 with high affinity both in vitro and in vivo .	parallel	1
14046	10788441	26160;89884	SLB;Lhx4	We demonstrate that ***SLB*** specifically ***binds*** to Lhx3 and ***Lhx4*** with high affinity both in vitro and in vivo .	parallel	1
14047	10788442	3785;3786	KCNQ2;KCNQ3	A ***KCNQ2*** mutant associated with BFNC that has a truncated cytoplasmic carboxyl terminus did not reach the surface and failed to ***stimulate*** ***KCNQ3*** surface expression .	negative	0
14048	10788447	5294;3479	PI3K;IGF-1	The effect of ***IGF-1*** was ***blocked*** by the phosphatidylinositide 3-kinase ( ***PI3K*** ) inhibitors LY294002 ( 50 micrometer ) and wortmannin ( 0.5 micrometer ) , but not by the MEK inhibitor PD98059 ( 50 micrometer ) or the p70 S6 kinase pathway inhibitor rapamycin ( 50 nm ) , suggesting that the stimulation of Akt by IGF-1 is mediated by the PI3K pathway .	negative	0
14049	10788447	3479;3667	IGF-1;insulin receptor substrate-1	PMA also decreased ***IGF-1-induced*** tyrosine ***phosphorylation*** of ***insulin receptor substrate-1*** and its association with PI3K .	target	1
14050	10788461	6813;6809	Munc18-2;syntaxin 3	***Munc18-2*** is a Sec1 homologue enriched in epithelial cells and forms a ***complex*** with ***syntaxin 3*** , a t-SNARE localized to the apical plasma membrane .	parallel	1
14051	10788464	2149;2150	PAR1;PAR2	From these observations we conclude that 1 ) PAR1 is the predominant thrombin receptor expressed in HUVEC and cleavage of PAR1 is required for endothelial cell responses to thrombin ; 2 ) although PAR3 may be expressed , there is still no evidence that it mediates thrombin responses ; 3 ) PAR4 is not expressed on HUVEC ; and 4 ) ***transactivation*** of ***PAR2*** by cleaved ***PAR1*** can contribute to endothelial cell responses to thrombin , particularly when signaling through PAR1 is blocked .	positive	1
14052	10788464	2149;2150	PAR1;PAR2	Since peptides mimicking the PAR1 tethered ligand domain can also activate PAR2 , we asked whether the remaining thrombin response in the presence of the antagonist could be due in part to the intermolecular ***transactivation*** of ***PAR2*** by cleaved ***PAR1*** .	positive	1
14053	10788465	5468;23054	PPARgamma;PRIP	Deletion of the last 12 amino acids from the carboxyl terminus of PPARgamma resulted in the abolition of the ***interaction*** between ***PRIP*** and ***PPARgamma*** .	parallel	1
14054	10788465	23054;5465	PRIP;PPARalpha	***PRIP*** also ***binds*** to ***PPARalpha*** , RARalpha , RXRalpha , ER , and TRbeta1 , and this binding is increased in the presence of specific ligands .	parallel	1
14055	10788465	23054;5914	PRIP;RARalpha	***PRIP*** also ***binds*** to PPARalpha , ***RARalpha*** , RXRalpha , ER , and TRbeta1 , and this binding is increased in the presence of specific ligands .	parallel	1
14056	10788465	23054;5468	PRIP;PPARgamma	***PRIP*** acts as a strong coactivator for PPARgamma in the yeast and also ***potentiates*** the transcriptional activities of ***PPARgamma*** and RXRalpha in mammalian cells .	positive	0
14057	10788465	23054;5468	PRIP;PPARgamma	***PRIP*** acts as a strong ***coactivator*** for ***PPARgamma*** in the yeast and also potentiates the transcriptional activities of PPARgamma and RXRalpha in mammalian cells .	positive	1
14058	10788491	53407;4905	Syntaxin 18;N-ethylmaleimide-sensitive factor	By using the yeast two-hybrid system , we have identified a novel member of the syntaxin family , ***Syntaxin 18*** , that ***binds*** to alpha-soluble ***N-ethylmaleimide-sensitive factor-attachment*** protein .	parallel	1
14059	10788495	8801;5291	Gbeta;PI3Kbeta	Accordingly , ***Gbeta*** ( 1 ) gamma ( 2-His ) , but not Gbeta ( 5 ) gamma ( 2-His ) , significantly ***stimulated*** the lipid kinase activity of ***PI3Kbeta*** in the presence or absence of tyrosine-phosphorylated peptides derived from the p85-binding domain of the platelet derived-growth factor receptor .	positive	0
14060	10788507	5781;2549	SHP2;Gab1	These results establish a role for Gab1 in the LPA-induced MAP kinase pathway and clearly demonstrate that ******Gab1-SHP2****** ***interaction*** is essential for ERK2 activation by LPA and EGF .	parallel	1
14061	10788507	5781;2549	SHP2;Grb2-associated binder-1	Requirement of ***SHP2*** ***binding*** to ***Grb2-associated binder-1*** for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor .	parallel	1
14062	10788507	2549;5781	Gab1;SHP2	Although the role of ******SHP2-Gab1****** ***interaction*** in cell signaling has not yet been characterized , SHP2 is known to mediate mitogen-activated protein ( MAP ) kinase activation induced by the epidermal growth factor ( EGF ) .	parallel	1
14063	10788507	2549;5594	Gab1;ERK2	Conversely , expression of the wild-type ***Gab1*** in HEK293 cells ***augmented*** the LPA receptor Edg2-mediated ***ERK2*** activation .	positive	0
14064	10788511	5594;4773	p38;NFATp	Here we show that ***p38*** MAPK phosphorylates in vitro and ***interacts*** in vivo with ***NFATp*** .	parallel	1
14065	10788511	5594;4773	p38;NFATp	In addition , the ***inhibition*** of the nuclear accumulation of ***NFATp*** by ***p38*** appears to be mediated through the activation of NFATp nuclear export and takes place in a Leptomycin B-sensitive fashion , suggesting the involvement of the exportin CRM1 in this process .	negative	1
14066	10788525	1778;27020	p22;gp65	Taken together , these data suggest that the formation of the ******gp65-p22****** ( phox ) ***heterodimer*** is relatively inefficient and that acquisition of heme by gp65 precedes and is required for its association with p22 ( phox ) , a process that requires neither the addition of N-linked oligosaccharides nor modification in the Golgi complex .	parallel	1
14067	10788617	26958;4232	Copg2;Peg1	Two mouse genes , Mit1/Lb9 and ***Copg2*** , ***linked*** to ***Peg1/Mest*** on mouse chromosome 6 , were identified to be imprinted maternally and paternally , respectively .	parallel	0
14068	10788628	3493;7133	IgA1;TNF-RII	Interestingly , ***IgA1*** protease specifically ***cleaved*** the TNF receptor II ( ***TNF-RII*** ) on the surface of intact cells whereas TNF-RI was not affected by the enzyme .	target	1
14069	10788628	3493;7133	IgA1;TNF-RII	Therefore , inhibition of TNFalpha-mediated apoptosis might be correlated to specific ***cleavage*** of the ***TNF-RII*** by neisserial ***IgA1*** protease .	target	1
14070	10788788	7422;2247	VEGF;FGF-2	In this study , the ***interactions*** between HCPSs of various molecular weights and heparin-binding growth factors , ***VEGF*** ( 165 ) , ***FGF-2*** , and HGF , were compared to the interactions of the same factors with native heparin , periodate-oxidized heparin ( IO ( 4 ) - heparin ) and periodate-oxidized alkaline-degraded heparin ( IO ( 4 ) - LMW-heparin ) .	parallel	1
14071	10788799	3553;1026	IL-1;p21	***IL-1*** ***induces*** expression of ***p21*** ( WAF1 ) independently of p53 in high-passage human embryonic fibroblasts WI38 .	target	1
14072	10788799	3553;1026	IL-1;p21	These results suggest that the ***induction*** of ***p21*** ( WAF1 ) by ***IL-1*** occurs at the transcriptional level , but p53 function is not required in these cells .	target	1
14073	10788799	3553;1026	IL-1;p21	Thus , ***IL-1*** ***mediates*** ***p21*** ( WAF1 ) induction through a p53-independent pathway ( s ) in high-passage WI38 cells , but the cell cycle is regulated independently of p21 ( WAF1 ) .	target	0
14074	10788819	688;1019	basic transcription element-binding protein 2;cyclin-dependent kinase 4	***basic transcription element-binding protein 2*** expression was closely ***associated*** with human ***cyclin-dependent kinase 4*** expression in the neointima , although Sp1 was not .	parallel	0
14075	10789510	2028;920	gp160;CD4	TA-1L may thus also interfere with the ***gp160*** ***interaction*** with ***CD4*** , which has an antisense sequence to TA-1 .	parallel	1
14076	10789719	2247;7422	bFGF;VEGF	An ***association*** between high ***VEGF*** and ***bFGF*** expression and high angiogenic potential was detected , suggesting an important role for VEGF/bFGF in the angiogenesis of melanomas .	parallel	0
14077	10790150	6714;4915	Src;TrkB	Thus ***Src*** and ***TrkB*** ( the receptor for BDNF ) can physiologically ***interact*** to modulate synaptic GABAA receptors .	parallel	1
14078	10790340	1026;1017	p21;cdk2	METHODS AND RESULTS : The expression of p27 ( Kip1 ) and ***p21*** ( Cip1 ) in serum-stimulated VSMCs ***inactivated*** ***cdk2*** and cdk4 , leading to G ( 1 ) growth arrest .	negative	1
14079	10790340	1026;1019	p21;cdk4	METHODS AND RESULTS : The expression of p27 ( Kip1 ) and ***p21*** ( Cip1 ) in serum-stimulated VSMCs ***inactivated*** cdk2 and ***cdk4*** , leading to G ( 1 ) growth arrest .	negative	1
14080	10790340	5715;1017	p27;cdk2	METHODS AND RESULTS : The expression of ***p27*** ( Kip1 ) and p21 ( Cip1 ) in serum-stimulated VSMCs ***inactivated*** ***cdk2*** and cdk4 , leading to G ( 1 ) growth arrest .	negative	1
14081	10790340	5715;1019	p27;cdk4	METHODS AND RESULTS : The expression of ***p27*** ( Kip1 ) and p21 ( Cip1 ) in serum-stimulated VSMCs ***inactivated*** cdk2 and ***cdk4*** , leading to G ( 1 ) growth arrest .	negative	1
14082	10790368	159296;8174	NKX2.3;MAdCAM-1	We provide evidence that ***NKX2.3*** can ***activate*** ***MAdCAM-1*** transcription directly , suggesting that MAdCAM-1 is at least partly responsible for the migration and homing defects of lymphocytes and macrophages in mutants .	positive	1
14083	10790369	7082;2064	tight junction protein ZO-1;ErbB-2	The ***tight junction protein ZO-1*** and an interacting transcription factor ***regulate*** ***ErbB-2*** expression .	target	1
14084	10790372	3725;595	c-Jun;cyclin D1	Since JunB represses and ***c-Jun*** ***activates*** the ***cyclin D1*** promoter , these modifications of AP-1 activity during the M-G ( 1 ) transition could provide an impetus for G ( 1 ) progression by a temporal increase in cyclin D1 transcription .	positive	1
14085	10790428	5272;3553	PI-9;IL-1beta	Furthermore , ***PI-9*** antisense oligonucleotides coordinately reduced PI-9 expression and ***promoted*** ***IL-1beta*** release .	positive	0
14086	10790428	5272;3553	PI-9;IL-1beta	In human atherosclerotic lesions , however , ***PI-9*** expression ***correlated*** inversely with immunoreactive ***IL-1beta*** , supporting a potential role of the endogenous caspase-1 inhibitor in this chronic inflammatory disease .	negative	0
14087	10790588	3479;5972	IGF-1;renin	In the rat there is an important ***interaction*** between the ***renin-angiotensin*** system and ***IGF-1*** .	parallel	1
14088	10790588	183;3479	angiotensin II;IGF-1	***angiotensin II*** reduces circulating and skeletal muscle IGF-1 but ***increases*** ***IGF-1*** and the IGF-IR expression in cardiac muscle .	positive	0
14089	10790588	183;3479	angiotensin II;IGF-1	***angiotensin II*** ***reduces*** circulating and skeletal muscle ***IGF-1*** but increases IGF-1 and the IGF-IR expression in cardiac muscle .	negative	1
14090	10790590	4878;5972	ANP;renin	It is also by a urinary pathway via the macula densa that ***ANP*** , and its potentiation by NEP inhibition , ***decreases*** ***renin*** secretion .	negative	0
14091	10790762	4792;4790	IkappaBalpha;NF-kappaB	***NF-kappaB*** is ***activated*** by ***IkappaBalpha*** , its inhibitor , which is phosphorylated and proteolytically degraded .	positive	1
14092	10790862	5187;1119	hPER;hCKI	Whereas phosphorylated ***hPER*** I had a half-life of approximately 12 h , unphosphorylated hPER I remained stable in the cell for > 24 h. hPER I protein could also be ***co-immunoprecipitated*** with transfected hCKI epsilon as well as endogenous ***hCKI*** epsilon , indicating physical association between hPER I and hCKI epsilon proteins in vivo .	parallel	1
14093	10790891	4803;5054	NGF;PAI-1	Genistein , an inhibitor of tyrosine protein kinase , completely inhibited ***NGF*** ***induced*** ***PAI-1*** mRNA in the presence of 100 microM .	target	1
14094	10791951	5715;1017	p27;CDK2	Our data suggest that ***repression*** of ***CDK2*** activity by ***p27*** ( Kip1 ) is required for the PI3K-induced senescence , yet mouse embryo fibroblasts derived from p27 ( Kip1 - / - ) mice entered cell cycle arrest after treatment with LY294002 .	negative	1
14095	10791955	7187;26146	TRAF3;MIP-T3	The ******MIP-T3-TRAF3****** ***interaction*** requires the coiled-coil TRAF-N domain of TRAF3 .	parallel	1
14096	10791955	26146;7187	MIP-T3;TRAF3	MIP-T3 binds to Taxol-stabilized microtubules and to tubulin in vitro , and ***MIP-T3*** ***recruits*** ***TRAF3*** to microtubules when both proteins are overexpressed in HeLa cells .	target	0
14097	10791955	7187;26146	TRAF3;MIP-T3	In a 293 cell line stably expressing CD40 , TRAF3 is released from the ******TRAF3.MIP-T3****** ***complex*** and recruited to the CD40 receptor upon CD40 ligand stimulation .	parallel	1
14098	10791964	356;355	FasL;fas	Macrophages from mice with mutations in either fas or ***fas*** ***ligand*** ( ***FasL*** ) demonstrated substantial resistance to FC-induced apoptosis , and FC-induced death in wild-type macrophages was blocked by an anti-FasL antibody .	parallel	1
14099	10791974	835;2802	Caspase-2;golgin-160	***Caspase-2*** is localized at the Golgi complex and ***cleaves*** ***golgin-160*** during apoptosis .	target	1
14100	10791986	5747;9564	FAK;p130Cas	The ******FAK-p130Cas****** ***complex*** activates c-Jun NH2-terminal kinase ( JNK ) via a Ras/Rac1/Pak1 / MAPK kinase 4 ( MKK4 ) pathway .	parallel	1
14101	10791986	5747;3725	FAK;c-Jun	The ***FAK-p130Cas*** complex ***activates*** ***c-Jun*** NH2-terminal kinase ( JNK ) via a Ras/Rac1/Pak1 / MAPK kinase 4 ( MKK4 ) pathway .	positive	1
14102	10791986	5747;5599	FAK;JNK	The ***FAK-p130Cas*** complex ***activates*** c-Jun NH2-terminal kinase ( ***JNK*** ) via a Ras/Rac1/Pak1 / MAPK kinase 4 ( MKK4 ) pathway .	positive	1
14103	10791986	9564;3725	p130Cas;c-Jun	The ***FAK-p130Cas*** complex ***activates*** ***c-Jun*** NH2-terminal kinase ( JNK ) via a Ras/Rac1/Pak1 / MAPK kinase 4 ( MKK4 ) pathway .	positive	1
14104	10791986	9564;5599	p130Cas;JNK	The ***FAK-p130Cas*** complex ***activates*** c-Jun NH2-terminal kinase ( ***JNK*** ) via a Ras/Rac1/Pak1 / MAPK kinase 4 ( MKK4 ) pathway .	positive	1
14105	10792001	7157;4363	p53;MRP1	***Regulation*** of expression of the multidrug resistance protein ***MRP1*** by ***p53*** in human prostate cancer cells .	target	1
14106	10792001	7157;1026	p53;p21	In the transfected cell line ( LVCaP ) , the wild-type ***p53*** produced growth arrest at the G1/S interface of the cell cycle , inhibited colony formation , and ***induced*** ***p21*** ( waf1/cip1 ) .	target	1
14107	10792001	7157;4363	p53;MRP1	These results provide the first mechanistic ***link*** between expression of ***MRP1*** and mutation of ***p53*** in human prostate cancer and support recent clinical associations .	parallel	0
14108	10792030	672;1033	BRCA1;cyclin-dependent kinase inhibitor	After IFN-gamma treatment , induction of the ***cyclin-dependent kinase inhibitor*** , p21WAF1 , was synergistically ***activated*** by ***BRCA1*** , whereas the IRF-1 gene was unaffected .	positive	1
14109	10792030	6772;672	STAT1;BRCA1	Significantly , ***STAT1*** proteins mutated at Ser-727 ***bind*** poorly to ***BRCA1*** , reinforcing the importance of Ser-727 in the recruitment of transcriptional coactivators by STAT proteins .	parallel	1
14110	10792047	5585;5170	PKN;PDK1	***PDK1*** and ***PKN*** ***interacted*** in vitro and in intact cells , and this interaction was mediated by the kinase domain of PDK1 and the carboxyl terminus of PKN .	parallel	1
14111	10792370	356;355	FasL;Fas	Among them , one is mediated by perforin and granzyme molecules , another is mediated by ***Fas*** ***ligand*** ( ***FasL*** ) which delivers apoptotic signals through Fas receptor on target cells .	parallel	1
14112	10792391	3586;3552	IL-10;IL-1alpha	Further analysis in the acute streptococcal cell wall-induced arthritis model revealed that local ***IL-10*** over-expression markedly ***suppressed*** the production of tumour necrosis factor-alpha ( TNF-alpha ) and ***IL-1alpha*** , but had no significant effect on IL-1beta and IL-12 production in the inflamed synovium .	negative	1
14113	10792391	3586;7124	IL-10;TNF-alpha	Further analysis in the acute streptococcal cell wall-induced arthritis model revealed that local ***IL-10*** over-expression markedly ***suppressed*** the production of tumour necrosis factor-alpha ( ***TNF-alpha*** ) and IL-1alpha , but had no significant effect on IL-1beta and IL-12 production in the inflamed synovium .	negative	1
14114	10792393	1437;5657	Granulocyte-macrophage colony-stimulating factor;PR3	***Granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) but not granulocyte colony-stimulating factor ( G-CSF ) ***induces*** plasma membrane expression of proteinase 3 ( ***PR3*** ) on neutrophils in vitro .	target	1
14115	10792393	1437;5657	GM-CSF;PR3	In contrast , ***GM-CSF*** significantly ***increased*** ***PR3*** membrane expression on both intact PMN and neutrophils primed with TNF-alpha .	positive	0
14116	10792393	1437;5657	GM-CSF;PR3	In summary , these data demonstrate that ***GM-CSF*** , but not G-CSF , ***induces*** plasma membrane expression of ***PR3*** on PMN in vitro .	target	1
14117	10792446	1476;1508	cystatin B;cysteine protease	Loss of function mutations in the gene encoding the ***cysteine protease*** ***inhibitor*** , ***cystatin B*** ( CSTB ) , are responsible for the primary defect in human progressive myoclonus epilepsy ( EPM1 ) .	negative	1
14118	10792494	3655;3908	VLA-6;merosin	In order to study the mechanisms leading to the selective death of DP cells in the absence of merosin , the role of the ***interaction*** between very late activation antigen-6 ( ***VLA-6*** ) , a candidate merosin ligand in the thymus , and ***merosin*** was examined .	parallel	1
14119	10792494	3908;3655	merosin;VLA-6	The results suggest that DP cells are more sensitive to an uncharacterized apoptotic death signal , and that survival is supported by the ***interaction*** between ***VLA-6*** and ***merosin*** .	parallel	1
14120	10792501	3458;3383	Interferon-gamma;intercellular adhesion molecule-1	***Interferon-gamma*** ***up-regulates*** ***intercellular adhesion molecule-1*** and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2 .	positive	1
14121	10792501	3458;7412	Interferon-gamma;vascular cell adhesion molecule-1	***Interferon-gamma*** ***up-regulates*** intercellular adhesion molecule-1 and ***vascular cell adhesion molecule-1*** and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2 .	positive	1
14122	10792503	841;836	caspase-8;caspase-3	When a potent NF-kappaB inhibitor , pyrrolidine dithiocarbamate ( PDTC ) , was added to U937 cell culture in the presence of PMA , apoptosis was triggered by activation of ***caspase-3*** , which was ***induced*** by ***caspase-8*** activation .	target	1
14123	10792618	3488;392	IGFBP-5;Cdc42GAP	***IGFBP-5*** ( 201-218 ) ***stimulates*** ***Cdc42GAP*** aggregation and filopodia formationin migrating mesangial cells .	positive	0
14124	10792824	1154;55503	Cis;Cat1	***Cis-elements*** and trans-factors that ***regulate*** expression of the maize ***Cat1*** antioxidant gene in response to ABA and osmotic stress : H2O2 is the likely intermediary signaling molecule for the response .	target	1
14125	10792853	8600;8792	RANKL;RANK	Led first by the discovery of Osteoprotegerin ( OPG ) , a naturally occurring protein with potent osteoclastogenesis inhibitory activity , rapid progress was made to the isolation of ***RANKL*** , a transmembrane ligand expressed on osteoblasts/stromal cells , that ***binds*** to ***RANK*** , a transmembrane receptor on hemopoietic osteoclast precursor cells .	parallel	1
14126	10792853	8600;8792	RANKL;RANK	The ***interaction*** of ***RANK*** and ***RANKL*** initiates a signaling and gene expression cascade that results in differentiation and maturation of osteoclast precursor cells to active osteoclasts capable of resorbing bone .	parallel	1
14127	10793000	7046;7040	transforming growth factor-beta (TGF-beta) receptor type I;TGF-beta	Loss of ***transforming growth factor-beta (TGF-beta) receptor type I*** ***mediates*** ***TGF-beta*** resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression .	target	0
14128	10793083	943;6667	CD30;Sp1	EMSA and DNase I footprinting showed specific DNA-protein ***interactions*** of the ***CD30*** promoter with the ***Sp1*** site and the CCAT repeat region .	parallel	1
14129	10793084	3383;7422	ICAM-1;VEGF	Vascular endothelial growth factor ( ***VEGF*** ) - induced retinal vascular permeability is ***mediated*** by intercellular adhesion molecule-1 ( ***ICAM-1*** ) .	target	0
14130	10793158	22920;5908	Smg GDS;small GTP-binding protein	***small GTP-binding protein*** GDP dissociation ***stimulator*** ( ***Smg GDS*** ) regulates GDP/GTP exchange reaction of Ki-Ras and the Rho and Rap1 family members and inhibits their binding to membranes .	positive	0
14131	10793228	796;2641	Calcitonin;glucagon-like peptide-1	***Calcitonin*** gene-related peptide potently ***stimulates*** ***glucagon-like peptide-1*** release in the isolated perfused rat ileum .	positive	0
14132	10793263	5970;4790	p65;NF-kappaB	In conclusion , a p50 and ***p65*** NF-kappaB heterodimer ***binds*** to a ***reverse-NF-kappaB*** site on the rat iNOS promoter and contributes to iNOS induction by IL-1beta and IFN-gamma in RASMCs .	parallel	1
14133	10793269	3486;3479	IGFBP-3;IGF-1	Thus , we strongly believe that the plasma IGF-1 and IGFBPs response to KP102 treatment is modulated by the nutritional status of growing Holstein steers and the increased plasma ***IGF-1*** concentration with KP102 treatment may be ***regulated*** by plasma 38-43 kDa ***IGFBP-3*** and 24 kDa IGFBP-4 in Holstein steers .	target	1
14134	10793269	3487;3479	IGFBP-4;IGF-1	Thus , we strongly believe that the plasma IGF-1 and IGFBPs response to KP102 treatment is modulated by the nutritional status of growing Holstein steers and the increased plasma ***IGF-1*** concentration with KP102 treatment may be ***regulated*** by plasma 38-43 kDa IGFBP-3 and 24 kDa ***IGFBP-4*** in Holstein steers .	target	1
14135	10794058	959;958	CD40 ligand;CD40	In addition to the difference in the magnitude , the activation requirements of CD8 and CD4 T-cell responses were different : CD8 T responses were not affected by blockade of ******CD40-CD40 ligand****** ***interaction*** whereas CD4 responses were reduced 90 % .	parallel	1
14136	10794504	183;185	angiotensin II;AT1	The results indicate that prolonged tissue storage has a differential effect upon 125I sar1ile8 ***angiotensin II*** ***binding*** to ***AT1*** and AT2 receptor sites .	parallel	1
14137	10794504	183;186	angiotensin II;AT2	The results indicate that prolonged tissue storage has a differential effect upon 125I sar1ile8 ***angiotensin II*** ***binding*** to AT1 and ***AT2*** receptor sites .	parallel	1
14138	10794524	4790;596	NF-kappaB;bcl-2	***Rel/NF-kappaB*** ***represses*** ***bcl-2*** transcription in pro-B lymphocytes .	negative	1
14139	10794524	4790;596	NF-kappaB;bcl-2	Cotransfection studies demonstrate that ***NF-kappaB*** factors can ***repress*** ***bcl-2*** transcription and that site-directed mutagenesis of the kappaB motifs abolishes this repression .	negative	1
14140	10794661	1432;2353	p38 MAP kinase;c-Fos	Ca ( 2 + ) and ***p38 MAP kinase*** ***regulate*** mAChR-mediated ***c-Fos*** expression in avian exocrine cells .	target	1
14141	10794707	811;821	CRT;CNX	The ***interaction*** between ******CNX/CRT****** and a monoglucosylated glycan is one of the alternative mechanisms by which cells retain not yet properly folded glycoproteins in the ER ; in addition , it enhances folding efficiency by preventing protein aggregation and thus allowing intervention of classical chaperones and other folding-assisting proteins .	parallel	1
14142	10794713	3952;1263	leptin;Fnk	***leptin*** treatment of leptin-deficient ob/ob mice ***increased*** the STAT-3 , SOCS-3 , MT-II and ***Fnk*** mRNA , and MT-I protein levels in liver , whereas , in jejunum , expression of PAP I mRNA was down-regulated .	positive	0
14143	10794713	3952;4502	leptin;MT-II	***leptin*** treatment of leptin-deficient ob/ob mice ***increased*** the STAT-3 , SOCS-3 , ***MT-II*** and Fnk mRNA , and MT-I protein levels in liver , whereas , in jejunum , expression of PAP I mRNA was down-regulated .	positive	0
14144	10794713	3952;9021	leptin;SOCS-3	***leptin*** treatment of leptin-deficient ob/ob mice ***increased*** the STAT-3 , ***SOCS-3*** , MT-II and Fnk mRNA , and MT-I protein levels in liver , whereas , in jejunum , expression of PAP I mRNA was down-regulated .	positive	0
14145	10794713	3952;6774	leptin;STAT-3	***leptin*** treatment of leptin-deficient ob/ob mice ***increased*** the ***STAT-3*** , SOCS-3 , MT-II and Fnk mRNA , and MT-I protein levels in liver , whereas , in jejunum , expression of PAP I mRNA was down-regulated .	positive	0
14146	10794713	3952;1263	leptin;Fnk	Furthermore , administration of ***leptin*** to starved wild-type mice ***enhanced*** the expression of MT-II and ***Fnk*** mRNA in liver , but decreased MT-II and PAP I mRNA expression in jejunum .	positive	0
14147	10794713	3952;4502	leptin;MT-II	Furthermore , administration of ***leptin*** to starved wild-type mice ***enhanced*** the expression of ***MT-II*** and Fnk mRNA in liver , but decreased MT-II and PAP I mRNA expression in jejunum .	positive	0
14148	10794857	4914;4803	TrkA;nerve growth factor	Cholinergic medial septum neurons express TrkA and p75 nerve growth factor receptor ( p75 ( NGFR ) ) and interactions between TrkA and p75 ( NGFR ) are necessary for high-affinity ***binding*** and signaling of ***nerve growth factor*** ( NGF ) through ***TrkA*** .	parallel	1
14149	10794857	4804;4914	p75;TrkA	Cholinergic medial septum neurons express TrkA and p75 nerve growth factor receptor ( p75 ( NGFR ) ) and ***interactions*** between ***TrkA*** and ***p75*** ( NGFR ) are necessary for high-affinity binding and signaling of nerve growth factor ( NGF ) through TrkA .	parallel	1
14150	10795524	7124;4790	TNF-alpha;NF-kappaB	Herpes simplex virus type 2 infection of macrophages impairs IL-4-mediated inhibition of NO production through ***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** .	positive	1
14151	10795524	3565;7124	IL-4;TNF-alpha	***IL-4*** ***reduced*** virus-induced ***TNF-alpha*** secretion and nuclear factor ( NF ) - kappaB activation significantly , but less in cells concomitantly treated with IFN-gamma .	negative	1
14152	10795738	11184;3725	HPK1;AP-1	***HPK1*** is activated by lymphocyte antigen receptors and negatively ***regulates*** ***AP-1*** .	negative	1
14153	10795738	11184;3725	HPK1;AP-1	Thus , ***HPK1*** is a negative ***regulator*** of the TCR-induced ***AP-1*** response pathway .	negative	1
14154	10795740	3267;7132	RIP;TNF-R1	Although TRAF2 or ***RIP*** can be independently ***recruited*** to the ***TNF-R1*** complex , neither one of them alone is capable of transducing the TNF signal that leads to IKK activation .	target	0
14155	10795740	7186;7132	TRAF2;TNF-R1	Although ***TRAF2*** or RIP can be independently ***recruited*** to the ***TNF-R1*** complex , neither one of them alone is capable of transducing the TNF signal that leads to IKK activation .	target	0
14156	10795919	133;5020	adrenomedullin;oxytocin	These results suggest that central ***adrenomedullin*** preferentially ***stimulates*** the secretion of ***oxytocin*** by activating hypothalamic oxytocin-secreting cells and may have an important role in salt appetite and body fluid homeostasis in rats .	positive	0
14157	10796883	332;1019	Survivin;cyclin-dependent kinase 4	Furthermore , we have found that ***Survivin*** ***interacted*** with ***cyclin-dependent kinase 4*** ( Cdk4 ) and overexpression of Survivin released p21 ( WAF1/Cip1 ) ( p21 ) from Cdk4 .	parallel	1
14158	10796884	7124;1281	Tumor necrosis factor alpha;alpha1(I) collagen	***Tumor necrosis factor alpha*** ***down-regulates*** expression of the ***alpha1(I) collagen*** gene in rat hepatic stellate cells through a p20C/EBPbeta - and C/EBPdelta-dependent mechanism .	negative	1
14159	10797287	999;596	E-cadherin;bcl-2	Therefore , ***E-cadherin*** may negatively ***regulate*** ***bcl-2*** expression by altering the availability of nuclear beta-catenin .	negative	1
14160	10797287	999;596	E-cadherin;bcl-2	Expression of ***E-cadherin*** ***reduces*** ***bcl-2*** expression and increases sensitivity to etoposide-induced apoptosis .	negative	1
14161	10797287	1499;999	beta-catenin;E-cadherin	Expression of ***beta-catenin*** and pp120 src substrate proteins , which ***associate*** with ***E-cadherin*** , was unaffected .	parallel	0
14162	10797304	8661;5294	p185;PI3K	Phosphatidylinositol 3-kinase ( ***PI3K*** ) is ***activated*** by ***p185*** ( erbB-2 ) / erbB-3 heterodimers in cells stimulated by HRG , and PI3K is constitutively activated by p185 ( erbB-2 ) / erbB-3 in breast carcinoma cells that overexpress c-erbB-2 .	positive	1
14163	10797304	8661;5294	p185;PI3K	Furthermore , erbB-3 principally mediated the direct recruitment of p85 in cells stimulated by HRG or EGF , indicating that , in addition to the high-level ***activation*** of ***PI3K*** by ***p185*** ( erbB-2 ) / erbB-3 , EGFR/erbB-3 heterodimer interaction is essential for the weak but significant level of PI3K activated by EGF in cells that express normal EGFR levels .	positive	1
14164	10797304	1956;2065	EGFR;erbB-3	Furthermore , erbB-3 principally mediated the direct recruitment of p85 in cells stimulated by HRG or EGF , indicating that , in addition to the high-level activation of PI3K by p185 ( erbB-2 ) / erbB-3 , ******EGFR/erbB-3****** heterodimer ***interaction*** is essential for the weak but significant level of PI3K activated by EGF in cells that express normal EGFR levels .	parallel	1
14165	10797304	2065;5295	erbB-3;p85	Furthermore , ***erbB-3*** principally ***mediated*** the direct recruitment of ***p85*** in cells stimulated by HRG or EGF , indicating that , in addition to the high-level activation of PI3K by p185 ( erbB-2 ) / erbB-3 , EGFR/erbB-3 heterodimer interaction is essential for the weak but significant level of PI3K activated by EGF in cells that express normal EGFR levels .	target	0
14166	10797306	4790;2064	ebp1;ErbB-2	These data demonstrate that ectopic expression of the ErbB-3 binding protein ***ebp1*** inhibits proliferation and ***induces*** differentiation of ***ErbB-2*** , ErbB-3-expressing human breast carcinoma cell lines .	target	1
14167	10797307	3481;3488	IGF-II;IGFBP-5	All treatments suppressed ***IGF-II*** production but only TNF-alpha ***blocked*** ***IGFBP-5*** secretion .	negative	0
14168	10797307	7124;3488	TNF-alpha;IGFBP-5	All treatments suppressed IGF-II production but only ***TNF-alpha*** ***blocked*** ***IGFBP-5*** secretion .	negative	0
14169	10797315	4084;4609	Mad;Myc	Recent studies have shown that ***Mad*** proteins can inhibit cellular growth and transformation and thus ***antagonize*** the function of ***Myc*** proteins .	negative	1
14170	10797315	4149;4609	Max;c-myc	DNA binding analyses revealed that the most prominent network complex both in cycling and in differentiating cells was Mnt/Max , whereas ******c-myc/Max****** ***complexes*** were detectable only during peak c-myc expression periods .	parallel	1
14171	10797498	4609;367	c-myc;androgen receptor	We evaluated the frequency and the ***association*** of ***c-myc*** and ***androgen receptor*** ( AR ) gene amplification and gain of chromosome 8 or X in prostate cancer in Japanese patients .	parallel	0
14172	10797573	1000;7431	N-cadherin;Vimentin	In this study , we sought to establish a ***link*** between expression of ***Vimentin*** and ***N-cadherin*** as oral squamous epithelial cells undergo a morphologic change resembling an epithelial-to-mesenchymal transition .	parallel	0
14173	10797574	8851;1020	p25;Cdk5	******Cdk5/p25****** ( nck5a ) ***interaction*** with synaptic proteins in bovine brain .	parallel	1
14174	10797574	8851;1020	p25;Cdk5	Thus , we demonstrate : an Amphiphysin-associated 400-kDa ******Cdk5/p25****** ( nck5a ) ***complex*** , a synapsin I-associated > 400-kDa Cdk5/p25 ( nck5a ) complex , and nck5a-free Cdk5 complexes ( 200 to > 400 kDa ) .	parallel	1
14175	10797593	348;341	ApoE;apoC1	Tests of ***association*** of ***ApoE*** levels with the ***apoC1*** locus , which is in complete linkage disequilibrium with the ApoE locus , also showed a significant effect , although the variance explained by apoC1 was only 1 % .	parallel	0
14176	10797611	3949;4018	LDLR;lipoprotein	We have studied the possible role of the AvaII ( exon 13 ) , HincII ( exon 12 ) , and PvuII ( intron 15 ) polymorphisms at the low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) gene on lipid-lowering response in 55 patients ( 36 to 70 years old ) with primary hypercholesterolemia treated with fluvastatin for 16 weeks .	parallel	1
14177	10797617	3458;355	IFN-gamma;Fas	Fas expression on untreated SC showed fluctuating levels , while addition of ***IFN-gamma*** and TNF-alpha ***suppressed*** ***Fas*** expression completely .	negative	1
14178	10797617	7124;355	TNF-alpha;Fas	Fas expression on untreated SC showed fluctuating levels , while addition of IFN-gamma and ***TNF-alpha*** ***suppressed*** ***Fas*** expression completely .	negative	1
14179	10798212	6414;213	Selenoprotein P;albumin	***Selenoprotein P*** was significantly ***correlated*** to plasma ***albumin*** , fasting blood glucose , and body mass index and inversely correlated to plasma alpha 1-antitrypsin and gamma-glutamyl transferase .	parallel	0
14180	10798271	7056;5624	thrombomodulin;protein C	Under physiological conditions endothelium mediates vascular dilatation ( formation of NO , PGI2 , adenosine , hyperpolarizing factor ) , prevents platelet adhesion and activation ( production of adenosine , NO and PGI2 , removal of ADP ) , blocks thrombin formation ( tissue factor pathway inhibitor , ***activation*** of ***protein C*** via ***thrombomodulin*** , activation of antithrombin III ) and mitigates fibrin deposition ( t - and scuplasminogen activator production ) .	positive	1
14181	10798608	3586;8626	IL-10;p40	Of note , ***anti-IL-10*** supplementation ***induced*** a lower IL-12 ***p40/p70*** ratio in HCV subjects as compared to controls .	target	1
14182	10798661	3565;6356	IL-4;eotaxin	Synergistic ***induction*** of ***eotaxin*** expression in human keratocytes by TNF-alpha and ***IL-4*** or IL-13 .	target	1
14183	10798661	7124;6356	TNF-alpha;eotaxin	Synergistic ***induction*** of ***eotaxin*** expression in human keratocytes by ***TNF-alpha*** and IL-4 or IL-13 .	target	1
14184	10798773	1234;3458	CCR5;interferon-gamma	METHODS : We have used this experimental model to sequentially analyze transcript levels of ***interferon-gamma*** and interleukin ( IL ) -2 ( T helper 1 cytokines ) , IL-4 and IL-10 ( T helper 2 cytokines ) , RANTES , MIP1beta ( beta chemokines ) and their ***receptor*** ***CCR5*** , and Fas ligand ( cytolytic effector molecule ) .	parallel	1
14185	10798775	4312;7040	matrix metalloproteinase-1;TGF-beta	Notably , ***matrix metalloproteinase-1*** promoter region , tissue inhibitor of matrix metalloproteinase-2 , and tissue inhibitor of matrix metalloproteinase-3 inversely ***correlated*** with ***TGF-beta*** mRNA expression ( P < or = 0.0027 for each ) .	negative	0
14186	10799299	207;4790	AKT;NF-kappaB	***PI3-K/AKT*** ***regulation*** of ***NF-kappaB*** signaling events in suppression of TNF-induced apoptosis .	target	1
14187	10799299	207;4790	AKT;NF-kappaB	PI3K and ***AKT*** ***stimulated*** ***NF-kappaB*** activation in a dose-dependent manner , suggesting a common link between these two pathways .	positive	0
14188	10799299	5291;4790	PI3K;NF-kappaB	***PI3K*** and AKT ***stimulated*** ***NF-kappaB*** activation in a dose-dependent manner , suggesting a common link between these two pathways .	positive	0
14189	10799299	207;4790	AKT;NF-kappaB	PI3K and ***AKT*** cell survival signaling were ***correlated*** with increased TNF-stimulated ***NF-kappaB*** activity in MCF-7 cells .	parallel	0
14190	10799299	5291;4790	PI3K;NF-kappaB	***PI3K*** and AKT cell survival signaling were ***correlated*** with increased TNF-stimulated ***NF-kappaB*** activity in MCF-7 cells .	parallel	0
14191	10799299	207;5291	AKT;PI3K	******PI3K-AKT****** ***signaling*** activated NF-kappaB through both TNFR signaling-dependent and - independent mechanisms , potentially representing a mechanism by which AKT functions to suppress apoptosis in cancer .	parallel	0
14192	10799299	207;4790	AKT;NF-kappaB	***PI3K-AKT*** signaling ***activated*** ***NF-kappaB*** through both TNFR signaling-dependent and - independent mechanisms , potentially representing a mechanism by which AKT functions to suppress apoptosis in cancer .	positive	1
14193	10799299	5291;4790	PI3K;NF-kappaB	***PI3K-AKT*** signaling ***activated*** ***NF-kappaB*** through both TNFR signaling-dependent and - independent mechanisms , potentially representing a mechanism by which AKT functions to suppress apoptosis in cancer .	positive	1
14194	10799303	7124;2920	TNF-alpha;MIP-2	These data demonstrate that ***TNF-alpha*** ***induces*** expression of ***MIP-2*** in endothelial cells and support the hypothesis that the anti-inflammatory action of dexamethasone may , at least in part , be attributable to an inhibition of MIP-2 induction on cytokine-activated endothelial cells .	target	1
14195	10799310	9530;7132	Silencer of death domains;TNFR-1	***Silencer of death domains*** ( SODD ) ***binds*** to TNF-alpha receptor ***TNFR-1*** , and prevents spontaneous self-association of death domains and inappropriate receptor signaling .	parallel	1
14196	10799311	2065;2064	erbB3;erbB2	Neuregulin induces the rapid association of focal adhesion kinase with the ******erbB2-erbB3****** receptor ***complex*** in schwann cells .	parallel	1
14197	10799311	2066;2064	erbB4;erbB2	Axonally derived neuregulin signals myelin forming cells of the central and peripheral nervous systems through different receptor complexes : oligodendrocytes through ******erbB2/erbB4****** ***heterodimers*** and Schwann cells through erbB2/erbB3 heterodimers .	parallel	1
14198	10799311	2065;2064	erbB3;erbB2	Axonally derived neuregulin signals myelin forming cells of the central and peripheral nervous systems through different receptor complexes : oligodendrocytes through erbB2/erbB4 heterodimers and Schwann cells through ******erbB2/erbB3****** ***heterodimers*** .	parallel	1
14199	10799311	5747;2064	FAK;HER2	Following stimulation with ligand , maximal ***binding*** of ***FAK*** to ***HER2*** occurred by 1 min whereas maximal binding to HER3 was delayed to approximately 7 min .	parallel	1
14200	10799436	10111;4361	hRad50;hMre11	The gene product , nibrin , is a novel protein , which is member of the ******hMre11/hRad50****** protein ***complex*** , suggesting that the gene is involved in DNA double strand break repair .	parallel	1
14201	10799501	998;4296	Cdc42;SPRK	These studies suggest an additional component or cellular environment is required for ***SPRK*** ***activation*** by ***Cdc42*** .	positive	1
14202	10799501	998;4296	Cdc42;SPRK	***Cdc42-induced*** ***activation*** of the mixed-lineage kinase ***SPRK*** in vivo .	positive	1
14203	10799501	998;4296	Cdc42;SPRK	Unlike the PAK family of protein kinases , we find that the ***activation*** of ***SPRK*** by ***Cdc42*** can not be recapitulated in an in vitro system using purified , recombinant proteins .	positive	1
14204	10799514	3458;4953	interferon-gamma;ODC	Intriguingly , a major immunomodulatory cytokine , ***interferon-gamma*** , appreciably ***enhanced*** the ***ODC*** degradation in HeLa and SW620 cells through induction of the hybrid proteasome , which may also be responsible for the immunological processing of intracellular antigens .	positive	0
14205	10799520	8317;3897	Cdc7;Spg1	These results suggest that Byr4 localization to SPBs maintains Spg1 in an inactive form , presumably by stimulating Spg1 GTPase activity with Cdc16 , and that loss of Byr4 from mitotic SPBs increases the active fraction of Spg1 and thereby increases ******Spg1-Cdc7****** ***binding*** .	parallel	1
14206	10799520	3897;8317	Spg1;Cdc7	As cells enter mitosis , ***Spg1*** accumulates in an active , GTP-bound form and ***binds*** the ***Cdc7*** protein kinase to cause Cdc7 translocation to SPBs .	parallel	1
14207	10799520	8317;3897	Cdc7;Spg1	These results led us to hypothesize that Byr4 localization to SPBs regulated the nucleotide state of Spg1 , due to its ability to form Spg1GAP activity with Cdc16 and thus the ***binding*** of ***Cdc7*** to ***Spg1*** at SPBs .	parallel	1
14208	10799521	8600;5468	OPGL;PPAR-gamma	These data establish a ***link*** between ***PPAR-gamma*** and ***OPGL*** signaling within Ocl progenitors , and support a role for PPAR-gamma pathway in the modulation of osteoclastogenesis .	parallel	0
14209	10799531	7124;1437	tumor necrosis factor-alpha;GM-CSF	We show both here and previously that mutation of any one of these binding sites greatly reduces ***tumor necrosis factor-alpha*** ***induction*** of the ***GM-CSF*** promoter .	target	1
14210	10799540	29927;7095	Sec61;Sec62	Mammalian ***Sec61*** is ***associated*** with ***Sec62*** and Sec63 .	parallel	0
14211	10799540	29927;11231	Sec61;Sec63	Mammalian ***Sec61*** is ***associated*** with Sec62 and ***Sec63*** .	parallel	0
14212	10799540	7095;29927	Sec62;Sec61	The probable function of the mammalian ******Sec61-Sec62-Sec63****** ***complex*** is discussed with respect to its abundance in ER membranes , which , in contrast to yeast ER membranes , apparently lack efficient post-translational translocation activity .	parallel	1
14213	10799540	7095;11231	Sec62;Sec63	The probable function of the mammalian ******Sec61-Sec62-Sec63****** ***complex*** is discussed with respect to its abundance in ER membranes , which , in contrast to yeast ER membranes , apparently lack efficient post-translational translocation activity .	parallel	1
14214	10799540	11231;29927	Sec63;Sec61	The probable function of the mammalian ******Sec61-Sec62-Sec63****** ***complex*** is discussed with respect to its abundance in ER membranes , which , in contrast to yeast ER membranes , apparently lack efficient post-translational translocation activity .	parallel	1
14215	10799542	2885;5781	GRB-2;SHP-2	Tyr ( 985 ) - mediated recruitment of SHP-2 does not alter tyrosine phosphorylation of Jak2 or STAT3 but results in ***GRB-2*** ***binding*** to tyrosine-phosphorylated ***SHP-2*** and is required for the majority of ERK activation during LRb signaling .	parallel	1
14216	10799542	5594;2353	ERK;c-fos	Tyr ( 985 ) and ***ERK*** activation similarly ***mediate*** ***c-fos*** mRNA accumulation .	target	0
14217	10799545	10657;1956	p62;epidermal growth factor receptor	Furthermore , we have found that ***p62*** ( dok ) ***co-immunoprecipitates*** with the activated ***epidermal growth factor receptor/LckF505*** and that phosphorylated Dok proteins bind to the Src homology 2 domain of Lck in vitro .	parallel	1
14218	10799548	867;3055	Cbl;Hck	Immunoprecipitation experiments revealed that ***Cbl*** ***associates*** with ***Hck*** in Bac1 .2 F5 cells , while expression of an activated form of Hck in Bac1 .2 F5 cells induces tyrosine phosphorylation of Cbl in the absence of lipopolysaccharide stimulation .	parallel	0
14219	10799548	3055;867	Hck;Cbl	Association of the p85 subunit of phosphatidylinositol ( PI ) 3-kinase with Cbl is enhanced following lipopolysaccharide stimulation of Bac1 .2 F5 cells , and transient expression experiments indicate that ***phosphorylation*** of ***Cbl*** by ***Hck*** can facilitate the association of p85 with Cbl .	target	1
14220	10799548	9139;867	p85;Cbl	***Association*** of the ***p85*** subunit of phosphatidylinositol ( PI ) 3-kinase with ***Cbl*** is enhanced following lipopolysaccharide stimulation of Bac1 .2 F5 cells , and transient expression experiments indicate that phosphorylation of Cbl by Hck can facilitate the association of p85 with Cbl .	parallel	0
14221	10799548	867;9139	Cbl;p85	Association of the p85 subunit of phosphatidylinositol ( PI ) 3-kinase with Cbl is enhanced following lipopolysaccharide stimulation of Bac1 .2 F5 cells , and transient expression experiments indicate that phosphorylation of ***Cbl*** by Hck can ***facilitate*** the association of ***p85*** with Cbl .	positive	0
14222	10799578	1033;1017	cyclin-dependent kinase inhibitor;cdk2	The p21/Waf1 protein , a known ***cyclin-dependent kinase inhibitor*** , ***interacts*** with the ***cdk2/cyclin*** E complex and inhibits progression of cells into S phase .	parallel	1
14223	10799578	1026;1017	p21;cdk2	The ***p21/Waf1*** protein , a known cyclin-dependent kinase inhibitor , ***interacts*** with the ***cdk2/cyclin*** E complex and inhibits progression of cells into S phase .	parallel	1
14224	10799580	7320;975	E2 protein;CD81	Although it has been shown that HCV ***E2 protein*** ***binds*** human ***CD81*** ( P.	parallel	1
14225	10799659	796;79109	CGRP;SIN-1	***CGRP*** ( 8-37 ) ( 0.63 microM ) ***induced*** rightward shifts in the vasodilatory concentration-response curves for nitroglycerin ( NTG ) , Piloty 's acid ( PA ) , and ***SIN-1*** ( linsidomine ) .	target	1
14226	10799659	79109;796	SIN-1;CGRP	These results indicate that only NTG and PA , and to a lesser extent ***SIN-1*** , ***stimulate*** the release of ***CGRP*** from the rat aorta , which subsequently contributes to the vasodilatory activity of these agents .	positive	0
14227	10799709	5610;1965	PKR;eIF-2alpha	The double stranded RNA-dependent protein kinase ***PKR*** has been shown to ***phosphorylate*** eukaryotic initiation factor 2 alpha ( ***eIF-2alpha*** ) , a well-characterized factor for down-regulating protein synthesis , in response to environmental stress conditions .	target	1
14228	10799709	5611;5610	P58;PKR	***P58*** ( IPK ) , a cellular ***inhibitor*** of ***PKR*** , was expressed in tissues from both age groups but to a greater extent in tissues of aging mice suggesting an up-regulation to control PKR activity .	negative	1
14229	10799735	3725;7040	AP-1;TGFbeta	Furthermore , RA and ( C16 :0 ) - CoA can regulate ***AP-1*** , which is a key ***regulator*** of the ***TGFbeta*** gene .	target	1
14230	10799849	54210;6347	TREM-1;monocyte chemotactic protein-1	Engagement of ***TREM-1*** ***triggers*** secretion of IL-8 , ***monocyte chemotactic protein-1*** , and TNF-alpha and induces neutrophil degranulation .	positive	0
14231	10799849	54210;7124	TREM-1;TNF-alpha	Engagement of ***TREM-1*** ***triggers*** secretion of IL-8 , monocyte chemotactic protein-1 , and ***TNF-alpha*** and induces neutrophil degranulation .	positive	0
14232	10799849	54210;7305	TREM-1;DAP12	To mediate activation , ***TREM-1*** ***associates*** with the transmembrane adapter molecule ***DAP12*** .	parallel	0
14233	10799856	356;355	FasL;Fas	The counterattack hypothesis , suggesting that cancer cells express ***Fas*** ***ligand*** ( ***FasL*** ) and are able to kill Fas-expressing tumor-infiltrating activated T cells , was supported by reports of the killing of Jurkat cells by FasL-expressing human colon cancer cell lines .	parallel	1
14234	10799861	958;7422	CD40;vascular endothelial growth factor	***CD40*** engagement on synovial fibroblast ***up-regulates*** production of ***vascular endothelial growth factor*** .	positive	1
14235	10799861	959;7422	CD40L;VEGF	The ***CD40L*** on activated T cells from rheumatoid synovial fluid also ***up-regulated*** ***VEGF*** production from FLS .	positive	1
14236	10799864	920;355	CD4;Fas	Engagement of ***CD4*** before TCR triggering ***regulates*** both Bax - and ***Fas*** ( CD95 ) - mediated apoptosis .	target	1
14237	10799864	920;581	CD4;Bax	The data show that the engagement of ***CD4*** separately from TCR ***influences*** the expression of the proapoptotic protein ***Bax*** independently of the anti-apoptotic protein Bcl-2 , whereas Ag activation coordinately modulates both Bax and Bcl-2 .	target	0
14238	10799868	1437;5594	GM-CSF;p40	Surprisingly , ***GM-CSF*** strikingly ***inhibited*** IL-12 ***p40*** production by anti-CD40 / IFN-gamma-stimulated LC ( % inhibition = 97.0 + / - 0.9 % at 1 ng/ml GM-CSF ) .	negative	1
14239	10799869	834;3553	caspase-1;IL-1 beta	We report that potassium leakage from cells leads to activation of the Ca2 + - independent phospholipase A2 ( iPLA2 ) , and the latter plays a pivotal role in regulating the ***cleavage*** of ***pro-IL-1 beta*** by the IL-converting enzyme ***caspase-1*** in human monocytes .	target	1
14240	10799871	5340;7040	plasmin;TGF-beta	The protease , ***plasmin*** , can ***activate*** ***TGF-beta*** , and activated T cells can express a receptor for the plasmin-producing enzyme urokinase-type plasminogen activator ( uPA ) , and can also produce both uPA and tissue-type plasminogen activator ( tPA ) .	positive	1
14241	10799875	3458;925	IFN-gamma;CD8	Addition of IL-12 and ***IFN-gamma*** at the time of initial Ag presentation ***enhanced*** ***CD8*** cytotoxicity to levels comparable with those stimulated by the adjuvants .	positive	0
14242	10799879	3932;10019	p56lck;hLnk	Following phosphorylation , ***p56lck*** ***binds*** to tyrosine-phosphorylated ***hLnk*** through its Src homology 2 domain .	parallel	1
14243	10799879	10019;919	hLnk;TCR zeta-chain	In COS cells cotransfected with hLnk , p56lck , and CD8-zeta , ***hLnk*** ***associated*** with tyrosine-phosphorylated ***TCR zeta-chain*** through its Src homology 2 domain .	parallel	0
14244	10799895	725;721	C4BP;C4b	In addition , six mAbs directed against the alpha-chain interfered with ******C4b-C4BP****** ***interaction*** , whereas only two of them efficiently inhibited binding of C4BP to M proteins .	parallel	1
14245	10799895	725;721	C4BP;C4b	Collectively , our results suggest that ***binding*** between ***C4b*** and ***C4BP*** is governed mostly by electrostatic interactions , while additional noncovalent forces cause tight binding of C4BP to streptococcal M proteins .	parallel	1
14246	10799895	725;721	C4BP;C4b	We have previously shown that a positively charged cluster at the interface between complement control protein domains 1 and 2 of C4BP alpha-chain is crucial for the ******C4b-C4BP****** ***interaction*** .	parallel	1
14247	10799895	721;725	C4b;C4BP	Furthermore , M proteins were able to displace C4BP from immobilized C4b , whereas ***C4b*** only weakly affected ***binding*** of ***C4BP*** to immobilized M proteins .	parallel	1
14248	10799895	721;725	C4b;C4BP	We found that the molecular mechanisms involved in these two interactions differ because the binding between M proteins and C4BP is relatively insensitive to salt in contrast to the ******C4BP-C4b****** ***binding*** .	parallel	1
14249	10799905	3725;2353	AP-1;c-Fos	PGE2 also stimulated activation of ***AP-1*** , a ***heterodimer*** of c-Jun and ***c-Fos*** , because the prostanoid increased specific binding of nuclear proteins to the AP-1 consensus sequence and stimulated AP-1-promoted luciferase activity .	parallel	1
14250	10799905	2353;3725	c-Fos;c-Jun	PGE2 also stimulated activation of AP-1 , a ***heterodimer*** of ***c-Jun*** and ***c-Fos*** , because the prostanoid increased specific binding of nuclear proteins to the AP-1 consensus sequence and stimulated AP-1-promoted luciferase activity .	parallel	1
14251	10799912	728;727	C5aR;C5a	In normal rat liver , anaphylatoxin ***C5a*** ***receptors*** ( ***C5aR*** ) are only expressed by nonparenchymal cells , mainly Kupffer cells and hepatic stellate cells , but not by parenchymal cells , i.e. , hepatocytes ( HC ) .	parallel	1
14252	10799913	356;355	FasL;Fas	We provide evidence in this study that ***Fas*** ***ligand*** ( ***FasL*** ) as well as Fas is present on muscle cells and inflammatory cells in myositis biopsies : Fas is present on most muscle cells and lymphocytes , and FasL is present on degenerating muscle cells and many infiltrating mononuclear cells .	parallel	1
14253	10800076	6304;925	SATB1;CD8a	Our results suggest that apoptosis-specific breakdown of ***SATB1*** , a transcriptional ***activator*** of the ***CD8a*** gene , might be of physiological relevance during thymic clonal deletion and apoptosis of peripheral T-lymphoid cells .	positive	1
14254	10800160	3082;1440	hepatocyte growth factor;granulocyte colony-stimulating factor	BACKGROUND AND OBJECTIVE : ***hepatocyte growth factor*** ( HGF ) is known to ***augment*** the effects of stem cell factor , interleukin-3 , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , erythropoetin , and ***granulocyte colony-stimulating factor*** , all of which are involved in hematopoiesis .	positive	0
14255	10800160	3082;1437	hepatocyte growth factor;granulocyte-macrophage colony-stimulating factor	BACKGROUND AND OBJECTIVE : ***hepatocyte growth factor*** ( HGF ) is known to ***augment*** the effects of stem cell factor , interleukin-3 , ***granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) , erythropoetin , and granulocyte colony-stimulating factor , all of which are involved in hematopoiesis .	positive	0
14256	10800160	3082;3562	hepatocyte growth factor;interleukin-3	BACKGROUND AND OBJECTIVE : ***hepatocyte growth factor*** ( HGF ) is known to ***augment*** the effects of stem cell factor , ***interleukin-3*** , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , erythropoetin , and granulocyte colony-stimulating factor , all of which are involved in hematopoiesis .	positive	0
14257	10800160	3082;4254	hepatocyte growth factor;stem cell factor	BACKGROUND AND OBJECTIVE : ***hepatocyte growth factor*** ( HGF ) is known to ***augment*** the effects of ***stem cell factor*** , interleukin-3 , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , erythropoetin , and granulocyte colony-stimulating factor , all of which are involved in hematopoiesis .	positive	0
14258	10800160	3569;1437	HGF;GM-CSF	***HGF*** was also found to ***potentiate*** the effect of ***GM-CSF*** on DC and monocyte development .	positive	0
14259	10800546	30835;3700	DC-SIGN;gp120	Second , they described another property of ***DC-SIGN*** , i.e. ***binding*** to the HIV-1 envelope protein ***gp120*** .	parallel	1
14260	10800929	627;794	brain-derived neurotrophic factor;calretinin	Opposite ***regulation*** of calbindin and ***calretinin*** expression by ***brain-derived neurotrophic factor*** in cortical neurons .	target	1
14261	10800929	627;794	brain-derived neurotrophic factor;calretinin	***Regulation*** of calbindin and ***calretinin*** expression by ***brain-derived neurotrophic factor*** ( BDNF ) was examined in primary cultures of cortical neurons using immunocytochemistry and northern blot analysis .	target	1
14262	10800929	627;794	BDNF;calretinin	Here we report that ***regulation*** of ***calretinin*** expression by ***BDNF*** is in marked contrast to that of calbindin .	target	1
14263	10800936	2185;5594	RAFTK;ERK1/2	Like RAFTK phosphorylation , ERK1/2 activation is PTX sensitive and can be attenuated by the depletion of intracellular Ca2 + and by PKC inhibition , suggesting that ***RAFTK*** might ***mediate*** the glutamate-dependent activation of ***ERK1/2*** .	target	0
14264	10800945	5781;3572	SHP-2;gp130	Coexpression of catalytically inactive , but not wild-type , ***SHP-2*** ***reduced*** LIFR - and ***gp130-mediated*** activation of MAPK up to 75 % .	negative	1
14265	10800945	5781;1103	SHP-2;choline acetyltransferase	***SHP-2*** also negatively ***regulates*** LIF-dependent expression of ***choline acetyltransferase*** , but this regulation could be dissociated from its effects on MAPK activation .	negative	1
14266	10800949	4803;6616	Nerve growth factor;SNAP-25	***Nerve growth factor-induced*** ***phosphorylation*** of ***SNAP-25*** in PC12 cells : a possible involvement in the regulation of SNAP-25 localization .	target	1
14267	10801128	608;10673	BCMA;zTNF4	We have identified two TNF receptor family members , TACI and ***BCMA*** , that ***bind*** ***zTNF4*** .	parallel	1
14268	10801128	23495;10673	TACI;zTNF4	We have identified two TNF receptor family members , ***TACI*** and BCMA , that ***bind*** ***zTNF4*** .	parallel	1
14269	10801129	1445;6714	Csk;c-Src	Cbp is involved in the membrane localization of Csk and in the ***Csk-mediated*** ***inhibition*** of ***c-Src*** .	negative	1
14270	10801129	55824;6714	Cbp;c-Src	***Cbp*** is involved in the membrane localization of Csk and in the Csk-mediated ***inhibition*** of ***c-Src*** .	negative	1
14271	10801186	7066;4352	thrombopoietin;c-mpl	The development of megakaryocytes is controlled by ***thrombopoietin*** , which ***binds*** to ***c-mpl*** on the surface of platelets and megakaryocytes .	parallel	1
14272	10801263	3488;3479	IGFBP-5;IGF-I	Human intestinal smooth muscle in culture produces insulin-like growth factor ( IGF ) - I and IGF binding protein (IGFBP)-3 , IGFBP-4 , and ***IGFBP-5*** , which ***modulate*** the effects of ***IGF-I*** .	target	0
14273	10801263	3479;3486	IGF-I;IGFBP-3	We conclude that endogenous ***IGF-I*** ***stimulates*** growth and ***IGFBP-3*** , IGFBP-4 , and IGFBP-5 production in human intestinal smooth muscle cells .	positive	0
14274	10801263	3479;3487	IGF-I;IGFBP-4	We conclude that endogenous ***IGF-I*** ***stimulates*** growth and IGFBP-3 , ***IGFBP-4*** , and IGFBP-5 production in human intestinal smooth muscle cells .	positive	0
14275	10801263	3479;3488	IGF-I;IGFBP-5	We conclude that endogenous ***IGF-I*** ***stimulates*** growth and IGFBP-3 , IGFBP-4 , and ***IGFBP-5*** production in human intestinal smooth muscle cells .	positive	0
14276	10801272	2587;51083	Gal1-R;galanin	This ligand causes Cl ( - ) secretion when colonic epithelial cells express the ***galanin-1*** ***receptor*** ( ***Gal1-R*** ) subtype .	parallel	1
14277	10801272	4790;2587	NF-kappaB;Gal1-R	Because ***Gal1-R*** expression by colonic epithelia is ***upregulated*** by the transcription factor nuclear factor-kappaB ( ***NF-kappaB*** ) , increasingly appreciated as critical in the pathophysiology of inflammatory bowel disease , we wondered whether the diarrhea associated with this condition could be due to NF-kappaB-mediated increases in Gal1-R expression .	positive	1
14278	10801326	1975;1973	eIF4B;eIF4A	Wheat germ translation initiation factor ***eIF4B*** ***affects*** ***eIF4A*** and eIFiso4F helicase activity by increasing the ATP binding affinity of eIF4A .	target	0
14279	10801347	4790;7124	NF-kappaB;TNF-alpha	Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the ***upregulation*** of the ***TNF-alpha*** gene expression in monocytic cells via ***NF-kappaB*** involving PKC , PI3-K and tyrosine kinases .	positive	1
14280	10801347	4790;7124	NF-kappaB;TNF-alpha	Furthermore , we demonstrate that activation of ***TNF-alpha*** by gp350 is ***mediated*** by ***NF-kappaB*** through signal transduction pathways involving PKC , PI3-K and tyrosine kinases .	target	0
14281	10801415	5170;84959	PDK1;p70	CONCLUSIONS : ***PDK1*** ***mediates*** activation of PKB , ***p70*** S6 kinase and p90 Rsk in vivo , but is not rate-limiting for activation of PKA , MSK1 and AMPK .	target	0
14282	10801415	5170;207	PDK1;PKB	CONCLUSIONS : ***PDK1*** ***mediates*** activation of ***PKB*** , p70 S6 kinase and p90 Rsk in vivo , but is not rate-limiting for activation of PKA , MSK1 and AMPK .	target	0
14283	10801415	5170;6197	PDK1;Rsk	CONCLUSIONS : ***PDK1*** ***mediates*** activation of PKB , p70 S6 kinase and p90 ***Rsk*** in vivo , but is not rate-limiting for activation of PKA , MSK1 and AMPK .	target	0
14284	10801437	4851;28514	Notch1;Delta1	In many developing tissues , signalling mediated by the transmembrane protein ***Delta1*** and its ***receptor*** ***Notch1*** inhibits differentiation .	parallel	1
14285	10801443	4087;4089	Smad2;Smad4	TGF-beta induces the phosphorylation of ***Smad2*** and Smad3 ( receptor-activated Smads ) which ***associate*** with ***Smad4*** and translocate to the nucleus , where they regulate gene transcription [ 1 ] .	parallel	0
14286	10801443	4088;4089	Smad3;Smad4	TGF-beta induces the phosphorylation of Smad2 and ***Smad3*** ( receptor-activated Smads ) which ***associate*** with ***Smad4*** and translocate to the nucleus , where they regulate gene transcription [ 1 ] .	parallel	0
14287	10801443	7040;4087	TGF-beta;Smad2	***TGF-beta*** ***induces*** the phosphorylation of ***Smad2*** and Smad3 ( receptor-activated Smads ) which associate with Smad4 and translocate to the nucleus , where they regulate gene transcription [ 1 ] .	target	1
14288	10801443	7040;4088	TGF-beta;Smad3	***TGF-beta*** ***induces*** the phosphorylation of Smad2 and ***Smad3*** ( receptor-activated Smads ) which associate with Smad4 and translocate to the nucleus , where they regulate gene transcription [ 1 ] .	target	1
14289	10801443	7040;4092	TGF-beta1;Smad7	***Smad7*** protein is ***induced*** by ***TGF-beta1*** and has been classified as an inhibitory Smad .	target	1
14290	10801460	4683;472	Nbs1;ATM	In addition , functions of the Mre11 complex have been biochemically linked to ATM , the large protein kinase that is defective in ataxia-telangiectasia cells by the observation that ***Nbs1*** is a bona fide ***substrate*** of the ***ATM*** kinase .	parallel	1
14291	10801775	4294;5599	mixed-lineage kinase 2;JNK	Extending this study , we now demonstrate a role of ***mixed-lineage kinase 2*** ( MLK2 ) , a ***JNK*** ***activator*** , in polyglutamine-expanded huntingtin-mediated neuronal toxicity .	positive	1
14292	10801775	4294;5599	MLK2;JNK	Similar to the expression of polyglutamine-expanded huntingtin , expression of ***MLK2*** also ***induces*** ***JNK*** activation and apoptosis in HN33 cells .	target	1
14293	10801777	351;5663	APP;PS1	However , the APP-C100 is rapidly degraded , and if it forms , then any ******PS1.APP****** ***complex*** is likely to be very transitory .	parallel	1
14294	10801780	440275;10985	GCN2;GCN1	GI domain-mediated ***association*** of the eukaryotic initiation factor 2alpha kinase ***GCN2*** with its activator ***GCN1*** is required for general amino acid control in budding yeast .	parallel	0
14295	10801780	440275;10985	GCN2;GCN1	Although it is known that in vivo activation of ***GCN2*** ***requires*** ***GCN1*** , the mode of GCN1 action remains to be elucidated at the molecular level .	target	0
14296	10801780	440275;10985	GCN2;GCN1	Here , we show that ***GCN2*** ***interacts*** with ***GCN1*** via the GI domain , a novel protein-binding module that occurs at the N terminus ; mutations to conserved residues of this domain abolish its binding to GCN1 .	parallel	1
14297	10801780	440275;10985	GCN2;GCN1	Thus , GI domain-mediated ***association*** of ***GCN2*** to ***GCN1*** is required for general amino acid control .	parallel	0
14298	10801780	10985;440275	GCN1;GCN2	This finding provides the first insight into the molecular mechanism for the ***activation*** of ***GCN2*** by ***GCN1*** .	positive	1
14299	10801783	1051;3553	NF-IL6;il1b	***NF-IL6*** ( C/EBPbeta ) vigorously ***activates*** ***il1b*** gene expression via a Spi-1 ( PU.1 ) protein-protein tether .	positive	1
14300	10801783	1051;3553	NF-IL6;il1b	The ETS domain factor Spi-1 ( also called PU.1 ) and the bZIP factor ***NF-IL6*** ( also called C/EBPbeta ) have been shown to be involved in the transcriptional ***regulation*** of interleukin-1beta gene ( ***il1b*** ) and other monocyte-specific genes .	target	1
14301	10801783	6688;3553	Spi-1;il1b	The ETS domain factor ***Spi-1*** ( also called PU.1 ) and the bZIP factor NF-IL6 ( also called C/EBPbeta ) have been shown to be involved in the transcriptional ***regulation*** of interleukin-1beta gene ( ***il1b*** ) and other monocyte-specific genes .	target	1
14302	10801783	1051;3553	NF-IL6;il1b	This is supported by the demonstration of in vitro interaction between the NF-IL6 bZIP and Spi-1 winged helix-turn-helix ( wHTH ) DNA binding domains , arguing that ***NF-IL6*** vigorously ***activates*** the ***il1b*** core promoter via protein-tethered transactivation mediated by Spi-1 .	positive	1
14303	10801796	6657;5460	Sox2;Oct-3	In contrast , R3 function is only observed when ***Sox2*** is ***complexed*** with ***Oct-3*** .	parallel	1
14304	10801798	4214;5599	MEKK1;JNK	NESK-induced ***JNK*** activation was ***inhibited*** by the dominant negative mutants of ***MEKK1*** and MKK4 .	positive	1
14305	10801798	6416;5599	MKK4;JNK	NESK-induced ***JNK*** activation was ***inhibited*** by the dominant negative mutants of MEKK1 and ***MKK4*** .	positive	1
14306	10801799	3827;4790	bradykinin;NF-kappa B	***Activation*** of ***NF-kappa B*** by ***bradykinin*** through a Galpha ( q ) - and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt .	positive	1
14307	10801799	8802;4790	Galpha;NF-kappa B	***Activation*** of ***NF-kappa B*** by bradykinin through a ***Galpha*** ( q ) - and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt .	positive	1
14308	10801799	8801;4790	Gbeta;NF-kappa B	***Activation*** of ***NF-kappa B*** by bradykinin through a Galpha ( q ) - and ***Gbeta*** gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt .	positive	1
14309	10801799	8802;3551	Galpha;IKK2	Co-expression of Galpha ( q ) potentiated BK-induced NF-kappaB activation , whereas co-expression of either an activated ***Galpha*** ( q ) ( Q209L ) or Gbeta ( 1 ) gamma ( 2 ) ***induced*** ***IKK2*** activity and NF-kappaB activation without BK stimulation .	target	1
14310	10801799	8802;4790	Galpha;NF-kappaB	Co-expression of Galpha ( q ) potentiated BK-induced NF-kappaB activation , whereas co-expression of either an activated ***Galpha*** ( q ) ( Q209L ) or Gbeta ( 1 ) gamma ( 2 ) ***induced*** IKK2 activity and ***NF-kappaB*** activation without BK stimulation .	target	1
14311	10801799	8802;4790	Galpha;NF-kappaB	Co-expression of ***Galpha*** ( q ) ***potentiated*** BK-induced ***NF-kappaB*** activation , whereas co-expression of either an activated Galpha ( q ) ( Q209L ) or Gbeta ( 1 ) gamma ( 2 ) induced IKK2 activity and NF-kappaB activation without BK stimulation .	positive	0
14312	10801799	207;4790	Akt;NF-kappaB	Furthermore , BK could activate the PI3K downstream kinase Akt , whereas a catalytically inactive mutant of ***Akt*** ***inhibited*** BK-induced ***NF-kappaB*** activation .	positive	1
14313	10801814	51562;7786	MAPK upstream kinase (MUK)-binding inhibitory protein;dual leucine zipper-bearing kinase	***MAPK upstream kinase (MUK)-binding inhibitory protein*** , a negative ***regulator*** of ***MUK/dual leucine zipper-bearing kinase/leucine zipper protein kinase*** .	negative	1
14314	10801814	51562;7786	MBIP;ZPK	***MBIP*** interacts with one of the two leucine-zipper-like motifs of MUK/DLK/ZPK and ***inhibits*** the activity of ***MUK/DLK/ZPK*** to induce JNK/SAPK activation .	negative	1
14315	10801814	51562;5599	MBIP;JNK	Furthermore , the overexpression of ***MBIP*** partially ***inhibits*** the activation of ***JNK*** by 0.3 m sorbitol in 293T cells .	negative	1
14316	10801814	51562;7786	MBIP;ZPK	Taken together , these observations indicate that ***MBIP*** can function as a ***regulator*** of ***MUK/DLK/ZPK*** , a finding that may provide a clue to understanding the molecular mechanism of JNK/SAPK activation by hyperosmotic stress .	target	1
14317	10801815	23414;1488	FOG-2;C-terminal-binding protein-2	The results demonstrated that 1 ) zinc fingers 1 and 6 of FOG-2 are each capable of interacting with evolutionarily conserved motifs within the N-terminal zinc finger of mammalian GATA proteins , 2 ) a nuclear localization signal ( RKRRK ) ( amino acids 736-740 ) is required to program nuclear targeting of FOG-2 , and 3 ) ***FOG-2*** can ***interact*** with the transcriptional co-repressor , ***C-terminal-binding protein-2*** via a conserved sequence motif in FOG-2 ( PIDLS ) .	parallel	1
14318	10801818	7408;55740	VASP;Mena	The reduction in ******Mena/VASP****** ***binding*** was confirmed by peptide tests , immunoprecipitation , and ectopic expression of zyxin variants at the surface of mitochondria .	parallel	1
14319	10801818	7791;55740	zyxin;Mena	By transfection assays we showed that ***zyxin*** ***interaction*** with ***Mena/VASP*** in vivo enhances the production of actin-rich structures at the apical surface of cells .	parallel	1
14320	10801818	7791;7408	zyxin;VASP	By transfection assays we showed that ***zyxin*** ***interaction*** with ***Mena/VASP*** in vivo enhances the production of actin-rich structures at the apical surface of cells .	parallel	1
14321	10801826	5175;1499	PECAM-1;beta-catenin	Recently we demonstrated that ***PECAM-1/beta-catenin*** association functions to ***regulate*** ***beta-catenin*** localization and , moreover , to modulate beta-catenin tyrosine phosphorylation levels .	target	1
14322	10801826	1499;5175	beta-catenin;PECAM-1	Recently we demonstrated that ******PECAM-1/beta-catenin****** ***association*** functions to regulate beta-catenin localization and , moreover , to modulate beta-catenin tyrosine phosphorylation levels .	parallel	0
14323	10801826	1499;5175	beta-catenin;PECAM-1	Here we show that : 1 ) not only ***beta-catenin*** , but also gamma-catenin is ***associated*** with ***PECAM-1*** in vitro and in vivo ; 2 ) PKC enzyme directly phosphorylates purified PECAM-1 ; 3 ) PKC-derived PECAM-1 serine/threonine phosphorylation inversely correlates with gamma-catenin association ; 4 ) PECAM-1 recruits gamma-catenin to cell-cell junctions in transfected SW480 cells ; and 5 ) gamma-catenin may recruit PECAM-1 into an insoluble cytoskeletal fraction .	parallel	0
14324	10801827	1915;10102	EF-Tu;EF-Ts	The ***binding*** of ***EF-Tu*** ( mt ) to ***EF-Ts*** ( mt ) is mutually exclusive with the formation of the ternary complex .	parallel	1
14325	10801838	860;1052	Runx-2;C/EBPdelta	***C/EBPdelta*** gene promoter activity was reduced by mutating the Runx binding sequence or by co-transfecting with Runx2 antisense expression plasmid , and was ***enhanced*** by overexpression of ***Runx-2*** .	positive	0
14326	10801838	860;1052	Runx2;C/EBPdelta	***Runx2*** ***bound*** directly to the carboxyl-terminal region of ***C/EBPdelta*** itself , and its ability to drive C/EBPdelta expression was suppressed when C/EBPdelta or its carboxyl-terminal fragment was increased by overexpression .	parallel	1
14327	10801838	1052;860	C/EBPdelta;Runx2	These ***interactions*** between ***Runx2*** and ***C/EBPdelta*** , and their activation by prostaglandin E ( 2 ) , provide new evidence for their importance during skeletal remodeling , inflammatory bone disease , or fracture repair .	parallel	1
14328	10801840	7432;7433	vasoactive intestinal peptide;VPAC1	Identification of key residues for ***interaction*** of ***vasoactive intestinal peptide*** with human ***VPAC1*** and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist .	parallel	1
14329	10801843	4091;7045	Smad6;transforming growth factor beta -induced	Smad7 and ***Smad6*** differentially ***modulate*** ***transforming growth factor beta -induced*** inhibition of embryonic lung morphogenesis .	target	0
14330	10801843	4092;7045	Smad7;transforming growth factor beta -induced	***Smad7*** and Smad6 differentially ***modulate*** ***transforming growth factor beta -induced*** inhibition of embryonic lung morphogenesis .	target	0
14331	10801843	4092;7040	Smad7;TGF-beta	Inhibitory ***Smad7*** was recently identified to ***antagonize*** ***TGF-beta*** family signaling by interfering with the activation of TGF-beta signal-transducing Smad complexes .	negative	1
14332	10801843	7040;6440	TGF-beta;surfactant protein C	Smad7 also prevented ***TGF-beta-mediated*** ***down-regulation*** of ***surfactant protein C*** gene expression , a marker of bronchial epithelial differentiation , in cultured embryonic lungs .	negative	1
14333	10801843	4092;4087	Smad7;Smad2	Moreover , we found that ***Smad7*** transgene expression ***blocked*** ***Smad2*** phosphorylation induced by exogenous TGF-beta ligand in lung culture , indicating that Smad7 exerts its inhibitory effect on both lung growth and epithelial cell differentiation through modulation of TGF-beta pathway-restricted Smad activity .	negative	0
14334	10801843	4091;7040	Smad6;TGF-beta	However , the above anti-TGF-beta signal transduction effects were not observed in cultured embryonic lungs with Smad6 adenoviral gene transfer , suggesting that Smad7 and ***Smad6*** differentially ***regulate*** ***TGF-beta*** signaling in developing lungs .	target	1
14335	10801843	4092;7040	Smad7;TGF-beta	However , the above anti-TGF-beta signal transduction effects were not observed in cultured embryonic lungs with Smad6 adenoviral gene transfer , suggesting that ***Smad7*** and Smad6 differentially ***regulate*** ***TGF-beta*** signaling in developing lungs .	target	1
14336	10801847	4790;4792	NF-kappaB;IkappaBalpha	***IkappaBalpha*** itself is transcriptionally ***regulated*** by ***NF-kappaB*** allowing for a tight autoregulatory loop that is both sensitive to and rapidly influenced by NF-kappaB activating stimuli .	target	1
14337	10801851	940;5599	CD28;JNK	In T cells , the ***JNK*** mitogen-activated protein kinase is ***activated*** by simultaneous stimulation of the T-cell receptor and ***CD28*** or by a number of stress stimuli including ultraviolet light , hydrogen peroxide , and anisomycin .	positive	1
14338	10801852	4331;1022	MAT1;cdk7	Distinct regions of ***MAT1*** ***regulate*** ***cdk7*** kinase and TFIIH transcription activities .	target	1
14339	10801852	4331;2967	MAT1;TFIIH	Distinct regions of ***MAT1*** ***regulate*** cdk7 kinase and ***TFIIH*** transcription activities .	target	1
14340	10801852	902;2967	CAK;TFIIH	The median portion of MAT1 , which contains a coiled-coil motif , allows the ***binding*** of ***CAK*** to the ***TFIIH*** core through interactions with both XPD and XPB helicases .	parallel	1
14341	10801854	23582;9402	GCIP;grap2	We found that ***GCIP*** ***bound*** to ***grap2*** in both yeast two-hybrid assays and in mammalian cells through binding to the COOH-terminal unique domain and SH3 domain ( designated QC domain ) of grap2 .	parallel	1
14342	10801861	51738;2693	Ghrelin;growth hormone secretagogue receptor	Purification and characterization of rat ***des-Gln14-Ghrelin*** , a second endogenous ***ligand*** for the ***growth hormone secretagogue receptor*** .	parallel	1
14343	10801873	5524;5894	PP2A;Raf-1	The ***PP2A*** core heterodimer forms ***complexes*** with ***Raf-1*** in vivo and in vitro .	parallel	1
14344	10801894	5594;1956	ERK-1 and -2;epidermal growth factor receptor	Activation of ***ERK-1 and -2*** by H ( 2 ) O ( 2 ) in a variety of cell types ***requires*** ***epidermal growth factor receptor*** ( EGFR ) phosphorylation .	target	0
14345	10801894	847;5594	Catalase;ERK	***Catalase*** ***blocked*** ***ERK*** activation by H ( 2 ) O ( 2 ) , but not by ONOO ( - ) , demonstrating that the effect of ONOO ( - ) was not due to the generation of H ( 2 ) O ( 2 ) .	negative	0
14346	10801950	2981;4883	uroguanylin;guanylate cyclase C	***uroguanylin*** , a natriuretic peptide hormone , is an endogenous ***ligand*** for the same ***guanylate cyclase C*** that the Escherichia coli heat-stable enterotoxin ( STa ) binds when it causes secretory diarrhea by activating the cystic fibrosis transmembrane conductance regulator , thus altering fluid balance in the intestine .	parallel	1
14347	10802049	387;5337	RhoA;PLD1	Cav-3-enriched light membrane ( CELM ) fractions obtained from C2C12 myotubes contain phospholipase D1 ( ***PLD1*** ) and its major ***regulators*** , ***RhoA*** and protein kinase Calpha ( PKCalpha ) .	target	1
14348	10802049	387;859	RhoA;Cav-3	The Cav-3-PLD1 complex was not affected by BK treatment , whereas the agonist induced a marked increase of ***RhoA*** ***association*** with ***Cav-3*** .	parallel	0
14349	10802049	5337;859	PLD1;Cav-3	The ******Cav-3-PLD1****** ***complex*** was not affected by BK treatment , whereas the agonist induced a marked increase of RhoA association with Cav-3 .	parallel	1
14350	10802050	8862;187	Apelin;APJ receptor	Because ***Apelin*** is an endogenous ***ligand*** for the ***APJ receptor*** , we examined the inhibitory effects of Apelin peptides on HIV infection , and found that the Apelin peptides inhibit the entry of some HIV-1 and HIV-2 into the NP-2 / CD4 cells expressing APJ .	parallel	1
14351	10802057	2023;4609	ENO1;c-myc	***ENO1*** gene product ***binds*** to the ***c-myc*** promoter and acts as a transcriptional repressor : relationship with Myc promoter-binding protein 1 ( MBP-1 ) .	parallel	1
14352	10802067	1316;3851	Zf9;keratin 4	Using transient transfection , ***Zf9*** ***transactivates*** the human ***keratin 4*** ( K4 ) promoter reporter gene construct in a subset of the esophageal cancer cell lines through indirect mechanisms .	positive	1
14353	10802154	3827;3643	Bradykinin;insulin receptor	Our results clearly demonstrated that ***Bradykinin*** ***enhanced*** insulin-stimulated tyrosine kinase activity of the ***insulin receptor*** and downstream insulin signal cascade through the BK2R mediated signal pathway .	positive	0
14354	10802154	3827;3643	Bradykinin;insulin receptor	***Bradykinin*** ***enhances*** ***insulin receptor*** tyrosine kinase in 32D cells reconstituted with Bradykinin and insulin signaling pathways .	positive	0
14355	10802154	3827;3643	Bradykinin;insulin receptor	In 32D cells that expressed BK2R , insulin receptor and IRS-1 ( 32D-BKR/IR/IRS1 ) , ***Bradykinin*** also ***enhanced*** insulin-stimulated tyrosine phosphorylation of the ***insulin receptor*** and IRS-1 .	positive	0
14356	10802154	3827;3667	Bradykinin;IRS-1	In 32D cells that expressed BK2R , insulin receptor and IRS-1 ( 32D-BKR/IR/IRS1 ) , ***Bradykinin*** also ***enhanced*** insulin-stimulated tyrosine phosphorylation of the insulin receptor and ***IRS-1*** .	positive	0
14357	10802655	7157;7161	p53;p73	Here we report that some tumour-derived ***p53*** mutants can ***bind*** to and inactivate ***p73*** .	parallel	1
14358	10802669	4361;4683	MRE11;nibrin	ATM phosphorylation of nibrin does not affect ******nibrin-MRE11-RAD50****** ***association*** as revealed by radiation-induced foci formation .	parallel	0
14359	10802669	10111;4361	RAD50;MRE11	ATM phosphorylation of nibrin does not affect ******nibrin-MRE11-RAD50****** ***association*** as revealed by radiation-induced foci formation .	parallel	0
14360	10802669	10111;4683	RAD50;nibrin	ATM phosphorylation of nibrin does not affect ******nibrin-MRE11-RAD50****** ***association*** as revealed by radiation-induced foci formation .	parallel	0
14361	10802669	472;4683	ATM;nibrin	***ATM*** ***phosphorylation*** of ***nibrin*** does not affect nibrin-MRE11-RAD50 association as revealed by radiation-induced foci formation .	target	1
14362	10802669	472;4683	ATM;nibrin	***ATM-dependent*** ***phosphorylation*** of ***nibrin*** in response to radiation exposure .	target	1
14363	10802669	472;4683	ATM;nibrin	We also show that ***ATM*** physically interacts with and ***phosphorylates*** ***nibrin*** on serine 343 both in vivo and in vitro .	target	1
14364	10803206	1137;4760	nAChR;beta 2	The alpha 4 ***nAChR*** is ***associated*** mainly with the ***beta 2*** subunit , and may form a component of the nicotinic pain pathways modulating the antinociceptive effect of nicotine .	parallel	0
14365	10803405	3726;1956	JunB;EGFR	***JunB*** , but not c-fos , also ***enhanced*** the ***EGFR*** promoter activity .	positive	0
14366	10803407	4846;5578	eNOS;PKCalpha	The translocation of PKCalpha , but not PKCiota , was susceptible to inhibition by Ro 31-8220 that also inhibited PAF-evoked NO release , suggesting that PKCalpha is the principal isozyme involved in this process and that ***eNOS*** may be a ***substrate*** for ***PKCalpha*** .	parallel	1
14367	10803460	1499;8945	beta-catenin;Beta-TrCP	These results suggest that while both plakoglobin and ***beta-catenin*** can comparably ***interact*** with ***Beta-TrCP*** and the ubiquitination system , the sequestration of plakoglobin by the membrane-cytoskeleton system renders it inaccessible to the proteolytic machinery and stabilizes it .	parallel	1
14368	10803462	22808;207	R-Ras3;Akt	***R-Ras3*** , a brain-specific Ras-related protein , ***activates*** ***Akt*** and promotes cell survival in PC12 cells .	positive	1
14369	10803462	22808;5599	R-Ras3;JNK	On the contrary , both ***R-Ras3*** and H-Ras ***activated*** the Jun N-terminal kinase ( ***JNK*** ) to a similar extent .	positive	1
14370	10803462	22808;207	R-Ras3;Akt	The ***activation*** of ***Akt*** by ***R-Ras3*** was most likely to be PI3-K-dependent since this biochemical event was blocked by the pharmacological inhibitors , Wortmannin and LY294002 , as well as by a dominant negative mutant of PI3-K .	positive	1
14371	10803464	4352;7066	Mpl;thrombopoietin	***Mpl*** is the ***receptor*** for ***thrombopoietin*** , the primary regulator of platelet production by megakaryocytes .	parallel	1
14372	10803465	4803;4914	NGF;TrkA	***Activation*** of the neurotrophin receptor ***TrkA*** by its ligand nerve growth factor ( ***NGF*** ) initiates a cascade of signaling events leading to neuronal differentiation in vitro and might play an important role in the differentiation of favorable neuroblastomas ( NB ) in vivo .	positive	1
14373	10803466	2886;3643	Grb7;insulin receptor	Evidence for an ***interaction*** between the ***insulin receptor*** and ***Grb7*** .	parallel	1
14374	10803567	5443;4158	ACTH;ACTH receptor	***ACTH*** , IGF-I , and AngII ***increased*** ***ACTH receptor*** mRNA , but the opposite was observed after TGFbeta1 treatment .	positive	0
14375	10803567	3479;4158	IGF-I;ACTH receptor	ACTH , ***IGF-I*** , and AngII ***increased*** ***ACTH receptor*** mRNA , but the opposite was observed after TGFbeta1 treatment .	positive	0
14376	10803567	5443;1586	ACTH;P450c17	***ACTH*** and IGF-I ***increased*** ***P450c17*** and 3betaHSD mRNAs , whereas AngII and TGFbeta1 had the opposite effects .	positive	0
14377	10803567	3479;1586	IGF-I;P450c17	ACTH and ***IGF-I*** ***increased*** ***P450c17*** and 3betaHSD mRNAs , whereas AngII and TGFbeta1 had the opposite effects .	positive	0
14378	10803577	1050;3175	CCAAT/enhancer-binding protein-alpha;hnf6	In protein-DNA interaction studies and in transfection experiments , we found that the liver-enriched transcription factor ***CCAAT/enhancer-binding protein-alpha*** ( C/EBPalpha ) ***binds*** to the ***hnf6*** gene and inhibits its expression .	parallel	1
14379	10803585	3589;7422	IL-11;vascular endothelial growth factor	At 16-72 h , ***IL-11*** ***stimulates*** the secretion of the angiogenic factor ***vascular endothelial growth factor*** by FS cells .	positive	0
14380	10803589	51083;5443	galanin;POMC	Taken together , these data indicate that ***galanin*** can directly ***modulate*** the activity of ***POMC*** neurons , via an action on GalR1 or GalR2 receptors , particularly in the rostral-arcuate nucleus .	target	0
14381	10803591	1385;3066	CREB;hD2	***CREB*** protein , once cotransfected with hD2 promoter construct and pKA in F9 teratocarcinoma cells , which are unresponsive to cAMP , was able to ***stimulate*** the ***hD2*** gene transcription .	positive	0
14382	10803598	3791;3976	Flk-1;LIF	Furthermore , wild-type and P4-treated PRLR - / - mice had similar expression of the implantation-specific genes , ***LIF*** , amphiregulin , HB-EGF , COX-1 , COX-2 , PPARdelta , Hoxa-10 , cyclin-D3 , VEGF , and its ***receptors*** , ***Flk-1*** and neuropilin-1 .	parallel	1
14383	10803598	8829;3976	neuropilin-1;LIF	Furthermore , wild-type and P4-treated PRLR - / - mice had similar expression of the implantation-specific genes , ***LIF*** , amphiregulin , HB-EGF , COX-1 , COX-2 , PPARdelta , Hoxa-10 , cyclin-D3 , VEGF , and its ***receptors*** , Flk-1 and ***neuropilin-1*** .	parallel	1
14384	10803599	57126;5741	cell surface receptor;PTH	Because of its structural similarity to PTH at the amino terminus , the two proteins interact with a common ***cell surface receptor*** , the ***PTH/PTHrP*** ***receptor*** .	parallel	1
14385	10803604	51052;2796	PrRP;LHRH	***PrRP*** significantly ***increased*** the release of ***LHRH*** from hypothalamic explants in vitro ( PrRP 100nmol/l 180.5 + / - 34.5 % of the basal secretion , p < 0.05 ) .	positive	0
14386	10803679	1565;10	CYP2D6;NAT2	We thus explored the possible ***association*** of ***NAT2*** and ***CYP2D6*** alleles and diabetes-related traits in a sample of 112 Oji-Cree subjects with type 2 diabetes and 481 Oji-Cree subjects without type 2 diabetes .	parallel	0
14387	10803841	7124;5284	TNF-alpha;pIgR	Furthermore , the ***stimulation*** of ***pIgR*** mRNA by ***TNF-alpha*** was decreased by pyrrolidinedithiocarbamate and L-1-4 ' - tosylamino-phenylethyl-chloromethyl ketone , which are known nuclear factor ( NF ) - kappaB inhibitors .	positive	0
14388	10803880	970;939	CD70;CD27	******CD27/CD70****** ***interactions*** regulate T dependent B cell differentiation .	parallel	1
14389	10803880	970;939	CD70;CD27	In complement of ligation of CD40 , another TNF receptor family member expressed by B cells , ******CD27/CD70****** ***interaction*** plays a key role in T dependent B cell responses and is responsible for plasma cell differentiation .	parallel	1
14390	10803931	3586;3558	IL-10;IL-2	***IL-10*** ***inhibits*** secretion of ***IL-2*** and interferon (IFN)gamma by T cells and downregulates major histocompatibility complex antigens .	negative	1
14391	10803931	3586;3458	IL-10;interferon (IFN)gamma	***IL-10*** ***inhibits*** secretion of IL-2 and ***interferon (IFN)gamma*** by T cells and downregulates major histocompatibility complex antigens .	negative	1
14392	10803982	7157;1026	p53;p21	The results suggested that high levels of p53 accumulation were associated with the expression of wild-type ***p53*** , which was able to ***activate*** the transcription of the ***p21*** gene .	positive	1
14393	10804015	5741;4982	PTH;OPG	PTH analog ***PTH*** ( 1-31 ) , which stimulates intracellular cAMP accumulation , ***inhibited*** ***OPG*** expression , whereas PTH analogs ( 3-34 and 7-34 ) that do not stimulate cAMP production had no effect on expression .	negative	1
14394	10804017	5741;7040	Parathyroid hormone;TGF-beta1	***Parathyroid hormone*** 1-34 [ PTH ( 1-34 ) ] was shown to ***increase*** transforming growth factor beta1 ( ***TGF-beta1*** ) and TGF-beta2 concentrations in supernatants of cultured human osteoblasts and to increase TGF-beta1 and TGF-beta2 messenger RNA ( mRNA ) concentrations and gene transcription in these cells .	positive	0
14395	10804017	5741;7042	Parathyroid hormone;TGF-beta2	***Parathyroid hormone*** 1-34 [ PTH ( 1-34 ) ] was shown to ***increase*** transforming growth factor beta1 ( TGF-beta1 ) and ***TGF-beta2*** concentrations in supernatants of cultured human osteoblasts and to increase TGF-beta1 and TGF-beta2 messenger RNA ( mRNA ) concentrations and gene transcription in these cells .	positive	0
14396	10804018	3569;3553	IL-6;IL-1beta	PDB pretreatment reduced IL-6 responses to 5 nM and 10 nM PTH by 61 % and 33 % , respectively , reduced IL-6 responses to 5nM and 10 nM TNF-a by 54 % and 42 % , respectively , and failed to inhibit the ***IL-6*** ***responses*** to 0.1-10 nM ***IL-1beta*** .	parallel	0
14397	10804018	3569;5741	IL-6;PTH	The PKC inhibitor calphostin C also decreased ***IL-6*** ***responses*** to ***PTH*** .	parallel	0
14398	10804021	3586;3569	IL-10;IL-6	***IL-10*** specifically ***abrogated*** the production of ***IL-6*** by enriched bone marrow-derived mononuclear cells ( BMM ) but not by osteoblastic cells .	negative	0
14399	10804175	388585;3280	HES5;HES1	***HES5*** ***synergizes*** with ***HES1*** and regulates neurogenesis at the level of Ngn1 expression .	parallel	0
14400	10804175	388585;429	HES5;Mash1	In contrast , expression of ***HES5*** is restricted to clusters of neural progenitor cells and ***requires*** ***Mash1*** function .	target	0
14401	10804175	3280;429	HES1;Mash1	Together , our results suggest that ***HES1*** ***regulates*** ***Mash1*** transcription in the olfactory placode in two different contexts , initially as a prepattern gene defining the placodal domain undergoing neurogenesis and , subsequently , as a neurogenic gene controlling the density of neural progenitors in this domain .	target	1
14402	10804178	5080;2019	Pax6;En1	***Pax6*** ***repressed*** ***En1*** , Pax2 and other tectum ( mesencephalon ) - related genes such as En2 , Pax5 , Pax7 , but induced Tcf4 , a diencephalon marker gene .	negative	1
14403	10804178	5080;5076	Pax6;Pax2	***Pax6*** ***repressed*** En1 , ***Pax2*** and other tectum ( mesencephalon ) - related genes such as En2 , Pax5 , Pax7 , but induced Tcf4 , a diencephalon marker gene .	negative	1
14404	10804178	5080;2019	Pax6;En1	To know how ***Pax6*** ***represses*** ***En1*** and Pax2 , we ectopically expressed a dominant-active or negative form of Pax6 .	negative	1
14405	10804178	5080;5076	Pax6;Pax2	To know how ***Pax6*** ***represses*** En1 and ***Pax2*** , we ectopically expressed a dominant-active or negative form of Pax6 .	negative	1
14406	10804178	2019;5080	En1;Pax6	The results of misexpression experiments , together with normal expression patterns of Pax6 , En1 and Pax2 , suggest that repressive ***interaction*** between ***Pax6*** and ***En1/Pax2*** defines the di-mesencephalic boundary .	parallel	1
14407	10804178	5076;2019	Pax2;En1	The results of misexpression experiments , together with normal expression patterns of Pax6 , En1 and Pax2 , suggest that repressive ***interaction*** between Pax6 and ******En1/Pax2****** defines the di-mesencephalic boundary .	parallel	1
14408	10804178	5076;5080	Pax2;Pax6	The results of misexpression experiments , together with normal expression patterns of Pax6 , En1 and Pax2 , suggest that repressive ***interaction*** between ***Pax6*** and ***En1/Pax2*** defines the di-mesencephalic boundary .	parallel	1
14409	10804186	9464;6469	dHAND;Sonic hedgehog	The bHLH transcription factor ***dHAND*** ***controls*** ***Sonic hedgehog*** expression and establishment of the zone of polarizing activity during limb development .	target	0
14410	10804204	7432;7124	VIP;TNF-alpha	We conclude that ***VIP*** and PACAP ***inhibit*** the production of ***TNF-alpha*** from activated microglia by a cAMP-dependent pathway .	negative	1
14411	10804204	7432;7124	Vasoactive intestinal peptide;tumor necrosis factor-alpha	***Vasoactive intestinal peptide*** and pituitary adenylyl cyclase-activating polypeptide ***inhibit*** ***tumor necrosis factor-alpha*** production in injured spinal cord and in activated microglia via a cAMP-dependent pathway .	negative	1
14412	10804204	7432;7124	VIP;TNF-alpha	***TNF-alpha*** protein levels were ***reduced*** 90 % by ***VIP*** or PACAP at 10 ( -7 ) m.	negative	1
14413	10804218	5829;5747	paxillin;FAK	***paxillin*** ***coimmunoprecipitates*** with ***FAK*** and fyn kinase in differentiating SC/N cocultures .	parallel	1
14414	10804218	5829;5747	paxillin;FAK	Collectively , our work indicates that beta1 integrin , ***FAK*** , ***paxillin*** , and fyn kinase form an actin-associated ***complex*** in SCs adhering to basal lamina in the presence of axons .	parallel	1
14415	10805093	7249;7248	tuberin;hamartin	These results provide evidence for the co-localization and ***interaction*** of ***hamartin*** and ***tuberin*** in vivo , and suggest that a mutation in one TSC gene may secondarily affect the expression of the other in some TSC lesions .	parallel	1
14416	10805215	7040;1508	TGFbeta;cathepsin B	These results suggest that ***induction*** of ***cathepsin B*** by ***TGFbeta*** , and its ability to activate TGFbeta1 , may represent a mechanism whereby the autocrine action of TGFbeta is facilitated through expression of a protein which can process its latent form .	target	1
14417	10805282	7450;6850	vWF;Syk	Botrocetin and ***vWF*** ***induced*** ***Syk*** activation .	target	1
14418	10805286	5104;5624	protein C inhibitor;protein C	***protein C inhibitor*** ( PCI ) is a plasma serine protease ***inhibitor*** of activated ***protein C*** , which is the main protease of the anticoagulant protein C pathway .	negative	1
14419	10805369	3439;894	IFN-alpha;cyclin D2	Furthermore , ***IFN-alpha*** alone ***induced*** ***cyclin D2*** mRNA and protein in normal BMM .	target	1
14420	10805371	3553;3458	IL-1;interferon-gamma	In macrophages , interleukin-1 ( ***IL-1*** ) and lipopolysaccharide ( LPS ) ***enhance*** the antichlamydial effect of ***interferon-gamma*** ( IFN-gamma ) by increasing indoleamine 2,3-dioxygenase ( IDO ) activity in a dose-dependent manner .	positive	0
14421	10805373	3456;3586	IFN-beta;IL-10	Finally , whereas IFN-beta inhibited antigen-driven generation of IL-5 , IL-12 , IL-13 , and IFN-gamma , ***IFN-beta*** ***enhanced*** generation of both IL-4 and ***IL-10*** .	positive	0
14422	10805373	3456;3565	IFN-beta;IL-4	Finally , whereas IFN-beta inhibited antigen-driven generation of IL-5 , IL-12 , IL-13 , and IFN-gamma , ***IFN-beta*** ***enhanced*** generation of both ***IL-4*** and IL-10 .	positive	0
14423	10805373	3456;3458	IFN-beta;IFN-gamma	Finally , whereas ***IFN-beta*** ***inhibited*** antigen-driven generation of IL-5 , IL-12 , IL-13 , and ***IFN-gamma*** , IFN-beta enhanced generation of both IL-4 and IL-10 .	negative	1
14424	10805373	3456;3596	IFN-beta;IL-13	Finally , whereas ***IFN-beta*** ***inhibited*** antigen-driven generation of IL-5 , IL-12 , ***IL-13*** , and IFN-gamma , IFN-beta enhanced generation of both IL-4 and IL-10 .	negative	1
14425	10805373	3456;3567	IFN-beta;IL-5	Finally , whereas ***IFN-beta*** ***inhibited*** antigen-driven generation of ***IL-5*** , IL-12 , IL-13 , and IFN-gamma , IFN-beta enhanced generation of both IL-4 and IL-10 .	negative	1
14426	10805374	3458;3627	IFN-gamma;IP-10	We studied the ***induction*** of ***IP-10*** from nonadherent peripheral blood mononuclear cells ( PBMC ) by ***IFN-gamma*** , interleukin-12 ( IL-12 ) , and the HER-2 peptide E75 , which forms a CTL-defined antigen .	target	1
14427	10805374	958;959	CD40;CD40L	IP-10 induction by E75 required HLA-A2 presentation and B7-CD28 interactions and was partially inhibited by blocking of ******CD40-CD40L****** ***interactions*** .	parallel	1
14428	10805722	841;637	caspase 8;Bid	Furthermore , we demonstrate that Granzyme B directly cleaves the proapoptotic molecule Bid , bypassing the need for ***caspase 8*** ***activation*** of ***Bid*** .	positive	1
14429	10805722	3002;637	Granzyme B;Bid	Furthermore , we demonstrate that ***Granzyme B*** directly ***cleaves*** the proapoptotic molecule ***Bid*** , bypassing the need for caspase 8 activation of Bid .	target	1
14430	10805722	637;3002	Bid;Granzyme B	These results provide evidence for a two-pronged strategy for mediating target cell destruction and provide evidence of a direct ***link*** between ***Granzyme B*** activity , ***Bid*** cleavage , and caspase 3 activation in whole cells .	parallel	0
14431	10805722	836;637	caspase 3;Bid	These results provide evidence for a two-pronged strategy for mediating target cell destruction and provide evidence of a direct ***link*** between Granzyme B activity , ***Bid*** cleavage , and ***caspase 3*** activation in whole cells .	parallel	0
14432	10805722	836;3002	caspase 3;Granzyme B	These results provide evidence for a two-pronged strategy for mediating target cell destruction and provide evidence of a direct ***link*** between ***Granzyme B*** activity , Bid cleavage , and ***caspase 3*** activation in whole cells .	parallel	0
14433	10805733	3643;3192	insulin receptor;pp120	Thus , it appears that ***pp120*** ***phosphorylation*** by the ***insulin receptor*** is required and sufficient to mediate its downregulatory effect on the mitogenic action of insulin .	target	1
14434	10805737	8894;1983	eIF2beta;eIF5	In this work , we have used a mutational approach to investigate the importance of ******eIF5-eIF2beta****** ***interaction*** in eIF5 function .	parallel	1
14435	10805737	1983;8894	eIF5;eIF2beta	The E346A , E347A and E384A , E385A double-point mutations each caused a severe defect in the ***binding*** of ***eIF5*** to ***eIF2beta*** but not to eIF3-Nip1p , while a eIF5 hexamutant ( E345A , E346A , E347A , E384A , E385A , E386A ) showed negligible binding to eIF2beta .	parallel	1
14436	10805737	8894;1983	eIF2beta;eIF5	These findings suggest that ******eIF5-eIF2beta****** ***interaction*** plays an essential role in eIF5 function in eukaryotic cells .	parallel	1
14437	10805738	5594;4654	p38;MyoD	Much evidence indicates that ***p38*** is an ***activator*** of ***MyoD*** : ( i ) p38 kinase activity is required for the expression of MyoD-responsive genes , ( ii ) enforced induction of p38 stimulates the transcriptional activity of a Gal4-MyoD fusion protein and allows efficient activation of chromatin-integrated reporters by MyoD , and ( iii ) MyoD-dependent myogenic conversion is reduced in mouse embryonic fibroblasts derived from p38alpha ( - / - ) embryos .	positive	1
14438	10805738	5594;4208	p38;MEF2C	Activation of ***p38*** also ***enhances*** the transcriptional activities of myocyte enhancer binding factor 2A ( MEF2A ) and ***MEF2C*** by direct phosphorylation .	positive	0
14439	10805749	7157;581	p53;Bax	Induced ***p53*** was transcriptionally active and ***mediated*** the induction of p21 and ***Bax*** in slip cells .	target	0
14440	10805749	7157;1026	p53;p21	Induced ***p53*** was transcriptionally active and ***mediated*** the induction of ***p21*** and Bax in slip cells .	target	0
14441	10805757	3661;1977	IRF-3;CBP	Following infection , phosphorylated ***IRF-3*** can ***bind*** to the ***CBP/p300*** proteins resident in the nucleus .	parallel	1
14442	10805757	3661;2033	IRF-3;p300	Following infection , phosphorylated ***IRF-3*** can ***bind*** to the ***CBP/p300*** proteins resident in the nucleus .	parallel	1
14443	10805757	2033;1977	p300;CBP	We provide the evidence of a role for ******CBP/p300****** ***binding*** in the nuclear sequestration of a transcription factor that normally resides in the cytoplasm .	parallel	1
14444	10805782	3689;3383	LFA-1;ICAM-1	These results indicate that ***LFA-1*** ***binding*** to ***ICAM-1*** is regulated by an I domain allosteric site ( IDAS ) and that this site is structurally linked to the MIDAS .	parallel	1
14445	10805782	3689;3383	LFA-1;ICAM-1	Substitution of residues in the core of this second I domain site resulted in constitutively active ***LFA-1*** ***binding*** to ***ICAM-1*** .	parallel	1
14446	10805787	6772;8554	Stat1;PIAS1	Distinct roles of the NH2 - and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 ( PIAS1 ) in cytokine-induced ******PIAS1-Stat1****** ***interaction*** .	parallel	1
14447	10805787	6772;8554	Stat1;PIAS1	IFN treatment induces the ***association*** of ***PIAS1*** and ***Stat1*** , which results in the inhibition of Stat1-mediated gene activation .	parallel	0
14448	10805787	3439;8554	IFN;PIAS1	***IFN*** treatment ***induces*** the association of ***PIAS1*** and Stat1 , which results in the inhibition of Stat1-mediated gene activation .	target	1
14449	10805787	3439;6772	IFN;Stat1	***IFN*** treatment ***induces*** the association of PIAS1 and ***Stat1*** , which results in the inhibition of Stat1-mediated gene activation .	target	1
14450	10805787	6772;8554	Stat1;PIAS1	The molecular basis of the cytokine-dependent ******PIAS1-Stat1****** ***interaction*** has not been understood .	parallel	1
14451	10805787	8554;6772	PIAS1;Stat1	By using a modified yeast two-hybrid assay , we demonstrated that ***PIAS1*** specifically ***interacts*** with the ***Stat1*** dimer , but not tyrosine-phosphorylated or - unphosphorylated Stat1 monomer .	parallel	1
14452	10805787	8554;6772	PIAS1;Stat1	In addition , whereas the NH ( 2 ) - terminal region of PIAS1 does not interact with Stat1 , it serves as a modulatory domain by preventing the ***interaction*** of the COOH-terminal domain of ***PIAS1*** with the ***Stat1*** monomer .	parallel	1
14453	10805787	8554;6772	PIAS1;Stat1	Thus , the cytokine-induced PIAS1-Stat1 interaction is mediated through the specific ***recognition*** of the dimeric form of ***Stat1*** by ***PIAS1*** .	target	1
14454	10805787	6772;8554	Stat1;PIAS1	Thus , the cytokine-induced ******PIAS1-Stat1****** ***interaction*** is mediated through the specific recognition of the dimeric form of Stat1 by PIAS1 .	parallel	1
14455	10805794	7157;5663	p53 tumor suppressor;presenilin 1	***presenilin 1*** ( PS1 ) expression is ***repressed*** by the ***p53 tumor suppressor*** .	negative	1
14456	10805805	25;84260	c-Abl;tumor suppressor protein	The ***c-Abl*** tyrosine kinase and the p53 ***tumor suppressor protein*** ***interact*** functionally and biochemically in cellular genotoxic stress response pathways and are implicated as downstream mediators of ATM ( ataxia-telangiectasia mutated ) .	parallel	1
14457	10805895	5502;5340	inhibitor-1;plasmin	Plasminogen activator ***inhibitor-1*** ( PAI-1 ) ***regulates*** ***plasmin*** activation through the tissue plasminogen activators .	target	1
14458	10805970	290;290	APN;CD13	Furthermore , we show that mRNA of the chemotactic cytokine IL-8 is upregulated under the influence of ******APN/CD13****** ***ligation*** .	parallel	1
14459	10805972	7040;6347	TGFbeta;MCP-1	Depletion of TGFbeta , TNFalpha , or both ***TGFbeta*** and TNFalpha from the mediator pool secreted by mast cells activated via the FcepsilonRI ***reduced*** the mast-cell-driven fibroblast ***MCP-1*** response by 80 + / -15 , 56 + / -11 , or 82 + / -5 % , respectively .	positive	1
14460	10805972	7124;6347	TNFalpha;MCP-1	Depletion of TGFbeta , ***TNFalpha*** , or both TGFbeta and TNFalpha from the mediator pool secreted by mast cells activated via the FcepsilonRI ***reduced*** the mast-cell-driven fibroblast ***MCP-1*** response by 80 + / -15 , 56 + / -11 , or 82 + / -5 % , respectively .	positive	1
14461	10806046	834;3553	ICE;IL-1beta	As the interleukin-1 converting enzyme ( ***ICE*** ) is the physiologic ***modulator*** of the production of active ***IL-1beta*** , we investigated the effect of diacerhein and its active metabolite rhein used in the treatment of OA patients , on the enzyme expression and synthesis on human OA cartilage .	target	0
14462	10806050	3557;8190	IL-1RA;MIA	The correlation analysis suggests ***associations*** between COMP , sIL-6R , TNF-alpha , ***IL-1RA*** on one hand and sTNFRII , and ***MIA*** and CRP on the other hand .	parallel	0
14463	10806050	3557;7124	IL-1RA;TNF-alpha	The correlation analysis suggests ***associations*** between COMP , sIL-6R , ***TNF-alpha*** , ***IL-1RA*** on one hand and sTNFRII , and MIA and CRP on the other hand .	parallel	0
14464	10806050	8190;7124	MIA;TNF-alpha	The correlation analysis suggests ***associations*** between COMP , sIL-6R , ***TNF-alpha*** , IL-1RA on one hand and sTNFRII , and ***MIA*** and CRP on the other hand .	parallel	0
14465	10806118	3630;3329	proinsulin;Cpn60	Double-labeling experiments showed ***associations*** between ***Cpn60*** and ***proinsulin*** , as well as between Cpn60 and PC1 convertase , with a preferential binding to proinsulin .	parallel	0
14466	10806118	3329;2641	Cpn60;glucagon	In vitro ***binding*** of ***Cpn60*** to proinsulin , insulin and ***glucagon*** was also documented .	parallel	1
14467	10806118	3329;3630	Cpn60;proinsulin	In vitro ***binding*** of ***Cpn60*** to ***proinsulin*** , insulin and glucagon was also documented .	parallel	1
14468	10806119	3458;100506658	interferon gamma;occludin	tumor necrosis factor alpha and ***interferon gamma*** ***diminished*** ***occludin*** promoter activity alone and even synergistically , suggesting a genomic regulation of alterations of the paracellular barrier .	negative	0
14469	10806119	7124;100506658	tumor necrosis factor alpha;occludin	***tumor necrosis factor alpha*** and interferon gamma ***diminished*** ***occludin*** promoter activity alone and even synergistically , suggesting a genomic regulation of alterations of the paracellular barrier .	negative	0
14470	10806190	7486;7341	Wrn;SUMO-1	The ***interaction*** between ***Wrn*** and ***SUMO-1*** was weaker than that between Wrn and Ubc9 .	parallel	1
14471	10806190	7341;7486	SUMO-1;Wrn	The interaction of Wrn and SUMO-1 was also abolished by deleting the Gly residue , indicating that the ***interaction*** of ***Wrn*** and ***SUMO-1*** is mediated by yUbc9 in the two-hybrid system .	parallel	1
14472	10806199	1440;1958	Granulocyte colony-stimulating factor;Egr-1	***Granulocyte colony-stimulating factor*** ***induces*** ***Egr-1*** up-regulation through interaction of serum response element-binding proteins .	target	1
14473	10806199	1440;1958	G-CSF;Egr-1	We showed that ***G-CSF*** rapidly and transiently ***induces*** expression of ***Egr-1*** in the NFS60 myeloid cell line .	target	1
14474	10806203	649;7453	BMP-1;gamma2	Recombinant ***BMP-1*** ***cleaves*** ***gamma2*** in vitro , both within intact laminin 5 and at the predicted site of a recombinant gamma2 short arm .	target	1
14475	10806209	5008;5972	Oncostatin M;renin	***Oncostatin M*** , a known endotoxin-responsive proinflammatory cytokine , proved to be an effective ***inhibitor*** of ***renin*** gene expression .	negative	1
14476	10806214	3308;836	HSP70;caspase-3	Moreover , the addition of purified recombinant ***HSP70*** to normal cytosolic fractions ***prevented*** ***caspase-3*** cleavage and DNA fragmentation , suggesting that HSP70 prevents apoptosis upstream of caspase-3 processing .	negative	0
14477	10806355	29893;5702	TBPIP;TBP-1	CAT assay reveals that human ***TBPIP*** could ***interact*** with human ***TBP-1*** , then enhance the function of TBP-1 on HIV ( human immunodeficiency virus ) - Tat-mediated transactivation .	parallel	1
14478	10806367	1385;5376	CREB;PMP22	Computer analysis of 2kb of the promoter predicted the presence of transcription factor binding sites , including ***CREB*** ( which may be involved in the ***response*** of ***PMP22*** expression to cAMP stimulation ) and steroid receptors .	parallel	0
14479	10806422	167359;983	Nim1;Cdc2	We show here genetic evidence that medium alkalization stimulates mitosis and consequently reduces cell size , either through the ***Nim1-Wee1*** cascade , which ***regulates*** the inhibitory phosphorylation of ***Cdc2*** at Tyr ( 15 ) , or through the Cdc2-activating phosphatase , Cdc25 .	target	1
14480	10806422	7465;983	Wee1;Cdc2	We show here genetic evidence that medium alkalization stimulates mitosis and consequently reduces cell size , either through the ***Nim1-Wee1*** cascade , which ***regulates*** the inhibitory phosphorylation of ***Cdc2*** at Tyr ( 15 ) , or through the Cdc2-activating phosphatase , Cdc25 .	target	1
14481	10806802	355;596	Apo-1;Bcl-2	The expression of ***Fas/Apo-1*** was inversely ***correlated*** with ***Bcl-2*** and seemed to be a good prognostic factor which may reflect the relative homeostasis of apoptotic pathway .	negative	0
14482	10807017	6401;7132	CD62E;TNFR-1	We hypothesized that the administration of monoclonal antibodies to intercellular adhesion molecule-1 ( CD54 ) or E - and L-selectin ( ***CD62E/L*** ) would ***decrease*** serum levels of the proinflammatory cytokines interleukin-1beta ( IL-1 ) , IL-6 , and IL-8 and tumor necrosis factor receptor ( ***TNFR-1*** ) in baboons during sepsis .	negative	0
14483	10807365	6774;1956	stat3;EGFR	The present study was conducted to study the ***association*** between ***EGFR*** stimulation and constitutive activation of ***stat3*** in SCCHN in vivo and to investigate the proliferative and apoptotic consequences of stat3 downmodulation in SCCHN cells in vitro .	parallel	0
14484	10807365	6774;1956	stat3;EGFR	CONCLUSIONS : These findings provide evidence that constitutively activated ***stat3*** is ***linked*** to ***EGFR*** signaling in SCCHN in vivo , which contributes to the loss of growth control by an anti-apoptotic mechanism .	parallel	0
14485	10807420	4760;6343	BETA2;Secretin	The basic helix-loop-helix protein , ***BETA2*** , binds to an E box sequence and associates with the p300 coactivator to ***activate*** transcription of the ***Secretin*** gene .	positive	1
14486	10807517	3606;356	IL-18;FasL	Propionibacterium acnes-primed lipopolysaccharide ( LPS ) - challenged liver injury is the prototype of IL-18-induced tissue injury , in which ***IL-18*** acts on natural killer cells to ***increase*** Fas ligand ( ***FasL*** ) that causes liver injury by induction of Fas-dependent hepatocyte apoptosis .	positive	0
14487	10807517	356;355	FasL;Fas	Propionibacterium acnes-primed lipopolysaccharide ( LPS ) - challenged liver injury is the prototype of IL-18-induced tissue injury , in which IL-18 acts on natural killer cells to increase ***Fas*** ***ligand*** ( ***FasL*** ) that causes liver injury by induction of Fas-dependent hepatocyte apoptosis .	parallel	1
14488	10807537	672;5888	BRCA1;Rad51	***BRCA1*** and BRCA2 proteins form a ***complex*** with ***Rad51*** , and these genes are thought to participate in a common DNA damage response pathway associated with the activation of homologous recombination and double-strand break repair .	parallel	1
14489	10807537	675;5888	BRCA2;Rad51	BRCA1 and ***BRCA2*** proteins form a ***complex*** with ***Rad51*** , and these genes are thought to participate in a common DNA damage response pathway associated with the activation of homologous recombination and double-strand break repair .	parallel	1
14490	10807582	183;6696	Angiotensinogen;osteopontin	Blockade of either ***Angiotensinogen*** or AT ( 1 ) mRNA translation by antisense oligonucleotide inhibition prior to cell stretch was found to significantly ***decrease*** ***osteopontin*** mRNA levels 2.4-fold ( P < 0.004 ) and 1.6-fold ( P < 0.001 ) , respectively , compared with values observed in control unstretched cells .	positive	0
14491	10807663	7124;4790	TNF-alpha;NF-kappaB	Nuclear ***NF-kappaB*** activity was robustly ***induced*** by ***TNF-alpha*** .	target	1
14492	10807665	9338;2885	p21;Grb2	Like dexamethasone , peptides containing E-Q-E-Y-V from the N-terminal domain of LC1 also blocked ligand-induced ***association*** of ***Grb2*** , ***p21*** ( ras ) and Raf .	parallel	0
14493	10807735	79109;3162	SIN-1;HO-1	***HO-1*** ***induction*** by ***SIN-1*** was inhibited in the presence of the NO scavenger phenyl-4 ,4,5,5 , - tetramethylimidazoline-1-oxyl-3-oxide and the soluble guanylyl cyclase inhibitor 1H - [ 1,2,4 ] oxadiazole [ 4 , 3-a ] quinoxalin-1-one .	target	1
14494	10807749	1071;4018	CETP;lipoprotein	The ***associations*** of the common ***CETP*** polymorphism , TaqIB in intron 1 , with ***lipoprotein*** levels and particle size distribution , CETP activity , and coronary heart disease ( CHD ) risk were examined in a population-based sample of 1411 men and 1505 women from the Framingham Offspring Study .	parallel	0
14495	10807756	2152;2155	tissue factor;factor VII	***tissue factor*** ( TF ) ***assembled*** with activated ***factor VII*** ( FVIIa ) initiates the coagulation cascade .	parallel	1
14496	10807756	2159;7422	FXa;VEGF	Moreover , thrombin and ***FXa*** ***induced*** VEGF secretion and ***VEGF*** mRNA accumulation , which were blocked by hirudin and FXa inhibitors , respectively .	target	1
14497	10807756	2159;5706	FXa;p42	Finally , FVIIa , by itself , had no effect on mitogen-activated protein ( MAP ) kinase activation , contrary to thrombin and ***FXa*** , which ***activate*** the ***p44/p42*** MAP kinase pathway , as shown by the blocking effect of PD 98059 and by Western blotting of activated MAP kinases .	positive	1
14498	10807756	2159;2966	FXa;p44	Finally , FVIIa , by itself , had no effect on mitogen-activated protein ( MAP ) kinase activation , contrary to thrombin and ***FXa*** , which ***activate*** the ***p44/p42*** MAP kinase pathway , as shown by the blocking effect of PD 98059 and by Western blotting of activated MAP kinases .	positive	1
14499	10807762	7040;596	TGF-beta1;bcl-2	***Modulation*** of ***bcl-2*** and p27 in human primitive proliferating hematopoietic progenitors by autocrine ***TGF-beta1*** is a cell cycle-independent effect and influences their hematopoietic potential .	target	0
14500	10807762	7040;5715	TGF-beta1;p27	***Modulation*** of bcl-2 and ***p27*** in human primitive proliferating hematopoietic progenitors by autocrine ***TGF-beta1*** is a cell cycle-independent effect and influences their hematopoietic potential .	target	0
14501	10807767	5608;4790	MKK6;NF-kappaB	In summary , our data suggest that LPS-induced ***NF-kappaB*** activation and IL-8 synthesis in HUVECs are ***regulated*** by both a Rho-dependent signaling pathway and the ***MKK6/p38*** kinase cascade .	target	1
14502	10807767	5594;4790	p38;NF-kappaB	In summary , our data suggest that LPS-induced ***NF-kappaB*** activation and IL-8 synthesis in HUVECs are ***regulated*** by both a Rho-dependent signaling pathway and the ***MKK6/p38*** kinase cascade .	target	1
14503	10807774	2247;7066	fibroblast growth factor (FGF) 2;TPO	We showed that platelet-derived growth factor ( PDGF ) BB and ***fibroblast growth factor (FGF) 2*** ***stimulated*** ***TPO*** mRNA expression in both a dose-dependent and time-dependent manner .	positive	0
14504	10807781	7124;3383	Tumor necrosis factor-alpha;ICAM-1	***Tumor necrosis factor-alpha*** ***induced*** the expression of VCAM-1 , E-selectin , and ***ICAM-1*** but had no effect on P-selectin expression .	target	1
14505	10807781	7124;7412	Tumor necrosis factor-alpha;VCAM-1	***Tumor necrosis factor-alpha*** ***induced*** the expression of ***VCAM-1*** , E-selectin , and ICAM-1 but had no effect on P-selectin expression .	target	1
14506	10807782	959;958	CD154;CD40	We hypothesize that in our model , anergy is induced in the CD4 ( + ) T-cell subset , whereby CD8 ( + ) cytotoxic effector function is impaired by the lack of both ******CD40-CD154****** ***signaling*** and cytokine-mediated help .	parallel	0
14507	10807783	959;958	CD40 ligand;CD40	Dendritic cell ( DC ) activation through ******CD40-CD40 ligand****** ***interactions*** is a key regulatory step for the development of protective T-cell immunity and also plays an important role in the initiation of T-cell responses involved in autoimmune diseases and allograft rejection .	parallel	1
14508	10807788	10125;3558	RasGRP;interleukin-2	Overexpression of ***RasGRP*** in T cells enhanced TCR-Ras-Erk signaling and ***augmented*** ***interleukin-2*** secretion in response to calcium ionophore plus DAG analogues phorbol ester myristate or bryostatin-1 .	positive	0
14509	10807793	3439;4210	IFN-alpha;MEFV	***IFN-alpha*** also ***induced*** ***MEFV*** expression .	target	1
14510	10807793	3439;4210	IFN-alpha;MEFV	In granulocytes , ***MEFV*** was ***up-regulated*** by IFN-gamma and the combination of ***IFN-alpha*** and colchicine .	positive	1
14511	10807793	3458;4210	IFN-gamma;MEFV	In granulocytes , ***MEFV*** was ***up-regulated*** by ***IFN-gamma*** and the combination of IFN-alpha and colchicine .	positive	1
14512	10807867	284;4313	Ang1;matrix metalloproteinase-2	***Ang1*** ***induced*** the secretion of plasmin and ***matrix metalloproteinase-2*** ( MMP-2 ) , which is inhibited by PI 3 ' - kinase inhibitors .	target	1
14513	10807867	284;5340	Ang1;plasmin	***Ang1*** ***induced*** the secretion of ***plasmin*** and matrix metalloproteinase-2 ( MMP-2 ) , which is inhibited by PI 3 ' - kinase inhibitors .	target	1
14514	10807867	284;7077	Ang1;tissue inhibitor of metalloproteinase-2	***Ang1*** ***suppressed*** the secretion of ***tissue inhibitor of metalloproteinase-2*** ( TIMP-2 ) , but not of TIMP-1 .	negative	1
14515	10807904	8797;8743	TRAIL-R1;TRAIL	Overexpression of the tumor necrosis factor ( TNF ) - related apoptosis-inducing ligand ( ***TRAIL*** ) ***receptors*** , ***TRAIL-R1*** and TRAIL-R2 , induces apoptosis and activation of NF-kappaB in cultured cells .	parallel	1
14516	10807904	8795;8743	TRAIL-R2;TRAIL	Overexpression of the tumor necrosis factor ( TNF ) - related apoptosis-inducing ligand ( ***TRAIL*** ) ***receptors*** , TRAIL-R1 and ***TRAIL-R2*** , induces apoptosis and activation of NF-kappaB in cultured cells .	parallel	1
14517	10807904	8743;3569	TRAIL;interleukin-6	Moreover , in these cell lines ***interleukin-6*** secretion and NF-kappaB activation were ***induced*** by cross-linked or non-cross-linked ***anti-TRAIL*** , as well as by both receptor-specific IgGs .	target	1
14518	10807904	8743;4790	TRAIL;NF-kappaB	Moreover , in these cell lines interleukin-6 secretion and ***NF-kappaB*** activation were ***induced*** by cross-linked or non-cross-linked ***anti-TRAIL*** , as well as by both receptor-specific IgGs .	target	1
14519	10807909	7124;10133	tumor necrosis factor alpha;NRP	We also show that de novo expression of ***NRP*** can be ***induced*** by interferon and ***tumor necrosis factor alpha*** and that these two stimuli have a synergistic effect on NRP expression .	target	1
14520	10807911	5617;5599	Prolactin;JNK	The ***Prolactin-induced*** ***activation*** of ***JNK*** was prolonged and accompanied by a significant increase in c-Jun mRNA abundance and c-Jun protein synthesis .	positive	1
14521	10807918	3479;5594	IGF-1;ERK1/2	Tyrphostin AG1478 , an inhibitor of the EGFR kinase , markedly attenuates ***IGF-1-stimulated*** ***phosphorylation*** of EGFR , Shc , and ***ERK1/2*** but has no effect on phosphorylation of IGF-1R , IRS-1 , and protein kinase B ( Akt ) .	target	1
14522	10807918	3479;5594	IGF-1;ERK	These data demonstrate that IGF-1 stimulation of the IRS-1/PI3K/Akt pathway and the EGFR/Shc/ERK1/2 pathway occurs by distinct mechanisms and suggest that IGF-1-mediated " transactivation " of EGFR accounts for the majority of ***IGF-1-stimulated*** Shc ***phosphorylation*** and subsequent activation of the ***ERK*** cascade .	target	1
14523	10807918	3479;207	IGF-1;Akt	These data demonstrate that ***IGF-1*** ***stimulation*** of the ***IRS-1/PI3K/Akt*** pathway and the EGFR/Shc/ERK1/2 pathway occurs by distinct mechanisms and suggest that IGF-1-mediated " transactivation " of EGFR accounts for the majority of IGF-1-stimulated Shc phosphorylation and subsequent activation of the ERK cascade .	positive	0
14524	10807918	3479;5594	IGF-1;ERK1/2	These data demonstrate that ***IGF-1*** ***stimulation*** of the IRS-1/PI3K/Akt pathway and the ***EGFR/Shc/ERK1/2*** pathway occurs by distinct mechanisms and suggest that IGF-1-mediated " transactivation " of EGFR accounts for the majority of IGF-1-stimulated Shc phosphorylation and subsequent activation of the ERK cascade .	positive	0
14525	10807918	3479;3667	IGF-1;IRS-1	These data demonstrate that ***IGF-1*** ***stimulation*** of the ***IRS-1/PI3K/Akt*** pathway and the EGFR/Shc/ERK1/2 pathway occurs by distinct mechanisms and suggest that IGF-1-mediated " transactivation " of EGFR accounts for the majority of IGF-1-stimulated Shc phosphorylation and subsequent activation of the ERK cascade .	positive	0
14526	10807920	551;6722	AVP;SRF	***AVP*** stimulation rapidly ***increased*** ***SRF*** phosphorylation .	positive	0
14527	10807932	3553;5156	IL-1beta;PDGF-Ralpha	Moreover , pretreatment of cells with cycloheximide blocked ***induction*** of ***PDGF-Ralpha*** mRNA by ***IL-1beta*** , suggesting that de novo protein synthesis was required for PDGF-Ralpha mRNA stabilization .	target	1
14528	10807932	1432;5156	p38 MAP kinase;PDGF-Ralpha	These data indicate that ***p38 MAP kinase*** ***regulates*** ***PDGF-Ralpha*** expression at the translational level by signaling the synthesis of an mRNA-stabilizing protein .	target	1
14529	10807932	3553;5156	IL-1beta;PDGF-Ralpha	SB203580 inhibited ***IL-1beta-induced*** ***up-regulation*** of ***PDGF-Ralpha*** mRNA and protein in a concentration-dependent manner .	positive	1
14530	10807933	6885;3551	TAK1;IKK2	We show that ***TAK1*** physically ***interacts*** with NIK and with ***IKK2*** , and both XIAP or active TAK1 can stimulate IKK2 kinase activity .	parallel	1
14531	10807933	6885;9020	TAK1;NIK	We show that ***TAK1*** physically ***interacts*** with ***NIK*** and with IKK2 , and both XIAP or active TAK1 can stimulate IKK2 kinase activity .	parallel	1
14532	10807933	6885;3551	TAK1;IKK2	We show that TAK1 physically interacts with NIK and with IKK2 , and both XIAP or active ***TAK1*** can ***stimulate*** ***IKK2*** kinase activity .	positive	0
14533	10808046	3553;1392	interleukin-1 (IL-1)beta;CRH	Since ***interleukin-1 (IL-1)beta*** is a powerful ***activator*** of ***CRH*** neurons , its immunohistochemical expression was studied in the postmortem hypothalamus of MS patients ( n = 11 ) and matched controls ( n = 11 ) .	positive	1
14534	10808055	7432;7040	Vasoactive intestinal peptide;TGF-beta1	***Vasoactive intestinal peptide*** ( VIP ) ***inhibits*** ***TGF-beta1*** production in murine macrophages .	negative	1
14535	10808055	116;820	PACAP;cAMP	The effect of VIP is mediated primarily through the cAMP pathway , whereas ***PACAP*** ***activates*** both the ***cAMP*** and the protein kinase C pathway .	positive	1
14536	10808055	7432;7040	VIP;TGF-beta1	***VIP*** ***reduces*** the ***TGF-beta1*** steady-state mRNA levels in both peritoneal macrophages and Raw 264.7 cells treated with LPS .	negative	1
14537	10808124	5747;4739	pp125FAK;Cas-L	Subsequent studies revealed that ***pp125FAK*** ***binds*** ***Cas-L*** on its SH3 domain and phosphorylates its tyrosine residues upon beta1-integrin stimulation .	parallel	1
14538	10808124	4739;2889	Cas-L;C3G	Cas-L is transiently phosphorylated following CD3 cross-linking , and tyrosine-phosphorylated ***Cas-L*** ***binds*** to Crk and ***C3G*** .	parallel	1
14539	10808124	4739;1398	Cas-L;Crk	Cas-L is transiently phosphorylated following CD3 cross-linking , and tyrosine-phosphorylated ***Cas-L*** ***binds*** to ***Crk*** and C3G .	parallel	1
14540	10808169	7076;4318	tissue inhibitor of metalloproteinase-1;matrix metalloproteinase-9	BACKGROUND : The ratio of ***matrix metalloproteinase-9*** ( MMP-9 ) and its ***inhibitor*** , ***tissue inhibitor of metalloproteinase-1*** ( TIMP-1 ) may be a marker of the balance between airway tissue destruction and repair .	negative	1
14541	10808179	3700;974	gp120;CD79b	Antigenic expression of the B-cell receptor ***CD79b*** was ***down-regulated*** by ***gp120*** but was not altered by the addition of TNF-alpha .	negative	1
14542	10808405	196;1543	Ah receptor;CYP1A1	The ***indolocarbazole-Ah receptor*** complex ***activates*** the gene of ***CYP1A1*** , an isoenzyme of cytochrome P450-dependent monoamine oxidase , which enhances the 2-hydroxylation ( inactivation ) of estrogens .	positive	1
14543	108088	7200;551	Thyrotropin-releasing hormone;arginine vasopressin	***Thyrotropin-releasing hormone*** ***stimulates*** release of ***arginine vasopressin*** and oxytocin in vivo .	positive	0
14544	108088	7200;5020	Thyrotropin-releasing hormone;oxytocin	***Thyrotropin-releasing hormone*** ***stimulates*** release of arginine vasopressin and ***oxytocin*** in vivo .	positive	0
14545	108088	7200;551	TRH;AVP	***TRH*** ***stimulates*** release of both ***AVP*** and OT after both intraventricular and iv injection , and these effects may be independent of behavioral activation .	positive	0
14546	10809232	3815;4254	c-kit;stem cell factor	Three animal models that display spermatogonial apoptosis induced by blockade of ******stem cell factor/c-kit****** ***interaction*** by a function-blocking anti-c-kit antibody , spermatocyte apoptosis induced by methoxyacetic acid , and apoptosis of spermatogonia , spermatocytes , and spermatids induced by testosterone withdrawal after ethylene dimethane sulfonate treatment were employed to check the changes of Bcl-w , Bax , and Bak protein levels during apoptosis of specific germ cells .	parallel	1
14547	10809232	599;578	Bcl-w;Bak	***Bcl-w*** forms ***complexes*** with Bax and ***Bak*** , and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis .	parallel	1
14548	10809232	599;581	Bcl-w;Bax	***Bcl-w*** forms ***complexes*** with ***Bax*** and Bak , and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis .	parallel	1
14549	10809232	599;581	Bcl-w;Bax	***Bcl-w*** could form ***complexes*** with ***Bax*** and Bak but not with Bad .	parallel	1
14550	10809234	2648;10499	GCN5;GRIP1	***GCN5*** and ADA adaptor proteins ***regulate*** ***triiodothyronine/GRIP1*** and SRC-1 coactivator-dependent gene activation by the human thyroid hormone receptor .	target	1
14551	10809234	2648;8648	GCN5;SRC-1	***GCN5*** and ADA adaptor proteins ***regulate*** triiodothyronine/GRIP1 and ***SRC-1*** coactivator-dependent gene activation by the human thyroid hormone receptor .	target	1
14552	10809234	2648;10499	GCN5;GRIP1	We have used yeast genetics and in vitro protein-protein interaction experiments to explore the possibility that ***GCN5*** ( general control nonrepressed protein 5 ) and several other ADA ( alteration/deficiency in activation ) adaptor proteins of the multimeric SAGA complex can ***regulate*** ***T3/GRIP1*** ( glucocorticoid receptor interacting protein 1 ) and SRC-1 ( steroid receptor coactivator-1 ) coactivator-dependent activation of transcription by the human T3 receptor beta1 ( hTRbeta1 ) .	target	1
14553	10809234	2648;8648	GCN5;SRC-1	We have used yeast genetics and in vitro protein-protein interaction experiments to explore the possibility that ***GCN5*** ( general control nonrepressed protein 5 ) and several other ADA ( alteration/deficiency in activation ) adaptor proteins of the multimeric SAGA complex can ***regulate*** T3/GRIP1 ( glucocorticoid receptor interacting protein 1 ) and ***SRC-1*** ( steroid receptor coactivator-1 ) coactivator-dependent activation of transcription by the human T3 receptor beta1 ( hTRbeta1 ) .	target	1
14554	10809378	958;959	CD40;CD154	We review observations on subpopulations and differentiation of mature B-cells by T/B cell interaction via CD27/CD70 as compared with ******CD40/CD154****** ***interaction*** , and discuss about memory B cells .	parallel	1
14555	108096	5617;7200	prolactin;TRH	Serum ***prolactin*** ***responses*** to ***TRH*** in recurrent breast cancer patients .	parallel	0
14556	108096	5617;7200	prolactin;thyrotropin-releasing hormone	The ***response*** of serum ***prolactin*** ( PRL ) to ***thyrotropin-releasing hormone*** ( TRH ) was evaluated by radioimmunoassay in 6 normal women and 44 breast cancer cases .	parallel	0
14557	108096	5617;7200	PRL;TRH	These results indicate that patients with recurrent breast cancer have a higher ***PRL*** ***response*** to ***TRH*** than those without recurrence of cancer .	parallel	0
14558	10809672	5046;7040	PACE4;TGFbeta	***SPC4/PACE4*** ***regulates*** a ***TGFbeta*** signaling network during axis formation .	target	1
14559	10809672	5046;4838	SPC4;Nodal	Furthermore , genetic ***interactions*** between ***Nodal*** and ***SPC4*** , together with our analysis of chimeric embryos , strongly suggest that during A/P axis formation , SPC4 acts primarily in the foregut .	parallel	1
14560	108097	5617;7200	prolactin;thyrotropin releasing hormone	***Response*** of human growth hormone , ***prolactin*** and thyrotropin to ***thyrotropin releasing hormone*** in liver cirrhosis and diabetes mellitus .	parallel	0
14561	10809723	573;3312	BAG-1;Hsc70	Distinct isoforms of the cofactor ***BAG-1*** differentially ***affect*** ***Hsc70*** chaperone function .	target	0
14562	10809746	7421;10499	VDR;GRIP1	Collectively , these mutations also suppressed ***association*** of ***VDR*** with the coactivators ***GRIP1*** and steroid receptor coactivator 1 in vitro but had little or no effect on ligand binding , heterodimerization with the retinoid X receptor , or association with a VDR-specific DNA recognition element .	parallel	0
14563	10809746	7421;8648	VDR;steroid receptor coactivator 1	Collectively , these mutations also suppressed ***association*** of ***VDR*** with the coactivators GRIP1 and ***steroid receptor coactivator 1*** in vitro but had little or no effect on ligand binding , heterodimerization with the retinoid X receptor , or association with a VDR-specific DNA recognition element .	parallel	0
14564	10809746	10499;7421	GRIP1;VDR	The ***interaction*** between ***VDR*** and ***GRIP1*** proved to be heavily dependent upon the integrity of nuclear box III in the latter protein .	parallel	1
14565	10809757	7124;1490	TNFalpha;CTGF	Although ***TNFalpha*** was able to ***repress*** TGF-beta-induced ***CTGF*** and collagen synthesis both in normal and scleroderma skin fibroblasts , fibroblasts cultured from scleroderma patients were more resistant to TNFalpha as TNFalpha was unable to suppress the basal level of CTGF expression in scleroderma fibroblasts .	negative	1
14566	10809757	7124;1490	Tumor necrosis factor alpha;connective tissue growth factor	***Tumor necrosis factor alpha*** ***suppresses*** the induction of ***connective tissue growth factor*** by transforming growth factor-beta in normal and scleroderma fibroblasts .	negative	1
14567	10809757	7040;1490	TGF-beta;CTGF	There was a constitutive expression of ***CTGF*** by scleroderma fibroblasts that was ***increased*** by ***TGF-beta*** treatment .	positive	0
14568	10809758	7161;10752	p73;neural cell adhesion molecule	Here we show that endogenous p73 levels increase in neuroblastoma cells induced to differentiate by retinoic acid and that exogenously expressed ***p73*** , but not p53 , is sufficient to ***induce*** both morphological ( neurite outgrowth ) and biochemical ( expression of neurofilaments and ***neural cell adhesion molecule*** ( N-CAM ) ; down-regulation of N-MYC and up-regulation of pRB ) markers of neuronal differentiation .	target	1
14569	10809771	5973;5972	renin-binding protein;renin	Normal blood pressure and plasma renin activity in mice lacking the ***renin-binding protein*** , a cellular ***renin*** ***inhibitor*** .	negative	1
14570	10809771	5972;5973	renin;renin-binding protein	In renal extracts , some renin is present as " high molecular weight renin , " a heterodimeric ***complex*** of ***renin*** with the 46-kDa ***renin-binding protein*** ( RnBP ) , also known as N-acyl-D-glucosamine 2-epimerase .	parallel	1
14571	10809771	5973;5972	RnBP;renin	Because ***RnBP*** specifically ***inhibits*** ***renin*** activity , the protein was proposed to play an important role in the regulation of the renin-angiotensin system ( RAS ) .	negative	1
14572	10809772	995;983	Cdc25C;Cdk1	Here we show that genistein exerts this effect by impairing the ***Cdc25C-dependent*** Tyr-15 ***dephosphorylation*** of ***Cdk1*** , as the overexpression of this phosphatase allows the cells to escape G ( 2 ) arrest and enter an abnormal chromatin condensation stage .	target	1
14573	10809798	7040;3553	TGF-beta;IL-1beta	By Northern blot analysis , ***TGF-beta*** ( 1 ) ( 10 ng/ml ) significantly ***suppressed*** the stimulatory effect of ***IL-1beta*** and TNF-alpha .	negative	1
14574	10809798	7040;7124	TGF-beta;TNF-alpha	By Northern blot analysis , ***TGF-beta*** ( 1 ) ( 10 ng/ml ) significantly ***suppressed*** the stimulatory effect of IL-1beta and ***TNF-alpha*** .	negative	1
14575	10809798	7040;7412	TGF-beta;VCAM-1	CONCLUSIONS : These results show that ***TGF-beta*** ( 1 ) ***down-regulates*** the inflammatory cytokine-induced expression of ***VCAM-1*** in human glomerular endothelial cells , which could be a novel mechanism for the anti-inflammatory action of TGF-beta ( 1 ) during the inflammatory processes in human glomerular diseases .	negative	1
14576	10809798	7040;7412	TGF-beta;VCAM-1	***TGF-beta*** ( 1 ) ***down-regulates*** inflammatory cytokine-induced ***VCAM-1*** expression in cultured human glomerular endothelial cells .	negative	1
14577	10809798	7040;7412	TGF-beta;VCAM-1	The addition of ***TGF-beta*** ( 1 ) ( 1 , 10 and 25 ng/ml ) also ***suppressed*** TNF-alpha - ( 10 ng/ml ) induced ***VCAM-1*** expression ( OD = 1 .	negative	1
14578	10809903	7040;632	TGF-beta1;osteocalcin	In both hOB and hMS ( OB ) cultures , ***TGF-beta1*** ***inhibited*** ***osteocalcin*** production .	negative	1
14579	10809903	7040;632	TGF-beta;osteocalcin	As ***TGF-beta*** ***inhibits*** ***osteocalcin*** production , other factors are necessary for inducing terminal differentiation of osteoblasts .	negative	1
14580	10810231	4792;4790	IkappaB-alpha;NF-kappaB	These data suggest that ***IkappaB-alpha*** does not form a negative autoregulatory loop for NF-kappaB in mesangial cells and may actually ***reduce*** ***NF-kappaB*** activity .	negative	1
14581	10810231	4790;4792	NF-kappaB;IkappaB-alpha	***IkappaB-alpha*** is itself ***upregulated*** by activation of ***NF-kappaB*** and is postulated to be part of a negative feedback loop .	positive	1
14582	10810289	3483;3488	ALS;IGFBP-5	In contrast , ***ALS*** ***bound*** similarly to ***IGFBP-5*** in the presence of pro-IGF-II and mature IGF-II .	parallel	1
14583	10810294	3569;6774	IL-6;Stat3	Thus , our studies suggest that while each cytokine , GH and IL-6 , may activate various members of the Jak-Stat pathway in overexpression studies , specific ***activation*** of ***Stat3*** by ***IL-6*** and of Jak2 and Stat5 by GH can be observed in HEK293 cells and that in this system the synergistic effect of dexamethasone appears specific for Stat5 .	positive	1
14584	10810313	7039;1956	TGF-alpha;epidermal growth factor (EGF) receptor	Since ***TGF-alpha*** ***binds*** to the ***epidermal growth factor (EGF) receptor*** , this action may be exerted through the EGF receptor .	parallel	1
14585	10810347	4089;7040	Smad4;TGF-beta	The loss of sensitivity to TGF-beta of cell lines derived from ovarian cancers may be related to ( 1 ) a decreased expression of ***Smad4*** , which ***mediates*** ***TGF-beta*** induced growth inhibition ; and/or ( 2 ) an overexpression of CDC25A .	target	0
14586	10810387	596;7157	bcl-2;p53	Possible ***associations*** between c-erbB-2 and T,N-stage , histological grade , microvessel density and the expression of ***bcl-2*** and ***p53*** proteins were sought .	parallel	0
14587	10810442	7422;1890	Vascular endothelial growth factor;thymidine phosphorylase	BACKGROUND : ***Vascular endothelial growth factor*** ( VEGF ) has been ***linked*** not only to angiogenic activity but also to ***thymidine phosphorylase*** ( TP ) , rapid tumor growth , and inhibition of apoptotic cell death .	parallel	0
14588	10810453	7124;5743	TNF-alpha;COX-2	Long-term treatment of ***TNF-alpha*** ***destabilized*** the induced ***COX-2*** mRNA .	negative	0
14589	10810453	3553;5743	interleukin-1 beta;COX-2	In this study , we examined the ***induction*** of ***COX-2*** expression by ***interleukin-1 beta*** ( IL-1 beta ) and tumor necrosis factor-alpha ( TNF-alpha ) in human primary in vitro differentiated macrophages .	target	1
14590	10810453	7124;5743	tumor necrosis factor-alpha;COX-2	In this study , we examined the ***induction*** of ***COX-2*** expression by interleukin-1 beta ( IL-1 beta ) and ***tumor necrosis factor-alpha*** ( TNF-alpha ) in human primary in vitro differentiated macrophages .	target	1
14591	10810453	3553;5743	IL-1 beta;COX-2	Both ***IL-1 beta*** and TNF-alpha ***stabilized*** cytokine-induced ***COX-2*** mRNA ( T1/2 > or = 2 hr ) .	positive	0
14592	10810453	7124;5743	TNF-alpha;COX-2	Both IL-1 beta and ***TNF-alpha*** ***stabilized*** cytokine-induced ***COX-2*** mRNA ( T1/2 > or = 2 hr ) .	positive	0
14593	10810514	7432;551	VIP;AVP	***VIP*** ***induces*** [ Ca2 + ] i increase in 14 % of the SCN cells and ***AVP*** release is stimulated by Ca2 + ionophore ionomycin .	target	1
14594	10810622	7157;8795	p53;KILLER/DR5	The TRAIL receptor ***KILLER/DR5*** , is induced by DNA damage and appears to be ***regulated*** by the tumor suppressor gene ***p53*** .	target	1
14595	10810874	5104;5624	protein C inhibitor;protein C	Activated ******protein C-protein C inhibitor****** ***complex*** and plasminogen activator inhibitor-I were useful for the diagnosis of DVT , PE , AMI or CT .	parallel	1
14596	10810875	5624;7124	protein C;TNF-alpha	Activated ***protein C*** ***inhibits*** ***TNF-alpha*** production by monocyte dependent of its protease activity .	negative	1
14597	10810875	7124;2152	TNF-alpha;tissue factor	antithrombin regulates ***TNF-alpha*** ***induced*** ***tissue factor*** expression on endothelial cells by an unknown mechanism .	target	1
14598	10810999	959;958	CD40L;CD40	It is important that ***CD40*** and its ***ligand*** , ***CD40L*** , have been implicated in the provision of this help and , in particular , the generation of long-lasting CTL memory .	parallel	1
14599	10811002	5578;5338	PKCalpha;PLD2	Based on these new findings we suggest that PLD2 activity is specifically up-regulated by H2O2 and that the H2O2-induced ***PLD2*** activation is ***mediated*** by Ca2 + influx and ***PKCalpha*** activation .	target	0
14600	10811011	6347;3684	MCP-1;CD11b	Moreover , ***CD11b*** surface expression was preferentially ***up-regulated*** by ***MCP-1*** in CD14 + + cells but by MIP-1alpha in CD14 + CD16 + monocytes , confirming the functional relevance of distinct CCR expression .	positive	1
14601	10811016	3576;3559	IL-8;CD25	Although its effects varied among donors , exogenous ***IL-8*** ***stimulated*** proliferation and ***CD25*** expression ( up to , respectively , 200 and 77 % ) of PB T lymphocytes in response to CD3 activation , in a PT-sensitive manner .	positive	0
14602	10811016	3576;3558	IL-8;IL-2	***IL-8*** also ***stimulated*** ***IL-2*** production ( by up to 42 % ) and CD69 expression , although weakly ( +27 % ) .	positive	0
14603	10811113	356;355	CD95L;CD95	Several inducers of cytotoxic stress promote apoptotic cell death , which , at least in some cases , involves the ***CD95/CD95*** ***ligand*** ( ***CD95L*** ) pathway .	parallel	1
14604	10811447	3458;8651	interferon-gamma;SOCS-1	Among them , we have shown that ***Jab/SOCS-1*** is strongly ***induced*** by ***interferon-gamma*** and forced expression of Jab/SOCS -1 I conferred cells interferon resistance .	target	1
14605	10811608	10671;1017	p27;Cdk2	The ***Cdk2*** ***inhibitor*** , ***p27*** ( Kip1 ) , is degraded in a phosphorylation - and ubiquitylation-dependent manner at the G ( 1 ) - S transition of the cell cycle .	negative	1
14606	10811609	55666;7353	npl4;ufd1	A ***complex*** of mammalian ***ufd1*** and ***npl4*** links the AAA-ATPase , p97 , to ubiquitin and nuclear transport pathways .	parallel	1
14607	10811609	55666;7353	npl4;ufd1	In rat liver cytosol , ***ufd1*** and ***npl4*** form a binary ***complex*** , which exists either alone or bound to p97 .	parallel	1
14608	10811609	55968;55666	p47;npl4	The fact that the ***binding*** of ***p47*** and ***ufd1/npl4*** is mutually exclusive suggests that these protein complexes act as adapters , directing a basic p97 activity into different cellular pathways .	parallel	1
14609	10811609	7353;55666	ufd1;npl4	The fact that the ***binding*** of p47 and ******ufd1/npl4****** is mutually exclusive suggests that these protein complexes act as adapters , directing a basic p97 activity into different cellular pathways .	parallel	1
14610	10811609	7353;55968	ufd1;p47	The fact that the ***binding*** of ***p47*** and ***ufd1/npl4*** is mutually exclusive suggests that these protein complexes act as adapters , directing a basic p97 activity into different cellular pathways .	parallel	1
14611	10811620	7091;5079	Grg4;Pax5	Moreover , ***Grg4*** efficiently ***represses*** the transcriptional activity of ***Pax5*** in an octapeptide-dependent manner .	negative	1
14612	10811623	1105;6594	CHD1;SWI	A synthetic-lethal screen uncovered genetic ***interactions*** between ***SWI/SNF*** genes and ***CHD1*** .	parallel	1
14613	10811629	10111;4361	RAD50;MRE11	Recombination-induced CAG trinucleotide repeat expansions in yeast involve the ******MRE11-RAD50-XRS2****** ***complex*** .	parallel	1
14614	10811630	10874;10316	Neuromedin U;FM3	Here we show that ***Neuromedin U*** potently ***activates*** the orphan G protein-coupled receptor ***FM3*** , with subnanomolar potency , when FM3 is transiently expressed in human HEK-293 cells .	positive	1
14615	10811631	4790;4982	NF-kappaB;Osteoprotegerin	These data suggest that alpha ( v ) beta ( 3 ) - mediated endothelial survival depends on ***Osteoprotegerin*** ***induction*** by ***NF-kappaB*** and indicate a new function for Osteoprotegerin in endothelial cells .	target	1
14616	10811631	6696;4982	Osteopontin;Osteoprotegerin	In contrast , ***Osteoprotegerin*** mRNA and protein levels were ***induced*** 5-7-fold following alpha ( v ) beta ( 3 ) ligation by ***Osteopontin*** .	target	1
14617	10811631	6696;4982	Osteopontin;Osteoprotegerin	***Osteoprotegerin*** ***induction*** by ***Osteopontin*** was time-dependent and observed as early as 3 h following treatment .	target	1
14618	10811631	6696;4982	Osteopontin;Osteoprotegerin	NF-kappaB inactivation achieved by over expression of an IkappaB super repressor in endothelial cells completely inhibited ***Osteoprotegerin*** ***induction*** by ***Osteopontin*** .	target	1
14619	10811631	4790;4982	NF-kappaB;Osteoprotegerin	***NF-kappaB*** inactivation achieved by over expression of an IkappaB super repressor in endothelial cells completely ***inhibited*** ***Osteoprotegerin*** induction by Osteopontin .	positive	1
14620	10811632	3479;3667	IGF-I;IRS-1	The addition of epidermal growth factor ( EGF ) maintained IRS-1 levels even in the presence of IGF-I and inhibits ***IGF-I-dependent*** ***ubiquitination*** of ***IRS-1*** .	target	1
14621	10811635	3175;1387	HNF-6;CREB-binding protein	We also demonstrate that , on a target gene to which HNF-6 binds without requirement for the homeodomain , transcriptional stimulation involves an ***interaction*** of ***HNF-6*** with the coactivator ***CREB-binding protein*** ( CBP ) .	parallel	1
14622	10811635	3175;8850	HNF-6;p300/CBP-associated factor	On a target gene for which the homeodomain is required for DNA binding , but not for transcriptional stimulation , ***HNF-6*** ***interacts*** with the coactivator ***p300/CBP-associated factor*** but not with CBP .	parallel	1
14623	10811636	1760;5348	DMPK;PLM	Co-expression of ***DMPK*** ***reduced*** the expression of ***PLM*** in oocyte membranes , suggesting a possible mechanism for the observed reduction in I ( Cl ( PLM ) ) amplitude .	negative	1
14624	10811636	1760;5348	DMPK;PLM	To test the idea that PLM is a substrate for DMPK , we measured in vitro ***phosphorylation*** of purified ***PLM*** by ***DMPK*** .	target	1
14625	10811636	5348;1760	PLM;DMPK	To test the idea that ***PLM*** is a ***substrate*** for ***DMPK*** , we measured in vitro phosphorylation of purified PLM by DMPK .	parallel	1
14626	10811636	5348;1760	PLM;DMPK	We found that ***PLM*** is indeed a good ***substrate*** for ***DMPK*** in vitro .	parallel	1
14627	10811644	3654;4615	IRAK;MyD88	LPS also triggers the ***association*** of ***IRAK*** with ***MyD88*** , the adaptor protein linking IRAK to the Toll-like receptor/interleukin -1 beta receptor intracellular domain .	parallel	0
14628	10811652	3458;5320	Interferon-gamma;group IIA phospholipase A2	***Interferon-gamma*** ***induces*** secretory ***group IIA phospholipase A2*** in human arterial smooth muscle cells .	target	1
14629	10811660	10728;3320	p23;hsp90	This tail is not needed for the ***binding*** of ***p23*** to ***hsp90*** or to complexes with the progesterone receptor .	parallel	1
14630	10811660	10728;5241	p23;progesterone receptor	This tail is not needed for the ***binding*** of ***p23*** to hsp90 or to complexes with the ***progesterone receptor*** .	parallel	1
14631	10811662	7181;7157	TR2;p53	In return , ***TR2*** could also ***control*** the expression of ***p53*** and Rb through the regulation of human papillomavirus 16 E6/E7 genes .	target	0
14632	10811804	1848;5594	MKP-3;ERK	This reflects tight and specific ***binding*** between ***ERK*** and the ***MKP-3*** amino terminus with consequent phosphatase activation and dephosphorylation of the bound MAP kinase .	parallel	1
14633	10811804	5594;1848	ERK;MKP-3	These data also reveal an overlap between ***ERK*** domains ***interacting*** with ***MKP-3*** and those known to confer substrate specificity on the ERK MAP kinase .	parallel	1
14634	10811804	5594;1848	ERK;MKP-3	Consistent with this , we show that peptides representing docking sites within the target substrates Elk-1 and p90 ( rsk ) inhibit ***ERK-dependent*** ***activation*** of ***MKP-3*** .	positive	1
14635	10811819	7074;207	Tiam1;Rac	Oncogenic Ras decreases Rac activity through sustained Raf/MAP kinase signaling , which causes transcriptional downregulation of ***Tiam1*** , an ***activator*** of ***Rac*** in epithelial cells .	positive	1
14636	10811851	3667;207	IRS-1;PKB	In primary hepatocytes isolated from null mice , expression of ***IRS-1*** ***enhanced*** both PI3K and ***PKB*** activities , but expression of IRS-1Deltap85 enhanced only PKB .	positive	0
14637	10811864	596;581	Bcl-2;Bax	Furthermore , although ***Bcl-2*** could be readily ***coimmunoprecipitated*** with ***Bax*** , associations with Apaf-1 were undetectable under conditions where Apaf-1 interactions with procaspase-9 were observed .	parallel	1
14638	10811865	2185;598	Protein kinase B;Bcl-X	***Protein kinase B*** ***regulates*** T lymphocyte survival , nuclear factor kappaB activation , and ***Bcl-X*** ( L ) levels in vivo .	target	1
14639	10811940	9260;7040	LMP-1;TGF-beta1	Studies of EBV-converted and stably transfected BL cell lines demonstrated that the EBV gene ***LMP-1*** is neither necessary nor sufficient to ***block*** the ***TGF-beta1*** response .	negative	0
14640	10811986	8795;8743	DR5;TRAIL	Expression of TRAIL ( Apo2L ) , DR4 ( TRAIL receptor 1 ) , ***DR5*** ( ***TRAIL*** ***receptor*** 2 ) and TRID ( TRAIL receptor 3 ) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 ( HL60/Tax ) or MRP ( HL60/AR ) .	parallel	1
14641	10811986	8794;8743	TRID;TRAIL	Expression of TRAIL ( Apo2L ) , DR4 ( TRAIL receptor 1 ) , DR5 ( TRAIL receptor 2 ) and ***TRID*** ( ***TRAIL*** ***receptor*** 3 ) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 ( HL60/Tax ) or MRP ( HL60/AR ) .	parallel	1
14642	10811986	8795;8743	DR5;TRAIL	TRAIL , a member of the TNF receptor family , induces apoptosis in many tumor cells by binding to DR4 ( TRAIL receptor 1 ) and ***DR5*** ( ***TRAIL*** ***receptor*** 2 ) .	parallel	1
14643	10811987	3082;213	hepatocyte growth factor;albumin	Diverse ***regulations*** of ***albumin*** gene expression by ***hepatocyte growth factor*** in HepG2 human hepatoma cells and primary culture of rat hepatocytes .	target	1
14644	10811987	3082;213	HGF;albumin	***HGF*** ***reduced*** the levels of ***albumin*** mRNA in HepG2 cells but the level was augmented in rat hepatocytes .	negative	1
14645	10811987	3082;174	HGF;AFP	By the transfection assay , ***HGF*** stimulated albumin promoter activity but ***repressed*** alpha-fetoprotein ( ***AFP*** ) enhancer activity regulating both AFP and albumin promoters in HepG2 cells .	negative	1
14646	10811987	3082;213	HGF;albumin	By the transfection assay , ***HGF*** ***stimulated*** ***albumin*** promoter activity but repressed alpha-fetoprotein ( AFP ) enhancer activity regulating both AFP and albumin promoters in HepG2 cells .	positive	0
14647	10811987	3082;174	HGF;AFP	In contrast , ***HGF*** ***stimulated*** albumin promoter and ***AFP*** enhancer activities in rat hepatocytes .	positive	0
14648	10811987	3082;213	HGF;albumin	In contrast , ***HGF*** ***stimulated*** ***albumin*** promoter and AFP enhancer activities in rat hepatocytes .	positive	0
14649	10812060	27344;5122	proSAAS;PC1	Endogenous inhibitors of both PC1 and PC2 have now been identified ; the 7B2 protein is a nanomolar inhibitor of PC2 , while the novel protein ***proSAAS*** was recently reported to be a micromolar ***inhibitor*** of ***PC1*** [ Fricker et al. ( 2000 ) J.	negative	1
14650	10812060	5122;27344	PC1;proSAAS	Lastly , recombinant ***PC1*** is able to ***cleave*** the ***proSAAS*** CT peptide to a product with a mass consistent with cleavage following the inhibitory hexapeptide .	target	1
14651	10812066	3791;7422	Flk-1;VEGF	Two distinct ***VEGF*** ***receptors*** , ***KDR/Flk-1*** and Flt-1 , were detectable in osteoclasts at the gene and protein levels , and VEGF induced tyrosine phosphorylation of proteins in osteoclasts .	parallel	1
14652	10812066	2321;7422	Flt-1;VEGF	Two distinct ***VEGF*** ***receptors*** , KDR/Flk-1 and ***Flt-1*** , were detectable in osteoclasts at the gene and protein levels , and VEGF induced tyrosine phosphorylation of proteins in osteoclasts .	parallel	1
14653	10812214	4790;4843	NFkappaB;iNOS	The results indicate that ammonia-induced apoptosis is a result of a complex interplay of at least three signalling molecules : NO , PKC and the transcription factor NFkappaB , with ***NFkappaB*** being possibly involved in the ***induction*** of ***iNOS*** and generation of toxic levels of NO in the cells .	target	1
14654	10812249	2120;6772	TEL;STAT1	***TEL/PDGFbetaR*** fusion protein ***activates*** ***STAT1*** and STAT5 : a common mechanism for transformation by tyrosine kinase fusion proteins .	positive	1
14655	10812249	2120;6776	TEL;STAT5	***TEL/PDGFbetaR*** fusion protein ***activates*** STAT1 and ***STAT5*** : a common mechanism for transformation by tyrosine kinase fusion proteins .	positive	1
14656	10812249	2120;6772	TEL;STAT1	RESULTS : ***TEL/PDGFbetaR*** ***activates*** ***STAT1*** and STAT5 in transformed Ba/F3 cells through a JAK-independent pathway .	positive	1
14657	10812249	2120;6776	TEL;STAT5	RESULTS : ***TEL/PDGFbetaR*** ***activates*** STAT1 and ***STAT5*** in transformed Ba/F3 cells through a JAK-independent pathway .	positive	1
14658	10812249	2120;6776	TEL;STAT5	However , ***TEL/PDGFbetaR*** can ***phosphorylate*** ***STAT5*** in transiently transfected COS cells , suggesting that TEL/PDGFbetaR may itself be the kinase involved in tyrosine phosphorylation of STAT proteins .	target	1
14659	10812249	3717;6772	JAK2;STAT1	***STAT1*** and STAT5 also are ***activated*** by TEL/ABL and ***TEL/JAK2*** fusion proteins associated with human leukemia .	positive	1
14660	10812249	3717;6776	JAK2;STAT5	STAT1 and ***STAT5*** also are ***activated*** by TEL/ABL and ***TEL/JAK2*** fusion proteins associated with human leukemia .	positive	1
14661	10812249	2120;6772	TEL;STAT1	***STAT1*** and STAT5 also are ***activated*** by TEL/ABL and ***TEL/JAK2*** fusion proteins associated with human leukemia .	positive	1
14662	10812249	2120;6776	TEL;STAT5	STAT1 and ***STAT5*** also are ***activated*** by TEL/ABL and ***TEL/JAK2*** fusion proteins associated with human leukemia .	positive	1
14663	10812583	7035;335	Tissue factor pathway inhibitor;apo	***Tissue factor pathway inhibitor*** activity ( TFPIa ) was ***correlated*** to LDL cholesterol and ***apo*** B concentrations and was highest in subjects with genotypes containing the E4 allele .	parallel	0
14664	10812968	1271;1270	CNTFR alpha;ciliary neurotrophic factor	The ***ciliary neurotrophic factor*** and its ***receptor*** , ***CNTFR alpha*** .	parallel	1
14665	10813377	5594;2002	ERK;Elk-1	We used GAL-Elk-1 expression plasmids to detect ***ERK-dependent*** ***activation*** of ***Elk-1*** .	positive	1
14666	10813377	3667;5290	IRS-1;PI3K	Neither early steps in insulin signaling nor the phosphatidylinositol 3-kinase ( PI3K ) branch of this pathway were affected by TRO , because it had no effect on IRS-1 phosphorylation , ******PI3K/IRS-1****** ***association*** , or Akt phosphorylation .	parallel	0
14667	10813537	3552;1435	IL-1alpha;M-CSF	In both types of cell cultures , ***IL-1alpha*** stimulation ***increased*** ***M-CSF*** mRNA levels 2-7-fold , whereas serum stimulation elicited a more modest effect ( 2-3-fold increase ) .	positive	0
14668	10813585	3791;7422	Flk-1;VEGF	Mitogenic actions of ***VEGF*** are ***mediated*** by the tyrosine kinase receptor KDR/murine homologue fetal liver kinase ***Flk-1*** .	target	0
14669	10814522	4093;4089	smad8;Smad4	Constitutively active BMP type I receptors , ALK-3 and ALK-6 , as well as ALK-2 , were phosphorylated smad8 and induced ***smad8*** ***interaction*** with ***Smad4*** .	parallel	1
14670	10814522	7046;7040	ALK-5;TGF-beta	In contrast , constitutively active ***TGF-beta*** type I ***receptor*** , ***ALK-5*** , did not exhibit any action on smad8 .	parallel	1
14671	10814526	3952;3953	leptin;leptin receptor	Differential ***regulation*** of ***leptin receptor*** expression by insulin and ***leptin*** in neuroblastoma cells .	target	1
14672	10814543	1906;6550	Endothelin-1;Na/H exchanger-3	***Endothelin-1*** chronically ***inhibits*** ***Na/H exchanger-3*** in ET ( B ) - overexpressing OKP cells .	negative	1
14673	10814674	472;25	ATM;c-Abl	Recent studies suggest that ***ATM*** is activated primarily in response to double-strand breaks , the major cytotoxic lesion caused by ionizing radiation , and can directly ***bind*** to and phosphorylate ***c-Abl*** , p53 , and replication protein A ( RPA ) .	parallel	1
14674	10814674	472;7157	ATM;p53	Recent studies suggest that ***ATM*** is activated primarily in response to double-strand breaks , the major cytotoxic lesion caused by ionizing radiation , and can directly ***bind*** to and phosphorylate c-Abl , ***p53*** , and replication protein A ( RPA ) .	parallel	1
14675	10814697	5788;3956	CD45;galectin-1	Characterization of the ***interaction*** between ***galectin-1*** and lymphocyte glycoproteins ***CD45*** and Thy-1 .	parallel	1
14676	10814697	3956;5788	galectin-1;CD45	Recently , galectin-1 has been shown to play a possible role in the immune system mediating apoptosis of activated T cells with indirect evidence suggesting that ***galectin-1*** ***interacts*** with the heavily glycosylated , transmembrane , protein phosphotyrosine phosphatase ***CD45*** .	parallel	1
14677	10814697	3956;5788	galectin-1;CD45	***galectin-1*** was shown to ***bind*** ***CD45*** and Thy-1 in a carbohydrate-dependent manner .	parallel	1
14678	10814697	3956;7070	galectin-1;Thy-1	***galectin-1*** was shown to ***bind*** CD45 and ***Thy-1*** in a carbohydrate-dependent manner .	parallel	1
14679	10814697	3956;5788	galectin-1;CD45	Several ***galectin-1*** molecules could ***bind*** each ***CD45*** molecule .	parallel	1
14680	10814697	3956;5788	galectin-1;CD45	The dissociation constant of dimeric ***galectin-1*** ***binding*** to ***CD45*** was measured at approximately 5 microM , indicating the concentration at which cross-linking of cell surface glycoproteins by galectin-1 would occur .	parallel	1
14681	10814712	54715;6311	A2BP1;ataxin-2	Using the yeast two-hybrid system , we identified a novel protein , ***A2BP1*** ( ataxin-2 binding protein 1 ) which ***binds*** to the C-terminus of ***ataxin-2*** .	parallel	1
14682	10814733	4915;627	TrkB;BDNF	A soluble ***TrkB-IgG*** fusion protein , which selectively ***binds*** ***BDNF*** and prevents its binding to the neuronal TrkB receptor , eliminated the neurotrophic effect of CM-GMF ; whereas anti-NGF antibody was ineffective in preventing this effect , suggesting that the neurotrophic effect was due to BDNF .	parallel	1
14683	10814733	2764;627	GMF;BDNF	In conclusion , ***GMF*** ***upregulates*** the expression of ***BDNF*** and NGF in C6 cells , and these factors exert neurotrophic and neuroprotective functions on primary neurons .	positive	1
14684	10814733	2764;4803	GMF;NGF	In conclusion , ***GMF*** ***upregulates*** the expression of BDNF and ***NGF*** in C6 cells , and these factors exert neurotrophic and neuroprotective functions on primary neurons .	positive	1
14685	10814741	1453;4137	Ckidelta;tau	These data establish that the ***association*** of ***Ckidelta*** with the ***tau*** pathology of AD is reflective of an increase in gene transcription .	parallel	0
14686	10814787	3565;5468	IL-4;peroxisome proliferator-activated receptor (PPAR)-gamma	***IL-4*** , however , ***induced*** ***peroxisome proliferator-activated receptor (PPAR)-gamma*** in cultured microglia .	target	1
14687	10814831	5813;2353	Puralpha;c-fos	The ***c-fos*** mRNA induced by forskolin , but not by NGF , was also ***suppressed*** by ***Puralpha*** transfection .	negative	1
14688	10815129	4035;351	LRP;amyloid precursor protein	The ***LRP*** also ***interacts*** with the ***amyloid precursor protein*** itself .	parallel	1
14689	10815620	3558;3802	interleukin-2;CD158a	Killer-cell inhibitory receptors , ***CD158a/b*** , are ***upregulated*** by ***interleukin-2*** , but not interferon-gamma or interleukin-4 .	positive	1
14690	10815620	3458;3802	IFN-gamma;CD158a	Neither IL-4 nor ***IFN-gamma*** ***affected*** the expression of ***CD158a/b*** , but incubation for 48 h with IL-2 , which enhances the killer activity of NK cells , upregulated the expression of the KIRs .	target	0
14691	10815620	3565;3802	IL-4;CD158a	Neither ***IL-4*** nor IFN-gamma ***affected*** the expression of ***CD158a/b*** , but incubation for 48 h with IL-2 , which enhances the killer activity of NK cells , upregulated the expression of the KIRs .	target	0
14692	10815772	3700;920	gp120;CD4	Sulfonated distamycin ( Suradista ) derivatives exhibit anti-HIV-1 activity by inhibiting the ***binding*** of the viral envelope glycoprotein ***gp120*** to its receptor ( ***CD4*** ) .	parallel	1
14693	10815799	3569;6774	interleukin-6;Stat3	PD180970 did not affect MAPK activation by PDGF or the JAK-dependent ***activation*** of ***Stat3*** by ***interleukin-6*** .	positive	1
14694	10815800	2113;6777	Ets-1;STAT5	Coimmunoprecipitation experiments evidenced that a ******STAT5/Ets-1/2****** ***complex*** is formed in vivo in absence of DNA .	parallel	1
14695	10815924	959;958	CD40L;CD40	Functional and in situ evidence for nitric oxide production driven by ******CD40-CD40L****** ***interactions*** in graft-versus-leukemia reactivity .	parallel	1
14696	10815924	958;959	CD40;CD40L	We now show that the ******CD40-CD40L****** ( CD154 ) ***interaction*** is involved in the induction of inducible nitric oxide synthase ( iNOS ) expression during adoptive immunotherapy ( ADI ) .	parallel	1
14697	10815928	836;142	caspase-3;PARP	Our results suggest that : ( a ) Pc 4-PDT is effective in the treatment of SW480 human colon cancer xenografts independent of p53 status ; ( b ) ***PARP*** cleavage may be ***mediated*** by caspase-9 and ***caspase-3*** activation in the Pc 4-PDT-treated tumors ; and ( c ) p38 phosphorylation may be a trigger of apoptosis in response to PDT in vivo in this tumor model .	target	0
14698	10815928	842;142	caspase-9;PARP	Our results suggest that : ( a ) Pc 4-PDT is effective in the treatment of SW480 human colon cancer xenografts independent of p53 status ; ( b ) ***PARP*** cleavage may be ***mediated*** by ***caspase-9*** and caspase-3 activation in the Pc 4-PDT-treated tumors ; and ( c ) p38 phosphorylation may be a trigger of apoptosis in response to PDT in vivo in this tumor model .	target	0
14699	10815932	1956;7039	EGFR;TGF-alpha	Overexpression of ***TGF-alpha*** and its specific ***receptor*** , the epidermal growth factor receptor ( ***EGFR*** ) , is associated with aggressive disease and poor prognosis .	parallel	1
14700	10816381	1234;920	CCR5;CD4	***Interactions*** of ***CCR5*** and CXCR4 with ***CD4*** and gp120 in human blood monocyte-derived dendritic cells .	parallel	1
14701	10816381	1234;3700	CCR5;gp120	***Interactions*** of ***CCR5*** and CXCR4 with CD4 and ***gp120*** in human blood monocyte-derived dendritic cells .	parallel	1
14702	10816381	7852;920	CXCR4;CD4	***Interactions*** of CCR5 and ***CXCR4*** with ***CD4*** and gp120 in human blood monocyte-derived dendritic cells .	parallel	1
14703	10816381	7852;3700	CXCR4;gp120	***Interactions*** of CCR5 and ***CXCR4*** with CD4 and ***gp120*** in human blood monocyte-derived dendritic cells .	parallel	1
14704	10816381	920;1234	CD4;CCR5	In addition , DC behaved similarly to macrophages , lymphocytes , and monocytes in their ability to support ***formation*** of complexes between ***CD4*** and the other major HIV-1 coreceptor ***CCR5*** even in the absence of gp120 as demonstrated by CD4 coimmunoprecipitation with anti-CCR5 antibodies .	parallel	0
14705	10816381	920;3700	CD4;gp120	These results demonstrate that of all the major types of host cells important for HIV-1 infection , the first central stage in the entry mechanism , the formation of gp120-CD4-coreceptor complexes , is not impaired except for the formation of the ******gp120-CD4-CXCR4****** ***complex*** in macrophages .	parallel	1
14706	10816381	7852;920	CXCR4;CD4	These results demonstrate that of all the major types of host cells important for HIV-1 infection , the first central stage in the entry mechanism , the formation of gp120-CD4-coreceptor complexes , is not impaired except for the formation of the ******gp120-CD4-CXCR4****** ***complex*** in macrophages .	parallel	1
14707	10816381	7852;3700	CXCR4;gp120	These results demonstrate that of all the major types of host cells important for HIV-1 infection , the first central stage in the entry mechanism , the formation of gp120-CD4-coreceptor complexes , is not impaired except for the formation of the ******gp120-CD4-CXCR4****** ***complex*** in macrophages .	parallel	1
14708	10816381	920;3700	CD4;gp120	These results demonstrate that of all the major types of host cells important for HIV-1 infection , the first central stage in the entry mechanism , the formation of ******gp120-CD4-coreceptor****** ***complexes*** , is not impaired except for the formation of the gp120-CD4-CXCR4 complex in macrophages .	parallel	1
14709	10816382	920;3700	CD4;gp120	To test the hypothesis that inefficient formation of ******gp120-CD4-CXCR4****** ***complexes*** could contribute to the mechanism of resistance to Env-mediated fusion in the minus clones , we incubated plus and minus cells with HIV-1 LAI gp120 and coimmunoprecipitated CD4 by using anti-CXCR4 antibodies .	parallel	1
14710	10816382	7852;920	CXCR4;CD4	To test the hypothesis that inefficient formation of ******gp120-CD4-CXCR4****** ***complexes*** could contribute to the mechanism of resistance to Env-mediated fusion in the minus clones , we incubated plus and minus cells with HIV-1 LAI gp120 and coimmunoprecipitated CD4 by using anti-CXCR4 antibodies .	parallel	1
14711	10816382	7852;3700	CXCR4;gp120	To test the hypothesis that inefficient formation of ******gp120-CD4-CXCR4****** ***complexes*** could contribute to the mechanism of resistance to Env-mediated fusion in the minus clones , we incubated plus and minus cells with HIV-1 LAI gp120 and coimmunoprecipitated CD4 by using anti-CXCR4 antibodies .	parallel	1
14712	10816382	920;3700	CD4;gp120	Overexpression of CD4 resulted in significant restoration of the minus clones ' susceptibility to fusion in parallel with an increase in the amount of the ******gp120-CD4-CXCR4****** ***complexes*** .	parallel	1
14713	10816382	7852;920	CXCR4;CD4	Overexpression of CD4 resulted in significant restoration of the minus clones ' susceptibility to fusion in parallel with an increase in the amount of the ******gp120-CD4-CXCR4****** ***complexes*** .	parallel	1
14714	10816382	7852;3700	CXCR4;gp120	Overexpression of CD4 resulted in significant restoration of the minus clones ' susceptibility to fusion in parallel with an increase in the amount of the ******gp120-CD4-CXCR4****** ***complexes*** .	parallel	1
14715	10816429	3479;3480	IGF-1;insulin-like growth factor-1 (IGF-1) receptor	Their effect requires ***stimulation*** of the ***insulin-like growth factor-1 (IGF-1) receptor*** by either ***IGF-1*** or insulin , which are not themselves mitogenic agents .	positive	0
14716	10816429	3082;2185	HGF;protein kinase B	In contrast , phosphatidylinositol 3-kinase ( PI 3-kinase ) and ***protein kinase B*** ( PKB ) ***activation*** by insulin and ***HGF*** is strong and sustained , whereas it is weak and transient with EGF and absent in the presence of TSH or PMA .	positive	1
14717	10816430	348;351	ApoE;Abeta	***ApoE*** isoforms ***bind*** directly to Alzheimer 's amyloid beta ( ***Abeta*** ) peptides both in vitro and in vivo .	parallel	1
14718	10816430	348;351	apoE4;Abeta	We examined the ***binding*** of lipid-associated and delipidated apoE3 and ***apoE4*** isoforms to ***Abeta*** utilizing a solid-phase binding assay and estimated the dissociation constants for the interaction of various ApoE and Abeta species .	parallel	1
14719	10816436	3479;3667	IGF-I;insulin receptor substrate-1	Pretreatment with TSH or dibutyryl cAMP did not affect the ***IGF-I-dependent*** tyrosine ***phosphorylation*** of ***insulin receptor substrate-1*** ( IRS-1 ) .	target	1
14720	10816480	3565;3458	IL-4;IFN-gamma	Recent studies have suggested that Interleukin-6 ( IL-6 ) is required for the induction of a protective T-cell response and that ***IL-4*** may ***suppress*** the induction of ***IFN-gamma*** .	negative	1
14721	10816504	3606;3458	IL-18;IFN-gamma	***IFN-gamma*** mediates macrophage activation and appears to be ***controlled*** by interleukin ( IL ) -12 and ***IL-18*** .	target	0
14722	10816515	3664;3586	LPS;IL-10	No isolated bacterial component could be identified that mimicked the potent induction of IL-12 by whole gram-positive bacteria , whereas purified ***LPS*** ***induced*** ***IL-10*** .	target	1
14723	10816557	3725;5743	c-Jun;COX-2	Conversely , dominant negative mutants of NFATc or ***c-Jun*** proteins ***inhibited*** ***COX-2*** induction .	positive	1
14724	10816557	4772;5743	NFATc;COX-2	Conversely , dominant negative mutants of ***NFATc*** or c-Jun proteins ***inhibited*** ***COX-2*** induction .	positive	1
14725	10816562	27344;5122	proSAAS;PC1	Taken together , these data support the proposal that ***proSAAS*** functions as an endogenous ***inhibitor*** of ***PC1*** .	negative	1
14726	10816562	27344;5122	proSAAS;prohormone convertase 1	The C-terminal region of ***proSAAS*** is a potent ***inhibitor*** of ***prohormone convertase 1*** .	negative	1
14727	10816562	27344;5122	proSAAS;PC1	Two microm ***proSAAS*** selectively ***inhibits*** ***PC1*** but not furin , PACE4 , PC5A , or PC7 .	negative	1
14728	10816562	27344;9159	proSAAS;PC7	Two microm ***proSAAS*** selectively ***inhibits*** PC1 but not furin , PACE4 , PC5A , or ***PC7*** .	negative	1
14729	10816569	8802;5962	Galpha;radixin	***Interaction*** between ***radixin*** and ***Galpha*** ( 13 ) was confirmed by in vitro binding assay and by co-immunoprecipitation technique .	parallel	1
14730	10816569	8802;5962	Galpha;radixin	Activated ***Galpha*** ( 13 ) ***induced*** conformational activation of ***radixin*** , as determined by binding of radixin to polymerized F-actin and by immunofluorescence in intact cells .	target	1
14731	10816569	5962;8802	radixin;Galpha	Finally , two dominant negative mutants of ***radixin*** ***inhibited*** ***Galpha*** ( 13 ) - induced focus formation of Rat-1 fibroblasts but did not affect Ras-induced focus formation .	positive	1
14732	10816571	8721;6908	EDF-1;TBP	On the basis of the high homology of EDF-1 with multiprotein bridging factor-1 , a transcriptional coactivator that binds TATA-binding protein ( TBP ) , we also demonstrate that ***EDF-1*** ***interacts*** with ***TBP*** in vitro and in human endothelial cells .	parallel	1
14733	10816572	51176;1499	Lef-1;beta-catenin	Caveolin-1 expression inhibits ******Wnt/beta-catenin/Lef-1****** ***signaling*** by recruiting beta-catenin to caveolae membrane domains .	parallel	0
14734	10816572	857;1499	Caveolin-1;beta-catenin	***Caveolin-1*** expression ***inhibits*** ***Wnt/beta-catenin/Lef-1*** signaling by recruiting beta-catenin to caveolae membrane domains .	negative	1
14735	10816572	857;51176	Caveolin-1;Lef-1	***Caveolin-1*** expression ***inhibits*** ***Wnt/beta-catenin/Lef-1*** signaling by recruiting beta-catenin to caveolae membrane domains .	negative	1
14736	10816572	7471;1499	Wnt-1;beta-catenin	Moreover , we demonstrate that ***activation*** of ***beta-catenin/Lef-1*** signaling by ***Wnt-1*** or by overexpression of beta-catenin itself is inhibited by Caveolin-1 expression .	positive	1
14737	10816572	7471;51176	Wnt-1;Lef-1	Moreover , we demonstrate that ***activation*** of ***beta-catenin/Lef-1*** signaling by ***Wnt-1*** or by overexpression of beta-catenin itself is inhibited by Caveolin-1 expression .	positive	1
14738	10816572	51176;1499	Lef-1;beta-catenin	Moreover , we demonstrate that activation of ******beta-catenin/Lef-1****** ***signaling*** by Wnt-1 or by overexpression of beta-catenin itself is inhibited by Caveolin-1 expression .	parallel	0
14739	10816572	857;1499	Caveolin-1;beta-catenin	We also show that recombinant expression of ***Caveolin-1*** in Caveolin-1 negative cells is sufficient to ***recruit*** ***beta-catenin*** to caveolae membranes , thereby blocking beta-catenin-mediated transactivation .	target	0
14740	10816572	51176;1499	Lef-1;beta-catenin	These results suggest that Caveolin-1 expression can modulate ******Wnt/beta-catenin/Lef-1****** ***signaling*** by regulating the intracellular localization of beta-catenin .	parallel	0
14741	10816572	857;1499	Caveolin-1;beta-catenin	These results suggest that ***Caveolin-1*** expression can ***modulate*** ***Wnt/beta-catenin/Lef-1*** signaling by regulating the intracellular localization of beta-catenin .	target	0
14742	10816572	857;51176	Caveolin-1;Lef-1	These results suggest that ***Caveolin-1*** expression can ***modulate*** ***Wnt/beta-catenin/Lef-1*** signaling by regulating the intracellular localization of beta-catenin .	target	0
14743	10816575	6667;2099	Sp1;ERalpha	Coimmunoprecipitation and pull-down assays demonstrated that Sp3 and ERalpha proteins physically interact , and the interacting domains of both proteins are different from those previously observed for ***interactions*** between ***Sp1*** and ***ERalpha*** proteins .	parallel	1
14744	10816575	6670;2099	Sp3;ERalpha	Coimmunoprecipitation and pull-down assays demonstrated that ***Sp3*** and ***ERalpha*** proteins physically ***interact*** , and the interacting domains of both proteins are different from those previously observed for interactions between Sp1 and ERalpha proteins .	parallel	1
14745	10816575	6670;2099	Sp3;ERalpha	Using a dominant negative form of Sp3 and transcriptional activation assays in Schneider SL-2 insect cells , it was confirmed that ******ERalpha-Sp3****** ***interactions*** define a pathway for E2-mediated inhibition of gene expression , and this represents a new mechanism for decreased gene expression by E2 .	parallel	1
14746	10816578	3725;3713	AP-1;involucrin	In conclusion , calcium-regulated ***involucrin*** gene expression is ***mediated*** at least in part by ***AP-1*** transcription factors .	target	0
14747	10816583	5663;351	Presenilin 1;Abeta	Using ***Presenilin 1*** ( PS1 ) mutants that ***inhibit*** ***Abeta*** production in conjunction with transmembrane domain mutants of the amyloid protein precursor that are cleaved by pharmacologically distinct gamma-secretases , we show that PS1 regulates multiple pharmacologically distinct gamma-secretase activities as well as inducible alpha-secretase activity .	positive	1
14748	10816593	5608;1432	MKK6;p38	The MAPK kinase ***MKK6*** selectively ***stimulates*** ***p38*** MAPK and confers protection against stress-induced apoptosis in cardiac myocytes .	positive	0
14749	10816593	1432;9261	p38;MAPKAP-K2	MKK6 ( Glu ) also induced ***p38-dependent*** ***activation*** of the downstream MAPK-activated protein kinase , ***MAPKAP-K2*** , and the phosphorylation of alphaB-crystallin on serine-59 .	positive	1
14750	10816593	5608;9261	MKK6;MAPKAP-K2	***MKK6*** ( Glu ) also ***induced*** p38-dependent activation of the downstream MAPK-activated protein kinase , ***MAPKAP-K2*** , and the phosphorylation of alphaB-crystallin on serine-59 .	target	1
14751	10816597	3297;5243	HSF1;MDR1	These results demonstrate that ***HSF1*** ***regulates*** ***MDR1*** expression , and that the HSEs present in the -315 to -285 region mediate the heat-induced activation of the MDR1 promoter .	target	1
14752	10816598	6714;5747	Src;FAK	Specifically , although ***v-Src*** ***induces*** tyrosine phosphorylation of ***FAK*** , there is no detectable phosphorylation of Tyr ( 397 ) .	target	1
14753	10816606	1051;3569	NF-IL-6;IL-6	In addition , overexpression of ***NF-IL-6*** ***induced*** ***IL-6*** transcription .	target	1
14754	10816640	7200;5443	thyrotropin-releasing hormone;alpha-MSH	In particular , the skin of certain species of amphibians harbours considerable amounts of ***thyrotropin-releasing hormone*** , a highly potent ***stimulator*** of ***alpha-MSH*** release .	positive	0
14755	10816643	3552;5443	IL-1 alpha;beta-endorphin	In particular , ***beta-endorphin*** , a POMC peptide , has been shown to be ***modulated*** by TPA , ***IL-1 alpha*** , and ultraviolet radiation in keratinocytes .	target	0
14756	10816651	5443;3553	alpha-MSH;interleukin-1 beta	In research on septic patients , ***alpha-MSH*** ***inhibited*** release of TNF-alpha , ***interleukin-1 beta*** ( IL-1 beta ) , and interleukin-8 ( IL-8 ) in whole blood samples in vitro .	negative	1
14757	10816651	5443;3576	alpha-MSH;interleukin-8	In research on septic patients , ***alpha-MSH*** ***inhibited*** release of TNF-alpha , interleukin-1 beta ( IL-1 beta ) , and ***interleukin-8*** ( IL-8 ) in whole blood samples in vitro .	negative	1
14758	10816651	5443;7124	alpha-MSH;TNF-alpha	In research on septic patients , ***alpha-MSH*** ***inhibited*** release of ***TNF-alpha*** , interleukin-1 beta ( IL-1 beta ) , and interleukin-8 ( IL-8 ) in whole blood samples in vitro .	negative	1
14759	10816656	3553;4790	IL-1 beta;NF kappa B	Electrophoretic mobility-shift-assays showed that alpha-MSH , in a dose range from 10 ( -6 ) to 10 ( -12 ) M , significantly downregulated the ***IL-1 beta-induced*** ***activation*** of ***NF kappa B*** 10 minutes after stimulation .	positive	1
14760	10816656	5443;4790	alpha-MSH;NF kappa B	Electrophoretic mobility-shift-assays showed that ***alpha-MSH*** , in a dose range from 10 ( -6 ) to 10 ( -12 ) M , significantly ***downregulated*** the IL-1 beta-induced activation of ***NF kappa B*** 10 minutes after stimulation .	negative	1
14761	10816656	5443;4790	alpha-MSH;NF kappa B	Therefore , ***NF kappa B*** ***inactivation*** by ***alpha-MSH*** appears to be a crucial event , one that is responsible for the downregulation of cytokine gene transcription .	negative	1
14762	10816658	5443;7412	alpha-MSH;VCAM-1	RT-PCR analysis showed that ***alpha-MSH*** significantly ***reduced*** LPS-induced expression of ***VCAM-1*** and E-selectin .	negative	1
14763	10816659	7040;5443	TGF-beta;POMC	The altered ***TGF-beta*** ***regulation*** of ***POMC*** mRNA levels suggest that POMC-derived peptides may play a role in the pathogenesis of keloid formation through an autocrine/paracrine network , resulting in modulation of extracellular matrix synthesis .	target	1
14764	10816659	7040;5443	TGF-beta;POMC	***POMC*** steady-state levels were significantly ***reduced*** by addition of ***TGF-beta*** .	negative	1
14765	10816661	5443;3725	Alpha-melanocyte-stimulating hormone;AP-1	***Alpha-melanocyte-stimulating hormone*** ***modulates*** activation of NF-kappa B and ***AP-1*** and secretion of interleukin-8 in human dermal fibroblasts .	target	0
14766	10816661	5443;3576	Alpha-melanocyte-stimulating hormone;interleukin-8	***Alpha-melanocyte-stimulating hormone*** ***modulates*** activation of NF-kappa B and AP-1 and secretion of ***interleukin-8*** in human dermal fibroblasts .	target	0
14767	10816661	5443;4790	Alpha-melanocyte-stimulating hormone;NF-kappa B	***Alpha-melanocyte-stimulating hormone*** ***modulates*** activation of ***NF-kappa B*** and AP-1 and secretion of interleukin-8 in human dermal fibroblasts .	target	0
14768	10816663	1392;7349	CRF;urocortin	On the basis of its greater affinity for urocortin , in comparison with CRF , as well as its brain distribution , ***CRF-R2*** may be the cognate ***receptor*** for ***urocortin*** .	parallel	1
14769	10816664	5443;7299	alpha-MSH;tyrosinase	The tyrosinase/6BH4 inhibition can be activated by 1:1 complex formation between 6BH4 and alpha-MSH , but an excess of ***alpha-MSH*** over 6BH4 can ***inhibit*** ***tyrosinase*** due to complex formation by tyr2 in the alpha-MSH sequence .	negative	1
14770	10816666	1392;5443	CRH;POMC	Given that murine skin also expresses ( in a hair-cycle-dependent way ) CRH and ***CRH-R*** , which ***control*** pituitary ***POMC*** expression and in view of the fact that CRH arrests follicles in telogen , this suggests the existence of a local skin POMC system ( SPS ) .	target	0
14771	10816675	5443;3303	alpha-MSH;HSP 72	Microinjection of ***alpha-MSH*** followed by UV-irradiation ***blocks*** ***HSP 72*** in human keratinocytes .	negative	0
14772	10817568	6774;4318	signal transducer and activator of transcription 1/3;MMP-9	IL-17-inducible activator protein 1 and ***signal transducer and activator of transcription 1/3*** may ***transactivate*** the ***MMP-9*** promoter .	positive	1
14773	10817569	5594;5595	extracellular signal-regulated kinase 2;Extracellular signal-regulated kinase 1	******Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2****** mitogen-activated protein kinase ***signaling*** and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells .	parallel	0
14774	10817584	4803;4914	NGF;trkA	The receptor tyrosine kinase Kit thus contrasts with the receptor tyrosine kinase ***trkA*** , which is ***activated*** by the sprouting stimulus ( ***NGF*** ) but not by the axonal regeneration signal .	positive	1
14775	10817623	3976;3479	LIF;IGF-1	Thus , ***LIF*** appears to ***regulate*** ***IGF-1*** expression in the peripheral nerve basally and early in the regeneration response in vivo .	target	1
14776	10817673	356;355	FasL;Fas	Apoptosis-inducing ligands such as ***Fas*** ***ligand*** ( ***FasL*** ) and tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL ) have been found to play an important role in cell regulation .	parallel	1
14777	10817673	355;8743	Fas;TRAIL	The purpose of this study was therefore to investigate expression of ***TRAIL*** , FasL , and its ***receptor*** ***Fas*** on protein and mRNA levels in breast carcinomas ( n = 40 ) , fibroadenomas ( n = 7 ) , and normal breast tissues ( n = 5 ) .	parallel	1
14778	10817756	10499;4656	GRIP-1;myogenin	The HLH region of myogenin mediates the direct ***interaction*** of ***myogenin*** and ***GRIP-1*** .	parallel	1
14779	10817756	4656;10499	myogenin;GRIP-1	The HLH region of ***myogenin*** ***mediates*** the direct interaction of myogenin and ***GRIP-1*** .	target	0
14780	10817756	2033;4654	p300;MyoD	PCAF and ***p300*** have also been demonstrated to function as critical ***coactivators*** for the muscle-specific basic helix-loop-helix ( bHLH ) protein ***MyoD*** during myogenic commitment .	positive	1
14781	10817756	8850;4654	PCAF;MyoD	***PCAF*** and p300 have also been demonstrated to function as critical ***coactivators*** for the muscle-specific basic helix-loop-helix ( bHLH ) protein ***MyoD*** during myogenic commitment .	positive	1
14782	10817928	1270;6774	CNTF;Stat3	Besides ***CNTF*** , which is known to ***recruit*** ***Stat3*** , we found that Stat3 was also tyrosine phosphorylated by bFGF .	target	0
14783	10818081	183;5594	angiotensin II;ERK	Similarly , ***angiotensin II*** ***increased*** JNK ( 1 ) and ***ERK*** ( 1/2 ) activity in a time - and concentration-dependent manner in WKY cells but not in SHR cells .	positive	0
14784	10818081	183;5599	angiotensin II;JNK	Similarly , ***angiotensin II*** ***increased*** ***JNK*** ( 1 ) and ERK ( 1/2 ) activity in a time - and concentration-dependent manner in WKY cells but not in SHR cells .	positive	0
14785	10818092	2064;1999	HER2;epithelial restricted with serine box	As measured by electrophoretic mobility shift assay , polyamides binding to flanking elements upstream ( ) or downstream ( 2 and 3 ) of the EBS were one to two orders of magnitude more effective than the natural product distamycin at inhibiting ***formation*** of complexes between the purified EBS protein , ***epithelial restricted with serine box*** ( ESX ) , and the ***HER2/neu*** promoter probe .	parallel	0
14786	10818102	10746;5586	MEKK2;PRK2	In cells , MEKK2 and PRK2 are co-immunoprecipitated and ***PRK2*** is ***activated*** by ***MEKK2*** .	positive	1
14787	10818102	10746;5586	MEKK2;PRK2	Similarly , purified recombinant ***MEKK2*** ***activated*** ***PRK2*** in vitro .	positive	1
14788	10818102	10746;5586	MEKK2;PRK2	***MEKK2*** ***activation*** of ***PRK2*** is independent of MEKK2 regulation of the c-Jun NH ( 2 ) - terminal kinase pathway .	positive	1
14789	10818102	10746;5586	MEKK2;PRK2	***MEKK2*** ***activation*** of ***PRK2*** results in a bifurcation of signaling for the dual control of MAPK pathways and PRK2 regulated responses .	positive	1
14790	10818102	10746;5586	MEK kinase 2;protein kinase C-related kinase 2	***MEK kinase 2*** ***binds*** and activates ***protein kinase C-related kinase 2*** .	parallel	1
14791	10818102	5586;387	PRK2;RhoA	protein kinase C-related kinase 2 ( PRK2 ) was found to bind MEKK2 ; ***PRK2*** has been previously shown to ***bind*** ***RhoA*** and the Src homology 3 domain of Nck .	parallel	1
14792	10818102	5586;10746	protein kinase C-related kinase 2;MEKK2	***protein kinase C-related kinase 2*** ( PRK2 ) was found to ***bind*** ***MEKK2*** ; PRK2 has been previously shown to bind RhoA and the Src homology 3 domain of Nck .	parallel	1
14793	10818128	351;5340	Abeta;plasmin	In summation , we interpret these results as consistent with the possibility that the ***plasmin*** pathway is ***induced*** by aggregated ***Abeta*** , which can lead to Abeta degradation and inhibition of Abeta actions .	target	1
14794	10818128	351;5327	Abeta;tPA	Because others have reported that Abeta aggregates can substitute for fibrin aggregates in activating tPA post-translationally , the result of ***tPA*** ***induction*** by ***Abeta*** would be cleavage of plasminogen to the active protease plasmin .	target	1
14795	10818128	5340;351	plasmin;Abeta	In evaluating these conflicting hypotheses , we found that purified ***plasmin*** ***degrades*** ***Abeta*** with physiologically relevant efficiency , i.e. , approximately 1/10th the rate of plasmin on fibrin .	negative	0
14796	10818128	5340;351	plasmin;Abeta	Mass spectral analyses show that ***plasmin*** ***cleaves*** ***Abeta*** at multiple sites .	target	1
14797	10818143	1270;6774	CNTF;STAT3	The observation that ***CNTF*** ***activates*** ***STAT3*** in ganglion cells , but not in photoreceptors , suggests that Jak-STAT signaling influences neuronal survival via both direct and indirect modes of action .	positive	1
14798	10818225	7076;102	TIMP-1;ADAM-10	The in vitro activity of ***ADAM-10*** is ***inhibited*** by ***TIMP-1*** and TIMP-3 .	negative	1
14799	10818225	7078;102	TIMP-3;ADAM-10	The in vitro activity of ***ADAM-10*** is ***inhibited*** by TIMP-1 and ***TIMP-3*** .	negative	1
14800	10818225	7076;102	TIMP-1;ADAM-10	The ***TIMP-1*** ***inhibition*** of ***ADAM-10*** could therefore prove useful in distinguishing its activity from that of TACE , which is only inhibited by TIMP-3 , in cell based assays .	negative	1
14801	10818225	7078;6868	TIMP-3;TACE	The TIMP-1 inhibition of ADAM-10 could therefore prove useful in distinguishing its activity from that of ***TACE*** , which is only ***inhibited*** by ***TIMP-3*** , in cell based assays .	negative	1
14802	10818227	11035;4790	RIP3;NF-kappaB	The RIP-like kinase , ***RIP3*** , ***induces*** apoptosis and ***NF-kappaB*** nuclear translocation and localizes to mitochondria .	target	1
14803	10818395	1393;1392	CRF-BP;CRF	A local ***CRF-BP*** ***modulates*** the paracrine effects of ***CRF*** and urocortin .	target	0
14804	10818395	1393;7349	CRF-BP;urocortin	A local ***CRF-BP*** ***modulates*** the paracrine effects of CRF and ***urocortin*** .	target	0
14805	10818483	348;351	apolipoprotein E;APP	The amyloidogenic processing of ***APP*** can be ***enhanced*** by ***apolipoprotein E*** , reduced by transthyretin , and modulated by several cytokines .	positive	0
14806	10819246	100507436;7124	MIC-A;TNFA	The aim of our study was to test the association of the polymorphism of the MIC-A gene with Type I ( insulin-dependent ) diabetes mellitus and evaluate the ***interaction*** between ***MIC-A*** and ***TNFA*** , HLA-B , HLA-DR and HLA-DQ gene polymorphism .	parallel	1
14807	10819444	2922;6714	Bombesin;Src	***Bombesin*** ***modulates*** the association of ***Src*** with a nuclear 110-kd protein expressed in dividing prostate cells .	target	0
14808	10819505	1026;1018	p21;cyclin-dependent kinase (CDK)3	Additionally , estrogen induces the formation of high specific activity forms of the cyclin E-Cdk2 enzyme complex lacking the ***cyclin-dependent kinase (CDK)3*** ***inhibitor*** , ***p21*** .	negative	1
14809	10819535	672;5888	BRCA1;HsRad51	The first clue of an ***interaction*** between ***HsRad51*** and ***BRCA1*** came from the colocalization of the characteristic nuclear foci formed by these two proteins during S phase of the cell cycle .	parallel	1
14810	10819746	10468;3815	follistatin;c-kit	The mRNAs encoding ***c-kit*** and its ***ligand*** stem cell factor ( SCF ) , FSH receptor ( FSH-R ) , ***follistatin*** , alpha-inhibin subunit , and the beta ( A ) - and beta ( B ) - activin/inhibin subunits were localized in ovaries of ewes with 0 ( + + ) , 1 ( I + ) , or 2 ( II ) copies of the FecX ( I ) gene ( n = 4-9 animals per genotype per gene ) using in situ hybridization .	parallel	1
14811	10819746	4254;3815	SCF;c-kit	The mRNAs encoding ***c-kit*** and its ***ligand*** stem cell factor ( ***SCF*** ) , FSH receptor ( FSH-R ) , follistatin , alpha-inhibin subunit , and the beta ( A ) - and beta ( B ) - activin/inhibin subunits were localized in ovaries of ewes with 0 ( + + ) , 1 ( I + ) , or 2 ( II ) copies of the FecX ( I ) gene ( n = 4-9 animals per genotype per gene ) using in situ hybridization .	parallel	1
14812	10819761	3815;6320	c-kit;stem cell growth factor	The current study investigates the potential role of the growth factor kit ligand ( KL ) / ***stem cell growth factor*** and its ***receptor*** ***c-kit*** in normal OSE biology and ovarian cancer .	parallel	1
14813	10819777	3439;1437	IFN;GM-CSF	This study provides the first evidence for ***stimulation*** of ***GM-CSF*** expression by ***IFN-tau*** in both leukocytes and endometrial stromal cells .	positive	0
14814	10819791	4233;3082	c-met;hepatocyte growth factor	Expression of ***hepatocyte growth factor*** and its ***receptor*** ***c-met*** in the ovine uterus .	parallel	1
14815	10819791	4233;3082	c-met;hepatocyte growth factor	The objective of this study was to determine if ***hepatocyte growth factor*** ( HGF , scatter factor ) and its ***receptor*** ***c-met*** were present in the ovine uterus and to characterize their temporal and spatial expression during the estrous cycle and pregnancy .	parallel	1
14816	10819792	3082;51478	hepatocyte growth factor;17beta-hydroxysteroid dehydrogenase	***Modulation*** of estrogen production and ***17beta-hydroxysteroid dehydrogenase-type*** 1 , cytochrome P450 aromatase , c-met , and protein kinase Balpha messenger ribonucleic acid content in rat ovarian granulosa cells by ***hepatocyte growth factor*** and follicle-stimulating hormone .	target	0
14817	10819977	462;9622	antithrombin;kallikrein	Previous investigations have shown that HK and its light chain bind heparin , preventing the enhancement of antithrombin inhibition of thrombin and potentiating the ***inhibition*** of plasma ***kallikrein*** by ***antithrombin*** .	negative	1
14818	10820009	1509;4155	cathepsin D;MBP	***Degradation*** of bovine ***MBP*** by ***cathepsin D*** , a myelin-associated protease , was increased when 6 arginyl residues were deiminated and became very rapid when all 18 arginyl residues were deiminated .	negative	1
14819	10820026	133482;760	GST;CAII	A ***GST*** fusion protein of the 33 residue Ct of AE2 could ***bind*** to ***CAII*** similarly to the Ct of AE1 .	parallel	1
14820	10820151	3741;2697	Kv1.5;Cx43	In atrial muscle , ***Kv1.5*** labeling was closely ***associated*** with labeling of ***Cx43*** ( gap junction protein ) and DPI/II ( desmosomal protein ) , whereas in SA node Kv1.5 labeling was closely associated with labeling of DPI/II but not labeling of Cx43 ( absent in the SA node ) or Cx45 ( another gap junction protein present in the SA node ) .	parallel	0
14821	10820151	3741;1832	Kv1.5;DPI	In atrial muscle , ***Kv1.5*** labeling was closely ***associated*** with labeling of Cx43 ( gap junction protein ) and ***DPI/II*** ( desmosomal protein ) , whereas in SA node Kv1.5 labeling was closely associated with labeling of DPI/II but not labeling of Cx43 ( absent in the SA node ) or Cx45 ( another gap junction protein present in the SA node ) .	parallel	0
14822	10820172	5744;7422	PTHrP;VEGF	***PTHrP*** ( 107-139 ) , at 10 nM , also ***stimulated*** cytosolic ***VEGF*** immunostaining in hOB cells , and VEGF secretion into the medium conditioned by hOB or MG-63 cells for 24 h , which was ( ng/mg protein ) : 10 + / - 1 or 5 + / - 3 ( control ) , respectively , and 21 + / - 1 or 11 + / - 2 ( PTHrP [ 107-139 ] - stimulated ) , respectively .	positive	0
14823	10820172	5744;7422	PTHrP;VEGF	These findings demonstrate that the C-terminal domain of ***PTHrP*** ***induces*** expression and secretion of ***VEGF*** , a main angiogenic factor , in hOB cells and MG-63 cells .	target	1
14824	10820172	5744;7422	PTHrP;VEGF	Using semiquantitative reverse transcription followed by PCR , we found that ***PTHrP*** ( 107-139 ) , between 10 nM and 1 pM , ***increased*** ***VEGF*** mRNA in human osteoblastic ( hOB ) cells from trabecular bone .	positive	0
14825	10820194	1019;595	cdk4;cyclin D1	Immunoprecipitation of cdk2 and cdk4 fractions of protein extracts at 4 days postlesion ( mitotic reaction peak ) versus control , followed by cyclin D1 immunoblotting , and vice versa , revealed that levels of both cyclin D1/cdk2 and ******cyclin D1/cdk4****** ***complexes*** , as well as their kinase activities , were dramatically increased after lesion .	parallel	1
14826	10820194	595;1017	cyclin D1;cdk2	In vivo proliferation of olfactory neuronal lineage cells thus involves functional ***binding*** of ***cyclin D1*** with ***cdk2*** and cdk4 , with differential activation mechanisms for cdk2 and cdk4 .	parallel	1
14827	10820194	595;1019	cyclin D1;cdk4	In vivo proliferation of olfactory neuronal lineage cells thus involves functional ***binding*** of ***cyclin D1*** with cdk2 and ***cdk4*** , with differential activation mechanisms for cdk2 and cdk4 .	parallel	1
14828	10820228	3586;3578	IL-10;IL-9	Both KL and ***IL-10*** considerably ***enhance*** the production of ***IL-9*** mRNA and protein .	positive	0
14829	10820259	9402;940	GRID;CD28	***GRID*** ***coimmunoprecipitates*** with ***CD28*** from Jurkat cell lysates following activation of CD28 .	parallel	1
14830	10820260	4792;4790	I kappa B alpha;NF-kappa B	This effect was mediated through inhibition of phosphorylation and degradation of ***I kappa B alpha*** , an ***inhibitor*** of ***NF-kappa B*** .	negative	1
14831	10820261	5897;5896	RAG2;RAG1	In this report , we use deletion mapping and site-directed mutagenesis to determine the minimal domains critical for ***interaction*** between ***RAG1*** and ***RAG2*** .	parallel	1
14832	10820262	3458;8651	IFN-gamma;SSI-1	Finally , mouse embryonal fibroblasts lacking IRF-1 showed impaired ***SSI-1*** mRNA ***induction*** by ***IFN-gamma*** .	target	1
14833	10820262	3659;8651	IRF-1;SSI-1	These results demonstrated that ***IRF-1*** , which is induced by activation of Stat1 , ***mediated*** transcriptional activation of the ***SSI-1*** gene by IFN-gamma via VIRE .	target	0
14834	10820262	6772;3659	Stat1;IRF-1	These results demonstrated that ***IRF-1*** , which is ***induced*** by activation of ***Stat1*** , mediated transcriptional activation of the SSI-1 gene by IFN-gamma via VIRE .	target	1
14835	10820262	3458;8651	IFN-gamma;STAT-induced STAT inhibitor-1	IFN regulatory factor-1-mediated transcriptional ***activation*** of mouse ***STAT-induced STAT inhibitor-1*** gene promoter by ***IFN-gamma*** .	positive	1
14836	10820262	6772;3458	Stat1;IFN-gamma	We also showed that IFN-gamma induced SSI-1 mRNA more strongly than IL-6 in NIH-3T3 fibroblasts and that this ***IFN-gamma*** effect was ***mediated*** by ***Stat1*** .	target	0
14837	10820262	3458;8651	IFN-gamma;SSI-1	We also showed that ***IFN-gamma*** ***induced*** ***SSI-1*** mRNA more strongly than IL-6 in NIH-3T3 fibroblasts and that this IFN-gamma effect was mediated by Stat1 .	target	1
14838	10820262	3659;3458	IRF-1;IFN-gamma	Furthermore , forced expression of ***IRF-1*** mimicked and that of IRF-2 ***inhibited*** the stimulatory effect of ***IFN-gamma*** on SSI-1 gene transcription .	negative	1
14839	10820264	6810;8773	syntaxin 4;SNAP23	Within the syntaxin family , ***syntaxin 4*** ***interacted*** with ***SNAP23*** and all vesicle-associated membrane proteins ( VAMPs ) examined , except tetanus neurotoxin insensitive VAMP ( TI-VAMP ) .	parallel	1
14840	10820265	959;958	CD40L;CD40	Our results link the required ******CD40/CD40L****** ***interactions*** for healing with DC-derived IL-12p70 production and provide a mechanism to explain the genesis of a protective T cell-mediated response in the face of local immune evasion within the macrophage at the site of Leishmania delivery .	parallel	1
14841	10820268	959;958	CD154;CD40	The role of ******CD40-CD154****** ***interaction*** in antiviral T cell-independent IgG responses .	parallel	1
14842	10820268	959;958	CD40L;CD40	Because ***CD40*** ***ligand*** ( ***CD40L*** ) can be expressed on numerous cell types in addition to activated T cells , it is possible that cells other than T cells provide CD40L to signal through CD40 on B cells and hence positively influence the antiviral TI IgG responses .	parallel	1
14843	10820268	959;958	CD40L;CD40	Our studies demonstrate that , although about half of the TI IgG responses to PyV are independent of ******CD40-CD40L****** ***interactions*** , these interactions occur in T cell-deficient mice and enhance antiviral TI Ab responses .	parallel	1
14844	10820273	959;51497	CD40 ligand;Th1	***CD40 ligand*** ( CD154 ) ***enhances*** the ***Th1*** and antibody responses to respiratory syncytial virus in the BALB/c mouse .	positive	0
14845	10820273	959;51497	CD40L;Th1	***CD40L*** expression ***promotes*** ***Th1*** cytokine responses to protein Ags and is responsible for Ig isotype switching in B cells .	positive	0
14846	10820273	959;51497	CD40L;Th1	These studies show that coincident expression of ***CD40L*** ***enhances*** the ***Th1*** ( IL-2 and IFN-gamma ) cytokine responses , increases the expression of TNF-alpha and NO , accelerates virus clearance , and increases the anti-F and anti-G Ab responses .	positive	0
14847	10820273	959;7124	CD40L;TNF-alpha	These studies show that coincident expression of ***CD40L*** enhances the Th1 ( IL-2 and IFN-gamma ) cytokine responses , ***increases*** the expression of ***TNF-alpha*** and NO , accelerates virus clearance , and increases the anti-F and anti-G Ab responses .	positive	0
14848	10820276	3567;7852	IL-5;CXCR4	In contrast to IL-4 and IFN-gamma , ***IL-5*** potently ***reduced*** the level of ***CXCR4*** mRNA .	negative	1
14849	10820282	4790;7412	NF-kappa B;VCAM-1	These results indicate that ***NF-kappa B*** ***mediates*** TNF-alpha-induced ***VCAM-1*** expression on mFLS .	target	0
14850	10820282	4790;7412	NF-kappa B;VCAM-1	***NF-kappa B*** ***regulates*** ***VCAM-1*** expression on fibroblast-like synoviocytes .	target	1
14851	10820282	5970;4790	P65;P50	Nuclear translocation of transcription factor NF-kappa B including P50/P50 homodimer and ******P65/P50****** ***heterodimer*** was activated by TNF-alpha treatment .	parallel	1
14852	10820282	7124;4790	TNF-alpha;NF-kappa B	Nuclear translocation of transcription factor ***NF-kappa B*** including P50/P50 homodimer and P65/P50 heterodimer was ***activated*** by ***TNF-alpha*** treatment .	positive	1
14853	10820284	959;958	CD154;CD40	Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4 + T cells by blocking the ******CD40-CD154****** ***interactions*** .	parallel	1
14854	10820284	959;958	CD40L;CD40	These data suggest that the ******CD40-CD40L****** ***interactions*** are essential for the Th1 inflammatory responses in the bowel in this experimental model of colitis .	parallel	1
14855	10820378	2885;971	Grb2;CD72	BLNK is associated with the ******CD72/SHP-1/Grb2****** ***complex*** in the WEHI231 cell line after membrane IgM cross-linking .	parallel	1
14856	10820378	5777;971	SHP-1;CD72	BLNK is associated with the ******CD72/SHP-1/Grb2****** ***complex*** in the WEHI231 cell line after membrane IgM cross-linking .	parallel	1
14857	10820378	5777;2885	SHP-1;Grb2	BLNK is associated with the ******CD72/SHP-1/Grb2****** ***complex*** in the WEHI231 cell line after membrane IgM cross-linking .	parallel	1
14858	10820378	29760;971	BLNK;CD72	***BLNK*** is ***associated*** with the ***CD72/SHP-1/Grb2*** complex in the WEHI231 cell line after membrane IgM cross-linking .	parallel	0
14859	10820378	29760;2885	BLNK;Grb2	***BLNK*** is ***associated*** with the ***CD72/SHP-1/Grb2*** complex in the WEHI231 cell line after membrane IgM cross-linking .	parallel	0
14860	10820378	29760;5777	BLNK;SHP-1	***BLNK*** is ***associated*** with the ***CD72/SHP-1/Grb2*** complex in the WEHI231 cell line after membrane IgM cross-linking .	parallel	0
14861	10820378	971;5777	CD72;SHP-1	We have previously shown that ***CD72*** carrying two immunoreceptor tyrosine-based inhibition motifs ( ITIM ) is an in vivo ***substrate*** of ***SHP-1*** .	parallel	1
14862	10820378	971;2885	CD72;Grb2	***CD72*** forms a ***complex*** with SHP-1 and ***Grb2*** via its tyrosine-phosphorylated ITIM when the WEHI231 cell line , which is representative of immature B cells , undergoes apoptosis .	parallel	1
14863	10820378	971;5777	CD72;SHP-1	***CD72*** forms a ***complex*** with ***SHP-1*** and Grb2 via its tyrosine-phosphorylated ITIM when the WEHI231 cell line , which is representative of immature B cells , undergoes apoptosis .	parallel	1
14864	10820378	29760;971	BLNK;CD72	Our experiments demonstrate that ***BLNK*** , a recently identified adaptor molecule predominantly expressed in B cells , is ***associated*** with the ***CD72*** complex via the Src homology 3 domain ( s ) of Grb2 in the cell line after membrane IgM ( mIgM ) engagement .	parallel	0
14865	10820385	958;959	CD40;CD40L	Blocking the ***interaction*** of ***CD40*** on APC with ***CD40L*** on T cells using mAb to CD40L resulted in a significant inhibition of IFN-gamma production .	parallel	1
14866	10820387	356;355	FasL;Fas	The Fas / ***Fas*** ***ligand*** ( ***FasL*** ) pathway has been implicated in apoptosis of various cell types .	parallel	1
14867	10820389	942;941	CD86;CD80	CD28 engagement by specific monoclonal antibody ( mAb ) or ***binding*** of the natural ligands , ***CD80*** and ***CD86*** , induces tyrosine phosphorylation of CD28 , which in turn recruits and activates the signal transducer and activator of transcription 6 ( Stat6 ) .	parallel	1
14868	10820389	6778;940	Stat6;CD28	The ***Stat6*** ***association*** with ***CD28*** is specifically induced by CD80 or CD86 ligand binding and is not dependent upon the secretion of IL-4 or IL-13 .	parallel	0
14869	10820389	941;6778	CD80;Stat6	The ***Stat6*** association with CD28 is specifically ***induced*** by ***CD80*** or CD86 ligand binding and is not dependent upon the secretion of IL-4 or IL-13 .	target	1
14870	10820389	942;6778	CD86;Stat6	The ***Stat6*** association with CD28 is specifically ***induced*** by CD80 or ***CD86*** ligand binding and is not dependent upon the secretion of IL-4 or IL-13 .	target	1
14871	10820393	3558;3458	IL-2;IFN-gamma	***IL-2*** ***augmented*** IL-12-dependent ***IFN-gamma*** production by DC purified from both splenocytes of wild-type and anti-asialoGM1 Ab-treated Rag-2 ( - / - ) splenocytes devoid of T , B , NK and NKT cells .	positive	0
14872	10820429	4804;627	p75;neurotrophin	We found previously that the common ***neurotrophin*** ***receptor*** , ***p75*** ( NTR ) , is a mediator of neurotrophin dependence and that this effect requires a novel type of domain dubbed a neurotrophin dependence domain .	parallel	1
14873	10820487	3553;1051	IL-1;C/EBPbeta	CAATT / enhancer binding protein , ( ***C/EBPbeta*** ) , which is ***activated*** by ***IL-1*** and TNFalpha , has been suggested to act as a mediator of this transcriptional downregulation .	positive	1
14874	10820517	1056;7184	BSDL;Grp94	Indeed , double immunogold and immunocoprecipitation revealed an ***association*** between Cpn60 and the colipase-dependent lipase ( CDL ) and between ***Grp94*** and the bile salt-dependent lipase ( ***BSDL*** ) .	parallel	0
14875	10820517	3329;1056	Cpn60;BSDL	Indeed , double immunogold and immunocoprecipitation revealed an ***association*** between ***Cpn60*** and the colipase-dependent lipase ( CDL ) and between Grp94 and the bile salt-dependent lipase ( ***BSDL*** ) .	parallel	0
14876	10820517	3329;7184	Cpn60;Grp94	Indeed , double immunogold and immunocoprecipitation revealed an ***association*** between ***Cpn60*** and the colipase-dependent lipase ( CDL ) and between ***Grp94*** and the bile salt-dependent lipase ( BSDL ) .	parallel	0
14877	10820517	1056;7184	BSDL;Grp94	Furthermore , we have shown that the ******Grp94-BSDL****** ***complexes*** are internalized by enterocytes through classical endocytosis .	parallel	1
14878	10820517	7184;1056	Grp94;BSDL	Upon dissociation of the ******BSDL-Grp94****** ***complex*** in the late endosome , BSDL is transferred to the basolateral membrane .	parallel	1
14879	10821329	3952;4852	leptin;NPY	Interestingly , both 5-HT and ***leptin*** ***modulate*** the action of ***NPY*** , which may form a part of a common output pathway for the expression of appetite .	target	0
14880	10821443	3458;3620	interferon-gamma;IDO	During immune response , ***interferon-gamma*** ***stimulates*** indoleamine 2,3-dioxygenase ( ***IDO*** ) converting tryptophan to N-formylkynurenine followed by kynurenine in an ensuing step .	positive	0
14881	10821644	2674;2668	GFR alpha-1;GDNF	Expression of human ***GFR alpha-1*** ( ***GDNF*** ***receptor*** ) at the neuromuscular junction and myelinated nerves .	parallel	1
14882	10821676	2979;3000	GCAP2;ROS-GC	The other GCAP protein , ***GCAP2*** , which is also a known ***modulator*** of ***ROS-GC*** in photoreceptors , was not present in the pineal gland .	target	0
14883	10821676	2978;3000	GCAP;ROS-GC	The other ***GCAP*** protein , GCAP2 , which is also a known ***modulator*** of ***ROS-GC*** in photoreceptors , was not present in the pineal gland .	target	0
14884	10821685	9368;7430	NHERF;ezrin	***NHERF*** ***associations*** with sodium-hydrogen exchanger isoform 3 ( NHE3 ) and ***ezrin*** are essential for cAMP-mediated phosphorylation and inhibition of NHE3 .	parallel	0
14885	10821685	9368;6550	NHERF;NHE3	***NHERF*** ***associations*** with sodium-hydrogen exchanger isoform 3 ( ***NHE3*** ) and ezrin are essential for cAMP-mediated phosphorylation and inhibition of NHE3 .	parallel	0
14886	10821685	6550;9368	NHE3;NHERF	Co-immunoprecipitation established that in PS120 cells , ***NHE3*** ***bound*** to full-length ***NHERF*** ( 1-355 ) , the C-terminal domain , NHERF ( 147-355 ) , and NHERF ( 1-325 ) , which lacks the proposed ezrin-binding domain .	parallel	1
14887	10821685	7430;9368	ezrin;NHERF	***ezrin*** was also ***co-immunoprecipitated*** with ***NHERF*** ( 1-355 ) but not with NHERF ( 1-325 ) .	parallel	1
14888	10821685	9368;7430	NHERF;ezrin	NHE3 phosphorylation in vivo was enhanced by 8Br-cAMP only in cells where ***NHERF*** ***bound*** to both NHE3 and ***ezrin*** .	parallel	1
14889	10821685	9368;6550	NHERF;NHE3	NHE3 phosphorylation in vivo was enhanced by 8Br-cAMP only in cells where ***NHERF*** ***bound*** to both ***NHE3*** and ezrin .	parallel	1
14890	10821702	4155;5594	MBP;ERK2	Furthermore , ***MBP*** ***binds*** to the ***ERK2*** x ATP complex at least 1500-fold more tightly than does ERKtide ( K ( d ( ERKtide ) ) > / = 1.5 mM ) .	parallel	1
14891	10821844	7124;3383	tumor necrosis factor alpha;intercellular adhesion molecule 1	We have previously shown that Alpha-melanocyte-stimulating hormone ( alpha-MSH ) can oppose ***tumor necrosis factor alpha*** ***activation*** of NF-kappaB ( 1-2 h ) and ***intercellular adhesion molecule 1*** up-regulation ( mRNA by 3 h and protein by 24 h ) in melanocytes and melanoma cells .	positive	1
14892	10821844	7124;4790	tumor necrosis factor alpha;NF-kappaB	We have previously shown that Alpha-melanocyte-stimulating hormone ( alpha-MSH ) can oppose ***tumor necrosis factor alpha*** ***activation*** of ***NF-kappaB*** ( 1-2 h ) and intercellular adhesion molecule 1 up-regulation ( mRNA by 3 h and protein by 24 h ) in melanocytes and melanoma cells .	positive	1
14893	10821852	9021;6777	SOCS-3;Stat5B	Once induced , ***SOCS-3*** ***inhibits*** insulin activation of ***Stat5B*** without modifying the insulin receptor tyrosine kinase activity .	negative	1
14894	10821852	9021;3643	SOCS-3;insulin receptor	First , using a yeast two-hybrid system , we show that ***SOCS-3*** ***binds*** to the ***insulin receptor*** at phosphotyrosine 960 , which is precisely where Stat5B binds .	parallel	1
14895	10821866	596;7157	Bcl-2;p53	Overexpression of anti-apoptotic ***Bcl-2*** or Bcl-xL ***abrogates*** stress signal-mediated mitochondrial ***p53*** accumulation and apoptosis but not cell cycle arrest , suggesting a feedback signaling loop between p53 and mitochondrial apoptotic regulators .	negative	0
14896	10821866	598;7157	Bcl-xL;p53	Overexpression of anti-apoptotic Bcl-2 or ***Bcl-xL*** ***abrogates*** stress signal-mediated mitochondrial ***p53*** accumulation and apoptosis but not cell cycle arrest , suggesting a feedback signaling loop between p53 and mitochondrial apoptotic regulators .	negative	0
14897	10822079	1511;7057	cathepsin G;TSP	The ***degradation*** of extracellular matrix ( ECM ) adhesive glycoproteins , fibronectin ( FN ) , thrombospondin ( ***TSP*** ) and von Willebrand factor ( vWF ) , by human leukocyte ***cathepsin G*** and elastase , and by plasmin or thrombin , was analysed by immunoblotting after incubation of physiologic doses of the proteases with confluent human umbilical vein endothelial cells .	negative	1
14898	10822085	7040;1437	TGF-beta;granulocyte-macrophage colony stimulating factor	***TGF-beta*** selectively ***induced*** production of ***granulocyte-macrophage colony stimulating factor*** ( GM-CSF ) without significant coordinate expression of IL-8 or RANTES .	target	1
14899	10822085	7124;1437	TNF-alpha;GM-CSF	***TNF-alpha*** ***induced*** expression of both IL-8 and ***GM-CSF*** , without detectable production of RANTES .	target	1
14900	10822085	7040;1437	TGF-beta;GM-CSF	***TGF-beta*** synergistically ***enhanced*** ***GM-CSF*** production with TNF-alpha , but suppressed production and release of IL-8 .	positive	0
14901	10822085	7040;6352	TGF-beta;RANTES	IFN-gamma induced RANTES production and release ; ***TGF-beta*** synergistically ***enhanced*** ***RANTES*** release induced by IFN-gamma , but had no effect on RANTES mRNA production .	positive	0
14902	10822085	3458;6352	IFN-gamma;RANTES	***IFN-gamma*** ***induced*** ***RANTES*** production and release ; TGF-beta synergistically enhanced RANTES release induced by IFN-gamma , but had no effect on RANTES mRNA production .	target	1
14903	10822133	3082;4323	HGF;MT1-MMP	In addition , both hepatocyte growth factor ( ***HGF*** ) and gastrin-releasing peptide ( GRP ) increased Matrigel invasion and ***induced*** the expression of ***MT1-MMP*** protein in DU-145 prostate cancer cells .	target	1
14904	10822156	4792;4790	IkappaB-alpha;NF-kappaB	More specifically , NO has been reported to suppress NF-kappaB activation inducing and stabilizing the ***NF-kappaB*** ***inhibitor*** , ***IkappaB-alpha*** .	negative	1
14905	10822170	5578;7124	PKC-alpha;TNF-alpha	These results suggest that : ( 1 ) PKC-alpha but not PKC-beta is involved in the release of superoxide and PGE ( 2 ) ; ( 2 ) ***TNF-alpha*** release and the phagocytosis of latex particles are ***mediated*** by ***PKC-alpha*** , PKC-beta , and other PKC isoenzymes ; and ( 3 ) PKC-alpha and PKC-beta play antagonistic roles in the differentiation process of THP-1 cells .	target	0
14906	10822170	5579;7124	PKC-beta;TNF-alpha	These results suggest that : ( 1 ) PKC-alpha but not PKC-beta is involved in the release of superoxide and PGE ( 2 ) ; ( 2 ) ***TNF-alpha*** release and the phagocytosis of latex particles are ***mediated*** by PKC-alpha , ***PKC-beta*** , and other PKC isoenzymes ; and ( 3 ) PKC-alpha and PKC-beta play antagonistic roles in the differentiation process of THP-1 cells .	target	0
14907	10822173	3635;1796	SHIP1;dok1	However , the ******dok1/SHIP1****** ***complex*** was only detected in the cytosolic fraction of Bcr-Abl transformed hematopoietic cells .	parallel	1
14908	10822173	3635;1796	SHIP1;dok1	We propose that ***interaction*** between ***dok1*** and ***SHIP1*** modulates the ability of these two proteins to interact with other cytosolic binding partners .	parallel	1
14909	10822173	1796;3635	dok1;SHIP1	Here , we report complex ***formation*** between endogenous ***dok1*** and the SH2 domain-containing phosphatidylinositol polyphosphate 5-phosphatase ***SHIP1*** in hematopoietic cells expressing Bcr-Abl .	parallel	0
14910	10822173	3635;1796	SHIP1;dok1	Expression of Bcr-Abl induced tyrosine phosphorylation of both dok1 and SHIP1 and the formation of a ******dok1/SHIP1****** ***complex*** .	parallel	1
14911	10822173	1796;6464	dok1;Shc	A small amount of ******Shc/SHIP1/dok1****** trimolecular ***complex*** was detected and this was due to binding of dok1 to SHIP1 that was bound to Shc .	parallel	1
14912	10822173	1796;3635	dok1;SHIP1	A small amount of ******Shc/SHIP1/dok1****** trimolecular ***complex*** was detected and this was due to binding of dok1 to SHIP1 that was bound to Shc .	parallel	1
14913	10822173	6464;3635	Shc;SHIP1	A small amount of ******Shc/SHIP1/dok1****** trimolecular ***complex*** was detected and this was due to binding of dok1 to SHIP1 that was bound to Shc .	parallel	1
14914	10822173	1796;3635	dok1;SHIP1	A small amount of Shc/SHIP1/dok1 trimolecular complex was detected and this was due to ***binding*** of ***dok1*** to ***SHIP1*** that was bound to Shc .	parallel	1
14915	10822173	1796;5921	dok1;RasGAP	In contrast , ***association*** of ***dok1*** with SHIP1 or ***RasGAP*** was mutually exclusive .	parallel	0
14916	10822173	1796;3635	dok1;SHIP1	In contrast , ***association*** of ***dok1*** with ***SHIP1*** or RasGAP was mutually exclusive .	parallel	0
14917	10822229	4902;5979	neurturin;RET	Glial cell line derived neurotropic factor ( GDNF ) and its membrane-bound GDNF family receptor alpha ( GFRalpha-1 ) , as well as ***neurturin*** ( NTN ) and its membrane-bound receptor GFRalpha-2 form a ***complex*** with the ***RET*** product , a receptor tyrosine kinase , resulting in downstream signaling to the nucleus .	parallel	1
14918	10822263	6047;2928	Rnf4;Gscl	***Rnf4*** , a RING protein expressed in the developing nervous and reproductive systems , ***interacts*** with ***Gscl*** , a gene within the DiGeorge critical region .	parallel	1
14919	10822263	6047;2928	Rnf4;Gscl	******Gscl/Rnf4****** ***interactions*** were confirmed by affinity chromatography and by immunoprecipitation .	parallel	1
14920	10822276	831;581	calpastatin;Bax	The results showed that overexpression of ***calpastatin*** ***suppressed*** down-regulation of Src , mu-calpain and ***Bax*** .	negative	1
14921	10822290	5054;5327	PAI-1;tPA	However , no significant differences between the two periods were seen in factor VII coagulant activity ( FVIIc ) , fibrinogen , prothrombin fragments 1 +2 ( F1 +2 ) , tissue plasminogen activator ( ***tPA*** ) plasminogen activator ***inhibitor*** 1 ( ***PAI-1*** ) or 2,3,-dinor-thromboxane B2 .	negative	1
14922	10822369	4609;7157	c-Myc;p53	These results suggest that ***c-Myc*** overexpression may ***antagonize*** the pro-apoptotic function of ***p53*** , thus providing a molecular mechanism for the frequently observed deregulation of c-Myc in human cancer .	negative	1
14923	10822369	4609;7157	c-Myc;p53	***c-Myc*** ***antagonizes*** the effect of ***p53*** on apoptosis and p21WAF1 transactivation in K562 leukemia cells .	negative	1
14924	10822369	7157;4609	p53;c-Myc	In the present study we used the K562 human myeloid leukemia cell line as a model to study the functional ***interaction*** between ***c-Myc*** and ***p53*** .	parallel	1
14925	10822369	4609;7157	c-Myc;p53	Expression of ***c-Myc*** significantly attenuated apoptosis and ***impaired*** the transcriptional activity of ***p53*** on p21WAF1 , Bax and cytomegalovirus promoters .	negative	0
14926	10822369	4609;1017	c-Myc;cyclin-dependent kinase 2	Consistently , ***c-Myc*** ***increased*** ***cyclin-dependent kinase 2*** activity in K562 cells expressing p53 in wild-type conformation .	positive	0
14927	10822371	207;5290	Akt;PI3K	Consistent with this finding , HGF/SF induced the phosphorylation of ***c-Akt*** ( protein kinase-B ) , a ***PI3K*** ***substrate*** implicated in apoptosis inhibition ; and an expression vector encoding a dominant negative kinase inactive Akt partially but significantly inhibited HGF/SF-mediated cell protection and DNA repair .	parallel	1
14928	10822371	3082;207	HGF;Akt	Consistent with this finding , ***HGF/SF*** ***induced*** the phosphorylation of ***c-Akt*** ( protein kinase-B ) , a PI3K substrate implicated in apoptosis inhibition ; and an expression vector encoding a dominant negative kinase inactive Akt partially but significantly inhibited HGF/SF-mediated cell protection and DNA repair .	target	1
14929	10822380	7076;2313	Epo;Fli-1	Furthermore , enforced expression of gp55 in HB60-5 cells by means of infection with the Spleen Focus Forming virus-P ( SFFV-P ) , confers ***Epo*** independent growth , which is ***associated*** with the up-regulation of ***Fli-1*** .	parallel	0
14930	10822382	1029;7157	p14ARF;p53	An N-terminal ***p14ARF*** peptide blocks Mdm2-dependent ubiquitination in vitro and can ***activate*** ***p53*** in vivo .	positive	1
14931	10822385	5580;836	protein kinase C (PKC) delta;caspase 3	There is no uniformly enhanced processing of three ***caspase 3*** ***substrates*** , poly-ADP ribose polymerase ( PARP ) , ***protein kinase C (PKC) delta*** and DNA fragmentation factor ( DFF ) 45 .	parallel	1
14932	10822386	2885;9564	GRB2;p130CAS	In contrast , LAR selectively inhibited the epidermal growth factor ( EGF ) - induced phosphorylation of p130CAS and the ***formation*** of the complex between ***p130CAS*** and ***GRB2*** but this effect did not influence the activation of MAPK by EGF .	parallel	0
14933	10822388	662;598	BNIP1;BCL-XL	Mutants containing the BH3 deletions were still able to heterodimerize with BCL-XL while mutants lacking both the N-terminal region and the BH3 domain were unable to heterodimerize , suggesting that ***BNIP1*** may ***bind*** to ***BCL-XL*** via two different binding motifs .	parallel	1
14934	10822388	662;596	BNIP1;BCL-2	By mutational analysis , we show that one of the cellular proteins , ***BNIP1*** ( previously Nip-1 ) , that ***interacts*** with ***BCL-2*** family anti-apoptosis proteins is a ' BH3 alone ' pro-apoptotic protein .	parallel	1
14935	10823267	2160;3827	coagulation factor XI;High molecular weight kininogen	We investigated the ***cleavage*** of ***High molecular weight kininogen*** ( HK ) by activated ***coagulation factor XI*** ( FXIa ) in vitro .	target	1
14936	10823418	940;941	CD28;B7-1	Following 5 days of co-culture , PBMC expression of ***CD28*** , the ***ligand*** for ***B7-1*** , was down-regulated in proportion to the level of B7-1 expression on the stimulating melanoma cells .	parallel	1
14937	10823661	3458;821	IFN-gamma;calnexin	Furthermore , since the stability of N-glycosylated proteins is known to be regulated by lectin family chaperones , such as calnexin , a type I transmembrane protein located in the endoplasmic reticulum ( ER ) , and calreticulin , a soluble protein in the ER lumen , the effect of the processing inhibitors on the ***interaction*** of ***IFN-gamma*** with ***calnexin*** and calreticulin was investigated .	parallel	1
14938	10823661	3458;811	IFN-gamma;calreticulin	Furthermore , since the stability of N-glycosylated proteins is known to be regulated by lectin family chaperones , such as calnexin , a type I transmembrane protein located in the endoplasmic reticulum ( ER ) , and calreticulin , a soluble protein in the ER lumen , the effect of the processing inhibitors on the ***interaction*** of ***IFN-gamma*** with calnexin and ***calreticulin*** was investigated .	parallel	1
14939	10823661	3458;821	IFN-gamma;calnexin	It was found that ***IFN-gamma*** formed ***complexes*** with ***calnexin*** and calreticulin in anti CD3-stimulated lymphocytes .	parallel	1
14940	10823661	3458;811	IFN-gamma;calreticulin	It was found that ***IFN-gamma*** formed ***complexes*** with calnexin and ***calreticulin*** in anti CD3-stimulated lymphocytes .	parallel	1
14941	10823661	3458;821	IFN-gamma;calnexin	Total ***binding*** of ***IFN-gamma*** to ***calnexin*** was not affected but that to calreticulin was increased in anti CD3-stimulated lymphocytes treated with the processing inhibitors .	parallel	1
14942	10823661	3458;811	IFN-gamma;calreticulin	However , ***binding*** of newly synthesized ***IFN-gamma*** to ***calreticulin*** was decreased in the lymphocytes under the same conditions as above .	parallel	1
14943	10823661	3458;811	IFN-gamma;calreticulin	These results suggest that these glycoprotein processing inhibitors block the release of IFN-gamma from already formed calreticulin complexes , which prevents the ***binding*** of newly synthesized ***IFN-gamma*** to ***calreticulin*** and results in the enhancement of IFN-gamma degradation .	parallel	1
14944	10823661	811;3458	calreticulin;IFN-gamma	These results suggest that these glycoprotein processing inhibitors block the release of IFN-gamma from already formed ***calreticulin*** complexes , which ***prevents*** the binding of newly synthesized ***IFN-gamma*** to calreticulin and results in the enhancement of IFN-gamma degradation .	negative	0
14945	10823801	3502;373156	IgG3;GST	Specific ***IgG3*** response was predominant in the male population with a low intensity of infection and was ***associated*** with maximal ***GST*** inhibition .	parallel	0
14946	10823814	4609;3939	c-Myc;lactate dehydrogenase A	We previously observed that the ***c-Myc*** oncogenic transcription factor ***regulates*** ***lactate dehydrogenase A*** and induces lactate overproduction .	target	1
14947	10823818	3551;1147	IKK2;IKK1	Characterization of the recombinant ******IKK1/IKK2****** ***heterodimer*** .	parallel	1
14948	10823821	355;330	APO-1;cIAP2	Under these conditions , TRAIL and ***anti-APO-1*** ***up-regulated*** the expression of the known NF-kappaB targets interleukin-6 , cellular inhibitor of apoptosis 2 ( ***cIAP2*** ) , and TRAF1 ( TRAF , tumor necrosis factor receptor-associate factor ) .	positive	1
14949	10823821	8743;330	TRAIL;cIAP2	Under these conditions , ***TRAIL*** and anti-APO-1 ***up-regulated*** the expression of the known NF-kappaB targets interleukin-6 , cellular inhibitor of apoptosis 2 ( ***cIAP2*** ) , and TRAF1 ( TRAF , tumor necrosis factor receptor-associate factor ) .	positive	1
14950	10823821	355;3569	APO-1;interleukin-6	Under these conditions , TRAIL and ***anti-APO-1*** ***up-regulated*** the expression of the known NF-kappaB targets ***interleukin-6*** , cellular inhibitor of apoptosis 2 ( cIAP2 ) , and TRAF1 ( TRAF , tumor necrosis factor receptor-associate factor ) .	positive	1
14951	10823821	355;7185	APO-1;TRAF1	Under these conditions , TRAIL and ***anti-APO-1*** ***up-regulated*** the expression of the known NF-kappaB targets interleukin-6 , cellular inhibitor of apoptosis 2 ( cIAP2 ) , and ***TRAF1*** ( TRAF , tumor necrosis factor receptor-associate factor ) .	positive	1
14952	10823821	8743;3569	TRAIL;interleukin-6	Under these conditions , ***TRAIL*** and anti-APO-1 ***up-regulated*** the expression of the known NF-kappaB targets ***interleukin-6*** , cellular inhibitor of apoptosis 2 ( cIAP2 ) , and TRAF1 ( TRAF , tumor necrosis factor receptor-associate factor ) .	positive	1
14953	10823821	8743;7185	TRAIL;TRAF1	Under these conditions , ***TRAIL*** and anti-APO-1 ***up-regulated*** the expression of the known NF-kappaB targets interleukin-6 , cellular inhibitor of apoptosis 2 ( cIAP2 ) , and ***TRAF1*** ( TRAF , tumor necrosis factor receptor-associate factor ) .	positive	1
14954	10823822	3553;3162	IL-1beta;HO-1	An inhibitor of TRX reductase , used to prevent TRX translocation in the reduced state , decreased ***HO-1*** ***induction*** by ***IL-1beta*** and LPS .	target	1
14955	10823823	836;118	caspase-3;alpha-adducin	Hemagglutinin-tagged human ***alpha-adducin*** was ***cleaved*** into a similar 74-kDa fragment by ***caspase-3*** in vitro but not by caspase-6 or -7 .	target	1
14956	10823823	836;118	caspase-3;alpha-adducin	In conclusion , the data support a model in which increased phosphorylation of alpha-adducin due to cisplatin leads to dissociation from the cytoskeleton , a situation rendered irreversible by ***caspase-3-mediated*** ***cleavage*** of ***alpha-adducin*** at Asp-Asp-Ser-Asp ( 633 ) - Ala .	target	1
14957	10823829	3716;6774	Jak1;Stat3	Based on these findings , we propose a model in which ***Jak1*** serves to ***recruit*** ***Stat3*** to a receptor complex with Src kinase , which in turn directly phosphorylates and activates Stat3 in Src-transformed fibroblasts .	target	0
14958	10823829	3716;6772	Jak1;Stat1	In addition , the JAK family member ***Jak1*** efficiently ***phosphorylates*** ***Stat1*** but not Stat3 in Sf-9 cells .	target	1
14959	10823830	3458;958	IFN-gamma;CD40	Collectively , our data demonstrate the involvement of STAT-1alpha , PU.1 , and Spi-B in ***IFN-gamma*** ***induction*** of ***CD40*** gene expression in cells of the macrophage lineage .	target	1
14960	10823830	3458;958	interferon-gamma;CD40	Involvement of STAT-1 and ets family members in ***interferon-gamma*** ***induction*** of ***CD40*** transcription in microglia/macrophages .	target	1
14961	10823830	3458;958	IFN-gamma;CD40	Herein , we have elucidated the molecular mechanisms underlying ***IFN-gamma*** ***induction*** of ***CD40*** gene expression in microglia/macrophages .	target	1
14962	10823830	3458;958	IFN-gamma;CD40	***IFN-gamma*** ***up-regulates*** ***CD40*** expression at the transcriptional level , and this regulation involves the STAT-1alpha transcription factor .	positive	1
14963	10823830	3458;958	IFN-gamma;CD40	Microglia from STAT-1alpha-deficient mice were refractive to ***IFN-gamma*** ***induction*** of ***CD40*** expression , illustrating the importance of STAT-1alpha in this response .	target	1
14964	10823830	3458;958	IFN-gamma;CD40	Functional analysis of the CD40 promoter indicates that two gamma activated sequence elements as well as two Ets elements are involved in ***IFN-gamma*** ***induction*** of ***CD40*** promoter activity .	target	1
14965	10823835	3753;3784	MinK;KvLQT1	In electrophysiological measurements we found that stimulation with the beta-adrenergic agonist isoproterenol increased the current amplitude of the beta ( 3 ) / ******KvLQT1/MinK****** ***complex*** up to 237 % with an ED ( 50 ) of 8 nm , a value similar to that found on IKs in guinea pig cardiomyocytes .	parallel	1
14966	10823835	3753;3784	MinK;KvLQT1	When oocytes with beta ( 3 ) / KvLQT1/MinK were preincubated with cholera toxin ( 2 microg/ml ) , an activator of G ( S ) proteins , the basal current amplitude of the beta ( 3 ) / ******KvLQT1/MinK****** ***complex*** was increased 3.1-fold , and the current amplitude increase by isoproterenol was drastically reduced , indicating that the signal transduction cascade was mediated via G ( s ) proteins .	parallel	1
14967	10823840	7124;5966	TNFalpha;c-Rel	Thus , TNFalpha-induced phosphorylation of Ser-471 seems to be absolutely necessary for ***TNFalpha*** ***activation*** of ***c-Rel*** .	positive	1
14968	10823840	7124;4790	Tumor necrosis factor-alpha;NF-kappa B	***Tumor necrosis factor-alpha*** ***activation*** of ***NF-kappa B*** requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel .	positive	1
14969	10823884	6387;7852	SDF1;CXCR4	These data suggest that ***SDF1*** , which is a ***ligand*** for the T-tropic HIV-1 coreceptor ***CXCR4*** , may affect the ability of a mother to transmit the virus to her infant .	parallel	1
14970	10823885	3558;5743	IL-2;COX-2	Here , we show that the level of COX-2 mRNA was decreased in PBMCs treated with IL-10 , while ***IL-2*** ***enhanced*** the level of ***COX-2*** mRNA .	positive	0
14971	10823886	7040;4092	TGF-beta;Smad7	In an effort to search for TGF-beta-inducible genes , we used a subtractive screening method and identified human ***Smad7*** , which can antagonize TGF-beta signaling and is rapidly ***up-regulated*** by ***TGF-beta*** .	positive	1
14972	10823886	4092;7040	Smad7;TGF-beta	In an effort to search for TGF-beta-inducible genes , we used a subtractive screening method and identified human ***Smad7*** , which can ***antagonize*** ***TGF-beta*** signaling and is rapidly up-regulated by TGF-beta .	negative	1
14973	10823886	7040;4092	TGF-beta;Smad7	In this report , we show that ***TGF-beta*** can stabilize Smad7 mRNA and ***activate*** ***Smad7*** transcription .	positive	1
14974	10823886	7040;4092	TGF-beta;Smad7	In this report , we show that ***TGF-beta*** can ***stabilize*** ***Smad7*** mRNA and activate Smad7 transcription .	positive	0
14975	10823896	1870;1871	E2F2;E2F3	In contrast , methylation of the E2F elements derived from the c-myc and c-myb promoters minimally affects the ***binding*** of ***E2F2*** , ***E2F3*** , E2F4 , and E2F5 but significantly inhibits the binding of E2F1 .	parallel	1
14976	10823896	1870;1874	E2F2;E2F4	In contrast , methylation of the E2F elements derived from the c-myc and c-myb promoters minimally affects the ***binding*** of ***E2F2*** , E2F3 , ***E2F4*** , and E2F5 but significantly inhibits the binding of E2F1 .	parallel	1
14977	10823896	1870;1875	E2F2;E2F5	In contrast , methylation of the E2F elements derived from the c-myc and c-myb promoters minimally affects the ***binding*** of ***E2F2*** , E2F3 , E2F4 , and ***E2F5*** but significantly inhibits the binding of E2F1 .	parallel	1
14978	10823896	1871;1874	E2F3;E2F4	In contrast , methylation of the E2F elements derived from the c-myc and c-myb promoters minimally affects the ***binding*** of E2F2 , ***E2F3*** , ***E2F4*** , and E2F5 but significantly inhibits the binding of E2F1 .	parallel	1
14979	10823896	1875;1871	E2F5;E2F3	In contrast , methylation of the E2F elements derived from the c-myc and c-myb promoters minimally affects the ***binding*** of E2F2 , ***E2F3*** , E2F4 , and ***E2F5*** but significantly inhibits the binding of E2F1 .	parallel	1
14980	10823896	1875;1874	E2F5;E2F4	In contrast , methylation of the E2F elements derived from the c-myc and c-myb promoters minimally affects the ***binding*** of E2F2 , E2F3 , ***E2F4*** , and ***E2F5*** but significantly inhibits the binding of E2F1 .	parallel	1
14981	10823934	3700;920	gp120;CD4	The HIV-1 envelope glycoprotein ***gp120*** ***interacts*** consecutively with ***CD4*** and the CCR5 coreceptor to mediate the entry of certain HIV-1 strains into target cells .	parallel	1
14982	10823934	920;3700	CD4;gp120	We tested the binding of a panel of CCR5 Nt peptides to different soluble ******gp120/CD4****** ***complexes*** and anti-CCR5 mAbs .	parallel	1
14983	10823934	920;3700	CD4;gp120	None of the ******gp120/CD4****** ***complexes*** associated with peptides containing unmodified or phosphorylated tyrosines .	parallel	1
14984	10823934	920;3700	CD4;gp120	The ******gp120/CD4****** ***complexes*** containing envelope glycoproteins from isolates that use CCR5 as a coreceptor associated with Nt peptides containing sulfotyrosines but not with peptides containing sulfotyrosines in scrambled Nt sequences .	parallel	1
14985	10823941	7299;821	tyrosinase;calnexin	Furthermore , evidence of protein misfolding was demonstrated by the prolonged ***association*** of ***tyrosinase*** mutants with ***calnexin*** and calreticulin , known ER chaperones that play a key role in the quality-control processes of the secretory pathway .	parallel	0
14986	10823941	7299;811	tyrosinase;calreticulin	Furthermore , evidence of protein misfolding was demonstrated by the prolonged ***association*** of ***tyrosinase*** mutants with calnexin and ***calreticulin*** , known ER chaperones that play a key role in the quality-control processes of the secretory pathway .	parallel	0
14987	10824457	7124;4843	TNF-alpha;inducible NOS	Fluorescent immunohistochemistry demonstrated that the expression of ***inducible NOS*** was ***augmented*** by ***TNF-alpha*** and attenuated by dexamethasone , whereas that of endothelial NOS remained unchanged .	positive	0
14988	10824544	28984;1027	regulator of cell cycle;p27KIP1	First ; p16INK4-Cyclin D1-RB pathway , which controls G1 to S progression of the cell cycle , second ; p53 pathway , which is involved in DNA damage repair , and third ; ***p27KIP1*** CDK ***inhibitor*** , a negative ***regulator of cell cycle*** , and decreased expression of which has been correlated to poor prognosis in cancer patients .	negative	1
14989	10824686	375;5337	ARF1;PLD1	***ARF1*** strongly ***activated*** ***PLD1*** in a dose-dependent manner , and PLD2 was slightly responsive .	positive	1
14990	10825132	1029;1021	p16INK4A;cyclin dependent kinase 4 and 6	***p16INK4A*** ***mediates*** ***cyclin dependent kinase 4 and 6*** inhibition in senescent prostatic epithelial cells .	target	0
14991	10825136	356;355	FasL;Fas	In thymidylate synthase-deficient ( TS - ) colon carcinoma cells , thymineless death is mediated via ***Fas/Fas*** ***ligand*** ( ***FasL*** ) interactions after thymidine deprivation and inhibited by the Fas-inhibitory monoclonal antibody NOK-1 .	parallel	1
14992	10825136	356;355	FasL;Fas	This was in contrast to the Fas-dependent regulation of thymineless death , which could be inhibited by blocking ******Fas/FasL****** ***interactions*** .	parallel	1
14993	10825149	1027;5934	p27Kip1;p130	These data suggest that ***pRb2/p130*** and ***p27Kip1*** may ***cooperate*** in regulating cellular proliferation , and both may be involved in a negative feedback regulatory loop with cyclin E.	parallel	0
14994	10825149	5934;5934	pRb2;p130	These data suggest that ******pRb2/p130****** and p27Kip1 may ***cooperate*** in regulating cellular proliferation , and both may be involved in a negative feedback regulatory loop with cyclin E.	parallel	0
14995	10825149	5934;1869	p130;E2F-1	***RB2/p130*** induction also ***decreased*** cyclin A and the transcription factor ***E2F-1*** while increasing cyclin E at both the transcriptional and protein levels of expression .	negative	0
14996	10825149	5934;1027	p130;p27Kip1	Interestingly , ***pRb2/p130*** expression negatively ***modulated*** the binding of ***p27Kip1*** to JCV TAg .	negative	0
14997	10825153	23523;4205	Cabin1;MEF2	It has been previously shown that ***Cabin1*** is ***associated*** with ***MEF2*** in a calcium-sensitive manner ; activated calmodulin binds to Cabin1 and releases it from MEF2 .	parallel	0
14998	10825157	1398;5829	Crk;paxillin	Whereas previous studies have shown that ***Crk*** SH2 ***binding*** to ***paxillin*** is critical for cell adhesion and migration , our data show that the phosphorylation cycle of c-Crk II determines its dynamic interaction with paxillin , thereby regulating turnover of multiprotein complexes , a critical aspect of cytoskeletal plasticity and actin dynamics .	parallel	1
14999	10825158	7852;6387	CXCR4;SDF-1	***CXCR4*** is a G-coupled ***receptor*** for the stromal cell-derived factor ( ***SDF-1*** ) chemokine , and a CD4-associated human immunodeficiency virus type 1 ( HIV-1 ) coreceptor .	parallel	1
15000	10825164	57332;6015	HPC3;RING1	Previous studies indicate that M33 and human Pc2 ( HPC2 ) can interact with RING1 , and we show here that ***HPC3*** also ***binds*** to ***RING1*** .	parallel	1
15001	10825164	84733;6015	M33;RING1	Previous studies indicate that ***M33*** and human Pc2 ( HPC2 ) can ***interact*** with ***RING1*** , and we show here that HPC3 also binds to RING1 .	parallel	1
15002	10825164	8535;6015	Pc2;RING1	Previous studies indicate that M33 and human ***Pc2*** ( HPC2 ) can ***interact*** with ***RING1*** , and we show here that HPC3 also binds to RING1 .	parallel	1
15003	10825164	57332;6015	HPC3;RING1	In contrast to HPC2 , ***HPC3*** ***interactions*** with ***RING1*** are only observed in vivo with covalently modified forms of RING1 .	parallel	1
15004	10825173	2006;2200	tropoelastin;fibrillin-1	***Interaction*** of ***tropoelastin*** with the amino-terminal domains of ***fibrillin-1*** and fibrillin-2 suggests a role for the fibrillins in elastic fiber assembly .	parallel	1
15005	10825173	2006;2201	tropoelastin;fibrillin-2	***Interaction*** of ***tropoelastin*** with the amino-terminal domains of fibrillin-1 and ***fibrillin-2*** suggests a role for the fibrillins in elastic fiber assembly .	parallel	1
15006	10825175	5970;4790	p65;p50	The DNA binding of three different NF-kappaB dimers , the p50 and p65 homodimers and the ******p50/p65****** ***heterodimer*** , has been examined using a combination of gel mobility shift and fluorescence anisotropy assays .	parallel	1
15007	10825175	4790;4790	NF-kappaB;p50	The DNA ***binding*** of three different ***NF-kappaB*** dimers , the ***p50*** and p65 homodimers and the p50/p65 heterodimer , has been examined using a combination of gel mobility shift and fluorescence anisotropy assays .	parallel	1
15008	10825175	5970;4790	p65;p50	The NF-kappaB ******p50/p65****** ***heterodimer*** is shown here to bind the kappaB DNA target site of the immunoglobulin kappa enhancer ( Ig-kappaB ) with an affinity of approximately 10 nm .	parallel	1
15009	10825175	5970;4790	p65;p50	We have further characterized the role of pH , salt , and temperature on the formation of the ******p50/p65****** heterodimer-Ig-kappaB ***complex*** .	parallel	1
15010	10825175	5970;4790	p65;p50	A strong salt-dependent interaction between Ig-kappaB and the ******p50/p65****** ***heterodimer*** is observed , with optimum binding occurring at monovalent salt concentrations below 75 mm , with binding becoming virtually nonspecific at a salt concentration of 200 mm .	parallel	1
15011	10825175	5970;4790	p65;p50	A strong salt-dependent ***interaction*** between Ig-kappaB and the ******p50/p65****** heterodimer is observed , with optimum binding occurring at monovalent salt concentrations below 75 mm , with binding becoming virtually nonspecific at a salt concentration of 200 mm .	parallel	1
15012	10825175	5970;4790	p65;p50	The sensitivity to ionic environment and insensitivity to temperature indicate that NF-kappaB ******p50/p65****** ***heterodimers*** form complexes with specific DNA in an entropically driven manner .	parallel	1
15013	10825177	51206;2207	GPVI;FcRgamma	Human ***GPVI*** belongs to the immunoglobulin superfamily and is noncovalently ***associated*** with the ***FcRgamma*** chain that is involved in signaling through the receptor .	parallel	0
15014	10825178	6670;5743	Sp3;cox-2	Electrophoretic mobility shift assays with hypoxic HUVEC nuclear protein showed that both Sp1 and the related protein ***Sp3*** specifically ***bound*** to the ***cox-2*** promoter .	parallel	1
15015	10825186	1026;983	p21;Cdc2	Abrogation of ***p21*** or pRB function in cells containing wild-type p53 ***blocked*** the down-regulation of cyclin B1 and ***Cdc2*** expression and led to an accelerated exit from G ( 2 ) after genotoxic stress .	negative	0
15016	10825186	1026;891	p21;cyclin B1	Abrogation of ***p21*** or pRB function in cells containing wild-type p53 ***blocked*** the down-regulation of ***cyclin B1*** and Cdc2 expression and led to an accelerated exit from G ( 2 ) after genotoxic stress .	negative	0
15017	10825186	5925;983	pRB;Cdc2	Abrogation of p21 or ***pRB*** function in cells containing wild-type p53 ***blocked*** the down-regulation of cyclin B1 and ***Cdc2*** expression and led to an accelerated exit from G ( 2 ) after genotoxic stress .	negative	0
15018	10825186	5925;891	pRB;cyclin B1	Abrogation of p21 or ***pRB*** function in cells containing wild-type p53 ***blocked*** the down-regulation of ***cyclin B1*** and Cdc2 expression and led to an accelerated exit from G ( 2 ) after genotoxic stress .	negative	0
15019	10825189	4149;4084	Max;Mad	Myc-Max dimers transactivate whereas ******Mad-Max-mSin3****** ***complexes*** repress Myc-mediated transcriptional activation .	parallel	1
15020	10825190	5594;5743	p38;cyclooxygenase 2	***Regulation*** of ***cyclooxygenase 2*** mRNA stability by the mitogen-activated protein kinase ***p38*** signaling cascade .	target	1
15021	10825190	9261;3043	MAPKAPK-2;beta-globin	Constitutively active ***MAPKAPK-2*** was also able to ***stabilize*** chimeric ***beta-globin-Cox-2*** transcripts .	positive	0
15022	10825190	9261;5743	MAPKAPK-2;Cox-2	Constitutively active ***MAPKAPK-2*** was also able to ***stabilize*** chimeric ***beta-globin-Cox-2*** transcripts .	positive	0
15023	10825200	3558;3718	IL-2;Jak3	Moreover , pharmacological abrogation of Lck activity did not inhibit ***IL-2-mediated*** ***phosphorylation*** of ***Jak3*** and Stat5a .	target	1
15024	10825200	3558;6776	IL-2;Stat5a	Moreover , pharmacological abrogation of Lck activity did not inhibit ***IL-2-mediated*** ***phosphorylation*** of Jak3 and ***Stat5a*** .	target	1
15025	10825206	3096;1280	CRYBP1;Col2a1	We herein demonstrate that ***CRYBP1*** is involved in the negative ***regulation*** of ***Col2a1*** enhancer activity .	negative	1
15026	10825206	3096;1280	CRYBP1;Col2a1	Expression of recombinant ***CRYBP1*** in a transfected rat chondrosarcoma cell line ***inhibited*** ***Col2a1*** enhancer activity .	negative	1
15027	10825206	6662;1280	Sox9;Col2a1	Electrophoretic mobility shift assays showed that CRYBP1 bound a specific sequence within the Col2a1 enhancer and inhibited the binding of ***Sox9*** , an ***activator*** for ***Col2a1*** , to the enhancer .	positive	1
15028	10825206	3096;6662	CRYBP1;Sox9	Electrophoretic mobility shift assays showed that ***CRYBP1*** bound a specific sequence within the Col2a1 enhancer and ***inhibited*** the binding of ***Sox9*** , an activator for Col2a1 , to the enhancer .	negative	1
15029	10825208	3175;50674	HNF-6;ngn3	Consistent with this , we demonstrated that ***HNF-6*** ***binds*** to and stimulates the ***ngn3*** gene promoter .	parallel	1
15030	10825208	3175;50674	HNF-6;ngn3	Taken together , our data demonstrate that ***HNF-6*** controls pancreatic endocrine differentiation at the precursor stage and identify HNF-6 as the first positive ***regulator*** of the proendocrine gene ***ngn3*** in the pancreas .	positive	1
15031	10825209	5994;5993	RFXAP;RFX5	Nevertheless , except for a weak ***binding*** between ***RFX5*** and ***RFXAP*** , no other interactions between RFX proteins have been described .	parallel	1
15032	10825209	8625;5994	RFXANK;RFXAP	In this study , we demonstrate that ***RFXANK*** ( B ) ***binds*** to ***RFXAP*** to form a scaffold for the assembly of the RFX complex , which then binds to DNA .	parallel	1
15033	10825232	1017;4091	cyclin-dependent kinase 2;Smad6	Studies on the mechanism of action indicate that BMP-7 treatment inhibits ***cyclin-dependent kinase 2*** ( cdk-2 ) that was stimulated during PDGF-BB-induced proliferation of SMCs and ***upregulates*** the expression of the inhibitory Smad , ***Smad6*** , which was shown to inhibit TGF-beta superfamily signaling .	positive	1
15034	10825232	655;1017	BMP-7;cyclin-dependent kinase 2	Studies on the mechanism of action indicate that ***BMP-7*** treatment ***inhibits*** ***cyclin-dependent kinase 2*** ( cdk-2 ) that was stimulated during PDGF-BB-induced proliferation of SMCs and upregulates the expression of the inhibitory Smad , Smad6 , which was shown to inhibit TGF-beta superfamily signaling .	negative	1
15035	10825233	3458;4790	interferon-gamma;NF-kappab	Synergistic ***activation*** of ***NF-kappab*** and inducible isoform of nitric oxide synthase induction by ***interferon-gamma*** and tumor necrosis factor-alpha in INS-1 cells .	positive	1
15036	10825233	7124;4790	tumor necrosis factor-alpha;NF-kappab	Synergistic ***activation*** of ***NF-kappab*** and inducible isoform of nitric oxide synthase induction by interferon-gamma and ***tumor necrosis factor-alpha*** in INS-1 cells .	positive	1
15037	10825233	3458;6772	IFN-gamma;STAT1	***IFN-gamma*** ***promoted*** tyrosine phosphorylation and DNA-binding of ***STAT1*** through Janus kinase (JAK)1 activation without apparent phosphorylation of JAK2 .	positive	0
15038	10825233	7124;4790	TNF-alpha;NF-kappab	***TNF-alpha*** did not affect STAT1 activation , but ***stimulated*** DNA-binding and transcriptional activity of ***NF-kappab*** , both of which were further increased by IFN-gamma .	positive	0
15039	10825233	3458;6772	IFN-gamma;STAT1	In conclusion , ***IFN-gamma*** ***activates*** ***STAT1*** and potentiates TNF-alpha-induced NF-kappab activation in INS-1 cells , thereby inducing iNOS and cell destruction .	positive	1
15040	10825233	3458;4790	IFN-gamma;NF-kappab	In conclusion , ***IFN-gamma*** activates STAT1 and ***potentiates*** TNF-alpha-induced ***NF-kappab*** activation in INS-1 cells , thereby inducing iNOS and cell destruction .	positive	0
15041	10825236	7040;1033	TGF-beta1;cyclin-dependent kinase inhibitor	In nonhematopoietic systems , ***TGF-beta1*** ***cooperates*** with the ***cyclin-dependent kinase inhibitor*** , p21 ( cip1 ) , to induce cell cycle arrest .	parallel	0
15042	10825236	7040;1026	TGF-beta1;p21	We observed that addition of anti-TGF-beta1 is followed by a rapid decrease in the level of p21 ( cip1 ) mRNA whereas ***TGF-beta1*** ***enhances*** ***p21*** ( cip1 ) mRNA expression concurrently with an inhibitory effect on progenitor cell proliferation .	positive	0
15043	10825239	3082;5715	HGF;p27	Using Twist-AS to lower Twist levels restored the ***HGF-dependent*** ***reduction*** of ***p27*** and MHC .	negative	0
15044	10825242	6772;4790	STAT1;NFkappaB	Interruption of ******NFkappaB-STAT1****** ***signaling*** mediates EGF-induced cell-cycle arrest .	parallel	0
15045	10825242	6772;4790	STAT1;NFkappaB	These observations suggest the ***activation*** of ***NFkappaB*** via IkappaB degradation and ***STAT1*** via specific receptor kinase activity synergistically induce WAF1 gene expression in A431 cells .	positive	1
15046	10825242	4790;1026	NFkappaB;WAF1	These observations suggest the activation of ***NFkappaB*** via IkappaB degradation and STAT1 via specific receptor kinase activity synergistically ***induce*** ***WAF1*** gene expression in A431 cells .	target	1
15047	10825242	4790;6772	NFkappaB;STAT1	Thus , ***NFkappaB*** and ***STAT1*** pathways mutually ***interact*** to play an important role in the EGF-induced intracellular reaction .	parallel	1
15048	10825282	2353;5045	AP-1;furin	***AP-1*** assembly proteins ***mediate*** transport of MPRs and ***furin*** , whereas AP-3 adaptors mediate transport of lysosomal membrane glycoproteins to the endosomal/lysosomal system .	target	0
15049	10825288	7033;5743	trefoil factor 3;cyclooxygenase-2	In summary , our results indicate that ***trefoil factor 3*** ***activates*** ***cyclooxygenase-2*** in intestinal epithelium to produce prostaglandin I ( 2 ) and prostaglandin E ( 2 ) , which function as survival factors and mediate the cytoprotective action of trefoil factor 3 against oxidant injury .	positive	1
15050	10825288	7033;5743	trefoil factor 3;cyclooxygenase-2	Western blot and immunohistochemistry revealed that ***trefoil factor 3*** ( 2.5 microM ) ***up-regulates*** the expression of ***cyclooxygenase-2*** but not cyclooxygenase-1 in IEC-18 cells .	positive	1
15051	10825299	9146;6616	Hrs;SNAP-25	***Hrs*** ***interacts*** with ***SNAP-25*** and regulates Ca ( 2 + ) - dependent exocytosis .	parallel	1
15052	10825299	9146;6616	Hrs;SNAP-25	***Hrs*** specifically ***interacts*** with ***SNAP-25*** , but not SNAP-23/syndet .	parallel	1
15053	10825299	6616;9146	SNAP-25;Hrs	The ***association*** of ***Hrs*** and ***SNAP-25*** is mediated via coiled-coil interactions .	parallel	0
15054	10825369	1081;983	HCG;cdc2	In leiomyomal cells , the expression of proliferating cell nuclear antigen ( PCNA ) , cyclin E and ***cdc2*** was significantly ***increased*** by ***HCG*** treatment ( P < 0.05 ) even at the lowest concentration used ( 3 nmol/l ) .	positive	0
15055	10825369	1081;983	HCG;cdc2	In myometrial cells , the expression of cyclin E and ***cdc2*** was significantly ***increased*** by ***HCG*** treatment ( P < 0.05 ) only at the highest concentration used ( 30 nmol/l ) .	positive	0
15056	10825374	5443;3576	beta-endorphin;interleukin-8	***beta-endorphin*** ***inhibits*** the production of ***interleukin-8*** by human chorio-decidual cells in culture .	negative	1
15057	10825575	6709;836	alpha II-spectrin;caspase-3	***alpha II-spectrin*** ( alpha-fodrin ) is a demonstrated endogenous ***substrate*** for ***caspase-3*** in neurons undergoing unscheduled apoptotic death .	parallel	1
15058	10826496	8572;7205	RIL;TRIP6	Here , we describe and characterise the ***interaction*** of the ***RIL*** PDZ domain with the zyxin-related protein ***TRIP6*** , a protein containing three C-terminal LIM domains .	parallel	1
15059	10826501	1906;3569	Endothelin-1;interleukin-6	***Endothelin-1*** ***induces*** ***interleukin-6*** release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells .	target	1
15060	10826697	10329;4049	type II membrane protein;LT-alpha	While the ' classic ' form of the molecule is a secreted homotrimer , now referred to in the literature as LT-alpha3 , it has more recently been recognised that a membrane-bound form of LT exists on activated T lymphocytes and that this represents a ***complex*** between ***LT-alpha*** and a closely related ***type II membrane protein*** , LT-beta .	parallel	1
15061	10827009	51083;5617	galanin;prolactin	Intravenous injection of ***galanin*** ***increases*** plasma growth hormone ( GH ) and ***prolactin*** ( PRL ) concentrations .	positive	0
15062	10827015	207;820	Rac;cAMP	The Src tyrosine kinase inhibitor PP1 and a dominant-negative mutant of the small G protein ***Rac*** also ***abolished*** the effect of ISO and ***cAMP*** .	positive	0
15063	10827017	1981;1977	eIF4G;eIF4E	Compared with control values , LPS-treated rats demonstrated 1 ) a transient increase in binding of the translation repressor 4E-binding protein-1 ( 4E-BP1 ) with eIF4E , 2 ) a transient decrease in the phosphorylated gamma-form of 4E-BP1 , and 3 ) a sustained decrease in the amount of ***eIF4G*** ***associated*** with ***eIF4E*** .	parallel	0
15064	10827017	1978;1977	4E-BP1;eIF4E	Compared with control values , LPS-treated rats demonstrated 1 ) a transient increase in ***binding*** of the translation repressor 4E-binding protein-1 ( ***4E-BP1*** ) with ***eIF4E*** , 2 ) a transient decrease in the phosphorylated gamma-form of 4E-BP1 , and 3 ) a sustained decrease in the amount of eIF4G associated with eIF4E .	parallel	1
15065	10827081	5511;988	NIPP1;CDC5L	Furthermore , an ***interaction*** between ***CDC5L*** , ***NIPP1*** , and PP1 in rat liver nuclear extracts could be demonstrated by co-immunoprecipitation and/or co-purification experiments .	parallel	1
15066	10827151	8731;3082	Met;hepatocyte growth factor	Recently , we observed that ***Met*** , the ***receptor*** for ***hepatocyte growth factor/scatter factor*** ( HGF/SF ) , is overexpressed in epithelial cells of both early-appearing intestinal metaplastic glands in precancerous hepatic cholangiofibrotic tissue and neoplastic glands in later developed intestinal-type of cholangiocarcinoma originated from the furan rat model of cholangiocarcinogenesis when compared with normal and hyperplastic intrahepatic biliary epithelia .	parallel	1
15067	10827174	9507;176	aggrecanase-1;aggrecan	Data from several studies indicate that this ***binding*** of ***aggrecanase-1*** to ***aggrecan*** through the TSP-1 motif is necessary for enzymatic cleavage of aggrecan .	parallel	1
15068	10827175	7077;4323	TIMP-2;MMP-14	Previous in vitro studies indicated that activation of proMMP-2 can occur through formation of a trimolecular ***complex*** between ***MMP-14*** , ***TIMP-2*** , and proMMP-2 at the cell surface .	parallel	1
15069	10827178	5468;5743	PPARgamma;cyclooxygenase-2	Feedback ***control*** of ***cyclooxygenase-2*** expression through ***PPARgamma*** .	target	0
15070	10827180	6631;2314	U1C;FLI	Here we report that ***U1C*** , one of three human U1 small nuclear ribonucleoprotein-specific proteins , ***interacts*** in vitro and in vivo with both EWS and ***EWS/FLI*** .	parallel	1
15071	10827182	10540;65108	dynamitin;MacMARCKS	We report that dynamitin is a Ca ( 2 + ) / calmodulin-binding protein and that ***dynamitin*** ***binds*** directly to macrophage-enriched myristoylated alanine-rice C kinase substrate ( ***MacMARCKS*** ) , a membrane-associated PKC substrate involved in macrophage spreading and integrin activation .	parallel	1
15072	10827182	65108;10540	MacMARCKS;dynamitin	These data suggest that the ******dynamitin-MacMARCKS****** ***interaction*** is involved in cell spreading .	parallel	1
15073	10827191	5728;207	PTEN;PKB	The PTEN tumor suppressor gene is frequently inactivated in human prostate cancers , particularly in more advanced cancers , suggesting that the AKT/protein kinase B ( ***PKB*** ) kinase , which is negatively ***regulated*** by ***PTEN*** , may be involved in human prostate cancer progression .	negative	1
15074	10827191	207;3692	AKT;p27	Furthermore , expression of the p27 ( Kip1 ) cell cycle regulator was diminished in LNAI cells , consistent with the notion that ***AKT*** directly ***inhibits*** AFX/Forkhead-mediated transcription of ***p27*** ( Kip1 ) .	negative	1
15075	10827196	4193;7157	Mdm2;p53	The ***Mdm2*** protein is a key ***regulator*** of ***p53*** activity and stability .	target	1
15076	10827196	4193;7157	Mdm2;p53	Upon binding , ***Mdm2*** ***inhibits*** the transcription regulatory activity of ***p53*** and promotes its rapid degradation .	negative	1
15077	10827199	2534;7804	Fyn;ApoER2	Cellular components of this signaling pathway characterized to date are cell surface receptors for reelin like apolipoprotein E receptor 2 ( ApoER2 ) , very low density lipoprotein receptor ( VLDLR ) , and cadherin-related neuronal receptors , and intracellular components like Disabled-1 and the nonreceptor tyrosine kinase ***Fyn*** , which ***bind*** to the intracellular domains of the ***ApoER2*** and VLDL receptor or of cadherin-related neuronal receptors , respectively .	parallel	1
15078	10827205	3667;5781	IRS-1;SHP2	Insulin-stimulated ***IRS-1*** ***association*** with ***SHP2*** was reduced to 79 + / - 5 % ( P < 0.05 ) in liver of the fructose-fed rats .	parallel	0
15079	10828007	6387;3683	SDF-1;LFA-1	The chemokine ***SDF-1*** ***activates*** the integrins ***LFA-1*** , VLA-4 , and VLA-5 on immature human CD34 ( + ) cells : role in transendothelial/stromal migration and engraftment of NOD/SCID mice .	positive	1
15080	10828007	6387;3678	SDF-1;VLA-5	The chemokine ***SDF-1*** ***activates*** the integrins LFA-1 , VLA-4 , and ***VLA-5*** on immature human CD34 ( + ) cells : role in transendothelial/stromal migration and engraftment of NOD/SCID mice .	positive	1
15081	10828014	51513;2120	TEL2;ETV6	Identification and characterization of a new human ETS-family transcription factor , ***TEL2*** , that is expressed in hematopoietic tissues and can ***associate*** with ***TEL1/ETV6*** .	parallel	0
15082	10828014	51513;472	TEL2;TEL1	Identification and characterization of a new human ETS-family transcription factor , ***TEL2*** , that is expressed in hematopoietic tissues and can ***associate*** with ***TEL1/ETV6*** .	parallel	0
15083	10828016	1438;1437	GMRalpha;GM-CSF	***GMRalpha*** in isolation ***binds*** to ***GM-CSF*** with low affinity .	parallel	1
15084	10828018	4092;7040	Smad7;TGF-beta	A distant family member , ***Smad7*** , is expressed in most mammalian tissues and cells and ***prevents*** ***TGF-beta*** signaling .	negative	0
15085	10828022	80781;2247	Endostatin;Fibroblast growth factor-2	***Fibroblast growth factor-2*** ( FGF-2 ) - induced angiogenesis in the chicken chorioallantoic membrane was ***inhibited*** by ***Endostatin*** , but not by an Endostatin mutant R158/270A , lacking heparin-binding ability .	negative	1
15086	10828022	80781;6461	Endostatin;Shb	***Endostatin*** treatment for 10 minutes or 24 hours ***induced*** tyrosine phosphorylation of ***Shb*** and formation of multiprotein complexes .	target	1
15087	10828025	7066;3673	Thrombopoietin;collagen receptor	***Thrombopoietin*** ***potentiates*** ***collagen receptor*** signaling in platelets through a phosphatidylinositol 3-kinase-dependent pathway .	positive	0
15088	10828054	3821;3824	NKG2A;CD94	All NK-cell lymphomas ( 4 nasal/oral and 1 intestinal ) expressed at least 1 NKR , the ******CD94/NKG2A****** ***complex*** .	parallel	1
15089	10828057	6875;5450	TAFII105;OCA-B	Specific ***interaction*** of ***TAFII105*** with ***OCA-B*** is involved in activation of octamer-dependent transcription .	parallel	1
15090	10828064	65125;4155	WNK1;myelin basic protein	***WNK1*** ***phosphorylates*** the exogenous substrate ***myelin basic protein*** as well as itself mostly on serine residues , confirming that it is a serine/threonine protein kinase .	target	1
15091	10828065	1647;5111	Gadd45;PCNA	These findings suggest that ***interaction*** of MyD118 or ***Gadd45*** with ***PCNA*** , in essence , serves to impede negative growth control .	parallel	1
15092	10828065	4616;5111	MyD118;PCNA	These findings suggest that ***interaction*** of ***MyD118*** or Gadd45 with ***PCNA*** , in essence , serves to impede negative growth control .	parallel	1
15093	10828070	4790;4897	NF-kappa B;neuronal cell adhesion molecule	***Regulation*** of ***neuronal cell adhesion molecule*** expression by ***NF-kappa B*** .	target	1
15094	10828094	338;335	apoB;apo	The binding of LDL to Lp [ a ] / apo [ a ] was inhibited by L-proline and lysine analogs , which are known to inhibit the non-covalent ***association*** between ***apo*** [ a ] and ***apoB*** .	parallel	0
15095	10828094	335;338	apo;apoB	Using this method we have found that nicotinic acid and captopril are able to inhibit the ***association*** of ***apo*** [ a ] with ***apoB*** .	parallel	0
15096	10828447	9447;7158	AIM2;p202	Moreover , ***AIM2*** can ***heterodimerize*** with ***p202*** in vitro .	parallel	1
15097	10828489	9340;2641	glucagon-like peptide-2 receptor;GLP-2	The actions of ***GLP-2*** are ***transduced*** by a recently cloned ***glucagon-like peptide-2 receptor*** ( GLP-2R ) that represents a new member of the G protein-coupled receptor superfamily .	positive	1
15098	10828755	4790;183	NF-kappaB;angiotensinogen	The ***angiotensinogen*** gene , which provides the precursor for angiotensin production , is ***stimulated*** by ***NF-kappaB*** activation .	positive	0
15099	10828755	183;4790	angiotensin II;NF-kappaB	***angiotensin II*** ***activates*** ***NF-kappaB*** through both AT1 and AT2 receptors .	positive	1
15100	10828839	3488;3479	IGFBP-5;IGF-I	***IGFBP-5*** has been shown in several cell types to ***enhance*** the mitogenic activity of ***IGF-I*** .	positive	0
15101	10828839	3479;3488	IGF-I;IGFBP-5	***IGF-I*** also ***enhanced*** the level of ***IGFBP-5*** mRNA .	positive	0
15102	10828839	3479;3488	IGF-I;IGFBP-5	LY294002 , a specific inhibitor of the intracellular signaling molecule phosphatidylinositol 3-kinase , inhibited ***stimulation*** of ***IGFBP-5*** by ***IGF-I*** .	positive	0
15103	10828841	650;860	BMP2;Cbfa1	Western blot analysis of the cell lysates using polyclonal antibody raised against Cbfa1 indicated that ***BMP2*** treatment ***increased*** the ***Cbfa1*** protein level in TC6 cells .	positive	0
15104	10828847	1803;2695	DPP IV;GIP	The formation of ***GIP*** ( 3-42 ) was almost completely ***abolished*** by inhibition of plasma ***DPP IV*** with diprotin A.	positive	0
15105	10828862	1440;3458	G-CSF;IFN-gamma	***G-CSF*** ***reduces*** ***IFN-gamma*** and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function .	negative	1
15106	10828862	1440;3565	G-CSF;IL-4	***G-CSF*** ***reduces*** IFN-gamma and ***IL-4*** production by T cells after allogeneic stimulation by indirectly modulating monocyte function .	negative	1
15107	10828880	3569;3791	HGF;tyrosine kinase growth factor receptor	***Activation*** of the Met ***tyrosine kinase growth factor receptor*** by its ligand ***HGF/SF*** has been shown to increase in vitro invasiveness in epithelial cell lines .	positive	1
15108	10828884	1027;983	p27Kip1;p34cdc2	In contrast , ***p27Kip1*** expression also ***inhibited*** ***p34cdc2*** but reduced mitotic arrest only slightly , from 87 .	negative	1
15109	10828886	2113;1003	ETS1;VE-cadherin	***ETS1*** lowers capillary endothelial cell density at confluence and ***induces*** the expression of ***VE-cadherin*** .	target	1
15110	10828886	2113;1003	ETS1;VE-cadherin	Indeed , ***ETS1*** ***increased*** the expression of the endothelial-specific ***VE-cadherin*** without affecting N-cadherin expression levels .	positive	0
15111	10828886	2113;1003	ETS1;VE-cadherin	In parallel , both a dominant negative mutant of Ets members and an ***ETS1*** anti-sense oligonucleotide ***inhibited*** ***VE-cadherin*** expression in endothelial cells .	negative	1
15112	10828887	4609;3569	c-myc;IL-6	Moreover , deregulated expression of ***c-myc*** in M1 cells , which had been previously shown to block terminal differentiation , was also found to ***block*** ***IL-6*** induced degradation of Cdc25A .	negative	0
15113	10828887	3569;993	IL-6;Cdc25A	Moreover , deregulated expression of c-myc in M1 cells , which had been previously shown to block terminal differentiation , was also found to block ***IL-6*** induced ***degradation*** of ***Cdc25A*** .	negative	1
15114	10828889	7157;3732	p53;KAI1	Absence of ***p53-dependent*** ***induction*** of the metastatic suppressor ***KAI1*** gene after DNA damage .	target	1
15115	10829012	4902;2675	neurturin;GDNF family receptor alpha 1 and 2	***Binding*** of GDNF and ***neurturin*** to human ***GDNF family receptor alpha 1 and 2*** .	parallel	1
15116	10829017	10226;4074	TIP47;mannose 6-phosphate receptor	We report here a quantitative analysis of the ***interaction*** of recombinant ***TIP47*** with ***mannose 6-phosphate receptor*** cytoplasmic domains .	parallel	1
15117	10829017	10226;3482	TIP47;cation-independent mannose 6-phosphate receptor	Recombinant ***TIP47*** ***binds*** more tightly to the ***cation-independent mannose 6-phosphate receptor*** ( K ( D ) = 1 microm ) than to the cation-dependent mannose 6-phosphate receptor ( K ( D ) = 3 microm ) .	parallel	1
15118	10829020	1856;5599	Dvl2;JNK	We found that in contrast to Axin , ***Dvl2*** ***activation*** of ***JNK*** does not require MEKK1 , and complex formation between Dvl2 and Axin is independent of Axin-MEKK1 binding .	positive	1
15119	10829020	1856;5599	Dvl2;JNK	Furthermore , Dvl2-DIX and ***Dvl2-DeltaDEP*** proteins deficient for JNK activation can ***attenuate*** Axin-activated ***JNK*** activity by disrupting Axin dimerization .	negative	0
15120	10829020	1856;5599	Dvl2;JNK	These results indicate that unlike the strict requirement of homodimerization for Axin function , ***Dvl2*** can ***activate*** ***JNK*** either as a monomer or homodimer/heterodimer .	positive	1
15121	10829021	3479;3480	IGF-I;IGF-I receptor	In parallel , ***IGF-I*** ***activates*** ***IGF-I receptor*** , insulin receptor substrate-1 ( IRS-1 ) , phosphatidylinositol 3 ( PI-3 ) - kinase , and FAK .	positive	1
15122	10829021	3479;3667	IGF-I;insulin receptor substrate-1	In parallel , ***IGF-I*** ***activates*** IGF-I receptor , ***insulin receptor substrate-1*** ( IRS-1 ) , phosphatidylinositol 3 ( PI-3 ) - kinase , and FAK .	positive	1
15123	10829021	3479;5266	IGF-I;PI-3	In parallel , ***IGF-I*** ***activates*** IGF-I receptor , insulin receptor substrate-1 ( IRS-1 ) , phosphatidylinositol 3 ( ***PI-3*** ) - kinase , and FAK .	positive	1
15124	10829062	6714;25	Src;Abl	The kinase-deficient ***Src*** acts as a ***suppressor*** of the ***Abl*** kinase for Cbl phosphorylation .	negative	1
15125	10829062	6714;867	Src;Cbl	The kinase-deficient ***Src*** acts as a ***suppressor*** of the Abl kinase for ***Cbl*** phosphorylation .	negative	1
15126	10829062	6714;867	Src;Cbl	Here we report that the kinase-deficient ***Src*** ( SrcKD ) directly ***inhibits*** the tyrosine phosphorylation of ***Cbl*** and other cellular proteins by Abl .	negative	1
15127	10829062	25;867	Abl;Cbl	To suppress the ***Cbl*** ***phosphorylation*** by ***Abl*** , the interaction between the SH3 domain of SrcKD and Cbl is required .	target	1
15128	10829062	25;867	Abl;Cbl	The ***binding*** of ***Abl*** to the extreme carboxyl-terminal region of ***Cbl*** unmasks the binding site of SrcKD to Cbl .	parallel	1
15129	10829062	25;867	Abl;Cbl	This results in a ternary complex that inhibits the ***Abl-mediated*** ***phosphorylation*** of ***Cbl*** by steric hindrance .	target	1
15130	10829066	9021;3572	SOCS-3;gp130	Taken together , these data suggest that the mechanism by which ***SOCS-3*** ***inhibits*** the ***gp130*** signaling pathway depends on recruitment to the phosphorylated gp130 receptor , and that some of the negative regulatory roles previously attributed to the phosphatase SHP-2 might in fact be caused by the action of SOCS-3 .	negative	1
15131	10829070	4067;695	Lyn;Btk	Loss of ***Lyn*** , PTEN ( phosphatase and tensin homolog ) , or SH2-containing inositol phosphatase ***suppressed*** the ***Btk*** ( lo ) phenotype in vitro but not in vivo , whereas CD19 and the p85alpha form of phosphoinositide 3-kinase behaved as Btk ( lo ) enhancers in vivo but not in vitro .	positive	1
15132	10829070	5728;695	PTEN;Btk	Loss of Lyn , ***PTEN*** ( phosphatase and tensin homolog ) , or SH2-containing inositol phosphatase ***suppressed*** the ***Btk*** ( lo ) phenotype in vitro but not in vivo , whereas CD19 and the p85alpha form of phosphoinositide 3-kinase behaved as Btk ( lo ) enhancers in vivo but not in vitro .	positive	1
15133	10829095	1636;3827	ACE;bradykinin	Both angiotensin converting enzyme ( ***ACE*** ) and neutral endopeptidase ( NEP ) inhibitors ***increased*** ***bradykinin*** peptide levels .	positive	0
15134	10829095	4311;3827	neutral endopeptidase;bradykinin	Both angiotensin converting enzyme ( ACE ) and ***neutral endopeptidase*** ( NEP ) inhibitors ***increased*** ***bradykinin*** peptide levels .	positive	0
15135	10830276	3553;3952	IL-1beta;leptin	***IL-1beta*** by either the iv or icv route significantly ***increased*** ***leptin*** levels in the aorta [ 1.19 + / -0.10 vs. 1.92 + / -0.15 ng/ml ( P = 0.0002 ) and 1.19 + / -0.10 vs. 1.57 + / -0.12 ng/ml ( P = 0.022 ) , respectively ] .	positive	0
15136	10830291	7422;3486	Vascular endothelial growth factor;IGFBP-3	***Vascular endothelial growth factor*** ***inhibited*** ***IGFBP-3*** mRNA ( P < 0.01 ) and protein expression and increased IGFBP-5 mRNA ( P < 0.001 ) and protein .	negative	1
15137	10830291	3479;3488	IGF-I;IGFBP-5	At the protein level , ***IGF-I*** clearly ***increased*** ***IGFBP-5*** levels in conditioned medium .	positive	0
15138	10830293	2247;7040	FGF-2;TGFbeta	In summary , FGF-2-induced VEGF expression by osteoblastic cells is a dose-dependent event that may be independent of concomitant ***FGF-2-induced*** ***modulation*** of ***TGFbeta*** activity .	target	0
15139	10830300	6714;5295	c-src;p85	The ***association*** between ***p85*** and ***c-src*** is due in part to a direct interaction between the proline-rich sequences of p85 and the SH3 domain of c-src .	parallel	0
15140	10830307	2247;4322	bFGF;collagenase-3	Basic fibroblast growth factor ( ***bFGF*** ) ***stimulates*** ***collagenase-3*** synthesis in fetal rat osteoblast-enriched ( Ob ) cells .	positive	0
15141	10830307	2247;4322	bFGF;collagenase-3	In conclusion , ***bFGF*** ***increases*** ***collagenase-3*** gene transcription , an effect mediated through an AP-1 site , due to the induction or activation of Jun and Fos family transcription factors .	positive	0
15142	10830307	2247;4322	bFGF;collagenase-3	The ***stimulation*** of ***collagenase-3*** synthesis by ***bFGF*** may be critical in mediating the actions of this growth factor in bone remodeling .	positive	0
15143	10830309	183;2822	angiotensin II;PLD	The ***activation*** of ***PLD*** in these cells by ***angiotensin II*** ( AngII ) , endothelin-1 ( ET-1 ) , and platelet-derived growth factor ( PDGF ) was found to be sensitive to inhibitors of the activation of ADP-ribosylation factor ( ARF ) but not to blockers of Rho protein function .	positive	1
15144	10830309	1906;2822	endothelin-1;PLD	The ***activation*** of ***PLD*** in these cells by angiotensin II ( AngII ) , ***endothelin-1*** ( ET-1 ) , and platelet-derived growth factor ( PDGF ) was found to be sensitive to inhibitors of the activation of ADP-ribosylation factor ( ARF ) but not to blockers of Rho protein function .	positive	1
15145	10830313	7040;6574	TGF-beta1;Glvr-1	In conclusion , ***TGF-beta1*** ***stimulates*** Pi transport and ***Glvr-1*** expression in chondrocytes , suggesting that , like proliferation , differentiation , and matrix synthesis , Pi handling is subject to regulation by TGF-beta3 family members in bone-forming cells .	positive	0
15146	10830316	3488;3479	IGFBP-5;IGF-I	Although treatment with a PI3K inhibitor induced apoptosis in both control and IGFBP-5-overexpressing LNCaP cells , this PI3K inhibitor-induced apoptosis was prevented by exogenous IGF-I treatment only in IGFBP-5 transfectants , suggesting that ***IGFBP-5*** overexpression can ***potentiate*** the antiapoptotic effects of ***IGF-I*** .	positive	0
15147	10830317	2099;1956	ERalpha;EGFR	Our studies demonstrated a dose-dependent ***activation*** of the ***EGFR*** gene transcription by ligand-bound estrogen receptor alpha ( ***ERalpha*** ) .	positive	1
15148	10830618	999;1499	E-cadherin;beta-catenin	Tumor-derived mutated ***E-cadherin*** ***influences*** ***beta-catenin*** localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate .	target	0
15149	10830618	999;1499	E-cadherin;beta-catenin	Moreover , the various mutant ***E-cadherin*** derivatives ***increased*** the steady-state levels of alpha - and ***beta-catenin*** and were found in association with these catenins even after induction of tyrosine phosphorylation by pervanadate .	positive	0
15150	10830731	5925;1869	pRb;E2F-1	The underphosphorylated pRb associates with E2F-4 in G1 phase , whereas the phosphorylated ***pRb*** mainly ***binds*** to ***E2F-1*** and E2F-3 in proliferating MV4-11 cells .	parallel	1
15151	10830731	5925;1871	pRb;E2F-3	The underphosphorylated pRb associates with E2F-4 in G1 phase , whereas the phosphorylated ***pRb*** mainly ***binds*** to E2F-1 and ***E2F-3*** in proliferating MV4-11 cells .	parallel	1
15152	10830731	5925;1874	pRb;E2F-4	The underphosphorylated ***pRb*** ***associates*** with ***E2F-4*** in G1 phase , whereas the phosphorylated pRb mainly binds to E2F-1 and E2F-3 in proliferating MV4-11 cells .	parallel	0
15153	10830746	3569;7422	IL-6;VEGF	Human ***IL-6*** produced in the affected lymph nodes of Castleman 's disease may ***induce*** paracrine ***VEGF-production*** by plasma cells and vascular proliferation in the lymph node .	target	1
15154	10830965	3146;177	amphoterin;RAGE	Inhibition of the ******RAGE-amphoterin****** ***interaction*** suppressed activation of p44/p42 , p38 and SAP/JNK MAP kinases ; molecular effector mechanisms importantly linked to tumour proliferation , invasion and expression of matrix metalloproteinases .	parallel	1
15155	10830966	8851;1020	p35;Cyclin-dependent kinase 5	***Cyclin-dependent kinase 5*** ( cdk5 ) and its neuron-specific ***activator*** ***p35*** are required for neurite outgrowth and cortical lamination .	positive	1
15156	10831317	4582;1437	MUC1;GM-CSF	Crosslinking of ***MUC1*** on peripheral blood T cells by plate-bound anti-MUC1 ( DF3-P ) antibody ***inhibits*** cell proliferation , IL-2 and ***GM-CSF*** production , and up-regulation of the IL-2 receptor upon anti-CD3 stimulation .	negative	1
15157	10831317	4582;3558	MUC1;IL-2	Crosslinking of ***MUC1*** on peripheral blood T cells by plate-bound anti-MUC1 ( DF3-P ) antibody ***inhibits*** cell proliferation , ***IL-2*** and GM-CSF production , and up-regulation of the IL-2 receptor upon anti-CD3 stimulation .	negative	1
15158	10831322	940;941	CD28;B7.1	While surface expression of B7.1 molecules on SCCHN cells enhanced T-cell costimulation via ******B7.1-CD28****** ***interactions*** , it did not rescue activated T cells from tumor-induced apoptosis .	parallel	1
15159	10831344	7076;4318	tissue inhibitor of metalloproteinase-1;MMP-9	The ***tissue inhibitor of metalloproteinase-1*** ( TIMP-1 ) is able to ***prevent*** activation of ***pro-MMP-9*** and forms a 1:1 complex with the active form of MMP-9 .	negative	0
15160	10831344	7076;4318	tissue inhibitor of metalloproteinase-1;MMP-9	The ***tissue inhibitor of metalloproteinase-1*** ( TIMP-1 ) is able to prevent activation of pro-MMP-9 and forms a 1:1 ***complex*** with the active form of ***MMP-9*** .	parallel	1
15161	10831352	2321;7422	Flt-1;VEGF	OBJECTIVE : The aim of this study has been to evaluate the clinical significance of expression of ***VEGF*** and its ***receptors*** , ***Flt-1*** , KDR , and Flt-4 , in endometrial carcinomas .	parallel	1
15162	10831352	2324;7422	Flt-4;VEGF	OBJECTIVE : The aim of this study has been to evaluate the clinical significance of expression of ***VEGF*** and its ***receptors*** , Flt-1 , KDR , and ***Flt-4*** , in endometrial carcinomas .	parallel	1
15163	10831352	3791;7422	KDR;VEGF	OBJECTIVE : The aim of this study has been to evaluate the clinical significance of expression of ***VEGF*** and its ***receptors*** , Flt-1 , ***KDR*** , and Flt-4 , in endometrial carcinomas .	parallel	1
15164	10831587	7056;5624	thrombomodulin;protein C	Function was measured with respect to fibrinogen clotting , platelet and factor V activation , inhibition by antithrombin , and the ***thrombomodulin-dependent*** ***activation*** of ***protein C*** and thrombin-activable fibrinolysis inhibitor ( TAFI ) .	positive	1
15165	10831587	7056;1361	thrombomodulin;TAFI	Function was measured with respect to fibrinogen clotting , platelet and factor V activation , inhibition by antithrombin , and the ***thrombomodulin-dependent*** ***activation*** of protein C and thrombin-activable fibrinolysis inhibitor ( ***TAFI*** ) .	positive	1
15166	10831611	9113;7791	h-warts;Zyxin	We have identified an ***interaction*** of ***h-warts/LATS1*** with ***Zyxin*** , a regulator of actin filament assembly .	parallel	1
15167	10831611	983;7791	Cdc2;Zyxin	We found that ***Zyxin*** is ***phosphorylated*** specifically during mitosis , most likely by ***Cdc2*** kinase , and that the phosphorylation regulates association with h-warts/LATS1 .	target	1
15168	10831612	402;6904	Arl2;tubulin-folding cofactor D	ADP ribosylation factor-like protein 2 ( ***Arl2*** ) ***regulates*** the interaction of ***tubulin-folding cofactor D*** with native tubulin .	target	1
15169	10831617	6382;8038	syndecan;ADAM 12	However , spreading could be efficiently induced by the addition of either 1 mM Mn ( 2 + ) or the beta1 integrin-activating monoclonal antibody 12G10 , suggesting that in these carcinoma cells , the ******ADAM 12-syndecan****** ***complex*** fails to modulate the function of beta1 integrin .	parallel	1
15170	10831641	5617;7200	PRL;TRH	METHODS : GH , ***PRL*** and TSH ***responses*** to ***TRH*** before and 1 month after rhGH therapy in a group of adult dialysis patients were evaluated .	parallel	0
15171	10832106	5443;3949	ACTH;LDL receptor	In primary cultures of normal adrenal cells , accumulation of both ***LDL receptor*** and CLA-1 mRNAs was ***upregulated*** by ***ACTH*** in a dose - and time-dependent manner , with an earlier induction of LDL receptor than CLA-1 mRNA expression .	positive	1
15172	10832612	5368;820	nociceptin;cAMP	J-113397 was shown to antagonize ( pA2 7.52 ) the ***nociceptin-induced*** ***inhibition*** of ***cAMP*** formation in cells expressing the recombinant human OP4 receptor ( CHOhOP4 ) and to displace [ 125I ] Tyr14nociceptin from CHOhOP4 membranes with a pKi of 8.56 .	negative	1
15173	10833263	84254;207	CaM-kinase kinase alpha;PKB	The ***activation*** of ***PKB*** by ***CaM-kinase kinase alpha*** was as high as 300-fold after incubation for 30 min under the phosphorylation conditions , and still increased thereafter , suggesting that the maximal activation of PKB on phosphorylation of the Thr ( 308 ) residue is several hundred fold .	positive	1
15174	10833301	627;4915	BDNF;TrkB	Taken together , our data indicate that serotonin acts on 5-HT1 ( A ) autoreceptors , causing up-regulation of ***BDNF*** , which ***activates*** ***TrkB*** to promote serotonergic phenotype-specific markers .	positive	1
15175	10833423	8936;10096	WAVE1;Arp2/3	***WAVE1*** has been reported to ***associate*** and activate ***Arp2/3*** complex at its C-terminal region that is rich in acidic residues .	parallel	0
15176	10833507	63941;351	XB51;amyloid precursor protein	***Regulation*** of X11L-dependent ***amyloid precursor protein*** metabolism by ***XB51*** , a novel X11L-binding protein .	target	1
15177	10833507	321;351	X11L;amyloid precursor protein	The protein XB51 inhibited the ***association*** of ***X11L*** with ***amyloid precursor protein*** through a non-competitive mechanism and abolished the suppression of beta-amyloid production by X11L .	parallel	0
15178	10833507	63941;321	XB51;X11L	The protein ***XB51*** ***inhibited*** the association of ***X11L*** with amyloid precursor protein through a non-competitive mechanism and abolished the suppression of beta-amyloid production by X11L .	negative	1
15179	10833507	63941;321	XB51;X11L	***Association*** of ***XB51*** with ***X11L*** changed the intracellular distribution of XB51 and resulted in redistribution of XB51 into the CHAPS buffer-soluble fraction .	parallel	0
15180	10833508	627;4915	brain-derived neurotrophic factor;TrkB	***TrkB*** ***activation*** by ***brain-derived neurotrophic factor*** inhibits the G protein-gated inward rectifier Kir3 by tyrosine phosphorylation of the channel .	positive	1
15181	10833509	860;4982	Cbfa1;OPG	These results indicate that ***Cbfa1*** ***regulates*** the expression of ***OPG*** , thereby further contributing to a molecular link between bone formation and resorption .	target	1
15182	10833509	860;4982	Cbfa1;OPG	Cloning and computer analysis of a 5.9-kilobase human OPG promoter sequence revealed the presence of 12 putative Cbfa1 binding elements ( osteoblast-specific element 2 ( OSE ( 2 ) ) ) , suggesting a possible ***regulation*** of ***OPG*** by ***Cbfa1*** .	target	1
15183	10833525	64100;4654	E12;MyoD	Analysis of the ***inhibition*** of ***MyoD*** activity by ITF-2B and full-length ***E12/E47*** .	negative	1
15184	10833525	6929;4654	E47;MyoD	Analysis of the ***inhibition*** of ***MyoD*** activity by ITF-2B and full-length ***E12/E47*** .	negative	1
15185	10833525	64100;4654	E12;MyoD	Previous studies that showed ***activation*** of ***MyoD*** by ***E12*** used an artificially N-terminally truncated form .	positive	1
15186	10833525	64100;4654	E12;MyoD	Here we show that the full-length form of ***E12*** ***inhibits*** ***MyoD*** function .	negative	1
15187	10834301	27306;4843	PGD2;iNOS	These results demonstrated that ***PGD2*** and its metabolites ***inhibit*** ***iNOS*** induction by LPS in isolated rat mesenteric arteries , resulting in reduced relaxing ability in response to L-arginine .	negative	1
15188	10834321	83716;1991	trypsin inhibitor;polymorphonuclear elastase	In the amniotic fluid , urinary ***trypsin inhibitor*** ( UTI ) seems to ***inhibit*** ***polymorphonuclear elastase*** ( PMNE ) activity .	negative	1
15189	10834541	7157;595	p53;cyclin D1	These findings suggested the hypothesis that prior aberrant ***p53*** expression may ***affect*** or regulate the overexpression of ***cyclin D1*** .	target	0
15190	10834607	1230;6348	CCR1;MIP-1alpha	Gene transcripts for the receptor ***CCR1*** , that ***binds*** RANTES and ***MIP-1alpha*** were also readily detected , as was CCR2 , the receptor for the monocyte chemotactic proteins ( MCP ) 1-4 .	parallel	1
15191	10834686	5443;3553	alpha-MSH;IL-1beta	Addition of ***alpha-MSH*** to LPS-stimulated whole blood samples ***inhibited*** production of TNF-alpha and ***IL-1beta*** in a concentration-dependent manner .	negative	1
15192	10834686	5443;7124	alpha-MSH;TNF-alpha	Addition of ***alpha-MSH*** to LPS-stimulated whole blood samples ***inhibited*** production of ***TNF-alpha*** and IL-1beta in a concentration-dependent manner .	negative	1
15193	10834862	948;7057	CD36;thrombospondin-1	Expression of ***thrombospondin-1*** and its ***receptor*** ***CD36*** in human osteoarthritic cartilage .	parallel	1
15194	10834929	596;5335	Bcl-2;PLC-gamma1	Cleavage of ***PLC-gamma1*** was ***blocked*** by overexpression of ***Bcl-2*** and by specific inhibitors of caspases such as Z-DEVD-CH ( 2 ) F and YVAD-cmk .	negative	0
15195	10834938	4790;3717	NF-kappaB;JAK2	Cotransfection experiments performed with 293 cells revealed an ***inhibition*** of the ***prolactin receptor/JAK2/STAT5*** pathway by ***NF-kappaB*** .	negative	1
15196	10834938	4790;5618	NF-kappaB;prolactin receptor	Cotransfection experiments performed with 293 cells revealed an ***inhibition*** of the ***prolactin receptor/JAK2/STAT5*** pathway by ***NF-kappaB*** .	negative	1
15197	10834938	4790;6776	NF-kappaB;STAT5	Cotransfection experiments performed with 293 cells revealed an ***inhibition*** of the ***prolactin receptor/JAK2/STAT5*** pathway by ***NF-kappaB*** .	negative	1
15198	10834938	4790;6776	NF-kappaB;STAT5	In HC11 cells , ***NF-kappaB*** p50/p65 activity was inversely ***correlated*** with prolactin-induced ***STAT5*** tyrosine phosphorylation , expression of endogenous beta-casein gene , and of a transfected beta-casein gene promoter reporter construct .	negative	0
15199	10834938	5970;6776	p65;STAT5	In HC11 cells , NF-kappaB ***p50/p65*** activity was inversely ***correlated*** with prolactin-induced ***STAT5*** tyrosine phosphorylation , expression of endogenous beta-casein gene , and of a transfected beta-casein gene promoter reporter construct .	negative	0
15200	10834941	51176;1499	LEF-1;beta-catenin	Although the molecular mechanism of the link is still under investigation , this effect of NO appears directly or indirectly to be a result of the increase in free soluble beta-catenin and the formation of nuclear ******beta-catenin/LEF-1****** DNA ***complex*** .	parallel	1
15201	10834941	3458;5743	IFN-gamma;PGHS-2	We found that the ***induction*** of ***PGHS-2*** and generation of PGE2 in these cells by ***IFN-gamma*** and lipopolysaccharide ( LPS ) were greatly reduced by two selective NOS II inhibitors , L-NIL and SMT .	target	1
15202	10835315	5578;7124	Protein kinase C-alpha;TNF-alpha	We tested the hypothesis that ***Protein kinase C-alpha*** ( PKC-alpha ) ***mediates*** tumor necrosis factor-alpha ( ***TNF-alpha*** ) - induced alterations in permeability of pulmonary microvessel endothelial monolayers ( PEM ) .	target	0
15203	10835320	3689;3383	LFA-1;intercellular adhesion molecule-1	To elucidate the mechanism of CAM-related mediation of altered airway responsiveness in the atopic asthmatic state , the expressions and actions of ***intercellular adhesion molecule-1*** ( ICAM-1 ) and its counterreceptor ***ligand*** lymphocyte function-associated antigen-1 ( ***LFA-1*** ; i.e. , CD11a/CD18 ) were examined in isolated rabbit airway smooth muscle ( ASM ) tissues and cultured human ASM cells passively sensitized with sera from atopic asthmatic patients or nonatopic nonasthmatic ( control ) subjects .	parallel	1
15204	10835320	3567;3383	IL-5;ICAM-1	Extended studies further demonstrated that 1 ) the enhanced expression and release of soluble ICAM-1 by atopic sensitized ASM cells was prevented when cells were pretreated with an interleukin (IL)-5-receptor-alpha blocking antibody and 2 ) administration of exogenous ***IL-5*** to naive ( nonsensitized ) ASM cells ***induced*** a pronounced soluble ***ICAM-1*** release from the cells .	target	1
15205	10835320	3568;3383	interleukin (IL)-5-receptor-alpha;ICAM-1	Extended studies further demonstrated that 1 ) the enhanced expression and release of soluble ICAM-1 by atopic sensitized ASM cells was prevented when cells were pretreated with an ***interleukin (IL)-5-receptor-alpha*** blocking antibody and 2 ) administration of exogenous IL-5 to naive ( nonsensitized ) ASM cells ***induced*** a pronounced soluble ***ICAM-1*** release from the cells .	target	1
15206	10835324	3458;1080	interferon-gamma;cystic fibrosis transmembrane conductance regulator	The ***cystic fibrosis transmembrane conductance regulator*** was also ***downregulated*** by ***interferon-gamma*** as evident at the protein level and by the decrease in the cAMP-dependent current .	negative	1
15207	10835326	831;3320	calpain inhibitor;HSP90	Exposure of PAEC to hypoxia also caused time-dependent decreases of heat shock protein 90 ( ***HSP90*** ) that were ***prevented*** by ***calpain inhibitor*** I and calpeptin .	negative	0
15208	10835342	5906;5911	RAP1;RAP2	***RAP1*** ***controls*** rhoptry targeting of ***RAP2*** in the malaria parasite Plasmodium falciparum .	target	0
15209	10835342	5911;5906	RAP2;RAP1	Rhoptry associated protein 1 ( ***RAP1*** ) and 2 ( ***RAP2*** ) , together with a poorly described third protein RAP3 , form the low molecular weight ***complex*** within the rhoptries of Plasmodium falciparum .	parallel	1
15210	10835343	11331;5245	Bap37;prohibitin	Using blue native electrophoresis we have demonstrated that human ***prohibitin*** and ***Bap37*** together form a large ***complex*** in the mitochondrial inner membrane .	parallel	1
15211	10835346	8813;8818	DPM1;DPM2	We reported previously that mammalian DPM synthase contains catalytic DPM1 and regulatory DPM2 subunits , and that ***DPM1*** ***requires*** ***DPM2*** for its stable expression in the endoplasmic reticulum .	target	0
15212	10835346	54344;8813	DPM3;DPM1	However , overexpression of DPM3 in Lec15 cells , a null mutant of DPM2 , restored the biosynthesis of DPM with an increase in DPM1 , indicating that ***DPM3*** directly ***stabilized*** ***DPM1*** .	positive	0
15213	10835346	54344;8813	DPM3;DPM1	Therefore , DPM2 stabilizes DPM3 and ***DPM3*** ***stabilizes*** ***DPM1*** .	positive	0
15214	10835348	2623;24	GATA-1;ATP-binding cassette (ABC) transporter	By subtractive analysis , we identified a new ***ATP-binding cassette (ABC) transporter*** that is strongly and rapidly ***induced*** by ***GATA-1*** .	target	1
15215	10835351	9267;3689	Cytohesin-1;LFA-1	Thus , ***Cytohesin-1*** is involved in the ***activation*** of ***LFA-1*** , most probably through direct interaction with the integrin , and induces cell spreading by its ARF-GEF activity .	positive	1
15216	10835381	10111;4361	Rad50;mre11	This result provides additional evidence on possible involvement of distinctive mechanisms in DNA repair and telomere maintenance by the ******mre11-Rad50-Xrs2****** ***complex*** .	parallel	1
15217	10835386	995;983	Cdc25;Cdc2	***Cdc25*** and Pyp3 phosphatases dephosphorylate tyrosine-15 and ***activate*** ***Cdc2*** .	positive	1
15218	10835420	5777;1500	protein-tyrosine phosphatase SHP-1;p120 catenin	The ***protein-tyrosine phosphatase SHP-1*** ***binds*** to and dephosphorylates ***p120 catenin*** .	parallel	1
15219	10835420	5777;1500	SHP-1;p120	***SHP-1*** ***associated*** transiently with ***p120*** ( ctn ) in EGF-stimulated A431 cells stably transfected with a tetracycline-responsive SHP-1 expression construct , and p120 ( ctn ) exhibited elevated phosphorylation upon a tetracycline-mediated decrease in the SHP-1 level .	parallel	0
15220	10835420	5777;1500	SHP-1;p120	Functions of ***p120*** ( ctn ) , which are regulated by tyrosine phosphorylation , may be ***modulated*** by the described ***SHP-1-p120*** ( ctn ) interaction .	target	0
15221	10835421	4656;859	myogenin;caveolin-3	Transient transfection assays indicated that overexpression of myogenin activates caveolin-3 reporter gene expression , whereas Id2 overexpression inhibited ***caveolin-3*** promoter ***activation*** by ***myogenin*** .	positive	1
15222	10835421	4656;859	myogenin;caveolin-3	Transient transfection assays indicated that overexpression of ***myogenin*** ***activates*** ***caveolin-3*** reporter gene expression , whereas Id2 overexpression inhibited caveolin-3 promoter activation by myogenin .	positive	1
15223	10835421	3398;859	Id2;caveolin-3	Transient transfection assays indicated that overexpression of myogenin activates caveolin-3 reporter gene expression , whereas ***Id2*** overexpression ***inhibited*** ***caveolin-3*** promoter activation by myogenin .	negative	1
15224	10835425	4609;4149	c-Myc;Max	These effects of p202a are consistent with our finding that the binding of p202a to c-Myc inhibited the ***binding*** of ***c-Myc*** to ***Max*** in vitro and in vivo .	parallel	1
15225	10835426	25780;5906	CalDAG-GEFIII;Rap1	***CalDAG-GEFIII*** ***activation*** of Ras , R-ras , and ***Rap1*** .	positive	1
15226	10835485	6777;6776	STAT5B;STAT5A	Thus , the comparison of evolutionary selection pressures resting on various domains suggests that the DNA-binding domain might contribute to differential DNA ***binding*** of ***STAT5A*** and ***STAT5B*** factors , while both might interact equally well with other cellular factors through a segment of the linker domain .	parallel	1
15227	10836206	3589;5266	Interleukin-11;PI-3	***Interleukin-11*** enhancement of VLA-5 mediated adhesion of CD34 + cells from cord blood to fibronectin is ***associated*** with the ***PI-3*** kinase pathway .	parallel	0
15228	10836321	6037;3576	eosinophil cationic protein;interleukin-8	The ***association*** between nasal ***interleukin-8*** and ***eosinophil cationic protein*** in common cold , particularly that observed in nasal lavage fluids after allergen-induced acute exudation of plasma , suggests the involvement of interleukin-8 in exacerbation of airway mucosal eosinophil activity .	parallel	0
15229	10836375	3553;3558	IL-1beta;IL-2	***IL-1beta*** ***enhanced*** ***IL-2*** production and proliferation of allostimulated resting T cells but its presence was not essential .	positive	0
15230	10836381	356;355	FasL;Fas	Dominant tolerance and linked suppression induced by therapeutic antibodies do not depend on ******Fas-FasL****** ***interactions*** .	parallel	1
15231	10836520	6288;1401	SAA;CRP	It was found that ***SAA*** ***correlates*** well with ESR , ***CRP*** , and BASDAI .	parallel	0
15232	10836611	7124;5266	TNF-alpha;SKALP	***TNF-alpha*** and serum ***induce*** ***SKALP/elafin*** gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway .	target	1
15233	10836611	7124;5266	TNF-alpha;SKALP	SB202190 or SB203580 , two specific p38 MAP kinase inhibitors almost completely blocked the ***induction*** of ***SKALP*** expression by ***TNF-alpha*** and serum .	target	1
15234	10836722	3553;7076	IL-1beta;TIMP-1	***TIMP-1*** levels also were significantly ***increased*** by ***IL-1beta*** , and its expression was slightly decreased by amlodipine , not by nifedipine .	positive	0
15235	10836994	3082;2118	HGF;E1AF	These results suggest that ***HGF*** ***induces*** expression of the Ets-related ***E1AF*** transcription factor gene whose product in turn activates MMP genes and leads to oral cancer cell invasion .	target	1
15236	10836994	3082;2078	HGF;Ets-related	These results suggest that ***HGF*** ***induces*** expression of the ***Ets-related*** E1AF transcription factor gene whose product in turn activates MMP genes and leads to oral cancer cell invasion .	target	1
15237	10836994	3082;2118	Hepatocyte growth factor;E1AF	***Hepatocyte growth factor*** ***upregulates*** ***E1AF*** that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes .	positive	1
15238	10836994	3082;2118	HGF;E1AF	***HGF*** ***stimulated*** expression of the ***E1AF*** gene .	positive	0
15239	10837055	8651;6776	CIS1;STAT5	Most of them appear to be induced after stimulation with several different cytokines , and at least three of them ( CIS1 , CIS3/SOCS3 , and JAB/SOCS1 ) negatively regulate cytokine signal transduction by various means : ***CIS1*** ***inhibits*** ***STAT5*** activation by binding to cytokine receptors that recruit STAT5 , whereas JAB/SOCS-1 and CIS3/SOCS-3 directly bind to the kinase domain of JAKs , thereby inhibiting tyrosine-kinase activity .	negative	1
15240	10837055	8651;3458	SSI-1;interferon gamma	Biochemical characterization as well as gene disruption studies indicate that ***JAB/SOCS1/SSI-1*** is an important negative ***regulator*** of ***interferon gamma*** signaling .	negative	1
15241	10837064	1380;930	CD21;CD19	Regulation of B lymphocyte responses to foreign and self-antigens by the ******CD19/CD21****** ***complex*** .	parallel	1
15242	10837141	2091;1655	fibrillarin;p68	Coimmunoprecipitation experiments confirmed that ***p68*** and ***fibrillarin*** can form ***complexes*** in cellular extracts , and deletion analysis identified regions in each protein responsible for mediating the interaction .	parallel	1
15243	10837141	1655;2091	p68;fibrillarin	These data are consistent with a role for p68 either in postmitotic nucleolar reassembly or in the activation of ribosomal DNA transcription/preribosomal RNA processing during telophase and suggest that differential subnuclear compartmentalization may be a mechanism by which ***interaction*** of ***p68*** with ***fibrillarin*** is regulated in the cell .	parallel	1
15244	10837221	25;7015	c-Abl;telomerase catalytic subunit	***Regulation*** of the hTERT ***telomerase catalytic subunit*** by the ***c-Abl*** tyrosine kinase .	target	1
15245	10837225	1020;207	Cdk5;Rac	The ***Cdk5-p35*** complex ***interacts*** with the ***Rac*** GTPase , a protein required for growth cone motility [ 5 ] .	parallel	1
15246	10837225	8851;207	p35;Rac	The ***Cdk5-p35*** complex ***interacts*** with the ***Rac*** GTPase , a protein required for growth cone motility [ 5 ] .	parallel	1
15247	10837225	8851;1020	p35;Cdk5	The ******Cdk5-p35****** ***complex*** interacts with the Rac GTPase , a protein required for growth cone motility [ 5 ] .	parallel	1
15248	10837225	8851;1020	p35;Cdk5	Mutant mice lacking p35 exhibit subtle axon-guidance defects [ 6 ] , but these mice have severe defects in neuronal migration [ 6 ] [ 7 ] [ 8 ] , making it difficult to define precisely the role of the ******Cdk5-p35****** ***complex*** in vivo .	parallel	1
15249	10837245	4342;5609	Mos;MEK	Activation of MAP kinase requires phosphorylation by ***MEK*** , which in turn is ***controlled*** by Raf , ***Mos*** or a group of structurally related kinases termed MEKKs .	target	0
15250	10837247	8837;5594	FLIP;Erk	The caspase-8 inhibitor ***FLIP*** ***promotes*** activation of NF-kappaB and ***Erk*** signaling pathways .	positive	0
15251	10837247	8837;4790	FLIP;NF-kappaB	The caspase-8 inhibitor ***FLIP*** ***promotes*** activation of ***NF-kappaB*** and Erk signaling pathways .	positive	0
15252	10837345	10525;1191	ORP150;clusterin	Exposure of MDCK cells to hypoxia resulted in an increase of ORP150 antigen and increased ***binding*** of ***ORP150*** to ***GP80/clusterin*** ( 80-kDa glycoprotein ) , a natural secretory protein in this cell line .	parallel	1
15253	10837345	10525;3570	ORP150;GP80	Exposure of MDCK cells to hypoxia resulted in an increase of ORP150 antigen and increased ***binding*** of ***ORP150*** to ***GP80/clusterin*** ( 80-kDa glycoprotein ) , a natural secretory protein in this cell line .	parallel	1
15254	10837360	3578;4583	IL-9;MUC2	In vitro , our studies showed that ***IL-9*** also ***induces*** expression of ***MUC2*** and MUC5AC in human primary lung cultures and in the human muccoepidermoid NCI-H292 cell line , indicating a direct effect of IL-9 on inducing mucin expression in these cells .	target	1
15255	10837360	3578;4586	IL-9;MUC5AC	In vitro , our studies showed that ***IL-9*** also ***induces*** expression of MUC2 and ***MUC5AC*** in human primary lung cultures and in the human muccoepidermoid NCI-H292 cell line , indicating a direct effect of IL-9 on inducing mucin expression in these cells .	target	1
15256	10837360	3578;4586	IL-9;mucin	Altogether , these results suggest that ***upregulation*** of ***mucin*** by ***IL-9*** might contribute to the pathogenesis of human inflammatory airway disorders , such as asthma .	positive	1
15257	10837365	7124;3383	TNF-alpha;ICAM-1	***TNF-alpha*** ***enhanced*** ***ICAM-1*** surface expression ( measured by flow cytometry ) and steady-state messenger RNA ( mRNA ) levels ( assessed by Northern hybridization ) in concentration - and time-dependent manners .	positive	0
15258	10837366	2908;3684	Glucocorticoid receptor;CD11b	***Glucocorticoid receptor*** activation ***reduces*** ***CD11b*** and CD49d levels on murine eosinophils : characterization and functional relevance .	negative	1
15259	10837366	2908;3676	Glucocorticoid receptor;CD49d	***Glucocorticoid receptor*** activation ***reduces*** CD11b and ***CD49d*** levels on murine eosinophils : characterization and functional relevance .	negative	1
15260	10837368	834;3606	ICE;IL-18	Interleukin ( IL ) -18 is a recently described cytokine released in its mature , active form after ***pro-IL-18*** is ***cleaved*** by the IL-1 converting enzyme ( ***ICE*** ) .	target	1
15261	10837368	3553;3606	IL-1;IL-18	Interleukin ( IL ) -18 is a recently described cytokine released in its mature , active form after ***pro-IL-18*** is ***cleaved*** by the ***IL-1*** converting enzyme ( ICE ) .	target	1
15262	10837369	3553;1673	IL-1beta;beta-defensin-2	Mucoid Pseudomonas aeruginosa , TNF-alpha , and ***IL-1beta*** , but not IL-6 , ***induce*** human ***beta-defensin-2*** in respiratory epithelia .	target	1
15263	10837369	7124;1673	TNF-alpha;beta-defensin-2	Mucoid Pseudomonas aeruginosa , ***TNF-alpha*** , and IL-1beta , but not IL-6 , ***induce*** human ***beta-defensin-2*** in respiratory epithelia .	target	1
15264	10837404	959;958	CD154;CD40	The influence of ******CD40-CD154****** ***interactions*** on the expressed human V ( H ) repertoire : analysis of V ( H ) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome .	parallel	1
15265	10837404	959;958	CD154;CD40	Analysis of the V ( H ) DJ ( H ) repertoire of peripheral blood IgM ( + ) B cells from a patient with X-linked hyper-IgM syndrome ( X-HIgM ) was undertaken to determine whether the distribution of V ( H ) families in the productive repertoire might be regulated by in vivo ******CD40-CD154****** ***interactions*** .	parallel	1
15266	10837404	959;958	CD154;CD40	These results have suggested that specific influences on the composition of the V ( H ) repertoire in normals require ******CD40-CD154****** ***interactions*** .	parallel	1
15267	10837406	959;958	CD154;CD40	While the critical relevance of this molecule in T cell-dependent B cell activation is already established , the biological role of ******CD40-CD154****** ***interaction*** in non-hematopoietic cells is still unknown .	parallel	1
15268	10837470	1432;836	p38 mitogen-activated protein kinase;caspase-3	***p38 mitogen-activated protein kinase*** ***mediates*** bid cleavage , mitochondrial dysfunction , and ***caspase-3*** activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide .	target	0
15269	10837476	338;335	apoB;apo	Our experiments demonstrated that both mouse ***apoB*** and the human apoB100-C4326G ***bind*** noncovalently to ***apo*** ( a ) .	parallel	1
15270	10837481	183;3091	Angiotensin II;HIF-1alpha	More interestingly , ***Angiotensin II*** ( Ang II ) , thrombin , platelet-derived growth factor , and other hormones can also ***increase*** ***HIF-1alpha*** in VSMC to levels that are substantially more elevated than the hypoxic treatment .	positive	0
15271	10837498	3725;7124	AP-1;TNFalpha	The following observations supported that both NF-kappaB and ***AP-1*** ***mediated*** enhanced ***TNFalpha*** transcription by CHG : 1 ) A 295-base pair fragment of the proximal TNFalpha promoter containing NF-kappaB and AP-1 sites reproduced the effects of CHG on TNFalpha transcription in a luciferase reporter assay , 2 ) mutational analyses of both NF-kappaB and the AP-1 sites abrogated 90 % of the luciferase activity , 3 ) gel-shift analysis using the binding sites showed activation of NF-kappaB and AP-1 in CHG nuclear extracts , and 4 ) Western blot analyses demonstrated elevated nuclear levels of p65 and p50 and decreased cytosolic levels of IkappaBalpha in CHG-treated monocytes .	target	0
15272	10837498	4790;7124	NF-kappaB;TNFalpha	The following observations supported that both ***NF-kappaB*** and AP-1 ***mediated*** enhanced ***TNFalpha*** transcription by CHG : 1 ) A 295-base pair fragment of the proximal TNFalpha promoter containing NF-kappaB and AP-1 sites reproduced the effects of CHG on TNFalpha transcription in a luciferase reporter assay , 2 ) mutational analyses of both NF-kappaB and the AP-1 sites abrogated 90 % of the luciferase activity , 3 ) gel-shift analysis using the binding sites showed activation of NF-kappaB and AP-1 in CHG nuclear extracts , and 4 ) Western blot analyses demonstrated elevated nuclear levels of p65 and p50 and decreased cytosolic levels of IkappaBalpha in CHG-treated monocytes .	target	0
15273	10837918	7471;4803	Wnt-1;NGF	***Wnt-1*** expression also partially ***blocked*** the ability of ***NGF*** to decrease the rate of cell multiplication .	negative	0
15274	10837918	7471;3164	Wnt-1;Nur77	***Wnt-1*** ***decreased*** the NGF-induced expression of the late-response gene SCG10 but not of the immediate early genes , fos , ***Nur77*** and UPAR ( urokinase-type plasminogen activator receptor ) nor of the late-response genes GAP-43 and collagenase .	negative	0
15275	10837918	7471;11075	Wnt-1;SCG10	***Wnt-1*** ***decreased*** the NGF-induced expression of the late-response gene ***SCG10*** but not of the immediate early genes , fos , Nur77 and UPAR ( urokinase-type plasminogen activator receptor ) nor of the late-response genes GAP-43 and collagenase .	negative	0
15276	10837918	7471;5329	Wnt-1;UPAR	***Wnt-1*** ***decreased*** the NGF-induced expression of the late-response gene SCG10 but not of the immediate early genes , fos , Nur77 and ***UPAR*** ( urokinase-type plasminogen activator receptor ) nor of the late-response genes GAP-43 and collagenase .	negative	0
15277	10838074	10454;65268	TAB1;mitogen-activated protein kinase kinase kinase	Phosphorylation-dependent ***activation*** of TAK1 ***mitogen-activated protein kinase kinase kinase*** by ***TAB1*** .	positive	1
15278	10838075	4609;1843	c-Myc;mkp-1	Synergistic ***activation*** of the ***mkp-1*** gene by protein kinase A signaling and USF , but not ***c-Myc*** .	positive	1
15279	10838081	2185;7041	CAKbeta;Hic-5	***Phosphorylation*** of ***Hic-5*** at tyrosine 60 by ***CAKbeta*** and Fyn .	target	1
15280	10838081	2534;7041	Fyn;Hic-5	***Phosphorylation*** of ***Hic-5*** at tyrosine 60 by CAKbeta and ***Fyn*** .	target	1
15281	10838081	2185;7041	CAKbeta;Hic-5	Coexpression experiments revealed that the phosphorylation of Hic-5 by CAKbeta required the kinase activation of CAKbeta and ***binding*** of ***Hic-5*** by ***CAKbeta*** .	parallel	1
15282	10838081	2185;7041	CAKbeta;Hic-5	Coexpression experiments revealed that the ***phosphorylation*** of ***Hic-5*** by ***CAKbeta*** required the kinase activation of CAKbeta and binding of Hic-5 by CAKbeta .	target	1
15283	10838081	2185;7041	CAKbeta;Hic-5	Specific ***phosphorylation*** of ***Hic-5*** by ***CAKbeta*** and Fyn may activate a signaling pathway mediated by Hic-5 .	target	1
15284	10838081	2534;7041	Fyn;Hic-5	Specific ***phosphorylation*** of ***Hic-5*** by CAKbeta and ***Fyn*** may activate a signaling pathway mediated by Hic-5 .	target	1
15285	10838160	7040;7422	TGF-beta1;vascular endothelial growth factor	In this study , we found that the addition of ***TGF-beta1*** to murine osteoblastic MC3T3-E1 cells ***induced*** ***vascular endothelial growth factor*** ( VEGF ) mRNA production .	target	1
15286	10838162	6464;2885	Shc;Grb2	In addition , there is an increased ***association*** between the ***Grb2*** protein and ***Shc*** proteins upon PRL stimulation .	parallel	0
15287	10838500	2100;2099	ER-beta;ER-alpha	In conclusion , the intact synchronized expression of ***ER-beta*** mRNA ***interacting*** with ***ER-alpha*** mRNA might be damaged in some ovarian cancers , which might lead to poor patient prognosis .	parallel	1
15288	10838501	2028;5111	AP-A;proliferating cell nuclear antigen	In addition , ***AP-A*** immunoreactivity was significantly ***correlated*** with ***proliferating cell nuclear antigen*** expression in both CIN and SCC cases .	parallel	0
15289	10838806	4683;4361	NBS1;hMRE11	Like yeast Xrs2 , the ***NBS1*** protein forms a ***complex*** with ***hRAD50/hMRE11*** , and the complex is condensed as foci in the nucleus after irradiation , indicative that this triple-complex is a crucial factor in DNA repair .	parallel	1
15290	10838806	4683;10111	NBS1;hRAD50	Like yeast Xrs2 , the ***NBS1*** protein forms a ***complex*** with ***hRAD50/hMRE11*** , and the complex is condensed as foci in the nucleus after irradiation , indicative that this triple-complex is a crucial factor in DNA repair .	parallel	1
15291	10839362	1742;2066	PSD-95;ErbB4	Regulation of neuregulin signaling by ***PSD-95*** ***interacting*** with ***ErbB4*** at CNS synapses .	parallel	1
15292	10839362	1742;2066	PSD-95;ErbB4	***PSD-95*** formed a ternary ***complex*** with two molecules of ***ErbB4*** , suggesting that PSD-95 facilitates ErbB4 dimerization .	parallel	1
15293	10839362	1742;2066	PSD-95;ErbB4	PSD-95 formed a ternary complex with two molecules of ErbB4 , suggesting that ***PSD-95*** ***facilitates*** ***ErbB4*** dimerization .	positive	0
15294	10839371	4804;2247	p75NTR;bFGF	Blockade of ***p75NTR*** ***prevented*** ***bFGF*** reduction and resulted in both structural and functional photoreceptor survival in vivo .	positive	0
15295	10839543	8517;4790	NEMO;NF-kappaB	The gene for ***NEMO*** ( ***NF-kappaB*** essential ***modulator*** ) / IKKgamma ( IkappaB kinase-gamma ) has been mapped to a position 200 kilobases proximal to the factor VIII locus .	target	0
15296	10839544	4683;472	NBS1;ATM	Here we show that phosphorylation of ***NBS1*** , induced by ionizing radiation , ***requires*** catalytically active ***ATM*** .	target	0
15297	10839591	7124;4843	TNF-alpha;iNOS	In the relationship between cardiomyopathy and encephalopathy , the ***activation*** of ***iNOS*** by ***TNF-alpha*** may have a significant pathogenetic role in HIV disease .	positive	1
15298	10839631	7039;2353	transforming growth factor-alpha;c-fos	Epidermal growth factor and ***transforming growth factor-alpha*** treatment ***induced*** ***c-fos*** mRNA and c-myc protein expression .	target	1
15299	10839631	7039;4609	transforming growth factor-alpha;c-myc	Epidermal growth factor and ***transforming growth factor-alpha*** treatment ***induced*** c-fos mRNA and ***c-myc*** protein expression .	target	1
15300	10839631	7039;1956	transforming growth factor-alpha;epidermal growth factor receptor	The ***induction*** of downstream targets of the ***epidermal growth factor receptor*** by epidermal growth factor and ***transforming growth factor-alpha*** indicates a functional epidermal growth factor signal transduction pathway in elongating bovine blastocysts .	target	1
15301	10839814	2204;2207	CD89;FcRgamma	This release was independent of ***CD89*** ***association*** with the ***FcRgamma*** chain .	parallel	0
15302	10839815	959;958	CD40 ligand;CD40	******CD40-CD40 ligand****** ***interactions*** in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes .	parallel	1
15303	10839815	959;958	CD40 ligand;CD40	Whereas ******CD40-CD40 ligand****** ***interactions*** are important for various dendritic cell ( DC ) functions in vitro , their in vivo relevance is unknown .	parallel	1
15304	10839815	958;959	CD40;CD40 ligand	Thus , ******CD40-CD40 ligand****** ***interactions*** in vivo regulate the migration of antigen-bearing DCs from the skin to DLNs via TNF-alpha production and play a vital role in the initiation of acquired T cell-mediated immunity .	parallel	1
15305	10839965	356;355	FasL;Fas	We sought to investigate its mechanism of action and determine if it is ***Fas*** ***ligand*** ( ***FasL*** ) - mediated .	parallel	1
15306	10839991	4790;4092	NF-kappaB;Smad7	Interestingly , we found that the ***Smad7*** promoter was also ***regulated*** by nuclear factor kappaB ( ***NF-kappaB*** ) , a transcription factor which plays an important role in inflammation and the immune response .	target	1
15307	10839991	4790;4092	NF-kappaB;Smad7	Activation of endogenous ***NF-kappaB*** by tumour necrosis factor-alpha ( TNF-alpha ) was also able to ***inhibit*** the ***Smad7*** promoter in human embryonic kidney 293 cells .	negative	1
15308	10839991	7124;4790	TNF-alpha;NF-kappaB	***Activation*** of endogenous ***NF-kappaB*** by tumour necrosis factor-alpha ( ***TNF-alpha*** ) was also able to inhibit the Smad7 promoter in human embryonic kidney 293 cells .	positive	1
15309	10839991	2033;4790	p300;NF-kappaB	Furthermore , overexpression of the transcription co-activator ***p300*** could ***abrogate*** the inhibitory effect of ***NF-kappaB*** on the Smad7 promoter .	negative	0
15310	10840014	5599;836	JNK1;caspase-3	Furthermore , we found that ***JNK1*** specific antisense oligonucleotide could ***suppress*** ***caspase-3*** activity but not affect H ( 2 ) O ( 2 ) generation and could block apoptosis induced by high glucose .	negative	1
15311	10840014	5599;836	JNK;caspase-3	CONCLUSIONS : The present study indicates that reactive oxygen species induced by high glucose may be involved in ***JNK*** activation , which in turn ***triggers*** the ***caspase-3*** that facilitates the apoptosis in HUVECs .	positive	0
15312	10840031	6000;8802	RGS7;Galpha	However , in transfected cells , RGS7 and Gbeta ( 5 ) - ***RGS7*** ***inhibited*** ***Galpha*** ( q ) - mediated Ca ( 2 + ) response to muscarinic M3 receptor activation .	negative	1
15313	10840033	2099;5970	ERalpha;RelA	Both ***ERalpha*** and ERbeta ***inhibit*** ***RelA*** in response to 17beta-estradiol but not in the presence of antihormones .	negative	1
15314	10840033	2100;5970	ERbeta;RelA	Both ERalpha and ***ERbeta*** ***inhibit*** ***RelA*** in response to 17beta-estradiol but not in the presence of antihormones .	negative	1
15315	10840064	1058;8337	CENP-A;H2A	Thus , we conclude that ***CENP-A*** forms an octameric ***complex*** with histones H4 , ***H2A*** , and H2B in the presence of DNA .	parallel	1
15316	10840064	1058;8349	CENP-A;H2B	Thus , we conclude that ***CENP-A*** forms an octameric ***complex*** with histones H4 , H2A , and ***H2B*** in the presence of DNA .	parallel	1
15317	10840163	1437;4313	Granulocyte-macrophage colony-stimulating factor;matrix metalloproteinase-2	***Granulocyte-macrophage colony-stimulating factor*** ***upregulates*** ***matrix metalloproteinase-2*** ( MMP-2 ) and membrane type-1 MMP ( MT1-MMP ) in human head and neck cancer cells .	positive	1
15318	10840163	1437;4323	Granulocyte-macrophage colony-stimulating factor;MT1-MMP	***Granulocyte-macrophage colony-stimulating factor*** ***upregulates*** matrix metalloproteinase-2 ( MMP-2 ) and membrane type-1 MMP ( ***MT1-MMP*** ) in human head and neck cancer cells .	positive	1
15319	10840163	1437;4313	GM-CSF;MMP-2	We hypothesized that ***GM-CSF*** may ***upregulate*** ***MMP-2*** and/or MT1-MMP expression in HNSCC cells , and may thereby influence their ability to invade and metastasize .	positive	1
15320	10840163	1437;4323	GM-CSF;MT1-MMP	We hypothesized that ***GM-CSF*** may ***upregulate*** MMP-2 and/or ***MT1-MMP*** expression in HNSCC cells , and may thereby influence their ability to invade and metastasize .	positive	1
15321	10840461	2952;2944	GSTT1;GSTM1	Also , we could not find any ***association*** between ***GSTM1*** , ***GSTT1*** , slow acetylator genotypes and bladder cancer risk among smokers .	parallel	0
15322	10840944	9112;3065	MTA1;HDAC1	Coimmunoprecipitation of myc-tagged MTA1 and FLAG-tagged histone deacetylase 1 ( HDAC1 ) , followed by western blot analysis using anti-myc and anti-FLAG monoclonal antibodies showed that ***MTA1*** physically ***bound*** with ***HDAC1*** in COS-7 cells .	parallel	1
15323	10841026	5594;4286	ERK2;MITF	MAP kinase , ***ERK2*** , ***phosphorylates*** ***MITF*** , thereby targeting the transcription factor to proteasomes for degradation .	target	1
15324	10841072	356;355	FasL;Fas	This article reviews advances in the study of the molecular mechanisms for ultraviolet ( UV ) - induced keratinocyte apoptosis , with particular reference to the cytokines tumor necrosis factor-alpha ( TNF-alpha ) and ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
15325	10841078	3569;7066	Interleukin-6;thrombopoietin	***Interleukin-6*** ***increases*** ***thrombopoietin*** production in human hepatoma cells HepG2 and Hep3B .	positive	0
15326	10841080	3791;7422	Flk-1;VEGF	******VEGF/Flk-1****** ***interaction*** , a requirement for malignant ascites recurrence .	parallel	1
15327	10841080	7422;3791	VEGF;Flk-1	These data demonstrate that the observed inhibitory effect of TNF on reestablishment of malignant ascites can be achieved equally by inhibition of the ***interaction*** of ***VEGF*** with its receptor ***Flk-1*** .	parallel	1
15328	10841183	3553;5743	IL-1;PGHS-2	Overexpression of p20C/EBPbeta , a dominant negative inhibitor of C/EBP function , blocked the ***stimulation*** of ***PGHS-2*** promoter activity by ***IL-1*** and blocked the ability of overexpressed C/EBPbeta and C/EBPdelta to increase basal and IL-1-stimulated promoter activity .	positive	0
15329	10841183	3553;5743	IL-1;PGHS-2	Mutagenesis of the C/EBP site reduced , but did not abolish , the ***stimulation*** of ***PGHS-2*** promoter activity by ***IL-1*** and blunted the effect of overexpressed C/EBPdelta on basal and IL-1-stimulated promoter activity .	positive	0
15330	10841183	3553;5743	IL-1;PGHS-2	These results suggest an essential role for C/EBPbeta and C/EBPdelta in the ***induction*** of ***PGHS-2*** gene expression by ***IL-1*** in osteoblastic cells .	target	1
15331	10841183	1052;1051	C/EBPdelta;C/EBPbeta	This region contains a putative CCAAT enhancer binding protein ( C/EBP ) site ( centered at -135 bp ) , which shows enhanced ***binding*** of ***C/EBPbeta*** and ***C/EBPdelta*** by mobility shift analysis after IL-1 treatment .	parallel	1
15332	10841356	5298;23413	phosphatidylinositol 4-kinase beta;neuronal calcium sensor-1	***neuronal calcium sensor-1*** ( NCS-1 ) and its putative ***substrate*** ***phosphatidylinositol 4-kinase beta*** ( PtdIns 4-kinase beta ) both indirectly regulate synaptic vesicle exocytosis and are located in DRG neurites .	parallel	1
15333	10841362	5173;3558	Leu-enkephalin;IL-2	***Leu-enkephalin*** induced by IL-2 administration ***mediates*** analgesic effect of ***IL-2*** .	target	0
15334	10841521	958;959	CD40;CD40L	Melanoma immunotherapy by targeted IL-2 depends on CD4 ( + ) T-cell help mediated by ******CD40/CD40L****** ***interaction*** .	parallel	1
15335	10841521	959;958	CD40L;CD40	A novel , humanized anti-ganglioside-GD ( 2 ) - IL-2 immunocytokine ( hu14.18-IL-2 ) induced CD8 ( + ) T cells to eradicate established pulmonary metastases of B78-D14 murine melanoma , in a process that required help by CD4 ( + ) T cells and was mediated by the ***CD40/CD40*** ***ligand*** ( ***CD40L*** ) interaction .	parallel	1
15336	10841521	958;959	CD40;CD40L	Three lines of evidence show that CD4 ( + ) T-cell help was mediated by ******CD40/CD40L****** ***interaction*** but not by endogenous IL-2 production .	parallel	1
15337	10841521	958;959	CD40;CD40L	These results suggest that help provided by CD4 ( + ) T cells via ******CD40/CD40L****** ***interactions*** in our tumor model is crucial for effective immunotherapy with an IL-2 immunocytokine .	parallel	1
15338	10841543	6667;3949	Sp1;LDL receptor	Our results also provide key in vivo support for the mechanism proposed from cell-free experiments , where SREBP increased the ***binding*** of ***Sp1*** to the ***LDL receptor*** promoter .	parallel	1
15339	10841761	914;962	CD2;CD48	The implications of these observations are discussed with respect to recent structural and functional analyses of the ***interaction*** of rat ***CD2*** with ***CD48*** .	parallel	1
15340	10841894	6285;627	s100beta;brain-derived neurotrophic factor	Trophic ***interactions*** between ***brain-derived neurotrophic factor*** and ***s100beta*** on cultured serotonergic neurons .	parallel	1
15341	10841894	627;6285	BDNF;s100beta	***BDNF*** ( 50 ng/ml ) treatment for 3 h ***enhanced*** ***s100beta*** immunoreactivity in both raphe and hippocampal glial cells .	positive	0
15342	10841894	6285;627	s100beta;BDNF	Our results suggest that ***BDNF*** and ***s100beta*** , which regulate different signal transduction cascades , ***interact*** to exert complimentary effects on neuronal maturation by acting sequentially , not concurrently .	parallel	1
15343	10841915	183;7040	angiotensin II;TGF-beta1	Interestingly , it could be demonstrated that ***angiotensin II*** also ***stimulates*** ***TGF-beta1*** production possibly via the same signal transduction pathway .	positive	0
15344	10841945	356;355	FasL;Fas	These results suggest that FDC may play a role in the apoptosis of germinal center B cells via ******Fas-FasL****** ***interaction*** .	parallel	1
15345	10842075	9353;6091	Slit2;Robo1	***Slit2*** has been shown to ***bind*** ***Robo1*** , mediating both neuronal and axonal guidance in the developing central nervous system ( CNS ) , ( Brose et al. , 1999 ; Hu , H. , 1999 .	parallel	1
15346	10842084	8646;7040	chordin;TGFbeta	Crim1 contains an IGF-binding protein motif and multiple cysteine-rich repeats , analogous to those of ***chordin*** and short gastrulation ( sog ) proteins that ***associate*** with ***TGFbeta*** superfamily members , namely Bone Morphogenic Protein ( BMP ) .	parallel	0
15347	10842092	3725;2353	AP1;c-fos	***AP1*** , a ***heterodimer*** of ***c-fos/c-JUN*** , functions as a transcription factor of downstream gene ( s ) .	parallel	1
15348	10842166	1958;2353	Egr1;AP-1	The results show that Egr1 can activate TH transcription and reveals ***cross-talk*** between ***Sp1/Egr1*** and ***AP-1*** factors .	parallel	0
15349	10842172	5606;1432	MKK3;p38	Treatment with pharmacological inhibitors of p38 MAPK or with a dominant negative form of ***MKK3*** , an upstream ***regulator*** of ***p38*** MAPK , significantly reduced or ablated the sorbitol induction of sgk promoter activity or protein production .	target	1
15350	10842180	5621;23627	PrP;Dpl	Biochemical and structural similarities between PrP ( C ) and Dpl documented here parallel the observation that ataxic Ngsk Prnp ( 0/0 ) mice can be rescued by overexpression of wild-type PrP transgenes , and suggest that cell surface ***PrP*** ( C ) can ***antagonize*** the toxic effect of ***Dpl*** expressed in the central nervous system .	negative	1
15351	10842181	2321;7422	flt-1;vascular endothelial growth factor	The interaction of neuropilin-1 with ***vascular endothelial growth factor*** and its ***receptor*** ***flt-1*** .	parallel	1
15352	10842181	8829;2321	neuropilin-1;flt-1	The ***interaction*** of ***neuropilin-1*** with vascular endothelial growth factor and its receptor ***flt-1*** .	parallel	1
15353	10842181	8829;7422	neuropilin-1;vascular endothelial growth factor	The ***interaction*** of ***neuropilin-1*** with ***vascular endothelial growth factor*** and its receptor flt-1 .	parallel	1
15354	10842183	9311;40	ASIC3;ASIC2a	Biochemical ***interaction*** between ***ASIC2a*** and ***ASIC3*** subunits was demonstrated by co-purification from transfected human embryonic kidney ( HEK293 ) cells and Xenopus oocytes .	parallel	1
15355	10842184	3717;2690	JAK2;growth hormone receptor	Negative regulation of ******growth hormone receptor/JAK2****** ***signaling*** by signal regulatory protein alpha .	parallel	0
15356	10842184	2690;3717	GHR;JAK2	GH-dependent tyrosyl phosphorylation of JAK2 is reduced when wild-type SIRPalpha1 compared with SIRPalpha1 lacking the four cytoplasmic tyrosines ( SIRP 4YF ) is expressed in cells , suggesting that SIRPalpha1 negatively regulates ******GHR/JAK2****** ***signaling*** .	parallel	0
15357	10842184	2690;3717	GHR;JAK2	These results suggest that SIRPalpha1 is a negative regulator of GH signaling and that the ability of SIRPalpha1 mutants to negatively regulate ******GHR-JAK2****** ***signaling*** correlates with their ability to bind SHP-2 .	parallel	0
15358	10842185	7157;174	p53;AFP	By utilizing in vitro chromatin assembly of DNA templates prior to transcription analysis , we have demonstrated that HBx functionally disrupts ***p53-mediated*** ***repression*** of ***AFP*** transcription through protein-protein interaction .	negative	1
15359	10842185	7157;174	p53;AFP	Our data suggest that the mechanism by which HBx alleviates ***p53*** ***repression*** of ***AFP*** transcription is through an association with DNA-bound p53 , resulting in a loss of p53 interaction with liver-specific transcriptional co-repressors .	negative	1
15360	10842245	3458;4804	IFN-gamma;NGF receptor	CONCLUSIONS : ***IFN-gamma*** could ***induce*** the functional ***NGF receptor*** even in the aggressive phenotype of NB .	target	1
15361	10842245	3458;4914	interferon-gamma;TrkA	Neuronal differentiation in human neuroblastoma cells by nerve growth factor following ***TrkA*** ***up-regulation*** by ***interferon-gamma*** .	positive	1
15362	10842245	3458;4914	interferon-gamma;TrkA	Previously , we found that ***interferon-gamma*** ( IFN-gamma ) can ***enhance*** ***TrkA*** mRNA expression in NB cell lines .	positive	0
15363	10842319	3717;1493	Jak2;CTLA-4	Here , we demonstrated that 1 ) Janus kinase 2 ( Jak2 ) was directly associated with a box 1-like motif in the cytoplasmic tail of CTLA-4 molecule , 2 ) Jak2 phosphorylated Y-165 residue in the cytoplasmic region of CTLA-4 molecule , and 3 ) ***Jak2*** was ***associated*** with ***CTLA-4*** in HUT 78 T cell lines .	parallel	0
15364	10842362	627;4915	BDNF;TrkB	Thus , in terms of the survival outcome , two main subpopulations of TMN neurons may exist during embryogenesis , one dependent on TrkC/NT3 functioning and the other utilizing ******TrkB/BDNF****** ***signaling*** .	parallel	0
15365	10842659	1050;5468	C/EBP alpha;PPAR gamma	Furthermore , ectopic expression of ***C/EBP alpha*** in NIH-3T3 cells ***induces*** ***PPAR gamma*** expression and adipogenesis , but also restores insulin-sensitive glucose transport .	target	1
15366	10843179	3953;3952	OB-R;leptin	leptin is secreted by adipocytes and regulates appetite through interaction with hypothalamic ***leptin*** ***receptors*** ( ***OB-R*** ) .	parallel	1
15367	10843380	643;10563	CXCR5;B lymphocyte chemoattractant	***CXCR5*** , the ***receptor*** for ***B lymphocyte chemoattractant*** ( BLC ) , is required for normal development of Peyer 's patches , inguinal lymph nodes , and splenic follicles .	parallel	1
15368	10843388	5880;207	Rac2;Akt	***Rac2*** ***stimulates*** ***Akt*** activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells .	positive	0
15369	10843390	834;3606	Caspase-1;IL-18	***Caspase-1*** ***activation*** of IL-1beta and ***IL-18*** are essential for Shigella flexneri-induced inflammation .	positive	1
15370	10843390	834;3553	Caspase-1;IL-1beta	***Caspase-1*** ***activation*** of ***IL-1beta*** and IL-18 are essential for Shigella flexneri-induced inflammation .	positive	1
15371	10843427	1432;6352	p38 mitogen-activated protein (MAP) kinase;RANTES	BACKGROUND : We have previously shown that ***p38 mitogen-activated protein (MAP) kinase*** ***regulates*** tumor necrosis factor-alpha ( TNF-alpha ) - induced ***RANTES*** production by human pulmonary vascular endothelial cells , and that sensitivity to TNF-alpha is inversely correlated with cellular reduction and oxidation ( redox ) state .	target	1
15372	10843427	1432;7124	p38 mitogen-activated protein (MAP) kinase;TNF-alpha	BACKGROUND : We have previously shown that ***p38 mitogen-activated protein (MAP) kinase*** ***regulates*** tumor necrosis factor-alpha ( ***TNF-alpha*** ) - induced RANTES production by human pulmonary vascular endothelial cells , and that sensitivity to TNF-alpha is inversely correlated with cellular reduction and oxidation ( redox ) state .	target	1
15373	10843656	4179;27040	CD46;LAT	Cutting edge : ***CD46*** , a new costimulatory molecule for T cells , that ***induces*** p120CBL and ***LAT*** phosphorylation .	target	1
15374	10843656	4179;718	CD46;C3b	The widely expressed transmembrane molecule ***CD46*** is the complement regulatory ***receptor*** for ***C3b*** as well as the receptor for several pathogens .	parallel	1
15375	10843656	4179;27040	CD46;linker for activation of T cells	We showed that ***CD46*** aggregation on human T cells ***induces*** p120CBL and ***linker for activation of T cells*** ( LAT ) phosphorylation .	target	1
15376	10843663	958;959	CD40;CD40L	Kinetic studies showed that IL-2 was required throughout the culture period for maximal autoantibody production and that both MHC-TCR and ******CD40-CD40L****** ***interactions*** were essential during the early phase of the culture .	parallel	1
15377	10843666	7040;4843	TGF-beta1;inducible NO synthase	Macrophage ***TGF-beta1*** , which ***inhibits*** ***inducible NO synthase*** and stimulates arginase , appears to play an important role in regulating the balance between M-1 and M-2 .	negative	1
15378	10843667	6347;4312	MCP-1;MMP-1	These data demonstrate that ***MCP-1*** ***up-regulates*** ***MMP-1*** mRNA expression and synthesis in human skin fibroblasts at a transcriptional level and provide evidence that this is mediated by an IL-1 alpha autocrine loop .	positive	1
15379	10843667	6347;4312	Monocyte chemoattractant protein-1;matrix metalloproteinase-1	***Monocyte chemoattractant protein-1*** ***enhances*** gene expression and synthesis of ***matrix metalloproteinase-1*** in human fibroblasts by an autocrine IL-1 alpha loop .	positive	0
15380	10843667	6347;4312	MCP-1;MMP-1	***MMP-1*** mRNA was ***induced*** by ***MCP-1*** ( 10 ng/ml ) as early as 6 h and reached a maximal expression at 24 h.	target	1
15381	10843667	6347;7076	MCP-1;tissue inhibitor of metalloproteinase-1	Interestingly , ***tissue inhibitor of metalloproteinase-1*** ( TIMP-1 ) mRNA was also ***up-regulated*** by ***MCP-1*** , and TIMP-1 mRNA expression peaked at 48 h in both types of fibroblasts .	positive	1
15382	10843667	6347;3552	MCP-1;IL-1 alpha	In addition , ***MCP-1*** strongly ***induced*** ***IL-1 alpha*** mRNA expression in dermal fibroblasts in parallel with the induction of MMP-1 .	target	1
15383	10843668	7133;3554	TNFR2;p80	The effect is mediated via the ***p80*** type II TNF ***receptor*** ( ***TNFR2*** ) , which induces NF-kappaB among other factors , leading to an enhanced secretion of the chemokines macrophage-inflammatory protein-1alpha , macrophage-inflammatory protein-1beta , and RANTES .	parallel	1
15384	10843668	7133;4790	TNFR2;NF-kappaB	The effect is mediated via the p80 type II TNF receptor ( ***TNFR2*** ) , which ***induces*** ***NF-kappaB*** among other factors , leading to an enhanced secretion of the chemokines macrophage-inflammatory protein-1alpha , macrophage-inflammatory protein-1beta , and RANTES .	target	1
15385	10843677	3558;5594	IL-2;ERK	***IL-2*** ***stimulates*** extracellular signal-regulated protein kinase ( ***ERK*** ) and p38 mitogen-activated protein kinase ( MAPK ) in various immune cell populations .	positive	0
15386	10843677	3558;1432	IL-2;p38 mitogen-activated protein kinase	***IL-2*** ***stimulates*** extracellular signal-regulated protein kinase ( ERK ) and ***p38 mitogen-activated protein kinase*** ( MAPK ) in various immune cell populations .	positive	0
15387	10843677	3558;5594	IL-2;ERK	***IL-2*** ***induced*** ***ERK*** activation within 5 min .	target	1
15388	10843677	3558;5594	IL-2;p38	***Activation*** of ***p38*** MAPK by ***IL-2*** was not detected in NK cells .	positive	1
15389	10843686	3458;6373	IFN-gamma;I-TAC	Murine ***I-TAC*** mRNA is ***induced*** in RAW 264.7 macrophages by ***IFN-gamma*** or LPS and is weakly induced by IFN-alphabeta .	target	1
15390	10843686	3458;6373	IFN-gamma;I-TAC	***IFN-gamma*** ***induction*** of murine ***I-TAC*** is markedly enhanced by costimulation with LPS or IL-1beta in RAW cells and by TNF-alpha in both RAW cells and Swiss 3T3 fibroblasts .	target	1
15391	10843690	5320;4790	sPLA2;NF-kappa B	Furthermore , EMSA analysis of the activation of the NF-kappa B involved in iNOS induction demonstrated that pyrrolidinedithiocarbamate prevented the ***NF-kappa B*** ***binding*** by ***sPLA2*** plus LPS .	parallel	1
15392	10843692	3565;5450	IL-4;OCA-B	Furthermore , we demonstrate that ***IL-4*** and anti-CD40 ***induce*** both the ***OCA-B*** promoter and octamer-dependent promoters , thus implicating OCA-B in B cell signaling events in the nucleus .	target	1
15393	10843711	2212;5594	Fc gamma RIIa;ERK	***Fc gamma RIIa*** and Fc gamma RIIIb ***stimulated*** distinct patterns of ***ERK*** and p38 activity , and heterotypic cross-linking failed to stimulate synergistic activation of either ERK or p38 activity .	positive	0
15394	10843711	2215;5594	Fc gamma RIIIb;ERK	Fc gamma RIIa and ***Fc gamma RIIIb*** ***stimulated*** distinct patterns of ***ERK*** and p38 activity , and heterotypic cross-linking failed to stimulate synergistic activation of either ERK or p38 activity .	positive	0
15395	10843711	2212;5594	Fc gamma RIIa;p38	Our data indicate that ***Fc gamma RIIa*** and Fc gamma RIIIb independently ***activate*** ERK and ***p38*** .	positive	1
15396	10843711	2215;5594	Fc gamma RIIIb;p38	Our data indicate that Fc gamma RIIa and ***Fc gamma RIIIb*** independently ***activate*** ERK and ***p38*** .	positive	1
15397	10843719	958;959	CD40;CD40 ligand	Increased CD40 expression on muscle cells of polymyositis and dermatomyositis : role of ******CD40-CD40 ligand****** ***interaction*** in IL-6 , IL-8 , IL-15 , and monocyte chemoattractant protein-1 production .	parallel	1
15398	10843719	3458;958	IFN-gamma;CD40	***IFN-gamma*** , which is known to ***induce*** ***CD40*** expression on various types of cells , was also expressed on the MNCs in four of the PM and four of the DM patients .	target	1
15399	10843719	3458;958	IFN-gamma;CD40	Although cultured human myoblasts ( SkMC 2859 ) did not express CD40 constitutively , ***IFN-gamma*** ***induced*** ***CD40*** expression in a dose-dependent manner .	target	1
15400	10843719	959;3600	CD40L;IL-15	Recombinant human ***CD40L*** markedly ***increased*** the production of IL-6 , IL-8 , ***IL-15*** , and monocyte chemoattractant protein-1 of SkMC 2859 .	positive	0
15401	10843719	959;6347	CD40L;monocyte chemoattractant protein-1	Recombinant human ***CD40L*** markedly ***increased*** the production of IL-6 , IL-8 , IL-15 , and ***monocyte chemoattractant protein-1*** of SkMC 2859 .	positive	0
15402	10843723	959;958	CD154;CD40	Our findings support the critical role of ******CD40/CD154****** ***interactions*** for the induction of cellular immune responses .	parallel	1
15403	10843724	3606;3586	IL-18;IL-10	The addition of recombinant human ***IL-18*** to the culture concentration-dependently stimulated IL-12 and IFN-gamma production and ***inhibited*** the IL-2 and ***IL-10*** production .	negative	1
15404	10843724	3606;3558	IL-18;IL-2	The addition of recombinant human ***IL-18*** to the culture concentration-dependently stimulated IL-12 and IFN-gamma production and ***inhibited*** the ***IL-2*** and IL-10 production .	negative	1
15405	10843724	3606;3458	IL-18;IFN-gamma	The addition of recombinant human ***IL-18*** to the culture concentration-dependently ***stimulated*** IL-12 and ***IFN-gamma*** production and inhibited the IL-2 and IL-10 production .	positive	0
15406	10843732	3565;596	IL-4;BCL-2	***IL-4-dependent*** ***induction*** of ***BCL-2*** and BCL-X ( L ) IN activated T lymphocytes through a STAT6 - and pi 3-kinase-independent pathway .	target	1
15407	10843732	3565;598	IL-4;BCL-X	***IL-4-dependent*** ***induction*** of BCL-2 and ***BCL-X*** ( L ) IN activated T lymphocytes through a STAT6 - and pi 3-kinase-independent pathway .	target	1
15408	10843732	3565;598	IL-4;Bcl-2/X	These results demonstrate that both the STAT6 and PI 3-kinase pathways can be dispensable for ***Bcl-2/X*** ***induction*** by ***IL-4*** , thus suggesting the involvement of an additional signal transduction pathway .	target	1
15409	10843734	7040;3569	TGF-beta1;interleukin 6	Both activin-A and ***TGF-beta1*** ***inhibited*** the in vitro production of ***interleukin 6*** by thymocytes in the presence of phytohemagglutinin and interleukin 1beta .	negative	1
15410	10843735	3553;5743	IL-1beta;COX-2	***IL-1beta*** also ***stimulated*** expression of cPLA ( 2 ) and ***COX-2*** only , while constitutive and IL-1beta-induced type IIA and type V secretory PLA ( 2 ) s ( sPLA ( 2 ) s ) expression could not be detected .	positive	0
15411	10843737	3552;3067	IL-1alpha;HDC	Recombinant ***IL-1alpha*** , IL-1beta , MCP-1 and RANTES all failed to ***induce*** ***HDC*** mRNA expression in the preimplantation uterus in a mouse pseudopregnancy model .	target	1
15412	10843737	3553;3067	IL-1beta;HDC	Recombinant IL-1alpha , ***IL-1beta*** , MCP-1 and RANTES all failed to ***induce*** ***HDC*** mRNA expression in the preimplantation uterus in a mouse pseudopregnancy model .	target	1
15413	10843737	6347;3067	MCP-1;HDC	Recombinant IL-1alpha , IL-1beta , ***MCP-1*** and RANTES all failed to ***induce*** ***HDC*** mRNA expression in the preimplantation uterus in a mouse pseudopregnancy model .	target	1
15414	10843752	3458;2353	IFN-gamma;c-fos	In contrast , the expression of JunB , c-jun and ***c-fos*** , but not JunD , was ***increased*** by LPS , TNF-alpha , ***IFN-gamma*** and IL-1 , albeit with different kinetics and magnitude of induction .	positive	0
15415	10843752	3458;3725	IFN-gamma;c-jun	In contrast , the expression of JunB , ***c-jun*** and c-fos , but not JunD , was ***increased*** by LPS , TNF-alpha , ***IFN-gamma*** and IL-1 , albeit with different kinetics and magnitude of induction .	positive	0
15416	10843752	3458;3726	IFN-gamma;JunB	In contrast , the expression of ***JunB*** , c-jun and c-fos , but not JunD , was ***increased*** by LPS , TNF-alpha , ***IFN-gamma*** and IL-1 , albeit with different kinetics and magnitude of induction .	positive	0
15417	10843752	7124;2353	TNF-alpha;c-fos	In contrast , the expression of JunB , c-jun and ***c-fos*** , but not JunD , was ***increased*** by LPS , ***TNF-alpha*** , IFN-gamma and IL-1 , albeit with different kinetics and magnitude of induction .	positive	0
15418	10843752	7124;3725	TNF-alpha;c-jun	In contrast , the expression of JunB , ***c-jun*** and c-fos , but not JunD , was ***increased*** by LPS , ***TNF-alpha*** , IFN-gamma and IL-1 , albeit with different kinetics and magnitude of induction .	positive	0
15419	10843752	7124;3726	TNF-alpha;JunB	In contrast , the expression of ***JunB*** , c-jun and c-fos , but not JunD , was ***increased*** by LPS , ***TNF-alpha*** , IFN-gamma and IL-1 , albeit with different kinetics and magnitude of induction .	positive	0
15420	10843754	3565;3559	Interleukin-4;CD25	***Interleukin-4*** ( IL-4 ) ***regulates*** the expression of the 55-kDa alpha-subunit ( ***CD25*** ) of the IL-2 receptor complex in human B lymphocytes .	target	1
15421	10843764	3458;3569	IFN-gamma;HGF	These results indicate that ***IFN-gamma*** synergistically stimulates cAMP-induced HGF production and ***inhibits*** ***HGF*** production induced by growth factors and protein kinase C activators in human skin fibroblasts .	negative	1
15422	10843764	3458;3569	IFN-gamma;HGF	These results indicate that ***IFN-gamma*** synergistically ***stimulates*** cAMP-induced ***HGF*** production and inhibits HGF production induced by growth factors and protein kinase C activators in human skin fibroblasts .	positive	0
15423	10843764	3458;3569	IFN-gamma;HGF	***IFN-gamma*** synergistically ***enhanced*** ***HGF*** production stimulated by 8-bromo-cAMP , one of the most effective inducers of HGF : HGF secreted from cells incubated with 1 mM of 8-bromo-cAMP , 1000 U/ml of IFN-gamma and both of these was approximately 8 , 1.5 and 24 times , respectively , that secreted from untreated cells .	positive	0
15424	10843764	3458;3569	IFN-gamma;HGF	***HGF*** gene expression upregulated by cholera toxin , forskolin and 8-bromo-cAMP was markedly ***enhanced*** by ***IFN-gamma*** , which was detected as early as 3 h after its addition .	positive	0
15425	10843764	3458;3569	IFN-gamma;HGF	The synergy between HGF inducers and IFN-gamma is not common to all HGF inducers , because ***HGF*** production stimulated by epidermal growth factor and protein-kinase-C-activating phorbol esters was significantly ***inhibited*** by ***IFN-gamma*** .	negative	1
15426	10843871	5585;2353	PKN;c-fos	Interestingly , ***PKN*** preferentially ***stimulated*** the ANF versus the ***c-fos*** SRE reporter gene .	positive	0
15427	10843878	3553;4790	IL-1beta;NF-kappaB	***IL-1beta*** ( 1 ng/ml ) ***induced*** marked and persistent ***NF-kappaB*** activation in VSMC that was maximal at 1 h and persisted for 3 days .	target	1
15428	10843878	4790;5970	p50;p65	Electrophoretic mobility shift assay and supershift analysis indicated that IL-1-induced NF-kappaB complexes consisted of ******p65/p50****** ***heterodimers*** and p50 homodimers .	parallel	1
15429	10843878	3553;5970	IL-1;p65	***IL-1*** ***induced*** nuclear localization of ***p65*** in 95 % of cells transfected with vector alone but in only 69 % and 26 % of cells expressing IKKalpha ( K44A ) or IKKbeta ( K44A ) , respectively .	target	1
15430	10843967	1991;4586	Neutrophil elastase;MUC5AC	***Neutrophil elastase*** ***induces*** ***MUC5AC*** messenger RNA expression by an oxidant-dependent mechanism .	target	1
15431	10843986	4089;7040	Smad4;TGFbeta	Transient expression of dominant-negative ***Smad4*** also ***inhibited*** the ability of ***TGFbeta*** ( 3 ) to transactivate the TGFbeta ( 1 ) promoter .	negative	1
15432	10843989	998;5879	Cdc42;Rac1	Here we have investigated the role of Mg ( 2 + ) cofactor in the guanine nucleotide ***binding*** and hydrolysis processes of the Rho family members , ***Cdc42*** , ***Rac1*** , and RhoA .	parallel	1
15433	10843989	998;387	Cdc42;RhoA	Here we have investigated the role of Mg ( 2 + ) cofactor in the guanine nucleotide ***binding*** and hydrolysis processes of the Rho family members , ***Cdc42*** , Rac1 , and ***RhoA*** .	parallel	1
15434	10843989	387;5879	RhoA;Rac1	Here we have investigated the role of Mg ( 2 + ) cofactor in the guanine nucleotide ***binding*** and hydrolysis processes of the Rho family members , Cdc42 , ***Rac1*** , and ***RhoA*** .	parallel	1
15435	10843991	183;595	angiotensin II;cyclin D1	The protein-tyrosine phosphatase SHP-2 is required during ***angiotensin II-mediated*** ***activation*** of ***cyclin D1*** promoter in CHO-AT1A cells .	positive	1
15436	10843995	183;1489	angiotensin II;cardiotrophin-1	***angiotensin II*** ***increased*** IL-6 , leukemia inhibitory factor ( LIF ) and ***cardiotrophin-1*** mRNA by 6.5 - , 10.2 - , and 2.0-fold , respectively , but did not affect IL-11 , ciliary neurotrophic factor , or oncostatin M in cardiac fibroblasts .	positive	0
15437	10843995	183;3569	angiotensin II;IL-6	***angiotensin II*** ***increased*** ***IL-6*** , leukemia inhibitory factor ( LIF ) and cardiotrophin-1 mRNA by 6.5 - , 10.2 - , and 2.0-fold , respectively , but did not affect IL-11 , ciliary neurotrophic factor , or oncostatin M in cardiac fibroblasts .	positive	0
15438	10843995	183;3976	angiotensin II;LIF	***angiotensin II*** ***increased*** IL-6 , leukemia inhibitory factor ( ***LIF*** ) and cardiotrophin-1 mRNA by 6.5 - , 10.2 - , and 2.0-fold , respectively , but did not affect IL-11 , ciliary neurotrophic factor , or oncostatin M in cardiac fibroblasts .	positive	0
15439	10843995	183;1489	angiotensin II;cardiotrophin-1	These results indicated that ***angiotensin II*** ***induced*** IL-6 , LIF , and ***cardiotrophin-1*** in cardiac fibroblasts , and that these cytokines , particularly LIF and cardiotrophin-1 , activated gp130-linked signaling and contributed to angiotensin II-induced cardiomyocyte hypertrophy .	target	1
15440	10843995	183;3569	angiotensin II;IL-6	These results indicated that ***angiotensin II*** ***induced*** ***IL-6*** , LIF , and cardiotrophin-1 in cardiac fibroblasts , and that these cytokines , particularly LIF and cardiotrophin-1 , activated gp130-linked signaling and contributed to angiotensin II-induced cardiomyocyte hypertrophy .	target	1
15441	10843995	183;3976	angiotensin II;LIF	These results indicated that ***angiotensin II*** ***induced*** IL-6 , ***LIF*** , and cardiotrophin-1 in cardiac fibroblasts , and that these cytokines , particularly LIF and cardiotrophin-1 , activated gp130-linked signaling and contributed to angiotensin II-induced cardiomyocyte hypertrophy .	target	1
15442	10844001	207;1432	Rac;p38 mitogen-activated protein (MAP) kinase	In turn ***Rac*** ***mediates*** ***p38 mitogen-activated protein (MAP) kinase*** activation and cytoskeletal reorganization , whereas factor VIIa-induced p42/p44 MAP kinase stimulation required PI3K enzymatic activity but was not inhibited by dominant negative Rac proteins .	target	0
15443	10844028	2149;2902	PAR1;NR1	Activation of recombinant ***PAR1*** also ***potentiates*** recombinant ***NR1/NR2A*** ( 1.7 + / - 0.06-fold ) and NR1/NR2B ( 1.41 + / - 0.11-fold ) receptor function but not NR1/NR2C or NR1/NR2D receptor responses .	positive	0
15444	10844028	2149;2903	PAR1;NR2A	Activation of recombinant ***PAR1*** also ***potentiates*** recombinant ***NR1/NR2A*** ( 1.7 + / - 0.06-fold ) and NR1/NR2B ( 1.41 + / - 0.11-fold ) receptor function but not NR1/NR2C or NR1/NR2D receptor responses .	positive	0
15445	10844120	3553;3827	interleukin-1 beta;bradykinin	bradykinin B ( 2 ) receptor mRNA and [ 3H ] ***bradykinin*** binding were ***upregulated*** by ***interleukin-1 beta*** , but not TNF-alpha .	positive	1
15446	10844136	1906;3827	Endothelin-1;bradykinin	In this study , we investigated the ability of ***Endothelin-1*** ***decrease*** the hypotensive effects of the vasodilator ***bradykinin*** in anesthetized rats .	negative	0
15447	10844408	7056;7422	thrombomodulin;vascular endothelial growth factor	Recombinant ***thrombomodulin*** ***inhibits*** thrombin-induced ***vascular endothelial growth factor*** production in neuronal cells .	negative	1
15448	10844408	7056;7422	thrombomodulin;VEGF	Thrombin-induced ***VEGF*** production was significantly ***attenuated*** by recombinant human ***thrombomodulin*** ( rTM ) and its minimal functional domain E456 .	negative	0
15449	10844533	3565;3586	IL-4;IL-10	Simultaneous administration of encephalitogenic peptide + ***IL-4*** by the nasal route thus suppressed ongoing EAE and ***induced*** IL-4 , ***IL-10*** and TGF-beta-related regulatory elements .	target	1
15450	10844548	3557;2252	interleukin-1 receptor antagonist;keratinocyte growth factor	The functional significance of this double paracrine pathway , i.e. , induction of keratinocyte growth factor expression in fibroblasts by keratinocytes via release of interleukin-1 , was confirmed by interfering with both signaling elements : ( i ) interleukin-1-neutralizing antibodies and ***interleukin-1 receptor antagonist*** significantly ***inhibited*** ***keratinocyte growth factor*** release , keratinocyte proliferation , and tissue formation comparable to the effect produced by keratinocyte-growth-factor-blocking antibodies ; ( ii ) addition of keratinocyte growth factor to cocultures with inactivated interleukin-1 pathway completely reverted growth inhibition ; ( iii ) in organotypic cocultures with subthreshold fibroblast numbers both interleukin-1 and keratinocyte growth factor restored the impaired epidermal morphogenesis .	negative	1
15451	10844594	3458;4790	IFN-gamma;NF-kappaB	The inability of alpha-MSH to inhibit LPS + ***IFN-gamma*** ***induction*** of ***NF-kappaB*** in murine macrophage cells , which contrasts with inhibitory effects of the neuropeptide in other cell types , suggests that cell-type-specific mechanisms are involved .	target	1
15452	10844594	5443;4843	alpha-MSH;NOS2	***alpha-MSH*** ***inhibits*** induction of C/EBPbeta-DNA binding activity and ***NOS2*** gene transcription in macrophages .	negative	1
15453	10844594	3458;4790	IFN-gamma;NF-kappaB	RESULTS : Gel shift assays demonstrated LPS + ***IFN-gamma*** ***induction*** of ***NF-kappaB*** and C/EBP family protein-DNA complexes in nuclei harvested from the cells .	target	1
15454	10844594	5443;4843	alpha-MSH;NOS2	CONCLUSIONS : These data indicate that alpha-MSH inhibits the induction of C/EBPbeta DNA binding activity and that this effect is a major mechanism by which ***alpha-MSH*** ***inhibits*** the transcription of the ***NOS2*** gene .	negative	1
15455	10844595	6772;3458	STAT1;interferon-gamma	The introduction of wild-type ***STAT1*** ***enhanced*** the effect of ***interferon-gamma*** and decreased [ 3H ] - thymidine incorporation , whereas tyrosine-mutated ( Y701F ) STAT1 and SH2 domain ( R602T ) - mutated STAT1 reversed INF-gamma-induced suppression of [ 3H ] - thymidine incorporation .	positive	0
15456	10844605	7124;6804	TNF-alpha;Stx-1	Interleukin-1 ( IL-1 ) , lipopolysaccharide ( LPS ) , tumor necrosis factor-alpha ( ***TNF-alpha*** ) , and butyrate ***increased*** ***Stx-1*** cytotoxicity and total cell Gb3 levels .	positive	0
15457	10845427	598;836	Bcl-X;caspase-3	Overexpression of ***Bcl-X*** ( L ) ***blocked*** cytochrome c release , ***caspase-3*** activation , and apoptosis in ara-C-treated cells .	negative	0
15458	10845427	598;836	Bcl-X;caspase-3	By contrast , CDDO-induced release of cytochrome c , and activation of ***caspase-3*** were ***diminished*** only in part by ***Bcl-X*** ( L ) .	negative	0
15459	10845428	10923;1021	p15;cdk6	Forty-eight h after SCF withdrawal and Epo stimulation , there was strong inhibition of cyclin-dependent kinase (cdk) 4 and cdk6 activities , associated with an increase in the ***binding*** of p27 and ***p15*** to ***cdk6*** .	parallel	1
15460	10845428	3429;1021	p27;cdk6	Forty-eight h after SCF withdrawal and Epo stimulation , there was strong inhibition of cyclin-dependent kinase (cdk) 4 and cdk6 activities , associated with an increase in the ***binding*** of ***p27*** and p15 to ***cdk6*** .	parallel	1
15461	10845553	596;1890	bcl-2;thymidine phosphorylase	***bcl-2*** and c-erbB-2 proteins are involved in the ***regulation*** of VEGF and of ***thymidine phosphorylase*** angiogenic activity in non-small-cell lung cancer .	target	1
15462	10845553	596;7422	bcl-2;VEGF	***bcl-2*** and c-erbB-2 proteins are involved in the ***regulation*** of ***VEGF*** and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer .	target	1
15463	10845553	2064;1890	erbB-2;thymidine phosphorylase	bcl-2 and ***c-erbB-2*** proteins are involved in the ***regulation*** of VEGF and of ***thymidine phosphorylase*** angiogenic activity in non-small-cell lung cancer .	target	1
15464	10845553	2064;7422	erbB-2;VEGF	bcl-2 and ***c-erbB-2*** proteins are involved in the ***regulation*** of ***VEGF*** and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer .	target	1
15465	10845589	4314;4318	MMP-3;MMP-9	Doxycycline added to the conditioned media did not affect ***activation*** of ***MMP-9*** by ***MMP-3*** .	positive	1
15466	10845589	4314;4318	MMP-3;MMP-9	***MMP-3*** alone is sufficient to ***activate*** ***MMP-9*** on the ocular surface .	positive	1
15467	10845613	7422;3082	VEGF;HGF	However , ***VEGF*** does not appear to ***mediate*** these initial ***HGF*** effects .	target	0
15468	10845620	2668;2902	GDNF;NMDAR1	Inasmuch as ***GDNF*** can ***increase*** levels of both EAAT1 and ***NMDAR1*** , it may be a useful therapeutic approach to restore homeostatic levels of these in glaucoma .	positive	0
15469	10845622	573;596	BAG-1;Bcl-2	***BAG-1*** has previously been shown to ***augment*** the inhibitory effect of ***Bcl-2*** on programmed cell death in cultured cell systems .	positive	0
15470	10845623	3458;133	IFN-gamma;ADM	***IFN-gamma*** and IL-1beta ***induced*** ***ADM*** expression in ARPE-19 cells .	target	1
15471	10845623	3553;133	IL-1beta;ADM	IFN-gamma and ***IL-1beta*** ***induced*** ***ADM*** expression in ARPE-19 cells .	target	1
15472	10845664	7157;355	p53;CD95	Expression of ***p53*** was also ***associated*** with an upregulation of ***CD95*** ( Apo-1/Fas ) gene expression , which may predispose the tumor cells to undergo apoptosis induced by the Fas Ligand/Fas cytolytic pathway .	parallel	0
15473	10845713	2017;1445	cortactin;c-Src kinase	Peroxynitrite treatment of human pancreatic carcinoma cells in vitro resulted in increased tyrosine nitration and tyrosine phosphorylation of c-Src kinase , increased ( > 2-fold ) c-Src kinase activity , and increased association between ***c-Src kinase*** and its downstream ***substrate*** ***cortactin*** .	parallel	1
15474	10845713	2017;1445	cortactin;c-Src kinase	Peroxynitrite treatment of human pancreatic carcinoma cells in vitro resulted in increased tyrosine nitration and tyrosine phosphorylation of c-Src kinase , increased ( > 2-fold ) c-Src kinase activity , and increased ***association*** between ***c-Src kinase*** and its downstream substrate ***cortactin*** .	parallel	0
15475	10845726	356;355	FasL;Fas	***Fas*** ***ligand*** ( ***FasL*** ) is a member of the tumor necrosis family and when bound to its receptor , Fas , induces apoptosis .	parallel	1
15476	10845774	375790;4593	agrin;MuSK	N-acetyllactosamine and the CT carbohydrate antigen mediate ***agrin-dependent*** ***activation*** of ***MuSK*** and acetylcholine receptor clustering in skeletal muscle .	positive	1
15477	10845774	375790;4593	agrin;MuSK	Neural ***agrin*** ***activated*** ***MuSK*** in vitro if the lactosamine-containing mucin domain was present , and this activation was blocked in large part by Galbeta1 ,3 GalNAc and Galbeta1 ,4 GIcNAc .	positive	1
15478	10845858	3816;3827	tissue kallikrein;kininogen	***tissue kallikrein*** ***cleaves*** ***kininogen*** to produce vasoactive kinin peptides .	target	1
15479	10845889	7040;5054	TGF-beta1;PAI-1	Transforming growth factor-beta1 ( ***TGF-beta1*** ) ***increased*** ***PAI-1*** secretion in a dose - and time-dependent manner .	positive	0
15480	10845889	7124;5054	TNF-alpha;PAI-1	Moreover , ***TNF-alpha*** and interkeukin-1beta ( IL-1beta ) also exerted a stimulatory effect on PAI-1 release and ***increased*** ***PAI-1*** mRNA levels .	positive	0
15481	10845889	3553;7040	IL-1beta;TGF-beta1	As assessed by a semiquantitative reverse transcription-polymerase chain reaction technique , ***TGF-beta1*** mRNA is expressed by differentiation of human preadipocytes and is moderately ***upregulated*** by TNF-alpha and ***IL-1beta*** .	positive	1
15482	10845889	7124;7040	TNF-alpha;TGF-beta1	As assessed by a semiquantitative reverse transcription-polymerase chain reaction technique , ***TGF-beta1*** mRNA is expressed by differentiation of human preadipocytes and is moderately ***upregulated*** by ***TNF-alpha*** and IL-1beta .	positive	1
15483	10845905	3458;355	IFN-gamma;Fas	***IFN-gamma*** ***induced*** ***Fas*** expression of the cells without the activation of caspase8 or caspase3 during 16 hours of incubation , while deprivation of EPO induced expression of Fas and the activation of both caspase8 and caspase3 .	target	1
15484	10845907	959;958	CD40L;CD40	***CD40*** ***ligand*** ( ***CD40L*** ) / CD40 interactions play a central role in T-cell-dependent B-cell activation as previously shown by in vitro studies , the phenotype of CD40L knockout mice and the defective expression of CD40L in patients who have X-linked immunodeficiency with hyper-IgM .	parallel	1
15485	10845908	3569;8651	IL-6;suppressor of cytokine signaling-1	The constitutive ***IL-6*** expression was ***associated*** with elevated levels of ***suppressor of cytokine signaling-1*** ( SOCS-1 ) and SOCS-3 mRNA expression , which were not down-regulated by anti-IL-6 .	parallel	0
15486	10845911	3827;3684	high molecular weight kininogen;CD11b	Cleaved ***high molecular weight kininogen*** ***binds*** directly to the integrin ***CD11b/CD18*** ( Mac-1 ) and blocks adhesion to fibrinogen and ICAM-1 .	parallel	1
15487	10845911	3827;3689	high molecular weight kininogen;CD18	Cleaved ***high molecular weight kininogen*** ***binds*** directly to the integrin ***CD11b/CD18*** ( Mac-1 ) and blocks adhesion to fibrinogen and ICAM-1 .	parallel	1
15488	10845915	3565;3718	IL-4;JAK3	Moreover , AG-490 markedly inhibited ***IL-4*** ***activation*** of ***JAK3*** and blocked the downstream activation of signal transducer and activator of transcription 6 , as judged by tyrosine phosphorylation , DNA binding , and transcription assays .	positive	1
15489	10845915	7124;4790	tumor necrosis factor alpha;NF-kappaB	In contrast , AG-490 did not affect ***tumor necrosis factor alpha*** ***activation*** of ***NF-kappaB*** at similar concentrations of drug .	positive	1
15490	10845922	3684;3553	CD11b;IL-1beta	Engagement of ***CD11b*** and CD11c beta2 integrin by antibodies or soluble CD23 ***induces*** ***IL-1beta*** production on primary human monocytes through mitogen-activated protein kinase-dependent pathways .	target	1
15491	10845922	2208;3684	CD23;CD11b	We demonstrate that ***ligation*** of ***CD11b*** ( Mac-1 , CR3 ) or CD11c ( p150 , CR4 ) alpha chains of beta2 integrins by mAbs or soluble chimeric ***CD23*** ( sCD23 ) on human freshly isolated monocytes rapidly stimulates high levels of interleukin-1beta production .	parallel	1
15492	10845922	2208;3687	CD23;CD11c	We demonstrate that ***ligation*** of CD11b ( Mac-1 , CR3 ) or ***CD11c*** ( p150 , CR4 ) alpha chains of beta2 integrins by mAbs or soluble chimeric ***CD23*** ( sCD23 ) on human freshly isolated monocytes rapidly stimulates high levels of interleukin-1beta production .	parallel	1
15493	10845936	2189;2176	FANCG;FANCC	Recent work has demonstrated that the functional activity of FA proteins requires the physical ***interaction*** of at least FANCA , ***FANCC*** , and ***FANCG*** , and possibly of other FA and non-FA proteins .	parallel	1
15494	10846066	10482;9768	Tap;p15	Although we were able to confirm that ***Tap*** can indeed ***bind*** ***p15*** specifically both in vivo and in vitro , a mutation in Tap that blocked p15 binding only modestly inhibited CTE-dependent nuclear RNA export .	parallel	1
15495	10846066	9768;10482	p15;Tap	However , ***p15*** did significantly enhance the affinity of Tap for the CTE in vitro and readily formed a ternary ***complex*** with ***Tap*** on the CTE .	parallel	1
15496	10846066	9768;10482	p15;Tap	However , ***p15*** did significantly ***enhance*** the affinity of ***Tap*** for the CTE in vitro and readily formed a ternary complex with Tap on the CTE .	positive	0
15497	10846067	2874;2033	AMF-1;p300	These results suggest that ***AMF-1*** ***facilitates*** the recruitment of ***p300*** and its histone acetylase activity into complexes with E2 and represents a novel mechanism of transcriptional activation .	positive	0
15498	10846067	2874;2033	AMF-1;p300	***AMF-1/Gps2*** ***binds*** ***p300*** and enhances its interaction with papillomavirus E2 proteins .	parallel	1
15499	10846067	2874;2033	AMF-1;p300	We show here that ***AMF-1*** also ***binds*** the transcriptional coactivator ***p300*** in vitro and in vivo .	parallel	1
15500	10846067	2874;2033	AMF-1;p300	These observations led to a model in which ***AMF-1*** ***recruits*** ***p300*** into a complex with E2 .	target	0
15501	10846164	2535;1499	Fz2;beta-catenin	We demonstrate that the cytoplasmic sequences of ***Fz2*** and Fz preferentially ***activate*** the ***beta-catenin*** and planar polarity cascade , respectively .	positive	1
15502	10846170	3065;3364	HDAC1;Hus1	***HDAC1*** , a histone deacetylase , forms a ***complex*** with ***Hus1*** and Rad9 , two G2/M checkpoint Rad proteins .	parallel	1
15503	10846170	3065;5883	HDAC1;Rad9	***HDAC1*** , a histone deacetylase , forms a ***complex*** with Hus1 and ***Rad9*** , two G2/M checkpoint Rad proteins .	parallel	1
15504	10846173	4547;338	MTP;apoB	In HepG2 cells , ***inhibition*** of apolipoprotein B100 ( ***apoB*** ) translocation across the endoplasmic reticulum by an microsomal triglyceride transfer protein ( ***MTP*** ) inhibitor ( CP-10447 ) in the presence of N-acetyl-leucinyl-norleucinal , a proteasomal inhibitor , results in accumulation of newly synthesized apoB in the translocation channel .	negative	1
15505	10846175	3667;84959	IRS-1;p70	In this report , we have focused on ***p70*** ( S6K ) , which is ***activated*** by the ***IRS-1*** pathway .	positive	1
15506	10846175	3667;84959	IRS-1;p70	We find that the ectopic expression of ***IRS-1*** and the inhibition of differentiation ***correlated*** with a sustained activation of ***p70*** ( S6K ) and an increase in cell size .	parallel	0
15507	10846177	8317;373156	huCdc7;GST	To facilitate purification of the kinase complex , glutathione S-transferase ( GST ) was fused to huCdc7 and ******GST-huCdc7-ASK****** ***complex*** was purified .	parallel	1
15508	10846177	8317;4173	huCdc7;MCM4	***MCM4*** and MCM6 are also ***phosphorylated*** by ***huCdc7*** albeit to less extent .	target	1
15509	10846177	8317;4175	huCdc7;MCM6	MCM4 and ***MCM6*** are also ***phosphorylated*** by ***huCdc7*** albeit to less extent .	target	1
15510	10846177	8317;4171	huCdc7;MCM2	MCM2 and -4 in the MCM2-4-6-7 complex are phosphorylated by Cdks as well , and prior phosphorylation of the MCM2-4-6-7 complex by Cdks facilitates ***phosphorylation*** of ***MCM2*** by ***huCdc7*** , suggesting collaboration between Cdks and Cdc7 in phosphorylation of MCM for initiation of S phase .	target	1
15511	10846182	6387;7852	SDF-1;CXCR4	***SDF-1*** ***binds*** to ***CXCR4*** primarily via the N terminus , which appears flexible in the recently determined three-dimensional structure of SDF-1 .	parallel	1
15512	10846185	8435;6646	ACAT-2;ACAT-1	***ACAT-1*** and ***ACAT-2*** do not form hetero-oligomeric ***complexes*** .	parallel	1
15513	10847581	3667;3643	insulin receptor substrate-1;insulin receptor	***insulin receptor substrate-1*** ( IRS-1 ) is a major ***substrate*** of the ***insulin receptor*** and acts as a docking protein for Src homology 2 domain containing signaling molecules that mediate many of the pleiotropic actions of insulin .	parallel	1
15514	10847582	183;186	angiotensin II;AT2	The present study demonstrates negative intracellular ***cross-talk*** between ***angiotensin II*** type 2 ( ***AT2*** ) and insulin receptors .	parallel	0
15515	10847583	3480;3667	IGF-I receptor;IRS-1	IGF-I induces signaling pathways that involve ***IGF-I receptor-mediated*** tyrosine ***phosphorylation*** of Shc and insulin receptor substrate 1 ( ***IRS-1*** ) .	target	1
15516	10847583	3480;6464	IGF-I receptor;Shc	IGF-I induces signaling pathways that involve ***IGF-I receptor-mediated*** tyrosine ***phosphorylation*** of ***Shc*** and insulin receptor substrate 1 ( IRS-1 ) .	target	1
15517	10847584	3651;6750	PDX-1;somatostatin	This is the first report of ***induction*** of the endogenous ***somatostatin*** gene by ***PDX-1*** .	target	1
15518	10847585	3667;8660	IRS-1;IRS-2	In fact , the ***IRS-1*** PH domain ***binds*** preferentially to phosphatidylinositol 3,4,5-trisphosphate ( PtdIns-3 ,4,5 - P3 ) , the ***IRS-2*** PH domain to phosphatidylinositol 3,4-bisphosphate ( PtdIns-3 ,4 - P2 ) , and the IRS-3 PH domain to phosphatidylinositol 3-phosphate .	parallel	1
15519	10847587	3091;133	HIF-1;adrenomedullin	Hypoxia-inducible factor-1 ( ***HIF-1*** ) ***up-regulates*** ***adrenomedullin*** expression in human tumor cell lines during oxygen deprivation : a possible promotion mechanism of carcinogenesis .	positive	1
15520	10847592	23054;3727	ASC-2;AP-1	Second , ***ASC-2*** specifically ***interacted*** with the activating protein-1 ( ***AP-1*** ) components c-Jun and c-Fos as well as the nuclear factor-kappaB ( NFkappaB ) components p50 and p65 , as demonstrated by the glutathione S-transferase pull-down assays as well as the yeast two-hybrid tests .	parallel	1
15521	10847592	23054;2353	ASC-2;c-Fos	Second , ***ASC-2*** specifically ***interacted*** with the activating protein-1 ( AP-1 ) components c-Jun and ***c-Fos*** as well as the nuclear factor-kappaB ( NFkappaB ) components p50 and p65 , as demonstrated by the glutathione S-transferase pull-down assays as well as the yeast two-hybrid tests .	parallel	1
15522	10847592	23054;4790	ASC-2;p50	Second , ***ASC-2*** specifically ***interacted*** with the activating protein-1 ( AP-1 ) components c-Jun and c-Fos as well as the nuclear factor-kappaB ( NFkappaB ) components ***p50*** and p65 , as demonstrated by the glutathione S-transferase pull-down assays as well as the yeast two-hybrid tests .	parallel	1
15523	10847630	3569;2244	IL-6;beta-fibrinogen	The ***induction*** of ***beta-fibrinogen*** mRNA by ***IL-6*** , a stat3 dependent process , is attenuated in AdiNOS-transduced cells and partially reversed by L-NMA .	target	1
15524	10847630	4843;6774	iNOS;stat3	Thus , ***iNOS*** overexpression ***suppresses*** IL-6-induced ***stat3*** activation and type II acute phase mRNA expression in cultured hepatocytes .	negative	1
15525	10847650	4600;4018	MX2;lipoprotein	***MX2*** is likely to be bound to the main plasma protein , albumin , and can also ***interact*** with the plasma lipoproteins , particularly high density ***lipoprotein*** .	parallel	1
15526	10848576	6714;4790	Src;NF-kappaB	On the basis of these findings , ***Src*** emerges as a critical upstream ***regulator*** of both PKC-iota and the ***NF-kappaB*** pathway .	target	1
15527	10848577	6772;4790	Stat1;NF-kappaB	Thus , ***Stat1*** acts as a TNFR1-signaling molecule to ***suppress*** ***NF-kappaB*** activation .	negative	1
15528	10848577	7132;7124	TNFR1;TNF-alpha	Activated tumor necrosis factor alpha ( ***TNF-alpha*** ) ***receptor*** 1 ( ***TNFR1*** ) recruits TNFR1-associated death domain protein ( TRADD ) , which in turn triggers two opposite signaling pathways leading to caspase activation for apoptosis induction and NF-kappaB activation for antiapoptosis gene upregulation .	parallel	1
15529	10848577	7132;8717	TNFR1;TRADD	Activated tumor necrosis factor alpha ( TNF-alpha ) receptor 1 ( ***TNFR1*** ) ***recruits*** TNFR1-associated death domain protein ( ***TRADD*** ) , which in turn triggers two opposite signaling pathways leading to caspase activation for apoptosis induction and NF-kappaB activation for antiapoptosis gene upregulation .	target	0
15530	10848577	8717;7132	TRADD;TNFR1	Here we show that Stat1 is involved in the ******TNFR1-TRADD****** signaling ***complex*** , as determined by employing a novel antibody array screening method .	parallel	1
15531	10848577	6772;7132	Stat1;TNFR1	In HeLa cells , ***Stat1*** was ***associated*** with ***TNFR1*** and this association was increased with TNF-alpha treatment .	parallel	0
15532	10848577	6772;7132	Stat1;TNFR1	Our in vitro recombinant protein-protein interaction studies demonstrated that ***Stat1*** could directly ***interact*** with ***TNFR1*** and TRADD but not with FADD .	parallel	1
15533	10848577	8737;6772	RIP;Stat1	***Interaction*** between ***Stat1*** and receptor-interacting protein ( ***RIP*** ) or TNFR-associated factor 2 ( TRAF2 ) was not detected .	parallel	1
15534	10848577	7186;8737	TRAF2;RIP	***Interaction*** between Stat1 and receptor-interacting protein ( ***RIP*** ) or TNFR-associated factor 2 ( ***TRAF2*** ) was not detected .	parallel	1
15535	10848577	7186;6772	TRAF2;Stat1	***Interaction*** between ***Stat1*** and receptor-interacting protein ( RIP ) or TNFR-associated factor 2 ( ***TRAF2*** ) was not detected .	parallel	1
15536	10848577	8772;8717	FADD;TRADD	Examination of Stat1-deficient cells showed an apparent increase in TNF-alpha-induced TRADD-RIP and TRADD-TRAF2 complex formation , while ***interaction*** between ***TRADD*** and ***FADD*** was unaffected .	parallel	1
15537	10848577	6772;4790	Stat1;NF-kappaB	As a consequence , TNF-alpha-mediated I-kappaB degradation and NF-kappaB activation were markedly enhanced in Stat1-deficient cells , whereas overexpression of ***Stat1*** in 293T cells ***blocked*** ***NF-kappaB*** activation by TNF-alpha .	negative	0
15538	10848580	5610;4790	PKR;NF-kappaB	Therefore , our results reveal a novel pathway by which ***PKR*** can ***modulate*** the ***NF-kappaB*** signaling pathway without using its kinase activity .	target	0
15539	10848580	5610;4790	PKR;NF-kappaB	***PKR*** ***stimulates*** ***NF-kappaB*** irrespective of its kinase function by interacting with the IkappaB kinase complex .	positive	0
15540	10848580	5610;3439	PKR;IFN	The interferon ( IFN ) - induced double-stranded RNA-activated protein kinase ***PKR*** mediates inhibition of protein synthesis through phosphorylation of the alpha subunit of eukaryotic initiation factor 2 ( eIF2alpha ) and is also involved in the ***induction*** of the ***IFN*** gene through the activation of the transcription factor NF-kappaB .	target	1
15541	10848580	5610;4790	PKR;NF-kappaB	Here , we have studied the ability of PKR to activate NF-kappaB in a reporter assay and have shown for the first time that two catalytically inactive PKR mutants , ***PKR/KR296*** and a deletion mutant ( PKR/Del42 ) which lacks the potential eIF2alpha-binding domain , can also ***activate*** ***NF-kappaB*** .	negative	1
15542	10848580	5610;4790	PKR;NF-kappaB	This result indicated that ***NF-kappaB*** ***activation*** by ***PKR*** does not require its kinase activity and that it is independent of the PKR-eIF2alpha relationship .	positive	1
15543	10848592	2247;5898	bFGF;Ral	Furthermore , we found that Ras and ***Ral*** are ***activated*** in C2C12 cells by ***bFGF*** , HGF and IGF-1 and that the Ral activation is regulated by the Ras - and the intracellular Ca ( 2 + ) - mediated pathways .	positive	1
15544	10848592	3082;5898	HGF;Ral	Furthermore , we found that Ras and ***Ral*** are ***activated*** in C2C12 cells by bFGF , ***HGF*** and IGF-1 and that the Ral activation is regulated by the Ras - and the intracellular Ca ( 2 + ) - mediated pathways .	positive	1
15545	10848592	3479;5898	IGF-1;Ral	Furthermore , we found that Ras and ***Ral*** are ***activated*** in C2C12 cells by bFGF , HGF and ***IGF-1*** and that the Ral activation is regulated by the Ras - and the intracellular Ca ( 2 + ) - mediated pathways .	positive	1
15546	10848596	3725;4790	AP-1;NF-kappaB	Inhibition of the iNOS promoter is achieved partially through ***antagonizing*** the activities of ***NF-kappaB*** , ***AP-1*** , and STAT1 , which are known to mediate effects of LPS and IFN-gamma .	negative	1
15547	10848596	3725;6772	AP-1;STAT1	Inhibition of the iNOS promoter is achieved partially through ***antagonizing*** the activities of NF-kappaB , ***AP-1*** , and ***STAT1*** , which are known to mediate effects of LPS and IFN-gamma .	negative	1
15548	10848596	4790;3725	NF-kappaB;AP-1	Inhibition of the iNOS promoter is achieved partially through ***antagonizing*** the activities of ***NF-kappaB*** , ***AP-1*** , and STAT1 , which are known to mediate effects of LPS and IFN-gamma .	negative	1
15549	10848596	4790;6772	NF-kappaB;STAT1	Inhibition of the iNOS promoter is achieved partially through ***antagonizing*** the activities of ***NF-kappaB*** , AP-1 , and ***STAT1*** , which are known to mediate effects of LPS and IFN-gamma .	negative	1
15550	10848596	6772;3725	STAT1;AP-1	Inhibition of the iNOS promoter is achieved partially through ***antagonizing*** the activities of NF-kappaB , ***AP-1*** , and ***STAT1*** , which are known to mediate effects of LPS and IFN-gamma .	negative	1
15551	10848596	6772;4790	STAT1;NF-kappaB	Inhibition of the iNOS promoter is achieved partially through ***antagonizing*** the activities of ***NF-kappaB*** , AP-1 , and ***STAT1*** , which are known to mediate effects of LPS and IFN-gamma .	negative	1
15552	10848596	3725;3458	AP-1;IFN-gamma	Inhibition of the iNOS promoter is achieved partially through antagonizing the activities of NF-kappaB , ***AP-1*** , and STAT1 , which are known to ***mediate*** effects of LPS and ***IFN-gamma*** .	target	0
15553	10848596	4790;3458	NF-kappaB;IFN-gamma	Inhibition of the iNOS promoter is achieved partially through antagonizing the activities of ***NF-kappaB*** , AP-1 , and STAT1 , which are known to ***mediate*** effects of LPS and ***IFN-gamma*** .	target	0
15554	10848596	6772;3458	STAT1;IFN-gamma	Inhibition of the iNOS promoter is achieved partially through antagonizing the activities of NF-kappaB , AP-1 , and ***STAT1*** , which are known to ***mediate*** effects of LPS and ***IFN-gamma*** .	target	0
15555	10848596	1387;5468	CBP;PPARgamma	CBP and p300 are thought to be recruited to nuclear receptors through bridging factors that include SRC-1 , although ***CBP*** also ***interacts*** directly with ***PPARgamma*** through its amino terminus .	parallel	1
15556	10848598	2176;6772	FANCC;STAT1	Consequently , because the ***FANCC*** protein is involved in the ***activation*** of ***STAT1*** through receptors for at least three hematopoietic growth and survival factor molecules , we reason that FA-C hematopoietic cells are excessively apoptotic because of an imbalance between survival cues ( owing to a failure of STAT1 activation in FA-C cells ) and apoptotic and mitogenic inhibitory cues ( constitutively activated in FA-C cells in a STAT1-independent fashion ) .	positive	1
15557	10848598	2176;6772	FANCC;STAT1	The Fanconi anemia protein ***FANCC*** ***binds*** to and facilitates the activation of ***STAT1*** by gamma interferon and hematopoietic growth factors .	parallel	1
15558	10848606	5451;5450	Oct-1;Oca-B	These data suggest that some residues involved in the contact of UNC-86 with MEC-3 also contribute to the ***interaction*** of the functionally nonrelated POU protein ***Oct-1*** with ***Oca-B*** , whereas other positions have different roles .	parallel	1
15559	10848607	3725;1386	c-jun;ATF-2	Here we report that within the IFN-beta enhanceosome the ******ATF-2-c-jun****** ***heterodimer*** binds in a specific orientation , which is required for assembly of a complex between ATF-2-c-jun and interferon regulatory factor 3 ( IRF-3 ) .	parallel	1
15560	10848607	3725;1386	c-jun;ATF-2	Here we report that within the IFN-beta enhanceosome the ATF-2-c-jun heterodimer binds in a specific orientation , which is required for assembly of a ***complex*** between ******ATF-2-c-jun****** and interferon regulatory factor 3 ( IRF-3 ) .	parallel	1
15561	10848607	3661;1386	IRF-3;ATF-2	Here we report that within the IFN-beta enhanceosome the ATF-2-c-jun heterodimer binds in a specific orientation , which is required for assembly of a ***complex*** between ***ATF-2-c-jun*** and interferon regulatory factor 3 ( ***IRF-3*** ) .	parallel	1
15562	10848607	3661;3725	IRF-3;c-jun	Here we report that within the IFN-beta enhanceosome the ATF-2-c-jun heterodimer binds in a specific orientation , which is required for assembly of a ***complex*** between ***ATF-2-c-jun*** and interferon regulatory factor 3 ( ***IRF-3*** ) .	parallel	1
15563	10848607	3725;1386	c-jun;ATF-2	We also show that in vitro the DNA-bound ******ATF-2-c-jun****** ***heterodimer*** adopts a fixed orientation upon the binding of IRF-3 at an adjacent site in the IFN-beta enhancer and that the DNA-binding domain of IRF-3 is sufficient to mediate this effect .	parallel	1
15564	10848607	3661;3456	IRF-3;IFN-beta	Strikingly , in vivo chromatin immunoprecipitation experiments with IFN-beta reporter constructs reveal that ***recruitment*** of ***IRF-3*** to the ***IFN-beta*** promoter upon virus infection is dependent on the orientation of the ATF-2-c-jun heterodimer binding site .	target	0
15565	10848610	7157;1387	p53;CREB binding protein	***p53*** ***recruitment*** of ***CREB binding protein*** mediated through phosphorylated CREB : a novel pathway of tumor suppressor regulation .	target	0
15566	10848610	1385;7157	CREB;p53	Although coactivator competition is an emerging theme in transcriptional regulation , we have made the fortuitous observation that protein kinase A-phosphorylated ***CREB*** strongly ***enhances*** ***p53*** association with KIX .	positive	0
15567	10848610	1385;1387	CREB;CBP	We propose that phosphorylated ***CREB*** ***mediates*** recruitment of ***CBP*** to p53-responsive promoters through direct interaction with p53 .	target	0
15568	10848615	6305;6839	Sbf1;SUV39H1	Growth suppression as well as the ability of ***SUV39H1*** to form nuclear bodies and silence transcription are ***antagonized*** by the oncogenic antiphosphatase ***Sbf1*** that when hyperexpressed interacts with the SET domain and stabilizes the phosphorylated form of SUV39H1 .	negative	1
15569	10848618	2520;3067	gastrin;HDC	Here we show that ***gastrin*** can ***increase*** the steady-state levels of at least six ***HDC*** isoforms without affecting HDC mRNA levels .	positive	0
15570	10848633	1874;5934	E2F4;p130	Regardless of cell density , the activities of cdk4 and cdk2 were markedly repressed by p27 ( kip1 ) expression , as was the cdk4-dependent dissociation of ******E2F4/p130****** ***complexes*** .	parallel	1
15571	10848633	3429;1017	p27;cdk2	Regardless of cell density , the activities of cdk4 and ***cdk2*** were markedly ***repressed*** by ***p27*** ( kip1 ) expression , as was the cdk4-dependent dissociation of E2F4/p130 complexes .	negative	1
15572	10848633	3429;1019	p27;cdk4	Regardless of cell density , the activities of ***cdk4*** and cdk2 were markedly ***repressed*** by ***p27*** ( kip1 ) expression , as was the cdk4-dependent dissociation of E2F4/p130 complexes .	negative	1
15573	10848684	2056;3558	erythropoietin;interleukin 2	Recombinant human ***erythropoietin*** ***stimulates*** production of ***interleukin 2*** by whole blood cell cultures of hemodialysis patients .	positive	0
15574	10848800	959;958	CD40L;CD40	Up-regulation of T-cell co-stimulatory receptors CD11a , ***CD40*** ***ligand*** ( ***CD40L*** ) and CTLA4 were inhibited in a dose-dependent manner by plasma-derived ( pd ) FVIII , but CD28 was unchanged .	parallel	1
15575	10848814	959;3569	CD40L;IL-6	This effect of ***IL-6*** was ***blocked*** by tumour necrosis factor alpha ( TNF-alpha ) , lipopolysaccharide ( LPS ) , IL-1beta , CD40 ligand ( ***CD40L*** ) and transforming growth factor beta1 ( TGF-beta1 ) .	negative	0
15576	10848814	3553;3569	IL-1beta;IL-6	This effect of ***IL-6*** was ***blocked*** by tumour necrosis factor alpha ( TNF-alpha ) , lipopolysaccharide ( LPS ) , ***IL-1beta*** , CD40 ligand ( CD40L ) and transforming growth factor beta1 ( TGF-beta1 ) .	negative	0
15577	10848814	7040;3569	TGF-beta1;IL-6	This effect of ***IL-6*** was ***blocked*** by tumour necrosis factor alpha ( TNF-alpha ) , lipopolysaccharide ( LPS ) , IL-1beta , CD40 ligand ( CD40L ) and transforming growth factor beta1 ( ***TGF-beta1*** ) .	negative	0
15578	10848814	7124;3569	TNF-alpha;IL-6	This effect of ***IL-6*** was ***blocked*** by tumour necrosis factor alpha ( ***TNF-alpha*** ) , lipopolysaccharide ( LPS ) , IL-1beta , CD40 ligand ( CD40L ) and transforming growth factor beta1 ( TGF-beta1 ) .	negative	0
15579	10848974	3337;3312	hsp40;hsc70	While addition of purified hsp40 did not have any effect on luciferase assembly , the stimulatory effect of ***hsc70*** was further ***increased*** by ***hsp40*** .	positive	0
15580	10848997	3689;3383	LFA-1;ICAM-1	One of them , cytohesin-1 , a 47-kDa cytoplasmic protein acts as an inside-out signaling molecule and regulates ***binding*** of the beta2 integrin leukocyte function antigen 1 ( ***LFA-1*** ) to its ligand intercellular adhesion molecule 1 ( ***ICAM-1*** ) .	parallel	1
15581	10848997	9267;375	cytohesin-1;ARF1	We show that both ***ARF1-Ig*** and ARF6-Ig chimeras are ***activated*** in vitro by ***cytohesin-1*** .	positive	1
15582	10848997	9267;382	cytohesin-1;ARF6	We show that both ARF1-Ig and ***ARF6-Ig*** chimeras are ***activated*** in vitro by ***cytohesin-1*** .	positive	1
15583	10849326	4601;4609	Mxi1;Myc	***Mxi1*** , a member of the Myc family of transcription factors , negatively ***regulates*** ***Myc*** oncoprotein activity and thus may be a tumor suppressor gene .	negative	1
15584	10849422	3815;896	c-kit;cyclin D3	***Stem cell factor/c-kit*** ***up-regulates*** ***cyclin D3*** and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia .	positive	1
15585	10849422	4254;896	Stem cell factor;cyclin D3	***Stem cell factor/c-kit*** ***up-regulates*** ***cyclin D3*** and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia .	positive	1
15586	10849422	4254;84959	SCF;p70	We now demonstrate that ***SCF*** ***activates*** phosphoinositide 3-kinase ( PI3-K ) and ***p70*** S6 kinase ( p70S6K ) and that rapamycin , a FRAP/mammalian target of rapamycin-dependent inhibitor of p70S6K , completely inhibited bromodeoxyuridine incorporation induced by SCF in primary cultures of spermatogonia .	positive	1
15587	10849422	4254;896	SCF;cyclin D3	***SCF*** ***induced*** ***cyclin D3*** expression and phosphorylation of the retinoblastoma protein through a pathway that is sensitive to both wortmannin and rapamycin .	target	1
15588	10849424	8611;5594	LPP-1;ERK	Conversely , decreasing ***LPP-1*** expression ***increased*** net LPA association , ***ERK*** stimulation , and DNA synthesis .	positive	0
15589	10849425	6047;6942	RNF4;SPBP	***Interaction*** between the transcription factor ***SPBP*** and the positive cofactor ***RNF4*** .	parallel	1
15590	10849425	6047;6942	RNF4;SPBP	This domain can form intra-chain protein-protein contacts in SPBP resulting in negative modulation of ******SPBP-RNF4****** ***interaction*** .	parallel	1
15591	10849426	4217;5599	ASK1;JNK	***ASK1*** ***activates*** ***JNK*** and p38 mitogen-activated protein kinases and constitutes a pivotal signaling pathway in cytokine - and stress-induced apoptosis .	positive	1
15592	10849426	4217;1432	ASK1;p38	***ASK1*** ***activates*** JNK and ***p38*** mitogen-activated protein kinases and constitutes a pivotal signaling pathway in cytokine - and stress-induced apoptosis .	positive	1
15593	10849426	4217;836	ASK1;caspase-3	Consistently , caspase-8-deficient ( Casp8 ( - / - ) ) cells were sensitive to ASK1-induced caspase-3 activation and apoptosis , suggesting that caspase-8 is dispensable for ASK1-induced apoptosis , whereas ***ASK1*** failed to ***activate*** ***caspase-3*** in caspase-9-dificient ( Casp9 ( - / - ) ) cells .	positive	1
15594	10849427	998;2246	Cdc42;fibroblast growth factor 1	The small GTPases Ras , Rac , and ***Cdc42*** transcriptionally ***regulate*** expression of human ***fibroblast growth factor 1*** .	target	1
15595	10849427	207;2246	Rac;fibroblast growth factor 1	The small GTPases Ras , ***Rac*** , and Cdc42 transcriptionally ***regulate*** expression of human ***fibroblast growth factor 1*** .	target	1
15596	10849427	5879;2247	Rac1;FGF2	Ras and ***Rac1*** also ***activated*** the ***FGF2*** promoter .	positive	1
15597	10849428	3600;9846	IL-15;gab2	We also demonstrate that only IL-2 and ***IL-15*** , but not other gammac cytokines ***induce*** ***gab2*** phosphorylation ; the ability to phosphorylate gab2 correlates with Shc phosphorylation and ERK1/ERK2 activation .	target	1
15598	10849428	3558;9846	IL-2;gab2	We also demonstrate that only ***IL-2*** and IL-15 , but not other gammac cytokines ***induce*** ***gab2*** phosphorylation ; the ability to phosphorylate gab2 correlates with Shc phosphorylation and ERK1/ERK2 activation .	target	1
15599	10849431	7057;7040	thrombospondin-1;TGF-beta1	***thrombospondin-1*** ( TSP-1 ) has been shown to ***bind*** and activate transforming growth factor-beta1 ( ***TGF-beta1*** ) .	parallel	1
15600	10849431	7057;7040	TSP-1;TGF-beta1	This observation raises the possibility that ***TSP-1*** helps to sequester TGF-beta1 in platelet alpha granules and ***activates*** ***TGF-beta1*** once both proteins are secreted .	positive	1
15601	10849438	940;3558	CD28;interleukin-2	Tyrosine-phosphorylated Vav1 as a point of integration for T-cell receptor - and ***CD28-mediated*** ***activation*** of JNK , p38 , and ***interleukin-2*** transcription .	positive	1
15602	10849438	940;5599	CD28;JNK	Tyrosine-phosphorylated Vav1 as a point of integration for T-cell receptor - and ***CD28-mediated*** ***activation*** of ***JNK*** , p38 , and interleukin-2 transcription .	positive	1
15603	10849438	940;1432	CD28;p38	Tyrosine-phosphorylated Vav1 as a point of integration for T-cell receptor - and ***CD28-mediated*** ***activation*** of JNK , ***p38*** , and interleukin-2 transcription .	positive	1
15604	10849438	7409;5599	Vav1;JNK	The ***Vav1-mediated*** ***activation*** of ***JNK*** employed a pathway involving Rac , HPK1 , MLK3 , and MKK7 .	positive	1
15605	10849438	5608;1432	MKK6;p38	The costimulation-induced activation of ***p38*** was ***inhibited*** by dominant negative forms of Vav1 , Rac , and ***MKK6*** .	negative	1
15606	10849438	207;1432	Rac;p38	The costimulation-induced activation of ***p38*** was ***inhibited*** by dominant negative forms of Vav1 , ***Rac*** , and MKK6 .	negative	1
15607	10849438	7409;1432	Vav1;p38	The costimulation-induced activation of ***p38*** was ***inhibited*** by dominant negative forms of ***Vav1*** , Rac , and MKK6 .	negative	1
15608	10849440	6875;5970	TAFII105;p65	***Interaction*** of ***TAFII105*** with selected ***p65/RelA*** dimers is associated with activation of subset of NF-kappa B genes .	parallel	1
15609	10849440	129685;4790	TAF;NF-kappaB	Analysis of the ***interaction*** between ***TAF*** ( II ) 105 and different ***NF-kappaB*** complexes has revealed substantial differences in the affinity of TAF ( II ) 105 toward different p65/RelA-containing dimers .	parallel	1
15610	10849440	7124;7128	TNF-alpha;A20	We have identified the ***TNF-alpha*** ***induced*** anti-apoptotic ***A20*** gene as a target gene of TAF ( II ) 105 .	target	1
15611	10849444	2057;2056	EpoR;Epo	The binding of erythropoietin ( Epo ) to its receptor leads to the transient phosphorylation of the ***Epo*** ***receptor*** ( ***EpoR*** ) and the activation of intracellular signaling pathways .	parallel	1
15612	10849444	2057;2056	EpoR;Epo	Proteasome inhibitors did not modify the internalization and degradation of ******Epo.EpoR****** ***complexes*** , but they allowed the continuous replacement of the internalized receptors by newly synthesized receptors .	parallel	1
15613	10849444	2057;2056	EpoR;Epo	N-Ac-Leu-Leu-norleucinal , but not lactacystin , also inhibited the degradation of internalized ******Epo.EpoR****** ***complexes*** , most probably through cathepsin inhibition .	parallel	1
15614	10849446	5598;3725	BMK1;c-jun	We have previously shown that ***BMK1*** ***regulates*** ***c-jun*** gene expression through direct phosphorylation and activation of transcription factor MEF2C .	target	1
15615	10849446	5598;4205	BMK1;MEF2A	Here , we demonstrate that , in addition to MEF2C , ***BMK1*** ***phosphorylates*** and activates ***MEF2A*** and MEF2D but not MEF2B .	target	1
15616	10849446	5598;4209	BMK1;MEF2D	Here , we demonstrate that , in addition to MEF2C , ***BMK1*** ***phosphorylates*** and activates MEF2A and ***MEF2D*** but not MEF2B .	target	1
15617	10849446	5598;4205	BMK1;MEF2A	Site-directed mutagenesis reveals that the phosphorylation of these sites in MEF2A and MEF2D are necessary for the ***induction*** of ***MEF2A*** and 2D transactivating activity by either ***BMK1*** or by epidermal growth factor .	target	1
15618	10849447	8038;3486	ADAM 12;insulin-like growth factor-binding protein-3	***ADAM 12*** , a disintegrin metalloprotease , ***interacts*** with ***insulin-like growth factor-binding protein-3*** .	parallel	1
15619	10849447	3486;8038	IGFBP-3;ADAM 12	To verify the ***interaction*** between ***ADAM 12*** and ***IGFBP-3*** , an expression construct containing an ADAM 12-S cDNA was transfected into COS-1 cells .	parallel	1
15620	10849448	3055;25	Hck;Abl	These data show that ***Hck*** ***interacts*** with ***Bcr-Abl*** through a complex mechanism involving kinase-dependent and - independent components and that interaction with Hck or other Src family members is essential for transformation signaling by Bcr-Abl .	parallel	1
15621	10849448	25;3055	Abl;Hck	Recent work shows that ***Hck*** , a member of the Src tyrosine kinase family with myeloid-restricted expression , associates with and is ***activated*** by ***Bcr-Abl*** .	positive	1
15622	10849448	3055;25	Hck;Abl	Here we investigated the mechanism of ***Hck*** ***interaction*** with ***Bcr-Abl*** and the requirement for Hck activation in Bcr-Abl transformation signaling .	parallel	1
15623	10849475	942;940	B7-2;CD28	Anti B7-2 treatment has similar effects suggesting that ***interaction*** of ***B7-2*** with ***CD28*** is important in the development of a Th-2 type inflammatory response in mice .	parallel	1
15624	10849475	1493;3596	CTLA4;IL-13	***CTLA4-Ig*** fusion protein effectively ***blocked*** allergen-induced production of IL-5 and ***IL-13*** in bronchial explants from atopic asthmatics .	negative	0
15625	10849475	1493;3567	CTLA4;IL-5	***CTLA4-Ig*** fusion protein effectively ***blocked*** allergen-induced production of ***IL-5*** and IL-13 in bronchial explants from atopic asthmatics .	negative	0
15626	10849730	7040;115209	TGF-beta;peptidase	Because APN/CD13 has been implicated in the trimming on the cell surface of peptides that protrude out of MHC class II molecules , we wanted to study the ***regulation*** of this membrane ***peptidase*** in antigen presenting cells by ***TGF-beta*** .	target	1
15627	10849730	7040;290	TGF-beta;CD13	Contrary to the IL-4-induced expression of APN/CD13 as well as of MHC class II in monocytic cells , we could show that ***TGF-beta*** is able to ***augment*** the ***APN/CD13*** expression but decreases the MHC class II expression .	positive	0
15628	10850382	3574;2322	interleukin-7;Flt-3	Two cytokines , ***interleukin-7*** ( IL-7 ) and ***Flt-3*** ***ligand*** ( FL ) , appear to act in conjunction to drive this development process .	parallel	1
15629	10850408	10642;4609	CRD-BP;c-myc	The coding region determinant-binding protein ( ***CRD-BP*** ) ***binds*** in vitro to ***c-myc*** mRNA and is thought to stabilize the mRNA and increase c-myc protein abundance .	parallel	1
15630	10850426	2668;5979	GDNF;RET	Finally , we show that in a papillary carcinoma-derived cell line expressing the proto-RET receptor and the related GFRalpha2 co-receptor , ***GDNF*** treatment ***induced*** ***RET*** tyrosine phosphorylation and subsequent signal transduction pathway , indicating that RET could be active in thyroid follicular cells .	target	1
15631	10850446	3565;6778	IL-4;STAT-6	IL-4R is functional because ***IL-4*** strongly ***induced*** activation of signal transducers and activators of transcription 6 ( ***STAT-6*** ) in these cell lines .	target	1
15632	10850450	1604;966	DAF;CD59	These results show that expression of complement inhibitors on a tumor cell has functional consequences with regard to complement deposition in vivo and indicate that CD59 can indirectly effect complement activation and C3 deposition in vivo via a ***link*** between ***CD59*** and ***DAF*** expression .	parallel	0
15633	10850453	7040;1030	TGF-beta1;p15INK4B	Interestingly , whereas the ***TGF-beta1-mediated*** ***up-regulation*** of ***p15INK4B*** and p21WAF1 transcription was abolished in TSU-Pr1 and V12Ha-Ras-transfected DU145 , inhibition of the Ras/MAPK pathway restored the TGF-beta1 induction of these genes .	positive	1
15634	10850458	1026;983	p21;cdc2	In addition , As2O3 markedly enhanced the ***binding*** of ***p21*** with CDK6 , ***cdc2*** , cyclin E , and cyclin A compared with untreated control cells .	parallel	1
15635	10850458	1026;1021	p21;CDK6	In addition , As2O3 markedly enhanced the ***binding*** of ***p21*** with ***CDK6*** , cdc2 , cyclin E , and cyclin A compared with untreated control cells .	parallel	1
15636	10850461	3791;5175	KDR;CD31	***Vascular endothelial growth factor/KDR*** ***activated*** microvessel density versus ***CD31*** standard microvessel density in non-small cell lung cancer .	positive	1
15637	10850461	7422;5175	Vascular endothelial growth factor;CD31	***Vascular endothelial growth factor/KDR*** ***activated*** microvessel density versus ***CD31*** standard microvessel density in non-small cell lung cancer .	positive	1
15638	10850461	3791;7422	KDR;VEGF	We used the 11B5 monoclonal antibody recognizing the ******VEGF/KDR****** ***complex*** ( R.	parallel	1
15639	10850489	7013;2972	TRF1;BRF	In vivo , the majority of ***TRF1*** is ***complexed*** with ***BRF*** and these two proteins colocalize at many polytene chromosome sites containing RNA pol III genes .	parallel	1
15640	10850489	7013;2972	TRF1;BRF	These data suggest that in Drosophila , ***TRF1*** rather than TBP forms a ***complex*** with ***BRF*** that plays a major role in RNA pol III transcription .	parallel	1
15641	10850574	2152;2155	tissue factor;factor VII	Initiation of haemostasis involves the formation of a ***complex*** between ***tissue factor*** ( TF ) and activated ***factor VII*** ( FVIIa ) following injury .	parallel	1
15642	10850581	2155;2152	coagulation factor VII;tissue factor	The starting point of blood coagulation in vivo is the formation of a ***complex*** between ***tissue factor*** ( TF ) , which is exposed following vascular disease or trauma , and activated blood ***coagulation factor VII*** ( FVIIa ) .	parallel	1
15643	10850853	3656;3725	IRAK-2;AP-1	***IRAK-2*** and PI 3-kinase synergistically ***activate*** NF-kappaB and ***AP-1*** .	positive	1
15644	10850853	3656;4790	IRAK-2;NF-kappaB	***IRAK-2*** and PI 3-kinase synergistically ***activate*** ***NF-kappaB*** and AP-1 .	positive	1
15645	10850853	3656;9733	interleukin-1 (IL-1) receptor associated kinase-2;p110	Antisense ***interleukin-1 (IL-1) receptor associated kinase-2*** ( IRAK-2 ) oligonucleotide ( ODN ) and antisense p110 PI 3-kinase ODN ***blocked*** IRAK-2 and ***p110*** PI 3-kinase expression , respectively .	negative	0
15646	10850853	3656;3725	IRAK-2;AP-1	The effects of IRAK-2 or PI 3-kinase on NF-kappaB and AP-1 activation were confirmed by the results that overexpression of ***IRAK-2*** failed to fully ***activate*** NF-kappaB and ***AP-1*** and that overexpression of p110 PI 3-kinase is insufficient for NF-kappaB full activation but sufficient for AP-1 activation .	positive	1
15647	10850853	3656;4790	IRAK-2;NF-kappaB	The effects of IRAK-2 or PI 3-kinase on NF-kappaB and AP-1 activation were confirmed by the results that overexpression of ***IRAK-2*** failed to fully ***activate*** ***NF-kappaB*** and AP-1 and that overexpression of p110 PI 3-kinase is insufficient for NF-kappaB full activation but sufficient for AP-1 activation .	positive	1
15648	10850853	3656;3725	IRAK-2;AP-1	These data suggest that ***IRAK-2*** and PI 3-kinase cooperate to ***activate*** NF-kappaB and ***AP-1*** .	positive	1
15649	10850853	3656;4790	IRAK-2;NF-kappaB	These data suggest that ***IRAK-2*** and PI 3-kinase cooperate to ***activate*** ***NF-kappaB*** and AP-1 .	positive	1
15650	10850962	3308;3297	hsp70;HSF1	Elevated protein levels were preceded by ***hsp70-mRNA*** transcription , which was ***associated*** with ***HSF1*** phosphorylation and activation stimulated by mechanical forces , suggesting that the response was regulated at the transcriptional level .	parallel	0
15651	10850962	3297;3308	HSF1;hsp70	Thus , our findings demonstrate that cyclic strain stress-induced ***hsp70*** expression is ***mediated*** by ***HSF1*** activation and regulated by Rac and ras GTP-binding proteins .	target	0
15652	10850988	2618;5471	GARS;GPAT	Evidence was obtained for ***coupling*** between ***GPAT*** and ***GARS*** for PRA transfer .	parallel	1
15653	10850988	2618;5471	GARS;GPAT	These results provide evidence that coupling involves direct PRA transfer through ******GPAT-GARS****** ***interaction*** rather than free diffusion .	parallel	1
15654	10851026	2885;10818	Grb2;FRS2	FGFs activate the endogenous FGFRs leading to the formation of a ******Grb2/FRS2/Shp2****** ***complex*** and activation of MAP kinase .	parallel	1
15655	10851026	5781;10818	Shp2;FRS2	FGFs activate the endogenous FGFRs leading to the formation of a ******Grb2/FRS2/Shp2****** ***complex*** and activation of MAP kinase .	parallel	1
15656	10851026	5781;2885	Shp2;Grb2	FGFs activate the endogenous FGFRs leading to the formation of a ******Grb2/FRS2/Shp2****** ***complex*** and activation of MAP kinase .	parallel	1
15657	10851047	1956;7039	EGFR;TGF-alpha	******TGF-alpha/EGFR****** autocrine ***signaling*** appears to play an important role in squamous cell carcinoma of the head and neck ( SCCHN ) and upregulation of TGF-alpha and EGFR is an early event in SCCHN carcinogenesis .	parallel	0
15658	10851066	55;2064	prostatic acid phosphatase;ErbB-2	Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates with a low phosphotyrosine ( p-Tyr ) level of ***ErbB-2*** , which is ***regulated*** by cellular ***prostatic acid phosphatase*** ( PAcP ) , a protein tyrosine phosphatase .	target	1
15659	10851075	266747;3725	Rgr;c-Jun	At the transcriptional level , ***Rgr*** ***enhances*** the activity of the serum response element and ***c-Jun*** .	positive	0
15660	10851075	266747;5898	Rgr;Ral	***Rgr*** induces phosphorylation of ERKs , p38 and JNK kinases , and ***increases*** the levels of the GTP-bound forms of ***Ral*** and Ras .	positive	0
15661	10851075	266747;5599	Rgr;JNK	***Rgr*** ***induces*** phosphorylation of ERKs , p38 and ***JNK*** kinases , and increases the levels of the GTP-bound forms of Ral and Ras .	target	1
15662	10851075	266747;5594	Rgr;p38	***Rgr*** ***induces*** phosphorylation of ERKs , ***p38*** and JNK kinases , and increases the levels of the GTP-bound forms of Ral and Ras .	target	1
15663	10851076	3718;3561	Jak3;gammac	Anti-IL-15 neutralizing mAb treatment resulted in down-regulation of gammac chain and disruption of ******gammac/Jak3****** ***interaction*** in normal but had no effect in leukemic progenitors .	parallel	1
15664	10851078	4292;324	Mlh1;Apc	***Mlh1*** deficiency ***enhances*** several phenotypes of ***Apc*** ( Min ) / + mice .	negative	0
15665	10851089	9616;8454	SAG;Cul1	Indeed , like ROC1/Rbx1/Hrt1 , ***SAG*** ***binds*** to Cul1 and ***SAG-Cul1*** complex has ubiquitin ligase activity to promote poly-ubiquitination of E2/Cdc34 .	parallel	1
15666	10851089	9616;8454	SAG;Cul1	Indeed , like ROC1/Rbx1/Hrt1 , SAG binds to Cul1 and ******SAG-Cul1****** ***complex*** has ubiquitin ligase activity to promote poly-ubiquitination of E2/Cdc34 .	parallel	1
15667	10851137	55502;3280	Hes6;Hes1	The bHLH gene ***Hes6*** , an ***inhibitor*** of ***Hes1*** , promotes neuronal differentiation .	negative	1
15668	10851137	55502;3280	Hes6;Hes1	***Hes6*** alone does not bind to the DNA but ***suppresses*** ***Hes1*** from repressing transcription .	negative	1
15669	10851137	6929;429	E47;Mash1	In addition , Hes6 suppresses Hes1 from inhibiting ******Mash1-E47****** ***heterodimer*** and thereby enables Mash1 and E47 to upregulate transcription in the presence of Hes1 .	parallel	1
15670	10851137	55502;3280	Hes6;Hes1	In addition , ***Hes6*** ***suppresses*** ***Hes1*** from inhibiting Mash1-E47 heterodimer and thereby enables Mash1 and E47 to upregulate transcription in the presence of Hes1 .	negative	1
15671	10851137	55502;3280	Hes6;Hes1	These results suggest that ***Hes6*** is an ***inhibitor*** of ***Hes1*** , supports Mash1 activity and promotes cell differentiation .	negative	1
15672	10851172	4804;627	p75NTR;Neurotrophin	Neurotrophins use two types of receptors , the Trk tyrosine kinase receptors and the p75 ***Neurotrophin*** ***receptor*** ( ***p75NTR*** ) , to regulate the growth , development , survival and repair of the nervous system .	parallel	1
15673	10851229	2033;2627	p300;GATA-6	In addition , we show that the transcriptional coactivator ***p300*** ***associated*** with ***GATA-6*** during the transcription of the Sm-MHC gene .	parallel	0
15674	10851229	2627;2033	GATA-6;p300	A ******p300/GATA-6****** ***complex*** in VSMCs was up-regulated by induction of the quiescent phenotype .	parallel	1
15675	10851232	1019;595	Cdk4;cyclin D1	Of relevance , cyclin D1-associated kinase activity is increased and the retinoblastoma protein ( Rb ) , a substrate of the ******cyclin D1-Cdk4****** / 6 ***complex*** , is phosphorylated during K ( + ) deprivation-evoked death of cerebellar granule neurons ( CGNs ) .	parallel	1
15676	10851246	5592;7408	cGK;VASP	These results indicate that ***cGK*** I ***phosphorylation*** of ***VASP*** results in loss of VASP and zyxin from focal adhesions , a response that could contribute to cGK alteration of cytoskeleton-regulated processes such as cell migration .	target	1
15677	10851247	56896;10570	CRAM;CRMP3	Indeed , ***CRAM*** physically ***associates*** with ***CRMP3*** when co-expressed in COS-7 cells .	parallel	0
15678	10851247	56896;10570	CRAM;CRMP3	Taken together , our results suggest that ***CRAM*** , which ***interacts*** with ***CRMP3*** and protein-tyrosine kinase ( s ) , is a new member of an emerging family of molecules that potentially mediate signals involved in the guidance and outgrowth of axons .	parallel	1
15679	10851248	25788;5888	Rad54B;Rad51	A novel human rad54 homologue , ***Rad54B*** , ***associates*** with ***Rad51*** .	parallel	0
15680	10851248	25788;5888	Rad54B;Rad51	Here we demonstrate that human ***Rad54B*** ( hRad54B ) , like human rad54 ( hRad54 ) , ***associates*** with human ***Rad51*** ( hRad51 ) .	parallel	0
15681	10851248	25788;5888	hRad54B;hRad51	Both ***hRad54B*** and hRad54 ***associate*** with ***hRad51*** through their NH ( 2 ) - terminal domains , but there are differences in their ways of association with hRad51 .	parallel	0
15682	10851248	8438;5888	hRad54;hRad51	Both hRad54B and ***hRad54*** ***associate*** with ***hRad51*** through their NH ( 2 ) - terminal domains , but there are differences in their ways of association with hRad51 .	parallel	0
15683	10851248	25788;5888	Rad54B;Rad51	In contrast to rad54 , whose association with Rad51 is induced by ionizing radiation , ***Rad54B*** ***associates*** with ***Rad51*** constitutively in immunoprecipitation experiments .	parallel	0
15684	10851248	5888;25788	hRad51;hRad54B	Also , the failure to detect the ***interaction*** between ***hRad54B*** and ***hRad51*** in the yeast two-hybrid assay suggests that their interaction , unlike that between hRad54 and hRad51 , may be indirect .	parallel	1
15685	10851461	3558;3458	interleukin-2;interferon-gamma	Human recombinant ***interleukin-2*** ( rIL-2 ) ***induced*** ***interferon-gamma*** ( IFN-gamma ) release in vivo was studied in 16 renal cell carcinoma patients treated with low-dose s.c. rIL-2 .	target	1
15686	10851483	3458;7124	interferon-gamma;tumor necrosis factor-alpha	The presence of ***interferon-gamma*** ***enhanced*** production of ***tumor necrosis factor-alpha*** by macrophages exposed to lower concentrations of JT3002 and induced the release of nitric oxide , a potent cytolytic molecule of activated macrophages .	positive	0
15687	10852110	3579;3576	CXCR2;Interleukin-8	***Interleukin-8*** and its ***receptor*** ***CXCR2*** in atherosclerosis .	parallel	1
15688	10852110	729230;6347	CCR2;monocyte chemoattractant protein-1	Although the C-C chemokine ***monocyte chemoattractant protein-1*** and its ***receptor*** , ***CCR2*** , have been implicated in atherosclerosis , the role of the classic C-X-C chemokine , Interleukin-8 ( KC/growth-related oncogene alpha in mice ) and its receptor CXCR2 has not been studied in the pathogenesis of atherosclerosis .	parallel	1
15689	10852386	57126;5777	cell surface receptor;protein-tyrosine phosphatase SHP-1	A porcine ***cell surface receptor*** identified by monoclonal antibodies to SWC3 is a member of the signal regulatory protein family and ***associates*** with ***protein-tyrosine phosphatase SHP-1*** .	parallel	0
15690	10852469	7351;3952	UCP-2;leptin	In the fasting state ***UCP-2*** expression ***correlated*** inversely with body mass index ( r = -0.45 ; P = 0.026 ) , percent body fat ( r = -0.41 ; P = 0.05 ) , plasma insulin ( r = -0.47 ; P = 0.02 ) , epigastric venous fatty acids ( r = -0.45 ; P = 0.04 ) , and ***leptin*** ( r = -0.50 ; P = 0.018 ) .	negative	0
15691	10852705	6318;1511	SCCA2;catG	SCCA1 neutralizes the papain-like cysteine proteinases , cathepsins ( cat ) S , L , and K ; and ***SCCA2*** ***inhibits*** the chymotrypsin-like serine proteinases , ***catG*** and human mast cell chymase .	negative	1
15692	10852705	6318;1215	SCCA2;chymase	SCCA1 neutralizes the papain-like cysteine proteinases , cathepsins ( cat ) S , L , and K ; and ***SCCA2*** ***inhibits*** the chymotrypsin-like serine proteinases , catG and human mast cell ***chymase*** .	negative	1
15693	10852745	3606;3458	IL-18;IFN-gamma	Circulating ***IL-18*** significantly ***correlated*** with circulating ***IFN-gamma*** .	parallel	0
15694	10852826	1832;5318	desmoplakin;PKP2	We postulate that ( 1 ) effective cellular regulatory mechanisms exist that prevent plakophilins from unscheduled IF-binding , and ( 2 ) specific ***desmoplakin*** ***interactions*** with either PKP1 , ***PKP2*** or PKP3 , or combinations thereof , are involved in the selective recruitment of plakophilins to the desmosomal plaques .	parallel	1
15695	10852826	1832;11187	desmoplakin;PKP3	We postulate that ( 1 ) effective cellular regulatory mechanisms exist that prevent plakophilins from unscheduled IF-binding , and ( 2 ) specific ***desmoplakin*** ***interactions*** with either PKP1 , PKP2 or ***PKP3*** , or combinations thereof , are involved in the selective recruitment of plakophilins to the desmosomal plaques .	parallel	1
15696	10852904	5883;3364	hRad9;hHus1	Additionally , extraction-resistant ***hRad9*** ***interacted*** with its binding partners , ***hHus1*** and an inducibly phosphorylated form of hRad1 .	parallel	1
15697	10852904	5883;5810	hRad9;hRad1	Additionally , extraction-resistant ***hRad9*** ***interacted*** with its binding partners , hHus1 and an inducibly phosphorylated form of ***hRad1*** .	parallel	1
15698	10852925	9368;1080	EBP50;CFTR	Point substitution of the C-terminal leucine ( Leu at position 0 ) with alanine abrogated apical polarization of CFTR , ***interaction*** between ***CFTR*** and ***EBP50*** , efficient expression of CFTR in the apical membrane , and chloride secretion .	parallel	1
15699	10852925	1080;9368	CFTR;EBP50	Point substitution of the threonine ( Thr at position -2 ) with alanine or valine had no effect on the apical polarization of CFTR , but reduced ***interaction*** between ***CFTR*** and ***EBP50*** , efficient expression of CFTR in the apical membrane as well as chloride secretion .	parallel	1
15700	10852925	1080;9368	CFTR;EBP50	We conclude that the PDZ-interacting domain , in particular the leucine ( position 0 ) and threonine ( position -2 ) residues , are required for the efficient , polarized expression of CFTR in the apical plasma membrane , ***interaction*** of ***CFTR*** with ***EBP50*** , and for the ability of CFTR to mediate chloride secretion .	parallel	1
15701	10852925	1080;9368	CFTR;EBP50	Mutations that delete the C terminus of CFTR may cause cystic fibrosis because ***CFTR*** is not polarized , ***complexed*** with ***EBP50*** , or efficiently expressed in the apical membrane of epithelial cells .	parallel	1
15702	10852954	6850;695	Syk;Btk	The present study provides genetic , biochemical , and pharmacological evidence that , on FcepsilonRI stimulation , ***Syk*** ***regulates*** ***Btk*** , and Btk selectively regulates the membrane translocation and enzymatic activity of PKCbetaI among the conventional PKC isoforms ( alpha , betaI , and betaII ) expressed in mast cells .	target	1
15703	10852958	8850;1523	histone acetyltransferase PCAF;CDP/cut	Here , we report the interaction of CDP/cut with CBP and p300/CREB-binding protein-associated factor ( PCAF ) along with the ***modification*** of ***CDP/cut*** by the ***histone acetyltransferase PCAF*** .	target	0
15704	10852958	1523;1387	CDP/cut;CBP	Here , we report the ***interaction*** of ***CDP/cut*** with ***CBP*** and p300/CREB-binding protein-associated factor ( PCAF ) along with the modification of CDP/cut by the histone acetyltransferase PCAF .	parallel	1
15705	10852963	7124;5599	TNFalpha;JNK	MEKK1 is not required for ***TNFalpha*** or IL-1 ***regulation*** of ***JNK*** or NF-kappaB activation in macrophages or fibroblasts .	target	1
15706	10852963	7124;4790	TNFalpha;NF-kappaB	MEKK1 is not required for ***TNFalpha*** or IL-1 ***regulation*** of JNK or ***NF-kappaB*** activation in macrophages or fibroblasts .	target	1
15707	10852966	4068;1796	SH2D1A;p62dok	The X-linked lymphoproliferative syndrome gene product ***SH2D1A*** ***associates*** with ***p62dok*** ( Dok1 ) and activates NF-kappa B .	parallel	0
15708	10852966	4068;4790	SH2D1A;NF-kappa B	The X-linked lymphoproliferative syndrome gene product ***SH2D1A*** associates with p62dok ( Dok1 ) and ***activates*** ***NF-kappa B*** .	positive	1
15709	10852966	4068;4790	SH2D1A;NF-kappaB	Further , overexpression of ***SH2D1A*** is found to ***activate*** ***NF-kappaB*** in 293T cells .	positive	1
15710	10852966	4068;4790	SH2D1A;NF-kappaB	***NF-kappaB*** ***activation*** by ***SH2D1A*** does not depend on the wild-type SH2 domain and is inhibited by a dominant-negative IkappaB kinase beta .	positive	1
15711	10852968	1432;4208	p38alpha;MEF2C	The mitogen-activated protein kinase ***p38alpha*** ***activates*** ***MEF2C*** .	positive	1
15712	10852976	355;836	Fas;caspase-3	Interestingly , ***Fas*** ligation ***activated*** caspase-8 and ***caspase-3*** with the cleavage of poly ( ADP-ribose ) polymerase ( PARP ) , corresponding to apoptosis of RA synoviocytes .	positive	1
15713	10852976	355;841	Fas;caspase-8	Interestingly , ***Fas*** ligation ***activated*** ***caspase-8*** and caspase-3 with the cleavage of poly ( ADP-ribose ) polymerase ( PARP ) , corresponding to apoptosis of RA synoviocytes .	positive	1
15714	10852976	8772;355	FADD;Fas	Importantly , ***FADD*** was selectively ***recruited*** to the ***Fas*** death domain during Fas-mediated apoptosis of RA synoviocytes , consistent with sensitivity to the Fas-mediated apoptosis .	target	0
15715	10853038	7157;995	p53;cdc25C	***Binding*** of the growth suppressor ***p53*** protein to the cell cycle regulator phosphatase ***cdc25C*** .	parallel	1
15716	10853038	995;7157	cdc25C;p53	We found that ***cdc25C*** directly ***interacts*** with ***p53*** .	parallel	1
15717	10853038	995;7157	cdc25C;p53	As shown by band shift experiments ***binding*** of ***cdc25C*** to ***p53*** does not modify the DNA binding activity of p53 .	parallel	1
15718	10853038	995;7157	cdc25C;p53	Our data suggest that the observed suppression of the p53 induced growth arrest by cdc25C might be achieved by direct ***binding*** of ***cdc25C*** to the C-terminus of ***p53*** .	parallel	1
15719	10853648	7124;4790	TNF-alpha;NF-kappaB	DHM2EQ inhibited ***TNF-alpha-induced*** ***activation*** of ***NF-kappaB*** in human T cell leukemia cells , and also inhibited collagen-induced arthritis in a rheumatoid model in mice .	positive	1
15720	10853853	5265;3576	alpha1AT;interleukin-8	The authors assessed the sputum concentration of the neutrophil chemoattractants ***interleukin-8*** ( IL-8 ) and leukotriene ( LT ) B4 , myeloperoxidase ( MPO ) as a marker of neutrophil influx , neutrophil elastase activity and its natural ***inhibitors*** , ***alpha1AT*** and secretory leukoprotease inhibitor ( SLPI ) .	negative	1
15721	10853924	4852;1803	neuropeptide Y;DPP IV	It is hypothesised that a combined dysregulation of DPP IV and neuroactive peptides , which are ***substrates*** of ***DPP IV*** , e.g. ***neuropeptide Y*** and peptide YY , could be an integral component of eating disorders .	parallel	1
15722	10853924	5697;1803	peptide YY;DPP IV	It is hypothesised that a combined dysregulation of DPP IV and neuroactive peptides , which are ***substrates*** of ***DPP IV*** , e.g. neuropeptide Y and ***peptide YY*** , could be an integral component of eating disorders .	parallel	1
15723	10853976	3569;7124	interleukin-6;tumor necrosis factor alpha	RESULTS : Using these analyses , significant correlations were found among plasma levels of ***tumor necrosis factor alpha*** ( TNFalpha ) and its type two ***receptor*** ( TNFrII ) , ***interleukin-6*** ( IL-6 ) , beta2-microglobulin , expression of CD38 and HLA-DR on CD8 + T lymphocytes and plasma levels of HIV-1 RNA .	parallel	1
15724	10854034	4915;627	trkB;brain-derived neurotrophic factor	We have investigated the potential role of neurotrophic factors in antipsychotic drug action by examining the effects of antipsychotic and psychotropic treatments on the mRNA expression of ***brain-derived neurotrophic factor*** ( BDNF ) , neurotrophin-3 ( NT-3 ) , and their ***receptors*** , ***trkB*** and trkC , respectively , in rat brain .	parallel	1
15725	10854034	4916;627	trkC;brain-derived neurotrophic factor	We have investigated the potential role of neurotrophic factors in antipsychotic drug action by examining the effects of antipsychotic and psychotropic treatments on the mRNA expression of ***brain-derived neurotrophic factor*** ( BDNF ) , neurotrophin-3 ( NT-3 ) , and their ***receptors*** , trkB and ***trkC*** , respectively , in rat brain .	parallel	1
15726	10854049	5865;7082	Rab3B;ZO-1	***Rab3B*** ***regulates*** ***ZO-1*** targeting and actin organization in PC12 neuroendocrine cells .	target	1
15727	10854050	994;983	cdc25B;Cdc2	Here we demonstrate biochemically that Cdc2/cyclin B1 accumulates at the centrosome in late G2 as the inactive , phosphotyrosine 15 form and that the centrosomal ***Cdc2/cyclin B1*** can be ***activated*** in vitro by recombinant ***cdc25B*** .	positive	1
15728	10854050	994;891	cdc25B;cyclin B1	Here we demonstrate biochemically that Cdc2/cyclin B1 accumulates at the centrosome in late G2 as the inactive , phosphotyrosine 15 form and that the centrosomal ***Cdc2/cyclin B1*** can be ***activated*** in vitro by recombinant ***cdc25B*** .	positive	1
15729	10854063	5757;5763	prothymosin alpha;parathymosin	Nuclear distribution of prothymosin alpha and parathymosin : evidence that ***prothymosin alpha*** is ***associated*** with RNA synthesis processing and ***parathymosin*** with early DNA replication .	parallel	0
15730	10854068	1026;1019	p21;CDK4	Accumulation of p21 ( CIP1/WAF1 ) resulted in increased ***binding*** of ***p21*** ( CIP1/WAF1 ) to ***CDK4*** and concomitantly caused a profound decrease in the in vitro retinoblastoma protein ( Rb ) kinase activity of CDK4 .	parallel	1
15731	10854130	373156;5599	GST;JNK	Furthermore , we discovered that c-raf induces oocyte maturation that is inhibited by glutathione-S-transferase ( ***GST*** ) , which we have found to be a potent and selective ***inhibitor*** of ***JNK*** .	negative	1
15732	10854153	940;941	CD28;B7-1	The rationale for this strategy is that T-cells need two signals before they can mount a cytotoxic response : the binding of the T-cell receptor ( TCR ) to an antigenic peptide presented on major histocompatibility complex ( MHC ) molecules and the ***binding*** of ***CD28*** to ***B7-1*** .	parallel	1
15733	10854177	959;958	CD154;CD40	The role of ******CD40-CD154****** ***interactions*** in the regulation of cell mediated immunity .	parallel	1
15734	10854211	4018;5599	lipoprotein;JNK	Furthermore , low-density ***lipoprotein*** ( LDL ) and oxidized LDL ***stimulated*** ***SAPK/JNK*** activation in cultured SMCs in a time - and dose-dependent manner .	positive	0
15735	10854229	284;7010	Ang-1;Tie-2	***Ang-1*** , the major physiological ***activator*** of ***Tie-2*** , promotes blood vessel maturation and stability .	positive	1
15736	10854229	284;7010	Ang-1;Tie-2	Ang-2 counteracts this effect by competitively inhibiting the ***binding*** of ***Ang-1*** to ***Tie-2*** .	parallel	1
15737	10854239	284;7010	Angiopoietin-1;Tie-2	***Angiopoietin-1*** and angiopoietin-2 ***activate*** trophoblast ***Tie-2*** to promote growth and migration during placental development .	positive	1
15738	10854239	285;7010	angiopoietin-2;Tie-2	Angiopoietin-1 and ***angiopoietin-2*** ***activate*** trophoblast ***Tie-2*** to promote growth and migration during placental development .	positive	1
15739	10854322	2081;9451	IRE1;PERK	Loss of BiP correlates with the formation of high-molecular-mass ***complexes*** of activated ***PERK*** or ***IRE1*** , and overexpression of BiP attenuates their activation .	parallel	1
15740	10854325	54472;3654	Tollip;IRAK	Here we show that , before IL-1beta treatment , Tollip is present in a complex with IRAK , and that recruitment of ******Tollip-IRAK****** ***complexes*** to the activated receptor complex occurs through association of Tollip with IL-1RAcP .	parallel	1
15741	10854325	54472;3556	Tollip;IL-1RAcP	Here we show that , before IL-1beta treatment , Tollip is present in a complex with IRAK , and that recruitment of Tollip-IRAK complexes to the activated receptor complex occurs through ***association*** of ***Tollip*** with ***IL-1RAcP*** .	parallel	0
15742	10854420	5564;31	AMPK;ACC	During contraction decreases in muscle malonyl-CoA concentration have been related to activation of AMP-activated protein kinase ( ***AMPK*** ) , which ***phosphorylates*** and inhibits acetyl-CoA carboxylase ( ***ACC*** ) , the rate-limiting enzyme in malonyl-CoA formation .	target	1
15743	10854421	7518;3981	XRCC4;DNA ligase IV	Interactions of the ******DNA ligase IV-XRCC4****** ***complex*** with DNA ends and the DNA-dependent protein kinase .	parallel	1
15744	10854421	7518;3981	XRCC4;DNA ligase IV	Here we demonstrate that the ******DNA ligase IV-XRCC4****** ***complex*** binds specifically to the ends of duplex DNA molecules and can act as a bridging factor , linking together duplex DNA molecules with complementary but non-ligatable ends .	parallel	1
15745	10854421	5591;3981	DNA-PKcs;DNA ligase IV	***DNA ligase IV-XRCC4*** and ***DNA-PKcs*** also formed ***complexes*** at the ends of DNA molecules , but DNA-PKcs did not inhibit ligation .	parallel	1
15746	10854421	5591;7518	DNA-PKcs;XRCC4	***DNA ligase IV-XRCC4*** and ***DNA-PKcs*** also formed ***complexes*** at the ends of DNA molecules , but DNA-PKcs did not inhibit ligation .	parallel	1
15747	10854421	7518;3981	XRCC4;DNA ligase IV	******DNA ligase IV-XRCC4****** and DNA-PKcs also formed ***complexes*** at the ends of DNA molecules , but DNA-PKcs did not inhibit ligation .	parallel	1
15748	10854423	5887;4350	hHR23A and -B;MPG	In this report , we show that the ***hHR23A and -B*** also ***interact*** with the ***MPG*** protein and can serve as accessory proteins for DNA damage recognition in base excision repair .	parallel	1
15749	10854533	2321;7422	Flt-1;vascular endothelial growth factor	***Flt-1*** ( VEGF receptor-1 ) and KDR/Flk -1 ( VEGF receptor-2 ) are the high-affinity ***receptors*** for the angiogenesis factor , ***vascular endothelial growth factor*** ( VEGF ) .	parallel	1
15750	10854533	3791;7422	KDR;vascular endothelial growth factor	Flt-1 ( VEGF receptor-1 ) and ***KDR/Flk*** -1 ( VEGF receptor-2 ) are the high-affinity ***receptors*** for the angiogenesis factor , ***vascular endothelial growth factor*** ( VEGF ) .	parallel	1
15751	10854553	7422;7157	VEGF;P53	***VEGF*** expression was ***associated*** with ***P53*** expression and poor patient prognosis , but dThdPase expression was not .	parallel	0
15752	10854763	6863;2353	substance P;c-Fos	The combined application of N-methyl-D-aspartate 340 microM + ***substance P*** ( at 0.74 or 3.7 microM ) significantly ***increased*** ipsilateral ***c-Fos*** compared to either agent alone .	positive	0
15753	10854787	6670;6667	Sp3;Sp1	Electrophoretic mobility shift assays indicate that both Sp1 and ***Sp3*** nuclear factors ***interact*** with the -836 ***Sp1*** element , while the AP1-related proteins Fra-2 and JunD bind to the AP1 motif .	parallel	1
15754	10854844	6863;7124	Substance P;tumor necrosis factor-alpha	***Substance P*** ***induces*** ***tumor necrosis factor-alpha*** release from human skin via mitogen-activated protein kinase .	target	1
15755	10854844	6863;7124	Substance P;TNF-alpha	***Substance P*** ***induced*** the release of histamine and ***TNF-alpha*** in a dose-dependent manner at concentrations from 0.8 to 100 microM .	target	1
15756	10854844	6863;7124	Substance P;TNF-alpha	These results suggest that ***Substance P*** , in addition to antigen , ***induced*** ***TNF-alpha*** release from human skin by a mitogen-activated protein ( MAP ) kinase , predominantly extracellular signaling-regulated protein kinase ( ERK ) - dependent , and dexamethasone-sensitive pathway , which is separate from that for histamine release from mast cells .	target	1
15757	10854852	10603;3643	APS;insulin receptor	The ***APS*** adapter protein couples the insulin receptor to the phosphorylation of c-Cbl and ***facilitates*** ligand-stimulated ubiquitination of the ***insulin receptor*** .	positive	0
15758	10854852	867;3643	c-Cbl;insulin receptor	APS-mediated ***recruitment*** of ***c-Cbl*** to the ***insulin receptor*** led to rapid ubiquitination of the insulin receptor beta-subunit in CHO .	target	0
15759	10854852	10603;3643	APS;insulin receptor	These results suggest that the function of ***APS*** is to ***facilitate*** coupling of the ***insulin receptor*** to c-Cbl in order to catalyse the ubiquitination of the receptor and initiation of internalisation or degradation .	positive	0
15760	10855687	5744;5741	PTH-related protein;PTH	***Regulation*** of ***PTH/PTH-related protein*** receptor expression by endogenous ***PTH-related protein*** in the rat osteosarcoma cell line ROS 17/2 .8 .	target	1
15761	10855792	7415;672	VCP;BRCA1	***VCP*** , a weak ATPase involved in multiple cellular events , ***interacts*** physically with ***BRCA1*** in the nucleus of living cells .	parallel	1
15762	10855792	672;7415	BRCA1;valosin-containing protein	Here , we demonstrate that the ***BRCA1*** protein physically ***associates*** with ***valosin-containing protein*** ( VCP ) , a member of the ATPases associated with a variety of cellular activities ( AAA ) superfamily .	parallel	0
15763	10856136	3596;3565	IL-13;IL-4	******IL-4/IL-13****** ***signaling*** beyond JAK/STAT .	parallel	0
15764	10856136	3565;2242	IL-4;Fes	The ***Fes*** tyrosine kinase is ***activated*** by ***IL-4*** and appears to be important in regulating IL-4-induced proliferation through the phosphorylation of insulin receptor substrate ( IRS ) molecules .	positive	1
15765	10856237	5170;6197	PDK1;RSK2	Our results suggest a novel regulatory mechanism based on phosphoserine-mediated ***recruitment*** of ***PDK1*** to ***RSK2*** , leading to coordinated phosphorylation and activation of PDK1 and RSK2 .	target	0
15766	10856240	2122;5599	evi-1;JNK	Here we show that ***evi-1*** acts as an ***inhibitor*** of c-Jun N-terminal kinase ( ***JNK*** ) , a class of mitogen-activated protein kinases implicated in stress responses of cells .	negative	1
15767	10856240	2122;5599	evi-1;JNK	***evi-1*** physically ***interacts*** with ***JNK*** , although it does not affect its phosphorylation .	parallel	1
15768	10856244	861;865	AML1;CBFbeta	Furthermore , the ***interaction*** of ***AML1*** with ***CBFbeta*** is essential for haematopoiesis .	parallel	1
15769	10856244	865;861	CBFbeta;AML1	We report the 2.6 A resolution crystal structure of the ***complex*** between the ***AML1*** Runt domain and ***CBFbeta*** , which represents a paradigm for the mode of interaction of this highly conserved family of transcription factors .	parallel	1
15770	10856257	56478;1977	4E-T;eIF4E	Taken together , these results demonstrate that the novel nucleocytoplasmic shuttling protein ***4E-T*** ***mediates*** the nuclear import of ***eIF4E*** via the importin alphabeta pathway by a piggy-back mechanism .	target	0
15771	10856262	1489;183	Cardiotrophin-1;angiotensinogen	***Cardiotrophin-1*** ***increases*** ***angiotensinogen*** mRNA in rat cardiac myocytes through STAT3 : an autocrine loop for hypertrophy .	positive	0
15772	10856262	1489;183	Cardiotrophin-1;angiotensinogen	We found that ***Cardiotrophin-1*** ***increased*** ***angiotensinogen*** mRNA expression in cardiac myocytes via STAT3 activation .	positive	0
15773	10856262	1489;6774	Cardiotrophin-1;STAT3	Tyrosine ***phosphorylation*** of ***STAT3*** by ***Cardiotrophin-1*** treatment resulted in STAT3 homodimer binding to the St-domain in the angiotensinogen gene promoter , which lead to promoter activation in a transient transfection assay .	target	1
15774	10856287	11345;4905	GATE-16;N-ethylmaleimide-sensitive fusion protein	The ***GATE-16*** protein participates in intra-Golgi transport and can ***associate*** with the ***N-ethylmaleimide-sensitive fusion protein*** and with Golgi SNAREs .	parallel	0
15775	10856292	51043;1280	C-Krox;COL2A1	We then demonstrated that a zinc finger protein , ***C-Krox*** , ***activates*** ***COL2A1*** gene transcription in differentiated chondrocytes through the enhancer region , whereas in subcultured cells , it inhibited the gene activity via a 266-bp promoter .	positive	1
15776	10856295	4301;50848	AF-6;JAM	***Binding*** of ***AF-6*** to ***JAM*** required the presence of the intact C terminus of JAM , which represents a classical type II PDZ domain-binding motif .	parallel	1
15777	10856296	196;4193	aryl-hydrocarbon receptor;Mdm2	However , we show that induction of Mdm2 mRNA by BaP is entirely dependent upon aryl-hydrocarbon-induced genotoxicity and does not involve direct ***aryl-hydrocarbon receptor-mediated*** transcriptional ***activation*** of the ***Mdm2*** gene .	positive	1
15778	10856300	2081;22926	IRE1;ATF6	A proximal sensor of the ER stress response , human ***IRE1*** ( hIRE1 ) , was sufficient to ***activate*** the ***ATF6*** reporter gene , while a dominant negative form of hIRE1 blocked ER stress activation , suggesting that hIRE1 is upstream of ATF6 in the ER stress signaling pathway .	positive	1
15779	10856305	6810;8773	syntaxin 4;SNAP-23	In platelets , cellular activation by thrombin or phorbol 12-myristate 13-acetate decreased the ***binding*** of ***syntaxin 4*** with ***SNAP-23*** , another platelet t-SNARE .	parallel	1
15780	10856305	8773;6810	SNAP-23;syntaxin 4	Phosphatase inhibitors increased syntaxin 4 phosphorylation and further decreased ******syntaxin 4-SNAP-23****** ***binding*** induced by cell activation .	parallel	1
15781	10856305	6810;8773	syntaxin 4;SNAP-23	PKC phosphorylation in vitro inhibited ( 71 + / - 8 % ) the ***binding*** of ***syntaxin 4*** to ***SNAP-23*** .	parallel	1
15782	10856699	959;958	CD154;CD40	The emerging picture indicates that ***ligation*** of the receptor ***CD40*** via ***CD154*** , most potently in its trimeric form , functions in two ways .	parallel	1
15783	10856699	959;958	CD154;CD40	Accordingly , ******CD40/CD154****** ***interactions*** have advanced as a potential therapeutic target for these diseases , whereby two opposing strategies , interruption as well as enhancement of CD40 signaling , are explored for beneficial outcomes .	parallel	1
15784	10856833	4436;9156	hMSH2;exonuclease 1	We demonstrate that ***hMSH2*** ***interacts*** with a human 5 ' -3 ' ***exonuclease 1*** ( hEXO1/HEX1 ) and that this interaction is mediated through their C-terminal domains .	parallel	1
15785	10856878	5741;5745	PTH;PTHR	Both ***PTH*** and PTHrP ***bind*** to the common type I PTH/PTHrP receptor ( ***PTHR*** ) , thereby activating phospholipase C and adenylate cyclase through various G proteins , in bone and renal cells .	parallel	1
15786	10856878	5744;5745	PTHrP;PTHR	Both PTH and ***PTHrP*** ***bind*** to the common type I PTH/PTHrP receptor ( ***PTHR*** ) , thereby activating phospholipase C and adenylate cyclase through various G proteins , in bone and renal cells .	parallel	1
15787	10856878	5745;5741	PTHR;PTH	Both PTH and PTHrP bind to the common type I ***PTH/PTHrP*** ***receptor*** ( ***PTHR*** ) , thereby activating phospholipase C and adenylate cyclase through various G proteins , in bone and renal cells .	parallel	1
15788	10856878	5745;5744	PTHR;PTHrP	Both PTH and PTHrP bind to the common type I ***PTH/PTHrP*** ***receptor*** ( ***PTHR*** ) , thereby activating phospholipase C and adenylate cyclase through various G proteins , in bone and renal cells .	parallel	1
15789	10856879	3483;3486	ALS;insulin-like growth factor-binding protein-3	The 140 kDa ternary ***complex*** of ***insulin-like growth factor-binding protein-3*** ( IGFBP-3 ) , IGFs and an acid-labile subunit ( ***ALS*** ) has previously been shown to be decreased in diabetes mellitus in humans and rats .	parallel	1
15790	10856880	3486;3479	IGFBP-3;IGF-I	The stimulatory effect of ***IGF-I*** was ***inhibited*** significantly by addition of ***IGFBP-3*** but enhanced slightly by IGFBP-5 .	negative	1
15791	10856890	3569;3630	Interleukin-6;preproinsulin	***Interleukin-6*** ***increases*** insulin secretion and ***preproinsulin*** mRNA expression via Ca2 + - dependent mechanism .	positive	0
15792	10856974	7035;2152	TFPI;Tissue Factor	The three major anticoagulant mechanisms appear to involve antithrombin-heparin , ***Tissue Factor*** pathway ***inhibitor*** ( ***TFPI*** ) and the Protein C pathway .	negative	1
15793	10856975	2152;2155	Tissue factor;Factor VII	The cascade of coagulation zymogen activations which leads to clot formation is initiated by exposure of flowing blood to ***Tissue factor*** ( TF ) , the cellular ***receptor*** and cofactor for ***Factor VII*** ( FVII ) .	parallel	1
15794	10856975	7035;2152	TFPI;Tissue factor	Further FXa generation by the FIXa-FVIIIa-Ca2 + - phospholipid complex is required to sustain the coagulation mechanism , since the TF-FVIIa complex is rapidly inactivated by ***Tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) .	negative	1
15795	10857749	6921;7428	elongin C;pVHL	Although an amino acid substitution ( K171T ) close to the pVHL elongin binding region was found in baboon , analysis of the structure of human pVHL suggested that this substitution would not interfere with ******pVHL/elongin C****** ***interaction*** .	parallel	1
15796	10857750	26528;1617	DAZAP1;DAZ	***DAZAP1*** and DAZAP2 ***bind*** similarly to both ***DAZ*** and DAZL1 through the DAZ repeats .	parallel	1
15797	10857750	26528;1618	DAZAP1;DAZL1	***DAZAP1*** and DAZAP2 ***bind*** similarly to both DAZ and ***DAZL1*** through the DAZ repeats .	parallel	1
15798	10857750	9802;1617	DAZAP2;DAZ	DAZAP1 and ***DAZAP2*** ***bind*** similarly to both ***DAZ*** and DAZL1 through the DAZ repeats .	parallel	1
15799	10857750	9802;1618	DAZAP2;DAZL1	DAZAP1 and ***DAZAP2*** ***bind*** similarly to both DAZ and ***DAZL1*** through the DAZ repeats .	parallel	1
15800	10857756	3565;6347	IL-4;MCP-1	In both responses , ***IL-4*** ***promoted*** ***MCP-1*** and MCP-5 mRNA , but IL-13 inhibited chemokines in type-1 GR .	positive	0
15801	10857756	3596;3458	IL-13;IFNgamma	In type-1 GR lungs , anti-IL-4 and ***anti-IL-13*** ***augmented*** ***IFNgamma*** and TNFalpha mRNA .	positive	0
15802	10857756	3596;7124	IL-13;TNFalpha	In type-1 GR lungs , anti-IL-4 and ***anti-IL-13*** ***augmented*** IFNgamma and ***TNFalpha*** mRNA .	positive	0
15803	10857756	3565;3458	IL-4;IFNgamma	In type-1 GR lungs , ***anti-IL-4*** and anti-IL-13 ***augmented*** ***IFNgamma*** and TNFalpha mRNA .	positive	0
15804	10857756	3565;7124	IL-4;TNFalpha	In type-1 GR lungs , ***anti-IL-4*** and anti-IL-13 ***augmented*** IFNgamma and ***TNFalpha*** mRNA .	positive	0
15805	10857756	3565;7124	IL-4;TNFalpha	In type 2 lungs , anti-IL-13 did likewise , but ***anti-IL-4*** ***decreased*** ***TNFalpha*** without affecting IFNgamma mRNA .	negative	0
15806	10857757	1437;3553	GM-CSF;IL-1 beta	The role of protein kinase C and calcium in ***induction*** of human polymorphonuclear leukocyte ***IL-1 beta*** gene expression by ***GM-CSF*** .	target	1
15807	10857757	1437;3553	GM-CSF;IL-1beta	We investigated the role of protein kinase C ( PKC ) and Ca2 + in the ***induction*** of PMN ***IL-1beta*** gene expression by ***GM-CSF*** .	target	1
15808	10857757	1437;3553	GM-CSF;IL1beta	The intracellular Ca2 + chelator BAPTA/AM inhibited ***induction*** of ***IL1beta*** mRNA accumulation and transcription by ***GM-CSF*** .	target	1
15809	10857758	960;6696	CD44;OPN	The similar actions of HA and OPN are consistent with the possibility that ***CD44*** may be a ***receptor*** for ***OPN*** .	parallel	1
15810	10857767	3565;3553	IL-4;IL-1beta	Addition of ***IL-4*** , but not IL-10 or TGF-beta , ***reduces*** the TNF-alpha-induced cell-associated ***IL-1beta*** .	negative	1
15811	10857767	7124;3553	TNF-alpha;IL-1beta	In conclusion the pro-inflammatory molecule ***TNF-alpha*** ***stimulates*** bone marrow stromal cell-associated ***IL-1beta*** levels while the anti-inflammatory cytokine IL-4 reduces the TNF-alpha-induced effect .	positive	0
15812	10857772	7124;652	TNF-alpha;BMP-4	Interestingly , ***TNF-alpha*** ***up-regulated*** the expression of ***BMP-4*** mRNA in undifferentiated ATDC5 cells in time - and dose-dependent manners .	positive	1
15813	10857772	7124;652	TNF-alpha;BMP-4	These results indicate that ***TNF-alpha*** ***stimulates*** both cell proliferation and ***BMP-4*** expression but inhibits chondrogenesis in chondroprogenitor-like ATDC5 cells .	positive	0
15814	10857790	3552;176	IL-1alpha;aggrecan	RESULTS : ***IL-1alpha*** stimulated the expression of HAS-2 and CD44 mRNA ( 3.5-fold and 3-fold , respectively ) , but ***inhibited*** the expression of ***aggrecan*** mRNA .	negative	1
15815	10857790	3552;960	IL-1alpha;CD44	RESULTS : ***IL-1alpha*** ***stimulated*** the expression of HAS-2 and ***CD44*** mRNA ( 3.5-fold and 3-fold , respectively ) , but inhibited the expression of aggrecan mRNA .	positive	0
15816	10858016	3569;4583	IL-6;MUC2	Incubation with IL-1 transiently stimulated the mRNA expression of MUC2 and MUC5AC , whereas ***IL-6*** ***induced*** an early response of ***MUC2*** , MUC5B and MUC6 .	target	1
15817	10858016	3569;727897	IL-6;MUC5B	Incubation with IL-1 transiently stimulated the mRNA expression of MUC2 and MUC5AC , whereas ***IL-6*** ***induced*** an early response of MUC2 , ***MUC5B*** and MUC6 .	target	1
15818	10858016	3569;4588	IL-6;MUC6	Incubation with IL-1 transiently stimulated the mRNA expression of MUC2 and MUC5AC , whereas ***IL-6*** ***induced*** an early response of MUC2 , MUC5B and ***MUC6*** .	target	1
15819	10858016	7124;4583	TNFalpha;MUC2	***TNFalpha*** ***upregulated*** the expression of ***MUC2*** and MUC5B for 3 hours , and had no effect on the expression of MUC 5AC and MUC6 .	positive	1
15820	10858016	7124;727897	TNFalpha;MUC5B	***TNFalpha*** ***upregulated*** the expression of MUC2 and ***MUC5B*** for 3 hours , and had no effect on the expression of MUC 5AC and MUC6 .	positive	1
15821	10858199	3458;3627	IFN-gamma;IP-10	In whole blood stimulated with heat-killed B. pseudomallei , neutralization of ***IFN-gamma*** and tumor necrosis factor alpha ( TNF-alpha ) partly ***attenuated*** ***IP-10*** and Mig release , while anti-interleukin-12 ( IL-12 ) and anti-IL-18 had a synergistic effect .	negative	0
15822	10858199	7124;3627	tumor necrosis factor alpha;IP-10	In whole blood stimulated with heat-killed B. pseudomallei , neutralization of IFN-gamma and ***tumor necrosis factor alpha*** ( TNF-alpha ) partly ***attenuated*** ***IP-10*** and Mig release , while anti-interleukin-12 ( IL-12 ) and anti-IL-18 had a synergistic effect .	negative	0
15823	10858244	356;355	FasL;Fas	Infection of C57BL/6 mice but not of C3H/HeJ mice induced massive production of tumor necrosis factor alpha ( TNF-alpha ) in serum , as well as an increase in Fas and ***Fas*** ***ligand*** ( ***FasL*** ) expression in T cells .	parallel	1
15824	10858244	355;356	Fas;FasL	In vitro addition of neutralizing anti-TNF-alpha antibodies led to a significant reduction in CD3-induced T-cell apoptosis of both CD4 ( + ) and CD8 ( + ) T cells of C57BL/6 mice , while the blockade of ******Fas-FasL****** ***interactions*** reduced apoptosis only in CD4 ( + ) but not in CD8 ( + ) T cells .	parallel	1
15825	10858244	355;356	Fas;FasL	Together , these results suggest that TNF-alpha and ******Fas-FasL****** ***interactions*** play a role in the activation-induced cell death ( AICD ) process associated with a defect in T-cell proliferation of the susceptible C57BL/6 mice .	parallel	1
15826	10858249	356;355	Fas ligand;Fas	Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through ******Fas/Fas ligand****** ***interactions*** .	parallel	1
15827	10858249	355;356	Fas;Fas ligand	We report that gastric T cells contribute to apoptosis of the epithelium by a ******Fas/Fas ligand****** ( FasL ) ***interaction*** .	parallel	1
15828	10858249	356;355	FasL;Fas	These observations demonstrate that local Th1 cells may contribute to the pathogenesis of gastric disease during H. pylori infection by increasing the expression of Fas on gastric epithelial cells and inducing apoptosis through ******Fas/FasL****** ***interactions*** .	parallel	1
15829	10858275	4914;4803	TrkA;NGF	We first investigated the immunoreactivity of ***TrkA*** , which is a high-affinity ***receptor*** of nerve growth factor ( ***NGF*** ) , in the periodontal ligament of rats .	parallel	1
15830	10858285	2152;2158	tissue factor;factor IX	The ***tissue factor*** region that ***interacts*** with substrates ***factor IX*** and Factor X.	parallel	1
15831	10858286	1026;5111	p21;PCNA	A quantitative study of the in vitro ***binding*** of the C-terminal domain of ***p21*** to ***PCNA*** : affinity , stoichiometry , and thermodynamics .	parallel	1
15832	10858286	1026;5111	p21;PCNA	Comparison of the data obtained by the competitive PCNA binding assay and the ITC measurements demonstrated the usefulness of this assay for screening for compounds that could modulate the ******PCNA-p21****** ***interaction*** .	parallel	1
15833	10858314	3320;4790	Hsp90;p50	The Hsp90 inhibitor geldanamycin does not directly disrupt the native ***association*** of ***Hsp90*** with ***p50*** ( cdc37 ) per se , but does result in the formation of salt-labile Hsp90-kinase heterocomplexes which lack the p50 ( cdc37 ) cohort .	parallel	0
15834	10858436	335;4018	apolipoprotein A-I;lipoprotein	A naturally occurring point mutant of human ***apolipoprotein A-I*** ( apoA-I ) , V156E , which is ***associated*** with extremely low plasma apoA-I and high density ***lipoprotein*** ( HDL ) levels , and coronary artery disease ( Huang , W. , Sasaki , J. , Matsunaga , A. , Nanimatsu , H. , Moriyama , K. , Han , H.	parallel	0
15835	10858439	2057;6774	EpoR;Stat3	We generated an erythropoietin receptor ( ***EpoR*** ) isoform ( ER343/401-S 3 ) that ***activates*** ***Stat3*** rather than Stat5 by substituting the Stat3 binding/activation sequence motif from gp130 for the sequences surrounding tyrosines 343 and 401 in the receptor cytoplasmic region .	positive	1
15836	10858447	949;4018	SR-BI;lipoprotein	In transfected cells ***SR-BI*** ***recognizes*** HDL , low density ***lipoprotein*** ( LDL ) and modified LDL , protein-free lipid vesicles containing anionic phospholipids , and recombinant lipoproteins containing apolipoprotein ( apo ) A-I , apoA-II , apoE , or apoCIII .	target	1
15837	10858459	4803;5594	NGF;ERK	Despite the presence of MKP-3 , ***ERK*** activity can be further ***stimulated*** by ***NGF*** , but it fails to translocate into the nucleus and consequently to induce immediate-early gene transcription .	positive	0
15838	10858507	5697;3952	PYY;leptin	Finally , ***PYY*** and Y ( 1 ) ligands ***enhanced*** adipocyte ***leptin*** secretion , an effect totally prevented by SR120819A .	positive	0
15839	10858544	4609;6834	Myc;Surf-1	***Myc*** and YY1 ***mediate*** activation of the ***Surf-1*** promoter in response to serum growth factors .	target	0
15840	10858596	351;3553	Abeta;IL-1beta	We have shown that Abeta 1-42 , fibrillar Abeta 1-40 , and ***Abeta*** 25-35 ***potentiate*** the release of interleukin-1beta ( ***IL-1beta*** ) from LPS activated human THP-1 monocytes [ 26 ] and LPS primed rat microglia .	positive	0
15841	10858596	351;3553	Abeta;IL-1beta	Several of the formyl chemotactic peptides and ***Abeta*** 1-42 significantly ***enhanced*** ***IL-1beta*** production in THP-1 monocytes .	positive	0
15842	10859164	545;1111	Atr;Chk1	Taken together , these data indicate that Chk1 plays an essential role in the mammalian DNA damage checkpoint , embryonic development , and tumor suppression , and that ***Atr*** ***regulates*** ***Chk1*** .	target	1
15843	10859214	4790;2353	NF-kappaB;c-Fos	The age-related activation of AP-1 and ***NF-kappaB*** in the gastric mucosa was ***associated*** with increased levels of c-Jun , ***c-Fos*** , and p52 , but not p50 or p65 .	parallel	0
15844	10859214	4790;3725	NF-kappaB;c-Jun	The age-related activation of AP-1 and ***NF-kappaB*** in the gastric mucosa was ***associated*** with increased levels of ***c-Jun*** , c-Fos , and p52 , but not p50 or p65 .	parallel	0
15845	10859214	4790;4791	NF-kappaB;p52	The age-related activation of AP-1 and ***NF-kappaB*** in the gastric mucosa was ***associated*** with increased levels of c-Jun , c-Fos , and ***p52*** , but not p50 or p65 .	parallel	0
15846	10859226	5747;5594	FRNK;ERK	Caco-2 motility was inhibited by transfection of ***FRNK*** ( the COOH-terminal region of FAK ) and PD-98059 , a mitogen-activated protein ***kinase-ERK*** kinase ***inhibitor*** , but not by SB-203580 , a p38 inhibitor , suggesting that FAK and ERK modulate Caco-2 migration .	negative	1
15847	10859228	7432;4883	VIP;NPR-C	***Interaction*** of ***VIP*** with ***NPR-C*** was confirmed by its ability to inhibit ( 125 ) I-ANP binding to membranes of NPR-C-transfected COS-1 cells .	parallel	1
15848	10859236	4082;5020	MARCKS;oxytocin	Phosphorylation of myristoylated alanine-rich C kinase substrate ( ***MARCKS*** ) protein is ***associated*** with bovine luteal ***oxytocin*** exocytosis .	parallel	0
15849	10859261	7432;820	VIP;cAMP	Pituitary adenylate cyclase-activating peptide and vasoactive intestinal peptide ( ***VIP*** ) dose-dependently ***stimulated*** ***cAMP*** accumulation and acute progesterone accumulation .	positive	0
15850	10859299	5715;2064	p27;HER-2/neu	Because many cancers with the overexpression of HER-2/neu overlap with those affected by reduced p27 expression , we studied the ***link*** between ***HER-2/neu*** oncogenic signals and ***p27*** regulation .	parallel	0
15851	10859299	5715;2064	p27;HER-2/neu	We found that down-regulation of ***p27*** ***correlates*** with ***HER-2/neu*** overexpression .	parallel	0
15852	10859299	2064;5715	HER-2/neu;p27	These results reveal that ***HER-2/neu*** signals ***reduce*** ***p27*** stability and thus present potential points for therapeutic intervention in HER-2/neu-associated cancers .	negative	1
15853	10859305	4488;1050	Msx2;C/EBPalpha	Electrophoresis mobility shift assays demonstrate that ***Msx2*** ***interferes*** with the binding of ***C/EBPalpha*** to its cognate site in the mouse amelogenin minimal promoter , although Msx2 itself does not bind to the same promoter fragment .	negative	0
15854	10859305	1050;4488	C/EBPalpha;Msx2	Protein-protein ***interaction*** between ***Msx2*** and ***C/EBPalpha*** is identified with co-immunoprecipitation analyses .	parallel	1
15855	10859305	4488;1050	Msx2;C/EBPalpha	Among three family members tested ( C/EBPalpha , - beta , and - gamma ) , ***Msx2*** preferentially ***interacts*** with ***C/EBPalpha*** .	parallel	1
15856	10859309	6734;58477	SRalpha;SRbeta	We demonstrate that the domain of ***SRalpha*** that ***binds*** ***SRbeta*** does so by binding directly to the nucleotide-bound form of the GTPase domain of SRbeta .	parallel	1
15857	10859312	3569;3572	IL-6;gp130	PTPepsilonC expression resulted in lower levels of ***IL-6-induced*** tyrosine ***phosphorylation*** of Jak1 , Tyk2 , ***gp130*** , and Stat3 compared with parent cells .	target	1
15858	10859312	3569;3716	IL-6;Jak1	PTPepsilonC expression resulted in lower levels of ***IL-6-induced*** tyrosine ***phosphorylation*** of ***Jak1*** , Tyk2 , gp130 , and Stat3 compared with parent cells .	target	1
15859	10859312	3569;6774	IL-6;Stat3	PTPepsilonC expression resulted in lower levels of ***IL-6-induced*** tyrosine ***phosphorylation*** of Jak1 , Tyk2 , gp130 , and ***Stat3*** compared with parent cells .	target	1
15860	10859312	3569;7297	IL-6;Tyk2	PTPepsilonC expression resulted in lower levels of ***IL-6-induced*** tyrosine ***phosphorylation*** of Jak1 , ***Tyk2*** , gp130 , and Stat3 compared with parent cells .	target	1
15861	10859317	6667;3880	Sp1;keratin 19	The tissue-dependent ***keratin 19*** gene transcription is ***regulated*** by GKLF/KLF4 and ***Sp1*** .	target	1
15862	10859319	4316;7035	matrilysin;TFPI	MMP-7 ( ***matrilysin*** ) rapidly ***cleaved*** ***TFPI*** to a major 35-kDa product .	target	1
15863	10859319	4321;7035	macrophage elastase;TFPI	In contrast , MMP-1 ( collagenase-1 ) , MMP-9 ( gelatinase B ) , and MMP-12 ( ***macrophage elastase*** ) ***cleaved*** ***TFPI*** into several fragments including the 35-kDa band .	target	1
15864	10859327	1994;4843	HuR;NOS	Inhibition of HuR with antisense constructs reduced the cytokine-induced NOS II mRNA , whereas overexpression of ***HuR*** ***potentiated*** the cytokine-induced ***NOS*** II expression .	positive	0
15865	10859327	1994;4843	HuR;NOS	Inhibition of ***HuR*** with antisense constructs ***reduced*** the cytokine-induced ***NOS*** II mRNA , whereas overexpression of HuR potentiated the cytokine-induced NOS II expression .	positive	1
15866	10859338	3659;5743	Interferon regulatory factor (IRF)-1;cyclooxygenase 2	***Interferon regulatory factor (IRF)-1*** and IRF-2 ***regulate*** interferon gamma-dependent ***cyclooxygenase 2*** expression .	target	1
15867	10859338	3660;5743	IRF-2;cyclooxygenase 2	Interferon regulatory factor (IRF)-1 and ***IRF-2*** ***regulate*** interferon gamma-dependent ***cyclooxygenase 2*** expression .	target	1
15868	10859352	10111;4361	hRad50;hMre11	We now have identified that XPV cells make use of a homologous recombination pathway involving the ******hMre11/hRad50/Nbs1****** protein ***complex*** , but not the Rad51 recombination pathway .	parallel	1
15869	10859352	10111;4683	hRad50;Nbs1	We now have identified that XPV cells make use of a homologous recombination pathway involving the ******hMre11/hRad50/Nbs1****** protein ***complex*** , but not the Rad51 recombination pathway .	parallel	1
15870	10859352	4683;4361	Nbs1;hMre11	We now have identified that XPV cells make use of a homologous recombination pathway involving the ******hMre11/hRad50/Nbs1****** protein ***complex*** , but not the Rad51 recombination pathway .	parallel	1
15871	10859480	7057;596	TSP1;Bcl-2	***TSP1*** also ***attenuated*** VEGF-mediated ***Bcl-2*** expression in endothelial cells in vitro and angiogenesis in vivo .	negative	0
15872	10859481	5443;3606	ACTH;IL-18	These data demonstrate that the production of ***IL-18*** in the adrenal cortex is ***stimulated*** by ***ACTH*** treatment and is not inhibited by the direct action of corticosterone .	positive	0
15873	10859491	5020;2353	oxytocin;C-fos	***Regulation*** of ***C-fos*** protein in gonadotrope cells by ***oxytocin*** and gonadotropin-releasing hormone .	target	1
15874	10859495	796;5617	Calcitonin;prolactin	***Calcitonin*** ***inhibition*** of ***prolactin*** secretion in lactating rats : mechanism of action .	negative	1
15875	10859633	3557;3553	IL-1RA;IL-1	It is , thus , proposed that ***IL-1RA*** not only may serve to ***inhibit*** HIV-induced ***IL-1*** , but may be the unidentified human chorionic gonadotropin-associated factor recently found to have anti-HIV and anti-Kaposi 's sarcoma activity .	negative	1
15876	10860020	355;356	Fas;FasL	In fact , GILZ over-expression in transfected cells inhibits the sequential increase of NF-kB/DNA-binding activity , IL-2 production and IL-2R expression , and transcription of the ******Fas/FasL****** ***complex*** that follows TCR triggering and plays an important role in the control of T-lymphocyte apoptosis .	parallel	1
15877	10860020	1831;3558	GILZ;IL-2	In fact , ***GILZ*** over-expression in transfected cells ***inhibits*** the sequential increase of NF-kB/DNA-binding activity , ***IL-2*** production and IL-2R expression , and transcription of the Fas/FasL complex that follows TCR triggering and plays an important role in the control of T-lymphocyte apoptosis .	negative	1
15878	10860730	3458;3459	IFN-gamma;IFN-gamma R alpha	This suggests that one domain of ***IFN-gamma*** is sufficient to ***recruit*** ***IFN-gamma R alpha*** and IFN-gamma R beta into a complex competent for eliciting biological activity .	target	0
15879	10860730	3458;3460	IFN-gamma;IFN-gamma R beta	This suggests that one domain of ***IFN-gamma*** is sufficient to ***recruit*** IFN-gamma R alpha and ***IFN-gamma R beta*** into a complex competent for eliciting biological activity .	target	0
15880	10860730	3458;3459	interferon-gamma;IFN-gamma R alpha	A mutant form of human ***interferon-gamma*** ( IFN-gamma SC1 ) that ***binds*** one IFN-gamma receptor alpha chain ( ***IFN-gamma R alpha*** ) has been designed and characterized .	parallel	1
15881	10860730	3459;3458	IFN-gamma R alpha;IFN-gamma	The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the ******IFN-gamma/IFN-gamma R alpha****** ***complex*** .	parallel	1
15882	10860736	4193;7157	hdm2;p53	This work validates with a low molecular mass molecule our current knowledge on the ***regulation*** of the ***p53*** pathway by the ***hdm2*** protein .	target	1
15883	10860736	4193;7157	hdm2;p53	It also shows that inhibitors of the ******p53-hdm2****** ***interaction*** are very attractive candidates for the activation of the p53 pathway in tumours expressing wild-type p53 .	parallel	1
15884	10860736	4193;7157	hdm2;p53	A small synthetic peptide , which inhibits the ******p53-hdm2****** ***interaction*** , stimulates the p53 pathway in tumour cell lines .	parallel	1
15885	10860736	4193;7157	hdm2;p53	The ***hdm2*** protein negatively ***regulates*** ***p53*** tumour suppressor activity .	negative	1
15886	10860736	4193;7157	hdm2;p53	Upon binding to p53 , ***hdm2*** ***stimulates*** ***p53*** degradation and inhibits its transcriptional activity .	positive	0
15887	10860736	4193;7157	hdm2;p53	We report here that an octamer synthetic peptide derived from p53 inhibits the ******p53-hdm2****** ***interaction*** in vitro .	parallel	1
15888	10860771	9261;5594	MAPKAPK-2;p38	Alpha B Crystallin ( alpha BC ) is a putative effector protein of ischemic preconditioning ( IPC ) , that is phosphorylated on Ser 45 by ERK1/2 and Ser 59 by the ***p38*** MAPK ***substrate*** , ***MAPKAPK-2*** .	parallel	1
15889	10860774	3553;7528	IL-1 beta;YY1	In summary , these results provide evidence that sequences within the SRE3 of the skeletal actin promoter represent an IL-1 beta response element and suggest that ***IL-1 beta*** ***activates*** the negative transcription factor ***YY1*** by both transcriptional and post-transcriptional mechanisms .	positive	1
15890	10860819	650;1026	BMP-2;p21	***BMP-2*** ***increases*** the level of cyclin kinase inhibitor ***p21*** .	positive	0
15891	10860819	1026;595	p21;cyclin D1	Furthermore , we show that exposure of MDA MB 231 cells to BMP-2 stimulates ***association*** of ***p21*** with ***cyclin D1*** and with cyclin E resulting in the inhibition of their associated kinase activities .	parallel	0
15892	10860821	7145;5599	Tensin;JNK	***Tensin*** can ***induce*** ***JNK*** and p38 activation .	target	1
15893	10860821	7145;5594	Tensin;p38	***Tensin*** can ***induce*** JNK and ***p38*** activation .	target	1
15894	10860821	7145;5599	Tensin;JNK	We suggest that ***Tensin*** may directly ***activate*** the ***JNK*** and p38 pathways , acting downstream or independent of the activities of the small GTP binding proteins Rac and Cdc42 .	positive	1
15895	10860821	7145;5594	Tensin;p38	We suggest that ***Tensin*** may directly ***activate*** the JNK and ***p38*** pathways , acting downstream or independent of the activities of the small GTP binding proteins Rac and Cdc42 .	positive	1
15896	10860835	6714;760	Src;CAII	***Activation*** of human ***CAII*** gene promoter by ***v-Src*** : existence of Ras-dependent and - independent pathways .	positive	1
15897	10860835	6714;760	Src;CAII	These findings suggest that ***Src*** can ***modulate*** the human ***CAII*** promoter by exerting its tyrosine kinase activity in certain human cells , and that two types of Src signaling pathways , Ras-dependent and - independent , exist in a cell type dependent manner .	target	0
15898	10860842	7187;4790	TRAF3;NF-kappaB	Thus , it is suggested that ***TRAF3*** actively ***inhibits*** ***NF-kappaB*** activation induced by OX40 .	negative	1
15899	10860842	7187;4790	TRAF3;NF-kappaB	Both amino - and carboxyl-terminal domains of ***TRAF3*** negatively ***regulate*** ***NF-kappaB*** activation induced by OX40 signaling .	negative	1
15900	10860842	7186;4790	TRAF2;NF-kappaB	We observed that overexpression of OX40 activated ***NF-kappaB*** , which was ***inhibited*** by dominant negative forms of ***TRAF2*** , NF-kappaB-inducing kinase ( NIK ) , and IkappaB kinase ( IKK ) alpha .	negative	1
15901	10860842	7293;4790	OX40;NF-kappaB	We observed that overexpression of ***OX40*** ***activated*** ***NF-kappaB*** , which was inhibited by dominant negative forms of TRAF2 , NF-kappaB-inducing kinase ( NIK ) , and IkappaB kinase ( IKK ) alpha .	positive	1
15902	10860842	7187;4790	TRAF3;NF-kappaB	***TRAF3*** ***blocked*** OX40 - , TRAF2-induced ***NF-kappaB*** activation , but not NIK - and IKKalpha-induced NF-kappaB activation , indicating that TRAF3 blocks the pathway between TRAF2 and NIK .	negative	0
15903	10860842	7187;7293	TRAF3;OX40	Since ***TRAF3*** ***bound*** to ***OX40*** through the C-terminal TRAF domain , the C-terminal domain is likely to work as a dominant negative mutant to compete the recruitment of TRAF2 to the receptor , which transmits the signal from OX40 to the downstream , NIK kinase .	parallel	1
15904	10860849	3082;4323	HGF;MT1-MMP	We showed that ***SF/HGF*** ***enhanced*** ***MT1-MMP*** synthesis and induced MMP-2 activation in two human EC lines : dermal microvessel EC and coronary arterial EC .	positive	0
15905	10860854	7186;7128	TRAF2;A20	In this report , we demonstrate that crosslinking of TNFR family members or ***interaction*** of ***TRAF2*** with the cytoplasmic protein ***A20*** leads to intracellular translocation of TRAF2 .	parallel	1
15906	10860867	7020;146712	AP-2;beta 1	Recombinant ***AP-2*** protein will ***bind*** to both the ***beta 1-AR*** GS-1 promoter fragment and commercially available AP-2 consensus element control probes .	parallel	1
15907	10860946	7132;3383	TNFR1;ICAM-1	These data suggest that ***TNFR1*** , through a TNF receptor-associated factor 2-NF-kappaB signaling pathway , ***mediates*** TNFalpha-induced expression of ***ICAM-1*** on ASM cells by involving a thapsigargin-sensitive signaling pathway .	target	0
15908	10860946	7124;3383	tumor necrosis factor-alpha;intercellular adhesion molecule-1	***tumor necrosis factor-alpha*** ( TNFalpha ) ***stimulates*** the expression of ***intercellular adhesion molecule-1*** ( ICAM-1 ) by activating the transcription factor nuclear factor-kappaB ( NF-kappaB ) in human airway smooth muscle ( ASM ) cells .	positive	0
15909	10860946	7124;3383	TNFalpha;ICAM-1	***TNFalpha*** stimulation for 1 to 4 h ***induced*** ***ICAM-1*** expression in human ASM cells .	target	1
15910	10860979	596;842	Bcl-2;caspase-9	HA14-1 effectively induced apoptosis of human acute myeloid leukemia ( HL-60 ) cells overexpressing ***Bcl-2*** protein that was ***associated*** with the decrease in mitochondrial membrane potential and activation of ***caspase-9*** followed by caspase-3 .	parallel	0
15911	10861047	5788;1234	CD45;CCR5	Moreover , we found an ***association*** of this ***CD45*** functional polymorphism in thymuses with the ***CCR5*** Delta 32 mutation ( p = 0.00258 ) .	parallel	0
15912	10861051	3458;6863	IFN-gamma;substance P	IL-4 and ***IFN-gamma*** ***up-regulate*** ***substance P*** receptor expression in murine peritoneal macrophages .	positive	1
15913	10861051	3565;6863	IL-4;substance P	***IL-4*** and IFN-gamma ***up-regulate*** ***substance P*** receptor expression in murine peritoneal macrophages .	positive	1
15914	10861054	6387;7852	SDF-1;CXCR4	Stimulation of human mast cells with ***SDF-1*** , the only known ***ligand*** for ***CXCR4*** , induced a significant increase in intracellular calcium levels .	parallel	1
15915	10861057	944;943	CD30L;CD30	We suggest therefore that CD30L-expressing MDC-producing medullary epithelial cells attract CCR4-expressing thymocytes , thus favoring the ******CD30/CD30L****** ***interaction*** , and therefore the apoptosis , of cells that are induced to express CD30 by autoantigen activation .	parallel	1
15916	10861061	3394;3578	ICSBP;p40	Deletion analysis of the human promoter indicated that the Ets site , known to be important for activation by IFN-gamma/LPS , also plays a role in the ***ICSBP*** ***activation*** of IL-12 ***p40*** .	positive	1
15917	10861063	6667;3586	Sp1;IL-10	These results suggest that the transcription of ***IL-10*** is positively ***regulated*** by both ***Sp1*** and Sp3 .	positive	1
15918	10861063	6670;3586	Sp3;IL-10	These results suggest that the transcription of ***IL-10*** is positively ***regulated*** by both Sp1 and ***Sp3*** .	positive	1
15919	10861077	1524;6376	CX3CR-1;fractalkine	These results , therefore , suggest that the ***interaction*** between ***fractalkine*** and ***CX3CR-1*** may play an important role in promoting and preserving microglial cell survival in the CNS .	parallel	1
15920	10861080	4790;7124	NF-kappaB;TNF-alpha	These results indicate that both ***NF-kappaB*** and AP-1 ( via p38 MAPK ) are involved in the ***regulation*** of ***TNF-alpha*** production in GBS-stimulated neonatal monocytes .	target	1
15921	10861091	959;958	CD154;CD40	Human cell engraftment depended on CD4 + cells and required ******CD40-CD154****** ***interaction*** , but engrafted CD4 + cells rapidly became nonresponsive to anti-CD3 Ab stimulation .	parallel	1
15922	10861205	207;6720	PKB;SREBP1	Thus acute activation of ***PKB*** is sufficient to ***induce*** ***SREBP1*** mRNA accumulation in primary hepatocytes , and might be the major signalling event by which insulin induces SREBP1 gene expression in the liver .	target	1
15923	10861213	348;2934	apoE;AGel	In the present study we have compared the ***interaction*** of ***apoE*** with A beta , the gelsolin-derived amyloid fragment ***AGel*** ( 183-210 ) and the amyloidogenic prion fragments PrP ( 109-122 ) and PrP ( 109-141 ) .	parallel	1
15924	10861213	2934;348	AGel;apoE	We show that , similar to A beta , also ***AGel*** and PrP fragments can form a ***complex*** with ***apoE*** , and that the interaction between apoE and the amyloidogenic protein fragments is mediated through the same binding site on apoE .	parallel	1
15925	10861213	5621;348	PrP;apoE	We show that , similar to A beta , also AGel and ***PrP*** fragments can form a ***complex*** with ***apoE*** , and that the interaction between apoE and the amyloidogenic protein fragments is mediated through the same binding site on apoE .	parallel	1
15926	10861231	3075;5199	factor H;properdin	Neither ***factor H*** nor factor B ***affected*** ***properdin*** binding .	target	0
15927	10861232	7039;2950	TGF alpha;GSTP1	GSTP1 enhancer I ( GPEI ) , which is required for the stimulation of GSTP1 expression by PenCB , also mediates EGF and ***TGF alpha*** ***stimulation*** of ***GSTP1*** gene expression .	positive	0
15928	10861232	7039;2950	TGF alpha;GSTP1	Our observations suggest that EGF and ***TGF alpha*** ***induce*** ***GSTP1*** by the same signal transduction pathway as PenCB .	target	1
15929	10861233	4018;5898	lipoprotein;Ral	Low-density ***lipoprotein*** ***activates*** the small GTPases Rap1 and ***Ral*** in human platelets .	positive	1
15930	10861233	4018;5906	lipoprotein;Rap1	Low-density ***lipoprotein*** ***activates*** the small GTPases ***Rap1*** and Ral in human platelets .	positive	1
15931	10861264	4322;4323	collagenase-3;MT1-MMP	Immunohistochemical studies revealed that collagenase-3 was localised predominantly in tumour cells and MT1-MMP was detected in the same collagenase-3 positive cells ; there was a significant ***association*** between ***collagenase-3*** and ***MT1-MMP*** protein expression ( p < 0.05 ) .	parallel	0
15932	10861283	84260;9146	tumor suppressor protein;hepatocyte growth factor-regulated tyrosine kinase substrate	The neurofibromatosis 2 ***tumor suppressor protein*** ***interacts*** with ***hepatocyte growth factor-regulated tyrosine kinase substrate*** .	parallel	1
15933	10861313	1029;1019	p16;CDK4	CDKN2A is a tumor suppressor gene that encodes ***p16*** ( which ***inhibits*** activity of the ***cyclin D1-CDK4*** complex ) with germline mutations detected in 10 % -25 % of melanoma-prone families , some of whom are also prone to pancreatic cancer .	negative	1
15934	10861313	1029;595	p16;cyclin D1	CDKN2A is a tumor suppressor gene that encodes ***p16*** ( which ***inhibits*** activity of the ***cyclin D1-CDK4*** complex ) with germline mutations detected in 10 % -25 % of melanoma-prone families , some of whom are also prone to pancreatic cancer .	negative	1
15935	10861313	1019;595	CDK4;cyclin D1	CDKN2A is a tumor suppressor gene that encodes p16 ( which inhibits activity of the ******cyclin D1-CDK4****** ***complex*** ) with germline mutations detected in 10 % -25 % of melanoma-prone families , some of whom are also prone to pancreatic cancer .	parallel	1
15936	10861448	7039;2520	Transforming growth factor-alpha;gastrin	Epidermal growth factor ( EGF ) and ***Transforming growth factor-alpha*** ( TGF-alpha ) ***increase*** transcription of the ***gastrin*** gene , and the gastrin peptide may be phosphorylated by EGF-stimulated tyrosine kinase .	positive	0
15937	10861527	10371;8829	Sema3A;neuropilin-1	***Sema3A*** , a ***ligand*** for ***neuropilin-1*** , is effective in repelling geniculate and trigeminal axons , and antineuropilin-1 , but not antineuropilin-2 , completely blocks the repulsion by arch explants that repel axon outgrowth from both ganglia .	parallel	1
15938	10861784	4914;627	TrkA;Neurotrophin	Prior reports demonstrated that cells of the oligodendroglial lineage are susceptible to excitotoxic necrosis mediated by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid glutamate receptors ( AMPA-GluR ) , and also showed that these cells express the high affinity ***Neurotrophin*** ***receptors*** , TrkC and ***TrkA*** .	parallel	1
15939	10861784	4916;627	TrkC;Neurotrophin	Prior reports demonstrated that cells of the oligodendroglial lineage are susceptible to excitotoxic necrosis mediated by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid glutamate receptors ( AMPA-GluR ) , and also showed that these cells express the high affinity ***Neurotrophin*** ***receptors*** , ***TrkC*** and TrkA .	parallel	1
15940	10861785	7124;2920	TNF-alpha;MIP-2	sICAM-1 and ***TNF-alpha*** ***induce*** ***MIP-2*** with distinct kinetics in astrocytes and brain microvascular endothelial cells .	target	1
15941	10861785	3579;2920	CXCR-2;MIP-2	The release of sICAM-1 was not influenced by IL-8 or MIP-2 , although astrocytes and MVEC expressed the IL-8 / ***MIP-2*** ***receptor*** ( ***CXCR-2*** ) as determined by FACS analysis .	parallel	1
15942	10861785	7124;2920	TNF-alpha;MIP-2	If added together , sICAM-1 and ***TNF-alpha*** synergistically ***induced*** ***MIP-2*** production suggesting the involvement of two different pathways for MIP-2 regulation .	target	1
15943	10861786	6616;4905	SNAP;NSF	GCVs bound SNAREs but not NSF or alpha-SNAP ; whereas in the rabphilin-supplied IGC , GCVs recruited both NSF and alpha-SNAP , to form the ******SNARE-NSF-SNAP****** ***complex*** .	parallel	1
15944	10861796	7471;4790	Wnt-1;NF-kappaB	***Wnt-1-induced*** ***activation*** of ***NF-kappaB*** is partially independent of PI-3 kinase and can be mimicked by inhibition of GSK-3beta .	positive	1
15945	10861796	4792;4790	IkappaB-alpha;NF-kappaB	NF-kappaB activity was also increased by the transient expression of Wnt-1 in PC12 cells and it was completely inhibited in both PC12 and PC12/Wnt-1 cells by a dominant negative mutant ***IkappaB-alpha*** that has been shown to ***prevent*** ***NF-kappaB*** activation .	negative	0
15946	10861796	7471;4790	Wnt-1;NF-kappaB	***NF-kappaB*** activity was also ***increased*** by the transient expression of ***Wnt-1*** in PC12 cells and it was completely inhibited in both PC12 and PC12/Wnt-1 cells by a dominant negative mutant IkappaB-alpha that has been shown to prevent NF-kappaB activation .	positive	0
15947	10861844	8731;3082	Met;hepatocyte growth factor	Osteopontin-induced , integrin-dependent migration of human mammary epithelial cells involves activation of the ***hepatocyte growth factor*** ***receptor*** ( ***Met*** ) .	parallel	1
15948	10861859	3479;4656	IGF-I;myogenin	In the first 24 h , we find that ***IGF-I*** ***inhibits*** ***myogenin*** gene transcription by > 80 % but has no effect on myogenin mRNA stability .	negative	1
15949	10861859	3479;4656	IGF-I;myogenin	Similarly , in the first 24 h , ***IGF-I*** markedly ***inhibits*** ***myogenin*** promoter activity ; the sequence -145 to -9 of the myogenin gene is sufficient to confer this inhibitory effect of IGF-I .	negative	1
15950	10861861	3958;596	galectin-3;Bcl-2	For example , the well-known lectin , galectin-3 , a lactose-binding protein , can act inside the nucleus in splicing events , and at the plasma membrane in adhesion , and it was demonstrated that ***galectin-3*** ***interacts*** in the cytoplasm with ***Bcl-2*** , an antiapoptotic protein .	parallel	1
15951	10861932	214;923	CD166;CD6	Cell surface receptors and their ligands : in vitro analysis of ******CD6-CD166****** ***interactions*** .	parallel	1
15952	10861932	214;923	CD166;CD6	CD166 was among the first molecules identified as a ligand for an SRCRSF receptor , and the ******CD6-CD166****** ***interaction*** was the first interaction characterized involving SRCRSF and IgSF proteins .	parallel	1
15953	10861932	214;923	CD166;CD6	We focus here on what has been learned about the specifics of the ******CD6-CD166****** ***interaction*** from in vitro analysis .	parallel	1
15954	10862083	2994;2993	GPB;GPA	Stone ( St ( a ) ) is a variant antigen carried on human erythrocyte MNSs glycophorins ( GPSt ( a ) ) that are genetically associated with splicing mutations in GPA genes or with hybrid ***formation*** between ***GPA*** and ***GPB*** genes .	parallel	0
15955	10862210	4288;7157	MIB-1;p53	Immunostaining with anti-Ki-67 antibodies ( MIB1 ) and p53 based on formalin-fixed paraffin-embedded material from 86 patients revealed that ***MIB-1*** > or = 10 % was ***associated*** with poorer metastasis-free survival but ***p53*** was not .	parallel	0
15956	10862210	6756;6760	SSX1;SYT	There was a significant ***association*** between ******SYT-SSX1****** and high tumor proliferation rate .	parallel	0
15957	10862521	2952;2944	GSTT1;GSTM1	To evaluate the potential ***association*** between ***GSTM1*** and ***GSTT1*** genotypes and development of breast cancer , a hospital based case-control study was conducted in a South Korean study population consisting of 189 histologically confirmed incident breast cancer cases and their 189 age-matched control subjects with no present or previous history of cancer .	parallel	0
15958	10862607	2;7422	alpha 2-macroglobulin;vascular endothelial growth factor	The conformation-dependent ***interaction*** of ***alpha 2-macroglobulin*** with ***vascular endothelial growth factor*** .	parallel	1
15959	10862694	51052;2834	PrRP;GPR10	prolactin-releasing peptide ( ***PrRP*** ) is a peptide ***ligand*** for the human orphan G-protein-coupled receptor ***hGR3/GPR10*** and causes the secretion of prolactin from anterior pituitary cells .	parallel	1
15960	10862755	940;4790	CD28;NF-kappaB	***CD3/CD28-induced*** ***activation*** of ***NF-kappaB*** was inhibited by dominant negative forms of Vav or PKCtheta , revealing their essential role in this activation pathway .	positive	1
15961	10862759	7040;2247	TGF-beta1;bFGF	Together , these results demonstrate that ***TGF-beta1*** ***regulates*** the autocrine induction of ***bFGF*** , resulting in activation of the ERK mitogen-activated protein kinase pathway and induction of AP-1 binding .	target	1
15962	10862762	8802;859	Galpha;caveolin-3	A caveolin-binding Galpha ( q/11 ) fragment blocked the ***binding*** of activated ***Galpha*** ( q/11 ) but not Galpha ( i3 ) to ***caveolin-3*** and prevented desensitization of the PLC-beta response mediated only by other G ( q/11 ) - coupled receptors .	parallel	1
15963	10862766	998;4296	Cdc42;SPRK	These studies suggest that zipper-mediated SPRK oligomerization is not required for ***SPRK*** ***activation*** by ***Cdc42*** but instead is critical for proper interaction and phosphorylation of a downstream target , MKK4 .	positive	1
15964	10862766	6416;5599	MKK4;JNK	SPRK is capable of activating MKK4 by phosphorylation of serine and threonine residues , and mutant forms of ***MKK4*** that lack the phosphorylation sites Ser ( 254 ) and Thr ( 258 ) ***block*** SPRK-induced ***JNK*** activation .	negative	0
15965	10862766	998;4296	Cdc42;SPRK	We demonstrate that constitutively activated ***Cdc42*** fully ***activates*** this monomeric ***SPRK*** mutant in terms of both autophosphorylation and histone phosphorylation activity and induces the same in vivo phosphorylation pattern as wild type SPRK .	positive	1
15966	10862785	3565;3605	IL-4;IL-17	***IL-4*** gene therapy for collagen arthritis ***suppresses*** synovial ***IL-17*** and osteoprotegerin ligand and prevents bone erosion .	negative	1
15967	10862785	3565;8600	IL-4;osteoprotegerin ligand	***IL-4*** gene therapy for collagen arthritis ***suppresses*** synovial IL-17 and ***osteoprotegerin ligand*** and prevents bone erosion .	negative	1
15968	10862785	3565;8600	IL-4;osteoprotegerin ligand	***osteoprotegerin ligand*** ( OPGL ) expression was markedly ***suppressed*** by local ***IL-4*** , but no loss of OPG expression was noted with Ad5E1mIL-4 treatment .	negative	1
15969	10862785	3565;1278	IL-4;type I procollagen	***IL-4*** also ***enhanced*** synthesis of ***type I procollagen*** , suggesting that it promoted tissue repair .	positive	0
15970	10862798	3952;6774	leptin;STAT3	In mice fed the low-fat diet , ***leptin*** ***activated*** ***STAT3*** signaling when administered via the intraperitoneal ( ip ) or the intracerebroventricular ( icv ) route , with the half-maximal dose being 30-fold less when given by the icv route .	positive	1
15971	10862973	5267;9622	kallistatin;kallikrein	The P2 phenylalanine is essential for retaining the hydrophobic environment for the ***interaction*** of ***kallistatin*** and ***kallikrein*** .	parallel	1
15972	10863037	56301;6520	hAsc-1;4F2 heavy chain	Consistent with mouse Asc-1 , ***hAsc-1*** ***required*** ***4F2 heavy chain*** for its functional expression in Xenopus oocytes .	target	0
15973	10863401	4087;7040	Smad2;TGF-beta	CONCLUSION : This study provides the first evidence of expression of Smad2 in human dental pulp cells , and indicates that ***TGF-beta*** signaling may be ***mediated*** by ***Smad2*** in human dental pulp cells .	target	0
15974	10863413	3458;5915	IFN gamma;RAR beta	ATRA ( 1 microM ) and ***IFN gamma*** ( 1000 u/mL ) ***increased*** ***RAR beta*** expression to 4 times and 3 times , respectively .	positive	0
15975	10863473	462;5345	antithrombin III;alpha 2-plasmin inhibitor	We measured ***antithrombin III*** ( AT III ) , an important ***inhibitor*** of coagulation and ***alpha 2-plasmin inhibitor*** ( alpha 2-PI ) , a factor inhibiting fibrinolysis in blood and gingival tissue of naturally occurring gingivitis rats ( ODUS/Odu ) and control rats ( Res ) .	negative	1
15976	10863529	3458;4843	IFN-gamma;NOS2	Our experiments indicate that low doses ( 1-5 Gy ) of ionizing radiation can enhance the ***induction*** of enzymatically active ***NOS2*** by ***IFN-gamma*** or LPS in J774 .1 and RAW264 .7 murine macrophage cell lines .	target	1
15977	10863542	3553;5594	IL-1 beta;p38	In rat primary astrocytes ***p38*** ***activation*** by the pro-inflammatory cytokine ***IL-1 beta*** , as well as by H2O2 , was significantly suppressed by PBN .	positive	1
15978	10863975	2057;2056	EpoR;Epo	As the cells matured during the intermediate period , GATA-2 levels remained high , and then declined , while the transcription factors GATA-1 , EKLF , NF-E2 , and the ***Epo*** ***receptor*** ( ***EpoR*** ) reached maximum expression .	parallel	1
15979	10863978	7852;6387	CXCR4;SDF-1	In the present study , we investigated the role of ***SDF-1*** and its ***receptor*** , ***CXCR4*** , in the chemotactic interaction between non-Hodgkin B-lymphoma cells and lymph node stromal cells .	parallel	1
15980	10864004	7037;3077	TfR;HFE	One hypothesis suggests that an ***interaction*** between the transferrin receptor ( ***TfR*** ) and the haemochromatosis protein ( ***HFE*** ) regulates the level of iron loading in crypt cells .	parallel	1
15981	10864206	7020;1026	AP-2alpha;WAF1	The immunohistochemical expression of ***AP-2alpha*** was ***correlated*** with clinicopathological variables , ***p21/WAF1*** protein expression and survival .	parallel	0
15982	10864648	7852;920	chemokine receptor;CD4	PPMP treatment of the cell lines did not significantly change the cell surface expression of CD4 , CXCR4 , and/or CCR5 , nor did it alter the ***chemokine receptor*** ***association*** with ***CD4*** .	parallel	0
15983	10864814	1499;999	beta-catenin;E-cadherin	Taken together , these observations indicate that the ******E-cadherin-beta-catenin****** ***complex*** plays a central role in the terminal differentiation of human trophoblasts in vitro and in vivo .	parallel	1
15984	10864872	207;3458	Rac;interferon-gamma	***Rac*** ***induces*** the ***interferon-gamma*** ( IFN-gamma ) promoter through cooperative activation of the nuclear factor kappa B and p38 mitogen-activated protein kinase pathways .	target	1
15985	10864872	207;3458	Rac;IFN-gamma	Dominant-negative ***Rac*** ***inhibited*** ***IFN-gamma*** production in murine T cells .	negative	1
15986	10864872	5880;3458	Rac2;IFN-gamma	Thus , ***Rac2*** ***activates*** TH1-specific signaling and ***IFN-gamma*** gene expression .	positive	1
15987	10864916	5294;1978	PI3K;4E-BP1	One mechanism involves ***PI3K/PKB-dependent*** ***phosphorylation*** of ***4E-BP1*** , which dissociates from eIF4E , allowing initiation of translation from the 7-methylGTP cap of mRNAs .	target	1
15988	10864916	207;1978	PKB;4E-BP1	One mechanism involves ***PI3K/PKB-dependent*** ***phosphorylation*** of ***4E-BP1*** , which dissociates from eIF4E , allowing initiation of translation from the 7-methylGTP cap of mRNAs .	target	1
15989	10864916	1978;1977	4E-BP1;eIF4E	This increased the ***association*** of ***4E-BP1*** with ***eIF4E*** , consistent with H ( 2 ) O ( 2 ) inhibition of protein synthesis .	parallel	0
15990	10864919	7124;4790	tumor necrosis factor-alpha;NF-kappaB	Functional studies demonstrate that cAMP represses whereas ***tumor necrosis factor-alpha*** , an ***activator*** of ***NF-kappaB*** , stimulates promoter activity .	positive	1
15991	10864920	7124;4790	tumor necrosis factor-alpha;NF-kappaB	Functional studies demonstrate that cAMP represses whereas ***tumor necrosis factor-alpha*** , an ***activator*** of ***NF-kappaB*** , stimulates promoter activity .	positive	1
15992	10864922	3383;5781	ICAM-1;SHP-2	These results indicate that ***ICAM-1*** ***interactions*** with ***SHP-2*** allow better cellular survival mediated through Fg-ICAM-1 ligation .	parallel	1
15993	10864922	3383;5781	ICAM-1;SHP-2	Phosphorylated ***ICAM-1*** ***bound*** ***SHP-2-N*** .	parallel	1
15994	10864922	5781;3383	SHP-2;ICAM-1	In immunoprecipitation experiments , ***SHP-2*** ***associated*** with phosphorylated ***ICAM-1*** .	parallel	0
15995	10864952	4155;9444	MBP;QKI	Finally , we observed ***interactions*** between ***QKI*** and ***MBP*** mRNAs , and removing MBP 3 ' UTR significantly reduced QKI-binding .	parallel	1
15996	10864952	9444;4155	QKI;MBP	Taken together , these observations suggest that misregulation at multiple posttranscriptional steps is responsible for the severe reduction of MBPs in qk ( v ) dysmyelination , presumably because of the lack of ***interactions*** between ***MBP*** mRNAs and the ***QKI*** RNA-binding proteins .	parallel	1
15997	10864977	56938;9575	MOP9;CLOCK	Like its homologs , ***MOP9*** forms a transcriptionally active ***heterodimer*** with the circadian ***CLOCK*** protein , the structurally related MOP4 , and hypoxia-inducible factors , such as HIF1alpha .	parallel	1
15998	10864977	56938;4862	MOP9;MOP4	Like its homologs , ***MOP9*** forms a transcriptionally active ***heterodimer*** with the circadian CLOCK protein , the structurally related ***MOP4*** , and hypoxia-inducible factors , such as HIF1alpha .	parallel	1
15999	10865075	5443;4159	beta-MSH;MC3-R	We have shown that alpha-MSH , desacetyl-alpha-MSH and ***beta-MSH*** ***bound*** to the ***MC3-R*** and MC4-R with similar affinity and stimulated cAMP with similar potency in HEK 293 cells transfected with MC3-R and MC4-R .	parallel	1
16000	10865075	5443;4160	beta-MSH;MC4-R	We have shown that alpha-MSH , desacetyl-alpha-MSH and ***beta-MSH*** ***bound*** to the MC3-R and ***MC4-R*** with similar affinity and stimulated cAMP with similar potency in HEK 293 cells transfected with MC3-R and MC4-R .	parallel	1
16001	10865082	3586;3569	IL-10;IL-6	Brain TNF and IL-6 levels were more elevated and persisted longer in IL-10-deficient mice compared with wild type mice , suggesting that ***IL-10*** is an important negative feedback ***inhibitor*** of TNF and ***IL-6*** production in the CNS .	negative	1
16002	10865188	7124;7097	TNF-alpha;TLR-2	***TLR-2*** mRNA was ***up-regulated*** by ***TNF-alpha*** .	positive	1
16003	10865236	3553;7124	IL-1;TNF-alpha	These results indicate that TNF-alpha is important in controlling L. pneumophila replication , and ***IL-1*** can ***regulate*** ***TNF-alpha*** levels , affecting susceptibility of macrophages to infection with an intracellular opportunistic pathogen like Legionella .	target	1
16004	10865838	5706;7422	p42;VEGF	We demonstrated that the ***p42/p44*** MAP kinase signaling cascade ***controls*** ***VEGF*** expression at least at two levels .	target	0
16005	10865838	5706;7422	p42;VEGF	We demonstrated that p42/p44MAPKs stoichiometrically phosphorylate HIF-1 alpha in vitro and that HIF-1-dependent ***VEGF*** gene expression is strongly ***enhanced*** by the exclusive activation of ***p42/p44MAPKs*** .	positive	0
16006	10865838	5706;3091	p42;HIF-1 alpha	We demonstrated that ***p42/p44MAPKs*** stoichiometrically ***phosphorylate*** ***HIF-1 alpha*** in vitro and that HIF-1-dependent VEGF gene expression is strongly enhanced by the exclusive activation of p42/p44MAPKs .	target	1
16007	10865839	2321;7422	Flt-1;VEGF	Properties of two ***VEGF*** ***receptors*** , ***Flt-1*** and KDR , in signal transduction .	parallel	1
16008	10865839	3791;7422	KDR;VEGF	Properties of two ***VEGF*** ***receptors*** , Flt-1 and ***KDR*** , in signal transduction .	parallel	1
16009	10865839	2321;7422	Flt-1;VEGF	The properties of two ***VEGF*** ***receptors*** , ***Flt-1*** and KDR , in the signal transduction of VEGF in human umbilical vein endothelial cells ( HUVECs ) were investigated by using two newly developed blocking monoclonal antibodies ( mAbs ) against Flt-1 and KDR .	parallel	1
16010	10865839	3791;7422	KDR;VEGF	The properties of two ***VEGF*** ***receptors*** , Flt-1 and ***KDR*** , in the signal transduction of VEGF in human umbilical vein endothelial cells ( HUVECs ) were investigated by using two newly developed blocking monoclonal antibodies ( mAbs ) against Flt-1 and KDR .	parallel	1
16011	10865839	7422;2113	VEGF;Ets-1	***VEGF*** ***stimulated*** the expression of transcription factor ***Ets-1*** as well as matrix metalloproteinase-1 ( MMP-1 ) and Flt-1 in HUVECs .	positive	0
16012	10865839	7422;4312	VEGF;matrix metalloproteinase-1	***VEGF*** ***stimulated*** the expression of transcription factor Ets-1 as well as ***matrix metalloproteinase-1*** ( MMP-1 ) and Flt-1 in HUVECs .	positive	0
16013	10865839	2321;2113	Flt-1;Ets-1	The ***KDR/Flt-1*** heterodimer and the KDR homodimer ***mediate*** the expression of ***Ets-1*** , MMP-1 , and Flt-1 .	target	0
16014	10865839	2321;4312	Flt-1;MMP-1	The ***KDR/Flt-1*** heterodimer and the KDR homodimer ***mediate*** the expression of Ets-1 , ***MMP-1*** , and Flt-1 .	target	0
16015	10865839	6647;2113	homodimer;Ets-1	The KDR/Flt-1 heterodimer and the KDR ***homodimer*** ***mediate*** the expression of ***Ets-1*** , MMP-1 , and Flt-1 .	target	0
16016	10865839	6647;2321	homodimer;Flt-1	The KDR/Flt-1 heterodimer and the KDR ***homodimer*** ***mediate*** the expression of Ets-1 , MMP-1 , and ***Flt-1*** .	target	0
16017	10865839	6647;4312	homodimer;MMP-1	The KDR/Flt-1 heterodimer and the KDR ***homodimer*** ***mediate*** the expression of Ets-1 , ***MMP-1*** , and Flt-1 .	target	0
16018	10865839	3791;2113	KDR;Ets-1	The ***KDR/Flt-1*** heterodimer and the KDR homodimer ***mediate*** the expression of ***Ets-1*** , MMP-1 , and Flt-1 .	target	0
16019	10865839	3791;2321	KDR;Flt-1	The ***KDR/Flt-1*** heterodimer and the KDR homodimer ***mediate*** the expression of Ets-1 , MMP-1 , and ***Flt-1*** .	target	0
16020	10865839	3791;4312	KDR;MMP-1	The ***KDR/Flt-1*** heterodimer and the KDR homodimer ***mediate*** the expression of Ets-1 , ***MMP-1*** , and Flt-1 .	target	0
16021	10865839	3791;2321	KDR;Flt-1	The ******KDR/Flt-1****** ***heterodimer*** and the KDR homodimer mediate the expression of Ets-1 , MMP-1 , and Flt-1 .	parallel	1
16022	10865839	3791;2321	KDR;Flt-1	The ******KDR/Flt-1****** ***heterodimer*** and the KDR homodimer are required for the assembly of vinculin in focal adhesion plaque by regulating the phosphorylation of focal adhesion kinase ( FAK ) and paxillin .	parallel	1
16023	10865841	1958;688	Egr-1;BTEB2	Functional studies using 5 ' - deletion and site-directed mutation constructs demonstrated that phorbol ester induces ***Egr-1*** , which can ***activate*** the ***BTEB2*** promoter through binding to -32 from the transcription start site .	positive	1
16024	10865845	7422;1003	VEGF;vascular endothelial-cadherin	In addition , a novel ***interaction*** between the junctional protein ***vascular endothelial-cadherin*** ( VE-cadherin ) and ***VEGF*** , essential for the endothelial survival function of VEGF , will be reviewed .	parallel	1
16025	10865857	7124;4973	TNF-alpha;LOX-1	Furthermore , expression of ***LOX-1*** in macrophages is also ***upregulated*** by an inflammatory cytokine ***TNF-alpha*** , which was shown to be present in atherosclerotic arterial wall .	positive	1
16026	10865998	3586;3458	IL-10;IFN-gamma	In an in vitro study , recombinant rat ***IL-10*** ( but not human or mouse IL-10 ) ***suppressed*** lymphocyte proliferation and ***IFN-gamma*** production by primed lymph node cells of R16 immunized rats , but did not suppress uveitogenic long-term T-cell lines polarized to the Thl phenotype , suggesting that mature effector lymphocytes in the rat may lose their ability to be suppressed by IL-10 .	negative	1
16027	10866048	5539;3375	pancreatic polypeptide;amylin	Reduced ***pancreatic polypeptide*** ***response*** to hypoglycemia and ***amylin*** response to arginine in subjects with a mutation in the HNF-4alpha / MODY1 gene .	parallel	0
16028	10866101	5444;4018	paraoxonase 1;lipoprotein	It has been reported that ***paraoxonase 1*** ( PON1 ) activity ***inhibits*** low-density ***lipoprotein*** ( LDL ) oxidation and modulates the risk of coronary heart disease .	negative	1
16029	10866129	356;355	FasL;CD95	Here we report that IFN-alpha stimulation of PBMC from healthy donors induces Fas ( ***CD95*** ) ***ligand*** ( ***FasL*** ) transcription and leads to increased cell surface FasL expression exclusively on the NK cell fraction .	parallel	1
16030	10866129	3439;356	IFN-alpha;FasL	In the context of innate immunity , ***induction*** of ***FasL*** by ***IFN-alpha*** can be viewed as an efficient mechanism to potentiate NK cell cytotoxicity in the presence of harmful targets , such as virally infected or transformed cells .	target	1
16031	10866303	8795;8743	death receptor 5;TRAIL	The binding analysis using the TRAIL protein and a ***TRAIL*** ***receptor*** ( ***death receptor 5*** ) revealed that both the dimer and the trimer bind to death receptor 5 with similar affinity .	parallel	1
16032	10866311	3458;6772	IFN-gamma;STAT1	The ***induction*** of ***STAT1*** DNA binding activity by ***IFN-gamma*** and p21WAF1 by PB , alone or in combination , correlated with growth inhibition and loss of clonogenicity .	target	1
16033	10866315	959;958	CD40L;CD40	The enhanced agonistic activity could be attributed to a dose-dependent increase in ***CD40L*** ***binding*** to ***CD40*** in the presence of SGN-14 .	parallel	1
16034	10866321	5914;2353	RARalpha;c-Fos	In a transient transfection assay , all three RAR subtypes , ***RARalpha*** , RARbeta , and RARgamma , could effectively ***inhibit*** phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity and the activity of oncogenes c-Jun and ***c-Fos*** on AP-1 containing reporter genes in the presence of retinoic acid ( RA ) .	negative	1
16035	10866321	5914;3725	RARalpha;c-Jun	In a transient transfection assay , all three RAR subtypes , ***RARalpha*** , RARbeta , and RARgamma , could effectively ***inhibit*** phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity and the activity of oncogenes ***c-Jun*** and c-Fos on AP-1 containing reporter genes in the presence of retinoic acid ( RA ) .	negative	1
16036	10866321	5915;2353	RARbeta;c-Fos	In a transient transfection assay , all three RAR subtypes , RARalpha , ***RARbeta*** , and RARgamma , could effectively ***inhibit*** phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity and the activity of oncogenes c-Jun and ***c-Fos*** on AP-1 containing reporter genes in the presence of retinoic acid ( RA ) .	negative	1
16037	10866321	5915;3725	RARbeta;c-Jun	In a transient transfection assay , all three RAR subtypes , RARalpha , ***RARbeta*** , and RARgamma , could effectively ***inhibit*** phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity and the activity of oncogenes ***c-Jun*** and c-Fos on AP-1 containing reporter genes in the presence of retinoic acid ( RA ) .	negative	1
16038	10866321	5916;2353	RARgamma;c-Fos	In a transient transfection assay , all three RAR subtypes , RARalpha , RARbeta , and ***RARgamma*** , could effectively ***inhibit*** phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity and the activity of oncogenes c-Jun and ***c-Fos*** on AP-1 containing reporter genes in the presence of retinoic acid ( RA ) .	negative	1
16039	10866321	5916;3725	RARgamma;c-Jun	In a transient transfection assay , all three RAR subtypes , RARalpha , RARbeta , and ***RARgamma*** , could effectively ***inhibit*** phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 activity and the activity of oncogenes ***c-Jun*** and c-Fos on AP-1 containing reporter genes in the presence of retinoic acid ( RA ) .	negative	1
16040	10866653	6041;4654	RNase L;MyoD	The 2 ' -5 ' ***oligoadenylate/RNase L/RNase L*** inhibitor pathway ***regulates*** both ***MyoD*** mRNA stability and muscle cell differentiation .	target	1
16041	10866653	6059;6041	RLI;RNase L	RNase L is a latent endoribonuclease which is activated by 2-5A and inhibited by a specific protein known as ***RLI*** ( ***RNase L*** ***inhibitor*** ) .	negative	1
16042	10866653	6059;6041	RLI;RNase L	Importantly , the overexpression of ***RLI*** in C2 cells was ***associated*** with diminished ***RNase L*** activity , an increased level of MyoD mRNA , and accelerated kinetics of muscle differentiation .	parallel	0
16043	10866654	5928;1385	RbAp48;CREB	Histone binding protein ***RbAp48*** ***interacts*** with a complex of CREB binding protein and phosphorylated ***CREB*** .	parallel	1
16044	10866654	5928;1387	RbAp48;CREB binding protein	Histone binding protein ***RbAp48*** ***interacts*** with a complex of ***CREB binding protein*** and phosphorylated CREB .	parallel	1
16045	10866654	1387;1385	CREB binding protein;CREB	A ******CREB-CREB binding protein****** ( CBP ) ***complex*** was used as bait to screen a mouse embryo cDNA library in yeast .	parallel	1
16046	10866654	5928;1387	RbAp48;CBP	***RbAp48*** also ***interacted*** weakly with ***CBP*** alone but did not interact with phosphorylated or nonphosphorylated CREB .	parallel	1
16047	10866654	5931;5928	RbAp46;RbAp48	These data indicate that the association of phosphorylated CREB with CBP promotes the ***binding*** of ***RbAp48*** and its homologue ***RbAp46*** , allowing the formation of a complex that facilitates histone acetylation during transcriptional activation .	parallel	1
16048	10866654	1385;1387	CREB;CBP	These data indicate that the ***association*** of phosphorylated ***CREB*** with ***CBP*** promotes the binding of RbAp48 and its homologue RbAp46 , allowing the formation of a complex that facilitates histone acetylation during transcriptional activation .	parallel	0
16049	10866654	1385;5931	CREB;RbAp46	These data indicate that the association of phosphorylated ***CREB*** with CBP ***promotes*** the binding of RbAp48 and its homologue ***RbAp46*** , allowing the formation of a complex that facilitates histone acetylation during transcriptional activation .	positive	0
16050	10866654	1385;5928	CREB;RbAp48	These data indicate that the association of phosphorylated ***CREB*** with CBP ***promotes*** the binding of ***RbAp48*** and its homologue RbAp46 , allowing the formation of a complex that facilitates histone acetylation during transcriptional activation .	positive	0
16051	10866655	25;4214	c-Abl;MEK kinase 1	***Activation*** of ***MEK kinase 1*** by the ***c-Abl*** protein tyrosine kinase in response to DNA damage .	positive	1
16052	10866655	25;4214	c-Abl;MEK kinase 1	Here we show that nuclear ***c-Abl*** ***associates*** with ***MEK kinase 1*** ( MEKK-1 ) , an upstream effector of the SEK1 -- > SAPK pathway , in the response of cells to genotoxic stress .	parallel	0
16053	10866655	25;4214	c-Abl;MEKK-1	The results demonstrate that the nuclear ***c-Abl*** ***binds*** to ***MEKK-1*** and that c-Abl phosphorylates MEKK-1 in vitro and in vivo .	parallel	1
16054	10866655	25;4214	c-Abl;MEKK-1	The results demonstrate that the nuclear c-Abl binds to MEKK-1 and that ***c-Abl*** ***phosphorylates*** ***MEKK-1*** in vitro and in vivo .	target	1
16055	10866655	25;4214	c-Abl;MEKK-1	Transient-transfection studies with wild-type and kinase-inactive c-Abl demonstrate ***c-Abl*** kinase-dependent ***activation*** of ***MEKK-1*** .	positive	1
16056	10866655	25;4214	c-Abl;MEKK-1	Moreover , ***c-Abl*** ***activates*** ***MEKK-1*** in vitro and in response to DNA damage .	positive	1
16057	10866655	4214;5601	MEKK-1;SAPK	The results also demonstrate that c-Abl induces ***MEKK-1-mediated*** ***phosphorylation*** and activation of ***SEK1-SAPK*** in coupled kinase assays .	target	1
16058	10866655	4214;6416	MEKK-1;SEK1	The results also demonstrate that c-Abl induces ***MEKK-1-mediated*** ***phosphorylation*** and activation of ***SEK1-SAPK*** in coupled kinase assays .	target	1
16059	10866655	25;5601	c-Abl;SAPK	The results also demonstrate that ***c-Abl*** ***induces*** MEKK-1-mediated phosphorylation and activation of ***SEK1-SAPK*** in coupled kinase assays .	target	1
16060	10866655	25;6416	c-Abl;SEK1	The results also demonstrate that ***c-Abl*** ***induces*** MEKK-1-mediated phosphorylation and activation of ***SEK1-SAPK*** in coupled kinase assays .	target	1
16061	10866655	4214;5601	MEKK-1;SAPK	These findings indicate that c-Abl functions upstream of ***MEKK-1-dependent*** ***activation*** of ***SAPK*** in the response to genotoxic stress .	positive	1
16062	10866657	5900;6908	RalGDS;TBP	Activation of either Raf or ***RalGDS*** , but not that of PI-3 kinase , was sufficient to ***induce*** ***TBP*** promoter activity .	target	1
16063	10866666	22926;3309	ATF6;grp78	To understand the mechanism of ***grp78*** ***induction*** by ***ATF6*** in cells subjected to ER calcium depletion stress mediated by thapsigargin ( Tg ) treatment , we discovered that ATF6 itself undergoes Tg stress-induced changes .	target	1
16064	10866677	5132;1406	Phd;CRX	Our findings demonstrate that both ***Phd*** and PhLOP1 ***interact*** directly with ***CRX*** and that each diminishes the transactivation activity of CRX on the IRBP promoter .	parallel	1
16065	10866677	5132;1406	Phd;CRX	Neither ***Phd*** nor PhLOP1 ***affected*** ***CRX*** binding to its consensus DNA element in electrophoretic mobility shift assays .	target	0
16066	10866677	5132;5705	Phd;SUG1	A model that illustrates separate functional roles for ***interactions*** between ***Phd*** and either ***SUG1*** or CRX is proposed .	parallel	1
16067	10866677	5132;1406	Phd;CRX	The model suggests further a mechanism by which ***Phd*** isoforms could ***inhibit*** ***CRX*** transcriptional activation .	negative	1
16068	10866677	5132;1406	phosducin;CRX	***Modulation*** of ***CRX*** transactivation activity by ***phosducin*** isoforms .	target	0
16069	10866677	5132;1406	Phd;CRX	Direct protein-protein ***interactions*** between ***Phd*** or PhLOP1 and ***CRX*** were demonstrated using a beta-galactosidase quantitative assay in the yeast two-hybrid system and were confirmed by an in vitro binding assay and a glutathione S-transferase ( GST ) pull-down assay .	parallel	1
16070	10866677	5132;1406	Phd;CRX	***Phd*** and PhLOP1 ***inhibited*** the transcriptional activation activity of ***CRX*** by 50 % during transient cotransfection in COS-7 cells and by 70 % in Weri-Rb-1 cells and COS-7 cells stably transfected with CRX .	negative	1
16071	10866677	5132;1406	Phd;CRX	***Phd*** ***inhibited*** ***CRX*** transactivation in a dose-dependent manner .	negative	1
16072	10866682	1958;3972	Egr1;luteinizing hormone beta subunit	***Egr1*** ***regulates*** ***luteinizing hormone beta subunit*** ( LHbeta ) gene expression in the pituitary gland .	target	1
16073	10866685	5610;5524	PKR;PP2A	Taken together , our data indicate that ***PKR*** can ***modulate*** ***PP2A*** activity by phosphorylating B56alpha to regulate cellular activities .	target	0
16074	10866689	64100;6886	E12;tal-1	In the pRb ( - ) SAOS-2 cell line transiently transfected with a reporter plasmid containing six tal-1 binding site , pRb enhances the transcriptional activity of tal-1-E12-Lmo2 and tal-1-E12-Lmo2-Ldb1 complexes but not that of a ******tal-1-E12****** ***heterodimer*** .	parallel	1
16075	10866800	3439;9636	IFN-alpha;ISG15	By this analysis , we showed that ***IFN-alpha*** ***induces*** the expression of ubiquitin cross-reactive protein ( ***ISG15*** ) and two ubiquitin-conjugating enzymes , UbcH5 and UbcH8 .	target	1
16076	10866800	3439;7321	IFN-alpha;UbcH5	By this analysis , we showed that ***IFN-alpha*** ***induces*** the expression of ubiquitin cross-reactive protein ( ISG15 ) and two ubiquitin-conjugating enzymes , ***UbcH5*** and UbcH8 .	target	1
16077	10866800	3439;7321	IFN-alpha;UbcH5	Northern-blot analysis showed that ***IFN-alpha*** rapidly ***enhances*** mRNA expression of ***UbcH5*** , UbcH6 and UbcH8 in T cells .	positive	0
16078	10866800	3439;7324	IFN-alpha;UbcH6	Northern-blot analysis showed that ***IFN-alpha*** rapidly ***enhances*** mRNA expression of UbcH5 , ***UbcH6*** and UbcH8 in T cells .	positive	0
16079	10866805	3068;1462	heparin-binding growth factor;versican	A ***heparin-binding growth factor*** , midkine , ***binds*** to a chondroitin sulfate proteoglycan , ***PG-M/versican*** .	parallel	1
16080	10866805	1462;4192	versican;midkine	***PG-M/versican*** isolated from day 13 mouse embryos ***bound*** ***midkine*** with a Kd of 1.0 nM .	parallel	1
16081	10866818	2247;7076	bFGF;TIMP-1	The tyrosine kinase inhibitor genistein caused a dose-dependent ***inhibition*** of ***TIMP-1*** protein induction by ATRA and ***bFGF*** .	negative	1
16082	10866818	2247;7076	bFGF;TIMP-1	At high concentrations , p38 MAP kinase inhibitors further enhanced the synergistic ***stimulation*** of ***TIMP-1*** protein by ATRA and ***bFGF*** , but at these concentrations , p42/44 MAP kinase was strongly activated .	positive	0
16083	10866818	2247;7076	bFGF;TIMP-1	The synergistic ***stimulation*** of ***TIMP-1*** protein by ATRA and ***bFGF*** increased across 72 h.	positive	0
16084	10866818	2247;7076	bFGF;TIMP-1	The ***induction*** of ***TIMP-1*** mRNA by ATRA and ***bFGF*** was greatly diminished by cycloheximide and therefore required new protein synthesis .	target	1
16085	10866993	5741;6550	parathyroid hormone;NHE3	Acute ***regulation*** of Na + / H + exchanger ***NHE3*** by ***parathyroid hormone*** via NHE3 phosphorylation and dynamin-dependent endocytosis .	target	1
16086	10866993	5741;6550	PTH;NHE3	When endocytic trafficking was arrested with a dominant negative dynamin mutant ( K44A ) , the early ***inhibition*** ( 5 min ) of ***NHE3*** activity by ***PTH*** was not affected , whereas the late inhibition ( 30 min ) and decreased surface NHE3 antigen induced by PTH were abrogated .	negative	1
16087	10866993	5741;6550	PTH;NHE3	We conclude that ***PTH*** acutely ***inhibits*** ***NHE3*** activity in a biphasic fashion by NHE3 phosphorylation followed by dynamin-dependent endocytosis .	negative	1
16088	10867011	6774;1052	Signal transducer and activator of transcription 3;CCAAT enhancer-binding protein delta	***Signal transducer and activator of transcription 3*** ***activates*** ***CCAAT enhancer-binding protein delta*** gene transcription in G0 growth-arrested mouse mammary epithelial cells and in involuting mouse mammary gland .	positive	1
16089	10867011	6774;1052	Stat3;C/EBPdelta	Overexpression of Stat3 increases C/EBPdelta promoter activity during G ( 0 ) growth arrest of HC11 cells , whereas dominant negative ***Stat3*** ***decreases*** ***C/EBPdelta*** promoter activity under the same conditions .	negative	0
16090	10867011	6774;1052	Stat3;C/EBPdelta	Overexpression of ***Stat3*** ***increases*** ***C/EBPdelta*** promoter activity during G ( 0 ) growth arrest of HC11 cells , whereas dominant negative Stat3 decreases C/EBPdelta promoter activity under the same conditions .	positive	0
16091	10867011	6774;1052	Stat3;C/EBPdelta	Neither Stat3 overexpression nor dominant negative ***Stat3*** expression ***influences*** ***C/EBPdelta*** promoter activity in growing HC11 cells or G ( 0 ) growth-arrested NIH3T3 cells , demonstrating that the effect is specific to G ( 0 ) growth arrest of mammary epithelial cells .	target	0
16092	10867011	6774;1052	Stat3;C/EBPdelta	These data indicate that ***Stat3*** ***activates*** ***C/EBPdelta*** transcription in G ( 0 ) growth-arrested mouse mammary epithelial cells and binds to the C/EBPdelta promoter during involution .	positive	1
16093	10867016	9982;2247	FGF-BP;FGF-2	Accordingly , ligand blotting experiments revealed that bovine ***FGF-BP*** ***bound*** ***FGF-2*** .	parallel	1
16094	10867020	5270;5328	PN1;uPA	In addition , the binding site in PN1 required for the LRP-mediated internalization of Th.PN1 complexes is not required for the LRP-mediated internalization of ******uPA.PN1****** ***complexes*** .	parallel	1
16095	10867020	5270;5328	PN1;uPA	Because cell surface heparins are only minimally involved in the binding and internalization of ******uPA.PN1****** ***complexes*** , we then predicted that complexes between uPA and the heparin binding-deficient PN1 variant , PN1 ( K7E ) , should be catabolized at the same rate as complexes formed with native PN1 .	parallel	1
16096	10867020	5270;5328	PN1;uPA	Because cell surface heparins are only minimally involved in the ***binding*** and internalization of ******uPA.PN1****** complexes , we then predicted that complexes between uPA and the heparin binding-deficient PN1 variant , PN1 ( K7E ) , should be catabolized at the same rate as complexes formed with native PN1 .	parallel	1
16097	10867020	5270;5328	PN1;uPA	Surprisingly , the ******uPA.PN1****** ( K7E ) ***complexes*** were degraded at only a fraction of the rate of native complexes .	parallel	1
16098	10867020	5270;5328	PN1;uPA	PN1 ( K7E ) and native uPA.PN1 complexes were initially internalized at the same rate , but ******uPA.PN1****** ( K7E ) ***complexes*** were rapidly retro-endocytosed in an intact form .	parallel	1
16099	10867020	5270;5328	PN1;uPA	By examining the pH dependence of complex binding in the range of 4.0-7 .0 , it was determined that the ******uPA.PN1****** inhibitory ***complexes*** must specifically bind to endosomal heparins at pH 5.5 to be retained and sorted to lysosomes .	parallel	1
16100	10867021	2185;7409	Pyk2;Vav	Furthermore , we found that ***Pyk2*** , when overexpressed , ***associates*** with Zap70 and ***Vav*** .	parallel	0
16101	10867021	2185;7535	Pyk2;Zap70	Furthermore , we found that ***Pyk2*** , when overexpressed , ***associates*** with ***Zap70*** and Vav .	parallel	0
16102	10867026	1874;5934	E2F4;p130	Administration of dexamethasone at this , but not earlier stages , results in reduction of cyclin A and CDK2 levels with a parallel decrease in the associated kinase activity , dissociation of cyclin A-CDK2 from the ******E2F4-p130****** ***complexes*** , and inhibition of G ( 1 ) / S transition .	parallel	1
16103	10867504	3458;969	interferon-gamma;CD69	***Regulation*** of ***CD69*** expression on eosinophil precursors by ***interferon-gamma*** .	target	1
16104	10867504	3458;969	IFN-gamma;CD69	On the other hand , ***IFN-gamma*** significantly ***upregulated*** ***CD69*** expression by the precursors after 24 h of incubation .	positive	1
16105	10867504	3458;969	IFN-gamma;CD69	In conclusion , these results indicate that ***IFN-gamma*** ***induces*** ***CD69*** expression by eosinophil precursors via the activation of JAK2 .	target	1
16106	10867506	3717;6777	JAK2;STAT5	These findings suggest that recombinant rat IL-5 activates ***JAK2*** tyrosine kinase , which ***phosphorylates*** ***STAT5*** , and induces protein synthesis required for the prolongation of rat eosinophil survival .	target	1
16107	10867509	6369;6356	eotaxin-2;eotaxin	In addition , RANTES or ***eotaxin-2*** but not MCP-3 at the higher concentrations ( 100 ng/ml ) , also ***induced*** slight ***eotaxin*** production .	target	1
16108	10867509	6352;6356	RANTES;eotaxin	In addition , ***RANTES*** or eotaxin-2 but not MCP-3 at the higher concentrations ( 100 ng/ml ) , also ***induced*** slight ***eotaxin*** production .	target	1
16109	10867510	3458;6356	IFN-gamma;eotaxin	On the other hand , Th1-type cytokine ***IFN-gamma*** ***inhibited*** ***eotaxin*** generation at the protein/mRNA levels .	negative	1
16110	10867510	3458;6356	IFN-gamma;eotaxin	In view of the Th1/Th2 paradigm , these results indicate that ( 1 ) eotaxin regulates eosinophil accumulation in the Th2-dominant state such as allergic disease , and ( 2 ) direct ***suppression*** of ***eotaxin*** production by ***IFN-gamma*** is one of the major mechanisms by which IFN-gamma suppresses eosinophilic inflammation .	negative	1
16111	10867518	3606;7422	Interleukin-18;vascular permeability factor	***Interleukin-18*** and interleukin-12 synergize to ***stimulate*** the production of ***vascular permeability factor*** by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome .	positive	0
16112	10867518	3606;7422	IL-18;VPF	Since IL-18 , a novel immunoregulatory cytokine with potent interferon-gamma inducing activities , has been shown to be a strong cofactor for T helper type 1 cell development , we tested the hypothesis that ***IL-18*** in combination with IL-12 can act synergistically to ***modulate*** the production of ***VPF*** .	target	0
16113	10867518	3606;7422	IL-18;VPF	Thus , these data show that ***IL-18*** can synergize with IL-12 to selectively ***increase*** the production of ***VPF*** from T cells .	positive	0
16114	10867521	3553;3312	IL-1beta;HSP 72/73	We suggest that the increased ***HSP 72/73*** expression of MC during peritonitis is in part ***induced*** by TNF-alpha and ***IL-1beta*** and may exert a cell-protective function , lessening MC damage during peritonitis .	target	1
16115	10867521	7124;3312	TNF-alpha;HSP 72/73	We suggest that the increased ***HSP 72/73*** expression of MC during peritonitis is in part ***induced*** by ***TNF-alpha*** and IL-1beta and may exert a cell-protective function , lessening MC damage during peritonitis .	target	1
16116	10867614	7124;4582	TNF-alpha;MUC1	In contrast , CAL51 cells were overall less sensitive to differentiation induction attempts ; only ***TNF-alpha*** ***stimulated*** ***MUC1*** , isoactin and epithelial cell adhesion molecule ( Ep-CAM ) expression .	positive	0
16117	10867648	2305;6439	HNF-3;SP-B	***HNF-3*** and TTF-1 transcription factors are known to ***stimulate*** ***SP-B*** transcription .	positive	0
16118	10867648	2305;6439	HNF-3;SP-B	Therefore , SP-A signals through PI3 kinase to increase SP-B transcription in type II pneumocytes by enhancing TTF-1 and ***HNF-3*** ***activation*** of the ***SP-B*** promoter .	positive	1
16119	10867658	3952;885	leptin;cholecystokinin	In the brainstem , we found that ***cholecystokinin*** neurons in the slPB and glucagon-like peptide-1 neurons in the NTS were ***activated*** by ***leptin*** .	positive	1
16120	10867799	5239;1756	Aciculin;dystrophin	These results suggest that ***Aciculin*** is associated with dystrophin and may ***interact*** with both the N - and C-terminal domains of ***dystrophin*** .	parallel	1
16121	10867799	5239;1756	Aciculin;dystrophin	These results suggest that ***Aciculin*** is ***associated*** with ***dystrophin*** and may interact with both the N - and C-terminal domains of dystrophin .	parallel	0
16122	10867812	4254;3815	SCF;c-kit	These results indicate that IL-1 alpha stimulates mast cell growth by a fibroblast-dependent mechanism , in which ******SCF/c-kit****** ***interaction*** may participate in a major way .	parallel	1
16123	10867821	348;4018	Apolipoprotein E;lipoprotein	***Apolipoprotein E*** gene expression ***correlates*** with endogenous lipid nutrition and yolk syncytial layer ***lipoprotein*** synthesis during fish development .	parallel	0
16124	10867821	348;4018	apoE;lipoprotein	YSL ***apoE*** expression was ***correlated*** with the synthesis of very low density ***lipoprotein*** ( VLDL ) particles .	parallel	0
16125	10867826	7039;7040	TGF alpha;TGF beta-1	We suggest that ***TGF alpha*** ***stimulates*** the expression of ***TGF beta-1*** in rats , as in implanting transgenic mice , and that it is involved in extracellular matrix remodelling in the lateral plasma membranes and basal lamina to inhibit invasion and implantation and to stimulate the production of basement membrane .	positive	0
16126	10868475	820;5972	cAMP;renin	***renin*** secretion and synthesis by the JG cells of the kidney is ***upregulated*** by ***cAMP*** and downregulated by intracellular calcium .	positive	1
16127	10868475	820;5972	cAMP;renin	In addition to its stimulatory effect on secretion , ***cAMP*** also effectively ***augments*** ***renin*** mRNA levels by acting at the transcriptional and posttranscriptional levels .	positive	0
16128	10868913	6696;4843	OPN;iNOS	***OPN*** ***inhibits*** inducible nitric oxide synthase ( ***iNOS*** ) , which generates large amounts of NO production .	negative	1
16129	10868937	3479;4843	IGF-I;NOS-2	However , in activated cells treated with N - [ 3 - ( aminomethyl ) benzyl ] acetamidine , a specific ***NOS-2*** ***inhibitor*** , ***IGF-I*** completely abolished the NO-independent apoptosis .	negative	1
16130	10869284	2520;5578	Gastrin;PKCalpha	***Gastrin*** ***induced*** translocation of ***PKCalpha*** from cholangiocyte cytoskeleton to membrane .	target	1
16131	10869284	5578;2520	PKCalpha;Gastrin	To evaluate if ***Gastrin*** effects on cholangiocyte proliferation are ***mediated*** by the isoform ***PKCalpha*** , we evaluated ( 1 ) for the presence of PKCalpha in cholangiocytes and ( 2 ) the effect of Gastrin on the PKCalpha protein expression in a triton-soluble ( containing cytoplasm + membrane ) and a triton-insoluble ( containing cytoskeleton ) fraction .	target	0
16132	10869285	3569;3572	IL-6;gp130	In both the CCs and BECs , exogenous HGF or ***IL-6*** ***induced*** phosphorylation of met or ***gp130*** , respectively , and a concentration-dependent increase in DNA synthesis .	target	1
16133	10869285	3569;8731	IL-6;met	In both the CCs and BECs , exogenous HGF or ***IL-6*** ***induced*** phosphorylation of ***met*** or gp130 , respectively , and a concentration-dependent increase in DNA synthesis .	target	1
16134	10869347	56288;207	ASIP;Akt	When overexpressed in these cells , which contain PKClambda but not PKCzeta , ***ASIP*** was ***co-immunoprecipitated*** with endogenous PKClambda but not with PKCepsilon or with ***Akt*** .	parallel	1
16135	10869359	207;673	Akt;B-Raf	Negative ***regulation*** of the serine/threonine kinase ***B-Raf*** by ***Akt*** .	negative	1
16136	10869359	207;673	Akt;B-Raf	We show that ***phosphorylation*** of ***B-Raf*** by ***Akt*** occurs at multiple residues within its amino-terminal regulatory domain , at both the conserved and unique phosphorylation sites .	target	1
16137	10869359	207;673	Akt;B-Raf	Furthermore , expression of ***Akt*** ***inhibits*** epidermal growth factor-induced ***B-Raf*** activity and inhibition of Akt with LY294002 up-regulates B-Raf activity , suggesting that Akt negatively regulates B-Raf in vivo .	negative	1
16138	10869359	207;673	Akt;B-Raf	Furthermore , expression of Akt inhibits epidermal growth factor-induced B-Raf activity and inhibition of Akt with LY294002 up-regulates B-Raf activity , suggesting that ***Akt*** negatively ***regulates*** ***B-Raf*** in vivo .	negative	1
16139	10869359	207;673	Akt;B-Raf	Our results demonstrate that ***B-Raf*** activity can be negatively ***regulated*** by ***Akt*** through phosphorylation in the amino-terminal regulatory domain of B-Raf .	negative	1
16140	10869359	673;207	B-Raf;Akt	This ***cross-talk*** between the ***B-Raf*** and ***Akt*** serine/threonine kinases is likely to play an important role in modulating the signaling specificity of the Ras/Raf pathway and in promoting biological outcome .	parallel	0
16141	10869426	5925;1877	pRB;p120E4F	***pRB*** ***binds*** to and modulates the transrepressing activity of the E1A-regulated transcription factor ***p120E4F*** .	parallel	1
16142	10869428	23479;150274	IscU;Hsc20	***Interaction*** of the iron-sulfur cluster assembly protein ***IscU*** with the ***Hsc66/Hsc20*** molecular chaperone system of Escherichia coli .	parallel	1
16143	10869428	150274;23479	Hsc20;IscU	Hsc20 also decreased the apparent K ( m ) for IscU stimulation of Hsc66 ATPase activity , and surface plasmon resonance studies revealed that ***Hsc20*** ***enhances*** binding of ***IscU*** to Hsc66 .	positive	0
16144	10869428	150274;23479	Hsc20;IscU	Surface plasmon resonance and isothermal titration calorimetry further showed that ***IscU*** and ***Hsc20*** form a ***complex*** , and Hsc20 may thereby aid in the targeting of IscU to Hsc66 .	parallel	1
16145	10869476	7040;632	TGF-beta;osteocalcin	While ***TGF-beta*** ( 1 ) ***inhibited*** ***osteocalcin*** secretion from HOB-M cells , both phenytoin and BMP-2 significantly stimulated it .	negative	1
16146	10869553	6271;6275	S100A1;S100A4	Heterocomplex ***formation*** between metastasis-related protein ***S100A4*** ( Mts1 ) and ***S100A1*** as revealed by the yeast two-hybrid system .	parallel	0
16147	10869553	6271;6275	S100A1;S100A4	Mutational analysis revealed that replacement of Cys ( 76 ) and/or Cys ( 81 ) of S100A4 by Ser abolishes the ******S100A4/S100A1****** ***heterodimerization*** , but does not affect the S100A4 homodimerization in vivo .	parallel	1
16148	10869558	5937;5422	MSSP;polymerase alpha	***MSSP*** , a protein binding to an origin of replication in the c-myc gene , ***interacts*** with a catalytic subunit of DNA ***polymerase alpha*** and stimulates its polymerase activity .	parallel	1
16149	10869564	2822;5743	PLD;cyclooxygenase-2	Interleukin-1-stimulated arachidonate release was accompanied by prostaglandin E ( 2 ) production via ***cyclooxygenase-2*** , the expression of which was ***augmented*** by ***PLD*** ( 2 ) .	positive	0
16150	10869570	5879;1760	Rac-1;DMPK	We show here that the actin cytoskeleton-linked GTPase ***Rac-1*** ***binds*** to ***DMPK*** , and coexpression of Rac-1 and DMPK activates its transphosphorylation activity in a GTP-sensitive manner .	parallel	1
16151	10869570	1760;5894	DMPK;Raf-1	***DMPK*** can also ***bind*** ***Raf-1*** kinase , the Ras-activated molecule of the MAP kinase pathway .	parallel	1
16152	10869570	5894;1760	Raf-1;DMPK	Purified ***Raf-1*** kinase ***phosphorylates*** and activates ***DMPK*** .	target	1
16153	10869574	1080;360	cystic fibrosis transmembrane conductance regulator;Aquaporin 3	***Aquaporin 3*** cloned from Xenopus laevis is ***regulated*** by the ***cystic fibrosis transmembrane conductance regulator*** .	target	1
16154	10869574	1080;360	CFTR;Aquaporin 3	Here , we show that ***CFTR*** ***activates*** ***Aquaporin 3*** expressed endogenously and exogenously in oocytes of Xenopus laevis .	positive	1
16155	10869810	3589;351	IL-11;Abeta	Moreover , ***IL-11*** ***inhibits*** ***Abeta*** ( 1-42 ) - induced neurotoxicity in a dose-dependent manner .	negative	1
16156	10870037	1392;2641	corticotropin-releasing hormone;glucagon	***Interaction*** between ***glucagon*** and human ***corticotropin-releasing hormone*** or vasopressin on ACTH and cortisol secretion in humans .	parallel	1
16157	10870037	2641;1392	glucagon;corticotropin-releasing hormone	DESIGN AND METHODS : To throw further light on the stimulatory effect of i.m. glucagon on the pituitary-adrenal axis , using six normal young female volunteers ( 26-32 years , body mass index 19.7-22 .5 kg/m ( 2 ) ) we studied the ***interaction*** between ***glucagon*** ( GLU ; 0.017 mg/kg i.m. ) and human ***corticotropin-releasing hormone*** ( hCRH ; 2.0 microg/kg i.v. ) or vasopressin ( AVP ; 0.17 U/kg i.m. ) .	parallel	1
16158	10870325	345;4023	APOCIII;lipoprotein lipase	ApoA1 is the main component of high-density lipoprotein ( HDL ) , and ***APOCIII*** ***inhibits*** ***lipoprotein lipase*** activity .	negative	1
16159	1087054	462;9622	antithrombin III;kallikrein	***Inactivation*** and binding of human plasma ***kallikrein*** by ***antithrombin III*** and heparin .	negative	1
16160	10871198	5167;3643	plasma cell membrane glycoprotein-1;insulin receptor	The membrane protein ***plasma cell membrane glycoprotein-1*** ( PC-1 ) has been identified as an ***inhibitor*** of ***insulin receptor*** tyrosine kinase ( IRTK ) activity .	negative	1
16161	10871198	5167;3643	PC-1;insulin receptor	***PC-1*** content was negatively ***correlated*** with ***insulin receptor*** phosphorylation ( r = -0.55 , P < 0.05 ) and IRTK activity ( r = -0.66 , P < 0.05 ) .	negative	0
16162	10871205	7040;1432	TGF-beta1;p38 MAP kinase	At 33 h , ***TGF-beta1*** blockade did not affect stretch-induced fibronectin production , but partially ***prevented*** stretch-induced ***p38 MAP kinase*** activation ( 59 % inhibition , P < 0.05 ) .	positive	0
16163	10871205	1432;7040	p38 MAP kinase;TGF-beta1	In human mesangial cells , stretch activates , via a PKC-dependent mechanism , ***p38 MAP kinase*** , which independently ***induces*** ***TGF-beta1*** and fibronectin .	target	1
16164	10871279	988;8881	Cdc5;Cdc16	However , although ***Cdc5*** can ***phosphorylate*** ***Cdc16*** and Cdc27 in vitro , this in vitro phosphorylation does not occur on in vivo sites of phosphorylation .	target	1
16165	10871279	988;996	Cdc5;Cdc27	However , although ***Cdc5*** can ***phosphorylate*** Cdc16 and ***Cdc27*** in vitro , this in vitro phosphorylation does not occur on in vivo sites of phosphorylation .	target	1
16166	10871282	2549;5781	Gab1;Shp2	In a trk-Met-Gab1-specific branching morphogenesis assay , ***association*** of ***Gab1*** with ***Shp2*** , but not PI ( 3 ) K , CRKL , or Shc was essential to induce a biological response in MDCK cells .	parallel	0
16167	10871282	2549;4233	Gab1;c-Met	***Gab1*** is a ***substrate*** of the receptor tyrosine kinase ***c-Met*** and involved in c-Met-specific branching morphogenesis .	parallel	1
16168	10871296	10267;799	RAMP1;CTR	Thus , ***RAMP1*** or RAMP3 can ***modify*** the calcitonin receptor ( ***CTR*** ) to also function as a high-affinity Amylin receptor-like phenotype .	target	0
16169	10871296	10268;799	RAMP3;CTR	Thus , RAMP1 or ***RAMP3*** can ***modify*** the calcitonin receptor ( ***CTR*** ) to also function as a high-affinity Amylin receptor-like phenotype .	target	0
16170	10871296	799;3375	hCTR;Amylin	Also , in CHO-P , ***hCTR*** ( I1 - ) ***induced*** ***Amylin*** binding with all three RAMPs , in contrast to COS-7 , where only RAMP1 or RAMP3 generate an Amylin receptor phenotype .	target	1
16171	10871373	7486;5111	hWRN;proliferating cell nuclear antigen	Finally , we show that ***hWRN*** forms a trimer and ***interacts*** with the ***proliferating cell nuclear antigen*** in vitro .	parallel	1
16172	10871379	58487;3054	Zhangfei;HCF	Here we report a second human protein , ***Zhangfei*** ( ZF ) that ***interacts*** with ***HCF*** in a fashion similar to Luman and VP16 .	parallel	1
16173	10871397	3364;5810	Hus1;Rad1	We used previously reported genetic and biochemical data for these proteins from yeast and human cells to predict a heterotrimeric PCNA-like ring structure for the functional ******Rad1/Rad9/Hus1****** ***complex*** and to determine their exact order within it .	parallel	1
16174	10871397	3364;5883	Hus1;Rad9	We used previously reported genetic and biochemical data for these proteins from yeast and human cells to predict a heterotrimeric PCNA-like ring structure for the functional ******Rad1/Rad9/Hus1****** ***complex*** and to determine their exact order within it .	parallel	1
16175	10871397	5883;5810	Rad9;Rad1	We used previously reported genetic and biochemical data for these proteins from yeast and human cells to predict a heterotrimeric PCNA-like ring structure for the functional ******Rad1/Rad9/Hus1****** ***complex*** and to determine their exact order within it .	parallel	1
16176	10871399	3087;7038	Hex;thyroglobulin	By using co-transfection assays we demonstrate that ***Hex*** is a ***repressor*** of the ***thyroglobulin*** promoter and that it is able to abolish the activating effects of both TTF-1 and Pax8 .	negative	1
16177	10871409	5395;4292	hPMS2;hMLH1	Our data also suggest that a considerable fraction of mutagenic intermediates are recognized by the hMutSbeta complex and processed via the ******hMLH1/hPMS2****** ***heterodimer*** .	parallel	1
16178	10871606	4609;9982	c-Myc;FGF-BP	Furthermore , chromatin immunoprecipitation assay showed that USF , ***c-Myc*** , and Max proteins were ***associated*** with the ***FGF-BP*** promoter in vivo .	parallel	0
16179	10871606	4149;9982	Max;FGF-BP	Furthermore , chromatin immunoprecipitation assay showed that USF , c-Myc , and ***Max*** proteins were ***associated*** with the ***FGF-BP*** promoter in vivo .	parallel	0
16180	10871607	7516;5892	XRCC2;RAD51L3	By using purified proteins , we demonstrate that the ***interaction*** between ***RAD51L3*** and ***XRCC2*** is direct .	parallel	1
16181	10871607	7516;5892	XRCC2;RAD51L3	Given the requirements for XRCC2 in genetic recombination and protection against DNA-damaging agents , we suggest that the ***complex*** of ***RAD51L3*** and ***XRCC2*** is likely to be important for these functions in human cells .	parallel	1
16182	10871633	5599;4088	JNK;Smad3	The ***inhibition*** of the ***Smad3*** pathway by the ***SAPK/JNK*** pathway , both triggered by TGF-beta , could participate in a negative feedback loop to control TGF-beta responses .	negative	1
16183	10871633	5601;4088	SAPK;Smad3	The ***inhibition*** of the ***Smad3*** pathway by the ***SAPK/JNK*** pathway , both triggered by TGF-beta , could participate in a negative feedback loop to control TGF-beta responses .	negative	1
16184	10871633	5599;4088	JNK;Smad3	Here , we report that the ***SAPK/JNK*** pathway ***inhibits*** the ***Smad3*** pathway .	negative	1
16185	10871633	5601;4088	SAPK;Smad3	Here , we report that the ***SAPK/JNK*** pathway ***inhibits*** the ***Smad3*** pathway .	negative	1
16186	10871633	3725;4088	c-Jun;Smad3	This effect is not dependent on blocking of Smad3 nuclear translocation but involves a functional ***interaction*** between ***Smad3*** and ***c-Jun*** , a transcription factor activated by the SAPK/JNK pathway .	parallel	1
16187	10871633	3725;4088	c-Jun;Smad3	Overexpression of constitutively active MEKK1 or MKK4 mutants stabilizes the physical ***interaction*** between ***Smad3*** and ***c-Jun*** , whereas dominant negative mutants inhibit this interaction .	parallel	1
16188	10871762	3700;7852	gp120;CXCR4	The neurodegenerative mechanisms may involve infection of microglia by certain CXCR4 tropic viruses in addition to cellular dysfunction and apoptosis induced by HIV-1 ***gp120*** ***binding*** to ***CXCR4*** .	parallel	1
16189	10871767	8862;187	apelin;APJ	We also analyzed the ability of a recently identified ***APJ*** peptide ***ligand*** , ***apelin*** , to induce calcium elevations in cultured neural cells .	parallel	1
16190	10871782	3456;3557	IFNbeta;IL-1ra	We now report that ***IFNbeta*** ***induced*** ***IL-1ra*** mRNA and mature protein in three myelomonocytic cell lines .	target	1
16191	10871840	2534;2887	Fyn;Grb10	In addition , ***Grb10*** tyrosine phosphorylation was ***stimulated*** by expression of constitutively active Src or ***Fyn*** in cells and by incubation with purified Src or Fyn in vitro .	positive	0
16192	10871840	6714;2887	Src;Grb10	In addition , ***Grb10*** tyrosine phosphorylation was ***stimulated*** by expression of constitutively active ***Src*** or Fyn in cells and by incubation with purified Src or Fyn in vitro .	positive	0
16193	10871841	6464;2885	Shc;Grb2	TPA treatment of MCF-7 cells caused an increased ***association*** of ***Shc*** with ***Grb2*** .	parallel	0
16194	10871843	2308;598	FKHR;BCL-XL	In the present study , we establish that ***BCL-XL*** is transcriptionally ***modulated*** by PAX3 and ***PAX3/FKHR*** , since enhanced expression of both PAX proteins stimulates transcription of endogenous BCL-XL mRNA in a cell type specific manner .	target	0
16195	10871843	5077;598	PAX3;BCL-XL	In the present study , we establish that ***BCL-XL*** is transcriptionally ***modulated*** by ***PAX3*** and PAX3/FKHR , since enhanced expression of both PAX proteins stimulates transcription of endogenous BCL-XL mRNA in a cell type specific manner .	target	0
16196	10871843	2308;598	FKHR;Bcl-x	Further , we present evidence that both PAX3 and ***PAX3/FKHR*** can transcriptionally ***activate*** the ***Bcl-x*** gene promoter in cotransfection assays .	positive	1
16197	10871843	5077;598	PAX3;Bcl-x	Further , we present evidence that both PAX3 and ***PAX3/FKHR*** can transcriptionally ***activate*** the ***Bcl-x*** gene promoter in cotransfection assays .	positive	1
16198	10871849	1029;4193	ARF;hdm2	The ***ARF*** protein ***inhibits*** ***hdm2*** activity , leading to the stabilization of the p53 tumour suppressor and cell cycle inhibition .	negative	1
16199	10871849	1029;4193	ARF;hdm2	The amino-terminal nucleolar-targeting domain of p14ARF is also important for ******ARF-hdm2****** ***binding*** and cell cycle inhibition .	parallel	1
16200	10871852	4217;355	ASK1;Fas	***ASK1/p38*** ***downregulates*** the expression of a ***Fas*** via NF-kappaB/SP1 site on the Fas promoter .	negative	1
16201	10871852	1432;355	p38;Fas	***ASK1/p38*** ***downregulates*** the expression of a ***Fas*** via NF-kappaB/SP1 site on the Fas promoter .	negative	1
16202	10871852	4790;1432	NF-kappaB;p38	Deletion or mutation of ***NF-kappaB/SP1*** within the Fas promoter ***abrogates*** ***p38*** effect .	positive	0
16203	10871852	1432;355	p38;Fas	Identifying ***p38-mediated*** ***down-regulation*** of ***Fas*** expression illustrates a novel regulatory pathway by which ASK1/MKK6/p38 alters the degree and nature of the UV-induced apoptosis of melanoma cells .	negative	1
16204	10871854	1978;1977	4E-BP1;eIF4E	Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor ( eIF ) 4E-binding protein 1 ( 4E-BP1 ) , resulting in decreased p70 S6 kinase activity and an increase in ***4E-BP1*** ***binding*** to ***eIF4E*** .	parallel	1
16205	10871855	25;7157	c-abl;p53	***c-abl*** is involved in the ***association*** of ***p53*** and trk A.	parallel	0
16206	10871856	4486;4233	Ron;Met	***Cross-talk*** between the proto-oncogenes ***Met*** and ***Ron*** .	parallel	0
16207	10871856	4486;4233	Ron;Met	Cross-linking experiments show that non-covalent ******Met-Ron****** ***complexes*** are present on the cell surface , before ligand-induced dimerization .	parallel	1
16208	10871861	5611;5610	P58;PKR	The nontransformed cells contain ***P58*** , a known cellular ***inhibitor*** of ***PKR*** that physically interacts with PKR and may be responsible for the low PKR activity in these cells .	negative	1
16209	10871861	5610;1965	PKR;eIF2	Activated ***PKR*** ***phosphorylates*** its cellular substrate , ***eIF2*** , an essential initiation factor of translation .	target	1
16210	10872376	6696;960	OPN;CD44	The ***interactions*** between ***CD44*** and ***OPN*** may have important clinical implications in the repair of skeletal tissues .	parallel	1
16211	10872376	6696;960	OPN;CD44	Our findings suggest that ***OPN*** , rather than HUA , is the major ***ligand*** for ***CD44*** on bone cells in the remodelling phase of healing of fractures .	parallel	1
16212	10872740	7037;7018	TfR;transferrin	Its action upon the ***transferrin*** ***receptor*** ( ***TfR*** ) and upon the expression of brain transferrin , as well as its effect on the proliferation and differentiation of oligodendroglial cells ( OLGc ) was one of the main objectives of our investigation .	parallel	1
16213	10872741	7037;7018	TfR;Transferrin	Previously we had demonstrated the presence of ***Transferrin*** ***receptor*** ( ***TfR*** ) on the plasma membrane of cultured rat cortical astrocytes .	parallel	1
16214	10872747	5594;3162	p38;HO-1	Collectively , the findings suggest that MAP kinase ERK and ***p38*** pathways are involved in the NO-mediated ***induction*** of ***HO-1*** and that SAPK/JNK pathway and increased DNA binding of AP-1 transcription factor are not involved in HO-1 gene activation by NO .	target	1
16215	10872747	6616;3162	SNAP;HO-1	ERK and p38 inhibitors also suppressed ***induction*** of ***HO-1*** by ***SNAP*** and GSNO .	target	1
16216	10872812	3479;2185	IGF-I;protein kinase B	The addition of ***IGF-I*** to floating cells ***induced*** activation of ***protein kinase B*** ( PKB ) / Akt , as to cells attached to the substratum .	target	1
16217	10872812	3479;5609	IGF-I;MEK	While the IGF-I-induced activation of PKB/Akt was inhibited by PI3-K inhibitor LY294002 but not by MEK inhibitor PD98059 , the ***activation*** of both ***MEK*** and ERK by ***IGF-I*** was inhibited by both .	positive	1
16218	10872826	10912;1647	CR6;Gadd45	***Interaction*** between ***Gadd45*** or ***CR6*** and RXR alpha was confirmed by a two-hybrid test in yeast .	parallel	1
16219	10872839	2358;1234	FPRL1;chemokine receptor CCR5	Activation of the chemotactic peptide receptor ***FPRL1*** in monocytes ***phosphorylates*** the ***chemokine receptor CCR5*** and attenuates cell responses to selected chemokines .	target	1
16220	10872894	356;355	FasL;Fas	Signaling through phosphorylation also regulates the expression of the ***Fas*** ***ligand*** ( ***FasL*** ) , the FasR , as well as various other proteins that affect the outcome of receptor stimulation .	parallel	1
16221	10873021	2668;5979	GDNF;RET	BACKGROUND/PURPOSE : Glial-derived growth factor ( ***GDNF*** ) , which is the ***ligand*** of ***RET*** is reported to be essential for the development of enteric nervous system .	parallel	1
16222	10873024	2641;3458	GLP-2;IFN-gamma	Furthermore , ***GLP-2*** ***reduced*** the mean band intensity ( MBI ) of TNF-alpha ( 0.4 + / - 0.04 in group 2 to 0 in group 3 , P < .01 ) and ***IFN-gamma*** ( 0.3 + / - 0.02 in group 2 to 0 in group 3 , P < .01 ) .	negative	1
16223	10873074	1956;7039	EGFR;transforming growth factor (TGF)-alpha	We have previously demonstrated that RA down-modulates ***transforming growth factor (TGF)-alpha*** and epidermal growth factor ***receptor*** ( ***EGFR*** ) levels in head and neck squamous cell carcinoma by decreasing the transcription rate of these two genes .	parallel	1
16224	10873097	1026;5111	p21;PCNA	An A -- > G transition at codon 149 resulted in amino acid substitution from aspartate to glycine in the proliferating cell nuclear antigen binding COOH-terminal domain of p21 ( Waf1/Cip1 ) that may affect ******PCNA-p21****** ( Waf1/Cip1 ) ***interactions*** , thereby affecting regulation of cellular proliferation , and may increase susceptibility for development of cancer .	parallel	1
16225	10873098	355;356	CD95;CD95 ligand	We report here that the progression of pancreatic carcinomas in tumor patients is associated with increased serum levels of both the soluble forms of ***CD95 ligand*** ( CD95L/FasL ) and its ***receptor*** , ***CD95*** ( Fas ) .	parallel	1
16226	10873156	7124;3576	TNF-alpha;IL-8	We found that ***TNF-alpha*** strongly ***enhanced*** ***IL-8*** release in a time - and concentration-dependent manner , whereas Salbu , Salme , the direct adenylyl cyclase activator forskolin ( FSK ) , and the cyclic monophosphate ( cAMP ) analogue 8-bromoadenosine 3 ' ,5 ' - cAMP ( 8-Br-cAMP ) alone weakly stimulated IL-8 release .	positive	0
16227	10873158	847;4790	catalase;NF-kappaB	Both nuclear translocation of ***NF-kappaB*** and enhanced kappaB-dependent transcription induced by V ( IV ) were ***inhibited*** by overexpression of ***catalase*** , but not Cu,Zn superoxide dismutase ( Cu,Zn-SOD ) , indicating that peroxides rather than superoxides initiated signaling .	negative	1
16228	10873158	847;5594	catalase;p38	Overexpression of ***catalase*** , but not Cu,Zn-SOD , ***inhibited*** ***p38*** activation , indicating that peroxides activated p38 .	negative	1
16229	10873158	5594;4790	p38;NF-kappaB	The data demonstrate that V ( IV ) - induced oxidative stress activates at least two distinct pathways , NF-kappaB nuclear translocation and ***p38-dependent*** ***transactivation*** of ***NF-kappaB*** , both of which are required to fully activate kappaB-dependent transcription .	positive	1
16230	10873159	7124;3569	Tumor necrosis factor-alpha;interleukin-6	***Tumor necrosis factor-alpha*** ***enhances*** mRNA expression and secretion of ***interleukin-6*** in cultured human airway smooth muscle cells .	positive	0
16231	10873388	6242;392	Rhotekin;RhoGAP	***Rhotekin*** , which is one of the downstream target molecules of Rho with a Rho binding motif class I domain , can ***inhibit*** endogenous or ***RhoGAP-stimulating*** Rho GTPase activity to regulate the signaling pathway .	negative	1
16232	10873465	7508;5887	XPC;hHR23B	Cells from humans with xeroderma pigmentosum group C do not perform NER in the bulk of the genome and are corrected by ***XPC*** protein , which forms a ***complex*** with ***hHR23B*** protein .	parallel	1
16233	10873465	5887;7508	hHR23B;XPC	Recombinant XPC , hHR23B , and ******XPC-hHR23B****** ***complex*** were purified .	parallel	1
16234	10873465	5887;7508	hHR23B;XPC	In a reconstituted repair system , ***hHR23B*** ***stimulated*** ***XPC*** activity tenfold .	positive	0
16235	10873465	5887;7508	hHR23B;XPC	Damaged ******DNA-XPC-hHR23B****** ***complexes*** were stable , with half of the complexes remaining four hours after challenge with excess UV-damaged DNA at 30 degrees C.	parallel	1
16236	10873514	1906;353	Endothelin-1;AMP	***Endothelin-1*** ***inhibited*** histamine-elicited [ ( 3 ) H ] cyclic ***AMP*** generation with an IC ( 50 ) value of 3 + / - 2.5 nM .	negative	1
16237	10873588	2932;4137	GSK-3beta;tau	These results suggest that PKNalpha and PKC directly inhibit GSK-3beta activity at least in part by phosphorylating Ser9 of GSK-3beta , and that they indirectly suppress ***GSK-3beta-stimulated*** ***phosphorylation*** of ***tau*** at amino acids Ser202/Thr205 and Thr181 , but enhanced phosphorylation at Thr231 through phosphorylation at other sites of tau .	target	1
16238	10873588	5585;2932	PKNalpha;GSK-3beta	These results suggest that ***PKNalpha*** and PKC directly ***inhibit*** ***GSK-3beta*** activity at least in part by phosphorylating Ser9 of GSK-3beta , and that they indirectly suppress GSK-3beta-stimulated phosphorylation of tau at amino acids Ser202/Thr205 and Thr181 , but enhanced phosphorylation at Thr231 through phosphorylation at other sites of tau .	negative	1
16239	10873592	3091;9915	HIF-1alpha;ARNT2	ARNT2 is a conserved ARNT homolog that is highly expressed in neurons , suggesting that ******ARNT2/HIF-1alpha****** ***heterodimers*** mediate transcriptional responses to oxygen deprivation in the nervous system .	parallel	1
16240	10873592	3091;9915	HIF-1alpha;ARNT2	Formation of neural ******ARNT2/HIF-1alpha****** ***complexes*** in Arnt ( - / - ) ES cell-derived teratocarcinomas may explain why these tumors express VEGF , vascularize and grow efficiently , in contrast to ARNT-deficient hepatomas .	parallel	1
16241	10873601	8711;5335	Tnk1;PLC-gamma1	The ***association*** of ***Tnk1*** with ***PLC-gamma1*** suggests a role for Tnk1 in phospholipid signal transduction .	parallel	0
16242	10873601	5335;8711	PLC-gamma1;Tnk1	In binding experiments with a panel of GST-fusion constructs , only ***GST-PLC-gamma1*** ( SH3 ) ***interacted*** with in vitro translated ***Tnk1*** .	parallel	1
16243	10873601	5335;8711	PLC-gamma1;Tnk1	GST-protein precipitations from cell lysates confirmed that ***GST-PLC-gamma1*** ( SH3 ) ***associated*** with endogenously expressed ***Tnk1*** .	parallel	0
16244	10873601	8711;5335	Tnk1;PLC-gamma1	Conversely , ***GST-Tnk1*** ( PR ) protein constructs ***complexed*** with endogenously expressed ***PLC-gamma1*** .	parallel	1
16245	10873603	3952;3553	leptin;IL-1beta	***leptin*** ***increased*** the expression of ***IL-1beta*** mRNA evaluated by RT-PCR .	positive	0
16246	10873603	3952;3553	leptin;IL-1beta	These results indicate that ***leptin*** could ***induce*** ***IL-1beta*** transcript in the brain and that one of the target cells of the leptin-induced IL-1beta transcript may be a glial cell .	target	1
16247	10873605	3479;207	IGF-1;Akt	Both ***Akt*** and ERK1/2 were rapidly ***phosphorylated*** by ***IGF-1*** and blocked by wortmannin and PD98059 , inhibitors of their upstream activators respectively .	target	1
16248	10873605	3479;5594	IGF-1;ERK1/2	Both Akt and ***ERK1/2*** were rapidly ***phosphorylated*** by ***IGF-1*** and blocked by wortmannin and PD98059 , inhibitors of their upstream activators respectively .	target	1
16249	10873625	91768;113130	ik3-1;p35	Coimmunoprecipitation indicated that p70 ( ***ik3-1*** ) ***binds*** to ***p35*** ( cdk3 ) in vivo .	parallel	1
16250	10873631	1026;5111	p21;PCNA	The complex formation was not impaired by point mutations of p21 at residues 147 , 149 , and 150 , which have been reported to abrogate ***interaction*** of ***p21*** with proliferating cell nuclear antigen ( ***PCNA*** ) , discriminating the Core-binding sequence from the PCNA-binding sequence .	parallel	1
16251	10873642	4790;5970	p50;p65	Gel mobility shift assays revealed two bands in NFSC nuclear extracts that correspond to ******p65/p50****** ***heterodimers*** and p50/p50 homodimers .	parallel	1
16252	10873645	5465;7352	PPARalpha;UCP-3	Synergistic ***activation*** of ***UCP-3*** expression in cultured fetal rat brown adipocytes by ***PPARalpha*** and PPARgamma ligands .	positive	1
16253	10873645	5465;7350	PPARalpha;UCP-1	Thus , activation of PPARgamma increases ***UCP-1*** and UCP-3 levels which are differentially ***regulated*** by ***PPARalpha*** .	target	1
16254	10873645	5465;7352	PPARalpha;UCP-3	Thus , activation of PPARgamma increases UCP-1 and ***UCP-3*** levels which are differentially ***regulated*** by ***PPARalpha*** .	target	1
16255	10873645	5468;7350	PPARgamma;UCP-1	Thus , activation of ***PPARgamma*** ***increases*** ***UCP-1*** and UCP-3 levels which are differentially regulated by PPARalpha .	positive	0
16256	10873645	5468;7352	PPARgamma;UCP-3	Thus , activation of ***PPARgamma*** ***increases*** UCP-1 and ***UCP-3*** levels which are differentially regulated by PPARalpha .	positive	0
16257	10873650	10084;10907	PQBP-1;U5-15kD	***PQBP-1/Npw38*** , a nuclear protein binding to the polyglutamine tract , ***interacts*** with ***U5-15kD/dim1p*** via the carboxyl-terminal domain .	parallel	1
16258	10873669	9693;1499	KIAA0313;beta-catenin	Taken together , our data suggest that ***KIAA0313*** ***associates*** with ***beta-catenin*** through KIAA0705 in vivo at sites of cell-cell contact .	parallel	0
16259	10873670	5609;2353	MKK7;c-fos	Stress-activated protein kinase-dependent induction of ***c-fos*** by Cd ( 2 + ) is ***mediated*** by ***MKK7*** .	target	0
16260	10873705	10024;7216	tastin;trophinin	The evidence for subsequent stabilization of cell adhesion via integrins or the ******trophinin-tastin****** ***complex*** is discussed .	parallel	1
16261	10873770	5269;5340	SPI-3;plasmin	The cowpox virus serpin ***SPI-3*** ***complexes*** with and inhibits urokinase-type and tissue-type plasminogen activators and ***plasmin*** .	parallel	1
16262	10873770	5340;5269	plasmin;SPI-3	Mutation of Arg-340 / Ser-341 at the predicted P1/P1 ' sites within the RCL prevented the ***formation*** of complexes between ***SPI-3*** and ***plasmin*** , uPA , or tPA , suggesting that the arginine at the P1 position was required for complex formation .	parallel	0
16263	10873786	2028;821	gp160;calnexin	The core glycosylated and signal-sequence-retained forms of ***gp160*** and gp120 ***associated*** with ***calnexin*** while the signal-sequence-cleaved forms of gp160 and gp120 had disassociated from calnexin and correctly folded as determined by their ability to associate with the CD4 cellular receptor .	parallel	0
16264	10873864	6011;6010	rhodopsin kinase;rhodopsin	This loop also interacts with ***rhodopsin kinase*** , which ***phosphorylates*** light-activated ***rhodopsin*** , and arrestin , which displaces transducin from light-activated phosphorylated rhodopsin .	target	1
16265	10873890	4358;10381	glomerulosclerosis;beta4	Congenital focal segmental ***glomerulosclerosis*** ***associated*** with ***beta4*** integrin mutation and epidermolysis bullosa .	parallel	0
16266	10874028	6256;3486	retinoid X receptor-alpha;insulin-like growth factor-binding protein-3	Direct functional ***interactions*** between ***insulin-like growth factor-binding protein-3*** and ***retinoid X receptor-alpha*** regulate transcriptional signaling and apoptosis .	parallel	1
16267	10874030	6714;1956	Src;epidermal growth factor receptor	In both cell types , ouabain stimulated Src kinase activity , Src translocation to the Triton-insoluble fraction , ***Src*** ***association*** with the ***epidermal growth factor receptor*** , and the tyrosine phosphorylation of this receptor on site ( s ) other than its major autophosphorylation site , Tyr ( 1173 ) .	parallel	0
16268	10874048	4088;4791	Smad3;p52	Furthermore , we show that ***Smad3*** ***interacts*** with ***p52*** in vivo .	parallel	1
16269	10874134	5594;5599	p38;JNK	The findings of the present study demonstrated that : ( i ) the release of arachidonic acid metabolites is mediated by the ERK pathway ; ( ii ) GM-CSF production may be driven by both the ERK and JNK pathways ; and ( iii ) the ***p38*** MAPK pathway negatively ***regulates*** the ***JNK*** pathway .	negative	1
16270	10874471	3476;7412	alpha 4;VCAM-1	Interestingly , lymphocyte ***alpha 4-integrin*** ***bound*** to ***VCAM-1*** as well as an unknown ligand on the mHEVa cell line .	parallel	1
16271	10874650	7040;4015	transforming growth factor beta 1;Lysyl oxidase	***Lysyl oxidase*** ( LO ) is produced by myofibroblast cells in some tissues and can be ***influenced*** by ***transforming growth factor beta 1*** ( TGF beta 1 ) .	target	0
16272	10874665	4193;7157	Mdm2;p53	***Mdm2*** , localized on chromosome 12 , is considered a negative ***regulator*** of ***p53*** function and seems to play a role in the pathogenesis of a variety of tumors .	negative	1
16273	10875232	3952;6774	leptin;STAT3	Lower concentrations of ***leptin*** ( 10 and 50 microg/kg ) also ***stimulated*** ***STAT3*** phosphorylation in fat .	positive	0
16274	10875232	3952;6774	leptin;STAT3	Furthermore , ***leptin*** ***activated*** ***STAT3*** and MAPK in adipose tissue explants ex vivo and in 3T3-L1 adipocytes .	positive	1
16275	10875232	3952;6774	leptin;STAT3	Both ***leptin*** ( 1 mg/kg iv x 3 min ) and insulin ( 10 U/kg iv x 3 min ) ***stimulated*** tyrosine phosphorylation of ***STAT3*** 5.6 - to 6.0-fold and of STAT1 4.0-fold in adipose tissue .	positive	0
16276	10875232	3952;6774	leptin;STAT3	***leptin*** tended to ***increase*** ***STAT3*** phosphorylation in liver and muscle .	positive	0
16277	10875239	5443;8013	ACTH;Nor1	We demonstrate here that Nor1 is expressed in the pituitary gland and adrenal cortex , and that ***ACTH*** and angiotensin II ( AngII ) treatment of adrenal fasciculata cells ***induces*** ***Nor1*** expression .	target	1
16278	10875239	183;8013	angiotensin II;Nor1	We demonstrate here that Nor1 is expressed in the pituitary gland and adrenal cortex , and that ACTH and ***angiotensin II*** ( AngII ) treatment of adrenal fasciculata cells ***induces*** ***Nor1*** expression .	target	1
16279	10875239	3164;5443	Nur77;POMC	In contrast , binding experiments of Nor1 with the palindromic NurRE sequence suggest that Nor1 is not an efficient substitute for the ***NGFI-B/Nur77*** ***activation*** of the ***POMC*** gene expression in pituitary glands .	positive	1
16280	10875254	5741;3569	PTH;IL-6	In vivo , ***PTH*** ***induced*** ***IL-6*** production was also increased in the estrogen-deficient state ( ovx ) such that at the end of a 5-day PTH infusion , the mean circulating level of IL-6 was significantly higher in ovx vs. sham/ovx mice ( 60.1 vs. 16.9 pg/ml ; P < 0.0001 ) .	target	1
16281	10875255	3082;2252	hepatocyte growth factor;keratinocyte growth factor	Autocrine ***interactions*** of ***keratinocyte growth factor*** , ***hepatocyte growth factor*** , and kit-ligand in the regulation of normal ovarian surface epithelial cells .	parallel	1
16282	10875255	3082;2252	HGF;KGF	***KGF*** messenger RNA expression in OSE was found to be ***stimulated*** by KGF and ***HGF*** , but not KL .	positive	0
16283	10875255	2252;3082	KGF;HGF	***HGF*** expression in OSE was found to be ***stimulated*** by ***KGF*** , HGF , and KL .	positive	0
16284	10875255	3082;2252	HGF;KGF	Observations suggest that ***KGF*** , ***HGF*** , and KL ***interact*** to promote OSE growth and growth factor expression .	parallel	1
16285	10875259	4233;3082	MET;Hepatocyte growth factor	Expression of ***MET*** , the ***receptor*** for ***Hepatocyte growth factor*** ( HGF ) , has been associated with androgen-insensitive prostate cancer .	parallel	1
16286	10875259	3082;4233	HGF;MET	In this study we evaluated ***MET*** ***activation*** by HGF and ***HGF*** action in prostate cancer cell lines .	positive	1
16287	10875267	3952;6774	leptin;signal transducer and activator of transcription-3	***leptin*** treatment ***induced*** phosphorylation of ***signal transducer and activator of transcription-3*** in cultured seminiferous tubules from adult and 5-day-old testes .	target	1
16288	10875276	1394;1392	CRFR1;CRF	Two distinct CRF receptor subtypes , ***CRFR1*** and CRFR2 , are thought to ***mediate*** ***CRF*** actions in the central nervous system .	target	0
16289	10875276	1395;1392	CRFR2;CRF	Two distinct CRF receptor subtypes , CRFR1 and ***CRFR2*** , are thought to ***mediate*** ***CRF*** actions in the central nervous system .	target	0
16290	10875316	3603;4314	IL-16;matrix metalloproteinase-3	Also , synovial ***IL-16*** levels in patients with rheumatoid arthritis ***correlated*** significantly , especially with synovial ***matrix metalloproteinase-3*** levels .	parallel	0
16291	10875489	2208;3497	CD23;IgE	Serum immunoglobulins , specific IgE , lymphocyte subsets , and the expression of low affinity ***IgE*** ***receptor*** ( ***CD23*** ) on B cells were determined .	parallel	1
16292	10875919	3454;3460	IFNAR1;IFNGR2	This cross talk is contingent on a constitutive subthreshold IFN-alpha/beta signaling and the ***association*** between the two nonligand-binding receptor components , ***IFNAR1*** and ***IFNGR2*** , in the caveolar membrane domains .	parallel	0
16293	10875927	3202;5241	HOXA5;progesterone receptor	***HOXA5*** ***regulates*** expression of the ***progesterone receptor*** .	target	1
16294	10875929	3481;283120	IGF-II;H19	The results suggest that IMP participates in H19 RNA localization and provides a ***link*** between the ***IGF-II*** and ***H19*** genes at post-transcriptional events during mammalian development .	parallel	0
16295	10875937	50616;3588	IL-22;CRF2-4	***IL-22*** is a ***ligand*** for ***CRF2-4*** , a member of the class II cytokine receptor family .	parallel	1
16296	10877000	7040;1543	TGF-beta1;CYP1	Transforming growth factor-beta1 ( ***TGF-beta1*** ) was previously shown to ***inhibit*** constitutive and induced ***CYP1*** expression in human cell lines and primary hepatocytes but not in rat cells .	negative	1
16297	10877000	7040;1543	TGF-beta1;CYP1	Thus , ***TGF-beta1*** not only ***inhibits*** ***CYP1*** expression in humans but also in rats , indicating that regulation of CYP1 expression in these two species is similar .	negative	1
16298	10877331	3952;3479	Leptin;IGF-I	RESULTS : There was no evidence for an ***association*** between ***IGF-I*** and either premenopausal or postmenopausal breast cancer risk or between ***Leptin*** and postmenopausal breast cancer .	parallel	0
16299	10877833	5329;5328	uPAR;uPA	We have identified a noncompetitive antagonist of the ******uPA-uPAR****** ***interaction*** derived from a nonreceptor binding region of uPA ( amino acids 136-143 ) .	parallel	1
16300	10877833	5329;5328	uPAR;uPA	These results identify a new epitope in uPA that is involved in the ******uPA-uPAR****** ***interaction*** and indicate that an antagonist based on this epitope is able to inhibit tumor progression by modulating the tumor microenvironment in the absence of direct cytotoxic effects in vivo .	parallel	1
16301	10877839	9318;7421	Alien;VDR	Finally , for a dissociation of ******VDR-Alien****** ***complexes*** in vitro and in vivo , higher ligand concentrations were needed than for a dissociation of VDR-NCoR complexes .	parallel	1
16302	10877843	50848;7082	JAM;ZO-1	A putative PDZ-binding motif at the cytoplasmic carboxyl terminus of JAM was required for mediating the ***interaction*** of ***JAM*** with ***ZO-1*** , as assessed by in vitro binding and coprecipitation experiments .	parallel	1
16303	10877845	23643;3576	MD-2;IL-8	TLR4-mediated NF-kappaB reporter activity and ***IL-8*** production was ***enhanced*** by the expression of ***MD-2*** .	positive	0
16304	10877845	23643;4790	MD-2;NF-kappaB	TLR4-mediated ***NF-kappaB*** reporter activity and IL-8 production was ***enhanced*** by the expression of ***MD-2*** .	positive	0
16305	10878006	5111;1026	PCNA;p21	In addition to binding of the cyclin-dependent kinase to the N-terminal region of p21 , ***p21*** is also ***bound*** at its C-terminal region by proliferating cell nuclear antigen ( ***PCNA*** ) , SET/TAF1 , and calmodulin , indicating the versatile function of p21 .	parallel	1
16306	10878006	56647;1026	TOK-1alpha;p21	***TOK-1alpha*** , but not TOK-1beta , directly ***bound*** to the C-terminal proximal region of ***p21*** , and both were expressed at the G ( 1 ) / S boundary of the cell cycle .	parallel	1
16307	10878006	56647;1026	TOK-1alpha;p21	Furthermore , the results of three different types of experiments showed that ***TOK-1alpha*** ***enhanced*** the inhibitory activity of ***p21*** toward histone H1 kinase activity of CDK2 .	positive	0
16308	10878010	2241;6774	FER;Stat3	***FER*** kinase ***activation*** of ***Stat3*** is determined by the N-terminal sequence .	positive	1
16309	10878012	4436;2956	hMSH2;hMSH6	In this study , oligonucleotides containing a single well defined O ( 6 ) - methylguanine adduct were used to examine the extent of lesion-provoked DNA binding , single-step ADP -- > ATP exchange , and steady-state ATPase activity by hMSH2-hMSH3 and ******hMSH2-hMSH6****** ***heterodimers*** .	parallel	1
16310	10878013	1432;6908	p38 MAP kinase;TBP	Due to the fact that we have shown that the ***p38 MAP kinase*** ***modulates*** ***TBP*** activation , we evaluated the effect of the constitutive active MEK -- > ERK pathway on p38 MAP kinase activity .	target	0
16311	10878015	2444;5906	GTK;Rap1	***GTK*** expression ***induces*** a nerve growth factor-independent ***Rap1*** activation , probably through altered CrkII signaling .	target	1
16312	10878015	2444;5747	GTK;FAK	The expression of ***GTK*** also ***correlates*** with a markedly increased content of ***FAK*** , phosphorylation of the adaptor protein Shb , and an association between these two proteins .	parallel	0
16313	10878015	2444;6461	GTK;Shb	The expression of ***GTK*** also ***correlates*** with a markedly increased content of FAK , phosphorylation of the adaptor protein ***Shb*** , and an association between these two proteins .	parallel	0
16314	10878019	6004;8802	RGS16;Galpha	The ***interaction*** of ***RGS16*** and its mutants with Galpha ( t ) and ***Galpha*** ( i1 ) was studied .	parallel	1
16315	10878024	7040;1026	TGF-beta;p21	In conclusion , Smad proteins play important roles in ***regulation*** of the ***p21*** gene by ***TGF-beta*** , and the functional cooperation of Smad proteins with Sp1 involves the physical interaction of these two types of transcription factors .	target	1
16316	10878024	7040;1026	TGF-beta1;p21	***Induction*** of the endogenous HaCaT ***p21*** gene by ***TGF-beta1*** is further enhanced after overexpression of Smad3 and Smad4 , whereas dominant negative mutants of Smad3 and Smad4 and the inhibitory Smad7 all inhibit p21 induction by TGF-beta1 in a dose-dependent manner .	target	1
16317	10878024	4092;1026	Smad7;p21	Induction of the endogenous HaCaT p21 gene by TGF-beta1 is further enhanced after overexpression of Smad3 and Smad4 , whereas dominant negative mutants of Smad3 and Smad4 and the inhibitory ***Smad7*** all ***inhibit*** ***p21*** induction by TGF-beta1 in a dose-dependent manner .	negative	1
16318	10878341	1493;7040	CTLA-4;TGF-beta	Finally , addition of ***CTLA-4/Fc*** or blocking F ( ab ' ) 2 anti-CTLA-4 mAb , plus optimally stimulated non-T cells , to cultures of self-MHC-reactive clones ***inhibited*** the induction of ***TGF-beta*** but not IL-10 or IFN-gamma production .	negative	1
16319	10878344	7293;7292	CD134;CD134L	Indeed , dendritic cell-mediated up-regulation of CXCR4 expression was found to depend on CD40/CD154 and ******CD134/CD134L****** ***interactions*** .	parallel	1
16320	10878344	958;959	CD40;CD154	Indeed , dendritic cell-mediated up-regulation of CXCR4 expression was found to depend on ******CD40/CD154****** and CD134/CD134L ***interactions*** .	parallel	1
16321	10878347	3458;355	IFN-gamma;Fas	TNF-alpha and ***IFN-gamma*** ***regulate*** expression and function of the ***Fas*** system in the seminiferous epithelium .	target	1
16322	10878347	7124;355	TNF-alpha;Fas	***TNF-alpha*** and IFN-gamma ***regulate*** expression and function of the ***Fas*** system in the seminiferous epithelium .	target	1
16323	10878347	356;355	FasL;Fas	However , the control of Fas and ***Fas*** ***ligand*** ( ***FasL*** ) expression in the testis remains unknown .	parallel	1
16324	10878352	943;944	CD30;CD153	Upon exposure to IL-4 , a critical Ig class switch-inducing cytokine , Ag-activated T cells express ***CD30*** , the ***CD153*** ***receptor*** .	parallel	1
16325	10878352	973;943	IgA;CD30	The observation that dysregulated IgG , ***IgA*** , and/or IgE production is often ***associated*** with up-regulation of T cell ***CD30*** prompted us to test the hypothesis that engagement of B cell CD153 by T cell CD30 modulates Ig class switching .	parallel	0
16326	10878352	944;973	CD153;IgA	In addition , ***CD153*** engagement ***inhibits*** IgG , ***IgA*** , and IgE production , and this effect is associated with reduced levels of B lymphocyte maturation protein-1 transcripts , and increased binding of B cell-specific activation protein to the Ig 3 ' enhancer .	negative	1
16327	10878360	3725;3558	AP-1;IL-2	The inducible expression of ***IL-2*** is highly ***regulated*** by multiple transcription factors , particularly ***AP-1*** , which coordinately activate the promoter .	target	1
16328	10878362	4153;715	mannan-binding lectin;C1r	***Interaction*** of C1q and ***mannan-binding lectin*** ( MBL ) with ***C1r*** , C1s , MBL-associated serine proteases 1 and 2 , and the MBL-associated protein MAp19 .	parallel	1
16329	10878362	4153;716	mannan-binding lectin;C1s	***Interaction*** of C1q and ***mannan-binding lectin*** ( MBL ) with C1r , ***C1s*** , MBL-associated serine proteases 1 and 2 , and the MBL-associated protein MAp19 .	parallel	1
16330	10878362	4153;10747	mannan-binding lectin;MAp19	***Interaction*** of C1q and ***mannan-binding lectin*** ( MBL ) with C1r , C1s , MBL-associated serine proteases 1 and 2 , and the MBL-associated protein ***MAp19*** .	parallel	1
16331	10878362	10747;4153	MAp19;MBL	In serum , C1r and C1s were found to be associated only with C1q , whereas MASP-1 , MASP-2 , and a third protein , ***MAp19*** ( 19-kDa MBL-associated protein ) , were found to be ***associated*** only with ***MBL*** .	parallel	0
16332	10878362	10747;4153	MAp19;MBL	The ***interactions*** of MASP-1 , MASP-2 , and ***MAp19*** with ***MBL*** differ from those of C1r and C1s with C1q in that both high salt concentrations and calcium chelation ( EDTA ) are required to fully dissociate the MASPs or MAp19 from MBL .	parallel	1
16333	10878369	3606;3458	IL-18;IFN-gamma	Administration of IL-12 as well as ***IL-18*** ***increased*** the serum levels of ***IFN-gamma*** and significantly restored the reduced host resistance .	positive	0
16334	10878374	3586;909	IL-10;CD1	In searching for the mechanism of growth inhibition , we found that ***IL-10*** ***induces*** the down-regulation of the DC marker ***CD1*** , while the macrophage marker CD14 was up-regulated .	target	1
16335	10878389	3565;1234	IL-4;CCR5	***IL-4*** treatment , which prevents diabetes in NOD mice by polarizing intraislet Th2 responses , ***decreased*** ***CCR5*** expression in islets and potentiated a high ratio of MIP-1beta and monocyte chemotactic protein-1 ( MCP-1 ) : MIP-1alpha in the pancreas .	negative	0
16336	10878389	3565;6347	IL-4;monocyte chemotactic protein-1	***IL-4*** treatment , which prevents diabetes in NOD mice by polarizing intraislet Th2 responses , decreased CCR5 expression in islets and ***potentiated*** a high ratio of MIP-1beta and ***monocyte chemotactic protein-1*** ( MCP-1 ) : MIP-1alpha in the pancreas .	positive	0
16337	10878498	1392;3952	CRH;leptin	However , the ***interactions*** between ***leptin*** , ***CRH*** and the HPA axis are poorly understood and are likely to be complex .	parallel	1
16338	10878498	551;5443	AVP;adrenocorticotropic hormone	***AVP*** ***stimulates*** the release of ***adrenocorticotropic hormone*** ( ACTH ) , but it also potentiates the action of CRH on ACTH release .	positive	0
16339	10878555	3921;5621	LRP;PrP	Recent data indicate that the 37-kD precursor ( ***LRP*** ) for this molecule acts as a ***receptor*** for prion proteins ( ***PrP*** ) , self-proteins implicated in the pathogenesis of transmissible spongiform encephalopathies including new variant Creutzfeldt-Jakob disease ( nvCJD ) .	parallel	1
16340	10878571	7037;3077	TfR;HFE	Whether the ***interaction*** between ***HFE*** and ***TfR*** explains the pathogenesis of HH is not so clear .	parallel	1
16341	10878810	7456;8976	WIP;N-WASP	A ***complex*** of ***N-WASP*** and ***WIP*** integrates signalling cascades that lead to actin polymerization .	parallel	1
16342	10878810	7456;8976	WIP;N-WASP	Recruitment of ***N-WASP*** to vaccinia is ***mediated*** by WASP-interacting protein ( ***WIP*** ) , whereas in Shigella WIP is recruited by N-WASP .	target	0
16343	10878810	998;8976	Cdc42;N-WASP	Our observations show that vaccinia and Shigella activate the Arp2/3 complex to achieve actin-based motility , by mimicking either the SH2/SH3-containing adaptor or ***Cdc42*** signalling pathways to ***recruit*** the ***N-WASP-WIP*** complex .	target	0
16344	10878810	998;7456	Cdc42;WIP	Our observations show that vaccinia and Shigella activate the Arp2/3 complex to achieve actin-based motility , by mimicking either the SH2/SH3-containing adaptor or ***Cdc42*** signalling pathways to ***recruit*** the ***N-WASP-WIP*** complex .	target	0
16345	10878810	7456;8976	WIP;N-WASP	Our observations show that vaccinia and Shigella activate the Arp2/3 complex to achieve actin-based motility , by mimicking either the SH2/SH3-containing adaptor or Cdc42 signalling pathways to recruit the ******N-WASP-WIP****** ***complex*** .	parallel	1
16346	10878810	7456;8976	WIP;N-WASP	We propose that the ******N-WASP-WIP****** ***complex*** has a pivotal function in integrating signalling cascades that lead to actin polymerization .	parallel	1
16347	10879542	3202;7157	HOXA5;p53	Transient transfection of ***Hox/HOXA5*** ***activated*** the ***p53*** promoter .	positive	1
16348	10879675	4852;3952	NPY;leptin	***Interactions*** between ***leptin*** and ***NPY*** affecting lipid mobilization in adipose tissue .	parallel	1
16349	10880057	3572;3569	gp130;IL-6	In vitro experiments revealed that ***gp130-RAPS*** ***inhibited*** ***IL-6*** activity , and this inhibition was neutralized by antibodies to the COOH-terminus of gp130-RAPS derived from patients with RA .	negative	1
16350	10880077	3553;3569	IL-1beta;interleukin-6	Interleukin-1beta ( ***IL-1beta*** ) , a proven ***activator*** of MCP-1 and ***interleukin-6*** , was used as a positive control .	positive	1
16351	10880077	3553;6347	IL-1beta;MCP-1	Interleukin-1beta ( ***IL-1beta*** ) , a proven ***activator*** of ***MCP-1*** and interleukin-6 , was used as a positive control .	positive	1
16352	10880227	4352;7066	c-mpl;thrombopoietin	The ***thrombopoietin*** ***receptor*** , ***c-mpl*** , is a crucial element not only in thrombopoietin ( TPO ) - initiated signaling pathways but also in the regulation of the circulating amount of TPO .	parallel	1
16353	10880231	1432;7124	p38 map kinase;TNF-alpha	***p38 map kinase*** ***regulates*** ***TNF-alpha*** production in human astrocytes and microglia by multiple mechanisms .	target	1
16354	10880231	1432;7124	p38 map kinase;TNF-alpha	The results demonstrate a key role played by p38 map kinase in upregulation of TNF-alpha mRNA levels in LPS-activated human microglia , whereas ***p38 map kinase*** is involved in post-transcriptional ***regulation*** of ***TNF-alpha*** production at translational level in IL-1beta-activated human astrocytes .	target	1
16355	10880236	4282;4313	Macrophage migration inhibitory factor;MMP-2	***Macrophage migration inhibitory factor*** ***increases*** ***MMP-2*** activity in DU-145 prostate cells .	positive	0
16356	10880243	7124;3725	TNF-alpha;c-jun	***TNF-alpha*** , but not IL-1alpha ***increased*** the expression of ***c-jun*** .	positive	0
16357	10880251	3576;2	interleukin 8;alpha-2-macroglobulin	Involvement of alpha-2-macroglobulin receptor in clearance of ******interleukin 8-alpha-2-macroglobulin****** ***complexes*** by human alveolar macrophages .	parallel	1
16358	10880256	3605;4312	IL-17;MMP-1	***IL-17*** ***increased*** the spontaneous production of ***MMP-1*** by synoviocytes five-fold .	positive	0
16359	10880256	3586;7076	IL-10;TIMP-1	Addition of IL-4 , IL-13 and ***IL-10*** to synoviocyte cultures reduced the spontaneous production of MMP-1 and ***induced*** ***TIMP-1*** production by synoviocytes stimulated with IL-17 or/and IL-1beta .	target	1
16360	10880256	3596;7076	IL-13;TIMP-1	Addition of IL-4 , ***IL-13*** and IL-10 to synoviocyte cultures reduced the spontaneous production of MMP-1 and ***induced*** ***TIMP-1*** production by synoviocytes stimulated with IL-17 or/and IL-1beta .	target	1
16361	10880256	3586;4312	IL-10;MMP-1	Addition of IL-4 , IL-13 and ***IL-10*** to synoviocyte cultures ***reduced*** the spontaneous production of ***MMP-1*** and induced TIMP-1 production by synoviocytes stimulated with IL-17 or/and IL-1beta .	negative	1
16362	10880256	3596;4312	IL-13;MMP-1	Addition of IL-4 , ***IL-13*** and IL-10 to synoviocyte cultures ***reduced*** the spontaneous production of ***MMP-1*** and induced TIMP-1 production by synoviocytes stimulated with IL-17 or/and IL-1beta .	negative	1
16363	10880264	7124;1803	TNF-alpha;CD26	The fact that translation and probably translocation of ***CD26*** toward the cell surface can be ***regulated*** by IL-12 and ***TNF-alpha*** reveals new aspects about the control of this T ( H1 ) marker .	target	1
16364	10880341	3439;5706	IFN-alpha;p42	Here , we report that ***IFN-alpha/beta*** and IFN-gamma rapidly ***activate*** the JAK-STAT1 ( Janus kinase-signal transducer and activator transcription factor 1 ) and ***p42/44*** mitogen-activated protein kinase ( p42/44 MAPK ) in freshly isolated rat hepatocytes .	positive	1
16365	10880341	3439;6772	IFN-alpha;STAT1	Here , we report that ***IFN-alpha/beta*** and IFN-gamma rapidly ***activate*** the ***JAK-STAT1*** ( Janus kinase-signal transducer and activator transcription factor 1 ) and p42/44 mitogen-activated protein kinase ( p42/44 MAPK ) in freshly isolated rat hepatocytes .	positive	1
16366	10880341	3458;5706	IFN-gamma;p42	Here , we report that IFN-alpha/beta and ***IFN-gamma*** rapidly ***activate*** the JAK-STAT1 ( Janus kinase-signal transducer and activator transcription factor 1 ) and ***p42/44*** mitogen-activated protein kinase ( p42/44 MAPK ) in freshly isolated rat hepatocytes .	positive	1
16367	10880341	3458;6772	IFN-gamma;STAT1	Here , we report that IFN-alpha/beta and ***IFN-gamma*** rapidly ***activate*** the ***JAK-STAT1*** ( Janus kinase-signal transducer and activator transcription factor 1 ) and p42/44 mitogen-activated protein kinase ( p42/44 MAPK ) in freshly isolated rat hepatocytes .	positive	1
16368	10880347	998;5058	Cdc42;PAK1	Furthermore , transfection of dominant negative Cdc42 and Rac1 inhibited 12-HETE-induced PAK1 , strongly suggesting that ***Cdc42*** and Rac1 are the upstream ***activators*** of 12-HETE-induced ***PAK1*** activation .	positive	1
16369	10880347	5879;5058	Rac1;PAK1	Furthermore , transfection of dominant negative Cdc42 and Rac1 inhibited 12-HETE-induced PAK1 , strongly suggesting that Cdc42 and ***Rac1*** are the upstream ***activators*** of 12-HETE-induced ***PAK1*** activation .	positive	1
16370	10880347	998;5058	Cdc42;PAK1	Furthermore , transfection of dominant negative ***Cdc42*** and Rac1 ***inhibited*** 12-HETE-induced ***PAK1*** , strongly suggesting that Cdc42 and Rac1 are the upstream activators of 12-HETE-induced PAK1 activation .	negative	1
16371	10880347	5879;5058	Rac1;PAK1	Furthermore , transfection of dominant negative Cdc42 and ***Rac1*** ***inhibited*** 12-HETE-induced ***PAK1*** , strongly suggesting that Cdc42 and Rac1 are the upstream activators of 12-HETE-induced PAK1 activation .	negative	1
16372	10880347	5058;5599	PAK1;JNK1	Transfection of dominant negative PAK1 blocked 12-HETE-induced PAK1 , cJun N-terminal kinase ( JNK1 ) and extracellular-signal-regulated kinase ( ERK ) activity , while transfection of constitutively active PAK1 stimulated PAK1 , JNK1 and ERK activity , suggesting that ***PAK1*** is an upstream ***activator*** of 12-HETE-induced ***JNK1*** and ERK activation in these cells .	positive	1
16373	10880347	5058;5599	PAK1;JNK1	Transfection of dominant negative ***PAK1*** ***blocked*** 12-HETE-induced PAK1 , cJun N-terminal kinase ( ***JNK1*** ) and extracellular-signal-regulated kinase ( ERK ) activity , while transfection of constitutively active PAK1 stimulated PAK1 , JNK1 and ERK activity , suggesting that PAK1 is an upstream activator of 12-HETE-induced JNK1 and ERK activation in these cells .	negative	0
16374	10880347	5058;5599	PAK1;JNK1	Transfection of dominant negative PAK1 blocked 12-HETE-induced PAK1 , cJun N-terminal kinase ( JNK1 ) and extracellular-signal-regulated kinase ( ERK ) activity , while transfection of constitutively active ***PAK1*** ***stimulated*** PAK1 , ***JNK1*** and ERK activity , suggesting that PAK1 is an upstream activator of 12-HETE-induced JNK1 and ERK activation in these cells .	positive	0
16375	10880350	11190;4751	C-Nap1;Nek2	The presence of a ternary complex containing centrosomal Nek2-associated protein ( C-Nap1 ) , Nek2 and PP1 has also been demonstrated , and ***C-Nap1*** is shown to be a ***substrate*** for both ***Nek2*** and PP1 in vitro and in cell extracts .	parallel	1
16376	10880354	3479;207	insulin-like growth factor 1;PKB	However ***insulin-like growth factor 1*** , a potent ***activator*** of PI3K and ***PKB*** does not increase the phosphorylation of Ser ( 136 ) in BAD-transfected HEK-293 cells , and nor is the basal level of Ser ( 136 ) phosphorylation suppressed by inhibitors of PI3K .	positive	1
16377	10880394	3552;2252	Il-1alpha;FGF7	Analysis of normal prostatic peripheral zone and BPH tissue by enzyme-linked immunoabsorption assay reveal that Il-1alpha is present at increased levels in hyperplastic prostate and that levels of ***Il-1alpha*** ***correlate*** strongly with tissue ***FGF7*** concentration in BPH .	parallel	0
16378	10880394	3552;2252	Il-1alpha;FGF7	Therefore ***Il-1alpha*** is produced by prostatic epithelial cells and can ***induce*** ***FGF7*** , a potent epithelial growth factor , which can in turn lead to further epithelial growth and increased Il-1alpha secretion , thus establishing a double paracrine loop that is functionally equivalent to an autocrine growth loop .	target	1
16379	10880445	4615;8772	MyD88;FADD	Moreover , ***MyD88*** ***binds*** ***FADD*** and is sufficient to induce apoptosis .	parallel	1
16380	10880446	1147;4792	IKKalpha;IkappaBalpha	Tumors sustained characteristics of immature thymocytes , including expression of CD25 , pTalpha and activated NF-kappaB via ***IKKalpha-dependent*** ***degradation*** of ***IkappaBalpha*** and enhancement of NF-kappaB-dependent anti-apoptotic and proliferative pathways .	negative	1
16381	10880451	7336;7334	MMS2;UBC13	Two ubiquitin-conjugating enzymes , RAD6 and the heteromeric ******UBC13-MMS2****** ***complex*** , have been implicated in post-replicative DNA damage repair in yeast .	parallel	1
16382	10880451	7336;7334	MMS2;UBC13	RAD5 recruits the ******UBC13-MMS2****** ***complex*** to DNA by means of its RING finger domain .	parallel	1
16383	10880459	8569;1981	Mnk1;eIF4G	A mutant adenovirus with a temperature-sensitive 100k protein that can not inhibit cellular protein synthesis at restrictive temperature no longer blocks ***Mnk1*** ***binding*** to ***eIF4G*** , or phosphorylation of eIF4E .	parallel	1
16384	10880460	4738;8454	NEDD8;cullin-1	Based on these findings , we propose that covalent ***modification*** of ***cullin-1*** by the ***NEDD8*** system plays an essential role in the function of SCF in fission yeast .	target	0
16385	10880468	57472;6908	CCR4;TBP	Functional ***interaction*** of ***CCR4-NOT*** proteins with TATAA-binding protein ( ***TBP*** ) and its associated factors in yeast .	parallel	1
16386	10880468	55304;6908	spt3;TBP	Fourth , spt3 , spt8 , and spt15-21 alleles ( all involved in affecting ***interaction*** of ***spt3*** with ***TBP*** ) suppressed CCR4 and caf1 defects .	parallel	1
16387	10880468	55304;9337	spt3;caf1	Fourth , ***spt3*** , spt8 , and spt15-21 alleles ( all involved in affecting interaction of spt3 with TBP ) ***suppressed*** CCR4 and ***caf1*** defects .	negative	1
16388	10880468	55304;57472	spt3;CCR4	Fourth , ***spt3*** , spt8 , and spt15-21 alleles ( all involved in affecting interaction of spt3 with TBP ) ***suppressed*** ***CCR4*** and caf1 defects .	negative	1
16389	10880512	10392;8767	Nod1;RICK	We show that self-association of ***Nod1*** ***mediates*** proximity of RICK and the interaction of ***RICK*** with the gamma subunit of the IkappaB kinase ( IKKgamma ) .	target	0
16390	10880512	8517;4790	IKKgamma;NF-kappaB	A mutant form of ***IKKgamma*** deficient in binding to IKKalpha and IKKbeta ***inhibited*** ***NF-kappaB*** activation induced by RICK or RIP .	negative	1
16391	10880513	5781;3569	SHP2;interleukin-6	***SHP2*** ***mediates*** the protective effect of ***interleukin-6*** against dexamethasone-induced apoptosis in multiple myeloma cells .	target	0
16392	10880513	3569;2185	interleukin-6;RAFTK	Our previous studies have shown that activation of a related adhesion focal tyrosine kinase ( RAFTK ) ( also known as Pyk2 ) is required for dexamethasone ( Dex ) - induced apoptosis in multiple myeloma ( MM ) cells and that human ***interleukin-6*** ( IL-6 ) , a known growth and survival factor for MM cells , ***blocks*** both ***RAFTK*** activation and apoptosis induced by Dex .	negative	0
16393	10880513	3569;5781	IL-6;SHP2	We show that ***IL-6*** ***triggers*** selective activation of ***SHP2*** and its association with RAFTK in Dex-treated MM cells .	positive	0
16394	10880513	5781;2185	SHP2;RAFTK	***SHP2*** ***interacts*** with ***RAFTK*** through a region other than its Src homology 2 domains .	parallel	1
16395	10880513	2185;5781	RAFTK;SHP2	We demonstrate that ***RAFTK*** is a direct ***substrate*** of ***SHP2*** both in vitro and in vivo , and that Tyr ( 906 ) in the C-terminal domain of RAFTK mediates its interaction with SHP2 .	parallel	1
16396	10880513	5781;3569	SHP2;IL-6	Moreover , overexpression of dominant negative ***SHP2*** ***blocked*** the protective effect of ***IL-6*** against Dex-induced apoptosis .	negative	0
16397	10880513	5781;3569	SHP2;IL-6	These findings demonstrate that ***SHP2*** ***mediates*** the anti-apoptotic effect of ***IL-6*** and suggest SHP2 as a novel therapeutic target in MM .	target	0
16398	10880515	6714;5747	Src;FAK	These include bombesin-induced assembly of focal adhesions , formation of parallel arrays of actin stress fibers , increase in the tyrosine phosphorylation of focal adhesion kinase ( FAK ) , p130 ( Cas ) , and paxillin , and ***formation*** of a complex between ***FAK*** and ***Src*** .	parallel	0
16399	10880522	974;973	Igbeta;Igalpha	The B cell antigen receptor ( BCR ) is a large complex that consists of a disulfide-linked tetramer of two transmembrane heavy ( mu ) chains and two light ( lambda or kappa ) chains in association with a ***heterodimer*** of ***Igalpha*** and ***Igbeta*** .	parallel	1
16400	10880523	4064;7099	RP105;TLR4	Using originally LPS-unresponsive Ba/F3 cells expressing exogenous TLR4 and RP105 , we demonstrate the functional ***cooperation*** between ***TLR4*** and ***RP105*** in LPS-induced nuclear factor kappaB activation .	parallel	0
16401	10880534	10673;608	BAFF;B cell maturation antigen	***BAFF*** ***binds*** to the tumor necrosis factor receptor-like molecule ***B cell maturation antigen*** and is important for maintaining the peripheral B cell population .	parallel	1
16402	10880534	608;10673	B cell maturation antigen;BAFF	We find that ***B cell maturation antigen*** ( BCMA ) , a predicted member of the TNF receptor family expressed primarily in mature B cells , is a ***receptor*** for ***BAFF*** .	parallel	1
16403	10880534	608;10673	BCMA;BAFF	A soluble form of ***BCMA*** , which ***inhibited*** the binding of ***BAFF*** to a B cell line , induced a dramatic decrease in the number of peripheral B cells when administered in vivo .	negative	1
16404	10880549	5747;7422	FAK;VEGF	CONCLUSIONS : Cell contact ***induction*** of ***VEGF*** transcription via ***FAK*** and Rap1 provides a novel Ras-independent , but transformation-dependent , mechanism for stimulus-specific regulation of tumor VEGF expression via MAPK .	target	1
16405	10880549	5906;7422	Rap1;VEGF	CONCLUSIONS : Cell contact ***induction*** of ***VEGF*** transcription via FAK and ***Rap1*** provides a novel Ras-independent , but transformation-dependent , mechanism for stimulus-specific regulation of tumor VEGF expression via MAPK .	target	1
16406	10880573	5649;9856	Reelin;neuronal migration	This study thus indicates that ***Reelin*** ***affects*** ***neuronal migration*** outside of the brain .	target	0
16407	10880736	940;1493	CD28;CTLA-4	******CD28/CTLA-4****** ***interactions*** with their specific B7-ligands ( CD80 and CD86 ) have decisive roles in antigenic and allogenic responses .	parallel	1
16408	10880736	1493;940	CTLA-4;CD28	Together , these findings indicate that intervention of ******CD28/CTLA-4/B7****** ***signaling*** could be therapeutically useful in clinical transplantation .	parallel	0
16409	10880751	3815;4254	c-Kit;SCF	Although most of DFC-a cells expressed c-Kit , ******SCF-c-Kit****** ***interaction*** was not always necessary for their growth .	parallel	1
16410	10880756	7422;1437	VEGF;GM-CSF	In addition , we show that ***VEGF*** ***induced*** the release of hematopoietic growth factors ( ***GM-CSF*** ) by bone marrow endothelial cells and that in vitro stromal cell-derived factor-1 ( SDF-1 ) driven transendothelial progenitor cell migration was increased by the presence of VEGF , which might be due to pore formation ( increased endothelial fenestration ) .	target	1
16411	10880756	7422;6387	VEGF;stromal cell-derived factor-1	In addition , we show that VEGF induced the release of hematopoietic growth factors ( GM-CSF ) by bone marrow endothelial cells and that in vitro ***stromal cell-derived factor-1*** ( SDF-1 ) driven transendothelial progenitor cell migration was ***increased*** by the presence of ***VEGF*** , which might be due to pore formation ( increased endothelial fenestration ) .	positive	0
16412	10880840	5604;5594	MEK-1;ERK	***ERK*** is ***phosphorylated*** by ***MEK-1*** and PD098059 and U0126 are specific inhibitors for this kinase .	target	1
16413	10880840	7040;3458	TGF-beta1;IFN-gamma	***TGF-beta1*** induced IL-10 production , slightly decreased TNF-alpha production and ***decreased*** ***IFN-gamma*** production .	negative	0
16414	10880840	7040;7124	TGF-beta1;TNF-alpha	***TGF-beta1*** induced IL-10 production , slightly ***decreased*** ***TNF-alpha*** production and decreased IFN-gamma production .	negative	0
16415	10880840	7040;3586	TGF-beta1;IL-10	***TGF-beta1*** ***induced*** ***IL-10*** production , slightly decreased TNF-alpha production and decreased IFN-gamma production .	target	1
16416	10880881	796;885	CGRP;cholecystokinin	An injection of ***CGRP*** ( 1 nmol/10 microl ) into the left lateral cerebral ventricle ( i.c.v. ) ***inhibited*** pancreatic secretion as well as ***cholecystokinin*** ( CCK ) release induced by bile-pancreatic juice diversion .	negative	1
16417	10880959	5608;1432	MKK6;p38	Identification of a nuclear export signal in ***MKK6*** , an ***activator*** of the carp ***p38*** mitogen-activated protein kinases .	positive	1
16418	10880959	5608;1432	MAPKK6;p38 mitogen-activated protein kinase	Carp homologues of ***p38 mitogen-activated protein kinase*** ( MAPK ) and its ***activator*** MAPK kinase 6 ( ***MAPKK6*** , referred to as MKK6 ) were identified .	positive	1
16419	10881172	10673;23495	BLyS;TACI	***Binding*** of ***BLyS*** to ***TACI*** activated signaling by nuclear factor-kappa B ( NF-kappa B ) .	parallel	1
16420	10881172	23495;4790	TACI;NF-kappa B	In vitro soluble ***TACI-Fc*** fusion protein ***blocked*** BLyS-induced ***NF-kappa B*** activation in B lymphoma cells and IgM production in peripheral blood B cells .	negative	0
16421	10881176	64109;85480	TSLPR;thymic stromal lymphopoietin	Binding of TSLP to the ***thymic stromal lymphopoietin*** ***receptor*** ( ***TSLPR*** ) is increased markedly in the presence of the IL-7 receptor alpha chain ( IL-7R alpha ) .	parallel	1
16422	10881176	85480;64109	TSLP;TSLPR	***Binding*** of ***TSLP*** to the thymic stromal lymphopoietin receptor ( ***TSLPR*** ) is increased markedly in the presence of the IL-7 receptor alpha chain ( IL-7R alpha ) .	parallel	1
16423	10881178	3439;3458	IFN-alpha;IFN-gamma	They also show that type 1 interferon signaling can occur through STAT1-dependent and independent mechanisms and suggest that efficient ***induction*** of ***IFN-gamma*** expression by ***IFN-alpha/beta*** requires STAT1 regulation .	target	1
16424	10881930	3553;6347	IL-1beta;MCP-1	The addition of ***IL-1beta*** and tumor necrosis factor (TNF)-alpha strongly ***enhanced*** IL-8 , ***MCP-1*** , and RANTES secretion ; these responses were observed at the mRNA level as well as at the protein level .	positive	0
16425	10881930	3553;6352	IL-1beta;RANTES	The addition of ***IL-1beta*** and tumor necrosis factor (TNF)-alpha strongly ***enhanced*** IL-8 , MCP-1 , and ***RANTES*** secretion ; these responses were observed at the mRNA level as well as at the protein level .	positive	0
16426	10881930	7124;6347	tumor necrosis factor (TNF)-alpha;MCP-1	The addition of IL-1beta and ***tumor necrosis factor (TNF)-alpha*** strongly ***enhanced*** IL-8 , ***MCP-1*** , and RANTES secretion ; these responses were observed at the mRNA level as well as at the protein level .	positive	0
16427	10881930	7124;6352	tumor necrosis factor (TNF)-alpha;RANTES	The addition of IL-1beta and ***tumor necrosis factor (TNF)-alpha*** strongly ***enhanced*** IL-8 , MCP-1 , and ***RANTES*** secretion ; these responses were observed at the mRNA level as well as at the protein level .	positive	0
16428	10882039	4792;4790	IkappaB alpha;NF-kappaB	Newly synthesized ***IkappaB alpha*** may thus ***bind*** to ***NF-kappaB*** and interfere with gene activation .	parallel	1
16429	10882055	958;959	CD40;CD154	***CD40*** ***interaction*** with its ligand ***CD154*** ( CD40L ) has been shown to be an obligatory step in the initiation of autoimmune disease in several animal models .	parallel	1
16430	10882073	10856;4609	TIP48;c-Myc	TIP49 and ***TIP48*** are ***complexed*** with ***c-Myc*** in vivo , and binding is dependent on a c-Myc domain essential for oncogenic activity .	parallel	1
16431	10882073	8607;4609	TIP49;c-Myc	***TIP49*** and TIP48 are ***complexed*** with ***c-Myc*** in vivo , and binding is dependent on a c-Myc domain essential for oncogenic activity .	parallel	1
16432	10882074	22827;8880	FIR;FBP	Recruited through FBP 's nucleic acid-binding domain , ***FIR*** formed a ternary ***complex*** with ***FBP*** and FUSE .	parallel	1
16433	10882101	23118;5599	TAB2;JNK	Expression of ***TAB2*** ***induces*** ***JNK*** and NF-kappaB activation , whereas a dominant-negative mutant TAB2 impairs their activation by IL-1 .	target	1
16434	10882101	23118;4790	TAB2;NF-kappaB	Expression of ***TAB2*** ***induces*** JNK and ***NF-kappaB*** activation , whereas a dominant-negative mutant TAB2 impairs their activation by IL-1 .	target	1
16435	10882101	3553;23118	IL-1;TAB2	***IL-1*** ***stimulates*** translocation of ***TAB2*** from the membrane to the cytosol where it mediates the IL-1-dependent association of TAK1 with TRAF6 .	positive	0
16436	10882110	1387;3172	CBP;HNF-4	Here , it is shown that ***CBP*** can ***acetylate*** hepatocyte nuclear factor-4 ( ***HNF-4*** ) , a member of the nuclear hormone receptor family , at lysine residues within the nuclear localization sequence .	target	1
16437	10882118	5371;5914	PML;RARalpha	We further provide evidence that altered stoichiometric interaction of SMRT with ******PML-RARalpha****** ***homodimers*** may underlie these processes .	parallel	1
16438	10882118	9612;5371	SMRT;PML	We further provide evidence that altered stoichiometric ***interaction*** of ***SMRT*** with ***PML-RARalpha*** homodimers may underlie these processes .	parallel	1
16439	10882118	9612;5914	SMRT;RARalpha	We further provide evidence that altered stoichiometric ***interaction*** of ***SMRT*** with ***PML-RARalpha*** homodimers may underlie these processes .	parallel	1
16440	10882122	7341;26168	Smt3;Ulp1	Selective reduction of the proteolytic reaction produced a covalent thiohemiacetal transition state complex between a ***Ulp1*** C-terminal fragment and its cellular ***substrate*** ***Smt3*** , the yeast SUMO homolog .	parallel	1
16441	10882122	7341;26168	Smt3;Ulp1	Selective reduction of the proteolytic reaction produced a covalent thiohemiacetal transition state ***complex*** between a ***Ulp1*** C-terminal fragment and its cellular substrate ***Smt3*** , the yeast SUMO homolog .	parallel	1
16442	10882123	1499;8945	beta-catenin;betaTrCP	Here evidence is presented that ***beta-catenin/Tcf*** signaling ***elevates*** the expression of ***betaTrCP*** mRNA and protein in a Tcf-dependent manner , which does not require betaTrCP transcription .	positive	0
16443	10882123	1499;8945	beta-catenin;betaTrCP	***Induction*** of ***betaTrCP*** expression by the ***beta-catenin/Tcf*** pathway results in an accelerated degradation of the wild-type beta-catenin , suggesting that the negative feedback loop regulation may control the beta-catenin/Tcf pathway .	target	1
16444	10882136	9641;4790	IKKepsilon;NF-kappaB	A dominant-negative mutant of ***IKKepsilon*** ***blocks*** induction of ***NF-kappaB*** by both PMA and activation of the T cell receptor but has no effect on the activation of NF-KB by TNFalpha or IL-1 .	positive	0
16445	10882304	685;2066	Betacellulin;ErbB-4	***Betacellulin*** also acts as a ***ligand*** for ***ErbB-4*** to stimulate its kinase activity in both homo - and hetero-dimers .	parallel	1
16446	10882332	3308;7157	Hsp70;p53	Microsequencing analysis has revealed that the p45 is a mixture of beta - and gamma-actin , whereas the p75 is HSC70 , a constitutive member of the ***Hsp70*** heat shock adenosine triphosphatase family , which ***inactivates*** the tumor suppressor ***p53*** .	negative	1
16447	10882409	3565;4843	IL-4;iNOS	Thus , ***IL-4*** may ***down-regulate*** IFN-gamma-inducible ***iNOS*** transcription by activation of STAT-6 which in turn inhibits IRF-1 expression .	negative	1
16448	10882409	6778;3659	STAT-6;IRF-1	Thus , IL-4 may down-regulate IFN-gamma-inducible iNOS transcription by activation of ***STAT-6*** which in turn ***inhibits*** ***IRF-1*** expression .	negative	1
16449	10882409	3458;4843	IFN-gamma;inducible NO synthase	***IFN-gamma*** and IL-4 differently ***regulate*** ***inducible NO synthase*** gene expression through IRF-1 modulation .	target	1
16450	10882409	3565;4843	IL-4;inducible NO synthase	IFN-gamma and ***IL-4*** differently ***regulate*** ***inducible NO synthase*** gene expression through IRF-1 modulation .	target	1
16451	10882409	3565;4843	IL-4;iNOS	Here , we investigated the molecular events responsible for the ***inhibition*** of ***iNOS*** gene expression by ***IL-4*** in the murine macrophage cell line RAW264 .7 .	negative	1
16452	10882409	3565;4843	IL-4;iNOS	Unidirectional deletion analysis on iNOS promoter demonstrated that an IFN-stimulated responsive element ( ISRE ) , contained in the -980 to -765 bp region of the iNOS promoter , may be involved in the ***IL-4-mediated*** ***inhibition*** of IFN-gamma-inducible ***iNOS*** transcription .	negative	1
16453	10882409	3565;3659	IL-4;IRF-1	Moreover , ***IL-4*** even ***down-regulated*** IFN-gamma-inducible expression of ***IRF-1*** mRNA .	negative	1
16454	10882410	959;958	CD40L;CD40	The critical role of ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) - mediated NKT-DC interaction during the development of CD69 ( + ) CD8 ( + ) CTL by alpha-GalCer was demonstrated by blocking experiments using anti-CD40L mAb .	parallel	1
16455	10882602	3606;3458	IL-18;IFN-gamma	M. tuberculosis-induced ***IFN-gamma*** production was ***inhibited*** by ***anti-IL-18*** and enhanced by recombinant IL-18 .	negative	1
16456	10882602	3606;3458	IL-18;IFN-gamma	These findings demonstrate that ***IL-18*** production by PBMC ***correlates*** with ***IFN-gamma*** production and effective immunity to tuberculosis , suggesting that IL-18 contributes to a protective type 1 cytokine response in persons with mycobacterial infection .	parallel	0
16457	10882621	1441;1440	CD114;granulocyte colony-stimulating factor	Endotoxin down-modulates ***granulocyte colony-stimulating factor*** ***receptor*** ( ***CD114*** ) on human neutrophils .	parallel	1
16458	10882715	5923;5594	Ras-GRF1;ERK2	Furthermore , Ras-dependent ***activation*** of ***ERK2*** by ***Ras-GRF1*** was enhanced following co-expression of activated ACK1 .	positive	1
16459	10882718	462;2159	antithrombin;factor Xa	The algal sulfated d-galactan has a potent anticoagulant activity ( similar potency as unfractionated heparin ) due to enhanced ***inhibition*** of thrombin and ***factor Xa*** by ***antithrombin*** and/or heparin cofactor II .	negative	1
16460	10882718	3053;2159	heparin cofactor II;factor Xa	The algal sulfated d-galactan has a potent anticoagulant activity ( similar potency as unfractionated heparin ) due to enhanced ***inhibition*** of thrombin and ***factor Xa*** by antithrombin and/or ***heparin cofactor II*** .	negative	1
16461	10882725	9021;2057	CIS3;EPOR	Moreover , overexpression of STAT5 , which also binds to Tyr ( 401 ) , reduced the ***binding*** of ***CIS3*** to the ***EPOR*** , and the inhibitory effect of CIS3 against EPO signaling , while it did not affect JAB/SOCS-1/SSI-1 .	parallel	1
16462	10882725	6777;9021	STAT5;CIS3	Moreover , overexpression of ***STAT5*** , which also binds to Tyr ( 401 ) , ***reduced*** the binding of ***CIS3*** to the EPOR , and the inhibitory effect of CIS3 against EPO signaling , while it did not affect JAB/SOCS-1/SSI-1 .	negative	1
16463	10882725	9021;2057	CIS3;EPOR	These data demonstrate that ***binding*** of ***CIS3*** to the ***EPOR*** augments the inhibitory effect of CIS3 .	parallel	1
16464	10882725	9021;2057	CIS3;EPOR	***CIS3*** ***binding*** to both ***EPOR*** and JAK2 may explain a specific regulatory role of CIS3 in erythropoiesis .	parallel	1
16465	10882725	9021;3717	CIS3;JAK2	***CIS3*** ***binding*** to both EPOR and ***JAK2*** may explain a specific regulatory role of CIS3 in erythropoiesis .	parallel	1
16466	10882725	9021;2056	SOCS-3;erythropoietin	***CIS3/SOCS-3*** ***suppresses*** ***erythropoietin*** ( EPO ) signaling by binding the EPO receptor and JAK2 .	negative	1
16467	10882725	9021;2057	CIS3;erythropoietin (EPO) receptor	Here , we studied the molecular mechanisms by which ***CIS3*** ***regulates*** the ***erythropoietin (EPO) receptor*** ( EPOR ) signaling in erythroid progenitors and Ba/F3 cells expressing the EPOR ( BF-ER ) .	target	1
16468	10882725	9021;2057	CIS3;EPOR	***CIS3*** ***binds*** directly to the ***EPOR*** as well as JAK2 and inhibits EPO-dependent proliferation and STAT5 activation .	parallel	1
16469	10882725	9021;3717	CIS3;JAK2	***CIS3*** ***binds*** directly to the EPOR as well as ***JAK2*** and inhibits EPO-dependent proliferation and STAT5 activation .	parallel	1
16470	10882725	9021;6777	CIS3;STAT5	***CIS3*** binds directly to the EPOR as well as JAK2 and ***inhibits*** EPO-dependent proliferation and ***STAT5*** activation .	negative	1
16471	10882725	9021;2057	CIS3;EPOR	Deletion of the Tyr ( 401 ) region of the EPOR reduced the inhibitory effect of CIS3 , suggesting that ***binding*** of ***CIS3*** to the ***EPOR*** augmented the negative effect of CIS3 .	parallel	1
16472	10882733	3683;3689	CD11a;CD18	***CD11a/CD18*** leukocyte-restricted expression is ***controlled*** by the ***CD11a*** gene promoter , which confers tissue-specific expression to reporter genes in vitro and in vivo .	target	0
16473	10882736	10203;796	CRLR;calcitonin	Expression of the calcitonin receptor-like receptor ( CRLR ) and its receptor activity modifying proteins ( RAMPs ) can produce ***calcitonin*** gene-related peptide ( CGRP ) ***receptors*** ( ***CRLR/RAMP1*** ) and adrenomedullin ( AM ) receptors ( CRLR/RAMP2 or -3 ) .	parallel	1
16474	10882736	10267;796	RAMP1;calcitonin	Expression of the calcitonin receptor-like receptor ( CRLR ) and its receptor activity modifying proteins ( RAMPs ) can produce ***calcitonin*** gene-related peptide ( CGRP ) ***receptors*** ( ***CRLR/RAMP1*** ) and adrenomedullin ( AM ) receptors ( CRLR/RAMP2 or -3 ) .	parallel	1
16475	10882737	6908;2959	TBP;TFIIB	The addition of increasing levels of TFIIB to this complex results in the formation of the ******TFIIB.TBP.TATA****** ***complex*** .	parallel	1
16476	10882738	4792;4790	I kappa B alpha;NF-kappa B	Mechanism of ***I kappa B alpha*** ***binding*** to ***NF-kappa B*** dimers .	parallel	1
16477	10882738	4792;4790	I kappa B alpha;NF-kappa B	X-ray crystal structures of the ******NF-kappa B.I kappa B alpha****** ***complex*** revealed an extensive and complex protein-protein interface involving independent structural elements present in both I kappa B alpha and NF-kappa B .	parallel	1
16478	10882738	4792;6647	I kappa B alpha;homodimer	***I kappa B alpha*** preferentially ***binds*** to the p50/p65 heterodimer and p65 ***homodimer*** , with binding to p50 homodimer being significantly weaker .	parallel	1
16479	10882738	4792;4790	I kappa B alpha;p50	***I kappa B alpha*** preferentially ***binds*** to the ***p50/p65*** heterodimer and p65 homodimer , with binding to p50 homodimer being significantly weaker .	parallel	1
16480	10882738	4792;5970	I kappa B alpha;p65	***I kappa B alpha*** preferentially ***binds*** to the ***p50/p65*** heterodimer and p65 homodimer , with binding to p50 homodimer being significantly weaker .	parallel	1
16481	10882738	4790;5970	p50;p65	I kappa B alpha preferentially binds to the ******p50/p65****** ***heterodimer*** and p65 homodimer , with binding to p50 homodimer being significantly weaker .	parallel	1
16482	10882739	2966;2068	p44;XPD	The amino-terminal portion of ***p44*** has been shown to be involved in the ***regulation*** of the ***XPD*** helicase activity ; here we show that its carboxyl-terminal domain is essential for TFIIH transcription activity and that it binds three zinc atoms through two independent modules .	target	1
16483	10882743	338;4023	apoB;LPL	To characterize the binding of LPL to lipoproteins , we studied the ***binding*** of low density lipoproteins ( LDL ) , apolipoprotein ( apo ) B17 , and various ***apoB-FLAG*** ( DYKDDDDK octapeptide ) chimeras to purified ***LPL*** .	parallel	1
16484	10882743	4023;338	LPL;apoB	Binding of various apoB fusion peptides suggested that ***LPL*** ***bound*** to ***apoB*** at multiple sites within apoB17 .	parallel	1
16485	10882743	4023;338	LPL;apoB	Tetrahydrolipstatin , a potent enzyme activity inhibitor , had no effect on ******apoB-LPL****** ***binding*** , indicating that the enzyme activity was not required for apoB binding .	parallel	1
16486	10882744	2526;2734	Fuc-TIV;E-selectin ligand-1	P-selectin glycoprotein ligand-1 and ***E-selectin ligand-1*** are differentially ***modified*** by fucosyltransferases ***Fuc-TIV*** and Fuc-TVII in mouse neutrophils .	target	0
16487	10882744	2529;2734	Fuc-TVII;E-selectin ligand-1	P-selectin glycoprotein ligand-1 and ***E-selectin ligand-1*** are differentially ***modified*** by fucosyltransferases Fuc-TIV and ***Fuc-TVII*** in mouse neutrophils .	target	0
16488	10882748	3600;3565	Interleukin-15;interleukin-4	***Interleukin-15*** ***induces*** rapid tyrosine phosphorylation of STAT6 and the expression of ***interleukin-4*** in mouse mast cells .	target	1
16489	10882748	3600;6778	Interleukin-15;STAT6	***Interleukin-15*** ***induces*** rapid tyrosine phosphorylation of ***STAT6*** and the expression of interleukin-4 in mouse mast cells .	target	1
16490	10882748	3600;3565	IL-15;IL-4	In the present study , we demonstrated that ***IL-15*** ***induced*** ***IL-4*** production from a mouse mast cell line , MC/9 , and bone marrow-derived mast cells .	target	1
16491	10882748	3600;3565	IL-15;IL-4	***IL-4*** mRNA expression was ***increased*** by ***IL-15*** , suggesting that IL-15 promotes IL-4 expression at the transcriptional level .	positive	0
16492	10882748	3600;3565	IL-15;IL-4	IL-4 mRNA expression was increased by IL-15 , suggesting that ***IL-15*** ***promotes*** ***IL-4*** expression at the transcriptional level .	positive	0
16493	10884023	116;1385	pituitary adenylate cyclase-activating polypeptide;CREB	***CREB*** phosphorylation is ***induced*** by the retino-hypothalamic transmitter ***pituitary adenylate cyclase-activating polypeptide*** ( PACAP ) .	target	1
16494	10884052	1395;1392	CRHR2;CRH	However , it still remains to be clarified whether those effects are mediated via either the CRH receptor 1 ( CRHR1 ) or the ***CRH*** ***receptor*** 2 ( ***CRHR2*** ) , or both receptor subtypes .	parallel	1
16495	10884290	3949;4018	LDLR;lipoprotein	Conserved lysines and arginines within amino acids 140-150 of apolipoprotein ( apo ) E are crucial for the interaction between apoE and the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) .	parallel	1
16496	10884290	348;3949	apoE;LDLR	Conserved lysines and arginines within amino acids 140-150 of apolipoprotein ( apo ) E are crucial for the ***interaction*** between ***apoE*** and the low density lipoprotein receptor ( ***LDLR*** ) .	parallel	1
16497	10884293	338;4018	apoB;lipoprotein	We investigated ***associations*** of the sialic acid-to-apolipoprotein B ( ***apoB*** ) ratio of LDL with ***lipoprotein*** lipid concentrations , kinetics of LDL , metabolism of cholesterol , and the presence of CAD in 98 subjects ( CAD ( + ) , n = 56 ; CAD ( - ) , n = 42 ) .	parallel	0
16498	10884308	3741;6714	Kv1.5;Src	Using immunoprecipitation , we show that ***Kv1.5*** is ***associated*** with ***Src*** family protein tyrosine kinases and that this association does not change with cell differentiation .	parallel	0
16499	10884313	3553;4790	IL-1beta;NF-kappaB	However , pretreatment with oATP downregulated ***activation*** of ***NF-kappaB*** and AP-1 by ***IL-1beta*** or TNFalpha .	positive	1
16500	10884313	7124;4790	TNFalpha;NF-kappaB	However , pretreatment with oATP downregulated ***activation*** of ***NF-kappaB*** and AP-1 by IL-1beta or ***TNFalpha*** .	positive	1
16501	10884338	1437;6750	GM-CSF;somatostatin	The release of ***somatostatin*** ( SRIF ) from the medial basal hypothalamus was ***stimulated*** by 1 x 10 ( - ) ( 11 ) M ***GM-CSF*** .	positive	0
16502	10884376	5727;3481	Ptch;Igf2	Since Igf2 is also overexpressed in non-tumor tissue deficient in Ptch , these observations suggest that ***Ptch*** ***regulates*** ***Igf2*** levels through a transcriptional mechanism .	target	1
16503	10884377	7473;5743	Wnt-3;cyclooxygenase-2	***Regulation*** of ***cyclooxygenase-2*** and periostin by ***Wnt-3*** in mouse mammary epithelial cells .	target	1
16504	10884377	7473;10631	Wnt-3;periostin	***Regulation*** of cyclooxygenase-2 and ***periostin*** by ***Wnt-3*** in mouse mammary epithelial cells .	target	1
16505	10884378	1020;8851	Cdk5;p35	Here we demonstrate that all known Pgammas preserve a consensus motif for cyclin-dependent protein kinase 5 ( Cdk5 ) , a protein kinase believed to be involved in neuronal cell development , and that Pgamma kinase is ***Cdk5*** ***complexed*** with ***p35*** , a neuronal Cdk5 activator .	parallel	1
16506	10884380	27101;6277	calcyclin-binding protein;calcyclin	Characterization of the ***interaction*** of ***calcyclin*** ( S100A6 ) and ***calcyclin-binding protein*** .	parallel	1
16507	10884381	156;5132	GRK2;phosducin	Phosphorylation of phosducin by GRK2 markedly reduces its G beta gamma binding ability , suggesting that ***GRK2*** may ***modulate*** the activity of the ***phosducin*** protein family by disrupting this interaction .	target	0
16508	10884381	156;5132	GRK2;phosducin	***Phosphorylation*** of ***phosducin*** by ***GRK2*** markedly reduces its G beta gamma binding ability , suggesting that GRK2 may modulate the activity of the phosducin protein family by disrupting this interaction .	target	1
16509	10884381	156;5132	G protein-coupled receptor kinase 2;phosducin	***Phosphorylation*** of ***phosducin*** and phosducin-like protein by ***G protein-coupled receptor kinase 2*** .	target	1
16510	10884382	1026;1017	p21;Cdk2	Here , we show that in apoptotic cells , the Cdk inhibitory protein ***p21*** ( WAF1/CIP1 ) , which is ***associated*** with the cyclin ***A-Cdk2*** complex , undergoes selective proteolytic cleavage .	parallel	0
16511	10884382	1030;1017	Cdk inhibitory protein;Cdk2	In contrast , another ***Cdk inhibitory protein*** , p27 ( KIP1 ) , which is ***associated*** with cyclin A-Cdk2 and cyclin ***E-Cdk2*** complexes , remained unaltered during apoptosis .	parallel	0
16512	10884382	1026;1017	p21;Cdk2	Ectopic overexpression of ***p21*** ( WAF1/CIP1 ) ***suppressed*** apoptosis as well as cyclin ***A-Cdk2*** activity induced by treatment of SK-HEP-1 cells with G-Rh2 .	negative	1
16513	10884382	836;1026	Caspase 3;p21	These data suggest that the induction of apoptosis in human hepatoma cells treated with G-Rh2 occurs by a mechanism that involves the activation of cyclin A-Cdk2 by ***Caspase 3-mediated*** ***cleavage*** of ***p21*** ( WAF1/CIP1 ) .	target	1
16514	10884389	7157;672	p53;BRCA1	These results , in conjunction with others , suggest a loop wherein BRCA1 initially participates in accumulation of p53 protein , whereas later ***p53*** acts to ***reduce*** ***BRCA1*** expression .	negative	1
16515	10884390	7161;7157	p73;p53	Physical and functional ***interaction*** between ***p53*** mutants and different isoforms of ***p73*** .	parallel	1
16516	10884390	7157;7161	p53;p73	Thus , human tumor-derived ***p53*** mutants can ***associate*** with ***p73*** not only physically but also functionally .	parallel	0
16517	10884395	3364;5884	hus1;rad17	These observations predict that rad1 , ***hus1*** , and rad9 might ***interact*** with ***rad17*** as a clamp-clamp loader pair during the DNA damage response .	parallel	1
16518	10884395	5810;5884	rad1;rad17	These observations predict that ***rad1*** , hus1 , and rad9 might ***interact*** with ***rad17*** as a clamp-clamp loader pair during the DNA damage response .	parallel	1
16519	10884395	5883;5884	rad9;rad17	These observations predict that rad1 , hus1 , and ***rad9*** might ***interact*** with ***rad17*** as a clamp-clamp loader pair during the DNA damage response .	parallel	1
16520	10884395	5111;5981	PCNA;RFC	Mutational analysis of hRad1 and hRad17 demonstrates that this interaction has properties similar to the ***interaction*** between ***RFC*** and ***PCNA*** , a well characterized clamp-clamp loader pair .	parallel	1
16521	10884395	5111;5981	PCNA;RFC	Collectively , these data provide the first experimental evidence that hRad17 interacts with the PCNA-like proteins hRad1 , hHus1 , and hRad9 in manner similar to the ***interaction*** between ***RFC*** and ***PCNA*** .	parallel	1
16522	10884419	1910;1908	ETRB;Endothelin 3	Functional signaling of ***Endothelin 3*** ( ET3 ) and its ***receptor*** B ( ***ETRB*** ) has been shown to be required for the development of neural crest ( NC ) - derived pigment cells in mouse , but the precise role of ET3 is not completely understood .	parallel	1
16523	10884438	7040;6446	TGF-beta;hSGK	As shown most recently , ***TGF-beta*** ***stimulates*** the expression of a distinct serine/threonine kinase ( ***hSGK*** ) which had previously been cloned as an early gene transcriptionally regulated by cell volume alterations .	positive	0
16524	10884568	3952;6774	leptin;STAT3	These data suggest that leptin signal transduction , in vivo , demonstrate a time and dose response increase paralleling the rise and fall in serum leptin , suggesting that serum leptin levels are the most important factor in determining ***leptin-induced*** ***phosphorylation*** of ***STAT3*** in the hypothalamus .	target	1
16525	10884916	596;595	Bcl-2;cyclin D1	CONCLUSIONS : These results suggest that p21 and ***cyclin D1*** expression in prostatic cancer might be ***modulated*** by ***Bcl-2*** and by androgens and in turn this could be relevant to the progression of prostatic cancer .	target	0
16526	10884916	596;1026	Bcl-2;p21	CONCLUSIONS : These results suggest that ***p21*** and cyclin D1 expression in prostatic cancer might be ***modulated*** by ***Bcl-2*** and by androgens and in turn this could be relevant to the progression of prostatic cancer .	target	0
16527	10886243	941;3565	CD80;IL-4	In accordance with this , ***CD80*** and phorbol myristate acetate ( PMA ) ( without anti-CD3 or calcium ionophore ) were sufficient to ***induce*** production of IL-5 and IL-13 , but not of ***IL-4*** .	target	1
16528	10886243	941;3567	CD80;IL-5	In accordance with this , ***CD80*** and phorbol myristate acetate ( PMA ) ( without anti-CD3 or calcium ionophore ) were sufficient to ***induce*** production of ***IL-5*** and IL-13 , but not of IL-4 .	target	1
16529	10886327	608;7852	B-cell maturation factor;chemokine receptor	SDF-1alpha was shown to function as a ***B-cell maturation factor*** , a ***ligand*** for the CXCR4 ( LESTR/fusin ) ***chemokine receptor*** , thereby inhibiting replication of T cell-tropic HIV-1 strains and inducing cell death in human neuronal cell lines .	parallel	1
16530	10886328	6416;5599	MKK4;JNK	We investigated these activities in vivo by comparing immunoreactivity for phosphorylated ( p ) SEK-1 ( or ***MKK4*** , which ***activates*** ***JNK*** ) , c-Jun ( ser63 , ser73 ) and nuclear translocation of NFKappaB-p50 in tissue sections through the forebrain of control and p75NGFR-deficient mice .	positive	1
16531	10886330	4915;627	trkB;brain-derived neurotrophic factor	Antibodies or a ***trkB*** fusion protein that ***block*** the biological activity of ***brain-derived neurotrophic factor*** synthesized by dorsal root ganglion neurons also block the survival-promoting actions of interleukin-6 on these neurons .	negative	0
16532	10886330	4915;3569	trkB;interleukin-6	Antibodies or a ***trkB*** fusion protein that block the biological activity of brain-derived neurotrophic factor synthesized by dorsal root ganglion neurons also ***block*** the survival-promoting actions of ***interleukin-6*** on these neurons .	negative	0
16533	10886330	3569;627	interleukin-6;brain-derived neurotrophic factor	Two results indicate that ***interleukin-6*** ***influences*** synthesis of ***brain-derived neurotrophic factor*** in adult dorsal root ganglion neurons .	target	0
16534	10886342	2668;7054	Glial cell line-derived neurotrophic factor;tyrosine hydroxylase	***Glial cell line-derived neurotrophic factor*** ***modulates*** ischemia-induced ***tyrosine hydroxylase*** expression in rat hippocampus .	target	0
16535	10886374	9748;5347	Ste20-like kinase;Plk1	RESULTS : We show here that human ***Ste20-like kinase*** ( SLK ) , which is a ubiquitously expressed mammalian protein related to xPlkk1 , can ***phosphorylate*** and activate murine ***Plk1*** .	target	1
16536	10886376	6647;1387	Homodimer;CBP	***Homodimer*** ***formation*** of CREB and the complex formation of phosphorylated CREB with ***CBP*** were observed under the electron microscope .	parallel	0
16537	10886376	1385;1387	CREB;CBP	Homodimer ***formation*** of ***CREB*** and the complex formation of phosphorylated CREB with ***CBP*** were observed under the electron microscope .	parallel	0
16538	10886399	941;940	CD80;CD28	We observed that neither sphingomyelinase nor C2 ceramide could costimulate human T-cell proliferation in combination with anti-CD3 antibody , whereas ***CD80*** , a natural ***CD28*** ***ligand*** , was strongly costimulatory .	parallel	1
16539	10886401	3600;959	Interleukin-15;CD154	***Interleukin-15*** ***up-regulates*** the expression of ***CD154*** on synovial fluid T cells .	positive	1
16540	10886401	959;958	CD154;CD40	To investigate the role of the ******CD40-CD154****** ***interaction*** in rheumatoid arthritis ( RA ) , we analysed the expression of CD154 on CD3 + and CD4 + T cells in synovial fluid ( SF ) from patients with RA and in peripheral blood ( PB ) from patients and normal controls .	parallel	1
16541	10886401	3600;959	IL-15;CD154	***IL-15*** significantly ***increased*** the expression of ***CD154*** on SF and PB T cells from patients , whereas IL-2 had minimal effects .	positive	0
16542	10886501	2321;7422	Flt-1;vascular endothelial growth factor	To test this hypothesis , we evaluated the expression and integrity of ***vascular endothelial growth factor*** , a potent angiogenic mediator , and its ***receptors*** , ***Flt-1*** and KDR , in chronic venous leg ulcerations .	parallel	1
16543	10886501	3791;7422	KDR;vascular endothelial growth factor	To test this hypothesis , we evaluated the expression and integrity of ***vascular endothelial growth factor*** , a potent angiogenic mediator , and its ***receptors*** , Flt-1 and ***KDR*** , in chronic venous leg ulcerations .	parallel	1
16544	10886512	3605;3557	Interleukin-17;interleukin-1 receptor antagonist	***Interleukin-17*** alone and in cooperation with interleukin-4 , or to a lesser extent with interferon-gamma , ***decreased*** the ***interleukin-1 receptor antagonist*** to interleukin-1alpha ratio in the supernatants as well as in cell lysates from keratinocytes .	negative	0
16545	10886512	3605;1437	Interleukin-17;granulocyte-macrophage colony stimulating factor	In addition , ***Interleukin-17*** ***stimulated*** the release of growth-regulated oncogene-alpha , ***granulocyte-macrophage colony stimulating factor*** , and interleukin-6 , with synergistic or additive effects when used together with interferon-gamma or interleukin-4 .	positive	0
16546	10886512	3605;3569	Interleukin-17;interleukin-6	In addition , ***Interleukin-17*** ***stimulated*** the release of growth-regulated oncogene-alpha , granulocyte-macrophage colony stimulating factor , and ***interleukin-6*** , with synergistic or additive effects when used together with interferon-gamma or interleukin-4 .	positive	0
16547	10886512	3605;4254	Interleukin-17;stem cell factor	***Interleukin-17*** and interleukin-4 also ***increased*** ***stem cell factor*** release , a function that was inhibited by interferon-gamma .	positive	0
16548	10886512	3565;4254	interleukin-4;stem cell factor	Interleukin-17 and ***interleukin-4*** also ***increased*** ***stem cell factor*** release , a function that was inhibited by interferon-gamma .	positive	0
16549	10886512	3605;3383	Interleukin-17;intercellular adhesion molecule 1	Moreover , ***Interleukin-17*** and interleukin-4 ***enhanced*** interferon-gamma-induced expression of ***intercellular adhesion molecule 1*** , but not CD40 , on keratinocytes .	positive	0
16550	10886512	3565;3383	interleukin-4;intercellular adhesion molecule 1	Moreover , Interleukin-17 and ***interleukin-4*** ***enhanced*** interferon-gamma-induced expression of ***intercellular adhesion molecule 1*** , but not CD40 , on keratinocytes .	positive	0
16551	10886512	3458;3566	interferon-gamma;interleukin-4 receptor	The constitutive expression of Interleukin-17 and interferon-gamma receptors on keratinocytes was not modulated by Interleukin-17 , interferon-gamma , or interleukin-4 , whereas the ***interleukin-4 receptor*** was significantly ***downregulated*** by ***interferon-gamma*** .	negative	1
16552	10886518	8829;5228	neuropilin-1;placenta growth factor	Expression patterns of the angiogenic ***placenta growth factor*** and its ***receptor*** ***neuropilin-1*** were assessed in normal human melanocytes , SV40T-transformed melanocytes , and melanoma cells derived from primary and metastatic lesions .	parallel	1
16553	10886557	4358;7040	glomerulosclerosis;TGF-beta1	A close ***association*** between elevated levels of ***TGF-beta1*** and the development of glomerulonephritis , ***glomerulosclerosis*** , and tubular hypertrophy has been documented .	parallel	0
16554	10886559	183;3162	Angiotensin II;HO-1	We also demonstrate that ***Angiotensin II*** at concentrations of 10-8 and 10-7 mol/L ***induces*** expression of ***HO-1*** mRNA in LLC-PK1 cells .	target	1
16555	10886559	183;3162	Angiotensin II;HO-1	Finally , ***Angiotensin II*** directly ***induces*** ***HO-1*** in renal proximal tubular epithelial cells in vitro .	target	1
16556	10886779	3586;3458	IL-10;IFN-gamma	Blocking of ***IL-10*** by neutralizing antibodies ***increased*** both E. coli-induced proliferation and ***IFN-gamma*** production markedly .	negative	0
16557	10886784	2322;2323	CD135;Flt3 ligand	The expression of the Flk2/FLT3 molecule ( ***CD135*** ) , the ***receptor*** for ***Flt3 ligand*** ( FL ) , was investigated in the human thymus .	parallel	1
16558	10887088	387755;8650	Insc;Numb	Resolution of distinct sibling neuronal fates requires correct apical localisation of ***Insc*** to ***facilitate*** the asymmetric localisation and preferential segregation of ***Pon/Numb*** to the basal daughter destined to become RP2 .	positive	0
16559	10887109	945;5777	CD33;SHP-1	Here we demonstrate that ***CD33*** is tyrosine phosphorylated in the presence of the phosphatase inhibitor , pervanadate , and ***recruits*** ***SHP-1*** and SHP-2 .	target	0
16560	10887109	945;5781	CD33;SHP-2	Here we demonstrate that ***CD33*** is tyrosine phosphorylated in the presence of the phosphatase inhibitor , pervanadate , and ***recruits*** SHP-1 and ***SHP-2*** .	target	0
16561	10887109	5777;5781	SHP-1;SHP-2	Further support for overlapping , but nonredundant , roles for Y340 and Y358 comes from peptide-binding studies that revealed the ***recruitment*** of both ***SHP-1*** and SHP-2 to Y340 but only ***SHP-2*** to Y358 .	target	0
16562	10887113	9622;3827	kallikrein;high molecular weight kininogen	Proteolytic ***cleavage*** of single-chain ***high molecular weight kininogen*** ( HK ) by ***kallikrein*** releases the short-lived vasodilator bradykinin and leaves behind 2-chain high molecular weight kininogen ( HKa ) that has been previously reported to exert antiadhesive properties as well as to bind to the urokinase receptor ( uPAR ) on endothelial cells .	target	1
16563	10887121	7534;2811	14-3-3 zeta;GP Ib alpha	Recent studies have revealed that the signaling protein ***14-3-3 zeta*** ***binds*** directly to the cytoplasmic domain of ***GP Ib alpha*** .	parallel	1
16564	10887126	8440;25	Grb4;Abl	***Grb4*** ***bound*** to ***Bcr-Abl*** in a variety of systems , both in vitro and in vivo , and is an excellent substrate of the Bcr-Abl tyrosine kinase .	parallel	1
16565	10887126	25;8440	Abl;Grb4	The ***association*** of ***Grb4*** and ***Bcr-Abl*** in intact cells was mediated by an src homology ( SH ) 2-mediated phosphotyrosine-dependent interaction as well as an SH3-mediated phosphotyrosine-independent interaction .	parallel	0
16566	10887126	8440;3725	Grb4;AP-1	Finally , coexpression of ***Grb4*** and oncogenic v-Abl strongly ***inhibited*** v-Abl-induced ***AP-1*** activation .	negative	1
16567	10887126	25;3725	v-Abl;AP-1	Finally , coexpression of Grb4 and oncogenic ***v-Abl*** strongly ***inhibited*** v-Abl-induced ***AP-1*** activation .	negative	1
16568	10887131	862;9139	AML1-MTG8;MTGR1	Analysis with deletion mutants of AML1-MTG8 demonstrated that the regulation of the majority of these genes requires the region of 51 residues ( 488-538 ) containing the Nervy homology region 2 ( NHR2 ) , through which ***AML1-MTG8*** ***interacts*** with ***MTGR1*** .	parallel	1
16569	10887132	2885;25	Grb2;Bcr/Abl	However , the Bcr/Abl Y177F mutant can transform hematopoietic cell lines and primary bone marrow cells in vitro , so the importance of the ******Bcr/Abl-Grb2****** ***interaction*** to myeloid and lymphoid leukemogenesis in vivo is unclear .	parallel	1
16570	10887135	6361;1233	TARC;CCR4	The chemokines Mig ( CXCR3 ligand ) , ***TARC*** ( ***CCR4*** ***ligand*** ) , and MCP-2 ( CCR5 ligand ) were detected in intratumoral blood vessels and histiocytes .	parallel	1
16571	10887135	4283;2833	Mig;CXCR3	The chemokines ***Mig*** ( ***CXCR3*** ***ligand*** ) , TARC ( CCR4 ligand ) , and MCP-2 ( CCR5 ligand ) were detected in intratumoral blood vessels and histiocytes .	parallel	1
16572	10887141	3553;4210	IL-1 beta;MEFV	***MEFV*** was expressed in peritoneal and skin fibroblasts at a lower level than in neutrophils and could be further ***induced*** by PMA and ***IL-1 beta*** .	target	1
16573	10887155	79753;7040	SNIP1;TGF-beta	A novel smad nuclear interacting protein , ***SNIP1*** , ***suppresses*** p300-dependent ***TGF-beta*** signal transduction .	negative	1
16574	10887155	1387;4089	CBP;Smad4	***Interaction*** between endogenous levels of SNIP1 and ***Smad4*** or ***CBP/p300*** is detected in NMuMg cells as well as in vitro .	parallel	1
16575	10887155	2033;1387	p300;CBP	***Interaction*** between endogenous levels of SNIP1 and Smad4 or ******CBP/p300****** is detected in NMuMg cells as well as in vitro .	parallel	1
16576	10887155	2033;4089	p300;Smad4	***Interaction*** between endogenous levels of SNIP1 and ***Smad4*** or ***CBP/p300*** is detected in NMuMg cells as well as in vitro .	parallel	1
16577	10887155	79753;1387	SNIP1;CBP	***Interaction*** between endogenous levels of ***SNIP1*** and Smad4 or ***CBP/p300*** is detected in NMuMg cells as well as in vitro .	parallel	1
16578	10887155	79753;2033	SNIP1;p300	***Interaction*** between endogenous levels of ***SNIP1*** and Smad4 or ***CBP/p300*** is detected in NMuMg cells as well as in vitro .	parallel	1
16579	10887155	79753;4089	SNIP1;Smad4	***Interaction*** between endogenous levels of ***SNIP1*** and ***Smad4*** or CBP/p300 is detected in NMuMg cells as well as in vitro .	parallel	1
16580	10887155	2033;4089	p300;Smad4	Overexpression of full-length SNIP1 or its amino terminus is sufficient to inhibit multiple gene responses to TGF-beta and CBP/p300 , as well as the formation of a ******Smad4/p300****** ***complex*** .	parallel	1
16581	10887155	79753;1387	SNIP1;CBP	Thus , ***SNIP1*** is a nuclear ***inhibitor*** of ***CBP/p300*** and its level of expression in specific cell types has important physiological consequences by setting a threshold for TGF-beta-induced transcriptional activation involving CBP/p300 .	negative	1
16582	10887155	79753;2033	SNIP1;p300	Thus , ***SNIP1*** is a nuclear ***inhibitor*** of ***CBP/p300*** and its level of expression in specific cell types has important physiological consequences by setting a threshold for TGF-beta-induced transcriptional activation involving CBP/p300 .	negative	1
16583	10887171	7124;5578	TNF-alpha;PKC alpha	In L929 murine fibroblasts , ***TNF-alpha*** ( 0.5 - 5 nm ) caused potent inhibition of PKC alpha activity and ***induced*** translocation of ***PKC alpha*** from the cytosol to the membrane .	target	1
16584	10887174	7124;3854	TNFalpha;K6b	By having shown previously that proliferative signals , such as epidermal growth factor ( EGF ) , induce expression of the cytoskeletal protein keratin K6b , we here demonstrate that the same isoform , ***K6b*** , is also ***induced*** by ***TNFalpha*** , a proinflammatory cytokine .	target	1
16585	10887174	7124;3854	TNFalpha;K6b	Specifically , ***TNFalpha*** ***induces*** the transcription of the ***K6b*** gene promoter .	target	1
16586	10887174	7124;3854	TNFalpha;K6b	Both transcription factors are necessary for the ***induction*** of ***K6b*** by ***TNFalpha*** and act as a complex , although only C/EBPbeta binds the K6b promoter DNA .	target	1
16587	10887185	7040;4092	TGF-beta;Smad7	We conclude that ***regulation*** of ***Smad7*** transcription by ***TGF-beta*** is mediated via a specific constellation of recognition motifs localized around the SBE , which is conserved in human , rat , and murine genes .	target	1
16588	10887185	7045;4092	transforming growth factor beta (TGF-beta)-induced;Smad7	Participation of Smad2 , Smad3 , and Smad4 in ***transforming growth factor beta (TGF-beta)-induced*** ***activation*** of ***Smad7*** .	positive	1
16589	10887185	7040;4092	TGF-beta;Smad7	***TGF-beta*** rapidly ***induces*** expression of ***Smad7*** mRNA in a variety of cell types , suggesting participation in a negative feedback loop to control TGF-beta responses .	target	1
16590	10887186	1406;6010	CRX;rhodopsin	Although NRL and ***CRX*** are each individually able to ***induce*** ***rhodopsin*** promoter activity , when expressed together they exhibit transcriptional synergy in rhodopsin promoter activation .	target	1
16591	10887186	4901;6010	NRL;rhodopsin	Although ***NRL*** and CRX are each individually able to ***induce*** ***rhodopsin*** promoter activity , when expressed together they exhibit transcriptional synergy in rhodopsin promoter activation .	target	1
16592	10887190	56923;10874	TGR-1;neuromedin U	These results show that ***TGR-1*** , like FM-3 , is a specific and functional ***receptor*** for ***neuromedin U*** .	parallel	1
16593	10887190	56923;10874	TGR-1;neuromedin U	TGR-1 mRNA was primarily expressed in the uterus , suggesting that ***TGR-1*** ***mediates*** the contractile activity of ***neuromedin U*** in this tissue .	target	0
16594	10887196	1977;9200	eIF4E;Cap	***Recognition*** of the mRNA ***Cap*** structure through its subunit ***eIF4E*** is a requirement for the recruitment of other translation initiation factors to the mRNA 5 ' - end and thereby for the attachment of the 40 S ribosomal subunit .	target	1
16595	10887196	1977;9200	eIF4E;Cap	In this study , we have investigated the mechanistic basis of the observation that ***eIF4E*** ***binding*** to the ***Cap*** is enhanced in the presence of the large eIF4F subunit , eIF4G .	parallel	1
16596	10887196	1981;1977	eIF4G;eIF4E	Full-length ***eIF4G*** is shown to ***induce*** increased ***eIF4E*** binding to Cap analogues that do not contain an RNA body .	target	1
16597	10887196	1981;9200	eIF4G;Cap	Both results show that interaction of ***eIF4G*** with the mRNA is not necessary to ***enhance*** ***Cap*** binding by eIF4E .	positive	0
16598	10887196	1977;9200	eIF4E;Cap	Both results show that interaction of eIF4G with the mRNA is not necessary to enhance ***Cap*** ***binding*** by ***eIF4E*** .	parallel	1
16599	10887196	26986;1981	Pab1;eIF4G	Moreover , we show that the effect of binding of full-length eIF4G on the Cap affinity of eIF4E can be further modulated through ***binding*** of ***Pab1*** to ***eIF4G*** .	parallel	1
16600	10887198	3558;3574	interleukin-2;interleukin-7	Three loops of the common gamma chain ectodomain required for the ***binding*** of ***interleukin-2*** and ***interleukin-7*** .	parallel	1
16601	10887198	3574;3558	IL-7;IL-2	These results are consistent with the involvement of three predicted loops in gammac that contribute to the ***binding*** of both ***IL-2*** and ***IL-7*** .	parallel	1
16602	10887314	3827;6356	Bradykinin;eotaxin	***Bradykinin*** ***stimulates*** ***eotaxin*** production by a human lung fibroblast cell line .	positive	0
16603	10887314	3827;6356	Bradykinin;eotaxin	RESULTS : HFL-1 cells released eotaxin constitutively without stimulation , but ***Bradykinin*** ***stimulated*** ***eotaxin*** release in a dose - and time-dependent manner and resulted in augmented expression of eotaxin messenger RNA .	positive	0
16604	10887317	3458;1437	IFN-gamma;GM-CSF	In contrast , ***IFN-gamma*** ***inhibited*** FcepsilonRI-induced production of MIP-1alpha , IL-8 , and ***GM-CSF*** .	negative	1
16605	10887317	3458;6348	IFN-gamma;MIP-1alpha	In contrast , ***IFN-gamma*** ***inhibited*** FcepsilonRI-induced production of ***MIP-1alpha*** , IL-8 , and GM-CSF .	negative	1
16606	10887516	5618;5617	PrlR;Prolactin	The cytoplasmic domain of the ***Prolactin*** ***receptor*** ( ***PrlR*** ) displays no enzymatic activity yet Prolactin treatment leads to the induction of protein tyrosine phosphorylation .	parallel	1
16607	10887516	5618;3717	PrlR;JAK2	***PrlR*** is ***associated*** with ***JAK2*** , a protein tyrosine kinase whose activity is stimulated following receptor dimerization .	parallel	0
16608	10887516	3717;5618	JAK2;PrlR	***JAK2*** subsequently ***phosphorylates*** ***PrlR*** and other cellular proteins which are recruited to the activated receptor complex .	target	1
16609	10887518	3488;3479	IGFBP-5;IGF-1	prolactin plays an essential role since it suppresses the secretion of ***IGFBP-5*** which would otherwise ***inhibit*** ***IGF-1*** action and lead to the induction of cell death .	negative	1
16610	10888241	4018;335	Lipoprotein;apo	Levels of ***Lipoprotein*** ( a ) by both apo-Tek and Mercodia assays ***correlated*** inversely with ***apo*** ( a ) isoform sizes .	negative	0
16611	10888249	5604;1906	MEK1;endothelin-1	In contrast , overexpression of ***MEK1*** DN in MCs ***inhibited*** ***endothelin-1*** ( ET-1 ) - , phenylephrine ( PE ) - , leukemia inhibitory factor ( LIF ) - , isoproterenol ( ISP ) - , and mechanical stretch-induced ERK activation and ANP mRNA expression .	negative	1
16612	10888249	5604;5594	MEK1;ERK	In contrast , overexpression of ***MEK1*** DN in MCs ***inhibited*** endothelin-1 ( ET-1 ) - , phenylephrine ( PE ) - , leukemia inhibitory factor ( LIF ) - , isoproterenol ( ISP ) - , and mechanical stretch-induced ***ERK*** activation and ANP mRNA expression .	negative	1
16613	10888249	5604;3976	MEK1;leukemia inhibitory factor	In contrast , overexpression of ***MEK1*** DN in MCs ***inhibited*** endothelin-1 ( ET-1 ) - , phenylephrine ( PE ) - , ***leukemia inhibitory factor*** ( LIF ) - , isoproterenol ( ISP ) - , and mechanical stretch-induced ERK activation and ANP mRNA expression .	negative	1
16614	10888350	1401;7124	CRP;TNF-alpha	These results indicate that ***CRP*** does not prevent the synthesis , but ***prevents*** the hepatotoxic action of ***TNF-alpha*** .	negative	0
16615	10888618	7528;3065	YY1;HDAC1	We find that HDAC1 copurifies with the LTR-binding YY1-LSF repressor complex , the domain of ***YY1*** that ***interacts*** with ***HDAC1*** is required to repress the HIV-1 promoter , expression of HDAC1 augments repression of the LTR by YY1 , and the deacetylase inhibitor trichostatin A blocks repression mediated by YY1 .	parallel	1
16616	10888633	1237;6346	CCR8;I-309	To determine whether human immunodeficiency virus type 1 ( HIV-1 ) coreceptors besides CXCR4 and CCR5 are involved in HIV-1 infection of the thymus , we focused on ***CCR8*** , a ***receptor*** for the chemokine ***I-309*** , because of its high expression in the thymus .	parallel	1
16617	10888646	10044;1981	NSP3;eIF4G	Efficient translation of rotavirus mRNA requires simultaneous ***interaction*** of ***NSP3*** with the eukaryotic translation initiation factor ***eIF4G*** and the mRNA 3 ' end .	parallel	1
16618	10888662	5867;5300	Rab4;pin1	Instead , phosphorylated ***Rab4*** is in a ***complex*** with the peptidyl-prolyl isomerase ***pin1*** during mitosis , but not during interphase .	parallel	1
16619	10888670	51529;7322	Apc11p;Ubc4	We found that the integrity of the Apc11p RING-H2 finger was essential for budding yeast cell viability , Using purified , recombinant proteins we showed that ***Apc11p*** ***interacted*** directly with the ***Ubc4*** ubiquitin conjugating enzyme ( E2 ) .	parallel	1
16620	10888741	9575;551	Clock;AVP	Densitometry of immunolabeled brains indicated that the ***Clock*** mutation ***reduced*** ***AVP*** expression specifically in the SCN and not in other brain areas .	positive	1
16621	10888742	4804;4803	p75;nerve growth factor	Levels of ***nerve growth factor*** and neurotrophin-3 are ***affected*** differentially by the presence of ***p75*** in sympathetic neurons in vivo .	target	0
16622	10888742	4804;4908	p75;neurotrophin-3	Levels of nerve growth factor and ***neurotrophin-3*** are ***affected*** differentially by the presence of ***p75*** in sympathetic neurons in vivo .	target	0
16623	10888742	4914;4908	trkA;NT3	The tyrosine receptor kinases , ***trkA*** and trkC , are the cognate ***receptors*** for NGF and ***NT3*** , respectively .	parallel	1
16624	10888742	4916;4908	trkC;NT3	The tyrosine receptor kinases , trkA and ***trkC*** , are the cognate ***receptors*** for NGF and ***NT3*** , respectively .	parallel	1
16625	10888872	55929;7251	DMAP1;TSG101	***DMAP1*** has intrinsic transcription repressive activity , and ***binds*** to the transcriptional co-repressor ***TSG101*** .	parallel	1
16626	10888888	4361;7014	MRE11;TRF2	Cell-cycle-regulated ***association*** of ***RAD50/MRE11/NBS1*** with ***TRF2*** and human telomeres .	parallel	0
16627	10888888	4683;7014	NBS1;TRF2	Cell-cycle-regulated ***association*** of ***RAD50/MRE11/NBS1*** with ***TRF2*** and human telomeres .	parallel	0
16628	10888888	10111;7014	RAD50;TRF2	Cell-cycle-regulated ***association*** of ***RAD50/MRE11/NBS1*** with ***TRF2*** and human telomeres .	parallel	0
16629	10888888	4683;7014	NBS1;TRF2	***NBS1*** was ***associated*** with ***TRF2*** and telomeres in S phase , but not in G1 or G2 .	parallel	0
16630	10888888	7014;4361	TRF2;MRE11	Although the MRE11 complex accumulated in irradiation-induced foci ( IRIFs ) in response to gamma-irradiation , TRF2 did not relocate to IRIFs and irradiation did not affect the ***association*** of ***TRF2*** with the ***MRE11*** complex , arguing against a role for TRF2 in DSB repair .	parallel	0
16631	10889021	5745;5741	PTH1R;parathyroid hormone	The structural features of the first extracellular loop ( ECL1 ) of the ***parathyroid hormone*** ***receptor*** ( ***PTH1R*** ) in the presence of dodecylphosphocholine micelles have been determined using high-resolution NMR techniques .	parallel	1
16632	10889138	3082;4312	HGF;matrix metalloprotease-1	METHODS AND RESULTS : In human fibroblasts , ***HGF*** significantly ***increased*** the production of ***matrix metalloprotease-1*** ( MMP-1 ) and urokinase plasminogen activator , whereas HGF also significantly attenuated the reduction of MMP-1 activity induced by Ang II .	positive	0
16633	10889138	3082;7040	HGF;TGF-beta	In contrast , HGF significantly decreased transforming growth factor ( TGF ) - beta mRNA stimulated by Ang II , whereas ***HGF*** also ***decreased*** basal ***TGF-beta*** protein level without affecting growth .	negative	0
16634	10889138	3082;7040	HGF;TGF-beta	Similarly , in rat cardiac fibroblasts , ***HGF*** ***inhibited*** the expression and production of ***TGF-beta*** , whereas HGF upregulated its specific receptor , c-met .	negative	1
16635	10889138	3082;4233	HGF;c-met	Similarly , in rat cardiac fibroblasts , HGF inhibited the expression and production of TGF-beta , whereas ***HGF*** ***upregulated*** its specific receptor , ***c-met*** .	positive	1
16636	10889156	5368;4987	Orphanin FQ;opiate receptor-like 1	BACKGROUND & AIMS : The endogenous ***opiate receptor-like 1*** ***ligand*** , ***Orphanin FQ*** ( OFQ ) , which structurally resembles dynorphin A , has been identified .	parallel	1
16637	10889159	9020;4790	NIK;NF-kappaB	***NF-kappaB*** activation was also ***inhibited*** by transfection of kinase-deficient ***NIK*** or a dominant negative mutant of upstream adapter protein TRAF2 or TRAF6 .	negative	1
16638	10889159	4792;4790	IkappaBalpha;NF-kappaB	RESULTS : H. pylori promotes degradation of ***IkappaBalpha*** , a cytoplasmic ***inhibitor*** of ***NF-kappaB*** .	negative	1
16639	10889171	3553;6347	IL-1beta;MCP-1	RESULTS : IL-8 and ***MCP-1*** secretion was rapidly ***induced*** by both ***IL-1beta*** and tumor necrosis factor (TNF)-alpha .	target	1
16640	10889171	7124;6347	tumor necrosis factor (TNF)-alpha;MCP-1	RESULTS : IL-8 and ***MCP-1*** secretion was rapidly ***induced*** by both IL-1beta and ***tumor necrosis factor (TNF)-alpha*** .	target	1
16641	10889171	7124;6352	TNF-alpha;RANTES	***RANTES*** secretion was induced more slowly and was ***induced*** mainly by ***TNF-alpha*** .	target	1
16642	10889189	9649;5898	RalGEF2;Ral	***RalGEF2*** is able to ***activate*** ***Ral*** both in vivo and in vitro .	positive	1
16643	10889302	4254;7124	Stem cell factor;TNF-alpha	***Stem cell factor*** ***enhances*** IgE-mediated histamine and ***TNF-alpha*** release from dispersed canine cutaneous mast cells .	positive	0
16644	10889302	4254;7124	SCF;TNF-alpha	***SCF*** alone failed to ***trigger*** either histamine or ***TNF-alpha*** release at any time .	positive	0
16645	10889343	11280;351	NaN;Abeta	However , ***NaN*** ( 3 ) ***reduced*** the accumulation of ***Abeta*** ( 1-40 ) in the cell lysates and decreased the acetylcholine esterase activity both in cell culture media and in cell lysates .	negative	1
16646	10889449	7124;6648	TNF-alpha;MnSOD	In the presence of the oxygen free radical spin trapping reagent , 5,5-dimethyl pyrroline-N-oxide ( DMPO ) , the ***induction*** of ***MnSOD*** gene expression by ***TNF-alpha*** was significantly reduced .	target	1
16647	10889449	7124;6648	TNF-alpha;MnSOD	Taken together , these observations suggest that the ***induction*** of ***MnSOD*** expression by ***TNF-alpha*** is at least partially mediated by intracellular formation of oxygen free radicals , and that superoxide is most likely the initiating species involved in the mediation of MnSOD gene expression by TNF-alpha .	target	1
16648	10889466	1906;7422	Endothelin-1;vascular endothelial growth factor	***Endothelin-1*** ***induces*** ***vascular endothelial growth factor*** synthesis in osteoblasts : involvement of p38 mitogen-activated protein kinase .	target	1
16649	10889466	1906;5706	Endothelin-1;p44	We previously reported that ***Endothelin-1*** ( ET-1 ) ***stimulates*** ***p44/p42*** mitogen-activated protein ( MAP ) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells .	positive	0
16650	10889512	4193;7157	Mdm2;p53	Both p53 function and stability are tightly controlled by ***Mdm2*** , which ***binds*** to the p53 N-terminus and targets ***p53*** for ubiquitin-mediated proteolysis .	parallel	1
16651	10889512	4193;7157	Mdm2;p53	Both ***p53*** function and stability are tightly ***controlled*** by ***Mdm2*** , which binds to the p53 N-terminus and targets p53 for ubiquitin-mediated proteolysis .	target	0
16652	10889512	4193;7157	Mdm2;p53	Increased p53 expression occurred despite the accumulation of its negative regulator , Mdm2 , and the formation of ******p53-Mdm2****** ***complexes*** .	parallel	1
16653	10889512	4193;7157	Mdm2;p53	The addition of exogenous ubiquitin to ******p53-Mdm2****** ***complexes*** from apoptotic neurons restored p53 degradation .	parallel	1
16654	10889596	30816;920	envelope glycoprotein;CD4 receptor	The process of HIV entry begins with ***binding*** of the viral ***envelope glycoprotein*** to both the ***CD4 receptor*** and one of several chemokine receptors and ends with fusion of viral and cell membranes .	parallel	1
16655	10889596	30816;920	envelope glycoprotein;CD4 receptor	Conceptually , there are 3 steps in the HIV entry process that could serve as therapeutic targets : ***binding*** of the viral ***envelope glycoprotein*** with the ***CD4 receptor*** , binding of the envelope-CD4 complex to chemokine receptors , and fusion of the viral and cell membranes .	parallel	1
16656	10889836	4233;3569	c-met;HGF	These immunolocalization and functional data indicate that ******HGF-c-met****** ***interactions*** play a key role in regulating the depth of CTB invasion in normal pregnancy and pre-eclampsia .	parallel	1
16657	10889869	6750;2641	somatostatin;glucagon	***somatostatin*** acts as a paracrine agent to ***inhibit*** both insulin and ***glucagon*** release , and , therefore , to modulate their output .	negative	1
16658	10889922	4193;7157	Mdm2;p53	***Mdm2*** protein is a cellular ***regulator*** of ***p53*** protein activity .	target	1
16659	10890197	3483;3486	ALS;IGFBP-3	Serum ***ALS*** levels were significantly ***correlated*** with serum IGF-I levels and ***IGFBP-3*** levels .	parallel	0
16660	10890197	3483;3479	ALS;IGF-I	Serum ***ALS*** levels were significantly ***correlated*** with serum ***IGF-I*** levels and IGFBP-3 levels .	parallel	0
16661	10890379	7132;7124	TNF-R55;TNFalpha	The soluble TNF receptor ***TNF-R55*** ( sTNF-R55 ) ***inhibits*** ***TNFalpha*** functioning .	negative	1
16662	10890911	7040;51176	TGFbeta;LEF1	Furthermore , we demonstrate that ***TGFbeta-dependent*** ***activation*** of ***LEF1/TCF*** target genes can occur in the absence of beta-catenin binding to LEF1/TCF and requires both Smad and LEF1/TCF DNA-binding sites in the Xtwn promoter .	positive	1
16663	10890911	1499;51176	beta-catenin;LEF1	Furthermore , we demonstrate that TGFbeta-dependent activation of LEF1/TCF target genes can occur in the absence of ***beta-catenin*** ***binding*** to ***LEF1/TCF*** and requires both Smad and LEF1/TCF DNA-binding sites in the Xtwn promoter .	parallel	1
16664	10890911	7040;51176	TGFbeta;LEF1	Thus , our results show that ***TGFbeta*** and Wnt signaling pathways can independently or cooperatively ***regulate*** ***LEF1/TCF*** target genes and suggest a model for how these pathways can synergistically activate target genes .	target	1
16665	10891328	3586;3567	IL-10;IL-5	Stimulus-specific ***inhibition*** of ***IL-5*** by cAMP-elevating agents and ***IL-10*** reveals differential mechanisms of action .	negative	1
16666	10891328	3586;940	IL-10;CD28	By contrast , ***IL-10*** totally ***inhibited*** CD3 + ***CD28-induced*** IL-5 release and inhibited mRNA by 50-60 % .	negative	1
16667	10891328	3586;3567	IL-10;IL-5	By contrast , ***IL-10*** totally ***inhibited*** CD3 + CD28-induced ***IL-5*** release and inhibited mRNA by 50-60 % .	negative	1
16668	10891363	4790;2908	NF-kappaB;glucocorticoid receptor	These results suggests that ***NF-kappaB*** ***interaction*** with the ***glucocorticoid receptor*** does not displace NF-kappaB from its DNA binding site but rather changes the complex into a transcriptionally inert form .	parallel	1
16669	10891367	3667;3643	IRS-1;insulin receptor	The relative phosphotyrosine ( Tyr ( P ) ) contents of the ***insulin receptor*** and its ***substrate*** 1 ( ***IRS-1*** ) were assessed in whole cell homogenates .	parallel	1
16670	10891369	1543;2052	CYP1A1;mEH	These results suggest that ***CYP1A1*** ***interacts*** with ***mEH*** and UGT to facilitate a series of multistep drug metabolic conversions .	parallel	1
16671	10891373	3458;2353	IFNgamma;c-fos	***IFNgamma*** significantly ***enhanced*** PDGF-induced ***c-fos*** transcription .	positive	0
16672	10891386	183;5594	angiotensin II;ERK	***angiotensin II*** ( Ang II ) ***stimulates*** the activation of extracellular signal-regulated kinase ( ***ERK*** ) , a subgroup of the mitogen-activated protein kinase ( MAPK ) family , in cultured vascular smooth muscle cells ( VSMC ) .	positive	0
16673	10891390	4790;329	NF-kappaB;cIAP-1	In addition , the expression of TRAF-2 and ***cIAP-1*** , which are transcriptionally ***regulated*** by ***NF-kappaB*** and function as anti-apoptotic molecules through the interruption of caspase pathway , was also inhibited by 5-FU .	target	1
16674	10891390	4790;7186	NF-kappaB;TRAF-2	In addition , the expression of ***TRAF-2*** and cIAP-1 , which are transcriptionally ***regulated*** by ***NF-kappaB*** and function as anti-apoptotic molecules through the interruption of caspase pathway , was also inhibited by 5-FU .	target	1
16675	10891400	5078;5080	Pax4;Pax6	Furthermore , ***Pax4*** ***represses*** ***Pax6*** independent transcription of the insulin promoter , suggesting that Pax4 can actively repress transcription in addition to acting by competition with the transcriptional activator Pax6 .	negative	1
16676	10891408	373156;975	GST;CD81	Baculovirus expressed E2 and a purified ***GST-E1E2*** protein ***bound*** to the second extracellular loop of ***CD81*** ( EC2 ) , a reported ligand for the molecule , but not to a truncated derivative of CD81 consisting of only the central domain of the loop .	parallel	1
16677	10891408	7320;975	E2 protein;CD81	Furthermore , ***E2 protein*** expressed in insect cells in the presence of N-butyldeoxynojirimycin , an inhibitor of terminal glucose residue processing , formed complexes with E1 and ***bound*** to ***CD81-EC2*** similarly to untreated protein .	parallel	1
16678	10891419	920;3700	CD4;gp120	Using various aggregation/syncytium assays that allow us to discriminate between ******gp120/CD4****** ***binding*** and binding followed by gp41-mediated fusion , we demonstrate that CLIV inhibits a step of the cell-to-cell fusion process after CD4 binding .	parallel	1
16679	10891427	729230;6347	CCR2;MCP-1	Moreover , the direct effect of MCP-1 on angiogenesis was consistent with the expression of ***CCR2*** , the ***receptor*** for ***MCP-1*** , on endothelial cells .	parallel	1
16680	10891429	7852;6387	CXCR4;Stromal cell-derived factor-1	Among the chemokine receptors expressed on platelets , the ***CXCR4*** is the ***receptor*** for chemokine ***Stromal cell-derived factor-1*** ( SDF-1 ) , and the CCR4 is the receptor for macrophage-derived chemokine ( MDC ) .	parallel	1
16681	10891429	1233;6367	CCR4;macrophage-derived chemokine	Among the chemokine receptors expressed on platelets , the CXCR4 is the receptor for chemokine Stromal cell-derived factor-1 ( SDF-1 ) , and the ***CCR4*** is the ***receptor*** for ***macrophage-derived chemokine*** ( MDC ) .	parallel	1
16682	10891451	356;355	FasL;Fas	Although in vivo and in vitro experiments have implicated the involvement of ******Fas/FasL****** ***interaction*** in this CD4 cross-linking ( CD4XL ) - induced apoptosis , detailed mechanisms to account for cell death induction have not been elucidated .	parallel	1
16683	10891451	940;598	CD28;Bcl-x	***CD28*** costimulation abrogated CD4XL/CD3-induced apoptosis with restoration of IL-2 production and ***prevented*** ***Bcl-x*** down-modulation .	negative	0
16684	10891462	6900;598	Tax1;Bcl-X	Whereas no effect was observed on the Bcl2 promoter , both ***Tax1*** and Tax2 ***increased*** transcription of the ***Bcl-X*** ( L ) promoter in T cells , although Tax1 appeared to be more efficient than Tax2 .	positive	0
16685	10891464	862;1440	AML1-MTG8;G-CSF	***AML1-MTG8*** leukemic protein ***induces*** the expression of granulocyte colony-stimulating factor ( ***G-CSF*** ) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon .	target	1
16686	10891479	1147;4790	IKK-1;NF-kappaB	As judged by kinase assays and transfection of dominant negative IKK-1 and IKK-2 expression vectors , ***NF-kappaB*** activation by Ras appeared to be ***mediated*** by both ***IKK-1*** and IKK-2 , while Raf-induced NF-kappaB activation was mediated by IKK-2 .	target	0
16687	10891479	3551;4790	IKK-2;NF-kappaB	As judged by kinase assays and transfection of dominant negative IKK-1 and IKK-2 expression vectors , ***NF-kappaB*** activation by Ras appeared to be ***mediated*** by both IKK-1 and ***IKK-2*** , while Raf-induced NF-kappaB activation was mediated by IKK-2 .	target	0
16688	10891480	4803;5594	nerve growth factor;ERK	In a previous report , we demonstrated that mitogen-activated protein ( MAP ) kinase ( ***ERK*** ) ***activation*** by the neurogenic agents fibroblast growth factor ( FGF ) and ***nerve growth factor*** is dependent on protein kinase Cdelta ( PKCdelta ) , whereas MAP kinase activation in response to the mitogen epidermal growth factor ( EGF ) is independent of PKCdelta in rat hippocampal ( H19-7 ) and pheochromocytoma ( PC12 ) cells .	positive	1
16689	10891484	5469;7421	TRAP220;VDR	Furthermore , we show that the presence and proper spacing of both RBD-1 and RBD-2 are required for an optimal ***association*** of ***TRAP220*** with RXR-TR or ***RXR-VDR*** heterodimers bound to DNA and for TRAP220 coactivator function .	parallel	0
16690	10891491	6035;23246	RNase A;Bop1	***RNase A*** treatment ***disrupts*** these particles and releases ***Bop1*** into a low-molecular-weight fraction .	negative	0
16691	10891492	8844;5609	KSR1;MEK	***B-KSR1*** protein is detectable in mouse brain throughout embryogenesis , is most abundant in adult forebrain neurons , and is ***complexed*** with activated mitogen-activated protein kinase ( MAPK ) and ***MEK*** in brain tissues .	parallel	1
16692	10891492	8844;5609	KSR1;MEK	In B-KSR1-expressing cells , the MAPK-B-KSR1 interaction was inducible and correlated with MAPK activation , while the ******MEK-B-KSR1****** ***interaction*** was constitutive .	parallel	1
16693	10891492	8844;5609	KSR1;MEK	Further examination of the ******MEK-B-KSR1****** ***interaction*** revealed that all genetically identified loss-of-function mutations in the catalytic domain severely diminished MEK binding .	parallel	1
16694	10891493	1387;7157	CBP;p53	It was shown recently that ***p53*** is ***acetylated*** by transcriptional coactivators p300 , CREB bidning protein ( ***CBP*** ) , and PCAF and that acetylation of p53 by these proteins enhances p53 sequence-specific DNA binding .	target	1
16695	10891493	1385;7157	CREB;p53	It was shown recently that ***p53*** is ***acetylated*** by transcriptional coactivators p300 , ***CREB*** bidning protein ( CBP ) , and PCAF and that acetylation of p53 by these proteins enhances p53 sequence-specific DNA binding .	target	1
16696	10891493	2033;7157	p300;p53	It was shown recently that ***p53*** is ***acetylated*** by transcriptional coactivators ***p300*** , CREB bidning protein ( CBP ) , and PCAF and that acetylation of p53 by these proteins enhances p53 sequence-specific DNA binding .	target	1
16697	10891493	8850;7157	PCAF;p53	It was shown recently that ***p53*** is ***acetylated*** by transcriptional coactivators p300 , CREB bidning protein ( CBP ) , and ***PCAF*** and that acetylation of p53 by these proteins enhances p53 sequence-specific DNA binding .	target	1
16698	10891493	8850;7157	PCAF;p53	We further show that the E1B 55-kDa protein interferes with the physical ***interaction*** between ***PCAF*** and ***p53*** , suggesting that the E1B 55-kDa protein inhibits PCAF acetylase function on p53 by preventing enzyme-substrate interaction .	parallel	1
16699	10891494	4193;7157	Mdm2;p53	The temperature-sensitive phenotype apparently results from inefficient ***inhibition*** of heat-induced ***p53*** by reduced ***Mdm2*** synthesis due to low Mdm2 promoter activity .	negative	1
16700	10891494	7157;4193	p53;Mdm2	These effects of ***Mdm2*** are ***mediated*** by ***p53*** .	target	0
16701	10891494	7157;4193	p53;Mdm2	The TAF ( II ) 250 rescue is blocked by inhibition of ******Mdm2-p53****** ***interactions*** .	parallel	1
16702	10891498	7157;57060	p53;MCG10	***MCG10*** can be ***induced*** by wild-type but not mutant ***p53*** and by DNA damage via two potential p53-responsive elements in the promoter of the MCG10 gene .	target	1
16703	10891499	7514;10762	CRM1;Nup50	Correspondingly , ***CRM1*** , the export receptor for leucine-rich export sequences , directly ***bound*** to a fragment of ***Nup50*** in vitro , whereas several other import and export receptors did not significantly interact with this fragment .	parallel	1
16704	10891502	5897;5896	RAG2;RAG1	The present experiments , performed with an extensive panel of site-directed mutations within each of the six kelch motifs , further support the critical role of both hydrophobic and glycine-rich regions within the second beta-strand for ******RAG1-RAG2****** ***interaction*** and recombination signal recognition and cleavage .	parallel	1
16705	10891502	5897;5896	RAG2;RAG1	In contrast , multiple mutations within the variable-loop regions of the kelch repeats had either mild or no effects on ******RAG1-RAG2****** ***interaction*** and hence on the ability to mediate recombination .	parallel	1
16706	10891503	841;5339	caspase 8;plectin	***plectin*** was quantitatively ***cleaved*** by ***caspase 8*** at Asp 2395 in the center of the molecule in all cells tested .	target	1
16707	10891597	4012;5594	AT(2) receptor;ERK	Angiotensin ***AT(2) receptor*** stimulates ERK1 and ERK2 in quiescent but ***inhibits*** ***ERK*** in NGF-stimulated PC12W cells .	negative	1
16708	10891597	4012;5595	AT(2) receptor;ERK1	Angiotensin ***AT(2) receptor*** ***stimulates*** ***ERK1*** and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells .	positive	0
16709	10891597	4012;5594	AT(2) receptor;ERK2	Angiotensin ***AT(2) receptor*** ***stimulates*** ERK1 and ***ERK2*** in quiescent but inhibits ERK in NGF-stimulated PC12W cells .	positive	0
16710	10891597	4012;5594	AT(2) receptor;ERK	These findings demonstrate that the ***AT(2) receptor*** ***modulates*** ***ERK*** activity depending on the overall cellular input .	target	0
16711	10891886	7124;3952	Tumor necrosis factor-alpha;leptin	***Tumor necrosis factor-alpha*** ***regulates*** secretion of the adipocyte-derived cytokine , ***leptin*** .	target	1
16712	10892347	7124;4790	TNF-alpha;NF-kappa B	Gel-shift analysis of HUVEC demonstrated that pretreatment with pycnogenol exhibited a concentration-dependent suppression of ***TNF-alpha-induced*** ***activation*** of ***NF-kappa B*** .	positive	1
16713	10892347	7124;3383	TNF-alpha;ICAM-1	***Induction*** of VCAM-1 and ***ICAM-1*** surface expression by ***TNF-alpha*** was dose-dependently reduced by pycnogenol .	target	1
16714	10892347	7124;7412	TNF-alpha;VCAM-1	***Induction*** of ***VCAM-1*** and ICAM-1 surface expression by ***TNF-alpha*** was dose-dependently reduced by pycnogenol .	target	1
16715	10892649	5897;5896	RAG2;RAG1	During B and T cell development , the ******RAG1/RAG2****** protein ***complex*** cleaves DNA at conserved recombination signal sequences ( RSS ) to initiate V ( D ) J recombination .	parallel	1
16716	10892746	7341;4193	SUMO-1;Mdm2	***SUMO-1*** ***modification*** of ***Mdm2*** prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53 .	target	0
16717	10892746	7341;4193	SUMO-1;Mdm2	***SUMO-1*** modification of Mdm2 prevents its self-ubiquitination and ***increases*** ***Mdm2*** ability to ubiquitinate p53 .	positive	0
16718	10892746	4193;7157	Mdm2;p53	Radiation caused a dose - and time-dependent decrease in the degree of ***Mdm2*** SUMO-1 modification , which is inversely ***correlated*** with the levels of ***p53*** .	negative	0
16719	10892746	7341;7157	SUMO-1;p53	Radiation caused a dose - and time-dependent decrease in the degree of Mdm2 ***SUMO-1*** modification , which is inversely ***correlated*** with the levels of ***p53*** .	negative	0
16720	10892748	7186;8717	TRAF2;TRADD	A novel mechanism of TRAF signaling revealed by structural and functional analyses of the ******TRADD-TRAF2****** ***interaction*** .	parallel	1
16721	10892748	7186;8717	TRAF2;TRADD	We now report the structure of the ******TRADD-TRAF2****** ***complex*** , which is highly distinct from receptor-TRAF2 interactions .	parallel	1
16722	10892748	7186;8717	TRAF2;TRADD	The stronger affinity and unique specificity of the ******TRADD-TRAF2****** ***interaction*** are crucial for the suppression of apoptosis and provide a mechanistic basis for the perturbation of TRAF recruitment in sensitizing cell death induction .	parallel	1
16723	10892805	1021;1029	CDK6;p16INK4A	The completion of p15INK4B coupled with refinement of p16INK4A made it possible to compare the structures of the four INK4 members in depth , and to compare the structures of p16INK4A in the free form and in the ******p16INK4A-CDK6****** ***complex*** .	parallel	1
16724	10892857	3553;4312	IL-1beta;MMP-1	RESULTS : ***IL-1beta*** and TNF-alpha dramatically ***increased*** the mRNA and protein expression of ***MMP-1*** and MMP-3 in cultured PBF when compared to normal HJF and to their nonstimulated counterparts cultured in a serum-free medium .	positive	0
16725	10892857	3553;4314	IL-1beta;MMP-3	RESULTS : ***IL-1beta*** and TNF-alpha dramatically ***increased*** the mRNA and protein expression of MMP-1 and ***MMP-3*** in cultured PBF when compared to normal HJF and to their nonstimulated counterparts cultured in a serum-free medium .	positive	0
16726	10892857	7124;4312	TNF-alpha;MMP-1	RESULTS : IL-1beta and ***TNF-alpha*** dramatically ***increased*** the mRNA and protein expression of ***MMP-1*** and MMP-3 in cultured PBF when compared to normal HJF and to their nonstimulated counterparts cultured in a serum-free medium .	positive	0
16727	10892857	7124;4314	TNF-alpha;MMP-3	RESULTS : IL-1beta and ***TNF-alpha*** dramatically ***increased*** the mRNA and protein expression of MMP-1 and ***MMP-3*** in cultured PBF when compared to normal HJF and to their nonstimulated counterparts cultured in a serum-free medium .	positive	0
16728	10892857	7039;4314	TGF-alpha;MMP-3	EGF and ***TGF-alpha*** also ***upregulated*** ***MMP-3*** in PBF when compared to HJF .	positive	1
16729	10892867	7040;7052	TGF-beta1;tissue transglutaminase	***Induction*** of ***tissue transglutaminase*** in the trabecular meshwork by ***TGF-beta1*** and TGF-beta2 .	target	1
16730	10892867	7042;7052	TGF-beta2;tissue transglutaminase	***Induction*** of ***tissue transglutaminase*** in the trabecular meshwork by TGF-beta1 and ***TGF-beta2*** .	target	1
16731	10892871	2944;2950	GSTM1;GSTP1	PURPOSE : To investigate the possible ***association*** between glutathione S-transferase ***GSTM1*** , GSTM3 , GSTT1 , and ***GSTP1*** polymorphism and the occurrence of age-related cataracts in Estonian patients .	parallel	0
16732	10892871	2947;2944	GSTM3;GSTM1	PURPOSE : To investigate the possible ***association*** between glutathione S-transferase ***GSTM1*** , ***GSTM3*** , GSTT1 , and GSTP1 polymorphism and the occurrence of age-related cataracts in Estonian patients .	parallel	0
16733	10892871	2947;2950	GSTM3;GSTP1	PURPOSE : To investigate the possible ***association*** between glutathione S-transferase GSTM1 , ***GSTM3*** , GSTT1 , and ***GSTP1*** polymorphism and the occurrence of age-related cataracts in Estonian patients .	parallel	0
16734	10893189	3689;3684	CD18;CD11b	Thus cytoskeletal rearrangement was directly implicated in upregulation and , later , downregulation of ******CD11b/CD18****** ***binding*** .	parallel	1
16735	10893192	3836;6772	Npi-1;STAT1	In cells activated with IFN gamma , IFN gamma was found to as part of a complex that contained STAT1 alpha and the importin-alpha analog ***Npi-1*** , which ***mediates*** ***STAT1*** alpha nuclear import .	target	0
16736	10893192	3836;3458	Npi-1;IFN gamma	The tyrosine phosphorylation of STAT1 alpha , the formation of the complex ******IFN gamma/Npi-1/STAT1****** alpha ***complex*** and the subsequent nuclear translocation of STAT1 alpha were all found to be dependent on the presence of the IFN gamma NLS .	parallel	1
16737	10893192	6772;3458	STAT1;IFN gamma	The tyrosine phosphorylation of STAT1 alpha , the formation of the complex ******IFN gamma/Npi-1/STAT1****** alpha ***complex*** and the subsequent nuclear translocation of STAT1 alpha were all found to be dependent on the presence of the IFN gamma NLS .	parallel	1
16738	10893192	6772;3836	STAT1;Npi-1	The tyrosine phosphorylation of STAT1 alpha , the formation of the complex ******IFN gamma/Npi-1/STAT1****** alpha ***complex*** and the subsequent nuclear translocation of STAT1 alpha were all found to be dependent on the presence of the IFN gamma NLS .	parallel	1
16739	10893219	7040;5743	TGF-beta1;COX-2	***TGF-beta1*** ***stimulates*** IL-8 release , ***COX-2*** expression , and PGE ( 2 ) release in human airway smooth muscle cells .	positive	0
16740	10893219	7040;3576	TGF-beta1;IL-8	***TGF-beta1*** ***stimulates*** ***IL-8*** release , COX-2 expression , and PGE ( 2 ) release in human airway smooth muscle cells .	positive	0
16741	10893219	7040;5743	TGF-beta1;COX-2	***TGF-beta1*** ***stimulated*** IL-8 release , ***COX-2*** induction , and PGE ( 2 ) generation in a concentration - and time-dependent manner .	positive	0
16742	10893219	7040;3576	TGF-beta1;IL-8	***TGF-beta1*** ***stimulated*** ***IL-8*** release , COX-2 induction , and PGE ( 2 ) generation in a concentration - and time-dependent manner .	positive	0
16743	10893219	7040;5743	TGF-beta1;COX-2	These results show for the first time that ***TGF-beta1*** ***stimulates*** IL-8 release , ***COX-2*** induction , and PGE ( 2 ) generation in human ASM cells and that PGE ( 2 ) generation is not critical for TGF-beta1-induced IL-8 release .	positive	0
16744	10893219	7040;3576	TGF-beta1;IL-8	These results show for the first time that ***TGF-beta1*** ***stimulates*** ***IL-8*** release , COX-2 induction , and PGE ( 2 ) generation in human ASM cells and that PGE ( 2 ) generation is not critical for TGF-beta1-induced IL-8 release .	positive	0
16745	10893221	6550;387	NHE3;RhoA	These data suggest that optimal ***NHE3*** activity ***requires*** a functional ***RhoA-ROK*** signaling pathway which acts , at least partly , by controlling the phosphorylation of myosin light chain and , ultimately , the organization of the actin cytoskeleton .	target	0
16746	10893221	387;6550	RhoA;NHE3	***RhoA*** and rho kinase ***regulate*** the epithelial Na + / H + exchanger ***NHE3*** .	target	1
16747	10893238	8795;8743	DR5;TRAIL	Crystal structure of ******TRAIL-DR5****** ***complex*** identifies a critical role of the unique frame insertion in conferring recognition specificity .	parallel	1
16748	10893263	1785;7157	dyn2;p53	A < / = 5-fold increase of ***dyn2*** relative to endogenous levels ***activates*** the transcription factor ***p53*** and induces apoptosis , as demonstrated by reduced cell proliferation , DNA fragmentation , and caspase-3 activation .	positive	1
16749	10893266	7074;5879	Tiam1;Rac1	***Ankyrin-Tiam1*** interaction ***promotes*** ***Rac1*** signaling and metastatic breast tumor cell invasion and migration .	positive	0
16750	10893268	375790;998	Agrin;Cdc42	By indicating that ***Agrin-dependent*** ***activation*** of Rac and ***Cdc42*** constitutes a critical step in the signaling pathway leading to AChR clustering , these findings suggest a novel role for these Rho-GTPases : the coupling of neuronal signaling to a key step in neuromuscular synaptogenesis .	positive	1
16751	10893268	375790;207	Agrin;Rac	By indicating that ***Agrin-dependent*** ***activation*** of ***Rac*** and Cdc42 constitutes a critical step in the signaling pathway leading to AChR clustering , these findings suggest a novel role for these Rho-GTPases : the coupling of neuronal signaling to a key step in neuromuscular synaptogenesis .	positive	1
16752	10893323	3429;595	p27;cyclin D1	Immunoprecipitation with an anti-cyclin D1 antibody of cell lysates prepared from cAMP-treated cells followed by immunoblotting with antisera to p27 ( kip1 ) disclosed a threefold increase in ***p27*** ( kip1 ) ***associated*** with ***cyclin D1*** compared with lysates treated with serum alone .	parallel	0
16753	10893327	2641;3643	GLP-1;insulin receptor	The present study tested the hypothesis that ***GLP-1*** may ***modulate*** ***insulin receptor*** binding .	target	0
16754	10893342	4790;7124	NF-kappaB;TNF-alpha	These results suggest that ***TNF-alpha*** inhibition of hormone-stimulated transcriptional activation may be ***mediated*** by activation of ***NF-kappaB*** .	target	0
16755	10893342	4790;7124	NF-kappaB;TNF-alpha	In contrast , the inhibitory effect of ***TNF-alpha*** on binding of receptors to DNA is unlikely to be ***mediated*** by ***NF-kappaB*** and is not necessary for inhibition of transcription .	target	0
16756	10893407	1511;2149	cathepsin G;PAR-1	However , thrombin receptor agonist peptide ( an agonist of protease activated receptor-1 ( PAR-1 ) ) , could not mimic the effect of thrombin , and ***cathepsin G*** , a ***PAR-1*** ***inhibitor*** , did not reduce the effect of thrombin .	negative	1
16757	10893408	2886;5747	Grb7;FAK	We have previously described ***Grb7*** ***association*** with focal adhesion kinase ( ***FAK*** ) and its possible roles in cell migration .	parallel	0
16758	10893408	5747;2886	FAK;Grb7	We also found that ***Grb7*** could be ***phosphorylated*** by ***FAK*** , which was dependent on the FAK kinase activity but not the presence of the Src family kinases .	target	1
16759	10893415	8518;7124	IKAP;tumor necrosis factor alpha	Overexpression of either IKK gamma or ***IKAP*** ***blocked*** ***tumor necrosis factor alpha*** induction of an NF-kappa B-dependent reporter construct , but IKAP in addition affected several NF-kappa B-independent promoters .	negative	0
16760	10893415	8517;7124	IKK gamma;tumor necrosis factor alpha	Overexpression of either ***IKK gamma*** or IKAP ***blocked*** ***tumor necrosis factor alpha*** induction of an NF-kappa B-dependent reporter construct , but IKAP in addition affected several NF-kappa B-independent promoters .	negative	0
16761	10893422	9351;1080	E3KARP;CFTR	Since ezrin has been shown previously to function as a protein kinase A anchoring protein , we suggest that one function served by the ***interaction*** of ***E3KARP*** with both ezrin and ***CFTR*** is to localize protein kinase A in the vicinity of the R-domain of CFTR .	parallel	1
16762	10893422	9351;7430	E3KARP;ezrin	Since ezrin has been shown previously to function as a protein kinase A anchoring protein , we suggest that one function served by the ***interaction*** of ***E3KARP*** with both ***ezrin*** and CFTR is to localize protein kinase A in the vicinity of the R-domain of CFTR .	parallel	1
16763	10893422	1080;9351	CFTR;E3KARP	Since ezrin is also an actin-binding protein , the formation of a ******CFTR.E3KARP.ezrin****** ***complex*** may be important also in stabilizing CFTR at the apical membrane domain of airway cells .	parallel	1
16764	10893422	7430;1080	ezrin;CFTR	Since ezrin is also an actin-binding protein , the formation of a ******CFTR.E3KARP.ezrin****** ***complex*** may be important also in stabilizing CFTR at the apical membrane domain of airway cells .	parallel	1
16765	10893422	7430;9351	ezrin;E3KARP	Since ezrin is also an actin-binding protein , the formation of a ******CFTR.E3KARP.ezrin****** ***complex*** may be important also in stabilizing CFTR at the apical membrane domain of airway cells .	parallel	1
16766	10893422	7430;1080	ezrin;cystic fibrosis transmembrane conductance regulator	E3KARP mediates the ***association*** of ***ezrin*** and protein kinase A with the ***cystic fibrosis transmembrane conductance regulator*** in airway cells .	parallel	0
16767	10893422	9351;7430	E3KARP;ezrin	***E3KARP*** ***mediates*** the association of ***ezrin*** and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells .	target	0
16768	10893422	7430;9351	ezrin;E3KARP	We also found that ***ezrin*** ***associates*** with ***E3KARP*** in vivo .	parallel	0
16769	10893422	1080;7430	CFTR;ezrin	These results support the concept that E3KARP functions as a scaffold protein that ***links*** ***CFTR*** to ***ezrin*** .	parallel	0
16770	10894148	6667;5241	Sp1;progesterone receptor	***Sp1*** binding sites and an estrogen response element half-site are involved in ***regulation*** of the human ***progesterone receptor*** A promoter .	target	1
16771	10894154	652;656	Bmp4;Bmp8b	Since Bmp4 heterozygote embryos have reduced numbers of PGCs , we used a genetic approach to generate double-mutant embryos to study ***interactions*** of ***Bmp8b*** and ***Bmp4*** .	parallel	1
16772	10894158	2796;7225	GnRH;Trp6	Based on the experimental data , three-dimensional models for ***binding*** of the superagonist ******D-Trp6-GnRH****** ( Triptorelin ) and the antagonist Cetrorelix to the hGnRH-R are proposed .	parallel	1
16773	10894160	841;8743	caspase-8;TRAIL	Differential precipitation of ligand-stimulated TRAIL receptors demonstrated that FADD/MORT1 and ***caspase-8*** were ***recruited*** to ***TRAIL-R1*** and TRAIL-R2 independently of each other .	target	0
16774	10894160	8772;8743	MORT1;TRAIL	Differential precipitation of ligand-stimulated TRAIL receptors demonstrated that ***FADD/MORT1*** and caspase-8 were ***recruited*** to ***TRAIL-R1*** and TRAIL-R2 independently of each other .	target	0
16775	10894161	355;8772	Fas;FADD	***Fas*** ***binds*** ***FADD*** directly , whereas TNFR1 binds FADD indirectly , through TRADD .	parallel	1
16776	10894161	7132;8772	TNFR1;FADD	Fas binds FADD directly , whereas ***TNFR1*** ***binds*** ***FADD*** indirectly , through TRADD .	parallel	1
16777	10894161	8717;8737	TRADD;RIP	***TRADD*** alternatively ***recruits*** the NF-kappaB-inducing adaptor ***RIP*** .	target	0
16778	10894161	8737;7132	RIP;TNFR1	TRADD and ***RIP*** , which ***bound*** ***TNFR1*** , did not bind DR4 and DR5 .	parallel	1
16779	10894161	8717;7132	TRADD;TNFR1	***TRADD*** and RIP , which ***bound*** ***TNFR1*** , did not bind DR4 and DR5 .	parallel	1
16780	10894163	8837;841	Casper;caspase-8	***Casper*** ( c-FLIP ) ***associates*** with FADD and ***caspase-8*** in signaling complexes downstream of death receptors like Fas .	parallel	0
16781	10894163	8837;8772	Casper;FADD	***Casper*** ( c-FLIP ) ***associates*** with ***FADD*** and caspase-8 in signaling complexes downstream of death receptors like Fas .	parallel	0
16782	10894164	4773;3565	NFAT1;IL-4	The antigen-inducible transcription factor ***NFAT1*** ***binds*** the IL-4 enhancer and the ***IL-4*** promoter only in stimulated Th2 cells ; conversely , NFAT1 binds to the interferon ( IFN ) - gamma promoter only in stimulated Th1 cells .	parallel	1
16783	10894267	356;355	FasL;FAS	***FasL*** , a cell-surface molecule on activated T-cells ***interacts*** with its receptor , ***FAS*** , to induce apoptosis in target cells .	parallel	1
16784	10894360	3586;942	IL-10;CD86	***IL-10*** levels were inversely ***correlated*** with lymphocyte proliferation and ***CD86*** expression .	negative	0
16785	10894547	2932;4790	GSK-3beta;NF-kappaB	The early steps leading to NF-kappaB activation ( degradation of I-kappaB and translocation of NF-kappaB to the nucleus ) were unaffected by the loss of GSK-3beta , indicating that ***NF-kappaB*** is ***regulated*** by ***GSK-3beta*** at the level of the transcriptional complex .	target	1
16786	10894547	2932;4790	GSK-3beta;NF-kappaB	Thus , ***GSK-3beta*** ***facilitates*** ***NF-kappaB*** function .	positive	0
16787	10894548	2290;375757	Fkh2;SWI5	***Fkh2*** protein is ***associated*** with the promoters of CLB2 , ***SWI5*** and other genes of the cluster .	parallel	0
16788	10894589	959;958	CD40L;CD40	OBJECTIVE : ***CD40-CD40*** ***ligand*** ( ***CD40L*** ) interaction is essential for the T-lymphocyte-dependent immune response .	parallel	1
16789	10894811	3458;199	interferon-gamma;AIF-1	***AIF-1*** protein is not expressed in quiescent cultured human VSMCs but is ***induced*** in cells challenged with various inflammatory cytokines , primarily by ***interferon-gamma*** , interleukin-1beta , and T-cell-conditioned media .	target	1
16790	10894816	3569;3949	Interleukin-6;LDL receptor	***Interleukin-6*** ***stimulates*** ***LDL receptor*** gene expression via activation of sterol-responsive and Sp1 binding elements .	positive	0
16791	10894816	6670;6667	Sp3;Sp1	In gel-shift assays , nuclear extracts of IL-6-treated HepG2 cells showed an induced binding of SRE binding protein ( SREBP ) -1 a and SRE binding protein ( SREBP ) -2 to the SRE-1 that was independent of the cellular sterol content and an induced ***binding*** of ***Sp1*** and ***Sp3*** to repeat 3 of the LDL-R promoter .	parallel	1
16792	10894826	4018;2155	lipoprotein;factor VII	Endotoxin-free preparations of lipoprotein fractions did not induce functional tissue factor in monocytes , whereas all ***lipoprotein*** fractions ***enhanced*** tissue factor-independent activation of ***factor VII*** by factor Xa and by factors Xa/Va .	positive	0
16793	10894826	2159;2155	factor Xa;factor VII	Endotoxin-free preparations of lipoprotein fractions did not induce functional tissue factor in monocytes , whereas all lipoprotein fractions enhanced tissue factor-independent ***activation*** of ***factor VII*** by ***factor Xa*** and by factors Xa/Va .	positive	1
16794	10894984	6469;5727	Shh;Ptc1	Dorsally expressed ***Shh*** signals ***induce*** ectopic transcription of its receptor ***Ptc1*** in the midbrain and the hindbrain .	target	1
16795	10894987	1943;2043	ephrin-A2;EphA4	Here , we examine the spatiotemporal distributions of the ***EphA4*** receptor tyrosine kinase ( RTK ) and its cognate ***ligands*** , ***ephrin-A2*** and ephrin-A5 , on motor neurons , their axons and their pathways to the avian hindlimb to determine whether these molecules may influence axonal projections .	parallel	1
16796	10894987	1946;2043	ephrin-A5;EphA4	Here , we examine the spatiotemporal distributions of the ***EphA4*** receptor tyrosine kinase ( RTK ) and its cognate ***ligands*** , ephrin-A2 and ***ephrin-A5*** , on motor neurons , their axons and their pathways to the avian hindlimb to determine whether these molecules may influence axonal projections .	parallel	1
16797	10895017	1026;7157	p21;p53	***p21*** ( WAF-1 / CIP-1 ) , a downstream ***regulator*** of functional ***p53*** loss , in transitional cell carcinoma of urothelium .	target	1
16798	10895017	1026;7157	p21;p53	OBJECTIVES : The expression of ***p21*** ( WAF-1 / CIP-1 ) , a downstream ***regulator*** of ***p53*** , is a universal cycline-dependent kinase inhibitor .	target	1
16799	10895049	2690;3479	GH receptor;IGF-I	Hyperinsulinemia and increased ***GH receptor*** activity may also ***affect*** the ***GH-IGF-I*** axis .	target	0
16800	1089535	6750;2641	somatostatin;glucagon	***Inhibition*** of ***glucagon*** and insulin secretion by ***somatostatin*** in the rat pancreas perfused in situ .	negative	1
16801	10895370	3553;4313	IL-1 beta;MMP-2	RESULTS : MMP-2 is not secreted by rheumatoid osteoblasts as a proenzyme ; however , ***IL-1 beta*** stimulation ***induced*** the secretion of ***MMP-2*** as an active form from rheumatoid osteoblasts .	target	1
16802	10895370	3553;4323	IL-1 beta;MT-MMP	In support of this result , ***IL-1 beta*** stimulation ***induced*** the expression of membrane type matrix-metalloproteinase ( ***MT-MMP*** ) , a newly-identified MMP-2 specific activator , in rheumatoid osteoblasts .	target	1
16803	10895370	3553;4313	IL-1 beta;MMP-2	CONCLUSION : These results suggest that ***IL-1 beta*** ***induces*** ***MMP-2*** activation in part by up-regulating MT-MMP expression and represents a new mechanism for cytokine-mediated articular destruction in RA .	target	1
16804	10895974	4313;4323	matrix metalloproteinase-2;membrane-type-1 matrix metalloproteinase	Matrix metalloproteinases in human gliomas : activation of ***matrix metalloproteinase-2*** ( MMP-2 ) may be ***correlated*** with ***membrane-type-1 matrix metalloproteinase*** ( MT1-MMP ) expression .	parallel	0
16805	10895976	5008;5443	oncostatin M;ACTH	***oncostatin M*** ( OSM ) , a cytokine of IL-6 family has been reported to ***increase*** ***ACTH*** secretion and pro-opiomelanocortin ( POMC ) transcription in murine corticotroph pituitary tumor cells ( AtT20 cells ) .	positive	0
16806	10895976	5008;5443	OSM;ACTH	***OSM*** ( 1 nM ) ***stimulated*** ***ACTH*** release ( 35.1 % increase versus control , p < 0.001 ) in dispersed pituitary cells of rat to a lesser extent than in AtT20 cells .	positive	0
16807	10896159	91768;1020	Cables;Cdk5	***Cables*** , a novel protein , ***interacts*** with ***Cdk5*** in brain lysates .	parallel	1
16808	10896159	25;1020	c-Abl;Cdk5	***Phosphorylation*** of ***Cdk5*** by ***c-Abl*** occurs on tyrosine 15 ( Y15 ) , which is stimulatory for p35/Cdk5 kinase activity .	target	1
16809	10896159	1020;25	Cdk5;c-Abl	The data provide evidence for a Cables-mediated ***interplay*** between the ***Cdk5*** and ***c-Abl*** signaling pathways in the developing nervous system .	parallel	1
16810	10896202	8850;7157	p300/CBP-Associated Factor;p53	The PCAF gene encodes the ***p300/CBP-Associated Factor*** ( PCAF ) , a histone acetyltransferase , which ***regulates*** ***p53*** by acetylation of Lys320 in the C-terminal portion of p53 .	target	1
16811	10896202	8850;7157	PCAF;p53	Since ***PCAF*** can ***regulate*** ***p53*** activity , abrogation of PCAF function by PCAF gene mutation could be an alternate mechanism to inactivate the p53 pathway in tumors lacking p53 mutations .	target	1
16812	10896233	7035;2152	TFPI;Tissue factor	We investigated the " in vivo " role of Hcy in affecting plasma levels of TF , its inhibitor ***Tissue factor*** Pathway ***Inhibitor*** ( ***TFPI*** ) and hypercoagulability .	negative	1
16813	10896250	4352;7066	c-Mpl;Tpo	thrombopoietin is produced at a constant rate by the liver and kidney and is removed from the circulation upon binding and subsequent uptake via the ***Tpo*** ***receptor*** , ***c-Mpl*** , expressed by platelets and mega-karyocytes .	parallel	1
16814	10896254	3552;7422	IL-1alpha;VEGF	Cycloheximide treatment of HUVEC slightly inhibited the IL-1alpha-induced expression of VEGF mRNA , and ***IL-1alpha*** may ***mediate*** , at least in part , ***VEGF*** expression in response to IL-1alpha .	target	0
16815	10896658	3082;5335	HGF;PLCgamma1	However , treatment of the cells with orthovanadate , a tyrosine phosphatase inhibitor , restored the ***HGF-induced*** tyrosine ***phosphorylation*** of ***PLCgamma1*** .	target	1
16816	10896671	4803;5594	Nerve growth factor;ERK	***Nerve growth factor*** ( NGF ) loop 4 dimeric mimetics ***activate*** ***ERK*** and AKT and promote NGF-like neurotrophic effects .	positive	1
16817	10896674	23037;8502	PAPIN;p0071	***PAPIN*** has six PDZ domains and ***binds*** to NPRAP/delta-catenin and ***p0071*** via the second PDZ domain .	parallel	1
16818	10896677	94234;4638	HFH-1;telokin	***HFH-1*** strongly ***represses*** ***telokin*** promoter activity when overexpressed in A10 vascular smooth muscle cells .	negative	1
16819	10896677	94234;4638	HFH-1;telokin	***HFH-1*** ***inhibits*** ***telokin*** promoter activity , by binding to a forkhead consensus site located within an AT-rich region of the telokin promoter .	negative	1
16820	10896681	4023;4018	LpL;Lipoprotein	Aside from its lipolytic activity , ***LpL*** ***promotes*** ***Lipoprotein*** uptake by increasing the association of these particles with cell surfaces allowing for the internalization by receptors and proteoglycans .	positive	0
16821	10896681	4023;4018	LpL;Lipoprotein	Recent studies also indicate that ***LpL*** ***stimulates*** selective uptake of lipids from high density Lipoprotein ( HDL ) and very low density ***Lipoprotein*** .	positive	0
16822	10896774	5329;5054	uPAR;PAI-1	At the cell surface , receptor ( ***uPAR*** ) - bound urokinase ( uPA ) ***binds*** its inhibitor ***PAI-1*** , localized in the matrix , and the complex is internalized by endocytic receptors , such as the low-density lipoprotein receptor-related protein ( LRP ) .	parallel	1
16823	10896788	7040;4088	TGF-beta1;SMAD3	The levels of SMAD3 and ***SMAD3*** mRNA were profoundly ***down-regulated*** by ***TGF-beta1*** or TGF-beta3 in a time-dependent manner , whereas expression of antagonistic Smad7 was rapidly and transiently induced .	negative	1
16824	10896788	7043;4088	TGF-beta3;SMAD3	The levels of SMAD3 and ***SMAD3*** mRNA were profoundly ***down-regulated*** by TGF-beta1 or ***TGF-beta3*** in a time-dependent manner , whereas expression of antagonistic Smad7 was rapidly and transiently induced .	negative	1
16825	10896792	2246;3553	FGF-1;IL-1	***FGF-1*** treatment did not affect PGHS-2 gene expression , but ***enhanced*** the effect of ***IL-1*** on PGHS-2 expression by an additional 2 - to 3-fold .	positive	0
16826	10896908	3557;3552	IL-1ra;IL-1alpha	The receptor antagonist ***IL-1ra*** ***blocked*** the ability of ***IL-1alpha*** to stimulate glucose transport .	negative	0
16827	10896935	5290;960	PI3K;CD44	The active mutant p110 subunit of PI3K has also been shown to enhance the CD44 cleavage , suggesting that ***PI3K*** ***mediates*** the Ras-induced ***CD44*** cleavage .	target	0
16828	10896938	9564;5898	p130Cas;Ral	***p130Cas*** ***regulates*** the activity of AND-34 , a novel ***Ral*** , Rap1 , and R-Ras guanine nucleotide exchange factor .	target	1
16829	10896938	9564;5906	p130Cas;Rap1	***p130Cas*** ***regulates*** the activity of AND-34 , a novel Ral , ***Rap1*** , and R-Ras guanine nucleotide exchange factor .	target	1
16830	10896940	19;949	ABC1;SR-BI	The goal of the present study was to determine a possible ***interaction*** between the ***SR-BI*** and ***ABC1*** cholesterol efflux pathways in macrophages .	parallel	1
16831	10896947	2247;1513	FGF-2;cathepsin K	***FGF-2*** ( > / = 10 ( -12 ) m ) also ***increased*** ***cathepsin K*** and MMP-9 mRNA levels in mouse and rabbit osteoclasts .	positive	0
16832	10896947	2247;4318	FGF-2;MMP-9	***FGF-2*** ( > / = 10 ( -12 ) m ) also ***increased*** cathepsin K and ***MMP-9*** mRNA levels in mouse and rabbit osteoclasts .	positive	0
16833	10897042	3486;7040	IGFBP-3;TGF beta 1	***IGFBP-3*** ***mediates*** ***TGF beta 1*** proliferative response in colon cancer cells .	target	0
16834	10897042	7040;3486	TGF beta 1;IGFBP-3	***TGF beta 1*** ***increases*** ***IGFBP-3*** abundance while phosphorothiolated antisense oligonucleotides to IGFBP-3 block the growth-promoting effect of TGF beta 1 in each of 3 lines.IGFBP-3 induces carcinoma cell growth in a dose-dependent and time-dependent manner in vitro .	positive	0
16835	10897390	834;355	ICE;Fas	These effects of ***Fas-activation*** on the HSF1/hsp70 stress response were ***blocked*** by ***ICE*** ( caspase 1 ) - inhibitors , suggesting an ICE-mediated process .	negative	0
16836	10898493	930;5594	CD19;extracellular signal-regulated kinase (ERK) 2	We have shown that ***CD19*** ***enhances*** the activation of ***extracellular signal-regulated kinase (ERK) 2*** by membrane ( m ) IgM but otherwise little is known of CD19 signaling in primary human cells .	positive	0
16837	10898493	959;5594	IgM;extracellular signal-regulated kinase (ERK) 2	We have shown that CD19 enhances the ***activation*** of ***extracellular signal-regulated kinase (ERK) 2*** by membrane ( m ) ***IgM*** but otherwise little is known of CD19 signaling in primary human cells .	positive	1
16838	10898493	930;5594	CD19;ERK2	***CD19*** consistently ***enhanced*** activation of ***ERK2*** and MEK1 .	positive	0
16839	10898493	930;5604	CD19;MEK1	***CD19*** consistently ***enhanced*** activation of ERK2 and ***MEK1*** .	positive	0
16840	10898494	7409;5594	Vav;ERK	***Vav*** ***modulation*** of the ***Ras/MEK/ERK*** signaling pathway plays a role in NFAT activation and CD69 up-regulation .	target	0
16841	10898494	7409;5609	Vav;MEK	***Vav*** ***modulation*** of the ***Ras/MEK/ERK*** signaling pathway plays a role in NFAT activation and CD69 up-regulation .	target	0
16842	10898494	7409;5594	Vav;ERK	Indirect evidence suggests that ***Vav*** ***interacts*** with the ***Ras/ERK*** pathway in T cells .	parallel	1
16843	10898494	7409;5594	Vav;ERK	Similarly to Ras , ***Vav*** ***cooperated*** with constitutively active calcineurin and with ***ERK*** to activate NFAT , and was capable of up-regulating CD69 expression in T cells .	parallel	0
16844	10898498	3824;3133	CD94;HLA-E	The overall effect of ***CD94/NKG2*** ***interaction*** with ***HLA-E*** is inhibition of cytotoxicity by decidual NK cells .	parallel	1
16845	10898498	3821;3133	NKG2;HLA-E	The overall effect of ***CD94/NKG2*** ***interaction*** with ***HLA-E*** is inhibition of cytotoxicity by decidual NK cells .	parallel	1
16846	10898498	3821;3824	NKG2;CD94	The overall effect of ******CD94/NKG2****** ***interaction*** with HLA-E is inhibition of cytotoxicity by decidual NK cells .	parallel	1
16847	10898505	3586;940	IL-10;CD28	***IL-10*** ***inhibited*** tyrosine phosphorylation of ***CD28*** ; thus , the phosphatidylinositol 3-kinase binding to CD28 was blocked .	negative	1
16848	10898514	1019;896	cdk4;cyclin D3	The decrease in cdk4 activity was concurrent with reduced levels of cyclin D3 protein and a decrease in the fraction of ***cdk4*** ***associated*** with ***cyclin D3*** .	parallel	0
16849	10898749	796;4586	CGRP;mucin	***CGRP*** ***modulates*** ***mucin*** synthesis in surface mucus cells of rat gastric oxyntic mucosa .	target	0
16850	10898749	796;4586	CGRP;mucin	***CGRP*** ***activated*** the ***mucin*** biosynthesis in the surface mucus cells .	positive	1
16851	10898789	56998;1499	ICAT;beta-catenin	Here , we identify a novel beta-catenin-interacting protein , ***ICAT*** , that was found to ***inhibit*** the interaction of ***beta-catenin*** with TCF-4 and represses beta-catenin-TCF-4-mediated transactivation .	negative	1
16852	10898789	1499;6934	beta-catenin;TCF-4	Here , we identify a novel beta-catenin-interacting protein , ICAT , that was found to inhibit the ***interaction*** of ***beta-catenin*** with ***TCF-4*** and represses beta-catenin-TCF-4-mediated transactivation .	parallel	1
16853	10898794	9988;1029	DMP1;ARF	The ***DMP1*** transcription factor ***induces*** the ***ARF*** tumor suppressor gene in mouse fibroblasts , leading to cell cycle arrest in a p53-dependent manner .	target	1
16854	10898795	54880;604	BCoR;BCL-6	The specificity of the ******BCL-6/BCoR****** ***interaction*** suggests that BCoR may have a role in BCL-6-associated lymphomas .	parallel	1
16855	10898795	604;54880	BCL-6;BCoR	Additionally , ***interactions*** between the ***BCL-6*** POZ domain and SMRT , N-CoR , and ***BCoR*** are mutually exclusive .	parallel	1
16856	10898795	604;9611	BCL-6;N-CoR	Additionally , ***interactions*** between the ***BCL-6*** POZ domain and SMRT , ***N-CoR*** , and BCoR are mutually exclusive .	parallel	1
16857	10898795	604;9612	BCL-6;SMRT	Additionally , ***interactions*** between the ***BCL-6*** POZ domain and ***SMRT*** , N-CoR , and BCoR are mutually exclusive .	parallel	1
16858	10898795	54880;9611	BCoR;N-CoR	Additionally , ***interactions*** between the BCL-6 POZ domain and SMRT , ***N-CoR*** , and ***BCoR*** are mutually exclusive .	parallel	1
16859	10898795	54880;9612	BCoR;SMRT	Additionally , ***interactions*** between the BCL-6 POZ domain and ***SMRT*** , N-CoR , and ***BCoR*** are mutually exclusive .	parallel	1
16860	10898795	9612;9611	SMRT;N-CoR	Additionally , ***interactions*** between the BCL-6 POZ domain and ***SMRT*** , ***N-CoR*** , and BCoR are mutually exclusive .	parallel	1
16861	10898801	4233;3082	c-met;HGF	We also used RT-PCR to analyze the expression patterns of the four tyrosine kinase FGF receptors ( FGFR1-FGFR4 ) and of the ***HGF*** ***receptor*** ( ***c-met*** ) in the myofiber cultures .	parallel	1
16862	10898936	3487;3481	IGFBP-4;IGF-II	Taken together , these findings provided strong evidence that the ***interaction*** between ***IGF-II*** and ***IGFBP-4*** , rather than the direct interaction between IGF-II and IGFBP-4 protease , is required for optimal IGFBP-4 proteolysis .	parallel	1
16863	10898936	3481;3487	IGF-II;IGFBP-4	This study sought to define the mechanism by which ***IGF-II*** ***enhances*** ***IGFBP-4*** proteolysis .	positive	0
16864	10898936	3487;3481	IGFBP-4;IGF-II	To further confirm that the ***interaction*** between ***IGF-II*** and ***IGFBP-4*** is required for IGFBP-4 protease activity , we prepared IGFBP-4 mutants , which contained the intact cleavage site ( Met135-Lys136 ) but lacked the IGF binding activity , by deleting the residues Leu72-His74 in the IGF binding domain or Cys183-Glu237 that contained an IGF binding enhancing motif .	parallel	1
16865	10898980	608;10673	BCMA;BLyS	Here we report a novel ***interaction*** between ***BLyS*** and another TNFR homologue , ***BCMA*** ( B cell maturation antigen ) [ 7 ] [ 8 ] .	parallel	1
16866	10898980	8741;608	APRIL;BCMA	Further , the TNF homologue ***APRIL*** [ 9 ] , a close relative of BLyS , also ***bound*** to ***BCMA*** and TACI .	parallel	1
16867	10898980	8741;23495	APRIL;TACI	Further , the TNF homologue ***APRIL*** [ 9 ] , a close relative of BLyS , also ***bound*** to BCMA and ***TACI*** .	parallel	1
16868	10898980	8741;4790	APRIL;NF-kappaB	BLyS or ***APRIL*** ***activated*** nuclear factor-kappaB ( ***NF-kappaB*** ) through TACI and BCMA , and each ligand stimulated immunoglobulin M ( IgM ) production by peripheral blood B cells .	positive	1
16869	10898980	10673;4790	BLyS;NF-kappaB	***BLyS*** or APRIL ***activated*** nuclear factor-kappaB ( ***NF-kappaB*** ) through TACI and BCMA , and each ligand stimulated immunoglobulin M ( IgM ) production by peripheral blood B cells .	positive	1
16870	10899077	1636;183	ACE;AGT	Furthermore , a significant ( P = 0.022 ) interaction ***effect*** between the ***AGT*** and ***ACE*** genes was noted for DBP ( 50 ) ; the AGT TT homozygotes carrying the ACE D allele showed no response to training .	parallel	0
16871	10899077	1636;183	ACE;AGT	These data suggest that , in men , the genetic variation in the AGT locus modifies the responsiveness of submaximal exercise DBP to endurance training , and ***interactions*** between the ***AGT*** and ***ACE*** loci can alter this response .	parallel	1
16872	10899080	1489;4843	CT-1;iNOS	Northern blot and RT-PCR analyses revealed that ***CT-1*** ***increased*** expression of inducible nitric oxide synthase ( ***iNOS*** ) in lung and aorta but not in heart or liver .	positive	0
16873	10899080	1489;4879	CT-1;BNP	Interestingly , ***CT-1*** ***increased*** ventricular expression of ANP and brain natriuretic peptide ( ***BNP*** ) .	positive	0
16874	10899080	1489;4879	CT-1;BNP	The data demonstrate that CT-1 elicits its hypotensive effect via a nitric oxide-dependent mechanism and that ***CT-1*** ***induces*** ANP and ***BNP*** mRNA expression in vivo .	target	1
16875	10899111	6814;6517	Munc18c;GLUT4	However , at the non-permissive temperature ( 37 degrees C ) only ***Munc18c/WT*** ***inhibited*** ***GLUT4/IRAP*** translocation whereas Munc18c/TS was without effect .	negative	1
16876	10899111	6814;4012	Munc18c;IRAP	However , at the non-permissive temperature ( 37 degrees C ) only ***Munc18c/WT*** ***inhibited*** ***GLUT4/IRAP*** translocation whereas Munc18c/TS was without effect .	negative	1
16877	10899111	6814;6810	Munc18c;syntaxin 4	Moreover , ***Munc18c/WT*** ***bound*** to ***syntaxin 4*** at both 23 and 37 degrees C whereas Munc18c/TS bound syntaxin 4 only at 23 degrees C.	parallel	1
16878	10899114	4671;3208	NAIP;hippocalcin	***NAIP*** ***interacts*** with ***hippocalcin*** and protects neurons against calcium-induced cell death through caspase-3-dependent and - independent pathways .	parallel	1
16879	10899114	4671;3208	NAIP;hippocalcin	Here we report that ***NAIP*** , through its third baculovirus inhibitory repeat domain ( BIR3 ) , ***binds*** the neuron-restricted calcium-binding protein , ***hippocalcin*** , in an interaction promoted by calcium .	parallel	1
16880	10899117	3458;4790	IFN-gamma;NF-kappaB	Furthermore , dsRNA + ***IFN-gamma*** ***stimulate*** inducible nitric oxide synthase expression , IkappaB degradation and ***NF-kappaB*** nuclear localization to similar levels in macrophages isolated from PKR ( - / - ) and PKR ( + / + ) mice .	positive	0
16881	10899127	5478;7046	Cyclophilin A;Ess1	We also show that overexpression of ***Cyclophilin A*** ***suppresses*** ***Ess1*** conditional and null mutations , and that Cyclophilin A enzymatic activity is required for suppression .	negative	1
16882	10899134	2237;5111	FEN1;PCNA	Two modes of ***FEN1*** ***binding*** to ***PCNA*** regulated by DNA .	parallel	1
16883	10899134	5111;2237	PCNA;FEN1	Like many other proliferating cell nuclear antigen ( PCNA ) - binding proteins , FEN1 interacts with the interdomain connector loop ( IDCL ) of PCNA , and ***PCNA*** greatly ***stimulates*** ***FEN1*** activity .	positive	0
16884	10899134	5111;2237	PCNA;FEN1	In this DNA-dependent binding assay , ***PCNA-79*** also ***stabilized*** retention of ***FEN1*** , but PCNA-90 was inactive .	positive	0
16885	10899134	2237;5111	FEN1;PCNA	Therefore , in the absence of DNA , ***FEN1*** ***interacts*** with ***PCNA*** mainly through the IDCL .	parallel	1
16886	10899165	7707;2033	ZBP-89;p300	This same deletion mutant abolished the ***ZBP-89*** ***interaction*** with ***p300*** .	parallel	1
16887	10899165	2033;1026	p300;p21	Cotransfection of ***p300*** with ZBP-89 ***stimulated*** the ***p21*** ( waf1 ) promoter in the absence of butyrate .	positive	0
16888	10899165	7707;2033	Transcription factor ZBP-89;histone acetyltransferase p300	***Transcription factor ZBP-89*** ***cooperates*** with ***histone acetyltransferase p300*** during butyrate activation of p21waf1 transcription in human cells .	parallel	0
16889	10899165	2033;6667	p300;Sp1	Although Sp1 and Sp3 collaborate with p300 , a direct ***interaction*** between ***Sp1*** and ***p300*** does not occur .	parallel	1
16890	10899169	4790;6290	NFkappaB;SAA3	Therefore , the molecular basis for the functional synergy between SEF and NFkappaB may , in part , be the ability of SEF to recruit NFkappaB through physical interactions that lead to enhancement or stabilization of ***NFkappaB*** ***binding*** to the ***SAA3*** promoter element .	parallel	1
16891	10899169	7024;6290	SEF;SAA3	When SEF-transfected cells were further stimulated with conditioned medium or interleukin-1 , SAA3 promoter activity was dramatically increased , suggesting that ***SEF*** may cooperate functionally with other interleukin-1-inducible transcription factors to synergistically ***up-regulate*** ***SAA3*** gene transcription .	positive	1
16892	10899169	7024;4790	SEF;NFkappaB	Functional cooperation between SEF and NFkappaB was further strengthened by the finding that ***SEF*** and ***NFkappaB*** formed stable cytokine-inducible protein-protein ***complexes*** .	parallel	1
16893	10899169	4790;7024	NFkappaB;SEF	Functional ***cooperation*** between ***SEF*** and ***NFkappaB*** was further strengthened by the finding that SEF and NFkappaB formed stable cytokine-inducible protein-protein complexes .	parallel	0
16894	10899172	6853;6714	synapsin I;Src	Specificity of the ***binding*** of ***synapsin I*** to ***Src*** homology 3 domains .	parallel	1
16895	10899288	4915;627	TrkB;BDNF	Truncated ***TrkB*** ***mediates*** the endocytosis and release of ***BDNF*** and neurotrophin-4/5 by rat astrocytes and schwann cells in vitro .	target	0
16896	10899288	4915;4909	TrkB;neurotrophin-4/5	Truncated ***TrkB*** ***mediates*** the endocytosis and release of BDNF and ***neurotrophin-4/5*** by rat astrocytes and schwann cells in vitro .	target	0
16897	10899310	10254;3717	STAM2;Jak2	***STAM2*** like STAM1 is ***associated*** with ***Jak2*** and Jak3 , and involved in the signaling for DNA synthesis and c-myc induction mediated by IL-2 and GM-CSF .	parallel	0
16898	10899310	10254;3718	STAM2;Jak3	***STAM2*** like STAM1 is ***associated*** with Jak2 and ***Jak3*** , and involved in the signaling for DNA synthesis and c-myc induction mediated by IL-2 and GM-CSF .	parallel	0
16899	10899322	920;3700	CD4;gp120	HIV-1 external envelope glycoprotein gp120 inhibits adenosine deaminase ( ADA ) binding to its cell surface receptor in lymphocytes , CD26 , by a mechanism that does not require the ******gp120-CD4****** ***interaction*** .	parallel	1
16900	10899322	3700;920	gp120;CD4	These data suggest that the interaction of gp120 with CD4 or CXCR4 is required for efficient inhibition of ADA binding to CD26 , although in the presence of CXCR4 the ***interaction*** of ***gp120*** with ***CD4*** may be dispensable .	parallel	1
16901	10899322	3700;7852	gp120;CXCR4	These data suggest that the ***interaction*** of ***gp120*** with CD4 or ***CXCR4*** is required for efficient inhibition of ADA binding to CD26 , although in the presence of CXCR4 the interaction of gp120 with CD4 may be dispensable .	parallel	1
16902	10899704	3458;6095	IFN-gamma;ROR alpha	However , in U937 cells activated with ***IFN-gamma*** , which ***induces*** the expression of the ***ROR alpha*** 1 and ROR alpha 2 nuclear receptors and represses the expression of the mt1 receptor , melatonin can activate IL-6 production .	target	1
16903	10899763	51497;3497	Th1;IgE	BACKGROUND : Although Candida albicans ( CA ) is known to induce ***Th1*** clones that ***suppress*** ***IgE*** synthesis , serum IgE antibody against CA is often increased in atopic patients .	negative	1
16904	10899765	356;355	FasL;Fas	The ***Fas-Fas*** ***ligand*** ( ***FasL*** ) system is one of the representative systems of apoptosis-signaling receptor molecules , and is involved in various inflammatory diseases .	parallel	1
16905	10899837	9739;3569	SET1;interleukin-6	Recombinant ***SET1*** ***stimulated*** the production of interleukin-1beta , ***interleukin-6*** , and tumor necrosis factor alpha by human peripheral blood mononuclear cells .	positive	0
16906	10899837	9739;7124	SET1;tumor necrosis factor alpha	Recombinant ***SET1*** ***stimulated*** the production of interleukin-1beta , interleukin-6 , and ***tumor necrosis factor alpha*** by human peripheral blood mononuclear cells .	positive	0
16907	10899843	6804;928	Stx1A;p24	***Stx1A*** ***inhibited*** expression of BLV ***p24*** protein by PBMC .	negative	1
16908	10899931	5008;3569	Oncostatin M;interleukin-6	***Oncostatin M*** ***regulation*** of ***interleukin-6*** expression in astrocytes : biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38 .	target	1
16909	10899933	5663;351	PS1;APP	We demonstrate that the D257A and the D385A ***PS1*** mutations , which had been shown previously to ***block*** ***APP*** gamma-secretase activity , also prevent notch1 cleavage and translocation to the nucleus but do not alter notch1 trafficking to the cell surface .	positive	0
16910	10899933	5663;4851	PS1;notch1	We demonstrate that the D257A and the D385A ***PS1*** mutations , which had been shown previously to block APP gamma-secretase activity , also ***prevent*** ***notch1*** cleavage and translocation to the nucleus but do not alter notch1 trafficking to the cell surface .	positive	0
16911	10899937	4137;836	microtubule-associated protein tau;caspase-3	The neuronal ***microtubule-associated protein tau*** is a ***substrate*** for ***caspase-3*** and an effector of apoptosis .	parallel	1
16912	10899938	3569;5594	interleukin-6;ERK	The inhibitory effects of ***interleukin-6*** on synaptic plasticity in the rat hippocampus are ***associated*** with an inhibition of mitogen-activated protein kinase ***ERK*** .	parallel	0
16913	10899942	5578;3643	protein kinase C-alpha;insulin receptor	***Up-regulation*** of cell surface ***insulin receptor*** by ***protein kinase C-alpha*** in adrenal chromaffin cells : involvement of transcriptional and translational events .	positive	1
16914	10899943	596;598	Bcl-2;Bcl-x	These findings suggest a pathway where NFkappaB activation ***induces*** overexpression of ***Bcl-2*** and ***Bcl-x*** , which function to prevent apoptotic cell death following H/R treatments .	target	1
16915	10899943	598;596	Bcl-x;Bcl-2	These findings suggest a pathway where NFkappaB activation ***induces*** overexpression of ***Bcl-2*** and ***Bcl-x*** , which function to prevent apoptotic cell death following H/R treatments .	target	1
16916	10899943	4790;596	NFkappaB;Bcl-2	These findings suggest a pathway where ***NFkappaB*** activation ***induces*** overexpression of ***Bcl-2*** and Bcl-x , which function to prevent apoptotic cell death following H/R treatments .	target	1
16917	10899943	4790;598	NFkappaB;Bcl-x	These findings suggest a pathway where ***NFkappaB*** activation ***induces*** overexpression of Bcl-2 and ***Bcl-x*** , which function to prevent apoptotic cell death following H/R treatments .	target	1
16918	1089999	6750;2641	somatostatin;Glucagon	***Glucagon*** ***suppression*** by ***somatostatin*** reduces or abolishes hyperglycemia in dogs made insulin-deficient by somatostatin , alloxan , or total pancreatectomy .	negative	1
16919	10900006	974;973	Ig-beta;Ig-alpha	The B cell antigen receptor ( BCR ) is a multiprotein complex consisting of the membrane-bound Ig molecule and the ******Ig-alpha/Ig-beta****** ***heterodimer*** .	parallel	1
16920	10900013	4790;1104	NF-kappaB;cell-cycle regulatory protein	***NF-kappaB*** ***transactivates*** the ***cell-cycle regulatory protein*** , cyclin D1 , which causes increased phosphorylation of retinoblastoma protein , more strongly in ER - cells .	positive	1
16921	10900017	11337;10243	GABARAP;gephyrin	The gamma-aminobutyric acid type A receptor ( GABAAR ) - associated protein ***GABARAP*** ***interacts*** with ***gephyrin*** but is not involved in receptor anchoring at the synapse .	parallel	1
16922	10900017	11337;10243	GABARAP;gephyrin	Here we show that ***GABARAP*** ***interacts*** with ***gephyrin*** in both biochemical assays and transfected cells .	parallel	1
16923	10900017	10243;11337	gephyrin;GABARAP	Our data indicate that ******GABARAP-gephyrin****** ***interactions*** are not important for postsynaptic GABA ( A ) R anchoring but may be implicated in receptor sorting and/or targeting mechanisms .	parallel	1
16924	10900076	4915;627	trkB;Brain-derived neurotrophic factor	To begin to understand downstream or parallel signaling pathways required for the PKA-mediated induction of serotonergic markers , we have studied the putative implication of ***Brain-derived neurotrophic factor*** ( BDNF ) and its ***receptor*** ***trkB*** .	parallel	1
16925	10900093	2065;2064	ErbB-3;ErbB-2	Because neuregulin-3 that signals only through ErbB-4 does not show an effect , these data suggest that activation of the ******ErbB-2-ErbB-3****** heterodimeric ***complexes*** , rather than ErbB-4 , is critical for the proliferative response in the utricular sensory epithelium .	parallel	1
16926	10900142	1469;1075	cystatin SN;cathepsin C	Differential effect toward ***inhibition*** of papain and ***cathepsin C*** by recombinant human salivary ***cystatin SN*** and its variants produced by a baculovirus system .	negative	1
16927	10900149	7025;7026	COUP-TFI;ARP-1	In addition , ARP-1/RXR , COUP-TFI/RXR , and ******ARP-1/COUP-TFI****** ***heterodimers*** bound the FP330-3 ' site .	parallel	1
16928	10900163	3426;3075	complement factor I;factor H	Deficiency of human ***complement factor I*** ***associated*** with lowered ***factor H*** .	parallel	0
16929	10900171	2048;2002	ERK;elk-1	***Phosphorylation*** of ***elk-1*** by ***MEK/ERK*** pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy .	target	1
16930	10900171	5609;2002	MEK;elk-1	***Phosphorylation*** of ***elk-1*** by ***MEK/ERK*** pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy .	target	1
16931	10900171	2048;2002	ERK;elk-1	These studies implicate that ***phosphorylation*** of ***elk-1*** by ***ERK*** kinase pathway is important for early gene activation during phenylephrine-induced myocyte hypertrophy .	target	1
16932	10900176	4790;3383	NF- kappa B;intercellular adhesion molecule-1	***NF- kappa B*** independent ***suppression*** of endothelial vascular cell adhesion molecule-1 and ***intercellular adhesion molecule-1*** gene expression by inhibition of flavin binding proteins and superoxide production .	negative	1
16933	10900176	4790;7412	NF- kappa B;vascular cell adhesion molecule-1	***NF- kappa B*** independent ***suppression*** of endothelial ***vascular cell adhesion molecule-1*** and intercellular adhesion molecule-1 gene expression by inhibition of flavin binding proteins and superoxide production .	negative	1
16934	10900176	3383;7412	ICAM-1;VCAM-1	DPI also inhibited TNF and LPS-induced VCAM-1 and ***ICAM-1*** cell surface expression and TNF - alpha , LPS , or IL-1 beta ***induced*** ***VCAM-1*** and ICAM-1 mRNA accumulation .	target	1
16935	10900195	998;7431	Cdc42Hs;vimentin	These data indicate that ***Cdc42Hs*** and Rac1 GTPases ***control*** ***vimentin*** IF organization involving tyrosine phosphorylation events .	target	0
16936	10900195	5879;7431	Rac1;vimentin	These data indicate that Cdc42Hs and ***Rac1*** GTPases ***control*** ***vimentin*** IF organization involving tyrosine phosphorylation events .	target	0
16937	10900195	3827;998	bradykinin;Cdc42Hs	Similar vimentin IF modifications were observed when endogenous ***Cdc42Hs*** was ***activated*** by ***bradykinin*** treatment , endogenous Rac1 by platelet-derived growth factor/epidermal growth factor , or both endogenous proteins upon expression of active RhoG .	positive	1
16938	10900205	4313;7057	MMP2;TSP1	Although ***MMP2*** ***interacted*** with ***TSP1*** and TSP2 via its gelatin-binding domain or a closely mapping site , neither TSP1 nor TSP2 was degraded by MMP2 in vitro .	parallel	1
16939	10900205	4313;7058	MMP2;TSP2	Although ***MMP2*** ***interacted*** with TSP1 and ***TSP2*** via its gelatin-binding domain or a closely mapping site , neither TSP1 nor TSP2 was degraded by MMP2 in vitro .	parallel	1
16940	10900205	4314;4318	MMP3;MMP9	The ability of TSP1 to inhibit ***MMP3-dependent*** ***activation*** of ***pro-MMP9*** and thrombin-induced activation of pro-MMP2 suggests that the TSPs may inhibit MMP activity by preventing activation of the MMP2 and MMP9 zymogens .	positive	1
16941	10900208	56993;10452	1C9-2;TOM40	Blue native polyacrylamide gel electrophoresis of digitonin-solubilized outer membranes revealed that ***1C9-2*** is firmly ***associated*** with ***TOM40*** in the approximately 400-kDa complex , with a size and composition similar to those of the fungal TOM core complex .	parallel	0
16942	10900231	5966;4790	Rel;NF-kappaB	Our data also show that the p38 kinase pathway is specifically involved in LPS-induced NF-kappaB/Rel activation and iNOS expression because ******NF-kappaB/Rel****** DNA ***binding*** and iNOS mRNA production in the presence of a specific inhibitor of p38 kinase , SB203580 , were dramatically diminished .	parallel	1
16943	10900332	4914;4803	TrkA;NGF	Nerve growth factor ( ***NGF*** ) and its signal-transducing ***receptor*** ***TrkA*** are expressed in the thymus .	parallel	1
16944	10900358	3627;2833	IP-10;CXCR3	Here we report the presence of the chemokine receptor ***CXCR3*** and its ***ligand*** , ***IP-10*** , in normal and Alzheimer 's disease ( AD ) brains .	parallel	1
16945	10900358	3627;5594	IP-10;ERK1/2	Moreover , we showed that CXCR3 ligands , ***IP-10*** and Mig , were able to ***activate*** ***ERK1/2*** pathway in mouse cortical neurons , suggesting a novel mechanism of neuronal-glial interaction .	positive	1
16946	10900358	4283;5594	Mig;ERK1/2	Moreover , we showed that CXCR3 ligands , IP-10 and ***Mig*** , were able to ***activate*** ***ERK1/2*** pathway in mouse cortical neurons , suggesting a novel mechanism of neuronal-glial interaction .	positive	1
16947	10900358	3627;2833	IP-10;CXCR3	Moreover , we showed that ***CXCR3*** ***ligands*** , ***IP-10*** and Mig , were able to activate ERK1/2 pathway in mouse cortical neurons , suggesting a novel mechanism of neuronal-glial interaction .	parallel	1
16948	10900358	4283;2833	Mig;CXCR3	Moreover , we showed that ***CXCR3*** ***ligands*** , IP-10 and ***Mig*** , were able to activate ERK1/2 pathway in mouse cortical neurons , suggesting a novel mechanism of neuronal-glial interaction .	parallel	1
16949	10901160	5970;4790	p65;p50	This may be due to formation of ******p50/p65****** ***heterodimer*** , which is mainly inducible NFkappaB .	parallel	1
16950	10901161	3604;3725	CD137;c-jun	***Activation*** of ***c-jun*** N-terminal kinase by 4-1BB ( ***CD137*** ) , a T cell co-stimulatory molecule .	positive	1
16951	10903152	7818;2908	death-associated protein 3;glucocorticoid receptor	The pro-apoptotic protein ***death-associated protein 3*** ( DAP3 ) ***interacts*** with the ***glucocorticoid receptor*** and affects the receptor function .	parallel	1
16952	10903204	5861;8615	Rab1;p115	***Rab1*** ***recruitment*** of ***p115*** into a cis-SNARE complex : programming budding COPII vesicles for fusion .	target	0
16953	10903204	5861;8615	Rab1;p115	***Rab1*** ***recruited*** ***p115*** to coat protein complex II ( COPII ) vesicles during budding from the endoplasmic reticulum , where it interacted with a select set of COPII vesicle-associated SNAREs ( soluble N-ethylmaleimide-sensitive factor attachment protein receptors ) to form a cis-SNARE complex that promotes targeting to the Golgi apparatus .	target	0
16954	10903311	6281;302	p11;annexin II	This increase was accompanied by the redistribution of caveolin from a high density to a low density membrane compartment , previously shown to require cholesterol , and increased binding of the ******annexin II-p11****** ***complex*** to membranes , consistent with other studies indicating cholesterol-dependent binding of annexin II to membranes .	parallel	1
16955	10903323	7124;7040	TNF-alpha;TGF-beta	Expression of antisense c-Jun mRNA prevents ***TNF-alpha*** ***inhibition*** of ***TGF-beta/Smad*** signaling whereas that of dominant-negative Ikappa-B kinase-alpha or antisense Smad7 does not .	negative	1
16956	10903323	3725;4088	c-Jun;Smad3	We provide evidence for off-DNA ***interactions*** between ***Smad3*** and both ***c-Jun*** and JunB accompanied with reduced Smad3-DNA interactions .	parallel	1
16957	10903323	3725;7040	AP-1;TGF-beta	Finally , we show that overexpression of the transcriptional co-activator p300 prevents ***TNF-alpha/AP-1*** ***inhibition*** of ***TGF-beta/Smad*** signaling .	negative	1
16958	10903323	7124;7040	TNF-alpha;TGF-beta	Finally , we show that overexpression of the transcriptional co-activator p300 prevents ***TNF-alpha/AP-1*** ***inhibition*** of ***TGF-beta/Smad*** signaling .	negative	1
16959	10903323	2033;3725	p300;AP-1	Finally , we show that overexpression of the transcriptional co-activator ***p300*** ***prevents*** ***TNF-alpha/AP-1*** inhibition of TGF-beta/Smad signaling .	negative	0
16960	10903323	2033;7124	p300;TNF-alpha	Finally , we show that overexpression of the transcriptional co-activator ***p300*** ***prevents*** ***TNF-alpha/AP-1*** inhibition of TGF-beta/Smad signaling .	negative	0
16961	10903324	27297;796	RCP;CGRP	We have previously shown that this accessory protein , the CGRP-receptor component protein ( RCP ) , is expressed in CGRP responsive tissues and that ***RCP*** protein expression ***correlates*** with the biological efficacy of ***CGRP*** in vivo .	parallel	0
16962	10903324	27297;10203	RCP;CRLR	A candidate CGRP receptor named calcitonin receptor-like receptor ( CRLR ) has been identified , and in this study ***RCP*** ***co-immunoprecipitated*** with ***CRLR*** indicating that these two proteins interact directly .	parallel	1
16963	10903423	650;1026	Bone morphogenetic protein-2;p21	***Bone morphogenetic protein-2*** ***induces*** cyclin kinase inhibitor ***p21*** and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells .	target	1
16964	10903423	650;1026	BMP-2;p21	***BMP-2*** significantly ***increased*** the level of the cyclin kinase inhibitor , ***p21*** , which in turn associated with and inactivated cyclin D1 .	positive	0
16965	10903423	1026;595	p21;cyclin D1	BMP-2 significantly increased the level of the cyclin kinase inhibitor , ***p21*** , which in turn associated with and ***inactivated*** ***cyclin D1*** .	negative	1
16966	10903424	960;10630	CD44;OTS-8	***Association*** of ***CD44*** with ***OTS-8*** in tumor vascular endothelial cells .	parallel	0
16967	10903424	960;10630	CD44;OTS-8	To test for a possible interaction between the two antigens on endothelial cells in tumor angiogenesis , we examined in vivo ***association*** of ***CD44*** with ***OTS-8*** using lysates of isolated rat TEC and COS-7 cells cotransfected with CD44 and OTS-8 expression plasmids .	parallel	0
16968	10903424	10630;960	OTS-8;CD44	Immunoblot analysis showed a crosslinked ******CD44/OTS-8****** protein ***complex*** of 120 kDa , suggesting the proximity of the two proteins .	parallel	1
16969	10903424	10630;960	OTS-8;CD44	These findings provide evidence of a weak physical ***association*** between ***CD44*** and ***OTS-8*** in TEC , and suggest that OTS-8 may alter the mode of endothelial cell growth and/or migration induced by CD44 in tumor angiogenesis .	parallel	0
16970	10903433	4904;355	YB-1;fas	We have shown that ***YB-1*** is a ***repressor*** of a cell death-associated gene ***fas*** .	negative	1
16971	10903433	3725;355	AP-1;fas	***Regulation*** of the human ***fas*** promoter by YB-1 , Puralpha and ***AP-1*** transcription factors .	target	1
16972	10903433	5813;355	Puralpha;fas	***Regulation*** of the human ***fas*** promoter by YB-1 , ***Puralpha*** and AP-1 transcription factors .	target	1
16973	10903433	4904;355	YB-1;fas	***Regulation*** of the human ***fas*** promoter by ***YB-1*** , Puralpha and AP-1 transcription factors .	target	1
16974	10903433	5813;355	Puralpha;fas	YB-1 and ***Puralpha*** are transcriptional ***repressors*** of ***fas*** and decreased basal transcription by 60-fold in reporter gene assays .	negative	1
16975	10903433	4904;355	YB-1;fas	***YB-1*** and Puralpha are transcriptional ***repressors*** of ***fas*** and decreased basal transcription by 60-fold in reporter gene assays .	negative	1
16976	10903500	5594;2002	p38;Elk1	Expression of immediate early gene pip92 during anisomycin-induced cell death is mediated by the JNK - and ***p38-dependent*** ***activation*** of ***Elk1*** .	positive	1
16977	10903508	5757;3005	prothymosin alpha;histone H1	Our data suggest that the modes of ***prothymosin alpha*** ***interaction*** with Rev and ***histone H1*** are distinct and that the observed zinc and calcium-binding properties of prothymosin alpha might be functionally relevant .	parallel	1
16978	10903731	3606;6774	IL-18;STAT3	***IL-18*** ***activates*** ***STAT3*** in the natural killer cell line 92 , augments cytotoxic activity , and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21 .	positive	1
16979	10903731	3606;3458	IL-18;IFN-gamma	***IL-18*** activates STAT3 in the natural killer cell line 92 , augments cytotoxic activity , and ***mediates*** ***IFN-gamma*** production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21 .	target	0
16980	10903731	3606;3458	IL-18;IFN-gamma	***IL-18*** alone failed to ***stimulate*** ***IFN-gamma*** protein production despite inducing expression of IFN-gamma mRNA .	positive	0
16981	10903733	608;7185	BCMA;TNF receptor-associated factor (TRAF) 1	TNF receptor family member ***BCMA*** ( B cell maturation ) ***associates*** with ***TNF receptor-associated factor (TRAF) 1*** , TRAF2 , and TRAF3 and activates NF-kappa B , elk-1 , c-Jun N-terminal kinase , and p38 mitogen-activated protein kinase .	parallel	0
16982	10903733	608;10010	BCMA;TRAF2	TNF receptor family member ***BCMA*** ( B cell maturation ) ***associates*** with TNF receptor-associated factor (TRAF) 1 , ***TRAF2*** , and TRAF3 and activates NF-kappa B , elk-1 , c-Jun N-terminal kinase , and p38 mitogen-activated protein kinase .	parallel	0
16983	10903733	608;7187	BCMA;TRAF3	TNF receptor family member ***BCMA*** ( B cell maturation ) ***associates*** with TNF receptor-associated factor (TRAF) 1 , TRAF2 , and ***TRAF3*** and activates NF-kappa B , elk-1 , c-Jun N-terminal kinase , and p38 mitogen-activated protein kinase .	parallel	0
16984	10903733	608;4790	BCMA;NF-kappa B	TNF receptor family member ***BCMA*** ( B cell maturation ) associates with TNF receptor-associated factor (TRAF) 1 , TRAF2 , and TRAF3 and ***activates*** ***NF-kappa B*** , elk-1 , c-Jun N-terminal kinase , and p38 mitogen-activated protein kinase .	positive	1
16985	10903733	608;1432	BCMA;p38 mitogen-activated protein kinase	TNF receptor family member ***BCMA*** ( B cell maturation ) associates with TNF receptor-associated factor (TRAF) 1 , TRAF2 , and TRAF3 and ***activates*** NF-kappa B , elk-1 , c-Jun N-terminal kinase , and ***p38 mitogen-activated protein kinase*** .	positive	1
16986	10903733	608;4790	BCMA;NF-kappa B	We also show that overexpression of ***BCMA*** in 293 cells ***activates*** ***NF-kappa B*** , Elk-1 , the c-Jun N-terminal kinase , and the p38 mitogen-activated protein kinase .	positive	1
16987	10903733	608;1432	BCMA;p38 mitogen-activated protein kinase	We also show that overexpression of ***BCMA*** in 293 cells ***activates*** NF-kappa B , Elk-1 , the c-Jun N-terminal kinase , and the ***p38 mitogen-activated protein kinase*** .	positive	1
16988	10903733	608;10010	BCMA;TRAF2	Coimmunoprecipitation experiments performed in transfected cells showed that ***BCMA*** ***associates*** with TNFR-associated factor ( TRAF ) 1 , ***TRAF2*** , and TRAF3 adaptor proteins .	parallel	0
16989	10903733	608;7187	BCMA;TRAF3	Coimmunoprecipitation experiments performed in transfected cells showed that ***BCMA*** ***associates*** with TNFR-associated factor ( TRAF ) 1 , TRAF2 , and ***TRAF3*** adaptor proteins .	parallel	0
16990	10903734	3479;355	IGF-1;Fas	***IGF-1*** also significantly ***inhibited*** PHA-induced ***Fas*** expression on cord blood T cells .	negative	1
16991	10903735	1616;355	DAXX;Fas	It has been reported that cross-linking Abs to Fas trigger c-Jun N-terminal kinase ( JNK ) signaling via caspase-mediated activation of MEKK1 ( JNK kinase kinase ) , elevation of ceramide levels or by ***recruitment*** of death domain associated protein ( ***DAXX*** ) to ***Fas*** .	target	0
16992	10903735	356;5599	Fas ligand;JNK	Like its ability to induce cell death , ***Fas ligand*** reliably ***activated*** ***JNK*** only upon extensive aggregation of the receptor .	positive	1
16993	10903736	613;3725	BCR;c-Jun	Furthermore , ***BCR-induced*** ***activation*** of ***c-Jun*** NH2-terminal kinase was shown to be significantly enhanced in SHP-1-C/S transfectants .	positive	1
16994	10903736	29760;5777	BLNK;SHP-1	Taken collectively , our results suggest that ***BLNK*** is a physiological ***substrate*** of ***SHP-1*** in B cells and that SHP-1 selectively regulates c-Jun NH2-terminal kinase activation .	parallel	1
16995	10903736	5777;3725	SHP-1;c-Jun	Taken collectively , our results suggest that BLNK is a physiological substrate of SHP-1 in B cells and that ***SHP-1*** selectively ***regulates*** ***c-Jun*** NH2-terminal kinase activation .	target	1
16996	10903737	1493;3558	CTLA-4;IL-2	In contrast , under B7-dependent costimulation , ***inhibition*** of ***IL-2*** production by ***CTLA-4*** engagement was directly proportional to CTLA-4 cell surface levels and did not require its cytoplasmic region .	negative	1
16997	10903743	3565;3627	IL-4;IP-10	***IL-4*** , but not IL-10 or IL-17 , significantly up-regulated IFN-gamma - or TNF-alpha-induced IP-10 , Mig , and I-TAC mRNA accumulation in keratinocytes and ***increased*** the levels of ***IP-10*** and Mig in keratinocyte supernatants .	positive	0
16998	10903743	3565;3627	IL-4;IP-10	***IL-4*** , but not IL-10 or IL-17 , significantly ***up-regulated*** IFN-gamma - or TNF-alpha-induced ***IP-10*** , Mig , and I-TAC mRNA accumulation in keratinocytes and increased the levels of IP-10 and Mig in keratinocyte supernatants .	positive	1
16999	10903743	3458;3627	IFN-gamma;IP-10	In conclusion , IL-4 exerts a proinflammatory function on keratinocytes by potentiating ***IFN-gamma*** and TNF-alpha ***induction*** of ***IP-10*** , Mig , and I-TAC , which in turn may determine a prominent recruitment of CXCR3 + T lymphocytes at inflammatory reaction sites .	target	1
17000	10903743	3458;6373	IFN-gamma;I-TAC	In conclusion , IL-4 exerts a proinflammatory function on keratinocytes by potentiating ***IFN-gamma*** and TNF-alpha ***induction*** of IP-10 , Mig , and ***I-TAC*** , which in turn may determine a prominent recruitment of CXCR3 + T lymphocytes at inflammatory reaction sites .	target	1
17001	10903743	7124;3627	TNF-alpha;IP-10	In conclusion , IL-4 exerts a proinflammatory function on keratinocytes by potentiating IFN-gamma and ***TNF-alpha*** ***induction*** of ***IP-10*** , Mig , and I-TAC , which in turn may determine a prominent recruitment of CXCR3 + T lymphocytes at inflammatory reaction sites .	target	1
17002	10903743	7124;6373	TNF-alpha;I-TAC	In conclusion , IL-4 exerts a proinflammatory function on keratinocytes by potentiating IFN-gamma and ***TNF-alpha*** ***induction*** of IP-10 , Mig , and ***I-TAC*** , which in turn may determine a prominent recruitment of CXCR3 + T lymphocytes at inflammatory reaction sites .	target	1
17003	10903752	925;3458	CD8;IFN-gamma	Soluble ***CD8*** selectively ***inhibited*** CD8 T cell proliferation and ***IFN-gamma*** production and could also attenuate peptide-specific CD8 T cell responses in vivo .	negative	1
17004	10903756	940;3458	CD28;IFN-gamma	Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites : dendritic cell activation after infection with viable parasites results in ***CD28*** and CD40 ligand signaling that ***controls*** IL-12-dependent and - independent T cell production of ***IFN-gamma*** .	target	0
17005	10903756	959;3458	CD40 ligand;IFN-gamma	Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites : dendritic cell activation after infection with viable parasites results in CD28 and ***CD40 ligand*** signaling that ***controls*** IL-12-dependent and - independent T cell production of ***IFN-gamma*** .	target	0
17006	10903756	942;941	CD86;CD80	IL-12-independent IFN-gamma production required ******CD80/CD86-GeneGene****** 6 ***interaction*** and , to a lesser extent , CD40-CD40L signaling .	parallel	1
17007	10903756	958;959	CD40;CD40L	IL-12-independent IFN-gamma production required CD80/CD86-GeneGene 6 interaction and , to a lesser extent , ******CD40-CD40L****** ***signaling*** .	parallel	0
17008	10903756	958;959	CD40;CD40L	Taken together , T. gondii-induced activation of human DC is associated with T cell production of IFN-gamma through CD40-CD40L-dependent release of IL-12 and through CD80/CD86-GeneGene 6 and ******CD40-CD40L****** ***signaling*** that mediate IFN-gamma secretion even in the absence of bioactive IL-12 .	parallel	0
17009	10903756	958;3458	CD40;IFN-gamma	Taken together , T. gondii-induced activation of human DC is associated with T cell production of IFN-gamma through CD40-CD40L-dependent release of IL-12 and through CD80/CD86-GeneGene 6 and ***CD40-CD40L*** signaling that ***mediate*** ***IFN-gamma*** secretion even in the absence of bioactive IL-12 .	target	0
17010	10903756	959;3458	CD40L;IFN-gamma	Taken together , T. gondii-induced activation of human DC is associated with T cell production of IFN-gamma through CD40-CD40L-dependent release of IL-12 and through CD80/CD86-GeneGene 6 and ***CD40-CD40L*** signaling that ***mediate*** ***IFN-gamma*** secretion even in the absence of bioactive IL-12 .	target	0
17011	10903756	941;3458	CD80;IFN-gamma	Taken together , T. gondii-induced activation of human DC is associated with T cell production of IFN-gamma through CD40-CD40L-dependent release of IL-12 and through ***CD80/CD86-GeneGene*** 6 and CD40-CD40L signaling that ***mediate*** ***IFN-gamma*** secretion even in the absence of bioactive IL-12 .	target	0
17012	10903756	942;3458	CD86;IFN-gamma	Taken together , T. gondii-induced activation of human DC is associated with T cell production of IFN-gamma through CD40-CD40L-dependent release of IL-12 and through ***CD80/CD86-GeneGene*** 6 and CD40-CD40L signaling that ***mediate*** ***IFN-gamma*** secretion even in the absence of bioactive IL-12 .	target	0
17013	10903757	959;958	CD40L;CD40	The ******CD40-CD40L****** ***interaction*** , which is not evident in lepromatous leprosy , probably participates in the cell-mediated immune response to microbial pathogens .	parallel	1
17014	10903757	959;958	CD40 ligand;CD40	A role for ******CD40-CD40 ligand****** ***interactions*** in the generation of type 1 cytokine responses in human leprosy .	parallel	1
17015	10903757	958;959	CD40;CD40L	In contrast , M. leprae-induced IL-12 production by PBMC from lepromatous patients was not dependent on ******CD40L-CD40****** ***ligation*** , nor was CD40L up-regulated by M. leprae .	parallel	1
17016	10903757	3458;958	IFN-gamma;CD40	Furthermore , IL-10 , a cytokine predominant in lepromatous lesions , blocked the ***IFN-gamma*** ***up-regulation*** of ***CD40*** on monocytes .	positive	1
17017	10903757	3586;3458	IL-10;IFN-gamma	Furthermore , ***IL-10*** , a cytokine predominant in lepromatous lesions , ***blocked*** the ***IFN-gamma*** up-regulation of CD40 on monocytes .	negative	0
17018	10903761	4790;5970	p50;p65	These data indicate that CQ inhibits TNF-alpha gene expression without altering translocation of NF-kappaB ******p50/p65****** ***heterodimers*** .	parallel	1
17019	10903763	1232;3627	chemokine receptor 3;gamma IP-10	CXC ***chemokine receptor 3*** ( CXCR3 ) , predominately expressed on memory/activated T lymphocytes , is a ***receptor*** for both IFN-gamma-inducible protein-10 ( ***gamma IP-10*** ) and monokine induced by IFN-gamma ( Mig ) .	parallel	1
17020	10903763	3586;2833	IL-10;CXCR3	Correspondingly , ***CXCR3*** protein and mRNA expressions in eosinophils are up - and ***down-regulated*** by IL-2 and ***IL-10*** , respectively , as detected using flow cytometry , immunocytochemical assay , and a real-time quantitative RT-PCR technique .	negative	1
17021	10903763	3558;2833	IL-2;CXCR3	Correspondingly , ***CXCR3*** protein and mRNA expressions in eosinophils are up - and ***down-regulated*** by ***IL-2*** and IL-10 , respectively , as detected using flow cytometry , immunocytochemical assay , and a real-time quantitative RT-PCR technique .	negative	1
17022	10903771	6774;3586	Stat3;IL-10	Our results show that ***Stat3*** , by binding to a single motif in the IL-10 promoter , is ***controlling*** expression of the human ***IL-10*** gene .	target	0
17023	10903772	3553;1437	IL-1beta;GM-CSF	TNF-alpha , ***IL-1beta*** , and PMA ***induced*** the release of ***GM-CSF*** in HBECs .	target	1
17024	10903772	7124;1437	TNF-alpha;GM-CSF	***TNF-alpha*** , IL-1beta , and PMA ***induced*** the release of ***GM-CSF*** in HBECs .	target	1
17025	10903772	7124;1437	TNF-alpha;GM-CSF	PMA and ***TNF-alpha*** ***stimulation*** of ***GM-CSF*** required activation of PKC ( inhibition by staurosporine and bisindolylmaleimide I ) .	positive	0
17026	10903780	959;3458	CD40 ligand;IFN-gamma	***CD40 ligand*** trimer and IL-12 ***enhance*** peripheral blood mononuclear cells and CD4 + T cell proliferation and production of ***IFN-gamma*** in response to p24 antigen in HIV-infected individuals : potential contribution of anergy to HIV-specific unresponsiveness .	positive	0
17027	10903796	3439;5551	IFN-alpha;perforin	***IFN-alpha*** ***increased*** ***perforin*** gene expression ( p < 0.003 ) , but this was not correlated with outcome .	positive	0
17028	10903798	3458;3606	IFN-gamma;IL-18	***IL-18*** mRNA was constitutively expressed in RIN cells , in FACS-purified rat beta-cells and in intact rat and mouse islets , and was ***up-regulated*** by ***IFN-gamma*** in an interferon regulatory factor-1 - IRF-1 ) and NO - independent manner .	positive	1
17029	10903798	3606;3553	IL-18;IL-1 beta	Since species differences have been shown between human and murine IL-18 , the aims of this study were to investigate 1 ) if species homologous IL-18 alone or following IL-12 pre-exposure affected rat islet function , 2 ) if ***IL-18*** dose-dependently ***modulated*** ***IL-1 beta*** or interferon-gamma ( IFN-gamma ) + tumor necrosis factor-alpha ( TNF-alpha ) actions on islet function , and 3 ) if IL-18 and IL-18 receptor ( IL-18R ) were expressed in rat islet beta-cells .	target	0
17030	10903798	3606;3458	IL-18;interferon-gamma	Since species differences have been shown between human and murine IL-18 , the aims of this study were to investigate 1 ) if species homologous IL-18 alone or following IL-12 pre-exposure affected rat islet function , 2 ) if ***IL-18*** dose-dependently ***modulated*** IL-1 beta or ***interferon-gamma*** ( IFN-gamma ) + tumor necrosis factor-alpha ( TNF-alpha ) actions on islet function , and 3 ) if IL-18 and IL-18 receptor ( IL-18R ) were expressed in rat islet beta-cells .	target	0
17031	10903806	3553;5594	IL-1 beta;ERK1/2	We conclude that ***IL-1 beta*** ***induces*** activation of both p38 and ***ERK1/2*** , and that ERK1/2 contributes to the pro-apoptotic effects of the cytokine in primary beta-cells .	target	1
17032	10903807	3596;6778	IL-13;STAT6	The lack of inhibitory function of IL-13 in infected macrophages , which was not overcome even at very high concentrations of IL-13 , was not due to impaired IL-13 signalling , since virus infection did not affect ***IL-13-mediated*** ***activation*** of ***STAT6*** ( signal transducer and activator of transcription 6 ) .	positive	1
17033	10903807	3596;7124	IL-13;TNF-alpha	Even though ***IL-13*** ***reduced*** ***TNF-alpha*** secretion by 50 % , this did not impair NF-kappa B activation in IFN-gamma-treated cells infected with HSV-2 .	negative	1
17034	10903807	3596;4843	IL-13;iNOS	The results indicate that TNF-alpha , secreted by virus-infected macrophages , activates NF-kappa B which impairs the ***IL-13-mediated*** ***inhibition*** of inducible NO synthase ( ***iNOS*** ) expression .	negative	1
17035	10903807	7124;4790	TNF-alpha;NF-kappa B	The results indicate that ***TNF-alpha*** , secreted by virus-infected macrophages , ***activates*** ***NF-kappa B*** which impairs the IL-13-mediated inhibition of inducible NO synthase ( iNOS ) expression .	positive	1
17036	10903844	1604;976	CD55;CD97	EMR2 fails to interact with ***CD55*** , the cellular ***ligand*** for ***CD97*** , suggesting the possibility of a different cellular ligand ( s ) .	parallel	1
17037	10903868	25801;3936	grancalcin;L-plastin	Our recent finding that ***grancalcin*** ***interacts*** with ***L-plastin*** , a protein known to have actin bundling activity , suggests that grancalcin may play a role in regulation of adherence and migration of neutrophils .	parallel	1
17038	10903877	7040;5594	TGFbeta;ERK	RESULTS : In vitro kinase and trans-reporting assays showed that ***TGFbeta*** preferentially ***activated*** ***ERK*** and JNK pathways in CRAC and HepG2 , respectively .	positive	1
17039	10903877	7040;5599	TGFbeta;JNK	RESULTS : In vitro kinase and trans-reporting assays showed that ***TGFbeta*** preferentially ***activated*** ERK and ***JNK*** pathways in CRAC and HepG2 , respectively .	positive	1
17040	10903887	4792;355	IkappaBalpha;Fas	Again , ectopic expression of ***IkappaBalpha*** in these cells ***abolished*** the enhanced ***anti-Fas*** / ActD killing effect .	negative	0
17041	10903887	4790;355	NF-kappaB;Fas	Also , inhibition of ***NF-kappaB*** by curcumin failed to ***inhibit*** the JNK-increased ***Fas*** cytotoxicity , suggesting that NF-kappaB is not involved in the observed effect .	positive	1
17042	10903890	6925;429	E2-2;HASH-1	We show that ***E2-2*** ***interacts*** with ***HASH-1*** in both yeast and mammalian cells .	parallel	1
17043	10903890	6925;429	E2-2;HASH-1	The ******HASH-1/E2-2****** ***complex*** binds an E-box ( CACCTG ) in vitro , and transactivates an E-box containing reporter construct in vivo .	parallel	1
17044	10903901	2885;1605	Grb2;beta-dystroglycan	Characterization of the ***beta-dystroglycan-growth*** factor ***receptor*** 2 ( ***Grb2*** ) interaction .	parallel	1
17045	10903901	2885;1605	Grb2;beta-dystroglycan	The ******beta-dystroglycan/Grb2****** ***interaction*** was investigated and a proline-rich region within beta-dystroglycan that binds Grb2-src homology 3 domains identified .	parallel	1
17046	10903901	2885;1605	Grb2;beta-dystroglycan	Both ***Grb2-SH3*** domains ***bind*** ***beta-dystroglycan*** but the N-terminal SH3 domain binds with an affinity approximately fourfold higher than that of the C-terminal SH3 domain .	parallel	1
17047	10903901	2885;1605	Grb2;beta-dystroglycan	The ******Grb2-beta-dystroglycan****** ***interaction*** was inhibited by dystrophin in a range of concentration of 160-400 nM .	parallel	1
17048	10903901	1756;1605	dystrophin;beta-dystroglycan	The ***Grb2-beta-dystroglycan*** interaction was ***inhibited*** by ***dystrophin*** in a range of concentration of 160-400 nM .	negative	1
17049	10903901	1756;2885	dystrophin;Grb2	The ***Grb2-beta-dystroglycan*** interaction was ***inhibited*** by ***dystrophin*** in a range of concentration of 160-400 nM .	negative	1
17050	10903904	3553;4583	IL-1beta;MUC2	The data suggest that ***IL-1beta*** ***up-regulates*** ***MUC2*** gene by transcriptional regulation and that budesonide suppresses the IL-1beta-medicated MUC2 expression via decreased transcriptional activation .	positive	1
17051	10903911	3700;7852	gp120;CXCR4	***Binding*** of ***gp120*** to solubilized ***CXCR4*** was demonstrated by coprecipitation of gp120 with anti-CXCR4 antibodies .	parallel	1
17052	10903915	2745;3725	glutaredoxin;AP-1	Nucleoredoxin , ***glutaredoxin*** , and thioredoxin differentially ***regulate*** NF-kappaB , ***AP-1*** , and CREB activation in HEK293 cells .	target	1
17053	10903915	2745;4790	glutaredoxin;NF-kappaB	Nucleoredoxin , ***glutaredoxin*** , and thioredoxin differentially ***regulate*** ***NF-kappaB*** , AP-1 , and CREB activation in HEK293 cells .	target	1
17054	10903915	64359;3725	Nucleoredoxin;AP-1	***Nucleoredoxin*** , glutaredoxin , and thioredoxin differentially ***regulate*** NF-kappaB , ***AP-1*** , and CREB activation in HEK293 cells .	target	1
17055	10903915	64359;4790	Nucleoredoxin;NF-kappaB	***Nucleoredoxin*** , glutaredoxin , and thioredoxin differentially ***regulate*** ***NF-kappaB*** , AP-1 , and CREB activation in HEK293 cells .	target	1
17056	10903991	1839;1956	heparin-binding EGF-like growth factor;epidermal growth factor (EGF) receptor	Heparin blockade of thrombin-induced smooth muscle cell migration involves ***inhibition*** of ***epidermal growth factor (EGF) receptor*** transactivation by ***heparin-binding EGF-like growth factor*** .	negative	1
17057	10903995	596;842	Bcl-2;caspase-3 and -9	These results suggest that apoptosis predominates in cardiomyocytes after reoxygenation through a mitochondrion-dependent apoptotic pathway , and ***Bcl-2*** prevents reoxygenation-induced apoptosis by inhibiting cytochrome c release from the mitochondria and ***prevents*** activation of ***caspase-3 and -9*** .	negative	0
17058	10904011	1432;27063	p38;CARP	Mutation analysis and electrophoretic mobility shift assays indicated that the M-CAT element can serve as a binding site for nuclear factors , and this element is important for the ***induction*** of ***CARP*** promoter activity by ***p38*** and Rac1 .	target	1
17059	10904110	1378;1604	CR1;DAF	Functional domains , structural variations and pathogen ***interactions*** of MCP , ***DAF*** and ***CR1*** .	parallel	1
17060	10904110	1378;4179	CR1;MCP	Functional domains , structural variations and pathogen ***interactions*** of ***MCP*** , DAF and ***CR1*** .	parallel	1
17061	10904110	4179;1604	MCP;DAF	Functional domains , structural variations and pathogen ***interactions*** of ***MCP*** , ***DAF*** and CR1 .	parallel	1
17062	10904433	9575;406	Clock;bmal1	These elements of biomolecular feedback loops are interpreted within a system theory as an elementary behavioral cycle consisting of intentional programs ( the per gene ) , environmental objects ( the ******bmal1-Clock****** ***heterodimer*** ) and the experiential realization of the intended programs ( the level of PER protein ) .	parallel	1
17063	10905482	2641;3651	GLP-1;IDX-1	Thus , in addition to stimulating insulin secretion , ***GLP-1*** ***stimulates*** the expression of the transcription factor ***IDX-1*** while stimulating beta-cell neogenesis and may thereby be an effective treatment for diabetes .	positive	0
17064	10905491	7124;5747	TNF-alpha;FAK	These data suggest that ***TNF-alpha*** promotes LAR expression and thus ***prevents*** insulin-mediated tyrosine phosphorylation of ***FAK*** .	negative	0
17065	10905491	7124;5792	TNF-alpha;LAR	These data suggest that ***TNF-alpha*** ***promotes*** ***LAR*** expression and thus prevents insulin-mediated tyrosine phosphorylation of FAK .	positive	0
17066	10905491	7124;5747	TNF-alpha;FAK	To explore the cellular mechanism whereby ***TNF-alpha*** ***regulates*** phosphorylation of ***FAK*** in the liver , we measured c-Src kinase activity and the abundance of 3 major protein tyrosine phosphatases ( PTPs ) ( PTP-1B , leukocyte antigen-related tyrosine phosphatase [ LAR ] , and src homology 2 domain-containing protein-tyrosine phosphatase [ SHPTP-2 ] ) in liver homogenates from obese Zucker rats after TNF-alpha blockade .	target	1
17067	10905564	3553;3569	IL-1;IL-6	Because P450 may be downregulated by interleukin-1 ( ***IL-1*** ) and IL-6 , the ***receptors*** for IL-1 and ***IL-6*** were analyzed .	parallel	1
17068	10906042	3479;3487	IGF-I;IGFBP-4	An excess of ***IGF-I*** ***enhanced*** ***IGFBP-4*** degradation .	positive	0
17069	10906057	3977;3976	LIFR;LIF	This goal of this study was to examine immunohistochemical distribution of Leukemia inhibitory factor ( LIF ) , ***LIF*** ***receptor*** ( ***LIFR*** ) , and glycoprotein ( gp ) 130 in rhesus monkey uterus during the menstrual cycle and early pregnancy .	parallel	1
17070	10906119	2033;1499	p300;beta-catenin	***CBP/p300*** ***potentiated*** Lef-mediated transactivation of ***beta-catenin*** , and E1A , a potent inhibitor of CBP/p300 , repressed its transactivation .	positive	0
17071	10906122	4904;10664	YB-1;CTCF	Thus our findings demonstrate , for the first time , the biological relevance of the ******CTCF/YB-1****** ***interaction*** .	parallel	1
17072	10906122	4904;10664	YB-1;CTCF	We examined ******CTCF/YB-1****** ***interaction*** by reciprocal immunoprecipitation experiments with anti-CTCF and anti-YB-1 antibodies , and found that CTCF and YB-1 form complexes in vivo .	parallel	1
17073	10906122	10664;4904	CTCF;YB-1	To assess possible functional significance of ******CTCF/YB-1****** ***binding*** , we employed the very first identified by us , negatively regulated , target for CTCF ( c-myc oncogene promoter ) as a model in co-transfection assays with both CTCF and YB-1 expression vectors .	parallel	1
17074	10906131	2932;1499	glycogen synthase kinase-3 beta;beta-catenin	Complex formation of adenomatous polyposis coli gene product and axin facilitates ***glycogen synthase kinase-3 beta-dependent*** ***phosphorylation*** of ***beta-catenin*** and down-regulates beta-catenin .	target	1
17075	10906131	2932;1499	GSK-3 beta;beta-catenin	The enhancement of the ***GSK-3 beta-dependent*** ***phosphorylation*** of ***beta-catenin*** was eliminated by the APC-binding site of Axin .	target	1
17076	10906131	2932;1499	GSK-3 beta;beta-catenin	These results indicate that the complex formation of APC and Axin enhances the ***phosphorylation*** of ***beta-catenin*** by ***GSK-3 beta*** , leading to the down-regulation of beta-catenin .	target	1
17077	10906133	27085;4193	MTBP;MDM2	A novel cellular protein ( ***MTBP*** ) ***binds*** to ***MDM2*** and induces a G1 arrest that is suppressed by MDM2 .	parallel	1
17078	10906133	27085;4193	MTBP;MDM2	Using a yeast two-hybrid screen , we have identified a gene that encodes a novel cellular protein ( ***MTBP*** ) that ***binds*** to ***MDM2*** .	parallel	1
17079	10906137	2139;8802	Eya2;Galpha	***Eya2*** ***interacts*** with activated Galpha ( z ) and at least one other member of the ***Galpha*** ( i ) family , Galpha ( i2 ) .	parallel	1
17080	10906137	8802;2139	Galpha;Eya2	Activated Galpha ( z ) and ***Galpha*** ( i2 ) ***prevent*** ***Eya2*** translocation and inhibit Six/Eya2-mediated activation of a reporter gene controlled through the MEF3/TATA promoter .	negative	0
17081	10906146	1017;5934	Cdk2;p130	***Cdk2-dependent*** ***phosphorylation*** and functional inactivation of the pRB-related ***p130*** protein in pRB ( - ) , p16INK4A ( + ) tumor cells .	target	1
17082	10906146	5934;1874	p130;E2F-4	Moreover , dominant negative Cdk2 prevented the dissociation of endogenous ******p130-E2F-4****** ***complexes*** and inhibited E2F-4-dependent transcription .	parallel	1
17083	10906151	183;4012	angiotensin II;AT(4) receptor	Low-affinity ***angiotensin II*** ***binding*** to the ***AT(4) receptor*** was also shifted toward high-affinity binding following renal metabolism of the peptide .	parallel	1
17084	10906156	7292;7293	CD134L;CD134	Interaction between ***CD134*** and its ***ligand*** ( ***CD134L*** ) is involved in costimulation of T and B lymphocyte activation , and in T cell adhesion to endothelium .	parallel	1
17085	10906156	7292;7293	CD134L;CD134	***Interaction*** between ***CD134*** and its ligand ( ***CD134L*** ) is involved in costimulation of T and B lymphocyte activation , and in T cell adhesion to endothelium .	parallel	1
17086	10906181	1026;1017	waf1;cdk2	The ***p21/waf1*** protein was reproducibly observed to be ***complexed*** with cyclin ***A/cdk2*** and not with any other known G ( 1 ) , S , or G ( 2 ) / M cyclins .	parallel	1
17087	10906181	1017;3005	cdk2;histone H1	Functionally , the association of p21/cyclin ***A/cdk2*** ***decreased*** ***histone H1*** phosphorylation in vitro , as observed in immunoprecipitations followed by kinase assays , and affected other substrates , such as the C terminus of Rb protein involved in c-Abl and histone deacetylase-1 ( HDAC1 ) regulation .	negative	0
17088	10906185	925;919	CD8;CD3zeta	To investigate further the ***link*** between ***CD3zeta*** down-modulation and possible ***CD8*** T-cell functional defects , we used flow cytometry to characterize further the properties of the CD3zeta-down-modulated subset .	parallel	0
17089	10906322	1051;1050	C/EBPbeta;C/EBPalpha	In contrast , ***C/EBPbeta*** is a relatively weak activator of 11beta-HSD1 transcription in hepatoma cells and ***attenuates*** ***C/EBPalpha*** induction , and mice that lack C/EBPbeta have increased hepatic 11beta-HSD1 mRNA .	negative	0
17090	10906330	4322;176	collagenase 3;aggrecan	These findings support previous observations that human ***collagenase 3*** can ***degrade*** ***aggrecan*** , type II and type IV collagens .	negative	0
17091	10906332	3309;3949	Grp78;LDL receptor	A pulse-chase study shows that the ***interaction*** between the wild type ***LDL receptor*** and ***Grp78*** is no longer detectable after 2 ( 1/2 ) h , whereas it persists for more than 4 h with the mutant receptors .	parallel	1
17092	10906337	7040;4609	TGF-beta;c-Myc	Our conclusion is that , whereas ***c-Myc*** ***down-regulation*** by ***TGF-beta*** is a required event in the cell cycle arrest response of epithelial cells , MDM-2 is not a direct participant in the normal TGF-beta antiproliferative response .	negative	1
17093	10906389	6387;7852	SDF-1;CXCR4	The chemokine receptor ***CXCR4*** and its ***ligand*** ***SDF-1*** are essential components of hematopoiesis , organogenesis and immunomodulation in mammalian species .	parallel	1
17094	10906706	5649;1600	Reelin;dab1	***Reelin*** binds to transmembrane receptors , including VLDLR and ApoER2 , and ***stimulates*** tyrosine phosphorylation of Disabled-1 ( ***dab1*** ) , which associates with an NPxY motif present in the cytoplasmic domain of the receptors .	positive	0
17095	10906757	650;10468	BMP-2;follistatin	***BMP-2*** ***induces*** the expression of activin betaA and ***follistatin*** in vitro .	target	1
17096	10906776	7040;753	TGF-beta;clone-22	Expression of ***TGF-beta*** ***stimulated*** ***clone-22*** ( TSC-22 ) in mouse development and TGF-beta signalling .	positive	0
17097	10906777	9181;998	GEF;Cdc42	Fgd1 encodes a guanine nucleotide exchange factor ( ***GEF*** ) that specifically ***activates*** the Rho GTPase ***Cdc42*** ; Fgd1 mutations result in Faciogenital Dysplasia ( FGDY , Aarskog syndrome ) , an X-linked developmental disorder that adversely affects the formation of multiple skeletal structures .	positive	1
17098	10906784	4091;7040	Smad6;TGF beta	***Smad6*** and Smad7 are ***inhibitors*** of ***TGF beta*** family signalling .	negative	1
17099	10906784	4092;7040	Smad7;TGF beta	Smad6 and ***Smad7*** are ***inhibitors*** of ***TGF beta*** family signalling .	negative	1
17100	10907115	3952;2056	leptin;erythropoietin	Cord plasma ***leptin*** ( n = 25 ) ***correlated*** directly with amniotic fluid erythropoietin ( r = 0.727 , p = 0.0001 ) , with cord plasma ***erythropoietin*** ( r = 0.644 , p = 0.0005 ) and with the maternal last trimester HbA1C ( r = 0.612 , p = 0.0019 ) and negatively with cord artery pO2 ( r = -0.440 , p = 0.032 ) , and pH ( r = -0.414 , p = 0.040 ) .	parallel	0
17101	10907122	5329;3082	uPAR;hepatocyte growth factor	These factors include ***hepatocyte growth factor*** ( HGF ) and its receptor c-MET , and urokinase plasminogen activator ( uPA ) and its ***receptor*** ***uPAR*** , basic fibroblast growth factor ( bFGF ) , TGF-alpha and TGF beta-1 .	parallel	1
17102	10907122	5329;5328	uPAR;uPA	These factors include hepatocyte growth factor ( HGF ) and its receptor c-MET , and urokinase plasminogen activator ( ***uPA*** ) and its ***receptor*** ***uPAR*** , basic fibroblast growth factor ( bFGF ) , TGF-alpha and TGF beta-1 .	parallel	1
17103	10907122	4233;3082	c-MET;hepatocyte growth factor	These factors include ***hepatocyte growth factor*** ( HGF ) and its ***receptor*** ***c-MET*** , and urokinase plasminogen activator ( uPA ) and its receptor uPAR , basic fibroblast growth factor ( bFGF ) , TGF-alpha and TGF beta-1 .	parallel	1
17104	10907125	185;183	AGTR1;angiotensin II	AIMS/HYPOTHESIS : Reports on a putative synergism between poor glycaemic control and carriage of the ***angiotensin II*** type 1 ***receptor*** ( ***AGTR1*** ) C1166-allele and risk of diabetic nephropathy have been conflicting .	parallel	1
17105	10907314	324;1499	APC;beta-catenin	***APC*** tumour suppressor gene mutations are conserved in synchronous carcinomas in Barrett 's dysplasia and are ***associated*** with ***beta-catenin*** accumulation in the nucleus and cellular migration with invasion .	parallel	0
17106	10907636	7066;1440	thrombopoietin;granulocyte colony-stimulating factor	OBJECTIVE : If administered in a sufficiently high dose to overcome receptor-mediated clearance and in a well-scheduled manner , ***thrombopoietin*** ( TPO ) prominently stimulates hematopoietic reconstitution following myelosuppressive treatment and ***potentiates*** the efficacy of both granulocyte-macrophage colony-stimulating factor ( GM-CSF ) and ***granulocyte colony-stimulating factor*** ( G-CSF ) .	positive	0
17107	10907636	7066;1437	thrombopoietin;granulocyte-macrophage colony-stimulating factor	OBJECTIVE : If administered in a sufficiently high dose to overcome receptor-mediated clearance and in a well-scheduled manner , ***thrombopoietin*** ( TPO ) prominently stimulates hematopoietic reconstitution following myelosuppressive treatment and ***potentiates*** the efficacy of both ***granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) and granulocyte colony-stimulating factor ( G-CSF ) .	positive	0
17108	10907644	1399;867	CrkL;CBL	Similarly , RA induced tyrosine phosphorylation of the CrkL adapter and the ***association*** of ***CrkL*** with ***CBL*** .	parallel	0
17109	10907644	1399;867	CrkL;CBL	The RA-dependent ***interaction*** of ***CrkL*** with ***CBL*** was mediated by binding of the SH2 domain of CrkL to tyrosine phosphorylated CBL , suggesting that CBL provides a docking site for engagement of CrkL in a RA-activated cellular pathway .	parallel	1
17110	10907644	2889;1399	C3G;CrkL	The guanine exchange factor ***C3G*** was found to be ***associated*** with ***CrkL*** at similar levels before and after RA treatment , but Rapl activation downstream of C3G was not inducible by RA .	parallel	0
17111	10908145	6776;5617	Stat5a;prolactin	The transcription factor ***Stat5a*** critically ***mediates*** ***prolactin*** ( PRL ) - induced mammary gland development and lactogenesis .	target	0
17112	10908156	7276;177	TTR;RAGE	Further insights into the consequences of the ***interaction*** of fibrillar ***TTR*** with ***RAGE*** may therefore provide a better understanding of neurodegeneration associated with FAP .	parallel	1
17113	10908156	177;7276	RAGE;TTR	Specific binding of TTR to RAGE-transfected Chinese hamster ovary cells ( which was completely blocked by anti-RAGE ) was observed , confirming that ***RAGE*** could ***mediate*** ***TTR*** binding to cellular surfaces .	target	0
17114	10908276	1081;596	HCG;Bcl-2	Although no changes were observed in Bcl-2 concentration during the corpus luteum life span , L-Arg inhibited , and ***HCG*** ***augmented*** , ***Bcl-2*** production ( P < 0.05 ) from mid and late corpus luteum cells in vitro .	positive	0
17115	10908286	5008;1081	Oncostatin M;HCG	***Oncostatin M*** is produced during pregnancy by decidual cells and ***stimulates*** the release of ***HCG*** .	positive	0
17116	10908310	2885;2549	Grb-2;Gab1	This phosphorylation appears to be necessary for association of PI3K1a with the ******Gab1-Grb-2****** ***complex*** .	parallel	1
17117	10908310	5291;1785	PI3K;dynamin II	Second , ***PI3K*** appears to ***promote*** the subsequent association of ***dynamin II*** ( which is involved in clathrin-mediated endocytic processing ) with the complex .	positive	0
17118	10908331	22976;5076	PTIP;Pax2	***PTIP*** , a novel BRCT domain-containing protein ***interacts*** with ***Pax2*** and is associated with active chromatin .	parallel	1
17119	10908331	22976;5076	PTIP;Pax2	***PTIP*** ***binds*** to ***Pax2*** in vitro , in the yeast two-hybrid assay and in tissue culture cells .	parallel	1
17120	10908331	22976;5076	PTIP;Pax2	The ***binding*** of ***PTIP*** to ***Pax2*** is inhibited by the octapeptide repression domain .	parallel	1
17121	10908344	56852;7319	RAD18;HHR6A	The human ***RAD18*** gene product ***interacts*** with ***HHR6A*** and HHR6B .	parallel	1
17122	10908344	56852;7320	RAD18;HHR6B	The human ***RAD18*** gene product ***interacts*** with HHR6A and ***HHR6B*** .	parallel	1
17123	10908344	7320;56852	HHR6B;hRAD18	When co-expressed in yeast cells , stable hRAD18-HHR6A and ******hRAD18-HHR6B****** protein ***complexes*** were identified and purified to near homogeneity .	parallel	1
17124	10908561	57109;2100	hPMC2;ER beta	Interestingly ***hPMC2*** ***interacts*** more strongly to ***ER beta*** when compared with ER alpha .	parallel	1
17125	10908564	1956;2064	EGFR;ErbB2	The mechanism by which EGFR recruits the PI3K/Akt pathway was in part differentially regulated at the level of Ras but independent of ***heterodimerization*** of ***EGFR*** with either ***ErbB2*** or ErbB3 based upon functional dissection of pathways in esophageal cancer cell lines .	parallel	1
17126	10908564	1956;2065	EGFR;ErbB3	The mechanism by which EGFR recruits the PI3K/Akt pathway was in part differentially regulated at the level of Ras but independent of ***heterodimerization*** of ***EGFR*** with either ErbB2 or ***ErbB3*** based upon functional dissection of pathways in esophageal cancer cell lines .	parallel	1
17127	10908564	1956;207	EGFR;Akt	The mechanism by which ***EGFR*** ***recruits*** the ***PI3K/Akt*** pathway was in part differentially regulated at the level of Ras but independent of heterodimerization of EGFR with either ErbB2 or ErbB3 based upon functional dissection of pathways in esophageal cancer cell lines .	target	0
17128	10908564	1956;5290	EGFR;PI3K	The mechanism by which ***EGFR*** ***recruits*** the ***PI3K/Akt*** pathway was in part differentially regulated at the level of Ras but independent of heterodimerization of EGFR with either ErbB2 or ErbB3 based upon functional dissection of pathways in esophageal cancer cell lines .	target	0
17129	10908570	6693;959	CD43;CD40-L	In this study we show that ***CD43*** ligation on human normal peripheral T cells was sufficient to ***induce*** interleukin-2 , CD69 , and ***CD40-L*** gene expression , without requiring signals provided by additional receptor molecules .	target	1
17130	10908570	6693;969	CD43;CD69	In this study we show that ***CD43*** ligation on human normal peripheral T cells was sufficient to ***induce*** interleukin-2 , ***CD69*** , and CD40-L gene expression , without requiring signals provided by additional receptor molecules .	target	1
17131	10908570	6693;3558	CD43;interleukin-2	In this study we show that ***CD43*** ligation on human normal peripheral T cells was sufficient to ***induce*** ***interleukin-2*** , CD69 , and CD40-L gene expression , without requiring signals provided by additional receptor molecules .	target	1
17132	10908575	836;1677	caspase-3;CAD	We conclude that a complex mechanism , involving the recognition of the NLSs of both ICAD and CAD , accounts for the constitutive accumulation of CAD/ICAD in the nucleus , where ***caspase-3-dependent*** ***regulation*** of ***CAD*** activity takes place .	target	1
17133	10908614	4803;4804	NGF;p75	Collectively , these results suggest that ***NGF-mediated*** ***activation*** of ***p75*** is likely to be an important mediator of Schwann cell apoptosis in the context of peripheral nerve injury .	positive	1
17134	10908618	5594;627	ERK;BDNF	Pharmacological inhibition of ***ERK*** , but not the PI3-kinase pathway , ***inhibited*** the ability of ***BDNF*** to block H-I-induced caspase-3 activation and tissue loss .	positive	1
17135	10908620	219699;9423	unc5h2;Netrin-1	DCC and neogenin , receptors implicated in mediating the attractant effects of Netrin-1 , are expressed in dorsal thalamus , whereas ***unc5h2*** and unc5h3 , ***Netrin-1*** ***receptors*** implicated in repulsion , are not .	parallel	1
17136	10908652	8815;7112	BAF;LAP2	The dual ***interaction*** of ***BAF*** with DNA and ***LAP2*** , a protein associated with the nuclear lamina , suggests a role for LAP2 in chromosome organization .	parallel	1
17137	10908663	608;10673	B cell maturation protein;TALL-1	***B cell maturation protein*** is a ***receptor*** for the tumor necrosis factor family member ***TALL-1*** .	parallel	1
17138	10908663	608;10673	B cell maturation protein;TALL-1	Here we show that ***B cell maturation protein*** ( BCMA ) , a member of the TNF receptor family that is expressed only by B lymphocytes , specifically ***binds*** to ***TALL-1*** .	parallel	1
17139	10908663	608;4790	BCMA;NF-kappaB	Overexpression of ***BCMA*** ***activates*** ***NF-kappaB*** , and this activation is potentiated by TALL-1 .	positive	1
17140	10908663	7188;4790	TNF receptor-associated factor 5;NF-kappaB	Moreover , BCMA-mediated ***NF-kappaB*** activation is ***inhibited*** by dominant negative mutants of ***TNF receptor-associated factor 5*** ( TRAF5 ) , TRAF6 , NF-kappaB-inducing kinase ( NIK ) , and IkappaB kinase ( IKK ) .	positive	1
17141	10908663	7189;4790	TRAF6;NF-kappaB	Moreover , BCMA-mediated ***NF-kappaB*** activation is ***inhibited*** by dominant negative mutants of TNF receptor-associated factor 5 ( TRAF5 ) , ***TRAF6*** , NF-kappaB-inducing kinase ( NIK ) , and IkappaB kinase ( IKK ) .	positive	1
17142	10908663	608;10673	BCMA;TALL-1	These data indicate that ***BCMA*** is a ***receptor*** for ***TALL-1*** and BCMA activates NF-kappaB through a TRAF5 - , TRAF6 - , NIK - , and IKK-dependent pathway .	parallel	1
17143	10908690	3565;3589	Interleukin-4;interleukin-11	***Interleukin-4*** ***inhibits*** ***interleukin-11*** production by rheumatoid synovial cells .	negative	1
17144	10908690	3565;3589	IL-4;IL-11	RESULTS : ***IL-4*** ***inhibited*** the production of ***IL-11*** by FRS in a dose-dependent manner .	negative	1
17145	10908690	3565;3589	IL-4;IL-11	***IL-4*** also ***inhibited*** ***IL-11*** production by IL-1alpha-stimulated cultured RSF .	negative	1
17146	10908690	3565;3589	IL-4;IL-11	CONCLUSION : ***IL-4*** ***inhibited*** ***IL-11*** production by rheumatoid synovial cells .	negative	1
17147	10908694	7124;4790	TNF-alpha;NFkappaB	These genes are regulated by the transcription factor ***NFkappaB*** which in turn is ***activated*** by tumour necrosis factor-alpha ( ***TNF-alpha*** ) and cytokines .	positive	1
17148	10908722	5624;2152	protein C;tissue factor	Activated ***protein C*** ***suppresses*** ***tissue factor*** expression on U937 cells in the endothelial protein C receptor-dependent manner .	negative	1
17149	10908722	10544;5624	EPCR;protein C	The effect was antagonized by the monoclonal antibody ( mAb ) to endothelial ***protein C/APC*** ***receptor*** ( ***EPCR*** ) , 252 , which strongly inhibited the interaction between APC and EPCR .	parallel	1
17150	10908726	841;84959	caspase-8;p70	In addition , activation of the Fas/CD95 receptor results in the ***caspase-8-dependent*** ***dephosphorylation*** and degradation of ***p70*** ( S6K ) , the enhanced binding of 4E-BP1 to eIF4E , and , at later times , the cleavage of eIF2alpha .	target	1
17151	10908726	1978;1977	4E-BP1;eIF4E	In addition , activation of the Fas/CD95 receptor results in the caspase-8-dependent dephosphorylation and degradation of p70 ( S6K ) , the enhanced ***binding*** of ***4E-BP1*** to ***eIF4E*** , and , at later times , the cleavage of eIF2alpha .	parallel	1
17152	10908889	3586;3458	IL-10;IFNgamma	Thus , the defect in ***regulation*** of both IL-12 and ***IFNgamma*** production by endogenous ***IL-10*** in progressive MS could be an important factor involved in the transition of MS from the relapsing to the progressive stage and has implications for treating MS patients with exogenous IL-10 .	target	1
17153	10908889	3586;3458	IL-10;IFNgamma	Defective ***regulation*** of ***IFNgamma*** and IL-12 by endogenous ***IL-10*** in progressive MS.	target	1
17154	10908889	3586;3458	IL-10;IFNgamma	***IL-10*** is a potent ***inhibitor*** of both IL-12 and ***IFNgamma*** expression .	negative	1
17155	10908988	3553;3383	IL-1 beta;ICAM-1	The findings indicate that stimulation of ***ICAM-1*** by endotoxin is ***mediated*** , at least in part , by TNF-alpha and ***IL-1 beta*** .	target	0
17156	10908988	7124;3383	TNF-alpha;ICAM-1	The findings indicate that stimulation of ***ICAM-1*** by endotoxin is ***mediated*** , at least in part , by ***TNF-alpha*** and IL-1 beta .	target	0
17157	10909770	3458;4023	IFN-gamma;lipoprotein lipase	The ***suppression*** of ***lipoprotein lipase*** expression in J774 .2 macrophages by ***IFN-gamma*** and TNF-alpha is mediated at the transcriptional level .	negative	1
17158	10909770	7124;4023	TNF-alpha;lipoprotein lipase	The ***suppression*** of ***lipoprotein lipase*** expression in J774 .2 macrophages by IFN-gamma and ***TNF-alpha*** is mediated at the transcriptional level .	negative	1
17159	10909960	5367;3952	MCH;leptin	We report that ***MCH*** ***stimulates*** leptin mRNA expression and ***leptin*** secretion .	positive	0
17160	10909973	2641;107	Glucagon-like peptide 1;adenyl cyclase	***Glucagon-like peptide 1*** ( GLP-1 ) , a hormonal ***activator*** of ***adenyl cyclase*** , stimulates insulin gene transcription , an effect mediated by the cAMP response element ( CRE ) of the rat insulin I gene promoter ( RIP1 ) .	positive	1
17161	10909981	3953;3952	OB-R;leptin	These findings strongly suggest that the ***leptin*** ***receptor*** ( ***OB-R*** ) in the BBB can be easily saturated .	parallel	1
17162	10909989	3479;3952	IGF-I;leptin	Moreover , basal insulin and circulating ***IGF-I*** were ***correlated*** significantly with ***leptin*** concentrations ( r = .47 and .62 , respectively , P < .001 ) .	parallel	0
17163	10910042	51176;1499	LEF-1;beta-catenin	Therefore , we examined the modulation by NO of cytoplasmic beta-catenin levels and the formation of the nuclear ******beta-catenin/LEF-1****** DNA binding ***complex*** in conditionally immortalized mouse colonic epithelial cells that differed in adenomatous polyposis coli ( Apc ) genotype , namely young adult mouse colon ( YAMC ; Apc + / + ) and immortal mouse colon epithelium ( IMCE ; ApcMin / + ) .	parallel	1
17164	10910042	51176;1499	LEF-1;beta-catenin	Using electrophoretic mobility shift assays , we found that NO-releasing agents ( E ) - methyl-2 - [ ( E ) - hydroxyimino ] -5 - nitro-6-methoxy-3-hexeneamide and S-nitroso-N-acetylpenicillamine greatly enhanced the formation of ******beta-catenin/LEF-1****** DNA binding ***complex*** in a concentration - and time-dependent fashion in YAMC and IMCE cells .	parallel	1
17165	10910042	51176;1499	LEF-1;beta-catenin	Significantly , IMCE cells showed a markedly greater amount of nuclear ******beta-catenin/LEF-1****** DNA binding ***complex*** in response to NO .	parallel	1
17166	10910058	5340;632	plasmin;osteocalcin	We have previously described the presence of the functional plasminogen activator system on the surfaces of bone neoplastic cells and the fact that ***plasmin*** specifically ***cleaves*** bone matrix protein ***osteocalcin*** ( OC ) .	target	1
17167	10910062	2475;207	mammalian target of rapamycin;AKT	A direct ***linkage*** between the phosphoinositide ***3-kinase-AKT*** signaling pathway and the ***mammalian target of rapamycin*** in mitogen-stimulated and transformed cells .	parallel	0
17168	10910062	207;2475	AKT;mTOR	The involvement of phosphoinositide 3 ' - kinase ( PI3K ) in the regulation of mTOR activity was further suggested by findings that ***mTOR*** was ***phosphorylated*** in vitro and in vivo by the PI3K-regulated protein kinase , ***AKT/PKB*** .	target	1
17169	10910064	2064;2065	HER2;HER3	Pretreatment of SKBr3 cells with ID5 decreased heregulin-induced ***association*** of ***HER2*** with ***HER3*** as well as the activation of c-Jun-NH2-terminal kinase and PI3-K activities .	parallel	0
17170	10910082	7157;7422	p53;vascular endothelial growth factor	The introduction of wt ***p53*** into sarcoma cells containing mutant p53 significantly ***reduced*** the expression of ***vascular endothelial growth factor*** ( VEGF ) , which is a key mediator of tumor angiogenesis .	negative	1
17171	10910100	3458;1026	IFN-gamma;p21	We found that ***IFN-gamma*** ***induced*** ***p21*** mRNA in MCF-7 cells but not in MDA-MB-231 cells .	target	1
17172	10910100	3458;1026	IFN-gamma;p21	Furthermore , ***IFN-gamma*** ***induced*** activation of a ***p21*** promoter-luciferase reporter construct that contained the STAT1-inducible element in MCF-7 cells , but not in MDA-MB-231 cells .	target	1
17173	10910128	6469;3239	Shh;Hoxd-13	This result indicates that ***Hoxd-13*** ***activation*** by ***Shh*** depends on non-ridge ectoderm and FGF-2 or FGF-4 , and that there may be a difference in the effect on AP axis formation of the limb bud between FGF-2 , -4 and -8 .	positive	1
17174	10910129	650;9241	BMP-2;Noggin	Ectopically expressed ***BMP-2*** was shown to ***induce*** the expression of the Ihh and ***Noggin*** genes .	target	1
17175	10910364	5371;7157	PML;p53	***PML*** ***regulates*** ***p53*** acetylation and premature senescence induced by oncogenic Ras .	target	1
17176	10910364	5371;7157	PML;p53	Here we report that the tumour suppressor ***PML*** ***regulates*** the ***p53*** response to oncogenic signals .	target	1
17177	10910364	5371;7157	PML;p53	Ras induces re-localization of p53 and the CBP acetyltransferase within the PML nuclear bodies and induces the formation of a trimeric ******p53-PML-CBP****** ***complex*** .	parallel	1
17178	10910364	7157;5371	p53;PML	Our data establish a ***link*** between ***PML*** and ***p53*** and indicate that integrity of the PML bodies is required for p53 acetylation and senescence upon oncogene expression .	parallel	0
17179	10910365	672;1647	BRCA1;GADD45	***BRCA1*** also directly interacts with proteins of the DNA repair machinery and ***regulates*** expression of both the p21 and ***GADD45*** genes .	target	1
17180	10910365	672;1026	BRCA1;p21	***BRCA1*** also directly interacts with proteins of the DNA repair machinery and ***regulates*** expression of both the ***p21*** and GADD45 genes .	target	1
17181	10910365	672;1647	BRCA1;GADD45	ATM phosphorylates CtIP at serine residues 664 and 745 , and mutation of these sites to alanine abrogates the dissociation of BRCA1 from CtIP , resulting in persistent repression of ***BRCA1-dependent*** ***induction*** of ***GADD45*** upon ionizing radiation .	target	1
17182	10910365	5932;672	CtIP;BRCA1	ATM phosphorylates ***CtIP*** at serine residues 664 and 745 , and mutation of these sites to alanine ***abrogates*** the dissociation of ***BRCA1*** from CtIP , resulting in persistent repression of BRCA1-dependent induction of GADD45 upon ionizing radiation .	negative	0
17183	10910365	672;1647	BRCA1;GADD45	We conclude that ATM , by phosphorylating CtIP upon ionizing radiation , may modulate ***BRCA1-mediated*** ***regulation*** of the DNA damage-response ***GADD45*** gene , thus providing a potential link between ATM deficiency and breast cancer .	target	1
17184	10910768	5898;1956	Ral;epidermal growth factor (EGF) receptor	We show that activated ***Ral*** ***interferes*** with both tranferrin receptor endocytosis and ***epidermal growth factor (EGF) receptor*** endocytosis in HeLa cells .	negative	0
17185	10910894	6360;1230	LEC;CCR1	***LEC*** ***induced*** maximal migration of ***CCR1*** and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L .	target	1
17186	10910894	6360;1237	LEC;CCR8	***LEC*** ***induced*** maximal migration of CCR1 and ***CCR8*** transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L .	target	1
17187	10910907	2056;5599	erythropoietin;JNK	***JNK*** and p38 are ***activated*** by ***erythropoietin*** ( EPO ) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells .	positive	1
17188	10910907	2056;5594	erythropoietin;p38	JNK and ***p38*** are ***activated*** by ***erythropoietin*** ( EPO ) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells .	positive	1
17189	10910908	2056;207	erythropoietin;Akt	This study found that ***erythropoietin*** ( EPO ) ***induced*** tyrosine phosphorylation of ***Akt*** in a time - and dose-dependent manner in EPO-dependent human leukemia cell line UT-7 / EPO .	target	1
17190	10910917	4603;4609	A-myb;c-myc	Furthermore , we and others have shown that the ***c-myc*** gene is potently ***transactivated*** by ***A-myb*** in several cell types .	positive	1
17191	10910921	356;355	FasL;Fas	Through the use of perforin - and ***Fas*** ***ligand*** ( ***FasL*** ) - deficient mice , it was demonstrated that CD4 ( + ) T cells mediate anti-MMB3 .19 effects in vivo primarily through the use of FasL and secondarily through perforin mechanisms .	parallel	1
17192	10910956	2932;595	GSK-3beta;cyclin D1	Recently , it has been shown that ***phosphorylation*** of ***cyclin D1*** by glycogen synthase kinase 3beta ( ***GSK-3beta*** ) on a single threonine residue ( Thr-286 ) positively regulates proteosomal degradation of cyclin D1 .	target	1
17193	10911023	624;3827	B2R;bradykinin	Firstly , a single class of GPCRs such as the ***bradykinin*** type 2 ***receptor*** ( ***B2R*** ) may couple to different classes of G proteins in a cell-specific and time-dependent manner , resulting in simultaneous or consecutive initiation of different signaling chains .	parallel	1
17194	10911903	324;1499	APC;beta-catenin	Fragments of ***APC*** that contain a conductin-binding domain also ***block*** ***beta-catenin*** degradation .	negative	0
17195	10911903	324;1499	APC;beta-catenin	In tumors , ***beta-catenin*** degradation is ***blocked*** by mutations of beta-catenin or of the tumor suppressor gene product ***APC*** .	positive	0
17196	10911903	324;8313	APC;conductin	The complex includes ***APC*** , the serine/threonine kinase GSK3 beta , and beta-catenin , which ***bind*** to ***conductin*** at distinct domains .	parallel	1
17197	10911903	1499;8313	beta-catenin;conductin	The complex includes APC , the serine/threonine kinase GSK3 beta , and ***beta-catenin*** , which ***bind*** to ***conductin*** at distinct domains .	parallel	1
17198	10911903	8313;1499	conductin;beta-catenin	In colon carcinoma cells , forced expression of ***conductin*** ***downregulates*** ***beta-catenin*** , whereas in normal cells mutants of conductin that are deficient in complex formation stabilize beta-catenin .	negative	1
17199	10911909	960;2119	CD44;ERM	Under these conditions the ***CD44*** proteins ***recruit*** ***ERM*** proteins -- for example , ezrin or moesin -- to their cytoplasmic tails , thereby producing links to the cytoskeleton .	target	0
17200	10911949	1029;1019	p16INK4a;CDK4	In these cells , senescence is associated with increased ***binding*** of ***p16INK4a*** to ***CDK4*** and loss of E2F-binding activity .	parallel	1
17201	10911949	5925;1869	pRB;E2F1	Here we demonstrate that in melanocytes derived from dark-skinned individuals , CT-induced melanogenesis is associated with accumulation of the tumor suppressor p16INK4a , underphosphorylated retinoblastoma protein ( ***pRB*** ) , downregulation of cyclin E , ***decreased*** expression of ***E2F1*** , and loss of E2F-regulated S-phase gene expression .	negative	0
17202	10911949	1029;1019	p16;CDK4	This delayed senescence may result from reduced ***association*** of ***p16*** with ***CDK4*** , reduced levels of underphosphorylated pRB , and steady levels of cyclin E and E2F1 .	parallel	0
17203	10911999	8717;7186	TRADD;TRAF2	Solution structure of N-TRADD and characterization of the ***interaction*** of ***N-TRADD*** and ***C-TRAF2*** , a key step in the TNFR1 signaling pathway .	parallel	1
17204	10911999	7186;7132	TRAF2;TNFR1	The N-terminal domain ( N-TRADD ) promotes the ***recruitment*** of ***TRAF2*** to ***TNFR1*** by binding to the C-terminal of TRAF2 , leading to the activation of JNK/AP1 and NF-kappa B .	target	0
17205	10911999	8717;7186	TRADD;TRAF2	The N-terminal domain ( ***N-TRADD*** ) ***promotes*** the recruitment of ***TRAF2*** to TNFR1 by binding to the C-terminal of TRAF2 , leading to the activation of JNK/AP1 and NF-kappa B .	positive	0
17206	10911999	8717;7186	TRADD;TRAF2	A combination of NMR , BIAcore , and mutagenesis experiments was used to help identify the site of ***interaction*** of ***N-TRADD*** with ***C-TRAF2*** , providing a framework for future attempts to selectively inhibit the TNF signaling pathways .	parallel	1
17207	10912457	183;6696	Angiotensin II;osteopontin	***Angiotensin II*** directly ***increases*** transforming growth factor beta1 and ***osteopontin*** and indirectly affects collagen mRNA expression in the human heart .	positive	0
17208	10912461	6670;6667	Sp3;Sp1	The introduction of mutations within the core sequence of the putative Sp1/Sp3 binding sites present in these regulatory elements reduced the level of transcriptional activity and abrogated ******Sp1/Sp3****** ***binding*** to these sites .	parallel	1
17209	10912517	3717;3643	JAK2;insulin receptor	In response to GH , ***JAK2*** is also known to ***phosphorylate*** the ***insulin receptor*** substrates , leading to activation of phosphatidyl inositol 3 ' kinase and most likely other molecules that have been implicated in the regulation of metabolism .	target	1
17210	10912524	3488;3486	IGFBP-5;IGFBP-3	There was a positive correlation between IGFBP-4 and IGFBP-2 ( r = 0.46 , P < 0.001 ) ; ***IGFBP-5*** was positively ***correlated*** with IGF-I ( r = 0.59 , P < 0.001 ) , IGF-II ( r = 0.42 , P < 0.001 ) and ***IGFBP-3*** ( r = 0.47 , P < 0.001 ) and inversely correlated with IGFBP-1 ( r = -0.41 , P < 0.001 ) .	positive	0
17211	10912524	3488;3479	IGFBP-5;IGF-I	There was a positive correlation between IGFBP-4 and IGFBP-2 ( r = 0.46 , P < 0.001 ) ; ***IGFBP-5*** was positively ***correlated*** with ***IGF-I*** ( r = 0.59 , P < 0.001 ) , IGF-II ( r = 0.42 , P < 0.001 ) and IGFBP-3 ( r = 0.47 , P < 0.001 ) and inversely correlated with IGFBP-1 ( r = -0.41 , P < 0.001 ) .	positive	0
17212	10912524	3488;3484	IGFBP-5;IGFBP-1	There was a positive correlation between IGFBP-4 and IGFBP-2 ( r = 0.46 , P < 0.001 ) ; ***IGFBP-5*** was positively correlated with IGF-I ( r = 0.59 , P < 0.001 ) , IGF-II ( r = 0.42 , P < 0.001 ) and IGFBP-3 ( r = 0.47 , P < 0.001 ) and inversely ***correlated*** with ***IGFBP-1*** ( r = -0.41 , P < 0.001 ) .	negative	0
17213	10912627	3553;847	Interleukin 1beta;catalase	***Interleukin 1beta*** ***decreases*** the GSH content and ***catalase*** activity in the human peritoneal mesothelial cells in vitro .	negative	0
17214	10912781	2247;5706	bFGF;p42	Our results indicate that ***bFGF*** could ***activate*** ***p42/p44*** MAPKs .	positive	1
17215	10912789	857;5578	caveolin-1;PKCalpha	The membranous localization of caveolins , and direct ***inhibition*** of receptor-coupled ***PKCalpha*** and rhoA translocation by the ***caveolin-1*** scaffolding domain , supports the concept that caveolins can regulate the integration of extracellular contractile stimuli and downstream intracellular effectors in smooth muscle .	negative	1
17216	10912789	857;387	caveolin-1;rhoA	The membranous localization of caveolins , and direct ***inhibition*** of receptor-coupled PKCalpha and ***rhoA*** translocation by the ***caveolin-1*** scaffolding domain , supports the concept that caveolins can regulate the integration of extracellular contractile stimuli and downstream intracellular effectors in smooth muscle .	negative	1
17217	10912790	7157;1026	p53;p21	X-ray-induced damage leads to cell-cycle " checkpoint " arrest by ***p53-dependent*** ***induction*** of the cyclin-dependent kinase inhibitor ***p21*** ( Waf1/Cip1/Sdi1 ) .	target	1
17218	10912791	1647;1026	Gadd45;p21	Results using both in vitro and in vivo methods have shown that the ***interaction*** of ***Gadd45*** with ***p21*** involves a central region of Gadd45 .	parallel	1
17219	10912791	1647;983	Gadd45;Cdc2	In addition , ***Gadd45*** ***inhibition*** of ***Cdc2*** kinase activity was compared with Myd118 and CR6 , two other members of the Gadd45 family .	negative	1
17220	10912792	983;891	CDK1;cyclin B1	The role of p21CIP1 in the inhibition of CDK1 was questionable , as we demonstrated that genistein impaired Tyr15 dephosphorylation of CDK1 and because ******CDK1-cyclin B1****** ***complexes*** from treated cells could be reactivated upon exposure to CDC25 phosphatase .	parallel	1
17221	10912923	356;355	FasL;Fas	******Fas-FasL****** ***interactions*** may for instance be involved in apoptosis of oligodendrocytes which occurs as a delayed phenomenon after trauma to the spinal cord .	parallel	1
17222	10912998	2925;2922	GRP-R;GRP	The hormone bombesin ( BBS ) and its mammalian equivalent gastrin-releasing peptide ( GRP ) act through specific ***GRP*** ***receptors*** ( ***GRP-R*** ) to affect multiple cellular functions in the gastrointestinal tract ; the intracellular signaling pathways leading to these effects are not clearly defined .	parallel	1
17223	10913000	841;835	caspase 8;caspase 2	These observations , together , suggest that ***caspase 8*** and/or caspase 9 ***mediates*** activation of caspase 3-like proteases and ***caspase 2*** during the apoptosis induced by peroxynitrite in HL-60 cells .	target	0
17224	10913000	842;835	caspase 9;caspase 2	These observations , together , suggest that caspase 8 and/or ***caspase 9*** ***mediates*** activation of caspase 3-like proteases and ***caspase 2*** during the apoptosis induced by peroxynitrite in HL-60 cells .	target	0
17225	10913017	355;356	Fas;FasL	This NO-induced macrophage apoptosis was inhibited by a ***Fas-Fc*** chimeric molecule that ***binds*** to Fas ligand ( ***FasL*** ) and prevents its interaction with endogenous cell surface Fas .	parallel	1
17226	10913017	356;355	FasL;Fas	This NO-induced macrophage apoptosis was inhibited by a Fas-Fc chimeric molecule that binds to ***Fas*** ***ligand*** ( ***FasL*** ) and prevents its interaction with endogenous cell surface Fas .	parallel	1
17227	10913062	3569;2353	IL6;c-fos	CONCLUSIONS : Although TNF alpha and ***IL6*** ***augmented*** ***c-fos*** gene expression of rheumatoid synovial cells , transactivation of c-fos gene became resistant against cytokine stimulation under prolonged expression of c-fos gene , which may impart a tumour-like characteristic to rheumatoid synovial cells .	positive	0
17228	10913062	7124;2353	TNF alpha;c-fos	CONCLUSIONS : Although ***TNF alpha*** and IL6 ***augmented*** ***c-fos*** gene expression of rheumatoid synovial cells , transactivation of c-fos gene became resistant against cytokine stimulation under prolonged expression of c-fos gene , which may impart a tumour-like characteristic to rheumatoid synovial cells .	positive	0
17229	10913111	4683;4361	NBS1;Mre11	The ***NBS1*** gene product , p95 ( NBS1 or nibrin ) forms a ***complex*** with Rad50 and ***Mre11*** .	parallel	1
17230	10913111	4683;10111	NBS1;Rad50	The ***NBS1*** gene product , p95 ( NBS1 or nibrin ) forms a ***complex*** with ***Rad50*** and Mre11 .	parallel	1
17231	10913114	8089;4926	GAS41;NuMA	The ******NuMA/GAS41****** ***interaction*** may provide a link between nuclear structure and gene expression .	parallel	1
17232	10913114	8089;4926	GAS41;NuMA	***GAS41*** , a highly conserved protein in eukaryotic nuclei , ***binds*** to ***NuMA*** .	parallel	1
17233	10913114	8089;4300	GAS41;AF-9	***GAS41*** is ***related*** to the ***AF-9*** and ENL proteins , which are putative transcription factors found as fusion proteins in some acute leukemias .	parallel	0
17234	10913114	8089;4298	GAS41;ENL	***GAS41*** is ***related*** to the AF-9 and ***ENL*** proteins , which are putative transcription factors found as fusion proteins in some acute leukemias .	parallel	0
17235	10913121	5553;5069	proMBP;PAPP-A	We further show that pregnancy serum and plasma contain traces ( < 1 % ) of uncomplexed PAPP-A with a much higher specific activity than the ******PAPP-A/proMBP****** ***complex*** .	parallel	1
17236	10913121	5553;5069	proMBP;PAPP-A	The measurable activity of the ******PAPP-A/proMBP****** ***complex*** probably results from the presence of a minor subpopulation of partly inhibited PAPP-A that exists in a 2:1 complex with proMBP .	parallel	1
17237	10913121	5553;5069	proMBP;PAPP-A	***Inhibition*** of ***PAPP-A*** by ***proMBP*** represents a novel inhibitory mechanism with the enzyme irreversibly bound to its inhibitor by disulfide bonds .	negative	1
17238	10913121	5069;3487	PAPP-A;IGF-binding protein (IGFBP)-4	***PAPP-A*** specifically ***cleaves*** ***IGF-binding protein (IGFBP)-4*** , one of six antagonists of IGF action , which results in release of IGF bound to IGFBP-4 .	target	1
17239	10913121	5553;5069	proMBP;PAPP-A	A comparison between rPAPP-A and pregnancy serum ******PAPP-A/proMBP****** ***complex*** surprisingly reveals a difference greater than 100-fold in proteolytic activity , showing that proMBP functions as a proteinase inhibitor in vivo .	parallel	1
17240	10913131	2549;4233	Gab1;Met	***Recruitment*** of ***Gab1*** to ***Met*** or epidermal growth factor ( EGF ) receptors requires a receptor-binding site for the Grb2 adapter protein and a proline-rich domain in Gab1 , defined as the Met-binding domain .	target	0
17241	10913131	2885;9402	Grb2;Gads	The PXXXR motif is required but not sufficient for Grb2 binding , whereas an extended motif , PX3RX2KPX7PLD , conserved in Gab proteins as well as the Grb2/Gads-docking protein , Slp-76 , efficiently competes ***binding*** of ***Grb2*** or ***Gads*** adapter proteins .	parallel	1
17242	10913131	2549;2885	Gab1;Grb2	The ***association*** of ***Gab1*** with ***Grb2*** is required for Gab1 recruitment to the EGF receptor but not the Met receptor .	parallel	0
17243	10913132	2641;5106	glucagon;PEPCK	Glucocorticoids , retinoic acid , and ***glucagon*** ( via its second messenger , cAMP ) ***stimulate*** ***PEPCK*** gene transcription , whereas insulin , phorbol esters , cytokines , and oxidative stress have an opposing effect .	positive	0
17244	10913132	5970;5106	p65;PEPCK	Further analysis suggests that ***p65*** ***represses*** ***PEPCK*** gene transcription through a protein.protein interaction with the coactivator , CREB binding protein .	negative	1
17245	10913135	5599;596	JNK;Bcl-2	Vinblastine-induced phosphorylation of ***Bcl-2*** and Bcl-XL is ***mediated*** by ***JNK*** and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade .	target	0
17246	10913135	5599;598	JNK;Bcl-XL	Vinblastine-induced phosphorylation of Bcl-2 and ***Bcl-XL*** is ***mediated*** by ***JNK*** and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade .	target	0
17247	10913135	3725;5599	c-Jun;JNK	A combination of AS-JNK1 with AS-JNK2 inhibited by 80 % vinblastine-induced phosphorylation of two known ***JNK*** ***substrates*** , ***c-Jun*** and ATF-2 .	parallel	1
17248	10913135	9479;3725	JIP-1;c-Jun	Stable expression of the JNK scaffold protein ***JIP-1*** ***blocked*** vinblastine-induced phosphorylation of ***c-Jun*** and ATF-2 , but did not affect Bcl-2/Bcl-X ( L ) phosphorylation , confirming a bifurcation in JNK signaling involving both nuclear and non-nuclear substrates .	negative	0
17249	10913138	6285;6271	S100B;S100A1	Deletion of the C-terminal domain or mutation of Phe ( 87 ) and Phe ( 88 ) residues has no effect on ***S100B*** ***homodimerization*** and heterodimerization with ***S100A1*** but drastically decreases interaction between S100B and S100A6 or S100A11 .	parallel	1
17250	10913138	6285;6277	S100B;S100A6	Deletion of the C-terminal domain or mutation of Phe ( 87 ) and Phe ( 88 ) residues has no effect on S100B homodimerization and heterodimerization with S100A1 but drastically decreases ***interaction*** between ***S100B*** and ***S100A6*** or S100A11 .	parallel	1
17251	10913138	6282;6277	S100A11;S100A6	Our data suggest that the ***interaction*** between S100B and ***S100A6*** or ***S100A11*** should not be viewed as a typical S100 heterodimerization but rather as a model of interaction between S100B and target proteins .	parallel	1
17252	10913138	6282;6285	S100A11;S100B	Our data suggest that the ***interaction*** between ***S100B*** and S100A6 or ***S100A11*** should not be viewed as a typical S100 heterodimerization but rather as a model of interaction between S100B and target proteins .	parallel	1
17253	10913138	6285;6277	S100B;S100A6	Our data suggest that the ***interaction*** between ***S100B*** and ***S100A6*** or S100A11 should not be viewed as a typical S100 heterodimerization but rather as a model of interaction between S100B and target proteins .	parallel	1
17254	10913141	4153;5648	MBP;MASP	In order to investigate the mechanisms of ***MASP*** ***activation*** by ***MBP*** , the cDNAs of rat MASP-1 and -2 have been isolated , and portions encompassing the N-terminal CUB and epidermal growth factor-like domains have been expressed and purified .	positive	1
17255	10913141	4153;5648	MBP;MASP	Analysis of ***MASP*** ***binding*** by rat ***MBP*** containing naturally occurring mutations equivalent to those associated with human immunodeficiency indicates that binding to both truncated MASP-1 and MASP-2 proteins is defective in such mutants .	parallel	1
17256	10913154	1026;983	p21;Cdc2	***p21*** ***inhibits*** Thr161 phosphorylation of ***Cdc2*** to enforce the G2 DNA damage checkpoint .	negative	1
17257	10913154	1026;983	p21;Cdc2	We show that ***p21*** ***blocks*** the activating phosphorylation of ***Cdc2*** on Thr ( 161 ) .	negative	0
17258	10913155	1634;1956	decorin;epidermal growth factor receptor	Sustained ***down-regulation*** of the ***epidermal growth factor receptor*** by ***decorin*** .	negative	1
17259	10913155	1634;1956	decorin;EGFR	The small leucine-rich proteoglycan ***decorin*** ***interacts*** with the epidermal growth factor receptor ( ***EGFR*** ) and triggers a signaling cascade that leads to elevation of endogenous p21 and growth suppression .	parallel	1
17260	10913161	3320;2058	hsp90;EPRS	***Interaction*** of ***hsp90*** with human glutamyl-prolyl-tRNA synthetase ( ***EPRS*** ) was found by genetic screening , co-immunoprecipitation , and in vitro binding experiments .	parallel	1
17261	10913161	2058;3320	EPRS;hsp90	***Interaction*** of ***EPRS*** with ***hsp90*** was targeted to the region of three tandem repeats linking the two catalytic domains of EPRS that is also responsible for the interaction with isoleucyl-tRNA synthetase ( IRS ) .	parallel	1
17262	10913161	3376;2058	IRS;EPRS	***Interaction*** of ***EPRS*** and ***IRS*** also depended on the activity of hsp90 , implying that their association was mediated by hsp90 .	parallel	1
17263	10913166	2120;4314	TEL;stromelysin-1	To begin to explain the morphology of Ras-plus TEL-expressing cells , we demonstrated that the endogenous matrix metalloproteinase ***stromelysin-1*** was ***repressed*** by ***TEL*** .	negative	1
17264	10913168	3960;1178	GAL4;GAL10	Finally , we show that ***activation*** of the ***GAL10*** promoter by ***GAL4*** , which requires chromatin remodeling , can occur even in swi gcn5 yeast , implying that remodeling pathways independent of gcn5 , the SWI-SNF complex , and TFIID can operate during transcriptional activation in vivo .	positive	1
17265	10913172	5884;5981	rad24;RFC	Together , these results indicate that Rfc5 , like rad24 , functions in all the G ( 1 ) - , S - and G ( 2 ) / M-phase DNA damage checkpoints and suggest that the ***interaction*** of ***rad24*** with the ***RFC*** proteins is essential for DNA damage checkpoint control .	parallel	1
17266	10913173	904;1025	cyclin T1;Cdk9	We show here that the P-TEFb ***heterodimer*** of ******Cdk9-cyclin T1****** is intrinsically incapable of forming a stable complex with Tat and TAR due to two built-in autoinhibitory mechanisms in P-TEFb .	parallel	1
17267	10913173	904;27336	cyclin T1;Tat-SF1	This inhibition is relieved by the ***binding*** of the C-terminal region of ***cyclin T1*** to the transcription elongation factor ***Tat-SF1*** and perhaps other cellular factors .	parallel	1
17268	10913176	7157;9013	p53;SL1	Protein-protein interaction assays indicate that ***p53*** ***binds*** to ***SL1*** , and this interaction is mostly mediated by direct contacts with TATA-binding protein and TAF ( I ) 110 .	parallel	1
17269	10913176	7343;9013	UBF;SL1	Moreover , template commitment assays show that while the formation of a ******UBF-SL1****** ***complex*** can partially relieve the inhibition of transcription , only the assembly of a UBF-SL1-Pol I initiation complex on the rDNA promoter confers substantial protection against p53 inhibition .	parallel	1
17270	10913176	7343;9013	UBF;SL1	Our biochemical analysis shows that p53 prevents the ***interaction*** between ***SL1*** and ***UBF*** .	parallel	1
17271	10913184	1981;1973	eIF4G;eIF4A	Physical ***association*** of eukaryotic initiation factor 4G ( ***eIF4G*** ) with ***eIF4A*** strongly enhances binding of eIF4G to the internal ribosomal entry site of encephalomyocarditis virus and is required for internal initiation of translation .	parallel	0
17272	10913184	1973;1981	eIF4A;eIF4G	These data indicate that the ******eIF4G-eIF4A****** ***complex*** , rather than eIF4G alone , is required for specific high-affinity binding to the EMCV IRES and for internal ribosomal entry on this RNA .	parallel	1
17273	10913187	4261;1385	CIITA;CREB	Transcriptional scaffold : ***CIITA*** ***interacts*** with NF-Y , RFX , and ***CREB*** to cause stereospecific regulation of the class II major histocompatibility complex promoter .	parallel	1
17274	10913187	4261;5989	CIITA;RFX	Transcriptional scaffold : ***CIITA*** ***interacts*** with NF-Y , ***RFX*** , and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter .	parallel	1
17275	10913187	4261;1385	CIITA;CREB	We propose that ***binding*** of NF-Y/CBF , RFX , and ***CREB*** by ***CIITA*** results in a macromolecular complex which allows transcription factors to interact with the class II MHC promoter in a spatially and helically constrained fashion .	parallel	1
17276	10913187	4261;5989	CIITA;RFX	We propose that ***binding*** of NF-Y/CBF , ***RFX*** , and CREB by ***CIITA*** results in a macromolecular complex which allows transcription factors to interact with the class II MHC promoter in a spatially and helically constrained fashion .	parallel	1
17277	10913187	5989;1385	RFX;CREB	We propose that ***binding*** of NF-Y/CBF , ***RFX*** , and ***CREB*** by CIITA results in a macromolecular complex which allows transcription factors to interact with the class II MHC promoter in a spatially and helically constrained fashion .	parallel	1
17278	10913188	84959;10213	STS1;RPN11	***STS1*** also ***interacted*** with the second suppressor , ***RPN11*** , a subunit of the 26S proteasome , in the two-hybrid system .	parallel	1
17279	10913189	5911;2002	Rap2;Elk1	***Rap2*** bound to the Ras-binding domain of Raf and ***inhibited*** Ras-dependent activation of ***Elk1*** transcription factor , as did Rap1 .	negative	1
17280	10913189	6714;5911	Src;Rap2	The level of ***GTP-Rap2*** in rat 3Y1 fibroblasts was ***decreased*** by the expression of ***v-Src*** , and expression of a GTPase-deficient Rap2 mutant inhibited v-Src-dependent transformation of 3Y1 cells .	negative	0
17281	10913190	5594;7124	ERK;TNF-alpha	In LPS-stimulated macrophages , the ***ERK*** substrates Ets and Elk-1 ***bind*** to the ***TNF-alpha*** promoter in vivo .	parallel	1
17282	10913193	5753;10657	BRK;Sam68	Sik ( ***BRK*** ) ***phosphorylates*** ***Sam68*** in the nucleus and negatively regulates its RNA binding ability .	target	1
17283	10913193	5753;10657	BRK;Sam68	Here we demonstrate that Sik and ***BRK*** ***associate*** with the RNA binding protein ***Sam68*** ( Src associated during mitosis , 68 kDa ) .	parallel	0
17284	10913197	3725;2521	c-jun;FUS	***FUS*** proteolysis is ***induced*** by ***c-jun*** , is suppressed by BCR-ABL or Jun kinase 1 , and does not depend on c-jun transactivation potential , ubiquitination , or its interaction with Jun kinase 1 .	target	1
17285	10913197	5601;2521	Jun kinase;FUS	***FUS*** proteolysis is induced by c-jun , is ***suppressed*** by BCR-ABL or ***Jun kinase*** 1 , and does not depend on c-jun transactivation potential , ubiquitination , or its interaction with Jun kinase 1 .	negative	1
17286	10913198	3280;1026	HES-1;p21	***HES-1*** expression strongly ***repressed*** transcription of the ***p21*** ( cip1 ) promoter , a cyclin-cyclin-dependent kinase inhibitor up regulated during NGF-induced differentiation , and the H-3 / 4 domain is necessary for this repression .	negative	1
17287	10913256	2064;2065	HER2;HER3	Binding of hrg releases HER3 which may then form signaling-competent ******HER3-HER2****** ***heterodimers*** .	parallel	1
17288	10913276	5335;3265	PLC-gamma1;p21Ras	This study is the first to demonstrate that the ***PLC-gamma1*** SH3 domain ***enhances*** ***p21Ras*** activity , and that the SH3 domain of PLC-gamma1 may be involved in the SOS1-mediated signaling pathway .	positive	0
17289	10913276	5335;6654	PLC-gamma1;SOS1	The ***interaction*** between ***SOS1*** and the ***PLC-gamma1*** SH3 domain is mediated by direct physical interaction .	parallel	1
17290	10913300	5745;5741	PTHR1;parathyroid hormone	These results demonstrate that the extracellular N-terminal domain of the ***parathyroid hormone*** ***receptor*** ( ***PTHR1*** ) possesses a well-defined , stable conformation , which shows a significant ligand binding activity .	parallel	1
17291	10913301	1803;2641	Dipeptidylpeptidase IV;GLP-2	***Dipeptidylpeptidase IV*** ***cleaves*** ***GLP-2*** at the position 2 alanine , resulting in the inactivation of peptide activity .	target	1
17292	10913304	2117;4312	PE1;MMP1	Recombinant PE1 binds authentic AGGAWG Ets DNA cognates , and transient transfection studies demonstrate that ***PE1*** ***represses*** ***MMP1*** promoter activity .	negative	1
17293	10913304	2117;4312	PE1;interstitial collagenase	Ets domain transcription factor ***PE1*** ***suppresses*** human ***interstitial collagenase*** promoter activity by antagonizing protein-DNA interactions at a critical AP1 element .	negative	1
17294	10913312	811;821	CRT;CNX	Trapping of apo ( a ) N-linked glycans in their monoglucosylated form , by posttranslational inhibition of ER glucosidase activity with castanospermine ( CST ) , enhanced apo ( a ) - ******CNX/CRT****** ***interaction*** and prevented both apo ( a ) secretion and ERAD .	parallel	1
17295	10913312	811;821	CRT;CNX	These results are consistent with a transient apo ( a ) - ******CNX/CRT****** ***association*** and suggest that events downstream of CNX/CRT interaction determine apo ( a ) intracellular targeting .	parallel	0
17296	10913312	811;821	CRT;CNX	These results are consistent with a transient apo ( a ) - CNX/CRT association and suggest that events downstream of ******CNX/CRT****** ***interaction*** determine apo ( a ) intracellular targeting .	parallel	1
17297	10913312	811;821	CRT;CNX	Inhibition of ER mannosidase I with deoxymannojirimycin or kifunensine had no effect on apo ( a ) secretion , but inhibited proteasome-mediated apo ( a ) ERAD even under conditions where apo ( a ) - ******CNX/CRT****** ***interaction*** was prevented .	parallel	1
17298	10913332	4982;8600	Osteoprotegerin;OPGL	Recombinant human ***Osteoprotegerin*** ( OPG ) , which ***binds*** strongly to ***OPGL*** , inhibited this translocation of osteoclasts that occurred with PGE ( 2 ) and 1,25 D ( 3 ) , leaving integrin beta-3-negative osteoclasts on the periosteum .	parallel	1
17299	10913336	3060;7054	orexin;tyrosine hydroxylase	***orexin-A*** and - B ( 100 nM ) significantly ***reduced*** basal and PACAP-induced ***tyrosine hydroxylase*** ( TH ) ( the rate-limiting enzyme in the biosynthesis of catecholamines ) mRNA levels .	negative	1
17300	10913368	7132;6610	TNF-R55;N-SMase	We have previously shown that a cytoplasmic region of ***TNF-R55*** distinct from the death domain ***regulates*** the activation of ***N-SMase*** through binding of the adapter protein FAN .	target	1
17301	10913370	7040;5747	TGF-beta1;FAK	Furthermore , our results showed that ***TGF-beta1*** treatment ***stimulated*** the tyrosine phosphorylation level of ***FAK*** , which can be activated by the ligation and clustering of integrins .	positive	0
17302	10913370	5728;5747	PTEN;FAK	***PTEN*** can directly ***dephosphorylate*** ***FAK*** , and the results that TGF-beta 1 could down-regulate PTEN at protein level suggested that TGF-beta 1 might stimulate FAK phosphorylation through increasing integrin signaling and reducing dephosphorylation of FAK .	target	1
17303	10913370	7040;5728	TGF-beta 1;PTEN	PTEN can directly dephosphorylate FAK , and the results that ***TGF-beta 1*** could ***down-regulate*** ***PTEN*** at protein level suggested that TGF-beta 1 might stimulate FAK phosphorylation through increasing integrin signaling and reducing dephosphorylation of FAK .	negative	1
17304	10913370	7040;5747	TGF-beta 1;FAK	PTEN can directly dephosphorylate FAK , and the results that TGF-beta 1 could down-regulate PTEN at protein level suggested that ***TGF-beta 1*** might ***stimulate*** ***FAK*** phosphorylation through increasing integrin signaling and reducing dephosphorylation of FAK .	positive	0
17305	10913668	7422;2152	VEGF;tissue factor	The expression of ***tissue factor*** ( TF ) , an initiator of extrinsic blood coagulation , was ***upregulated*** by ***VEGF*** in retinal vascular endothelial cells ( REC ) .	positive	1
17306	10913818	1938;29904	eEF-2;eEF-2K	TS-2 inhibited ATP or ***eEF-2*** ***binding*** to ***eEF-2K*** in a competitive or non-competitive manner , respectively .	parallel	1
17307	10913841	1081;3973	hCG;LHR	***Interactions*** of the placental glycoprotein hormone human choriogonadotropin ( ***hCG*** ) with lutropin receptors ( ***LHR*** ) are required for maintenance of early pregnancy .	parallel	1
17308	10913841	1081;3973	hCG;LHR	Knowledge of how ***hCG*** ***interacts*** with ***LHR*** is useful for understanding the mechanism of receptor function , an issue of considerable debate .	parallel	1
17309	10913841	3973;1081	LHR;hCG	This extends the area of hCG known to be exposed in the hormone receptor complex , an observation that further restricts models of ******hCG-LHR****** ***interaction*** .	parallel	1
17310	10913939	5617;7200	prolactin;thyrotropin-releasing hormone	OBJECTIVE : Our aim has been to evaluate the effects of i.v. infusion of recombinant human erythropoietin ( rhEPO ) on the ***responses*** of growth hormone ( GH ) , ***prolactin*** ( PRL ) and thyrotropin ( TSH ) to ***thyrotropin-releasing hormone*** ( TRH ) stimulation in acromegalic patients .	parallel	0
17311	10913943	7124;3952	TNF-alpha;leptin	As ***TNF-alpha*** appears to ***regulate*** ***leptin*** secretion , we speculated that TNF-alpha might be involved in leptin variations during the menstrual cycle .	target	1
17312	10913950	5618;5617	prolactin receptor;prolactin	Our results suggest that the short form of the ***prolactin receptor*** alone is unlikely to ***mediate*** the luteolytic action of ***prolactin*** , but that luteolytic events may be influenced via a change in the ratio of the two receptor isoforms .	target	0
17313	10913950	5617;5618	prolactin;prolactin receptor	In corpora lutea responding to a trophic prolactin signal , the long form of the ***prolactin receptor*** is the dominant form and is ***upregulated*** by ***prolactin*** .	positive	1
17314	10914028	8795;8743	DR5;TRAIL	Protocols are given for a specific ligand-receptor pair , namely TRAIL ( Apo-2L ) and ***TRAIL*** ***receptor*** 2 ( ***DR5*** ) , but can be applied to other ligands and receptors of the TNF family .	parallel	1
17315	10914492	3689;3383	Mac-1;intercellular adhesion molecule-1	The respiratory burst of neutrophils stimulated by chemotactic factors is markedly augmented by Mac-1-dependent adhesion such as the ***interaction*** of ***Mac-1*** ( CD11b/CD18 ) with ***intercellular adhesion molecule-1*** ( ICAM-1 ; CD54 ) expressed on the surface of parenchymal cells ( e.g. , cardiac myocytes ) .	parallel	1
17316	10914492	3689;3383	LFA-1;ICAM-1	To isolate ******LFA-1/ICAM-1****** ***interactions*** from Mac-1 / ICAM-1 interactions , full-length chimeric ICAM-1 was developed and expressed in L cells with domains 1 and 2 from canine ICAM-1 and domains 3-5 from human ICAM-1 ( C1 ,2 ; H3-5 ) .	parallel	1
17317	10914493	356;355	FasL;Fas	C57BL/6 and BALB/c T cells can lyse Renca cells through the use of both granule - and ***Fas*** ***ligand*** ( ***FasL*** ) - mediated pathways .	parallel	1
17318	10914496	4914;596	TrkA;Bcl-2	***TrkA*** stimulation ***up-regulates*** the expression of the anti-apoptotic Bcl-2 family members , ***Bcl-2*** , Bcl-XL , and Bfl-1 .	positive	1
17319	10914496	4914;598	TrkA;Bcl-XL	***TrkA*** stimulation ***up-regulates*** the expression of the anti-apoptotic Bcl-2 family members , Bcl-2 , ***Bcl-XL*** , and Bfl-1 .	positive	1
17320	10914496	4914;597	TrkA;Bfl-1	***TrkA*** stimulation ***up-regulates*** the expression of the anti-apoptotic Bcl-2 family members , Bcl-2 , Bcl-XL , and ***Bfl-1*** .	positive	1
17321	10914554	1440;5777	granulocyte colony-stimulating factor;protein tyrosine phosphatase SHP-1	The SH2 domain-containing ***protein tyrosine phosphatase SHP-1*** is ***induced*** by ***granulocyte colony-stimulating factor*** ( G-CSF ) and modulates signaling from the G-CSF receptor .	target	1
17322	10914734	1869;1029	E2F-1;p14	Here we report that sequential transfer of the wild-type p53 and E2F-1 genes efficiently induces apoptosis in human esophageal cancer cells and that ***E2F-1*** overexpression directly , ***activates*** expression of ***p14*** ( ARF ) , which inhibits MDM2-mediated p53 degradation , resulting in the stabilization of p53 .	positive	1
17323	10914734	1029;7157	p14;p53	Here we report that sequential transfer of the wild-type p53 and E2F-1 genes efficiently induces apoptosis in human esophageal cancer cells and that E2F-1 overexpression directly , activates expression of ***p14*** ( ARF ) , which ***inhibits*** MDM2-mediated ***p53*** degradation , resulting in the stabilization of p53 .	negative	1
17324	10914734	4193;7157	MDM2;p53	Transfection of ARF plasmid decreased ***MDM2*** protein expression , which in turn ***increased*** ***p53*** protein expression .	positive	0
17325	10914734	7157;4193	p53;MDM2	Moreover , Ad-E2F-1-mediated ARF expression inhibited the ***up-regulation*** of ***MDM2*** by overexpressed ***p53*** in TE8 cells .	positive	1
17326	10914841	2353;7076	c-fos;TIMP-1	RESULTS : Introduction of ***c-fos*** in the chondrocytes ***decreased*** endogenous transcription of Type II collagen and ***TIMP-1*** , and increased that of MMP-1 .	negative	0
17327	10915217	7349;1393	urocortin;CRF-binding protein	The expression and activities of corticotrophin-releasing factor ( CRF ) , ***urocortin*** ( UCN ) , the ***CRF-binding protein*** ( CRF-BP ) and CRF ***receptors*** in rat brain have been well documented ; however , information regarding their peripheral distributions remains incomplete .	parallel	1
17328	10915556	356;355	CD95L;CD95	******CD95/CD95L****** ***interactions*** are vital to normal lymphoid homeostasis and in the protection against autoimmunity .	parallel	1
17329	10915556	356;959	CD95L;IgM	Moreover , despite the specific caspase-8 inhibitor z-IETD-fmk substantially protecting transformed CL-01 B cells from CD95L fp-mediated apoptosis and permitting their ongoing proliferation , caspase-8 inhibition had no protective effects on ***CD95L*** fp-mediated ***inhibition*** of constitutive ***IgM*** production by CL-01 B cells .	negative	1
17330	10915569	7040;4803	TGFbeta;NGF	The aim of this study was to investigate if ***TGFbeta*** may ***influence*** NGF-induced neuronal transformation and regulation of ***NGF*** , TGFbeta1 , and their receptors in the adult rat chromaffin tissue after grafting .	target	0
17331	10915727	7040;4092	TGF-beta;Smad 7	Taken together , these results indicate that endogenous ***TGF-beta-mediated*** ***induction*** of ***Smad 7*** results in a higher " threshold " for the antiproliferative signals mediated by receptor-regulated Smads , and can be involved in reduced responsiveness to the cytokine in some human HCC cells .	target	1
17332	10915759	7249;7248	tuberin;hamartin	An ***interaction*** of ***hamartin*** and ***tuberin*** can be detected in every phase of the cell cycle .	parallel	1
17333	10915759	7248;7249	hamartin;tuberin	We provide evidence that this effect could depend on a coiled-coil region earlier proposed to be involved in ***binding*** of ***hamartin*** to ***tuberin*** .	parallel	1
17334	10915780	3611;595	ILK;cyclin D1	We conclude that the cyclin D1 gene is regulated by the Wnt-1 and ILK signaling pathways and that ***ILK*** ***induction*** of ***cyclin D1*** involves the CREB signaling pathway in mammary epithelial cells .	target	1
17335	10915780	3611;595	ILK;cyclin D1	We conclude that the ***cyclin D1*** gene is ***regulated*** by the Wnt-1 and ***ILK*** signaling pathways and that ILK induction of cyclin D1 involves the CREB signaling pathway in mammary epithelial cells .	target	1
17336	10915780	7471;595	Wnt-1;cyclin D1	We conclude that the ***cyclin D1*** gene is ***regulated*** by the ***Wnt-1*** and ILK signaling pathways and that ILK induction of cyclin D1 involves the CREB signaling pathway in mammary epithelial cells .	target	1
17337	10915780	3611;595	integrin-linked kinase;cyclin D1	The ***integrin-linked kinase*** ***regulates*** the ***cyclin D1*** gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways .	target	1
17338	10915780	3611;595	ILK;cyclin D1	We show here that ***ILK*** overexpression ***elevates*** ***cyclin D1*** protein levels and directly induces the cyclin D1 gene in mammary epithelial cells .	positive	0
17339	10915780	3611;595	ILK;cyclin D1	We show here that ***ILK*** overexpression elevates cyclin D1 protein levels and directly ***induces*** the ***cyclin D1*** gene in mammary epithelial cells .	target	1
17340	10915780	3611;595	ILK;cyclin D1	***ILK*** ***activation*** of the ***cyclin D1*** promoter was abolished by point mutation of a cAMP-responsive element-binding protein ( CREB ) / ATF-2 binding site at nucleotide -54 in the cyclin D1 promoter , and by overexpression of either glycogen synthase kinase-3beta ( GSK-3beta ) or dominant negative mutants of CREB or ATF-2 .	positive	1
17341	10915780	3611;595	ILK;cyclin D1	Inhibition of the PI 3-kinase and AKT/protein kinase B , but not of the p38 , ERK , or JNK signaling pathways , reduced ***ILK*** ***induction*** of ***cyclin D1*** expression .	target	1
17342	10915780	3611;1385	ILK;CREB	***ILK*** ***induced*** CREB transactivation and ***CREB*** binding to the cyclin D1 promoter CRE .	target	1
17343	10915780	7471;595	Wnt-1;cyclin D1	Wnt-1 overexpression in mammary epithelial cells induced cyclin D1 mRNA and targeted overexpression of ***Wnt-1*** in the mammary gland of transgenic mice ***increased*** both ILK activity and ***cyclin D1*** levels .	positive	0
17344	10915780	7471;3611	Wnt-1;ILK	Wnt-1 overexpression in mammary epithelial cells induced cyclin D1 mRNA and targeted overexpression of ***Wnt-1*** in the mammary gland of transgenic mice ***increased*** both ***ILK*** activity and cyclin D1 levels .	positive	0
17345	10915780	7471;595	Wnt-1;cyclin D1	***Wnt-1*** overexpression in mammary epithelial cells ***induced*** ***cyclin D1*** mRNA and targeted overexpression of Wnt-1 in the mammary gland of transgenic mice increased both ILK activity and cyclin D1 levels .	target	1
17346	10915785	2353;8061	AP-1;fra-1	The ***AP-1*** sequence specifically ***bound*** to ***fra-1*** , junD , and junB in H441 lung adenocarcinoma nuclear extracts .	parallel	1
17347	10915785	2353;3726	AP-1;junB	The ***AP-1*** sequence specifically ***bound*** to fra-1 , junD , and ***junB*** in H441 lung adenocarcinoma nuclear extracts .	parallel	1
17348	10915785	2353;3727	AP-1;junD	The ***AP-1*** sequence specifically ***bound*** to fra-1 , ***junD*** , and junB in H441 lung adenocarcinoma nuclear extracts .	parallel	1
17349	10915788	2185;5594	PYK2;ERK	Overexpression of a wild-type ***PYK2*** ***enhanced*** ***ERK*** activation in response to histamine , whereas a kinase-deficient mutant substantially inhibited this response .	positive	0
17350	10915799	7306;821	TRP-1;calnexin	During the normal folding pathway , ***TRP-1*** ***interacts*** with ***calnexin*** .	parallel	1
17351	10915800	5594;7555	Erk1/2;sterol regulatory element-binding protein	MAP kinases ***Erk1/2*** ***phosphorylate*** ***sterol regulatory element-binding protein*** ( SREBP ) -1 a at serine 117 in vitro .	target	1
17352	10915862	2067;2072	Rad10;Rad1	This reaction requires the damage binding factors Rad14 , RPA , and the Rad4-Rad23 complex , the transcription factor TFIIH which contains the two DNA helicases Rad3 and Rad25 , essential for creating a bubble structure , and the two endonucleases , the ******Rad1-Rad10****** ***complex*** and Rad2 , which incise the damaged DNA strand on the 5 ' - and 3 ' - side of the lesion , respectively .	parallel	1
17353	10915907	2247;5594	bFGF;ERK1/2	Recombinant human ***bFGF*** ( 0.1-10 ng/ml ) ***induced*** phosphorylation of p44/42 MAPK ( ***ERK1/2*** ) in a concentration - and time-dependent manner .	target	1
17354	10915907	2247;5706	bFGF;p44	Recombinant human ***bFGF*** ( 0.1-10 ng/ml ) ***induced*** phosphorylation of ***p44/42*** MAPK ( ERK1/2 ) in a concentration - and time-dependent manner .	target	1
17355	10916078	6714;1956	Src;EGFR	CONCLUSION : Our data suggest that EGFR serves as a role in mitogenic signaling following stimulation with Ang I through a ligand-independent and ***Src-dependent*** ***transactivation*** of the ***EGFR*** .	positive	1
17356	10916078	6714;1956	Src;epidermal growth factor receptor	Angiotensin II-induced growth of vascular smooth muscle cells requires an ***Src-dependent*** ***activation*** of the ***epidermal growth factor receptor*** .	positive	1
17357	10916092	1432;6696	p38 MAP kinase;OPN	In addition , hypoxia causes an activation of p38 MAP kinase in a calcium - and PKC-dependent manner , and the activation of PKC and ***p38 MAP kinase*** appears to be involved in the ***stimulation*** of both ***OPN*** and mesangial cell proliferation induced by hypoxia .	positive	0
17358	10916096	3816;3827	tissue kallikrein;kininogen	BACKGROUND : ***tissue kallikrein*** ***cleaves*** ***kininogen*** substrate to produce the potent vasodilating peptide kinin , which plays important roles in cardiovascular and renal function .	target	1
17359	10916096	9622;213	kallikrein;albumin	***kallikrein*** gene delivery significantly ***decreased*** total urinary protein and ***albumin*** excretion and increased levels of urinary kinin , nitrite/nitrate , and cGMP levels .	negative	0
17360	10917533	643;10563	CXCR5;B-lymphocyte chemoattractant	Using gene-targeted mice , we establish that ***B-lymphocyte chemoattractant*** ( BLC/BCA1 ) and its ***receptor*** , ***CXCR5*** , are needed for B-cell homing to follicles in lymph nodes as well as in spleen .	parallel	1
17361	10917756	1499;324	beta-catenin;APC	[ Discovery of new frizzled gene of human esophageal neoplasms regulating ******APC/beta-catenin****** ***signaling*** ] .	parallel	0
17362	10918061	4352;7066	c-Mpl;thrombopoietin	A structure-function analysis of serine/threonine phosphorylation of the ***thrombopoietin*** ***receptor*** , ***c-Mpl*** .	parallel	1
17363	10918063	3725;6699	AP-1;SPRR1B	Together , these results suggest that a PKCdelta/Ras/MEKK1 / ***MKK1-dependent/AP-1*** pathway ***regulates*** the PMA-inducible expression of the ***SPRR1B*** in tracheobronchial epithelial cells .	target	1
17364	10918063	4214;6699	MEKK1;SPRR1B	Together , these results suggest that a ***PKCdelta/Ras/MEKK1*** / MKK1-dependent/AP-1 pathway ***regulates*** the PMA-inducible expression of the ***SPRR1B*** in tracheobronchial epithelial cells .	target	1
17365	10918063	5604;6699	MKK1;SPRR1B	Together , these results suggest that a PKCdelta/Ras/MEKK1 / ***MKK1-dependent/AP-1*** pathway ***regulates*** the PMA-inducible expression of the ***SPRR1B*** in tracheobronchial epithelial cells .	target	1
17366	10918063	5604;6699	MKK1;SPRR1B	However , ***MKK1-mediated*** ***induction*** of ***SPRR1B*** probably does not depend on extracellular signal-regulated kinases 1 and 2 , suggesting the requirement of another kinase ( s ) .	target	1
17367	10918184	2355;595	fra-2;cyclin D1	Fra-1 expression was significantly associated with p16 and cyclin E over-expression , whereas ***fra-2*** results ***correlated*** with both ***cyclin D1*** and cyclin E.	parallel	0
17368	10918184	8061;1029	Fra-1;p16	***Fra-1*** expression was significantly ***associated*** with ***p16*** and cyclin E over-expression , whereas fra-2 results correlated with both cyclin D1 and cyclin E.	parallel	0
17369	10918187	2065;1956	c-erbB-3;erbB	Therefore , the patterns of expression of the receptors , epidermal growth factor receptor ( EGF-R ) , c-erbB-2 , ***c-erbB-3*** , c-erbB-4 , and one of the ***erbB*** ***ligands*** , heregulin ( HRG ) , were examined in normal and malignant breast cell lines and compared with expression of oestrogen receptor ( ER ) , a classical indicator of good prognosis .	parallel	1
17370	10918195	941;3458	B7-1;IFN gamma	Our results indicate that ***B7-1*** , ***IFN gamma*** and the blockade of CTLA-4 ***cooperate*** to tilt the balance in favour of tumor elimination , while either factor alone fails to do so or even promotes tumor growth .	parallel	0
17371	10918195	1493;941	CTLA-4;B7-1	Our results indicate that ***B7-1*** , IFN gamma and the blockade of ***CTLA-4*** ***cooperate*** to tilt the balance in favour of tumor elimination , while either factor alone fails to do so or even promotes tumor growth .	parallel	0
17372	10918195	1493;3458	CTLA-4;IFN gamma	Our results indicate that B7-1 , ***IFN gamma*** and the blockade of ***CTLA-4*** ***cooperate*** to tilt the balance in favour of tumor elimination , while either factor alone fails to do so or even promotes tumor growth .	parallel	0
17373	10918218	8829;7422	neuropilin-1;VEGF	The expression of ***neuropilin-1*** , an isoform-specific ***receptor*** for ***VEGF*** ( 165 ) which enhances the binding of VEGF ( 165 ) to KDR , was also up-regulated in the same RA synovia that expressed KDR .	parallel	1
17374	10918218	7422;3791	VEGF;KDR	The expression of neuropilin-1 , an isoform-specific receptor for VEGF ( 165 ) which enhances the ***binding*** of ***VEGF*** ( 165 ) to ***KDR*** , was also up-regulated in the same RA synovia that expressed KDR .	parallel	1
17375	10918446	836;1026	Procaspase 3;p21	Inside the cell , ***Procaspase 3*** ***interacts*** with ***p21*** on mitochondria .	parallel	1
17376	10918446	1026;836	p21;Procaspase 3	This mitochondrial damage occurs before an estrangement of the ******Procaspase 3/p21****** ***complex*** , and we demonstrate that intracellular ATP-deprivation also initiates an estrangement of Procaspase 3/p21 complex formation and accelerates Fas-mediated cell death .	parallel	1
17377	10918446	1026;836	p21;Procaspase 3	In addition , our current results revealed that the phosphorylated ***p21*** by PKA ***interacts*** with ***Procaspase 3*** .	parallel	1
17378	10918504	7124;4790	tumor necrosis factor alpha;NFkappaB	The expression of several cytokines and adhesion molecules is regulated by the transcription factor ***NFkappaB*** , which is ***activated*** by ***tumor necrosis factor alpha*** ( TNF-alpha ) .	positive	1
17379	10918540	2908;3952	glucocorticoid receptor;leptin	Lymphocyte ***glucocorticoid receptor*** mRNA ***correlates*** negatively to serum ***leptin*** in normal weight subjects .	negative	0
17380	10918571	5781;207	Shp-2;Akt	***Shp-2*** ***mediates*** v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase ***Akt*** .	target	0
17381	10918571	5781;6714	Shp-2;Src	The protein-tyrosine phosphatase ***Shp-2*** is a positive ***modulator*** of the Ras/mitogen-activated protein kinase pathway and a putative substrate of the transforming non-receptor tyrosine kinase ***v-Src*** .	positive	0
17382	10918571	6714;207	Src;Akt	Shp-2 deficiency also reduced ***v-Src-induced*** ***activation*** of the anti-apoptotic protein kinase ***Akt*** .	positive	1
17383	10918571	5781;207	Shp-2;Akt	***Shp-2*** deficiency also ***reduced*** v-Src-induced activation of the anti-apoptotic protein kinase ***Akt*** .	positive	1
17384	10918571	23368;867	p85;Cbl	The reduced activation of Akt in Shp-2-deficient cells correlated with a reduction in the ***association*** of the ***p85*** regulatory subunit of PI3-kinase with the adapter protein ***Cbl*** .	parallel	0
17385	10918571	867;23368	Cbl;p85	Activation of PI3-kinase by v-Src may be mediated by the ***association*** of the adapter protein ***Cbl*** with the ***p85*** subunit .	parallel	0
17386	10918577	2885;25	Grb2;c-Abl	We now report that plating cells on fibronectin triggers ***association*** of ***Grb2*** with ***c-Abl*** , suggesting possible involvement of c-Abl with integrin activation of the MAP kinase pathway .	parallel	0
17387	10918579	332;1019	Survivin;Cdk4	Further , we also observed that ***Survivin*** competitively ***interacted*** with the ***Cdk4/p16*** ( INK4a ) complex in a cell free system and in vivo .	parallel	1
17388	10918579	332;1029	Survivin;p16	Further , we also observed that ***Survivin*** competitively ***interacted*** with the ***Cdk4/p16*** ( INK4a ) complex in a cell free system and in vivo .	parallel	1
17389	10918579	1029;1019	p16;Cdk4	Further , we also observed that Survivin competitively interacted with the ******Cdk4/p16****** ( INK4a ) ***complex*** in a cell free system and in vivo .	parallel	1
17390	10918581	3667;5595	IRS-1;ERK-1	Concomitant expression of ***IRS-1*** and v-Ha-Ras synergistically ***phosphorylates*** ***ERK-1*** and ERK-2 whereas a MEK inhibitor rapidly induces death of 32D/IRS1/Ras transformed cells .	target	1
17391	10918581	3667;5594	IRS-1;ERK-2	Concomitant expression of ***IRS-1*** and v-Ha-Ras synergistically ***phosphorylates*** ERK-1 and ***ERK-2*** whereas a MEK inhibitor rapidly induces death of 32D/IRS1/Ras transformed cells .	target	1
17392	10918582	4609;857	c-myc;Caveolin-1	***Caveolin-1*** is ***regulated*** by ***c-myc*** and suppresses c-myc-induced apoptosis .	target	1
17393	10918582	4609;857	c-myc;Caveolin-1	Recent data indicating that overexpression of Caveolin-1 as well as c-myc are relatively common features of advanced prostate cancer prompted us to test for potential cooperative ***interactions*** between ***Caveolin-1*** and ***c-myc*** that would be consistent with malignant progression .	parallel	1
17394	10918582	4609;857	c-myc;Caveolin-1	We used the well-characterized Rat1AmycERT cells to show that the ***Caveolin-1*** gene is ***down-regulated*** at the level of transcription by ***c-myc*** .	negative	1
17395	10918585	1440;6774	granulocyte colony-stimulating factor;STAT3	***granulocyte colony-stimulating factor*** ( G-CSF ) , a regulator of granulocytic differentiation , ***induces*** a robust and sustained activation of ***STAT3*** .	target	1
17396	10918587	2260;5266	FGFR1;PI-3	Finally , we demonstrate that ***FGFR1*** , FGFR3 , and FGFR4 derivatives can ***stimulate*** ***PI-3*** kinase activity .	positive	0
17397	10918587	2261;5266	FGFR3;PI-3	Finally , we demonstrate that FGFR1 , ***FGFR3*** , and FGFR4 derivatives can ***stimulate*** ***PI-3*** kinase activity .	positive	0
17398	10918587	2264;5266	FGFR4;PI-3	Finally , we demonstrate that FGFR1 , FGFR3 , and ***FGFR4*** derivatives can ***stimulate*** ***PI-3*** kinase activity .	positive	0
17399	10918592	5933;2353	p107;c-Fos	Collectively , these data imply that pRB and ***p107*** can ***cooperate*** with ***c-Fos*** to activate TF gene transcription in fibroblasts and suggest a requirement for another , as yet unidentified , E1A-binding protein .	parallel	0
17400	10918592	5925;2353	pRB;c-Fos	Collectively , these data imply that ***pRB*** and p107 can ***cooperate*** with ***c-Fos*** to activate TF gene transcription in fibroblasts and suggest a requirement for another , as yet unidentified , E1A-binding protein .	parallel	0
17401	10918594	3456;6772	IFN-beta;Stat-1	***IFN-beta*** ***induces*** serine phosphorylation of ***Stat-1*** in Ewing 's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7 .	target	1
17402	10918595	1026;1017	p21;cyclin-dependent kinase 2	In stable or transient HBV-X transformed Hep3B cells , HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor ( CDKI ) p21 ( waf1/cip1 ) increased ***binding*** of ***p21*** ( waf1/cip1 ) with ***cyclin-dependent kinase 2*** ( CDK2 ) , markedly inhibited cyclin E and CDK2 associated phosphorylation of histone H1 and induced the activation of a p21 promoter reporter construct .	parallel	1
17403	10918598	3725;2118	AP1;PEA3	***Cooperation*** between ***AP1*** and ***PEA3*** sites within the progression elevated gene-3 ( PEG-3 ) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells .	parallel	0
17404	10918605	7161;7422	p73;VEGF	Our results demonstrate that ***p73*** can ***down-regulate*** endogenous ***VEGF*** gene expression on mRNA and protein level .	negative	1
17405	10918610	3815;4254	c-Kit;stem cell factor	Small cell lung cancer ( SCLC ) is an aggressive cancer characterized by several autocrine growth mechanisms including ***stem cell factor*** and its ***receptor*** ***c-Kit*** .	parallel	1
17406	10918611	997;4792	Ubc3;I kappa B alpha	We demonstrate specific ***ubiquitination*** of ***I kappa B alpha*** by ***Ubc3*** and Ubc4 in a phosphorylation and SCF beta-TRCP dependent manner and that both are capable of associating with the SCF beta-TRCP complex isolated from human cells .	target	1
17407	10918611	7322;4792	Ubc4;I kappa B alpha	We demonstrate specific ***ubiquitination*** of ***I kappa B alpha*** by Ubc3 and ***Ubc4*** in a phosphorylation and SCF beta-TRCP dependent manner and that both are capable of associating with the SCF beta-TRCP complex isolated from human cells .	target	1
17408	10918613	7040;1278	TGF-beta;COL1A2	Transforming growth factor-beta ( ***TGF-beta*** ) ***stimulation*** of Type I collagen gene ( ***COL1A2*** ) transcription involves the Smad signal transduction pathway , but the mechanisms of Smad-mediated transcriptional activation are not fully understood .	positive	0
17409	10918613	2033;1278	p300;COL1A2	***Transactivation*** of ***COL1A2*** by ***p300*** involved the Smad signaling pathway , as Smad4-deficient cells failed to respond to p300 , and stimulation was rescued by overexpression of Smad4 .	positive	1
17410	10919255	1394;7349	CRFR1;Ucn	***CRFR1*** and CRFR2 , the ***receptors*** for CRF and ***Ucn*** , are expressed in neurons associated with appetite-control and metabolism , but their relative contributions in mediating CRF - or Ucn-induced hypophagia and weight loss are not known .	parallel	1
17411	10919265	4852;1392	NPY;CRF	The ***stimulation*** of ***CRF*** synthesis by ***NPY*** seems to depend mainly on a PLC-beta to InsP3-R axis and on CaMKII activity .	positive	0
17412	10919268	3553;5337	IL-1beta;PLD1	In conclusion , we have shown that the cytokine ***IL-1beta*** ***regulates*** ***PLD1*** expression in primary and clonal beta-cells .	target	1
17413	10919276	3479;5617	IGF-I;PRL	Taken together , these findings clearly indicate that ***IGF-I*** disparately ***regulates*** ***PRL*** and GH synthesis and secretion .	target	1
17414	10919276	3481;5617	IGF-II;PRL	***IGF-II*** and insulin also ***increased*** ***PRL*** release , but only at 10-fold higher concentrations than the lowest effective IGF-I dose .	positive	0
17415	10919277	2516;6667	SF-1;Sp1	Coimmunoprecipitation cross-linking experiments indicated that ***SF-1*** physically ***interacts*** with ***Sp1*** in vitro .	parallel	1
17416	10919277	8879;2516	Spl;SF-1	An Sp1 binding site mutation ( pGL2Sp1M ) did not support promoter activity , suggesting that ***Spl*** ***cooperates*** with ***SF-1*** in regulating StAR promoter function .	parallel	0
17417	10919277	2516;8879	SF-1;Spl	In gel shift assays , the ***SF-1*** binding site formed a ***complex*** with an SF-1-GST fusion protein and ***Spl*** .	parallel	1
17418	10919290	7124;5010	TNFalpha;OSP	***TNFalpha*** was also shown to ***inhibit*** ***OSP*** expression in cultured Sertoli cells .	negative	1
17419	10919290	7124;5010	TNFalpha;OSP	Together , our results indicate that ***OSP*** expression 1 ) starts during fetal life at a critical period , probably under SRY control and during testicular formation ; and 2 ) is ***regulated*** by hormones ( FSH ) and cytokines ( ***TNFalpha*** ) in the adult testis , suggesting a critical role for these molecules in the ( re ) modeling process of the hematotesticular barrier during spermatogenesis .	target	1
17420	10919640	7157;6376	p53;fractalkine	Using the differential display method for examining gene expression in p53-defective cells transfected by adenovirus containing wild-type p53 , we observed that ***fractalkine*** was ***induced*** by ectopic expression of ***p53*** .	target	1
17421	10919658	4792;4790	IkappaBalpha;NF-kappaB	This effect was mediated through inhibition of phosphorylation and degradation of ***IkappaBalpha*** , an ***inhibitor*** of ***NF-kappaB*** .	negative	1
17422	10919662	6925;1499	transcription factor-4;beta-catenin	The human T cell ***transcription factor-4*** ( hTCF-4 ) ***interacts*** functionally with ***beta-catenin*** in the Wnt signaling pathway , which regulates many developmental processes .	parallel	1
17423	10919667	3458;2064	interferon-gamma;HER-2	***Down-regulation*** of ***neu/HER-2*** by ***interferon-gamma*** in prostate cancer cells .	negative	1
17424	10919667	3458;6772	IFN-gamma;signal transducer and activator of transcription (STAT) 1	In addition , ***IFN-gamma*** ***induced*** phosphorylation of ***signal transducer and activator of transcription (STAT) 1*** in DU145 and PC-3 cells , but not in LNCaP cells .	target	1
17425	10919667	3458;2064	IFN-gamma;HER-2	We propose that the ***down-regulation*** of ***neu/HER-2*** by ***IFN-gamma*** occurs via the interaction of phosphorylated STAT1 with p300 because IFN-gamma activities requiring phosphorylated STAT1 are reduced in cells overexpressing p300 .	negative	1
17426	10919667	6772;2033	STAT1;p300	We propose that the down-regulation of neu/HER-2 by IFN-gamma occurs via the ***interaction*** of phosphorylated ***STAT1*** with ***p300*** because IFN-gamma activities requiring phosphorylated STAT1 are reduced in cells overexpressing p300 .	parallel	1
17427	10919673	841;355	caspase-8;CD95	CHX - or ActD-mediated sensitization to CD95-induced apoptosis was predominantly found in type I cells in which FADD and ***caspase-8*** are ***recruited*** to ***CD95*** upon stimulation but not in type II cells in which no DISC formation is detected .	target	0
17428	10919673	8772;355	FADD;CD95	CHX - or ActD-mediated sensitization to CD95-induced apoptosis was predominantly found in type I cells in which ***FADD*** and caspase-8 are ***recruited*** to ***CD95*** upon stimulation but not in type II cells in which no DISC formation is detected .	target	0
17429	10919710	3791;7422	flk-1;VEGF	The addition of acidic Fibroblast Growth Factor ( aFGF ) , basic FGF ( bFGF ) or Vascular Endothelial Growth Factor ( VEGF ) substantially improved proliferation of TdMEC ; and kidney carcinoma derived endothelial cells were more responsive to FGFs , whereas glioblastoma derived endothelial cells greatly responded to VEGF TdMEC expressed high levels of the ***VEGF*** ***receptors*** , ***KDR/flk-1*** and Flt-1 , as shown by northern blot analysis .	parallel	1
17430	10919710	2321;7422	Flt-1;VEGF	The addition of acidic Fibroblast Growth Factor ( aFGF ) , basic FGF ( bFGF ) or Vascular Endothelial Growth Factor ( VEGF ) substantially improved proliferation of TdMEC ; and kidney carcinoma derived endothelial cells were more responsive to FGFs , whereas glioblastoma derived endothelial cells greatly responded to VEGF TdMEC expressed high levels of the ***VEGF*** ***receptors*** , KDR/flk-1 and ***Flt-1*** , as shown by northern blot analysis .	parallel	1
17431	10919712	3676;7412	integrin alpha4;VCAM-1	These observations suggest that an ***interaction*** of ***integrin alpha4/beta1*** on RAW117 cells with liver endothelial ***VCAM-1*** occurs during the early stages of the adhesion process and may be important in liver metastasis .	parallel	1
17432	10919713	4313;7077	MMP-2;TIMP-2	In addition , Western blotting results confirmed a higher expression of ***MMP-2*** ***associated*** with a lower expression of ***TIMP-2*** in HaCaT-ras compared with HaCaT .	parallel	0
17433	10919714	5743;7422	cyclooxygenase-2;vascular endothelial growth factor	Upregulation of ***vascular endothelial growth factor*** by cobalt chloride-simulated hypoxia is ***mediated*** by persistent induction of ***cyclooxygenase-2*** in a metastatic human prostate cancer cell line .	target	0
17434	10919987	948;7057	CD36;TSP-1	The TSP-1/L-GeneGene 1 complex was associated with ***CD36*** , a ***receptor*** for ***TSP-1*** .	parallel	1
17435	10919987	7057;948	TSP-1;CD36	The ***TSP-1/L-GeneGene*** 1 complex was ***associated*** with ***CD36*** , a receptor for TSP-1 .	parallel	0
17436	10919987	7057;948	TSP-1;CD36	The ***association*** of ***TSP-1/L-GeneGene*** 1 to ***CD36*** was critical for plasmin-mediated release of mature TGF-beta1 .	parallel	0
17437	10920185	4609;1026	c-Myc;p21CIP1	A role for transcriptional ***repression*** of ***p21CIP1*** by ***c-Myc*** in overcoming transforming growth factor beta - induced cell-cycle arrest .	negative	1
17438	10920200	5649;1600	Reelin;Dab1	Mutated ***Reelin*** , which lacks the CR-50 epitope region , can not form a homopolymer and fails to ***induce*** efficient tyrosine phosphorylation of Disabled 1 ( ***Dab1*** ) , which should occur to transduce the Reelin signal .	target	1
17439	10920205	92610;7189	T6BP;TRAF6	We report the identification of a TRAF-interacting protein , ***T6BP*** , that specifically ***associates*** with ***TRAF6*** .	parallel	0
17440	10920205	3553;92610	IL-1;T6BP	***IL-1*** , but not tumor necrosis factor , ***induces*** ***TRAF6-T6BP*** complex formation in a ligand-dependent manner .	target	1
17441	10920205	3553;7189	IL-1;TRAF6	***IL-1*** , but not tumor necrosis factor , ***induces*** ***TRAF6-T6BP*** complex formation in a ligand-dependent manner .	target	1
17442	10920205	92610;7189	T6BP;TRAF6	Formation of the ******TRAF6-T6BP****** ***complex*** depends on the presence of the IL-1 receptor-associated kinase ( IRAK ) .	parallel	1
17443	10920205	92610;7189	T6BP;TRAF6	After IL-1 stimulation , TRAF6 can exist in two separate complexes , TRAF6-IRAK or TRAF6-T6BP , but IRAK is not present in ******TRAF6-T6BP****** ***complexes*** .	parallel	1
17444	10920209	7157;1647	p53;GADD45	Our results suggest that prolonged laminar shear stress causes a sustained ***p53*** activation , which ***induces*** the up-regulation of ***GADD45*** and p21 ( cip1 ) .	target	1
17445	10920209	7157;1026	p53;p21	Our results suggest that prolonged laminar shear stress causes a sustained ***p53*** activation , which ***induces*** the up-regulation of GADD45 and ***p21*** ( cip1 ) .	target	1
17446	10920228	51684;2735	Sufu;Gli	***Sufu*** ***binds*** with all three ***Gli*** proteins , with different affinities .	parallel	1
17447	10920266	1387;3661	CBP;IRF-3	Analyses of virus-induced homomeric and heteromeric protein ***associations*** between ***IRF-3*** and coactivator ***CBP/p300*** .	parallel	0
17448	10920266	2033;1387	p300;CBP	Analyses of virus-induced homomeric and heteromeric protein ***associations*** between IRF-3 and coactivator ******CBP/p300****** .	parallel	0
17449	10920266	2033;3661	p300;IRF-3	Analyses of virus-induced homomeric and heteromeric protein ***associations*** between ***IRF-3*** and coactivator ***CBP/p300*** .	parallel	0
17450	10920266	3661;2033	IRF-3;p300	While virus-induced IRF-7 did not bind to p300 , the phosphorylated ***IRF-3*** complex formed a stable multimeric ***complex*** with ***p300*** ( active holocomplex ) .	parallel	1
17451	10920278	596;356	Bcl-2;Fas ligand	***Bcl-2*** ***inhibits*** calcineurin-mediated ***Fas ligand*** expression in antitumor drug-treated baby hamster kidney cells .	negative	1
17452	10920278	596;356	Bcl-2;FasL	Overexpression of ***Bcl-2*** and cyclosporin A treatment ***inhibited*** the nuclear import and ***FasL*** expression , and as a result , both inhibited apoptosis .	negative	1
17453	10920278	596;356	Bcl-2;FasL	Furthermore , ***Bcl-2*** inhibits the nuclear import of calcineurin and ***suppresses*** calcineurin-mediated ***FasL*** expression during antitumor drug-induced apoptosis .	negative	1
17454	10921001	4193;1026	mdm-2;WAF1	The p53 and ***mdm-2*** protein expression levels and cytobiological features of the 2 cell lines were compared and ***correlated*** to their ***WAF1/CIP1*** gene expression levels .	parallel	0
17455	10921001	7157;1026	p53;WAF1	The ***p53*** and mdm-2 protein expression levels and cytobiological features of the 2 cell lines were compared and ***correlated*** to their ***WAF1/CIP1*** gene expression levels .	parallel	0
17456	10921001	1026;7157	WAF1;p53	CONCLUSION : The ***WAF1/CIP1*** gene expression at mRNA and protein levels is ***associated*** with ***p53*** phenotype and some cytobiological features of human breast cancer .	parallel	0
17457	10921465	7178;3497	HRF;IgE	CONCLUSIONS : ***HRF*** ***reacts*** with monomeric ***IgE*** , and not ( exclusively ) with polymeric IgE .	parallel	1
17458	10921577	462;1906	antithrombin III;endothelin-1	***Stimulation*** of pulmonary big endothelin-1 and ***endothelin-1*** by ***antithrombin III*** : a rationale for combined application of antithrombin III and endothelin antagonists in sepsis-related acute respiratory distress syndrome ?	positive	0
17459	10921872	682;9122	CD147;MCT4	***CD147*** is tightly ***associated*** with lactate transporters MCT1 and ***MCT4*** and facilitates their cell surface expression .	parallel	0
17460	10921872	682;9122	CD147;MCT4	Here we use co-immunoprecipitation and chemical cross-linking to demonstrate that ***CD147*** specifically ***interacts*** with MCT1 and ***MCT4*** , two members of the proton-linked monocarboxylate ( lactate ) transporter family that play a fundamental role in metabolism , but not with MCT2 .	parallel	1
17461	10921872	682;9122	CD147;MCT4	We conclude that ***CD147*** ***facilitates*** proper expression of MCT1 and ***MCT4*** at the cell surface , where they remain tightly bound to each other .	positive	0
17462	10921873	11316;1029	epsilon-COP;ARF	Further , we demonstrate novel direct interactions of coatomer subunits with regulatory proteins : beta ' - and gamma-COP interact with the ARF-GTP-activating protein ( GAP ) Glo3p , but not Gcs1p , and beta - and ***epsilon-COP*** ***interact*** with ***ARF-GTP*** .	parallel	1
17463	10921877	5524;995	PP2A;cdc25	We provide here biochemical and functional evidence demonstrating that human immunodeficiency virus type 1 ( HIV-1 ) Vpr mediates G ( 2 ) arrest by forming a complex with protein phosphatase 2A ( ***PP2A*** ) , an upstream ***regulator*** of ***cdc25*** .	target	1
17464	10921879	8825;1499	LIN-7;beta-catenin	Mammalian ***LIN-7*** PDZ proteins ***associate*** with ***beta-catenin*** at the cell-cell junctions of epithelia and neurons .	parallel	0
17465	10921879	8825;1499	LIN-7;beta-catenin	We report here that mammalian ***LIN-7*** PDZ proteins form a ***complex*** with cadherin and ***beta-catenin*** in epithelia and neurons .	parallel	1
17466	10921879	8825;1499	LIN-7;beta-catenin	The ***association*** of ***LIN-7*** with cadherin and ***beta-catenin*** is Ca ( 2 + ) dependent and is mediated by the direct binding of LIN-7 to the C-terminal PDZ target sequence of beta-catenin , as demonstrated by means of co-immunoprecipitation experiments and in vitro binding assays with the recombinant glutathione S-transferase : LIN-7A .	parallel	0
17467	10921884	5967;3741	PTP;Kv1.5	***PTP*** epsilon markedly ***reduces*** ***Kv1.5*** or Kv2.1 current amplitudes in Xenopus oocytes .	negative	1
17468	10921884	5967;3745	PTP;Kv2.1	***PTP*** epsilon markedly ***reduces*** Kv1.5 or ***Kv2.1*** current amplitudes in Xenopus oocytes .	negative	1
17469	10921884	5967;2534	PTP;Fyn	Kv2.1 associates with a substrate-trapping mutant of PTP epsilon , and ***PTP*** epsilon profoundly ***reduces*** Src - or ***Fyn-stimulated*** Kv2.1 currents and tyrosine phosphorylation in transfected HEK 293 cells .	negative	1
17470	10921886	2668;5979	GDNF;RET	In addition , we report that Hirschsprung-associated RET mutations impair ***GDNF*** ***control*** of ***RET*** pro-apoptotic activity .	target	0
17471	10921886	5979;2668	RET;GDNF	In addition , we report that Hirschsprung-associated ***RET*** mutations ***impair*** ***GDNF*** control of RET pro-apoptotic activity .	positive	0
17472	10921891	3659;6772	IRF1;Stat1	How Stat1 mediates constitutive gene expression : a ***complex*** of unphosphorylated ***Stat1*** and ***IRF1*** supports transcription of the LMP2 gene .	parallel	1
17473	10921891	6772;3659	Stat1;IRF1	Unphosphorylated ***Stat1*** ***binds*** to ***IRF1*** directly and we conclude that this complex uses the ICS-2 / GAS element to mediate constitutive LMP2 transcription in vivo .	parallel	1
17474	10921895	7072;1437	TIA-1;granulocyte-macrophage colony-stimulating factor	***TIA-1*** does not appear to ***regulate*** the production of interleukin 1 beta , ***granulocyte-macrophage colony-stimulating factor*** or interferon gamma , indicating that its effects are , at least partially , transcript specific .	target	1
17475	10921895	7072;3458	TIA-1;interferon gamma	***TIA-1*** does not appear to ***regulate*** the production of interleukin 1 beta , granulocyte-macrophage colony-stimulating factor or ***interferon gamma*** , indicating that its effects are , at least partially , transcript specific .	target	1
17476	10921895	7072;3553	TIA-1;interleukin 1 beta	***TIA-1*** does not appear to ***regulate*** the production of ***interleukin 1 beta*** , granulocyte-macrophage colony-stimulating factor or interferon gamma , indicating that its effects are , at least partially , transcript specific .	target	1
17477	10921914	6885;7189	TAK1;TRAF6	ASK1 inhibits interleukin-1-induced NF-kappa B activity through disruption of ******TRAF6-TAK1****** ***interaction*** .	parallel	1
17478	10921914	4217;4790	ASK1;NF-kappa B	***ASK1*** ***inhibits*** interleukin-1-induced ***NF-kappa B*** activity through disruption of TRAF6-TAK1 interaction .	negative	1
17479	10921914	4217;6885	ASK1;TAK1	Here we show that ***ASK1*** directly ***interacts*** with transforming growth factor-beta-activated kinase 1 ( ***TAK1*** ) , another MAPKKK that has been identified as a signaling intermediate in the interleukin 1 ( IL-1 ) - induced NF-kappaB pathway as well as the transforming growth factor-beta superfamily-induced JNK/p38 pathway .	parallel	1
17480	10921914	4217;6885	ASK1;TAK1	Overexpression of ***ASK1*** ***inhibits*** IL-1 - , TRAF6 - , or ***TAK1-induced*** , but not NF-kappaB-inducing kinase-induced , NF-kappaB activation .	negative	1
17481	10921914	4217;4790	ASK1;NF-kappaB	It thus appears that the ***inhibition*** of ***NF-kappaB*** by ***ASK1*** may result at least in part from the disruption of the TRAF6.TAK1 complex formation in the IL-1 signaling pathway .	negative	1
17482	10921917	2534;2017	Fyn;cortactin	We have shown previously that shrinkage induces ***Fyn-dependent*** tyrosine ***phosphorylation*** of the cortical actin-binding protein , ***cortactin*** .	target	1
17483	10921920	57680;1499	Duplin;Armadillo	***Duplin*** ***bound*** directly to the ***Armadillo*** repeats of beta-catenin , thereby inhibiting the binding of Tcf to beta-catenin .	parallel	1
17484	10921922	6464;2885	Shc;Grb2	Stimulation with SCF + ET-1 induced a more rapid and stronger tyrosyl phosphorylation of proteins corresponding to p52 and p66 Shc than did stimulation with SCF only , and this was accompanied by a stronger ***association*** of tyrosine-phosphorylated ***Shc*** with ***Grb2*** .	parallel	0
17485	10921923	8454;9978	CUL1;ROC1	Conjugation of Nedd8 to CUL1 enhances the ability of the ******ROC1-CUL1****** ***complex*** to promote ubiquitin polymerization .	parallel	1
17486	10921923	4738;8454	Nedd8;CUL1	***Conjugation*** of ***Nedd8*** to ***CUL1*** enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization .	parallel	1
17487	10921923	8454;9978	CUL1;ROC1	This report describes that the CUL1 subunit of the bacterially expressed , unmodified ******ROC1-CUL1****** ***complex*** is conjugated with Nedd8 at Lys-720 by HeLa cell extracts or by a purified Nedd8 conjugation system ( consisting of APP-BP1/Uba3 , Ubc12 , and Nedd8 ) .	parallel	1
17488	10921923	8454;9978	CUL1;ROC1	This covalent linkage of Nedd8 to CUL1 is both necessary and sufficient to markedly enhance the ability of the ******ROC1-CUL1****** ***complex*** to promote ubiquitin polymerization .	parallel	1
17489	10921923	9978;8454	ROC1;CUL1	A mutation of Lys-720 to arginine in CUL1 eliminates the Nedd8 modification , abolishes the activation of the ******ROC1-CUL1****** ubiquitin ligase ***complex*** , and significantly reduces the ability of SCF ( HOS/beta ) ( - TRCP ) - ROC1 to support the ubiquitination of phosphorylated IkappaBalpha .	parallel	1
17490	10921926	7134;7137	cardiac troponin C;cTnI	Using isothermal titration microcalorimetry we have studied the ***binding*** of human ***cardiac troponin C*** ( cTnC ) and its isolated domains to human cardiac troponin I ( ***cTnI*** ) .	parallel	1
17491	10922058	920;3700	CD4;gp120	HIV infection is initiated by the selective ***interaction*** between the cellular receptor ***CD4*** and ***gp120*** , the external envelope glycoprotein of the virus .	parallel	1
17492	10922058	3700;920	gp120;CD4	We used analytical ultracentrifugation , titration calorimetry , and surface plasmon resonance biosensor analysis to characterize the assembly state , thermodynamics , and kinetics of the ******CD4-gp120****** ***interaction*** .	parallel	1
17493	10922060	5906;4301	Rap1;AF-6	We further demonstrate that both Ras and ***Rap1*** ***interact*** with full-length ***AF-6*** in vivo in mammalian cells and that a fraction of Rap1 colocalizes with AF-6 at the membrane .	parallel	1
17494	10922063	3091;664	HIF-1alpha;Nip3	The ***Nip3*** promoter contains a functional HIF-1-responsive element ( HRE ) and is potently ***activated*** by both hypoxia and forced expression of ***HIF-1alpha*** .	positive	1
17495	10922073	2155;2152	factor VII;tissue factor	One targeting domain is ***factor VII*** that ***binds*** to ***tissue factor*** expressed on endothelial cells lining the tumor neovasculature and on tumor cells ; the active site of factor VII was mutated to inhibit the initiation of blood coagulation .	parallel	1
17496	10922078	351;5663	APP;PS1	Here we report that the ***APP*** C-terminal fragments , C83 and C99 , which are the direct substrates of gamma-secretase , can be ***coimmunoprecipitated*** with both ***PS1*** and PS2 .	parallel	1
17497	10922078	351;5664	APP;PS2	Here we report that the ***APP*** C-terminal fragments , C83 and C99 , which are the direct substrates of gamma-secretase , can be ***coimmunoprecipitated*** with both PS1 and ***PS2*** .	parallel	1
17498	10922363	10728;10728	cPGES;p23	Thus , functional ***coupling*** between COX-1 and ******cPGES/p23****** may contribute to production of the PGE ( 2 ) that plays a role in maintenance of tissue homeostasis .	parallel	1
17499	10922363	10728;5742	p23;COX-1	Thus , functional ***coupling*** between ***COX-1*** and ***cPGES/p23*** may contribute to production of the PGE ( 2 ) that plays a role in maintenance of tissue homeostasis .	parallel	1
17500	10922367	26986;1981	PABP;eIF4G	Maximal cap-poly ( A ) cooperativity required the integrity of the eukaryotic initiation factor 4G-poly ( A ) - binding protein ( ******eIF4G-PABP****** ) ***interaction*** , suggesting that synergy results from mRNA circularization .	parallel	1
17501	10922367	26986;1981	PABP;eIF4G	These effects of poly ( A ) were also sensitive to disruption of the ******eIF4G-PABP****** ***interaction*** , suggesting that 5 ' -3 ' end cross-talk is functionally conserved between classical mRNAs and an IRES-containing mRNA .	parallel	1
17502	10922378	7035;7057	Tissue factor pathway inhibitor;thrombospondin-1	***Tissue factor pathway inhibitor*** ***binds*** to platelet ***thrombospondin-1*** .	parallel	1
17503	10922378	7035;7057	TFPI;TSP-1	***TFPI*** ***bound*** to immobilized ***TSP-1*** remains an active proteinase inhibitor .	parallel	1
17504	10922378	7035;2152	TFPI;Tissue factor	Additionally , in solution phase assays measuring ***TFPI*** ***inhibition*** of factor ***VIIa/Tissue factor*** catalytic activity , the rate of factor Xa generation was decreased 55 % in the presence of TSP-1 compared with TFPI alone .	negative	1
17505	109224	2641;435	glucagon;argininosuccinase	This study indicates that glucocorticosteroids are required for the ***induction*** of the ***argininosuccinase*** activity by ***glucagon*** .	target	1
17506	10922467	6453;7018	ITSN1;transferrin	Moreover , their overexpression , as well as the corresponding ***ITSN1*** protein forms , ***inhibits*** ***transferrin*** internalization .	negative	1
17507	10922493	4193;7157	MDM2;p53	***MDM2*** ***mediates*** ubiquitination of ***p53*** and targets the protein to the cytoplasm for 26S proteosome-dependent degradation .	target	0
17508	10922982	3565;6778	IL-4;Stat6	***IL-4-induced*** ***activation*** of the ***Stat6*** pathway contributes to the suppression of cell-mediated immunity and death in sepsis .	positive	1
17509	10922992	5594;5743	p38;COX-2	The inhibition of ***p38*** with SB202190 ***abrogated*** the osmotic and LPS-induced ***COX-2*** expression and PGI ( 2 ) production .	positive	0
17510	10922995	2353;3565	c-fos;IL-4	Overexpression of ***c-fos*** completely ***inhibited*** ***IL-4*** primed LPS-induced IL-12 p70 protein synthesis .	negative	1
17511	10923191	4880;4882	CNP;NPR-B	***CNP*** ***activates*** the type B natriuretic peptide receptor ( ***NPR-B*** ) , known as the guanylate cyclase B membrane enzyme , which results in the cGMP release .	positive	1
17512	10923281	3952;4852	leptin;NPY	Both ***leptin*** and insulin can ***reduce*** hypothalamic ***NPY*** production and secretion .	negative	1
17513	10923636	3953;3952	leptin receptor;leptin	This finding suggests that the ***leptin receptor*** itself may not be specifically involved in the ***control*** of ***leptin*** secretion , and it supports the concept of relative resistance to leptin in common obesity .	target	0
17514	10923673	3725;1020	p39;cdk5	Synaptic localization of ***p39*** , a neuronal ***activator*** of ***cdk5*** .	positive	1
17515	10923681	1605;7402	beta-dystroglycan;utrophin	These data suggest the presence of a ******utrophin-beta-dystroglycan****** ***complex*** in PC12 cells that participates in the formation and/or stabilization of the growth cone-extracellular matrix adhesion .	parallel	1
17516	10924055	3557;4843	IL-1ra;iNOS	Added IL-1beta augmented , whereas the IL-1beta receptor antagonist ***IL-1ra*** ***blocked*** , spontaneous ***iNOS*** induction .	negative	0
17517	10924061	4790;7124	NF-kappaB;tumor necrosis factor-alpha	Finally , inhibition of ERK phosphorylation reduced , and ***NF-kappaB*** nuclear translocation ***prevented*** , ***tumor necrosis factor-alpha*** production .	negative	0
17518	10924066	183;3162	angiotensin II;HO-1	***angiotensin II*** also ***upregulated*** cardiac ***HO-1*** expression .	positive	1
17519	10924066	183;3162	angiotensin II;HO-1	Our data suggest that ***angiotensin II*** ***upregulates*** cardiac ***HO-1*** expression in the newly formed inflammatory lesion , which may represent an adaptive response to angiotensin II-induced cardiac damage .	positive	1
17520	10924071	3553;5743	IL-1beta;COX-2	These findings indicate that : 1 ) PMA , acting through PKC and p38 kinase , enhances COX-2 expression , but chronic treatment with PMA partially inhibits ***IL-1beta*** ***stimulation*** of ***COX-2*** ; and 2 ) exogenous PGF ( 2alpha ) is involved in neonatal ventricular myocyte growth but endogenous COX-2 products are not .	positive	0
17521	10924106	8815;7112	BAF;LAP2	***BAF*** also ***binds*** to the nuclear protein lamina-associated polypeptide 2 ( ***LAP2*** ) , and is localized with chromatin during interphase and mitosis .	parallel	1
17522	10924113	345;348	apoC-III;ApoE	All ***apoC-III*** proteins ***bound*** to the ***ApoE*** : DPPC complexes ; the amount of ApoE displaced from the complex was dependent on the apoC-III lipid binding affinity .	parallel	1
17523	10924113	345;4023	apoC-III;LPL	All apoC-III proteins inhibited LPL in the presence or absence of apoC-II , with F64A/W65A displaying the most inhibition , suggesting that ***apoC-III*** ***inhibition*** of ***LPL*** is independent of lipid binding and therefore of apoC-II displacement .	negative	1
17524	10924113	345;4023	apoC-III;LPL	All ***apoC-III*** proteins ***inhibited*** ***LPL*** in the presence or absence of apoC-II , with F64A/W65A displaying the most inhibition , suggesting that apoC-III inhibition of LPL is independent of lipid binding and therefore of apoC-II displacement .	negative	1
17525	10924123	653361;4688	p47-phox;P67-phox	In the processes that were studied , P67-phox displayed a critical function ; it was shown to be involved in both assembly and activation of oxidase complex while ***p47-phox*** proceeded as a positive effector and ***increased*** the affinity of ***P67-phox*** with cytochrome b ( 558 ) , and p40-phox stabilizes the resting state .	positive	0
17526	10924142	7039;1956	transforming growth factor alpha;epidermal growth factor receptor	Real-time kinetic studies on the ***interaction*** of ***transforming growth factor alpha*** with the ***epidermal growth factor receptor*** extracellular domain reveal a conformational change model .	parallel	1
17527	10924145	890;983	cyclin A2;CDC2	All the ***cyclin A2*** and cyclin E1 are in ***complexes*** with ***CDC2*** and CDK2 , but there are some indications that a significant portion of cyclin B1 may not be in complex with CDC2 .	parallel	1
17528	10924145	898;983	cyclin E1;CDC2	All the cyclin A2 and ***cyclin E1*** are in ***complexes*** with ***CDC2*** and CDK2 , but there are some indications that a significant portion of cyclin B1 may not be in complex with CDC2 .	parallel	1
17529	10924255	5663;351	PS1;APP	However , it is unclear how Notch cleavage and ***APP*** processing events which occur at or near the cell surface are ***influenced*** by ***PS1*** .	target	0
17530	10924255	5663;351	PS1;APP	These findings identify an early endosomal pool of PS1 and suggest alternative mechanisms for ***PS1*** ***interactions*** with ***APP*** and Notch .	parallel	1
17531	10924320	4790;5970	p50;p65	Here we show that TFF3 activated NF-kappaB ******p50/p65****** ***heterodimer*** within 1 h in IEC-18 cells ( a nontransformed rat intestinal epithelial cell line ) .	parallel	1
17532	10924320	7033;4790	TFF3;NF-kappaB	Here we show that ***TFF3*** ***activated*** ***NF-kappaB*** p50/p65 heterodimer within 1 h in IEC-18 cells ( a nontransformed rat intestinal epithelial cell line ) .	positive	1
17533	10924320	7033;5970	TFF3;p65	Here we show that ***TFF3*** ***activated*** NF-kappaB ***p50/p65*** heterodimer within 1 h in IEC-18 cells ( a nontransformed rat intestinal epithelial cell line ) .	positive	1
17534	10924320	7033;4790	TFF3;NF-kappaB	Taken together , these data indicate that ( 1 ) TFF3 is an endogenous gastrointestinal peptide with anti-anoikic property ; ( 2 ) ***TFF3*** ***activates*** ***NF-kappaB*** in enterocytes ; and ( 3 ) TFF3-induced resistance to anoikis in intestinal epithelial cells is mediated by a distinct signaling cascade linked to NF-kappaB .	positive	1
17535	10924322	4929;7054	nurr1;tyrosine hydroxylase	Identification of a potential ***nurr1*** response element that ***activates*** the ***tyrosine hydroxylase*** gene promoter in cultured cells .	positive	1
17536	10924326	2641;3651	Glucagon-like peptide 1;IDX-1	***Glucagon-like peptide 1*** ***increases*** glucose-dependent activity of the homeoprotein ***IDX-1*** transactivating domain in pancreatic beta-cells .	positive	0
17537	10924333	1466;57325	CRP2;CRP2BP	The cysteine - and glycine-rich LIM domain protein ***CRP2*** specifically ***interacts*** with a novel human protein ( ***CRP2BP*** ) .	parallel	1
17538	10924340	3569;8856	Interleukin-6;pregnane X receptor	***Interleukin-6*** negatively ***regulates*** the expression of ***pregnane X receptor*** and constitutively activated receptor in primary human hepatocytes .	negative	1
17539	10924340	3569;8856	Interleukin-6;PXR	Using primary cultures of human hepatocytes , we show here that ***Interleukin-6*** ( IL-6 ) rapidly and markedly ***decreases*** the expression of ***PXR*** ( pregnane X receptor ) and CAR ( constitutively activated receptor ) mRNAs , but does not affect the levels of dioxin receptor and glucocorticoid receptor mRNA .	negative	0
17540	10924347	5443;2182	adrenocorticotropic hormone;ACS4	We demonstrate that ***ACS4*** expression in steroidogenic tissues in vivo is ***induced*** by ***adrenocorticotropic hormone*** ( ACTH ) and suppressed by glucocorticoid .	target	1
17541	10924347	5443;2182	ACTH;ACS4	***ACTH*** also ***induced*** ***ACS4*** protein but not its mRNA in Y1 adrenocortical tumor cells , whereas both ACS4 mRNA and protein were increased by dibutyryl cAMP ( db-cAMP ) and forskolin .	target	1
17542	10924365	2885;3667	Grb2;IRS-1	There was little or no tyrosine phosphorylation of Shc or ***association*** of ***Grb2*** with Shc or ***IRS-1*** .	parallel	0
17543	10924365	2885;6464	Grb2;Shc	There was little or no tyrosine phosphorylation of Shc or ***association*** of ***Grb2*** with ***Shc*** or IRS-1 .	parallel	0
17544	10924462	7334;7336	UBC13;MMS2	Our data also suggest that MMS2 and UBC13 play a key role in coordinating the response of the error-free subpathways ; ***MMS2*** and ***UBC13*** form a ***complex*** required for a novel polyubiquitin chain assembly , which probably serves as a signal transducer to promote both RAD5 and POL30 error-free postreplication repair pathways .	parallel	1
17545	10924503	7849;7173	Pax 8;thyroperoxidase	Role for p300 in ***Pax 8*** ***induction*** of ***thyroperoxidase*** gene expression .	target	1
17546	10924507	10482;1660	Tap;RNA helicase A	Specific ***interaction*** between ***RNA helicase A*** and ***Tap*** , two cellular proteins that bind to the constitutive transport element of type D retrovirus .	parallel	1
17547	10924507	1660;10482	RHA;Tap	The in vitro ***binding*** of ***RHA*** to ***Tap*** is direct and independent of either CTE or the nuclear transport domain of RHA .	parallel	1
17548	10924514	2068;2966	XPD;p44	By using a site-directed mutagenesis approach within the p44 region from amino acids 66 to 200 , we indicate how a decrease in the ***interaction*** between ***p44*** and ***XPD*** results in a decrease of the XPD helicase activity and leads to a defect in the first steps of the transcription reaction , namely the first phosphodiester bond formation and promoter clearance .	parallel	1
17549	10924514	2068;2966	XPD;p44	Moreover , this study shows how the activity of the the cyclin-dependent kinase-activating kinase associated with TFIIH complex in stimulating transcription is mediated in part by ******p44/XPD****** ***interaction*** .	parallel	1
17550	10924699	5594;2353	p38;c-fos	Our results suggest that the phosphorylation of ERK , ***p38*** , and CREB may be involved in the ***regulation*** of synergistic ***c-fos*** mRNA expression induced by LPS plus CHX in C6 rat glioma cells .	target	1
17551	10924720	3458;6649	interferon-gamma;EC-SOD	The expression of ***EC-SOD*** was ***up-regulated*** by ***interferon-gamma*** ( IFN-gamma ) and interleukin 4 ( IL-4 ) .	positive	1
17552	10924720	3565;6649	interleukin 4;EC-SOD	The expression of ***EC-SOD*** was ***up-regulated*** by interferon-gamma ( IFN-gamma ) and ***interleukin 4*** ( IL-4 ) .	positive	1
17553	10924720	3552;6648	IL-1alpha;Mn-SOD	The ***Mn-SOD*** activity was strongly ***up-regulated*** by TNF-alpha and ***IL-1alpha*** and moderately by IFN-gamma .	positive	1
17554	10924720	7124;6648	TNF-alpha;Mn-SOD	The ***Mn-SOD*** activity was strongly ***up-regulated*** by ***TNF-alpha*** and IL-1alpha and moderately by IFN-gamma .	positive	1
17555	10924721	4023;4018	LPL;lipoprotein	Previously , we have shown an increased incidence of mutations in the ***LPL*** gene which was ***associated*** with elevated levels of very low density ***lipoprotein*** ( VLDL ) and decreased levels of high density lipoprotein among the families studied .	parallel	0
17556	10924722	5360;336	PLTP;apoA-II	***PLTP*** mass ***correlated*** positively with HDL-cholesterol ( r = 0.36 , P < 0.001 ) , apoA-I ( r = 0.37 , P < 0.001 ) , ***apoA-II*** ( r = 0.20 , P < 0.05 ) , Lp ( A-I ) ( r = 0.26 , P = 0.001 ) and Lp ( A-I/A-II ) particles ( r = 0.34 , P < 0.001 ) , and negatively with body mass index ( BMI ) ( r = -0.28 , P < 0.001 ) and serum triacylglycerol ( TG ) concentration ( r = -0.34 , P < 0.001 ) .	positive	0
17557	10924728	1071;4018	CETP;lipoprotein	With this in mind we assessed the ***association*** of the Taq1B ***CETP*** polymorphism , plasma CETP mass and plasma lipid , ***lipoprotein*** and apolipoprotein concentrations in a sample of 884 Jerusalem residents aged 28-32 .	parallel	0
17558	10924736	7453;4018	gamma 2;lipoprotein	In our previous study the Pro12A1a substitution of peroxisome proliferator receptor ***gamma 2*** ( PPARgamma2 ) ***associated*** with insulin sensitivity , low body mass index ( BMI ) and high-density ***lipoprotein*** ( HDL ) cholesterol levels .	parallel	0
17559	10924744	3565;1081	IL-4;hCG	The Th2-derived cytokines , ***IL-4*** and IL-6 , ***induce*** the release of ***hCG*** from trophoblasts , and the hCG stimulate progesterone production from corpus luteum in pregnancy .	target	1
17560	10924744	3569;1081	IL-6;hCG	The Th2-derived cytokines , IL-4 and ***IL-6*** , ***induce*** the release of ***hCG*** from trophoblasts , and the hCG stimulate progesterone production from corpus luteum in pregnancy .	target	1
17561	10924747	11055;7783	Sp38;ZP2	We found that ***Sp38*** protein ***bind*** to porcine ***ZP2*** and expressed in murine and human sperm cells .	parallel	1
17562	10924763	1453;4137	Casein kinase 1 delta;tau	***Casein kinase 1 delta*** is ***associated*** with pathological accumulation of ***tau*** in several neurodegenerative diseases .	parallel	0
17563	10924763	4137;1453	tau;Cki delta	The colocalization of the kinase ***Cki delta*** and its apparent ***substrate*** ***tau*** suggests a function for Cki delta in the abnormal processing of tau .	parallel	1
17564	10925157	4915;627	trkB;brain-derived neurotrophic factor	In the present study , we examined the effects of 6 weeks of chronic ethanol administration on lateral fluid percussion ( FP ) brain injury-induced alterations in expression of mRNAs for the neurotrophin ***brain-derived neurotrophic factor*** ( BDNF ) and its high affinity ***receptor*** , ***trkB*** , in rat hippocampus .	parallel	1
17565	10925251	940;3551	CD28;IKK beta	Taken together , these data demonstrate that ***CD3/CD28-induced*** ***activation*** of ***IKK beta*** and expression of Bcl-xL promote the survival of primary human CD4 + T lymphocytes .	positive	1
17566	10925274	9450;929	MD-1;CD14	***MD-1*** is ***linked*** to ***CD14*** , a " danger receptor complex , " and activation of this complex can regulate cell surface expression of CD80/CD86 , which signal T cells .	parallel	0
17567	10925275	3439;3606	IFN-alpha;IL-18	***IFN-alpha*** and IL-12 ***induce*** ***IL-18*** receptor gene expression in human NK and T cells .	target	1
17568	10925275	3439;4615	IFN-alpha;MyD88	In addition , ***IFN-alpha*** ***enhanced*** the expression of ***MyD88*** , an adaptor molecule involved in IL-18 signaling .	positive	0
17569	10925286	3456;1051	IFN-beta;C/EBPbeta	***IFN-beta*** ***induced*** inhibitory 16-kDa ***C/EBPbeta*** in macrophages , but had no effect on C/EBPbeta expression in monocytes .	target	1
17570	10925288	715;716	C1r;C1s	The ***cleavage*** of two ***C1s*** subunits by a single active ***C1r*** reveals substantial flexibility of the C1s-C1r-C1r-C1s tetramer in the C1 complex .	target	1
17571	10925288	715;716	C1r;C1s	After triggering the C1 by IgG-Sepharose , both ***C1s*** subunits are ***cleaved*** by the single proteolytically active ***C1r*** subunit in the C1s-C1rQI-C1r-C1s tetramer .	target	1
17572	10925288	715;716	C1r;C1s	This finding indicates that the tetramer is flexible enough to adopt different conformations within the C1 complex during the activation process , enabling the single active ***C1r*** to ***cleave*** both ***C1s*** , the neighboring and the sequentially distant one .	target	1
17573	10925291	925;3932	CD8;p56lck	First , ***association*** of ***CD8*** with the src kinase ***p56lck*** takes place nearly exclusively in rafts , mainly due to increased concentration of both components in this compartment .	parallel	0
17574	10925291	3932;919	p56lck;CD3zeta	Third , CD8-associated activated ***p56lck*** ***phosphorylates*** ***CD3zeta*** in rafts and hence induces TCR signaling and T cell activation .	target	1
17575	10925291	925;3932	CD8;p56lck	This study shows that palmitoylation of CD8beta is required for efficient CD8 coreceptor function , mainly because it dramatically increases ***CD8*** ***association*** with ***p56lck*** and CD8-mediated activation of p56lck in lipid rafts .	parallel	0
17576	10925297	3717;5747	Jak2;p125FAK	Immunoprecipitation experiments revealed a physical ***association*** of ***Jak2*** with ***p125FAK*** via STAT3 in vivo .	parallel	0
17577	10925304	959;958	CD40 ligand;CD40	Colitis induced by enteric bacterial antigen-specific CD4 + T cells requires ******CD40-CD40 ligand****** ***interactions*** for a sustained increase in mucosal IL-12 .	parallel	1
17578	10925305	728;727	C5aR;C5a	This indicates that the G protein-coupled ***C5a*** ***receptor*** ( ***C5aR*** ) can induce long-lasting cellular responses .	parallel	1
17579	10925306	7040;3569	TGF-beta1;IL-6	***TGF-beta1*** treatment ***stimulated*** ***IL-6*** gene expression and protein synthesis in human lung fibroblast cells .	positive	0
17580	10925307	3567;5594	IL-5;p38	***IL-5*** ***induced*** phosphorylation and activation of extracellular signal-regulated kinases ( ERK ) and ***p38*** MAP kinases in eosinophils .	target	1
17581	10925307	5594;1386	p38;activating transcription factor-2	SB202190 , a p38 inhibitor , blocked ***p38-dependent*** ***phosphorylation*** of ***activating transcription factor-2*** .	target	1
17582	10925310	3589;7412	IL-11;VCAM-1	These studies demonstrate that ***IL-11*** selectively ***inhibits*** Ag-induced eosinophilia , Th2 inflammation , and ***VCAM-1*** gene expression in pulmonary tissues .	negative	1
17583	10925311	3553;1270	IL-1beta;CNTF	Analysis of their temporal relationship suggests the ***up-regulation*** of ***CNTF*** by ***IL-1beta*** , which was confirmed through three lines of evidence .	positive	1
17584	10925316	5970;7040	RelA;TGF-beta	It is unlikely that ***RelA*** could be ***interacting*** directly with the ***TGF-beta*** gene .	parallel	1
17585	10926206	6059;6041	RLI;ribonuclease L	RNase L is a latent endoribonuclease that is activated on its binding by 2-5A and inhibited by the ***ribonuclease L*** ***inhibitor*** ( ***RLI*** ) .	negative	1
17586	10926317	3569;5443	Interleukin-6;ACTH	***Interleukin-6*** is inhibited by glucocorticoids and ***stimulates*** ***ACTH*** secretion and POMC expression in human corticotroph pituitary adenomas .	positive	0
17587	10926553	5966;3383	c-Rel;ICAM-1	Gel supershift assay revealed the presence of p65 ( Rel A ) , p50 , and ***c-Rel*** in both H ( 2 ) O ( 2 ) - and TNF-alpha-induced NF-kappaB complexes ***bound*** to the ***ICAM-1*** promoter , with the binding of the p65 subunit being the most prominent .	parallel	1
17588	10926553	4790;3383	p50;ICAM-1	Gel supershift assay revealed the presence of p65 ( Rel A ) , ***p50*** , and c-Rel in both H ( 2 ) O ( 2 ) - and TNF-alpha-induced NF-kappaB complexes ***bound*** to the ***ICAM-1*** promoter , with the binding of the p65 subunit being the most prominent .	parallel	1
17589	10926553	5970;3383	p65;ICAM-1	Gel supershift assay revealed the presence of ***p65*** ( Rel A ) , p50 , and c-Rel in both H ( 2 ) O ( 2 ) - and TNF-alpha-induced NF-kappaB complexes ***bound*** to the ***ICAM-1*** promoter , with the binding of the p65 subunit being the most prominent .	parallel	1
17590	10926553	7124;5970	TNF-alpha;p65	In vivo phosphorylation studies , however , showed that ***TNF-alpha*** exposure ***induced*** marked phosphorylation of NF-kappaB ***p65*** in HMEC-1 cells , whereas H ( 2 ) O ( 2 ) had no effect .	target	1
17591	10926555	7124;8802	TNF-alpha;Galpha	***TNF-alpha*** ***increases*** transcription of ***Galpha*** ( i-2 ) in human airway smooth muscle cells .	positive	0
17592	10926555	7124;8802	TNF-alpha;Galpha	We have shown previously that ***TNF-alpha*** ***upregulates*** the expression of ***Galpha*** ( i-2 ) protein without significantly increasing G ( s ) alpha protein and enhances adenylyl cyclase inhibition by carbachol in cultured human airway smooth muscle cells ( Hotta K , Emala CW , and Hirshman CA .	positive	1
17593	10926555	7124;8802	TNF-alpha;Galpha	The present study was designed to investigate the molecular mechanisms by which ***TNF-alpha*** ***upregulates*** ***Galpha*** ( i-2 ) protein in these cells .	positive	1
17594	10926555	7124;8802	TNF-alpha;Galpha	***TNF-alpha*** pretreatment for 48 h ***increased*** the expression of ***Galpha*** ( i-2 ) protein without significantly altering the Galpha ( i-2 ) protein half-life ( 41.0 + / - 8.2 h for control and 46.8 + / - 5.2 h for TNF-alpha-treated cells ) .	positive	0
17595	10926555	7124;8802	TNF-alpha;Galpha	Furthermore , ***TNF-alpha*** treatment for 12-24 h ***increased*** the steady-state level of ***Galpha*** ( i-2 ) mRNA without significantly altering Galpha ( i-2 ) mRNA half-life ( 9.0 + / - 0.75 h for control and 8.9 + / - 1.1 h for TNF-alpha-treated cells ) .	positive	0
17596	10926756	159296;8174	Nkx2-3;MAdCAM-1	Homeodomain factor ***Nkx2-3*** ***controls*** regional expression of leukocyte homing coreceptor ***MAdCAM-1*** in specialized endothelial cells of the viscera .	target	0
17597	10926759	6469;2247	Shh;bFGF	IGFs , insulin , ***Shh*** , ***bFGF*** , and TGF-beta1 ***interact*** synergistically to promote somite myogenesis in vitro .	parallel	1
17598	10926759	7040;2247	TGF-beta1;bFGF	IGFs , insulin , Shh , ***bFGF*** , and ***TGF-beta1*** ***interact*** synergistically to promote somite myogenesis in vitro .	parallel	1
17599	10926759	7040;6469	TGF-beta1;Shh	IGFs , insulin , ***Shh*** , bFGF , and ***TGF-beta1*** ***interact*** synergistically to promote somite myogenesis in vitro .	parallel	1
17600	10926775	8900;993	cyclin A1;Cdc25A	The highest levels of Cdc25A and Cdc25C expression and their subcellular localization during meiotic prophase coincide with that of cyclin A1 , and when overexpressed in HeLa cells , ***cyclin A1*** ***coimmunoprecipitates*** with ***Cdc25A*** .	parallel	1
17601	10926777	4916;4908	trkC;NT3	To determine if NT3 can promote the differentiation of this phenotype in afferents with cutaneous targets , we analyzed the effects of chronic NT3 on cutaneous and muscle sensory neurons that express ***trkC*** , a ***receptor*** for ***NT3*** .	parallel	1
17602	10926779	5727;6469	Ptc;Shh	We have tested whether this activity of cyclopamine is related to disruption of cellular cholesterol transport and putative secondary effects on the ***Shh*** ***receptor*** , Patched ( ***Ptc*** ) .	parallel	1
17603	10926822	10636;8802	RGS14;Galpha	RGS14 is distinguished from other RGS proteins by its marked preference for Galpha ( o ) over other Galpha subunits : ***RGS14*** ***binds*** preferentially to ***Galpha*** ( o ) in isolated brain membranes , and also interacts preferentially with Galpha ( o ) ( as compared with Galpha ( i1 ) ) to stimulate its GTPase activity .	parallel	1
17604	10926822	10636;8802	RGS14;Galpha	RGS14 is distinguished from other RGS proteins by its marked preference for Galpha ( o ) over other Galpha subunits : ***RGS14*** binds preferentially to Galpha ( o ) in isolated brain membranes , and also ***interacts*** preferentially with ***Galpha*** ( o ) ( as compared with Galpha ( i1 ) ) to stimulate its GTPase activity .	parallel	1
17605	10926822	10636;8802	RGS14;Galpha	Double in situ hybridization experiments revealed that certain cells in the hippocampus express both RGS14 and Galpha ( o ) , as well as both RGS14 and Rap2 , showing that the ***interaction*** of ***RGS14*** with ***Galpha*** ( o ) and Rap2 is physiologically possible .	parallel	1
17606	10926822	10636;5911	RGS14;Rap2	Double in situ hybridization experiments revealed that certain cells in the hippocampus express both RGS14 and Galpha ( o ) , as well as both RGS14 and Rap2 , showing that the ***interaction*** of ***RGS14*** with Galpha ( o ) and ***Rap2*** is physiologically possible .	parallel	1
17607	10926834	3552;4790	IL-1alpha;NF-kappaB	Electromobility shift assays showed that ***IL-1alpha*** predominantly ***activated*** nuclear factor kappaB ( ***NF-kappaB*** ) , while PMA preferentially activated activator protein-1 ( AP-1 ) .	positive	1
17608	10926836	7124;4790	TNF-alpha;NF-kappaB	In electrophoretic mobility-shift and immunologic assays , we showed that IRF-1 was induced after cells were treated with IFN-gamma and that ***NF-kappaB*** was ***activated*** by ***TNF-alpha*** treatment .	positive	1
17609	10926840	5594;6514	p38;GLUT2	***Regulation*** of GLUT5 , ***GLUT2*** and intestinal brush-border fructose absorption by the extracellular signal-regulated kinase , ***p38*** mitogen-activated kinase and phosphatidylinositol 3-kinase intracellular signalling pathways : implications for adaptation to diabetes .	target	1
17610	10926840	5594;6518	p38;GLUT5	***Regulation*** of ***GLUT5*** , GLUT2 and intestinal brush-border fructose absorption by the extracellular signal-regulated kinase , ***p38*** mitogen-activated kinase and phosphatidylinositol 3-kinase intracellular signalling pathways : implications for adaptation to diabetes .	target	1
17611	10926840	5594;5594	ERK;p38	It is concluded that there is extensive ***cross-talk*** between the ***ERK*** , ***p38*** and PI 3-kinase pathways in their control of brush-border fructose transport by modulation of both the levels and intrinsic activities of GLUT5 and GLUT2 .	parallel	0
17612	10926857	10174;4638	SCaM-1;myosin light-chain kinase	***SCaM-1*** ***activated*** ***myosin light-chain kinase*** as effectively as brain CaM ( K ( act ) 1.8 and 1.7 nM respectively ) , but SCaM-4 produced no activation of this enzyme .	positive	1
17613	10926857	10174;2752	SCaM-1;glutamate decarboxylase	Plant ***glutamate decarboxylase*** was ***activated*** fully by ***SCaM-1*** , but SCaM-4 exhibited an approx .	positive	1
17614	10926925	5586;207	protein kinase C-related kinase 2;Akt	***Inhibition*** of ***Akt*** and its anti-apoptotic activities by tumor necrosis factor-induced ***protein kinase C-related kinase 2*** ( PRK2 ) cleavage .	negative	1
17615	10926925	5586;207	protein kinase C-related kinase 2;Akt	We found that the C-terminal region of ***protein kinase C-related kinase 2*** ( PRK2 ) , containing amino acids 862 to 908 , specifically ***binds*** to ***Akt*** in yeast and mammalian cells .	parallel	1
17616	10926925	5586;207	PRK2;Akt	During early stages of apoptosis , the C-terminal region of ***PRK2*** is cleaved from the inhibitory N-terminal region and can ***bind*** ***Akt*** .	parallel	1
17617	10926925	5586;207	PRK2;Akt	The protein-protein ***interaction*** between ***Akt*** and the ***PRK2*** C-terminal region specifically down-modulates the protein kinase activities of Akt by inhibiting phosphorylation at threonine 308 and serine 473 of Akt .	parallel	1
17618	10926925	5586;207	PRK2;Akt	The ***PRK2*** C-terminal fragment strongly inhibits the Akt-mediated phosphorylation of BAD , a pro-apoptotic Bcl-2 family protein , and ***blocks*** the anti-apoptotic activities of ***Akt*** in vivo .	negative	0
17619	10926929	8682;5338	PEA-15;PLD2	***PEA-15*** similarly ***increased*** protein expressions level of ***PLD2*** and co-immunoprecipitated with it .	positive	0
17620	10926929	8682;2822	PEA-15;PLD	These results suggest that ***PEA-15*** may ***stabilize*** ***PLD*** or act as a PLD chaperone .	positive	0
17621	10926929	8682;5338	PEA-15;phospholipase D1 and D2	***Regulation*** of expression of ***phospholipase D1 and D2*** by ***PEA-15*** , a novel protein that interacts with them .	target	1
17622	10926930	1399;6777	CrkL;STAT5	Stimulation of AML14 .3 D10 cells or blood eosinophils with IL-5 induced rapid tyrosine phosphorylation of the CrkL adapter and STAT5 and the ***association*** of ***CrkL*** and ***STAT5*** in vivo as evidenced by the detection of STAT5 in anti-CrkL immunoprecipitates .	parallel	0
17623	10926930	1399;6777	CrkL;STAT5	The resulting ******CrkL.STAT5****** ***complexes*** translocated to the nucleus and bound STAT5 consensus DNA-binding sites present in the promoters of IL-5-regulated genes , as shown in gel mobility and antibody supershift assays .	parallel	1
17624	10926935	161882;2623	FOG;GATA-1	***FOG*** is a multitype zinc finger protein that is essential for megakaryopoiesis , ***binds*** to the amino-terminal finger of ***GATA-1*** , and modulates the transcription of GATA-1 target genes .	parallel	1
17625	10926935	161882;2623	FOG;GATA-1	***FOG*** is a multitype zinc finger protein that is essential for megakaryopoiesis , binds to the amino-terminal finger of GATA-1 , and ***modulates*** the transcription of ***GATA-1*** target genes .	target	0
17626	10927031	5966;4790	Rel;NF-kappaB	These findings suggest that certain adenyl carbocyclic nucleosides inhibit the activation of ******NF-kappaB/Rel****** ***complexes*** by a novel mechanism that results in an inhibition of their DNA-binding activities , without blocking their dissociation from IkappaBalpha or their nuclear translocation .	parallel	1
17627	10927032	727;728	C5a;CD88	A cyclic peptide , Phe - [ Orn-Pro-D-Cyclohexylalanine-Trp-Arg ] ( F - [ OPdChaWR ] ) , was recently shown in vitro to antagonise the ***binding*** of ***C5a*** to its receptor ( ***CD88*** ) on human polymorphonuclear leukocytes ( PMNs ) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide ( LPS ) in rats .	parallel	1
17628	10927032	727;3553	C5a;IL-1beta	However , in the presence of low concentrations of LPS ( 50 ng/mL ) , both ***IL-1beta*** and TNF-alpha were ***stimulated*** by 1 nM ***C5a*** .	positive	0
17629	10927032	727;7124	C5a;TNF-alpha	However , in the presence of low concentrations of LPS ( 50 ng/mL ) , both IL-1beta and ***TNF-alpha*** were ***stimulated*** by 1 nM ***C5a*** .	positive	0
17630	1092707	6750;2641	somatostatin;glucagon	These data establish that the administration of ***somatostatin*** can effectively block the release of insulin stimulated by arginine and glucose , can ***attenuate*** the release of ***glucagon*** induced by arginine and can enhance the glucose-mediated glucagon suppression .	negative	0
17631	1092707	6750;2641	somatostatin;glucagon	These data establish that the administration of ***somatostatin*** can effectively block the release of insulin stimulated by arginine and glucose , can attenuate the release of glucagon induced by arginine and can ***enhance*** the glucose-mediated ***glucagon*** suppression .	positive	0
17632	109272	7200;2641	TRH;glucagon	***TRH*** ***enhanced*** arginine-induced ***glucagon*** release ; mean summated glucagon was 8228 + / - 1138 ( SE ) pg/ml compared to controls ( 4530 + / - 447 pg/ml ; P less than 0.01 ) .	positive	0
17633	10928081	1029;1019	p16INK4;cyclin-dependent kinase 4	BACKGROUND : The ***p16INK4*** ( MTS1/CDNK2A ) gene , located on chromosome 9p21 , is an ***inhibitor*** of ***cyclin-dependent kinase 4*** .	negative	1
17634	10928095	5617;672	prolactin;BRCA1	Cyclosporine A inhibition of ***prolactin-dependent*** ***up-regulation*** of ***BRCA1*** protein expression in human breast cell lines .	positive	1
17635	10928095	5617;672	prolactin;BRCA1	This emphasized the hypothesis that ***BRCA1*** may be ***stimulated*** by ***prolactin*** .	positive	0
17636	10928100	3458;2543	interferon-gamma;GAGE-1	In cultivated UCNT cells , ***interferon-gamma*** ( IFN-gamma ) ***induced*** synthesis of ***GAGE-1*** / -2 mRNA .	target	1
17637	10928132	1028;595	p57;cyclin D1	Our in vivo findings suggested that ***p57*** protein expression was positively ***correlated*** with ***cyclin D1*** expression and that loss of p57 protein expression alone does not affect progression of esophageal SCC .	positive	0
17638	109283	5617;7200	prolactin;thyrotropin-releasing hormone	Effects of 17 beta-estradiol on serum protlactin levels and on ***prolactin*** ***responses*** to ***thyrotropin-releasing hormone*** in female rhesus monkeys .	parallel	0
17639	10928482	7035;2152	TFPI;Tissue factor	Functional factor VIIa activity fell significantly in the systemic circulation , probably due to the heparin-induced increase ( approximately 15-fold ) in ***Tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) , but was elevated in pericardial blood compared with that taken from the central line catheter ( p < 0.006 ) .	negative	1
17640	109288	4922;5617	neurotensin;PRL	Among other unrelated peptides tested ( beta-endorphin , neurotensin , substance P , and TRH ; 5 microgram ivt ) , only ***neurotensin*** ***decreased*** plasma ***PRL*** levels in rats subjected to restraint in the cold for 1 h.	negative	0
17641	10928955	6037;1506	ECP;chymotrypsin-like	Eosinophils regulate PHA-induced T-lymphocyte proliferation via the ***ECP-mediation*** ***associated*** with ***chymotrypsin-like*** protease activity .	parallel	0
17642	10928955	3689;3683	CD18;CD11a	These cells also control ***interactions*** with lymphocyte between adhesion molecules , ***CD11a*** , ***CD18*** and CD54 .	parallel	1
17643	10928955	3689;3383	CD18;CD54	These cells also control ***interactions*** with lymphocyte between adhesion molecules , CD11a , ***CD18*** and ***CD54*** .	parallel	1
17644	10928955	3383;3683	CD54;CD11a	These cells also control ***interactions*** with lymphocyte between adhesion molecules , ***CD11a*** , CD18 and ***CD54*** .	parallel	1
17645	10928981	5970;4790	p65;p50	This NF-kappaB binding site preferentially binds Rel p65-p65 homodimers as well as some ******p50-p65****** ***heterodimers*** in response to stimulation by invasin .	parallel	1
17646	10928981	4790;5970	NF-kappaB;p65	This ***NF-kappaB*** binding site preferentially ***binds*** Rel p65-p65 homodimers as well as some ***p50-p65*** heterodimers in response to stimulation by invasin .	parallel	1
17647	10928981	4790;5966	NF-kappaB;Rel	This ***NF-kappaB*** binding site preferentially ***binds*** ***Rel*** p65-p65 homodimers as well as some p50-p65 heterodimers in response to stimulation by invasin .	parallel	1
17648	10928981	4790;4792	NF-kappaB;IkappaBalpha	Invasin-induced ***NF-kappaB*** activation ***correlated*** with degradation of ***IkappaBalpha*** and the inhibition of NF-kappaB by specific inhibitors of IkappaB activation blocked invasin-induced IL-8 secretion .	parallel	0
17649	10928988	4438;4292	hMSH4;hMLH1	Here we show that ***hMSH4*** ***interacts*** with ***hMLH1*** .	parallel	1
17650	10929029	7852;6387	CXCR4;SDF-1	The reduced migration was related to a lower expression of ***CXCR4*** , the ***receptor*** for ***SDF-1*** , on megakaryocytes from the proliferating cultures .	parallel	1
17651	10929036	3569;3572	IL-6;gp130	Cytokines of the interleukin 6 ( ***IL-6*** ) family , which ***activates*** the signal transducer ***gp130*** , are major survival and growth factors for human multiple myeloma ( MM ) cells .	positive	1
17652	10929050	356;355	FasL;Fas	It was found that activated T cells rapidly acquire the expression of both Fas and ***Fas*** ***ligand*** ( ***FasL*** ) on their surface and contain high levels of the precursor form of the pro-apoptotic enzyme , caspase 8 ( FLICE ) .	parallel	1
17653	10929070	958;7412	CD40;vascular cell adhesion molecule-1	***CD40*** ligation alone ***enhanced*** expression of ***vascular cell adhesion molecule-1*** ( VCAM-1 ) , intracellular adhesion molecule-1 ( ICAM-1 ) and E-selectin whereas IL-4 and IL-13 increased expression of VCAM-1 and P-selectin but not ICAM-1 or E-selectin .	positive	0
17654	10929070	3596;7412	IL-13;VCAM-1	CD40 ligation alone enhanced expression of vascular cell adhesion molecule-1 ( VCAM-1 ) , intracellular adhesion molecule-1 ( ICAM-1 ) and E-selectin whereas IL-4 and ***IL-13*** ***increased*** expression of ***VCAM-1*** and P-selectin but not ICAM-1 or E-selectin .	positive	0
17655	10929070	3565;7412	IL-4;VCAM-1	CD40 ligation alone enhanced expression of vascular cell adhesion molecule-1 ( VCAM-1 ) , intracellular adhesion molecule-1 ( ICAM-1 ) and E-selectin whereas ***IL-4*** and IL-13 ***increased*** expression of ***VCAM-1*** and P-selectin but not ICAM-1 or E-selectin .	positive	0
17656	10929070	958;3565	CD40;IL-4	These results show that ***interactions*** between ***IL-4*** and ***CD40*** on endothelial cells give rise to specific patterns of adhesion molecule expression and cytokine production that may have important implications for lymphocyte and neutrophil migration and function at sites of inflammation .	parallel	1
17657	10929711	56616;842	Smac;caspase-9	***Smac*** ***promotes*** ***caspase-9*** activation by binding to inhibitor of apoptosis proteins , IAPs , and removing their inhibitory activity .	positive	0
17658	10929768	3553;3576	IL-1beta;IL-8	Immortalized human dermal microvascular endothelial cells ( HMEC-1 cells ) were maintained for 4 h in vitro with serum from 18 ABD patients or with ***IL-1beta*** , a known ***stimulator*** of ***IL-8*** synthesis , TNF-alpha or their combination at five - to tenfold higher concentrations than those found in the serum of ABD patients .	positive	0
17659	10929768	3553;7124	IL-1beta;TNF-alpha	Immortalized human dermal microvascular endothelial cells ( HMEC-1 cells ) were maintained for 4 h in vitro with serum from 18 ABD patients or with ***IL-1beta*** , a known ***stimulator*** of IL-8 synthesis , ***TNF-alpha*** or their combination at five - to tenfold higher concentrations than those found in the serum of ABD patients .	positive	0
17660	10929768	7124;3576	TNF-alpha;IL-8	Increased IL-8 secretion was found after incubation with ABD patients ' serum ( median 20 pg/ml ) , but IL-1beta , TNF-alpha and IL-1beta + ***TNF-alpha*** failed to ***induce*** ***IL-8*** secretion by HMEC-1 cells ( < or = 1-1 .2 pg/ml ) in biologically relevant concentrations .	target	1
17661	10929868	727;3569	C5a;interleukin-6	***C5a*** ***modulation*** of interleukin-1 beta-induced ***interleukin-6*** production by human osteoblast-like cells .	target	0
17662	10929868	728;727	C5aR;C5a	Incubation of IL-1beta-treated cells with anti-human ***C5a*** ***receptor*** ( ***C5aR*** ) Ab resulted in a 78 % suppression of the C5a-induced release of IL-6 , but C5aR neutralization did not affect C5a/IL-1beta co-stimulation of IL-6 .	parallel	1
17663	10930091	6251;5601	Rsu-1;Jun kinase	Exposure of serum-starved cells to EGF revealed that expression of ***HA-Rsu-1*** increased ERK-2 kinase activation , ***decreased*** activation of ***Jun kinase*** and inhibited Rho-dependent Rho-alpha kinase ( ROK ) activity compared to control cells .	negative	0
17664	10930091	6251;5594	Rsu-1;ERK-2	Exposure of serum-starved cells to EGF revealed that expression of ***HA-Rsu-1*** ***increased*** ***ERK-2*** kinase activation , decreased activation of Jun kinase and inhibited Rho-dependent Rho-alpha kinase ( ROK ) activity compared to control cells .	positive	0
17665	10930117	3689;3383	LFA-1;ICAM-1	ICAM-1 interstitial tissue may facilitate the homing and persistence of an interstitial infiltrate by ******ICAM-1/LFA-1****** ***interactions*** , thereby preceding the development of renal interstitial fibrosis .	parallel	1
17666	10930123	6647;79109	SOD;SIN-1	On the other hand , pretreatment of endothelial cells with diethylmaleate , a glutathione depleter , aggravated the cytotoxicity induced by ***SIN-1*** , which was ***prevented*** by addition of exogenous glutathione and/or ***SOD/CAT*** .	negative	0
17667	10930193	185;183	AT1;angiotensin II	Autoantibodies against the ***angiotensin II*** ***receptor*** ( ***AT1*** ) were detected in 14 , 33 , 18 and 14 % of patients with malignant essential hypertension , malignant secondary hypertension , renovascular diseases and control patients , respectively .	parallel	1
17668	10930296	4254;4916	SCF;tyrosine kinase receptor c	Stem cell factor ( ***SCF*** ) , the ***ligand*** for the ***tyrosine kinase receptor c-kit*** , usually induces differentiation of the CD34-negative stem cells into CD34-positive haematopoietic precursors .	parallel	1
17669	10930301	7040;3458	TGF-beta;IFN-gamma	In contrast neither IL-4 or ***TGF-beta*** ***suppressed*** ***IFN-gamma*** production ( 837 + / -244 pg/ml and 759 + / -523 pg/ml ) .	negative	1
17670	10930307	5008;1636	OSM;ACE	RESULTS : ***OSM*** caused a dose dependent increase in ACE amount and ***increased*** the expression of ***ACE*** mRNA .	positive	0
17671	10930307	5008;1636	OSM;ACE	Local ***induction*** of ***ACE*** by ***OSM*** in the vascular wall may be a consequence of inflammatory processes leading to locally increased production of angiotensin II and breakdown of bradykinin .	target	1
17672	10930380	8772;836	FADD;caspase-3	In an in vivo FHF model , the Fas-associated death domain ( ***FADD*** ) , adenovirus selectively ***blocked*** the intracellular pathway , leading to mitochondrial cytochrome c release , ***caspase-3*** activation , and , thus , apoptosis of hepatocytes .	negative	0
17673	10930384	1050;5743	C/EBP-alpha;COX-2	Moreover , transient expression of ***C/EBP-alpha*** , but not C/EBP-delta , in the hepatoma cell line AT3F cells ***abolished*** the ***COX-2*** promoter activity .	negative	0
17674	10930399	4323;2161	MMP-14;Hageman factor	Moreover , rapid proteolytic ***inactivation*** of Factor XII ( ***Hageman factor*** ) by MMP-12 , MMP-13 , and ***MMP-14*** was noted .	negative	1
17675	10930400	4780;5468	NRF2;PPARgamma	Finally , a direct ***interaction*** between ***PPARgamma*** and ***NRF2*** was confirmed by glutathione S-transferase pull-down assay .	parallel	1
17676	10930400	5468;6916	PPARgamma;TXS	In conclusion , the NRF2-binding site ( -98 / -88 ) is the major promoter of 5 ' ***FL-TXS*** which can be ***suppressed*** by activated ***PPARgamma*** via a protein-protein interaction with NRF2 in macrophages .	negative	1
17677	10930400	5468;6916	peroxisome proliferator-activated receptor gamma;TXS	We have studied the transcription ***regulation*** of the rat thromboxane synthase ( ***TXS*** ) gene by ***peroxisome proliferator-activated receptor gamma*** ( PPARgamma ) in macrophages .	target	1
17678	10930412	367;11143	Androgen receptor;HBO1	***Androgen receptor*** ***interacts*** with a novel MYST protein , ***HBO1*** .	parallel	1
17679	10930419	331;842	XIAP;caspase-9	In addition , we show that ara-C induces the ***association*** of ***XIAP*** with the cleaved fragments of ***caspase-9*** and thereby inhibition of caspase-9 activity .	parallel	0
17680	10930419	331;836	XIAP;caspase-3	The results also demonstrate that ara-C induces cleavage of procaspase-3 by a caspase-8-dependent mechanism and that ***XIAP*** ***inhibits*** ***caspase-3*** activity .	negative	1
17681	10930425	1017;5111	Cdk2;proliferating cell nuclear antigen	A direct ***interaction*** between ***proliferating cell nuclear antigen*** ( PCNA ) and ***Cdk2*** targets PCNA-interacting proteins for phosphorylation .	parallel	1
17682	10930425	1017;5111	Cdk2;PCNA	Here we show a direct ***interaction*** between ***PCNA*** and ***Cdk2*** .	parallel	1
17683	10930425	1017;5111	Cdk2;PCNA	This ternary ***PCNA-Cdk2-cyclin*** A complex was able to ***phosphorylate*** the ***PCNA*** binding region of the large subunit of replication factor C as well as DNA ligase I.	target	1
17684	10930425	1017;5111	Cdk2;PCNA	This ternary ******PCNA-Cdk2-cyclin****** A ***complex*** was able to phosphorylate the PCNA binding region of the large subunit of replication factor C as well as DNA ligase I.	parallel	1
17685	10930429	5423;7515	DNA polymerase beta;x-ray repair cross-complementing protein-1	Thus , poly(ADP-ribose) polymerase-1 , ***DNA polymerase beta*** , and ligase III ***interact*** with ***x-ray repair cross-complementing protein-1*** within the BER complex , which ensures that ATP is generated and specifically used for DNA ligation .	parallel	1
17686	10930429	142;7515	poly(ADP-ribose) polymerase-1;x-ray repair cross-complementing protein-1	Thus , ***poly(ADP-ribose) polymerase-1*** , DNA polymerase beta , and ligase III ***interact*** with ***x-ray repair cross-complementing protein-1*** within the BER complex , which ensures that ATP is generated and specifically used for DNA ligation .	parallel	1
17687	10930442	7124;1733	TNF-alpha;type I 5'-deiodinase	Elevated ***TNF-alpha*** levels , which accompany severe illness , are ***associated*** with decreased activity of ***type I 5'-deiodinase*** ( 5 ' - DI ) in liver , leading us to speculate that high levels of this factor contribute to euthyroid sick syndrome .	parallel	0
17688	10930442	7124;4790	TNF-alpha;NF-kappa B	Here we demonstrate that the ***activation*** of ***NF-kappa B*** by ***TNF-alpha*** interferes with thyroid-hormone action as demonstrated by impairment of T ( 3 ) - dependent induction of 5 ' - DI gene expression in HepG2 cells .	positive	1
17689	10930442	7124;4790	TNF-alpha;NF-kappa B	Furthermore , we show that an inhibitor of NF-kappa B activation , clarithromycin ( CAM ) , can inhibit ***TNF-alpha-induced*** ***activation*** of ***NF-kappa B*** and restore T ( 3 ) - dependent induction of 5 ' - DI mRNA and enzyme activity .	positive	1
17690	10930442	7124;4790	TNF-alpha;NF-kappa B	These results suggest that ***NF-kappa B*** ***activation*** by ***TNF-alpha*** is involved in the pathogenesis of euthyroid sick syndrome and that CAM could help prevent a decrease in serum T ( 3 ) levels and thus ameliorate euthyroid sick syndrome .	positive	1
17691	10930463	4052;7040	LTBP-1;TGF-beta	***LTBP-1*** and LTBP-3 ***bound*** efficiently all ***TGF-beta*** isoforms , LTBP-4 had a much weaker binding capacity , whereas LTBP-2 as well as fibrillins -1 and -2 were negative .	parallel	1
17692	10930463	4053;7040	LTBP-3;TGF-beta	LTBP-1 and ***LTBP-3*** ***bound*** efficiently all ***TGF-beta*** isoforms , LTBP-4 had a much weaker binding capacity , whereas LTBP-2 as well as fibrillins -1 and -2 were negative .	parallel	1
17693	10930576	9510;176	ADAMTS-1;aggrecan	***ADAMTS-1*** ***cleaves*** a cartilage proteoglycan , ***aggrecan*** .	target	1
17694	10930576	9510;176	ADAMTS-1;aggrecan	In this study we have demonstrated that ***ADAMTS-1*** is able to ***cleave*** a major cartilage proteoglycan , ***aggrecan*** .	target	1
17695	10931136	3553;4179	IL-1beta;CD46	The combination of tumour necrosis factor-alpha , ***IL-1beta*** , and IL-6 caused increased expression of CD55 ( three-fold ) and CD59 ( two-fold ) and ***decreased*** expression of ***CD46*** at day 3 post-exposure .	negative	0
17696	10931136	3458;966	Interferon-gamma;CD59	***Interferon-gamma*** ***reduced*** expression of ***CD59*** and strongly antagonized the up-regulatory effects on CD59 mediated by the other cytokines .	negative	1
17697	10931152	959;958	CD40 ligand;CD40	Absence of ******CD40-CD40 ligand****** ***interactions*** in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets .	parallel	1
17698	10931152	959;958	CD40 ligand;CD40	The aim of this study was to investigate the effect of absent ******CD40-CD40 ligand****** ***interactions*** in patients with X-linked hyper-IgM syndrome ( XHIGM ) on the generation of Th1 and Th2 immunity .	parallel	1
17699	10931177	5320;2159	group IIA phospholipase A2;prothrombinase	Human secreted ***group IIA phospholipase A2*** ( hGIIA ) was reported to ***inhibit*** ***prothrombinase*** activity because of binding to factor Xa .	negative	1
17700	10931177	26279;2159	sPLA2s;factor Xa	Other basic , but not neutral or acidic , mammalian secreted phospholipases A2 ( sPLA2s ) exert a phospholipid-independent inhibitory effect on prothrombinase activity , suggesting that these basic ***sPLA2s*** also ***bind*** to ***factor Xa*** .	parallel	1
17701	10931187	5829;5747	paxillin;pp125FAK	Echistatin inhibits pp125FAK autophosphorylation , paxillin phosphorylation and ******pp125FAK-paxillin****** ***interaction*** in fibronectin-adherent melanoma cells .	parallel	1
17702	10931834	4265;4609	MHS4;c-myc	We found that the most 3 ' enhancer region ( ***MHS4*** ) ***activated*** the ***c-myc*** promoter by 46-fold in the Raji Burkitt 's lymphoma cell line , and it was the most active enhancer in these cells .	positive	1
17703	10931848	4862;406	MOP4;bmal1	Co-transfection experiments in COS cells demonstrated that chicken bmal1/CLOCK and human ******bmal1/MOP4****** ***heterodimers*** bound the AANAT E box element and enhanced transcription .	parallel	1
17704	10931848	406;15	bmal1;AANAT	Co-transfection experiments in COS cells demonstrated that chicken bmal1/CLOCK and human ***bmal1/MOP4*** heterodimers ***bound*** the ***AANAT*** E box element and enhanced transcription .	parallel	1
17705	10931848	4862;15	MOP4;AANAT	Co-transfection experiments in COS cells demonstrated that chicken bmal1/CLOCK and human ***bmal1/MOP4*** heterodimers ***bound*** the ***AANAT*** E box element and enhanced transcription .	parallel	1
17706	10931853	7200;7252	TRH;TSH-beta	CBP and Pit-1 acted synergistically in ***TRH*** ***stimulation*** of the ***TSH-beta*** promoter , and amino acids 1-450 of CBP were sufficient for the TRH effect .	positive	0
17707	10931853	1385;7200	CREB;TRH	In contrast , on the human alpha-GSU promoter , ***CREB*** and P-Lim ***mediated*** ***TRH*** signaling .	target	0
17708	10931861	2801;2804	GM130;Giantin	However , the ability of p115 to ***link*** ***GM130*** to ***Giantin*** and the phosphorylation of p115 at serine 941 are required for NSF-catalyzed cisternal regrowth .	parallel	0
17709	10931861	2801;8615	GM130;p115	However , the ability of p115 to ***link*** ***GM130*** to Giantin and the phosphorylation of ***p115*** at serine 941 are required for NSF-catalyzed cisternal regrowth .	parallel	0
17710	10931868	1500;7410	p120ctn;Vav2	Exploring how p120ctn may regulate Rho family GTPases , we find that ***p120ctn*** ***binds*** the Rho family exchange factor ***Vav2*** .	parallel	1
17711	10931916	4791;22974	p52;p100	The peptide sequences of hPOMp100 revealed identity to the human splicing factor PSF and a DNA-binding subunit of ******p100/p52****** ***heterodimer*** of unknown function .	parallel	1
17712	10932075	3553;6037	IL-1beta;ECP	In the GC-treated patients ***IL-1beta*** and TNF-alpha levels ***correlated*** with neutrophils and ***ECP*** , and IL-1beta correlated with eosinophils .	parallel	0
17713	10932075	7124;6037	TNF-alpha;ECP	In the GC-treated patients IL-1beta and ***TNF-alpha*** levels ***correlated*** with neutrophils and ***ECP*** , and IL-1beta correlated with eosinophils .	parallel	0
17714	10932193	814;5620	Camk4;protamine-2	***protamine-2*** is ***phosphorylated*** by ***Camk4*** in vitro , implicating a connection between Camk4 signalling and the exchange of basic nuclear proteins in mammalian male germ cells .	target	1
17715	10932245	1756;1605	dystrophin;beta-dystroglycan	The C-terminal region of ***dystrophin*** ***binds*** the cytoplasmic tail of ***beta-dystroglycan*** , in part through the interaction of its WW domain with a proline-rich motif in the tail of beta-dystroglycan .	parallel	1
17716	10932250	1676;1677	ICAD;CAD	Point mutations of the charged amino acids at this interface , on either CAD or ICAD , prevented formation of the functional ******CAD-ICAD****** ***complex*** .	parallel	1
17717	10933057	3082;4323	HGF;MT1-MMP	However , hepatocyte growth factor ( ***HGF*** ) ***induced*** ***MT1-MMP*** expression on the surface of JHH-7 cells and markedly increased invasiveness of JHH-7 in a concentration-dependent manner .	target	1
17718	10933167	7124;3553	TNF-alpha;IL-1beta	RESULTS : Microencapsulated islets were suppressed after exposure to ***IL-1beta*** , which was ***potentiated*** by ***TNF-alpha*** .	positive	0
17719	10933198	3458;821	IFN-gamma;calnexin	***IFN-gamma*** treatment corrected the TAP , LMP and tapasin deficiencies and ***enhanced*** the constitutive PA28alpha , LMP7 , ***calnexin*** and calreticulin expression which was accompanied with increased levels of MHC class I antigens .	positive	0
17720	10933198	3458;811	IFN-gamma;calreticulin	***IFN-gamma*** treatment corrected the TAP , LMP and tapasin deficiencies and ***enhanced*** the constitutive PA28alpha , LMP7 , calnexin and ***calreticulin*** expression which was accompanied with increased levels of MHC class I antigens .	positive	0
17721	10933198	3458;5696	IFN-gamma;LMP7	***IFN-gamma*** treatment corrected the TAP , LMP and tapasin deficiencies and ***enhanced*** the constitutive PA28alpha , ***LMP7*** , calnexin and calreticulin expression which was accompanied with increased levels of MHC class I antigens .	positive	0
17722	10933198	3458;5720	IFN-gamma;PA28alpha	***IFN-gamma*** treatment corrected the TAP , LMP and tapasin deficiencies and ***enhanced*** the constitutive ***PA28alpha*** , LMP7 , calnexin and calreticulin expression which was accompanied with increased levels of MHC class I antigens .	positive	0
17723	10933394	4067;930	Lyn;CD19	Herein , we demonstrate a novel molecular mechanism where ***interactions*** between ***CD19*** and ***Lyn*** amplify basal and antigen receptor-induced Src family kinase activation .	parallel	1
17724	10933394	930;4067	CD19;Lyn	This led to processive phosphorylation of ***CD19-Y482*** , which ***recruited*** a second ***Lyn*** molecule , allowing for transphosphorylation and amplification of Lyn activation .	target	0
17725	10933394	930;4067	CD19;Lyn	In vivo , CD19 deficiency impaired , and ***CD19*** overexpression ***enhanced*** , ***Lyn*** kinase activity .	positive	0
17726	10933397	23523;3164	Cabin1;Nur77	***Cabin1*** ***represses*** MEF2-dependent ***Nur77*** expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2 .	negative	1
17727	10933582	841;596	Caspase 8;Bcl-2	Bid is a novel pro-apoptosis ***Bcl-2*** family protein that is ***activated*** by ***Caspase 8*** in response to Fas/TNF-R1 death receptor activation .	positive	1
17728	10933610	3458;960	IFN-gamma;CD44	***IFN-gamma*** ***upregulated*** ***CD44*** expression on RIE ( 155 % of unstimulated control ) and IEC 6 ( 209 % of unstimulated control ) cells , whereas TNF-alpha had no effect .	positive	1
17729	10933700	3700;1234	gp120;CCR5	MAbs that inhibited ***gp120*** ***binding*** to CD4 , ***CCR5*** , or both were identified in both groups .	parallel	1
17730	10933700	3700;920	gp120;CD4	MAbs that inhibited ***gp120*** ***binding*** to ***CD4*** , CCR5 , or both were identified in both groups .	parallel	1
17731	10933707	3661;3439	interferon regulatory factor 3;IFN-alpha	The double-stranded RNA ( dsRNA ) binding protein NS1 of influenza virus is shown to prevent the potent antiviral interferon response by inhibiting the activation of ***interferon regulatory factor 3*** ( IRF-3 ) , a key ***regulator*** of ***IFN-alpha/beta*** gene expression .	target	1
17732	10933923	7157;8793	p53;TRUNDD	Therefore , the ***p53-dependent*** ***induction*** of ***TRUNDD*** may provide a mechanism to transiently favor cell survival over cell death , and overexpression of TRUNDD may be another mechanism of escape from p53-mediated apoptosis in gene therapy experiments .	target	1
17733	10933930	348;4018	apoE;lipoprotein	Plasma ***apoE*** ( derived primarily from the liver ) ***regulates*** plasma ***lipoprotein*** metabolism , but macrophage-derived apoE was shown to slow the progression of atherosclerosis independent of plasma lipid levels .	target	1
17734	10934025	3172;51176	Tcf;Lef1	The promoter region of the Cdx1 gene contains several Tcf-binding motifs , and these bind ******Tcf/Lef1****** / ( beta ) - catenin ***complexes*** and mediate ( beta ) - catenin-dependent transactivation .	parallel	1
17735	10934044	2185;2534	Pyk2;Fyn	Interestingly , both ***Pyk2*** and FPhy2 ( to a greater extent ) were tyrosine phosphorylated and ***associated*** with Src and ***Fyn*** .	parallel	0
17736	10934044	2185;6714	Pyk2;Src	Interestingly , both ***Pyk2*** and FPhy2 ( to a greater extent ) were tyrosine phosphorylated and ***associated*** with ***Src*** and Fyn .	parallel	0
17737	10934044	2185;5747	Pyk2;FAK	This model is further supported by an ***inhibition*** of endogenous ***FAK*** association with active Src by ***Pyk2*** and FPhy2 and a partial rescue by FAK of Pyk2-mediated cell cycle inhibition .	negative	1
17738	10934044	5747;6714	FAK;Src	This model is further supported by an inhibition of endogenous ***FAK*** ***association*** with active ***Src*** by Pyk2 and FPhy2 and a partial rescue by FAK of Pyk2-mediated cell cycle inhibition .	parallel	0
17739	10934044	2185;5599	Pyk2;JNK	Biochemical analyses indicated that Pyk2 and FPhy2 stimulated JNK activation whereas FAK or PFhy1 had little effect on it , suggesting that differential ***activation*** of ***JNK*** by ***Pyk2*** may contribute to its inhibition of cell cycle progression .	positive	1
17740	10934044	2185;5599	Pyk2;JNK	Biochemical analyses indicated that ***Pyk2*** and FPhy2 ***stimulated*** ***JNK*** activation whereas FAK or PFhy1 had little effect on it , suggesting that differential activation of JNK by Pyk2 may contribute to its inhibition of cell cycle progression .	positive	0
17741	10934044	2185;5594	Pyk2;Erk	In addition , ***Pyk2*** and FPhy2 to a greater extent also ***inhibited*** ***Erk*** activation in cell adhesion whereas FAK and PFhy1 stimulated it , suggesting a role for Erk activation in mediating differential regulation of cell cycle by Pyk2 and FAK .	negative	1
17742	10934049	7040;5784	TGFbeta;Pez	***TGFbeta*** , which inhibits cell proliferation but not migration , ***inhibited*** the translocation of ***Pez*** to the nucleus in the cells at the ' wound ' edge , further strengthening the argument that Pez plays a role in the nucleus during cell proliferation .	negative	1
17743	10934108	356;355	FasL;Fas	The results of this study show that bleomycin-induced pulmonary fibrosis does not require ******Fas-FasL****** ***interaction*** , and that epithelial cell apoptosis after bleomycin exposure is mediated by Fas-independent pathways .	parallel	1
17744	10934112	3553;6357	IL-1beta;MCP-4	In support of our in situ findings demonstrating MCP-4 expression in epithelial cells and mononuclear cells in vivo , we have found that ***MCP-4*** expression can be ***induced*** in these cells in vitro by tumor necrosis factor-alpha ( TNF-alpha ) and interleukin-1beta ( ***IL-1beta*** ) .	target	1
17745	10934112	7124;6357	TNF-alpha;MCP-4	In support of our in situ findings demonstrating MCP-4 expression in epithelial cells and mononuclear cells in vivo , we have found that ***MCP-4*** expression can be ***induced*** in these cells in vitro by tumor necrosis factor-alpha ( ***TNF-alpha*** ) and interleukin-1beta ( IL-1beta ) .	target	1
17746	10934144	1191;5241	clusterin;progesterone receptor	***clusterin*** expression was ***associated*** with large tumor size ( P = 0.04 ) , estrogen and ***progesterone receptor*** negative status ( P = 0.02 and P = 0.001 , respectively ) and with the progression from primary carcinoma to metastatic carcinoma in lymph nodes ( 80 % metastatic nodes had positive expression ) ( P = 0.004 ) .	parallel	0
17747	10934147	2331;7040	fibromodulin;TGF-beta	This inverse relationship between fibromodulin expression and scarring in both fetal and adult rat wound repair suggests that ***fibromodulin*** may be a biologically relevant ***modulator*** of ***TGF-beta*** activity during scar formation .	target	0
17748	10934148	1435;596	CSF-1;bcl-2	***CSF-1*** maintained NF-kappaB activation and ***increased*** the expression of ***bcl-2*** and bcl-X ( L ) mRNA , but had no effect on JNK activation .	positive	0
17749	10934148	1435;598	CSF-1;bcl-X	***CSF-1*** maintained NF-kappaB activation and ***increased*** the expression of bcl-2 and ***bcl-X*** ( L ) mRNA , but had no effect on JNK activation .	positive	0
17750	10934148	8600;6714	OPGL;c-src	In contrast , ***OPGL*** enhanced both NF-kappaB and JNK kinase activation and ***increased*** the expression of ***c-src*** , but not bcl-2 and bcl-X ( L ) mRNA .	positive	0
17751	10934148	8600;4790	OPGL;NF-kappaB	In contrast , ***OPGL*** ***enhanced*** both ***NF-kappaB*** and JNK kinase activation and increased the expression of c-src , but not bcl-2 and bcl-X ( L ) mRNA .	positive	0
17752	10934192	4790;5468	NF-kappaB;peroxisome proliferator-activated receptor-gamma	The ***NF-kappaB*** components p50 and p65 directly ***bound*** ***peroxisome proliferator-activated receptor-gamma*** ( PPAR-gamma ) in vitro .	parallel	1
17753	10934192	5468;4790	PPAR-gamma;NF-kappaB	In cotransfections of CV-1 and HeLa cells , ***PPAR-gamma*** ***inhibited*** the ***NF-kappaB*** transactivation in an oxLDL-dependent manner .	negative	1
17754	10934192	5468;4790	PPAR-gamma;NF-kappaB	From these results , we propose that oxLDL-mediated suppression of the IL-12 production from LPS-activated mouse macrophages may , at least in part , involve both inhibition of the NF-kappaB-DNA interactions and physical ***interactions*** between ***NF-kappaB*** and ***PPAR-gamma*** .	parallel	1
17755	10934195	4221;3727	menin;JunD	JunD appears to be one mediator of this effect , since JunD was a major component of the AP1-DNA binding complex in granulosa cells , and ***menin*** , a selective ***inhibitor*** of ***JunD*** , blocked transcription of -73 COL-luciferase .	negative	1
17756	10934204	22808;9771	M-Ras;MR-GEF	Co-immunoprecipitation studies confirmed the ***interaction*** of ***M-Ras-GTP*** with ***MR-GEF*** in vivo .	parallel	1
17757	10934204	22808;9771	M-Ras;MR-GEF	In addition , a constitutively active ***M-Ras*** ( 71L ) mutant ***inhibited*** the ability of ***MR-GEF*** to promote Rap1A activation in a dose-dependent manner .	negative	1
17758	10934204	22808;5906	M-Ras;Rap1	These data suggest that ***M-Ras*** may ***inhibit*** ***Rap1*** in order to elicit its biological effects .	negative	1
17759	10934204	25780;5906	GRP3;Rap1	A third GEF , ***GRP3*** ( KIAA0846 ) , ***activated*** both Ras and ***Rap1*** and shared significant sequence homology with the calcium - and diacylglycerol-activated GEFs , GRP1 and GRP2 .	positive	1
17760	10934204	9771;22808	MR-GEF;M-Ras	By searching for in vitro interaction with Ras-GTP proteins , PDZ-GEF specifically bound to Rap1A - and Rap2B-GTP , whereas ***MR-GEF*** ***bound*** to ***M-Ras-GTP*** .	parallel	1
17761	10934209	331;836	XIAP;caspase-3	These results suggest that ***XIAP*** ***inhibits*** ***caspase-3*** and caspase-9 in a different manner .	negative	1
17762	10934209	331;842	XIAP;caspase-9	These results suggest that ***XIAP*** ***inhibits*** caspase-3 and ***caspase-9*** in a different manner .	negative	1
17763	10934212	6195;6197	Rsk1;Rsk2	Xenopus Rsk1 and ***Rsk2*** are specifically ***recognized*** by commercially available ***Rsk1*** and Rsk2 antisera on immunoblots , but both Rsk1 and Rsk2 are immunoprecipitated by Rsk1 , Rsk2 , and RSK3 sera .	target	1
17764	10934212	6197;5706	Rsk2;p42	***Rsk2*** , like Rsk1 , forms a heteromeric ***complex*** with ***p42*** MAP kinase .	parallel	1
17765	10934212	5706;6197	p42;Rsk2	Finally , we demonstrate that ***p42*** MAP kinase can ***activate*** recombinant ***Rsk2*** in vitro to a specific activity comparable to that found in Rsk2 that has been activated maximally in vivo .	positive	1
17766	10934220	2833;2185	CXCR3;protein kinase B	In contrast to other chemokines , such as monocyte chemotactic protein 1 ( CC chemokine receptor 2 [ CCR2 ] ) , macrophage inflammatory protein 1beta ( CCR5 ) , liver and activation-regulated chemokine ( LARC [ CCR6 ] ) , Epstein-Barr virus-induced molecule 1 ligand chemokine ( ELC [ CCR7 ] ) , and IP10 ( ***CXCR3*** ) , SDF-1 ***stimulates*** the prolonged activation of ***protein kinase B*** and extracellular signal-regulated kinase ( ERK ) -2 .	positive	0
17767	10934220	6387;2185	SDF-1;protein kinase B	In contrast to other chemokines , such as monocyte chemotactic protein 1 ( CC chemokine receptor 2 [ CCR2 ] ) , macrophage inflammatory protein 1beta ( CCR5 ) , liver and activation-regulated chemokine ( LARC [ CCR6 ] ) , Epstein-Barr virus-induced molecule 1 ligand chemokine ( ELC [ CCR7 ] ) , and IP10 ( CXCR3 ) , ***SDF-1*** ***stimulates*** the prolonged activation of ***protein kinase B*** and extracellular signal-regulated kinase ( ERK ) -2 .	positive	0
17768	10934220	6387;7852	SDF-1;CXCR4	Although increasing concentrations of ***SDF-1*** ***enhance*** ***CXCR4*** internalization , kinase activation is prolonged .	positive	0
17769	10934247	375790;1145	agrin;AChR epsilon subunit	We find that neural ***agrin-mediated*** ***activation*** of the ***AChR epsilon subunit*** promoter is abolished by the inhibition of GABP function .	positive	1
17770	10934248	857;6616	caveolin1;SNAP25	After the induction of persistent synaptic potentiation , an abundant 40 kDa ******SNAP25-caveolin1****** ***complex*** was observed .	parallel	1
17771	10934248	857;6616	caveolin1;SNAP25	The ******SNAP25-caveolin1****** ***complex*** was not abundant in control slices and , therefore , represents the first demonstration of a reorganization of protein complexes in intact hippocampal slices during the induction of synaptic potentiation .	parallel	1
17772	10934248	6616;857	SNAP25;caveolin1	The ***interaction*** between ***caveolin1*** and ***SNAP25*** was confirmed biochemically by demonstration of the association of caveolin with recombinant-immobilized SNAP25 and by the coimmunoprecipitation of SNAP25 using caveolin-specific antisera .	parallel	1
17773	10934288	7035;2152	TFPI;tissue factor	To clarify factors that may contribute to the development of intratumoral hemorrhage , we analyzed the expression of tissue factor ( TF ) , an initiator of the extrinsic coagulation pathway , and of ***tissue factor*** pathway ***inhibitor*** ( ***TFPI*** ) in glioblastomas with or without massive intratumoral hematoma .	negative	1
17774	10934317	5879;223117	Rac1;sema3D	Repulsive effects of myelin and ***sema3D*** on growth cones are ***blocked*** by expression of constitutively active Rac1 and dominant negative ***Rac1*** , respectively .	negative	0
17775	10934324	8829;10154	neuropilin-1;plexin	Instead , the ***Sema3A/neuropilin-1*** complex ***interacts*** with another transmembrane protein , ***plexin*** , on the surface of growth cones .	parallel	1
17776	10934324	10371;10154	Sema3A;plexin	Instead , the ***Sema3A/neuropilin-1*** complex ***interacts*** with another transmembrane protein , ***plexin*** , on the surface of growth cones .	parallel	1
17777	10934324	8829;10371	neuropilin-1;Sema3A	Instead , the ******Sema3A/neuropilin-1****** ***complex*** interacts with another transmembrane protein , plexin , on the surface of growth cones .	parallel	1
17778	10934324	10154;5879	plexin;Rac1	Rac1 is likely to be involved in semaphorin-induced rearrangements of the actin cytoskeleton , but how ***plexin*** ***controls*** ***Rac1*** activity is not known .	target	0
17779	10934466	3308;317	Hsp70;Apaf-1	***Hsp70*** ***binds*** to ***Apaf-1*** but not to procaspase-9 , and prevents recruitment of caspases to the apoptosome complex .	parallel	1
17780	10934467	317;3308	Apaf-1;Hsp70	The ***interaction*** between ***Hsp70*** and ***Apaf-1*** prevents oligomerization of Apaf-1 and association of Apaf-1 with procaspase-9 .	parallel	1
17781	10934467	3308;317	Hsp70;Apaf-1	On the basis of these results , we propose that resistance to apoptosis exhibited by stressed cells and some tumours , which constitutively express high levels of Hsp70 , may be due in part to ***modulation*** of ***Apaf-1*** function by ***Hsp70*** .	target	0
17782	10934474	50855;998	Par6;Cdc42	***Par6*** forms a ***complex*** with ***Cdc42-GTP*** , with a human homologue of the multi-PDZ protein PAR-3 and with the regulatory domains of atypical protein kinase C ( PKC ) proteins .	parallel	1
17783	10934475	50855;56288	PAR-6;PAR-3	A mammalian ******PAR-3-PAR-6****** ***complex*** implicated in Cdc42/Rac1 and aPKC signalling and cell polarity .	parallel	1
17784	10934618	3486;3479	IGFBP-3;IGF-I	Taken together , these observations confirm that ***IGFBP-3-fibronectin*** interactions ***affect*** the ***IGF-I*** axis , and they indicate that IGF-I is stored in the chondrocyte territorial matrix through binding to a complex of IGFBP-3 and intact fibronectin .	target	0
17785	10935448	5663;1499	presenilin-1;Beta-catenin	Recent studies have shown that an unstable ***interaction*** between ***Beta-catenin*** and the mutant ***presenilin-1*** induces neuronal apoptosis , and that Beta-catenin levels are decreased in the brains of patients with Alzheimer 's disease ( AD ) .	parallel	1
17786	10935492	2353;4318	c-fos;matrix metalloproteinase 9	Transcriptional ***inhibition*** of ***matrix metalloproteinase 9*** ( MMP-9 ) activity by a ***c-fos/estrogen*** receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion .	negative	1
17787	10935492	3725;4318	AP-1;matrix metalloproteinase 9	Transcriptional inhibition of ***matrix metalloproteinase 9*** ( MMP-9 ) activity by a c-fos/estrogen receptor fusion protein is ***mediated*** by the proximal ***AP-1*** site of the MMP-9 promoter and correlates with reduced tumor cell invasion .	target	0
17788	10935498	7040;5743	TGF-beta1;COX-2	In the present studies , we found that transforming growth factor beta1 ( ***TGF-beta1*** ) and epidermal growth factor ( EGF ) synergistically ***induced*** the expression of ***COX-2*** and prostaglandin E2 ( PGE2 ) production in mink lung epithelial ( Mv1Lu ) cells .	target	1
17789	10935498	7040;5743	TGF-beta1;COX-2	The combination of ***TGF-beta1*** and EGF also significantly ***induced*** ***COX-2*** expression in rat intestinal epithelial ( RIE-1 ) cells and completely prevented sodium butyrate ( NaBu ) - induced apoptosis .	target	1
17790	10935498	7040;5743	TGF-beta1;COX-2	The synergistic ***induction*** of ***COX-2*** by ***TGF-beta1*** and EGF was not observed in R1B-L17 cells , a line derived from Mv1Lu cells that lacks the TGF-beta type-I receptor .	target	1
17791	10935500	2120;960	Tel;CD44	Exogenous ***Tel*** expression is ***associated*** with transcriptional upregulation of entactin/nidogen , Smad5 , Col3a1 , ***CD44*** and fibronectin , and downregulation of Col1a1 and secretory leukocyte protease inhibitor .	parallel	0
17792	10935500	2120;1281	Tel;Col3a1	Exogenous ***Tel*** expression is ***associated*** with transcriptional upregulation of entactin/nidogen , Smad5 , ***Col3a1*** , CD44 and fibronectin , and downregulation of Col1a1 and secretory leukocyte protease inhibitor .	parallel	0
17793	10935500	2120;4811	Tel;entactin	Exogenous ***Tel*** expression is ***associated*** with transcriptional upregulation of ***entactin/nidogen*** , Smad5 , Col3a1 , CD44 and fibronectin , and downregulation of Col1a1 and secretory leukocyte protease inhibitor .	parallel	0
17794	10935500	2120;4090	Tel;Smad5	Exogenous ***Tel*** expression is ***associated*** with transcriptional upregulation of entactin/nidogen , ***Smad5*** , Col3a1 , CD44 and fibronectin , and downregulation of Col1a1 and secretory leukocyte protease inhibitor .	parallel	0
17795	10935506	7157;581	p53;Bax	Driving ***p53*** ***response*** to ***Bax*** activation greatly enhances sensitivity to taxol by inducing massive apoptosis .	parallel	0
17796	10935511	598;596	bcl-xS;bcl-2	We hypothesized that ***inhibition*** of ***bcl-2/bcl-xL*** by the pro-apoptotic ***bcl-xS*** protein , would result in selective induction of apoptosis in mammary carcinoma cells compared to their nontransformed counterparts .	negative	1
17797	10935542	5479;3717	CypB;Jak2	***CypB*** did not alter the affinity of the PRL receptor ( PRLr ) for its ligand , or ***increase*** the phosphorylation of PRLr-associated ***Jak2*** or Stat5a .	positive	0
17798	10935542	5479;6776	CypB;Stat5a	***CypB*** did not alter the affinity of the PRL receptor ( PRLr ) for its ligand , or ***increase*** the phosphorylation of PRLr-associated Jak2 or ***Stat5a*** .	positive	0
17799	10935559	958;959	CD40;CD40 Ligand	Because of the increased state of T-cell activation and the selective loss of Th1 cytokine producing CD4 T cells , LVAD recipients also develop B-cell hyperreactivity and dysregulated immunoglobulin syntheses by unopposed production of Th2 cytokines and increased ******CD40 Ligand-CD40****** ***interactions*** .	parallel	1
17800	10935886	3558;6542	Interleukin-2;cat2	***Interleukin-2*** and concanavalin A ***upregulate*** a ***cat2*** isoform encoding a high affinity L-arginine transporter in feline lymphocytes .	positive	1
17801	10936029	959;958	CD154;CD40	******CD40-CD154****** ***interactions*** play a key role in regulating immune response and are involved in the development of some autoimmune diseases .	parallel	1
17802	10936035	1392;5443	corticotropin-releasing hormone;alpha-melanocyte-stimulating hormone	Pituitary proopiomelanocortin-derived peptides and hypothalamus-pituitary-interrenal axis activity in gilthead sea bream ( Sparus aurata ) during prolonged crowding stress : differential ***regulation*** of adrenocorticotropin hormone and ***alpha-melanocyte-stimulating hormone*** release by ***corticotropin-releasing hormone*** and thyrotropin-releasing hormone .	target	1
17803	10936035	7200;5443	thyrotropin-releasing hormone;alpha-melanocyte-stimulating hormone	Pituitary proopiomelanocortin-derived peptides and hypothalamus-pituitary-interrenal axis activity in gilthead sea bream ( Sparus aurata ) during prolonged crowding stress : differential ***regulation*** of adrenocorticotropin hormone and ***alpha-melanocyte-stimulating hormone*** release by corticotropin-releasing hormone and ***thyrotropin-releasing hormone*** .	target	1
17804	10936035	7200;5443	TRH;alpha-MSH	However , at that time , CRH - and ***TRH-induced*** ***responses*** of ***alpha-MSH*** secretion , and the unstimulated secretory activity of the MSH cells , were enhanced in crowded sea bream .	parallel	0
17805	10936177	5604;5594	MEK1;ERK	ATP-induced TNF-alpha release was inhibited by PD 098059 , an inhibitor of extracellular signal-regulated protein kinase ( ERK ) kinase 1 ( ***MEK1*** ) , which ***activates*** ***ERK*** , and also by SB 203580 , an inhibitor of p38 mitogen-activated protein kinase .	positive	1
17806	10936190	1020;351	cyclin-dependent kinase 5;beta-amyloid precursor protein	Neuron-specific ***phosphorylation*** of Alzheimer 's ***beta-amyloid precursor protein*** by ***cyclin-dependent kinase 5*** .	target	1
17807	10936504	84260;1026	tumor suppressor protein;p21	This was accompanied by a parallel decrease in mucosal p53 , a ***tumor suppressor protein*** that is known to ***regulate*** ***p21*** ( Waf1/Cip1 ) .	target	1
17808	10936508	7040;3558	TGF-beta 1;IL-2	***TGF-beta 1*** differentially ***regulates*** ***IL-2*** expression and [ 3H ] - thymidine incorporation in CD3 epsilon mAb - and CD28 mAb-activated splenocytes and thymocytes .	target	1
17809	10936508	7040;3558	TGF-beta;IL-2	Our results suggest that ***TGF-beta*** ( 1 ) stimulates IL-2 production at low concentrations ( 0.1-1 pg/ml ) and conversely ***inhibits*** ***IL-2*** production at high concentrations ( 1-10 ng/ml ) in CD3epsilon monoclonal antibody ( mAb ) + / - CD28 mAb-activated splenocytes .	negative	1
17810	10936508	7040;3558	TGF-beta;IL-2	Our results suggest that ***TGF-beta*** ( 1 ) ***stimulates*** ***IL-2*** production at low concentrations ( 0.1-1 pg/ml ) and conversely inhibits IL-2 production at high concentrations ( 1-10 ng/ml ) in CD3epsilon monoclonal antibody ( mAb ) + / - CD28 mAb-activated splenocytes .	positive	0
17811	10936508	7040;3558	TGF-beta;IL-2	Additionally , concentrations of ***TGF-beta*** ( 1 ) that ***stimulate*** ***IL-2*** production in CD3epsilon mAb + CD28 mAb-activated splenocytes concominantly inhibit splenocyte proliferation under similar conditions .	positive	0
17812	10936671	999;4323	E-cadherin;Membrane type 1-matrix metalloproteinase	***Membrane type 1-matrix metalloproteinase*** expression is ***regulated*** by ***E-cadherin*** through the suppression of mitogen-activated protein kinase cascade .	target	1
17813	10936671	999;4323	E-cadherin;MT1-MMP	These results suggest that ***E-cadherin*** suppresses MAP kinase cascade and ***down-regulates*** ***MT1-MMP*** .	negative	1
17814	10936763	2520;2922	Gastrin;Gastrin-releasing peptide	Both vasoactive-intestinal peptide ( VIP ) and gastric-inhibitory peptide ( GIP ) increased somatostatin release but did not inhibit basal Gastrin secretion , although VIP was effective in reducing the ***Gastrin*** ***response*** to ***Gastrin-releasing peptide*** ( GRP ) .	parallel	0
17815	10936763	7432;6750	vasoactive-intestinal peptide;somatostatin	Both ***vasoactive-intestinal peptide*** ( VIP ) and gastric-inhibitory peptide ( GIP ) ***increased*** ***somatostatin*** release but did not inhibit basal Gastrin secretion , although VIP was effective in reducing the Gastrin response to Gastrin-releasing peptide ( GRP ) .	positive	0
17816	10936861	5104;5624	protein C inhibitor;protein C	Plasma levels of activated ******protein C-protein C inhibitor****** ***complex*** in patients with hypercoagulable states .	parallel	1
17817	10936878	351;348	Abeta;apoE	Specifically apoE , alpha2m , secreted APP , and amyloid beta-protein ( ***Abeta*** ) ***complexed*** to either ***apoE*** or alpha2m are ligands of LRP .	parallel	1
17818	10936886	348;351	ApoE;Abeta	Lipoproteins , ***ApoE*** , and ApoJ ***influence*** the uptake and degradation of ***Abeta*** in vitro and in vivo .	target	0
17819	10936886	1191;351	ApoJ;Abeta	Lipoproteins , ApoE , and ***ApoJ*** ***influence*** the uptake and degradation of ***Abeta*** in vitro and in vivo .	target	0
17820	10937355	344;4023	ApoC-II;lipoprotein lipase	***ApoC-II*** , on the other hand , is a major ***activator*** of ***lipoprotein lipase*** , which is required for an efficient processing of triglyceride-rich lipoproteins in the circulation .	positive	1
17821	10937355	4023;960	lipoprotein lipase;heparan sulfate proteoglycan	From studies with APOC3 transgenic and APOC3-knockout mice , it appears that apoC-III inhibits the lipolysis of triglyceride-rich lipoproteins by hampering the interaction of these lipoproteins with the ******heparan sulfate proteoglycan-lipoprotein lipase****** ***complex*** .	parallel	1
17822	10937546	2321;7422	flt-1;VEGF	CONCLUSIONS : Adenovirus-mediated gene transfer of a soluble form of ***VEGF*** ***receptor*** ( ***flt-1*** ) gene inhibited the growth of the experimental eyelid malignant melanoma .	parallel	1
17823	10937562	3791;7422	Flk-1;VEGF	Expression of both ***VEGF*** ***receptors*** , Flt-1 and ***Flk-1*** , was increased on endothelial cells of newly formed vessels in the stroma of inflamed corneas compared with limbal vessels of normal control corneas .	parallel	1
17824	10937562	2321;7422	Flt-1;VEGF	Expression of both ***VEGF*** ***receptors*** , ***Flt-1*** and Flk-1 , was increased on endothelial cells of newly formed vessels in the stroma of inflamed corneas compared with limbal vessels of normal control corneas .	parallel	1
17825	10937564	841;836	caspase-8;CPP32	Apoptosis was confirmed by a ***cleavage*** of PARP and ***CPP32*** , by ***caspase-8*** activation , and by an index Hoechst/neutral red greater than one .	target	1
17826	10937578	11168;133482	LEDGF;GST	Heparin-Sepharose was used to characterize ******heparin-GST-LEDGF****** ***binding*** , and GST-LEDGF or heparin-GST-LEDGF was used to quantitate heparin 's stabilization of LEDGF in the face of heat , pH , and proteolytic stresses .	parallel	1
17827	10938077	1457;5970	CKII;p65	Furthermore , our results indicate that the association between IkappaBalpha and p65 inhibits p65 phosphorylation by CKII and that degradation of IkappaBalpha allows ***CKII*** to ***phosphorylate*** ***p65*** to increase NF-kappaB transactivation potential .	target	1
17828	10938077	5970;4792	p65;IkappaBalpha	Furthermore , our results indicate that the ***association*** between ***IkappaBalpha*** and ***p65*** inhibits p65 phosphorylation by CKII and that degradation of IkappaBalpha allows CKII to phosphorylate p65 to increase NF-kappaB transactivation potential .	parallel	0
17829	10938077	7124;5970	Tumor necrosis factor alpha;RelA	***Tumor necrosis factor alpha-induced*** ***phosphorylation*** of ***RelA/p65*** on Ser529 is controlled by casein kinase II .	target	1
17830	10938077	7124;4790	TNFalpha;NF-kappaB	***TNFalpha*** , as well as certain other stimuli , also ***induces*** the phosphorylation of the ***NF-kappaB*** proteins .	target	1
17831	10938077	7124;5970	TNFalpha;p65	Previously , we have shown that ***TNFalpha*** ***induces*** ***RelA/p65*** phosphorylation at serine 529 and that this inducible phosphorylation increases NF-kappaB transcriptional activity on an exogenously supplied reporter ( ) .	target	1
17832	10938077	1457;5970	CKII;p65	In this report , we demonstrate that casein kinase II ( ***CKII*** ) ***interacts*** with ***p65*** in vivo and can phosphorylate p65 at serine 529 in vitro .	parallel	1
17833	10938077	1457;5970	CKII;p65	In this report , we demonstrate that casein kinase II ( ***CKII*** ) interacts with p65 in vivo and can ***phosphorylate*** ***p65*** at serine 529 in vitro .	target	1
17834	10938089	5076;2641	Pax-2;glucagon	The paired homeodomain transcription factor ***Pax-2*** is expressed in the endocrine pancreas and ***transactivates*** the ***glucagon*** gene promoter .	positive	1
17835	10938091	3952;7350	leptin;UCP1	Central ***leptin*** ***regulates*** the ***UCP1*** and ob genes in brown and white adipose tissue via different beta-adrenoceptor subtypes .	target	1
17836	10938094	3700;1234	gp120;CCR5	The N terminus of CCR5 , which contains several sulfated tyrosines , plays a critical role in the CD4-dependent ***association*** of ***gp120*** with ***CCR5*** and in viral entry .	parallel	0
17837	10938100	7027;5934	DP-1;p130	T antigen dissociates from a ******p130-E2F-4-DP-1****** ***complex*** , coincident with the release of p130 from E2F-4-DP-1 .	parallel	1
17838	10938100	1874;7027	E2F-4;DP-1	T antigen dissociates from a ******p130-E2F-4-DP-1****** ***complex*** , coincident with the release of p130 from E2F-4-DP-1 .	parallel	1
17839	10938100	1874;5934	E2F-4;p130	T antigen dissociates from a ******p130-E2F-4-DP-1****** ***complex*** , coincident with the release of p130 from E2F-4-DP-1 .	parallel	1
17840	10938104	5371;2624	promyelocytic leukemia protein;GATA-2	Here we report that the ***promyelocytic leukemia protein*** ( PML ) can ***complex*** with ***GATA-2*** and potentiate its transactivation capacity .	parallel	1
17841	10938104	2624;5371	GATA-2;PML	Consistent with this , we provide evidence that ***GATA-2*** can physically ***associate*** with ***PML-RARalpha*** .	parallel	0
17842	10938104	2624;5914	GATA-2;RARalpha	Consistent with this , we provide evidence that ***GATA-2*** can physically ***associate*** with ***PML-RARalpha*** .	parallel	0
17843	10938105	7072;2263	TIA-1;K-SAM	Overexpression of ***TIA-1*** in cultured cells ***activates*** ***K-SAM*** exon splicing in an IAS1-dependent manner .	positive	1
17844	10938111	3665;3448	IRF-7;IFNA14	Using coexpression analysis , the human IFNB , IFNA1 , and RANTES promoters were stimulated by IRF-3 coexpression , whereas the IFNA4 , IFNA7 , and ***IFNA14*** promoters were preferentially ***induced*** by ***IRF-7*** only .	target	1
17845	10938111	3665;3441	IRF-7;IFNA4	Using coexpression analysis , the human IFNB , IFNA1 , and RANTES promoters were stimulated by IRF-3 coexpression , whereas the ***IFNA4*** , IFNA7 , and IFNA14 promoters were preferentially ***induced*** by ***IRF-7*** only .	target	1
17846	10938111	3665;3444	IRF-7;IFNA7	Using coexpression analysis , the human IFNB , IFNA1 , and RANTES promoters were stimulated by IRF-3 coexpression , whereas the IFNA4 , ***IFNA7*** , and IFNA14 promoters were preferentially ***induced*** by ***IRF-7*** only .	target	1
17847	10938111	3661;3439	IRF-3;IFNA1	Using coexpression analysis , the human IFNB , ***IFNA1*** , and RANTES promoters were ***stimulated*** by ***IRF-3*** coexpression , whereas the IFNA4 , IFNA7 , and IFNA14 promoters were preferentially induced by IRF-7 only .	positive	0
17848	10938111	3661;3456	IRF-3;IFNB	Using coexpression analysis , the human ***IFNB*** , IFNA1 , and RANTES promoters were ***stimulated*** by ***IRF-3*** coexpression , whereas the IFNA4 , IFNA7 , and IFNA14 promoters were preferentially induced by IRF-7 only .	positive	0
17849	10938111	3661;6352	IRF-3;RANTES	Using coexpression analysis , the human IFNB , IFNA1 , and ***RANTES*** promoters were ***stimulated*** by ***IRF-3*** coexpression , whereas the IFNA4 , IFNA7 , and IFNA14 promoters were preferentially induced by IRF-7 only .	positive	0
17850	10938111	3661;1387	IRF-3;CBP	Chimeric proteins containing combinations of different IRF-7 and IRF-3 domains were also tested , and the results provided evidence of distinct DNA binding properties of IRF-3 and IRF-7 , as well as a preferential ***association*** of ***IRF-3*** with the CREB binding protein ( ***CBP*** ) coactivator .	parallel	0
17851	10938111	3661;1387	IRF-3;CBP	These studies demonstrate that ***IRF-3*** possesses a restricted DNA binding site specificity and ***interacts*** with ***CBP*** , whereas IRF-7 has a broader DNA binding specificity that contributes to its capacity to stimulate delayed-type IFN gene expression .	parallel	1
17852	10938111	3661;3439	IRF-3;IFN-alpha	These results provide an explanation for the differential ***regulation*** of ***IFN-alpha/beta*** gene expression by ***IRF-3*** and IRF-7 and suggest that these factors have complementary rather than redundant roles in the activation of the IFN-alpha/beta genes .	target	1
17853	10938111	3665;3439	IRF-7;IFN-alpha	These results provide an explanation for the differential ***regulation*** of ***IFN-alpha/beta*** gene expression by IRF-3 and ***IRF-7*** and suggest that these factors have complementary rather than redundant roles in the activation of the IFN-alpha/beta genes .	target	1
17854	10938112	28964;5829	GIT1;paxillin	This is due to the direct ***interaction*** of a C-terminal 125-residue domain of ***GIT1*** with ***paxillin*** , under the regulation of PIX .	parallel	1
17855	10938112	5747;28964	FAK;GIT1	We propose that ***GIT1*** and ***FAK*** ***cooperate*** to promote motility both by directly regulating focal complex dynamics and by the activation of Rac .	parallel	0
17856	10938113	7409;7410	Vav;Vav2	Each ***Vav*** protein coprecipitated with activated epidermal growth factor and platelet-derived growth factor ( PDGF ) receptors , and multiple phosphorylated tyrosine residues on the PDGF receptor were able to ***mediate*** ***Vav2*** tyrosine phosphorylation .	target	0
17857	10938122	23468;10155	HP1;KAP-1	In this report , we have reconstituted and characterized the ******HP1-KAP-1****** ***interaction*** using purified proteins and have compared KAP-1 to three other known HP1 binding proteins : SP100 , lamin B receptor ( LBR ) , and the p150 subunit from chromatin assembly factor ( CAF-1 p150 ) .	parallel	1
17858	10938237	3315;126393	HSP27;HSP20	To determine if ***P-HSP27*** ***inhibits*** phosphorylation of ***HSP20*** , P-HSP27 was added to a reaction mixture containing recombinant HSP20 and the catalytic subunit of cAMP-dependent protein kinase .	negative	1
17859	10938237	3315;126393	HSP27;HSP20	***P-HSP27*** ***inhibited*** phosphorylation of ***HSP20*** in a concentration-dependent manner .	negative	1
17860	10938237	3315;126393	HSP27;HSP20	These data demonstrate that ***P-HSP27*** can ***inhibit*** phosphorylation of ***HSP20*** .	negative	1
17861	10938265	6663;4286	SOX10;microphthalmia-associated transcription factor	***Regulation*** of the ***microphthalmia-associated transcription factor*** gene by the Waardenburg syndrome type 4 gene , ***SOX10*** .	target	1
17862	10938265	5077;4286	Pax3;MITF	WS1 and WS3 are caused by mutation in the gene encoding the transcription factor ***Pax3*** , which ***regulates*** ***MITF*** expression .	target	1
17863	10938265	6663;4286	SOX10;MITF	In the present report , we demonstrate that ***SOX10*** is a strong ***activator*** of the ***MITF*** promoter , and we identify a SOX10 binding site between -264 and -266 of the MITF promoter .	positive	1
17864	10938266	3717;2064	Jak2;ErbB-2	Constitutive tyrosine ***phosphorylation*** of ***ErbB-2*** via ***Jak2*** by autocrine secretion of prolactin in human breast cancer .	target	1
17865	10938282	7042;4585	TGF-beta2;MUC4	The exogenous addition of ***TGF-beta2*** also ***increased*** the ***MUC4*** expression .	positive	0
17866	10938282	7042;4585	transforming growth factor-beta 2;MUC4	Retinoic acid-dependent ***transforming growth factor-beta 2-mediated*** ***induction*** of ***MUC4*** mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway .	target	1
17867	10938282	7042;4586	transforming growth factor-beta 2;mucin	Retinoic acid-dependent ***transforming growth factor-beta 2-mediated*** ***induction*** of MUC4 ***mucin*** expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway .	target	1
17868	10938285	355;356	Fas;Fas ligand	Subsequent mapping of the apoptotic pathway induced by growth factor withdrawal demonstrated that BRCA1 enhanced signaling through a pathway that sequentially involved H-Ras , MEKK4 , JNK , ******Fas ligand/Fas****** ***interactions*** , and caspase-9 activation .	parallel	1
17869	10938287	2956;4436	hMSH6;hMSH2	The most abundant mismatch binding factor in human cells , hMutSalpha , is a ***heterodimer*** of ***hMSH2*** and ***hMSH6*** , two homologues of the bacterial MutS protein .	parallel	1
17870	10938397	7048;7040	TbetaR-II;TGF-beta1	Alterations in transforming growth factor beta1 ( ***TGF-beta1*** ) and its type II ***receptor*** ( ***TbetaR-II*** ) have been implicated in the pathogenesis of a variety of human cancers and animal tumor models .	parallel	1
17871	10938436	3479;4137	Insulin-like growth factor-1;tau	Thus , the phosphorylation state and distribution of ***tau*** can be ***modulated*** by insulin and ***Insulin-like growth factor-1*** signaling pathways involving glycogen synthase kinase-3beta .	target	0
17872	10938446	3952;5617	leptin;prolactin	Plasma ***leptin*** concentrations were negatively correlated with baseline plasma cortisol levels ( n = 49 , r = -0.49 , P < 0.001 ) and positively ***correlated*** with ***prolactin*** responses following L-tryptophan ( n = 49 , r = 0.37 , P < 0.009 ) and m-chlorophenylpiperazine ( n = 52 , r = 0.24 , P < 0.09 ) .	positive	0
17873	10938545	7054;2643	tyrosine hydroxylase;GTP cyclohydrolase I	Functional ***interactions*** between ***GTP cyclohydrolase I*** and ***tyrosine hydroxylase*** in Drosophila .	parallel	1
17874	10938587	2908;3320	Glucocorticoid receptor;Hsp90	***Glucocorticoid receptor*** ***interaction*** with ***Hsp90*** remains unaltered after whole body hyperthermia .	parallel	1
17875	10938587	2908;3320	Glucocorticoid receptor;Hsp90	The influence of 41 degrees C whole body hyperthermic stress on ***Glucocorticoid receptor*** ( GR ) ***association*** with 90-kDa heat shock protein ( ***Hsp90*** ) in the rat liver cytosol was examined .	parallel	0
17876	10938894	4067;6714	Lyn;Src	However , the A1 domain , in contrast to vWF , did not induce platelet cytoskeletal ***association*** of tyrosine kinases , ***Src*** and ***Lyn*** .	parallel	0
17877	10939301	356;355	fasL;Fas	In the present investigations , the effects of irradiation with UVA and UVB on the Fas ( CD95 ) / fasL system have been studied because apoptosis mediated by the ***interaction*** between ***Fas*** and ***fasL*** has been suggested recently to be associated with UVB-induced immunosuppression in mouse skin .	parallel	1
17878	10939329	5649;9856	Reelin;neuronal migration	***Reelin*** binds alpha3beta1 integrin and ***inhibits*** ***neuronal migration*** .	negative	1
17879	10939334	9568;2550	GB2;GB1	***Interaction*** of ***GB1*** and ***GB2*** through their C-terminal coiled-coil alpha helices masks the retention signal in GB1 , allowing the plasma membrane expression of the assembled complexes .	parallel	1
17880	10939335	1742;9495	PSD-95;AKAP79	In this report , we demonstrate that glutamate receptors and PKA are recruited into a macromolecular signaling complex through direct ***interaction*** between the MAGUK proteins , ***PSD-95*** and SAP97 , and ***AKAP79/150*** .	parallel	1
17881	10939335	1742;1739	PSD-95;SAP97	In this report , we demonstrate that glutamate receptors and PKA are recruited into a macromolecular signaling complex through direct ***interaction*** between the MAGUK proteins , ***PSD-95*** and ***SAP97*** , and AKAP79/150 .	parallel	1
17882	10939335	1739;9495	SAP97;AKAP79	In this report , we demonstrate that glutamate receptors and PKA are recruited into a macromolecular signaling complex through direct ***interaction*** between the MAGUK proteins , PSD-95 and ***SAP97*** , and ***AKAP79/150*** .	parallel	1
17883	10939335	9495;1739	AKAP79;SAP97	Cell-based studies indicate that phosphorylation of AMPA receptors is enhanced by a ******SAP97-AKAP79****** ***complex*** that directs PKA to GluR1 via a PDZ domain interaction .	parallel	1
17884	10939589	10728;3320	p23;Hsp90	Loss of ******Hsp90/p23****** ***association*** and acquisition of Hsp70/p60Hop association of both p210bcr-abl and v-src precede GA-induced degradation of these kinases .	parallel	0
17885	10939592	2925;2922	GRP-R;GRP	Although epithelial cells lining the mouse colon do not normally express ***GRP*** and its ***receptor*** ( ***GRP-R*** ) , both are aberrantly expressed by all better differentiated cancers in wild-type C57BL/6J mice treated with the carcinogen azoxymethane .	parallel	1
17886	10939617	3565;6778	IL-4;STAT6	***IL-4*** had no effect on liver NF-kappaB activation , but greatly ***increased*** the activation of ***STAT6*** .	positive	0
17887	10939617	3565;6778	IL-4;STAT6	CONCLUSIONS : The data suggest that ***STAT6*** ***activation*** by ***IL-4*** may be responsible for the protective effects of this cytokine .	positive	1
17888	10940084	3824;3821	CD94;NKG2	Like its human counterpart , the mouse ***CD94*** protein ***associates*** with different ***NKG2*** isoforms and recognizes the atypical MHC class I molecule Qa-1b .	parallel	0
17889	10940259	7454;10096	WASp;Arp2/3	***WASp*** family proteins ***stimulate*** ***Arp2/3*** complex to nucleate actin filaments , which grow at a fixed 70 degrees angle from the side of pre-existing actin filaments .	positive	0
17890	10940294	30851;6242	TIP-1;rhotekin	The PDZ protein ***TIP-1*** ***interacts*** with the Rho effector ***rhotekin*** and is involved in Rho signaling to the serum response element .	parallel	1
17891	10940294	6242;30851	rhotekin;TIP-1	Mutation of the serine and valine residues to alanine impairs ***interaction*** of ***rhotekin*** with ***TIP-1*** .	parallel	1
17892	10940295	3949;4018	LDLR;lipoprotein	Experiments using two concentrations of receptor-associated protein , an inhibitor of apoE receptors with a differential affinity for the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) and the LDLR-related protein ( LRP ) , suggest that LRP mediates Abeta-induced astrocyte activation , whereas LDLR mediates the Abeta-induced changes in apoE levels .	parallel	1
17893	10940305	2641;836	GLP-2;caspase-3	Both ***GLP-2*** and forskolin reduced mitochondrial cytochrome c release and ***decreased*** the cycloheximide-induced cleavage of ***caspase-3*** in the presence or absence of the PKA inhibitor H-89 .	negative	0
17894	10940312	2057;2056	EpoR;Epo	Protein kinase C ( PKC ) is implied in the activation of multiple targets of erythropoietin ( Epo ) signaling , but its exact role in ***Epo*** ***receptor*** ( ***EpoR*** ) signal transduction and in the regulation of erythroid proliferation and differentiation remained elusive .	parallel	1
17895	10940312	2056;207	Epo;AKT	Active PKC appeared essential for ***Epo-induced*** ***phosphorylation*** of the Epo receptor itself , STAT5 , Gab1 , Erk1/2 , ***AKT*** , and other downstream targets .	target	1
17896	10940312	2056;5594	Epo;Erk1/2	Active PKC appeared essential for ***Epo-induced*** ***phosphorylation*** of the Epo receptor itself , STAT5 , Gab1 , ***Erk1/2*** , AKT , and other downstream targets .	target	1
17897	10940312	207;2056	AKT;Epo	Active PKC appeared essential for Epo-induced phosphorylation of the ***Epo*** ***receptor*** itself , STAT5 , Gab1 , Erk1/2 , ***AKT*** , and other downstream targets .	parallel	1
17898	10940312	5594;2056	Erk1/2;Epo	Active PKC appeared essential for Epo-induced phosphorylation of the ***Epo*** ***receptor*** itself , STAT5 , Gab1 , ***Erk1/2*** , AKT , and other downstream targets .	parallel	1
17899	10940312	3717;2057	JAK2;EpoR	PKC inhibitors or LY294002 did not affect membrane expression of the EpoR , the ***association*** of ***JAK2*** with the ***EpoR*** , or the in vitro kinase activity of JAK2 .	parallel	0
17900	10940481	7200;3741	TRH;Kv1.5	***TRH*** ***regulates*** ***Kv1.5*** gene expression through a Galphaq-mediated PLC-independent pathway .	target	1
17901	10940481	7200;3741	TRH;Kv1.5	These results indicate that ***TRH-induced*** ***down-regulation*** of ***Kv1.5*** gene expression is mediated by Galphaq proteins , but does not require PLC activation .	negative	1
17902	10940483	5617;6303	Prolactin;SAT	In the spleen , ***Prolactin*** ***increased*** ***SAT*** activity only 24 h after administration and was ineffective on PAO activity .	positive	0
17903	10940512	1026;1019	WAF-1;Cdk4	Overexpression of wild-type ***WAF-1*** in melanoma cells reduced growth of subconfluent cells , ***decreased*** ***Cdk4*** activity with a concomitant increase in hypophosphorylated Rb , and promoted cell death by apoptosis .	negative	0
17904	10940627	10253;2247	SPRY2;FGF2	Human ***SPRY2*** ***inhibits*** ***FGF2*** signalling by a secreted factor .	negative	1
17905	10940627	10253;2885	SPRY2;GRB2	However , ***SPRY2*** protein ***binds*** the intracellular adaptor protein ***GRB2*** , indicating an intracellular localization .	parallel	1
17906	10940717	959;958	CD40L;CD40	In the present review we will discuss the potential implications of ******CD40-CD40L****** ***interactions*** for the activation of TECs and its immunological function .	parallel	1
17907	10940738	7200;5594	TRH;ERK	***ERK*** ***activation*** by VIP or PACAP38 and ***TRH*** were additive and both sensitive to the MEK inhibitors PD98059 and U0126 .	positive	1
17908	10940742	846;5741	calcium-sensing receptor;parathyroid hormone	The present study was performed to investigate the ***association*** of ***calcium-sensing receptor*** ( CaSR ) genotypes with ***parathyroid hormone*** ( PTH ) secretion in hemodialysis patients .	parallel	0
17909	10940886	4790;5966	p50;c-Rel	The p65/c-Rel and p65/p50 heterodimer occupied this site shortly after CpG ODN administration ( 0.5-2 h ) , while the ******p50/c-Rel****** ***heterodimer*** dominated binding in the late stage ( 8-12 h ) .	parallel	1
17910	10940886	5970;5966	p65;c-Rel	The ******p65/c-Rel****** and p65/p50 ***heterodimer*** occupied this site shortly after CpG ODN administration ( 0.5-2 h ) , while the p50/c-Rel heterodimer dominated binding in the late stage ( 8-12 h ) .	parallel	1
17911	10940886	5970;4790	p65;p50	The p65/c-Rel and ******p65/p50****** ***heterodimer*** occupied this site shortly after CpG ODN administration ( 0.5-2 h ) , while the p50/c-Rel heterodimer dominated binding in the late stage ( 8-12 h ) .	parallel	1
17912	10940886	4790;5966	p50;c-Rel	The induction of ******p50/c-Rel****** ***heterodimer*** was associated with a significant expression of IL-12 p40 mRNA .	parallel	1
17913	10940889	3606;3596	IL-18;IL-13	We have recently reported that ***IL-18*** can ***induce*** ***IL-13*** production in both NK cells and T cells in synergy with IL-2 but not IL-12 , suggesting IL-18 can induce Th1 and Th2 cytokines when accompanied by the appropriate first signals for T cells .	target	1
17914	10940889	3606;959	IL-18;CD40 ligand	***IL-18*** can rapidly ***induce*** ***CD40 ligand*** ( CD154 ) mRNA and surface expression on CD4 + but not CD8 + T cells .	target	1
17915	10940889	3606;959	IL-18;CD154	These results suggest that ***IL-18*** can ***induce*** Th2 cytokines and ***CD154*** expression , and can contribute to CD4 + T cell-dependent , IL-4-independent IgE production .	target	1
17916	10940895	959;958	CD40L;CD40	******CD40-CD40L****** ***interaction*** was essential for IL-12 production by DC .	parallel	1
17917	10940903	961;140885	CD47;SIRP	***CD47*** is a ***ligand*** for rat macrophage membrane signal regulatory protein ***SIRP*** ( OX41 ) and human SIRPalpha 1 .	parallel	1
17918	10940903	961;140885	CD47;SIRP	A direct ***interaction*** between human ***SIRP*** and human ***CD47*** was demonstrated using purified recombinant proteins and surface plasmon resonance ruling out the involvement of other proteins known to be associated with CD47 .	parallel	1
17919	10940903	961;140885	CD47;SIRP	The affinity of the ******SIRP/CD47****** ***interaction*** was K ( d ) approximately 8 microM at 37 degrees C with a k ( off ) > / = 2.1 s ( -1 ) .	parallel	1
17920	10940905	7305;7305	DAP-12;KARAP	The physical ***association*** between SIRPbeta1 and ******KARAP/DAP-12****** results in the functional coupling of SIRPbeta1 engagement to the recruitment of the protein tyrosine kinase Syk and to serotonin release in RBL cell transfectants .	parallel	0
17921	10940929	5335;6655	PLCgamma1;hSos2	We observed ***association*** between the ***PLCgamma1-SH3*** domain and the human Ras guanine nucleotide exchange factor son-of-sevenless-2 ( ***hSos2*** ) through a proline-rich domain interaction .	parallel	0
17922	10940929	5335;27040	PLCgamma1;linker for activation of T cells	The kinetics of protein complex enhancement correlated with TCR / CD3-induced tyrosine phosphorylation of PLCgamma1 ; however , those PLCgamma1 molecules in complex with hSos2 were non-phosphorylated after TCR / CD3 stimulation , in contrast to the phosphorylated ***PLCgamma1*** ***associated*** with the ***linker for activation of T cells*** , LAT .	parallel	0
17923	10941840	7501;4267	XGR;CD99	These findings further support the hypothesis of a single genetic ***control*** of ***CD99*** and Xga expression by the ***XGR*** locus .	target	0
17924	10941840	7501;4267	XGR;MIC2	The co-expression of X-linked ***MIC2*** and XG genes is presumably ***controlled*** at the transcriptional level by a single ***XGR*** locus in the pseudoautosomal region of sexual chromosomes .	target	0
17925	10941902	3458;836	IFNgamma;caspase-3	***IFNgamma*** also ***increased*** ***pro-caspase-3*** protein expression and its subsequent activation in SW480 cells following Ag-specific CTL attack .	positive	0
17926	10941932	920;3700	CD4;gp120	We generated recombinant soluble gp120s derived from T-cell line-tropic ( T-tropic ) and macrophage-tropic ( M-tropic ) HIV-1 strains using a baculovirus expression system and investigated the association of ******CD4-gp120****** ***complex*** with the chemokine receptor and/or other surface molecule ( s ) .	parallel	1
17927	10941932	920;7852	CD4;chemokine receptor	We generated recombinant soluble gp120s derived from T-cell line-tropic ( T-tropic ) and macrophage-tropic ( M-tropic ) HIV-1 strains using a baculovirus expression system and investigated the ***association*** of ***CD4-gp120*** complex with the ***chemokine receptor*** and/or other surface molecule ( s ) .	parallel	0
17928	10941932	3700;7852	gp120;chemokine receptor	We generated recombinant soluble gp120s derived from T-cell line-tropic ( T-tropic ) and macrophage-tropic ( M-tropic ) HIV-1 strains using a baculovirus expression system and investigated the ***association*** of ***CD4-gp120*** complex with the ***chemokine receptor*** and/or other surface molecule ( s ) .	parallel	0
17929	10941932	3700;920	gp120;CD4	For monitoring the co-down-modulations of the ******CD4-gp120****** ***complex*** , a cytoplasmic domain deletion mutant ( tailless CD4 ) , which is not capable of undergoing down-modulation by itself in response to phorbol ester PMA , was used .	parallel	1
17930	10941932	920;3700	CD4;gp120	Nevertheless , the observation that IIIB gp120 strongly primed tailless CD4 co-down-modulation on human osteosarcoma HOS cells that express undetectable levels of surface CXCR4 raised the possibility that membrane component ( s ) other than those recently identified can be involved in down-modulation of the ******CD4/gp120****** ***complexes*** .	parallel	1
17931	10942060	3439;3659	IFN-alpha;IRF-1	RESULTS : ***IFN-alpha*** ***up-regulated*** the expression of ***IRF-1*** and IRF-2 both in vivo and in vitro .	positive	1
17932	10942060	3439;3660	IFN-alpha;IRF-2	RESULTS : ***IFN-alpha*** ***up-regulated*** the expression of IRF-1 and ***IRF-2*** both in vivo and in vitro .	positive	1
17933	10942060	3659;5610	IRF-1;p68 kinase	In addition , expressions of ***IRF-1*** and IRF-2 were significantly ***correlated*** with the ***p68 kinase*** expression ( P = 0.032 and P = 0.0176 , respectively ) and the expression of IRF-1 protein was positively correlated with that of IRF-2 ( r = 0.671 , P = 0.0001 ) tested in the same specimens .	parallel	0
17934	10942060	3660;5610	IRF-2;p68 kinase	In addition , expressions of IRF-1 and ***IRF-2*** were significantly ***correlated*** with the ***p68 kinase*** expression ( P = 0.032 and P = 0.0176 , respectively ) and the expression of IRF-1 protein was positively correlated with that of IRF-2 ( r = 0.671 , P = 0.0001 ) tested in the same specimens .	parallel	0
17935	10942140	6037;6356	ECP;eotaxin	Tissue eosinophilia and nasal ***ECP*** levels were significantly ***correlated*** with ***eotaxin*** mRNA level but not with RANTES mRNA expression .	parallel	0
17936	10942208	3553;5743	IL-1beta;COX-2	Northern hybridization analysis revealed that ***IL-1beta*** ( 200 pg/ml ) ***increased*** the expression of ***COX-2*** mRNA in HGF .	positive	0
17937	10942362	2833;3458	chemokine receptor 3;interferon gamma	CXC ***chemokine receptor 3*** ( CXCR3 ) , which is known to be expressed predominately on memory and activated T lymphocytes , is a ***receptor*** for both ***interferon gamma*** ( IFN-gamma ) - inducible protein 10 ( gamma IP-10 ) and monokine induced by IFN-gamma ( Mig ) .	parallel	1
17938	10942389	3700;581	gp120;Bax	It was also observed that ***gp120/160*** treatment slightly ***increased*** the expression of the pro-apoptotic molecule ***Bax*** .	positive	0
17939	10942396	3558;573	IL-2;bag-1	Although histone hyperacetylation is believed to lead to transcriptional activation , the results showed an abrogation of ***IL-2-mediated*** ***induction*** of c-myc , ***bag-1*** , and LC-PTP gene expression .	target	1
17940	10942396	3558;4609	IL-2;c-myc	Although histone hyperacetylation is believed to lead to transcriptional activation , the results showed an abrogation of ***IL-2-mediated*** ***induction*** of ***c-myc*** , bag-1 , and LC-PTP gene expression .	target	1
17941	10942396	3558;5778	IL-2;LC-PTP	Although histone hyperacetylation is believed to lead to transcriptional activation , the results showed an abrogation of ***IL-2-mediated*** ***induction*** of c-myc , bag-1 , and ***LC-PTP*** gene expression .	target	1
17942	10942418	5077;4286	PAX3;MITF	***PAX3*** has been shown to ***regulate*** ***MITF*** gene expression .	target	1
17943	10942418	6663;4286	SOX10;MITF	Here we show that ***SOX10*** , in synergy with PAX3 , strongly ***activates*** ***MITF*** expression in transfection assays .	positive	1
17944	10942418	5077;6663	PAX3;SOX10	Analyses revealed that ***PAX3*** and ***SOX10*** ***interact*** directly by binding to a proximal region of the MITF promoter containing binding sites for both factors .	parallel	1
17945	10942418	6663;4286	SOX10;MITF	In situ hybridization experiments carried out in the dominant megacolon ( DOM :) mouse , confirmed that ***SOX10*** dysfunction ***impairs*** ***MITF*** : expression as well as melanocytic development and survival .	negative	0
17946	10942522	655;659	OP-1;BMPR-II	***OP-1*** ***upregulated*** ***BMPR-II*** mRNA expression by a maximum of 2-fold .	positive	1
17947	10942522	655;652	OP-1;BMP-4	***OP-1*** ***downregulated*** the ***BMP-4*** , -5 , and -6 mRNA levels by a maximal of 2-fold , 1.5-fold , and 6-fold , respectively .	negative	1
17948	10942524	7040;595	TGF-beta1;cyclin D1	We report here that in accord with DNA synthesis kinetics , ***TGF-beta1*** initially ***suppresses*** EGF-induced ***cyclin D1*** expression then later releases the inhibition .	negative	1
17949	10942524	7040;5604	TGF-beta1;MEK1	Furthermore , ***TGF-beta1*** also first decreases and later ***potentiates*** the levels of EGF-activated ***MEK1/MAPK*** and PKB , indicating the existence of cross talk between TGF-beta 1 - and EGF-activated signal transduction pathways .	positive	0
17950	10942524	7040;207	TGF-beta1;PKB	Furthermore , ***TGF-beta1*** also first decreases and later ***potentiates*** the levels of EGF-activated MEK1/MAPK and ***PKB*** , indicating the existence of cross talk between TGF-beta 1 - and EGF-activated signal transduction pathways .	positive	0
17951	10942524	7040;207	TGF-beta1;PKB	Although we found that EGF-stimulated p70s6K phosphorylates through a MAPK-dependent and a MAPK-independent ( wortmannin-sensitive ) pathway , TGF-beta1 failed to block EGF-triggered phosphorylation of p70s6K at thr ( 389 ) and thr ( 421 ) / ser ( 424 ) sites , implying that ***PKB*** ***inhibition*** by ***TGF-beta1*** may result from inhibition of PDK1 activity instead of inhibition of PI3K activity .	negative	1
17952	10942532	3845;1026	Ki-ras;p21	One hypothesis is that Ki-ras mutation and/or a ***Ki-ras*** p21 increase could ***enhance*** Ki-ras ***p21-GTP*** and cell-cycle stimulation through raf-1 and extracellularly regulated protein kinases ( Erks ) .	positive	0
17953	10942578	4157;5443	MC1R;MSH	The switch between the synthesis of eu - and pheomelanins is modulated by the interaction of two paracrine signaling molecules , alpha-melanocyte stimulating hormone ( MSH ) and agouti signal protein ( ASP ) , which interact with melanocytes via the ***MSH*** ***receptor*** ( ***MC1R*** ) .	parallel	1
17954	10942578	5443;5650	alpha-melanocyte stimulating hormone;signal protein	The switch between the synthesis of eu - and pheomelanins is modulated by the ***interaction*** of two paracrine signaling molecules , ***alpha-melanocyte stimulating hormone*** ( MSH ) and agouti ***signal protein*** ( ASP ) , which interact with melanocytes via the MSH receptor ( MC1R ) .	parallel	1
17955	10942578	434;4157	ASP;MC1R	Identification of the specific ***ASP*** epitope that ***interacts*** with the ***MC1R*** has potential pharmacological applications in treating dysfunctions of skin pigmentation .	parallel	1
17956	10942587	7040;7157	TGF-beta1;p53	Increased p53 appeared to be active , since ***TGF-beta1*** treatment ***increased*** the activity of a ***p53*** transcriptional response element in a luciferase reporter plasmid .	positive	0
17957	10942593	7040;1490	TGFbeta;CTGF	***TGFbeta*** ***stimulates*** ***CTGF*** production in both normal and systemic sclerosis fibroblasts with the latter found to be higher producers .	positive	0
17958	10942601	1956;8731	Epidermal growth factor receptor;met	***Epidermal growth factor receptor*** signaling ***activates*** ***met*** in human anaplastic thyroid carcinoma cells .	positive	1
17959	10942756	9402;3937	Gads;SLP-76	***Gads*** is constitutively ***associated*** with ***SLP-76*** and is probably the protein bridging its association with LAT .	parallel	0
17960	10942756	27040;2885	LAT;Grb2	There was no detectable association between Grb2 and SLP-76 in control or stimulated cells , suggesting that the ***interaction*** of ***LAT*** with ***Grb2*** is present in a separate complex to that of LAT-Gads-SLP-76 .	parallel	1
17961	10942761	4015;1281	Lysyl oxidase;COL3A1	The binding was specifically competed by the cold probe , and the mutagenesis of this region abolished both the binding activity in gel retardation and ***Lysyl oxidase*** ***stimulation*** of ***COL3A1*** promoter in transfection experiments .	positive	0
17962	10942766	1457;7153	protein kinase CK2;topoisomerase II alpha	Mitotic ***phosphorylation*** of DNA ***topoisomerase II alpha*** by ***protein kinase CK2*** creates the MPM-2 phosphoepitope on Ser-1469 .	target	1
17963	10942770	7157;5663	p53;PS1	Hence the ***repression*** of ***PS1*** transcription by ***p53*** is likely to be mediated through protein-protein interactions .	negative	1
17964	10942770	7157;5663	p53;presenilin-1	We show here that ***p53*** also ***suppresses*** the transcription of a ***presenilin-1*** promoter-chloramphenicol acetyltransferase reporter synthetic gene in transient infection assays in neuroblastoma ( SK-N-SH ) and hepatoma ( HepG2 ) cell lines .	negative	1
17965	10942770	7157;5663	p53;PS1	We have previously defined a crucial DNA element controlling 90 % of the expression of the gene within the same short area , and the identification of the transcription factors involved should also provide insights into the ***regulation*** of ***PS1*** by ***p53*** .	target	1
17966	10942770	2113;5663	Ets1;PS1	Therefore , ***Ets1/2*** factors bind specifically to the -10 Ets element and ***activate*** ***PS1*** transcription .	positive	1
17967	10942774	2475;1978	Mammalian target of rapamycin;PHAS-I	***Mammalian target of rapamycin-dependent*** ***phosphorylation*** of ***PHAS-I*** in four ( S/T ) P sites detected by phospho-specific antibodies .	target	1
17968	10942774	1978;1977	PHAS-I;mRNA cap-binding protein	The role and control of the four rapamycin-sensitive phosphorylation sites that govern the ***association*** of ***PHAS-I*** with the ***mRNA cap-binding protein*** , eukaryotic initiation factor 4E ( eIF4E ) , were investigated by using newly developed phospho-specific antibodies .	parallel	0
17969	10942774	2475;1978	mTOR;PHAS-I	In these respects the ***phosphorylation*** of ***PHAS-I*** by ***mTOR*** in vitro resembles the ordered phosphorylation of PHAS-I in cells .	target	1
17970	10942781	1634;1956	decorin;epidermal growth factor receptor	The leucine-rich proteoglycan ***decorin*** ***interacts*** with the ***epidermal growth factor receptor*** and triggers a signaling pathway that leads to growth suppression .	parallel	1
17971	10942884	627;367	BDNF;androgen receptor	These results indicate that the regulation of androgen receptor by testosterone does not require BDNF , but the ***regulation*** of ***androgen receptor*** by ***BDNF*** does require testosterone .	target	1
17972	10943714	2892;2891	GluR3;GluR2	These results suggest that drastic alterations in the diversity of ******GluR2/GluR3/NR1****** receptor ***complexes*** in the surviving spiral ganglion cells , which result in alterations in Ca2 + permeability , may contribute to the deafness-related alterations in the structure and function of the cochlea .	parallel	1
17973	10943714	2892;2902	GluR3;NR1	These results suggest that drastic alterations in the diversity of ******GluR2/GluR3/NR1****** receptor ***complexes*** in the surviving spiral ganglion cells , which result in alterations in Ca2 + permeability , may contribute to the deafness-related alterations in the structure and function of the cochlea .	parallel	1
17974	10943714	2902;2891	NR1;GluR2	These results suggest that drastic alterations in the diversity of ******GluR2/GluR3/NR1****** receptor ***complexes*** in the surviving spiral ganglion cells , which result in alterations in Ca2 + permeability , may contribute to the deafness-related alterations in the structure and function of the cochlea .	parallel	1
17975	10943845	672;6597	BRCA1;BRG1	We show that ***BRCA1*** can directly ***interact*** with the ***BRG1*** subunit of the SWI/SNF complex .	parallel	1
17976	10943866	4790;4318	NF-kappaB;matrix metalloproteinase 9	Because ***matrix metalloproteinase 9*** ( MMP-9 ) is ***regulated*** by nuclear factor kappaB ( ***NF-kappaB*** ) , we investigated the effect of a super-repressor form of inhibitor of nuclear factor kappaBalpha ( srIkappaBalpha ) on the suppression of TNFalpha-induced MMP-9 production in acinar cells .	target	1
17977	10943866	7124;4318	TNFalpha;MMP-9	RESULTS : ***TNFalpha*** ***induced*** the production of ***MMP-9*** in the ACpRc-1 cell clone , but greatly suppressed MMP-9 production in ACMT-6 and ACMT-7 clones .	target	1
17978	10943866	7124;4318	TNFalpha;MMP-9	RESULTS : ***TNFalpha*** induced the production of MMP-9 in the ACpRc-1 cell clone , but greatly ***suppressed*** ***MMP-9*** production in ACMT-6 and ACMT-7 clones .	negative	1
17979	10944114	3320;317	Hsp90;Apaf-1	The present studies demonstrate that heat shock protein 90 ( ***Hsp90*** ) forms a cytosolic ***complex*** with ***Apaf-1*** and thereby inhibits the formation of the active complex .	parallel	1
17980	10944114	317;3320	Apaf-1;Hsp90	Furthermore , treatment of cells with diverse DNA-damaging agents dissociates the ******Hsp90-Apaf-1****** ***complex*** and relieves the inhibition of procaspase-9 activation .	parallel	1
17981	10944115	4773;4209	NFATp;MEF2D	We report here that ***NFATp*** ***synergizes*** with ***MEF2D*** to recruit the coactivator p300 for the transcription of Nur77 .	parallel	0
17982	10944115	4773;2033	NFATp;p300	We report here that ***NFATp*** synergizes with MEF2D to ***recruit*** the coactivator ***p300*** for the transcription of Nur77 .	target	0
17983	10944115	4773;4209	NFATp;MEF2D	Surprisingly , the enhancement of transcriptional activity of MEF2D by NFATp does not require its DNA-binding activity , suggesting that ***NFATp*** acts as a ***coactivator*** for ***MEF2D*** .	positive	1
17984	10944117	9611;8841	N-CoR;HDAC3	We demonstrate further that in Xenopus oocytes , both SMRT and ***N-CoR*** also ***associate*** with ***HDAC3*** in large protein complexes and that injection of antibodies against HDAC3 or SMRT/N-CoR led to a partial relief of repression by unliganded TR/RXR .	parallel	0
17985	10944117	9612;8841	SMRT;HDAC3	We demonstrate further that in Xenopus oocytes , both ***SMRT*** and N-CoR also ***associate*** with ***HDAC3*** in large protein complexes and that injection of antibodies against HDAC3 or SMRT/N-CoR led to a partial relief of repression by unliganded TR/RXR .	parallel	0
17986	10944120	196513;1977	Dcp1;eIF4E	We show that ***Dcp1*** ***binds*** to eIF4G and Pab1 as free proteins , as well as to the complex ***eIF4E-eIF4G-Pab1*** .	parallel	1
17987	10944120	196513;1981	Dcp1;eIF4G	We show that ***Dcp1*** ***binds*** to eIF4G and Pab1 as free proteins , as well as to the complex ***eIF4E-eIF4G-Pab1*** .	parallel	1
17988	10944120	196513;26986	Dcp1;Pab1	We show that ***Dcp1*** ***binds*** to eIF4G and Pab1 as free proteins , as well as to the complex ***eIF4E-eIF4G-Pab1*** .	parallel	1
17989	10944120	196513;1981	Dcp1;eIF4G	***Dcp1*** ***interacts*** with the N-terminal region of ***eIF4G*** but does not compete significantly with eIF4E or Pab1 for binding to eIF4G .	parallel	1
17990	10944123	51227;9091	PIG-P;GPI1	***PIG-P*** , a 134-amino acid protein having two hydrophobic domains , ***associates*** with PIG-A and ***GPI1*** .	parallel	0
17991	10944123	51227;5277	PIG-P;PIG-A	***PIG-P*** , a 134-amino acid protein having two hydrophobic domains , ***associates*** with ***PIG-A*** and GPI1 .	parallel	0
17992	10944203	2661;5732	GDF-9;EP2	In addition , ***GDF-9*** ***stimulates*** ***EP2*** mRNA synthesis by a prostaglandin - and progesterone-independent pathway .	positive	0
17993	10944203	2661;5732	GDF-9;EP2	Thus , ***GDF-9*** ***induces*** an ***EP2*** signal transduction pathway which appears to be required for progesterone synthesis in cumulus granulosa cells .	target	1
17994	10944203	2661;5743	GDF-9;Cox2	***GDF-9*** ***stimulated*** ***Cox2*** mRNA within 2 h , and PGE ( 2 ) within 6 h ; however , progesterone was not increased until 12 h after addition of GDF-9 .	positive	0
17995	10944420	3458;4843	IFN-gamma;NOS	In the presence of N ( G ) - monomethyl-l-arginine ( l-NMMA ) , a ***NOS*** ***inhibitor*** , the suppressive effect of IFN-gamma and ***IFN-gamma/LPS*** was abolished and TBARS formation was even increased to a level above that of untreated iNOS ( + / + ) macrophage .	negative	1
17996	10944433	4254;207	SCF;Akt	Our results demonstrate that ***PKB/Akt*** is ***activated*** by Epo and ***SCF*** , but not by IGF-1 in human primary erythroid progenitors .	positive	1
17997	10944445	5645;2150	trypsin-2;proteinase-activated receptor-2	Extrapancreatic ***trypsin-2*** ***cleaves*** ***proteinase-activated receptor-2*** .	target	1
17998	10944455	9810;5925	RBP95;pRb	***Interaction*** between ***pRb*** and ***RBP95*** was confirmed in vivo and in vitro .	parallel	1
17999	10944457	3953;3952	leptin receptor;leptin	Homology modeling of human ******leptin/leptin receptor****** ***complex*** .	parallel	1
18000	10944457	3952;3953	leptin;leptin receptor	Because of the similarity between leptin/leptin receptor complex and G-CSF/G-CSF receptor complex , we tried to build a model structure of ******leptin/leptin receptor****** ***complex*** with the crystal structure of the G-CSF/G-CSF receptor complex as the template .	parallel	1
18001	10944457	1440;1441	G-CSF;G-CSF receptor	Because of the similarity between leptin/leptin receptor complex and G-CSF/G-CSF receptor complex , we tried to build a model structure of leptin/leptin receptor complex with the crystal structure of the ******G-CSF/G-CSF receptor****** ***complex*** as the template .	parallel	1
18002	10944523	6900;4067	TAG-1;Lyn	Antibody-mediated cross-linking of ***TAG-1*** ***induced*** ***Lyn*** activation and rapid tyrosine phosphorylation of p80 .	target	1
18003	10944526	1387;4654	CREB-binding protein;MyoD	***CREB-binding protein/p300*** ***activates*** ***MyoD*** by acetylation .	positive	1
18004	10944526	2033;4654	p300;MyoD	***CREB-binding protein/p300*** ***activates*** ***MyoD*** by acetylation .	positive	1
18005	10944526	4654;1387	MyoD;CREB-binding protein	The myogenic protein ***MyoD*** ***requires*** two nuclear histone acetyltransferases , ***CREB-binding protein*** ( CBP ) / p300 and PCAF , to transactivate muscle promoters .	target	0
18006	10944526	8850;4654	PCAF;MyoD	***MyoD*** is ***acetylated*** by ***PCAF*** in vitro , which seems to increase its affinity for DNA .	target	1
18007	10944526	1387;4654	CBP;MyoD	In vitro , ***MyoD*** is ***acetylated*** both by ***CBP/p300*** and by PCAF on two lysines located at the boundary of the DNA binding domain .	target	1
18008	10944526	2033;4654	p300;MyoD	In vitro , ***MyoD*** is ***acetylated*** both by ***CBP/p300*** and by PCAF on two lysines located at the boundary of the DNA binding domain .	target	1
18009	10944526	1387;4654	CBP;MyoD	***MyoD*** ***acetylation*** by ***CBP/p300*** ( as well as by PCAF ) increases its activity on a muscle-specific promoter , as assessed by microinjection experiments .	target	1
18010	10944526	2033;4654	p300;MyoD	***MyoD*** ***acetylation*** by ***CBP/p300*** ( as well as by PCAF ) increases its activity on a muscle-specific promoter , as assessed by microinjection experiments .	target	1
18011	10944532	2247;4792	FGF-2;IkappaBalpha	Moreover , ***FGF-2*** also ***stimulated*** the transient degradation of ***IkappaBalpha*** and IkappaBbeta .	positive	0
18012	10944532	2247;4793	FGF-2;IkappaBbeta	Moreover , ***FGF-2*** also ***stimulated*** the transient degradation of IkappaBalpha and ***IkappaBbeta*** .	positive	0
18013	10944533	2932;1499	GSK-3beta;beta-catenin	In the Axin complex , ***GSK-3beta*** efficiently ***phosphorylates*** ***beta-catenin*** , which is then ubiquitinated and degraded by proteasome .	target	1
18014	10944610	4233;599	HGF receptor;bcl-w	***Met/HGF receptor*** ***modulates*** ***bcl-w*** expression and inhibits apoptosis in human colorectal cancers .	target	0
18015	10944610	8731;599	Met;bcl-w	***Met/HGF receptor*** ***modulates*** ***bcl-w*** expression and inhibits apoptosis in human colorectal cancers .	target	0
18016	10944610	4233;599	c-met;bcl-w	The ***c-met*** mRNA level in human colorectal adenomas and carcinomas was ***correlated*** with ***bcl-w*** but not with bcl-2 or with bcl-x ( L ) mRNA level .	parallel	0
18017	10944610	4233;598	c-met;bcl-x	The ***c-met*** mRNA level in human colorectal adenomas and carcinomas was ***correlated*** with bcl-w but not with bcl-2 or with ***bcl-x*** ( L ) mRNA level .	parallel	0
18018	10945226	7037;3077	transferrin receptor;HFE	A functional link between HFE and iron metabolism has been established by the discovery of a physical ***association*** between ***HFE*** and the ***transferrin receptor*** .	parallel	0
18019	10945226	3077;7037	HFE;transferrin receptor	By inhibiting transferrin receptor internalization , ***HFE*** functions as a negative ***modulator*** of ***transferrin receptor*** function .	negative	0
18020	10945227	3456;1234	IFN-beta;CCR5	Recent experimental evidence indicates that gp41 and ***IFN-beta*** were involved in ***downregulation*** of ***CCR5*** expression and induction of cell activation or signal transduction .	negative	1
18021	10945233	7297;11140	TYK2;CDC37	Interestingly , the ***TYK2*** gene is ***linked*** to ***CDC37*** in a head-to-tail manner with a small intergenic region of 292 bp .	parallel	0
18022	10945495	596;7124	BCL-2;TNF-alpha	Our results showed a significant direct ***association*** between ***TNF-alpha*** and ***BCL-2*** ( P = 0.05 ) and an inverse association between TNF-alpha and microvessel count ( P = 0.03 ) .	parallel	0
18023	10945503	5594;5604	ERK1/2;MEK1	We demonstrate here that 24-48 h following treatment of transformed T - and monocytoid cell lines with recombinant human IFN-alpha2b both the phosphorylation and activity of ***MEK1*** and its ***substrates*** ***ERK1/2*** were reduced .	parallel	1
18024	10945503	3439;5594	IFN-alpha;ERK	In conclusion , our results indicate that ***IFN-alpha*** ***regulates*** the activity of the ***MEK/ERK*** pathway and consequently modulates cellular proliferation through a Ras/Raf-independent mechanism .	target	1
18025	10945503	3439;5609	IFN-alpha;MEK	In conclusion , our results indicate that ***IFN-alpha*** ***regulates*** the activity of the ***MEK/ERK*** pathway and consequently modulates cellular proliferation through a Ras/Raf-independent mechanism .	target	1
18026	10945571	7018;1356	transferrin;ceruloplasmin	After adjustment for age and time on dialysis , ***transferrin*** iron binding capacity ( P = 0.013 ) and copper ( P = 0.019 ) continued to be ***associated*** with CVD risk but ***ceruloplasmin*** ( P = 0.065 ) and CRP ( P = 0.634 ) were not .	parallel	0
18027	10945608	2950;6416	GSTp;mitogen-activated protein (MAP) kinase kinase 4	Under nonstressed conditions , increased expression of ***GSTp*** via a tet-off-inducible GSTp in NIH 3T3 cells ***increased*** the phosphorylation of ***mitogen-activated protein (MAP) kinase kinase 4*** , p38 , extracellular receptor kinase ( ERK ) , and inhibitor of kappa-kinase ( IKK ) , and reduced phosphorylation of MAP kinase kinase 7 and Jun NH2-terminal kinase ( JNK ) .	positive	0
18028	10945608	2950;5594	GSTp;p38	Under nonstressed conditions , increased expression of ***GSTp*** via a tet-off-inducible GSTp in NIH 3T3 cells ***increased*** the phosphorylation of mitogen-activated protein (MAP) kinase kinase 4 , ***p38*** , extracellular receptor kinase ( ERK ) , and inhibitor of kappa-kinase ( IKK ) , and reduced phosphorylation of MAP kinase kinase 7 and Jun NH2-terminal kinase ( JNK ) .	positive	0
18029	10945608	2950;5609	GSTp;MAP kinase kinase 7	Under nonstressed conditions , increased expression of ***GSTp*** via a tet-off-inducible GSTp in NIH 3T3 cells increased the phosphorylation of mitogen-activated protein (MAP) kinase kinase 4 , p38 , extracellular receptor kinase ( ERK ) , and inhibitor of kappa-kinase ( IKK ) , and ***reduced*** phosphorylation of ***MAP kinase kinase 7*** and Jun NH2-terminal kinase ( JNK ) .	negative	1
18030	10945619	355;841	FAS;caspase 8	Cross-linking of ***FAS*** failed to ***induce*** recruitment and activation of ***caspase 8*** , whereas transfection of a constitutively active caspase 8 construct effectively killed the SW579 papillary carcinoma cell line , arguing that the action of the putative inhibitor occurs upstream of caspase 8 .	target	1
18031	10945642	3082;4233	HGF;c-met	These findings demonstrate that ***c-met*** receptor ***activation*** by ***SF/HGF*** protects certain glioblastoma cells from DNA-damaging agents by activating phosphoinositol 3-kinase-dependent and AKT-dependent antiapoptotic pathways .	positive	1
18032	10945642	4233;3082	c-met;Scatter factor	We have shown recently that the multifunctional growth factor , ***Scatter factor/hepatocyte growth factor*** ( SF/HGF ) , and its ***receptor*** ***c-met*** enhance the malignancy of human glioblastoma through an autocrine stimulatory loop ( R.	parallel	1
18033	10945898	375790;1605	Agrin;alpha-dystroglycan	These results suggest that ***binding*** of the larger ***Agrin*** fragments to ***alpha-dystroglycan*** and/or heparan sulfate proteoglycans may sequester the fragments and inhibit their activity in embryonic muscle .	parallel	1
18034	109459	5617;7200	prolactin;thyrotropin-releasing hormone	Impaired ***prolactin*** ***response*** to ***thyrotropin-releasing hormone*** in isolated gonadotropin deficiency and exaggerated response in primary testicular failure .	parallel	0
18035	10945975	672;466	BRCA1;ATF1	***BRCA1*** physically and functionally ***interacts*** with ***ATF1*** .	parallel	1
18036	10945975	672;466	BRCA1;ATF1	Using the yeast two-hybrid system , we identified an ***interaction*** between the ***BRCA1*** RING finger and ***ATF1*** , a member of the cAMP response element-binding protein/activating transcription factor ( CREB/ATF ) family .	parallel	1
18037	10945984	7520;2547	Ku80;Ku70	Association of the DNA end-binding ******Ku70/Ku80****** ***heterodimer*** with the 460-kDa serine/threonine kinase catalytic subunit forms the DNA-dependent protein kinase ( DNA-PK ) that is required for double-strand break repair by non-homologous recombination in mammalian cells .	parallel	1
18038	10945997	51466;25	EVL;Abl	***EVL*** ***bound*** directly to the ***Abl*** , Lyn , and nSrc SH3 domains ; the FE65 WW domain ; and profilin , likely via its proline-rich core .	parallel	1
18039	10945997	51466;4067	EVL;Lyn	***EVL*** ***bound*** directly to the Abl , ***Lyn*** , and nSrc SH3 domains ; the FE65 WW domain ; and profilin , likely via its proline-rich core .	parallel	1
18040	10946088	1440;3684	G-CSF;CD11b	Expression of ***CD11b*** on PMN surface was ***augmented*** by ***G-CSF*** or fMLP .	positive	0
18041	109462	5617;7200	prolactin;thyrotropin-releasing hormone	Thyrotropin : alpha - and beta-subunits of thyrotropin , and ***prolactin*** ***responses*** to four-hour constant infusions of ***thyrotropin-releasing hormone*** in normal subjects and patients with pituitary-thyroid disorders .	parallel	0
18042	10946255	5594;3586	P40;IL-10	Furthermore , ***P40*** ***up-regulates*** the production of IL-1beta , IL-8 , ***IL-10*** , IL-12 , and TNF-alpha by human macrophages and of NO by the RAW 264.7 murine macrophage cell line .	positive	1
18043	10946255	5594;3553	P40;IL-1beta	Furthermore , ***P40*** ***up-regulates*** the production of ***IL-1beta*** , IL-8 , IL-10 , IL-12 , and TNF-alpha by human macrophages and of NO by the RAW 264.7 murine macrophage cell line .	positive	1
18044	10946255	5594;3576	P40;IL-8	Furthermore , ***P40*** ***up-regulates*** the production of IL-1beta , ***IL-8*** , IL-10 , IL-12 , and TNF-alpha by human macrophages and of NO by the RAW 264.7 murine macrophage cell line .	positive	1
18045	10946255	5594;7124	P40;TNF-alpha	Furthermore , ***P40*** ***up-regulates*** the production of IL-1beta , IL-8 , IL-10 , IL-12 , and ***TNF-alpha*** by human macrophages and of NO by the RAW 264.7 murine macrophage cell line .	positive	1
18046	10946255	5594;3458	P40;IFN-gamma	***P40*** also ***synergizes*** with ***IFN-gamma*** and suboptimal concentrations of LPS to up-regulate the production of these mediators .	parallel	0
18047	10946268	3558;1027	IL-2;p27kip1	We find that this anergic state is associated with defects in both TCR-coupled activation of the p42/44 mitogen-activated protein kinase ( extracellular signal-related kinase 1/2 ) and ***IL-2-mediated*** ***down-regulation*** of the cell cycle inhibitor ***p27kip1*** .	negative	1
18048	10946277	4261;3565	MHC class II transactivator;IL-4	***MHC class II transactivator*** ***inhibits*** ***IL-4*** gene transcription by competing with NF-AT to bind the coactivator CREB binding protein ( CBP ) / p300 .	negative	1
18049	10946277	1387;3565	CBP;IL-4	The introduction of ***CBP/p300*** and NF-AT ***enhances*** the ***IL-4*** promoter activity , and this activation was repressed by CIITA .	positive	0
18050	10946277	2033;3565	p300;IL-4	The introduction of ***CBP/p300*** and NF-AT ***enhances*** the ***IL-4*** promoter activity , and this activation was repressed by CIITA .	positive	0
18051	10946277	4261;1387	CIITA;CBP	Furthermore , our data show that ***CIITA*** competes with NF-AT to ***bind*** ***CBP/p300*** and that this competition dramatically influences transcriptional activation of the IL-4 promoter .	parallel	1
18052	10946277	4261;2033	CIITA;p300	Furthermore , our data show that ***CIITA*** competes with NF-AT to ***bind*** ***CBP/p300*** and that this competition dramatically influences transcriptional activation of the IL-4 promoter .	parallel	1
18053	10946277	4261;1387	CIITA;CBP	We identified two domains of ***CIITA*** that ***interact*** with two distinct domains of ***CBP/p300*** that are also recognized by NF-AT .	parallel	1
18054	10946277	4261;2033	CIITA;p300	We identified two domains of ***CIITA*** that ***interact*** with two distinct domains of ***CBP/p300*** that are also recognized by NF-AT .	parallel	1
18055	10946277	4261;3565	CIITA;IL-4	***CIITA*** mutants that retain the ability to interact with CBP/p300 are sufficient to ***inhibit*** NF-AT-mediated ***IL-4*** gene expression .	positive	1
18056	10946285	3320;3308	hsp90;hsp70	Interestingly , the phylogenetically related ***hsp90*** also ***competes*** quite effectively with gp96 for binding to macrophages , whereas the unrelated ***hsp70*** does so relatively poorly , although it binds CD11b + cells just as effectively .	negative	0
18057	10946303	7124;5743	TNF-alpha;COX-2	NF-kappaB DNA-protein binding and ***COX-2*** promoter activity were ***enhanced*** by ***TNF-alpha*** , and these effects were inhibited by genistein , U73122 , staurosporine , or pyrolidine dithiocarbamate .	positive	0
18058	10946303	7124;4790	TNF-alpha;NF-kappaB	***NF-kappaB*** DNA-protein binding and COX-2 promoter activity were ***enhanced*** by ***TNF-alpha*** , and these effects were inhibited by genistein , U73122 , staurosporine , or pyrolidine dithiocarbamate .	positive	0
18059	10946304	598;6347	Bcl-xL;monocyte chemoattractant protein 1	Overexpression of ***Bcl-xL*** in this macrophage cell line was also ***associated*** with a marked inhibition of LPS-induced TNF-alpha , ***JE/monocyte chemoattractant protein 1*** , and macrophage inflammatory protein 2 secretion .	parallel	0
18060	10946304	598;7124	Bcl-xL;TNF-alpha	Overexpression of ***Bcl-xL*** in this macrophage cell line was also ***associated*** with a marked inhibition of LPS-induced ***TNF-alpha*** , JE/monocyte chemoattractant protein 1 , and macrophage inflammatory protein 2 secretion .	parallel	0
18061	10946304	598;4790	Bcl-xL;NF-kappaB	Although the composition of NF-kappaB complexes detected by EMSA and supershift analysis in nuclear lysates derived from Bcl-xL transfectants and control cells was indistinguishable , LPS-induced inhibitory kappaBalpha degradation , as well as ***NF-kappaB*** binding and AP-1 activation , were slightly ***decreased*** by ectopic expression of ***Bcl-xL*** .	negative	0
18062	10946304	598;1432	Bcl-xL;p38 mitogen-activated protein kinase	More strikingly , LPS-induced phosphorylation of ***p38 mitogen-activated protein kinase*** and c-Jun N-terminal kinase was strongly ***repressed*** by ***Bcl-xL*** overexpression , offering a possible mechanism for the inhibition of LPS-induced cytokine production .	negative	1
18063	10946305	7124;6352	TNF-alpha;RANTES	Here we studied the ***interplay*** between a pleiotropic cytokine , ***TNF-alpha*** , and two prototypic chemoattractants , ***RANTES*** and stromal cell-derived factor-1alpha ( SDF-1alpha ) , on human CD45RO + T cells migrating within an ECM-like context .	parallel	1
18064	10946309	5320;5321	sPLA2;cPLA2	Addition of partially purified ***sPLA2*** from BMMC ***enhanced*** ***cPLA2*** activity and AA release .	positive	0
18065	10946310	3586;3458	IL-10;IFN-gamma	***IL-10*** treatment , particularly when administered after LPS , ***enhanced*** LPS-induced ***IFN-gamma*** release , as well as the release of the IFN-gamma-dependent chemokines IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma , while inhibiting or not influencing the production of IFN-gamma-inducing cytokines .	positive	0
18066	10946314	3596;7412	IL-13;VCAM-1	Both IL-4 and ***IL-13*** markedly ***increased*** mRNA levels of ***VCAM-1*** in vascular endothelial cells , and the production of the soluble form of VCAM-1 was also stimulated in response to IL-4 or IL-13 .	positive	0
18067	10946314	3565;7412	IL-4;VCAM-1	Both ***IL-4*** and IL-13 markedly ***increased*** mRNA levels of ***VCAM-1*** in vascular endothelial cells , and the production of the soluble form of VCAM-1 was also stimulated in response to IL-4 or IL-13 .	positive	0
18068	10946556	7124;1437	TNF-alpha;GM-CSF	[ IL-1 and ***TNF-alpha-mediated*** ***regulation*** of IL-6 , IL-8 , and ***GM-CSF*** release from cultured nasal epithelial cells ] .	target	1
18069	10946816	356;355	FasL;Fas	A variety of malignancies express ***Fas*** ***ligand*** ( ***FasL*** ) , which can induce apoptosis in effector lymphocytes and may limit the success of cellular immunotherapy .	parallel	1
18070	10946829	6863;7124	Substance P;tumor necrosis factor-alpha	***Substance P*** ( SP ) can ***stimulate*** production of ***tumor necrosis factor-alpha*** ( TNF-alpha ) from astrocytes stimulated with lipopolysaccharide ( LPS ) .	positive	0
18071	10946872	7133;7124	TNFR2;tumor necrosis factor-alpha	***tumor necrosis factor-alpha*** ( TNFalpha ) and its soluble ***receptor*** 2 ( ***TNFR2*** ) are expressed in adipose tissue and are possibly involved in the pathogenesis of insulin resistance .	parallel	1
18072	10946877	7026;2516	COUP-TFII;adrenal 4-binding protein	***COUP-TFII*** has been demonstrated to negatively ***regulate*** the transcriptional activity of ***adrenal 4-binding protein*** , a steroidogenic cell-specific transcription factor that activates the transcription of various steroidogenic P450 genes .	negative	1
18073	10946907	5020;6528	oxytocin;NIS	These findings suggest that RAIU and ***NIS*** expression in mammary gland are at least in part ***modulated*** by ***oxytocin*** and PRL .	target	0
18074	10946907	5617;6528	PRL;NIS	These findings suggest that RAIU and ***NIS*** expression in mammary gland are at least in part ***modulated*** by oxytocin and ***PRL*** .	target	0
18075	10946907	5020;6528	oxytocin;NIS	Indeed , we showed that ***NIS*** messenger ribonucleic acid level was ***increased*** in a dose-dependent manner by ***oxytocin*** and PRL in histocultured human breast tumors .	positive	0
18076	10946907	5617;6528	PRL;NIS	Indeed , we showed that ***NIS*** messenger ribonucleic acid level was ***increased*** in a dose-dependent manner by oxytocin and ***PRL*** in histocultured human breast tumors .	positive	0
18077	10947071	3458;3620	IFN-gamma;IDO	***IFN-gamma*** ***induced*** indoleamine 2,3-dioxygenase ( ***IDO*** ) and NO synthase ( NOS ) and increased the synthesis of 3OH-kynurenine , QUIN , and NO that accumulated in the incubation medium where they reached neurotoxic levels .	target	1
18078	10947072	4790;5966	p50;c-rel	Electrophoretic mobility shift assays with the kappaB elements of the murine TNF-alpha promoter and enhancer revealed that nuclear mobilization of ***heterodimers*** of p65/p50 , ***c-rel/p50*** and ***p65/c-rel*** , and homodimers of p65 was markedly reduced in LPS-tolerant cells , whereas that of p50 homodimers was only slightly increased .	parallel	1
18079	10947072	5970;5966	p65;c-rel	Electrophoretic mobility shift assays with the kappaB elements of the murine TNF-alpha promoter and enhancer revealed that nuclear mobilization of ***heterodimers*** of p65/p50 , c-rel/p50 and ******p65/c-rel****** , and homodimers of p65 was markedly reduced in LPS-tolerant cells , whereas that of p50 homodimers was only slightly increased .	parallel	1
18080	10947072	5970;4790	p65;p50	Electrophoretic mobility shift assays with the kappaB elements of the murine TNF-alpha promoter and enhancer revealed that nuclear mobilization of ***heterodimers*** of p65/p50 , ***c-rel/p50*** and ***p65/c-rel*** , and homodimers of p65 was markedly reduced in LPS-tolerant cells , whereas that of p50 homodimers was only slightly increased .	parallel	1
18081	10947077	8648;196	SRC-1;AhR	***SRC-1*** ***interacted*** weakly with ***AhR*** in the absence of TCDD and the addition of ligand further increased SRC-1 binding to AhR .	parallel	1
18082	10947077	8648;196	SRC-1;AhR	SRC-1 interacted weakly with AhR in the absence of TCDD and the addition of ligand further increased ***SRC-1*** ***binding*** to ***AhR*** .	parallel	1
18083	10947077	8648;196	SRC-1;AhR	Deletional mapping studies of the AhR revealed that ***SRC-1*** ***binds*** to the ***AhR*** transactivation domain .	parallel	1
18084	10947844	121512;998	frabin;Cdc42	CONCLUSION : These results indicate that the ***frabin-dependent*** spatial ***activation*** of ***Cdc42*** and Rac is important for the formation of microspikes .	positive	1
18085	10947844	121512;5880	frabin;small G protein	***frabin*** furthermore ***induces*** indirect activation of Rac ***small G protein*** ( Rac ) in intact cells .	target	1
18086	10947844	121512;999	frabin;E-cadherin	Furthermore , ***frabin*** weakly ***increased*** the accumulation of F-actin and ***E-cadherin*** at cell-cell AJs and the formation of stress fibres through the activation of Cdc42 and Rac , under conditions where the dominant active mutant of Cdc42 or Rac markedly showed these effects .	positive	0
18087	10947852	53615;8932	MBD3;MBD2	We hypothesize that the ******MBD2-MBD3****** ***complex*** recognizes hemi-methylated DNA concurrent with DNA replication and recruits histone deacetylase complexes , as well as DNMT1 , to establish and/or maintain the transcriptionally repressed chromatin .	parallel	1
18088	10947852	53615;8932	MBD3;MBD2	******MBD2-MBD3****** ***complex*** binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase .	parallel	1
18089	10947852	53615;8932	MBD3;MBD2	Significantly , the ******MBD2-MBD3****** ***complex*** showed an affinity to hemi-methylated DNAs , a property that has never been reported with any member of the family proteins .	parallel	1
18090	10947953	7040;8576	TGF-beta;TSF1	***TSF1*** mRNA as well as its protein level were ***stimulated*** by ***TGF-beta*** treatment .	positive	0
18091	10948067	283489;7408	cAMP;vasodilator-stimulated phosphoprotein	The 2-arachidonoyl glycerol-induced phosphorylation of ***vasodilator-stimulated phosphoprotein*** is ***mediated*** by ***cAMP*** .	target	0
18092	10948117	1081;960	hCG;LHr	This model proposes that gonococci express a surface feature that mimics human chorionic gonadotropin ( ***hCG*** ) , the cognate ***ligand*** for ***LHr*** , and that this structure is responsible for the specific and productive interaction of GC with LHr .	parallel	1
18093	10948149	3565;7124	IL-4;TNF-alpha	However , MCP-1 did not appear to be induced by IL-4 or to be required for the ***TNF-alpha*** ***regulation*** by ***IL-4*** .	target	1
18094	10948149	3565;6347	IL-4;MCP-1	However , ***MCP-1*** did not appear to be ***induced*** by ***IL-4*** or to be required for the TNF-alpha regulation by IL-4 .	target	1
18095	10948188	959;958	CD154;CD40	******CD40-CD154****** ***interaction*** was not involved in IgM enhancement , in such a system .	parallel	1
18096	10948192	3589;3572	IL-11;gp130	We also show that a stable high affinity ***complex*** of ***IL-11*** , IL-11R , and ***gp130*** can be resolved by nondenaturing polyacrylamide gel electrophoresis , and its composition verified by second dimension denaturing polyacrylamide gel electrophoresis .	parallel	1
18097	10949025	57099;317	Aven;Apaf-1	***Aven*** , a novel inhibitor of caspase activation , ***binds*** Bcl-xL and ***Apaf-1*** .	parallel	1
18098	10949025	57099;598	Aven;Bcl-xL	***Aven*** , a novel inhibitor of caspase activation , ***binds*** ***Bcl-xL*** and Apaf-1 .	parallel	1
18099	10949025	57099;317	Aven;Apaf-1	The possibility that Bcl-x ( L ) inhibits cell death at a late ( postmitochondrial ) step in the death pathway is supported by this report of a novel apoptosis inhibitor , ***Aven*** , which ***binds*** to both Bcl-x ( L ) and the caspase regulator , ***Apaf-1*** .	parallel	1
18100	10949025	57099;598	Aven;Bcl-x	The possibility that Bcl-x ( L ) inhibits cell death at a late ( postmitochondrial ) step in the death pathway is supported by this report of a novel apoptosis inhibitor , ***Aven*** , which ***binds*** to both ***Bcl-x*** ( L ) and the caspase regulator , Apaf-1 .	parallel	1
18101	10949025	57099;317	Aven;Apaf-1	***Aven*** ***interferes*** with the ability of ***Apaf-1*** to self-associate , suggesting that Aven impairs Apaf-1-mediated activation of caspases .	negative	0
18102	10949040	1977;1981	eIF4F;eIF4G	Here we report genetic and biochemical evidence that the yeast translation initiation factor eIF4G associates with CBC , and that eIF4E , the ***eIF4F*** component that ***binds*** both the cap and ***eIF4G*** , antagonizes this interaction .	parallel	1
18103	10949040	1977;1981	eIF4E;eIF4G	These data suggest that ***eIF4E*** ***binding*** to the ***eIF4G-CBC*** complex on newly exported mRNA displaces CBC , and that the first round of translation on mRNA may occur via a different mechanism than subsequent rounds .	parallel	1
18104	10949049	7048;7040	TbetaR-II;TGF-beta	However , ***TGF-beta*** type II ***receptor*** ( ***TbetaR-II*** ) is expressed by all palatal epithelial cells during palatal fusion ( Cui et al. , 1998 ) and therefore can not localize TGF-beta3 responsiveness .	parallel	1
18105	10949049	7043;7048	TGF-beta3;TbetaR-II	TbetaR-III may modulate ***TGF-beta3*** ***binding*** to ***TbetaR-II*** in the MEE cells to locally enhance TGF-beta3 autocrine signaling through the TbetaR-I/TbetaR-II receptor complex , which contributes to MEE selective epithelial-mesenchymal transformation .	parallel	1
18106	10949049	7046;7048	TbetaR-I;TbetaR-II	TbetaR-III may modulate TGF-beta3 binding to TbetaR-II in the MEE cells to locally enhance TGF-beta3 autocrine signaling through the ******TbetaR-I/TbetaR-II****** receptor ***complex*** , which contributes to MEE selective epithelial-mesenchymal transformation .	parallel	1
18107	10949653	7075;5781	Tie-1;SHP2	***Tie-1*** receptor tyrosine kinase endodomain ***interaction*** with ***SHP2*** : potential signalling mechanisms and roles in angiogenesis .	parallel	1
18108	10949659	2321;7422	Flt-1;VEGF	We investigated the properties of two ***VEGF*** ***receptors*** , ***Flt-1*** and KDR , by using two newly developed blocking monoclonal antibodies ( mAbs ) , i.e. , anti-human Flt-1 mAb and anti-human KDR mAb .	parallel	1
18109	10949659	3791;7422	KDR;VEGF	We investigated the properties of two ***VEGF*** ***receptors*** , Flt-1 and ***KDR*** , by using two newly developed blocking monoclonal antibodies ( mAbs ) , i.e. , anti-human Flt-1 mAb and anti-human KDR mAb .	parallel	1
18110	10949659	3791;2321	KDR;Flt-1	This induction was mediated by the ******KDR/Flt-1****** ***heterodimer*** and the KDR homodimer .	parallel	1
18111	10949923	4193;7157	MDM2;p53	One of its transcriptional targets is ***MDM2*** , which in turn ***down-regulates*** ***p53*** .	negative	1
18112	10949938	1029;7157	P14ARF;p53	Recent experiments performed with mouse embryonic fibroblasts have shown that ***P14ARF*** is an upstream ***regulator*** of the ***p53*** pathway .	target	1
18113	10949998	3439;999	IFN-alpha;E-cadherin	***E-cadherin*** expression was only ***up-regulated*** by butyrate and interferon-alpha ( ***IFN-alpha*** ) in both cell lines , studied by means of fluorescence immunostaining and flow cytometry .	positive	1
18114	10950784	7124;4586	tumor necrosis factor-alpha;mucin	***Induction*** of ***mucin*** gene expression in middle ear of rats by ***tumor necrosis factor-alpha*** : potential cause for mucoid otitis media .	target	1
18115	10950835	5741;820	parathyroid hormone;cAMP	Using a human umbilical vein endothelial cell line , we found that ***parathyroid hormone*** ***increased*** both intracellular calcium and cellular ***cAMP*** content in these endothelial cells .	positive	0
18116	10950864	8788;55384	Dlk1;Gtl2	Furthermore , we show that ***Dlk1*** is tightly ***linked*** to the maternally expressed ***Gtl2*** gene .	parallel	0
18117	10950866	5371;1029	PML;p16	Like oncogenic ras , ***PML*** ***increased*** the levels of ***p16*** , hypophosphorylated Rb , phosphoserine-15 p53 , and expression of p53 transcriptional targets .	positive	0
18118	10950866	5371;7157	PML;p53	Like oncogenic ras , ***PML*** ***increased*** the levels of p16 , hypophosphorylated Rb , phosphoserine-15 ***p53*** , and expression of p53 transcriptional targets .	positive	0
18119	10950867	1981;1973	eIF4G;eIF4A	Specific binding sites for ITAF ( 45 ) , PTB , and a ***complex*** of the ***eIF4G*** and ***eIF4A*** subunits of eIF4F were mapped onto the FMDV IRES , and the cooperative function of PTB and ITAF ( 45 ) in promoting stable binding of eIF4G/4A to the IRES was characterized by chemical and enzymatic footprinting .	parallel	1
18120	10950950	1462;960	versican;CD44	***Binding*** of a large chondroitin sulfate/dermatan sulfate proteoglycan , ***versican*** , to L-selectin , P-selectin , and ***CD44*** .	parallel	1
18121	10950950	1462;960	versican;CD44	Here we show that a large chondroitin sulfate proteoglycan , ***versican*** , derived from a renal adenocarcinoma cell line ACHN , ***binds*** L-selectin , P-selectin , and ***CD44*** .	parallel	1
18122	10950951	999;998	E-cadherin;Cdc42	By fusing the Wiskott-Aldrich syndrome protein/GTPase-binding domain to a green fluorescent protein , ***activation*** of endogenous ***Cdc42*** by ***E-cadherin*** was demonstrated in live cells .	positive	1
18123	10950951	999;998	E-cadherin;Cdc42	These data indicate that ***E-cadherin*** ***activates*** ***Cdc42*** , demonstrating bi-directional interactions between the Rho - and E-cadherin signaling pathways .	positive	1
18124	10950954	5906;1385	Rap1;CREB	Calcium-mediated ***phosphorylation*** of ***CREB*** through the ***PKA-Rap1-ERK*** pathway .	target	1
18125	10950963	9111;3430	Nmi;IFP 35	A deletion analysis revealed that ***Nmi*** must ***interact*** with ***IFP 35*** to prevent its degradation and that the amino terminus of Nmi is required , but not sufficient , for this function .	parallel	1
18126	10950963	9111;3430	Nmi;IFP 35	Thus , we have shown that Nmi and IFP 35 associate into a protein complex , that IFP 35 is degraded in a proteasome-mediated process , and that a novel function of ***Nmi*** is to ***prevent*** ***IFP 35*** degradation .	negative	0
18127	10950963	9111;3430	Nmi;IFP 35	Interferon-inducible Myc/STAT-interacting protein ***Nmi*** ***associates*** with ***IFP 35*** into a high molecular mass complex and inhibits proteasome-mediated degradation of IFP 35 .	parallel	0
18128	10950963	9111;3430	Nmi;IFP 35	Interferon-inducible Myc/STAT-interacting protein ***Nmi*** associates with IFP 35 into a high molecular mass complex and ***inhibits*** proteasome-mediated degradation of ***IFP 35*** .	negative	1
18129	10950963	3430;9111	IFP 35;Nmi	The homology consists of a novel ***Nmi/IFP 35*** domain ( NID ) of 90-92 amino acids that is repeated in tandem in each protein and ***mediates*** ***Nmi-Nmi*** protein interactions and subcellular localization .	target	0
18130	10950963	3430;9111	IFP 35;Nmi	In a yeast two-hybrid screen with a fragment of Nmi protein containing both NIDs , we identified an ***interaction*** between ***Nmi*** and ***IFP 35*** .	parallel	1
18131	10950963	3430;9111	IFP 35;Nmi	Deletion derivatives of the proteins indicate that both NIDs are required for the ***interaction*** between ***Nmi*** and ***IFP 35*** .	parallel	1
18132	10950963	3430;9111	IFP 35;Nmi	The ***association*** of ***Nmi*** and ***IFP 35*** into a complex can be demonstrated in multiple cell lines and is not dependent on treatment with IFN .	parallel	0
18133	10950967	1154;3565	suppressor of cytokine signaling;interleukin-4	Identification of critical residues required for ***suppressor of cytokine signaling-specific*** ***regulation*** of ***interleukin-4*** signaling .	target	1
18134	10950967	9021;3565	SOCS-3;IL-4	We demonstrate that both SOCS-1 - and ***SOCS-3-mediated*** ***down-regulation*** of ***IL-4*** signaling is due to an inhibition of the receptor associated Jak1 activity .	negative	1
18135	10951198	1471;1522	cystatin C;cathepsin X	***cathepsin X*** was ***inhibited*** by stefin A , ***cystatin C*** and chicken cystatin ( Ki = 1.7-15 .0 nM ) , but poorly or not at all by stefin B ( Ki > 250 nM ) and L-kininogen , respectively .	negative	1
18136	10951198	1475;1522	stefin A;cathepsin X	***cathepsin X*** was ***inhibited*** by ***stefin A*** , cystatin C and chicken cystatin ( Ki = 1.7-15 .0 nM ) , but poorly or not at all by stefin B ( Ki > 250 nM ) and L-kininogen , respectively .	negative	1
18137	10951214	2022;7040	Endoglin;TGF-beta	The initial interactions on the cell surface between Endoglin and TGF-beta receptors may be an important mechanism by which ***Endoglin*** ***modulates*** ***TGF-beta*** signalling , and thereby responses .	target	0
18138	10951214	7049;7040	betaglycan;TGF-beta	Here it is shown that on human microvascular endothelial cells , Endoglin is co-expressed and is associated with ***betaglycan*** , a ***TGF-beta*** accessory ***receptor*** with which Endoglin shares limited amino acid homology .	parallel	1
18139	10951214	2022;7049	Endoglin;betaglycan	Here it is shown that on human microvascular endothelial cells , ***Endoglin*** is co-expressed and is ***associated*** with ***betaglycan*** , a TGF-beta accessory receptor with which Endoglin shares limited amino acid homology .	parallel	0
18140	10951214	2022;7040	Endoglin;TGF-beta	Our findings suggest that ***Endoglin*** may ***modify*** ***TGF-beta*** signalling by interacting with both betaglycan and the TGF-beta signalling receptors at physiological receptor concentrations and ratios .	target	0
18141	10951238	4318;7076	matrix metalloproteinase 9;tissue inhibitor of metalloproteinase-1	As ( i ) tissue inhibitor of metalloproteinase-1 antibody nearly totally abrogated keratinocyte growth and ( ii ) ***complexes*** of ***tissue inhibitor of metalloproteinase-1*** and ***matrix metalloproteinase 9*** were recovered in membrane extracts of sphingomyelinase-treated psoriatic keratinocytes , we postulate that an increased level of cell-associated matrix metalloproteinase 9 might compete for tissue inhibitor of metalloproteinase-1 binding to its receptor .	parallel	1
18142	10951273	5228;7422	PlGF;vascular endothelial growth factor	PlGF and vascular endothelial growth factor homodimers as well as ******vascular endothelial growth factor/PlGF****** ***heterodimers*** could be detected in keratinocyte conditioned medium .	parallel	1
18143	10951379	7124;3569	TNF-alpha;interleukin-6	On the other hand , production of ***interleukin-6*** , which is well known to induce osteoclastogenesis and to directly stimulate bone resorption , was additively ***stimulated*** by the combination of ***TNF-alpha*** and titanium particles .	positive	0
18144	10951396	5715;595	p27;cyclin D1	To clarify the significance of p27 aberrations in the tumourigenesis of lung adenocarcinoma , ***p27*** expression was investigated by immunohistochemistry in lung adenocarcinoma and its precursor lesion , atypical adenomatous hyperplasia ( AAH ) , and ***correlated*** with the expression of Ki-67 , ***cyclin D1*** , and cyclin E.	parallel	0
18145	10951406	4982;8600	osteoprotegerin;OPGL	Both ***OPGL*** and its soluble decoy ***receptor*** , ***osteoprotegerin*** ( OPG ) , which inhibits osteoclast formation , are known to be produced by osteoblasts and inflammatory cells found in the rheumatoid arthritis ( RA ) synovium .	parallel	1
18146	10951562	1660;10657	RHA;Sam68	***RHA*** ***binds*** to ***Sam68*** and to Tap both in vivo and in vitro .	parallel	1
18147	10951562	1660;10482	RHA;Tap	***RHA*** ***binds*** to Sam68 and to ***Tap*** both in vivo and in vitro .	parallel	1
18148	10951572	7443;7157	VRK1;p53	***VRK1*** ***phosphorylates*** murine ***p53*** in threonine 18 .	target	1
18149	10951572	7443;7157	VRK1;p53	We conclude that ***VRK1*** is an upstream ***regulator*** of ***p53*** that belongs to a new signalling pathway .	target	1
18150	10951573	8772;841	FADD;caspase 8	The interferon-induced protein kinase ( PKR ) , triggers apoptosis through ***FADD-mediated*** ***activation*** of ***caspase 8*** in a manner independent of Fas and TNF-alpha receptors .	positive	1
18151	10951573	5610;355	PKR;Fas	***Upregulation*** of ***Fas*** mRNA by ***PKR*** has been suggested to play a role in PKR-induced apoptosis .	positive	1
18152	10951573	5610;355	PKR;Fas	Significantly , despite the ***PKR-mediated*** ***upregulation*** of ***Fas*** mRNA expression , the Fas receptor-ligand pathway is not needed for PKR-induced apoptosis .	positive	1
18153	10951574	3569;1027	IL-6;p27kip1	Inhibition of MEK activation completely abrogated OSM and ***IL-6*** ***induced*** ***p27kip1*** accumulation , while expression of dominant negative STAT5 decreased the OSM and IL-6 mediated inhibition of DNA-synthesis and partially inhibited p27kip1 accumulation .	target	1
18154	10951574	5008;1027	OSM;p27kip1	Inhibition of MEK activation completely abrogated ***OSM*** and IL-6 ***induced*** ***p27kip1*** accumulation , while expression of dominant negative STAT5 decreased the OSM and IL-6 mediated inhibition of DNA-synthesis and partially inhibited p27kip1 accumulation .	target	1
18155	10951574	6777;1027	STAT5;p27kip1	Inhibition of MEK activation completely abrogated OSM and IL-6 induced p27kip1 accumulation , while expression of dominant negative ***STAT5*** decreased the OSM and IL-6 mediated inhibition of DNA-synthesis and partially ***inhibited*** ***p27kip1*** accumulation .	negative	1
18156	10951575	5292;993	Pim-1;cdc25a	Recently , ***Pim-1*** has been shown to ***enhance*** the activities of p100 , c-Myb and ***cdc25a*** , and in part this might explain reported effects on mitogenesis .	positive	0
18157	10951575	5292;4602	Pim-1;c-Myb	Recently , ***Pim-1*** has been shown to ***enhance*** the activities of p100 , ***c-Myb*** and cdc25a , and in part this might explain reported effects on mitogenesis .	positive	0
18158	10951575	5292;22974	Pim-1;p100	Recently , ***Pim-1*** has been shown to ***enhance*** the activities of ***p100*** , c-Myb and cdc25a , and in part this might explain reported effects on mitogenesis .	positive	0
18159	10951578	4193;7157	MDM2;p53	The ***MDM2*** oncoprotein ***binds*** to ***p53*** and abrogates p53-mediated G1 arrest and apoptosis .	parallel	1
18160	10951578	4193;7157	MDM2;p53	Surprisingly , several point mutants in the zinc binding sites of the RING finger are fully competent for cell cycle stimulation even though they abolish ***MDM2-directed*** ***degradation*** of ***p53*** and MDM2 E3-ligase activity .	negative	1
18161	10951989	7124;3689	TNF-alpha;CD18	Both ***TNF-alpha*** and C5a ( desArg ) ***increased*** expression of beta2 integrins ( ***CD18*** ) , with the highest expression when they were used in combination .	positive	0
18162	10952235	3082;6575	HGF;Ram-1	CONCLUSIONS : Stimulation of hepatocellular mitosis and ***upregulation*** of ***Ram-1*** expression by ***HGF*** and T3 augment retrovirus-mediated gene transfer into hepatocytes .	positive	1
18163	10952315	1499;51176	Armadillo;Lef-1	In flies and vertebrates , ***Armadillo/beta-catenin*** forms a ***complex*** with ***Tcf/Lef-1*** transcription factors , serving as an essential co-activator to mediate Wnt signalling .	parallel	1
18164	10952390	3815;4286	c-Kit;MITF	Most notably , ***Steel factor/c-Kit*** signaling pathway was ***linked*** to phosphorylation of ***MITF*** at Ser73 and Ser409 through activation of MAP kinase and RSK-1 , respectively .	parallel	0
18165	10952390	4254;4286	Steel factor;MITF	Most notably , ***Steel factor/c-Kit*** signaling pathway was ***linked*** to phosphorylation of ***MITF*** at Ser73 and Ser409 through activation of MAP kinase and RSK-1 , respectively .	parallel	0
18166	10952659	133;3827	Adrenomedullin;bradykinin	***Adrenomedullin*** ***inhibits*** spontaneous and ***bradykinin-induced*** but not oxytocin - or prostaglandin F ( 2alpha ) - induced periodic contraction of rat uterus .	negative	1
18167	10952726	3146;3552	HMG-1;IL-1alpha	Addition of purified recombinant ***HMG-1*** to human monocyte cultures significantly ***stimulated*** the release of TNF , ***IL-1alpha*** , IL-1beta , IL-1RA , IL-6 , IL-8 , macrophage inflammatory protein ( MIP ) -1 alpha , and MIP-1beta ; but not IL-10 or IL-12 .	positive	0
18168	10952726	3146;3553	HMG-1;IL-1beta	Addition of purified recombinant ***HMG-1*** to human monocyte cultures significantly ***stimulated*** the release of TNF , IL-1alpha , ***IL-1beta*** , IL-1RA , IL-6 , IL-8 , macrophage inflammatory protein ( MIP ) -1 alpha , and MIP-1beta ; but not IL-10 or IL-12 .	positive	0
18169	10952726	3146;3557	HMG-1;IL-1RA	Addition of purified recombinant ***HMG-1*** to human monocyte cultures significantly ***stimulated*** the release of TNF , IL-1alpha , IL-1beta , ***IL-1RA*** , IL-6 , IL-8 , macrophage inflammatory protein ( MIP ) -1 alpha , and MIP-1beta ; but not IL-10 or IL-12 .	positive	0
18170	10952726	3146;6351	HMG-1;MIP-1beta	Addition of purified recombinant ***HMG-1*** to human monocyte cultures significantly ***stimulated*** the release of TNF , IL-1alpha , IL-1beta , IL-1RA , IL-6 , IL-8 , macrophage inflammatory protein ( MIP ) -1 alpha , and ***MIP-1beta*** ; but not IL-10 or IL-12 .	positive	0
18171	10952728	4773;7124	NFATp;TNF-alpha	These results demonstrate that ***NFATp*** is an essential ***activator*** of immediate early ***TNF-alpha*** gene expression in T cells and they present in vivo evidence of the inducer - and cell type-specific regulation of TNF-alpha gene expression .	positive	1
18172	10952922	7039;2252	transforming growth factor alpha;keratinocyte growth factor	***transforming growth factor alpha*** ***stimulates*** both kit ligand/stem cell factor and ***keratinocyte growth factor*** production by OSE .	positive	0
18173	10952922	1081;1956	hCG;EGFR	Both ***hCG*** and FSH ***stimulated*** ***EGFR*** expression by OSE .	positive	0
18174	10952989	1432;595	p38;cyclin D1	We found that ***p38*** ( SAPK2 ) ***phosphorylates*** ***cyclin D1*** in vitro at Thr ( 286 ) and that this phosphorylation triggers the ubiquitination of cyclin D1 .	target	1
18175	10952994	7099;5743	Tlr4;COX-2	However , the truncated form ( delta Tlr4 ( P712H ) ) of the missense mutant ***Tlr4*** ( P712H ) found in LPS-hyporesponsive mouse strain ( C3H/HeJ ) ***inhibits*** LPS-induced NF kappa B activation and ***COX-2*** expression .	negative	1
18176	10952994	7099;4790	Tlr4;NF kappa B	However , the truncated form ( delta Tlr4 ( P712H ) ) of the missense mutant ***Tlr4*** ( P712H ) found in LPS-hyporesponsive mouse strain ( C3H/HeJ ) ***inhibits*** LPS-induced ***NF kappa B*** activation and COX-2 expression .	negative	1
18177	10952994	4615;7099	MyD88;Tlr4	Furthermore , ***MyD88*** is ***co-immunoprecipitated*** with the wild-type delta ***Tlr4*** but not with the delta Tlr4 ( P712H ) mutant .	parallel	1
18178	10953003	2357;998	FMLP receptor;Cdc42	Using GTP analogues , phosphoinositides , a phosphoinositide-binding peptide , constitutively active or inactive Rho GTPase mutants , and activating or inhibitory peptides derived from neural Wiskott-Aldrich syndrome family proteins ( N-WASP ) , we identified signaling pathways leading from the ***FMLP receptor*** to actin nucleation that ***require*** ***Cdc42*** , but then diverge .	target	0
18179	10953026	7422;3791	VEGF;VEGFR-2	***VEGF*** ( 165 ) ***induced*** phosphorylation of ***VEGFR-2*** and increased proliferation of leukemic cells , demonstrating these receptors were functional .	target	1
18180	10953026	7422;4318	VEGF;MMP-9	***VEGF*** ( 165 ) also ***induced*** the expression of ***MMP-9*** by leukemic cells and promoted their migration through reconstituted basement membrane .	target	1
18181	10953028	1499;2520	beta-catenin;Gastrin	***Activation*** of ***Gastrin*** by ***beta-catenin*** may therefore represent an early event in colorectal tumorigenesis and may contribute significantly toward neoplastic progression .	positive	1
18182	10953046	4217;5599	apoptosis signal-regulating kinase 1;JNK	Marked ***activation*** of the ***JNK*** pathway through SEK1 and ***apoptosis signal-regulating kinase 1*** ( ASK1 ) , an upstream kinase of SEK1 , was demonstrated by the transient transfection of cDNA for wild-type SEK1 or ASK1 together with JNK into COS-7 cells .	positive	1
18183	10953132	4288;596	MIB-1;bcl-2	p53 accumulation ***associated*** with ***bcl-2*** , the proliferation marker ***MIB-1*** and survival in patients with prostate cancer subjected to watchful waiting .	parallel	0
18184	10953132	7157;596	p53;bcl-2	***p53*** accumulation ***associated*** with ***bcl-2*** , the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting .	parallel	0
18185	10953132	7157;596	p53;bcl-2	PURPOSE : We describe the ***association*** of ***p53*** nuclear protein accumulation with ***bcl-2*** expression , tumor cell proliferation and clinical outcome in a prostate cancer population undergoing watchful waiting .	parallel	0
18186	10953163	1000;1499	N-cadherin;beta-catenin	On the other hand , ***N-cadherin*** is present at cell-cell borders in the very anaplastic cell lines , T24 and TCCSUP , and is able to ***link*** ***beta-catenin*** or plakoglobin .	parallel	0
18187	10953177	3552;348	IL-1A;APOE	They found no evidence for an ***interaction*** between the ***IL-1A*** and the ***APOE*** epsilon 4 polymorphisms ( carriers and homozygotes ) , age , or gender with regard to conferred risk .	parallel	1
18188	10953306	7157;1033	p53;cyclin-dependent kinase inhibitor	p21 is a ***cyclin-dependent kinase inhibitor*** that is ***activated*** by ***p53*** .	positive	1
18189	10953324	3953;3952	Obr;Leptin	***Leptin*** ( ob gene ) and its cognate ***receptor*** ( ***Obr*** ) are relevant for fat metabolism .	parallel	1
18190	10953350	7157;7057	p53;thrombospondin-1	Our recent in vitro findings for ***suppression*** of ***thrombospondin-1*** ( TSP1 ; an antiangiogenic factor ) expression by wild-type ( wt ) ***p53*** in a p53-null thyroid carcinoma cell line , FRO , prompted us to investigate the in vivo effect of exogenous wt-p53 and TSP1 expression on tumor growth and angiogenesis of FRO xenografts in nude mice .	negative	1
18191	10954125	6464;2885	Shc;Grb2	It suggests that tyrosine kinase-mediated mitogenic signaling involves a series of protein-protein ***interactions*** between tyrosine-phosphorylated receptors , ***Shc*** and ***Grb2*** , resulting in an AlFx-induced mitogenic effect .	parallel	1
18192	10954418	6616;6804	SNAP-25;syntaxin 1A	The mutant ***SNAP-25*** forms were all found to ***bind*** ***syntaxin 1A*** with equal efficacy .	parallel	1
18193	10954424	56288;50855	PAR-3;PAR-6	Furthermore , co-immunoprecipitation experiments , employing Cos-1 cells , demonstrated that mammalian ***PAR-6*** and ***PAR-3*** formed a direct ***complex*** .	parallel	1
18194	10954424	50855;998	PAR-6;Cdc42	Mammalian ***PAR-6*** ***interacted*** with ***Cdc42*** and Rac1 both in the yeast two-hybrid system and in in vitro binding assays .	parallel	1
18195	10954424	50855;5879	PAR-6;Rac1	Mammalian ***PAR-6*** ***interacted*** with Cdc42 and ***Rac1*** both in the yeast two-hybrid system and in in vitro binding assays .	parallel	1
18196	10954535	3700;920	gp120;CD4	T-20 is a synthetic peptide that potently inhibits replication of human immunodeficiency virus type 1 by interfering with the transition of the transmembrane protein , gp41 , to a fusion active state following ***interactions*** of the surface glycoprotein , ***gp120*** , with ***CD4*** and coreceptor molecules displayed on the target cell surface .	parallel	1
18197	10954544	2056;57126	erythropoietin;cell surface receptor	***Interaction*** of ***erythropoietin*** ( Epo ) with its ***cell surface receptor*** activates signal transduction pathways which result in the proliferation and differentiation of erythroid cells .	parallel	1
18198	10954548	30816;57126	envelope glycoprotein;cell surface receptor	Retrovirus entry into cells is mediated by specific ***interactions*** between the retrovirally encoded Env ***envelope glycoprotein*** and a host ***cell surface receptor*** .	parallel	1
18199	10954702	796;4739	calcitonin;HEF1	In contrast to the phosphorylation of paxillin and HEF1 in cells attached to fibronectin-coated dishes , ***calcitonin*** failed to ***stimulate*** the phosphorylation of paxillin and ***HEF1*** in suspended cells , in cells attached to poly-d-lysine-coated dishes , and in attached cells pretreated with the RGD-containing peptide GRGDS .	positive	0
18200	10954702	796;5829	calcitonin;paxillin	In contrast to the phosphorylation of paxillin and HEF1 in cells attached to fibronectin-coated dishes , ***calcitonin*** failed to ***stimulate*** the phosphorylation of ***paxillin*** and HEF1 in suspended cells , in cells attached to poly-d-lysine-coated dishes , and in attached cells pretreated with the RGD-containing peptide GRGDS .	positive	0
18201	10954702	6714;4739	c-Src;HEF1	Overexpression of wild-type ***c-Src*** ***increased*** calcitonin-induced paxillin and ***HEF1*** phosphorylation , whereas overexpression of kinase-dead Src or Src lacking a functional SH2 domain inhibited the calcitonin-stimulated tyrosine phosphorylation of these proteins .	positive	0
18202	10954702	6714;5829	c-Src;paxillin	Overexpression of wild-type ***c-Src*** ***increased*** calcitonin-induced ***paxillin*** and HEF1 phosphorylation , whereas overexpression of kinase-dead Src or Src lacking a functional SH2 domain inhibited the calcitonin-stimulated tyrosine phosphorylation of these proteins .	positive	0
18203	10954702	796;4739	calcitonin;HEF1	Overexpression of Src lacking the SH3 domain did not affect the ***calcitonin-induced*** ***phosphorylation*** of paxillin and ***HEF1*** .	target	1
18204	10954702	796;5829	calcitonin;paxillin	Overexpression of Src lacking the SH3 domain did not affect the ***calcitonin-induced*** ***phosphorylation*** of ***paxillin*** and HEF1 .	target	1
18205	10954702	796;5595	calcitonin;Erk1	In contrast to the regulation of paxillin and HEF1 phosphorylation , the ***calcitonin-induced*** ***phosphorylation*** of ***Erk1*** and Erk2 did not appear to involve c-Src and was only partially dependent on cell adhesion to the extracellular matrix and an intact actin cytoskeleton .	target	1
18206	10954702	796;5594	calcitonin;Erk2	In contrast to the regulation of paxillin and HEF1 phosphorylation , the ***calcitonin-induced*** ***phosphorylation*** of Erk1 and ***Erk2*** did not appear to involve c-Src and was only partially dependent on cell adhesion to the extracellular matrix and an intact actin cytoskeleton .	target	1
18207	10954702	796;4739	calcitonin;HEF1	Furthermore , inhibition of Erk1 and Erk2 phosphorylation had no effect on the ***calcitonin-induced*** ***phosphorylation*** of paxillin and ***HEF1*** .	target	1
18208	10954702	796;5829	calcitonin;paxillin	Furthermore , inhibition of Erk1 and Erk2 phosphorylation had no effect on the ***calcitonin-induced*** ***phosphorylation*** of ***paxillin*** and HEF1 .	target	1
18209	10954705	6342;4018	SCP-2;lipoprotein	As shown herein , ***SCP-2*** expression ***inhibited*** high density ***lipoprotein*** ( HDL ) - mediated efflux of [ ( 3 ) H ] cholesterol and fluorescent 22 - ( N - ( 7-nitrobenz-2-oxa-1 , 3-diazol-4-yl ) amino ) -23,24 - bisnor-5-cholen-3b-ol ( NBD-cholesterol ) up to 61 and 157 % , respectively .	negative	1
18210	10954711	392;663	Cdc42GAP;BNIP-2	Using glutathione S-transferase recombinant proteins , immunoprecipitation studies , and yeast two-hybrid assays , it was found that ***BNIP-2*** and ***Cdc42GAP*** could form homo and hetero ***complexes*** via their conserved BCH domains .	parallel	1
18211	10954721	7980;5340	TFPI-2;plasmin	Despite the fact that recombinant ***TFPI-2*** readily ***inhibits*** ***plasmin*** , we show that it potentiates HGF-induced invasion of HCC cells and is capable of inducing invasion on its own .	negative	1
18212	10954749	5864;4905	Rab3A;NSF	Furthermore , ***Rab3A*** activation of acrosomal exocytosis ***requires*** active ***NSF*** .	target	0
18213	10954858	3082;4233	HGF;c-met	Uterine hepatocyte growth factor ( ***HGF*** ) , the ***ligand*** for ***c-met*** , and FGFR2IIIb mRNA expression was substantially lower in NOR ewes , but expression of FGF-7 and FGF-10 mRNAs , ligands for FGFR2IIIb , was unaffected .	parallel	1
18214	10954860	1843;4342	CL100;Mos	***Inhibition*** of ***Mos*** synthesis by c-mos antisense RNA and inactivation of MAPK by ***CL100*** phosphatase did not prevent progesterone-induced MPF activation and GVBD .	negative	1
18215	10954903	3456;6348	IFN-beta;MIP-1alpha	Moreover , constitutive ***IFN-beta*** production by DCs ***increases*** the synthesis of IL-12 and IFN-gamma Th1-type cytokines and of the beta-chemokines ***MIP-1alpha*** , MIP-1beta , and RANTES .	positive	0
18216	10954903	3456;6351	IFN-beta;MIP-1beta	Moreover , constitutive ***IFN-beta*** production by DCs ***increases*** the synthesis of IL-12 and IFN-gamma Th1-type cytokines and of the beta-chemokines MIP-1alpha , ***MIP-1beta*** , and RANTES .	positive	0
18217	10954903	3456;6352	IFN-beta;RANTES	Moreover , constitutive ***IFN-beta*** production by DCs ***increases*** the synthesis of IL-12 and IFN-gamma Th1-type cytokines and of the beta-chemokines MIP-1alpha , MIP-1beta , and ***RANTES*** .	positive	0
18218	10954916	598;4790	Bcl-x;NF-kappaB	***NF-kappaB*** activation induced by serum-activated lipopolysaccharide ( SALPS ) , ceramide , and okadaic acid was also ***inhibited*** by overexpression of ***Bcl-x*** ( L ) , whereas that by phorbol myristate acetate ( PMA ) and H2O2 was unaffected .	negative	1
18219	10954916	598;3725	Bcl-x;AP-1	Besides NF-kappaB , the activation of ***AP-1*** by TNF also was ***blocked*** by ***Bcl-x*** ( L ) .	negative	0
18220	10954918	3725;7124	c-Jun;TNF-alpha	Likewise , phosphorylated c-Jun bound to the TAC element , suggesting that ***c-Jun*** is activated by JNK to ***transactivate*** the ***TNF-alpha*** promoter in LPS-treated monocytes .	positive	1
18221	10954918	5599;3725	JNK;c-Jun	Likewise , phosphorylated c-Jun bound to the TAC element , suggesting that ***c-Jun*** is ***activated*** by ***JNK*** to transactivate the TNF-alpha promoter in LPS-treated monocytes .	positive	1
18222	10955790	4288;7157	mib-1;p53	Low ***mib-1*** staining ***correlated*** with negative ***p53*** staining ( P = 0.001 ) , and mdm-2 and p21 stainings correlated positively with each other ( P < 0.001 ) .	parallel	0
18223	10955812	7157;1026	p53;p21	Statistically significant ***associations*** between concentrations of ***p53*** and ***p21*** were not found , nor were relationships demonstrated between concentrations of p21 and other clinicopathological variables or treatment response .	parallel	0
18224	10955814	3565;3586	IL-4;IL-10	***IL-4*** concentration was ***correlated*** significantly with IL-8 and ***IL-10*** .	parallel	0
18225	10955814	3565;3576	IL-4;IL-8	***IL-4*** concentration was ***correlated*** significantly with ***IL-8*** and IL-10 .	parallel	0
18226	10955916	2247;5594	bFGF;ERK-2	Since the cAMP and the mitogen-activated protein kinase ( MAPK ) pathways can modulate the growth of RTEc , we studied whether two cAMP elevating agents , isoproterenol and 8-bromo-cAMP , would modulate basic fibroblast growth factor ( ***bFGF*** ) ***induction*** of MAPK activity ( ***ERK-2*** ) and cell proliferation in human renal proximal tubular epithelial cells ( RPTEc ) and Madin-Darby canine kidney cells ( MDCK clone EI1 ) .	target	1
18227	10955916	2247;5594	bFGF;ERK-2	However , isoproterenol and 8-bromo-cAMP partially inhibited the ***bFGF*** ***induction*** of ***ERK-2*** activity , but only isoproterenol inhibited the proliferation of both cell types .	target	1
18228	10955990	7037;7018	transferrin receptor;transferrin	These results imply that titanium ***transferrin*** might be ***recognized*** by the ***transferrin receptor*** and be taken up into cancer cells .	target	1
18229	10956212	5164;207	PDK1 and 2;Akt	Binding of the pleckstrin homology ( PH ) domain of Akt to membrane PI ( 3 ) P 's causes the translocation of Akt to the plasma membrane bringing it into contact with membrane-bound Akt kinase ( ***PDK1 and 2*** ) , which ***phosphorylates*** and activates ***Akt*** .	target	1
18230	10956389	3660;4261	IRF-2;CIITA	For example , ***IRF-2*** is an ***activator*** of the interferon ( IFN ) - gamma-inducible MHC class II transactivator ( ***CIITA*** ) type IV promoter .	positive	1
18231	10956421	836;4137	caspase-3;tau	Further ***tau*** in the cell lysates was ***cleaved*** by active recombinant ***caspase-3*** at a rate , and to an extent similar to that observed for the well-established caspase-3 substrate poly ( ADP-ribose ) polymerase ( PARP ) .	target	1
18232	10956421	4137;836	tau;caspase-3	These results suggest that oxidative stress-induced cell death occurs through both caspase-dependent and-independent pathways , and that ***tau*** is likely an in situ ***substrate*** of ***caspase-3*** .	parallel	1
18233	10956555	6590;1991	secretory leukocyte protease inhibitor;leukocyte elastase	***secretory leukocyte protease inhibitor*** ( SLPI ) is a potent ***inhibitor*** of human ***leukocyte elastase*** .	negative	1
18234	10956637	7124;4790	TNF-alpha;NF-kappaB	Gel shift and Western blot analyses confirmed that ***TNF-alpha*** ***activated*** ***NF-kappaB*** and depleted IkappaB in this system and that these effects were prevented by MG-132 and pyrrolidine dithiocarbamate .	positive	1
18235	10956639	283489;301	cAMP;annexin I	Our data suggest that ***cAMP*** and AMP ( but not cGMP ) may ***regulate*** ***annexin I*** histidine phosphorylation .	target	1
18236	10956646	23495;10673	TACI;BLyS	***TACI*** mRNA is found predominantly in B-cells and ***correlates*** with ***BLyS*** binding in a panel of B-cell lines .	parallel	0
18237	10956646	23495;8741	TACI;APRIL	We conclude that ***TACI*** is a ***receptor*** for BLyS and ***APRIL*** and discuss the implications for B-cell biology .	parallel	1
18238	10956646	23495;10673	TACI;BLyS	We conclude that ***TACI*** is a ***receptor*** for ***BLyS*** and APRIL and discuss the implications for B-cell biology .	parallel	1
18239	10957889	983;891	cdc2;cyclin B1	Cyclin D1/cdk4 and -6 complexes , which functions as a G1-S checkpoint and ******cyclin B1/cdc2****** ***complexes*** , a G2-M checkpoint are essential for DNA synthesis and mitosis , respectively .	parallel	1
18240	10957889	1021;595	cdk4 and -6;Cyclin D1	******Cyclin D1/cdk4 and -6****** ***complexes*** , which functions as a G1-S checkpoint and cyclin B1/cdc2 complexes , a G2-M checkpoint are essential for DNA synthesis and mitosis , respectively .	parallel	1
18241	10958648	57096;6103	RPGRIP1;RPGR	The ***interaction*** between ***RPGR*** and ***RPGRIP1*** isoforms was impaired in vivo by RP3-associated mutations in RPGR .	parallel	1
18242	10958661	8743;8797	Apo2L;Apo2	Tumor necrosis factor ( TNF ) - related apoptosis-inducing ligand ( TRAIL ) ( ***Apo2*** ***ligand*** [ ***Apo2L*** ] ) is a member of the TNF superfamily and has been shown to have selective antitumor activity .	parallel	1
18243	10958661	8743;5599	TRAIL;Jun N-terminal kinase	Although it is known that ***TRAIL*** ( Apo2L ) induces apoptosis and ***activates*** NF-kappaB and ***Jun N-terminal kinase*** ( JNK ) through receptors such as TRAIL-R1 ( DR4 ) and TRAIL-R2 ( DR5 ) , the components of its signaling cascade have not been well defined .	positive	1
18244	10958661	8743;4790	TRAIL;NF-kappaB	Although it is known that ***TRAIL*** ( Apo2L ) induces apoptosis and ***activates*** ***NF-kappaB*** and Jun N-terminal kinase ( JNK ) through receptors such as TRAIL-R1 ( DR4 ) and TRAIL-R2 ( DR5 ) , the components of its signaling cascade have not been well defined .	positive	1
18245	10958661	3267;5599	RIP;JNK	We found that ectopic expression of the dominant negative mutant ***RIP*** , RIP ( 559-671 ) , ***blocks*** TRAIL-induced IKK and ***JNK*** activation .	negative	0
18246	10958662	104;5932	RED1;sae2	Furthermore , ***RED1-K348E*** ***suppresses*** the ***sae2/com1*** defects in meiotic progression and sporulation , indicating a previously unknown role for HOP1 in the meiotic recombination checkpoint .	negative	1
18247	10958664	2648;8349	Gcn5;H2B	Preferential accessibility is independent of the Swi-Snf chromatin remodeling complex , ***Gcn5*** histone acetylase complexes Ada and SAGA , and Rad6 , which ***ubiquitinates*** histone ***H2B*** .	target	1
18248	10958665	6938;6929	HEB;E2A	Functions of ******E2A-HEB****** ***heterodimers*** in T-cell development revealed by a dominant negative mutation of HEB .	parallel	1
18249	10958665	6938;6929	HEB;E2A	******E2A-HEB****** ***heterodimers*** , the major bHLH dimers found in thymocyte extracts , are thought to play a similar role in T-cell development .	parallel	1
18250	10958665	6938;6929	HEB;E2A	The exact role of ******E2A-HEB****** ***heterodimers*** and possibly the E2A and HEB homodimers in T-cell development can not be distinguished in simple disruption analysis due to a functional compensation from the residual bHLH homodimers .	parallel	1
18251	10958665	6938;6929	HEB;E2A	To further define the function of ******E2A-HEB****** ***heterodimers*** , we generated and analyzed a dominant negative allele of HEB , which produces a physiological amount of HEB proteins capable of forming nonfunctional heterodimers with E2A proteins .	parallel	1
18252	10958665	6938;6929	HEB;E2A	These results indicate that ******E2A-HEB****** ***heterodimers*** play obligatory roles both before and after TCRbeta gene rearrangement during the alpha/beta lineage T-cell development .	parallel	1
18253	10958671	355;841	fas;caspase 8	To examine the consequences of maintaining the structural integrity of BAP31 during apoptosis , the caspase recognition aspartate residues were mutated to alanine residues , and ***fas-mediated*** ***activation*** of ***caspase 8*** and cell death were examined in human KB epithelial cells stably expressing the caspase-resistant mutant crBAP31 .	positive	1
18254	10958673	22926;1649	ATF6;CHOP	We report here that overexpression of soluble ***ATF6*** ***activates*** transcription of the ***CHOP*** and XBP-1 genes as well as of ER chaperone genes constitutively , whereas overexpression of a dominant negative mutant of ATF6 blocks the induction by ER stress .	positive	1
18255	10958673	22926;7494	ATF6;XBP-1	We report here that overexpression of soluble ***ATF6*** ***activates*** transcription of the CHOP and ***XBP-1*** genes as well as of ER chaperone genes constitutively , whereas overexpression of a dominant negative mutant of ATF6 blocks the induction by ER stress .	positive	1
18256	10958675	1435;9846	CSF-1;Gab2	***CSF-1*** ***induced*** ***Gab2*** tyrosyl phosphorylation and association with PI3-kinase in cells expressing WT or DeltaKI receptors .	target	1
18257	10958675	1435;207	CSF-1;Akt	Thus in myeloid progenitors , ***CSF-1*** can ***activate*** the ***PI3-kinase/Akt*** pathway by at least two mechanisms , one involving direct receptor binding and one involving SFKs .	positive	1
18258	10958675	1436;1435	CSF-1R;CSF-1	In the myeloid progenitor 32D cell line expressing ***CSF-1*** ***receptor*** ( ***CSF-1R*** ) , CSF-1 activation of the extracellular signal-regulated kinase ( ERK ) pathway is both Ras and phosphatidylinositol 3-kinase ( PI3-kinase ) dependent .	parallel	1
18259	10958675	1435;2534	CSF-1;Fyn	To determine if Src family kinases ( SFKs ) are involved , we demonstrated that ***CSF-1*** ***activated*** ***Fyn*** and Lyn in cells expressing wild-type ( WT ) or DeltaKI receptors .	positive	1
18260	10958675	1435;4067	CSF-1;Lyn	To determine if Src family kinases ( SFKs ) are involved , we demonstrated that ***CSF-1*** ***activated*** Fyn and ***Lyn*** in cells expressing wild-type ( WT ) or DeltaKI receptors .	positive	1
18261	10958679	3303;5599	Hsp72;JNK	***Hsp72-mediated*** ***suppression*** of ***JNK*** is therefore critical for acquired thermotolerance and may play a role in tolerance to other stresses .	negative	1
18262	10958682	5728;207	PTEN;PKB	Reexpression of ***PTEN*** or treatment with the PI3K inhibitor LY294002 abolished the levels of both PtdIns ( 3 , 4 ) P2 and PtdIns ( 3,4,5 ) P3 , reduced phosphorylation of PKB on Thr308 and Ser473 , and ***inhibited*** ***PKB*** activity .	negative	1
18263	10958682	5728;207	PTEN;PKB	Reexpression of ***PTEN*** or treatment with the PI3K inhibitor LY294002 abolished the levels of both PtdIns ( 3 , 4 ) P2 and PtdIns ( 3,4,5 ) P3 , ***reduced*** phosphorylation of ***PKB*** on Thr308 and Ser473 , and inhibited PKB activity .	negative	1
18264	10958682	5728;207	PTEN;PKB	***PTEN*** and SHIP-2 also significantly ***decreased*** the amount of ***PKB*** associated with cell membranes .	negative	0
18265	10958682	3636;207	SHIP-2;PKB	PTEN and ***SHIP-2*** also significantly ***decreased*** the amount of ***PKB*** associated with cell membranes .	negative	0
18266	10958684	1499;51176	Beta-catenin;LEF1	***Beta-catenin-histone*** deacetylase interactions ***regulate*** the transition of ***LEF1*** from a transcriptional repressor to an activator .	target	1
18267	10958684	51176;3065	LEF1;HDAC1	Further , ***LEF1*** ***associates*** in vivo with ***HDAC1*** , and transcription of a model LEF1-dependent target gene is modulated by the ratio of HDAC1 to Beta-catenin , implying that repression by LEF1 is mediated by promoter-targeted HDAC .	parallel	0
18268	10958684	3065;1499	HDAC1;Beta-catenin	Coexpression of Beta-catenin with LEF1 and HDAC1 results in the formation of a ******Beta-catenin/HDAC1****** ***complex*** .	parallel	1
18269	10958684	3065;1499	HDAC1;Beta-catenin	Surprisingly , the enzymatic activity of ***HDAC1*** ***associated*** with ***Beta-catenin*** is attenuated .	parallel	0
18270	10958684	51176;1499	LEF1;Beta-catenin	Second , once HDAC1-dependent repression has been overridden , Beta-catenin binds LEF1 and the ******Beta-catenin-LEF1****** ***complex*** is competent to activate the expression of downstream target genes .	parallel	1
18271	10958684	1499;51176	Beta-catenin;LEF1	Second , once HDAC1-dependent repression has been overridden , ***Beta-catenin*** ***binds*** ***LEF1*** and the Beta-catenin-LEF1 complex is competent to activate the expression of downstream target genes .	parallel	1
18272	10958685	2908;3066	Glucocorticoid receptor;histone deacetylase 2	***Glucocorticoid receptor*** ***recruitment*** of ***histone deacetylase 2*** inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12 .	target	0
18273	10958685	5970;1977	p65;CBP	Furthermore , we show that GR acts both as a direct inhibitor of CREB binding protein ( CBP ) - associated HAT activity and also by recruiting HDAC2 to the ******p65-CBP****** HAT ***complex*** .	parallel	1
18274	10958685	3066;1977	HDAC2;CBP	Furthermore , we show that GR acts both as a direct inhibitor of CREB binding protein ( CBP ) - associated HAT activity and also by ***recruiting*** ***HDAC2*** to the ***p65-CBP*** HAT complex .	target	0
18275	10958685	3066;5970	HDAC2;p65	Furthermore , we show that GR acts both as a direct inhibitor of CREB binding protein ( CBP ) - associated HAT activity and also by ***recruiting*** ***HDAC2*** to the ***p65-CBP*** HAT complex .	target	0
18276	10958687	28514;4853	Delta1;Notch2	***Binding*** of ***Delta1*** , Jagged1 , and Jagged2 to ***Notch2*** rapidly induces cleavage , nuclear translocation , and hyperphosphorylation of Notch2 .	parallel	1
18277	10958687	182;4853	Jagged1;Notch2	***Binding*** of Delta1 , ***Jagged1*** , and Jagged2 to ***Notch2*** rapidly induces cleavage , nuclear translocation , and hyperphosphorylation of Notch2 .	parallel	1
18278	10958687	3714;4853	Jagged2;Notch2	***Binding*** of Delta1 , Jagged1 , and ***Jagged2*** to ***Notch2*** rapidly induces cleavage , nuclear translocation , and hyperphosphorylation of Notch2 .	parallel	1
18279	10958687	28514;4853	Delta1;Notch2	Binding of ***Delta1*** , Jagged1 , and Jagged2 to Notch2 rapidly ***induces*** cleavage , nuclear translocation , and hyperphosphorylation of ***Notch2*** .	target	1
18280	10958687	182;4853	Jagged1;Notch2	Binding of Delta1 , ***Jagged1*** , and Jagged2 to Notch2 rapidly ***induces*** cleavage , nuclear translocation , and hyperphosphorylation of ***Notch2*** .	target	1
18281	10958687	3714;4853	Jagged2;Notch2	Binding of Delta1 , Jagged1 , and ***Jagged2*** to Notch2 rapidly ***induces*** cleavage , nuclear translocation , and hyperphosphorylation of ***Notch2*** .	target	1
18282	10958687	28514;4851	Delta1;Notch1	***Delta1*** , Jagged1 , and Jagged2 , commonly designated Delta/Serrate/LAG-2 ( DSL ) proteins , are known to be ***ligands*** for ***Notch1*** .	parallel	1
18283	10958687	182;4851	Jagged1;Notch1	Delta1 , ***Jagged1*** , and Jagged2 , commonly designated Delta/Serrate/LAG-2 ( DSL ) proteins , are known to be ***ligands*** for ***Notch1*** .	parallel	1
18284	10958687	3714;4851	Jagged2;Notch1	Delta1 , Jagged1 , and ***Jagged2*** , commonly designated Delta/Serrate/LAG-2 ( DSL ) proteins , are known to be ***ligands*** for ***Notch1*** .	parallel	1
18285	10958691	1025;904	CDK9;CycT1	ATP incubation lead to autophosphorylation of CDK9 at multiple C-terminal Ser and Thr residues , and full-length ***CycT1*** ( amino acids 728 ) [ CycT1 ( 1-728 ) ] , but not truncated CycT1 ( 1-303 ) , was also ***phosphorylated*** by ***CDK9*** .	target	1
18286	10958694	10592;10051	hCAP-E;hCAP-C	Previously , we identified two human SMC family proteins , ***hCAP-C*** and ***hCAP-E*** , which form a heterodimeric ***complex*** ( hCAP-C-hCAP-E ) in the cell .	parallel	1
18287	10958694	10592;10051	hCAP-E;hCAP-C	Coimmunoprecipitation of the endogenous ******hCAP-C-hCAP-E****** ***complex*** from HeLa extracts identified a 155-kDa protein interacting with hCAP-C-hCAP-E , termed condensation-related SMC-associated protein 1 ( CNAP1 ) .	parallel	1
18288	10958731	3553;3576	IL-1beta;IL-8	In vitro studies demonstrated that SK-N-MC and SK-N-SH cells express low levels of IL-8 under normal conditions and that ***IL-1beta*** and tumor necrosis factor-alpha significantly ***increased*** expression of ***IL-8*** at 24 and 48 hours .	positive	0
18289	10958731	7124;3576	tumor necrosis factor-alpha;IL-8	In vitro studies demonstrated that SK-N-MC and SK-N-SH cells express low levels of IL-8 under normal conditions and that IL-1beta and ***tumor necrosis factor-alpha*** significantly ***increased*** expression of ***IL-8*** at 24 and 48 hours .	positive	0
18290	10958787	1022;3094	Cdk7;Hint	***Interactions*** of ***Cdk7*** and Kin28 with ***Hint/PKCI-1*** and Hnt1 histidine triad proteins .	parallel	1
18291	10958787	1022;902	Cyclin-dependent kinase 7;cyclin H	***Cyclin-dependent kinase 7*** ( Cdk7 ) forms a trimeric ***complex*** with ***cyclin H*** and Mat1 to form the mammalian Cdk-activating kinase , CAK , as well as a part of the basal transcription factor TFIIH , where Cdk7 phosphorylates the C-terminal domain ( CTD ) of the large subunit of RNA polymerase II .	parallel	1
18292	10958787	1022;4331	Cyclin-dependent kinase 7;Mat1	***Cyclin-dependent kinase 7*** ( Cdk7 ) forms a trimeric ***complex*** with cyclin H and ***Mat1*** to form the mammalian Cdk-activating kinase , CAK , as well as a part of the basal transcription factor TFIIH , where Cdk7 phosphorylates the C-terminal domain ( CTD ) of the large subunit of RNA polymerase II .	parallel	1
18293	10958787	3094;1022	Hint;Cdk7	The physical and genetic ***interactions*** of ***Hint*** and Hnt1 with ***Cdk7*** and Kin28 suggest a role for this class of histidine triad proteins in the regulation of Cdk7 and Kin28 functions .	parallel	1
18294	10958792	7157;5594	p53;ERK1/2	We also demonstrated that ***p53*** protein ***co-immunoprecipitated*** with ***ERK1/2*** protein and was phosphorylated by activated recombinant murine ERK2 in vitro .	parallel	1
18295	10958792	5594;7157	ERK2;p53	We also demonstrated that ***p53*** protein co-immunoprecipitated with ERK1/2 protein and was ***phosphorylated*** by activated recombinant murine ***ERK2*** in vitro .	target	1
18296	10958799	50944;22859	Shank1;CL1	Furthermore , ***Shank1*** ***induces*** a clustering of ***CL1*** in transfected cells , strongly supporting an interaction of both proteins in vivo .	target	1
18297	10958870	3949;4018	LDLR;lipoprotein	The possible association of genetic markers at the apolipoprotein E ( HhaI polymorphism ) , apolipoprotein B ( XbaI , EcoRI and Ins/Del polymorphisms ) , and low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) ( AvaII , HincII and PvuII polymorphisms ) with coronary artery disease ( CAD ) was evaluated in 50 Brazilian women with CAD diagnosed by angiography and in 100 healthy women ( controls ) .	parallel	1
18298	10959033	5664;351	presenilin (PS) 1 and 2;Abeta	Mutations in the ***presenilin (PS) 1 and 2*** genes that ***increase*** production of the highly amyloidogenic ***Abeta*** ( 42 ) are the most common cause of familial AD .	positive	0
18299	10959033	5663;351	PS1;Abeta	Deletion of ***PS1*** in mice ***reduces*** ***Abeta*** generation , indicating that PS1 mediates the last step in the generation of Abeta from beta-amyloid precursor protein ( APP ) by the unidentified gamma-secretase .	positive	1
18300	10959036	3553;351	IL-1;beta-amyloid precursor protein	Interleukin-1 ( IL-1 ) has been implicated as a key molecule in Alzheimer pathogenesis based on findings of an IL-1 overexpression in Alzheimer brain that is directly related to plaque progression and tangle formation , and on findings that ***IL-1*** ***induces*** excessive synthesis , translation , and processing of neuronal ***beta-amyloid precursor protein*** ( betaAPP ) as well as synthesis of most known plaque-associated proteins .	target	1
18301	10959407	3485;3479	IGFBP-2;IGF-I	The mitogenic effect of ***IGF-I*** could be ***inhibited*** by both ***IGFBP-2*** and IGFBP-3 showing that these binding proteins modulate the bioactivity of IGF-I in the mammary gland at the cellular level .	negative	1
18302	10959407	3486;3479	IGFBP-3;IGF-I	The mitogenic effect of ***IGF-I*** could be ***inhibited*** by both IGFBP-2 and ***IGFBP-3*** showing that these binding proteins modulate the bioactivity of IGF-I in the mammary gland at the cellular level .	negative	1
18303	10959408	5617;5327	prolactin;tPA	In support of this hypothesis we have shown that both ***prolactin*** and GH ***inhibit*** ***tPA*** activity and plasminogen activation in the involuting mammary gland .	negative	1
18304	10959408	3488;5054	IGFBP-5;PAI-1	A potential interaction between the cell death and extracellular matrix remodelling is evident from the observation that ***IGFBP-5*** ***binds*** to plasminogen activator inhibitor-I ( ***PAI-1*** ) .	parallel	1
18305	10959420	7124;5617	TNF-alpha;prolactin	As an example for an antagonistic interaction we can demonstrate ***inhibition*** of ***prolactin*** signalling by ***TNF-alpha*** , which is mediated by NF-kappa B .	negative	1
18306	10959420	4790;7124	NF-kappa B;TNF-alpha	As an example for an antagonistic interaction we can demonstrate inhibition of prolactin signalling by ***TNF-alpha*** , which is ***mediated*** by ***NF-kappa B*** .	target	0
18307	10959692	4790;1051	NFkappaB;C/EBPbeta	While ***binding*** of ***C/EBPbeta*** and ***NFkappaB*** is still observed in gel retardation studies using acute phase nuclear extracts and a probe containing mutations to the downstream C/EBP site , neither NFkappaB nor C/EBP appear to bind to a probe in which the NFkappaB site has been mutated .	parallel	1
18308	10959797	836;142	caspase-3;PARP	The results clearly suggest that fluoride causes cell death in HL-60 cells by causing the activation of ***caspase-3*** which in turn ***cleaves*** ***PARP*** leading to DNA damage and ultimately cell death .	target	1
18309	10959835	5649;1600	Reln;Dab1	CONCLUSIONS : ***Dab1*** is ***downregulated*** by the ***Reln*** signal in neurons in the absence of tyrosine phosphorylation .	negative	1
18310	10959835	5649;1600	Reln;Dab1	In vivo , absence of ***Reln*** ***correlates*** with up-regulation of the docking protein ***Dab1*** and decreased Dab1 tyrosine phosphorylation .	parallel	0
18311	10959835	5649;1600	Reln;Dab1	In vivo , absence of ***Reln*** correlates with up-regulation of the docking protein Dab1 and ***decreased*** ***Dab1*** tyrosine phosphorylation .	positive	0
18312	10959840	7153;1677	topoisomerase IIalpha;CAD	DNA ***topoisomerase IIalpha*** ***interacts*** with ***CAD*** nuclease and is involved in chromatin condensation during apoptotic execution .	parallel	1
18313	10960063	4846;3320	eNOS;Hsp90	The ***interaction*** between ***Hsp90*** and ***eNOS*** enhances the activation of the enzyme in cells and in intact blood vessels leading to NO production .	parallel	1
18314	10960064	2247;5594	bFGF;ERK	Thrombin ( 0.3 and 3 u ml ( -1 ) ) and ***bFGF*** ( 0.3 and 3 nM ) ***increased*** ***ERK*** activity for more than 2 h and increased cell number , whereas ET-1 ( 100 nM ) transiently stimulated ERK activity and was non-mitogenic .	positive	0
18315	10960064	2247;595	bFGF;cyclin D1	Thrombin and ***bFGF*** ***increased*** both ***cyclin D1*** mRNA and protein levels .	positive	0
18316	10960075	4790;5594	NF-kappaB;p38	TF-1 cells stimulated with the phosphatase inhibitor okadaic acid ( OA ) demonstrated enhanced ***NF-kappaB*** and GAL4p65-regulated transcriptional activity which was ***associated*** with elevated ***p38*** phosphorylation .	parallel	0
18317	10960075	5894;4790	Raf-1;NF-kappaB	Overexpression of kinase-deficient mutants belonging to the ERK1/2 , JNK , and p38 pathways showed that only dominant-negative ***Raf-1*** ***abrogated*** SB203580-enhanced ***NF-kappaB*** activity .	negative	0
18318	10960075	1432;4790	p38 MAP kinase;NF-kappaB	This study demonstrates that the ***p38 MAP kinase*** pathway is not involved in the OA-induced ***activation*** of ***NF-kappaB*** .	positive	1
18319	10960082	3553;5594	IL-1beta;ERK1/2	***ERK1/2*** ***activation*** by ***IL-1beta*** was sensitive to inhibition by the PKC inhibitor bisindolylmaleimide suggesting that ERK phosphorylation is a downstream signal of PKC activation .	positive	1
18320	10960361	116;885	PACAP;CCK	We conclude that ***PACAP*** ***increases*** ***CCK*** gene expression via a cAMP-mediated pathway involving CREB phosphorylation by protein kinase A and activation of a composite CRE/AP1 site .	positive	0
18321	10960361	116;885	PACAP;CCK	***Control*** of ***CCK*** gene transcription by ***PACAP*** in STC-1 cells .	target	0
18322	10960361	1385;3725	CREB;AP1	Electrophoretic mobility shift assay and supershift analysis revealed that ***CREB*** and not AP1 ***bound*** to the ***CRE/AP1*** site and that PACAP increased the proportion of phosphorylated CREB that was bound .	parallel	1
18323	10960361	116;1385	PACAP;CREB	Electrophoretic mobility shift assay and supershift analysis revealed that CREB and not AP1 bound to the CRE/AP1 site and that ***PACAP*** ***increased*** the proportion of phosphorylated ***CREB*** that was bound .	positive	0
18324	10960439	8743;4790	TRAIL;NF-kappaB	Actinomycin D and camptothecin almost completely suppressed ***NF-kappaB*** ***induction*** by ***TRAIL*** , whereas doxorubicin had little effect .	target	1
18325	10960443	3569;6774	IL-6;Stat3	In summary , strong ***IL-6-dependent*** ***activation*** of ***Stat3*** before hepatectomy results in delay and inhibition of cell cycle progression after hepatectomy .	positive	1
18326	10960479	2056;3717	EPO;JAK2	In T-ER transformants expressing JAK2 ( T-JER ) , ***EPO*** ***induced*** tyrosine phosphorylation of the EPOR , ***JAK2*** , and STAT5 , and consequently STAT5-responsive genes including bcl-X and cis1 were normally induced .	target	1
18327	10960479	2056;6776	EPO;STAT5	In T-ER transformants expressing JAK2 ( T-JER ) , ***EPO*** ***induced*** tyrosine phosphorylation of the EPOR , JAK2 , and ***STAT5*** , and consequently STAT5-responsive genes including bcl-X and cis1 were normally induced .	target	1
18328	10960723	1906;3039	endothelin-1;HbA1	Plasma ***endothelin-1*** ***correlated*** with fasting plasma glucose ( r = 0.33 ; P < 0.001 ) and ***HbA1*** ( c ) ( r = 0.29 ; P < 0.001 ) .	parallel	0
18329	10960761	841;355	Caspase-8;Fas	Activation of Caspase-8 in response to Fas triggering by ***recruitment*** of ***Caspase-8*** to the ***Fas*** has also been found , however , MMC did not induce FasL and Fas expression , as evidenced by reverse transcriptase-polymerase chain reaction and Western blotting .	target	0
18330	10960761	355;356	Fas;FasL	Taken together , these findings indicate that MMC-induced apoptosis in SNU-16 cells was mediated by Caspase-8 , caspase-9 , and caspase-3 activation independently of ******FasL/Fas****** ***interactions*** .	parallel	1
18331	10960781	2735;6469	Gli;Shh	The observation argues that overall inhibition of ******Shh-Gli****** ***signaling*** leads the adenohypophysis anlage to transdifferentiate into lens .	parallel	0
18332	10961504	65108;4082	MRP;MARCKS	This domain is also involved in the ***interaction*** between ******MARCKS/MRP****** and actin .	parallel	1
18333	10961875	4170;3567	Mcl-1;interleukin-5	The results revealed that only the expression of ***Mcl-1*** highly ***correlated*** with the antiapoptotic activity of ***interleukin-5*** ( IL-5 ) and the synergistic effect of SCF .	parallel	0
18334	10961875	4170;4254	Mcl-1;SCF	The results revealed that only the expression of ***Mcl-1*** highly ***correlated*** with the antiapoptotic activity of interleukin-5 ( IL-5 ) and the synergistic effect of ***SCF*** .	parallel	0
18335	10961875	3567;207	IL-5;PKB	In TF-1 cells , the defect of ***IL-5*** in apoptosis suppression and Mcl-1 induction was ***associated*** with the incapability to highly phosphorylate Janus kinases ( JAK1 , JAK2 ) , signal transducer and activator of transcription-5 ( STAT5 ) , mitogen-activated protein kinase ( MAPK ) , and ***Akt/PKB*** , whereas SCF costimulation restored the potent phosphorylation of MAPK and Akt/PKB , but not STAT5 .	parallel	0
18336	10961875	3567;6776	IL-5;STAT5	In TF-1 cells , the defect of ***IL-5*** in apoptosis suppression and Mcl-1 induction was ***associated*** with the incapability to highly phosphorylate Janus kinases ( JAK1 , JAK2 ) , signal transducer and activator of transcription-5 ( ***STAT5*** ) , mitogen-activated protein kinase ( MAPK ) , and Akt/PKB , whereas SCF costimulation restored the potent phosphorylation of MAPK and Akt/PKB , but not STAT5 .	parallel	0
18337	10961876	7422;1958	vascular endothelial growth factor;Egr-1	***Egr-1*** gene is ***induced*** by the systemic administration of the ***vascular endothelial growth factor*** and the epidermal growth factor .	target	1
18338	10961876	7422;1958	VEGF;Egr-1	In Northern blot analyses , ***VEGF*** ***induced*** ***Egr-1*** mRNA levels in all tissues examined except lung and kidney , whereas EGF led to increased transcripts in all tissues except kidney .	target	1
18339	10961876	7422;1958	VEGF;Egr-1	In immunofluorescence studies , ***VEGF*** ***induced*** ***Egr-1*** in microvascular endothelial cells of the heart and liver , and EGF induced Egr-1 in the microvascular bed of skeletal muscle .	target	1
18340	10961885	5608;1432	MKK6;p38alpha	Moreover , we demonstrate that ***p38alpha*** and its upstream ***activator*** , ***MKK6*** , phosphorylate STAT4 on serine 721 , and are required for STAT4 full transcriptional activity induced by IL-12 , establishing the MKK6/p38alpha/STAT4 pathway as an important mediator of IL-12 actions .	positive	1
18341	10961885	5608;6775	MKK6;STAT4	Moreover , we demonstrate that p38alpha and its upstream activator , ***MKK6*** , ***phosphorylate*** ***STAT4*** on serine 721 , and are required for STAT4 full transcriptional activity induced by IL-12 , establishing the MKK6/p38alpha/STAT4 pathway as an important mediator of IL-12 actions .	target	1
18342	10961885	1432;6775	p38alpha;STAT4	Moreover , we demonstrate that ***p38alpha*** and its upstream activator , MKK6 , ***phosphorylate*** ***STAT4*** on serine 721 , and are required for STAT4 full transcriptional activity induced by IL-12 , establishing the MKK6/p38alpha/STAT4 pathway as an important mediator of IL-12 actions .	target	1
18343	10961889	7124;3574	tumor necrosis factor alpha;IL-7	We now show that interleukin-1 ( IL-1 ) and ***tumor necrosis factor alpha*** ( TNFalpha ) , cytokines typically produced in inflammatory conditions , ***increase*** the stromal cell production of ***IL-7*** .	positive	0
18344	10961889	7124;3574	TNFalpha;IL-7	On the basis of our data , we propose a novel mechanism for inflammatory bone loss in which ***induction*** of ***IL-7*** from stromal cells by IL-1 and ***TNFalpha*** leads to the production of soluble osteoclastogenic cytokines by T cells .	target	1
18345	10961890	3586;2214	IL-10;CD16	Human ***IL-10*** ***stimulated*** ***CD16*** and CD64 expression on the monocyte/macrophage population within peripheral blood mononuclear cells , with optimal concentrations between 1 and 10 ng/mL .	positive	0
18346	10961890	3586;2209	IL-10;CD64	Human ***IL-10*** ***stimulated*** CD16 and ***CD64*** expression on the monocyte/macrophage population within peripheral blood mononuclear cells , with optimal concentrations between 1 and 10 ng/mL .	positive	0
18347	10961893	6929;5087	E2A;PBX1	Among these , approximately half created a Notch ( IC ) allele , encoding the intracellular , signaling portion of Notch1 , suggesting a synergistic ***interaction*** between the Notch and ******E2A-PBX1****** pathways in oncogenesis .	parallel	1
18348	10961925	25942;10664	Sin3A;CTCF	Taking these results together , the synergy in repression mediated by T3R and CTCF might be achieved by the ***binding*** of multiple molecules of ***Sin3A*** to the ***T3R/CTCF-DNA*** complex , thus providing a large platform for the recruitment of histone deacetylases .	parallel	1
18349	10961932	6869;6863	NK1R;substance P	We have investigated the mechanisms that terminate the proinflammatory effects of the neuropeptide ***substance P*** ( SP ) , which are ***mediated*** by the neurokinin 1 receptor ( ***NK1R*** ) .	target	0
18350	10961947	26519;26520	Tim10;Tim9	This consists of a ***complex*** of ***Tim9*** and ***Tim10*** , two homologous , Zn ( 2 + ) - binding proteins that chaperone the passage of the hydrophobic precursor across the aqueous intermembrane space .	parallel	1
18351	10961983	5228;2321	placenta growth factor;VEGFR1	We found that ***placenta growth factor*** , which selectively ***activates*** ***VEGFR1*** , has no effect on the STATs .	positive	1
18352	10961990	196;3320	AhR;hsp90	Mutation of K266A in AIP reduces binding to AhR by 75-80 % ; the geldanamycin sensitivity of this complex shows that AhR stabilizes the ******AIP-hsp90-AhR****** ***complex*** .	parallel	1
18353	10961990	196;3320	AhR;hsp90	Mutation of K266A in AIP reduces binding to AhR by 75-80 % ; the geldanamycin sensitivity of this complex shows that ***AhR*** ***stabilizes*** the ***AIP-hsp90-AhR*** complex .	positive	0
18354	10961990	196;3320	AhR;hsp90	The data support a model where 1 ) AIP binds to both hsp90 and AhR ; 2 ) hsp90 is required for AhR-AIP binding ; and 3 ) the binding of AhR to AIP stabilizes the ******AIP-hsp90-AhR****** ***complex*** .	parallel	1
18355	10961990	196;3320	AhR;hsp90	The data support a model where 1 ) AIP binds to both hsp90 and AhR ; 2 ) hsp90 is required for AhR-AIP binding ; and 3 ) the binding of ***AhR*** to AIP ***stabilizes*** the ***AIP-hsp90-AhR*** complex .	positive	0
18356	10961992	4790;675	NFkappaB;BRCA2	Thus , ***NFkappaB*** and USF ***regulate*** ***BRCA2*** expression through the BRCA2 promoter .	target	1
18357	10962008	5601;5590	SAPK;PKCzeta	Co-immunoprecipitation studies reveal that ceramide induces the ***association*** of ***SAPK*** with ***PKCzeta*** , but not with PKCepsilon .	parallel	0
18358	10962008	5590;4214	PKCzeta;MEKK1	In addition , ceramide treatment induces ***PKCzeta*** ***association*** with phosphorylated SEK and ***MEKK1*** , elements of the SAPK signaling complex .	parallel	0
18359	10962009	6768;3082	matriptase;hepatocyte growth factor	***Activation*** of ***hepatocyte growth factor*** and urokinase/plasminogen activator by ***matriptase*** , an epithelial membrane serine protease .	positive	1
18360	10962015	3784;3753	KvLQT1;MinK	Chimeras between MinK and beta1 could only modulate KvLQT1 if they contained both the MinK transmembrane domain and COOH terminus , suggesting that the MinK COOH terminus alone is not sufficient for KvLQT1 modulation , and requires an additional , possibly associative ***interaction*** between the ***MinK*** transmembrane domain and ***KvLQT1*** .	parallel	1
18361	10962015	3753;3784	MinK;KvLQT1	***MinK*** , a 129 amino acid protein containing one transmembrane-spanning domain ***modulates*** ***KvLQT1*** , greatly slowing activation , increasing current amplitude , and removing inactivation .	target	0
18362	10962024	10758;4790	Act1;NF-kappaB	Use of an NF-kappaB-dependent selectable marker facilitated the isolation of a cell line containing a cDNA encoding ***Act1*** , an ***NF-kappaB*** ***activator*** .	positive	1
18363	10962024	10758;5599	Act1;JNK	***Act1*** also ***activates*** ***JNK*** , suggesting that it might be part of a multifunctional complex involved in the activation of both NF-kappaB and JNK .	positive	1
18364	10962024	10758;4790	Act1;NF-kappaB	***Act1*** fails to ***activate*** ***NF-kappaB*** in an IL-1-unresponsive mutant cell line in which all known signaling components are present , suggesting that it interacts with an unknown component in IL-1 signaling .	positive	1
18365	10962033	10758;5599	CIKS;JNK	When ectopically expressed , ***CIKS*** ***stimulates*** IKK and ***SAPK/JNK*** kinases and it transactivates an NF-kappaB-dependent reporter .	positive	0
18366	10962200	847;7124	catalase;tumor necrosis factor alpha	The same concentration of ***catalase*** that suppressed MMP-9 elaboration also ***inhibited*** the production of ***tumor necrosis factor alpha*** .	negative	1
18367	10962206	5599;5782	JNK1;PTP-PEST	Expression of a dominant-negative mutant of c-Jun NH ( 2 ) - terminal kinase ( ***JNK1*** ) ***suppressed*** glucose deprivation-induced JNK1 activation , ***PTP-PEST*** gene expression , and alteration of paxillin .	negative	1
18368	10962276	999;6352	E-cadherin;RANTES	We discuss the invasion-related molecular ***interactions*** of ***E-cadherin*** , integrins , matrix metalloproteinases and the chemokine receptor ***RANTES*** .	parallel	1
18369	10962556	23368;5781	p85;SHP2	SIRPalpha1 overexpression also reduced the EGF-induced ***association*** between ***SHP2*** and the ***p85*** regulatory subunit of PI3-K .	parallel	0
18370	10962559	9181;27342	GEF;Rap 1	Thus , cAMP activation of Rap 1 in HL-60 cells is likely through a cAMP-regulated guanine nucleotide exchange factor ( cAMP-GEF ) and since cAMP does not activate Rap 1 in the variant cells , the data suggest that full post-translational processing of Rap 1 is necessary for ***cAMP-GEF*** ***activation*** of ***Rap 1*** .	positive	1
18371	10962562	672;1647	BRCA1;GADD45	Taken together , these results demonstrate that the mechanism by which ***BRCA1*** ***induces*** ***GADD45*** is mainly through the transactivation of the GADD45 promoter , further demonstrating the evidence that GADD45 acts as one of the BRCA1-regulated genes .	target	1
18372	10962562	672;1647	BRCA1;GADD45	***BRCA1*** ***activation*** of the ***GADD45*** promoter .	positive	1
18373	10962562	672;1647	BRCA1;GADD45	Overexpression of ***BRCA1*** ***induces*** ***GADD45*** , a p53-regulated and stress-inducible gene .	target	1
18374	10962562	672;1647	BRCA1;GADD45	However , the molecular mechanism by which ***BRCA1*** ***induces*** the expression ***GADD45*** remains unclear .	target	1
18375	10962562	672;1647	BRCA1;GADD45	In contrast , both the tumor-derived BRCA1 mutants ( p1749R and Y1853insA ) and truncated BRCA1 mutant protein ( Delta500 - 1863 BRCA1 ) , which lack transactivation activity , were unable to activate the GADD45 promoter , indicating that the ***BRCA1-mediated*** ***activation*** of the ***GADD45*** promoter requires normal transcriptional properties of BRCA1 .	positive	1
18376	10962562	672;1647	BRCA1;GADD45	Expression of the human papillomavirus E6 and the dominant-negative mutant p53 proteins had no effect on the induction of the GADD45 promoter by BRCA1 , suggesting that ***activation*** of the ***GADD45*** promoter by ***BRCA1*** is independent of cellular p53 function .	positive	1
18377	10962562	672;1647	BRCA1;GADD45	Expression of the human papillomavirus E6 and the dominant-negative mutant p53 proteins had no effect on the ***induction*** of the ***GADD45*** promoter by ***BRCA1*** , suggesting that activation of the GADD45 promoter by BRCA1 is independent of cellular p53 function .	target	1
18378	10962563	1398;2549	Crk;Gab1	We have previously shown that the ***interaction*** between phosphorylated ***Gab1*** and the adaptor protein ***Crk*** mediates activation of the JNK pathway downstream of Met .	parallel	1
18379	10962574	7040;1026	TGF-beta1;p21Cip1	Smad4 mediates ***TGF-beta1-induced*** ***up-regulation*** of ***p21Cip1*** and growth arrest in MCA3D cells .	positive	1
18380	10962574	4089;1026	Smad4;p21Cip1	***Smad4*** ***mediates*** TGF-beta1-induced up-regulation of ***p21Cip1*** and growth arrest in MCA3D cells .	target	0
18381	10962574	7040;5594	TGF-beta1;Erk	***TGF-beta1*** ***activates*** ***Ras/Erk*** signalling activity in both cell lines .	positive	1
18382	10962574	7040;1026	TGF-beta1;p21Cip1	PD098059 , a specific inhibitor of MEK , disminishes TGF-beta1-induced p21Cip1 levels in PDV but not in MCA3D cells , suggesting an involvement of Erk in ***up-regulation*** of ***p21Cip1*** by ***TGF-beta1*** in PDV cells .	positive	1
18383	10962576	1440;660	G-CSF;Bmx	The ***Bmx*** tyrosine kinase is ***activated*** by IL-3 and ***G-CSF*** in a PI-3K dependent manner .	positive	1
18384	10962576	3562;660	IL-3;Bmx	The ***Bmx*** tyrosine kinase is ***activated*** by ***IL-3*** and G-CSF in a PI-3K dependent manner .	positive	1
18385	10962576	1440;660	G-CSF;Bmx	Here we show that ***Bmx*** is catalytically ***activated*** by interleukin-3 ( IL-3 ) and granulocyte-colony stimulating factor ( ***G-CSF*** ) receptors .	positive	1
18386	10962576	3562;660	interleukin-3;Bmx	Here we show that ***Bmx*** is catalytically ***activated*** by ***interleukin-3*** ( IL-3 ) and granulocyte-colony stimulating factor ( G-CSF ) receptors .	positive	1
18387	10963053	3479;207	IGF-I;Akt	***IGF-I*** ***stimulated*** the phosphorylation and activation of ***Akt*** in a time - and concentration-dependent manner .	positive	0
18388	10963053	3479;207	IGF-I;Akt	These data suggest that ***IGF-I-induced*** ***phosphorylation*** of ***Akt*** is mediated through PI 3-kinase and that inactivation of this pathway results in granulosa cell apoptosis .	target	1
18389	10963054	2691;4254	GHRH;SCF	***GHRH-RP*** and p75-92NH2 , similar to GHRH , ***induce*** ***SCF*** expression , at least in part , via the activation of the protein kinase A/cyclic adenosine monophosphate intracellular signaling pathway .	target	1
18390	10963376	4193;7157	MDM2;Tp53	***MDM2*** overexpression also ***correlated*** with ***Tp53*** overexpression ( P < 0.03 ) and Ki-67 labeling index ( P < 0.03 ) .	parallel	0
18391	10963670	7320;56852	UBC2;Rad18	***UBC2*** ( Rad6 ) is ***complexed*** with the ring finger DNA-binding protein ***Rad18*** , and we find that Ho is stabilized in Rad18 mutants .	parallel	1
18392	10963806	3456;4790	interferon-beta;P50	Human ***interferon-beta*** inhibits binding of HIV-1 gp41 to lymphocyte and monocyte cells and ***binds*** the potential receptor protein ***P50*** for HIV-1 gp41 .	parallel	1
18393	10963806	3456;4790	IFN-beta;P50	In ELISA-assay , the human ***IFN-beta*** , but not IFN-alpha , could ***bind*** to ***P50*** which was identified as a potential cellular receptor protein for gp41-binding .	parallel	1
18394	10963806	4790;3456	P50;IFN-beta	By the affinity capillary electrophoresis ( ACE ) analysis , formation of stable ******IFN-beta-P50****** ***complex*** was observed .	parallel	1
18395	10963806	3456;4790	IFN-beta;P50	These results indicate that ***IFN-beta*** ***binds*** the potential receptor protein ***P50*** .	parallel	1
18396	10963846	7039;1956	transforming growth factor-alpha;epidermal growth factor receptor	The interaction of ***epidermal growth factor receptor*** ( EGFR ) and its ***ligand*** ***transforming growth factor-alpha*** ( TGF-alpha ) leads to an autocrine activation of the ras signaling pathway and putatively its oncogenic activity .	parallel	1
18397	10963846	7039;1956	transforming growth factor-alpha;epidermal growth factor receptor	The ***interaction*** of ***epidermal growth factor receptor*** ( EGFR ) and its ligand ***transforming growth factor-alpha*** ( TGF-alpha ) leads to an autocrine activation of the ras signaling pathway and putatively its oncogenic activity .	parallel	1
18398	10964085	1026;595	p21;Cyclin D1	However , higher levels of p27 , and to a lesser extent ***p21*** , were ***associated*** with reduced cytoplasmic ***Cyclin D1*** protein ( p = 0.029 and p = 0.054 , respectively ) .	parallel	0
18399	10964107	5742;4790	cyclooxygenase-1;NF-kappaB	The induction of ***cyclooxygenase-1*** by a tobacco carcinogen in U937 human macrophages is ***correlated*** to the activation of ***NF-kappaB*** .	parallel	0
18400	10964107	4790;5742	NF-kappaB;COX-1	These data suggest that ROS , generated during pulmonary metabolism of NNK could act as signal transduction messengers and activate ***NF-kappaB*** , which will subsequently ***induce*** ***COX-1*** activity and increase PGE ( 2 ) synthesis .	target	1
18401	10964324	3732;7157	KAI1;p53	It also has been reported that the ***KAI1*** gene is ***related*** to the tumor suppressor gene ***p53*** .	parallel	0
18402	10964417	3700;7852	gp120;chemokine receptor	The fusion of the human immunodeficiency virus ( HIV ) with the target cell was assisted by the ***interaction*** between the viral envelope glycoprotein HIV-1 ***gp120*** and a ***chemokine receptor*** .	parallel	1
18403	10964473	652;2719	Bmp4;glypican-3	This previously unknown ***link*** between ***glypican-3*** and ***Bmp4*** function provides evidence of a role for glypicans in vertebrate limb patterning and skeletal development and suggests a mechanism for the skeletal defects seen in SGBS .	parallel	0
18404	10964504	1950;5906	EGF;Rap1	We demonstrate that NGF and ***EGF*** ***induce*** ***Rap1*** activation in PC12-Shb cells , while FGF-2 fails to do so .	target	1
18405	10964568	8772;841	FADD;caspase-8	The properties of the FADD-DD structure are discussed with respect to previously reported mutagenesis data and emerging models for FasL-induced ***FADD*** ***recruitment*** to Fas and ***caspase-8*** activation .	target	0
18406	10964568	8772;355	FADD;Fas	The properties of the FADD-DD structure are discussed with respect to previously reported mutagenesis data and emerging models for FasL-induced ***FADD*** ***recruitment*** to ***Fas*** and caspase-8 activation .	target	0
18407	10964611	6647;7157	SOD1;p53	We further demonstrated that ectopic expression of the G86R mutant ***SOD1*** in PC12 cells ***enhanced*** both ***p53*** expression and phosphorylation , leading to transcriptional stimulation of p53-responsive genes .	positive	0
18408	10964681	3479;3488	IGF-I;IGFBP-5	***IGF-I*** ***increased*** ***IGFBP-5*** nuclear transcripts by reverse transcription-polymerase chain reaction ( RT-PCR ) , suggesting that IGF-I acts at least partially by increasing IGFBP-5 mRNA transcription .	positive	0
18409	10964689	4804;627	p75NTR;neurotrophin	In the present study , we assessed the temporal change in gene expression of neurotrophins , NGF , BDNF , and NT-3 , and their receptors , low affinity ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) and Trks A , B , and C , by RT-PCR technique in the liver of rats treated with lead nitrate ( LN ; 0.1 mmol/kg body weight ) , an inducer of liver hyperplasia .	parallel	1
18410	10964699	846;5599	calcium-sensing receptor;JNK	The ***calcium-sensing receptor*** ***stimulates*** ***JNK*** in MDCK cells .	positive	0
18411	10964771	3458;634	IFN-gamma;Bgp1	Besides the evidence that ***IFN-gamma*** may ***modulate*** the expression of the ***Bgp1*** ( a ) isoform of carcinoembryonic antigen family , these data show that IFN-gamma , which induces resistance against MHV3 infection , may be involved in the down-regulation of the main viral receptor expression , a key step forward in our understanding of the molecular basis of resistance against virus infection .	target	0
18412	10964835	185;183	AT1R;angiotensin II	OBJECTIVE : To determine the role of angiotensin converting enzyme ( ACE ) and ***angiotensin II*** type 1 ***receptor*** ( ***AT1R*** ) polymorphisms in the pathogenesis of nonartertic anterior ischemic optic neuropathy ( NAION ) .	parallel	1
18413	10964907	22859;22941	CIRL1;ProSAP1	The specificity of this interaction has been verified by in vivo experiments using solubilized rat brain membrane fractions and ProSAP1 antibodies ; only ***CIRL1*** , but not CIRL2 , was ***co-immunoprecipitated*** with ***ProSAP1*** .	parallel	1
18414	10964914	961;140885	CD47;macrophage fusion receptor	***CD47*** , a ***ligand*** for the ***macrophage fusion receptor*** , participates in macrophage multinucleation .	parallel	1
18415	10964914	961;140885	CD47;MFR	The recent finding that ***IAP/CD47*** acts as a ***ligand*** for ***MFR*** led us to hypothesize that it interacts with CD47 at the onset of cell-cell fusion .	parallel	1
18416	10964914	961;140885	CD47;MFR	A glutathione S-transferase ***CD47*** fusion protein engineered to contain the extracellular domain of CD47 , binds macrophages , ***associates*** with ***MFR*** , and prevents multinucleation .	parallel	0
18417	10964914	961;140885	CD47;MFR	Of the nine monoclonal antibodies raised against the extracellular domain of CD47 , three block fusion , as well as ******MFR-CD47****** ***interaction*** , whereas the others have no effect .	parallel	1
18418	10964928	3309;9159	BiP;lymphoma proprotein convertase	***Binding*** of ***BiP*** to the processing enzyme ***lymphoma proprotein convertase*** prevents aggregation , but slows down maturation .	parallel	1
18419	10964928	9159;3309	LPC;BiP	Using a reducible cross-linker , we found that glycosylated ***pro-LPC*** is ***associated*** with the molecular chaperone ***BiP*** .	parallel	0
18420	10964928	3309;9159	BiP;LPC	***BiP*** is ***associated*** mainly with non-aggregated pro-LPC and ***pro-LPC*** dimers and trimers , suggesting that BiP prevents aggregation .	parallel	0
18421	10964928	3309;9159	BiP;LPC	Taken together , these results suggest that ***binding*** of ***BiP*** to ***pro-LPC*** prevents aggregation , but results in slower maturation .	parallel	1
18422	10964933	1270;7432	CNTF;vasoactive intestinal peptide	The neuropoietic cytokine ciliary neurotrophic factor ( ***CNTF*** ) potently ***induces*** transcription of the ***vasoactive intestinal peptide*** ( VIP ) gene through a 180-base pair ( bp ) cytokine response element ( CyRE ) in the VIP promoter .	target	1
18423	10964933	1270;7432	CNTF;VIP	We have previously shown that CNTF induction of STAT and AP-1 protein binding within the CyRE is necessary to mediate ***CNTF*** ***induction*** of ***VIP*** gene transcription .	target	1
18424	10964933	1270;3725	CNTF;AP-1	We have previously shown that ***CNTF*** ***induction*** of STAT and ***AP-1*** protein binding within the CyRE is necessary to mediate CNTF induction of VIP gene transcription .	target	1
18425	10964933	1270;7432	CNTF;VIP	Thus , we have identified a protein complex binding to a novel DNA sequence that is necessary for full ***CNTF*** ***induction*** of ***VIP*** gene transcription .	target	1
18426	10965038	1603;4170	DAD1;Mcl-1	Consistently , ***DAD1*** ***binds*** well to ***Mcl-1*** in COS cells when overexpressed .	parallel	1
18427	10965042	4633;6197	Regulatory light chain of myosin;ribosomal S6 kinase (RSK)-2	***Regulatory light chain of myosin*** II ( MRLC ) was identified as a novel ***substrate*** of p90 ***ribosomal S6 kinase (RSK)-2*** , a Ser/Thr protein kinase which is phosphorylated and activated by mitogen-activated protein kinase ( MAPK ) in vitro and in vivo .	parallel	1
18428	10965053	2516;190	Ad4BP;DAX-1	Even though the ***Ad4BP-dependent*** transcriptional ***regulation*** of the ***DAX-1*** gene has been reported , DAX-1 did not affect the transcriptional activity of the hFTZ-F1 gene in our study .	target	1
18429	10965088	1401;3082	CRP;HGF	Both CRP and SAA levels peaked on day 3 , and the ***CRP*** level on day 3 ***correlate*** with both VEGF and ***HGF*** levels on day 7 .	parallel	0
18430	10965088	1401;7422	CRP;VEGF	Both CRP and SAA levels peaked on day 3 , and the ***CRP*** level on day 3 ***correlate*** with both ***VEGF*** and HGF levels on day 7 .	parallel	0
18431	10965142	23216;5236	TBC1D1;Pgm1	Segregation analysis of a TBC1D1 RFLP in two independent mouse RI ( recombinant inbred ) lines reveals that mouse ***TBC1D1*** is closely ***linked*** to ***Pgm1*** on chromosome 5 .	parallel	0
18432	10965499	2100;2099	ER beta;ER alpha	Indeed , several observations seem to indicate that they may even have opposite effects so that ***ER beta*** ***diminishes*** the activity of ***ER alpha*** .	negative	0
18433	10965500	3725;1977	Jun;CBP	ER binds to the coactivators , ***CBP*** and GRIP1 , that have been ***recruited*** by ***Jun/Fos*** and through this contact ' triggers ' these coactivators into full activity .	target	0
18434	10965883	2247;3485	Fibroblast growth factor-2;insulin-like growth factor binding protein-2	***Fibroblast growth factor-2*** ***inhibits*** the maturation of pro-insulin-like growth factor-II ( Pro-IGF-II ) and the expression of ***insulin-like growth factor binding protein-2*** ( IGFBP-2 ) in the human adrenocortical tumor cell line NCI-H295R .	negative	1
18435	10965886	3553;3484	IL-1beta;IGFBP-1	Our data demonstrate that the MAP kinase signal transduction pathway plays an important role in the ***regulation*** of ***IGFBP-1*** synthesis by ***IL-1beta*** .	target	1
18436	10965886	3553;5594	IL-1beta;ERK-1 and -2	We show that ***IL-1beta*** ***stimulates*** the phosphorylation of ***ERK-1 and -2*** in a time - and dose-dependent manner .	positive	0
18437	10965886	1385;6195	CREB;RSK-1	The transcription factor ***CREB*** , a potential ***substrate*** of both protein kinase A ( PKA ) and ***RSK-1*** , is phosphorylated in response to IL-1beta and cAMP in HepG2 cells .	parallel	1
18438	10965892	2984;2981	GC-C;uroguanylin	These observations suggest that GC-C 's activity may be posttranslationally regulated , demonstrate that the distribution of ***GC-C*** is appropriate to ***mediate*** the actions of both ***uroguanylin*** and guanylin , and help to refine current hypotheses about the physiological role ( s ) of these peptides .	target	0
18439	10965904	4852;2796	neuropeptide Y;GnRH	***neuropeptide Y*** ( NPY ) ***stimulates*** the release of ***GnRH*** in an estrogen ( E2 ) - dependent manner , which is important in generating preovulatory GnRH surges .	positive	0
18440	10965904	4852;2796	NPY;GnRH	In parallel experiments , the same in vivo PR antagonist treatments also blocked ***NPY*** ***stimulation*** of ***GnRH*** release in vitro .	positive	0
18441	10965913	2099;4790	ERalpha;NF-kappaB	Coexpression of the transcription coactivator CREB binding protein ( CBP ) , but not steroid receptor coactivator 1a , reversed the ***ERalpha-mediated*** ***inhibition*** of ***NF-kappaB*** activity .	negative	1
18442	10965913	2099;1387	ERalpha;CBP	Mammalian two-hybrid experiments also revealed that ligand-bound ***ERalpha*** can ***interact*** functionally with ***CBP-NF-kappaB*** complexes .	parallel	1
18443	10965913	2099;4790	ERalpha;NF-kappaB	Mammalian two-hybrid experiments also revealed that ligand-bound ***ERalpha*** can ***interact*** functionally with ***CBP-NF-kappaB*** complexes .	parallel	1
18444	10965913	1387;4790	CBP;NF-kappaB	Mammalian two-hybrid experiments also revealed that ligand-bound ERalpha can interact functionally with ******CBP-NF-kappaB****** ***complexes*** .	parallel	1
18445	10966114	7332;867	UbcH7;c-Cbl	Structure of a ******c-Cbl-UbcH7****** ***complex*** : RING domain function in ubiquitin-protein ligases .	parallel	1
18446	10966616	9244;23529	CLF;CLC	***CLF*** ***associates*** with ***CLC*** to form a functional heteromeric ligand for the CNTF receptor complex .	parallel	0
18447	10966616	23529;9244	CLC;CLF	The ******CLF/CLC****** ***complex*** activated gp130 , LIFR and signal transducer and activator of transcription 3 ( STAT3 ) and supported motor neuron survival .	parallel	1
18448	10966616	9244;23529	CLF;CLC	Our results indicate that the ******CLF/CLC****** ***complex*** is a second ligand for CNTFR with potentially important implications in nervous system development .	parallel	1
18449	10966616	23529;1271	CLC;CNTFR	Our results indicate that the ***CLF/CLC*** complex is a second ***ligand*** for ***CNTFR*** with potentially important implications in nervous system development .	parallel	1
18450	10966616	9244;1271	CLF;CNTFR	Our results indicate that the ***CLF/CLC*** complex is a second ***ligand*** for ***CNTFR*** with potentially important implications in nervous system development .	parallel	1
18451	10966653	324;1499	APC;beta-catenin	***Interactions*** between ***beta-catenin*** and LEF-1/TCF , ***APC*** and conductin/axin are essential for wnt-controlled stabilization of beta-catenin and transcriptional activation .	parallel	1
18452	10966653	8313;324	conductin;APC	***Interactions*** between beta-catenin and LEF-1/TCF , ***APC*** and ***conductin/axin*** are essential for wnt-controlled stabilization of beta-catenin and transcriptional activation .	parallel	1
18453	10966653	8313;1499	conductin;beta-catenin	***Interactions*** between ***beta-catenin*** and LEF-1/TCF , APC and ***conductin/axin*** are essential for wnt-controlled stabilization of beta-catenin and transcriptional activation .	parallel	1
18454	10966653	8313;51176	conductin;LEF-1	***Interactions*** between beta-catenin and ***LEF-1/TCF*** , APC and ***conductin/axin*** are essential for wnt-controlled stabilization of beta-catenin and transcriptional activation .	parallel	1
18455	10966653	51176;324	LEF-1;APC	***Interactions*** between beta-catenin and ***LEF-1/TCF*** , ***APC*** and conductin/axin are essential for wnt-controlled stabilization of beta-catenin and transcriptional activation .	parallel	1
18456	10966653	51176;1499	LEF-1;beta-catenin	***Interactions*** between ***beta-catenin*** and ***LEF-1/TCF*** , APC and conductin/axin are essential for wnt-controlled stabilization of beta-catenin and transcriptional activation .	parallel	1
18457	10966653	8313;1499	conductin;beta-catenin	Moreover , we demonstrate that ***conductin/axin*** ***binding*** to ***beta-catenin*** is essential for beta-catenin degradation , and that APC acts as a cofactor of conductin/axin in this process .	parallel	1
18458	10966653	324;8313	APC;conductin	***Binding*** of ***APC*** to ***conductin/axin*** activates the latter and occurs between their SAMP and RGS domains , respectively .	parallel	1
18459	10966812	7018;7037	transferrin;transferrin receptor	Both antibodies were able to induce additional functional effects besides triggering endocytosis : F5 scFv induces downstream signaling through the ErbB2 receptor and H7 prevents ***transferrin*** ***binding*** to the ***transferrin receptor*** and inhibits cell growth .	parallel	1
18460	10966919	7430;6550	ezrin;NHE3	This article reviews studies on the ***regulation*** of ***NHE3*** by NHERF , PKA , and ***ezrin*** and introduces the concept of regulation of renal transporters by signal complexes .	target	1
18461	10966981	356;355	Fas ligand;Fas	Both ***Fas*** ( APO-1 , CD95 ) , an apoptosis-inducing receptor , and its ***ligand*** , ***Fas ligand*** ( FasL , CD95L ) , have been localized to the ovary .	parallel	1
18462	10967029	3565;959	IL-4;IgM	Earlier studies have shown that ***IL-4*** ***enhances*** ***IgM*** secretion upon stimulation with alpha delta-dex plus IL-5 and induces IgG1 isotype-switching , without altering the proliferative response to alpha delta-dex .	positive	0
18463	10967029	3458;3565	IFN-gamma;IL-4	The stimulatory effect of ***IL-4*** required a minimum of 4 h of preincubation and could be ***inhibited*** by the addition of ***IFN-gamma*** .	negative	1
18464	10967068	4233;3082	c-Met;HGF	METHODS : Sections of epiretinal membranes were stained immunohistochemically for cytokeratins , to identify HRPE cells , and for ***HGF/SF*** ***receptor*** ( ***c-Met*** ) .	parallel	1
18465	10967094	57381;998	TCL;Cdc42	Using the yeast two-hybrid system and GST pull-down assays , we show that GTP-bound but not GDP-bound ***TCL*** protein directly ***interacts*** with ***Cdc42/Rac*** interacting binding domains , such as those found in PAK and WASP .	parallel	1
18466	10967094	57381;207	TCL;Rac	Using the yeast two-hybrid system and GST pull-down assays , we show that GTP-bound but not GDP-bound ***TCL*** protein directly ***interacts*** with ***Cdc42/Rac*** interacting binding domains , such as those found in PAK and WASP .	parallel	1
18467	10967094	998;57381	Cdc42;TCL	Interestingly , ***TCL*** morphogenic activity is ***blocked*** by dominant negative Rac1 and ***Cdc42*** mutants , suggesting a cross-talk between these three Rho GTPases .	positive	0
18468	10967094	5879;57381	Rac1;TCL	Interestingly , ***TCL*** morphogenic activity is ***blocked*** by dominant negative ***Rac1*** and Cdc42 mutants , suggesting a cross-talk between these three Rho GTPases .	negative	0
18469	10967106	4615;3458	MyD88;interferon-gamma	Dominant negative ***MyD88*** proteins ***inhibit*** interleukin-1beta / ***interferon-gamma*** - mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells .	negative	1
18470	10967114	5058;7422	Pak1;VEGF	Conversely , kinase-active T423E ***Pak1*** ***promotes*** the expression and secretion of ***VEGF*** .	positive	0
18471	10967114	5058;7422	Pak1;VEGF	Because the activation of Pak1 and VEGF expression are positively regulated by heregulin-beta1 , we hypothesized that ***Pak1*** ***regulates*** ***VEGF*** expression , and hence explored the role of Pak1 in angiogenesis .	target	1
18472	10967118	5054;4314	PAI-1;MMP-3	Biospecific interaction analysis indicated comparable ***binding*** of active , stable , and substrate ***PAI-1*** to both proMMP-3 and ***MMP-3*** ( K ( A ) of 12-22 x 10 ( 6 ) m ( -1 ) ) , whereas binding of latent PAI-1 occurred with lower affinity ( 1.7-2 .3 x 10 ( 6 ) m ( -1 ) ) .	parallel	1
18473	10967118	5054;7448	PAI-1;vitronectin	Stable ***PAI-1*** ***bound*** to ***vitronectin*** was cleaved and inactivated by MMP-3 in a manner comparable with that of free PAI-1 ; however , the cleaved protein did not bind to vitronectin .	parallel	1
18474	10967118	4314;5054	MMP-3;PAI-1	***Cleavage*** and inactivation of ***PAI-1*** by ***MMP-3*** may thus constitute a mechanism decreasing the antiproteolytic activity of PAI-1 and impairing the potential inhibitory effect of vitronectin-bound PAI-1 on cell adhesion and/or migration .	target	1
18475	10967121	4691;7150	nucleolin;topoisomerase I	In previous work we showed that human ***nucleolin*** ***associates*** with the N-terminal region of human ***topoisomerase I*** ( Top1 ) .	parallel	0
18476	10967121	4691;7150	nucleolin;topoisomerase I	We also show that the Saccharomyces cerevisiae ***nucleolin*** ortholog , Nsr1p , physically ***interacts*** with yeast ***topoisomerase I*** , yTop1p .	parallel	1
18477	10967123	3479;1026	IGF-1;p21	***IGF-1*** ***increased*** the protein level of ***p21*** and the luciferase activity of the p21 promoter , whereas it only reduced the protein level of p27 without affecting p27 promoter activity .	positive	0
18478	10967123	3479;1026	IGF-1;p21	These effects of both mitogens were also observed at the level of association of both cyclin-dependent kinase inhibitors with CDK2 suggesting that ***IGF-1*** and E2 ***affect*** the activity of both ***p21*** and p27 .	target	0
18479	10967123	3479;3429	IGF-1;p27	These effects of both mitogens were also observed at the level of association of both cyclin-dependent kinase inhibitors with CDK2 suggesting that ***IGF-1*** and E2 ***affect*** the activity of both p21 and ***p27*** .	target	0
18480	10967123	3479;1026	IGF-1;p21	Moreover , ***IGF-1*** and E2 ***regulate*** the expression of ***p21*** and p27 and their association with CDK2 differently .	target	1
18481	10967123	3479;3429	IGF-1;p27	Moreover , ***IGF-1*** and E2 ***regulate*** the expression of p21 and ***p27*** and their association with CDK2 differently .	target	1
18482	10967128	10948;2064	CAB1;ERBB-2	In many cases of human gastric cancer , a proto-oncogene ERBB-2 is co-amplified with ***CAB1*** genes physically ***linked*** to ***ERBB-2*** , and both genes are over-expressed .	parallel	0
18483	10967546	5741;4322	PTH;collagenase-3	We observed that parathyroid hormone ( ***PTH*** ) ***induces*** ***collagenase-3*** expression only in UMR cells but not in BC1 ( which express collagenase-3 constitutively ) or ROS and NIH3T3 cells .	target	1
18484	10967546	5741;4322	PTH;collagenase-3	Since Jun B is inhibitory of Fos and Jun in the regulation of the rat collagenase-3 gene in UMR cells , it is likely that high levels of Jun B prevent ***PTH*** ***stimulation*** of ***collagenase-3*** in ROS cells .	positive	0
18485	10967549	8777;1464	MUPP1;NG2	The multi-PDZ domain protein ***MUPP1*** is a cytoplasmic ***ligand*** for the membrane-spanning proteoglycan ***NG2*** .	parallel	1
18486	10967549	51388;1464	NIP-7;NG2	NIP-2 and ***NIP-7*** GST fusion proteins effectively ***recognize*** ***NG2*** in pull-down assays , demonstrating the ability of these polypeptide segments to interact with the intact proteoglycan .	target	1
18487	10967549	8777;1464	MUPP1;NG2	The existence of an ******NG2/MUPP1****** ***interaction*** in situ is demonstrated by the ability of NG2 antibodies to co-immunoprecipitate both NG2 and MUPP1 from detergent extracts of cells expressing the two molecules .	parallel	1
18488	10967554	7421;6714	VDR;Src	Activation of Src kinase in skeletal muscle cells by 1 , 1,25 - ( OH ( 2 ) ) - vitamin D ( 3 ) correlates with tyrosine phosphorylation of the vitamin D receptor ( VDR ) and ******VDR-Src****** ***interaction*** .	parallel	1
18489	10967554	6714;7421	Src;VDR	In agreement with Src being a SH2-domain containing protein involved in recognition of tyrosine-phosphorylated targets , immunoprecipitation with anti-Src antibody under native conditions followed by blotting with anti-VDR antibody , or using the antibodies in inverse order , showed that the VDR co-precipitates with Src , thus indicating the existence of a ******VDR/Src****** ***complex*** .	parallel	1
18490	10967923	1508;2159	cysteine protease;coagulation factor X	This procoagulant is ***cysteine protease*** which directly ***activates*** ***coagulation factor X*** to factor Xa .	positive	1
18491	10968204	133;551	adrenomedullin;AVP	These results indicate that ***adrenomedullin*** ***inhibits*** the ***AVP*** activation of MAP kinase mediated through cAMP in glomerular mesangial cells and that the site of action of adrenomedullin is behind the site of activation of protein kinase C.	negative	1
18492	10968913	2152;7035	Tissue factor;tissue factor pathway inhibitor	Potential mechanisms contributing to upregulation of the Tissue factor pathway include increased expression of ***Tissue factor*** due to increased transcription , increased functional activity of Tissue factor molecules due to de-encryption and ***decreased*** activity of ***tissue factor pathway inhibitor*** .	negative	0
18493	10968999	3784;3753	KvLQT1;MinK	I ( Ks ) channels are heteromeric ***complexes*** of pore-forming ***KvLQT1*** subunits and pore-associated ***MinK*** subunits .	parallel	1
18494	10969034	7124;7010	Tumor necrosis factor-alpha;Tie2	***Tumor necrosis factor-alpha*** ***induced*** ***Tie2*** in a time - and dose-dependent fashion in all 3 EC types ( HUVEC , 2.3-fold ; HMEC-1 , 2 .	target	1
18495	10969042	59272;3827	ACE2;bradykinin	***ACE2*** can also ***cleave*** des-Arg ***bradykinin*** and neurotensin but not bradykinin or 15 other vasoactive and hormonal peptides tested .	target	1
18496	10969042	59272;4922	ACE2;neurotensin	***ACE2*** can also ***cleave*** des-Arg bradykinin and ***neurotensin*** but not bradykinin or 15 other vasoactive and hormonal peptides tested .	target	1
18497	10969074	4792;4790	IkappaBalpha;NF-kappaB	***IkappaBalpha*** ***inhibits*** the transcriptional activity of ***NF-kappaB*** both in the cytoplasm by preventing the nuclear translocation of NF-kappaB and in the nucleus where it dissociates NF-kappaB from DNA and transports it back to the cytoplasm .	negative	1
18498	10969074	4792;4790	IkappaBalpha;NF-kappaB	Cytoplasmic localization of inactive ******NF-kappaB/IkappaBalpha****** ***complexes*** is controlled by mutual masking of nuclear import sequences of NF-kappaB p65 and IkappaBalpha and active CRM1-mediated nuclear export .	parallel	1
18499	10969074	4792;4790	IkappaBalpha;NF-kappaB	Here , we describe an additional mechanism accounting for the cytoplasmic anchoring of IkappaBalpha or ******NF-kappaB/IkappaBalpha****** ***complexes*** .	parallel	1
18500	10969074	8548;4792	cytoplasmic protein;IkappaBalpha	The N-terminal domain of IkappaBalpha contains a sequence responsible for the cytoplasmic retention of IkappaBalpha that is specifically recognized by G3BP2 , a ***cytoplasmic protein*** that ***interacts*** with both ***IkappaBalpha*** and IkappaBalpha/NF-kappaB complexes .	parallel	1
18501	10969074	8548;4790	cytoplasmic protein;NF-kappaB	The N-terminal domain of IkappaBalpha contains a sequence responsible for the cytoplasmic retention of IkappaBalpha that is specifically recognized by G3BP2 , a ***cytoplasmic protein*** that ***interacts*** with both IkappaBalpha and ***IkappaBalpha/NF-kappaB*** complexes .	parallel	1
18502	10969074	4790;4792	NF-kappaB;IkappaBalpha	The N-terminal domain of IkappaBalpha contains a sequence responsible for the cytoplasmic retention of IkappaBalpha that is specifically recognized by G3BP2 , a cytoplasmic protein that interacts with both IkappaBalpha and ******IkappaBalpha/NF-kappaB****** ***complexes*** .	parallel	1
18503	10969074	9908;4792	G3BP2;IkappaBalpha	The N-terminal domain of IkappaBalpha contains a sequence responsible for the cytoplasmic retention of ***IkappaBalpha*** that is specifically ***recognized*** by ***G3BP2*** , a cytoplasmic protein that interacts with both IkappaBalpha and IkappaBalpha/NF-kappaB complexes .	target	1
18504	10969074	4792;4790	IkappaBalpha;NF-kappaB	Overexpression of G3BP2 directly promotes retention of IkappaBalpha in the cytoplasm , indicating that subcellular distribution of IkappaBalpha and ******NF-kappaB/IkappaBalpha****** ***complexes*** likely results from a equilibrium between nuclear import , nuclear export , and cytoplasmic retention .	parallel	1
18505	10969074	9908;4792	G3BP2;IkappaBalpha	Overexpression of ***G3BP2*** directly ***promotes*** retention of ***IkappaBalpha*** in the cytoplasm , indicating that subcellular distribution of IkappaBalpha and NF-kappaB/IkappaBalpha complexes likely results from a equilibrium between nuclear import , nuclear export , and cytoplasmic retention .	positive	0
18506	10969078	1523;7082	p110;ZO-1	LY294002 , an inhibitor of the p110 catalytic subunit of PI3K , and a dominant-negative mutant of Akt blocked the delocalization of ZO-1 induced by TGFbeta1 , whereas transfection of constitutively active ***p110*** ***induced*** loss of ***ZO-1*** from tight junctions .	target	1
18507	10969078	7040;4087	TGFbeta;Smad2	In addition , LY294002 blocked ***TGFbeta-mediated*** C-terminal ***phosphorylation*** of ***Smad2*** .	target	1
18508	10969078	7040;207	TGFbeta;Akt	Dominant-negative RhoA inhibited ***TGFbeta-induced*** ***phosphorylation*** of ***Akt*** at Ser-473 , whereas constitutively active RhoA increased the basal phosphorylation of Akt , suggesting that RhoA in involved in TGFbeta-induced EMT .	target	1
18509	10969078	387;207	RhoA;Akt	Dominant-negative RhoA inhibited TGFbeta-induced phosphorylation of Akt at Ser-473 , whereas constitutively active ***RhoA*** ***increased*** the basal phosphorylation of ***Akt*** , suggesting that RhoA in involved in TGFbeta-induced EMT .	positive	0
18510	10969078	387;207	RhoA;Akt	Dominant-negative ***RhoA*** ***inhibited*** TGFbeta-induced phosphorylation of ***Akt*** at Ser-473 , whereas constitutively active RhoA increased the basal phosphorylation of Akt , suggesting that RhoA in involved in TGFbeta-induced EMT .	negative	1
18511	10969078	207;5294	Akt;PI3K	Taken together , these data suggest that ******PI3K-Akt****** ***signaling*** is required for TGFbeta-induced transcriptional responses , EMT , and cell migration .	parallel	0
18512	10969079	4214;5594	MEKK1;ERK2	***MEKK1*** ***binds*** raf-1 and the ***ERK2*** cascade components .	parallel	1
18513	10969079	4214;5894	MEKK1;raf-1	***MEKK1*** ***binds*** ***raf-1*** and the ERK2 cascade components .	parallel	1
18514	10969079	4214;5599	MEKK1;JNK	We showed previously that ***MEKK1*** ***binds*** directly to ***JNK/SAPK*** .	parallel	1
18515	10969079	4214;5601	MEKK1;SAPK	We showed previously that ***MEKK1*** ***binds*** directly to ***JNK/SAPK*** .	parallel	1
18516	10969079	4214;5594	MEKK1;ERK2	In this study we demonstrate that endogenous ***MEKK1*** ***binds*** to endogenous ***ERK2*** , MEK1 , and another MEKK level kinase , raf-1 , suggesting that it can assemble all three proteins of the ERK2 MAP kinase module .	parallel	1
18517	10969079	4214;5894	MEKK1;raf-1	In this study we demonstrate that endogenous ***MEKK1*** ***binds*** to endogenous ERK2 , MEK1 , and another MEKK level kinase , ***raf-1*** , suggesting that it can assemble all three proteins of the ERK2 MAP kinase module .	parallel	1
18518	10969082	7124;5468	Tumor necrosis factor alpha;PPARgamma	***Tumor necrosis factor alpha*** ( 10 ng/ml ) ***reduced*** ***PPARgamma*** mRNA , and this effect was prevented by the treatment with 15dPGJ ( 2 ) .	negative	1
18519	10969178	3565;3976	IL-4;LIF	Leukemia inhibitory factor ( ***LIF*** ) , essential for embryo implantation , is ***up-regulated*** by ***IL-4*** and progesterone .	positive	1
18520	10969179	3458;8835	IFN-gamma;SOCS-2	In THP-1 myeloid leukemia cells pretreated with TPA ( to induce receptors for IFN-gamma ) , ***IFN-gamma*** ***induced*** ***SOCS-2*** .	target	1
18521	10969179	5617;9021	PRL;SOCS-3	***SOCS-3*** expression was ***enhanced*** by ***PRL*** or by IFN-gamma .	positive	0
18522	10969179	3553;8835	IL-1beta;SOCS-2	In tonsillar cells , CIS expression was increased and ***SOCS-2*** was ***induced*** by ***IL-1beta*** , IL-6 , PRL and GH .	target	1
18523	10969179	3569;8835	IL-6;SOCS-2	In tonsillar cells , CIS expression was increased and ***SOCS-2*** was ***induced*** by IL-1beta , ***IL-6*** , PRL and GH .	target	1
18524	10969179	5617;8835	PRL;SOCS-2	In tonsillar cells , CIS expression was increased and ***SOCS-2*** was ***induced*** by IL-1beta , IL-6 , ***PRL*** and GH .	target	1
18525	10969179	3553;9021	IL-1beta;SOCS-3	***SOCS-3*** expression was ***enhanced*** by ***IL-1beta*** .	positive	0
18526	10969179	3569;122809	IL-6;SOCS-7	The expression of ***SOCS-7*** was ***increased*** by ***IL-6*** , PRL and GH .	positive	0
18527	10969179	5617;122809	PRL;SOCS-7	The expression of ***SOCS-7*** was ***increased*** by IL-6 , ***PRL*** and GH .	positive	0
18528	10969179	3553;8835	IL-1beta;SOCS-2	In Raji B-lymphoma cells , the expression of ***SOCS-2*** and SOCS-7 was ***enhanced*** by ***IL-1beta*** .	positive	0
18529	10969179	3553;122809	IL-1beta;SOCS-7	In Raji B-lymphoma cells , the expression of SOCS-2 and ***SOCS-7*** was ***enhanced*** by ***IL-1beta*** .	positive	0
18530	10969180	5617;5292	prolactin;pim-1	Transcriptional ***regulation*** of ***pim-1*** by ***prolactin*** : independence of a requirement for Jak2/Stat signaling .	target	1
18531	10969180	5618;5617	PRLR;prolactin	Lactogen-dependent Nb2 cell lines have been widely employed to investigate signaling mechanisms coupled to ***prolactin*** ***receptor*** ( ***PRLR*** ) - stimulated transcription of hormone-responsive genes .	parallel	1
18532	10969180	5617;5292	PRL;pim-1	We previously reported that ***PRL*** rapidly ***induced*** expression of the immediate-early protooncogene , ***pim-1*** .	target	1
18533	10969180	5618;5292	PRLR;pim-1	Results from pharmacological antagonism of several signaling mechanisms indicated that ***PRLR*** ***activation*** of the ***pim-1*** promoter reflected contributions from the ras-MAPK and PI-3 kinase pathways .	positive	1
18534	10969180	5618;5292	PRLR;pim-1	Together these observations suggest that ***PRLR*** ***stimulation*** of ***pim-1*** transcription occurs independently of a requirement for signaling through a Jak2/Stat mechanism .	positive	0
18535	10969681	3689;7124	CD18;tumor necrosis factor alpha	The mRNA expression of ***tumor necrosis factor alpha*** ( TNFalpha ) , interleukin 1beta ( IL-1beta ) , inducible and endothelial nitric oxide synthase ( iNOS and eNOS ) , endothelin-1 ( ET-1 ) , E-selectin ( CD62E ) , intercellular adhesion molecule-1 ( ICAM-1 ) and its ***ligand*** ***CD18*** , and intercellular adhesion molecule-10 was evaluated with semiquantitative reverse transcription-polymerase chain reaction ( RT-PCR ) .	parallel	1
18536	10969788	4792;4790	IkappaB-alpha;NF-kappaB	In the current study , through analyses of a number of apoptosis-associated genes or regulatory proteins , we discovered that paclitaxel significantly down-regulated ***IkappaB-alpha*** , the cytoplasmic inhibitor of transcription factor nuclear factor-kappaB ( NF-kappaB ) , which in turn ***promoted*** the nuclear translocation of ***NF-kappaB*** and its DNA binding activity .	positive	0
18537	10969796	959;3586	CD40 ligand;interleukin 10	Tumor necrosis factor alpha and ***CD40 ligand*** ***antagonize*** the inhibitory effects of ***interleukin 10*** on T-cell stimulatory capacity of dendritic cells .	negative	1
18538	10969796	7124;3586	Tumor necrosis factor alpha;interleukin 10	***Tumor necrosis factor alpha*** and CD40 ligand ***antagonize*** the inhibitory effects of ***interleukin 10*** on T-cell stimulatory capacity of dendritic cells .	negative	1
18539	10969796	3586;3569	IL-10;IL-6	***IL-10*** ***decreased*** the production of ***IL-6*** and the expression of IL-12 in the presence of TNF-alpha or sCD40L , but it had no effect on IL-15 , IL-18 , and TNF-alpha secretion .	negative	0
18540	10969803	3065;5934	histone deacetylase 1;p130	Transforming growth factor-beta1 ***recruits*** ***histone deacetylase 1*** to a ***p130*** repressor complex in transgenic mice in vivo .	target	0
18541	10969803	3065;5934	histone deacetylase 1;p130	The reduction in cdc25A protein levels was associated with increased ***binding*** of ***histone deacetylase 1*** to ***p130*** in the hepatic extracts .	parallel	1
18542	10969803	3065;993	HDAC1;cdc25A	In cultured cells , ***HDAC1/p130*** overexpression ***inhibited*** activity of the ***cdc25A*** promoter through an E2F site .	negative	1
18543	10969803	5934;993	p130;cdc25A	In cultured cells , ***HDAC1/p130*** overexpression ***inhibited*** activity of the ***cdc25A*** promoter through an E2F site .	negative	1
18544	10969803	5934;993	p130;cdc25A	TGF-beta1 treatment enhanced ***p130*** ***binding*** to the ***cdc25A*** promoter E2F site assessed in chromatin immunoprecipitation assays .	parallel	1
18545	10969803	7040;5934	TGF-beta1;p130	***TGF-beta1*** treatment ***enhanced*** ***p130*** binding to the cdc25A promoter E2F site assessed in chromatin immunoprecipitation assays .	positive	0
18546	10969803	3065;5934	HDAC1;p130	Hepatic proliferation induced by partial hepatectomy was associated with a decrease in the amount of HDAC1 bound to p130 , without a significant decrease in p130 abundance , suggesting that ***HDAC1*** ***binding*** to ***p130*** may be regulated by proliferative stimuli .	parallel	1
18547	10969803	3065;5934	HDAC1;p130	These studies suggest that TGF-beta1 may enhance ***HDAC1*** ***binding*** to ***p130*** in vivo , thereby inhibiting cdc25A gene expression .	parallel	1
18548	10969803	7040;3065	TGF-beta1;HDAC1	These studies suggest that ***TGF-beta1*** may ***enhance*** ***HDAC1*** binding to p130 in vivo , thereby inhibiting cdc25A gene expression .	positive	0
18549	10969803	7040;3065	TGF-beta1;HDAC1	***TGF-beta1*** ***regulation*** of ***HDAC1/pocket*** protein associations may provide a link between chromatin remodeling proteins and cdk inhibition through induction of cdc25A in vivo .	target	1
18550	10969805	1437;5914	granulocyte macrophage colony-stimulating factor;retinoic acid receptor-alpha	***Induction*** of ***retinoic acid receptor-alpha*** by ***granulocyte macrophage colony-stimulating factor*** in human myeloid leukemia cell lines .	target	1
18551	10969805	1437;5914	GM-CSF;RAR alpha	We reveal that ***GM-CSF*** ***induces*** the expression of ***RAR alpha*** mRNA and protein and stimulates the binding of nuclear proteins to direct repeat 5 , a consensus sequence with high affinity for RAR-RXR heterodimers .	target	1
18552	10969805	1437;5914	GM-CSF;RAR alpha	The ***induction*** of ***RAR alpha*** by ***GM-CSF*** may therefore be a mechanism for stimulation by GM-CSF .	target	1
18553	10969805	1437;5914	GM-CSF;RAR alpha	The ***induction*** of ***RAR alpha*** by ***GM-CSF*** was also detected in other myeloid leukemia cell lines ( THP-1 and KG-1 ) that showed a synergistic effect similar to that seen in ML-1 cells in response to ATRA + GM-CSF .	target	1
18554	10969805	1437;5914	GM-CSF;RAR alpha	We also found that ***GM-CSF*** ***induced*** the expression of ***RAR alpha*** in blood cells obtained from patients with acute myeloid leukemia .	target	1
18555	10969809	3479;5594	IGF-I;extracellular signal-regulated kinase 2	***IGF-I*** ***stimulated*** phosphatidylinositol 3-kinase ( PI3-kinase ) , p70 S6 kinase ( p70s6k ) , and ***extracellular signal-regulated kinase 2*** activity in BON cells .	positive	0
18556	10969809	3479;84959	IGF-I;p70	***IGF-I*** ***stimulated*** phosphatidylinositol 3-kinase ( PI3-kinase ) , ***p70*** S6 kinase ( p70s6k ) , and extracellular signal-regulated kinase 2 activity in BON cells .	positive	0
18557	10969809	3479;5594	IGF-I;extracellular signal-regulated kinase 2	Furthermore , immunoneutralization of endogenously released ***IGF-I*** markedly ***reduced*** the high basal activity of p70s6k and ***extracellular signal-regulated kinase 2*** in serum-starved BON cells .	negative	1
18558	10969809	3479;1113	IGF-I;chromogranin A	In addition , immunoneutralization of endogenously released ***IGF-I*** markedly ***reduced*** basal ***chromogranin A*** release by BON cells .	negative	1
18559	10969836	5468;6514	PPAR-gamma;GLUT2	Electrophoretic mobility shift assay using nuclear extracts of CV-1 cells , which were transfected with various combinations of PPARs or RXR-alpha expression plasmids , revealed that heterodimers of ***PPAR-gamma*** and RXR-alpha preferentially ***bound*** to ***GLUT2-PPRE*** .	parallel	1
18560	10969849	5167;3643	PC-1;insulin receptor	The human plasma-cell membrane differentiation antigen-1 ( ***PC-1*** ) has been shown to ***inhibit*** ***insulin receptor*** tyrosine kinase activity .	negative	1
18561	10970737	2956;4436	MSH6;MSH2	The yeast ******MSH2-MSH6****** ***complex*** is required to repair both base-pair and single base insertion/deletion mismatches .	parallel	1
18562	10970737	5378;4292	PMS1;MLH1	Here we show that this binding is not accompanied by either a modulation in MSH2-MSH6 ATPase activity or an ATP-dependent recruitment of the ******MLH1-PMS1****** ***complex*** .	parallel	1
18563	10970739	1234;920	CCR5;CD4	All ENV containing the GPG V3 crown showed ***CCR5*** ***binding*** in the presence of soluble ***CD4*** , whereas it was not detected with the GAG variants .	parallel	1
18564	10970739	1234;3700	CCR5;gp120	These studies demonstrate that sequences in the third hypervariable region determine the specificity of coreceptor utilization for fusion , and that a conserved motif in the crown directly influences the molecular anatomy of the ***interaction*** between ***gp120*** and ***CCR5*** .	parallel	1
18565	10970776	5540;5697	PP1;PYY	The Src-family tyrosine kinase inhibitor ***PP1*** , as well as specific inhibition of the epidermal growth factor receptor tyrosine kinase ( EGFR TK ) by PD153035 , also ***blocks*** ***PYY*** stimulation of MAPK .	negative	0
18566	10970786	958;4790	CD40;NF-kappaB	The ***activation*** of ***NF-kappaB*** by ***CD40*** is a key process in facilitating this transcription by promoting the activation of the Cepsilon promoter .	positive	1
18567	10970786	9020;4790	NIK;NF-kappaB	The overexpression of TRAF-6 or ***NIK*** was sufficient to ***activate*** ***NF-kappaB*** and the Cepsilon promoter , whereas their dominant-negative counterparts decreased the ability of CD40 to activate NF-kappaB and the Cepsilon promoter .	positive	1
18568	10970786	7189;4790	TRAF-6;NF-kappaB	The overexpression of ***TRAF-6*** or NIK was sufficient to ***activate*** ***NF-kappaB*** and the Cepsilon promoter , whereas their dominant-negative counterparts decreased the ability of CD40 to activate NF-kappaB and the Cepsilon promoter .	positive	1
18569	10970786	1147;4790	IKK-1;NF-kappaB	These results suggest that CD40 employs TRAF-6 , which presumably recruits NIK , which in turn employs ***IKK-1/IKK-2*** to ***activate*** ***NF-kappaB*** and the Cepsilon promoter , the prologue to IgE switching .	positive	1
18570	10970786	3551;4790	IKK-2;NF-kappaB	These results suggest that CD40 employs TRAF-6 , which presumably recruits NIK , which in turn employs ***IKK-1/IKK-2*** to ***activate*** ***NF-kappaB*** and the Cepsilon promoter , the prologue to IgE switching .	positive	1
18571	10970786	7189;9020	TRAF-6;NIK	These results suggest that CD40 employs ***TRAF-6*** , which presumably ***recruits*** ***NIK*** , which in turn employs IKK-1/IKK-2 to activate NF-kappaB and the Cepsilon promoter , the prologue to IgE switching .	target	0
18572	10970787	6814;6810	munc18c;syntaxin 4	Definition of a minimal ***munc18c*** domain that ***interacts*** with ***syntaxin 4*** .	parallel	1
18573	10970787	6814;6810	munc18c;syntaxin 4	Full-length munc18c ( 1-592 ) , munc18c ( 1-139 ) and ***munc18c*** ( 1-225 ) , but not munc18c ( 226-592 ) , munc18c ( 1-100 ) , munc18c ( 43-139 ) or munc18c ( 66-139 ) , ***interacted*** with the cytoplasmic portion of ***syntaxin 4*** , Stx4 ( 2-273 ) , as assessed by yeast two-hybrid assay of growth on nutritionally deficient media and by beta-galactosidase reporter induction .	parallel	1
18574	10970787	6814;6810	munc18c;Stx4	Full-length munc18c ( 1-592 ) , munc18c ( 1-139 ) and ***munc18c*** ( 1-225 ) ***interacted*** with ***Stx4*** ( 2-273 ) whereas munc18c ( 1-100 ) did not , consistent with the yeast two-hybrid data .	parallel	1
18575	10970810	4233;6654	MET;HGF	CrkII was found to be phosphorylated in response to hepatocyte growth factor/scatter factor ( HGF/SF ) and to associate with the beta-subunit of the ***HGF*** ***receptor*** ( ***MET*** ) .	parallel	1
18576	10970828	3553;3082	IL-1beta;HGF	In contrast , human skin fibroblasts exerted no SLPI-stimulated increase in HGF production , despite the fact that ***IL-1beta*** ***increased*** ***HGF*** production with an intensity similar to that of human lung fibroblasts .	positive	0
18577	10970838	4154;1760	EXP;DMPK	We propose that DM1 disease is caused by aberrant ***recruitment*** of the ***EXP*** proteins to the ***DMPK*** transcript ( CUG ) ( n ) expansion .	target	0
18578	10970843	30001;64714	Ero1-Lalpha;PDI	Here we show that ***Ero1-Lalpha*** , the human homolog of Ero1p , exists as a collection of oxidized and reduced forms and covalently ***binds*** ***PDI*** .	parallel	1
18579	10970843	64714;30001	PDI;Ero1-Lalpha	Our results demonstrate that this motif is important for protein folding , structural integrity , protein half-life and the stability of the ******Ero1-Lalpha-PDI****** ***complex*** .	parallel	1
18580	10970850	387;7430	RhoA;Ezrin	***RhoA*** effector loop mutants which can bind ROCK ***induce*** relocalization of ***Ezrin*** to dorsal actin-containing cell surface protrusions , as do Net and Dbl .	target	1
18581	10970882	8454;5715	Cul1;p27	These functional and biochemical data provide a direct link between c-Myc transcriptional regulation and ubiquitin-mediated proteolysis and together support the view that c-Myc promotes G ( 1 ) exit in part via ***Cul1-dependent*** ***ubiquitination*** and degradation of the CDK inhibitor , ***p27*** ( kip1 ) .	target	1
18582	10970884	5888;25788	Rad51;Rdh54	Physical ***interaction*** between ***Rdh54*** and ***Rad51*** is functionally important because Rdh54 does not enhance the recombinase activity of the Escherichia coli RecA protein .	parallel	1
18583	10970890	5350;488	Phospholamban;SERCA2	***Phospholamban*** , which ***inhibits*** ***SERCA2*** , was decreased by approximately 40 % in heterozygous hearts , and basal phosphorylation of Ser-16 and Thr-17 , which relieves the inhibition , was increased approximately 2 - and 2.1-fold .	negative	1
18584	10970890	488;5350	SERCA2;Phospholamban	However , the resulting deficit is partially compensated by alterations in ******Phospholamban/SERCA2****** ***interactions*** and by up-regulation of the Na ( + ) - Ca ( 2 + ) exchanger .	parallel	1
18585	10970892	3309;5621	BiP;prion protein	The chaperone protein ***BiP*** ***binds*** to a mutant ***prion protein*** and mediates its degradation by the proteasome .	parallel	1
18586	10971174	4233;3082	c-Met;HGF	Hepatocyte growth factor ( ***HGF*** ) and its ***receptor*** , ***c-Met*** , are known to induce mitosis and cell movement and to promote tumor progression .	parallel	1
18587	10971319	199699;596	CER-2;Bcl-2	Western blot analysis showed that ***CER-2*** ***induces*** downregulation of ***Bcl-2*** at 24-96 h.	target	1
18588	10971326	7040;7422	TGF-beta1;VEGF	Both ***TGF-beta1*** and UVA1 strongly ***increased*** ***VEGF*** secretion in a dose - and time-dependent manner , without significantly affecting ET-1 release .	positive	0
18589	10971406	4352;7066	Mpl;thrombopoietin	Mutations in the ***thrombopoietin*** ***receptor*** , ***Mpl*** , in children with congenital amegakaryocytic thrombocytopenia .	parallel	1
18590	10971426	7076;4313	tissue inhibitor of metalloproteinases (TIMP) 1;MMP-2	This was associated with increasing expression of ***tissue inhibitor of metalloproteinases (TIMP) 1*** , an ***inhibitor*** of ***MMP-2*** , and of transforming growth factor ( TGF ) beta , a profibrotic cytokine , by 24 weeks following injury .	negative	1
18591	10971457	7133;7124	TNF-RII;TNF-alpha	The biological activities of ***TNF-alpha*** are ***mediated*** by two structurally related , but functionally distinct receptors , TNF-RI and ***TNF-RII*** .	target	0
18592	10971457	7132;7124	TNF-RI;TNF-alpha	The biological activities of ***TNF-alpha*** are ***mediated*** by two structurally related , but functionally distinct receptors , ***TNF-RI*** and TNF-RII .	target	0
18593	10971470	268;6037	MIF;ECP	***MIF*** levels in induced sputum were ***correlated*** with ***ECP*** levels in induced sputum .	parallel	0
18594	10971474	3586;5743	IL-10;COX-2	Dexamethasone and ***IL-10*** ***abrogated*** cytokine-induced ***COX-2*** mRNA and protein expression .	negative	0
18595	10971656	6464;6714	Shc;c-Src	Adaptor protein ***Shc*** undergoes translocation and ***mediates*** up-regulation of the tyrosine kinase ***c-Src*** in EGF-stimulated A431 cells .	target	0
18596	10971656	6464;6714	Shc;c-Src	In our previous studies , ***Shc*** was shown to be a ***substrate*** of the tyrosine kinase ***c-Src*** in vitro and in vivo .	parallel	1
18597	10971831	7037;7018	TfR;transferrin	Recent investigations indicate that this cumbersome procedure can be avoided by measuring an important new iron-related measurement , the serum ***transferrin*** ***receptor*** ( ***TfR*** ) .	parallel	1
18598	10972213	3458;3383	interferon-gamma;ICAM-1	Recombinant porcine ***interferon-gamma*** weakly ***stimulated*** ***ICAM-1*** expression when incubated alone with PAEC but had an inhibitory effect on the increase in ICAM-1 due to TNF-alpha , both at 8 and 24 hr .	positive	0
18599	10972280	56616;836	Smac;procaspase-3	Here we show that ***Smac/DIABLO*** ***promotes*** not only the proteolytic activation of ***procaspase-3*** but also the enzymatic activity of mature caspase-3 , both of which depend upon its ability to interact physically with IAPs .	positive	0
18600	10972686	348;4018	apoE;lipoprotein	VLDL1 ***apoE*** deficiency is associated with smaller VLDL1 particles but not altered VLDL1 surface lipid content , and may ***reduce*** receptor-mediated clearance of this ***lipoprotein*** .	positive	1
18601	10972960	5580;10752	protein kinase C delta;neural cell adhesion molecule	***Regulation*** of ***neural cell adhesion molecule*** polysialylation state by cell-cell contact and ***protein kinase C delta*** .	target	1
18602	10972965	356;355	fasL;Fas	Immunohistochemistry was performed to detect expression of both Fas and ***Fas*** ***ligand*** ( ***fasL*** ) .	parallel	1
18603	10972974	5594;596	ERK;Bcl-2	***MEK/ERK*** signaling pathway ***regulates*** the expression of ***Bcl-2*** , Bcl-X ( L ) , and Mcl-1 and promotes survival of human pancreatic cancer cells .	target	1
18604	10972974	5594;598	ERK;Bcl-X	***MEK/ERK*** signaling pathway ***regulates*** the expression of Bcl-2 , ***Bcl-X*** ( L ) , and Mcl-1 and promotes survival of human pancreatic cancer cells .	target	1
18605	10972974	5594;4170	ERK;Mcl-1	***MEK/ERK*** signaling pathway ***regulates*** the expression of Bcl-2 , Bcl-X ( L ) , and ***Mcl-1*** and promotes survival of human pancreatic cancer cells .	target	1
18606	10972974	5609;596	MEK;Bcl-2	***MEK/ERK*** signaling pathway ***regulates*** the expression of ***Bcl-2*** , Bcl-X ( L ) , and Mcl-1 and promotes survival of human pancreatic cancer cells .	target	1
18607	10972974	5609;598	MEK;Bcl-X	***MEK/ERK*** signaling pathway ***regulates*** the expression of Bcl-2 , ***Bcl-X*** ( L ) , and Mcl-1 and promotes survival of human pancreatic cancer cells .	target	1
18608	10972974	5609;4170	MEK;Mcl-1	***MEK/ERK*** signaling pathway ***regulates*** the expression of Bcl-2 , Bcl-X ( L ) , and ***Mcl-1*** and promotes survival of human pancreatic cancer cells .	target	1
18609	10972975	4830;4249	nm23-H1;GnT-V	Our findings indicate that the ***down-regulation*** of ***GnT-V*** by ***nm23-H1*** contributes to the alterations in metastasis-related phenotypes , and is an important molecular mechanism of metastasis suppression mediated by nm23-H1 .	negative	1
18610	10973254	659;7040	BMPR-II;TGF-beta	We now show that FPPH is caused by mutations in BMPR2 , encoding a ***TGF-beta*** type II ***receptor*** ( ***BMPR-II*** ) .	parallel	1
18611	10973264	7157;55367	p53;Pidd	***Pidd*** , a new death-domain-containing protein , is ***induced*** by ***p53*** and promotes apoptosis .	target	1
18612	10973278	604;6354	BCL-6;MCP-3	We identified three chemokines , MCP-1 , ***MCP-3*** and MRP-1 , which are negatively ***regulated*** by ***BCL-6*** in macrophages .	negative	1
18613	10973278	604;6347	BCL-6;MCP-1	Promoter analysis revealed that ***BCL-6*** is a potent ***repressor*** of ***MCP-1*** transcription .	negative	1
18614	10973284	608;8741	BCMA;APRIL	Soluble ***BCMA*** and TACI specifically ***prevent*** binding of ***APRIL*** and block APRIL-stimulated proliferation of primary B cells .	negative	0
18615	10973284	23495;8741	TACI;APRIL	Soluble BCMA and ***TACI*** specifically ***prevent*** binding of ***APRIL*** and block APRIL-stimulated proliferation of primary B cells .	negative	0
18616	10973490	472;11200	Ataxia telangiectasia-mutated;Chk2	***Ataxia telangiectasia-mutated*** ***phosphorylates*** ***Chk2*** in vivo and in vitro .	target	1
18617	10973490	472;11200	ATM;Chk2	These results suggest that in vivo , ***Chk2*** is directly ***phosphorylated*** by ***ATM*** in response to IR and that Chk2 is regulated by phosphorylation of the SCD .	target	1
18618	10973491	25;1033	BCR/ABL;cyclin-dependent kinase inhibitor	Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34 + cell proliferation : ***BCR/ABL*** ***up-regulates*** the ***cyclin-dependent kinase inhibitor*** , p27Kip , which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity .	positive	1
18619	10973491	1033;1017	cyclin-dependent kinase inhibitor;cdk2	( NL ) CD34 ( + ) cells increases levels of the ***cyclin-dependent kinase inhibitor*** ( cdki ) , p27 ( Kip ) , ***decreases*** ***cdk2*** activity , and inhibits G ( 1 ) / S-phase progression .	negative	0
18620	10973491	25;3692	BCR/ABL;p27	Thus , presence of ***BCR/ABL*** ***induces*** elevated levels of ***p27*** ( Kip ) and relocation of p27 ( Kip ) to the cytoplasm , which contributes to the loss of integrin-mediated proliferation inhibition , characteristic of CML .	target	1
18621	10973497	1387;3484	CREB-binding protein;insulin-like growth factor binding protein 1	DAF-16 ***recruits*** the ***CREB-binding protein*** coactivator complex to the ***insulin-like growth factor binding protein 1*** promoter in HepG2 cells .	target	0
18622	10973497	1387;2033	CBP;p300	Thus , we conclude that DAF-16 and FKHR act as accessory factors to the glucocorticoid response , by recruiting the ******p300/CBP/SRC****** coactivator ***complex*** to an FKH factor site in the IGFBP-1 promoter , which allows the cell to integrate the effects of glucocorticoids and insulin on genes that carry this site .	parallel	1
18623	10973498	2054;6804	Stx2;Stx1	Immunohistochemistry was used to define ***binding*** of ***Stx1*** and ***Stx2*** overlaid onto sections from cattle tissues .	parallel	1
18624	10973499	7428;3091	von Hippel-Lindau (VHL) tumor suppressor;HIF1alpha	***Activation*** of ***HIF1alpha*** ubiquitination by a reconstituted ***von Hippel-Lindau (VHL) tumor suppressor*** complex .	positive	1
18625	10973500	10111;4361	Rad50;Mre11	Spo11 and the ******Rad50-Mre11****** ***complex*** have been indirectly implicated in processes associated with DNA replication .	parallel	1
18626	10973564	5744;6347	PTHrP;MCP-1	Immunoblotting revealed that ***PTHrP*** also ***enhanced*** secretion of ***MCP-1*** by the follicle cells .	positive	0
18627	10973564	5744;6347	PTHrP;MCP-1	By reverse transcription-polymerase chain reaction , it was demonstrated that ***PTHrP*** ***enhanced*** ***MCP-1*** expression in a concentration-dependent fashion , with 50 ng PTHrP/ml inducing maximal expression of either MCP-1 or CSF-1 .	positive	0
18628	10973589	2254;1103	FGF-9;choline acetyltransferase	***FGF-9*** enhanced survival of AChE-positive neurons , increased their mean soma size , and ***up-regulated*** their ***choline acetyltransferase*** ( ChAT ) activity .	positive	1
18629	10973693	7124;3684	TNF-alpha;CD11b	The effect of IPN and DX could at least partly be mediated through a decreased TNF-alpha production by monocytes since tumor necrosis factor-alpha ( ***TNF-alpha*** ) is shown to ***mediate*** a dose-dependent ***CD11b*** up-regulation .	target	0
18630	10973796	1029;1019	p16;Cdk4	Oxidative stress regulates the ***interaction*** of ***p16*** with ***Cdk4*** .	parallel	1
18631	10973805	8620;5368	NPFF;nociceptin	In rat dorsal raphe neurones , EFW-NPSF , NPFF , and ***NPA-NPFF*** maximally ***reduce*** the inhibitory effect of ***nociceptin*** on the [ Ca ( 2 + ) ] ( i ) transients triggered by depolarization by 39 , 31 , and 58 % , respectively .	negative	1
18632	10973866	5360;335	PLTP;apolipoprotein (apo) A-I	Plasma ***PLTP*** concentration was positively ***correlated*** with HDL-cholesterol ( r = 0.72 ; P : < 0.001 ) , ***apolipoprotein (apo) A-I*** ( r = 0.62 ; P : < 0.001 ) and HDL ( 2 ) - cholesterol ( r = 0.72 ; P : < 0.001 ) , and was negatively correlated with triacylglycerol ( r = -0.45 ; P : < 0 .	positive	0
18633	10973933	642;351	bleomycin hydrolase;amyloid precursor protein	Human ***bleomycin hydrolase*** ***regulates*** the secretion of ***amyloid precursor protein*** .	target	1
18634	10973944	4092;4087	Smad7;Smad2	Unlike other Smads , ***Smad7*** ***inhibits*** phosphorylation of ***Smad2*** and Smad3 , and its transcription is induced by TGF-beta , suggesting a negative feedback loop .	negative	1
18635	10973944	4092;4088	Smad7;Smad3	Unlike other Smads , ***Smad7*** ***inhibits*** phosphorylation of Smad2 and ***Smad3*** , and its transcription is induced by TGF-beta , suggesting a negative feedback loop .	negative	1
18636	10973944	7040;4088	TGF-beta;Smad3	Previously , we showed that a similar arrangement between a SBE and an E-box of an element is essential for TGF-beta-dependent transcription of the plasminogen activator inhibitor-1 gene ( PAI-1 ) and that ***TGF-beta-induced*** ***phosphorylation*** of ***Smad3*** triggers its association with TFE3 .	target	1
18637	10973957	3479;4790	IGF-I;NFkappaB	Here , we demonstrate that in astrocyte cultures ***IGF-I*** ***regulates*** ***NFkappaB*** , a transcription factor known to play a key role in the inflammatory reaction .	target	1
18638	10973957	3479;4792	IGF-I;IkappaBalpha	***IGF-I*** ***induces*** a site-specific dephosphorylation of ***IkappaBalpha*** ( phospho-Ser ( 32 ) ) in astrocytes .	target	1
18639	10973957	3479;4792	IGF-I;IkappaBalpha	Moreover , ***IGF-I-mediated*** ***dephosphorylation*** of ***IkappaBalpha*** protects this molecule from tumor necrosis factor alpha ( TNFalpha ) - stimulated degradation ; therefore , IGF-I also inhibits the nuclear translocation of NFkappaB ( p65 ) induced by TNFalpha exposure .	target	1
18640	10973957	3479;4790	IGF-I;NFkappaB	Moreover , IGF-I-mediated dephosphorylation of IkappaBalpha protects this molecule from tumor necrosis factor alpha ( TNFalpha ) - stimulated degradation ; therefore , ***IGF-I*** also ***inhibits*** the nuclear translocation of ***NFkappaB*** ( p65 ) induced by TNFalpha exposure .	negative	1
18641	10973957	3479;4792	IGF-I;IkappaBalpha	Finally , we show that ***dephosphorylation*** of ***IkappaBalpha*** by ***IGF-I*** pathways requires activation of calcineurin .	target	1
18642	10973962	207;4656	Akt;myogenin	The insulin-like growth factor-phosphatidylinositol ***3-kinase-Akt*** signaling pathway ***regulates*** ***myogenin*** expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells .	target	1
18643	10973962	207;4656	Akt;myogenin	Simultaneous mutation of all three elements completely abolishes ***activation*** of the ***myogenin*** promoter by ***PI3K/Akt*** .	positive	1
18644	10973962	5291;4656	PI3K;myogenin	Simultaneous mutation of all three elements completely abolishes ***activation*** of the ***myogenin*** promoter by ***PI3K/Akt*** .	positive	1
18645	10973962	207;4654	Akt;MyoD	We demonstrate that ***PI3K/Akt*** can ***increase*** both the ***MyoD*** and the MEF2-dependent reporter activity by enhancing the transcriptional activity of MyoD and MEF2 .	positive	0
18646	10973962	5291;4654	PI3K;MyoD	We demonstrate that ***PI3K/Akt*** can ***increase*** both the ***MyoD*** and the MEF2-dependent reporter activity by enhancing the transcriptional activity of MyoD and MEF2 .	positive	0
18647	10973963	1647;983	GADD45;Cdc2	Therefore , the ***binding*** of ***GADD45*** to ***Cdc2*** was insufficient to induce a G ( 2 ) / M arrest , and additional activity contributed by the DEDDDR residues may be necessary to regulate the G ( 2 ) / M checkpoint .	parallel	1
18648	10973963	4616;983	GADD45beta;Cdc2	Consistently , either ***GADD45beta*** or GADD45gamma ***bind*** to ***Cdc2*** in vivo .	parallel	1
18649	10973963	10912;983	GADD45gamma;Cdc2	Consistently , either GADD45beta or ***GADD45gamma*** ***bind*** to ***Cdc2*** in vivo .	parallel	1
18650	10973971	3416;3375	insulin-degrading enzyme;amylin	***Degradation*** of ***amylin*** by ***insulin-degrading enzyme*** .	negative	1
18651	10973971	3416;3375	IDE;amylin	Other substrates of ***IDE*** such as atrial natriuretic peptide and glucagon also competitively ***inhibited*** ***amylin*** degradation .	negative	1
18652	10973986	1822;862	Atrophin-1;MTG8	***Atrophin-1*** , the dentato-rubral and pallido-luysian atrophy gene product , ***interacts*** with ***ETO/MTG8*** in the nuclear matrix and represses transcription .	parallel	1
18653	10973986	862;1822	MTG8;Atrophin-1	Cotransfection of ***ETO/MTG8*** with Atrophin-1 ***recruits*** ***Atrophin-1*** to the nuclear matrix , while Atrophin-1 and ETO/MTG8 cofractionate in nuclear matrix preparations from brains of DRPLA transgenic mice .	target	0
18654	10973996	960;2064	CD44;erbB2	***CD44*** constitutively ***associated*** with ***erbB2*** and erbB3 , receptor tyrosine kinases that heterodimerize and signal in Schwann cells in response to neuregulins .	parallel	0
18655	10973996	960;2065	CD44;erbB3	***CD44*** constitutively ***associated*** with erbB2 and ***erbB3*** , receptor tyrosine kinases that heterodimerize and signal in Schwann cells in response to neuregulins .	parallel	0
18656	10973996	2065;2064	erbB3;erbB2	Moreover , CD44 significantly enhanced neuregulin-induced erbB2 phosphorylation and ******erbB2-erbB3****** ***heterodimerization*** .	parallel	1
18657	10973996	960;2064	CD44;erbB2	Moreover , ***CD44*** significantly ***enhanced*** neuregulin-induced erbB2 phosphorylation and ***erbB2-erbB3*** heterodimerization .	positive	0
18658	10973996	960;2065	CD44;erbB3	Moreover , ***CD44*** significantly ***enhanced*** neuregulin-induced erbB2 phosphorylation and ***erbB2-erbB3*** heterodimerization .	positive	0
18659	10973998	11336;60412	Sec6;Sec8	Dissociation of actin filaments in the immunoprecipitate had no effect on the ***interaction*** between ***Sec6*** and ***Sec8*** , but released the actin and dissociated the interaction between the Sec6/8 complex and Ca ( 2 + ) signaling proteins .	parallel	1
18660	10974003	5818;4301	nectin;l-afadin	Both the trans-interaction of nectin and the ***interaction*** of ***nectin*** with ***l-afadin*** are necessary for their colocalization with E-cadherin and catenins at AJs .	parallel	1
18661	10974006	7124;3725	TNF-alpha;AP-1	Our results show that glucocorticoids antagonize the ***TNF-alpha-induced*** ***activation*** of ***AP-1*** by causing the accumulation of inactive JNK without affecting its subcellular distribution .	positive	1
18662	10974021	5743;5972	COX-2;renin	Dietary salt restriction increases local expression of ***COX-2*** , which ***mediates*** ***renin*** production and secretion .	target	0
18663	10974032	64109;85480	TSLPR;TSLP	***TSLP*** ***receptor*** ( ***TSLPR*** ) is a member of the hematopoietin receptor family .	parallel	1
18664	10974032	64109;3575	TSLPR;IL-7Ralpha	Thus , the functional ***TSLPR*** ***requires*** the ***IL-7Ralpha*** chain , but not the gammac chain for signaling .	target	0
18665	10974037	2323;6776	Flt3 ligand;Stat5a	***Stat5a*** , but not Stats 1-4 , 5b , or 6 , was potently ***activated*** by ***Flt3 ligand*** ( FL ) stimulation .	positive	1
18666	10974038	695;207	Btk;Akt	Phosphorylation of ***Akt*** is ***regulated*** positively by ***Btk*** and Syk and negatively by Lyn .	positive	1
18667	10974038	6850;207	Syk;Akt	Phosphorylation of ***Akt*** is ***regulated*** positively by Btk and ***Syk*** and negatively by Lyn .	positive	1
18668	10974038	8548;4790	cytoplasmic protein;NF-kappaB	Accordingly , the signaling pathway involving IkappaB-alpha , a ***cytoplasmic protein*** that ***binds*** ***NF-kappaB*** and inhibits its nuclear translocation , appears to be regulated by Akt in mast cells .	parallel	1
18669	10974038	207;3558	Akt;IL-2	Importantly , ***Akt*** ***regulates*** the production and secretion of ***IL-2*** and TNF-alpha in FcepsilonRI-stimulated mast cells .	target	1
18670	10974038	207;7124	Akt;TNF-alpha	Importantly , ***Akt*** ***regulates*** the production and secretion of IL-2 and ***TNF-alpha*** in FcepsilonRI-stimulated mast cells .	target	1
18671	10974041	6370;10803	TECK;CCR9	These results imply a restricted role for lymphocyte ***CCR9*** and its ***ligand*** ***TECK*** in the small intestine , and provide the first evidence for distinctive mechanisms of lymphocyte recruitment that may permit functional specialization of immune responses in different segments of the gastrointestinal tract .	parallel	1
18672	10974538	3727;3725	JunD;AP1	In super-shift analysis , c-Jun and ***JunD*** formed ***complexes*** with both the ***AP1*** and CRE sequences .	parallel	1
18673	10974559	9044;6908	Mot1;TBP	Once TBP is bound to DNA , factors such as TAF ( II ) 250 and ***Mot1*** ***induce*** ***TBP*** to dissociate , while other factors such as NC2 and the NOT complex convert the TBP/DNA complex into an inactive state .	target	1
18674	10974665	8648;8856	steroid receptor coactivator-1;SXR	SJW ***recruits*** ***steroid receptor coactivator-1*** to ***SXR*** in a two-hybrid assay and competes with radiolabelled ligand in binding studies , suggesting it interacts directly with the receptor LBD .	target	0
18675	10974928	7157;1026	P53;P21	Wild-type ***P53*** , which is undetectable by immunohistochemistry , ***induces*** transcriptionally ***P21*** ( WAF1 ) and in tumours it may cause its accumulation , while mutations of the P53 may result in a sufficient increase of intracellular protein having no ability to transactivate P21 ( WAF1 ) .	target	1
18676	10975280	3479;6462	IGF-1;SHBG	***IGF-1*** was found to be ***associated*** negatively with ***SHBG*** .	negative	0
18677	10975285	3606;3586	Interleukin 18;IL-10	***Interleukin 18*** ( IL-18 ) reportedly ***synergizes*** with IL-12 and ***IL-10*** for interferon gamma ( IFN-gamma ) synthesis and natural killer ( NK ) cell activity , respectively .	parallel	0
18678	10975285	3606;3458	IL-18;IFN-gamma	Here we show that ***IL-18*** alone ***induces*** low level ***IFN-gamma*** production by unstimulated Balb/c mouse spleen cells , but production is enhanced synergistically in cocultures of spleen cells and allogeneic living or fixed Yac-1 cells .	target	1
18679	10975285	3586;3458	IL-10;IFN-gamma	***IL-10*** moderately ***inhibited*** ***IFN-gamma*** production induced by IL-18 .	negative	1
18680	10975464	6667;54363	Sp1;hAOX1	***Activation*** of the human aldehyde oxidase ( ***hAOX1*** ) promoter by tandem cooperative ***Sp1/Sp3*** binding sites : identification of complex architecture in the hAOX upstream DNA that includes a proximal promoter , distal activation sites , and a silencer element .	positive	1
18681	10975464	6670;54363	Sp3;hAOX1	***Activation*** of the human aldehyde oxidase ( ***hAOX1*** ) promoter by tandem cooperative ***Sp1/Sp3*** binding sites : identification of complex architecture in the hAOX upstream DNA that includes a proximal promoter , distal activation sites , and a silencer element .	positive	1
18682	10975521	4254;997	SCF;Cdc34	Polyubiquitination of proteins by ******Cdc34/SCF****** ***complexes*** targets them for degradation by the 26S proteasome .	parallel	1
18683	10975678	3562;3383	IL-3;intercellular adhesion molecule-1	Systemic ***IL-3*** vaccine treatment ***increased*** intratumoral levels of ***intercellular adhesion molecule-1*** , Mac-1 , EB22/5 .3 , tumor necrosis factor-alpha , and IL-1 mRNA in irradiated tumors , indicating that cellular infiltration was part of the response .	positive	0
18684	10975678	3562;7124	IL-3;tumor necrosis factor-alpha	Systemic ***IL-3*** vaccine treatment ***increased*** intratumoral levels of intercellular adhesion molecule-1 , Mac-1 , EB22/5 .3 , ***tumor necrosis factor-alpha*** , and IL-1 mRNA in irradiated tumors , indicating that cellular infiltration was part of the response .	positive	0
18685	10975791	182;4851	Jagged 1;Notch 1	Finally , in Alagille syndrome , mutations in the JAG1 gene cause deficiency ***Jagged 1*** , a ***ligand*** for ***Notch 1*** , a receptor determining cell fate during early embryogenesis .	parallel	1
18686	10975797	7535;919	Zap-70;CD3zeta	Furthermore , TSAd inhibited ***Zap-70*** ***recruitment*** to the ***CD3zeta-chains*** in a dose-dependent manner .	target	0
18687	10975797	9047;7535	TSAd;Zap-70	Furthermore , ***TSAd*** ***inhibited*** ***Zap-70*** recruitment to the CD3zeta-chains in a dose-dependent manner .	negative	1
18688	10975798	4068;6504	SAP;SLAM	***SAP*** ***associates*** with 2B4 and ***SLAM*** , activating receptors expressed by NK and T cells , and prevents recruitment of SH2 domain-containing protein tyrosine phosphatase-2 SHP-2 ) to the cytoplasmic domains of these receptors .	parallel	0
18689	10975800	2826;10850	CCR10;CTACK	Although MEC is poorly expressed in skin , its closest homologue is the keratinocyte-expressed cutaneous T cell-attracting chemokine ( CTACK ; CCL27 ) , and MEC supports chemotaxis of transfected lymphoid cells expressing ***CCR10*** , a known ***CTACK*** ***receptor*** .	parallel	1
18690	10975802	6750;3553	Somatostatin;IL-1 beta	***Somatostatin*** through its specific receptor ***inhibits*** spontaneous and TNF-alpha - and bacteria-induced IL-8 and ***IL-1 beta*** secretion from intestinal epithelial cells .	negative	1
18691	10975802	6750;3553	Somatostatin;IL-1beta	***Somatostatin*** , at physiological nanomolar concentrations , markedly ***inhibited*** the spontaneous and TNF-alpha-induced secretion of IL-8 and ***IL-1beta*** .	negative	1
18692	10975802	6750;3553	Somatostatin;IL-1beta	Furthermore , ***Somatostatin*** completely ***abrogated*** the increased secretion of IL-8 and ***IL-1beta*** after invasion by Salmonella .	negative	0
18693	10975813	941;1493	CD80;CD152	***CD152*** ***ligation*** by ***CD80*** on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation .	parallel	1
18694	10975815	116;6772	pituitary adenylate cyclase-activating polypeptide;STAT1	***Inhibition*** of IFN-gamma-induced janus ***kinase-1-STAT1*** activation in macrophages by vasoactive intestinal peptide and ***pituitary adenylate cyclase-activating polypeptide*** .	negative	1
18695	10975815	7432;6772	vasoactive intestinal peptide;STAT1	***Inhibition*** of IFN-gamma-induced janus ***kinase-1-STAT1*** activation in macrophages by ***vasoactive intestinal peptide*** and pituitary adenylate cyclase-activating polypeptide .	negative	1
18696	10975815	116;5594	PACAP;p40	The vasoactive intestinal peptide ( VIP ) and the pituitary adenylate cyclase-activating polypeptide ( ***PACAP*** ) , two immunomodulatory neuropeptides that affect both innate and acquired immunity , ***down-regulate*** IL-12 ***p40*** and inducible NO synthase expression in LPS/IFN-gamma-stimulated macrophages .	negative	1
18697	10975815	7432;5594	VIP;p40	The vasoactive intestinal peptide ( ***VIP*** ) and the pituitary adenylate cyclase-activating polypeptide ( PACAP ) , two immunomodulatory neuropeptides that affect both innate and acquired immunity , ***down-regulate*** IL-12 ***p40*** and inducible NO synthase expression in LPS/IFN-gamma-stimulated macrophages .	negative	1
18698	10975815	116;4790	PACAP;NF-kappaB	We showed previously that ***VIP/PACAP*** ***inhibit*** ***NF-kappaB*** nuclear translocation through the stabilization of IkappaB and reduce IFN regulatory factor-1 ( IRF-1 ) binding to the regulatory elements found in the IL-12 p40 and inducible NO synthase promoters .	negative	1
18699	10975815	7432;4790	VIP;NF-kappaB	We showed previously that ***VIP/PACAP*** ***inhibit*** ***NF-kappaB*** nuclear translocation through the stabilization of IkappaB and reduce IFN regulatory factor-1 ( IRF-1 ) binding to the regulatory elements found in the IL-12 p40 and inducible NO synthase promoters .	negative	1
18700	10975815	116;3659	PACAP;IRF-1	In this paper we studied the molecular mechanisms involved in the ***VIP/PACAP*** ***regulation*** of ***IRF-1*** transactivating activity .	target	1
18701	10975815	7432;3659	VIP;IRF-1	In this paper we studied the molecular mechanisms involved in the ***VIP/PACAP*** ***regulation*** of ***IRF-1*** transactivating activity .	target	1
18702	10975815	116;3716	PACAP;Jak1	In agreement with the described Janus kinase (Jak)1/Jak2/STAT1 / IRF-1 activation pathway , ***VIP/PACAP*** ***inhibit*** ***Jak1/Jak2*** , STAT1 phosphorylation , and the binding of STAT1 to the GAS sequence motif in the IRF-1 promoter .	negative	1
18703	10975815	116;3717	PACAP;Jak2	In agreement with the described Janus kinase (Jak)1/Jak2/STAT1 / IRF-1 activation pathway , ***VIP/PACAP*** ***inhibit*** ***Jak1/Jak2*** , STAT1 phosphorylation , and the binding of STAT1 to the GAS sequence motif in the IRF-1 promoter .	negative	1
18704	10975815	116;6772	PACAP;STAT1	In agreement with the described Janus kinase (Jak)1/Jak2/STAT1 / IRF-1 activation pathway , ***VIP/PACAP*** ***inhibit*** Jak1/Jak2 , STAT1 phosphorylation , and the binding of ***STAT1*** to the GAS sequence motif in the IRF-1 promoter .	negative	1
18705	10975815	7432;3716	VIP;Jak1	In agreement with the described Janus kinase (Jak)1/Jak2/STAT1 / IRF-1 activation pathway , ***VIP/PACAP*** ***inhibit*** ***Jak1/Jak2*** , STAT1 phosphorylation , and the binding of STAT1 to the GAS sequence motif in the IRF-1 promoter .	negative	1
18706	10975815	7432;3717	VIP;Jak2	In agreement with the described Janus kinase (Jak)1/Jak2/STAT1 / IRF-1 activation pathway , ***VIP/PACAP*** ***inhibit*** ***Jak1/Jak2*** , STAT1 phosphorylation , and the binding of STAT1 to the GAS sequence motif in the IRF-1 promoter .	negative	1
18707	10975815	7432;6772	VIP;STAT1	In agreement with the described Janus kinase (Jak)1/Jak2/STAT1 / IRF-1 activation pathway , ***VIP/PACAP*** ***inhibit*** Jak1/Jak2 , STAT1 phosphorylation , and the binding of ***STAT1*** to the GAS sequence motif in the IRF-1 promoter .	negative	1
18708	10975834	3458;6890	IFN-gamma;Tap-1	Synergistic ***induction*** of the ***Tap-1*** gene by ***IFN-gamma*** and lipopolysaccharide in macrophages is regulated by STAT1 .	target	1
18709	10975835	3458;3606	IFN-gamma;IL-18	Taken together , these results indicate that ***IFN-gamma*** ***increased*** ***IL-18*** gene expression via ICSBP and AP-1 elements .	positive	0
18710	10975835	3458;3606	IFN-gamma;IL-18	***IFN-gamma*** ***up-regulates*** ***IL-18*** gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages .	positive	1
18711	10975857	3576;4790	IL-8;p50	The ***IL-8*** oligonucleotide ***bound*** recombinant ***p50*** with only about one-tenth the efficiency of the IL-6 oligonucleotide , even though epithelial cells produced more IL-8 protein than IL-6 .	parallel	1
18712	10975862	7040;7852	TGF-beta 1;CXCR4	Persistent ***induction*** of the chemokine receptor ***CXCR4*** by ***TGF-beta 1*** on synovial T cells contributes to their accumulation within the rheumatoid synovium .	target	1
18713	10975862	7040;7852	TGF-beta;CXCR4	Extensive screening revealed that ***TGF-beta*** isoforms ***induce*** the expression of ***CXCR4*** on CD4 T cells in vitro .	target	1
18714	10975862	7040;7852	TGF-beta1;CXCR4	These results suggest that the persistent ***induction*** of ***CXCR4*** on synovial T cells by ***TGF-beta1*** leads to their active , SDF-1-mediated retention in a perivascular distribution within the rheumatoid synovium .	target	1
18715	10975872	959;958	CD40L;CD40	Although interruption of ******CD40-CD40L****** ***interactions*** via their respective mAbs yields prolonged allograft survival , the relative importance of CD40 or CD40L on donor or host cells remains unknown .	parallel	1
18716	10975908	356;355	CD95L;Fas	Reactive astrocytes upregulate Fas ( CD95 ) and ***Fas*** ***ligand*** ( ***CD95L*** ) expression but do not undergo programmed cell death during the course of anterograde degeneration .	parallel	1
18717	10975909	7124;4843	TNF-alpha;NOS-2	In vitro astrocytes constitutively express TNF-R1 and ***TNF-alpha*** stimulation ***induces*** expression of ***NOS-2*** .	target	1
18718	10975909	7132;4843	TNF-R1;NOS-2	In vitro astrocytes constitutively express ***TNF-R1*** and TNF-alpha stimulation ***induces*** expression of ***NOS-2*** .	target	1
18719	10975915	356;355	CD95L;Fas	It was previously shown that reactive astrocytes express high levels of Fas ( CD95 ) and respond to ***Fas*** ***ligand*** ( ***CD95L*** ) by apoptosis or IL-8 production .	parallel	1
18720	10975915	8742;8718	TWEAK;Apo-3	***TWEAK*** ( ***Apo-3*** ***ligand*** ) is a recently identified member of the TNF family that is produced mainly by leukocytes that can infiltrate the inflamed brain and thus influence astrocyte behavior .	parallel	1
18721	10975915	8742;3383	TWEAK;ICAM-1	***TWEAK*** significantly ***increased*** ***ICAM-1*** expression on astrocytes , whereas no modification was detected in the expression of Fas , TNFRI , B7-1 , or MHC molecules .	positive	0
18722	10975987	8651;3717	JAB;JAK2	IL-5-Induced ******JAB-JAK2****** ***interaction*** .	parallel	1
18723	10975987	8651;3717	JAB;JAK2	***JAB*** has recently been identified as a ***regulator*** of ***JAK2*** phosphorylation and activity by binding phosphorylated JAK2 and inducing its degradation .	target	1
18724	10975987	8651;3717	JAB;JAK2	Since JAB has already been shown to bind JAK2 via a phosphorylated tyrosine , the current data suggest that ***JAB*** ***binds*** to phosphorylated JAK2 , enhances JAK2 dephosphorylation and remains associated in a complex , with dephosphorylated ***JAK2*** , that may be a precursor leading to irreversible JAK2 degradation .	parallel	1
18725	10975987	8651;3717	JAB;JAK2	Since ***JAB*** has already been shown to ***bind*** ***JAK2*** via a phosphorylated tyrosine , the current data suggest that JAB binds to phosphorylated JAK2 , enhances JAK2 dephosphorylation and remains associated in a complex , with dephosphorylated JAK2 , that may be a precursor leading to irreversible JAK2 degradation .	parallel	1
18726	10975987	8651;3717	JAB;JAK2	Since JAB has already been shown to bind JAK2 via a phosphorylated tyrosine , the current data suggest that ***JAB*** binds to phosphorylated JAK2 , ***enhances*** ***JAK2*** dephosphorylation and remains associated in a complex , with dephosphorylated JAK2 , that may be a precursor leading to irreversible JAK2 degradation .	positive	0
18727	10975989	3586;9332	IL-10;CD163	Human monocytes express ***CD163*** , which is ***upregulated*** by ***IL-10*** and identical to p155 .	positive	1
18728	10975989	3586;9332	IL-10;CD163	We also show that ***IL-10*** , like glucocorticoids , ***induces*** high ***CD163*** expression on cultured human monocytes .	target	1
18729	10975991	3458;5696	IFN-gamma;LMP7	***IFN-gamma*** ***upregulated*** ***LMP7*** levels , as did TNF-alpha to a lesser extent .	positive	1
18730	10975994	3586;4790	IL-10;NF-kappa B	***IL-10*** also ***inhibited*** TNF secretion and ***NF-kappa B*** activation induced by another stimulus , staphylococcal toxin .	negative	1
18731	10975998	6352;3565	RANTES;IL-4	***RANTES*** ***enhanced*** ***IL-4*** production in the presence of IL-4 , whereas it suppressed IL-4 production in the absence of IL-4 .	positive	0
18732	10976101	7040;1490	TGF-beta;CTGF	Induction of CTGF mRNA was transient with maximal expression after 1 to 2 h , whereas ***induction*** of ***CTGF*** by transforming growth factor beta ( ***TGF-beta*** ) increased over time .	target	1
18733	10976101	7040;1490	TGF-beta;CTGF	Inhibition of the downstream mediator of RhoA , the Rho kinase by Y-27632 partially reduced ***induction*** of ***CTGF*** by LPA and ***TGF-beta*** .	target	1
18734	10976102	6464;2885	Shc;Grb2	Analysis of these cells indicates that FAK is not necessary for efficient tyrosine phosphorylation of Shc , ***association*** of ***Shc*** with ***Grb2*** , and activation of ERK in response to matrix adhesion .	parallel	0
18735	10976102	673;5594	B-Raf;ERK	To examine if FAK could contribute to the ***activation*** of ***ERK*** in a cell type-specific manner through the ***Rap1/B-Raf*** pathway , we have used Swiss-3T3 cells , which in contrast to primary fibroblasts express B-Raf .	positive	1
18736	10976104	2660;1017	Myostatin;Cdk2	Western analysis indicated that ***Myostatin*** specifically up-regulated p21 ( Waf1 , Cip1 ) , a cyclin-dependent kinase inhibitor , and ***decreased*** the levels and activity of ***Cdk2*** protein in myoblasts .	negative	0
18737	10976104	2660;1026	Myostatin;p21	Western analysis indicated that ***Myostatin*** specifically ***up-regulated*** ***p21*** ( Waf1 , Cip1 ) , a cyclin-dependent kinase inhibitor , and decreased the levels and activity of Cdk2 protein in myoblasts .	positive	1
18738	10976773	3725;2624	AP-1;GATA-2	We have previously reported that expression of the human ET-1 gene is positively regulated by a cooperative ***interaction*** between ***GATA-2*** and ***AP-1*** transcription factors in cultured endothelial cells , however these factors are not sufficient to mediate cell type-specific expression .	parallel	1
18739	10976912	7200;1956	Thyrotropin-releasing hormone;epidermal growth factor receptor	***Thyrotropin-releasing hormone*** ***stimulates*** phosphorylation of the ***epidermal growth factor receptor*** in GH3 pituitary cells .	positive	0
18740	10976913	5781;6777	SHP-2;STAT5B	These data suggest that tyrosine 595 is a major site of interaction of GHR with SHP-2 , and that GHR-bound ***SHP-2*** negatively ***regulates*** GHR/JAK2 and ***STAT5B*** signaling .	negative	1
18741	10976916	2908;4609	glucocorticoid receptor;c-myc	We conclude that the ***glucocorticoid receptor*** ***binds*** to the ***c-myc*** promoter in competition with this protein , which is a repressor of transcription .	parallel	1
18742	10976919	6777;7068	Stat5;thyroid hormone receptor-beta 1	***Cross-talk*** between signal transducer and activator of transcription ( ***Stat5*** ) and ***thyroid hormone receptor-beta 1*** ( TRbeta1 ) signaling pathways .	parallel	0
18743	10976925	5916;6256	retinoic acid receptor-gamma;retinoid X receptor-alpha	Electrophoretic mobility shift assays using this element demonstrated the specific ***binding*** of murine ***retinoic acid receptor-gamma*** ( RARgamma ) and ***retinoid X receptor-alpha*** ( RXRalpha ) proteins .	parallel	1
18744	10976953	1020;4137	cdk5;tau	Studies suggest that the role of ***tau*** in the sequence of molecular events leading to extension of neurites in neuroblastoma cells is ***mediated*** by selective phosphorylations by ***cdk5*** .	target	0
18745	10976987	3553;2697	IL-1;Cx43	***IL-1-dependent*** ***up-regulation*** of ***Cx43*** could be prevented by intracellular Ca2 + chelation but not by inhibitors of protein tyrosine kinases , suggesting a crucial role of cytosolic Ca2 + in regulating the expression of Cx43 .	positive	1
18746	10976990	2885;5594	Grb2;Erk	In contrast to their implication in epidermal growth factor (EGF) receptor tyrosine kinase signaling , the adaptor protein Shc , the ***Grb2/Sos*** complex , and the small G protein Ras were not involved in the ***activation*** of ***Erk*** induced by either LPA or PGF2alpha in MC3T3-E1 cells , suggesting that activation of Erk by Gi and Gq protein-coupled receptors is Ras independent in these cells .	positive	1
18747	10976990	6464;5594	Shc;Erk	In contrast to their implication in epidermal growth factor (EGF) receptor tyrosine kinase signaling , the adaptor protein ***Shc*** , the Grb2/Sos complex , and the small G protein Ras were not involved in the ***activation*** of ***Erk*** induced by either LPA or PGF2alpha in MC3T3-E1 cells , suggesting that activation of Erk by Gi and Gq protein-coupled receptors is Ras independent in these cells .	positive	1
18748	10976991	7124;3383	tumor necrosis factor alpha;intercellular adhesion molecule 1	Recently , we showed that ***tumor necrosis factor alpha*** ( TNF-alpha ) ***stimulates*** expression of the ***intercellular adhesion molecule 1*** ( ICAM-1 ) and interleukin-6 ( IL-6 ) genes through activation of p65-p50 heterodimer nuclear factor KB ( NF-kappaB ) in rat osteoblast-like ROS17/2 .8 cells .	positive	0
18749	10976991	7124;3569	tumor necrosis factor alpha;interleukin-6	Recently , we showed that ***tumor necrosis factor alpha*** ( TNF-alpha ) ***stimulates*** expression of the intercellular adhesion molecule 1 ( ICAM-1 ) and ***interleukin-6*** ( IL-6 ) genes through activation of p65-p50 heterodimer nuclear factor KB ( NF-kappaB ) in rat osteoblast-like ROS17/2 .8 cells .	positive	0
18750	10976991	7124;4790	TNF-alpha;NF-kappaB	In the present study , we investigated effects of a synthetic glucocorticoid , dexamethasone ( Dex ) , on ***TNF-alpha-dependent*** ***activation*** of ***NF-kappaB*** and expression of the ICAM-1 gene .	positive	1
18751	10976991	7124;4790	TNF-alpha;NF-kappaB	Electrophoretic mobility shift assay ( EMSA ) revealed that ***TNF-alpha-dependent*** ***activation*** of ***NF-kappaB*** was almost completely suppressed by Dex treatment .	positive	1
18752	10977134	2321;7422	Flt-1;VEGF	VEGF also enhanced tube formation in dog endothelial cells and increased the expression of two ***VEGF*** ***receptors*** , ***Flt-1*** and KDR/Flk -1 .	parallel	1
18753	10977134	3791;7422	KDR;VEGF	VEGF also enhanced tube formation in dog endothelial cells and increased the expression of two ***VEGF*** ***receptors*** , Flt-1 and ***KDR/Flk*** -1 .	parallel	1
18754	10977134	7422;2321	VEGF;Flt-1	***VEGF*** also enhanced tube formation in dog endothelial cells and ***increased*** the expression of two VEGF receptors , ***Flt-1*** and KDR/Flk -1 .	positive	0
18755	10977134	7422;3791	VEGF;KDR	***VEGF*** also enhanced tube formation in dog endothelial cells and ***increased*** the expression of two VEGF receptors , Flt-1 and ***KDR/Flk*** -1 .	positive	0
18756	10977134	7422;2321	VEGF;Flt-1	***VEGF*** also ***increases*** the expression of the receptors , KDR and ***Flt-1*** , and activates the p44/42 MAP kinase pathway .	positive	0
18757	10977134	7422;3791	VEGF;KDR	***VEGF*** also ***increases*** the expression of the receptors , ***KDR*** and Flt-1 , and activates the p44/42 MAP kinase pathway .	positive	0
18758	10978054	627;581	brain-derived neurotrophic factor;Bax	Intravenous ***brain-derived neurotrophic factor*** ***reduces*** infarct size and counterregulates ***Bax*** and Bcl-2 expression after temporary focal cerebral ischemia .	negative	1
18759	10978054	627;596	brain-derived neurotrophic factor;Bcl-2	Intravenous ***brain-derived neurotrophic factor*** ***reduces*** infarct size and counterregulates Bax and ***Bcl-2*** expression after temporary focal cerebral ischemia .	negative	1
18760	10978250	3553;9934	IL-1beta;P2Y(2) receptor	Actinomycin D completely blocked the ***upregulation*** of ***P2Y(2) receptor*** mRNA expression by ***IL-1beta*** , indicating de novo mRNA synthesis .	positive	1
18761	10978250	3553;9934	IL-1beta;P2Y(2) receptor	The cyclooxygenase inhibitor indomethacin and the protein kinase C inhibitor RO-31-8220 inhibited ***IL-1beta-induced*** ***upregulation*** of ***P2Y(2) receptor*** mRNA expression , whereas rapamycin and PD098059 had no effects .	positive	1
18762	10978279	55823;23355	PEP5;VPS8	***PEP5*** ***interacts*** genetically with ***VPS8*** , implicating Pep5p in the earlier Golgi to endosome step and/or in recycling from the endosome to the Golgi .	parallel	1
18763	10978311	959;958	CD40L;CD40	It has been reported that ligation of CD40 with ***CD40*** ***ligand*** ( ***CD40L*** ) results in microglial activation as evidenced by p44/42 mitogen-activated protein kinase ( MAPK ) dependent tumor necrosis factor alpha ( TNF-alpha ) production .	parallel	1
18764	10978315	4803;1026	NGF;WAF1	With p53 functionally inactivated , ***NGF*** failed to activate growth arrest , as measured by bromodeoxyuridine incorporation , and also failed to ***induce*** ***p21/WAF1*** expression , as measured by Western blotting .	target	1
18765	10978317	5594;5321	p38;cPLA2	We have previously reported that in thrombin-stimulated human platelets , cytosolic phospholipase A ( 2 ) ( ***cPLA2*** ) is ***phosphorylated*** on Ser-505 by ***p38*** protein kinase and on Ser-727 by an unknown kinase .	target	1
18766	10978333	64376;10320	pegasus;Ikaros	***pegasus*** is ***related*** to other ***Ikaros*** proteins in its C-terminal dimerization domain but contains a divergent N-terminal zinc finger domain .	parallel	0
18767	10978339	4170;5111	MCL1;proliferating cell nuclear antigen	Here we show in vitro and in vivo that ***MCL1*** ***interacts*** with the cell cycle regulator , ***proliferating cell nuclear antigen*** ( PCNA ) .	parallel	1
18768	10978340	3303;5599	HSP72;JNK	***HSP72*** ***suppressed*** activation of ***JNK*** and did not increase ERK activity , suggesting that inhibition of JNK is the important component of HSP72-mediated protection .	negative	1
18769	10978340	6416;5599	SEK1;JNK	Upon transient energy deprivation , activation of JNK proceeds via two distinct pathways , ***stimulation*** of ***JNK*** phosphorylation by a protein kinase ***SEK1*** and inhibition of JNK dephosphorylation .	positive	0
18770	10978340	3303;5599	HSP72;JNK	Therefore , it appears that ***HSP72*** specifically ***down-regulates*** ***JNK*** by accelerating its dephosphorylation , which reduces the susceptibility of cardiac cells to simulated ischemia/reperfusion .	negative	1
18771	10978346	341;1071	apoC-I;CETP	Pure ***apoC-I*** was able to ***abolish*** ***CETP*** activity in a concentration-dependent manner and with a high efficiency ( IC ( 50 ) = 100 nmol/liter ) .	negative	0
18772	10978362	348;1636	APOE;ACE	While the APOE epsilon4 allele was strongly associated with AD risk in our series , we found no evidence for an ***interaction*** between the ***APOE*** and ***ACE*** loci .	parallel	1
18773	10978533	85302;355	Fbf-1;FAS	A novel protein ( ***Fbf-1*** ) that ***binds*** to ***CD95/APO-1/FAS*** and shows sequence similarity to trichohyalin and plectin .	parallel	1
18774	10978779	4914;4803	trkA;Nerve growth factor	We have recently reported that retinoic acid ( RA ) induced the expression of ***trkA*** , the high affinity ***receptor*** for ***Nerve growth factor*** ( NGF ) , in human chronic myelogenous leukemia K562 cells .	parallel	1
18775	10978848	5617;2822	Prolactin;PLD	***Prolactin*** concurrently ***activates*** ***src-PLD*** and JAK/Stat signaling pathways to induce proliferation while promoting differentiation in embryonic astrocytes .	positive	1
18776	10978848	5617;3717	Prolactin;Janus kinase (JAK) 2	In exploring the signaling for Prolactin-induced differentiation we found that ***Prolactin*** ***activated*** the tyrosine kinase ***Janus kinase (JAK) 2*** and significantly stimulated tyrosine , phosphorylation of the prolactin receptor .	positive	1
18777	10979047	5617;7200	PRL;TRH	In most cases the ***PRL*** ***response*** to ***TRH*** was diminished , but in three patients excessive secretion of PRL was found .	parallel	0
18778	10979209	1440;2209	granulocyte colony-stimulating factor;CD64	***CD64*** expression is ***induced*** in a slow kinetic manner by interferon ( IFN ) - gamma and ***granulocyte colony-stimulating factor*** ( G-CSF ) after 12 to 24 hours of exposure to these agents .	target	1
18779	10979212	3675;3655	CD49c;CD49f	In pre-B ALL , expression of CD11a positively correlated with that of CD11b ( P < .05 ) and CD54 ( P < .01 ) , and ***CD49c*** positively ***correlated*** with ***CD49f*** ( P < .01 ) .	positive	0
18780	10979212	3683;3383	CD11a;CD54	In pre-B ALL , expression of ***CD11a*** positively ***correlated*** with that of CD11b ( P < .05 ) and ***CD54*** ( P < .01 ) , and CD49c positively correlated with CD49f ( P < .01 ) .	positive	0
18781	10979241	1991;6590	neutrophil elastase;SLPI	Previous studies using airway epithelial cell lines indicated that ***neutrophil elastase*** ( NE ) ***increases*** ***SLPI*** mRNA transcripts while decreasing SLPI protein release .	positive	0
18782	10979933	6280;6279	MRP14;MRP8	These results suggest that intact calprotectin , consisting of a ***heterodimer*** of ***MRP8*** and ***MRP14*** , is necessary to form a zinc-binding site capable of inhibiting microbial growth .	parallel	1
18783	10979940	650;598	BMP-2;Bcl-x	In studies of apoptosis-associated proteins , ***BMP-2*** was seen to ***down-regulate*** the expression of ***Bcl-x*** ( L ) ; however , BMP-2 had no effects on the expression of Bcl-2 , Bax , or Bad .	negative	1
18784	10979950	6387;7852	SDF-1;CXCR4	These results demonstrate an essential role of ***CXCR4*** and its ***ligand*** ***SDF-1*** in adult hematopoiesis , and they indicate the intrakine method as a powerful tool for functional analysis of chemokines/chemokine receptors in vivo and as a potential therapeutic approach for acquired immunodeficiency syndrome .	parallel	1
18785	10979953	3439;7066	IFN-alpha;thrombopoietin	Using several marrow cell purification techniques and quantitative culture methods , it was found that ***IFN-alpha*** directly ***inhibits*** ***thrombopoietin*** ( TPO ) - induced MK growth .	negative	1
18786	10979953	7066;3717	TPO;JAK2	It was found that IFN-alpha directly suppresses ***TPO-induced*** ***phosphorylation*** of the ***JAK2*** substrates c-Mpl and STAT 5 in a TPO-dependent hematopoietic cell line and of Mpl and STAT3 in primary murine MK .	target	1
18787	10979953	3439;3717	IFN-alpha;JAK2	It was found that ***IFN-alpha*** directly ***suppresses*** TPO-induced phosphorylation of the ***JAK2*** substrates c-Mpl and STAT 5 in a TPO-dependent hematopoietic cell line and of Mpl and STAT3 in primary murine MK .	negative	1
18788	10979953	3439;8651	IFN-alpha;SOCS-1	Moreover , ***IFN-alpha*** ***induces*** ***SOCS-1*** production in these cells , which has been shown to inhibit TPO-induced cell growth .	target	1
18789	10979962	3581;3578	IL-9R;IL-9	To examine the interaction between IL-9 and eosinophils , we evaluated mature peripheral blood eosinophils for their expression of the specific alpha-subunit of the ***IL-9*** ***receptor*** ( ***IL-9R-alpha*** ) .	parallel	1
18790	10979965	7124;3576	tumor necrosis factor alpha;interleukin (IL) 8	In purified eosinophils primed with granulocyte-macrophage colony-stimulating factor , both ***tumor necrosis factor alpha*** ( TNF-alpha ) and HrHRF ***induced*** increased secretion of ***interleukin (IL) 8*** .	target	1
18791	10979969	959;958	CD40L;CD40	***Interaction*** between ***CD40*** and the CD40 ligand ( ***CD40L*** ) is critical for the survival and proliferation of B cells during immunopoiesis .	parallel	1
18792	10979976	25;598	Bcr/Abl;Bcl-X	***Bcr/Abl*** ***activates*** transcription of the ***Bcl-X*** gene through STAT5 .	positive	1
18793	10979976	25;598	Bcr/Abl;Bcl-X	We found that the proviability protein ***Bcl-X*** ( L ) , but not Bcl-2 , was ***induced*** by both p210 ( ***Bcr/Abl*** ) and STAT5-1 * 6 .	target	1
18794	10979976	25;598	Bcr/Abl;Bcl-X	Using a Bcl-X gene promoter construct fused to a luciferase complementary DNA ( cDNA ) , both p210 ( ***Bcr/Abl*** ) and STAT5-1 * 6 were shown to ***induce*** transcription of ***Bcl-X*** .	target	1
18795	10979976	6776;598	STAT5;Bcl-X	Using a Bcl-X gene promoter construct fused to a luciferase complementary DNA ( cDNA ) , both p210 ( Bcr/Abl ) and ***STAT5-1*** * 6 were shown to ***induce*** transcription of ***Bcl-X*** .	target	1
18796	10979978	10728;3320	p23;Hsp90	Immunoprecipitation analysis showed that p210 ( Bcr-Abl ) formed multiple complexes with Hsp90 , some containing p23 and others Hsp70 ; KF58333 treatment dissociated p210 ( Bcr-Abl ) from ******Hsp90/p23****** chaperone ***complexes*** .	parallel	1
18797	10980109	2146;4288	EZH2;Mib-1	In the germinal center , expression of BMI-1 is restricted to resting Mib-1/Ki -67 ( - ) centrocytes , whereas ***EZH2*** expression is ***associated*** with dividing ***Mib-1/Ki*** -67 ( + ) centroblasts .	parallel	0
18798	10980129	1435;351	M-CSF;Abeta	***M-CSF*** is increased in the brain in AD and dramatically ***augments*** the effects of ***Abeta*** on cultured microglia .	positive	0
18799	10980190	9020;4790	NIK;NF-kappa B	As expected , ***NIK*** expression led to I kappa B kinase activation and ***induced*** nuclear translocation of ***NF-kappa B*** .	target	1
18800	10980190	4792;4790	I kappa B alpha;NF-kappa B	However , NIK-induced neurite outgrowth was only partially blocked by concomitant expression of a nondegradable form of ***I kappa B alpha*** that completely ***blocks*** ***NF-kappa B*** induction .	negative	0
18801	10980190	9020;5604	NIK;MEK1	In search of additional signaling pathways activated by NIK , we now demonstrate that ***NIK*** ***activates*** ***MEK1*** phosphorylation and induces the Erk1/Erk2 MAPK pathway .	positive	1
18802	10980190	9020;5595	NIK;Erk1	In search of additional signaling pathways activated by NIK , we now demonstrate that ***NIK*** activates MEK1 phosphorylation and ***induces*** the ***Erk1/Erk2*** MAPK pathway .	target	1
18803	10980190	9020;5594	NIK;Erk2	In search of additional signaling pathways activated by NIK , we now demonstrate that ***NIK*** activates MEK1 phosphorylation and ***induces*** the ***Erk1/Erk2*** MAPK pathway .	target	1
18804	10980197	4193;7157	Mdm2;p53	***Mdm2*** ***inhibits*** the apoptotic function of ***p53*** mainly by targeting it for degradation .	negative	1
18805	10980197	7157;4193	p53;Mdm2	The ability of Mdm2 to inhibit the activities of a C-terminal truncated p53 mutant , ***p53-Delta30*** , which can ***bind*** ***Mdm2*** but is resistant to Mdm2-mediated protein degradation was investigated .	parallel	1
18806	10980197	4193;7157	Mdm2;p53	The inhibitory function of an Mdm2 mutant , ***Mdm2-Delta*** ( 222-437 ) , which can ***bind*** ***p53*** but is defective in targeting p53 for degradation was also studied .	parallel	1
18807	10980197	4193;7157	Mdm2;p53	We have demonstrated that targeting p53 for degradation is the most effective way for ***Mdm2*** to ***inhibit*** the apoptotic function of ***p53*** .	negative	1
18808	10980197	4193;7157	Mdm2;p53	However , we have also shown that ***Mdm2*** can ***inhibit*** the transactivation function of ***p53*** without targeting it for degradation , although Mdm2 releases the transrepression ability of p53 mainly by targeting it for degradation .	negative	1
18809	10980202	7223;9368	trp4;NHERF	***Association*** of mammalian ***trp4*** and phospholipase C isozymes with a PDZ domain-containing protein , ***NHERF*** .	parallel	0
18810	10980202	7223;9368	trp4;NHERF	We demonstrated the ***association*** of ***trp4*** and phospholipase C-beta1 with ***NHERF*** in vivo in an HEK293 cell line expressing trp4 and in adult mouse brain by immuno-coprecipitation .	parallel	0
18811	10980203	8517;8797	IKKgamma;DR4	Substitution of the C-terminal region of ***IKKgamma*** , which ***interacts*** with RIP , with a truncated ***DR4*** lacking its cytoplasmic death domain , produced a molecule that could induce IKK and NF-kappaB activation in cells in response to TRAIL .	parallel	1
18812	10980203	8517;3267	IKKgamma;RIP	Substitution of the C-terminal region of ***IKKgamma*** , which ***interacts*** with ***RIP*** , with a truncated DR4 lacking its cytoplasmic death domain , produced a molecule that could induce IKK and NF-kappaB activation in cells in response to TRAIL .	parallel	1
18813	10980203	1147;4790	IKKalpha;NF-kappaB	Enforced oligomerization of the N terminus of IKKgamma or truncated ***IKKalpha*** or IKKbeta lacking their serine-cluster domains can also ***induce*** IKK and ***NF-kappaB*** activation .	target	1
18814	10980213	4846;102723508	endothelial nitric oxide synthase;spasm	Recently , we discovered a T ( -786 ) -- > C mutation in the 5 ' - flanking region of the ***endothelial nitric oxide synthase*** gene that is ***associated*** with coronary ***spasm*** .	parallel	0
18815	10980416	5741;3381	Parathyroid hormone;BSP	***Parathyroid hormone*** ( PTH ) , which regulates serum calcium through its actions on bone cells , ***increases*** the expression of ***BSP*** in the rat osteosarcoma cell line ( ROS 17/2 .8 ) .	positive	0
18816	10980464	959;958	CD40L;CD40	******CD40-CD40L****** ***interactions*** in epidermal tumors may play a role in the proliferation , and the lack of CD40 in tumor cells from SCC might be involved in the mechanisms of escape from the growth inhibitory effect .	parallel	1
18817	10980593	51083;387	galanin;RhoA	In support of G ( i ) coupling , stimulation of GALR2 expressed in HEK293 cells inhibited isoproterenol-induced cAMP accumulation and raised cAMP levels in COS-7 cells when coexpressed with a chimeric G alpha ( S ) - G alpha ( i ) protein In H69 cells , ***galanin*** ***activated*** the monomeric GTPase ***RhoA*** and induced stress fiber formation in Swiss 3T3 cells expressing GALR2 .	positive	1
18818	10980593	51083;8811	galanin;GALR2	Thus , we provide the first direct evidence that in SCLC the mitogenic neuropeptide ***galanin*** , ***interacting*** with ***GALR2*** , simultaneously activates multiple classes of G proteins and signals through the G ( q ) phospholipase C/calcium sequence and a G ( 12 ) / Rho pathway .	parallel	1
18819	10980594	356;8797	CD95 (Fas/APO-1) ligand;Apo2	In contrast , sFRPs do not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines , ***CD95 (Fas/APO-1) ligand*** ( CD95L ) or ***Apo2*** ligand/tumor necrosis factor-related apoptosis-inducing ***ligand*** ( Apo2L/TRAIL ) , or various cytotoxic drugs .	parallel	1
18820	10980594	8743;8797	TRAIL;Apo2	In contrast , sFRPs do not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines , CD95 (Fas/APO-1) ligand ( CD95L ) or ***Apo2*** ligand/tumor necrosis factor-related apoptosis-inducing ***ligand*** ( ***Apo2L/TRAIL*** ) , or various cytotoxic drugs .	parallel	1
18821	10980602	7161;50484	p73;p53R2	Several isoforms of the p53 family member ***p73*** were also shown to ***induce*** ***p53R2*** expression .	target	1
18822	10980604	2130;2247	EWS/FLI-1;bFGF	A ***link*** between basic fibroblast growth factor ( ***bFGF*** ) and ***EWS/FLI-1*** in Ewing 's sarcoma cells .	parallel	0
18823	10980604	2130;2247	EWS/FLI-1;bFGF	Experiments using specific cell cycle blockers ( thymidine and colcemide ) suggest that ***EWS/FLI-1*** is directly ***linked*** to ***bFGF*** stimulation , and not indirectly to cell proliferation .	parallel	0
18824	10980606	581;293	Bax;ANT	However , it has been reported that it is adenine nucleotide translocator ( ***ANT*** ) with which ***Bax/Bcl-xL*** ***interacts*** that modulate the channel activity .	parallel	1
18825	10980606	598;293	Bcl-xL;ANT	However , it has been reported that it is adenine nucleotide translocator ( ***ANT*** ) with which ***Bax/Bcl-xL*** ***interacts*** that modulate the channel activity .	parallel	1
18826	10980608	64006;5371	cORF;promyelocytic leukemia	Human endogenous retrovirus protein ***cORF*** supports cell transformation and ***associates*** with the ***promyelocytic leukemia*** zinc finger protein .	parallel	0
18827	10980611	5604;5594	MEK-1;ERK	MEK inhibitor U0126 blocked the induction , while activated ***MEK-1*** transfected into a rat mammary adenocarcinoma cell line ***induced*** a sustained activation of ***ERK*** and up-regulated SMC/Muc4 expression .	target	1
18828	10980614	9531;3312	CAIR-1;Hsc70	We show that ***CAIR-1/BAG-3*** ***binds*** to PLC-gamma and ***Hsp70/Hsc70*** through separate and distinct domains .	parallel	1
18829	10980614	9531;3308	CAIR-1;Hsp70	We show that ***CAIR-1/BAG-3*** ***binds*** to PLC-gamma and ***Hsp70/Hsc70*** through separate and distinct domains .	parallel	1
18830	10980614	9531;3312	CAIR-1;Hsc70	***CAIR-1/BAG-3*** forms an EGF-regulated ternary ***complex*** with phospholipase C-gamma and ***Hsp70/Hsc70*** .	parallel	1
18831	10980614	9531;3308	CAIR-1;Hsp70	***CAIR-1/BAG-3*** forms an EGF-regulated ternary ***complex*** with phospholipase C-gamma and ***Hsp70/Hsc70*** .	parallel	1
18832	10980614	9531;3312	CAIR-1;Hsc70	We show that ***CAIR-1/BAG-3*** ***binds*** to ***Hsp70/Hsc70*** in intact cells and this binding is increased by short term exposure to CAI ( P < 0.007 ) .	parallel	1
18833	10980614	9531;3308	CAIR-1;Hsp70	We show that ***CAIR-1/BAG-3*** ***binds*** to ***Hsp70/Hsc70*** in intact cells and this binding is increased by short term exposure to CAI ( P < 0.007 ) .	parallel	1
18834	10980695	4193;7157	HDM2;p53	The ***p53*** tumour-suppressor protein is negatively ***regulated*** by ***HDM2*** .	negative	1
18835	10980695	7157;4193	p53;HDM2	This activity is dependent on ***binding*** of ***p53*** to ***HDM2*** , and requires an intact p53 NES , but is independent of the HDM2 NES .	parallel	1
18836	10980696	4193;7157	MDM2;p53	The ***MDM2*** RING-finger domain is required to ***promote*** ***p53*** nuclear export .	positive	0
18837	10980696	4193;7157	MDM2;p53	***MDM2*** can ***bind*** to ***p53*** and promote its ubiquitination and subsequent degradation by the proteasome .	parallel	1
18838	10980696	4193;7157	MDM2;p53	Here we show that ***MDM2*** can ***promote*** the nuclear export of ***p53*** in transiently transfected cells .	positive	0
18839	10980705	1500;387	p120 catenin;RhoA	***Inhibition*** of ***RhoA*** by ***p120 catenin*** .	negative	1
18840	10980705	1500;387	p120;RhoA	Here we show that ***p120*** selectively ***inhibits*** ***RhoA*** activity in vitro and in vivo .	negative	1
18841	10980706	3315;317	Hsp27;Apaf-1	***Hsp27*** binds to cytochrome c released from the mitochondria to the cytosol and ***prevents*** cytochrome-c-mediated interaction of ***Apaf-1*** with procaspase-9 .	negative	0
18842	10980707	324;1499	APC;beta-catenin	Nuclear-cytoplasmic shuttling of ***APC*** ***regulates*** ***beta-catenin*** subcellular localization and turnover .	target	1
18843	10980707	324;1499	APC;beta-catenin	Transient expression of wild-type ***APC*** in SW480 ( APCmut/mut ) colon cancer cells ***enhances*** nuclear export and degradation of ***beta-catenin*** , and these effects can be blocked by mutagenesis of the APC NES .	positive	0
18844	10980707	324;1499	APC;beta-catenin	These findings suggest that wild-type ***APC*** ***controls*** the nuclear accumulation of ***beta-catenin*** by a combination of nuclear export and cytoplasmic degradation .	target	0
18845	10980893	4879;4881	BNP;NPR-A	ANP and ***BNP*** ***bind*** to the natriuretic peptide-A receptor ( ***NPR-A*** ) , which , via 3 ' ,5 ' - cyclic guanosine monophosphate ( cGMP ) , mediates natriuresis , vasodilatation , renin inhibition , antimitogenesis , and lusitropic properties .	parallel	1
18846	10981059	4012;183	AT(2) receptor;angiotensin II	The ***AT(2) receptor*** ***mediates*** several renal actions of ***angiotensin II*** , appears to be important in the physiologic regulation of blood pressure , and may be involved in the pathophysiology of hypertension .	target	0
18847	10981064	5972;5502	renin;inhibitor-1	The ***renin-angiotensin*** system is now recognized to be ***linked*** to induction of plasminogen activator ***inhibitor-1*** ( PAI-1 ) , possibly via the AT ( 4 ) receptor , thus promoting both thrombosis and fibrosis .	parallel	0
18848	10981064	5972;3827	renin;bradykinin	***Interactions*** of the ***renin-angiotensin*** system with aldosterone and ***bradykinin*** may have impact on both blood pressure and tissue injury .	parallel	1
18849	10981147	183;7040	angiotensin II;TGF-beta1	Based on our hypotheses , and the observations that angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists reduce ***angiotensin II-mediated*** ***stimulation*** of ***TGF-beta1*** production , we propose that treatment with these agents might be efficacious in preventing or slowing the progression of target organ damage in hypertensive blacks .	positive	0
18850	10981515	4790;5970	p50;p65	PMA-primed neutrophils resulted in the activation of two species of NF-kappaB dimers ( a ******p50/p65****** ***heterodimer*** and a p50 homodimer ) .	parallel	1
18851	10981868	596;7157	bcl-2;p53	Expression of ***bcl-2*** in carcinoma was ***associated*** with a lower ***p53*** levels and lower mean Ki67 LI and with favorable histopathologic parameters .	parallel	0
18852	10981960	7010;284	Tek;angiopoietin-1	Mice with a targeted null mutation in the Fli-1 locus die at day 11.5 of embryogenesis with loss of vascular integrity leading to bleeding within the vascular plexus of the cerebral meninges and specific downregulation of ***Tek/Tie-2*** , the ***receptor*** for ***angiopoietin-1*** .	parallel	1
18853	10981962	6608;6469	Smo;Shh	Shh is produced by the thymic stroma , and Patched and Smoothened ( ***Smo*** ) , the transmembrane ***receptors*** for ***Shh*** , are expressed in DN thymocytes .	parallel	1
18854	10982026	5077;4286	PAX3;MITF	Transcription factor hierarchy in Waardenburg syndrome : ***regulation*** of ***MITF*** expression by SOX10 and ***PAX3*** .	target	1
18855	10982026	6663;4286	SOX10;MITF	Transcription factor hierarchy in Waardenburg syndrome : ***regulation*** of ***MITF*** expression by ***SOX10*** and PAX3 .	target	1
18856	10982026	6663;4286	SOX10;MITF	Promoter deletion and mutational analyses indicate that ***SOX10*** can ***activate*** ***MITF*** expression through binding to a region that is evolutionarily conserved between the mouse and human MITF promoters .	positive	1
18857	10982026	6663;4286	SOX10;MITF	A SOX10 mutant that models C-terminal truncations in WS can reduce wild-type ***SOX10*** ***induction*** of ***MITF*** , suggesting these mutations may act in a dominant-negative fashion .	target	1
18858	10982244	3569;7066	IL-6;TPO	The combination of TPO plus other cytokines , including EPO , IL-3 , and SCF , resulted in a synergistic enhancement of the number of CFU-Meg colonies , but ***IL-6*** failed to ***enhance*** the effect of ***TPO*** .	positive	0
18859	10982373	1759;920	dynamin-1;CD4	A transdominant-negative mutant of ***dynamin-1*** ***inhibited*** A2-endo constitutive internalization and Nef-induced ***CD4*** down-regulation , whereas it did not affect the activity of Nef on MHC-I .	positive	1
18860	10982390	1051;1026	C/EBPbeta;p21	Eight hours after MAPK activation , loss of ***C/EBPbeta*** or Ets2 function significantly reduced MAPK-stimulated transcription from the p21 promoter and ***abolished*** increased ***p21*** protein expression .	positive	0
18861	10982404	5175;5175	CD31;PECAM-1	******PECAM-1/CD31****** trans-homophilic ***binding*** at the intercellular junctions is independent of its cytoplasmic domain ; evidence for heterophilic interaction with integrin alphavbeta3 in Cis .	parallel	1
18862	10982404	3685;5175	integrin alphavbeta3;PECAM-1	However , based on cocapping experiments performed on proT cells , we provide evidence that the ***integrin alphavbeta3*** ***associates*** with ***PECAM-1*** on the same cell surface as in a Cis manner .	parallel	0
18863	10982406	8417;8673	Syntaxin 7;Vamp 8	***Syntaxin 7*** is localized to late endosome compartments , ***associates*** with ***Vamp 8*** , and Is required for late endosome-lysosome fusion .	parallel	0
18864	10982406	8417;8673	Syntaxin 7;Vamp 8	Coimmunoprecipitation experiments show that ***Syntaxin 7*** is ***associated*** with the endosomal v-SNARE ***Vamp 8*** , which partially colocalizes with Syntaxin 7 .	parallel	0
18865	10982407	5999;358	RGS4;aquaporin 1	In addition , ***RGS4*** expression ***inhibited*** trafficking of ***aquaporin 1*** to the plasma membrane in LLC-PK1 cells and impaired secretion of placental alkaline phosphatase from HEK293T cells .	negative	1
18866	10982409	114610;387	SAX-1;RhoA	Dominant negative mutations in the C. elegans RhoA GTPase cause neuronal cell shape defects similar to those of SAX-1 mutants , and genetic ***interactions*** between ***RhoA*** and ***SAX-1*** suggest shared functions .	parallel	1
18867	10982414	5747;5829	FAK;Paxillin	Focal adhesion targeting was also a requirement for maximal ***FAK-dependent*** tyrosine ***phosphorylation*** of ***Paxillin*** and FAK-related nonkinase ( FRNK ) - dependent inhibition of endogenous FAK function .	target	1
18868	10982546	9370;4792	Adiponectin;IkappaB-alpha	***Adiponectin*** ***suppressed*** TNF-alpha-induced ***IkappaB-alpha*** phosphorylation and subsequent NF-kappaB activation without affecting other TNF-alpha-mediated phosphorylation signals , including Jun N-terminal kinase , p38 kinase , and Akt kinase .	negative	1
18869	10982546	9370;4790	Adiponectin;NF-kappaB	***Adiponectin*** ***suppressed*** TNF-alpha-induced IkappaB-alpha phosphorylation and subsequent ***NF-kappaB*** activation without affecting other TNF-alpha-mediated phosphorylation signals , including Jun N-terminal kinase , p38 kinase , and Akt kinase .	negative	1
18870	10982546	9370;4790	Adiponectin;NF-kappaB	***Adiponectin*** , an adipocyte-derived plasma protein , ***inhibits*** endothelial ***NF-kappaB*** signaling through a cAMP-dependent pathway .	negative	1
18871	10982546	9370;7124	Adiponectin;TNF-alpha	We recently demonstrated that ***Adiponectin*** ***inhibited*** tumor necrosis factor-alpha ( ***TNF-alpha*** ) - induced expression of endothelial adhesion molecules and that plasma Adiponectin level was reduced in patients with coronary artery disease ( CIRCULATION : 1999 ; 100:2473 -2476 ) .	negative	1
18872	10982792	7276;4036	TTR;megalin	In the present study we observed that ***TTR*** , the transporter of both T ( 4 ) and retinol-binding protein , ***binds*** to ***megalin*** , the multiligand receptor expressed on the luminal surface of various epithelia including the renal proximal tubules .	parallel	1
18873	10982793	841;637	caspase-8;Bid	***Bid*** , a pro-apoptosis " BH3-only " member of the Bcl-2 family , can be ***cleaved*** by ***caspase-8*** after Fas/TNF-R1 engagement .	target	1
18874	10982794	2671;1956	HPO;epidermal growth factor receptor	***HPO*** ***stimulates*** tyrosine phosphorylation of ***epidermal growth factor receptor*** ( EGFR ) .	positive	0
18875	10982804	715;3488	C1r;IGFBP-5	In summary , human fibroblasts secrete ***C1r*** and C1s that actively ***cleave*** ***IGFBP-5*** .	target	1
18876	10982804	716;3488	C1s;IGFBP-5	In summary , human fibroblasts secrete C1r and ***C1s*** that actively ***cleave*** ***IGFBP-5*** .	target	1
18877	10982804	3488;3479	IGFBP-5;IGF-I	Because ***IGFBP-5*** has been shown to ***regulate*** ***IGF-I*** actions , understanding the chemical identity and regulation of this protease is important for understanding how IGF-I stimulates anabolic functions .	target	1
18878	10982806	6778;6772	STAT6;STAT1	Interleukin-4 / ***STAT6*** ***represses*** ***STAT1*** and NF-kappa B-dependent transcription through distinct mechanisms .	negative	1
18879	10982806	6778;3565	STAT6;Interleukin-4	***STAT6*** ***mediates*** ***Interleukin-4*** ( IL-4 ) - dependent positive and negative regulation of inflammatory gene expression .	target	0
18880	10982806	3565;4790	IL-4;NF-kappaB	Overexpression of CREB-binding protein dramatically enhanced IL-4/STAT6-stimulated transcription and overcame ***IL-4-mediated*** ***repression*** of ***TNFalpha/NF-kappaB-dependent*** but not IFNgamma/STAT1-dependent transcription .	negative	1
18881	10982806	3565;7124	IL-4;TNFalpha	Overexpression of CREB-binding protein dramatically enhanced IL-4/STAT6-stimulated transcription and overcame ***IL-4-mediated*** ***repression*** of ***TNFalpha/NF-kappaB-dependent*** but not IFNgamma/STAT1-dependent transcription .	negative	1
18882	10982806	6778;6772	STAT6;STAT1	Taken together these results demonstrate that ***STAT6*** ***mediates*** suppression of ***STAT1*** and NF-kappaB-dependent transcription by distinct mechanisms .	target	0
18883	10982822	7320;1874	E2 protein;E2F4	Expression of the ***E2 protein*** also led to posttranscriptional increase in the level of E2F4 , p105 ( Rb ) , and p130 and ***induced*** the formation of nuclear ***E2F4-p130*** and E2F4-p105 ( Rb ) complexes .	target	1
18884	10982822	7320;5934	E2 protein;p130	Expression of the ***E2 protein*** also led to posttranscriptional increase in the level of E2F4 , p105 ( Rb ) , and p130 and ***induced*** the formation of nuclear ***E2F4-p130*** and E2F4-p105 ( Rb ) complexes .	target	1
18885	10982827	6464;9846	Shc;Gab2	When fused directly to a mutant form of IL-2Rbeta that lacks other cytoplasmic tyrosines , ***Shc*** can ***promote*** ***Gab2*** tyrosyl phosphorylation .	positive	0
18886	10982828	3439;6775	IFN-alpha;Stat4	Mutation of the N domain at tryptophan residue W37 , predicted to interrupt N domain dimer formation , unexpectedly prevented ***IFN-alpha-induced*** tyrosine ***phosphorylation*** of the ***Stat4*** monomer , blocking dimer formation and nuclear translocation .	target	1
18887	10982831	3308;5599	hsp70;JNK	***JNK*** activation was ***inhibited*** by both ***hsp70*** and hsc70 and by each of the hsp70 domain mutant proteins .	negative	1
18888	10982832	7410;5879	Vav2;Rac1	Expression of a carboxy-terminal fragment of Vav2 decreased the elevation of Rac1 activity induced by epidermal growth factor , consistent with ***Vav2*** ***mediating*** activation of ***Rac1*** downstream from growth factor receptors .	target	0
18889	10982832	7410;998	Vav2;Cdc42	***Vav2*** ***activates*** Rac1 , ***Cdc42*** , and RhoA downstream from growth factor receptors but not beta1 integrins .	positive	1
18890	10982832	7410;5879	Vav2;Rac1	***Vav2*** ***activates*** ***Rac1*** , Cdc42 , and RhoA downstream from growth factor receptors but not beta1 integrins .	positive	1
18891	10982832	7410;387	Vav2;RhoA	***Vav2*** ***activates*** Rac1 , Cdc42 , and ***RhoA*** downstream from growth factor receptors but not beta1 integrins .	positive	1
18892	10982837	56993;9804	Tom22;Tom20	***Tom22*** forms a ***complex*** with ***Tom20*** , and its cytosolic domain functions as an import receptor as in fungi .	parallel	1
18893	10982844	3716;6772	Jak1;STAT1	***Regulation*** of ***STAT1*** nuclear export by ***Jak1*** .	target	1
18894	10982847	1387;2115	CBP;ER81	Consistent with the physical interaction between ER81 and the coactivators CBP and p300 , ***ER81*** transcriptional activity was ***potentiated*** by ***CBP/p300*** overexpression .	positive	0
18895	10982847	2033;2115	p300;ER81	Consistent with the physical interaction between ER81 and the coactivators CBP and p300 , ***ER81*** transcriptional activity was ***potentiated*** by ***CBP/p300*** overexpression .	positive	0
18896	10982849	4150;1187	myc-associated zinc finger protein;CLC-K1	Transcriptional ***regulation*** of the ***CLC-K1*** promoter by ***myc-associated zinc finger protein*** and kidney-enriched Krüppel-like factor , a novel zinc finger repressor .	target	1
18897	10982849	4150;1187	MAZ;CLC-K1	A gel mobility shift assay revealed sequence-specific ***binding*** of recombinant KKLF and ***MAZ*** proteins to the ***CLC-K1*** GA element , and the fine-mutation assay clarified that the consensus sequence for the KKLF binding site was GGGGNGGNG .	parallel	1
18898	10982853	5906;6714	Rap1;c-Src	***c-Src*** signaling induced by the adapters Sin and Cas is ***mediated*** by ***Rap1*** GTPase .	target	0
18899	10982853	5906;6714	Rap1;Src	In addition , we found that ***Rap1*** also ***mediates*** oncogenic ***Src*** signaling .	target	0
18900	10982853	5906;1445	Rap1;c-Src kinase	Our results show for the first time that ***Rap1*** ***mediates*** ***c-Src kinase*** signaling and reveal mechanistic differences in the signaling properties of wild-type and transforming Src proteins .	target	0
18901	10982864	9136;6079	U3-55k;snoRNA	***Interaction*** of the ***U3-55k*** protein with U3 ***snoRNA*** is mediated by the box B/C motif of U3 and the WD repeats of U3-55k .	parallel	1
18902	10982866	79991;29946	RPA32;RBT1	******RBT1-RPA32****** ***binding*** was confirmed by glutathione S : - transferase pull-down and co-immunoprecipitation .	parallel	1
18903	10982879	7157;4193	p53;MDM2	***MDM2*** is ***induced*** by ***p53*** in response to cellular insults such as DNA damage and can have effects upon the cell cycle that are independent or downstream of p53 .	target	1
18904	10983602	3557;3553	IL-1RA;interleukin-1 beta	METHOD : We therefore investigated the frequency of polymorphisms in the genes encoding ***interleukin-1 beta*** ( IL-1 beta ) and its ***receptor*** antagonist ( ***IL-1RA*** ) in 70 EOP patients , including a subgroup of 21 localised EOP ( L-EOP ) patients and 72 periodontally healthy controls .	parallel	1
18905	10983629	3479;7422	IGF-I;VEGF	It was recently found that insulin-like growth factor-I ( ***IGF-I*** ) ***enhances*** ***VEGF*** gene expression .	positive	0
18906	10983632	6750;3576	Somatostatin;interleukin-8	***Somatostatin*** ( SOM ) and octreotide ( OCT ) ***inhibit*** the secretion of ***interleukin-8*** ( IL-8 ) from human peripheral blood mononuclear cells ( PBMC ) in vitro .	negative	1
18907	10983863	356;355	FasL;Fas	The expression of ***Fas*** , a cell surface receptor directly responsible for triggering cell death by apoptosis , and its ***ligand*** ( ***FasL*** ) was investigated on both human colonic intraepithelial T lymphocytes ( IELs ) and peripheral blood mononuclear lymphocytes ( PBMLs ) .	parallel	1
18908	10983896	5578;3725	PKCalpha;AP-1	These data demonstrate that PKCdelta , PKCepsilon , and ***PKCalpha*** ***mediate*** arsenite-induced ***AP-1*** activation in JB6 cells through different MAP kinase ( Erks , JNKs , and p38 kinases ) pathways .	target	0
18909	10983986	8115;207	TCL1;Akt	In yeast two-hybrid screening , we found that ***TCL1*** ***interacts*** with ***Akt*** .	parallel	1
18910	10983986	8115;207	TCL1;Akt	All ***TCL1*** isoforms ***bind*** to the ***Akt*** pleckstrin homology domain .	parallel	1
18911	10983986	8115;207	TCL1;Akt	Both in vitro and in vivo ***TCL1*** ***increases*** ***Akt*** kinase activity and as a consequence enhances substrate phosphorylation .	positive	0
18912	10983986	8115;207	TCL1;Akt	***TCL1*** ***facilitates*** the oligomerization and activation of ***Akt*** .	positive	0
18913	10983988	3708;7222	IP3R;hTrp3	Biochemical and functional evidence suggest that mutually exclusive coupling reflects clustering and segregation of ******hTrp3-IP3R****** and hTrp3-RyR ***complexes*** in plasma membrane microdomains .	parallel	1
18914	10984100	3880;3856	CK19;CK8	We hypothesized that CK8 or CK19 released from epithelial cells may bind to and cause damage to extracellular matrixes through ***binding*** of ***anti-CK8*** or ***anti-CK19*** autoantibodies .	parallel	1
18915	10984246	1154;6777	CIS;STAT5b	In males , termination of the intracellular signalling stimulated by a plasma GH pulse is proposed to be additionally facilitated by GH-STAT5b-inducible ***SOCS-CIS*** proteins , which ***block*** the further activation of ***STAT5b*** by binding to and inhibiting the action of the GHR-JAK2 complex via multiple mechanisms .	negative	0
18916	10984246	2690;3717	GHR;JAK2	In males , termination of the intracellular signalling stimulated by a plasma GH pulse is proposed to be additionally facilitated by GH-STAT5b-inducible SOCS-CIS proteins , which block the further activation of STAT5b by binding to and inhibiting the action of the ******GHR-JAK2****** ***complex*** via multiple mechanisms .	parallel	1
18917	10984297	3479;3486	IGF-I;IGFBP-3	***IGF-I*** ***increased*** ***IGFBP-3*** and IGFBP-6 while decreasing IGFBP-4 .	positive	0
18918	10984297	3479;3489	IGF-I;IGFBP-6	***IGF-I*** ***increased*** IGFBP-3 and ***IGFBP-6*** while decreasing IGFBP-4 .	positive	0
18919	10984315	3481;3489	IGF-II;IGFBP-6	The effects of cAMP agonists and ***IGF-II*** , which ***increases*** ***IGFBP-6*** protein but not mRNA levels , were not inhibited by rapamycin , suggesting that p70 S6 kinase is not involved .	positive	0
18920	10984432	7402;1605	utrophin;beta-dystroglycan	Here we demonstrate that Dp71 and/or ***utrophin*** from rat retinal Müller glial cells form a complex ***with*** beta-dystroglycan ***,*** delta-sarcoglycan and alpha1-syntrophin .	parallel	1
18921	10984432	1605;1740	beta-dystroglycan;PSD-93	We also show that ***beta-dystroglycan*** is ***associated*** with alpha-dystrobrevin-1 and ***PSD-93*** and that anti-PSD antibodies coimmunoprecipitated alpha-syntrophin with PSD-93 .	parallel	0
18922	10984483	5515;5524	PP2A-alpha;PP2A	These results indicate that the ***PP2A-alpha*** ( 1C ) interaction constitutively ***recruits*** ***PP2A*** to the channel complex rather than being a transient substrate-catalytic site interaction .	target	0
18923	10984498	58529;8557	FATZ;telethonin	Furthermore , by using a glutathione S-transferase overlay assay we find that ***FATZ*** also ***binds*** ***telethonin*** .	parallel	1
18924	10984535	958;7187	CD40;TRAF3	Comparison of the ***interactions*** of ***CD40*** with ***TRAF3*** vs.	parallel	1
18925	10984605	7124;4792	TNF alpha;I kappa B alpha	***TNF alpha*** ***stimulated*** serine phosphorylation and degradation of the inhibitory protein ***I kappa B alpha*** and strongly induced nuclear NF-kappa B translocation and binding activity .	positive	0
18926	10984605	7124;4790	TNF alpha;NF-kappa B	***TNF alpha*** stimulated serine phosphorylation and degradation of the inhibitory protein I kappa B alpha and strongly ***induced*** nuclear ***NF-kappa B*** translocation and binding activity .	target	1
18927	10984610	7980;4313	Tissue factor pathway inhibitor-2;matrix metalloproteinase-2	***Tissue factor pathway inhibitor-2*** ***suppresses*** the production of active ***matrix metalloproteinase-2*** and is down-regulated in cells harboring activated ras oncogenes .	negative	1
18928	10984615	7157;51512	p53;B99	Therefore , B99 expression is modulated both by cell-cycle regulatory mechanisms and by ***p53*** , and p53 can ***increase*** the cellular levels of ***B99*** only during the window of the cell cycle when it is normally expressed .	positive	0
18929	10984620	2547;7014	Ku70;TRF2	***Interaction*** of human ***Ku70*** with ***TRF2*** .	parallel	1
18930	10985305	6285;3558	Nef;interleukin-2	***HIV-Nef*** ***enhances*** ***interleukin-2*** production and phosphatidylinositol 3-kinase activity in a human T cell line .	positive	0
18931	10985348	4804;627	p75NTR;neurotrophin	The mechanisms employed by the p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) to mediate neurotrophin-dependent apoptosis are poorly defined .	parallel	1
18932	10985348	9500;4804	NRAGE;p75NTR	***NRAGE*** ***binds*** ***p75NTR*** in vitro and in vivo , and NRAGE associates with the plasma membrane when NGF is bound to p75NTR .	parallel	1
18933	10985348	4804;4914	p75NTR;TrkA	NRAGE blocks the physical ***association*** of ***p75NTR*** with ***TrkA*** , and , conversely , TrkA overexpression eliminates NRAGE-mediated NGF-dependent death , indicating that interactions of NRAGE or TrkA with p75NTR are functionally and physically exclusive .	parallel	0
18934	10985348	9500;4804	NRAGE;p75NTR	NRAGE blocks the physical association of p75NTR with TrkA , and , conversely , TrkA overexpression eliminates NRAGE-mediated NGF-dependent death , indicating that ***interactions*** of ***NRAGE*** or TrkA with ***p75NTR*** are functionally and physically exclusive .	parallel	1
18935	10985348	4914;4804	TrkA;p75NTR	NRAGE blocks the physical association of p75NTR with TrkA , and , conversely , TrkA overexpression eliminates NRAGE-mediated NGF-dependent death , indicating that ***interactions*** of NRAGE or ***TrkA*** with ***p75NTR*** are functionally and physically exclusive .	parallel	1
18936	10985348	9500;4804	NRAGE;p75NTR	***NRAGE*** ***blocks*** the physical association of ***p75NTR*** with TrkA , and , conversely , TrkA overexpression eliminates NRAGE-mediated NGF-dependent death , indicating that interactions of NRAGE or TrkA with p75NTR are functionally and physically exclusive .	negative	0
18937	10985351	23426;2891	GRIP;GluR2	Mutagenesis reveals a role for ***ABP/GRIP*** ***binding*** to ***GluR2*** in synaptic surface accumulation of the AMPA receptor .	parallel	1
18938	10985351	2891;23426	GluR2;GRIP	We conclude that the ***association*** of ***GluR2*** with ABP and/or ***GRIP*** but not PICK1 is essential for maintaining the synaptic surface accumulation of the receptor , possibly by limiting its endocytotic rate .	parallel	0
18939	10985858	6469;2249	Shh;fgf4	This suggests that ***Shh*** ***mediates*** ***fgf4*** activation in the myotomes through mechanisms independent of its role in the activation of myogenic factors .	target	0
18940	10985890	6678;7422	SPARC;VEGF	Recent work has shown that ***SPARC*** ***modulates*** the mitogenic activity of ***VEGF*** in normal endothelium .	target	0
18941	10985964	183;2028	angiotensin II;AP-A	***angiotensin II*** ***evoked*** ***AP-A*** activity in first trimester trophoblast , and Losartan and PD 123177 in combination significantly inhibited this induction of AP-A activity .	positive	0
18942	10986281	9507;63827	aggrecanase-1;Brevican	***Brevican*** is ***degraded*** by matrix metalloproteinases and ***aggrecanase-1*** ( ADAMTS4 ) at different sites .	negative	0
18943	10986282	4217;3162	ASK1;heme oxygenase-1	Furthermore , when overexpressed , MEKK1 , TAK1 , and ***ASK1*** ***induced*** the expression of ***heme oxygenase-1*** , a gene regulated by ARE , and the cotransfection with the dominant-negative mutant of Nrf2 abolished the induction .	target	1
18944	10986282	4214;3162	MEKK1;heme oxygenase-1	Furthermore , when overexpressed , ***MEKK1*** , TAK1 , and ASK1 ***induced*** the expression of ***heme oxygenase-1*** , a gene regulated by ARE , and the cotransfection with the dominant-negative mutant of Nrf2 abolished the induction .	target	1
18945	10986282	6885;3162	TAK1;heme oxygenase-1	Furthermore , when overexpressed , MEKK1 , ***TAK1*** , and ASK1 ***induced*** the expression of ***heme oxygenase-1*** , a gene regulated by ARE , and the cotransfection with the dominant-negative mutant of Nrf2 abolished the induction .	target	1
18946	10986288	3458;838	interferon-gamma;CASP5	Expression analysis of the human caspase-1 subfamily reveals specific ***regulation*** of the ***CASP5*** gene by lipopolysaccharide and ***interferon-gamma*** .	target	1
18947	10986288	834;3606	caspase-1;interleukin-18	Only ***caspase-1*** is known to ***activate*** interleukin-1beta and ***interleukin-18*** , and caspase-11 activates pro-caspase-1 in vivo .	positive	1
18948	10986288	3458;834	interferon-gamma;CASP1	***interferon-gamma*** strongly ***induced*** ***CASP1*** and CASP5 but not CASP4 or CASP13 gene expression in HT-29 colon carcinoma cells .	target	1
18949	10986288	3458;838	interferon-gamma;CASP5	***interferon-gamma*** strongly ***induced*** CASP1 and ***CASP5*** but not CASP4 or CASP13 gene expression in HT-29 colon carcinoma cells .	target	1
18950	10986288	3458;834	interferon-gamma;caspase-1	In contrast to the mRNA , ***interferon-gamma*** ***up-regulated*** ***caspase-1*** but not caspase-5 protein .	positive	1
18951	10986288	3458;834	interferon-gamma;caspase-1	Our results demonstrate that ***caspase-1*** and caspase-5 levels are ***modulated*** by ***interferon-gamma*** and lipopolysaccharide , respectively , and suggest that caspase-1 subfamily members are differentially regulated and may have distinct functions .	target	0
18952	10986288	3458;838	interferon-gamma;caspase-5	Our results demonstrate that caspase-1 and ***caspase-5*** levels are ***modulated*** by ***interferon-gamma*** and lipopolysaccharide , respectively , and suggest that caspase-1 subfamily members are differentially regulated and may have distinct functions .	target	0
18953	10986289	8802;207	Galpha;Akt	In HEK-293 cells ***Galpha*** ( q ) - Q209L transfection ***inhibited*** insulin-like growth factor-1 activation of epitope-tagged ***Akt*** .	negative	1
18954	10986289	3479;207	insulin-like growth factor-1;Akt	In HEK-293 cells Galpha ( q ) - Q209L transfection inhibited ***insulin-like growth factor-1*** ***activation*** of epitope-tagged ***Akt*** .	positive	1
18955	10986289	8802;3479	Galpha;insulin-like growth factor-1	In HEK-293 cells ***Galpha*** ( q ) - Q209L transfection ***inhibited*** ***insulin-like growth factor-1*** activation of epitope-tagged Akt .	negative	1
18956	10986290	10499;2099	GRIP1;ERalpha	Weak tamoxifen-dependent ***interactions*** between the ***ERalpha*** D351Y AF-2 function and ***GRIP1*** , a representative p160 , can be detected in glutathione S-transferase binding assays and mammalian two-hybrid assays .	parallel	1
18957	10986477	142;836	PARP;caspase 3	Fibres did not cause ***PARP*** ***cleavage*** or activation of ***caspase 3*** further confirming previous results about relatively low apoptotic potential of asbestos fibres .	target	1
18958	10987068	7273;7414	titin;vinculin	This region of ***titin*** ***binds*** alpha-actinin and less avidly ***vinculin*** .	parallel	1
18959	10987085	825;7273	p94;connectin	In myofibrils , ***p94*** specifically ***binds*** to ***connectin/titin*** , and the activity of p94 is probably suppressed by this binding .	parallel	1
18960	10987183	1471;1508	cystatin C;cathepsin B	This study was designed to investigate the expression of the matrix degrading proteinase ***cathepsin B*** and its endogenous ***inhibitor*** ***cystatin C*** in rheumatoid arthritis ( RA ) with special regard to multinucleated synovial giant cells ( SGC ) .	negative	1
18961	10987273	1499;367	Beta-catenin;androgen receptor	***Beta-catenin*** ***affects*** ***androgen receptor*** transcriptional activity and ligand specificity .	target	0
18962	10987283	1499;6934	beta-catenin;T-cell factor 4	Transactivation of the multidrug resistance 1 gene by ******T-cell factor 4/beta-catenin****** ***complex*** in early colorectal carcinogenesis .	parallel	1
18963	10987283	1499;6925	beta-catenin;TCF4	A colorectal carcinoma cell line , DLD-1 , was engineered to suppress transactivation by the ******TCF4/beta-catenin****** ***complex*** in a dominant-negative manner under the strict control of the tetracycline regulatory system .	parallel	1
18964	10987283	6925;1499	TCF4;beta-catenin	A large-scale comparison of the expression profiles , using two-color fluorescence hybridization of cDNA microarray , led to the identification of MDR1 as a target gene of the ******TCF4/beta-catenin****** ***complex*** .	parallel	1
18965	10987284	4803;10855	nerve growth factor;heparanase	To test this hypothesis , we used purified in vitro astrocyte cultures and found that they express ***heparanase*** transcript and functional enzyme that were ***up-regulated*** by the prototypic NT , ***nerve growth factor*** .	positive	1
18966	10987310	4790;6347	NF-kappaB;MCP-1	Through the use of an electrophoretic mobility shift assay , we demonstrated that Tax induced ***NF-kappaB*** ***binding*** to both ***MCP-1*** kappaB sites .	parallel	1
18967	10987817	4790;598	NF-kappaB;bcl-x	These results support the hypothesis that ***NF-kappaB*** can act to ***enhance*** ***bcl-x*** ( L ) expression via highly selective interactions , where NF-kappaB binding and bcl-x promoter activation are dependent on both DNA binding site sequence and NF-kappaB subunit composition .	positive	0
18968	10987820	4137;7020	Tau;AP-2	***Tau*** promoter confers neuronal specificity and ***binds*** Sp1 and ***AP-2*** .	parallel	1
18969	10987820	4137;6667	Tau;Sp1	***Tau*** promoter confers neuronal specificity and ***binds*** ***Sp1*** and AP-2 .	parallel	1
18970	10987830	627;207	BDNF;Akt	In contrast , ***BDNF-induced*** ***activation*** of ***Akt*** was enhanced in neurons expressing wild-type or 4F mutant BIT/SHPS -1 .	positive	1
18971	10987859	7257;7247	Trax;Translin	Somatodendritic localization of Translin , a component of the ******Translin/Trax****** RNA binding ***complex*** .	parallel	1
18972	10987859	7257;7247	Trax;Translin	These findings demonstrate that Translin is expressed in neuronal dendrites and therefore support the hypothesis that the ******Translin/Trax****** ***complex*** may be involved in dendritic RNA processing .	parallel	1
18973	10988132	7080;3567	NK-2;IL-4 and -5	Likewise , the ***NK-2*** , but not NK-1 , antagonist ***decreased*** both Th1 ( INF-gamma ) and Th2 ( ***IL-4 and -5*** ) cytokine expression in BAL cells by in situ hybridization .	negative	0
18974	10988245	5465;3576	PPARalpha;IL-8	Furthermore , activation of ***PPARalpha*** with synthetic ligand Wy14 ,643 ***stimulates*** the synthesis of ***IL-8*** and MCP-1 by HAECs .	positive	0
18975	10988245	5465;6347	PPARalpha;MCP-1	Furthermore , activation of ***PPARalpha*** with synthetic ligand Wy14 ,643 ***stimulates*** the synthesis of IL-8 and ***MCP-1*** by HAECs .	positive	0
18976	10988265	729230;6347	chemokine receptor 2;monocyte chemoattractant protein-1	To obtain insights into this potential mechanism , we made use of mice deficient in the CC ***chemokine receptor 2*** ( CCR2 ) , the ***receptor*** for ***monocyte chemoattractant protein-1*** .	parallel	1
18977	10988288	6670;6667	SP3;SP1	Up-regulation of Na,K-ATPase beta 1 transcription by hyperoxia is mediated by ******SP1/SP3****** ***binding*** .	parallel	1
18978	10988288	6670;6667	SP3;SP1	In addition , electrophoretic mobility shift assays demonstrated increased ***binding*** of ******SP1/SP3****** in cells exposed to hyperoxia while mutation of this element eliminated protein binding .	parallel	1
18979	10988289	8575;5610	PACT;PKR	Following exposure of cells to these stress agents , ***PACT*** is phosphorylated and ***associates*** with ***PKR*** with increased affinity .	parallel	0
18980	10988289	8575;5610	PACT;PKR	***PACT-mediated*** ***activation*** of ***PKR*** leads to enhanced eIF2alpha phosphorylation followed by apoptosis .	positive	1
18981	10988289	8575;5610	PACT;PKR	Based on the results presented here , we propose that ***PACT*** is a novel stress-modulated physiological ***activator*** of ***PKR*** .	positive	1
18982	10988289	8575;5610	PACT;double-stranded RNA-activated protein kinase	***PACT*** , a stress-modulated cellular ***activator*** of interferon-induced ***double-stranded RNA-activated protein kinase*** , PKR .	positive	1
18983	10988289	8575;5610	PACT;PKR	We have recently reported cloning of ***PACT*** , a novel protein ***activator*** of ***PKR*** .	positive	1
18984	10988289	8575;5610	PACT;PKR	***PACT*** ***heterodimerizes*** with ***PKR*** and activates it by direct protein-protein interaction .	parallel	1
18985	10988289	8575;5610	PACT;PKR	Here , we present evidence that endogenous ***PACT*** acts as a protein ***activator*** of ***PKR*** in response to diverse stress signals such as serum starvation , and peroxide or arsenite treatment .	positive	1
18986	10988290	859;1605	Caveolin-3;beta-dystroglycan	Here , we demonstrate that ***Caveolin-3*** directly ***interacts*** with ***beta-dystroglycan*** , an integral membrane component of the dystrophin complex .	parallel	1
18987	10988290	1756;1605	dystrophin;beta-dystroglycan	As the WW domain of dystrophin recognizes the same site within beta-dystroglycan , we also demonstrate that Caveolin-3 can effectively block the ***interaction*** of ***dystrophin*** with ***beta-dystroglycan*** .	parallel	1
18988	10988290	859;1756	Caveolin-3;dystrophin	As the WW domain of dystrophin recognizes the same site within beta-dystroglycan , we also demonstrate that ***Caveolin-3*** can effectively ***block*** the interaction of ***dystrophin*** with beta-dystroglycan .	negative	0
18989	10988290	859;1605	Caveolin-3;beta-dystroglycan	In this regard , ***interaction*** of ***Caveolin-3*** with ***beta-dystroglycan*** may competitively regulate the recruitment of dystrophin to the sarcolemma .	parallel	1
18990	10988290	859;1756	Caveolin-3;dystrophin	In this regard , interaction of ***Caveolin-3*** with beta-dystroglycan may competitively ***regulate*** the recruitment of ***dystrophin*** to the sarcolemma .	target	1
18991	10988297	5600;9261	p38beta;mitogen-activated protein kinase-activated protein kinase-2	Here we show that estradiol ( E2 ) rapidly activates ***p38beta*** mitogen-activated protein kinase in endothelial cells ( EC ) , which ***activates*** the ***mitogen-activated protein kinase-activated protein kinase-2*** and the phosphorylation of heat shock protein 27 .	positive	1
18992	10988352	3439;3458	IFN alpha;IFN gamma	***IFN alpha*** ***inhibited*** ***IFN gamma*** stimulated IL-8 secretion in a concentration-dependent manner .	negative	1
18993	10988352	3458;3383	IFN gamma;ICAM-1	In contrast , ***IFN gamma*** also ***induced*** ***ICAM-1*** expression by HBECs but co-stimulation with IFN alpha had no significant effect on the expression of this surface antigen .	target	1
18994	10989122	10111;4361	hRad50;hMre11	Examples of molecules that may have a role in the repair of telomeric DNA prior to replicative senescence include ATM , p53 , PARP , DNA-PK , Ku70/80 , the human ******hRad50-hMre11-BRCA 1 and 20****** ***complex*** , BRCA 1 and 2 and the helicases implicated in Bloom 's and Werner 's syndrome .	parallel	1
18995	10989122	10111;4683	hRad50;p95	Examples of molecules that may have a role in the repair of telomeric DNA prior to replicative senescence include ATM , p53 , PARP , DNA-PK , Ku70/80 , the human ******hRad50-hMre11-BRCA 1 and 20****** ***complex*** , BRCA 1 and 2 and the helicases implicated in Bloom 's and Werner 's syndrome .	parallel	1
18996	10989122	4683;4361	p95;hMre11	Examples of molecules that may have a role in the repair of telomeric DNA prior to replicative senescence include ATM , p53 , PARP , DNA-PK , Ku70/80 , the human ******hRad50-hMre11-BRCA 1 and 20****** ***complex*** , BRCA 1 and 2 and the helicases implicated in Bloom 's and Werner 's syndrome .	parallel	1
18997	10989285	133;820	ADM;cAMP	In addition , ***ADM*** ***increased*** ***cAMP*** accumulation in SV-CISM-2 cells and in primary cultured cells by 18 .	positive	0
18998	10989541	3077;567	HFE;beta-2-microglobulin	The link between iron overload and HFE mutation is explained by the ***interaction*** between ***HFE*** protein , ***beta-2-microglobulin*** and transferrin receptor , which is abolished by the C282Y mutation , but is not yet fully understood .	parallel	1
18999	10989541	7037;567	transferrin receptor;beta-2-microglobulin	The link between iron overload and HFE mutation is explained by the ***interaction*** between HFE protein , ***beta-2-microglobulin*** and ***transferrin receptor*** , which is abolished by the C282Y mutation , but is not yet fully understood .	parallel	1
19000	10989541	7037;3077	transferrin receptor;HFE	The link between iron overload and HFE mutation is explained by the ***interaction*** between ***HFE*** protein , beta-2-microglobulin and ***transferrin receptor*** , which is abolished by the C282Y mutation , but is not yet fully understood .	parallel	1
19001	10990076	4547;2875	MTP;alanine aminotransferase	In multivariate analysis , the ***MTP*** genotype was independently ***associated*** with ***alanine aminotransferase*** concentration ( p = 0.0023 ) as well as sex and body mass index but not HDL-cholesterol .	parallel	0
19002	10990439	2690;3717	growth hormone receptor;Jak2	Specific cytoplasmic domains of the ***growth hormone receptor*** ***mediate*** ***Jak2*** activation , metabolic actions of growth hormone , Stat activation , and calcium influx .	target	0
19003	10990461	29110;10010	NAK;TRAF2	In this study , we purified and characterized a novel kinase ( T2K , also known as TBK1 or ***NAK*** ) , which ***associates*** with ***TRAF2*** and exhibits kinase activity towards I-kappaBalpha in vitro .	parallel	0
19004	10990494	239;2641	12-lipoxygenase;glucagon	The results suggest that the ***12-lipoxygenase*** of the leukocyte type ***augments*** ***glucagon*** secretion from pancreatic islets .	positive	0
19005	10990520	1813;4129	DRD2;MAO-B	When genotypes for DRD2 were considered in combination with genotypes for intron 13 of MAO-B , genotype combinations with high risk of Parkinson 's disease were found ; although the ******MAO-B/DRD2****** ***interaction*** did not reach statistical significance after Bonferroni correction for multiple comparisons , these results are suggestive of a possible synergism between MAOB and DRD2 genes with respect to Parkinson 's disease .	parallel	1
19006	10991927	7124;2920	TNF-alpha;MIP-2	***TNF-alpha*** ( 0.1 microg ml ( -1 ) ) markedly ***increased*** the levels of ***MIP-2*** in the air pouches 1 h after challenge and after 4 h the MIP-2 values returned to baseline .	positive	0
19007	10991938	1874;5934	E2F4;p130	A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of ******p130-E2F4****** ***complexes*** characteristic of quiescence .	parallel	1
19008	10991938	1019;595	cyclin dependent kinase (Cdk) 4;cyclin D1	Antiestrogen-mediated G ( 0 ) / G ( 1 ) arrest is associated with decreased cyclin D1 gene expression , inactivation of ******cyclin D1-cyclin dependent kinase (Cdk) 4****** ***complexes*** , and decreased phosphorylation of the retinoblastoma protein ( pRb ) .	parallel	1
19009	10991938	1874;5934	E2F4;p130	While both pRb and p107 levels were significantly decreased , p130 was increased 4-fold and was accompanied by the formation of ******p130.E2F4****** ***complexes*** and the accumulation of hyperphophorylated E2F4 , putative markers of cellular quiescence .	parallel	1
19010	10991939	2690;3717	GHR;JAK2	Presently , we investigate the mechanism of CIS inhibition and CIS 's role in down-regulating ******GHR-JAK2****** ***signaling*** to STAT5b in cells exposed to GH continuously .	parallel	0
19011	10991939	1154;2690	CIS;GHR	***CIS*** is shown to ***inhibit*** ***GHR-JAK2*** signaling by two distinct mechanisms : by a partial inhibition that is decreased at elevated STAT5b levels and may involve competition between CIS and STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites ; and by a time-dependent inhibition , not seen with SOCS-1 or SOCS-3 , that involves proteasome action .	negative	1
19012	10991939	1154;3717	CIS;JAK2	***CIS*** is shown to ***inhibit*** ***GHR-JAK2*** signaling by two distinct mechanisms : by a partial inhibition that is decreased at elevated STAT5b levels and may involve competition between CIS and STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites ; and by a time-dependent inhibition , not seen with SOCS-1 or SOCS-3 , that involves proteasome action .	negative	1
19013	10991939	2690;3717	GHR;JAK2	CIS is shown to inhibit ******GHR-JAK2****** ***signaling*** by two distinct mechanisms : by a partial inhibition that is decreased at elevated STAT5b levels and may involve competition between CIS and STAT5b for common GHR cytoplasmic tail phosphotyrosine-binding sites ; and by a time-dependent inhibition , not seen with SOCS-1 or SOCS-3 , that involves proteasome action .	parallel	0
19014	10991939	2690;3717	GHR;JAK2	Finally , the down-regulation of ******GHR-JAK2****** ***signaling*** to STAT5b seen in continuous GH-treated cells could be prevented by treatment of cells with the proteasome inhibitor MG132 or by expression of CIS-R107K , a selective , dominant-negative inhibitor of CIS activity .	parallel	0
19015	10991942	9622;5267	kallikrein;kallistatin	A synthetic peptide derived from the sequence between the H helix and C2 sheet of kallistatin was shown to suppress the ******kallistatin-kallikrein****** ***interaction*** through competition for tissue kallikrein binding .	parallel	1
19016	10991943	7077;4323	TIMP-2;MT1-MMP	Domain interactions in the gelatinase ******A.TIMP-2.MT1-MMP****** activation ***complex*** .	parallel	1
19017	10991943	4323;4313	MT1-MMP;MMP-2	On the cell surface , the 59-kDa membrane type 1-matrix metalloproteinase ( ***MT1-MMP*** ) ***activates*** the 72-kDa progelatinase A ( ***MMP-2*** ) after binding the tissue inhibitor of metalloproteinases (TIMP)-2 .	positive	1
19018	10991943	3263;7077	hemopexin;TIMP-2	A strong ***interaction*** between the ***TIMP-2*** C domain ( Glu ( 153 ) - Pro ( 221 ) ) and the gelatinase A ***hemopexin*** C domain ( Gly ( 446 ) - Cys ( 660 ) ) was demonstrated by the yeast two-hybrid system .	parallel	1
19019	10991943	4323;3263	MT1-MMP;hemopexin	The ***MT1-MMP*** ***hemopexin*** C domain did not form ***homodimers*** nor did it bind the gelatinase A hemopexin C domain , the C tail of TIMP-2 , or full-length TIMP-2 .	parallel	1
19020	10991949	5781;5618	SHP-2;PRLR	Using SHP-2 and PRLR immunoprecipitation studies in 293 cells and in the mouse mammary epithelial cell line HC11 , we found that ***SHP-2*** ***co-immunoprecipitates*** with the ***PRLR*** and that the C-terminal tyrosine of the PRLR plays a regulatory role in both the tyrosine phosphorylation and the recruitment of SHP-2 .	parallel	1
19021	10992446	7174;834	Tripeptidyl peptidase II;caspase-1	***Tripeptidyl peptidase II*** ***promotes*** maturation of ***caspase-1*** in Shigella flexneri-induced macrophage apoptosis .	positive	0
19022	10993067	23385;351	Nicastrin;beta-amyloid precursor protein	***Nicastrin*** also ***binds*** carboxy-terminal derivatives of ***beta-amyloid precursor protein*** ( betaAPP ) , and modulates the production of the amyloid beta-peptide ( A beta ) from these derivatives .	parallel	1
19023	10993082	892;1024	cyclin C;cdk8	The ******cdk8/cyclin C****** protein ***complex*** is also found in a number of mammalian Mediator-like protein complexes , which repress activated transcription independently of the CTD in vitro .	parallel	1
19024	10993082	1024;902	cdk8;cyclin H	In addition , mimicking ***cdk8*** ***phosphorylation*** of ***cyclin H*** in vivo has a dominant-negative effect on cell growth .	target	1
19025	10993153	920;3700	CD4;gp120	Sulfated fibroins also abolished cell-to-cell infection-induced syncytium formation upon cocultivation of MOLT-4 and MOLT-4 / HIV-IIIB cells , suggesting that they would interfere with gp120 and prevent the formation of ******gp120/CD4****** ***complex*** .	parallel	1
19026	10993175	3685;6696	integrin alphavbeta3;OPN	Results suggested that the ******OPN-integrin alphavbeta3****** ***binding*** plays a more important role than CoI-alpha2beta1 binding in the regulation of osteoclast activity .	parallel	1
19027	10993690	729230;6347	CCR2;monocyte chemoattractant protein-1	Acute excitotoxic injury induces expression of ***monocyte chemoattractant protein-1*** and its ***receptor*** , ***CCR2*** , in neonatal rat brain .	parallel	1
19028	10993690	729230;6347	CCR2;MCP-1	These results demonstrate that in the neonatal brain , acute excitotoxic injury stimulates expression of both ***MCP-1*** and its ***receptor*** , ***CCR2*** , and suggests that MCP-1 regulates the microglial/monocyte response to acute brain injury .	parallel	1
19029	10993692	627;4804	BDNF;p75	The study is the first to show changes in truncated trkB receptor expression that extend beyond the site of a spinal cord lesion and is one of the first to show that ***BDNF*** and NT-3 ***affect*** Schwann cells and/or ***p75*** expression following spinal cord damage .	target	0
19030	10993697	1271;1270	CNTFRalpha;CNTF	Immunohistochemistry established that virtually all SNB motoneurons of both males and females express the ***CNTF*** alpha ***receptor*** ( ***CNTFRalpha*** ) between embryonic day 20 and postnatal day 6 .	parallel	1
19031	10993753	4790;4792	NF-kappa B;I kappa B alpha	Activation of ***NF-kappa B*** by cytokines , including tumor necrosis factor-alpha ( TNF-alpha ) , ***requires*** the phosphorylation and degradation of ***I kappa B alpha*** .	target	0
19032	10993881	596;3458	bcl-2;interferon-gamma	Overexpression of ***bcl-2*** ***enhances*** LIGHT - and ***interferon-gamma*** - mediated apoptosis in Hep3BT2 cells .	positive	0
19033	10993881	3458;836	IFN-gamma;caspase-3	It appears that LIGHT and ***IFN-gamma*** act synergistically to ***activate*** ***caspase-3*** , with the resultant cleavage of bcl-2 , removal of the BH4 domain , leading to conversion of bcl-2 from an antiapoptotic to a proapoptotic form in p53-deficient hepatocellular carcinoma Hep3BT2 cells .	positive	1
19034	10993888	5770;6776	PTP1B;STAT5a	These results strongly suggest that ***PTP1B*** ***dephosphorylates*** PRL-activated ***STAT5a*** and STAT5b , thereby negatively regulating PRL-mediated signaling pathway .	target	1
19035	10993888	5770;6777	PTP1B;STAT5b	These results strongly suggest that ***PTP1B*** ***dephosphorylates*** PRL-activated STAT5a and ***STAT5b*** , thereby negatively regulating PRL-mediated signaling pathway .	target	1
19036	10993888	5770;6776	PTP1B;STAT5a	Among the 12 phosphatases including SHP-2 examined , a cytosolic phosphatase ***PTP1B*** was found to specifically ***dephosphorylate*** ***STAT5a*** and STAT5b in transfected COS7 and in vitro .	target	1
19037	10993888	5770;6777	PTP1B;STAT5b	Among the 12 phosphatases including SHP-2 examined , a cytosolic phosphatase ***PTP1B*** was found to specifically ***dephosphorylate*** STAT5a and ***STAT5b*** in transfected COS7 and in vitro .	target	1
19038	10993892	5595;10287	Erk1;GAIP	Here we show that ***GAIP*** is ***phosphorylated*** by an extracellular signal-regulated ( ***Erk1/2*** ) MAP kinase-dependent pathway sensitive to amino acids , MEK1/2 ( PD098059 ) , and protein kinase C ( GF109203X ) inhibitors .	target	1
19039	10993892	5594;10287	Erk2;GAIP	An in vitro phosphorylation assay demonstrates that ***Erk2-dependent*** ***phosphorylation*** of ***GAIP*** stimulates its GTPase-activating protein activity toward the Galpha ( i3 ) protein ( k = 0.187 + / - 0.001 s ( - ) ( 1 ) , EC ( 50 ) = 1.12 + / - 0.10 microm ) when compared with unphosphorylated recombinant GAIP ( k = 0.145 + / - 0.003 s ( - ) ( 1 ) , EC ( 50 ) = 3.16 + / - 0 .	target	1
19040	10993898	3486;7040	IGFBP-3;TGF-beta	These data suggest that ***IGFBP-3*** inhibitory signaling ***requires*** an active ***TGF-beta*** signaling pathway and implicate Smad2 and Smad3 in IGFBP-3 signal transduction .	target	0
19041	10993901	7040;596	Transforming growth factor-beta 1;Bcl-2	***Transforming growth factor-beta 1*** induces apoptosis independently of p53 and selectively ***reduces*** expression of ***Bcl-2*** in multipotent hematopoietic cells .	negative	1
19042	10993906	3558;4609	IL-2;c-Myc	Finally , overexpression of wild type STAM2 led to an increase in ***IL-2-mediated*** ***induction*** of ***c-Myc*** promoter activation indicating that it potentiates cytokine receptor signaling .	target	1
19043	10993913	3565;6647	IL-4;homodimer	***IL-4*** alone or together with granulocyte/macrophage colony-stimulating factor or interferon gamma effectively enhanced the production of the bioactive heterodimer and selectively ***reduced*** the antagonistic ***homodimer*** of IL-12 .	negative	1
19044	10993992	348;1471	APOE;CST3	Analysis of only the community-based cases versus controls reveals a significant three-way ***interaction*** between ***APOE*** , ***CST3*** and age/age of onset .	parallel	1
19045	10994551	4803;4914	NGF;TrkA	***Activation*** of ***TrkA*** by its ligand nerve growth factor ( ***NGF*** ) initiates a cascade of signaling events and promotes neuronal differentiation in vitro .	positive	1
19046	10995387	1017;4863	Cdk2;p220	Cell cycle-regulated ***phosphorylation*** of ***p220*** ( NPAT ) by cyclin ***E/Cdk2*** in Cajal bodies promotes histone gene transcription .	target	1
19047	10995388	2908;4790	glucocorticoid receptor;NFkappaB	The ***glucocorticoid receptor*** ***inhibits*** ***NFkappaB*** by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain .	negative	1
19048	10995431	991;4085	Cdc20;Mad2	Recent studies have suggested a catalytic model for kinetochore function where unattached kinetochores provide sites for assembling and releasing ******Mad2-Cdc20****** ***complexes*** , which sequester Cdc20 and prevent it from activating the APC .	parallel	1
19049	10995442	2549;4233	Gab1;c-Met	The docking protein ***Gab1*** ***binds*** phosphorylated ***c-Met*** receptor tyrosine kinase directly and mediates signals of c-Met in cell culture .	parallel	1
19050	10995442	2549;4233	Gab1;c-Met	The docking protein ***Gab1*** binds phosphorylated c-Met receptor tyrosine kinase directly and ***mediates*** signals of ***c-Met*** in cell culture .	target	0
19051	10995442	4233;2549	c-Met;Gab1	***Gab1*** is ***phosphorylated*** by ***c-Met*** and by other receptor and nonreceptor tyrosine kinases .	target	1
19052	10995457	207;3320	Akt;Hsp90	We found that ***Akt*** formed a ***complex*** with a 90-kDa heat-shock protein ( ***Hsp90*** ) in vivo .	parallel	1
19053	10995457	3320;207	Hsp90;Akt	Inhibition of ******Akt-Hsp90****** ***binding*** led to the dephosphorylation and inactivation of Akt , which increased sensitivity of the cells to apoptosis-inducing stimulus .	parallel	1
19054	10995467	6863;6869	substance P;NK1R	Here we report that ***substance P*** ( SP ) ***activation*** of neurokinin-1 receptor ( ***NK1R*** ) stimulates the formation of a scaffolding complex comprising internalized receptor , beta-arrestin , src , and ERK1/2 ( detected by gel filtration , immunoprecipitation , and immunofluorescence ) .	positive	1
19055	10995739	3479;2309	IGF-1;FKHRL1	As ***IGF-1*** also ***induced*** the phosphorylation of ***FKHRL1*** in primary cortical and cerebellar neuronal cultures , these data , taken together , demonstrate that IGF-1 , acting via the PI3K/Akt kinase pathway , can regulate the phosphorylation of FKHRL1 , leading to inhibition of this apoptotic transcription factor in neuronal cells .	target	1
19056	10995739	3479;2309	IGF-1;FKHRL1	As IGF-1 also induced the phosphorylation of FKHRL1 in primary cortical and cerebellar neuronal cultures , these data , taken together , demonstrate that ***IGF-1*** , acting via the PI3K/Akt kinase pathway , can ***regulate*** the phosphorylation of ***FKHRL1*** , leading to inhibition of this apoptotic transcription factor in neuronal cells .	target	1
19057	10995739	3479;2309	Insulin-like growth factor-1;FKHRL1	***Insulin-like growth factor-1-induced*** ***phosphorylation*** of the forkhead family transcription factor ***FKHRL1*** is mediated by Akt kinase in PC12 cells .	target	1
19058	10995739	3479;2309	IGF-1;FKHRL1	***IGF-1*** rapidly ***induced*** the phosphorylation of Akt and ***FKHRL1*** in PC12 cells .	target	1
19059	10995745	7342;7024	LBP-1a;CP2	Furthermore , we demonstrate that recombinant ***LBP-1a*** can ***bind*** to known ***CP2*** consensus sites and form protein complexes with previously defined heteromeric partners of CP2 .	parallel	1
19060	10995748	4088;2353	Smad3;c-Fos	Accordingly , we have previously shown that the heteromeric complex of ***Smad3*** and Smad4 ***synergizes*** with ***c-Jun/c-Fos*** at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta .	parallel	0
19061	10995748	4088;3725	Smad3;c-Jun	Accordingly , we have previously shown that the heteromeric complex of ***Smad3*** and Smad4 ***synergizes*** with ***c-Jun/c-Fos*** at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta .	parallel	0
19062	10995748	4089;2353	Smad4;c-Fos	Accordingly , we have previously shown that the heteromeric complex of Smad3 and ***Smad4*** ***synergizes*** with ***c-Jun/c-Fos*** at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta .	parallel	0
19063	10995748	4089;3725	Smad4;c-Jun	Accordingly , we have previously shown that the heteromeric complex of Smad3 and ***Smad4*** ***synergizes*** with ***c-Jun/c-Fos*** at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta .	parallel	0
19064	10995748	4088;4089	Smad3;Smad4	Accordingly , we have previously shown that the heteromeric ***complex*** of ***Smad3*** and ***Smad4*** synergizes with c-Jun/c-Fos at the AP-1 binding site of the collagenase I promoter to induce transcriptional activation in response to TGF-beta .	parallel	1
19065	10995748	4088;3725	Smad3;c-Jun	Using the collagenase I promoter as model system , we have now investigated the role of the c-Jun and Smad3 interactions with the promoter DNA and have further characterized the physical basis of the ******c-Jun/Smad3****** ***interaction*** in the transcriptional response .	parallel	1
19066	10995749	958;4092	CD40;Smad7	***Smad7*** is ***induced*** by ***CD40*** and protects WEHI 231 B-lymphocytes from transforming growth factor-beta -induced growth inhibition and apoptosis .	target	1
19067	10995749	958;4092	CD40;Smad7	The ***transactivation*** of ***Smad7*** by ***CD40*** is NFkappaB-dependent in that pharmacological inhibitors of this pathway , N-tosyl-l-phenylalanine chloromethyl ketone and pyrrolidine dithiocarbamate , abrogate CD40-induced Smad7 expression .	positive	1
19068	10995749	4092;4087	Smad7;Smad2	Ectopic overexpression of ***Smad7*** ***inhibited*** ***Smad2*** activation , TGF-beta-mediated growth inhibition , and apoptosis in WEHI 231 cells .	negative	1
19069	10995751	1051;3458	C/EBP-beta;IFN-gamma	Thus , our data ***link*** ***C/EBP-beta*** to ***IFN-gamma*** signaling through ERKs .	parallel	0
19070	10995752	1051;216	CCAAT/enhancer-binding protein beta;ALDH1	Feedback ***inhibition*** of the retinaldehyde dehydrogenase gene ***ALDH1*** by retinoic acid through retinoic acid receptor alpha and ***CCAAT/enhancer-binding protein beta*** .	negative	1
19071	10995752	5914;216	retinoic acid receptor alpha;ALDH1	Feedback ***inhibition*** of the retinaldehyde dehydrogenase gene ***ALDH1*** by retinoic acid through ***retinoic acid receptor alpha*** and CCAAT/enhancer-binding protein beta .	negative	1
19072	10995752	5914;6257	RARalpha;retinoid X receptor beta	retinoic acid receptor alpha ( RARalpha ) transactivates the ALDH1 gene promoter through a complex with an RA response-like element ( RARE ) located at -91 / -75 bp , which bound to the ******RARalpha/retinoid X receptor beta****** ***heterodimer*** .	parallel	1
19073	10995752	5914;216	retinoic acid receptor alpha;ALDH1	***retinoic acid receptor alpha*** ( RARalpha ) ***transactivates*** the ***ALDH1*** gene promoter through a complex with an RA response-like element ( RARE ) located at -91 / -75 bp , which bound to the RARalpha/retinoid X receptor beta heterodimer .	positive	1
19074	10995752	1051;216	C/EBPbeta;ALDH1	CCAAT/enhancer-binding protein ( ***C/EBPbeta*** ) also ***transactivates*** the ***ALDH1*** gene promoter through a CCAAT box located 3 ' and directly adjacent to the RARE , and the ALDH1 gene is down-regulated in C/EBPbeta-null mouse liver .	positive	1
19075	10995752	1051;216	C/EBPbeta;ALDH1	These data support a model in which the RARalpha and ***C/EBPbeta*** ***activate*** the ***ALDH1*** gene promoter through the RARE and C/EBP response elements , and in Hepa-1 cells , high levels of RA inhibit this activation by decreasing cellular levels of C/EBPbeta .	positive	1
19076	10995752	5914;216	RARalpha;ALDH1	These data support a model in which the ***RARalpha*** and C/EBPbeta ***activate*** the ***ALDH1*** gene promoter through the RARE and C/EBP response elements , and in Hepa-1 cells , high levels of RA inhibit this activation by decreasing cellular levels of C/EBPbeta .	positive	1
19077	10995753	2056;2623	Epo;transcription factor GATA-1	In erythroid progenitor cells , ***Epo*** ***stimulates*** induction of ***transcription factor GATA-1*** and EpoR ; in C2C12 cells , GATA-3 and EpoR expression are induced .	positive	0
19078	10995762	5170;5058	PDK1;PAK1	p21-activated kinase ( ***PAK1*** ) is ***phosphorylated*** and activated by 3-phosphoinositide-dependent kinase-1 ( ***PDK1*** ) .	target	1
19079	10995762	5170;5058	PDK1;p21-activated kinase 1	In this study , we show that phosphorylated 3-phosphoinositide-dependent kinase 1 ( ***PDK1*** ) ***phosphorylates*** ***p21-activated kinase 1*** ( PAK1 ) in the presence of sphingosine .	target	1
19080	10995762	5170;5058	PDK1;PAK1	***PDK1*** ***phosphorylation*** of ***PAK1*** was not blocked by pretreatment with wortmannin or when PDK1 was mutated to prevent phosphatidylinositol binding , indicating this process is independent of phosphatidylinositol 3-kinase activity .	target	1
19081	10995764	2668;5290	GDNF;PI3K	This latter complex can also assemble directly onto phosphorylated Tyr-1096 , offering an alternative route to ***PI3K*** ***activation*** by ***GDNF*** .	positive	1
19082	10995764	2668;5594	GDNF;Erk	Mutation of Tyr-1096 ( Y1096F ) , a binding site for the adaptor Grb2 , had no effect on ***Erk*** ***activation*** by ***GDNF*** .	positive	1
19083	10995764	2668;5290	GDNF;PI3K	In agreement with Ras-independent ***activation*** of ***PI3K*** by ***GDNF*** in neuronal cells , survival of sympathetic neurons induced by GDNF was dependent on PI3K but was not affected by microinjection of blocking anti-Ras antibodies , which did compromise neuronal survival by nerve growth factor , suggesting that Ras is not required for GDNF-induced survival of sympathetic neurons .	positive	1
19084	10995770	7075;7010	TIE-1;TIE-2	This study provides the first evidence for the existence of a pre-formed ***complex*** of ***TIE-1*** and ***TIE-2*** in endothelial cells .	parallel	1
19085	10995770	7010;7075	TIE-2;TIE-1	The physical ***association*** between ***TIE-1*** and ***TIE-2*** is consistent with TIE-1 having a role in modulating TIE-2 signaling .	parallel	0
19086	10995770	7075;7010	TIE-1;TIE-2	***TIE-1*** ***bound*** to ***TIE-2*** was not tyrosine-phosphorylated under basal conditions or following TIE-2 stimulation .	parallel	1
19087	10995777	4088;345	SMAD3;ApoCIII	Cotransfection of HepG2 cells with SMADs established that SMAD3 and ***SMAD3-SMAD4*** ***transactivated*** ( 15-70-fold ) the -890 / +24 ***ApoCIII*** promoter and shorter promoter segments , whereas cotransfection with a dominant negative SMAD4 mutant repressed the ApoCIII promoter activity by 50 % , suggesting that SMAD proteins participate in ApoCIII gene regulation .	positive	1
19088	10995777	4089;345	SMAD4;ApoCIII	Cotransfection of HepG2 cells with SMADs established that SMAD3 and ***SMAD3-SMAD4*** ***transactivated*** ( 15-70-fold ) the -890 / +24 ***ApoCIII*** promoter and shorter promoter segments , whereas cotransfection with a dominant negative SMAD4 mutant repressed the ApoCIII promoter activity by 50 % , suggesting that SMAD proteins participate in ApoCIII gene regulation .	positive	1
19089	10995777	4089;4088	SMAD4;SMAD3	Co-immunoprecipitation and GST pull-down assays provided evidence for physical ***interactions*** between ***SMAD3*** , ***SMAD4*** , and hepatic nuclear factor-4 .	parallel	1
19090	10995778	5579;4150	PKC-beta;SAF-1	In vitro ***phosphorylation*** of ***SAF-1*** by ***PKC-beta*** markedly increased its DNA binding ability .	target	1
19091	10995825	3553;5599	IL-1beta;JNK	Intracerebroventricular injection of IL-1beta increased reactive oxygen species production in hippocampal tissue , whereas ***IL-1beta*** and H ( 2 ) O ( 2 ) ***increased*** activities of both ***JNK*** and p38 in vitro .	positive	0
19092	10995825	3553;1432	IL-1beta;p38	Intracerebroventricular injection of IL-1beta increased reactive oxygen species production in hippocampal tissue , whereas ***IL-1beta*** and H ( 2 ) O ( 2 ) ***increased*** activities of both JNK and ***p38*** in vitro .	positive	0
19093	10995840	627;2185	BDNF;protein kinase B	Here , we report that ***BDNF*** ***activates*** both ***protein kinase B*** ( PKB ) via a phosphatidyl-inositol-3 ' - kinase ( PI-3-K ) - dependent mechanism and the mitogen-activated protein kinases extracellular signal-regulated kinase 1 ( ERK1 ) and ERK2 .	positive	1
19094	10995840	627;836	BDNF;caspase-3	Furthermore , we provide evidence that ***BDNF*** ***suppresses*** cleavage and enzymatic activity of the neuronal cell death effector ***caspase-3*** .	negative	1
19095	10995876	4846;5241	eNOS;progesterone receptor	***eNOS*** expression is ***associated*** with the estrogen and ***progesterone receptor*** status in invasive breast carcinoma .	parallel	0
19096	10995887	10987;1027	JAB1;p27KIP1	***JAB1*** , which is thought to ***bind*** ***p27KIP1*** and transport it from the nucleus to the cytoplasm for proteasome/ubiquitin-mediated degradation , was found to be localized both in the cytoplasm and the nucleus in undifferentiated and differentiating tumors whereas located predominantly in the nucleus of differentiated tumor cells .	parallel	1
19097	10995895	3458;5698	IFN-gamma;LMP-2	***IFN-gamma*** treatment ***induced*** the TAP-1 and ***LMP-2*** genes , continuously up-regulated the HLA class I expression and increased cytolysis .	target	1
19098	10995895	3458;6890	IFN-gamma;TAP-1	***IFN-gamma*** treatment ***induced*** the ***TAP-1*** and LMP-2 genes , continuously up-regulated the HLA class I expression and increased cytolysis .	target	1
19099	10996021	3654;4790	IRAK-1;NF-kappa B	Antisense ***IRAK-1*** oligonucleotide ***blocks*** activation of ***NF-kappa B*** and AP-1 induced by IL-18 .	negative	0
19100	10996021	3606;4790	IL-18;NF-kappaB	Interleukin-1 receptor-associated kinase-1 ( IRAK-1 ) has recently been shown to be involved in ***IL-18-stimulated*** ***activation*** of ***NF-kappaB*** and AP-1 .	positive	1
19101	10996021	3654;4790	Interleukin-1 receptor-associated kinase-1;NF-kappaB	***Interleukin-1 receptor-associated kinase-1*** ( IRAK-1 ) has recently been shown to be involved in IL-18-stimulated ***activation*** of ***NF-kappaB*** and AP-1 .	positive	1
19102	10996021	3606;4790	IL-18;NF-kappaB	The purpose of this study is to investigate the effects of preventing IRAK-1 expression by antisense IRAK-1 oligodeoxynucleotide ( ODN ) on ***IL-18-stimulated*** ***activation*** of ***NF-kappaB*** and AP-1 .	positive	1
19103	10996021	3606;4790	IL-18;NF-kappaB	As a result , antisense IRAK-1 ODN attenuated ***IL-18-induced*** ***activation*** of ***NF-kappaB*** and AP-1 as measured by sandwich ELISA in a concentration ( 1-8 microg ml ( -1 ) ) - and time ( 5-24 h ) - dependent fashion .	positive	1
19104	10996141	3458;7124	IFN-gamma;TNF-alpha	The data also demonstrate that the signaling cascade activated by IFN-gamma binding to its receptor is critical for iNOS induction , and the synergistic action of LPS and ***TNF-alpha*** as iNOS inducers in brain cells is largely ***mediated*** by the receptor-regulated action of ***IFN-gamma*** .	target	0
19105	10996218	728;727	CD88;C5a	Intracerebral complement ***C5a*** ***receptor*** ( ***CD88*** ) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice .	parallel	1
19106	10996218	728;727	C5aR;C5a	We analyzed the intracerebral expression of the ***C5a*** ***receptor*** ( ***C5aR*** ) in a model of closed head injury ( CHI ) in mice .	parallel	1
19107	10996218	4049;728	lymphotoxin-alpha;C5aR	These data show that the posttraumatic neuronal expression of the ***C5aR*** is , at least in part , ***regulated*** by TNF and ***lymphotoxin-alpha*** at 7 days after trauma .	target	1
19108	10996221	939;970	CD27;CD70	Involvement of ******CD70-CD27****** ***interactions*** in the induction of experimental autoimmune encephalomyelitis .	parallel	1
19109	10996221	970;939	CD70;CD27	***Ligation*** of ***CD27*** by its ligand ***CD70*** is thought to be important in T cell activation and T cell-B cell interaction .	parallel	1
19110	10996221	939;970	CD27;CD70	In this study , we examined the contribution of ******CD70-CD27****** ***interactions*** to cell-mediated immunity by investigating the effect of anti-CD70 mAb on the development of experimental autoimmune encephalomyelitis ( EAE ) .	parallel	1
19111	10996221	939;970	CD27;CD70	These results indicate that the ******CD70-CD27****** ***interaction*** plays a pivotal role in the development of cell-mediated autoimmune disease .	parallel	1
19112	10996309	5883;596	Rad9;Bcl-2	Schizosaccharomyces pombe ***Rad9*** contains a BH3-like region and ***interacts*** with the anti-apoptotic protein ***Bcl-2*** .	parallel	1
19113	10996339	7048;7040	TbetaR-II;TGF-beta	We tested the effect of hypercholesterolemia , a well-known risk factor for atherosclerosis , on liver type II ***TGF-beta*** ***receptor*** ( ***TbetaR-II*** ) expression in atherosclerosis-susceptible C57BL/6 mouse strain fed atherogenic diet .	parallel	1
19114	10996355	346;4018	apoC-IV;lipoprotein	In transgenic mice , human ***apoC-IV*** is predominantly ***associated*** with very low-density ***lipoprotein*** ( VLDL ) and thus may play an important role in lipid metabolism .	parallel	0
19115	10996358	356;355	FasL;Fas	This stability may be greatly influenced by pro-inflammatory mediators such as IFN-gamma , TNF-alpha , and Il-1beta and ***Fas*** ***ligand*** ( ***FasL*** ) that are present in human atheroma .	parallel	1
19116	10996358	356;3553	FasL;Il-1beta	This stability may be greatly influenced by pro-inflammatory mediators such as IFN-gamma , TNF-alpha , and ***Il-1beta*** and Fas ***ligand*** ( ***FasL*** ) that are present in human atheroma .	parallel	1
19117	10996361	7040;2022	TGFbeta;CD105	The significance of CD105 , TGFbeta and ******CD105/TGFbeta****** ***complexes*** in coronary artery disease .	parallel	1
19118	10996361	7040;2022	TGFbeta;CD105	We have quantified levels of ***CD105*** , its ***ligand*** ***TGFbeta*** and receptor-ligand complexes in sera from healthy individuals ( n = 31 ) , patients with triple vessel disease documented by coronary angiography ( TVD ; n = 36 ) and patients with chest pain and a positive exercise electrocardiogram but with normal coronary angiogram ( NCA ; n = 30 ) .	parallel	1
19119	10996384	7124;4790	TNF-alpha;NF-kappaB	The binding activity of NF-kappaB was decreased by IL-10 and IL-13 in UM-SCV-1A cells suggesting that the pathway by which ***TNF-alpha*** ***activates*** ***NF-kappaB*** differs from that activated by interleukins .	positive	1
19120	10996391	7124;5175	TNFalpha;PECAM-1	***TNFalpha*** treatment of cultured rat SECs and of small and large MCs from normal liver ***decreased*** ***PECAM-1*** specific transcript level in parallel to the increase of ICAM-1 transcript level .	negative	0
19121	10996391	7124;3383	TNFalpha;ICAM-1	CONCLUSIONS : Early production of ***TNFalpha*** after liver injury could ***induce*** an increased ***ICAM-1-expression*** and a decreased PECAM-1 expression , which might be essential for the transmigration of inflammatory cells into the parenchyma .	target	1
19122	10996391	7124;5175	TNFalpha;PECAM-1	CONCLUSIONS : Early production of ***TNFalpha*** after liver injury could ***induce*** an increased ICAM-1-expression and a decreased ***PECAM-1*** expression , which might be essential for the transmigration of inflammatory cells into the parenchyma .	target	1
19123	10996427	6776;6464	Stat5a;Shc	In coimmunoprecipitation experiments , we show GH-induced formation of complexes consisting of Stat5a and Erk2 , and ***Stat5a*** and Stat5b ***association*** with the protein adaptor ***Shc*** .	parallel	0
19124	10996427	6777;6464	Stat5b;Shc	In coimmunoprecipitation experiments , we show GH-induced formation of complexes consisting of Stat5a and Erk2 , and Stat5a and ***Stat5b*** ***association*** with the protein adaptor ***Shc*** .	parallel	0
19125	10996427	6464;6777	Shc;Stat5	In contrast , ***Shc*** proteins ***interact*** with non-phosphorylated forms of ***Stat5*** .	parallel	1
19126	10996427	5594;6776	Erk2;Stat5a	In addition , tyrosine residues of this region of the GHR are not required for ******Stat5a/Erk2****** ***interaction*** but are essential for Stat5a serine phosphorylation .	parallel	1
19127	10996723	7124;4313	TNF-alpha;MMP-2	These results indicate that ***TNF-alpha*** and INF-gamma could ***regulate*** the production of ***MMP-2*** or MMP-9 on bladder cancer cells and their patterns of regulation are cell specific .	target	1
19128	10996723	7124;4318	TNF-alpha;MMP-9	These results indicate that ***TNF-alpha*** and INF-gamma could ***regulate*** the production of MMP-2 or ***MMP-9*** on bladder cancer cells and their patterns of regulation are cell specific .	target	1
19129	10996726	1029;5925	p16;pRb	***Inhibition*** of ***pRb*** phosphorylation and cell cycle progression by an ***antennapedia-p16*** ( INK4A ) fusion peptide in pancreatic cancer cells .	negative	1
19130	10996799	26986;1981	PABP;eIF4G	Although the ******eIF4G-PABP****** ***interaction*** has also been demonstrated in a mammalian system [ 3,4 ] , its biological significance in vertebrates is unknown .	parallel	1
19131	10996799	26986;1981	PABP;eIF4G	Because the amount of PABP is very low in oocytes [ 8 ] , it has been argued that the ******eIF4G-PABP****** ***interaction*** does not play a major role in translational activation during oocyte maturation .	parallel	1
19132	10996799	26986;1981	PABP;eIF4G	Our results show that the ******eIF4G-PABP****** ***interaction*** is critical for translational control of maternal mRNAs during Xenopus development .	parallel	1
19133	10997341	3606;3458	IL-18;IFN-gamma	Exogenous IL-12 or ***IL-18*** was able to ***increase*** ***IFN-gamma*** production in IL-18 KO mice ; whereas , only exogenous IL-12 , but not IL-18 , enhanced IFN-gamma production in IL-12 KO mice .	positive	0
19134	10997557	7124;2152	TNF-alpha;tissue factor	We have investigated the role for the sphingomyelin/ceramide pathway in the ***TNF-alpha-induced*** ***upregulation*** of adhesion molecule expression and ***tissue factor*** production of human endothelial cells .	positive	1
19135	10997599	3953;3952	leptin receptor;leptin	In animal obesity , defective hypothalamic ***leptin receptor*** activation ***prevent*** ***leptin*** from acting , with resulting obesity , insulin and leptin resistance .	negative	0
19136	10997599	3952;4852	leptin;NPY	When infused i.c.v. to normal rats to mimic its central effects , ***leptin*** ***decreases*** ***NPY*** levels , thus food intake and body weight .	negative	0
19137	10997622	3952;5617	leptin;prolactin	To date , no molecular basis has been identified which links prolactin with increasing body fatness , weight and appetite : new data suggests a possible ***link*** in obese men between fasting plasma ***prolactin*** and ***leptin*** concentrations .	parallel	0
19138	10997691	7048;7040	TbetaR-II;TGF-beta	Initiation of signaling requires binding of TGF-beta1 to ***TGF-beta*** type II ***receptor*** ( ***TbetaR-II*** ) , a constitutively active serine/threonine kinase , which subsequently transphosphorylates TGF-beta type I receptor ( TbetaR-I ) .	parallel	1
19139	10997691	7040;7048	TGF-beta1;TbetaR-II	Initiation of signaling requires ***binding*** of ***TGF-beta1*** to TGF-beta type II receptor ( ***TbetaR-II*** ) , a constitutively active serine/threonine kinase , which subsequently transphosphorylates TGF-beta type I receptor ( TbetaR-I ) .	parallel	1
19140	10997899	3308;3337	Hsp70;Sis1	We propose that the Sis1 cleft functions as a docking site for the Hsp70 peptide-binding domain and that ******Sis1-Hsp70****** ***interaction*** serves to facilitate the efficient transfer of peptides from Sis1 to Hsp70 .	parallel	1
19141	10997899	3337;3308	Sis1;Hsp70	CONCLUSIONS : ***Sis1*** ( 1-337 ) , which lacks the dimerization motif , exhibited severe defects in chaperone activity , but could ***regulate*** ***Hsp70*** ATPase activity .	target	1
19142	10997905	9180;5008	OSMR;oncostatin M	Its mechanism of action is via specific binding to gp130 and either the leukaemia inhibitory factor receptor ( LIFR ) or ***oncostatin M*** ***receptor*** ( ***OSMR*** ) systems at the cell surface to form an active signalling complex .	parallel	1
19143	10997919	5594;5595	ERK2;ERK1	Enhanced mesangial cell ******ERK1/ERK2****** ***signaling*** in response to the combined effects of mechanical stretch and HG may contribute to the pathogenesis of diabetic nephropathy .	parallel	0
19144	10997929	4868;23607	nephrin;CD2AP	Mice lacking CD2AP exhibit a congenital nephrotic syndrome characterized by extensive foot process effacement , suggesting that ******CD2AP-nephrin****** ***interactions*** are critical to maintaining slit diaphragm function .	parallel	1
19145	10998055	3952;7351	Leptin;uncoupling protein-2	***Leptin*** ***stimulates*** ***uncoupling protein-2*** mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes .	positive	0
19146	10998055	3952;7351	Leptin;uncoupling protein-2	Eventually , ***Leptin*** ***upregulated*** the ***uncoupling protein-2*** ( UCP2 ) mRNA level by 63 % and had no effect on uncoupling protein-3 ( UCP3 ) mRNA in isolated adipocytes .	positive	1
19147	10998058	836;5888	Caspase-3;HsRad51	***Caspase-3*** ***mediated*** cleavage of ***HsRad51*** at an unconventional site .	target	0
19148	10998058	840;5888	caspase-7;HsRad51	Similarly , HsRad51 of Jurkat cell extracts was cleaved into the 33-kDa product by recombinant Caspase-3 , whereas ***caspase-7*** failed to ***cleave*** endogenous ***HsRad51*** .	target	1
19149	10998058	836;5888	Caspase-3;HsRad51	Similarly , ***HsRad51*** of Jurkat cell extracts was ***cleaved*** into the 33-kDa product by recombinant ***Caspase-3*** , whereas caspase-7 failed to cleave endogenous HsRad51 .	target	1
19150	10998059	8851;84152	p25;DARPP-32	Alsterpaullone also inhibits the ***CDK5/p25-dependent*** ***phosphorylation*** of ***DARPP-32*** in mouse striatum slices in vitro .	target	1
19151	10998136	3458;6361	interferon-gamma;TARC	To gain insight in the stimulatory mechanisms for TARC production in keratinocytes , as previously observed in mice , we cultured HaCaT cells and found that ***interferon-gamma*** and tumor necrosis factor alpha work synergistically to ***induce*** ***TARC*** production .	target	1
19152	10998141	7020;4162	AP-2;melanoma cell adhesion molecule	***AP-2-driven*** ***downregulation*** of the ***melanoma cell adhesion molecule*** promoter , however , did not depend only on a functional SCA element .	negative	1
19153	10998178	5783;2280	FAP1;FKBP12	We provide genetic and biochemical evidence that ***FAP1*** ***interacts*** physically with ***FKBP12*** in vivo and in vitro , and that it competes with rapamycin for interaction .	parallel	1
19154	10998178	5783;2280	FAP1;FKBP12	Our results suggest that ***FAP1*** is a physiological ***ligand*** for ***FKBP12*** that is highly conserved from yeast to man .	parallel	1
19155	10998360	7074;5879	Tiam1;Rac1	These results reveal novel facets of ***Tiam1-dependent*** ***regulation*** of ***Rac1*** function .	target	1
19156	10998369	6774;624	STAT3;B2R	Furthermore , Tyk2 and ***STAT3*** form a ***complex*** with the ***B2R*** in response to BK stimulation .	parallel	1
19157	10998369	7297;624	Tyk2;B2R	Furthermore , ***Tyk2*** and STAT3 form a ***complex*** with the ***B2R*** in response to BK stimulation .	parallel	1
19158	10998417	57498;5587	Kidins220;protein kinase D	Identification and cloning of ***Kidins220*** , a novel neuronal ***substrate*** of ***protein kinase D*** .	parallel	1
19159	10998420	7079;4323	TIMP-4;MT1-MMP	In contrast , ***TIMP-4*** , an efficient ***MT1-MMP*** ***inhibitor*** , had no synergistic effect .	negative	1
19160	10998424	4793;4790	IkappaB-beta;NF-kappaB	These findings indicate that ***IkappaB-beta*** is the key ***regulator*** of the activity of ***NF-kappaB*** in human glial cells .	target	1
19161	10998425	9971;5360	farnesoid X-activated receptor;phospholipid transfer protein	The ***farnesoid X-activated receptor*** ***mediates*** bile acid activation of ***phospholipid transfer protein*** gene expression .	target	0
19162	10998425	9971;5360	FXR;PLTP	Here we report the ***regulation*** of ***PLTP*** gene expression by ***FXR*** and bile acids .	target	1
19163	10998426	3486;581	Insulin-like growth factor-binding protein-3;Bax	***Insulin-like growth factor-binding protein-3*** ***modulates*** expression of ***Bax*** and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells .	target	0
19164	10998426	3486;596	Insulin-like growth factor-binding protein-3;Bcl-2	***Insulin-like growth factor-binding protein-3*** ***modulates*** expression of Bax and ***Bcl-2*** and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells .	target	0
19165	10998447	10856;1082	TIP49b;CGB	The ***TIP49b/RUVBL2*** gene is physically ***linked*** to the human ***CGB/LHB*** gene cluster on chromosome 19q13 .3 .	parallel	0
19166	10998447	10856;3972	TIP49b;LHB	The ***TIP49b/RUVBL2*** gene is physically ***linked*** to the human ***CGB/LHB*** gene cluster on chromosome 19q13 .3 .	parallel	0
19167	10998456	633;7040	biglycan;TGF-beta	Proteoglycans decorin and ***biglycan*** , which ***bind*** to ***TGF-beta*** , are thought to participate in regulation of extracellular matrix accumulation in arterial intimal hyperplasia .	parallel	1
19168	10998456	1634;7040	decorin;TGF-beta	Proteoglycans ***decorin*** and biglycan , which ***bind*** to ***TGF-beta*** , are thought to participate in regulation of extracellular matrix accumulation in arterial intimal hyperplasia .	parallel	1
19169	10998539	5368;4987	orphanin FQ;ORL-1	***orphanin FQ/nociceptin*** ( OFQ ) is a recently discovered endogenous ***ligand*** for the novel opioid receptor-like receptor ( ***ORL-1*** ) .	parallel	1
19170	10998550	4987;5368	ORL1;nociceptin	Species differences in the efficacy of compounds at the ***nociceptin*** ***receptor*** ( ***ORL1*** ) .	parallel	1
19171	10998641	4776;2626	NF-AT3;GATA-4	Upon activation , ***NF-AT3*** translocates to the nucleus and ***interacts*** with ***GATA-4*** to stimulate beta-MHC expression .	parallel	1
19172	10999464	356;355	FasL;Fas	The local release of sFas by AML blasts may then function as a protective mechanism by competing with membrane-bound Fas for binding sites on the common ***Fas*** ***ligand*** ( ***FasL*** ) .	parallel	1
19173	10999534	627;4852	BDNF;NPY	Chronic infusion of ***BDNF*** ***increased*** the expression of ***NPY*** in the hippocampus , with a time course similar to that of the protective effect of the neurotrophin on kindling .	positive	0
19174	10999534	627;4852	BDNF;neuropeptide Y	Moreover ***BDNF*** is known to ***regulate*** the expression of ***neuropeptide Y*** ( NPY ) , which displays modulatory properties on seizure activity .	target	1
19175	10999534	4852;627	NPY;BDNF	This suggests that the effects of ***BDNF*** on epileptogenesis may be ***mediated*** by ***NPY*** .	target	0
19176	10999534	627;4852	BDNF;NPY	The long-term ***regulation*** of ***NPY*** expression by ***BDNF*** was also studied by immunohistochemistry and radioimmunoassay .	target	1
19177	10999739	7490;1958	EWS-WT1;EGR-1	We present evidence that various ***EWS-WT1*** proteins ***up-regulated*** ***EGR-1*** promoter activity and that this up-regulation is specifically dependent upon the absence of the exon 9 KTS domain of WT1 .	positive	1
19178	10999742	7124;283	tumor necrosis factor-alpha;Angiogenin	In an in vitro study , interleukin-1beta and ***tumor necrosis factor-alpha*** ***induced*** ***Angiogenin*** mRNA expression in colon cancer cells in a dose - and time-dependent manner , and these cytokines significantly upregulated the expression of Angiogenin mRNA , especially in colon cancer cells rather than in other cells in the stroma of tumor tissues ( fibroblasts , tumor infiltrating lymphocytes , macrophages ) .	target	1
19179	10999744	356;355	FasL;fas	Moreover , ***fas*** ***ligand*** ( ***FasL*** ) expression was detected on the cell surface as well as the cytoplasm of colorectal cancer cells in 61 % of cases .	parallel	1
19180	10999756	5915;5914	RARbeta;RARalpha	Lung ***RARalpha*** was ***induced*** by 4.7-fold , ***RARbeta*** by 8.0-fold , and RARgamma by 8.1-fold .	target	1
19181	10999756	5916;5914	RARgamma;RARalpha	Lung ***RARalpha*** was ***induced*** by 4.7-fold , RARbeta by 8.0-fold , and ***RARgamma*** by 8.1-fold .	target	1
19182	10999773	847;5979	Catalase;RET	In addition , ***Catalase*** treatment ***down-regulated*** ***RET*** expression at both the mRNA and protein levels and induced apoptosis in the parental TT cell line and uninduced TT : deltaRaf-1 : ER human MTC cells .	negative	1
19183	10999829	652;1586	BMP-4;CYP17	In conclusion , ***BMP-4*** ***inhibits*** HOTT cell expression of ***CYP17*** , leading to an alteration of steroidogenic pathway resulting in reduced androstenedione accumulation and increased progesterone production .	negative	1
19184	10999850	3553;5743	IL-1beta;Cox-2	***IL-1beta*** also ***induced*** expression of biologically active ***Cox-2*** protein , as detected by immunofluorescence , Western blot analysis , and measuring the conversion of arachidonic acid to prostanoids in the presence and absence of a Cox-2-selective inhibitor , NS-398 .	target	1
19185	10999850	3553;5734	IL-1beta;EP4	However , ***IL-1beta*** ***stimulated*** expression of ***EP4*** receptor mRNA .	positive	0
19186	10999851	23414;2626	FOG-2;GATA-4	We also found that mRNA for ***FOG-2*** , a recently discovered ***regulator*** of ***GATA-4*** , is coexpressed with GATA-4 in human ovary samples , normal granulosa cells , and in sex cord-derived tumors .	target	1
19187	10999937	3164;8648	hMR;SRC-1	An agonist-dependent ***hMR*** ***interaction*** with ***SRC-1*** was observed for both the wild-type and the mutant receptors .	parallel	1
19188	10999956	196;2033	AHR;p300	Immunoprecipitation revealed that ***AHR*** directly ***bound*** to ***p300*** , thus suggesting the intriguing possibility that AHR is involved in control of the cell cycle via interaction with p300 .	parallel	1
19189	10999960	10874;10316	NmU;GPR66	Here we demonstrate that ***GPR66/FM*** -3 is specifically ***stimulated*** by ***NmU*** , causing the mobilization of intracellular calcium .	positive	0
19190	11000046	6464;2885	Shc;Grb2	The metabolite inhibited significantly the binding between the Grb2-SH2 domain and the phosphopeptide derived from the Shc protein and also blocked the protein-protein ***interactions*** of ******Grb2-Shc****** in cell-based experiments , with IC ( 50 ) values of 5.3 and 50 microM , respectively .	parallel	1
19191	11000249	3700;920	gp120;CD4 receptor	In addition to being highly strain specific , the chimpanzee antiserum did not bind to the V3 loop peptide of HIV-1 ( DH12 ) , nor did it block the ***interaction*** of ***gp120*** with the ***CD4 receptor*** .	parallel	1
19192	11000405	5452;5451	Oct-2;Oct-1	Furthermore , the ***interaction*** of ***Oct-1*** and ***Oct-2*** contributed to the regulation of the mb-1 promoter as site-directed mutations within the octamer motif substantially reduced its activity .	parallel	1
19193	11000445	4803;4914	NGF;TrkA	Our data show that unilateral peripheral nerve injury results in dynamic downregulation of TrkA in sensory neurons in bilateral DRG and spinal cord , and that ***TrkA*** expression in sensory neurons is partially ***regulated*** by target-derived ***NGF*** .	target	1
19194	11000462	3557;3553	IL-1RA;IL-1beta	Injections of ***IL-1RA*** ***decreased*** the concentration of ***IL-1beta*** and TNF-alpha and resulted in survival of all infected mice ( treatment group ) .	negative	0
19195	11000462	3557;7124	IL-1RA;TNF-alpha	Injections of ***IL-1RA*** ***decreased*** the concentration of IL-1beta and ***TNF-alpha*** and resulted in survival of all infected mice ( treatment group ) .	negative	0
19196	11000521	8660;5979	IRS-2;Ret	Besides the signaling steps leading to MAPK activation , we could demonstrate that Ret-9bp induced constitutive activation of a signaling pathway involving ***IRS-2*** , PI 3-kinase and PKB/AKT which could ***transduce*** the oncogenic ***Ret*** signal to increased gene transcription via activation of the jun/AP -1 transcription factor family .	positive	1
19197	11000521	207;5979	PKB;Ret	Besides the signaling steps leading to MAPK activation , we could demonstrate that Ret-9bp induced constitutive activation of a signaling pathway involving IRS-2 , PI 3-kinase and ***PKB/AKT*** which could ***transduce*** the oncogenic ***Ret*** signal to increased gene transcription via activation of the jun/AP -1 transcription factor family .	positive	1
19198	11000521	5979;6464	Ret;SHC	Moreover , ***Ret-9bp*** ***induces*** phosphorylation of ***SHC*** resulting in growth factor receptor binding protein-2 ( Grb-2 ) binding and activation of the mitogen activating protein ( MAP ) kinase pathway .	target	1
19199	11000524	4803;4804	NGF;NGF receptor	***NGF*** also ***induced*** the expression of the p75 ***NGF receptor*** .	target	1
19200	11000528	2099;367	ERalpha;androgen receptor	We have demonstrated that the ***androgen receptor*** ( AR ) and estrogen receptor-alpha ( ***ERalpha*** ) can ***interact*** directly using the yeast and mammalian two-hybrid systems .	parallel	1
19201	11000584	3002;836	granzyme B;caspase-3	These results indicate that anticancer drugs and gamma-rays prime squamous cell carcinoma cells to be susceptible to apoptosis by LAK cells , that LAK cell-induced apoptosis largely depends on the ***activation*** of ***caspase-3*** by the Fas/Fas-ligand signal and ***granzyme B*** , and that LAK cells induce ROI in the target cells , which is largely mediated by Fas and granzyme B .	positive	1
19202	11001060	867;3643	Cbl;insulin receptor	***Cbl*** is ***recruited*** to the ***insulin receptor*** by interaction with the adapter protein CAP , through one of three adjacent SH3 domains in the carboxy terminus of CAP .	target	0
19203	11001060	867;10580	Cbl;CAP	Upon phosphorylation of Cbl , the ******CAP-Cbl****** ***complex*** dissociates from the insulin receptor and moves to a caveolin-enriched , triton-insoluble membrane fraction .	parallel	1
19204	11001060	867;10580	Cbl;CAP	Flotillin forms a ternary complex with CAP and Cbl , directing the localization of the ******CAP-Cbl****** ***complex*** to a lipid raft subdomain of the plasma membrane .	parallel	1
19205	11001060	10580;867	CAP;Cbl	Thus , localization of the ******Cbl-CAP****** ***complex*** to lipid rafts generates a pathway that is crucial in the regulation of glucose uptake .	parallel	1
19206	11001366	958;959	CD40;CD40 ligand	The interaction between ***CD40 ligand*** ( CD40L , CD154 ) and its ***receptor*** ***CD40*** on antigen-presenting cells , is essential for the initiation of cell-mediated and humoral immune responses .	parallel	1
19207	11001366	958;959	CD40;CD40 ligand	The ***interaction*** between ***CD40 ligand*** ( CD40L , CD154 ) and its receptor ***CD40*** on antigen-presenting cells , is essential for the initiation of cell-mediated and humoral immune responses .	parallel	1
19208	11001563	7124;6610	TNF-alpha;N-SMase	A further role of ceramide and N-SMase in atherosclerosis was uncovered by the finding that Ox-LDL and ***TNF-alpha*** ***stimulated*** ***N-SMase*** activity .	positive	0
19209	11001753	5468;4018	PPAR-gamma;lipoprotein	***PPAR-gamma*** mRNA levels were negatively correlated with FPI ( P < 0.05 ) and HOMA ( P < 0.05 ) and positively ***correlated*** with high-density ***lipoprotein*** ( HDL ) cholesterol ( P < 0.05 ) , membrane SM ( P < 0.05 ) , and cholesterol contents ( P < 0.05 ) .	positive	0
19210	11001757	5617;6528	PRL;NIS	These studies suggest that the PRL stimulation of iodide accumulation in milk is mediated , at least in part , by the ***PRL*** ***stimulation*** of ***NIS*** accumulation in mammary gland tissues .	positive	0
19211	11001896	4602;2623	c-Myb;GATA-1	In addition , ***c-Myb*** ***bound*** to ***GATA-1*** and inhibited its DNA-binding activities .	parallel	1
19212	11001908	5970;4790	p65;p50	We observed that NF-kappaB is constitutively activated in all KSHV-infected lymphomas , and consists of 2 predominant complexes , ******p65/p50****** ***heterodimers*** and p50/p50 homodimers .	parallel	1
19213	11001911	2120;861	TEL;AML1	Although AML1 stimulates transcription , ***TEL-AML1*** functions as a ***repressor*** of some ***AML1*** target genes .	negative	1
19214	11001911	861;9611	AML1;N-CoR	In contrast to the wild type AML1 protein , both TEL and ***TEL-AML1*** ***interact*** with ***N-CoR*** , a component of the nuclear receptor corepressor complex with histone deacetylase activity .	parallel	1
19215	11001911	2120;9611	TEL;N-CoR	In contrast to the wild type AML1 protein , both TEL and ***TEL-AML1*** ***interact*** with ***N-CoR*** , a component of the nuclear receptor corepressor complex with histone deacetylase activity .	parallel	1
19216	11001911	2120;9611	TEL;N-CoR	The ***interaction*** between ***TEL*** and ***N-CoR*** requires the central region of TEL , which is retained in TEL-AML1 , and TEL lacking this domain is impaired in transcriptional repression .	parallel	1
19217	11001911	9611;861	N-CoR;AML1	Taken together , our results suggest that TEL-AML1 may contribute to leukemogenesis by ***recruiting*** ***N-CoR*** to ***AML1*** target genes and thus imposing an altered pattern of their expression .	target	0
19218	11001913	3586;7422	IL-10;VEGF	Recombinant human IL-10 abolished and viral ***IL-10*** ***reduced*** vascular endothelial growth factor ( ***VEGF*** ) -165 - induced neovascularization .	negative	1
19219	11001914	8773;10228	SNAP-23;syntaxin 6	In vitro binding studies established that ***SNAP-23*** ***binds*** to ***syntaxin 6*** .	parallel	1
19220	11001914	8773;10228	SNAP-23;syntaxin 6	Coimmunoprecipitation assays indicated that ***SNAP-23*** ***interacts*** with ***syntaxin 6*** in vivo , and this interaction was dramatically increased on neutrophil activation .	parallel	1
19221	11001921	356;355	CD95L;CD95	To evaluate the role of death ligands in elimination of DCs , we analyzed the sensitivity of human DCs to ***CD95*** ***ligand*** ( ***CD95L*** ) and tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL ) .	parallel	1
19222	11001923	1641;5048	DCX;LIS1	Here we report that ***LIS1*** and ***DCX*** ***interact*** physically both in vitro and in vivo .	parallel	1
19223	11001923	1641;5048	DCX;LIS1	Epitope-tagged ***DCX*** transiently expressed in COS cells can be ***co-immunoprecipitated*** with endogenous ***LIS1*** .	parallel	1
19224	11001923	1641;5048	DCX;LIS1	Furthermore , endogenous ***DCX*** could be ***co-immunoprecipitated*** with endogenous ***LIS1*** in embryonic brain extracts , demonstrating an in vivo association .	parallel	1
19225	11001931	5664;2274	presenilin 2;DRAL	Alzheimer 's disease-associated ***presenilin 2*** ***interacts*** with ***DRAL*** , an LIM-domain protein .	parallel	1
19226	11001931	2274;5664	DRAL;PS2	This suggests that ***DRAL*** ***recognizes*** the ***PS2*** structure specifically .	target	1
19227	11001931	2274;5664	DRAL;PS2	The in vitro interaction was confirmed by affinity column assay and the physiological ***interactions*** between endogenous ***PS2*** and ***DRAL*** by co-immunoprecipitation from human lung fibroblast MRC5 cells .	parallel	1
19228	11001931	2274;5664	DRAL;PS2	Furthermore , in PS2-overexpressing HEK293 cells , we found an increase in the amount of DRAL in the membrane fraction and an increase in the amount of ***DRAL*** that was ***co-immunoprecipitated*** with ***PS2*** .	parallel	1
19229	11001933	5777;3815	PTPN6;c-Kit	***Association*** of ***PTPN6*** with ***c-Kit*** and negative modulation of the myeloid leukocyte signal transduction pathways prompted us to examine the expression of the protein tyrosine phosphatase PTPN6 gene in CD34 ( + ) / CD117 ( + ) blasts from acute myeloid leukemia patients .	parallel	0
19230	11001934	56893;6310	A1Up;ataxin-1	In the nucleus , A1Up co-localized with mutant ataxin-1 , further demonstrating that ***A1Up*** ***interacts*** with ***ataxin-1*** .	parallel	1
19231	11001934	56893;6310	A1Up;ataxin-1	These results suggest that ***A1Up*** may ***link*** ***ataxin-1*** with the chaperone and ubiquitin-proteasome pathways .	parallel	0
19232	11001946	7039;1956	transforming growth factor (TGF)-alpha;erbB1	Both EGF and ***transforming growth factor (TGF)-alpha*** only ***bind*** to ***erbB1*** and activate it .	parallel	1
19233	11002391	3458;3684	interferon gamma;CD11b	Phenotyping of U937 cells for complement receptors ( CRs ) and Fcgamma receptors ( FcgammaRs ) showed that ***interferon gamma*** ( INFgamma ) ***increased*** expression of FcgammaRI , CR3 ( ***CD11b/CD18*** ) and CR4 ( CD11c/CD18 ) and that phorbol-12-myristate-13-acetate ( PMA ) increased expression of CR4 .	positive	0
19234	11002391	3458;3687	interferon gamma;CD11c	Phenotyping of U937 cells for complement receptors ( CRs ) and Fcgamma receptors ( FcgammaRs ) showed that ***interferon gamma*** ( INFgamma ) ***increased*** expression of FcgammaRI , CR3 ( CD11b/CD18 ) and CR4 ( ***CD11c/CD18*** ) and that phorbol-12-myristate-13-acetate ( PMA ) increased expression of CR4 .	positive	0
19235	11002391	3458;3689	interferon gamma;CD18	Phenotyping of U937 cells for complement receptors ( CRs ) and Fcgamma receptors ( FcgammaRs ) showed that ***interferon gamma*** ( INFgamma ) ***increased*** expression of FcgammaRI , CR3 ( ***CD11b/CD18*** ) and CR4 ( CD11c/CD18 ) and that phorbol-12-myristate-13-acetate ( PMA ) increased expression of CR4 .	positive	0
19236	11002413	7124;4843	TNF-alpha;iNOS	***TNF-alpha*** alone neither induced iNOS in USAC cells nor caused production of NO , but addition of TNF-alpha to USAC cells pretreated with LPS and IFN-gamma ***enhanced*** the expression of ***iNOS*** mRNA , induced iNOS protein and produced NO .	positive	0
19237	11002417	841;4790	caspase 8;NF-kappaB	***Activation*** of the ***NF-kappaB*** pathway by ***caspase 8*** and its homologs .	positive	1
19238	11002417	841;4790	caspase 8;NF-kappaB	We have discovered that ***caspase 8*** can ***activate*** the ***NF-kappaB*** pathway independent of its activity as a pro-apoptotic protease .	positive	1
19239	11002417	843;4790	Caspase 10;NF-kappaB	***Caspase 10*** and MRIT , two DEDs-containing homologs of caspase 8 , can similarly ***activate*** the ***NF-kappaB*** pathway .	positive	1
19240	11002417	8837;4790	MRIT;NF-kappaB	Caspase 10 and ***MRIT*** , two DEDs-containing homologs of caspase 8 , can similarly ***activate*** the ***NF-kappaB*** pathway .	positive	1
19241	11002419	6464;2549	SHC;GAB1	In response to GDNF stimulation , ***SHC*** ***bound*** to ***GAB1*** and GRB2 adaptor proteins as well as RET , and SHC and GAB1 were highly phosphorylated on tyrosine .	parallel	1
19242	11002419	6464;2885	SHC;GRB2	In response to GDNF stimulation , ***SHC*** ***bound*** to GAB1 and ***GRB2*** adaptor proteins as well as RET , and SHC and GAB1 were highly phosphorylated on tyrosine .	parallel	1
19243	11002419	6464;5979	SHC;RET	In response to GDNF stimulation , ***SHC*** ***bound*** to GAB1 and GRB2 adaptor proteins as well as ***RET*** , and SHC and GAB1 were highly phosphorylated on tyrosine .	parallel	1
19244	11002419	6464;2885	SHC;GRB2	Tyrosine-phosphorylated GAB1 was also associated with p85 subunit of PI3-K , resulting in PI3-K and AKT activation , whereas ******SHC-GRB2-SOS****** ***complex*** was responsible for the RAS/ERK signaling pathway .	parallel	1
19245	11002421	1026;1017	p21;cdk2	G1 arrest was accompanied by increased ***association*** of ***p21*** with cyclin E/cdk2 and cyclin ***A/cdk2*** , increased binding of p27 to cyclin E/cdk2 and inhibition of these kinases .	parallel	0
19246	11002421	1019;595	cdk4;cyclin D1	Reduced cyclin D1 protein and increased binding of p21 and p27 to ******cyclin D1/cdk4****** ***complexes*** were also observed .	parallel	1
19247	11002421	1026;1019	p21;cdk4	Reduced cyclin D1 protein and increased ***binding*** of ***p21*** and p27 to ***cyclin D1/cdk4*** complexes were also observed .	parallel	1
19248	11002421	1026;595	p21;cyclin D1	Reduced cyclin D1 protein and increased ***binding*** of ***p21*** and p27 to ***cyclin D1/cdk4*** complexes were also observed .	parallel	1
19249	11002421	983;891	cdk1;cyclin B1	Losses in cyclin B1 expression and an increased binding of p21 to ******cyclin B1/cdk1****** ***complexes*** also contributed to inhibition of this kinase activity , and G2/M arrest .	parallel	1
19250	11002421	1026;983	p21;cdk1	Losses in cyclin B1 expression and an increased ***binding*** of ***p21*** to ***cyclin B1/cdk1*** complexes also contributed to inhibition of this kinase activity , and G2/M arrest .	parallel	1
19251	11002421	1026;891	p21;cyclin B1	Losses in cyclin B1 expression and an increased ***binding*** of ***p21*** to ***cyclin B1/cdk1*** complexes also contributed to inhibition of this kinase activity , and G2/M arrest .	parallel	1
19252	11002422	841;8737	caspase-8;RIP	In this study , we demonstrate that the proteolytic ***cleavage*** of receptor interacting protein ( ***RIP*** ) by ***caspase-8*** during TNF-induced apoptosis abrogates the stimulatory role of RIP on TNF-induced NF-kappaB activation .	target	1
19253	11002422	8737;4790	RIP;NF-kappaB	The present study suggest that the C-terminal fragment of ***RIP*** produced by caspase-8 activates death-inducing signaling complex ( DISC ) , ***attenuates*** ***NF-kappaB*** activation , and thereby amplifies the activation of caspase-8 which initiates the downstream apoptotic events .	negative	0
19254	11002423	7157;5888	p53;Rad51	Role of heteroduplex joints in the functional ***interactions*** between human ***Rad51*** and wild-type ***p53*** .	parallel	1
19255	11002425	2130;5594	EWS/FLI-1;ERK	An ***EWS/FLI-1*** mutant defective in DNA-binding and transcriptional activation failed to ***activate*** ***ERK*** and was also defective in 3T3 cell transformation .	negative	1
19256	11003570	5590;3383	Protein kinase C-zeta;ICAM-1	***Protein kinase C-zeta*** ***mediates*** TNF-alpha-induced ***ICAM-1*** gene transcription in endothelial cells .	target	0
19257	11003570	4790;3383	NF-kappaB;ICAM-1	We observed that PKC-zeta also induced the TNF-alpha-induced ***NF-kappaB*** ***binding*** to the ***ICAM-1*** promoter and the resultant ICAM-1 gene transcription .	parallel	1
19258	11003570	5590;3383	PKC-zeta;ICAM-1	We observed that ***PKC-zeta*** also ***induced*** the TNF-alpha-induced NF-kappaB binding to the ICAM-1 promoter and the resultant ***ICAM-1*** gene transcription .	target	1
19259	11003570	5590;4790	PKC-zeta;NF-kappaB	We observed that ***PKC-zeta*** also ***induced*** the TNF-alpha-induced ***NF-kappaB*** binding to the ICAM-1 promoter and the resultant ICAM-1 gene transcription .	target	1
19260	11003590	7124;7351	tumor necrosis factor-alpha;UCP-2	Nitric oxide-dependent ***downregulation*** of adipocyte ***UCP-2*** expression by ***tumor necrosis factor-alpha*** .	negative	1
19261	11003590	7124;7351	TNF-alpha;UCP-2	Cell treatment with the NOS inhibitor N ( G ) - nitro-L-arginine methyl ester ( L-NAME ; 1 mmol/l ) significantly diminished the ***TNF-alpha-mediated*** sustained ***downregulation*** of ***UCP-2*** expression , whereas cell treatment with a nitric oxide ( NO ) donor ( 10 ( -3 ) mol/l S-nitroso-L-glutathione ) mimicked the TNF-alpha effect on UCP-2 expression .	negative	1
19262	11003590	7124;7351	TNF-alpha;UCP-2	These experiments demonstrate that ***TNF-alpha*** directly ***downregulates*** ***UCP-2*** expression via NO-dependent pathways that involve the induction of iNOS expression .	negative	1
19263	11003621	3458;4843	IFN-gamma;iNOS	Treatment of hepatocytes with interleukin 1beta ( IL-1beta ) plus interferon gamma ( ***IFN-gamma*** ) , which ***induced*** ***iNOS*** expression and NO production , suppressed TNF-alpha/ActD-induced Bid cleavage and mitochondrial cytochrome c release .	target	1
19264	11003621	3553;4843	IL-1beta;iNOS	Treatment of hepatocytes with interleukin 1beta ( ***IL-1beta*** ) plus interferon gamma ( IFN-gamma ) , which ***induced*** ***iNOS*** expression and NO production , suppressed TNF-alpha/ActD-induced Bid cleavage and mitochondrial cytochrome c release .	target	1
19265	11003625	3082;207	Hepatocyte growth factor;Akt	In the current study , we showed that ***Hepatocyte growth factor*** ( HGF ) ***activates*** the ***Akt/PI*** -3 kinase pathway to suppress fas-mediated cell death in human hepatocellular carcinoma ( HCC ; 3 lines ; SK-Hep1 , HLE , and Chang Liver cell lines ) , hepatoblastoma ( 1 line ; HepG2 ) , and embryonic hepatocyte ( 1 line ; WRL ) .	positive	1
19266	11003625	3082;8772	HGF;FADD	fas-death-inducing signaling complex ( DISC ) formation , especially ***FADD*** and caspase 8 interaction , was ***suppressed*** by ***HGF*** and the suppression of the Akt/PI -3 kinase pathway by transient expression of PTEN , resulting in acquisition of fas-DISC formation and fas-mediated cell death in HGF-treated cells .	negative	1
19267	11003625	5728;8772	PTEN;FADD	fas-death-inducing signaling complex ( DISC ) formation , especially ***FADD*** and caspase 8 interaction , was ***suppressed*** by HGF and the suppression of the Akt/PI -3 kinase pathway by transient expression of ***PTEN*** , resulting in acquisition of fas-DISC formation and fas-mediated cell death in HGF-treated cells .	negative	1
19268	11003642	7157;672	p53;BRCA1	Tumor suppressor ***p53*** is required to ***modulate*** ***BRCA1*** expression .	target	0
19269	11003642	672;7157	BRCA1;p53	We have analyzed a possible functional ***link*** between ***p53*** and ***BRCA1*** genes .	parallel	0
19270	11003642	7157;672	p53;BRCA1	In conclusion , the data show that ***BRCA1*** expression levels are ***controlled*** by the presence and activity of wild-type ***p53*** and suggest the existence of an intracellular p53/BRCA1 pathway in the response of cells to stress conditions .	target	0
19271	11003656	3315;1616	HSP27;Daxx	Here we show that phosphorylated dimers of ***HSP27*** ***interact*** with ***Daxx*** , a mediator of Fas-induced apoptosis , preventing the interaction of Daxx with both Ask1 and Fas and blocking Daxx-mediated apoptosis .	parallel	1
19272	11003656	1616;4217	Daxx;Ask1	Here we show that phosphorylated dimers of HSP27 interact with Daxx , a mediator of Fas-induced apoptosis , preventing the ***interaction*** of ***Daxx*** with both ***Ask1*** and Fas and blocking Daxx-mediated apoptosis .	parallel	1
19273	11003656	1616;355	Daxx;Fas	Here we show that phosphorylated dimers of HSP27 interact with Daxx , a mediator of Fas-induced apoptosis , preventing the ***interaction*** of ***Daxx*** with both Ask1 and ***Fas*** and blocking Daxx-mediated apoptosis .	parallel	1
19274	11003667	4261;5993	CIITA;RFX5	We demonstrate direct ***interaction*** of ***CIITA*** with the MHC class II promoter binding protein ***RFX5*** and could also detect novel interactions with RFXANK , NF-YB , and - YC .	parallel	1
19275	11003668	1029;5925	p16;pRb	The tumor suppressor ***p16*** ( INK4A ) ***inhibits*** phosphorylation of ***pRb*** by CDK4 and CDK6 and can thereby block cell cycle progression at the G ( 1 ) / S boundary .	negative	1
19276	11003668	1029;1022	p16;CDK7	***Regulation*** of ***CDK7-CTD*** kinase activity by ***p16*** ( INK4A ) thus may represent an alternative pathway for controlling cell cycle progression .	target	1
19277	11003669	2064;5594	ErbB-2;ERK 1 and 2	Overexpression of gene 33 protein in mouse fibroblasts inhibited ( i ) cell proliferation driven by ErbB-2 but not by serum , ( ii ) cell transformation induced by ErbB-2 but not by Ras or Src , and ( iii ) sustained ***activation*** of ***ERK 1 and 2*** by ***ErbB-2*** but not by serum .	positive	1
19278	11003753	3458;3383	interferon-gamma;intercellular adhesion molecule 1	Expression of human leukocyte antigen 1 , human leukocyte antigen 2 , and ***intercellular adhesion molecule 1*** by fibroblasts was significantly ***upregulated*** by ***interferon-gamma*** , and cryopreservation did not downregulate this expression .	positive	1
19279	11003833	5080;5076	Pax6;Pax2	Co-transfection experiments revealed a reciprocal ***inhibition*** of ***Pax2*** promoter/enhancer activity by ***Pax6*** protein and vice versa .	negative	1
19280	11003834	4902;2668	NTN;GDNF	Positive and negative ***interactions*** of ***GDNF*** , ***NTN*** and ART in developing sensory neuron subpopulations , and their collaboration with neurotrophins .	parallel	1
19281	11003839	2736;6899	Gli2;brachyury	***Gli2*** directly ***induces*** ***brachyury*** , a gene required and sufficient for mesodermal development , and Gli2 is in turn induced by FGF signaling .	target	1
19282	11003979	7124;4790	TNF-alpha;NF-kappaB	We recently reported that tumor necrosis factor-alpha ( ***TNF-alpha*** ) rapidly ***activates*** ***NF-kappaB*** in differentiated skeletal muscle myotubes and that TNF-alpha acts directly on the muscle cell to induce protein degradation .	positive	1
19283	11004006	249;5167	TNAP;PC-1	***TNAP*** also paradoxically ***regulates*** ***PC-1*** expression and NTPPPH activity in osteoblasts .	target	1
19284	11004213	4973;4018	LOX-1;lipoprotein	Expression of ***LOX-1*** , an oxidized low-density ***lipoprotein*** ***receptor*** , in experimental hypertensive glomerulosclerosis .	parallel	1
19285	11004241	3479;3938	IGF-I;LPH	Thus , oral ***IGF-I*** ***increased*** jejunal LPH activity and ***LPH*** mRNA abundance and stimulated intestinal cell hyperplasia in normal piglets .	positive	0
19286	11004479	7040;6439	TGF beta;SP-B	***TGF beta*** ( 1 ) ( 10 ng/ml ) ***reduced*** ***SP-B*** mRNA content in a time-dependent fashion , and transient transfection studies localized responsiveness to the region of the SP-B promoter ( -112 / -72 bp ) containing binding sites for thyroid transcription factor-1 ( TTF-1 ) and hepatocyte nuclear factor 3 ( HNF3 ) , transcription factors that are important enhancers of SP gene expression .	negative	1
19287	11004479	7040;2305	TGF beta;HNF3	We conclude that ***TGF beta*** ( 1 ) , acting via protein phosphorylation , ***blocks*** nuclear translocation of TTF-1 and ***HNF3*** which results in down-regulation of the SP-B gene and presumably other pulmonary genes which are transactivated by these factors .	negative	0
19288	11004486	3569;10379	IL-6;p48	Rather , ***IL-6*** ***induces*** expression of ISGF3 gamma ( ***p48*** ) , a subunit of the multimeric transcription factor ISGF3 .	target	1
19289	11004486	3569;10379	IL-6;ISGF3	We show here ***IL-6*** ***induces*** the ***ISGF3*** gamma gene through GATE .	target	1
19290	11004486	1051;3569	C/EBP-beta;IL-6	A mutant ***C/EBP-beta*** ***inhibits*** the ***IL-6*** inducible ISGF3 gamma gene expression through GATE .	negative	1
19291	11004486	1051;10379	C/EBP-beta;ISGF3	A mutant ***C/EBP-beta*** ***inhibits*** the IL-6 inducible ***ISGF3*** gamma gene expression through GATE .	negative	1
19292	11004522	51199;2932	hNinein;GSK-3beta	Our findings suggest that ***hNinein*** may be involved in the formation of centrosome matrix and ***interacts*** with the ***GSK-3beta*** , implying that it may also be regulated by GSK-3beta phosphorylation signaling .	parallel	1
19293	11004551	83716;2159	trypsin inhibitor;factor Xa	Momordica charantia ***trypsin inhibitor*** II ( MCTI-II ) ***inhibits*** the amidolytic activity of ***factor Xa*** with a K ( i ) value 10-100-fold smaller than those of other squash family inhibitors .	negative	1
19294	11004633	1906;999	Endothelin-1;E-cadherin	***Endothelin-1*** ***down-regulates*** ***E-cadherin*** in melanocytic cells by apoptosis-independent activation of caspase-8 .	negative	1
19295	11004667	7157;3315	p53;hsp27	***p53-dependent*** ***induction*** of heat shock protein 27 ( ***hsp27*** ) expression .	target	1
19296	11004694	6667;943	Sp1;CD30	The transcription factor ***Sp1*** and members of the Ets family ***induce*** ***CD30*** expression , whereas the transcription factor Sp3 diminishes its induction .	target	1
19297	11004695	836;1677	caspase-3;CAD	Following FAS stimulation , caspase-8 activates ***caspase-3*** , which in turn ***activates*** the caspase-activated DNAse ( ***CAD*** ) by proteolysis of its inhibitor ( ICAD ) .	positive	1
19298	11004695	841;836	caspase-8;caspase-3	Following FAS stimulation , ***caspase-8*** ***activates*** ***caspase-3*** , which in turn activates the caspase-activated DNAse ( CAD ) by proteolysis of its inhibitor ( ICAD ) .	positive	1
19299	11004712	1392;5443	corticotropin-releasing hormone;adrenocorticotropin	The release of ***adrenocorticotropin*** ( ACTH ) from the corticotrophs is ***controlled*** principally by vasopressin and ***corticotropin-releasing hormone*** ( CRH ) .	target	0
19300	11004712	5020;5443	Oxytocin;ACTH	***Oxytocin*** may ***augment*** the release of ***ACTH*** under certain conditions , whereas atrial natriuretic peptide acts as a corticotropin release-inhibiting factor to inhibit ACTH release by direct action on the pituitary .	positive	0
19301	11004713	595;2353	cyclin D1;c-fos	FGF2 elicits a strong mitogenic response in G0/G1-arrested Y1 adrenocortical cells , that includes a ) rapid and transient activation of extracellular signal-regulated kinases-mitogen-activated protein kinases ( ERK-MAPK ) ( 2 to 10 min ) , b ) transcription activation of c-fos , c-jun and c-myc genes ( 10 to 30 min ) , c ) ***induction*** of ***c-fos*** and c-myc proteins by 1 h and ***cyclin D1*** protein by 5 h , and d ) onset of DNA synthesis stimulation within 8 h.	target	1
19302	11004713	595;4609	cyclin D1;c-myc	FGF2 elicits a strong mitogenic response in G0/G1-arrested Y1 adrenocortical cells , that includes a ) rapid and transient activation of extracellular signal-regulated kinases-mitogen-activated protein kinases ( ERK-MAPK ) ( 2 to 10 min ) , b ) transcription activation of c-fos , c-jun and c-myc genes ( 10 to 30 min ) , c ) ***induction*** of c-fos and ***c-myc*** proteins by 1 h and ***cyclin D1*** protein by 5 h , and d ) onset of DNA synthesis stimulation within 8 h.	target	1
19303	11004802	3558;3458	IL-2;IFN-gamma	Addition of recombinant BCG secreting alpha antigen-fused ***IL-2*** to peritoneal exudate cells ***induced*** ***IFN-gamma*** resulting in killing bladder cancer cells more efficiently than parental BCG did .	target	1
19304	11005204	7249;7248	Tsc2;Tsc1	In recent years , a second gene ( Tsc1 ) responsible for human TSC has been cloned , and ***binding*** between ***Tsc1*** and ***Tsc2*** proteins was reported .	parallel	1
19305	11005210	3586;7124	IL-10;TNF-alpha	These effects of ***TNF-alpha*** in HSG cells were ***antagonized*** by IL-1beta , TGF-beta1 , or ***IL-10*** .	negative	1
19306	11005210	3553;7124	IL-1beta;TNF-alpha	These effects of ***TNF-alpha*** in HSG cells were ***antagonized*** by ***IL-1beta*** , TGF-beta1 , or IL-10 .	negative	1
19307	11005210	7040;7124	TGF-beta1;TNF-alpha	These effects of ***TNF-alpha*** in HSG cells were ***antagonized*** by IL-1beta , ***TGF-beta1*** , or IL-10 .	negative	1
19308	11005381	10923;3298	PC4;HSF2	***PC4*** ***interacted*** weakly with ***HSF2*** and showed even less affinity for HSF1 .	parallel	1
19309	11005381	6908;3297	TBP;HSF1	Assays based on transcriptional interference confirmed predictions that both ***TBP*** and TFIIB can ***interact*** with ***HSF1*** activation domains in HeLa cells .	parallel	1
19310	11005381	2959;3297	TFIIB;HSF1	Assays based on transcriptional interference confirmed predictions that both TBP and ***TFIIB*** can ***interact*** with ***HSF1*** activation domains in HeLa cells .	parallel	1
19311	11005382	3320;2288	hsp90;FKBP52	Taken together , these results suggest that XAP2/hsp90 and ******FKBP52/hsp90****** ***complexes*** are similar yet exhibit unique functional specificity .	parallel	1
19312	11005382	9049;3320	XAP2;hsp90	Taken together , these results suggest that ******XAP2/hsp90****** and FKBP52/hsp90 ***complexes*** are similar yet exhibit unique functional specificity .	parallel	1
19313	11005382	9049;196	XAP2;AhR	***XAP2*** forms a ***complex*** with hsp90 and the ***AhR*** but can also bind to both independently .	parallel	1
19314	11005382	9049;3320	XAP2;hsp90	***XAP2*** forms a ***complex*** with ***hsp90*** and the AhR but can also bind to both independently .	parallel	1
19315	11005382	9049;196	XAP2;AhR	Single-point mutations in this region are sufficient to disrupt the ***association*** of ***XAP2*** with both the ***AhR*** and hsp90 in cells .	parallel	0
19316	11005382	9049;3320	XAP2;hsp90	Single-point mutations in this region are sufficient to disrupt the ***association*** of ***XAP2*** with both the AhR and ***hsp90*** in cells .	parallel	0
19317	11005570	7040;595	TGFbeta;Cyclin D1	***Cyclin D1*** protein expression was ***repressed*** by ***TGFbeta*** treatment in parental RIE and RIE-Raf cells , whereas levels of Cyclin D1 in RIE-Ras and RIE-Sos cells remained unchanged .	negative	1
19318	11005628	3569;4803	IL-6;NGF	Our results suggest that ***IL-6*** and histamine ***stimulate*** release of ***NGF*** by two different and independent molecular pathways .	positive	0
19319	11005791	25942;4204	transcriptional co-repressor Sin3A;MECP2	A physical ***interaction*** between ***MECP2*** , histone deacetylases and the ***transcriptional co-repressor Sin3A*** has been demonstrated , as well as an association of MECP2 with the basal transcription apparatus .	parallel	1
19320	11005803	4436;4437	MSH2;MSH3	Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 and ******MSH2-MSH3****** ***complexes*** .	parallel	1
19321	11005803	5111;4436	proliferating cell nuclear antigen;MSH2	Functional ***interaction*** of ***proliferating cell nuclear antigen*** with MSH2-MSH6 and ***MSH2-MSH3*** complexes .	parallel	1
19322	11005803	5111;4437	proliferating cell nuclear antigen;MSH3	Functional ***interaction*** of ***proliferating cell nuclear antigen*** with MSH2-MSH6 and ***MSH2-MSH3*** complexes .	parallel	1
19323	11005803	5111;2956	proliferating cell nuclear antigen;MSH6	Functional ***interaction*** of ***proliferating cell nuclear antigen*** with ***MSH2-MSH6*** and MSH2-MSH3 complexes .	parallel	1
19324	11005803	5111;4437	proliferating cell nuclear antigen;MSH3	Eukaryotic DNA mismatch repair requires the concerted action of several proteins , including ***proliferating cell nuclear antigen*** ( PCNA ) and heterodimers of MSH2 ***complexed*** with either ***MSH3*** or MSH6 .	parallel	1
19325	11005803	5111;2956	proliferating cell nuclear antigen;MSH6	Eukaryotic DNA mismatch repair requires the concerted action of several proteins , including ***proliferating cell nuclear antigen*** ( PCNA ) and heterodimers of MSH2 ***complexed*** with either MSH3 or ***MSH6*** .	parallel	1
19326	11005803	2956;4436	MSH6;MSH2	MSH3 and MSH6 peptides containing these motifs bound PCNA , as did the intact ******MSH2-MSH6****** ***complex*** .	parallel	1
19327	11005803	4437;5111	MSH3;PCNA	***MSH3*** and MSH6 peptides containing these motifs ***bound*** ***PCNA*** , as did the intact MSH2-MSH6 complex .	parallel	1
19328	11005803	2956;5111	MSH6;PCNA	MSH3 and ***MSH6*** peptides containing these motifs ***bound*** ***PCNA*** , as did the intact MSH2-MSH6 complex .	parallel	1
19329	11005803	4437;5111	MSH3;PCNA	Thus , ***MSH3*** and MSH6 ***interactions*** with ***PCNA*** may facilitate early steps in DNA mismatch repair and may also be important for other roles of these eukaryotic MutS homologs .	parallel	1
19330	11005803	2956;5111	MSH6;PCNA	Thus , MSH3 and ***MSH6*** ***interactions*** with ***PCNA*** may facilitate early steps in DNA mismatch repair and may also be important for other roles of these eukaryotic MutS homologs .	parallel	1
19331	11005810	183;1163	angiotensin II;Cks1	In addition , ***angiotensin II*** infusion dramatically ***increased*** ***Cks1*** protein levels at capacitance arteries of normotensive rats , and angiotensin II treatment of isolated VSMC abrogated their ability to down-regulate Cks1 and maintain cyclin B protein expression in response to colcemid .	positive	0
19332	11005857	25788;11144	Rdh54;dmc1	***Tid1/Rdh54*** ***promotes*** colocalization of rad51 and ***dmc1*** during meiotic recombination .	positive	0
19333	11005857	25788;5888	Rdh54;rad51	***Tid1/Rdh54*** ***promotes*** colocalization of ***rad51*** and dmc1 during meiotic recombination .	positive	0
19334	11005857	9093;11144	Tid1;dmc1	***Tid1/Rdh54*** ***promotes*** colocalization of rad51 and ***dmc1*** during meiotic recombination .	positive	0
19335	11005857	9093;5888	Tid1;rad51	***Tid1/Rdh54*** ***promotes*** colocalization of ***rad51*** and dmc1 during meiotic recombination .	positive	0
19336	11005857	25788;11144	Rdh54;dmc1	The role of Tid1/Rdh54 in coordinating RecA homolog assembly may be very direct , because ***Tid1/Rdh54*** is known to physically ***bind*** both ***dmc1*** and rad51 .	parallel	1
19337	11005857	25788;5888	Rdh54;rad51	The role of Tid1/Rdh54 in coordinating RecA homolog assembly may be very direct , because ***Tid1/Rdh54*** is known to physically ***bind*** both dmc1 and ***rad51*** .	parallel	1
19338	11005857	9093;11144	Tid1;dmc1	The role of Tid1/Rdh54 in coordinating RecA homolog assembly may be very direct , because ***Tid1/Rdh54*** is known to physically ***bind*** both ***dmc1*** and rad51 .	parallel	1
19339	11005857	9093;5888	Tid1;rad51	The role of Tid1/Rdh54 in coordinating RecA homolog assembly may be very direct , because ***Tid1/Rdh54*** is known to physically ***bind*** both dmc1 and ***rad51*** .	parallel	1
19340	11006007	3567;596	IL-5;Bcl-2	***Bcl-2*** expression was ***augmented*** by ***IL-5*** stimulation , yet it was considerably inhibited by theophylline treatment .	positive	0
19341	11006011	3565;7412	IL-4;VCAM-1	In addition , ***IL-4*** with LTalpha1beta2 synergistically ***increased*** the expression of ***VCAM-1*** , but not ICAM-1 .	positive	0
19342	11006016	4790;3593	NF-kappa B;interleukin 12 p40	***NF-kappa B*** ***regulates*** the LPS-induced expression of ***interleukin 12 p40*** in murine peritoneal macrophages : roles of PKC , PKA , ERK , p38 MAPK , and proteasome .	target	1
19343	11006087	7124;4790	TNF-alpha;NF-kappaB	Pyrrolidine dithiocarbamate inhibits ***TNF-alpha-dependent*** ***activation*** of ***NF-kappaB*** by increasing intracellular copper level in human aortic smooth muscle cells .	positive	1
19344	11006087	7124;4790	TNF-alpha;NF-kappaB	In the present study , we investigated effects of PDTC and another antioxidant , N-acetyl-l-cysteine ( NAC ) , on ***TNF-alpha-dependent*** ***activation*** of ***NF-kappaB*** in human aortic smooth muscle cells ( HASMC ) .	positive	1
19345	11006087	4790;6347	NF-kappaB;MCP-1	Pretreatment with PDTC markedly suppressed the ***NF-kappaB*** ***activation*** and expression of ***MCP-1*** by inhibiting IkappaB-alpha degradation .	positive	1
19346	11006087	7124;4790	TNF-alpha;NF-kappaB	These results indicate that TNF-alpha-dependent expression of MCP-1 in HASMC is tightly regulated by NF-kappaB and that intracellular copper level is crucial for the ***TNF-alpha-dependent*** ***activation*** of ***NF-kappaB*** in HASMC .	positive	1
19347	11006087	4790;6347	NF-kappaB;MCP-1	These results indicate that TNF-alpha-dependent expression of ***MCP-1*** in HASMC is tightly ***regulated*** by ***NF-kappaB*** and that intracellular copper level is crucial for the TNF-alpha-dependent activation of NF-kappaB in HASMC .	target	1
19348	11006108	2230;2232	adrenodoxin;adrenodoxin reductase	Evidence for the cluster model of mitochondrial steroid hydroxylase system derived from dissociation constants of the ***complex*** between ***adrenodoxin reductase*** and ***adrenodoxin*** .	parallel	1
19349	11006108	2232;2230	adrenodoxin reductase;adrenodoxin	Using biotinylated adrenodoxin and avidin-Sepharose 4B , dissociation constants for the ***complex*** between ***adrenodoxin reductase*** and ***adrenodoxin*** in the oxidized and reduced states were determined as 50 + / - 11 and 296 + / - 44 nM , respectively .	parallel	1
19350	11006129	7428;8453	VHL;Cul-2	Biochemical studies have shown that Drosophila ***VHL*** protein binds to Elongins B and C directly , and via this Elongin BC complex , ***associates*** with ***Cul-2*** and Rbx1 .	parallel	0
19351	11006129	7428;9978	VHL;Rbx1	Biochemical studies have shown that Drosophila ***VHL*** protein binds to Elongins B and C directly , and via this Elongin BC complex , ***associates*** with Cul-2 and ***Rbx1*** .	parallel	0
19352	11006133	28514;4851	Delta1;Notch1	Physical ***interaction*** of ***Delta1*** , Jagged1 , and Jagged2 with ***Notch1*** and Notch3 receptors .	parallel	1
19353	11006133	182;4851	Jagged1;Notch1	Physical ***interaction*** of Delta1 , ***Jagged1*** , and Jagged2 with ***Notch1*** and Notch3 receptors .	parallel	1
19354	11006133	3714;4851	Jagged2;Notch1	Physical ***interaction*** of Delta1 , Jagged1 , and ***Jagged2*** with ***Notch1*** and Notch3 receptors .	parallel	1
19355	11006164	4254;3815	KIT LIGAND;KIT	Evidence from mouse mutants indicates that the KIT gene encoding KIT , a receptor present on the oocyte and theca cells , and the Mgf gene encoding ***KIT LIGAND*** , the ***ligand*** of ***KIT*** , are important regulators of oogenesis and folliculogenesis .	parallel	1
19356	11006164	4254;3815	KIT LIGAND;KIT	Recently , in vitro cultures of fetal gonads , of follicles and of oocytes have identified specific targets for the ******KIT-KIT LIGAND****** ***interaction*** .	parallel	1
19357	11006164	4254;3815	KIT LIGAND;KIT	In fetal gonads , an anti-apoptotic effect of ******KIT-KIT LIGAND****** ***interactions*** on primordial germ cells , oogonia and oocytes has been demonstrated .	parallel	1
19358	11006164	4254;3815	KIT LIGAND;KIT	In postnatal ovaries , the initiation of follicular growth from the primordial pool and progression beyond the primary follicle stage appear to involve ******KIT-KIT LIGAND****** ***interactions*** .	parallel	1
19359	11006164	4254;3815	KIT LIGAND;KIT	In large antral follicles , the ******KIT-KIT LIGAND****** ***interaction*** modulates the ability of the oocyte to undergo cytoplasmic maturation and helps to maximize thecal androgen output .	parallel	1
19360	11006212	7040;3037	TGF-beta1;HAS2	The expression of ***HAS2*** at the mRNA level was ***stimulated*** by ***TGF-beta1*** and/or PDGF-BB treatment .	positive	0
19361	11006212	7040;3037	TGF-beta;HAS2	The ***stimulation*** of the expression of ***HAS2*** at the mRNA level by ***TGF-beta*** was accelerated by the overexpression of Smad2 , Smad3 , and Smad4 and inhibited by that of Smad7 , all of which were confirmed to be involved in the signal transduction from TGF-beta through HAS expression .	positive	0
19362	11006212	7040;3037	TGF-beta1;HAS2	CONCLUSIONS : Although three HAS isoforms were expressed in the corneal endothelial cells , the expression of ***HAS2*** was ***upregulated*** by ***TGF-beta1*** and/or PDGF-BB .	positive	1
19363	11006212	7040;3037	TGF-beta;HAS2	***HAS2*** expression was ***regulated*** by ***TGF-beta*** through Smad family members .	target	1
19364	11006243	959;958	CD40L;CD40	If the exact molecular mechanisms are unclear , it is likely that ******CD40-CD40L****** ***interaction*** could play a role in this process .	parallel	1
19365	11006243	3458;3569	interferongamma;IL-6	Although ***interferongamma*** ***enhanced*** ***IL-6*** and IL-8 production , CD40 triggering of IFNgamma-activated hRPE cells did not induce IL-12 secretion .	positive	0
19366	11006243	3458;3576	interferongamma;IL-8	Although ***interferongamma*** ***enhanced*** IL-6 and ***IL-8*** production , CD40 triggering of IFNgamma-activated hRPE cells did not induce IL-12 secretion .	positive	0
19367	11006271	5170;207	PDK1;PKB	In addition , activation of ***PDK1*** is sufficient to ***phosphorylate*** ***PKB*** at Thr ( 308 ) in the cytosol .	target	1
19368	11006271	5586;5170	PRK2;PDK1	Finally , unlike the carboxyl-terminal fragment of ***PRK2*** , which has been shown to ***bind*** ***PDK1*** and allow the enzyme to phosphorylate PKB at both Thr ( 308 ) and Ser ( 473 ) , full-length PRK2 and its related kinase PRK1/PKN may both play negative roles in PKB-mediated downstream biological events .	parallel	1
19369	11006271	5170;207	PDK1;PKB	***Phosphorylation*** of ***PKB*** by ***PDK1*** ( A280V ) was not affected by treatment of cells with inhibitors of phosphatidylinositol 3-kinase or by deletion of the pleckstrin homology ( PH ) domain of PKB .	target	1
19370	11006271	5586;5170	PRK2;PDK1	On the other hand , co-expression of full-length protein kinase C-related kinase-1 ( PRK1/PKN ) or 2 ( ***PRK2*** ) ***inhibited*** ***PDK1*** ( A280V ) - mediated PKB phosphorylation .	negative	1
19371	11006271	5585;5170	protein kinase C-related kinase-1;PDK1	On the other hand , co-expression of full-length ***protein kinase C-related kinase-1*** ( PRK1/PKN ) or 2 ( PRK2 ) ***inhibited*** ***PDK1*** ( A280V ) - mediated PKB phosphorylation .	negative	1
19372	11006273	3065;100188830	histone deacetylase 1;Ad12	The ***histone deacetylase 1*** as well as Roscovitine , which blocks the activation of the histone acetyltransferase ( HAT ) activity of CBP by cyclin E-Cdk2 , ***prevents*** E2 ( ***Ad12*** ) promoter activation through E1A ( 12S ) .	negative	0
19373	11006275	8204;8841	RIP140;HDAC3	Direct ***interaction*** of ***RIP140*** with HDAC1 and ***HDAC3*** occurs in vitro and in vivo as demonstrated in co-immunoprecipitation and glutathione S-transferase pull-down experiments .	parallel	1
19374	11006283	4803;5367	nerve growth factor;MCH	Melanin-concentrating hormone ( ***MCH*** ) mRNA expression is ***induced*** by ***nerve growth factor*** and lithium in PC12 cells , whereas three large MCH RNA species are found in untreated cells .	target	1
19375	11006354	7124;581	TNFalpha;Bax	However , ***TNFalpha*** is not required for apoptotic signaling at the mRNA transcript level within the liver and instead may actually ***decrease*** ***Bax*** production .	negative	0
19376	11006446	3439;355	IFN-alpha;Fas	In addition , ***IFN-alpha/beta*** treatment significantly ***increased*** ***Fas*** ( CD95 ) expression ( P < / = 0.05 ) on NK cells from both adult and aged mice .	positive	0
19377	11007194	2152;7035	Tissue factor;tissue factor pathway inhibitor	***Tissue factor*** ***inhibition*** and clinical trial results of ***tissue factor pathway inhibitor*** in sepsis .	negative	1
19378	11007194	7035;2152	tissue factor pathway inhibitor;Tissue factor	***tissue factor pathway inhibitor*** ( TFPI ) is an endogenous ***inhibitor*** of ***Tissue factor*** associated coagulation cascades .	negative	1
19379	11007759	933;5777	CD22;SHP-1	It has been reported that BCR-mediated signaling in B-1 cells is negatively regulated by signals from CD22 , CD5 and CD72 co-receptors , and that Lyn kinase plays a crucial role in tyrosine phosphorylation of immunoreceptor tyrosine-based inhibitory motifs on the ***CD22*** and CD72 , which ***recruits*** ***SHP-1*** to the BCR complex .	target	0
19380	11007759	971;5777	CD72;SHP-1	It has been reported that BCR-mediated signaling in B-1 cells is negatively regulated by signals from CD22 , CD5 and CD72 co-receptors , and that Lyn kinase plays a crucial role in tyrosine phosphorylation of immunoreceptor tyrosine-based inhibitory motifs on the CD22 and ***CD72*** , which ***recruits*** ***SHP-1*** to the BCR complex .	target	0
19381	11007762	7124;23308	tumor necrosis factor (TNF)-alpha;B7RP-1	Interestingly , ***tumor necrosis factor (TNF)-alpha*** differentially ***regulates*** the expression of human ***B7RP-1*** on B cells , monocytes and dendritic cells ( DC ) .	target	1
19382	11007762	7124;23308	TNF-alpha;B7RP-1	***TNF-alpha*** ***enhances*** ***B7RP-1*** expression on B cells and monocytes , while it inhibits it on DC .	positive	0
19383	11007767	5524;8312	PP2A;Axin	Different subunits of ***PP2A*** ***bind*** to ***Axin*** and Adenomatous Polyposis Coli , components of the Wnt signal transduction pathway .	parallel	1
19384	11007770	4089;4088	Smad4;Smad3	Synergistic ***cooperation*** between Sp1 and ******Smad3/Smad4****** mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen ( COL1A2 ) transcription .	parallel	0
19385	11007770	4089;4088	Smad4;Smad3	Here we report that the CAGA box of the TbRE is the binding site of the ******Smad3/Smad4****** ***complex*** , and that the binding of the complex is required for TGFbeta-induced COL1A2 up-regulation .	parallel	1
19386	11007770	4089;4088	Smad4;Smad3	Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2 ; TGFbeta treatment of cultured fibroblasts induces ******Smad3/Smad4****** ***binding*** to the TbRE ; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription ; and COL1A2 gene up-regulation by TGFbeta is abolished in cells stably transfected with plasmids that express dominant negative forms of Smad3 or Smad4 .	parallel	1
19387	11007770	7040;1278	TGFbeta;COL1A2	Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2 ; TGFbeta treatment of cultured fibroblasts induces Smad3/Smad4 binding to the TbRE ; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription ; and ***COL1A2*** gene ***up-regulation*** by ***TGFbeta*** is abolished in cells stably transfected with plasmids that express dominant negative forms of Smad3 or Smad4 .	positive	1
19388	11007770	7040;4088	TGFbeta;Smad3	Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2 ; ***TGFbeta*** treatment of cultured fibroblasts ***induces*** ***Smad3/Smad4*** binding to the TbRE ; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription ; and COL1A2 gene up-regulation by TGFbeta is abolished in cells stably transfected with plasmids that express dominant negative forms of Smad3 or Smad4 .	target	1
19389	11007770	7040;4089	TGFbeta;Smad4	Recombinant Smad3 and Smad4 bind in vitro to the CAGA box of COL1A2 ; ***TGFbeta*** treatment of cultured fibroblasts ***induces*** ***Smad3/Smad4*** binding to the TbRE ; transient overexpression of Smad3 and Smad4 in fibroblasts transactivates TbRE-driven transcription ; and COL1A2 gene up-regulation by TGFbeta is abolished in cells stably transfected with plasmids that express dominant negative forms of Smad3 or Smad4 .	target	1
19390	11007770	4088;4089	Smad3;Smad4	These results provide the first ***linkage*** between the ***Smad3*** and ***Smad4*** proteins and TGFbeta stimulation of type I collagen biosynthesis .	parallel	0
19391	11007770	7040;4088	TGFbeta;Smad3	These results provide the first ***linkage*** between the ***Smad3*** and Smad4 proteins and ***TGFbeta*** stimulation of type I collagen biosynthesis .	parallel	0
19392	11007770	7040;4089	TGFbeta;Smad4	These results provide the first ***linkage*** between the Smad3 and ***Smad4*** proteins and ***TGFbeta*** stimulation of type I collagen biosynthesis .	parallel	0
19393	11007779	4087;7040	Smad2;TGF-beta	Smad1 transduces bone morphogenetic protein signals , inducing formation of ventral mesoderm in Xenopus embryos , whereas ***Smad2*** ***transduces*** ***activin/TGF-beta*** signals , generating dorsal mesoderm .	positive	1
19394	11007787	177;6285	RAGE;S100B	We suggest that ***RAGE*** is a signal-transducing ***receptor*** for both trophic and toxic effects of ***S100B*** .	parallel	1
19395	11007787	6271;177	S100A1;RAGE	Here we show that two S100 family proteins , S100B and ***S100A1*** , ***activate*** ***RAGE*** in concert with amphoterin inducing neurite outgrowth and activation of transcription factor NF-kappaB .	positive	1
19396	11007787	6285;177	S100B;RAGE	Here we show that two S100 family proteins , ***S100B*** and S100A1 , ***activate*** ***RAGE*** in concert with amphoterin inducing neurite outgrowth and activation of transcription factor NF-kappaB .	positive	1
19397	11007787	3146;177	amphoterin;RAGE	Furthermore , ***activation*** of ***RAGE*** by ***amphoterin*** and S100B promotes cell survival through increased expression of the anti-apoptotic protein Bcl-2 .	positive	1
19398	11007787	6285;177	S100B;RAGE	Furthermore , ***activation*** of ***RAGE*** by amphoterin and ***S100B*** promotes cell survival through increased expression of the anti-apoptotic protein Bcl-2 .	positive	1
19399	11007869	7453;10681	gamma2;Gbeta5	However , GGL domain-containing RGS proteins ( e.g. , RGS6 and RGS11 ) did block the ability of ******Gbeta5/gamma2****** ***heterodimers*** to inhibit Ca channels .	parallel	1
19400	11007879	4803;581	NGF;Bax	However , PI-3-K activity was not required for ***NGF*** to ***inhibit*** the translocation of ***Bax*** from the cytoplasm to the mitochondria , nor was it required for NGF to inhibit the subsequent release of mitochondrial cytochrome c , two events required for NGF deprivation-induced apoptosis .	negative	1
19401	11007882	9463;2917	PICK1;mGLUR7	***PICK1*** interacts with and ***regulates*** PKC phosphorylation of ***mGLUR7*** .	target	1
19402	11007882	9463;5578	PICK1;PKCalpha	***PICK1*** has previously been shown to ***bind*** protein kinase C alpha-subunit ( ***PKCalpha*** ) , and mGluR7a is known to be phosphorylated by PKC .	parallel	1
19403	11007883	2891;23426	GluR2;GRIP1	In vitro binding and coimmunoprecipitation studies show that phosphorylation of serine-880 within the GluR2 PDZ ligand significantly decreases ***GluR2*** ***binding*** to ***GRIP1*** but not to PICK1 .	parallel	1
19404	11007921	2056;3717	Epo;JAK2	While ***Epo*** ***induces*** the activation of ***JAK2*** and STAT5 , SCF stimulation shows no activation of JAK2 or STATs 1 , 3 , or 5 .	target	1
19405	11007921	2056;6777	Epo;STAT5	While ***Epo*** ***induces*** the activation of JAK2 and ***STAT5*** , SCF stimulation shows no activation of JAK2 or STATs 1 , 3 , or 5 .	target	1
19406	11007921	2056;1154	Epo;CIS	In addition , ***CIS*** was ***activated*** by ***Epo*** but not SCF .	positive	1
19407	11007932	3440;8743	IFN-alpha2;TRAIL	This may be due to factors from melanoma cells in that supernatants from some melanoma cultures suppressed ***IFN-alpha2*** ***upregulation*** of ***TRAIL*** .	positive	1
19408	11007940	7124;4790	TNF-alpha;NF-kappa B	***TNF-alpha*** also ***induces*** the activation of ***NF-kappa B*** and AP-1 and the subsequent increase in gamma-GCS heavy subunit transcription in these cells .	target	1
19409	11007941	7039;1956	transforming growth factor-alpha;erbB1	In androgen-independent human prostate carcinoma DU145 cells , silymarin , genistein , and EGCG resulted in a significant to complete inhibition of ***transforming growth factor-alpha-caused*** ***activation*** of membrane receptor ***erbB1*** followed by inhibition of downstream cytoplasmic signaling target Shc activation and a decrease in its binding with erbB1 , without an alteration in their protein expression .	positive	1
19410	11007941	5594;1956	ERK1/2;erbB1	Silymarin and genistein also inhibited ERK1/2 activation , suggesting that these agents impair the activation of ******erbB1-Shc-ERK1/2****** ***signaling*** in DU145 cells .	parallel	0
19411	11007941	5594;6464	ERK1/2;Shc	Silymarin and genistein also inhibited ERK1/2 activation , suggesting that these agents impair the activation of ******erbB1-Shc-ERK1/2****** ***signaling*** in DU145 cells .	parallel	0
19412	11007941	6464;1956	Shc;erbB1	Silymarin and genistein also inhibited ERK1/2 activation , suggesting that these agents impair the activation of ******erbB1-Shc-ERK1/2****** ***signaling*** in DU145 cells .	parallel	0
19413	11007942	2247;5595	bFGF;ERK1	TR006 decreased the ***bFGF*** ***activation*** of extracellular signal-regulated kinase 1 ( ***ERK1*** ) , suggesting its involvement in inhibiting Ras activity .	positive	1
19414	11007945	7124;4790	tumor necrosis factor (TNF)-alpha;NF-kappa B	It has also been reported that ***NF-kappa B*** ***activation*** by ***tumor necrosis factor (TNF)-alpha*** , chemotherapeutic drugs , or ionizing radiations can protect several cell types against apoptosis , suggesting that NF-kappa B could participate in resistance to cancer treatment .	positive	1
19415	11007949	3611;207	ILK;PKB	***ILK*** also ***phosphorylates*** protein kinase B ( ***PKB/Akt*** ) and stimulates its activity .	target	1
19416	11007949	3611;207	ILK;PKB	***ILK*** has been shown to ***phosphorylate*** ***PKB/Akt*** on Ser-473 in vitro and in vivo .	target	1
19417	11007955	5706;7422	p44;VEGF	We demonstrate that p42/p44 MAP kinases play a pivotal role in angiogenesis by exerting a determinant action at three levels : i ) persistent activation of p42/p44 MAP kinases abrogates apoptosis ; ii ) p42/p44 MAP kinase activity is critical for controlling proliferation and growth arrest of confluent endothelial cells ; and iii ) ***p42/p44*** MAP kinases ***promote*** ***VEGF*** ( vascular endothelial growth factor ) expression by activating its transcription via recruitment of the AP-2 / Sp1 ( activator protein-2 ) complex on the proximal region ( -88 / -66 ) of the VEGF promoter and by direct phosphorylation of hypoxia-inducible factor 1 alpha ( HIF-1 alpha ) .	positive	0
19418	11007958	1387;5371	CBP;PML	Recently , we demonstrated that the CREB-binding protein ( ***CBP*** ) ***associates*** with ***PML*** protein in vitro and is recruited to the PODs in vivo in a signal-dependent manner .	parallel	0
19419	11007962	8569;1977	Mnk1;eIF4E	***Phosphorylation*** of the cap-binding protein ***eIF4E*** by the MAPK-activated protein kinase ***Mnk1*** .	target	1
19420	11007962	1981;1977	eIF4G;eIF4E	The possibility that integrity of the ******eIF4E/eIF4G/Mnk1****** ***complex*** also impinges upon eIF4E phosphorylation is discussed .	parallel	1
19421	11007962	1981;8569	eIF4G;Mnk1	The possibility that integrity of the ******eIF4E/eIF4G/Mnk1****** ***complex*** also impinges upon eIF4E phosphorylation is discussed .	parallel	1
19422	11007962	8569;1977	Mnk1;eIF4E	The possibility that integrity of the ******eIF4E/eIF4G/Mnk1****** ***complex*** also impinges upon eIF4E phosphorylation is discussed .	parallel	1
19423	11007965	471;5564	AICAR;AMPK	***Activation*** of ***AMPK*** by ***AICAR*** counteracted the inhibitory effect of glucose on the PEPCK gene expression , both at the mRNA and the transcriptional levels .	positive	1
19424	11007966	10587;10499	TRbeta;GRIP-1	Here we show the effect of a drug metabolite on the ***interaction*** of ***TRbeta*** ( 1 ) with the co-activator ***GRIP-1*** ( glucocorticoid receptor interacting protein-1 ) .	parallel	1
19425	11007966	10499;10587	GRIP-1;TRbeta	The T ( 3 ) - dependent ***binding*** of ***GRIP-1*** to the ***TRbeta*** ( 1 ) is disrupted by DEA .	parallel	1
19426	11007969	7124;4323	tumor necrosis factor alpha;MT1-MMP	In primary astrocyte cultures , ***MT1-MMP*** mRNA was ***upregulated*** by exogeneous ***tumor necrosis factor alpha*** .	positive	1
19427	11008013	7124;1437	TNF-alpha;GM-CSF	Supporting this notion , ***TNF-alpha-induced*** ***upregulation*** of ***GM-CSF*** mRNA levels and protein secretion in the TNF-alpha-proliferative , but not in the TNF-alpha-apoptotic cell lines .	positive	1
19428	11008134	958;959	CD40;CD40L	Activated platelets directly bind to vascular endothelial cells via ******CD40L/CD40****** ***interactions*** and induce inflammatory reactions that initiate or aggravate atherosclerotic lesions .	parallel	1
19429	11008640	6227;3553	HLDF;IL-1 beta	It was shown that the synthetic peptide ***HLDF-6*** has no specific receptors on the surface of the HL-60 cells but can ***affect*** the binding of interleukin ***IL-1 beta*** , a cytokine involved in proliferation , to the cell surface .	target	0
19430	11008705	4353;1738	myeloperoxidase;dihydrolipoamide dehydrogenase	***Inactivation*** of Trypanosoma cruzi ***dihydrolipoamide dehydrogenase*** by leukocyte ***myeloperoxidase*** systems : role of hypochloride and nitrite related radicals .	negative	1
19431	11009078	4609;3683	c-Myc;CD11a	***c-Myc*** ***inhibits*** ***CD11a*** and CD11c leukocyte integrin promoters .	negative	1
19432	11009078	4609;3687	c-Myc;CD11c	***c-Myc*** ***inhibits*** CD11a and ***CD11c*** leukocyte integrin promoters .	negative	1
19433	11009088	959;958	CD154;CD40	Our data demonstrate that the ******CD40-CD154****** ***interaction*** is critical for B cell homeostasis and the secondary immune response to FVIII .	parallel	1
19434	11009091	1051;3565	C/EBPbeta;IL-4	***C/EBPbeta*** ***enhances*** ***IL-4*** but impairs IL-2 and IFN-gamma induction in T cells .	positive	0
19435	11009091	1051;3458	C/EBPbeta;IFN-gamma	***C/EBPbeta*** enhances IL-4 but ***impairs*** IL-2 and ***IFN-gamma*** induction in T cells .	negative	0
19436	11009091	1051;3558	C/EBPbeta;IL-2	***C/EBPbeta*** enhances IL-4 but ***impairs*** ***IL-2*** and IFN-gamma induction in T cells .	negative	0
19437	11009093	3600;634	IL-15;CD66a	A fraction of T cells in the lamina propria express ***CD66a*** , which is ***induced*** by IL-7 and ***IL-15*** cytokines .	target	1
19438	11009093	3574;634	IL-7;CD66a	A fraction of T cells in the lamina propria express ***CD66a*** , which is ***induced*** by ***IL-7*** and IL-15 cytokines .	target	1
19439	11009093	634;3558	CD66a;lymphokine	Triggering of ***CD66a*** on T cells with physiological ligands or with specific mAb ***increases*** TCR-mediated ***lymphokine*** release , in an antigen dose-independent manner .	positive	0
19440	11009097	7535;919	ZAP-70;CD3zeta	We show that ***ZAP-70*** fails to ***bind*** the signaling-competent ***CD3zeta*** tyrosine phosphorylation isoform and to become activated following TCR engagement , suggesting that defective recruitment of ZAP-70 might underlie the TCR signaling dysfunction in these patients .	parallel	1
19441	11009097	919;7535	CD3zeta;ZAP-70	Hence , while the T cell defect in these CVID patients can be pinpointed to the ***interaction*** between ***ZAP-70*** and ***CD3zeta*** , the integrity in the components of the signaling machinery involved in this process suggests that additional components might be required for completion of this step .	parallel	1
19442	11009098	7040;2625	TGF-beta;GATA-3	***TGF-beta*** ***down-regulated*** ***GATA-3*** expression in developing Th2 and these cells showed a diminished IL-4-induced STAT6 activation .	negative	1
19443	11009109	51497;3458	Th1-like;IFN-gamma	Substitution with IL-2 specifically restored a ***Th1-like*** ***response*** with proliferation and release of ***IFN-gamma*** .	parallel	0
19444	11009423	6872;3005	TAFII250;histone H1	***TAFII250*** ***mediates*** monoubiquitination of ***histone H1*** in vitro .	target	0
19445	11009425	4790;4654	NF-kappaB;MyoD	In contrast , in differentiated myotubes , TNF plus interferon-gamma ( IFN-gamma ) signaling was required for ***NF-kappaB-dependent*** ***down-regulation*** of ***MyoD*** and dysfunction of skeletal myofibers .	negative	1
19446	11009425	3458;4654	IFN-gamma;MyoD	***MyoD*** mRNA was also ***down-regulated*** by TNF and ***IFN-gamma*** expression in mouse muscle in vivo .	negative	1
19447	11009450	3976;5594	LIF;ERK1/2	***LIF*** sequentially ***activated*** Raf-1 , MEK1/2 , ***ERK1/2*** , and p90 ( RSK ) .	positive	1
19448	11009450	3976;5605	LIF;MEK1/2	***LIF*** sequentially ***activated*** Raf-1 , ***MEK1/2*** , ERK1/2 , and p90 ( RSK ) .	positive	1
19449	11009450	3976;57650	LIF;p90	***LIF*** sequentially ***activated*** Raf-1 , MEK1/2 , ERK1/2 , and ***p90*** ( RSK ) .	positive	1
19450	11009450	3976;5894	LIF;Raf-1	***LIF*** sequentially ***activated*** ***Raf-1*** , MEK1/2 , ERK1/2 , and p90 ( RSK ) .	positive	1
19451	11009560	2885;5747	Grb2;Fak	These events were paralleled by c-Src activation and binding to Fak and by an ***association*** of ***Grb2*** and p85 subunit of phosphatidylinositol 3-kinase with ***Fak*** .	parallel	0
19452	11009565	5465;7124	PPARalpha;TNF-alpha	These results suggest that both ***PPARalpha*** and PPARgamma activators ***inhibit*** cardiac expression of ***TNF-alpha*** in part by antagonizing nuclear factor-kappaB activity and that treatment with PPAR activators may lead to improvement in congestive heart failure .	negative	1
19453	11009566	284;5175	Angiopoietin-1;PECAM-1	Here we show that ***Angiopoietin-1*** , a cytokine essential in fetal angiogenesis , not only supports the localization of proteins such as platelet endothelial cell adhesion molecule-1 ( PECAM-1 ) into junctions between endothelial cells and ***decreases*** the phosphorylation of ***PECAM-1*** and vascular endothelial cadherin , but it also strengthens these junctions , as evidenced by a decrease in basal permeability and inhibition of permeability responses to thrombin and vascular endothelial growth factor .	negative	0
19454	11009566	284;1003	Angiopoietin-1;vascular endothelial cadherin	Here we show that ***Angiopoietin-1*** , a cytokine essential in fetal angiogenesis , not only supports the localization of proteins such as platelet endothelial cell adhesion molecule-1 ( PECAM-1 ) into junctions between endothelial cells and ***decreases*** the phosphorylation of PECAM-1 and ***vascular endothelial cadherin*** , but it also strengthens these junctions , as evidenced by a decrease in basal permeability and inhibition of permeability responses to thrombin and vascular endothelial growth factor .	negative	0
19455	11009619	1121;7879	REP-1;Rab7	The affinity of GGpp and Fpp for GGTase-II was also determined in the presence of the ******Rab7-REP-1****** ***complex*** .	parallel	1
19456	11009624	2159;462	factor Xa;antithrombin	Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate ******heparin-antithrombin-factor Xa****** bridging ***complex*** .	parallel	1
19457	11009624	462;2159	antithrombin;factor Xa	Heparin catalyzes the ***inhibition*** of ***factor Xa*** by ***antithrombin*** mainly through an allosteric activation of the serpin inhibitor , but an alternative heparin bridging mechanism has been suggested to enhance the catalysis in the presence of physiologic calcium levels due to calcium interactions with the Gla domain exposing a heparin binding exosite in factor Xa .	negative	1
19458	11009624	462;2159	antithrombin;factor Xa	To provide direct evidence for this bridging mechanism , we studied the heparin-catalyzed ***reaction*** of ***antithrombin*** with factor Xa , Gla-domainless ***factor Xa*** ( GDFXa ) , and a heparin binding exosite mutant of GDFXa in the absence and presence of calcium using rapid kinetic methods .	parallel	1
19459	11009624	462;2159	antithrombin;factor Xa	The pseudo-first-order rate constant for ***factor Xa*** ***inhibition*** by ***antithrombin*** complexed with a long-chain approximately 70-saccharide heparin showed a saturable dependence on inhibitor concentration in the presence but not in the absence of 2.5 mM Ca ( 2 + ) , indicating the formation of an intermediate heparin-serpin-proteinase encounter complex with a dissociation constant of approximately 90 nM prior to formation of the stable serpin-proteinase complex with a rate constant of approximately 20 s ( -1 ) .	negative	1
19460	11009624	462;2159	antithrombin;factor Xa	By contrast , no Ca ( 2 + ) - dependent saturation of the inhibition rate constant was detectable over the same range of inhibitor concentrations for reactions of either a short-chain approximately 26-saccharide high-affinity ***heparin-antithrombin*** ***complex*** with ***factor Xa*** or the long-chain heparin-antithrombin complex with the heparin binding exosite mutant , GDFXa R240A .	parallel	1
19461	11009624	2159;462	factor Xa;antithrombin	These findings suggest that binding of full-length heparin chains to an exosite of factor Xa in the presence of Ca ( 2 + ) produces a chain-length-dependent lowering of the dissociation constant for assembly of the intermediate ******heparin-antithrombin-factor Xa****** encounter ***complex*** , resulting in a several 100-fold rate enhancement by a heparin bridging mechanism .	parallel	1
19462	11010807	836;5055	caspase 3;PAI-2	PAI-2 was not a substrate for caspases during apoptosis of monocytes , although some ***cleavage*** of recombinant ***PAI-2*** by ***caspase 3*** was evident in vitro .	target	1
19463	11010811	4335;4149	Myc antagonist;Max	Mad1 is a ***Myc antagonist*** that ***heterodimerizes*** with ***Max*** and functions as a transcriptional repressor .	parallel	1
19464	11010960	10316;10874	GPR66;neuromedin U	Recently , ***GPR66/FM*** -3 ( NmU-R1 ) was identified as a specific ***receptor*** for ***neuromedin U*** .	parallel	1
19465	11010967	348;10498	AD2;coactivator-associated arginine methyltransferase 1	AD1 is a binding site for the related coactivators cAMP-response element binding protein binding protein ( CBP ) and p300 , whereas ***AD2*** ***binds*** to another coactivator , ***coactivator-associated arginine methyltransferase 1*** ( CARM1 ) , a protein-arginine methyltransferase .	parallel	1
19466	11010967	10498;348	CARM1;AD2	Thus , both binding of p300 to AD1 and ***binding*** of ***CARM1*** to ***AD2*** are required for their respective coactivator functions and for their synergy .	parallel	1
19467	11010972	25;5715	BCR/ABL;p27	Overall , these data are consistent with a model in which ***BCR/ABL*** ***suppresses*** ***p27*** ( Kip1 ) protein levels through PI3K/AKT , leading to accelerated entry into S phase .	negative	1
19468	11010972	25;1027	BCR/ABL;p27Kip1	***BCR/ABL*** ***regulates*** expression of the cyclin-dependent kinase inhibitor ***p27Kip1*** through the phosphatidylinositol 3-Kinase/AKT pathway .	target	1
19469	11010972	25;5715	BCR/ABL;p27	In this study , we demonstrate that ***BCR/ABL*** ***inhibits*** the expression of a key cell cycle inhibitor , ***p27*** ( Kip1 ) , by signaling through a pathway involving phosphatidylinositol 3-kinase ( PI3K ) .	negative	1
19470	11010972	25;5715	BCR/ABL;p27	First , induction of ***BCR/ABL*** by a tetracycline-regulated promoter is ***associated*** with a reversible down-regulation of ***p27*** ( Kip1 ) .	parallel	0
19471	11010974	142;7003	PARP;TEF-1	Protein-protein interaction assays revealed ***interactions*** between nominal ***TEF-1*** , ***PARP*** , and Max .	parallel	1
19472	11010976	5608;1432	MKK6;p38alpha	We have investigated the ability of the mitogen-activated protein kinase ( MAPK ) kinase MKK6 to activate different members of the p38 subfamily of MAPKs and found that some ***MKK6*** mutants can efficiently ***activate*** ***p38alpha*** but not p38gamma .	negative	1
19473	11010976	5608;5594	MKK6;p38	In contrast , a constitutively active ***MKK6*** mutant ***activated*** both ***p38*** MAPK isoforms to similar extents .	negative	1
19474	11010976	1432;5608	p38alpha;MKK6	We also found that the preferential activation of ***p38alpha*** by MKK6 ***correlated*** with more efficient binding of ***MKK6*** to p38alpha than to p38gamma .	parallel	0
19475	11010976	5608;1432	MKK6;p38alpha	We also found that the preferential ***activation*** of ***p38alpha*** by ***MKK6*** correlated with more efficient binding of MKK6 to p38alpha than to p38gamma .	positive	1
19476	11010976	5608;1432	MKK6;p38alpha	We also found that the preferential activation of p38alpha by MKK6 correlated with more efficient ***binding*** of ***MKK6*** to ***p38alpha*** than to p38gamma .	parallel	1
19477	11010976	5608;6300	MKK6;p38gamma	We also found that the preferential activation of p38alpha by MKK6 correlated with more efficient ***binding*** of ***MKK6*** to p38alpha than to ***p38gamma*** .	parallel	1
19478	11010976	5608;1432	MKK6;p38alpha	Furthermore , increasing concentrations of constitutively active ***MKK6*** differentially ***activated*** either ***p38alpha*** alone ( low MKK6 activity ) or both p38alpha and p38gamma ( high MKK6 activity ) , both in vitro and in injected oocytes .	positive	1
19479	11010978	320;351	X11alpha;amyloid precursor protein	***Modulation*** of ***amyloid precursor protein*** metabolism by ***X11alpha*** / Mint-1 .	target	0
19480	11011119	3553;1440	IL-1beta;G-CSF	TNF-alpha or ***IL-1beta*** ***induced*** both ***G-CSF*** and PTHrP production in the conditioned medium .	target	1
19481	11011119	3553;5744	IL-1beta;PTHrP	TNF-alpha or ***IL-1beta*** ***induced*** both G-CSF and ***PTHrP*** production in the conditioned medium .	target	1
19482	11011119	7124;1440	TNF-alpha;G-CSF	***TNF-alpha*** or IL-1beta ***induced*** both ***G-CSF*** and PTHrP production in the conditioned medium .	target	1
19483	11011119	7124;5744	TNF-alpha;PTHrP	***TNF-alpha*** or IL-1beta ***induced*** both G-CSF and ***PTHrP*** production in the conditioned medium .	target	1
19484	11011119	7124;3553	TNF-alpha;IL-1beta	***TNF-alpha*** ***synergized*** with ***IL-1beta*** to significantly increase G-CSF production .	parallel	0
19485	11011119	7124;1440	TNF-alpha;G-CSF	***TNF-alpha*** synergized with IL-1beta to significantly ***increase*** ***G-CSF*** production .	positive	0
19486	11011119	3553;1440	IL-1beta;G-CSF	In addition , TNF-alpha and ***IL-1beta*** strongly ***induced*** ***G-CSF*** mRNA with peaks at 2 and 6 h respectively .	target	1
19487	11011119	7124;1440	TNF-alpha;G-CSF	In addition , ***TNF-alpha*** and IL-1beta strongly ***induced*** ***G-CSF*** mRNA with peaks at 2 and 6 h respectively .	target	1
19488	11011119	7124;5744	TNF-a;PTHrP	Although ***PTHrP*** production was also strongly ***induced*** by ***TNF-a*** PTHrP mRNA expression was more strongly induced by PMA than by TNF-alpha .	target	1
19489	11011784	3479;3488	IGF-I;IGFBP-5	***IGF-I*** strongly ***stimulated*** ***IGFBP-5*** expression in the lamina propria and the muscularis and induced a twofold increase in IGFBP-5 mRNA based on RNase protection assay of intact jejunum total RNA .	positive	0
19490	11011784	3479;3486	IGF-I;IGFBP-3	***IGF-I*** or GH ***stimulated*** ***IGFBP-3*** expression .	positive	0
19491	11011914	3953;3952	ObR;leptin	This investigation determined if altered expression of ***leptin*** ***receptors*** ( ***ObR*** ) in the hypothalamus could potentially contribute to altered sensitivity to diet-induced obesity between OM and S5B/P1 rats .	parallel	1
19492	11012173	4352;7066	c-Mpl;TPO	The concentration of ***TPO*** in blood is ***regulated*** by ***c-Mpl*** mass on platelets and megakaryocytes .	target	1
19493	11012190	4352;7066	Mpl;TPO	However , expression of the platelet ***TPO*** ***receptor*** , ***Mpl*** , as determined by immunoblotting , chemical crosslinking or flow cytometry was markedly reduced or absent in 34 of 34 PV patients and also in 13 of 14 IMF patients .	parallel	1
19494	11012211	4352;7066	c-Mpl;thrombopoietin	The physiological roles and mechanisms of action of ***thrombopoietin*** ( TPO ) and its ***receptor*** ***c-Mpl*** have been studied through the analysis of mice genetically deficient in these molecules , as well as through the dissection of signaling events utilizing chimeric receptors .	parallel	1
19495	11012218	7066;4352	Thrombopoietin;c-mpl	***Thrombopoietin*** ( TPO ) , the ***ligand*** for ***c-mpl*** , has recently been demonstrated to be the primary regulator of megakaryocytopoiesis and platelet production .	parallel	1
19496	11012616	3605;3586	IL-17;IL-10	We therefore investigated the in vitro IL-17 response to a variety of mitogens and antigens , and compared the ***IL-17*** ***response*** to interferon-gamma ( IFN-gamma ) , IL-4 , ***IL-10*** and TNF-alpha .	parallel	0
19497	11012616	3605;3565	IL-17;IL-4	We therefore investigated the in vitro IL-17 response to a variety of mitogens and antigens , and compared the ***IL-17*** ***response*** to interferon-gamma ( IFN-gamma ) , ***IL-4*** , IL-10 and TNF-alpha .	parallel	0
19498	11012616	3605;3458	IL-17;interferon-gamma	We therefore investigated the in vitro IL-17 response to a variety of mitogens and antigens , and compared the ***IL-17*** ***response*** to ***interferon-gamma*** ( IFN-gamma ) , IL-4 , IL-10 and TNF-alpha .	parallel	0
19499	11012616	3605;7124	IL-17;TNF-alpha	We therefore investigated the in vitro IL-17 response to a variety of mitogens and antigens , and compared the ***IL-17*** ***response*** to interferon-gamma ( IFN-gamma ) , IL-4 , IL-10 and ***TNF-alpha*** .	parallel	0
19500	11012671	10682;10912	EBP;Gadd45gamma	***Regulation*** of ***Gadd45gamma*** expression by ***C/EBP*** .	target	1
19501	11012671	1051;1052	C/EBPbeta;C/EBPdelta	In addition , a noncanonical C/EBP-binding site within the Gadd45gamma promoter where ***C/EBPbeta*** and ***C/EBPdelta*** could ***bind*** , was identified by electrophoretic mobility shift assay ( EMSA ) and reporter gene analysis .	parallel	1
19502	11012680	6464;5594	Shc;ERK2	The Grb2 adaptor was recruited by the upstream Src homology 2/alpha-collagen-related ( Shc ) effector , as the ***SH2-Shc*** domain ***prevented*** the GVBD and the ***ERK2*** phosphorylation induced by FGF1 .	negative	0
19503	11012680	2246;2260	FGF1;FGFR1	This study shows that the transduction cascade induced by the ******FGFR1-FGF1****** ***interaction*** in Xenopus oocytes represents the sum of Ras-dependent and PLCgamma-dependent pathways .	parallel	1
19504	11012754	796;3578	CGRP;p40	Using the reverse transcription-polymerase chain reaction ( RT-PCR ) , we found that ***CGRP*** also ***decreased*** the LPS-induced IL-12 ***p40*** mRNA levels .	negative	0
19505	11012758	3586;7124	IL-10;TNF-alpha	Because ***IL-10*** is involved in the UV-induced ***suppression*** of delayed-type hypersensitivity and ***TNF-alpha*** in the UV-induced suppression of contact allergy , these findings provide a mechanism to explain how rIL-12 overcomes UV-induced immune suppression in these related but different immune reactions .	negative	1
19506	11012765	3576;3569	IL-8;IL-6	However , ***IL-8*** at 100 ng/ml did not significantly alter the effect of IL-1beta , ***synergized*** with ***IL-6*** in enhancing , and marginally suppressed TNF-beta-induced HIV-1 expression .	parallel	0
19507	11012765	3576;3458	IL-8;interferon-gamma	***IL-8*** suppressed granulocyte-macrophage colony-stimulating factor ( GM-CSF ) and ***enhanced*** ***interferon-gamma*** ( IFN-gamma ) - induced HIV-1 expression in a dose-dependent manner .	positive	0
19508	11012765	3576;1437	IL-8;granulocyte-macrophage colony-stimulating factor	***IL-8*** ***suppressed*** ***granulocyte-macrophage colony-stimulating factor*** ( GM-CSF ) and enhanced interferon-gamma ( IFN-gamma ) - induced HIV-1 expression in a dose-dependent manner .	negative	1
19509	11012773	959;958	CD40L;CD40	When cultured with anti-IgM maintained at high density on CD32-tranfected mouse L cells to model TI responses or on ***CD40*** ***ligand*** ( ***CD40L*** ) - bearing L cells ( with or without captured anti-IgM ) to model TD encounters , DNA synthesis was stimulated to a similar extent in all three populations .	parallel	1
19510	11012779	1437;3569	GM-CSF;interleukin-6	We found that ***GM-CSF*** may ***modify*** the tumour necrosis factor-alpha ( TNF-alpha ) and ***interleukin-6*** ( IL-6 ) response to lipopolysaccharide ( LPS ) through two different mechanisms .	target	0
19511	11012779	1437;7124	GM-CSF;TNF-alpha	We found that ***GM-CSF*** may ***modify*** the tumour necrosis factor-alpha ( ***TNF-alpha*** ) and interleukin-6 ( IL-6 ) response to lipopolysaccharide ( LPS ) through two different mechanisms .	target	0
19512	11012874	7040;1490	TGF-beta;CTGF	In model systems in vitro , mesangial cell ***CTGF*** expression is ***induced*** by high extracellular glucose , cyclic mechanical strain and ***TGF-beta*** .	target	1
19513	11012879	5745;5741	PTH1R;PTH	However , altered regulation of cellular PTH/PTH-related protein ( ***PTH/PTHrP*** ) ***receptor*** ( ***PTH1R*** ) has been assumed to be important .	parallel	1
19514	11012896	5741;6550	PTH;NHE3	In the present study , we investigate whether changes in protein abundance as well as in mRNA levels play a significant role in the long-term ***modulation*** of ***NHE3*** by ***PTH*** .	target	0
19515	11012904	1401;213	CRP;albumin	CONCLUSION : We have shown an ***association*** of ***CRP*** and fibrinogen with urinary ***albumin*** excretion in the microalbuminuric range in type 2 diabetic and nondiabetic individuals .	parallel	0
19516	11012984	1029;7157	p14ARF;p53	Immunohistochemical inactivation of ***p14ARF*** concomitant with MDM2 overexpression inversely ***correlates*** with ***p53*** overexpression in oral squamous cell carcinoma .	parallel	0
19517	11012984	1033;5925	cyclin-dependent kinase inhibitor;pRb	The CDKN2 gene encodes two structurally different proteins : a ***cyclin-dependent kinase inhibitor*** called p16 , which ***regulates*** retinoblastoma protein ( ***pRb*** ) - dependent G1 arrest , and a cell cycle inhibitor designated p14ARF , which arrests cell growth in G1-S and also in G2-M .	target	1
19518	11012984	4193;1029	MDM2;p14ARF	A physical ***association*** between ***p14ARF*** and ***MDM2*** blocks MDM2-induced p53 degradation , resulting in increased levels of p53 , which in turn leads to cell cycle arrest .	parallel	0
19519	11013121	4790;4318	NF- kappa B;MMP-9	In conclusion , cardiomyocyte nuclear ***NF- kappa B*** translocation in response to Ang II via PKC pathway ***activates*** cardiomyocyte-specific transcription of ***MMP-9*** and may activate transcription from responsive genes which are involved in cardiac hypertrophy process and/or cardiac remodeling .	positive	1
19520	11013215	355;7430	CD95;ezrin	In fact , ***CD95*** ***co-immunoprecipitates*** with ***ezrin*** exclusively in lymphoblastoid CD4 ( + ) T cells and primary long-term activated T lymphocytes , which are prone to CD95-mediated apoptosis , but not in short-term activated T lymphocytes , which are refractory to the same stimuli , even expressing equal levels of CD95 on the cell membrane .	parallel	1
19521	11013217	5609;5599	MKK7;JNK	We identified the Caenorhabditis elegans mek-1 gene , which encodes a 347 amino acid protein highly homologous to mammalian ***MKK7*** , an ***activator*** of ***JNK*** .	positive	1
19522	11013220	4087;10923	Smad2;p15	***Smad2*** , Smad3 and Smad4 cooperate with Sp1 to ***induce*** ***p15*** ( Ink4B ) transcription in response to TGF-beta .	target	1
19523	11013220	4088;10923	Smad3;p15	Smad2 , ***Smad3*** and Smad4 cooperate with Sp1 to ***induce*** ***p15*** ( Ink4B ) transcription in response to TGF-beta .	target	1
19524	11013220	4089;10923	Smad4;p15	Smad2 , Smad3 and ***Smad4*** cooperate with Sp1 to ***induce*** ***p15*** ( Ink4B ) transcription in response to TGF-beta .	target	1
19525	11013220	4087;4088	Smad2;Smad3	In this study , we demonstrate that p15 ( Ink4B ) induction was mediated by a TGF-beta-induced ***complex*** of ***Smad2*** , ***Smad3*** , Smad4 and Sp1 .	parallel	1
19526	11013220	4087;4089	Smad2;Smad4	In this study , we demonstrate that p15 ( Ink4B ) induction was mediated by a TGF-beta-induced ***complex*** of ***Smad2*** , Smad3 , ***Smad4*** and Sp1 .	parallel	1
19527	11013220	4088;4089	Smad3;Smad4	In this study , we demonstrate that p15 ( Ink4B ) induction was mediated by a TGF-beta-induced ***complex*** of Smad2 , ***Smad3*** , ***Smad4*** and Sp1 .	parallel	1
19528	11013220	4087;10923	Smad2;p15	In this study , we demonstrate that ***p15*** ( Ink4B ) induction was ***mediated*** by a TGF-beta-induced complex of ***Smad2*** , Smad3 , Smad4 and Sp1 .	target	0
19529	11013220	4088;10923	Smad3;p15	In this study , we demonstrate that ***p15*** ( Ink4B ) induction was ***mediated*** by a TGF-beta-induced complex of Smad2 , ***Smad3*** , Smad4 and Sp1 .	target	0
19530	11013220	4089;10923	Smad4;p15	In this study , we demonstrate that ***p15*** ( Ink4B ) induction was ***mediated*** by a TGF-beta-induced complex of Smad2 , Smad3 , ***Smad4*** and Sp1 .	target	0
19531	11013220	4087;10923	Smad2;p15	Interference with , or deficiency in , ***Smad2*** , Smad3 or Smad4 functions also ***reduced*** or abolished the TGF-beta-dependent ***p15*** ( Ink4B ) induction , whereas the absence of Sp1 reduced the basal and TGF-beta-induced p15 ( Ink4B ) transcription .	negative	1
19532	11013220	4088;10923	Smad3;p15	Interference with , or deficiency in , Smad2 , ***Smad3*** or Smad4 functions also ***reduced*** or abolished the TGF-beta-dependent ***p15*** ( Ink4B ) induction , whereas the absence of Sp1 reduced the basal and TGF-beta-induced p15 ( Ink4B ) transcription .	negative	1
19533	11013220	4089;10923	Smad4;p15	Interference with , or deficiency in , Smad2 , Smad3 or ***Smad4*** functions also ***reduced*** or abolished the TGF-beta-dependent ***p15*** ( Ink4B ) induction , whereas the absence of Sp1 reduced the basal and TGF-beta-induced p15 ( Ink4B ) transcription .	negative	1
19534	11013220	4088;10923	Smad3;p15	***Smad3*** interacted indirectly with Sp1 through its association with Smad2 and/or Smad4 , and ***bound*** directly to the ***p15*** ( Ink4B ) promoter .	parallel	1
19535	11013220	4088;4087	Smad3;Smad2	Our data demonstrate the physical interactions and functional cooperativity of Sp1 with a ***complex*** of ***Smad2*** , ***Smad3*** and Smad4 in the induction of the p15 ( Ink4B ) gene .	parallel	1
19536	11013220	4089;4087	Smad4;Smad2	Our data demonstrate the physical interactions and functional cooperativity of Sp1 with a ***complex*** of ***Smad2*** , Smad3 and ***Smad4*** in the induction of the p15 ( Ink4B ) gene .	parallel	1
19537	11013220	4089;4088	Smad4;Smad3	Our data demonstrate the physical interactions and functional cooperativity of Sp1 with a ***complex*** of Smad2 , ***Smad3*** and ***Smad4*** in the induction of the p15 ( Ink4B ) gene .	parallel	1
19538	11013233	4780;1728	Nrf2;NQO1	In similar experiments , overexpression of small Maf proteins also repressed ***Nrf2-mediated*** ***up-regulation*** of ARE-mediated ***NQO1*** and GST Ya genes expression in Hep-G2 cells co-transfected with Nrf2 and small Maf proteins .	positive	1
19539	11013253	7158;7157	p202;p53 tumor suppressor	The gene encoding ***p202*** , an interferon-inducible negative ***regulator*** of the ***p53 tumor suppressor*** , is a target of p53-mediated transcriptional repression .	negative	1
19540	11013253	7158;7157	p202;p53	We reported previously that overexpression of ***p202*** , an interferon-inducible negative regulator of cell growth , negatively ***regulates*** the transcriptional activity of ***p53*** .	negative	1
19541	11013261	10728;3320	p23;hsp90	Whereas hsp90 has a role in maintenance of the high-affinity ligand binding conformation of the dioxin receptor complex , and ***p23*** ***stabilizes*** ***receptor-hsp90*** interaction , the exact role of XAP2 is largely unknown .	positive	0
19542	11013261	10728;3320	p23;hsp90	In order to mediate these effects , XAP2 required stable association with the ******hsp90-p23****** molecular chaperone ***complex*** .	parallel	1
19543	11013262	660;11099	Etk;PTPD1	The ******Etk-PTPD1****** ***interaction*** also increased Stat3 activation .	parallel	1
19544	11013262	660;6774	Etk;Stat3	The ***Etk-PTPD1*** interaction also ***increased*** ***Stat3*** activation .	positive	0
19545	11013262	11099;6774	PTPD1;Stat3	The ***Etk-PTPD1*** interaction also ***increased*** ***Stat3*** activation .	positive	0
19546	11013262	11099;7006	PTPD1;Tec	In addition , ***Tec*** ( but not Btk ) kinase can also be ***activated*** by ***PTPD1*** .	positive	1
19547	11013262	11099;6774	PTPD1;Stat3	Taken together , these findings indicate that ***PTPD1*** can selectively associate with and stimulate Tec family kinases and ***modulate*** ***Stat3*** activation .	target	0
19548	11013262	11099;7006	PTPD1;Tec	Taken together , these findings indicate that ***PTPD1*** can selectively associate with and ***stimulate*** ***Tec*** family kinases and modulate Stat3 activation .	positive	0
19549	11013262	11099;660	PTPD1;Etk	The ***binding*** of ***PTPD1*** to ***Etk*** is specific since PTPD1 can not associate with either the Akt PH domain or lamin .	parallel	1
19550	11013262	11099;660	PTPD1;Etk	In vitro and in vivo binding studies demonstrated that ***PTPD1*** can ***interact*** with ***Etk*** and that residues 726-848 of PTPD1 are essential for this interaction .	parallel	1
19551	11013262	11099;660	PTPD1;Etk	Furthermore , the ***Etk-PTPD1*** interaction ***stimulated*** the kinase activity of ***Etk*** , resulting in an increased phosphotyrosine content in both factors .	positive	0
19552	11013262	11099;660	PTPD1;Etk	Furthermore , the ******Etk-PTPD1****** ***interaction*** stimulated the kinase activity of Etk , resulting in an increased phosphotyrosine content in both factors .	parallel	1
19553	11013307	4018;5360	lipoprotein;PLTP	Thus , the two PLTP pools are associated with different types of lipoprotein particles , suggesting that the ***PLTP*** activity in circulation is ***modulated*** by the plasma ***lipoprotein*** profile and lipid composition .	target	0
19554	11013310	348;338	apolipoprotein E;apolipoprotein B	Hepatic ***apolipoprotein E*** expression ***promotes*** very low density ***lipoprotein-apolipoprotein B*** production in vivo in mice .	positive	0
19555	11013310	348;4018	apolipoprotein E;lipoprotein	Hepatic ***apolipoprotein E*** expression ***promotes*** very low density ***lipoprotein-apolipoprotein B*** production in vivo in mice .	positive	0
19556	11013346	799;1026	CTR;p21	***CTR-mediated*** transcriptional ***activation*** of ***p21*** was specific for the insert-negative isoform of the human CTR .	positive	1
19557	11014212	2516;1584	steroidogenic factor-1;CYP11B1	Transcription of ***CYP11B1*** also appeared to be ***regulated*** by ***steroidogenic factor-1*** ( SF-1 ) .	target	1
19558	11014215	2796;2798	GnRH;gonadotropin-releasing hormone (GnRH) receptor	Transcriptional ***down-regulation*** of human ***gonadotropin-releasing hormone (GnRH) receptor*** gene by ***GnRH*** : role of protein kinase C and activating protein 1 .	negative	1
19559	11014215	2798;2796	GnRHR;GnRH	Clinical applications of GnRH agonists ( GnRHa ) are based primarily on the decrease in gonadotropin release after down-regulation of the ***GnRH*** ***receptor*** ( ***GnRHR*** ) by continuous GnRHa administration .	parallel	1
19560	11014221	4803;1114	nerve growth factor;chromogranin B	The adenylyl cyclase activator forskolin , ***nerve growth factor*** , and retinoic acid also ***activated*** the ***chromogranin B*** gene .	positive	1
19561	11014223	3569;9021	IL-6;SOCS-3	In contrast , ***IL-6*** alone markedly ***induced*** ***SOCS-3*** mRNA , but did not potentiate the GH action on SOCS-3 and CIS mRNAs .	target	1
19562	11014226	2696;2695	GIPR;GIP	Antisera to an extracellular epitope of the ***GIP*** ***receptor*** ( ***GIPR*** ) detected immunoreactive GIPR on rat pancreatic beta-cells .	parallel	1
19563	11014241	5617;2099	PRL;ERalpha	Using decidual cells in primary culture obtained from pseudopregnant rats and a decidua-derived cell line ( GG-AD ) , we show a differential ***regulation*** of ***ERalpha*** and ERbeta by ***PRL*** and ovarian steroid hormones .	target	1
19564	11014241	5617;2100	PRL;ERbeta	Using decidual cells in primary culture obtained from pseudopregnant rats and a decidua-derived cell line ( GG-AD ) , we show a differential ***regulation*** of ERalpha and ***ERbeta*** by ***PRL*** and ovarian steroid hormones .	target	1
19565	11014241	5617;2099	PRL;ERalpha	Interestingly , progesterone , which up-regulates the ability of PRL to signal to a PRL-regulated gene in mammary-gland derived cells , prevented ***PRL*** ***stimulation*** of decidual ***ERalpha*** and had no synergistic effect on ERbeta expression .	positive	0
19566	11014248	7056;5624	thrombomodulin;protein C	***Regulation*** of the ***protein C*** pathway via ***thrombomodulin*** on vascular endothelium may be a novel mechanism by which SERMs could potentially confer cardioprotective effects and reduce the thrombotic risk associated with HRT in compromised patients .	target	1
19567	11014343	6625;836	U1-70K;caspase 3	Induction of apoptosis by SSZ was confirmed by TUNEL analysis and by the detection of cleaved ***U1-70K*** , a ***substrate*** of ***caspase 3*** .	parallel	1
19568	11014890	581;596	Bax;Bcl-2	The anti-apoptotic ******Bcl-2/Bax****** ***heterodimers*** peaked during early leukemic phases and declined during regression .	parallel	1
19569	11014890	581;596	Bax;Bcl-2	The data suggest that wt p53 , Bcl-x ( L ) , and ******Bcl-2/Bax****** ***heterodimers*** support the accumulation of activated leukemic cells during the leukemic phases , while Bax and Bak may be involved in their decline during regression .	parallel	1
19570	11015084	7157;1026	p53 tumor suppressor;p21	BACKGROUND : Cell cycle arrest after DNA damage is partly mediated through the transcriptional ***activation*** of ***p21*** ( WAF1 ) by the ***p53 tumor suppressor*** gene .	positive	1
19571	11015226	23621;351	memapsin 2;beta-amyloid precursor protein	***memapsin 2*** ( beta-secretase ) , a membrane-anchored aspartic protease , is involved in the ***cleavage*** of ***beta-amyloid precursor protein*** to form beta-amyloid peptide .	target	1
19572	11015226	9622;23621	kallikrein;memapsin 2	Clostripain , ***kallikrein*** , and trypsin ***increased*** the activity of ***pro-memapsin 2*** .	positive	0
19573	11015437	10673;959	BLyS;CD40L	***BLyS*** acts on primary splenic B cells autonomously , and directly ***cooperates*** with CD40 ligand ( ***CD40L*** ) in B cell activation in vitro by protecting replicating B cells from apoptosis .	parallel	0
19574	11015442	7124;5594	TNF-alpha;p38	Expression of HO-1 or exposure of ECs to exogenous CO enhanced ***p38*** MAPK ***activation*** by ***TNF-alpha*** .	positive	1
19575	11015442	3162;5594	HO-1;p38	Expression of ***HO-1*** or exposure of ECs to exogenous CO ***enhanced*** ***p38*** MAPK activation by TNF-alpha .	positive	0
19576	11015448	729230;6347	chemokine receptor (CCR)2;MCP-1	Here we report that deficiency in CC ***chemokine receptor (CCR)2*** , the ***receptor*** for ***MCP-1*** , confers resistance to EAE induced with a peptide derived from myelin oligodendrocyte glycoprotein peptide 35-55 ( MOGp35-55 ) .	parallel	1
19577	11015454	590;348	BCHE;apolipoprotein E	Dipeptidyl carboxypeptidase 1 ( DCP1 ) and butyrylcholinesterase ( ***BCHE*** ) gene ***interactions*** with the ***apolipoprotein E*** epsilon4 allele as risk factors in Alzheimer 's disease and in Parkinson 's disease with coexisting Alzheimer pathology .	parallel	1
19578	11015466	1977;1981	eIF4E;eIF4G	Leucine-dependent hyperphosphorylation of 4E-BP1 increased the availability of eIF4E to form the active ******eIF4G.eIF4E****** ***complex*** .	parallel	1
19579	11015466	1978;1977	4E-BP1;eIF4E	Leucine-dependent hyperphosphorylation of ***4E-BP1*** ***increased*** the availability of ***eIF4E*** to form the active eIF4G.eIF4E complex .	positive	0
19580	11016452	1390;820	ICER;cAMP	We show that Glucagon , but not Glucagon-like peptide 1 ( GLP-1 ) , or pituitary adenylyl cyclase-activating peptide ( PACAP ) specifically induces the expression of the transcriptional repressor inducible ***cAMP*** early ***repressor*** ( ***ICER*** ) in pancreatic beta-cells , resulting in a repression of the transcriptional expression of the insulin gene .	negative	1
19581	11016452	2641;1390	Glucagon;ICER	Remarkably , Glucagon , GLP-1 , and PACAP all stimulate the formation of cAMP to a comparable extent in rat pancreatic islets , but only ***Glucagon*** ***activates*** the expression of ***ICER*** and represses insulin gene transcription in beta-cells .	positive	1
19582	11016452	2641;820	GLP-1;cAMP	Remarkably , Glucagon , ***GLP-1*** , and PACAP all ***stimulate*** the formation of ***cAMP*** to a comparable extent in rat pancreatic islets , but only Glucagon activates the expression of ICER and represses insulin gene transcription in beta-cells .	positive	0
19583	11016645	2885;6464	Grb2;Shc	The electrophoretic mobility shift of p66shc caused by Taxol is not the result of tyrosine phosphorylation , and there is no indication of a ******Shc/Grb2****** ***complex*** in Taxol-treated A549 cells .	parallel	1
19584	11016654	1019;595	CDK4;cyclin D1	Nevertheless , p27Kip1 was present in the active ******cyclin D1/CDK4****** ***complexes*** in the cells but absent from the cyclin E/CDK2 complexes .	parallel	1
19585	11016686	3458;6347	IFN-gamma;MCP-1	Together , TNF-alpha and ***IFN-gamma*** acted synergistically to ***increase*** ***MCP-1*** production .	positive	0
19586	11016686	7124;6347	TNF-alpha;MCP-1	Together , ***TNF-alpha*** and IFN-gamma acted synergistically to ***increase*** ***MCP-1*** production .	positive	0
19587	11016747	5008;6623	oncostatin M;synuclein gamma	Transcriptional ***suppression*** of ***synuclein gamma*** ( SNCG ) expression in human breast cancer cells by the growth inhibitory cytokine ***oncostatin M*** .	negative	1
19588	11016807	1644;9622	AADC;kallikrein	These results suggest that exercise enhances renal dopamine production by activating renal ***AADC*** activity , which in turn ***stimulates*** the renal ***kallikrein-kinin*** system .	positive	0
19589	11016859	3586;7124	IL-10;TNFalpha	Recombinant preparations of human anti-inflammatory cytokines : IL-4 , IL-13 and ***IL-10*** , ***inhibited*** LPS-induced synthesis of ***TNFalpha*** and IL-6 in the whole human blood tested in vitro .	negative	1
19590	11016859	3596;7124	IL-13;TNFalpha	Recombinant preparations of human anti-inflammatory cytokines : IL-4 , ***IL-13*** and IL-10 , ***inhibited*** LPS-induced synthesis of ***TNFalpha*** and IL-6 in the whole human blood tested in vitro .	negative	1
19591	11016863	4586;4153	mucin;MBP	In contrast , in pair-fed controls , the ***mucin*** ***binding*** to ***MBP*** remained the same or increased up to 20 % .	parallel	1
19592	11016863	4586;4153	mucin;MBP	Moreover , in chronic ethanol ingestion , the individual variations are accompanied by a decrease in ***mucin*** ***binding*** to ***MBP*** .	parallel	1
19593	11016863	4586;4153	gastric mucin;MBP	The retention of mucin on the surface of gastric mucosa was quantitated by measuring the ***binding*** of ***gastric mucin*** to mucin Binding Protein ( ***MBP*** ) of gastric mucosa .	parallel	1
19594	11016863	4586;4153	mucin;MBP	The ***binding*** of ***mucin*** to ***MBP*** before ethanol , and after 2 , 4 , 6 , and 8 weeks of ethanol diet was quantitated with Enzyme Linked Lectin Assay ( ELLA ) .	parallel	1
19595	11016863	4586;4153	mucin;MBP	The study with standard mucin revealed that ***binding*** of ***mucin*** to ***MBP*** differs substantially between individual animals .	parallel	1
19596	11016863	4586;4153	mucin;MBP	In five animals , after two weeks of ethanol diet , ***mucin*** ***binding*** to ***MBP*** decreased by 50 % ; in two animals , the drastic decrease in binding was observed in mucin collected after four weeks of alcohol feeding ; and in one animal a 20 % decrease in binding persisted for six weeks , and then decreased to 50 % in the last collection .	parallel	1
19597	11016919	64750;4087	Smurf2;Smad2	Consistent with these results , ***Smurf2*** potently ***reduced*** the transcriptional activity of ***Smad2*** .	negative	1
19598	11016919	64750;4086	Smurf2;Smad1	Ectopic expression of ***Smurf2*** was sufficient to ***reduce*** the steady-state levels of ***Smad1*** and Smad2 but not Smad3 or Smad4 .	negative	1
19599	11016919	64750;4087	Smurf2;Smad2	Ectopic expression of ***Smurf2*** was sufficient to ***reduce*** the steady-state levels of Smad1 and ***Smad2*** but not Smad3 or Smad4 .	negative	1
19600	11016919	64750;4088	Smurf2;Smad3	Ectopic expression of ***Smurf2*** was sufficient to ***reduce*** the steady-state levels of Smad1 and Smad2 but not ***Smad3*** or Smad4 .	negative	1
19601	11016922	3636;3635	SHIP2;SHIP1	Loss of function and gain of function substitutions identified the Y +2 leucine , in the FcgammaRIIB ITIM , as determining the ***binding*** of both ***SHIP1*** and ***SHIP2*** , but not the binding of SHP-1 or SHP-2 .	parallel	1
19602	11016922	5781;5777	SHP-2;SHP-1	Conversely , the Y-2 isoleucine that determines the in vitro ***binding*** of ***SHP-1*** and ***SHP-2*** affected neither the binding nor the recruitment of SHIP1 or SHIP2 .	parallel	1
19603	11016927	5008;6464	oncostatin M;Shc	In the present study , we demonstrate that ***oncostatin M*** ( OSM ) , but not IL-6 or leukemia inhibitory factor , ***induces*** tyrosine phosphorylation of the ***Shc*** isoforms p52 and p66 and their association with Grb2 .	target	1
19604	11016927	5008;5594	OSM;ERK1/2	Concomitantly , ***OSM*** turns out to be a stronger ***activator*** of ***ERK1/2*** MAPKs .	positive	1
19605	11016930	7111;4703	Tmod;nebulin	Sk-Tmod binds nebulin with higher affinity than E-Tmod does , suggesting that the ******Tmod/nebulin****** ***interaction*** exhibits isoform specificity .	parallel	1
19606	11016930	29765;4703	Sk-Tmod;nebulin	***Sk-Tmod*** ***binds*** ***nebulin*** with higher affinity than E-Tmod does , suggesting that the Tmod/nebulin interaction exhibits isoform specificity .	parallel	1
19607	11016939	5058;4790	p21-activated kinase 1;NF-kappa B	***p21-activated kinase 1*** ***activates*** the nuclear factor kappa B ( ***NF-kappa B*** ) - inducing kinase-Ikappa B kinases NF-kappa B pathway and proinflammatory cytokines in Helicobacter pylori infection .	positive	1
19608	11016947	840;5590	caspase-3 and -7;PKCzeta	Caspase-3 , -6 , -7 , and -8 chiefly cleaved human PKCzeta at EETD downward arrowG , and ***caspase-3 and -7*** also ***cleaved*** ***PKCzeta*** at DGMD downward arrowG and DSED downward arrowL , respectively .	target	1
19609	11016947	836;5590	Caspase-3;PKCzeta	***Caspase-3*** , -6 , -7 , and -8 chiefly cleaved human PKCzeta at EETD downward arrowG , and caspase-3 and -7 also ***cleaved*** ***PKCzeta*** at DGMD downward arrowG and DSED downward arrowL , respectively .	target	1
19610	11016948	3557;3553	IL-1Ra;IL-1beta	***IL-1beta*** and its endogenous ***receptor*** antagonist ( ***IL-1Ra*** ) are rapidly induced by seizures in the rodent hippocampus .	parallel	1
19611	11016951	672;367	BRCA1;androgen receptor	Here , we report that ***BRCA1*** ***interacts*** with ***androgen receptor*** ( AR ) and enhances AR target genes , such as p21 ( ( WAF1/CIP1 ) ) , that may result in the increase of androgen-induced cell death in prostate cancer cells .	parallel	1
19612	11016959	50615;3716	NILR;Jak1	Like IL-2Rbeta , ***NILR*** ***associates*** with ***Jak1*** and mediates Stat5 activation .	parallel	0
19613	11016968	7157;4193	p53;Mdm2	A delay in ***p53-dependent*** ***induction*** of ***Mdm2*** is predicted to be required , albeit not sufficient , for this oscillatory behavior .	target	1
19614	11017046	2261;6804	FGFR3;syntaxin 1a	We demonstrate ***interaction*** between known binding partners , ***syntaxin 1a*** with neuronal Sec1 ( nSec1 ) , and the fibroblast-derived growth factor receptor 3 ( ***FGFR3*** ) with SNT-1 .	parallel	1
19615	11017109	3384;30835	ICAM-2;DC-SIGN	******DC-SIGN-ICAM-2****** ***interaction*** mediates dendritic cell trafficking .	parallel	1
19616	11017109	3384;30835	ICAM-2;DC-SIGN	The ******DC-SIGN-ICAM-2****** ***interaction*** regulates chemokine-induced transmigration of DCs across both resting and activated endothelium .	parallel	1
19617	11017169	2737;6469	Gli3;Shh	Specification of ventral neuron types is mediated by an antagonistic ***interaction*** between ***Shh*** and ***Gli3*** .	parallel	1
19618	11017169	6469;2737	Shh;Gli3	We propose that ***Shh*** is required to ***antagonize*** ***Gli3*** , which would otherwise repress ventral fates .	negative	1
19619	11017907	9733;5594	p110;ERK	Wortmannin and LY294002 failed to attenuate PDGF-induced ERK activation , and overexpression of ***p110*** ( PI ) ( 3-K ) CAAX was insufficient to ***activate*** ***ERK*** .	positive	1
19620	11017907	847;1386	catalase;ATF-2	Finally , PI 3-kinase and Rac1-induced ***CREB/ATF-2*** transactivation were each ***inhibited*** by ***catalase*** .	negative	1
19621	11017907	847;1385	catalase;CREB	Finally , PI 3-kinase and Rac1-induced ***CREB/ATF-2*** transactivation were each ***inhibited*** by ***catalase*** .	negative	1
19622	11018012	6599;6597	BAF155;BRG1	Remodeling is achieved with only the ******BRG1-BAF155****** minimal ***complex*** and the EKLF zinc finger DBD , whereas transcription requires , in addition , an activation domain .	parallel	1
19623	11018012	6597;6599	BRG1;BAF155	In contrast , the ******BRG1-BAF155****** ***complex*** does not interact or function with two unrelated transcription factors , TFE3 and NF-kappaB .	parallel	1
19624	11018018	2623;161882	GATA-1;FOG	Furthermore , our results indicate that maintenance of a multipotent state in hematopoiesis is achieved through ***cooperation*** between ***FOG*** and ***GATA-1*** .	parallel	0
19625	11018020	8661;10209	eIF3;eIF1	A multifactor ***complex*** of eukaryotic initiation factors , ***eIF1*** , eIF2 , ***eIF3*** , eIF5 , and initiator tRNA ( Met ) is an important translation initiation intermediate in vivo .	parallel	1
19626	11018020	8661;1983	eIF3;eIF5	A multifactor ***complex*** of eukaryotic initiation factors , eIF1 , eIF2 , ***eIF3*** , ***eIF5*** , and initiator tRNA ( Met ) is an important translation initiation intermediate in vivo .	parallel	1
19627	11018020	1983;10209	eIF5;eIF1	A multifactor ***complex*** of eukaryotic initiation factors , ***eIF1*** , eIF2 , eIF3 , ***eIF5*** , and initiator tRNA ( Met ) is an important translation initiation intermediate in vivo .	parallel	1
19628	11018020	10209;8661	eIF1;eIF3	These findings suggest the occurrence of an ******eIF3/eIF1/eIF5****** / eIF2 multifactor ***complex*** , which was observed in cell extracts free of 40S ribosomes and found to contain stoichiometric amounts of tRNA ( i ) ( Met ) .	parallel	1
19629	11018020	10209;1983	eIF1;eIF5	These findings suggest the occurrence of an ******eIF3/eIF1/eIF5****** / eIF2 multifactor ***complex*** , which was observed in cell extracts free of 40S ribosomes and found to contain stoichiometric amounts of tRNA ( i ) ( Met ) .	parallel	1
19630	11018020	1983;8661	eIF5;eIF3	These findings suggest the occurrence of an ******eIF3/eIF1/eIF5****** / eIF2 multifactor ***complex*** , which was observed in cell extracts free of 40S ribosomes and found to contain stoichiometric amounts of tRNA ( i ) ( Met ) .	parallel	1
19631	11018022	3667;3643	insulin receptor substrate-1;insulin receptor	***insulin receptor substrate-1*** ( IRS-1 ) protein is a major ***substrate*** of the ***insulin receptor*** tyrosine kinase and is essential for transducing many of the biological effects of insulin including mitogenesis , gene expression , and glucose transport .	parallel	1
19632	11018022	3643;3667	insulin receptor;IRS-1	The N terminus of IRS-1 contains a pleckstrin homology ( PH ) domain that is critical for ***recognition*** and subsequent phosphorylation of ***IRS-1*** by the activated ***insulin receptor*** .	target	1
19633	11018022	55023;3667	PHIP;IRS-1	Here we report the isolation of a novel protein , ***PHIP*** ( PH-interacting protein ) , which selectively binds to the PH domain of IRS-1 in vitro and stably ***associates*** with ***IRS-1*** in vivo .	parallel	0
19634	11018022	3667;3643	IRS-1;insulin receptor	We conclude that PHIP represents a novel protein ligand of the IRS-1 PH domain that may serve to ***link*** ***IRS-1*** to the ***insulin receptor*** .	parallel	0
19635	11018023	56938;5054	CLIF;PAI-1	In endothelial cells , ***CLIF*** forms a heterodimer with CLOCK and ***up-regulates*** the ***PAI-1*** gene through E-box sites .	positive	1
19636	11018023	1407;5054	Cryptochrome1;PAI-1	Furthermore , Period2 and ***Cryptochrome1*** , whose expression show a circadian oscillation in peripheral tissues , ***inhibit*** the ***PAI-1*** promoter activation by the CLOCK : CLIF heterodimer .	negative	1
19637	11018029	7040;4087	TGF-beta;SMAD2	***TGF-beta*** receptor ***phosphorylation*** of ***SMAD2*** or SMAD3 causes their association with SMAD4 and accumulation in the nucleus where the SMAD complex binds cofactors that determine the choice of target genes .	target	1
19638	11018029	7040;4088	TGF-beta;SMAD3	***TGF-beta*** receptor ***phosphorylation*** of SMAD2 or ***SMAD3*** causes their association with SMAD4 and accumulation in the nucleus where the SMAD complex binds cofactors that determine the choice of target genes .	target	1
19639	11018029	4089;4087	SMAD4;SMAD2	Upon cell stimulation with TGF-beta , SMAD proteins become engaged in a multitude of complexes ranging in size from ******SMAD2-SMAD4****** ***heterodimers*** to assemblies of > 650 kDa .	parallel	1
19640	11018030	7020;126961	AP-2;H3.2	In addition , we discovered that YY1 is an interactive partner of ***AP-2*** , which also ***binds*** the ***H3.2*** promoter and regulates its cell cycle-dependent expression .	parallel	1
19641	11018037	7422;1490	Vascular endothelial growth factor;connective tissue growth factor	***Vascular endothelial growth factor*** ***induces*** expression of ***connective tissue growth factor*** via KDR , Flt1 , and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells .	target	1
19642	11018037	7422;1490	Vascular endothelial growth factor;CTGF	Since connective tissue growth factor ( CTGF ) is a potent mitogen for fibrosis , extracellular matrix production , and angiogenesis , we have studied the effects and mechanism by which ***Vascular endothelial growth factor*** ( VEGF ) ***regulates*** ***CTGF*** gene expression in retinal capillary cells .	target	1
19643	11018037	7422;1490	VEGF;CTGF	In our study , ***VEGF*** ***increased*** ***CTGF*** mRNA levels in a time - and concentration-dependent manner in bovine retinal endothelial cells and pericytes , without the need of new protein synthesis and without altering mRNA stability .	positive	0
19644	11018037	7422;2321	VEGF;Flt1	***VEGF*** ***activated*** the tyrosine receptor phosphorylation of KDR and ***Flt1*** and increased the binding of phosphatidylinositol 3-kinase ( PI3-kinase ) p85 subunit to KDR and Flt1 , both of which could mediate CTGF gene induction .	positive	1
19645	11018037	7422;3791	VEGF;KDR	***VEGF*** ***activated*** the tyrosine receptor phosphorylation of ***KDR*** and Flt1 and increased the binding of phosphatidylinositol 3-kinase ( PI3-kinase ) p85 subunit to KDR and Flt1 , both of which could mediate CTGF gene induction .	positive	1
19646	11018037	7422;1490	VEGF;CTGF	These data suggest that ***VEGF*** can ***increase*** ***CTGF*** gene expression in bovine retinal capillary cells via KDR or Flt receptors and the activation of PI3-kinase-Akt pathway independently of PKC or Ras-ERK pathway , possibly inducing the fibrosis observed in retinal neovascular diseases .	positive	0
19647	11018038	4092;3162	Smad7;heme oxygenase-1	***Smad7-dependent*** ***regulation*** of ***heme oxygenase-1*** by transforming growth factor-beta in human renal epithelial cells .	target	1
19648	11018038	7040;3162	TGF-beta1;HO-1	We hypothesize that the release of ***TGF-beta1*** via autocrine and/or paracrine pathways may ***induce*** ***HO-1*** and serve as a protective response in renal injury .	target	1
19649	11018038	7040;3162	TGF-beta1;HO-1	To understand the molecular mechanism of ***HO-1*** ***induction*** by ***TGF-beta1*** , we exposed confluent human renal proximal tubule cells to TGF-beta1 and observed a significant induction of HO-1 mRNA at 4 h with a maximal induction at 8 h.	target	1
19650	11018038	7040;3162	TGF-beta1;HO-1	Overexpression of Smad7 , but not Smad6 , inhibited ***TGF-beta1-mediated*** ***induction*** of endogenous ***HO-1*** gene expression .	target	1
19651	11018042	5879;3984	Rac1;LIMK1	Activation of LIMK2 by RhoA was inhibited by Y-27632 , a specific inhibitor of ROCK , but ***Rac1-mediated*** ***activation*** of ***LIMK1*** was not .	positive	1
19652	11018042	387;3985	RhoA;LIMK2	***Activation*** of ***LIMK2*** by ***RhoA*** was inhibited by Y-27632 , a specific inhibitor of ROCK , but Rac1-mediated activation of LIMK1 was not .	positive	1
19653	11018042	3985;3984	LIMK2;LIMK1	Together with the finding that ***LIMK1*** is ***regulated*** by Pak1 , LIMK1 and ***LIMK2*** are regulated by different protein kinases downstream of distinct Rho family GTPases .	target	1
19654	11018042	5058;3984	Pak1;LIMK1	Together with the finding that ***LIMK1*** is ***regulated*** by ***Pak1*** , LIMK1 and LIMK2 are regulated by different protein kinases downstream of distinct Rho family GTPases .	target	1
19655	11018053	51399;6383	Synbindin;syndecan-2	***Synbindin*** ***coimmunoprecipitates*** with ***syndecan-2*** from synaptic membrane fractions .	parallel	1
19656	11018074	4790;7124	NF-kappaB;TNF-alpha	These data strongly support the hypothesis that free radicals from NADPH oxidase in hepatic Kupffer cells play a predominant role in the pathogenesis of early alcohol-induced hepatitis by activating ***NF-kappaB*** , which ***activates*** production of cytotoxic ***TNF-alpha*** .	positive	1
19657	11018079	5340;1113	plasmin;CgA	We show here that the major fibrinolytic enzyme , ***plasmin*** , can ***cleave*** ***CgA*** to form a series of large fragments as well as small trichloroacetic acid-soluble peptides .	target	1
19658	11018079	5340;1113	plasmin;CgA	Peptides generated by ***plasmin-mediated*** ***cleavage*** of ***CgA*** significantly inhibited nicotinic cholinergic stimulation of catecholamine release from PC12 cells and primary bovine adrenal chromaffin cells .	target	1
19659	11018079	5340;1113	plasmin;CgA	***Interactions*** between ***CgA*** and ***plasmin*** ( ogen ) define a previously unrecognized autocrine/paracrine system that may have a dramatic impact upon catecholamine secretion .	parallel	1
19660	11018467	335;3931	apolipoprotein A-I;LCAT	Accumulation of cholestatic lipoproteins in ANIT-treated human apolipoprotein A-I transgenic rats is diminished through dose-dependent ***apolipoprotein A-I*** ***activation*** of ***LCAT*** .	positive	1
19661	11018756	207;5617	PKB;PRL	These results suggest that the ***PI3-kinase/PKB*** pathway may ***mediate*** the anti-apoptotic effect of ***PRL*** in Nb2 cells .	target	0
19662	11018802	185;183	AT1R;angiotensin II	In this study we have examined 105 hypertensive subjects and 192 controls from the Indian population for I/D polymorphism of angiotensin I converting enzyme ( ACE ) and A ( 1166 ) C polymorphism of ***angiotensin II*** type I ***receptor*** ( ***AT1R*** ) genes by polymerase chain reaction ( PCR ) and PCR-based restriction enzyme analysis method , respectively .	parallel	1
19663	11019486	94;7040	ALK-1;TGF-beta	Binding of TGF-beta to the type II TGF-beta receptor on endothelial cells , which is accelerated in the presence of endoglin , phosphorylates type I ***TGF-beta*** ***receptors*** , ALK-5 and ***ALK-1*** , and phosphorylated ALK-5 and ALK-1 activate the downstream proteins Smad2/3 and Smad1/5 , respectively .	parallel	1
19664	11019486	7046;7040	ALK-5;TGF-beta	Binding of TGF-beta to the type II TGF-beta receptor on endothelial cells , which is accelerated in the presence of endoglin , phosphorylates type I ***TGF-beta*** ***receptors*** , ***ALK-5*** and ALK-1 , and phosphorylated ALK-5 and ALK-1 activate the downstream proteins Smad2/3 and Smad1/5 , respectively .	parallel	1
19665	11019567	3569;1440	IL-6;G-CSF	It appeared that the elevation of ***G-CSF*** was ***induced*** by ***IL-6*** produced from PTH-rP in cancer tissue .	target	1
19666	11019780	1956;7039	epidermal growth factor receptor;TGF-alpha	We analyzed the expression of ***TGF-alpha*** and its ***receptor*** , ***epidermal growth factor receptor*** ( EGF-r ) , in the colonic mucosa of patients with Crohn 's disease ( CD ) or ulcerative colitis ( UC ) , in active or inactive stages , as compared with controls .	parallel	1
19667	11019784	3558;596	IL-2;bcl-2	The increased expressions of ***IL-2*** and its receptors in the epithelium of prostates in BPH , ***associated*** with increased ***bcl-2*** expression which would account for the decrease in the apoptosis index that has been reported in this disorder .	parallel	0
19668	11019830	5741;1594	parathyroid hormone;25-hydroxyvitamin D3 1alpha-hydroxylase	***Regulation*** of ***25-hydroxyvitamin D3 1alpha-hydroxylase*** gene expression by ***parathyroid hormone*** and 1,25-dihydroxyvitamin D3 .	target	1
19669	11019907	551;1392	AVP;CRH	***Interactions*** of ***CRH*** , ***AVP*** and cortisol in the secretion of ACTH from perifused equine anterior pituitary cells : " permissive " roles for cortisol and CRH .	parallel	1
19670	11019907	551;1392	AVP;CRH	To further elucidate the ***interaction*** of ***CRH*** , ***AVP*** and cortisol in the control of ACTH secretion , we used an in vitro perifusion model with dispersed equine anterior pituitary cells .	parallel	1
19671	11019907	551;1392	AVP;CRH	Total ( baseline + incremental ) ACTH secretion increased as both the CRH ( p < 0.001 ) and the AVP ( p < 0.001 ) concentration increased and ***interaction*** between ***CRH*** and ***AVP*** was significant ( p = 0.042 ) .	parallel	1
19672	11019907	551;1392	AVP;CRH	For incremental ACTH there was ***interaction*** between ***CRH*** and ***AVP*** ( p < 0.0001 ) , with increased secretion at higher concentrations , and no significant main effect of cortisol .	parallel	1
19673	11020215	4803;4914	NGF;TrkA	The lack of palmitoylation had no effect on the ability of p75 to enhance the short-term ***NGF-induced*** tyrosine ***phosphorylation*** of ***TrkA*** over a wide range of NGF concentrations .	target	1
19674	11020244	4790;5970	p50;p65	Cell fractionation studies were consistent with IkappaBbeta being a major regulator of ******p65-p50****** NF-kappaB ***complexes*** in HT-29 cells .	parallel	1
19675	11020244	4793;4790	IkappaBbeta;NF-kappaB	Cell fractionation studies were consistent with ***IkappaBbeta*** being a major ***regulator*** of p65-p50 ***NF-kappaB*** complexes in HT-29 cells .	target	1
19676	11020244	4793;5970	IkappaBbeta;p65	Cell fractionation studies were consistent with ***IkappaBbeta*** being a major ***regulator*** of ***p65-p50*** NF-kappaB complexes in HT-29 cells .	target	1
19677	11020244	5707;4790	p112;NF-kappaB	The p106 and ***p112*** proteins ***bound*** to ***NF-kappaB*** , and their levels changed during the transient interleukin-1beta activation of NF-kappaB in HT-29 cells .	parallel	1
19678	11020468	5340;5345	plasmin;alpha 2-antiplasmin	To evaluate the relationship of soluble TM in plasma between coagulation and/or fibrinolysis system in patients with diabetes , we measured plasma soluble TM , protein C activity ( a natural anticoagulant induced by thrombin-TM complex ) , prothrombin F1 +2 ( a direct marker of thrombin generation ) , and ******plasmin-alpha 2-antiplasmin****** ***complex*** ( PAP ) and D dimer ( measures of fibrinolytic activity ) in 55 patients with type 2 diabetes mellitus .	parallel	1
19679	11020863	760;759	carbonic anhydrase I and II;carbonic anhydrase I	CONCLUSIONS : The expressions of ***carbonic anhydrase I and II*** ***correlated*** with biological aggressiveness of colorectal cancer and synchronous distant metastasis , especially ***carbonic anhydrase I*** for colon cancer and carbonic anhydrase II for rectal cancer .	parallel	0
19680	11021529	5524;940	PP2A;CD28	The ***association*** of ***PP2A*** with ***CD28*** was negatively regulated by tyrosine phosphorylation of the CD28 cytoplasmic domain .	parallel	0
19681	11021758	6387;7852	SDF-1;CXCR4	These results demonstrate that : ( 1 ) HIV-related receptors are widely expressed on human hematopoietic cell lines ; ( 2 ) ***stimulation*** of ***CXCR4*** by ***SDF-1*** induces calcium flux and chemotaxis in several hematopoietic cell lines more efficiently than stimulation of CCR5 by receptor-specific beta-chemokines ; ( 3 ) chemokines do not regulate proliferation of the hematopoietic cells ; and finally ( 4 ) infectability of the hematopoietic cells by HIV-1 may be auto-modulated by endogenously secreted chemokines .	positive	0
19682	11021801	5879;6774	Rac1;STAT3	Dominant negative ***Rac1*** ***inhibited*** ***STAT3*** activation by growth factors , whereas activated Rac1 stimulated STAT3 phosphorylation on both tyrosine and serine residues .	negative	1
19683	11021801	5879;6774	Rac1;STAT3	Dominant negative Rac1 inhibited STAT3 activation by growth factors , whereas activated ***Rac1*** ***stimulated*** ***STAT3*** phosphorylation on both tyrosine and serine residues .	positive	0
19684	11021801	5879;6774	Rac1;STAT3	Moreover , activated ***Rac1*** formed a ***complex*** with ***STAT3*** in mammalian cells .	parallel	1
19685	11021822	4254;3586	SCF;interleukin-10	In addition , ***SCF*** pretreatment significantly ***augmented*** circulating levels of SCF and the immunomodulatory cytokine ***interleukin-10*** in septic mice , in part because the SCF pretreatment seemed to promote the release of both mediators from the liver .	positive	0
19686	11021829	7133;627	p75;neurotrophin	Here we demonstrate that a second ***neurotrophin*** ***receptor*** , ***p75*** ( NTR ) , is expressed by established human atherosclerotic lesions and late lesions that develop after balloon injury of the rat thoracic aorta .	parallel	1
19687	11021838	7057;7040	thrombospondin-1;TGF-beta	Previously we showed that ***thrombospondin-1*** ( TSP-1 ) ***activates*** latent ***TGF-beta*** both in vitro and in vivo .	positive	1
19688	11021838	7040;7057	TGF-beta;TSP-1	Activation occurs as the result of specific ***interactions*** of latent ***TGF-beta*** with ***TSP-1*** , which potentially alter the conformation of latent TGF-beta .	parallel	1
19689	11021838	7057;7040	TSP-1;TGF-beta	As glucose also up-regulates TSP-1 expression , we hypothesized that the increased TGF-beta bioactivity observed in rat and human mesangial cells cultured with high glucose concentrations is the result of latent ***TGF-beta*** ***activation*** by autocrine ***TSP-1*** .	positive	1
19690	11021838	7057;7040	TSP;TGF-beta	Glucose-induced bioactivity of TGF-beta in mesangial cell cultures was reduced to basal levels by peptides from two different sequences that antagonize ***activation*** of latent ***TGF-beta*** by ***TSP*** , but not by the plasmin inhibitor , aprotinin .	positive	1
19691	11021959	185;183	AT1R;angiotensin II	OBJECTIVES : To discuss the importance of 24 h blood pressure control , and to review the antihypertensive efficacy of conventional antihypertensive agents and of ***angiotensin II*** type I ***receptor*** ( ***AT1R*** ) blockers as assessed by ABP monitoring .	parallel	1
19692	11021985	796;5599	CGRP;JNK	While exposure of these cells to CGRP had no significant effect on ERK-1 or p38 MAP kinases , ***JNK*** activity was ***stimulated*** by ***CGRP*** in a time - and concentration-dependent fashion .	positive	0
19693	11022002	3439;3627	IFN-alpha;IP-10	***IFN-alpha*** or IFN-gamma were found to directly ***enhance*** MCP-1 , MCP-3 , and ***IP-10*** mRNA expression .	positive	0
19694	11022002	3439;6347	IFN-alpha;MCP-1	***IFN-alpha*** or IFN-gamma were found to directly ***enhance*** ***MCP-1*** , MCP-3 , and IP-10 mRNA expression .	positive	0
19695	11022002	3439;6354	IFN-alpha;MCP-3	***IFN-alpha*** or IFN-gamma were found to directly ***enhance*** MCP-1 , ***MCP-3*** , and IP-10 mRNA expression .	positive	0
19696	11022002	3458;3627	IFN-gamma;IP-10	IFN-alpha or ***IFN-gamma*** were found to directly ***enhance*** MCP-1 , MCP-3 , and ***IP-10*** mRNA expression .	positive	0
19697	11022002	3458;6347	IFN-gamma;MCP-1	IFN-alpha or ***IFN-gamma*** were found to directly ***enhance*** ***MCP-1*** , MCP-3 , and IP-10 mRNA expression .	positive	0
19698	11022002	3458;6354	IFN-gamma;MCP-3	IFN-alpha or ***IFN-gamma*** were found to directly ***enhance*** MCP-1 , ***MCP-3*** , and IP-10 mRNA expression .	positive	0
19699	11022003	400668;10045	nsP4;nsP1	The results from this study and from a previous report on the shutoff of minus-strand RNA synthesis at 40 degrees C with the nsP1-A348T mutation in ts11 suggests that the N-terminus ***nsP4*** ***interacts*** with ***nsP1*** during initiation of minus-strand RNA synthesis .	parallel	1
19700	11022003	400668;10045	nsP4;nsP1	Suppressor mutations that allow sindbis virus RNA polymerase to function with nonaromatic amino acids at the N-terminus : evidence for ***interaction*** between ***nsP1*** and ***nsP4*** in minus-strand RNA synthesis .	parallel	1
19701	11022036	10912;5111	CR6;proliferating cell nuclear antigen	***Interaction*** of ***CR6*** ( GADD45gamma ) with ***proliferating cell nuclear antigen*** impedes negative growth control .	parallel	1
19702	11022036	1647;5111	GADD45;proliferating cell nuclear antigen	Recently , we have shown that both MyD118 and ***GADD45*** ***interact*** with ***proliferating cell nuclear antigen*** ( PCNA ) , a protein that plays a central role in DNA replication , DNA repair , and cell cycle progression , as well as with the universal cyclin-dependent kinase inhibitor p21 .	parallel	1
19703	11022036	4616;1026	MyD118;p21	Recently , we have shown that both ***MyD118*** and GADD45 ***interact*** with proliferating cell nuclear antigen ( PCNA ) , a protein that plays a central role in DNA replication , DNA repair , and cell cycle progression , as well as with the universal cyclin-dependent kinase inhibitor ***p21*** .	parallel	1
19704	11022036	4616;5111	MyD118;proliferating cell nuclear antigen	Recently , we have shown that both ***MyD118*** and GADD45 ***interact*** with ***proliferating cell nuclear antigen*** ( PCNA ) , a protein that plays a central role in DNA replication , DNA repair , and cell cycle progression , as well as with the universal cyclin-dependent kinase inhibitor p21 .	parallel	1
19705	11022036	10912;1026	CR6;p21	In this work we show that also ***CR6*** ***interacts*** with PCNA and ***p21*** .	parallel	1
19706	11022036	10912;5111	CR6;PCNA	In this work we show that also ***CR6*** ***interacts*** with ***PCNA*** and p21 .	parallel	1
19707	11022036	10912;5111	CR6;PCNA	Moreover , it is shown that ***CR6*** ***interacts*** with ***PCNA*** via a domain that also mediates interaction of both GADD45 and MyD118 with PCNA .	parallel	1
19708	11022036	1647;5111	GADD45;PCNA	Moreover , it is shown that CR6 interacts with PCNA via a domain that also mediates ***interaction*** of both ***GADD45*** and MyD118 with ***PCNA*** .	parallel	1
19709	11022036	4616;5111	MyD118;PCNA	Moreover , it is shown that CR6 interacts with PCNA via a domain that also mediates ***interaction*** of both GADD45 and ***MyD118*** with ***PCNA*** .	parallel	1
19710	11022036	10912;5111	CR6;PCNA	Importantly , evidence has been obtained that ***interaction*** of ***CR6*** with ***PCNA*** impedes the function of this protein in negative growth control , similar to observations reported for MyD118 and GADD45 .	parallel	1
19711	11022043	1981;8661	eIF4G;eIF3	The central region of ***eIF4G*** ***binds*** the ATP-dependent RNA helicase eIF4A , the 40 S binding factor ***eIF3*** , and RNA .	parallel	1
19712	11022043	1981;1973	eIF4G;eIF4A	The central region of ***eIF4G*** ***binds*** the ATP-dependent RNA helicase ***eIF4A*** , the 40 S binding factor eIF3 , and RNA .	parallel	1
19713	11022043	8661;1981	eIF3;eIF4G	This region does not overlap with the RNA-binding site , which suggests that ***eIF3*** ***binds*** ***eIF4G*** directly and not through an RNA bridge , or the central eIF4A-binding site .	parallel	1
19714	11022043	8661;1981	eIF3;eIF4G	Surprisingly , the binding of eIF3 and eIF4A to the central region was mutually cooperative ; ***eIF3*** ***binding*** to ***eIF4G*** increased 4-fold in the presence of eIF4A , and conversely , eIF4A binding to the central ( but not COOH-terminal ) region of eIF4G increased 2.4-fold in the presence of eIF3 .	parallel	1
19715	11022120	51284;4790	hTLR7;NF-kappaB	Expression of constitutively active ***hTLR7-9*** ***stimulates*** an ***NF-kappaB*** signaling pathway indirectly supporting the contention that these receptors are involved in cellular responses to stimuli , which activate innate immunity .	positive	0
19716	11022122	3606;3458	IL-18;IFN-gamma	The recently discovered IL-1 isoform ***IL-18*** ( also known as interferon gamma-inducing factor ( IGIF ) or IL-1gamma ) , ***promotes*** ***IFN-gamma*** expression by T cells in concert with IL-12 .	positive	0
19717	11022125	5624;4282	protein C;macrophage migration inhibitory factor	Activated ***protein C*** ***inhibits*** tumor necrosis factor and ***macrophage migration inhibitory factor*** production in monocytes .	negative	1
19718	11022126	3553;3600	IL-1beta;IL-15	The constitutive expression and the TNF-alpha - or ***IL-1beta-mediated*** ***upregulation*** of intracellular ***IL-15*** protein was not inhibited by dexamethasone , in contrast , the release of IL-8 protein was inhibited .	positive	1
19719	11022129	5617;3659	Prolactin;interferon regulatory factor-1	***Prolactin*** ***activates*** ***interferon regulatory factor-1*** expression in normal lympho-hemopoietic cells .	positive	1
19720	11022129	6777;3659	signal transducer and activator of transcription (Stat) 5b;interferon regulatory factor-1	This leads to the activation and subsequent ***binding*** of ***signal transducer and activator of transcription (Stat) 5b*** to an ***interferon regulatory factor-1*** ( IRF-1 ) gamma activation sequence ( GAS ) as visualized by electromobility shift assay .	parallel	1
19721	11022134	6387;5595	SDF-1;ERK-1	***SDF-1*** ***activates*** ***ERK-1*** and ERK-2 in Jurkat cells .	positive	1
19722	11023262	1672;4586	hBD-1;mucin	***Association*** of ***hBD-1*** with salivary ***mucin*** may facilitate peptide distribution and adherence to oral surfaces and aid its function within the oral cavity .	parallel	0
19723	11023262	1672;4586	hBD-1;mucin	However , ***hBD-1*** peptide ***associated*** with salivary ***mucin*** resulted in loss of the detection in a dot-immunoblot assay .	parallel	0
19724	11023281	7422;2353	VEGF;c-fos	***VEGF*** ***induced*** the activation of activator protein 1 ( AP-1 ) and ***c-fos*** mRNA expression in human dental pulp cells .	target	1
19725	11023493	6688;2623	PU.1;GATA-1	***PU.1*** ***inhibits*** ***GATA-1*** function and erythroid differentiation by blocking GATA-1 DNA binding .	negative	1
19726	11023493	6688;2623	PU.1;GATA-1	The lineage-specific transcription factors GATA-1 and PU.1 can physically interact to inhibit each other 's function , but the mechanism of ***repression*** of ***GATA-1*** function by ***PU.1*** has not been elucidated .	negative	1
19727	11023494	3458;7852	IFN gamma;CXCR4	LPS-stimulated up-regulation of ***CXCR4*** and CCR5 in vitro was ***inhibited*** by anti-TNF and ***anti-IFN gamma*** .	negative	1
19728	11023515	23308;29851	B7-H2;ICOS	The results indicate that ***B7-H2*** is a putative ***ligand*** for the ***ICOS*** T-cell molecule .	parallel	1
19729	11023520	7187;958	TRAF3;CD40	Using a Hodgkin cell line , this study demonstrates that ***CD40*** activation of NF-kappa B is ***mediated*** by proteolysis of ***TRAF3*** .	target	0
19730	11023520	7187;958	TRAF3;CD40	The stability of ***TRAF3*** ***regulates*** ***CD40/NF-kappa*** B-mediated control of the immune response , which is central to the biologic activity of the Reed-Sternberg cell .	target	1
19731	11023523	861;4353	AML1;myeloperoxidase	As ***AML1*** protein ***regulates*** the expression of the ***myeloperoxidase*** gene , the relationship between AML1 mutations and Mo phenotype in AML will have to be further explored .	target	1
19732	11023661	3725;4312	AP-1;MMP-1	We have reported previously that NF-kappaB and ***AP-1*** cooperate to ***mediate*** IL-1-induced ***MMP-1*** transcription .	target	0
19733	11023661	4790;4312	NF-kappaB;MMP-1	We have reported previously that ***NF-kappaB*** and AP-1 cooperate to ***mediate*** IL-1-induced ***MMP-1*** transcription .	target	0
19734	11023661	3725;4790	AP-1;NF-kappaB	We have reported previously that ***NF-kappaB*** and ***AP-1*** ***cooperate*** to mediate IL-1-induced MMP-1 transcription .	parallel	0
19735	11023662	2919;3579	GROalpha;CXCR2	In conclusion , high-affinity ***binding*** of IL-8 , NAP-2 , and ***GROalpha*** to ***CXCR2*** involves interaction with specific and different amino acid residues of CXCR2 .	parallel	1
19736	11023662	3576;3579	IL-8;CXCR2	In conclusion , high-affinity ***binding*** of ***IL-8*** , NAP-2 , and GROalpha to ***CXCR2*** involves interaction with specific and different amino acid residues of CXCR2 .	parallel	1
19737	11023662	5473;3579	NAP-2;CXCR2	In conclusion , high-affinity ***binding*** of IL-8 , ***NAP-2*** , and GROalpha to ***CXCR2*** involves interaction with specific and different amino acid residues of CXCR2 .	parallel	1
19738	11023663	6348;1234	MIP-1alpha;CCR5	We report here that treating monocyte-derived macrophages ( MDM ) with a trimeric soluble form of CD40L ( CD40LT ) induced them to secrete high levels of the beta-chemokines RANTES , ***MIP-1alpha*** and MIP-1beta that are ***ligands*** for ***CCR5*** and able to inhibit HIV-1 entry .	parallel	1
19739	11023663	6351;1234	MIP-1beta;CCR5	We report here that treating monocyte-derived macrophages ( MDM ) with a trimeric soluble form of CD40L ( CD40LT ) induced them to secrete high levels of the beta-chemokines RANTES , MIP-1alpha and ***MIP-1beta*** that are ***ligands*** for ***CCR5*** and able to inhibit HIV-1 entry .	parallel	1
19740	11023663	6352;1234	RANTES;CCR5	We report here that treating monocyte-derived macrophages ( MDM ) with a trimeric soluble form of CD40L ( CD40LT ) induced them to secrete high levels of the beta-chemokines ***RANTES*** , MIP-1alpha and MIP-1beta that are ***ligands*** for ***CCR5*** and able to inhibit HIV-1 entry .	parallel	1
19741	11023664	958;3586	CD40;IL-10	The addition of exogenous IL-1 augments ***CD40*** ***induced*** ***IL-10*** production by IFN-gamma-primed monocytes .	target	1
19742	11023664	958;3586	CD40;interleukin 10	Route of monocyte differentiation determines their cytokine production profile : ***CD40*** ligation ***induces*** ***interleukin 10*** expression .	target	1
19743	11023706	3082;4018	hepatocyte growth factor;lipoprotein	A deleted form of human ***hepatocyte growth factor*** ***stimulates*** hepatic lipogenesis and ***lipoprotein*** synthesis in rats .	positive	0
19744	11023800	3553;7422	IL-1beta;VEGF	***IL-1beta*** , expressed by the blastocyst , ***induces*** vascular endothelial growth factor ( ***VEGF*** ) which , in turn , promotes angiogenesis and integrin expression in endometrial cells .	target	1
19745	11023800	3553;3458	IL-1;IFN-gamma	The ***IL-1*** system also ***triggers*** the expression of gamma interferon ( ***IFN-gamma*** ) from T lymphocytes .	positive	0
19746	11023817	1978;1977	4E-BP1;eIF4E	Ischaemia induces changes in the ***association*** of the binding protein ***4E-BP1*** and eukaryotic initiation factor ( eIF ) 4G to ***eIF4E*** in differentiated PC12 cells .	parallel	0
19747	11023817	1978;1977	4E-BP1;eIF4E	In addition , ischaemia induced an enhancement of the ***association*** of ***4E-BP1*** to ***eIF4E*** , which in turn decreased eIF4F formation , whereas no degradation of initiation factor 4G was observed .	parallel	0
19748	11023817	1977;1981	eIF4E;eIF4F	In addition , ischaemia induced an enhancement of the association of 4E-BP1 to ***eIF4E*** , which in turn ***decreased*** ***eIF4F*** formation , whereas no degradation of initiation factor 4G was observed .	negative	0
19749	11023820	1318;10267	hCTR2;RAMP1	Cell-surface ***complexes*** of human ***RAMP1*** ( hRAMP1 ) and human calcitonin (CT) receptor isotype 2 ( ***hCTR2*** ) or rat CT-receptor-like receptor ( rCRLR ) have now been identified through protein cross-linking , co-immunoprecipitation and confocal microscopy .	parallel	1
19750	11023820	10267;1318	hRAMP1;hCTR2	Thus direct molecular ***interactions*** of ***hRAMP1*** with ***hCTR2*** or rCRLR are required for CGRP recognition .	parallel	1
19751	11023826	831;7145	calpain inhibitor;tensin	Incubation of cells with a ***calpain inhibitor*** , MDL , ***prevented*** ***tensin*** cleavage and induced morphological change in these cells , suggesting that cleavage of tensin and other focal-adhesion constituents by calpain disrupts maintenance of normal cell shape .	negative	0
19752	11023832	7124;5294	TNFalpha;PI3K	In these cells ***TNFalpha*** ***triggered*** phosphoinositide 3-kinase ( ***PI3K*** ) - dependent PC hydrolysis within 4-8 min with concomitant production of both diacylglycerol ( DAG ) and phosphocholine ( P-chol ) .	positive	0
19753	11023838	3416;351	insulin-degrading enzyme;Abeta	Recently , ***insulin-degrading enzyme*** ( IDE ) , a 110-kDa metalloendopeptidase , was found to ***degrade*** both endogenously secreted and synthetic ***Abeta*** peptides .	negative	0
19754	11023838	3416;351	IDE;Abeta	Our data demonstrate that ( i ) ***IDE*** alone is sufficient to ***cleave*** purified ***Abeta*** that is either unlabelled , iodinated or ( 35 ) S-labelled ; ( ii ) the initial cleavage sites are His ( 14 ) - Gln ( 15 ) , Phe ( 19 ) - Phe ( 20 ) and Phe ( 20 ) - Ala ( 21 ) ; and ( iii ) incubation of IDE with [ ( 125 ) I ] Abeta , but not with [ ( 35 ) S ] - Abeta , leads to the formation of slower migrating species on gels .	target	1
19755	11023838	3416;351	IDE;Abeta	These results indicate that ***IDE*** alone is sufficient to ***degrade*** ***Abeta*** at specific sites , and that its degradation products do not promote oligomerization of the intact Abeta peptide .	negative	0
19756	11023871	1896;10913	Eda;Edar	******Edar/Eda****** ***interactions*** regulate enamel knot formation in tooth morphogenesis .	parallel	1
19757	11023871	10913;1896	Edar;Eda	As predicted by the similarity in adult mutant phenotype and the structure of the proteins , we demonstrate that ***Eda*** and ***Edar*** specifically ***interact*** in vitro .	parallel	1
19758	11023976	7057;373156	Thrombospondin-1;GST	Here we demonstrate that human ***Thrombospondin-1*** ( TSP ) , a plasma glycoprotein and constituent of the extracellular matrix , ***binds*** to glutathione-S-transferase ( ***GST*** ) - Tat protein but not to GST .	parallel	1
19759	11023976	373156;7057	GST;TSP	Scatchard plot analysis of the ***binding*** of free ***GST-Tat*** to immobilized ***TSP*** reveals a high-affinity interaction ( Kd equal to 25 nM ) .	parallel	1
19760	11023977	4804;627	p75NTR;neurotrophin	To examine the mechanisms that underlie the neurotrophin-induced , apoptosis-driven hair follicle involution ( catagen ) , the expression and function of p75 ***neurotrophin*** ***receptor*** ( ***p75NTR*** ) , which is implicated in apoptosis control , were studied during spontaneous catagen development in murine skin .	parallel	1
19761	11023978	6833;3767	SUR;Kir6.2	ATP-sensitive K + ( KATP ) channels are unique metabolic sensors formed by ***association*** of ***Kir6.2*** , an inwardly rectifying K+ channel , and the sulfonylurea receptor ***SUR*** , an ATP binding cassette protein .	parallel	0
19762	11023984	356;355	FasL;Fas	Blocking of ***Fas*** ***ligand*** ( ***FasL*** ) reduced apoptosis by 50 % and simultaneous blocking of FasL and TNF receptors by 70 % .	parallel	1
19763	11023989	596;842	bcl-2;caspase 9	Finally , enforced expression of ***bcl-2*** significantly ***prevents*** GD3-induced mitochondrial changes , ***caspase 9*** activation , and apoptosis .	negative	0
19764	11023993	2277;3791	VEGF-D;VEGFR-2	VEGF-C and ***VEGF-D*** , which ***bind*** both ***VEGFR-2*** and VEGFR-3 were expressed in vascular smooth muscle cells .	parallel	1
19765	11023998	4842;596	NOS1;bcl-2	Preconditioning ***regulation*** of ***bcl-2*** and p66shc by human ***NOS1*** enhances tolerance to oxidative stress .	target	1
19766	11024001	7352;4654	uncoupling protein-3;MyoD	The human ***uncoupling protein-3*** gene promoter ***requires*** ***MyoD*** and is induced by retinoic acid in muscle cells .	target	0
19767	11024015	8620;64106	NPFF;NPFF1	***NPFF*** specifically ***bound*** to ***NPFF1*** ( K ( d ) = 1.13 nm ) and NPFF2 ( K ( d ) = 0.37 nm ) , and both receptors were activated by NPFF in a variety of heterologous expression systems .	parallel	1
19768	11024015	8620;10886	NPFF;NPFF2	***NPFF*** specifically ***bound*** to NPFF1 ( K ( d ) = 1.13 nm ) and ***NPFF2*** ( K ( d ) = 0.37 nm ) , and both receptors were activated by NPFF in a variety of heterologous expression systems .	parallel	1
19769	11024037	6693;867	CD43;Cbl	***Regulation*** of ***Cbl*** molecular interactions by the co-receptor molecule ***CD43*** in human T cells .	target	1
19770	11024037	6693;867	CD43;Cbl	***CD43*** signals ***induced*** a ***Cbl*** serine phosphorylation-dependent interaction with the tau-isoform of 14-3-3 .	target	1
19771	11024037	867;3725	Cbl;AP-1	Overexpression of ***Cbl*** in Jurkat cells ***inhibited*** the CD43-dependent activation of the mitogen-activated protein kinase ( MAPK ) pathway and ***AP-1*** transcriptional activity , confirming nevertheless a negative role for Cbl in T cell signaling .	negative	1
19772	11024044	348;4018	apoE;lipoprotein	Plasma ***apoE*** is largely liver-derived and known to ***regulate*** ***lipoprotein*** metabolism .	target	1
19773	11024045	79444;836	Livin;caspase-3	In vitro binding studies demonstrated a direct ***interaction*** between ***Livin*** and the active form of the downstream caspases , ***caspase-3*** and -7 , that was dependent on the BIR domain of Livin .	parallel	1
19774	11024045	842;79444	caspase-9;Livin	In addition , the unprocessed and cleaved forms of ***caspase-9*** ***co-immunoprecipitated*** with ***Livin*** in vivo , and recombinant Livin could inhibit the activation of caspase-9 induced by Apaf-1 , cytochrome c , and dATP .	parallel	1
19775	11024045	79444;842	Livin;caspase-9	In addition , the unprocessed and cleaved forms of caspase-9 co-immunoprecipitated with Livin in vivo , and recombinant ***Livin*** could ***inhibit*** the activation of ***caspase-9*** induced by Apaf-1 , cytochrome c , and dATP .	negative	1
19776	11024047	4087;4838	Smad2;Nodal	These results provide the first direct biochemical evidence that ***Nodal*** signaling is ***mediated*** by both activin-TGF-beta pathway Smads , ***Smad2*** and Smad3 .	target	0
19777	11024047	4088;4838	Smad3;Nodal	These results provide the first direct biochemical evidence that ***Nodal*** signaling is ***mediated*** by both activin-TGF-beta pathway Smads , Smad2 and ***Smad3*** .	target	0
19778	11024052	3439;6772	IFN-alpha;STAT-1	Further , our findings support the view that gammaRF-2 is the ***IFN-alpha/beta*** ***induced*** ***STAT-1*** complex , IFN-alpha-activated factor .	target	1
19779	11024052	3439;4283	IFN-alpha;Mig	We have found that , in the absence of IFN-gamma , ***IFN-alpha/beta*** are able to ***induce*** ***Mig*** in response to a viral infection in vivo .	target	1
19780	11024053	1499;999	beta-catenin;E-cadherin	Thus , the addition of a specific N-glycan structure , the bisecting GlcNAc to ******E-cadherin-beta-catenin****** ***complex*** , down-regulates the intracellular signaling pathway , suggesting its implication in cell motility and the suppression of cancer metastasis .	parallel	1
19781	11024054	6114;54110	rP22;rP29	SGL ***binding*** of ***rP29*** and ***rP22*** was severely reduced .	parallel	1
19782	11024059	7428;8453	VHL;cullin-2	Exon 3-encoded alpha-helical domain is required for ***VHL*** complex ***formation*** with ***BC/cullin-2*** and E3 ubiquitin ligase activity , for binding to HIFalpha/fibronectin , but this domain is not essential for transcription-dependent nuclear/cytoplasmic trafficking .	parallel	0
19783	11024059	7428;5071	VHL;E3 ubiquitin ligase	Exon 3-encoded alpha-helical domain is required for ***VHL*** complex ***formation*** with BC/cullin-2 and ***E3 ubiquitin ligase*** activity , for binding to HIFalpha/fibronectin , but this domain is not essential for transcription-dependent nuclear/cytoplasmic trafficking .	parallel	0
19784	11024060	8514;3739	Kv beta 2;Kv1.4	Like the wild-type Kv beta 2 , both types of mutation increased the rate of inactivation of Kv1.4 , confirming the physical ***association*** of mutant ***Kv beta 2*** subunits with ***Kv1.4*** .	parallel	0
19785	11024134	4018;3949	lipoprotein;LDLr	Hepatitis C virus ( HCV ) or HCV-low-density ***lipoprotein*** ( LDL ) complexes ***interact*** with the LDL receptor ( ***LDLr*** ) and the HCV envelope glycoprotein E2 interacts with CD81 in vitro .	parallel	1
19786	11024281	8888;4172	GANP;MCM3	Structure , expression , and chromosomal localization of the human gene encoding a germinal center-associated nuclear protein ( ***GANP*** ) that ***associates*** with ***MCM3*** involved in the initiation of DNA replication .	parallel	0
19787	11024460	3578;8660	IL-9;IRS2	We show that ***IL-9*** ***induces*** ***IRS2*** phosphorylation and association with phosphatidylinositol-3 kinase ( PI 3-K ) p85 subunit in TS1 cells and BaF/9R cells , which proliferate upon IL-9 stimulation .	target	1
19788	11024538	116;5599	pituitary adenylate cyclase activating polypeptide;JNK	Vasoactive intestinal peptide and ***pituitary adenylate cyclase activating polypeptide*** ***inhibit*** the ***MEKK1/MEK4/JNK*** signaling pathway in LPS-stimulated macrophages .	negative	1
19789	11024538	116;6416	pituitary adenylate cyclase activating polypeptide;MEK4	Vasoactive intestinal peptide and ***pituitary adenylate cyclase activating polypeptide*** ***inhibit*** the ***MEKK1/MEK4/JNK*** signaling pathway in LPS-stimulated macrophages .	negative	1
19790	11024538	116;4214	pituitary adenylate cyclase activating polypeptide;MEKK1	Vasoactive intestinal peptide and ***pituitary adenylate cyclase activating polypeptide*** ***inhibit*** the ***MEKK1/MEK4/JNK*** signaling pathway in LPS-stimulated macrophages .	negative	1
19791	11024538	7432;5599	Vasoactive intestinal peptide;JNK	***Vasoactive intestinal peptide*** and pituitary adenylate cyclase activating polypeptide ***inhibit*** the ***MEKK1/MEK4/JNK*** signaling pathway in LPS-stimulated macrophages .	negative	1
19792	11024538	7432;6416	Vasoactive intestinal peptide;MEK4	***Vasoactive intestinal peptide*** and pituitary adenylate cyclase activating polypeptide ***inhibit*** the ***MEKK1/MEK4/JNK*** signaling pathway in LPS-stimulated macrophages .	negative	1
19793	11024538	7432;4214	Vasoactive intestinal peptide;MEKK1	***Vasoactive intestinal peptide*** and pituitary adenylate cyclase activating polypeptide ***inhibit*** the ***MEKK1/MEK4/JNK*** signaling pathway in LPS-stimulated macrophages .	negative	1
19794	11024538	7432;7124	VIP;TNFalpha	The vasoactive intestinal peptide ( ***VIP*** ) and the pituitary adenylate cyclase activating polypeptide ( PACAP ) , two immunomodulatory neuropeptides that affect both innate and acquired immunity , ***downregulate*** ***TNFalpha*** expression in LPS-stimulated peritoneal macrophages and Raw 264.7 cells .	negative	1
19795	11024538	116;4214	PACAP;MEKK1	Our studies indicate that ***VIP/PACAP*** ***inhibit*** ***MEKK1*** activity , and the subsequent phosphorylation of MEK4 , JNK , and c-Jun .	negative	1
19796	11024538	7432;4214	VIP;MEKK1	Our studies indicate that ***VIP/PACAP*** ***inhibit*** ***MEKK1*** activity , and the subsequent phosphorylation of MEK4 , JNK , and c-Jun .	negative	1
19797	11024538	7432;3726	VIP;JunB	Western blots confirm that ***VIP*** ***stimulates*** ***JunB*** production in LPS-stimulated macrophages .	positive	0
19798	11024558	3952;9607	leptin;CART	In contrast , ***leptin*** decreased body weight and adiposity , ***increased*** ***CART*** and suppressed NPY and AGRP mRNA expression in adult mice .	positive	0
19799	11024558	3952;4852	leptin;NPY	In contrast , ***leptin*** decreased body weight and adiposity , increased CART and ***suppressed*** ***NPY*** and AGRP mRNA expression in adult mice .	negative	1
19800	11024560	3952;2796	Leptin;GnRH	In the female , ***GnRH*** pulse amplitude was significantly ***increased*** by ***Leptin*** ( 10 ( -7 ) M ) and CART ( 10 ( -6 ) M ) irrespective of the estrus cycle phase while no such effects were seen in the male .	positive	0
19801	11024562	3060;3952	orexin;leptin	Morphological evidence for neural ***interactions*** between ***leptin*** and ***orexin*** in the hypothalamus .	parallel	1
19802	11024562	3060;3952	orexin;leptin	The morphological evidence of neural ***interaction*** between ***leptin*** and ***orexin*** , one considered to inhibit food intake and the other to stimulate it in the central nervous system ( CNS ) , was studied by use of double immunostaining method .	parallel	1
19803	11025357	2520;6750	gastrin;somatostatin	CONCLUSIONS : ( 1 ) Ability of Hp-WE to induce superficial damage , the reduction in HDC mRNA and accompanying fall in gastric histamine release , contribute , at least in part , to marked hypochlorhydria observed in the stomach exposed to repeated Hp-WE treatments , and ( 2 ) the deleterious effect of Hp-WE on the gastric mucosa involves an impairment of ******gastrin-somatostatin****** ***link*** possibly resulting from the action of Hp-derived toxins and the induction in mucosal cells of proinflammatory cytokine such as IL-1beta .	parallel	0
19804	11025405	3458;7124	IFNgamma;TNFalpha	In contrast , the spontaneous as well as ***TNFalpha-induced*** secretion of ESM-1 is strongly ***inhibited*** by ***IFNgamma*** .	negative	1
19805	11025449	29117;3660	celtix-1;IRF-2	***celtix-1*** directly ***interacts*** with ***IRF-2*** based on binding studies with glutathione S-transferase ( GST ) / IRF-2 fusion proteins , and immunofluorescence studies suggest that celtix-1 and IRF-2 associate in situ .	parallel	1
19806	11025450	355;356	Fas;FasL	Blocking TNF/TNFR or ******FasL/Fas****** ***interactions*** did not interfere with the factor B-induced apoptosis .	parallel	1
19807	11025451	3553;2729	interleukin 1beta;gamma-glutamylcysteine synthetase	***Induction*** of MRP1 and ***gamma-glutamylcysteine synthetase*** gene expression by ***interleukin 1beta*** is mediated by nitric oxide-related signalings in human colorectal cancer cells .	target	1
19808	11025451	3553;4363	interleukin 1beta;MRP1	***Induction*** of ***MRP1*** and gamma-glutamylcysteine synthetase gene expression by ***interleukin 1beta*** is mediated by nitric oxide-related signalings in human colorectal cancer cells .	target	1
19809	11025451	3553;4363	IL-1beta;MRP1	Collectively , our results demonstrate that ***induction*** of ***MRP1*** and gamma-GCSh by ***IL-1beta*** is regulated , at least in part , by an NO-related signaling , and induction of gamma-GCSh is by NO-related ceramide signaling .	target	1
19810	11025483	596;5241	Bcl-2;progesterone (P = 0.0045) receptor	***Bcl-2*** levels ranged from 4 % to 91 % , ***correlated*** positively with estrogen ( P = 0.0004 ) and ***progesterone (P = 0.0045) receptor*** positivity , and were more associated with low S-phase tumor values .	positive	0
19811	11025561	3667;3643	insulin receptor substrate-1;insulin receptor	BACKGROUND : ***insulin receptor substrate-1*** ( IRS-1 ) is an endogenous ***substrate*** for the ***insulin receptor*** tyrosine kinase , which plays an important role in insulin signaling .	parallel	1
19812	11025661	10540;7157	dynamitin;p53	Overexpression of ***dynamitin*** or microinjection of anti-dynein antibody before DNA damage ***abrogates*** nuclear accumulation of ***p53*** .	negative	0
19813	11025670	11200;7157	Cds1;p53	***Cds1*** also directly ***phosphorylates*** ***p53*** in vitro at a site that is implicated in its stabilization , and is required for stabilization of p53 and induction of p53-dependent transcripts in vivo upon gamma-ionizing radiation .	target	1
19814	11025670	472;11200	ATM;Cds1	***ATM*** is necessary for phosphorylation and activation of Cds1 in vivo and can ***phosphorylate*** ***Cds1*** in vitro , although evidence that the sites that are phosphorylated by ATM are required for activation is lacking .	target	1
19815	11025760	7040;4843	TGF-beta1;iNOS	***TGF-beta1*** ***inhibited*** ***iNOS*** protein and nitric oxide , whereas an anti-TGF-beta antibody enhanced iNOS .	negative	1
19816	11025760	183;7040	angiotensin II;TGF-beta1	RESULTS : ***angiotensin II*** ***stimulated*** ***TGF-beta1*** and nitric oxide .	positive	0
19817	11026557	3479;3486	IGF-I;IGFBP-3	The combined treatment of ***IGF-I*** and FSH ***increased*** the concentration of ***IGFBP-3*** in OCC and MGC conditioned media by 4 - and 6-fold , respectively .	positive	0
19818	11026652	2321;7422	FLT-1;VEGF	The soluble form of ***VEGF*** ***receptor*** , ***FLT-1*** ( sFLT-1 ) , is a potent antagonist of VEGF .	parallel	1
19819	11027142	335;949	apolipoprotein A-I;SR-BI	***Binding*** of ***apolipoprotein A-I*** to ***SR-BI*** of rabbit brush border membrane is cooperative , characterized by a dissociation constant K ( d ) = 0.45 microM and a Hill coefficient of n = 2.8 .	parallel	1
19820	11027214	4804;4790	p75;NF-kappaB	Blocking ***p75-mediated*** ***activation*** of ***NF-kappaB*** by ecdysone-inducible expression of a nondegradable mutant of IkappaBalpha significantly enhanced apoptosis .	positive	1
19821	11027214	4803;4804	nerve growth factor;p75	***nerve growth factor*** ***binds*** to the TrkA and ***p75*** ( NTR ) ( p75 ) and generates signals leading to neuronal cell survival , differentiation , and programmed cell death .	parallel	1
19822	11027214	4803;4914	nerve growth factor;TrkA	***nerve growth factor*** ***binds*** to the ***TrkA*** and p75 ( NTR ) ( p75 ) and generates signals leading to neuronal cell survival , differentiation , and programmed cell death .	parallel	1
19823	11027214	4804;4790	p75;NF-kappaB	Although both ***p75*** and TrkA ***activated*** nuclear factor-kappaB ( ***NF-kappaB*** ) , we show that distinct proximal-signaling intermediates are used by each receptor .	positive	1
19824	11027214	4914;4790	TrkA;NF-kappaB	Although both p75 and ***TrkA*** ***activated*** nuclear factor-kappaB ( ***NF-kappaB*** ) , we show that distinct proximal-signaling intermediates are used by each receptor .	positive	1
19825	11027214	6464;4914	Shc;TrkA	Conversely a dominant-negative mutant of ***Shc*** ***inhibited*** ***TrkA*** but not p75 activation of NF-kappaB .	positive	1
19826	11027239	1404;2353	hcrt1;c-fos	Iontophoretic application of hcrt1 enhanced the firing rate of LC neurons in vivo , and local injection of ***hcrt1*** into the LC ***induced*** the expression of ***c-fos*** in the LC area .	target	1
19827	11027261	3184;595	AUF1;cyclin D1	The RNA-binding protein ***AUF1*** , previously associated with the degradation of target mRNAs , ***bound*** ***cyclin D1*** mRNA , because anti-AUF1 antibodies were capable of supershifting or immunoprecipitating cyclin D1 mRNA-protein complexes .	parallel	1
19828	11027271	5469;5468	DRIP205;PPARgamma	A single DRIP subunit , ***DRIP205*** ( TRAP220 , PBP ) , ***binds*** directly to ***PPARgamma*** .	parallel	1
19829	11027271	5468;5469	PPARgamma;DRIP205	Here we report that ***PPARgamma*** and RXR selectively ***interacted*** with ***DRIP205*** and p160 proteins in a ligand-dependent manner .	parallel	1
19830	11027277	4803;5594	NGF;ERK	To examine potential interactions between the ERK and PI3-K pathways , we studied the requirement of PI3-K for ***NGF*** ***activation*** of the ***ERK*** signaling cascade in dorsal root ganglion cells and PC12 cells .	positive	1
19831	11027277	4803;5906	NGF;Rap1	In PC12 cells , ***NGF*** ***activates*** Ras and ***Rap1*** to elicit the rapid and sustained activation of ERKs respectively .	positive	1
19832	11027277	5906;4914	Rap1;TrkA	We show here that ***Rap1*** activation ***requires*** both ***TrkA*** internalization and PI3-K , whereas Ras activation requires neither TrkA internalization nor PI3-K .	target	0
19833	11027278	5898;595	Ral;cyclin D1	The ***regulation*** of ***cyclin D1*** transcription by ***Ral*** is dependent on NF-kappaB activation and is mediated through an NF-kappaB binding site in the cyclin D1 promoter .	target	1
19834	11027278	5898;5337	Ral;phospholipase D1	Ral activation of these responses is likely through an as yet uncharacterized effector pathway , as we find activation of NF-kappaB and the cyclin D1 promoter by Ral is independent of ***association*** of ***Ral*** with active ***phospholipase D1*** or Ral-binding protein 1 , two proteins proposed to mediate Ral function in cells .	parallel	0
19835	11027280	4087;4088	Smad2;Smad3	Furthermore , Cam kinase II blocked nuclear accumulation of a Smad2 and induced Smad2-Smad4 hetero-oligomerization independently of TGF-beta receptor activation , while preventing TGF-beta-dependent ******Smad2-Smad3****** ***interactions*** .	parallel	1
19836	11027287	7011;7015	TEP1;telomerase reverse transcriptase	Like p80 , ***TEP1*** is ***associated*** with telomerase activity and the ***telomerase reverse transcriptase*** , and it specifically interacts with the telomerase RNA .	parallel	0
19837	11027287	7011;56664	TEP1;vRNA	***TEP1*** can also specifically ***bind*** to a small RNA , ***vRNA*** , which is associated with the vault particle and is unrelated in sequence to mammalian telomerase RNA .	parallel	1
19838	11027288	4738;8454	NEDD8;CUL1	Disruption of ROC1 binding impaired nuclear accumulation of CUL1 and decreased NEDD8 modification in vivo but had no effect on ***NEDD8*** ***modification*** of ***CUL1*** in vitro , suggesting that ROC1 promotes CUL1 nuclear accumulation to facilitate its NEDD8 modification .	target	0
19839	11027288	9978;8454	ROC1;CUL1	Disruption of ROC1 binding impaired nuclear accumulation of CUL1 and decreased NEDD8 modification in vivo but had no effect on NEDD8 modification of CUL1 in vitro , suggesting that ***ROC1*** ***promotes*** ***CUL1*** nuclear accumulation to facilitate its NEDD8 modification .	positive	0
19840	11027288	8454;4738	CUL1;NEDD8	These results identify a pathway for regulation of CUL1 activity-ROC1 and the ***CUL1*** C-terminal sequence collaboratively ***mediate*** nuclear accumulation and ***NEDD8*** modification , facilitating assembly of active CUL1 ubiquitin ligase .	target	0
19841	11027307	5727;6469	Ptc-1;Shh	These findings suggest that ***Shh*** internalization is ***mediated*** by ***Ptc-1*** and may be linked to signaling .	target	0
19842	11027342	5971;958	RelB;CD40	***RelB*** nuclear translocation ***regulates*** B cell MHC molecule , ***CD40*** expression , and antigen-presenting cell function .	target	1
19843	11027342	958;5971	p50;RelB	After transient transfection of BJAB with RelB , strong nuclear expression of ******RelB-p50****** ***heterodimers*** was associated with increased APC function and expression of CD40 and MHC class I.	parallel	1
19844	11027342	5971;958	RelB;CD40	The data indicate that ***RelB*** transcriptional activity directly ***affects*** antigen presentation and ***CD40*** synthesis .	target	0
19845	11027427	3082;4323	HGF;MT1-MMP	***HGF/SF*** ***stimulated*** the expression of MMP-1 , 9 and ***MT1-MMP*** and had a slight effect on expression of the MMP inhibitor TIMP-1 but not TIMP-2 .	positive	0
19846	11027463	4318;4314	MMP-9;MMP-3	***MMP-9*** tended to be coexpressed with uPA , and was consistently ***associated*** with ***MMP-3*** localized at the tumor-invasive front with inflammatory cells such as monocyte-macrophages .	parallel	0
19847	11027488	207;5743	Rac;COX-2	A CRE/ATF element located at -56 was critical for Ras - and ***Rac-induced*** ***transactivation*** of the ***COX-2*** promoter , but was not required for transactivation by Rho .	positive	1
19848	11027509	3700;920	gp120;CD4	Since BA did not inhibit ***binding*** of HIV-1 ***gp120*** to ***CD4*** , we propose that BA may interfere with the interaction of HIV-1 Env with chemokine coreceptors and block HIV-1 entry of target cells .	parallel	1
19849	11027530	3553;3240	IL-1;haptoglobin	Inhibition by deacetylase inhibitors of ***IL-1-dependent*** ***induction*** of ***haptoglobin*** involves CCAAT/Enhancer-binding protein isoforms in intestinal epithelial cells .	target	1
19850	11027530	3553;3240	IL-1;haptoglobin	In contrast , both NaBu and TSA attenuated the ***IL-1-dependent*** ***induction*** of the acute phase protein gene ***haptoglobin*** , as well as C/EBPbeta and C/EBPdelta transcription factors mRNAs .	target	1
19851	11027532	7040;672	TGF-beta1;BRCA1	***TGF-beta1*** ***inhibits*** ***BRCA1*** expression through a pathway that requires pRb .	negative	1
19852	11027532	7040;672	TGF-beta1;BRCA1	***TGF-beta1*** ***inhibits*** ***BRCA1*** expression , which contradicts the model that TGF-beta1 prevents carcinogenesis by activating tumor suppressor genes .	negative	1
19853	11027532	5925;7040	pRb;TGF-beta1	We found that inactivation of ***pRb*** by the papillomavirus type 16 E7 protein increased BRCA1 expression and ***abolished*** the ability of ***TGF-beta1*** to inhibit BRCA1 expression .	positive	0
19854	11027532	5925;672	pRb;BRCA1	We found that inactivation of ***pRb*** by the papillomavirus type 16 E7 protein ***increased*** ***BRCA1*** expression and abolished the ability of TGF-beta1 to inhibit BRCA1 expression .	negative	0
19855	11027532	7040;672	TGF-beta1;BRCA1	We conclude that ***TGF-beta1*** ***inhibits*** ***BRCA1*** expression through a pathway that requires pRb .	negative	1
19856	11027532	7040;5925	TGF-beta1;pRb	Our results suggest that the tumor suppressor functions of BRCA1 are initiated by the inactivation of pRb , and therefore that the ***activation*** of ***pRb*** by ***TGF-beta1*** might alleviate the requirement for BRCA1 function .	positive	1
19857	11027547	5005;5004	AGP2;ORM	The human alpha ( 1 ) - acid glycoprotein ( AGP ) or orosomucoid ( ***ORM*** ) is ***controlled*** by the two tandemly arranged genes , AGP1 and ***AGP2*** .	target	0
19858	11027549	7124;6347	TNF-alpha;MCP-1	***TNF-alpha*** ***stimulation*** of ***MCP-1*** expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells .	positive	0
19859	11027549	207;7124	PKB;TNF-alpha	***TNF-alpha*** stimulation of MCP-1 expression is ***mediated*** by the ***Akt/PKB*** signal transduction pathway in vascular endothelial cells .	target	0
19860	11027549	7124;6347	TNF-alpha;MCP-1	Although TNF-alpha stimulates MCP-1 expression and secretion , the mechanism by which ***TNF-alpha*** ***stimulates*** expression of the ***MCP-1*** gene is not known .	positive	0
19861	11027549	7124;6347	TNF-alpha;MCP-1	These findings show that Akt/PKB participates in the ***TNF-alpha*** ***induction*** of ***MCP-1*** gene transcription in endothelial cells .	target	1
19862	11027561	7040;3458	TGFbeta;IFN-gamma	However , ***TGFbeta*** ( 1 ) , which has opposing actions to IFN-gamma on diverse cellular functions , was able to ***antagonize*** the effect of ***IFN-gamma*** .	negative	1
19863	11027571	7040;5925	Transforming growth factor beta (TGFbeta)1;pRB	***Transforming growth factor beta (TGFbeta)1*** ***induced*** dephosphorylation of ***pRB*** at multiple serine and threonine residues including Ser249/Thr252 , Thr373 , Ser780 , and Ser807/811 in MV4-11 cells .	target	1
19864	11027571	1869;1871	E2F-1;E2F-3	Phosphorylated pRB was detected to ***bind*** ***E2F-1*** and ***E2F-3*** , which appears to be a major form of pRB complexes in actively cycling cells .	parallel	1
19865	11027571	1871;1869	E2F-3;E2F-1	Phosphorylated pRB was detected to ***bind*** ***E2F-1*** and ***E2F-3*** , which appears to be a major form of pRB complexes in actively cycling cells .	parallel	1
19866	11027571	5925;1869	pRB;E2F-1	Phosphorylated ***pRB*** was detected to ***bind*** ***E2F-1*** and E2F-3 , which appears to be a major form of pRB complexes in actively cycling cells .	parallel	1
19867	11027571	5925;1871	pRB;E2F-3	Phosphorylated ***pRB*** was detected to ***bind*** E2F-1 and ***E2F-3*** , which appears to be a major form of pRB complexes in actively cycling cells .	parallel	1
19868	11027571	5925;1869	pRB;E2F-1	TGFbeta1 significantly downregulated ******pRB-E2F-1****** and pRB-E2F-3 ***complexes*** as a result of inhibition of E2F-1 and E2F-3 .	parallel	1
19869	11027571	5925;1871	pRB;E2F-3	TGFbeta1 significantly downregulated pRB-E2F-1 and ******pRB-E2F-3****** ***complexes*** as a result of inhibition of E2F-1 and E2F-3 .	parallel	1
19870	11027571	1874;5925	E2F-4;pRB	In contrast , ***complexes*** of ***E2F-4*** with ***pRB*** and with p130 were increased markedly upon TGFbeta1 treatment , whereas p107 associated E2F-4 was dramatically decreased .	parallel	1
19871	11027624	7980;5340	TFPI-2;plasmin	The refolded E. coli ***TFPI-2*** ***inhibited*** ***plasmin*** with an inhibition constant ( K ( i ) ) of 5 nM that is similar with the TFPI-2 expressed in a mammalian system .	negative	1
19872	11027624	7980;5340	TFPI-2;plasmin	The refolded E. coli ***TFPI-2*** bound heparin and also ***inhibited*** ***plasmin*** , regardless of whether the enzyme was in the fluid phase or was bound to the membranes of HT-1080 fibrosarcoma cells .	negative	1
19873	11027633	9021;3952	SOCS-3;Leptin	Since transgenic overexpression of ***SOCS-3*** in islets ***reduced*** the lipopenic effect of ***Leptin*** by 75 % , we conclude that the increased expression of SOCS-1 and -3 in WAT of rats with acquired obesity could have blocked Leptin 's lipopenic action in the Leptin-resistant WAT population .	negative	1
19874	11027634	2207;51206	Fc receptor gamma chain;GPVI	When COS-7 cells were cotransfected with the GPVI isoforms and Fc receptor gamma chain , ***Fc receptor gamma chain*** was ***associated*** with ***GPVI-1*** and -2 but did not affect the GPVI expression levels .	parallel	0
19875	11027635	6347;3553	Monocyte chemotactic protein 1;IL-1beta	***Monocyte chemotactic protein 1*** ***upregulates*** ***IL-1beta*** expression in human monocytes .	positive	1
19876	11027635	3553;6347	IL-1beta;MCP-1	Since ***IL-1beta*** is known to ***induce*** ***MCP-1*** synthesis , the present demonstration that MCP-1 induces IL-1beta synthesis suggests that the induction of each other would amplify the biological effects of these cytokines during inflammation .	target	1
19877	11027635	6347;3553	MCP-1;IL-1beta	Since IL-1beta is known to induce MCP-1 synthesis , the present demonstration that ***MCP-1*** ***induces*** ***IL-1beta*** synthesis suggests that the induction of each other would amplify the biological effects of these cytokines during inflammation .	target	1
19878	11027636	4323;4313	MT1-MMP;MMP-2	In addition , toxin B treatment induced expression and processing of ***MT1-MMP*** , a major ***activator*** of ***MMP-2*** .	positive	1
19879	11027648	1111;995	chk1;cdc25C	***chk1*** ***phosphorylates*** ***cdc25C*** on serine 216 and inactivates it whereas cdc25C dephosphorylates tyrosine 15 phosphate of cdc2 and activates the cdc2-cyclin B complex .	target	1
19880	11027663	2323;2549	Flt3 ligand;gab1	***Flt3 ligand*** ***induces*** tyrosine phosphorylation of ***gab1*** and gab2 and their association with shp-2 , grb2 , and PI3 kinase .	target	1
19881	11027663	2323;9846	Flt3 ligand;gab2	***Flt3 ligand*** ***induces*** tyrosine phosphorylation of gab1 and ***gab2*** and their association with shp-2 , grb2 , and PI3 kinase .	target	1
19882	11027676	7036;3077	transferrin receptor 2;HFE	Comparison of the ***interactions*** of transferrin receptor and ***transferrin receptor 2*** with transferrin and the hereditary hemochromatosis protein ***HFE*** .	parallel	1
19883	11027676	7037;3077	transferrin receptor;HFE	Comparison of the ***interactions*** of ***transferrin receptor*** and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein ***HFE*** .	parallel	1
19884	11027677	6670;6667	Sp3;Sp1	Gel shift analysis indicated enhanced ***binding*** of ***Sp3*** from MCF-7L cells to a consensus ***Sp1*** oligonucleotide .	parallel	1
19885	11027685	1535;27020	p22phox;gp65	Moreover , 7D5 precipitated precursor ******gp65-p22phox****** ***complexes*** from detergent extracts of the biosynthetically active gp91-PLB cells , demonstrating that complex carbohydrates were not required for epitope recognition .	parallel	1
19886	11027834	4352;7066	c-mpl;thrombopoietin	As underlying mechanisms , deregulated ***thrombopoietin*** ***receptor*** ( ***c-mpl*** ) - mediated signaling pathways have been suggested .	parallel	1
19887	11027947	3479;5140	IGF-1;PDE3B	Therefore , ***IGF-1-dependent*** ***regulation*** of ***PDE3B*** may be linked to cell survival through PI3K and not p42/p44 MAPK .	target	1
19888	11027947	3479;5140	IGF-1;PDE3B	We also demonstrated that insulin growth factor-1 ( ***IGF-1*** ) ***activates*** ***PDE3B*** in BRIN-BD11 cells .	positive	1
19889	11027947	3479;5140	IGF-1;PDE3B	We report here that the PI3K inhibitor , wortmannin , prevented the ***IGF-1-dependent*** ***stimulation*** of ***PDE3B*** activity .	positive	0
19890	11027947	3479;5706	IGF-1;p42	Furthermore , ***IGF-1-dependent*** ***stimulation*** of ***p42/p44*** MAPK and PDE3B was abolished in serum-deprived cells and this was associated with apoptosis .	positive	0
19891	11027947	3479;5140	IGF-1;PDE3B	Furthermore , ***IGF-1-dependent*** ***stimulation*** of p42/p44 MAPK and ***PDE3B*** was abolished in serum-deprived cells and this was associated with apoptosis .	positive	0
19892	11027948	3082;5595	hepatocyte growth factor;Erk1	Protein kinase C decreases the ***hepatocyte growth factor-induced*** ***activation*** of ***Erk1/Erk2*** MAP kinases .	positive	1
19893	11027948	3082;5594	hepatocyte growth factor;Erk2	Protein kinase C decreases the ***hepatocyte growth factor-induced*** ***activation*** of ***Erk1/Erk2*** MAP kinases .	positive	1
19894	11028544	3576;7124	IL-8;TNFalpha	Neutralization of ***IL-8*** ***inhibited*** the ability of ***TNFalpha*** to suppress apoptosis ( P < 0.05 ) .	negative	1
19895	11028544	7124;3576	TNFalpha;IL-8	To a lesser extent , incubation of ***TNFalpha*** with inhibitors to NF-kappaB ( SN50 ) and PI3K ( LY294002 ) also increased apoptosis and ***decreased*** ***IL-8*** production ( P < 0.05 ) .	negative	0
19896	11028545	7124;7185	TNFalpha;TRAF-1	These data demonstrate that ***inhibition*** of PMN apoptosis and ***TRAF-1*** induction by LPS and ***TNFalpha*** is NF-kappaB dependent .	negative	1
19897	11028545	7124;5970	TNFalpha;p65	Lipopolysaccharide ( LPS ) and ***TNFalpha*** ***increased*** PMN nuclear ***p65*** and steady state TRAF-1 mRNA .	positive	0
19898	11028545	7124;7185	TNFalpha;TRAF-1	Lipopolysaccharide ( LPS ) and ***TNFalpha*** ***increased*** PMN nuclear p65 and steady state ***TRAF-1*** mRNA .	positive	0
19899	11028653	7356;3458	CC10;IFN-gamma	***CC10*** ***inhibited*** , in part , ***IFN-gamma*** production from LPS-stimulated sarcoid BAL fluid cells ( CC10 inhibition : 1,000 ng x mL ( -1 ) , 30 % ; 100 ng x mL ( -1 ) , 14 % ) .	negative	1
19900	11028755	3439;3067	IFNalpha;HDC	RESULTS : Our data show that both ***IFNalpha*** and IFNgamma ***decreased*** the ***HDC*** mRNA and protein expression , though with dissimilar kinetics .	negative	0
19901	11028755	3458;3067	IFNgamma;HDC	RESULTS : Our data show that both IFNalpha and ***IFNgamma*** ***decreased*** the ***HDC*** mRNA and protein expression , though with dissimilar kinetics .	negative	0
19902	11028824	1392;6750	CRH;somatostatin	In addition to the stimulation of pituitary ACTH secretion , ***CRH*** ***activates*** ***somatostatin*** on the hypothalamic level , which in turn inhibits the release of GH and TSH on the hypophyseal level .	positive	1
19903	11029007	4040;7471	LRP6;Wnt-1	The extracellular domain of ***LRP6*** ***bound*** ***Wnt-1*** and associated with Fz in a Wnt-dependent manner .	parallel	1
19904	11029009	2099;5295	ER alpha;p85alpha	Here we show that the ER isoform , ***ER alpha*** , ***binds*** in a ligand-dependent manner to the ***p85alpha*** regulatory subunit of phosphatidylinositol-3-OH kinase ( PI ( 3 ) K ) .	parallel	1
19905	11029043	23165;23511	Nup205;Nup188	The ******Nup93-Nup188-Nup205****** ***complex*** does not bind directly to WGA but binds indirectly via the N-acetylglucosamine-modified nucleoporins .	parallel	1
19906	11029043	23165;9688	Nup205;Nup93	The ******Nup93-Nup188-Nup205****** ***complex*** does not bind directly to WGA but binds indirectly via the N-acetylglucosamine-modified nucleoporins .	parallel	1
19907	11029043	9688;23511	Nup93;Nup188	The ******Nup93-Nup188-Nup205****** ***complex*** does not bind directly to WGA but binds indirectly via the N-acetylglucosamine-modified nucleoporins .	parallel	1
19908	11029050	8773;7431	SNAP23;Vimentin	Here we show that ***SNAP23*** ***associates*** with ***Vimentin*** filaments in a Triton X-100 insoluble fraction in fibroblasts in primary culture and HeLa cells .	parallel	0
19909	11029309	7422;4082	VEGF;MARCKS	In contrast , ***VEGF*** ***stimulated*** ***MARCKS*** phosphorylation without alteration of protein expression during BPMEC proliferation , which may result in reduced interaction between MARCKS and actin or CaM , leading to actin reorganization and MLC phosphorylation .	positive	0
19910	11029344	3586;7076	IL-10;TIMP-1	***IL-10*** ***increased*** ***TIMP-1*** release without modifying that of MMP-9 , leading to a decrease in the MMP-9 to TIMP-1 ratio .	positive	0
19911	11029402	4313;796	matrix metalloproteinase-2;calcitonin	Vascular ***matrix metalloproteinase-2-dependent*** ***cleavage*** of ***calcitonin*** gene-related peptide promotes vasoconstriction .	target	1
19912	11029402	4313;796	MMP-2;CGRP	Inhibition of ***MMP-2*** ***increased*** the amount of intact ***CGRP*** in arteries and enhanced vasorelaxation induced by anandamide , which stimulates CGRP release .	negative	0
19913	11029403	2852;4846	Membrane estrogen receptor;endothelial nitric oxide synthase	***Membrane estrogen receptor*** engagement ***activates*** ***endothelial nitric oxide synthase*** via the PI3-kinase-Akt pathway in human endothelial cells .	positive	1
19914	11029408	5747;5594	FRNK;ERK1/2	Similarly , ***FRNK*** overexpression ***blocked*** Ang II-induced FAK phosphorylation and ***ERK1/2*** activation , but not p70 ( S6K ) phosphorylation , and markedly inhibited protein synthesis .	negative	0
19915	11029422	10111;4361	Rad50;Mre11	The core component involved in double-strand break repair in eukaryotic cells is the ******Mre11-Rad50****** protein ***complex*** , which includes a third protein , p95 , in humans and Xrs2 in yeasts .	parallel	1
19916	11029422	10111;4361	Rad50;Mre11	In eukaryotes the ******Mre11-Rad50****** ***complex*** has nuclease activity that is modulated by the addition of ATP .	parallel	1
19917	11029459	7040;1026	TGF-beta1;p21	Antisense oligonucleotides directed to Ki-ras decreased both TbetaRIII post-translational modification in Ki-ras ( G12V ) cells and ***TGF-beta1*** ***down-regulation*** of ***p21*** , demonstrating the direct effect of mutant Ras .	negative	1
19918	11029465	10096;10097	Arp3;Arp2	We propose that ActA and endogenous WASP family proteins promote Arp2/3-dependent nucleation by similar mechanisms and require simultaneous ***binding*** of ***Arp2*** and ***Arp3*** .	parallel	1
19919	11029466	3646;50813	eIF3e;CSN7	Arabidopsis ***eIF3e*** ( INT-6 ) ***associates*** with both eIF3c and the COP9 signalosome subunit ***CSN7*** .	parallel	0
19920	11029466	3646;8663	eIF3e;eIF3c	Arabidopsis ***eIF3e*** ( INT-6 ) ***associates*** with both ***eIF3c*** and the COP9 signalosome subunit CSN7 .	parallel	0
19921	11029467	116;4790	PACAP;NF-kappa B	The ***VIP/PACAP*** ***inhibition*** of ***NF-kappa B*** at various levels and through different transduction pathways could offer a significant advantage over other anti-inflammatory agents .	negative	1
19922	11029467	116;4790	PACAP;NF-kappa B	***VIP/PACAP*** ***inhibit*** ***NF-kappa B*** transactivation in the lipopolysaccharide-stimulated human monocytic cell line THP-1 at multiple levels .	negative	1
19923	11029467	116;4790	PACAP;NF-kappa B	First , ***VIP/PACAP*** ***inhibit*** p65 nuclear translocation and ***NF-kappa B*** DNA binding by stabilizing the inhibitor I kappa B alpha .	negative	1
19924	11029467	116;5970	PACAP;p65	First , ***VIP/PACAP*** ***inhibit*** ***p65*** nuclear translocation and NF-kappa B DNA binding by stabilizing the inhibitor I kappa B alpha .	negative	1
19925	11029467	116;1385	PACAP;CREB	Second , ***VIP/PACAP*** ***induce*** phosphorylation of the CRE-binding protein ( ***CREB*** ) and its binding to the CREB-binding protein ( CBP ) .	target	1
19926	11029467	5970;1387	p65;CBP	This results in a decrease in ******p65.CBP****** ***complexes*** , which further reduces NF-kappa B transactivation .	parallel	1
19927	11029467	116;6908	PACAP;TBP	Third , VIP and ***PACAP*** ***reduce*** the phosphorylation of the TATA box-binding protein ( ***TBP*** ) , resulting in a reduction in TBP binding to both p65 and the TATA box .	negative	1
19928	11029467	6908;5970	TBP;p65	Third , VIP and PACAP reduce the phosphorylation of the TATA box-binding protein ( TBP ) , resulting in a reduction in ***TBP*** ***binding*** to both ***p65*** and the TATA box .	parallel	1
19929	11029471	4342;5599	Mos;JNK	***JNK*** was ***activated*** by microinjection of ***Mos*** , by activation of an estrogen-inducible form of Raf , and by a constitutively active MEK-1 ( MEK R4F ) , indicating that the p42 MAPK cascade can trigger JNK activation .	positive	1
19930	11029496	3458;5175	interferon-gamma;PECAM-1	In vitro studies have suggested that ***interferon-gamma*** ( IFN-gamma ) may ***regulate*** ***PECAM-1*** expression on endothelial cells .	target	1
19931	11029551	7432;820	VIP;cAMP	In cultured RPE cells , ***VIP*** is the one most effective ***stimulator*** of the ***cAMP*** signaling pathway among a long list of neurotransmitters and modulators tested .	positive	0
19932	11029580	4314;5327	Matrix metalloproteinase-3;t-PA	***Matrix metalloproteinase-3*** ( MMP-3 or stromelysin-1 ) specifically ***binds*** to tissue-type plasminogen activator ( ***t-PA*** ) , without however , hydrolyzing the protein .	parallel	1
19933	11029614	4233;3082	c-Met;HGF	Here we show that ***c-Met*** , the ***receptor*** for ***HGF*** , is expressed in developing rat hippocampus , with the highest levels during the first postnatal weeks .	parallel	1
19934	11029631	2890;1739	GluR1;SAP97	Using highly specific new antibodies , we show that SAP97 in rat cerebral cortex is associated with heteromeric AMPA receptors via a selective biochemical ***interaction*** between ***SAP97*** and the ***GluR1*** subunit .	parallel	1
19935	11029666	5966;4790	Rel;NF-kappa B	Activity is inhibited by p50 , a mammalian ***Rel*** protein that competitively ***binds*** ***NF-kappa B*** sites , and virtually abolished by p40 , an avian I kappa B protein that inhibits nuclear translocation .	parallel	1
19936	11029753	551;1432	AVP;p38 MAP kinase	SB203580 inhibited the ***AVP-induced*** ***phosphorylation*** of ***p38 MAP kinase*** .	target	1
19937	11029753	7124;51477	Tumor necrosis factor-alpha;IPs	***Tumor necrosis factor-alpha*** ***enhanced*** the AVP-induced formation of ***IPs*** .	positive	0
19938	11029800	1890;596	Thymidine phosphorylase;Bcl-2	***Thymidine phosphorylase*** expression ***correlates*** with tumor differentiation and ***Bcl-2*** in invasive breast cancer .	parallel	0
19939	11030144	991;701	p55CDC;BUBR1	***p55CDC/hCDC20*** is ***associated*** with ***BUBR1*** and may be a downstream target of the spindle checkpoint kinase .	parallel	0
19940	11030144	991;701	p55CDC;BUBR1	Yeast two-hybrid system and GST-pulldown analyses show that ***p55CDC/hCDC20*** , a protein known to link spindle checkpoint components such as MAD2 to anaphase promoting complex ( APC ) , ***interacts*** with ***BUBR1*** .	parallel	1
19941	11030144	991;701	p55CDC;BUBR1	Moreover , immunoprecipitation followed by Western blot analyses confirmed that native ***p55CDC*** is ***associated*** with ***BUBR1*** in HeLa cells .	parallel	0
19942	11030144	701;991	BUBR1;p55CDC	Spindle checkpoint activation by nocodazole treatment enhances the ***association*** between ***p55CDC*** and ***His6-BUBR1*** .	parallel	0
19943	11030144	701;991	BUBR1;p55CDC	Furthermore , BUBR1 phosphorylates p55CDC in vitro , and the ***phosphorylation*** of ***p55CDC*** by ***BUBR1*** appears to be correlated with spindle checkpoint activation .	target	1
19944	11030144	701;991	BUBR1;p55CDC	Furthermore , ***BUBR1*** ***phosphorylates*** ***p55CDC*** in vitro , and the phosphorylation of p55CDC by BUBR1 appears to be correlated with spindle checkpoint activation .	target	1
19945	11030145	598;841	Bcl-x;Caspase-8	Overexpression of ***Bcl-x*** ( L ) ***prevented*** the processing of ***Caspase-8*** as well as caspase-9 , -6 and Bid in response to drugs , but was less effective in CD95-induced apoptosis .	negative	0
19946	11030145	598;842	Bcl-x;caspase-9	Overexpression of ***Bcl-x*** ( L ) ***prevented*** the processing of Caspase-8 as well as ***caspase-9*** , -6 and Bid in response to drugs , but was less effective in CD95-induced apoptosis .	negative	0
19947	11030153	10671;1017	p27;CDK2	Furthermore , we propose that the changes in binding of p18 and cyclin D3 to CDKs are due to changes at the protein expression level and that the increase in ***p27*** ***binding*** to ***CDK2*** is due to a novel mechanism .	parallel	1
19948	11030154	2919;22808	MGSA;M-Ras	Over-expression of ***MGSA/GRO*** ***upregulates*** ***M-Ras*** expression at both the mRNA and protein levels , and this induction requires an intact glutamine-leucine-arginine ( ELR ) - motif in the MGSA/GRO protein .	positive	1
19949	11030154	22808;2353	M-Ras;AP-1	The effects of MGSA/GRO on AP-1 activation could be mimicked by over-expression of wild-type M-Ras or a constitutively activated M-Ras mutant in control melan-a cells as monitored by an AP-1-luciferase reporter , while expression of a dominant negative ***M-Ras*** ***blocked*** ***AP-1-luciferase*** activity in MGSA/GRO-transformed melan-a clones .	negative	0
19950	11030155	6667;7046	Sp1;transforming growth factor-beta receptor type I	***Repression*** of ***transforming growth factor-beta receptor type I*** promoter expression by ***Sp1*** deficiency .	negative	1
19951	11030331	8431;2494	SHP;LRH-1	Elevated ***SHP*** protein then ***inactivates*** ***LRH-1*** by forming a heterodimeric complex that leads to promoter-specific repression of both CYP7A1 and SHP .	negative	1
19952	11030332	9971;8431	FXR;small heterodimer partner	We have used a potent , nonsteroidal FXR ligand to show that ***FXR*** ***induces*** expression of ***small heterodimer partner*** 1 ( SHP-1 ) , an atypical member of the nuclear receptor family that lacks a DNA-binding domain .	target	1
19953	11030332	2103;1581	orphan nuclear receptor;CYP7A1	SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 ( LRH-1 ) , an ***orphan nuclear receptor*** that is known to ***regulate*** ***CYP7A1*** expression positively .	positive	1
19954	11030332	8431;1581	SHP-1;CYP7A1	***SHP-1*** ***represses*** expression of ***CYP7A1*** by inhibiting the activity of liver receptor homolog 1 ( LRH-1 ) , an orphan nuclear receptor that is known to regulate CYP7A1 expression positively .	negative	1
19955	11030338	5888;546	Rad51;Rad54	Reciprocally , the ***Rad51-ssDNA*** filament ***enhances*** both the dsDNA-dependent ATPase and the dsDNA unwinding activities of ***Rad54*** .	positive	0
19956	11030349	9519;6908	TLF;TBP	Four models have been proposed for the role of TLF in RNA polymerase II ( Pol II ) transcription : ( 1 ) ***TLF*** and TBP function redundantly , ( 2 ) TLF ***antagonizes*** ***TBP*** , ( 3 ) TLF is a tissue-specific TBP , or ( 4 ) TLF and TBP have distinct activities .	negative	1
19957	11030373	7040;3383	TGF-beta;ICAM-1	***ICAM-1*** expression was significantly ***decreased*** by ***TGF-beta*** and IL-4 , unchanged by EGF , and significantly increased by IL-5 .	negative	0
19958	11030434	885;5594	CCK;ERK2	***CCK-8*** ***induced*** activation of ***ERK2*** which is associated with its phosphorylation and localization in the nucleus .	target	1
19959	11030627	2033;6760	p300;SYT	***p300*** ***interacts*** with the nuclear proto-oncoprotein ***SYT*** as part of the active control of cell adhesion .	parallel	1
19960	11030627	2033;6760	p300;SYT	The mechanism linking the action of ******SYT/p300****** ***complexes*** to adhesion function is , at least in part , transcription activation-independent and results in proper activation of beta1 integrin , a major adhesion receptor .	parallel	1
19961	11030716	5617;2834	prolactin;GPR10	Human ***prolactin-releasing*** peptide ( PrRP ) has been identified as an endogenous ***ligand*** for ***GPR10*** , and occurs as 31 and 20 amino acid forms .	parallel	1
19962	11030716	51052;2834	PrRP;GPR10	Human prolactin-releasing peptide ( ***PrRP*** ) has been identified as an endogenous ***ligand*** for ***GPR10*** , and occurs as 31 and 20 amino acid forms .	parallel	1
19963	11031113	1742;4842	PSD-95;nNOS	The flexibility of the NOS PDZ beta-finger is likely to play a critical role in supporting the formation of ******nNOS/PSD-95****** ***complex*** .	parallel	1
19964	11031226	335;5444	apo;PON1	The ***apo*** E deficiency was ***associated*** with a 1.6-fold ( P = 0.008 ) lower PAF-AH and a 2.0-fold ( P = 0.012 ) lower ***PON1*** activity .	parallel	0
19965	11031227	3949;4018	LDLR;lipoprotein	Familial hypercholesterolemia and familial ligand-defective apolipoprotein B-100 ( FDB ) are dominantly inherited disorders leading to impaired low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) and apolipoprotein B-100 ( APOB ) interaction , plasma LDL elevation , and hypercholesterolemia .	parallel	1
19966	11031258	3635;1399	SHIP1;CRKL	***SHIP1*** , an SH2 domain containing polyinositol-5-phosphatase , regulates migration through two critical tyrosine residues and forms a novel signaling ***complex*** with DOK1 and ***CRKL*** .	parallel	1
19967	11031258	3635;1796	SHIP1;DOK1	***SHIP1*** , an SH2 domain containing polyinositol-5-phosphatase , regulates migration through two critical tyrosine residues and forms a novel signaling ***complex*** with ***DOK1*** and CRKL .	parallel	1
19968	11031258	25;3635	BCR/ABL;SHIP1	The tyrosine kinase oncogene ***BCR/ABL*** drastically ***reduces*** expression of ***SHIP1*** .	negative	1
19969	11031258	1796;3635	DOK1;SHIP1	We found that ***DOK1*** ***binds*** directly through its PTB domain to ***SHIP1*** .	parallel	1
19970	11031258	3635;1399	SHIP1;CRKL	Direct ***interaction*** of ***SHIP1*** with ***CRKL*** was mediated through the CRKL-SH2 domain .	parallel	1
19971	11031321	3557;3552	IL-1Ra;interleukin-1 alpha	After a 22-h incubation , levels of ***interleukin-1 alpha*** ( IL-1alpha ) , its ***receptor*** antagonist ( ***IL-1Ra*** ) , soluble type II receptor ( sIL-1RII ) and prostaglandin-E ( 2 ) ( PGE ( 2 ) ) were determined .	parallel	1
19972	11031341	1956;4586	epidermal growth factor receptor;mucin	BACKGROUND : Because the ***epidermal growth factor receptor*** ( EGFR ) system ***regulates*** ***mucin*** production in airway epithelium , we hypothesized a role for this system in mucus hypersecretion that occurs in nasal polyposis .	target	1
19973	11032020	3727;4221	JunD;menin	In conclusion , a small N-terminal region of JunD mediates a key difference between JunD and c-jun , and a component of this difference is dependent on ***JunD*** ***binding*** to ***menin*** .	parallel	1
19974	11032020	4221;3727	menin;JunD	***menin*** , the product of the MEN1 tumor suppressor gene , ***binds*** to the AP1 transcription factor ***JunD*** and represses JunD transcriptional activity .	parallel	1
19975	11032020	4221;3727	menin;JunD	***menin*** , the product of the MEN1 tumor suppressor gene , binds to the AP1 transcription factor JunD and ***represses*** ***JunD*** transcriptional activity .	negative	1
19976	11032020	3727;4221	JunD;menin	Mouse ***JunD*** missense mutants P41A , G42R , G42E and P44A failed to ***bind*** ***menin*** and also escaped menin 's control over their transcriptional activity .	parallel	1
19977	11032021	1875;5933	E2F-4 and 5;p107	E2F-1-3 localize in the nucleus , and preferentially bind pRb , while ***E2F-4 and 5*** have no nuclear localization signal and preferentially ***bind*** ***p107/p130*** .	parallel	1
19978	11032021	1875;5934	E2F-4 and 5;p130	E2F-1-3 localize in the nucleus , and preferentially bind pRb , while ***E2F-4 and 5*** have no nuclear localization signal and preferentially ***bind*** ***p107/p130*** .	parallel	1
19979	11032021	1869;5925	E2F-1;pRb	***E2F-1-3*** localize in the nucleus , and preferentially ***bind*** ***pRb*** , while E2F-4 and 5 have no nuclear localization signal and preferentially bind p107/p130 .	parallel	1
19980	11032030	8651;6774	JAB;STAT3	In contrast , ***JAB*** could ***downregulate*** phosphorylation of STAT1 and ***STAT3*** induced by interferon gamma ( IFNgamma ) and interleukin-6 ( IL-6 ) plus soluble IL6 receptor ( sIL-6R ) , respectively .	negative	1
19981	11032244	3717;5781	JAK2;SHP2	The acute treatment with epinephrine showed no difference in insulin-induced JAK2 tyrosine phosphorylation or JAK2/STAT1 and ******JAK2/SHP2****** ***association*** in comparison with the control .	parallel	0
19982	11032244	3717;5781	JAK2;SHP2	In fasted rats the JAK2 protein concentration decreased , accompanied by a decrease in the stoichiometry of the phosphorylation to 70 % , an increase in association of JAK2/STAT1 to 160 % , and a decrease in ******JAK2/SHP2****** ***association*** to 85 % .	parallel	0
19983	11032244	3717;6772	JAK2;STAT1	In fasted rats the JAK2 protein concentration decreased , accompanied by a decrease in the stoichiometry of the phosphorylation to 70 % , an increase in ***association*** of ******JAK2/STAT1****** to 160 % , and a decrease in JAK2/SHP2 association to 85 % .	parallel	0
19984	11032244	3717;5781	JAK2;SHP2	In the dexamethasone-treated group , the JAK2 protein concentrations increased but the stoichiometry of its phosphorylation decreased to 20 % , whereas the JAK2/STAT1 and ******JAK2/SHP2****** ***associations*** changed by 70 % and 170 % , respectively .	parallel	0
19985	11032244	3717;5781	JAK2;SHP2	In fasting and dexamethasone-treated rats , therefore , insulin-induced JAK2 tyrosine phosphorylation decreases , and the JAK2 protein expression is differentially regulated such that the insulin-induced ***JAK2*** ***association*** with ***SHP2*** and STAT1 shows opposite interactions with the kinase .	parallel	0
19986	11032244	3717;6772	JAK2;STAT1	In fasting and dexamethasone-treated rats , therefore , insulin-induced JAK2 tyrosine phosphorylation decreases , and the JAK2 protein expression is differentially regulated such that the insulin-induced ***JAK2*** ***association*** with SHP2 and ***STAT1*** shows opposite interactions with the kinase .	parallel	0
19987	11032359	3553;2678	IL-1beta;GGT	***IL-1beta*** ***decreased*** both ***GGT*** activity and intracellular GSH content and increased apoE secretion , initiating astroglial response to injury .	negative	0
19988	11032391	4923;4922	NTSR1;neurotensin	***neurotensin*** and its high affinity ***receptor*** ( ***NTSR1*** ) localise within dopaminergic neurones in the mesocortical , mesolimbic and nigrostriatal systems and it is now clear that neurotensin can selectively modulate dopaminergic neurotransmission .	parallel	1
19989	11032391	4923;4922	NTSR1;neurotensin	In keeping with this hypothesis , an association has recently been reported between schizophrenia and the gene encoding the ***neurotensin*** high affinity ***receptor*** ( ***NTSR1*** ) .	parallel	1
19990	11032398	3439;10379	IFN-alpha;p48	IFN-gamma pretreatment enhanced the ***upregulation*** of ***p48*** levels by ***IFN-alpha*** .	positive	1
19991	11032416	7157;4193	p53;hdm2	Thermodynamics of ***p53*** ***binding*** to ***hdm2*** ( 1-126 ) : effects of phosphorylation and p53 peptide length .	parallel	1
19992	11032416	4193;7157	hdm2;p53	Fluorescence anisotropy was employed to measure directly the ***binding*** of ***hdm2*** ( 1-126 ) to a ***p53*** N-terminal peptide labeled with Oregon Green ( an analogue of fluorescein ) .	parallel	1
19993	11032416	7157;4193	p53;hdm2	Phosphorylation of Ser15 and Ser2O did not affect the ***binding*** of the ***p53*** peptide to ***hdm2*** .	parallel	1
19994	11032416	7157;4193	p53;hdm2	This suggests that phosphorylation of Thr18 could be a regulatory mechanism that disrupts the ******hdm2-p53****** ***complex*** , thus activating p53 in response to DNA damage .	parallel	1
19995	11032419	405;196	ARNT;AhR	Phosphorylation is known to regulate the transformation process of unliganded AhR into functionally active ******AhR/ARNT****** ***heterodimer*** that has high affinity for dioxin-responsive elements ( DRE ) and transactivation activity .	parallel	1
19996	11032419	405;196	ARNT;AhR	Here , we report that DRE binding activity of the AhR is regulated by phosphorylation on the ******AhR/ARNT****** ***complex*** itself .	parallel	1
19997	11032422	5741;1591	parathyroid hormone;1,25-dihydroxyvitamin D3-24-hydroxylase	***Regulation*** of the procine ***1,25-dihydroxyvitamin D3-24-hydroxylase*** ( CYP24 ) by 1,25-dihydroxyvitamin D3 and ***parathyroid hormone*** in AOK-B50 cells .	target	1
19998	11032671	51497;3458	Th1-like;IFN-gamma	Both mouse strains showed a ***Th1-like*** immune ***response*** , with high concentrations of ***IFN-gamma*** and minimal levels of IL-4 ; however , C57 mice differed from CBA mice in showing milder clinical signs and earlier resolution of infection .	parallel	0
19999	11032743	7040;1490	TGF-beta1;connective tissue growth factor	***connective tissue growth factor*** ( CTGF ) is ***up-regulated*** by ***TGF-beta1*** during wound healing .	positive	1
20000	11032748	598;581	Bcl-x;Bax	Bax/Bcl-x ( l ) coimmunoprecipitation by anti-Bax antibody showed reduced ******Bax/Bcl-x****** ( l ) ***interaction*** at the membrane at 72 h , but not at 24 or 48 h.	parallel	1
20001	11032749	8074;2251	FGF-23;FGF-6	Human ***FGF-23*** gene was localized on the chromosome 12p13 and found to be tandem ***linked*** ( within 5.5 kb ) to human ***FGF-6*** gene .	parallel	0
20002	11032752	28996;7132	HIPK2;TNF-R1	The serine/threonine kinase ***HIPK2*** ***interacts*** with TRADD , but not with CD95 or ***TNF-R1*** in 293T cells .	parallel	1
20003	11032752	28996;8717	HIPK2;TRADD	The serine/threonine kinase ***HIPK2*** ***interacts*** with ***TRADD*** , but not with CD95 or TNF-R1 in 293T cells .	parallel	1
20004	11032752	28996;8717	HIPK2;TRADD	Here we describe that ***HIPK2*** can also ***associate*** with ***TRADD*** , a protein that interacts with tumor necrosis factor receptor type 1 ( TNF-R1 ) .	parallel	0
20005	11032752	28996;8717	HIPK2;TRADD	Under the conditions where ******HIPK2/TRADD****** ***association*** was found , no direct interaction of HIPK2 with CD95 , TNF-R1 , FADD or caspase-8 could be detected .	parallel	0
20006	11032804	6500;9978	Skp1;Rbx1	Furthermore , recombinant Cul1-Roc1 / ******Rbx1-Skp1****** ***complexes*** can catalyse Skp2 ubiquitylation in vitro .	parallel	1
20007	11032808	367;6714	androgen receptor;Src	Treatment of human prostate carcinoma-derived LNCaP cells with androgen or oestradiol triggers simultaneous ***association*** of ***androgen receptor*** and oestradiol receptor beta with ***Src*** , activates the Src/Raf -1 / Erk-2 pathway and stimulates cell proliferation .	parallel	0
20008	11032808	6714;367	Src;androgen receptor	Hormone-stimulated ***Src*** ***interaction*** with the ***androgen receptor*** and oestradiol receptor alpha or beta is detected using glutathione S : - transferase fusion constructs .	parallel	1
20009	11032826	861;7040	AML1;transforming growth factor beta 1	***Inhibition*** of the ***transforming growth factor beta 1*** signaling pathway by the ***AML1/ETO*** leukemia-associated fusion protein .	negative	1
20010	11032826	862;7040	ETO;transforming growth factor beta 1	***Inhibition*** of the ***transforming growth factor beta 1*** signaling pathway by the ***AML1/ETO*** leukemia-associated fusion protein .	negative	1
20011	11032828	1874;7157	E2F4;p53	***p130/E2F4*** ***binds*** to and represses the cdc2 promoter in response to ***p53*** .	parallel	1
20012	11032828	1874;983	E2F4;cdc2	***p130/E2F4*** ***binds*** to and represses the ***cdc2*** promoter in response to p53 .	parallel	1
20013	11032828	1026;983	waf1;cdc2	R box-dependent repression requires p21/waf1 , and overexpression of ***p21/waf1*** also ***represses*** the ***cdc2*** promoter .	negative	1
20014	11032828	1874;983	E2F4;cdc2	These observations suggest that p53 represses the cdc2 promoter by inducing p21/waf1 , which inhibits cyclin-dependent kinase activity , enhancing the binding of p130 and ***E2F4*** , which together ***bind*** to and repress the ***cdc2*** promoter .	parallel	1
20015	11032828	7157;983	p53;cdc2	These observations suggest that ***p53*** ***represses*** the ***cdc2*** promoter by inducing p21/waf1 , which inhibits cyclin-dependent kinase activity , enhancing the binding of p130 and E2F4 , which together bind to and repress the cdc2 promoter .	negative	1
20016	11032833	3083;3082	HGF activator;hepatocyte growth factor	***Activation*** of ***hepatocyte growth factor*** ( HGF ) by endogenous ***HGF activator*** is required for metanephric kidney morphogenesis in vitro .	positive	1
20017	11032833	3082;4233	hepatocyte growth factor;c-Met	The ***interaction*** of ***hepatocyte growth factor*** ( HGF ) with ***c-Met*** has been implicated in morphogenesis of the kidney , lung , mammary gland , liver , placenta , and limb bud .	parallel	1
20018	11032842	836;3603	caspase-3;IL-16	These diverse functions are exclusively attributed to the secreted C-terminal peptide of 121 amino acids ( mature ***IL-16*** ) , which is ***cleaved*** from the precursor protein ( pro-IL-16 ) by ***caspase-3*** .	target	1
20019	11032857	5742;5743	COX1;COX2	The present studies were designed to examine the potential ***link*** between medullary ***COX1*** and ***COX2*** expression in hypertonic stress .	parallel	0
20020	11032879	6354;6347	MCP-3;MCP-1	Specifically , labeled ***MCP-1*** binding to isolated brain microvessels was ***inhibited*** by unlabeled MCP-1 and ***MCP-3*** , the latter another CCR2 ligand , but not by MIP-1alpha .	negative	1
20021	11032879	6354;6348	MCP-3;MIP-1alpha	Labeled ***MIP-1alpha*** binding was also ***antagonized*** by unlabeled ***MCP-3*** , which is also recognized by CCR1 , and MIP-1beta , which is a ligand for CCR5 .	negative	1
20022	11032879	6351;6348	MIP-1beta;MIP-1alpha	Labeled ***MIP-1alpha*** binding was also ***antagonized*** by unlabeled MCP-3 , which is also recognized by CCR1 , and ***MIP-1beta*** , which is a ligand for CCR5 .	negative	1
20023	11032891	3553;5594	IL-1beta;p38	***IL-1beta*** ***induces*** ***p38*** MAPK phosphorylation and activation of the nuclear factor-kappaB independently from each other .	target	1
20024	11032900	10681;8802	Gbeta5;Galpha	RGS7 and its binding partners Galpha and Gbeta5 are enriched in brain , but biochemical mechanisms governing ******RGS7/Galpha/Gbeta5****** ***interactions*** and membrane association are poorly defined .	parallel	1
20025	11032900	10681;6000	Gbeta5;RGS7	RGS7 and its binding partners Galpha and Gbeta5 are enriched in brain , but biochemical mechanisms governing ******RGS7/Galpha/Gbeta5****** ***interactions*** and membrane association are poorly defined .	parallel	1
20026	11032900	6000;8802	RGS7;Galpha	RGS7 and its binding partners Galpha and Gbeta5 are enriched in brain , but biochemical mechanisms governing ******RGS7/Galpha/Gbeta5****** ***interactions*** and membrane association are poorly defined .	parallel	1
20027	11032900	6000;8802	RGS7;Galpha	Both unmodified ( cytosolic ) and palmitoylated ( membrane-derived ) forms of RGS7 , when complexed with Gbeta5 , are equally effective stimulators of Galpha ( o ) GTPase activity , suggesting that palmitoylation does not prevent ******RGS7/Galpha****** ( o ) ***interactions*** .	parallel	1
20028	11032900	6000;8802	RGS7;Galpha	Both unmodified ( cytosolic ) and palmitoylated ( membrane-derived ) forms of ***RGS7*** , when complexed with Gbeta5 , are equally effective ***stimulators*** of ***Galpha*** ( o ) GTPase activity , suggesting that palmitoylation does not prevent RGS7/Galpha ( o ) interactions .	positive	0
20029	11032900	10681;8802	Gbeta5;Galpha	In contrast , the ***RGS7/Gbeta5*** complex selectively ***interacts*** with ***Galpha*** ( o ) only , suggesting that features outside the RGS domain and/or Gbeta5 association dictate RGS7-Galpha interactions .	parallel	1
20030	11032900	6000;8802	RGS7;Galpha	In contrast , the ***RGS7/Gbeta5*** complex selectively ***interacts*** with ***Galpha*** ( o ) only , suggesting that features outside the RGS domain and/or Gbeta5 association dictate RGS7-Galpha interactions .	parallel	1
20031	11032900	6000;10681	RGS7;Gbeta5	In contrast , the ******RGS7/Gbeta5****** ***complex*** selectively interacts with Galpha ( o ) only , suggesting that features outside the RGS domain and/or Gbeta5 association dictate RGS7-Galpha interactions .	parallel	1
20032	11032900	6000;8802	RGS7;Galpha	In contrast , the RGS7/Gbeta5 complex selectively interacts with Galpha ( o ) only , suggesting that features outside the RGS domain and/or Gbeta5 association dictate ******RGS7-Galpha****** ***interactions*** .	parallel	1
20033	11032905	4137;5524	tau;PP2A	We also show that ***tau*** protein can be specifically ***coimmunoprecipitated*** with endogenous ***PP2A*** from both rat brain and transfected cell extracts .	parallel	1
20034	11032905	4137;5524	tau;PP2A	We propose that altered protein-protein ***interactions*** between ***PP2A*** and ***tau*** may contribute to FTDP-17 pathogenesis .	parallel	1
20035	11032907	5327;351	tPA;Abeta	Moreover , the combined ***tPA*** and plgn treatment markedly ***inhibited*** ***Abeta*** accumulation .	negative	1
20036	11032985	5368;4987	nociceptin;opiate receptor like 1	The binding sites of ***nociceptin*** ( also named orphanin FQ ) , the endogenous ***ligand*** of ORL1 ( ***opiate receptor like 1*** ) , were localized in rat brain , using an autoradiographic procedure .	parallel	1
20037	11033056	7349;1392	UCN;CRF	Because of the higher relative affinity of UCN for the CRF ( 2 ) receptor and the corresponding neuroanatomical distribution of the highest density of UCN expression and innervation to brain regions preferentially expressing the CRF ( 2 ) receptor subtype , it has been hypothesized that ***UCN*** is the preferred endogenous ***ligand*** for the ***CRF*** ( 2 ) receptor .	parallel	1
20038	11033117	3479;5594	IGF-1;ERK 1/2	METHODS AND RESULTS : Incubation of rat VSMC with FCS , insulin or IGF-1 time-dependently stimulated the phosphorylation of Akt , however FCS but not insulin or ***IGF-1*** ***activated*** the MAP-kinase ***ERK 1/2*** .	positive	1
20039	11033420	4790;5970	p50;p65	PMA-primed neutrophils resulted in the activation of two species of NF-kappaB dimers ( a ******p50/p65****** ***heterodimer*** and a p50 homodimer ) in acinar cells .	parallel	1
20040	11033437	10268;799	RAMP3;calcitonin receptor	The finding suggests that ***RAMP3*** might ***modify*** the active states of ***calcitonin receptor*** in such a way as to create a new receptor phenotype that is " amylin-like . "	target	0
20041	11033441	5741;632	PTH;osteocalcin	Weekly evaluations of serum osteocalcin levels demonstrated that daily injections of ***PTH*** ( 1-34 ) and PTH ( 1-31 ) at 80 microg/kg body weight ***increased*** serum ***osteocalcin*** levels within 1 week of the start of treatment , which were maintained during the entire 22 week treatment .	positive	0
20042	11033442	650;760	BMP-2;carbonic anhydrase II	Just as it increased bone resorption , ***BMP-2*** also ***elevated*** the messenger RNA expressions of cathepsin K and ***carbonic anhydrase II*** , which are key enzymes for the degradation of organic and inorganic bone matrices , respectively .	positive	0
20043	11033442	650;1513	BMP-2;cathepsin K	Just as it increased bone resorption , ***BMP-2*** also ***elevated*** the messenger RNA expressions of ***cathepsin K*** and carbonic anhydrase II , which are key enzymes for the degradation of organic and inorganic bone matrices , respectively .	positive	0
20044	11033842	7421;5741	VDR;PTH	CONCLUSION : From these results , we speculate that although the ***VDR*** gene polymorphism may ***affect*** the serum ***PTH*** level , it is not a risk factor for hypercalcemia in sarcoidosis .	target	0
20045	11034077	207;1026	AKT;p21	These data indicate that the ***PI3K/AKT*** signal transduction pathway ***mediates*** ***p21*** expression and suggest that this pathway contributes to cell cycle regulation promoted by p53 in response to drug-induced stress .	target	0
20046	11034077	5294;1026	PI3K;p21	These data indicate that the ***PI3K/AKT*** signal transduction pathway ***mediates*** ***p21*** expression and suggest that this pathway contributes to cell cycle regulation promoted by p53 in response to drug-induced stress .	target	0
20047	11034077	207;5294	AKT;PI3K	However , inactivation of ******PI3K/AKT****** ***signaling*** did not result in significant alteration of the drug sensitivity of A2780 cells , suggesting that the cell death induced by cisplatin or paclitaxel proceeds independently of cell protective effects of PI3K and AKT .	parallel	0
20048	11034081	80781;4313	Endostatin;MMP-2	Furthermore , enzymatic assays using a peptide substrate demonstrated that ***Endostatin*** ***inhibited*** the catalytic activities of both ***MMP-2*** and membrane-type 1 MMP .	negative	1
20049	11034120	3557;3553	IL-1ra;IL-1beta	BACKGROUND/AIMS : This study aimed to investigate the cytokine ***IL-1beta*** and its ***receptor*** antagonist ***IL-1ra*** in gingival crevicular fluid ( GCF ) , in patients with adult periodontitis .	parallel	1
20050	11034215	1029;7157	p14ARF;p53	The p53-dependent pathway involves the induction by E2F-1 of the human tumour-suppressor protein ***p14ARF*** , which neutralizes HDM2 ( human homologue of MDM2 ) and thereby ***stabilizes*** the ***p53*** protein .	positive	0
20051	11034215	1869;7161	E2F-1;p73	Here we show that ***E2F-1*** ***induces*** the transcription of the p53 homologue ***p73*** .	target	1
20052	11034310	1435;5594	M-CSF;ERK	We found that ***M-CSF*** ***induced*** late and massive phosphorylation of ***ERK*** molecules in Mona-expressing myeloid cells compared to non-expressing cells .	target	1
20053	11034310	9402;1435	Mona;M-CSF	These results suggest that ***Mona*** expression might ***modify*** ***M-CSF*** signaling during monocytic differentiation .	target	0
20054	11034314	3586;6772	IL-10;STAT1	***IL-10*** ***attenuates*** IFN-alpha-activated ***STAT1*** in the liver : involvement of SOCS2 and SOCS3 .	negative	0
20055	11034314	3588;3586	IL-10R2;IL-10	Reverse transcriptase-polymerase chain reaction assay demonstrated that mouse liver expressed high levels of ***IL-10*** ***receptor*** 2 ( ***IL-10R2*** ) but low levels of IL-10R1 .	parallel	1
20056	11034314	3586;6772	IL-10;STAT1	These findings suggest that ***IL-10*** ***inhibits*** IFN-alpha-activated ***STAT1*** in the liver , at least in part , by inducing SOCS2 , SOCS3 , and CIS expression , which may be responsible for the resistance of IFN-alpha therapy in patients who have high levels of IL-10 and recommends that IL-10 treatment for viral hepatitis should be cautious .	negative	1
20057	11034315	9992;3785	KCNE2;KCNQ2	M-type ***KCNQ2-KCNQ3*** potassium channels are ***modulated*** by the ***KCNE2*** subunit .	target	0
20058	11034315	9992;3786	KCNE2;KCNQ3	M-type ***KCNQ2-KCNQ3*** potassium channels are ***modulated*** by the ***KCNE2*** subunit .	target	0
20059	11034315	9992;3785	KCNE2;KCNQ2	We demonstrate that ***KCNE2*** ***associates*** with ***KCNQ2*** and/or KCNQ3 subunits .	parallel	0
20060	11034315	9992;3786	KCNE2;KCNQ3	We demonstrate that ***KCNE2*** ***associates*** with KCNQ2 and/or ***KCNQ3*** subunits .	parallel	0
20061	11034315	3785;3786	KCNQ2;KCNQ3	In transiently transfected COS cells , KCNE2 expression produces an acceleration of deactivation kinetics of KCNQ2 and of the ******KCNQ2-KCNQ3****** ***complex*** .	parallel	1
20062	11034352	7099;929	TLR4;CD14	Using fluorescence resonance energy transfer ( RET ) techniques , we demonstrate that LPS triggers a physical ***association*** between ***CD14*** and ***TLR4*** .	parallel	0
20063	11034352	7099;929	TLR4;CD14	Therefore , we suggest that a close ***interaction*** between ***CD14*** and ***TLR4*** participates in LPS signaling , leading to nuclear translocation of NF-kappaB .	parallel	1
20064	11034363	959;958	CD40L;CD40	This indicated that direct ***interaction*** of ******CD40/CD40L****** between APCs and CD8 cells may be an accessory signal in CTL induction ( as well as the indirect pathway via APC/CD4 interaction ) .	parallel	1
20065	11034365	3586;3552	IL-10;IL-1alpha	***IL-10*** also ***suppressed*** ***IL-1alpha*** production by macrophages in a dose-dependent fashion in vitro , whereas IL-4 had weak and variable effects .	negative	1
20066	11034377	3956;919	Galectin-1;TCR zeta-chain	***Galectin-1*** ***induces*** partial ***TCR zeta-chain*** phosphorylation and antagonizes processive TCR signal transduction .	target	1
20067	11034388	3937;7409	SLP-76;Vav-1	Together , these data suggest that CD28 engagement activates Vav-1 to boost TCR signals through a synergistic ***cooperation*** between ***Vav-1*** and ***SLP-76*** and probably via cortical actin changes to facilitate the organization of a signaling zone .	parallel	0
20068	11034388	940;7409	CD28;Vav-1	Together , these data suggest that ***CD28*** engagement ***activates*** ***Vav-1*** to boost TCR signals through a synergistic cooperation between Vav-1 and SLP-76 and probably via cortical actin changes to facilitate the organization of a signaling zone .	positive	1
20069	11034397	3565;6778	IL-4;STAT6	***IL-4*** treatment ***induced*** binding of ***STAT6*** to the intronic STAT6 site , but cooperation with nearby upstream and downstream DNA elements was required for IL-4 responsiveness .	target	1
20070	11034398	7124;3458	TNF-alpha;IFN-gamma	The present study investigates the regulatory mechanisms involved in the ***cooperation*** between ***IFN-gamma*** and ***TNF-alpha*** to promote transcription from IFN regulatory factor-1 ( IRF-1 ) .	parallel	0
20071	11034404	3553;3439	IL-1 beta;IFN-alpha	***IL-1 beta*** ***attenuates*** ***IFN-alpha*** beta-induced antiviral activity and STAT1 activation in the liver : involvement of proteasome-dependent pathway .	negative	0
20072	11034404	3553;6772	IL-1 beta;STAT1	***IL-1 beta*** ***attenuates*** IFN-alpha beta-induced antiviral activity and ***STAT1*** activation in the liver : involvement of proteasome-dependent pathway .	negative	0
20073	11034404	3553;6772	IL-1beta;STAT1	Furthermore , ***IL-1beta*** ***attenuated*** IFN-alphabeta-induced ***STAT1*** binding and tyrosine phosphorylation without affecting the level of STAT1 protein .	negative	0
20074	11034404	3553;6772	IL-1beta;STAT1	Taken together , these findings suggest that ***IL-1beta*** ***attenuates*** IFN-alphabeta-induced ***STAT1*** activation by a proteasome-dependent mechanism .	negative	0
20075	11034410	4179;718	MCP;C3b	Thus , the activities of DAF and MCP , when present together , are greater than the sum of the two proteins individually , and DAF is required for ***MCP*** to ***catalyze*** the cleavage of cell-bound ***C3b*** in the presence of excess factors B and D.	positive	1
20076	11034546	2247;2353	bFGF;c-fos	Both ***bFGF*** and TGFalpha ***induced*** the expression of the early response gene ***c-fos*** while not altering the expression of c-actin or c-myc .	target	1
20077	11034546	7039;2353	TGFalpha;c-fos	Both bFGF and ***TGFalpha*** ***induced*** the expression of the early response gene ***c-fos*** while not altering the expression of c-actin or c-myc .	target	1
20078	11034563	100507436;4277	MICA;MICB	Conversely , the remaining three possessed an intact ***MICA*** gene of MICA008 or MICA010 allelic variant ***associated*** this time with a putative expressed ***MICB*** allele , MICB0102 .	parallel	0
20079	11034601	958;960	CD40;CD44	Our results demonstrate that the BCR and ***CD40*** ***control*** the expression of HSPGs , specifically ***CD44-HS*** .	target	0
20080	11034602	3565;8660	IL-4;insulin receptor substrate 2	It was found that ***IL-4-induced*** ***phosphorylation*** of Janus kinases 1 and 3 , IL-4R alpha , signal transducer and activator of transcription 6 , and ***insulin receptor substrate 2*** was strikingly but transiently inhibited by TCR ligation both in conventional and TCR transgenic T cells .	target	1
20081	11034602	3565;6778	IL-4;signal transducer and activator of transcription 6	It was found that ***IL-4-induced*** ***phosphorylation*** of Janus kinases 1 and 3 , IL-4R alpha , ***signal transducer and activator of transcription 6*** , and insulin receptor substrate 2 was strikingly but transiently inhibited by TCR ligation both in conventional and TCR transgenic T cells .	target	1
20082	11034606	1616;355	Daxx;Fas	Fas-associated death domain ( FADD ) , which couples Fas to procaspase-8 , and ***Daxx*** , which couples Fas to the Jun NH ( 2 ) - terminal kinase pathway , ***bind*** independently to the ***Fas*** death domain .	parallel	1
20083	11034606	8772;355	FADD;Fas	Fas-associated death domain ( ***FADD*** ) , which couples Fas to procaspase-8 , and Daxx , which couples Fas to the Jun NH ( 2 ) - terminal kinase pathway , ***bind*** independently to the ***Fas*** death domain .	parallel	1
20084	11034606	10114;10114	FIST;HIPK3	In transfected cell lines , FIST/HIPK3 causes FADD phosphorylation , thereby promoting ******FIST/HIPK3-GeneGene****** 2-Fas ***interaction*** .	parallel	1
20085	11034899	26993;7112	HA95;LAP2	Cross-linking experiments , however , illustrate a tight ***association*** of ***HA95*** with LBR and ***LAP2*** only .	parallel	0
20086	11034899	26993;3930	HA95;LBR	Cross-linking experiments , however , illustrate a tight ***association*** of ***HA95*** with ***LBR*** and LAP2 only .	parallel	0
20087	11034993	7124;3383	TNFalpha;ICAM-1	Although the TNFalpha response element is sufficient for ***TNFalpha*** ***induction*** of the ***ICAM-1*** promoter , LMP1 also required the cooperation of additional upstream sequences for optimal induction .	target	1
20088	11035001	387;6722	RhoA;SRF	We and others have shown that serum response factor ( SRF ) contributes to SMC-specific gene transcription , and because the small GTPase ***RhoA*** has been shown to ***regulate*** ***SRF*** , the goal of the present study was to test the hypothesis that RhoA signaling is a critical mechanism for regulating SMC differentiation .	target	1
20089	11035005	7082;2697	ZO-1;connexin-43	c-Src regulates the ***interaction*** between ***connexin-43*** and ***ZO-1*** in cardiac myocytes .	parallel	1
20090	11035005	7082;2697	ZO-1;connexin-43	In cardiac myocytes , constitutively active c-Src inhibited endogenous ***interaction*** between ***connexin-43*** and ***ZO-1*** by binding to connexin-43 .	parallel	1
20091	11035005	2697;7082	connexin-43;ZO-1	In HEK293 cells , by contrast , a ***connexin-43*** mutant lacking the Src phosphorylation site ( Tyr265 ) ***interacted*** with ***ZO-1*** despite cotransfection of a constitutively active c-Src .	parallel	1
20092	11035005	6714;2697	c-Src;connexin-43	Cell surface biotinylation revealed that , by phosphorylating Tyr265 , constitutively active ***c-Src*** ***reduces*** total and cell surface ***connexin-43*** down to the levels seen in cells expressing a mutant connexin-43 lacking the ZO-1 binding domain .	negative	1
20093	11035005	7082;2697	ZO-1;connexin-43	We therefore conclude that c-Src regulates the ***interaction*** between ***connexin-43*** and ***ZO-1*** through tyrosine phosphorylation and through the binding of its SH2 domain to connexin-43 .	parallel	1
20094	11035013	4018;948	lipoprotein;Cd36	Upon incubation at 37 degrees C , ( 125 ) I-AGE-bovine serum albumin ( AGE-BSA ) and ( 125 ) I-oxidized low density ***lipoprotein*** ( LDL ) , an authentic ***ligand*** for ***Cd36*** , were endocytosed in a dose-dependent fashion and underwent lysosomal degradation by Cd36-CHO cells , but not wild-type CHO cells .	parallel	1
20095	11035016	10435;998	CEP2;Cdc42	Experimentally , we have verified that ***CEP2*** and CEP5 ***bind*** ***Cdc42*** .	parallel	1
20096	11035016	148170;998	CEP5;Cdc42	Experimentally , we have verified that CEP2 and ***CEP5*** ***bind*** ***Cdc42*** .	parallel	1
20097	11035023	860;3280	RUNX2;Hes1	In contrast , the Runt-related protein ***RUNX2*** , which localizes to the nuclear matrix and ***interacts*** with Groucho and ***Hes1*** , can inhibit both the Groucho.Hes1 interaction and the transcription repression ability of Hes1 .	parallel	1
20098	11035023	860;3280	RUNX2;Hes1	In contrast , the Runt-related protein ***RUNX2*** , which localizes to the nuclear matrix and interacts with Groucho and Hes1 , can ***inhibit*** both the ***Groucho.Hes1*** interaction and the transcription repression ability of Hes1 .	negative	1
20099	11035026	9554;9570	sec22b;membrin	Interestingly , although ***sec22b*** ***binds*** to the combination of syntaxin 5 , ***membrin*** , and rbet1 , it can only bind if it is present while the others assemble ; sec22b can not bind to a pre-assembled ternary complex of syntaxin 5 , membrin , and rbet1 .	parallel	1
20100	11035026	9554;6811	sec22b;syntaxin 5	Interestingly , although ***sec22b*** ***binds*** to the combination of ***syntaxin 5*** , membrin , and rbet1 , it can only bind if it is present while the others assemble ; sec22b can not bind to a pre-assembled ternary complex of syntaxin 5 , membrin , and rbet1 .	parallel	1
20101	11035026	9570;6811	membrin;syntaxin 5	Interestingly , although sec22b binds to the combination of syntaxin 5 , membrin , and rbet1 , it can only bind if it is present while the others assemble ; sec22b can not bind to a pre-assembled ternary ***complex*** of ***syntaxin 5*** , ***membrin*** , and rbet1 .	parallel	1
20102	11035035	51022;4790	Grx2;NF-kappaB	Although DA significantly reduced NF-kappaB binding activity , ***Grx2*** could ***stimulate*** the binding of ***NF-kappaB*** to DNA by : ( i ) translocating NF-kappaB from the cytoplasm to the nucleus after promoting the phosphorylation and degradation of I-kappaBalpha , and ( ii ) activating the binding of pre existing nuclear NF-kappaB .	positive	0
20103	11035039	10913;1896	ectodermal dysplasia receptor;ectodysplasin A	The ***ectodermal dysplasia receptor*** activates the nuclear factor-kappaB , JNK , and cell death pathways and ***binds*** to ***ectodysplasin A*** .	parallel	1
20104	11035039	10913;5599	ectodermal dysplasia receptor;JNK	The ***ectodermal dysplasia receptor*** ***activates*** the nuclear factor-kappaB , ***JNK*** , and cell death pathways and binds to ectodysplasin A .	positive	1
20105	11035039	1896;10913	ectodysplasin A;EDAR	Finally , ***ectodysplasin A*** can physically ***interact*** with the extracellular domain of ***EDAR*** and thus represents its biological ligand .	parallel	1
20106	11035041	4193;7157	MDM2;p53	Elevated amounts of the ******p53-MDM2****** ***complex*** and low amounts of Rb-MDM-2 complex were observed in Egr-1 ( - / - ) cells after radiation .	parallel	1
20107	11035041	4193;7157	MDM2;p53	Because of a reduction in Rb binding to MDM2 and an increase in MDM2 binding with p53 , ***p53*** is directly ***degraded*** by ***MDM2*** , and this leads to inactivation of the p53-mediated apoptotic pathway in Egr-1 ( - / - ) MEF cells .	negative	0
20108	11035045	1457;5728	protein kinase CK2;PTEN	The tumor suppressor ***PTEN*** is ***phosphorylated*** by the ***protein kinase CK2*** at its C terminus .	target	1
20109	11035070	959;3586	CD40 ligand;IL-10	In vitro stimulation by Staphylococcus aureus Cowan 1 strain or ***CD40 ligand*** ***associated*** with ***IL-10*** and IL-2 induces a rapid decrease in p27 ( Kip1 ) expression combined with cell cycle entry and progression .	parallel	0
20110	11035070	959;3558	CD40 ligand;IL-2	In vitro stimulation by Staphylococcus aureus Cowan 1 strain or ***CD40 ligand*** ***associated*** with IL-10 and ***IL-2*** induces a rapid decrease in p27 ( Kip1 ) expression combined with cell cycle entry and progression .	parallel	0
20111	11035073	356;355	Fas ligand;Fas	******Fas/Fas ligand****** ***interactions*** promote activation-induced cell death of NK T lymphocytes .	parallel	1
20112	11035074	7852;6387	CXCR4;SDF-1	As SDF-1alpha expression by RPE cells was detected constitutively , we postulate that ******SDF-1-CXCR4****** ***interactions*** may modulate the affects of chronic inflammation and subretinal neovascularization at the RPE site of the blood-retina barrier .	parallel	1
20113	11035093	5199;718	properdin;C3b	The envelope surface glycoprotein C ( gC ) of HSV-1 interferes with the complement cascade by binding C3 and activation products C3b , iC3b , and C3c , and by blocking the ***interaction*** of C5 and ***properdin*** with ***C3b*** .	parallel	1
20114	11035101	4790;1051	P50;C/EBPbeta	These findings suggest that IL-1beta induces nuclear translocation of P50-containing dimers and that ***P50*** ***interacts*** with ***C/EBPbeta*** activated by both IL-6 and IL-1beta to induce CRP expression .	parallel	1
20115	11035101	4790;1401	P50;CRP	These findings suggest that IL-1beta induces nuclear translocation of P50-containing dimers and that ***P50*** interacts with C/EBPbeta activated by both IL-6 and IL-1beta to ***induce*** ***CRP*** expression .	target	1
20116	11035101	4790;1401	P50;C-reactive protein	The Rel family member ***P50*** ***mediates*** cytokine-induced ***C-reactive protein*** expression by a novel mechanism .	target	0
20117	11035101	3569;1401	IL-6;C-reactive protein	Transcription of ***C-reactive protein*** ( CRP ) in Hep 3B cells is ***induced*** by ***IL-6*** , acting through C/EBP isoforms and STAT3 .	target	1
20118	11035101	3553;4790	IL-1beta;NF-kappaB	Because ***IL-1beta*** ***activates*** the ***NF-kappaB*** system , we explored the effects of overexpressed Rel family members on CRP expression .	positive	1
20119	11035101	4790;1401	P50;CRP	In contrast , overexpressed p65 abolished ***CRP*** ***induction*** by ***P50*** and by cytokines .	target	1
20120	11035101	5970;1401	p65;CRP	In contrast , overexpressed ***p65*** ***abolished*** ***CRP*** induction by P50 and by cytokines .	negative	0
20121	11035106	5609;5594	MEK;ERK	Kinase activity assays showed that LPS activates PKC zeta , mitogen-activated protein/ERK kinase ( ***MEK*** , the upstream ***activator*** of ***ERK*** ) , and ERK .	positive	1
20122	11035108	3606;3383	IL-18;ICAM-1	These studies demonstrate that even in the absence of IL-12 , ***IL-18*** can induce in vivo DTH responses and ***up-regulate*** ***ICAM-1*** without inducing IFN-gamma , GM-CSF , or TNF-alpha production .	positive	1
20123	11035113	10544;5657	EPCR;proteinase-3	Using affinity chromatography , binding studies with purified components , and/or blockade with specific Abs , it was found that soluble ***EPCR*** ***binds*** to ***proteinase-3*** ( PR3 ) , a neutrophil granule proteinase .	parallel	1
20124	11035116	3606;3558	IL-18;IL-2	Addition of ***IL-18*** to normal ELF also ***induced*** ***IL-2*** mRNA accumulation , whereas correspondent depletion of IL-18 from sarcoid ELF using neutralizing Abs abrogated all of the effects .	target	1
20125	11035254	4780;3725	Nrf2;c-Jun	***Nrf2*** in the nucleus ***heterodimerizes*** with ***c-Jun*** and binds to the ARE resulting in the induction of NQO1 and other ARE-regulated genes expression .	parallel	1
20126	11035713	113246;7124	C10;TNF-alpha	In vitro studies showed that the combination of IL-1beta and ***C10*** markedly ***augmented*** ***TNF-alpha*** synthesis by peritoneal macrophages and that C10 synthesis was induced in these cells following their exposure to IL-13 .	positive	0
20127	11035713	3553;7124	IL-1beta;TNF-alpha	In vitro studies showed that the combination of ***IL-1beta*** and C10 markedly ***augmented*** ***TNF-alpha*** synthesis by peritoneal macrophages and that C10 synthesis was induced in these cells following their exposure to IL-13 .	positive	0
20128	11035727	7124;4843	TNF-alpha;iNOS	LPS and ***TNF-alpha*** exclusively ***modulated*** the activity of ***iNOS*** once its expression was triggered by IFN-gamma .	target	0
20129	11035755	5829;5747	paxillin;FAK	E. coli induced tyrosine phosphorylation of HBMEC cytoskeletal proteins , focal adhesion kinase ( FAK ) , and paxillin , with a concomitant increase in the ***association*** of ***paxillin*** with ***FAK*** .	parallel	0
20130	11035789	3479;1499	Insulin-like growth factor 1;beta-catenin	***Insulin-like growth factor 1*** ***regulates*** the location , stability , and transcriptional activity of ***beta-catenin*** .	target	1
20131	11035789	1499;999	beta-catenin;E-cadherin	IGFs can enhance cell migration , which is known to be influenced via regulation of the ******E-cadherin/beta-catenin****** ***complex*** .	parallel	1
20132	11035789	3479;1499	IGF-1;beta-catenin	We found that ***IGF-1*** stimulation ***enhanced*** tyrosine phosphorylation of two proteins , ***beta-catenin*** and insulin-receptor substrate 1 , which formed a complex with E-cadherin .	positive	0
20133	11035789	3479;3667	IGF-1;insulin-receptor substrate 1	We found that ***IGF-1*** stimulation ***enhanced*** tyrosine phosphorylation of two proteins , beta-catenin and ***insulin-receptor substrate 1*** , which formed a complex with E-cadherin .	positive	0
20134	11035789	1499;999	beta-catenin;E-cadherin	We found that IGF-1 stimulation enhanced tyrosine phosphorylation of two proteins , ***beta-catenin*** and insulin-receptor substrate 1 , which formed a ***complex*** with ***E-cadherin*** .	parallel	1
20135	11035789	3667;999	insulin-receptor substrate 1;E-cadherin	We found that IGF-1 stimulation enhanced tyrosine phosphorylation of two proteins , beta-catenin and ***insulin-receptor substrate 1*** , which formed a ***complex*** with ***E-cadherin*** .	parallel	1
20136	11035797	9451;595	PERK;cyclin D1	Overexpression of wild-type ***PERK*** ***inhibited*** ***cyclin D1*** synthesis in the absence of ER stress , thereby inducing a G ( 1 ) phase arrest .	negative	1
20137	11035811	317;842	Apaf-1;caspase 9	In the apoptosis pathway in mammals , cytochrome c and dATP are critical cofactors in the ***activation*** of ***caspase 9*** by ***Apaf-1*** .	positive	1
20138	11035813	5364;207	plexin-B1;Rac	The semaphorin receptor ***plexin-B1*** specifically ***interacts*** with active ***Rac*** in a ligand-dependent manner .	parallel	1
20139	11035813	207;5364	Rac;plexin-B1	We have demonstrated a direct ***interaction*** between ***plexin-B1*** and activated ***Rac*** .	parallel	1
20140	11035813	207;5364	Rac;plexin-B1	***Rac*** specifically ***interacts*** with the cytosolic domain of ***plexin-B1*** , but not with that of plexin-A3 or - C1 .	parallel	1
20141	11035813	998;5364	Cdc42;plexin-B1	Neither RhoA nor ***Cdc42*** ***interacts*** with ***plexin-B1*** , indicating that the Rac/plexin-B1 interaction is highly specific .	parallel	1
20142	11035813	387;5364	RhoA;plexin-B1	Neither ***RhoA*** nor Cdc42 ***interacts*** with ***plexin-B1*** , indicating that the Rac/plexin-B1 interaction is highly specific .	parallel	1
20143	11035813	207;5364	Rac;plexin-B1	Neither RhoA nor Cdc42 interacts with plexin-B1 , indicating that the ******Rac/plexin-B1****** ***interaction*** is highly specific .	parallel	1
20144	11035813	207;998	Rac;Cdc42	Furthermore , we have identified that a ******Cdc42/Rac****** interactive ***binding*** ( CRIB ) motif in the cytosolic domain of plexin-B1 is essential for its interaction with active Rac .	parallel	1
20145	11035813	10507;5364	CD100;plexin-B1	We have also observed that the semaphorin ***CD100*** , a ***ligand*** for ***plexin-B1*** , stimulates the interaction between plexin-B1 and active Rac .	parallel	1
20146	11035813	207;5364	Rac;plexin-B1	We have also observed that the semaphorin CD100 , a ligand for plexin-B1 , stimulates the ***interaction*** between ***plexin-B1*** and active ***Rac*** .	parallel	1
20147	11035932	634;5829	CEACAM1;paxillin	Cell adhesion molecule ***CEACAM1*** ***associates*** with ***paxillin*** in granulocytes and epithelial and endothelial cells .	parallel	0
20148	11035932	5829;634	paxillin;CEACAM1	******CEACAM1-paxillin****** ***complexes*** were coimmunoprecipitated from extracts of granulocytes , the colonic cell line HT29 , and HUVECs .	parallel	1
20149	11035932	5829;634	paxillin;CEACAM1	The ******CEACAM1-paxillin****** ***interaction*** was confirmed using laser scanning confocal microscopy analyses in granulocytes and HT29 cells , where CEACAM1 colocalizes with paxillin at the plasma membrane .	parallel	1
20150	11035936	4613;960	MYCN;CD44	***MYCN-related*** ***suppression*** of functional ***CD44*** expression enhances tumorigenic properties of human neuroblastoma cells .	negative	1
20151	11035987	2353;2697	AP-1;cx43	However , estrogen did not induce myometrial cx43 gene transcription in vitro ; instead , it inhibited ***AP-1*** ***induction*** of ***cx43*** expression .	target	1
20152	11035987	2100;2353	ER-beta;AP-1	This is likely because the myometrial and leiomyoma cells begin to express the novel ER-beta upon culturing , and agonist-bound ***ER-beta*** is known to ***inhibit*** ***AP-1*** activity .	negative	1
20153	11035987	2353;2697	AP-1;cx43	Results from an examination of pregnancy myometrial tissue support the concept that ***AP-1*** activity is involved in the ***induction*** of myometrial ***cx43*** expression at term and that suppression of ER-beta expression is needed for this induction .	target	1
20154	11036064	320;8573	Mint1;CASK	Various Mint and/or CASK-containing complexes can be assembled on neurexins , and we demonstrate that ***Mint1*** can ***bind*** to Munc18 and ***CASK*** simultaneously .	parallel	1
20155	11036069	8802;2822	Galpha;PLD	***PLD*** stimulation by the M ( 3 ) mAChR was ***enhanced*** by the overexpression of Galpha ( 12 ) and ***Galpha*** ( 13 ) , whereas the overexpression of Galpha ( q ) strongly increased PLC activity without affecting PLD activity .	positive	0
20156	11036073	4790;1999	NF-kappaB;ESE-1	This induction occurs within hours of stimulation and is mediated by ***NF-kappaB*** ***transactivation*** of the ***ESE-1*** promoter .	positive	1
20157	11036073	1999;4790	ESE-1;p50	***ESE-1*** can ***bind*** to the ***p50*** subunit of NF-kappaB , and cotransfection of ESE-1 with the p50 and p65 subunits of NF-kappaB synergistically enhances transactivation of the NOS2 promoter by ESE-1 .	parallel	1
20158	11036079	3320;4790	Hsp90;p50	***Hsp90*** ***regulates*** ***p50*** ( Cdc37 ) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase .	target	1
20159	11036079	4790;3320	p50;Hsp90	Analysis of mutant Cdc37 gene products indicated that the N-terminal portion of p50 ( Cdc37 ) interacted with immature HRI , but not with Hsp90 , while the C-terminal portion of ***p50*** ( Cdc37 ) ***interacted*** with ***Hsp90*** .	parallel	1
20160	11036079	4790;3320	p50;Hsp90	The Hsp90-specific inhibitor geldanamycin disrupted the ability of both Hsp90 and p50 ( Cdc37 ) to bind HRI and promote its activation , but did not disrupt the native ***association*** of ***p50*** ( Cdc37 ) with ***Hsp90*** .	parallel	0
20161	11036079	4790;3320	p50;Hsp90	A C-terminal truncated mutant of ***p50*** ( Cdc37 ) inhibited HRI 's activation , ***prevented*** the interaction of ***Hsp90*** with HRI , and bound to HRI irrespective of geldanamycin treatment .	positive	0
20162	11036080	5080;4094	Pax6;Maf	***Pax6*** , whose homeodomain is relatively similar to MHox , also could ***interact*** with ***Maf*** .	parallel	1
20163	11036083	10933;7223	EAF3;TRP4	The EAF3 deletion and the ESA1 mutation lead to a decrease in PHO5 gene expression ; the ***EAF3*** deletion also significantly ***reduces*** HIS4 and ***TRP4*** expressions .	positive	1
20164	11036085	5757;3005	Prothymosin alpha;histone H1	***Prothymosin alpha*** ( ProTalpha ) , a cellular molecule known to be associated with cell proliferation , is transcriptionally up-regulated on expression of c-myc and interacts with histones in vitro and ***associates*** with ***histone H1*** in cells .	parallel	0
20165	11036165	7124;3383	TNFalpha;intercellular adhesion molecule 1	***TNFalpha*** ( 100 U/ml , 24 h ) ***upregulated*** ***intercellular adhesion molecule 1*** ( ICAM1 ) expression on brain microvascular endothelial cell ( BMEC ) culture .	positive	1
20166	11036197	5621;836	prion protein;Caspase-3	***Caspase-3*** ***activation*** by beta-amyloid and ***prion protein*** peptides is independent from their neurotoxic effect .	positive	1
20167	11036266	4905;2891	NSF;GluR2	The enhanced transmission resulting from this delivery and subsequent exchange was maintained for at least several days and required an ***interaction*** between ***GluR2*** and ***NSF*** .	parallel	1
20168	11036591	7074;5879	Tiam1;Rac1	***Activation*** of ***Rac1*** by human ***Tiam1*** .	positive	1
20169	11036592	10672;9181	G alpha 13;GEF	***Activation*** of Rho ***GEF*** activity by ***G alpha 13*** .	positive	1
20170	11036825	3600;969	interleukin 15;CD69	OBJECTIVE : To study the ***modulation*** of ***CD69*** expression on peripheral blood ( PB ) and synovial fluid ( SF ) lymphocytes by ***interleukin 15*** ( IL-15 ) and several other cytokines and chemokines widely detected in the rheumatoid microenvironment .	target	0
20171	11036930	5449;2624	Pit-1;GATA-2	The mechanisms by which these transient gradients of signaling molecules lead to the appearance of four ventral pituitary cell types appear to involve the reciprocal ***interactions*** of two transcription factors , ***Pit-1*** and ***GATA-2*** , which are epistatic to the remainder of the cell type-specific transcription programs and serve as a molecular memory of the transient signaling events .	parallel	1
20172	11036938	5452;7039	Oct-2;TGFalpha	While ***Oct-2*** ***transactivates*** the ***TGFalpha*** promoter , TTF-1 does so to the erbB-2 and LHRH genes but inhibits preproenkephalin promoter activity , suggesting that both transcriptional regulators may act coordinately in the normal hypothalamus to activate genes involved in facilitating the advent of puberty and repress those restraining sexual development .	positive	1
20173	11036939	1454;8312	CKIepsilon;Axin	***CKIepsilon*** forms a ***complex*** with ***Axin*** and the other downstream components of the Wnt pathway .	parallel	1
20174	11036939	8312;1499	Axin;beta-catenin	CKIepsilon is a positive regulator of the Wnt pathway and a possible functional link between upstream signals and the intracellular ***Axin*** signaling complex that ***regulates*** ***beta-catenin*** .	target	1
20175	11036940	2692;2691	GHRH receptor;GHRH	The GHRH receptor signals predominantly through cAMP-dependent pathways ; however , a variant form of the ***GHRH receptor*** with an insertion into the third intracellular domain , generated through alternative RNA processing , ***binds*** ***GHRH*** but fails to signal , suggesting potential modulation of receptor function at a post-transcriptional level .	parallel	1
20176	11036942	140885;5781	SIRP;SHP2	The phosphorylated ***SIRP*** ***recruits*** one or more molecules of the tyrosine phosphatase ***SHP2*** that , in turn , de-phosphorylates SIRP and most likely JAK2 .	target	0
20177	11037343	1026;7157	Cip1;p53	Predominantly , higher ***p21Waf1/Cip1*** expression was ***associated*** with wt ***p53*** ( P < 0.001 ) .	parallel	0
20178	11037346	2798;2796	GnRHR;GnRH	The findings of this study suggest that the ***interaction*** between ***GnRH*** and ***GnRHR*** may play a role in paracrine/autocrine regulation of different types of normal pituitary cells and pituitary adenomas .	parallel	1
20179	11037878	3553;1280	IL-1beta;COL2A1	These studies also show , for the first time , that p38 MAPK is one of the signals required for ***IL-1beta-induced*** ***inhibition*** of ***COL2A1*** gene expression .	negative	1
20180	11037878	3553;5599	IL-1beta;JNK	***IL-1beta*** also ***stimulated*** phosphorylation of p38 MAPK , ***SAPK/JNK*** , and ATF-2 .	positive	0
20181	11037878	3553;1432	IL-1beta;p38	***IL-1beta*** also ***stimulated*** phosphorylation of ***p38*** MAPK , SAPK/JNK , and ATF-2 .	positive	0
20182	11037878	3553;5601	IL-1beta;SAPK	***IL-1beta*** also ***stimulated*** phosphorylation of p38 MAPK , ***SAPK/JNK*** , and ATF-2 .	positive	0
20183	11037878	3553;1280	IL-1beta;COL2A1	The p38 MAPK-selective inhibitor , SB203580 , partially reversed ***IL-1beta-induced*** ***inhibition*** of ***COL2A1*** mRNA levels and COL2A1-luciferase reporter gene expression .	negative	1
20184	11037881	4782;1277	CCAAT binding transcription factor;COL1A1	***CCAAT binding transcription factor*** ***binds*** and regulates human ***COL1A1*** promoter activity in human dermal fibroblasts : demonstration of increased binding in systemic sclerosis fibroblasts .	parallel	1
20185	11037970	6696;959	Osteopontin;CD40 ligand	***Osteopontin*** ***augments*** CD3-mediated interferon-gamma and ***CD40 ligand*** expression by T cells , which results in IL-12 production from peripheral blood mononuclear cells .	positive	0
20186	11037970	6696;3458	Osteopontin;interferon-gamma	***Osteopontin*** ***augments*** CD3-mediated ***interferon-gamma*** and CD40 ligand expression by T cells , which results in IL-12 production from peripheral blood mononuclear cells .	positive	0
20187	11037970	6696;959	Osteopontin;CD40L	Further , ***Osteopontin*** ***up-regulation*** of ***CD40L*** provides mechanistic support for the association of Osteopontin with polyclonal B cell proliferation and humoral autoimmune disease .	positive	1
20188	11038176	5861;27095	YPT1;BET3	Previous studies have shown that ***YPT1*** , which encodes the small GTP-binding protein that regulates membrane traffic at this stage of the secretory pathway , ***interacts*** genetically with ***BET3*** and BET5 .	parallel	1
20189	11038176	5861;58485	YPT1;BET5	Previous studies have shown that ***YPT1*** , which encodes the small GTP-binding protein that regulates membrane traffic at this stage of the secretory pathway , ***interacts*** genetically with BET3 and ***BET5*** .	parallel	1
20190	11038190	10490;4905	v-SNARE;N-ethylmaleimide-sensitive factor	Exocytosis in yeast requires the assembly of the secretory vesicle soluble ***N-ethylmaleimide-sensitive factor*** attachment protein ***receptor*** ( ***v-SNARE*** ) Sncp and the plasma membrane t-SNAREs Ssop and Sec9p into a SNARE complex .	parallel	1
20191	11038252	5008;3716	OSM;Jak1	Using specific antibodies recognizing proteins of the janus kinase ( Jak - ) / signal transducers and activator of transcription ( Stat - ) signaling cascade that has been shown to transduce the signals of the IL-6 cytokines to the nucleus , we could show that ***Jak1*** , Jak2 and Tyk2 , as well as the Stat proteins Stat1 , Stat3 and Stat5b were ***phosphorylated*** in all three cell lines by ***OSM*** and , at least in part , by LIF .	target	1
20192	11038252	5008;3717	OSM;Jak2	Using specific antibodies recognizing proteins of the janus kinase ( Jak - ) / signal transducers and activator of transcription ( Stat - ) signaling cascade that has been shown to transduce the signals of the IL-6 cytokines to the nucleus , we could show that Jak1 , ***Jak2*** and Tyk2 , as well as the Stat proteins Stat1 , Stat3 and Stat5b were ***phosphorylated*** in all three cell lines by ***OSM*** and , at least in part , by LIF .	target	1
20193	11038252	5008;7297	OSM;Tyk2	Using specific antibodies recognizing proteins of the janus kinase ( Jak - ) / signal transducers and activator of transcription ( Stat - ) signaling cascade that has been shown to transduce the signals of the IL-6 cytokines to the nucleus , we could show that Jak1 , Jak2 and ***Tyk2*** , as well as the Stat proteins Stat1 , Stat3 and Stat5b were ***phosphorylated*** in all three cell lines by ***OSM*** and , at least in part , by LIF .	target	1
20194	11038252	5008;5594	OSM;erk2	Consistent with our recent findings , ***OSM*** treatment also ***induced*** the activation of the MAPK ***erk2*** and the tyrosine phosphatase SHP-2 in cells of the A172 , T98G and U343-MG cell lines .	target	1
20195	11038252	5008;5781	OSM;SHP-2	Consistent with our recent findings , ***OSM*** treatment also ***induced*** the activation of the MAPK erk2 and the tyrosine phosphatase ***SHP-2*** in cells of the A172 , T98G and U343-MG cell lines .	target	1
20196	11038257	2353;1385	AP-1;CREB	In addition , injections of METH to mice induced increases in the ***binding*** of ***AP-1*** and ***CREB*** , which were depleted by preincubating the nuclear extract with anti-METH antibody .	parallel	1
20197	11038318	752014;3558	Cp23;IL-2	***Cp23*** stimulation also ***induced*** TNF-alpha , ***IL-2*** , and IL-5 mRNA production by spleen cells from infected animals .	target	1
20198	11038318	752014;3567	Cp23;IL-5	***Cp23*** stimulation also ***induced*** TNF-alpha , IL-2 , and ***IL-5*** mRNA production by spleen cells from infected animals .	target	1
20199	11038318	752014;7124	Cp23;TNF-alpha	***Cp23*** stimulation also ***induced*** ***TNF-alpha*** , IL-2 , and IL-5 mRNA production by spleen cells from infected animals .	target	1
20200	11038351	4067;3673	Lyn;GPIa	In vitro kinase assays and Western blotting of GPIa immunoprecipitates revealed that Src and ***Lyn*** constitutively ***associate*** with ***GPIa/IIa*** and that Src activity increases transiently after rhodocytin stimulation .	parallel	0
20201	11038354	176;2199	aggrecan;fibulin-2	We here demonstrate that ***aggrecan*** , Versican , and brevican lectin domains ***bind*** ***fibulin-2*** , whereas neurocan does not .	parallel	1
20202	11038354	63827;2199	brevican;fibulin-2	We here demonstrate that aggrecan , Versican , and ***brevican*** lectin domains ***bind*** ***fibulin-2*** , whereas neurocan does not .	parallel	1
20203	11038354	1462;2199	Versican;fibulin-2	We here demonstrate that aggrecan , ***Versican*** , and brevican lectin domains ***bind*** ***fibulin-2*** , whereas neurocan does not .	parallel	1
20204	11038731	3356;1605	5-HT2 receptor;DAG	It was found that : ( 1 ) the activation of ***5-HT2 receptor*** coupled to IAP-insensitive G-proteins ***increases*** intracellular ***DAG*** formation through the activation of phospholipase C ( PLC ) .	positive	0
20205	11038824	185;183	AT1;angiotensin II	OBJECTIVE : To investigate the effects of angiotensin II type 2 receptor ( AT2 ) on the cell proliferation and fibronectin release induced by ***angiotensin II*** type 1 ***receptor*** ( ***AT1*** ) .	parallel	1
20206	11039466	5327;885	TPA;CCK	Phorbol 12-myristate 13-acetate ( ***TPA*** ) significantly ***stimulated*** ***CCK*** release .	positive	0
20207	11039605	7422;2321	VEGF;Flt-1	Although BREC expressed Flt-1 and Flk-1 as VEGF receptors at similar levels , ***VEGF*** stimulation preferentially ***enhanced*** the activity of ***Flt-1*** tyrosine kinase .	positive	0
20208	11039605	7422;6778	VEGF;Stat6	These molecules were tyrosine phosphorylated under culture conditions used , and the phosphorylation of Tyk2 and ***Stat6*** was specifically ***enhanced*** by ***VEGF*** stimulation .	positive	0
20209	11039605	7422;7297	VEGF;Tyk2	These molecules were tyrosine phosphorylated under culture conditions used , and the phosphorylation of ***Tyk2*** and Stat6 was specifically ***enhanced*** by ***VEGF*** stimulation .	positive	0
20210	11039666	2057;2056	EPO-R;erythropoietin	Erythropoiesis is severely impaired in mice with inactivating mutations in the steel factor ( SF ) gene ( Sl/Sl mice ) or in c-kit , in the SF receptor gene ( W/W mice ) , and in mice with null mutations in the genes for either erythropoietin ( EPO ) or the ***erythropoietin*** ***receptor*** ( ***EPO-R*** ) .	parallel	1
20211	11039666	3815;2057	c-kit;EPO-R	However , recent studies have shown that there is a physical association between these 2 receptors and that ***c-kit*** can ***phosphorylate*** ***EPO-R*** .	target	1
20212	11039728	5443;2796	beta-endorphin;GnRH	Nitric oxide ( NO ) as well as ***beta-endorphin*** are involved in the neuroendocrine ***control*** of gonadotropin-releasing hormone ( ***GnRH*** ) secretion .	target	0
20213	11039902	1601;2353	Dab2;c-fos	***Dab2*** expression ***suppressed*** MAPK activation and ***c-fos*** expression .	negative	1
20214	11039909	5594;2260	ERK2;FGFR1	Secreted FGF1 ***induced*** long-term activation of ***FGFR1*** and ***ERK2*** , which was necessary to induce a constant and high level of Bcl-x production , and to induce cell survival in FGFI cells .	target	1
20215	11039909	2260;5594	FGFR1;ERK2	Secreted FGF1 ***induced*** long-term activation of ***FGFR1*** and ***ERK2*** , which was necessary to induce a constant and high level of Bcl-x production , and to induce cell survival in FGFI cells .	target	1
20216	11039909	2246;5594	FGF1;ERK2	Secreted ***FGF1*** ***induced*** long-term activation of FGFR1 and ***ERK2*** , which was necessary to induce a constant and high level of Bcl-x production , and to induce cell survival in FGFI cells .	target	1
20217	11039909	2246;2260	FGF1;FGFR1	Secreted ***FGF1*** ***induced*** long-term activation of ***FGFR1*** and ERK2 , which was necessary to induce a constant and high level of Bcl-x production , and to induce cell survival in FGFI cells .	target	1
20218	11039909	2246;5594	FGF1;ERK2	Secreted ***FGF1*** ***induced*** short-term activation of both FGFR1 and ***ERK2*** , which were required for cell proliferation .	target	1
20219	11039909	2246;2260	FGF1;FGFR1	Secreted ***FGF1*** ***induced*** short-term activation of both ***FGFR1*** and ERK2 , which were required for cell proliferation .	target	1
20220	11039911	7124;598	TNF-alpha;Bcl-x	In A549 human lung adenocarcinoma cells , we found that ***TNF-alpha*** and several commonly used chemotherapeutic agents ***upregulated*** the expression of ***Bcl-x*** and/or Bfl-1/A1 through an NF-kappaB-dependent pathway .	positive	1
20221	11039911	7124;597	TNF-alpha;Bfl-1	In A549 human lung adenocarcinoma cells , we found that ***TNF-alpha*** and several commonly used chemotherapeutic agents ***upregulated*** the expression of Bcl-x and/or ***Bfl-1/A1*** through an NF-kappaB-dependent pathway .	positive	1
20222	11039935	1896;10913	EDA-A1;EDAR	This insertion functions to determine receptor binding specificity , such that ***EDA-A1*** ***binds*** only the receptor ***EDAR*** , whereas EDA-A2 binds only the related , but distinct , X-linked ectodysplasin-A2 receptor ( XEDAR ) .	parallel	1
20223	11039935	1896;60401	EDA-A2;XEDAR	This insertion functions to determine receptor binding specificity , such that EDA-A1 binds only the receptor EDAR , whereas ***EDA-A2*** ***binds*** only the related , but distinct , X-linked ectodysplasin-A2 receptor ( ***XEDAR*** ) .	parallel	1
20224	11039936	356;355	CD95 ligand;CD95	******CD95/CD95 ligand****** ***interactions*** on epithelial cells in host defense to Pseudomonas aeruginosa .	parallel	1
20225	11040041	4772;3569	NFATc1;IL-6	Expression of recombinant ***NFATc1*** markedly ***augments*** ***IL-6*** mRNA induction by these and other agonists , which is partially attributable to NFAT-regulated paracrine mediators .	positive	0
20226	11040041	3553;3569	IL-1beta;IL-6	However , trans-dominant NFkappaB inhibitors strongly interfere with ***IL-6*** mRNA ***induction*** both by ***IL-1beta*** and by UTP , which synergistically evoke IL-6 mRNA expression .	target	1
20227	11040055	7421;10499	VDR;TIF2	Most derivatives of compound 1 reacted as typical agonists , because they were able to promote ligand-dependent ***interaction*** of the ***VDR*** with the coactivator ***TIF2*** , stabilized the VDR preferentially in its agonistic conformation c1 ( LPD ) , and stimulated VDR-dependent gene activity with a potency similar to 1alpha ,25 ( OH ) ( 2 ) D ( 3 ) .	parallel	1
20228	11040089	1906;4843	Endothelin-1;nitric oxide synthase-2	***Endothelin-1*** ***induces*** ***nitric oxide synthase-2*** expression in human non-pigmented ciliary epithelial cells .	target	1
20229	11040093	3949;4018	LDLR;lipoprotein	Familial hypercholesterolemia ( FH ) and familial defective apolipoprotein B-100 ( FDB ) are relatively common lipid disorders caused by mutations in the low-density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) and apolipoprotein B ( apo B ) genes , respectively .	parallel	1
20230	11040101	3553;5594	IL-1 beta;p38	Together , these results indicate that IL-1 beta induces VEGF gene expression at both transcriptional and post-transcriptional levels , and ***IL-1 beta*** ***evokes*** ***p38*** MAPK and JNK signalings , which in turn stimulate the transcription of the VEGF gene through Sp1-binding sites .	positive	0
20231	11040186	3600;355	IL-15;FAS	RESULTS : Only ***IL-15*** ***induced*** enterocyte expression of Ki67 , TFR , and ***FAS*** in treated celiac ( P < 0.01 vs. medium ) and enterocyte apoptosis in untreated celiac disease specimens .	target	1
20232	11040186	3600;7037	IL-15;TFR	RESULTS : Only ***IL-15*** ***induced*** enterocyte expression of Ki67 , ***TFR*** , and FAS in treated celiac ( P < 0.01 vs. medium ) and enterocyte apoptosis in untreated celiac disease specimens .	target	1
20233	11040212	3206;1026	HOXA10;p21	In this paper , we describe a mechanism by which p21 and HOXA10 may act in concert , where ***HOXA10*** can ***bind*** directly to the ***p21*** promoter and , together with its trimeric partners PBX1 and MEIS1 , activate p21 transcription , resulting in cell cycle arrest and differentiation .	parallel	1
20234	11040212	3206;1026	HOXA10;p21	In this paper , we describe a mechanism by which p21 and HOXA10 may act in concert , where ***HOXA10*** can bind directly to the p21 promoter and , together with its trimeric partners PBX1 and MEIS1 , ***activate*** ***p21*** transcription , resulting in cell cycle arrest and differentiation .	positive	1
20235	11040215	5594;7040	ERK;TGFbeta	***ERK*** has been reported previously to ***inhibit*** ***TGFbeta*** signaling via phosphorylation of the linker region of Smads , which prevents their translocation to the nucleus .	negative	1
20236	11040215	5594;4087	ERK;Smad2	However , we found no evidence in this system that ***ERK*** can significantly ***influence*** the function of ***Smad2*** , Smad3 , and Smad4 at the level of nuclear translocation , DNA binding , or transcriptional activation .	target	0
20237	11040215	5594;4088	ERK;Smad3	However , we found no evidence in this system that ***ERK*** can significantly ***influence*** the function of Smad2 , ***Smad3*** , and Smad4 at the level of nuclear translocation , DNA binding , or transcriptional activation .	target	0
20238	11040215	5594;4089	ERK;Smad4	However , we found no evidence in this system that ***ERK*** can significantly ***influence*** the function of Smad2 , Smad3 , and ***Smad4*** at the level of nuclear translocation , DNA binding , or transcriptional activation .	target	0
20239	11040216	6829;6827	Spt5;Spt4	In contrast , a ***complex*** of ***Spt4*** and ***Spt5*** is required in vitro for the inhibition of RNA polymerase II ( Pol II ) elongation by the drug DRB , suggesting also a negative role in vivo .	parallel	1
20240	11040216	6827;6829	Spt4;Spt5	To learn more about the function of the ******Spt4/Spt5****** ***complex*** and spt6 in vivo , we have identified Drosophila homologs of Spt5 and spt6 and characterized their localization on Drosophila polytene chromosomes .	parallel	1
20241	11040336	1906;7040	endothelin-1;TGF-beta1	***endothelin-1*** ***stimulated*** ***TGF-beta1*** and collagen synthesis via endothelin ET ( A ) and endothelin ET ( B ) receptors , respectively , in control stellate cells , but did not elicit these effects in the cirrhotic cells despite increased density of the respective receptor subtypes in them .	positive	0
20242	11040994	1029;1356	P16;ceruloplasmin	Kinetics of the ******ceruloplasmin-P16****** ***binding*** was studied by affinity chromatography on P16 immobilized on a macroporous disk , and the Kd value ( 1.5 x 10 ( -6 ) M ) of this interaction was determined .	parallel	1
20243	11041112	596;581	Bcl-2;Bax	***Heterodimerization*** of ***Bcl-2*** and Bcl-X ( L ) with ***Bax*** and Bad in colorectal cancer .	parallel	1
20244	11041112	598;581	Bcl-X;Bax	***Heterodimerization*** of Bcl-2 and ***Bcl-X*** ( L ) with ***Bax*** and Bad in colorectal cancer .	parallel	1
20245	11041112	581;596	Bax;Bcl-2	A reduced ***heterodimerization*** of ***Bax*** with ***Bcl-2*** may contribute to the development of colorectal cancer .	parallel	1
20246	11041200	820;5925	cAMP;pRb	In addition , PKA stimulation significantly decreased the pRb phosphorylation status but did not elicit CD14 expression , indicating that ***cAMP-induced*** ***dephosphorylation*** of ***pRb*** can not by itself trigger differentiation in ML-1 cells .	target	1
20247	11041214	7306;7299	Tyrp1;tyrosinase	We report evidence that Tyrp1 stabilizes tyrosinase , confirming previous observations , and , in addition , demonstrate that ***Tyrp1*** ***decreases*** ***tyrosinase*** activity .	negative	0
20248	11041214	7306;7299	Tyrp1;tyrosinase	We report evidence that ***Tyrp1*** ***stabilizes*** ***tyrosinase*** , confirming previous observations , and , in addition , demonstrate that Tyrp1 decreases tyrosinase activity .	positive	0
20249	11041214	1638;7299	Tyrp2;tyrosinase	By contrast , ***Tyrp2*** ***increases*** ***tyrosinase*** activity by stabilizing the protein .	positive	0
20250	11041227	1232;6356	CCR3;eotaxin	The expression patterns of ***eotaxin*** and its ***receptor*** ***CCR3*** in endometrium support a role in chemoattraction of eosinophils but expression of monocyte chemotactic proteins 1 and 2 does not correlate with macrophage numbers .	parallel	1
20251	11041368	7299;7306	tyrosinase;DHICA oxidase	On the other hand , aggregated and degraded forms of that mutant gp87 protein are found in the cytosolic fraction of melan-si , suggesting that misrouting and aberrant processing of the gp87 and ***tyrosinase*** may also be ***related*** to the high ***DHICA oxidase*** activity of these melanocytes .	parallel	0
20252	11041370	4286;5077	MITF;Waardenburg syndrome (WS) 1	Heterozygous mutations of PAX3 , ***MITF*** , or c-kit genes ***induce*** ***Waardenburg syndrome (WS) 1/3*** , WS 2 or Piebaldism , respectively .	target	1
20253	11041375	5443;4157	alpha-MSH;MC1R	We have shown that ***alpha-MSH*** and ACTH ***bind*** the human ***MC1R*** with equal affinity , and are equipotent in their mitogenic and melanogenic effects on human melanocytes .	parallel	1
20254	11041450	595;5925	Cyclin D1;pRB	In our series of 54 thyroid carcinomas , ***Cyclin D1*** overexpression ( detected by both immunohistochemistry and by Northern blotting ) was ***correlated*** with prognostic variables , proliferative activity and ***pRB*** .	parallel	0
20255	11041555	183;5972	angiotensin II;renin	For this purpose we examined the effects of the K + channel blockers 4-aminopyridine ( 1 mmol/l ) , barium ( 100 micromol/l ) , tetraethylammonium ( 2 mmol/l ) and apamin ( 200 nmol/l ) on basal renin secretion , on renin secretion stimulated by isoproterenol ( 10 nmol/l ) and on the ***inhibition*** of ***renin*** secretion by ***angiotensin II*** ( 100-300 pmol/l ) in the isolated rat kidney perfused at constant pressure .	negative	1
20256	11041557	355;285335	CD95;NHE	In conclusion , ***CD95-receptor*** stimulation ***inhibits*** ***NHE*** activity through a mechanism that depends directly or indirectly on the activation of the Src-like kinase Lck56 .	negative	1
20257	11041557	355;285335	CD95;NHE	As apparent from the effect of osmotic cell shrinkage , ***inhibition*** of the ***NHE*** by ***CD95-receptor*** stimulation was absent in Lck56-deficient J-CaM1 .6 cells and restored by retransfection of J-CaM1 .6 - cells with Lck56 .	negative	1
20258	11041858	8890;1965	eIF2B;eIF2	Analysis of these mutants has provided novel insight into the role of 51 serine in the ***interaction*** between ***eIF2*** and ***eIF2B*** .	parallel	1
20259	11041858	8890;1965	eIF2B;eIF2	Our results show that the increased ***interaction*** between ***eIF2*** and ***eIF2B*** protein , occurring in reticulocyte lysates due to increased eIF2alpha phosphorylation , is decreased significantly by the addition of mutant 51A protein but not 51D .	parallel	1
20260	11042034	1440;6777	G-CSF;Stat5	In this study , we demonstrated that ***G-CSF*** ***activated*** a ***Stat5*** complex in human myeloid cells containing three isoforms of Stat5 : Stat5A , Stat5B , and Stat5 p80 .	positive	1
20261	11042034	6776;6774	Stat5A;Stat3	G-CSF-activated ***Stat5A/B*** , but not Stat5 p80 , formed a ***heterodimer*** with ***Stat3*** .	parallel	1
20262	11042084	57530;7082	cingulin;ZO-1	Human and Xenopus cingulin heads are only 33 % identical , yet a human ***cingulin*** N-terminal fragment still ***interacts*** with canine ***ZO-1*** and ZO-2 in vitro .	parallel	1
20263	11042084	57530;9414	cingulin;ZO-2	Human and Xenopus cingulin heads are only 33 % identical , yet a human ***cingulin*** N-terminal fragment still ***interacts*** with canine ZO-1 and ***ZO-2*** in vitro .	parallel	1
20264	11042114	4023;6382	lipoprotein lipase;syndecan	Similar results were obtained with ( 125 ) I-labelled ***lipoprotein lipase*** ***bound*** to authentic cell-surface ***syndecan*** .	parallel	1
20265	11042115	5578;5338	PKC alpha;PLD2	Finally , we provide evidence that ***PKC alpha*** is constitutively ***associated*** with ***PLD2*** .	parallel	0
20266	11042130	5465;1581	PPAR alpha;CYP7A1	It is concluded that , whereas ***PPAR alpha*** can ***affect*** ***CYP7A1*** gene transcription in vitro through an indirect action , probably by competing for co-factors , this is unlikely to be a major influence on CYP7A1 activity under normal physiological conditions .	target	0
20267	11042130	3172;5465	HNF4;PPAR alpha	Co-expression of ***HNF4*** increased promoter activity and ***decreased*** the effect of ***PPAR alpha*** .	negative	0
20268	11042164	930;207	Cd19;Akt	***Cd19-dependent*** ***activation*** of ***Akt*** kinase in B-lymphocytes .	positive	1
20269	11042164	930;207	Cd19;Akt	Thus , ***Cd19*** is a key ***regulator*** of ***Akt*** activity in B-cells ; as such it may contribute to pre-BCR or BCR-mediated cell survival in vivo .	target	1
20270	11042168	26086;8802	AGS3;Galpha	***AGS3*** ***coimmunoprecipitated*** with ***Galpha*** ( i3 ) from cell and tissue lysates , indicating that a subpopulation of AGS3 and Galpha ( i ) exist as a complex in the cell .	parallel	1
20271	11042168	26086;8802	AGS3;Galpha	The regions of ***AGS3*** that ***bound*** ***Galpha*** ( i ) were localized to four amino acid repeats ( G-protein regulatory motif ( GPR ) ) in the carboxyl terminus ( Pro ( 463 ) - Ser ( 650 ) ) , each of which were capable of binding Galpha ( i ) .	parallel	1
20272	11042168	26086;8802	AGS3;Galpha	***AGS3-GPR*** domains selectively ***interacted*** with Galpha ( i ) in tissue and cell lysates and with purified ***Galpha*** ( i ) / Galpha ( t ) .	parallel	1
20273	11042172	4088;6696	Smad3;OPN	***Smad3*** ***binds*** directly to the ***OPN*** promoter as a sequence-specific activator , and Smad4 displaces the transcription repressor , Hoxa-9 , by formation of Smad4/Hox complex as part of the transcription mechanism in response to TGF-beta stimulation .	parallel	1
20274	11042172	3205;6696	Hoxa-9;osteopontin	***Hoxa-9*** ***represses*** transforming growth factor-beta-induced ***osteopontin*** gene transcription .	negative	1
20275	11042172	3205;7045	Hoxa-9;transforming growth factor-beta-induced	***Hoxa-9*** ***represses*** ***transforming growth factor-beta-induced*** osteopontin gene transcription .	negative	1
20276	11042172	4088;6696	Smad3;osteopontin	In the present study , we report that ***Smad3*** ***binds*** directly to the ***osteopontin*** ( OPN ) promoter and that Smad4 interacts with the Hox protein and displaces it from its cognate DNA binding site in response to TGF-beta stimulation .	parallel	1
20277	11042172	4089;3205	Smad4;Hoxa-9	FLAG-tagged ***Smad4*** ***coimmunoprecipitated*** with HA-tagged ***Hoxa-9*** from cotransfected COS-1 cells , demonstrating an interaction between Smad4 and Hoxa-9 .	parallel	1
20278	11042172	3205;4089	Hoxa-9;Smad4	FLAG-tagged Smad4 coimmunoprecipitated with HA-tagged Hoxa-9 from cotransfected COS-1 cells , demonstrating an ***interaction*** between ***Smad4*** and ***Hoxa-9*** .	parallel	1
20279	11042182	3815;2057	c-Kit;erythropoietin receptor	A novel mechanism of ***cooperation*** between ***c-Kit*** and ***erythropoietin receptor*** .	parallel	0
20280	11042182	4254;3815	Stem cell factor;c-Kit	We demonstrate that ***c-Kit*** ***stimulation*** by ***Stem cell factor*** is essential for the maintenance of Epo-R and Stat5 protein expression , which results in significantly enhanced Bcl-x ( L ) induction and survival of erythroid progenitors in response to Epo stimulation .	positive	0
20281	11042189	51776;5598	MLTKbeta;ERK5	When overexpressed in cells , both MLTKalpha and ***MLTKbeta*** are able to ***activate*** the ERK , JNK/SAPK , p38 , and ***ERK5*** pathways .	positive	1
20282	11042189	51776;5594	MLTKbeta;ERK	When overexpressed in cells , both MLTKalpha and ***MLTKbeta*** are able to ***activate*** the ***ERK*** , JNK/SAPK , p38 , and ERK5 pathways .	positive	1
20283	11042189	51776;5599	MLTKbeta;JNK	When overexpressed in cells , both MLTKalpha and ***MLTKbeta*** are able to ***activate*** the ERK , ***JNK/SAPK*** , p38 , and ERK5 pathways .	positive	1
20284	11042189	51776;5601	MLTKbeta;SAPK	When overexpressed in cells , both MLTKalpha and ***MLTKbeta*** are able to ***activate*** the ERK , ***JNK/SAPK*** , p38 , and ERK5 pathways .	positive	1
20285	11042193	5336;695	PLC-gamma2;BTK	We now demonstrate that induction of NF-kappaB via this pathway requires the intermediate action of the - gamma2 isoform of phospholipase C ( ***PLC-gamma2*** ) , a potential phosphorylation ***substrate*** of ***BTK*** .	parallel	1
20286	11042197	1482;159296	Nkx2.5;Nkx2.3	***Csx/Nkx2.5*** can ***heterodimerize*** with other NK2 homeodomain proteins , ***Nkx2.3*** and Nkx2 .6 / Tix , with different affinities .	parallel	1
20287	11042198	3418;3417	IDH2;IDH1	In this study , ***interactions*** between ***IDH1*** and ***IDH2*** were detected using the yeast two-hybrid system , but interactions between identical subunit polypeptides were not detected with this or other methods .	parallel	1
20288	11042198	3418;3417	IDH2;IDH1	Collectively , these results suggest that the basic structural/functional unit of yeast isocitrate dehydrogenase is a ***heterodimer*** of ***IDH1*** and ***IDH2*** subunits and that each subunit contributes to the isocitrate binding site of the other .	parallel	1
20289	11042199	348;1385	APOE4;CREB	In this report , we demonstrate that ***APOE4*** ***stimulates*** the transcriptional activity of cAMP-response element-binding protein ( ***CREB*** ) by activating the extracellular signal-regulated kinase ( ERK ) cascade in rat primary hippocampal neurons .	positive	0
20290	11042204	1432;207	p38;Akt	The present study shows that phosphatidylinositol 3-kinase-dependent ***p38*** kinase activation ***regulates*** ***Akt*** phosphorylation and activity in human neutrophils .	target	1
20291	11042204	207;3315	Akt;Hsp27	Immunoprecipitation and glutathione S-transferase ( GST ) pull-down studies showed that ***Akt*** was ***associated*** with p38 kinase , MK2 , and ***Hsp27*** in neutrophils , and Hsp27 dissociated from the complex upon activation .	parallel	0
20292	11042204	207;9261	Akt;MK2	Immunoprecipitation and glutathione S-transferase ( GST ) pull-down studies showed that ***Akt*** was ***associated*** with p38 kinase , ***MK2*** , and Hsp27 in neutrophils , and Hsp27 dissociated from the complex upon activation .	parallel	0
20293	11042204	207;1432	Akt;p38	Immunoprecipitation and glutathione S-transferase ( GST ) pull-down studies showed that ***Akt*** was ***associated*** with ***p38*** kinase , MK2 , and Hsp27 in neutrophils , and Hsp27 dissociated from the complex upon activation .	parallel	0
20294	11042209	4067;930	Lyn;CD19	As ***CD19*** tyrosine phosphorylation is ***modulated*** by the ***Lyn*** protein-tyrosine kinase , Lyn activity was evaluated in wild-type and motheaten B cells .	target	0
20295	11042209	4067;5777	Lyn;SHP-1	The data also demonstrated SHP-1 to be associated with Lyn in stimulated but not in resting B cells and indicated this interaction to be mediated via ***Lyn*** ***binding*** to the ***SHP-1*** N-terminal SH2 domain .	parallel	1
20296	11042209	5777;4067	SHP-1;Lyn	These findings , together with cyanogen bromide cleavage data revealing that ***SHP-1*** ***dephosphorylates*** the ***Lyn*** autophosphorylation site , identify Lyn deactivation/dephosphorylation as a likely mechanism whereby SHP-1 exerts its influence on CD19 tyrosine phosphorylation and , by extension , its inhibitory effect on B cell antigen receptor signaling .	target	1
20297	11042212	836;8394	caspase 3;PIP5KIalpha	An anti-apoptotic role for PIP ( 2 ) is further substantiated by our finding that ***PIP5KIalpha*** was ***cleaved*** by ***caspase 3*** during apoptosis , and cleavage inactivated PIP5KIalpha in vitro .	target	1
20298	11042214	8890;1965	eIF2B;eIF2	These data indicate that eIF2alpha is required for structural ***interactions*** between ***eIF2*** and ***eIF2B*** that promote wild-type rates of nucleotide exchange .	parallel	1
20299	11042220	5594;4691	ERK;nucleolin	These data suggest ***ERK*** ***up-regulates*** ***nucleolin*** posttranscriptionally thereby controlling APP production .	positive	1
20300	11042347	3458;4843	IFN-gamma;iNOS	The roles of PKC in ***iNOS*** ***induction*** by ***IFN-gamma*** have been shown in some cell types .	target	1
20301	11042507	959;958	CD154;CD40	Investigations in our laboratory have focused on ***CD40*** , a critical regulator of B cell survival and differentiation , and its ***ligand*** , ***CD154*** ( CD40L ) .	parallel	1
20302	11042507	959;958	CD154;CD40	We have established that in some cases of CLL the malignant cells express both CD40 and CD154 , and on the basis of those observations , proposed a model for CLL tumor growth due to ******CD40-CD154****** ***interactions*** within and among the malignant cells , and for the occurrence of autoimmune syndromes in some cases of CLL .	parallel	1
20303	11042507	958;959	CD40;CD154	The implications for therapy , such as by impedance to ******CD154-CD40****** ***interaction*** using antibody to CD154 , or by selective inhibitors of NF-kappa B , are considered .	parallel	1
20304	11042675	581;596	Bax;Bcl-2	In addition , the functional ***interaction*** between ***Bcl-2*** and ***Bax*** is conserved .	parallel	1
20305	11042687	56654;1869	NPDC-1;E2F-1	***NPDC-1*** , a regulator of neural cell proliferation and differentiation , ***interacts*** with ***E2F-1*** , reduces its binding to DNA and modulates its transcriptional activity .	parallel	1
20306	11042687	56654;1869	NPDC-1;E2F-1	In addition , two-hybrid experiments in mammalian cells show that the ***interaction*** between ***NPDC-1*** and ***E2F-1*** can also occur in vivo .	parallel	1
20307	11042688	4193;7157	MDM2;p53	Collectively , these results suggest that changes in constitutive mutant p53 protein levels , ******p53-MDM2****** binding ***interactions*** , and altered regulation of the DNA damage-inducible p53-dependent pathway may play a role in drug - and radiation-responsiveness in these cells .	parallel	1
20308	11042688	4193;7157	MDM2;p53	Of note , however , is the fact that the increased p53 protein half-lives in the two drug-resistant cell lines corresponds to a proportional decrease in MDM2 protein levels but an increase in ******p53-MDM2****** binding ***interactions*** .	parallel	1
20309	11042689	3725;6678	Jun;SPARC	Transcriptional ***control*** of ***SPARC*** by ***v-Jun*** and other members of the AP1 family of transcription factors .	target	0
20310	11042689	3725;6678	Jun;SPARC	We show here that ( i ) ***v-c-Fos0-mediated*** ***repression*** of the endogenous ***SPARC*** gene is enhanced by Fra2 but alleviated by ATF2 , Fra2 and ATF2 being the two major partners of v-c-Fos0 in the transformed cells ; ( ii ) high basal activity as well as repression by v-c-Fos0 and modulation by Fra2 and ATF2 is restricted to a small proximal fragment ( -124 / +16 ) of the chicken SPARC promoter ; ( iii ) the activity of this minimal promoter is modulated by all the AP1 family members known in chickens ( c-Jun and JunD ; c-Fos and Fra2 ; ATF2 ; c-Maf , MafA , and MafB ) .	negative	1
20311	11042693	4609;1869	c-myc;E2F-1	In conclusion , E2F-1 overexpression in the liver causes dysplasia and tumors and suggests a ***cooperation*** between ***E2F-1*** and ***c-myc*** oncogenes during liver oncogenesis .	parallel	0
20312	11042698	7157;4193	p53;Mdm2	Phosphorylation of p53 occurs after DNA damage thereby modulating its activity and impeding the ***interaction*** of ***p53*** with its negative regulator oncogene ***Mdm2*** .	parallel	1
20313	11042699	27020;6688	gp55;SPI-1	This ***cooperation*** between ***SPI-1*** and ***gp55*** to induce primary erythroblast transformation suggests that progression of Friend erythroleukemia critically depends upon inter-dependent interactions between the molecular events specific of the early and late phase of the disease .	parallel	0
20314	11043379	959;958	CD40L;CD40	CD40 and ***CD40*** ***ligand*** ( ***CD40L*** ) have been implicated as important molecules for the transformation of nonactivated antigen-presenting cells ( APC ) into cells that are potent inducers of cytotoxic T lymphocyte ( CTL ) immunity .	parallel	1
20315	11043379	959;958	CD40L;CD40	Blocking of ******CD40-CD40L****** ***interactions*** can also have profound effects on the generation of T cell immunity .	parallel	1
20316	11043379	959;958	CD40L;CD40	In most sites of the periphery interruption of ******CD40-CD40L****** ***interactions*** can lead to the induction of T cell tolerance whereas in mucosal tissues this interruption can lead to abrogation of T cell tolerance .	parallel	1
20317	11043379	959;958	CD40L;CD40	Thus intervention of ******CD40-CD40L****** ***interactions*** can result in enhancement or down-modulation of T cell reactivity and therefore modulation of these interactions may form the foundation of new treatment modalities directed against malignancies , allergies , organ rejections and autoimmunity .	parallel	1
20318	11043403	4760;5798	beta2;ICA512	In vitro ***binding*** of the ***beta2-syntrophin*** PDZ domain to ***ICA512*** required both ICA512 's C-terminal region and an internal polypeptide preceding its tyrosine phosphatase-like domain .	parallel	1
20319	11043403	4760;5798	beta2;ICA512	Immunomicroscopy and co-immunoprecipitations from insulinoma INS-1 cells confirmed the occurrence of ******ICA512-beta2-syntrophin****** ***complexes*** in vivo .	parallel	1
20320	11043558	9607;7351	CART;UCP2	***CART*** ***induced*** gene expression of uncoupling protein 1 ( UCP1 ) , ***UCP2*** , and UCP3 in brown and white adipose tissue and biceps femoris muscle respectively .	target	1
20321	11043558	9607;7352	CART;UCP3	***CART*** ***induced*** gene expression of uncoupling protein 1 ( UCP1 ) , UCP2 , and ***UCP3*** in brown and white adipose tissue and biceps femoris muscle respectively .	target	1
20322	11043558	9607;7350	CART;uncoupling protein 1	***CART*** ***induced*** gene expression of ***uncoupling protein 1*** ( UCP1 ) , UCP2 , and UCP3 in brown and white adipose tissue and biceps femoris muscle respectively .	target	1
20323	11043571	1387;5468	CREB-binding protein;PPARgamma	The differences between CDDO and rosiglitazone as either partial or full agonists , respectively , are seen in the weaker ability of CDDO to ***recruit*** the coactivator ***CREB-binding protein*** , CBP , to ***PPARgamma*** .	target	0
20324	11043573	1843;796	MKP-1;CGRP	We then showed that ionomycin repression of promoter activity involved selective induction of MAP kinase phosphatase-1 ( MKP-1 ) , but not MKP-2 , and that overexpression of ***MKP-1*** was sufficient to ***repress*** ***CGRP*** enhancer activity .	negative	1
20325	11043574	4087;4089	Smad2;Smad4	In a Smad4-deficient cell line , SW480 .7 , Smad2-2E did not affect basal signaling ; however , cotransfection with full-length Smad4 , but not transfection of Smad4 alone , resulted in enhanced basal transcriptional activity , suggesting that the constitutively active ***Smad2*** mutant also ***requires*** ***Smad4*** for function .	target	0
20326	11043574	4087;4089	Smad2;Smad4	In vitro protein interaction analysis revealed that ***Smad2-2E*** ***bound*** more tightly to ***Smad4*** than did wild-type Smad2 ; dissociation constants were 270 + / - 66 nM for wild-type Smad2 : Smad4 complexes and 79 + / - 18 nM for Smad2-2E : Smad4 complexes .	parallel	1
20327	11043575	5617;3725	Prolactin;c-jun	***Prolactin*** ***stimulates*** activation of ***c-jun*** N-terminal kinase ( JNK ) .	positive	0
20328	11043575	5617;5599	Prolactin;JNK	***Prolactin*** ***stimulates*** activation of c-jun N-terminal kinase ( ***JNK*** ) .	positive	0
20329	11043579	5595;2852	Erk-1;GPR30	Estrogen-induced activation of ***Erk-1*** and Erk-2 ***requires*** the G protein-coupled receptor homolog , ***GPR30*** , and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF .	target	0
20330	11043579	5594;2852	Erk-2;GPR30	Estrogen-induced activation of Erk-1 and ***Erk-2*** ***requires*** the G protein-coupled receptor homolog , ***GPR30*** , and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF .	target	0
20331	11043765	695;5336	Btk;PLC-gamma2	The activated ***Btk*** then ***phosphorylates*** ***PLC-gamma2*** , leading to its activation .	target	1
20332	11043771	959;4609	CD40L;c-Myc	Rescue from apoptosis induced by anti-mu or steroids occurs with T-cell signals , like CD40L , or a broad-range caspase inhibitor , but only ***CD40L*** ***prevents*** the loss of ***c-Myc*** , p27 accumulation and growth arrest .	negative	0
20333	11043837	355;834	FAS;caspase 1	***FAS-L*** expression ***correlated*** significantly with the expression of the ***caspase 1*** .	parallel	0
20334	11044085	7320;975	E2 protein;CD81	Human monoclonal antibodies that inhibit ***binding*** of hepatitis C virus ***E2 protein*** to ***CD81*** and recognize conserved conformational epitopes .	parallel	1
20335	11044211	285;7010	angiopoietin-2;Tie-2	Hypoxia up-regulates ***angiopoietin-2*** , a ***Tie-2*** ***ligand*** , in mouse mesangial cells .	parallel	1
20336	11044356	596;672	bcl-2;Brca1	The ***association*** between ***Brca1*** status and ***bcl-2*** expression remained significant after adjustment for the oestrogen receptor status .	parallel	0
20337	11044363	7124;4790	TNF-alpha;NF-kappaB	We conclude that HNSCC that exhibit constitutive and ***TNF-alpha-inducible*** ***activation*** of transcription factor ***NF-kappaB*** are resistant to TNF-alpha , and that inhibition of NF-kappaB sensitizes HNSCC to TNF-alpha caspase-mediated cytotoxicity .	positive	1
20338	11044363	7124;4790	TNF-alpha;NF-kappaB	These TNF-alpha resistant HNSCC lines expressed TNF receptor I , and exhibited constitutive and ***TNF-alpha-inducible*** ***activation*** of ***NF-kappaB*** as demonstrated by nuclear localization of NF-kappaB p65 by immunohistochemistry .	positive	1
20339	11044395	1630;9423	Dcc;netrin 1	We show that ***netrin 1*** and its ***receptor*** , ***Dcc*** , are expressed in the developing fimbria and in projection neurons , respectively , and that netrin 1 promotes the outgrowth of hippocampal axons in vitro via Dcc receptors .	parallel	1
20340	11044432	2281;6262	FKBP12.6;RyR	Here , we report a novel mechanism of cardiac dysfunction revealed by assessing the functional ***interaction*** of FK506-binding protein ( ***FKBP12.6*** ) with the cardiac ryanodine receptor ( ***RyR*** ) in a canine model of pacing-induced heart failure .	parallel	1
20341	11044439	5604;23162	MEK1;JSAP1	In that study we also found ***MEK1*** and Raf-1 , which are involved in the extracellular signal-regulated kinase ( ERK ) MAPK cascades , ***bind*** to ***JSAP1*** .	parallel	1
20342	11044439	5894;23162	Raf-1;JSAP1	In that study we also found MEK1 and ***Raf-1*** , which are involved in the extracellular signal-regulated kinase ( ERK ) MAPK cascades , ***bind*** to ***JSAP1*** .	parallel	1
20343	11044439	23162;5604	JSAP1;MEK1	Finally , we investigated the molecular mechanism of JSAP1 's inhibitory function and showed that ***JSAP1*** ***prevents*** ***MEK1*** phosphorylation and activation by Raf-1 , resulting in the suppression of the activation of ERK .	negative	0
20344	11044444	5604;4776	MEK1;NFAT3	Pharmacological inhibition of ***MEK1*** or expression of a dominant negative form of c-Raf or ERK2 ***inhibits*** phenylephrine-stimulated ***NFAT3*** activation .	positive	1
20345	11044560	3565;6347	interleukin-4;MCP-1	We also report the early induction ( 2h ) of equine eotaxin and MCP-4 , and the ***up-regulation*** of ***MCP-1*** by ***interleukin-4*** in dermal fibroblasts , suggesting these chemokines might be involved in equine skin allergic diseases .	positive	1
20346	11044605	3725;652	c-Jun;BMP-4	***c-Jun*** ( AP-1 ) ***activates*** ***BMP-4*** transcription in Xenopus embryos .	positive	1
20347	11044605	2353;652	c-Fos;BMP-4	RNA injection experiments revealed that both heteromeric ***c-Fos/c-Jun*** and homodimeric c-Jun/c-Jun strongly ***activate*** ***BMP-4*** transcription , whereas BMP signaling was found to activate the Xenopus c-Jun gene only at a rather low extent .	positive	1
20348	11044605	3725;652	c-Jun;BMP-4	RNA injection experiments revealed that both heteromeric c-Fos/c-Jun and homodimeric ***c-Jun/c-Jun*** strongly ***activate*** ***BMP-4*** transcription , whereas BMP signaling was found to activate the Xenopus c-Jun gene only at a rather low extent .	positive	1
20349	11044621	4435;4089	Cited1;Smad4	While ***Cited1*** also ***binds*** to the TGFbeta signal transducer ***Smad4*** , this has not been shown for CITED2 .	parallel	1
20350	11044623	1911;3213	rae28;Hoxb3	***Regulation*** of ***Hoxb3*** expression in the hindbrain and pharyngeal arches by ***rae28*** , a member of the mammalian Polycomb group of genes .	target	1
20351	11044623	1959;3213	Krox20;Hoxb3	Expression of kreisler and ***Krox20*** , which function as positive ***regulators*** of ***Hoxb3*** expression , was not affected in rae28-deficient embryos .	positive	1
20352	11044648	959;958	CD154;CD40	The interaction between CD40 on antigen-presenting cells ( APC ) like Langerhans cells and ***CD40*** ***ligand*** ( CD40L ) ( ***CD154*** ) expressed by activated CD4 + T cells , is essential for the activation of both the APC and the T cells and results in upregulation of APC functions and initiation of immunoreactivity .	parallel	1
20353	11044648	959;958	CD40L;CD40	The effects of ******CD40-CD40L****** ***interaction*** include increased expression of co-stimulatory and adhesion molecules , proliferation , and production of pro-inflammatory cytokines and proteolytic enzymes , all features of LCH .	parallel	1
20354	11044892	3481;3479	IGF-II;IGF-I	In control brains , [ ( 125 ) I ] ***IGF-I*** binding was ***inhibited*** more potently by IGF-I than by Des ( 1-3 ) IGF-I , ***IGF-II*** or insulin .	negative	1
20355	11045167	952;6382	CD38;CD138	A significant positive correlation was found in both groups with the level of S-thymidine kinase , in the whole group of indexes PI/CD38 and PI/B-B 4 ( CD138 ) with the severity of anaemia , index ***PI/CD38*** ***correlated*** with S-albumin and index PI/B-B 4 ( ***CD138*** ) with the percentage ratio of plasmocytes in bone marrow .	parallel	0
20356	11045296	958;959	CD40;CD40 ligand	******CD40-CD40 ligand****** ( CD40L ) ***interaction*** plays an important role in macrophage/monocyte-mediated inflammatory processes by up-regulating cytokine production by macrophages/monocytes and by preventing macrophage apoptosis at the inflammation sites .	parallel	1
20357	11045427	7124;4790	TNF-alpha;NF-kappaB	METHODS : In order to provide further understanding of determinants of TNF-alpha responses , we studied ***TNF-alpha*** ***induced*** ***NF-kappaB*** activation and variable tumour responses .	target	1
20358	11045427	4790;7124	NF-kappaB;TNF-alpha	RESULTS : We demonstrated that sustained ***NF-kappaB*** activation exceeding 16 h was observed in HRT18 and SW480 cells and was ***associated*** with ***TNF-alpha*** resistance .	parallel	0
20359	11045427	8743;4790	TRAIL;NF-kappaB	Despite variable TNF-alpha responses and NF-kappaB kinetics , all three colorectal cancer cell lines were highly sensitive to treatment with the TNF-related apoptosis-inducing ligand ( ***TRAIL*** ) which ***induced*** only transient ***NF-kappaB*** activation .	target	1
20360	11045599	5443;3558	ACTH;IL-2	These results demonstrated that ***ACTH*** ***modulates*** ***IL-2*** secretion from activated lymphocytes , which is both biphasic and concentration dependent .	target	0
20361	11045624	1915;10102	EF-Tu;EF-Ts	During the elongation cycle , ***EF-Tu*** ***interacts*** with guanine nucleotides , aa-tRNA and its nucleotide exchange factor ( ***EF-Ts*** ) .	parallel	1
20362	11045652	183;81	angiotensinogen;FSGS	We conclude that increased NF-kappaB and ***angiotensinogen*** gene expression are ***associated*** with ***R-FSGS*** .	parallel	0
20363	11045652	4790;81	NF-kappaB;FSGS	We conclude that increased ***NF-kappaB*** and angiotensinogen gene expression are ***associated*** with ***R-FSGS*** .	parallel	0
20364	11045665	351;348	Abeta;apoE	To examine the in vivo ***interactions*** between ***apoE*** and ***Abeta*** deposition , we examined 12-month-old transgenic ( tg ) mice expressing human amyloid precursor protein ( APP ) with the V717F mutation ( APP ( V717F ) homozygous ) on an apoE null background .	parallel	1
20365	11045949	5599;7057	JNK1;TSP	In summary , these studies support the hypothesis that TGF-beta-induced ***JNK1*** activation and proliferation of RASMC ***require*** secretion of ***TSP*** and ligation of alpha ( v ) beta ( 3 ) - integrins .	target	0
20366	11045949	7040;7057	TGF-beta1;TSP	We found that ***TGF-beta1*** ***enhanced*** production and secretion of ***TSP*** , with peak levels of secreted TSP observed 24 h after treatment .	positive	0
20367	11045949	7040;5599	TGF-beta;JNK1	Treatment with C6 .7 or F11 inhibited ***TGF-beta-induced*** ***activation*** of ***JNK1*** .	positive	1
20368	11045997	7040;2625	TGF-beta;GATA-3	We demonstrate that ***TGF-beta*** ***inhibits*** ***GATA-3*** expression in developing Th cells .	negative	1
20369	11045997	7040;2625	TGF-beta;GATA-3	We also show that ***inhibition*** of ***GATA-3*** expression by ***TGF-beta*** is a major mechanism of inhibition of Th2 differentiation by TGF-beta as ectopic expression of GATA-3 in developing T cells overcomes the ability of TGF-beta to inhibit Th2 differentiation .	negative	1
20370	11045997	7040;2625	TGF-beta;GATA-3	***TGF-beta*** likely ***inhibits*** ***GATA-3*** expression at the transcriptional level and does so without interfering with IL-4 signaling .	negative	1
20371	11046018	3439;4790	IFN-alpha;NF-kappaB	We tested this hypothesis by pretreating human Jurkat T cells with ***IFN-alpha*** , which ***blocked*** TNF-induced activation of ***NF-kappaB*** and AP-1 in a time - and dose-dependent manner as determined by EMSA .	negative	0
20372	11046018	3439;4790	IFN-alpha;NF-kappaB	***IFN-alpha*** blocked TNF-induced phosphorylation and degradation of the inhibitor subunit of NF-kappaB , and ***suppressed*** ***NF-kappaB*** and AP-1 activation induced by various other inflammatory stimuli .	negative	1
20373	11046021	3606;4790	IL-18;NF-kappaB	We prepared anti-IL-1RAcPL mAb TC30-28E3 , which , in contrast to soluble R proteins , effectively inhibited the ***IL-18-induced*** ***activation*** of ***NF-kappaB*** .	positive	1
20374	11046032	940;80381	CD28;costimulatory molecule	Mouse inducible ***costimulatory molecule*** ( ICOS ) expression is ***enhanced*** by ***CD28*** costimulation and regulates differentiation of CD4 + T cells .	positive	0
20375	11046032	940;941	CD28;CD80	Strikingly , ICOS up-regulation is significantly reduced in the absence of CD80 and CD86 and can be restored by CD28 stimulation , suggesting that ******CD28-CD80****** / CD86 ***interactions*** may optimize ICOS expression .	parallel	1
20376	11046036	1493;7020	CTLA-4;AP-2	We previously demonstrated that the ***association*** of ***CTLA-4*** with the clathrin-associated adaptor complex ***AP-2*** induces internalization of CTLA-4 and keeps the surface expression low .	parallel	0
20377	11046037	10803;6370	CCR9;thymus-expressed chemokine	The role of ***thymus-expressed chemokine*** and its ***receptor*** ***CCR9*** on lymphocytes in the regional specialization of the mucosal immune system .	parallel	1
20378	11046040	3558;3718	IL-2;Jak3	We recently reported that tyrphostin AG-490 selectively blocked ***IL-2*** ***activation*** of ***Jak3/Stat5*** and growth of murine T cell lines .	positive	1
20379	11046040	3558;6776	IL-2;Stat5	We recently reported that tyrphostin AG-490 selectively blocked ***IL-2*** ***activation*** of ***Jak3/Stat5*** and growth of murine T cell lines .	positive	1
20380	11046040	3718;6776	Jak3;Stat5a	Here we demonstrate that disruption of ******Jak3/Stat5a/b****** ***signaling*** with AG-490 ( 50 microM ) blocked the proliferation of primary human T lymphocytes , but paradoxically failed to inhibit the proliferation of HTLV-1-transformed human T cell lines , HuT-102 and MT-2 .	parallel	0
20381	11046041	943;356	CD30;Fas ligand	In the large granular lymphoma line YT , ***CD30*** signals ***down-regulate*** the expression of cytotoxic effector molecules , ***Fas ligand*** , perforin , granzyme B , and abrogate cytotoxicity .	negative	1
20382	11046041	943;3002	CD30;granzyme B	In the large granular lymphoma line YT , ***CD30*** signals ***down-regulate*** the expression of cytotoxic effector molecules , Fas ligand , perforin , ***granzyme B*** , and abrogate cytotoxicity .	negative	1
20383	11046041	943;5551	CD30;perforin	In the large granular lymphoma line YT , ***CD30*** signals ***down-regulate*** the expression of cytotoxic effector molecules , Fas ligand , ***perforin*** , granzyme B , and abrogate cytotoxicity .	negative	1
20384	11046041	943;1236	CD30;CCR7	Furthermore , ***CD30*** signals strongly ***induce*** ***CCR7*** , suggesting a role for CD30 signals in the homing of lymphocytes to lymph nodes .	target	1
20385	11046041	943;355	CD30;Fas	The ***up-regulation*** of ***Fas*** , death receptor 3 , and TNF-related apoptosis-inducing ligand by ***CD30*** indicates an increase in susceptibility to apoptotic signals whereas up-regulation of TNFR-associated factor 1 and cellular inhibitor of apoptosis 2 protect cells from certain types of apoptosis .	positive	1
20386	11046044	3439;10399	IFN;RACK-1	We report here a specific ***interaction*** between the cytoplasmic domain of ***IFN-alphaRbetaL*** and a previously identified protein , ***RACK-1*** ( receptor for activated C kinase ) .	parallel	1
20387	11046044	10399;3439	RACK-1;IFN	***RACK-1*** ***binding*** to ***IFN-alphaRbetaL*** did not require the first 91 aa of RACK-1 , which includes two WD domains , WD1 and WD2 .	parallel	1
20388	11046044	3439;10399	IFN;RACK-1	The ***interaction*** between ***RACK-1*** and ***IFN-alphaRbetaL*** , but not the human IFN receptor chain 1 ( IFNAR1 or IFN-alphaRalpha ) , was also detected in human Daudi cells by coimmunoprecipitation .	parallel	1
20389	11046044	10399;3439	RACK-1;IFN	***RACK-1*** was shown to be constitutively ***associated*** with ***IFN-alphaRbetaL*** , and this association was not effected by stimulation of Daudi cells with type I IFNs ( IFN-beta1b ) .	parallel	0
20390	11046046	5777;4179	protein-tyrosine phosphatase SHP-1;CD46	Functional modulation of human macrophages through CD46 ( measles virus receptor ) : production of IL-12 p40 and nitric oxide in association with ***recruitment*** of ***protein-tyrosine phosphatase SHP-1*** to ***CD46*** .	target	0
20391	11046046	4179;718	CD46;C3b	Human ***CD46*** , formerly membrane cofactor protein , ***binds*** and inactivates complement ***C3b*** and serves as a receptor for measles virus ( MV ) , thereby protecting cells from homologous complement and sustaining systemic measles infection .	parallel	1
20392	11046046	5777;4179	protein-tyrosine phosphatase SHP-1;CD46	In this study , we found that 6 - to 8-day GM-CSF-treated peripheral blood monocytes acquired the capacity to ***recruit*** ***protein-tyrosine phosphatase SHP-1*** to their ***CD46*** and concomitantly were able to produce IL-12 p40 and NO .	target	0
20393	11046057	5594;3621	ERK1/2;p47	Two-dimensional phosphopeptide mapping analysis showed that , in fMLP-induced p47 ( phox ) phosphorylation , PD98059 affected the phosphorylation of all the major phosphopeptides , suggesting that ***ERK1/2*** may ***regulate*** ***p47*** ( phox ) phosphorylation either directly or indirectly via other kinases .	target	1
20394	11046064	6347;729230	Monocyte chemotactic protein-1;CCR2B	***Monocyte chemotactic protein-1*** ( MCP-1 ) ***binding*** to its receptor , ***CCR2B*** , plays an important role in a variety of diseases involving infection , inflammation , and/or injury .	parallel	1
20395	11046070	6737;7124	SSA;TNF-alpha	Compared with nonapoptotic cardiocytes or apoptotic cardiocytes incubated with normal sera , apoptotic cardiocytes preincubated with affinity-purified Abs to SSB/La , 52-kDa SSA/Ro , or 60-kDa ***SSA/Ro*** ***increased*** the secretion of ***TNF-alpha*** from cocultured macrophages .	positive	0
20396	11046131	5431;29101	Rpb2;Ssu72	The Ssu72 protein interacts directly with purified RNAP II in a coimmunoprecipitation assay , suggesting that the genetic ***interactions*** between ***Ssu72-2*** and ***Rpb2-100*** are a consequence of physical interactions .	parallel	1
20397	11046131	5431;29101	Rpb2;Ssu72	Functional ***interaction*** between ***Ssu72*** and the ***Rpb2*** subunit of RNA polymerase II in Saccharomyces cerevisiae .	parallel	1
20398	11046132	9368;5159	NHERF;PDGFR	NHERF oligomerizes in vitro when bound with PDGFR-CT , and a truncated version of the first ***NHERF*** PDZ domain that can ***bind*** ***PDGFR-CT*** but which does not oligomerize reduces PDGFR tyrosine kinase activity when transiently overexpressed in cells .	parallel	1
20399	11046132	9368;5159	NHERF;PDGFR	These findings reveal that ***NHERF*** can directly ***bind*** to the ***PDGFR*** and potentiate PDGFR activity , thus elucidating both a novel mechanism by which PDGFR activity can be regulated and a new cellular role for the PDZ domain-containing adapter protein NHERF .	parallel	1
20400	11046132	9368;5159	NHERF;PDGFR	These findings reveal that ***NHERF*** can directly bind to the PDGFR and ***potentiate*** ***PDGFR*** activity , thus elucidating both a novel mechanism by which PDGFR activity can be regulated and a new cellular role for the PDZ domain-containing adapter protein NHERF .	positive	0
20401	11046133	375757;7276	Swi5;Cts1	Finally , these studies illustrate how mother-daughter cell adhesion can be accomplished by two distinct mechanisms : one involving Flo11 and the other involving ***regulation*** of the endochitinase ***Cts1*** and the endoglucanase Egt2 by ***Swi5*** .	target	1
20402	11046135	5598;4205	ERK5;MEF2	The ******MEF2-ERK5****** ***interaction*** was found to be activation dependent in vivo and inhibitable in vitro by the calcium-sensitive MEF2 repressor Cabin 1 .	parallel	1
20403	11046138	940;5906	CD28;Rap1	***CD28*** ***inhibits*** ***Rap1*** activation because it selectively stimulates an extrinsic Rap1 GTPase activity .	negative	1
20404	11046139	7157;1019	p53;cdk4	p53 binds selectively to the 5 ' untranslated region of cdk4 , an RNA element necessary and sufficient for transforming growth factor beta - and ***p53-mediated*** translational ***inhibition*** of ***cdk4*** .	negative	1
20405	11046139	7157;1019	p53;cdk4	Here , we show that the 5 ' untranslated region ( UTR ) of the cdk4 mRNA is both necessary and sufficient for wild-type ***p53-dependent*** TGF-beta-regulated translational ***inhibition*** of ***cdk4*** .	negative	1
20406	11046139	7040;1019	TGF-beta;cdk4	Here , we show that the 5 ' untranslated region ( UTR ) of the cdk4 mRNA is both necessary and sufficient for wild-type p53-dependent ***TGF-beta-regulated*** translational ***inhibition*** of ***cdk4*** .	negative	1
20407	11046144	5898;3725	Ral;c-Jun	***Ral-dependent*** ***regulation*** of ***c-Jun*** phosphorylation includes JNK , a still elusive JNKK , and possibly Src .	target	1
20408	11046145	4261;1387	CIITA;CBP	The class II transactivator ( ***CIITA*** ) , the master regulator of the tissue-specific and interferon gamma-inducible expression of major histocompatibility complex class II genes , ***synergizes*** with the histone acetylase coactivator ***CBP*** to activate gene transcription .	parallel	0
20409	11046145	8850;4261	PCAF;CIITA	Here we demonstrate that in addition to CBP , ***PCAF*** ***binds*** to ***CIITA*** both in vivo and in vitro and enhances CIITA-dependent transcriptional activation of class II promoters .	parallel	1
20410	11046145	8850;4261	PCAF;CIITA	The shuttling behavior and activity of the protein are regulated by acetylation : overexpression of ***PCAF*** or inhibition of cellular deacetylases by trichostatin A ***increases*** the nuclear accumulation of ***CIITA*** in a manner determined by the presence of the acetylation target lysines .	positive	0
20411	11046146	7038;7080	Thyroglobulin;thyroid transcription factor 1	***Thyroglobulin*** ***repression*** of ***thyroid transcription factor 1*** ( TTF-1 ) gene expression is mediated by decreased DNA binding of nuclear factor I proteins which control constitutive TTF-1 expression .	negative	1
20412	11046147	128869;5781	Gab1;SHP-2	To elucidate the Gab1-dependent signals required for epithelial morphogenesis , we undertook a structure-function approach and demonstrate that ***association*** of ***Gab1*** with the tyrosine phosphatase ***SHP-2*** is required for sustained Erk activation and for epithelial morphogenesis downstream from the met receptor .	parallel	0
20413	11046208	7124;3557	TNFalpha;IL-1ra	Plasma ***TNFalpha*** at 2 h ***correlated*** with urinary NAG/creatinine ratio at 2 and 6 h ( P < 0.05 ) and with urinary ***IL-1ra*** at 2 h ( P < 0.05 ) .	parallel	0
20414	11048516	1636;3827	kininase II;bradykinin	The first dual endopeptidase inhibitors were ACE inhibitors blocking the conversion of angiotensin I to A II and inhibiting at the same time the ***degradation*** of ***bradykinin*** by ***kininase II*** which is identical with ACE .	negative	1
20415	11048644	3725;203074	c-Jun;TSP-1	PMA treatment and ***c-Jun*** overexpression ***suppressed*** the transcription of ***TSP-1*** promotor-luciferase reporter gene .	negative	1
20416	11048721	1630;9423	DCC;Netrin-1	The ***DCC*** ( for deleted in colorectal cancer ) protein was proposed as a ***receptor*** for ***Netrin-1*** in the light of many observations including the inhibition of Netrin-1-mediated axon outgrowth and attraction in the presence of an anti-DCC antiserum , the similitude of nervous system defects in DCC and Netrin-1 knockout mice and the results of receptor swapping experiments .	parallel	1
20417	11048721	1630;9423	DCC;Netrin-1	Previous studies have failed to show a direct ***interaction*** of ***DCC*** with ***Netrin-1*** ( ref .	parallel	1
20418	11048721	1630;136	DCC;adenosine A2b receptor	Here we show that ***DCC*** ***interacts*** with the membrane-associated ***adenosine A2b receptor*** , a G-protein-coupled receptor that induces cAMP accumulation on binding adenosine .	parallel	1
20419	11048951	2959;6908	TFIIB;TBP	Ninety-five percent of the quaternary ******TBP-TFIIA-TFIIB-TATA****** ***complex*** contained yTBP bound in the orientation expected on the basis of crystallographic and genetic experiments , and more than 70 % is restricted axially to the 8 bp sequence TATAAAAG .	parallel	1
20420	11049026	3458;931	interferon-gamma;CD20	The use of agents to induce MM - and WM-selective antigens for targeting in serotherapy has been proposed based on studies demonstrating the ***upregulation*** of ***CD20*** by ***interferon-gamma*** ( IFN-gamma ) , and of MUC1 core protein by dexamethasone ( DEX ) on malignant plasma cells .	positive	1
20421	11049971	2028;920	gp120/160;CD4 receptor	The many mechanisms that contribute to HIV-associated lymphocyte apoptosis include chronic immunologic activation ; ***gp120/160*** ***ligation*** of the ***CD4 receptor*** ; enhanced production of cytotoxic ligands or viral proteins by monocytes , macrophages , B cells , and CD8 T cells from HIV-infected patients that kill uninfected CD4 T cells ; and direct infection of target cells by HIV , resulting in apoptosis .	parallel	1
20422	11049983	51156;2159	ZPI;factor Xa	The ******factor Xa-ZPI****** ***complex*** is not stable to sodium dodecyl sulfate-polyacrylamide gel electrophoresis , but is detectable by alkaline-polyacrylamide gel electrophoresis .	parallel	1
20423	11049984	4018;2152	lipoprotein;tissue factor	Smooth muscle cell surface ***tissue factor*** pathway ***activation*** by oxidized low-density ***lipoprotein*** requires cellular lipid peroxidation .	positive	1
20424	11049984	4018;2152	lipoprotein;tissue factor	We demonstrate that oxidized low-density ***lipoprotein*** ( LDL ) ***induces*** surface ***tissue factor*** pathway activity ( ie , activity of the tissue factor : factor VIIa complex ) on human and rat smooth muscle cells .	target	1
20425	11049991	6387;7852	SDF-1;CXCR4	The enhanced fusion of cytokine-treated MDMs with T-tropic envelopes was inhibited by the ***CXCR4*** ***ligand*** , ***SDF-1*** , and by T22 peptide .	parallel	1
20426	11049999	356;355	CD95L;CD95	Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells : role of ******CD95-CD95L****** ***interaction*** .	parallel	1
20427	11050006	814;57118	CaMK;CKLiK	Additionally , ***CaMK-kinasealpha*** ***enhanced*** ***CKLiK*** activity .	positive	0
20428	11050052	959;958	CD40L;CD40	The current study evaluated the role of ***CD40/CD40*** ***ligand*** ( ***CD40L*** ) and CD28/B7 costimulation signals during alloimmune responses independently mediated by CD4 ( + ) or CD8 ( + ) T cells .	parallel	1
20429	11050052	959;958	CD40L;CD40	Treatment of CD8 or CD4 KO mice with anti-CD40L monoclonal antibody ( mAb ; MR1 ) resulted in significant prolongation of hepatocyte survival indicating that ******CD40/CD40L****** ***interactions*** were critical in both CD4 ( + ) and CD8 ( + ) T-cell initiated hepatocyte rejection .	parallel	1
20430	11050077	3276;348	PRMT1;AD2	***PRMT1*** , like CARM1 , ***bound*** to the C-terminal ***AD2*** activation domain of p160 coactivators and thereby enhanced the activity of NRs in transient transfection assays .	parallel	1
20431	11050084	5465;7350	Peroxisome proliferator-activated receptor alpha;uncoupling protein-1	***Peroxisome proliferator-activated receptor alpha*** ***activates*** transcription of the brown fat ***uncoupling protein-1*** gene .	positive	1
20432	11050085	725;5627	C4BP;protein S	In this study , we have mutated potentially important amino acids located at the surface of CCP1 of the beta-chain to probe the ******protein S-C4BP****** ***interaction*** .	parallel	1
20433	11050087	9984;472	p84N5;ataxia telangiectasia-mutated	We conclude that ***p84N5*** ***induces*** an ***ataxia telangiectasia-mutated*** kinase ( ATM ) - independent , caffeine-sensitive G ( 2 ) / M cell cycle arrest prior to the onset of apoptosis .	target	1
20434	11050116	7124;101	Tumor necrosis factor alpha;ADAM8	***Tumor necrosis factor alpha*** ***induces*** a metalloprotease-disintegrin , ***ADAM8*** ( CD 156 ) : implications for neuron-glia interactions during neurodegeneration .	target	1
20435	11050116	7124;101	TNF-alpha;ADAM8	In primary astrocytes from wild-type and WR mice , in primary cerebellar neurons , and in mouse motoneuron-like NSC19 cells , ***ADAM8*** expression was ***induced*** up to 15-fold by mouse ***TNF-alpha*** , in a dose-dependent manner .	target	1
20436	11050116	7124;101	TNF-alpha;ADAM8	In both cell types , ***ADAM8*** was also ***induced*** by human ***TNF-alpha*** , indicating that TNF receptor type I ( p55 ) is involved .	target	1
20437	11050116	3659;101	IRF-1;ADAM8	We conclude that ***IRF-1-mediated*** ***induction*** of ***ADAM8*** by TNF-alpha is a signaling pathway relevant for neurodegenerative disorders with glia activation , proposing a role for ADAM8 in cell adhesion during neurodegeneration .	target	1
20438	11050116	7124;101	TNF-alpha;ADAM8	We conclude that IRF-1-mediated ***induction*** of ***ADAM8*** by ***TNF-alpha*** is a signaling pathway relevant for neurodegenerative disorders with glia activation , proposing a role for ADAM8 in cell adhesion during neurodegeneration .	target	1
20439	11050151	2033;1499	p300;beta-catenin	We report that the transcriptional coactivator ***p300*** ***interacts*** with ***beta-catenin*** in vitro and in vivo and is critical for beta-catenin-mediated neoplastic transformation .	parallel	1
20440	11050161	1020;84152	cyclin-dependent kinase 5;DARPP-32	In resting neostriatal slices , ***cyclin-dependent kinase 5*** ( Cdk5 ) ***phosphorylates*** ***DARPP-32*** at Thr-75 , thereby reducing the efficacy of dopaminergic signaling .	target	1
20441	11050165	64689;5347	GRASP65;Plk	In this report we demonstrate ***binding*** between ***Plk*** and ***GRASP65*** and provide in vitro and in vivo evidence that Plk is a GRASP65 kinase .	parallel	1
20442	11050165	983;64689	Cdc2;GRASP65	Moreover , we show that ***Cdc2*** can also ***phosphorylate*** ***GRASP65*** .	target	1
20443	11050168	137902;213	PMR-1;albumin	Whereas recombinant Vigilin has no detectable protective effect on ***PMR-1*** ***cleavage*** of ***albumin*** mRNA , it retards in vitro cleavage of the vitellogenin mRNA 3 ' - UTR by purified PMR-1 .	target	1
20444	11050169	1051;1050	C/EBPbeta;C/EBPalpha	***C/EBPbeta*** , a transcriptional ***activator*** of the ***C/EBPalpha*** gene , is expressed early in the differentiation program , but lacks DNA-binding activity and fails to localize to centromeres until preadipocytes traverse the G ( 1 ) - S checkpoint of mitotic clonal expansion .	positive	1
20445	11050169	1649;1050	CHOP-10;C/EBPalpha	In support of these findings , up-regulation of ***CHOP-10*** with the protease inhibitor N-acetyl-Leu-Leu-norleucinal ***prevents*** activation of C/EBPbeta , expression of ***C/EBPalpha*** , and adipogenesis .	negative	0
20446	11050169	1649;1051	CHOP-10;C/EBPbeta	In support of these findings , up-regulation of ***CHOP-10*** with the protease inhibitor N-acetyl-Leu-Leu-norleucinal ***prevents*** activation of ***C/EBPbeta*** , expression of C/EBPalpha , and adipogenesis .	negative	0
20447	11050170	6670;1050	Sp3;C/EBPalpha	***Sp3*** is a strong transcriptional ***activator*** of the ***C/EBPalpha*** gene promoter in 3T3-L1 preadipocytes and Schneider cells , this activation being repressed by CUP/AP-2alpha .	positive	1
20448	11050175	10728;3320	p23;hsp90	One co-chaperone , ***p23*** , ***binds*** selectively to the ATP-bound state of ***hsp90*** .	parallel	1
20449	11050175	373156;10728	GST;p23	Full-length ***GST-hsp90*** is able to ***bind*** ***p23*** , and also , to chaperone assembly of progesterone receptor complexes .	parallel	1
20450	11050175	3320;10728	hsp90;p23	Full-length ***GST-hsp90*** is able to ***bind*** ***p23*** , and also , to chaperone assembly of progesterone receptor complexes .	parallel	1
20451	11050175	2280;10728	FK506-binding protein12;p23	These regions are only effective when hsp90 is in a dimeric state as shown by loss of p23 binding upon removal of GST or as shown by use of ***FK506-binding protein12-hsp90*** constructs that form dimers and ***bind*** ***p23*** only in the presence of a bivalent drug .	parallel	1
20452	11050175	3320;10728	hsp90;p23	These regions are only effective when hsp90 is in a dimeric state as shown by loss of p23 binding upon removal of GST or as shown by use of ***FK506-binding protein12-hsp90*** constructs that form dimers and ***bind*** ***p23*** only in the presence of a bivalent drug .	parallel	1
20453	11050175	10728;3320	p23;hsp90	Thus , ***p23*** binding ***requires*** an ***hsp90*** dimer with close proximity between N-terminal regions of hsp90 and a conformation specified by ATP .	target	0
20454	11050235	5178;581	Peg3;Bax	We further demonstrate that ***Peg3/Pw1*** , a protein up-regulated in p53-mediated cell death process , ***induces*** ***Bax*** translocation independent of apoptosis .	target	1
20455	11050239	387;6722	RhoA;serum response factor	G2A elicits ***RhoA-dependent*** transcriptional ***activation*** of ***serum response factor*** .	positive	1
20456	11050245	2621;558	GAS6;Axl	***GAS6*** is a ***ligand*** for the ***Axl*** ( Ufo/Ark ) , Sky ( Dtk/Tyro3/Rse / Brt/Tif ) , and Mer ( Eyk ) family of tyrosine kinase receptors and binds to these receptors via tandem G domains at its C terminus .	parallel	1
20457	11050389	355;4609	Fas;c-Myc	A ' non-canonical ' DNA-binding element mediates the ***response*** of the ***Fas-ligand*** promoter to ***c-Myc*** .	parallel	0
20458	11050389	356;355	FasL;Fas	Although the mechanism of c-Myc-induced apoptosis remains unclear , it is susceptible to regulation by survival factors [ 2,3 ] and can proceed through the interaction of ***Fas*** ***ligand*** ( ***FasL*** ) with its receptor , Fas [ 4 ] .	parallel	1
20459	11050389	356;355	FasL;Fas	Although the mechanism of c-Myc-induced apoptosis remains unclear , it is susceptible to regulation by survival factors [ 2,3 ] and can proceed through the ***interaction*** of Fas ligand ( ***FasL*** ) with its receptor , ***Fas*** [ 4 ] .	parallel	1
20460	11050389	4149;356	Max;FasL	The FasL promoter can be driven by c-Myc overexpression , and functional inhibitors of Myc and its binding partner , ***Max*** , ***inhibit*** the transcriptional activity of the ***FasL*** promoter [ 9,10 ] .	negative	1
20461	11050389	4149;4609	Max;c-Myc	We identified a non-canonical binding site ( ATTCTCT ) for ******c-Myc-Max****** ***heterodimers*** in the FasL promoter , which , when mutated , abolished activity in response to c-Myc .	parallel	1
20462	11050771	2321;7422	Flt-1;Vascular endothelial growth factor	***Vascular endothelial growth factor*** and its ***receptor*** , ***Flt-1*** , in smokers and non-smokers .	parallel	1
20463	11051042	3569;4986	Interleukin-6;kappa opioid receptor	***Interleukin-6*** ***regulation*** of ***kappa opioid receptor*** gene expression in primary sertoli cells .	target	1
20464	11051042	3569;4986	Interleukin-6;kappa opioid receptor	In a semiquantitative PCR analysis using the S16 ribosomal RNA gene as an internal control , we show that ***Interleukin-6*** ***reduces*** ***kappa opioid receptor*** mRNA levels from 6 to 24 h of treatment in primary Sertoli cells .	negative	1
20465	11051046	2798;2796	GnRH-R;GnRH	In a previous study , we showed that even continuous application of gonadotropin-releasing hormone ( GnRH ) could increase the steady-state levels of ***GnRH*** ***receptor*** ( ***GnRH-R*** ) mRNA if treated for a relatively short period ( 6 h ) .	parallel	1
20466	11051195	3559;3558	IL2R;interleukin 2	Regulatory effect of CD25 , an activation antigen the alpha subunit of ***interleukin 2*** ***receptor*** ( ***IL2R*** ) on the activity of natural killer ( NK ) cells was studied in fifty elderly ( 57-70 years old ) and fifty young people ( 19-35 years old ) .	parallel	1
20467	11051196	4803;1103	NGF;ChAT	In 4-month-old rats , ***NGF*** infusion ***decreased*** the intensity of both ***ChAT*** and p75NTR immunostaining .	negative	0
20468	11051267	5592;4214	PKG;MEKK1	Thus , it appears that sulindac sulfone and related compounds induce apoptosis , at least in part , through activation of ***PKG*** , which then ***activates*** the ***MEKK1-SEK1-JNK1*** cascade .	positive	1
20469	11051267	5592;6416	PKG;SEK1	Thus , it appears that sulindac sulfone and related compounds induce apoptosis , at least in part , through activation of ***PKG*** , which then ***activates*** the ***MEKK1-SEK1-JNK1*** cascade .	positive	1
20470	11051551	59082;3553	ICEBERG;IL-1beta	Consistent with this , enforced retroviral expression of ***ICEBERG*** ***inhibits*** lipopolysaccharide-induced ***IL-1beta*** generation .	negative	1
20471	11052333	5617;7124	prolactin;TNF-alpha	The T3 , T4 , ***prolactin*** , and corticosterone alterations are ***associated*** with a persistent increase of ***TNF-alpha*** and NO , whose serum concentrations at 45 days postop are , respectively , 1838.33 + / - 247.07 vs 48.89 + / - 8.75 pg/ml and 0.43 + / - 0.13 vs 0.19 + / - 0.01 mmol/ml .	parallel	0
20472	11052808	3383;3689	cd54;LFA-1	The ***interaction*** between leukocyte function-associated antigen-1 ( ***LFA-1*** ) , a member of the beta ( 2 ) - integrin family of adhesion molecules , and intracellular adhesion molecule ICAM-1 ( ***cd54*** ) is thought to play a critical role in the inflammatory process .	parallel	1
20473	11052818	3569;3458	IL-6;IFN-gamma	Thus , ***IL-6*** ***mediates*** ***IFN-gamma*** production following burn .	target	0
20474	11052828	7124;4586	TNF-alpha;MUC5AC	***TNF-alpha*** ***stimulates*** ***MUC5AC*** mucin secretion in a dose-dependent manner , with 20 ng/ml producing maximal stimulation .	positive	0
20475	11052828	7124;4586	TNF-alpha;mucin	These results suggest that ***TNF-alpha*** ***stimulation*** of ***mucin*** secretion could play an important role in the early acute phase of the development of OME .	positive	0
20476	11052866	356;355	FasL;Fas	In the present study these pathogenic protozoans were developed as a model system to describe the potential role of the ***Fas*** ***ligand*** ( ***FasL*** ) - Fas receptor ( FasR ) system as a means of innate immunity in teleosts .	parallel	1
20477	11052868	4035;2	A2MR;A2M	In addition , up-regulation of the ***A2M*** ***receptor*** ( ***A2MR/LRP*** ) was observed in peritoneal macrophages during T. cruzi infection .	parallel	1
20478	11052943	10096;8976	Arp2/3;N-WASP	Integration of multiple signals through cooperative regulation of the ******N-WASP-Arp2/3****** ***complex*** .	parallel	1
20479	11052957	1977;1981	eIF4E;eIF4G	Acute alcohol exposure increased the binding of 4E-binding protein 1 ( 4E-BP1 ) to eIF4E ( 55 % ) , diminished the amount of ***eIF4E*** ***bound*** to ***eIF4G*** ( 70 % ) , reduced the amount of 4E-BP1 in the phosphorylated gamma-form ( 40 % ) , and decreased the phosphorylation of p70S6 kinase and the ribosomal protein S6 .	parallel	1
20480	11052957	1978;1977	4E-BP1;eIF4E	Acute alcohol exposure increased the ***binding*** of 4E-binding protein 1 ( ***4E-BP1*** ) to ***eIF4E*** ( 55 % ) , diminished the amount of eIF4E bound to eIF4G ( 70 % ) , reduced the amount of 4E-BP1 in the phosphorylated gamma-form ( 40 % ) , and decreased the phosphorylation of p70S6 kinase and the ribosomal protein S6 .	parallel	1
20481	11052963	1977;1981	eIF4E;eIF4G	Previous studies in rats and pigs have shown that the feeding-induced stimulation of protein synthesis is associated with activation of the 70-kDa ribosomal protein S6 kinase ( S6K1 ) as well as enhanced ***binding*** of eukaryotic initiation factor ***eIF4E*** to ***eIF4G*** to form the active eIF4F complex .	parallel	1
20482	11052971	1977;1978	eIF4E;4E-BP1	Assessment of potential mechanisms regulating translational efficiency showed that neither the sepsis-induced change in gastrocnemius content of eukaryotic initiation factor 2B ( eIF2B ) , the amount of ***eIF4E*** ***associated*** with 4E binding protein-1 ( ***4E-BP1*** ) , nor the phosphorylation state of 4E-BP1 or eIF4E were altered by the binary complex .	parallel	0
20483	11052974	1978;1977	4E-BP1;eIF4E	Moreover , no changes in the amount of the binding protein ***4E-BP1*** ***associated*** with ***eIF4E*** or in the phosphorylation of 4E-BP1 were observed during sepsis or sterile inflammation .	parallel	0
20484	11052974	1981;1977	eIF4G;eIF4E	The diminished amount of ***eIF4G*** ***bound*** to ***eIF4E*** was not the result of a reduced abundance of eIF4E .	parallel	1
20485	11052978	5564;6517	AMPK;GLUT-4	***AMPK*** phosphorylates and inhibits acetyl-coenzyme A ( CoA ) carboxylase ( ACC ) and ***enhances*** ***GLUT-4*** translocation .	positive	0
20486	11053014	7124;6439	TNF-alpha;SP-B	Taken together these data indicated that in NCI-H441 cells 1 ) ***TNF-alpha*** ***inhibition*** of ***SP-B*** promoter activity may be caused by decreased binding activities of TTF-1 and HNF-3 elements , 2 ) the decreased binding activities of TTF-1 and HNF-3 alpha are not due to decreased nuclear levels of the proteins , and 3 ) okadaic acid-sensitive phosphatases may be involved in mediating TNF-alpha inhibition of SP-B promoter activity .	negative	1
20487	11053014	7124;6439	TNF-alpha;SP-B	In the present study , we investigated the ***TNF-alpha*** ***inhibition*** of rabbit ***SP-B*** promoter activity in a human lung adenocarcinoma cell line ( NCI-H441 ) .	negative	1
20488	11053014	7124;6439	TNF-alpha;SP-B	Inhibitors of NF-kappa B activation such as dexamethasone and N-tosyl-L-phenylalanine chloromethyl ketone and mutation of the NF-kappa B element did not reverse ***TNF-alpha*** ***inhibition*** of ***SP-B*** promoter , indicating that TNF-alpha inhibition of SP-B promoter activity occurs independently of NF-kappa B activation .	negative	1
20489	11053014	7124;2305	TNF-alpha;HNF-3	***TNF-alpha*** treatment ***decreased*** the binding activities of TTF-1 and ***HNF-3*** elements without altering the nuclear levels of TTF-1 and HNF-3 alpha proteins .	negative	0
20490	11053014	7124;6439	TNF-alpha;SP-B	Pretreatment of cells with okadaic acid reversed ***TNF-alpha*** ***inhibition*** of ***SP-B*** promoter activity .	negative	1
20491	11053030	3553;5743	IL-1 beta;COX-2	These results are consistent with the hypothesis that p38 is involved in the signal transduction pathway through which ***IL-1 beta*** ***induces*** ***COX-2*** expression , PGE ( 2 ) release , and beta-adrenergic hyporesponsiveness .	target	1
20492	11053030	1432;3553	p38 MAP kinase;IL-1 beta	***p38 MAP kinase*** ***regulates*** ***IL-1 beta*** responses in cultured airway smooth muscle cells .	target	1
20493	11053031	3082;5594	HGF;p38	We show , using H441 cells , that 1 ) HGF activates membrane-associated protein kinase C ( PKC ) ; the activity is transient and peaks within 30 min ; 2 ) ***HGF*** ***activates*** p42/p44 and ***p38*** mitogen-activated protein kinases ( MAPKs ) ; maximum activity in both is within 10 min ; and 3 ) the activation of neither p38 nor p42/p44 MAPK is dependent on PKC , indicating that HGF uses separate and nonintersecting pathways to activate these two classes of kinase .	positive	1
20494	11053031	3082;5706	HGF;p42	We show , using H441 cells , that 1 ) HGF activates membrane-associated protein kinase C ( PKC ) ; the activity is transient and peaks within 30 min ; 2 ) ***HGF*** ***activates*** ***p42/p44*** and p38 mitogen-activated protein kinases ( MAPKs ) ; maximum activity in both is within 10 min ; and 3 ) the activation of neither p38 nor p42/p44 MAPK is dependent on PKC , indicating that HGF uses separate and nonintersecting pathways to activate these two classes of kinase .	positive	1
20495	11053056	5594;2353	ERK;c-fos	Suppression of ***ERK*** by PD098059 ***abrogated*** induction of ***c-fos*** and c-jun , and the p38 MAP kinase inhibitor SB203580 attenuated c-fos expression .	positive	0
20496	11053056	5594;3725	ERK;c-jun	Suppression of ***ERK*** by PD098059 ***abrogated*** induction of c-fos and ***c-jun*** , and the p38 MAP kinase inhibitor SB203580 attenuated c-fos expression .	positive	0
20497	11053080	10068;3458	IL18BP;IFNgamma	Because IL18 is an important inducer of interferon gamma ( IFNgamma ) , ***IL18BP*** ***suppresses*** the production of ***IFNgamma*** resulting in reduced T-helper type 1 immune responses .	negative	1
20498	11053081	3570;3569	IL6R;IL6	Successful treatment of the model animals for immune-inflammatory diseases with ***anti-IL6*** ***receptor*** ( ***IL6R*** ) antibody thus indicates the possible application of IL6 blocking agents to treat the IL6 related immune-inflammatory diseases of humans .	parallel	1
20499	11053090	4792;4790	IkappaBalpha;NFkappaB	Using a virus encoding ***IkappaBalpha*** , the natural ***inhibitor*** of ***NFkappaB*** , we show that the requirement for the transcription factor is not universal , but is dependent on the nature of the stimulus .	negative	1
20500	11053099	3557;27179	interleukin 1 receptor antagonist;IL1	***interleukin 1 receptor antagonist*** ( IL1Ra ) selectively ***inhibits*** the effects of ***IL1*** by competing for the IL1 receptor on all surfaces of the synovium .	negative	1
20501	11053223	7039;6281	TGF-alpha;p11	Under the conditions , ***TGF-alpha*** was found to ***increase*** ***p11*** , an endogenous cPLA ( 2 ) suppressor , also known as annexin II light chain .	positive	0
20502	11053245	1432;5594	p38alpha;p38	Moreover , cells expressing a dominant negative ***p38alpha*** , which ***prevented*** ischemic ***p38*** activation , were resistant to lethal simulated ischemia ( CK release 82.9 + / -3.9 % and MTT bioreduction 130.2 + / -6.5 % of control , n = 8 , P < 0.05 ) .	negative	0
20503	11053255	5290;3952	p110alpha;Leptin	The ***Leptin*** effect on invasion was potentiated by the activated form of the small GTPase RhoA and was ***abrogated*** by dominant negative mutants of RhoA , Rac1 , and the ***p110alpha*** of PI3 ' - K.	positive	0
20504	11053255	5879;3952	Rac1;Leptin	The ***Leptin*** effect on invasion was potentiated by the activated form of the small GTPase RhoA and was ***abrogated*** by dominant negative mutants of RhoA , ***Rac1*** , and the p110alpha of PI3 ' - K.	positive	0
20505	11053255	387;3952	RhoA;Leptin	The ***Leptin*** effect on invasion was potentiated by the activated form of the small GTPase RhoA and was ***abrogated*** by dominant negative mutants of ***RhoA*** , Rac1 , and the p110alpha of PI3 ' - K.	positive	0
20506	11053255	387;3952	RhoA;Leptin	The ***Leptin*** effect on invasion was ***potentiated*** by the activated form of the small GTPase ***RhoA*** and was abrogated by dominant negative mutants of RhoA , Rac1 , and the p110alpha of PI3 ' - K.	positive	0
20507	11053288	6863;3576	Substance P;IL-8	***Substance P*** differentially ***stimulates*** ***IL-8*** synthesis in human corneal epithelial cells .	positive	0
20508	11053408	2057;2056	EpoR;Epo	Gbeta and Galpha ( i ) coprecipitated with the ***Epo*** ***receptor*** ( ***EpoR*** ) in extracts from human and murine cell lines and from normal human erythroid progenitor cells .	parallel	1
20509	11053412	5457;596	BRN-3A;Bcl-2	Similarly , overexpression of ***BRN-3A*** ***activated*** the endogenous ***Bcl-2*** gene in trigeminal neurons , but not in sympathetic neurons .	positive	1
20510	11053413	836;8505	Caspase-3;PARG	Consistently , recombinant ***Caspase-3*** efficiently ***cleaved*** ***PARG*** in vitro , suggesting the involvement of this protease in PARG processing in vivo .	target	1
20511	11053413	836;8505	Caspase-3;PARG	Kinetic studies have shown similar maximal velocity ( V ( max ) ) and affinity ( K ( m ) ) for both full-length PARG and its apoptotic fragments , suggesting that ***Caspase-3*** may ***affect*** ***PARG*** function without altering its enzymatic activity .	target	0
20512	11053425	8915;4790	BCL10;NF-kappaB	***BCL10/CLAP*** is an ***activator*** of apoptosis and ***NF-kappaB*** signaling pathways and has been implicated in B cell lymphomas of mucosa-associated lymphoid tissue .	positive	1
20513	11053425	8915;4790	BCL10;NF-kappaB	Although its role in apoptosis remains to be determined , ***BCL10*** likely ***activates*** ***NF-kappaB*** through the IKK complex in response to upstream stimuli .	positive	1
20514	11053425	64170;8915	CARD9;BCL10	When expressed in cells , ***CARD9*** ***binds*** to ***BCL10*** and activates NF-kappaB .	parallel	1
20515	11053425	64170;4790	CARD9;NF-kappaB	When expressed in cells , ***CARD9*** binds to BCL10 and ***activates*** ***NF-kappaB*** .	positive	1
20516	11053425	64170;8915	CARD9;BCL10	We propose here that ***CARD9*** is an upstream ***activator*** of ***BCL10*** and NF-kappaB signaling .	positive	1
20517	11053425	64170;4790	CARD9;NF-kappaB	We propose here that ***CARD9*** is an upstream ***activator*** of BCL10 and ***NF-kappaB*** signaling .	positive	1
20518	11053428	998;4296	Cdc42;MLK-3	We have demonstrated previously that ***Cdc42*** ***induced*** ***MLK-3*** homodimerization leads to both autophosphorylation and activation of MLK-3 and postulated that autophosphorylation is an intermediate step of MLK-3 activation following its dimerization .	target	1
20519	11053428	11184;4296	HPK1;MLK-3	Interestingly , HPK1 also phosphorylated MLK-3 activation loop in vitro , and Ser281 was found to be the major phosphorylation site , indicating that ***HPK1*** also ***activates*** ***MLK-3*** via phosphorylation of the kinase activation loop .	positive	1
20520	11053433	6095;345	RORalpha;apolipoprotein C-III	Transcriptional ***regulation*** of ***apolipoprotein C-III*** gene expression by the orphan nuclear receptor ***RORalpha*** .	target	1
20521	11053437	10253;867	hSPRY2;c-Cbl	Here , we demonstrate that ***hSPRY2*** ***associates*** directly with ***c-Cbl*** , a known down-regulator of RTK signaling .	parallel	0
20522	11053437	10253;867	hSPRY2;c-Cbl	Our results suggest that one function of ***hSPRY2*** in signaling processes downstream of RTKs may be to ***modulate*** ***c-Cbl*** physiological function such as that seen with receptor-mediated endocytosis .	target	0
20523	11053443	4193;7157	Mdm2;p53	Here we describe the role of this region in the ***regulation*** of ***p53*** by its inhibitor ***Mdm2*** .	target	1
20524	11053446	356;355	FasL;Fas	Subtypes of SMC expressing abundant levels of Sp1 produce the death agonist , ***Fas*** ***ligand*** ( ***FasL*** ) and undergo greater spontaneous apoptosis .	parallel	1
20525	11053446	5590;356	protein kinase C-zeta;FasL	Inducible ***FasL*** transcription and apoptosis are ***blocked*** by dominant-negative ***protein kinase C-zeta*** , whose wild-type counterpart phosphorylates Sp1 .	negative	0
20526	11053448	2353;3725	Fos;Jun	***Fos*** family proteins form stable ***heterodimers*** with ***Jun*** family proteins , and each heterodimer shows distinctive transactivating potential for regulating cellular growth , differentiation , and development via AP-1 binding sites .	parallel	1
20527	11053448	2353;3725	Fos;Jun	BAF60a binds to a specific subset of ******Fos/Jun****** ***heterodimers*** using two different interfaces for c-Fos and c-Jun , respectively .	parallel	1
20528	11053476	3725;7040	AP-1;TGF-beta1	***AP-1*** proteins ***mediate*** hyperglycemia-induced activation of the human ***TGF-beta1*** promoter in mesangial cells .	target	0
20529	11053526	3952;1392	Leptin;CRH	The current study demonstrates that ***Leptin*** rapidly ***influences*** the secretion of hypothalamic NPY and ***CRH*** and that these actions of Leptin within the hypothalamus are restrained by the presence of endogenous corticosterone .	target	0
20530	11053526	3952;4852	Leptin;NPY	The current study demonstrates that ***Leptin*** rapidly ***influences*** the secretion of hypothalamic ***NPY*** and CRH and that these actions of Leptin within the hypothalamus are restrained by the presence of endogenous corticosterone .	target	0
20531	11053526	3952;4852	Leptin;neuropeptide Y	***Leptin*** rapidly ***inhibits*** hypothalamic ***neuropeptide Y*** secretion and stimulates corticotropin-releasing hormone secretion in adrenalectomized mice .	negative	1
20532	11053526	3952;1392	Leptin;corticotropin-releasing hormone	***Leptin*** rapidly inhibits hypothalamic neuropeptide Y secretion and ***stimulates*** ***corticotropin-releasing hormone*** secretion in adrenalectomized mice .	positive	0
20533	11053526	3952;1392	Leptin;CRH	Consistent with this , ***Leptin*** administration to adrenalectomized mice markedly ***reduced*** ***CRH*** concentrations in the ARC within 3 h after injection .	negative	1
20534	11053526	3952;1392	Leptin;CRH	This rapid reduction in CRH concentration in the ARC after Leptin administration is more likely due to stimulated CRH release from this region than to decreased synthesis/transport from the PVN because ***Leptin*** ***stimulates*** ***CRH*** synthesis in the PVN .	positive	0
20535	11053628	4261;3106	CIITA;HLA-B	Transfection of ***CIITA*** in JEG-3 cells also ***upregulated*** functional ***HLA-B*** and HLA-C expression .	positive	1
20536	11053628	4261;3107	CIITA;HLA-C	Transfection of ***CIITA*** in JEG-3 cells also ***upregulated*** functional HLA-B and ***HLA-C*** expression .	positive	1
20537	11053628	3458;4261	IFN-gamma;CIITA	Noteworthy , this lack of ***IFN-gamma-mediated*** ***induction*** of ***CIITA*** was also found to exist in normal trophoblast cells expanded from chorionic villus biopsies .	target	1
20538	11053650	7157;5111	p53;PCNA	The mutant ***p53*** protein is ***correlated*** to deregulation of ***PCNA*** .	parallel	0
20539	11053650	596;5111	bcl-2;proliferating cell nuclear antigen	Co-expression of p53 and ***bcl-2*** may ***correlate*** to the presence of epstein-barr virus genome and the expression of ***proliferating cell nuclear antigen*** in nasopharyngeal carcinoma .	parallel	0
20540	11053650	7157;5111	p53;proliferating cell nuclear antigen	Co-expression of ***p53*** and bcl-2 may ***correlate*** to the presence of epstein-barr virus genome and the expression of ***proliferating cell nuclear antigen*** in nasopharyngeal carcinoma .	parallel	0
20541	11053673	3553;3162	IL-1beta;HO-1	Our laboratory has shown that cysteamine , dopamine , beta-amyloid , ***IL-1beta*** and TNF-alpha ***up-regulate*** ***HO-1*** followed by mitochondrial sequestration of non-transferrin-derived 55Fe in cultured rat astroglia .	positive	1
20542	11053673	7124;3162	TNF-alpha;HO-1	Our laboratory has shown that cysteamine , dopamine , beta-amyloid , IL-1beta and ***TNF-alpha*** ***up-regulate*** ***HO-1*** followed by mitochondrial sequestration of non-transferrin-derived 55Fe in cultured rat astroglia .	positive	1
20543	11053674	5663;351	PS1;Abeta	APP/LoxPS1 , clinical mutant ***PS1*** [ A246E ] but not wild-type human PS1 ***increased*** ***Abeta*** , and plaques and vascular amyloid developed at age 6-9 months .	positive	0
20544	11053681	825;8291	calpain 3;Dysferlin	These results suggest that there may be an ***association*** between ***Dysferlin*** and ***calpain 3*** , and further analysis of both genes may elucidate a novel functional interaction .	parallel	0
20545	11053774	4790;4843	NF-kappaB;iNOS	The transcription factor nuclear factor kappaB ( ***NF-kappaB*** ) ***regulates*** the expression of inducible nitric oxide synthase ( ***iNOS*** ) .	target	1
20546	11054110	3458;4891	Interferon-gamma;Nramp2	***Interferon-gamma*** and lipopolysaccharide ***regulate*** the expression of ***Nramp2*** and increase the uptake of iron from low relative molecular mass complexes by macrophages .	target	1
20547	11054122	80273;3578	GrpE;p40	While protein disulfide isomerase ( PDI ) , GroEL/ES or DnaK/J/GrpE suppressed aggregation during refolding of p40 , only ***DnaK/J/GrpE*** and PDI ***enhanced*** ***p40*** dimerization .	positive	0
20548	11054122	5034;3578	PDI;p40	While protein disulfide isomerase ( PDI ) , GroEL/ES or DnaK/J/GrpE suppressed aggregation during refolding of p40 , only DnaK/J/GrpE and ***PDI*** ***enhanced*** ***p40*** dimerization .	positive	0
20549	11054278	3558;3586	IL-2;IL-10	The levels of ***IL-2*** produced by IL-12-treated T cells ***correlated*** inversely with the levels of ***IL-10*** .	negative	0
20550	11054280	3553;7097	IL-1;TLR2	Like LPS treatment , administration of ***IL-1*** , IL-6 , or tumor necrosis factor ( TNF ) ***upregulated*** ***TLR2*** mRNA .	positive	1
20551	11054280	3569;7097	IL-6;TLR2	Like LPS treatment , administration of IL-1 , ***IL-6*** , or tumor necrosis factor ( TNF ) ***upregulated*** ***TLR2*** mRNA .	positive	1
20552	11054345	183;7040	angiotensin II;TGF-beta	It has been proposed that ***angiotensin II*** ***stimulates*** ***TGF-beta*** production .	positive	0
20553	11054406	7045;5502	transforming growth factor-beta -induced;inhibitor-1	***Regulation*** of plasminogen activator ***inhibitor-1*** expression by ***transforming growth factor-beta -induced*** physical and functional interactions between smads and Sp1 .	target	1
20554	11054406	7040;1026	TGF-beta;p21	***TGF-beta*** ***induction*** of PAI-1 and ***p21*** is blocked by the Sp1 inhibitor mithramycin , implicating Sp1 in the in vivo regulation of these genes by TGF-beta .	target	1
20555	11054406	7040;5054	TGF-beta;PAI-1	***TGF-beta*** ***induction*** of ***PAI-1*** and p21 is blocked by the Sp1 inhibitor mithramycin , implicating Sp1 in the in vivo regulation of these genes by TGF-beta .	target	1
20556	11054408	9846;5290	pp100;PI3K	Instead , a 100-kDa tyrosine-phosphorylated protein ( ***pp100*** ) ***co-immunoprecipitated*** with the regulatory subunit of ***PI3K*** .	parallel	1
20557	11054408	7066;5290	TPO;PI3K	In this report we demonstrate that the ***TPO-induced*** ***activation*** of phosphoinositol 3-kinase ( ***PI3K*** ) , a signaling intermediate vital for cellular survival and proliferation , occurs through its association with inducible signaling complexes in both BaF3 cells engineered to express Mpl ( BaF3/Mpl ) and in primary murine MKs .	positive	1
20558	11054408	4352;5290	Mpl;PI3K	Although a direct ***association*** between ***PI3K*** and ***Mpl*** could not be demonstrated , we found that several proteins , including SHP2 , Gab2 , and IRS2 , undergo phosphorylation and association in BaF3/Mpl cells in response to TPO stimulation , complexes that recruit and enhance the enzymatic activity of PI3K .	parallel	0
20559	11054408	9846;5781	Gab2;SHP2	To verify the physiological relevance of the complex , ******SHP2-Gab2****** ***association*** was disrupted by overexpressing a dominant negative SHP2 construct .	parallel	0
20560	11054408	7066;5781	TPO;SHP2	In primary murine MKs , ***TPO*** also ***induced*** phosphorylation of ***SHP2*** , its association with p85 and enhanced PI3K activity , but in contrast to the results in cell lines , neither Gab2 nor IRS2 are phosphorylated in MKs .	target	1
20561	11054408	7066;5290	TPO;PI3K	In primary murine MKs , ***TPO*** also ***induced*** phosphorylation of SHP2 , its association with p85 and enhanced ***PI3K*** activity , but in contrast to the results in cell lines , neither Gab2 nor IRS2 are phosphorylated in MKs .	target	1
20562	11054413	598;79370	Bcl-X;Bcl-G	***Bcl-X*** ( L ) also ***coimmunoprecipitated*** with ***Bcl-G*** ( S ) but not with mutants of Bcl-G ( S ) in which the BH3 domain was deleted or mutated or with Bcl-G ( L ) .	parallel	1
20563	11054418	6814;6517	Munc18c;glut4	***Munc18c*** ***regulates*** insulin-stimulated ***glut4*** translocation to the transverse tubules in skeletal muscle .	target	1
20564	11054418	6814;6517	Munc18c;glut4	Surprisingly , however , ***Munc18c*** ***inhibited*** ***glut4*** translocation to the transverse-tubule membrane without affecting translocation to the sarcolemma membrane .	negative	1
20565	11054430	4353;4018	myeloperoxidase;lipoprotein	The nitric oxide congener nitrite inhibits ***myeloperoxidase/H2O2*** / Cl - - mediated ***modification*** of low density ***lipoprotein*** .	target	0
20566	11054558	6667;5979	Sp1;RET proto-oncogene	***Sp1*** and Sp3 ***transactivate*** the ***RET proto-oncogene*** promoter .	positive	1
20567	11054558	6670;5979	Sp3;RET proto-oncogene	Sp1 and ***Sp3*** ***transactivate*** the ***RET proto-oncogene*** promoter .	positive	1
20568	11054566	10907;10084	dim1;Npw38	Evidence that dim1 associates with proteins involved in pre-mRNA splicing , and delineation of residues essential for ***dim1*** ***interactions*** with hnRNP F and ***Npw38/PQBP-1*** .	parallel	1
20569	11054640	3488;3479	IGFBP-5;IGF-I	We propose that GH and PRL inhibit apoptosis and ECM remodelling by a process that involves the ***control*** of ***IGF-I*** and PAI-1 availability by ***IGFBP-5*** , thus allowing these processes to be tightly coordinated .	target	0
20570	11054640	3488;5054	IGFBP-5;PAI-1	We propose that GH and PRL inhibit apoptosis and ECM remodelling by a process that involves the ***control*** of IGF-I and ***PAI-1*** availability by ***IGFBP-5*** , thus allowing these processes to be tightly coordinated .	target	0
20571	11054640	5617;3488	PRL;insulin-like growth factor-binding protein-5	GH increases insulin-like growth factor-I ( IGF-I ) synthesis whereas ***PRL*** ***suppresses*** the production of ***insulin-like growth factor-binding protein-5*** ( IGFBP-5 ) in the epithelial cells , which would otherwise inhibit IGF-mediated cell survival .	negative	1
20572	11054640	3488;5502	IGFBP-5;inhibitor-1	Since alpha ( s2 ) - casein also binds plasminogen and tissue-type plasminogen activator ( t-PA ) , resulting in the conversion of plasminogen to plasmin , and since ***IGFBP-5*** ***binds*** to plasminogen activator ***inhibitor-1*** ( PAI-1 ) , we investigated whether apoptosis and extracellular matrix ( ECM ) degradation might be coordinately controlled by GH and PRL possibly acting through IGFBP-5 .	parallel	1
20573	11054645	3488;5741	IGFBP-5;PTH	IGF-I and/or ***IGFBP-5*** seemed to be involved in the estrogen-induced ***modulation*** of ***PTH*** action on osteoblast proliferation and function .	target	0
20574	11054645	3479;5741	IGF-I;PTH	***IGF-I*** and/or IGFBP-5 seemed to be involved in the estrogen-induced ***modulation*** of ***PTH*** action on osteoblast proliferation and function .	target	0
20575	11054665	5879;7074	Rac1;Tiam1	Tiam1 activates the Rho-like GTPase Rac1 , and studies indicate that ******Tiam1-Rac1****** ***signaling*** affects invasion in different ways depending on the cell type studied .	parallel	0
20576	11054665	7074;5879	Tiam1;Rac1	***Tiam1*** ***activates*** the Rho-like GTPase ***Rac1*** , and studies indicate that Tiam1-Rac1 signaling affects invasion in different ways depending on the cell type studied .	positive	1
20577	11054668	4869;3659	B23;IRF-1	Significantly more ***nucleophosmin/B23*** was ***co-immunoprecipitated*** with ***IRF-1*** from pCR3-B23 cells than from pCR3 cells during RA treatment ( 10 microM ; 24 hr , 96 hr ) .	parallel	1
20578	11054669	4851;429	Notch1;HASH-1	Induced neuroblastoma cell differentiation , associated with transient HES-1 activity and reduced ***HASH-1*** expression , is ***inhibited*** by ***Notch1*** .	negative	1
20579	11054669	3280;429	HES-1;HASH-1	In gel mobility shift assays , using extracts from neuroblastoma cells , HES-1 bound to an oligonucleotide corresponding to a sequence in the HASH-1 promoter including the so-called N-box , suggesting that the transiently increased ***HES-1*** activity in differentiating neuroblastoma cells is involved in ***down-regulation*** of ***HASH-1*** .	negative	1
20580	11054669	4851;3280	Notch1;HES-1	Constitutive expression of the intracellular domain of ***Notch1*** , which ***activates*** the ***HES-1*** promoter in SH-SY5Y cells , inhibited spontaneous and induced morphological differentiation of these neuroblastoma cells .	positive	1
20581	11054671	7124;4322	TNF-alpha;MMP-13	In these cell lines , ***TNF-alpha*** potently ***induced*** ***MMP-13*** mRNA expression .	target	1
20582	11054812	3727;2354	JunD;FosB	Possible role for the ******FosB/JunD****** AP-1 transcription factor ***complex*** in glutamate-mediated excitotoxicity in cultured cerebellar granule cells .	parallel	1
20583	11054812	3727;2354	JunD;FosB	Here we demonstrate , using primary cultures of mouse brain cerebellar granule cells as an in vitro model system , a possible involvement of the ******FosB/JunD****** ***heterodimer*** in excitotoxicity .	parallel	1
20584	11054812	3727;2354	JunD;FosB	Because Fos family members are unable to form homodimers , this finding raises the possibility that the ******FosB/JunD****** ***heterodimer*** may have special significance in the mechanism of excitotoxic neuronal death .	parallel	1
20585	11055326	4790;596	NFkappaB;Bcl-2	The data provide evidence for a ***link*** between ***Bcl-2*** and the ***NFkappaB*** signalling pathway for the suppression of apoptosis in ventricular myocytes .	parallel	0
20586	11055326	596;4792	Bcl-2;IkappaBalpha	The mode by which ***Bcl-2*** ***regulates*** ***IkappaBalpha*** was related to the N-terminal phosphorylation and degradation of IkappaBalpha by the proteasome since an N-terminal deletion mutant of IkappaBalpha or the proteasome inhibitor lactacystin abrogated Bcl-2 's inhibitory effects on IkappaBalpha and prevented NFkappaB activation .	target	1
20587	11055624	2944;1565	GSTM1;CYP2D6	We used categorical methods and logistic regression models to evaluate the individual and combined ***associations*** of ***CYP2D6*** and ***GSTM1*** polymorphisms with dysmenorrhea and its subgroups , occasional ( N = 70 ) and recurrent ( N = 59 ) , with adjustment for age , education , occupation , passive smoke exposure , age of menarche , parity , contraceptive method , height , and body mass index .	parallel	0
20588	11055838	842;840	caspase-9;caspase-3 and -7	***caspase-9*** can signal downstream and ***activate*** ***pro-caspase-3 and -7*** .	positive	1
20589	11055983	5478;5594	CyPA;ERK1/2	The peptidyl-prolyl isomerase activity is required for ***ERK1/2*** ***activation*** by ***CyPA*** .	positive	1
20590	11056003	3458;834	IFN-gamma;caspase-1	The extent of IFN-gamma-mediated apoptosis sensitization in these two cell lines correlated well with the degree of ***IFN-gamma-mediated*** ***upregulation*** of the proapoptotic protease ***caspase-1*** .	positive	1
20591	11056083	959;958	CD40-l;CD40	Immune regulation by ******CD40-CD40-l****** ***interactions*** - 2 ; Y2K update .	parallel	1
20592	11056083	959;958	CD40-l;CD40	The present paper reviews recent developments in this field of research , with main emphasis on CD40 signal transduction and on in vivo functions of ******CD40/CD40-l****** ***interactions*** .	parallel	1
20593	11056090	1232;6356	CCR3;eotaxin	Immunohistochemical analysis demonstrated overexpression of ***eotaxin*** protein and its ***receptor*** , ***CCR3*** , in the human atheroma , with negligible expression in normal vessels .	parallel	1
20594	11056090	1232;6356	CCR3;eotaxin	CONCLUSIONS : ***eotaxin*** and its ***receptor*** , ***CCR3*** , are overexpressed in human atherosclerosis , suggesting that eotaxin participates in vascular inflammation .	parallel	1
20595	11056091	3827;5327	Bradykinin;tPA	CONCLUSIONS : These data indicate that ***Bradykinin*** ***stimulates*** ***tPA*** release from human endothelium through a B ( 2 ) receptor-dependent , NO synthase-independent , and cyclooxygenase-independent pathway .	positive	0
20596	11056164	7040;4843	TGF-beta1;NOS2	The aim of the present study was to determine whether regulation of HMG-I ( Y ) by TGF-beta1 contributes to the ***TGF-beta1-mediated*** ***suppression*** of ***NOS2*** .	negative	1
20597	11056164	7040;4843	TGF-beta1;NOS2	Overexpression of HMG-I ( Y ) was able to restore cytokine inducibility of the ***NOS2*** promoter that was ***suppressed*** by ***TGF-beta1*** .	negative	1
20598	11056214	4176;4331	MCM7;MAT1	The physical ***interaction*** between ***MAT1*** and ***MCM7*** was confirmed in vivo in yeast cells and verified with in vitro protein binding assays .	parallel	1
20599	11056392	7453;1315	gamma2;beta-COP	Like gamma1-COP , ***gamma2-COP*** can form a ***complex*** with ***beta-COP*** in vivo .	parallel	1
20600	11056392	7453;51226	gamma2;zeta2-COP	These results indicate that ***gamma2-COP*** and ***zeta2-COP*** can form a COP I-like ***complex*** in place of gamma1-COP and zeta1-COP , respectively , and suggest that the COP I complex and the COP I-like complex are functionally redundant .	parallel	1
20601	11056393	7138;7134	TnT;TnC	Ternary complex constructed from scallop TnT , TnI , and TnC ( W ) conferred Ca ( 2 + ) - sensitivity to the Mg-ATPase of rabbit actomyosin to the same extent as native troponin , but the TnC ( N ) - TnT-TnI and ******TnC-ZEQ-TnT-TnI****** ***complexes*** conferred no Ca ( 2 + ) - sensitivity , while the TnC ( C ) - TnT-TnI complex conferred weak Ca ( 2 + ) - sensitivity .	parallel	1
20602	11056472	4683;4361	NBS1;MRE11	Furthermore , new recent studies have shown now that all three gene products interact ; the ATM kinase phosphorylates ***NBS1*** , which , in turn , ***associates*** with ***MRE11*** to regulate DNA repair .	parallel	0
20603	11056472	472;4683	ATM;NBS1	Furthermore , new recent studies have shown now that all three gene products interact ; the ***ATM*** kinase ***phosphorylates*** ***NBS1*** , which , in turn , associates with MRE11 to regulate DNA repair .	target	1
20604	11056535	11069;9699	cAMP-GEFII;Rim2	Here we show that ***cAMP-GEFII*** , a cAMP sensor , ***binds*** to Rim ( Rab3-interacting molecule , Rab3 being a small G protein ) and to a new isoform , ***Rim2*** , both of which are putative regulators of fusion of vesicles to the plasma membrane .	parallel	1
20605	11056535	11069;22999	cAMP-GEFII;Rim	Here we show that ***cAMP-GEFII*** , a cAMP sensor , ***binds*** to ***Rim*** ( Rab3-interacting molecule , Rab3 being a small G protein ) and to a new isoform , Rim2 , both of which are putative regulators of fusion of vesicles to the plasma membrane .	parallel	1
20606	11056537	1021;596	CDK6;Bcl-2	The apoptotic ***v-cyclin-CDK6*** complex ***phosphorylates*** and inactivates ***Bcl-2*** .	target	1
20607	11056537	1021;596	CDK6;Bcl-2	A Bcl-2 mutant with a S70A S87A double substitution in the loop region is not phosphorylated and provides resistance to apoptosis , indicating that ***inactivation*** of ***Bcl-2*** by ***v-cyclin-CDK6*** may be required for the observed apoptosis .	negative	1
20608	11056663	3565;3557	IL-4;IL-1Ra	Systemic ***IL-4*** administration ***increased*** serum ***IL-1Ra*** levels and reduced anticollagen type II antibody levels .	positive	0
20609	11057428	3082;5594	HGF;ERK	***ERK*** was markedly ***phosphorylated*** by ***HGF*** .	target	1
20610	11057439	6696;4843	osteopontin;NOS2	Tubular expression of ***osteopontin*** ( OPN ) , which is an ***inhibitor*** of ***NOS2*** , correlated with the systolic BP in individual Dahl-SS rats ( r2 = 0.80 , P < 0.0001 ) .	negative	1
20611	11057670	51738;2693	Ghrelin;growth hormone secretagogue (GHS) receptor	The discovery of the peptide hormone ***Ghrelin*** , an endogenous ***ligand*** for the ***growth hormone secretagogue (GHS) receptor*** , yielded the surprising result that the principal site of Ghrelin synthesis is the stomach and not the hypothalamus .	parallel	1
20612	11057670	51738;2688	Ghrelin;pituitary growth hormone	Although ***Ghrelin*** is likely to ***regulate*** ***pituitary growth hormone*** ( GH ) secretion along with GH-releasing hormone and somatostatin , GHS receptors have also been identified on hypothalamic neurons and in the brainstem .	target	1
20613	11057747	836;472	caspase-3;ATM	In vitro studies showed that ***ATM*** was ***cleaved*** by ***caspase-3*** or related subfamily members at a DIVD/G site .	target	1
20614	11057754	2516;1385	SF1;CREB	The EMSA demonstrated potential ***binding*** of ***SF1*** protein to -1617 / -1609 , and ***CREB*** like protein and AP1 family to -1637 / -1626 and -1559 / -1545 .	parallel	1
20615	11057852	5624;462	protein C;antithrombin III	***protein C*** and protein S were significantly ***associated*** with PAI-1 activity , tPA activity ( negatively ) , tPA antigen and ***antithrombin III*** .	parallel	0
20616	11057852	5624;5054	protein C;PAI-1	***protein C*** and protein S were significantly ***associated*** with ***PAI-1*** activity , tPA activity ( negatively ) , tPA antigen and antithrombin III .	parallel	0
20617	11057852	5624;5327	protein C;tPA	***protein C*** and protein S were significantly ***associated*** with PAI-1 activity , ***tPA*** activity ( negatively ) , tPA antigen and antithrombin III .	parallel	0
20618	11057852	5627;462	protein S;antithrombin III	protein C and ***protein S*** were significantly ***associated*** with PAI-1 activity , tPA activity ( negatively ) , tPA antigen and ***antithrombin III*** .	parallel	0
20619	11057852	5627;5054	protein S;PAI-1	protein C and ***protein S*** were significantly ***associated*** with ***PAI-1*** activity , tPA activity ( negatively ) , tPA antigen and antithrombin III .	parallel	0
20620	11057852	5627;5327	protein S;tPA	protein C and ***protein S*** were significantly ***associated*** with PAI-1 activity , ***tPA*** activity ( negatively ) , tPA antigen and antithrombin III .	parallel	0
20621	11057874	4018;5502	lipoprotein;inhibitor-1	In vivo ***stimulation*** of vascular plasminogen activator ***inhibitor-1*** production by very low-density ***lipoprotein*** involves transcription factor binding to a VLDL-responsive element .	positive	0
20622	11057874	4018;5054	lipoprotein;PAI-1	Cell culture studies have shown that very low density ***lipoprotein*** ( VLDL ) ***increases*** the production and secretion of ***PAI-1*** in endothelial cells and hepatocytes , suggesting a possible mechanism for this association .	positive	0
20623	11057875	4790;3725	NF-kappaB;AP-1	Curcumin also inhibited ***NF-kappaB*** and AP-1 ***binding*** to TF-kappaB and proximal ***TF-AP-1*** oligonucleotides , respectively , in a dose-dependent manner .	parallel	1
20624	11057875	4790;3725	NF-kappaB;AP-1	The present work suggests that both the ***NF-kappaB/Rel*** and AP-1 activated in endothelial cells by stimulation with VT-1 ***binds*** to the TF-kappaB and proximal ***AP-1*** binding sites , respectively , of the TF promoter .	parallel	1
20625	11057875	5966;3725	Rel;AP-1	The present work suggests that both the ***NF-kappaB/Rel*** and AP-1 activated in endothelial cells by stimulation with VT-1 ***binds*** to the TF-kappaB and proximal ***AP-1*** binding sites , respectively , of the TF promoter .	parallel	1
20626	11057904	4193;7157	mdm2;p53	***mdm2*** acts as a major ***regulator*** of the tumor suppressor ***p53*** by targeting its destruction .	target	1
20627	11057904	4193;7157	mdm2;p53	***mdm2*** induced by activated Raf ***degrades*** ***p53*** in the absence of the mdm2 inhibitor p19ARF .	negative	0
20628	11057923	3565;3458	interleukin-4;interferon-gamma	Finally , Crohn 's disease cells were significantly more resistant to ***interleukin-4-mediated*** ***inhibition*** of spontaneous and interleukin-2-induced expression of interleukin-2Ralpha and ***interferon-gamma*** mRNA compared to control cells .	negative	1
20629	11058088	4487;1747	Msx1;Dlx3	In addition to transactivation , data are presented to demonstrate specific DNA binding and an ***association*** between ***Dlx3*** and the ***Msx1*** protein in vitro .	parallel	0
20630	11058101	26986;1981	PABP;eIF4G	Biochemical characterisation of cap-poly ( A ) synergy in rabbit reticulocyte lysates : the ******eIF4G-PABP****** ***interaction*** increases the functional affinity of eIF4E for the capped mRNA 5 ' - end .	parallel	1
20631	11058101	1981;1977	eIF4G;eIF4E	Biochemical characterisation of cap-poly ( A ) synergy in rabbit reticulocyte lysates : the ***eIF4G-PABP*** interaction ***increases*** the functional affinity of ***eIF4E*** for the capped mRNA 5 ' - end .	positive	0
20632	11058101	26986;1977	PABP;eIF4E	Biochemical characterisation of cap-poly ( A ) synergy in rabbit reticulocyte lysates : the ***eIF4G-PABP*** interaction ***increases*** the functional affinity of ***eIF4E*** for the capped mRNA 5 ' - end .	positive	0
20633	11058101	26986;1981	PABP;eIF4G	Additionally , we show that the ******eIF4G-PABP****** ***interaction*** on mRNAs which are capped and polyadenylated significantly increases the affinity of eIF4E for the 5 ' cap .	parallel	1
20634	11058119	11321;7507	XAB1;XPA	Using the yeast two-hybrid system , we elucidated that ***XAB1*** ***binds*** to the N-terminal region of ***XPA*** .	parallel	1
20635	11058119	11321;7507	XAB1;XPA	A novel cytoplasmic GTPase ***XAB1*** ***interacts*** with DNA repair protein ***XPA*** .	parallel	1
20636	11058129	4088;8850	Smad3;P/CAF	Our results indicate a direct physical and functional ***interplay*** between two negative regulators of cell proliferation , ***Smad3*** and ***P/CAF*** .	parallel	1
20637	11058129	8850;7040	P/CAF;TGF-beta	The transcriptional co-activator ***P/CAF*** ***potentiates*** ***TGF-beta/Smad*** signaling .	positive	0
20638	11058129	4087;8850	Smad2;P/CAF	Moreover , ***Smad2*** and Smad3 ***interacted*** with ***P/CAF*** upon TGF-beta type I receptor activation in cultured mammalian cells .	parallel	1
20639	11058129	4088;8850	Smad3;P/CAF	Moreover , Smad2 and ***Smad3*** ***interacted*** with ***P/CAF*** upon TGF-beta type I receptor activation in cultured mammalian cells .	parallel	1
20640	11058129	8850;3960	P/CAF;Gal4	***P/CAF*** ***potentiated*** the transcriptional activity of heterologous Gal4-Smad2 and ***Gal4-Smad3*** fusion proteins .	positive	0
20641	11058129	8850;4087	P/CAF;Smad2	***P/CAF*** ***potentiated*** the transcriptional activity of heterologous ***Gal4-Smad2*** and Gal4-Smad3 fusion proteins .	positive	0
20642	11058129	8850;4088	P/CAF;Smad3	***P/CAF*** ***potentiated*** the transcriptional activity of heterologous Gal4-Smad2 and ***Gal4-Smad3*** fusion proteins .	positive	0
20643	11058146	8976;10096	N-WASP;Arp2/3	These results indicate that strong ***activation*** of ***Arp2/3*** complex by ***N-WASP*** is mainly caused by its two tandem V motifs , which are essential for actin microspike formation .	positive	1
20644	11058167	4790;5966	p50;c-Rel	In nuclear extracts from lipopolysaccharideactivated macrophages , the predominant Rel dimers capable of binding the IL-12 P40 Rel site were the p50/p65 and ******p50/c-Rel****** ***heterodimers*** and p50/p50 homodimer .	parallel	1
20645	11058167	4790;5970	p50;p65	In nuclear extracts from lipopolysaccharideactivated macrophages , the predominant Rel dimers capable of binding the IL-12 P40 Rel site were the ******p50/p65****** and p50/c-Rel ***heterodimers*** and p50/p50 homodimer .	parallel	1
20646	11058530	356;355	FasL;Fas	Our previous studies have shown that bovine granulosa cells cultured in basal media supplemented with 5 % fetal bovine serum ( BM-FBS ) are resistant to apoptosis induced by recombinant ***Fas*** ***ligand*** ( ***FasL*** ) unless pretreated with interferon-gamma ( IFN ) .	parallel	1
20647	11058530	355;356	Fas;FasL	IFN increased expression of Fas antigen ( ***Fas*** , the ***receptor*** for ***FasL*** ) mRNA five - to sevenfold ( P : < 0 .	parallel	1
20648	11058553	356;355	FasL;Fas	***Fas*** ***ligand*** ( ***FasL*** ) was not detected by RNase protection assay , but RT-PCR revealed a significant increase in FasL expression 4 h after the repair of torsion .	parallel	1
20649	11058553	355;356	Fas;FasL	Results suggest that germ cell apoptosis following ischemia/reperfusion of the rat testis is initiated through the mitochondria-associated molecule Bax as well as ******Fas-FasL****** ***interactions*** .	parallel	1
20650	11058569	3596;6774	IL-13;STAT3	Expression of IL-13R alpha 1 evoked ***STAT3*** ***activation*** by IL-4 and ***IL-13*** , and in stimulated human B cells , on which IL-13R alpha 1 was highly expressed , IL-4 and IL-13 induced STAT3 activation .	positive	1
20651	11058569	3565;6774	IL-4;STAT3	Expression of IL-13R alpha 1 evoked ***STAT3*** ***activation*** by ***IL-4*** and IL-13 , and in stimulated human B cells , on which IL-13R alpha 1 was highly expressed , IL-4 and IL-13 induced STAT3 activation .	positive	1
20652	11058569	3596;6774	IL-13;STAT3	Expression of IL-13R alpha 1 evoked STAT3 activation by IL-4 and IL-13 , and in stimulated human B cells , on which IL-13R alpha 1 was highly expressed , IL-4 and ***IL-13*** ***induced*** ***STAT3*** activation .	target	1
20653	11058569	3565;6774	IL-4;STAT3	Expression of IL-13R alpha 1 evoked STAT3 activation by IL-4 and IL-13 , and in stimulated human B cells , on which IL-13R alpha 1 was highly expressed , ***IL-4*** and IL-13 ***induced*** ***STAT3*** activation .	target	1
20654	11058585	64283;387	p190RhoGEF;RhoA	In contrast , full-length ***p190RhoGEF*** fails to ***activate*** ***RhoA*** in vitro .	positive	1
20655	11058585	64283;387	p190RhoGEF;RhoA	When overexpressed in intact cells , however , ***p190RhoGEF*** does ***activate*** ***RhoA*** with subsequent F-actin reorganization and serum response factor-mediated transcription .	positive	1
20656	11058585	64283;387	p190RhoGEF;RhoA	Our results indicate that ***p190RhoGEF*** is a specific ***activator*** of ***RhoA*** that requires as yet unknown binding partners to unmask its GDP/GTP exchange activity in vivo , and they suggest that p190RhoGEF may provide a link between microtubule dynamics and RhoA signaling .	positive	1
20657	11058592	81494;718	FHR-5;C3b	Recombinant ***FHR-5*** , expressed in insect cells , was shown to ***bind*** ***C3b*** in vitro .	parallel	1
20658	11058594	3791;2152	KDR;tissue factor	Vascular endothelial growth factor ***KDR*** receptor signaling ***potentiates*** tumor necrosis factor-induced ***tissue factor*** expression in endothelial cells .	positive	0
20659	11058594	7422;2152	Vascular endothelial growth factor;tissue factor	***Vascular endothelial growth factor*** KDR receptor signaling ***potentiates*** tumor necrosis factor-induced ***tissue factor*** expression in endothelial cells .	positive	0
20660	11058594	7124;2152	TNF-alpha;tissue factor	Vascular endothelial growth factor ( VEGF ) and tumor necrosis factor-alpha ( ***TNF-alpha*** ) have been shown to synergistically ***increase*** ***tissue factor*** ( TF ) expression in endothelial cells ; however , the role of the VEGF receptors ( KDR , Flt-1 , and neuropilin ) in this process is unclear .	positive	0
20661	11058594	7422;2152	Vascular endothelial growth factor;tissue factor	***Vascular endothelial growth factor*** ( VEGF ) and tumor necrosis factor-alpha ( TNF-alpha ) have been shown to synergistically ***increase*** ***tissue factor*** ( TF ) expression in endothelial cells ; however , the role of the VEGF receptors ( KDR , Flt-1 , and neuropilin ) in this process is unclear .	positive	0
20662	11058597	64806;55540	IL-17E;IL-17Rh1	***IL-17E*** , a novel proinflammatory ***ligand*** for the IL-17 receptor homolog ***IL-17Rh1*** .	parallel	1
20663	11058597	64806;4790	IL-17E;NF-kappaB	***IL-17E*** ***induces*** activation of ***NF-kappaB*** and stimulates production of the proinflammatory chemokine IL-8 .	target	1
20664	11058597	64806;3576	IL-17E;IL-8	***IL-17E*** induces activation of NF-kappaB and ***stimulates*** production of the proinflammatory chemokine ***IL-8*** .	positive	0
20665	11058604	4899;4899	Nrf-1;alpha-Pal	We also show that methylation abolishes ******alpha-Pal/Nrf-1****** ***binding*** to the promoter and affects binding of USF1 and USF2 to a lesser degree .	parallel	1
20666	11058713	4023;4018	LpL;lipoprotein	Preheparin ***LpL*** mass ***correlated*** positively with high-density ***lipoprotein-cholesterol*** ( HDL-C ) ( r = 0.418 , P < 0.01 ) and negatively with triglyceride ( TG ) ( r = -0.256 , P < 0.01 ) , but did not correlate with total cholesterol ( TC ) in 64 hyperlipidemic ( type IIa , IIb and IV ) patients .	positive	0
20667	11058804	3827;5338	Bradykinin;phospholipase D2	***Bradykinin*** ***activates*** ***phospholipase D2*** via protein kinase cdelta in PC12 cells .	positive	1
20668	11058804	3827;2822	Bradykinin;PLD	***Bradykinin*** ( BK ) ***activates*** phospholipase D ( ***PLD*** ) and induces several responses such as catecholamine secretion , collapse of growth cones , and gene expression in PC12 pheochromocytoma cells .	positive	1
20669	11058804	5578;5338	PKCalpha;PLD2	***PKCalpha*** and PKCdelta translocated from cytosol to membrane upon BK treatment , and rottlerin potently ***inhibited*** the activation of ***PLD2*** by BK .	negative	1
20670	11058870	1029;1019	p16;cdk4	The cell-cycle regulator ***p16*** ***inhibits*** the complex ***cdk4-cyclin D1*** and controls G1-S transition .	negative	1
20671	11058870	1029;595	p16;cyclin D1	The cell-cycle regulator ***p16*** ***inhibits*** the complex ***cdk4-cyclin D1*** and controls G1-S transition .	negative	1
20672	11059638	959;958	CD40 ligand;CD40	In contrast to these effects , ***CD40*** ***stimulation*** by either anti-CD40 antibodies or a recombinant soluble ***CD40 ligand*** can inhibit the growth of human breast carcinomas and aggressive histology B lymphomas in vitro and in vivo .	positive	0
20673	11059688	7124;4790	TNFalpha;NFkappaB	We demonstrate that both ***TNFalpha*** and adriamycin ***activate*** ***NFkappaB*** in hepatoma cells .	positive	1
20674	11059753	672;2099	BRCA1;ER-alpha	These findings may be explained , in part , by an EtOH-induced down-regulation of the expression of ***BRCA1*** , a potent ***inhibitor*** of ***ER-alpha*** activity , and , in part , by a modest increase in the ER-alpha levels .	negative	1
20675	11059759	3458;841	Interferon-gamma;caspase-8	***Interferon-gamma*** treatment ***elevates*** ***caspase-8*** expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program .	positive	0
20676	11059759	355;841	CD95;caspase-8	Furthermore , IFN-gamma sensitized MCF-7 and MDA-MB231 cells to ***CD95-mediated*** ***activation*** of ***caspase-8*** , induction of cytochrome c release from mitochondria , and processing of caspase-9 .	positive	1
20677	11059768	356;355	fasL;Fas	CM101 infusion led to elevated levels of Fas protein within the tumors as well as a decrease in the expression of ***Fas*** ***ligand*** ( ***fasL*** ) .	parallel	1
20678	11059775	3716;5698	Jak1;LMP2	However , overexpression of ***Jak1*** did ***increase*** TAP1 and ***LMP2*** expression independent of IFN-gamma , indicating that the Stat1 and IFN-regulatory factor 1 proteins present in Caki-2 can be activated .	positive	0
20679	11059775	3716;6890	Jak1;TAP1	However , overexpression of ***Jak1*** did ***increase*** ***TAP1*** and LMP2 expression independent of IFN-gamma , indicating that the Stat1 and IFN-regulatory factor 1 proteins present in Caki-2 can be activated .	positive	0
20680	11059786	1956;7422	Epidermal growth factor receptor;vascular endothelial growth factor	***Epidermal growth factor receptor*** transcriptionally ***up-regulates*** ***vascular endothelial growth factor*** expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3 ' - kinase and distinct from that induced by hypoxia .	positive	1
20681	11059788	4193;7157	mdm2;p53	The antiproliferative activities of wild-type ( wt ) ***p53*** are ***inhibited*** by ***mdm2*** ( murine double minute2 ) oncogene product .	negative	1
20682	11059795	5649;1600	Reln;DAB1	Experiments in rodents ( including wild type or reeler heterozygous mice ) and non-human primates suggest the ***Reln*** secreted in the extracellular matrix of neocortex , via integrin receptors , ***modulates*** the function of the adaptor protein ***DAB1*** ( drosophila disable-gene ) homologous product ) thereby participating in dynamic processes associated with plasticity changes in dendrites , dendritic spines and their synapses .	target	0
20683	11059894	6469;7054	Sonic hedgehog;tyrosine hydroxylase	***Sonic hedgehog*** ***promotes*** proliferation and ***tyrosine hydroxylase*** induction of postnatal sympathetic cells in vitro .	positive	0
20684	11060020	23479;9054	IscU;IscS	Biochemical analyses demonstrate that ***IscU*** proteins specifically ***associate*** with ***IscS*** , a cysteine desulfurase that is proposed to sequester inorganic sulfur for Fe-S cluster assembly .	parallel	0
20685	11060025	1739;9229	SAP97;GKAP	Intramolecular interactions regulate ***SAP97*** ***binding*** to ***GKAP*** .	parallel	1
20686	11060035	2672;6774	Gfi-1;STAT3	The zinc finger protein ***Gfi-1*** can ***enhance*** ***STAT3*** signaling by interacting with the STAT3 inhibitor PIAS3 .	positive	0
20687	11060035	10401;6774	PIAS3;STAT3	The recently discovered protein ***PIAS3*** ***binds*** directly to ***STAT3*** and blocks transcriptional activation .	parallel	1
20688	11060043	10728;3320	p23;Hsp90	The co-chaperone ***p23*** greatly ***stimulates*** ***Hsp90*** substrate release with ATP , but not with the non-hydrolysable nucleotides ATPgammaS or AMP-PNP .	positive	0
20689	11060239	6469;23316	Sonic hedgehog;cux2	Several manipulations of the chick limb bud show that ***cux2*** expression is ***regulated*** by retinoic acid , ***Sonic hedgehog*** and the posterior AER .	target	1
20690	11060291	1981;1973	eIF4G;eIF4A	Recombinant ***eIF4G*** fragments that contained each of these sites separately ***bound*** ***eIF4A*** with a 1:1 stoichiometry , but fragments containing both sites bound eIF4A with a 1:2 stoichiometry .	parallel	1
20691	11060291	1973;1981	eIF4A;eIF4G	***Binding*** of ***eIF4A*** to an immobilized fragment of ***eIF4G*** containing the COOH-terminal site was competed by a soluble eIF4G fragment containing the central site , indicating that a single eIF4A molecule can not bind simultaneously to both sites .	parallel	1
20692	11060291	1981;1973	eIF4G;eIF4A	Binding of ***eIF4A*** to an immobilized fragment of eIF4G containing the COOH-terminal site was ***competed*** by a soluble ***eIF4G*** fragment containing the central site , indicating that a single eIF4A molecule can not bind simultaneously to both sites .	negative	0
20693	11060306	983;891	Cdc2;cyclin B1	We and others recently reported that ******cyclin B1/Cdc2****** ***complexes*** , which appear to be constitutively cytoplasmic during interphase , actually shuttle continually into and out of the nucleus , with the rate of nuclear export exceeding the import rate ( ) .	parallel	1
20694	11060311	3814;4318	KiSS-1;MMP-9	Thus , ***KiSS-1*** ***diminishes*** ***MMP-9*** expression by effecting reduced NF-kappaB binding to the promoter .	negative	0
20695	11060311	3725;4318	AP-1;MMP-9	Although ***MMP-9*** expression is ***regulated*** by ***AP-1*** , Sp1 , and Ets transcription factors , KiSS-1 did not alter the binding of these factors to the MMP-9 promoter .	target	1
20696	11060311	6667;4318	Sp1;MMP-9	Although ***MMP-9*** expression is ***regulated*** by AP-1 , ***Sp1*** , and Ets transcription factors , KiSS-1 did not alter the binding of these factors to the MMP-9 promoter .	target	1
20697	11060311	4790;4318	NF-kappaB;MMP-9	However , ***NF-kappaB*** ***binding*** to the ***MMP-9*** promoter required for expression of this collagenase was reduced by KiSS-1 expression .	parallel	1
20698	11060311	3814;4790	KiSS-1;NF-kappaB	However , ***NF-kappaB*** binding to the MMP-9 promoter required for expression of this collagenase was ***reduced*** by ***KiSS-1*** expression .	negative	1
20699	11060313	64112;581	MAP-1;Bax	***MAP-1*** ***homodimerizes*** and associates with the proapoptotic ***Bax*** and the prosurvival Bcl-2 and Bcl-X ( L ) of the Bcl-2 family in vitro and in vivo in mammalian cells .	parallel	1
20700	11060313	64112;596	MAP-1;Bcl-2	***MAP-1*** ***homodimerizes*** and associates with the proapoptotic Bax and the prosurvival ***Bcl-2*** and Bcl-X ( L ) of the Bcl-2 family in vitro and in vivo in mammalian cells .	parallel	1
20701	11060313	64112;581	MAP-1;Bax	Interestingly , in contrast to other Bax-associating proteins such as Bcl-X ( L ) and Bid , which require the BH3 and BH1 domains of Bax , respectively , for binding , the ***binding*** of ***MAP-1*** to ***Bax*** appears to require all three BH domains ( BH1 , BH2 , and BH3 ) of Bax , because point mutation of the critical amino acid in any one of these domains is sufficient to abolish its binding to MAP-1 .	parallel	1
20702	11060341	3949;4018	LDLR;lipoprotein	apolipoprotein E ( apoE ) is a ligand for the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) and the low density lipoprotein receptor-related protein ( LRP ) .	parallel	1
20703	11060341	348;3949	apolipoprotein E;LDLR	***apolipoprotein E*** ( apoE ) is a ***ligand*** for the low density lipoprotein receptor ( ***LDLR*** ) and the low density lipoprotein receptor-related protein ( LRP ) .	parallel	1
20704	11060341	348;4018	apolipoprotein E;lipoprotein	***apolipoprotein E*** ( apoE ) is a ***ligand*** for the low density lipoprotein receptor ( LDLR ) and the low density ***lipoprotein*** receptor-related protein ( LRP ) .	parallel	1
20705	11060341	348;4035	apolipoprotein E;LRP	***apolipoprotein E*** ( apoE ) is a ***ligand*** for the low density lipoprotein receptor ( LDLR ) and the low density lipoprotein receptor-related protein ( ***LRP*** ) .	parallel	1
20706	11060345	345;4023	apoC-III;lipoprotein lipase	The ***inhibition*** of ***lipoprotein lipase*** ( LPL ) by ***apoC-III-Thr23*** was comparable to that of wild type , and therefore effects on LPL activity could not explain the lower triglyceride ( Tg ) levels in Thr-23 carriers .	negative	1
20707	11061246	8743;355	TRAIL;Fas	METHODS : Messenger RNA ( mRNA ) levels of two apoptosis-related members of the tumor necrosis factor ( TNF ) receptor family , ***Fas*** and TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 ( TRAIL-R2 ) , and their ***ligands*** , Fas ligand ( fasL ) and ***TRAIL*** , were quantified by competitive reverse transcription PCR in unstimulated peripheral blood mononuclear cells in 47 untreated patients with MS and 46 control subjects .	parallel	1
20708	11061246	8743;8795	TRAIL;TNF-related apoptosis-inducing ligand (TRAIL) receptor 2	METHODS : Messenger RNA ( mRNA ) levels of two apoptosis-related members of the tumor necrosis factor ( TNF ) receptor family , Fas and ***TNF-related apoptosis-inducing ligand (TRAIL) receptor 2*** ( TRAIL-R2 ) , and their ***ligands*** , Fas ligand ( fasL ) and ***TRAIL*** , were quantified by competitive reverse transcription PCR in unstimulated peripheral blood mononuclear cells in 47 untreated patients with MS and 46 control subjects .	parallel	1
20709	11061246	356;355	fasL;Fas	METHODS : Messenger RNA ( mRNA ) levels of two apoptosis-related members of the tumor necrosis factor ( TNF ) receptor family , Fas and TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 ( TRAIL-R2 ) , and their ligands , ***Fas*** ***ligand*** ( ***fasL*** ) and TRAIL , were quantified by competitive reverse transcription PCR in unstimulated peripheral blood mononuclear cells in 47 untreated patients with MS and 46 control subjects .	parallel	1
20710	11061246	8743;355	TRAIL;Fas	METHODS : Messenger RNA ( mRNA ) levels of two apoptosis-related members of the tumor necrosis factor ( TNF ) receptor family , Fas and TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 ( TRAIL-R2 ) , and their ligands , ***Fas*** ***ligand*** ( fasL ) and ***TRAIL*** , were quantified by competitive reverse transcription PCR in unstimulated peripheral blood mononuclear cells in 47 untreated patients with MS and 46 control subjects .	parallel	1
20711	11061344	7157;7422	p53;vascular endothelial growth factor	Angiogenic ***interactions*** of ***vascular endothelial growth factor*** , of thymidine phosphorylase , and of ***p53*** protein expression in locally advanced gastric cancer .	parallel	1
20712	11061546	1081;2099	hCG;ERalpha	The ***regulation*** of ***ERalpha*** and ERbeta expression by ***hCG*** was examined .	target	1
20713	11061546	1081;2100	hCG;ERbeta	The ***regulation*** of ERalpha and ***ERbeta*** expression by ***hCG*** was examined .	target	1
20714	11061559	3976;3135	Leukemia inhibitory factor;HLA-G	***Leukemia inhibitory factor*** ( LIF ) ***stimulates*** the human ***HLA-G*** promoter in JEG3 choriocarcinoma cells .	positive	0
20715	11061569	3606;3458	IL-18;IFN-gamma	About 90 % of IFN-gamma production induced by MLR was inhibited by an anti-IL-18 antibody , showing that ***IL-18*** can ***trigger*** ***IFN-gamma*** production in MLR .	positive	0
20716	11061569	3606;3458	IL-18;IFN-gamma	These results suggest that dual signaling consisting of antigen-driven nuclear factor of activated T cells ( NFAT ) activation and LPS-mediated NF-kappaB activation is crucial for IL-18 production in macrophages , and that ***IL-18*** can ***trigger*** ***IFN-gamma*** production in T-cells by MLR .	positive	0
20717	11061591	1435;3678	CSF-1;VLA 5	The observed effects were specific because ***CSF-1*** ***enhanced*** ***VLA 5*** expression and blocking FN-treated resident PMphi in vitro with VLA 5 monoclonal antibodies inhibited the IL-6 response .	positive	0
20718	11061594	356;355	FasL;Fas	Overall , our data suggest that NB-induced apoptosis of Fas-sensitive Jurkat T cells is mediated by functional FasL expressed on NB and ******Fas/FasL****** ***interaction*** may be responsible for the elimination of T cells in the NB microenvironment .	parallel	1
20719	11061669	3606;3558	IL-18;IL-2	***IL-18*** underexpression ***reduces*** ***IL-2*** levels during HIV infection : a critical step towards the faulty cell-mediated immunity ?	negative	1
20720	11061972	5973;5972	RnBP;renin	This completely ruled out the previously accepted hypothesis that the formation of the RnBP homodimer and ******RnBP-renin****** ***heterodimer*** requires the leucine zipper motif present in RnBP .	parallel	1
20721	11062012	3553;5743	IL-1beta;COX-2	However , as ERK is not required for ***IL-1beta-dependent*** ***induction*** of ***COX-2*** , the mechanism of ceramide and SMase induction of COX-2 remains unclear .	target	1
20722	11062025	2065;2064	ErbB3;ErbB2	Together , our results suggest that coexpression of EGFR or ***ErbB3*** with ErbB2 ***induces*** high phosphorylation of ***ErbB2*** and renders the cells more resistant to various anti-cancer drugs .	target	1
20723	11062049	4089;4088	Smad4;Smad3	This repression involves the interaction of a ******Smad3/Smad4****** ***complex*** and the transcriptional repressor TGIF , as determined by cotransfection assay and coimmunoprecipitation analysis .	parallel	1
20724	11062049	4089;4088	Smad4;Smad3	This repression involves the ***interaction*** of a ******Smad3/Smad4****** complex and the transcriptional repressor TGIF , as determined by cotransfection assay and coimmunoprecipitation analysis .	parallel	1
20725	11062058	2281;6262	FKBP12.6;RyR	The possible ***interactions*** between calcineurin , the ***RyR*** and ***FKBP12.6*** were further studied by co-immunoprecipitation using CHAPS-solubilized cardiac-membrane fractions ( CSMFs ) or SR preparations .	parallel	1
20726	11062058	6262;2281	RyR;FKBP12.6	The Ca ( 2 + ) - dependent ***interaction*** between ***FKBP12.6*** and the ***RyR*** was also found by co-immunoprecipitation .	parallel	1
20727	11062067	5609;5594	MKK7;p38	***MKK7*** also ***phosphorylates*** ***SAPK2a/p38*** at a low rate ( but not SAPK3/p38 gamma or SAPK4/p38 delta ) , and phosphorylation occurs exclusively at the tyrosine residue , demonstrating that MKK7 is intrinsically a ' dual-specific ' protein kinase .	target	1
20728	11062067	5609;1432	MKK7;SAPK2a	***MKK7*** also ***phosphorylates*** ***SAPK2a/p38*** at a low rate ( but not SAPK3/p38 gamma or SAPK4/p38 delta ) , and phosphorylation occurs exclusively at the tyrosine residue , demonstrating that MKK7 is intrinsically a ' dual-specific ' protein kinase .	target	1
20729	11062067	6416;5599	MKK4;SAPK1	Synergistic ***activation*** of stress-activated protein kinase 1/c-Jun N-terminal kinase ( ***SAPK1/JNK*** ) isoforms by mitogen-activated protein kinase kinase 4 ( ***MKK4*** ) and MKK7 .	positive	1
20730	11062067	5609;5599	MKK7;SAPK1	Synergistic ***activation*** of stress-activated protein kinase 1/c-Jun N-terminal kinase ( ***SAPK1/JNK*** ) isoforms by mitogen-activated protein kinase kinase 4 ( MKK4 ) and ***MKK7*** .	positive	1
20731	11062067	5609;5601	MKK7;JNK2 alpha	***MKK7*** also ***phosphorylates*** ***JNK2 alpha*** 2 at Thr-404 and Ser-407 in vitro , Ser-407 being phosphorylated much more rapidly than Thr-183 in vitro .	target	1
20732	11062068	1843;1432	MKP-1;p38 MAP kinase	Here we have shown that ***MKP-1*** ***associates*** directly with ***p38 MAP kinase*** both in vivo and in vitro , and that this interaction enhances the catalytic activity of MKP-1 .	parallel	0
20733	11062069	5867;4905	Rab4;NSF	Furthermore , we found that Rab3 and ***Rab4*** can also ***associate*** with ***NSF*** and stimulate its ATPase activity .	parallel	0
20734	11062069	4905;51560	N-ethylmaleimide-sensitive fusion protein;small GTP-binding protein	In this study we show the ***interaction*** of ***N-ethylmaleimide-sensitive fusion protein*** ( NSF ) with a ***small GTP-binding protein*** , Rab6 .	parallel	1
20735	11062069	4905;5870	NSF;Rab6	We demonstrated that the N-terminal domain of ***NSF*** ***interacted*** with the C-terminal domain of ***Rab6*** , and these proteins were co-immunoprecipitated from the rat brain extract .	parallel	1
20736	11062069	5870;4905	Rab6;NSF	Surprisingly , ***Rab6*** ***stimulates*** the ATPase activity of ***NSF*** by approx .	positive	0
20737	11062143	958;959	CD40;CD40L	***Interaction*** of ***CD40*** on B cells and antigen presenting cells , with its ligand ( ***CD40L*** ) expressed transiently on activated T cells , is known to augment both T cell-driven inflammation and humoral immune responses , especially IgE production .	parallel	1
20738	11062143	959;958	CD40L;CD40	Considering both the prominent role of inflammation in asthma and the association of the disease with IgE , we hypothesized that ******CD40-CD40L****** ***interactions*** would be important in pathogenesis .	parallel	1
20739	11062143	959;958	CD40L;CD40	We conclude that ******CD40/CD40L****** ***interactions*** , although critical in the induction of IgE responses to inhaled allergen , are not required for the induction of EOS-predominant inflammation .	parallel	1
20740	11062235	4683;4361	NBS1;hMRE11	Here , we show in vivo direct evidence that ***NBS1*** ***recruits*** the ***hMRE11*** nuclease complex into the cell nucleus and leads to the formation of foci by utilizing different functions from several domains .	target	0
20741	11062238	388;4790	Rhob;NF-kappaB	Ras-related GTPase ***Rhob*** ***represses*** ***NF-kappaB*** signaling .	negative	1
20742	11062238	388;4790	Rhob;NF-kappaB	This indicates that ***Rhob*** ***represses*** ***NF-kappaB*** activation by inhibiting dissociation and subsequent degradation of IkappaBalpha .	negative	1
20743	11062238	388;4790	Rhob;NF-kappaB	On the basis of the data , we suggest that ***Rhob*** is a novel negative ***regulator*** of ***NF-kappaB*** signaling .	negative	1
20744	11062239	2919;4790	GROalpha;NF-kappaB	We show here that either exogenous addition or continuous expression of ***MGSA/GROalpha*** in immortalized melanocytes ***enhances*** ***NF-kappaB*** activation , as well as mitogen-activated protein (MAP) kinase kinase kinase (MEKK) 1 , MAP kinase kinase (MEK) 3/6 , and p38 MAP kinase activation .	positive	0
20745	11062239	4214;4790	MEKK1;NF-kappaB	Expression of dominant active Ras or dominant active ***MEKK1*** alone can also ***stimulate*** ***NF-kappaB*** activation .	positive	0
20746	11062239	4214;4790	MEKK1;NF-kappaB	The expression of dominant negative ***MEKK1*** ***inhibits*** the Ras-induced ***NF-kappaB*** activation , suggesting that MEKK1 is a downstream target of Ras .	negative	1
20747	11062239	2919;5594	GROalpha;ERK	Moreover , MGSA/GROalpha induction of NF-kappaB is independent of the MEK1/ERK cascade , because ***MGSA/GROalpha*** failed to ***increase*** ***ERK*** and ELK activation , and specific chemical inhibitors for MEK1 ( PD98059 ) had no effect on MGSA/GROalpha-enhanced NF-kappaB activation .	positive	0
20748	11062239	2919;4790	GROalpha;NF-kappaB	Moreover , ***MGSA/GROalpha*** ***induction*** of ***NF-kappaB*** is independent of the MEK1/ERK cascade , because MGSA/GROalpha failed to increase ERK and ELK activation , and specific chemical inhibitors for MEK1 ( PD98059 ) had no effect on MGSA/GROalpha-enhanced NF-kappaB activation .	target	1
20749	11062248	2520;25865	gastrin;PKD2	Finally , ***gastrin*** was found to be a physiological ***activator*** of ***PKD2*** in human AGS-B cells stably transfected with the CCK ( B ) / gastrin receptor .	positive	1
20750	11062261	64145;11311	Rabenosyn-5;hVPS45	***Rabenosyn-5*** , a novel Rab5 effector , is ***complexed*** with ***hVPS45*** and recruited to endosomes through a FYVE finger domain .	parallel	1
20751	11062261	64145;1509	Rabenosyn-5;cathepsin D	Furthermore , although both EEA1 and Rabenosyn-5 are required for early endosomal fusion , only overexpression of ***Rabenosyn-5*** ***inhibits*** ***cathepsin D*** processing , suggesting that the two proteins play distinct roles in endosomal trafficking .	negative	1
20752	11062467	6909;1029	TBX2;Cdkn2a	Senescence bypass screen identifies ***TBX2*** , which ***represses*** ***Cdkn2a*** ( p19 ( ARF ) ) and is amplified in a subset of human breast cancers .	negative	1
20753	11062467	3265;1029	HRAS;Cdkn2a	TBX2 represses the Cdkn2a ( p19 ( ARF ) ) promoter and attenuates E2F1 , Myc or ***HRAS-mediated*** ***induction*** of ***Cdkn2a*** ( p19 ( ARF ) ) .	target	1
20754	11062467	6909;1029	TBX2;Cdkn2a	***TBX2*** represses the Cdkn2a ( p19 ( ARF ) ) promoter and ***attenuates*** E2F1 , Myc or HRAS-mediated induction of ***Cdkn2a*** ( p19 ( ARF ) ) .	negative	0
20755	11062467	6909;1869	TBX2;E2F1	***TBX2*** represses the Cdkn2a ( p19 ( ARF ) ) promoter and ***attenuates*** ***E2F1*** , Myc or HRAS-mediated induction of Cdkn2a ( p19 ( ARF ) ) .	negative	0
20756	11062467	6909;4609	TBX2;Myc	***TBX2*** represses the Cdkn2a ( p19 ( ARF ) ) promoter and ***attenuates*** E2F1 , ***Myc*** or HRAS-mediated induction of Cdkn2a ( p19 ( ARF ) ) .	negative	0
20757	11062467	6909;1029	TBX2;Cdkn2a	***TBX2*** ***represses*** the ***Cdkn2a*** ( p19 ( ARF ) ) promoter and attenuates E2F1 , Myc or HRAS-mediated induction of Cdkn2a ( p19 ( ARF ) ) .	negative	1
20758	11062605	4323;4313	MMP-14;MMP-2	Tissue expression of ***MMP-14*** , the ***activator*** for ***pro-MMP-2*** , was significantly higher in RA than in non-RA patients ( 8.4 + / - 5 versus 3.7 + / - 4 cells/high-power field ; P = 0.009 ) .	positive	1
20759	11062605	7077;4313	TIMP-2;MMP-2	In contrast , the expression of ***TIMP-2*** , an ***inhibitor*** of ***MMP-2*** , was lower in the RA than in the non-RA samples ( 25 + / - 12 versus 39 + / - 9 cells/high-power field ; P = 0.01 ) .	negative	1
20760	11062724	308;836	annexin V;caspase 3	In addition , we also analyzed changes of apoptosis markers such as ***annexin V*** ***binding*** to membrane and ***caspase 3*** activity in SC-M1 cells after treatment with AMI .	parallel	1
20761	11062725	1027;1017	p27Kip1;CDK2	***Binding*** of ***p27Kip1*** to ***CDK2*** increased significantly following treatment with PA .	parallel	1
20762	11062761	3458;7037	IFN gamma;TfR	This data suggests that ***IFN gamma*** may enhance iron uptake during the early phase of macrophage activation , and in later phases , ***down-regulate*** ***TfR*** expression by inducing NO , thus contributing to intracellular oxidative stress reduction .	negative	1
20763	11063258	9026;3092	HIP12;HIP1	Interestingly , ***HIP12*** does not interact with huntingtin but can ***interact*** with ***HIP1*** .	parallel	1
20764	11063339	185;183	AT1R;angiotensin II	Angiotensin converting enzyme inhibitors ( ACEI ) are efficacious in lowering the hematocrit of patients with PTE and ***angiotensin II*** ( AII ) type I ***receptors*** ( ***AT1R*** ) were recently detected on red blood cell precursors , burst-forming unit-erythroid - ( BFU-E ) derived cells .	parallel	1
20765	11063339	2057;2056	EpoR;erythropoietin	Western blotting was used to detect AT1R and ***erythropoietin*** ***receptor*** ( ***EpoR*** ) expression .	parallel	1
20766	11063570	133482;760	GST;CAII	Further specificity for the interaction of AE1 and CAII is provided by a conserved leucine residue ( L886 ) in AE1 that , when mutated to alanine , resulted in loss of ***GST-Ct*** ***binding*** to immobilized ***CAII*** .	parallel	1
20767	11063570	760;6521	CAII;AE1	Further specificity for the ***interaction*** of ***AE1*** and ***CAII*** is provided by a conserved leucine residue ( L886 ) in AE1 that , when mutated to alanine , resulted in loss of GST-Ct binding to immobilized CAII .	parallel	1
20768	11063570	760;133482	CAII;GST	Mutation of pairs of these histidines ( and one lysine ) in CAII to the analogous residues in CAI ( H3P/H4D or K9D/H10K or H15Q/H17S ) , or combinations of these various double mutants , did not greatly affect ***binding*** between ***GST-Ct*** and the mutant ***CAII*** .	parallel	1
20769	11063650	1029;1019	p16;Cdk4	OBJECTIVES : The aim of this study was to elucidate the expression and the correlation of two cell cycle regulators , ***Cdk4*** and its ***inhibitor*** ***p16*** , in a series of benign , borderline , and malignant ovarian tumors and to evaluate whether their alterations correlate with clinicopathologial parameters and patients ' prognosis in epithelial ovarian carcinomas .	negative	1
20770	11063676	22978;3251	GMP;HGPRT	Third , we show that purified yeast ***HGPRT*** is ***inhibited*** by ***GMP*** in vitro .	negative	1
20771	11063722	6117;4846	Replication protein A1;endothelial nitric oxide synthase	***Replication protein A1*** ***reduces*** transcription of the ***endothelial nitric oxide synthase*** gene containing a -786 T -- > C mutation associated with coronary spastic angina .	negative	1
20772	11063725	2188;2176	FANCF;FANCC	The Fanconi anemia protein ***FANCF*** forms a nuclear ***complex*** with FANCA , ***FANCC*** and FANCG .	parallel	1
20773	11063725	2188;2189	FANCF;FANCG	The Fanconi anemia protein ***FANCF*** forms a nuclear ***complex*** with FANCA , FANCC and ***FANCG*** .	parallel	1
20774	11063739	5867;6810	Rab4;syntaxin 4	Direct ***interaction*** of ***Rab4*** with ***syntaxin 4*** .	parallel	1
20775	11063739	5867;6810	Rab4;syntaxin 4	In the present study , we examined the possible ***interaction*** between ***Rab4*** and ***syntaxin 4*** , both having been implicated in insulin-induced GLUT4 translocation .	parallel	1
20776	11063739	5867;6810	Rab4;syntaxin 4	Although insulin stimulated [ gamma - ( 32 ) P ] GTP binding to Rab4 in a time-dependent fashion , its effect on the ***Rab4*** ***interaction*** with ***syntaxin 4*** was apparently biphasic ; an initial increase in Rab4 associated with syntaxin 4 was followed by a gradual dissociation of the GTPase from syntaxin 4 .	parallel	1
20777	11063739	5867;373156	Rab4;GST	Finally , the ***binding*** of ***Rab4*** ( Q67L ) to ***GST-syntaxin*** 4 - ( 1-273 ) was inhibited by munc-18c in a dose-dependent manner , indicating that GTP-loaded Rab4 binds to syntaxin 4 in the open conformation .	parallel	1
20778	11063739	5867;6810	Rab4;syntaxin 4	These results suggest that 1 ) ***Rab4*** ***interacts*** with ***syntaxin 4*** in a direct and specific manner , and 2 ) the interaction is regulated by the guanine nucleotide status of Rab4 as well as by the conformational status of syntaxin 4 .	parallel	1
20779	11063742	5599;4790	JNK;NF-kappaB	In contrast , wild-type MEKK1 or ***JNK*** kinase ***induced*** ***NF-kappaB*** activation alone or in combination with thioredoxin expression plasmid .	target	1
20780	11063742	4214;4790	MEKK1;NF-kappaB	In contrast , wild-type ***MEKK1*** or JNK kinase ***induced*** ***NF-kappaB*** activation alone or in combination with thioredoxin expression plasmid .	target	1
20781	11063744	3667;5590	IRS-1;PKC-zeta	Taken together , our results raise the possibility that ***IRS-1*** is a novel physiological ***substrate*** for ***PKC-zeta*** .	parallel	1
20782	11063744	5590;3667	Protein kinase C-zeta;insulin receptor substrate-1	***Protein kinase C-zeta*** ***phosphorylates*** ***insulin receptor substrate-1*** and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin .	target	1
20783	11063744	3667;5590	IRS-1;PKC-zeta	In rat adipose cells , endogenous ***IRS-1*** ***coimmunoprecipitated*** with endogenous ***PKC-zeta*** , and this association was increased 2-fold upon insulin stimulation .	parallel	1
20784	11063746	5997;8802	RGS2;Galpha	***RGS2*** has been shown to ***regulate*** ***Galpha*** ( q ) - mediated inositol lipid signaling .	target	1
20785	11063749	2033;3091	p300;HIF1alpha	We propose that hypoxia-induced ******HIF1alpha-p300****** ***interaction*** relies upon a leucine-rich hydrophobic interface that is regulated by the hydrophilic and hydrophobic sulfhydryls of HIF1alpha Cys-800 .	parallel	1
20786	11063755	5290;5295	p110alpha;p85	CONCLUSIONS : This study indicates that the ******p85/p110alpha****** ***complex*** of PI 3-kinase is present in ROS and tyrosine phosphorylation is involved in the regulation of its activity .	parallel	1
20787	11063837	3456;3676	IFN-beta;CD49d	***IFN-beta*** treatment specifically ***downregulated*** ***CD49d*** expression on CD8 + and CD4 + / CD45RO + ' memory ' T lymphocytes and differentially modulated the proportion of CD4 + , CD8 + and CD27 + T cells .	negative	1
20788	11063839	8837;355	FLIP;Fas	The intracellular protein ***FLIP*** , a naturally occurring caspase-antagonist , is a potent ***inhibitor*** of the ***Fas*** signalling pathway that may block Fas-mediated apoptosis of activated lymphocytes .	negative	1
20789	11063873	8935;6714	SKAP55R;SRC	In this report , we describe the cloning and functional characterization of murine ***SKAP55R*** ( mSKAP55R ) , an ***SRC*** family kinase ***substrate*** .	parallel	1
20790	11063939	5077;4233	Pax3;c-Met	The development of this lineage is controlled by ***Pax3*** , the ***c-Met*** tyrosine kinase ***receptor*** , its ligand SF/HGF ( scatter factor/hepatocyte growth factor ) and the homeobox factor Lbx1 .	parallel	1
20791	11063939	3082;5077	HGF;Pax3	The development of this lineage is controlled by ***Pax3*** , the c-Met tyrosine kinase receptor , its ***ligand*** ***SF/HGF*** ( scatter factor/hepatocyte growth factor ) and the homeobox factor Lbx1 .	parallel	1
20792	11063941	2253;2637	Fgf8;Gbx2	Otx2 , ***Gbx2*** and ***Fgf8*** ***interact*** to position and maintain a mid-hindbrain organizer .	parallel	1
20793	11063941	2253;5015	Fgf8;Otx2	***Otx2*** , Gbx2 and ***Fgf8*** ***interact*** to position and maintain a mid-hindbrain organizer .	parallel	1
20794	11063941	2637;5015	Gbx2;Otx2	***Otx2*** , ***Gbx2*** and Fgf8 ***interact*** to position and maintain a mid-hindbrain organizer .	parallel	1
20795	11064004	196;1543	AhR;CYP1A1	The aryl hydrocarbon receptor ( ***AhR*** ) ***mediates*** the transcriptional activation of ***CYP1A1*** and CYP1A2 .	target	0
20796	11064004	196;1544	AhR;CYP1A2	The aryl hydrocarbon receptor ( ***AhR*** ) ***mediates*** the transcriptional activation of CYP1A1 and ***CYP1A2*** .	target	0
20797	11064099	3603;920	IL-16;CD4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , ***CD4*** , CXCR4 and CCR5 , as well as their ***ligands*** , ***IL-16*** , SDF-1 , MIP-1alpha , MIP-1beta , and RANTES , by RT-PCR .	parallel	1
20798	11064099	3603;7852	IL-16;CXCR4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , CD4 , ***CXCR4*** and CCR5 , as well as their ***ligands*** , ***IL-16*** , SDF-1 , MIP-1alpha , MIP-1beta , and RANTES , by RT-PCR .	parallel	1
20799	11064099	6348;920	MIP-1alpha;CD4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , ***CD4*** , CXCR4 and CCR5 , as well as their ***ligands*** , IL-16 , SDF-1 , ***MIP-1alpha*** , MIP-1beta , and RANTES , by RT-PCR .	parallel	1
20800	11064099	6348;7852	MIP-1alpha;CXCR4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , CD4 , ***CXCR4*** and CCR5 , as well as their ***ligands*** , IL-16 , SDF-1 , ***MIP-1alpha*** , MIP-1beta , and RANTES , by RT-PCR .	parallel	1
20801	11064099	6351;920	MIP-1beta;CD4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , ***CD4*** , CXCR4 and CCR5 , as well as their ***ligands*** , IL-16 , SDF-1 , MIP-1alpha , ***MIP-1beta*** , and RANTES , by RT-PCR .	parallel	1
20802	11064099	6351;7852	MIP-1beta;CXCR4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , CD4 , ***CXCR4*** and CCR5 , as well as their ***ligands*** , IL-16 , SDF-1 , MIP-1alpha , ***MIP-1beta*** , and RANTES , by RT-PCR .	parallel	1
20803	11064099	6352;920	RANTES;CD4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , ***CD4*** , CXCR4 and CCR5 , as well as their ***ligands*** , IL-16 , SDF-1 , MIP-1alpha , MIP-1beta , and ***RANTES*** , by RT-PCR .	parallel	1
20804	11064099	6352;7852	RANTES;CXCR4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , CD4 , ***CXCR4*** and CCR5 , as well as their ***ligands*** , IL-16 , SDF-1 , MIP-1alpha , MIP-1beta , and ***RANTES*** , by RT-PCR .	parallel	1
20805	11064099	6387;920	SDF-1;CD4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , ***CD4*** , CXCR4 and CCR5 , as well as their ***ligands*** , IL-16 , ***SDF-1*** , MIP-1alpha , MIP-1beta , and RANTES , by RT-PCR .	parallel	1
20806	11064099	6387;7852	SDF-1;CXCR4	We have therefore utilized H9 cells to test the effects of Product R on expression of mRNAs encoding the chemokine receptors , CD4 , ***CXCR4*** and CCR5 , as well as their ***ligands*** , IL-16 , ***SDF-1*** , MIP-1alpha , MIP-1beta , and RANTES , by RT-PCR .	parallel	1
20807	11064099	6387;7852	SDF-1;CXCR4	We also assayed the effect of Product R on surface receptor expression by flow cytometry , and on the chemotactic activity of these cells towards the ***CXCR4*** ***ligand*** , ***SDF-1*** , and the CCR5 ligands , MIP-1alpha and RANTES .	parallel	1
20808	11064148	3952;3725	Leptin;AP-1	***Leptin*** ***activates*** Stat3 , Stat1 and ***AP-1*** in mouse adipose tissue .	positive	1
20809	11064148	3952;6772	Leptin;Stat1	***Leptin*** ***activates*** Stat3 , ***Stat1*** and AP-1 in mouse adipose tissue .	positive	1
20810	11064148	3952;6774	Leptin;Stat3	***Leptin*** ***activates*** ***Stat3*** , Stat1 and AP-1 in mouse adipose tissue .	positive	1
20811	11064148	3952;3725	Leptin;AP-1	***AP-1*** binding activity was also ***induced*** in adipose tissue by in vivo ***Leptin*** treatment with a time course that suggests a post-transcriptional inductive mechanism .	target	1
20812	11064286	3557;3553	IL-1ra;IL-1beta	***IL-1ra*** and the neutralizing antibody significantly ***blocked*** the ability of ***IL-1beta*** to stimulate secretion of IL-8 by MAC-T cells .	negative	0
20813	11064345	7157;1026	p53;p21	RESULTS : Radiation caused an increase in nuclear p53 and p21 ( waf1/cip1 ) proteins in HCT-116 cells , indicating that ***p53*** functionally ***induced*** ***p21*** ( waf1/cip1 ) .	target	1
20814	11064355	1030;1029	p15;p14	Although p16 ( INK4a ) and ***p15*** ( INK4b ) are involved in the ***phosphorylation*** of the retinoblastoma ( Rb ) protein , ***p14*** ( ARF ) interacts with the MDM-2 oncoprotein antagonizing its function as a suppressor of p53 .	target	1
20815	11064392	3458;596	IFN-gamma;Bcl-2	***IFN-gamma*** increased BAK protein levels and ***decreased*** ***Bcl-2*** and Bcl-X ( S ) protein levels in TSGH9201 cells .	negative	0
20816	11064392	3458;598	IFN-gamma;Bcl-X	***IFN-gamma*** increased BAK protein levels and ***decreased*** Bcl-2 and ***Bcl-X*** ( S ) protein levels in TSGH9201 cells .	negative	0
20817	11064392	3458;578	IFN-gamma;BAK	***IFN-gamma*** ***increased*** ***BAK*** protein levels and decreased Bcl-2 and Bcl-X ( S ) protein levels in TSGH9201 cells .	positive	0
20818	11064449	7157;7015	p53;telomerase reverse transcriptase	***Downregulation*** of ***telomerase reverse transcriptase*** mRNA expression by wild type ***p53*** in human tumor cells .	negative	1
20819	11064449	7157;7015	p53;telomerase reverse transcriptase	In the present study we demonstrated that ***p53*** is also a powerful ***inhibitor*** of human ***telomerase reverse transcriptase*** ( hTERT ) , a key component for telomerase .	negative	1
20820	11064451	1843;5599	CL100;JNK	***CL100/MKP-1*** ***modulates*** ***JNK*** activation and apoptosis in response to cisplatin .	target	0
20821	11064451	1848;5599	Pyst1;JNK	In contrast , expression of the ERK-specific phosphatase ***Pyst1*** ***inhibits*** ***JNK/SAPK*** activity only when expressed at very high levels and does not confer protection against cisplatin .	negative	1
20822	11064451	1848;5601	Pyst1;SAPK	In contrast , expression of the ERK-specific phosphatase ***Pyst1*** ***inhibits*** ***JNK/SAPK*** activity only when expressed at very high levels and does not confer protection against cisplatin .	negative	1
20823	11064452	7186;4790	TRAF2;NF-kappaB	Since ***TRAF2*** ***activates*** the transcription factor ***NF-kappaB*** , IL-15 through IL-15Ralpha , could have a role in the control of this pathway .	positive	1
20824	11064455	6670;1026	Sp3;WAF1	Sp1 and ***Sp3*** ***activate*** p21 ( ***WAF1/CIP1*** ) gene transcription in the Caco-2 colon adenocarcinoma cell line .	positive	1
20825	11064455	7157;1026	p53;p21	Expression of ***p21*** is ***controlled*** at the transcriptional level by both ***p53-dependent*** and - independent mechanisms .	target	0
20826	11064455	6670;1026	Sp3;p21	Our data suggest that induction of p21 transcription during Caco-2 differentiation is modulated by ***Sp1/Sp3*** ***interactions*** with the ***p21*** promoter .	parallel	1
20827	11064465	1380;2208	CD21;CD23	INTERPRETATION AND CONCLUSIONS : Since ***interaction*** between ***CD23*** and ***CD21*** is important for B-cell activation , proliferation and tumor formation , findings that both molecules are upregulated in prolymphocytes suggest that this is the proliferating cell component in CLL and underline the association between progression and increased prolymphocytes in typical CLL and CLL/PL .	parallel	1
20828	11064465	1380;2208	CD21;CD23	Quantitative expression of ***CD23*** and its ***ligand*** ***CD21*** in chronic lymphocytic leukemia .	parallel	1
20829	11066092	2239;2247	Glypican-4;FGF2	Recombinant ***Glypican-4*** produced in immortalized neural precursor cells ***binds*** ***FGF2*** through its heparan sulfate chains and suppressed the mitogenic effect of FGF2 on E13 cortical precursor cells .	parallel	1
20830	11066092	2239;2247	Glypican-4;FGF2	Recombinant ***Glypican-4*** produced in immortalized neural precursor cells binds FGF2 through its heparan sulfate chains and ***suppressed*** the mitogenic effect of ***FGF2*** on E13 cortical precursor cells .	negative	1
20831	11067764	6281;302	p11;annexin II	Using these structural results , as well as electron microscopy observations of liposome junctions formed in the presence of such complexes ( Lambert et al. , 1997 J Mol Biol 272 , 42-55 ) , we propose a computer generated model for the entire ******annexin II/p11****** ***complex*** .	parallel	1
20832	11067861	3596;4313	IL-13;MMP-2	***MMP-2*** , -9 , -12 , -13 , and -14 and cathepsins B , S , L , H , and K were ***induced*** by ***IL-13*** in this setting .	target	1
20833	11067862	6777;3479	Stat5;IGF-I	The actions of GH are transduced by the Jak/Stat signaling pathway via ***Stat5*** , which is thought to ***regulate*** ***IGF-I*** expression .	target	1
20834	11067868	348;4035	apoE;LRP	Remarkably , the LDL receptor-related protein ( ***LRP*** ) and its ***ligands*** , ***apoE*** and alpha2M , are all genetically associated with AD .	parallel	1
20835	11067868	4035;351	LRP;Abeta	Although LRP has been proposed to be a clearance pathway for Abeta , this work provides the first in vivo evidence that the ***LRP*** pathway may ***modulate*** ***Abeta*** deposition and AD susceptibility by regulating the removal of soluble Abeta .	target	0
20836	11067888	7099;3664	TLR4;LPS	We previously showed that TLR2 recognizes Gram-positive bacterial components whereas ***TLR4*** ***recognizes*** ***LPS*** , a component of Gram-negative bacteria .	target	1
20837	11067893	4792;4790	IkappaB-alpha;NF-kappaB	We have evaluated the in vivo effects of deletion of ***IkappaB-alpha*** , a major ***inhibitor*** of ***NF-kappaB*** , on lymphocyte development , proliferation , and function .	negative	1
20838	11067899	3439;3565	IFN-alpha;IL-4	IFN-gamma and ***IFN-alpha*** posttranscriptionally ***down-regulate*** the IL-4-induced ***IL-4*** receptor gene expression .	negative	1
20839	11067899	3458;3565	IFN-gamma;IL-4	***IFN-gamma*** and IFN-alpha posttranscriptionally ***down-regulate*** the IL-4-induced ***IL-4*** receptor gene expression .	negative	1
20840	11067899	3439;3497	IFN-alpha;IgE	In particular , IFN-gamma and ***IFN-alpha*** have been reported to markedly ***suppress*** the IL-4-induced ***IgE*** production and type II IgE receptor ( FcepsilonRII/CD23 ) expression .	negative	1
20841	11067899	3458;3497	IFN-gamma;IgE	In particular , ***IFN-gamma*** and IFN-alpha have been reported to markedly ***suppress*** the IL-4-induced ***IgE*** production and type II IgE receptor ( FcepsilonRII/CD23 ) expression .	negative	1
20842	11067900	355;356	Fas;Fas ligand	The ******Fas-Fas ligand****** ( FasL ) ***interaction*** is important for maintaining lymphocyte homeostasis by signaling for activation-induced cell death .	parallel	1
20843	11067901	356;355	FasL;Fas	Bioactive ***Fas*** ***ligand*** ( ***FasL*** ) - expressing vesicles were generated ( vesicle preparation , VP ) from two cell lines overexpressing FasL .	parallel	1
20844	11067903	3458;133418	IFN-gamma;gp70	We show that ***IFN-gamma*** ***down-regulates*** intracellular and surface levels of ***gp70*** protein resulting in a reduced lysis by CTL , which is restored by pulsing IFN-gamma-treated CT26 with the L ( d ) - restricted immunodominant AH1 epitope derived from gp70 .	negative	1
20845	11067906	958;1493	CD40;CTLA-4	Our results show that ***CD40*** or LPS stimulation in the presence of IL-4 ***induces*** ***CTLA-4*** expression in purified B cells ; the maximum level is reached in both membrane and intracellular compartments after 48-72 h.	target	1
20846	11067914	933;5777	CD22;protein tyrosine phosphatase SHP-1	Phosphorylation of ***CD22*** was ***associated*** with increased recruitment and binding of the ***protein tyrosine phosphatase SHP-1*** .	parallel	0
20847	11067916	6863;1432	substance P;p38 mitogen-activated protein kinase	The neuropeptide ***substance P*** ***activates*** ***p38 mitogen-activated protein kinase*** resulting in IL-6 expression independently from NF-kappa B .	positive	1
20848	11067916	5594;4790	p38;NF-kappaB	As shown by EMSA , ***p38*** MAPK was not involved in SP-induced ***activation*** of ***NF-kappaB*** .	positive	1
20849	11067933	3458;7124	IFN-gamma;TNF-alpha	LT and LTR72 suppressed LPS and ***IFN-gamma*** ***induced*** ***TNF-alpha*** and IL-12 production , but enhanced IL-10 secretion by macrophages in vitro and suppressed IL-12 production in vivo in a murine model of LPS-induced shock .	target	1
20850	11067936	356;355	Fas ligand;Fas	Two subsets of human CTL have been defined based upon phenotype and function : CD4 ( - ) CD8 ( - ) double-negative ( DN ) CTL lyse susceptible targets via ******Fas-Fas ligand****** ***interaction*** and CD8 ( + ) CTL via the granule exocytosis pathway .	parallel	1
20851	11067938	7076;4318	TIMP-1;MMP-9	Cytokine-induced steady state mRNA levels of ***TIMP-1*** , an endogenous ***inhibitor*** of ***MMP-9*** , were affected similarly by HXXO .	negative	1
20852	11067938	3553;4318	IL-1beta;MMP-9	Mutation of either response element completely prevented ***MMP-9*** promoter ***activation*** by ***IL-1beta*** .	positive	1
20853	11067942	3553;4790	IL-1beta;NF-kappaB	These results indicate that sustained ***NF-kappaB*** activation in asthmatic bronchi is driven by granulocytes and is ***mediated*** by ***IL-1beta*** and TNF-alpha .	target	0
20854	11067942	7124;4790	TNF-alpha;NF-kappaB	These results indicate that sustained ***NF-kappaB*** activation in asthmatic bronchi is driven by granulocytes and is ***mediated*** by IL-1beta and ***TNF-alpha*** .	target	0
20855	11067942	4790;4792	NF-kappaB;IkappaB-alpha	In most cells trans-activating ***NF-kappaB*** ***induces*** many inflammatory proteins as well as its own inhibitor , ***IkappaB-alpha*** , thus assuring a transient response upon stimulation .	target	1
20856	11067942	3553;4790	IL-1beta;NF-kappaB	Before granulocytic death , ***NF-kappaB*** activity was ***suppressed*** by simultaneous addition of neutralizing ***anti-IL-1beta*** and anti-TNF-alpha Abs to the medium of cultured BBSs .	negative	1
20857	11067944	3565;6369	IL-4;eotaxin-2	Furthermore , ***eotaxin-2*** mRNA was strongly ***induced*** by both transgenic over-expression of ***IL-4*** in the lung and administration of intranasal IL-4 .	target	1
20858	11068015	820;133	cAMP;adrenomedullin	The attenuated ***cAMP*** ***response*** of ***adrenomedullin*** was restored to original levels within 2 h of agonist removal .	parallel	0
20859	11068016	7124;836	TNF-alpha;caspase-3	***caspase-3*** ***activation*** by ***TNF-alpha*** was significantly enhanced by pretreatment with both cycloheximide and pyrrolidine dithiocarbamate .	positive	1
20860	11068016	7124;4790	TNF-alpha;NF-kappaB	Furthermore , ***TNF-alpha*** ***increased*** ***NF-kappaB*** DNA binding , which was abolished by pretreatment with pyrrolidine dithiocarbamate .	positive	0
20861	11068043	5501;4659	PP1c;MYPT1	***Binding*** of ***PP1c*** or P-MLC20 to phosphorylated ***MYPT1*** ( 1-296 ) was also attenuated .	parallel	1
20862	11068097	4852;2641	NPY;glucagon	In conclusion , ***NPY*** and SP ***stimulated*** ***glucagon*** secretion from the pancreas of normal rat .	positive	0
20863	11068097	4852;2641	NPY;glucagon	In contrast , ***NPY*** and SP ***inhibited*** ***glucagon*** secretion from diabetic rat pancreas .	negative	1
20864	11068097	4852;2641	NPY;glucagon	In contrast to this , ***NPY*** ***inhibited*** ***glucagon*** secretion from the pancreas of diabetic rat .	negative	1
20865	11068098	2641;9340	GLP-2;GLP-2 receptor	In the small intestine , ( 125 ) I-GLP-2 was displaced both by non-radioactive GLP-2 ( 1-33 ) and ( 3-33 ) , suggesting that the uptake of GLP-2 ( 1-33 ) in the small intestine is receptor-specific and that the metabolite ***GLP-2*** ( 3-33 ) may ***interact*** with the ***GLP-2 receptor*** .	parallel	1
20866	11068104	3060;4852	orexin;NPY	Since previous investigations demonstrated that an NPY Y1 receptor antagonist also inhibits feeding induced by orexin A , the current results further underscore the existence of a functional ***link*** between ***orexin*** and ***NPY*** producing neurons as the orexin network appears to be capable of influencing NPYergic signaling through Y1 and Y5 receptors to stimulate feeding .	parallel	0
20867	11068150	1906;5829	Endothelin-1;paxillin	***Endothelin-1*** ( 1 nM ) ***increased*** tyrosine phosphorylation of focal adhesion kinase and ***paxillin*** .	positive	0
20868	11068878	2896;3098	granulin precursor;hexokinase	***Interaction*** of insulin-like growth factor binding protein-4 , Miz-1 , leptin , lipocalin-type prostaglandin D synthase , and ***granulin precursor*** with the N-terminal half of type III ***hexokinase*** .	parallel	1
20869	11068878	3487;3098	insulin-like growth factor binding protein-4;hexokinase	***Interaction*** of ***insulin-like growth factor binding protein-4*** , Miz-1 , leptin , lipocalin-type prostaglandin D synthase , and granulin precursor with the N-terminal half of type III ***hexokinase*** .	parallel	1
20870	11068878	3952;3098	leptin;hexokinase	***Interaction*** of insulin-like growth factor binding protein-4 , Miz-1 , ***leptin*** , lipocalin-type prostaglandin D synthase , and granulin precursor with the N-terminal half of type III ***hexokinase*** .	parallel	1
20871	11068878	5730;3098	lipocalin-type prostaglandin D synthase;hexokinase	***Interaction*** of insulin-like growth factor binding protein-4 , Miz-1 , leptin , ***lipocalin-type prostaglandin D synthase*** , and granulin precursor with the N-terminal half of type III ***hexokinase*** .	parallel	1
20872	11068935	6863;6750	substance P;somatostatin	Various inflammatory mediators induce this expression , whereas ***substance P*** ***inhibits*** ***somatostatin*** production .	negative	1
20873	11068935	6750;3458	somatostatin;IFN-gamma	***somatostatin*** can ***suppress*** ***IFN-gamma*** secretion from T cells via interaction with the SSTR2 receptor expressed on these cells .	negative	1
20874	11069054	3903;4790	leukocyte-associated Ig-like receptor-1;NF-kappaB	Engagement of the ***leukocyte-associated Ig-like receptor-1*** induces programmed cell death and ***prevents*** ***NF-kappaB*** nuclear translocation in human myeloid leukemias .	negative	0
20875	11069056	356;355	CD95L;CD95	AICD is mediated predominantly by ***CD95*** ( APO-1 / Fas ) and its cognate ***ligand*** ( ***CD95L*** ) .	parallel	1
20876	11069065	3824;3822	CD94;NKG2C	The ******CD94/NKG2C****** ***heterodimer*** constitutes an activating receptor involved in NK cell-mediated recognition of the class lb molecule HLA-E .	parallel	1
20877	11069068	3458;5594	IFN-gamma;p40	Despite enhancing expression of the other gene products , cytokines such as interferon-gamma ( IFN-gamma ) or tumor necrosis factor-alpha , alone or in combination , failed to induce IL-12 p40 expression , whereas ***IFN-gamma*** markedly ***augmented*** CD154-induced IL-12 ***p40*** and p70 release .	positive	0
20878	11069068	3458;84959	IFN-gamma;p70	Despite enhancing expression of the other gene products , cytokines such as interferon-gamma ( IFN-gamma ) or tumor necrosis factor-alpha , alone or in combination , failed to induce IL-12 p40 expression , whereas ***IFN-gamma*** markedly ***augmented*** CD154-induced IL-12 p40 and ***p70*** release .	positive	0
20879	11069075	6387;7852	SDF-1;chemokine receptor 4	Previous reports have shown that the Gi-protein-coupled CXC ***chemokine receptor 4*** is ***activated*** by stromal cell-derived factor 1 ( ***SDF-1*** ) .	positive	1
20880	11069075	6387;7852	SDF-1;CXCR4	The fact that only 19 of these residues are specifically present in the extracellular portions of CXCR4 suggests that these residues may be involved in recognizing SDF-1 and/or mediating ***CXCR4*** ***activation*** by ***SDF-1*** .	positive	1
20881	11069082	7124;3586	TNF-alpha;IL-10	In contrast , ***TNF-alpha*** ***stimulated*** ***IL-10*** production in dendritic cells but not monocytes .	positive	0
20882	11069087	652070;6625	scFv;U1-70K	Using several U1-70K deletion and point mutants of both human ( h ) and Drosophila melanogaster ( Dm ) origin , it was established that the ***U1-70K*** epitope that is ***recognized*** by the anti-hU1-70K ***scFv*** is located within the RNA binding domain .	target	1
20883	11069090	3606;3569	IL-18;IL-6	***IL-6*** synthesis was also strongly ***induced*** by ***IL-18*** and , as revealed by studies in knockout mice , this production was not dependent on interactions between endogenous cytokines of the TNF/TNF receptor family : TNF-alpha , lymphotoxin-alpha , Fas/Fas ligand ( L ) or CD40/CD40L .	target	1
20884	11069105	5562;5209	AMPK;PFK-2	CONCLUSIONS : ***AMPK*** ***phosphorylates*** and activates heart ***PFK-2*** in vitro and in intact cells .	target	1
20885	11069105	5562;5209	AMPK;PFK-2	***Phosphorylation*** and activation of heart ***PFK-2*** by ***AMPK*** has a role in the stimulation of glycolysis during ischaemia .	target	1
20886	11069105	5562;5209	AMPK;PFK-2	In perfused rat hearts , anaerobic conditions or inhibitors of oxidative phosphorylation ( oligomycin and antimycin ) induced ***AMPK*** activation , which ***correlated*** with ***PFK-2*** activation and with an increase in fructose 2,6-bisphosphate concentration .	parallel	0
20887	11069105	5562;5209	AMPK;PFK-2	A dominant-negative construct of ***AMPK*** abolished the activation of endogenous and cotransfected AMPK , and ***prevented*** both the activation and phosphorylation of transfected ***PFK-2*** by oligomycin .	negative	0
20888	11069108	2934;1072	ADF;cofilin	***Interactions*** of ******ADF/cofilin****** , Arp2/3 complex , capping protein and profilin in remodeling of branched actin filament networks .	parallel	1
20889	11069108	10096;2934	Arp2/3;ADF	***Interactions*** of ***ADF/cofilin*** , ***Arp2/3*** complex , capping protein and profilin in remodeling of branched actin filament networks .	parallel	1
20890	11069108	10096;1072	Arp2/3;cofilin	***Interactions*** of ***ADF/cofilin*** , ***Arp2/3*** complex , capping protein and profilin in remodeling of branched actin filament networks .	parallel	1
20891	11069113	8658;7013	Tankyrase;TRF1	Overexpression of ***Tankyrase*** in the nucleus ***diminished*** the level of unmodified ***TRF1*** in immunoblots and led to reduced immunofluorescence of TRF1 at interphase telomeres .	negative	0
20892	11069113	8658;7013	Tankyrase;TRF1	A PARP-deficient form of ***Tankyrase*** failed to ***affect*** ***TRF1*** and did not alter telomere length dynamics , consistent with ADP-ribosylation of TRF1 as the main cause of altered telomere homeostasis .	target	0
20893	11069117	5727;6608	Ptc;Smo	Evidence for a physical ***interaction*** between ***Smo*** and ***Ptc*** is so far limited to studies of the vertebrate versions of these proteins when overexpressed in tissue culture systems [ 8,12 ] .	parallel	1
20894	11069119	51738;1958	ghrelin;Egr-1	Systemic administration of ***ghrelin*** ***induces*** Fos and ***Egr-1*** proteins in the hypothalamic arcuate nucleus of fasted and fed rats .	target	1
20895	11069119	51738;2693	ghrelin;growth hormone secretagogue (GHS) receptor	***ghrelin*** , a recently identified endogenous ***ligand*** for the ***growth hormone secretagogue (GHS) receptor*** , induces growth hormone ( GH ) secretion following systemic administration .	parallel	1
20896	11069122	551;1392	AVP;CRH	***CRH*** mRNA levels were maximally ***increased*** by medium interval pulses and ***AVP*** mRNA by rapid interval pulses .	positive	0
20897	11069129	5367;3952	MCH;leptin	MCH neurones are present in the zona incerta and administration of this hormone into the medial preoptic area ( mPOA ) stimulates LH release , therefore we investigated the possibility that ***MCH*** might ***mediate*** this effect of ***leptin*** .	target	0
20898	11069129	5443;3952	ACTH;leptin	In addition , melanocortin receptor antagonists ( [ D-Arg8 ] ***ACTH*** ( 4-10 ) and [ Ala6 ] ACTH ( 4-10 ) ) , previously shown to inhibit the stimulatory effect of MCH on LH release , also ***inhibited*** the effect of ***leptin*** .	negative	1
20899	11069186	2263;2246	FGFR2;FGF1	The structure of the ******FGF1-FGFR2-heparin****** ternary ***complex*** provides a structural basis for the essential role of heparan sulphate in FGF signalling .	parallel	1
20900	11069201	3553;3952	IL-1beta;leptin	In this study we demonstrate that the pro-inflammatory/hemopoietic cytokines , ***IL-1beta*** , IL-6 , TNF-alpha , and interferon-gamma , significantly ***inhibit*** gene expression and secretion of ***leptin*** by bone marrow adipocytes .	negative	1
20901	11069201	3458;3952	interferon-gamma;leptin	In this study we demonstrate that the pro-inflammatory/hemopoietic cytokines , IL-1beta , IL-6 , TNF-alpha , and ***interferon-gamma*** , significantly ***inhibit*** gene expression and secretion of ***leptin*** by bone marrow adipocytes .	negative	1
20902	11069201	7124;3952	TNF-alpha;leptin	In this study we demonstrate that the pro-inflammatory/hemopoietic cytokines , IL-1beta , IL-6 , ***TNF-alpha*** , and interferon-gamma , significantly ***inhibit*** gene expression and secretion of ***leptin*** by bone marrow adipocytes .	negative	1
20903	11069245	7133;3576	p75;IL-8	Native soluble ***p75*** ***increased*** TNF-alpha-induced ***IL-8*** , versus a 61 % reduction by native p55 .	positive	0
20904	11069245	7133;3576	p75;IL-8	Spontaneous ***IL-8*** production was ***increased*** by ***p75-Fc*** or native p75 but not by p55-PEG or native p55 .	positive	0
20905	11069295	7157;5625	p53;Proline oxidase	***Proline oxidase*** , a mitochondrial enzyme involved in the proline/pyrroline -5 - carboxylate redox cycle , was ***up-regulated*** by ***p53*** in ECV but not in DECV cells .	positive	1
20906	11069302	983;332	p34cdc2;survivin	Regulation of apoptosis at cell division by ***p34cdc2*** ***phosphorylation*** of ***survivin*** .	target	1
20907	11069302	332;902	survivin;p34	Here , we show that ***survivin*** , an inhibitor of apoptosis over-expressed in cancer , physically ***associates*** with the cyclin-dependent kinase ***p34*** ( cdc2 ) on the mitotic apparatus , and is phosphorylated on Thr ( 34 ) by p34 ( cdc2 ) - cyclin B1 , in vitro and in vivo .	parallel	0
20908	11069302	902;332	p34;survivin	Here , we show that ***survivin*** , an inhibitor of apoptosis over-expressed in cancer , physically associates with the cyclin-dependent kinase p34 ( cdc2 ) on the mitotic apparatus , and is ***phosphorylated*** on Thr ( 34 ) by ***p34*** ( cdc2 ) - cyclin B1 , in vitro and in vivo .	target	1
20909	11069302	842;332	caspase-9;survivin	Loss of phosphorylation on Thr ( 34 ) resulted in dissociation of a ******survivin-caspase-9****** ***complex*** on the mitotic apparatus , and caspase-9-dependent apoptosis of cells traversing mitosis .	parallel	1
20910	11069614	7124;4319	tumor necrosis factor-alpha;Stromelysin-2	In keratinocyte cultures , ***tumor necrosis factor-alpha*** , epidermal growth factor , and transforming growth factor-beta1 ***induced*** ***Stromelysin-2*** expression as measured by quantitative reverse transcriptase-polymerase chain reaction , whereas different matrices did not upregulate the mRNA .	target	1
20911	11069615	23543;3852	rTA;keratin 5	To produce conditional expression of genes in the mouse epidermis we have generated transgenic mouse lines in which the tetracycline-regulated transcriptional transactivators , tTA and ***rTA*** , are ***linked*** to the bovine ***keratin 5*** promoter .	parallel	0
20912	11069622	1308;3569	BP180;interleukin-6	Autoantibodies to ***BP180*** ***associated*** with bullous pemphigoid release ***interleukin-6*** and interleukin-8 from cultured human keratinocytes .	parallel	0
20913	11069622	1308;3576	BP180;interleukin-8	Autoantibodies to ***BP180*** ***associated*** with bullous pemphigoid release interleukin-6 and ***interleukin-8*** from cultured human keratinocytes .	parallel	0
20914	11069716	3458;2920	IFN-gamma;MIP-2	***IFN-gamma*** suppressed the LPS-induced MIP-1alpha release but ***enhanced*** the LPS-induced ***MIP-2*** secretion in both macrophages .	positive	0
20915	11069716	3458;6348	IFN-gamma;MIP-1alpha	***IFN-gamma*** ***suppressed*** the LPS-induced ***MIP-1alpha*** release but enhanced the LPS-induced MIP-2 secretion in both macrophages .	negative	1
20916	11069718	6520;6714	CD98HC;c-Src	These findings suggest that the tyrosine kinase ( s ) - Ras-MAPK-Sp1 pathway ( s ) is involved in ***CD98HC-mediated*** ***induction*** of ***c-Src*** in human blood monocytes .	target	1
20917	11069728	3553;1432	IL-1 beta;p38 MAP kinase	In primary human chondrocytes , ***IL-1 beta*** ***induction*** of ***p38 MAP kinase*** was inhibited by SB 242235 with an IC ( 50 ) of approximately 1 microM .	target	1
20918	11069732	3458;3553	IFN gamma;IL-1 beta	Interestingly , ***IFN gamma*** ***synergized*** with ***IL-1 beta*** to increase NO , IL-6 , IL-1ra and to depress PG production .	parallel	0
20919	11069732	3458;3557	IFN gamma;IL-1ra	Interestingly , ***IFN gamma*** synergized with IL-1 beta to ***increase*** NO , IL-6 , ***IL-1ra*** and to depress PG production .	positive	0
20920	11069732	3458;3569	IFN gamma;IL-6	Interestingly , ***IFN gamma*** synergized with IL-1 beta to ***increase*** NO , ***IL-6*** , IL-1ra and to depress PG production .	positive	0
20921	11069732	3458;3557	IFN gamma;IL-1ra	CONCLUSIONS : These findings suggest that ***IFN gamma*** and IL-1 synergistically ***stimulate*** the production of IL-6 , ***IL-1ra*** , NO and PGE ( 2 ) and inhibit PG synthesis .	positive	0
20922	11069732	3458;3569	IFN gamma;IL-6	CONCLUSIONS : These findings suggest that ***IFN gamma*** and IL-1 synergistically ***stimulate*** the production of ***IL-6*** , IL-1ra , NO and PGE ( 2 ) and inhibit PG synthesis .	positive	0
20923	11069732	3553;3557	IL-1;IL-1ra	CONCLUSIONS : These findings suggest that IFN gamma and ***IL-1*** synergistically ***stimulate*** the production of IL-6 , ***IL-1ra*** , NO and PGE ( 2 ) and inhibit PG synthesis .	positive	0
20924	11069732	3553;3569	IL-1;IL-6	CONCLUSIONS : These findings suggest that IFN gamma and ***IL-1*** synergistically ***stimulate*** the production of ***IL-6*** , IL-1ra , NO and PGE ( 2 ) and inhibit PG synthesis .	positive	0
20925	11069732	3553;3586	IL-1 beta;IL-10	RESULTS : As expected , ***IL-1 beta*** highly ***stimulated*** NO , IL-6 , IL-8 , ***IL-10*** , IL-1ra , PGE ( 2 ) and stromelysin synthesis , but dramatically decreased PG production .	positive	0
20926	11069732	3553;3557	IL-1 beta;IL-1ra	RESULTS : As expected , ***IL-1 beta*** highly ***stimulated*** NO , IL-6 , IL-8 , IL-10 , ***IL-1ra*** , PGE ( 2 ) and stromelysin synthesis , but dramatically decreased PG production .	positive	0
20927	11069732	3553;3569	IL-1 beta;IL-6	RESULTS : As expected , ***IL-1 beta*** highly ***stimulated*** NO , ***IL-6*** , IL-8 , IL-10 , IL-1ra , PGE ( 2 ) and stromelysin synthesis , but dramatically decreased PG production .	positive	0
20928	11069732	3553;3576	IL-1 beta;IL-8	RESULTS : As expected , ***IL-1 beta*** highly ***stimulated*** NO , IL-6 , ***IL-8*** , IL-10 , IL-1ra , PGE ( 2 ) and stromelysin synthesis , but dramatically decreased PG production .	positive	0
20929	11069732	3458;3557	IFN gamma;IL-1ra	NO , IL-6 , ***IL-1ra*** and PGE ( 2 ) production by non-stimulated chondrocytes was dose-dependently ***increased*** by ***IFN gamma*** while PG production was inhibited .	positive	0
20930	11069732	3458;3569	IFN gamma;IL-6	NO , ***IL-6*** , IL-1ra and PGE ( 2 ) production by non-stimulated chondrocytes was dose-dependently ***increased*** by ***IFN gamma*** while PG production was inhibited .	positive	0
20931	11069732	3458;3586	IFN gamma;IL-10	At the doses of 10 and 100 U/ml , ***IFN gamma*** markedly ***inhibited*** the constitutive and IL-1 beta-stimulated IL-8 , ***IL-10*** and stromelysin productions .	negative	1
20932	11069732	3458;3576	IFN gamma;IL-8	At the doses of 10 and 100 U/ml , ***IFN gamma*** markedly ***inhibited*** the constitutive and IL-1 beta-stimulated ***IL-8*** , IL-10 and stromelysin productions .	negative	1
20933	11069843	3606;3458	IL-18;IFN-gamma	In patients with sarcoidosis , ***IL-18*** seems to ***induce*** ***IFN-gamma*** production and IL-18 levels in sera may reflect disease activity of sarcoidosis .	target	1
20934	11069843	3606;3458	IL-18;IFN-gamma	Serum ***IL-18*** levels significantly ***correlated*** with serum ***IFN-gamma*** levels and lysozyme activity .	parallel	0
20935	11069897	571;7975	BACH1;MafK	***BACH1*** forms a ***heterodimer*** with ***MafK*** , a member of the small Maf protein family ( MafF , MafG , and MafK ) , which recognizes the NF-E2 / Maf recognition element , a cis-regulatory motif containing a 12-O-tetradecanoylphorbol-13-acetate-responsive element .	parallel	1
20936	11069907	3356;407	5-HT2A;Arr-3	Interestingly , ***5-HT2A*** receptor activation by agonists , but not antagonists , ***induced*** greater ***Arr-3*** than Arr-2 translocation to the plasma membrane .	target	1
20937	11069927	8648;3960	SRC1;GAL4	The ***binding*** of a ******GAL4-SRC1****** chimeric protein completely restores the glucocorticoid induction that is lost when any one of these elements is replaced with a GAL4 binding site .	parallel	1
20938	11069927	8648;26056	SRC1;gAF1	Thus , when ***SRC1*** is ***recruited*** directly to ***gAF1*** , gAF2 , or gAF3 , the requirement for the corresponding AF is bypassed .	target	0
20939	11069927	8648;3960	SRC1;GAL4	Surprisingly , glucocorticoid receptor is still required when ***SRC1*** is ***recruited*** directly to the ***GAL4*** site , suggesting a role for the receptor in activating SRC1 in the context of the GRU .	target	0
20940	11070003	836;5062	caspase 3;Pak2	We first confirm that ***Pak2*** but not Pak1 is ***cleaved*** by ***caspase 3*** in vitro and then demonstrate that Nak is caspase 3 sensitive , regardless of Nef allele or cell type used .	target	1
20941	11070019	5610;1965	PKR;eIF2	Upon activation by double-stranded RNA in virus-infected cells , the cellular ***PKR*** kinase ***phosphorylates*** the translation initiation factor eukaryotic initiation factor 2 ( ***eIF2*** ) and thereby inhibits protein synthesis .	target	1
20942	11070080	4193;7157	MDM2;p53	***MDM2*** ***inhibits*** p300-mediated ***p53*** acetylation and activation by forming a ternary complex with the two proteins .	negative	1
20943	11070080	4193;7157	MDM2;p53	Here , we show that ***MDM2*** , a negative-feedback ***regulator*** of ***p53*** , inhibited p300-mediated p53 acetylation by complexing with these two proteins .	target	1
20944	11070080	4193;7157	MDM2;p53	Here , we show that ***MDM2*** , a negative-feedback regulator of p53 , ***inhibited*** p300-mediated ***p53*** acetylation by complexing with these two proteins .	negative	1
20945	11070080	4193;2033	MDM2;p300	First , we purified a ******p300-MDM2-p53****** protein ***complex*** from HeLa nuclear extracts , which was inactive in p53 acetylation , but active in histone acetylation .	parallel	1
20946	11070080	4193;7157	MDM2;p53	First , we purified a ******p300-MDM2-p53****** protein ***complex*** from HeLa nuclear extracts , which was inactive in p53 acetylation , but active in histone acetylation .	parallel	1
20947	11070080	7157;2033	p53;p300	First , we purified a ******p300-MDM2-p53****** protein ***complex*** from HeLa nuclear extracts , which was inactive in p53 acetylation , but active in histone acetylation .	parallel	1
20948	11070080	4193;7157	MDM2;p53	Also , wild-type , but not N-terminally deleted , ***MDM2*** ***inhibited*** ***p53*** acetylation by p300 in vitro and in vivo .	negative	1
20949	11070080	2033;7157	p300;p53	These results demonstrate that an additional mechanism of p53 inactivation by MDM2 is to inhibit ***p53*** ***acetylation*** by ***p300*** .	target	1
20950	11070174	3586;7297	IL-10;Tyk2	In contrast , these mice respond normally to IL-6 and ***IL-10*** , both of which ***activate*** ***Tyk2*** in vitro .	positive	1
20951	11070174	3569;7297	IL-6;Tyk2	In contrast , these mice respond normally to ***IL-6*** and IL-10 , both of which ***activate*** ***Tyk2*** in vitro .	positive	1
20952	11070188	51052;1392	PrRP;corticotropin releasing hormone	From the distribution pattern of PrRP and its receptor , it is suggested that ***PrRP*** is involved in ***control*** of secretion of oxytocin , ***corticotropin releasing hormone*** and somatostatin .	target	0
20953	11070188	51052;5020	PrRP;oxytocin	From the distribution pattern of PrRP and its receptor , it is suggested that ***PrRP*** is involved in ***control*** of secretion of ***oxytocin*** , corticotropin releasing hormone and somatostatin .	target	0
20954	11070188	51052;6750	PrRP;somatostatin	From the distribution pattern of PrRP and its receptor , it is suggested that ***PrRP*** is involved in ***control*** of secretion of oxytocin , corticotropin releasing hormone and ***somatostatin*** .	target	0
20955	11070416	1906;5972	endothelin-1;renin	Plasma ***renin*** activity was ***reduced*** by ***endothelin-1*** and increased by TAK-044 .	negative	1
20956	11070492	7430;4771	ezrin;merlin	***Interaction*** between two isoforms of the NF2 tumor suppressor protein , merlin , and between ***merlin*** and ***ezrin*** , suggests modulation of ERM proteins by merlin .	parallel	1
20957	11070492	4771;7430	merlin;ezrin	We found by immunoprecipitation and yeast two-hybrid assays that both ***merlin*** isoforms ***interact*** with ***ezrin*** .	parallel	1
20958	11070492	7430;4771	ezrin;merlin	The heterodimerization of merlin is a much stronger interaction than the interaction between either merlin isoform and ezrin , and can inhibit ******merlin-ezrin****** ***binding*** .	parallel	1
20959	11070492	7430;4771	ezrin;merlin	The heterodimerization of merlin is a much stronger interaction than the ***interaction*** between either ***merlin*** isoform and ***ezrin*** , and can inhibit merlin-ezrin binding .	parallel	1
20960	11070492	4771;7430	merlin;ezrin	The heterodimerization of ***merlin*** is a much stronger interaction than the interaction between either merlin isoform and ezrin , and can ***inhibit*** ***merlin-ezrin*** binding .	negative	1
20961	11070505	335;351	apo;Abeta	We recently found that ***apo*** ( E-AII ) complex ***binds*** to ***Abeta*** much more strongly than does monomeric ApoE .	parallel	1
20962	11070505	348;351	ApoE;Abeta	Here , we investigated the effect of apoAII on the ***interaction*** between ***ApoE*** and ***Abeta*** .	parallel	1
20963	1107095	6750;2641	somatostatin;glucagon	Both ***somatostatin*** and propranolol completely ***prevented*** ***glucagon*** responses and diminished the glycemic response to epinephrine by 40 to 50 per cent .	negative	0
20964	11071109	7292;7293	gp34;OX40	Expression of OX40 and ***OX40*** ***ligand*** ( ***gp34*** ) in the normal and myasthenic thymus .	parallel	1
20965	11071281	1508;286	cysteine protease;erythrocyte ankyrin	A ***cysteine protease*** activity from Plasmodium falciparum ***cleaves*** human ***erythrocyte ankyrin*** .	target	1
20966	11071371	1508;4155	cathepsin B;MBP	The ***degradation*** of myelin basic protein ( ***MBP*** ) by ***cathepsin B*** , a lysosomal cysteine protease , was significantly inhibited by indomethacin .	negative	1
20967	11071635	1796;4067	Dok-1;Lyn	The study shows that Tec and ***Dok-1*** form a stable ***complex*** with ***Lyn*** and 2 unidentified phosphoproteins of 56 and 140 kd .	parallel	1
20968	11071635	7006;4067	Tec;Lyn	The study shows that ***Tec*** and Dok-1 form a stable ***complex*** with ***Lyn*** and 2 unidentified phosphoproteins of 56 and 140 kd .	parallel	1
20969	11071635	4067;1796	Lyn;Dok-1	In addition , Tec and ***Lyn*** were shown to ***phosphorylate*** ***Dok-1*** , whereas phosphorylated Dok-1 was demonstrated to bind to the SH2 domains of several signaling molecules activated by SCF , including Abl , CrkL , SHIP , and PLCgamma-1 , but not those of Vav and Shc .	target	1
20970	11071635	7006;1796	Tec;Dok-1	In addition , ***Tec*** and Lyn were shown to ***phosphorylate*** ***Dok-1*** , whereas phosphorylated Dok-1 was demonstrated to bind to the SH2 domains of several signaling molecules activated by SCF , including Abl , CrkL , SHIP , and PLCgamma-1 , but not those of Vav and Shc .	target	1
20971	11071637	1440;2353	G-CSF;c-fos	In addition , SCF and ***G-CSF*** ***induce*** the synergistic activation of ***c-fos*** , a proto-oncogene involved in propagation of mitogenic signals in hematopoietic cells .	target	1
20972	11071637	1440;6772	G-CSF;STAT1	***G-CSF*** , but not SCF , ***induces*** the tyrosine phosphorylation of ***STAT1*** and STAT3 , transcription factors that can mediate the induction of c-fos .	target	1
20973	11071637	1440;6774	G-CSF;STAT3	***G-CSF*** , but not SCF , ***induces*** the tyrosine phosphorylation of STAT1 and ***STAT3*** , transcription factors that can mediate the induction of c-fos .	target	1
20974	11071642	9902;2158	endocytic receptor;coagulation factor IX	The ***interaction*** between the ***endocytic receptor*** low density lipoprotein receptor-related protein ( LRP ) and either ***coagulation factor IX*** or its active derivative factor IXa was studied .	parallel	1
20975	11071642	9902;4035	endocytic receptor;LRP	The ***interaction*** between the ***endocytic receptor*** low density lipoprotein receptor-related protein ( ***LRP*** ) and either coagulation factor IX or its active derivative factor IXa was studied .	parallel	1
20976	11071642	4035;2158	LRP;coagulation factor IX	The ***interaction*** between the endocytic receptor low density lipoprotein receptor-related protein ( ***LRP*** ) and either ***coagulation factor IX*** or its active derivative factor IXa was studied .	parallel	1
20977	11071643	6774;4790	STAT3;NF-kappaB	The competitive ***binding*** of ***NF-kappaB*** and ***STAT3*** on the overlapping binding site provides a mechanism for the inhibition by IL-1beta of the IL-6-mediated transactivation of rat gamma fibrinogen .	parallel	1
20978	11071645	2811;2316	GPIbalpha;actin-binding protein-280	Studies of CHO cells expressing ***GPIbalpha*** cytoplasmic tail truncation mutants that failed to ***bind*** ***actin-binding protein-280*** ( deletion of residues 569-610 or 535-568 ) demonstrated that the linkage between GPIb and actin-binding protein-280 was not required for vWf-induced actin polymerization , but was critical for the enhancing effects of cytochalasin D on vWf-induced cell aggregation .	parallel	1
20979	11071655	5728;207	PTEN;Akt	Despite the expression of PTEN with the concomitant low Akt activity in all mouse PCT lines , their p70S6K activities were generally higher than those in 3 human MM lines , arguing for specific negative ***regulation*** of ***Akt*** , but not p70S6K by ***PTEN*** .	negative	1
20980	11071667	1441;1440	G-CSF-R;G-CSF	In this communication acute myelogenous leukemia ( AML ) associated with a mutation of the ***G-CSF*** ***receptor*** ( ***G-CSF-R*** ) developed in a patient with SCN maintained on long-term G-CSF therapy .	parallel	1
20981	11071766	1499;1499	Armadillo;beta-catenin	The ***interaction*** between ******Armadillo/beta-catenin****** and Presenilin 1 requires a third protein which may be delta-catenin .	parallel	1
20982	11071766	5663;1499	Presenilin 1;beta-catenin	The ***interaction*** between ***Armadillo/beta-catenin*** and ***Presenilin 1*** requires a third protein which may be delta-catenin .	parallel	1
20983	11071777	1756;375790	dystrophin;agrin	Dystroglycan is a member of the transmembrane ***dystrophin*** glycoprotein complex in muscle that ***binds*** to the synapse-organizing molecule ***agrin*** .	parallel	1
20984	11071847	10401;6774	PIAS3;STAT3	***PIAS3*** ***binds*** to ***STAT3*** and inhibits its DNA-binding activity , and thereby STAT3-mediated gene activation .	parallel	1
20985	11071852	3480;3479	IGFIR;IGF-I	In a yeast two-hybrid screen of a human fetal brain library , we have previously identified SOCS-2 as a binding partner of the activated ***IGF-I*** ***receptor*** ( ***IGFIR*** ) .	parallel	1
20986	11071852	9021;3480	SOCS-3;IGFIR	We found that human ***SOCS-3*** protein ***interacts*** directly with the cytoplasmic domains of the activated ***IGFIR*** and the insulin receptor ( IR ) in the yeast two-hybrid assay .	parallel	1
20987	11071852	9021;3480	SOCS-3;IGFIR	In GST-SOCS-3 pull-down experiments using IGFIR from mammalian cells and in immunoprecipitation experiments in which IGFIR and FLAG-SOCS-3 were transiently expressed in human embryonic kidney 293 cells , we found that ***SOCS-3*** ***interacts*** constitutively with ***IGFIR*** in vitro and in intact cells .	parallel	1
20988	11071852	9021;3480	SOCS-3;IGFIR	We conclude that ***SOCS-3*** ***binds*** to the ***IGFIR*** and may be a direct substrate for the receptor tyrosine kinase .	parallel	1
20989	11071869	30011;29760	CIN85;BLNK	Coimmunoprecipitation experiments using mammalian cells revealed that ***CIN85*** directly ***bound*** to ***BLNK*** through its SH3 domains .	parallel	1
20990	11071876	7124;3569	TNF-alpha;IL-6	Using neutrophils from EP2 - and EP4-deficient mice in combination with EP2 - and EP4-selective agonists , it was found that the augmentation of ***IL-6*** was ***mediated*** mainly by the EP2 receptor and the suppression of ***TNF-alpha*** by the EP4 receptor and partially by the EP2 receptor .	target	0
20991	11071876	5732;3569	EP2;IL-6	These findings indicate that casein-induced peritoneal neutrophils express Gs-coupled PGE ( 2 ) receptors , ***EP2*** and EP4 , which might differentially ***regulate*** the LPS-induced production of TNF-alpha and ***IL-6*** .	target	1
20992	11071876	5732;7124	EP2;TNF-alpha	These findings indicate that casein-induced peritoneal neutrophils express Gs-coupled PGE ( 2 ) receptors , ***EP2*** and EP4 , which might differentially ***regulate*** the LPS-induced production of ***TNF-alpha*** and IL-6 .	target	1
20993	11071876	5734;3569	EP4;IL-6	These findings indicate that casein-induced peritoneal neutrophils express Gs-coupled PGE ( 2 ) receptors , EP2 and ***EP4*** , which might differentially ***regulate*** the LPS-induced production of TNF-alpha and ***IL-6*** .	target	1
20994	11071876	5734;7124	EP4;TNF-alpha	These findings indicate that casein-induced peritoneal neutrophils express Gs-coupled PGE ( 2 ) receptors , EP2 and ***EP4*** , which might differentially ***regulate*** the LPS-induced production of ***TNF-alpha*** and IL-6 .	target	1
20995	11071882	3091;2056	HIF-1;erythropoietin	Adaptation to hypoxic stress provokes activation of the hypoxia-inducible-factor-1 ( ***HIF-1*** ) which ***mediates*** gene expression of , e.g. , ***erythropoietin*** or vascular endothelial growth factor .	target	0
20996	11071882	3091;7422	HIF-1;vascular endothelial growth factor	Adaptation to hypoxic stress provokes activation of the hypoxia-inducible-factor-1 ( ***HIF-1*** ) which ***mediates*** gene expression of , e.g. , erythropoietin or ***vascular endothelial growth factor*** .	target	0
20997	11071883	7040;4656	TGF-beta;myogenin	In contrast , adenovirally induced decorin expression in wild type cells resulted in a 5-fold increased sensitivity to ***TGF-beta-mediated*** ***inhibition*** of ***myogenin*** expression .	negative	1
20998	11071883	7040;4656	TGF-beta;myogenin	Reduced synthesis of decorin resulted in a 7-fold decreased sensitivity to ***TGF-beta-mediated*** ***inhibition*** of ***myogenin*** expression .	negative	1
20999	11071885	1173;4074	mu2;MPR46	Both ***mu2*** and mu3A ***bind*** specifically to the ***MPR46-CT*** .	parallel	1
21000	11071886	3320;2064	Hsp90;Erbb2	***Hsp90*** ***co-immunoprecipitated*** with all ***Erbb2*** constructs that were sensitive to GA , but not with Erbb2/DK or ErbB1 .	parallel	1
21001	11071886	3320;2064	Hsp90;Erbb2	These data suggest that Hsp90 uniquely stabilizes Erbb2 via interaction with its kinase domain and that GA stimulates Erbb2 degradation secondary to disruption of ******Erbb2/Hsp90****** ***association*** .	parallel	0
21002	11071886	3320;2064	Hsp90;Erbb2	These data suggest that ***Hsp90*** uniquely ***stabilizes*** ***Erbb2*** via interaction with its kinase domain and that GA stimulates Erbb2 degradation secondary to disruption of Erbb2/Hsp90 association .	positive	0
21003	11071886	3320;2064	Hsp90;Erbb2	Sensitivity of mature ***Erbb2*** to geldanamycin is conferred by its kinase domain and is ***mediated*** by the chaperone protein ***Hsp90*** .	target	0
21004	11071904	3082;5599	scatter factor;JNK	Sequential activation of ERK and ***repression*** of ***JNK*** by ***scatter factor/hepatocyte growth factor*** in madin-darby canine kidney epithelial cells .	negative	1
21005	11071904	5594;5599	ERK;JNK	We further demonstrated that depending on cell density , the ***RAS-ERK-MKP2*** pathway ***controls*** this transrepressing effect of ***JNK*** .	target	0
21006	11071904	1846;5599	MKP2;JNK	We further demonstrated that depending on cell density , the ***RAS-ERK-MKP2*** pathway ***controls*** this transrepressing effect of ***JNK*** .	target	0
21007	11071904	5594;5599	ERK;JNK	Together , these data demonstrate that in a sequential manner SF/HGF activates ***ERK*** and MKP2 , which in turn ***dephosphorylates*** ***JNK*** .	target	1
21008	11071904	1846;5599	MKP2;JNK	Together , these data demonstrate that in a sequential manner SF/HGF activates ERK and ***MKP2*** , which in turn ***dephosphorylates*** ***JNK*** .	target	1
21009	11071909	5870;23637	Rab6A;GAPCenA	In addition , ***Rab6A*** ' ***interacts*** with two Rab6A partners , ***GAPCenA*** and " clone 1 , " but not with the kinesin-like protein Rabkinesin-6 , a Golgi-associated Rab6A effector .	parallel	1
21010	11071917	2006;60681	tropoelastin;FKBP65	Taken together , these results support an ER-localized ******FKBP65-tropoelastin****** ***interaction*** that occurs specifically during growth and development of tissues .	parallel	1
21011	11071939	64210;2071	hMMS19;XPB	Co-immunoprecipitation experiments revealed that ***hMMS19*** directly ***interacts*** with the ***XPB*** and XPD subunits of NER-transcription factor TFIIH .	parallel	1
21012	11071939	64210;2068	hMMS19;XPD	Co-immunoprecipitation experiments revealed that ***hMMS19*** directly ***interacts*** with the XPB and ***XPD*** subunits of NER-transcription factor TFIIH .	parallel	1
21013	11072066	1977;5594	eIF4E;ERK1/2	An inhibitor that ***blocks*** ***ERK1/2*** phosphorylation only slightly reduced protein synthesis rates stimulated by I+P or PMA , but greatly reduced ***eIF4E*** phosphorylation and eIF2B activity .	negative	0
21014	11072066	1978;1977	4E-BP1;eIF4E	In contrast , inhibitors of the PI-3 kinase and mTOR pathways strongly blocked early protein synthesis rate stimulated by I+P and PMA and also blocked ***4E-BP1*** ***phosphorylation*** and release of ***eIF4E*** suggesting that these pathways regulate protein synthesis activities , which are important for proliferation in T cells .	target	1
21015	11072069	4790;2668	NF-kappaB;GDNF	Gel retardation assays suggested that the ***NF-kappaB*** binding site in intron 1 would be involved in the cytokine ***response*** of the mouse ***GDNF*** gene .	parallel	0
21016	11072077	11140;7297	CDC37;TYK2	In addition , the ***CDC37*** gene is ***linked*** to the ***TYK2*** gene in a tail-to-head manner with a small intergenic region of 292 bp .	parallel	0
21017	11072238	1499;999	beta-catenin;E-cadherin	Furthermore , expression of laminin-5 gamma2 and beta3 subunits in budding cells was associated with focal under-expression of the ******E-cadherin-beta-catenin****** ***complex*** .	parallel	1
21018	11072751	7132;7124	TNFR1;TNFalpha	In order to investigate functionally important genes of the tumor necrosis factor alpha ( TNFalpha ) pathway we studied the frequency of DNA polymorphisms in the interleukin 6 ( IL6 ) , the TNFalpha , and the ***TNFalpha*** ***receptor*** 1 ( ***TNFR1*** ) genes in 264 sporadic German PD patients and in 183 age and sex matched German healthy controls .	parallel	1
21019	11072801	2230;954	ADX;ecto-ATPase	The results obtained indicate that ***ADX*** and OVX ***upregulate*** the expression of ***ecto-ATPase*** , potentiating the production of adenosine in synaptic cleft thus modulating the activity of numerous neurotransmitter systems in distinct areas of the CNS .	positive	1
21020	11073109	4157;5443	MC1R;alpha-MSH	Because U1 cells express the ***alpha-MSH*** ***receptor*** 1 ( ***MC1R*** ) , an autocrine-inhibitory circuit based on the peptide and its receptor likely occurs in these cells .	parallel	1
21021	11073111	3606;3458	IL-18;IFN-gamma	In contrast , ***IL-18*** ***enhanced*** IFN-gamma mRNA accumulation and ***IFN-gamma*** secretion in IL-12-stimulated , but not - untreated , cultures .	positive	0
21022	11073115	7124;4318	TNF-alpha;matrix metalloproteinase-9	Fibronectin-bound ***TNF-alpha*** ***stimulates*** monocyte ***matrix metalloproteinase-9*** expression and regulates chemotaxis .	positive	0
21023	11073115	7124;4318	TNF-alpha;MMP-9	FN-bound ***TNF-alpha*** ( FN/TNF-alpha ) significantly ***up-regulated*** ***MMP-9*** expression and secretion by the human monocytic cell line MonoMac-6 and peripheral blood monocytes .	positive	1
21024	11073118	10748;7305	Ly49L;DAP12	Antibody-mediated cross-linking of ***Ly49L*** ***induced*** ***DAP12*** phosphorylation , providing evidence that Ly49L is a functional activating receptor .	target	1
21025	11073119	6670;249	Sp3;liver/bone/kidney-type alkaline phosphatase	Transcription factor ***Sp3*** ***activates*** the ***liver/bone/kidney-type alkaline phosphatase*** promoter in hematopoietic cells .	positive	1
21026	11073164	973;7040	IgA;TGF-beta1	Increased serum ***IgA*** and decreased IgG3 strongly ***correlate*** with increased serum ***TGF-beta1*** levels in patients with nonimmune chronic idiopathic neutropenia of adults .	parallel	0
21027	11073164	3502;7040	IgG3;TGF-beta1	Increased serum IgA and decreased ***IgG3*** strongly ***correlate*** with increased serum ***TGF-beta1*** levels in patients with nonimmune chronic idiopathic neutropenia of adults .	parallel	0
21028	11073815	3082;4233	HGF;c-Met	Interaction with HS moieties on colorectal carcinoma ( HT29 ) cells promoted ***HGF/SF-induced*** ***activation*** of ***c-Met*** and of the Ras-MAP kinase pathway .	positive	1
21029	11073815	960;3082	CD44;hepatocyte growth factor	Recently , we obtained evidence for functional collaboration between these two molecules : ***CD44*** isoforms decorated with heparan sulfate chains ( CD44-HS ) can ***bind*** the c-Met ligand , the growth and motility factor ***hepatocyte growth factor/scatter*** factor ( HGF/SF ) .	parallel	1
21030	11073823	7040;596	TGF-beta1;BCL2	We generated a dysplastic kidney epithelial-like cell line that expressed cytokeratin , ZO1 , and MET , and found that exogenous ***TGF-beta1*** inhibited proliferation and ***decreased*** expression of PAX2 and ***BCL2*** , molecules characterizing dysplastic tubules in vivo .	negative	0
21031	11073823	7040;5076	TGF-beta1;PAX2	We generated a dysplastic kidney epithelial-like cell line that expressed cytokeratin , ZO1 , and MET , and found that exogenous ***TGF-beta1*** inhibited proliferation and ***decreased*** expression of ***PAX2*** and BCL2 , molecules characterizing dysplastic tubules in vivo .	negative	0
21032	11073828	3082;7039	HGF;TGF-alpha	Our results suggest that ***HGF*** ***stimulates*** ***TGF-alpha*** production in rat hepatocytes , and that the mitogenic activity of HGF depends on endogenous TGF-alpha activity .	positive	0
21033	11073835	3949;4018	LDLR;lipoprotein	Experimental investigation of the effects of these determinants on the development and progression of atherosclerosis has been greatly facilitated by the use of targeted mouse models of the disease , particularly those resulting from the absence of functional genes for apolipoprotein E or the low density ***lipoprotein*** ***receptor*** ( ***LDLR*** ) .	parallel	1
21034	11073854	4018;857	Lipoprotein;caveolin-1	***Lipoprotein*** ***promotes*** ***caveolin-1*** and Ras translocation to caveolae : role of cholesterol in endothelial signaling .	positive	0
21035	11073863	2159;2150	Factor Xa;PAR-2	Direct ***cleavage*** of ***PAR-2*** by ***Factor Xa*** on endothelial cells was demonstrated by cleavage of a synthetic peptide duplicating the PAR-2 cleavage site and by immunofluorescence with an antibody to a peptide containing the 40-amino acid PAR-2 extracellular extension .	target	1
21036	11073940	10746;5598	MEKK2;BMK1	***MEKK2*** expression ***stimulates*** ***BMK1/ERK5*** activity , the downstream substrate for MEK5 .	positive	0
21037	11073940	5607;10746	MEK5;MEKK2	Compared with MEKK3 , MEKK2 activated BMK1/ERK5 to a greater extent , which might correlate with a higher affinity ******MEKK2-MEK5****** ***interaction*** .	parallel	1
21038	11073940	10746;5598	MEKK2;BMK1	Compared with MEKK3 , ***MEKK2*** ***activated*** ***BMK1/ERK5*** to a greater extent , which might correlate with a higher affinity MEKK2-MEK5 interaction .	positive	1
21039	11073940	10746;5598	MEKK2;BMK1	A dominant negative form of MEK5 blocked the ***activation*** of ***BMK1/ERK5*** by ***MEKK2*** , whereas activation of c-Jun N-terminal kinase ( JNK ) was unaffected , showing that MEK5 is a specific downstream effector of MEKK2 in the BMK1/ERK5 pathway .	positive	1
21040	11073940	5607;5598	MEK5;BMK1	A dominant negative form of ***MEK5*** ***blocked*** the activation of ***BMK1/ERK5*** by MEKK2 , whereas activation of c-Jun N-terminal kinase ( JNK ) was unaffected , showing that MEK5 is a specific downstream effector of MEKK2 in the BMK1/ERK5 pathway .	negative	0
21041	11073940	4215;5598	MEKK3;BMK1	Activation of ***BMK1/ERK5*** by epidermal growth factor and H2O2 in Cos7 and HEK293 cells was completely ***blocked*** by a kinase-inactive ***MEKK3*** ( MEKK3kin ( - ) ) , whereas MEKK2kin ( - ) had no effect .	negative	0
21042	11073966	2033;4208	p300;MEF2C	Delivery of exogenous ***p300*** , a ***coactivator*** of ***MEF2C*** and NKX2.5 in cardiomyocytes , restored cardiac transcription despite the presence of doxorubicin .	positive	1
21043	11073966	2033;1482	p300;NKX2.5	Delivery of exogenous ***p300*** , a ***coactivator*** of MEF2C and ***NKX2.5*** in cardiomyocytes , restored cardiac transcription despite the presence of doxorubicin .	positive	1
21044	11073970	639;4609	Blimp-1;c-myc	Our data show that ***Blimp-1-dependent*** ***repression*** of ***c-myc*** is required for BCL-1 differentiation , since constitutive expression of c-myc blocked differentiation .	negative	1
21045	11073973	8648;1387	SRC-1;CREB binding protein	8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional ***cooperation*** between ***SRC-1*** and ***CREB binding protein*** .	parallel	0
21046	11073973	8648;1387	SRC-1;CREB binding protein	This was due , in part , to loss of functional ***cooperation*** between ***SRC-1*** and ***CREB binding protein*** for coactivation of cPR ( A ) .	parallel	0
21047	11073976	1019;896	cdk4;cyclin D3	Analysis of ******cyclin D3-cdk4****** ***complexes*** in fibroblasts expressing and lacking p27 ( kip1 ) and p21 ( cip1 ) .	parallel	1
21048	11073976	1019;896	cdk4;cyclin D3	Our studies examined the effects of p27 ( kip1 ) and p21 ( cip1 ) on the assembly and activity of ******cyclin D3-cdk4****** ***complexes*** and determined the composition of the cyclin D3 pool in cells containing and lacking these cyclin-dependent kinase inhibitors .	parallel	1
21049	11073976	1019;896	cdk4;cyclin D3	We found that catalytically active ******cyclin D3-cdk4****** ***complexes*** were present in fibroblasts derived from p27 ( kip1 ) - p21 ( cip1 ) - null mice and that immunodepletion of extracts of wild-type cells with antibody to p27 ( kip1 ) and/or p21 ( cip1 ) removed cyclin D3 protein but not cyclin D3-associated activity .	parallel	1
21050	11073976	1019;896	cdk4;cyclin D3	Data obtained using mixed cell extracts demonstrated that p27 ( kip1 ) interacted with ******cyclin D3-cdk4****** ***complexes*** in vitro and that this interaction was paralleled by a loss of cyclin D3-cdk4 activity .	parallel	1
21051	11073976	1019;896	cdk4;cyclin D3	We conclude that neither p27 ( kip1 ) nor p21 ( cip1 ) is required for the formation of ******cyclin D3-cdk4****** ***complexes*** and that cyclin D3-cdk4 complexes containing p27 ( kip1 ) or p21 ( cip1 ) are inactive .	parallel	1
21052	11073977	80198;11200	Mus81;Cds1	We propose that ***Mus81*** is involved in the ***recruitment*** of ***Cds1*** to aberrant DNA structures where Cds1 modulates the activity of damage tolerance enzymes .	target	0
21053	11073979	650;860	BMP-2;Runx2	Consistent with the observation that ***Runx2*** can be ***induced*** by either TGF-beta1 or ***BMP-2*** , the exogenous expression of Runx2 mediated some of the effects of TGF-beta1 and BMP-2 but not osteoblast-specific gene expression .	target	1
21054	11073979	7040;860	TGF-beta1;Runx2	Consistent with the observation that ***Runx2*** can be ***induced*** by either ***TGF-beta1*** or BMP-2 , the exogenous expression of Runx2 mediated some of the effects of TGF-beta1 and BMP-2 but not osteoblast-specific gene expression .	target	1
21055	11073979	860;650	Runx2;BMP-2	Consistent with the observation that Runx2 can be induced by either TGF-beta1 or BMP-2 , the exogenous expression of ***Runx2*** ***mediated*** some of the effects of TGF-beta1 and ***BMP-2*** but not osteoblast-specific gene expression .	target	0
21056	11073979	860;7040	Runx2;TGF-beta1	Consistent with the observation that Runx2 can be induced by either TGF-beta1 or BMP-2 , the exogenous expression of ***Runx2*** ***mediated*** some of the effects of ***TGF-beta1*** and BMP-2 but not osteoblast-specific gene expression .	target	0
21057	11073980	7421;5617	VDR;prolactin	Here we show that , in the presence of Ets-1 , ***VDR*** ***stimulates*** the ***prolactin*** promoter in a ligand-independent manner , behaving as a constitutive activator .	positive	0
21058	11073985	6945;4084	Mlx;Mad1	We recently characterized a novel Max-like protein , ***Mlx*** , which ***interacts*** with ***Mad1*** and Mad4 .	parallel	1
21059	11073985	6945;10608	Mlx;Mad4	We recently characterized a novel Max-like protein , ***Mlx*** , which ***interacts*** with Mad1 and ***Mad4*** .	parallel	1
21060	11073990	23741;2033	EID-1;p300	Thus , ***EID-1*** ***binds*** both Rb and ***p300*** and is a novel repressor of MyoD function .	parallel	1
21061	11073993	1387;2033	CBP;p300	Here , we describe a new level of p300-dependent control mediated through the functional ***interaction*** between ******p300/CBP****** and members of the family of nucleosome assembly proteins ( NAP ) , which includes NAP1 , NAP2 , and TAF1 .	parallel	1
21062	11074002	4087;4089	Smad2;Smad4	We propose that , upon TGF-beta signaling , complex ***formation*** between ***Smad4*** and activated ***Smad2*** or -3 leads to nuclear accumulation of Smad4 through inhibition of its nuclear export .	parallel	0
21063	11074005	7032;545	Sml1;mec1	Previously we reported that ***mec1*** or rad53 lethality is ***suppressed*** by removal of ***Sml1*** , a protein that binds to the large subunit of ribonucleotide reductase ( Rnr1 ) and inhibits RNR activity .	positive	1
21064	11074005	7032;11200	Sml1;rad53	Previously we reported that mec1 or ***rad53*** lethality is ***suppressed*** by removal of ***Sml1*** , a protein that binds to the large subunit of ribonucleotide reductase ( Rnr1 ) and inhibits RNR activity .	positive	1
21065	11074256	5079;5897	BSAP;RAG2	Transfection of ***BSAP*** into cell lines ***trans-activates*** the human ***RAG2*** promoter .	positive	1
21066	11074455	857;6714	caveolin-1;c-Src	The purified ***caveolin-1*** ***binds*** ***c-Src*** , suppressing its autophosphorylation .	parallel	1
21067	11074560	3815;4254	c-kit;stem cell factor	***Interaction*** of ***c-kit*** with its ligand ***stem cell factor*** induces dimerization , receptor phosphorylation , and signal transduction .	parallel	1
21068	11074596	3488;3486	IGF binding protein-5;IGF binding protein-3	Differential insulin-like growth factor ( IGF ) - independent ***interactions*** of ***IGF binding protein-3*** and ***IGF binding protein-5*** on apoptosis in human breast cancer cells .	parallel	1
21069	11075717	6464;2885	Shc;Grb2	Sos complex while ***Shc*** is still ***complexed*** with ***Grb2*** .	parallel	1
21070	11075717	3643;6464	insulin receptor;Shc	Upon insulin stimulation , the activated ***insulin receptor*** ***interacts*** with ***Shc*** .	parallel	1
21071	11075717	6464;2885	Shc;Grb2	Phosphorylated ***Shc*** ***binds*** to ***Grb2*** which forms a complex with Sos guanine nucleotide exchange factor for p21ras .	parallel	1
21072	11075717	6464;2885	Shc;Grb2	Both tyrosine-phosphorylated ***Shc*** and IRS can ***bind*** to ***Grb2*** , but Shc .	parallel	1
21073	11075810	2886;857	Grb7;caveolin-1	Furthermore , we demonstrate that ***binding*** of ***Grb7*** to tyrosine 14-phosphorylated ***caveolin-1*** functionally augments anchorage-independent growth and epidermal growth factor ( EGF ) - stimulated cell migration .	parallel	1
21074	11075811	7421;8648	VDR;SRC-1	We found that heterodimerization of the ligand-binding domains of RXRalpha and VDR was primarily deltanoid dependent as was the ***interaction*** of ***VDR*** with the ***SRC-1*** or with GRIP-1 .	parallel	1
21075	11075811	7421;8648	VDR;SRC-1	However , the ED50 for induction of ***VDR*** ***interaction*** with ***SRC-1*** was similar for both 1,25 D3 and the 20-epi analog ( ED50 = 0.7-1 .0 nM ) as was the ED50 for ligand-mediated interaction of VDR with GRIP-1 ( ED50 = 0.1-0 .3 nM ) .	parallel	1
21076	11075811	7421;10499	VDR;GRIP-1	However , the ED50 for induction of VDR interaction with SRC-1 was similar for both 1,25 D3 and the 20-epi analog ( ED50 = 0.7-1 .0 nM ) as was the ED50 for ligand-mediated ***interaction*** of ***VDR*** with ***GRIP-1*** ( ED50 = 0.1-0 .3 nM ) .	parallel	1
21077	11075815	2623;3623	GATA-1;inhibin alpha-subunit	We have recently demonstrated that a testicular GATA-binding protein , ***GATA-1*** , ***up-regulates*** the transcription of ***inhibin alpha-subunit*** gene through interaction with GATA motifs in the promoter region in MA-10 , a mouse Leydig tumor cell line .	positive	1
21078	11075947	3479;3486	IGF-I;IGFBP-3	Moreover , the ***IGF-I*** incubation ***induced*** a release of ***IGFBP-3*** in the culture media as the consequence of an interaction between IGF-I and the cell-associated IGFBP-3 .	target	1
21079	11075947	3486;3479	IGFBP-3;IGF-I	Moreover , the IGF-I incubation induced a release of IGFBP-3 in the culture media as the consequence of an ***interaction*** between ***IGF-I*** and the cell-associated ***IGFBP-3*** .	parallel	1
21080	11075956	1457;3725	CKII;Jun	We have also shown that ***phosphorylation*** of the transcription factor ***Jun*** by ***CKII*** is regulated by the redox state .	target	1
21081	11075992	885;5599	CCK;JNK	Whereas ***CCK-induced*** ***activation*** of MAPK or ***JNK*** was totally or partially blocked by protein kinase C ( PKC ) inhibitor GF-109203X , ROS-induced activation of MAPK , JNK , and p38 MAPK was PKC independent .	positive	1
21082	11076030	6256;7067	retinoid X receptor alpha;thyroid hormone receptor alpha	In electrophoretic mobility shift assays using in vitro translated proteins , the rCx-480 element formed stronger complexes with ******thyroid hormone receptor alpha/retinoid X receptor alpha****** ***heterodimers*** than with vitamin D receptor/retinoid X receptor alpha heterodimers .	parallel	1
21083	11076030	7421;6256	vitamin D receptor;retinoid X receptor alpha	In electrophoretic mobility shift assays using in vitro translated proteins , the rCx-480 element formed stronger complexes with thyroid hormone receptor alpha/retinoid X receptor alpha heterodimers than with ******vitamin D receptor/retinoid X receptor alpha****** ***heterodimers*** .	parallel	1
21084	11076095	3815;4254	c-kit;SCF	Reverse transcription-polymerase chain reaction ( RT-PCR ) analysis to detect gene expression of ***c-kit*** , the ***receptor*** for ***SCF*** , was performed using the endometriotic tissue and the eutopic endometrium collected during the operation .	parallel	1
21085	11076534	1026;1017	p21;Cdk2	Using purified , full-length proteins of known concentration ( determined by absorbance ) and cyclin A-Cdk2 of known activity ( calibrated with staurosporine ) , we find that a 1:1 molar ratio of ***p21*** to cyclin A-Cdk2 is able to ***inhibit*** ***Cdk2*** activity both in the binary cyclin A-Cdk2 complex and in the presence of proliferating cell nuclear antigen ( PCNA ) .	negative	1
21086	11076682	3481;3480	IGF-II;IGF1R	Thus , we propose a novel model in which the ***binding*** of ***IGF-II*** to its principal signaling receptor , ***IGF1R*** , at the surface of mesoderm precursor cells increases the formation of mesoderm cells .	parallel	1
21087	11076685	3815;4254	c-Kit;Stem cell factor	The significance of the interaction between Sertoli cell-produced ***Stem cell factor*** ( SCF ) and its ***receptor*** , ***c-Kit*** , on Leydig cells ( LCs ) during LC development and differentiation is unknown .	parallel	1
21088	11076685	3815;4254	c-Kit;Stem cell factor	The significance of the ***interaction*** between Sertoli cell-produced ***Stem cell factor*** ( SCF ) and its receptor , ***c-Kit*** , on Leydig cells ( LCs ) during LC development and differentiation is unknown .	parallel	1
21089	11076685	3815;4254	c-Kit;SCF	A function-blocking anti-c-Kit antibody , ACK-2 , was used to block ******SCF/c-Kit****** ***interaction*** at four time points , corresponding to the peak of LC apoptosis and three waves of proliferation of precursor LCs .	parallel	1
21090	11076685	3815;4254	c-Kit;SCF	Blockade of ******SCF/c-Kit****** ***interaction*** by ACK-2 accelerated LC apoptosis and inhibited proliferation of precursor LCs during the first two waves of precursor LC proliferation around days 3-4 and day 10 , but not the third wave of precursor LC proliferation around day 20 after EDS treatment .	parallel	1
21091	11076759	3815;4286	KIT;MITF	Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage : ***interactions*** between ***KIT*** and ***MITF*** .	parallel	1
21092	11076793	2246;2247	fibroblast growth factor-1;fibroblast growth factor-2	TGF-beta1 and ***fibroblast growth factor-1*** ***modify*** ***fibroblast growth factor-2*** production in type II cells .	target	0
21093	11076793	7040;2247	TGF-beta1;fibroblast growth factor-2	***TGF-beta1*** and fibroblast growth factor-1 ***modify*** ***fibroblast growth factor-2*** production in type II cells .	target	0
21094	11076795	3553;6356	IL-1beta;eotaxin	***IL-1beta*** ***induces*** ***eotaxin*** gene transcription in A549 airway epithelial cells through NF-kappaB .	target	1
21095	11076795	3553;6356	IL-1beta;eotaxin	Our findings implicate NF-kappaB and its binding sequence in ***IL-1beta-induced*** transcriptional ***activation*** of the ***eotaxin*** gene .	positive	1
21096	11076803	2919;3579	GROalpha;CXCR2	Melanoma growth-stimulatory activity/growth-related protein-alpha ( ***MGSA/GROalpha*** ) , which ***binds*** ***CXCR2*** but not CXCR1 , was unable to either stimulate IL-8 secretion in MNCs or desensitize these cells to respond to immobilized IL-8 .	parallel	1
21097	11076936	1432;7124	p38 MAP kinase;TNF-alpha	Finally , addressing mechanisms involved , we show that inhibition of ***p38 MAP kinase*** selectively ***destabilizes*** ***TNF-alpha*** transcripts but does not affect degradation of c-jun transcripts .	positive	0
21098	11076940	4654;32	MyoD;ACCbeta	The ***ACCbeta*** promoter showed myoblast-specific promoter activity and was strongly ***induced*** by ***MyoD*** in NIH3T3 cells .	target	1
21099	11076956	573;3308	Bag-1;HSP70	***Modulation*** of in vivo ***HSP70*** chaperone activity by Hip and ***Bag-1*** .	target	0
21100	11076956	6767;3308	Hip;HSP70	***Modulation*** of in vivo ***HSP70*** chaperone activity by ***Hip*** and Bag-1 .	target	0
21101	11076956	573;3308	Bag-1;HSP70	***Bag-1*** , which ***inhibits*** the ***HSP70*** chaperone activity both in vitro and in vivo , was found to compete with the stimulatory action of Hip .	negative	1
21102	11077039	355;356	CD95;CD95-L	Caspase-8 activation independent of ******CD95/CD95-L****** ***interaction*** during paclitaxel-induced apoptosis in human colon cancer cells ( HT29-D4 ) .	parallel	1
21103	11077046	7124;706	TNFalpha;PBR	We found that ***TNFalpha*** ***up-regulated*** mRNA and protein expression of the mitochondrial peripheral benzodiazepine receptor ( ***PBR*** ) , an outer membrane-derived constituent of the pore .	positive	1
21104	11077046	7124;596	TNFalpha;Bcl-2	Concomitantly , ***TNFalpha*** ***down-regulated*** ***Bcl-2*** mRNA and protein expression .	negative	1
21105	11077046	7124;706	TNFalpha;PBR	As Bcl-2 has been shown to be an endogenous inhibitor of the PT pore , we hypothesize that the ***TNFalpha-induced*** ***up-regulation*** of ***PBR*** expression may compensate for the decrease in Bcl-2 levels to prevent the opening of the PT pore .	positive	1
21106	11077387	7157;4843	p53;iNOS	***Downregulation*** of the enzyme ***iNOS*** by wild-type ***p53*** ( but not mutant ) protein has been shown to occur in normal cells and some tumors , but the relationship has not been reported in oral epithelial dysplasia .	negative	1
21107	11077427	8829;10371	neuropilin-1;SEMA3A	Consistent with the insensitivity of trkC ( + ) collaterals to SEMA3A , these collaterals did not express ***neuropilin-1*** , a ***receptor*** for ***SEMA3A*** .	parallel	1
21108	11077443	5599;596	JNK1;bcl-2	Cdc42/PAK1 activates ***JNK1-induced*** ***phosphorylation*** of ***bcl-2*** , thereby inactivating its function , and that a phosphorylation resistant mutant ( Bcl-2S70 ,87 A , T56 ,74 A ) gains the ability to inhibit Cdc42 - and p53-mediated apoptosis .	target	1
21109	11077443	5058;596	PAK1;bcl-2	***Cdc42/PAK1*** ***activates*** JNK1-induced phosphorylation of ***bcl-2*** , thereby inactivating its function , and that a phosphorylation resistant mutant ( Bcl-2S70 ,87 A , T56 ,74 A ) gains the ability to inhibit Cdc42 - and p53-mediated apoptosis .	positive	1
21110	11077443	7157;596	p53;bcl-2	***p53*** ***mediates*** ***bcl-2*** phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway .	target	0
21111	11077446	5111;3364	PCNA;hHus1	***PCNA*** ***interacts*** with ***hHus1/hRad9*** in response to DNA damage and replication inhibition .	parallel	1
21112	11077446	5111;5883	PCNA;hRad9	***PCNA*** ***interacts*** with ***hHus1/hRad9*** in response to DNA damage and replication inhibition .	parallel	1
21113	11077446	5111;3364	PCNA;Hus1	Using a yeast two-hybrid system to detect protein-protein interactions , we found that human proliferating cell nuclear antigen ( ***PCNA*** ) , a protein known to function in both DNA replication and repair , ***interacts*** with the human checkpoint-related protein ***Hus1*** ( hHus1 ) .	parallel	1
21114	11078328	10329;1906	type II membrane protein;endothelin-1	Endothelin-converting enzyme-1 ( ECE-1 ) is a ***type II membrane protein*** that ***cleaves*** big ***endothelin-1*** ( big ET-1 ) to endothelin-1 ( ET-1 ) .	target	1
21115	11078449	6833;3767	SUR1;Kir6.2	The factors that influence functional ***coupling*** between the sulfonylurea receptor ( ***SUR1*** ) and ***Kir6.2*** subunits of ATP-sensitive K + ( K + ( ATP ) ) channels were studied in rat pancreatic beta-cells using patch clamp and microfluorometric techniques .	parallel	1
21116	11078456	3952;181	leptin;AgRP	***leptin*** administration ***decreased*** NPY and ***AgRP*** and increased POMC mRNA levels toward baseline , but CNTF administration in fasted mice had no effect of comparable significance .	negative	0
21117	11078456	3952;4852	leptin;NPY	***leptin*** administration ***decreased*** ***NPY*** and AgRP and increased POMC mRNA levels toward baseline , but CNTF administration in fasted mice had no effect of comparable significance .	negative	0
21118	11078456	1270;8835	CNTF;SOCS-2	***CNTF*** also ***induced*** hypothalamic ***SOCS-2*** mRNA expression .	target	1
21119	11078523	7341;861	SUMO-1;AML1	Posttranslational ***modification*** of TEL and ***TEL/AML1*** by ***SUMO-1*** and cell-cycle-dependent assembly into nuclear bodies .	target	0
21120	11078523	7341;2120	SUMO-1;TEL	Posttranslational ***modification*** of TEL and ***TEL/AML1*** by ***SUMO-1*** and cell-cycle-dependent assembly into nuclear bodies .	target	0
21121	11078523	7341;861	SUMO-1;AML1	We also show that the leukemia-associated fusion protein ***TEL/AML1*** is ***modified*** by ***SUMO-1*** and found in the TEL bodies , in a pattern quite different from what we observe and report for AML1 .	target	0
21122	11078523	7341;2120	SUMO-1;TEL	We also show that the leukemia-associated fusion protein ***TEL/AML1*** is ***modified*** by ***SUMO-1*** and found in the TEL bodies , in a pattern quite different from what we observe and report for AML1 .	target	0
21123	11078523	7341;2120	SUMO-1;TEL	Therefore , ***SUMO-1*** ***modification*** of ***TEL*** could be a critical signal necessary for normal functioning of the protein .	target	0
21124	11078524	5413;5071	CDCrel-1;Parkin	We also identify and show that the synaptic vesicle-associated protein , ***CDCrel-1*** , ***interacts*** with ***Parkin*** through its ring-finger domains .	parallel	1
21125	11078608	3815;4254	c-kit;Stem cell factor	Murine intraepithelial lymphocytes ( IEL ) that express the gamma/delta form of the T cell receptor for antigen ( TCRgammadelta ) also express ***c-kit*** , the ***receptor*** for ***Stem cell factor*** ( SCF ) .	parallel	1
21126	11078691	177;351	RAGE;Abeta	The Abeta-mediated migration of monocytes was inhibited by antibody to ***Abeta*** ***receptor*** ( ***RAGE*** ) and platelet endothelial cell adhesion molecule ( PECAM-1 ) .	parallel	1
21127	11078691	351;177	Abeta;RAGE	We conclude that ***interaction*** of ***Abeta*** with ***RAGE*** expressed on brain endothelial cells initiates cellular signaling leading to the transendothelial migration of monocytes .	parallel	1
21128	11078732	8525;3953	Diacylglycerol kinase zeta;leptin receptor	***Diacylglycerol kinase zeta*** in hypothalamus ***interacts*** with long form ***leptin receptor*** .	parallel	1
21129	11078733	3975;3611	LIM1;integrin-linked kinase	The ***LIM1*** domain of PINCH ***interacts*** with ***integrin-linked kinase*** ( ILK ) , thereby mediating focal adhesions via a specific integrin/ILK signaling pathway .	parallel	1
21130	11078762	1029;1029	ARF;INK4a	***Association*** between ******INK4a-ARF****** and p53 mutations in skin carcinomas of xeroderma pigmentosum patients .	parallel	0
21131	11078762	7157;1029	p53;INK4a	***Association*** between ***INK4a-ARF*** and ***p53*** mutations in skin carcinomas of xeroderma pigmentosum patients .	parallel	0
21132	11078794	7422;4318	VEGF;MMP-9	There was a significant ***association*** of ***MMP-9*** and ***VEGF*** expression ( p < 0.05 ) .	parallel	0
21133	11078803	5618;6774	hPRL;STAT3	***Inhibition*** of oncogene ***STAT3*** phosphorylation by a prolactin antagonist , ***hPRL-G129R*** , in T-47D human breast cancer cells .	negative	1
21134	11078803	5618;6774	hPRL;STAT3	We first demonstrated that STAT5 and ***STAT3*** could be ***activated*** by either hGH or ***hPRL*** in T-47D breast cancer cells .	positive	1
21135	11078803	5618;6776	hPRL;STAT5	We first demonstrated that ***STAT5*** and STAT3 could be ***activated*** by either hGH or ***hPRL*** in T-47D breast cancer cells .	positive	1
21136	11078803	5618;6776	hPRL;STAT5	Although the patterns of ***STAT5*** ***activation*** by hGH and ***hPRL*** are similar , we observed a nearly 10-fold greater efficacy of hPRL in STAT3 activation as compared to that of hGH .	positive	1
21137	11078803	5618;6774	hPRL;STAT3	More importantly , we have demonstrated that ***activation*** of ***STAT3*** by ***hPRL*** could be inhibited by hPRL-G129R .	positive	1
21138	11078803	5618;6774	hPRL;STAT3	More importantly , we have demonstrated that activation of ***STAT3*** by hPRL could be ***inhibited*** by ***hPRL-G129R*** .	negative	1
21139	11078813	995;7157	cdc25C;p53	In order to understand the ***interplay*** between ***p53*** and ***cdc25C*** in mammalian cells we isolated and sequenced cdc25C cDNA from the epidermoid carcinoma cell line A431 , which is known to carry the p53His273 mutation .	parallel	1
21140	11078882	5590;5170	PKCzeta;PDK1	This provides the first genetic evidence that ***PKCzeta*** is a physiological ***substrate*** for ***PDK1*** .	parallel	1
21141	11078891	3077;7037	HFE;transferrin receptor	***Interactions*** of the ectodomain of ***HFE*** with the ***transferrin receptor*** are critical for iron homeostasis in cells .	parallel	1
21142	11078891	3077;7037	HFE;transferrin receptor	These results implicate a role for the ***interaction*** of ***HFE*** with the ***transferrin receptor*** in lowering cellular ferritin levels .	parallel	1
21143	11078894	49;2150	acrosin;PAR-2	Evidence for the ***activation*** of ***PAR-2*** by the sperm protease , ***acrosin*** : expression of the receptor on oocytes .	positive	1
21144	11078894	23430;2150	mast cell tryptase;PAR-2	This substrate was cleaved with kinetics similar to those of the known ***PAR-2*** ***activators*** , trypsin and ***mast cell tryptase*** .	positive	1
21145	11078915	355;1440	fas;granulocyte colony-stimulating factor	Expression of ***fas*** ( CD95 ) ligand is ***correlated*** with IL-10 and ***granulocyte colony-stimulating factor*** expression in oral and oropharyngeal squamous cell carcinoma .	parallel	0
21146	11078915	355;3586	fas;IL-10	Expression of ***fas*** ( CD95 ) ligand is ***correlated*** with ***IL-10*** and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma .	parallel	0
21147	11078915	356;355	FasL;fas	The ***fas/fas*** ***ligand*** ( ***FasL*** ) pathway has been shown to be an important cellular pathway mediating apoptosis .	parallel	1
21148	11078915	356;1440	FasL;granulocyte colony-stimulating factor	However , ***FasL*** expression was ***associated*** with IL-10 and ***granulocyte colony-stimulating factor*** expression in oral and oropharyngeal SCC .	parallel	0
21149	11078915	356;3586	FasL;IL-10	However , ***FasL*** expression was ***associated*** with ***IL-10*** and granulocyte colony-stimulating factor expression in oral and oropharyngeal SCC .	parallel	0
21150	11078983	5443;2641	ACTH;glucagon	DESIGN AND METHODS : To clarify the mechanisms underlying the stimulatory effects of both glucagon and GHS on somatotroph and corticotroph secretion , we studied the GH , ***ACTH*** and cortisol ***responses*** to ***glucagon*** ( GLU , 0.017 mg/kg i.m. ) and Hexarelin , a peptidyl GHS ( HEX , 2.0 microg/kg i.v. ) given alone or in combination in 6 normal young volunteers ( females , aged 26-32 years , body mass index 19.7-22 .5 kg/m ) .	parallel	0
21151	11079480	847;3048	catalase;methemoglobin	However , both GSHPer and ***catalase*** ***inhibited*** POP-induced conversion of ***methemoglobin*** .	negative	1
21152	11079571	2674;2668	GFR-alpha1;GDNF	The aim of the present study was to knockdown ***GDNF*** , its ***receptor*** ***GFR-alpha1*** , and the related family member persephin by using antisense oligonucleotides and to observe the effects on cell proliferation .	parallel	1
21153	11079752	1803;2641	dipeptidylpeptidase IV;glucagon-like peptide-1	As ***glucagon-like peptide-1*** is rapidly ***cleaved*** at L-ala2 by ***dipeptidylpeptidase IV*** , D-ala2-glucagon-like peptide-1 was synthesized and shown to have dipeptidylpeptidase IV resistance in vitro and enhanced bioactivity in mice during an oral glucose challenge .	target	1
21154	11079778	4137;1432	PHF-tau;p38	Moreover , the finding that ***PHF-tau*** ***co-immunoprecipitates*** with ***p38*** , and that p38 co-purifies with PHF-tau , strongly suggests that they are physically associated in vivo .	parallel	1
21155	11080149	4647;55591	myosin VIIA;Vezatin	In myosin VIIA-defective mutants , inactivity of the ******Vezatin-myosin VIIA****** ***complex*** at both sites could account for splaying out of the hair cell stereocilia .	parallel	1
21156	11080152	2908;7157	glucocorticoid receptor;p53	Negative ***cross-talk*** between ***p53*** and the ***glucocorticoid receptor*** and its role in neuroblastoma cells .	parallel	0
21157	11080155	55294;84188	Cdc4;Far1	Nuclear-specific degradation of ***Far1*** is ***controlled*** by the localization of the F-box protein ***Cdc4*** .	target	0
21158	11080158	8607;1499	Pontin52;beta-catenin	***Pontin52*** and reptin52 function as antagonistic ***regulators*** of ***beta-catenin*** signalling activity .	target	1
21159	11080158	10856;1499	reptin52;beta-catenin	Pontin52 and ***reptin52*** function as antagonistic ***regulators*** of ***beta-catenin*** signalling activity .	target	1
21160	11080158	10856;1499	reptin52;beta-catenin	Highly homologous to Pontin52 , ***reptin52*** likewise ***binds*** ***beta-catenin*** and TBP .	parallel	1
21161	11080158	10856;6908	reptin52;TBP	Highly homologous to Pontin52 , ***reptin52*** likewise ***binds*** beta-catenin and ***TBP*** .	parallel	1
21162	11080175	5557;1103	p49;ChAT	Treatment of PC12 cells with NGF resulted in a drastic reduction in nuclear ***p49*** ***binding*** to the ***ChAT*** NF-kappaB site after 24 h , but nuclear p49 levels were not altered , suggesting that late NGF-mediated events prevent binding of p49 to the ChAT promoter by an unknown mechanism other than nuclear translocation .	parallel	1
21163	11080175	5557;4790	p49;NF-kappaB	Treatment of PC12 cells with NGF resulted in a drastic reduction in nuclear ***p49*** ***binding*** to the ChAT ***NF-kappaB*** site after 24 h , but nuclear p49 levels were not altered , suggesting that late NGF-mediated events prevent binding of p49 to the ChAT promoter by an unknown mechanism other than nuclear translocation .	parallel	1
21164	11080175	5557;1103	p49;ChAT	These data indicate that ***p49*** is a negative ***regulator*** of ***ChAT*** expression and suggest a possible mechanism for aging-associated declines in cholinergic function .	negative	1
21165	11080179	3751;5594	Kv4.2;ERK	These observations indicate that ***Kv4.2*** is a ***substrate*** for ***ERK*** in vitro and in vivo , and suggest that ERK may regulate potassium-channel function by direct phosphorylation of the pore-forming alpha subunit .	parallel	1
21166	11080179	3751;5594	Kv4.2;ERK	The A-type potassium channel ***Kv4.2*** is a ***substrate*** for the mitogen-activated protein kinase ***ERK*** .	parallel	1
21167	11080191	2932;3297	GSK-3beta;HSF-1	Because Akt inhibits glycogen synthase kinase-3beta ( GSK-3beta ) , an enzyme that facilitates cell death , we tested if ***GSK-3beta*** is a negative ***regulator*** of ***HSF-1*** activation .	negative	1
21168	11080191	207;2932	Akt;GSK-3beta	Because ***Akt*** ***inhibits*** glycogen synthase kinase-3beta ( ***GSK-3beta*** ) , an enzyme that facilitates cell death , we tested if GSK-3beta is a negative regulator of HSF-1 activation .	negative	1
21169	11080191	207;2932	Akt;GSK-3beta	Thus , heat shock-induced activation of PI-3K and the inhibitory effect of GSK-3beta on HSF-1 activation and HSP-70 expression imply that ***Akt-induced*** ***inhibition*** of ***GSK-3beta*** contributes to the activation of HSF-1 .	negative	1
21170	11080198	4852;3569	NPY;IL-6	Under these conditions , ***NPY*** dose-dependently ***inhibited*** ***IL-6*** secretion with a maximum effect at 10 ( -10 ) M : ( p = 0.012 ) and 10 ( -9 ) M : ( p < 0.001 ) .	negative	1
21171	11080454	3124;4155	HLA-DR2b;MBP	A comparison of this structure with that of ***HLA-DR2b*** ***complexed*** with ***MBP*** 85-99 , reported previously , reveals that the peptide register is shifted by three residues , such that the MBP peptide is bound in strikingly different conformations by the two MHC molecules .	parallel	1
21172	11080475	3586;3456	IL-10;IFN-beta	***Inhibition*** of the constitutive and induced ***IFN-beta*** production by IL-4 and ***IL-10*** in murine peritoneal macrophages .	negative	1
21173	11080475	3565;3456	IL-4;IFN-beta	***Inhibition*** of the constitutive and induced ***IFN-beta*** production by ***IL-4*** and IL-10 in murine peritoneal macrophages .	negative	1
21174	11080496	1437;6667	granulocyte/macrophage colony-stimulating factor;Sp1	A causal relationship was established between these observations by demonstrating that ***up-regulation*** of ***Sp1*** DNA binding activity by ***granulocyte/macrophage colony-stimulating factor*** rapidly reversed the EGF-induced decrease in ATM protein and restored radiosensitivity to normal levels .	positive	1
21175	11080497	3553;3576	IL-1;IL-8	Transfection with the dominant negative mutant , Ras ( Asn-17 ) , inhibited ***IL-1*** induced ***activation*** of the ***IL-8*** promoter as well as of NF-kappa B and AP-1 synthetic promoters in transient transfection assays .	positive	1
21176	11080497	7189;4790	TRAF6;NF-kappa B	Constitutively active Ras ( Val-12 ) increased the ***TRAF6*** ***induced*** activity of the ***NF-kappa B*** pathway similar to the effect induced by IL-1 , while the Ras ( Val-12 ) induced activity was not inhibited by co-transfection with a dominant negative TRAF6 .	target	1
21177	11080497	7189;4790	TRAF6;NF-kappa B	In addition , they show that the Ras induced effect selectively regulates ***TRAF6-mediated*** ***activation*** of the ***NF-kappa B*** pathway , suggesting that Ras GTPase represents a convergence point in structural and cytokine responses , with distinct effects on a subset of downstream signaling events .	positive	1
21178	11080499	8517;3551	IKKgamma;IKKbeta	The amino-terminal region of ***IKKgamma/NEMO*** , which ***interacts*** directly with ***IKKbeta*** , was required for formation of the high molecular weight IKK complex and for stimulation of IKKbeta kinase activity .	parallel	1
21179	11080615	1398;25	Crk;Abl	In this study , we examine the phosphorylation of ***Crk*** , a protein ***substrate*** of ***Abl*** that is phosphorylated in the sequence Tyr221-Ala-Gln-Pro .	parallel	1
21180	11080615	25;1398	Abl;Crk	In vitro , ***phosphorylation*** of ***Crk*** by Y569W ***Abl*** is greatly reduced relative to wild-type Abl .	target	1
21181	11080615	25;1398	Abl;Crk	However , ***phosphorylation*** of ***Crk*** by Y569W ***Abl*** in these cells is markedly reduced relative to wild-type Abl .	target	1
21182	11080615	25;1398	Abl;Crk	Thus , proper ***phosphorylation*** of ***Crk*** by ***Abl*** depends not only on the interaction of the Crk SH3 domain with the Abl polyproline region , but also on the recognition of amino acids surrounding tyrosine by the Abl catalytic domain .	target	1
21183	11080615	1398;25	Crk;Abl	Thus , proper phosphorylation of Crk by Abl depends not only on the ***interaction*** of the ***Crk*** SH3 domain with the ***Abl*** polyproline region , but also on the recognition of amino acids surrounding tyrosine by the Abl catalytic domain .	parallel	1
21184	11080619	5266;5590	PI-3;protein kinase C zeta	Of note , the activation of ***PI-3-kinase*** ***correlated*** with the modulation of the activation of another enzyme , the atypical ***protein kinase C zeta*** ( aPKC zeta ) .	parallel	0
21185	11080800	2288;3662	FKBP52;IRF-4	In an effort to further characterize IRF-4 function , we identified a novel ***interaction*** between ***IRF-4*** and ***FKBP52*** , a 59-kDa member of the immunophilin family with peptidyl-prolyl isomerase activity ( PPIase ) .	parallel	1
21186	11080800	2288;3662	FKBP52;IRF-4	***IRF-4-FKBP52*** association ***inhibited*** the interaction between IRF-4 and its DNA-binding partner PU.1 , as well as the trans-activation function of ***IRF-4/PU.1*** .	negative	1
21187	11080800	2288;6688	FKBP52;PU.1	***IRF-4-FKBP52*** association ***inhibited*** the interaction between IRF-4 and its DNA-binding partner PU.1 , as well as the trans-activation function of ***IRF-4/PU.1*** .	negative	1
21188	11080800	3662;6688	IRF-4;PU.1	***IRF-4-FKBP52*** association ***inhibited*** the interaction between IRF-4 and its DNA-binding partner PU.1 , as well as the trans-activation function of ***IRF-4/PU.1*** .	negative	1
21189	11080800	2288;3662	FKBP52;IRF-4	******IRF-4-FKBP52****** ***association*** inhibited the interaction between IRF-4 and its DNA-binding partner PU.1 , as well as the trans-activation function of IRF-4/PU.1 .	parallel	0
21190	11080800	6688;3662	PU.1;IRF-4	IRF-4-FKBP52 association inhibited the ***interaction*** between ***IRF-4*** and its DNA-binding partner ***PU.1*** , as well as the trans-activation function of IRF-4/PU.1 .	parallel	1
21191	11080812	1017;3005	cdk2;histone H1	Functionally , the association of p21/cyclin ***A/cdk2*** ***decreased*** the ***histone H1*** phosphorylation in vitro , as observed in immunoprecipitations followed by kinase assays , as well as affecting other substrates such as the C-terminus of Rb protein involved in c-Abl and HDAC1 regulation .	negative	0
21192	11080813	3312;871	HSC70;gp46	We now have evidence that the molecular ***association*** between HTLV-1 ***gp46*** envelope protein and ***HSC70*** led to pore formation on the surface of target cell membrane and cell death followed .	parallel	0
21193	11080813	871;3312	gp46;HSC70	Taken together , the ***interaction*** between ***HSC70*** and ***gp46*** of HTLV-1 through the hydrophilic face of gp46-197 may lead to pore formation in lipid bilayers to be followed by membrane fusion or cell death .	parallel	1
21194	11081156	1437;5443	GM-CSF;ACTH	***GM-CSF*** at 45 ( P < 0.01 ) , 90 ( P < 0.01 ) and at 45 ( P < 0.001 ) , 90 ( P < 0.001 ) and 180 min ( P < 0.001 ) ***increased*** the secretion of ***ACTH*** and corticosterone , respectively .	positive	0
21195	11081157	2516;2488	SF-1;FSH beta	Furthermore , tumor Pit-1 mRNA positively correlates with GH , PRL and TSH beta mRNA while tumor ***SF-1*** mRNA ***correlates*** well with ***FSH beta*** mRNA .	parallel	0
21196	11081157	5449;5617	Pit-1;PRL	Furthermore , tumor ***Pit-1*** mRNA positively ***correlates*** with GH , ***PRL*** and TSH beta mRNA while tumor SF-1 mRNA correlates well with FSH beta mRNA .	positive	0
21197	11081157	5449;7252	Pit-1;TSH beta	Furthermore , tumor ***Pit-1*** mRNA positively ***correlates*** with GH , PRL and ***TSH beta*** mRNA while tumor SF-1 mRNA correlates well with FSH beta mRNA .	positive	0
21198	11081184	3479;632	IGF-I;osteocalcin	In 18 patients with hypothalamo-pituitary diseases aged over 60 years and in 18 sex , age - and BMI-matched healthy subjects , the results of plasma ***IGF-I*** and IGF-BP3 levels and the GH response to GHRH + arginine test ( GHRH + ATT ) were ***correlated*** to the results of body composition , serum ***osteocalcin*** ( OC ) and urinary cross-linked N-telopeptides of type I collagen ( Ntx ) and the bone mineral density ( BMD ) .	parallel	0
21199	11081197	7040;5122	TGF beta 1;PC1	These results indicate that a ) there is a differential distribution of PC1 in human pituitary adenomas with PRL adenomas expressing very little PC1 mRNA and protein and b ) that ***PC1*** expression in gonadotropin hormone-producing adenomas is ***regulated*** by PMA and ***TGF beta 1*** .	target	1
21200	11081197	1113;5122	chromogranin A;PC1	These findings support the observation that ***chromogranin A*** is a ***substrate*** for the endoproteinase ***PC1*** in human pituitary adenoma cells .	parallel	1
21201	11081412	3479;5184	IGF-I;prolidase	Insulin-like growth factor-I ( ***IGF-I*** ) is an important ***stimulator*** of collagen biosynthesis and ***prolidase*** activity in connective tissue cells .	positive	0
21202	11081456	373156;2947	GST;GSTM3	Certain ***GST*** loci are polymorphic , demonstrating alleles that are null ( GSTM1 and GSTT1 ) , encode low-activity variants ( GSTP1 ) or are ***associated*** with variable inducibility ( ***GSTM3*** ) .	parallel	0
21203	11081626	9700;9985	separin;Rec8	Disjunction of homologous chromosomes in meiosis I depends on proteolytic ***cleavage*** of the meiotic cohesin ***Rec8*** by ***separin*** .	target	1
21204	11081626	9700;9985	separin;Rec8	We show here that ***cleavage*** of ***Rec8*** by ***separin*** at one of two different sites is necessary for the resolution of chiasmata and the disjunction of homologous chromosomes during meiosis .	target	1
21205	11081635	3482;3002	CI-MPR;granzyme B	Inhibition of the ******granzyme B-CI-MPR****** ***interaction*** prevented granzyme B cell surface binding , uptake , and the induction of apoptosis .	parallel	1
21206	11082122	1432;1437	p38 mitogen-activated protein (MAP) kinase;granulocyte/macrophage colony-stimulating factor	The extent to which the ***p38 mitogen-activated protein (MAP) kinase*** and MAP kinase kinase ( MKK ) -1 - signalling pathways ***regulate*** the expression of ***granulocyte/macrophage colony-stimulating factor*** ( GM-CSF ) from LPS-stimulated human monocytes has been investigated and compared to the well studied cytokine tumour necrosis factor-alpha ( TNF alpha ) .	target	1
21207	11082122	1437;5595	GM-CSF;ERK-1	LPS-induced ***GM-CSF*** release and mRNA expression were ***associated*** with a rapid and time-dependent activation of p38 MAP kinase , ***ERK-1*** and ERK-2 .	parallel	0
21208	11082122	1437;5594	GM-CSF;ERK-2	LPS-induced ***GM-CSF*** release and mRNA expression were ***associated*** with a rapid and time-dependent activation of p38 MAP kinase , ERK-1 and ***ERK-2*** .	parallel	0
21209	11082122	1437;1432	GM-CSF;p38 MAP kinase	LPS-induced ***GM-CSF*** release and mRNA expression were ***associated*** with a rapid and time-dependent activation of ***p38 MAP kinase*** , ERK-1 and ERK-2 .	parallel	0
21210	11082200	472;672	A-T-mutated;BRCA1	Although early studies failed to detect DNA-repair defects in A-T cells exposed to ionizing radiation and radiomimetic agents , more recent experiments performed in non-dividing A-T cells and the demonstrated ***interaction*** of the ***A-T-mutated*** protein ( ATM ) with the ***BRCA1*** gene product suggest that a DNA-repair defect may underlie , at least in part , the radiation sensitivity in A-T cells .	parallel	1
21211	11082271	7422;634	VEGF;CEACAM1	The expression of ***CEACAM1*** is ***up-regulated*** by ***VEGF*** , and VEGF-induced in vitro tube formation is blocked completely by a monoclonal CEACAM1 antibody .	positive	1
21212	11082283	4830;7431	Nm23;vimentin	In addition , while ***Nm23-R2*** was colocalized and ***coimmunoprecipitated*** with ***vimentin*** in nondifferentiated cells , both isoforms were associated with GFAP in differentiated cells .	parallel	1
21213	11082922	185;183	AT1;angiotensin II	However , the role of the gene coding for ***angiotensin II*** ***receptor*** ( ***AT1*** ) polymorphism in PIH is not fully understood , thus the aim of the present study was to determine the frequency of A1166C mutation in women with gestational hypertension ( GH ) and to establish the role of this polymorphism on the susceptibility to the PIH development .	parallel	1
21214	11083259	7124;3553	tumor necrosis factor alpha;IL-1beta	OBJECTIVE : To investigate the hypothesis that ***tumor necrosis factor alpha*** ( TNFalpha ) blockade in rheumatoid arthritis ( RA ) ***diminishes*** synovial synthesis of TNFalpha , interleukin-1alpha ( IL-1alpha ) , and ***IL-1beta*** .	positive	0
21215	11083263	7124;3557	TNFalpha;IL-1Ra	In contrast , the ***TNFalpha*** ( high ) phenotype was significantly ***associated*** with the less frequent allele of ***IL-1Ra*** , which carries two 86-bp repeats in the second intron and is assumed to lead to an elevated expression of the antagonist .	parallel	0
21216	11083263	3557;3553	IL-1Ra;IL-1beta	CONCLUSION : These results point to an ***association*** between the ***IL-1beta*** polymorphism and the TNFalpha ( high ) phenotype and between the ***IL-1Ra*** polymorphism and the TNFalpha ( low ) phenotype found in OA .	parallel	0
21217	11083263	7124;3553	TNFalpha;IL-1beta	CONCLUSION : These results point to an ***association*** between the ***IL-1beta*** polymorphism and the TNFalpha ( high ) phenotype and between the IL-1Ra polymorphism and the ***TNFalpha*** ( low ) phenotype found in OA .	parallel	0
21218	11083263	7124;3557	TNFalpha;IL-1Ra	CONCLUSION : These results point to an ***association*** between the IL-1beta polymorphism and the TNFalpha ( high ) phenotype and between the ***IL-1Ra*** polymorphism and the ***TNFalpha*** ( low ) phenotype found in OA .	parallel	0
21219	11083268	3605;3553	IL-17;IL-1	Moreover , ***IL-17*** enhanced the proliferation of fibroblasts and ***induced*** the expression of adhesion molecules and ***IL-1*** production in endothelial cells in vitro .	target	1
21220	11083278	7124;301	Tumor necrosis factor alpha;Annexin I	***Tumor necrosis factor alpha*** ***increased*** ***Annexin I*** binding sites on OA and RA FLS .	positive	0
21221	11083772	2736;7124	THP-1;tumor necrosis factor alpha	In the human monocytic cell line , ***THP-1*** , combining SP-A with lipid A or rough LPS further ***enhanced*** lipid A - or rough LPS-stimulated ***tumor necrosis factor alpha*** ( TNF-alpha ) mRNA levels , while SP-A-elicited increases in TNF-alpha mRNA levels were partially neutralized .	positive	0
21222	11083814	3586;3553	IL-10;IL-1beta	In line with its downregulatory effects on neutrophil-derived proinflammatory cytokines , ***IL-10*** potently ***inhibited*** TNF-alpha , ***IL-1beta*** , IL-8 , and MIP-1beta production triggered by OMV .	negative	1
21223	11083814	3586;7124	IL-10;TNF-alpha	In line with its downregulatory effects on neutrophil-derived proinflammatory cytokines , ***IL-10*** potently ***inhibited*** ***TNF-alpha*** , IL-1beta , IL-8 , and MIP-1beta production triggered by OMV .	negative	1
21224	11083848	3586;3458	IL-10;IFN-gamma	The differential effect of IL-10 on IFN-gamma production in C57BL/6J and C3H/HeJ mice suggests that ***IL-10*** is probably involved in the ***regulation*** of ***IFN-gamma*** production by LN cells during infection and may be at the root of the differential susceptibility to Lyme arthritis in these two strains of mice .	target	1
21225	11083861	351;836	Abeta;caspase 3	***Abeta*** ***increased*** the activity of ***caspase 3*** by 10.6-fold and to a lesser extent for caspase 2 , 8 , and 9 .	positive	0
21226	11083861	351;836	Abeta;caspase 3	The ***Abeta-induced*** ***activation*** of ***caspase 3*** and release of cytochrome c showed a biphasic pattern .	positive	1
21227	11083862	2796;5594	GnRH;ERK	Our results suggest that the ***activation*** of ***ERK*** by ***GnRH*** involves two distinct signaling pathways , which converge at the level of Raf-1 .	positive	1
21228	11083864	1432;3725	p38 mitogen-activated protein kinase;c-Jun	***p38 mitogen-activated protein kinase*** ***regulates*** low potassium-induced ***c-Jun*** phosphorylation and apoptosis in cultured cerebellar granule neurons .	target	1
21229	11083865	1462;6366	Versican;SLC	We next examined if ***Versican*** or GAGs ***affect*** secondary lymphoid tissue chemokine ( ***SLC*** ) - induced integrin activation and Ca ( 2 + ) mobilization in lymphoid cells expressing a receptor for SLC , CC chemokine receptor 7 .	target	0
21230	11083865	1462;6366	Versican;SLC	These findings suggest that different proteoglycans have different functions in the regulation of chemokine activities and that ***Versican*** may negatively ***regulate*** the function of ***SLC*** via its GAG chains .	negative	1
21231	11083866	5054;7448	PAI-1;vitronectin	The first is dependent on PAI-1 inhibition of proteinase activity , most likely chicken plasmin , while the second is independent of PAI-1 's anti-proteinase activity and instead appears to act through ***PAI-1*** ***binding*** to ***vitronectin*** .	parallel	1
21232	11083868	1387;2353	CREB-binding protein;c-fos	Induction-independent ***recruitment*** of ***CREB-binding protein*** to the ***c-fos*** serum response element through interactions between the bromodomain and Elk-1 .	target	0
21233	11083868	1387;2002	CREB-binding protein;Elk-1	Transactivation by both components of this complex , serum response factor ( SRF ) and the ternary complex factor ***Elk-1*** , can be ***potentiated*** by the coactivator ***CREB-binding protein*** ( CBP ) .	positive	0
21234	11083868	1387;6722	CREB-binding protein;SRF	Transactivation by both components of this complex , serum response factor ( ***SRF*** ) and the ternary complex factor Elk-1 , can be ***potentiated*** by the coactivator ***CREB-binding protein*** ( CBP ) .	positive	0
21235	11083874	1131;5594	m3-muscarinic receptor;ERK-1/2	Phosphorylation of the Gq/11-coupled ***m3-muscarinic receptor*** is involved in receptor ***activation*** of the ***ERK-1/2*** mitogen-activated protein kinase pathway .	positive	1
21236	11083918	320;5663	X11 alpha;presenilin-1	***X11 alpha*** and x11 beta ***interact*** with ***presenilin-1*** via their PDZ domains .	parallel	1
21237	11083918	321;5663	x11 beta;presenilin-1	X11 alpha and ***x11 beta*** ***interact*** with ***presenilin-1*** via their PDZ domains .	parallel	1
21238	11083918	320;351	X11 alpha;APP	***X11 alpha*** and x11 beta stabilise APP and ***inhibit*** production of proteolytic ***APP*** fragments including the A beta peptide that is deposited in the brains of Alzheimer 's disease patients .	negative	1
21239	11083918	320;351	X11 alpha;APP	The mechanisms by which ***X11 alpha*** and x11 beta ***modulate*** ***APP*** processing are not clear but one possibility is that they influence the activity of the secretases that cleave APP to give rise to A beta .	target	0
21240	11083918	321;351	x11 beta;APP	The mechanisms by which X11 alpha and ***x11 beta*** ***modulate*** ***APP*** processing are not clear but one possibility is that they influence the activity of the secretases that cleave APP to give rise to A beta .	target	0
21241	11083918	320;5663	X11 alpha;presenilin-1	presenilin-1 is required for gamma-secretase activity and here we demonstrate that both ***X11 alpha*** and x11 beta ***interact*** with ***presenilin-1*** .	parallel	1
21242	11083918	321;5663	x11 beta;presenilin-1	presenilin-1 is required for gamma-secretase activity and here we demonstrate that both X11 alpha and ***x11 beta*** ***interact*** with ***presenilin-1*** .	parallel	1
21243	11083918	5663;320	presenilin-1;X11	******X11/presenilin-1****** ***binding*** is via two X11 PDZ domains and sequences within the carboxy-terminus of presenilin-1 .	parallel	1
21244	11083918	351;5663	APP;presenilin-1	We also demonstrate that both X11 alpha and x11 beta mediate the ***formation*** of complexes between ***APP*** and ***presenilin-1*** .	parallel	0
21245	11083918	320;351	X11;APP	These results suggest that the ***X11*** ***regulation*** of ***APP*** processing is controlled , at least in part , via their interactions with APP and presenilin-1 .	target	1
21246	11083921	3084;2066	NDF;ErbB-4	***ErbB-4*** receptor tyrosine kinase and its ***ligand*** neu differentiation factor ( ***NDF/neuregulin*** ) are widely expressed in the brain .	parallel	1
21247	11083922	25825;351	ASP1;amyloid precursor protein	***ASP1*** ( BACE2 ) ***cleaves*** the ***amyloid precursor protein*** at the beta-secretase site .	target	1
21248	11084022	130399;3725	ALK7;AP-1	Reporter assays demonstrated that ***ALK7*** activation ***stimulates*** transcription from the Smad-binding element of the Jun-B gene , the plasminogen activator inhibitor-1 gene , and ***AP-1*** elements .	positive	0
21249	11084022	130399;5502	ALK7;inhibitor-1	Reporter assays demonstrated that ***ALK7*** activation ***stimulates*** transcription from the Smad-binding element of the Jun-B gene , the plasminogen activator ***inhibitor-1*** gene , and AP-1 elements .	positive	0
21250	11084024	960;1445	CD44;c-Src kinase	***CD44*** ***interaction*** with ***c-Src kinase*** promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration .	parallel	1
21251	11084024	960;1445	CD44;c-Src kinase	Using a recombinant cytoplasmic domain of CD44 and an in vitro binding assay , we have detected a specific ***interaction*** between ***CD44*** and ***c-Src kinase*** .	parallel	1
21252	11084024	960;1445	CD44;c-Src kinase	Taken together , these findings strongly suggest that ***CD44*** ***interaction*** with ***c-Src kinase*** plays a pivotal role in initiating cortactin-regulated cytoskeleton function and HA-dependent tumor cell migration , which may be required for human ovarian cancer progression .	parallel	1
21253	11084030	2621;7301	Gas6;Tyro 3	***Gas6*** up-regulated the phosphorylation of cellular proteins including p42/p44 mitogen-activated protein kinase ( MAPK ) , but not p38 or c-Jun N-terminal kinase MAPK , and ***increased*** the kinase activity of immunoprecipitated ***Tyro 3*** in isolated osteoclasts .	positive	0
21254	11084035	9500;1749	Dlxin-1;Dlx5	To understand the molecular mechanism underlying the transcriptional regulation by Dlx5 , we performed yeast two-hybrid screening and isolated a novel protein , ***Dlxin-1*** , that ***binds*** ***Dlx5*** and regulates its transcriptional function .	parallel	1
21255	11084035	9500;1749	Dlxin-1;Dlx5	***Dlxin-1*** ***binds*** not only ***Dlx5*** but also Dlx7 and Msx2 and forms homomultimers in vivo .	parallel	1
21256	11084035	9500;1748	Dlxin-1;Dlx7	***Dlxin-1*** ***binds*** not only Dlx5 but also ***Dlx7*** and Msx2 and forms homomultimers in vivo .	parallel	1
21257	11084035	9500;4488	Dlxin-1;Msx2	***Dlxin-1*** ***binds*** not only Dlx5 but also Dlx7 and ***Msx2*** and forms homomultimers in vivo .	parallel	1
21258	11084035	9500;1749	Dlxin-1;Dlx5	Transfection and reporter gene assays indicate that ***Dlxin-1*** ***activates*** the transcriptional function of ***Dlx5*** .	positive	1
21259	11084041	638;596	BIK;BCL-2	***BIK*** ***complexes*** with various anti-apoptotic ***BCL-2*** family proteins such as adenovirus E1B-19K and BCL-2 via the BH3 domain .	parallel	1
21260	11084046	1523;3065	CDP/cut;HDAC1	Repression of HLA-B and C gene expression by CDP/cut does not involve displacement of NF-Y , nor is ***CDP/cut*** ***associated*** with the histone deacetylase ***HDAC1*** when bound to the HLA-B7 repressor element .	parallel	0
21261	11084046	1523;3107	CDP/cut;HLA-B and C	***Repression*** of ***HLA-B and C*** gene expression by ***CDP/cut*** does not involve displacement of NF-Y , nor is CDP/cut associated with the histone deacetylase HDAC1 when bound to the HLA-B7 repressor element .	negative	1
21262	11084331	3763;3619	Bir1;INCENP	Because the yeast homolog of INCENP , Sli15 , regulates the Aurora kinase homolog Ipl1p , and the yeast Survivin homolog ***Bir1*** ***binds*** to Ndc10p , a substrate of Ipl1p , yeast Survivin , ***INCENP*** and Aurora homologs function in concert during cell division .	parallel	1
21263	11084331	3763;332	Bir1;Survivin	Because the yeast homolog of INCENP , Sli15 , regulates the Aurora kinase homolog Ipl1p , and the yeast Survivin homolog ***Bir1*** ***binds*** to Ndc10p , a substrate of Ipl1p , yeast ***Survivin*** , INCENP and Aurora homologs function in concert during cell division .	parallel	1
21264	11084340	8871;5879	Synaptojanin 2;Rac1	***Synaptojanin 2*** directly and specifically ***interacts*** with ***Rac1*** in a GTP-dependent manner .	parallel	1
21265	11084340	8871;5879	Synaptojanin 2;Rac1	Thus , these results suggest that ***Synaptojanin 2*** may ***mediate*** the inhibitory effect of ***Rac1*** on endocytosis and could contribute to Rac1-mediated control of cell growth .	target	0
21266	11084652	405;3091	ARNT;hypoxia inducible factor1alpha	***ARNT*** also ***dimerizes*** with ***hypoxia inducible factor1alpha*** ( HIF1alpha ) , inducing expression of vascular endothelial cell growth factor ( VEGF ) to promote angiogenesis .	parallel	1
21267	11084955	1392;6750	CRH;somatostatin	In addition to its control of the adrenal hormones , ***CRH*** ***stimulates*** ***somatostatin*** secretion at the hypothalamic level , which , in turn , causes inhibition of growth hormone and thyroid-stimulating hormone at the pituitary level .	positive	0
21268	11085506	472;11200	ATM;Chk2	Together , these data are consistent with the model that ***ATM*** directly ***phosphorylates*** ***Chk2*** in vivo and that this event contributes to the activation of Chk2 in irradiated cells .	target	1
21269	11085522	2697;4240	Connexin43;MFG-E8	***Connexin43*** ***suppresses*** ***MFG-E8*** while inducing contact growth inhibition of glioma cells .	negative	1
21270	11085539	3083;3082	HGFA;HGF	It was concluded that ***HGFA*** is expressed in colorectal mucosa and tumors and could be involved in the ***activation*** of ***HGF/SF*** in colorectal carcinomas .	positive	1
21271	11085539	3083;3082	HGFA;HGF	This processing activity was enhanced by thrombin treatment but was inhibited significantly by a neutralizing antibody against ***HGF*** ***activator*** ( ***HGFA*** ) , a factor XIIa-like serine proteinase believed to be expressed mainly in the liver .	positive	1
21272	11085749	7392;3214	USF-2;HOXB4	Hematopoietic expression of HOXB4 is regulated in normal and leukemic stem cells through transcriptional ***activation*** of the ***HOXB4*** promoter by upstream stimulating factor ( USF ) -1 and ***USF-2*** .	positive	1
21273	11085749	7392;3214	USF-2;HOXB4	Cotransfection assays in both K562 and CD34 ( + ) cells showed that USF-1 and ***USF-2*** , but not MITF , ***induce*** the ***HOXB4*** promoter in response to signals stimulating stem cell self-renewal , through activation of the mitogen-activated protein kinase pathway .	target	1
21274	11085902	3700;551	gp120;AVP	It would therefore appear that ***gp120*** ***activates*** CRH and ***AVP-producing*** neurons in the hypothalamic PVN and stimulates the release of both peptides in vitro via NO-dependent mechanisms .	positive	1
21275	11085902	3700;1392	gp120;CRH	It would therefore appear that ***gp120*** ***activates*** ***CRH*** and AVP-producing neurons in the hypothalamic PVN and stimulates the release of both peptides in vitro via NO-dependent mechanisms .	positive	1
21276	11085902	3700;2353	gp120;Fos	***gp120*** ***induced*** the expression of ***Fos*** protein in both the parvo - and the magnocellular PVN , which was significantly attenuated by l-NMMA 10 ( -6 ) nM/L ( P < 0.001 vs gp120 alone ) .	target	1
21277	11085919	4018;7035	lipoprotein;tissue-factor-pathway inhibitor	Oxidized low-density ***lipoprotein*** ***impairs*** the anti-coagulant function of ***tissue-factor-pathway inhibitor*** through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells .	negative	0
21278	11085938	2272;7329	FHIT;hUBC9	***Association*** of ***FHIT*** ( fragile histidine triad ) , a candidate tumour suppressor gene , with the ubiquitin-conjugating enzyme ***hUBC9*** .	parallel	0
21279	11085938	7329;2272	hUBC9;FHIT	Mutational analysis indicated that ***hUBC9*** was ***associated*** with the C-terminal portion of ***FHIT*** .	parallel	0
21280	11085938	7329;2272	hUBC9;FHIT	Neither a single amino acid substitution at codon 96 ( His -- > Asn ) nor triple amino acid substitutions ( His -- > Asn ) at a histidine triad ( codons 94 , 96 and 98 ) affected the association , whereas FHIT triphosphate ( diadenosine 5 ' ,5 " ' - P ( 1 ) , P ( 3 ) - triphosphate ) hydrolase activity has been reported to be eliminated by either type of mutation , suggesting that the ***interaction*** between ***FHIT*** and ***hUBC9*** is independent of FHIT enzymic activity .	parallel	1
21281	11085943	382;2822	ARF6;PLD	Finally , the ***stimulation*** of ***PLD*** by ***ARF6*** was inhibited by AlF ( - ) ( 4 ) and this inhibition was counteracted by the fusion protein glutathione S-transferase-beta-adrenergic receptor kinase 1 ( 495-689 ) and by the QEHA peptide ( from adenylate cyclase ACII ) , which act as G-protein betagamma-subunit scavengers .	positive	0
21282	11085943	382;2822	ARF6;PLD	It is concluded that G-protein subunits betagamma are involved in a pathway modulating ***PLD*** ***activation*** by ***ARF6*** , illustrating cross-talk between heterotrimeric and monomeric G-proteins .	positive	1
21283	11085968	860;1385	Osf2;CREB	Electrophoretic mobility shift assay demonstrated that TNF-alpha enhanced DNA ***binding*** of osteoblast specific factor ( ***Osf2*** ) , AP1 , and ***CREB*** , transcription factors that are important for osteoblastic differentiation .	parallel	1
21284	11085983	1845;5594	VHR;Erk	Our results suggest that ***VHR*** is a negative ***regulator*** of the ***Erk*** and Jnk pathways in T cells and , therefore , may play a role in aspects of T lymphocyte physiology that depend on these kinases .	negative	1
21285	11085983	1845;5599	VHR;Jnk	Our results suggest that ***VHR*** is a negative ***regulator*** of the Erk and ***Jnk*** pathways in T cells and , therefore , may play a role in aspects of T lymphocyte physiology that depend on these kinases .	negative	1
21286	11085984	7124;4846	tumor necrosis factor-alpha;endothelial nitric-oxide synthase	***Activation*** of the ***endothelial nitric-oxide synthase*** by ***tumor necrosis factor-alpha*** .	positive	1
21287	11085988	11140;367	Cdc37;androgen receptor	Functional ***interaction*** of human ***Cdc37*** with the ***androgen receptor*** but not with the glucocorticoid receptor .	parallel	1
21288	11085989	5781;3952	SHP-2;leptin	The protein tyrosine phosphatase ***SHP-2*** has been proposed to serve as a ***regulator*** of ***leptin*** signaling , but its specific roles are not fully examined .	target	1
21289	11085990	7124;414325	Tumor necrosis factor alpha;hBD-3	***Tumor necrosis factor alpha*** and contact with bacteria were found to ***induce*** ***hBD-3*** mRNA expression .	target	1
21290	11085994	3336;3329	GroES;GroEL	We investigated the effects of high hydrostatic pressure in the range of 1 -- 3 kilobars on tetradecameric GroEL , heptameric GroES , and the ******GroEL-GroES****** ***complex*** .	parallel	1
21291	11085994	3336;3329	GroES;GroEL	Interestingly , the ******GroEL-GroES****** ***complex*** is very stable in the range of 1 -- 2.5 kilobars .	parallel	1
21292	11086022	356;355	FasL;Fas	These results suggest that the ******Fas-FasL****** ***interaction*** plays an important role in the normal remodeling of mammary tissue .	parallel	1
21293	11086030	268;7124	MIF;TNF-alpha	The catabolic effect of ***TNF-alpha*** on myotubes was ***mediated*** by ***MIF*** , which served as an autocrine stimulus for F2 , 6BP production .	target	0
21294	11086038	1524;6376	CX3CR1;fractalkine	A role for ***fractalkine*** and its ***receptor*** ( ***CX3CR1*** ) in cardiac allograft rejection .	parallel	1
21295	11086053	1432;3458	p38;IFN-gamma	In contrast , following differentiation into Th1 or Th2 cells , ***p38*** inhibition ***blocked*** IL-2 and ***IFN-gamma*** without affecting IL-4 secretion .	positive	0
21296	11086053	1432;3558	p38;IL-2	In contrast , following differentiation into Th1 or Th2 cells , ***p38*** inhibition ***blocked*** ***IL-2*** and IFN-gamma without affecting IL-4 secretion .	positive	0
21297	11086053	8744;1432	4-1BB ligand;p38	Aggregation of 4-1BB alone induces p38 activation in a T cell hybridoma , whereas , in normal T cells , ***p38*** MAPK is ***activated*** synergistically by immobilized anti-CD3 plus immobilized ***4-1BB ligand*** .	positive	1
21298	11086053	1432;7186	p38;TRAF2	A ***link*** between ***TRAF2*** and the ***p38*** cascade is provided by the MAPK kinase kinase , apoptosis-signal-regulating kinase 1 .	parallel	0
21299	11086055	965;914	LFA-3;CD2	The induction of proliferation and cytokine secretion required the engagement of costimulatory molecules , particularly ******CD2-LFA-3****** ***interaction*** .	parallel	1
21300	11086058	6778;958	STAT-6;CD40	These results suggest that IL-4 inhibition of IFN-gamma-induced CD40 gene expression is mediated by direct ***STAT-6*** ***binding*** to the ***CD40*** promoter .	parallel	1
21301	11086058	3565;958	IL-4;CD40	These results suggest that ***IL-4*** ***inhibition*** of IFN-gamma-induced ***CD40*** gene expression is mediated by direct STAT-6 binding to the CD40 promoter .	negative	1
21302	11086058	6778;3565	STAT-6;IL-4	These results suggest that ***IL-4*** inhibition of IFN-gamma-induced CD40 gene expression is ***mediated*** by direct ***STAT-6*** binding to the CD40 promoter .	target	0
21303	11086058	6778;958	STAT-6;CD40	IL-4-activated ***STAT-6*** ***inhibits*** IFN-gamma-induced ***CD40*** gene expression in macrophages/microglia .	negative	1
21304	11086058	3565;958	IL-4;CD40	In this report , we describe the molecular mechanisms by which ***IL-4*** ***inhibits*** IFN-gamma-induced ***CD40*** expression .	negative	1
21305	11086058	3565;958	IL-4;CD40	***IL-4*** ***suppresses*** IFN-gamma-induced ***CD40*** gene expression in both macrophages and microglia , and such inhibition is dependent on the activation of STAT-6 .	negative	1
21306	11086058	3565;958	IL-4;CD40	Furthermore , ***IL-4*** ***inhibition*** of IFN-gamma-induced ***CD40*** expression is specific , since IL-4 does not inhibit IFN-gamma-induced IFN-responsive factor-1 gene expression .	negative	1
21307	11086058	3565;958	IL-4;CD40	Site-directed mutagenesis studies demonstrate that two STAT binding sites , named proximal and distal IFN-gamma-activated sequences , in the human CD40 promoter are important for ***IL-4*** ***inhibition*** of IFN-gamma-induced ***CD40*** promoter activity .	negative	1
21308	11086072	7520;2547	Ku86;Ku70	Ku is a ***heterodimer*** of ***Ku70*** and ***Ku86*** that binds to double-stranded DNA breaks ( DSBs ) , activates the catalytic subunit ( DNA-PKcs ) when DNA is bound , and is essential in DSB repair and V ( D ) J recombination .	parallel	1
21309	11086072	7520;5591	Ku86;DNA-PKcs	***Ku86*** forms ***complexes*** with ***DNA-PKcs*** and activates kinase activity , but Ku86v neither binds DNA-PKcs nor activates kinase activity .	parallel	1
21310	11086073	920;7852	CD4;CXCR4	***IL-16/CD4*** ***inhibition*** of SDF-1alpha / ***CXCR4*** signals requires the presence of the Src homology 3 domain of p56 ( lck ) and most likely involves activation of phosphatidylinositol-3 kinase .	negative	1
21311	11086073	3603;7852	IL-16;CXCR4	***IL-16/CD4*** ***inhibition*** of SDF-1alpha / ***CXCR4*** signals requires the presence of the Src homology 3 domain of p56 ( lck ) and most likely involves activation of phosphatidylinositol-3 kinase .	negative	1
21312	11086073	920;3603	CD4;IL-16	These studies demonstrate that ******IL-16/CD4****** ***signaling*** in T lymphocytes also results in loss of stromal derived factor-1alpha ( SDF-1alpha ) / CXCR4-induced chemotaxis ; however , unlike MIP-1ss / CCR5 , the effects were not reciprocal .	parallel	0
21313	11086074	3458;4843	IFN-gamma;inducible NO synthase	This inhibition is specific , because , under the same conditions , ***IFN-gamma*** ***induces*** the expression of Fcgamma receptors and the ***inducible NO synthase*** mRNA .	target	1
21314	11086091	23430;2150	mast cell tryptase;PAR2	We hypothesized that ***activation*** of endothelial ***PAR2*** by ***mast cell tryptase*** or other proteases also contributes to inflammatory responses .	positive	1
21315	11086103	3600;7852	IL-15;CXCR4	***CXCR4*** expression could be ***enhanced*** by ***IL-15*** , whereas stromal cell-derived factor ( SDF ) -1 , the ligand of CXCR4 , was expressed in the RA synovium and could be increased by CD40 stimulation .	positive	0
21316	11086103	7852;6387	CXCR4;SDF-1	These results indicate that ******SDF-1-CXCR4****** ***interactions*** play important roles in CD4 ( + ) memory T cell accumulation in the RA synovium , and emphasize the role of stromal cells in regulating rheumatoid inflammation .	parallel	1
21317	11086202	3482;3481	M6P/IGF2R;insulin-like growth factor 2	Mutation analysis of the gene encoding the human mannose ***6-phosphate/insulin-like growth factor 2*** ***receptor*** ( ***M6P/IGF2R*** ) in human cell lines resistant to growth inhibition by transforming growth factor beta ( 1 ) ( TGF-beta ( 1 ) ) .	parallel	1
21318	11086202	3482;3481	M6P/IGF2R;insulin-like growth factor 2	The mannose ***6-phosphate/insulin-like growth factor 2*** ***receptor*** ( ***M6P/IGF2R*** ) is involved in activating the transforming growth factor beta ( 1 ) ( TGF-beta ( 1 ) ) , an inhibitor of the cell proliferation , and limiting the insulin-like growth factor 2 mediated-growth stimulation .	parallel	1
21319	11086993	9722;51655	CAPON;Dexras1	Here we identify a selective ***interaction*** of the nNOS adaptor protein ***CAPON*** with ***Dexras1*** , a brain-enriched member of the Ras family of small monomeric G proteins .	parallel	1
21320	11086993	51655;9722	Dexras1;CAPON	We also find that nNOS , ***CAPON*** , and ***Dexras1*** form a ternary ***complex*** that enhances the ability of nNOS to activate Dexras1 .	parallel	1
21321	11087233	3553;4843	IL-1beta;NOS	To this end , we first found that administration of ***IL-1beta*** in the lateral ventricle of control and CRF rats decreased blood pressure and norepinephrine ( NE ) secretion from the posterior hypothalamus ( PH ) and ***increased*** ***NOS*** mRNA expression .	positive	0
21322	11087238	7040;7076	TGF-beta;TIMP-1	The increase in alpha ( 2 ) ( I ) collagen mRNA levels and alpha ( 2 ) ( I ) collagen promoter activity , as well as ***TIMP-1*** secretion , in response to BK were ***blocked*** by anti-transforming growth factor-beta ( ***anti-TGF-beta*** ) neutralizing antibodies .	negative	0
21323	11087242	3082;1906	Hepatocyte growth factor;endothelin-1	***Hepatocyte growth factor*** is upregulated by low-density lipoproteins and ***inhibits*** ***endothelin-1*** release .	negative	1
21324	11087273	1398;4790	p38;NF-kappaB	Thus HIV-gp120 enhancement of IL-1beta-induced NO production is associated with ***p38-mediated*** ***activation*** of ***NF-kappaB*** .	positive	1
21325	11087273	3700;4790	gp120;NF-kappaB	Thus ***HIV-gp120*** enhancement of IL-1beta-induced NO production is ***associated*** with p38-mediated activation of ***NF-kappaB*** .	parallel	0
21326	11087273	3700;4843	gp120;iNOS	However , the addition of ***gp120*** to IL-1beta significantly ***enhanced*** ***iNOS*** mRNA expression ( 70 + / - 1.5 vs. 26 + / - 2.4 optical units , IL-1beta + gp120 vs.	positive	0
21327	11087380	3308;10728	hsp70;p23	Using purified proteins , we have prepared a five-protein heterocomplex assembly system consisting of two proteins essential for heterocomplex assembly-hsp90 and ***hsp70-and*** three proteins that act as co-chaperones to ***enhance*** assembly-Hop , hsp40 , ***p23*** [ Morishima , Y. , Kanelakis , K.	positive	0
21328	11087380	3320;10728	hsp90;p23	Using purified proteins , we have prepared a five-protein heterocomplex assembly system consisting of two proteins essential for heterocomplex ***assembly-hsp90*** and hsp70-and three proteins that act as co-chaperones to ***enhance*** assembly-Hop , hsp40 , ***p23*** [ Morishima , Y. , Kanelakis , K.	positive	0
21329	11087629	650;6909	BMP2;Tbx2	Expression of chick Tbx-2 , Tbx-3 , and Tbx-5 genes during early heart development : evidence for ***BMP2*** ***induction*** of ***Tbx2*** .	target	1
21330	11087668	331;836	XIAP;caspase-3	***XIAP*** specifically ***binds*** and inhibits the function of ***caspase-3*** , -7 , and -9 , key effector proteases of apoptosis .	parallel	1
21331	11087671	11341;8819	SCRG1;sap30	Sequencing revealed that the mouse ***SCRG1*** gene is physically ***linked*** to ***sap30*** , a gene that encodes a protein of the histone deacetylase complex , and genetic linkage mapping assigned the localization of SCRG1 to chromosome 8 between Ant1 and Hmg2 .	parallel	0
21332	11087725	6857;2246	Syt1;FGF1	However , unlike the FGF1 release pathway , the IL1alpha release pathway appears to function independently of synaptotagmin (Syt)1 because the expression of a dominant-negative form of ***Syt1*** , which ***represses*** the release of ***FGF1*** , did not inhibit the release of mIL1alpha in response to temperature stress .	negative	1
21333	11087727	7124;4790	Tumor necrosis factor-alpha;NF-kappa B	***Tumor necrosis factor-alpha*** ***induces*** distinctive ***NF-kappa B*** signaling within human dermal fibroblasts .	target	1
21334	11087727	7124;4790	TNF-alpha;NF-kappa B	The ***TNF-alpha*** receptor-associated factor 2 ( TRAF2 ) and its downstream mediator , the NF-kappa B-inducing kinase ( NIK ) , have been shown to ***induce*** ***NF-kappa B*** activation in 293 cells .	target	1
21335	11087727	7186;4790	TRAF2;NF-kappa B	The TNF-alpha receptor-associated factor 2 ( ***TRAF2*** ) and its downstream mediator , the NF-kappa B-inducing kinase ( NIK ) , have been shown to ***induce*** ***NF-kappa B*** activation in 293 cells .	target	1
21336	11087727	7124;4790	TNF-alpha;NF-kappa B	Further , ***NF-kappa B*** ***activation*** by ***TNF-alpha*** was unaffected by overexpression of a dominant negative mutant NIK in fibroblasts , despite detection of endogenous TRAF2 and NIK by Western analysis .	positive	1
21337	11087727	831;4790	calpain inhibitor;NF-kappa B	To explore alternative signaling mechanisms in dermal fibroblasts , we found that the intracellular calcium chelator , 3,4,5-trimethoxybenzoic acid , and the ***calpain inhibitor*** , N-acetyl-Leu-Leu-norleucinal , both ***blocked*** ***NF-kappa B*** activation ; however , the specific proteosome inhibitor , lactacystin , failed to do so .	negative	0
21338	11087727	7124;4790	TNF-alpha;NF-kappa B	Furthermore , ***TNF-alpha*** receptor mutants lacking a functional death domain failed to ***stimulate*** ***NF-kappa B*** , while phosphatidylcholine-phospholipase C inhibition and alkalization of endolysosomal compartments blocked its activation by TNF-alpha .	negative	0
21339	11087733	5170;207	PDK1;Akt1	The insulin-stimulated ***Akt1*** activity was also ***enhanced*** by ***wt-PDK1*** expression but was maintained even at 15 min .	positive	0
21340	11087742	317;4790	Apaf-1;NF-kappaB	Nod2 , a ***Nod1/Apaf-1*** family member that is restricted to monocytes and ***activates*** ***NF-kappaB*** .	positive	1
21341	11087742	10392;4790	Nod1;NF-kappaB	Nod2 , a ***Nod1/Apaf-1*** family member that is restricted to monocytes and ***activates*** ***NF-kappaB*** .	positive	1
21342	11087742	64127;8767	Nod2;RICK	***Nod2*** ***interacted*** with the serine-threonine kinase ***RICK*** via a homophilic CARD-CARD interaction .	parallel	1
21343	11087742	8767;4790	RICK;NF-kappaB	Furthermore , ***NF-kappaB*** activity induced by Nod2 correlated with its ability to interact with RICK and was specifically ***inhibited*** by a truncated mutant form of ***RICK*** containing its CARD .	negative	1
21344	11087747	3456;3135	Interferon beta;HLA-G	Despite mutation of the class I ISRE sequence within the nonclassical HLA-G class I gene promoter , we show that ***Interferon beta*** ***enhances*** both transcription and cell surface expression of ***HLA-G*** in trophoblasts and amniotic and thymic epithelial cells that selectively express it in vivo .	positive	0
21345	11087747	3659;3135	IRF-1;HLA-G	Our results provide evidence that ***IRF-1*** binding to a functional ISRE within the HLA-G promoter ***mediates*** Interferon beta-induced expression of the ***HLA-G*** gene .	target	0
21346	11087752	868;7409	Cbl-b;Vav	The data suggest a molecular link for ***Cbl-b-mediated*** negative ***regulation*** of ***Vav*** , with phosphatidylinositol 3-kinase as a direct target for Cbl-b E3 ubiquitin ligase .	negative	1
21347	11087753	2247;3381	fibroblast growth factor 2;BSP	We have found that expression of ***BSP*** in osteoblastic ROS 17/2 .8 cells is ***stimulated*** by ***fibroblast growth factor 2*** ( FGF2 ) , a potent mitogen for mesenchymal cells .	positive	0
21348	11087758	5738;975	FPRP;CD81	***FPRP*** , a cell-surface Ig superfamily protein , ***associates*** specifically with CD81 or with ***CD81*** and CD9 , but not with integrins or other TM4SF proteins .	parallel	0
21349	11087758	5738;928	FPRP;CD9	***FPRP*** , a cell-surface Ig superfamily protein , ***associates*** specifically with CD81 or with CD81 and ***CD9*** , but not with integrins or other TM4SF proteins .	parallel	0
21350	11087758	5738;10103	FPRP;TM4SF	***FPRP*** , a cell-surface Ig superfamily protein , ***associates*** specifically with CD81 or with CD81 and CD9 , but not with integrins or other ***TM4SF*** proteins .	parallel	0
21351	11087758	928;975	CD9;CD81	Also , ******CD81.CD9.FPRP****** ***complexes*** have a discrete size ( < 4 x 10 ( 6 ) Da ) as measured by gel permeation chromatography and remain intact after disruption of cholesterol-rich membrane microdomains by methyl-beta-cyclodextrin .	parallel	1
21352	11087758	5738;975	FPRP;CD81	Also , ******CD81.CD9.FPRP****** ***complexes*** have a discrete size ( < 4 x 10 ( 6 ) Da ) as measured by gel permeation chromatography and remain intact after disruption of cholesterol-rich membrane microdomains by methyl-beta-cyclodextrin .	parallel	1
21353	11087758	5738;928	FPRP;CD9	Also , ******CD81.CD9.FPRP****** ***complexes*** have a discrete size ( < 4 x 10 ( 6 ) Da ) as measured by gel permeation chromatography and remain intact after disruption of cholesterol-rich membrane microdomains by methyl-beta-cyclodextrin .	parallel	1
21354	11087760	3553;4843	IL-1beta;iNOS	The results indicate that , in addition to transcriptional activation , mRNA stabilization is a key component of the mechanism by which ***IL-1beta*** ***stimulates*** ***iNOS*** expression in beta-cells and that PKCdelta plays an essential role in this process .	positive	0
21355	11087817	7415;6811	p97;syntaxin 5	By contrast , the tyrosine kinase inhibitor , genistein , promoted tER formation and prevented p97 dissociation from membranes while increasing ***p97*** ***association*** with the t-SNARE ***syntaxin 5*** .	parallel	0
21356	11087869	5465;190	PPAR;nuclear hormone receptor	We previously have reported that COX-2-derived prostacyclin promotes embryo implantation in the mouse uterus via activation of the ***nuclear hormone receptor*** peroxisome proliferator-activated ***receptor*** ( ***PPAR*** ) delta .	parallel	1
21357	11087871	5914;5371	RARalpha;promyelocytic leukemia	We previously generated a transgenic mouse model for acute promyelocytic leukemia ( APL ) by expressing the ***promyelocytic leukemia*** ( PML ) - retinoic acid ***receptor*** ( ***RARalpha*** ) cDNA in early myeloid cells .	parallel	1
21358	11087995	6750;1325	somatostatin;cortistatin-17	The ***somatostatin*** receptor subtypes , sst1-sst5 , ***bind*** their natural ligands , somatostatin-14 , somatostatin-28 and ***cortistatin-17*** , with high affinity but do not much discriminate between them .	parallel	1
21359	11087999	6752;6750	SSTR2;somatostatin	Simultaneous traditional chemical synthesis yielded an additional series of ***somatostatin*** subtype-2 ***receptor*** ( ***SSTR2*** ) selective agonists .	parallel	1
21360	11087999	6755;6750	SSTR5;somatostatin	In vitro experiments demonstrated the role of the SSTR2 in inhibition of glucagon release from mouse pancreatic alpha-cells and the ***somatostatin*** subtype-5 ***receptor*** ( ***SSTR5*** ) as a mediator of insulin secretion from pancreatic beta-cells .	parallel	1
21361	11088001	6751;5781	SSTR1;SHP-2	Thus , the ***activation*** of ***SHP-2*** by ***SSTR1*** may mediate the antiproliferative activity of Somatostatin .	positive	1
21362	11088001	5781;6750	SHP-2;Somatostatin	Thus , the activation of ***SHP-2*** by SSTR1 may ***mediate*** the antiproliferative activity of ***Somatostatin*** .	target	0
21363	11089522	1033;1017	cyclin-dependent kinase (cdk) inhibitor;cyclin-dependent kinase 2	This arrest was accompanied by an increase in the expression of the ***cyclin-dependent kinase (cdk) inhibitor*** proteins , p2Waf1 and p27Kip1 , which served to ***decrease*** the activity of ***cyclin-dependent kinase 2*** and cyclin-dependent kinase 6 , whereas the expression and phosphorylation of pRB were unchanged .	negative	0
21364	11089522	1033;1021	cyclin-dependent kinase (cdk) inhibitor;cyclin-dependent kinase 6	This arrest was accompanied by an increase in the expression of the ***cyclin-dependent kinase (cdk) inhibitor*** proteins , p2Waf1 and p27Kip1 , which served to ***decrease*** the activity of cyclin-dependent kinase 2 and ***cyclin-dependent kinase 6*** , whereas the expression and phosphorylation of pRB were unchanged .	negative	0
21365	11089522	1027;1017	p27Kip1;cyclin-dependent kinase 2	This arrest was accompanied by an increase in the expression of the cyclin-dependent kinase (cdk) inhibitor proteins , p2Waf1 and ***p27Kip1*** , which served to ***decrease*** the activity of ***cyclin-dependent kinase 2*** and cyclin-dependent kinase 6 , whereas the expression and phosphorylation of pRB were unchanged .	negative	0
21366	11089522	1027;1021	p27Kip1;cyclin-dependent kinase 6	This arrest was accompanied by an increase in the expression of the cyclin-dependent kinase (cdk) inhibitor proteins , p2Waf1 and ***p27Kip1*** , which served to ***decrease*** the activity of cyclin-dependent kinase 2 and ***cyclin-dependent kinase 6*** , whereas the expression and phosphorylation of pRB were unchanged .	negative	0
21367	11089522	1027;1017	p27Kip1;cdk2	Furthermore , antibody neutralization studies suggest that transforming growth factor-beta may mediate the ***coassociations*** between ***cdk2*** and ***p27Kip1*** and cyclin E induced by F6-D3 .	parallel	0
21368	11089524	3952;6774	leptin;STAT3	In vivo studies have shown that ***leptin*** ***activates*** specifically ***STAT3*** in the hypothalamus .	positive	1
21369	11089525	7124;632	TNF-alpha;osteocalcin	***TNF-alpha*** treatment of fetal calvaria precursor cells , which spontaneously differentiate to the osteoblast phenotype over 21 days , inhibited differentiation as shown by reduced formation of multilayered , mineralizing nodules and ***decreased*** secretion of the skeletal-specific matrix protein ***osteocalcin*** .	negative	0
21370	11089531	1803;2641	Dipeptidyl peptidase IV;glucagon-like peptide-2	***Dipeptidyl peptidase IV*** inhibition ***enhances*** the intestinotrophic effect of ***glucagon-like peptide-2*** in rats and mice .	negative	0
21371	11089531	1803;2641	Dipeptidyl peptidase IV;GLP-2	glucagon-like peptide-2 ( GLP-2 ) induces intestinal growth in mice ; but in normal rats , it seems less potent , possibly because of ***degradation*** of ***GLP-2*** by the enzyme ***Dipeptidyl peptidase IV*** ( DPP-IV ) .	negative	1
21372	11089533	3976;5443	Leukemia inhibitory factor;POMC	The pleiotropic cytokine ***Leukemia inhibitory factor*** ( LIF ) is expressed in murine hypothalamus and pituitary and ***increases*** ***POMC*** gene transcription and ACTH secretion in vitro and in vivo .	positive	0
21373	11089533	3976;5443	LIF;POMC	Injection of exogenous ***LIF*** ( 5 microg ) to turpentine-treated LIFKO mice ***induces*** ***POMC*** gene expression .	target	1
21374	11089534	5295;3667	p85;IRS1	As in PM , almost all ***p85*** was ***associated*** with ***IRS1/2*** .	parallel	0
21375	11089542	2289;2908	FKBP51;glucocorticoid receptor	Squirrel monkey immunophilin ***FKBP51*** is a potent ***inhibitor*** of ***glucocorticoid receptor*** binding .	negative	1
21376	11089552	5741;5594	PTH;ERK2	***PTH*** also ***induced*** ***ERK2*** phosphorylation in PCT cells .	target	1
21377	11089552	5741;5594	PTH;ERK	We examined ***PTH*** ***activation*** of the mitogen-activated protein kinase ( MAPK ) cascade ***raf-MEK-ERK*** in PCT and DCT cells and its effects on calcium transport and signaling .	positive	1
21378	11089552	5741;5609	PTH;MEK	We examined ***PTH*** ***activation*** of the mitogen-activated protein kinase ( MAPK ) cascade ***raf-MEK-ERK*** in PCT and DCT cells and its effects on calcium transport and signaling .	positive	1
21379	11089552	5741;5594	PTH;ERK2	In DCT cells , ***PTH*** ***stimulates*** phosphorylation of ERK2 and activation of ***ERK2*** kinase and is blocked by the MEK inhibitor PD98059 .	positive	0
21380	11089552	5741;5594	PTH;ERK2	***ERK2*** ***activation*** by ***PTH*** was blocked by the protein kinase C inhibitor calphostin-C but was unaffected by the protein kinase A inhibitor Rp-cAMPs .	positive	1
21381	11089553	9340;2641	GLP-2 receptor;GLP-2	The actions of ***GLP-2*** are ***mediated*** by the ***GLP-2 receptor*** , a new member of the G protein-coupled receptor superfamily .	target	0
21382	11089563	5617;644076	prolactin;Glycosylation-dependent cell adhesion molecule 1	***Glycosylation-dependent cell adhesion molecule 1*** ( GlyCAM 1 ) is ***induced*** by ***prolactin*** and suppressed by progesterone in mammary epithelium .	target	1
21383	11089563	5617;644076	PRL;Glycosylation-dependent cell adhesion molecule 1	***Glycosylation-dependent cell adhesion molecule 1*** ( GlyCAM 1 ) , a mucin-like endothelial glycoprotein , was ***induced*** by ***PRL*** and suppressed by progesterone in the mammary gland of mice , and in HC11 mouse mammary epithelial cells .	target	1
21384	11089570	51738;2693	ghrelin;GHS-R	***ghrelin*** , a novel 28 amino acid peptide found in hypothalamus and stomach , was recently identified as the endogenous ***ligand*** for the growth hormone secretagogue receptor ( ***GHS-R*** ) .	parallel	1
21385	11089749	671;1401	BPI;CRP	BPI and ***BPI/neutrophil*** ratios ***correlated*** positively with PLA2-II , ***CRP*** , TNF and IL-8 and negatively with blood pressure .	positive	0
21386	11089749	671;3576	BPI;IL-8	BPI and ***BPI/neutrophil*** ratios ***correlated*** positively with PLA2-II , CRP , TNF and ***IL-8*** and negatively with blood pressure .	positive	0
21387	11089877	4313;7077	MMP-2;TIMP-2	The object of this study was to analyze the potential ***association*** between the expression of ***MMP-2*** , MMP-9 , MT1-MMP and ***TIMP-2*** , and disease outcome in advanced-stage ovarian carcinomas .	parallel	0
21388	11089877	4318;4313	MMP-9;MMP-2	The object of this study was to analyze the potential ***association*** between the expression of ***MMP-2*** , ***MMP-9*** , MT1-MMP and TIMP-2 , and disease outcome in advanced-stage ovarian carcinomas .	parallel	0
21389	11089877	4318;7077	MMP-9;TIMP-2	The object of this study was to analyze the potential ***association*** between the expression of MMP-2 , ***MMP-9*** , MT1-MMP and ***TIMP-2*** , and disease outcome in advanced-stage ovarian carcinomas .	parallel	0
21390	11089877	4323;4313	MT1-MMP;MMP-2	The object of this study was to analyze the potential ***association*** between the expression of ***MMP-2*** , MMP-9 , ***MT1-MMP*** and TIMP-2 , and disease outcome in advanced-stage ovarian carcinomas .	parallel	0
21391	11089877	4323;4318	MT1-MMP;MMP-9	The object of this study was to analyze the potential ***association*** between the expression of MMP-2 , ***MMP-9*** , ***MT1-MMP*** and TIMP-2 , and disease outcome in advanced-stage ovarian carcinomas .	parallel	0
21392	11089877	4323;7077	MT1-MMP;TIMP-2	The object of this study was to analyze the potential ***association*** between the expression of MMP-2 , MMP-9 , ***MT1-MMP*** and ***TIMP-2*** , and disease outcome in advanced-stage ovarian carcinomas .	parallel	0
21393	11089878	2821;5578	AMF;PKCalpha	However , ***AMF*** ***induced*** robust translocation of ***PKCalpha*** to the stress fibers and cortical actin suggesting a critical role for this kinase in the generation of the motility signal .	target	1
21394	11089884	3553;290	IL-1beta;APN	Although ***IL-1beta*** significantly ***stimulated*** ***APN*** mRNA expression in both cell lines , it influenced the enzyme activity only in MG63 .	positive	0
21395	11089885	6275;7157	S100A4;p53	Since wild-type p53 is known to down regulate stathmin expression , we further postulate this might also involve ***S100A4-mediated*** ***sequestration*** of ***p53*** .	negative	0
21396	11089886	4233;3082	c-Met;hepatocyte growth factor	Several lines of evidence indicate that ***hepatocyte growth factor/scatter factor*** ( HGF/SF ) and its ***receptor*** , ***c-Met*** , may play an important role in progression of human glioma .	parallel	1
21397	11089886	4233;3082	c-Met;HGF	Since concomitant expression of ***HGF*** and its ***receptor*** ***c-Met*** are frequently observed in malignant gliomas , these results suggest that HGF/SF participates in invasive process of malignant glioma cells not only by its motility-stimulating activity but also through enhanced degradation of the extracellular matrix induced by autocrine activation of uPA proteolysis network .	parallel	1
21398	11089917	4023;1634	LpL;decorin	Regardless of the presence or absence of LDL , ***LpL*** ***stimulated*** the endocytosis of ***decorin*** 1.5-fold , whereas LpL mediated a 4-fold stimulation of LDL uptake in the absence of decorin .	positive	0
21399	11089976	10987;4282	Jab1;MIF	We conclude that MIF may act broadly to negatively regulate Jab1-controlled pathways and that the ******MIF-Jab1****** ***interaction*** may provide a molecular basis for key activities of MIF .	parallel	1
21400	11089976	4282;10987	MIF;Jab1	Here we show that ***MIF*** specifically ***interacts*** with an intracellular protein , ***Jab1*** , which is a coactivator of AP-1 transcription that also promotes degradation of the cyclin-dependent kinase inhibitor p27Kip1 ( ref .	parallel	1
21401	11089976	10987;3725	Jab1;AP-1	Here we show that MIF specifically interacts with an intracellular protein , ***Jab1*** , which is a ***coactivator*** of ***AP-1*** transcription that also promotes degradation of the cyclin-dependent kinase inhibitor p27Kip1 ( ref .	positive	1
21402	11089976	4282;10987	MIF;Jab1	MIF colocalizes with Jab1 in the cytosol , and both endogenous and exogenously added ***MIF*** following endocytosis ***bind*** ***Jab1*** .	parallel	1
21403	11089976	10987;3725	Jab1;c-Jun	***Jab1*** activates c-Jun amino-terminal kinase ( JNK ) activity and ***enhances*** endogenous ***phospho-c-Jun*** levels , and MIF inhibits these effects .	positive	0
21404	11090054	4254;3815	Steel Factor;c-Kit	Differential ***stimulation*** of ***c-Kit*** mutants by membrane-bound and soluble ***Steel Factor*** correlates with leukemic potential .	positive	0
21405	11090061	51206;2207	GPVI;FcR gamma	Roles of SLP-76 , phosphoinositide 3-kinase , and gelsolin in the platelet shape changes initiated by the collagen receptor ******GPVI/FcR gamma-chain****** ***complex*** .	parallel	1
21406	11090061	51206;2207	GPVI;FcR gamma	How platelet shape change initiated by a collagen-related peptide ( CRP ) specific for the ******GPVI/FcR gamma-chain****** ***complex*** ( GPVI/FcR gamma-chain ) is coupled to SLP-76 , phosphoinositide ( PI ) 3-kinase , and gelsolin is reported .	parallel	1
21407	11090063	958;7422	CD40;vascular endothelial growth factor	Ligation of ***CD40*** ***induces*** the expression of ***vascular endothelial growth factor*** by endothelial cells and monocytes and promotes angiogenesis in vivo .	target	1
21408	11090063	958;959	CD40;CD40L	Taken together , these findings are consistent with a function for ******CD40L-CD40****** ***interactions*** in VEGF-induced angiogenesis and define a mechanistic link between the immune response and angiogenesis .	parallel	1
21409	11090068	3565;10344	IL-4;iMac	Whereas culture with the cytokine interleukin 4 ( ***IL-4*** ) ***increased*** ***iMac*** inhibitory activity , these cells could be differentiated into a nonadherent population of fully mature and highly activated dendritic cells when cultured in the presence of IL-4 and GM-CSF .	positive	0
21410	11090070	7040;241	TGF-beta-1;FLAP	***TGF-beta-1*** further ***increased*** 5-LO and ***FLAP*** expression , recruited additional cells into the 5-LO ( + ) DC population , and promoted production of 5-hydroxyeicosatetraenoic acid and leukotriene B ( 4 ) in response to calcium ( Ca ( + + ) ) ionophore A23187 .	positive	0
21411	11090074	4297;3204	MLL;HoxA7	The R4 domain demonstrates potent transcriptional activation properties and is required for ***transactivation*** of a ***HoxA7*** promoter by ***MLL-ELL*** in a transient transcriptional assay .	positive	1
21412	11090075	5914;8900	RAR alpha;cyclin A1	Further studies using ligands selective for various retinoic acid receptors suggested that ***cyclin A1*** expression is negatively ***regulated*** by activated ***RAR alpha*** .	negative	1
21413	11090081	862;5914	ETO;RAR alpha	Finally , ***ETO*** ***interacted*** with ***PLZF/RAR alpha*** and enhanced its ability to repress through the RARE .	parallel	1
21414	11090084	7124;1235	TNF-alpha;CCR6	Among recombinant cytokines , ***TNF-alpha*** ***induced*** high levels of ***CCR6*** mRNA expression , whereas interferon ( IFN ) - gamma induced low levels .	target	1
21415	11090097	2837;10911	GPR14;U-II	Urotensin-II ( ***U-II*** ) and its G-protein-coupled ***receptor*** , ***GPR14*** , are expressed within mammalian cardiac and peripheral vascular tissue and , as such , may regulate mammalian cardiovascular function .	parallel	1
21416	11090138	920;3700	CD4 receptor;gp120	Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 ******gp120-CD4 receptor****** ***complex*** .	parallel	1
21417	11090138	920;3700	CD4;gp120	One such intermediate , the ******gp120-CD4****** ***complex*** , arises from the interaction of gp120 with the CD4 receptor and enables interactions with specific coreceptors needed for viral entry .	parallel	1
21418	11090138	3700;920	gp120;CD4 receptor	One such intermediate , the gp120-CD4 complex , arises from the ***interaction*** of ***gp120*** with the ***CD4 receptor*** and enables interactions with specific coreceptors needed for viral entry .	parallel	1
21419	11090138	920;3700	CD4;gp120	The development of such strategies would be greatly facilitated by a means to produce the ******gp120-CD4****** ***complexes*** in a wide variety of contexts .	parallel	1
21420	11090138	920;3700	CD4;gp120	Accordingly , we have developed single-chain polypeptide analogues that accurately replicate structural , functional , and antigenic features of the ******gp120-CD4****** ***complex*** .	parallel	1
21421	11090199	8862;187	Apelin;APJ	***Apelin*** , the natural ***ligand*** of the orphan seven-transmembrane receptor ***APJ*** , inhibits human immunodeficiency virus type 1 entry .	parallel	1
21422	11090202	2033;1387	p300;CBP	We demonstrate that a Tax mutant defective for the ******CBP/p300****** ***interaction*** retains the capacity to immortalize primary human T lymphocytes when it is expressed from a functional molecular clone of HTLV-1 .	parallel	1
21423	11090428	4908;1956	NT3;epidermal growth factor receptor	nerve growth factor and NT3 alone or in combination inhibited expression of mRNA for TGF alpha while ***NT3*** ***increased*** mRNA expression of ***epidermal growth factor receptor*** .	positive	0
21424	11090440	3552;3371	interleukin-1 alpha;TN-C	Addition of ***interleukin-1 alpha*** ( IL-1 alpha ) and prostaglandin E ( 2 ) ( PGE ( 2 ) ) and F ( 2 alpha ) ( PGF ( 2 alpha ) ) ***induced*** ***TN-C*** expression in the stromal cells at both protein and mRNA levels , while the sex steroid hormones , progesterone and ss-estradiol , exerted little effect .	target	1
21425	11090458	2798;2796	GnRH-R;GnRH	A full-length cDNA encoding a ***GnRH*** ***receptor*** ( ***GnRH-R*** ) has been obtained from the brain of rainbow trout .	parallel	1
21426	11090630	3660;3456	IRF-2;IFN-beta	We show that the ***IRF-2*** oncoprotein ***represses*** virus-induced ***IFN-beta*** gene transcription via a novel mechanism .	negative	1
21427	11090630	100616496;1977	Pol;CBP	Enhanceosomes bearing IRF-2 can not activate transcription , due to the presence of a domain in IRF-2 that prevents enhanceosome-dependent recruitment of the ******CBP-Pol****** II holoenzyme ***complex*** .	parallel	1
21428	11090945	3553;4790	IL-1beta;NF-kappaB	We demonstrated that ***NF-kappaB*** ***activation*** by ***IL-1beta*** follows three distinct cell-specific pathways .	positive	1
21429	11090984	4792;4790	IkappaBalpha;NF-kappaB	GCs increased the expression of ***IkappaBalpha*** , the physiological ***inhibitor*** of ***NF-kappaB*** .	negative	1
21430	11091071	652;650	Bmp4;Bmp2	Transgenically ectopic expression of ***Bmp4*** to the Msx1 mutant dental mesenchyme restores downstream gene expression but ***represses*** Shh and ***Bmp2*** in the enamel knot of wild type tooth germ .	negative	1
21431	11091071	652;6469	Bmp4;Shh	Transgenically ectopic expression of ***Bmp4*** to the Msx1 mutant dental mesenchyme restores downstream gene expression but ***represses*** ***Shh*** and Bmp2 in the enamel knot of wild type tooth germ .	negative	1
21432	11091071	652;650	Bmp4;Bmp2	In contrast , overexpression of ***Bmp4*** in the wild type molar mesenchyme ***down-regulated*** Shh and ***Bmp2*** expression in the enamel knot , the putative signaling center for tooth patterning , but did not produce a tooth phenotype .	negative	1
21433	11091071	652;6469	Bmp4;Shh	In contrast , overexpression of ***Bmp4*** in the wild type molar mesenchyme ***down-regulated*** ***Shh*** and Bmp2 expression in the enamel knot , the putative signaling center for tooth patterning , but did not produce a tooth phenotype .	negative	1
21434	11091139	5604;5609	MEK-1;MEK	In fMLP-responsive cells , the ***MEK-1*** / 2 inhibitor PD098059 ( 50 microM ) ***attenuated*** ***MEK*** phosphorylation and abolished 5-LO activation at the translocation step .	negative	0
21435	11091218	1440;1441	Granulocyte colony-stimulating factor;CD114	***Granulocyte colony-stimulating factor*** ( G-CSF ) ***downregulates*** its receptor ( ***CD114*** ) on neutrophils and induces gelatinase B release in humans .	negative	1
21436	11091218	1440;1441	G-CSF;CD114	***G-CSF*** dose-independently induced profound neutropenia ( > 95 % ) within minutes and ***downregulated*** its own receptor ( ***CD114*** ) on neutrophils by 75 % .	negative	1
21437	11091218	1441;1440	CD114;G-CSF	The ******G-CSF/CD114****** ***interaction*** dose-independently induced degranulation of neutrophils as evidenced by a 300-400 % increase in CD11b expression .	parallel	1
21438	11091227	3553;4778	IL-1beta;NF-E2	This study demonstrated for the first time the presence of IL-1 receptors on megakaryocytic cells and the ***induction*** of ***NF-E2*** by ***IL-1beta*** .	target	1
21439	11091275	3569;7040	IL-6;TGF-beta	We therefore conclude that ***IL-6*** plays an important role in bacterial clearance and directly ***influences*** the ***TGF-beta*** levels in experimental acute pyelonephritis .	target	0
21440	11091361	3211;3198	HOXB1;HOXA1	No statistically significant effects were detected when the same analyses were applied to the HOXB1 locus , but there was evidence of an ***interaction*** between ***HOXA1*** , ***HOXB1*** , and gender in susceptibility to ASDs .	parallel	1
21441	11092395	5744;3381	PTHrP;BSP	***PTHrP*** stimulation ***repressed*** mRNA expression of ***BSP*** and OCN in CMs and blocked CM-mediated mineralization , in vitro .	negative	1
21442	11092396	4323;4313	MMP-14;MMP-2	Developmentally associated changes in the activation of MMP-2 are detected , associated in their timing with the expression of MMP-14 in both populations of ROB , and ***MMP-14*** ***activates*** ***pro-MMP-2*** in vitro .	positive	1
21443	11092501	5444;4018	PON1;lipoprotein	Human serum paraoxonase ( ***PON1*** ) is ***associated*** with high-density ***lipoprotein*** ( HDL ) and inhibits the oxidation of low-density lipoprotein ( LDL ) in vitro , suggesting that PON1 protects against atherosclerosis .	parallel	0
21444	11092501	5444;4018	PON1;lipoprotein	Human serum paraoxonase ( ***PON1*** ) is associated with high-density lipoprotein ( HDL ) and ***inhibits*** the oxidation of low-density ***lipoprotein*** ( LDL ) in vitro , suggesting that PON1 protects against atherosclerosis .	negative	1
21445	11092515	3952;3953	Leptin;leptin receptor	***Leptin*** resistance is ***associated*** with hypothalamic ***leptin receptor*** mRNA and protein downregulation .	parallel	0
21446	11092515	3952;3953	Leptin;leptin receptor	We hypothesize that ***Leptin*** resistance is ***associated*** with hypothalamic ***leptin receptor*** downregulation .	parallel	0
21447	11092531	5617;1509	Prolactin;cathepsin B and D	***Prolactin*** ***up-regulates*** ***cathepsin B and D*** expression in minor salivary glands of patients with Sjögren 's syndrome .	positive	1
21448	11092683	3659;4843	IRF-1;iNOS	We propose that ***IRF-1*** may ***modulate*** the expression of cytokine-induced ***iNOS*** activity in differentiating enterocytes .	target	0
21449	11092768	64946;1059	CENP-H;CENP-B	In vitro binding assays of human CENP-H with centromere-kinetochore proteins suggest that the ***CENP-H*** ***binds*** to itself and MCAK , but not to CENP-A , ***CENP-B*** or CENP-C .	parallel	1
21450	11092768	64946;1060	CENP-H;CENP-C	In vitro binding assays of human CENP-H with centromere-kinetochore proteins suggest that the ***CENP-H*** ***binds*** to itself and MCAK , but not to CENP-A , CENP-B or ***CENP-C*** .	parallel	1
21451	11092808	7855;7480	Fzd5;Wnt10b	***Fzd5*** specifically ***synergized*** with Wnt2 , Wnt5a and ***Wnt10b*** in ectopic axis induction assays in Xenopus embryos .	parallel	0
21452	11092808	7855;7472	Fzd5;Wnt2	***Fzd5*** specifically ***synergized*** with ***Wnt2*** , Wnt5a and Wnt10b in ectopic axis induction assays in Xenopus embryos .	parallel	0
21453	11092808	7855;7474	Fzd5;Wnt5a	***Fzd5*** specifically ***synergized*** with Wnt2 , ***Wnt5a*** and Wnt10b in ectopic axis induction assays in Xenopus embryos .	parallel	0
21454	11092885	1051;5743	C/EBP beta;cyclooxygenase-2	Fluid shear stress-induced ***cyclooxygenase-2*** expression is ***mediated*** by ***C/EBP beta*** , cAMP-response element-binding protein , and AP-1 in osteoblastic MC3T3-E1 cells .	target	0
21455	11092985	7039;1806	TGF-alpha;DPD	The tumor environmental factors , EGF and ***TGF-alpha*** , may act as intrinsic ***regulators*** of ***DPD*** and PyNPase activities that affect the 5-FU sensitivity of individual tumors .	target	1
21456	11093032	355;3932	CD95;p56lck	Furthermore , osmotic cell shrinkage blunted the ***CD95-induced*** ***activation*** of the Src-like kinase ***p56lck*** .	positive	1
21457	11093125	3565;6347	IL-4;Monocyte chemotactic protein-1	***Monocyte chemotactic protein-1*** stimulates the killing of leishmania major by human monocytes , acts synergistically with IFN-gamma and is ***antagonized*** by ***IL-4*** .	negative	1
21458	11093125	3565;6347	IL-4;MCP-1	The data demonstrate that IFN-gamma and MCP-1 synergistically activate monocytes to clear intracellular parasites , whereas ***IL-4*** ***abrogates*** the effect of ***MCP-1*** .	negative	0
21459	11093125	3565;6347	IL-4;MCP-1	Furthermore , ***IL-4*** ***inhibits*** ***MCP-1*** expression by infected monocytes , a finding that may explain the lack of MCP-1 in chronic lesions .	negative	1
21460	11093138	959;958	CD40L;CD40	DC were also cultured with L cells expressing human ***CD40*** ***ligand*** ( ***CD40L*** ) .	parallel	1
21461	11093138	958;959	CD40;CD40L	Similar effects were observed when DC were cultured with CD40L-expressing transfectants , although the amount of IFN-alpha produced was reduced , suggesting that the ******CD40-CD40L****** ***interaction*** may be important .	parallel	1
21462	11093139	7434;7432	VPAC2;VIP	Both the type 1 VIP receptor ( VPAC1 ) agonist , [ K ( 15 ) , R ( 16 ) , L ( 27 ) ] VIP 1-7-GRF 8-27 , and the type 2 ***VIP*** ***receptor*** ( ***VPAC2*** ) agonist , Ro25-1553 , protected mice from lethal endotoxemia by inhibiting the macrophage-derived pro-inflammatory mediators IL-6 , TNF-alpha , IL-12 and NO , and by stimulating the production of the anti-inflammatory cytokine IL-10 .	parallel	1
21463	11093139	7433;7432	VPAC1;VIP	Both the type 1 ***VIP*** ***receptor*** ( ***VPAC1*** ) agonist , [ K ( 15 ) , R ( 16 ) , L ( 27 ) ] VIP 1-7-GRF 8-27 , and the type 2 VIP receptor ( VPAC2 ) agonist , Ro25-1553 , protected mice from lethal endotoxemia by inhibiting the macrophage-derived pro-inflammatory mediators IL-6 , TNF-alpha , IL-12 and NO , and by stimulating the production of the anti-inflammatory cytokine IL-10 .	parallel	1
21464	11093148	23607;914	CD2AP;CD2	CD3 stimulation is known to enhance CD2 avidity for its ligand and to induce the ***binding*** of the ***CD2AP*** protein to the ***CD2*** cytoplasmic tail .	parallel	1
21465	11093148	914;1796	CD2;p62Dok	Kinetic studies indicated that a short treatment with anti-CD3 was sufficient to amplify the ***CD2-induced*** tyrosine ***phosphorylation*** of ***p62Dok*** .	target	1
21466	11093148	1796;5335	p62Dok;PLCgamma-1	Finally , enhanced amounts of tyrosine phosphorylated ***p62Dok*** were ***recruited*** to p21RasGAP and ***PLCgamma-1*** after CD2 stimulation in CD3-activated cells .	target	0
21467	11093173	3565;6404	IL-4;CLA	In serum containing medium , ***IL-4*** ***inhibited*** ***CLA*** and related alpha-fucosyltransferase mRNA expression .	negative	1
21468	11093284	3952;2353	leptin;c-fos	***leptin*** ***increased*** ***c-fos*** mRNA expression by 2.8-fold in isolated fetal islets after 30 min treatment .	positive	0
21469	11093432	7124;5054	TNF-alpha;PAI-1	***TNF-alpha*** and IL-6 ***correlated*** positively with ***PAI-1*** and negatively with t-PA and D-dimer .	positive	0
21470	11093432	7124;5327	TNF-alpha;t-PA	***TNF-alpha*** and IL-6 ***correlated*** positively with PAI-1 and negatively with ***t-PA*** and D-dimer .	positive	0
21471	11093434	796;3569	CGRP;IL-6	RESULTS : In RA fibroblasts , ***CGRP*** ***increased*** ***IL-6*** and IL-8 secretion at 10 ( -10 ) to 10 ( -8 ) M ( p at least < 0.01 ) , which was not observed in OA fibroblasts .	positive	0
21472	11093434	796;3576	CGRP;IL-8	RESULTS : In RA fibroblasts , ***CGRP*** ***increased*** IL-6 and ***IL-8*** secretion at 10 ( -10 ) to 10 ( -8 ) M ( p at least < 0.01 ) , which was not observed in OA fibroblasts .	positive	0
21473	11093434	5443;3576	beta-endorphin;IL-8	In RA fibroblasts , ***beta-endorphin*** and MENK ***inhibited*** ***IL-8*** secretion at 10 ( -9 ) to 10 ( -7 ) M ( p < 0.01 ) , whereas in OA fibroblasts the dose response curve was shifted to lower concentrations ( 10 ( -12 ) M , 10 ( -11 ) M ; p < 0.01 ) .	negative	1
21474	11093732	6647;4790	SOD1;NF-kappaB	***SOD1*** blunted this increase and ***reduced*** the activation of ***NF-kappaB*** .	negative	1
21475	11093734	3553;4790	IL-1beta;NF-kappaB	Pretreatment with TNF-alpha or interleukin-1beta ( ***IL-1beta*** ) , which ***activated*** ***NF-kappaB*** in the liver , dramatically prevented TNF-alpha-induced liver-cell apoptosis in D-galactosamine ( GalN ) - sensitized mice , but not anti-fas antibody-induced hepatotoxicity .	positive	1
21476	11093734	7124;4790	TNF-alpha;NF-kappaB	Pretreatment with ***TNF-alpha*** or interleukin-1beta ( IL-1beta ) , which ***activated*** ***NF-kappaB*** in the liver , dramatically prevented TNF-alpha-induced liver-cell apoptosis in D-galactosamine ( GalN ) - sensitized mice , but not anti-fas antibody-induced hepatotoxicity .	positive	1
21477	11093734	7124;841	TNF-alpha;caspase-8	Prior ***TNF-alpha*** administration was not found to ***block*** the activation of ***caspase-8*** , although caspase-3 was inhibited in mice treated with TNF-alpha plus GalN/TNF-alpha compared with mice treated with GalN/TNF-alpha .	negative	0
21478	11093745	2305;4763	HNF3;NF1	Super-shift experiments indicated that HNF3beta was the major form of ***HNF3*** ***interacting*** with the ***HNF3/NF1*** site .	parallel	1
21479	11093761	10963;3312	p60;HSC54	The resonant mirror detection analysis showed that ***p60*** ***binds*** to ***HSC54*** with a higher association rate constant than HSC70 with a similar affinity constant .	parallel	1
21480	11093761	3312;3337	HSC54;HSP40	In pull-down experiments , ***HSC54*** ***interacted*** with cochaperones , p60 , ***HSP40*** , and p48 , as HSC70 did .	parallel	1
21481	11093761	3312;10963	HSC54;p60	In pull-down experiments , ***HSC54*** ***interacted*** with cochaperones , ***p60*** , HSP40 , and p48 , as HSC70 did .	parallel	1
21482	11093777	886;885	CCK-AR;cholecystokinin	It has previously been reported that the cholecystokinin analog JMV-180 behaves differently on the rat and the mouse ***cholecystokinin-A*** ***receptor*** ( ***CCK-AR*** ) .	parallel	1
21483	11093788	3551;3383	IKK2;ICAM-1	Dominant-negative PKCalpha , NIK , or ***IKK2*** , but not IKK1 mutant , ***inhibited*** IL-1beta - or TPA-induced ***ICAM-1*** promoter activity .	negative	1
21484	11093788	9020;3383	NIK;ICAM-1	Dominant-negative PKCalpha , ***NIK*** , or IKK2 , but not IKK1 mutant , ***inhibited*** IL-1beta - or TPA-induced ***ICAM-1*** promoter activity .	negative	1
21485	11093788	3553;3383	IL-1beta;ICAM-1	NF-kappaB DNA-protein binding and ***ICAM-1*** promoter activity were ***enhanced*** by ***IL-1beta*** and these effects were inhibited by tyrphostin 23 , but not by PD 98059 or SB 203580 .	positive	0
21486	11093788	3553;4790	IL-1beta;NF-kappaB	***NF-kappaB*** DNA-protein binding and ICAM-1 promoter activity were ***enhanced*** by ***IL-1beta*** and these effects were inhibited by tyrphostin 23 , but not by PD 98059 or SB 203580 .	positive	0
21487	11093792	196;3320	AhR;hsp90	We hypothesized that this conserved domain B region may be involved with mediating ***interactions*** between either ***AhR-hsp90*** , ***AhR-XAP2*** , and/or AhR-AhR nuclear translocator protein .	parallel	1
21488	11093792	706;196	translocator protein;AhR	We hypothesized that this conserved domain B region may be involved with mediating ***interactions*** between either AhR-hsp90 , ***AhR-XAP2*** , and/or AhR-AhR nuclear ***translocator protein*** .	parallel	1
21489	11093792	706;3320	translocator protein;hsp90	We hypothesized that this conserved domain B region may be involved with mediating ***interactions*** between either ***AhR-hsp90*** , AhR-XAP2 , and/or AhR-AhR nuclear ***translocator protein*** .	parallel	1
21490	11093792	706;9049	translocator protein;XAP2	We hypothesized that this conserved domain B region may be involved with mediating ***interactions*** between either AhR-hsp90 , ***AhR-XAP2*** , and/or AhR-AhR nuclear ***translocator protein*** .	parallel	1
21491	11093792	9049;196	XAP2;AhR	We hypothesized that this conserved domain B region may be involved with mediating ***interactions*** between either AhR-hsp90 , ******AhR-XAP2****** , and/or AhR-AhR nuclear translocator protein .	parallel	1
21492	11093792	9049;3320	XAP2;hsp90	We hypothesized that this conserved domain B region may be involved with mediating ***interactions*** between either ***AhR-hsp90*** , ***AhR-XAP2*** , and/or AhR-AhR nuclear translocator protein .	parallel	1
21493	11093792	196;3320	AhR;hsp90	The inability of A78D and the reduction of A82F to trans-activate XRE-driven reporter activity did not result from impaired ******AhR-XAP2-hsp90****** ***interactions*** , TCDD-dependent AhR translocation to the nucleus , or AhR-AhR nuclear translocator protein interactions .	parallel	1
21494	11093792	9049;196	XAP2;AhR	The inability of A78D and the reduction of A82F to trans-activate XRE-driven reporter activity did not result from impaired ******AhR-XAP2-hsp90****** ***interactions*** , TCDD-dependent AhR translocation to the nucleus , or AhR-AhR nuclear translocator protein interactions .	parallel	1
21495	11093792	9049;3320	XAP2;hsp90	The inability of A78D and the reduction of A82F to trans-activate XRE-driven reporter activity did not result from impaired ******AhR-XAP2-hsp90****** ***interactions*** , TCDD-dependent AhR translocation to the nucleus , or AhR-AhR nuclear translocator protein interactions .	parallel	1
21496	11093920	3741;4624	Kv1.5;alpha-MHC	Although beta-MHC and ***Kv1.5*** mRNA content was returned to ***control*** levels , ***alpha-MHC*** and SERCA2 were unresponsive to T ( 3 ) at replacement doses , and only at higher doses of T ( 3 ) was alpha-MHC mRNA returned to control values .	target	0
21497	11093952	5970;4790	p65;p50	Immunohistochemical , immunoblot , and DNA binding analyses indicate that NF-kappaB complexes change as colonocytes mature : ******p65-p50****** ***complexes*** predominate in proliferating epithelial cells of the colon , whereas the p50-p50 dimer is prevalent in mature epithelial cells .	parallel	1
21498	11094063	5970;4790	p65;p50	A natural polymorphism at nucleotide -863 in the human TNF promoter ( encoding tumor necrosis factor [ TNF ] ) region provides an opportunity to dissect the functional ***interaction*** of ******p65-p50****** and p50-p50 at a single NF-kappaB binding site .	parallel	1
21499	11094063	4790;5970	p50;p65	This finding adds to a growing body of experimental evidence that ***p50-p50*** can ***inhibit*** the transactivating effects of ***p65-p50*** and illustrates the potential for genetic modulation of inflammatory gene regulation in humans by subtle nucleotide changes that alter the relative binding affinities of different forms of the NF-kappaB complex .	negative	1
21500	11094066	3562;10671	IL-3;p27	***IL-3*** was found to ***repress*** the expression of the cyclin-dependent kinase inhibitor ***p27*** ( KIP1 ) through activation of PI3K , and this occurs at the level of transcription .	negative	1
21501	11094067	5335;27040	PLC-gamma1;LAT	On the other hand , the amino-terminal SH2 [ SH2 ( N ) ] domain was not essential for reconstitution of RE/AP - or IL-2 promoter-dependent transcription but was required for the ***association*** of ***PLC-gamma1*** with ***LAT*** , as well as the tyrosine phosphorylation of PLC-gamma1 itself , in activated P98 cells .	parallel	0
21502	11094072	4602;5897	c-Myb;RAG-2	Finally , this lack of ***binding*** of ***c-Myb*** to a chromosomally integrated mutant ***RAG-2*** promoter construct in vivo was associated with a striking decrease in promoter activity .	parallel	1
21503	11094072	4602;5897	c-Myb;RAG-2	We conclude that ***c-Myb*** ***regulates*** the ***RAG-2*** promoter in T cells by binding to this consensus c-Myb binding site .	target	1
21504	11094072	5079;5897	BSAP;RAG-2	Previously , we reported that the transcription factor ***BSAP*** ( PAX-5 ) ***regulates*** the murine ***RAG-2*** promoter in B-cell lines .	target	1
21505	11094072	4602;5897	c-Myb;RAG-2	We show that ***c-Myb*** can ***transactivate*** a ***RAG-2*** promoter-reporter construct in cotransfection assays and that this transactivation depends on the proximal promoter Myb consensus site .	positive	1
21506	11094076	8720;998	S1P;Cdc42	Neither ***S1P*** nor IGF I ***increased*** the amount of GTP-bound ***Cdc42*** .	positive	0
21507	11094076	8720;207	S1P;Rac	In EDG5 cells , ***S1P*** stimulated PI 3-kinase activity as it did in EDG1 cells but ***inhibited*** the basal ***Rac*** activity and totally abolished IGF I-induced Rac activation , which involved stimulation of Rac-GTPase-activating protein activity rather than inhibition of Rac-guanine nucleotide exchange activity .	negative	1
21508	11094082	55870;1387	ASH1;CREB-binding protein	Functional ***interaction*** between the coactivator Drosophila ***CREB-binding protein*** and ***ASH1*** , a member of the trithorax group of chromatin modifiers .	parallel	1
21509	11094085	9146;4087	Hgs;Smad2	We demonstrated that ***Hgs*** , a FYVE domain protein , ***binds*** to ***Smad2*** in its C-terminal half and cooperates with another FYVE domain protein , the Smad anchor for receptor activation ( SARA ) , to stimulate activin receptor-mediated signaling through efficient recruitment of Smad2 to the receptor .	parallel	1
21510	11094148	348;4137	apolipoprotein E;tau	Previously published data have shown an allele-specific variation in the in vitro ***binding*** of ***apolipoprotein E*** ( apoE ) to ***tau*** , which prompted the hypothesis that apoE binding may protect tau from phosphorylation , apoE3 being more efficient than apoE4 .	parallel	1
21511	11094153	3565;836	IL-4;caspase-3	In addition , ***IL-4*** markedly ***increased*** activity of ***caspase-3*** , and inhibition of this enzyme suppressed IL-4-induced apoptosis in a dose-dependent manner .	positive	0
21512	11094332	3848;3827	cytokeratin 1;Kininogen	******Kininogen-cytokeratin 1****** ***interactions*** in endothelial cell biology .	parallel	1
21513	11094334	2621;558	Gas6;Axl receptor tyrosine kinase	In this review , we consider the experimental evidence pointing to significant roles for the ***Axl receptor tyrosine kinase*** and its ***ligand*** , ***Gas6*** , in the vasculature .	parallel	1
21514	11094334	558;2621	Axl;Gas6	We conclude by discussing mechanisms by which ******Gas6/Axl****** ***signaling*** may impact on the response of blood vessels to injury , thereby contributing to the development of atherosclerosis and/or restenosis .	parallel	0
21515	11094862	7040;7157	TGF-beta;p53	***TGF-beta*** also ***enhanced*** the MC expression of ***p53*** .	positive	0
21516	11094865	3479;2673	IGF-1;GFA	CONCLUSIONS : ***GFA*** activity is ***downregulated*** by HG , TGF-beta , and ***IGF-1*** in rat MCs .	negative	1
21517	11094865	7040;2673	TGF-beta;GFA	CONCLUSIONS : ***GFA*** activity is ***downregulated*** by HG , ***TGF-beta*** , and IGF-1 in rat MCs .	negative	1
21518	11094865	7040;2673	TGF-beta;GFA	METHODS : Because of the known effects of hyperglycemia on mesangial cell ( MC ) function and growth factor regulation , we examined the ***regulation*** of ***GFA*** by glucose and ***TGF-beta*** in cultured SV40 rat MCs .	target	1
21519	11094865	7040;2673	TGF-beta;GFA	***TGF-beta-mediated*** ***downregulation*** of ***GFA*** activity was inhibited by a TGF-beta-neutralizing antibody , but HG 's effects were not .	negative	1
21520	11095245	596;1026	bcl-2;p21	Neither did expression of ***bcl-2*** ***interfere*** with p53-induced expression of endogenous ***p21*** , suggesting that p53-induced differentiation might be dependent on the transcriptional activity of p53 .	negative	0
21521	11095246	7076;4318	Epo;MMP-9	Our findings strongly suggest an inversely coordinated ***regulation*** of the TIMP-1 gene and ***MMP-9*** production by ***Epo*** via mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways .	target	1
21522	11095407	355;356	Fas;FasL	However , soluble Fas ( sFas ) blocks apoptosis by inhibiting ***binding*** between ***Fas*** and ***FasL*** or sFasL .	parallel	1
21523	11095465	3482;3481	IGF2R;IGF-II	Experimental rodent studies demonstrate that insulin-like growth factor II ( IGF-II ) promotes fetal growth , whereas the nonsignaling ***IGF-II*** ***receptor*** ( ***IGF2R*** ) is inhibitory ; in humans their influence is as yet unclear .	parallel	1
21524	11095465	3482;3481	IGF2R;IGF-II	A soluble , circulating form of ***IGF2R*** ***inhibits*** ***IGF-II*** mediated DNA synthesis and may therefore restrain fetal growth .	negative	1
21525	11095465	3481;3482	IGF-II;IGF2R	***IGF-II*** levels ***correlated*** with levels of IGF-I ( r = 0.29 ; P < 0.0005 ) , IGFBP-3 ( r = 0.45 ; P < 0.0005 ) , and soluble ***IGF2R*** ( r = 0.20 ; P < 0.005 ) .	parallel	0
21526	11095465	3481;3486	IGF-II;IGFBP-3	***IGF-II*** levels ***correlated*** with levels of IGF-I ( r = 0.29 ; P < 0.0005 ) , ***IGFBP-3*** ( r = 0.45 ; P < 0.0005 ) , and soluble IGF2R ( r = 0.20 ; P < 0.005 ) .	parallel	0
21527	11095465	3481;3479	IGF-II;IGF-I	***IGF-II*** levels ***correlated*** with levels of ***IGF-I*** ( r = 0.29 ; P < 0.0005 ) , IGFBP-3 ( r = 0.45 ; P < 0.0005 ) , and soluble IGF2R ( r = 0.20 ; P < 0.005 ) .	parallel	0
21528	11095470	1375;5468	mCPT1;PPAR-gamma	The expression of LPL ( r2 = 0.54 ; P = 0.003 ) , ***mCPT1*** ( r2 = 0.42 ; P = 0.012 ) , and FABP ( r2 = 0.324 ; P = 0.034 ) all ***correlated*** significantly with ***PPAR-gamma*** expression in the same samples .	parallel	0
21529	11095471	3952;1081	Leptin;hCG	Furthermore , release of ***Leptin*** into the fetal circulation was positively ***correlated*** with release of fetal ***hCG*** ( r = 0.661 ; P < 0.05 ) .	positive	0
21530	11095472	7010;284	tie-2;Ang-1	The aim of this study was to investigate the localization of ***Ang-1*** , Ang-2 , their common ***receptor*** ***tie-2*** , and VEGF messenger ribonucleic acid ( mRNA ) at the different stages of the functional luteal phase and after rescue by hCG .	parallel	1
21531	11095473	3486;3483	IGFBP-3;ALS	In the circulation insulin-like growth factor I ( IGF-I ) , IGF-binding protein 3 ( ***IGFBP-3*** ) , and the acid-labile subunit ( ***ALS*** ) form a 150-kDa ternary ***complex*** that is of importance for the regulation of IGF-I bioactivity .	parallel	1
21532	11095491	3060;80303	orexin;SWS2	Compared to saline vehicle control , ***orexin-A*** induced an increase in wakefulness for 70 min and ***suppressed*** all sleep stages , especially ***SWS2*** and REM for 80 and 90 min , respectively .	negative	1
21533	11095498	4803;4843	nerve growth factor;iNOS	Tumor necrosis factor-alpha and ***nerve growth factor*** synergistically ***induce*** ***iNOS*** in pheochromocytoma cells .	target	1
21534	11095498	7124;4843	Tumor necrosis factor-alpha;iNOS	***Tumor necrosis factor-alpha*** and nerve growth factor synergistically ***induce*** ***iNOS*** in pheochromocytoma cells .	target	1
21535	11095498	7124;4843	Tumor necrosis factor-alpha;iNOS	Inducible nitric oxide synthase ( ***iNOS*** ) has been reported in tangle-bearing neurons of patients with Alzheimer 's disease ( AD ) , and can be ***induced*** by ***Tumor necrosis factor-alpha*** ( TNFalpha ) .	target	1
21536	11095498	4803;4843	NGF;iNOS	Our results suggest that synergistic ***iNOS*** ***induction*** by TNFalpha and ***NGF*** may occur in selective population of NGF-responsive neurons in the presence of elevated CNS levels of TNFalpha .	target	1
21537	11095498	7124;4843	TNFalpha;iNOS	Our results suggest that synergistic ***iNOS*** ***induction*** by ***TNFalpha*** and NGF may occur in selective population of NGF-responsive neurons in the presence of elevated CNS levels of TNFalpha .	target	1
21538	11095525	79109;4915	SIN-1;TrkB	***TrkB*** ***phosphorylation*** by ***SIN-1*** was blocked by superoxide dismutase , which converts O2 to H2O2 and prevents its reaction with NO to form peroxynitrite , and by K252a , an inhibitor of TrkB phosphorylation by BDNF .	target	1
21539	11095525	79109;5335	SIN-1;PLC-gamma1	***SIN-1*** treatment ***induced*** tyrosine phosphorylation of phospholipase C-gamma1 ( ***PLC-gamma1*** ) and induced its binding with activated TrkB , similar to that seen with BDNF downstream signaling pathways .	target	1
21540	11095618	4233;3082	c-Met;Hepatocyte growth factor	PURPOSE : ***Hepatocyte growth factor*** ( HGF ) and its ***receptor*** ***c-Met*** perform a multitude of functions .	parallel	1
21541	11095640	5716;4036	ankyrin repeat protein;megalin	Characterization of ANKRA , a novel ***ankyrin repeat protein*** that ***interacts*** with the cytoplasmic domain of ***megalin*** .	parallel	1
21542	11095640	57763;4036	ANKRA;megalin	***ANKRA*** ***interacts*** with ***megalin*** but not with low-density lipoprotein receptor related protein , in keeping with the fact that the sequence of the megalin tail is unique .	parallel	1
21543	11095644	3082;4916	HGF;tyrosine kinase receptor c	***HGF*** ***activates*** the ***tyrosine kinase receptor c-met*** , initiating a series of complex events that regulate cell morphology , cell-cell interactions , and cell-matrix interactions and eventually result in the formation of branching tubular structures .	positive	1
21544	11095645	5609;5594	MEK;ERK	To clarify the role of ERK activation , mouse mesangial cells were exposed to normal ( 5.5 mM ) or high ( 25 mM ) glucose with or without addition of PD98059 , a specific inhibitor of MAPK/ERK kinase ( ***MEK*** ) , an upstream kinase ***activator*** of ***ERK*** .	positive	1
21545	11095645	1843;7040	CL 100;TGF-beta1	Overexpression of MAPK phosphatase ***CL 100*** ***prevented*** ***TGF-beta1*** promoter activation by high glucose , confirming the involvement of the MEK-ERK pathway in response to high glucose .	negative	0
21546	11095646	729230;6347	chemokine receptor 2;monocyte chemoattractant protein-1	Expression of the chemokine ***monocyte chemoattractant protein-1*** and its ***receptor*** ***chemokine receptor 2*** in human crescentic glomerulonephritis .	parallel	1
21547	11095646	729230;6347	CCR2B;monocyte chemoattractant protein-1	Therefore , the expression of ***monocyte chemoattractant protein-1*** ( MCP-1 ) , its ***receptor*** chemokine receptor 2B ( ***CCR2B*** ) , and CCR5 in human cGN was studied .	parallel	1
21548	11095689	55388;4999	HsMcm10;Orc2	***HsMcm10*** ***associated*** with human ***Orc2*** protein when overexpressed in COS-1 cells .	parallel	0
21549	11095689	55388;4171	HsMcm10;Mcm2	***HsMcm10*** also ***interacted*** with Orc2 , ***Mcm2*** and Mcm6 proteins in the yeast two-hybrid system .	parallel	1
21550	11095689	55388;4175	HsMcm10;Mcm6	***HsMcm10*** also ***interacted*** with Orc2 , Mcm2 and ***Mcm6*** proteins in the yeast two-hybrid system .	parallel	1
21551	11095689	55388;4999	HsMcm10;Orc2	***HsMcm10*** also ***interacted*** with ***Orc2*** , Mcm2 and Mcm6 proteins in the yeast two-hybrid system .	parallel	1
21552	11095741	3439;4790	IFNalpha;NF-kappaB	We show that ***IFNalpha/beta*** ***activates*** another important transcription factor , ***NF-kappaB*** .	positive	1
21553	11095741	3439;4790	IFNalpha;NF-kappaB	We conclude that ***NF-kappaB*** ***activation*** by ***IFNalpha/beta*** is integrated into a signaling pathway through the IFNalpha/beta receptor-1 chain of the type 1 IFN receptor that promotes cell survival in apposition to various apoptotic stimuli .	positive	1
21554	11095929	7037;7018	TfR;transferrin	Whereas ***transferrin*** ***receptor*** ( ***TfR*** ) is responsible for iron uptake from maternal serum by the syncytiotrophoblast , the proteins responsible for intracytoplasmic transport and for delivery to the fetal serum remain unknown .	parallel	1
21555	11095942	7078;8038	TIMP-3;ADAM 12	***ADAM 12-S*** cleaves IGFBP-3 and IGFBP-5 and is ***inhibited*** by ***TIMP-3*** .	negative	1
21556	11095942	8038;3486	ADAM 12;IGFBP-3	***ADAM 12-S*** ***cleaves*** ***IGFBP-3*** and IGFBP-5 and is inhibited by TIMP-3 .	target	1
21557	11095942	8038;3488	ADAM 12;IGFBP-5	***ADAM 12-S*** ***cleaves*** IGFBP-3 and ***IGFBP-5*** and is inhibited by TIMP-3 .	target	1
21558	11095942	8038;3488	ADAM 12;IGFBP-5	Furthermore , we tested for proteolysis of other members of the IGF binding protein family and found that ***ADAM 12-S*** ***cleaves*** ***IGFBP-5*** in addition to IGFBP-3 , but does not cleave IGFBP-1 , -2 , -4 , or -6 .	target	1
21559	11095942	8038;3488	ADAM 12;IGFBP-3 and -5	***Cleavage*** of both ***IGFBP-3 and -5*** by ***ADAM 12-S*** was inhibited by TIMP-3 , raising the possibility that TIMP-3 is a physiological inhibitor of ADAM 12-S .	target	1
21560	11095942	7078;8038	TIMP-3;ADAM 12	Cleavage of both IGFBP-3 and -5 by ADAM 12-S was inhibited by TIMP-3 , raising the possibility that ***TIMP-3*** is a physiological ***inhibitor*** of ***ADAM 12-S*** .	negative	1
21561	11095942	7078;3488	TIMP-3;IGFBP-3 and -5	Cleavage of both ***IGFBP-3 and -5*** by ADAM 12-S was ***inhibited*** by ***TIMP-3*** , raising the possibility that TIMP-3 is a physiological inhibitor of ADAM 12-S .	negative	1
21562	11095944	5747;5829	FAK;paxillin	***FAK*** was ***associated*** with fibronectin and ***paxillin*** , which were maximal at day 3 of culture .	parallel	0
21563	11095963	5621;23627	PrP;Dpl	A prediction that ***PrP*** will ***interact*** with the PrP-like protein ( ***Dpl*** ) to form a heterodimer , but that Dpl will not form a homodimer , can be tested .	parallel	1
21564	11095974	7020;1475	AP-2;cystatin A	We report ***AP-2-dependent*** transcriptional ***regulation*** of ***cystatin A*** gene expression of keratinocytes .	target	1
21565	11095980	4803;1432	NGF;p38	***NGF*** withdrawal ***induces*** ***p38*** MAPK , but not JNK , activation in CESS cells , and SB203580 , a specific inhibitor of p38 MAPK , is able to prevent both Bcl-2 phosphorylation and apoptosis , indicating that p38 MAPK is the enzyme responsible for these events .	target	1
21566	11096063	940;942	CD28;B7-2	The increase of NF-kappa B activity was abolished when infection with B7-2-bearing HIV-1 particles was performed in the presence of the fusion protein CTLA-4 Ig suggesting that the ***interaction*** between virally embedded ***B7-2*** and ***CD28*** on the target cell is responsible for the observed NF-kappa B induction .	parallel	1
21567	11096073	5829;8874	paxillin;PAK3	We show here that ***paxillin*** can ***bind*** directly to ***PAK3*** .	parallel	1
21568	11096075	7157;983	p53;cdk1	Furthermore , a dominant-negative ***p53*** protein , impairing doxorubicin-induced G2 arrest , ***prevents*** transcriptional down-regulation of the mitotic cyclins , ***cdk1*** , and cdc25C genes .	negative	0
21569	11096076	5859;4217	glutaminyl-tRNA synthetase;apoptosis signal-regulating kinase 1	Glutamine-dependent antiapoptotic ***interaction*** of human ***glutaminyl-tRNA synthetase*** with ***apoptosis signal-regulating kinase 1*** .	parallel	1
21570	11096076	355;4217	Fas;apoptosis signal-regulating kinase 1	***Fas*** ligation ***activated*** ***apoptosis signal-regulating kinase 1*** ( ASK1 ) and c-Jun N-terminal kinase ( JNK ; also known as stress-activated protein kinase ( SAPK ) ) in Gln-deprived cells but not in normal cells , suggesting that Gln might be involved in the activity control of ASK1 and JNK/SAPK .	positive	1
21571	11096076	4217;5859	ASK1;glutaminyl-tRNA synthetase	As one of the possible mechanisms for the suppressive effect of Gln on ASK1 , we investigated the molecular ***interaction*** between human ***glutaminyl-tRNA synthetase*** ( QRS ) and ***ASK1*** and found the Gln-dependent association of the two molecules .	parallel	1
21572	11096084	847;5594	Catalase;p38	***Catalase*** ***inhibited*** phosphorylation of ERKs and ***p38*** kinase , as well as AP-1 activation induced by FFSi , suggesting the involvement of H ( 2 ) O ( 2 ) in the mechanism of silica-induced AP-1 activation .	negative	1
21573	11096089	6908;2959	TBP;TFIIB	The sequence of the TATA box and the sequences that flank it can influence the kinetics of the ******TFIIB.TBP.DNA****** ***complex*** .	parallel	1
21574	11096091	7157;5243	p53;mdr1	The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that ***mdr1*** is transcriptionally ***up-regulated*** by ***p53*** in response to DNA damage .	positive	1
21575	11096091	5243;196	mdr1;AhR	This increase is not observed in the Aromatic hydrocarbon receptor ( AhR ) - defective TAOc1BP ( r ) c1 and the AhR nuclear translocator ( Arnt ) - defective BP ( r ) c1 variants , demonstrating that the induction of ***mdr1*** by 3-MC ***requires*** ***AhR.Arnt*** .	target	0
21576	11096091	7157;5243	p53;mdr1	Mutations in the p53 binding site abrogated induction of mdr1 by 3-MC , indicating that ***p53*** ***binding*** to the ***mdr1*** promoter is essential for the induction .	parallel	1
21577	11096091	7157;5243	p53;mdr1	These results indicate that the transcriptional induction of ***mdr1*** by 3-MC and benzo ( a ) pyrene is directly ***mediated*** by ***p53*** but that the metabolic activation of these compounds into reactive species is necessary to trigger p53 activation .	target	0
21578	11096118	134728;4790	SIMPL;NF-kappaB	Overexpression of SIMPL leads to the activation of NF-kappaB-dependent promoters , and inactivation of ***SIMPL*** ***inhibits*** IRAK/mPLK as well as tumor necrosis factor receptor type I-induced ***NF-kappaB*** activity .	positive	1
21579	11096118	134728;4790	SIMPL;NF-kappaB	Dominant inhibitory alleles of IkappaB kinase ( IKKalpha or IKKbeta ) block the ***activation*** of ***NF-kappaB*** by IRAK/mPLK and ***SIMPL*** .	positive	1
21580	11096118	134728;3551	SIMPL;IKKbeta	Moreover , dominant-negative ***SIMPL*** ***blocks*** IKKalpha - or ***IKKbeta-induced*** NF-kappaB activity .	negative	0
21581	11096118	134728;4790	SIMPL;NF-kappaB	Moreover , dominant-negative ***SIMPL*** ***blocks*** IKKalpha - or IKKbeta-induced ***NF-kappaB*** activity .	negative	0
21582	11096118	134728;4790	SIMPL;NF-kappaB	These results lead us to propose a model in which ***SIMPL*** functions to ***regulate*** ***NF-kappaB*** activity by linking IRAK/mPLK to IKKbeta/alpha-containing complexes .	target	1
21583	11096256	1493;940	CTLA-4;CD28	Lack of ***association*** between ******CD28/CTLA-4****** gene polymorphisms and atopic asthma in the Japanese population .	parallel	0
21584	11096256	940;1493	CD28;CTLA-4	Thus , the present study was unable to reveal any ***association*** between ******CTLA-4/CD28****** gene polymorphisms and atopic asthma in the Japanese population .	parallel	0
21585	11096344	3077;7037	HFE;TFR	The wild-type HH ( HFE ) protein complexes with the transferrin receptor ( TFR ) , and two ***HFE*** mutations ( Cys282Tyr and His63Asp ) have been found to ***increase*** the affinity of the ***TFR*** for transferrin resulting in an increased cellular uptake of iron .	negative	0
21586	11096344	7037;3077	TFR;HFE	In previous studies we found an ***interaction*** between ***HFE*** and ***TFR*** genotypes in multiple myeloma and breast and colorectal carcinomas .	parallel	1
21587	11096344	7037;3077	TFR;HFE	The same ******HFE-TFR****** ***interaction*** as in the previously studied neoplastic disorders was found .	parallel	1
21588	11096450	3725;3576	AP-1;IL-8	Also , point-mutation analysis indicated that mutation of NF-kappaB , ***AP-1*** , or NF-IL-6 binding sites significantly ***reduced*** or eliminated the constitutive ***IL-8*** promoter activity .	positive	1
21589	11096450	4790;3576	NF-kappaB;IL-8	Also , point-mutation analysis indicated that mutation of ***NF-kappaB*** , AP-1 , or NF-IL-6 binding sites significantly ***reduced*** or eliminated the constitutive ***IL-8*** promoter activity .	positive	1
21590	11096452	940;10346	CD28;Staf50	The interferon-inducible ***Staf50*** gene is ***downregulated*** during T cell costimulation by CD2 and ***CD28*** .	negative	1
21591	11096452	914;10346	CD2;Staf50	The interferon-inducible ***Staf50*** gene is ***downregulated*** during T cell costimulation by ***CD2*** and CD28 .	negative	1
21592	11096454	3456;3455	IFN-beta;IFNAR-1/2	The receptor blockade by mAb 51.44 and 234.28 resulted in the inhibition of IFN-alpha2a and ***IFN-beta-induced*** tyrosine ***phosphorylation*** of Jak1 , Tyk2 , Stat1/2/3 , and ***IFNAR-1/2*** and inhibition of IFN-stimulated gene factor 3 ( ISGF3 ) formation .	target	1
21593	11096454	3456;3716	IFN-beta;Jak1	The receptor blockade by mAb 51.44 and 234.28 resulted in the inhibition of IFN-alpha2a and ***IFN-beta-induced*** tyrosine ***phosphorylation*** of ***Jak1*** , Tyk2 , Stat1/2/3 , and IFNAR-1/2 and inhibition of IFN-stimulated gene factor 3 ( ISGF3 ) formation .	target	1
21594	11096454	3456;6772	IFN-beta;Stat1	The receptor blockade by mAb 51.44 and 234.28 resulted in the inhibition of IFN-alpha2a and ***IFN-beta-induced*** tyrosine ***phosphorylation*** of Jak1 , Tyk2 , ***Stat1/2/3*** , and IFNAR-1/2 and inhibition of IFN-stimulated gene factor 3 ( ISGF3 ) formation .	target	1
21595	11096454	3456;7297	IFN-beta;Tyk2	The receptor blockade by mAb 51.44 and 234.28 resulted in the inhibition of IFN-alpha2a and ***IFN-beta-induced*** tyrosine ***phosphorylation*** of Jak1 , ***Tyk2*** , Stat1/2/3 , and IFNAR-1/2 and inhibition of IFN-stimulated gene factor 3 ( ISGF3 ) formation .	target	1
21596	11097365	959;958	CD40L;CD40	These results support the hypothesis that ******CD40-CD40L****** ***interaction*** is involved in atherogenesis and that it might provide a target for future therapeutic interventions .	parallel	1
21597	11097743	7124;1026	TNF-alpha;p21	***TNF-alpha*** ***induced*** ***p21*** ( WAF1 ) but not Bax in colon cancer cells WiDr with mutated p53 : important role of protein stabilization .	target	1
21598	11097743	7124;1026	TNF-alpha;p21	***TNF-alpha*** ***induced*** expression of ***p21*** ( WAF1 ) at protein and mRNA levels in a dose-dependent fashion with an association with G ( 1 ) - arrest in human colon cancer cells WiDr that carry mutated p53 at codon 273 ( His ( 273 ) ) .	target	1
21599	11097743	7124;1026	TNF-alpha;p21	Further study found that ***TNF-alpha*** markedly ***stabilized*** the ***p21*** ( WAF1 ) protein .	positive	0
21600	11097743	7124;1026	TNF-alpha;p21	These findings suggest that ***TNF-alpha*** ***induces*** expression of ***p21*** ( WAF1 ) through a distinct pathway from Bax and that protein stabilization is an important mechanism in the expression of p21 ( WAF1 ) independent of p53 .	target	1
21601	11097834	1398;6776	CRK;STAT5	Thrombopoietin and interleukin-2 induce ***association*** of ***CRK*** with ***STAT5*** .	parallel	0
21602	11097834	3558;1398	interleukin-2;CRK	Thrombopoietin and ***interleukin-2*** ***induce*** association of ***CRK*** with STAT5 .	target	1
21603	11097834	7066;1398	Thrombopoietin;CRK	***Thrombopoietin*** and interleukin-2 ***induce*** association of ***CRK*** with STAT5 .	target	1
21604	11097834	1398;6776	CRK;STAT5	By coprecipitation and far Western blotting analysis , we demonstrate that ***CRK*** ( I/II ) ***binds*** to tyrosine phosphorylated ***STAT5*** in cells stimulated by cytokines such as Thrombopoietin ( TPO ) and interleukin-2 ( IL-2 ) .	parallel	1
21605	11097836	3481;4790	IGF-II;NFkappaB	Western blot data that IkappaB was reduced by IGF-II significantly suggest that ***NFkappaB*** ***activation*** by ***IGF-II*** may be mediated through the downregulation of IkappaB .	positive	1
21606	11097840	598;836	Bcl-xL;Caspase-3	These data suggest that HGF exerts an antiapoptotic effect through dual induction of ***Bcl-xL*** and Cox-2 , which ***suppresses*** ***Caspase-3*** activity .	negative	1
21607	11097840	5743;836	Cox-2;Caspase-3	These data suggest that HGF exerts an antiapoptotic effect through dual induction of Bcl-xL and ***Cox-2*** , which ***suppresses*** ***Caspase-3*** activity .	negative	1
21608	11097854	2247;6382	FGF-2;syndecan-1	Proximal promoter independent ***activation*** of ***syndecan-1*** gene by ***FGF-2*** might be required during development when syndecan-1 proximal promoter needs to be largely attenuated but simultaneous transient and rapid FGF-2 induced transcription is required .	positive	1
21609	11097859	3558;328	IL-2;redox factor-1	Our previous study of interleukin-2 ( IL-2 ) signaling found that ***redox factor-1*** ( ref-1 ) mRNA was ***upregulated*** by ***IL-2*** .	positive	1
21610	11097859	3558;7003	IL-2;ref-1	Western blot analysis confirmed that ***IL-2*** stimulation ***increases*** ***ref-1*** protein .	positive	0
21611	11097862	5594;4780	ERK;Nrf2	Inhibition of ***ERK*** and p38 MAP kinases ***inhibits*** binding of ***Nrf2*** and induction of GCS genes .	positive	1
21612	11098049	5741;1432	PTH;p38	Thus , protein kinase C , but not protein kinase A , is required for the ***inhibition*** of ***p38*** MAPK by ***PTH*** .	negative	1
21613	11098049	5741;1432	PTH;p38	***Inhibition*** of ***p38*** MAPK in hypertrophic chondrocytes by either ***PTH*** , SB303580 , or both together leads to a decrease of hypertrophic marker type X collagen mRNA and an increase of the expression of prehypertrophic marker cartilage matrix protein .	negative	1
21614	11098052	1017;1026	CDK2;p21	The ***binding*** of ***CDK2*** , CDK4 , or proliferating cell nuclear antigen to ***p21*** ( WAF-1 ) and its subcellular localization were unchanged in the presence or absence of IL-3 .	parallel	1
21615	11098052	1019;1026	CDK4;p21	The ***binding*** of CDK2 , ***CDK4*** , or proliferating cell nuclear antigen to ***p21*** ( WAF-1 ) and its subcellular localization were unchanged in the presence or absence of IL-3 .	parallel	1
21616	11098052	5111;1026	proliferating cell nuclear antigen;p21	The ***binding*** of CDK2 , CDK4 , or ***proliferating cell nuclear antigen*** to ***p21*** ( WAF-1 ) and its subcellular localization were unchanged in the presence or absence of IL-3 .	parallel	1
21617	11098053	1956;598	Epidermal growth factor receptor;Bcl-xL	***Epidermal growth factor receptor-dependent*** ***control*** of keratinocyte survival and ***Bcl-xL*** expression through a MEK-dependent pathway .	target	0
21618	11098056	7040;3791	Transforming growth factor-beta 1;KDR	***Transforming growth factor-beta 1-mediated*** ***inhibition*** of the flk-1 / ***KDR*** gene is mediated by a 5 ' - untranslated region palindromic GATA site .	negative	1
21619	11098056	2623;3791	GATA-1;KDR	Finally , in cotransfection assays , ***transactivation*** of the flk-1 / ***KDR*** promoter by ***GATA-1*** or GATA-2 was attenuated in TGF-beta ( 1 ) - treated cells .	positive	1
21620	11098056	2624;3791	GATA-2;KDR	Finally , in cotransfection assays , ***transactivation*** of the flk-1 / ***KDR*** promoter by GATA-1 or ***GATA-2*** was attenuated in TGF-beta ( 1 ) - treated cells .	positive	1
21621	11098056	7040;3791	TGF-beta-1;KDR	Taken together , these results suggest that the ***TGF-beta-1-mediated*** ***inhibition*** of the flk-1 / ***KDR*** gene is mediated by a 5 ' - untranslated region palindromic GATA site .	negative	1
21622	11098059	3553;1026	IL-1;p21	***IL-1*** quickly ***enhances*** the protein expression of the CDK inhibitor ***p21*** ( cip1 ) .	positive	0
21623	11098089	8771;356	DcR3;FasL	The recently identified decoy receptor 3 ( ***DcR3*** ) ***binds*** to ***FasL*** and inhibits FasL-induced apoptosis , and is considered to play a role in the immune escape system of neoplastic cells .	parallel	1
21624	11098126	5741;5746	parathyroid hormone;parathyroid hormone-2 receptor	The human parathyroid hormone-2 receptor is activated by parathyroid hormone and a recently purified hypothalamic polypeptide , tubero-infundibular peptide of 39 residues , while the rat ***parathyroid hormone-2 receptor*** is poorly ***activated*** by ***parathyroid hormone*** and is potently activated by tubero-infundibular peptide of 39 residues .	positive	1
21625	11098130	351;4311	Abeta;neprilysin	Furthermore , kinetic analysis , giving a K ( m ) value of 2.8 + / - 0.76 microM , indicated that ***Abeta*** ( 1-42 ) is a relevant ***substrate*** for ***neprilysin*** .	parallel	1
21626	11098137	5972;5973	Renin;Renin-binding protein	***Renin*** ***inhibits*** N-acetyl-D-glucosamine 2-epimerase ( ***Renin-binding protein*** ) .	negative	1
21627	11098137	5973;5972	RnBP;Renin	The recombinant human ( rh ) RnBP existed as a dimer and its GlcNAc 2-epimerase activity was strongly inhibited by the purified Renin concomitant with the formation of ******RnBP-Renin****** ***heterodimer*** , so-called high molecular weight ( HMW ) Renin .	parallel	1
21628	11098137	5972;5973	Renin;GlcNAc 2-epimerase	These results indicate that ***Renin*** is an ***inhibitor*** of ***GlcNAc 2-epimerase*** , and the Renin-RnBP heterodimer HMW Renin is an inactive form of both Renin and GlcNAc 2-epimerase activities .	negative	1
21629	11099046	2059;9712	Eps8;RN-tre	Through its src homology-3 domain , ***Eps8*** ***interacts*** with ***RN-tre*** .	parallel	1
21630	11099047	9219;7157	PID;p53	***PID*** specifically ***interacts*** with ***p53*** both in vitro and in vivo , and its expression reduces significantly the steady-state levels of acetylated p53 .	parallel	1
21631	11099048	6502;6500	Skp2;Skp1	Insights into SCF ubiquitin ligases from the structure of the ******Skp1-Skp2****** ***complex*** .	parallel	1
21632	11099302	356;355	FasL;Fas	The expression of Fas and ***Fas*** ***ligand*** ( ***FasL*** ) mRNA in thyroids was also determined by RT-PCR in both CD8 ( + ) and CD8-depleted recipient mice .	parallel	1
21633	11099315	4068;6504	SAP;SLAM	Potential pathways for regulation of NK and T cell responses : differential X-linked lymphoproliferative syndrome gene product ***SAP*** ***interactions*** with ***SLAM*** and 2B4 .	parallel	1
21634	11099315	4068;6504	SAP;SLAM	By contrast , ******SLAM-SAP****** ***interactions*** were independent of phosphorylation of Y281 and Y327 on SLAM .	parallel	1
21635	11099318	55;1437	PAP;granulocyte-macrophage colony-stimulating factor	PURPOSE : Provenge ( Dendreon Corp , Seattle , WA ) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein consisting of prostatic acid phosphatase ( ***PAP*** ) ***linked*** to ***granulocyte-macrophage colony-stimulating factor*** .	parallel	0
21636	11099378	3148;5460	HMG-2;Oct-4	HMG-1 , and the closely related factor ***HMG-2*** , ***interact*** with ***Oct-4*** when co-expressed in mammalian cells .	parallel	1
21637	11099417	64241;64240	ABCG8;ABCG5	These data suggest that ***ABCG5*** and ***ABCG8*** normally ***cooperate*** to limit intestinal absorption and to promote biliary excretion of sterols , and that mutated forms of these transporters predispose to sterol accumulation and atherosclerosis .	parallel	0
21638	11099474	10399;5579	RACK1;PKC beta	We detected the receptor for activated C kinase 1 ( ***RACK1*** ) , the specific ***receptor*** for activated protein kinase C beta ( ***PKC beta*** ) , to be up-regulated in bovine cord-forming EC in vitro and in angiogenically active stages of bovine corpora lutea in vivo .	parallel	1
21639	11099474	10399;5579	RACK1;PKC beta	Our data suggest that downstream signaling of ***PKC beta*** in angiogenically active vs. inactive tissues and endothelium is ***affected*** by the availability of ***RACK1*** .	target	0
21640	11099496	2213;3635	fc gamma RIIB;SHIP1	Phosphorylated ***fc gamma RIIB*** , however , ***recruit*** selectively ***SHIP1/2*** in vivo .	target	0
21641	11099506	5624;10544	protein C;EPCR	protein C activation studies on 293 cells that coexpress EPCR variants and thrombomodulin demonstrate that ***protein C*** ***binding*** to ***EPCR*** is necessary for the EPCR-dependent enhancement in protein activation by the thrombin-thrombomodulin complex .	parallel	1
21642	11099506	10544;5624	EPCR;protein C	***EPCR*** ***regulates*** the ***protein C*** anticoagulant pathway by binding protein C and augmenting protein C activation by the thrombin-thrombomodulin complex .	target	1
21643	11099659	2934;836	gelsolin;Caspase 3	The ***Caspase 3*** ***substrate*** , ***gelsolin*** , began to undergo proteolysis after 3 to 4 days of storage , and the addition of the caspase inhibitor z-VAD-fmt substantially inhibited this process .	parallel	1
21644	11099781	7040;836	TGF-beta1;caspase-3	***TGF-beta1*** ***inhibits*** ***caspase-3*** activation and neuronal apoptosis in rat hippocampal cultures .	negative	1
21645	11099781	7040;836	TGF-beta1;caspase-3	Furthermore , ***TGF-beta1*** ( 1 and 10 ng/ml ) markedly ***inhibited*** the activation of ***caspase-3*** induced by staurosporine as demonstrated by both caspase-3 activity assay and Western blotting .	negative	1
21646	11099781	7040;836	TGF-beta1;caspase-3	This study provides evidence that ***TGF-beta1*** is able to efficiently ***inhibit*** ***caspase-3*** activation , and thereby protects cultured hippocampal neurons against apoptosis .	negative	1
21647	11100124	1385;4018	transactivator (Tat) protein;lipoprotein	Here we report that ***binding*** of HIV-1 ***transactivator (Tat) protein*** to low-density ***lipoprotein*** receptor-related protein ( LRP ) promoted efficient uptake of Tat into neurons .	parallel	1
21648	11100124	1385;4035	transactivator (Tat) protein;LRP	Here we report that ***binding*** of HIV-1 ***transactivator (Tat) protein*** to low-density lipoprotein receptor-related protein ( ***LRP*** ) promoted efficient uptake of Tat into neurons .	parallel	1
21649	11100316	5925;1029	pRb;p16INK4	***Associations*** between expression of ***pRb*** and ***p16INK4*** and the clinicopathological features were analyzed by using the chi 2 test and survival analysis was performed by Log-rank test .	parallel	0
21650	11100378	999;1500	E-cadherin;p120	The expression of ***E-cadherin*** ***correlated*** significantly with alpha - , beta - and gamma-catenin , and ***p120*** expression , respectively .	parallel	0
21651	11100897	4193;84260	Mdm2;tumor-suppressor protein	The ***Mdm2*** protein is most probably the main negative cellular ***regulator*** of the p53 ***tumor-suppressor protein*** .	negative	1
21652	11100897	7157;4193	p53;Mdm2	The main functional domains as well as the ***interaction*** between ***Mdm2*** and ***p53*** are conserved in zebrafish .	parallel	1
21653	11101004	3565;1571	interleukin 4;CYP2E1	The ***induction*** of the human hepatic ***CYP2E1*** gene by ***interleukin 4*** is transcriptional and regulated by protein kinase C.	target	1
21654	11101004	3565;6778	IL-4;STAT6	As expected , ***IL-4*** ***induced*** tyrosine phosphorylation of the ***STAT6*** transcription factor , an effect prevented by the tyrosine kinase inhibitor tyrphostin A25 .	target	1
21655	11101004	3565;1571	IL-4;CYP2E1	However , this inhibitor as well as genistein ( another inhibitor of tyrosine kinases ) had no effect on the ***IL-4*** ***induction*** of ***CYP2E1*** .	target	1
21656	11101004	3565;1571	IL-4;CYP2E1	Taken together , our results show that ***IL-4*** coordinately ***induces*** ***CYP2E1*** transcription , mRNA and apoprotein levels in human hepatoma cells in a PKC-dependent manner , potentially through the activity of the PKCzeta isoform .	target	1
21657	11101147	3569;8837	IL-6;FLIP	However , ***IL-6*** failed to ***enhance*** the protein levels of ***FLIP*** molecules in either of the tested cells .	positive	0
21658	11101147	8837;355	FLIP;Fas	Interestingly , mRNA levels of ***FLIP*** ( L ) , an endogenous ***inhibitor*** of ***Fas*** signaling , were constitutively elevated in U266 cells .	negative	1
21659	11101154	11124;355	hFAF1;Fas	Human Fas associated factor 1 protein ( ***hFAF1*** ) is involved in the positive ***regulation*** of ***Fas*** signaling even though it can not initiate the signal for itself .	positive	1
21660	11101278	183;5972	angiotensin II;renin	CONCLUSIONS : ( 1 ) angiotensin II contributes to the regulation of renal function in 120-day preterm lambs without changing blood pressure and ( 2 ) ***angiotensin II-mediated*** feedback ***inhibition*** of ***renin*** release is uncoupled in preterm newborns .	negative	1
21661	11101307	3667;3643	IRS-1;insulin receptor	Chronic ***activation*** of ***insulin receptor*** signaling by ***IRS-1*** overexpression in the beta-cell inhibited gene expression of SERCA3 , an endoplasmic reticulum Ca ( 2 + ) - ATPase .	positive	1
21662	11101505	9992;3784	KCNE2;KCNQ1	Here we demonstrate the ***interaction*** of ***KCNE2*** with the ***KCNQ1*** subunit , which results in a drastic change of KCNQ1 current amplitude and gating properties .	parallel	1
21663	11101509	596;142	Bcl-2;PARP	***PARP*** cleavage was ***antagonized*** specifically by co-transfection of DNA encoding ***Bcl-2*** , known to block mitochondria-dependent apoptotic signals .	negative	1
21664	11101512	1678;100287932	TIM8;Tim23	The ***TIM8-13*** complex ***binds*** to the N-terminal or intermediate domain of ***Tim23*** .	parallel	1
21665	11101517	2081;64374	IRE1;SIL1	We conclude that the ***IRE1-dependent*** ***induction*** of ***SIL1*** is a vital adaptation in Deltalhs1 cells , and that the activities associated with the Lhs1 and SIL1 proteins constitute an essential function required for protein translocation into the ER .	target	1
21666	11101518	8673;9482	endobrevin;syntaxin 8	We report that syntaxin 7 , ***syntaxin 8*** , vti1b and ***endobrevin/VAMP-8*** form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21667	11101518	8673;8673	endobrevin;VAMP-8	We report that syntaxin 7 , syntaxin 8 , vti1b and ******endobrevin/VAMP-8****** form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21668	11101518	9482;8417	syntaxin 8;syntaxin 7	We report that ***syntaxin 7*** , ***syntaxin 8*** , vti1b and endobrevin/VAMP-8 form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21669	11101518	9482;8673	syntaxin 8;VAMP-8	We report that syntaxin 7 , ***syntaxin 8*** , vti1b and ***endobrevin/VAMP-8*** form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21670	11101518	8673;8417	VAMP-8;syntaxin 7	We report that ***syntaxin 7*** , syntaxin 8 , vti1b and ***endobrevin/VAMP-8*** form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21671	11101518	10490;8417	vti1b;syntaxin 7	We report that ***syntaxin 7*** , syntaxin 8 , ***vti1b*** and endobrevin/VAMP-8 form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21672	11101518	10490;9482	vti1b;syntaxin 8	We report that syntaxin 7 , ***syntaxin 8*** , ***vti1b*** and endobrevin/VAMP-8 form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21673	11101518	10490;8673	vti1b;VAMP-8	We report that syntaxin 7 , syntaxin 8 , ***vti1b*** and ***endobrevin/VAMP-8*** form a ***complex*** that functions in the fusion of late endosomes .	parallel	1
21674	11101523	573;3308	RAP46;Hsp70	******Hsp70-RAP46****** ***interaction*** in downregulation of DNA binding by glucocorticoid receptor .	parallel	1
21675	11101523	573;2908	RAP46;glucocorticoid receptor	Surface plasmon resonance studies showed that ***RAP46*** ***binds*** the ***glucocorticoid receptor*** only when it has interacted with Hsp70/Hsc70 , and confocal immunofluorescence analyses revealed a nuclear transport of Hsp70/Hsc70 by the liganded receptor .	parallel	1
21676	11101523	573;2908	RAP46;glucocorticoid receptor	Together these findings demonstrate an important contribution of Hsp70/Hsc70 in the binding of RAP46 to the glucocorticoid receptor and suggest a role for this molecular chaperone in the ***RAP46-mediated*** ***downregulation*** of ***glucocorticoid receptor*** activity .	negative	1
21677	11101523	573;2908	RAP46;glucocorticoid receptor	Together these findings demonstrate an important contribution of Hsp70/Hsc70 in the ***binding*** of ***RAP46*** to the ***glucocorticoid receptor*** and suggest a role for this molecular chaperone in the RAP46-mediated downregulation of glucocorticoid receptor activity .	parallel	1
21678	11101524	1432;7157	p38;p53	These results suggest that p53-dependent expression of wip1 mediates a negative feedback regulation of ******p38-p53****** ***signaling*** and contributes to suppression of the UV-induced apoptosis .	parallel	0
21679	11101524	1432;7157	p38;p53	The stress-responsive ***p38*** MAPK , when activated by genotoxic stresses such as UV radiation , ***enhances*** ***p53*** activity by phosphorylation and leads to cell cycle arrest or apoptosis .	positive	0
21680	11101524	1432;7157	p38;p53	Here we report that a member of the protein phosphatase type 2C family , wip1 , has a role in down-regulating ******p38-p53****** ***signaling*** during the recovery phase of the damaged cells .	parallel	0
21681	11101524	8493;1432	wip1;p38	***wip1*** selectively ***inactivates*** ***p38*** by specific dephosphorylation of its conserved threonine residue .	negative	1
21682	11101524	8493;7157	wip1;p53	Furthermore , ***wip1*** expression ***attenuates*** UV-induced ***p53*** phosphorylation at Ser33 and Ser46 , residues previously reported to be phosphorylated by p38 .	negative	0
21683	11101534	10985;440275	GCN1;GCN2	GCN2 function in vivo requires the ***GCN1/GCN20*** complex , which ***binds*** to the N-terminal domain of ***GCN2*** .	parallel	1
21684	11101534	440275;10985	GCN2;GCN1	***GCN2*** function in vivo ***requires*** the ***GCN1/GCN20*** complex , which binds to the N-terminal domain of GCN2 .	target	0
21685	11101534	440275;10985	GCN2;GCN1	Overexpression of this fragment in wild-type cells impaired ***association*** of ***GCN2*** with native ***GCN1*** and had a dominant Gcn ( - ) phenotype , dependent on Arg2259 in the GCN1 fragment .	parallel	0
21686	11101534	440275;10985	GCN2;GCN1	These findings prove that ***GCN2*** ***binding*** to the C-terminal domain of ***GCN1*** , dependent on Arg2259 , is required for high level GCN2 function in vivo .	parallel	1
21687	11101534	10985;440275	GCN1;GCN2	GCN1 expression conferred sensitivity to paromomycin in a manner dependent on its ribosome binding domain , supporting the idea that ***GCN1*** binds near the ribosomal acceptor site to ***promote*** ***GCN2*** activation by uncharged tRNA .	positive	0
21688	11101839	54362;23714	DFNM1;DFNB26	Dominant modifier ***DFNM1*** ***suppresses*** recessive deafness ***DFNB26*** .	negative	1
21689	11101847	1869;7161	E2F1;TP73	Here we provide evidence that ***E2F1*** directly ***activates*** transcription of ***TP73*** , leading to activation of p53-responsive target genes and apoptosis .	positive	1
21690	11101847	1869;7161	E2F1;p73	Thus , ***p73*** ***activation*** by deregulated ***E2F1*** activity might constitute a p53-independent , anti-tumorigenic safeguard mechanism .	positive	1
21691	11101849	5346;3991	perilipin;HSL	***perilipin*** ( encoded by the gene Plin ) , an adipocyte protein , has been postulated to ***modulate*** ***HSL*** activity .	target	0
21692	11101867	356;355	FasL;Fas	Although Fas deficiency in humans and mice predisposes them towards systemic autoimmunity , ******Fas-FasL****** ***interactions*** can also facilitate organ-specific immunopathology .	parallel	1
21693	11101869	356;355	CD95L;CD95	After autoimmune inflammation , interactions between ***CD95*** and its ***ligand*** ( ***CD95L*** ) mediate thyrocyte destruction in Hashimoto 's thyroiditis ( HT ) .	parallel	1
21694	11101869	356;355	CD95L;CD95	After autoimmune inflammation , ***interactions*** between ***CD95*** and its ligand ( ***CD95L*** ) mediate thyrocyte destruction in Hashimoto 's thyroiditis ( HT ) .	parallel	1
21695	11101889	23309;4084	Sin3B;Mad1	The ******Mad1-Sin3B****** ***interaction*** involves a novel helical fold .	parallel	1
21696	11101893	8349;3015	H2B;H2A.Z	However , distinct localized changes result in the subtle destabilization of the ***interaction*** between the ( ******H2A.Z-H2B****** ) dimer and the ( H3-H4 ) ( 2 ) tetramer .	parallel	1
21697	11102446	7040;4087	TGF-beta;Smad-2	Additionally , Cav-1 is able to suppress ***TGF-beta-mediated*** ***phosphorylation*** of ***Smad-2*** and subsequent downstream events .	target	1
21698	11102446	857;4087	Cav-1;Smad-2	Additionally , ***Cav-1*** is able to ***suppress*** TGF-beta-mediated phosphorylation of ***Smad-2*** and subsequent downstream events .	negative	1
21699	11102481	3416;351	Insulysin;Abeta	***Insulysin*** was further shown to ***prevent*** the deposition of ***Abeta*** ( 1-40 ) onto a synthetic amyloid .	negative	0
21700	11102483	2668;11280	Glial-derived neurotrophic factor;NaN	***Glial-derived neurotrophic factor*** ***upregulates*** expression of functional SNS and ***NaN*** sodium channels and their currents in axotomized dorsal root ganglion neurons .	positive	1
21701	11102483	2668;6336	Glial-derived neurotrophic factor;SNS	***Glial-derived neurotrophic factor*** ***upregulates*** expression of functional ***SNS*** and NaN sodium channels and their currents in axotomized dorsal root ganglion neurons .	positive	1
21702	11102484	2066;2064	erbB4;ErbB2	This distribution strongly argues that ******ErbB2/erbB4****** ***heterodimers*** are the functional postsynaptic neuregulin receptors of the NMJ .	parallel	1
21703	11102524	4052;7040	LTBP-1;TGF-beta	Originally described as a TGF-beta-masking protein , ***LTBP-1*** is involved both in the ***sequestration*** of latent ***TGF-beta*** in the extracellular matrix and the regulation of its activation in the extracellular environment .	negative	0
21704	11102529	387;5337	RhoA;PLD1	Our results demonstrate that direct ***stimulation*** of ***PLD1*** in vivo by ***RhoA*** ( and by PKC ) is critical for significant PLD1 activation but that PLD1 subcellular localization and regulated phosphorylation occur independently of these stimulatory pathways .	positive	0
21705	11102571	2247;3569	FGF-2;IL-6	Using rat Schwann cells we found that IL-6 did not exert any effects on the expression of FGF-2 and FGF receptor type 1 ( R1 ) whereas exogenously applied 18-kD ***FGF-2*** strongly ***increased*** the expression of the mRNAs of ***IL-6*** and its receptor .	positive	0
21706	11102746	7058;4313	TSP2;matrix metalloproteinase 2	Our laboratory has established that ***TSP2*** ***binds*** ***matrix metalloproteinase 2*** ( MMP2 ) and that the adhesive defect in TSP2-null fibroblasts results from increased MMP2 activity .	parallel	1
21707	11102752	7040;1634	TGF-beta;decorin	Complex ***formation*** of transforming growth factor-beta ( ***TGF-beta*** ) with the small proteoglycan ***decorin*** has been considered to inactivate the cytokine .	parallel	0
21708	11102891	7039;1956	transforming growth factor-alpha;epidermal growth factor receptor	***epidermal growth factor receptor*** ( EGF-R ) and its ***ligand*** , ***transforming growth factor-alpha*** ( TGF-alpha ) , play an important role through the autocrine growth-regulation system in several human cancers , including breast cancer .	parallel	1
21709	11102927	351;348	Abeta;ApoE	The ***Abeta*** 40 and 42 plasma levels were then ***correlated*** with apolipoprotein E ( ***ApoE*** ) genotypes in all groups of cases , and with I.	parallel	0
21710	11103777	842;29108	caspase-9;TMS1	The ability of ***TMS1*** to trigger apoptosis was also ***suppressed*** by a dominant negative form of ***caspase-9*** but not by a dominant negative form of caspase-8 , indicating that TMS1 functions through activation of caspase-9 .	negative	1
21711	11103785	7490;1499	WT1;beta-catenin	Frequent ***association*** of ***beta-catenin*** and ***WT1*** mutations in Wilms tumors .	parallel	0
21712	11103785	1499;7490	beta-catenin;WT1	Surprisingly , we observed a highly significant ( P = 3.6 x 10 ( -13 ) ) ***association*** between ***WT1*** and ***beta-catenin*** mutations ; 19 of 20 beta-catenin-mutant tumors had also sustained WT1 mutations .	parallel	0
21713	11103792	4609;581	c-myc;Bax	We show here that over-expression of ***c-myc*** delivered by an adenovirus vector ***up-regulates*** endogenous proapoptotic ***Bax*** mRNA and protein expression in human cells .	positive	1
21714	11103803	958;959	CD40;CD40L	The ***interactions*** between ***CD40L*** and ***CD40*** within treated tumors were critical because tumor suppression was abrogated by coadministration to the tumors of neutralizing monoclonal antibody against CD40L along with the DCs .	parallel	1
21715	11103932	993;1017	Cdc25A;Cdk2	In contrast , in the breast cancer-derived MCF-7 line , ***Cdc25A*** overexpression ***increased*** both cyclin ***E-Cdk2*** activity and the S phase fraction .	positive	0
21716	11103932	993;1017	Cdc25A;Cdk2	Recombinant ***Cdc25A*** strongly ***reactivated*** cyclin ***E-Cdk2*** from senescent HMECs suggesting that reduction of Cdc25A contributes to cyclin E-Cdk2 inhibition and G1 arrest at senescence .	positive	1
21717	11103937	1029;7157	p16;p53	Furthermore , when wt-p53 protein expression was restored in H1299 using Ad / p53 , ***Ad/p16*** ***stabilized*** ***p53*** protein expression and radiosensitized the cells .	positive	0
21718	11104682	7124;6004	TNFalpha;RGS16	Indeed , addition of recombinant ***TNFalpha*** to CEM cells rapidly ***stimulated*** ***RGS16*** mRNA expression independently of PKC .	positive	0
21719	11104682	7124;6004	TNFalpha;RGS16	Furthermore , mobilization of calcium by A23187 and thapsigargin blocked the ***TNFalpha-mediated*** ***induction*** of ***RGS16*** , which was reversed by EGTA and by the immunosuppressants FK506 and cyclosporin A , suggesting that the calcineurin/NF-AT ( nuclear factor of activated T cells ) pathway may repress the up-regulation process .	target	1
21720	11104699	8038;6714	ADAM 12;Src	Metalloprotease-disintegrin ***ADAM 12*** binds to the SH3 domain of Src and ***activates*** ***Src*** tyrosine kinase in C2C12 cells .	positive	1
21721	11104699	8038;6714	ADAM 12;Src	Moreover , endogenous ***ADAM 12*** ***associates*** with and activates endogenous ***Src*** in differentiating C2C12 cells .	parallel	0
21722	11104703	3569;3553	IL-6;interleukin 1beta	***Cross-talk*** between ***interleukin 1beta*** ( IL-1beta ) and ***IL-6*** signalling pathways : IL-1beta selectively inhibits IL-6-activated signal transducer and activator of transcription factor 1 ( STAT1 ) by a proteasome-dependent mechanism .	parallel	0
21723	11104703	3569;6772	IL-6;STAT1	Furthermore , IL-1beta selectively down-regulated the ***IL-6-induced*** tyrosine ***phosphorylation*** of ***STAT1*** without affecting the level of STAT1 or tyrosine phosphorylation of STAT3 .	target	1
21724	11104703	3553;6772	IL-1beta;STAT1	Furthermore , ***IL-1beta*** selectively ***down-regulated*** the IL-6-induced tyrosine phosphorylation of ***STAT1*** without affecting the level of STAT1 or tyrosine phosphorylation of STAT3 .	negative	1
21725	11104703	3553;6772	IL-1beta;STAT1	Kinase assays in vitro indicated that the ***inhibition*** of ***STAT1*** phosphorylation by ***IL-1beta*** was not due to an upstream blockade of Janus kinase ( JAK1 or JAK2 ) activation .	negative	1
21726	11104703	3553;4790	IL-1beta;NF-kappaB	However , pretreatment with the proteasome inhibitor MG132 under conditions that prevented the ***IL-1beta-dependent*** ***activation*** of the nuclear factor ***NF-kappaB*** also blocked the inhibitory effect of IL-1beta on IL-6-activated STAT1 .	positive	1
21727	11104703	3569;6772	IL-6;STAT1	In related experiments , the protein tyrosine phosphatase inhibitor Na ( 3 ) VO ( 4 ) also antagonized the inhibitory effect of IL-1beta on the ***activation*** of ***STAT1*** by ***IL-6*** .	positive	1
21728	11104703	3553;6772	IL-1beta;STAT1	Taken together , these findings indicate that , by using a proteasome-dependent mechanism , ***IL-1beta*** concomitantly induces NF-kappaB activation and ***dephosphorylates*** IL-6-activated ***STAT1*** ; the latter might partly account for the inhibition by IL-1beta of the IL-6-dependent induction of type II acute-phase genes .	target	1
21729	11104703	3553;4790	IL-1beta;NF-kappaB	Taken together , these findings indicate that , by using a proteasome-dependent mechanism , ***IL-1beta*** concomitantly ***induces*** ***NF-kappaB*** activation and dephosphorylates IL-6-activated STAT1 ; the latter might partly account for the inhibition by IL-1beta of the IL-6-dependent induction of type II acute-phase genes .	target	1
21730	11104730	653509;4843	SP-A;iNOS	***SP-A*** ***inhibited*** production of NO and ***iNOS*** in macrophages stimulated with smooth LPS , which did not significantly bind SP-A , or rough LPS , which avidly bound SP-A .	negative	1
21731	11104730	653509;4843	SP-A;iNOS	In contrast , ***SP-A*** ***enhanced*** production of NO and ***iNOS*** in cells stimulated with IFN-gamma or INF-gamma plus LPS .	positive	0
21732	11104733	3569;4790	IL-6;NF-kappaB	Together , our data suggest that TNF-alpha-induced ***IL-6*** and RANTES secretion may be ***associated*** with ***NF-kappaB*** activation , and that inhibition of TNF-alpha-stimulated RANTES secretion and augmentation of IL-6 secretion by increased [ cAMP ] ( i ) in HASM cells occurs via an NF-kappaB-independent mechanism .	parallel	0
21733	11104755	1499;5663	beta-catenin;PS1	These results argue against a pathologically relevant role for the ***association*** between ***PS1*** and ***beta-catenin*** in familial Alzheimer 's disease .	parallel	0
21734	11104755	1499;5663	beta-catenin;PS1	The physiological relevance of the ***association*** between ***PS1*** and ***beta-catenin*** remains controversial .	parallel	0
21735	11104755	5663;1499	PS1;beta-catenin	By disrupting this interaction , we demonstrate that the ***association*** between ***PS1*** and ***beta-catenin*** has no effect on Abeta peptide production , beta-catenin stability , or cellular susceptibility to apoptosis .	parallel	0
21736	11104755	5663;1499	PS1;beta-catenin	Significantly , in the absence of ******PS1/beta-catenin****** ***association*** , we found no alteration in beta-catenin signaling using induction of this pathway by exogenous expression of Wnt-1 or beta-catenin and a Tcf/Lef transcriptional assay .	parallel	0
21737	11104762	5585;4137	PKN;tau	Phosphorylation of ***tau*** is ***regulated*** by ***PKN*** .	target	1
21738	11104762	5585;4137	PKN;tau	When we investigated the effects of PKN activation on tau phosphorylation , we found that ***PKN*** triggers disruption of the microtubule array both in vitro and in vivo and predominantly ***phosphorylates*** ***tau*** in microtubule binding domains ( MBDs ) .	target	1
21739	11104763	5495;3725	PP2Cbeta;c-Jun	Ectopic expression of ***PP2Cbeta-1*** ***inhibited*** the TAK1-mediated ***mitogen-activated protein kinase kinase 4-c-Jun*** amino-terminal kinase and mitogen-activated protein kinase kinase 6-p38 signaling pathways .	negative	1
21740	11104763	5495;6416	PP2Cbeta;mitogen-activated protein kinase kinase 4	Ectopic expression of ***PP2Cbeta-1*** ***inhibited*** the TAK1-mediated ***mitogen-activated protein kinase kinase 4-c-Jun*** amino-terminal kinase and mitogen-activated protein kinase kinase 6-p38 signaling pathways .	negative	1
21741	11104763	5495;5608	PP2Cbeta;mitogen-activated protein kinase kinase 6	Ectopic expression of ***PP2Cbeta-1*** ***inhibited*** the TAK1-mediated mitogen-activated protein kinase kinase 4-c-Jun amino-terminal kinase and ***mitogen-activated protein kinase kinase 6-p38*** signaling pathways .	negative	1
21742	11104763	5495;1432	PP2Cbeta;p38	Ectopic expression of ***PP2Cbeta-1*** ***inhibited*** the TAK1-mediated mitogen-activated protein kinase kinase 4-c-Jun amino-terminal kinase and ***mitogen-activated protein kinase kinase 6-p38*** signaling pathways .	negative	1
21743	11104763	5495;6885	PP2Cbeta;TAK1	Coimmunoprecipitation experiments indicated that ***PP2Cbeta-1*** ***associates*** with the central region of ***TAK1*** .	parallel	0
21744	11104763	5495;6885	PP2Cbeta;TAK1	Collectively , these results indicate that ***PP2Cbeta*** negatively ***regulates*** the ***TAK1*** signaling pathway by direct dephosphorylation of TAK1 .	negative	1
21745	11104775	1848;5594	MKP3;ERK2	Mitogen-activated protein kinase phosphatase 3 ( ***MKP3*** ) is a specific ***regulator*** of extracellular signal-regulated protein kinase 2 ( ***ERK2*** ) .	target	1
21746	11104775	5594;1848	ERK2;MKP3	***Association*** of ***ERK2*** with ***MKP3*** results in a powerful increase in MKP3 phosphatase activity .	parallel	0
21747	11104775	1848;5594	MKP3;ERK2	To determine the molecular basis of the specific ***ERK2*** ***recognition*** by ***MKP3*** and the ERK2-induced MKP3 activation , we have carried out a systematic mutational and deletion analysis of MKP3 .	target	1
21748	11104775	5594;1848	ERK2;MKP3	Our results show that ***recognition*** and activation of ***MKP3*** by ***ERK2*** involves multiple regions of MKP3 .	target	1
21749	11104781	3753;3784	KCNE1;KvLQT1	The emerging family of KCNE1-related peptides includes ***KCNE1*** and KCNE3 , both of which ***complex*** with ***KvLQT1*** to produce functionally distinct currents .	parallel	1
21750	11104781	10008;3784	KCNE3;KvLQT1	The emerging family of KCNE1-related peptides includes KCNE1 and ***KCNE3*** , both of which ***complex*** with ***KvLQT1*** to produce functionally distinct currents .	parallel	1
21751	11104793	4311;5747	NEP;FAK	These experiments demonstrate that ***NEP*** can ***inhibit*** ***FAK*** phosphorylation on tyrosine and PC cell migration through multiple pathways and suggest that cell migration which contributes to invasion and metastases in PC cells can be regulated by NEP .	negative	1
21752	11104793	4311;5747	NEP;FAK	This results from ***NEP-induced*** ***inhibition*** of neuropeptide-stimulated association of ***FAK*** with cSrc protein .	negative	1
21753	11104793	5266;4311	PI3;NEP	Coimmunoprecipitation experiments show that NEP associates with tyrosine-phosphorylated Lyn kinase , which then binds the p85 subunit of phosphatidylinositol 3-kinase ( PI3-K ) resulting in an ******NEP-Lyn-PI3-K****** protein ***complex*** .	parallel	1
21754	11104795	6774;5443	STAT3;proopiomelanocortin	Direct ***regulation*** of pituitary ***proopiomelanocortin*** by ***STAT3*** provides a novel mechanism for immuno-neuroendocrine interfacing .	target	1
21755	11104795	6774;5443	STAT3;POMC	Whereas pathways shown thus far to regulate POMC expression exclusively involve cAMP or calcium , we here describe a direct and indirect ***STAT3-dependent*** ***regulation*** of ***POMC*** transcription by LIF .	target	1
21756	11104795	3976;5443	LIF;POMC	Whereas pathways shown thus far to regulate POMC expression exclusively involve cAMP or calcium , we here describe a direct and indirect STAT3-dependent ***regulation*** of ***POMC*** transcription by ***LIF*** .	target	1
21757	11104795	6774;3976	STAT3;LIF	Moreover , LIF-activated ***STAT3*** indirectly ***mediates*** ***LIF*** corticotroph action by inducing and potentiating CRH-induced c-fos and JunB expression and binding to the POMC AP-1 element .	target	0
21758	11104795	3976;5443	LIF;POMC	We therefore conclude that both a direct and indirect route mediate ***LIF-induced*** STAT3 ***activation*** of ***POMC*** transcription .	positive	1
21759	11104795	6774;5443	STAT3;POMC	We therefore conclude that both a direct and indirect route mediate LIF-induced ***STAT3*** ***activation*** of ***POMC*** transcription .	positive	1
21760	11104795	6774;5443	STAT3;POMC	Demonstration of ***STAT3-dependent*** ***regulation*** of the ***POMC*** gene represents a powerful mechanism for immuno-neuroendocrine interfacing and implies a direct stimulation of ACTH secretion by inflammatory and stress-derived STAT3-inducing cytokines .	target	1
21761	11104810	608;8741	B cell maturation antigen;APRIL	A soluble form of ***B cell maturation antigen*** , a ***receptor*** for the tumor necrosis factor family member ***APRIL*** , inhibits tumor cell growth .	parallel	1
21762	11104810	8741;608	APRIL;BCMA	***APRIL*** ***binds*** ***BCMA*** with higher affinity than TACI .	parallel	1
21763	11104810	608;8741	BCMA;APRIL	A soluble form of ***BCMA*** , which ***inhibits*** the proliferative activity of ***APRIL*** in vitro , decreases tumor cell proliferation in nude mice .	negative	1
21764	11104827	6387;7852	stromal cell-derived factor-1;CXCR4	The alpha chemokine receptor ***CXCR4*** and its only characterized chemokine ***ligand*** , ***stromal cell-derived factor-1*** ( SDF-1 ) , are postulated to be important in the development of the B-cell arm of the immune system .	parallel	1
21765	11104827	6387;7852	SDF-1;CXCR4	Furthermore , using Bordetella pertussis toxin , we observe that high affinity ***binding*** of ***SDF-1*** to ***CXCR4*** is independent of the G-protein coupled state of the receptor , as uncoupling of G-protein did not lead to the appearance of measurable low affinity SDF-1 binding sites .	parallel	1
21766	11104865	3952;7132	Leptin;TNF-RI	***Leptin*** levels ***correlate*** with ***TNF-RI*** in cachectic heart failure patients ( r = 0.58 , P = 0.018 ) .	parallel	0
21767	11104865	7132;355	TNF-RI;Fas	The ***TNF-RI*** levels were also ***correlated*** with ***Fas*** , both in all the patients taken together ( r = 0.5 , P = 0.006 ) and in those with cachexia ( r = 0.52 , P = 0.036 ) .	parallel	0
21768	11105212	6751;290	SSTR1;ANPEP	***SSTR1*** was found to be closely ***linked*** to CYP1A1 ( 0.0 cM ; LOD = 11.1 ) and ***ANPEP*** ( 0.0 cM ; LOD = 9.0 ) .	parallel	0
21769	11105212	6751;1543	SSTR1;CYP1A1	***SSTR1*** was found to be closely ***linked*** to ***CYP1A1*** ( 0.0 cM ; LOD = 11.1 ) and ANPEP ( 0.0 cM ; LOD = 9.0 ) .	parallel	0
21770	11105614	653509;729238	SP-A1;SP-A2	As surfactant protein A ( SP-A ) has several major immunological and metabolic intrapulmonary functions , we aimed at investigating an ***association*** of polymorphisms of ***SP-A1*** and ***SP-A2*** encoding genes and the risk of BPD .	parallel	0
21771	11105759	8480;55599	RAE1;RNP	However , the mechanism by which RAE1 functions in mRNA export is still unknown and the time point at which ***RAE1*** ***interacts*** with the exported ***RNP*** has not been directly investigated .	parallel	1
21772	11105759	8480;55599	RAE1;RNP	Moreover , the localization of ***Ct-RAE1*** at the NPC is ***correlated*** with the presence of an exported ***RNP*** in the NPC .	parallel	0
21773	11105899	865;861	CBFbeta;AML1	A surprising finding that has emerged from this work is that many of these chromosomal alterations target the genes encoding the ******AML1/CBFbeta****** transcription factor ***complex*** , a critical regulator of normal hematopoiesis .	parallel	1
21774	11105988	7124;3558	TNF-alpha;IL-2	Furthermore , ***TNF-alpha*** , but not leptin , was positively correlated to sIL-2R and negatively ***correlated*** to ***IL-2*** production .	negative	0
21775	11106244	2324;7422	flt-4;VEGF	These findings strongly support a role for ******VEGF-C/flt-4****** ***signaling*** in tumor growth by enhancement of angiogenesis and/or lymphangiogenesis and suggest that differential regulation of these processes may be controlled via flt-4 isoform transcription .	parallel	0
21776	11106244	2324;7422	flt-4;VEGF	Although the importance of VEGF has been shown in many human tumor types , the contribution of ***VEGF-C*** and its primary ***receptor*** ***flt-4*** to tumor progression is less well understood .	parallel	1
21777	11106322	183;348	angiotensinogen;apolipoprotein E	Synergistic ***effect*** between ***apolipoprotein E*** and ***angiotensinogen*** gene polymorphisms in the risk for early myocardial infarction .	parallel	0
21778	11106403	7040;4087	TGF-beta;Smad2	Ligand-induced activation of TGF-beta family receptors with intrinsic serine/threonine kinase activity trigger phosphorylation of receptor-regulated Smads ( R-Smads ) , whereas ***Smad2*** and Smad3 are ***phosphorylated*** by ***TGF-beta*** , and activin type I receptors , Smad1 , Smad5 and Smad8 , act downstream of BMP type I receptors .	target	1
21779	11106403	7040;4088	TGF-beta;Smad3	Ligand-induced activation of TGF-beta family receptors with intrinsic serine/threonine kinase activity trigger phosphorylation of receptor-regulated Smads ( R-Smads ) , whereas Smad2 and ***Smad3*** are ***phosphorylated*** by ***TGF-beta*** , and activin type I receptors , Smad1 , Smad5 and Smad8 , act downstream of BMP type I receptors .	target	1
21780	11106407	7048;7040	TbetaR-II;TGF-beta	To learn about the role of TGF-beta in vivo , phenotypes of targeted mutations of molecules within the TGF-beta signalling pathway , TGF-beta1 , - beta2 , - beta3 , ***TGF-beta*** ***receptor*** ( ***TbetaR-II*** ) and the signalling molecules SMAD2 , SMAD3 and SMAD4 , are discussed in this review .	parallel	1
21781	11106428	4792;5783	IkappaBalpha;FAP-1	Taken together , our data confirm that ***IkappaBalpha*** is a ***substrate*** of ***FAP-1*** .	parallel	1
21782	11106428	5783;4792	FAP-1;IkappaBalpha	Using an in vitro dephosphorylation reaction , we found that ***FAP-1*** ***dephosphorylates*** ***IkappaBalpha*** .	target	1
21783	11106432	3055;8548	Hck;cytoplasmic protein	Concomitant with the activation of Hck , there is a physical ***association*** of ***Hck*** with another ***cytoplasmic protein*** tyrosine kinase , Syk .	parallel	0
21784	11106497	6281;302	p11;annexin 2	Modulation by Ca ( 2 + ) and by membrane binding of the dynamics of domain III of annexin 2 ( p36 ) and the ******annexin 2-p11****** ***complex*** ( p90 ) : implications for their biochemical properties .	parallel	1
21785	11106498	302;6281	p36;p11	This protein exists as a monomer ( p36 ) or as a heterotetramer ( p90 ) in which two ***p36*** chains are ***associated*** with a dimer of ***p11*** , a member of the S100 protein family .	parallel	0
21786	11106551	596;7157	Bcl2;p53	Strong cytoplasmic staining was observed for ***Bcl2*** , which can ***inhibit*** both ***p53-dependent*** and - independent apoptosis .	negative	1
21787	11106584	4254;3815	stem cell factor;c-kit	We analyzed the expression of ***c-kit*** and its ***ligand*** ***stem cell factor*** ( SCF ) in a panel of six Ewing 's sarcoma cell lines .	parallel	1
21788	11106640	1482;811	Nkx2.5;calreticulin	COUP-TF1 antagonizes ***Nkx2.5-mediated*** ***activation*** of the ***calreticulin*** gene during cardiac development .	positive	1
21789	11106640	7025;811	COUP-TF1;calreticulin	***COUP-TF1*** ***antagonizes*** Nkx2.5-mediated activation of the ***calreticulin*** gene during cardiac development .	negative	1
21790	11106640	1482;811	Nkx2.5;calreticulin	Here we show that the transcription factor ***Nkx2.5*** ***activates*** expression of the ***calreticulin*** gene in the heart .	positive	1
21791	11106646	7430;9368	ezrin;EBP50	Both the ***ezrin*** and merlin N-ERMAD ***bind*** ***EBP50*** .	parallel	1
21792	11106648	5770;1000	PTP1B;N-cadherin	Essential tyrosine residues for ***interaction*** of the non-receptor protein-tyrosine phosphatase ***PTP1B*** with ***N-cadherin*** .	parallel	1
21793	11106648	5770;1000	PTP1B;N-cadherin	***PTP1B*** ***interacts*** directly with the cytoplasmic domain of ***N-cadherin*** , and this association is regulated by phosphorylation of tyrosine residues in PTP1B .	parallel	1
21794	11106650	3458;5468	Interferon-gamma;peroxisome proliferator-activated receptor gamma	***Interferon-gamma-induced*** ***regulation*** of ***peroxisome proliferator-activated receptor gamma*** and STATs in adipocytes .	target	1
21795	11106650	3458;5468	IFN-gamma;PPARgamma	Moreover , ***IFN-gamma*** also ***inhibited*** the transcription of ***PPARgamma*** , which was accompanied b